FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Quach, JM
   Askmyr, M
   Jovic, T
   Baker, EK
   Walsh, NC
   Harrison, SJ
   Neeson, P
   Ritchie, D
   Ebeling, PR
   Purton, LE
AF Quach, Julie M.
   Askmyr, Maria
   Jovic, Tanja
   Baker, Emma K.
   Walsh, Nicole C.
   Harrison, Simon J.
   Neeson, Paul
   Ritchie, David
   Ebeling, Peter R.
   Purton, Louise E.
TI Myelosuppressive Therapies Significantly Increase ProInflammatory
   Cytokines and Directly Cause Bone Loss
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PRECLINICAL STUDIES; BONE HISTOMORPHOMETRY; BONE mu CT; CYTOKINES;
   OSTEOCLASTS
ID STEM CELL TRANSPLANTATION; ZOLEDRONIC ACID; MINERAL DENSITY;
   OSTEOPOROSIS; MECHANISMS; CYCLOPHOSPHAMIDE; CHEMOATTRACTANT;
   DIFFERENTIATION; NICHES; CANCER
AB Skeletal related events resulting from accelerated bone loss are common complications in patients treated for a range of cancers. However, the mechanisms and rate of bone loss after myelosuppression are unclear. We, therefore, investigated this in mice and humans. We treated mice with different myelosuppressive therapies (chemotherapy or irradiation with or without transplantation) and studied their effects on bone structure. Myelosuppression of mice rapidly caused an increase in bone resorption that was not matched by bone formation. The resultant significant and persistent bone loss early after therapy was associated with increased inflammatory cytokines, in particular, monocyte chemoattractant protein 1 (MCP1). Therapy induced bone loss was prevented with a single dose of the bisphosphonate zoledronic acid (ZA), administered before myelosuppression. Importantly, ZA treatment of mice did not impair hematopoiesis, including hematopoietic stem cell function. Furthermore, examination of serum from patients before and after autologous or allogeneic stem cell transplantion (SCT) revealed altered levels of bone turnover markers and elevated inflammatory cytokines. MCP1 levels in serum obtained between days 7 and 14 post SCT positively correlated with bone loss observed at 100 days after allogeneic SCT. Similar to that observed in our studies in mice, the bone loss was long term, persisting at 12 months post SCT. Furthermore, patients who received chemotherapy less than 100 days before SCT had significantly more bone loss at the hip. In these patients, serum levels of MCP1, but not routine biomarkers of bone turnover, including C terminal cross linking telopeptide of type 1 collagen ( CTx), positively correlated with their bone loss. Hence, myelosuppressive therapies increase inflammation and directly contribute to bone loss. Administration of an osteoclast inhibitor before the initiation of cancer therapy is likely to have the best outcome in preventing bone loss in patients with cancer. (c) 2014 American Society for Bone and Mineral Research.
C1 [Quach, Julie M.; Askmyr, Maria; Jovic, Tanja; Baker, Emma K.; Purton, Louise E.] St Vincents Inst Med Res, Stem Cell Regulat Unit, Fitzroy, Vic 3065, Australia.
   [Baker, Emma K.; Walsh, Nicole C.; Harrison, Simon J.; Ritchie, David; Ebeling, Peter R.; Purton, Louise E.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia.
   [Walsh, Nicole C.] St Vincents Inst Med Res, Bone Cell Biol & Dis Unit, Fitzroy, Vic 3065, Australia.
   [Harrison, Simon J.; Neeson, Paul; Ritchie, David] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [Harrison, Simon J.; Neeson, Paul; Ritchie, David] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.
   [Ritchie, David] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Ebeling, Peter R.] Monash Univ, Sch Clin Sci, Dept Med, Melbourne, Vic 3004, Australia.
C3 St. Vincent's Institute of Medical Research; University of Melbourne;
   St. Vincent's Institute of Medical Research; Peter Maccallum Cancer
   Center; University of Melbourne; Peter Maccallum Cancer Center;
   Melbourne Health; Royal Melbourne Hospital; Monash University
RP Purton, LE (通讯作者)，St Vincents Inst Med Res, Stem Cell Regulat Unit, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM lpurton@svi.edu.au
RI Neeson, Paul/ABD 4686 2020; Ebeling, Peter/A 9129 2012; Harrison,
   Simon/AGO 8958 2022; Walsh, Nicole/KYQ 7959 2024; Purton,
   Louise/AAI 8956 2021
OI Ebeling, Peter/0000 0002 2921 3742; Purton, Louise/0000 0001 6593 3168;
   Harrison, Simon/0000 0003 4555 6582; Neeson, Paul/0000 0002 2729 5887;
   Ritchie, David/0000 0001 7329 6605; 
FU Leukaemia Foundation; National Health and Medical Research Council of
   Australia (NHMRC); NHMRC Career Development Award; NHMRC Senior Research
   Fellowship; Post doctoral Fellowship from the Swedish Research Council;
   Victorian State Government Operational Infrastructure Support Program;
   Australian Institute of Musculoskeletal Science; Monash University; Jack
   Brockhoff Foundation; Ian Potter Foundation
FX This work was supported by grants from the Leukaemia Foundation (to LP
   and MA); National Health and Medical Research Council of Australia
   (NHMRC; to LP); NHMRC Career Development Award (to LP); NHMRC Senior
   Research Fellowship (to LP); Post doctoral Fellowship from the Swedish
   Research Council (to MA); and in part by the Victorian State Government
   Operational Infrastructure Support Program (to St Vincent's Institute);
   and The Australian Institute of Musculoskeletal Science and Monash
   University (to PRE). Generous support from the Ian Potter Foundation
   assisted with the purchase of the mu CT and irradiator used in these
   studies, and the Osteomeasure system was purchased with funds provided
   from the Jack Brockhoff Foundation.
CR Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   D'Souza AB, 2006, INTERN MED J, V36, P600, DOI 10.1111/j.1445 5994.2006.01154.x
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dominici M, 2009, BLOOD, V114, P2333, DOI 10.1182/blood 2008 10 183459
   Ebeling PR, 1999, J BONE MINER RES, V14, P342, DOI 10.1359/jbmr.1999.14.3.342
   Gandhi MK, 2003, BRIT J HAEMATOL, V121, P462, DOI 10.1046/j.1365 2141.2003.04303.x
   Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040 8428(11)70003 8
   Grigg AP, 2006, J CLIN ENDOCR METAB, V91, P3835, DOI 10.1210/jc.2006 0684
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hari P, 2013, BIOL BLOOD MARROW TR, V19, P1361, DOI 10.1016/j.bbmt.2013.06.015
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Ito R, 2012, EXP HEMATOL, V40, P953, DOI 10.1016/j.exphem.2012.07.002
   Jones D, 2011, J CLIN INVEST, V121, P2534, DOI 10.1172/JCI46262
   Lee WY, 2004, BONE MARROW TRANSPL, V34, P89, DOI 10.1038/sj.bmt.1704535
   Lee WY, 2002, J CLIN ENDOCR METAB, V87, P329, DOI 10.1210/jc.87.1.329
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Lymperi S, 2011, BLOOD, V117, P1540, DOI 10.1182/blood 2010 05 282855
   Mansour A, 2012, J EXP MED, V209, P537, DOI 10.1084/jem.20110994
   Martin TJ, 2008, BEST PRACT RES CL EN, V22, P701, DOI 10.1016/j.beem.2008.07.006
   McClune BL, 2011, BONE MARROW TRANSPL, V46, P1, DOI 10.1038/bmt.2010.198
   Morgan GJ, 2011, LANCET ONCOL, V12, P743, DOI 10.1016/S1470 2045(11)70157 7
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Park SI, 2012, CANCER RES, V72, P2522, DOI 10.1158/0008 5472.CAN 11 2928
   Purton LE, 2007, CELL STEM CELL, V1, P263, DOI 10.1016/j.stem.2007.08.016
   Rossini M, 2012, J BONE MINER RES, V27, P227, DOI 10.1002/jbmr.521
   Schepers K, 2012, BLOOD, V120, P3425, DOI 10.1182/blood 2011 11 395418
   Sul OJ, 2012, J CELL PHYSIOL, V227, P1619, DOI 10.1002/jcp.22879
   Tauchmanovà L, 2005, J CLIN ENDOCR METAB, V90, P627, DOI 10.1210/jc.2004 0509
   Tauchmanovà L, 2003, OSTEOPOROSIS INT, V14, P1013, DOI 10.1007/s00198 003 1520 2
   Weilbaecher KN, 2000, BIOL BLOOD MARROW TR, V6, P165, DOI 10.1016/S1083 8791(00)70039 5
   Winkler IG, 2012, LEUKEMIA, V26, P1594, DOI 10.1038/leu.2012.17
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Yadav A, 2010, CLIN CHIM ACTA, V411, P1570, DOI 10.1016/j.cca.2010.07.006
NR 36
TC 36
Z9 38
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2015
VL 30
IS 5
BP 886
EP 897
DI 10.1002/jbmr.2415
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG2JQ
UT WOS:000353101100013
PM 25418357
OA Bronze
DA 2025 08 17
ER

PT J
AU Ebner, JK
   König, GM
   Kostenis, E
   Siegert, P
   Aktories, K
   Orth, JHC
AF Ebner, Julia K.
   Koenig, Gabriele M.
   Kostenis, Evi
   Siegert, Peter
   Aktories, Klaus
   Orth, Joachim H. C.
TI Activation of Gq signaling by Pasteurella multocida
   toxin inhibits the osteoblastogenic like actions of Activin A in C2C12
   myoblasts, a cell model of fibrodysplasia ossificans progressiva
SO BONE
LA English
DT Article
DE Osteoblast differentiation; FOP; BMP; Activin A; Alk2; Smad
ID HETEROTRIMERIC G PROTEINS; DIFFERENTIATION; G ALPHA(Q)
AB The human disease fibrodysplasia ossificans progressiva (FOP) is a rare and highly disabling disorder of extensive heterotopic bone growth that is caused by a point mutation (R206H) in the activation domain of Alk2, a BMP (bone morphogenic protein) type 1 receptor. The mutation leads to extensive BMP signaling induced by Activin A, which is normally an antagonist for wildtype receptors, resulting in excessive and uncontrolled bone formation. Here, we studied the effects of Pasteurella multocida toxin (PMT), which activates osteoclasts and inhibits osteoblast activity, in C2C12 myoblasts expressing the mutant Alk2(R206H) receptor as model of FOP. In our study, we mainly used alkaline phosphatase (ALP) activity as marker to determine osteoblast differentiation.
   BMP 4 stimulated an increase in ALP activity in C2C12 Alk2wt and C2C12 Alk2(R206H) cells. By contrast, Activin A only induced ALP activity in C2C12 Alk2(R206H) cells. In both cases, PMT acted as a potent inhibitor of ALP activity. PMT induced inhibition of ALP activity was paralleled by a constitutive activation of the heterotrimeric G(q) protein. Expression of a permanently active G alpha(q) blocked Activin A/Alk2(R206H) dependent increase in ALP activity. Inactivation of G(q) by specific inhibitor FR900359 blocked the PMT effect. Similarly, canonical second messengers and effectors of G alpha(q) (e.g. ionophore A23187 induced increase in intracellular Ca2+ and activation of PKC by PMA (phorbol 12 myristate 13 acetate)) inhibited Alk2(R206H) mediated induction of ALP activity. Notably, Activin A induced increase in ALP activity in C2C12 Alk2(R206H) cells was also inhibited by stimulation of the alpha(1A) adrenoceptor, which couples to G alpha(q), by phenylephrine. PMT did not alter tail phosphorylation of the major downstream effectors of the Alk2 receptor, Smad1/5/9; neither did the toxin affect nuclear translocation of the Smad complex. However, PMT diminished BMP responsive element induced gene expression.
   The data indicate that PMT potently inhibits the induction of osteoblast markers in a FOP model via activation of G proteins. Moreover, our findings indicate that activation of G protein coupled receptors and of G protein signaling might be a rationale for pharmacological therapy of FOP.
C1 [Ebner, Julia K.; Siegert, Peter; Aktories, Klaus; Orth, Joachim H. C.] Univ Freiburg, Fac Med, Inst Expt & Clin Pharmacol & Toxicol, Albertstr 25, D 79104 Freiburg, Germany.
   [Ebner, Julia K.] Univ Freiburg, Fac Biol, Schanzlestr 1, D 79104 Freiburg, Germany.
   [Ebner, Julia K.; Aktories, Klaus] Univ Freiburg, Spemann Grad Sch Biol & Med, Albertstr 19A, D 79104 Freiburg, Germany.
   [Koenig, Gabriele M.; Kostenis, Evi] Univ Bonn, Inst Pharmaceut Biol, Mol Cellular & Pharmacobiol Sect, Nussallee 6, D 53115 Bonn, Germany.
   [Aktories, Klaus] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Schanzlestr 18, D 79104 Freiburg, Germany.
C3 University of Freiburg; University of Freiburg; University of Freiburg;
   University of Bonn
RP Aktories, K (通讯作者)，Univ Freiburg, Fac Med, Inst Expt & Clin Pharmacol & Toxicol, Albertstr 25, D 79104 Freiburg, Germany.
EM klaus.aktories@pharmakol.uni freiburg.de
RI ; Aktories, Klaus/CAJ 5682 2022
OI Aktories, Klaus/0000 0002 5397 0436; 
FU Deutsche Forschungsgemeinschaft (DFG) [FOR2372/1, FOR2372/6, OR218]
FX We thank Dr. Y. Horiguchi (Osaka University, Japan) for deamidation
   specific antibody, Prof. T. Brummer (University of Freiburg, Germany)
   for pFRIPZ vector and Prof. A. Hecht and Patrick Frey (University of
   Freiburg, Germany) for pGL3 BREmut and empty pGL3 vectors. Further, we
   thank Petra Barthlome and SiIke Fieber for excellent technical
   assistance. The study was financially supported by the Deutsche
   Forschungsgemeinschaft (DFG, OR218). E.K. and G.M.K. were supported by
   the Deutsche Forschungsgemeinschaft (DFG, FOR2372/1 and FOR2372/6).
CR BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846
   Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628 3634.2001
   Glaser DL, 2005, CLIN REV BONE MINER, V3, P243, DOI 10.1385/BMM:3:3 4:243
   Gregson CL, 2011, BONE, V48, P654, DOI 10.1016/j.bone.2010.10.164
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Hino K, 2015, P NATL ACAD SCI USA, V112, P15438, DOI 10.1073/pnas.1510540112
   Jeong HM, 2012, BBA MOL CELL RES, V1823, P1225, DOI 10.1016/j.bbamcr.2012.05.018
   Kamitani S, 2011, FEBS J, V278, P2702, DOI 10.1111/j.1742 4658.2011.08197.x
   KAMP EM, 1988, AM J VET RES, V49, P1844
   Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007
   Kaplan FS, 2005, CLIN REV BONE MINER, V3, P213, DOI 10.1385/BMM:3:3 4:213
   Kaplan FS, 2012, DIS MODEL MECH, V5, P756, DOI 10.1242/dmm.010280
   Kaplan Frederick S, 2009, Hum Mutat, V30, P379, DOI 10.1002/humu.20868
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287 136 1 81
   Nakura A, 2011, BONE, V48, P476, DOI 10.1016/j.bone.2010.09.238
   Ogata N, 2007, J BIOL CHEM, V282, P35757, DOI 10.1074/jbc.M611902200
   Orth JHC, 2005, J BIOL CHEM, V280, P36701, DOI 10.1074/jbc.M507203200
   Orth JHC, 2013, FASEB J, V27, P832, DOI 10.1096/fj.12 213900
   Orth JHC, 2010, TOXINS, V2, P205, DOI 10.3390/toxins2020205
   Orth JHC, 2009, P NATL ACAD SCI USA, V106, P7179, DOI 10.1073/pnas.0900160106
   Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304 3940(02)01423 4
   Rao XY, 2013, J COMPUT BIOL, V20, P703, DOI 10.1089/cmb.2012.0279
   ROBISON R, 1991, CLIN ORTHOP RELAT R, P2
   Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Siegert P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003385
   Strack J, 2014, MBIO, V5, DOI 10.1128/mBio.02190 14
   Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445
   Wilkie IW, 2012, CURR TOP MICROBIOL, V361, P1, DOI 10.1007/82_2012_216
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0
NR 33
TC 10
Z9 10
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2019
VL 127
BP 592
EP 601
DI 10.1016/j.bone.2019.07.031
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IU2ZR
UT WOS:000483449000068
PM 31376533
DA 2025 08 17
ER

PT J
AU Shimizu, R
   Sukegawa, S
   Sukegawa, Y
   Hasegawa, K
   Ono, S
   Nakamura, T
   Fujimura, A
   Fujisawa, A
   Nakano, K
   Takabatake, K
   Kawai, H
   Nagatsuka, H
   Furuki, Y
AF Shimizu, Rieko
   Sukegawa, Shintaro
   Sukegawa, Yuka
   Hasegawa, Kazuaki
   Ono, Sawako
   Nakamura, Tomoya
   Fujimura, Ai
   Fujisawa, Ayaka
   Nakano, Keisuke
   Takabatake, Kiyofumi
   Kawai, Hotaka
   Nagatsuka, Hitoshi
   Furuki, Yoshihiko
TI Incidence and Risk of Anti Resorptive Agent Related Osteonecrosis of the
   Jaw after Tooth Extraction: A Retrospective Study
SO HEALTHCARE
LA English
DT Article
DE anti resorptive agent related osteonecrosis of the jaw; bisphosphonate;
   denosumab; retrospective study; risk factor; tooth extraction
ID BISPHOSPHONATE RELATED OSTEONECROSIS; MEDICATION RELATED OSTEONECROSIS;
   POSITION PAPER; DIAGNOSIS; COMMITTEE; BONE
AB Bone modifying agents (BMA) such as bisphosphonates and denosumab are frequently used for the treatment of bone metastases, osteoporosis, and multiple myeloma. BMA may lead to anti resorptive agent related osteonecrosis of the jaw (ARONJ). This study aimed to clarify the risk factors for and probabilities of developing ARONJ after tooth extraction in patients undergoing BMA therapy. In this study, the records of 505 target sites of 302 patients undergoing BMA who presented with mandibular fractures at the Department of Oral and Maxillofacial Surgery, Kagawa Prefectural Central Hospital, from March 2014 to January 2022, were retrospectively analyzed for the onset of ARONJ after tooth extraction. The following variables were investigated as attributes: anatomy, health status, and dental treatment. The correlation coefficient was calculated for the success or failure of endodontic surgery for each variable, the odds ratio was calculated for the upper variable, and the factors related to the onset of ARONJ were identified. The incidence rate of ARONJ was found to be 3.2%. Hypoparathyroidism was an important factor associated with ARONJ development. Thus, systemic factors are more strongly related to the onset of ARONJ after tooth extraction than local factors.
C1 [Shimizu, Rieko; Sukegawa, Shintaro; Sukegawa, Yuka; Hasegawa, Kazuaki; Nakamura, Tomoya; Fujimura, Ai; Fujisawa, Ayaka; Furuki, Yoshihiko] Kagawa Prefectural Cent Hosp, Dept Oral & Maxillofacial Surg, Takamatsu, Kagawa 7608557, Japan.
   [Sukegawa, Shintaro; Nakano, Keisuke; Takabatake, Kiyofumi; Kawai, Hotaka; Nagatsuka, Hitoshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Pathol & Med, Okayama 7008525, Japan.
   [Ono, Sawako] Kagawa Prefectural Cent Hosp, Dept Pathol, Takamatsu, Kagawa 7608557, Japan.
C3 Okayama University
RP Sukegawa, S (通讯作者)，Kagawa Prefectural Cent Hosp, Dept Oral & Maxillofacial Surg, Takamatsu, Kagawa 7608557, Japan.; Sukegawa, S (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Pathol & Med, Okayama 7008525, Japan.
EM de421021@s.okayama u.ac.jp; gouwan19@gmail.com; yuka611225@gmail.com;
   de421040@s.okayama u.ac.jp; de19008@s.okayama u.ac.jp;
   tmy.nakamura@s.okayama u.ac.jp; sugar.x.48@gmail.com;
   ayafuji05@gmail.com; pir19btp@okayama u.ac.jp;
   gmd422094@s.okayama u.ac.jp; de18018@s.okayama u.ac.jp;
   jin@md.okayama u.ac.jp; furukiy@ma.pikara.ne.jp
RI Sukegawa, Shintaro/AAI 2176 2019
OI Sukegawa, Shintaro/0000 0001 7986 2735; Rieko,
   Shimizu/0000 0002 9562 016X; Nakano, Keisuke/0000 0001 8316 8543
FU JSPS KAKENHI [JP19K19158, JP20K10178, JP20K10094, JP20H03888,
   JP21K10043, JP21K17089]
FX This work was supported by JSPS KAKENHI (grant number JP19K19158,
   JP20K10178, JP20K10094, JP20H03888, JP21K10043, JP21K17089).
CR Abate EG, 2017, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00172
   Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379
   [Anonymous], 1968, World Health Organ Tech Rep Ser, V405, P5
   Badescu MC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020640
   Bagan L, 2017, MED ORAL PATOL ORAL, V22, pE582, DOI 10.4317/medoral.22133
   Beth Tasdogan NH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012432.pub2
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kuo PI, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80622 5
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09 9033
   Otto S, 2020, J BONE MINER RES, V35, P2179, DOI 10.1002/jbmr.4119
   Rubin MR, 2011, J BONE MINER RES, V26, P2727, DOI 10.1002/jbmr.452
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Starr JR, 2020, OSTEOPOROSIS INT, V31, P327, DOI 10.1007/s00198 019 05177 2
   Sukegawa S, 2022, MATERIALS, V15, DOI 10.3390/ma15093353
   Sukegawa S, 2016, J HARD TISSUE BIOL, V25, P447, DOI 10.2485/jhtb.25.447
   Sukegawa S, 2016, J ORAL MAX SURG MED, V28, P255, DOI 10.1016/j.ajoms.2015.10.001
   Van Poznak CH, 2021, JAMA ONCOL, V7, P246, DOI 10.1001/jamaoncol.2020.6353
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
NR 19
TC 1
Z9 1
U1 1
U2 6
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9032
J9 HEALTHCARE BASEL
JI Healthcare
PD JUL
PY 2022
VL 10
IS 7
AR 1332
DI 10.3390/healthcare10071332
PG 8
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA 3G8NS
UT WOS:000831605200001
PM 35885858
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huang, M
   Zhou, JX
   Li, XX
   Liu, R
   Jiang, YZ
   Chen, KX
   Jiao, YR
   Yin, X
   Liu, L
   Sun, YC
   Wang, WS
   Xiao, Y
   Su, T
   Guo, Q
   Huang, Y
   Yang, M
   Wei, J
   Quarles, LD
   Xiao, ZS
   Zeng, C
   Luo, XH
   Lei, GH
   Li, CJ
AF Huang, Mei
   Zhou, Jingxuan
   Li, Xiaoxiao
   Liu, Ran
   Jiang, Yangzi
   Chen, Kaixuan
   Jiao, Yurui
   Yin, Xin
   Liu, Ling
   Sun, Yuchen
   Wang, Weishan
   Xiao, Ye
   Su, Tian
   Guo, Qi
   Huang, Yan
   Yang, Mi
   Wei, Jie
   Quarles, L. Darryl
   Xiao, Zhousheng
   Zeng, Chao
   Luo, Xianghang
   Lei, Guanghua
   Li, Changjun
TI Mechanical protein polycystin 1 directly regulates osteoclastogenesis
   and bone resorption
SO SCIENCE BULLETIN
LA English
DT Article
DE Polycystin1; Osteoclastogenesis; Bone resorption; Mechanical stress
ID MICROGRAVITY; STIMULATION; PKD1; DIFFERENTIATION; SKELETOGENESIS;
   EXPRESSION; DELETION; CELLS
AB Mechanical loading is required for bone homeostasis, but the underlying mechanism is still unclear. Our previous studies revealed that the mechanical protein polycystin 1 (PC1, encoded by Pkd1 ) is critical for bone formation. However, the role of PC1 in bone resorption is unknown. Here, we found that PC1 directly regulates osteoclastogenesis and bone resorption. The conditional deletion of Pkd1 in the osteoclast lineage resulted in a reduced number of osteoclasts, decreased bone resorption, and increased bone mass. A cohort study of 32,500 patients further revealed that autosomal dominant polycystic kidney disease, which is mainly caused by loss  of  function mutation of the PKD1 gene, is associated with a lower risk of hip fracture than those with other chronic kidney diseases. Moreover, mice with osteoclastspecific knockout of Pkd1 showed complete resistance to unloading  induced bone loss. A mechanistic study revealed that PC1 facilitated TAZ nuclear translocation via the C  terminal tail TAZ complex and that conditional deletion of Taz in the osteoclast lineage resulted in reduced osteoclastogenesis and increased bone mass. Pharmacological regulation of the PC1 TAZ axis alleviated unloading  and estrogen deficiency  induced bone loss. Thus, the PC1 TAZ axis may be a potential therapeutic target for osteoclast related osteoporosis. (c) 2024 Science China Press. Published by Elsevier B.V. and Science China Press. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This is an open access article under the CC BY  NC  ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Huang, Mei; Zhou, Jingxuan; Liu, Ran; Chen, Kaixuan; Jiao, Yurui; Yin, Xin; Liu, Ling; Sun, Yuchen; Xiao, Ye; Su, Tian; Guo, Qi; Huang, Yan; Yang, Mi; Luo, Xianghang; Li, Changjun] Cent South Univ, Xiangya Hosp, Endocrinol Res Ctr, Dept Endocrinol, Changsha 410008, Peoples R China.
   [Li, Xiaoxiao; Wei, Jie; Zeng, Chao; Lei, Guanghua] Hunan Key Lab Joint Degenerat & Injury, Changsha 410008, Peoples R China.
   [Li, Xiaoxiao; Wei, Jie; Zeng, Chao; Luo, Xianghang; Lei, Guanghua; Li, Changjun] Cent South Univ, Xiangya Hosp, Key Lab Aging related Bone & Joint Dis Prevent & T, Minist Educ, Changsha 410008, Peoples R China.
   [Jiang, Yangzi] Chinese Univ Hong Kong, Inst Tissue Engn & Regenerat Med, Sch Biomed Sci, Fac Med, Hong Kong 999077, Peoples R China.
   [Jiang, Yangzi] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Key Lab Regenerat Med,Minist Educ, Hong Kong 999077, Peoples R China.
   [Jiang, Yangzi] Chinese Univ Hong Kong, Ctr Neuromusculoskeletal Restorat Med CNRM, Hong Kong 999077, Peoples R China.
   [Wang, Weishan] Shihezi Univ, Affiliated Hosp 1, Dept Orthopaed, Shihezi 832061, Peoples R China.
   [Wei, Jie; Zeng, Chao; Lei, Guanghua] Cent South Univ, Xiangya Hosp, Dept Orthopaed, Changsha 410008, Peoples R China.
   [Wei, Jie] Cent South Univ, XiangYa Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha 410008, Peoples R China.
   [Quarles, L. Darryl; Xiao, Zhousheng] Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38163 USA.
   [Zeng, Chao; Luo, Xianghang; Lei, Guanghua; Li, Changjun] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Peoples R China.
   [Li, Changjun] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Peoples R China.
C3 Central South University; Central South University; Chinese University
   of Hong Kong; Chinese University of Hong Kong; Chinese University of
   Hong Kong; Shihezi University; Central South University; Central South
   University; University of Tennessee System; University of Tennessee
   Health Science Center; Central South University; Central South
   University
RP Luo, XH; Li, CJ (通讯作者)，Cent South Univ, Xiangya Hosp, Endocrinol Res Ctr, Dept Endocrinol, Changsha 410008, Peoples R China.; Zeng, C; Lei, GH (通讯作者)，Hunan Key Lab Joint Degenerat & Injury, Changsha 410008, Peoples R China.; Zeng, C; Luo, XH; Lei, GH; Li, CJ (通讯作者)，Cent South Univ, Xiangya Hosp, Key Lab Aging related Bone & Joint Dis Prevent & T, Minist Educ, Changsha 410008, Peoples R China.; Zeng, C; Lei, GH (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Orthopaed, Changsha 410008, Peoples R China.; Zeng, C; Luo, XH; Lei, GH; Li, CJ (通讯作者)，Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Peoples R China.; Li, CJ (通讯作者)，Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Peoples R China.
EM zengchao@csu.edu.cn; xianghangluo@csu.edu.cn; lei_guanghua@csu.edu.cn;
   lichangjun@csu.edu.cn
RI Wei, Jie/ACR 8087 2022; zhou, jingxuan/GZM 6373 2022; Jiang,
   Yangzi/AAY 9232 2020; Guo, Qi/KCK 4678 2024; Jiao, Yurui/I 9626 2018;
   Wang, Weishan/C 4493 2018; Jiang, Yangzi/S 3571 2018; Li,
   xiaoxiao/JXY 6371 2024
OI Jiang, Yangzi/0000 0002 7475 3182; Li, Changjun/0000 0003 2718 0921; 
FU National Key Research and Development Program of China [2019YFA0111900,
   2022YFC3601900, 2022YFC2505500]; National Natural Science Foundation of
   China [82261160397, 82272560, 81922017, 92149306, 82120108009,
   N_CUHK483/22]; NSFC/RGC Joint Research Scheme; Research Grants Council
   (UGC) of the Hong Kong Special Administrative Region; Center for
   Neuromusculoskeletal Restorative Medicine by Innovation and Technology
   Commission (ITC) of Hong Kong SAR, China (CNRM at InnoHK); National
   Institutes of Health [R61 AR073518, R01 AR071930]; Key Research and
   Development Program of Hunan Province [2022SK2023]; Science and
   Technology Innovation Program of Hunan Province [2023RC1027, 2022RC1009,
   2022RC3075]; Hunan Provincial Science and Technology Department
   [2023JJ30896]
FX This work was supported by the National Key Research and Development
   Program of China (2019YFA0111900, 2022YFC3601900 and 2022YFC2505500),
   the National Natural Science Foundation of China (82261160397, 82272560,
   81922017, 92149306 and 82120108009), the NSFC/RGC Joint Research Scheme,
   the Research Grants Council (UGC) of the Hong Kong Special
   Administrative Region and the National Natural Science Foundation of
   China (N_CUHK483/22), the Center for Neuromusculoskeletal Restorative
   Medicine by Innovation and Technology Commission (ITC) of Hong Kong SAR,
   China (CNRM at InnoHK), the National Institutes of Health (R61 AR073518
   and R01 AR071930), the Key Research and Development Program of Hunan
   Province (2022SK2023), the Science and Technology Innovation Program of
   Hunan Province (2023RC1027, 2022RC1009 and 2022RC3075), and the Hunan
   Provincial Science and Technology Department (2023JJ30896).
CR Alexandre C, 2011, JOINT BONE SPINE, V78, P572, DOI 10.1016/j.jbspin.2011.04.007
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bratengeier C, 2020, FASEB J, V34, P3755, DOI 10.1096/fj.201901458R
   Chen MM, 2020, BIOACT MATER, V5, P880, DOI 10.1016/j.bioactmat.2020.05.004
   Chen YJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.803880
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dalagiorgou G, 2017, CELL MOL LIFE SCI, V74, P921, DOI 10.1007/s00018 016 2394 8
   Dalagiorgou G, 2013, CELL MOL LIFE SCI, V70, P167, DOI 10.1007/s00018 012 1164 5
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Ethiraj P, 2018, J CELL BIOCHEM, V119, P5696, DOI 10.1002/jcb.26750
   Evenepoel P, 2019, KIDNEY INT, V95, P412, DOI 10.1016/j.kint.2018.09.018
   Feng H, 2020, J CLIN INVEST, V130, P6354, DOI 10.1172/JCI132518
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gargalionis AN, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092182
   Garrett Bakelman FE, 2019, SCIENCE, V364, P144, DOI 10.1126/science.aau8650
   Gitomer B, 2021, KIDNEY INT, V99, P977, DOI 10.1016/j.kint.2020.07.041
   HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695 151
   Jaul E, 2009, J AM GERIATR SOC, V57, P1318, DOI 10.1111/j.1532 5415.2009.02334.x
   Kaji T, 2007, BONE, V40, P1088, DOI 10.1016/j.bone.2006.11.018
   Li CJ, 2021, CELL METAB, V33, P1957, DOI 10.1016/j.cmet.2021.08.009
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li P, 2018, CELL CALCIUM, V71, P45, DOI 10.1016/j.ceca.2017.12.001
   MacKay CE, 2022, ELIFE, V11, DOI 10.7554/eLife.74765
   Merrick D, 2019, HUM MOL GENET, V28, P16, DOI 10.1093/hmg/ddy322
   Merrick D, 2012, DEV CELL, V22, P197, DOI 10.1016/j.devcel.2011.10.028
   Nabavi N, 2011, BONE, V49, P965, DOI 10.1016/j.bone.2011.07.036
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Nauli SM, 2006, J AM SOC NEPHROL, V17, P1015, DOI 10.1681/ASN.2005080830
   Nigro EA, 2021, AM J PHYSIOL RENAL, V320, pF693, DOI 10.1152/ajprenal.00545.2020
   Oppl B, 2014, J BONE MINER RES, V29, P1096, DOI 10.1002/jbmr.2122
   Peng H, 2022, CELL METAB, V34, P1168, DOI 10.1016/j.cmet.2022.05.009
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Sambandam Y, 2014, BONE, V61, P125, DOI 10.1016/j.bone.2014.01.004
   Saxena R, 2011, J BONE MINER METAB, V29, P111, DOI 10.1007/s00774 010 0201 4
   Shalish M, 2014, ANGLE ORTHOD, V84, P885, DOI 10.2319/082313 620.1
   Shanmugarajan S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112443
   Stavnichuk M, 2020, NPJ MICROGRAVITY, V6, DOI 10.1038/s41526 020 0103 2
   Sun WJ, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 04806 1
   Sutor TW, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020608
   Tamma R, 2009, FASEB J, V23, P2549, DOI 10.1096/fj.08 127951
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Torres VE, 2019, NAT REV NEPHROL, V15, P70, DOI 10.1038/s41581 018 0108 1
   VANADELSBERG JS, 1995, NAT MED, V1, P359, DOI 10.1038/nm0495 359
   Vico L, 2018, NAT REV RHEUMATOL, V14, P229, DOI 10.1038/nrrheum.2018.37
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang QX, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13172
   Xiang SY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004405
   Xiao ZS, 2008, J BIOL CHEM, V283, P12624, DOI 10.1074/jbc.M710407200
   Xiao ZS, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00295 4
   Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200
   Xiao ZS, 2018, J CLIN INVEST, V128, P157, DOI 10.1172/JCI93725
   Xiao ZS, 2011, FASEB J, V25, P2418, DOI 10.1096/fj.10 180299
   Xiao ZS, 2010, J BIOL CHEM, V285, P1177, DOI 10.1074/jbc.M109.050906
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yang WL, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00151 3
   Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
   Zhao HY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00627 y
NR 59
TC 5
Z9 6
U1 18
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095 9273
EI 2095 9281
J9 SCI BULL
JI Sci. Bull.
PD JUN 30
PY 2024
VL 69
IS 12
BP 1964
EP 1979
DI 10.1016/j.scib.2024.04.044
EA JUN 2024
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA XL7P9
UT WOS:001261908000001
PM 38760248
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Margiotta, N
   Ostuni, R
   Piccinonna, S
   Natile, G
   Zanellato, I
   Boidi, CD
   Bonarrigo, I
   Osella, D
AF Margiotta, Nicola
   Ostuni, Rosa
   Piccinonna, Sara
   Natile, Giovanni
   Zanellato, Ilaria
   Boidi, Carla Doriana
   Bonarrigo, Ilaria
   Osella, Domenico
TI Platinum bisphosphonate complexes have proven to be inactive
   chemotherapeutics targeted for malignant mesothelioma because of
   inappropriate hydrolysis
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Bisphosphonates; Malignant mesothelioma; Platinum complexes; Drug
   targeting and delivery; Bifunctional drug candidates
ID NITROGEN CONTAINING BISPHOSPHONATES; CELLS IN VITRO; ANTITUMOR ACTIVITY;
   CANCER CELLS; CISPLATIN; DRUGS; CIS 1,4 DIAMINOCYCLOHEXANE;
   NANOCRYSTALS; EXPRESSION; DELIVERY
AB Bisphosphonates (Bps), the synthetic analogues of pyrophosphate, are widely used in the treatment of metabolic bone diseases. BPs exhibit a preferential accumulation in malignant pleural mesothelioma (MPM) and, furthermore, nitrogen containing BPs (n BPs) show significant inhibition of MPM cell proliferation. We synthesised dinuclear platinum(II) complexes containing a n BP moiety as bridging ligand and am(m)ines as terminal ligands (Pt n BP)s, with the aim of obtaining bifunctional mesothelioma targeted drugs. We compared the antiproliferative effect of the single drugs (i.e. Pt model and n BPS) with that of the preformed Pt n BP complexes by means of the combination index (CI) in order to assess the synergistic/additive/antagonistic effect of the two constituents in the resulting conjugates. The combination of the two individual drugs was almost additive, while the preformed Pt n BP produced an antagonistic effect. Furthermore, (Pt n BP)s neither inhibited the mevalonate pathway (as n BPs normally do) nor increased the Pt uptake. The minimal biological results of these conjugates could be traced back to a slow and inappropriate hydrolysis, that does not split the adduct into active components. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Margiotta, Nicola; Ostuni, Rosa; Piccinonna, Sara; Natile, Giovanni] Univ Bari A Moro, Dipartimento Farmacochim, I 70125 Bari, Italy.
   [Zanellato, Ilaria; Boidi, Carla Doriana; Bonarrigo, Ilaria; Osella, Domenico] Univ Piemonte Orientale, Dipartimento Sci Ambiente & Vita, I 15125 Alessandria, Italy.
C3 Universita degli Studi di Bari Aldo Moro; University of Eastern Piedmont
   Amedeo Avogadro
RP Natile, G (通讯作者)，Univ Bari A Moro, Dipartimento Farmacochim, Via E Orabona 4, I 70125 Bari, Italy.
EM domenico.osella@mfn.unipmn.it
RI osella, domenico/E 6389 2015; Margiotta, Nicola/AAE 3975 2021;
   Zanellato, Ilaria/F 7831 2011; Zanellato, Ilaria/X 8704 2019
OI osella, domenico/0000 0002 6706 9454; Margiotta,
   Nicola/0000 0003 4034 875X; Zanellato, Ilaria/0000 0003 2174 508X;
   Natile, Giovanni/0000 0002 1790 6365; 
FU European Union (COST) [D39]; Regione Piemonte (CIPE) [A370];
   Inter University Consortium for Research on the Chemistry of Metal Ions
   in Biological Systems (C.I.R.C.M.S.B., Bari)
FX We are indebted to Prof. P. G. Betta (Mesothelioma Biobank Regional
   Reference Center, Alessandria National Hospital) for providing MPM cell
   lines. We acknowledge the Italian Ministero dell'Universita e della
   Ricerca (MiUR), the European Union (COST D39/Metallo Drug Design and
   Action), the Ambiente Territorio Formazione Association (ATF,
   Alessandria), and the Regione Piemonte (CIPE project code A370). I.B.
   thanks the Inter University Consortium for Research on the Chemistry of
   Metal Ions in Biological Systems (C.I.R.C.M.S.B., Bari) for a research
   grant.
CR ADAMS VI, 1986, CANCER AM CANCER SOC, V58, P1540, DOI 10.1002/1097 0142(19861001)58:7<1540::AID CNCR2820580727>3.0.CO;2 5
   Berners Price SJ, 2006, PROG NUCL MAG RES SP, V49, P65, DOI 10.1016/j.pnmrs.2006.05.002
   Casolaro M, 2006, BIOMACROMOLECULES, V7, P3417, DOI 10.1021/bm0607630
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   FELTHAM RD, 1964, J CHEM SOC, P4587, DOI 10.1039/jr9640004587
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Ghezzi A, 2004, J INORG BIOCHEM, V98, P73, DOI 10.1016/j.jinorgbio.2003.08.014
   HOESCHELE JD, 1994, J MED CHEM, V37, P2630, DOI 10.1021/jm00043a003
   Iafisco M, 2009, J MATER CHEM, V19, P8385, DOI 10.1039/b914379c
   Kasparkova J, 2010, BIOCHEM PHARMACOL, V79, P552, DOI 10.1016/j.bcp.2009.09.019
   Kindler HL, 2008, CURR TREAT OPTION ON, V9, P171, DOI 10.1007/s11864 008 0071 3
   Lee YA, 1997, J INORG BIOCHEM, V68, P289, DOI 10.1016/S0162 0134(97)00109 8
   MANTEL N, 1958, ANN NY ACAD SCI, V76, P909, DOI 10.1111/j.1749 6632.1958.tb54909.x
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Margiotta N, 2009, DALTON T, P10904, DOI 10.1039/b919721d
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   Merrell MA, 2007, EUR J PHARMACOL, V570, P27, DOI 10.1016/j.ejphar.2007.05.075
   Monti E, 2005, J MED CHEM, V48, P857, DOI 10.1021/jm049508t
   OLIVER MH, 1989, J CELL SCI, V92, P513
   Orecchia S, 2004, LUNG CANCER, V45, pS37, DOI 10.1016/j.lungcan.2004.04.027
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Ranaldo R, 2008, INORG CHEM, V47, P2820, DOI 10.1021/ic702202x
   Ray M, 2009, CHEST, V136, P888, DOI 10.1378/chest.08 2665
   Reidman D, 2006, CLIN NUCL MED, V31, P71, DOI 10.1097/01.rlu.0000195917.56036.cd
   Rochon FD, 2005, INORG CHIM ACTA, V358, P2040, DOI 10.1016/j.ica.2004.12.030
   Rochon FD, 2000, INORG CHIM ACTA, V306, P193, DOI 10.1016/S0020 1693(00)00171 7
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SANDLER ED, 1994, J NUCL MED, V35, P429
   Shamsuddin S, 1996, J INORG BIOCHEM, V61, P291, DOI 10.1016/0162 0134(95)00084 4
   Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174
   Tanabe Y, 1998, CLIN NUCL MED, V23, P180, DOI 10.1097/00003072 199803000 00017
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Toma S, 2002, J CELL PHYSIOL, V193, P37, DOI 10.1002/jcp.10150
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Wakchoure S, 2006, CLIN CANCER RES, V12, P2862, DOI 10.1158/1078 0432.CCR 05 2766
   Zanellato I, 2011, CANCER CHEMOTH PHARM, V67, P265, DOI 10.1007/s00280 010 1314 0
NR 37
TC 20
Z9 23
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0162 0134
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD APR
PY 2011
VL 105
IS 4
BP 548
EP 557
DI 10.1016/j.jinorgbio.2010.12.011
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 768GW
UT WOS:000290923000007
PM 21334282
DA 2025 08 17
ER

PT J
AU Luedders, DW
   Steinhoff, J
   Thill, M
   Rody, A
   Bohlmann, MK
AF Luedders, Doerte W.
   Steinhoff, Juergen
   Thill, Marc
   Rody, Achim
   Bohlmann, Michael K.
TI Lack of Difference in Acute Nephrotoxicity of Intravenous
   Bisphosphonates Zoledronic Acid and Ibandronate in Women with Breast
   Cancer and Bone Metastases
SO ANTICANCER RESEARCH
LA English
DT Article
DE Nephrotoxicity; ibandronate; zoledronic acid; breast cancer; metastases
ID RENAL SAFETY; SKELETAL COMPLICATIONS; MULTIPLE MYELOMA; DOUBLE BLIND;
   PAMIDRONATE; HYPERCALCEMIA; MALIGNANCY; PROTEINS; EFFICACY; EVENTS
AB Background: More than 50% of patients with advanced breast cancer develop bone metastases that may lead to multiple complications such as pathological fractures, bone pain or hypercalcaemia. The standard treatment, besides endocrine, targeted therapy or chemotherapy, is the use of bisphosphonates. However, one of their main adverse side effects is bisphosphonate induced nephrotoxicity. The mechanism by which the latter occurs is not well understood, although emerging evidence suggests that the effect of bisphosphonates on the kidney may differ between agents. Patients and Methods: The aim of this evaluation was to compare the renal toxicity of 6 mg ibandronate i.v. versus 4 mg zoledronic acid i.v. over a period of six months in women with breast cancer and bone metastases. A prospective randomized trial was carried out to examine specific kidney and other parameters (alpha 1  and beta 2 microglobulin. albumin, alpha 2 macroglobulin, IgG and C reactive protein (CRP) generated from spontaneous urine samples from 17 patients of each group. Results: We were unable to find any significant difference between the two treatment groups with regard to renal toxicity. All patients, independently of the applied bisphosphonate, experienced only temporary renal dysfunction without any evidence of irreversible damage in terms of acute nephrotoxicity during the study period, alpha 1 Microglobulin, a marker for proximal tubular damage, in particular, was not differently elevated in either group. Conclusion: Both applied bisphosphonates were found to be well tolerated and safe with regard to renal toxicity during a six month treatment period in patients with otherwise healthy kidneys having advanced breast cancer and bone metastases.
C1 [Luedders, Doerte W.] Univ Hosp Oldenburg, Dept Obstet & Gynaecol, D 26133 Oldenburg, Germany.
   [Steinhoff, Juergen] Univ Hosp Schleswig Holstein, Dept Internal Med, Lubeck, Germany.
   [Luedders, Doerte W.; Rody, Achim; Bohlmann, Michael K.] Univ Hosp Schleswig Holstein, Dept Obstet & Gynaecol, Lubeck, Germany.
   [Thill, Marc] Agaplesion Markus Hosp, Dept Gynaecol & Obstet, Frankfurt, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; Schleswig Holstein University Hospital
RP Luedders, DW (通讯作者)，Univ Hosp Oldenburg, Dept Obstet & Gynaecol, Rahel Strauss Str 10, D 26133 Oldenburg, Germany.
EM doerte.luedders@gmx.de
FU Hoffmann La Roche Pharmaceuticals, Basel, Switzerland
FX The study was supported by an unrestricted grant from Hoffmann La Roche
   Pharmaceuticals, Basel, Switzerland.
CR [Anonymous], 2017, COCHRANE DB SYST REV
   Balla J, 2005, ONCOLOGIST, V10, P306, DOI 10.1634/theoncologist.10 5 306
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bodmer M, 2007, NEPHROL DIAL TRANSPL, V22, P2366, DOI 10.1093/ndt/gfm209
   Body JJ, 2005, ONCOLOGIST, V10, P3, DOI 10.1634/theoncologist.10 90001 3
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Bondronat, SUMM PROD CHAR
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Ding XY, 2012, BREAST, V21, P544, DOI 10.1016/j.breast.2012.04.008
   Edwards BJ, 2013, J ONCOL PRACT, V9, P101, DOI 10.1200/JOP.2011.000486
   Guder WG, 2008, SCAND J CLIN LAB INV, V68, P95, DOI 10.1080/00365510802150174
   Heidenreich A, 2002, PROSTATE CANCER P D, V5, P231, DOI 10.1038/sj.pcan.4500574
   Jackson GH, 2005, ONCOLOGIST, V10, P14, DOI 10.1634/theoncologist.10 90001 14
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Neugebauer G., 2001, P AN M AM SOC CLIN, V20, p122a
   Novartis International AG, 2005, ZOM ZOL AC EU SUMM P
   Novartis Pharmaceuticals Corporation, 2004, ZOM ZOL AC US SUMM P
   Pecherstorfer M, 2003, SUPPORT CARE CANCER, V11, P539, DOI 10.1007/s00520 003 0477 1
   Penders J, 2004, CLIN CHIM ACTA, V346, P107, DOI 10.1016/j.cccn.2004.03.037
   Pfister T, 2003, TOXICOLOGY, V191, P159, DOI 10.1016/S0300 483X(03)00257 9
   Ralston SH, 1997, BRIT J CANCER, V75, P295, DOI 10.1038/bjc.1997.48
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Steinhoff J, 1997, TRANSPLANTATION, V64, P443, DOI 10.1097/00007890 199708150 00013
   Tolia M, 2014, ANTICANCER RES, V34, P23
   von Moos R, 2008, ANN ONCOL, V19, P1266, DOI 10.1093/annonc/mdn038
   Von Moos R, 2005, ONCOLOGIST, V10, P19, DOI 10.1634/theoncologist.10 90001 19
   WOOD WG, 1990, ARZTL LAB, V36, P260
NR 35
TC 9
Z9 9
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAR
PY 2015
VL 35
IS 3
BP 1797
EP 1802
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CF3QF
UT WOS:000352462900077
PM 25750345
DA 2025 08 17
ER

PT J
AU Feng, XL
   Liu, ZJ
   Su, YA
   Lian, HY
   Gao, YJ
   Zhao, JM
   Xu, JK
   Liu, Q
   Song, FM
AF Feng, Xiaoliang
   Liu, Zhijuan
   Su, Yuangang
   Lian, Haoyu
   Gao, Yijie
   Zhao, Jinmin
   Xu, Jiake
   Liu, Qian
   Song, Fangming
TI Tussilagone inhibits osteoclastogenesis by modulating mitochondrial
   function and ROS production involved Nrf2 activation
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Mitochondria; ROS; Nrf2; Tussilagone; Osteoclast
ID NF KAPPA B; OXIDATIVE STRESS; GENE EXPRESSION; BONE RESORPTION;
   OSTEOPOROSIS; PATHWAY; COMPLEX; KINASE
AB Reactive Oxygen Species (ROS) play an essential role in the pathogenesis of osteoporosis mainly characterized by excessive osteoclasts (OCs) activity. OCs are rich in mitochondria for energy support, which is a major source of total ROS. Tussilagone (TSG), a natural Sesquiterpenes from the flower of Tussilago farfara, has plentiful bene ficial pharmacological characteristics with anti inflammatory and anti oxidative activity, but its effects and mechanism in osteopathology are still unclear. In our study, we investigated the regulation of ROS generated from the mitochondria in OCs. We found that TSG inhibited OCs differentiation and bone resorption without any cytotoxicity. Mechanistically, TSG reduced RANKL mediated total ROS level by down regulating intracellular ROS production and mitochondrial function, leading to the suppression of NFATc1 transcription. We also found that nuclear factor erythroid 2 related factor 2 (Nrf2) could enhance ROS scavenging enzymes in response to RANKL induced oxidative stress. Furthermore, TSG up regulated the expression of Nrf2 by inhibiting its pro teosomal degradation. Interestingly, Nrf2 deficiency reversed the suppressive effect of TSG on mitochondrial activity and ROS signaling in OCs. Consistent with this finding, TSG attenuated post ovariectomy (OVX) and lipopolysaccharide (LPS) induced bone loss by ameliorating osteoclastogenesis. Taken together, TSG has an anti bone resorptive effect by modulating mitochondrial function and ROS production involved Nrf2 activation.
C1 [Feng, Xiaoliang; Liu, Zhijuan; Su, Yuangang; Lian, Haoyu; Gao, Yijie; Zhao, Jinmin; Liu, Qian; Song, Fangming] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Guangxi Key Lab Regenerat Med Orthopaed Trauma & H, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Feng, Xiaoliang; Liu, Zhijuan; Su, Yuangang; Lian, Haoyu; Gao, Yijie; Zhao, Jinmin; Song, Fangming] Guangxi Med Univ, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Nanning, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, Australia.
   [Xu, Jiake] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; University of
   Western Australia; Chinese Academy of Sciences; Shenzhen Institute of
   Advanced Technology, CAS
RP Liu, Q; Song, FM (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Guangxi Key Lab Regenerat Med Orthopaed Trauma & H, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, Australia.
EM jiake.xu@uwa.edu.au; liuqian@gxmu.edu.cn; songfangming@gxmu.edu.cn
RI Liu, Zhijuan/AEA 8412 2022; zhao, jin/LBH 0351 2024; Lian,
   Haoyu/W 3317 2017; Su, Yuangang/KKU 6952 2024
OI Xu, Jiake/0000 0003 2021 8309
FU Natural Science Foundation of China [82060760, 82360175]; Natural
   Science Foundation of Guangxi Province [2023GXNSFFA026015]; General
   Program of National Natural Science Foundation of Guangxi Province
   [2023GXNSFDA026058]; Guangxi Science and Technology Base and Talent
   Special Project [GuikeAD19254003]; Nanning Qingxiu District Science and
   Technology Bureau Project [2020028]
FX This work was supported by grants from the Natural Science Foundation of
   China (82060760, 82360175) , the Natural Science Foundation of Guangxi
   Province (2023GXNSFFA026015) , The General Program of National Natural
   Science Foundation of Guangxi Province (2023GXNSFDA026058) , Guangxi
   Science and Technology Base and Talent Special Project (Grant No.
   GuikeAD19254003) . Nanning Qingxiu District Science and Technology
   Bureau Project (No.2020028).
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Ahmed SMU, 2017, BBA MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248
   Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Batoon L, 2021, J BONE MINER RES, V36, P2214, DOI 10.1002/jbmr.4413
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cadenas S, 2018, BBA BIOENERGETICS, V1859, P940, DOI 10.1016/j.bbabio.2018.05.019
   Chen DL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664836
   Cheon HJ, 2018, CHEM BIOL INTERACT, V294, P74, DOI 10.1016/j.cbi.2018.08.022
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Diab DL, 2014, EXPERT OPIN DRUG SAF, V13, P247, DOI 10.1517/14740338.2014.860133
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Dong J, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121742
   Fitzpatrick Lorraine A., 2006, Arq Bras Endocrinol Metab, V50, P705, DOI 10.1590/S0004 27302006000400016
   Ghoreshi ZAS, 2020, IRAN J BASIC MED SCI, V23, P30, DOI 10.22038/IJBMS.2019.33663.8047
   Gu W, 2020, J CARDIOVASC PHARM, V75, P200, DOI 10.1097/FJC.0000000000000788
   Guo Q., 2022, J Biol Chem
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Hu XT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00385
   Huntley R, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100207
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Kang TC, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9070617
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Li ZK, 2018, CALCIFIED TISSUE INT, V103, P324, DOI 10.1007/s00223 018 0425 1
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Liu Y, 2019, J CELL PHYSIOL, V234, P13832, DOI 10.1002/jcp.28063
   Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Morimoto H, 2021, GENE DEV, V35, DOI 10.1101/gad.339903.120
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park Y, 2014, INT IMMUNOPHARMACOL, V22, P400, DOI 10.1016/j.intimp.2014.07.023
   Qiu H, 2021, J CELL PHYSIOL, V236, P2800, DOI 10.1002/jcp.30045
   Reziwan K, 2019, CELL BIOCHEM FUNCT, V37, P256, DOI 10.1002/cbf.3394
   Ryoo GH, 2020, BIOCHEM BIOPH RES CO, V531, P508, DOI 10.1016/j.bbrc.2020.07.083
   Sanin DE, 2018, IMMUNITY, V49, P1021, DOI 10.1016/j.immuni.2018.10.011
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Sun Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788680
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Ulasov AV, 2022, LIFE SCI, V291, DOI 10.1016/j.lfs.2021.120111
   Wang G, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.810322
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wu XQ, 2022, REDOX BIOL, V57, DOI 10.1016/j.redox.2022.102485
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xu Y, 2022, REDOX BIOL, V53, DOI 10.1016/j.redox.2022.102349
   Yuan Y, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13194
   Zhang XR, 2021, FREE RADICAL BIO MED, V176, P298, DOI 10.1016/j.freeradbiomed.2021.09.027
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 54
TC 13
Z9 13
U1 7
U2 27
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD DEC
PY 2023
VL 218
AR 115895
DI 10.1016/j.bcp.2023.115895
EA NOV 2023
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA Y5FT1
UT WOS:001105520300001
PM 38084677
DA 2025 08 17
ER

PT J
AU Eda, H
   Aoki, K
   Kato, S
   Okawa, Y
   Takada, K
   Tanaka, T
   Marumo, K
   Ohkawa, K
AF Eda, Homare
   Aoki, Katsuhiko
   Kato, Soki
   Okawa, Yutaka
   Takada, Koji
   Tanaka, Takaaki
   Marumo, Keishi
   Ohkawa, Kiyoshi
TI The proteasome inhibitor bortezomib inhibits FGF 2 induced reduction of
   TAZ levels in osteoblast like cells
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE bortezomib; multiple myeloma; fibroblast growth factor 2; TAZ;
   osteoblast differentiation
ID FIBROBLAST GROWTH FACTOR; BONE MARROW; MULTIPLE MYELOMA; ELEVATED
   LEVELS; CANCER CELLS; BREAST; TUMOR; DIFFERENTIATION; EXPRESSION;
   SECRETION
AB Objectives: Bortezomib (PS 341; Velcade (TM)), a proteasome inhibitor, is used as a therapeutic agent for multiple myeloma. Bortezomib has been shown to strongly induce osteoblast differentiation and elevate the levels of osteoblast related differentiation markers in the serum of patients with myeloma. Bortezomib also reportedly increases the activity of the transcription factor, Runx2. However, the mechanism of action by which bortezomib elevated Runx2 activity mediates osteoblast differentiation remains unclear. On the other hand, fibroblast growth factor 2 (FGF 2) is found at high levels in patients with multiple myeloma. We previously reported that FGF 2 reduces the levels of the transcriptional coactivator with PDZ binding motif (TAZ). We therefore investigated the effects of bortezomib on TAZ protein levels in the presence of FGF 2. Methods: Osteoblastic MC3T3 E1 cells were treated with different concentrations of bortezomib in the presence or absence of FGF 2 and various biologic responses were investigated by immunoblotting, RT PCR, quantitative PCR, and alizarin red staining. Results: We found that bortezomib inhibited FGF 2 induced reduction of TAZ levels through a pathway other than that used for proteasome inhibition, while maintaining TAZ function, which in turn, enhanced the expression of Runx2 transcribed osteogenic differentiation markers. Bortezomib also suppressed the antimineralization effect of FGF 2. Conclusions: These findings suggest that bortezomib inhibited FGF 2 induced reduction of TAZ and consequently stimulated osteogenic differentiation independently of proteasome inhibition. These findings may contribute to elucidate the osteolytic mechanism in multiple myeloma, and to the development of new drugs for multiple myeloma and other osteolytic diseases.
C1 [Ohkawa, Kiyoshi] Jikei Univ, Sch Med, Dept Biochem, Minato Ku, Tokyo 1058461, Japan.
   [Kato, Soki; Tanaka, Takaaki; Marumo, Keishi] Jikei Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1058461, Japan.
   [Okawa, Yutaka] Jikei Univ, Sch Med, Dept Internal Med, Tokyo 1058461, Japan.
C3 Jikei University; Jikei University; Jikei University
RP Ohkawa, K (通讯作者)，Jikei Univ, Sch Med, Dept Biochem, Minato Ku, 3 25 8 Nishishinbashi, Tokyo 1058461, Japan.
EM pko@jikei.ac.jp
OI Aoki, Katsuhiko/0009 0008 3974 4783
FU Grants in Aid for Scientific Research [22510074] Funding Source: KAKEN
CR Bellamy WT, 1999, CANCER RES, V59, P728
   Bisping G, 2003, BLOOD, V101, P2775, DOI 10.1182/blood 2002 09 2907
   Chilosi M, 1999, MODERN PATHOL, V12, P1101
   Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378
   Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800
   Dirix LY, 1997, BRIT J CANCER, V76, P238, DOI 10.1038/bjc.1997.368
   Eda H, 2008, BIOCHEM BIOPH RES CO, V366, P471, DOI 10.1016/j.bbrc.2007.11.140
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256
   Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204
   NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Perrone G, 2009, LEUKEMIA, V23, P1679, DOI 10.1038/leu.2009.83
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600 0609.2001.00348.x
   SOUTTER AD, 1993, CANCER RES, V53, P5297
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Vacca A, 1999, BLOOD, V93, P3064
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
NR 27
TC 11
Z9 11
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0902 4441
EI 1600 0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD JUL
PY 2010
VL 85
IS 1
BP 68
EP 75
DI 10.1111/j.1600 0609.2010.01435.x
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 612RM
UT WOS:000278920100011
PM 20192985
DA 2025 08 17
ER

PT J
AU Rahimi, H
   Ritchlin, CT
AF Rahimi, Homaira
   Ritchlin, Christopher T.
TI Altered Bone Biology in Psoriatic Arthritis
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Psoriatic arthritis; Ankylosing spondylitis; Osteoclastogenesis;
   Osteoblastogenesis; New bone formation; Bone biology; Imaging
ID TUMOR NECROSIS FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; REDUCE
   RADIOGRAPHIC PROGRESSION; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS;
   STRUCTURAL DAMAGE; MINERAL DENSITY; IMMUNE SYSTEM; TGF BETA;
   OSTEOIMMUNOLOGY
AB Psoriatic arthritis (PsA) is characterized by focal bone erosions mediated by osteoclasts at the bone pannus junction. The bulk of research over the past decade has centered on mechanisms that underlie osteoclastogenesis along with new insights into osteoimmunology; however, recent advances that focus on steps that lead to new bone formation are beginning to emerge. New revelations about bone formation may have direct relevance to PsA given the presence of enthesophytes, syndesmophytes, and bony ankylosis frequently observed in patients with this disorder. In this review, we discuss current developments in the pathogenesis of new bone formation, novel imaging approaches to study bone remodeling and highlight innovative approaches to study the effect of inflammation on bone. Lastly, we discuss promising therapies that target joint inflammation and osteitis with the potential to mediate pathologic bone formation.
C1 [Rahimi, Homaira] Univ Rochester, Med Ctr, Dept Pediat, Div Rheumatol, Rochester, NY 14642 USA.
   [Ritchlin, Christopher T.] Univ Rochester, Med Ctr, Allergy Immunol & Rheumatol Unit, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester
RP Rahimi, H (通讯作者)，Univ Rochester, Med Ctr, Dept Pediat, Div Rheumatol, 601 Elmwood Ave,Box 777, Rochester, NY 14642 USA.
EM homaira_rahimi@urmc.rochester.edu;
   christopher_ritchlin@urmc.rochester.edu
OI Rahimi, Homaira/0000 0003 4028 7723; ritchlin,
   christopher/0000 0002 2602 1219
CR Alten R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2438
   Anandarajah AP, 2008, ANN RHEUM DIS, V67, P296, DOI 10.1136/ard.2007.076091
   Anandarajah A, 2013, CLIN REV ALLERG IMMU, V44, P157, DOI 10.1007/s12016 012 8304 4
   Antoni C, 2005, ANN RHEUM DIS, V64, P1150, DOI 10.1136/ard.2004.032268
   Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Blüml S, 2010, ARTHRITIS RHEUM US, V62, P1608, DOI 10.1002/art.27399
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Ch'ng ES, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 251
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Danks L, 2011, J BONE MINER RES, V26, P182, DOI 10.1002/jbmr.210
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   Day MS, 2012, J AM ACAD ORTHOP SUR, V20, P28, DOI 10.5435/JAAOS 20 01 028
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dore RK, 2010, ANN RHEUM DIS, V69, P872, DOI 10.1136/ard.2009.112920
   Eguchi Y, 2010, J BONE MINER METAB, V28, P157, DOI 10.1007/s00774 009 0127 x
   Finzel S, 2011, ANN RHEUM DIS, V70, P1587, DOI 10.1136/ard.2010.148395
   Finzel S, 2011, ANN RHEUM DIS, V70, P122, DOI 10.1136/ard.2010.132423
   Gelse K, 2011, ARTHRITIS RHEUM US, V63, P871, DOI 10.1002/art.30153
   Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668
   Gottlieb A, 2009, LANCET, V373, P1340
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Gutierrez M, 2011, SEMIN ARTHRITIS RHEU, V40, P407, DOI 10.1016/j.semarthrit.2010.05.009
   Haroon N, 2011, ARTHRITIS RHEUM US, V63, pS510
   Healy PJ, 2008, ARTHRIT RHEUM ARTHR, V59, P686, DOI 10.1002/art.23568
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Hoffmann M, 2011, XENOBIOTICA, V41, P1063, DOI 10.3109/00498254.2011.604745
   Jones D, 2011, J CLIN INVEST, V121, P2534, DOI 10.1172/JCI46262
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Lories R, 2011, NAT REV RHEUMATOL, V7, P700, DOI 10.1038/nrrheum.2011.156
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   McCann FE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3041
   McGonagle D, 2009, CURR OPIN RHEUMATOL, V21, P340, DOI 10.1097/BOR.0b013e32832c6ab9
   McQueen F, 2011, ANN RHEUM DIS, V70, P1091, DOI 10.1136/ard.2010.142539
   Mease PJ, 2005, ARTHRITIS RHEUM US, V52, P3279, DOI 10.1002/art.21306
   Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140 6736(00)02530 7
   Miller AM, 2011, J INFLAMM LOND, V8, DOI 10.1186/1476 9255 8 22
   Nakashima Tomoki, 2011, Clin Calcium, V21, P93, DOI CliCa111218431852
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Ormsby T, 2011, BLOOD, V118, P936, DOI 10.1182/blood 2010 11 317016
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Park H, 2010, FEBS LETT, V584, P173, DOI 10.1016/j.febslet.2009.11.043
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Rodgers M, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI [10.3310/hta15100, 10.3310/hta15suppl1/01]
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schafer P, 2012, BIOCHEM PHARMACOL, V83, P1583, DOI 10.1016/j.bcp.2012.01.001
   Schett G, 2011, EUR J CLIN INVEST, V41, P1361, DOI 10.1111/j.1365 2362.2011.02545.x
   Solivetti FM, 2010, DERMATOLOGY, V220, P25, DOI 10.1159/000258049
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Tessarz AAS, 2008, IMMUNOL LETT, V116, P111, DOI 10.1016/j.imlet.2007.11.021
   van der Heijde D, 2011, ARTHRITIS RHEUM US, V63, pS1017
   Waite JC, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/819467
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Yago T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2297
   Zaiss MM, 2011, J IMMUNOL, V186, P6097, DOI 10.4049/jimmunol.1003487
   Zhang XP, 2002, J CLIN INVEST, V110, P1211, DOI 10.1172/JCI200215681C
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
NR 64
TC 22
Z9 22
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD AUG
PY 2012
VL 14
IS 4
BP 349
EP 357
DI 10.1007/s11926 012 0259 1
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 225UX
UT WOS:000324990600008
PM 22592745
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Abdelsamie, AS
   Salah, M
   Siebenbürger, L
   Merabet, A
   Scheuer, C
   Frotscher, M
   Müller, ST
   Zierau, O
   Vollmer, G
   Menger, MD
   Laschke, MW
   van Koppen, CJ
   Marchais Oberwinkler, S
   Hartmann, RW
AF Abdelsamie, Ahmed S.
   Salah, Mohamed
   Siebenbuerger, Lorenz
   Merabet, Ahmed
   Scheuer, Claudia
   Frotscher, Martin
   Mueller, Sebastian T.
   Zierau, Oliver
   Vollmer, Guenter
   Menger, Michael D.
   Laschke, Matthias W.
   van Koppen, Chris J.
   Marchais Oberwinkler, Sandrine
   Hartmann, Rolf W.
TI Design, Synthesis, and Biological Characterization of Orally Active
   17β Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the
   Prevention of Osteoporosis
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID GENE EXPRESSION; BONE RESORPTION; CELL LINES; ESTROGEN; ANDROGENS;
   HORMONE; ENZYME; TISSUE
AB Osteoporosis is predominantly treated with drugs that inhibit further bone resorption due to estrogen deficiency. Yet, osteoporosis drugs that not only inhibit bone resorption but also stimulate bone formation, such as potentially inhibitors of 17/3 hydroxysteroid dehydrogenase type 2 (17/3 beta HSD2), may be more efficacious in the treatment of osteoporosis. Blockade of 17 beta HSD2 is thought to increase intracellular estradiol and testosterone in bone, thereby inhibiting bone resorption by osteoclasts and stimulating bone formation by osteoblasts, respectively. We here describe the design, synthesis, and biological characterization of a novel bicyclic substituted hydroxyphenylmethanone 17 beta HSD2 inhibitor (compound 24). Compound 24 is a nanomolar potent inhibitor of human 17 beta HSD2 (ICso of 6.1 nM) and rodent 17P HSD2 with low in vitro cellular toxicity, devoid of detectable estrogen receptor a affinity, displays high aqueous solubility and in vitro metabolic stability, and has an excellent oral pharmacokinetic profile for testing in a rat osteoporosis model. Administration of 24 in a rat osteoporosis model demonstrates its bone sparing efficacy.
C1 [Abdelsamie, Ahmed S.; Merabet, Ahmed; van Koppen, Chris J.] ElexoPharm GmbH, Bldg A1 2, D 66123 Saarbrucken, Germany.
   [Abdelsamie, Ahmed S.] Natl Res Ctr, Chem Nat & Microbial Prod Dept, Cairo 12622, Egypt.
   [Salah, Mohamed; Frotscher, Martin; van Koppen, Chris J.; Hartmann, Rolf W.] Saarland Univ, Dept Pharmaceut & Med Chem, D 66123 Saarbrucken, Germany.
   [Siebenbuerger, Lorenz] PharmBioTec GmbH, D 66123 Saarbrucken, Germany.
   [Merabet, Ahmed; Marchais Oberwinkler, Sandrine] Philipps Univ, Inst Pharmaceut Chem, D 35032 Marburg, Germany.
   [Scheuer, Claudia; Menger, Michael D.; Laschke, Matthias W.] Saarland Univ, Inst Clin Expt Surg, D 66421 Homburg, Germany.
   [Mueller, Sebastian T.; Zierau, Oliver; Vollmer, Guenter] Tech Univ Dresden, Inst Zool Mol Cell Physiol & Endocrinol, D 01062 Dresden, Germany.
   [Hartmann, Rolf W.] Helmholtz Inst Pharmaceut Res Saarland HIPS, Dept Drug Design & Optimizat, D 66123 Saarbrucken, Germany.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Saarland
   University; Philipps University Marburg; Universitatsklinikum des
   Saarlandes; Technische Universitat Dresden; Helmholtz Association
RP van Koppen, CJ; Hartmann, RW (通讯作者)，Saarland Univ, Dept Pharmaceut & Med Chem, D 66123 Saarbrucken, Germany.; Marchais Oberwinkler, S (通讯作者)，Philipps Univ, Inst Pharmaceut Chem, D 35032 Marburg, Germany.; Hartmann, RW (通讯作者)，Helmholtz Inst Pharmaceut Res Saarland HIPS, Dept Drug Design & Optimizat, D 66123 Saarbrucken, Germany.
EM vankoppen@elexopharm.de; marchais@staff.uni marburg.de;
   rolf.hartmann@helmholtz hips.de
RI ; Salah, Mohamed/KYQ 4193 2024
OI Salah, Mohamed/0000 0002 9535 6741; Abdelsamie,
   Ahmed/0000 0002 5326 4400; Laschke, Matthias W./0000 0002 7847 8456; 
FU KMU innovativ 12 grant of the Bundesministerium fur Bildung and
   Forschung [031A467]; Deutsche Forschungsgemeinschaft [Vo410/16 1,
   Ha1315/16 1]
FX This research was supported by a KMU innovativ 12 grant (031A467) of the
   Bundesministerium fur Bildung and Forschung as well as by research
   grants of the Deutsche Forschungsgemeinschaft (Vo410/16 1 and
   Ha1315/16 1). We thank Julia Parakenings for excellent technical
   assistance. We thank Dr. David G. Monroe (Mayo Clinic, Rochester, USA)
   for providing U2OS ER alpha cells and Dr. Luisella Toschi (Bayer
   Pharmaceuticals) for providing the 2xERE tk luc plasmid.
CR Abdelsamie AS, 2019, J MED CHEM, V62, P1362, DOI 10.1021/acs.jmedchem.8b01493
   Abdelsamie AS, 2017, EUR J MED CHEM, V127, P944, DOI 10.1016/j.ejmech.2016.11.004
   Abdelsamie AS, 2014, EUR J MED CHEM, V82, P394, DOI 10.1016/j.ejmech.2014.05.074
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Bagi C. M., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P267
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Dong Y, 1998, J BONE MINER RES, V13, P1539, DOI 10.1359/jbmr.1998.13.10.1539
   Ellis AJ, 2015, EXPERT OPIN DRUG SAF, V14, P921, DOI 10.1517/14740338.2015.1014799
   Emmerich J, 2017, J MED CHEM, V60, P5086, DOI 10.1021/acs.jmedchem.7b00437
   Eyre LJ, 1998, J BONE MINER RES, V13, P996, DOI 10.1359/jbmr.1998.13.6.996
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Gargano EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134754
   Janssen JMMF, 1999, J CELL BIOCHEM, V75, P528
   Keiler AM, 2015, PLANTA MED, V81, P1263, DOI 10.1055/s 0035 1546194
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lobo RA, 2017, NAT REV ENDOCRINOL, V13, P220, DOI 10.1038/nrendo.2016.164
   Lu ML, 2002, J BIOL CHEM, V277, P22123, DOI 10.1074/jbc.M111726200
   Markham A, 2019, DRUGS, V79, P471, DOI 10.1007/s40265 019 01072 6
   Miettinen MM, 1996, BIOCHEM J, V314, P839, DOI 10.1042/bj3140839
   MILEWICH L, 1985, METABOLISM, V34, P938, DOI 10.1016/0026 0495(85)90142 8
   Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633
   Müller ST, 2019, J STEROID BIOCHEM, V192, DOI 10.1016/j.jsbmb.2019.105405
   PUROHIT A, 1992, ENDOCRINOLOGY, V131, P2027, DOI 10.1210/en.131.4.2027
   Rachner TD, 2019, J MOL ENDOCRINOL, V62, pR145, DOI 10.1530/JME 18 0173
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Salah M, 2019, MOL CELL ENDOCRINOL, V489, P66, DOI 10.1016/j.mce.2018.10.001
   Siebenbuerger L, 2018, J MED CHEM, V61, P10724, DOI 10.1021/acs.jmedchem.8b01373
   Speirs V, 1998, J STEROID BIOCHEM, V67, P267, DOI 10.1016/S0960 0760(98)00119 8
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   WAKLEY GK, 1991, J BONE MINER RES, V6, P325
   Walker MK, 2012, TOXICOL APPL PHARM, V260, P65, DOI 10.1016/j.taap.2012.01.025
   WU L, 1993, J BIOL CHEM, V268, P12964
NR 34
TC 8
Z9 10
U1 1
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 8
PY 2019
VL 62
IS 15
BP 7289
EP 7301
DI 10.1021/acs.jmedchem.9b00932
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA IQ1HJ
UT WOS:000480500600028
PM 31343176
DA 2025 08 17
ER

PT J
AU Qiu, HQ
   Zhang, LY
   He, XQ
   Wei, YS
   Wang, MR
   Ma, B
   Hu, DL
   Shi, ZL
AF Qiu, Huiqing
   Zhang, Liyan
   He, Xinqi
   Wei, Yusen
   Wang, Miaoran
   Ma, Bin
   Hu, Dailun
   Shi, Zhongli
TI Promotion of angiogenesis in vitro by Astragalus polysaccharide via
   activation of TLR4 signaling pathway
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article
DE Astragalus polysaccharide; angiogenesis; osteoblasts; TLR4;
   tissue engineered bone
ID ENDOTHELIAL PROGENITOR CELLS; GROWTH FACTOR; STEM CELLS; RECEPTOR 4;
   INTERLEUKIN 6; MEMBRANACEUS; RECRUITMENT; GAMMA; VEGF
AB During the implantation of functional tissue engineered constructs for treating bone defects, a functional vascular network is critical for the survival of the construct. One strategy to achieve rapid angiogenesis for this application is the co culture of outgrowth endothelial cells (OECs) and primary human osteoblasts (POBs) within a scaffold prior to implantation. In the present study, we aim to investigate whether Astragalus polysaccharide (APS) promotes angiogenesis or vascularization via the TLR4 signaling pathway in a co culture of OECs and POBs. The co cultures were treated with various concentrations of APS for 24 h and, subsequently, another 7 days, followed by CD31 staining and analysis of micro vessel formation areas using software. Additionally, APS (0.4 mg/ml for 24 h) was added to monocultures of OECs or POBs for evaluating proliferation, apoptosis, angiogenesis, osteogenesis, TLR4 signaling pathway, and inflammatory cytokine release. We found that APS promoted angiogenesis in the co culture at the optimal concentration of 0.4 mg/ml. TLR4 activation by APS up regulated the expression level of TLR4/MyD88 and enhanced angiogenesis and osteogenesis in monocultures of OECs and POBs. The levels of E selectin adhesion molecules, three cytokines (IL 6, TNF alpha, and IFN gamma), and VEGF and PDGF BB, which can induce angiogenesis, increased significantly (p < .05) following APS treatment. Therefore, APS appears to promote angiogenesis and ossification in the co culture system via the TLR4 signaling pathway. Practical applications This study demonstrates that APS may promote angiogenesis and osteocyte proliferation in OEC and POB co culture systems through the MyD88 dependent TLR4 signaling pathway. APS might represent a potential therapeutic strategy in tissue engineered bone implantation for the treatment of large bone defects; additionally, it has the advantage of safety, as it exhibits low or no side effects. In the future, it is expected to be used in vitro for the construction of tissue engineered bone and in vivo after implantation in patients with bone defects for promoting rapid vascularization and ossification of tissue engineered bone and early fusion with the recipient's bone. In addition, as a food additive, Astragalus membranaceus can be used as a tonic material in patients recovering from a fracture for promoting blood vessel formation at the fracture site and fracture recovery. Combining traditional Chinese medicine with tissue engineering can provide further strategies for promoting the development of regenerative medicine.
C1 [Qiu, Huiqing] Hebei Med Univ, Dept Geriatr, Hosp 1, Shijiazhuang, Hebei, Peoples R China.
   [Qiu, Huiqing; Shi, Zhongli] Hebei Key Lab Brain Sci & Psychiat Psychol Dis, Shijiazhuang, Hebei, Peoples R China.
   [Zhang, Liyan; Wei, Yusen; Wang, Miaoran] Hebei Med Univ, Grad Sch, Shijiazhuang, Hebei, Peoples R China.
   [He, Xinqi] Hebei Med Univ, Dept Vasc Surg, Hosp 1, Shijiazhuang, Hebei, Peoples R China.
   [Ma, Bin] Murdoch Univ, Med Mol & Forens Sci, Murdoch, WA, Australia.
   [Hu, Dailun] Hebei Med Univ, Dept Pathogen Biol, Shijiazhuang, Hebei, Peoples R China.
   [Shi, Zhongli] Hebei Med Univ, Hosp 1, Coll Chinese Integrat Med, Cent Lab, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University; Hebei Medical
   University; Murdoch University; Hebei Medical University; Hebei Medical
   University
RP Hu, DL (通讯作者)，Hebei Med Univ, Dept Pathogen Biol, Shijiazhuang, Hebei, Peoples R China.; Shi, ZL (通讯作者)，Hebei Med Univ, Hosp 1, Cent Lab, Shijiazhuang, Hebei, Peoples R China.; Shi, ZL (通讯作者)，Hebei Med Univ, Coll Chinese Integrat Med, Shijiazhuang, Hebei, Peoples R China.
EM 17300574@hebmu.edu.cn; 16301050@hebmu.edu.cn
RI He, xin/KIC 8869 2024; ly, zhang/GPX 0750 2022
OI Ma, Bin/0000 0001 7053 0355; 
FU program of Traditional Chinese Medicine Scientific Research Foundation
   in Hebei Administration of Traditional Chinese Medicine [2022389];
   Medical Science Research Project of Hebei Provincial Health and Health
   Commission [LS201908]; Important Project of Hebei Province Education
   Department [ZD2020198]; Geriatric Disease Prevention and Control Project
   of Hebei Provincial Department of Finance [LNB201801]
FX This work has been supported by the program of Traditional Chinese
   Medicine Scientific Research Foundation in Hebei Administration of
   Traditional Chinese Medicine (Grant no. 2022389), the Medical Science
   Research Project of Hebei Provincial Health and Health Commission (Grant
   no. LS201908), Important Project of Hebei Province Education Department
   (Grant no. ZD2020198), and the Geriatric Disease Prevention and Control
   Project of Hebei Provincial Department of Finance (Grant no. LNB201801).
CR Alabanza LM, 2012, J NEUROIMMUNOL, V245, P48, DOI 10.1016/j.jneuroim.2012.02.004
   Behl T, 2016, PROSTAG OTH LIPID M, V122, P1, DOI 10.1016/j.prostaglandins.2015.12.001
   Chen YH, 2020, TAIWAN J OBSTET GYNE, V59, P248, DOI 10.1016/j.tjog.2020.01.013
   Cho ML, 2007, IMMUNOL LETT, V108, P121, DOI 10.1016/j.imlet.2006.11.005
   Fan, 2010, EXPT STUDY ASTRAGALU
   Fan YF, 2008, J CEREBR BLOOD F MET, V28, P90, DOI 10.1038/sj.jcbfm.9600509
   Fu J, 2014, PHYTOTHER RES, V28, P1275, DOI 10.1002/ptr.5188
   Grote K, 2010, BLOOD, V115, P2543, DOI 10.1182/blood 2009 05 224402
   Han RH, 2017, MOL MED REP, V15, P4027, DOI 10.3892/mmr.2017.6515
   He C, 2013, ARTERIOSCL THROM VAS, V33, P330, DOI 10.1161/ATVBAHA.112.300679
   Hernández Rodríguez J, 2003, CIRCULATION, V107, P2428, DOI 10.1161/01.CIR.0000066907.83923.32
   Herzog DPE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/320123
   HOLZINGER C, 1993, IMMUNOL LETT, V35, P109, DOI 10.1016/0165 2478(93)90078 G
   Hu SP, 2019, AM J TRANSL RES, V11, P6207
   Huo J., 2016, GENET MOL RES, V15, pgmr15049169, DOI [10.4238/gmr15049169, DOI 10.4238/GMR15049169]
   Jagavelu K, 2010, HEPATOLOGY, V52, P590, DOI 10.1002/hep.23739
   Jee SH, 2004, J INVEST DERMATOL, V123, P1169, DOI 10.1111/j.0022 202X.2004.23497.x
   Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589
   Kim JW, 2013, CANCER RES TREAT, V45, P325, DOI 10.4143/crt.2013.45.4.325
   Kong X.H., 2011, CHINESE HERBAL MED, V10, P2065
   Li M, 2014, TISSUE ENG PART C ME, V20, P328, DOI [10.1089/ten.tec.2013.0087, 10.1089/ten.TEC.2013.0087]
   Lin Q, 2011, ARTERIOSCL THROM VAS, V31, P1024, DOI 10.1161/ATVBAHA.111.224048
   Liu P, 2017, AGING DIS, V8, P868, DOI 10.14336/AD.2017.0816
   Ma B, 2017, J TISSUE ENG REGEN M, V11, P1779, DOI 10.1002/term.2075
   Middleton K, 2014, CRIT REV ONCOL HEMAT, V89, P129, DOI 10.1016/j.critrevonc.2013.08.004
   Mohr T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179065
   Napolitano A, 2013, J PHARMACEUT BIOMED, V85, P46, DOI 10.1016/j.jpba.2013.06.021
   Oh IY, 2007, BLOOD, V110, P3891, DOI 10.1182/blood 2006 10 048991
   Ou L, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102 865020190050000002
   Riddell JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050394
   ROTH M, 1995, P NATL ACAD SCI USA, V92, P1312, DOI 10.1073/pnas.92.5.1312
   Shao BM, 2004, BIOCHEM BIOPH RES CO, V320, P1103, DOI 10.1016/j.bbrc.2004.06.065
   Tu S, 2014, CHINESE MED J PEKING, V127, P2121, DOI 10.3760/cma.j.issn.0366 6999.20140004
   Unger RE, 2015, ADV DRUG DELIVER REV, V94, P116, DOI 10.1016/j.addr.2015.03.012
   Varoga D, 2006, J PATHOL, V210, P315, DOI 10.1002/path.2059
   Wang XF, 2013, INT J BIOL MACROMOL, V61, P347, DOI 10.1016/j.ijbiomac.2013.07.013
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep33719
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wu YJ, 2006, CIRC RES, V99, P315, DOI 10.1161/01.RES.0000235986.35957.a3
   Wu Zhiwei, 2017, Sheng Wu Gong Cheng Xue Bao, V33, P1850, DOI 10.13345/j.cjb.170025
   [徐寒松 Xu Hansong], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P4272
   Yang Y, 2015, COLLOID SURFACE B, V136, P111, DOI 10.1016/j.colsurfb.2015.09.006
   Yao C, 2011, INT J BURNS TRAUMA, V1, P17
   Zaklos Szyda M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144909
   Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106674
   Zhang LJ, 2011, J AGR FOOD CHEM, V59, P1131, DOI 10.1021/jf103610j
   Zhang SY, 2021, KAOHSIUNG J MED SCI, V37, P1089, DOI 10.1002/kjm2.12426
   Zhang XX, 2016, INT J BIOL MACROMOL, V82, P711, DOI 10.1016/j.ijbiomac.2015.09.051
   Zhao BJ, 2017, MOL MED REP, V15, P4077, DOI 10.3892/mmr.2017.6488
   Zheng YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00349
   Zhou LJ, 2017, SCI REP UK, V7, DOI 10.1038/srep44822
   Zhu GW, 2016, ONCOTARGET, V7, P73711, DOI 10.18632/oncotarget.12449
NR 52
TC 6
Z9 6
U1 2
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0145 8884
EI 1745 4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
PD OCT
PY 2022
VL 46
IS 10
AR e14329
DI 10.1111/jfbc.14329
EA JUL 2022
PG 15
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA 8F0LA
UT WOS:000828756800001
PM 35867029
DA 2025 08 17
ER

PT J
AU Damasco, JA
   Yu, GY
   Kumar, A
   Perez, J
   Lirag, RCM
   Whitley, EM
   Lin, SH
   Melancon, MP
AF Damasco, Jossana A.
   Yu, Guoyu
   Kumar, Ajay
   Perez, Joy
   Lirag, Rio Carlo M.
   Whitley, Elizabeth M.
   Lin, Sue Hwa
   Melancon, Marites P.
TI Alendronate conjugate for targeted delivery to bone forming prostate
   cancer
SO TALANTA
LA English
DT Article
DE Alendronate; Prostate cancer; Bone; Near infrared; Optical imaging
ID BISPHOSPHONATE; PALLIATION; PAIN
AB Bone is the primary metastasis site for lethal prostate cancer, often resulting in poor prognosis, crippling pain, and diminished functioning that drastically reduce both quality of life and survivability Uniquely, prostate cancer bone metastasis induces aberrant bone overgrowth, due to an increase of osteoblasts induced by tumor secreted bone morphogenetic protein 4 (BMP4). Conjugating drugs to substances that target the tumor induced bone area within the metastatic tumor foci would be a promising strategy for drug delivery. To develop such a strategy, we conjugated a near infrared (NIR) fluorescent probe, the dye Cy5.5, to serve as a surrogate for drugs, with alendronate, which targets bone. Characterization, such as infrared spectroscopy, confirmed the synthesis of the Cy5.5 ALN conjugate. The maximum absorbance of free Cy5.5, which was at 675 nm, did not change upon conjugation. Alendronate targeted the bone component hydroxyapatite in a dose dependent manner up to 2.5 mu M, with a maximum of 85% of Cy5.5 ALN bound to hydroxyapatite, while free Cy5.5 alone had 6% binding. In in vitro cell binding studies, Cy5.5 ALN bound specifically with mineralized bone matrix of differentiated MC3T3 E1 cells or 2H11 endothelial cells that were induced to become osteoblasts through endothelial to osteoblast transition, the underlying mechanism of prostate cancer induced bone formation. Neither Cy5.5 ALN nor free Cy5.5 bound to undifferentiated MC3T3 E1 or 2H11 cells. Bone targeting efficiency studies in non tumor bearing mice revealed accumulation over time in the spine, jaw, knees, and paws injected with Cy5.5 ALN, and quantification showed higher accumulation in femurs than in muscle at up to 28 days, while the free Cy5.5 dye was observed circulating without preferential accumulation and decreased over time. There was a linear relationship with fluorescence when the injected concentration of Cy5.5 ALN was between 0.313 and 1.25 nmol/27 g of mouse, as quantified in mouse femurs both in vivo and ex vivo. Ex vivo evaluation of bone targeting efficiency in nude mice was 3 times higher for bone forming C4 2b BMP4 tumors compared to non bone forming C4 2b tumors (p value <0.001). Fluorescence microscopy imaging of the tumors showed that Cy5.5 ALN co localized with the bone matrix surrounding tumor induced bone, but not with the viable tumor cells. Together, these results suggest that a drug ALN conjugate is a promising approach for targeted delivery of drug to the tumor induced bone area in the metastatic foci of prostate cancer.
C1 [Damasco, Jossana A.; Kumar, Ajay; Perez, Joy; Melancon, Marites P.] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Unit 471,1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Yu, Guoyu; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Unit 0089,1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Kumar, Ajay] Rice Univ, Dept Biomed Engn, Houston, TX 77004 USA.
   [Lirag, Rio Carlo M.] Cameron Univ Duncan, Dept Chem Phys &, Duncan, OK 73533 USA.
   [Whitley, Elizabeth M.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA.
   [Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Lin, Sue Hwa; Melancon, Marites P.] Univ Texas MD Anderson Canc Ctr UT Hlth Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Rice University; University
   of Texas System; UTMD Anderson Cancer Center; University of Texas
   System; UTMD Anderson Cancer Center
RP Melancon, MP (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Unit 471,1515 Holcombe Blvd, Houston, TX 77030 USA.; Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Unit 0089,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM jdamasco@fortislife.com; gyu1@mdanderson.org; ak105@rice.edu;
   jdperez1@up.edu.ph; rlirag@cameron.edu; emwhitley24@gmail.com;
   slin@mdanderson.org; mmelancon@mdanderson.org
RI ; Melancon, Marites/B 4114 2009
OI Damasco, Jossana/0000 0003 1164 3979; Perez, Joy
   Vanessa/0000 0002 1437 8501; Lirag, Rio Carlo/0000 0001 6119 0432;
   Melancon, Marites/0000 0002 7447 0705
FU National Institutes of Health (NIH) /National Heart, Lung, and Blood
   Institute [5R01HL141831 03, 1R01HL159960 01A1]; Cancer Prevention and
   Research Institute of Te tas [P3OCA016672, R01CA174798]; NIH/NCI
   [5P50CA140388]; NIH/National Cancer Institute;  [RP150179];  [RP190252]
FX This work was supported in part by grants from the National Institutes
   of Health (NIH) /National Heart, Lung, and Blood Institute
   [5R01HL141831 03 and 1R01HL159960 01A1 to M.P.M.] , NIH/National Cancer
   Institute [R01CA174798 and 5P50CA140388 to S. H.L.] , and Cancer
   Prevention and Research Institute of Tetas [RP150179 and RP190252 to
   S. H.L.] . MD Anderson's Research Animal Support Facility and Small
   Animal I itaging Facility are supported by NIH/NCI through MD Anderson's
   Cancer Center Support Grant [P3OCA016672] . The authors would like to
   acknowledge Sunita Patterson in MD Ander  son's Research Medical Library
   for editing the manuscript.
CR Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Lam MGEH, 2007, ANTI CANCER AGENT ME, V7, P381
   Lee Y.C., CANCER RES, V75
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Lenkinski RE, 2003, ACAD RADIOL, V10, P1159, DOI 10.1016/S1076 6332(03)00253 8
   Lin S. C., MOL CANCER RES
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Nadar R.A., 2017, ADV HEALTHC MATER, V6
   Ogawa K, 2005, BIOCONJUGATE CHEM, V16, P751, DOI 10.1021/bc040249w
   Sim AM, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 35454 9
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Ye G., ISCIENCE, V24
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zilberman Y, 2008, J ORTHOP RES, V26, P522, DOI 10.1002/jor.20518
NR 14
TC 5
Z9 5
U1 2
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0039 9140
EI 1873 3573
J9 TALANTA
JI Talanta
PD MAY 1
PY 2023
VL 256
AR 124308
DI 10.1016/j.talanta.2023.124308
EA FEB 2023
PG 8
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 9S6SM
UT WOS:000946467900001
PM 36774896
OA Bronze, Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Tomomura, M
   Suzuki, R
   Shirataki, Y
   Sakagami, H
   Tamura, N
   Tomomura, A
AF Tomomura, Mineko
   Suzuki, Ryuichiro
   Shirataki, Yoshiaki
   Sakagami, Hiroshi
   Tamura, Nobuaki
   Tomomura, Akito
TI Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption:
   Roles of TRAF6/TAK1/MAPKs/NF κB/NFATc1 Signaling
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; TUMOR NECROSIS FACTOR; CALCIUM DECREASING FACTOR; RECEPTOR
   ACTIVATOR; LIGAND RANKL; NFATC1; LIPOPOLYSACCHARIDE; TRAF6;
   OSTEOPOROSIS; SUPPRESSION
AB Rhinacanthin C is a naphthoquinone ester with anti inflammatory activity, found in Rhinacanthus nasutus (L) Kurz (Acanthaceae). We found that rhinacanthin C inhibited osteoclast differentiation stimulated by the receptor activator of nuclear factor kappa B ligand (RANKL) in mouse bone marrow macrophage cultures, although the precise molecular mechanisms underlying this phenomenon are unclear. In this study, we investigated the inhibitory mechanisms of rhinacanthin C in osteoclastogenesis. Rhinacanthin C suppressed RANKL induced nuclear factor of activated T cells c1 (NFATc1) expression. Phosphorylation of ERK, JNK, and NF kappa B, but not p38, was inhibited by rhinacanthin C, which also inhibited RANKL stimulated TRAF6 TAK1 complex formation. Thus, the anti osteoclastogenic effect of rhinacanthin C is mediated by a cascade of inhibition of RANKL induced TRAF6 TAK1 association followed by activation of MAPKs/NF kappa B; this leads to suppression of c Fos and NFATc1, which regulate transcription of genes associated with osteoclast differentiation. In vivo, rhinacanthin C also reduced RANKL induced osteoclast formation and bone resorption in mouse calvaria. Rhinacanthin C also suppressed LPS stimulated osteoclastogenesis and bone resorption in vitro and in vivo. Rhinacanthin C may provide a novel therapy for abnormal bone lysis that occurs during inflammatory bone resorption.
C1 [Tomomura, Mineko; Sakagami, Hiroshi] Meikai Univ, Sch Dent, Meikai Pharmaco Med Lab MPL, Sakado, Saitama 35002, Japan.
   [Tomomura, Mineko; Tomomura, Akito] Meikai Univ, Sch Dent, Dept Oral Biol & Tissue Engn, Div Biochem, Sakado, Saitama 35002, Japan.
   [Suzuki, Ryuichiro; Shirataki, Yoshiaki] Josai Univ, Fac Pharmaceut Sci, Lab Pharmacognosy & Nat Med, Sakado, Saitama 35002, Japan.
   [Sakagami, Hiroshi] Meikai Univ, Sch Dent, Dept Diagnost & Therapeut Sci, Div Pharmacol, Sakado, Saitama 35002, Japan.
   [Tamura, Nobuaki] Meikai Univ, Sch Dent, Dept Diagnost & Therapeut Sci, Div Oral & Maxillofacial Surg 1, Sakado, Saitama 35002, Japan.
C3 Meikai University; Meikai University; Josai University; Meikai
   University; Meikai University
RP Tomomura, M (通讯作者)，Meikai Univ, Sch Dent, Meikai Pharmaco Med Lab MPL, Sakado, Saitama 35002, Japan.
EM mineko t@dent.meikai.ac.jp
OI Sakagami, Hiroshi/0000 0001 8001 2121
FU Japan Society for the promotion of Science [25462898]; Grants in Aid for
   Scientific Research [25462898] Funding Source: KAKEN
FX This work was supported by JSPS Grant in Aid for Scientific Research
   (25462898 to MT) from the Japan Society for the promotion of Science
   (http://www.JSPS.go.jp/). The funder had no role in study design, data
   collection and analysis, decision to publish, or operation of the
   manuscript.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chiou WF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089159
   Gotoh A, 2004, BIOL PHARM BULL, V27, P1070, DOI 10.1248/bpb.27.1070
   Hasegawa H, 2010, J BIOL CHEM, V285, P25448, DOI 10.1074/jbc.M109.068742
   Horii H, 2013, ANTICANCER RES, V33, P453
   Horii H, 2011, IN VIVO, V25, P367
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Martin MU, 2002, BBA MOL CELL RES, V1592, P265, DOI 10.1016/S0167 4889(02)00320 8
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Sakuma Y, 2000, INFECT IMMUN, V68, P6819, DOI 10.1128/IAI.68.12.6819 6825.2000
   Sendl A, 1996, J NAT PROD, V59, P808, DOI 10.1021/np9601871
   Siripong P, 2006, BIOL PHARM BULL, V29, P2279, DOI 10.1248/bpb.29.2279
   Siriwatanametanon N, 2010, J ETHNOPHARMACOL, V130, P196, DOI 10.1016/j.jep.2010.04.036
   Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097 2765(00)80244 0
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tewtrakul S, 2009, PHYTOMEDICINE, V16, P929, DOI 10.1016/j.phymed.2009.03.010
   Tomomura M, 2012, J BIOL CHEM, V287, P17963, DOI 10.1074/jbc.M112.358796
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   Wei ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059171
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yen ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038048
   Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
NR 38
TC 20
Z9 22
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 17
PY 2015
VL 10
IS 6
AR e0130174
DI 10.1371/journal.pone.0130174
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CK9NS
UT WOS:000356567400128
PM 26083531
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Artsi, H
   Cohen Kfir, E
   Gurt, I
   Shahar, R
   Bajayo, A
   Kalish, N
   Bellido, TM
   Gabet, Y
   Dresner Pollak, R
AF Artsi, Hanna
   Cohen Kfir, Einav
   Gurt, Irina
   Shahar, Ron
   Bajayo, Alon
   Kalish, Noga
   Bellido, Teresita M.
   Gabet, Yankel
   Dresner Pollak, Rivka
TI The Sirtuin1 Activator SRT3025 Down Regulates Sclerostin and Rescues
   Ovariectomy Induced Bone Loss and Biomechanical Deterioration in Female
   Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID PARATHYROID HORMONE; SIRT1; ANTIBODY; MODEL; MASS; SENESCENCE;
   OSTEOCYTE; STRENGTH; PROTECTS; ESTROGEN
AB Estrogen deficiency leads to rapid bone loss and skeletal fragility. Sclerostin, encoded by the sost gene, and a product of the osteocyte, is a negative regulator of bone formation. Blocking sclerostin increases bone mass and strength in animals and humans. Sirtuin1 (Sirt1), a player in aging and metabolism, regulates bone mass and inhibits sost expression by deacetylating histone 3 at its promoter. We asked whether a Sirt1 activating compound could rescue ovariectomy (OVX) induced bone loss and biomechanical deterioration in 9 week old C57BL/6 mice. OVX resulted in a substantial decrease in skeletal Sirt1 expression accompanied by an increase in sclerostin. Oral administration of SRT3025, a Sirt1 activator, at 50 and 100 mg/kg.d for 6 weeks starting 6 weeks after OVX fully reversed the deleterious effects of OVX on vertebral bone mass, microarchitecture, and femoral biomechanical properties. Treatment with SRT3025 decreased bone sclerostin expression and increased cortical periosteal mineralizing surface and serum propeptide of type I procollagen, a bone formation marker. In vitro, in the murine long bone osteocyte Y4 osteocyte like cell line SRT3025 down regulated sclerostin and inactive beta catenin, whereas a reciprocal effect was observed with EX 527, a Sirt1 inhibitor. Sirt1 activation by Sirt1 activating compounds is a potential novel pathway to down regulate sclerostin and design anabolic therapies for osteoporosis concurrently ameliorating other metabolic and age associated conditions.
C1 [Artsi, Hanna; Cohen Kfir, Einav; Gurt, Irina; Dresner Pollak, Rivka] Hadassah Hebrew Univ, Med Ctr, Endocrinol & Metab Serv, Dept Med, IL 91120 Jerusalem, Israel.
   [Shahar, Ron; Kalish, Noga] Hebrew Univ Jerusalem, Koret Sch Vet Med, Lab Bone Biomech, IL 76100 Rehovot, Israel.
   [Bajayo, Alon] Hebrew Univ Jerusalem, Bone Lab, IL 91120 Jerusalem, Israel.
   [Bellido, Teresita M.] Indiana Univ Sch Med, Div Endocrinol, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Gabet, Yankel] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL 69978 Tel Aviv, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hebrew University of Jerusalem; Indiana
   University System; Indiana University Bloomington; Tel Aviv University;
   Sackler Faculty of Medicine
RP Dresner Pollak, R (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Endocrinol & Metab Serv, Postal Off Box 12000, IL 91120 Jerusalem, Israel.
EM rivkap@hadassah.org.il
RI ; Dresner Pollak, Rivka/JEP 6550 2023; Gabet, Yankel/I 6244 2019
OI Gabet, Yankel/0000 0002 7494 0631; Bellido,
   Teresita/0000 0002 8203 7004; 
FU Israel Science Foundation [842/10]; Chief Scientist, Ministry of Health,
   Israel [3_3926]
FX This work was supported by the Israel Science Foundation Grant 842/10
   (to R.D. P.) and the Chief Scientist, Ministry of Health, Israel, Grant
   3_3926 (to R.D. P.).
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Chen Y, 2012, MOL CELL PROTEOMICS, V11, P1048, DOI 10.1074/mcp.M112.019547
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008 5472.CAN 11 1446
   Elbaz A, 2009, BIOGERONTOLOGY, V10, P747, DOI 10.1007/s10522 009 9221 7
   Fujita K, 2014, J CLIN ENDOCR METAB, V99, pE81, DOI 10.1210/jc.2013 3249
   García Martín A, 2012, J CLIN ENDOCR METAB, V97, P234, DOI 10.1210/jc.2011 2186
   Gertz M, 2013, P NATL ACAD SCI USA, V110, pE2772, DOI 10.1073/pnas.1303628110
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Hamann C, 2013, J BONE MINER RES, V28, P627, DOI 10.1002/jbmr.1803
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001
   Hie M, 2011, INT J MOL MED, V28, P455, DOI 10.3892/ijmm.2011.697
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hubbard BP, 2014, TRENDS PHARMACOL SCI, V35, P146, DOI 10.1016/j.tips.2013.12.004
   Hubbard BP, 2013, SCIENCE, V339, P1216, DOI 10.1126/science.1231097
   Ichikawa T, 2013, RESPIROLOGY, V18, P332, DOI 10.1111/j.1440 1843.2012.02284.x
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mödder UI, 2011, BONE, V49, P202, DOI 10.1016/j.bone.2011.04.015
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Nuche Berenguer B, 2010, REGUL PEPTIDES, V159, P61, DOI 10.1016/j.regpep.2009.06.010
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Shindler KS, 2010, J NEURO OPHTHALMOL, V30, P328, DOI 10.1097/WNO.0b013e3181f7f833
   Simsa Maziel S, AM J PHYSL ENDOCRINO, V305, pE15
   Tong C, 2013, FASEB J, V27, P4332, DOI 10.1096/fj.12 216473
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yao HW, 2012, J CLIN INVEST, V122, P2032, DOI 10.1172/JCI60132
   Zhang J, 2013, AGE, V35, P807, DOI 10.1007/s11357 012 9412 z
NR 40
TC 60
Z9 65
U1 1
U2 14
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2014
VL 155
IS 9
BP 3508
EP 3515
DI 10.1210/en.2014 1334
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AP8QQ
UT WOS:000342344300029
PM 24949665
OA Bronze
DA 2025 08 17
ER

PT J
AU Ma, L
   Zhang, XG
   Wang, HC
   Feng, XB
   Lei, J
   He, YQ
   Wei, JY
   Zhang, YK
   Tan, L
   Yang, C
AF Ma, Liang
   Zhang, Xiaoguang
   Wang, Hongchuan
   Feng, Xiaobo
   Lei, Jie
   He, Yaqi
   Wei, Junyu
   Zhang, Yukun
   Tan, Lei
   Yang, Cao
TI Two dimensional Nb2C based nanoplatform augmented sonodynamic
   antibacterial therapy and bone regeneration
SO SCIENCE CHINA MATERIALS
LA English
DT Article
DE sonodynamic therapy; niobium carbide; disinfection; osteogenic;
   osteomyelitis; stem cell
ID NIOBIUM CARBIDE MXENE; ERADICATION; GDF 5
AB Rapid disinfection and promotion of bone regeneration are two crucial aspects of the clinical treatment of osteomyelitis. There is an urgent need to develop highly efficient bioactive sonosensitizers for sonodynamic therapy (SDT). Herein, a type of two dimensional (2D) Nb2C nanosheet decorated porphyrin metal organic framework hollow nanotubes (HNTM/Nb2C) was designed to simultaneously eliminate infection and accelerate bone regeneration under ultrasound (US) irradiation. Building a Schottky junction between HNTM and Nb2C nanosheets allowed enough reactive oxygen species (ROS) to be produced because of the rapid charge transfer and suppressed recombination of electron hole pairs under US irradiation. The sonosensitizer accelerated the osteoblastic differentiation of stem cells. RNA seq indicated that the HNTM/Nb2C nanoplatform induced stem cell differentiation via cation transport and ATP synthesis coupled electron transport through an ultrasonic current. Moreover, Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that the Nb ion may further improve osteogenesis via the activation of Wnt signaling. Our study provides novel strategies for improving SDT efficiency by simultaneously eliminating infections and promoting bone regeneration through US current combined ion therapy for osteomyelitis treatment.
C1 [Ma, Liang; Zhang, Xiaoguang; Wang, Hongchuan; Feng, Xiaobo; Lei, Jie; He, Yaqi; Wei, Junyu; Zhang, Yukun; Tan, Lei; Yang, Cao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Tan, L; Yang, C (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Peoples R China.
EM tanlei_union@hust.edu.cn; caoyangunion@hust.edu.cn
RI Tan, Lei/AEI 6088 2022; Ray, Zit/KUF 2232 2024; MA, Liang/JDU 5044 2023;
   zhang, yukun/CAI 0644 2022; Zhang, Xiaoguang/LOS 4256 2024
OI Zhang, Xiaoguang/0000 0002 0000 5245
FU National Natural Science Foundation of China [81902261, 22175058,
   81772401]; Application Foundation and Advanced Program of Wuhan Science
   and Technology Bureau [2019020701011457]; Fundamental Research Funds for
   the Central Universities [2019kfyXMBZ063]
FX AcknowledgementsThis work was supported by the National Natural Science
   Foundation of China (81902261, 22175058, and 81772401), the Application
   Foundation and Advanced Program of Wuhan Science and Technology Bureau
   (2019020701011457), and the Fundamental Research Funds for the Central
   Universities (2019kfyXMBZ063).
CR Babar ZUD, 2020, 2D MATER, V7, DOI 10.1088/2053 1583/ab86d2
   Bae MS, 2013, CARBOHYD POLYM, V92, P167, DOI 10.1016/j.carbpol.2012.09.044
   Cao FF, 2019, ANGEW CHEM INT EDIT, V58, P16236, DOI 10.1002/anie.201908289
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Cui X, 2020, BIOACT MATER, V5, P334, DOI 10.1016/j.bioactmat.2020.02.016
   de Castro LF, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00169 7
   Deepagan VG, 2016, NANO LETT, V16, P6257, DOI 10.1021/acs.nanolett.6b02547
   Dong YS, 2021, ADV MATER, V33, DOI 10.1002/adma.202106838
   Er DQ, 2014, ACS APPL MATER INTER, V6, P11173, DOI 10.1021/am501144q
   Feng DW, 2012, ANGEW CHEM INT EDIT, V51, P10307, DOI 10.1002/anie.201204475
   Feng XB, 2022, ACS NANO, V16, P2546, DOI 10.1021/acsnano.1c09189
   Fu JN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27217 4
   Fu JN, 2021, ADV MATER, V33, DOI 10.1002/adma.202102926
   Fu JN, 2019, ACS NANO, V13, P13581, DOI 10.1021/acsnano.9b08115
   Gao XQ, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121708
   Guan W, 2021, ADV MATER, V33, DOI 10.1002/adma.202006047
   Guan X, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202000326
   Han DL, 2022, CHEM SOC REV, V51, P7138, DOI 10.1039/d2cs00460g
   Han XX, 2018, THERANOSTICS, V8, P4491, DOI 10.7150/thno.26291
   Huang YF, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00178 4
   Lee AS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.33
   Lei DD, 2022, ADV MATER, V34, DOI 10.1002/adma.202110608
   Lei J, 2022, CHEM ENG J, V435, DOI 10.1016/j.cej.2022.134624
   Lesniak Ziólkowska K, 2020, BIOACT MATER, V5, P709, DOI 10.1016/j.bioactmat.2020.04.020
   Li BY, 2012, CHEM COMMUN, V48, P6151, DOI 10.1039/c2cc32384b
   Li GQ, 2022, ADV SCI, V9, DOI 10.1002/advs.202201069
   Li GQ, 2022, BIOACT MATER, V8, P409, DOI 10.1016/j.bioactmat.2021.06.021
   Li J, 2021, J AM CHEM SOC, V143, P15427, DOI 10.1021/jacs.1c07875
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Li YA, 2020, ACS NANO, V14, P8157, DOI 10.1021/acsnano.0c01486
   Lin H, 2018, ADV MATER, V30, DOI 10.1002/adma.201703284
   Lin H, 2017, J AM CHEM SOC, V139, P16235, DOI 10.1021/jacs.7b07818
   Liu Y, 2020, BIOMATERIALS, V251, DOI 10.1016/j.biomaterials.2020.120075
   Ma L, 2020, MATER TODAY, V36, P48, DOI 10.1016/j.mattod.2019.12.005
   Obata A, 2012, ACS APPL MATER INTER, V4, P5684, DOI 10.1021/am301614a
   Ren XY, 2019, ACS NANO, V13, P6438, DOI 10.1021/acsnano.8b09327
   Rodvold KA, 2014, CLIN INFECT DIS, V58, pS20, DOI 10.1093/cid/cit614
   Song CH, 2022, ADV SCI, V9, DOI 10.1002/advs.202202829
   Song K, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202102503
   Tao N, 2022, ACS NANO, V16, P485, DOI 10.1021/acsnano.1c07504
   Trousil J, 2022, SMALL, V18, DOI 10.1002/smll.202201853
   Wang DAW, 2022, ADV MATER, V34, DOI 10.1002/adma.202205924
   Wang H, 2022, CHEM SCI, V13, P6704, DOI 10.1039/d1sc07073h
   Wang YD, 2020, ACS NANO, V14, P10492, DOI 10.1021/acsnano.0c04390
   Wei Y, 2021, ADV MATER, V33, DOI 10.1002/adma.202103148
   Yamano S, 2014, BIOMATERIALS, V35, P2446, DOI 10.1016/j.biomaterials.2013.12.006
   Yang C, 2021, ACS NANO, V15, P1086, DOI 10.1021/acsnano.0c08045
   Yin JH, 2021, NANO MICRO LETT, V13, DOI 10.1007/s40820 020 00547 6
   Yu Y, 2021, ACS NANO, V15, P10628, DOI 10.1021/acsnano.1c03424
   Zhang BJ, 2022, ADV SCI, V9, DOI 10.1002/advs.202200670
   Zhang HX, 2022, J HAZARD MATER, V435, DOI 10.1016/j.jhazmat.2022.128965
   Zhang QH, 2023, BIOACT MATER, V20, P638, DOI 10.1016/j.bioactmat.2022.06.012
   Zhao YC, 2022, ACS NANO, V16, P9304, DOI 10.1021/acsnano.2c01968
   Zheng C, 2022, ADV MATER, V34, DOI 10.1002/adma.202204988
   Zhu KN, 2022, ACS NANO, V16, P11136, DOI 10.1021/acsnano.2c03971
   Zhu YL, 2022, CHEM SOC REV, V51, P1377, DOI 10.1039/d1cs00871d
NR 56
TC 14
Z9 14
U1 9
U2 117
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 2095 8226
EI 2199 4501
J9 SCI CHINA MATER
JI Sci. China Mater.
PD JUL
PY 2023
VL 66
IS 7
BP 2913
EP 2924
DI 10.1007/s40843 022 2413 4
EA APR 2023
PG 12
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA M0GN1
UT WOS:000980592200002
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, CC
   Hu, S
   Chen, G
   Georgiou, J
   Arns, S
   Kumar, NS
   Young, RN
   Grynpas, MD
AF Liu, Careesa C.
   Hu, Sally
   Chen, Gang
   Georgiou, John
   Arns, Steve
   Kumar, Nag S.
   Young, Robert N.
   Grynpas, Marc D.
TI Novel EP4 Receptor Agonist Bisphosphonate Conjugate Drug (C1) Promotes
   Bone Formation and Improves Vertebral Mechanical Properties in the
   Ovariectomized Rat Model of Postmenopausal Bone Loss
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; ANABOLICS; ANTIRESORPTIVES; PRECLINICAL STUDIES; BONE
   HISTOMORPHOMETRY
ID PROSTAGLANDIN E 2; PARATHYROID HORMONE; CANCELLOUS BONE; BIOMECHANICAL
   PROPERTIES; OSTEOGENIC CAPACITY; SPHINGOSINE KINASE; TRABECULAR BONE;
   STROMAL CELLS; CORTICAL BONE; MARROW CELLS
AB Current treatments for postmenopausal osteoporosis aim to either promote bone formation or inhibit bone resorption. The C1 conjugate drug represents a new treatment approach by chemically linking the antiresorptive compound alendronate (ALN) with the anabolic agent prostanoid EP4 receptor agonist (EP4a) through a linker molecule (LK) to form a conjugate compound. This enables the bone targeting ability of ALN to deliver EP4a to bone sites and mitigate the systemic side effects of EP4a, while also facilitating dual antiresorptive and anabolic effects. In vivo hydrolysis is required to release the EP4a and ALN components for pharmacological activity. Our study investigated the in vivo efficacy of this drug in treating established bone loss using an ovariectomized (OVX) rat model of postmenopausal osteopenia. In a curative experiment, 3 month old female Sprague Dawley rats were OVX, allowed to lose bone for 7 weeks, then treated for 6 weeks. Treatment groups consisted of C1 conjugate at low and high doses, vehicle treated OVX and sham, prostaglandin E 2 (PGE(2)), and mixture of unconjugated ALN LK and EP4a to assess the effect of conjugation. Results showed that weekly administration of C1 conjugate dose dependently increased bone volume in trabecular bone, which partially or completely reversed OVX induced bone loss in the lumbar vertebra and improved vertebral mechanical strength. The conjugate also dose dependently stimulated endocortical woven bone formation and intracortical resorption in cortical bone, with high dose treatment increasing the mechanical strength but compromising the material properties. Conjugation between the EP4a and ALN LK components was crucial to the drug's anabolic efficacy. To our knowledge, the C1 conjugate represents the first time that a combined therapy using an anabolic agent and the antiresorptive compound ALN has shown significant anabolic effects which reversed established osteopenia. (c) 2014 American Society for Bone and Mineral Research.
C1 [Liu, Careesa C.; Grynpas, Marc D.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.
   [Liu, Careesa C.; Hu, Sally; Georgiou, John; Grynpas, Marc D.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
   [Hu, Sally; Grynpas, Marc D.] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada.
   [Chen, Gang; Arns, Steve; Kumar, Nag S.; Young, Robert N.] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada.
C3 University of Toronto; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto;
   Simon Fraser University
RP Grynpas, MD (通讯作者)，25 Orde St,Suite 417, Toronto, ON M5T 3H7, Canada.
EM grynpas@lunenfeld.ca
RI Georgiou, John/E 9873 2013; Grynpas, Marc/E 4576 2013
OI Georgiou, John/0000 0003 4503 6384; Young, Robert/0000 0002 8235 6080
FU Collaborative Health Research Grant from the Natural Sciences and
   Engineering Research Council of Canada; Canadian Institutes of Health
   Research (Institute of Musculoskeletal Health and Arthritis) [CHRPJ
   351731 08]; Ontario Student Opportunities Trust Fund (OSOTF)
FX This work was supported by a Collaborative Health Research Grant from
   the Natural Sciences and Engineering Research Council of Canada and the
   Canadian Institutes of Health Research (Institute of Musculoskeletal
   Health and Arthritis), awarded to RNY and MDG (grant number CHRPJ
   351731 08). CCL was supported by a scholarship from the Ontario Student
   Opportunities Trust Fund (OSOTF). We thank the following individuals for
   assistance with this study: Adeline Ng and Richard Cheung for general
   experimental techniques and laboratory management; Kate Banks and
   Jennifer Baksh for animal care; Thomas Willet for biomechanical testing;
   Douglas Holmyard for BSE; and Richard Renlund for animal pathology.
CR Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Billot X, 2003, BIOORG MED CHEM LETT, V13, P1129, DOI 10.1016/S0960 894X(03)00042 8
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Chen GX, 2014, PLOS ONE, V9
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Compston JE, 2007, BONE, V40, P1447, DOI 10.1016/j.bone.2006.09.008
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   FARNUM CE, 1989, J ORTHOP RES, V7, P654, DOI 10.1002/jor.1100070505
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   GRUBER HE, 1992, BIOTECH HISTOCHEM, V67, P30, DOI 10.3109/10520299209110002
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756 3282(90)90078 D
   JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   KE HZ, 1993, BONE MINER, V21, P189, DOI 10.1016/S0169 6009(08)80230 9
   Ke HZ, 1998, BONE, V23, P249, DOI 10.1016/S8756 3282(98)00102 1
   Ke HZ, 2006, J BONE MINER RES, V21, P565, DOI 10.1359/JBMR.051110
   KE HZ, 1992, BONE MINER, V19, P45, DOI 10.1016/0169 6009(92)90843 3
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Khosla S, 2003, NEW ENGL J MED, V349, P1277, DOI 10.1056/NEJMe038143
   LAURITZEN DB, 1993, J BONE MINER RES, V8, P871
   LEE ER, 1995, J HISTOCHEM CYTOCHEM, V43, P525, DOI 10.1177/43.5.7730591
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Li M, 2005, BONE, V37, P46, DOI 10.1016/j.bone.2005.03.016
   LIN BY, 1994, BONE, V15, P489, DOI 10.1016/8756 3282(94)90272 0
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   Mano M, 2000, CALCIFIED TISSUE INT, V67, P85, DOI 10.1007/s00223001102
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200
   MORI S, 1992, CALCIFIED TISSUE INT, V50, P80, DOI 10.1007/BF00297302
   MORI S, 1990, BONE, V11, P103, DOI 10.1016/8756 3282(90)90057 6
   Ono K, 1998, J ENDOCRINOL, V158, pR1, DOI 10.1677/joe.0.158R001
   PAPADOPOULOS G, 1991, J AM OIL CHEM SOC, V68, P669, DOI 10.1007/BF02662292
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031
   Rundhaug JE, 2011, CANCER METAST REV, V30, P465, DOI 10.1007/s10555 011 9317 9
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sarrazin P, 2004, J RHEUMATOL, V31, P1598
   Sarrazin P, 2001, PROSTAG LEUKOTR ESS, V64, P203, DOI 10.1054/plef.1999.0127
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   SEEDOR JG, 1991, J BONE MINER RES, V6, P339
   Shamir D, 2004, BONE, V34, P157, DOI 10.1016/j.bone.2003.09.008
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Tian X. Y., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P372
   Tomita M, 2002, BONE, V30, P159, DOI 10.1016/S8756 3282(01)00688 3
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927
   Weinreb M, 2006, PROSTAG LEUKOTR ESS, V75, P81, DOI 10.1016/j.plefa.2006.06.004
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Weinreb M, 2001, BONE, V28, P275, DOI 10.1016/S8756 3282(00)00447 6
   Weinreb M, 1996, J BONE MINER RES  S1, V11, pS1
   Woodward DF, 2011, PHARMACOL REV, V63, P471, DOI 10.1124/pr.110.003517
   WRONSKI TJ, 1987, CALCIFIED TISSUE INT, V40, P155, DOI 10.1007/BF02555700
   WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756 3282(86)90683 6
   WRONSKI TJ, 1985, CALCIFIED TISSUE INT, V37, P324, DOI 10.1007/BF02554882
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
NR 68
TC 24
Z9 26
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2015
VL 30
IS 4
BP 670
EP 680
DI 10.1002/jbmr.2382
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CE8PB
UT WOS:000352104400012
PM 25284325
OA Bronze
DA 2025 08 17
ER

PT J
AU Ihle, CL
   Owens, P
AF Ihle, Claire L.
   Owens, Philip
TI Integrating the immune microenvironment of prostate cancer induced bone
   disease
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE bone metastasis; immmunotherapy; prostate cancer; tumor microenvironment
ID ANDROGEN DEPRIVATION THERAPY; SIPULEUCEL T IMMUNOTHERAPY;
   SKELETAL RELATED EVENTS; CONTROLLED TRIAL; METASTASES; DENOSUMAB; MEN;
   FLUTAMIDE; DIAGNOSIS; SURVIVAL
AB Prostate cancer (PCa) is the most frequently diagnosed cancer for men in the U.S. but does not impede patient survival until the disease is metastatic. Metastatic lesions most frequently occur in the bone, which exhibits a distinct microenvironment of immune and bone cell populations. Advances in the diagnosis and treatment of primary PCa allow for the use of tailored therapeutic approaches based on biomarkers, protein expression, and histopathology. Understanding the molecular and cellular characteristics of primary tumors has advanced therapeutic development and survival for patients with PCa. Personalized medicine has only recently emerged for the treatment of metastatic bone lesions. Tumor induced bone disease (TIBD) in patients with PCa can be classified into lytic, blastic, or mixed pathologies, with most patients exhibiting the blastic phenotype. Progress has been made in treating TIBD, but metastatic PCa has yet to be cured. Immune checkpoint inhibitors have exhibited limited responses in immunosuppressive PCa tumors, but have yet to be assessed in metastatic sites which may be susceptible to an increased inflammatory response. Recent discoveries have uncovered distinct tumor microenvironments (TMEs) of blastic and lytic bone metastases from patients with PCa, identifying actionable targets for therapeutic applications, including immune checkpoint inhibitors and targeted therapeutics. Enrichment for macrophages and T cells in patient samples suggests metastatic sites may be reappraised as immunologically targetable, despite their immunologically "cold" primary tumors. The practice of performing bone biopsies will help identify unique cellular and protein targets in the bone TME that can guide therapy decisions.
C1 [Ihle, Claire L.; Owens, Philip] Univ Colorado, Dept Pathol, Anschutz Med Campus,P18 5122 12800 East 19th Ave, Aurora, CO 80045 USA.
   [Owens, Philip] Eastern Colorado Hlth Care Syst, Res Serv, Dept Vet Affairs, Aurora, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Owens, P (通讯作者)，Univ Colorado, Dept Pathol, Anschutz Med Campus,P18 5122 12800 East 19th Ave, Aurora, CO 80045 USA.
EM philip.owens@cuanschutz.edu
OI Ihle, Claire/0000 0003 4212 2324
FU U.S. Department of Veterans Affairs [1KBX00002929]
FX U.S. Department of Veterans Affairs, Grant/Award Number: 1KBX00002929
CR Abdel Wahab N, 2019, RHEUMATOLOGY, V58, P40, DOI 10.1093/rheumatology/kez297
   Alford Ashley V, 2017, Rev Urol, V19, P221, DOI 10.3909/riu0772
   [Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210
   Armstrong AJ, 2019, J CLIN ONCOL, V37, P2974, DOI 10.1200/JCO.19.00799
   Becker JT, 2010, J IMMUNOTHER, V33, P639, DOI 10.1097/CJI.0b013e3181dda23e
   BOETTCHER AN, 2019, FRONT ONCOL, V9
   Bouchelouche K, 2016, SEMIN NUCL MED, V46, P522, DOI 10.1053/j.semnuclmed.2016.07.006
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Cogdill AP, 2017, BRIT J CANCER, V117, P1, DOI 10.1038/bjc.2017.136
   Conteduca V, 2019, EUR J CANCER, V121, P7, DOI 10.1016/j.ejca.2019.08.011
   CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Dai C, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a030452
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Di Lorenzo G, 2003, ONCOL REP, V10, P399
   Drake CG, 2014, ONCOLOGY NY, V28, P974
   Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504
   Filella X, 2018, PHARMACOGEN PERS MED, V11, P83, DOI 10.2147/PGPM.S136026
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573 018 0007 y
   Gandaglia G, 2014, PROSTATE, V74, P210, DOI 10.1002/pros.22742
   Gooding S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12296 1
   Graff JN, 2015, CORE EVID, V10, P1, DOI 10.2147/CE.S54712
   Hagiwara M, 2013, PROSTATE CANCER P D, V16, P23, DOI 10.1038/pcan.2012.42
   Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568 019 0116 x
   Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Hesse E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125543
   Hjortholm N, 2013, ANN HEMATOL, V92, P145, DOI 10.1007/s00277 012 1641 9
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Holko P, 2014, EXPERT REV ANTICANC, V14, P63, DOI 10.1586/14737140.2014.856270
   Hu R, 2016, THER ADV UROL, V8, P272, DOI 10.1177/1756287216645314
   Idorn M, 2014, CANCER IMMUNOL IMMUN, V63, P1177, DOI 10.1007/s00262 014 1591 2
   Ihle CL, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0753 3
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kiessling Andrea, 2012, Cancers (Basel), V4, P193, DOI 10.3390/cancers4010193
   Kostine M, 2019, RHEUMATOLOGY, V58, P68, DOI 10.1093/rheumatology/kez295
   Lecouvet FE, 2012, EUR UROL, V62, P68, DOI 10.1016/j.eururo.2012.02.020
   Litwin MS, 2017, JAMA J AM MED ASSOC, V317, P2532, DOI 10.1001/jama.2017.7248
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   McDougall JA, 2016, ONCOLOGIST, V21, P320, DOI 10.1634/theoncologist.2015 0327
   McKay R, 2017, PROSTATE CANCER P D, V20, P276, DOI 10.1038/pcan.2017.4
   McKay RR, 2014, PROSTATE CANCER P D, V17, P325, DOI 10.1038/pcan.2014.28
   McNaughton Collins M, 2004, AM J MED, V117, P719, DOI 10.1016/j.amjmed.2004.06.036
   Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078 0432.CCR 03 0735
   Mlecnik B, 2018, JNCI J NATL CANCER I, V110, DOI 10.1093/jnci/djx123
   Mohler JL, 2019, J NATL COMPR CANC NE, V17, P479, DOI 10.6004/jnccn.2019.0023
   Moreira DM, 2017, CLIN GENITOURIN CANC, V15, P60, DOI 10.1016/j.clgc.2016.08.018
   Moseley KF, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425 018 0417 8
   Nevedomskaya E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051359
   Parimi V, 2014, AM J CLIN EXP UROL, V2, P273
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Reddington Justin A, 2016, Surg Neurol Int, V7, pS361, DOI 10.4103/2152 7806.182549
   Redman JM, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425 018 0409 8
   Sailer V, 2018, CANCER AM CANCER SOC, V124, P1008, DOI 10.1002/cncr.31173
   Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252
   Smith MR, 2011, J BONE MINER RES, V26, P2827, DOI 10.1002/jbmr.492
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Sohail A, 2018, CANCER MANAG RES, V10, P1619, DOI 10.2147/CMAR.S162525
   Sonnenburg DW, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912 018 0692 z
   Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470 2045(17)30906 3
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   US Preventive Services Task Force, 2018, JAMA, V319, P1901, DOI 10.1001/jama.2018.3710
   Vitkin N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00603
   Wadosky KM, 2016, ONCOTARGET, V7, P64447, DOI 10.18632/oncotarget.10901
   Wargowski E, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425 018 0333 y
   Yarchoan M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126908
NR 77
TC 10
Z9 11
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0899 1987
EI 1098 2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD JUL
PY 2020
VL 59
IS 7
BP 822
EP 829
DI 10.1002/mc.23192
EA MAR 2020
PG 8
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA LV3AX
UT WOS:000522535000001
PM 32233011
DA 2025 08 17
ER

PT J
AU Bian, YX
   Hu, TT
   Zhao, KX
   Cai, XJ
   Li, MY
   Tan, CL
   Liang, RZ
   Weng, XS
AF Bian, Yixin
   Hu, Tingting
   Zhao, Kexin
   Cai, Xuejie
   Li, Mengyang
   Tan, Chaoliang
   Liang, Ruizheng
   Weng, Xisheng
TI A LDH Derived Metal Sulfide Nanosheet Functionalized Bioactive Glass
   Scaffold for Vascularized Osteogenesis and Periprosthetic Infection
   Prevention/Treatment
SO ADVANCED SCIENCE
LA English
DT Article
DE layered double hydroxides; periprosthetic infection; photothermal
   therapy; sulfide; vascularized osteogenesis
ID STAPHYLOCOCCUS AUREUS; KNEE ARTHROPLASTY; BONE FORMATION; FAILURE;
   MECHANISMS; EXPRESSION; NONUNION; FIXATION; STEMS; TIBIA
AB Periprosthetic infection and prosthetic loosing stand out as prevalent yet formidable complications following orthopedic implant surgeries. Synchronously addressing the two complications is long time challenging. Herein, a bioactive glass scaffold (BGS) functionalized with MgCuFe layered double hydroxide (LDH) derived sulfide nanosheets (BGS/MCFS) is developed for vascularized osteogenesis and periprosthetic infection prevention/treatment. Apart from the antibacterial cations inhibiting bacterial energy and material metabolism, the exceptional near infrared II (NIR II) photothermal performance empowers BGS/MCFS to eliminate periprosthetic infections, outperforming previously reported functionalized BGS. The rough surface topography and the presence of multi bioactive metal ions bestow BGS/MCFS with exceptional osteogenic and angiogenic properties, with 8.5 fold and 2.3 fold enhancement in bone mass and neovascularization compared with BGS. Transcriptome sequencing highlights the involvement of the TGF beta signaling pathway in these processes, while single cell sequencing reveals a significant increase in osteoblasts and endothelial cells around BGS/MCFS compared to BGS.
   A bioactive glass scaffold functionalized with LDH derived sulfide nanosheets is proposed for bioactive ion mediated vascularized osteogenesis and photothermal effect mediated antibacterial, synchronously addressing periprosthetic infection and prosthesis loosening. image
C1 [Bian, Yixin; Cai, Xuejie; Weng, Xisheng] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Orthoped Surg, Beijing 100730, Peoples R China.
   [Hu, Tingting; Tan, Chaoliang] Univ Hong Kong, Dept Elect & Elect Engn, Pokfulam Rd, Hong Kong 999077, Peoples R China.
   [Zhao, Kexin; Li, Mengyang; Liang, Ruizheng] Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
   [Liang, Ruizheng] Quzhou Inst Innovat Resource Chem Engn, Quzhou 324000, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College Hospital; Peking Union Medical College;
   University of Hong Kong; Beijing University of Chemical Technology
RP Weng, XS (通讯作者)，Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Orthoped Surg, Beijing 100730, Peoples R China.; Tan, CL (通讯作者)，Univ Hong Kong, Dept Elect & Elect Engn, Pokfulam Rd, Hong Kong 999077, Peoples R China.; Liang, RZ (通讯作者)，Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.; Liang, RZ (通讯作者)，Quzhou Inst Innovat Resource Chem Engn, Quzhou 324000, Peoples R China.
EM cltan@hku.hk; liangrz@mail.buct.edu.cn; xshweng@pumch.cams.cn
RI Zhao, Kexin/NVM 4284 2025; Yixin, Bian/JTU 2888 2023; Tan,
   Chaoliang/T 3036 2017
OI Tan, Chaoliang/0000 0003 1695 5285
FU National Natural Science Foundation of China (NSFC) [22288102,
   81630064]; National Natural Science Foundation of China Excellent Young
   Scientists Fund [52322317]; Fundamental Research Funds for the Central
   Universities [XK1803 05]; National Natural Science Foundation of
   China Excellent Young Scientists Fund (Hong Kong and Macau) [52122002]
FX Y.B. and T.H. are equally contributed to this work. R.L. thanks the
   funding support from the National Natural Science Foundation of China
   (NSFC: 22288102), National Natural Science Foundation of China Excellent
   Young Scientists Fund (52322317), and Fundamental Research Funds for the
   Central Universities (XK1803 05). C.T. thanks the funding support from
   the National Natural Science Foundation of China Excellent Young
   Scientists Fund (Hong Kong and Macau) (52122002). X.W. thanks the
   funding support from the National Natural Science Foundation of China
   (Grant ID: 81630064). All animal experiments were carried out in
   accordance with the National Institutes of Health Guidelines for the use
   of experimental animals, and all protocols were approved by the Animal
   Care and Use Committee of Peking Union Medical College Hospital with the
   ethics number of XHDW 2023 021.
CR Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev immunol 020711 074942
   An L, 2022, NANO TODAY, V43, DOI 10.1016/j.nantod.2022.101397
   Bian Y., 2023, WENG ADV SCI, V10
   Cooper HJ, 2011, J ARTHROPLASTY, V26, P78, DOI 10.1016/j.arth.2011.04.003
   Eriksson E, 2021, ACTA BIOMATER, V126, P463, DOI 10.1016/j.actbio.2021.03.035
   Frei A, 2023, NAT REV CHEM, V7, P202, DOI 10.1038/s41570 023 00463 4
   Garvin KL, 2011, J BONE JOINT SURG AM, V93A, P1167, DOI 10.2106/00004623 201106150 00012
   Guan GJ, 2015, J AM CHEM SOC, V137, P6152, DOI 10.1021/jacs.5b02780
   Gupta S, 2018, BONE JOINT J, V100B, P1094, DOI 10.1302/0301 620X.100B8.BJJ 2017 1442.R1
   HARRIS WH, 1992, CLIN ORTHOP RELAT R, P67
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Hu TT, 2022, CHEM SOC REV, V51, P6126, DOI 10.1039/d2cs00236a
   Jiao Z, 2023, ACTA PHYS CHIM SIN, V39, DOI 10.3866/PKU.WHXB202301018
   Kapadia BH, 2016, LANCET, V387, P386, DOI 10.1016/S0140 6736(14)61798 0
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Kynaston Pearson F, 2013, BMJ BRIT MED J, V347, DOI 10.1136/bmj.f6956
   Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140 6736(07)60457 7
   Lex JR, 2022, ACTA BIOMATER, V140, P136, DOI 10.1016/j.actbio.2021.11.045
   Li BH, 2023, SMARTMAT, V4, DOI 10.1002/smm2.1243
   Li DY, 2024, ADV MATER, V36, DOI 10.1002/adma.202308747
   Li J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12429 6
   Li XS, 2020, NAT REV CLIN ONCOL, V17, P657, DOI 10.1038/s41571 020 0410 2
   Lombardi Adolph V Jr, 2009, J Bone Joint Surg Am, V91 Suppl 5, P52, DOI 10.2106/JBJS.I.00403
   Lv ZH, 2023, ADV MATER, V35, DOI 10.1002/adma.202206545
   Melin F, 2020, CHEM REV, V120, P10244, DOI 10.1021/acs.chemrev.0c00249
   Morrey ME, 2013, J BONE JOINT SURG AM, V95A, P1117, DOI 10.2106/JBJS.L.00747
   Niu HY, 2019, BIOMATERIALS, V216, DOI 10.1016/j.biomaterials.2019.05.027
   Perni S, 2020, J CONTROL RELEASE, V326, P91, DOI 10.1016/j.jconrel.2020.06.013
   Qi XL, 2023, COORDIN CHEM REV, V496, DOI 10.1016/j.ccr.2023.215426
   Qiao W, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28203 0
   Qiao ZZ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34883 5
   Ribera A, 2014, J INFECTION, V69, P235, DOI 10.1016/j.jinf.2014.05.003
   Rohilla R, 2019, BONE JOINT J, V101B, P1416, DOI 10.1302/0301 620X.101B11.BJJ 2019 0189.R1
   ROSENQVIST R, 1986, J BONE JOINT SURG AM, V68A, P538, DOI 10.2106/00004623 198668040 00009
   Sánchez Salcedo S, 2023, ACTA BIOMATER, V155, P654, DOI 10.1016/j.actbio.2022.10.045
   Sendi P, 2011, J INFECTION, V63, P17, DOI 10.1016/j.jinf.2011.05.005
   Shao ES, 2009, BLOOD, V114, P2197, DOI 10.1182/blood 2009 01 199166
   Shen WC, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31106 9
   Tan CL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8873
   Thiele K, 2015, J BONE JOINT SURG AM, V97A, P715, DOI 10.2106/JBJS.M.01534
   Urban RM, 1996, J BONE JOINT SURG AM, V78A, P1068, DOI 10.2106/00004623 199607000 00012
   Wang G., 2022, Adv. Sci, V10
   Wang LY, 2021, ADV MATER, V33, DOI 10.1002/adma.202100150
   Wang QS, 2019, ADV MATER, V31, DOI 10.1002/adma.201904836
   Wang S, 2021, CHEM ENG J, V419, DOI 10.1016/j.cej.2021.129458
   Wang YJ, 2021, ACS NANO, V15, P9732, DOI 10.1021/acsnano.1c00461
   Wu JJ, 2021, BIOMATERIALS, V273, DOI 10.1016/j.biomaterials.2021.120807
   Wu JJ, 2020, ACS APPL MATER INTER, V12, P48310, DOI 10.1021/acsami.0c13364
   Wu XZ, 2020, NANO MICRO LETT, V12, DOI 10.1007/s40820 020 0378 6
   Xiong Y., 2023, ADV MATER, V35
   Xu C, 2021, CHEM SOC REV, V50, P1111, DOI 10.1039/d0cs00664e
   Xue BL, 2023, CHINESE CHEM LETT, V34, DOI 10.1016/j.cclet.2023.108140
   Yang Y, 2023, ADV MATER, V35, DOI 10.1002/adma.202211205
   Zhou H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19945 w
   Zhou Z, 2020, SMALL, V16, DOI 10.1002/smll.202004173
   Zhu H, 2021, ACTA BIOMATER, V129, P1, DOI 10.1016/j.actbio.2021.05.007
   Zhu Y, 2020, ADV SCI, V7, DOI 10.1002/advs.202000272
NR 57
TC 8
Z9 8
U1 14
U2 52
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD OCT
PY 2024
VL 11
IS 39
DI 10.1002/advs.202403009
EA AUG 2024
PG 13
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA J8G0E
UT WOS:001293111000001
PM 39159063
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Luo, LY
   Guan, ZY
   Jin, X
   Guan, ZQ
   Jiang, YY
AF Luo, Liying
   Guan, Zhiyuan
   Jin, Xiao
   Guan, Zhiqiang
   Jiang, Yanyun
TI Identification of kukoamine a as an anti osteoporosis drug target using
   network pharmacology and experiment verification
SO MOLECULAR MEDICINE
LA English
DT Article
DE Osteoporosis; Kukoamine A; Osteoblast cells; Ovariectomized mice;
   Network pharmacology
ID OXIDATIVE STRESS; IN VITRO; INSULIN RESISTANCE; DOWN REGULATION; CORTEX
   LYCII; BONE MASS; OSTEOARTHRITIS; POLYMORPHISMS; METABOLISM; OSTEOBLAST
AB BackgroundOsteoporosis (OP) is a major and growing public health problem characterized by decreased bone mineral density and destroyed bone microarchitecture. Previous studies found that Lycium Chinense Mill (LC) has a potent role in inhibiting bone loss. Kukoamine A (KuA), a bioactive compound extract from LC was responsible for the anti osteoporosis effect. This study aimed to investigate the anti osteoporosis effect of KuA isolated from LC in treating OP and its potential molecular mechanism.MethodIn this study, network pharmacology and molecular docking were investigated firstly to find the active ingredients of LC such as KuA, and the target genes of OP by the TCMSP platform. The LC OP potential Target gene network was constructed by the STRING database and network maps were built by Cytoscape software. And then, the anti osteoporotic effect of KuA in OVX induced osteoporosis mice and MC3T3 E1 cell lines were investigated and the potential molecular mechanism including inflammation level, cell apoptosis, and oxidative stress was analyzed by dual energy X ray absorptiometry (DXA), micro CT, ELISA, RT PCR, and Western Blotting.ResultA total of 22 active compounds were screened, and we found KuA was identified as the highest active ingredient. Glycogen Phosphorylase (PYGM) was the target gene associated with a maximum number of active ingredients of LC and regulated KuA. In vivo, KuA treatment significantly increased the bone mineral density and improve bone microarchitecture for example increased BV/TV, Tb.N and Tb.Th but reduced Tb.Sp in tibia and lumber 4. Furthermore, KuA increased mRNA expression of osteoblastic differentiation related genes in OVX mice and protects against OVX induced cell apoptosis, oxidative stress level and inflammation level. In vitro, KuA significantly improves osteogenic differentiation and mineralization in cells experiment. In addition, KuA also attenuated inflammation levels, cell apoptosis, and oxidative stress level.ConclusionThe results suggest that KuA could protect against the development of OP in osteoblast cells and ovariectomized OP model mice and these found to provide a better understanding of the pharmacological activities of KuA again bone loss.
C1 [Luo, Liying; Jiang, Yanyun] Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
   [Guan, Zhiyuan] Tongji Univ, Shanghai Peoples Hosp 10, Dept Orthoped, Shanghai, Peoples R China.
   [Jin, Xiao] First Peoples Hosp Xuzhou, Dept Rheumatol & Immunol, Xuzhou 221002, Jiangsu, Peoples R China.
   [Guan, Zhiqiang] Xuzhou Med Univ, Xuzhou Municipal Hosp, Dept Dermatol, Xuzhou 221002, Jiangsu, Peoples R China.
C3 Shanghai Jiao Tong University; Tongji University; Xuzhou Medical
   University
RP Luo, LY (通讯作者)，Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.; Jin, X (通讯作者)，First Peoples Hosp Xuzhou, Dept Rheumatol & Immunol, Xuzhou 221002, Jiangsu, Peoples R China.; Guan, ZQ (通讯作者)，Xuzhou Med Univ, Xuzhou Municipal Hosp, Dept Dermatol, Xuzhou 221002, Jiangsu, Peoples R China.
EM miss_lyluo@163.com; 13685138802@163.com; gzq199207@163.com
RI 关, 智元/JSK 1964 2023
CR Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Bai LL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.690118
   Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104
   Chen HX, 2018, PAK J PHARM SCI, V31, P2419
   Chen L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9102012
   Chow SKH, 2020, BONE JOINT RES, V9, P368, DOI 10.1302/2046 3758.97.BJR 2019 0300.R2
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cortet B, 2019, JOINT BONE SPINE, V86, P315, DOI 10.1016/j.jbspin.2018.08.002
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fischer V., 2021, SEMIN CELL DEV BIOL, V78, P7
   Gennari L, 2007, EXPERT OPIN PHARMACO, V8, P537, DOI 10.1517/14656566.8.5.537
   Gomes CP, 2020, ACTA NEUROL BELG, V120, P705, DOI 10.1007/s13760 019 01159 7
   Gruver Yates Amanda L, 2013, Cells, V2, P202, DOI 10.3390/cells2020202
   Hadjipavlou Litina D, 2009, J ENZYM INHIB MED CH, V24, P1188, DOI 10.1080/14756360902779193
   Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159 8290.CD 15 0011
   He H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147475
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Hu XL, 2015, BBA GEN SUBJECTS, V1850, P287, DOI 10.1016/j.bbagen.2014.11.006
   Inada Masaki, 2011, Clin Calcium, V21, P164, DOI CliCa1102164170
   Jeong JC, 2012, ONCOL REP, V27, P1467, DOI 10.3892/or.2012.1637
   Jiang GD, 2020, J NAT MED TOKYO, V74, P247, DOI 10.1007/s11418 019 01337 0
   Jiang YB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01435
   Jilka RL, 2014, J BONE MINER RES, V29, P103, DOI 10.1002/jbmr.2007
   Jin Y, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191612
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Karim N, 2021, PHYTOMEDICINE, V90, DOI 10.1016/j.phymed.2021.153646
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Lee B, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4988
   Lee CS, 2020, PROBIOTICS ANTIMICRO, V12, P623, DOI 10.1007/s12602 019 09577 y
   Lei T, 2018, BONE, V108, P10, DOI 10.1016/j.bone.2017.12.008
   Li GY, 2017, BIOMED PHARMACOTHER, V89, P536, DOI 10.1016/j.biopha.2017.02.024
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Li XC, 2018, MOLECULES, V23, DOI 10.3390/molecules23040973
   Liu J, 2017, NEUROCHEM INT, V107, P191, DOI 10.1016/j.neuint.2016.12.024
   Liu J, 2014, BONE, V67, P81, DOI 10.1016/j.bone.2014.06.040
   Liu Y, 2020, ACTA PHARMACOL SIN, V41, P138, DOI 10.1038/s41401 019 0228 6
   Liu YQ, 2021, J CHROMATOGR A, V1642, DOI 10.1016/j.chroma.2021.462041
   Myers SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079316
   Nogales Gadea G, 2015, HUM MUTAT, V36, P669, DOI 10.1002/humu.22806
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   PACIFICI R, 1993, J CLIN ENDOCR METAB, V77, P1135, DOI 10.1210/jc.77.5.1135
   Park E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113565
   Park E, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112716
   Park E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112784
   Park E, 2014, MOLECULES, V19, P19594, DOI 10.3390/molecules191219594
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Silverstein WK, 2021, JAMA INTERN MED, V181, P1635, DOI 10.1001/jamainternmed.2021.5972
   Spitz AZ, 2022, TRENDS PHARMACOL SCI, V43, P206, DOI 10.1016/j.tips.2021.11.001
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Tantowi NACA, 2020, DARU, V28, P443, DOI 10.1007/s40199 020 00343 y
   Tarnopolsky MA, 2018, NEUROTHERAPEUTICS, V15, P915, DOI 10.1007/s13311 018 00684 2
   Villarreal Salazar M, 2021, GENES BASEL, V13
   VIRTANEN P, 1980, ACTA ANAT, V108, P202
   Wang JX, 2013, PROTEOM CLIN APPL, V7, P181, DOI 10.1002/prca.201200068
   Wang QP, 2016, SCI REP UK, V6, DOI 10.1038/srep36543
   Wang YJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.723988
   Watts NB, 1999, CLIN CHEM, V45, P1359
   Wei MQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5217405
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yang Y, 2015, J CELL MOL MED, V19, P1055, DOI 10.1111/jcmm.12498
   Ye Z, 2008, PHYTOTHER RES, V22, P1665, DOI 10.1002/ptr.2552
   Zhang L, 2019, FUNCT PLANT BIOL, V46, P107, DOI [10.1071/FP18080, 10.1071/fp18080]
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
   Zhang YQ, 2017, NEUROTOX RES, V31, P259, DOI 10.1007/s12640 016 9679 4
   Zhang YQ, 2016, NEUROCHEM RES, V41, P2549, DOI 10.1007/s11064 016 1967 0
   Zheng WW, 2020, FASEB J, V34, P3399, DOI 10.1096/fj.201902117R
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
   Zhou WA, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153543
   Zhou XH, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20210609
NR 75
TC 11
Z9 12
U1 2
U2 19
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076 1551
EI 1528 3658
J9 MOL MED
JI Mol. Med.
PD MAR 20
PY 2023
VL 29
IS 1
AR 36
DI 10.1186/s10020 023 00625 6
PG 21
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA A3AA4
UT WOS:000953879800002
PM 36941586
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Cui, CP
   Huo, QJ
   Xiong, X
   Na, SS
   Mitsuda, M
   Minami, K
   Li, BY
   Yokota, H
AF Cui, Changpeng
   Huo, Qingji
   Xiong, Xue
   Na, Sungsoo
   Mitsuda, Masaru
   Minami, Kazumasa
   Li, Baiyan
   Yokota, Hiroki
TI P18: Novel Anticancer Peptide from Induced Tumor Suppressing Cells
   Targeting Breast Cancer and Bone Metastasis
SO CANCERS
LA English
DT Article
DE breast cancer; anticancer peptides; iTSCs; bone metastasis; GTPase
ID GTPASES
AB Simple Summary This study focused on finding effective anticancer peptides (ACPs) from induced tumor suppressing cells (iTSCs) to combat breast cancer metastasis to the skeletal system. This study identified P18 as the most potent ACP from a pool of candidates, derived from a protein called Arhgdia. P18 showed significant inhibitory effects on breast cancer cell viability, migration, and invasion, as well as interfering with certain cancer promoting proteins and GTPase signaling. Importantly, P18 demonstrated enhanced effectiveness when combined with traditional chemotherapy drugs, without significantly affecting healthy cells. Moreover, it mitigated the bone loss associated with breast cancer spread to bones. This study suggests that P18, especially in its modified form (Ac P18 NH2), could be a promising candidate for breast cancer treatment and preventing bone destruction by regulating specific cellular signaling pathways.Abstract Background: The skeletal system is a common site for metastasis from breast cancer. In our prior work, we developed induced tumor suppressing cells (iTSCs) capable of secreting a set of tumor suppressing proteins. In this study, we examined the possibility of identifying anticancer peptides (ACPs) from trypsin digested protein fragments derived from iTSC proteomes. Methods: The efficacy of ACPs was examined using an MTT based cell viability assay, a Scratch based motility assay, an EdU based proliferation assay, and a transwell invasion assay. To evaluate the mechanism of inhibitory action, a fluorescence resonance energy transfer (FRET) based GTPase activity assay and a molecular docking analysis were conducted. The efficacy of ACPs was also tested using an ex vivo cancer tissue assay and a bone microenvironment assay. Results: Among the 12 ACP candidates, P18 (TDYMVGSYGPR) demonstrated the most effective anticancer activity. P18 was derived from Arhgdia, a Rho GDP dissociation inhibitor alpha, and exhibited inhibitory effects on the viability, migration, and invasion of breast cancer cells. It also hindered the GTPase activity of RhoA and Cdc42 and downregulated the expression of oncoproteins such as Snail and Src. The inhibitory impact of P18 was additive when it was combined with chemotherapeutic drugs such as Cisplatin and Taxol in both breast cancer cells and patient derived tissues. P18 had no inhibitory effect on mesenchymal stem cells but suppressed the maturation of RANKL stimulated osteoclasts and mitigated the bone loss associated with breast cancer. Furthermore, the P18 analog modified by N terminal acetylation and C terminal amidation (Ac P18 NH2) exhibited stronger tumor suppressor effects. Conclusions: This study introduced a unique methodology for selecting an effective ACP from the iTSC secretome. P18 holds promise for the treatment of breast cancer and the prevention of bone destruction by regulating GTPase signaling.
C1 [Cui, Changpeng; Huo, Qingji; Xiong, Xue; Li, Baiyan] Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin 150081, Peoples R China.
   [Cui, Changpeng; Huo, Qingji; Xiong, Xue; Na, Sungsoo; Yokota, Hiroki] Indiana Univ Purdue Univ Indianapolis, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Mitsuda, Masaru] Chubu Univ, Frontier Res Inst, Kasugai, Aichi 4878501, Japan.
   [Minami, Kazumasa] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Suita 5650871, Japan.
   [Yokota, Hiroki] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46202 USA.
   [Yokota, Hiroki] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
C3 Harbin Medical University; Purdue University System; Purdue University;
   Purdue University in Indianapolis; Chubu University; University of
   Osaka; Indiana University System; Indiana University Indianapolis;
   Indiana University System; Indiana University Bloomington
RP Li, BY (通讯作者)，Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin 150081, Peoples R China.; Yokota, H (通讯作者)，Indiana Univ Purdue Univ Indianapolis, Dept Biomed Engn, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
EM cuich@iu.edu; qingjihuo1106@gmail.com; xiongxue@iu.edu; sungna@iu.edu;
   mitsuda0620@isc.chubu.ac.jp; k_minami@radonc.med.osaka u.ac.jp;
   liby@ems.hrbmu.edu.cn; hyokota@iu.edu
RI Xiong, Xue/NFU 0252 2025
OI Yokota, Hiroki/0000 0002 7881 8959; Li, Bai yan/0000 0002 1853 0216;
   Minami, Kazumasa/0000 0002 3864 6478
FU The 100 Voices of Hope; National Natural Science Foundation of China
   [81971326]
FX This research was funded by the 100 Voices of Hope (H.Y.) and the
   National Natural Science Foundation of China, 81971326 (BYL).
CR Alizadeh AA, 2021, CURR COMPUT AID DRUG, V17, P225, DOI 10.2174/1573409916666200217091456
   Anand U, 2023, GENES DIS, V10, P1367, DOI 10.1016/j.gendis.2022.02.007
   Barrios CH, 2022, BREAST, V62, pS3, DOI 10.1016/j.breast.2022.02.003
   Bezu L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1511506
   Cui CP, 2023, AM J CANCER RES, V13, P4057
   Cui CP, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15102447
   Debela DT, 2021, SAGE OPEN MED, V9, DOI 10.1177/20503121211034366
   Dominari Asimina, 2020, World J Virol, V9, P67, DOI 10.5501/wjv.v9.i5.67
   Gähwiler EKN, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.639699
   Garaci E, 2000, INT J IMMUNOPHARMACO, V22, P1067, DOI 10.1016/S0192 0561(00)00075 8
   Houthuijzen JM, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 35793 w
   Huang Y, 2017, ONCOL REP, V37, P2063, DOI 10.3892/or.2017.5440
   Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582 6591.2002
   Li KX, 2022, THERANOSTICS, V12, P3084, DOI 10.7150/thno.70549
   Liu HH, 2023, J MOL MODEL, V29, DOI 10.1007/s00894 023 05507 6
   Marazzi F, 2020, CANCERS, V12, DOI 10.3390/cancers12092390
   Miura K, 2003, PROTEOMICS, V3, P1097, DOI 10.1002/pmic.200300428
   Palazzi L, 2020, J PEPT SCI, V26, DOI 10.1002/psc.3279
   Quandt J, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1500671
   Quemé Peña M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168613
   Rossi M, 2022, MOLECULES, V27, DOI 10.3390/molecules27123751
   Tyagi A, 2015, NUCLEIC ACIDS RES, V43, pD837, DOI 10.1093/nar/gku892
   Wan QQ, 2013, BIOCHEM BIOPH RES CO, V433, P502, DOI 10.1016/j.bbrc.2013.03.020
   Wang XY, 2021, AM J CANCER RES, V11, P2401
   Wang XY, 2022, INT J BIOL MACROMOL, V222, P1531, DOI 10.1016/j.ijbiomac.2022.09.259
   Yang QB, 2023, ADV SCI, V10, DOI 10.1002/advs.202300898
   Yewdell JW, 2022, MOL CELL PROTEOMICS, V21, DOI 10.1016/j.mcpro.2022.100230
   Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049
   Zhang B, 2017, CHEM BIOL DRUG DES, V90, P972, DOI 10.1111/cbdd.13023
   Zhou HX, 2018, CHEM REV, V118, P1691, DOI 10.1021/acs.chemrev.7b00305
NR 30
TC 3
Z9 3
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD JUN
PY 2024
VL 16
IS 12
AR 2230
DI 10.3390/cancers16122230
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA WJ5M1
UT WOS:001254515800001
PM 38927935
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Russell, MR
   Liu, QX
   Fatatis, A
AF Russell, Mike R.
   Liu, Qingxin
   Fatatis, Alessandro
TI Targeting the α Receptor for Platelet Derived Growth Factor as a Primary
   or Combination Therapy in a Preclinical Model of Prostate Cancer
   Skeletal Metastasis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID IN VIVO; MOLECULAR MECHANISMS; ZOLEDRONIC ACID; BONE METASTASES; TUMOR;
   BISPHOSPHONATES; CELLS; MICROENVIRONMENT; EXPRESSION; DISEASE
AB Purpose: Platelet derived growth factor a (PDGFR alpha) is highly expressed in primary prostate cancer and associated skeletal metastases. Here, we tested whether targeting this receptor could impair metastatic colonization and progression, as well as prolong survival, either as primary or as combination therapy.
   Experimental Design: We used a preclinical animal model of metastasis in which PC3 ML human prostate cancer cells are inoculated directly in the blood circulation. First, the humanized, monoclonal antibody IMC 3G3 was administered to mice bearing established skeletal metastases. Second, we targeted the stromal PDGFR alpha with IMC 1E10, an antibody specific for the murine receptor. Third, IMC 3G3 and the bisphosphonate zoledronic acid (ZA), administered separately or in combination, were tested on the progression of skeletal lesions and overall survival. In addition, the ability of IMC 3G3 and ZA to impair initial colonization of the bone marrow by prostate cancer cells was investigated.
   Results: The blockade of PDGFR alpha on prostate cancer cells by IMC 3G3 reduces the size of established skeletal metastases, whereas the IMC 1E10 antibody directed against the stromal PDGFR alpha fails to inhibit metastatic progression. IMC 3G3 and ZA, either separately or in combination, significantly slow tumor growth and seem to prolong survival. Lastly, the blockade of PDGFR alpha by IMC 3G3 inhibits the initial phase of bone colonization, whereas ZA is ineffective at this stage.
   Conclusion: This study presents compelling evidence that targeting PDGFR alpha with IMC 3G3 delays the progression of early metastatic foci and reduces the size of more established lesions. In addition, IMC 3G3, either alone or in combination with ZA, prolongs survival in animal models. Clin Cancer Res; 16(20); 5002 10. (C) 2010 AACR.
C1 [Russell, Mike R.; Liu, Qingxin; Fatatis, Alessandro] Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA.
   [Fatatis, Alessandro] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA.
C3 Drexel University; Drexel University
RP Fatatis, A (通讯作者)，Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St,MS 488, Philadelphia, PA 19102 USA.
EM afatatis@drexelmed.edu
OI Russell, Mike/0009 0009 5898 2020
FU W.W. Smith Charitable Trust; Department of Defense [PC080987, PC094227]
FX W.W. Smith Charitable Trust and Department of Defense Prostate Cancer
   Program grant PC080987 (A. Fatatis), and Department of Defense Prostate
   Cancer Predoctoral Fellowship Award (PC094227; M. R. Russell).
CR Abrahamsen B, 2010, CURR OPIN RHEUMATOL, V22, P404, DOI 10.1097/BOR.0b013e32833ad677
   Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008 5472.CAN 08 2724
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Bagi CM, 2005, ADV DRUG DELIVER REV, V57, P995, DOI 10.1016/j.addr.2004.12.014
   Ball SG, 2007, J CELL BIOL, V177, P489, DOI 10.1083/jcb.200608093
   Body JJ, 2002, SUPPORT CARE CANCER, V10, P399, DOI 10.1007/s005200100292
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002 9440(10)65229 7
   Clarke NW, 2009, ASIAN J ANDROL, V11, P57, DOI 10.1038/aja.2008.29
   Coleman RE, 2008, CLIN CANCER RES, V14, P6387, DOI 10.1158/1078 0432.CCR 08 1572
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   D'Ambrosio J, 2009, CLIN EXP METASTAS, V26, P955, DOI 10.1007/s10585 009 9286 3
   Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801
   Dolloff NG, 2007, CANCER RES, V67, P555, DOI 10.1158/0008 5472.CAN 06 2593
   Dolloff NG, 2005, ONCOGENE, V24, P6848, DOI 10.1038/sj.onc.1208815
   FUDGE K, 1994, MODERN PATHOL, V7, P549
   Gassmann P, 2008, CLIN EXP METASTAS, V25, P171, DOI 10.1007/s10585 007 9130 6
   Gnant M, 2009, CURR CANCER DRUG TAR, V9, P824, DOI 10.2174/156800909789760267
   Gomes RR, 2009, CLIN EXP METASTAS, V26, P641, DOI 10.1007/s10585 009 9263 x
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hatoum HT, 2008, CANCER, V113, P1438, DOI 10.1002/cncr.23775
   HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460 2075.1992.tb05523.x
   Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283
   Hofer MD, 2004, NEOPLASIA, V6, P503, DOI 10.1593/neo.04157
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097 2765(01)00182 4
   Loberg RD, 2005, J CELL BIOCHEM, V96, P439, DOI 10.1002/jcb.20522
   Loizos N, 2005, MOL CANCER THER, V4, P369
   Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585 008 9182 2
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Mohammad KS, 2009, ANTI CANCER AGENT ME, V9, P1079, DOI 10.2174/187152009789735008
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Orr F. William, 2000, Cancer, V88, P2912, DOI 10.1002/1097 0142(20000615)88:12+<2912::AID CNCR6>3.0.CO;2 8
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Russell MR, 2009, ONCOGENE, V28, P412, DOI 10.1038/onc.2008.390
   Russell MR, 2010, CANCER RES, V70, P4195, DOI 10.1158/0008 5472.CAN 09 4712
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saad F, 2004, EUR UROL, V45, P26, DOI 10.1016/j.eururo.2003.10.003
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Shah GD, 2010, CANCER AM CANCER SOC, V116, P1018, DOI 10.1002/cncr.24788
   Shen JQ, 2006, J BIOL CHEM, V281, P10706, DOI 10.1074/jbc.M513415200
   Thiolloy S, 2009, CANCER RES, V69, P6747, DOI 10.1158/0008 5472.CAN 08 3949
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432 0436.1991.tb00250.x
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
NR 45
TC 38
Z9 48
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2010
VL 16
IS 20
BP 5002
EP 5010
DI 10.1158/1078 0432.CCR 10 1863
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 663IT
UT WOS:000282877700012
PM 20813817
DA 2025 08 17
ER

PT J
AU Chen, LQ
   Wang, YJ
   Wells, D
   Toh, D
   Harold, H
   Zhou, J
   DiGiammarino, E
   Meehan, EJ
AF Chen, Liqing
   Wang, Yujun
   Wells, David
   Toh, Diana
   Harold, Hunt
   Zhou, Jing
   DiGiammarino, Enrico
   Meehan, Edward J.
TI Structure of the SH3 domain of human osteoclast stimulating factor at
   atomic resolution
SO ACTA CRYSTALLOGRAPHICA SECTION F STRUCTURAL BIOLOGY COMMUNICATIONS
LA English
DT Article
ID HIGH AFFINITY PEPTIDE; CRYSTAL STRUCTURE; PROTEIN STRUCTURES; LIGAND;
   SRC
AB Osteoclast stimulating factor (OSF) is an intracellular signaling protein, produced by osteoclasts themselves, that enhances osteoclast formation and bone resorption. It is thought to act via an Src related signaling pathway and contains SH3 and ankyrin repeat domains which are involved in protein protein interactions. As part of a structure based anti bone  loss drug design program, the atomic resolution X ray structure of the recombinant human OSF SH3 domain (hOSF SH3) has been determined. The domain, residues 12 72, yielded crystals that diffracted to the ultrahigh resolution of 1.07 angstrom. The overall structure shows a characteristic SH3 fold consisting of two perpendicular beta sheets that form a alpha barrel. Structure based sequence alignment reveals that the putative proline rich peptide binding site of hOSF SH3 consists of (i) residues that are highly conserved in the SH3 domain family, including residues Tyr21, Phe23, Trp49, Pro62, Asn64 and Tyr65, and (ii) residues that are less conserved and/or even specific to hOSF, including Thr22, Arg26, Thr27, Glu30, Asp46, Thr47, Asn48 and Leu60, which might be key to designing specific inhibitors for hOSF to fight osteoporosis and related bone loss diseases. There are a total of 13 well defined water molecules forming hydrogen bonds with the above residues in and around the peptide binding pocket. Some of those water molecules might be important for drug design approaches. The hOSF SH3 structure at atomic resolution provides an accurate framework for structure based design of its inhibitors.
C1 Univ Alabama, Struct Biol Lab, Huntsville, AL 35899 USA.
   Univ Alabama, Dept Chem, Huntsville, AL 35899 USA.
   Univ Alabama, Grad Program Biotechnol, Huntsville, AL 35899 USA.
C3 University of Alabama System; University of Alabama Huntsville;
   University of Alabama System; University of Alabama Huntsville;
   University of Alabama System; University of Alabama Huntsville
RP Chen, LQ (通讯作者)，Univ Alabama, Struct Biol Lab, Huntsville, AL 35899 USA.
EM chenlq@uah.edu
RI Wang, Yujun/C 6962 2013
CR Berisio R, 2001, ACTA CRYSTALLOGR D, V57, P337, DOI 10.1107/S090744490001581X
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
   ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0
   Fazi B, 2002, J BIOL CHEM, V277, P5290, DOI 10.1074/jbc.M109848200
   Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001
   Hoelz A, 2006, J MOL BIOL, V358, P509, DOI 10.1016/j.jmb.2006.02.027
   Holm L, 1998, PROTEINS, V33, P88, DOI 10.1002/(SICI)1097 0134(19981001)33:1<88::AID PROT8>3.0.CO;2 H
   HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Kurihara N, 2001, J BIOL CHEM, V276, P41035, DOI 10.1074/jbc.M100233200
   MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522
   Massenet C, 2005, J BIOL CHEM, V280, P13752, DOI 10.1074/jbc.M412897200
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Pisabarro MT, 1998, J MOL BIOL, V281, P513, DOI 10.1006/jmbi.1998.1932
   Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097 4652(199812)177:4<636::AID JCP14>3.0.CO;2 H
   Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.10
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076 6879(97)77018 6
   Wisniewska M, 2005, J MOL BIOL, V347, P1005, DOI 10.1016/j.jmb.2005.02.017
   WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969 2126(01)00151 4
   Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0
NR 22
TC 4
Z9 4
U1 0
U2 1
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
EI 2053 230X
J9 ACTA CRYSTALLOGR F
JI Acta Crystallogr. F Struct. Biol. Commun.
PD SEP
PY 2006
VL 62
BP 844
EP 848
DI 10.1107/S1744309106030004
PN 9
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA 079XZ
UT WOS:000240212500004
PM 16946461
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Iwatake, M
   Okamoto, K
   Tanaka, T
   Tsukuba, T
AF Iwatake, Mayumi
   Okamoto, Kuniaki
   Tanaka, Takashi
   Tsukuba, Takayuki
TI Punicalagin attenuates osteoclast differentiation by impairing NFATc1
   expression and blocking Akt  and JNK dependent pathways
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Osteoclasts; Punicalagin; NFATc1
ID NF KAPPA B; CYSTEINE PROTEINASE; CATHEPSIN K; POMEGRANATE JUICE;
   MOLECULAR CLONING; HEME OXYGENASE 1; BONE RESORPTION; GRANATUM L; RANKL;
   ACTIVATION
AB Punicalagin is a bioactive polyphenol that is classified as an ellagitannin. Although punicalagin has been shown to have various pharmacological effects, such as anti oxidative, anti inflammatory, and anti tumor effects, no studies have reported the effects of punicalagin on osteoclasts (OCLs). In this study, we investigated the effects of punicalagin on OCL differentiation by receptor activator of nuclear factor kappa B ligand in the murine monocytic RAW D cell line and bone marrow derived macrophages (BMMs). Treatment with punicalagin significantly inhibited OCL formation from RAW D cells and BMMs and prevented bone resorption of BMM derived OCLs. Moreover, punicalagin impaired multinucleation and actin ring formation in OCLs, and decreased the protein levels of nuclear factor of activated T cells cytoplasmic 1 (NFATc1), which is a master regulator of OCL differentiation, and concomitantly reduced the expression levels of Src and cathepsin K, which are transcriptionally regulated by NFATc1. The effects of punicalagin on intracellular signaling during the OCL differentiation of BMMs indicated that punicalagin treated OCLs displayed markedly reduced phosphorylation of Jun N terminal kinase and Akt, and partially impaired phosphorylation of extracellular signal regulated kinase, p38 mitogen activated protein kinase, and inhibitor of nuclear factor kappa B alpha compared with untreated OCLs. Thus, punicalagin may affect bone metabolism by inhibiting OCL differentiation.
C1 [Iwatake, Mayumi; Okamoto, Kuniaki; Tsukuba, Takayuki] Nagasaki Univ, Div Dent Pharmacol, Grad Sch Biomed Sci, Nagasaki 8528588, Japan.
   [Tanaka, Takashi] Nagasaki Univ, Div Nat Prod Chem, Grad Sch Biomed Sci, Bunkyo Ku, Nagasaki 8528521, Japan.
C3 Nagasaki University; Nagasaki University
RP Tsukuba, T (通讯作者)，Nagasaki Univ, Div Dent Pharmacol, Grad Sch Biomed Sci, Sakamoto 1 7 1, Nagasaki 8528588, Japan.
EM tsuta@nagasaki u.ac.jp
RI ; Tsukuba, Takayuki/I 9542 2018
OI Tanaka, Takashi/0000 0001 7762 7432; 
FU [25293383];  [15H05298];  [30264055]; Grants in Aid for Scientific
   Research [25293383, 25462920, 15H00662, 26670906, 15H05298] Funding
   Source: KAKEN
FX We thank Dr. Kazuhisa Nishishita for providing recombinant RANKL, and
   Dr. Eiko Sakai for useful comments. This study was supported in part by
   Grants in Aid for Scientific Research (B) Grant Numbers 25293383,
   15H05298, and for Exploratory Research Grant Number 30264055 (T.T).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cerdá B, 2003, EUR J NUTR, V42, P18, DOI 10.1007/s00394 003 0396 4
   Chen BS, 2012, AM J PHYSIOL ENDOC M, V302, pE1142, DOI 10.1152/ajpendo.00003.2012
   Chen PS, 2006, TOXICOL LETT, V163, P44, DOI 10.1016/j.toxlet.2005.09.026
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795
   HAYMAN AR, 1994, J BIOL CHEM, V269, P1294
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SI, 2008, BIOCHEM BIOPH RES CO, V371, P799, DOI 10.1016/j.bbrc.2008.04.150
   Lin CC, 1998, J PHARM PHARMACOL, V50, P789, DOI 10.1111/j.2042 7158.1998.tb07141.x
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Maus M, 2013, J LEUKOCYTE BIOL, V93, P537, DOI 10.1189/jlb.0312169
   Narahara S, 2012, CELL TISSUE RES, V348, P81, DOI 10.1007/s00441 012 1325 8
   Olajide OA, 2014, MOL NUTR FOOD RES, V58, P1843, DOI 10.1002/mnfr.201400163
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   SATOMI H, 1993, BIOL PHARM BULL, V16, P787, DOI 10.1248/bpb.16.787
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TANAKA T, 1986, CHEM PHARM BULL, V34, P650
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
   Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193
   Xu XL, 2014, INFLAMMATION, V37, P956, DOI 10.1007/s10753 014 9816 2
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05 4278fje
NR 32
TC 13
Z9 13
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD SEP
PY 2015
VL 407
IS 1 2
BP 161
EP 172
DI 10.1007/s11010 015 2466 3
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CP3KX
UT WOS:000359778900017
PM 26048715
DA 2025 08 17
ER

PT J
AU Wu, D
   Piao, LH
   Wang, GB
AF Wu, Dong
   Piao, Longhuan
   Wang, Guangbin
TI Tescalcin modulates bone marrow derived mesenchymal stem cells
   osteogenic differentiation via the Wnt/β catenin signaling pathway
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE BMSCs; marker; osteogenesis; TESC; Wnt/beta catenin signaling
AB Background: Bone mesenchymal stem cells (BMSCs) are recognized for their intrinsic capacity for self renewal and differentiation into osteoblasts, adipocytes, and chondrocytes, making them pivotal entities within the field of bone research. Tescalcin (TESC) is known to play a role in specific cellular processes related to proliferation and differentiation. However, the precise involvement of TESC in the regulation of BMSCs remains unclear. The present study was designed to verify the functional implications of TESC in BMSCs.Methods: An adenovirus vector was engineered to downregulate TESC expression, and the Wnt/beta catenin signaling pathway was activated using BML 284. The assessment of mRNA was conducted by quantitative real time polymerase chain reaction (qRT PCR). The assessment of protein expression was conducted by Western blotting and immunofluorescence techniques (IF), respectively. Alkaline phosphatase (ALP) staining and activity assays were performed to verify ALP changes, while Alizarin Red S (ARS) staining and quantitative analysis were employed to assess mineralization capacity.Results: Initially, we observed an upregulation of TESC expression during osteogenic differentiation. Subsequently, TESC knockdown was demonstrated to decrease the osteogenic related genes expression and diminish BMSCs mineralization. Concomitantly, we identified the inhibition of Wnt/beta catenin signaling following the TESC knockdown. Furthermore, the administration of BML 284 effectively activated the Wnt/beta catenin pathway, successfully rescuing the compromised TESC mediated osteogenic differentiation.Conclusion: Our findings indicate that TESC knockdown exerts an inhibitory effect on the osteogenic differentiation of BMSCs through the modulation of the Wnt/beta catenin signaling pathway. This study unveils a novel target with potential applications for enhancing the regenerative potential of BMSCs in the realm of regenerative medicine.
C1 [Wu, Dong; Wang, Guangbin] China Med Univ, Dept Orthopaed, Shengjing Hosp, Shenyang, Liaoning, Peoples R China.
   [Piao, Longhuan] Fudan Univ, Sch Life Sci, Shanghai, Peoples R China.
C3 China Medical University; Fudan University
RP Wang, GB (通讯作者)，China Med Univ, Dept Orthopaed, Shengjing Hosp, Shenyang, Liaoning, Peoples R China.
EM wanggb@sj hospital.org
OI Wu, Dong/0000 0002 5488 4548
FU Natural Science Foundation of Liaoning Province
FX We appreciate the support and fund from Professor Guangbin Wang.
CR Arjmand B, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00430
   Arthur A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249759
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gao JL, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6666836
   Gao QM, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.787118
   Jiang Y, 2020, EXP THER MED, V19, P817, DOI 10.3892/etm.2019.8308
   Kobayashi S, 2015, J MOL CELL CARDIOL, V84, P133, DOI 10.1016/j.yjmcc.2015.04.018
   Kolobynina KG, 2016, J CELL SCI, V129, P3533, DOI 10.1242/jcs.191486
   Komori T, 2020, J ORAL BIOSCI, V62, P223, DOI 10.1016/j.job.2020.05.004
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313
   Lee JH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29142 x
   Levay K, 2007, J CLIN INVEST, V117, P2672, DOI 10.1172/JCI27465
   Levay K, 2010, EXP CELL RES, V316, P1254, DOI 10.1016/j.yexcr.2010.01.007
   Long HT, 2017, DNA CELL BIOL, V36, P715, DOI 10.1089/dna.2017.3657
   Luo AJ, 2019, EXP MOL PATHOL, V107, P110, DOI 10.1016/j.yexmp.2018.12.004
   Meng YL, 2020, CHEMOSPHERE, V255, DOI 10.1016/j.chemosphere.2020.126889
   Papukashvili D, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112957
   Si JY, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919159
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Zeng X, 2020, GENE, V744, DOI 10.1016/j.gene.2020.144564
   Zhang R, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03812 7
   Zhou ZG, 2020, CANCER COMMUN, V40, P355, DOI 10.1002/cac2.12069
NR 24
TC 2
Z9 2
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1520 4081
EI 1522 7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD MAR
PY 2024
VL 39
IS 3
BP 1836
EP 1846
DI 10.1002/tox.24070
EA DEC 2023
PG 11
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA HI4B0
UT WOS:001128642800001
PM 38124301
DA 2025 08 17
ER

PT J
AU Wu, ZX
   Hu, LF
   Zhang, WJ
   Ru, K
   Xu, X
   Liu, SY
   Liu, H
   Jia, YX
   Chen, ZH
   Qian, AR
AF Wu, Zixiang
   Hu, Lifang
   Zhang, Wenjuan
   Ru, Kang
   Xu, Xia
   Liu, Shuyu
   Liu, Hua
   Jia, Yunxia
   Chen, Zhihao
   Qian, Airong
TI Fisetin enhances osteoblast differentiation and bone formation under
   simulated microgravity
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Fisetin; CDK12; Osteoblast differentiation; Simulated microgravity;
   Osteoporosis
ID IN VITRO
AB Osteoporosis is a systemic bone disease characterized by decreased bone density and mass, compromised bone microstructure, increased bone fragility, and susceptibility to fractures. In recent years, as space exploration activities have intensified, the health issues faced by astronauts during prolonged space missions have increasingly become a focal point in scientific research. In particular, the problem of bone loss resulting from astronauts' extended exposure to microgravity environments has emerged as a significant area of study within space medicine and biological sciences. Currently, small natural product have become promising intervention strategies in this field. Previous studies have proved that cyclin dependent kinase 12 (CDK12) is an effective screening target for the treatment strategy of osteoporosis. The purpose of this paper is to evaluate the preventive and therapeutic effects of a small natural product, Fisetin, which was screened with targeting CDK12. In this study, based on the method of weighted set similarity (WES), the small natural product Fisetin, was screened and obtained by targeting CDK12. The Alkaline Phosphatase (ALP) staining and Alizarin red S (ARS) staining, as well as the mRNA and protein expression levels of osteoblast related markers, Runt related Transcription Factor 2 (RUNX2) and Collagen Type I Alpha 1 (COL1A1), were used to detect the effect of Fisetin on osteoblast differentiation. The micro CT and Dual energy X ray absorptiometry (DXA) analysis were used to evaluate the efficacy of Fisetin in preventing and treating osteoporosis in hindlimb unloaded (HU) mice and ovariectomized (OVX) mice model. The findings revealed that Fisetin promotes osteoblast differentiation and further proved that Fisetin could alleviate the bone loss in HU mice and OVX mice. Additionally, the expression of CDK12 and phospho RUNX2 (pRUNX2) were significantly down regulated in the process of promoting osteoblast differentiation and bone formation. Further research revealed the potential and preliminary molecular mechanism that Fisetin might release RUNX2 and reduce the phosphorylation of p RUNX2 by down regulating the expression of CDK12, thereby enhancing the transcription of osteoblast differentiation. In conclusion, Fisetin demonstrates efficacy in improving osteoporosis and holds promise as a potential small natural product to prevent and treat osteoporosis.
C1 [Wu, Zixiang; Hu, Lifang; Zhang, Wenjuan; Ru, Kang; Xu, Xia; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Lab Bone Metab, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.
   [Wu, Zixiang; Hu, Lifang; Zhang, Wenjuan; Ru, Kang; Xu, Xia; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Xian Key Lab Special Med & Hlth Engn, Xian 710072, Peoples R China.
   [Wu, Zixiang; Hu, Lifang; Zhang, Wenjuan; Ru, Kang; Xu, Xia; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn, Sch Life Sci, Xian 710072, Peoples R China.
   [Wu, Zixiang; Hu, Lifang; Zhang, Wenjuan; Ru, Kang; Xu, Xia; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian 710072, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; Northwestern
   Polytechnical University
RP Hu, LF; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Lab Bone Metab, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.
EM hulifang@nwpu.edu.cn; qianair@nwpu.edu.cn
RI Hu, Lifang/W 8020 2019; chen, zhihao/GXM 3816 2022
FU National Natural Science Foundation of China [81772017, 82072106]; Young
   Talent Fund of the University Association for Science and Technology in
   Shaanxi, China [20170401]; Natural Science Basic Research Plan in
   Shaanxi Province of China [2023 JC YB 163]
FX The authors would like to express their gratitude for the financial
   support received from the National Natural Science Foundation of China
   (Grant numbers 81772017 and 82072106) , the Young Talent Fund of the
   University Association for Science and Technology in Shaanxi, China
   (Grant number 20170401) , and the Natural Science Basic Research Plan in
   Shaanxi Province of China (Grant number 2023 JC YB 163.
CR Bonanni R, 2023, LIFE BASEL, V13, DOI 10.3390/life13071423
   Chiang SS, 2013, APPL MICROBIOL BIOT, V97, P1489, DOI 10.1007/s00253 012 4675 y
   Choi SW, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/810563
   Donaldson Julie G, 2015, Curr Protoc Cell Biol, V69, DOI 10.1002/0471143030.cb0403s69
   Droppert P M, 1990, J Br Interplanet Soc, V43, P19
   Feng P, 2022, J OLEO SCI, V71, P105, DOI 10.5650/jos.ess21252
   Globus RK, 2016, J APPL PHYSIOL, V120, P1196, DOI 10.1152/japplphysiol.00997.2015
   Grimm D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136697
   Hambright WS, 2023, J OSTEOPOROS, V2023, DOI 10.1155/2023/5572754
   Hodkinson PD, 2017, BRIT J ANAESTH, V119, pI143, DOI 10.1093/bja/aex336
   Inada Masaki, 2011, Clin Calcium, V21, P164, DOI CliCa1102164170
   Jin X, 2022, NPJ MICROGRAVITY, V8, DOI 10.1038/s41526 022 00210 x
   Kheiry EV, 2018, IRAN J BASIC MED SCI, V21, P965, DOI 10.22038/IJBMS.2018.25465.6296
   Kim YH, 2014, J NUTR BIOCHEM, V25, P295, DOI 10.1016/j.jnutbio.2013.11.003
   Lóotoing L, 2014, MOL NUTR FOOD RES, V58, P1239, DOI 10.1002/mnfr.201300836
   Léotoing L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068388
   Li W, 2019, METHODS MOL BIOL, V1854, P175, DOI 10.1007/7651_2018_124
   Lin KH, 2023, PHYTOTHER RES, V37, P3964, DOI 10.1002/ptr.7855
   Loomer PM, 2001, CRIT REV ORAL BIOL M, V12, P252, DOI 10.1177/10454411010120030401
   Ma XL, 2021, EUR J PHARMACOL, V911, DOI 10.1016/j.ejphar.2021.174555
   Molagoda IMN, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114676
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev bioeng 062117 121139, 10.1146/annurev bioeng 062117121139]
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Wang X, 2022, FOOD FUNCT, V13, P2913, DOI [10.1039/d1fo02755g, 10.1039/D1FO02755G]
   Zhang WJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00743
   Zhang WJ, 2016, CURR PHARM DESIGN, V22, P3171, DOI 10.2174/1381612822666160224142812
   Zhu Bin, 2012, Zhongguo Gu Shang, V25, P611
NR 27
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094 5765
EI 1879 2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD MAR
PY 2025
VL 228
BP 724
EP 739
DI 10.1016/j.actaastro.2024.12.045
EA DEC 2024
PG 16
WC Engineering, Aerospace
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA T1Z6C
UT WOS:001403077200001
DA 2025 08 17
ER

PT J
AU Bellini, G
   Torella, M
   Manzo, I
   Tortora, C
   Luongo, L
   Punzo, F
   Colacurci, N
   Nobili, B
   Maione, S
   Rossi, F
AF Bellini, Giulia
   Torella, Marco
   Manzo, Iolanda
   Tortora, Chiara
   Luongo, Livio
   Punzo, Francesca
   Colacurci, Nicola
   Nobili, Bruno
   Maione, Sabatino
   Rossi, Francesca
TI PKCβII mediated cross talk of TRPV1/CB2 modulates the
   glucocorticoid induced osteoclast overactivity
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Osteoporosis; Endovanilloids; Endocannabinoids; Osteoclasts; Steroids
ID SUPPRESS BONE FORMATION; INDUCED OSTEOPOROSIS; CANNABINOID RECEPTORS;
   INCREASED RISK; FRACTURE; CORTICOSTEROIDS; MECHANISMS; DENSITY;
   EPIDEMIOLOGY; METAANALYSIS
AB In this study, we investigated the role of the endovanilloid/endocannabinoid system in the glucocorticoid induced osteoclast overactivity.
   Receptorial and enzymatic component of the endovanilloid/endocannabinoid system are expressed in bone cells, and dysregulated when bone mass is reduced. Moreover, blockade or desensitization of vanilloid receptor I (TRPV1) and/or stimulation of cannabinoid receptor 2 (CB2) are beneficial for reducing number and activity of the bone cells modulating resorption, the osteoclasts.
   We have treated in vitro healthy woman derived osteoclasts with methylprednisolone in presence or not of CB2 or TRPV1 agonists/antagonists, analysing the effect on osteoclast function and morphology through a multidisciplinary approach. Moreover, a treatment with a protein kinase C inhibitor to evaluate osteoclast activity and endovanilloid/endocannabinoid component expression levels was performed in osteoclasts derived from healthy subjects in presence of not of methylprednisolone.
   Our results show, for the first time, that the endovanilloid/endocannabinoid system is dysregulated by the treatment with methylprednisolone, that the osteoclast activity is increased and that pharmacological compounds stimulating CB2 or inhibiting TRPVI might reduce, possible inhibiting protein kinase C beta II, the methylprednisolone induced osteoclast over activation, suggesting their therapeutic use for protecting from the glucocorticoid induced bone mass loss. (C) 2016 Published by Elsevier Ltd.
C1 [Bellini, Giulia; Manzo, Iolanda; Tortora, Chiara; Luongo, Livio; Maione, Sabatino] Univ Naples 2, Dept Expt Med, I 80138 Naples, Italy.
   [Torella, Marco; Punzo, Francesca; Colacurci, Nicola; Nobili, Bruno; Rossi, Francesca] Univ Naples 2, Dept Woman Child & Gen & Specialist Surg, I 80138 Naples, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli
RP Rossi, F (通讯作者)，Univ Naples 2, Dept Woman Child & Gen & Specialist Surg, I 80138 Naples, Italy.
EM francesca.rossi@unina2.it
RI ; Luongo, Livio/GXV 1993 2022; torella, marco/I 7608 2012; maione,
   sabatino/HTM 5113 2023; Rossi, Francesca/HTP 5870 2023
OI Torella, Marco/0000 0001 8853 5760; Rossi,
   Francesca/0000 0003 2879 6277; Maione, Sabatino/0000 0003 3850 6704
CR [Anonymous], 2014, J. Am. Ceram. Soc
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Corsini E, 2014, PHARMACOL RES, V81, P10, DOI 10.1016/j.phrs.2014.01.002
   Cote Vélez A, 2008, NEUROCHEM RES, V33, P1582, DOI 10.1007/s11064 008 9698 5
   Di Marzo V, 2012, PHILOS T R SOC B, V367, P3216, DOI 10.1098/rstb.2011.0382
   Di Marzo V, 2009, PHARMACOL RES, V60, P77, DOI 10.1016/j.phrs.2009.02.010
   Fattore L, 2007, PHARMACOL RES, V56, P418, DOI 10.1016/j.phrs.2007.09.004
   Gray RD, 2013, J INFLAMM LOND, V10, DOI 10.1186/1476 9255 10 12
   Hayakawa Nobuki, 2013, Clin Calcium, V23, P1337, DOI CliCa130913371344
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Kalpakcioglu BB, 2011, BONE, V48, P1221, DOI 10.1016/j.bone.2011.02.005
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kim HJ, 2010, BMB REP, V43, P524, DOI 10.5483/BMBRep.2010.43.8.524
   Kuroki Y, 2008, J BONE MINER METAB, V26, P271, DOI 10.1007/s00774 007 0821 5
   Manolagas SC, 2013, J CLIN INVEST, V123, P1919, DOI 10.1172/JCI68062
   Mazziotti G, 2013, NAT REV ENDOCRINOL, V9, P265, DOI 10.1038/nrendo.2013.5
   Natsui K, 2006, OSTEOPOROSIS INT, V17, P105, DOI 10.1007/s00198 005 1923 3
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Riccardi C, 2002, PHARMACOL RES, V45, P361, DOI 10.1006/phrs.2002.0969
   Rossi F, 2014, BRIT J PHARMACOL, V171, P2621, DOI 10.1111/bph.12542
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Rossi F, 2015, PHARMACOL RES, V99, P194, DOI 10.1016/j.phrs.2015.06.010
   Rossi F, 2014, HAEMATOLOGICA, V99, P1876, DOI 10.3324/haematol.2014.104463
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001
   Sato Yukio, 2007, Nihon Rinsho, V65 Suppl 8, P218
   Shin J, 2014, MOL CELLS, V37, P747, DOI 10.14348/molcells.2014.0220
   Steinbuch M, 2004, OSTEOPOROSIS INT, V15, P323, DOI 10.1007/s00198 003 1548 3
   van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223 006 0019 1
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   van Staa TP, 2004, OSTEOPOROSIS INT, V15, P785, DOI 10.1007/s00198 004 1606 5
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Whittier X, 2016, RHEUM DIS CLIN N AM, V42, P177, DOI 10.1016/j.rdc.2015.08.005
   Yao J, 2015, J CELL PHYSIOL, V230, P1235, DOI 10.1002/jcp.24858
NR 41
TC 30
Z9 34
U1 0
U2 2
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JAN
PY 2017
VL 115
BP 267
EP 274
DI 10.1016/j.phrs.2016.11.039
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EI8XB
UT WOS:000392790400025
PM 27919827
DA 2025 08 17
ER

PT J
AU Mahajan, A
   Nengroo, MA
   Datta, D
   Katti, DS
AF Mahajan, Aman
   Nengroo, Mushtaq A.
   Datta, Dipak
   Katti, Dhirendra S.
TI Converse modulation of Wnt/β catenin signaling during expansion and
   differentiation phases of Infrapatellar fat pad derived MSCs for
   improved engineering of hyaline cartilage
SO BIOMATERIALS
LA English
DT Article
DE Cartilage tissue engineering; TGF beta signaling; Wnt modulation;
   Infrapatellar fat pad derived MSCs; Plasma hydrogel; Chondrogenesis;
   Hyaline cartilage
ID MESENCHYMAL STEM CELLS; IN VITRO CHONDROGENESIS; BONE MARROW;
   CHONDROCYTE CULTURES; GROWTH; TISSUE; HYPERTROPHY; REPAIR; PLASMA; WNT
AB Mesenchymal stem cells (MSCs) are potential candidates in cell based therapy for cartilage repair and regeneration. However, during chondrogenic differentiation, MSCs undergo undesirable hypertrophic maturation. This poses a risk of ossification in the neo tissue formed that eventually impedes the clinical use of MSCs for cartilage repair. TGF beta is a potent growth factor used for chondrogenic differentiation of MSCs, however, its role in hypertrophy remains ambiguous. In the present work, we decipher that TGF beta activates Wnt/beta catenin signaling through SMAD3 and increases the propensity of Infrapatellar fat pad derived MSCs (IFP MSCs) towards hypertrophy. Notably, inhibiting TGF beta induced Wnt/beta catenin signaling suppresses hypertrophic progression and enhances chondrogenic ability of IFP MSCs in plasma hydrogels. Additionally, we demonstrate that activating Wnt signaling during expansion phase, promotes proliferation and reduces senescence, while improving stemness of IFP MSCs. Thus, conversely modulating Wnt signaling in vitro during expansion and differentiation phases generates hyaline like cartilage with minimal hypertrophy. Importantly, pre treatment of IFP MSCs encapsulated in plasma hydrogel with Wnt modulators followed by subcutaneous implantation in nude mice resulted in formation of a cartilage tissue with negligible calcification. Overall, this study provides technological advancement on targeting Wnt/beta catenin pathway in a 3D scaffold, while maintaining the standard chondro induction protocol to overcome the challenges associated with the clinical use of MSCs to engineer hyaline cartilage.
C1 [Mahajan, Aman; Katti, Dhirendra S.] Indian Inst Technol Kanpur, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.
   [Mahajan, Aman; Katti, Dhirendra S.] Indian Inst Technol Kanpur, Mehta Family Ctr Engn Med, Kanpur 208016, Uttar Pradesh, India.
   [Nengroo, Mushtaq A.; Datta, Dipak] CSIR Cent Drug Res Inst, Div Canc Biol, Lucknow 226031, Uttar Pradesh, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Kanpur; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT)   Kanpur; Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Katti, DS (通讯作者)，Indian Inst Technol Kanpur, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.
EM dsk@iitk.ac.in
FU Department of Biotechnology, India [BT/PR22445/MED/32/571/2016]; Indian
   Institute of Technology Kanpur (IIT Kanpur); Mehta Family Centre for
   Engineering in Medicine at IIT  Kanpur
FX The work was funded by a Department of Biotechnology, India grant
   (BT/PR22445/MED/32/571/2016) to DSK. AM thanks Indian Institute of
   Technology Kanpur (IIT Kanpur) for institute fellowship. AM and DSK
   thank The Mehta Family Centre for Engineering in Medicine at IIT  Kanpur
   for generous support. DSK gratefully acknowledges the Gireesh Jankinath
   Chair Professorship (2018 2021) and the Rajeeva and San geeta Lahri
   Chair Professorship (2022 2025).
CR Ahmed MR, 2014, OSTEOARTHR CARTILAGE, V22, P1894, DOI 10.1016/j.joca.2014.07.028
   Akeda K, 2006, OSTEOARTHR CARTILAGE, V14, P1272, DOI 10.1016/j.joca.2006.05.008
   Amable PR, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt218
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   Bentley G, 2012, J BONE JOINT SURG BR, V94B, P504, DOI 10.1302/0301 620X.94B4.27495
   Chang CH, 2008, ARTIF ORGANS, V32, P561, DOI 10.1111/j.1525 1594.2008.00575.x
   Chen FH, 2006, NAT CLIN PRACT RHEUM, V2, P373, DOI 10.1038/ncprheum0216
   Chen JL, 2017, ONCOTARGET, V8, P91316, DOI 10.18632/oncotarget.20509
   Dahlin RL, 2014, BIOMATERIALS, V35, P7460, DOI 10.1016/j.biomaterials.2014.05.055
   De Pieri A, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00133 3
   De Ugarte L, 2018, HUM CELL, V31, P33, DOI 10.1007/s13577 017 0181 y
   Deng YH, 2019, BIOMATERIALS, V192, P569, DOI 10.1016/j.biomaterials.2018.11.036
   Dexheimer V, 2016, SCI REP UK, V6, DOI 10.1038/srep36655
   Ding DC, 2015, CELL TRANSPLANT, V24, P1221, DOI 10.3727/096368914X681937
   Eslaminejad MB, 2013, HISTOCHEM CELL BIOL, V140, P623, DOI 10.1007/s00418 013 1121 x
   Fox AJS, 2009, SPORTS HEALTH, V1, P461, DOI 10.1177/1941738109350438
   Frisch J, 2016, J CELL MOL MED, V20, P430, DOI 10.1111/jcmm.12774
   Futrega K, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 020 01520 0
   Goel S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25623 2
   Gudas R, 2012, AM J SPORT MED, V40, P2499, DOI 10.1177/0363546512458763
   Hellingman CA, 2011, TISSUE ENG PT A, V17, P1157, DOI [10.1089/ten.tea.2010.0043, 10.1089/ten.TEA.2010.0043]
   Huang AH, 2009, TISSUE ENG PT A, V15, P3461, DOI [10.1089/ten.tea.2009.0198, 10.1089/ten.TEA.2009.0198]
   Huang XB, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020561
   Im GI, 2010, TISSUE ENG PT A, V16, P2405, DOI [10.1089/ten.tea.2009.0359, 10.1089/ten.TEA.2009.0359]
   Im GI, 2011, BIOTECHNOL LETT, V33, P1061, DOI 10.1007/s10529 010 0514 3
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kouroupis D, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47391 2
   Kwon H, 2019, NAT REV RHEUMATOL, V15, P550, DOI 10.1038/s41584 019 0255 1
   Lamandé SR, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2211510120
   Lehmann J, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 021 04035 x
   Lopa S, 2014, EUR CELLS MATER, V27, P298
   Mahajan A, 2022, JOVE J VIS EXP, DOI 10.3791/63617
   Mahajan A, 2022, ACS APPL MATER INTER, V14, P7531, DOI 10.1021/acsami.1c11840
   Mehlhorn AT, 2006, TISSUE ENG, V12, P1393, DOI 10.1089/ten.2006.12.1393
   Mueller MB, 2008, ARTHRITIS RHEUM US, V58, P1377, DOI 10.1002/art.23370
   Mueller MB, 2010, CELLS TISSUES ORGANS, V192, P158, DOI 10.1159/000313399
   Narcisi R, 2015, STEM CELL REP, V4, P459, DOI 10.1016/j.stemcr.2015.01.017
   Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001
   Park JS, 2011, BIOMATERIALS, V32, P3921, DOI 10.1016/j.biomaterials.2011.02.019
   Pelttari K, 2006, ARTHRITIS RHEUM US, V54, P3254, DOI 10.1002/art.22136
   Peng LY, 2008, STEM CELLS DEV, V17, P761, DOI 10.1089/scd.2007.0217
   Pizzute T, 2016, TISSUE ENG PT A, V22, P1036, DOI [10.1089/ten.tea.2016.0102, 10.1089/ten.TEA.2016.0102]
   Riewruja K, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020890
   Rikkert LG, 2021, PLATELETS, V32, P440, DOI 10.1080/09537104.2020.1779924
   SCHIEBOUTCLARK RC, 1990, AM J CLIN PATHOL, V94, P206, DOI 10.1093/ajcp/94.2.206
   Schulz RM, 2014, J TISSUE ENG REGEN M, V8, P566, DOI 10.1002/term.1561
   Scotti C, 2010, P NATL ACAD SCI USA, V107, P7251, DOI 10.1073/pnas.1000302107
   Shi AY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1281 2
   Solchaga LA, 2010, TISSUE ENG PT A, V16, P1009, DOI [10.1089/ten.tea.2009.0100, 10.1089/ten.TEA.2009.0100]
   Stradner MH, 2016, J ORTHOP RES, V34, P1569, DOI 10.1002/jor.23167
   Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200
   Tanthaisong P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168059
   Tekari A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120857
   ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176
   Tickle C, 2002, AM J MED GENET, V112, P250, DOI 10.1002/ajmg.10774
   Toh WS, 2014, STEM CELL REV REP, V10, P686, DOI 10.1007/s12015 014 9526 z
   Wu CL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20598 y
   Xia HM, 2018, NAT REV MATER, V3, P174, DOI 10.1038/s41578 018 0027 6
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35
   Yang YHK, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0876 3
   Ying J, 2018, LIFE SCI, V192, P84, DOI 10.1016/j.lfs.2017.11.028
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1165 5
   Zhang LM, 2010, BIOTECHNOL LETT, V32, P1339, DOI 10.1007/s10529 010 0293 x
   Zhang Lijie, 2009, Critical Reviews in Biomedical Engineering, V37, P1, DOI 10.1615/CritRevBiomedEng.v37.i1 2.10
   Zhang M, 2010, J BIOL CHEM, V285, P8703, DOI 10.1074/jbc.M109.093526
   Zhang XP, 2004, BONE, V34, P809, DOI 10.1016/j.bone.2003.12.026
   Zhou SH, 2011, J CELL BIOCHEM, V112, P1651, DOI 10.1002/jcb.23079
NR 68
TC 11
Z9 12
U1 1
U2 13
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2023
VL 302
AR 122296
DI 10.1016/j.biomaterials.2023.122296
EA SEP 2023
PG 22
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA U1EC5
UT WOS:001082295400001
PM 37696204
DA 2025 08 17
ER

PT J
AU Bago Horvath, Z
   Schmid, K
   Rössler, F
   Nagy Bojarszky, K
   Funovics, P
   Sulzbacher, I
AF Bago Horvath, Zsuzsanna
   Schmid, Katharina
   Roessler, Fabian
   Nagy Bojarszky, Katalin
   Funovics, Philipp
   Sulzbacher, Irene
TI Impact of RANK signalling on survival and chemotherapy response in
   osteosarcoma
SO PATHOLOGY
LA English
DT Article
DE Chemotherapy response; osteosarcoma; prognosis; RANK; RANKL
ID OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; ZOLEDRONIC ACID;
   GENE EXPRESSION; HIGH GRADE; BONE; PROLIFERATION; PREDICTOR; PATHWAY;
   FAMILY
AB The receptor activator of NF kappa B (RANK) signalling pathway represents a promising target for the therapy of bone related tumours. In the present study we evaluated the impact of the expression of RANK and its ligand (RANKL) on survival and response to chemotherapy in osteosarcoma patients. Expression of RANK and RANKL was examined in 91 human osteosarcomas by immunohistochemistry using formalin fixed, paraffin embedded (FFPE) tumour samples. Results of the stainings were correlated with clinicopathological parameters and patient survival. Sixty three osteosarcomas (69.2%) expressed RANK, whereas only eight cases (8.8%) showed expression of RANKL. Expression of RANK was significantly associated with shorter disease free survival by Kaplan Meier analysis (p = 0.031). We further observed worse response to chemotherapy in RANK expressing tumours, which was statistically not significant (p = 0.099). RANKL expression was significantly more frequent in osteosarcoma of the lower extremity than in any other location. Analysis of RANKL expression did not reveal any statistically significant correlation with disease free or osteosarcoma specific survival. In our study, we identified RANK expression as a negative prognostic factor regarding disease free survival in osteosarcoma. Moreover, RANK might modulate response of human osteosarcoma to chemotherapy. Therefore, RANK signalling cascade is likely to provide a novel alternative to targeted therapy of osteosarcoma and deserves further investigation.
C1 [Bago Horvath, Zsuzsanna; Roessler, Fabian; Nagy Bojarszky, Katalin; Sulzbacher, Irene] Med Univ Vienna, Clin Inst Pathol, A 1090 Vienna, Austria.
   [Schmid, Katharina] Univ Hosp Hamburg Eppendorf, Dept Anat 2, Hamburg, Germany.
   [Funovics, Philipp] Med Univ Vienna, Dept Orthopaed, A 1090 Vienna, Austria.
C3 Medical University of Vienna; University of Hamburg; University Medical
   Center Hamburg Eppendorf; Medical University of Vienna
RP Sulzbacher, I (通讯作者)，Med Univ Vienna, Clin Inst Pathol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM irene.sulzbacher@meduniwien.ac.at
RI ; BagoHorvath, Zsuzsanna/LJK 3308 2024
OI Funovics, Philipp Theodor/0000 0001 9662 5942; Bago Horvath, MD, PhD,
   Zsuzsanna/0000 0002 8555 7806; 
CR Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Atkins GJ, 2001, BONE, V28, P370, DOI 10.1016/S8756 3282(01)00404 5
   Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029
   Bernthal NM, 2012, CANCER AM CANCER SOC, V118, P5888, DOI 10.1002/cncr.27651
   Bielack S, 2009, CANCER TREAT RES, V152, P289, DOI 10.1007/978 1 4419 0284 9_15
   Chen Y, 2012, ONCOL LETT, V3, P1011, DOI 10.3892/ol.2012.604
   Dass CR, 2007, MOL CANCER THER, V6, P3263, DOI 10.1158/1535 7163.MCT 07 0546
   Findlay D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2348
   Gill J, 2013, PHARMACOL THERAPEUT, V137, P89, DOI 10.1016/j.pharmthera.2012.09.003
   Goessl C, 2012, ANN NY ACAD SCI, V1263, P29, DOI 10.1111/j.1749 6632.2012.06674.x
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jin S, 2007, CANCER BIOL THER, V6, P261, DOI 10.4161/cbt.6.2.3621
   Kaste SC, 2004, PEDIATR BLOOD CANCER, V43, P723, DOI 10.1002/pbc.20077
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kubista B, 2006, J ORTHOP RES, V24, P1145, DOI 10.1002/jor.20129
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lee JA, 2011, PEDIATR BLOOD CANCER, V56, P738, DOI 10.1002/pbc.22720
   Mankin HJ, 2004, CLIN ORTHOP RELAT R, P286, DOI 10.1097/01.blo.0000145991.65770.e6
   Mori K, 2007, J PATHOL, V211, P555, DOI 10.1002/path.2140
   Mori K, 2007, ONCOL REP, V18, P1365
   Na KY, 2012, PATHOLOGY, V44, P540, DOI 10.1097/PAT.0b013e32835803bc
   Rousseau J, 2011, J BONE MINER RES, V26, P2452, DOI 10.1002/jbmr.455
   Salinas Souza C, 2013, HUM PATHOL, V44, P2188, DOI 10.1016/j.humpath.2013.04.013
   SALZERKUNTSCHIK M, 1983, PATHOLOGE, V4, P135
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Shimo T, 2007, J CELL COMMUN SIGNAL, V1, P103, DOI 10.1007/s12079 007 0010 2
   Sulzbacher I, 2010, PATHOLOGY, V42, P664, DOI 10.3109/00313025.2010.520310
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Taylor R, 2011, J PATHOL, V225, P195, DOI 10.1002/path.2869
   Wang YM, 2006, J ENDOCRINOL, V189, P279, DOI 10.1677/joe.1.06351
   Wittrant Y, 2006, INT J ONCOL, V28, P261
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
   Zhang WY, 1999, J BONE MINER RES, V14, P528, DOI 10.1359/jbmr.1999.14.4.528
NR 35
TC 33
Z9 35
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0031 3025
EI 1465 3931
J9 PATHOLOGY
JI Pathology
PD AUG
PY 2014
VL 46
IS 5
BP 411
EP 415
DI 10.1097/PAT.0000000000000116
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA AL5LG
UT WOS:000339174500006
PM 24842377
DA 2025 08 17
ER

PT J
AU Zheng, DL
   Decker, KF
   Zhou, TH
   Chen, JQ
   Qi, ZT
   Jacobs, K
   Weilbaecher, KN
   Corey, E
   Long, FX
   Jia, L
AF Zheng, Dali
   Decker, Keith F.
   Zhou, Tianhua
   Chen, Jianquan
   Qi, Zongtai
   Jacobs, Kathryn
   Weilbaecher, Katherine N.
   Corey, Eva
   Long, Fanxin
   Jia, Li
TI Role of WNT7B induced Noncanonical Pathway in Advanced Prostate Cancer
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID RECEPTOR MEDIATED TRANSCRIPTION; OSTEOBLASTIC BONE METASTASES;
   KINASE C DELTA; T CELL FACTOR; BETA CATENIN; ANDROGEN RECEPTOR;
   PKC DELTA; GROWTH; ACTIVATION; PHOSPHORYLATION
AB Advanced prostate cancer is characterized by incurable castration resistant progression and osteoblastic bone metastasis. While androgen deprivation therapy remains the primary treatment for advanced prostate cancer, resistance inevitably develops. Importantly, mounting evidence indicates that androgen receptor (AR) signaling continues to play a critical role in the growth of advanced prostate cancer despite androgen deprivation. While the mechanisms of aberrant AR activation in advanced prostate cancer have been extensively studied, the downstream AR target genes involved in the progression of castration resistance are largely unknown. Here, we identify WNT7B as a direct AR target gene highly expressed in castration resistant prostate cancer (CRPC) cells. Our results show that expression of WNT7B is necessary for the growth of prostate cancer cells and that this effect is enhanced under androgen deprived conditions. Further analyses reveal that WNT7B promotes androgen independent growth of CRPC cells likely through the activation of protein kinase C isozymes. Our results also show that prostate cancer produced WNT7B induces osteoblast differentiation in vitro through a direct cell cell interaction, and that WNT7B is upregulated in human prostate cancer xenografts that cause an osteoblastic reaction when grown in bone. Taken together, these results suggest that AR regulated WNT7B signaling is critical for the growth of CRPC and development of the osteoblastic bone response characteristic of advanced prostate cancer. (C)2013 AACR.
C1 [Zheng, Dali; Decker, Keith F.; Zhou, Tianhua; Qi, Zongtai; Jacobs, Kathryn; Jia, Li] Washington Univ, Sch Med, Ctr Pharmacogenom, St Louis, MO 63110 USA.
   [Weilbaecher, Katherine N.] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA.
   [Zheng, Dali; Decker, Keith F.; Zhou, Tianhua; Chen, Jianquan; Qi, Zongtai; Jacobs, Kathryn; Weilbaecher, Katherine N.; Long, Fanxin; Jia, Li] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Chen, Jianquan; Long, Fanxin] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Corey, Eva] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL); University of
   Washington; University of Washington Seattle
RP Jia, L (通讯作者)，Washington Univ, Sch Med, Ctr Pharmacogenom, Dept Med, 660 S Euclid Ave,Campus Box 8220, St Louis, MO 63110 USA.
EM ljia@dom.wustl.edu
RI Jia, li/GPW 8015 2022; chen, Jianquan/E 3325 2013; Zheng,
   Dali/J 2973 2019; Jacobs, Kathryn/AAL 7876 2021; Zhou,
   Tianhua/C 7826 2012
OI Jacobs, Kathryn A/0000 0003 3632 6400; Zheng, Dali/0000 0003 2345 4040; 
FU Concern Foundation; Siteman Cancer Center Developmental Research Award
   in Prostate Cancer Research; BRIGHT Institute at Washington University
   School of Medicine/P50 Molecular Imaging Center Pilot Research Fund
FX This work was supported by the Concern Foundation, the Siteman Cancer
   Center Developmental Research Award in Prostate Cancer Research, and the
   BRIGHT Institute at Washington University School of Medicine/P50
   Molecular Imaging Center Pilot Research Fund.
CR Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Basu A, 2010, THESCIENTIFICWORLDJO, V10, P2272, DOI 10.1100/tsw.2010.214
   Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078 0432.CCR 05 0585
   Caino MC, 2011, J BIOL CHEM, V286, P11254, DOI 10.1074/jbc.M110.194332
   Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930
   Chen XY, 2010, CELL SIGNAL, V22, P1097, DOI 10.1016/j.cellsig.2010.03.003
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   Cronauer MV, 2005, INT J ONCOL, V26, P1033
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Decker KF, 2012, NUCLEIC ACIDS RES, V40, P10765, DOI 10.1093/nar/gks888
   Disatnik MH, 2004, J CELL SCI, V117, P4469, DOI 10.1242/jcs.01309
   Gavrielides MV, 2006, CANCER RES, V66, P11792, DOI 10.1158/0008 5472.CAN 06 1139
   Gregory CW, 2001, CANCER RES, V61, P2892
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jia L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000597
   Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497 402
   Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108
   Lahn M, 2004, BJU INT, V93, P1076, DOI 10.1111/j.1464 410X.2003.04784.x
   Li ZG, 2008, ONCOGENE, V27, P596, DOI 10.1038/sj.onc.1210694
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Masiello D, 2004, MOL ENDOCRINOL, V18, P2388, DOI 10.1210/me.2003 0436
   Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802
   Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200
   Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026
   Ortiz A, 2012, RECENT RESULTS CANC, V192, P225, DOI 10.1007/978 3 642 21892 7_11
   Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008 5472.CAN 07 6289
   Rombouts K, 2012, AM J PHYSIOL CELL PH, V303, pC357, DOI 10.1152/ajpcell.00093.2012
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saha B, 2008, PROSTATE, V68, P78, DOI 10.1002/pros.20670
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824
   Techasen A, 2010, CANCER SCI, V101, P658, DOI 10.1111/j.1349 7006.2009.01427.x
   Thiele S, 2011, J CELL BIOCHEM, V112, P1593, DOI 10.1002/jcb.23070
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001
   Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008 5472.CAN 04 2370
   Voeller HJ, 1998, CANCER RES, V58, P2520
   Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008 5472.CAN 08 1718
   Wang Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010456
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200
   Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877
NR 49
TC 61
Z9 69
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1541 7786
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAY
PY 2013
VL 11
IS 5
BP 482
EP 493
DI 10.1158/1541 7786.MCR 12 0520
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 145XQ
UT WOS:000319053400005
PM 23386686
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Cong, Q
   Liu, YC
   Zhou, TF
   Zhou, YX
   Xu, RS
   Cheng, CQ
   Chung, HS
   Yan, MJ
   Zhou, H
   Liao, ZH
   Gao, B
   Bocobo, GA
   Covington, TA
   Song, HJ
   Su, PQ
   Yu, PB
   Yang, YZ
AF Cong, Qian
   Liu, Yuchen
   Zhou, Taifeng
   Zhou, Yaxing
   Xu, Ruoshi
   Cheng, Caiqi
   Chung, Hye Soo
   Yan, Meijun
   Zhou, Hang
   Liao, Zhiheng
   Gao, Bo
   Bocobo, Geoffrey A.
   Covington, Taylor A.
   Song, Hyeon Ju
   Su, Peiqiang
   Yu, Paul B.
   Yang, Yingzi
TI A self amplifying loop of YAP and SHH drives formation and expansion of
   heterotopic ossification
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HIPPO SIGNALING PATHWAY; SONIC HEDGEHOG; BONE FORMATION;
   TUMOR SUPPRESSOR; DEVELOPING LIMB; ALPHA SUBUNIT; G PROTEIN; CELLS;
   MOUSE; DIFFERENTIATION
AB Heterotopic ossification (HO) occurs as a common complication after injury or in genetic disorders. The mechanisms underlying HO remain incompletely understood, and there are no approved prophylactic or secondary treatments available. Here, we identify a self amplifying, self propagating loop of Yes associated protein (YAP) Sonic hedgehog (SHH) as a core molecular mechanism underlying diverse forms of HO. In mouse models of progressive osseous heteroplasia (POH), a disease caused by null mutations in GNAS, we found that Gnas( / ) mesenchymal cells secreted SHH, which induced osteoblast differentiation of the surrounding wild type cells. We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression. Secreted SHH further induced YAP activation, Shh expression, and osteoblast differentiation in surrounding wild type cells. This self propagating positive feedback loop was both necessary and sufficient for HO expansion and could act independently of Gnas in fibrodysplasia ossificans progressiva (FOP), another genetic HO, and non hereditary HO mouse models. Genetic or pharmacological inhibition of YAP or SHH abolished HO in POH and FOP and acquired HO mouse models without affecting normal bone homeostasis, providing a previously unrecognized therapeutic rationale to prevent, reduce, and shrink HO.
C1 [Cong, Qian; Liu, Yuchen; Zhou, Taifeng; Zhou, Yaxing; Xu, Ruoshi; Cheng, Caiqi; Chung, Hye Soo; Gao, Bo; Yang, Yingzi] Harvard Sch Dent Med, Harvard Stem Cell Inst, Dept Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA.
   [Yan, Meijun; Zhou, Hang; Bocobo, Geoffrey A.; Covington, Taylor A.; Song, Hyeon Ju; Yu, Paul B.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
   [Zhou, Taifeng; Liao, Zhiheng; Su, Peiqiang] Sun Yat Sen Univ, Dept Orthopaed Surg, Guangdong Prov Key Lab Orthoped & Traumatol, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.
   [Xu, Ruoshi] Sichuan Univ, State Key Lab Oral Dis, Natl Clin Res Ctr Oral Dis, Dept Cariol & Endodontol,West China Hosp Stomatol, Chengdu, Peoples R China.
C3 Harvard University; Harvard School of Dental Medicine; Harvard
   University; Harvard Medical School; Harvard University Medical
   Affiliates; Brigham & Women's Hospital; Sun Yat Sen University; Sichuan
   University
RP Yang, YZ (通讯作者)，Harvard Sch Dent Med, Harvard Stem Cell Inst, Dept Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA.
EM yingzi_yang@hsdm.harvard.edu
RI Cong, Qian/AAZ 4404 2021; Chung, Hye/AAG 8591 2020; Zhou,
   Taifeng/JZT 3781 2024; Yan, Meijun/AAE 6966 2019; Yu, Paul/J 7540 2019;
   Liu, Yuchen/AAH 6098 2021; Yang, Yingzi/J 3501 2012
OI Liu, Yuchen/0000 0001 8922 9976; Zhou, Taifeng/0000 0001 7066 0117;
   Cong, Qian/0000 0002 9493 5784; Yu, Paul/0000 0003 2145 4944
FU National Institutes of Health (NIH) grants from the National Institute
   of Dental and Craniofacial Research [DE025866]; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [AR070877]; National
   Cancer Institute [CA222571]; Million Dollar Bike Ride grant program of
   the Orphan Disease Center at the University of Pennsylvania
   [MDBR 18 115 FD/MAS]; NIH grants from NIAMS [AR057374, R01AR057374S1,
   UG3 TR002617]; International Fibrodysplasia Ossificans Progressiva
   Research Award; China Scholarship Council of the Chinese Ministry of
   Education; Sun Yat sen University; National Natural Science Foundation
   of China [81772293]
FX The work in the Yang laboratory is supported by National Institutes of
   Health (NIH) grants from the National Institute of Dental and
   Craniofacial Research (DE025866), National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (AR070877), and National Cancer
   Institute (CA222571) and a pilot grant from Million Dollar Bike Ride
   grant program of the Orphan Disease Center at the University of
   Pennsylvania (MDBR 18 115 FD/MAS) to Y.Y. The work in the Yu laboratory
   is supported by NIH grants from NIAMS (AR057374, R01AR057374S1, and
   UG3 TR002617) and an International Fibrodysplasia Ossificans Progressiva
   Research Award to P.B.Y. T.Z. and R.X. were supported by visiting
   graduate student fellowships from the China Scholarship Council of the
   Chinese Ministry of Education. B.G. was supported by a visiting graduate
   student fellowship from Sun Yat sen University. Z.L. was supported by
   the National Natural Science Foundation of China (no. 81772293).
CR Adegbite NS, 2008, AM J MED GENET A, V146A, P1788, DOI 10.1002/ajmg.a.32346
   Agarwal S, 2017, STEM CELLS, V35, P705, DOI 10.1002/stem.2515
   AHRENGART L, 1991, CLIN ORTHOP RELAT R, P49
   Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Bagarova J, 2013, MOL CELL BIOL, V33, P2413, DOI 10.1128/MCB.01595 12
   Barron DA, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001 1326 3 25
   Chakkalakal SA, 2019, METHODS MOL BIOL, V1891, P247, DOI 10.1007/978 1 4939 8904 1_18
   Chakkalakal SA, 2012, J BONE MINER RES, V27, P1746, DOI 10.1002/jbmr.1637
   CHAZAL J, 1985, J BIOMECH, V18, P167, DOI 10.1016/0021 9290(85)90202 7
   Cheeseman MT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051835
   Chen M, 2005, J CLIN INVEST, V115, P3217, DOI 10.1172/JCI24196
   Cho YS, 2020, GENE DEV, V34, P53, DOI 10.1101/gad.333146.119
   Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090
   ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092 8674(93)90627 3
   Eddy MC, 2000, J BONE MINER RES, V15, P2074, DOI 10.1359/jbmr.2000.15.11.2074
   Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54
   Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792
   Frazier TP, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471 2121 14 34
   Fukuda T, 2006, GENESIS, V44, P159, DOI 10.1002/dvg.20201
   Giraud J, 2020, INT J CANCER, V146, P2255, DOI 10.1002/ijc.32667
   Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109
   Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   He XL, 2014, NAT MED, V20, P1035, DOI 10.1038/nm.3666
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hino K, 2015, P NATL ACAD SCI USA, V112, P15438, DOI 10.1073/pnas.1510540112
   Huang ZH, 2016, DEVELOPMENT, V143, P2398, DOI 10.1242/dev.130658
   Huber AK, 2020, J CLIN INVEST, V130, P5444, DOI 10.1172/JCI136142
   Huso DL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021755
   Ideno N, 2018, GASTROENTEROLOGY, V155, P1593, DOI 10.1053/j.gastro.2018.08.006
   Iglesias Bartolome R, 2015, NAT CELL BIOL, V17, P793, DOI 10.1038/ncb3164
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kaplan, 1994, J Am Acad Orthop Surg, V2, P288
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393
   Lees Shepard JB, 2018, ELIFE, V7, DOI 10.7554/eLife.40814
   Lees Shepard JB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02872 2
   Lettice LA, 2003, HUM MOL GENET, V12, P1725, DOI 10.1093/hmg/ddg180
   Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092 8674(01)00369 5
   Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104
   Luo Jie, 2010, Zhongguo Gu Shang, V23, P305
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Maglic D, 2018, EMBO J, V37, DOI 10.15252/embj.201798642
   Mavrogenis AF, 2011, ORTHOPEDICS, V34, DOI 10.3928/01477447 20110124 08
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256 005 0958 z
   Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   Neal B, 2002, ANZ J SURG, V72, P808, DOI 10.1046/j.1445 2197.2002.02549.x
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535 7163.MCT 16 0847
   Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS191
   Potter BK, 2010, J BONE JOINT SURG AM, V92A, P74, DOI 10.2106/JBJS.J.00776
   Potuijt JWP, 2018, GENET MED, V20, P1405, DOI 10.1038/gim.2018.18
   Regard JB, 2013, NAT MED, V19, P1505, DOI 10.1038/nm.3314
   RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092 8674(93)90626 2
   Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012
   Ritter A, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101288
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Russo V, 2014, STEM CELL TRANSL MED, V3, P206, DOI 10.5966/sctm.2013 0125
   Sagai T, 2005, DEVELOPMENT, V132, P797, DOI 10.1242/dev.01613
   Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101
   Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804
   Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Shore EM, 2002, NEW ENGL J MED, V346, P99, DOI 10.1056/NEJMoa011262
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630
   van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309
   Wang X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02988 5
   Xu RS, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0034 7
   Xu RS, 2018, BONE, V109, P134, DOI 10.1016/j.bone.2017.08.025
   Yan L, 2017, AGING DIS, V8, P570, DOI 10.14336/AD.2017.0201
   Yeo NC, 2018, NAT METHODS, V15, P611, DOI 10.1038/s41592 018 0048 5
   Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073
   Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216
   Zheng YG, 2019, DEV CELL, V50, P264, DOI 10.1016/j.devcel.2019.06.003
   Zhu JJ, 2008, DEV CELL, V14, P624, DOI 10.1016/j.devcel.2008.01.008
NR 80
TC 34
Z9 35
U1 1
U2 37
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUN 23
PY 2021
VL 13
IS 599
AR eabb2233
DI 10.1126/scitranslmed.abb2233
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA SW9YA
UT WOS:000664868300003
PM 34162750
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Craven, M
   Vajravelu, ME
   Shekdar, KV
   Levine, MA
   Mumm, S
   Whyte, MP
   Mancilla, EE
AF Craven, Meghan
   Vajravelu, Mary Ellen
   Shekdar, Karuna V.
   Levine, Michael A.
   Mumm, Steven
   Whyte, Michael P.
   Mancilla, Edna E.
TI Early identification of a 12 bp tandem duplication in TNFRSF11A
   encoding receptor activator of nuclear factor kappa B (RANK): Clinical
   characterization and response to bisphosphonate therapy
SO BONE
LA English
DT Article
DE Deafness; Metabolic bone disease; Osteoclast; Osteolysis; Osteoporosis;
   Tooth resorption
ID EXPANSILE SKELETAL HYPERPHOSPHATASIA; ONSET PAGETS DISEASE; SIGNAL
   PEPTIDE; TNFRSF11A GENE; OSTEOLYSIS; MUTATIONS
AB Introduction: Ultra rare mendelian osteolytic disorders caused by different length in frame activating duplications within exon 1 of TNFRSF11A encoding receptor activator of nuclear factor kappa B (RANK) comprise familial expansile osteolysis (FEO), expansile skeletal hyperphosphatasia (ESH), early onset familial Paget's disease of bone (PDB2), juvenile Paget's disease 2 (JPD2), and panostotic expansile bone disease (PEBD). FEO typically presents with childhood onset deafness followed by resorption of permanent dentition, and then appendicular bone pain, fractures, and deformities from progressive focal expansile osteolytic lesions emerging from a background of generalized high bone turnover. An 18 bp duplication in TNFRSF11A has been reported in all kindreds with FEO, whereas a 12 bp duplication was found in the young man with PEBD complicated by a massive jaw tumor. We report the clinical course and successful treatment with bisphosphonates of a girl with the 12 bp duplication yet a skeletal phenotype seemingly milder than PEBD.Case presentation and discussion: This 10 year old girl presented for dental and orthodontic treatment and was found to have progressive external tooth root resorption. Speech delay was identified at age 18 months, and audiological evaluation showed both conductive and sensorineural hearing loss subsequently treated with a cochlear implant at age 3 years. Biochemical studies indicated increased bone turnover with elevated urinary N telopeptide levels and serum alkaline phosphatase in the upper normal range. Low lumbar spine bone mineral density (BMD) was revealed by dual energy X ray absorptiometry, but whole body Technetium 99 m bone scintigraphy was normal. Genetic testing identified the identical de novo 12 bp duplication within exon 1 of TNFRSF11A harbored by the young man with PEBD and massive jaw tumor. Bisphosphonate treatment, initiated with one dose of intravenous zoledronic acid that caused prolonged hypocalcemia, then comprised weekly oral alendronate that decreased bone turnover markers and normalized her BMD.Conclusion: Constitutive activation of RANK signaling should be considered a possible cause in any young person with rapid bone turnover, particularly in the context of early onset deafness and/or root resorption of permanent
C1 [Craven, Meghan; Vajravelu, Mary Ellen; Levine, Michael A.; Mancilla, Edna E.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
   [Shekdar, Karuna V.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Radiol,Div Neuroradiol, Philadelphia, PA 19104 USA.
   [Mumm, Steven; Whyte, Michael P.] Washington Univ, Sch Med, Dept Internal Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
   [Mumm, Steven; Whyte, Michael P.] Shriners Hosp Children St Louis, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63110 USA.
   [Mancilla, Edna E.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, HUB Clin Collaborat, 3500 Civ Ctr Blvd,7th floor, Philadelphia, PA 19104 USA.
   [Craven, Meghan] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Div Diabet & Endocrinol, Houston, TX 77030 USA.
   [Vajravelu, Mary Ellen] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Div Pediat Endocrinol Diabet & Metab, 4401 Penn Ave,Fac Pavil 6th Floor, Pittsburgh, PA 15224 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; Pennsylvania Medicine;
   Childrens Hospital of Philadelphia; Washington University (WUSTL);
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; Baylor College of Medicine; Baylor College Medical
   Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh
RP Mancilla, EE (通讯作者)，Childrens Hosp Philadelphia, Div Endocrinol & Diabet, HUB Clin Collaborat, 3500 Civ Ctr Blvd,7th floor, Philadelphia, PA 19104 USA.
EM mecraven@texaschildrens.org; vajravelume@upmc.edu; shekdar@chop.edu;
   levinem@chop.edu; smumm@wustl.edu; MWhyte@shrinenet.org;
   mancillae@chop.edu
RI Vajravelu, Mary Ellen/KIH 2754 2024; Mumm, Steven/KPA 1206 2024; Levine,
   Michael/JED 8261 2023
OI Craven, Meghan/0000 0001 9727 6123; 
CR Alonso N, 2021, J BONE MINER RES, V36, P1376, DOI 10.1002/jbmr.4288
   BARR RJ, 1989, AM J MED GENET, V32, P556, DOI 10.1002/ajmg.1320320430
   Crockett JC, 2011, J BONE MINER RES, V26, P1926, DOI 10.1002/jbmr.399
   ENDERLE A, 1979, PATHOL RES PRACT, V166, P131, DOI 10.1016/S0344 0338(79)80014 X
   Hosking D, 2007, J BONE MINER RES, V22, P142, DOI 10.1359/JBMR.061001
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Iwamoto SJ, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115224
   Johnson Pais TL, 2003, J BONE MINER RES, V18, P376, DOI 10.1359/jbmr.2003.18.2.376
   Ke YH, 2009, ACTA PHARMACOL SIN, V30, P1204, DOI 10.1038/aps.2009.90
   Macaraeg K, 2020, PEDIATR DENT, V42, P62
   Nakatsuka K, 2003, J BONE MINER RES, V18, P1381, DOI 10.1359/jbmr.2003.18.8.1381
   OSTERBERG PH, 1988, J BONE JOINT SURG BR, V70, P255, DOI 10.1302/0301 620X.70B2.3346299
   Palenzuela L, 2002, J MED GENET, V39, DOI 10.1136/jmg.39.10.e67
   Schafer AL, 2014, J BONE MINER RES, V29, P911, DOI 10.1002/jbmr.2094
   Turan S, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10663
   WALLACE RGH, 1989, CLIN ORTHOP RELAT R, P265
   Whyte MP, 2018, GENETICS OF BONE BIOLOGY AND SKELETAL DISEASE, 2ND EDITION, P453, DOI 10.1016/B978 0 12 804182 6.00026 5
   Whyte MP, 2014, BONE, V68, P153, DOI 10.1016/j.bone.2014.07.019
   Whyte MP, 2002, MEDICINE, V81, P101, DOI 10.1097/00005792 200203000 00002
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Whyte MP, 2000, J BONE MINER RES, V15, P2330, DOI 10.1359/jbmr.2000.15.12.2330
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
NR 22
TC 2
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2023
VL 170
AR 116698
DI 10.1016/j.bone.2023.116698
EA FEB 2023
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 9N8OU
UT WOS:000943170300001
PM 36740137
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Du, Y
   Zhang, YX
   Luo, WQ
   Gan, FH
   Yang, M
   Gong, P
   Yao, Y
AF Du, Yu
   Zhang, Yixin
   Luo, Wenqiong
   Gan, Feihong
   Yang, Mao
   Gong, Ping
   Yao, Yang
TI The influence of radiation induced bystander effect in osteoblasts
   mediated by plasma derived extracellular vesicles (EVs)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Radiation induced bystander effect; Tumor radiotherapy; Extracellular
   vesicles; Bone metabolism; Osteogenesis; Therapeutic resistance to
   radiation
ID CANCER CELLS; THERAPY; COMPLICATIONS; EXOSOMES; HEAD; SOD1; GPX1
AB Objectives: Head and neck tumor patients may develop post radiotherapy diseases after radiotherapy treatment. And radiotherapy can elicit radiation induced bystander effect, wherein extracellular vesicles (EVs) play a crucial role. For normal parts of the body that have not been directly irradiated, the effect of EVs on them needs to be further explored. This study aims to investigate the functions of plasma derived EVs in regulating normal osteoblasts during radiation induced bystander effects. Methods and materials: Rat plasma derived EVs were isolated and identified firstly, followed by an evaluation of their intracellular biological effects on normal osteoblasts in vitro. Transcriptome sequencing analysis and confirmations were performed to identify potential mechanisms. Results: Irradiated plasma derived EVs were found to enhance osteoblast proliferation, migration, and cell cycle progression, concurrently suppressing the expression of osteogenesis related genes and proteins. Furthermore, these EVs attenuated the expression of osteogenesis and oxidative stress resistance related genes, while upregulating the PI3K AKT pathway and intracellular reactive oxygen species in osteoblasts. Conclusions: Irradiated plasma derived EVs could alter the biological effects in osteoblasts, which is closely associated with the levels of GPX1 and the PI3K AKT signaling pathway. This suggests that plasma derived EVs serve as a crucial factor contributing to radiation induced bystander effect in osteoblasts.
C1 [Du, Yu; Zhang, Yixin; Yang, Mao; Gong, Ping; Yao, Yang] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Du, Yu; Yang, Mao; Gong, Ping; Yao, Yang] Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, Chengdu, Peoples R China.
   [Luo, Wenqiong] First Peoples Hosp Liangshan Yi Autonomous Prefect, Dept Stomatol, Xichang, Sichuan, Peoples R China.
   [Gan, Feihong] Zhejiang Univ, Stomatol Hosp, Sch Stomatol, Sch Med, Hangzhou, Peoples R China.
   [Yao, Yang] 14,Sect 3,Renmin Nan Rd, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University; Zhejiang University
RP Yao, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, Chengdu, Peoples R China.; Yao, Y (通讯作者)，14,Sect 3,Renmin Nan Rd, Chengdu 610041, Peoples R China.
EM cercocody@foxmail.com; 2020224035084@stu.scu.edu.cn; lwqads@163.com;
   Agan94@foxmail.com; yangmaodentist@163.com; dentistgong@hotmail.com;
   yangmaodentist@163.com
OI Gong, Ping/0000 0002 4782 1741; Gan, Feihong/0000 0001 5081 5732
FU National Natural Science Founda  tion of China [81700941, 82170935]; Key
   Research and Development projects in Sichuan Province [2020YFS0172];
   Sichuan University Luzhou City Cooperation Program [2021CDLZ  8]
FX <BOLD>Acknowledgements</BOLD> This study was supported by the National
   Natural Science Founda  tion of China (No. 81700941 and 82170935) , the
   Key Research and Development projects in Sichuan Province (No.
   2020YFS0172) and Sichuan University Luzhou City Cooperation Program (No.
   2021CDLZ  8) . We sincerely thank Yanxi Li for giving guidance in
   experimental techniques. The authors declare no potential conflicts of
   interest.
CR Abels ER, 2016, CELL MOL NEUROBIOL, V36, P301, DOI 10.1007/s10571 016 0366 z
   Al Mayah A, 2015, MUTAT RES FUND MOL M, V772, P38, DOI 10.1016/j.mrfmmm.2014.12.007
   Al Mayah AHJ, 2017, RADIAT RES, V187, P98, DOI 10.1667/RR14201.1
   Ali J, 2017, ORAL ONCOL, V70, P23, DOI 10.1016/j.oraloncology.2017.05.004
   Berkey FJ, 2010, AM FAM PHYSICIAN, V82, P381
   Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051
   Boriachek K, 2018, SMALL, V14, DOI 10.1002/smll.201702153
   Chen Q, 2023, AGING US, V15, P6905, DOI 10.18632/aging.204882
   Choi YY, 2023, J EXTRACELL VESICLES, V12, DOI 10.1002/jev2.12325
   Deng ZY, 2010, OTOLARYNG HEAD NECK, V143, P242, DOI 10.1016/j.otohns.2010.02.003
   Du Y, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6646323
   Ferreira DMS, 2019, SKELET MUSCLE, V9, DOI 10.1186/s13395 019 0214 1
   Gan FH, 2021, J BIOMED NANOTECHNOL, V17, P100, DOI 10.1166/jbn.2021.3008
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guo Haoyu, 2022, Biomater Transl, V3, P240, DOI 10.12336/biomatertransl.2022.04.003
   Guo Y, 2023, CELL BIOL TOXICOL, V39, P1203, DOI 10.1007/s10565 022 09736 y
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jella KK, 2014, RADIAT RES, V181, P138, DOI 10.1667/RR13337.1
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Lane RE, 2015, SCI REP UK, V5, DOI 10.1038/srep07639
   Laomeephol Chavee, 2022, Biomater Transl, V3, P213, DOI 10.12336/biomatertransl.2022.03.005
   Lehmann TP, 2023, BIOMED PHARMACOTHER, V166, DOI 10.1016/j.biopha.2023.115308
   Liao W, 2019, ACTA BIOMATER, V86, P1, DOI 10.1016/j.actbio.2018.12.045
   Lin WZ, 2020, THERANOSTICS, V10, P4871, DOI 10.7150/thno.43539
   Liu H, 2022, BIOACT MATER, V14, P169, DOI 10.1016/j.bioactmat.2021.12.006
   Lobb RJ, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27031
   Ma CK, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052770
   Maacha S, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0965 7
   Madeo M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06640 0
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Meng QC, 2018, ONCOGENE, V37, P5843, DOI 10.1038/s41388 018 0392 z
   Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277
   Najafi M, 2017, INFLAMMOPHARMACOLOGY, V25, P403, DOI 10.1007/s10787 017 0332 5
   Ning WL, 2021, CELL SIGNAL, V77, DOI 10.1016/j.cellsig.2020.109812
   Palviainen M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236439
   Pasetto L, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024 021 00470 3
   Peng Y, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2545 6
   Rastogi S, 2018, MOL BIOL CELL, V29, P2228, DOI 10.1091/mbc.E18 02 0130
   Rose Ped AM, 2002, CANCER NURS, V25, P461, DOI 10.1097/00002820 200212000 00010
   Roy P, 2007, FASEB J, V21, pA114
   Soo CY, 2012, IMMUNOLOGY, V136, P192, DOI 10.1111/j.1365 2567.2012.03569.x
   Spanier G, 2009, J PHYSIOL PHARMACOL, V60, P111
   Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084
   Sroussi HY, 2017, CANCER MED US, V6, P2918, DOI 10.1002/cam4.1221
   Stuendl A, 2021, MOVEMENT DISORD, V36, P2508, DOI 10.1002/mds.28639
   Sun Q, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101694
   Szatmári T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225527
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Torricelli P, 2000, J BIOMED MATER RES, V52, P177, DOI 10.1002/1097 4636(200010)52:1<177::AID JBM23>3.0.CO;2 F
   Tóth EA, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12140
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Wang HZ, 2015, CANCER LETT, V356, P137, DOI 10.1016/j.canlet.2013.09.031
   Wei RLO, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.36
   Willms E, 2016, SCI REP UK, V6, DOI 10.1038/srep22519
   Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360
   Wu JP, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13123
   Yentrapalli R, 2017, INT J RADIAT BIOL, V93, P569, DOI 10.1080/09553002.2017.1294772
   Zeng Zhao Lin, 2022, Biomater Transl, V3, P175, DOI 10.12336/biomatertransl.2022.03.002
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhong WQ, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.113224
NR 60
TC 1
Z9 1
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 5
PY 2024
VL 695
AR 149425
DI 10.1016/j.bbrc.2023.149425
EA JAN 2024
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GZ4M0
UT WOS:001156489200001
PM 38211533
DA 2025 08 17
ER

PT J
AU El Mabhouh, AA
   Mercer, JR
AF El Mabhouh, Amal A.
   Mercer, John R.
TI <SUP>188</SUP>Re labelled gemcitabine/bisphosphonate (Gem/BP):: a
   multi functional, bone specific agent as a potential treatment for bone
   metastases
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE palliative therapy; bone neoplasm; chemotherapy; bisphosphonates;
   radiotherapy; rhenium radioisotopes
ID RE 188 HYDROXYETHYLIDENE DIPHOSPHONATE; MINERAL AFFINITY; BREAST CANCER;
   BISPHOSPHONATES; DRUG; PROTEINS; THERAPY; MICROENVIRONMENT; CONJUGATION;
   MECHANISMS
AB Purpose This study investigated the bone  binding affinity and biodistribution of a Re 188 labelled gemcitabine/bisphosphonate (Gem/BP) conjugate, a multi functional drug designed to deliver tumour specific combined radiotherapy and chemotherapy to the bone using the high bone binding affinity of the bisphosphonate group.
   Methods The Gem/BP conjugate was labelled at high radiochemical purity with Re 188. The bone  binding affinity of the Re 188 Gem/BP was studied in vitro in purified hydroxyapatite emulsion and powdered bovine bone. In vivo biodistribution studies were carried out in normal BALB/c mice.
   Results Re 188 Gem/BP demonstrated strong and stable binding in both in vitro systems. In vivo Re 188 Gem/BP showed bone uptake, rapid blood clearance and rapid elimination of unbound activity. The bone tissue demonstrated the highest concentration of bound radioactivity exempting the kidneys. Approximately 67% of retained whole body activity was bound to the bone at 8 h after Re 188 Gem/BP administration.
   Conclusions Re 188 Gem/BP demonstrated high, selective and persistent bone binding and can be considered as a model compound for multi functional bone  specific therapy for bone metastases.
C1 [Mercer, John R.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
   [El Mabhouh, Amal A.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
C3 University of Alberta; University of Alberta
RP Mercer, JR (通讯作者)，Cross Canc Inst, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.
EM johnmerc@cancerboard.ab.ca
CR Allerheiligen S, 1994, P AN M AM SOC CLIN, V136, p339a
   Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Bansal G, 2004, J PHARM SCI US, V93, P2788, DOI 10.1002/jps.20186
   Body JJ, 2006, CLIN CANCER RES, V12, p6258S, DOI 10.1158/1078 0432.CCR 06 0840
   Cher ML, 2006, AM J PATHOL, V168, P1405, DOI 10.2353/ajpath.2006.050874
   Clézardin P, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.37420
   de Murphy CA, 2001, APPL RADIAT ISOTOPES, V54, P435, DOI 10.1016/S0969 8043(00)00296 7
   El Mabhouh A, 2005, APPL RADIAT ISOTOPES, V62, P541, DOI 10.1016/j.apradiso.2004.10.004
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   El Mabhouh AA, 2006, NUCL MED BIOL, V33, P715, DOI 10.1016/j.nucmedbio.2006.06.004
   Gittens SA, 2004, J CONTROL RELEASE, V98, P255, DOI 10.1016/j.jconrel.2004.05.001
   Gittens SA, 2004, PHARM RES DORDR, V21, P608, DOI 10.1023/B:PHAM.0000022407.05163.01
   Gittens SA, 2003, PHARMACEUT RES, V20, P978, DOI 10.1023/A:1024445903306
   Gittens SA, 2005, MOL PHARMACEUT, V2, P392, DOI 10.1021/mp050017u
   Graham MC, 1999, CLIN CANCER RES, V5, P1307
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Guhlke S, 2000, J NUCL MED, V41, P1271
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hosain F, 1996, J NUCL MED, V37, P105
   Hsieh BT, 1999, NUCL MED BIOL, V26, P973, DOI 10.1016/S0969 8051(99)00075 X
   Kishimoto Hideaki, 2006, Clin Calcium, V16, P1513
   Knapp FF Jr, 1998, CANCER BIOTHER RADIO, V13, P337, DOI 10.1089/cbr.1998.13.337
   Liepe K, 2003, BRIT J CANCER, V89, P625, DOI 10.1038/sj.bjc.6601158
   Liepe K, 2003, J NUCL MED, V44, P953
   Lin WY, 1997, EUR J NUCL MED, V24, P590, DOI 10.1007/s002590050091
   Lin WY, 1999, NUCL MED BIOL, V26, P455, DOI 10.1016/S0969 8051(99)00007 4
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   Maxon HR, 1998, J NUCL MED, V39, P659
   Palmedo H, 2000, EUR J NUCL MED, V27, P123, DOI 10.1007/s002590050017
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Serafini AN, 2001, Q J NUCL MED, V45, P91
   Serafini AN, 2001, J NUCL MED, V42, P895
   SUBRAMANIAN G, 1975, J NUCL MED, V16, P744
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yuen KK, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006250
NR 41
TC 23
Z9 24
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619 7070
EI 1619 7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD JUL
PY 2008
VL 35
IS 7
BP 1240
EP 1248
DI 10.1007/s00259 008 0728 y
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 313QM
UT WOS:000256755100003
PM 18265977
DA 2025 08 17
ER

PT J
AU Bongiovanni, A
   Foca, F
   Menis, J
   Stucci, SL
   Artioli, F
   Guadalupi, V
   Forcignano, MR
   Fantini, M
   Recine, F
   Mercatali, L
   Spadazzi, C
   Burgio, MA
   Fausti, V
   Miserocchi, A
   Ibrahim, T
AF Bongiovanni, Alberto
   Foca, Flavia
   Menis, Jessica
   Stucci, Stefania Luigia
   Artioli, Fabrizio
   Guadalupi, Valentina
   Forcignano, Maria Rosachiara
   Fantini, Manuela
   Recine, Federica
   Mercatali, Laura
   Spadazzi, Chiara
   Burgio, Marco Angelo
   Fausti, Valentina
   Miserocchi, Anna
   Ibrahim, Toni
TI Immune Checkpoint Inhibitors With or Without Bone Targeted Therapy in
   NSCLC Patients With Bone Metastases and Prognostic Significance of
   Neutrophil to Lymphocyte Ratio
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE immune checkpoint inhibitors; NSCLC; bone metastases; zoledronate;
   denosumab; lung cancer
ID LUNG CANCER; RESPONSE CRITERIA; OPEN LABEL; DOCETAXEL; NIVOLUMAB;
   BISPHOSPHONATES; PEMBROLIZUMAB; ORGANIZATION
AB IntroductionBone metastases (BMs) are a negative prognostic factor in patients with non small cell lung cancer (NSCLC). Although immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic landscape of NSCLC, little information is available on BMs from NSCLC treated with ICIs alone or in association with bone targeted therapy (BTT) such as zoledronate or denosumab. MethodsFrom 2014 to 2020, 111 of the 142 patients with BMs secondary to NSCLC extrapolated from the prospective multicenter Italian BM Database were eligible for analysis. Information on blood count, comorbidities, and toxicity was retrospectively collected. The neutrophil to lymphocyte ratio (NLR) pre  and post treatment was calculated. Survival was analyzed using the Kaplan Meier method, with statistical significance of survival differences assessed using the log rank test. ResultsMedian age was 66 (range, 42 84) years. Performance status (PS) Eastern Cooperative Oncology Group (ECOG) was 0 1 in 79/111 patients. The majority of patients (89.2%) had adenocarcinoma histology. At a median follow up of 47.4 months, median progression free (mPFS) and overall survival (mOS) was 4.9 (95%CI, 2.8 10.0) and 11.9 (95%CI, 8.2 14.4) months, respectively. Forty six (43.4%) patients with BM NSCLC underwent first  or further line therapy with ICIs: 28 (60.8%) received nivolumab, 9 (19.6%) pembrolizumab, and 9 (19.6%) atezolizumab. Of the 46 patients treated with ICIs, 30 (65.2%) underwent BTT: 24 (80.0%) with zoledronate and 6 (20.0%) with denosumab. The ICI alone group had an mOS of 15.8 months [95%CI, 8.2 not evaluable (NE)] vs. 21.8 months (95%CI, 14.5 not evaluable) for the ICI plus BTT group and 7.5 (95%CI, 6.1 10.9) months for the group receiving other treatments (p < 0.001). NLR <= 5 had a positive impact on OS. ConclusionBTT appears to have a synergistic effect when used in combination with ICIs, improving patient survival.
C1 [Bongiovanni, Alberto; Mercatali, Laura; Spadazzi, Chiara; Fausti, Valentina; Ibrahim, Toni] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Osteoncol & Rare Tumors Ctr CDOTR, Meldola, Italy.
   [Foca, Flavia; Miserocchi, Anna] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Unit Biostat & Clin Trials, Meldola, Italy.
   [Menis, Jessica] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy.
   [Menis, Jessica] Ist Oncol Veneto IRCCS, Med Oncol Dept, Padua, Italy.
   [Menis, Jessica; Stucci, Stefania Luigia] Univ Verona, Azienda Osped Univ Integrata AOUI Verona, Dept Med, Med Oncol, Verona, Italy.
   [Stucci, Stefania Luigia] Univ Bari A Moro, Policlin Hosp Bari, Dept Biomed Sci & Human Oncol, Med Oncol Unit, Bari, Italy.
   [Artioli, Fabrizio] Ramazzini Hosp, Div Med Oncol, Carpi, Italy.
   [Guadalupi, Valentina] IRCCS Natl Canc Inst INT, Milan, Italy.
   [Forcignano, Maria Rosachiara] UOC Oncol Med Osped Sacro Cuore Gesu, Gallipoli, Italy.
   [Fantini, Manuela] Infermi Hosp, Oncol Unit, Rimini, Italy.
   [Recine, Federica] ASL Rieti, San Camillo Lellis Hosp, Rieti, Italy.
   [Burgio, Marco Angelo] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Dept Med Oncol, Meldola, Italy.
C3 University of Padua; IRCCS Istituto Oncologico Veneto (IOV); University
   of Verona; Azienda Ospedaliera Universitaria Integrata Verona;
   Universita degli Studi di Bari Aldo Moro; Hospital of Rimini
RP Bongiovanni, A (通讯作者)，IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Osteoncol & Rare Tumors Ctr CDOTR, Meldola, Italy.
EM alberto.bongiovanni@irst.emr.it
RI Ibrahim, Toni/IQR 9219 2023; Fausti, Valentina/AAA 6071 2021; Guadalupi,
   Valentina/AAB 3460 2021; Spadazzi, Chiara/AAB 5917 2021; Mercatali,
   Laura/J 9154 2016; Foca, Flavia/K 1906 2018; Bongiovanni,
   Alberto/J 9802 2018; Miserocchi, Anna/LRB 5803 2024
OI Miserocchi, Anna/0000 0003 1087 9146; Fausti,
   Valentina/0000 0003 0432 1445; 
CR Bongiovanni A, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 83749 1
   Bongiovanni A, 2019, SUPPORT CARE CANCER, V27, P3395, DOI 10.1007/s00520 019 4635 5
   Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643
   Brzezianska E, 2006, MUTAT RES FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013
   Carbonare LD, 2010, DRUG HEALTHC PATIENT, V2, P121, DOI 10.2147/DHPS.S6285
   Costelloe CM, 2010, J CANCER, V1, P80
   da Silva LM, 2021, FUTURE ONCOL, V17, P775, DOI 10.2217/fon 2020 0587
   Daniele S, 2015, SCI REP UK, V5, DOI 10.1038/srep18670
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Fukui T, 2019, CLIN LUNG CANCER, V20, P208, DOI 10.1016/j.cllc.2018.04.021
   Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005
   Giustini N, 2021, LUNG CANCER TARGETS, V12, P21, DOI 10.2147/LCTT.S235102
   Hamaoka T, 2010, BRIT J CANCER, V102, P651, DOI 10.1038/sj.bjc.6605546
   Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568 019 0116 x
   Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946
   Hsu ML, 2020, THORAC SURG CLIN, V30, P187, DOI 10.1016/j.thorsurg.2020.01.009
   Ibrahim T, 2013, CLIN CASES MINER BON, V10, P121, DOI 10.11138/ccmbm/2013.10.2.121
   Ishihara M, 2021, TRANSL LUNG CANCER R, V10, P221, DOI 10.21037/tlcr 20 777
   Ksienski D, 2021, TRANSL LUNG CANCER R, V10, DOI 10.21037/tlcr 20 541
   Kuchuk M, 2013, J BONE ONCOL, V2, P22, DOI 10.1016/j.jbo.2012.12.004
   Landi L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0793 8
   Li Y, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4412 8
   Liede A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1480301
   Malvezzi M, 2015, ANN ONCOL, V26, P779, DOI 10.1093/annonc/mdv001
   Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078 0432.CCR 07 5143
   Peters S, 2020, J THORAC ONCOL, V15, P1647, DOI 10.1016/j.jtho.2020.06.011
   Peters S, 2017, J THORAC ONCOL, V12, pS253, DOI 10.1016/j.jtho.2016.11.241
   Petrova MP, 2020, BIOSCI TRENDS, V14, P48, DOI 10.5582/bst.2019.01279
   Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774
   Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140 6736(16)32517 X
   Silva Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904
   Simatou A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207570
   Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute, 2009, COMMON TERMINOLOGY C
   Yang KL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01098
   Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07
NR 38
TC 30
Z9 32
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 10
PY 2021
VL 12
AR 697298
DI 10.3389/fimmu.2021.697298
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA XI4DA
UT WOS:000726063200001
PM 34858389
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Marie, P
AF Marie, P. J.
TI Cell and gene therapy for bone repair
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone repair; Cell therapy; Gene therapy; Mesenchymal stromal cells;
   Osteoblast
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; CARTILAGE REPAIR;
   DIFFERENTIATION; REGENERATION; DEFECTS
AB Improving bone repair remains an important and challenging issue. Therapeutic approaches to amplify osteogenic cell pool or function include cell and gene therapies. We identified genes that promote human mesenchymal cell differentiation and bone formation. Targeting these or other genes may improve the efficacy of cell therapy for bone repair.
C1 [Marie, P. J.] INSERM, UMR606, Lab Osteoblast Biol & Pathol, F 75475 Paris 10, France.
   [Marie, P. J.] Univ Paris Diderot, Hop Lariboisiere, F 75475 Paris 10, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP
RP Marie, P (通讯作者)，INSERM, UMR606, Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
FU Servier
FX The publication of the proceedings of the fifth Bone Quality Seminar
   2010 has been made possible through an educational grant from Servier.
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Charbord P, 2011, STEM CELL REV REP, V7, P32, DOI 10.1007/s12015 010 9125 6
   Fromigué O, 2004, CURR PHARM DESIGN, V10, P2593, DOI 10.2174/1381612043383773
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hernigou P, 2002, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000038472.05771.79
   Hsu WK, 2007, BONE, V40, P931, DOI 10.1016/j.bone.2006.10.030
   Ito H, 2005, NAT MED, V11, P291, DOI 10.1038/nm1190
   Jabbarzadeh E, 2008, P NATL ACAD SCI USA, V105, P11099, DOI 10.1073/pnas.0800069105
   Kimelman N, 2007, TISSUE ENG, V13, P1135, DOI 10.1089/ten.2007.0096
   Kofron MD, 2004, CURR OPIN BIOTECH, V15, P399, DOI 10.1016/j.copbio.2004.07.004
   Kon E, 2000, J BIOMED MATER RES, V49, P328
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Matsumoto T, 2008, BONE, V43, P434, DOI 10.1016/j.bone.2008.05.001
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Sotiropoulou PA, 2006, STEM CELLS, V24, P462, DOI 10.1634/stemcells.2004 0331
   Vilquin JT, 2006, REGEN MED, V1, P589, DOI 10.2217/17460751.1.4.589
   Wozney JM, 2004, CURR OPIN BIOTECH, V15, P392, DOI 10.1016/j.copbio.2004.08.001
NR 20
TC 5
Z9 10
U1 0
U2 20
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2011
VL 22
IS 6
BP 2023
EP 2026
DI 10.1007/s00198 011 1615 0
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 763HA
UT WOS:000290544900043
PM 21523396
DA 2025 08 17
ER

PT J
AU Sugden, CJ
   Roper, JR
   Williams, JG
AF Sugden, CJ
   Roper, JR
   Williams, JG
TI Engineered gene over expression as a method of drug target
   identification
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Dictyostelium; osteoclast; bone resorption; drug target;
   aminobisphosphonate; FDP synthase; gene over expression; drug resistance
ID DICTYOSTELIUM DISCOIDEUM; NUCLEAR PLASMID; GROWTH; DDP2
AB The proposed target of aminobisphosphonate (aBP) bone resorption inhibitors, both in mammalian osteoclasts and in Dictyostelium, is the enzyme farnesyl diphosphate synthase (FDP synthase). The genetic evidence, obtained with Dictyostelium?, derives from variant strains that over express FDP synthase and that are relatively resistant to aBPs. We show that forced FDP synthase overexpression also leads to aBP resistance; by placing FDP synthase under control of a semi constitutive promoter, transforming it into Dictyostelium cells and selecting with the aBP alendronate. This combination of drug and dominant selectable marker provides a novel selection system for transformation. We further show that, when a population of Dictyostelium cells expressing an entire growth stage cDNA library is placed under alendronate selection, FDP synthase is the only cDNA insert that confers drug resistance. This confirms FDP synthase as the primary target of aBPs and suggests a general method of drug target identification based upon engineered gene over expression. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.
C3 University of Dundee
RP Williams, JG (通讯作者)，Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dow St, Dundee DD1 5EH, Scotland.
EM j.g.williams@dundee.ac.uk
CR CHANG ACM, 1990, PLASMID, V24, P208, DOI 10.1016/0147 619X(90)90004 V
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Robinson DN, 2000, J CELL BIOL, V150, P823, DOI 10.1083/jcb.150.4.823
   ROGERS MJ, 1994, J BONE MINER RES, V9, P1029
   SCHIMKE RT, 1984, CANCER RES, V44, P1735
   SLADE MB, 1990, PLASMID, V24, P195, DOI 10.1016/0147 619X(90)90003 U
   VASU SK, 1993, J BIOL CHEM, V268, P15356
   WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171
NR 9
TC 13
Z9 14
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 26
PY 2005
VL 334
IS 2
BP 555
EP 560
DI 10.1016/j.bbrc.2005.06.117
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 950TI
UT WOS:000230880200036
PM 16005849
DA 2025 08 17
ER

PT J
AU Rossi, M
   De Martino, V
   Di Giuseppe, L
   Battafarano, G
   Di Gregorio, J
   Terreri, S
   Marampon, F
   Minisola, S
   Del Fattore, A
AF Rossi, Michela
   De Martino, Viviana
   Di Giuseppe, Laura
   Battafarano, Giulia
   Di Gregorio, Jacopo
   Terreri, Sara
   Marampon, Francesco
   Minisola, Salvatore
   Del Fattore, Andrea
TI Anti proliferative, pro apototic and anti migratory properties of HDAC
   inhibitor PXD 101 on osteosarcoma cell lines
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Bone; Osteosarcoma; Osteoblast; Osteoclast; Therapy; Tumor
ID HISTONE DEACETYLASE INHIBITORS; TRANSCRIPTION FACTOR; RUNX2; MAD2;
   TUMOR; PROLIFERATION; TUMORIGENESIS; OSTEOCLASTS; METASTASIS; BELINOSTAT
AB The therapeutic strategies for osteosarcoma involve both surgical approach and chemotherapy, but the identification of new therapeutic targets is particularly necessary in patients with local chemo resistance, recurrence and lung metastases. The role of epigenetic regulation in osteosarcoma is largely unknown. Thus, in this study we disclosed the effects of histone deacetylase inhibitor drug PXD 101 on human osteosarcoma (OS) cell lines with different aggressiveness, including Saos 2, HOS and 143B cell lines. XTT assays revealed that treatment of Saos 2, HOS and 143B cells with PXD 101 decreased cell viability in a concentration dependent manner. Fluorescenceactivated cell sorting (FACS) analysis showed that PXD 101 inhibited proliferation and induced cell apoptosis. Wound healing assay indicated that PXD 101 inhibited migration of osteosarcoma cells. Real Time RT qPCR and protein analysis highlighted reduced expression of Runx2, Osterix and Mad2, probably due to Cyclin B1 inhibition by PXD 101 treatment. To our knowledge, this is the first study that characterized the anti tumoral effect of PXD 101 in OS cells, suggesting a potential new therapeutic approach in osteosarcoma patients.
C1 [Rossi, Michela; Battafarano, Giulia; Terreri, Sara; Del Fattore, Andrea] Bambino Gesu Pediat Hosp, Bone Physiopathol Res Unit, Genet & Rare Dis Res Area, IRCCS, viale San Paolo 15, I 00146 Rome, Italy.
   [De Martino, Viviana; Di Giuseppe, Laura; Di Gregorio, Jacopo; Minisola, Salvatore] Sapienza Univ, Dept Clin Internal Anaesthesiol & Cardiovasc Sci, viale Policlin 155, I 00161 Rome, Italy.
   [Marampon, Francesco] Sapienza Univ, Dept Radiol Oncol & Pathol Sci, viale Policlin 155, I 00161 Rome, Italy.
C3 IRCCS Bambino Gesu; Sapienza University Rome; Sapienza University Rome
RP Del Fattore, A (通讯作者)，Bambino Gesu Pediat Hosp, Bone Physiopathol Res Unit, Genet & Rare Dis Res Area, IRCCS, viale San Paolo 15, I 00146 Rome, Italy.
EM michela1.rossi@opbg.net; viviana.demartino@uniroma1.it;
   laura.digiuseppe14@gmail.com; giulia.battafarano@opbg.net;
   jacopodigregorio@gmail.com; sara.terreri@opbg.net;
   francesco.marampon@uniroma1.it; salvatore.minisola@uniroma1.it;
   andrea.delfattore@opbg.net
RI Di Giuseppe, Laura/AHC 7787 2022; Del Fattore, Andrea/AAP 2045 2020;
   Battafarano, Giulia/N 8048 2013; Rossi, Michela/AAC 7774 2021; Del
   Fattore, Andrea/H 4409 2015; Di Gregorio, Jacopo/HKW 0312 2023; De
   Martino, Viviana/ABA 3813 2021; Terreri, Sara/J 2903 2018
OI Di Giuseppe, Laura/0000 0002 5996 4686; Di Gregorio,
   Jacopo/0000 0001 8865 2967; Del Fattore, Andrea/0000 0003 3848 412X; De
   Martino, Viviana/0000 0002 7034 7718; 
CR Androutsopoulos VP, 2017, ONCOL REP, V38, P3412, DOI 10.3892/or.2017.6015
   Bargiela Iparraguirre J, 2014, CELL CYCLE, V13, P3590, DOI 10.4161/15384101.2014.962952
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Chien WW, 2014, MOL CARCINOGEN, V53, P722, DOI 10.1002/mc.22024
   Chun P, 2015, ARCH PHARM RES, V38, P933, DOI 10.1007/s12272 015 0571 1
   Conde C, 2020, EMBO J, V39, DOI 10.15252/embj.2020105279
   Daw NC, 2015, BRIT J CANCER, V112, P278, DOI 10.1038/bjc.2014.585
   Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140 6736(07)60781 8
   EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21
   Endo Munoz L, 2012, BBA REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Endo Munoz L, 2010, CANCER RES, V70, P7063, DOI 10.1158/0008 5472.CAN 09 4291
   Friebele Jill C, 2015, Am J Orthop (Belle Mead NJ), V44, P547
   Gravina GL, 2012, INT J ONCOL, V40, P711, DOI 10.3892/ijo.2011.1270
   Hayward D, 2019, J CELL BIOL, V218, P1182, DOI 10.1083/jcb.201808014
   Hong AM, 2013, ANN ONCOL, V24, P2676, DOI 10.1093/annonc/mdt252
   Jaffe N, 2008, J CLIN ONCOL, V26, P4365, DOI 10.1200/JCO.2007.14.7793
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Keshelava N, 2009, PEDIATR BLOOD CANCER, V53, P505, DOI 10.1002/pbc.21988
   Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045045
   Kong FY, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 00870 y
   Li N, 2015, ANTI CANCER AGENT ME, V15, P881, DOI 10.2174/1871520615666150304151228
   Livyatan I, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.33
   Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218
   Mararnpon F, 2019, CANCER LETT, V461, P90, DOI 10.1016/j.canlet.2019.07.009
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Marks PA, 2010, BBA GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   Martin DT, 2013, NANOMED NANOTECHNOL, V9, P1124, DOI 10.1016/j.nano.2013.05.017
   Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320
   Norregaard KS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136865
   Patiño García A, 2009, J PEDIATR US, V154, P688, DOI 10.1016/j.jpeds.2008.11.030
   PosthumaDeBoer J, 2011, CLIN EXP METASTAS, V28, P493, DOI 10.1007/s10585 011 9384 x
   Rajgopal A, 2007, J CELL BIOCHEM, V100, P1509, DOI 10.1002/jcb.21137
   Sakamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145985
   Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017
   Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019
   Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803
   Torres HM, 2021, CANCERS, V13, DOI 10.3390/cancers13164199
   Valenzuela Fernández A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003
   Whetstine JR, 2005, MOL CELL, V18, P483, DOI 10.1016/j.molcel.2005.04.006
   Yao B, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04545 x
   Yu L, 2012, ONCOL REP, V28, P2170, DOI 10.3892/or.2012.2032
   Yu L, 2010, APMIS, V118, P222, DOI 10.1111/j.1600 0463.2009.02583.x
   Zeng H, 2015, ONCOL LETT, V9, P2455, DOI 10.3892/ol.2015.3124
   Zhang RY, 2016, TUMOR BIOL, V37, P3479, DOI 10.1007/s13277 015 4086 7
NR 44
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003 9861
EI 1096 0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JAN 15
PY 2023
VL 734
AR 109489
DI 10.1016/j.abb.2022.109489
EA DEC 2022
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 7I6FW
UT WOS:000903982300001
PM 36526001
DA 2025 08 17
ER

PT J
AU Xie, F
   Li, PC
   Gong, JH
   Zhang, JH
   Ma, JP
AF Xie, Fan
   Li, Pengcheng
   Gong, Jianhua
   Zhang, Jiahong
   Ma, Jingping
TI The bisphosphonate zoledronic acid effectively targets lung cancer cells
   by inhibition of protein prenylation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Lung cancer; Bisphosphonate; Zoledronic acid; Prenylation; Ras
   signalling
ID MEVALONATE PATHWAY; BONE METASTASES; APOPTOSIS; MYELOMA; RAS; PI3K
AB Aberrant activation of oncoproteins such as members of the Ras family is common in human lung cancers. The proper function of Ras largely depends on a post translational modification termed prenylation. Bisphosphonates have been shown to inhibit prenylation in cancer cells. In this study, we show that zoledronic acid, a third generation bisphosphonate, is effective in targeting lung cancer cells. This is achieved by the induction of apoptosis and inhibition of proliferation, through suppressing the activation of downstream Ras and EGFR signalling by zoledronic acid. The combination of zoledronic acid and paclitaxel or cisplatin (commonly used chemotherapeutic drugs for lung cancer) augmented the activity of either drug alone in in vitro lung cancer cellular system and in vivo lung xenograft mouse model. Importantly, zoledronic acid inhibits protein prenylation as shown by the increased levels of unprenylated Ras and Rap1A. In addition, the effects of zoledronic acid were reversed in the presence of geranylgeraniol and farnesol, further confirming that mechanism of zoledroinc acid's action in lung cancer cells is through prenylation inhibition. Since zoledronic acid is already available for clinic use, these results suggest that it may be an effective addition to the armamentarium of drugs for the treatment of lung cancer. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Xie, Fan; Gong, Jianhua; Zhang, Jiahong; Ma, Jingping] Huazhong Univ Sci & Technol, Tongji Med Coll, Jingzhou Hosp, Dept Resp Med, Jingzhou 434020, Peoples R China.
   [Li, Pengcheng] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Dept Oncol, Wuhan 430074, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Ma, JP (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Jingzhou Hosp, Dept Resp Med, Renmin Rd 1, Jingzhou 434020, Peoples R China.
EM mjpjzhospital@hotmail.com
RI li, pengcheng/AAK 7315 2021
FU JingZhou Hospital Affiliated to Huazhong University of Science and
   Technology [201306018]; Science and Technology Department of Hubei
   Province [EK2014D160105001880]
FX We are grateful to Dr. Wei Xiang for her technical assistance. This work
   was supported by a research grant provided by JingZhou Hospital
   Affiliated to Huazhong University of Science and Technology (201306018).
   Fan Xie was supported by a research grant provided by Science and
   Technology Department of Hubei Province (EK2014D160105001880).
CR [Anonymous], PATHOL RES INT
   Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949
   Dancey J, 1997, EUR J CANCER, V33, pS2, DOI 10.1016/S0959 8049(96)00325 5
   Downward J, 2008, NAT MED, V14, P1315, DOI 10.1038/nm1208 1315
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Garay T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117021
   Gazdar AF, 2009, NEW ENGL J MED, V361, P1018, DOI 10.1056/NEJMe0905763
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Hiraga T, 2001, CANCER RES, V61, P4418
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Major P, 2002, ONCOLOGIST, V7, P481, DOI 10.1634/theoncologist.7 6 481
   Mortazavi F, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1360 4
   Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008 5472.CAN 14 0184
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   SASAKI A, 1995, CANCER RES, V55, P3551
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood 2003 03 0970
   Wang S, 2015, TRANSL LUNG CANCER R, V4, P119, DOI 10.3978/j.issn.2218 6751.2015.01.05
   Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459
   Winter Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
NR 24
TC 14
Z9 16
U1 0
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 27
PY 2015
VL 467
IS 4
BP 664
EP 669
DI 10.1016/j.bbrc.2015.10.089
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CW6YV
UT WOS:000365145300010
PM 26498526
DA 2025 08 17
ER

PT J
AU Axmann, R
   Böhm, C
   Krönke, G
   Zwerina, J
   Smolen, J
   Schett, G
AF Axmann, Roland
   Boehm, Christina
   Kroenke, Gerhard
   Zwerina, Jochen
   Smolen, Josef
   Schett, Georg
TI Inhibition of Interleukin 6 Receptor Directly Blocks Osteoclast
   Formation In Vitro and In Vivo
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID RHEUMATOID ARTHRITIS PATIENTS; KAPPA B LIGAND; BONE RESORPTION; SOLUBLE
   INTERLEUKIN 6; CELL FORMATION; RADIOGRAPHIC BENEFIT; SIGNALING PATHWAYS;
   MARROW CULTURES; DOUBLE BLIND; IL 6
AB Objective. To investigate the efficacy of a murine anti interleukin 6 receptor (anti IL 6R) antibody in directly blocking tumor necrosis factor (TNF)  and RANKL mediated osteoclastogenesis in vitro and in vivo.
   Methods. The efficacy of a murine antibody against IL 6R in blocking osteoclast differentiation of mononuclear cells stimulated with RANKL was tested. In addition, arthritic human TNF alpha transgenic mice were treated with anti IL 6R antibody, and osteoclast formation and bone erosion were assessed in arthritic paws.
   Results. Blockade of IL 6R dose dependently reduced osteoclast differentiation and bone resorption in monocyte cultures stimulated with RANKL or RANKL plus TNF. In human TNF alpha transgenic mice, IL 6R blockade did not inhibit joint inflammation, but it strongly reduced osteoclast formation in inflamed joints as well as bone erosion in vivo. Neither the cell influx into joints nor the synovial expression of IL 6 and RANKL changed with IL 6R blockade, while the synovial expression of IL 1 was significantly reduced. In contrast, TNF mediated systemic bone loss was not inhibited by IL 6R blockade.
   Conclusion. These data suggest that blockade of IL 6R directly affects osteoclast formation in vitro and in vivo, suggesting a direct and specific effect of anti IL 6R therapy on osteoclasts independently of its anti inflammatory effects. This effect adds significantly to the structure sparing potential of pharmacologic blockade of IL 6R in arthritis.
C1 [Axmann, Roland; Boehm, Christina; Kroenke, Gerhard; Zwerina, Jochen; Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
   [Smolen, Josef; Schett, Georg] Med Univ Vienna, Vienna, Austria.
C3 University of Erlangen Nuremberg; Medical University of Vienna
RP Schett, G (通讯作者)，Univ Erlangen Nurnberg, Dept Internal Med 3, Krankenhausstr 12, D 91054 Erlangen, Germany.
EM georg.schett@uk erlangen.de
RI Krönke, Gerhard/C 6615 2014; Smolen, Josef/ADI 7087 2022; Kronke,
   Gerhard/C 6615 2014
OI Kronke, Gerhard/0000 0002 7566 4325
FU DFG Sonderforschungsbereich [C6, C7]; Austrian Ministry of Sciences
FX Supported by DFG Sonderforschungsbereich 643, the Interdisciplinary
   Center of Clinical Research Erlangen (IZKF Project C6 and C7 grants),
   and Forschcrgruppe 661. Dr. Schett is recipient of the START Prize from
   the Austrian Ministry of Sciences.
CR Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Dai JL, 2000, J CLIN INVEST, V106, P887, DOI 10.1172/JCI10483
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   Devlin RD, 1998, J BONE MINER RES, V13, P393, DOI 10.1359/jbmr.1998.13.3.393
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   FLANAGAN AM, 1995, J PATHOL, V176, P289, DOI 10.1002/path.1711760311
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Herman S, 2008, ARTHRITIS RHEUM US, V58, P3041, DOI 10.1002/art.23943
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   KANATANI M, 1994, AM J PHYSIOL ENDOC M, V267, pE868, DOI 10.1152/ajpendo.1994.267.6.E868
   Kawasaki K, 1997, ENDOCRINOLOGY, V138, P4959, DOI 10.1210/en.138.11.4959
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Liu XH, 2005, ENDOCRINOLOGY, V146, P1991, DOI 10.1210/en.2004 1167
   LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006 291x(89)90851 6
   Maini RN, 2006, ARTHRITIS RHEUM US, V54, P2817, DOI 10.1002/art.22033
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064
   Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338
   OHSAKI Y, 1992, ENDOCRINOLOGY, V131, P2229, DOI 10.1210/en.131.5.2229
   Okazaki M, 2002, IMMUNOL LETT, V84, P231, DOI 10.1016/S0165 2478(02)00202 X
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872
   Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140 6736(08)60453 5
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zwerina J, 2007, P NATL ACAD SCI USA, V104, P11742, DOI 10.1073/pnas.0610812104
NR 39
TC 218
Z9 244
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD SEP
PY 2009
VL 60
IS 9
BP 2747
EP 2756
DI 10.1002/art.24781
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 497JI
UT WOS:000270054900026
PM 19714627
DA 2025 08 17
ER

PT J
AU Ohashi, E
   Kohno, K
   Arai, N
   Harashima, A
   Ariyasu, T
   Ushio, S
AF Ohashi, Emiko
   Kohno, Keizo
   Arai, Norie
   Harashima, Akira
   Ariyasu, Toshio
   Ushio, Shimpei
TI Adenosine N1 Oxide Exerts Anti inflammatory Effects through the
   PI3K/Akt/GSK 3β Signaling Pathway and Promotes Osteogenic and Adipocyte
   Differentiation
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE adenosine N1 oxide (ANO); anti inflammatory effect; regenerative
   medicine; phosphatidylinositol 3 kinase (PI3K) Akt glycogen synthase
   kinase 3 beta (GSK 3 beta) signaling pathway
ID PHOSPHATIDYLINOSITOL 3 KINASE; KINASE; EXPRESSION; RECEPTORS; TARGET
AB Previously, we reported that adenosine N1 oxide (ANO), which is found in royal jelly, inhibited the secretion of inflammatory mediators by activated macrophages and reduced lethality in lipopolysaccharide (LPS) induced endotoxin shock. Here, we examined the regulatory mechanisms of ANO on the release of pro inflammatory cytokines, with a focus on the signaling pathways activated by toll like receptor (TLR)4 in response to LPS. ANO inhibited both tumor necrosis factor (TNF) alpha and interleukin (IL) 6 secretion from LPS stimulated RAW264.7 cells without affecting cell proliferation. In this response, phosphorylation of mitogen activated protein kinase (MAPK) family members (extracellular signal regulated kinase (ERK)1/2, p38 and SAPK/c Jun N terminal kinase (JNK)) and nuclear factor kappa B (NF kappa B) p65 was not affected by treatment with ANO. In contrast, phosphorylation of Akt (Ser473) and its downstream molecule glycogen synthase kinase 3 beta (GSK 3 beta) (Ser9) was up regulated by ANO, suggesting that ANO stimulated GSK 3 beta phosphorylation via phosphatidylinositol 3 kinase (PI3K)/Akt signaling pathway. The phosphorylation of GSK 3 beta on Ser9 has been shown to negatively regulate the LPS induced inflammatory response. Activation of PI3K/Akt signaling pathway has also been implicated in differentiation of mesenchymal stem cells into osteoblasts and adipocytes. As expected, ANO induced alkaline phosphatase activity and promoted calcium deposition in a mouse pre osteoblastic MC3T3 E1 cell line. The ANO induced differentiation into osteoblasts was abrogated by coincubation with Wortmannin. Furthermore, ANO promoted insulin/dexamethasone induced differentiation of mouse 3T3 L1 preadipocytes into adipocytes at much lower concentrations than adenosine. The protective roles of PI3K/Akt/GSK 3 beta signaling pathway in inflammatory disorders have been well documented. Our data suggest that ANO may serve as a potential candidate for the treatment of inflammatory disorders. Promotion of osteogenic and adipocyte differentiation further suggests its application for regenerative medicine.
C1 [Ohashi, Emiko; Kohno, Keizo; Arai, Norie; Harashima, Akira; Ariyasu, Toshio; Ushio, Shimpei] Hayashibara Co Ltd, Res & Dev Div, Naka Ku, 675 1 Fujisaki, Okayama 7028006, Japan.
RP Ohashi, E (通讯作者)，Hayashibara Co Ltd, Res & Dev Div, Naka Ku, 675 1 Fujisaki, Okayama 7028006, Japan.
EM emiko.ohashi@hb.nagase.co.jp
CR Castillo Quan JI, 2016, CELL REP, V15, P638, DOI 10.1016/j.celrep.2016.03.041
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   Du XL, 2015, EXP BIOL MED, V240, P1472, DOI 10.1177/1535370215584939
   Dubey RK, 2015, HYPERTENSION, V66, P1207, DOI 10.1161/HYPERTENSIONAHA.115.05912
   Feoktistov Igor, 2009, Handb Exp Pharmacol, P383, DOI 10.1007/978 3 540 89615 9_13
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092 8674(75)90087 2
   Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200
   Haskó G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   Hofmann C, 2010, INFLAMM BOWEL DIS, V16, P1850, DOI 10.1002/ibd.21294
   Jain V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062235
   KLABUNDE RE, 1983, EUR J PHARMACOL, V93, P21, DOI 10.1016/0014 2999(83)90026 2
   Koga K, 2009, IMMUNITY, V30, P372, DOI 10.1016/j.immuni.2008.12.021
   Kohno K, 2015, J INFLAMM LOND, V12, DOI 10.1186/s12950 014 0045 0
   Lal H, 2015, CIRC RES, V116, P138, DOI 10.1161/CIRCRESAHA.116.303613
   Law NC, 2016, J BIOL CHEM, V291, P27160, DOI 10.1074/jbc.M116.763235
   Li DW, 2014, MOL MED REP, V9, P2043, DOI 10.3892/mmr.2014.2080
   Liu G., 2017, British Biomedical Bulletin, V5, P301
   Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221
   Milne GR, 2011, THESCIENTIFICWORLDJO, V11, P320, DOI 10.1100/tsw.2011.22
   Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046 08
   OHKI K, 1995, BRAIN RES, V696, P140, DOI 10.1016/0006 8993(95)00914 C
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Rao V, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00185
   Scott MA, 2011, STEM CELLS DEV, V20, P1793, DOI 10.1089/scd.2011.0040
   Tanabe K, 2008, PLOS BIOL, V6, P307, DOI 10.1371/journal.pbio.0060037
   Tian YK, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/585297
   Wang HZ, 2011, J IMMUNOL, V186, P5217, DOI 10.4049/jimmunol.1002513
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200
   Zhang WJ, 2007, P NATL ACAD SCI USA, V104, P4077, DOI 10.1073/pnas.0700305104
NR 31
TC 20
Z9 24
U1 0
U2 8
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD JUN
PY 2019
VL 42
IS 6
BP 968
EP 976
DI 10.1248/bpb.b18 00988
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IB1UU
UT WOS:000470051200016
PM 31155593
OA gold
DA 2025 08 17
ER

PT J
AU Juárez, P
   Fournier, PGJ
   Mohammad, KS
   McKenna, RC
   Davis, HW
   Peng, XH
   Niewolna, M
   Mauviel, A
   Chirgwin, JM
   Guise, TA
AF Juarez, Patricia
   Fournier, Pierrick G. J.
   Mohammad, Khalid S.
   McKenna, Ryan C.
   Davis, Holly W.
   Peng, Xiang H.
   Niewolna, Maria
   Mauviel, Alain
   Chirgwin, John M.
   Guise, Theresa A.
TI Halofuginone inhibits TGF β/BMP signaling and in combination with
   zoledronic acid enhances inhibition of breast cancer bone metastasis
SO ONCOTARGET
LA English
DT Article
DE halofuginone; zoledronic acid; bone metastases; TGF beta; BMP
ID RECEPTOR KINASE INHIBITOR; MORPHOGENETIC PROTEINS; GROWTH;
   BISPHOSPHONATES; MECHANISMS; PROGRESSION; ACTIVATION; FIBROSIS; DISEASE;
   CELLS
AB More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloid derivative with antiangiogenic and antiproliferative effects. Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGF beta and BMP signaling. Halofuginone blocked TGF beta signaling in MDA MB 231 and PC3 cells showed by inhibition of TGF beta induced Smad reporter, phosphorylation of Smad proteins, and expression of TGF beta regulated metastatic genes.
   Halofuginone increased inhibitory Smad7 mRNA and reduced TGF beta receptor II protein. Proline supplementation but not Smad7 knockdown reversed halofuginone inhibition of TGF beta signaling. Halofuginone also decreased BMP signaling. Treatment of MDA MB 231 and PC3 cells with halofuginone reduced the BMP Smad reporter (BRE) 4, Smad1/5/8 phosphorylation and mRNA of the BMP regulated gene Id 1. Halofuginone decreased immunostaining of phospho Smad2/3 and phospho Smad1/5/8 in cancer cells in vivo.
   Furthermore, halofuginone decreased tumor take and growth of orthotopictumors. Mice with breast or prostate bone metastases treated with halofuginone had significantly less osteolysis than control mice. Combined treatment with halofuginone and zoledronic acid significantly reduced osteolytic area more than either treatment alone. Thus, halofuginone reduces breast and prostate cancer bone metastases in mice and combined with treatment currently approved by the FDA is an effective treatment for this devastating complication of breast and prostate cancer.
C1 [Juarez, Patricia; Fournier, Pierrick G. J.; Mohammad, Khalid S.; Peng, Xiang H.; Niewolna, Maria; Chirgwin, John M.; Guise, Theresa A.] Indiana Univ Purdue Univ, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
   [Juarez, Patricia; Fournier, Pierrick G. J.] Ensenada Ctr Sci Res & Higher Educ, Ensenada, Baja California, Mexico.
   [McKenna, Ryan C.; Davis, Holly W.] Univ Virginia, Charlottesville, VA USA.
   [Mauviel, Alain] Inst Curie, Orsay, France.
   [Mauviel, Alain] INSERM U1021, Orsay, France.
   [Mauviel, Alain] CNRS UMR3347, Orsay, France.
   [Mauviel, Alain] Univ Paris 11, Orsay, France.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; University of Virginia; UNICANCER; Universite PSL;
   Institut Curie; Universite PSL; UNICANCER; Institut Curie; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay;
   Universite Paris Saclay; Universite PSL; UNICANCER; Institut Curie;
   Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); CNRS   National
   Institute for Biology (INSB); Universite Paris Saclay
RP Guise, TA (通讯作者)，Indiana Univ Purdue Univ, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
EM tguise@iu.edu
RI Mohammad, Khalid/AFE 4205 2022; MAUVIEL, Alain/F 6251 2013; Juarez,
   Patricia/AAA 2791 2020; Fournier, Pierrick/B 6560 2015
OI Mauviel, Alain/0000 0002 0438 2793; Chirgwin, John/0009 0001 7638 0842;
   Fournier, Pierrick/0000 0001 7633 8129
FU NIH [R01CA69158, R01DK067333, R01DK065837, U01CA143057]; Mary Kay Ash
   Foundation; V Foundation; Aurbach Endowment of the University of
   Virginia; Indiana University; Indiana Economic Development Fund; Susan
   Komen Foundation
FX This work was supported by NIH grants R01CA69158, R01DK067333,
   R01DK065837, U01CA143057; the Mary Kay Ash Foundation, the V Foundation,
   the Aurbach Endowment of the University of Virginia, the Jerry W. and
   Peggy S. Throgmartin Endowment of Indiana University and the Indiana
   Economic Development Fund (to T.A.G.) as well as a grants from the Susan
   Komen Foundation (to P.J. and T.A.G.)
CR Abramovitch R, 2004, NEOPLASIA, V6, P480, DOI 10.1593/neo.03520
   Alarmo EL, 2010, ENDOCR RELAT CANCER, V17, pR123, DOI 10.1677/ERC 09 0273
   Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008 5472.CAN 05 3565
   Biswas S, 2008, J BONE MINER RES, V23, pS170
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   de Jonge MJA, 2006, EUR J CANCER, V42, P1768, DOI 10.1016/j.ejca.2005.12.027
   Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091
   Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349 7006.2006.00357.x
   Gavish Z, 2002, PROSTATE, V51, P73, DOI 10.1002/pros.10059
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   GRANOT I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P107, DOI 10.1016/0304 4165(93)90123 P
   Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008 5472.CAN 06 3950
   Juárez P, 2012, CANCER RES, V72, P6247, DOI 10.1158/0008 5472.CAN 12 1444
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Kallioniemi A, 2012, CANCER GENET NY, V205, P267, DOI 10.1016/j.cancergen.2012.05.009
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Keller TL, 2012, NAT CHEM BIOL, V8, P311, DOI [10.1038/NCHEMBIO.790, 10.1038/nchembio.790]
   Koon HB, 2011, JAIDS J ACQ IMM DEF, V56, P64, DOI 10.1097/QAI.0b013e3181fc0141
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432 0436.2006.00083.x
   Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008 5472.CAN 10 2651
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Pines M, 2008, EXPERT OPIN DRUG DIS, V3, P11, DOI 10.1517/17460441.3.1.11
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Sethi N, 2011, BONE, V48, P16, DOI 10.1016/j.bone.2010.07.005
   Spector I, 2010, PANCREAS, V39, P1008, DOI 10.1097/MPA.0b013e3181da8aa3
   Sundrud MS, 2009, SCIENCE, V324, P1334, DOI 10.1126/science.1172638
   Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xavier S, 2004, J BIOL CHEM, V279, P15167, DOI 10.1074/jbc.M309798200
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yuan Joshua S., 2008, Biotechnology Journal, V3, P112, DOI 10.1002/biot.200700169
NR 37
TC 34
Z9 38
U1 2
U2 25
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 17
PY 2017
VL 8
IS 49
BP 86447
EP 86462
DI 10.18632/oncotarget.21200
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FJ9FN
UT WOS:000413077800152
PM 29156807
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, GC
   Xing, CC
   Zeng, LT
   Huang, YJ
   Sun, X
   Liu, YQ
AF Sun, Guangchen
   Xing, Congcong
   Zeng, Luting
   Huang, Yijie
   Sun, Xin
   Liu, Yingqin
TI Flemingia philippinensis Flavonoids Relieve Bone Erosion and
   Inflammatory Mediators in CIA Mice by Downregulating NF B and MAPK
   Pathways
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; FIBROBLAST LIKE SYNOVIOCYTES; KAPPA B;
   C JUN; SIGNAL TRANSDUCTION; TERMINAL KINASE; ACTIVATION; DESTRUCTION;
   EXPRESSION; INHIBITORS
AB Background. The dry root of Flemingia philippinensis has been widely used in the treatment of rheumatism, arthropathy, and osteoporosis in traditional Chinese medicine; the therapeutic effects of Flemingia philippinensis are associated with antiarthritis in traditional Chinese medicine theory. This study was undertaken to investigate the mechanism of bone erosion protection and anti inflammatory effect of Flemingia philippinensis flavonoids (FPF) in collagen induced arthritis (CIA) in mice. Methods. Flavonoids were extracted from the dry root of Flemingia philippinensis. Collagen induced arthritis in C57BL/6 mice was used as a rheumatoid arthritis model, and the mice were orally fed with FPF prior to induction to mimic clinical prophylactic therapy for a total of 39 days. After treatment, histology and immunohistochemistry staining were performed, and the levels of anti collagen type II (CII) antibody and inflammatory mediators, as well as the key proteins of nuclear factor kappa B (NF B) and mitogen activated protein kinase (MAPK) pathways, were detected in the samples taken from ankle joints, plasma, and paws. Results. FPF administration significantly suppressed the paw swelling and arthritic score in CIA mice. FPF reduced inflammatory infiltration and pannus formation, articular cartilage destruction and osteoclast infiltration, and the expression of MMP 9 and cathepsin K in the ankle joint. FPF inhibited plasma anti CII antibody levels and the production of inflammatory cytokines and chemokines in CIA paws. FPF treatment suppressed the activation of NF B as indicated by downregulating the phosphorylation of NF B p65 and mitogen activated protein kinases in CIA paws. Additionally, FPF significantly inhibited inflammation signaling by suppressing the activation of activator protein 1 subset and signal transducers and activators of transcription 3 (STAT3). Conclusions. Our data suggest that FPF might be an active therapeutic agent for rheumatoid arthritis and the preventive effect of FPF on arthritis is attributable to an anti inflammatory effect on CIA by preventing bone destruction, regulating inflammatory mediators, and suppressing NF B and MAPK signaling pathways.
C1 [Sun, Guangchen; Xing, Congcong; Zeng, Luting; Huang, Yijie] Guilin Med Univ, Coll Pharm, Guilin, Guangxi, Peoples R China.
   [Sun, Xin] Xiamen Univ, Coll Med, Xiamen, Fujian, Peoples R China.
   [Liu, Yingqin] Guilin Med Univ, Biotechnol Coll, Guilin, Guangxi, Peoples R China.
C3 Guilin Medical University; Xiamen University; Guilin Medical University
RP Liu, YQ (通讯作者)，Guilin Med Univ, Biotechnol Coll, Guilin, Guangxi, Peoples R China.
EM sungc@glmc.edu.cn; 1035852782@qq.com; 879853108@qq.com;
   286692267@qq.com; 673510036@qq.com; liuyq@glmc.edu.cn
RI Sun, Guangchen/ABI 7533 2020
OI Sun, Guangchen/0000 0001 8266 6014
FU National Natural Science Foundation of China [81260462, 81660304,
   81460474]; Natural Science Foundation of Guangxi Province
   [2015GXNFAA139104, 2017GXNSFAA198334, 2018GXNSFAA138072]
FX The authors are thankful for the grants of the National Natural Science
   Foundation of China (81260462, 81660304, and 81460474;
   https://isisn.nsfc.gov.cn/egrantweb/) and the Natural Science Foundation
   of Guangxi Province (2015GXNFAA139104, 2017GXNSFAA198334, and
   2018GXNSFAA138072; http://gxnsf.gxsti.net/stms/login.jsp). The funding
   bodies were not involved in any aspects of the study. The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ahn EM, 2004, BIOL PHARM BULL, V27, P548, DOI 10.1248/bpb.27.548
   Bao CM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176672
   Ceponis A, 2001, ARTHRITIS RHEUM, V44, P1908
   CHEN M, 1991, Yaoxue Xuebao, V26, P42
   DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600 065X.2012.01099.x
   Eekman DA, 2011, ANN RHEUM DIS, V70, P389, DOI 10.1136/ard.2009.127787
   Finnegan A, 2003, ARTHRITIS RES THER, V5, pR18, DOI 10.1186/ar601
   Finzel S, 2011, ANN RHEUM DIS, V70, P1587, DOI 10.1136/ard.2010.148395
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Fu MQ, 2013, NAT PROD RES, V27, P1237, DOI 10.1080/14786419.2012.724414
   Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707
   Ganesan R, 2016, IMMUNOL RES, V64, P1071, DOI 10.1007/s12026 016 8794 x
   Gilmore TD, 2012, IMMUNOL REV, V246, P14, DOI 10.1111/j.1600 065X.2012.01096.x
   Han Z., 1991, J PHARM EXPT THERAPE, V291, P124
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092 8674(00)81999 6
   Kotthoff P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04558 z
   Li H, 2012, MOLECULES, V17, P7637, DOI 10.3390/molecules17077637
   Li L, 2011, FITOTERAPIA, V82, P615, DOI 10.1016/j.fitote.2011.01.019
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859
   Ohori M, 2007, N S ARCH PHARMACOL, V374, P311, DOI 10.1007/s00210 006 0117 7
   Pan BS, 2005, LIFE SCI, V77, P2830, DOI 10.1016/j.lfs.2005.05.027
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Rengasamy KRR, 2019, PHARMACOL THERAPEUT, V194, P107, DOI 10.1016/j.pharmthera.2018.09.009
   Ross EA, 2017, ANN RHEUM DIS, V76, P612, DOI 10.1136/annrheumdis 2016 209424
   Saxena A, 2015, CYTOKINE, V74, P27, DOI 10.1016/j.cyto.2014.10.031
   Saxena Charu Chandra, 2016, J Clin Orthop Trauma, V7, P109, DOI 10.1016/j.jcot.2015.09.006
   Scatizzi JC, 2006, ARTHRITIS RHEUM, V54, P3182, DOI 10.1002/art.22133
   Schepetkin IA, 2015, J PHARMACOL EXP THER, V353, P505, DOI 10.1124/jpet.114.220251
   Schett G, 2008, ANN RHEUM DIS, V67, P909, DOI 10.1136/ard.2007.074278
   Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Sucur A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1337 6
   Sun F, 2017, CHEM BIODIVERS, V14, DOI 10.1002/cbdv.201600193
   Sweeney SE, 2007, NAT CLIN PRACT RHEUM, V3, P651, DOI 10.1038/ncprheum0631
   Szekanecz Z, 2016, NAT REV RHEUMATOL, V12, P5, DOI 10.1038/nrrheum.2015.157
   Vincenti MP, 2001, J CLIN INVEST, V108, P181
   Wang Y, 2013, BIOORGAN MED CHEM, V21, P6398, DOI 10.1016/j.bmc.2013.08.049
   Wojcikowski K, 2014, PHYTOTHER RES, V28, P22, DOI 10.1002/ptr.4966
   Yang YL, 2016, INT IMMUNOPHARMACOL, V41, P8, DOI 10.1016/j.intimp.2016.10.005
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Young K, 2018, JOVE J VIS EXP, DOI 10.3791/57648
   Zwerina J, 2006, ARTHRITIS RHEUM US, V54, P463, DOI 10.1002/art.21626
NR 45
TC 15
Z9 16
U1 4
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962 9351
EI 1466 1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2019
VL 2019
AR 5790291
DI 10.1155/2019/5790291
PG 11
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA HN6IF
UT WOS:000460288500001
PM 30906224
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Breathwaite, E
   Weaver, J
   Odanga, J
   dela Pena Ponce, M
   Lee, JB
AF Breathwaite, Erick
   Weaver, Jessica
   Odanga, Justin
   dela Pena Ponce, Myra
   Lee, Jung Bok
TI 3D Bioprinted Osteogenic Tissue Models for In Vitro Drug Screening
SO MOLECULES
LA English
DT Article
DE scaffold free; 3D bioprinting; BM MSC; bone; drug screening
ID OSTEOCLAST ACTIVITY; SMALL MOLECULES; STEM CELLS; BONE; SCAFFOLD;
   DIFFERENTIATION; PURMORPHAMINE; REGENERATION; ICARIIN; PROLIFERATION
AB Metabolic bone disease affects hundreds of millions of people worldwide, and as a result, in vitro models of bone tissue have become essential tools to help analyze bone pathogenesis, develop drug screening, and test potential therapeutic strategies. Drugs that either promote or impair bone formation are in high demand for the treatment of metabolic bone diseases. These drugs work by targeting numerous signaling pathways responsible for regulating osteogenesis such as Hedgehog, Wnt/beta catenin, and PI3K AKT. In this study, differentiated bone marrow derived mesenchymal stem cell (BM MSC) scaffold free 3D bioprinted constructs and 2D monolayer cultures were utilized to screen four drugs predicted to either promote (Icariin and Purmorphamine) or impair osteogenesis (PD98059 and U0126). Osteogenic differentiation capacity was analyzed over a four week culture period by evaluating mineralization, alkaline phosphatase (ALP) activity, and osteogenesis related gene expression. Responses to drug treatment were observed in both 3D differentiated constructs and 2D monolayer cultures. After four weeks in culture, 3D differentiated constructs and 2D monolayer cultures treated with Icariin or Purmorphamine showed increased mineralization, ALP activity, and the gene expression of bone formation markers (BGLAP,SSP1, andCOL1A1), signaling molecules (MAPK1,WNT1, andAKT1), and transcription factors (RUNX2andGLI1) that regulate osteogenic differentiation relative to untreated. 3D differentiated constructs and 2D monolayer cultures treated with PD98059 or U0126 showed decreased mineralization, ALP activity, and the expression of the aforementioned genesBGLAP,SPP1,COL1A1,MAPK1,AKT1,RUNX2, andGLI1relative to untreated. Differences in ALP activity and osteogenesis related gene expression relative to untreated cells cultured in a 2D monolayer were greater in 3D constructs compared to 2D monolayer cultures. These findings suggest that our bioprinted bone model system offers a more sensitive, biologically relevant drug screening platform than traditional 2D monolayer in vitro testing platforms.
C1 [Breathwaite, Erick; Weaver, Jessica; Odanga, Justin; dela Pena Ponce, Myra; Lee, Jung Bok] LifeNet Hlth, Inst Regenerat Med, 1864 Concert Dr, Virginia Beach, VA 23453 USA.
RP Lee, JB (通讯作者)，LifeNet Hlth, Inst Regenerat Med, 1864 Concert Dr, Virginia Beach, VA 23453 USA.
EM erick_breathwaite@lifenethealth.org; jessica_weaver@lifenethealth.org;
   justin_odanga@lifenethealth.org; myra_delapenaponce@lifenethealth.org;
   jungbok_lee@lifenethealth.org
OI Breathwaite, Erick/0000 0003 1191 2569
FU non profit LifeNet Health
FX This study was supported by the non profit LifeNet Health.
CR Agidigbi TS, 2020, FREE RADICAL RES, V54, P894, DOI 10.1080/10715762.2020.1742896
   Aguilar Izath Nizeet, 2019, Bioprinting, V15, pe00050, DOI 10.1016/j.bprint.2019.e00050
   Bahrami N, 2017, ARTIF CELL NANOMED B, V45, P1343, DOI 10.1080/21691401.2016.1236804
   Bellesini LS, 2009, BONE, V44, pS333, DOI 10.1016/j.bone.2009.03.638
   Breathwaite EK, 2019, BIOMED MATER, V14, DOI 10.1088/1748 605X/ab4243
   Cao Y, 2013, CELL PROLIFERAT, V46, P447, DOI 10.1111/cpr.12039
   Cassuto J, 2018, BONE, V107, P66, DOI 10.1016/j.bone.2017.11.004
   Chang CY, 2016, RADIOGRAPHICS, V36, P1871, DOI 10.1148/rg.2016160004
   Cheng YH, 2019, WORLD J STEM CELLS, V11, P1084, DOI 10.4252/wjsc.v11.i12.1084
   Cui Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1428 1
   Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016
   Fontaine C, 2008, STEM CELLS, V26, P1037, DOI 10.1634/stemcells.2007 0974
   Gellynck K, 2013, BONE, V57, P405, DOI 10.1016/j.bone.2013.09.012
   Goonoo N, 2019, RSC ADV, V9, P18124, DOI 10.1039/c9ra02765c
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hu JH, 2017, BIOCHEM PHARMACOL, V136, P109, DOI 10.1016/j.bcp.2017.04.010
   Huang JM, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/8085325
   Huang YK, 2020, SCI CHINA LIFE SCI, V63, P429, DOI 10.1007/s11427 019 1555 9
   Jafary F, 2017, INT J TRANSPLANT MED, V8, P195
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Kusuyama J, 2017, MOL BIOL CELL, V28, P1326, DOI 10.1091/mbc.E16 10 0716
   Lai YX, 2018, BIOMATERIALS, V153, P1, DOI 10.1016/j.biomaterials.2017.10.025
   Lee CS, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7822
   Lee HR, 2019, PHARMACOL RES, V149, DOI 10.1016/j.phrs.2019.104466
   Li CS, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3764372
   Li XJ, 2016, PROG BIOPHYS MOL BIO, V122, P101, DOI 10.1016/j.pbiomolbio.2016.05.008
   Liu C, 2016, OBES SURG, V26, P91, DOI 10.1007/s11695 015 1724 5
   Lou D, 2019, BRAZ J PHARM SCI, V55, DOI 10.1590/s2175 97902019000218300
   Mazzocchi A, 2019, APPL PHYS REV, V6, DOI 10.1063/1.5056188
   Otero CE, 2019, J APPL TOXICOL, V39, P888, DOI 10.1002/jat.3777
   Peng WJ, 2016, TRENDS BIOTECHNOL, V34, P722, DOI 10.1016/j.tibtech.2016.05.013
   Pirosa A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0847 8
   Shahabipour F, 2020, TRANSL RES, V216, P57, DOI 10.1016/j.trsl.2019.08.010
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tang XP, 2017, TROP J PHARM RES, V16, P279, DOI 10.4314/tjpr.v16i2.4
   Trombetta R, 2017, ANN BIOMED ENG, V45, P23, DOI 10.1007/s10439 016 1678 3
   Vanderburgh J, 2017, ANN BIOMED ENG, V45, P164, DOI 10.1007/s10439 016 1640 4
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang YJ, 2015, BIOTECHNOL ADV, V33, P1626, DOI 10.1016/j.biotechadv.2015.08.005
   Wöltje M, 2015, IN VIVO, V29, P247
   Wu T, 2009, CHINESE SCI BULL, V54, P2953, DOI 10.1007/s11434 009 0250 z
   Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010
   Yang AF, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5747298
   Yao XD, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00163
   Zhang X, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00201
   [张艳苹 Zhang Yanping], 2017, [中华骨科杂志, Chinese Journal of Orthopedics], V37, P59
   Zhu ML, 2016, J BONE MINER RES, V31, P864, DOI 10.1002/jbmr.2733
   Zlobina MV, 2015, EUROPE PMC, V57, P269, DOI DOI 10.1134/S1990519X15040124
NR 50
TC 18
Z9 22
U1 0
U2 19
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2020
VL 25
IS 15
AR 3442
DI 10.3390/molecules25153442
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MZ4XQ
UT WOS:000559128600001
PM 32751124
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liou, SF
   Hsu, JH
   Lin, IL
   Ho, ML
   Hsu, PC
   Chen, LW
   Chen, IJ
   Yeh, JL
AF Liou, Shu Fen
   Hsu, Jong Hau
   Lin, I Ling
   Ho, Mei Ling
   Hsu, Pei Chuan
   Chen, Li Wen
   Chen, Ing Jun
   Yeh, Jwu Lai
TI KMUP 1 Suppresses RANKL Induced Osteoclastogenesis and Prevents
   Ovariectomy Induced Bone Loss: Roles of MAPKs, Akt, NF κB and
   Calcium/Calcineurin/NFATc1 Pathways
SO PLOS ONE
LA English
DT Article
ID RECEPTOR ACTIVATOR; SMOOTH MUSCLE; K+ CHANNELS; CYCLIC GMP;
   PHOSPHODIESTERASE 4 INHIBITOR; CARDIAC HYPERTROPHY; SIGNAL TRANSDUCTION;
   DOWN REGULATION; DIFFERENTIATION; CELLS
AB Background: KMUP 1 is a xanthine derivative with inhibitory activities on the phosphodiesterase (PDE) 3,4 and 5 isoenzymes to suppress the degradation of cyclic AMP and cyclic GMP. However, the effects of KMUP 1 on osteoclast differentiation are still unclear. In this study, we investigated whether KMUP 1 inhibits osteoclastogenesis induced by RANKL in RAW 264.7 cells and bone loss induced by ovariectomy in mice, and the underlying mechanisms.
   Principal Findings: In vitro, KMUP 1 inhibited RANKL induced TRAP activity, the formation of multinucleated osteoclasts and resorption pit formation. It also inhibited key mediators of osteoclastogenesis including IL 1 beta, IL 6, TNF alpha and HMGB1. In addition, KMUP 1 inhibited RANKL induced activation of signaling molecules (Akt, MAPKs, calcium and NF kappa B), mRNA expression of osteoclastogensis associated genes (TRAP, MMP 9, Fra 1, and cathepsin K) and transcription factors (c Fos and NFATc1). Furthermore, most inhibitory effects of KMUP 1 on RANKL mediated signal activations were reversed by a protein kinase A inhibitor (H89) and a protein kinase G inhibitor (KT5823). In vivo, KMUP 1 prevented loss of bone mineral content, preserved serum alkaline phosphate and reduced serum osteocalcin in ovariectomized mice.
   Conclusions: KMUP 1 inhibits RANKL induced osteoclastogenesis in vitro and protects against ovariectomy induced bone loss in vivo. These effects are mediated, at least in part, by cAMP and cGMP pathways. Therefore, KMUP 1 may have a role in pharmacologic therapy of osteoporosis.
C1 [Liou, Shu Fen] Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan.
   [Hsu, Jong Hau] Kaohsiung Med Univ Hosp, Dept Paediat, Kaohsiung, Taiwan.
   [Hsu, Jong Hau] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Paediat, Kaohsiung, Taiwan.
   [Lin, I Ling] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Coll Hlth Sci, Kaohsiung, Taiwan.
   [Ho, Mei Ling] Kaohsiung Med Univ, Sch Med, Coll Med, Dept & Grad Inst Pharmacol, Kaohsiung, Taiwan.
   [Hsu, Pei Chuan; Chen, Li Wen; Chen, Ing Jun; Yeh, Jwu Lai] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Physiol, Kaohsiung, Taiwan.
C3 Chia Nan University of Pharmacy & Science; Kaohsiung Medical University;
   Kaohsiung Medical University Hospital; Kaohsiung Medical University;
   Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University
RP Yeh, JL (通讯作者)，Kaohsiung Med Univ, Coll Med, Sch Med, Dept Physiol, Kaohsiung, Taiwan.
EM jwulai@kmu.edu.tw
RI ; Ho, Mei Ling/D 5515 2009; Hsu, Jong Hau/A 1507 2010; Chen,
   Ing Jan/A 1530 2010; Yeh, Jwu Lai/A 1535 2010
OI Ho, Mei Ling/0000 0001 8064 8488; Yeh, Jwu Lai/0000 0001 7101 5865; 
FU National Science Council, Taiwan [NSC 99 2320 B 037 015 MY3]
FX This work was supported by research grant NSC 99 2320 B 037 015 MY3
   (J LY) from the National Science Council, Taiwan. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Bahlous Afef, 2006, Tunis Med, V84, P751
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Braun T, 2012, CURR OSTEOPOROS REP, V10, P101, DOI 10.1007/s11914 012 0104 5
   Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671, DOI 10.1067/mai.2001.119555
   Holliday LS, 1997, AM J PHYSIOL RENAL, V272, pF283, DOI 10.1152/ajprenal.1997.272.3.F283
   Hong MH, 2000, J BONE MINER RES, V15, P911, DOI 10.1359/jbmr.2000.15.5.911
   Hsu YY, 2010, TOXICOLOGY, V268, P46, DOI 10.1016/j.tox.2009.11.021
   Kim HH, 2003, EXP CELL RES, V289, P368, DOI 10.1016/S0014 4827(03)00288 X
   Kim YY, 2010, MOL CELLS, V29, P277, DOI 10.1007/s10059 010 0027 x
   Kinoshita T, 2000, BONE, V27, P811, DOI 10.1016/S8756 3282(00)00395 1
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lin RJ, 2002, BRIT J PHARMACOL, V135, P1159, DOI 10.1038/sj.bjp.0704554
   Liu CM, 2007, PROSTATE, V67, P1397, DOI 10.1002/pros.20634
   Liu CM, 2009, PROSTATE, V69, P610, DOI 10.1002/pros.20919
   Mediero A, 2013, BRIT J PHARMACOL, V3, DOI [10.1111/bph.12227, DOI 10.1111/BPH.12227.[]
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991
   Szulc P, 2001, CALCIFIED TISSUE INT, V69, P229, DOI 10.1007/s00223 001 1059 1
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takimoto E, 2005, NAT MED, V11, P214, DOI 10.1038/nm1175
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200
   Tsutsumimoto T, 2002, BONE, V31, P396, DOI 10.1016/S8756 3282(02)00839 6
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Waki Y, 1999, JPN J PHARMACOL, V79, P477, DOI 10.1254/jjp.79.477
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wu BN, 2006, MOL PHARMACOL, V70, P977, DOI 10.1124/mol.106.024919
   Wu BN, 2004, BRIT J PHARMACOL, V142, P1105, DOI 10.1038/sj.bjp.0705791
   Wu BN, 2001, BRIT J PHARMACOL, V134, P265, DOI 10.1038/sj.bjp.0704231
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Yamagami H, 2003, BIOCHEM PHARMACOL, V66, P801, DOI 10.1016/S0006 2952(03)00409 X
   Yeh JL, 2013, ATHEROSCLEROSIS, V226, P364, DOI 10.1016/j.atherosclerosis.2012.12.005
   Yeh JL, 2010, BRIT J PHARMACOL, V159, P1151, DOI 10.1111/j.1476 5381.2009.00587.x
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
NR 41
TC 26
Z9 30
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 25
PY 2013
VL 8
IS 7
AR e69468
DI 10.1371/journal.pone.0069468
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 191SQ
UT WOS:000322433300041
PM 23936022
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Shi, F
   Ni, L
   Gao, YM
AF Shi, Fang
   Ni, Lei
   Gao, Ye Mei
TI Tetrandrine Attenuates Cartilage Degeneration, Osteoclast Proliferation,
   and Macrophage Transformation through Inhibiting P65 Phosphorylation in
   Ovariectomy induced Osteoporosis
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Article
DE Tetrandrine; osteoporosis; RANKL; NF &#954; B; p65 phosphorylation
ID SIGNALING PATHWAY; RAT MODEL; BONE LOSS; ACTIVATION; POLARIZATION;
   RESVERATROL; GROWTH
AB Background
   Osteoporosis is a common metabolic bone disease with high prevalence. Tetrandrine (TET) suppressed osteoclastogenesis, while the roles of TET in osteoporosis regulation remained unclear. Thus, the study aimed to investigate the effect of TET on osteoporosis and the underlying mechanism.
   Methods
   The osteoporosis rabbit model was established through anterior cruciate ligament transection (ACLT) and bilateral ovariectomy (OVX). The degeneration of articular cartilage was assessed using HE staining and Alcian blue staining. The liver and kidney tissue injury was determined using HE staining. The activity of osteoclasts was evaluated using Tartrate resistant acid phosphatase (TRAP) staining. The changes in bone structural parameters were determined through measuring the BMD, BV/TV, Tb.Th, Tb.N, and Tb.Sp, and the serum levels of calcium and phosphorus. Macrophage polarization was determined using Flow cytometry.
   Results
   The bone structural parameters including BMD, BV/TV, Tb.N, Tb.Th and Tb.Sp were changed in osteoporosis rabbit, which was reversed by TET. Besides, TET suppressed the increased serum levels of calcium and phosphorus in osteoporosis rabbit. Furthermore, TET inhibited the degeneration of articular cartilage and the activity of osteoclasts induced by osteoporosis. Moreover, TET inhibited the levels of MMP 9, PPAR gamma, RANKL, beta CTX and TRACP 5b, and increased the levels of OPG, ALP and osteocalcin (OC) in osteoporosis. Additionally, TET promoted macrophage transformation from M1 to M2 in osteoporotic and inhibited the production of IL 1 beta, TNF alpha, and IL 6. TET also inhibited the p65 phosphorylation in osteoporosis. Besides, TET reversed RANKL induced osteoclasts proliferation, p65 phosphorylation, and the expression changes of RANKL, Ki67, PPAR gamma, ALP, OPG.
   Conclusion
   TET attenuated bone structural parameters including BMD, BV/TV, Tb.N, Tb.Th and Tb.Sp, inhibited articular cartilage degeneration, promoted bone formation, inhibited the inflammatory response, and promoted macrophage transformation from M1 to M2 via NF kappa B inactivation in osteoporosis. TET may be a promising drug for osteoporosis therapy.
C1 [Shi, Fang; Gao, Ye Mei] Beijing JiShuitan Hosp, Dept Tradit Chinese Med, Beijing 100035, Peoples R China.
   [Ni, Lei] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine
RP Gao, YM (通讯作者)，Beijing JiShuitan Hosp, Dept Tradit Chinese Med, Beijing 100035, Peoples R China.
EM gaoyemeidoc@aliyun.com
CR Alswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970w
   Asai H, 2016, BIOL PHARM BULL, V39, P1035, DOI 10.1248/bpb.b16 00066
   Azevedo A, 2018, CURR PHARM DESIGN, V24, P1801, DOI 10.2174/1381612824666180604112925
   Bobinac D, 2013, OSTEOARTHR CARTILAGE, V21, P1724, DOI 10.1016/j.joca.2013.06.030
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cheng YZ, 2018, LIFE SCI, V205, P184, DOI 10.1016/j.lfs.2018.04.042
   Chu LY, 2020, J BONE MINER RES, V35, P505, DOI 10.1002/jbmr.3909
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Feng J, 2014, ACTA BIOCH BIOPH SIN, V46, P1024, DOI 10.1093/abbs/gmu103
   Gabusi E, 2018, BIOMED RES INT, V2018, P1
   Gao LN, 2016, J ORTHOP RES, V34, P1557, DOI 10.1002/jor.23155
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074 7613(03)00174 2
   Gong X, 2010, INT IMMUNOPHARMACOL, V10, P357, DOI 10.1016/j.intimp.2009.12.010
   Guo YB, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/7517431
   Hasan D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 222
   He FQ, 2011, BRAIN RES, V1384, P89, DOI 10.1016/j.brainres.2011.01.103
   Jia YG, 2018, FASEB J, V32, P3398, DOI 10.1096/fj.201701148RR
   Kim Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164038
   Lee JH, 2015, GROWTH FACTORS, V33, P31, DOI 10.3109/08977194.2014.957759
   Lei T, 2018, BONE, V108, P10, DOI 10.1016/j.bone.2017.12.008
   Li X, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0442 3
   Li YK, 2010, BONE, V47, pS369, DOI 10.1016/j.bone.2010.09.112
   Li ZK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00599
   Liu C, 2015, SCI REP UK, V5, DOI 10.1038/srep09530
   Liu TT, 2016, GENES BASEL, V7, DOI 10.3390/genes7070038
   Ma JW, 2015, EUR J PHARMACOL, V764, P228, DOI 10.1016/j.ejphar.2015.06.017
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471 4906(02)02302 5
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Mukherjee M, 2007, PHYTOTHER RES, V21, P1045, DOI 10.1002/ptr.2209
   Pan W, 2018, J CELL PHYSIOL, V233, P6273, DOI 10.1002/jcp.26512
   Proff P, 2009, CLIN ORAL INVEST, V13, P355, DOI 10.1007/s00784 009 0268 2
   Rao SS, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0012 0
   Ruan L, 2013, NEUROCHEM RES, V38, P1871, DOI 10.1007/s11064 013 1093 1
   Shao J, 2015, IN VITRO CELL DEV AN, V51, P808, DOI 10.1007/s11626 015 9895 x
   Shishodia G, 2016, CANCER RES, V76, DOI 10.1158/1538 7445.AM2016 253
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Sotornik I, 2016, VNITR LEK S6, V62, pS84
   Sun G, 2018, ZHEN CI YAN JIU, V43
   Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515
   Wang XW, 2017, EXP THER MED, V14, P5032, DOI 10.3892/etm.2017.5147
   Wong VKW, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00351
   Yu B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01181
   Zhang YJ, 2016, INT J ONCOL, V48, P2035, DOI 10.3892/ijo.2016.3415
   Zheng X, 2016, J MED FOOD, V19, P1
   Zhu W, 2019, BIOCHEM BIOPH RES CO, V509, P294, DOI 10.1016/j.bbrc.2018.12.125
   Zou J, 2014, CONNECT TISSUE RES, V55, P304, DOI 10.3109/03008207.2014.930140
NR 48
TC 13
Z9 16
U1 0
U2 30
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882 0139
EI 1532 4311
J9 IMMUNOL INVEST
JI Immunol. Invest.
PD APR 3
PY 2022
VL 51
IS 3
BP 465
EP 479
DI 10.1080/08820139.2020.1837864
EA NOV 2020
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 0F0IM
UT WOS:000584069400001
PM 33140671
DA 2025 08 17
ER

PT J
AU Tang, Q
   Su, YW
   Fan, CM
   Chung, R
   Hassanshahi, M
   Peymanfar, Y
   Xian, CJ
AF Tang, Qian
   Su, Yu Wen
   Fan, Chia Ming
   Chung, Rosa
   Hassanshahi, Mohammadhossein
   Peymanfar, Yaser
   Xian, Cory J.
TI 被撤回的出版物: Release of CXCL12 From Apoptotic Skeletal Cells Contributes to
   Bone Growth Defects Following Dexamethasone Therapy in Rats (Retracted
   Article)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Retracted Publication
DE MOLECULAR PATHWAYS DEVELOPMENT; BONE LOSS; OSTEOCYTES; GROWTH PLATE;
   PRECLINICAL STUDIES
ID MARROW ADIPOSITY; OXIDATIVE STRESS; PLATE CARTILAGE; YOUNG RATS;
   CHEMOTHERAPY; DAMAGE; DIFFERENTIATION; RECRUITMENT; OSTEOCYTES;
   GLUCOCORTICOIDS
AB Dexamethasone (Dex) is known to cause significant bone growth impairment in childhood. Although previous studies have suggested roles of osteocyte apoptosis in the enhanced osteoclastic recruitment and local bone loss, whether it is so in the growing bone following Dex treatment requires to be established. The current study addressed the potential roles of chemokine CXCL12 in chondroclast/osteoclast recruitment and bone defects following Dex treatment. Significant apoptosis was observed in cultured mature ATDC5 chondrocytes and IDG SW3 osteocytes after 48 hours of 10( 6) M Dex treatment, and CXCL12 was identified to exhibit the most prominent induction in Dex treated cells. Conditioned medium from the treated chondrocytes/osteocytes enhanced migration of RAW264.7 osteoclast precursor cells, which was significantly inhibited by the presence of the anti CXCL12 neutralizing antibody. To investigate the roles of the induced CXCL12 in bone defects caused by Dex treatment, young rats were orally gavaged daily with saline or Dex at 1 mg/kg/day for 2 weeks, and received an intraperitoneal injection of anti CXCL12 antibody or control IgG (1 mg/kg, three times per week). Aside from oxidative stress induction systemically, Dex treatment caused reductions in growth plate thickness, primary spongiosa height, and metaphysis trabecular bone volume, which are associated with induced chondrocyte/osteocyte apoptosis and enhanced chondroclast/osteoclast recruitment and osteoclastogenic differentiation potential. CXCL12 was induced in apoptotic growth plate chondrocytes and metaphyseal bone osteocytes. Anti CXCL12 antibody supplementation considerably attenuated Dex induced chondroclast/osteoclast recruitment and loss of growth plate cartilage and trabecular bone. CXCL12 neutralization did not affect bone marrow osteogenic potential, adiposity, and microvasculature. Thus, CXCL12 was identified as a potential molecular linker between Dex induced skeletal cell apoptosis and chondroclastic/osteoclastic recruitment, as well as growth plate cartilage/bone loss, revealing a therapeutic potential of CXCL12 functional blockade in preventing bone growth defects during/after Dex treatment. (c) 2018 American Society for Bone and Mineral Research.
C1 [Tang, Qian; Su, Yu Wen; Fan, Chia Ming; Chung, Rosa; Hassanshahi, Mohammadhossein; Peymanfar, Yaser; Xian, Cory J.] Univ South Australia, Sch Pharm & Med Sci, Bldg HB,City West Campus,North Terrace, Adelaide, SA 5001, Australia.
   [Tang, Qian; Su, Yu Wen; Fan, Chia Ming; Chung, Rosa; Hassanshahi, Mohammadhossein; Peymanfar, Yaser; Xian, Cory J.] Univ South Australia, Canc Res Inst, Adelaide, SA 5001, Australia.
   [Xian, Cory J.] Ningbo 6 Hosp, Ningbo 315040, Zhejiang, Peoples R China.
C3 University of South Australia; University of South Australia
RP Xian, CJ (通讯作者)，Univ South Australia, Sch Pharm & Med Sci, Bldg HB,City West Campus,North Terrace, Adelaide, SA 5001, Australia.
EM Cory.Xian@unisa.edu.au
RI Xian, Cory/D 2646 2009; Su, Yu Wen/V 4948 2018; SU, Yu Wen/V 4948 2018;
   Hassanshahi, Mohammadhossein/ABF 5123 2020; Peymanfar,
   Yaser/AHI 8022 2022
OI Peymanfar, Yaser/0000 0002 5793 0474; Hassanshahi,
   Mohammadhossein/0000 0002 4097 8527; SU, Yu Wen/0000 0002 2067 5270;
   Chung, Rosa/0009 0000 2624 4191
FU Channel 7 Children's Research Foundation of South Australia [171494];
   National Health and Medical Research Council of Australia [1127396];
   Natural Science Foundation of China [81671928]
FX This project is supported by grants from the Channel 7 Children's
   Research Foundation of South Australia (#171494). CJX is funded by
   grants from the National Health and Medical Research Council of
   Australia (No. 1127396) and the Natural Science Foundation of China (No.
   81671928).
CR Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Altaf FM, 2006, EUR CELLS MATER, V12, P64, DOI 10.22203/eCM.v012a08
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bjelakovic G, 2007, J Basic Clin Physiol Pharmacol, V18, P115
   Bouvard B, 2010, CLIN REV BONE MINER, V8, P15, DOI 10.1007/s12018 009 9051 9
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chen LH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092227
   Crofton PM, 2000, PEDIATR RES, V48, P490, DOI 10.1203/00006450 200010000 00012
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Fan C, 2011, CURR MOL MED, V11, P140, DOI 10.2174/156652411794859223
   Fan CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046915
   Fan CM, 2016, J BONE MINER METAB, V34, P277, DOI 10.1007/s00774 015 0679 x
   Fan CM, 2009, BONE, V44, P61, DOI 10.1016/j.bone.2008.09.014
   Feng YL, 2014, CHEM BIOL INTERACT, V207, P26, DOI 10.1016/j.cbi.2013.11.004
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Georgiou KR, 2012, BONE, V50, P1223, DOI 10.1016/j.bone.2012.03.027
   Georgiou KR, 2012, INT J EXP PATHOL, V93, P104, DOI 10.1111/j.1365 2613.2011.00800.x
   Gilchrist A, 2015, CLIN REV BONE MINER, V13, P61, DOI 10.1007/s12018 015 9184 y
   Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092 8674(00)81728 6
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Hassanshahi M, 2019, J CELL BIOCHEM, V120, P3220, DOI 10.1002/jcb.27589
   Hassanshahi M, 2017, ANGIOGENESIS, V20, P427, DOI 10.1007/s10456 017 9577 2
   Heshiki W., 2015, J CANC SCI THERAPY, V7, P75
   Hofbauer LC, 2009, MOL ENDOCRINOL, V23, P1525, DOI 10.1210/me.2009 0069
   Hosogane N, 2010, INT J BIOCHEM CELL B, V42, P1132, DOI 10.1016/j.biocel.2010.03.020
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jilka RL, 2014, J BONE MINER RES, V29, P103, DOI 10.1002/jbmr.2007
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Kollmar O, 2010, INT J CANCER, V126, P1302, DOI 10.1002/ijc.24956
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Litvinov IS, 2015, RUSS J BIOORG CHEM+, V41, P383, DOI 10.1134/S1068162015040093
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Melgert BN, 2003, J DRUG TARGET, V11, P1, DOI 10.1080/1061186031000072969
   Moll NM, 2010, EXPERT REV HEMATOL, V3, P315, DOI [10.1586/ehm.10.16, 10.1586/EHM.10.16]
   Noble BS, 2003, METH MOLEC MED, V80, P225
   Olney RC, 2009, HORM RES, V72, P30, DOI 10.1159/000229761
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plotkin LI, 2014, CURR OSTEOPOROS REP, V12, P121, DOI 10.1007/s11914 014 0194 3
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Sasaki N, 2002, BONE, V30, P853, DOI 10.1016/S8756 3282(02)00742 1
   Shandala T, 2012, J CELL PHYSIOL, V227, P2889, DOI 10.1002/jcp.23034
   Su YW, 2017, ANN NY ACAD SCI, V1403, P109, DOI 10.1111/nyas.13380
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555 010 9256 x
   Veerman AJ, 2009, LANCET ONCOL, V10, P957, DOI 10.1016/S1470 2045(09)70228 1
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Wei L, 2006, J RHEUMATOL, V33, P1818
   Wei L, 2010, DEV BIOL, V341, P236, DOI 10.1016/j.ydbio.2010.02.033
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021
   Xian CJ, 2004, BONE, V35, P739, DOI 10.1016/j.bone.2004.04.027
   Xian CJ, 2004, J ORTHOPAED RES, V22, P417, DOI 10.1016/j.orthres.2003.08.003
   Xian CJ, 2007, BONE, V41, P842, DOI 10.1016/j.bone.2007.07.021
   Xian CJ, 2007, ENDOCR REV, V28, P284, DOI 10.1210/er.2006 0049
   Xian CJ, 2006, J CELL BIOCHEM, V99, P1688, DOI 10.1002/jcb.20889
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   Zaman F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033168
NR 63
TC 6
Z9 6
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2019
VL 34
IS 2
BP 310
EP 326
DI 10.1002/jbmr.3597
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HL3ZC
UT WOS:000458653600012
PM 30395366
OA Bronze
DA 2025 08 17
ER

PT J
AU Ho, ATV
   Palla, AR
   Blake, MR
   Yucel, ND
   Wang, YX
   Magnusson, KEG
   Holbrook, CA
   Kraft, PE
   Delp, SL
   Blau, HM
AF Ho, Andrew T. V.
   Palla, Adelaida R.
   Blake, Matthew R.
   Yucel, Nora D.
   Wang, Yu Xin
   Magnusson, Klas E. G.
   Holbrook, Colin A.
   Kraft, Peggy E.
   Delp, Scott L.
   Blau, Helen M.
TI Prostaglandin E2 is essential for efficacious skeletal muscle stem cell
   function, augmenting regeneration and strength
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE muscle stem cells; PGE2; regeneration; NSAIDs; strength
ID SATELLITE CELL; SELF RENEWAL; ARACHIDONIC ACID; INJURY; EXPRESSION;
   TRACKING; DAMAGE; PROLIFERATION; PROGENITORS; EXPANSION
AB Skeletal muscles harbor quiescent muscle specific stem cells (MuSCs) capable of tissue regeneration throughout life. Muscle injury precipitates a complex inflammatory response in which a multiplicity of cell types, cytokines, and growth factors participate. Here we show that Prostaglandin E2 (PGE2) is an inflammatory cytokine that directly targets MuSCs via the EP4 receptor, leading to MuSC expansion. An acute treatment with PGE2 suffices to robustly augment muscle regeneration by either endogenous or transplanted MuSCs. Loss of PGE2 signaling by specific genetic ablation of the EP4 receptor in MuSCs impairs regeneration, leading to decreased muscle force. Inhibition of PGE2 production through nonsteroidal anti inflammatory drug (NSAID) administration just after injury similarly hinders regeneration and compromises muscle strength. Mechanistically, the PGE2 EP4 interaction causes MuSC expansion by triggering a cAMP/phosphoCREB pathway that activates the proliferation inducing transcription factor, Nurr1. Our findings reveal that loss of PGE2 signaling to MuSCs during recovery from injury impedes muscle repair and strength. Through such gain or loss of function experiments, we found that PGE2 signaling acts as a rheostat for muscle stem cell function. Decreased PGE2 signaling due to NSAIDs or increased PGE2 due to exogenous delivery dictates MuSC function, which determines the outcome of regeneration. The markedly enhanced and accelerated repair of damaged muscles following intramuscular delivery of PGE2 suggests a previously unrecognized indication for this therapeutic agent.
C1 [Ho, Andrew T. V.; Palla, Adelaida R.; Blake, Matthew R.; Yucel, Nora D.; Wang, Yu Xin; Magnusson, Klas E. G.; Holbrook, Colin A.; Kraft, Peggy E.; Blau, Helen M.] Stanford Sch Med, Inst Stem Cell Biol & Regenerat Med, Dept Microbiol & Immunol, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA.
   [Magnusson, Klas E. G.] Royal Inst Technol, Signals & Syst Linnaeus Ctr, Dept Signal Proc Auton Complex Commun Networks, S 10044 Stockholm, Sweden.
   [Delp, Scott L.] Stanford Univ, Dept Bioengn, Sch Med, Stanford, CA 94305 USA.
C3 Stanford University; Royal Institute of Technology; Stanford University
RP Blau, HM (通讯作者)，Stanford Sch Med, Inst Stem Cell Biol & Regenerat Med, Dept Microbiol & Immunol, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA.
EM hblau@stanford.edu
RI ; Ho, Andrew Tri Van/D 9681 2019
OI Delp, Scott/0000 0002 9643 7551; Palla, Adelaida/0000 0003 2695 9335;
   Wang, Yu Xin/0000 0001 8440 9388; Ho, Andrew Tri Van/0000 0002 5501 6419
FU Baxter Foundation; NIH [AG020961]
FX We apologize to those investigators whose important work we were unable
   to cite or describe owing to space constraints. We thank D. Burns for
   critical discussions of the manuscript; K. Koleckar for technical
   assistance; K. Andreasson (Department of Neurology & Neurological
   Sciences, Stanford University School of Medicine) for the
   EP4<SUP>f/f</SUP> mice; and the Stanford Center for Innovation in
   In Vivo Imaging (SCI3), the Stanford Shared FACS Facility (SSFF), FACS
   Core Facility in Stanford Lokey Stem Cell Research Building, the
   Stanford Functional Genomics Facility, and the Stanford Veterinary
   Service Center (VSC) for technical support. This study was supported by
   the Baxter Foundation, and NIH Grant AG020961 (to H.M.B.).
CR Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 10 r106
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   BARACOS V, 1983, NEW ENGL J MED, V308, P553, DOI 10.1056/NEJM198303103081002
   Beaulieu D, 2012, NEUROBIOL DIS, V45, P122, DOI 10.1016/j.nbd.2011.06.014
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207
   Bygdeman M, 2003, BEST PRACT RES CL OB, V17, P707, DOI 10.1016/S1521 6934(03)00043 9
   Chakkalakal JV, 2012, NATURE, V490, P355, DOI 10.1038/nature11438
   Chazaud B, 2016, IMMUNOL CELL BIOL, V94, P140, DOI 10.1038/icb.2015.97
   Chenouard N, 2014, NAT METHODS, V11, P281, DOI 10.1038/nmeth.2808
   Cosgrove BD, 2014, NAT MED, V20, P255, DOI 10.1038/nm.3464
   Crameri RM, 2004, J PHYSIOL LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846
   DARR KC, 1987, J APPL PHYSIOL, V63, P1816, DOI 10.1152/jappl.1987.63.5.1816
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dreyer HC, 2006, MUSCLE NERVE, V33, P242, DOI 10.1002/mus.20461
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035
   Hakim Chady H, 2013, J Vis Exp, DOI 10.3791/50183
   Ho ATV, 2016, METHODS MOL BIOL, V1460, P181, DOI 10.1007/978 1 4939 3810 0_13
   Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200
   Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015
   Korotkova M, 2014, NAT REV RHEUMATOL, V10, P295, DOI 10.1038/nrrheum.2014.2
   Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Lundberg I, 2000, ARTHRITIS RHEUM, V43, P336, DOI 10.1002/1529 0131(200002)43:2<336::AID ANR13>3.0.CO;2 V
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Magnusson KEG, 2015, IEEE T MED IMAGING, V34, P911, DOI 10.1109/TMI.2014.2370951
   Maska M, 2014, BIOINFORMATICS, V30, P1609, DOI 10.1093/bioinformatics/btu080
   MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493
   Mo CL, 2015, CELL CYCLE, V14, P1507, DOI 10.1080/15384101.2015.1026520
   Mo Chenglin, 2012, Recent Pat Biotechnol, V6, P223
   Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758
   Moyle LA, 2014, METHODS MOL BIOL, V1210, P63, DOI 10.1007/978 1 4939 1435 7_6
   Murphy MM, 2011, DEVELOPMENT, V138, P3625, DOI 10.1242/dev.064162
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009
   Papapetrou EP, 2011, NAT BIOTECHNOL, V29, P73, DOI 10.1038/nbt.1717
   Paulsen G, 2012, EXERC IMMUNOL REV, V18, P42
   Pawlikowski B, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395 015 0067 1
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   RODEMANN HP, 1982, J BIOL CHEM, V257, P1632
   Rodgers JT, 2014, NATURE, V510, P393, DOI 10.1038/nature13255
   Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384
   Safran Michal, 2003, Mol Imaging, V2, P297, DOI 10.1162/153535003322750637
   Schneider A, 2004, GENESIS, V40, P7, DOI 10.1002/gene.20048
   Schoenfeld BJ, 2012, SPORTS MED, V42, P1017, DOI 10.2165/11635190 000000000 00000
   Shen W, 2006, J APPL PHYSIOL, V101, P1215, DOI 10.1152/japplphysiol.01331.2005
   Shi XZ, 2006, GENE DEV, V20, P1692, DOI 10.1101/gad.1419406
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   SMETHURST M, 1977, PROSTAG OTH LIPID M, V13, P719, DOI 10.1016/0090 6980(77)90244 1
   Thomas J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003101.pub3
   Tidball JG, 2017, NAT REV IMMUNOL, V17, P165, DOI 10.1038/nri.2016.150
   Tidball JG, 2011, COMPR PHYSIOL, V1, P2029, DOI 10.1002/cphy.c100092
   Tierney MT, 2014, NAT MED, V20, P1182, DOI 10.1038/nm.3656
   Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014
   Volakakis N, 2010, P NATL ACAD SCI USA, V107, P12317, DOI 10.1073/pnas.1007088107
   Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340
   Zu G, 2017, J MOL MED, V95, P83, DOI 10.1007/s00109 016 1464 6
NR 58
TC 165
Z9 186
U1 0
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 27
PY 2017
VL 114
IS 26
BP 6675
EP 6684
DI 10.1073/pnas.1705420114
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EY6QN
UT WOS:000404108400040
PM 28607093
OA Green Published
DA 2025 08 17
ER

PT J
AU Shim, KS
   Gu, DR
   Hwang, YH
   Yang, H
   Ryuk, JA
   Ha, H
AF Shim, Ki Shuk
   Gu, Dong Ryun
   Hwang, Youn Hwan
   Yang, Hyun
   Ryuk, Jin Ah
   Ha, Hyunil
TI Water Extract of Fritillariae thunbergii Bulbus Inhibits
   RANKL Mediated Osteoclastogenesis and Ovariectomy Induced Trabecular
   Bone Loss
SO MOLECULES
LA English
DT Article
DE Fritillariae thunbergii bulbus; osteoclast differentiation; ovariectomy;
   osteoporosis
ID STEROIDAL ALKALOIDS; PROTECTS BONE; CELL FUSION; DIFFERENTIATION;
   MARROW; IDENTIFICATION; ACTIVATION; EXPRESSION; BEIMU; MIQ.
AB Fritillariae thunbergii bulbus has been widely used to treat symptoms of coughs and airway congestion in the chest due to pathological colds and damp phlegm in traditional Chinese medicine. Despite its long history of traditional use, its pharmacological activities on osteoclastogenesis and osteoporosis have not been evaluated. This study investigated the effects of the water extract of Fritillariae thunbergii bulbus (WEFT) on osteoclast differentiation in bone marrow derived macrophage cells and on ovariectomy (OVX) induced osteoporosis in mice. We found that WEFT significantly inhibited osteoclastogenesis by downregulating the receptor activator of the NF kappa B ligand (RANKL) signaling induced nuclear factor of activated T cells cytoplasmic 1 (NFATc1) expression. In an OVX induced osteoporosis model, WEFT significantly prevented the OVX induced trabecular loss of femurs, accompanied by a reduction in fat accumulation in the bone marrow and liver. In addition, WEFT significantly prevented weight gain and gonadal fat gain without recovering uterine atrophy. Using ultrahigh performance liquid chromatography tandem mass spectrometry, seven alkaloids (peimisine glucoside, yibeissine, peiminoside, sipeimine glucoside, peimisine, peimine, and peiminine) were identified in WEFT. The results of this study suggest that WEFT can be a potential pharmacological candidate to reduce menopausal osteoporosis and menopause related symptoms, such as fat accumulation.
C1 [Shim, Ki Shuk; Gu, Dong Ryun; Hwang, Youn Hwan; Yang, Hyun; Ryuk, Jin Ah; Ha, Hyunil] Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
   [Hwang, Youn Hwan] Univ Sci & Technol UST, Korean Convergence Med Major KIOM, Daejeon 34054, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); University of Science &
   Technology (UST)
RP Ha, H (通讯作者)，Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM angeloshim@kiom.re.kr; mrwonsin@kiom.re.kr; hyhhwang@kiom.re.kr;
   hyunyang@kiom.re.kr; yukjinah@kiom.re.kr; hyunil74@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
OI Hwang, Youn Hwan/0000 0002 4959 2436
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Korea [KSN2013330]
FX FundingThis research was funded by the Korea Institute of Oriental
   Medicine, Ministry of Education, Science and Technology, Korea (grant
   number KSN2013330).
CR Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2019, INT J MOL MED, V43, P2241, DOI 10.3892/ijmm.2019.4141
   Chen LH, 2011, PHARMAZIE, V66, P684, DOI 10.1691/ph.2011.1022
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Ha H, 2013, MOLECULES, V18, P7376, DOI 10.3390/molecules18077376
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hwang YH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081831
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Kim EJ, 2016, PHYTOMEDICINE, V23, P95, DOI 10.1016/j.phymed.2015.12.016
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Kurata K, 2006, J BONE MINER RES, V21, P616, DOI 10.1359/JBMR.060106
   Li H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071667
   Liu SM, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106047
   Muruganandan S, 2018, CURR OSTEOPOROS REP, V16, P434, DOI 10.1007/s11914 018 0451 y
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Seeman E, 2003, OSTEOPOROSIS INT, V14, pS2, DOI 10.1007/s00198 002 1340 9
   Song L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8417814
   State Pharmacopoeia Commission of the PRC, 2015, PHARMACOPOEIA PEOPLE, V1
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Suh WS, 2018, HETEROCYCLES, V96, P925, DOI 10.3987/COM 18 13891
   Syed FA, 2008, OSTEOPOROSIS INT, V19, P1323, DOI 10.1007/s00198 008 0574 6
   Syed M, 2021, J KING SAUD UNIV SCI, V33, DOI 10.1016/j.jksus.2021.101461
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   WRONSKI TJ, 1988, ENDOCRINOLOGY, V123, P681, DOI 10.1210/endo 123 2 681
   Wu X, 2018, J ETHNOPHARMACOL, V210, P39, DOI 10.1016/j.jep.2017.08.027
   Xu YY, 2017, J CHROMATOGR B, V1058, P24, DOI 10.1016/j.jchromb.2017.05.016
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   [晏子俊 Yan Zijun], 2012, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V23, P2522
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zhou JL, 2010, J CHROMATOGR A, V1217, P7109, DOI 10.1016/j.chroma.2010.09.019
   Zhou Y, 2006, AM J CHINESE MED, V34, P901, DOI 10.1142/S0192415X06004375
   Zhu MB, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.736863
NR 43
TC 6
Z9 6
U1 3
U2 18
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2022
VL 27
IS 1
AR 169
DI 10.3390/molecules27010169
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ZE1BM
UT WOS:000758625700001
PM 35011398
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, ZB
   Gerseny, H
   Zhang, ZW
   Chen, YJ
   Berg, A
   Zhang, ZL
   Stock, S
   Seth, P
AF Hu, Zebin
   Gerseny, Helen
   Zhang, Zhenwei
   Chen, Yun Ju
   Berg, Arthur
   Zhang, Zhiling
   Stock, Stuart
   Seth, Prem
TI Oncolytic Adenovirus Expressing Soluble TGFβ Receptor II Fc mediated
   Inhibition of Established Bone Metastases: A Safe and Effective Systemic
   Therapeutic Approach for Breast Cancer
SO MOLECULAR THERAPY
LA English
DT Article
ID MOUSE MODELS; MECHANISMS; INDUCTION; DISEASE; BIOLOGY; PROTEIN; TARGET;
   HEXON; CELLS; SMAD
AB In recent years, oncolytic adenoviruses have shown some promise as a novel class of antitumor agents. However, their utility in targeting bone metastases is relatively less studied. We have examined whether the systemic therapy of oncolytic adenoviruses expressing the soluble form of transforming growth factor beta (TGF beta) receptor II fused with human immunoglobulin G1 can be developed for the treatment of established breast cancer bone metastases. MDA MB 231 luc2 human breast cancer cells were injected in the left heart ventricle of nude mice to establish bone metastasis. Mice with hind limb tumors were administered (on days 8 and 11) oncolytic adenoviruses Ad.sT beta RFc or mhTERTAd.sT beta RFc. Skeletal tumor growth was monitored weekly by bioluminescence imaging (BLI) and radiography. At the termination time on day 28, hind limb bones were analyzed for tumor burden, synchrotron micro computed tomography, and osteoclast activation. Intravenous delivery of Ad.sT beta RFc and mhTERTAd.sT beta RFc induced significant inhibition of tumor growth, reduction of tumor burden, osteoclast activation, and increased animals' survival. Oncolytic adenoviruses were safer than dl309, a wild type virus. A slight elevation of liver enzyme activity was observed after Ad.sT beta RFc administration; this subsided with time. Based on these studies, we believe that Ad.sT beta RFc and mhTERTAd.sT beta RFc can be developed as a safe and effective approach for the treatment of established bone metastasis.
C1 [Hu, Zebin; Gerseny, Helen; Zhang, Zhenwei; Chen, Yun Ju; Berg, Arthur; Zhang, Zhiling; Seth, Prem] Univ Chicago, NorthShore Res Inst, Gene Therapy Program, Dept Med, Evanston, IL 60201 USA.
   [Stock, Stuart] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
C3 NorthShore University Health System; University of Chicago; Northwestern
   University
RP Seth, P (通讯作者)，Univ Chicago, Evanston Hosp, NorthShore Res Inst, Gene Therapy Program,Dept Med, 2650 Ridge Ave,Room B 652, Evanston, IL 60201 USA.
EM pseth@northshore.org
RI ; Zhang, Zhiling/GPS 8205 2022; ZHANG, ZHENWEI/AAW 7973 2021
OI Stock, Stuart R./0000 0002 8886 4035; 
FU National Institutes of Health [R01CA12738]; U.S. Department of Energy,
   Office of Science, Office of Basic Energy Sciences [DE AC02 06CH11357]
FX The work was funded by the National Institutes of Health grant #
   R01CA12738 (P.S.). Use of the Advanced Photon Source was supported by
   the U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences, under Contract No. DE AC02 06CH11357. The authors declared no
   conflict of interest. The authors thank Dr Khandekar, Maxine, and James
   Farrell, Carol Gollob Foundation, and an Anonymous source for their
   generous support. We thank Francesco De Carlo (APS) for his help in
   collecting the synchrotron microCT data. We thank Dr Manolova Rairoff
   and Rebecca Orr for help in tissue processing, and Dr Jovanovic for
   reviewing the hematoxylin and eosin stained liver sections.
CR Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   [Anonymous], 2010, CANC FACTS FIG 2010
   BETT AJ, 1995, VIRUS RES, V39, P75
   Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373
   Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078 0432.CCR 06 0952
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Crompton AM, 2007, CURR CANCER DRUG TAR, V7, P133
   Engler H, 2004, VIROLOGY, V328, P52, DOI 10.1016/j.virol.2004.06.043
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Guise TA, 2009, GENE DEV, V23, P2117, DOI 10.1101/gad.1854909
   Gupta J, 2011, CANCER BIOL THER, V11, P311, DOI 10.4161/cbt.11.3.14096
   Hoffman RM, 1999, INVEST NEW DRUG, V17, P343, DOI 10.1023/A:1006326203858
   Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717
   Howe JA, 2000, MOL THER, V2, P485, DOI 10.1006/mthe.2000.0206
   Hu Z, 2010, CANCER GENE THER, V17, P235, DOI 10.1038/cgt.2009.72
   Hu ZB, 2010, HUM GENE THER, V21, P1623, DOI 10.1089/hum.2010.018
   Huang TG, 2003, GENE THER, V10, P1241, DOI 10.1038/sj.gt.3301987
   Iyer S, 2005, CANCER BIOL THER, V4, P261, DOI 10.4161/cbt.4.3.1566
   Janckila AJ, 2003, J BONE MINER RES, V18, P1916, DOI 10.1359/jbmr.2003.18.10.1916
   Kalyuzhniy O, 2008, P NATL ACAD SCI USA, V105, P5483, DOI 10.1073/pnas.0711757105
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Katayose D, 1995, CLIN CANCER RES, V1, P889
   Kim E, 2003, HUM GENE THER, V14, P1415, DOI 10.1089/104303403769211637
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kishimoto H, 2009, MOL CANCER THER, V8, P3001, DOI 10.1158/1535 7163.MCT 09 0556
   Kishimoto H, 2009, P NATL ACAD SCI USA, V106, P14514, DOI 10.1073/pnas.0906388106
   Kuroda S, 2010, CANCER RES, V70, P9339, DOI 10.1158/0008 5472.CAN 10 2333
   Li JL, 2009, GENE THER, V16, P376, DOI 10.1038/gt.2008.179
   Lu Jing, 2009, Cancer Res, V69, P4951, DOI 10.1158/0008 5472.CAN 09 0099
   McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064
   Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316
   Schowalter DB, 1999, J VIROL, V73, P4755, DOI 10.1128/JVI.73.6.4755 4766.1999
   Seth P., 1999, ADENOVIRUSES BASIC B
   Seth P, 2006, HUM GENE THER, V17, P1152, DOI 10.1089/hum.2006.17.1152
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066
   Stock SR., 2008, MICROCOMPUTED TOMOGR
   Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549 008 0184 1
   Tester AM, 2002, CLIN EXP METASTAS, V19, P377, DOI 10.1023/A:1016381416463
   Waddington SN, 2008, CELL, V132, P397, DOI 10.1016/j.cell.2008.01.016
   Wang YX, 2001, REV SCI INSTRUM, V72, P2062, DOI 10.1063/1.1355270
   Yamamoto M, 2010, MOL THER, V18, P243, DOI 10.1038/mt.2009.266
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yun CO, 2008, CURR OPIN MOL THER, V10, P356
NR 50
TC 37
Z9 41
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD SEP
PY 2011
VL 19
IS 9
BP 1609
EP 1618
DI 10.1038/mt.2011.114
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 817LO
UT WOS:000294674700008
PM 21712815
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Zhu, DL
   Chen, XF
   Hu, WX
   Dong, SS
   Lu, BJ
   Rong, Y
   Chen, YX
   Chen, H
   Thynn, HN
   Wang, NN
   Guo, Y
   Yang, TL
AF Zhu, Dong Li
   Chen, Xiao Feng
   Hu, Wei Xin
   Dong, Shan Shan
   Lu, Bing Jie
   Rong, Yu
   Chen, Yi Xiao
   Chen, Hao
   Thynn, Hlaing Nwe
   Wang, Nai Ning
   Guo, Yan
   Yang, Tie Lin
TI Multiple Functional Variants at 13q14 Risk Locus for Osteoporosis
   Regulate RANKL Expression Through Long Range Super Enhancer
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; RANKL; LONG RANGE; SUPER ENHANCER; CRISPR; CAS9
ID BONE MINERAL DENSITY; KAPPA B LIGAND; RECEPTOR ACTIVATOR; OSTEOCLAST
   DIFFERENTIATION; 1,25 DIHYDROXYVITAMIN D 3; DISTAL ENHANCERS;
   GENE EXPRESSION; OSTEOBLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND;
   BLOCKING ACTIVITY
AB RANKL is a key regulator involved in bone metabolism, and a drug target for osteoporosis. The clinical diagnosis and assessment of osteoporosis are mainly based on bone mineral density (BMD). Previous powerful genomewide association studies (GWASs) have identified multiple intergenic single nucleotide polymorphisms (SNPs) located over 100kb upstream of RANKL and 65kb downstream of AKAP11 at 13q14.11 for osteoporosis. Whether these SNPs exert their roles on osteoporosis through RANKL is unknown. In this study, we conducted integrative analyses combining expression quantitative trait locus (eQTL), genomic chromatin interaction (high throughput chromosome conformation capture [Hi C]), epigenetic annotation, and a series of functional assays. The eQTL analysis identified six potential functional SNPs (rs9533090, rs9594738, r8001611, rs9533094, rs9533095, and rs9594759) exclusively correlated with RANKL gene expression (p<0.001) at 13q14.11. Co localization analyses suggested that eQTL signal for RANKL and BMD GWAS signal shared the same causal variants. Hi C analysis and functional annotation further validated that the first five osteoporosis SNPs are located in a super enhancer region to regulate the expression of RANKL via long range chromosomal interaction. Particularly, dual luciferase assay showed that the region harboring rs9533090 in the super enhancer has the strongest enhancer activity, and rs9533090 is an allele specific regulatory SNP. Furthermore, deletion of the region harboring rs9533090 using CRISPR/Cas9 genome editing significantly reduced RANKL expression in both mRNA level and protein level. Finally, we found that the rs9533090 C robustly recruits transcription factor NFIC, which efficiently elevates the enhancer activity and increases the RANKL expression. In summary, we provided a feasible method to identify regulatory noncoding SNPs to distally regulate their target gene underlying the pathogenesis of osteoporosis by using bioinformatics data analyses and experimental validation. Our findings would be a potential and promising therapeutic target for precision medicine in osteoporosis. (c) 2018 American Society for Bone and Mineral Research.
C1 [Yang, Tie Lin] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China.
   [Yang, Tie Lin] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Inst Mol Genet, Xian 710049, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University
RP Yang, TL (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China.; Yang, TL (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Inst Mol Genet, Xian 710049, Shaanxi, Peoples R China.
EM yangtielin@mail.xjtu.edu.cn
RI Chen, Yixiao/JYP 1060 2024; Yang, Tie Lin/G 8365 2014; Chen,
   Xiao Feng/AAN 8808 2020
OI Yang, Tie Lin/0000 0001 7062 3025; Hu, Weixin/0000 0002 7572 5482
FU National Natural Science Foundation of China [81573241, 31771399,
   31471188, 31701095]; China Postdoctoral Science Foundation
   [2016M602797]; Natural Science Basic Research Program Shaanxi Province
   [2016JQ3026]; Fundamental Research Funds for the Central Universities
FX This work was supported by the National Natural Science Foundation of
   China (81573241, 31771399, 31471188, and 31701095); China Postdoctoral
   Science Foundation (2016M602797); Natural Science Basic Research Program
   Shaanxi Province (2016JQ3026); and the Fundamental Research Funds for
   the Central Universities. We are grateful to the Framingham cohort
   participants and staff. Framingham Heart Study (FHS), which embarked on
   a novel and ambitious project in health research, provided phenotype
   data, genotypes, expression data of cardiovascular disease and other
   major chronic illnesses (including osteoporosis), and other molecular
   data. Therefore, our study does not necessarily reflect their opinions.
   The data sets we used were obtained through database of Genotypes and
   Phenotypes (dbGaP) authorized access at
   http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap with the accession
   number of dbGap: phs000007.v26.p10.c1.
CR Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092 8674(00)81967 4
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Belton JM, 2012, METHODS, V58, P268, DOI 10.1016/j.ymeth.2012.05.001
   Bishop KA, 2015, J CELL BIOCHEM, V116, P320, DOI 10.1002/jcb.24974
   Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024
   Claussnitzer M, 2015, NEW ENGL J MED, V373, P895, DOI 10.1056/NEJMoa1502214
   Coetzee SG, 2015, BIOINFORMATICS, V31, P3847, DOI 10.1093/bioinformatics/btv470
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   French JD, 2013, AM J HUM GENET, V92, P489, DOI 10.1016/j.ajhg.2013.01.002
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Gallagher MD, 2017, AM J HUM GENET, V101, P643, DOI 10.1016/j.ajhg.2017.09.004
   Guo HY, 2016, NAT GENET, V48, P1142, DOI 10.1038/ng.3637
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Javierre BM, 2016, CELL, V167, P1369, DOI 10.1016/j.cell.2016.09.037
   Jeong Y, 2008, NAT GENET, V40, P1348, DOI 10.1038/ng.230
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960 9822(00)00597 2
   Kanis J.A., 2008, WHO Sci. Gr. Assess. osteoprosis Prim. Heal. care Lev, P5
   Kim S, 2007, J STEROID BIOCHEM, V103, P430, DOI 10.1016/j.jsbmb.2006.12.020
   Kim S, 2007, MOL ENDOCRINOL, V21, P197, DOI 10.1210/me.2006 0315
   Kim S, 2006, MOL CELL BIOL, V26, P6469, DOI 10.1128/MCB.00353 06
   Kim T, 2014, P NATL ACAD SCI USA, V111, P4173, DOI 10.1073/pnas.1400350111
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuosmanen SM, 2016, NUCLEIC ACIDS RES, V44, P1760, DOI 10.1093/nar/gkw052
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531
   LeBlanc SE, 2016, NUCLEIC ACIDS RES, V44, P5133, DOI 10.1093/nar/gkw129
   Lee DS, 2014, STEM CELLS, V32, P2467, DOI 10.1002/stem.1733
   Liebermanaiden E., 2009, COLD SPRING HARBOR P, V2009, P5137
   Liu NQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14418
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Martowicz ML, 2011, J CELL BIOCHEM, V112, P2030, DOI 10.1002/jcb.23123
   Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176
   Mifsud B, 2015, NAT GENET, V47, P598, DOI 10.1038/ng.3286
   Nerenz RD, 2008, MOL ENDOCRINOL, V22, P1044, DOI 10.1210/me.2007 0380
   Nora EP, 2013, BIOESSAYS, V35, P818, DOI 10.1002/bies.201300040
   Paternoster L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003247
   Paternoster L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001217
   Pérez Casellas LA, 2009, BBA GENE REGUL MECH, V1789, P78, DOI 10.1016/j.bbagrm.2008.08.013
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Sapkota Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15539
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Styrkarsdottir U, 2008, NEW ENGL J MED, V358, P2355, DOI 10.1056/NEJMoa0801197
   Styrkarsdottir U, 2009, NAT GENET, V41, P15, DOI 10.1038/ng.284
   Sudmant PH, 2015, NATURE, V526, P75, DOI 10.1038/nature15394
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Visser M, 2012, GENOME RES, V22, P446, DOI 10.1101/gr.128652.111
   Ward LD, 2016, NUCLEIC ACIDS RES, V44, pD877, DOI 10.1093/nar/gkv1340
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Zhang L, 2014, HUM MOL GENET, V23, P1923, DOI 10.1093/hmg/ddt575
   Zheng HF, 2015, NATURE, V526, P112, DOI 10.1038/nature14878
   Zhou J, 2017, FASEB J, V31, P1939, DOI 10.1096/fj.201600975RR
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 66
TC 34
Z9 37
U1 0
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2018
VL 33
IS 7
BP 1335
EP 1346
DI 10.1002/jbmr.3419
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GL6HH
UT WOS:000437284400017
PM 29528523
DA 2025 08 17
ER

PT J
AU Popwell, SJ
   Schulz, MD
   Wagener, KB
   Batich, CD
   Milner, RJ
   Lagmay, J
   Bolch, WE
AF Popwell, Sam J.
   Schulz, Michael D.
   Wagener, Kenneth B.
   Batich, Christopher D.
   Milner, Rowan J.
   Lagmay, Joanne
   Bolch, Wesley E.
TI Synthesis of Polymeric Phosphonates for Selective Delivery of
   Radionuclides to Osteosarcoma
SO CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
LA English
DT Article
DE enhanced permeability and retention; radiopharmaceutical; tumor therapy
ID MACROMOLECULAR THERAPEUTICS; DRUG; BISPHOSPHONATES; CARRIERS
AB Discussed in detail is the synthesis and primary structure characterization of two polymers aimed at advancing the treatment of pediatric osteosarcoma. These polymers are designed to systemically deliver radiometals specifically to osteosarcomas using the passive targeting mechanism of enhanced permeability and retention (the EPR effect). The approach begins with the synthesis of a polymer capable of binding radiometals, for which prior data show improved site specific targeting of solid tumors. Building on this success, a second polymer has been designed for improving the efficacy of currently available radionuclide therapies by incorporating the FDA approved small molecule ligand Quadramet (R) directly onto the polymer structure. Time activity curves of the phosphonate functionalized polymers show rapid clearance from the central compartment and nontargeted organs, with up to 65% of injected activity being excreted within 3 hours. Both polymer ligands demonstrate good osteosarcoma targeting capability with little to no uptake in organs associated with the dose limiting bone marrow. Additionally, biodistribution studies in nonosseous tumor models demonstrate the tumor targeting mechanism of the polymer ligands, which appears to be influenced by the high affinity of the phosphonate functionality for the positively charged hydroxyapatite mineral found in bone tumors.
C1 [Popwell, Sam J.; Batich, Christopher D.] Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA.
   [Schulz, Michael D.; Wagener, Kenneth B.] Univ Florida, Dept Chem, Gainesville, FL 32611 USA.
   [Milner, Rowan J.] Univ Florida, Dept Small Anim Clin Sci, Gainesville, FL 32611 USA.
   [Lagmay, Joanne] Univ Florida, Div Pediat Oncol, Dept Pediat, Gainesville, FL 32611 USA.
   [Bolch, Wesley E.] Univ Florida, J Crayton Pruitt Family Dept Biomed Engn, Gainesville, FL 32611 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida; State University System of Florida;
   University of Florida
RP Bolch, WE (通讯作者)，Univ Florida, J Crayton Pruitt Family Dept Biomed Engn, 1275 Ctr Dr,Biomed Sci Bldg JG56, Gainesville, FL 32611 USA.
EM wbolch@ufl.edu
RI ; Schulz, Michael/JEP 6630 2023; Wagener, Kenneth/LIF 3723 2024; Batich,
   Chris/H 3966 2017
OI Schulz, Michael/0000 0001 8499 6025; BATICH,
   CHRISTOPHER/0000 0003 0419 6496; Wagener, Ken/0000 0001 9542 0259; 
FU National Science Foundation; University of Florida, Division of
   Sponsored Research; Hyundai Hope on Wheels Foundation for Pediatric
   Cancer Research; Direct For Mathematical & Physical Scien; Division Of
   Materials Research [1203136] Funding Source: National Science Foundation
FX This work was sponsored, in part, by grants from the National Science
   Foundation, University of Florida, Division of Sponsored Research, and
   the Hyundai Hope on Wheels Foundation for Pediatric Cancer Research.
CR BANKS CV, 1959, ANAL CHIM ACTA, V20, P301
   Belting M, 2009, MOL BIOTECHNOL, V43, P89, DOI 10.1007/s12033 009 9185 5
   Botelho MF., 2003, Eur J Nucl Med Mol Imaging, V30, pS338
   Dhal PK, 2006, ADV POLYM SCI, V192, P9, DOI 10.1007/12_020
   Duncan R, 2005, ENDOCR RELAT CANCER, V12, pS189, DOI 10.1677/erc.1.01045
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Duncan R, 2013, ADV DRUG DELIVER REV, V65, P60, DOI 10.1016/j.addr.2012.08.012
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   FOLKMAN J, 1990, JNCI J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
   Hamada YZ, 2006, INORG CHIM ACTA, V359, P1135, DOI 10.1016/j.ica.2005.11.027
   Kopecek J, 2013, ADV DRUG DELIVER REV, V65, P49, DOI 10.1016/j.addr.2012.10.014
   Liu S, 2008, ADV DRUG DELIVER REV, V60, P1347, DOI 10.1016/j.addr.2008.04.006
   Maeda H, 2009, EUR J PHARM BIOPHARM, V71, P409, DOI 10.1016/j.ejpb.2008.11.010
   Maeda H, 2012, J CONTROL RELEASE, V164, P138, DOI 10.1016/j.jconrel.2012.04.038
   Maeda H, 2011, ADV DRUG DELIVER REV, V63, P129, DOI 10.1016/j.addr.2010.05.001
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Matsumura Y, 2011, ADV DRUG DELIVER REV, V63, P184, DOI 10.1016/j.addr.2010.05.008
   Milner RJ, 2004, J VET INTERN MED, V18, P597, DOI 10.1892/0891 6640(2004)18<597:BAC>2.0.CO;2
   Milner RJ, 1999, EUR J NUCL MED, V26, P1220
   Milner RJ, THESIS U PRETORIA S
   MOEDRITZ.K, 1966, J ORG CHEM, V31, P1603, DOI 10.1021/jo01343a067
   Paoloni M, 2008, NAT REV CANCER, V8, P147, DOI 10.1038/nrc2273
   Serafini AN, 2001, Q J NUCL MED, V45, P91
   Sofou S, 2008, INT J NANOMED, V3, P181
   Studenovsky M, 2012, MACROMOL BIOSCI, V12, P1714, DOI 10.1002/mabi.201200270
   Ting G, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/953537
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u
NR 28
TC 17
Z9 18
U1 1
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1084 9785
EI 1557 8852
J9 CANCER BIOTHER RADIO
JI Cancer Biother. Radiopharm.
PD SEP
PY 2014
VL 29
IS 7
BP 273
EP 282
DI 10.1089/cbr.2014.1615
PG 10
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
GA AP1WT
UT WOS:000341863500002
PM 25111903
DA 2025 08 17
ER

PT J
AU Wang, Y
   Wang, XR
   Wang, KJ
   Qin, WW
   Li, N
AF Wang, Ying
   Wang, Xueru
   Wang, Kaijin
   Qin, Weiwei
   Li, Ning
TI Extract of Curculigo capitulata Ameliorates Postmenopausal
   Osteoporosis by Promoting Osteoblast Proliferation and Differentiation
SO CELLS
LA English
DT Article
DE Curculigo capitulata; ER alpha; osteoblast
   proliferation and differentiation; PMOP; PI3K/AKT
AB Postmenopausal osteoporosis (PMOP) is a bone disease characterized by bone thinning and an increased risk of fractures due to estrogen deficiency. Current PMOP therapies often result in adverse side effects. The traditional medicinal plant Curculigo capitulata is commonly used to strengthen bones and support kidney function, but its role in treating PMOP is not well understood. This study aims to investigate the therapeutic effects of the total extract of Curculigo capitulata (Eocc) on PMOP and to explore the underlying mechanisms. The major components of the extract were identified using HPLC. Transcriptomics was employed to predict potential targets. An osteogenic differentiation model of MC3T3 E1 cells was used in vitro. The osteogenic potential of the Eocc was assessed through CCK 8 cell viability assays, alkaline phosphatase (ALP) staining, Alizarin Red staining, Western blotting, and qPCR. MCF 7 and HEK 293 cells were utilized to evaluate the estrogen like activity of Eocc. Apoptosis rates were detected by flow cytometry. In vivo, a bilateral ovariectomized mouse model of PMOP was used to further validate the in vitro findings through histopathological analysis and WB results. The results demonstrated that the Eocc promoted the proliferation of MC3T3 E1 cells, increased ALP activity, and stimulated the formation of osteogenic mineralized nodules. It also upregulated the expression of osteogenic markers (Runx2, OCN, OPN, and BSP) at both the protein and mRNA levels. The Eocc induced the activation of ER alpha both in vitro and in vivo, initiating the Src/PI3K/AKT signaling pathway, leading to the phosphorylation of GSK3 beta and subsequent osteogenesis. The activation of this pathway also stimulated the phosphorylation of mTOR and p70S6K while downregulating cleaved caspase 3 and caspase 9. Additionally, the Eocc reduced apoptosis during osteogenic differentiation and promoted cell proliferation. These findings suggest that the Eocc facilitates osteoblast proliferation and differentiation, improving bone integrity in PMOP mice, and may represent a promising therapeutic candidate for managing PMOP.
C1 [Wang, Ying; Wang, Xueru; Wang, Kaijin; Qin, Weiwei; Li, Ning] Anhui Med Univ, Sch Pharm, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei 230032, Peoples R China.
C3 Anhui Medical University
RP Qin, WW; Li, N (通讯作者)，Anhui Med Univ, Sch Pharm, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei 230032, Peoples R China.
EM 18326039565@163.com; 19855867686@139.com; wkjahla@163.com;
   qinww@ahmu.edu.cn; 1993500019@ahmu.edu.cn
FU National Natural Science Foundation of China;  [3227020699]
FX This study was funded by the National Natural Science Foundation of
   China (3227020699).
CR Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Cai XY, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114044
   Chai S, 2024, PHYTOMEDICINE, V128, DOI 10.1016/j.phymed.2024.155516
   Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001 0045
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Cui J, 2020, J CELL MOL MED, V24, P6149, DOI 10.1111/jcmm.15229
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092 8674(00)80405 5
   Dirkes RK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041734
   Ge L, 2019, MOL MED REP, V19, P3469, DOI 10.3892/mmr.2019.9999
   Gong W, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5410377
   Guo YY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00976 4
   Han JW, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.772944
   He JQ, 2020, AGING US, V12, P8583, DOI 10.18632/aging.103168
   He XG, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13275
   Hua P, 2020, PHYTOMEDICINE, V75, DOI 10.1016/j.phymed.2020.153234
   Hwang JH, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.115
   Jiang ZJ, 2024, PHYTOMEDICINE, V124, DOI 10.1016/j.phymed.2023.155284
   Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005
   Khatpe AS, 2021, CANCERS, V13, DOI 10.3390/cancers13030369
   Kim P, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31697 3
   Komori T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105776
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Li JL, 2023, J CELL BIOCHEM, V124, P1155, DOI 10.1002/jcb.30439
   Lin HM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1052922
   Liu MM, 2014, STEM CELLS DEV, V23, P146, DOI 10.1089/scd.2013.0261
   Liu YL, 2023, J ETHNOPHARMACOL, V311, DOI 10.1016/j.jep.2023.116399
   Ma Yujie, 2023, J Ethnopharmacol, V301, P115835, DOI 10.1016/j.jep.2022.115835
   Meng XY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00189 x
   Mulik Rohit S, 2012, Cancer Nanotechnol, V3, P65, DOI 10.1007/s12645 012 0031 2
   Nie Y, 2013, J ETHNOPHARMACOL, V147, P547, DOI 10.1016/j.jep.2013.03.066
   Poulard C, 2012, EMBO MOL MED, V4, P1200, DOI 10.1002/emmm.201201615
   Qian Z, 2020, J CELL MOL MED, V24, P10112, DOI 10.1111/jcmm.15622
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rozenberg S, 2020, OSTEOPOROSIS INT, V31, P2271, DOI 10.1007/s00198 020 05497 8
   Sachaniya Jainy, 2018, Int J Nanomedicine, V13, P51, DOI 10.2147/IJN.S124707
   Sahoo G, 2023, MOL NEUROBIOL, V60, P5805, DOI 10.1007/s12035 023 03433 5
   Shang ZZ, 2014, INT J ORAL SCI, V6, P142, DOI 10.1038/ijos.2014.2
   Shi Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109566
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Tao MH, 2018, ANN ONCOL, V29, P1476, DOI 10.1093/annonc/mdy097
   Teveroni E, 2017, J CLIN INVEST, V127, P1531, DOI 10.1172/JCI89401
   Wang SS, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.874849
   Wang XQ, 2019, CARBOHYD POLYM, V203, P292, DOI 10.1016/j.carbpol.2018.09.059
   Wang XQ, 2017, CARBOHYD POLYM, V174, P48, DOI 10.1016/j.carbpol.2017.06.051
   Wang ZH, 2013, FITOTERAPIA, V86, P64, DOI 10.1016/j.fitote.2013.01.008
   Xie BP, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109045
   Yang F, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.581991
   Yu Z, 2020, CLIN TRANSL MED, V10, P57, DOI 10.1002/ctm2.19
   Yuan F, 2019, INT J SURG, V66, P1, DOI 10.1016/j.ijsu.2019.03.004
   Zhang DM, 2016, INT J ORAL SCI, V8, P84, DOI 10.1038/ijos.2015.57
   Zhang FX, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.835286
   Zhang QL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9281481
   Zhao BK, 2022, CELLS BASEL, V11, DOI 10.3390/cells11111724
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
   Zhao XF, 2009, EXPERT OPIN THER TAR, V13, P1085, DOI 10.1517/14728220903103833
   Zhou XY, 2019, DRUG DES DEV THER, V13, P2703, DOI 10.2147/DDDT.S208458
NR 56
TC 2
Z9 2
U1 6
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD DEC
PY 2024
VL 13
IS 23
AR 2028
DI 10.3390/cells13232028
PG 26
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA P2E7I
UT WOS:001376114300001
PM 39682775
OA gold
DA 2025 08 17
ER

PT J
AU Komatsu, Y
   Ibi, M
   Chosa, N
   Kyakumoto, S
   Kamo, M
   Shibata, T
   Sugiyama, Y
   Ishisaki, A
AF Komatsu, Yuko
   Ibi, Miho
   Chosa, Naoyuki
   Kyakumoto, Seiko
   Kamo, Masaharu
   Shibata, Toshiyuki
   Sugiyama, Yoshiki
   Ishisaki, Akira
TI Zoledronic acid suppresses transforming growth factor β induced
   fibrogenesis by human gingival fibroblasts
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE zoledronic acid; human gingival fibroblasts; transforming growth
   factor beta; myofibroblast differentiation; migratory activity
ID BISPHOSPHONATE RELATED OSTEONECROSIS; RISK FACTORS; IN VITRO;
   MYOFIBROBLAST DIFFERENTIATION; MOLECULAR MECHANISMS; CELL MIGRATION;
   JAWS; GROWTH FACTOR BETA 1; PROLIFERATION; TRANSITION
AB Bisphosphonates (BPs) are analogues of pyrophosphate that are known to prevent bone resorption by inhibiting osteoclast activity. Nitrogen containing BPs, such as zoledronic acid (ZA), are widely used in the treatment of osteoporosis and bone metastasis. However, despite having benefits, ZA has been reported to induce BP related osteonecrosis of the jaw (BRONJ) in cancer patients. The molecular pathological mechanisms responsible for the development of BRONJ, including necrotic bone exposure after tooth extraction, remain to be elucidated. In this study, we examined the effects of ZA on the transforming growth factor beta (TGF beta) induced myofibroblast (MF) differentiation of human gingival fibroblasts (hGFs) and the migratory activity of hGFs, which are important for wound closure by fibrous tissue formation. The ZA maximum concentration in serum (Cmax) was found to be approximately 1.47 mu M, which clinically, is found after the intravenous administration of 4 mg ZA, and ZA at this dose is considered appropriate for the treatment of cancer bone metastasis or bone diseases, such as Erdheim Chester disease. At Cmax, ZA significantly suppressed i) the TGF beta induced promotion of cell viability, ii) the TGF beta induced expression of MF markers such as alpha smooth muscle actin (alpha SMA) and type I collagen, iii) the TGF beta induced migratory activity of hGFs and iv) the expression level of TGF beta type I receptor on the surfaces of hGFs, as well as the TGF beta induced phosphorylation of Smad2/3. Thus, ZA suppresses TGF beta induced fibrous tissue formation by hGFs, possibly through the inhibition of Smad dependent signal transduction. Our findings partly elucidate the molecular mechanisms underlying BRONJ and may prove to be beneficial to the identification of drug targets for the treatment of this symptom at the molecular level.
C1 [Komatsu, Yuko; Ibi, Miho; Chosa, Naoyuki; Kyakumoto, Seiko; Kamo, Masaharu; Ishisaki, Akira] Iwate Med Univ, Dept Biochem, Div Cellular Biosignal Sci, 2 1 1 Nishitokuta, Yahaba, Iwate 0283694, Japan.
   [Komatsu, Yuko; Sugiyama, Yoshiki] Iwate Med Univ, Dept Reconstruct Oral & Maxillofacial Surg, Div Oral & Maxillofacial Surg, Yahaba, Iwate 0208505, Japan.
   [Ibi, Miho] Iwate Med Univ, Sch Pharmaceut Sci, Dept Mol & Cellular Pharmacol, Yahaba, Iwate 0283694, Japan.
   [Shibata, Toshiyuki] Gifu Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Gifu 5011194, Japan.
C3 Iwate Medical University; Iwate Medical University; Iwate Medical
   University; Gifu University
RP Ishisaki, A (通讯作者)，Iwate Med Univ, Dept Biochem, Div Cellular Biosignal Sci, 2 1 1 Nishitokuta, Yahaba, Iwate 0283694, Japan.
EM aishisa@iwate med.ac.jp
RI ; Chosa, Naoyuki/G 5538 2014; Kamo, Masaharu/IZP 8096 2023
OI Kamo, Masaharu/0000 0001 6791 8754; Ishisaki, Akira/0000 0001 6704 4436;
   Chosa, Naoyuki/0000 0002 5399 2061; 
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24791981, 25463053, 26462823, 22592076, 26293426, 24593002, 26670852];
   Dental Society of Iwate Medical University; Ministry of Education,
   Culture, Sports, Science, and Technology of Japan; Grants in Aid for
   Scientific Research [16K11654, 24791981, 26462823, 22592076, 26670852,
   26293426, 25463053, 24593002] Funding Source: KAKEN
FX This study was supported in part by Grants in Aid for Scientific
   Research (KAKENHI) (grant nos. 24791981 awarded to M.I., 25463053
   awarded to N.C., 26462823 awarded to S.K., 22592076 awarded to M.K.,
   26293426 awarded to T.S., 24593002 awarded to Y.S., and 26670852 awarded
   to A. I.) from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan; Grant in Aid from the Dental Society of Iwate
   Medical University; and Grant in Aid for Strategic Medical Science
   Research Centre from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan, 2010 2014.
CR Aloisi AL, 2013, HISTOL HISTOPATHOL, V28, P839, DOI 10.14670/HH 28.839
   Bakin AV, 2002, J CELL SCI, V115, P3193
   Berti Couto SA, 2014, HEAD NECK J SCI SPEC, V36, P84, DOI 10.1002/hed.23260
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Chen YJ, 2009, IMMUNOPHARM IMMUNOT, V31, P499, DOI 10.1080/08923970902814103
   Cotrim P, 2003, J PERIODONTOL, V74, P1625, DOI 10.1902/jop.2003.74.11.1625
   De Ceulaer J, 2014, EUR J CLIN MICROBIOL, V33, P1873, DOI 10.1007/s10096 014 2160 5
   DeMaio L, 2012, J PATHOL, V226, P633, DOI 10.1002/path.3016
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Gong L, 2011, PHARMACOGENET GENOM, V21, P50, DOI 10.1097/FPC.0b013e328335729c
   Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613
   Hoefert S, 2006, BONE, V38, pS76, DOI 10.1016/j.bone.2006.01.031
   Hu HL, 2008, MOL CELL BIOL, V28, P1573, DOI 10.1128/MCB.01087 07
   Kardassis D, 2009, FEBS J, V276, P2947, DOI 10.1111/j.1742 4658.2009.07031.x
   Kimura H, 2013, CELL PHYSIOL BIOCHEM, V32, P899, DOI 10.1159/000354493
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Koch FP, 2011, J CRANIO MAXILL SURG, V39, P562, DOI 10.1016/j.jcms.2010.10.007
   Kurishima K, 2014, EXP THER MED, V8, P1267, DOI 10.3892/etm.2014.1914
   Liu T, 2010, BIOCHEM J, V430, P191, DOI 10.1042/BJ20100427
   Lu Q, 2008, AM J PHYSIOL LUNG C, V295, pL123, DOI 10.1152/ajplung.00402.2007
   Manaka K, 2014, ENDOCR J, V61, P185, DOI 10.1507/endocrj.EJ13 0419
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785
   Molcho S, 2013, J CLIN ENDOCR METAB, V98, pE1807, DOI 10.1210/jc.2013 2434
   Motizuki M, 2013, J BIOL CHEM, V288, P18911, DOI 10.1074/jbc.M113.480996
   Nakano N, 2014, J BIOL CHEM, V289, P12680, DOI 10.1074/jbc.M114.558981
   Nisi M, 2015, INT J ORAL MAX SURG, V44, P586, DOI 10.1016/j.ijom.2015.01.014
   Okamoto S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.475
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Saito T, 2014, INT J ORAL MAX SURG, V43, P373, DOI 10.1016/j.ijom.2013.06.016
   Sandbo N, 2011, TRANSL RES, V158, P181, DOI 10.1016/j.trsl.2011.05.004
   Sarrazy V, 2011, WOUND REPAIR REGEN, V19, pS10, DOI 10.1111/j.1524 475X.2011.00708.x
   Sawada S, 2013, BIOMED RES TOKYO, V34, P31, DOI 10.2220/biomedres.34.31
   Short M, 2004, AM J PHYSIOL CELL PH, V286, pC416, DOI 10.1152/ajpcell.00169.2003
   Sobral LM, 2011, J PERIODONTOL, V82, P642, DOI 10.1902/jop.2010.100510
   Song B, 2009, CYTOKINE GROWTH F R, V20, P379, DOI 10.1016/j.cytogfr.2009.10.010
   Tarnawski AS, 2005, DIGEST DIS SCI, V50, pS24, DOI 10.1007/s10620 005 2803 6
   Tipton DA, 1998, J PERIODONTOL, V69, P609, DOI 10.1902/jop.1998.69.6.609
   Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Valluru M, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00089
   Van De Water L, 2013, ADV WOUND CARE, V2, P122, DOI 10.1089/wound.2012.0393
   Wang X, 2015, EXP CELL RES, V332, P202, DOI 10.1016/j.yexcr.2015.01.015
   Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012
   Xiao YQ, 2009, INVEST OPHTH VIS SCI, V50, P1698, DOI 10.1167/iovs.08 1675
   Xu XF, 2013, INT J MOL MED, V32, P430, DOI 10.3892/ijmm.2013.1415
   Yoshinami T, 2011, INTERNAL MED, V50, P1075, DOI 10.2169/internalmedicine.50.4855
NR 54
TC 22
Z9 23
U1 1
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUL
PY 2016
VL 38
IS 1
BP 139
EP 147
DI 10.3892/ijmm.2016.2582
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DT2CZ
UT WOS:000381289700016
PM 27176567
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Shropshire, DB
   Acosta, FM
   Fang, K
   Benavides, J
   Sun, LZ
   Jin, VX
   Jiang, JX
AF Shropshire, Daniel Brian
   Acosta, Francisca M.
   Fang, Kun
   Benavides, Jaime
   Sun, Lu Zhe
   Jin, Victor X.
   Jiang, Jean X.
TI Association of adenosine signaling gene signature with estrogen
   receptor positive breast and prostate cancer bone metastasis
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE metastasis; bone; breast; prostate; purinergic; osteocyte
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; EVOLUTIONARY HISTORY; SURVIVAL
   ANALYSIS; CLINICAL COURSE; IN VITRO; HEMICHANNELS; DENOSUMAB;
   RECURRENCE; OSTEOCYTES
AB Bone metastasis is a common and devastating consequence of several major cancer types, including breast and prostate. Osteocytes are the predominant bone cell, and through connexin (Cx) 43 hemichannels release ATP to the bone microenvironment that can be hydrolyzed to adenosine. Here, we investigated how genes related to ATP paracrine signaling are involved in two common bone metastasizing malignancies, estrogen receptor positive (ER+) breast and prostate cancers. Compared to other sites, bone metastases of both cancer types expressed higher levels of ENTPD1 and NT5E, which encode CD39 and CD73, respectively, and hydrolyze ATP to adenosine. ADORA3, encoding the adenosine A3 receptor, had a similar expression pattern. In primary ER+ breast cancer, high levels of the triplet ENTPD1/NT5E/ADORA3 expression signature was correlated with lower overall, distant metastasis free, and progression free survival. In ER+ bone metastasis biopsies, this expression signature is associated with lower survival. This expression signature was also higher in bone metastasizing primary prostate cancers than in those that caused other tumor events or did not lead to progressive disease. In 3D culture, a non hydrolyzable ATP analog inhibited the growth of breast and prostate cancer cell lines more than ATP did. A3 inhibition also reduced spheroid growth. Large scale screens by the Drug Repurposing Hub found ER+ breast cancer cell lines were uniquely sensitive to adenosine receptor antagonists. Together, these data suggest a vital role for extracellular ATP degradation and adenosine receptor signaling in cancer bone metastasis, and this study provides potential diagnostic means for bone metastasis and specific targets for treatment and prevention.
C1 [Shropshire, Daniel Brian; Acosta, Francisca M.; Benavides, Jaime; Jiang, Jean X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, San Antonio, TX 78229 USA.
   [Fang, Kun; Jin, Victor X.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI USA.
   [Fang, Kun; Jin, Victor X.] Med Coll Wisconsin, MCW Canc Ctr, Milwaukee, WI USA.
   [Benavides, Jaime] Univ Texas San Antonio, Dept Biomed Engn & Chem Engn, San Antonio, TX USA.
   [Sun, Lu Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell Syst & Anat, San Antonio, TX USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; Medical College of Wisconsin; Medical College of Wisconsin;
   University of Texas System; University of Texas at San Antonio (UTSA);
   University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Jiang, JX (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, San Antonio, TX 78229 USA.
EM jiangj@uthscsa.edu
RI Jiang, Jia Xing/F 4036 2012; , LuZhe/AAW 4095 2021
OI Fang, Kun/0000 0002 2569 8543; 
FU National Cancer Institute [U54CA217297] Funding Source: NIH RePORTER;
   National Institute of General Medical Sciences [R01GM114142] Funding
   Source: NIH RePORTER
CR Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025
   Allard B, 2020, NAT REV CLIN ONCOL, V17, P611, DOI 10.1038/s41571 020 0382 2
   Amaral ML, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859 018 2308 x
   Bado IL, 2021, DEV CELL, V56, P1100, DOI 10.1016/j.devcel.2021.03.008
   BEAVO JA, 1970, MOL PHARMACOL, V6, P597
   Boison D, 2019, CANCER CELL, V36, P582, DOI 10.1016/j.ccell.2019.10.007
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Buenzli PR, 2015, BONE, V75, P144, DOI 10.1016/j.bone.2015.02.016
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159 8290.CD 12 0095
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04 10 0912
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Corsello SM, 2017, NAT MED, V23, P405, DOI 10.1038/nm.4306
   Dillekås H, 2019, CANCER MED US, V8, P5574, DOI 10.1002/cam4.2474
   Egevad L, 2002, BJU INT, V89, P538, DOI 10.1046/j.1464 410X.2002.02669.x
   Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855
   FIDLER IJ, 1970, JNCI J NATL CANCER I, V45, P773
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Fong L, 2020, CANCER DISCOV, V10, P40, DOI 10.1158/2159 8290.CD 19 0980
   Gandaglia G, 2014, PROSTATE, V74, P210, DOI 10.1002/pros.22742
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021
   Gerhauser C, 2018, CANCER CELL, V34, P996, DOI 10.1016/j.ccell.2018.10.016
   Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587 020 0546 8
   Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549 009 0674 9
   Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014
   Haider M, 2016, CLIN EXP METASTAS, V33, P239, DOI 10.1007/s10585 015 9773 7
   Henry MD, 2005, PROSTATE, V65, P347, DOI 10.1002/pros.20300
   Hong MKH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7605
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jensen AO, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 29
   Kamel MH, 2018, UROL ANNALS, V10, P203, DOI 10.4103/UA.UA_124_17
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Leapman MS, 2017, EUR UROL, V71, P750, DOI 10.1016/j.eururo.2016.11.032
   Li XY, 2019, CANCER DISCOV, V9, P1754, DOI 10.1158/2159 8290.CD 19 0541
   Lovero D, 2022, BRIT J CANCER, V126, P419, DOI 10.1038/s41416 021 01481 z
   Moreira DM, 2017, CLIN GENITOURIN CANC, V15, P60, DOI 10.1016/j.clgc.2016.08.018
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   O'Sullivan GJ, 2015, WORLD J RADIOL, V7, P202, DOI 10.4329/wjr.v7.i8.202
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Perrot I, 2019, CELL REP, V27, P2411, DOI 10.1016/j.celrep.2019.04.091
   Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757
   PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Solomayer EF, 2000, BREAST CANCER RES TR, V59, P271, DOI 10.1023/A:1006308619659
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Sramkoski RM, 1999, IN VITRO CELL DEV AN, V35, P403
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Thomsen FB, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228447
   Tomlinson RE, 2013, BONE RES, V1, P311, DOI 10.4248/BR201304002
   Tosoian JJ, 2020, PROSTATE CANCER P D, V23, P646, DOI 10.1038/s41391 020 0226 2
   Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010
   Ullah I, 2018, J CLIN INVEST, V128, P1355, DOI 10.1172/JCI96149
   Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0129 6
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Yu CN, 2016, NAT BIOTECHNOL, V34, P419, DOI 10.1038/nbt.3460
   Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011
   Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101
   Zhou JZ, 2015, ONCOGENE, V34, P1831, DOI 10.1038/onc.2014.113
NR 70
TC 3
Z9 3
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 858X
J9 FRONT MED LAUSANNE
JI Front. Med.
PD SEP 15
PY 2022
VL 9
AR 965429
DI 10.3389/fmed.2022.965429
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 4Z3ER
UT WOS:000862097100001
PM 36186774
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, LJ
   Sun, SX
   Zhao, XJ
   Zhang, J
   Guo, JZ
   Tang, L
   Ta, D
AF Sun, Lijun
   Sun, Shuxin
   Zhao, Xinjuan
   Zhang, Jing
   Guo, Jianzhong
   Tang, Liang
   Ta, Dean
TI Inhibition of myostatin signal pathway may be involved in low intensity
   pulsed ultrasound promoting bone healing
SO JOURNAL OF MEDICAL ULTRASONICS
LA English
DT Article
DE Low intensity pulsed ultrasound; Bone healing; Bone micro architectures;
   Proliferation; Myostatin; Wnt
ID MESENCHYMAL STEM CELLS; MICROARCHITECTURE DETERIORATION; OSTEOGENIC
   DIFFERENTIATION; MUSCLE MASS; TGF BETA; MICE; REGENERATION; INDUCTION;
   INCREASES; THERAPY
AB Purpose Low intensity pulsed ultrasound (LIPUS) is effective in promoting bone healing, and a myostatin deficiency also has a positive effect on bone formation. In this study, we evaluated the effects of LIPUS on bone healing in rats in vivo and investigated the mechanisms in vitro, aiming to explore whether LIPUS promotes bone healing through inhibition of the myostatin signaling pathway. Methods Rats with both drill hole defects and MC3T3 E1 cells were randomly assigned to a LIPUS group and a control group. The LIPUS group received LIPUS treatment (1.5 MHz, 30 mW/cm(2)) for 20 min/day. Results After 21 days, the myostatin expression in quadriceps was significantly inhibited in the LIPUS group, and remodeling of the newly formed bone in the drill hole site was significantly better in the LIPUS group than that in the control group, which was confirmed by micro CT analysis. After 3 days, LIPUS significantly promoted osteoblast proliferation; inhibited the expression of AcvrIIB (the myostatin receptor), Smad3, p Smad3, and GSK 3 beta; and increased Wnt1 and beta catenin expression. Moreover, translocation of beta catenin from the cytolemma to the nucleus was observed in the LIPUS group. However, these effects were blocked by treatment with myostatin recombinant protein. Conclusions The results indicate that LIPUS may promote bone healing through inhibition of the myostatin signal pathway.
C1 [Sun, Lijun; Zhao, Xinjuan; Zhang, Jing; Tang, Liang] Shaanxi Normal Univ, Inst Sports Biol, Xian 710119, Shaanxi, Peoples R China.
   [Sun, Shuxin; Ta, Dean] Fudan Univ, Dept Elect Engn, Shanghai 200433, Peoples R China.
   [Guo, Jianzhong] Shaanxi Normal Univ, Shaanxi Key Lab Ultrason, Xian 710119, Shaanxi, Peoples R China.
   [Ta, Dean] Fudan Univ, Human Phenome Inst, Shanghai 201203, Peoples R China.
   [Ta, Dean] Key Lab Med Imaging Comp & Comp Assisted Interven, Shanghai 200032, Peoples R China.
C3 Shaanxi Normal University; Fudan University; Shaanxi Normal University;
   Fudan University
RP Tang, L (通讯作者)，Shaanxi Normal Univ, Inst Sports Biol, Xian 710119, Shaanxi, Peoples R China.; Ta, D (通讯作者)，Fudan Univ, Dept Elect Engn, Shanghai 200433, Peoples R China.; Ta, D (通讯作者)，Fudan Univ, Human Phenome Inst, Shanghai 201203, Peoples R China.; Ta, D (通讯作者)，Key Lab Med Imaging Comp & Comp Assisted Interven, Shanghai 200032, Peoples R China.
EM tl531@snnu.edu.cn; tda@fudan.edu.cn
OI Guo, Jianzhong/0000 0003 1909 3510
FU National Natural Science Foundation of China [11827808, 11774213,
   11727813, 11502134, 11525416]; Natural Science Foundation of Shaanxi
   Province [2018JM1022]; Fundamental Research Funds for the Central
   Universities [GK201703092, GK201703091]; Shanghai Municipal Science and
   Technology Major Project [2017SHZDZX01]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 11827808, 11774213, 11727813, 11502134, and 11525416), the
   Natural Science Foundation of Shaanxi Province (2018JM1022), the
   Fundamental Research Funds for the Central Universities (GK201703092 and
   GK201703091), and Shanghai Municipal Science and Technology Major
   Project (2017SHZDZX01).
CR Acar AH, 2016, ARCH ORAL BIOL, V61, P60, DOI 10.1016/j.archoralbio.2015.10.011
   Angle SR, 2014, J ORTHOP TRAUMA, V28, P605, DOI 10.1097/BOT.0000000000000067
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   Cui JH, 2007, TISSUE ENG, V13, P351, DOI 10.1089/ten.2006.0080
   Egerman MA, 2015, CELL METAB, V22, P164, DOI 10.1016/j.cmet.2015.05.010
   Elkasrawy MN, 2010, J MUSCULOSKEL NEURON, V10, P56
   Funaba M, 2001, EUR J ENDOCRINOL, V144, P63, DOI 10.1530/eje.0.1440063
   Fung CH, 2014, ULTRASONICS, V54, P1358, DOI 10.1016/j.ultras.2014.02.003
   Guo W, 2008, J BIOL CHEM, V283, P9136, DOI 10.1074/jbc.M708968200
   Hamrick MW, 2007, BONE, V40, P1544, DOI 10.1016/j.bone.2007.02.012
   Hamrick MW, 2003, ANAT REC PART A, V272A, P388, DOI 10.1002/ar.a.10044
   Harslof T, 2013, CALCIFIED TISSUE INT, V92, P467, DOI 10.1007/s00223 013 9702 1
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Inoue Y, 2009, J CELL BIOCHEM, V108, P285, DOI 10.1002/jcb.22252
   Jung YJ, 2015, ULTRASOUND MED BIOL, V41, P999, DOI 10.1016/j.ultrasmedbio.2014.11.008
   Kim WK, 2012, INT J BIOCHEM CELL B, V44, P327, DOI 10.1016/j.biocel.2011.11.004
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Lei HG, 2015, UROLOGY, V86, DOI 10.1016/j.urology.2015.07.026
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Lim K, 2013, BIOMED RES INT UK, V2013, DOI 10.1155/2013/269724
   Lu Q, 2016, CALCIFIED TISSUE INT, V99, P500, DOI 10.1007/s00223 016 0173 z
   Marchitelli C, 2003, MAMM GENOME, V14, P392, DOI 10.1007/s00335 002 2176 5
   Maréchal M, 2005, CLIN ORAL IMPLAN RES, V16, P708, DOI 10.1111/j.1600 0501.2005.01205.x
   Mayr E, 2000, ARCH ORTHOP TRAUM SU, V120, P1
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   Mitchell AD, 2007, GROWTH DEVELOP AGING, V70, P25
   Morissette MR, 2009, AGING CELL, V8, P573, DOI 10.1111/j.1474 9726.2009.00508.x
   Noda T, 2009, BRIT J CANCER, V100, P1647, DOI 10.1038/sj.bjc.6605064
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711
   RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623 198466030 00012
   Sakurakichi K, 2004, J ORTHOP RES, V22, P395, DOI 10.1016/S0736 0266(03)00181 5
   Schöne M, 2017, BIOMECH MODEL MECHAN, V16, P1171, DOI 10.1007/s10237 017 0880 z
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   Sheyn D, 2008, GENE THER, V15, P257, DOI 10.1038/sj.gt.3303070
   Shimazaki A, 2000, J BONE JOINT SURG BR, V82B, P1077, DOI 10.1302/0301 620X.82B7.9948
   Sun JS, 1999, J BIOMED MATER RES, V46, P253, DOI 10.1002/(SICI)1097 4636(199908)46:2<253::AID JBM15>3.3.CO;2 Y
   Takayama T, 2007, LIFE SCI, V80, P965, DOI 10.1016/j.lfs.2006.11.037
   Takikawa S, 2001, J ULTRAS MED, V20, P197, DOI 10.7863/jum.2001.20.3.197
   Tang L, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395 017 0145 7
   Tang L, 2017, ULTRASOUND MED BIOL, V43, P1411, DOI 10.1016/j.ultrasmedbio.2017.02.017
   Tang L, 2016, EXP BIOL MED, V241, P308, DOI 10.1177/1535370215606814
   Tang L, 2016, CALCIFIED TISSUE INT, V98, P85, DOI 10.1007/s00223 015 0063 9
   Tang L, 2014, CHINESE MED J PEKING, V127, P2342, DOI 10.3760/cma.j.issn.0366 6999.20140022
   Tis JE, 2002, J ORTHOP RES, V20, P793, DOI 10.1016/S0736 0266(02)00003 7
   Tobita K, 2012, J ORTHOP SCI, V17, P470, DOI 10.1007/s00776 012 0233 9
   Tran TNHT, 2018, BIOMECH MODEL MECHAN, V17, P1269, DOI 10.1007/s10237 018 1025 8
   Yarasheski K E, 2002, J Nutr Health Aging, V6, P343
   Zhou SX, 2004, J BIOL CHEM, V279, P54463, DOI 10.1074/jbc.M404786200
   Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525
NR 56
TC 14
Z9 14
U1 1
U2 35
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 1346 4523
EI 1613 2254
J9 J MED ULTRASON
JI J. Med. Ultrason.
PD OCT
PY 2019
VL 46
IS 4
BP 377
EP 388
DI 10.1007/s10396 019 00962 2
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA JA6AD
UT WOS:000487923000003
PM 31377938
DA 2025 08 17
ER

PT J
AU Qian, Z
   Zhong, ZY
   Ni, S
   Li, DJ
   Zhang, FX
   Zhou, Y
   Kang, ZR
   Qian, J
   Yu, BQ
AF Qian, Zhi
   Zhong, Zeyuan
   Ni, Shuo
   Li, Dejian
   Zhang, Fangxue
   Zhou, Ying
   Kang, Zhanrong
   Qian, Jun
   Yu, Baoqing
TI Cytisine attenuates bone loss of ovariectomy mouse by preventing
   RANKL induced osteoclastogenesis
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE AKT NFATc1; cytisine; MAPK; NF kappa B; osteoclastogenesis; SC79
ID NF KAPPA B; INHIBITS OSTEOCLASTOGENESIS; ESTROGEN DEFICIENCY;
   DIFFERENTIATION; SUPPRESSES
AB Postmenopausal Osteoporosis (PMOP) is oestrogen withdrawal characterized of much production and activation by osteoclast in the elderly female. Cytisine is a quinolizidine alkaloid that comes from seeds or other plants of the Leguminosae (Fabaceae) family. Cytisine has been shown several potential pharmacological functions. However, its effects on PMOP remain unknown. This study designed to explore whether Cytisine is able to suppress RANKL induced osteoclastogenesis and prevent the bone loss induced by oestrogen deficiency in ovariectomized (OVX) mice. In this study, we investigated the effect of Cytisine on RAW 264.7 cells and bone marrow monocytes (BMMs) derived osteoclast culture system in vitro and observed the effect of Cytisine on ovariectomized (OVX) mice model to imitate postmenopausal osteoporosis in vivo. We found that Cytisine inhibited F actin ring formation and tartrate resistant acid phosphatase (TRAP) staining in dose dependent ways, as well as bone resorption by pit formation assays. For molecular mechanism, Cytisine suppressed RANK related trigger RANKL by phosphorylation JNK/ERK/p38 MAPK, I kappa B alpha/p65 NF kappa B, and PI3K/AKT axis and significantly inhibited these signalling pathways. However, the suppression of PI3K AKT NFATc1 axis was rescued by AKT activator SC79. Meanwhile, Cytisine inhibited RANKL induced RANK TRAF6 association and RANKL related gene and protein markers such as NFATc1, Cathepsin K, MMP 9 and TRAP. Our study indicated that Cytisine could suppress bone loss in OVX mouse through inhibited osteoclastogenesis. All data provide the evidence that Cytisine may be a promising agent in the treatment of osteoclast related diseases such as osteoporosis.
C1 [Qian, Zhi; Zhong, Zeyuan; Ni, Shuo; Li, Dejian; Zhang, Fangxue; Zhou, Ying; Kang, Zhanrong; Yu, Baoqing] Fudan Univ, Pudong Med Ctr, Dept Orthopaed Surg, Shanghai Pudong Hosp, Huinan Town, Peoples R China.
   [Qian, Zhi; Qian, Jun] Hexi Univ, Dept Orthopaed Surg, Zhangye Peoples Hosp, Zhangye City, Peoples R China.
C3 Fudan University; Hexi University
RP Yu, BQ (通讯作者)，Fudan Univ, Shanghai Pudong Hosp, Dept Orthoped, Pudong Med Ctr, 2800 Gongwei Rd,Pudong New Area, Shanghai 201301, Peoples R China.; Qian, J (通讯作者)，Hexi Univ, Dept Orthoped, Zhangye Peoples Hosp, 67 Xihuan Rd, Zhangye City 734000, Gansu, Peoples R China.
EM qianjun0936@163.com; doctorybq@163.com
RI ; Li, Dejian/ABG 3740 2021; Qian, Zhimin/P 1823 2018
OI Zhong, Zeyuan/0000 0001 6990 8648; Qian, Zhi/0000 0003 3265 7560; 
FU Health & Family Planning Commission of Gansu Province [GWGL2014 24];
   Outstanding Clinical Discipline Project of Shanghai Pudong
   [PWYgy2018 09]; Young Teacher Research Project Fund of Hexi University
   [QN2017003]; Program for Outstanding Leader of Shanghai [046]; Research
   Grant for the Key Disciplines Group Construction Project of Pudong
   Health Bureau of Shanghai [PWZxq2017 11]
FX Health & Family Planning Commission of Gansu Province, Grant/Award
   Number: GWGL2014 24; Outstanding Clinical Discipline Project of Shanghai
   Pudong, Grant/Award Number: PWYgy2018 09; Young Teacher Research Project
   Fund of Hexi University, Grant/Award Number: QN2017003; Program for
   Outstanding Leader of Shanghai, Grant/Award Number: 046; Research Grant
   for the Key Disciplines Group Construction Project of Pudong Health
   Bureau of Shanghai, Grant/Award Number: PWZxq2017 11
CR Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Fedorova VA, 2021, NAT PROD RES, V35, P4256, DOI 10.1080/14786419.2019.1696791
   Herber CB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08046 4
   Jin HM, 2019, J CELL MOL MED, V23, P522, DOI 10.1111/jcmm.13955
   Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim KJ, 2015, BONE, V81, P208, DOI 10.1016/j.bone.2015.07.023
   Kuranov SO, 2018, BIOORGAN MED CHEM, V26, P4402, DOI 10.1016/j.bmc.2018.07.018
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li JB, 2017, J BONE MINER RES, V32, P962, DOI 10.1002/jbmr.3059
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Mineur YS, 2007, NEUROPHARMACOLOGY, V52, P1256, DOI 10.1016/j.neuropharm.2007.01.006
   Mori G, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/108451
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Ochi S, 2007, P NATL ACAD SCI USA, V104, P11394, DOI 10.1073/pnas.0701971104
   Park JH, 2017, MOL CELLS, V40, P706
   Peng TT, 2018, MOLECULES, V23, DOI 10.3390/molecules23123059
   Tang S, 2019, BIOORG CHEM, V90, DOI 10.1016/j.bioorg.2019.103032
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Thomas D, 2019, ADDICTION, V114, P923, DOI 10.1111/add.14541
   Tutka P, 2019, ADDICTION, V114, P1951, DOI 10.1111/add.14721
   Wang TY, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0010 2
   Weitzmann MN, 2017, TOXICOL PATHOL, V45, P911, DOI 10.1177/0192623317735316
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu WT, 2020, ARTIF CELL NANOMED B, V48, P84, DOI 10.1080/21691401.2019.1699813
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhao P, 2018, NEUROCHEM RES, V43, P1575, DOI 10.1007/s11064 018 2572 1
   Zhu DX, 2018, TRENDS ENDOCRIN MET, V29, P571, DOI 10.1016/j.tem.2018.06.001
   Zou W, 2016, NAT MED, V22, P1203, DOI 10.1038/nm.4208
NR 38
TC 20
Z9 26
U1 1
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD SEP
PY 2020
VL 24
IS 17
BP 10112
EP 10127
DI 10.1111/jcmm.15622
EA AUG 2020
PG 16
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NT3AD
UT WOS:000558801200001
PM 32790170
OA Green Published
DA 2025 08 17
ER

PT J
AU Yun, HM
   Lee, JY
   Kim, SH
   Kwon, IK
   Park, KR
AF Yun, Hyung Mun
   Lee, Joon Yeop
   Kim, Soo Hyun
   Kwon, Il Keun
   Park, Kyung Ran
TI Effects of Triterpene Soyasapogenol B from Arachis hypogaea
   (Peanut) on Differentiation, Mineralization, Autophagy, and Necroptosis
   in Pre Osteoblasts
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Arachis hypogaea; peanut; osteoblast; RUNX2; Soyasapogenol B
ID ALKALINE PHOSPHATASE; ADHESION; EXPRESSION; EXTRACTS;
   METALLOPROTEINASE 13; APOPTOSIS; HEALTH
AB Triterpenes are a diverse group of natural compounds found in plants. Soyasapogenol B (SoyB) from Arachis hypogaea (peanut) has various pharmacological properties. This study aimed to elucidate the pharmacological properties and mechanisms of SoyB in bone forming cells. In the present study, 1 20 mu M of SoyB showed no cell proliferation effects, whereas 30 100 mu M of SoyB increased cell proliferation in MC3T3 E1 cells. Next, osteoblast differentiation was analyzed, and it was found that SoyB enhanced ALP staining and activity and bone mineralization. SoyB also induced RUNX2 expression in the nucleus with the increased phosphorylation of Smad1/5/8 and JNK2 during osteoblast differentiation. In addition, SoyB mediated osteoblast differentiation was not associated with autophagy and necroptosis. Furthermore, SoyB increased the rate of cell migration and adhesion with the upregulation of MMP13 levels during osteoblast differentiation. The findings of this study provide new evidence that SoyB possesses biological effects in bone forming cells and suggest a potentially beneficial role for peanut based foods.
C1 [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Lee, Joon Yeop; Kim, Soo Hyun] Natl Dev Inst Korean Med, Gyongsan 38540, South Korea.
   [Kwon, Il Keun] Kyung Hee Univ, Sch Dent, Dept Dent Mat, Seoul 02447, South Korea.
   [Park, Kyung Ran] Korea Basic Sci Inst KBSI, Gwangju Ctr, Gwangju 61751, South Korea.
C3 Kyung Hee University; Kyung Hee University; Korea Basic Science
   Institute (KBSI)
RP Park, KR (通讯作者)，Korea Basic Sci Inst KBSI, Gwangju Ctr, Gwangju 61751, South Korea.
EM yunhm@khu.ac.kr; chool9090@nikom.or.kr; beluga81@nikom.or.kr;
   kwoni@khu.ac.kr; krpark83@kbsi.re.kr
RI Kim, Soo Hyun/D 1577 2019
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2022R1C1C1003491, 2020R1A2C2011937]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (2022R1C1C1003491;
   2020R1A2C2011937).
CR Akram NA, 2018, COMPR REV FOOD SCI F, V17, P1325, DOI 10.1111/1541 4337.12383
   Cho YS, 2014, BIOMOL THER, V22, P167, DOI 10.4062/biomolther.2014.046
   Choi CW, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31118 w
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   Deng T, 2021, BMC ENDOCR DISORD, V21, DOI 10.1186/s12902 021 00715 8
   Fu L, 2019, J CELL MOL MED, V23, P7517, DOI 10.1111/jcmm.14620
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Guo M, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3027954
   Hoang VH, 2008, CZECH J FOOD SCI, V26, P447, DOI 10.17221/29/2008 CJFS
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Khotib J, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14070615
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Kinjo J, 2003, BIOL PHARM BULL, V26, P1357, DOI 10.1248/bpb.26.1357
   Kobayashi T, 2021, METHODS MOL BIOL, V2230, P3, DOI 10.1007/978 1 0716 1028 2_1
   Kusuyama J, 2019, FASEB J, V33, P7331, DOI 10.1096/fj.201802465R
   Lertkaeo P, 2017, ASIAN PAC J TROP BIO, V7, P64, DOI 10.1016/j.apjtb.2016.11.007
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Luo F, 2018, INT J NANOMED, V13, P7657, DOI 10.2147/IJN.S175536
   Ma XY, 2017, BIOMATER SCI UK, V6, P225, DOI 10.1039/c7bm00652g
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Pan XM, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.182031
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111362
   Park KR, 2021, AM J CANCER RES, V11, P4919
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136899
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052483
   Park KR, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153347
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Sasaki K, 2005, BIOORGAN MED CHEM, V13, P4900, DOI 10.1016/j.bmc.2005.04.074
   Shalehin N, 2020, J DENT SCI, V15, P437, DOI 10.1016/j.jds.2019.09.009
   Shi G, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20187844, 10.1590/1414 431x20187844]
   Sista S, 2013, MAT SCI ENG C MATER, V33, P1573, DOI 10.1016/j.msec.2012.12.063
   Tian Q, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1295382
   Toriseva M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042596
   Uusitalo H, 2000, CALCIFIED TISSUE INT, V67, P382, DOI 10.1007/s002230001152
   Wang KH, 2005, J AGR FOOD CHEM, V53, P242, DOI 10.1021/jf048804b
   Wang LP, 2019, LIFE SCI, V218, P16, DOI 10.1016/j.lfs.2018.12.023
   Wang ZK, 2021, BIO MED MATER ENG, V32, P29, DOI 10.3233/BME 201139
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Yamagiwa H, 1999, BONE, V25, P197, DOI 10.1016/S8756 3282(99)00157 X
   Yang S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0869 2
   Yang Y, 2021, J BIOMED MATER RES A, V109, P1429, DOI 10.1002/jbm.a.37134
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2016, SCI REP UK, V6, DOI 10.1038/srep30985
   Zhang W, 2008, J AGR FOOD CHEM, V56, P2603, DOI 10.1021/jf0731550
NR 50
TC 7
Z9 8
U1 0
U2 12
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2022
VL 23
IS 15
AR 8297
DI 10.3390/ijms23158297
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 3R4KU
UT WOS:000838884600001
PM 35955423
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ji, X
   Seeley, R
   Li, K
   Song, FF
   Liao, XY
   Song, C
   Angelozzi, M
   Valeri, A
   Marmo, T
   Lee, WC
   Shi, Y
   Long, FX
AF Ji, Xing
   Seeley, Rebecca
   Li, Ke
   Song, Fangfang
   Liao, Xueyang
   Song, Chao
   Angelozzi, Marco
   Valeri, Arianna
   Marmo, Tyler
   Lee, Wen Chih
   Shi, Yu
   Long, Fanxin
TI Genetic activation of glycolysis in osteoblasts preserves bone mass in
   type I diabetes
SO CELL CHEMICAL BIOLOGY
LA English
DT Article
ID SINGLE CELL; FRACTURE; EXPRESSION; RISK; METABOLISM; MECHANISMS;
   ANABOLISM
AB Type I diabetes (T1D) impairs bone accrual in patients, but the mechanism is unclear. Here in a murine mono  genic model for T1D, we demonstrate that diabetes suppresses bone formation resulting in a rapid loss of both cortical and trabecular bone. Single cell RNA sequencing uncovers metabolic dysregulation in bone marrow osteogenic cells of diabetic mice. In vivo stable isotope tracing reveals impaired glycolysis in diabetic bone that is highly responsive to insulin stimulation. Remarkably, deletion of the insulin receptor reduces cortical but not trabecular bone. Increasing glucose uptake by overexpressing Glut1 in osteoblasts exacerbates bone defects in T1D mice. Conversely, activation of glycolysis by Pfkfb3 overexpression preserves both trabecular and cortical bone mass in the face of diabetes. The study identifies defective glucose metabolism in osteoblasts as a pathogenic mechanism for osteopenia in T1D, and furthermore implicates boosting osteoblast glycolysis as a potential bone anabolic therapy.
C1 [Ji, Xing; Seeley, Rebecca; Li, Ke; Song, Fangfang; Liao, Xueyang; Song, Chao; Angelozzi, Marco; Valeri, Arianna; Marmo, Tyler; Lee, Wen Chih; Shi, Yu; Long, Fanxin] Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.
   [Long, Fanxin] Univ Penn, Dept Orthoped Surg, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania
RP Long, FX (通讯作者)，Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.; Long, FX (通讯作者)，Univ Penn, Dept Orthoped Surg, Philadelphia, PA 19104 USA.
EM longf1@chop.edu
RI Angelozzi, Marco/MZR 4675 2025
OI CHAO, SONG/0000 0002 1209 1056
FU NIH [R01 DK125498, P30 AR069619]
FX The work is supported by NIH grant R01 DK125498 (F.L.). We thank Penn
   Center for Musculoskeletal Disorders (PCMD) supported by NIH P30
   AR069619 for service. We thank Haoran Liu for assistance with
   bioinformatics of scRNA seq.
CR Baccin C, 2020, NAT CELL BIOL, V22, P38, DOI 10.1038/s41556 019 0439 6
   Baryawno N, 2019, CELL, V177, P1915, DOI 10.1016/j.cell.2019.04.040
   Coe LM, 2013, J CELL PHYSIOL, V228, P689, DOI 10.1002/jcp.24177
   Dixit M, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10483
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Ferrari SL, 2018, OSTEOPOROSIS INT, V29, P2585, DOI 10.1007/s00198 018 4650 2
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343 14
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   HAHN TJ, 1988, J BONE MINER RES, V3, P359
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Hu P, 2021, BONE, V147, DOI 10.1016/j.bone.2021.115906
   Irwin R, 2006, ENDOCRINOLOGY, V147, P5760, DOI 10.1210/en.2006 0700
   Janghorbani M, 2006, DIABETES CARE, V29, P1573, DOI 10.2337/dc06 0440
   Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Lee SY, 2018, J CLIN INVEST, V128, P5573, DOI 10.1172/JCI96221
   Lee WC, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108108
   Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017 02163
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550
   Pereira RO, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000301
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192
   Sellmeyer DE, 2016, DIABETES, V65, P1757, DOI 10.2337/db16 0063
   Shah MS, 2016, CIRC RES, V118, P1808, DOI 10.1161/CIRCRESAHA.116.306923
   Song DY, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0081 8
   Song FF, 2023, ELIFE, V12, DOI 10.7554/eLife.85714
   Starup Linde J, 2016, BONE, V82, P69, DOI 10.1016/j.bone.2015.02.019
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teppala S, 2010, DIABETES CARE, V33, P2257, DOI 10.2337/dc10 0770
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   van Gastel N, 2012, STEM CELLS, V30, P2460, DOI 10.1002/stem.1210
   Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431
   Weber DR, 2015, DIABETES CARE, V38, P1913, DOI 10.2337/dc15 0783
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Yamamoto M, 2016, CURR OSTEOPOROS REP, V14, P320, DOI 10.1007/s11914 016 0332 1
   Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887
   Zoch ML, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.4
NR 41
TC 8
Z9 9
U1 7
U2 27
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2451 9456
EI 2451 9448
J9 CELL CHEM BIOL
JI Cell Chem. Biol.
PD SEP 21
PY 2023
VL 30
IS 9
BP 1053
EP +
DI 10.1016/j.chembiol.2023.07.003
EA SEP 2023
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA U0VQ3
UT WOS:001082074400001
PM 37562406
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, XD
   Ma, HD
   Sun, J
   Zheng, TY
   Zhao, P
   Li, HT
   Yang, MW
AF Wang, XinDong
   Ma, HongDong
   Sun, Jun
   Zheng, TianYu
   Zhao, Peng
   Li, HaiTian
   Yang, MaoWei
TI Mitochondrial Ferritin Deficiency Promotes Osteoblastic Ferroptosis Via
   Mitophagy in Type 2 Diabetic Osteoporosis
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Mitochondrial ferritin; Ferroptosis; Mitophagy; Reactive oxygen species;
   Osteoblast; Type 2 diabetic osteoporosis
ID PROTECTS; APOPTOSIS; AUTOPHAGY; MELLITUS; DMT1
AB The incidence of type 2 diabetic osteoporosis (T2DOP), which seriously threatens elderly people's health, is rapidly increasing in recent years. However, the specific mechanism of the T2DOP is still unclear. Studies have shown the relationship between iron overload and T2DOP. Mitochondrial ferritin (FtMt) is a protein that stores iron ions and intercepts toxic ferrous ions in cells mitochondria. Ferroptosis, an iron dependent cell injured way, may be related to the pathogenesis of T2DOP. In this study, we intend to elucidate the effect of FtMt on ferroptosis in osteoblasts and explain the possible mechanism. We first detected the occurrence of ferroptosis in bone tissue and the expression of FtMt after inducing T2DOP rat model. Then we used hFOB1.19 cells to study the influence of high glucose on FtMt, ferroptosis, and osteogenic function of osteoblasts. Then we observed the effect of FtMt on ferroptosis and osteoblast function by lentiviral silencing and overexpression of FtMt. We found ferroptosis in T2DOP rats bone. Overexpression of FtMt reduced osteoblastic ferroptosis under high glucose condition while silent FtMt induced mitophagy through ROS / PINK1/Parkin pathway. Then we found increased ferroptosis in osteoblasts after activating mitophagy by carbonyl cyanide m chlorophenyl hydrazine (CCCP, a mitophagy agonist). Our study demonstrated that FtMt inhibited the occurrence of ferroptosis in osteoblasts by reducing oxidative stress caused by excess ferrous ions, and FtMt deficiency induced mitophagy in the pathogenesis of T2DOP. This study suggested that FtMt might serve as a potential target for T2DOP therapy.
C1 [Wang, XinDong; Ma, HongDong; Zhao, Peng; Li, HaiTian; Yang, MaoWei] China Med Univ, Dept Orthoped, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
   [Sun, Jun] Jinzhou Med Univ, Dept Orthoped, Hosp 3, Jinzhou, Liaoning, Peoples R China.
   [Zheng, TianYu] China Med Univ, Sch & Hosp Stomatol, VIP Dept, Liaoning Prov Key Lab Oral Dis, Shenyang, Liaoning, Peoples R China.
C3 China Medical University; Jinzhou Medical University; China Medical
   University
RP Yang, MW (通讯作者)，China Med Univ, Dept Orthoped, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
EM mwyang@cmu.edu.cn
CR Altamura S, 2017, J MOL MED, V95, P1387, DOI 10.1007/s00109 017 1596 3
   Anagnostis P, 2018, ENDOCRINE, V60, P373, DOI 10.1007/s12020 018 1548 x
   Basit F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.133
   Braymer JJ, 2019, BBA MOL CELL RES, V1866, P240, DOI 10.1016/j.bbamcr.2018.11.003
   Che JM, 2020, BIOL TRACE ELEM RES, V195, P353, DOI 10.1007/s12011 019 01867 4
   DeGregorio Rocasolano N, 2019, FRONT NEUROSCI SWITZ, V13, DOI 10.3389/fnins.2019.00085
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Drysdale J, 2002, BLOOD CELL MOL DIS, V29, P376, DOI 10.1006/bcmd.2002.0577
   Forcina GC, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800311
   Gao GF, 2017, AGING DIS, V8, P458, DOI 10.14336/AD.2016.1108
   Ge ZD, 2019, INT HEART J, V60, P512, DOI 10.1536/ihj.18 476
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Guan HP, 2017, EXP NEUROL, V291, P51, DOI 10.1016/j.expneurol.2017.02.001
   Huang LL, 2019, J CELL MOL MED, V23, P4153, DOI 10.1111/jcmm.14302
   Imai H, 2017, CURR TOP MICROBIOL, V403, P143, DOI 10.1007/82_2016_508
   Jaacks LM, 2016, BEST PRACT RES CL EN, V30, P331, DOI 10.1016/j.beem.2016.05.003
   Levi S, 2001, J BIOL CHEM, V276, P24437, DOI 10.1074/jbc.C100141200
   Li BX, 2013, ENDOCRINE, V43, P136, DOI 10.1007/s12020 012 9757 1
   Li S, 2020, FREE RADICAL BIO MED, V152, P632, DOI 10.1016/j.freeradbiomed.2019.12.005
   Li YQ, 2018, BIOMETALS, V31, P749, DOI 10.1007/s10534 018 0133 3
   Liang C, 2019, ADV MATER, V31, DOI 10.1002/adma.201904197
   Liang DY, 2020, BIOCHIMIE, V170, P10, DOI 10.1016/j.biochi.2019.12.001
   Liang XY, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104846
   Liu F, 2017, INT J MED SCI, V14, P275, DOI 10.7150/ijms.17860
   Sakellariou GK, 2016, SCI REP UK, V6, DOI 10.1038/srep33944
   Sui SY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1564 7
   Walker OS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229332
   Wang H, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101148
   Wang LG, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170942
   Wang LY, 2020, CELL DEATH DIFFER, V27, P662, DOI 10.1038/s41418 019 0380 z
   Wang YQ, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00308
   Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211
   Wei X, 2014, TOXICOL MECH METHOD, V24, P504, DOI 10.3109/15376516.2014.943444
   Wolff NA, 2014, CHANNELS, V8, P458, DOI 10.4161/19336950.2014.956564
   Wu WY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.372
   Yamada N, 2020, AM J TRANSPLANT, V20, P1606, DOI 10.1111/ajt.15773
   Zhang WL, 2015, INT J MED SCI, V12, P441, DOI 10.7150/ijms.11986
   Zhang YY, 2020, J DRUG TARGET, V28, P449, DOI 10.1080/1061186X.2019.1705312
   Zhang YP, 2019, BIOMED PHARMACOTHER, V111, P1315, DOI 10.1016/j.biopha.2019.01.034
   Zhang ZL, 2020, AUTOPHAGY, V16, P1482, DOI 10.1080/15548627.2019.1687985
   Zhao S, 2013, NEURAL REGEN RES, V8, P3423, DOI 10.3969/j.issn.1673 5374.2013.36.008
   Zhao W, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59743 4
   Zheng Y, 2018, NAT REV ENDOCRINOL, V14, P88, DOI 10.1038/nrendo.2017.151
NR 43
TC 105
Z9 130
U1 4
U2 76
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD JAN
PY 2022
VL 200
IS 1
BP 298
EP 307
DI 10.1007/s12011 021 02627 z
EA FEB 2021
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA WV9MF
UT WOS:000618586700002
PM 33594527
DA 2025 08 17
ER

PT J
AU Okamoto, A
   Ohnishi, T
   Bandow, K
   Kakimoto, K
   Chiba, N
   Maeda, A
   Fukunaga, T
   Miyawaki, S
   Matsuguchi, T
AF Okamoto, Atsuko
   Ohnishi, Tomokazu
   Bandow, Kenjiro
   Kakimoto, Kyoko
   Chiba, Norika
   Maeda, Aya
   Fukunaga, Tomohiro
   Miyawaki, Shouichi
   Matsuguchi, Tetsuya
TI Reduction of orthodontic tooth movement by experimentally induced
   periodontal inflammation in mice
SO EUROPEAN JOURNAL OF ORAL SCIENCES
LA English
DT Article
DE orthodontic therapy; osteoclast; receptor activator of nuclear
   factor kappa B ligand
ID LIGATURE INDUCED PERIODONTITIS; ALVEOLAR BONE DESTRUCTION; OSTEOCLAST
   DIFFERENTIATION; PORPHYROMONAS GINGIVALIS; LIGAMENT CELLS; MAP KINASE;
   EXPRESSION; LIGAND; RANKL; PROSTAGLANDIN E 2
AB Orthodontic therapy is known to have an aggravating effect on the progression of destructive periodontitis if oral hygiene is not maintained. However, it is largely unknown how active periodontitis affects the velocity of orthodontic tooth movement. In this study, we examined the effect of periodontal inflammation on orthodontic tooth movement using a mouse model. Orthodontic force was applied on the maxillary first molar of mice, with or without ligature wire to induce experimental periodontitis. The distance moved by the first molar was significantly reduced by the ligature induced experimental periodontitis. Tartrate resistant acid phosphatase staining revealed that the number of osteoclasts present during orthodontic treatment was lower in the pressure zone of alveolar bone in the presence of periodontal inflammation. Consistently, the expression level of receptor activator of nuclear factor kappa B ligand (RANKL) in the pressure zone was decreased in the ligature group. By contrast, experimental periodontitis increased the expression of cyclooxygenase 2 mRNA in the periodontal tissues, while in vitro treatment with prostaglandin E 2 decreased extracellular signal regulated kinase phosphorylation and RANKL expression induced by mechanical stress in osteoblasts. Taken together, these results suggest that the orthodontic force induced osteoclastogenesis in alveolar bone was inhibited by the accompanying periodontal inflammation, at least partly through prostaglandin E 2, resulting in reduced orthodontic tooth movement.
C1 [Okamoto, Atsuko; Maeda, Aya; Fukunaga, Tomohiro; Miyawaki, Shouichi] Kagoshima Univ, Dept Orthodont, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.
   [Ohnishi, Tomokazu; Bandow, Kenjiro; Kakimoto, Kyoko; Chiba, Norika; Matsuguchi, Tetsuya] Kagoshima Univ, Dept Oral Biochem, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.
C3 Kagoshima University; Kagoshima University
RP Matsuguchi, T (通讯作者)，Kagoshima Univ, Div Oral Biochem, Dept Dev Med, Grad Sch Med & Dent Sci, 8 35 1 Sakuragaoka, Kagoshima 890, Japan.
EM tmatsugu@denta.hal.kagoshima u.ac.jp
RI Fukunaga, Tomohiro/T 4339 2019; Matsuguchi, Tetsuya/HGU 0412 2022
OI Bandow, Kenjiro/0000 0002 1362 3034; Miyawaki,
   Shouichi/0000 0002 4867 2610; Fukunaga, Tomohiro/0000 0003 0533 6454;
   Maeda Iino, Aya/0000 0002 8090 7395
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [17591943, 19390474]; Grants in Aid for Scientific Research [19390474,
   17591943] Funding Source: KAKEN
FX This work was supported by grants from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan (Grants 17591943 &
   19390474).
CR Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Bezerra MM, 2000, J PERIODONTOL, V71, P1009, DOI 10.1902/jop.2000.71.6.1009
   BOYD RL, 1989, AM J ORTHOD DENTOFAC, V96, P191, DOI 10.1016/0889 5406(89)90455 1
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600 0765.2007.00989.x
   Cardaropoli D, 2004, J CLIN PERIODONTOL, V31, P79, DOI 10.1111/j.0303 6979.2004.00451.x
   Cavanaugh P. F. Jr., 1995, Inflammopharmacology, V3, P109, DOI 10.1007/BF02674916
   Choi BK, 2005, J PERIODONTOL, V76, P813, DOI 10.1902/jop.2005.76.5.813
   ERICSSON I, 1982, J CLIN PERIODONTOL, V9, P497, DOI 10.1111/j.1600 051X.1982.tb02111.x
   ERICSSON I, 1977, J CLIN PERIODONTOL, V4, P278, DOI 10.1111/j.1600 051X.1977.tb01900.x
   Garat JA, 2005, J PERIODONTAL RES, V40, P441, DOI 10.1111/j.1600 0765.2005.00809.x
   Garlet TP, 2007, EUR J ORAL SCI, V115, P355, DOI 10.1111/j.1600 0722.2007.00469.x
   Henriksen K, 2003, J BIOL CHEM, V278, P48745, DOI 10.1074/jbc.M309193200
   Ho YP, 2008, J CLIN PERIODONTOL, V35, P1, DOI 10.1111/j.1600 051X.2007.01167.x
   HUSSAIN MZ, 1994, J PERIODONTOL, V65, P771, DOI 10.1902/jop.1994.65.8.771
   IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330
   Kang SS, 2000, INVEST OPHTH VIS SCI, V41, P2164
   Kanzaki H, 2001, J DENT RES, V80, P887, DOI 10.1177/00220345010800030801
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   KLOEHN JS, 1974, ANGLE ORTHOD, V44, P127
   Lalla E, 2000, J CLIN INVEST, V105, P1117, DOI 10.1172/JCI8942
   LEIKER BJ, 1995, AM J ORTHOD DENTOFAC, V108, P380, DOI 10.1016/S0889 5406(95)70035 8
   Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898 6568(00)00096 6
   LI XM, 1995, AM J PHYSIOL CELL PH, V269, pC986, DOI 10.1152/ajpcell.1995.269.4.C986
   LINDHE J, 1974, J CLIN PERIODONTOL, V1, P3, DOI 10.1111/j.1600 051X.1974.tb01234.x
   Lohinai Z, 1998, BRIT J PHARMACOL, V123, P353, DOI 10.1038/sj.bjp.0701604
   Lohinai Z, 2001, LIFE SCI, V70, P279, DOI 10.1016/S0024 3205(01)01391 1
   Maeda A, 2007, J DENT RES, V86, P629, DOI 10.1177/154405910708600709
   Martuscelli G, 2000, J PERIODONTOL, V71, P573, DOI 10.1902/jop.2000.71.4.573
   Mehrotra M, 2006, J CELL BIOCHEM, V98, P1271, DOI 10.1002/jcb.20864
   OHNISHI T, 1991, J BIOL CHEM, V266, P14636
   OHNISHI T, J PERIODONTAL RES
   Ong MA, 1998, J CLIN PERIODONTOL, V25, P271, DOI 10.1111/j.1600 051X.1998.tb02440.x
   Pavlin D., 2000, CLIN ORTHODONTICS RE, V3, P55
   POLSON A, 1984, J PERIODONTOL, V55, P197, DOI 10.1902/jop.1984.55.4.197
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Taubman MA, 2001, CRIT REV ORAL BIOL M, V12, P125, DOI 10.1177/10454411010120020301
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Teng YTA, 2002, INFECT IMMUN, V70, P5269, DOI 10.1128/IAI.70.9.5269 5273.2002
   Thilander B, 1996, Semin Orthod, V2, P55
   Volozhin A. I., 1993, Voprosy Meditsinskoi Khimii, V39, P53
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   WENNSTROM JL, 1993, AM J ORTHOD DENTOFAC, V103, P313, DOI 10.1016/0889 5406(93)70011 C
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshimatsu M, 2006, J BONE MINER METAB, V24, P20, DOI 10.1007/s00774 005 0641 4
   ZACHRISSON BU, 1973, ANGLE ORTHOD, V43, P402
   Zhong Y, 2007, J CLIN PERIODONTOL, V34, P285, DOI 10.1111/j.1600 051X.2007.01057.x
NR 46
TC 28
Z9 30
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0909 8836
EI 1600 0722
J9 EUR J ORAL SCI
JI Eur. J. Oral Sci.
PD JUN
PY 2009
VL 117
IS 3
BP 238
EP 247
DI 10.1111/j.1600 0722.2009.00625.x
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 443BE
UT WOS:000265884400005
PM 19583750
DA 2025 08 17
ER

PT J
AU Gothard, D
   Smith, EL
   Kanczler, JM
   Rashidi, H
   Qutachi, O
   Henstock, J
   Rotherham, M
   El Haj, A
   Shakesheff, KM
   Oreffo, ROC
AF Gothard, D.
   Smith, E. L.
   Kanczler, J. M.
   Rashidi, H.
   Qutachi, O.
   Henstock, J.
   Rotherham, M.
   El Haj, A.
   Shakesheff, K. M.
   Oreffo, R. O. C.
TI TISSUE ENGINEERED BONE USING SELECT GROWTH FACTORS: A COMPREHENSIVE
   REVIEW OF ANIMAL STUDIES AND CLINICAL TRANSLATION STUDIES IN MAN
SO EUROPEAN CELLS & MATERIALS
LA English
DT Article
DE Animal model; bone tissue engineering; BMP 2; BMP 7; clinical
   translation; FGF; human studies; in vivo; OP 1; PDGF; PTH; PTHrP;
   TGF beta 3; VEGF; Wnt proteins
ID HUMAN PARATHYROID HORMONE; MESENCHYMAL STEM CELLS; HUMAN OSTEOGENIC
   PROTEIN 1; LUMBAR SPINE FUSION; ILIAC CREST AUTOGRAFT; PLATELET RICH
   PLASMA; BETA TRICALCIUM PHOSPHATE; MARROW STROMAL CELLS; OP 1 PUTTY
   RHBMP 7; IN VIVO EVALUATION
AB There is a growing socio economic need for effective strategies to repair damaged bone resulting from disease, trauma and surgical intervention. Bone tissue engineering has received substantial investment over the last few decades as a result. A multitude of studies have sought to examine the efficacy of multiple growth factors, delivery systems and biomaterials within in vivo animal models for the repair of critical sized bone defects. Defect repair requires recapitulation of in vivo signalling cascades, including osteogenesis, chondrogenesis and angiogenesis, in an orchestrated spatiotemporal manner. Strategies to drive parallel, synergistic and consecutive signalling of factors including BMP 2, BMP 7/OP 1, FGF, PDGF, PTH, PTHrP, TGF beta 3, VEGF and Wnts have demonstrated improved bone healing within animal models. Enhanced bone repair has also been demonstrated in the clinic following European Medicines Agency and Food and Drug Administration approval of BMP 2, BMP 7/OP 1, PDGF, PTH and PTHrP. The current review assesses the in vivo and clinical data surrounding the application of growth factors for bone regeneration. This review has examined data published between 1965 and 2013. All bone tissue engineering studies investigating in vivo response of the growth factors listed above, or combinations thereof, utilising animal models or human trials were included. All studies were compiled from PubMed NCBI using search terms including 'growth factor name', 'in vivo', 'model/ animal', 'human', and 'bone tissue engineering'. Focus is drawn to the in vivo success of osteoinductive growth factors incorporated within material implants both in animals and humans, and identifies the unmet challenges within the skeletal regenerative area.
C1 [Gothard, D.; Smith, E. L.; Kanczler, J. M.; Oreffo, R. O. C.] Univ Southampton, Ctr Human Dev Stem Cells & Regenerat, Bone & Joint Res Grp, Southampton SO16 6YD, Hants, England.
   [Rashidi, H.; Qutachi, O.; Shakesheff, K. M.] Univ Nottingham, Wolfson Ctr Stem Cells, Nottingham NG7 2RD, England.
   [Henstock, J.; Rotherham, M.; El Haj, A.] Keele Univ, Inst Sci & Technol Med, Stoke On Trent, Staffs, England.
C3 University of Southampton; University of Nottingham; Keele University
RP Gothard, D (通讯作者)，Univ Southampton, Southampton Gen Hosp, Sch Med, Inst Dev Sci,Bone & Joint Res Grp, Mail Point 887,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM D.Gothard@soton.ac.uk; richard.oreffo@soton.ac.uk
RI ; Rotherham, Michael/K 7275 2019; Rashidi, Hassan/N 9313 2014; Qutachi,
   Omar/AAD 7332 2019; Shakesheff, Kevin/O 6371 2018; Oreffo,
   Richard/A 4615 2011
OI Qutachi, Omar/0000 0002 5026 7358; Rotherham,
   Michael/0000 0002 9297 7681; Rashidi, Hassan/0000 0001 8078 6688;
   Kanczler, Janos/0000 0001 7249 0414; Shakesheff,
   Kevin/0000 0003 3236 2439; Oreffo, Richard/0000 0001 5995 6726;
   Henstock, James/0000 0002 8517 0679
FU Biotechnology and Biological Sciences Research Council, UK
   [BB/G010579/1]; Biotechnology and Biological Sciences Research Council
   [BB/G010560/1, BB/G010579/1] Funding Source: researchfish; BBSRC
   [BB/G010579/1, BB/G010560/1] Funding Source: UKRI
FX This work was supported by a strategic longer and larger grant (sLOLA)
   from the Biotechnology and Biological Sciences Research Council,
   UK grant number BB/G010579/1 to AEH, KMS and ROCO. Prof. Kevin M.
   Shakesheff is Director of Locate Therapeutics Ltd.. Apart from this, the
   authors wish to confirm that there are no further known conflicts of
   interest associated with this publication and there has been no
   significant financial support for this work that could have influenced
   its outcome.
CR Abbah SA, 2011, SPINE, V36, P1752, DOI 10.1097/BRS.0b013e31822576a4
   Abe N, 2002, BIOCHEM BIOPH RES CO, V297, P523, DOI 10.1016/S0006 291X(02)02193 9
   Abe Y, 2007, BONE, V41, P775, DOI 10.1016/j.bone.2007.06.025
   Abu Serriah MM, 2004, BRIT J ORAL MAX SURG, V42, P410, DOI 10.1016/j.bjoms.2004.05.005
   Aerssens J, 1998, ENDOCRINOLOGY, V139, P663, DOI 10.1210/en.139.2.663
   Akamaru T, 2003, SPINE, V28, P429, DOI 10.1097/00007632 200303010 00004
   Al Zube L, 2009, J ORTHOP RES, V27, P1074, DOI 10.1002/jor.20842
   Aleksyniene R, 2009, ACTA ORTHOP, V80, P716, DOI 10.3109/17453670903350032
   Ali MN, 2012, OR SURG OR MED OR PA, V114, pE36, DOI 10.1016/j.oooo.2011.08.009
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Alpaslan C, 1996, BRIT J ORAL MAX SURG, V34, P414, DOI 10.1016/S0266 4356(96)90098 4
   Andreassen TT, 2004, J CRANIOFAC SURG, V15, P424, DOI 10.1097/00001665 200405000 00014
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Anticevic D, 2006, J PEDIATR ORTHOP B, V15, P220, DOI 10.1097/01.bpb.0000194439.75378.ac
   Anusaksathien O, 2004, J PERIODONTOL, V75, P429, DOI 10.1902/jop.2004.75.3.429
   Arrighi I, 2009, BIOMATERIALS, V30, P1763, DOI 10.1016/j.biomaterials.2008.12.023
   Ascenzi MG, 2012, J BONE MINER RES, V27, P702, DOI 10.1002/jbmr.1497
   Aspenberg P, 2008, ACTA ORTHOP, V79, P111, DOI 10.1080/17453670710014851
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bae JH, 2011, TISSUE ENG PT A, V17, P2389, DOI 10.1089/ten.tea.2011.0032
   Bai B, 2009, SPINE, V34, P1887, DOI 10.1097/BRS.0b013e3181b0e579
   Baim S, 2012, CURR OSTEOPOROS REP, V10, P28, DOI 10.1007/s11914 011 0093 9
   Baltzer AWA, 2000, GENE THER, V7, P734, DOI 10.1038/sj.gt.3301166
   Barnes B, 2005, SPINE, V30, P1127, DOI 10.1097/01.brs.0000162623.48058.8c
   Barr T, 2010, ORAL SURG ORAL MED O, V109, P531, DOI 10.1016/j.tripleo.2009.10.027
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Baskin DS, 2003, SPINE, V28, P1219, DOI 10.1097/00007632 200306150 00003
   Basmanav FB, 2008, BIOMATERIALS, V29, P4195, DOI 10.1016/j.biomaterials.2008.07.017
   Bax BE, 1999, CALCIFIED TISSUE INT, V65, P83, DOI 10.1007/s002239900662
   BECKER W, 1992, J PERIODONTOL, V63, P929, DOI 10.1902/jop.1992.63.11.929
   Behr B, 2012, TISSUE ENG PT A, V18, P1079, DOI [10.1089/ten.tea.2011.0537, 10.1089/ten.TEA.2011.0537]
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Berner A, 2012, CELL TISSUE RES, V347, P501, DOI 10.1007/s00441 011 1184 8
   Betz OB, 2007, GENE THER, V14, P1039, DOI 10.1038/sj.gt.3302956
   Betz OB, 2006, J BONE JOINT SURG AM, V88A, P355, DOI 10.2106/JBJS.E.00464
   Betz VM, 2007, HUM GENE THER, V18, P907, DOI 10.1089/hum.2007.077
   Bilic R, 2006, INT ORTHOP, V30, P128, DOI 10.1007/s00264 005 0045 z
   Bland YS, 1995, ACTA ORTHOP SCAND, V66, P543, DOI 10.3109/17453679509002313
   Blattert TR, 2002, SPINE, V27, P2697, DOI 10.1097/00007632 200212010 00009
   Blokhuis TJ, 2001, BIOMATERIALS, V22, P725, DOI 10.1016/S0142 9612(00)00238 6
   Blum JS, 2003, HUM GENE THER, V14, P1689, DOI 10.1089/104303403322611719
   Bodde EWH, 2008, J BIOMED MATER RES A, V87A, P780, DOI 10.1002/jbm.a.31830
   Boden SD, 2000, TISSUE ENG, V6, P383, DOI 10.1089/107632700418092
   Boerckel JD, 2012, J ORTHOP RES, V30, P1067, DOI 10.1002/jor.22042
   Bonfield W, 2006, PHILOS T R SOC A, V364, P227, DOI 10.1098/rsta.2005.1692
   Bordei P, 2011, J BONE JOINT SURG BR, V93B, P1653, DOI 10.1302/0301 620X.93B12.27244
   Borgström F, 2010, OSTEOPOROSIS INT, V21, P495, DOI 10.1007/s00198 009 0989 8
   Borgström F, 2010, OSTEOPOROSIS INT, V21, P339, DOI 10.1007/s00198 009 0971 5
   Bostrom MPG, 2000, BONE, V26, P437, DOI 10.1016/S8756 3282(00)00251 9
   Bouxsein ML, 2001, J BONE JOINT SURG AM, V83A, P1219, DOI 10.2106/00004623 200108000 00012
   Boyne PJ, 2005, J ORAL MAXIL SURG, V63, P1693, DOI 10.1016/j.joms.2005.08.018
   Boyne PJ, 1997, INT J PERIODONT REST, V17, P10
   Boyne PJ, 1998, BRIT J ORAL MAX SURG, V36, P84, DOI 10.1016/S0266 4356(98)90173 5
   Brick KE, 2009, CLIN ORTHOP RELAT R, V467, P3096, DOI 10.1007/s11999 008 0599 3
   Bright C, 2006, SPINE, V31, P2163, DOI 10.1097/01.brs.0000232721.59901.45
   Brouwers JEM, 2009, OSTEOPOROSIS INT, V20, P1823, DOI 10.1007/s00198 009 0882 5
   Brown KV, 2011, TISSUE ENG PT A, V17, P1735, DOI [10.1089/ten.TEA.2010.0446, 10.1089/ten.tea.2010.0446]
   Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131
   Burge R.T., 2001, Journal of Medical Economics, V4, P51
   Burkhart KJ, 2008, J BONE JOINT SURG BR, V90B, P806, DOI 10.1302/0301 620X.90B6.20147
   Burkus JK, 2009, J BONE JOINT SURG AM, V91A, P1181, DOI 10.2106/JBJS.G.01485
   Burkus JK, 2003, J SPINAL DISORD TECH, V16, P113, DOI 10.1097/00024720 200304000 00001
   Burkus JK, 2003, SPINE, V28, P372, DOI 10.1097/00007632 200302150 00012
   Butler DL, 2000, J BIOMECH ENG T ASME, V122, P570, DOI 10.1115/1.1318906
   Buttermann GR, 2008, SPINE J, V8, P426, DOI 10.1016/j.spinee.2006.12.006
   Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582 4934.2005.tb00379.x
   Calori GM, 2008, INJURY, V39, P1391, DOI 10.1016/j.injury.2008.08.011
   Campbell GM, 2011, BONE, V49, P225, DOI 10.1016/j.bone.2011.04.008
   Carli A, 2012, EUR CELLS MATER, V24, P107, DOI 10.22203/eCM.v024a08
   Carreon LY, 2008, SPINE, V33, P391, DOI 10.1097/BRS.0b013e3181642a49
   Carstens MH, 2005, J CRANIOFAC SURG, V16, P1033, DOI 10.1097/01.scs.0000186307.09171.20
   Carter TG, 2008, J ORAL MAXIL SURG, V66, P1417, DOI 10.1016/j.joms.2008.01.058
   Cartmell S, 2009, J PHARM SCI US, V98, P430, DOI 10.1002/jps.21431
   Castañeda S, 2006, SKELETAL RADIOL, V35, P34, DOI 10.1007/s00256 005 0022 z
   Chan G, 2008, TRENDS BIOTECHNOL, V26, P382, DOI 10.1016/j.tibtech.2008.03.011
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chang PC, 2010, GENE THER, V17, P95, DOI 10.1038/gt.2009.117
   Chang PC, 2009, HUM GENE THER, V20, P486, DOI 10.1089/hum.2008.114
   Chang SCN, 2003, GENE THER, V10, P2013, DOI 10.1038/sj.gt.3302106
   Chen XQ, 2006, J BONE JOINT SURG AM, V88A, P1510, DOI 10.2106/JBJS.E.01136
   Chen XQ, 2002, J ORTHOP RES, V20, P142, DOI 10.1016/S0736 0266(01)00060 2
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Choi KS, 2011, ARCH PHARM RES, V34, P599, DOI 10.1007/s12272 011 0410 y
   Choi SJ, 2007, J BIOMED MATER RES A, V83A, P897, DOI 10.1002/jbm.a.31403
   Chu TMG, 2007, BIOMATERIALS, V28, P459, DOI 10.1016/j.biomaterials.2006.09.004
   Chung YI, 2007, J CONTROL RELEASE, V121, P91, DOI 10.1016/j.jconrel.2007.05.029
   Cicciù M, 2012, OPEN DENT J, V6, P51, DOI 10.2174/1874210601206010051
   Cipitria A, 2013, BIOMATERIALS, V34, P9960, DOI 10.1016/j.biomaterials.2013.09.011
   COHEN S, 1993, CLIN MATER, V13, P3, DOI 10.1016/0267 6605(93)90082 I
   COOK SD, 1995, J BONE JOINT SURG AM, V77A, P734, DOI 10.2106/00004623 199505000 00010
   Cook SD, 2002, J INVEST SURG, V15, P69, DOI 10.1080/08941930290085822
   COOK SD, 1994, CLIN ORTHOP RELAT R, P302
   Cook SD, 2005, J BIOMED MATER RES B, V75B, P137, DOI 10.1002/jbm.b.30271
   COOK SD, 1994, J BONE JOINT SURG AM, V76A, P827, DOI 10.2106/00004623 199406000 00006
   Cook SD, 1998, J ORTHOP TRAUMA, V12, P407, DOI 10.1097/00005131 199808000 00007
   COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3
   Cornish J, 1997, ENDOCRINOLOGY, V138, P1299, DOI 10.1210/en.138.3.1299
   Cowan CM, 2007, TISSUE ENG, V13, P501, DOI 10.1089/ten.2006.0141
   Cullinane DM, 2002, J ORTHOPAED RES, V20, P1240, DOI 10.1016/S0736 0266(02)00056 6
   Dahabreh Z, 2007, INJURY, V38, P371, DOI 10.1016/j.injury.2006.08.055
   Daugaard H, 2012, ACTA ORTHOP, V83, P411, DOI 10.3109/17453674.2012.702388
   Daugaard H, 2011, CALCIFIED TISSUE INT, V88, P294, DOI 10.1007/s00223 010 9458 9
   Dawson E, 2009, J BONE JOINT SURG AM, V91A, P1604, DOI 10.2106/JBJS.G.01157
   Dawson JI, 2014, STEM CELLS, V32, P35, DOI 10.1002/stem.1559
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Delgado JJ, 2012, J MATER SCI MATER M, V23, P1903, DOI 10.1007/s10856 012 4661 z
   Delmas PD, 2005, J BONE MINER RES, V20, P557, DOI 10.1359/JBMR.041214
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   den Boer FC, 2003, J ORTHOP RES, V21, P521, DOI 10.1016/S0736 0266(02)00205 X
   den Boer FC, 2002, BONE, V31, P158, DOI 10.1016/S8756 3282(02)00816 5
   Dickinson BP, 2008, PLAST RECONSTR SURG, V121, P209, DOI 10.1097/01.prs.0000293870.64781.12
   Dimar JR, 2009, J BONE JOINT SURG AM, V91A, P1377, DOI 10.2106/JBJS.H.00200
   Dimitriou R, 2005, INJURY, V36, pS51, DOI 10.1016/j.injury.2005.10.010
   Djapic T, 2003, INT ORTHOP, V27, P326, DOI 10.1007/s00264 003 0496 z
   Dohin B, 2009, CLIN ORTHOP RELAT R, V467, P3230, DOI 10.1007/s11999 009 0967 7
   Dohzono S, 2009, CLIN ORTHOP RELAT R, V467, P3206, DOI 10.1007/s11999 009 0960 1
   Doi Y, 2011, BONE, V49, P777, DOI 10.1016/j.bone.2011.07.005
   Donaldson LJ, 2008, J EPIDEMIOL COMMUN H, V62, P174, DOI 10.1136/jech.2006.056622
   Donati D, 2008, INJURY, V39, pS65, DOI 10.1016/S0020 1383(08)70017 2
   Duneas N, 1998, GROWTH FACTORS, V15, P259, DOI 10.3109/08977199809017482
   Dunn CA, 2005, MOL THER, V11, P294, DOI 10.1016/j.ymthe.2004.10.005
   Dunstan CR, 1999, J BONE MINER RES, V14, P953, DOI 10.1359/jbmr.1999.14.6.953
   Dupont KM, 2012, CELL TISSUE RES, V347, P575, DOI 10.1007/s00441 011 1197 3
   Edwards RB, 2004, J BONE JOINT SURG AM, V86A, P1425, DOI 10.2106/00004623 200407000 00010
   Egermann M, 2006, GENE THER, V13, P1290, DOI 10.1038/sj.gt.3302785
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS129, DOI 10.1007/s00198 005 1859 7
   Ekrol I, 2008, INJURY, V39, pS73, DOI 10.1016/S0020 1383(08)70018 4
   El Backly RM, 2013, TISSUE ENG PT A, V19, P152, DOI [10.1089/ten.tea.2012.0357, 10.1089/ten.TEA.2012.0357]
   El Haj AJ, 2005, PATHOL BIOL, V53, P581, DOI 10.1016/j.patbio.2004.12.002
   Engel E, 2008, TISSUE ENG PT A, V14, P1341, DOI 10.1089/ten.tea.2007.0287
   Even J, 2012, J AM ACAD ORTHOP SUR, V20, P547, DOI 10.5435/JAAOS 20 09 547
   Fabeck L, 2006, J BONE JOINT SURG BR, V88B, P116, DOI 10.1302/0301 620X.88B1.16619
   de Castro LF, 2012, J CELL PHYSIOL, V227, P1752, DOI 10.1002/jcp.22902
   Fiorellini JP, 2005, J PERIODONTOL, V76, P605, DOI 10.1902/jop.2005.76.4.605
   Forriol F, 2009, INJURY, V40, P44
   FRAHER LJ, 1992, J CLIN ENDOCR METAB, V75, P417, DOI 10.1210/jc.75.2.417
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Fu K, 2010, J BIOMED MATER RES A, V92A, P1256, DOI 10.1002/jbm.a.32453
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003 4819 158 12 201306180 00006
   Fu TS, 2009, J ORTHOP RES, V27, P380, DOI 10.1002/jor.20644
   Fu YC, 2008, BIOTECHNOL BIOENG, V99, P996, DOI 10.1002/bit.21648
   Fujimura K, 2002, ARCH ORAL BIOL, V47, P577, DOI 10.1016/S0003 9969(02)00046 8
   Fukuroku J, 2007, J BONE JOINT SURG AM, V89A, P1486, DOI 10.2106/JBJS.F.00290
   Gao Y, 2009, J CONTROL RELEASE, V139, P15, DOI 10.1016/j.jconrel.2009.05.032
   Gazit D, 1999, J GENE MED, V1, P121, DOI 10.1002/(SICI)1521 2254(199903/04)1:2<121::AID JGM26>3.0.CO;2 J
   Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301 620X.81B4.9311
   Geetha Loganathan P, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 32
   Geiger F, 2007, BONE, V41, P516, DOI 10.1016/j.bone.2007.06.018
   Gelse K, 2011, TISSUE ENG PT A, V17, P2101, DOI [10.1089/ten.TEA.2010.0691, 10.1089/ten.tea.2010.0691]
   GERHART TN, 1993, CLIN ORTHOP RELAT R, P317
   Geuze RE, 2012, TISSUE ENG PT A, V18, P2052, DOI [10.1089/ten.tea.2011.0560, 10.1089/ten.TEA.2011.0560]
   Ghosh K, 2007, ADV DRUG DELIVER REV, V59, P1306, DOI 10.1016/j.addr.2007.08.014
   Giannoudis PV, 2007, INJURY, V38, pS43, DOI 10.1016/S0020 1383(08)70008 1
   Giannoudis PV, 2009, CLIN ORTHOP RELAT R, V467, P3239, DOI 10.1007/s11999 009 0846 2
   Glassman SD, 2007, SPINE J, V7, P44, DOI 10.1016/j.spinee.2006.06.381
   Glatt V, 2009, J ORTHOP TRAUMA, V23, P693, DOI 10.1097/BOT.0b013e3181b01b2f
   Gomes PS, 2011, LAB ANIM UK, V45, P14, DOI 10.1258/la.2010.010085
   Goodman SB, 2003, J BIOMED MATER RES A, V65A, P454, DOI 10.1002/jbm.a.3000
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Grauer JN, 2004, SPINE, V29, P1405, DOI 10.1097/01.BRS.0000129028.25671.96
   Gray SK, 2012, BONE, V51, P578, DOI 10.1016/j.bone.2012.05.003
   Green D, 2002, BONE, V30, P810, DOI 10.1016/S8756 3282(02)00727 5
   Grimes R, 2011, J BONE MINER RES, V26, P2597, DOI 10.1002/jbmr.486
   Groeneveld EHJ, 1999, CLIN ORAL IMPLAN RES, V10, P499, DOI 10.1034/j.1600 0501.1999.100608.x
   Gu Y, 2011, J BIOMED MATER RES A, V97A, P177, DOI 10.1002/jbm.a.33018
   Guan LM, 2004, J BIOMED MATER RES A, V71A, P480, DOI 10.1002/jbm.a.30173
   Gugala Z, 2007, MACROMOL SYMP, V253, P147, DOI 10.1002/masy.200750722
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Guo X, 2006, BIOMED MATER, V1, P93, DOI 10.1088/1748 6041/1/3/001
   Gutwald R, 2010, J CRANIO MAXILL SURG, V38, P571, DOI 10.1016/j.jcms.2010.02.010
   Haid Regis W Jr, 2004, Spine J, V4, P527, DOI 10.1016/j.spinee.2004.03.025
   Haidar ZS, 2010, BIOMATERIALS, V31, P2746, DOI 10.1016/j.biomaterials.2009.12.034
   Haidar ZS, 2010, GROWTH FACTORS, V28, P44, DOI 10.3109/08977190903367788
   Hak DJ, 2006, J ORTHOP RES, V24, P11, DOI 10.1002/jor.20022
   Hall SL, 2007, MOL THER, V15, P1881, DOI 10.1038/sj.mt.6300258
   Hamdy RC, 2003, BONE, V33, P248, DOI 10.1016/S8756 3282(03)00154 6
   Han SH, 2008, J BIOMED MATER RES A, V87A, P850, DOI 10.1002/jbm.a.31828
   Hasharoni A, 2005, J NEUROSURG SPINE, V3, P47, DOI 10.3171/spi.2005.3.1.0047
   Hayashi C, 2009, J CELL PHYSIOL, V220, P1, DOI 10.1002/jcp.21760
   He DM, 2010, J NEUROSURG, V112, P319, DOI 10.3171/2009.1.JNS08976
   HECKMAN JD, 1991, J BONE JOINT SURG AM, V73A, P750, DOI 10.2106/00004623 199173050 00015
   Henslee AM, 2011, ACTA BIOMATER, V7, P3627, DOI 10.1016/j.actbio.2011.06.043
   Herford AS, 2008, J ORAL MAXIL SURG, V66, P616, DOI 10.1016/j.joms.2007.11.021
   Herford AS, 2012, INT J ORAL MAX IMPL, V27, P1351
   Herford Alan Scott, 2012, Natl J Maxillofac Surg, V3, P172, DOI 10.4103/0975 5950.111374
   Hernández A, 2012, J BIOMED MATER RES A, V100A, P2382, DOI 10.1002/jbm.a.34183
   Hernandez Alfaro Federico, 2012, Int J Periodontics Restorative Dent, V32, pe82
   Hidaka C, 2003, SPINE, V28, P2049, DOI 10.1097/01.BRS.0000091661.11228.C3
   Higuchi T, 1999, J PERIODONTOL, V70, P1026, DOI 10.1902/jop.1999.70.9.1026
   Hirata E, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957 4484/24/43/435101
   HOCK JM, 1989, ENDOCRINOLOGY, V125, P2022, DOI 10.1210/endo 125 4 2022
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Hong KS, 2010, J BIOMED MATER RES A, V94A, P1187, DOI 10.1002/jbm.a.32799
   Horner EA, 2010, TISSUE ENG PART B RE, V16, P263, DOI [10.1089/ten.teb.2009.0224, 10.1089/ten.TEB.2009.0224]
   Horwitz MJ, 2011, J BONE MINER RES, V26, P2287, DOI 10.1002/jbmr.415
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Hosokawa R, 2000, CLIN ORAL IMPLAN RES, V11, P345, DOI 10.1034/j.1600 0501.2000.011004345.x
   Hou J, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/3/035002
   Hou R, 2007, J BIOMED MATER RES A, V80A, P85, DOI 10.1002/jbm.a.30840
   Howard D, 2008, J ANAT, V213, P66, DOI 10.1111/j.1469 7580.2008.00878.x
   Hussein KA, 2012, TISSUE ENG PT A, V18, P665, DOI [10.1089/ten.tea.2011.0148, 10.1089/ten.TEA.2011.0148]
   Hwang CJ, 2010, J NEUROSURG SPINE, V13, P484, DOI 10.3171/2010.4.SPINE09957
   Hyun SJ, 2005, J PERIODONTOL, V76, P1667, DOI 10.1902/jop.2005.76.10.1667
   Inui K, 1998, CALCIFIED TISSUE INT, V63, P490, DOI 10.1007/s002239900563
   Ishihara A, 2008, J ORTHOP RES, V26, P764, DOI 10.1002/jor.20585
   Ishihara A, 2010, J ORTHOP RES, V28, P403, DOI 10.1002/jor.20978
   Itoh T, 1998, J VET MED SCI, V60, P451, DOI 10.1292/jvms.60.451
   Iwaniec UT, 2003, BONE, V33, P380, DOI 10.1016/S8756 3282(03)00118 2
   Iyomasa MM, 2012, MICROSC RES TECHNIQ, V75, P117, DOI 10.1002/jemt.21033
   Jacobson JA, 2011, TISSUE ENG PT A, V17, P389, DOI [10.1089/ten.tea.2010.0115, 10.1089/ten.TEA.2010.0115]
   Jensen TB, 2002, ACTA ORTHOP SCAND, V73, P31, DOI 10.1080/000164702317281378
   Jeppsson C, 1999, ACTA ORTHOP SCAND, V70, P559, DOI 10.3109/17453679908997842
   Jeyabalan J, 2012, J ENDOCRINOL, V214, P349, DOI 10.1530/JOE 12 0184
   JOHNSON EE, 1988, CLIN ORTHOP RELAT R, P249
   JOHNSON EE, 1988, CLIN ORTHOP RELAT R, P257
   Johnsson R, 2002, SPINE, V27, P2654, DOI 10.1097/00007632 200212010 00004
   Jones AL, 2006, J BONE JOINT SURG AM, V88A, P1431, DOI 10.2106/JBJS.E.00381
   Jung RE, 2008, CLIN ORAL IMPLAN RES, V19, P188, DOI 10.1111/j.1600 0501.2007.01431.x
   Jung RE, 2007, CLIN ORAL IMPLAN RES, V18, P319, DOI 10.1111/j.1600 0501.2007.01342.x
   Jung RE, 2007, INT J ORAL MAX IMPL, V22, P258
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kaipel M, 2012, J ORTHOP RES, V30, P1563, DOI 10.1002/jor.22132
   Kaito T, 2005, BIOMATERIALS, V26, P73, DOI 10.1016/j.biomaterials.2004.02.010
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kallai I, 2010, J BIOMECH, V43, P2315, DOI 10.1016/j.jbiomech.2010.04.031
   Kanakaris NK, 2007, INJURY, V38, pS77, DOI 10.1016/S0020 1383(07)80012 X
   Kanakaris NK, 2009, INJURY, V40, P54
   Kanakaris NK, 2008, INJURY, V39, pS83, DOI 10.1016/S0020 1383(08)70019 6
   Kanayama M, 2006, SPINE, V31, P1067, DOI 10.1097/01.brs.0000216444.01888.21
   Kanczler JA, 2008, BIOMATERIALS, V29, P1892, DOI 10.1016/j.biomaterials.2007.12.031
   Kanczler JM, 2012, TISSUE ENG PART C ME, V18, P747, DOI 10.1089/ten.tec.2012.0033
   Kanczler JM, 2010, BIOMATERIALS, V31, P1242, DOI 10.1016/j.biomaterials.2009.10.059
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198 004 1811 2
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Karageorgiou V, 2006, J BIOMED MATER RES A, V78A, P324, DOI 10.1002/jbm.a.30728
   Karaplis AC, 2001, CURR PHARM DESIGN, V7, P655, DOI 10.2174/1381612013397753
   Katayama Y, 2009, INT ORTHOP, V33, P1061, DOI 10.1007/s00264 008 0600 5
   Kawai M, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 62
   Kawai M, 2009, BIOCHEM BIOPH RES CO, V390, P1012, DOI 10.1016/j.bbrc.2009.10.099
   Keaveny TM, 2012, BONE, V50, P165, DOI 10.1016/j.bone.2011.10.002
   Keaveny TM, 2008, J BONE MINER RES, V23, P1974, DOI [10.1359/jbmr.080805, 10.1359/JBMR.080805]
   KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248
   Keeney M, 2010, BIOMATERIALS, V31, P2893, DOI 10.1016/j.biomaterials.2009.12.041
   Kelpke SS, 2004, J BIOMED MATER RES A, V71A, P316, DOI 10.1002/jbm.a.30163
   Kempen DHR, 2010, TISSUE ENG PT A, V16, P3769, DOI [10.1089/ten.tea.2010.0173, 10.1089/ten.TEA.2010.0173]
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   KENLEY R, 1994, J BIOMED MATER RES, V28, P1139, DOI 10.1002/jbm.820281004
   Khan SN, 2004, BIOMATERIALS, V25, P1475, DOI 10.1016/S0142 9612(03)00491 5
   Kidder LS, 2009, CLIN ORTHOP RELAT R, V467, P3249, DOI 10.1007/s11999 008 0405 2
   Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116
   Kim HM, 2011, CONNECT TISSUE RES, V52, P87, DOI 10.3109/03008207.2010.483026
   Kim H W, 1999, Iowa Orthop J, V19, P71
   Kim HK, 2009, TISSUE ENG PT A, V15, P923, DOI 10.1089/ten.tea.2007.0407
   Kim J, 2012, J TISSUE ENG REGEN M, V6, P404, DOI 10.1002/term.442
   Kim PD, 2010, J SPINAL DISORD TECH, V23, P215, DOI 10.1097/BSD.0b013e31819cc5fb
   Kim SJ, 2010, INT J ORAL MAX SURG, V39, P883, DOI 10.1016/j.ijom.2010.05.004
   Kim SS, 2008, J BIOMED MATER RES A, V87A, P245, DOI 10.1002/jbm.a.31782
   Kimelman Bleich N, 2009, BIOMATERIALS, V30, P4639, DOI 10.1016/j.biomaterials.2009.05.027
   KIMMEL DB, 1982, ANAT RECORD, V203, P31, DOI 10.1002/ar.1092030104
   Kimura Y, 2010, TISSUE ENG PT A, V16, P1263, DOI [10.1089/ten.tea.2009.0322, 10.1089/ten.TEA.2009.0322]
   Kinsella CR, 2011, PLAST RECONSTR SURG, V127, P1865, DOI 10.1097/PRS.0b013e31820cf2c9
   Kirker Head CA, 1998, CLIN ORTHOP RELAT R, P205, DOI 10.1097/00003086 199804000 00026
   Klimo P, 2009, SPINE J, V9, P959, DOI 10.1016/j.spinee.2009.05.008
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Kodama N, 2009, BONE, V44, P699, DOI 10.1016/j.bone.2008.12.017
   Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906
   Kokubo S, 2004, BIOMATERIALS, V25, P1795, DOI 10.1016/j.biomaterials.2003.08.030
   Kolambkar YM, 2011, BONE, V49, P485, DOI 10.1016/j.bone.2011.05.010
   Komaki H, 2006, BIOMATERIALS, V27, P5118, DOI 10.1016/j.biomaterials.2006.05.031
   Komatsu DE, 2009, ENDOCRINOLOGY, V150, P1570, DOI 10.1210/en.2008 0814
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Komrakova M, 2011, J ENDOCRINOL, V209, P9, DOI 10.1530/JOE 10 0353
   Kovacevic D, 2011, AM J SPORT MED, V39, P811, DOI 10.1177/0363546511399378
   Kraiwattanapong C, 2005, SPINE, V30, P1001, DOI 10.1097/01.brs.0000160997.91502.3b
   Kuchler U, 2011, J DENT RES, V90, P1001, DOI 10.1177/0022034511407920
   Kumar S, 2010, GENE THER, V17, P105, DOI 10.1038/gt.2009.116
   Kumar S, 2010, MOL THER, V18, P1026, DOI 10.1038/mt.2009.315
   Kwan MD, 2011, J BIOL CHEM, V286, P11307, DOI 10.1074/jbc.M110.180042
   Kwon YD, 2012, OSTEOPOROSIS INT, V23, P2721, DOI 10.1007/s00198 011 1882 9
   Lamerigts NMP, 2000, BIOMATERIALS, V21, P741, DOI 10.1016/S0142 9612(99)00247 1
   Lammens J, 2009, ACTA ORTHOP BELG, V75, P103
   Lane NE, 2003, OSTEOPOROSIS INT, V14, P374, DOI 10.1007/s00198 003 1374 7
   Lane NE, 2003, J BONE MINER RES, V18, P2105, DOI 10.1359/jbmr.2003.18.12.2105
   Laschke MW, 2008, J BIOMED MATER RES A, V85A, P397, DOI 10.1002/jbm.a.31503
   Laursen M, 1999, EUR SPINE J, V8, P485, DOI 10.1007/s005860050210
   Lawrence James P, 2006, Spine J, V6, P385, DOI 10.1016/j.spinee.2005.10.010
   Lazard ZW, 2011, J CELL BIOCHEM, V112, P1563, DOI 10.1002/jcb.23068
   Lee FYI, 2006, J BONE JOINT SURG AM, V88A, P627, DOI 10.2106/JBJS.D.02201
   Lee JH, 2004, IEEE ROBOT AUTOM MAG, V11, P41
   Lee JY, 2001, J BONE JOINT SURG AM, V83A, P1032, DOI 10.2106/00004623 200107000 00008
   Lee JY, 2002, J CONTROL RELEASE, V78, P187, DOI 10.1016/S0168 3659(01)00498 9
   Lee KB, 2011, SPINE J, V11, P568, DOI 10.1016/j.spinee.2011.02.001
   Lee SJ, 2001, J BIOMED MATER RES, V55, P295, DOI 10.1002/1097 4636(20010605)55:3<295::AID JBM1017>3.0.CO;2 W
   Lee SJ, 2010, BIOMATERIALS, V31, P5652, DOI 10.1016/j.biomaterials.2010.03.019
   Lee YM, 2000, J PERIODONTOL, V71, P418, DOI 10.1902/jop.2000.71.3.418
   Lee YJ, 2013, BIOMATERIALS, V34, P5059, DOI 10.1016/j.biomaterials.2013.03.051
   Lehman RA, 2010, SPINE, V35, P146, DOI 10.1097/BRS.0b013e3181b71a96
   Leknes KN, 2008, J CLIN PERIODONTOL, V35, P914, DOI 10.1111/j.1600 051X.2008.01308.x
   Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102
   Leslie WD, 2012, OSTEOPOROSIS INT, V23, P75, DOI 10.1007/s00198 011 1747 2
   Leung KS, 2001, J BONE MINER RES, V16, P2348, DOI 10.1359/jbmr.2001.16.12.2348
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Li GH, 2009, TISSUE ENG PT A, V15, P2123, DOI 10.1089/ten.tea.2008.0214
   Li JH, 2010, J BIOMED MATER RES A, V95A, P973, DOI 10.1002/jbm.a.32926
   Li M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P77
   Li M, 2010, CLIN ORTHOP RELAT R, V468, P1978, DOI 10.1007/s11999 010 1321 9
   Li RH, 2003, J ORTHOP RES, V21, P997, DOI 10.1016/S0736 0266(03)00082 2
   Li R, 2009, J ORTHOP RES, V27, P8, DOI 10.1002/jor.20658
   Li YF, 2013, OSTEOPOROSIS INT, V24, P1063, DOI 10.1007/s00198 012 2258 5
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   Liebschner MAK, 2004, BIOMATERIALS, V25, P1697, DOI 10.1016/S0142 9612(03)00515 5
   Lin CY, 2012, BIOMATERIALS, V33, P3682, DOI 10.1016/j.biomaterials.2012.02.007
   Lin CY, 2010, BIOMATERIALS, V31, P3222, DOI 10.1016/j.biomaterials.2010.01.030
   Lin EA, 2012, J ORTHOP TRAUMA, V26, P719, DOI 10.1097/BOT.0b013e31826f5b9e
   Lin YF, 2008, HISTOCHEM CELL BIOL, V129, P203, DOI 10.1007/s00418 007 0351 1
   Lin Z, 2013, GENE THER, V20, P1, DOI 10.1038/gt.2011.203
   Lind M, 2001, J BIOMED MATER RES, V55, P89
   Lindsey RW, 2006, J ORTHOP RES, V24, P1438, DOI 10.1002/jor.20154
   Liu FJ, 2012, J ORTHOP RES, V30, P1095, DOI 10.1002/jor.22038
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu SSY, 2013, AM J ORTHOD DENTOFAC, V144, P210, DOI 10.1016/j.ajodo.2013.03.017
   Lozano D, 2010, BRIT J PHARMACOL, V162, P1424
   Lozano D, 2009, ENDOCRINOLOGY, V150, P2027, DOI 10.1210/en.2008 1108
   Luca L, 2011, J BIOMED MATER RES A, V96A, P66, DOI 10.1002/jbm.a.32957
   Luca L, 2010, J CONTROL RELEASE, V147, P38, DOI 10.1016/j.jconrel.2010.06.011
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Ma T, 2007, BONE, V41, P386, DOI 10.1016/j.bone.2007.05.015
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Madry H, 2010, ARCH ORTHOP TRAUM SU, V130, P1311, DOI 10.1007/s00402 010 1130 3
   Maehara H, 2010, J ORTHOP RES, V28, P677, DOI 10.1002/jor.21032
   Magin MN, 2001, SPINE, V26, P469, DOI 10.1097/00007632 200103010 00009
   Makino T, 2005, J ORTHOP RES, V23, P632, DOI 10.1016/j.orthres.2004.09.009
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Issa JPM, 2012, MICROSC RES TECHNIQ, V75, P145, DOI 10.1002/jemt.21037
   Issa JPM, 2010, ANAT REC, V293, P794, DOI 10.1002/ar.21097
   Issa JPM, 2009, MICRON, V40, P560, DOI 10.1016/j.micron.2009.03.003
   MARDEN LJ, 1994, J BIOMED MATER RES, V28, P1127, DOI 10.1002/jbm.820281003
   MARDEN LJ, 1993, J CLIN INVEST, V92, P2897, DOI 10.1172/JCI116912
   Marques MR, 2005, ARCH ORAL BIOL, V50, P421, DOI 10.1016/j.archoralbio.2004.08.014
   Martino MM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002614
   Marukawa E, 2002, INT J ORAL MAX SURG, V31, P287, DOI 10.1054/ijom.2001.0207
   Marukawa E, 2001, BRIT J ORAL MAX SURG, V39, P452, DOI 10.1054/bjom.2001.0673
   Maus U, 2008, J BIOMATER APPL, V22, P559, DOI 10.1177/0885328207083311
   MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583
   Mayer M, 1996, PLAST RECONSTR SURG, V98, P247, DOI 10.1097/00006534 199608000 00006
   McGee MA, 2004, J ORTHOP RES, V22, P1008, DOI 10.1016/j.orthres.2004.01.005
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   McMahon LA, 2008, REGEN MED, V3, P743, DOI 10.2217/17460751.3.5.743
   Menendez MI, 2011, OSTEOARTHR CARTILAGE, V19, P1066, DOI 10.1016/j.joca.2011.05.007
   Meng XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037569
   Meraw SJ, 2000, J PERIODONTOL, V71, P8, DOI 10.1902/jop.2000.71.1.8
   Mesfin A, 2013, J BONE JOINT SURG AM, V95A, P1546, DOI 10.2106/JBJS.L.01730
   Mimura T, 2011, J BIOMED MATER RES B, V98B, P360, DOI 10.1002/jbm.b.31859
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Miyazaki M, 2008, J SPINAL DISORD TECH, V21, P372, DOI 10.1097/BSD.0b013e31814cf51d
   Mizumoto Y, 2003, J BONE JOINT SURG AM, V85A, P124, DOI 10.2106/00004623 200300003 00019
   Mladenov KV, 2010, EUR SPINE J, V19, pS135, DOI 10.1007/s00586 009 1179 2
   Mohan S, 2000, BONE, V27, P471, DOI 10.1016/S8756 3282(00)00355 0
   Mont MA, 2001, J BONE JOINT SURG AM, V83A, P1013, DOI 10.2106/00004623 200107000 00006
   Moore DC, 2009, J BONE JOINT SURG AM, V91A, P1973, DOI 10.2106/JBJS.H.00540
   Morgan EF, 2008, BONE, V43, P1031, DOI 10.1016/j.bone.2008.07.251
   Mori M, 2000, J BIOMED MATER RES, V50, P191, DOI 10.1002/(SICI)1097 4636(200005)50:2<191::AID JBM14>3.0.CO;2 0
   MOSEKILDE L, 1993, BONE, V14, P379, DOI 10.1016/8756 3282(93)90167 9
   Moshel YA, 2008, J NEUROSURG SPINE, V8, P589, DOI 10.3171/SPI/2008/8/6/589
   Mrugala D, 2008, ANN RHEUM DIS, V67, P288, DOI 10.1136/ard.2007.076620
   Mumaw J, 2012, INT J BIOMATER, V2012, DOI 10.1155/2012/861794
   Murakami N, 2003, BIOMATERIALS, V24, P2153, DOI 10.1016/S0142 9612(03)00041 3
   Murakami N, 2002, J BIOMED MATER RES, V62, P169, DOI 10.1002/jbm.10236
   Murphy WL, 1999, J PERIODONTAL RES, V34, P413, DOI 10.1111/j.1600 0765.1999.tb02275.x
   Musgrave DS, 1999, BONE, V24, P541, DOI 10.1016/S8756 3282(99)00086 1
   Na K, 2006, BIOMATERIALS, V27, P5951, DOI 10.1016/j.biomaterials.2006.08.012
   NAGAI H, 1995, BONE, V16, P367, DOI 10.1016/8756 3282(94)00049 2
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nakamura T, 1998, J BONE MINER RES, V13, P942, DOI 10.1359/jbmr.1998.13.6.942
   Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011 3479
   Nakamura Y, 2005, BONE, V36, P399, DOI 10.1016/j.bone.2004.11.010
   Nakasa T, 2005, J BIOMED MATER RES A, V75A, P350, DOI 10.1002/jbm.a.30435
   Nakasa T, 2008, J BIOMED MATER RES A, V85A, P1090, DOI 10.1002/jbm.a.31673
   Nalesso G, 2011, J CELL BIOL, V193, P551, DOI 10.1083/jcb.201011051
   NASH TJ, 1994, BONE, V15, P203, DOI 10.1016/8756 3282(94)90709 9
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nevins M, 2003, J PERIODONTOL, V74, P1282, DOI 10.1902/jop.2003.74.9.1282
   NEWMAN E, 1995, BONE, V16, pS277, DOI 10.1016/S8756 3282(95)80121 9
   Neyt J G, 1998, Iowa Orthop J, V18, P118
   NILSSON OS, 1986, J BONE JOINT SURG BR, V68, P635, DOI 10.1302/0301 620X.68B4.3733844
   Niziolek PJ, 2009, J CELL PHYSIOL, V221, P579, DOI 10.1002/jcp.21887
   Nociti Junior F H, 2000, Implant Dent, V9, P321, DOI 10.1097/00008505 200009040 00007
   Nozaka K, 2008, BONE, V42, P90, DOI 10.1016/j.bone.2007.08.041
   Nussenbaum B, 2003, HUM GENE THER, V14, P1107, DOI 10.1089/104303403322124819
   O'Loughlin PF, 2008, J BONE JOINT SURG AM, V90A, P79, DOI 10.2106/JBJS.G.01585
   O'Loughlin PF, 2009, SPINE, V34, P121, DOI 10.1097/BRS.0b013e318191e687
   O'Shaughnessy BA, 2008, SPINE, V33, pE132, DOI 10.1097/BRS.0b013e3181657ee3
   Oest ME, 2007, J ORTHOP RES, V25, P941, DOI 10.1002/jor.20372
   Ohura K, 1999, J BIOMED MATER RES, V44, P168, DOI 10.1002/(SICI)1097 4636(199902)44:2<168::AID JBM7>3.0.CO;2 4
   Olabisi RM, 2010, TISSUE ENG PT A, V16, P3727, DOI 10.1089/ten.TEA.2010.0234
   Ong KL, 2010, SPINE, V35, P1794, DOI 10.1097/BRS.0b013e3181ecf6e4
   ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756 3282(95)00332 2
   Opperman LA, 2002, ANAT RECORD, V267, P120, DOI 10.1002/ar.10094
   Ornitz DM, 2001, GENOME BIOL, V2
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Osawa K, 2009, J GENE MED, V11, P633, DOI 10.1002/jgm.1331
   Papanna MC, 2012, INJURY, V43, P1135, DOI 10.1016/j.injury.2012.03.007
   Park J, 2007, BIOMATERIALS, V28, P2772, DOI 10.1016/j.biomaterials.2007.02.009
   Park J, 2003, GENE THER, V10, P1089, DOI 10.1038/sj.gt.3301960
   Park JS, 2011, BIOMATERIALS, V32, P1495, DOI 10.1016/j.biomaterials.2010.11.003
   Park JS, 2012, BIOMATERIALS, V33, P7151, DOI 10.1016/j.biomaterials.2012.06.023
   Park JS, 2010, J BIOMED MATER RES A, V92A, P988, DOI 10.1002/jbm.a.32341
   Park JS, 2010, J BIOMED MATER RES A, V92A, P806, DOI 10.1002/jbm.a.32388
   Park JS, 2009, J BIOMED MATER RES A, V91A, P408, DOI 10.1002/jbm.a.32271
   Park SY, 2013, TISSUE ENG PT A, V19, P2495, DOI 10.1089/ten.tea.2012.0648
   Park YJ, 2000, BIOMATERIALS, V21, P153
   Park YJ, 1998, J CONTROL RELEASE, V51, P201, DOI 10.1016/S0168 3659(97)00169 7
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Pearce AI, 2007, EUR CELLS MATER, V13, P1
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Phillips Frank M, 2006, Spine J, V6, P500, DOI 10.1016/j.spinee.2006.01.014
   Plotkin H, 1998, J CLIN ENDOCR METAB, V83, P2786, DOI 10.1210/jc.83.8.2786
   PODBESEK R, 1983, ENDOCRINOLOGY, V112, P1000, DOI 10.1210/endo 112 3 1000
   Portal Núñez S, 2010, FEBS LETT, V584, P3095, DOI 10.1016/j.febslet.2010.05.047
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Qing W., 2012, J BIOMED BIOTECHNOL, V2012, DOI 10.1155/2012/ 410879.84
   Qiu Z, 2013, OSTEOPOROSIS INT, V24, P2693, DOI 10.1007/s00198 013 2385 7
   Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009
   Quaglia F, 2008, INT J PHARMACEUT, V364, P281, DOI 10.1016/j.ijpharm.2008.04.030
   Quesada Gómez JM, 2011, OSTEOPOROSIS INT, V22, P2529, DOI 10.1007/s00198 010 1460 6
   Ramazanoglu M, 2011, CLIN ORAL IMPLAN RES, V22, P1433, DOI 10.1111/j.1600 0501.2010.02133.x
   Ranly DM, 2005, J BONE JOINT SURG AM, V87A, P2052, DOI 10.2106/JBJS.D.02752
   Ravaglioli A, 1996, BIOMATERIALS, V17, P617, DOI 10.1016/0142 9612(96)88712 6
   Reddi AH, 2000, TISSUE ENG, V6, P351, DOI 10.1089/107632700418074
   Reichert JC, 2011, J TISSUE ENG REGEN M, V5, P831, DOI 10.1002/term.392
   Reichert JC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003720
   Reichert JC, 2009, BIOMATERIALS, V30, P2149, DOI 10.1016/j.biomaterials.2008.12.050
   Ren YX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023060
   Reyes R, 2012, INJURY, V43, P334, DOI 10.1016/j.injury.2011.10.008
   Reynolds DG, 2011, BONE, V48, P562, DOI 10.1016/j.bone.2010.10.003
   Riedel GE, 1999, ORTHOPEDICS, V22, P663
   Rihani Bisharat S, 1998, ENDOCRINOLOGY, V139, P974, DOI 10.1210/en.139.3.974
   Rimondini L, 2005, ORAL SURG ORAL MED O, V99, P148, DOI 10.1016/j.tripleo.2004.05.010
   Ripamonti U, 1996, GROWTH FACTORS, V13, P273, DOI 10.3109/08977199609003228
   Ripamonti U, 1997, J BONE MINER RES, V12, P1584, DOI 10.1359/jbmr.1997.12.10.1584
   Ripamonti U, 2009, J PERIODONTAL RES, V44, P81, DOI 10.1111/j.1600 0765.2008.01086.x
   Ripamonti U, 2001, PLAST RECONSTR SURG, V107, P977, DOI 10.1097/00006534 200104010 00012
   Ripamonti U, 2001, J BONE JOINT SURG AM, V83A, pS116
   Ripamonti U, 2000, J BONE MINER RES, V15, P1798, DOI 10.1359/jbmr.2000.15.9.1798
   Ripamonti U, 2008, J CELL MOL MED, V12, P1029, DOI 10.1111/j.1582 4934.2008.00126.x
   Ripamonti U, 2010, BIOMATERIALS, V31, P6400, DOI 10.1016/j.biomaterials.2010.04.037
   Ripamonti U, 2009, J CRANIOFAC SURG, V20, P1544, DOI 10.1097/SCS.0b013e3181b09ca6
   Ristiniemi J, 2007, J BONE JOINT SURG BR, V89B, P265, DOI 10.1302/0301 620X.89B2.18230
   Rizk A, 2013, CYTOTHERAPY, V15, P712, DOI 10.1016/j.jcyt.2013.01.012
   Roberts MD, 2009, J BIOMECH, V42, P2431, DOI 10.1016/j.jbiomech.2009.08.030
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Roldán JC, 2010, J CRANIO MAXILL SURG, V38, P423, DOI 10.1016/j.jcms.2010.01.003
   Roldán JC, 2004, BONE, V34, P80, DOI 10.1016/j.bone.2003.09.011
   Ronga M, 2006, INJURY, V37, pS51, DOI 10.1016/j.injury.2006.08.024
   Roosa SMM, 2010, J BIOMED MATER RES A, V92A, P359, DOI 10.1002/jbm.a.32381
   Rowshan HH, 2010, J ORAL MAXIL SURG, V68, P260, DOI 10.1016/j.joms.2009.09.045
   Rozen N, 2007, BONE, V41, P437, DOI 10.1016/j.bone.2007.04.193
   Ryder KM, 2010, J BONE MINER METAB, V28, P233, DOI 10.1007/s00774 009 0123 1
   Saito N, 2003, BONE, V32, P381, DOI 10.1016/S8756 3282(03)00028 0
   Salkeld SL, 2001, J BONE JOINT SURG AM, V83A, P803, DOI 10.2106/00004623 200106000 00001
   Samee M, 2008, J PHARMACOL SCI, V108, P18, DOI 10.1254/jphs.08036FP
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   Sandhu HS, 1995, SPINE, V20, P2669, DOI 10.1097/00007632 199512150 00008
   Santana RB, 2006, INT J ORAL MAX IMPL, V21, P711
   Sarban S, 2009, CLIN ORTHOP RELAT R, V467, P3113, DOI 10.1007/s11999 009 1004 6
   Sawada Y, 2009, ORAL SURG ORAL MED O, V108, P812, DOI 10.1016/j.tripleo.2009.06.040
   Schafer AL, 2013, OSTEOPOROSIS INT, V24, P2591, DOI 10.1007/s00198 013 2349 y
   Schauss SM, 2006, ARCH ORTHOP TRAUM SU, V126, P324, DOI 10.1007/s00402 006 0132 7
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Schmidmaier G, 2002, BONE, V30, P816, DOI 10.1016/S8756 3282(02)00740 8
   Schopper C, 2008, J BIOMED MATER RES A, V85A, P954, DOI 10.1002/jbm.a.31525
   Schwarz C, 2013, TISSUE ENG PT A, V19, P247, DOI [10.1089/ten.TEA.2012.0265, 10.1089/ten.tea.2012.0265]
   Sciadini MF, 2000, J ORTHOP RES, V18, P289, DOI 10.1002/jor.1100180218
   Seeherman HJ, 2004, J BONE JOINT SURG AM, V86A, P1961, DOI 10.2106/00004623 200409000 00015
   Semino CE, 2008, J DENT RES, V87, P606, DOI 10.1177/154405910808700710
   Sheehan JP, 2003, J NEUROSURG, V98, P125, DOI 10.3171/jns.2003.98.1.0125
   Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142 9612(03)00339 9
   Shirakata Y, 2010, J CLIN PERIODONTOL, V37, P374, DOI 10.1111/j.1600 051X.2010.01539.x
   Sigurdsson TJ, 1996, INT J PERIODONT REST, V16, P525
   Sigurdsson TJ, 1997, CLIN ORAL IMPLAN RES, V8, P367, DOI 10.1034/j.1600 0501.1997.080503.x
   SIGURDSSON TJ, 1995, J PERIODONTOL, V66, P131, DOI 10.1902/jop.1995.66.2.131
   Simmons CA, 2004, BONE, V35, P562, DOI 10.1016/j.bone.2004.02.027
   Singh K, 2006, J SPINAL DISORD TECH, V19, P416, DOI 10.1097/00024720 200608000 00008
   Skurla CP, 2005, J BIOMED MATER RES B, V73B, P260, DOI 10.1002/jbm.b.30204
   Sloan AV, 2010, BONE, V47, P235, DOI 10.1016/j.bone.2010.05.015
   Smith EL, 2014, ACTA BIOMATER, V10, P4186, DOI 10.1016/j.actbio.2014.06.011
   Smith EL, 2014, ACTA BIOMATER, V10, P4197, DOI 10.1016/j.actbio.2014.05.025
   Smith EL, 2013, EUR CELLS MATER, V26, P91, DOI 10.22203/eCM.v026a07
   Smith EL, 2012, TISSUE ENG PART C ME, V18, P984, DOI [10.1089/ten.tec.2012.0132, 10.1089/ten.TEC.2012.0132]
   Soballe K, 2004, J BIOMED MATER RES A, V71A, P569, DOI 10.1002/jbm.a.30115
   Southwood LL, 2004, J ORTHOP RES, V22, P66, DOI 10.1016/S0736 0266(03)00129 3
   Southwood LL, 2012, VET SURG, V41, P345, DOI 10.1111/j.1532 950X.2011.00947.x
   Spiro AS, 2010, J ORTHOP RES, V28, P785, DOI 10.1002/jor.21044
   Wang CF, 2013, J ORTHOP RES, V31, P1366, DOI 10.1002/jor.22369
   Lian Z, 2010, J ORTHOP RES, V28, P412, DOI 10.1002/jor.20973
   Springer ING, 2008, J CRANIO MAXILL SURG, V36, P210, DOI 10.1016/j.jcms.2007.09.001
   Srouji S, 2011, TISSUE ENG PT A, V17, P269, DOI [10.1089/ten.tea.2010.0250, 10.1089/ten.TEA.2010.0250]
   Steinhardt Y, 2008, TISSUE ENG PT A, V14, P1763, DOI 10.1089/ten.tea.2008.0007
   Stephan SJ, 2010, LARYNGOSCOPE, V120, P895, DOI 10.1002/lary.20624
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Ström O, 2013, OSTEOPOROSIS INT, V24, P1491, DOI 10.1007/s00198 012 2115 6
   Sumner DR, 2004, J ORTHOP RES, V22, P58, DOI 10.1016/S0736 0266(03)00127 X
   Sun HL, 2012, TISSUE ENG PT A, V18, P2095, DOI [10.1089/ten.tea.2011.0742, 10.1089/ten.TEA.2011.0742]
   Sun P, 2012, DENT MATER J, V31, P239, DOI 10.4012/dmj.2011 191
   Sundelacruz S, 2009, SEMIN CELL DEV BIOL, V20, P646, DOI 10.1016/j.semcdb.2009.03.017
   Suzuki Y, 2000, J BIOMED MATER RES, V50, P405, DOI 10.1002/(SICI)1097 4636(20000605)50:3<405::AID JBM15>3.0.CO;2 Z
   Swiontkowski MF, 2006, J BONE JOINT SURG AM, V88A, P1258, DOI 10.2106/JBJS.E.00499
   Tabata Y, 2003, TISSUE ENG, V9, pS5, DOI 10.1089/10763270360696941
   Taghavi CE, 2010, SPINE, V35, P1144, DOI 10.1097/BRS.0b013e3181bb5203
   Tägil M, 2003, ACTA ORTHOP SCAND, V74, P742, DOI 10.1080/00016470310018306
   Tägil M, 2010, BONE, V46, P852, DOI 10.1016/j.bone.2009.11.009
   Takahata M, 2012, J BONE MINER RES, V27, P26, DOI 10.1002/jbmr.518
   Takayama S, 2001, J DENT RES, V80, P2075, DOI 10.1177/00220345010800121001
   Takechi M, 2008, J MATER SCI MATER M, V19, P2949, DOI 10.1007/s10856 008 3416 3
   Takigami H, 2007, J ORTHOP RES, V25, P1333, DOI 10.1002/jor.20411
   Takimoto Y, 2003, CELL TRANSPLANT, V12, P413, DOI 10.3727/000000003108746966
   Tan Z, 2009, CYTOTHERAPY, V11, P317, DOI 10.1080/14653240902824757
   Tang QO, 2009, EXPERT OPIN BIOL TH, V9, P689, DOI [10.1517/14712590902936823 , 10.1517/14712590902936823]
   Teare JA, 2008, J PERIODONTAL RES, V43, P1, DOI 10.1111/j.1600 0765.2007.00987.x
   Terella A, 2010, ARCH FACIAL PLAST S, V12, P166, DOI 10.1001/archfacial.2010.37
   Terheyden H, 2001, INT J ORAL MAX SURG, V30, P469, DOI 10.1054/ijom.2000.0008
   Thorey F, 2011, INDIAN J ORTHOP, V45, P57, DOI 10.4103/0019 5413.73659
   Thorwarth M, 2005, J ORAL MAXIL SURG, V63, P1626, DOI 10.1016/j.joms.2005.06.010
   Tölli H, 2011, INT ORTHOP, V35, P615, DOI 10.1007/s00264 010 1034 4
   Trejo CG, 2010, BIOMATERIALS, V31, P8564, DOI 10.1016/j.biomaterials.2010.07.103
   Tressler MA, 2011, ORTHOPEDICS, V34, P955, DOI 10.3928/01477447 20111021 09
   Triplett RG, 2009, J ORAL MAXIL SURG, V67, P1947, DOI 10.1016/j.joms.2009.04.085
   Tsiridis E, 2007, J ORTHOP RES, V25, P1425, DOI 10.1002/jor.20387
   Tsiridis E, 2007, J ORTHOP RES, V25, P1193, DOI 10.1002/jor.20420
   Tsuchie H, 2013, TOHOKU J EXP MED, V229, P19, DOI 10.1620/tjem.229.19
   Tsurushima H, 2010, ACTA BIOMATER, V6, P2751, DOI 10.1016/j.actbio.2009.12.045
   Tsuzuki N, 2012, RES VET SCI, V93, P1021, DOI 10.1016/j.rvsc.2011.12.002
   Turgeman G, 2001, J GENE MED, V3, P240
   Turner NJ, 2013, BIRTH DEFECTS RES C, V99, P149, DOI 10.1002/bdrc.21040
   Ueki K, 2003, J CRANIO MAXILL SURG, V31, P107, DOI 10.1016/S1010 5182(02)00187 7
   URIST MR, 1971, J DENT RES, V50, P1392, DOI 10.1177/00220345710500060601
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Vaccaro AR, 2004, SPINE, V29, P1885, DOI 10.1097/01.brs.0000137062.79201.98
   Vaccaro AR, 2003, EUR SPINE J, V12, P495, DOI 10.1007/s00586 003 0561 8
   Vaccaro AR, 2005, EUR SPINE J, V14, P623, DOI 10.1007/s00586 004 0845 7
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Vahle JL, 2008, J BONE MINER RES, V23, P2033, DOI 10.1359/JBMR.080807
   van Amerongen R, 2012, DEV BIOL, V369, P101, DOI 10.1016/j.ydbio.2012.06.020
   van den Bergh JPA, 2000, J CLIN PERIODONTOL, V27, P627, DOI 10.1034/j.1600 051x.2000.027009627.x
   van der Stok J, 2013, TISSUE ENG PT A, V19, P2605, DOI [10.1089/ten.tea.2013.0181, 10.1089/ten.TEA.2013.0181]
   Van Staa TP, 2001, BONE, V29, P517, DOI 10.1016/S8756 3282(01)00614 7
   Vickery BH, 1996, J BONE MINER RES, V11, P1943
   Vogt S, 2009, BIOMATERIALS, V30, P2385, DOI 10.1016/j.biomaterials.2009.01.016
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Wang JX, 2012, J CLIN PERIODONTOL, V39, P98, DOI 10.1111/j.1600 051X.2011.01807.x
   Wang RY, 2009, ANAT REC, V292, P777, DOI 10.1002/ar.20904
   Warnke PH, 2006, BIOMATERIALS, V27, P1081, DOI 10.1016/j.biomaterials.2005.07.042
   Wei GB, 2007, BIOMATERIALS, V28, P2087, DOI 10.1016/j.biomaterials.2006.12.028
   WEIR EC, 1992, CALCIFIED TISSUE INT, V51, P30, DOI 10.1007/BF00296214
   Welch RD, 1998, J BONE MINER RES, V13, P1483, DOI 10.1359/jbmr.1998.13.9.1483
   Wernike E, 2010, EUR CELLS MATER, V19, P30
   Whang K, 1998, J BIOMED MATER RES, V42, P491, DOI 10.1002/(SICI)1097 4636(19981215)42:4<491::AID JBM3>3.0.CO;2 F
   Wikesjö UME, 2008, J CLIN PERIODONTOL, V35, P1001, DOI 10.1111/j.1600 051X.2008.01321.x
   Wolf M, 2012, TISSUE ENG PT A, V18, P1849, DOI [10.1089/ten.TEA.2011.0626, 10.1089/ten.tea.2011.0626]
   Woo BH, 2001, PHARMACEUT RES, V18, P1747, DOI 10.1023/A:1013382832091
   Xiao CW, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/1/015013
   Xiao CW, 2010, INT J MOL MED, V26, P517, DOI 10.3892/ijmm_00000494
   Xu L, 2012, J MATER SCI MATER M, V23, P1073, DOI 10.1007/s10856 012 4558 x
   Xue YB, 2005, J BONE MINER RES, V20, P1766, DOI 10.1359/JBMR.050608
   Yang L, 2010, J PERIODONTAL RES, V45, P532, DOI 10.1111/j.1600 0765.2009.01268.x
   Yang M, 2005, CYTOTHERAPY, V7, P273, DOI 10.1080/14653240510027244
   Yang XB, 2003, J BONE MINER RES, V18, P47, DOI 10.1359/jbmr.2003.18.1.47
   Yang X, 2013, BONE, V52, P308, DOI 10.1016/j.bone.2012.09.039
   Yang XC, 2020, J BIOMED MATER RES A, V108, P2519, DOI 10.1002/jbm.a.34064
   YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623 199274050 00005
   Yazici C, 2011, MOL THER, V19, P1416, DOI 10.1038/mt.2010.294
   Yokota S, 2001, INT J PHARMACEUT, V223, P69, DOI 10.1016/S0378 5173(01)00728 1
   Young S, 2009, TISSUE ENG PT A, V15, P2347, DOI 10.1089/ten.tea.2008.0510
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Yu NYC, 2010, EUR CELLS MATER, V20, P431
   Yu XH, 2012, J MATER SCI MATER M, V23, P2177, DOI 10.1007/s10856 012 4682 7
   Yu YY, 2010, BONE, V47, P65, DOI 10.1016/j.bone.2010.03.012
   Yudell RM, 2000, J ORAL MAXIL SURG, V58, P761, DOI 10.1053/joms.2000.7261
   Yun JI, 2010, J CLIN PERIODONTOL, V37, P419, DOI 10.1111/j.1600 051X.2010.01547.x
   Zabka AG, 2001, J ORTHOP RES, V19, P318, DOI 10.1016/S0736 0266(00)90003 2
   Zachos T, 2007, MOL THER, V15, P1543, DOI 10.1038/sj.mt.6300192
   Zakhary K, 2005, J OTOLARYNGOL, V34, P407, DOI 10.2310/7070.2005.34608
   Zellin G, 2000, BONE, V26, P161, DOI 10.1016/S8756 3282(99)00252 5
   Zhang C, 2010, ACTA PHARMACOL SIN, V31, P821, DOI 10.1038/aps.2010.67
   Zhang J, 2009, J TISSUE ENG REGEN M, V3, P63, DOI 10.1002/term.135
   Zhang Q, 2008, TISSUE ENG PT A, V14, P237, DOI 10.1089/tea.2007.0261
   Zhang Q, 2010, J BONE MINER RES, V25, P1350, DOI 10.1002/jbmr.25
   Zhang R, 2004, J BIOMED MATER RES B, V71B, P408, DOI 10.1002/jbm.b.30110
   Zhang WJ, 2011, BIOMATERIALS, V32, P9415, DOI 10.1016/j.biomaterials.2011.08.047
   Zhang YF, 2007, BIOMATERIALS, V28, P4635, DOI 10.1016/j.biomaterials.2007.07.009
   Zhang YF, 2012, BONE, V51, P704, DOI 10.1016/j.bone.2012.06.029
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhang YF, 2011, TISSUE ENG PART C ME, V17, P789, DOI 10.1089/ten.tec.2010.0453
   Zhang YF, 2010, ACTA BIOMATER, V6, P3021, DOI 10.1016/j.actbio.2010.02.030
   Zhang YF, 2009, J CONTROL RELEASE, V136, P172, DOI 10.1016/j.jconrel.2009.02.016
   Zhao J, 2012, TISSUE ENG PT A, V18, P185, DOI [10.1089/ten.tea.2011.0297, 10.1089/ten.TEA.2011.0297]
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
   Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821
   Zimmermann G, 2009, INJURY, V40, P50
NR 605
TC 145
Z9 164
U1 0
U2 77
PU AO RESEARCH INSTITUTE DAVOS ARI
PI DAVOS
PA CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND
SN 1473 2262
J9 EUR CELLS MATER
JI Eur. Cells Mater.
PD JUL DEC
PY 2014
VL 28
BP 166
EP 208
DI 10.22203/eCM.v028a13
PG 43
WC Cell & Tissue Engineering; Engineering, Biomedical; Materials Science,
   Biomaterials; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science; Orthopedics
GA AU4EQ
UT WOS:000345562600013
PM 25284140
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wu, H
   Luo, Y
   Xu, DM
   Ke, X
   Ci, TY
AF Wu, Hao
   Luo, Yuan
   Xu, Dongmei
   Ke, Xue
   Ci, Tianyuan
TI Low molecular weight heparin modified bone targeting liposomes for
   orthotopic osteosarcoma and breast cancer bone metastatic tumors
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Osteosarcoma Bone targeting; Anti metastasis; Anti osteoporosis;
   Liposomes Alendronate (ALN); Low molecular weight heparin (LMWH)
ID IN VITRO; NANOPARTICLES; DELIVERY; ALENDRONATE; MECHANISMS; ANTITUMOR;
   BISPHOSPHONATES; OSTEOPOROSIS; CHEMOTHERAPY; INHIBITOR
AB The standard of care chemotherapy is important in the treatment of osteosarcoma and bone metastastic tumors. However, the efficacy is limited by the specific physiological environment of the bone. Thus, developing an efficient antitumor and anti metastasis chemotherapeutic formulation is desired for treatment of bone tumors. Herein, we utilized the alendronate (ALN) and low molecular weight heparin (LMWH) modified liposomes to deliver the antitumor drug doxorubicin (DOX), where traditionally believed non active drug carrier, targeting moiety could also exhibit biological functions and realize anti tumor and anti metastasis efficiency synergistically with the antitumor drug. Specifically, ALN could serve as the bone targeting moiety and the therapeutic agents of anti osteoporosis. LMWH could enhance the blood circulation time of liposomes and exhibit anti metastasis efficiency. Besides characterization of typical physiochemical properties of the delivery system, both the orthotopic osteosarcoma model and bone metastasis cancer model were adopted to evaluate the in vivo efficacy. The results proved this system could remarkably suppress tumor growth and inhibit tumor metastasis. (C) 2020 Published by Elsevier B.V.
C1 [Wu, Hao; Luo, Yuan; Xu, Dongmei; Ke, Xue; Ci, Tianyuan] China Pharmaceut Univ, Dept Pharmaceut, State Key Lab Nat Med, 24 Tongjiaxiang, Nanjing 210009, Peoples R China.
C3 China Pharmaceutical University
RP Ke, X; Ci, TY (通讯作者)，China Pharmaceut Univ, Dept Pharmaceut, State Key Lab Nat Med, 24 Tongjiaxiang, Nanjing 210009, Peoples R China.
EM kexue1973@vip.sina.com; citianyuan_cpu@163.com
RI Xu, Dongmei/X 6544 2019
FU Natural Science Foundation of China [81773908]
FX Thisworkwas financial supported byNational Natural Science Foundation of
   China (grant No. 81773908).
CR Allain TJ, 2006, GERONTOLOGY, V52, P107, DOI 10.1159/000090956
   Banerjee I, 2019, BIOMATER SCI UK, V7, P1161, DOI 10.1039/c8bm01403e
   Bonzi G, 2015, BIOCONJUGATE CHEM, V26, P489, DOI 10.1021/bc500614b
   Caliskan Y, 2019, INT J PHARMACEUT, V557, P97, DOI 10.1016/j.ijpharm.2018.12.041
   Casper CL, 2005, BIOMACROMOLECULES, V6, P1998, DOI 10.1021/bm050007e
   Chen QC, 2018, ACS APPL MATER INTER, V10, P23700, DOI 10.1021/acsami.8b08606
   Chen Y, 2015, J DRUG TARGET, V23, P335, DOI 10.3109/1061186X.2014.996760
   Chi J., 2015, INT J BIOL MACROMOL, V136, P1
   Choubey AK, 2014, BIOORG CHEM, V54, P1, DOI 10.1016/j.bioorg.2014.03.002
   Chu WJ, 2017, INT J PHARMACEUT, V516, P352, DOI 10.1016/j.ijpharm.2016.11.051
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Crasto Jared Anthony, 2018, Oncotarget, V9, P30163, DOI 10.18632/oncotarget.25733
   Cui YM, 2006, MICROCHEM J, V83, P35, DOI 10.1016/j.microc.2006.01.020
   Du HL, 2017, INT J PHARMACEUT, V523, P427, DOI 10.1016/j.ijpharm.2017.03.065
   Du S, 2019, BIOMATER SCI UK, V7, P1147, DOI 10.1039/c8bm01350k
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fourman MS, 2018, CLIN ORTHOP RELAT R, V476, P479, DOI 10.1007/s11999.0000000000000003
   Gebremeskel S, 2015, INT J CANCER, V136, P234, DOI 10.1002/ijc.28947
   Gifre L, 2017, OSTEOPOROSIS INT, V28, P2707, DOI 10.1007/s00198 017 4090 4
   Gupta A, 2011, EUR BIOPHYS J BIOPHY, V40, P727, DOI 10.1007/s00249 011 0685 4
   Hauser M, 2018, BONE, V112, P107, DOI 10.1016/j.bone.2018.04.017
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Huang YJ, 2017, NANOSCALE, V9, P10002, DOI 10.1039/c7nr02662e
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jin A, 2017, BONE JOINT RES, V6, P602, DOI 10.1302/2046 3758.610.BJR 2016 0321.R1
   Kazemi MS, 2019, INT J BIOL MACROMOL, V136, P823, DOI 10.1016/j.ijbiomac.2019.06.132
   Ke ZC, 2018, INT J PHARMACEUT, V545, P306, DOI 10.1016/j.ijpharm.2018.04.016
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Kudsiova L, 2019, BIOMATER SCI UK, V7, P149, DOI 10.1039/c8bm00965a
   Li YK, 2016, J CONTROL RELEASE, V228, P107, DOI 10.1016/j.jconrel.2016.02.044
   Lv M, BIOMATER SCI, V4, P1113
   Ma Lang, 2018, INT J BIOL MACROMOL, V122, P784
   Mei L, 2016, ACS APPL MATER INTER, V8, P9577, DOI 10.1021/acsami.5b12347
   Mei L, 2014, J CONTROL RELEASE, V196, P324, DOI 10.1016/j.jconrel.2014.10.017
   Mekhail GM, 2016, NANOMEDICINE UK, V11, P2251, DOI 10.2217/nnm 2016 0151
   Meng JA, 2011, J PHARM PHARMACOL, V63, P400, DOI 10.1111/j.2042 7158.2010.01229.x
   Miller K, 2013, BIOMATERIALS, V34, P3795, DOI 10.1016/j.biomaterials.2013.01.052
   Modarres HP, 2018, J CONTROL RELEASE, V273, P108, DOI 10.1016/j.jconrel.2018.01.024
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Nafee N, 2018, J DRUG TARGET, V26, P563, DOI 10.1080/1061186X.2017.1390670
   Papachristou DJ, 2012, MED RES REV, V32, P611, DOI 10.1002/med.20224
   Przybyla BD, 2014, INT J ONCOL, V44, P600, DOI 10.3892/ijo.2013.2185
   Rahimi M, 2018, CARBOHYD POLYM, V196, P299, DOI 10.1016/j.carbpol.2018.05.059
   Ratzkowski E, 1967, Clin Radiol, V18, P146, DOI 10.1016/S0009 9260(67)80007 2
   Rehman M, 2017, NANOSCALE, V9, P15434, DOI 10.1039/c7nr05216b
   Sanderson RD, 2017, FEBS J, V284, P42, DOI 10.1111/febs.13932
   Song J, 2014, NUTR CANCER, V66, P682, DOI 10.1080/01635581.2014.895392
   Sun HF, 2018, BIOMATER SCI UK, V6, P2172, DOI 10.1039/c8bm00486b
   Sun HF, 2018, INT J BIOL MACROMOL, V112, P343, DOI 10.1016/j.ijbiomac.2018.01.195
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Tan XB, 2014, ONCOL REP, V31, P1855, DOI 10.3892/or.2014.3007
   Tian MP, 2018, INT J BIOL MACROMOL, V120, P702, DOI 10.1016/j.ijbiomac.2018.08.146
   Wang J, 2015, MOL MED REP, V11, P3585, DOI 10.3892/mmr.2015.3164
   Wang YZ, 2017, ACS NANO, V11, P2227, DOI 10.1021/acsnano.6b08731
   Wang YT, 2017, BIOMATERIALS, V114, P97, DOI 10.1016/j.biomaterials.2016.11.010
   Wu H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00273
   Wu H, 2016, INT J NANOMED, V11, P6337, DOI 10.2147/IJN.S119839
   Xiao L, 2011, BIOMATERIALS, V32, P5148, DOI 10.1016/j.biomaterials.2011.03.071
   Xiong H, 2018, BIOMATER SCI UK, V6, P2527, DOI 10.1039/c8bm00570b
   Yu QW, 2019, THERANOSTICS, V9, P355, DOI 10.7150/thno.29137
   Zhang BM, 2017, MAT SCI ENG C MATER, V75, P198, DOI 10.1016/j.msec.2017.02.048
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
   Zhu AP, 2005, COLLOID SURFACE B, V43, P143, DOI 10.1016/j.colsurfb.2005.04.009
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
NR 66
TC 43
Z9 45
U1 2
U2 53
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC 1
PY 2020
VL 164
BP 2583
EP 2597
DI 10.1016/j.ijbiomac.2020.08.068
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OP4ZV
UT WOS:000588093700241
PM 32795579
DA 2025 08 17
ER

PT J
AU Li, ZX
   Yang, XH
   Fu, RF
   Wu, ZP
   Xu, SZ
   Jiao, J
   Qian, M
   Zhang, L
   Wu, CB
   Xie, TY
   Yao, JQ
   Wu, ZX
   Li, WJ
   Ma, GL
   You, Y
   Chen, YH
   Zhang, HK
   Cheng, YY
   Tang, XL
   Wu, PF
   Lian, GW
   Wei, HF
   Zhao, J
   Xu, JR
   Ai, LZ
   Siwko, S
   Wang, Y
   Ding, J
   Song, GJ
   Luo, J
   Liu, MY
   Xiao, JR
AF Li, Zhenxi
   Yang, Xinghai
   Fu, Ruifeng
   Wu, Zhipeng
   Xu, Shengzhao
   Jiao, Jian
   Qian, Ming
   Zhang, Long
   Wu, Chunbiao
   Xie, Tianying
   Yao, Jiqiang
   Wu, Zhixiang
   Li, Wenjun
   Ma, Guoli
   You, Yu
   Chen, Yihua
   Zhang, Han kun
   Cheng, Yiyun
   Tang, Xiaolong
   Wu, Pengfei
   Lian, Gewei
   Wei, Haifeng
   Zhao, Jian
   Xu, Jianrong
   Ai, Lianzhong
   Siwko, Stefan
   Wang, Yue
   Ding, Jin
   Song, Gaojie
   Luo, Jian
   Liu, Mingyao
   Xiao, Jianru
TI Kisspeptin 10 binding to Gpr54 in osteoclasts prevents bone loss by
   activating Dusp18 mediated dephosphorylation of Src
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TYROSINE KINASE; SH3 DOMAINS; C SRC; RECEPTOR; OSTEOPOROSIS; INHIBITOR;
   PEPTIDE; ROLES; DIFFERENTIATION; SPECIFICITY
AB Osteoclasts are over activated as we age, which results in bone loss. Src deficiency in mice leads to severe osteopetrosis due to a functional defect in osteoclasts, indicating that Src function is essential in osteoclasts. G protein coupled receptors (GPCRs) are the targets for similar to 35% of approved drugs but it is still unclear how GPCRs regulate Src kinase activity. Here, we reveal that GPR54 activation by its natural ligand Kisspeptin 10 (Kp 10) causes Dusp18 to dephosphorylate Src at Tyr 416. Mechanistically, Gpr54 recruits both active Src and the Dusp18 phosphatase at its proline/arginine rich motif in its C terminus. We show that Kp 10 binding to Gpr54 leads to the up regulation of Dusp18. Kiss1, Gpr54 and Dusp18 knockout mice all exhibit osteoclast hyperactivation and bone loss, and Kp 10 abrogated bone loss by suppressing osteoclast activity in vivo. Therefore, Kp 10/Gpr54 is a promising therapeutic target to abrogate bone resorption by Dusp18 mediated Src dephosphorylation.
   The authors of this manuscript identify that Gpr54 activation by its natural ligand Kisspeptin 10 can abrogate bone resorption. Mechanistically, Gpr54 recruits both active Src and the Dusp18 phosphatase, which causes Dusp18 to dephosphorylate Src at Tyr 416.
C1 [Li, Zhenxi; Fu, Ruifeng; Zhang, Long; Wu, Chunbiao; Xie, Tianying; Ai, Lianzhong; Xiao, Jianru] Univ Shanghai Sci & Technol, Inst Orthoped Biomed & Device Innovat, Sch Hlth Sci & Engn, Shanghai 200093, Peoples R China.
   [Li, Zhenxi; Yang, Xinghai; Fu, Ruifeng; Wu, Zhipeng; Jiao, Jian; Qian, Ming; Wu, Chunbiao; Xie, Tianying; Yao, Jiqiang; Wu, Zhixiang; Wei, Haifeng; Zhao, Jian; Xiao, Jianru] Naval Med Univ, Shanghai Changzheng Hosp, Inst Orthoped, Dept Orthoped Oncol, Shanghai 200003, Peoples R China.
   [Li, Zhenxi; Xu, Shengzhao; Li, Wenjun; Ma, Guoli; You, Yu; Chen, Yihua; Zhang, Han kun; Cheng, Yiyun; Song, Gaojie; Liu, Mingyao; Xiao, Jianru] East China Normal Univ, East China Normal Univ & Shanghai Changzheng Hosp, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
   [Li, Zhenxi; Xu, Shengzhao; Li, Wenjun; Ma, Guoli; You, Yu; Chen, Yihua; Zhang, Han kun; Cheng, Yiyun; Song, Gaojie; Liu, Mingyao; Xiao, Jianru] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Li, Zhenxi] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
   [Tang, Xiaolong] Hunan Univ, Sch Biomed Sci, Changsha 410082, Peoples R China.
   [Wu, Pengfei; Lian, Gewei] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
   [Xu, Jianrong] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai 201203, Peoples R China.
   [Siwko, Stefan] Texas A&M Univ, Inst Biosci & Technol, Hlth Sci Ctr, Dept Translat Med Sci, Houston, TX USA.
   [Wang, Yue] Naval Med Univ, Translat Med Res Ctr, Shanghai Key Lab Cell Engn, Shanghai 200433, Peoples R China.
   [Ding, Jin] Naval Med Univ, Clin Canc Inst, Ctr Translat Med, Shanghai 200433, Peoples R China.
   [Luo, Jian] Tongji Univ, Yangzhi Rehabil Hosp, Shanghai Sunshine Rehabil Ctr, Sch Med, Shanghai, Peoples R China.
C3 University of Shanghai for Science & Technology; Naval Medical
   University; East China Normal University; East China Normal University;
   Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Beth Israel Deaconess Medical Center; Hunan University;
   Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Beth Israel Deaconess Medical Center; Shanghai University of
   Traditional Chinese Medicine; University of Texas System; University of
   Texas Health Science Center Houston; Texas A&M University System; Texas
   A&M University College Station; Texas A&M Health Science Center; Naval
   Medical University; Naval Medical University; Tongji University
RP Li, ZX; Xiao, JR (通讯作者)，Univ Shanghai Sci & Technol, Inst Orthoped Biomed & Device Innovat, Sch Hlth Sci & Engn, Shanghai 200093, Peoples R China.; Li, ZX; Xiao, JR (通讯作者)，Naval Med Univ, Shanghai Changzheng Hosp, Inst Orthoped, Dept Orthoped Oncol, Shanghai 200003, Peoples R China.; Li, ZX; Song, GJ; Liu, MY; Xiao, JR (通讯作者)，East China Normal Univ, East China Normal Univ & Shanghai Changzheng Hosp, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.; Li, ZX; Song, GJ; Liu, MY (通讯作者)，East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.; Li, ZX (通讯作者)，Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.; Luo, J (通讯作者)，Tongji Univ, Yangzhi Rehabil Hosp, Shanghai Sunshine Rehabil Ctr, Sch Med, Shanghai, Peoples R China.
EM zxli@usst.edu.cn; gjsong@bio.ecnu.edu.cn; jluo@tongji.edu.cn;
   myliu@bio.ecnu.edu.cn; jianruxiao83@163.com
RI ; Cheng, Jessica Yi Yun/MSZ 1589 2025; Chen, Yihua/A 4323 2013; Chen,
   Wei/GZK 7348 2022; li, wenjun/B 1078 2018; Wu, Zhi Peng/AAZ 4873 2021;
   Xiaolong, Tang/HJB 4028 2022; Zhang, Hankun/NSU 3511 2025
OI Li, Zhenxi/0000 0002 7220 6177; Chen, Yihua/0000 0003 1733 7980; 
FU Science and Technology Commission of Shanghai Municipality (Shanghai
   Municipal Science and Technology Commission) [2019YFC1316000]; National
   Key Research and Development Program of China [22PJ1416000]; Shanghai
   Pujiang Talent Program [20ZR1457500]; Natural Science Foundation of
   Shanghai Science and Technology Program [2022ZZ01013]; Construction
   project of Key research center of Shanghai Municipal Health Program
   [21MC1930100]; Orthopedic clinical medical Research Center construction
   project of Shanghai Science and Technology Program
FX This work was supported by the grants National Key Research and
   Development Program of China (2019YFC1316000 to X.Y.), Shanghai Pujiang
   Talent Program (22PJ1416000 to Z.L.), Natural Science Foundation of
   Shanghai Science and Technology Program (20ZR1457500 to Z.L.),
   Construction project of Key research center of Shanghai Municipal Health
   Program (2022ZZ01013 to J.X.),Orthopedic clinical medical Research
   Center construction project of Shanghai Science and Technology Program
   (21MC1930100 to J.X.). The authors would like to thank Dr. Robert J.
   Lefkowitz and Dr. Wenyi Wei for sharing the Arrb1 and Arrb2 double
   knockout MEFs, Dr. Gang Pei for providing Arrb1, Arrb2 knockout mice,
   Dr. Richard D Ye for providing Gq alpha flox/flox:G11 alpha /  mice,
   Lujian Liao for helping us with Mass Spectrometry assay.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Ahow M, 2014, ENDOCRINOLOGY, V155, P4433, DOI 10.1210/en.2014 1304
   Aparicio SAJR, 2005, CELL METAB, V1, P293, DOI 10.1016/j.cmet.2005.04.001
   Asami T, 2012, BIOORG MED CHEM LETT, V22, P6391, DOI 10.1016/j.bmcl.2012.08.069
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200
   Chen WZ, 2015, NAT CELL BIOL, V17, P434, DOI 10.1038/ncb3120
   Civciristov S, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan1188
   Davenport AP, 2020, NAT REV DRUG DISCOV, V19, P389, DOI 10.1038/s41573 020 0062 z
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evan BJ, 2008, BIOCHEM BIOPH RES CO, V377, P1067, DOI 10.1016/j.bbrc.2008.10.108
   FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465
   Funes S, 2003, BIOCHEM BIOPH RES CO, V312, P1357, DOI 10.1016/j.bbrc.2003.11.066
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Heckel T, 2009, P NATL ACAD SCI USA, V106, P1451, DOI 10.1073/pnas.0804464106
   Herber CB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08046 4
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   HOSKING DJ, 1976, LANCET, V1, P615
   Jiang YJ, 2013, FEBS LETT, V587, P2905, DOI 10.1016/j.febslet.2013.07.021
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kobayashi T, 2010, BIOORGAN MED CHEM, V18, P5157, DOI 10.1016/j.bmc.2010.05.061
   Li ZX, 2022, J GENET GENOMICS, V49, P181, DOI 10.1016/j.jgg.2021.10.005
   Li ZX, 2019, J BONE MINER RES, V34, P765, DOI 10.1002/jbmr.3652
   LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0
   Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Luan B, 2009, NATURE, V457, P1146, DOI 10.1038/nature07617
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092 8674(00)00086 6
   MACINTYRE I, 1988, LANCET, V1, P900
   Mayer BJ, 2001, J CELL SCI, V114, P1253
   Meng YL, 2017, ACCOUNTS CHEM RES, V50, P1193, DOI 10.1021/acs.accounts.7b00012
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894 546
   Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304
   Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135
   PARFITT AM, 1987, J BONE MINER RES, V2, P427
   Perez Riverol Y, 2022, NUCLEIC ACIDS RES, V50, pD543, DOI 10.1093/nar/gkab1038
   Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577
   Pinilla L, 2012, PHYSIOL REV, V92, P1235, DOI 10.1152/physrev.00037.2010
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994
   Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322
   Sharma SV, 2001, ONCOGENE, V20, P2068, DOI 10.1038/sj.onc.1204296
   Shi YF, 2007, NAT IMMUNOL, V8, P817, DOI 10.1038/ni1489
   Son HE, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20571 2
   Sun YT, 2007, EMBO J, V26, P53, DOI 10.1038/sj.emboj.7601502
   Susa M, 2000, TRENDS PHARMACOL SCI, V21, P489, DOI 10.1016/S0165 6147(00)01567 4
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101 1236
   Winter G, 2013, ACTA CRYSTALLOGR D, V69, P1260, DOI 10.1107/S0907444913015308
   Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0
   Xu X, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0005 4
   Yun HM, 2007, J BIOL CHEM, V282, P5496, DOI 10.1074/jbc.M606215200
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang ZZ, 2011, BLOOD, V118, P1912, DOI 10.1182/blood 2011 01 330324
NR 61
TC 11
Z9 11
U1 17
U2 51
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 12
PY 2024
VL 15
IS 1
AR 1300
DI 10.1038/s41467 024 44852 9
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HS6Z1
UT WOS:001161546900020
PM 38346942
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Mukherjee, S
   Raje, N
   Schoonmaker, JA
   Liu, JC
   Hideshima, T
   Wein, MN
   Jones, DC
   Vallet, S
   Bouxsein, ML
   Pozzi, S
   Chhetri, S
   Seo, YD
   Aronson, JP
   Patel, C
   Fulciniti, M
   Purton, LE
   Glimcher, LH
   Lian, JB
   Stein, G
   Anderson, KC
   Scadden, DT
AF Mukherjee, Siddhartha
   Raje, Noopur
   Schoonmaker, Jesse A.
   Liu, Julie C.
   Hideshima, Teru
   Wein, Marc N.
   Jones, Dallas C.
   Vallet, Sonia
   Bouxsein, Mary L.
   Pozzi, Samantha
   Chhetri, Shweta
   Seo, Y. David
   Aronson, Joshua P.
   Patel, Chirayu
   Fulciniti, Mariateresa
   Purton, Louise E.
   Glimcher, Laurie H.
   Lian, Jane B.
   Stein, Gary
   Anderson, Kenneth C.
   Scadden, David T.
TI Pharmacologic targeting of a stem/progenitor population in vivo is
   associated with enhanced bone regeneration in mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID MESENCHYMAL STEM CELLS; TRANSCRIPTION FACTOR CBFA1; MULTIPLE MYELOMA;
   STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; MORPHOGENETIC PROTEIN 2;
   OSTEOGENESIS; RUNX2; VITRO; BORTEZOMIB
AB Drug targeting of adult stem cells has been proposed as a strategy for regenerative medicine, but very few drugs are known to target stem cell populations in vivo. Mesenchymal stem/progenitor cells (MSCs) are a multipotent population of cells that can differentiate into muscle, bone, fat, and other cell types in context specific manners. Bortezomib (Bzb) is a clinically available proteasome inhibitor used in the treatment of multiple myeloma. Here, we show that Bzb induces MSCs to preferentially undergo osteoblastic differentiation, in part by modulation of the bone specifying transcription factor runt related transcription factor 2 (Runx 2) in mice. Mice implanted with MSCs showed increased ectopic ossicle and bone formation when recipients received low doses of Bzb. Furthermore, this treatment increased bone formation and rescued bone loss in a mouse model of osteoporosis. Thus, we show that a tissue resident adult stem cell population in vivo can be pharmacologically modified to promote a regenerative function in adult animals.
C1 [Mukherjee, Siddhartha; Schoonmaker, Jesse A.; Seo, Y. David; Aronson, Joshua P.; Purton, Louise E.; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02115 USA.
   [Mukherjee, Siddhartha; Schoonmaker, Jesse A.; Bouxsein, Mary L.; Seo, Y. David; Aronson, Joshua P.; Purton, Louise E.; Scadden, David T.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Mukherjee, Siddhartha; Scadden, David T.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
   [Mukherjee, Siddhartha; Raje, Noopur; Scadden, David T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
   [Mukherjee, Siddhartha; Schoonmaker, Jesse A.; Seo, Y. David; Aronson, Joshua P.; Patel, Chirayu; Purton, Louise E.; Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
   [Raje, Noopur; Hideshima, Teru; Vallet, Sonia; Pozzi, Samantha; Chhetri, Shweta; Fulciniti, Mariateresa; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   [Liu, Julie C.; Lian, Jane B.; Stein, Gary] Univ Massachusetts, Dept Cell Biol, Worcester, MA 01605 USA.
   [Wein, Marc N.; Jones, Dallas C.; Glimcher, Laurie H.] Harvard Univ, Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, Boston, MA 02215 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School; Harvard
   University; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard University; Harvard University;
   Harvard University Medical Affiliates; Dana Farber Cancer Institute;
   Harvard Medical School; University of Massachusetts System; University
   of Massachusetts Worcester; Harvard University; Harvard T.H. Chan School
   of Public Health; Harvard University; Harvard University Medical
   Affiliates; Beth Israel Deaconess Medical Center
RP Scadden, DT (通讯作者)，Massachusetts Gen Hosp, Ctr Regenerat Med, 185 Cambridge St, Boston, MA 02115 USA.
EM dscadden@mgh.harvard.edu
RI Purton, Louise/AAI 8956 2021; Anderson, Kenneth/ACP 5073 2022; Liu,
   Julie/H 7496 2013; Vallet, Sonia/AHE 3935 2022; Pozzi,
   Samantha/A 7617 2012
OI Seo, Yongwoo/0000 0001 6837 5018; Purton, Louise/0000 0001 6593 3168;
   Liu, Julie/0000 0003 0784 2529; Aronson, Joshua/0000 0001 5326 805X;
   Pozzi, Samantha/0000 0001 7917 1774; Vallet, Sonia/0000 0003 0146 8089
FU NCI NIH HHS [P01 CA082834] Funding Source: Medline; NHLBI NIH HHS
   [HL044851, HL081030, R01 HL044851, U54 HL081030, K08HL085872, K08
   HL085872] Funding Source: Medline; NIDDK NIH HHS [R01 DK050234,
   DK050234] Funding Source: Medline
CR Anjos Afonso F, 2004, J CELL SCI, V117, P5655, DOI 10.1242/jcs.01488
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   Barnes GL, 2003, CANCER RES, V63, P2631
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Ding S, 2005, CURR TOP MED CHEM, V5, P383, DOI 10.2174/1568026053828402
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Elsubeihi ES, 2007, CELL TISSUE RES, V330, P515, DOI 10.1007/s00441 007 0506 3
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   Hideshima T, 2001, CANCER RES, V61, P3071
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Janderová L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kuznetsov SA, 2004, J CELL BIOL, V167, P1113, DOI 10.1083/jcb.200408079
   Lengner CJ, 2005, J BIOL CHEM, V280, P15872, DOI 10.1074/jbc.M411144200
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365 2141.2003.04669.x
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pierroz DD, 2006, BONE, V39, P260, DOI 10.1016/j.bone.2006.01.145
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pratap J, 2003, CANCER RES, V63, P5357
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Quarto N, 2006, TISSUE ENG, V12, P1405, DOI 10.1089/ten.2006.12.1405
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200
   Sheng MHC, 1999, BONE, V25, P421, DOI 10.1016/S8756 3282(99)00184 2
   Shimazaki C, 2005, LEUKEMIA, V19, P1102, DOI 10.1038/sj.leu.2403758
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875
   Vallet S, 2007, BLOOD, V110, P3744, DOI 10.1182/blood 2007 05 093294
   Wang LP, 2005, BLOOD, V106, P3650, DOI 10.1182/blood 2005 02 0582
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zarrinkalam K. H., 2005, European Journal of Morphology, V42, P81
NR 43
TC 202
Z9 219
U1 0
U2 10
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2008
VL 118
IS 2
BP 491
EP 504
DI 10.1172/JC133102
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 257CS
UT WOS:000252777400018
PM 18219387
DA 2025 08 17
ER

PT J
AU Bedogni, A
   Blandamura, S
   Lokmic, Z
   Palumbo, C
   Ragazzo, M
   Ferrari, F
   Tregnaghi, A
   Pietrogrande, F
   Procopio, O
   Saia, G
   Ferretti, M
   Bedogni, G
   Chiarini, L
   Ferronato, G
   Ninfo, V
   Russo, LL
   Lo Muzio, L
   Nocini, PF
AF Bedogni, Alberto
   Blandamura, Stella
   Lokmic, Zerina
   Palumbo, Carla
   Ragazzo, Mirko
   Ferrari, Francesca
   Tregnaghi, Alberto
   Pietrogrande, Francesco
   Procopio, Olindo
   Saia, Giorgia
   Ferretti, Marzia
   Bedogni, Giorgio
   Chiarini, Luigi
   Ferronato, Giuseppe
   Ninfo, Vito
   Russo, Lucio Lo
   Lo Muzio, Lorenzo
   Nocini, Pier Francesco
TI Bisphosphonate associated jawbone osteonecrosis: a correlation between
   imaging techniques and histopathology
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Article
ID GTP BINDING PROTEIN; AVASCULAR NECROSIS; CANCER PATIENTS; RISK FACTORS;
   JAWS; BONE; OSTEOCLASTS; THERAPY
AB Objectives. Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration. This paper considers and highlights histopathologic and radiologic features of this condition.
   Study design. Eleven patients, owing to unresponsiveness to conservative treatment and uncontrollable pain, underwent surgical resection of diseased jawbone after extensive hyperbaric oxygen therapy. A thorough clinical, laboratory, and imaging study was performed. Surgical specimens underwent histopathologic and immunohistochemical evaluation.
   Results. Computerized tomography (CT) scans showed increased bone density, periosteal reaction, and bone sequestration in advanced stages. With magnetic resonance imaging (MRI), exposed areas showed a low signal in T1 and T2 weighted and inversion recovery images, which suggests low water content and is histopathologically correlated with paucity in cells and vessels (osteonecrotic pattern). Unexposed diseased bone was characterized by T1 hypointensity and T2 and IR hyperintensity, which suggests high water content and inflammation, associated with hypercellularity, osteogenesis, and hypervascularity (osteomyelitic pattern).
   Conclusions. Diseased bone extends beyond the limits of the bone exposed in the oral cavity. Histopathologic examination correlated well with CT and MRI, which are the choice for the evaluation of bisphosphonate associated jawbone osteonecrosis.
C1 [Bedogni, Alberto; Ferrari, Francesca; Nocini, Pier Francesco] Univ Verona, Unit Dent & Maxillofacial Surg, I 37100 Verona, Italy.
   [Blandamura, Stella; Ninfo, Vito] Univ Padua, Inst Pathol, I 35100 Padua, Italy.
   [Lokmic, Zerina] Univ Munester, Inst Physiol Chem & Pathobiochem, Munster, Germany.
   [Palumbo, Carla; Ferretti, Marzia] Univ Modena & Reggio Emilia, Dept Anat & Histol, Modena, Italy.
   [Ragazzo, Mirko; Procopio, Olindo; Saia, Giorgia; Ferronato, Giuseppe] Univ Padua, Unit Maxillofacial Surg, I 35100 Padua, Italy.
   [Tregnaghi, Alberto] Univ Padua, Inst Radiol, I 35100 Padua, Italy.
   [Pietrogrande, Francesco] Univ Padua, Dept Med & Surg Sci, I 35100 Padua, Italy.
   [Bedogni, Giorgio] Liver Res Ctr, Trieste, Italy.
   [Chiarini, Luigi] Univ Modenna Reggio Emilia, Dept Surg Sci, Modena, Italy.
   [Russo, Lucio Lo; Lo Muzio, Lorenzo] Univ Foggia, Dept Surg Sci, Foggia, Italy.
C3 University of Verona; University of Padua; Universita di Modena e Reggio
   Emilia; University of Padua; University of Padua; University of Padua;
   Universita di Modena e Reggio Emilia; University of Foggia
RP Chiarini, L (通讯作者)，Via Carelli 28, I 71100 Foggia, Italy.
EM llomuzio@unifg.it
RI Chiarini, Luigi/Q 6291 2016; CHIARINI, Luigi/Q 6291 2016; Russo,
   Lucio/B 5610 2015; Blandamura, Stella/AAN 1124 2021; Bedogni,
   Giorgio/K 1911 2018; Ferretti, Marzia/F 1153 2016; Albano,
   Francesco/J 2352 2016; Tomkins, Zerina/AAC 6962 2022; Palumbo,
   Carla/E 5802 2012; Lo Muzio, Lorenzo/C 8533 2011; SAIA,
   GIORGIA/T 9340 2018; Muzio, Lorenzo/C 8533 2011
OI CHIARINI, Luigi/0000 0002 5541 1574; Bedogni,
   Giorgio/0000 0002 1495 9306; Ferretti, Marzia/0000 0003 0280 3598;
   Tomkins (nee lokmic), Zerina/0000 0003 0266 9536; LO RUSSO,
   LUCIO/0000 0001 6127 6105; Bedogni, Alberto/0000 0003 4742 4508;
   Palumbo, Carla/0000 0003 0587 0112; Lo Muzio,
   Lorenzo/0000 0003 4633 4893; SAIA, GIORGIA/0000 0001 7350 796X; 
CR Aspenberg P, 2006, EXPERT OPIN DRUG SAF, V5, P743, DOI 10.1517/14740338.5.6.743
   Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Chiandussi S, 2006, DENTOMAXILLOFAC RAD, V35, P236, DOI 10.1259/dmfr/27458726
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Gay CV, 2000, CRIT REV EUKAR GENE, V10, P213, DOI 10.1615/CritRevEukarGeneExpr.v10.i3 4.10
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hortobagyi GN, 2005, CANCER TREAT REV, V31, pS9, DOI 10.1016/j.ctrv.2005.09.003
   Kanis John A., 2000, Cancer, V88, P3022, DOI 10.1002/1097 0142(20000615)88:12+<3022::AID CNCR19>3.0.CO;2 R
   KRISTENSEN HK, 1949, ACTA PATHOL MIC SC, V26, P715
   Luckman SP, 2005, J BONE MINER RES, V20, P1265, DOI 10.1359/jbmr.2005.20.7.1265
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Niinikoski JHA, 2004, WORLD J SURG, V28, P307, DOI 10.1007/s00268 003 7401 1
   Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P391, DOI 10.1016/j.joms.2003.11.003
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092 8674(92)90164 8
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088 200342100 00001
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Vaananen K., 2002, Principles of Bone Biology, Vsecond, P127
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   ZHANG D, 1995, J CELL SCI, V108, P2285
NR 27
TC 166
Z9 176
U1 0
U2 9
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1079 2104
EI 1528 395X
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD MAR
PY 2008
VL 105
IS 3
BP 358
EP 364
DI 10.1016/j.tripleo.2007.08.040
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 268TW
UT WOS:000253603600017
PM 18280968
DA 2025 08 17
ER

PT J
AU Li, Z
   Wang, HX
   Zhang, KY
   Yang, BG
   Xie, X
   Yang, ZM
   Kong, LC
   Shi, P
   Zhang, Y
   Ho, YP
   Zhang, ZY
   Li, G
   Bian, LM
AF Li, Zhuo
   Wang, Haixing
   Zhang, Kunyu
   Yang, Boguang
   Xie, Xian
   Yang, Zhengmeng
   Kong, Lingchi
   Shi, Peng
   Zhang, Yuan
   Ho, Yi Ping
   Zhang, Zhi Yong
   Li, Gang
   Bian, Liming
TI Bisphosphonate based hydrogel mediates biomimetic negative feedback
   regulation of osteoclastic activity to promote bone regeneration
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Bisphosphonate; Hydrogel; Tissue engineering; Bone regeneration
ID NANOCOMPOSITE HYDROGELS; DIFFERENTIATION; OSTEONECROSIS; NANOPARTICLES;
   RESORPTION; MAGNESIUM
AB The intricate dynamic feedback mechanisms involved in bone homeostasis provide valuable inspiration for the design of smart biomaterial scaffolds to enhance in situ bone regeneration. In this work, we assembled a biomimetic hyaluronic acid nanocomposite hydrogel (HA BP hydrogel) by coordination bonds with bisphosphonates (BPs), which are antiosteoclastic drugs. The HA BP hydrogel exhibited expedited release of the loaded BP in response to an acidic environment. Our in vitro studies showed that the HA BP hydrogel inhibits mature osteoclastic differentiation of macrophage like RAW264.7 cells via the released BP. Furthermore, the HA BP hydrogel can support the initial differentiation of primary macrophages to preosteoclasts, which are considered essential during bone regeneration, whereas further differentiation to mature osteoclasts is effectively inhibited by the HA BP hydrogel via the released BP. The in vivo evaluation showed that the HA BP hydrogel can enhance the in situ regeneration of bone. Our work demonstrates a promising strategy to design biomimetic biomaterial scaffolds capable of regulating bone homeostasis to promote bone regeneration.
C1 [Li, Zhuo; Yang, Boguang; Xie, Xian; Ho, Yi Ping] Chinese Univ Hong Kong, Dept Biomed Engn, Sha Tin, Hong Kong 999077, Peoples R China.
   [Wang, Haixing; Yang, Zhengmeng; Li, Gang] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Sha Tin, Hong Kong 999077, Peoples R China.
   [Zhang, Kunyu] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.
   [Kong, Lingchi] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Shanghai 200233, Peoples R China.
   [Zhang, Kunyu; Shi, Peng; Zhang, Yuan; Bian, Liming] South China Univ Technol, Sch Biomed Sci & Engn, Guangzhou 510006, Peoples R China.
   [Zhang, Zhi Yong] Guangzhou Med Univ, Translat Res Ctr Regenerat Med & 3D Printing, Guangdong Prov Engn Res Ctr Biomed Engn, State Key Lab Resp Dis,Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
   [Zhang, Kunyu; Shi, Peng; Zhang, Yuan; Bian, Liming] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China.
   [Zhang, Kunyu; Bian, Liming] South China Univ Technol, Key Lab Biomed Mat & Engn, Minist Educ, Guangzhou 510006, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Johns
   Hopkins University; Shanghai Jiao Tong University; South China
   University of Technology; Guangzhou Medical University; State Key
   Laboratory of Respiratory Disease; South China University of Technology;
   South China University of Technology
RP Li, G (通讯作者)，Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Sha Tin, Hong Kong 999077, Peoples R China.; Bian, LM (通讯作者)，South China Univ Technol, Sch Biomed Sci & Engn, Guangzhou 510006, Peoples R China.; Zhang, ZY (通讯作者)，Guangzhou Med Univ, Translat Res Ctr Regenerat Med & 3D Printing, Guangdong Prov Engn Res Ctr Biomed Engn, State Key Lab Resp Dis,Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
EM drzhiyong@126.com; gangli@cuhk.edu.hk; bianlm@scut.edu.cn
RI ; zhang, zhiyong/G 3227 2010; Ho, Megan/G 3878 2010; Bian,
   Liming/AAV 3801 2021; wang, haixing/LKM 5456 2024; Zhang,
   Yuan/O 9358 2017; Zhang, Kunyu/AAG 3278 2021
OI Ho, Megan Yi Ping/0000 0002 2052 9724; Zhang, Kunyu/0000 0003 2481 4781;
   
FU Research Grants Council of Hong Kong [14120118, 14202920, 14204618];
   Hong Kong Research Grants Council Theme based Research Scheme
   [T13 402/17 N, AoE/402/20]
FX This project is supported by theGeneral Research Fund grants from the
   Research Grants Council of Hong Kong (14120118, 14202920 and 14204618).
   The work was partially supported by Hong Kong Research Grants Council
   Theme based Research Scheme (Ref. T13 402/17 N and AoE/402/20).
CR Bergman J, 2019, OSTEOPOROSIS INT, V30, P1973, DOI 10.1007/s00198 019 05097 1
   Bliuc D, 2019, J BONE MINER RES, V34, P2001, DOI 10.1002/jbmr.3816
   Calvo PR, 2021, MACROMOL RAPID COMM, V42, DOI 10.1002/marc.202000578
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   Crane JL, 2014, J MOL MED, V92, P107, DOI 10.1007/s00109 013 1084 3
   Cremers S, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115501
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Cui WT, 2020, NANOSCALE, V12, P17196, DOI 10.1039/d0nr03731a
   Cui YT, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901073
   De Simone A, 2021, NATURE, V590, P129, DOI 10.1038/s41586 020 03085 8
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Gao B, 2019, J CLIN INVEST, V129, P2578, DOI 10.1172/JCI98857
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang J, 2021, J CELL MOL MED, V25, P5525, DOI 10.1111/jcmm.16562
   Jiang PL, 2021, BIOACT MATER, V6, P1118, DOI 10.1016/j.bioactmat.2020.10.006
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kim SH, 2018, MOLECULES, V23, DOI 10.3390/molecules23123119
   Kim Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15897 3
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Lin JG, 2021, CHEM BIOL DRUG DES, V97, P121, DOI 10.1111/cbdd.13767
   Liu SX, 2016, INT J MOL MED, V37, P284, DOI 10.3892/ijmm.2015.2423
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Mailoo VJ, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr 2018 225385
   Maruotti N, 2017, J CELL PHYSIOL, V232, P2957, DOI 10.1002/jcp.25969
   McDonald MM, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10539
   Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219
   Naylor KE, 2019, OSTEOPOROSIS INT, V30, P917, DOI 10.1007/s00198 018 04823 5
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Roy M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207655
   Savino S, 2018, EUR J MED CHEM, V158, P184, DOI 10.1016/j.ejmech.2018.08.044
   Scheven BAA, 1999, BIOCHEM BIOPH RES CO, V254, P773, DOI 10.1006/bbrc.1998.9909
   Shi LY, 2018, BIOPOLYMERS, V109, DOI 10.1002/bip.23090
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Takagi Y., 2020, MICROSCOPY JPN
   Takagi Y, 2021, MICROSCOPY JPN, V70, P302, DOI 10.1093/jmicro/dfaa073
   Takahashi N, 2007, ODONTOLOGY, V95, P1, DOI 10.1007/s10266 007 0071 y
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Thavornyutikarn B, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109937
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Utari TR, 2021, SAUDI DENT J, V33, P292, DOI 10.1016/j.sdentj.2020.03.003
   Walia B, 2018, ANN NY ACAD SCI, V1415, P57, DOI 10.1111/nyas.13629
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Wang W, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03915 1
   Wittkowske C, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00087
   Wotton CJ, 2019, BONE, V124, P69, DOI 10.1016/j.bone.2019.04.003
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yang P, 2018, BONE, V114, P1, DOI 10.1016/j.bone.2018.05.025
   Yuan WH, 2020, BIOACT MATER, V5, P819, DOI 10.1016/j.bioactmat.2020.06.002
   Zhang B.Y., 2021, CELL DEATH DIS, V12
   Zhang KY, 2018, ADV SCI, V5, DOI 10.1002/advs.201800875
   Zhang KY, 2017, ACTA BIOMATER, V64, P389, DOI 10.1016/j.actbio.2017.09.039
   Zhang KY, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201701642
   Zhao ZY, 2021, ACS NANO, V15, P13041, DOI 10.1021/acsnano.1c02147
   Zheng LZ, 2020, BIOMATERIALS, V238, DOI 10.1016/j.biomaterials.2020.119828
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
NR 61
TC 58
Z9 61
U1 22
U2 312
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD JUL
PY 2022
VL 13
BP 9
EP 22
DI 10.1016/j.bioactmat.2021.11.004
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ZP7YS
UT WOS:000766636300002
PM 35224288
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yeom, M
   Kim, EY
   Kim, JH
   Jung, HS
   Sohn, Y
AF Yeom, Mijung
   Kim, Eun Young
   Kim, Jae Hyun
   Jung, Hyuk Sang
   Sohn, Youngjoo
TI High Doses of Bupleurum falcatum Partially Prevents Estrogen
   Deficiency Induced Bone Loss With Anti osteoclastogenic Activity Due to
   Enhanced iNOS/NO Signaling
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Bupleurum falcatum; postmenopausal osteoporosis; bone resorption;
   osteoclasts; ovariectomized rats
ID NF KAPPA B; HORMONE REPLACEMENT THERAPY; NITRIC OXIDE; C FOS;
   DIFFERENTIATION; SAIKOSAPONIN; OSTEOPOROSIS; EXPRESSION
AB Background and Objective: Bupleurum falcatum (BF) extract, a natural product with anti inflammatory properties, has been traditionally used to treat menopausal symptoms, but its role in osteoporosis, another serious health concern of menopausal women, remains unknown. Here we investigated whether and how BF prevents estrogen deficiency induced bone loss using both in vitro and in vivo models.
   Methods: Female Sprague Dawley rats were ovariectomized (OVX) and subjected to oral BF treatment daily for 8 weeks. Additionally, pre osteoclastic RAW 264.7 cells were employed to evaluate the effects of BF and its underlying mechanism on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation in vitro.
   Results: A high dose of BF partially prevented ovariectomy (OVX) induced bone loss and reduced the levels of tartrate resistant acid phosphatase (TRAP) in serum and osteoclast numbers in femurs of OVX rats. Furthermore, BF clearly inhibited RANKLinduced osteoclast differentiation and bone resorption activity in RAW 264.7 cells. BF also inhibited the osteoclastogenic transcription factors c Fos and nuclear factor of activated T cells c1 (NFATc1) and, consequently, downregulated the expression of osteoclast marker genes. Moreover, BF upregulated interferon b (IFN b)/inducible nitric oxide synthase (iNOS)/nitric oxide (NO) signaling, even though it had no impact on mitogen activated protein kinases (MAPK) or NF k B. The inhibition of osteoclast formation by BF was abrogated by iNOS specific inhibitors. Consistent with cellular studies, BF upregulated iNOS protein expression in femurs from OVX rats.
   Conclusion: Taken together, our results indicate that BF partially prevented estrogen deficiency induced bone loss with anti osteoclastogenic activity potentially due to enhanced iNOS/NO signaling.
C1 [Yeom, Mijung] Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea.
   [Kim, Eun Young; Kim, Jae Hyun; Jung, Hyuk Sang; Sohn, Youngjoo] Kyung Hee Univ, Dept Anat, Coll Korean Med, Seoul, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Sohn, Y (通讯作者)，Kyung Hee Univ, Dept Anat, Coll Korean Med, Seoul, South Korea.
EM youngjoos@khu.ac.kr
RI KIM, YOUNG JIN/E 9374 2011
OI Kim, Eun young/0000 0002 4671 8400
FU National Research Foundation of Korea (NRF)   Korea Government (MSIT)
   [2017R1A2B4010163]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea Government (MSIT) (No.
   2017R1A2B4010163).
CR Abraham AK, 2009, BIOCHEM PHARMACOL, V77, P1757, DOI 10.1016/j.bcp.2009.01.007
   Amarasekara DS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/832127
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brincat S D, 2014, Minerva Ginecol, V66, P391
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Herrera L, 2015, OSTEOPOROSIS INT, V26, P1499, DOI 10.1007/s00198 014 3020 y
   Hidaka T, 2013, J OBSTET GYNAECOL RE, V39, P223, DOI 10.1111/j.1447 0756.2012.01936.x
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Khan A, 2014, J OBSTET GYNAECOL CA, V36, P839, DOI 10.1016/S1701 2163(15)30489 8
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Kwon S, 2010, PROG NEURO PSYCHOPH, V34, P265, DOI 10.1016/j.pnpbp.2009.11.015
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lei T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00668 w
   Li Yong, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P657, DOI 10.3736/jcim20090710
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Nilforoushan D, 2009, NITRIC OXIDE BIOL CH, V21, P27, DOI 10.1016/j.niox.2009.04.002
   Shin JC, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/630932
   Singh S, 2015, J CLIN DIAGN RES, V9, pRC4, DOI 10.7860/JCDR/2015/14857.6318
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   TAKAGI K, 1969, YAKUGAKU ZASSHI, V89, P712, DOI 10.1248/yakushi1947.89.5_712
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Wang P, 2010, EUR J PHARMACOL, V626, P159, DOI 10.1016/j.ejphar.2009.09.047
   Wark JD, 1996, MATURITAS, V23, P193, DOI 10.1016/0378 5122(95)00974 4
   Yang B., 2006, BUPLEURUM SPECIES SC
   Yang FD, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7597596
   Yu JQ, 2013, FITOTERAPIA, V85, P101, DOI 10.1016/j.fitote.2013.01.005
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zhou C, 2015, INT IMMUNOPHARMACOL, V25, P49, DOI 10.1016/j.intimp.2015.01.010
NR 40
TC 6
Z9 7
U1 1
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 16
PY 2018
VL 9
AR 1314
DI 10.3389/fphar.2018.01314
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HA7FT
UT WOS:000450447300001
PM 30524278
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, DY
   Lin, LY
   Yang, BW
   Meng, Z
   Zhang, B
AF Zhang, Dongyan
   Lin, Liying
   Yang, Bingwu
   Meng, Zhen
   Zhang, Bin
TI Knockdown of Tcirg1 inhibits large osteoclast generation by
   down regulating NFATc1 and IP3R2 expression
SO PLOS ONE
LA English
DT Article
ID TERMINAL DIFFERENTIATION; LYSOSOMAL BIOGENESIS; V ATPASE; AUTOPHAGY;
   PROTEIN; TRANSCRIPTION; ACTIVATION; MECHANISM
AB TheTCIRG1gene encodes the a3 isoform of vacuolar H+ ATPase (V ATPase), which forms a proton transport channel in osteoclasts. Defects in this gene lead to functional impairment of osteoclasts and increased bone mass; however, the molecular mechanisms ofTCIRG1loss have not been fully elucidated. In the current study, we transfected mouse bone marrow derived monocytes with control orTcirg1 knockdown lentiviruses to further investigate the mechanisms ofTCIRG1. Our results demonstrate that knockdown ofTcirg1inhibits large osteoclast (>100 mu m) generation by decreasing the expression of nuclear factor of activated T cells 1 (NFATc1) and inositol 1,4,5 trisphosphate receptor 2 (IP3R2). The decreased IP3R2 reduces intracellular calcium levels, which limits the nuclear translocation of NFATc1 in RANKL induced mouse bone marrow derived monocytes. These findings provide a mechanism to explain the effects ofTCIRG1impairment, with potential implications for the development of therapies for osteopetrosis.
C1 [Zhang, Dongyan; Zhang, Bin] Shandong Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Jinan, Shandong, Peoples R China.
   [Zhang, Dongyan; Zhang, Bin] Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.
   [Zhang, Dongyan; Zhang, Bin] Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan, Shandong, Peoples R China.
   [Zhang, Dongyan; Lin, Liying; Yang, Bingwu; Meng, Zhen; Zhang, Bin] Liaocheng Peoples Hosp, Dept Stomatol, Liaocheng, Shandong, Peoples R China.
   [Zhang, Dongyan; Lin, Liying; Yang, Bingwu; Meng, Zhen; Zhang, Bin] Liaocheng Peoples Hosp, Key Lab Oral Maxillofacial Head & Neck Med Biol S, Liaocheng, Shandong, Peoples R China.
   [Zhang, Dongyan; Lin, Liying; Yang, Bingwu; Meng, Zhen; Zhang, Bin] Liaocheng Peoples Hosp, Precis Biomed Key Lab, Liaocheng, Shandong, Peoples R China.
C3 Shandong University
RP Zhang, B (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Jinan, Shandong, Peoples R China.; Zhang, B (通讯作者)，Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.; Zhang, B (通讯作者)，Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan, Shandong, Peoples R China.; Zhang, B (通讯作者)，Liaocheng Peoples Hosp, Dept Stomatol, Liaocheng, Shandong, Peoples R China.; Zhang, B (通讯作者)，Liaocheng Peoples Hosp, Key Lab Oral Maxillofacial Head & Neck Med Biol S, Liaocheng, Shandong, Peoples R China.; Zhang, B (通讯作者)，Liaocheng Peoples Hosp, Precis Biomed Key Lab, Liaocheng, Shandong, Peoples R China.
EM 15166572287@126.com
RI Lin, Li Ying/GLU 9854 2022
FU Natural Science Foundation of Shandong province [ZR2017PH075]
FX This work was supported by Natural Science Foundation of Shandong
   province (http://kjt.shandong.gov.cn/) through grant ZR2017PH075,
   awarded to DZ.
CR BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092 8674(95)90179 5
   Cuervo AM, 2011, SCIENCE, V332, P1392, DOI 10.1126/science.1208607
   Ferron M, 2013, GENE DEV, V27, P955, DOI 10.1101/gad.213827.113
   Heaney C, 1998, HUM MOL GENET, V7, P1407, DOI 10.1093/hmg/7.9.1407
   HUNG SW, 2017, J CLIN ENDOCRINOLOGY, V5, DOI DOI 10.1210/JC.2017 0112728655174
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Ko SY, 2012, ARCH ORAL BIOL, V57, P1623, DOI 10.1016/j.archoralbio.2012.06.012
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsumoto N, 2014, BBA BIOENERGETICS, V1837, P744, DOI 10.1016/j.bbabio.2014.02.011
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538
   Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143 4160(03)00042 3
   Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729
   Roczniak Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002 9440(10)63798 4
   Toei M, 2010, BIOCHEMISTRY US, V49, P4715, DOI 10.1021/bi100397s
   Uwe K, 2000, HUM MOL GENET, P13, DOI [10.1093/hmg/9.13.2059, DOI 10.1093/HMG/9.13.2059]
   Xia L, 2012, FEBS LETT, V586, P3341, DOI 10.1016/j.febslet.2012.07.015
   Zhang SB, 2011, NEUROCHEM RES, V36, P1175, DOI 10.1007/s11064 011 0457 7
NR 34
TC 8
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2020
VL 15
IS 8
AR e0237354
DI 10.1371/journal.pone.0237354
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NE5VG
UT WOS:000562668300094
PM 32790690
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Limonard, EJ
   Schoenmaker, T
   de Vries, TJ
   Tanck, MW
   Heijboer, AC
   Endert, E
   Fliers, E
   Everts, V
   Bisschop, PH
AF Limonard, E. J.
   Schoenmaker, T.
   de Vries, T. J.
   Tanck, M. W.
   Heijboer, A. C.
   Endert, E.
   Fliers, E.
   Everts, V.
   Bisschop, P. H.
TI Clonidine increases bone resorption in humans
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Alpha 2 adrenergic receptor; Bone turnover; Osteoclast; Sympathetic
   nervous system
ID SYMPATHETIC NERVOUS SYSTEM; BETA BLOCKER USE; FRACTURE RISK;
   POSTMENOPAUSAL WOMEN; MINERAL DENSITY; MASS; TURNOVER; BLOOD
AB A Summary Inhibition of sympathetic signaling to bone reduces bone resorption in rodents. In contrast, we show that pharmacological reduction of the sympathetic tone increases bone resorption in humans in vivo. This effect does not appear to be mediated via a direct pharmacological effect on the osteoclast.
   Introduction Inhibition of sympathetic signaling to bone reduces bone resorption in rodents. It is uncertain whether a similar role for the sympathetic nervous system exists in humans. The sympathetic tone can be reduced by clonidine, which acts via alpha 2 adrenergic receptors in the brainstem. Our objective was to determine the effect of clonidine on bone turnover in humans.
   Methods The acute effect of a single oral dose of 0.3 mg clonidine on serum bone turnover markers (C terminal cross linking telopeptides of collagen type I (CTx), a marker for bone resorption, and procollagen type 1 N propeptide (P1NP), a marker for bone formation) was determined in a randomized crossover design in 12 healthy volunteers, aged 18 70 years. In addition, we assessed the effect of clonidine on the number of tartrate resistant acid phosphatase positive multinucleated cells (TRAcP+ MNCs) and bone resorption.
   Results CTx concentrations increased after clonidine treatment compared to the control condition (p = 0.035). P1NP concentrations were not affected by clonidine (p = 0.520).
   In vitro, clonidine had no effect on the number of TRAcP+ MNCs (p = 0.513) or on bone resorption (p = 0.996).
   Conclusions We demonstrated that clonidine increases bone resorption in humans in vivo. This effect does not appear to be mediated via a direct effect on the osteoclast.
C1 [Limonard, E. J.; Fliers, E.; Bisschop, P. H.] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, POB 22660, NL 1100 DD Amsterdam, Netherlands.
   [Schoenmaker, T.; de Vries, T. J.] Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Periodontol, Gustav Mahlerlaan 3004, NL 1081 LA Amsterdam, Netherlands.
   [Schoenmaker, T.; de Vries, T. J.; Everts, V.] Vrije Univ Amsterdam, MOVE Res Inst, Gustav Mahlerlaan 3004, NL 1081 LA Amsterdam, Netherlands.
   [Tanck, M. W.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, POB 22660, NL 1100 DD Amsterdam, Netherlands.
   [Heijboer, A. C.] Vrije Univ Amsterdam, Med Ctr, Endocrine Lab, Dept Clin Chem, POB 7057, NL 1007 MB Amsterdam, Netherlands.
   [Endert, E.] Univ Amsterdam, Acad Med Ctr, Lab Endocrinol, Dept Clin Chem, POB 22660, NL 1100 DD Amsterdam, Netherlands.
   [Everts, V.] Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Cell Biol, Gustav Mahlerlaan 3004, NL 1081 LA Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; Vrije
   Universiteit Amsterdam; University of Amsterdam; Academic Center for
   Dentistry Amsterdam; Vrije Universiteit Amsterdam; Academic Center for
   Dentistry Amsterdam; University of Amsterdam; Academic Medical Center
   Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam;
   Academic Medical Center Amsterdam; Academic Center for Dentistry
   Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam
RP Bisschop, PH (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, POB 22660, NL 1100 DD Amsterdam, Netherlands.
EM e.j.limonard@amc.uva.nl; t.schoenmaker@acta.nl; teun.devries@acta.nl;
   m.w.tanck@amc.uva.nl; a.heijboer@vumc.nl; e.endert@amc.uva.nl;
   e.fliers@amc.uva.nl; v.everts@acta.nl; p.h.bisschop@amc.uva.nl
RI Tanck, Michael/AFY 1138 2022; Fliers, Eric/JKH 9635 2023
OI Fliers, Eric/0000 0001 8048 9050; Schoenmaker, Ton/0000 0001 6649 374X;
   Heijboer, Annemieke/0000 0002 6712 9955; Tanck,
   Michael/0000 0001 9828 4459; Bisschop, Peter/0000 0002 3583 6567
FU Netherlands Organization for Health Research and Development (ZonMw)
   [90700308]
FX Peter H Bisschop is supported by The Netherlands Organization for Health
   Research and Development (ZonMw) Ref: 90700308.
CR Arai M, 2003, BBA MOL CELL RES, V1640, P137, DOI 10.1016/S0167 4889(03)00042 9
   Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756 3282(99)00232 X
   Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006
   Bonnet N, 2006, J PHARMACOL EXP THER, V318, P1118, DOI 10.1124/jpet.106.105437
   Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012
   Bredella MA, 2014, BONE, V62, P29, DOI 10.1016/j.bone.2014.01.022
   Davison NL, 2014, BIOMATERIALS, V35, P7441, DOI 10.1016/j.biomaterials.2014.05.048
   de Jong WHA, 2007, CLIN CHEM, V53, P1684, DOI 10.1373/clinchem.2007.087114
   de Vries F, 2007, CALCIFIED TISSUE INT, V80, P69, DOI 10.1007/s00223 006 0213 1
   de Vries TJ, 1999, BRIT J CANCER, V80, P883, DOI 10.1038/sj.bjc.6690436
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Eekman DA, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 167
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Fagerholm V, 2011, BASIC CLIN PHARMACOL, V108, P365, DOI 10.1111/j.1742 7843.2011.00699.x
   Fonseca TL, 2011, J BONE MINER RES, V26, P591, DOI 10.1002/jbmr.243
   GILAD I, 1979, LANCET, V2, P1242
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   KERANEN A, 1978, EUR J CLIN PHARMACOL, V13, P97, DOI 10.1007/BF00609752
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   Levasseur R, 2005, J AM GERIATR SOC, V53, P550, DOI 10.1111/j.1532 5415.2005.53178_7.x
   Meisinger C, 2007, OSTEOPOROSIS INT, V18, P1189, DOI 10.1007/s00198 007 0354 8
   Mlakar V, 2015, J CELL MOL MED, V19, P1520, DOI 10.1111/jcmm.12505
   Motyl KJ, 2012, J CLIN ENDOCR METAB, V97, P3908, DOI 10.1210/jc.2012 3205
   Pasco JA, 2004, J BONE MINER RES, V19, P19, DOI 10.1359/JBMR.0301214
   Pérez Castrilón JL, 2007, JOINT BONE SPINE, V74, P259, DOI 10.1016/j.jbspin.2006.09.015
   Reid IR, 2005, J BONE MINER RES, V20, P613, DOI 10.1359/JBMR.041202
   Reid IR, 2005, J CLIN ENDOCR METAB, V90, P5212, DOI 10.1210/jc.2005 0573
   Rejnmark L, 2006, J HYPERTENS, V24, P581, DOI 10.1097/01.hjh.0000203845.26690.cb
   Rejnmark L, 2004, CALCIFIED TISSUE INT, V75, P365, DOI 10.1007/s00223 004 0222 x
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Schlienger RG, 2004, JAMA J AM MED ASSOC, V292, P1326, DOI 10.1001/jama.292.11.1326
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Togari A, 2005, EXPERT OPIN THER TAR, V9, P931, DOI 10.1517/14728222.9.5.931
   Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121
   Toulis KA, 2014, OSTEOPOROSIS INT, V25, P121, DOI 10.1007/s00198 013 2498 z
   Veldhuis Vlug AG, 2015, BONE, V71, P196, DOI 10.1016/j.bone.2014.10.024
   Veldhuis Vlug AG, 2012, J CLIN ENDOCR METAB, V97, pE2093, DOI 10.1210/jc.2012 2823
   WING LMH, 1977, EUR J CLIN PHARMACOL, V12, P463, DOI 10.1007/BF00561067
   Yang S, 2012, BONE, V51, P969, DOI 10.1016/j.bone.2012.07.013
   Yang SM, 2011, BONE, V48, P451, DOI 10.1016/j.bone.2010.10.170
NR 40
TC 4
Z9 6
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2016
VL 27
IS 3
BP 1063
EP 1071
DI 10.1007/s00198 015 3312 x
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DF4IO
UT WOS:000371311400025
PM 26439240
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU An, JD
   Li, GJ
   Zhang, J
   Zhou, HY
   Jian, J
   Wang, XW
   Feng, XF
   Wang, SK
AF An, Jiangdong
   Li, Guangjie
   Zhang, Jin
   Zhou, Haiyu
   Jian, Jin
   Wang, Xingwen
   Feng, Xiaofei
   Wang, Shuanke
TI GNAS knockdown suppresses osteogenic differentiation of mesenchymal stem
   cells via activation of Hippo signaling pathway
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE GNAS; hippo signaling pathway; knockout; mesenchymal stem cells;
   osteogenic differentiation
ID OSTEOBLAST DIFFERENTIATION; METHYLATION; EXPRESSION; ROLES; LOCUS
AB Bone marrow derived mesenchymal stem cells (BMSCs) are a suitable option for cell based tissue engineering therapies due to their ability to renew and differentiate into multiple different tissue types, such as bone. Over the last decade, the effect of GNAS on the regulation of osteoblast differentiation has attracted great attention. Herein, this study aimed to explore the role of GNAS in osteogenic differentiation of MSCs. A total of 85 GNAS(f/f) male mice were selected for animal experiments and 10 GNAS(f/f) male mice for BMSC isolation to conduct cell experiments. The mice and BMSCs were treated with Verteporfin (a Hippo signaling pathway inhibitor) to inhibit the Hippo signaling pathway or recombinant adenovirus expressing Cre to knockout the GNAS expression. Next, computed tomography scan, Von Kossa staining, and alizarin red staining were performed to detect osteogenic differentiation ability. Moreover, immunohistochemistry and alkaline phosphatase (ALP) staining were used to assess the expression of Oc and Osx in femur tissues and ALP activity. At last, the expression of GNAS, osteogenic markers, and factors related to the Hippo signaling pathway was evaluated. Initially, the results displayed successful knockout of the GNAS gene from mice and BMSCs. Moreover, the data indicated that GNAS knockout inhibits expression of Oc, Osx, ALP, BMP 2, and Runx2, and ALP activity. Additionally, GNAS knockout promotes activation of the Hippo signaling pathway, so as to repress osteogenic differentiation. Collectively, depleted GNAS exerts an inhibitory role in osteogenic differentiation of MSCs by activating Hippo signaling pathway, providing a candidate mediator for osteoporosis.
C1 [An, Jiangdong; Zhang, Jin; Zhou, Haiyu; Jian, Jin; Wang, Xingwen; Feng, Xiaofei; Wang, Shuanke] Lanzhou Univ, Hosp 2, 82 Cuiyingmen, Lanzhou 730030, Gansu, Peoples R China.
   [Li, Guangjie] Lanzhou Univ, Hosp 1, Lanzhou, Gansu, Peoples R China.
C3 Lanzhou University; Lanzhou University
RP Wang, SK (通讯作者)，Lanzhou Univ, Hosp 2, 82 Cuiyingmen, Lanzhou 730030, Gansu, Peoples R China.
EM wsk1959@163.com
RI Feng, xiaofei/NZO 5554 2025
CR Bae SE, 2012, BIOMACROMOLECULES, V13, P2811, DOI 10.1021/bm300791h
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Byun MR, 2014, CELL DEATH DIFFER, V21, P854, DOI 10.1038/cdd.2014.8
   Duplomb L, 2007, STEM CELLS, V25, P544, DOI 10.1634/stemcells.2006 0395
   Elli FM, 2017, HORM METAB RES, V49, P250, DOI 10.1055/s 0042 115305
   Fei Wang, 2016, Hua Xi Kou Qiang Yi Xue Za Zhi, V34, P286
   Fu G, 2016, CURR STEM CELL RES T, V11, P235, DOI 10.2174/1574888X10666150528153313
   Grybek V, 2014, STEM CELL REP, V3, P432, DOI 10.1016/j.stemcr.2014.07.002
   Guillot PV, 2008, DIFFERENTIATION, V76, P946, DOI 10.1111/j.1432 0436.2008.00279.x
   Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458
   Hong AW, 2016, NAT REV GASTRO HEPAT, V13, P324, DOI 10.1038/nrgastro.2016.59
   Huang H, 2011, CELL PROLIFERAT, V44, P420, DOI 10.1111/j.1365 2184.2011.00769.x
   Jiang YP, 2013, ACTA BIOMATER, V9, P7564, DOI 10.1016/j.actbio.2013.03.010
   Kelsey G, 2010, AM J MED GENET C, V154C, P377, DOI 10.1002/ajmg.c.30271
   Kim K, 2011, ACTA BIOMATER, V7, P1249, DOI 10.1016/j.actbio.2010.11.007
   Lee SY, 2013, CELL CYCLE, V12, P67, DOI 10.4161/cc.22962
   Li Lang, 2017, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V29, P731, DOI 10.3760/cma.j.issn.2095 4352.2017.08.012
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Liu ZP, 2017, ONCOTARGET, V8, P62298, DOI 10.18632/oncotarget.19749
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Moon JS, 2014, J BONE MINER RES, V29, P1586, DOI 10.1002/jbmr.2197
   Pignolo RJ, 2011, J BONE MINER RES, V26, P2647, DOI 10.1002/jbmr.481
   Ramasubramanian A, 2011, PHARM RES DORDR, V28, P1328, DOI 10.1007/s11095 011 0406 9
   Rojo AI, 2012, FREE RADICAL BIO MED, V52, P473, DOI 10.1016/j.freeradbiomed.2011.11.003
   Rui YF, 2011, J ORTHOP RES, V29, P390, DOI 10.1002/jor.21218
   Sebio A, 2016, PHARMACOGENOMICS J, V16, P312, DOI 10.1038/tpj.2015.64
   Sun J, 2015, MOL MED REP, V12, P4230, DOI 10.3892/mmr.2015.3954
   Vlaikou AM, 2017, BBA MOL CELL RES, V1864, P1371, DOI 10.1016/j.bbamcr.2017.05.005
   Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238
   Watt KI, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00942
   Wegman F, 2011, EUR CELLS MATER, V21, P230, DOI 10.22203/eCM.v021a18
   Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037
   Zhang K, 2015, ENDOCRINE, V50, P239, DOI 10.1007/s12020 015 0554 5
   Zhang Q, 2019, J CELL PHYSIOL, V234, P13969, DOI 10.1002/jcp.28082
   Zhang S, 2012, HORM METAB RES, V44, P724, DOI 10.1055/s 0032 1321845
   Zhou N, 2016, CELL TISSUE RES, V366, P101, DOI 10.1007/s00441 016 2403 0
NR 36
TC 18
Z9 19
U1 1
U2 46
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2019
VL 234
IS 12
BP 22299
EP 22310
DI 10.1002/jcp.28796
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA IV6KF
UT WOS:000484376600073
PM 31148202
DA 2025 08 17
ER

PT J
AU Kong, YL
   Zhou, L
   Liao, SY
   Wang, CP
   Chen, J
   Cai, XP
   Zhao, SC
   Song, DW
   Zhang, YD
AF Kong, Yanlong
   Zhou, Lei
   Liao, Shiyang
   Wang, Changping
   Chen, Jing
   Cai, Xiaopan
   Zhao, Shichang
   Song, Dianwen
   Zhang, Yadong
TI Dual peptide engineered and gadolinium doped polydopamine particles as
   targeted nanotheranostics for the treatment of osteosarcoma and related
   osteolysis
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Bone targeting; Multifunctional nanoparticles; Peptide; Melanin like
   nanoparticles; Osteosarcoma
ID OSTEOCLAST DIFFERENTIATION; PHOTOTHERMAL THERAPY; BREAST CANCER; BONE;
   TUMOR; NANOPARTICLES; INHIBITION
AB The treatment of malignant bone tumors such as osteosarcoma and tumor associated bone destruction is challenging in clinic. Here, we designed a type of bone targeted nanotheranostics to treat osteosarcoma. A bone targeting peptide consisting of eight aspartic acids and a tumor targeting peptide were conjugated onto poly dopamine nanoparticles bearing gadolinium ions at different molar ratios. The optimized nanoformulation showed high photothermal efficiency, bone targeting affinity, and were efficiently accumulated at tumor site and osteolysis lesions after systematic administration. In addition, the peptide conjugated on nanoparticle surface efficiently inhibited osteoclast formation and bone destruction both in vitro and in vivo. As a result, the prepared nanoparticles combination with near infrared laser irradiation efficiently inhibited tumor growth and tumor associated bone resorption in an osteosarcoma xenograft mice model. This study provides a new nanotheranostic to treat osteosarcoma and related osteolysis.
C1 [Kong, Yanlong; Liao, Shiyang; Zhang, Yadong] Anhui Univ Sci & Technol, Dept Orthoped, Fengxian Hosp, Shanghai 201499, Peoples R China.
   [Zhou, Lei; Wang, Changping; Song, Dianwen] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai 200080, Peoples R China.
   [Chen, Jing] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 201203, Peoples R China.
   [Cai, Xiaopan] Navy Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai 200003, Peoples R China.
   [Zhao, Shichang] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Orthoped Surg, Shanghai 200233, Peoples R China.
   [Zhang, Yadong] Southern Med Univ, Ctr Orthopaed Surg, Dept Spine, Affiliated Hosp 3, Guangzhou 510515, Peoples R China.
C3 Anhui University of Science & Technology; Shanghai Jiao Tong University;
   Shanghai University of Traditional Chinese Medicine; Naval Medical
   University; Shanghai Jiao Tong University; Southern Medical University  
   China
RP Zhang, YD (通讯作者)，Anhui Univ Sci & Technol, Dept Orthoped, Fengxian Hosp, Shanghai 201499, Peoples R China.; Song, DW (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai 200080, Peoples R China.; Cai, XP (通讯作者)，Navy Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai 200003, Peoples R China.; Zhao, SC (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Orthoped Surg, Shanghai 200233, Peoples R China.; Zhang, YD (通讯作者)，Southern Med Univ, Ctr Orthopaed Surg, Dept Spine, Affiliated Hosp 3, Guangzhou 510515, Peoples R China.
EM caipan1982@163.com; zhaoshichang0404@163.com; dianwen.song@shgh.cn;
   zhangyadong@smu.edu.cn
RI Kong, Yanlong/HGV 2222 2022; Wang, Changping/JSK 6142 2023; Zhou,
   Lei/S 3956 2017
FU National Natural Science Foundation of China [51972212, 81871470,
   81871774]
FX Acknowledgements This work is supported by the National Natural Science
   Foundation of China (51972212, 81871470 and 81871774) .
CR Bayles I, 2019, J CLIN INVEST, V129, P4377, DOI 10.1172/JCI127718
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coury F, 2013, P NATL ACAD SCI USA, V110, P2163, DOI 10.1073/pnas.1206392110
   Dang WT, 2018, BIOMATERIALS, V160, P92, DOI 10.1016/j.biomaterials.2017.11.020
   Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Dickerson TJ, 2012, J AUTOIMMUN, V39, P369, DOI 10.1016/j.jaut.2012.06.001
   Gao P, 2022, CHINESE CHEM LETT, V33, P575, DOI 10.1016/j.cclet.2021.08.023
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70
   Grey A, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa062
   Grünherz L, 2020, J CELL MOL MED, V24, P5665, DOI 10.1111/jcmm.15227
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040 8428(01)00179 2
   Huang P, 2013, ANGEW CHEM INT EDIT, V52, P13958, DOI 10.1002/anie.201308986
   Liu YL, 2013, ADV MATER, V25, P1353, DOI 10.1002/adma.201204683
   Min SK, 2018, CELL DEATH DIFFER, V25, P268, DOI 10.1038/cdd.2017.153
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Rathore R, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061182
   Rocha LA, 2018, BIOTECHNOL ADV, V36, P208, DOI 10.1016/j.biotechadv.2017.11.004
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Tucci M, 2016, BRIT J HAEMATOL, V173, P59, DOI 10.1111/bjh.13922
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Wang CP, 2015, SMALL, V11, P2080, DOI 10.1002/smll.201403315
   Wang LY, 2019, SMALL, V15, DOI 10.1002/smll.201903254
   Wang YT, 2021, SCI CHINA MATER, V64, P474, DOI 10.1007/s40843 020 1405 8
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wang YT, 2017, BIOMATERIALS, V114, P97, DOI 10.1016/j.biomaterials.2016.11.010
   Wang Z, 2017, SMALL, V13, DOI 10.1002/smll.201701830
   Westhrin M, 2020, BLOOD, V136, P2656, DOI 10.1182/blood.2020006045
   Wu YZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1007 1
   Yan Y, 2019, ACS APPL MATER INTER, V11, P160, DOI 10.1021/acsami.8b15827
   Zaveri TD, 2017, BIOMATERIALS, V115, P128, DOI 10.1016/j.biomaterials.2016.10.038
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhang PC, 2016, THERANOSTICS, V6, P948, DOI 10.7150/thno.15217
   Zhang WX, 2019, MAT SCI ENG C MATER, V102, P458, DOI 10.1016/j.msec.2019.04.025
   Zhou ZJ, 2019, BIOMATERIALS, V203, P63, DOI 10.1016/j.biomaterials.2019.02.023
   Zhou ZJ, 2019, BIOMATERIALS, V194, P130, DOI 10.1016/j.biomaterials.2018.12.024
NR 44
TC 4
Z9 4
U1 6
U2 81
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD SEP 15
PY 2022
VL 444
AR 136516
DI 10.1016/j.cej.2022.136516
EA APR 2022
PG 9
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 1N1GY
UT WOS:000800412400002
DA 2025 08 17
ER

PT J
AU Gao, XL
   Qin, W
   Chen, LL
   Fan, WG
   Ma, T
   Schneider, A
   Yang, MY
   Obianom, ON
   Chen, JY
   Weir, MD
   Shu, Y
   Zhao, L
   Lin, ZM
   Xu, HHK
AF Gao, Xianling
   Qin, Wei
   Chen, Lingling
   Fan, Wenguo
   Ma, Tao
   Schneider, Abraham
   Yang, Mengyao
   Obianom, Obinna N.
   Chen, Jiayao
   Weir, Michael D.
   Shu, Yan
   Zhao, Liang
   Lin, Zhengmei
   Xu, Hockin H. K.
TI Effects of Targeted Delivery of Metformin and Dental Pulp Stem Cells on
   Osteogenesis via Demineralized Dentin Matrix under High Glucose
   Conditions
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE demineralized dentin matrix; metformin; mesenchymal stem cell
   transplantation; diabetes mellitus; osteogenesis
ID ANTIDIABETIC DRUG METFORMIN; BONE REGENERATION; DIABETES MELLITUS;
   MARROW; PROLIFERATION; DIFFERENTIATION; TEETH; MASS
AB High glucose condition inhibited osteoblast differentiation could be a main mechanism contributing to the decreased bone repair associated with diabetes. Metformin, a widely prescribed antidiabetic drug, was shown to have osteogenic properties in our previous study. Transplanted mesenchymal stromal cells (MSCs) may differentiate into osteoblasts and promote bone regeneration. Our study aimed to combine the benefits of metformin and MSCs transplantation on osteogenesis in high glucose conditions. We developed demineralized dentin matrix (DDM) as a carrier to target deliver metformin and dental pulp derived MSCs (DPSCs). We collected clinically discarded teeth, isolated DPSCs from the dental pulp, and prepared the DDM from the dentin. The DDM was observed by scanning electron microscopy and was found to have well distributed tubes. Then, metformin was loaded into the DDM to form the DDM Met complex (DDM Met); DDM Met released metformin at a favorable concentration. The DPSCs seeded with the DDM Met in a high glucose medium showed satisfactory attachment and viability together with increased mineralization and upregulated osteogenesis related genes, including alkaline phosphatase (ALP), osteocalcin (OCN), runt related transcription factor 2 (Runx2), and osteopontin (OPN). A possible mechanism of the enhanced osteogenic differentiation of DPSCs was explored, and the adenosine 5' monophosphate (AMP) activated protein kinase (AMPK) pathway was found to play a role in the enhancement of osteogenesis. DDM Met appeared to be a successful metformin and DPSC carrier that allowed for the local delivery of metformin and DPSCs in high glucose conditions. DDM Met DPSC construct has promising prospects to promote osteogenesis and enhance the much needed diabetic bone regeneration.
C1 [Gao, Xianling; Qin, Wei; Weir, Michael D.; Zhao, Liang; Xu, Hockin H. K.] Univ Maryland, Dept Adv Oral Sci & Therapeut, Sch Dent, Baltimore, MD 21201 USA.
   [Xu, Hockin H. K.] Univ Maryland, Ctr Stem Cell Biol & Regenerat Med, Sch Med, Baltimore, MD 21201 USA.
   [Xu, Hockin H. K.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Sch Med, Baltimore, MD 21201 USA.
   [Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Orthoped Surg, Guangzhou 510515, Guangdong, Peoples R China.
   [Gao, Xianling; Qin, Wei; Chen, Lingling; Fan, Wenguo; Yang, Mengyao; Chen, Jiayao; Lin, Zhengmei] Sun Yat Sen Univ, Guanghua Sch Stomatol, Guangzhou 510055, Peoples R China.
   [Gao, Xianling; Qin, Wei; Chen, Lingling; Fan, Wenguo; Yang, Mengyao; Chen, Jiayao; Lin, Zhengmei] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Peoples R China.
   [Ma, Tao; Schneider, Abraham] Univ Maryland, Dept Oncol & Diagnost Sci, Sch Dent, Baltimore, MD 21201 USA.
   [Obianom, Obinna N.; Shu, Yan] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   Southern Medical University   China; Sun Yat Sen University; University
   System of Maryland; University of Maryland Baltimore; University System
   of Maryland; University of Maryland Baltimore
RP Zhao, L; Xu, HHK (通讯作者)，Univ Maryland, Dept Adv Oral Sci & Therapeut, Sch Dent, Baltimore, MD 21201 USA.; Xu, HHK (通讯作者)，Univ Maryland, Ctr Stem Cell Biol & Regenerat Med, Sch Med, Baltimore, MD 21201 USA.; Xu, HHK (通讯作者)，Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Sch Med, Baltimore, MD 21201 USA.; Zhao, L (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthoped Surg, Guangzhou 510515, Guangdong, Peoples R China.; Lin, ZM (通讯作者)，Sun Yat Sen Univ, Guanghua Sch Stomatol, Guangzhou 510055, Peoples R China.; Lin, ZM (通讯作者)，Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Peoples R China.
EM lzhaonf@126.com; linzhm@mail.sysu.edu.cn; hxu@umaryland.edu
RI Zhao, Liang/T 9147 2019; Schneider, Abraham/AAR 5941 2021; Obianom,
   Obinna/AAV 4396 2021; Gao, Xianling/ITU 4818 2023; yang,
   mengyao/MGA 6651 2025
OI Obianom, Obinna (Obi)/0000 0002 2957 6615; 
FU National Science Foundation of China [81670984, 81873713]; International
   Cooperation Project of Science and Technology in Guangdong Province
   [2016B050502008]; University of Maryland Baltimore Seed Grant;
   University of Maryland School of Dentistry Bridge Grant
FX This study was supported by the National Science Foundation of China
   81670984 (Z.L.) and 81873713 (Z.L.), the International Cooperation
   Project of Science and Technology in Guangdong Province 2016B050502008
   (Z.L.), the University of Maryland Baltimore Seed Grant (H.X.), and the
   University of Maryland School of Dentistry Bridge Grant (H.X.).
CR Al Jofi FE, 2018, CYTOTHERAPY, V20, P650, DOI 10.1016/j.jcyt.2018.02.369
   Arandjelovic S, 2015, NAT IMMUNOL, V16, P907, DOI 10.1038/ni.3253
   Bahrambeigi S, 2019, BIOMED PHARMACOTHER, V109, P1593, DOI 10.1016/j.biopha.2018.11.032
   Bertassoni LE, 2017, DENT MATER, V33, P637, DOI 10.1016/j.dental.2017.03.008
   Bertassoni LE, 2010, SCANNING, V32, P312, DOI 10.1002/sca.20199
   Bornstein S, 2017, ENDOCRINOLOGY, V158, P3369, DOI 10.1210/en.2017 00299
   Cao BR, 2016, BIOMED PHARMACOTHER, V84, P544, DOI 10.1016/j.biopha.2016.09.058
   Chen FM, 2012, BIOMATERIALS, V33, P6320, DOI 10.1016/j.biomaterials.2012.05.048
   Chen WC, 2013, BIOMATERIALS, V34, P9917, DOI 10.1016/j.biomaterials.2013.09.002
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Filion TM, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0521 6
   Gao XL, 2018, TISSUE ENG PT A, V24, P1341, DOI [10.1089/ten.tea.2018.0016, 10.1089/ten.TEA.2018.0016]
   Gao XL, 2019, APPL SCI BASEL, V9, DOI 10.3390/app9051013
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hankamolsiri W, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9674614
   He L, 2019, NAT MATER, V18, P627, DOI 10.1038/s41563 019 0368 6
   Hegazy SK, 2015, J BONE MINER METAB, V33, P207, DOI 10.1007/s00774 014 0581 y
   Isobe Y, 2016, INT J ORAL MAX SURG, V45, P124, DOI 10.1016/j.ijom.2015.06.022
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Khorsand B, 2017, J CONTROL RELEASE, V248, P53, DOI 10.1016/j.jconrel.2017.01.008
   Kim YK, 2013, J KOR ASSOC ORAL MAX, V39, P103, DOI 10.5125/jkaoms.2013.39.3.103
   Koga T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147235
   Li J, 2012, XENOTRANSPLANTATION, V19, P273, DOI 10.1111/xen.12000
   Li X, 2015, BIOMATERIALS, V36, P44, DOI 10.1016/j.biomaterials.2014.09.012
   Li YM, 2007, BIOCHEM BIOPH RES CO, V363, P209, DOI 10.1016/j.bbrc.2007.08.161
   Liu DW, 2018, CELL RES, V28, P918, DOI 10.1038/s41422 018 0070 2
   Liu GL, 2015, CELLS TISSUES ORGANS, V201, P65, DOI 10.1159/000440952
   Looker AC, 2016, BONE, V82, P9, DOI 10.1016/j.bone.2014.12.008
   Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440 1681.1998.tb02179.x
   Mao JJ, 2012, CELL STEM CELL, V11, P291, DOI 10.1016/j.stem.2012.08.010
   Martin V, 2018, MAT SCI ENG C MATER, V82, P363, DOI 10.1016/j.msec.2017.04.038
   MARYCZ K, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/4710326
   Minamizato T, 2018, INT J ORAL MAX SURG, V47, P125, DOI 10.1016/j.ijom.2017.02.1279
   Qin W, 2018, J ENDODONT, V44, P576, DOI 10.1016/j.joen.2017.11.017
   Ranc V, 2018, ANAL BIOANAL CHEM, V410, P7113, DOI 10.1007/s00216 018 1311 4
   Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862
   Salehi S, 2016, DENT MATER, V32, P334, DOI 10.1016/j.dental.2015.11.004
   Schmidt Schultz TH, 2005, BIOL CHEM, V386, P767, DOI 10.1515/BC.2005.090
   Setter SM, 2003, CLIN THER, V25, P2991, DOI 10.1016/S0149 2918(03)90089 0
   Shanbhogue VV, 2017, LANCET DIABETES ENDO, V5, P827, DOI 10.1016/S2213 8587(17)30134 1
   Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581 018 0023 5
   Tabatabaei FS, 2016, J BIOMED MATER RES A, V104, P2616, DOI 10.1002/jbm.a.35790
   Taguchi T, 2019, STEM CELLS DEV, V28, P1562, DOI 10.1089/scd.2019.0118
   Takeno A, 2015, BONE, V77, P135, DOI 10.1016/j.bone.2015.04.025
   Tang J, 2016, INT ENDOD J, V49, P670, DOI 10.1111/iej.12498
   von Bahr L, 2012, STEM CELLS, V30, P1575, DOI 10.1002/stem.1118
   Wallner C, 2016, STEM CELL TRANSL MED, V5, P836, DOI 10.5966/sctm.2015 0158
   Wang C, 2012, J BONE MINER METAB, V30, P630, DOI 10.1007/s00774 012 0374 0
   Wang P, 2018, J TISSUE ENG REGEN M, V12, P437, DOI 10.1002/term.2470
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Zhang DY, 2017, MOL MED REP, V16, P1685, DOI 10.3892/mmr.2017.6832
   Zhao YF, 2013, INT J MOL MED, V31, P614, DOI 10.3892/ijmm.2013.1227
   Zhou WN, 2018, J CELL PHYSIOL, V233, P3465, DOI 10.1002/jcp.26199
   Zimmet P, 2016, NAT REV ENDOCRINOL, V12, P616, DOI 10.1038/nrendo.2016.105
NR 55
TC 21
Z9 23
U1 4
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD APR
PY 2020
VL 6
IS 4
BP 2346
EP 2356
DI 10.1021/acsbiomaterials.0c00124
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LD9AU
UT WOS:000526319100047
PM 33455311
DA 2025 08 17
ER

PT J
AU Shimizu, H
   Nakagami, H
   Morita, S
   Tsukamoto, I
   Osako, MK
   Nakagami, F
   Shimosato, T
   Minobe, N
   Morishita, R
AF Shimizu, Hideo
   Nakagami, Hironori
   Morita, Shosuke
   Tsukamoto, Ikuyo
   Osako, Mariana Kiomy
   Nakagami, Futoshi
   Shimosato, Takashi
   Minobe, Noriko
   Morishita, Ryuichi
TI New Treatment of Periodontal Diseases by Using NF κB Decoy
   Oligodeoxynucleotides via Prevention of Bone Resorption and
   Promotion of Wound Healing
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION FACTOR; PORPHYROMONAS GINGIVALIS;
   GENE EXPRESSION; RANKL; CELLS; OSTEOPROTEGERIN; CYTOKINE;
   LIPOPOLYSACCHARIDE; OSTEOPOROSIS; DESTRUCTION
AB Nuclear factor kappa B (NF kappa B) is involved in osteoclast differentiation and activation. Thus, the blockade of the NF kappa B pathway might be a novel therapeutic strategy for treating bone metabolic diseases. Periodontitis is subgingival inflammation caused by bacterial infection; this disease also is thought to be a chronic focal point responsible for systemic diseases. In this study, NF kappa B decoy oligodeoxynucleotides (ODNs) were topically applied for experimental periodontitis in a debris accumulation model and wound healing in a bone defect model of beagle dogs to investigate the effect of decoy ODN on bone metabolism. Application of NF kappa B decoy ODN significantly reduced interleukin 6 activity in crevicular fluid and improved alveolar bone loss in the analysis of dental radiographs and DEXA. Direct measurement of exposed root that lost alveolar bone support revealed that NF kappa B decoy treatment dramatically protected bone from loss. In a bone defect model, NF kappa B decoy ODN promoted the healing process as compared with control scrambled decoy in micro CT analysis. Overall, inhibition of NF kappa B by decoy strategy prevented the progression of bone loss in periodontitis and promoted the wound healing in bone defects through the inhibition of osteoclastic bone resorption. Targeting of NF kappa B might be a potential therapy in various bone metabolic diseases. Antioxid. Redox Signal. 11, 2065 2075.
C1 [Morishita, Ryuichi] Osaka Univ, Div Clin Gene Therapy, Grad Sch Med, Dept Clin Gene Therapy, Suita, Osaka 5650871, Japan.
   [Shimizu, Hideo; Osako, Mariana Kiomy; Nakagami, Futoshi] Osaka Univ, Dept Geriatr Med, Grad Sch Med, Suita, Osaka 5650871, Japan.
   [Nakagami, Hironori] Osaka Univ, Dept Gene Therapy Sci, Grad Sch Med, Suita, Osaka 5650871, Japan.
   [Morita, Shosuke] Osaka Dent Univ, Dept Oral & Maxillofacial Surg 1, Osaka, Japan.
   [Tsukamoto, Ikuyo] Nara Womens Univ, Dept Food Sci & Nutr, Nara 630, Japan.
   [Shimosato, Takashi; Minobe, Noriko] NISSEI BILIS Co Ltd, Res Dept, Shiga, Japan.
C3 University of Osaka; University of Osaka; University of Osaka; Nara
   Womens University
RP Morishita, R (通讯作者)，Osaka Univ, Div Clin Gene Therapy, Grad Sch Med, Dept Clin Gene Therapy, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM morishit@cgt.med.osaka u.ac.jp
RI Nakagami, Hironori/GLU 0570 2022; Osako, Mariana/H 3337 2019
OI Nakagami, Hironori/0000 0003 4494 3601; 
FU National Institute of Biomedical Innovation; Ministry of Public Health
   and Welfare; Japan Promotion of Science; Ministry of Education, Culture,
   Sports, Science and Technology; Japanese Government
FX This work was partially supported by the National Institute of
   Biomedical Innovation, by a grant in aid from the Ministry of Public
   Health and Welfare, by a grant in aid from Japan Promotion of Science,
   and through Special Coordinated Funds of the Ministry of Education,
   Culture, Sports, Science and Technology, the Japanese Government.
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Farman M, 2008, BRIT DENT J, V205, DOI 10.1038/sj.bdj.2008.874
   Farman M, 2008, BR DENT J, V205, P496
   Fujihashi K, 1996, CLIN EXP IMMUNOL, V103, P422
   Garlet GP, 2006, ORAL MICROBIOL IMMUN, V21, P12, DOI 10.1111/j.1399 302X.2005.00245.x
   Han XZ, 2006, J IMMUNOL, V176, P625, DOI 10.4049/jimmunol.176.1.625
   Holmstrup Palle, 2003, Dent Clin North Am, V47, P575, DOI 10.1016/S0011 8532(03)00023 5
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   LOHINAI Z, 2004, BRIT J PHARMACOL, V83, P353
   Martuscelli G, 2000, J PERIODONTOL, V71, P573, DOI 10.1902/jop.2000.71.4.573
   Mogi M, 2004, J DENT RES, V83, P166, DOI 10.1177/154405910408300216
   Murakami S, 1999, J PERIODONTAL RES, V34, P425, DOI 10.1111/j.1600 0765.1999.tb02277.x
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   OGAWA T, 1995, FEMS IMMUNOL MED MIC, V11, P197
   Page RC, 1997, PERIODONTOL 2000, V14, P9, DOI 10.1111/j.1600 0757.1997.tb00189.x
   Rodrigues DC, 2003, J PERIODONTOL, V74, P1361, DOI 10.1902/jop.2003.74.9.1361
   Sacco G, 2008, Minerva Stomatol, V57, P233
   Sakallioglu U, 2004, BIOMATERIALS, V25, P1831, DOI 10.1016/S0142 9612(03)00468 X
   Shimizu H, 2006, GENE THER, V13, P933, DOI 10.1038/sj.gt.3302711
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   SOCRANSKY SS, 1984, J CLIN PERIODONTOL, V11, P21, DOI 10.1111/j.1600 051X.1984.tb01305.x
   Sone T, 2004, BONE, V35, P432, DOI 10.1016/j.bone.2004.05.011
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Tomita T, 2000, RHEUMATOLOGY, V39, P749, DOI 10.1093/rheumatology/39.7.749
   Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186
   Venken K, 2005, BONE, V36, P663, DOI 10.1016/j.bone.2005.01.003
   Wara aswapati N, 2007, J PERIODONTOL, V78, P1062, DOI 10.1902/jop.2007.060398
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang D, 2008, INNATE IMMUN LONDON, V14, P99, DOI 10.1177/1753425907088244
NR 32
TC 36
Z9 38
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523 0864
EI 1557 7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD SEP
PY 2009
VL 11
IS 9
BP 2065
EP 2075
DI 10.1089/ars.2008.2355
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 481LW
UT WOS:000268813900004
PM 19186992
DA 2025 08 17
ER

PT J
AU Grünblatt, E
   Nemoda, Z
   Werling, AM
   Roth, A
   Angyal, N
   Tarnok, Z
   Thomsen, H
   Peters, T
   Hinney, A
   Hebebrand, J
   Lesch, KP
   Romanos, M
   Walitza, S
AF Gruenblatt, Edna
   Nemoda, Zsofia
   Werling, Anna Maria
   Roth, Alexander
   Angyal, Nora
   Tarnok, Zsanett
   Thomsen, Hauke
   Peters, Triinu
   Hinney, Anke
   Hebebrand, Johannes
   Lesch, Klaus Peter
   Romanos, Marcel
   Walitza, Susanne
TI The involvement of the canonical Wnt signaling receptor LRP5 and
   LRP6 gene variants with ADHD and sexual dimorphism: Association
   study and meta analysis
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE attention deficit hyperactivity disorder; gender; genetics;
   polymorphism; SNP
ID GENOME WIDE ASSOCIATION; DEFICIT HYPERACTIVITY DISORDER; BONE MINERAL
   DENSITY; NEURAL TUBE DEFECTS; FUNCTIONAL ANNOTATION; BIPOLAR DISORDER;
   OVERLAP; RISK; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6;
   DIFFERENTIATION
AB Wnt signaling is one of the most abundant pathways involved in processes such as cell proliferation,  polarity, and  differentiation. Altered Wnt signaling has been linked with several neurodevelopmental disorders including attention deficit/hyperactivity disorder (ADHD) as well as with cognitive functions, learning and memory. Particularly, lipoprotein receptor related protein 5 (LRP5) or LRP6 coreceptors, responsible in the activation of the canonical Wnt pathway, were associated with cognitive alterations in psychiatric disorders. Following the hypothesis of Wnt involvement in ADHD, we investigated the association of genetic variations in LRP5 and LRP6 genes with three independent child and adolescent ADHD (cADHD) samples (total 2,917 participants), followed by a meta analysis including previously published data. As ADHD is more prevalent in males, we stratified the analysis according to sex and compared the results with the recent ADHD Psychiatric Genomic Consortium (PGC) GWAS. Meta analyzing our data including previously published cADHD studies, association of LRP5 intronic rs4988319 and rs3736228 (Ala1330Val) with cADHD was observed among girls (OR = 1.80 with 95% CI = 1.07 3.02, p = .0259; and OR = 2.08 with 95% CI = 1.01 4.46, p = .0026, respectively), whereas in boys association between LRP6 rs2302685 (Val1062Ile) and cADHD was present (OR = 1.66, CI = 1.20 2.31, p = .0024). In the PGC ADHD dataset (using pooled data of cADHD and adults) tendency of associations were observed only among females with OR = 1.09 (1.02 1.17) for LRP5 rs3736228 and OR = 1.18 (1.09 1.25) for LRP6 rs2302685. Together, our findings suggest a potential sex specific link of cADHD with LRP5 and LRP6 gene variants, which could contribute to the differences in brain maturation alterations in ADHD affected boys and girls, and suggest possible therapy targets.
C1 [Gruenblatt, Edna; Werling, Anna Maria; Roth, Alexander; Walitza, Susanne] Univ Zurich, Univ Hosp Psychiat Zurich, Dept Child & Adolescent Psychiat & Psychotherapy, Zurich, Switzerland.
   [Gruenblatt, Edna; Walitza, Susanne] Univ Zurich, Neurosci Ctr Zurich, Zurich, Switzerland.
   [Gruenblatt, Edna; Walitza, Susanne] Swiss Fed Inst Technol, Zurich, Switzerland.
   [Gruenblatt, Edna; Walitza, Susanne] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland.
   [Nemoda, Zsofia; Angyal, Nora] Semmelweis Univ, Inst Med Chem Mol Biol & Pathobiochem, Budapest, Hungary.
   [Nemoda, Zsofia] Hungarian Acad Sci, Mol Psychiat Res Grp, MTA SE NAP B, Budapest, Hungary.
   [Tarnok, Zsanett] Vadaskert Child & Adolescent Psychiat Hosp, Budapest, Hungary.
   [Thomsen, Hauke] German Canc Res Ctr, Div Mol Genet Epidemiol C050, Heidelberg, Germany.
   [Peters, Triinu; Hinney, Anke; Hebebrand, Johannes] Univ Duisburg Essen, Univ Hosp Essen, Dept Child & Adolescent Psychiat, Psychosomat & Psychotherapy, Essen, Germany.
   [Lesch, Klaus Peter] Univ Wuezburg, Div Mol Psychiat, Ctr Mental Hlth, Wurzburg, Germany.
   [Lesch, Klaus Peter] IM Sechenov First Moscow State Med Univ, Inst Mol Med, Lab Psychiat Neurobiol, Moscow, Russia.
   [Lesch, Klaus Peter] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Neurosci, Maastricht, Netherlands.
   [Romanos, Marcel] Univ Hosp Wuerzburg, Dept Child & Adolescent Psychiat, Psychosomat & Psychotherapy, Ctr Mental Hlth, Wurzburg, Germany.
C3 University of Zurich; University of Zurich; Swiss Federal Institutes of
   Technology Domain; ETH Zurich; University of Zurich; Zurich Center
   Integrative Human Physiology (ZIHP); Semmelweis University; Hungarian
   Academy of Sciences; Helmholtz Association; German Cancer Research
   Center (DKFZ); University of Duisburg Essen; University of Wurzburg;
   Sechenov First Moscow State Medical University; Maastricht University;
   University of Wurzburg
RP Grünblatt, E (通讯作者)，Univ Zurich, Univ Hosp Psychiat Zurich, Dept Child & Adolescent Psychiat & Psychotherapy, Wagistr 12, CH 8952 Schlieren, Switzerland.
EM edna.gruenblatt@kjpd.uzh.ch
RI tarnok, zsanett/X 1700 2018; Grünblatt, Edna/A 6762 2016; Grunblatt,
   Edna/A 6762 2016; Romanos, Marcel/D 7695 2017; Lesch,
   Klaus Peter/J 4906 2013; Hinney, Anke/D 6953 2011; Thomsen,
   Hauke/M 6515 2017; Walitza, Susanne/AAF 5616 2019; Peters,
   Triinu/AAB 3968 2021
OI Romanos, Marcel/0000 0001 7628 8299; Nemoda, Zsofia/0000 0002 9550 7730;
   Grunblatt, Edna/0000 0001 8505 7265; Walitza,
   Susanne/0000 0002 8161 8683; Lesch, Klaus Peter/0000 0001 8348 153X;
   Hinney, Anke/0000 0001 5659 0706; Thomsen, Hauke/0000 0001 5951 3116;
   Hebebrand, Johannes/0000 0001 5364 6073; 
FU Hungarian Brain Research Program [NAP B KTIA_NAP_13 2014 0011];
   University of Zurich, Filling the Gap; University of Zurich; Deutsche
   Forschungsgemeinschaft [HE1446/9 1HI865/2 1KFO125]
FX Hungarian Brain Research Program, Grant/Award Number: NAP B
   KTIA_NAP_13 2014 0011; University of Zurich, Filling the Gap,
   Grant/Award Number: Postdoctoral to Anna Maria Werling; University of
   Zurich; Deutsche Forschungsgemeinschaft, Grant/Award Number:
   HE1446/9 1HI865/2 1KFO125
CR Aebi M, 2016, AM J MED GENET B, V171, P573, DOI 10.1002/ajmg.b.32346
   Alarcón MA, 2013, NEUROBIOL AGING, V34, DOI 10.1016/j.neurobiolaging.2012.11.004
   Allache R, 2014, HUM MOL GENET, V23, P1687, DOI 10.1093/hmg/ddt558
   [Anonymous], SNIJDERS OOMEN NONVE
   Anttila V, 2018, SCIENCE, V360, P1313, DOI 10.1126/science.aap8757
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belinson H, 2016, MOL PSYCHIATR, V21, P1417, DOI 10.1038/mp.2015.207
   Bengoa Vergniory N, 2015, CELL MOL LIFE SCI, V72, P4157, DOI 10.1007/s00018 015 2028 6
   Bulik Sullivan Brendan, 2015, Nat Genet, V47, P1236, DOI 10.1038/ng.3406
   Caracci Mario O, 2016, Neural Plast, V2016, P9603751, DOI 10.1155/2016/9603751
   Carter M, 2005, P NATL ACAD SCI USA, V102, P12843, DOI 10.1073/pnas.0501963102
   Castelo Branco G, 2010, DEV DYNAM, V239, P211, DOI 10.1002/dvdy.22094
   Chelala C, 2009, BIOINFORMATICS, V25, P655, DOI 10.1093/bioinformatics/btn653
   Curatolo P, 2010, ITAL J PEDIATR, V36, DOI 10.1186/1824 7288 36 79
   Davies W, 2014, FRONT NEUROENDOCRIN, V35, P331, DOI 10.1016/j.yfrne.2014.03.003
   Dayem Ullah Abu Z, 2012, Nucleic Acids Res, V40, pW65, DOI 10.1093/nar/gks364
   De Ferrari GV, 2007, P NATL ACAD SCI USA, V104, P9434, DOI 10.1073/pnas.0603523104
   Demontis D., 2017, bioRxiv
   Dilling H, 1996, PSYCHOPATHOLOGY, V29, P258
   Egger M, 1997, BMJ BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Fortress AM, 2013, J NEUROSCI, V33, P12619, DOI 10.1523/JNEUROSCI.0659 13.2013
   Grob A., 2009, Intelligence and Development Scales
   Grünblatt E, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398 018 0096 8
   Guo YF, 2006, J MED GENET, V43, P798, DOI 10.1136/jmg.2006.041715
   Harriott AM, 2015, EUR J NEUROL, V22, P1235, DOI 10.1111/ene.12735
   Hinney A, 2011, AM J MED GENET B, V156B, P888, DOI 10.1002/ajmg.b.31246
   Hussaini SMQ, 2014, NEUROSCI BIOBEHAV R, V47, P369, DOI 10.1016/j.neubiorev.2014.09.005
   Kaufman A.S., 1983, K ABC Kaufman Assessment Battery for Children
   Kereszturi E, 2007, AM J MED GENET B, V144B, P231, DOI 10.1002/ajmg.b.30444
   Khanzada NS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030527
   Kokubu C, 2004, DEVELOPMENT, V131, P5469, DOI 10.1242/dev.01405
   Kwan V, 2016, J NEURODEV DISORD, V8, DOI 10.1186/s11689 016 9176 3
   Lasky Su J, 2008, AM J MED GENET B, V147B, P1355, DOI 10.1002/ajmg.b.30869
   Lei YP, 2015, HUM MUTAT, V36, P342, DOI 10.1002/humu.22750
   Lesch KP, 2008, J NEURAL TRANSM, V115, P1573, DOI 10.1007/s00702 008 0119 3
   Libro R, 2016, LIFE SCI, V158, P78, DOI 10.1016/j.lfs.2016.06.024
   Liu CC, 2014, NEURON, V84, P63, DOI 10.1016/j.neuron.2014.08.048
   Liu J, 2015, AM J MED GENET B, V168, P236, DOI 10.1002/ajmg.b.32304
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maguschak KA, 2012, J NEUROIMMUNE PHARM, V7, P763, DOI 10.1007/s11481 012 9350 7
   Maguschak KA, 2011, J NEUROSCI, V31, P13057, DOI 10.1523/JNEUROSCI.3248 11.2011
   Mallick B, 2011, RNA BIOL, V8, P665, DOI 10.4161/rna.8.4.15584
   Martin J, 2018, BIOL PSYCHIAT, V83, P1044, DOI 10.1016/j.biopsych.2017.11.026
   Melchers P., 1994, K ABC KAUFMAN ASSESS
   Mulligan Kimberly A, 2017, Mol Neuropsychiatry, V2, P219, DOI 10.1159/000453266
   Neale BM, 2008, AM J MED GENET B, V147B, P1337, DOI 10.1002/ajmg.b.30866
   Noelanders R, 2017, NEUROSCIENTIST, V23, P314, DOI 10.1177/1073858416667270
   Oron O, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040828
   Packer A, 2018, MOL PSYCHIATR, V23, P492, DOI 10.1038/mp.2016.228
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Polanczyk GV, 2014, INT J EPIDEMIOL, V43, P434, DOI 10.1093/ije/dyt261
   Polimanti R, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006618
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ríos JA, 2014, PROG NEUROBIOL, V121, P125, DOI 10.1016/j.pneurobio.2014.07.004
   Rosch KS, 2018, PSYCHIAT RES NEUROIM, V271, P67, DOI 10.1016/j.pscychresns.2017.10.013
   Rothschild PR, 2013, MOL VIS, V19, P2040
   Sedlmeier EM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 941
   Suwazono Y, 2006, LIFE SCI, V78, P2475, DOI 10.1016/j.lfs.2005.10.001
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Taurines R, 2012, ADHD ATTEND DEFICIT, V4, P115, DOI 10.1007/s12402 012 0086 2
   Tewes U, 1999, HAMBURG WECHSLER INT
   Thomas R, 2015, PEDIATRICS, V135, pE994, DOI 10.1542/peds.2014 3482
   Tran BNH, 2008, BMC MED GENET, V9, DOI 10.1186/1471 2350 9 55
   Ullah AZD, 2013, BRIEF BIOINFORM, V14, P437, DOI 10.1093/bib/bbt004
   Urano T, 2009, ENDOCR J, V56, P625, DOI 10.1507/endocrj.K09E 133
   Van den Bergh BRH, 2020, NEUROSCI BIOBEHAV R, V117, P26, DOI 10.1016/j.neubiorev.2017.07.003
   van Hulzen KJE, 2017, BIOL PSYCHIAT, V82, P634, DOI 10.1016/j.biopsych.2016.08.040
   van Meurs JBJ, 2006, J BONE MINER RES, V21, P141, DOI 10.1359/JBMR.050904
   Walitza S, 2005, MOL PSYCHIATR, V10, P1126, DOI 10.1038/sj.mp.4001734
   Wang Z, 2017, TRANSL LUNG CANCER R, V6, P6, DOI 10.21037/tlcr.2017.02.04
   Wechsler D.I., 1991, Examiners manual: Wechsler intelligence scale for childrenthird edition, VThird
   Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110
   Weiss R.H., 2006, GRUNDINTELLIGENZTEST
   Weissflog L, 2013, EUR NEUROPSYCHOPHARM, V23, P436, DOI 10.1016/j.euroneuro.2012.07.017
   World Health Organization, 2016, 10 INT CLASS DIS ICD
   Xu Y., 2014, ASIAN AGR RES US CHI, V6, P1
   Yang CW, 2013, MOL BIOL REP, V40, P525, DOI 10.1007/s11033 012 2089 7
   Zhang LQ, 2015, NEUROCHEM INT, V87, P13, DOI 10.1016/j.neuint.2015.05.001
   Zhang YH, 2014, CNS NEUROL DISORD DR, V13, P765, DOI 10.2174/1871527312666131223114149
   Zhao HY, 2017, HUM GENET, V136, P263, DOI 10.1007/s00439 016 1755 6
   Zhou CJ, 2004, J NEUROSCI, V24, P121, DOI 10.1523/JNEUROSCI.4071 03.2004
NR 83
TC 24
Z9 24
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4841
EI 1552 485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD SEP
PY 2019
VL 180
IS 6
SI SI
BP 365
EP 376
DI 10.1002/ajmg.b.32695
PG 12
WC Genetics & Heredity; Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity; Psychiatry
GA IM6EN
UT WOS:000478086300005
PM 30474181
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Doolittle, ML
   Saul, D
   Kaur, J
   Rowsey, JL
   Vos, SJ
   Pavelko, KD
   Farr, JN
   Monroe, DG
   Khosla, S
AF Doolittle, Madison L.
   Saul, Dominik
   Kaur, Japneet
   Rowsey, Jennifer L.
   Vos, Stephanie J.
   Pavelko, Kevin D.
   Farr, Joshua N.
   Monroe, David G.
   Khosla, Sundeep
TI Multiparametric senescent cell phenotyping reveals targets of senolytic
   therapy in the aged murine skeleton
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; MESENCHYMAL STROMAL CELLS; DENTIN MATRIX
   PROTEIN 1; DNA DAMAGE RESPONSE; BONE MARROW; SINGLE CELL; OSTEOBLAST
   DIFFERENTIATION; TRANSCRIPTION FACTOR; GENE EXPRESSION; PPAR GAMMA
AB Senescence drives organismal aging, yet the deep characterization of senescent cells in vivo remains incomplete. Here, we apply mass cytometry by time of flight using carefully validated antibodies to analyze senescent cells at single cell resolution. We use multiple criteria to identify senescent mesenchymal cells that are growth arrested and resistant to apoptosis. These p16 + Ki67 BCL 2+ cells are highly enriched for senescence associated secretory phenotype and DNA damage markers, are strongly associated with age, and their percentages are increased in late osteoblasts/osteocytes and CD24(high) osteolineage cells. Moreover, both late osteoblasts/osteocytes and CD24(high) osteolineage cells are robustly cleared by genetic and pharmacologic senolytic therapies in aged mice. Following isolation, CD24+ skeletal cells exhibit growth arrest, senescence associated & beta; galactosidase positivity, and impaired osteogenesis in vitro. These studies thus provide an approach using multiplexed protein profiling to define senescent mesenchymal cells in vivo and identify specific skeletal cell populations cleared by senolytics.
   Technical challenges have previously hindered the detailed study of in vivo senescent cells. Here, the authors deeply characterize senescent skeletal cells across murine aging, establishing CD24 as a marker of osteolineage cells cleared by senolytics.
C1 [Doolittle, Madison L.; Saul, Dominik; Kaur, Japneet; Rowsey, Jennifer L.; Vos, Stephanie J.; Farr, Joshua N.; Monroe, David G.; Khosla, Sundeep] Mayo Clin, Div Endocrinol Diabet & Metab, Rochester, MN 55905 USA.
   [Doolittle, Madison L.; Saul, Dominik; Kaur, Japneet; Rowsey, Jennifer L.; Vos, Stephanie J.; Farr, Joshua N.; Monroe, David G.; Khosla, Sundeep] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA.
   [Saul, Dominik] Univ Tubingen, Dept Trauma & Reconstruct Surg, BG Clin, Tubingen, Germany.
   [Pavelko, Kevin D.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Eberhard Karls University of Tubingen; Mayo
   Clinic
RP Khosla, S (通讯作者)，Mayo Clin, Div Endocrinol Diabet & Metab, Rochester, MN 55905 USA.; Khosla, S (通讯作者)，Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA.
EM khosla.sundeep@mayo.edu
RI Doolittle, Madison/AAB 3047 2022; KAUR, JAPNEET/JFT 0765 2023; Saul,
   Dominik/K 7355 2019; Khosla, Sundeep/AAE 6170 2020; Farr,
   Joshua/B 3355 2011; Pavelko, Kevin/K 7072 2019
OI Farr, Joshua/0000 0002 3179 6414; Monroe, David/0000 0002 4818 0114;
   Saul, Dominik/0000 0002 0673 3710; Khosla, Sundeep/0000 0002 2936 4372;
   Doolittle, Madison/0000 0003 0912 0095; Pavelko,
   Kevin/0000 0001 7555 1315; Rowsey, Jennifer/0009 0005 0677 7907; 
FU Mayo Clinic Center for Clinical and Translational Science (CCaTS);
   American Federation of Aging Research (AFAR) Glenn Foundation for
   Medical Research Postdoctoral Fellowship in Aging Research; Robert and
   Arlene Kogod Center on Aging Pilot Funds; Mayo Clinic Edward C. Kendall
   Fellowship; National Institutes of Health (NIH) [UL1 TR002377, P01
   AG062413, R01 AG076515, U54 AG079754, R01 AG063707, R01 DK128552, T32
   AG049672]; German Research Foundation [413501650]
FX We would like to thank the Mayo Clinic Immune Monitoring Core, and
   specifically Samera Farwana, for the efforts in planning and running
   CyTOF samples. We would also like to thank the Mayo Clinic Genome
   Analysis Core and Co Directors, Julie M. Cunningham, Ph.D., and Eric
   Wieben, Ph.D. in planning and running sequencing experiments. In
   addition, this work was supported by the Mayo Clinic Center for Clinical
   and Translational Science (CCaTS). This work was supported by the
   American Federation of Aging Research (AFAR) Glenn Foundation for
   Medical Research Postdoctoral Fellowship in Aging Research (M.L.D.),
   Robert and Arlene Kogod Center on Aging Pilot Funds (M.L.D.), Mayo
   Clinic Edward C. Kendall Fellowship (M.L.D.), the National Institutes of
   Health (NIH) grants UL1 TR002377 (M.L.D.), P01 AG062413 (S.K., D.G.M.,
   J.N.F.), R01 AG076515 (S.K., D.G.M.), U54 AG079754 (S.K.), R01 AG063707
   (D.G.M.), R01 DK128552 (J.N.F.), T32 AG049672 (M.L.D.), and the German
   Research Foundation (D.F.G., 413501650) (D.S.).
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Lopez Dominguez JA, 2021, AGING US, V13, P13380, DOI 10.18632/aging.203110
   Alquicira Hernandez J, 2021, BIOINFORMATICS, V37, P2485, DOI 10.1093/bioinformatics/btab003
   Althubiti M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.489
   Ambrosi TH, 2021, ELIFE, V10, DOI 10.7554/eLife.66063
   Ambrosi TH, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00189
   Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594
   Amor C, 2020, NATURE, V583, P127, DOI 10.1038/s41586 020 2403 9
   Anh DJ, 1998, CALCIFIED TISSUE INT, V62, P332, DOI 10.1007/s002239900441
   Arnegard ME, 2020, J WOMENS HEALTH, V29, P858, DOI 10.1089/jwh.2019.8247
   Ayre DC, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00146
   Baccin C, 2020, NAT CELL BIOL, V22, P38, DOI 10.1038/s41556 019 0439 6
   Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744
   Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Baryawno N, 2019, CELL, V177, P1915, DOI 10.1016/j.cell.2019.04.040
   Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314
   Bruggner RV, 2014, P NATL ACAD SCI USA, V111, pE2770, DOI 10.1073/pnas.1408792111
   Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010
   Bussian TJ, 2018, NATURE, V562, P578, DOI 10.1038/s41586 018 0543 y
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chandra A, 2022, AGING CELL, V21, DOI 10.1111/acel.13602
   Chandra A, 2020, J BONE MINER RES, V35, P1119, DOI 10.1002/jbmr.3978
   Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Chen TJ, 2014, CURR TOP MICROBIOL, V377, P127, DOI 10.1007/82_2014_364
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Chini EN, 2018, TRENDS PHARMACOL SCI, V39, P424, DOI 10.1016/j.tips.2018.02.001
   Dai YT, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859 021 04054 2
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   DUPERRAY C, 1990, J IMMUNOL, V145, P3678
   Dvinge H, 2014, P NATL ACAD SCI USA, V111, P16802, DOI 10.1073/pnas.1413374111
   Eckhardt BA, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135236
   Eden E, 2011, SCIENCE, V331, P764, DOI 10.1126/science.1199784
   Fang XF, 2010, CELL MOL IMMUNOL, V7, P100, DOI 10.1038/cmi.2009.119
   Farr JN, 2020, CURR OSTEOPOROS REP, V18, P559, DOI 10.1007/s11914 020 00619 x
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822
   Frescas D, 2017, CELL CYCLE, V16, P1526, DOI 10.1080/15384101.2017.1339850
   Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69
   Garcia Sifuentes Y, 2021, ELIFE, V10, DOI [10.7554/eLife.70817, 10.7554/eLife.70817.sa1, 10.7554/eLife.70817.sa2]
   González Gualda E, 2021, FEBS J, V288, P56, DOI 10.1111/febs.15570
   Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Grosse L, 2020, CELL METAB, V32, P87, DOI 10.1016/j.cmet.2020.05.002
   Hall BM, 2017, AGING US, V9, P1867, DOI 10.18632/aging.101268
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Hartman ML, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2417 0
   Helbling PM, 2019, CELL REP, V29, P3313, DOI 10.1016/j.celrep.2019.11.004
   Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125
   Hu L, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.822816
   Idda ML, 2020, AGING US, V12, P4052, DOI 10.18632/aging.102903
   Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21246 9
   Jing X, 2018, CELL PHYSIOL BIOCHEM, V48, P111, DOI 10.1159/000491667
   Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006
   Karnan S, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420 020 00364 1
   Khosla S, 2020, NAT REV ENDOCRINOL, V16, P263, DOI 10.1038/s41574 020 0335 y
   Kirschner K, 2020, BIOCHEM SOC T, V48, P765, DOI 10.1042/BST20190109
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53
   KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516
   Kristiansen G, 2003, CLIN CANCER RES, V9, P4906
   Lagnado A, 2021, EMBO J, V40, DOI 10.15252/embj.2020106048
   Laurent JM, 2010, PROTEOMICS, V10, P4209, DOI 10.1002/pmic.201000327
   LeBrasseur NK, 2015, NESTLE NUTR WORKS SE, V83, P11, DOI 10.1159/000382054
   Liu WJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0029 4
   Mangialardi G, 2016, REGEN MED, V11, P883, DOI 10.2217/rme 2016 0121
   Matsushita Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14029 w
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Muss HB, 2020, TRANSL CANCER RES, V9, P5732, DOI 10.21037/tcr.2020.03.39
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474 9726.2012.00795.x
   NIH, 2015, CONS SEX BIOL VAR NI
   Palmer AK, 2019, AGING CELL, V18, DOI 10.1111/acel.12950
   Payea MJ, 2021, MOL CELL BIOL, V41, DOI 10.1128/MCB.00512 20
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102
   Reyes NS, 2022, SCIENCE, V378, P192, DOI 10.1126/science.abf3326
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Sabath N, 2020, P NATL ACAD SCI USA, V117, P31902, DOI 10.1073/pnas.2018138117
   Saul D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32552 1
   Saul D, 2021, ELIFE, V10, DOI [10.7554/eLife.69958, 10.7554/eLife.69958.sa1, 10.7554/eLife.69958.sa2]
   Schäck LM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1319578
   Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532
   Schwanhäusser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Severe N, 2019, CELL STEM CELL, V25, P570, DOI 10.1016/j.stem.2019.06.003
   Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592
   Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074
   Shen B, 2019, ELIFE, V8, DOI 10.7554/eLife.42274
   Slobodnyuk K, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1607 0
   Spitzer MH, 2016, CELL, V165, P780, DOI 10.1016/j.cell.2016.04.019
   Stein GH, 1999, MOL CELL BIOL, V19, P2109
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Suire C, 2012, BLOOD, V119, pE86, DOI 10.1182/blood 2011 08 372334
   Swanson EC, 2013, J CELL BIOL, V203, P929, DOI 10.1083/jcb.201306073
   Takarada T, 2016, DEVELOPMENT, V143, P211, DOI 10.1242/dev.128793
   Tarhriz V, 2019, J CELL PHYSIOL, V234, P2134, DOI 10.1002/jcp.27581
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Troiani M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29824 1
   van de Peppel J, 2021, STEM CELLS DEV, V30, P325, DOI 10.1089/scd.2021.0027
   Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185
   Walaszczyk A, 2019, AGING CELL, V18, DOI 10.1111/acel.12945
   Wang BS, 2021, NATURE AGING, V1, P962, DOI 10.1038/s43587 021 00107 6
   Wang JLS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26571 7
   Wang LC, 2022, CELL METAB, V34, P75, DOI 10.1016/j.cmet.2021.11.002
   Weng PW, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23137043
   Wetzig A, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471 2121 14 54
   Wiley CD, 2017, AGING CELL, V16, P1043, DOI 10.1111/acel.12632
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wolock SL, 2019, CELL REP, V28, P302, DOI 10.1016/j.celrep.2019.06.031
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591 018 0092 9
   Xu S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/105940
   Yang MY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05401 1
   Yen HCS, 2008, SCIENCE, V322, P918, DOI 10.1126/science.1160489
   Yosef R, 2017, EMBO J, V36, P2280, DOI 10.15252/embj.201695553
   Yousefzadeh MJ, 2018, EBIOMEDICINE, V36, P18, DOI 10.1016/j.ebiom.2018.09.015
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhang JZ, 2016, J BONE MINER RES, V31, P2001, DOI 10.1002/jbmr.2877
   Zhong LL, 2020, ELIFE, V9, DOI 10.7554/eLife.54695
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
   Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987
NR 134
TC 27
Z9 28
U1 4
U2 24
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 31
PY 2023
VL 14
IS 1
AR 4587
DI 10.1038/s41467 023 40393 9
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA O0RZ2
UT WOS:001040993200014
PM 37524694
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheng, HM
   Xing, MM
   Zhou, YP
   Zhang, WT
   Liu, ZY
   Li, L
   Zheng, ZG
   Ma, YC
   Li, PP
   Liu, XX
   Li, P
   Xu, XJ
AF Cheng, Hui Min
   Xing, Mingming
   Zhou, Ya Ping
   Zhang, Weitao
   Liu, Zeyu
   Li, Lan
   Zheng, Zuguo
   Ma, Yuanchen
   Li, Pingping
   Liu, Xiaoxuan
   Li, Ping
   Xu, Xiaojun
TI HSP90β promotes osteoclastogenesis by dual activation of cholesterol
   synthesis and NF κB signaling
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID TRANSCRIPTION FACTORS; INHIBITION; DIFFERENTIATION; PROTEIN; SREBP;
   IDENTIFICATION; OSTEOPOROSIS; DEGRADATION; INVOLVEMENT; HOMEOSTASIS
AB Heat shock protein 90 beta (Hsp90 beta, encoded by Hsp90ab1 gene) is the most abundant proteins in the cells and contributes to variety of biological processes including metabolism, cell growth and neural functions. However, genetic evidences showing Hsp90 beta in vivo functions using tissue specific knockout mice are still lacking. Here, we showed that Hsp90 beta exerted paralogue specific role in osteoclastogenesis. Using myeloid specific Hsp90ab1 knockout mice, we provided the first genetic evidence showing the in vivo function of Hsp90 beta. Hsp90 beta binds to Ikk beta and reduces its ubiquitylation and proteasomal degradation, thus leading to activated NF kappa B signaling. Meanwhile, Hsp90 beta increases cholesterol biosynthesis by activating Srebp2. Both pathways promote osteoclastogenic genes expression. Genetic deletion of Hsp90ab1 in osteoclast or pharmacological inhibition of Hsp90 beta alleviates bone loss in ovariectomy induced mice. Therefore, Hsp90 beta is a promising druggable target for the treatment of osteoporosis.
C1 [Cheng, Hui Min; Xing, Mingming; Zhou, Ya Ping; Zhang, Weitao; Liu, Zeyu; Li, Lan; Zheng, Zuguo; Liu, Xiaoxuan; Li, Ping; Xu, Xiaojun] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China.
   [Ma, Yuanchen; Xu, Xiaojun] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Orthoped, 106 Zhongshan Second Rd, Guangzhou 510000, Peoples R China.
   [Li, Pingping] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China.
   [Li, Pingping] Chinese Acad Med Sci, Diabet Res Ctr, Beijing 100050, Peoples R China.
C3 China Pharmaceutical University; Southern Medical University   China;
   Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Chinese Academy of Medical Sciences  
   Peking Union Medical College
RP Xu, XJ (通讯作者)，China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China.; Xu, XJ (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Orthoped, 106 Zhongshan Second Rd, Guangzhou 510000, Peoples R China.
EM xiaojunxu2000@163.com
RI Li, Ping/A 2615 2013; Li, pingping/JPW 9278 2023; Zhong,
   Qing/GLT 4858 2022; Li, Ping/GYV 4914 2022
OI Xu, Xiaojun/0000 0003 4379 8748; 
FU National Key Research & Development Program of China for International
   S&T Cooperation Projects [2018YFE0117800]; National Natural Science
   Foundation of China [81773957]; CAMS Innovation Fund for Medical
   Sciences [2016 I2M 4 001]; Beijing Outstanding Young Scientist Program
   [BJJWZYJH01201910023028]; Chinese Academy of Medical Sciences (CAMS)
   Central Public interest Scientific Institution Basal Research Fund
   [2018RC350004, 2017PT31046]
FX This work was supported by National Key Research & Development Program
   of China for International S&T Cooperation Projects (2018YFE0117800),
   National Natural Science Foundation of China (81773957), CAMS Innovation
   Fund for Medical Sciences (2016 I2M 4 001), Beijing Outstanding Young
   Scientist Program (BJJWZYJH01201910023028), the Chinese Academy of
   Medical Sciences (CAMS) Central Public interest Scientific Institution
   Basal Research Fund (2018RC350004, 2017PT31046).
CR ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0
   Berghaus LJ, 2010, COMP IMMUNOL MICROB, V33, P443, DOI 10.1016/j.cimid.2009.07.001
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092 8674(00)80213 5
   Clohisy JC, 2006, J ORTHOP RES, V24, P1358, DOI 10.1002/jor.20184
   Cowen LE, 2005, SCIENCE, V309, P2185, DOI 10.1126/science.1118370
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Fu R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14076 3
   Grad I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015770
   Grasser W. A., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P53
   Huang JX, 2020, CLIMACTERIC, V23, P581, DOI 10.1080/13697137.2020.1758055
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Inoue K, 2015, BBA MOL BASIS DIS, V1852, P2432, DOI 10.1016/j.bbadis.2015.08.018
   Inoue K, 2014, J BONE MINER RES, V29, P1823, DOI 10.1002/jbmr.2229
   Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010
   Jie ZW, 2019, BBA MOL BASIS DIS, V1865, P115, DOI 10.1016/j.bbadis.2018.10.026
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   Katiyar A, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 90424 y
   Koga F, 2006, P NATL ACAD SCI USA, V103, P11318, DOI 10.1073/pnas.0604705103
   Kuan YC, 2017, J BIOL CHEM, V292, P3016, DOI 10.1074/jbc.M116.767277
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lamoureux F, 2011, CLIN CANCER RES, V17, P2301, DOI 10.1158/1078 0432.CCR 10 3077
   Li LC, 2013, AM J PHYSIOL HEART C, V304, pH874, DOI 10.1152/ajpheart.00096.2012
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790
   Tran MT, 2021, BBA MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2021.119096
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Miyata Y, 2013, CURR PHARM DESIGN, V19, P347, DOI 10.2174/138161213804143725
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008 5472.CAN 04 4458
   Ruan F, 2012, BIOSCIENCE REP, V32, P511, DOI 10.1042/BSR20110118
   Rychkov D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638066
   Sato T, 1998, BONE, V23, P135, DOI 10.1016/S8756 3282(98)00082 9
   Seo YH, 2015, ARCH PHARM RES, V38, P1582, DOI 10.1007/s12272 015 0636 1
   Sha LZ, 2017, J EXP MED, V214, P547, DOI 10.1084/jem.20160667
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Starling S, 2021, NAT REV ENDOCRINOL, V17, P5, DOI 10.1038/s41574 020 00441 6
   Sun Y, 2020, INT J MOL MED, V45, P1543, DOI 10.3892/ijmm.2020.4529
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Thangjam GS, 2014, AM J RESP CELL MOL, V50, P942, DOI 10.1165/rcmb.2013 0214OC
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tu Kristie N, 2018, P T, V43, P92
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Voss AK, 2000, DEVELOPMENT, V127, P1
   Wang QY, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/2993374
   Wei HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108252
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Wei WN, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.684836
   Yano A, 2008, P NATL ACAD SCI USA, V105, P15541, DOI 10.1073/pnas.0805354105
   Yu ZC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.838891
   Zhang S, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.796974
   Zhang XN, 2016, AM J CHINESE MED, V44, P35, DOI 10.1142/S0192415X16500038
   Zheng ZG, 2020, CELL DEATH DIFFER, V27, P2048, DOI 10.1038/s41418 019 0484 5
   Zheng ZG, 2019, THERANOSTICS, V9, P5769, DOI 10.7150/thno.36505
   Zheng ZG, 2017, EUR J PHARMACOL, V809, P156, DOI 10.1016/j.ejphar.2017.05.017
NR 61
TC 18
Z9 20
U1 6
U2 43
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350 9047
EI 1476 5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD MAR
PY 2023
VL 30
IS 3
BP 673
EP 686
DI 10.1038/s41418 022 01071 3
EA OCT 2022
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA I3KI9
UT WOS:000864328900001
PM 36198833
DA 2025 08 17
ER

PT J
AU Inanc, M
   Kaynar, L
   Enhos, S
   Pala, C
   Karaca, H
   Berk, V
   Ozkan, M
   Sivgin, S
   Eser, B
   Cetin, M
   Elmali, F
AF Inanc, Mevlude
   Kaynar, Leylagul
   Enhos, Sukru
   Pala, Cigdem
   Karaca, Halit
   Berk, Veli
   Ozkan, Metin
   Sivgin, Serdar
   Eser, Bulent
   Cetin, Mustafa
   Elmali, Ferhan
TI Nuclear factor kappa B ligand and osteoprotegerin levels in serum and
   gingival crevicular fluid in patients with bone metastases treated with
   zoledronic acid
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Bone metastasis; Zoledronic acid; RANKL; OPG
ID RECEPTOR ACTIVATOR; BREAST CANCER; MULTIPLE MYELOMA; SKELETAL
   COMPLICATIONS; RANKL; TUMORS; BISPHOSPHONATES; OSTEONECROSIS;
   MECHANISMS; MANAGEMENT
AB Bone metastases are frequently observed in patients with certain types of cancer and are significant cause of morbidity. Zoledronic acid (ZA) is routinely prescribed for patients with bone metastases by affecting osteoclast function. We aimed to assess the effect of ZA over time in patients with bone metastases by analyzing novel bone turnover marker levels including receptor activator of nuclear factor k B ligand (RANKL) and osteoprotegerin (OPG) in serum and gingival crevicular fluid (GCF). Also, associations between these bone turnover markers with hematological and biochemistry dysregulation were studied. The study enrolled patients with bone metastases including 32 patients diagnosed with solid tumors and 15 patients with multiple myeloma. In these patients, GCF and serum RANKL and OPG levels were measured and compared with measures of hematological and biochemical parameters before and after 3 months of ZA therapy. Mean subject age was 54 years old with a range of 28 80 years. Skeletal related events were observed in 8.5 % of all patients. After the 3 month treatment of ZA therapy, no significant differences were found in serum and GCF levels of RANKL and OPG when compared with before treatment levels. GCF RANKL levels at baseline and following 3 months of ZA therapy were significantly higher in patients with solid tumors when compared patients diagnosed with multiple myeloma (p = 0.001; p < 0.001, respectively). GCF OPG levels after the entire course of ZA therapy were greater in patients with 5 or more bone metastases (p = 0.04). For patients with multiple myeloma, control GCF OPG was negatively correlated with control platelet and WBC counts (p = 0.018 and p = 0.027, respectively). A negative correlation was observed between control serum RANKL and control serum OPG levels in myeloma patients (p = 0.001). After 3 months of ZA therapy, no significant differences were observed in GCF and serum RANKL and OPG levels when compared with baseline. A negative correlation was observed between serum control RANKL and OPG levels in myeloma patients. OPG levels were greater in patients with 5 or more bone metastases. In patients diagnosed with multiple myeloma, GCF OPG levels were negatively associated with WBC and platelet counts.
C1 [Inanc, Mevlude] Kayseri Training & Res Hosp, Dept Med Oncol, TR 38039 Kayseri, Turkey.
   [Kaynar, Leylagul; Pala, Cigdem; Sivgin, Serdar; Eser, Bulent; Cetin, Mustafa] Erciyes Univ, Fac Med, Dept Hematol, Kayseri, Turkey.
   [Enhos, Sukru] Erciyes Univ, Fac Dent, Dept Periodontol, Kayseri, Turkey.
   [Karaca, Halit; Berk, Veli; Ozkan, Metin] Erciyes Univ, Dept Med Oncol, Fac Med, Kayseri, Turkey.
   [Elmali, Ferhan] Erciyes Univ, Biostat Dept, Fac Med, Kayseri, Turkey.
C3 Kayseri Training & Research Hospital; Erciyes University; Erciyes
   University; Erciyes University; Erciyes University
RP Inanc, M (通讯作者)，Kayseri Training & Res Hosp, Dept Med Oncol, TR 38039 Kayseri, Turkey.
EM mevludeinanc@hotmail.com
RI ; Berk, Veli/IXE 0017 2023; Enhoş, Şükrü/JWA 0818 2024; Kaynar,
   Leylagul/F 6991 2013; CETIN, Mustafa/B 3607 2015; Elmalı,
   Ferhan/E 2943 2015
OI Eser, Bulent/0000 0002 4513 3486; ELMALI, FERHAN/0000 0002 1967 1811;
   Kaynar, Leylagul/0000 0002 2035 9462; CETIN,
   Mustafa/0000 0003 4512 1124; 
CR Cafro AM, 2008, CLIN LYMPHOMA MYELOM, V8, P111, DOI 10.3816/CLM.2008.n.013
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   D'Amico L, 2013, ONCOL REP, V29, P1453, DOI 10.3892/or.2013.2280
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fohr B, 2003, J CLIN ENDOCR METAB, V88, P5059, DOI 10.1210/jc.2003 030910
   GALASKO CSB, 1976, NATURE, V263, P507, DOI 10.1038/263507a0
   Hofbauer LC, 2001, CANCER AM CANCER SOC, V92, P460, DOI 10.1002/1097 0142(20010801)92:3<460::AID CNCR1344>3.0.CO;2 D
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jakob C, 2009, CLIN LYMPHOMA MYELOM, V9, P430, DOI 10.3816/CLM.2009.n.085
   Krüger TB, 2013, ACTA ODONTOL SCAND, V71, P1386, DOI 10.3109/00016357.2013.764007
   Lee S, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 350
   Li Shuling, 2012, Clin Epidemiol, V4, P87, DOI 10.2147/CLEP.S28339
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Ma X, 2013, J OBSTET GYNAECOL RE
   Mihou D, 2007, HEMATOLOGY, V12, P527, DOI 10.1080/10245330701384161
   Mori K, 2009, HISTOL HISTOPATHOL, V24, P235, DOI 10.14670/HH 24.235
   Mountzios G, 2007, ACTA ONCOL, V46, P221, DOI 10.1080/02841860600635870
   Mountzios G, 2010, TRANSL RES, V155, P247, DOI 10.1016/j.trsl.2010.01.002
   Owen S, 2013, ANTICANCER RES, V33, P199
   Plunkett TA, 2000, EUR J CANCER, V36, P476, DOI 10.1016/S0959 8049(99)00331 7
   Sfiridaki K, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/867576
   Steele JPC, 2005, LUNG CANCER, V49, pS49, DOI 10.1016/j.lungcan.2005.03.009
   Wang YP, 2013, CLIN LUNG CANCER, V14, P254, DOI 10.1016/j.cllc.2012.09.001
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
NR 27
TC 2
Z9 4
U1 0
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357 0560
EI 1559 131X
J9 MED ONCOL
JI Med. Oncol.
PD MAR
PY 2014
VL 31
IS 3
AR 837
DI 10.1007/s12032 013 0837 8
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AJ5MV
UT WOS:000337728700004
PM 24448976
DA 2025 08 17
ER

PT J
AU Wang, DH
   Chen, JS
   Hou, R
   Li, Y
   An, JH
   He, P
   Cai, ZG
   Liang, XH
   Liu, YL
AF Wang, Dong Hui
   Chen, Jia Song
   Hou, Rong
   Li, Yuan
   An, Jun Hui
   He, Ping
   Cai, Zhi Gang
   Liang, Xiao Hu
   Liu, Yu Liang
TI Comparison of transcriptome profiles of mesenchymal stem cells derived
   from umbilical cord and bone marrow of giant panda (Ailuropoda
   melanoleuca)
SO GENE
LA English
DT Article
DE Giant panda; Umbilical cord mesenchymal stem cells; Bone marrow
   mesenchymal stem cells; RNA  sequencing
ID ADIPOSE TISSUE; BLOOD; PROLIFERATION; PATHWAY
AB Mesenchymal stem cells (MSCs) have pluripotent differentiation ability and play an important role in human clinical cell therapy. While, the research on MSCs in endangered wild animals is extremely rare. In our previous studies, the bone marrow mesenchymal stem cells (bmMSCs) and umbilical cord mesenchymal stem cells (ucMSCs) of giant panda (Ailuropoda melanoleuca) were successfully isolated. We aimed to characterize the differences in gene expression profiles between these two types of MSCs using RNA sequencing (RNA Seq) and to determine which potential pathways are involved in functional regulation. In total, 1079 significantly differ entially expressed genes (DEGs) were identified, of which 478 genes were upregulated and 601 genes were downregulated. The significantly enriched Gene Ontology (GO) terms mainly contained cell adhesion, biological adhesion, intracellular signal transduction, molecular function regulator, Ras protein signal transduction, small GTPase mediated signal transduction, and regulation of Rho protein signal transduction. The most enrichment pathways of DEGs enriched in Kyoto Encyclopedia of Genes Genomes (KEGG) were PI3K AKT signaling pathway, Rap1 signaling pathway, MAPK signaling pathway, Hippo signaling pathway, Wnt signaling pathway, cGMP PKG signaling pathway and Signaling pathways regulating pluripotency of stem cells. In addition, quantitative real time polymerase chain reaction (qRT PCR) showed that the AKT3, CDK2, MAPK3, mTOR, PI3K and PTK2 genes associated with PI3K AKT pathway were highly expressed (P < 0.01), and Caspase 3 was low expressed (P < 0.05) in ucMSCs group when compared with bmMSCs. After treatment with the PI3K inhibitor LY294002, genes AKT3, CDK2, MAPK3, mTOR, and PTK2 were significantly decreased in ucMSCs (P < 0.01), and Caspase 3 was significantly up regulated (P < 0.001). In conclusion, we for the first time compared and analyzed the tran scriptome profiles of giant panda ucMSCs and bmMSCs, and found the PI3K AKT pathway was highly activated and might be a key signaling pathway in the ucMSCs regulation. This study will be beneficial for the research on MSCs proliferation regulation and differentiation of giant pandas in the future, and lay the foundation for MSCs application and clinical therapy for endangered wild animals.
C1 [Wang, Dong Hui; Chen, Jia Song; Hou, Rong; An, Jun Hui; He, Ping; Cai, Zhi Gang; Liu, Yu Liang] Chengdu Res Base Giant Panda Breeding, Chengdu 610081, Sichuan, Peoples R China.
   [Wang, Dong Hui; Chen, Jia Song; Hou, Rong; Li, Yuan; An, Jun Hui; He, Ping; Cai, Zhi Gang; Liang, Xiao Hu; Liu, Yu Liang] Sichuan Key Lab Conservat Biol Endangered Wildlif, Chengdu 610081, Sichuan, Peoples R China.
   [Wang, Dong Hui; Chen, Jia Song; Hou, Rong; An, Jun Hui; He, Ping; Cai, Zhi Gang; Liu, Yu Liang] Sichuan Acad Giant Panda, Chengdu 610081, Sichuan, Peoples R China.
RP Liu, YL (通讯作者)，Chengdu Res Base Giant Panda Breeding, Chengdu 610081, Sichuan, Peoples R China.
EM sdliuyuliang@163.com
RI Chen, Jiayu/ABF 3722 2021; Wang, Dong Hui/AAG 7297 2020
OI Wang, Dong Hui/0000 0002 4099 1924
FU Natural Science Foundation of Sichuan Province [2022NSFSC1608]; Chengdu
   Giant Panda Breeding Research Foundation [CPF2017 16]; National Nature
   Science Foundation of China [32100386]; Chengdu Research Base of Giant
   Panda Breeding [2020CPB B07]
FX This work was supported by the Natural Science Foundation of Sichuan
   Province (2022NSFSC1608) , Chengdu Giant Panda Breeding Research
   Foundation (CPF2017 16) , National Nature Science Foundation of China
   (32100386) , Chengdu Research Base of Giant Panda Breeding (2020CPB B07)
   .
CR Alzahrani AS, 2019, SEMIN CANCER BIOL, V59, P125, DOI 10.1016/j.semcancer.2019.07.009
   Archacka K, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02530 3
   Blokzijl F, 2016, NATURE, V538, P260, DOI 10.1038/nature19768
   Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   Chen XX, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 021 02691 1
   Djouad F, 2005, ARTHRITIS RES THER, V7, pR1304, DOI 10.1186/ar1827
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Götherström C, 2003, BONE MARROW TRANSPL, V32, P265, DOI 10.1038/sj.bmt.1704111
   Jiang JX, 2021, J AGR FOOD CHEM, V69, P12456, DOI 10.1021/acs.jafc.1c04011
   Kacham S, 2021, CELLS BASEL, V10, DOI 10.3390/cells10051254
   Kisiel AH, 2012, AM J VET RES, V73, P1305, DOI 10.2460/ajvr.73.8.1305
   Lee JH, 2018, MAR DRUGS, V16, DOI 10.3390/md16040121
   Lin F, 2018, EXP THER MED, V16, P3504, DOI 10.3892/etm.2018.6634
   Ling L, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12383
   Liu H, 2012, PROTEIN CELL, V3, P291, DOI 10.1007/s13238 012 2919 3
   Liu YL, 2021, TISSUE CELL, V71, DOI 10.1016/j.tice.2021.101518
   Liu YL, 2013, STEM CELLS DEV, V22, P2394, DOI 10.1089/scd.2013.0102
   Maharlooei MK, 2011, DIABETES RES CLIN PR, V93, P228, DOI 10.1016/j.diabres.2011.04.018
   Mori Y, 2015, TISSUE ENG PART C ME, V21, P367, DOI [10.1089/ten.tec.2014.0385, 10.1089/ten.TEC.2014.0385]
   Nagata S, 2018, ANNU REV IMMUNOL, V36, P489, DOI 10.1146/annurev immunol 042617 053010
   Perry BC, 2008, TISSUE ENG PART C ME, V14, P149, DOI 10.1089/ten.tec.2008.0031
   Rebelatto CK, 2008, EXP BIOL MED, V233, P901, DOI 10.3181/0712 RM 356
   Seo MS, 2009, J VET SCI, V10, P181, DOI 10.4142/jvs.2009.10.3.181
   Shen M, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/9498876
   Shinde A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10030577
   Tang SJ, 2021, INT J NANOMED, V16, P8185, DOI 10.2147/IJN.S336062
   Tögel F, 2007, DEV DYNAM, V236, P3321, DOI 10.1002/dvdy.21258
   Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901 778
   Toupadakis CA, 2010, AM J VET RES, V71, P1237, DOI 10.2460/ajvr.71.10.1237
   Van Camp J, 2014, STEM CELL REV REP, V10, P207, DOI 10.1007/s12015 013 9486 8
   Vidal MA, 2012, STEM CELLS DEV, V21, P273, DOI 10.1089/scd.2010.0589
   Wang DH, 2022, CONSERV PHYSIOL, V10, DOI 10.1093/conphys/coac004
   Xiao B, 2016, NEURAL REGEN RES, V11, P1172, DOI 10.4103/1673 5374.187061
   Xiao H, 2020, NEUROCHEM INT, V133, DOI 10.1016/j.neuint.2019.104630
   Yuan WJ, 2012, STEM CELL RES, V9, P110, DOI 10.1016/j.scr.2012.05.003
NR 36
TC 2
Z9 2
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD DEC 15
PY 2022
VL 845
AR 146854
DI 10.1016/j.gene.2022.146854
EA SEP 2022
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 5A4IW
UT WOS:000862853400008
PM 36055605
DA 2025 08 17
ER

PT J
AU Cano, FJ
   Azocar, MA
   Guerrero, JL
   Delucchi, MA
   Lillo, AM
   Emilfork, M
   Rodríguez, EE
AF Cano, Francisco J.
   Azocar, Marta A.
   Guerrero, Jose Luis
   Delucchi, Maria A.
   Lillo, Ana Maria
   Emilfork, Marcos
   Rodriguez, Eugenio E.
TI Intraperitoneal calcitriol in infants on peritoneal dialysis
SO PERITONEAL DIALYSIS INTERNATIONAL
LA English
DT Article
DE renal osteodystrophy; calcitriol; pulses; intraperitoneal vitamin D;
   parathyroid hormone; children
ID STAGE RENAL DISEASE; INTRAVENOUS CALCITRIOL; BIOCHEMICAL MARKERS;
   BONE DISEASE; SECONDARY HYPERPARATHYROIDISM; PARATHYROID HORMONE;
   ADYNAMIC BONE; ORAL PULSE; VITAMIN D; THERAPY
AB Background: Calcitriol has long been used as the main therapy in renal osteodystrophy, but the efficacy of the oral route is not always as high as expected.
   Objective: To asses the safety and efficacy of intraperitoneal calcitriol in infants undergoing peritoneal dialysis (PD).
   Patients and Methods: PD patients on oral calcitriol therapy, with serum parathyroid hormone (PTH) > 1000 pg/mL during the previous 3 months of treatment, were switched to intraperitoneal calcitriol therapy, 1 m g twice per week. Dose was increased to 1 m g three times per week if PTH remained > 1000 pg/mL, and was later readjusted. Target PTH was 200 300 pg/ mL according DOQI guidelines. Statistics: All results are expressed as mean +/  SE. The Wilcoxon signed rank test was used to evaluate differences in measurements for each pair of values. The confidence interval for differences between population medians was 96.9%. A p value less than 0.05 was considered significant.
   Results: Six male children, mean age 17 +/  3.86 months, completed a 12 month follow up. Mean pretreatment PTH was 1654 +/  209 pg/ mL. Mean PTH at months 0, 3, 6, 9, and 12 was 1448 +/  439*, 1277 +/  723, 910 +/  704, 582 +/  282*, and 465 +/  224* pg/ mL, respectively (* p < 0.05). Twelve hypercalcemic and 10 hyperphosphatemic episodes were successfully treated.
   Conclusion: Infants on PD who fail to respond to oral calcitriol therapy can be safely treated with intraperitoneal administration of active vitamin D.
C1 [Cano, Francisco J.; Azocar, Marta A.; Guerrero, Jose Luis; Delucchi, Maria A.; Lillo, Ana Maria; Rodriguez, Eugenio E.] Univ Chile, Luis Calvo Mackenna Childrens Hosp, Dept Pediat, Div Pediat Nephrol, Santiago, Chile.
   [Emilfork, Marcos] Clin Santa Maria, Div Pediat, Santiago, Chile.
C3 Universidad de Chile
RP Cano, FJ (通讯作者)，El Vergel2828,Appt 603, Santiago 6650813, Chile.
EM fcano@med.uchile.cl
RI Lopez, Jose/HZL 8909 2023
CR Andress DL, 2001, AM J KIDNEY DIS, V38, pS41, DOI 10.1053/ajkd.2001.28108
   ARORA N, 1992, ADV PERIT D, V8, P62
   Bervoets ARJ, 2003, AM J KIDNEY DIS, V41, P997, DOI 10.1016/S0272 6386(03)00197 5
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   BROWN AJ, 1989, J CLIN INVEST, V84, P728, DOI 10.1172/JCI114229
   CANO F, 1995, PEDIATR NEPHROL, V9, P606, DOI 10.1007/BF00860951
   Coburn JW, 2003, KIDNEY INT, V64, pS125, DOI 10.1046/j.1523 1755.64.s87.19.x
   Couttenye MM, 1997, NEPHROL DIAL TRANSPL, V12, P2144, DOI 10.1093/ndt/12.10.2144
   DELMEZ JA, 1987, KIDNEY INT, V31, P795, DOI 10.1038/ki.1987.68
   Divieti P, 2002, ENDOCRINOLOGY, V143, P171, DOI 10.1210/en.143.1.171
   DRESSLER R, 1995, CLIN NEPHROL, V43, P324
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Frazao JM, 2000, AM J KIDNEY DIS, V36, P550, DOI 10.1053/ajkd.2000.16193
   Gadallah M F, 2000, Adv Perit Dial, V16, P303
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Gerakis A, 1996, NEPHROL DIAL TRANSPL, V11, P2430, DOI 10.1093/oxfordjournals.ndt.a027210
   Goodman W G., 1999, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P347
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Hruska K, 2000, PEDIATR NEPHROL, V14, P636, DOI 10.1007/s004670000341
   JONES CL, 1994, CLIN NEPHROL, V42, P44
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   *K DOQI CLIN PRACT, 2005, AM J KIDNEY DIS S, V46, P53
   Kuizon BD, 2002, PEDIATR NEPHROL, V17, P777, DOI 10.1007/s00467 002 0919 x
   Kurokawa K, 1996, NEPHROL DIAL TRANSPL, V11, P121, DOI 10.1093/ndt/11.supp3.121
   LLACH F, 1995, AM J KIDNEY DIS, V26, P845, DOI 10.1016/0272 6386(95)90454 9
   Llach F, 2003, KIDNEY INT, V64, pS113, DOI 10.1046/j.1523 1755.64.s87.17.x
   Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P723, DOI 10.1093/ndt/17.5.723
   MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187
   Monier Faugere MC, 2001, KIDNEY INT, V60, P1460, DOI 10.1046/j.1523 1755.2001.00949.x
   QUARLES LD, 1994, KIDNEY INT, V45, P1710, DOI 10.1038/ki.1994.223
   Rigden SPA, 1996, PEDIATR NEPHROL, V10, P653, DOI 10.1007/s004670050184
   SALUSKY IB, 1990, AM J KIDNEY DIS, V16, P126, DOI 10.1016/S0272 6386(12)80566 X
   Salusky IB, 1998, KIDNEY INT, V54, P907, DOI 10.1046/j.1523 1755.1998.00045.x
   Salusky IB, 2001, J AM SOC NEPHROL, V12, P1978, DOI 10.1681/ASN.V1291978
   SALUSKY IB, 1994, KIDNEY INT, V45, P253, DOI 10.1038/ki.1994.31
   Salusky IB, 1996, PEDIATR NEPHROL, V10, P651, DOI 10.1007/s004670050183
   SchmidtGayk H, 1996, NEPHROL DIAL TRANSPL, V11, P415
   SCHOMIG M, 2000, MANAGEMENT RENAL PAT, P43
   Slatopolsky E, 2000, KIDNEY INT, V58, P753, DOI 10.1016/S0085 2538(15)47156 X
   SLATOPOLSKY E, 1984, J CLIN INVEST, V74, P2136, DOI 10.1172/JCI111639
   Türk S, 2002, NEPHRON, V90, P188, DOI 10.1159/000049041
   VIETH R, 1989, PERITON DIALYSIS INT, V9, P277
NR 42
TC 4
Z9 4
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0896 8608
EI 1718 4304
J9 PERITON DIALYSIS INT
JI Perit. Dial. Int.
PD NOV DEC
PY 2007
VL 27
IS 6
BP 681
EP 686
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 284OE
UT WOS:000254714900015
PM 17984431
DA 2025 08 17
ER

PT J
AU Kim, Y
   Zhang, Z
   Shim, JH
   Lee, TS
   Tung, CH
AF Kim, Young
   Zhang, Zhe
   Shim, Jae Hyuck
   Lee, Tae Sup
   Tung, Ching Hsuan
TI A cell surface clicked navigation system to direct specific bone
   targeting
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Cell therapy; Cell homing; Bioorthogonal chemistry; Bisphosphonate; Bone
ID MESENCHYMAL STEM CELLS; IN VIVO DISTRIBUTION; T CELLS; THERAPY;
   BISPHOSPHONATES; IMMUNOTHERAPY; GLYCANS
AB Cell therapies are promising up and coming therapeutic strategies for many diseases. For maximal therapeutic benefits, injected cells have to navigate their way to a designated area, including organ and tissue; unfortunately, the majority of therapeutic cells are currently administered without a guide or homing device. To improve this serious shortcoming, a functionalization method was developed to equip cells with a homing signal. Its application was demonstrated by applying an Azadibenzocyclooctyne bisphosphonate (ADIBO BP) and azide paired bioorthogonal chemistry on cells for bone specific homing. Jurkat T cells and bone marrow derived stromal cells (BMSCs) were cultured with tetraacetylated N azidoacetyl D mannosamine (Ac(4)ManNAz) to place unnatural azido groups onto the cell's surface; these azido groups were then reacted with ADIBO BP. The tethered bisphosphonates were able to bring Jurkat cells to hydroxyapatite, the major component of bone, and mineralized SAOS 2 cells. The incorporated BP groups also enhanced the specific affinity of BMSCs to mouse femur bone fragments in vitro. The introduced navigation strategy is expected to have a broad application in cell therapy, because through the biocompatible ADIBO and azide reactive pair, various homing signals could be efficiently anchored onto therapeutic cells. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Kim, Young; Zhang, Zhe; Lee, Tae Sup; Tung, Ching Hsuan] Weill Cornell Med, Mol Imaging Innovat Inst, Dept Radiol, 413 East 69th St, New York, NY 10021 USA.
   [Shim, Jae Hyuck] Univ Massachusetts, Div Rheumatol, Dept Med, Sch Med, Worcester, MA 01605 USA.
   [Kim, Young] Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Gwangju 61186, South Korea.
   [Lee, Tae Sup] Korea Inst Radiol & Med Sci, Div RI Convergence Res, Seoul 01812, South Korea.
C3 Cornell University; Weill Cornell Medicine; University of Massachusetts
   System; University of Massachusetts Worcester; Chonnam National
   University; Korea Institute of Radiological & Medical Sciences
RP Tung, CH (通讯作者)，Weill Cornell Med, Mol Imaging Innovat Inst, Dept Radiol, 413 East 69th St, New York, NY 10021 USA.
EM cht2018@med.cornell.edu
RI Zhang, Zhe/F 2546 2010; LEE, TAE/K 9638 2019; Tung,
   Ching Hsuan/AIE 6009 2022
OI Zhang, Zhe/0000 0003 4331 7887; Lee, Tae Sup/0000 0002 8266 7380; Tung,
   Ching Hsuan/0000 0001 6648 6195; Shim, Jae Hyuck/0000 0002 4947 3293
CR Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225
   Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Baskin JM, 2007, P NATL ACAD SCI USA, V104, P16793, DOI 10.1073/pnas.0707090104
   Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326 6066.CIR 13 0170
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Cundy T, 2012, CLIN BIOCHEM, V45, P43, DOI 10.1016/j.clinbiochem.2011.09.026
   D'Souza S, 2014, BIOMATERIALS, V35, P9447, DOI 10.1016/j.biomaterials.2014.07.041
   Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226
   Gage FH, 1998, NATURE, V392, P18
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Garbern JC, 2013, CELL STEM CELL, V12, P689, DOI 10.1016/j.stem.2013.05.008
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Gutwald R, 2010, BRIT J ORAL MAX SURG, V48, P285, DOI 10.1016/j.bjoms.2009.06.226
   Halleux C., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P71
   Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055
   Hong V, 2010, BIOCONJUGATE CHEM, V21, P1912, DOI 10.1021/bc100272z
   Karantalis V, 2015, CIRC RES, V116, P1413, DOI 10.1161/CIRCRESAHA.116.303614
   Karantalis V, 2015, CIRC RES, V116, P12, DOI 10.1161/CIRCRESAHA.114.305495
   Katz SC, 2015, CLIN CANCER RES, V21, P3149, DOI 10.1158/1078 0432.CCR 14 1421
   Kumar S, 2010, GENE THER, V17, P105, DOI 10.1038/gt.2009.116
   Laughlin ST, 2008, SCIENCE, V320, P664, DOI 10.1126/science.1155106
   Laughlin ST, 2006, METHOD ENZYMOL, V415, P230, DOI 10.1016/S0076 6879(06)15015 6
   Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140 6736(14)61403 3
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   Meyerrose TE, 2007, STEM CELLS, V25, P220, DOI 10.1634/stemcells.2006 0243
   Muraglia A, 2000, J CELL SCI, V113, P1161
   OWEN M, 1988, CIBA F SYMP, V136, P42
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415
   Prescher JA, 2004, NATURE, V430, P873, DOI 10.1038/nature02791
   Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910
   Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Skovrij B, 2015, J NEUROSURG SCI, V59, P25
   Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621
   Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309
   Vertenten G, 2009, TISSUE ENG PT A, V15, P1501, DOI 10.1089/ten.tea.2008.0367
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
   Zeckser J, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3908389
   Zhang YJ, 2010, BIOMATERIALS, V31, P5312, DOI 10.1016/j.biomaterials.2010.03.029
NR 45
TC 3
Z9 3
U1 0
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD FEB 1
PY 2018
VL 26
IS 3
BP 758
EP 764
DI 10.1016/j.bmc.2017.12.037
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA FW8BA
UT WOS:000425550800021
PM 29306547
DA 2025 08 17
ER

PT J
AU Zheng, CP
   Wang, JS
   Liu, YN
   Yu, QQ
   Liu, Y
   Deng, N
   Liu, J
AF Zheng, Chuping
   Wang, Jinsheng
   Liu, Yanan
   Yu, Qianqian
   Liu, Ying
   Deng, Ning
   Liu, Jie
TI Functional Selenium Nanoparticles Enhanced Stem Cell Osteoblastic
   Differentiation through BMP Signaling Pathways
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
ID PROMOTE OSTEOGENIC DIFFERENTIATION; MARROW STROMAL CELLS; UMBILICAL CORD
   BLOOD; BONE MARROW; GOLD NANOPARTICLES; MESENCHYMAL CELLS; HUMAN HEALTH;
   GROWTH; INHIBITION; PROLIFERATION
AB Stem cells have generated a great deal of excitement in tissue engineering and regenerative medicine, and it is important to understand the interaction mechanisms between nanomaterials and mesenchymal stem cells (MSCs) for biomedical applications. In this study, ruthenium (II) functional selenium nanoparticles (Ru@Se) are used for stem cell research. Specifically, Ru@Se are compared with citric acid selenium nanoparticles (Cit@Se) to identify their effects on MSCs differentiation and associated molecular mechanism. These data suggest that the effective adsorbing abilities of Ru@Se and Cit@Se allow them to act as preconcentration materials for osteogenic chemical inducers, which accelerates MSCs differentiation into osteoblasts. Further results suggest that selenium nanoparticles enhance the differentiation of MSCs toward osteogenic lineage over adipocytes by promoting osteogenic transcription and attenuating adipogenic transcription. Ru@Se and Cit@Se exert these effects by activating Smad dependent BMP signaling pathway, which regulates the expression of relevant genes to induce osteogenic differentiation.
C1 [Zheng, Chuping; Liu, Yanan; Yu, Qianqian; Liu, Ying; Liu, Jie] Jinan Univ, Dept Chem, Guangzhou 510632, Guangdong, Peoples R China.
   [Wang, Jinsheng; Deng, Ning] Jinan Univ, Guangdong Prov Key Lab Mol Immunol & Antibody Eng, Guangzhou 510632, Guangdong, Peoples R China.
   [Liu, Ying] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China.
C3 Jinan University; Jinan University; Hong Kong Polytechnic University
RP Zheng, CP (通讯作者)，Jinan Univ, Dept Chem, Guangzhou 510632, Guangdong, Peoples R China.
EM tliuliu@jnu.edu.cn; tdengn@jnu.edu.cn
RI Wang, Jinsheng/AAZ 1470 2021; liu, ying/GXF 4294 2022
OI Yu, Qianqian/0000 0001 5731 3356; 
FU National Natural Science Foundation of China [21171070, 21371075];
   Planned Item of Science and Technology of Guangdong Province
   [c1211220800571]; Fundamental Research Funds for the Central
   Universities
FX C. Z. and J. W. contributed equally to this work. This work was
   supported by the National Natural Science Foundation of China (21171070,
   21371075), the Planned Item of Science and Technology of Guangdong
   Province (c1211220800571), and the Fundamental Research Funds for the
   Central Universities.
CR Alzhavan O, 2013, CARBON, V59, P200, DOI 10.1016/j.carbon.2013.03.010
   Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen CY, 2005, NANO LETT, V5, P2050, DOI 10.1021/nl051624b
   Choi ST, 2008, RHEUMATOLOGY, V47, P1775, DOI 10.1093/rheumatology/ken385
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Du D, 2005, BIOMATERIALS, V26, P6487, DOI 10.1016/j.biomaterials.2005.03.048
   Elmes RBP, 2011, J AM CHEM SOC, V133, P15862, DOI 10.1021/ja2061159
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   FARLEY JR, 1983, SCIENCE, V222, P330
   Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200
   Holinka J, 2013, BONE JOINT J, V95B, P678, DOI 10.1302/0301 620X.95B5.31216
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kilin DS, 2008, CHEM PHYS LETT, V458, P113, DOI 10.1016/j.cplett.2008.04.046
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Li Baojie, 2008, Endocrine Metabolic & Immune Disorders Drug Targets, V8, P208, DOI 10.2174/187153008785700127
   Liu DD, 2010, ACS NANO, V4, P2185, DOI 10.1021/nn901479w
   Liu Y, 2009, BIOMATERIALS, V30, P3934, DOI 10.1016/j.biomaterials.2009.04.001
   Menter DG, 2000, CANCER EPIDEM BIOMAR, V9, P1171
   Mishra J, 2013, CRIT REV ONCOL HEMAT, V86, P232, DOI 10.1016/j.critrevonc.2012.09.014
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   Ode A, 2013, EUR CELLS MATER, V25, P37, DOI 10.22203/eCM.v025a03
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   Patra CR, 2010, ADV DRUG DELIVER REV, V62, P346, DOI 10.1016/j.addr.2009.11.007
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140 6736(11)61452 9
   Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140 6736(00)02490 9
   Reilly C., 1996, Selenium in Food and Health
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Singh A, 2013, ADV FUNCT MATER, V23, P575, DOI 10.1002/adfm.201201902
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Sun DD, 2014, BIOMATERIALS, V35, P1572, DOI 10.1016/j.biomaterials.2013.11.007
   Sun DD, 2013, BIOMATERIALS, V34, P171, DOI 10.1016/j.biomaterials.2012.09.031
   Taghizadeh RR, 2011, PLACENTA, V32, pS311, DOI 10.1016/j.placenta.2011.06.010
   Umulis D, 2009, DEVELOPMENT, V136, P3715, DOI 10.1242/dev.031534
   Wabitsch M, 1996, DIABETES, V45, P1435, DOI 10.2337/diabetes.45.10.1435
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yu YQ, 2011, J MATER CHEM, V21, P12622, DOI 10.1039/c1jm11843a
NR 44
TC 62
Z9 64
U1 0
U2 129
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD NOV 19
PY 2014
VL 24
IS 43
BP 6872
EP 6883
DI 10.1002/adfm.201401263
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA AT9CO
UT WOS:000345225800015
DA 2025 08 17
ER

PT J
AU Wang, YX
   Wang, K
   Zhang, LJ
   Tan, YJ
   Hu, ZB
   Dang, L
   Zhou, H
   Li, GZ
   Wang, H
   Zhang, S
   Shi, F
   Cao, XS
   Zhang, G
AF Wang, Yixuan
   Wang, Ke
   Zhang, Lijun
   Tan, Yingjun
   Hu, Zebing
   Dang, Lei
   Zhou, Hua
   Li, Gaozhi
   Wang, Han
   Zhang, Shu
   Shi, Fei
   Cao, Xinsheng
   Zhang, Ge
TI Targeted overexpression of the long noncoding RNA ODSM can regulate
   osteoblast function in vitro and in vivo
SO CELL DEATH & DISEASE
LA English
DT Article
ID BONE FORMATION; GENE EXPRESSIONS; MICROGRAVITY; ROLES
AB Ameliorating bone loss caused by mechanical unloading is a substantial clinical challenge, and the role of noncoding RNAs in this process has attracted increasing attention. In this study, we found that the long noncoding RNA osteoblast differentiation related lncRNA under simulated microgravity (lncRNA ODSM) could inhibit osteoblast apoptosis and promote osteoblast mineralization in vitro. The increased expression level of the lncRNA ODSM partially reduced apoptosis and promoted differentiation in MC3T3 E1 cells under microgravity unloading conditions, and the effect was partially dependent on miR 139 3p. LncRNA ODSM supplementation in hindlimb unloaded mice caused a decrease in the number of apoptotic cells in bone tissue and an increase in osteoblast activity. Furthermore, targeted overexpression of the lncRNA ODSM in osteoblasts partially reversed bone loss induced by mechanical unloading at the microstructural and biomechanical levels. These findings are the first to suggest the potential value of the lncRNA ODSM in osteoporosis therapy and the treatment of pathological osteopenia.
C1 [Wang, Yixuan; Wang, Ke; Zhang, Lijun; Hu, Zebing; Zhou, Hua; Li, Gaozhi; Wang, Han; Zhang, Shu; Shi, Fei; Cao, Xinsheng] Air Force Med Univ, Minist Educ, Key Lab Aerosp Med, Xian 710032, Shaanxi, Peoples R China.
   [Tan, Yingjun] China Astronaut Res & Training Ctr, Key Key Lab Space Med Fundamentals & Applicat, Beijing 100094, Peoples R China.
   [Dang, Lei; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Inst Adv Translat Med Bone & Joint Dis, Hong Kong, Peoples R China.
C3 Air Force Medical University; Hong Kong Baptist University
RP Shi, F; Cao, XS (通讯作者)，Air Force Med Univ, Minist Educ, Key Lab Aerosp Med, Xian 710032, Shaanxi, Peoples R China.; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Inst Adv Translat Med Bone & Joint Dis, Hong Kong, Peoples R China.
EM shifei719@sina.com; caoxinsh@fmmu.edu.cn; zhangge@hkbu.edu.hk
RI ; Zhang, Ge/N 4150 2013
OI Zhang, Shu/0000 0002 4380 1268; 
FU National Natural Science Foundation of China [31570939, 81701856,
   31971171]; Key Pre research Project of Manned Spaceflight [020106]; Key
   Research and Development Program of Shaanxi [2018SF 039]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (grant nos. 31570939, 81701856, and
   31971171), the Key Pre research Project of Manned Spaceflight (grant no.
   020106), and the Key Research and Development Program of Shaanxi
   (program no. 2018SF 039).
CR Alemdehy MF, 2015, BLOOD, V125, P3937, DOI 10.1182/blood 2014 11 612507
   Arfat Y, 2014, CALCIFIED TISSUE INT, V94, P569, DOI 10.1007/s00223 014 9851 x
   Arumugam B, 2019, BIOCHIMIE, V158, P43, DOI 10.1016/j.biochi.2018.12.006
   Bu YM, 2018, CONNECT TISSUE RES, V59, P534, DOI 10.1080/03008207.2017.1413362
   Caillot Augusseau A, 1998, CLIN CHEM, V44, P578
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   Feng L, 2018, MOL THER NUCL ACIDS, V11, P345, DOI 10.1016/j.omtn.2018.03.004
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Grimm D, 2016, BONE, V87, P44, DOI 10.1016/j.bone.2015.12.057
   He SW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2148 2
   Huynh NPT, 2017, CONNECT TISSUE RES, V58, P116, DOI 10.1080/03008207.2016.1194406
   Jin XJ, 2017, CANCER MED US, V6, P1409, DOI 10.1002/cam4.1084
   Kim HK, 2014, FOOD FUNCT, V5, P573, DOI 10.1039/c3fo60509d
   Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Liang C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05974 z
   Liu J, 2017, AGING CELL, V16, P360, DOI 10.1111/acel.12566
   Long HT, 2017, DNA CELL BIOL, V36, P715, DOI 10.1089/dna.2017.3657
   Morey Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001
   Morse LR, 2012, J BONE MINER RES, V27, P352, DOI 10.1002/jbmr.546
   Nagaraja MP, 2013, J CELL BIOCHEM, V114, P1001, DOI 10.1002/jcb.24454
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev biochem 051410 092902
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Schwarz R P, 1992, J Tissue Cult Methods, V14, P51, DOI 10.1007/BF01404744
   Sheng K, 2018, BIOCHEM BIOPH RES CO, V501, P612, DOI 10.1016/j.bbrc.2018.04.224
   Shi WG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02049 9
   Stein EM, 2013, J CLIN ENDOCR METAB, V98, P541, DOI 10.1210/jc.2012 2394
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Tsao Y D, 1992, Physiologist, V35, pS49
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Wang H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0210 5
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Wu CC, 2006, J CELL BIOCHEM, V98, P632, DOI 10.1002/jcb.20697
   Yang L, 2019, MOL THER, V27, P394, DOI 10.1016/j.ymthe.2018.11.019
   Yin C, 2019, J CELL PHYSIOL, V234, P11524, DOI 10.1002/jcp.27815
   Ying W, 2016, SCI REP UK, V6, DOI 10.1038/srep20176
   Yonemori M, 2016, CANCER SCI, V107, P1233, DOI 10.1111/cas.13002
   Yuan HR, 2019, CELL DEATH DIFFER, V26, P2029, DOI 10.1038/s41418 019 0296 7
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang Y, 2009, J BIOL CHEM, V284, P3125, DOI 10.1074/jbc.M807466200
   Zhang ZK, 2018, MOL THER, V26, P2669, DOI 10.1016/j.ymthe.2018.09.014
   Zhang ZK, 2018, J CACHEXIA SARCOPENI, V9, P613, DOI 10.1002/jcsm.12281
   Zou ZC, 2018, ONCOL RES, V26, P1391, DOI 10.3727/096504018X15178798885361
NR 47
TC 27
Z9 35
U1 0
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB 18
PY 2020
VL 11
IS 2
AR 133
DI 10.1038/s41419 020 2325 3
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA KQ9KA
UT WOS:000517238700009
PM 32071307
OA Green Published
DA 2025 08 17
ER

PT J
AU Wang, W
   Sun, DF
   Dong, Z
   Zhang, WL
AF Wang, Wei
   Sun, Dan Fang
   Dong, Zhe
   Zhang, Wen Lu
TI Icariin suppresses osteogenic differentiation and promotes bone
   regeneration in Porphyromonas gingivalis infected conditions through
   EphA2 RhoA signaling pathway
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Icariin; EphA2; P. gingivalis; Osteogenic differentiation
ID PERIODONTAL DISEASE; CELL PROLIFERATION; MECHANISMS; OSTEOBLASTS;
   EXPRESSION; PHYSIOLOGY; LINE
AB Periodontitis is associated with multiple systemic diseases and can cause bone loss. Porphyromonas gingivalis (P. gingivalis) is one of the most virulent periodontal pathogens. Icariin is a flavonoid extracted from the traditional Chinese herbal medicine Herba Epimedii, and can regulate bone metabolism. However, its effects on promoting bone metabolism have not been fully elucidated. In this experiment, we infected MC3T3 E1 cells with P. gingivalis. Flow cytometry results show that persistent bacterial infection does not affect cell proliferative activity. Western blotting, ALP activity detection, mineral content determination, and immunofluorescence blotting confirmed that icariin improved osteogenic differentiation in the inflammatory state, and this effect may be more obvious in the early stage of osteogenic differentiation. The antibacterial assays, ROS and MMP fluorescence assays demonstrated that icariin exerted a significant inhibitory effect on bacterial growth and attenuated the inflammatory response in bacterial infected conditions. The results of in vivo experiments in animals further validated the excellent properties exerted by icariin in the repair of bone defects. Additionally, in the P. gingivalis infected state, icariin exert a regulatory effect on EphA2 RhoA signaling pathway to augment osteogenic differentiation. These exciting findings suggest that icariin holds significant potential for therapeutic application in the management of periodontal bone loss.
C1 [Wang, Wei; Sun, Dan Fang; Dong, Zhe] Jinzhou Med Univ, Jinzhou 121000, Peoples R China.
   [Zhang, Wen Lu] Jinzhou Med Univ, Affiliated Hosp 1, Jinzhou 121000, Peoples R China.
C3 Jinzhou Medical University; Jinzhou Medical University
RP Zhang, WL (通讯作者)，Jinzhou Med Univ, Affiliated Hosp 1, Jinzhou 121000, Peoples R China.
EM wenlu5460@126.com
RI Zhang, Wenlu/ABD 7533 2020
FU Beijing Xisike Clinical Oncology Research Foundation [Y QL202201 0096]
FX <BOLD>Funding Information</BOLD> This work was supported by a grant from
   the Beijing Xisike Clinical Oncology Research Foundation. The director
   of this project is Wen lu Zhang and the project number is
   Y QL202201 0096.
CR Arthur A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.598612
   Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574 6968.2012.02579.x
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Chang XR, 2023, REDOX BIOL, V63, DOI 10.1016/j.redox.2023.102739
   Gao AC, 2016, IN VITRO CELL DEV AN, V52, P228, DOI 10.1007/s11626 015 9965 0
   Gao LF, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15040397
   Geng FX, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00057
   Ha NH, 2015, TUMOR BIOL, V36, P9947, DOI 10.1007/s13277 015 3764 9
   Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006
   HavemosePoulsen A, 1997, CRIT REV ORAL BIOL M, V8, P217, DOI 10.1177/10454411970080020801
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Huang ZF, 2018, EXP THER MED, V15, P5159, DOI 10.3892/etm.2018.6127
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Izumiya M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147752
   Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16
   Kapila YL, 2021, PERIODONTOL 2000, V87, P11, DOI 10.1111/prd.12398
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lamont RJ, 2022, PERIODONTOL 2000, V89, P154, DOI 10.1111/prd.12425
   Lamont RJ, 1998, MICROBIOL MOL BIOL R, V62, P1244, DOI 10.1128/MMBR.62.4.1244 1263.1998
   Li M, 2017, J PERIODONTAL RES, V52, P913, DOI 10.1111/jre.12463
   Lin Z, 2017, BIOMED PHARMACOTHER, V90, P237, DOI 10.1016/j.biopha.2017.03.042
   Liu HJ, 2018, MOL MED REP, V18, P3325, DOI 10.3892/mmr.2018.9302
   Liu LY, 2018, MOL MED REP, V17, P1609, DOI 10.3892/mmr.2017.8042
   Liu W, 2019, INT J ENDOCRINOL, V2019, DOI 10.1155/2019/3054820
   Marycz K, 2022, MATERIALS, V15, DOI 10.3390/ma15113990
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mombelli A, 2018, PERIODONTOL 2000, V76, P85, DOI 10.1111/prd.12147
   Ohno T, 2006, MICROBES INFECT, V8, P1025, DOI 10.1016/j.micinf.2005.10.021
   Otomo Corgel Joan, 2012, J Evid Based Dent Pract, V12, P20, DOI 10.1016/S1532 3382(12)70006 4
   Parahitiyawa NB, 2010, ORAL DIS, V16, P136, DOI 10.1111/j.1601 0825.2009.01607.x
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pei ZH, 2013, MOL MED REP, V8, P1499, DOI 10.3892/mmr.2013.1696
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Qiu L, 2022, TISSUE CELL, V76, DOI 10.1016/j.tice.2022.101791
   Ribaudo G, 2016, CURR MED CHEM, V23, P1239, DOI 10.2174/0929867323666160428110059
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sacks D, 2018, INT J STROKE, V13, P612, DOI [10.1177/1747493018778713, 10.1016/j.jvir.2017.11.026]
   Shi JY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01175 x
   Sun MY, 2018, INT J MED SCI, V15, P257, DOI 10.7150/ijms.21620
   Vargas Sanchez PK, 2017, J APPL ORAL SCI, V25, P490, DOI 10.1590/1678 7757 2016 0517
   Walters John, 2015, Dent Clin North Am, V59, P919, DOI 10.1016/j.cden.2015.06.011
   Wang BQ, 2023, ARCH TOXICOL, V97, P1439, DOI 10.1007/s00204 023 03476 6
   Wang GQ, 2022, REDOX BIOL, V52, DOI 10.1016/j.redox.2022.102297
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wu ZD, 2017, BIOMED PHARMACOTHER, V94, P1, DOI 10.1016/j.biopha.2017.07.071
   Xie Yan fang, 2015, Zhejiang Da Xue Xue Bao Yi Xue Ban, V44, P301
   Xu HY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12743
   Yang HW, 2004, J PERIODONTOL, V75, P1077, DOI 10.1902/jop.2004.75.8.1077
   Zhang DW, 2016, CALCIFIED TISSUE INT, V99, P187, DOI 10.1007/s00223 016 0138 2
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0046 1
   Zhang WJ, 2010, MICROBES INFECT, V12, P838, DOI 10.1016/j.micinf.2010.05.011
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zheng D, 2012, BONE, V51, P85, DOI 10.1016/j.bone.2012.04.006
NR 55
TC 0
Z9 0
U1 8
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC 25
PY 2024
VL 143
AR 113302
DI 10.1016/j.intimp.2024.113302
EA OCT 2024
PN 1
PG 18
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA J1W2F
UT WOS:001335035100001
PM 39388889
OA hybrid
DA 2025 08 17
ER

PT J
AU Ho, MH
   Yao, CJ
   Liao, MH
   Lin, PI
   Liu, SH
   Chen, RM
AF Ho, Ming Hua
   Yao, Chih Jung
   Liao, Mei Hsiu
   Lin, Pei I
   Liu, Shing Hwa
   Chen, Ruei Ming
TI Chitosan nanofiber scaffold improves bone healing via stimulating
   trabecular bone production due to upregulation of the
   Runx2/osteocalcin/alkaline phosphatase signaling pathway
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE chitosan nanofibers; bone healing; micro computed tomography; bone
   histomorphometry; Runx2/OCN/ALP
ID BLOOD BRAIN BARRIER; OSTEOBLASTS; GROWTH; EXPRESSION;
   HYDROXYAPATITE/CHITOSAN
AB Osteoblasts play critical roles in bone formation. Our previous study showed that chitosan nanofibers can stimulate osteoblast proliferation and maturation. This translational study used an animal model of bone defects to evaluate the effects of chitosan nanofiber scaffolds on bone healing and the possible mechanisms. In this study, we produced uniform chitosan nanofibers with fiber diameters of approximately 200 nm. A bone defect was surgically created in the proximal femurs of male C57LB/6 mice, and then the left femur was implanted with chitosan nanofiber scaffolds for 21 days and compared with the right femur, which served as a control. Histological analyses revealed that implantation of chitosan nanofiber scaffolds did not lead to hepatotoxicity or nephrotoxicity. Instead, imaging analyses by X ray transmission and microcomputed tomography showed that implantation of chitosan nanofiber scaffolds improved bone healing compared with the control group. In parallel, microcomputed tomography and bone histomorphometric assays further demonstrated augmentation of the production of new trabecular bone in the chitosan nanofiber treated group. Furthermore, implantation of chitosan nanofiber scaffolds led to a significant increase in the trabecular bone thickness but a reduction in the trabecular parameter factor. As to the mechanisms, analysis by confocal microscopy showed that implantation of chitosan nanofiber scaffolds increased levels of Runt related transcription factor 2 (Runx2), a key transcription factor that regulates osteogenesis, in the bone defect sites. Successively, amounts of alkaline phosphatase and osteocalcin, two typical biomarkers that can simulate bone maturation, were augmented following implantation of chitosan nanofiber scaffolds. Taken together, this translational study showed a beneficial effect of chitosan nanofiber scaffolds on bone healing through stimulating trabecular bone production due to upregulation of Runx2 mediated alkaline phosphatase and osteocalcin gene expressions. Our results suggest the potential of chitosan nanofiber scaffolds for therapy of bone diseases, including bone defects and bone fractures.
C1 [Ho, Ming Hua] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei, Taiwan.
   [Ho, Ming Hua; Chen, Ruei Ming] Taipei Med Univ, Cell Physiol & Mol Image Res Ctr, Wan Fang Hosp, Taipei 110, Taiwan.
   [Yao, Chih Jung] Taipei Med Univ, Sch Med, Dept Internal Med, Taipei 110, Taiwan.
   [Liao, Mei Hsiu; Lin, Pei I; Chen, Ruei Ming] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan.
   [Liu, Shing Hwa] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10764, Taiwan.
   [Chen, Ruei Ming] Taipei Med Univ Hosp, Anesthet & Toxicol Res Ctr, Taipei, Taiwan.
C3 National Taiwan University of Science & Technology; Taipei Municipal
   WanFang Hospital; Taipei Medical University; Taipei Medical University;
   National Taiwan University; Taipei Medical University Hospital; Taipei
   Medical University
RP Chen, RM (通讯作者)，Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Xing St, Taipei 110, Taiwan.
EM rmchen@tmu.edu.tw
OI LIU, SHING HWA/0000 0002 9976 1197
FU Taipei Medical University; Taipei Medical University and National Taiwan
   University of Science and Technology [TMU NTUST 101 01]; Ministry of
   Science and Technology, Taipei, Taiwan [MOST 104 2314 B 038 004 MY3];
   National Research Program for Biopharmaceuticals at the Ministry of
   Science and Technology of Taiwan [MOST 104 2325 B 001 011]
FX This study was supported by Taipei Medical University and National
   Taiwan University of Science and Technology (TMU NTUST 101 01), Wan Fang
   Hospital (104swf04), and the Ministry of Science and Technology (MOST
   104 2314 B 038 004 MY3), Taipei, Taiwan. We thank the Taiwan Mouse
   Clinic (MOST 104 2325 B 001 011) which is funded by the National
   Research Program for Biopharmaceuticals at the Ministry of Science and
   Technology of Taiwan for technical support in micro computed tomographic
   experiment.
CR AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Cauley JA, 2014, NAT REV ENDOCRINOL, V10, P338, DOI 10.1038/nrendo.2014.51
   Chang HC, 2014, J AGR FOOD CHEM, V62, P3466, DOI 10.1021/jf403286w
   Chen JW, 2008, DESALINATION, V233, P48, DOI 10.1016/j.desal.2007.09.026
   Chen ZG, 2010, ACTA BIOMATER, V6, P372, DOI 10.1016/j.actbio.2009.07.024
   Costa Pinto AR, 2011, TISSUE ENG PART B RE, V17, P331, DOI 10.1089/ten.teb.2010.0704
   Deitzel JM, 2001, POLYMER, V42, P261, DOI 10.1016/S0032 3861(01)00336 6
   Di Martino A, 2005, BIOMATERIALS, V26, P5983, DOI 10.1016/j.biomaterials.2005.03.016
   Fernández T, 2014, TISSUE ENG PT A, V20, P1948, DOI [10.1089/ten.tea.2013.0696, 10.1089/ten.TEA.2013.0696]
   Frohbergh ME, 2012, BIOMATERIALS, V33, P9167, DOI 10.1016/j.biomaterials.2012.09.009
   Geris L, 2008, J THEOR BIOL, V251, P137, DOI 10.1016/j.jtbi.2007.11.008
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Hawse JR, 2008, J CELL BIOCHEM, V103, P383, DOI 10.1002/jcb.21425
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Ho MH, 2014, INT J NANOMED, V9, P4293, DOI 10.2147/IJN.S68012
   Ho WP, 2009, J CELL BIOCHEM, V108, P1084, DOI 10.1002/jcb.22338
   Hung TY, 2010, J ETHNOPHARMACOL, V131, P70, DOI 10.1016/j.jep.2010.05.063
   Jancár J, 2007, PHYSIOL RES, V56, pS17, DOI 10.33549/physiolres.931297
   Jayakumar R, 2010, BIOTECHNOL ADV, V28, P142, DOI 10.1016/j.biotechadv.2009.11.001
   Koç A, 2014, J BIOMATER APPL, V29, P748, DOI 10.1177/0885328214544769
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Lee YE, 2014, J ETHNOPHARMACOL, V158, P94, DOI 10.1016/j.jep.2014.10.016
   Lin JW, 2012, NEURO ONCOLOGY, V14, P302, DOI 10.1093/neuonc/nor217
   Liu HH, 2013, BIOMATERIALS, V34, P4404, DOI 10.1016/j.biomaterials.2013.02.048
   Ohkawa K, 2004, MACROMOL RAPID COMM, V25, P1600, DOI 10.1002/marc.200400253
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sambudi NS, 2015, COMPOS SCI TECHNOL, V106, P76, DOI 10.1016/j.compscitech.2014.11.003
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Seul KJ, 2011, J BONE MINER RES, V26, P341, DOI 10.1002/jbmr.208
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Shin SY, 2005, J PERIODONTOL, V76, P1778, DOI 10.1902/jop.2005.76.10.1778
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Suh JKF, 2000, BIOMATERIALS, V21, P2589
   Takahashi Tomihisa, 2005, J Oral Sci, V47, P199, DOI 10.2334/josnusd.47.199
   Tan ML, 2014, BIOMATERIALS, V35, P7828, DOI 10.1016/j.biomaterials.2014.05.087
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Torres Giner S, 2008, ENG LIFE SCI, V8, P303, DOI 10.1002/elsc.200700066
   Trzeciakiewicz A, 2010, J NUTR BIOCHEM, V21, P424, DOI 10.1016/j.jnutbio.2009.01.017
   Ueno H, 2001, ADV DRUG DELIVER REV, V52, P105, DOI 10.1016/S0169 409X(01)00189 2
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   van Leeuwen JPTM, 2001, CRIT REV EUKAR GENE, V11, P199, DOI 10.1615/CritRevEukarGeneExpr.v11.i1 3.100
   Vandenput L, 2009, NAT REV ENDOCRINOL, V5, P437, DOI 10.1038/nrendo.2009.112
   Wang H, 2012, J BIOMECH, V45, P2417, DOI 10.1016/j.jbiomech.2012.06.024
   Wang HA, 2010, MOL CELL BIOCHEM, V342, P191, DOI 10.1007/s11010 010 0483 9
   Wang W, 2009, J BIOMED MATER RES A, V91A, P994, DOI 10.1002/jbm.a.32329
   Wohl GR, 2009, BONE, V44, P320, DOI 10.1016/j.bone.2008.09.010
   Wongdee K, 2012, J PHYSIOL SCI, V62, P299, DOI 10.1007/s12576 012 0212 0
   Zhang YZ, 2008, BIOMATERIALS, V29, P4314, DOI 10.1016/j.biomaterials.2008.07.038
   Zhang YZ, 2010, TISSUE ENG PT A, V16, P1949, DOI [10.1089/ten.tea.2009.0221, 10.1089/ten.TEA.2009.0221]
   ZHOU H, 1994, J BONE MINER RES, V9, P1489
   Zhu WM, 2013, ARTIF CELL NANOMED B, V41, P304, DOI 10.3109/10731199.2012.742098
NR 52
TC 68
Z9 70
U1 2
U2 35
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 5941
EP 5954
DI 10.2147/IJN.S90669
PG 14
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA CR8RL
UT WOS:000361621500001
PM 26451104
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kondegowda, NG
   Fenutria, R
   Pollack, IR
   Orthofer, M
   Garcia Ocaña, A
   Penninger, JM
   Vasavada, RC
AF Kondegowda, Nagesha Guthalu
   Fenutria, Rafael
   Pollack, Ilana R.
   Orthofer, Michael
   Garcia Ocana, Adolfo
   Penninger, Josef M.
   Vasavada, Rupangi C.
TI Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation
   through Inhibition of the Receptor Activator of NF κB Ligand Pathway
SO CELL METABOLISM
LA English
DT Article
ID PLACENTAL LACTOGEN; BONE RESORPTION; HUMAN ISLETS; PROTEIN; MICE; MASS;
   PREGNANCY; DENSITY; DEATH; EXPRESSION
AB Diabetes results from a reduction of pancreatic beta cells. Stimulating replication could normalize beta cell mass. However, adult human beta cells are recalcitrant to proliferation. We identified osteoprotegerin, a bone related decoy receptor, as a beta cell mitogen. Osteoprotegerin was induced by and required for lactogen mediated rodent beta cell replication. Osteoprotegerin enhanced beta cell proliferation in young, aged, and diabetic mice. This resulted in increased beta cell mass in young mice and significantly delayed hyperglycemia in diabetic mice. Osteoprotegerin stimulated replication of adult human beta cells, without causing dedifferentiation. Mechanistically, osteoprotegerin induced human and rodent beta cell replication by modulating CREB and GSK3 pathways, through binding Receptor Activator of NF kappa B (RANK) Ligand (RANKL), a brake in beta cell proliferation. Denosumab, an FDA approved osteoporosis drug, and RANKL specific antibody induced human beta cell proliferation in vitro, and in vivo, in humanized mice. Thus, osteoprotegerin and Denosumab prevent RANKL/RANK interaction to stimulate beta cell replication, highlighting the potential for repurposing an osteoporosis drug to treat diabetes.
C1 [Kondegowda, Nagesha Guthalu; Fenutria, Rafael; Pollack, Ilana R.; Garcia Ocana, Adolfo; Vasavada, Rupangi C.] Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA.
   [Kondegowda, Nagesha Guthalu; Fenutria, Rafael; Pollack, Ilana R.; Garcia Ocana, Adolfo; Vasavada, Rupangi C.] Icahn Sch Med Mt Sinai, Div Endocrinol & Bone Dis, New York, NY 10029 USA.
   [Garcia Ocana, Adolfo; Vasavada, Rupangi C.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA.
   [Orthofer, Michael; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A 1030 Vienna, Austria.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Vienna Biocenter
   (VBC); Institute of Molecular Biotechnology (IMBA); Austrian Academy of
   Sciences
RP Vasavada, RC (通讯作者)，Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA.
EM rupangi.vasavada@mssm.edu
RI ; Penninger, Josef/I 6860 2013
OI Garcia Ocana, Adolfo/0000 0002 6883 6176; Penninger,
   Josef/0000 0002 8194 3777; Pollack, Ilana/0000 0001 8274 7818
FU ERC grant; Innovator award by Era of Hope/DoD; National Institutes of
   Health [R01DK072264, DK102893]; Juvenile Diabetes Research Foundation
   [17 2012 37]
FX We are grateful to Drs. A. Stewart, D. Scott, and N. Fiaschi Taesch for
   their critical input; to Dr. D. Scott for manuscript editing; to C.
   Chin, T. Buch, A. Amlani, A. Otero, and Dr. J.F. Lopez Acosta for
   experimental assistance; to the NIDDK supported Integrated Islet
   Distribution Program (IIDP) for providing human islets; and to the
   microscopy cores at the University of Pittsburgh and the Icahn School of
   Medicine at Mount Sinai for their assistance and use of their
   facilities. J.P. is supported by advanced ERC grant and Innovator award
   by Era of Hope/DoD. This work was supported by grants from the National
   Institutes of Health (R01DK072264; DK102893) and the Juvenile Diabetes
   Research Foundation (17 2012 37) to R.C.V.
CR Beattie GM, 1999, DIABETES, V48, P1013, DOI 10.2337/diabetes.48.5.1013
   Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520
   Freemark M, 2002, ENDOCRINOLOGY, V143, P1378, DOI 10.1210/en.143.4.1378
   Fujinaka Y, 2004, DIABETES, V53, P3120, DOI 10.2337/diabetes.53.12.3120
   Fujinaka Y, 2007, J BIOL CHEM, V282, P30707, DOI 10.1074/jbc.M702607200
   Guthalu N.K., 2010, OPEN ENDOCR J, V4, P80
   Hanada R, 2010, BIOL CHEM, V391, P1365, DOI 10.1515/BC.2010.149
   Hong JS, 2005, AM J OBSTET GYNECOL, V193, P1011, DOI 10.1016/j.ajog.2005.06.051
   Huang C, 2009, ENDOCRINOLOGY, V150, P1618, DOI 10.1210/en.2008 1003
   Hussain MA, 2006, MOL CELL BIOL, V26, P7747, DOI 10.1128/MCB.02353 05
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kondegowda NG, 2012, DIABETOLOGIA, V55, P1721, DOI 10.1007/s00125 012 2501 9
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kulkarni RN, 2012, DIABETES, V61, P2205, DOI 10.2337/db12 0018
   Kutlu B, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755 8794 2 3
   LEITER EH, 1982, P NATL ACAD SCI BIOL, V79, P630, DOI 10.1073/pnas.79.2.630
   Liu H, 2009, DIABETES, V58, P663, DOI 10.2337/db07 1208
   Isidro ML, 2010, CURR DIABETES REV, V6, P144, DOI 10.2174/157339910791162970
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Mochizuki S, 2002, J BONE MINER METAB, V20, P14, DOI 10.1007/s774 002 8441 x
   Ominsky MS, 2009, J BONE MINER RES, V24, P1234, DOI [10.1359/JBMR.090215, 10.1359/jbmr.090215]
   Oram RA, 2014, DIABETOLOGIA, V57, P187, DOI 10.1007/s00125 013 3067 x
   Padgett LE, 2013, ANN NY ACAD SCI, V1281, P16, DOI 10.1111/j.1749 6632.2012.06826.x
   Parnaud G, 2008, DIABETOLOGIA, V51, P91, DOI 10.1007/s00125 007 0855 1
   Perl S, 2010, J CLIN ENDOCR METAB, V95, pE234, DOI 10.1210/jc.2010 0932
   Rao P, 2005, DIABETES, V54, P1664, DOI 10.2337/diabetes.54.6.1664
   Rieck S, 2010, TRENDS ENDOCRIN MET, V21, P151, DOI 10.1016/j.tem.2009.11.001
   Rieck S, 2009, MOL ENDOCRINOL, V23, P1702, DOI 10.1210/me.2009 0144
   Saito M, 2014, CURR OSTEOPOROS REP, V12, P181, DOI 10.1007/s11914 014 0202 7
   Schrader J, 2007, DIABETOLOGIA, V50, P1243, DOI 10.1007/s00125 007 0672 6
   Schwartz AV, 2013, J BONE MINER RES, V28, P1348, DOI 10.1002/jbmr.1865
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Teta M, 2005, DIABETES, V54, P2557, DOI 10.2337/diabetes.54.9.2557
   Toffoli B, 2011, MOL CELL ENDOCRINOL, V331, P136, DOI 10.1016/j.mce.2010.08.019
   Vasavada RC, 2006, INT J BIOCHEM CELL B, V38, P931, DOI 10.1016/j.biocel.2005.08.003
   Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399
   Vasavada RC, 2007, DIABETES, V56, P2732, DOI 10.2337/db07 0461
   Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200
   Weir GC, 2013, ANN NY ACAD SCI, V1281, P92, DOI 10.1111/nyas.12031
   Williams K, 2011, DIABETOLOGIA, V54, P2867, DOI 10.1007/s00125 011 2260 z
NR 41
TC 131
Z9 140
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550 4131
EI 1932 7420
J9 CELL METAB
JI Cell Metab.
PD JUL 7
PY 2015
VL 22
IS 1
BP 77
EP 85
DI 10.1016/j.cmet.2015.05.021
PG 9
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA CM4LU
UT WOS:000357656900013
PM 26094891
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Xu, RY
   Shi, GH
   Xu, L
   Gu, QY
   Fu, Y
   Zhang, P
   Cheng, J
   Jiang, HB
AF Xu, Rongyao
   Shi, Guanghui
   Xu, Ling
   Gu, Qinyi
   Fu, Yu
   Zhang, Ping
   Cheng, Jie
   Jiang, Hongbing
TI Simvastatin improves oral implant osseointegration via enhanced
   autophagy and osteogenesis of BMSCs and inhibited osteoclast activity
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE autophagy; bone marrow stromal cells (BMSCs); implant; osseointegration;
   osteoclasts; simvastatin
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; ALVEOLAR BONE LOSS;
   IN VIVO; MUSCULAR DYSTROPHY; DIFFERENTIATION; PATHWAY; MODEL;
   NANOPARTICLES; PERIODONTITIS
AB Dental implants have become a widely accepted and successful treatment for fully and partially edentulous patients. Simvastatin has been applied to improve and accelerate the osseointegration of implants by increasing the quantity and quality of bone tissue. However, its potential mechanism has not been elucidated completely. Here, we found that simvastatin significantly enhanced the autophagy level of jaw derived bone marrow stromal cells (BMSCs) and alleviated production of reactive oxygen species under unfavourable conditions. Simvastatin promoted osteogenic differentiation of BMSCs via enhanced autophagy. Furthermore, simvastatin inhibited the bone resorption activity of osteoclasts. With the use of a rat model of oral implant osseointegration, we found local injection of simvastatin displayed more new bone formation at the interface of the bone and implant compared with that of oral administration. Fluorochrome labelling histomorphometrical analysis and micro CT also showed that simvastatin promoted the osseointegration of implants. Notably, fewer activated osteoclasts were observed in the region of osseointegration of implants from the simvastatin treatment groups, especially the local delivery of simvastatin. Collectively, our results revealed that simvastatin can increase osteoblastic differentiation of BMSCs via enhanced autophagy and decreased osteoclast activity. Thus, simvastatin could be a viable and promising drug to improve and even accelerate the osseointegration of a dental implant.
C1 [Xu, Rongyao; Shi, Guanghui; Xu, Ling; Gu, Qinyi; Fu, Yu; Zhang, Ping; Cheng, Jie; Jiang, Hongbing] Nanjing Med Univ, Jiangsu Key Lab Oral Dis, 136 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Xu, Rongyao; Shi, Guanghui; Xu, Ling; Fu, Yu; Zhang, Ping; Cheng, Jie; Jiang, Hongbing] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Oral & Maxillofacial Surg, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Jiang, HB (通讯作者)，Nanjing Med Univ, Jiangsu Key Lab Oral Dis, 136 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM jhb@njmu.edu.cn
RI Jiang, Hongbing/AAQ 6331 2021; Fu, Yu/LBI 0598 2024; Xu,
   Rongyao/AHB 8403 2022
OI Jiang, Hongbing/0000 0002 3748 0381
FU Postgraduate Research & Practice Innovation Program of Jiangsu Province
   [KYCX17_1229]; National Natural Science Foundation of China [81470723];
   Priority Academic Program for the Development of Jiangsu Higher
   Education Institutions [2014 37]
FX National Natural Science Foundation of China Grant, Grant/Award Number:
   81470723; Priority Academic Program for the Development of Jiangsu
   Higher Education Institutions, Grant/Award Number: 2014 37; Postgraduate
   Research & Practice Innovation Program of Jiangsu Province, Grant/Award
   Number: KYCX17_1229
CR Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Apostu D, 2017, DRUG METAB REV, V49, P92, DOI 10.1080/03602532.2016.1277737
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Bing WD, 2016, J CELL MOL MED, V20, P949, DOI 10.1111/jcmm.12795
   Björnsson ES, 2017, LIVER INT, V37, P173, DOI 10.1111/liv.13308
   Brama M, 2007, BIOMATERIALS, V28, P595, DOI 10.1016/j.biomaterials.2006.08.018
   Cao HL, 2016, SCI REP UK, V6, DOI 10.1038/srep21761
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Di Meo S, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1245049
   Douglas T, 2008, J BIOMED MATER RES A, V84A, P805, DOI 10.1002/jbm.a.31501
   Fu Y, 2014, INT J BIOCHEM CELL B, V54, P68, DOI 10.1016/j.biocel.2014.07.003
   Gao K, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/260161
   Ge J, 2015, J DENT RES, V94, P936, DOI 10.1177/0022034515578908
   Ghavami S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.61
   Gómez Puerto MC, 2016, AUTOPHAGY, V12, P1804, DOI 10.1080/15548627.2016.1203484
   Gu W, 2017, RESPIROLOGY, V22, P533, DOI 10.1111/resp.12926
   Hu DD, 2017, J BIOMATER APPL, V31, P1135, DOI 10.1177/0885328217692140
   Jimi Eijiro, 2017, Clin Calcium, V27, P1689, DOI CliCa171216891695
   Lai EHH, 2012, J ENDODONT, V38, P757, DOI 10.1016/j.joen.2012.02.023
   Lee YH, 2013, BIOMATERIALS, V34, P10199, DOI 10.1016/j.biomaterials.2013.08.080
   Li X, 2015, BIOMATERIALS, V36, P44, DOI 10.1016/j.biomaterials.2014.09.012
   Liu CC, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00439
   Lorincz P, 2017, CELLS BASEL, V6, DOI 10.3390/cells6030022
   Martin Monge E, 2017, INT J ORAL MAX IMPL, V32, P751, DOI 10.11607/jomi.5320
   Mathai BJ, 2017, CELLS BASEL, V6, DOI 10.3390/cells6030021
   ME L, ANTIOXID REDOX SIGN, DOI [10.1089/ars.2017.7223, DOI 10.1089/ARS.2017.7223]
   Montazerolghaem M, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5692 7
   Moshiri A, 2016, CLIN EXP PHARMACOL P, V43, P659, DOI 10.1111/1440 1681.12577
   Mouraret S, 2014, BONE, V58, P177, DOI 10.1016/j.bone.2013.07.021
   Nakashima Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072033
   Narby B, 2008, INT J PROSTHODONT, V21, P481
   Niu JY, 2015, MOL MED REP, V12, P8237, DOI 10.3892/mmr.2015.4476
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Okamoto Y, 2009, J ENDODONT, V35, P367, DOI 10.1016/j.joen.2008.11.024
   Pagkalos J, 2010, J BONE MINER RES, V25, P2470, DOI 10.1002/jbmr.163
   Park JB, 2009, MED ORAL PATOL ORAL, V14, pE485
   Popelut A, 2010, BIOMATERIALS, V31, P9173, DOI 10.1016/j.biomaterials.2010.08.045
   Saraswat K, 2017, EXPERT OPIN DRUG DIS, V12, P955, DOI 10.1080/17460441.2017.1349750
   Sendyk DI, 2016, J ORAL REHABIL, V43, P873, DOI 10.1111/joor.12438
   Song CJ, 2014, CYTOTHERAPY, V16, P1361, DOI 10.1016/j.jcyt.2014.04.006
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Stellaard F, 2017, CHOLESTEROL, DOI 10.1155/2017/5046294
   Tai IC, 2015, INT J NANOMED, V10, P5881, DOI 10.2147/IJN.S84273
   Takahashi M, 2016, INT J ORAL MAX IMPL, V31, P1320, DOI 10.11607/jomi.4706
   Ueno T, 2016, BIOMATERIALS, V108, P177, DOI 10.1016/j.biomaterials.2016.08.050
   Wang CZ, 2014, J COLLOID INTERF SCI, V432, P190, DOI 10.1016/j.jcis.2014.06.037
   Wang L, 2016, COLLOID SURFACE B, V148, P440, DOI 10.1016/j.colsurfb.2016.09.018
   Wang L, 2015, MOL MED REP, V11, P2711, DOI 10.3892/mmr.2014.3099
   Whitehead NP, 2016, AUTOPHAGY, V12, P705, DOI 10.1080/15548627.2016.1144005
   Whitehead NP, 2015, P NATL ACAD SCI USA, V112, P12864, DOI 10.1073/pnas.1509536112
   Xie CM, 2014, ACS APPL MATER INTER, V6, P8580, DOI 10.1021/am501428e
   Xu RY, 2016, EXP GERONTOL, V84, P71, DOI 10.1016/j.exger.2016.09.001
   Xu XC, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0284 0
   Yamashita M, 2010, REGUL PEPTIDES, V162, P99, DOI 10.1016/j.regpep.2010.03.003
   Yue XX, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/11/115708
   Zhao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054645
NR 56
TC 45
Z9 49
U1 1
U2 54
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD MAY
PY 2018
VL 12
IS 5
BP 1209
EP 1219
DI 10.1002/term.2652
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA GF5OX
UT WOS:000432018500006
PM 29498229
DA 2025 08 17
ER

PT J
AU Liu, XY
   Liu, YQ
   Cheng, MC
   Zhang, XZ
   Xiao, HB
AF Liu, Xiaoyan
   Liu, Yanqiu
   Cheng, Mengchun
   Zhang, Xiaozhe
   Xiao, Hongbin
TI A metabolomics study of the inhibitory effect of 17 beta estradiol on
   osteoclast proliferation and differentiation
SO MOLECULAR BIOSYSTEMS
LA English
DT Article
ID LECITHIN CHOLESTEROL ACYLTRANSFERASE; CHROMATOGRAPHY MASS SPECTROMETRY;
   PHOSPHOLIPASE A(2) ACTIVITY; RECEPTOR ALPHA GENE; OXIDATIVE STRESS;
   IN VITRO; POSTMENOPAUSAL WOMEN; ESTROGEN RECEPTOR; BONE RESORPTION;
   AMINO ACIDS
AB Estradiol is a major drug used clinically to alleviate osteoporosis, partly through inhibition of the activity of osteoclasts, which play a crucial role in bone resorption. So far, little is known about the effects of estradiol on osteoclast metabolism. In this study, ultra high performance liquid chromatography tandem mass spectrometry (UPLC/MS) based metabolomics strategy was used to investigate the metabolite response to 17b estradiol in mouse osteoclast RAW264.7, a commonly used cell model for studying osteoporosis. Our results showed that the application of estradiol altered the levels of 27 intracellular metabolites, including lysophosphatidylcholines (LysoPCs), other lipids and amino acid derivants. The changes of all the 27 metabolites were observed in the study of estradiol induced osteoclast proliferation inhibition (1 mu M estradiol applied), while the changes of only 18 metabolites were observed in the study of differentiation inhibition (0.1 mu M estradiol applied). Further pathway impact analysis determined glycerophospholipid metabolism as the main potential target pathway of estradiol, which was further confirmed by LCAT (phosphatidylcholine sterol acyltransferase) activity changes and lipid peroxidative product (MDA, methane dicarboxylic aldehyde) changes caused by estradiol. Additionally, we found that estradiol significantly decreased intracellular oxidative stress during cell proliferation but not during cell differentiation. Our study suggested that estradiol generated a highly condition dependent influence on osteoclast metabolism.
C1 [Liu, Xiaoyan; Liu, Yanqiu; Cheng, Mengchun; Zhang, Xiaozhe; Xiao, Hongbin] Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China.
   [Liu, Yanqiu] Dalian Med Univ, Acad Integrat Med, Dalian 116044, Peoples R China.
   [Xiao, Hongbin] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
C3 Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS;
   Dalian Medical University; China Academy of Chinese Medical Sciences;
   Institute of Chinese Materia Medica, CACMS
RP Xiao, HB (通讯作者)，Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China.
EM hbxiao69@163.com
RI Zhang, Xiaozhe/NKP 7188 2025
OI liu, Yan Qiu/0000 0002 1905 7168
FU National Basic Research Program [2012CB518303]; National Natural Science
   Foundation of China [81102739]
FX This work was supported by grants from the National Basic Research
   Program (2012CB518303) and National Natural Science Foundation of China
   (81102739).
CR Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Catalá A, 2009, CHEM PHYS LIPIDS, V157, P1, DOI 10.1016/j.chemphyslip.2008.09.004
   Chan ECY, 2011, NAT PROTOC, V6, P1483, DOI 10.1038/nprot.2011.375
   Chen J, 2008, ANAL CHEM, V80, P1280, DOI 10.1021/ac702089h
   Conconi MT, 2001, FARMACO, V56, P755, DOI 10.1016/S0014 827X(01)01126 0
   Cui Z, 2002, BBA MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388 1981(02)00328 1
   David M, 2010, BONE, V46, pS41, DOI 10.1016/j.bone.2010.01.091
   de Kraker AT, 2004, MATURITAS, V49, P253, DOI 10.1016/j.maturitas.2004.05.006
   Dettmer K, 2011, ANAL BIOANAL CHEM, V399, P1127, DOI 10.1007/s00216 010 4425 x
   Eriksson L, 2010, J CHEMOMETR, V24, P779, DOI 10.1002/cem.1372
   Fallah A, 2013, MOL MEMBR BIOL, V30, P315, DOI 10.3109/09687688.2013.828855
   Fan YG, 2005, LIFE SCI, V76, P2893, DOI 10.1016/j.lfs.2004.10.059
   Fang NB, 2003, J AGR FOOD CHEM, V51, P6676, DOI 10.1021/jf034793v
   Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707
   Fukunaga J, 2004, BONE, V34, P425, DOI 10.1016/j.bone.2003.05.003
   GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668
   Höckerstedt A, 2004, J CLIN ENDOCR METAB, V89, P5088, DOI 10.1210/jc.2004 0141
   Hong L, 2006, TISSUE ENG, V12, P2747, DOI 10.1089/ten.2006.12.2747
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Itabe H, 1999, J BIOCHEM TOKYO, V126, P153, DOI 10.1093/oxfordjournals.jbchem.a022416
   Kalyvioti ES, 2012, BONE, V50, pS136, DOI 10.1016/j.bone.2012.02.418
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kanji SS, 1999, J CLIN ENDOCR METAB, V84, P2481, DOI 10.1210/jc.84.7.2481
   Karieb S, 2012, BRIT J NUTR, V108, P1736, DOI 10.1017/S0007114511007355
   Katao Y, 2011, ORTHOD WAVES, V70, P8, DOI 10.1016/j.odw.2010.07.002
   Kim M., 2010, FASEB J, V24
   Kuo YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040272
   Lakatos LP, 2002, EUR J GASTROEN HEPAT, V14, P733, DOI 10.1097/00042737 200207000 00004
   Lee EJ, 2010, ASIAN AUSTRAL J ANIM, V23, P649, DOI 10.5713/ajas.2010.90227
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Long Wei Fu, 2009, Sichuan Da Xue Xue Bao Yi Xue Ban, V40, P843
   Ma B, 2013, EUR J PHARMACOL, V718, P524, DOI 10.1016/j.ejphar.2013.06.030
   Ma B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054965
   Manassiev NA, 2002, MATURITAS, V42, P233, DOI 10.1016/S0378 5122(02)00069 5
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Morón FJ, 2006, BONE, V39, P213, DOI 10.1016/j.bone.2005.12.079
   Nicholson JK, 2008, NATURE, V455, P1054, DOI 10.1038/4551054a
   NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093
   Ongphiphadhanakul B, 2000, CLIN ENDOCRINOL, V52, P581, DOI 10.1046/j.1365 2265.2000.00979.x
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Periwal SB, 1996, PROSTAGLANDINS, V51, P191
   Pisetsky DS, 2011, CLIN VACCINE IMMUNOL, V18, P1420, DOI 10.1128/CVI.05110 11
   Rainville PD, 2007, J PROTEOME RES, V6, P552, DOI 10.1021/pr060611b
   Rego AC, 1996, J NEUROCHEM, V66, P2506
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Ryborg AK, 2004, ACTA DERM VENEREOL, V84, P433, DOI 10.1080/00015550410016930
   Saintier D, 2006, J STEROID BIOCHEM, V99, P165, DOI 10.1016/j.jsbmb.2006.01.009
   Saintier D, 2004, J CELL PHYSIOL, V198, P269, DOI 10.1002/jcp.10406
   Sergeev PV, 2000, B EXP BIOL MED+, V129, P60, DOI 10.1007/BF02433870
   Sunyer T, 1999, J CLIN INVEST, V103, P1409, DOI 10.1172/JCI4682
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Takarada T, 2012, J CELL PHYSIOL, V227, P3477, DOI 10.1002/jcp.24048
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   THOMSON BM, 1987, J IMMUNOL, V138, P775
   Torricelli P, 2003, ARTIF CELL BLOOD SUB, V31, P35, DOI 10.1081/BIO 120018002
   Ulloa N, 1998, METABOLISM, V47, P297, DOI 10.1016/S0026 0495(98)90260 8
   Vijayan V, 2014, BRIT J PHARMACOL, V171, P107, DOI 10.1111/bph.12434
   Wang XJ, 2012, J PROTEOMICS, V75, P1411, DOI 10.1016/j.jprot.2011.11.011
   Wang XJ, 2012, ANAL CHEM, V84, P428, DOI 10.1021/ac202828r
   Wright MM, 2004, BIOCHEM CELL BIOL, V82, P18, DOI 10.1139/o03 092
   Xu WJ, 2012, CHEMOMETR INTELL LAB, V118, P173, DOI 10.1016/j.chemolab.2012.06.008
   Yan DJ, 2010, BIOSCI BIOTECH BIOCH, V74, P2103, DOI 10.1271/bbb.100286
   Yin H, 2012, EUR J PHARMACOL, V674, P200, DOI 10.1016/j.ejphar.2011.11.024
   Zhang AH, 2013, ANALYST, V138, P353, DOI 10.1039/c2an36382h
   Zhang Shangshang, 2012, Zhongguo Zhong Yao Za Zhi, V37, P658
NR 67
TC 21
Z9 24
U1 1
U2 45
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1742 206X
EI 1742 2051
J9 MOL BIOSYST
JI Mol. Biosyst.
PY 2015
VL 11
IS 2
BP 635
EP 646
DI 10.1039/c4mb00528g
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AZ4SB
UT WOS:000348211900031
PM 25474166
DA 2025 08 17
ER

PT J
AU Tsukamoto, S
   Righi, A
   Vanel, D
   Honoki, K
   Donati, DM
   Errani, C
AF Tsukamoto, Shinji
   Righi, Alberto
   Vanel, Daniel
   Honoki, Kanya
   Donati, Davide Maria
   Errani, Costantino
TI Development of high grade osteosarcoma in a patient with recurrent giant
   cell tumor of the ischium while receiving treatment with denosumab
SO JAPANESE JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE giant cell tumor of bone; malignancy in giant cell tumor of bone;
   osteosarcoma; denosumab
ID OPEN LABEL; BONE; EXPRESSION; SAFETY; CANCER; CDK4; MDM2
AB Malignant transformation of giant cell tumor of bone (GCTB) without radiotherapy exposure is exceptionally rare, occurring in less than 1% of GCTBs. The safety and efficacy of denosumab in patients with GCTB was recently reported. We herein report a case of a benign recurrent GCTB with an H3F3A mutation that underwent secondary malignant transformation during treatment with denosumab. A 29 year old woman underwent curettage of a GCTB of the left ischium in 2005. Ten years after the first surgery, the GCTB recurred locally. We started treatment with denosumab. During the first 5 months of treatment, we observed a demarcated area of osteosclerosis in the recurrent lesion, and the patient's clinical condition improved. At 6 months, however, the patient developed pain, and a rapidly growing mass was detected by computed tomography. An incisional biopsy was performed. Histologic analysis showed a high grade osteosarcoma. The patient developed lung metastases and died soon after beginning chemotherapy. The mechanism of sarcomatous transformation of GCTB during denosumab therapy is unclear. These findings suggest that the scientific community should be aware of the possible malignant transformation of GCTB during denosumab treatment.
C1 [Tsukamoto, Shinji; Honoki, Kanya] Nara Med Univ, Dept Orthopaed Surg, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
   [Righi, Alberto] Rizzoli Inst, Dept Pathol, Bologna, Italy.
   [Donati, Davide Maria; Errani, Costantino] Rizzoli Inst, Dept Orthopaed Oncol, Bologna, Italy.
C3 Nara Medical University
RP Tsukamoto, S (通讯作者)，Nara Med Univ, Dept Orthopaed Surg, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
EM shinji104@mail.goo.ne.jp
RI Errani, Costantino/C 6918 2019; Honoki, Kanya/C 8814 2009; Donati,
   Davide/C 8102 2019; righi, alberto/J 6028 2016; Righi,
   Alberto/J 6028 2016; Tsukamoto, Shinji/L 6013 2019
OI Errani, Costantino/0000 0002 4504 2867; righi,
   alberto/0000 0002 1074 0155; 
FU Grants in Aid for Scientific Research [15K10455] Funding Source: KAKEN
CR Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020
   Aponte Tinao LA, 2015, CLIN ORTHOP RELAT R, V473, P3050, DOI 10.1007/s11999 015 4249 2
   Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Broehm CJ, 2015, CASE REP MED, V2015, P767
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Chen FX, 2016, ONCOL RES TREAT, V39, P453, DOI 10.1159/000447372
   Chow LTC, 2016, VIRCHOWS ARCH, V468, P741, DOI 10.1007/s00428 016 1926 9
   Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512
   Criscitiello C, 2015, CANCER TREAT REV, V41, P61, DOI 10.1016/j.ctrv.2014.12.001
   Dickson BC, 2008, MODERN PATHOL, V21, P369, DOI 10.1038/modpathol.2008.29
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Fletcher C. D. M. B. J., 2013, WHO CLASSIFICATION T, V5
   Gaston CL, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0056 0
   Mori K, 2007, ONCOL REP, V18, P1365
   Righi A, 2015, HUM PATHOL, V46, P549, DOI 10.1016/j.humpath.2014.12.006
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   SCHUUR ER, 1995, CELL GROWTH DIFFER, V6, P219
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Thomas D, 2010, LANCET ONCOL, V11, P815, DOI 10.1016/S1470 2045(10)70170 4
   Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006
   Uni KK, 2010, DAHLINS BONE TUMOURS
NR 24
TC 44
Z9 46
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0368 2811
EI 1465 3621
J9 JPN J CLIN ONCOL
JI Jpn. J. Clin. Oncol.
PD NOV
PY 2017
VL 47
IS 11
BP 1090
EP 1096
DI 10.1093/jjco/hyx112
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FL6NR
UT WOS:000414362800015
PM 29048579
DA 2025 08 17
ER

PT J
AU Ma, YL
   Peng, T
   Yao, XD
   Sun, CN
   Wang, XW
AF Ma, Yulong
   Peng, Tao
   Yao, Xudong
   Sun, Chaonan
   Wang, Xiaowei
TI KLF2 reduces dexamethasone induced injury to growth plate chondrocytes
   by inhibiting the Runx2 mediated PI3K/AKT and ERK signalling pathways
SO AUTOIMMUNITY
LA English
DT Article
DE KLF2; Runx2; growth plate chondrocytes; PI3K; AKT pathways; apoptosis
AB Dexamethasone (Dex) is a type of glucocorticoid drug. Long term use can induce growth plate chondrocytes (GPCs) apoptosis, impair differentiation, and inhibit cell proliferation and bone growth. It has been reported that Kruppel like factor 2 (KLF2) inhibits osteoblast damage induced by Dex, but the role in Dex induced GPCs remains unclear. Dex was used to construct a model of growth plate injury in vitro. CCK 8 and TUNEL kits were used to determine cell viability and apoptosis. A model of growth plate injury was established by intraperitoneal injection of Dex. Immunohistochemistry was used to investigate the expression of KLF2 in rats. The results showed that KLF2 expression of rat tibial GPCs was down regulated after Dex stimulation. Overexpression of KLF2 promoted cell viability and cell cycle, while inhibited apoptosis of growth plate Dex induced chondrocytes. Moreover, KLF2 inhibited Runx2 mediated PI3K/AKT and ERK signalling pathways. And PI3K/AKT and ERK signalling pathways, which were involved in the regulation of KLF2 on GPCs. Further studies showed that KLF2 alleviated growth plate injury in vivo. In conclusion, our study found that KLF2 promoted proliferation and inhibited apoptosis of Dex induced GPCs by targeting the Runx2 mediated PI3K/AKT and ERK signalling pathways.
C1 [Ma, Yulong; Peng, Tao; Yao, Xudong; Sun, Chaonan; Wang, Xiaowei] Xian Childrens Hosp, Dept Orthoped, 69 Xijuyuan Lane, Xian 710002, Shaanxi, Peoples R China.
RP Wang, XW (通讯作者)，Xian Childrens Hosp, Dept Orthoped, 69 Xijuyuan Lane, Xian 710002, Shaanxi, Peoples R China.
EM little11ww@163.com
RI yao, xvdong/HSG 0200 2023
CR Chauhan Devendra Kumar, 2009, Foot (Edinb), V19, P133, DOI 10.1016/j.foot.2008.12.002
   Chen D, 2020, J ORTHOP TRANSL, V23, P132, DOI 10.1016/j.jot.2019.11.008
   Deng JH, 2019, SEMIN ARTHRITIS RHEU, V49, P251, DOI 10.1016/j.semarthrit.2019.03.010
   Harrington J, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969 016 0119 z
   Hoshino M, 2017, FREE RADICAL BIO MED, V110, P63, DOI 10.1016/j.freeradbiomed.2017.05.022
   Hou ZY, 2019, LAB INVEST, V99, P271, DOI 10.1038/s41374 018 0149 x
   Huang Y, 2018, J STEROID BIOCHEM, V181, P52, DOI 10.1016/j.jsbmb.2018.03.001
   Jha P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112383
   Kim B, 2020, J BONE MINER RES, V35, P155, DOI 10.1002/jbmr.3869
   Kim I, 2019, BMB REP, V52, P469, DOI 10.5483/BMBRep.2019.52.7.104
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Laha D, 2019, AUTOPHAGY, V15, P2063, DOI 10.1080/15548627.2019.1596491
   Launay F, 2015, ORTHOP TRAUMATOL SUR, V101, pS139, DOI 10.1016/j.otsr.2014.06.030
   Lin Z, 2019, J CELL PHYSIOL, V234, P6042, DOI 10.1002/jcp.27225
   Liu X, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0424 6
   Lu HB, 2018, CELL PHYSIOL BIOCHEM, V49, P217, DOI 10.1159/000492872
   Maity J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04903 9
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Rashid Harunur, 2021, Matrix Biol Plus, V12, P100088, DOI 10.1016/j.mbplus.2021.100088
   SCHWAB SA, 1977, CAN MED ASSOC J, V117, P626
   Scindia Y, 2019, SEMIN NEPHROL, V39, P76, DOI 10.1016/j.semnephrol.2018.10.006
   Sinner B, 2019, ANAESTHESIST, V68, P676, DOI 10.1007/s00101 019 00672 x
   Su YW, 2021, J CELL PHYSIOL, V236, P5966, DOI 10.1002/jcp.30278
   Turpaev KT, 2020, BIOCHEMISTRY MOSCOW+, V85, P54, DOI 10.1134/S0006297920010058
   Yu X, 2019, OSTEOARTHR CARTILAGE, V27, P526, DOI 10.1016/j.joca.2018.12.007
   Zaman F, 2019, FASEB J, V33, P4962, DOI 10.1096/fj.201801741R
NR 27
TC 9
Z9 9
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0891 6934
EI 1607 842X
J9 AUTOIMMUNITY
JI Autoimmunity
PD JAN 1
PY 2023
VL 56
IS 1
DI 10.1080/08916934.2022.2141233
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 5Y9FA
UT WOS:000879584400001
PM 36343159
OA hybrid
DA 2025 08 17
ER

PT J
AU Bao, YZ
   Chen, F
   Jin, WH
   Dai, JH
   Mao, GX
   Song, BS
AF Bao, Yizhong
   Chen, Fen
   Jin, Weihua
   Dai, Jihua
   Mao, Genxiang
   Song, Boshan
TI Sulfated galactofucan from Sargassum fusiforme protects against
   postmenopausal osteoporosis by regulating bone remodeling
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID MOLECULAR WEIGHT FUCOIDAN; IN VITRO; OSTEOBLAST DIFFERENTIATION;
   OSTEOCLAST DIFFERENTIATION; POLYSACCHARIDE; METABOLISM; MATRIX; TISSUE
AB Osteoporosis is a degenerative bone disease highly prevalent in older women, causing high morbidity and mortality rates. Fourteen kinds of fucoidan were isolated from Sargassum fusiforme through acid (named as SFS), alkaline (SFJ) and water (SFW). SFW was passed through an anion exchange column to obtain SFW 0, SFW 0.5 and SFW 2. SFW 0.5 and SFW 2 were degraded to obtain different sulfate group contents SFW x M/S/O (x for 0.5 or 2). We further confirmed SFW 0.5 O was the most effective fraction of SFW. SFW 0.5 O may have alternating backbones of (Gal)n and (Fuc)n, and the main sulfation may be at C2/C3 of the Fuc/Gal residues. SFW 0.5 O inhibition of OC differentiation was associated with IRF 8 signaling; meanwhile, SFW 0.5 O promoted osteoblast differentiation and bone mineral nodule formation. SFW 0.5 O also effectively ameliorated osteoporosis symptom caused by estrogen deprivation in vivo. We uncovered that the fucoidan active fraction SFW 0.5 O demonstrated effective bone protection, may be exploited for osteoporosis therapy.
   Fucoidan active ingredient SFW 0.5 O can effectively inhibit osteoclastogenesis, promote osteoblast differentiation, and improve osteoporosis symptoms caused by estrogen deprivation.
C1 [Bao, Yizhong; Dai, Jihua; Mao, Genxiang] Zhejiang Hosp, Zhejiang Key Lab Geriatr, Hangzhou, Peoples R China.
   [Bao, Yizhong; Dai, Jihua; Mao, Genxiang] Zhejiang Hosp, Geriatr Inst Zhejiang Prov, Hangzhou, Peoples R China.
   [Chen, Fen; Jin, Weihua] Zhejiang Univ Technol, Coll Biotechnol & Bioengn, Hangzhou, Peoples R China.
   [Song, Boshan] Zhejiang Hosp, Dept Orthopaed Surg, Hangzhou, Peoples R China.
C3 Zhejiang University of Technology
RP Mao, GX (通讯作者)，Zhejiang Hosp, Zhejiang Key Lab Geriatr, Hangzhou, Peoples R China.; Mao, GX (通讯作者)，Zhejiang Hosp, Geriatr Inst Zhejiang Prov, Hangzhou, Peoples R China.; Song, BS (通讯作者)，Zhejiang Hosp, Dept Orthopaed Surg, Hangzhou, Peoples R China.
EM maogenxiang@163.com; 735395261@qq.com
OI Bao, Yizhong/0000 0002 5245 1212
FU National Natural Science Foundation of China (National Science
   Foundation of China) [81801397]; National Natural Science Foundation of
   China
FX This study was supported by National Natural Science Foundation of China
   (No. 81801397).
CR Bernar A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010723
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Cho YD, 2009, J BIOL CHEM, V284, P25230, DOI 10.1074/jbc.M109.008391
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Deng LM, 2024, IND CROP PROD, V207, DOI 10.1016/j.indcrop.2023.117749
   Eleniste PP, 2014, INT J BIOCHEM CELL B, V46, P9, DOI 10.1016/j.biocel.2013.10.008
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gregson CL, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01061 5
   Gupta D, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25042085
   Hwang PA, 2016, CYTOTECHNOLOGY, V68, P1349, DOI 10.1007/s10616 015 9894 5
   Imam B, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.5328
   Izawa N, 2019, J BONE MINER RES, V34, P1143, DOI 10.1002/jbmr.3689
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jeong HS, 2013, INT J BIOL MACROMOL, V57, P138, DOI 10.1016/j.ijbiomac.2013.03.011
   Jeong YT, 2016, J MED FOOD, V19, P805, DOI 10.1089/jmf.2015.3646
   Jin WH, 2023, EXP GERONTOL, V172, DOI 10.1016/j.exger.2022.112057
   Jin WH, 2020, INT J BIOL MACROMOL, V160, P26, DOI 10.1016/j.ijbiomac.2020.05.183
   Jin X, 2017, MOL MED REP, V15, P890, DOI 10.3892/mmr.2016.6062
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kim KJ, 2012, FITOTERAPIA, V83, P1628, DOI 10.1016/j.fitote.2012.09.014
   Kim YW, 2014, INT J MOL SCI, V15, P18840, DOI 10.3390/ijms151018840
   Kiyomiya H, 2015, BIOCHEM BIOPH RES CO, V460, P320, DOI 10.1016/j.bbrc.2015.03.033
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Liu XQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00627
   Liu YJ, 2020, FOOD FUNCT, V11, P10700, DOI [10.1039/d0fo01488e, 10.1039/D0FO01488E]
   Liyanage NM, 2022, INT J BIOL MACROMOL, V223, P500, DOI 10.1016/j.ijbiomac.2022.11.047
   Lu SH, 2019, MAR DRUGS, V17, DOI 10.3390/md17060345
   Lyritis GP, 2010, ANN NY ACAD SCI, V1205, P277, DOI 10.1111/j.1749 6632.2010.05666.x
   Mann SN, 2020, EXP GERONTOL, V142, DOI 10.1016/j.exger.2020.111113
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pereira J, 2014, TISSUE ENG PT A, V20, P275, DOI [10.1089/ten.tea.2013.0028, 10.1089/ten.TEA.2013.0028]
   Saito E, 2017, CYTOTECHNOLOGY, V69, P443, DOI 10.1007/s10616 016 0013 z
   Savage PE, 2012, SCIENCE, V338, P1039, DOI 10.1126/science.1224310
   Schlesinger PH, 2020, AM J PHYSIOL CELL PH, V318, pC111, DOI 10.1152/ajpcell.00120.2019
   Shim NY, 2022, ORAL DIS, V28, P1628, DOI 10.1111/odi.13829
   Silva MMCL, 2022, INT J BIOL MACROMOL, V216, P757, DOI 10.1016/j.ijbiomac.2022.07.110
   Tang Y, 2021, CLIMACTERIC, V24, P253, DOI 10.1080/13697137.2020.1828853
   Thuy TTT, 2015, CARBOHYD POLYM, V115, P122, DOI 10.1016/j.carbpol.2014.08.068
   Wang JR, 2020, EXP GERONTOL, V140, DOI 10.1016/j.exger.2020.111057
   Wang QQ, 2019, J CELL MOL MED, V23, P380, DOI 10.1111/jcmm.13942
   Wei HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108252
   Xia XL, 2020, CYTOKINE GROWTH F R, V55, P48, DOI 10.1016/j.cytogfr.2020.03.003
   Xiao F, 2015, EXP CELL RES, V330, P91, DOI 10.1016/j.yexcr.2014.07.005
   Yu J, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.636930
   Zhang R, 2020, CARBOHYD POLYM, V228, DOI 10.1016/j.carbpol.2019.115381
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao R, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118044
   Zhi X, 2020, J CELL MOL MED, V24, P785, DOI 10.1111/jcmm.14790
   Zhu KF, 2024, CARDIOVASC DRUG THER, V38, P69, DOI 10.1007/s10557 022 07383 3
NR 50
TC 1
Z9 1
U1 4
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399 3642
J9 COMMUN BIOL
JI Commun. Biol.
PD NOV 8
PY 2024
VL 7
IS 1
AR 1471
DI 10.1038/s42003 024 07097 2
PG 13
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Science & Technology   Other
   Topics
GA L7F0U
UT WOS:001352326900002
PM 39516319
OA gold
DA 2025 08 17
ER

PT J
AU Yamamoto, K
   Kishida, T
   Nakai, K
   Sato, Y
   Kotani, S
   Nishizawa, Y
   Yamamoto, T
   Kanamura, N
   Mazda, O
AF Yamamoto, Kenta
   Kishida, Tsunao
   Nakai, Kei
   Sato, Yoshiki
   Kotani, Shin ichiro
   Nishizawa, Yuta
   Yamamoto, Toshiro
   Kanamura, Narisato
   Mazda, Osam
TI Direct phenotypic conversion of human fibroblasts into functional
   osteoblasts triggered by a blockade of the transforming growth factor β
   signal
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PLURIPOTENT STEM CELLS; PROMOTES OSTEOGENIC DIFFERENTIATION; TGF BETA;
   MOUSE FIBROBLASTS; SOMATIC CELLS; GENERATION; INDUCTION; OCT4; GENE;
   CARDIOMYOCYTES
AB A procedure to generate functional osteoblasts from human somatic cells may pave the way to a novel and effective transplantation therapy in bone disorders. Here, we report that human fibroblasts were induced to show osteoblast phenotypes by culturing with ALK5 i II, which is a specific inhibitor for activin like kinase 5 (ALK5) (tumor growth factor beta receptor 1 (TGF beta R1)). Cells cultured with ALK5 i II expressed osteoblast specific genes and massively produced calcified bone matrix, similar to the osteoblasts induced from mesenchymal stem cells (MSC OBs). Treatment with vitamin D3 in addition to ALK5 i II induced more osteoblast like characters, and the efficiency of the conversion reached approximately 90%. The chemical compound mediated directly converted osteoblasts (cOBs) were similar to human primary osteoblasts in terms of expression profiles of osteoblast related genes. The cOBs abundantly produced bone matrix in vivo and facilitated bone healing after they were transplanted into immunodeficient mice at an artificially induced defect lesion in femoral bone. The present procedure realizes a highly efficient direct conversion of human fibroblasts into transgene free and highly functional osteoblasts, which might be applied in a novel strategy of bone regeneration therapy in bone diseases.
C1 [Yamamoto, Kenta; Kishida, Tsunao; Nakai, Kei; Kotani, Shin ichiro; Nishizawa, Yuta; Mazda, Osam] Kyoto Prefectural Univ Med, Dept Immunol, Kamigyo Ku, Kyoto 6028566, Japan.
   [Yamamoto, Kenta; Nakai, Kei; Sato, Yoshiki; Yamamoto, Toshiro; Kanamura, Narisato] Kyoto Prefectural Univ Med, Dept Dent Med, Kamigyo Ku, Kyoto 6028566, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine
RP Mazda, O (通讯作者)，Kyoto Prefectural Univ Med, Dept Immunol, Kamigyo Ku, Kyoto 6028566, Japan.
EM mazda@koto.kpu m.ac.jp
OI Mazda, Osam/0000 0001 9489 3556; Yamamoto, Kenta/0000 0003 0203 8603
FU JSPS [26861679, 26293340, 17H04316]; JST [AS262Z02511P]; Uehara Memorial
   Foundation; Mochida Memorial Foundation; JSPS Overseas Research
   Fellowships; Grants in Aid for Scientific Research [26293340, 26861679,
   17H04316] Funding Source: KAKEN
FX This work was supported by Grants in Aids from JSPS (26861679, 26293340
   and 17H04316), grants from JST (AS262Z02511P), the Uehara Memorial
   Foundation and the Mochida Memorial Foundation, and JSPS Overseas
   Research Fellowships.
CR Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Bikle DD, 2012, CURR OSTEOPOROS REP, V10, P151, DOI 10.1007/s11914 012 0098 z
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   de Gorter DJJ, 2011, J BONE MINER RES, V26, P1178, DOI 10.1002/jbmr.313
   de Peppel JV, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00137
   Fu YB, 2015, CELL RES, V25, P1013, DOI 10.1038/cr.2015.99
   Gellibert FO, 2004, J MED CHEM, V47, P4494, DOI 10.1021/jm0400247
   Hiramatsu K, 2011, J CLIN INVEST, V121, P640, DOI 10.1172/JCI44605
   Hu WX, 2015, CELL STEM CELL, V17, P204, DOI 10.1016/j.stem.2015.07.006
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012
   Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002
   Ifkovits JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089678
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Johnson NA, 2010, J GENE MED, V12, P892, DOI 10.1002/jgm.1516
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Kawahara T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125590
   Kim J, 2011, P NATL ACAD SCI USA, V108, P7838, DOI 10.1073/pnas.1103113108
   Kishida T, 2015, STEM CELL REP, V5, P569, DOI 10.1016/j.stemcr.2015.08.007
   Li WL, 2009, STEM CELLS, V27, P2992, DOI 10.1002/stem.240
   Li X, 2015, CELL STEM CELL, V17, P195, DOI 10.1016/j.stem.2015.06.003
   Lin TX, 2009, NAT METHODS, V6, P805, DOI [10.1038/NMETH.1393, 10.1038/nmeth.1393]
   Lyssiotis CA, 2009, P NATL ACAD SCI USA, V106, P8912, DOI 10.1073/pnas.0903860106
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Mohamed TMA, 2017, CIRCULATION, V135, P978, DOI 10.1161/CIRCULATIONAHA.116.024692
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Nizzardo M, 2013, CELL TRANSPLANT, V22, P921, DOI 10.3727/096368912X657477
   Qiao LJ, 2011, MOL CELLS, V32, P437, DOI 10.1007/s10059 011 0107 6
   Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048
   Shui CX, 2002, J CELL PHYSIOL, V193, P164, DOI 10.1002/jcp.10157
   Sowa Y, 2017, STEM CELL TRANSL MED, V6, P1207, DOI 10.1002/sctm.16 0122
   Suzuki E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112566
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Takeyama K, 2016, BONE, V86, P68, DOI 10.1016/j.bone.2016.03.001
   Tan FZ, 2015, J BIOL CHEM, V290, P4500, DOI 10.1074/jbc.M114.609016
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Trokovic R, 2013, STEM CELLS DEV, V22, P114, DOI 10.1089/scd.2012.0157
   Wakao J, 2017, BIOCHEM BIOPH RES CO, V488, P368, DOI 10.1016/j.bbrc.2017.05.059
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xue P, 2013, BIOCHEM BIOPH RES CO, V433, P226, DOI 10.1016/j.bbrc.2013.02.088
   Yamamoto K, 2011, ORAL DIS, V17, P712, DOI 10.1111/j.1601 0825.2011.01832.x
   Yamamoto K, 2016, J CELL BIOCHEM, V117, P2538, DOI 10.1002/jcb.25546
   Yamamoto K, 2015, P NATL ACAD SCI USA, V112, P6152, DOI 10.1073/pnas.1420713112
   Yu JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017557
   Yuan X, 2011, STEM CELLS, V29, P549, DOI 10.1002/stem.594
   Zhao Y, 2015, CELL, V163, P1678, DOI 10.1016/j.cell.2015.11.017
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015
NR 47
TC 30
Z9 30
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 31
PY 2018
VL 8
AR 8463
DI 10.1038/s41598 018 26745 2
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GH6IM
UT WOS:000433547600024
PM 29855543
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Narayanan, NK
   Duan, B
   Butcher, JT
   Mazumder, A
   Narayanan, BA
AF Narayanan, Narayanan K.
   Duan, Bin
   Butcher, Jonathan T.
   Mazumder, Amitabha
   Narayanan, Bhagavathi A.
TI Characterization of Multiple Myeloma Clonal Cell Expansion and Stromal
   Wnt/β catenin Signaling in Hyaluronic Acid based 3D Hydrogel
SO IN VIVO
LA English
DT Article
DE Multiple myeloma (MM); Wnt; beta catenin; colony forming units (CFU);
   three dimensional (3D); methacrylated hyaluronic acid (Me HA);
   methacrylated gelatin (Me Gel)
ID BONE MARROW; GROWTH; DIFFERENTIATION; SECRETION; SCAFFOLDS; STIFFNESS;
   ADHESION; CULTURE; BIOLOGY; DESIGN
AB Background: Emerging interest on three dimensional (3D) cell culture models to replace two dimensional cultures of cancer cells and their xenografts in immunocompromised animal hosts prompted us to investigate the use of new biodegradable gels to recapitulate the physiological conditions of the microenvironment of multiple myeloma (MM) cells. Materials and Methods: In the present study, for the first time, we used a new 3D model of hyaluronic acid (HA) based hydrogels with difference in their matrix composition and stiffness. Results: We demonstrated that hyaluronic acid (HA) based hydrogels perfectly accommodate MM cells; confirmed by cell survival, migration, colony forming units and expression of cell adhesion proteins of the Wnt signaling pathways over a period of time. Conclusion: This study provides the first 3D microenvironment data that HA based hydro gels could provide with a suitable 3D substratum for MM cells to comprehensively analyze phenotypic changes and the influence of bone marrow stromal stem cells on Wnt/beta catenin signaling in response to targeted drug treatments.
C1 [Narayanan, Narayanan K.; Narayanan, Bhagavathi A.] NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA.
   [Duan, Bin; Butcher, Jonathan T.] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA.
   [Mazumder, Amitabha] NYU, Sch Med, Dept Med, New York, NY USA.
   [Mazumder, Amitabha] NYU, Sch Med, NYU Canc Inst, New York, NY USA.
C3 New York University; Cornell University; New York University; New York
   University
RP Narayanan, BA (通讯作者)，NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA.
EM Bhagavathi.narayanan@nyumc.org
RI Duan, Bin/A 1600 2013; Butcher, Jonathan/D 2280 2012
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asosingh K, 2000, Hematol J, V1, P351, DOI 10.1038/sj.thj.6200052
   Bataille R, 1997, HEMATOL ONCOL CLIN N, V11, P349, DOI 10.1016/S0889 8588(05)70435 4
   Bataille R, 1997, SEMIN HEMATOL, V34, P23
   Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307
   Butcher JT, 2012, JOVE J VIS EXP, DOI 10.3791/3674
   CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142 9612(03)00340 5
   Duan B, 2013, ACTA BIOMATER, V9, P7640, DOI 10.1016/j.actbio.2013.04.050
   Duan B, 2013, J BIOMED MATER RES A, V101, P1255, DOI 10.1002/jbm.a.34420
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   Haycock JW, 2011, METHODS MOL BIOL, V695, P1, DOI 10.1007/978 1 60761 984 0_1
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Jabbari E, 2011, CURR OPIN BIOTECH, V22, P655, DOI 10.1016/j.copbio.2011.01.003
   Jelinek DF, 2008, BLOOD, V112, P2600, DOI 10.1182/blood 2008 06 164178
   Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood 2008 02 142430
   Kloxin AM, 2010, NAT PROTOC, V5, P1867, DOI 10.1038/nprot.2010.139
   Kloxin AM, 2010, ADV MATER, V22, P61, DOI 10.1002/adma.200900917
   Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x
   Narayanan BA, 2006, MOL CANCER THER, V5, P1117, DOI 10.1158/1535 7163.MCT 05 0520
   Narayanan BA, 2012, ANTICANCER RES, V32, P4697
   Niemeyer P, 2004, MMW Fortschr Med, V146, P107
   Nyga A, 2011, J CELL COMMUN SIGNAL, V5, P239, DOI 10.1007/s12079 011 0132 4
   Santos E, 2012, TRENDS BIOTECHNOL, V30, P331, DOI 10.1016/j.tibtech.2012.03.005
   UCHIYAMA H, 1993, BLOOD, V82, P3712
   Vincent T, 2005, LEUKEMIA LYMPHOMA, V46, P803, DOI 10.1080/10428190500051448
   Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913
   Yang XBB, 2004, TISSUE ENG, V10, P1148, DOI 10.1089/ten.2004.10.1148
   Zaman MH, 2006, P NATL ACAD SCI USA, V103, P10889, DOI 10.1073/pnas.0604460103
NR 29
TC 16
Z9 17
U1 0
U2 11
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258 851X
EI 1791 7549
J9 IN VIVO
JI In Vivo
PD JAN FEB
PY 2014
VL 28
IS 1
BP 67
EP 73
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 290NL
UT WOS:000329765500009
PM 24425838
DA 2025 08 17
ER

PT J
AU Shashkova, EV
   Trivedi, J
   Cline Smith, AB
   Ferris, C
   Buchwald, ZS
   Gibbs, J
   Novack, D
   Aurora, R
AF Shashkova, Elena V.
   Trivedi, Jahnavi
   Cline Smith, Anna B.
   Ferris, Chloe
   Buchwald, Zachary S.
   Gibbs, Jesse
   Novack, Deborah
   Aurora, Rajeev
TI Osteoclast Primed Foxp3<SUP>+</SUP> CD8 T Cells Induce T bet,
   Eomesodermin, and IFN γ To Regulate Bone Resorption
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INTERFERON GAMMA; RHEUMATOID ARTHRITIS; EFFECTOR FUNCTION; CROSS TALK;
   NOTCH; ACTIVATION; EXPRESSION; INTEGRINS; DIFFERENTIATION; PROLIFERATION
AB Osteoimmunology arose from the recognition that cytokines produced by lymphocytes can affect bone homeostasis. We have previously shown that osteoclasts, cells that resorb bone, act as APCs. Cross presentation of Ags by osteoclasts leads to expression of CD25 and Foxp3, markers of regulatory T cells in the CD8 T cells. Octeoclast induced Foxp3(+) CD25(+) regulatory CD8 T cells (OC iTc(REG)) suppress priming of CD4 and CD8 T cells by dendritic cells. OC iTc(REG) also limit bone resorption by osteoclasts, forming a negative feedback loop. In this study, we show that OC iTc(REG) express concurrently T bet and Eomesodermin (Eomes) and IFN gamma. Pharmacological inhibition of I kappa K blocked IFN gamma, T bet, and Eomes production by Tc REG. Furthermore, we show, using chromatin immunoprecipitation, NF kappa B enrichment in the T bet and Eomes promoters. We demonstrate that IFN gamma produced by Tc REG is required for suppression of osteoclastogenesis and for degradation of TNFR associated factor 6 in osteoclast precursors. The latter prevents signaling by receptor activator of NF kappa B ligand needed for osteoclastogenesis. Knockout of IFN gamma rendered Tc REG inefficient in preventing actin ring formation in osteoclasts, a process required for bone resorption. Tc REG generated in vivo using IFN gamma( / ) T cells had impaired ability to protect mice from bone resorption and bone loss in response to high dose receptor activator of NF kappa B ligand. The results of this study demonstrate a novel link between NF kappa B signaling and induction of IFN gamma in Tc REG and establish an important role for IFN gamma in Tc REG mediated protection from bone loss.
C1 [Shashkova, Elena V.; Trivedi, Jahnavi; Cline Smith, Anna B.; Ferris, Chloe; Buchwald, Zachary S.; Aurora, Rajeev] St Louis Univ, Dept Mol Microbiol & Immunol, Sch Med, 1100 South Grand Blvd,DRC605, St Louis, MO 63104 USA.
   [Gibbs, Jesse; Novack, Deborah] Washington Univ, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
   [Buchwald, Zachary S.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA USA.
C3 Saint Louis University; Washington University (WUSTL); Emory University
RP Aurora, R (通讯作者)，St Louis Univ, Dept Mol Microbiol & Immunol, Sch Med, 1100 South Grand Blvd,DRC605, St Louis, MO 63104 USA.
EM aurorar@slu.edu
RI ; Aurora, Rajeev/A 4588 2008
OI Shashkova, Elena/0009 0002 1093 5283; Novack,
   Deborah/0000 0001 7101 5582
FU NIAMS NIH HHS [R01 AR068438, R01 AR064821, P30 AR057235] Funding Source:
   Medline
CR Balto K, 2001, INFECT IMMUN, V69, P744, DOI 10.1128/IAI.69.2.744 750.2001
   Brimnes J, 2005, J IMMUNOL, V174, P5814, DOI 10.4049/jimmunol.174.9.5814
   Buchwald ZS, 2015, J BONE MINER RES, V30, P1508, DOI 10.1002/jbmr.2472
   Buchwald ZS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/429373
   Buchwald ZS, 2013, BONE, V56, P163, DOI 10.1016/j.bone.2013.05.024
   Buchwald ZS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038199
   Chang SJ, 2008, J IMMUNOL, V181, P8372, DOI 10.4049/jimmunol.181.12.8372
   Cho OH, 2009, J IMMUNOL, V182, P3380, DOI 10.4049/jimmunol.0802598
   Correale J, 2010, ANN NEUROL, V67, P625, DOI 10.1002/ana.21944
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Eisenstein EM, 2009, PEDIATR RES, V65, p26R, DOI 10.1203/PDR.0b013e31819e76c7
   Eriksson U, 2001, J IMMUNOL, V167, P5464, DOI 10.4049/jimmunol.167.9.5464
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Flaishon L, 2002, J IMMUNOL, V168, P3707, DOI 10.4049/jimmunol.168.8.3707
   Fox SW, 2000, BIOCHEM BIOPH RES CO, V276, P868, DOI 10.1006/bbrc.2000.3577
   Fukuoka N, 2016, GENES CELLS, V21, P146, DOI 10.1111/gtc.12328
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543
   Gogoi D, 2014, J IMMUNOL, V192, P2054, DOI 10.4049/jimmunol.1300369
   Gong W, 2008, INT J CANCER, V123, P702, DOI 10.1002/ijc.23553
   Greenblatt Matthew B, 2013, Immune Netw, V13, P111, DOI 10.4110/in.2013.13.4.111
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Hatton RD, 2006, IMMUNITY, V25, P717, DOI 10.1016/j.immuni.2006.09.007
   Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Kelchtermans H, 2008, TRENDS IMMUNOL, V29, P479, DOI 10.1016/j.it.2008.07.002
   Kiesel J, 2007, DEV DYNAM, V236, P2181, DOI 10.1002/dvdy.21206
   Kiesel JR, 2009, J IMMUNOL, V182, P5477, DOI 10.4049/jimmunol.0803897
   Kiniwa Y, 2007, CLIN CANCER RES, V13, P6947, DOI 10.1158/1078 0432.CCR 07 0842
   Kohara H, 2011, IMMUNOL LETT, V137, P53, DOI 10.1016/j.imlet.2011.02.017
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 2005, EUR J IMMUNOL, V35, P3353, DOI 10.1002/eji.200526141
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lee JK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0084256, 10.1371/journal.pone.0066555]
   Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miller NM, 2015, FRONT NEUROSCI SWITZ, V9, DOI 10.3389/fnins.2015.00287
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
   Nazarian A, 2008, BONE, V43, P302, DOI 10.1016/j.bone.2008.04.009
   Niederkorn JY, 2008, CURR OPIN IMMUNOL, V20, P327, DOI 10.1016/j.coi.2008.02.003
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700
   Pacifici R, 2012, J BONE MINER RES, V27, P231, DOI 10.1002/jbmr.1500
   Palaga T, 2003, J IMMUNOL, V171, P3019, DOI 10.4049/jimmunol.171.6.3019
   Pappalardo A, 2013, CLIN EXP IMMUNOL, V174, P281, DOI 10.1111/cei.12165
   Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148
   Popescu I, 2014, J IMMUNOL, V193, P5709, DOI 10.4049/jimmunol.1401436
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830
   Russo E, 2013, J ENDOCRINOL INVEST, V36, P375, DOI 10.3275/8649
   Rutz S, 2008, P NATL ACAD SCI USA, V105, P3497, DOI 10.1073/pnas.0712102105
   Salzano M, 2012, J ENDOCRINOL, V215, P439, DOI 10.1530/JOE 12 0335
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schett G, 2009, J BONE MINER RES, V24, P1142, DOI 10.1359/jbmr.090533
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026 008 8025 1
   Soysa Niroshani Surangika, 2009, Journal of Medical and Dental Sciences, V56, P107
   Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tenaud I, 2002, INT J DERMATOL, V41, P836, DOI 10.1046/j.1365 4362.2002.01598.x
   Yang Y, 2008, J IMMUNOL, V181, P8700, DOI 10.4049/jimmunol.181.12.8700
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zhang Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/284836
   Zhao HB, 2005, J BONE MINER RES, V20, P2116, DOI 10.1359/JBMR.050724
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
NR 69
TC 28
Z9 32
U1 1
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 1
PY 2016
VL 197
IS 3
BP 726
EP 735
DI 10.4049/jimmunol.1600253
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA DS1EM
UT WOS:000380338600007
PM 27324129
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Alzahrani, M
   Stober, C
   Liu, M
   Awan, A
   Ng, TL
   Pond, G
   Alshamsan, B
   Vandermeer, L
   Clemons, M
AF Alzahrani, Mashari
   Stober, Carol
   Liu, Michelle
   Awan, Arif
   Ng, Terry L.
   Pond, Gregory
   Alshamsan, Bader
   Vandermeer, Lisa
   Clemons, Mark
TI Symptomatic skeletal related events in patients receiving longer term
   bone modifying agents for bone metastases from breast and castration
   resistant prostate cancers
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Breast cancer; Prostate cancer; Bone metastases; Skeletal related events
ID ESCALATED BISPHOSPHONATE THERAPY; ZOLEDRONIC ACID; DOUBLE BLIND;
   MULTIPLE MYELOMA; TARGETED THERAPY; PHASE II; LOW RISK; EFFICACY;
   COMPLICATIONS; TRIAL
AB Background The effect of longer term use of bone modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with bone metastases remains unclear. This retrospective study of a cohort of patients in a randomized controlled trial evaluated SSEs in patients receiving BMAs at a single cancer center. Methods Data from patients with metastatic breast and castration resistant prostate cancer (CRPC) were interrogated to evaluate the effects of longer term use of BMAs on incidence, type, and risk factors for SSEs. Results Of 162 patients, 109 (67%) had breast cancer (BC) and 53 (33%) CRPC. Median age at diagnosis of bone metastases was 61.9 years (range 27.5 97.2) for BC patients and 72.1 (range 37.0 92.2) for CRPC patients. Median duration of BMA use was 2.3 years (range 0.1 9.9 years) for BC and 3.8 years (range 1.5 9.4) for CRPC patients. The initial BMAs in BC patients were pamidronate (46.8%), denosumab (31.2%), and zoledronate (22%). All CRPC patients received denosumab. During follow up, 59% of BC and 75% of CRPC patients had at least one SSE. The number of patients experiencing >= 1 SSE per year was higher in the first year after bone metastasis diagnosis (63/162; 38.9%) compared with that in the second (26/149; 17.5%) and third years (30/123; 24.4%). Neither age, visceral disease, multiple bone metastases, nor biological markers for BC had a significant impact on time to first SSE. Conclusions The risk for SSEs was greatest in the first year after diagnosis of bone metastasis. Studies evaluating de escalation and even stopping of BMAs with longer term use may therefore be warranted.
C1 [Alzahrani, Mashari; Awan, Arif; Ng, Terry L.; Alshamsan, Bader; Clemons, Mark] Univ Ottawa, Ottawa Hosp, Dept Med, Div Med Oncol, 501 Smyth Rd, Ottawa, ON, Canada.
   [Stober, Carol; Liu, Michelle; Vandermeer, Lisa; Clemons, Mark] Ottawa Hosp, Canc Therapeut Program, Res Inst, Ottawa, ON, Canada.
   [Pond, Gregory] McMaster Univ, Dept Oncol, Hamilton, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; Ottawa Hospital Research Institute; McMaster University
RP Clemons, M (通讯作者)，Univ Ottawa, Ottawa Hosp, Dept Med, Div Med Oncol, 501 Smyth Rd, Ottawa, ON, Canada.; Clemons, M (通讯作者)，Ottawa Hosp, Canc Therapeut Program, Res Inst, Ottawa, ON, Canada.
EM mclemons@toh.ca
RI ; Alshamsan, Bader/AAH 6208 2019; Ng, Terry/AEX 1224 2022; Pond,
   Gregory/JOZ 2926 2023
OI Pond, Gregory/0000 0003 1033 0882; Alshamsan, Bader/0000 0003 2462 0581;
   Clemons, Mark/0000 0002 0738 2713; 
FU Rethinking Clinical Trials (REaCT) Program platform at the Ottawa
   Hospital; Ottawa Hospital Foundation
FX The research did not receive any specific grant from funding agencies in
   the public, commercial, or not for profit sectors. This work was
   supported by the Rethinking Clinical Trials (REaCT) Program platform at
   the Ottawa Hospital which is supported by The Ottawa Hospital Foundation
   and its generous donors.
CR Addison CL, 2016, J BONE ONCOL, V5, P173, DOI 10.1016/j.jbo.2016.06.003
   Addison CL, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193 1801 3 577
   Addison CL, 2014, BREAST CANCER RES TR, V144, P615, DOI 10.1007/s10549 014 2906 x
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Amir E, 2013, AM J CLIN ONCOL CANC, V36, P436, DOI 10.1097/COC.0b013e3182568f7a
   Awan AA, 2019, BREAST CANCER RES TR, V176, P507, DOI 10.1007/s10549 019 05265 1
   Bongiovanni A, 2019, SUPPORT CARE CANCER, V27, P3395, DOI 10.1007/s00520 019 4635 5
   Brufsky AM, 2013, BREAST J, V19, P504, DOI 10.1111/tbj.12152
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Clemons M, 2012, CURR ONCOL, V19, P259, DOI 10.3747/co.19.1011
   Clemons M, 2021, J BONE ONCOL, V30, DOI 10.1016/j.jbo.2021.100388
   Clemons M, 2021, EUR J CANCER, V142, P132, DOI 10.1016/j.ejca.2020.08.019
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549 008 0086 2
   Fernandes R, 2016, J BONE ONCOL, V5, P57, DOI 10.1016/j.jbo.2016.02.004
   Gradishar WJ, 2020, J NATL COMPR CANC NE, V18, P452, DOI 10.6004/jnccn.2020.0016
   Guarneri V, 2005, ONCOLOGIST, V10, P842, DOI 10.1634/theoncologist.10 10 842
   Hatoum HT, 2011, CLIN BREAST CANCER, V11, P177, DOI 10.1016/j.clbc.2011.03.015
   Henk H, 2012, CURR MED RES OPIN, V28, P1119, DOI 10.1185/03007995.2012.689254
   Hernandez RK, 2018, BMC CANCER, V18, DOI 10.1186/s12885 017 3922 0
   Holen I, 2010, CURR PHARM DESIGN, V16, P1262, DOI 10.2174/138161210791034003
   Hong BY, 2016, CURR ONCOL, V23, pE77, DOI 10.3747/co.23.2913
   Hussain A, 2016, CANCER MED US, V5, P3300, DOI 10.1002/cam4.914
   Hutton B, 2015, JAMA INTERN MED, V175, P1864, DOI 10.1001/jamainternmed.2015.4789
   Ibrahim MFK, 2015, ANN ONCOL, V26, P2205, DOI 10.1093/annonc/mdv284
   Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765
   Jacobs C, 2014, EXPERT OPIN PHARMACO, V15, P1109, DOI 10.1517/14656566.2014.903925
   James ND, 2015, EUR UROL, V67, P1028, DOI 10.1016/j.eururo.2014.09.032
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Kuchuk I, 2013, J BONE ONCOL, V2, P154, DOI 10.1016/j.jbo.2013.07.004
   Liauw W, 2005, BMC CANCER, V5, DOI 10.1186/1471 2407 5 89
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Major PP, 2002, AM J CLIN ONCOL CANC, V25, pS10, DOI 10.1097/00000421 200212001 00003
   Miyashita H, 2020, BREAST CANCER RES TR, V182, P381, DOI 10.1007/s10549 020 05712 4
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Tan CJ, 2020, SUPPORT CARE CANCER, V28, P5901, DOI 10.1007/s00520 020 05430 z
   Templeton A., 2014, Eur Soc Med Oncol, V25, P540, DOI 10.1093/annonc/mdu356.71
   van der Pol CB, 2014, BREAST CANCER RES TR, V146, P583, DOI 10.1007/s10549 014 3046 z
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Zhu XF, 2014, J BONE ONCOL, V3, P1, DOI [10.1016/j.jho.2014.01.001, 10.1016/j.jbo.2014.01.001]
NR 47
TC 11
Z9 12
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941 4355
EI 1433 7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY
PY 2022
VL 30
IS 5
BP 3977
EP 3984
DI 10.1007/s00520 021 06714 8
EA JAN 2022
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA ZY3CD
UT WOS:000744869400002
PM 35059864
DA 2025 08 17
ER

PT J
AU Qiao, XJ
   Wu, XJ
   Zhao, Y
   Yang, Y
   Zhang, L
   Cai, XJ
   Ma, JA
   Ji, JD
   Lyons, K
   Boström, KI
   Yao, YC
AF Qiao, Xiaojing
   Wu, Xiuju
   Zhao, Yan
   Yang, Yang
   Zhang, Li
   Cai, Xinjiang
   Ma, Jocelyn A. A.
   Ji, Jaden
   Lyons, Karen
   Bostrom, Kristina I. I.
   Yao, Yucheng
TI Cell Transitions Contribute to Glucocorticoid Induced Bone Loss
SO CELLS
LA English
DT Article
DE glucocorticoid; bone loss; osteoblast; transition; endothelial like
   cells
ID TRANSCRIPTION FACTOR OSTERIX; OSTEOBLAST DIFFERENTIATION; NEGATIVE
   REGULATOR; COLLAGEN PROMOTER; CRE RECOMBINASE; TRANSGENIC MICE;
   OSTEOGENESIS; EXPRESSION; FOXC2; TRANSDIFFERENTIATION
AB Glucocorticoid induced bone loss is a toxic effect of long term therapy with glucocorticoids resulting in a significant increase in the risk of fracture. Here, we find that glucocorticoids reciprocally convert osteoblast lineage cells into endothelial like cells. This is confirmed by lineage tracing showing the induction of endothelial markers in osteoblast lineage cells following glucocorticoid treatment. Functional studies show that osteoblast lineage cells isolated from glucocorticoid treated mice lose their capacity for bone formation but simultaneously improve vascular repair. We find that the glucocorticoid receptor directly targets Foxc2 and Osterix, and the modulations of Foxc2 and Osterix drive the transition of osteoblast lineage cells to endothelial like cells. Together, the results suggest that glucocorticoids suppress osteogenic capacity and cause bone loss at least in part through previously unrecognized osteoblast endothelial transitions.
C1 [Qiao, Xiaojing; Wu, Xiuju; Zhao, Yan; Yang, Yang; Zhang, Li; Cai, Xinjiang; Ma, Jocelyn A. A.; Ji, Jaden; Bostrom, Kristina I. I.; Yao, Yucheng] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA.
   [Lyons, Karen] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.
   [Bostrom, Kristina I. I.] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles
RP Boström, KI; Yao, YC (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA.; Boström, KI (通讯作者)，Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA.
EM xqiao@mednet.ucla.edu; xiujuwu@mednet.ucla.edu; yanzhao@mednet.ucla.edu;
   yanyang@mednet.ucla.edu; liz@mednet.ucla.edu;
   xinjiangcai@mednet.ucla.edu; jocelynma@g.ucla.edu; jj152111@g.ucla.edu;
   klyons@mednet.ucla.edu; kbostrom@mednet.ucla.edu; yyao@mednet.ucla.edu
RI Cai, Xinjiang/F 4843 2010; yang, yang/JNE 9457 2023; Yao,
   Yu Cheng/AAT 4812 2020
OI Ma, Jocelyn/0000 0002 3259 2333; , Xiuju/0000 0002 7499 0137; Cai,
   Xinjiang/0000 0001 8933 7133; Zhang, Li/0000 0003 2638 2919; 
FU NIH [NS79353, HL139675, HL162643, HL81397, HL158053]; National Heart
   Lung and Blood Institute [R01HL158053, R01HL081397, R01HL162643,
   R01HL139675] Funding Source: NIH RePORTER; National Institute of
   Neurological Disorders and Stroke [R01NS079353] Funding Source: NIH
   RePORTER
FX This work was supported in part by NIH grants NS79353 (Y.Y.), HL139675
   (Y.Y.), HL162643 (Y.Y.), HL81397 (K.I.B.), and HL158053 (K.I.B.).
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018 013 1440 z
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Compston J, 2010, RADIOL CLIN N AM, V48, P477, DOI 10.1016/j.rcl.2010.02.010
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   De Val S, 2009, DEV CELL, V16, P180, DOI 10.1016/j.devcel.2009.01.014
   Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887
   Foo C, 2007, GYNECOL ENDOCRINOL, V23, P535, DOI 10.1080/09513590701556483
   Gao B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099137
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200
   Itkin T, 2016, NATURE, V532, P323, DOI 10.1038/nature17624
   Kassem M, 2008, ARCH BIOCHEM BIOPHYS, V473, P183, DOI 10.1016/j.abb.2008.03.028
   Kim JE, 2004, AM J PATHOL, V165, P1875, DOI 10.1016/S0002 9440(10)63240 3
   Kim JH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050770
   Kim SW, 2005, BIOCHEM BIOPH RES CO, V327, P811, DOI 10.1016/j.bbrc.2004.12.076
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Krumbholz G, 2017, CLIN EXP RHEUMATOL, V35, P406
   Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301
   Kume T, 2009, ADV EXP MED BIOL, V665, P63
   Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lapunzina P, 2010, AM J HUM GENET, V87, P110, DOI 10.1016/j.ajhg.2010.05.016
   Li XH, 2005, ACTA PHARMACOL SIN, V26, P1081, DOI 10.1111/j.1745 7254.2005.00161.x
   Matsushita Y, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115359
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Owen M, 1970, Int Rev Cytol, V28, P213, DOI 10.1016/S0074 7696(08)62544 9
   Paul S, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.81
   Ramasamy SK, 2016, ANNU REV CELL DEV BI, V32, P649, DOI 10.1146/annurev cellbio 111315 124936
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Rasheed N, 2006, HUM MOL GENET, V15, P1938, DOI 10.1093/hmg/ddl116
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421
   Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027
   SASAKI H, 1993, DEVELOPMENT, V118, P47
   Sawa N, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50236 7
   Seo S, 2006, DEV BIOL, V294, P458, DOI 10.1016/j.ydbio.2006.03.035
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Sinha KM, 2010, EMBO J, V29, P68, DOI 10.1038/emboj.2009.332
   Sivaraj KK, 2016, DEVELOPMENT, V143, P2706, DOI 10.1242/dev.136861
   Tu Q, 2007, TISSUE ENG, V13, P2431, DOI 10.1089/ten.2006.0406
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Yang L, 2009, J ORTHOP RES, V27, P169, DOI 10.1002/jor.20733
   Yao JY, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.143023
   Yao JY, 2015, CIRC RES, V117, P758, DOI 10.1161/CIRCRESAHA.115.306751
   Yao YC, 2013, CIRC RES, V113, P495, DOI 10.1161/CIRCRESAHA.113.301792
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 49
TC 1
Z9 1
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JUL
PY 2023
VL 12
IS 14
AR 1810
DI 10.3390/cells12141810
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA N2EO2
UT WOS:001035208500001
PM 37508475
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Verron, E
   Gauthier, O
   Janvier, P
   Pilet, P
   Lesoeur, J
   Bujoli, B
   Guicheux, J
   Bouler, JM
AF Verron, Elise
   Gauthier, Olivier
   Janvier, Pascal
   Pilet, Paul
   Lesoeur, Julie
   Bujoli, Bruno
   Guicheux, Jerome
   Bouler, Jean Michel
TI In vivo bone augmentation in an osteoporotic environment using
   bisphosphonate loaded calcium deficient apatite
SO BIOMATERIALS
LA English
DT Article
DE Calcium phosphates; Drug delivery; Osteoporosis; Animal model; Bone
   regeneration
ID PROXIMAL FEMUR; MEVALONATE PATHWAY; MINERAL DENSITY; HIP FRACTURES;
   PREVENTION; PHOSPHATE; WOMEN; PERSISTENCE; ALENDRONATE; THERAPY
AB Resorbable calcium phosphate (CaP) biomaterials have demonstrated considerable efficacy in bone reconstructive surgery. Furthermore, bisphosphonates (BPs) are well known anti resorptive agents largely used in clinical treatments for osteoporosis. An injectable BP combined CaP matrix has been developed in order to biologically reinforce osteoporotic bone by increasing the bone fraction and improving bone micro architecture. Our previous in vitro studies have shown that CaP is effective for loading and releasing BPs at doses that can inhibit excessive bone resorption without affecting osteoblasts. In vivo studies in relevant animal models are necessary to explore the effect of our injectable BP combined biomaterial on femur bone structure by performing three dimensional microtomography analysis, histological studies and SEM observations. Firstly, in rat model, our BP combined CaP matrix significantly improved the bone micro architecture as compared to CaP alone. The implantation of the BP loaded biomaterial within proximal femurs of osteoporotic ewes led to a significant increase in relative bone content and an improvement of its micro architecture. These modifications were confirmed by histological and SEM observations, which revealed CaP granule resorption and new bone trabeculae formation. This approach could be considered in the future for preventing osteoporotic fractures that are preferentially localized in the proximal femur, vertebral bodies or wrist. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Verron, Elise; Gauthier, Olivier; Pilet, Paul; Lesoeur, Julie; Guicheux, Jerome; Bouler, Jean Michel] PRES UNAM, INSERM, UMR 791, LIOAD, F 44042 Nantes 1, France.
   [Gauthier, Olivier] ONIRIS, Plateforme Chirurg Expt, F 44307 Nantes 3, France.
   [Janvier, Pascal; Bujoli, Bruno] PRES UNAM, CNRS, UMR 6230, CEISAM, F 44322 Nantes 3, France.
   [Verron, Elise] GRAFTYS SA, F 13854 Aix En Provence, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation
   Nantes Atlantique; Ecole Nationale Veterinaire, Agroalimentaire et de
   l'Alimentation Nantes Atlantique; Centre National de la Recherche
   Scientifique (CNRS); CNRS   Institute of Chemistry (INC)
RP Bouler, JM (通讯作者)，PRES UNAM, INSERM, UMR 791, LIOAD, BP 84215, F 44042 Nantes 1, France.
EM Jean michel.bouler@univ nantes.fr
RI Gauthier, Olivier/A 4639 2015; Paul, Pilet/A 3755 2015; BUJOLI,
   Bruno/E 4924 2019; BOULER, Jean Michel/C 2099 2011; Guicheux,
   Jerome/F 7767 2013; guicheux, Jerome/F 7767 2013; Verron,
   Elise/P 2645 2014
OI BUJOLI, Bruno/0000 0002 2256 0792; BOULER,
   Jean Michel/0000 0001 9784 5584; Guicheux, Jerome/0000 0003 2754 3024;
   Verron, Elise/0000 0003 4276 5127
FU ANR (MIADROS) [RNTS 05 00401]; Graftys SA (Aix en Provence, France)
FX This work was supported by the ANR (MIADROS, RNTS 05 00401) and Graftys
   SA (Aix en Provence, France).
CR Aulakh TS, 2009, BIOMATERIALS, V30, P1732, DOI 10.1016/j.biomaterials.2008.12.035
   Beckmann J, 2007, MED ENG PHYS, V29, P755, DOI 10.1016/j.medengphy.2006.08.006
   Bobyn JD, 2009, J BONE JOINT SURG AM, V91A, P23, DOI 10.2106/JBJS.I.00518
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Cavagna R, 1999, J LONG TERM EFF MED, V9, P403
   Cesareo R, 2007, Minerva Endocrinol, V32, P275
   Chavassieux P, 2001, J BONE MINER RES, V16, P89, DOI 10.1359/jbmr.2001.16.1.89
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cranney A, 2007, CAN MED ASSOC J, V177, P575, DOI 10.1503/cmaj.070234
   Dinah AF, 2002, INJURY, V33, P393, DOI 10.1016/S0020 1383(02)00015 3
   Emkey RD, 2006, AM J MED, V119, p18S, DOI 10.1016/j.amjmed.2005.12.019
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532 5415.2000.tb02641.x
   Erben RG, 2002, J BONE MINER RES, V17, P1498, DOI 10.1359/jbmr.2002.17.8.1498
   Faucheux C, 2009, J BIOMED MATER RES A, V89A, P46, DOI 10.1002/jbm.a.31989
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   FROST HM, 1992, BONE MINER, V18, P227, DOI 10.1016/0169 6009(92)90809 R
   Fulfaro F, 1998, PAIN, V78, P157, DOI 10.1016/S0304 3959(98)00135 3
   Gallagher AM, 2008, J BONE MINER RES, V23, P1569, DOI 10.1359/JBMR.080510
   Heini PF, 2004, CLIN BIOMECH, V19, P506, DOI 10.1016/j.clinbiomech.2004.01.014
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   ISHIKAWA K, 1993, J MATER SCI MATER M, V4, P165, DOI 10.1007/BF00120386
   Ito M, 2003, BONE, V33, P90, DOI 10.1016/S8756 3282(03)00170 4
   Jiang Guizhen, 2004, J Oral Sci, V46, P75, DOI 10.2334/josnusd.46.75
   JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Josse S, 2004, ADV MATER, V16, P1423, DOI 10.1002/adma.200306340
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101
   KHAIROUN I, 2009, 19 GRIBOI INT RES C
   KHAIROUN I, 2008, 8 WORLD BIOM C 2008
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   McClung M R, 2000, Expert Opin Pharmacother, V1, P225, DOI 10.1517/14656566.1.2.225
   McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005
   McHutchison JG, 2007, AM J MANAG CARE, V13, pS327
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Müller R, 1998, BONE, V23, P59, DOI 10.1016/S8756 3282(98)00068 4
   Newton BI, 2004, J COMP PATHOL, V130, P323, DOI 10.1016/j.jcpa.2003.12.007
   Obadia L, 2007, J BIOMED MATER RES B, V80B, P32, DOI 10.1002/jbm.b.30565
   Orcel P, 2005, JOINT BONE SPINE, V72, P461, DOI 10.1016/j.jbspin.2005.09.002
   Owens G, 2007, AM J MANAG CARE, V13, pS290
   Papapoulos SE, 2005, OSTEOPOROSIS INT, V16, P468, DOI 10.1007/s00198 004 1725 z
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   PECK WA, 1993, AM J MED, V94, P646
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Quigley PA, 2007, REHABIL NURS, V32, P120, DOI 10.1002/j.2048 7940.2007.tb00163.x
   Rabenda V, 2008, OSTEOPOROSIS INT, V19, P811, DOI 10.1007/s00198 007 0506 x
   Rabenda V, 2008, J BONE JOINT SURG AM, V90A, P2142, DOI 10.2106/JBJS.G.00864
   Ransom S., 1998, TEXAS J AGING, V1, P8
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roussière H, 2005, J MATER CHEM, V15, P3869, DOI 10.1039/b503680a
   Roussiere H, 2008, CHEM MATER, V20, P182, DOI 10.1021/cm702584d
   Russell RGG, 2006, BONE, V38, pS7, DOI 10.1016/j.bone.2006.01.151
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Stadelmann VA, 2008, EUR CELLS MATER, V16, P10, DOI 10.22203/eCM.v016a02
   Stadelmann VA, 2009, J BIOMECH, V42, P1206, DOI 10.1016/j.jbiomech.2009.03.024
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140 6736(07)61342 7
   TURNER AS, 1995, BONE, V17, pS395, DOI 10.1016/8756 3282(95)00317 7
   TURNER AS, 1995, BONE, V17, pS421, DOI 10.1016/8756 3282(95)00321 4
   van Balen R, 2001, CLIN ORTHOP RELAT R, P232
   van der Steenhoven TJ, 2009, CLIN BIOMECH, V24, P286, DOI 10.1016/j.clinbiomech.2008.11.009
NR 63
TC 78
Z9 84
U1 0
U2 51
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 2010
VL 31
IS 30
BP 7776
EP 7784
DI 10.1016/j.biomaterials.2010.06.047
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 645XD
UT WOS:000281498600019
PM 20643480
DA 2025 08 17
ER

PT J
AU Ding, ZD
   Li, RM
   Duan, YF
   Li, ZX
   Fang, B
   Jing, D
AF Ding, Ziduan
   Li, Ruomei
   Duan, Yufeng
   Li, Zhenxia
   Fang, Bing
   Jing, Dian
TI A 3 D Visualization Technique for Bone Remodeling in a Suture Expansion
   Mouse Model
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID CELLS; OSTEOBLASTS; STRESS
AB Craniofacial sutures play a crucial role beyond being fibrous joints connecting craniofacial bones; they also serve as the primary niche for calvarial and facial bone growth, housing mesenchymal stem cells and osteoprogenitors. As most craniofacial bones develop through intramembranous ossification, the sutures' marginal regions act as initiation points. Due to this significance, these sutures have become intriguing targets in orthopedic therapies like spring assisted cranial vault expansion, rapid maxillary expansion, and maxillary protraction. Under orthopedic tracing force, suture stem cells are rapidly activated, becoming a dynamic source for bone remodeling during expansion. Despite their importance, the physiological changes during bone remodeling periods remain poorly understood. Traditional sectioning methods, primarily in the sagittal direction, do not capture the comprehensive changes occurring throughout the entire suture. This study established a standard mouse model for sagittal suture expansion. To fully visualize bone remodeling changes post suture expansion, the PEGASOS tissue clearing method was combined with whole mount EdU staining and calcium chelating double labeling. This allowed the visualization of highly proliferating cells and new bone formation across the entire calvarial bones following expansion. This protocol offers a standardized suture expansion mouse model and a 3 D visualization method, shedding light on the mechanobiological changes in sutures and bone remodeling under tensile force loading.
C1 [Ding, Ziduan; Li, Ruomei; Duan, Yufeng; Li, Zhenxia; Fang, Bing; Jing, Dian] Shanghai Jiao Tong Univ, Sch Med, Coll Stomatol, China Shanghai Peoples Hosp 9,Dept Orthodont, Shanghai, Peoples R China.
   [Ding, Ziduan; Li, Ruomei; Duan, Yufeng; Li, Zhenxia; Fang, Bing; Jing, Dian] Shanghai Jiao Tong Univ, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis, Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Fang, B; Jing, D (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Coll Stomatol, China Shanghai Peoples Hosp 9,Dept Orthodont, Shanghai, Peoples R China.; Fang, B; Jing, D (通讯作者)，Shanghai Jiao Tong Univ, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis, Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
EM fangbing@sjtu.edu.cn; janetjingdian@hotmail.com
RI Jing, Dian/GXA 1939 2022; Li, Ruomei/AAW 6770 2021; Ding,
   Ziduan/JDW 2807 2023
FU Shanghai Pujiang Program [22PJ1409200]; National Natural Science
   Foundation of China [11932012]; Postdoctoral Scientific Research
   Foundation of Shanghai Ninth People's Hospital, Shanghai Jiao Tong
   University School of Medicine; Fundamental research program funding of
   Ninth People's Hospital affiliated to Shanghai Jiao Tong University
   School of Medicine [JYZZ154]
FX We thank for the laboratory platform and assistance of Ear Institute,
   Shanghai Jiaotong University School of Medicine. This work was supported
   by Shanghai Pujiang Program (22PJ1409200); National Natural Science
   Foundation of China (No.11932012); Postdoctoral Scientific Research
   Foundation of Shanghai Ninth People's Hospital, Shanghai Jiao Tong
   University School of Medicine;Fundamental research program funding of
   Ninth People's Hospital affiliated to Shanghai Jiao Tong University
   School of Medicine (JYZZ154).
CR Hwang S, 2020, KOREAN J ORTHOD, V50, P42, DOI 10.4041/kjod.2020.50.1.42
   Ikegame M, 2001, J BONE MINER RES, V16, P24, DOI 10.1359/jbmr.2001.16.1.24
   Jing D, 2019, J DENT RES, V98, P621, DOI 10.1177/0022034519844510
   Jing DA, 2022, J BONE MINER RES, V37, P1307, DOI 10.1002/jbmr.4561
   Jing D, 2018, CELL RES, V28, P803, DOI 10.1038/s41422 018 0049 z
   Kong LL, 2020, INT J STEM CELLS, V13, P377, DOI 10.15283/ijsc20024
   Liang W, 2021, DRUG DES DEV THER, V15, P905, DOI 10.2147/DDDT.S299641
   Liu SSY, 2009, AM J ORTHOD DENTOFAC, V136, DOI 10.1016/j.ajodo.2009.03.035
   Thenier Villa JL, 2018, J NEUROSURG PEDIATR, V22, P120, DOI 10.3171/2018.2.PEDS17717
   Luo WJ, 2019, STEM CELLS DEV, V28, P1310, DOI 10.1089/scd.2019.0104
   Mao JJ, 2003, ANGLE ORTHOD, V73, P128
   Markiewicz MR, 2022, ORAL MAXIL SURG CLIN, V34, P395, DOI 10.1016/j.coms.2022.01.005
   Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1073>3.0.CO;2 F
   Roth DM, 2022, EUR J CELL BIOL, V101, DOI 10.1016/j.ejcb.2022.151258
   Shayani A, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12112774
   Suzuki Hideo, 2016, Dental Press J. Orthod., V21, P17, DOI 10.1590/2177 6709.21.4.017 023.oin
   Xu Y, 2007, PLAST RECONSTR SURG, V119, P819, DOI 10.1097/01.prs.0000255540.91987.a0
   Yu MF, 2021, CELL, V184, P243, DOI 10.1016/j.cell.2020.11.037
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
NR 20
TC 0
Z9 0
U1 2
U2 13
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD AUG
PY 2023
IS 198
AR e65709
DI 10.3791/65709
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA X2CC3
UT WOS:001096574500012
PM 37607095
DA 2025 08 17
ER

PT J
AU Zhang, K
   Lu, SY
   Jiang, MY
   Zou, XC
   Chen, CL
   Lan, YY
   Zhao, HA
   Ma, RL
   Yan, HW
AF Zhang, Ke
   Lu, Shenyi
   Jiang, Mingyang
   Zou, Xiaochong
   Chen, Chuanliang
   Lan, Yuanyuan
   Zhao, Huaan
   Ma, Ruilan
   Yan, Haiwei
TI Development of a Risk Model and Genotyping Patterns Based on
   Disulfidptosis Related lncRNAs to Predict Prognosis and Immune Landscape
   in Osteosarcoma
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE osteosarcoma; disulfidptosis; lncRNA; prognostic model; immune landscape
ID MECHANISM; FAMILY
AB Background : Osteosarcoma (OS) is the most prevalent orthopedic malignancy with a dismal prognosis. Disulfidptosis related lncRNAs (DRLncs) may be related to the progression of OS, but their potential molecular regulatory role is still unclear. Methods : Based on the data collected from The Cancer Genome Atlas (TCGA), we conducted correlation analysis and the univariate Cox analysis to screen prognosis  related DRLncs, followed by developing genotyping patterns and corresponding classifier. Subsequently, the survival analysis, enrichment analysis, drug sensitivity analysis and immune infiltration analysis were performed. Afterward, multivariate Cox regression was used to construct a risk model, which was further validated by the receiver operating characteristic (ROC) curve. The aberrant expression of hub DRLncs in OS was validated using the Reverse Transcription Polymerase Chain Reaction (RT qPCR) assay. Results : We identified 262 DRLncs and eleven prognosis  related DRLncs through filtering. We then constructed two distinct expression patterns of prognosis  related DRLncs and developed a classifier. We obtained 393 differentially expressed genes (DEGs) between different subtypes, which were significantly enriched in biological processes related to the extracellular matrix, integrin binding, focal adhesion, and Wnt signaling pathways. Through immune infiltration analysis, the activated CD4 memory T cells, resting natural killer (NK) cells, M1 macrophages, and resting dendritic cells (DC) were observed to exhibit different abundance in distinct subtypes. In the drug sensitivity analysis, tamoxifen showed a promising effect for drug  resistant OS. Furthermore, we identified five hub DRLncs and constructed a risk model. The RT qPCR confirmed the aberrant expression of five hub DRLncs in OS. Conclusions : The present study identified DRLncs in OS, and conducted a comprehensive investigation of DRLncs related expression patterns, survival status, immune landscape and drug sensitivity to reveal the difference in prognostic, pharmacological and immunological phenotype characteristics between distinct subtypes. Additionally, we developed a risk model to predict the prognosis, and constructed a genotyping classifier to predict the above phenotype characteristics in OS.
C1 [Zhang, Ke; Jiang, Mingyang; Zou, Xiaochong; Chen, Chuanliang] Guangxi Med Univ, Affiliated Hosp 1, Dept Bone & Joint Surg, Nanning 530021, Guangxi, Peoples R China.
   [Lu, Shenyi] Youjiang Med Univ Nationalities, Affiliated Hosp, Dept Rehabil Med, Baise 533000, Guangxi, Peoples R China.
   [Lan, Yuanyuan; Zhao, Huaan; Ma, Ruilan] Guangxi Med Univ, Sch Basic Med Sci, Nanning 530021, Guangxi, Peoples R China.
   [Yan, Haiwei] Guangxi Med Univ, Affiliated Hosp 4, Liuzhou Workers Hosp, Dept Sports Med, Liuzhou 545000, Guangxi, Peoples R China.
C3 Guangxi Medical University; Youjiang Medical University for
   Nationalities; Guangxi Medical University; Guangxi Medical University
RP Yan, HW (通讯作者)，Guangxi Med Univ, Affiliated Hosp 4, Liuzhou Workers Hosp, Dept Sports Med, Liuzhou 545000, Guangxi, Peoples R China.
EM yhw19163927212@163.com
RI ; Yan, Haiwei/HPB 6821 2023; Jiang, Mingyang/O 9748 2019
OI Zhang, Ke/0009 0002 5161 8030; 
CR Amer RG, 2022, J NEURO ONCOL, V158, P435, DOI 10.1007/s11060 022 04030 7
   Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078 0432.CCR 10 2616
   Chen CL, 2021, CANCER LETT, V500, P1, DOI 10.1016/j.canlet.2020.12.024
   Cortes E, 2019, EMBO REP, V20, DOI 10.15252/embr.201846557
   Cui JC, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01685 w
   Eaton BR, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28352
   Grassie ME, 2011, ARCH BIOCHEM BIOPHYS, V510, P147, DOI 10.1016/j.abb.2011.01.018
   He JJ, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.770857
   Heim X, 2022, J INVEST DERMATOL, V142, P3200, DOI 10.1016/j.jid.2022.03.038
   Hu ZG, 2022, CELLS BASEL, V11, DOI 10.3390/cells11213507
   Jayasuriya R, 2022, BIOMED PHARMACOTHER, V145, DOI 10.1016/j.biopha.2021.112421
   Jiang N, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00407 1
   Kim JS, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0441 y
   Lin XZ, 2020, CANCERS, V12, DOI 10.3390/cancers12113471
   Liu XG, 2023, NAT CELL BIOL, V25, P404, DOI 10.1038/s41556 023 01091 2
   MacDonald BT, 2014, J BIOL CHEM, V289, P18122, DOI 10.1074/jbc.M114.575027
   Ren K, 2015, ONCOTARGET, V6, P31085, DOI 10.18632/oncotarget.5044
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Schein A, 2016, SCI REP UK, V6, DOI 10.1038/srep33605
   Singh A, 2010, CYTOKINE GROWTH F R, V21, P299, DOI 10.1016/j.cytogfr.2010.06.003
   Song M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20140 0
   Stopa JD, 2018, THROMB RES, V164, pS130, DOI 10.1016/j.thromres.2018.01.005
   Tang LN, 2022, ONCOLOGIE, V24, P913, DOI 10.32604/oncologie.2022.026296
   Wang DW, 2019, ONCOGENE, V38, P3458, DOI 10.1038/s41388 019 0675 z
   Wu BB, 2022, THERANOSTICS, V12, P5086, DOI 10.7150/thno.74989
   Wu Y, 2022, ONCOLOGIE, V24, P927, DOI 10.32604/oncologie.2022.026720
   Xu F, 2023, TRANSL ANDROL UROL, V12, P33, DOI 10.21037/tau 22 663
   Xu ZP, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420 022 00933 6
   Zhou J, 2018, ANN HEPATOL, V17, P355, DOI 10.5604/01.3001.0011.7381
NR 29
TC 1
Z9 1
U1 0
U2 8
PU IMR PRESS
PI ROBINSON
PA 112 ROBINSON RD, ROBINSON, SINGAPORE
SN 2768 6701
EI 2768 6698
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD MAY
PY 2024
VL 29
IS 5
AR 193
DI 10.31083/j.fbl2905193
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA SZ7M8
UT WOS:001238337400018
PM 38812298
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, C
   Zhang, X
   Yang, SJ
   Chen, XH
AF Zhang, Cheng
   Zhang, Xi
   Yang, Shi Jie
   Chen, Xing Hua
TI Growth of tyrosine kinase inhibitor resistant Philadelphia positive
   acute lymphoblastic leukemia: Role of bone marrow stromal cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE growth; tyrosine kinase inhibitors; resistant; Philadelphia positive
   acute lymphoblastic leukemia; mechanism; bone marrow stromal cells
ID DRUG INDUCED APOPTOSIS; DOMAIN MUTATIONS; STEM CELLS; IMATINIB
   TREATMENT; MESENCHYMAL STEM; MICROENVIRONMENT; MECHANISMS; CONTRIBUTES;
   ACTIVATION; THERAPY
AB Human bone marrow stromal cells (hBMSCs) may contribute to the growth of tyrosine kinase inhibitor (TKI) resistant chronic myelogenous leukemia (CML). However, there are certain differences in biology between CML and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Little is known about the role and mechanism of hBMSCs on the growth of TKI resistant Ph+ ALL. The current study co cultured hBMSCs with the TKI resistant SUP B15. Next, the proliferation of SUP B15 was detected using a Cell Counting Kit 8. Additionally, quantitative polymerase chain reaction and flow cytometry were used to detect the expression of the associated genes and proteins. The present study explores the role and mechanism of hBMSCs on the growth of TKI resistant Ph+ ALL. The current study showed that hBMSCs promoted the proliferation of TKI resistant Ph+ ALL. This was shown by the increase in cells in the S+ G2 M phase of the cell cycle. It was also found that the expression of cyclins A, C, D1 and E was increased. Apoptosis was inhibited through upregulation of anti apoptotic genes [B cell lymphoma 2 (BCL 2) and BCL extra large] and downregulation of apoptotic genes (BCL XS, BCL 2 associated X protein, and caspases 3, 7 and 9). Expression of the breakpoint cluster region (BCR) Abelson murine leukemia viral oncogene homolog 1 (ABL) gene, Wnt5a, and Wnt signaling pathway associated genes (glycogen synthase kinase 3 beta, beta catenin, E cadherin and phosphoinositide 3 kinase) and transcription factors (c myc, ephrin type B2, fibroblast growth factor 20 and matrix metalloproteinase 7) was also increased. Furthermore, the expression of drug resistance genes (low density lipoprotein receptor, multidrug resistanceasso ciated protein and multi drug resistance gene) was increased and the expression of anti oncogenes (death associated protein kinase and interferon regulatory factor 1) was decreased. It was concluded that hBMSCs promote the growth of TKI resistant Ph+ ALL by these aforementioned mechanisms. Therefore, targeting hBMSCs may be a promising approach for preventing the growth of TKI resistant Ph+ ALL.
C1 [Zhang, Cheng; Zhang, Xi; Yang, Shi Jie; Chen, Xing Hua] Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, 183 Xinqiao St, Chongqing 400037, Peoples R China.
C3 Army Medical University
RP Chen, XH (通讯作者)，Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, 183 Xinqiao St, Chongqing 400037, Peoples R China.
EM xhchen888@aliyun.com
FU National Natural Science Foundation [81170467]; Special Foundation for
   the '1130 project' of Xinqiao Hospital of the Third Military Medical
   University
FX The present study was funded by grants from the National Natural Science
   Foundation (grant no. 81170467) and Special Foundation for the '1130
   project' of Xinqiao Hospital of the Third Military Medical University.
   The authors thank Professor Zhong (Department of Diagnostic Sciences &
   Biomedical Sciences, Ostrow School of Dentistry, University of Southern
   California, Los Angeles, CA, USA) for revising the paper.
CR Ahn JO, 2015, ANTICANCER RES, V35, P159
   Azizidoost S, 2014, HEMATOLOGY, V19, P232, DOI 10.1179/1607845413Y.0000000111
   Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555 010 9222 7
   Bewry NN, 2008, MOL CANCER THER, V7, P3169, DOI 10.1158/1535 7163.MCT 08 0314
   Brady MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097597
   Colavita I, 2013, PROTEOMICS, V13, P2414, DOI 10.1002/pmic.201200444
   Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721
   Donner Amy, 2012, Nat Chem Biol, V8, P739, DOI 10.1038/nchembio.1055
   DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386
   Esposito N, 2011, BLOOD, V118, P3634, DOI 10.1182/blood 2011 03 341073
   Garrido SM, 2001, EXP HEMATOL, V29, P448, DOI 10.1016/S0301 472X(01)00612 9
   Gregory MA, 2010, CANCER CELL, V18, P74, DOI 10.1016/j.ccr.2010.04.025
   Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood 2010 12 326843
   Hao L, 2009, CROAT MED J, V50, P351, DOI 10.3325/cmj.2009.50.351
   Hazlehurst LA, 2007, BRIT J HAEMATOL, V136, P269, DOI 10.1111/j.1365 2141.2006.06435.x
   Jones D, 2008, CANCER AM CANCER SOC, V113, P985, DOI 10.1002/cncr.23666
   Kang YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113520
   Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006
   Lee HJ, 2011, CANCER AM CANCER SOC, V117, P1583, DOI 10.1002/cncr.25690
   Li L, 2011, J CELL PHYSIOL, V226, P1860, DOI 10.1002/jcp.22511
   Liang X, 2010, TRANSPL P, V42, P3767, DOI 10.1016/j.transproceed.2010.08.055
   Maino E, 2014, EXPERT REV ANTICANC, V14, P723, DOI 10.1586/14737140.2014.895669
   McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Medina DJ, 2012, HAEMATOL HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659
   Nair RR, 2012, LEUKEMIA RES, V36, P756, DOI 10.1016/j.leukres.2011.12.002
   Nwajei Felix, 2013, Adv Hematol, V2013, P953982, DOI 10.1155/2013/953982
   Pfeifer H, 2012, LEUKEMIA, V26, P1475, DOI 10.1038/leu.2012.5
   Pfeifer H, 2007, BLOOD, V110, P727, DOI 10.1182/blood 2006 11 052373
   Quentmeier H, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756 8722 4 6
   Quintarelli C, 2014, LEUKEMIA RES, V38, P236, DOI 10.1016/j.leukres.2013.11.006
   Ren F, 2016, BBA REV CANCER, V1866, P266, DOI 10.1016/j.bbcan.2016.10.001
   Singh H, 2014, J BIOMOL SCREEN, V19, P158, DOI 10.1177/1087057113501081
   Soverini S, 2011, HAEMATOL HEMATOL J, V96, P552, DOI 10.3324/haematol.2010.034173
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Sun B, 2009, CYTOTHERAPY, V11, P289, DOI 10.1080/14653240902807026
   Tabe Y, 2014, BRIT J HAEMATOL, V164, P767, DOI 10.1111/bjh.12725
   TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497
   Traer E, 2012, LEUKEMIA, V26, P1140, DOI 10.1038/leu.2011.325
   Wegmeyer H, 2013, STEM CELLS DEV, V22, P2606, DOI 10.1089/scd.2013.0016
   Xing HY, 2012, LEUKEMIA RES, V36, P509, DOI 10.1016/j.leukres.2011.12.018
   Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood 2012 02 412890
   Zhang C, 2011, J BIOL CHEM, V286, P13723, DOI 10.1074/jbc.M110.144691
NR 44
TC 3
Z9 3
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD APR
PY 2017
VL 13
IS 4
BP 2059
EP 2070
DI 10.3892/ol.2017.5686
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA ER0YF
UT WOS:000398514200008
PM 28454362
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Newa, M
   Bhandari, KH
   Tang, LL
   Kalvapalle, R
   Suresh, M
   Doschak, MR
AF Newa, Madhuri
   Bhandari, Krishna Hari
   Tang, Lili
   Kalvapalle, Rohit
   Suresh, Mavanur
   Doschak, Michael R.
TI Antibody Mediated "Universal" Osteoclast Targeting Platform using
   Calcitonin as a Model Drug
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE drug delivery system; monoclonal antibody; osteoclast; osteoporosis;
   post traumatic osteoarthritis; RANK receptor; salmon calcitonin
ID SALMON CALCITONIN; METHYL 4 MERCAPTOBUTYRIMIDATE; DIFFERENTIATION
   FACTOR; POSTMENOPAUSAL WOMEN; SULFHYDRYL GROUPS; BONE RESORPTION;
   DELIVERY; CELLS; RANK; OSTEOPETROSIS
AB To generate and characterize a specific monoclonal antibody (mAb) against recombinant human RANK receptor and to develop an antiresorptive strategy using this mAb as an osteoclast targeting platform that selectively targets osteoclast cells whilst delivering an attached (i.e. chemically conjugated) active drug cargo.
   Using hybridoma technology, we generated a specific monoclonal antibody (mAb) against recombinant human RANK receptor and characterized by SDS PAGE, ELISA, Western Blot and immunocytochemistry, then synthesized osteoclast targeting bioconjugates of salmon calcitonin (sCT) using this antibody by generating thiol groups on mAb using 2 Iminothiolane and subsequently reacting them with sCT PEG MAL synthesised from sCT and NHS PEG MAL. To test the efficacy of the conjugate in vitro, osteoclasts were generated from precursor RAW 264.7 cells by dosing with the cytokines macrophage colony stimulating factor (M CSF), and RANK Ligand (RANKL) and TRAP activity assay, Resorption Pit Assay, TRAP staining were performed. Cytotoxicity of the mAb sCT conjugate was also evaluated in RAW 264.7 cells; sCT bioactivity and CTR binding potential were evaluated by in vitro intracellular cAMP stimulation assay in human T47D breast cancer cells.
   Generation of antibody against human RANK receptor was confirmed by SDS PAGE, ELISA and Western Blot. Immunocytochemistry confirmed the osteoclast targeting potential of the antibody. Successful conjugation of the antibody with sCT was confirmed by SDS PAGE and ELISA.Multinucleated osteoclast formation was confirmed by staining for tartrate resistant acid phosphatase (TRAP). Conjugate functionality was confirmed by TRAP activity and Resorption Pit assay, showing the inhibitory effect on osteoclast differentiation. cAMP assay confirmed the retention of calcitonin bioactivity after conjugation.
   Our strategy offers the potential for a "universal" osteoclast targeting platform one that targets the RANK receptor on osteoclast cells by simply altering the conjugated cargo in order to affect the specific regulation of osteoclast cells.
C1 [Newa, Madhuri; Bhandari, Krishna Hari; Tang, Lili; Kalvapalle, Rohit; Suresh, Mavanur; Doschak, Michael R.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
C3 University of Alberta
RP Doschak, MR (通讯作者)，Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
EM newa@ualberta.ca; kbhanda@ualberta.ca; xinli@ualberta.ca;
   rohitk@ualberta.ca; msuresh@pharmacy.ualberta.ca; mdoschak@ualberta.ca
OI Doschak, Michael/0000 0002 0293 6596; Bhandari,
   Krishna/0000 0003 4526 2023
FU Alberta Heritage Foundation for Medical Research (AHFMR)
FX This paper was presented in part as a poster at the 13th Annual Canadian
   Society for Pharmaceutical Sciences (CSPS) Symposium, Richmond BC, June
   2 5, 2010. This research was funded by the Osteoarthritis (OA) Alberta
   Team Grant from the Alberta Heritage Foundation for Medical Research
   (AHFMR).
CR Bhandari KH, 2010, INT J PHARMACEUT, V394, P26, DOI 10.1016/j.ijpharm.2010.04.015
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BREIMER LH, 1988, BIOCHEM J, V255, P377, DOI 10.1042/bj2550377
   Bu RF, 2003, BONE, V33, P760, DOI 10.1016/j.bone.2003.07.006
   Cleland JL, 2001, CURR OPIN BIOTECH, V12, P212, DOI 10.1016/S0958 1669(00)00202 0
   de Villiers TJ, 2009, CLIMACTERIC, V12, P108, DOI 10.1080/13697130903010953
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003 9861(59)90090 6
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Fee CJ, 2007, BIOTECHNOL BIOENG, V98, P725, DOI 10.1002/bit.21482
   FERRARILACRAZ S, 2010, OSTEOPOROS INT
   FOUCHEREAUPERON M, 1981, P NATL ACAD SCI BIOL, V78, P3973, DOI 10.1073/pnas.78.6.3973
   Gonzalez Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298 06
   Halleen J M, 2001, Am Clin Lab, V20, P29
   Hamidi M, 2006, DRUG DELIV, V13, P399, DOI 10.1080/10717540600814402
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   HUWYLER R, 1979, AM J PHYSIOL, V236, pE15, DOI 10.1152/ajpendo.1979.236.1.E15
   JUE R, 1978, BIOCHEMISTRY US, V17, P5399, DOI 10.1021/bi00618a013
   Kammila S, 2008, J VIROL METHODS, V152, P77, DOI 10.1016/j.jviromet.2008.05.023
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Lee KC, 1999, PHARMACEUT RES, V16, P813, DOI 10.1023/A:1018861616465
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V279, P391, DOI 10.1006/bbrc.2000.3953
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   MOONGA BS, 1990, J PHYSIOL LONDON, V429, P29, DOI 10.1113/jphysiol.1990.sp018242
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Okubo Y, 2000, BIOCHEM BIOPH RES CO, V269, P317, DOI 10.1006/bbrc.2000.2294
   Pelletier JP, 2004, BONE, V34, P527, DOI 10.1016/j.bone.2003.11.021
   Rahman MM, 2006, J LIPID RES, V47, P1739, DOI 10.1194/jlr.M600151 JLR200
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Shahhosseini S, 2007, J VIROL METHODS, V143, P29, DOI 10.1016/j.jviromet.2007.02.004
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Stevenson CL, 2000, J PEPT RES, V55, P129, DOI 10.1034/j.1399 3011.2000.00160.x
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   TRAUT RR, 1973, BIOCHEMISTRY US, V12, P3266, DOI 10.1021/bi00741a019
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vääräniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756 3282(02)00688 9
NR 44
TC 9
Z9 12
U1 1
U2 23
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724 8741
EI 1573 904X
J9 PHARM RES DORDR
JI Pharm. Res.
PD MAY
PY 2011
VL 28
IS 5
BP 1131
EP 1143
DI 10.1007/s11095 011 0376 y
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 747EB
UT WOS:000289302000018
PM 21301934
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Khan, AA
   Rubin, MR
   Schwarz, P
   Vokes, T
   Shoback, DM
   Gagnon, C
   Palermo, A
   Marcocci, C
   Clarke, BL
   Abbott, LG
   Hofbauer, LC
   Kohlmeier, L
   Pihl, S
   An, XB
   Eng, WF
   Smith, AR
   Ukena, J
   Sibley, CT
   Shu, AD
   Rejnmark, L
AF Khan, Aliya A.
   Rubin, Mishaela R.
   Schwarz, Peter
   Vokes, Tamara
   Shoback, Dolores M.
   Gagnon, Claudia
   Palermo, Andrea
   Marcocci, Claudio
   Clarke, Bart L.
   Abbott, Lisa G.
   Hofbauer, Lorenz C.
   Kohlmeier, Lynn
   Pihl, Susanne
   An, Xuebei
   Eng, Walter Frank
   Smith, Alden R.
   Ukena, Jenny
   Sibley, Christopher T.
   Shu, Aimee D.
   Rejnmark, Lars
TI Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH
   in Hypoparathyroidism: 26 Week Results From the Phase 3 PaTHway Trial
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CLINICAL TRIALS; DISORDERS OF CALCIUM; PHOSPHATE; HORMONE REPLACEMENT;
   PARATHYROID RELATED DISORDERS; PTH; VIT D; FGF23
ID QUALITY OF LIFE; RECEIVING STANDARD TREATMENT; EPIDEMIOLOGY; MANAGEMENT;
   PTH(1 84); DIAGNOSIS; THERAPY
AB Conventional therapy for hypoparathyroidism consisting of active vitamin D and calcium aims to alleviate hypocalcemia but fails to restore normal parathyroid hormone (PTH) physiology. PTH replacement therapy is the ideal physiologic treatment for hypoparathyroidism. The double blind, placebo controlled, 26 week, phase 3 PaTHway trial assessed the efficacy and safety of PTH replacement therapy for hypoparathyroidism individuals with the investigational drug TransCon PTH (palopegteriparatide). Participants (n = 84) were randomized 3:1 to once daily TransCon PTH (initially 18 mu g/d) or placebo, both co administered with conventional therapy. The study drug and conventional therapy were titrated according to a dosing algorithm guided by serum calcium. The composite primary efficacy endpoint was the proportion of participants at week 26 who achieved normal albumin adjusted serum calcium levels (8.3 10.6 mg/dL), independence from conventional therapy (requiring no active vitamin D and <= 600 mg/d of calcium), and no increase in study drug over 4 weeks before week 26. Other outcomes of interest included health related quality of life measured by the 36 Item Short Form Survey (SF 36), hypoparathyroidism related symptoms, functioning, and well being measured by the Hypoparathyroidism Patient Experience Scale (HPES), and urinary calcium excretion. At week 26, 79% (48/61) of participants treated with TransCon PTH versus 5% (1/21) wiplacebo met the composite primary efficacy endpoint (p < 0.0001). TransCon PTH treatment demonstrated a significant improvement in all key secondary endpoint HPES domain scores (all p < 0.01) and the SF 36 Physical Functioning subscale score (p = 0.0347) compared with placebo. Additionally, 93% (57/61) of participants treated with TransCon PTH achieved independence from conventional therapy. TransCon PTH treatment normalized mean 24 hour urine calcium. Overall, 82% (50/61) treated with TransCon PTH and 100% (21/21) wiplacebo experienced adverse events; most were mild (46%) or moderate (46%). No study drug related withdrawals occurred. In conclusion, TransCon PTH maintained normocalcemia while permitting independence from conventional therapy and was well tolerated in individuals with hypoparathyroidism. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Khan, Aliya A.] McMaster Univ, Endocrinol Metab & Geriatr, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
   [Rubin, Mishaela R.] Columbia Univ, Endocrinol, New York, NY USA.
   [Schwarz, Peter] Rigshosp, Internal Med & Endocrinol, Copenhagen, Denmark.
   [Vokes, Tamara] Univ Chicago, Endocrinol Diabet & Metab, Chicago, IL 60637 USA.
   [Shoback, Dolores M.] UCSF VA Med Ctr, Endocrinol, San Francisco, CA USA.
   [Gagnon, Claudia] Univ Laval, CHU Quebec, Univ Laval Res Ctr, Quebec City, PQ, Canada.
   [Gagnon, Claudia] Univ Laval, Dept Med, Quebec City, PQ, Canada.
   [Palermo, Andrea] Campus Biomed Univ, Fdn Policlin Campus Biomed, Unit Metab Bone & Thyroid Disorders, Rome, Italy.
   [Palermo, Andrea] Campus Biomed Univ, Unit Endocrinol & Diabet, Rome, Italy.
   [Marcocci, Claudio] Univ Pisa, Endocrinol, Pisa, Italy.
   [Clarke, Bart L.] Mayo Clin, Endocrinol, E18 A, Rochester, MN USA.
   [Abbott, Lisa G.] Univ Nevada, Northern Nevada Endocrinol, Reno, NV 89557 USA.
   [Hofbauer, Lorenz C.] Tech Univ Dresden Med Ctr, Endocrinol Diabet & Metab Bone Dis, Dresden, Germany.
   [Kohlmeier, Lynn] Endocrinol Endocrinol & Spokane Osteoporosis, Spokane, WA USA.
   [Pihl, Susanne] Ascendis Pharma AS, Biolanal & Pharmacokinet Pharmacodynam, Hellerup, Denmark.
   [An, Xuebei; Eng, Walter Frank; Smith, Alden R.; Ukena, Jenny; Sibley, Christopher T.; Shu, Aimee D.] Ascendis Pharma Inc, Endocrine Med Sci, Palo Alto, CA USA.
   [Rejnmark, Lars] Aarhus Univ Hosp, Clin Med & Endocrinol, Aarhus, Denmark.
C3 McMaster University; Columbia University; Rigshospitalet; University of
   Copenhagen; Copenhagen University Hospital; University of Chicago; Laval
   University; Laval University Hospital; Laval University; University
   Campus Bio Medico   Rome Italy; Fondazione Policlinico Universitario
   Campus Bio Medico; University Campus Bio Medico   Rome Italy; University
   of Pisa; Mayo Clinic; Nevada System of Higher Education (NSHE);
   University of Nevada Reno; Aarhus University
RP Khan, AA (通讯作者)，McMaster Univ, Endocrinol Metab & Geriatr, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
EM draliyakhan@gmail.com
RI Sibley, Christopher/C 9900 2013; Palermo, Andrea/D 7406 2015; Schwarz,
   Peter/AAF 1558 2020; palermo, andrea/D 7406 2015; Hofbauer, Lorenz
   C./G 2490 2010; Hofbauer, Lorenz/G 2490 2010
OI Palermo, Andrea/0000 0002 1143 4926; Hofbauer, Lorenz
   C./0000 0002 8691 8423; Sibley, Christopher/0009 0002 7534 7175; 
FU Ascendis Pharma Bone Diseases A/S, Hellerup, Denmark
FX This work was supported by Ascendis Pharma Bone Diseases A/S, Hellerup,
   Denmark. The ClinicalTrials.gov number is NCT04009291. The authors thank
   the trial participants and their families, investigators, and the trial
   staff. Medical writing support was provided by Kristin Hirahatake, PhD,
   and Nayna Sanathara, PhD, of Ascendis Pharma Inc.
CR Arlt W, 2002, EUR J ENDOCRINOL, V146, P215, DOI 10.1530/eje.0.1460215
   Astor MC, 2016, J CLIN ENDOCR METAB, V101, P3045, DOI 10.1210/jc.2016 1477
   Bilezikian JP, 2020, J CLIN ENDOCR METAB, V105, P1722, DOI 10.1210/clinem/dgaa113
   Bilezikian JP, 2016, J CLIN ENDOCR METAB, V101, P2313, DOI 10.1210/jc.2015 3910
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Brandi ML, 2016, J CLIN ENDOCR METAB, V101, P2273, DOI 10.1210/jc.2015 3907
   Brod M, 2021, J PATIENT REP OUTCOM, V5, DOI 10.1186/s41687 021 00320 2
   Büttner M, 2017, ENDOCRINE, V58, P14, DOI 10.1007/s12020 017 1377 3
   Center for Drug Evaluation and Research, 2014, CLIN PHARM BIOPH REV
   Clarke BL, 2016, J CLIN ENDOCR METAB, V101, P2284, DOI 10.1210/jc.2015 3908
   Cusano NE, 2018, ENDOCRIN METAB CLIN, V47, P759, DOI 10.1016/j.ecl.2018.07.001
   Cusano NE, 2015, BEST PRACT RES CL EN, V29, P47, DOI 10.1016/j.beem.2014.09.001
   Cusano NE, 2014, J CLIN ENDOCR METAB, V99, P3694, DOI 10.1210/jc.2014 2267
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P2356, DOI 10.1210/jc.2013 1239
   Hadker N, 2014, ENDOCR PRACT, V20, P671, DOI 10.4158/EP13328.OR
   Holten Andersen L, 2019, J BONE MINER RES, V34, P2075, DOI 10.1002/jbmr.3824
   Karpf DB, 2020, J BONE MINER RES, V35, P1430, DOI 10.1002/jbmr.4016
   Khan AA, 2022, J CLIN ENDOCR METAB, V107, pE372, DOI 10.1210/clinem/dgab577
   Mannstadt M, 2019, J CLIN ENDOCR METAB, V104, P5133, DOI 10.1210/jc.2019 01010
   Mannstadt M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.55
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   Shoback DM, 2016, J CLIN ENDOCR METAB, V101, P2300, DOI 10.1210/jc.2015 3909
   Siggelkow H, 2020, CLIN ENDOCRINOL, V92, P159, DOI 10.1111/cen.14128
   Tay YKD, 2019, J CLIN ENDOCR METAB, V104, P5601, DOI 10.1210/jc.2019 00893
   Vokes T, 2019, BONE, V120, P542, DOI 10.1016/j.bone.2018.09.017
   Vokes TJ, 2018, J CLIN ENDOCR METAB, V103, P722, DOI 10.1210/jc.2017 01471
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
NR 29
TC 50
Z9 57
U1 6
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2023
VL 38
IS 1
BP 14
EP 25
DI 10.1002/jbmr.4726
EA NOV 2022
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8L2LH
UT WOS:000881940600001
PM 36271471
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Pantano, F
   Croset, M
   Driouch, K
   Bednarz Knoll, N
   Iuliani, M
   Ribelli, G
   Bonnelye, E
   Wikman, H
   Geraci, S
   Bonin, F
   Simonetti, S
   Vincenzi, B
   Hong, SS
   Sousa, S
   Pantel, K
   Tonini, G
   Santini, D
   Clézardin, P
AF Pantano, Francesco
   Croset, Martine
   Driouch, Keltouma
   Bednarz Knoll, Natalia
   Iuliani, Michele
   Ribelli, Giulia
   Bonnelye, Edith
   Wikman, Harriet
   Geraci, Sandra
   Bonin, Florian
   Simonetti, Sonia
   Vincenzi, Bruno
   Hong, Saw See
   Sousa, Sofia
   Pantel, Klaus
   Tonini, Giuseppe
   Santini, Daniele
   Clezardin, Philippe
TI Integrin alpha5 in human breast cancer is a mediator of bone metastasis
   and a therapeutic target for the treatment of osteolytic lesions
SO ONCOGENE
LA English
DT Article
ID CELL MIGRATION; OSTEOBLAST DIFFERENTIATION; TUMOR CELLS; EXPRESSION;
   LUNG; VOLOCIXIMAB; SURVIVAL; GROWTH; COLONIZATION; INHIBITION
AB Bone metastasis remains a major cause of mortality and morbidity in breast cancer. Therefore, there is an urgent need to better select high risk patients in order to adapt patient's treatment and prevent bone recurrence. Here, we found that integrin alpha5 (ITGA5) was highly expressed in bone metastases, compared to lung, liver, or brain metastases. High ITGA5 expression in primary tumors correlated with the presence of disseminated tumor cells in bone marrow aspirates from early stage breast cancer patients (n = 268; p = 0.039). ITGA5 was also predictive of poor bone metastasis free survival in two separate clinical data sets (n = 855, HR = 1.36, p = 0.018 and n = 427, HR = 1.62, p = 0.024). This prognostic value remained significant in multivariate analysis (p = 0.028). Experimentally, ITGA5 silencing impaired tumor cell adhesion to fibronectin, migration, and survival. ITGA5 silencing also reduced tumor cell colonization of the bone marrow and formation of osteolytic lesions in vivo. Conversely, ITGA5 overexpression promoted bone metastasis. Pharmacological inhibition of ITGA5 with humanized monoclonal antibody M200 (volociximab) recapitulated inhibitory effects of ITGA5 silencing on tumor cell functions in vitro and tumor cell colonization of the bone marrow in vivo. M200 also markedly reduced tumor outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted cancer associated bone destruction. ITGA5 was not only expressed by tumor cells but also osteoclasts. In this respect, M200 decreased human osteoclast mediated bone resorption in vitro. Overall, this study identifies ITGA5 as a mediator of breast to bone metastasis and raises the possibility that volociximab/M200 could be repurposed for the treatment of ITGA5 positive breast cancer patients with bone metastases.
C1 [Pantano, Francesco; Croset, Martine; Bonnelye, Edith; Geraci, Sandra; Sousa, Sofia; Clezardin, Philippe] INSERM, UMR S1033, LYOS, Lyon, France.
   [Pantano, Francesco; Croset, Martine; Bonnelye, Edith; Geraci, Sandra; Hong, Saw See; Sousa, Sofia; Clezardin, Philippe] Univ Lyon, Villeurbanne, France.
   [Pantano, Francesco; Iuliani, Michele; Ribelli, Giulia; Simonetti, Sonia; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy.
   [Driouch, Keltouma; Bonin, Florian] Inst Curie, Serv Genet, Unite Pharmacogen, Paris, France.
   [Bednarz Knoll, Natalia; Wikman, Harriet; Pantel, Klaus] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany.
   [Bednarz Knoll, Natalia] Med Univ Gdansk, Lab Translat Oncol, Gdansk, Poland.
   [Hong, Saw See] INRA, UMR 754, Lyon, France.
   [Clezardin, Philippe] Univ Sheffield, Oncol & Metab Dept, Sheffield, S Yorkshire, England.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; University Campus Bio Medico   Rome
   Italy; UNICANCER; Universite PSL; Institut Curie; University of Hamburg;
   University Medical Center Hamburg Eppendorf; Fahrenheit Universities;
   Medical University Gdansk; INRAE; University of Sheffield
RP Clézardin, P (通讯作者)，INSERM, UMR S1033, LYOS, Lyon, France.; Clézardin, P (通讯作者)，Univ Lyon, Villeurbanne, France.; Clézardin, P (通讯作者)，Univ Sheffield, Oncol & Metab Dept, Sheffield, S Yorkshire, England.
RI Clezardin, Philippe/M 8071 2014; Bednarz Knoll, Natalia/D 3663 2011;
   Pantano, Francesco/D 8459 2012; Bonnelye, Edith/AAT 9134 2021
OI Clezardin, Philippe/0000 0003 0149 4463; Bednarz Knoll,
   Natalia/0000 0001 9506 942X; Pantano, Francesco/0000 0002 2894 9686;
   Iuliani, Michele/0000 0003 3536 7630; Wikman,
   Harriet/0000 0001 6862 0888; 
FU "Ligue contre le cancer" cd69, 2016; Breast Cancer Research Foundation
   (BCRF, USA) [BCRF 16 096]; Deutsche Forschungsgemeinschaft, SPP
   microBONE; INSERM, University Claude Bernard Lyon 1; "Project LIA/LEA
   2016" of the University of Lyon, within the program "Investissements
   d'Avenir" [ASC17018CSA, ANR 11 IDEX 0007]; LabEX DEVweCAN of the
   University of Lyon, within the program "Investissements d'Avenir"
   [ANR 11 IDEX 0007, ANR 10 LABX 61]; Inca [Transla09 112]
FX MC acknowledges the support of "Ligue contre le cancer" cd69, 2016. KD
   acknowledges the support of Inca (Grant No. Transla09 112). FB is
   supported by the Breast Cancer Research Foundation (BCRF, USA)
   (BCRF 16 096, 2016 2017). KP is supported by the Deutsche
   Forschungsgemeinschaft, SPP microBONE. PC is supported by INSERM,
   University Claude Bernard Lyon 1, the "Project LIA/LEA 2016" (Grant No.:
   ASC17018CSA), and the LabEX DEVweCAN (ANR 10 LABX 61) of the University
   of Lyon, within the program "Investissements d'Avenir"
   (ANR 11 IDEX 0007) operated by the French National Research Agency
   (ANR).
CR Aguirre Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Alix Panabières C, 2014, NAT REV CANCER, V14, P623, DOI 10.1038/nrc3820
   Almokadem S, 2012, EXPERT OPIN BIOL TH, V12, P251, DOI 10.1517/14712598.2012.646985
   Anderson JA, 2007, BRIT J CANCER, V96, P1394, DOI 10.1038/sj.bjc.6603720
   Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008 5472.CAN 14 3728
   Bednarz Knoll N, 2015, ONCOTARGET, V6, P26789, DOI 10.18632/oncotarget.4628
   Bell McGuinn KM, 2011, GYNECOL ONCOL, V121, P273, DOI 10.1016/j.ygyno.2010.12.362
   Besse B, 2013, ANN ONCOL, V24, P90, DOI 10.1093/annonc/mds281
   Bièche I, 2001, CANCER RES, V61, P1652
   Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971
   Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801
   Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Croset M, 2018, CANCER RES, V78, P5259, DOI 10.1158/0008 5472.CAN 17 3058
   Croset M, 2014, J BONE MINER RES, V29, P1886, DOI 10.1002/jbmr.2215
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Duffy MJ, 2008, CLIN CHEM, V54, P1770, DOI 10.1373/clinchem.2008.110056
   Fan LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162933
   Fehm T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1869
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568 018 0038 z
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549 011 1619 7
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   HUGHES DE, 1993, J BONE MINER RES, V8, P527
   Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008 5472.CAN 06 4100
   Iuliani M, 2015, ONCOTARGET, V6, P12520, DOI 10.18632/oncotarget.3724
   Jami MS, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 194
   Ju JLA, 2017, MOL CANCER RES, V15, P723, DOI 10.1158/1541 7786.MCR 16 0338
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535 7163.MCT 06 0100
   Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008 5472.CAN 03 3853
   Landemaine T, 2008, CANCER RES, V68, P6092, DOI 10.1158/0008 5472.CAN 08 0436
   Lehtinen L, 2012, J PATHOL, V226, P674, DOI 10.1002/path.3956
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Oudin MJ, 2016, CANCER DISCOV, V6, P516, DOI 10.1158/2159 8290.CD 15 1183
   Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165
   Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01 0911fje
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143
   Qin L, 2011, CANCER RES, V71, P1742, DOI 10.1158/0008 5472.CAN 10 3453
   Reynaud C, 2017, CANCER RES, V77, P268, DOI 10.1158/0008 5472.CAN 15 2621
   Ricart AD, 2008, CLIN CANCER RES, V14, P7924, DOI 10.1158/1078 0432.CCR 08 0378
   Schnitt SJ, 2010, MODERN PATHOL, V23, pS60, DOI 10.1038/modpathol.2010.33
   Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380
   Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290
   Truong HH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004751
   VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405
   Wiedswang G, 2003, CYTOTHERAPY, V5, P40, DOI 10.1080/14653240310000065
   Wu ZG, 2018, BIOCHEM BIOPH RES CO, V498, P495, DOI 10.1016/j.bbrc.2018.03.007
   Yao HR, 2016, BREAST CANCER RES TR, V157, P489, DOI 10.1007/s10549 016 3844 6
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
   Zhang ZZ, 2015, AM J CANCER RES, V5, P772
   Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008 5472.CAN 06 4499
   Zuo T, 2018, TRANSL ONCOL, V11, P346, DOI 10.1016/j.tranon.2018.01.021
NR 55
TC 70
Z9 74
U1 1
U2 14
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD FEB 18
PY 2021
VL 40
IS 7
BP 1284
EP 1299
DI 10.1038/s41388 020 01603 6
EA JAN 2021
PG 16
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA QK0LS
UT WOS:000607346000004
PM 33420367
OA Green Published, Green Submitted, hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Samoto, M
   Matsuyama, H
   Matsumoto, H
   Hirata, H
   Ueno, K
   Ozawa, S
   Mori, J
   Inoue, R
   Yano, S
   Yamamoto, Y
   Haginaka, J
   Horiyama, S
   Tamada, K
AF Samoto, Masahiro
   Matsuyama, Hideyasu
   Matsumoto, Hiroaki
   Hirata, Hiroshi
   Ueno, Koji
   Ozawa, Sho
   Mori, Junichi
   Inoue, Ryo
   Yano, Seiji
   Yamamoto, Yoshiaki
   Haginaka, Jun
   Horiyama, Shizuyo
   Tamada, Koji
TI Novel bone microenvironment model of castration resistant prostate
   cancer with chitosan fiber matrix and osteoblasts
SO ONCOLOGY LETTERS
LA English
DT Article
DE bone metastasis; drug screening; osteoblast; prostate cancer;
   three dimensional co culture
ID EPITHELIAL MESENCHYMAL TRANSITION; NANOFIBER SCAFFOLDS; TGF BETA; CELLS;
   DUTASTERIDE; METASTASIS; EXPRESSION; ACETATE
AB The interaction between prostate cancer cells and osteoblasts is essential for the development of bone metastasis. Previously, novel androgen receptor axis targeted agents (ARATs) were approved for metastatic castration naive and non metastatic castration resistant prostate cancer (CRPC); both of which are pivotal for investigating the association between the bone microenvironment and tumors. The present study established a novel in vitro 3D microenvironment model that simulated the bone microenvironment of CRPC, and evaluated the drug susceptibility of ARATs and the efficacy of the combination of abiraterone and dutasteride. Green fluorescent protein transferred C4 2 cells (a CRPC cell line) and red fluorescent protein transferred human osteoblasts differentiated from human mesenchymal stem cells were co cultured in chitosan nanofiber matrix coated culture plates to simulate the 3D scaffold of the bone microenvironment. The growth of C4 2 was quantified using live cell imaging and the Cell3 iMager duos analysis system. The growth of C4 2 colonies were quantified for a maximum of 30 days. The expression of TGF beta increased and promoted EMT in C4 2 cells co cultured with osteoblasts, indicating resistance to ARATs. The IC50 of each drug and the combination effect of abiraterone and dutasteride were evaluated using this model. Combination treatment with abiraterone and dutasteride synergistically inhibited the growth of C2 4 colonies compared with individual investigational agents. This could be attributed to the reduction of 3 keto 5 alpha abiraterone, an androgen receptor agonist. The bone microenvironment model of the present study is unique and useful for evaluating new drug susceptibility testing in prostate cancer cells. This model may help to reveal the unknown mechanisms underlying micro  to clinical bone metastasis in prostate cancer.
C1 [Samoto, Masahiro; Matsuyama, Hideyasu; Matsumoto, Hiroaki; Hirata, Hiroshi; Ozawa, Sho; Mori, Junichi; Inoue, Ryo; Yano, Seiji; Yamamoto, Yoshiaki] Yamaguchi Univ, Grad Sch Med, Dept Urol, 1 1 1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.
   [Ueno, Koji] Yamaguchi Univ, Grad Sch Med, Ctr Regenerat Med, Ube, Yamaguchi 7558505, Japan.
   [Haginaka, Jun; Horiyama, Shizuyo] Mukogawa Womens Univ, Sch Pharm & Pharmaceut Sci, Nishinomiya, Hyogo 6638179, Japan.
   [Tamada, Koji] Yamaguchi Univ, Grad Sch Med, Dept Immunol, Ube, Yamaguchi 7558505, Japan.
C3 Yamaguchi University; Yamaguchi University; Mukogawa Women's University;
   Yamaguchi University
RP Matsuyama, H (通讯作者)，Yamaguchi Univ, Grad Sch Med, Dept Urol, 1 1 1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.
EM hidde@yamaguchi u.ac.jp
RI ; Matsuyama, Hideyasu/AAC 7487 2020; Haginaka, Jun/K 5672 2012
OI Haginaka, Jun/0000 0001 6760 7745; 
FU Japan Society for the Promotion of Science [17H04330, B20H03806]; Jansen
   Pharma [ARN I 17 JPN 001 V01]; Grants in Aid for Scientific Research
   [17H04330] Funding Source: KAKEN
FX The present study was supported by a Grant in Aid for Scientific
   Research Foundation B (KAKENHI) from the Japan Society for the Promotion
   of Science (grant nos. 17H04330 and B20H03806) and the Jansen Pharma
   non clinical investigator initiated study (grant no.
   ARN I 17 JPN 001 V01).
CR Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127
   [Anonymous], 2020, SEER Cancer Stat Facts: Female Breast Cancer
   Antunes J, 2019, ACTA BIOMATER, V94, P392, DOI 10.1016/j.actbio.2019.06.012
   Bartucci M, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00064
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008 5472.CAN 11 0532
   Chiechi Antonella, 2013, Adv Biosci Biotechnol, V4, P15
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Elbadawy M, 2020, CANCERS, V12, DOI 10.3390/cancers12040777
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220
   Ho MH, 2014, INT J NANOMED, V9, P4293, DOI 10.2147/IJN.S68012
   HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809
   Hussain A, 2013, BIOTECHNOL BIOENG, V110, P637, DOI 10.1002/bit.24727
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Kimura Y, 2017, SCI REP UK, V7, DOI 10.1038/srep44824
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628
   Kuchimaru T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05366 3
   Li ZF, 2016, NATURE, V533, P547, DOI 10.1038/nature17954
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsuyama H, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.112
   Montanari M, 2017, ONCOTARGET, V8, P35376, DOI 10.18632/oncotarget.15686
   Nakazawa M, 2017, J STEROID BIOCHEM, V166, P84, DOI 10.1016/j.jsbmb.2016.05.007
   Pezaro CJ, 2014, EUR UROL, V65, P270, DOI 10.1016/j.eururo.2013.10.055
   Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603
   Rajendran D, 2017, J BIOMED MATER RES A, V105, P2119, DOI 10.1002/jbm.a.36072
   Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470 2045(14)71205 7
   Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070
   Shiota M, 2015, ENDOCR RELAT CANCER, V22, P889, DOI 10.1530/ERC 15 0225
   Sumanasuriya S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030635
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Wadosky KM, 2016, ONCOTARGET, V7, P64447, DOI 10.18632/oncotarget.10901
   Wang K, 2015, BIOMACROMOLECULES, V16, P3362, DOI 10.1021/acs.biomac.5b01032
   Wang N, 2014, J BONE MINER RES, V29, P2688, DOI 10.1002/jbmr.2300
   Weckermann D, 2009, J CLIN ONCOL, V27, P1549, DOI 10.1200/JCO.2008.17.0563
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xu KL, 2020, BIOMATERIALS, V254, DOI 10.1016/j.biomaterials.2020.120126
   Xu KL, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119311
NR 40
TC 4
Z9 4
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD OCT
PY 2021
VL 22
IS 4
AR 689
DI 10.3892/ol.2021.12950
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA UA1SB
UT WOS:000684944500001
PM 34457044
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wei, R
   Zhang, L
   Hu, W
   Wu, J
   Zhang, W
AF Wei, Rui
   Zhang, Lin
   Hu, Wei
   Wu, Jie
   Zhang, Wei
TI CSTA plays a role in osteoclast formation and bone resorption by
   mediating the DAP12/TREM2 pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE CSTA; DAP12; TREM2; Osteoclasts; Osteoporosis
ID CYSTATIN A; DIFFERENTIATION; OSTEOPOROSIS; RECEPTOR; MUTATIONS
AB Cystatin A (CSTA) is a cysteine protease inhibitor that is expressed highly during osteoporosis. However, the exact role of CSTA in osteoporosis remains unknown. In this study, we examined the role of CSTA in the formation, differentiation, and bone resorption of osteoclasts. We extracted bone marrow cells from 8 week old wildtype mice to obtain RANKL and M CSF induced osteoclasts. We performed CSTA overexpression and knockdown experiments in the cells. We analyzed the role of CSTA in the process of osteoclasts by trap staining. In addition, we studied the contribution of CSTA to osteogenesis through the DAP12/TREM2 (DNAX activating protein of 12 kDa/Triggering receptor expressed on myeloid cells 2) complex. We analyzed the role of CSTA in postmenopausal osteoporosis using OVX mouse models. We found that the silencing of CSTA inhibited the differentiation and formation of osteoclasts. The loss of CSTA weakened the expression of osteoclast marker genes. In contrast, overexpression of CSTA significantly increased differentiation and formation of osteoclasts and enhanced bone resorption. Immunofluorescence staining indicated that CSTA and DAP12 are co expressed in osteoclasts, and the loss of either DAP12 or TREM2 inhibited osteoclast differentiation and bone resorption. Suppression of CSTA decreased DAP12 and TREM2 expression, whereas overexpression of CSTA rescued the loss of TREM2 expression caused by DAP12 knockdown. Co immunoprecipitation and co localization experiments indicated that CSTA interacted with DAP12. In addition, we found that injection of si CSTA into OVX mice significantly improved bone parameters. Our research indicates that CSTA interacts with the DAP12/ TREM2 complex and could be a potential targeted therapy for osteoporosis management.(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Wei, Rui; Hu, Wei; Wu, Jie; Zhang, Wei] Kunming Med Univ, Affiliated Hosp 1, Dept Emergency Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China.
   [Zhang, Lin] Kunming Med Univ, Affiliated Hosp 1, Dept Rehabil Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China.
C3 Kunming Medical University; Kunming Medical University
RP Zhang, W (通讯作者)，Kunming Med Univ, Affiliated Hosp 1, Dept Emergency Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China.
EM zhangwei@ydyy.cn
RI zhang, Weihua/JJD 6447 2023
FU Committee of Yunnan Province [2018NS0135]
FX Funding The research leading to these results received funding from the
   Committee of Yunnan Province under Grant Agreement No. 2018NS0135.
CR Anagnostis P, 2021, HORM INT J ENDOCRINO, V20, P13, DOI 10.1007/s42000 020 00218 6
   BERNSTEIN HG, 1994, BRAIN RES BULL, V33, P477, DOI 10.1016/0361 9230(94)90071 X
   Blankenvoorde MFJ, 1997, J PERIODONTAL RES, V32, P583, DOI 10.1111/j.1600 0765.1997.tb00935.x
   Blaydon DC, 2011, AM J HUM GENET, V89, P564, DOI 10.1016/j.ajhg.2011.09.001
   Cai XF, 2017, J BONE MINER RES, V32, P2207, DOI 10.1002/jbmr.3205
   Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220
   Chen L, 2015, STEM CELL RES, V15, P281, DOI 10.1016/j.scr.2015.06.009
   Cui X, 2021, BRAIN RES BULL, V166, P21, DOI 10.1016/j.brainresbull.2020.10.006
   Despars G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065297
   El Gazzar A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020625
   Gambari L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176001
   Humphrey MB, 2016, CLIN REV ALLERG IMMU, V51, P48, DOI 10.1007/s12016 015 8521 8
   Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016
   Ibach M, 2021, GLIA, V69, P1126, DOI 10.1002/glia.23953
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kelly JJ, 2019, CURR OPIN ENDOCRINOL, V26, P291, DOI 10.1097/MED.0000000000000507
   Kim Ju Young, 2015, Bone Rep, V3, P83, DOI 10.1016/j.bonr.2015.10.003
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Kubatzky KF, 2018, CYTOKINE, V112, P102, DOI 10.1016/j.cyto.2018.06.013
   Li QQ, 2021, AGING CELL, V20, DOI 10.1111/acel.13301
   Lin X, 2019, MOL CELL ENDOCRINOL, V494, DOI 10.1016/j.mce.2019.110494
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Ma M, 2016, AGING CLIN EXP RES, V28, P1067, DOI 10.1007/s40520 015 0509 y
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Mary DJSJ, 2020, MOL CELL ENDOCRINOL, V504, DOI 10.1016/j.mce.2020.110701
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Paccou J, 2022, CALCIFIED TISSUE INT, V110, P576, DOI 10.1007/s00223 020 00798 w
   Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027
   Paloneva J, 2002, AM J HUM GENET, V71, P656, DOI 10.1086/342259
   Paradowska Gorycka A, 2013, HUM IMMUNOL, V74, P730, DOI 10.1016/j.humimm.2013.02.003
   Park JH, 2017, MOL CELLS, V40, P706
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Shigehara K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030530
   Sowers MR, 2013, J CLIN ENDOCR METAB, V98, P2854, DOI 10.1210/jc.2012 4113
   Stepan JJ, 2019, CURR OSTEOPOROS REP, V17, P465, DOI 10.1007/s11914 019 00549 3
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Weng YT, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101849
   Yang YS, 2020, MOL THER METH CLIN D, V17, P922, DOI 10.1016/j.omtm.2020.04.010
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Zhang Y, 2020, INT J BIOL SCI, V16, P1629, DOI 10.7150/ijbs.41867
   Zhang Y, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005835
   Zhong L, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00204
NR 46
TC 10
Z9 12
U1 2
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 30
PY 2022
VL 627
BP 12
EP 20
DI 10.1016/j.bbrc.2022.08.033
EA AUG 2022
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 5V3RG
UT WOS:000877149500003
PM 36007331
DA 2025 08 17
ER

PT J
AU Terheyden, H
   Lang, NP
   Bierbaum, S
   Stadlinger, B
AF Terheyden, Hendrik
   Lang, Niklaus P.
   Bierbaum, Susanne
   Stadlinger, Bernd
TI Osseointegration   communication of cells
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article
DE angiogenesis; bone morphogenetic proteins; chemokines; cytokines;
   extracellular matrix; growth factors; osseointegration; osteoblast;
   osteoclastogenesis; wound healing
ID HYDROPHOBIC IMPLANT SURFACES; BONE FORMATION ADJACENT; ADSORBED
   PROTEINS; GROWTH FACTORS; NITRIC OXIDE; OSTEOCLASTS; CHEMOTAXIS;
   MECHANISMS; EXPRESSION; DYNAMICS
AB Background The article provides the scientific documentation for the 3D animated film Osseointegration Communication of cells. Aim The aim of this article and of the film is to visualise the molecular and cellular events during the healing of an osseous wound after installation of a dental implant with special emphasis on the process of osseointegration. Material and Results In this review article for didactic reasons the concept of the four phases of a healing soft tissue wound was transferred to a bone wound after insertion of a dental implant: haemostasis, inflammatory phase, proliferative phase and remodelling phase. Wound healing throughout these phases is the result of a coordinated action of different cell types which communicate with each other by their interaction using signalling molecules like cytokines, extracellular matrix proteins and small molecules. A regular sequence of cell types controlled by adequate concentrations of signalling molecules results in undisturbed healing. Disturbed healing is associated with a continuation of the early inflammatory phase and the development of a toxic wound environment. The latter is characterized by high counts of polymorphnuclear cells, high concentrations of toxic radicals and proteolytic enzymes and low concentrations of growth factors and extracellular matrix molecules. Clinically the development of a toxic wound environment should be avoided, e.g. by antibacterial measures. Discussion and Conclusion Experiencing implant osseointegration as a biological process may provide the clinician new targets to improve the therapy with dental implants.
C1 [Terheyden, Hendrik] Red Cross Hosp, Clin Oral & Maxillofacial Surg, Dept Oral & Maxillofacial Surg, D 34121 Kassel, Germany.
   [Lang, Niklaus P.] Univ Hong Kong, Fac Implant Dent, Hong Kong, Hong Kong, Peoples R China.
   [Lang, Niklaus P.] Univ Bern, CH 3012 Bern, Switzerland.
   [Bierbaum, Susanne] Tech Univ Dresden, Max Bergmann Ctr Biomat, Dresden, Germany.
   [Stadlinger, Bernd] Univ Zurich, Clin Craniomaxillofacial & Oral Surg, CH 8006 Zurich, Switzerland.
C3 University of Hong Kong; University of Bern; Technische Universitat
   Dresden; University of Zurich
RP Terheyden, H (通讯作者)，Red Cross Hosp, Clin Oral & Maxillofacial Surg, Dept Oral & Maxillofacial Surg, Hansteinstr 29, D 34121 Kassel, Germany.
EM terheyden@rkh kassel.de
RI Terheyden, Hendrik/HDM 7610 2022; Lang, Niklaus/B 2154 2009
OI Stadlinger, Bernd/0000 0001 5044 7052; Terheyden,
   Hendrik/0000 0002 0709 114X; Lang, Niklaus Peter/0000 0002 6938 9611
FU Astratech, Elz, Germany
FX The authors thank Alexander Ammann from Quintessence Publishers (Berlin,
   Germany) who initiated the film project and produced the film. The
   authors thank Prof Dr Christoph Hammerle and Prof Dr Thomas Hoffmann,
   for their function in the scientific advisory board of the film project.
   This work was performed in consultation with scientists of the research
   project SFB Transregio 67 of the German Research Foundation   DFG. The
   authors thank the team of iAS interActive Systems GmbH, Berlin Germany,
   chaired by Marco Reschke for digital graphical artwork. A special thank
   is given to Dieter Bosshardt, Giovanni Salvi, Nikos Donos and Saso
   Ivanovski for the provision of the histological figures and Fig. 8. The
   project was sponsored by Astratech, Elz, Germany.
CR Abrahamsson I, 2004, CLIN ORAL IMPLAN RES, V15, P381, DOI 10.1111/j.1600 0501.2004.01082.x
   Asano M, 2011, ORAL DIS, V17, P489, DOI 10.1111/j.1601 0825.2010.01780.x
   Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600 0501.2003.00972.x
   Bosco MC, 2008, IMMUNOBIOLOGY, V213, P733, DOI 10.1016/j.imbio.2008.07.031
   Bosshardt DD, 2011, CLIN ORAL IMPLAN RES, V22, P357, DOI 10.1111/j.1600 0501.2010.02107.x
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2006, NAT MED, V12, P1356, DOI 10.1038/nm1206 1356
   Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Cölfen H, 2010, NAT MATER, V9, P960, DOI 10.1038/nmat2911
   Colopy SA, 2004, BONE, V35, P881, DOI 10.1016/j.bone.2004.05.024
   Corselli M, 2010, ARTERIOSCL THROM VAS, V30, P1104, DOI 10.1161/ATVBAHA.109.191643
   Degidi Marco, 2003, Clin Implant Dent Relat Res, V5, P89, DOI 10.1111/j.1708 8208.2003.tb00189.x
   Donos N, 2011, CLIN ORAL IMPLAN RES, V22, P365, DOI 10.1111/j.1600 0501.2010.02113.x
   Dossa T, 2010, J CELL BIOCHEM, V110, P960, DOI 10.1002/jcb.22609
   Ferencyk M., 2006, KOMPENDIUM IMMUNOLOG
   Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498
   Garimella R, 2008, J HISTOCHEM CYTOCHEM, V56, P569, DOI 10.1369/jhc.2008.950394
   Golub EE, 2009, BBA GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   Graves DT, 2011, J DENT RES, V90, P143, DOI 10.1177/0022034510385236
   Gray C, 1996, BONE, V18, P115, DOI 10.1016/8756 3282(95)00456 4
   Hitchon C, 2002, ARTHRITIS RHEUM, V46, P2587, DOI 10.1002/art.10520
   Ivanovski S, 2011, CLIN ORAL IMPLAN RES, V22, P373, DOI 10.1111/j.1600 0501.2010.02112.x
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P677, DOI 10.1189/jlb.0506309
   Lang NP, 2011, CLIN ORAL IMPLAN RES, V22, P349, DOI 10.1111/j.1600 0501.2011.02172.x
   Lansdown ABG, 2002, WOUND REPAIR REGEN, V10, P271, DOI 10.1046/j.1524 475X.2002.10502.x
   Lansdown ABG, 2001, INT J EXP PATHOL, V82, P35, DOI 10.1046/j.1365 2613.2001.00180.x
   Lee MH, 2010, BIOMATERIALS, V31, P3804, DOI 10.1016/j.biomaterials.2010.01.117
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Midwood KS, 2004, INT J BIOCHEM CELL B, V36, P1031, DOI 10.1016/j.biocel.2003.12.003
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood 2004 03 1109
   Nakanishi K, 2001, J BIOSCI BIOENG, V91, P233, DOI 10.1016/S1389 1723(01)80127 4
   Nguyen DT, 2009, WOODHEAD PUBL MATER, P25, DOI 10.1533/9781845695545.1.25
   Olszta MJ, 2007, MAT SCI ENG R, V58, P77, DOI 10.1016/j.mser.2007.05.001
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Perkins DJ, 1999, J LEUKOCYTE BIOL, V65, P792, DOI 10.1002/jlb.65.6.792
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092 8674(91)90308 L
   Santos A, 2009, OSTEOPOROSIS INT, V20, P1027, DOI 10.1007/s00198 009 0858 5
   Schenk RK, 1998, PERIODONTOL 2000, V17, P22, DOI 10.1111/j.1600 0757.1998.tb00120.x
   Schultz GS, 2009, WOUND REPAIR REGEN, V17, P153, DOI 10.1111/j.1524 475X.2009.00466.x
   Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821
   Stadelmann WK, 1998, AM J SURG, V176, p39S, DOI 10.1016/S0002 9610(98)00184 6
   Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Tate MLK, 2003, J BIOMECH, V36, P1409, DOI 10.1016/S0021 9290(03)00123 4
   Temiyasathit S, 2010, ANN NY ACAD SCI, V1192, P422, DOI 10.1111/j.1749 6632.2009.05243.x
   ten Dijke P, 2008, J BONE JOINT SURG AM, V90A, P31, DOI 10.2106/JBJS.G.01183
   Turner CH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268pt3
   Väänänen HK, 2000, J CELL SCI, V113, P377
   VROMAN L, 1962, NATURE, V196, P476, DOI 10.1038/196476a0
   Vukicevic S, 2009, CYTOKINE GROWTH F R, V20, P441, DOI 10.1016/j.cytogfr.2009.10.020
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wierzbicka Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670
   Wilson CJ, 2005, TISSUE ENG, V11, P1, DOI 10.1089/ten.2005.11.1
   Witte MB, 2002, AM J SURG, V183, P406, DOI 10.1016/S0002 9610(02)00815 2
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
NR 64
TC 204
Z9 230
U1 3
U2 61
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0905 7161
EI 1600 0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD OCT
PY 2012
VL 23
IS 10
BP 1127
EP 1135
DI 10.1111/j.1600 0501.2011.02327.x
PG 9
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Engineering
GA 008DW
UT WOS:000308938600001
PM 22092345
DA 2025 08 17
ER

PT J
AU Folestad, A
   Ålund, M
   Asteberg, S
   Fowelin, J
   Aurell, Y
   Göthlin, J
   Cassuto, J
AF Folestad, Agnetha
   Alund, Martin
   Asteberg, Susanne
   Fowelin, Jesper
   Aurell, Ylva
   Gothlin, Jan
   Cassuto, Jean
TI Role of Wnt/β catenin and RANKL/OPG in bone healing of diabetic Charcot
   arthropathy patients A prospective study in 24 patients followed for 2
   years
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID PLASMA OSTEOPROTEGERIN CONCENTRATIONS; RECEPTOR ACTIVATOR; METAPHYSEAL
   BONE; SCLEROSTIN; DICKKOPF 1; NEUROARTHROPATHY; NEUROPATHY; MELLITUS;
   FRACTURE; LIGAND
AB Background and purpose   Charcot neuropathy is characterized by bone destruction in a foot leading to deformity, instability, and risk of amputation. Little is known about the pathogenic mechanisms. We hypothesized that the bone regulating Wnt/beta catenin and RANKL/OPG pathways have a role in Charcot arthropathy.
   Patients and methods   24 consecutive Charcot patients were treated by off loading, and monitored for 2 years by repeated foot radiography, MRI, and circulating levels of sclerostin, dickkopf 1, Wnt inhibitory factor 1, Wnt ligand 1, OPG, and RANKL. 20 neuropathic diabetic controls and 20 healthy controls served as the reference.
   Results   Levels of sclerostin, Dkk 1 and Wnt 1, but not of Wif 1, were significantly lower in Charcot patients than in the diabetic controls at inclusion. Dkk 1 and Wnt 1 levels responded to off loading by increasing. Sclerostin levels were significantly higher in the diabetic controls than in the other groups whereas Wif 1 levels were significantly higher in the healthy controls than in the other groups. OPG and RANKL levels were significantly higher in the Charcot patients than in the other groups at inclusion, but decreased to the levels in healthy controls at 2 years. OPG/RANKL ratio was balanced in all groups at inclusion, and it remained balanced in Charcot patients on repeated measurement throughout the study.
   Interpretation   High plasma RANKL and OPG levels at diagnosis of Charcot suggest that there is high bone remodeling activity before gradually normalizing after off loading treatment. The consistently balanced OPG/RANKL ratio in Charcot patients suggests that there is low key net bone building activity by this pathway following diagnosis and treatment. Inter group differences at diagnosis and changes in Wnt signaling following off loading treatment were sufficiently large to be reflected by systemic levels, indicating that this pathway has a role in bone remodeling and bone repair activity in Charcot patients. This is of particular clinical relevance considering the recent emergence of promising drugs that target this system.
C1 [Folestad, Agnetha] CapioLundby Hosp, Dept Orthoped Surg, Gothenburg, Sweden.
   [Alund, Martin; Asteberg, Susanne] Sahlgrens Univ Hosp, Dept Orthoped Surg, Molndal, Sweden.
   [Fowelin, Jesper] Frolunda Specialist Hosp, Dept Med, Diabet Care Unit, Vastra Frolunda, Sweden.
   [Aurell, Ylva; Gothlin, Jan] Sahlgrens Univ Hosp, Dept Radiol, Molndal, Sweden.
   [Cassuto, Jean] Sahlgrens Univ Hosp, Orthoped Res Unit, Molndal, Sweden.
   [Cassuto, Jean] Univ Gothenburg, Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital;
   Sahlgrenska University Hospital; University of Gothenburg
RP Cassuto, J (通讯作者)，Sahlgrens Univ Hosp, Dept Radiol, Molndal, Sweden.
EM jean.cassuto@aniv.gu.se
RI Aurell, Ylva/H 4540 2019
FU Vastra Gotaland Region (VGRFOU) [306311, 374761, 478171]
FX The study was supported financially by the Vastra Gotaland Region
   (VGRFOU, grants 306311, 374761, and 478171).
CR Agholme F, 2014, J ORTHOP RES, V32, P471, DOI 10.1002/jor.22525
   Agholme F, 2011, ACTA ORTHOP, V82, P125, DOI [10.3109/17453674.2011.572252, 10.3109/17453674.2011.625539]
   Agholme F, 2011, BONE, V48, P988, DOI 10.1016/j.bone.2011.02.008
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Arasu A, 2012, J CLIN ENDOCR METAB, V97, P2027, DOI 10.1210/jc.2011 3419
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bjerre M, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193 1801 2 658
   Chantelau E, 2007, ARCH ORTHOP TRAUM SU, V127, P171, DOI 10.1007/s00402 006 0271 x
   Chantelau EA, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13948
   Daoussis D, 2011, SEMIN ARTHRITIS RHEU, V41, P170, DOI 10.1016/j.semarthrit.2011.01.006
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Gaudio A, 2014, DIABETES VASC DIS RE, V11, P48, DOI 10.1177/1479164113510923
   Gaudio A, 2012, J CLIN ENDOCR METAB, V97, P3744, DOI 10.1210/jc.2012 1901
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Gouveri E, 2011, WORLD J DIABETES, V2, P59, DOI 10.4239/wjd.v2.i5.59
   Jeffcoate W, 2008, CLIN PODIATR MED SUR, V25, pvi
   Jeffcoate William, 2008, Clin Podiatr Med Surg, V25, P29, DOI 10.1016/j.cpm.2007.10.003
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Klejna K, 2009, FOLIA HISTOCHEM CYTO, V47, P199, DOI 10.2478/v10042 009 0035 x
   Kohli Sarvraj Singh, 2011, Indian J Endocrinol Metab, V15, P175, DOI 10.4103/2230 8210.83401
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Mabilleau G, 2008, DIABETOLOGIA, V51, P1035, DOI 10.1007/s00125 008 0992 1
   Macias BR, 2013, BONE, V53, P515, DOI 10.1016/j.bone.2013.01.018
   Mascarenhas JV, 2013, MED CLIN N AM, V97, P857, DOI 10.1016/j.mcna.2013.05.002
   Ndip A, 2011, DIABETES, V60, P2187, DOI 10.2337/db10 1220
   Nybo M, 2010, DIABETIC MED, V27, P289, DOI 10.1111/j.1464 5491.2010.02940.x
   Papanas N, 2013, DIABET FOOT ANKLE, P4
   Rogers A, 2005, J CLIN ENDOCR METAB, V90, P6323, DOI 10.1210/jc.2005 0794
   Samuelsson P, 1996, CLIN PHYSIOL, V16, P463, DOI 10.1111/j.1475 097X.1996.tb00733.x
   Sapir Koren R, 2014, OSTEOPOROSIS INT, V25, P2685, DOI 10.1007/s00198 014 2808 0
   Sella E J, 1999, J Foot Ankle Surg, V38, P34
   Stock M, 2013, ARTHRITIS RHEUM US, V65, P2310, DOI 10.1002/art.38054
   Terekeci HM, 2009, EXP CLIN ENDOCR DIAB, V117, P119, DOI 10.1055/s 0028 1085425
   Thambiah S, 2012, CALCIFIED TISSUE INT, V90, P473, DOI 10.1007/s00223 012 9595 4
   Viapiana O, 2013, CALCIFIED TISSUE INT, V92, P324, DOI 10.1007/s00223 012 9665 7
   Wilson Carol, 2013, Nat Rev Endocrinol, V9, P377, DOI 10.1038/nrendo.2013.105
NR 38
TC 45
Z9 50
U1 1
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1745 3674
EI 1745 3682
J9 ACTA ORTHOP
JI Acta Orthop.
PD AUG
PY 2015
VL 86
IS 4
BP 415
EP 425
DI 10.3109/17453674.2015.1033606
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA CO4CC
UT WOS:000359106700005
PM 25811776
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lau, KHW
   Kothari, V
   Das, A
   Zhang, XB
   Baylink, DJ
AF Lau, K.  H. William
   Kothari, Vishal
   Das, Amitava
   Zhang, Xiao Bing
   Baylink, David J.
TI Cellular and molecular mechanisms of accelerated fracture healing by
   COX2 gene therapy Studies in a mouse model of multiple fractures
SO BONE
LA English
DT Article
DE COX2; Gene therapy; Fracture healing; Angiogenesis; Cartilage
   remodeling; Mesenchymal stem cells
ID MESENCHYMAL STEM CELLS; PARATHYROID HORMONE 1 34; IN VIVO; PROSTAGLANDIN
   E 2; FEMORAL FRACTURES; BONE FORMATION; GROWTH FACTORS; REPAIR;
   EXPRESSION; RATS
AB This study sought to determine the cellular and molecular mechanisms of cyclooxygenase 2 (COX2) gene therapy to accelerate fracture repair in a mouse multiple tibial fractures model. The lenti COX2 (or lenti gfp control vector) was injected into fractures on day 1 post fracture. At days 3 7, the COX2 treatment increased Sdf1 , Cxcr4 , Nes , and Podxl expressing mesenchymal stem cells (MSCs) within fracture calluses, suggesting an enhanced MSC recruitment or expansion. The COX2 treated mice formed smaller cartilaginous calluses that had less cartilage tissues than control mice. The expression of Sox9 mRNA was 7 fold less in COX2 treated than in control calluses at day 14, implying that COX2 reduces chondrocytic differentiation of MSCs. The therapy also enhanced angiogenesis as reflected by increased immunostaining of CD31, vWF, and alpha SMA over controls in the cartilaginous callus at day 14 21. At which time, the COX2 gene therapy promoted bony remodeling of the cartilaginous callus to bridge the fracture gap that was accompanied by 2 fold increase in osteoclasts along the surface of the woven bone and an onset of osteogenesis. Blocking angiogenesis with daily injection of endostatin from day 4 to day 10 into fracture sites blocked the COX2 mediated reduction of callus size that was associated with an increase in hypertrophic chondrocytes and concomitant reduction in osteoclasts. In conclusion, COX2 accelerates fracture healing in part through three biological actions: 1) increased recruitment/expansion of MSCs; 2) decreased cartilaginous callus formation; and 3) increased angiogenesis dependent cartilage remodeling. These effects were associated with an earlier onset of bony bridging of the fracture gap. Published by Elsevier Inc.
C1 [Lau, K.  H. William; Kothari, Vishal; Das, Amitava; Zhang, Xiao Bing; Baylink, David J.] Loma Linda Univ, Sch Med, Dept Med, Div Regenerat Med, Loma Linda, CA 92350 USA.
   [Lau, K.  H. William] Jerry L Pettis Mem VA Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA.
C3 Loma Linda University
RP Lau, KHW (通讯作者)，Jerry L Pettis Mem VA Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.
EM William.Lau@med.va.gov
RI ; Das, Amitava/AAJ 5682 2020
OI Das, Amitava/0000 0002 7510 1805; Lau, Kin Hing/0000 0003 1109 5052;
   Kothari, Vishal/0000 0001 7453 1435
FU Telemedicine and Advanced Technology Research Center (TATRC) at the US
   Army Medical Research and Material Command (USAMRMC) [W81XWH 12 1 0023]
FX This work is supported by the Telemedicine and Advanced Technology
   Research Center (TATRC) at the US Army Medical Research and Material
   Command (USAMRMC) under Grant No. W81XWH 12 1 0023. The views, opinions
   and/or findings contained in this report are those of the author(s) and
   should not be construed as an official Department of the Army position,
   policy or decision unless so designated by other documentation.
CR Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bhattacharyya T, 2005, ARTHRIT RHEUM ARTHR, V53, P364, DOI 10.1002/art.21170
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Chikazu D, 2011, INT J ORAL MAX SURG, V40, P322, DOI 10.1016/j.ijom.2010.10.011
   Draper ERC, 2003, J BIOMECH, V36, P1497, DOI 10.1016/S0021 9290(03)00129 5
   Eckardt H, 2005, J BONE JOINT SURG BR, V87B, P1434, DOI 10.1302/0301 620X.87B10
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P1425, DOI 10.2106/00004623 200308000 00002
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   EKELAND A, 1982, ACTA ORTHOP SCAND, V53, P527, DOI 10.3109/17453678208992252
   Gerstenfeld L. C., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P297
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Hannouche D, 2001, J BONE JOINT SURG BR, V83B, P157, DOI 10.1302/0301 620X.83B2.12106
   HILTUNEN A, 1993, J ORTHOP RES, V11, P305, DOI 10.1002/jor.1100110219
   JINGUSHI S, 1990, J ORTHOP RES, V8, P364, DOI 10.1002/jor.1100080308
   JOYCE ME, 1990, ORTHOP CLIN N AM, V21, P199
   Kawaguchi H, 2001, J CLIN ENDOCR METAB, V86, P875, DOI 10.1210/jc.86.2.875
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020 1383(08)70015 9
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Kumar S, 2012, BONE, V50, P1012, DOI 10.1016/j.bone.2012.01.027
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Manigrasso MB, 2004, J ORTHOP TRAUMA, V18, P687, DOI 10.1097/00005131 200411000 00006
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Meyer RA, 2003, J BONE JOINT SURG AM, V85A, P1243, DOI 10.2106/00004623 200307000 00010
   Meyer RA, 2001, J ORTHOP RES, V19, P428, DOI 10.1016/S0736 0266(00)90034 2
   Moalic S, 2001, INT J ONCOL, V18, P533
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   O'Neill KR, 2012, BONE, V50, P1357, DOI 10.1016/j.bone.2012.03.008
   Oteo Alvaro Angel, 2010, J Shoulder Elbow Surg, V19, pe22, DOI 10.1016/j.jse.2010.05.005
   Panagiotis M, 2005, INJURY, V36, pS30, DOI 10.1016/j.injury.2005.10.008
   Paralkar VM, 2002, J CELL PHYSIOL, V190, P207, DOI 10.1002/JCP.10048
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Rubery PT, 2010, J SPINAL DISORD TECH, V23, P151, DOI 10.1097/BSD.0b013e31819a8b7a
   Rundle CH, 2003, BONE, V32, P591, DOI 10.1016/S8756 3282(03)00096 6
   Rundle CH, 2008, J GENE MED, V10, P229, DOI 10.1002/jgm.1148
   Sato Yutaka, 1997, Journal of Medical and Dental Sciences, V44, P81
   Seebach C, 2007, CALCIFIED TISSUE INT, V80, P294, DOI 10.1007/s00223 007 9020 6
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Tägil M, 2010, BONE, V46, P852, DOI 10.1016/j.bone.2009.11.009
   Terry Canale S., 2003, CAMPBELLS OPERATIVE, V10th
   von Rahden BHA, 2005, CANCER RES, V65, P5038, DOI 10.1158/0008 5472.CAN 04 1107
   Xu Z, 2007, BONE, V41, P68, DOI 10.1016/j.bone.2007.03.009
   Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 49
TC 27
Z9 29
U1 2
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2013
VL 53
IS 2
BP 369
EP 381
DI 10.1016/j.bone.2013.01.003
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 101GR
UT WOS:000315763700007
PM 23314071
DA 2025 08 17
ER

PT J
AU Vogg, B
   Poetzl, J
   El Galta, R
   Fuhr, R
   Schwebig, A
   Sekhar, S
AF Vogg, Barbara
   Poetzl, Johann
   El Galta, Rachid
   Fuhr, Rainard
   Schwebig, Arnd
   Sekhar, Susmit
TI Pharmacokinetics and pharmacodynamics of the proposed biosimilar
   denosumab GP2411 and reference denosumab in healthy males
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Biosimilar; denosumab; GP2411; immunogenicity; pharmacodynamics;
   pharmacokinetics; phase I; safety
ID BONE TURNOVER MARKERS; MEN
AB Background: This Phase I study compared the pharmacokinetic (PK) and pharmacodynamic (PD) similarity of GP2411 proposed denosumab biosimilar to reference denosumab (a monoclonal antibody for specific pro resorptive conditions). Research design and methods: Healthy males (28 65 years, 50 90 kg) were randomized to a single sub therapeutic subcutaneous injection of 35 mg GP2411, EU Xgeva (R) or US Xgeva (R), and followed for 39 weeks. The primary endpoints were AUC(inf), AUC(last), and C max. Results: Four hundred ninety two participants completed treatment. The 90% confidence intervals (CIs) (AUC(inf), AUC(last), and C max) and 95% CI of the geometric mean ratios of AUEC of % change from baseline in serum CTX were fully contained within the prespecified equivalence margins (0.80, 1.25), demonstrating similarity. The occurrence of treatment emergent adverse events (TEAEs) with GP2411, EU Xgeva (R) and US Xgeva (R) was similar (72.9%, 76.0%, and 71.0% of participants, respectively). Most were Grade 1 or 2, <30% were treatment related, and there was only one TEAE related study discontinuation. Rates of positive anti drug antibodies (ADAs) were similar (57.8%, 64.9%, and 69.1% of participants respectively), but immunogenicity was only borderline detectable and of very low magnitude. Ninety nine percent of positive ADAs were transient. Conclusion: GP2411 demonstrated similarity with EU Xgeva (R) and US Xgeva (R) in PK, PD, safety, and immunogenicity in this population.
C1 [Vogg, Barbara; Poetzl, Johann; El Galta, Rachid; Schwebig, Arnd; Sekhar, Susmit] Hexal AG, Clin Dev Biopharmaceut, Industriestr 25, D 83607 Holzkirchen, Germany.
   [Fuhr, Rainard] Parexel Int GmbH, Early Phase Clin Unit, Berlin, Germany.
C3 Hexal AG; Parexel International
RP Vogg, B (通讯作者)，Hexal AG, Clin Dev Biopharmaceut, Industriestr 25, D 83607 Holzkirchen, Germany.
EM barbara.vogg@sandoz.com
RI El Galta, Rachid/JWP 5173 2024
FU Hexal AG, Holzkirchen, Germany [16_suppl, (2023) e14500 e14500]; Hexal
   AG, Holzkirchen, Germany
FX We thank the people who participated in this study. Medical writing
   assistance was provided by Syneos Health Medical Communications, and
   funded by Hexal AG, Holzkirchen, Germany. Data from this study was
   previously presented in summary form at the 2023 ASCO Annual Meeting I,
   held from 2 to 6 June in Chicago. The corresponding abstract was
   published in Journal of Clinical Oncology: Vogg B, Poetzl J, El Galta R,
   Fuhr R, Schwebig A, and Sekhar S. Pharmacokinetics and pharmacodynamics
   of proposed denosumab biosimilar and reference denosumab in healthy male
   subjects. DOI: 10.1200/JCO.2023.41.16_suppl.e14500 Journal of Clinical
   Oncology 41, no. 16_suppl (June 01, 2023) e14500 e14500. Published
   online May 31, 2023.
CR Amgen Inc, 2020, XGEV US PI
   [Anonymous], 2015, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Elango J, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155559
   EMA, 2016, XGEV EU SMPC
   EMA, 2020, PROL EU SMPC
   EMA, 2023, ICH GUID M10 BIOAN M
   European Medicines Agency, 2014, GUID SIM BIOL MED PR
   European Medicines Agency (EMA), 2012, GUIDELINE BIOANALYTI
   FDA, 2022, XGEV DEN US PACK INS
   FDA, 2018, Bioanalytical method validation guidance for Industry
   FDA, 2019, IMMUNOGENICITY TESTI
   FDA, IMM INF HUM PRESCR T
   FDA. Prolia (denosumab) [US package insert], 2023, PROL DEN PACK INS
   Franconi F, 2014, BRIT J PHARMACOL, V171, P580, DOI 10.1111/bph.12362
   Gandhi M, 2004, ANNU REV PHARMACOL, V44, P499, DOI 10.2165/00003088 200948030 00001
   García JJ, 2020, TRANSL LUNG CANCER R, V9, P2113, DOI 10.21037/tlcr 20 601
   Hou J, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108666
   Humphreys SZ, 2022, FUTURE ONCOL, V18, P1997, DOI 10.2217/fon 2021 1584
   Jeka S., 2023, WORLD C OST OST MUSC, pOCT4
   Jeka S., 2023, WORLD C OST OST MUSC, pP303
   Joshi D, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122721
   Karnon J, 2016, COST EFFECT RESOUR A, V14, DOI 10.1186/s12962 016 0060 5
   Lin YQ, 2022, EXPERT OPIN INV DRUG, V31, P1125, DOI 10.1080/13543784.2022.2123737
   Matsumoto T, 2021, J BONE MINER METAB, V39, P91, DOI 10.1007/s00774 020 01153 7
   Michelsen J, 2013, BONE, V57, P399, DOI 10.1016/j.bone.2013.09.010
   Nakamura T, 2012, OSTEOPOROSIS INT, V23, P1131, DOI 10.1007/s00198 011 1786 8
   SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Szulc P, 2017, OSTEOPOROSIS INT, V28, P2541, DOI 10.1007/s00198 017 4082 4
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zhang Y, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1063815
   Zheng J, 2015, J PHARMACOKINET PHAR, V42, P333, DOI 10.1007/s10928 015 9422 4
NR 34
TC 5
Z9 5
U1 1
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD FEB 1
PY 2024
VL 24
IS 1 2
BP 91
EP 100
DI 10.1080/14712598.2024.2308645
EA JAN 2024
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA IA1U6
UT WOS:001152003200001
PM 38269652
OA hybrid
DA 2025 08 17
ER

PT J
AU Chandra, A
   Lagnado, AB
   Farr, JN
   Monroe, DG
   Park, S
   Hachfeld, C
   Tchkonia, T
   Kirkland, JL
   Khosla, S
   Passos, JF
   Pignolo, RJ
AF Chandra, Abhishek
   Lagnado, Anthony B.
   Farr, Joshua N.
   Monroe, David G.
   Park, Sean
   Hachfeld, Christine
   Tchkonia, Tamar
   Kirkland, James L.
   Khosla, Sundeep
   Passos, Joao F.
   Pignolo, Robert J.
TI Targeted Reduction of Senescent Cell Burden Alleviates Focal
   Radiotherapy Related Bone Loss
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; RADIOTHERAPY; SENESCENCE; SENOLYTICS; TELOMERE DYSFUNCTION
ID OSTEOCLAST FORMATION; SECRETORY PHENOTYPE; DNA DAMAGE; IRRADIATION;
   OSTEOBLAST; DYSFUNCTION; MARROW; REPAIR
AB Clinical radiotherapy treats life threatening cancers, but the radiation often affects neighboring normal tissues including bone. Acute effects of ionizing radiation include oxidative stress, DNA damage, and cellular apoptosis. We show in this study that a large proportion of bone marrow cells, osteoblasts, and matrix embedded osteocytes recover from these insults only to attain a senescent profile. Bone analyses of senescence associated genes, senescence associated beta galactosidase (SA beta gal) activity, and presence of telomere dysfunction induced foci (TIF) at 1, 7, 14, 21, and 42 days post focal radiation treatment (FRT) in C57BL/6 male mice confirmed the development of senescent cells and the senescence associated secretory phenotype (SASP). Accumulation of senescent cells and SASP markers were correlated with a significant reduction in bone architecture at 42 days post FRT. To test if senolytic drugs, which clear senescent cells, alleviate FRT related bone damage, we administered the senolytic agents, dasatinib (D), quercetin (Q), fisetin (F), and a cocktail of D and Q (D+Q). We found moderate alleviation of radiation induced bone damage with D and Q as stand alone compounds, but no such improvement was seen with F. However, the senolytic cocktail of D+Q reduced senescent cell burden as assessed by TIF(+)osteoblasts and osteocytes, markers of senescence (p16(Ink4a)andp21), and key SASP factors, resulting in significant recovery in the bone architecture of radiated femurs. In summary, this study provides proof of concept that senescent cells play a role in radiotherapy associated bone damage, and that reduction in senescent cell burden by senolytic agents is a potential therapeutic option for alleviating radiotherapy related bone deterioration. (c) 2020 American Society for Bone and Mineral Research.
C1 [Chandra, Abhishek; Lagnado, Anthony B.; Kirkland, James L.; Passos, Joao F.; Pignolo, Robert J.] Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, 200 First St SW, Rochester, MN 55905 USA.
   [Chandra, Abhishek; Kirkland, James L.; Passos, Joao F.; Pignolo, Robert J.] Mayo Clin, Div Geriatr Med & Gerontol, Dept Med, Coll Med, 200 First St SW, Rochester, MN 55905 USA.
   [Chandra, Abhishek; Lagnado, Anthony B.; Farr, Joshua N.; Monroe, David G.; Hachfeld, Christine; Tchkonia, Tamar; Kirkland, James L.; Khosla, Sundeep; Passos, Joao F.; Pignolo, Robert J.] Mayo Clin, Coll Med, Robert & Arlene Kogod Ctr Aging, Rochester, MN USA.
   [Farr, Joshua N.; Monroe, David G.; Khosla, Sundeep; Pignolo, Robert J.] Mayo Clin, Coll Med, Div Endocrinol, Dept Med, Rochester, MN USA.
   [Park, Sean] Mayo Clin, Coll Med, Dept Radiat Oncol, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Chandra, A; Pignolo, RJ (通讯作者)，Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, 200 First St SW, Rochester, MN 55905 USA.; Chandra, A; Pignolo, RJ (通讯作者)，Mayo Clin, Div Geriatr Med & Gerontol, Dept Med, Coll Med, 200 First St SW, Rochester, MN 55905 USA.
EM chandra.abhishek1@mayo.edu; pignolo.robert@mayo.edu
RI ; Khosla, Sundeep/AAE 6170 2020; Chandra, Anchal/AAT 5644 2021; Passos,
   Joao/LTF 6572 2024; Kirkland, James/F 9159 2016; Farr,
   Joshua/B 3355 2011
OI Passos, Joao/0000 0001 8765 1890; Farr, Joshua/0000 0002 3179 6414;
   Monroe, David/0000 0002 4818 0114; Khosla, Sundeep/0000 0002 2936 4372;
   Chandra, Abhishek/0000 0001 9423 9669; 
FU BBSRC [BB/H022384/1, BB/K017314/1] Funding Source: UKRI; Biotechnology
   and Biological Sciences Research Council [BB/H022384/1] Funding Source:
   Medline; NCATS NIH HHS [UL1TR002377, UL1 TR000135, UL1 TR002377] Funding
   Source: Medline; NIAMS NIH HHS [K01 AR070241, R01 AR068275] Funding
   Source: Medline; NIA NIH HHS [P01 AG004875, R01 AG048792, R56 AG063707,
   P01 AG062413, R01 AG013925] Funding Source: Medline; NIH HHS [P01
   AG062413, K01 AR070241, R01 AR068275, R01 AG048792, P01 AG004875, R01 AG
   013925, UL1TR000135] Funding Source: Medline; Biotechnology and
   Biological Sciences Research Council [BB/K017314/1, BB/H022384/1]
   Funding Source: researchfish
CR Almeida Porada G, 2018, STEM CELLS DEV, V27, P1237, DOI 10.1089/scd.2018.0005
   Anderson R, 2019, EMBO J, V38, DOI 10.15252/embj.2018100492
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chandra A, 2019, BONE, V120, P423, DOI 10.1016/j.bone.2018.12.006
   Chandra A, 2018, FASEB J, V32, P52, DOI 10.1096/fj.201700375R
   Chandra A, 2017, J BONE MINER RES, V32, P360, DOI 10.1002/jbmr.2996
   Chandra A, 2015, J BIOL CHEM, V290, P157, DOI 10.1074/jbc.M114.608158
   Chandra A, 2014, BONE, V67, P33, DOI 10.1016/j.bone.2014.06.030
   Chandra ARA, 2018, OSTEOBIOLOGY AGING, P3
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Coppé JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009188
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Fumagalli M, 2012, NAT CELL BIOL, V14, P355, DOI 10.1038/ncb2466
   Hamilton SA, 2006, J APPL PHYSIOL, V101, P789, DOI 10.1152/japplphysiol.01078.2005
   Hewitt G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1708
   Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069
   Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013
   Muralidharan S, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00231
   Oest ME, 2015, J ORTHOP RES, V33, P334, DOI 10.1002/jor.22761
   Özcan S, 2016, AGING US, V8, P1316, DOI 10.18632/aging.100971
   Pereira BI, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10335 5
   Rodrigues Moreira S, 2017, CELL REP, V20, P3199, DOI 10.1016/j.celrep.2017.09.013
   Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458
   Schafer MJ, 2017, MOL CELL ENDOCRINOL, V455, P93, DOI 10.1016/j.mce.2016.08.047
   SCHEVEN BAA, 1987, RADIAT RES, V111, P107, DOI 10.2307/3577026
   SCHEVEN BAA, 1987, BONE MINER, V2, P291
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Singh L, 2016, BONE, V85, P29, DOI 10.1016/j.bone.2016.01.014
   So EY, 2014, CANCER BIOL THER, V15, P906, DOI 10.4161/cbt.28883
   Wang HT, 2012, AGING CELL, V11, P704, DOI 10.1111/j.1474 9726.2012.00838.x
   Wang Y, 2006, CELL CYCLE, V5, P35, DOI 10.4161/cc.5.1.2280
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591 018 0092 9
   Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112
   Yousefzadeh MJ, 2018, EBIOMEDICINE, V36, P18, DOI 10.1016/j.ebiom.2018.09.015
   Zhu Y, 2017, AGING US, V9, P955, DOI 10.18632/aging.101202
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 42
TC 87
Z9 93
U1 0
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2020
VL 35
IS 6
BP 1119
EP 1131
DI 10.1002/jbmr.3978
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LX6GO
UT WOS:000539928200013
PM 32023351
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Zhao, RH
   Luo, JH
   Chung, SK
   Xu, BJ
AF Zhao, Ruohan
   Luo, Jinhai
   Chung, Sookja Kim
   Xu, Baojun
TI Anti depression molecular mechanism elucidation of the phytochemicals in
   edible flower of Hemerocallis citrina Baroni
SO FOOD SCIENCE & NUTRITION
LA English
DT Article
DE core targets; depression; Hemerocallis citrina Baroni;
   molecular docking; network pharmacology
ID ETHANOL EXTRACTS; CHAIGUI GRANULES; BEHAVIOR; ANXIETY;
   LIPOPOLYSACCHARIDE; PHARMACOLOGY; INFLAMMATION; MEDIATORS; SYSTEMS;
   STRESS
AB The edible flower of Hemerocallis citrina Baroni, commonly known as "Huang Huacai" in China, has anti depressant effects. However, targets and molecular mechanisms of Hemerocallis citrina Baroni edible flowers (HEF) in depression treatment are still unclear. The potential anti depression targets in HEF were identified by the intersecting results from typical drug databases. The network construction and Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analysis were carried out for core targets. The molecular docking was conducted to predict the binding affinity between the active components and the central targets. The intersecting results indicated that there were 24 active components in HEF, with 449 anti depression targets identified. After screening through degree centrality (DC), betweenness centrality (BC), and closeness centrality (CC), 166 core targets were determined. Tumor protein 53 (TP53) and interleukin 6 (IL 6) had the highest degree values. The results of GO enrichment analysis associated with anti depression revealed that the biological processes were negative regulation of osteoclast differentiation and positive regulation of phosphorus metabolic process. KEGG enrichment analysis results revealed that pathways, such as the phosphatidylinositol 3 kinase protein kinase B (PI3K Akt) signaling pathway and mitogen activated protein kinase (MAPK) signaling pathway, were primarily associated with anti depression. Molecular docking results indicated that the top 10 active ingredients in HEF could bind to the central targets. This study applied network pharmacology to unveil the potential anti depressive mechanisms of HEF, providing a theoretical basis for further exploration of the effective components in H. citrina edible flower parts.
C1 [Zhao, Ruohan; Luo, Jinhai; Xu, Baojun] BNU HKBU United Int Coll, Dept Life Sci, Food Sci & Technol Program, 2000 Jintong Rd, Zhuhai 519087, Guangdong, Peoples R China.
   [Chung, Sookja Kim] Macau Univ Sci & Technol, Fac Med, Macau, Peoples R China.
C3 Beijing Normal University   Hong Kong Baptist University United
   International College; Macau University of Science & Technology
RP Xu, BJ (通讯作者)，BNU HKBU United Int Coll, Dept Life Sci, Food Sci & Technol Program, 2000 Jintong Rd, Zhuhai 519087, Guangdong, Peoples R China.; Chung, SK (通讯作者)，Macau Univ Sci & Technol, Fac Med, Macau, Peoples R China.
EM skchung@must.edu.mo; baojunxu@uic.edu.cn
RI ; Xu, Baojun/B 7971 2017; LUO, Jinhai/JEF 2316 2023
OI LUO, Jinhai/0000 0003 0183 160X; Xu, Baojun/0000 0003 0739 3735; 
FU BNU HKBU United International College [UICR0400015  24, UICR0400016 24]
FX BNU  HKBU United International College, Grant/Award Number: UICR0400015 
   24 and UICR0400016 24
CR Aher A, 2020, CURR COMPUT AID DRUG, V16, P641, DOI 10.2174/1573409915666190902142524
   Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS12, DOI 10.2337/dc08 S012
   Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024
   Bai RB, 2020, FOOD FUNCT, V11, P3306, DOI [10.1039/c9fo02969a, 10.1039/C9FO02969A]
   Bai YT, 2018, STEROIDS, V135, P73, DOI 10.1016/j.steroids.2018.03.005
   Bateman A, 2023, NUCLEIC ACIDS RES, V51, pD523, DOI 10.1093/nar/gkac1052
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bian XQ, 2023, PSYCHIAT CLIN NEUROS, V77, P196, DOI 10.1111/pcn.13517
   Blizniewska Kowalska K, 2023, BMC PSYCHIATRY, V23, DOI 10.1186/s12888 023 05153 5
   Cade C, 2014, BIOCHEMISTRY US, V53, P7582, DOI 10.1021/bi500874k
   Carhart Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994
   Chen G., 2023, FOOD INDUSTRY, V44, P135
   Chen YF, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.1004945
   Cheng YY, 2018, BRAIN BEHAV IMMUN, V69, P556, DOI 10.1016/j.bbi.2018.02.003
   Chottekalapanda RU, 2020, MOL PSYCHIATR, V25, P1364, DOI 10.1038/s41380 020 0767 8
   D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Donoso F, 2020, PSYCHONEUROENDOCRINO, V116, DOI 10.1016/j.psyneuen.2020.104673
   Du Bingjian, 2014, BMC Complement Altern Med, V14, P326, DOI 10.1186/1472 6882 14 326
   Du H., 2023, CHINA J CHINESE MAT, V49, P1, DOI [10.19540/j.cnki.cjcmm.20231013.703, DOI 10.19540/J.CNKI.CJCMM.20231013.703]
   Ekici M, 2023, J HELL VET MED SOC, V74, P5753, DOI 10.12681/jhvms.30232
   Gu L, 2012, J ETHNOPHARMACOL, V139, P780, DOI 10.1016/j.jep.2011.11.059
   Guan LP, 2016, EUR J MED CHEM, V121, P47, DOI 10.1016/j.ejmech.2016.05.026
   Guo S, 2023, J ETHNOPHARMACOL, V313, DOI 10.1016/j.jep.2023.116536
   Hao ZL, 2022, MOLECULES, V27, DOI 10.3390/molecules27092964
   He QM, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1102581
   Ishisaka M, 2011, BIOL PHARM BULL, V34, P1481, DOI 10.1248/bpb.34.1481
   Jiang N, 2024, LIFE SCI SPACE RES, V40, P35, DOI 10.1016/j.lssr.2023.04.001
   Jiao YQ, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043594
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Kim S, 2023, NUCLEIC ACIDS RES, V51, pD1373, DOI 10.1093/nar/gkac956
   Lai GH, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/3776340
   Li CF, 2017, BIOMED PHARMACOTHER, V91, P167, DOI 10.1016/j.biopha.2017.04.089
   Li XM, 2023, TRANSL PSYCHIAT, V13, DOI 10.1038/s41398 023 02486 3
   Liang YX, 2023, FOOD RES INT, V172, DOI 10.1016/j.foodres.2023.112562
   Liang YX, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24054844
   Liang YX, 2021, FOODS, V10, DOI 10.3390/foods10040883
   Lin HY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051868
   Lindqvist D, 2009, BIOL PSYCHIAT, V66, P287, DOI 10.1016/j.biopsych.2009.01.030
   Liu JH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.967670
   Liu LY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241210370
   Ma TC, 2023, J FOOD COMPOS ANAL, V120, DOI 10.1016/j.jfca.2023.105329
   Ma TC, 2022, MOLECULES, V27, DOI 10.3390/molecules27185809
   McKusick V., 2009, ONLINE MENDELIAN INH
   Mir WR, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1135898
   Moisan MP, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398 021 01323 9
   Monje FJ, 2011, J NEUROSCI, V31, P9075, DOI 10.1523/JNEUROSCI.1537 11.2011
   Niemegeers P, 2016, NEUROPSYCHOBIOLOGY, V74, P150, DOI 10.1159/000466698
   Oliveros JC, 2007, VENNY INTERACTIVE TO
   Olugbemide AS, 2021, BRAIN RES BULL, V169, P214, DOI 10.1016/j.brainresbull.2020.12.003
   Park S. H., 2010, NEUROBIOLOGY, V19, P30, DOI [10.5607/en.2010.19.1.30, DOI 10.5607/EN.2010.19.1.30]
   Peric I, 2021, BRAIN RES BULL, V166, P128, DOI 10.1016/j.brainresbull.2020.11.013
   Piñero J, 2015, DATABASE OXFORD, DOI 10.1093/database/bav028
   Radjabzadeh D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34502 3
   Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006
   Ramasubbu R, 2003, CAN J PSYCHIAT, V48, P250, DOI 10.1177/070674370304800409
   Rammal H, 2008, BRAIN BEHAV IMMUN, V22, P1156, DOI 10.1016/j.bbi.2008.06.005
   Ren L, 2021, FOOD CHEM, V340, DOI 10.1016/j.foodchem.2020.127933
   Rizzo SJS, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.120
   Saghaei E, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/5725361
   Sang TY, 2023, NUTR CANCER, V75, P1658, DOI 10.1080/01635581.2023.2216915
   Sedger LM, 2014, CYTOKINE GROWTH F R, V25, P453, DOI 10.1016/j.cytogfr.2014.07.016
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Siam MKS, 2021, J BIOMOL STRUCT DYN, V39, P6467, DOI 10.1080/07391102.2020.1802335
   Silvestro S, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11157116
   Stelzer G., 2016, CURR PROTOC BIOINFOR, V54, p1.30.31, DOI [10.1002/cpbi.5, DOI 10.1002/CPBI.5]
   Sun Y, 2021, ACS CHEM NEUROSCI, V12, P3387, DOI 10.1021/acschemneuro.1c00371
   Szklarczyk D, 2023, NUCLEIC ACIDS RES, V51, pD638, DOI 10.1093/nar/gkac1000
   Thomas AF, 2022, CELL DEATH DIFFER, V29, P961, DOI 10.1038/s41418 022 00996 z
   Tian JS, 2023, METAB BRAIN DIS, V38, P2849, DOI 10.1007/s11011 023 01312 5
   Uzzan S, 2021, MOLECULES, V26, DOI 10.3390/molecules26082368
   Van der Kooy K, 2007, INT J GERIATR PSYCH, V22, P613, DOI 10.1002/gps.1723
   Wang J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1526125
   Wang JQ, 2019, MOL NEUROBIOL, V56, P6197, DOI 10.1007/s12035 019 1524 3
   [王力文 Wang Liwen], 2022, [中草药, Chinese Traditional and Herbal Drugs], V53, P2031
   WHO, 2017, DEPR OTH COMM MENT D
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450 11.2011
   Yang CX, 2012, NEURAL REGEN RES, V7, P235, DOI 10.3969/j.issn.1673 5374.2012.03.014
   Yang M, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/731969
   Yi LT, 2012, J ETHNOPHARMACOL, V144, P328, DOI 10.1016/j.jep.2012.09.016
   Yu P, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046 022 02559 z
   Zhao L, 2023, J ETHNOPHARMACOL, V309, DOI 10.1016/j.jep.2023.116306
   Zhong J, 2021, FOODS, V10, DOI 10.3390/foods10081863
   Zhou Yan jiao, 2019, Nature Communications, V10, DOI [10.1038/s41467 019 12821 2, 10.1038/s41467 019 13698 x]
NR 85
TC 2
Z9 2
U1 5
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2048 7177
J9 FOOD SCI NUTR
JI Food Sci. Nutr.
PD DEC
PY 2024
VL 12
IS 12
BP 10164
EP 10180
DI 10.1002/fsn3.4446
EA OCT 2024
PG 17
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA Q5V9S
UT WOS:001357323100001
PM 39723076
OA hybrid
DA 2025 08 17
ER

PT J
AU Choi, EB
   Agidigbi, TS
   Kang, IS
   Kim, C
AF Choi, Eun Bi
   Agidigbi, Taiwo Samuel
   Kang, In Soon
   Kim, Chaekyun
TI ERK Inhibition Increases RANKL Induced Osteoclast Differentiation in RAW
   264.7 Cells by Stimulating AMPK Activation and RANK Expression and
   Inhibiting Anti Osteoclastogenic Factor Expression
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoclast; macrophage; ERK; RANKL; AMPK; anti osteoclastogenic
   mediators
ID PROTEIN KINASE; PERIPHERAL BLOOD; DOWN REGULATION; BONE MARROW; P38;
   PROLIFERATION; PRECURSORS; REGULATOR; PATHWAY; PD98059
AB Bone absorption is necessary for the maintenance of bone homeostasis. An osteoclast (OC) is a monocyte macrophage lineage cell that absorbs bone tissue. Extracellular signal regulated kinases (ERKs) are known to play important roles in regulating OC growth and differentiation. In this study, we examined specific downstream signal pathways affected by ERK inhibition during OC differentiation. Our results showed that the ERK inhibitors PD98059 and U0126 increased receptor activator of NF kappa B ligand (RANKL) induced OC differentiation in RAW 264.7 cells, implying a negative role in OC differentiation. This is supported by the effect of ERK2 specific small interfering RNA on increasing OC differentiation. In contrast to our findings regarding the RAW 264.7 cells, the ERK inhibitors attenuated the differentiation of bone marrow derived cells into OCs. The ERK inhibitors significantly increased the phosphorylation of adenosine 5 ' monophosphate activated protein kinase (AMPK) but not the activation of p38 MAPK, Lyn, and mTOR. In addition, while the ERK inhibition increased the expression of the RANKL receptor RANK, it decreased the expression of negative mediators of OC differentiation, such as interferon regulatory factor 8, B cell lymphoma 6, and interferon gamma. These dichotomous effects of ERK inhibition suggest that while ERKs may play positive roles in bone marrow derived cells, ERKs may also play negative regulatory roles in RAW 264.7 cells. These data provide important information for drug development utilizing ERK inhibitors in OC related disease treatment.
C1 [Choi, Eun Bi; Agidigbi, Taiwo Samuel; Kang, In Soon; Kim, Chaekyun] Inha Univ, Coll Med, Dept Pharmacol & Toxicol, Lab Leukocyte Signaling Res, Incheon 22212, South Korea.
   [Choi, Eun Bi; Kang, In Soon; Kim, Chaekyun] Inha Univ, Program Biomed Sci & Engn BK21, Incheon 22212, South Korea.
   [Kim, Chaekyun] Inha Univ, Convergent Res Ctr Metab & Immunoregulat, Incheon 22212, South Korea.
C3 Inha University; Inha University; Inha University
RP Kang, IS; Kim, C (通讯作者)，Inha Univ, Coll Med, Dept Pharmacol & Toxicol, Lab Leukocyte Signaling Res, Incheon 22212, South Korea.; Kang, IS; Kim, C (通讯作者)，Inha Univ, Program Biomed Sci & Engn BK21, Incheon 22212, South Korea.; Kim, C (通讯作者)，Inha Univ, Convergent Res Ctr Metab & Immunoregulat, Incheon 22212, South Korea.
EM round001@hanmail.net; chaekyun@inha.ac.kr
RI AGIDIGBI, TAIWO/GLQ 9690 2022
FU National Research Foundation of Korea [2020R1F1A1068065,
   2022R1I1A1A01055015]
FX This study was supported by the National Research Foundation of Korea
   (2020R1F1A1068065 and 2022R1I1A1A01055015).
CR Agidigbi TS, 2020, FREE RADICAL RES, V54, P894, DOI 10.1080/10715762.2020.1742896
   Al Shanti N, 2008, J ENDOCRINOL, V198, P243, DOI 10.1677/JOE 08 0151
   Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buscà R, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862 015 0450 x
   Cai ZY, 2018, BIOCHEM BIOPH RES CO, V503, P428, DOI 10.1016/j.bbrc.2018.04.052
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Fox SW, 2000, BIOCHEM BIOPH RES CO, V276, P868, DOI 10.1006/bbrc.2000.3577
   Frémin C, 2015, CELL REP, V12, P913, DOI 10.1016/j.celrep.2015.07.011
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Guo HH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0261127
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ihn HJ, 2017, BMB REP, V50, P150, DOI 10.5483/BMBRep.2017.50.3.223
   Ihn HJ, 2015, EXP BIOL MED, V240, P1690, DOI 10.1177/1535370215576310
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Kang H, 2013, J BIOL CHEM, V288, P12187, DOI 10.1074/jbc.M112.430389
   Kang IS, 2016, SCI REP UK, V6, DOI 10.1038/srep38014
   Kim BH, 2017, MOL CELLS, V40, P752, DOI 10.14348/molcells.2017.0098
   Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223
   Kim HJ, 2009, P NATL ACAD SCI USA, V106, P2325, DOI 10.1073/pnas.0806963106
   Koyama M, 2007, MOL CANCER THER, V6, P1579, DOI 10.1158/1535 7163.MCT 06 0814
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   Li MJ, 2015, INT J MOL MED, V36, P1335, DOI 10.3892/ijmm.2015.2330
   Li SF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101683
   Li ZK, 2018, CALCIFIED TISSUE INT, V103, P324, DOI 10.1007/s00223 018 0425 1
   Madyastha PR, 2000, J INTERF CYTOK RES, V20, P645, DOI 10.1089/107999000414826
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Ng AY, 2018, JBMR PLUS, V2, P328, DOI 10.1002/jbm4.10058
   Oh JH, 2015, MOL CELLS, V38, P279, DOI 10.14348/molcells.2015.2340
   Oh SJ, 2016, BIOCHEM BIOPH RES CO, V475, P125, DOI 10.1016/j.bbrc.2016.05.055
   Park JH, 2017, MOL CELLS, V40, P706
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Quinn JMW, 2010, FASEB J, V24, P275, DOI 10.1096/fj.09 137158
   Rahman MM, 2015, BONE, V81, P392, DOI 10.1016/j.bone.2015.08.008
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI [10.1152/physrev.00011.2008, 10.15252/embj.201488104]
   TAKAHASHI N, 1986, J IMMUNOL, V137, P3544
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tong XS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12714
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yuan JM, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00949 4
   Zhao BH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3379
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao HY, 2015, CYTOKINE, V71, P199, DOI 10.1016/j.cyto.2014.10.007
   Zhu S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082284
NR 58
TC 14
Z9 14
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2022
VL 23
IS 21
AR 13512
DI 10.3390/ijms232113512
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 6F4YE
UT WOS:000884067500001
PM 36362318
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Matsuura, Y
   Kikuta, J
   Kishi, Y
   Hasegawa, T
   Okuzaki, D
   Hirano, T
   Minoshima, M
   Kikuchi, K
   Kumanogoh, A
   Ishii, M
AF Matsuura, Yoshinobu
   Kikuta, Junichi
   Kishi, Yuika
   Hasegawa, Tetsuo
   Okuzaki, Daisuke
   Hirano, Toru
   Minoshima, Masafumi
   Kikuchi, Kazuya
   Kumanogoh, Atsushi
   Ishii, Masaru
TI In vivo visualisation of different modes of action of biological
   DMARDs inhibiting osteoclastic bone resorption
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID RHEUMATOID ARTHRITIS; TNF ALPHA; H+ ATPASE; RECEPTOR ACTIVATOR; A3
   ISOFORM; B LIGAND; PRECURSORS; EXPRESSION; MIGRATION; DAMAGE
AB Objectives Osteoclasts play critical roles in inflammatory bone destruction. Precursor cell migration, cell differentiation, and functional cell activation are all in play. Biological disease modifying antirheumatic drugs (DMARDs) have been shown to significantly inhibit both bone erosion as well as synovitis, although how such agents reduce osteoclastic bone destructionin vivo has not been fully explained. Here, we used an intravital time lapse imaging technique to directly visualise mature osteoclasts and their precursors, and explored how different biological DMARDs acted in vivo.
   Methods Lipopolysaccharide (LPS) was injected into the calvarial periosteum of fluorescent reporter mice to induce inflammatory bone destruction. Time lapse imaging was performed via intravital multiphoton microscopy 5 days after LPS injection. Biological DMARDs, including monoclonal antibodies (mAbs) against the interleukin (IL) 6 receptor (IL 6R) and tumour necrosis factor alpha (TNF alpha), or cytotoxic T lymphocyte associated protein 4 (CTLA4)w Ig, were intraperitoneally administered at the time of LPS injection. We determined CD80/86 expression levels in mature osteoclasts and their precursors by flow cytometry, quantitative PCR and immunohistochemistry.
   Results Of the biologicals tested, anti IL 6R and anti TNF alpha mAbs affected mature osteoclasts and switched bone resorbing osteoclasts to non resorbing cells. CTLA4 Ig had no action on mature osteoclasts but mobilised osteoclast precursors, eliminating their firm attachment to bone surfaces. In agreement with these results, CD80/86 (the target molecules of CTLA4 Ig) were prominently expressed only in osteoclast precursor cells, being suppressed during osteoclast maturation.
   Conclusions Intravital imaging revealed that various biological DMARDs acted at specific therapeutic time points during osteoclastic bone destruction, with different efficacies. These results enable us to grasp the real modes of action of drugs, optimising the usage of drug regimens.
C1 [Matsuura, Yoshinobu; Kikuta, Junichi; Kishi, Yuika; Hasegawa, Tetsuo; Ishii, Masaru] Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Suita, Osaka 5650871, Japan.
   [Matsuura, Yoshinobu; Hirano, Toru; Kumanogoh, Atsushi] Osaka Univ, Grad Sch Med, Dept Resp Med & Clin Immunol, Osaka, Japan.
   [Matsuura, Yoshinobu; Kikuta, Junichi; Kikuchi, Kazuya; Kumanogoh, Atsushi; Ishii, Masaru] Osaka Univ, WPI Immunol Frontier Res Ctr, Osaka, Japan.
   [Okuzaki, Daisuke] Osaka Univ, Microbial Dis Res Inst, Genome Informat Res Ctr, Osaka, Japan.
   [Minoshima, Masafumi; Kikuchi, Kazuya] Osaka Univ, Grad Sch Engn, Dept Mat & Life Sci, Osaka, Japan.
C3 University of Osaka; University of Osaka; University of Osaka;
   University of Osaka; University of Osaka
RP Kikuta, J; Ishii, M (通讯作者)，Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Suita, Osaka 5650871, Japan.
EM jkikuta@icb.med.osaka u.ac.jp; mishii@icb.med.osaka u.ac.jp
RI Kumanogoh, Atsushi/C 7354 2009; Okuzaki, Daisuke/AAN 5641 2020; Kikuta,
   Junichi/HHS 8875 2022
OI Okuzaki, Daisuke/0000 0002 4552 783X; Minoshima,
   Masafumi/0000 0002 9352 3454; 
FU Ono Pharmaceutical; Bristol Myers Squibb; Chugai Pharmaceutical;
   Grants in Aid for Scientific Research [15H05671] Funding Source: KAKEN
FX This research was supported by research grants from Ono Pharmaceutical,
   Bristol Myers Squibb and Chugai Pharmaceutical.
CR Axmann R, 2008, ANN RHEUM DIS, V67, P1603, DOI 10.1136/ard.2007.080713
   BARON R, 1986, AM J PATHOL, V122, P363
   Bombardier C, 2012, ANN RHEUM DIS, V71, P836, DOI 10.1136/annrheumdis 2011 200343
   Bonelli M, 2013, ARTHRITIS RHEUM US, V65, P599, DOI 10.1002/art.37787
   Bozec A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007764
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Ikebe T, 2013, ORAL SCI INT, V10, P1, DOI 10.1016/S1348 8643(12)00045 6
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jones G, 2012, BIOL TARGETS THER, V6, P155, DOI 10.2147/BTT.S20659
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106 4114.2000
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   KHARAZMI A, 1988, IMMUNOBIOLOGY, V177, P363, DOI 10.1016/S0171 2985(88)80004 4
   Kikuta J, 2013, P NATL ACAD SCI USA, V110, P7009, DOI 10.1073/pnas.1218799110
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Koizumi K, 2009, J IMMUNOL, V183, P7825, DOI 10.4049/jimmunol.0803627
   Kotani M, 2013, J IMMUNOL, V190, P605, DOI 10.4049/jimmunol.1201345
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Maeda H, 2016, NAT CHEM BIOL, V12, P579, DOI [10.1038/NCHEMBIO.2096, 10.1038/nchembio.2096]
   Molenaar ETH, 2004, ARTHRITIS RHEUM, V50, P36, DOI 10.1002/art.11481
   Nevius E, 2016, CLIN REV ALLERG IMMU, V51, P59, DOI 10.1007/s12016 015 8520 9
   Odegård S, 2006, ARTHRITIS RHEUM, V54, P68, DOI 10.1002/art.21548
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schiff M, 2014, ANN RHEUM DIS, V73, P86, DOI 10.1136/annrheumdis 2013 203843
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Smolen JS, 2015, NAT REV RHEUMATOL, V11, P276, DOI 10.1038/nrrheum.2015.8
   Sun Wada GH, 2009, J CELL SCI, V122, P2504, DOI 10.1242/jcs.050443
   Takegahara N, 2016, J BIOL CHEM, V291, P3439, DOI 10.1074/jbc.M115.677427
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Tanaka K, 2014, CLIN EXP IMMUNOL, V175, P172, DOI 10.1111/cei.12201
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200
   Webb SE, 1996, J CELL SCI, V109, P793
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
NR 41
TC 31
Z9 31
U1 0
U2 12
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD AUG
PY 2018
VL 77
IS 8
BP 1220
EP 1226
DI 10.1136/annrheumdis 2017 212880
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA GO6PF
UT WOS:000440169600028
PM 29705743
DA 2025 08 17
ER

PT J
AU Knowles, HJ
   Chanalaris, A
   Koutsikouni, A
   Cribbs, AP
   Grover, LM
   Hulley, PA
AF Knowles, Helen J.
   Chanalaris, Anastasios
   Koutsikouni, Argyro
   Cribbs, Adam P.
   Grover, Liam M.
   Hulley, Philippa A.
TI Mature primary human osteocytes in mini organotypic cultures secrete
   FGF23 and PTH1 34 regulated sclerostin
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE osteocyte; sclerostin; FGF23; mineralization; osteoclast; organoid
ID HYPOXIA INDUCIBLE FACTOR; MECHANICAL STIMULATION; SOST GENE; EX VIVO;
   BONE; EXPRESSION; GROWTH; DIFFERENTIATION; PHENOTYPE; PATHWAYS
AB IntroductionFor decades, functional primary human osteocyte cultures have been crucially needed for understanding their role in bone anabolic processes and in endocrine phosphate regulation via the bone kidney axis. Mature osteocyte proteins (sclerostin, DMP1, Phex and FGF23) play a key role in various systemic diseases and are targeted by successful bone anabolic drugs (anti sclerostin antibody and teriparatide (PTH1 34)). However, cell lines available to study osteocytes produce very little sclerostin and low levels of mature osteocyte markers. We have developed a primary human 3D organotypic culture system that replicates the formation of mature osteocytes in bone. MethodsPrimary human osteoblasts were seeded in a fibrinogen / thrombin gel around 3D printed hanging posts. Following contraction of the gel around the posts, cells were cultured in osteogenic media and conditioned media was collected for analysis of secreted markers of osteocyte formation. ResultsThe organoids were viable for at least 6 months, allowing co culture with different cell types and testing of bone anabolic drugs. Bulk RNAseq data displayed the developing marker trajectory of ossification and human primary osteocyte formation in vitro over an initial 8  week period. Vitamin D3 supplementation increased mineralization and sclerostin secretion, while hypoxia and PTH1 34 modulated sclerostin. Our culture system also secreted FGF23, enabling the future development of a bone kidney parathyroid vascular multi organoid or organ on a chip system to study disease processes and drug effects using purely human cells. DiscussionThis 3D organotypic culture system provides a stable, long lived, and regulated population of mature human primary osteocytes for a variety of research applications.
C1 [Knowles, Helen J.; Chanalaris, Anastasios; Cribbs, Adam P.; Hulley, Philippa A.] Univ Oxford, Botnar Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Rheumatol & Musculoskeleta, Oxford, England.
   [Koutsikouni, Argyro] Aristotle Univ Thessaloniki, Sch Biol, Thessaloniki, Greece.
   [Cribbs, Adam P.] Univ Oxford, Botnar Inst Musculoskeletal Sci, Oxford Ctr Translat Myeloma Res, Oxford, England.
   [Grover, Liam M.] Univ Birmingham, Healthcare Technol Inst, Sch Chem Engn, Birmingham, England.
C3 University of Oxford; Aristotle University of Thessaloniki; University
   of Oxford; University of Birmingham
RP Hulley, PA (通讯作者)，Univ Oxford, Botnar Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Rheumatol & Musculoskeleta, Oxford, England.
EM philippa.hulley@ndorms.ox.ac.uk
RI Knowles, Helen/JLL 7005 2023; Cribbs, Adam/AAN 4387 2020; Hulley,
   Philippa/A 8538 2011; Grover, Liam/F 2713 2011
OI Cribbs, Adam/0000 0001 5288 3077; 
FU Paget's Association [PA21010]; Organ on a Chip Technologies Network  
   UKRI (MRC) via the Technologies Touching Life Scheme [R61746/AA001]
FX This study was funded by grants from the Paget's Association (grant
   number PA21010) and the Organ on a Chip Technologies Network
   (www.organonachip.org.uk/), which is funded by UKRI (MRC) via the
   Technologies Touching Life Scheme (R61746/AA001).
CR Atkins GJ, 2009, OSTEOPOROSIS INT, V20, P653, DOI 10.1007/s00198 008 0728 6
   Atkins GJ, 2009, AM J PHYSIOL CELL PH, V297, pC1358, DOI 10.1152/ajpcell.00216.2009
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Bernhardt A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147316
   Bernhardt A, 2020, TISSUE ENG PT A, V26, P647, DOI [10.1089/ten.TEA.2019.0085, 10.1089/ten.tea.2019.0085]
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816 888d
   Brolese E, 2015, CLIN ORAL IMPLAN RES, V26, P1211, DOI 10.1111/clr.12432
   Choudhary S, 2018, TISSUE ENG PT A, V24, P458, DOI [10.1089/ten.tea.2017.0103, 10.1089/ten.TEA.2017.0103]
   Dhillon S, 2019, DRUGS, V79, P563, DOI 10.1007/s40265 019 01077 1
   Dobrosak Cale, 2017, Bone Rep, V7, P114, DOI 10.1016/j.bonr.2017.10.002
   Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004 1039
   Galea Gabriel L, 2020, Gene X, V5, P100027, DOI 10.1016/j.gene.2020.100027
   Geng S, 2011, J BONE MINER RES, V26, P1145, DOI 10.1002/jbmr.298
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Honma M, 2013, J BONE MINER RES, V28, P1936, DOI 10.1002/jbmr.1941
   HOWARD GA, 1981, J BIOL CHEM, V256, P7738
   Hulley PA, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10370
   Iordachescu A, 2021, NPJ MICROGRAVITY, V7, DOI 10.1038/s41526 021 00146 8
   Iordachescu Alexandra, 2019, Curr Protoc Stem Cell Biol, V48, pe79, DOI 10.1002/cpsc.79
   Iordachescu A, 2018, RSC ADV, V8, P7622, DOI 10.1039/c7ra12511a
   Kim J, 2021, TISSUE ENG PT A, V27, P1037, DOI [10.1089/ten.TEA.2020.0228, 10.1089/ten.tea.2020.0228]
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Knowles HJ, 2009, HISTOL HISTOPATHOL, V24, P337, DOI 10.14670/HH 24.337
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10 162230
   Mann V., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P408
   Marini F, 2023, OSTEOPOROSIS INT, V34, P213, DOI 10.1007/s00198 022 06523 7
   Maurer P, 2006, INT J ORAL MAX SURG, V35, P231, DOI 10.1016/j.ijom.2005.07.016
   Michigami T, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.967774
   Michigami T, 2022, BONE, V161, DOI 10.1016/j.bone.2022.116430
   Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08 114397
   Need AG, 2007, J BONE MINER RES, V22, P757, DOI [10.1359/jbmr.070203, 10.1359/JBMR.070203]
   Pajevic PD, 2020, CURR OSTEOPOROS REP, V18, P551, DOI 10.1007/s11914 020 00613 3
   Pathak JL, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00405
   Pathak JL, 2016, CALCIFIED TISSUE INT, V98, P596, DOI 10.1007/s00223 016 0116 8
   Paxton JZ, 2010, ANN BIOMED ENG, V38, P2155, DOI 10.1007/s10439 010 0044 0
   Perwad F, 2005, ENDOCRINOLOGY, V146, P5358, DOI 10.1210/en.2005 0777
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Qin QY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231911201
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200
   Sasaki F, 2021, J BONE MINER METAB, V39, P34, DOI 10.1007/s00774 020 01145 7
   Shomento SH, 2010, J CELL BIOCHEM, V109, P196, DOI 10.1002/jcb.22396
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Sun QL, 2018, BONE, V106, P148, DOI 10.1016/j.bone.2017.10.019
   Suzuki N, 2016, BIOMECH MODEL MECHAN, V15, P1091, DOI 10.1007/s10237 015 0746 1
   Takashi Y, 2021, CURR OSTEOPOROS REP, V19, P669, DOI 10.1007/s11914 021 00709 4
   Takashi Y, 2019, P NATL ACAD SCI USA, V116, P11418, DOI 10.1073/pnas.1815166116
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   Wang K, 2019, J BONE MINER RES, V34, P979, DOI 10.1002/jbmr.3720
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Wijenayaka AR, 2016, J STEROID BIOCHEM, V164, P369, DOI 10.1016/j.jsbmb.2015.12.006
   Yashiro M, 2020, J PHARMACEUT BIOMED, V182, DOI 10.1016/j.jpba.2020.113139
   Zahm AM, 2008, BONE, V43, P25, DOI 10.1016/j.bone.2008.03.010
   Zarei A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165462
   Zhang C, 2019, CURR OSTEOPOROS REP, V17, P207, DOI 10.1007/s11914 019 00521 1
   Zhang JH, 2022, BIOFABRICATION, V14, DOI 10.1088/1758 5090/ac73b9
   Zhao DZ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00222 z
NR 63
TC 4
Z9 4
U1 5
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 8
PY 2023
VL 14
AR 1167734
DI 10.3389/fendo.2023.1167734
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA G8IY0
UT WOS:000991540900001
PM 37223031
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, Y
   Li, LZ
   Zhang, YL
   Sun, WJ
   Zhu, YQ
   Cui, Y
   Qi, L
AF Wang, Yue
   Li, Ling Zhi
   Zhang, Yong Liang
   Sun, Wei Jia
   Zhu, Ya Qin
   Cui, Ying
   Qi, Lin
TI LC, a novel estrone rhein hybrid compound, promotes proliferation and
   differentiation and protects against cell death in human osteoblastic
   MG 63 cells
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE LC; Proliferation; Differentiation; Survival; Osteoblast
ID BONE SEEKING ESTROGEN; LYSINATE SUPPRESSES; INDUCED APOPTOSIS;
   RECEPTOR ALPHA; SEX STEROIDS; EXPRESSION; ESTRADIOL; GROWTH; INHIBITOR;
   OSTEOPOROSIS
AB Estrogen analogs are promising drugs for postmenopausal osteoporosis, but because of their possible side effects, estrogens which exert their estrogenic effects selectively on bone are desired. Based on our previous studies that rhein had high affinity for the bone mineral, we synthesized estrone rhein hybrid compounds and confirmed that one of these hybrid compounds, LC, exhibited a selective profile in the bone and prevented bone loss but had no effect on endometrium growth in ovariectomized rats. However, the mechanisms underlying its actions on human bone cells have remained largely unknown. Here we show that LC increases proliferation and differentiation and opposes cisplatin induced apoptosis in human osteoblastic MG 63 cells containing two estrogen receptor (ER) isoforms. LC promotes proliferation by altering cell cycle distribution whereas LC mediated survival may be associated with up regulation of X linked inhibitor of apoptosis (XIAP) expression. Treatment with the ER antagonist ICI 182,780 abolishes the above actions of LC on osteoblast derived cells. Using small interfering double stranded RNAs technology, we further demonstrate that the effects of LC on proliferation and survival are mediated by both ER alpha and ER beta but those on differentiation primarily by ER alpha. Moreover, we demonstrate that LC may promote activation of the classic estrogen response element (ERE) pathway through increasing steroid receptor coactivator (SRC) 3 expression. Meanwhile, we find that regulation of osteoblastic proliferation and survival by LC involves Ras/MEK/ERK and PI3K/Akt signaling. Therefore, using rhein for conjugating compounds is a promising method of effectively targeting estrogens to the bone. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Li, Ling Zhi; Cui, Ying] Med Coll Chinese Peoples Armed Police Forces, Dept Pharmaceut Chem, Tianjin 300162, Peoples R China.
   [Wang, Yue; Sun, Wei Jia; Zhu, Ya Qin; Qi, Lin] Med Coll Chinese Peoples Armed Police Forces, Dept Immunol, Tianjin 300162, Peoples R China.
   [Wang, Yue; Li, Ling Zhi; Zhang, Yong Liang] TianJin Key Lab Biomarkers Occupat & Environm Haz, Tianjin, Peoples R China.
RP Li, LZ (通讯作者)，Med Coll Chinese Peoples Armed Police Forces, Dept Pharmaceut Chem, Chenlin Rd 211, Tianjin 300162, Peoples R China.
EM wy68wy68@yahoo.com.cn; llzhx@tom.com
RI Li, Lingzhi/K 9055 2016
FU Tianjin Municipal Science and Technology Commission [033609811,
   08JCYBJC06900]; Postdoctoral Science Foundation of China [20080441340];
   National Natural Science Foundation of China [81073152, 81041071];
   Science Foundation of Tianjin [10JCZDJC21100]
FX We thank the assistance of Xin Zhou, Li Jie Dong, and Qiong Xu. This
   work was supported by grants from Tianjin Municipal Science and
   Technology Commission (No. 033609811, 08JCYBJC06900), Postdoctoral
   Science Foundation of China (No. 20080441340), the National Natural
   Science Foundation of China (No. 81073152, 81041071) and the Great
   Program of Science Foundation of Tianjin (No. 10JCZDJC21100).
CR Bauss F, 1996, CALCIFIED TISSUE INT, V59, P168, DOI 10.1007/s002239900104
   Boileau C, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2444
   Bynoe MS, 2000, P NATL ACAD SCI USA, V97, P2703, DOI 10.1073/pnas.040577497
   Chen JR, 2006, J PHARMACOL EXP THER, V319, P1182, DOI 10.1124/jpet.106.109454
   Choi KC, 2001, ENDOCRINOLOGY, V142, P2351, DOI 10.1210/en.142.6.2351
   CUI LZ, 2004, Patent No. 100941317
   [崔颖 CUI Ying], 2008, [中国新药杂志, Chinese Journal New Drugs], V17, P1154
   Dang ZC, 2002, J BONE MINER RES, V17, P394, DOI 10.1359/jbmr.2002.17.3.394
   DAVIS VL, 1994, J BONE MINER RES, V9, P983
   Feng J, 2008, BIOL PHARM BULL, V31, P1067, DOI 10.1248/bpb.31.1067
   Florian M, 2008, STEROIDS, V73, P47, DOI 10.1016/j.steroids.2007.08.010
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Harris Steven A., 1996, P507
   Ip SW, 2007, ANTICANCER RES, V27, P379
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Kallio A, 2008, MOL CELL ENDOCRINOL, V289, P38, DOI 10.1016/j.mce.2008.03.005
   Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039 128X(99)00107 5
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Li HZ, 2008, MOL CANCER RES, V6, P917, DOI 10.1158/1541 7786.MCR 08 0093
   [李灵芝 LI Lingzhi], 2007, [中国药科大学学报, Journal of China Pharmaceutical University], V38, P6
   Lin YJ, 2009, AM J CHINESE MED, V37, P923, DOI 10.1142/S0192415X09007417
   Lin YJ, 2009, ANTI CANCER DRUG, V20, P65, DOI 10.1097/CAD.0b013e3283182913
   Luo XH, 2003, ENDOCR RES, V29, P343, DOI 10.1081/ERC 120025041
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Nakashima T, 1998, ENDOCRINOLOGY, V139, P2032, DOI 10.1210/en.139.4.2032
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Ofiate SA, 1995, SCIENCE, V270, P1354
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960 894X(01)80365 6
   Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890 2901.2000
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Salvatori L, 2009, J CELL PHYSIOL, V220, P35, DOI 10.1002/jcp.21724
   Schiff R, 2003, CLIN CANCER RES, V9, p447S
   Shi P, 2008, AM J CHINESE MED, V36, P805, DOI 10.1142/S0192415X08006259
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594
   Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200
   Tsushima N, 2000, J PHARM PHARMACOL, V52, P27, DOI 10.1211/0022357001773652
   Urayama S, 2000, J LAB CLIN MED, V136, P181, DOI 10.1067/mlc.2000.108754
   Wang Lin, 2006, Yao Xue Xue Bao, V41, P555
   Wang Y, 2011, MOL CELL ENDOCRINOL, V337, P43, DOI 10.1016/j.mce.2011.01.018
   Wang Y, 2010, CANCER LETT, V295, P110, DOI 10.1016/j.canlet.2010.02.019
   Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002
   Watson CS, 2003, EXP BIOL MED, V228, P1272, DOI 10.1177/153537020322801106
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Willson TM, 1996, BIOORG MED CHEM LETT, V6, P1043, DOI 10.1016/0960 894X(96)00164 3
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Yokogawa K, 2006, BIOL PHARM BULL, V29, P1229, DOI 10.1248/bpb.29.1229
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
   ZHANG L, 2010, ACTA ACAD MED CPAF, V19, P841
   ZHANG L, 2008, ACTA ACAD MED CPAF, V17, P1048
   Zhang Y, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21 20 j0007.2001
NR 55
TC 11
Z9 15
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD SEP 15
PY 2011
VL 344
IS 1 2
BP 59
EP 68
DI 10.1016/j.mce.2011.06.027
PG 10
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 825XK
UT WOS:000295315200006
PM 21767602
DA 2025 08 17
ER

PT J
AU Zuo, Q
   Ou, YS
   Zhong, SX
   Yu, HY
   Zhan, FBA
   Zhang, MZ
AF Zuo, Qiang
   Ou, Yunsheng
   Zhong, Shenxi
   Yu, Haoyang
   Zhan, Fangbiao
   Zhang, Muzi
TI Targeting GRP78 enhances the sensitivity of HOS osteosarcoma cells to
   pyropheophorbide α methyl ester mediated photodynamic therapy via the
   Wnt/β catenin signaling pathway
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE glucose regulated protein 78; osteosarcoma; photodynamic therapy;
   pyropheophorbide alpha methyl ester; Wnt signaling pathway; reactive
   oxygen species
ID ENDOPLASMIC RETICULUM STRESS; CARCINOMA PROGRESSION; CANCER CELLS;
   APOPTOSIS; AUTOPHAGY; RESISTANCE; PROLIFERATION; SUPPRESSES; ACTIVATION;
   EFFICACY
AB Photodynamic therapy (PDT), which is a new method for treating tumors, has been used in the treatment of cancer. In depth research has shown that PDT cannot completely kill tumor cells, indicating that tumor cells are resistant to PDT. Glucose regulatory protein 78 (GRP78), which is a key regulator of endoplasmic reticulum stress, has been confirmed to be related to tumor resistance and recurrence, but there are relatively few studies on the further mechanism of GRP78 in PDT. Our experiment aimed to observe the role of GRP78 in HOS human osteosarcoma cells treated with pyropheophorbide alpha methyl ester mediated photodynamic therapy (MPP alpha PDT) and to explore the possible mechanism by which the silencing of GRP78 expression enhances the sensitivity of HOS osteosarcoma cells to MPP alpha PDT. HOS osteosarcoma cells were transfected with siRNA GRP78. Apoptosis and reactive oxygen species (ROS) levels were detected by Hoechst staining and flow cytometry, cell viability was detected by Cell Counting Kit 8 assay, GRP78 protein fluorescence intensity was detected by immunofluorescence, and apoptosis related proteins, cell proliferation related proteins, and Wnt pathway related proteins were detected by western blot. The results showed that MPP alpha PDT can induce HOS cell apoptosis and increase GRP78 expression. After successful siRNA GRP78 transfection, HOS cell proliferation was decreased, and apoptosis related proteins expressions was increased, Wnt/beta catenin related proteins expressions was decreased, and ROS levels was increased. In summary, siRNA GRP78 enhances the sensitivity of HOS cells to MPP alpha PDT, the mechanism may be related to inhibiting Wnt pathway activation and increasing ROS levels.
C1 [Zuo, Qiang; Ou, Yunsheng; Zhong, Shenxi; Yu, Haoyang; Zhan, Fangbiao; Zhang, Muzi] Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University
RP Ou, YS (通讯作者)，Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
EM ouyunsheng2001@163.com
RI 于, 浩阳/GRJ 1069 2022; WANG, XIAOLONG/AAA 4301 2022; Zhang,
   Muzi/GQB 1230 2022
OI ou, yunsheng/0000 0001 8578 3523; Zhan, Fangbiao/0000 0001 6965 7404; 
FU National Natural Science Foundation of China [81572634]; Natural Science
   Foundation of Chongqing [cstc2019jcyj msxmX0358]; Basic Research and
   Frontiers Exploration Project of Yuzhong District, Chongqing [2018114];
   Science and Technology Innovation Project for Postgraduate of Chongqing
   Municipal Education Commission [CYS18200]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (No. 81572634), the Natural Science Foundation of
   Chongqing (No. cstc2019jcyj msxmX0358), the Basic Research and Frontiers
   Exploration Project of Yuzhong District, Chongqing (No. 2018114), and
   the Science and Technology Innovation Project for Postgraduate of
   Chongqing Municipal Education Commission (No. CYS18200).
CR Cao DG, 2020, AM J CANCER RES, V10, P3248
   Cerezo M, 2017, AUTOPHAGY, V13, P216, DOI 10.1080/15548627.2016.1246107
   Chen YY, 2020, INT J MOL MED, V45, P971, DOI 10.3892/ijmm.2020.4494
   Clarke WR, 2019, INT J CANCER, V144, P1367, DOI 10.1002/ijc.32012
   Cultrara CN, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 5178 8
   Dadey DYA, 2017, CLIN CANCER RES, V23, P2556, DOI 10.1158/1078 0432.CCR 16 1935
   Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014
   de Jeude JFV, 2017, ONCOGENE, V36, P3397, DOI 10.1038/onc.2016.326
   Dores Silva PR, 2020, CELL STRESS CHAPERON, V25, P979, DOI 10.1007/s12192 020 01134 9
   Firczuk M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.265
   Gabrysiak M, 2016, ONCOL REP, V35, P3151, DOI 10.3892/or.2016.4723
   Gan PP, 2017, CELL PHYSIOL BIOCHEM, V44, P133, DOI 10.1159/000484622
   Gifford JB, 2016, MOL CANCER THER, V15, P1043, DOI 10.1158/1535 7163.MCT 15 0774
   Gopal U, 2019, J BIOL CHEM, V294, P13939, DOI 10.1074/jbc.RA119.009091
   Huang LY, 2019, PHOTODIAGN PHOTODYN, V25, P148, DOI 10.1016/j.pdpdt.2018.12.002
   Huang Q, 2016, APOPTOSIS, V21, P749, DOI 10.1007/s10495 016 1243 4
   Huang X, 2020, ACTA BIOMATER, V109, P229, DOI 10.1016/j.actbio.2020.04.009
   Khorsandi K, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 01616 x
   La XQ, 2019, CELL SIGNAL, V60, P1, DOI 10.1016/j.cellsig.2019.04.004
   Lei ZL, 2020, BIOCHEM BIOPH RES CO, V526, P764, DOI 10.1016/j.bbrc.2020.03.147
   Li KT, 2016, CANCER MED US, V5, P3186, DOI 10.1002/cam4.895
   Li ZW, 2014, ONCOTARGET, V5, P5369, DOI 10.18632/oncotarget.2105
   Liu Y, 2018, INT J BIOL MACROMOL, V109, P424, DOI 10.1016/j.ijbiomac.2017.12.110
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martins Neves SR, 2016, CANCER LETT, V370, P286, DOI 10.1016/j.canlet.2015.11.013
   Morgan J, 1998, PHOTOCHEM PHOTOBIOL, V67, P155, DOI 10.1562/0031 8655(1998)067<0155:GIBCIP>2.3.CO;2
   Niyonizigiye I, 2019, INT J BIOL MACROMOL, V137, P844, DOI 10.1016/j.ijbiomac.2019.07.043
   Pandey V, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110751
   Purushothaman B, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00661 y
   Raiter A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01500
   Shen JL, 2017, P NATL ACAD SCI USA, V114, pE4020, DOI 10.1073/pnas.1616060114
   Shin DH, 2018, J GINSENG RES, V42, P165, DOI 10.1016/j.jgr.2017.01.015
   Srivastava NS, 2019, PHYTOMEDICINE, V52, P117, DOI 10.1016/j.phymed.2018.09.224
   Tang HL, 2018, CURR CANCER DRUG TAR, V18, P390, DOI 10.2174/1568009617666170914155355
   Tao Y, 2017, INT J ONCOL, V51, P1427, DOI 10.3892/ijo.2017.4136
   Tu PH, 2016, ONCOL REP, V35, P3209, DOI 10.3892/or.2016.4703
   Wang CL, 2017, CELL PHYSIOL BIOCHEM, V43, P2405, DOI 10.1159/000484394
   Wang N, 2014, CARCINOGENESIS, V35, P2544, DOI 10.1093/carcin/bgu187
   Wang XW, 2020, ONCOTARGETS THER, V13, P10315, DOI 10.2147/OTT.S255586
   Wang Y, 2016, J CANCER RES CLIN, V142, P813, DOI 10.1007/s00432 015 2066 3
   Wei CR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.557429
   Wu YZ, 2020, CANCER BIOL MED, V17, P782, DOI 10.20892/j.issn.2095 3941.2020.0162
   Xin DW, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 5549
   Xiong HX, 2019, EXP CELL RES, V383, DOI 10.1016/j.yexcr.2019.07.006
   Zhang N, 2018, AM J TRANSL RES, V10, P3542
   Zhu XF, 2020, NANOSCALE, V12, P22317, DOI 10.1039/d0nr03931d
NR 46
TC 6
Z9 7
U1 1
U2 13
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, 100009,
   PEOPLES R CHINA
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD OCT
PY 2021
VL 53
IS 10
BP 1387
EP 1397
DI 10.1093/abbs/gmab115
EA SEP 2021
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA WM6SD
UT WOS:000711212200013
PM 34494093
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Ge, YW
   Feng, K
   Liu, XL
   Zhu, ZA
   Chen, HF
   Chang, YY
   Sun, ZY
   Wang, HW
   Zhang, JW
   Yu, DG
   Mao, YQ
AF Ge, Yu Wei
   Feng, Kai
   Liu, Xiao Liang
   Zhu, Zhen An
   Chen, Hong Fang
   Chang, Yong Yun
   Sun, Zhen Yu
   Wang, Hao Wei
   Zhang, Jing Wei
   Yu, De Gang
   Mao, Yuan Qing
TI Quercetin inhibits macrophage polarization through the p 38α/β
   signalling pathway and regulates OPG/RANKL balance in a mouse skull
   model
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE macrophage; osteoclasts; polarization; signalling; titanium
ID NF KAPPA B; PARTICLE INDUCED OSTEOLYSIS; WEAR PARTICLES; BONE LOSS;
   INDUCED OSTEOCLASTOGENESIS; INDUCED INFLAMMATION; JOINT REPLACEMENT; M2
   MACROPHAGES; ACTIVATION; RANKL
AB Aseptic loosening caused by wear particles is a common complication after total hip arthroplasty. We investigated the effect of the quercetin on wear particle mediated macrophage polarization, inflammatory response and osteolysis. In vitro, we verified that Ti particles promoted the differentiation of RAW264.7 cells into M1 macrophages through p 38 alpha/beta signalling pathway by using flow cytometry, immunofluorescence assay and small interfering p 38 alpha/beta RNA. We used enzyme linked immunosorbent assays to confirm that the protein expression of M1 macrophages increased in the presence of Ti particles and that these pro inflammatory factors further regulated the imbalance of OPG/RANKL and promoted the differentiation of osteoclasts. However, this could be suppressed, and the protein expression of M2 macrophages was increased by the presence of the quercetin. In vivo, we revealed similar results in the mouse skull by mu CT, H&E staining, immunohistochemistry and immunofluorescence assay. We obtained samples from patients with osteolytic tissue. Immunofluorescence analysis indicated that most of the macrophages surrounding the wear particles were M1 macrophages and that pro inflammatory factors were released. Titanium particle mediated M1 macrophage polarization, which caused the release of pro inflammatory factors through the p 38 alpha/beta signalling pathway, regulated OPG/RANKL balance. Macrophage polarization is expected to become a new clinical drug therapeutic target.
C1 [Ge, Yu Wei; Feng, Kai; Liu, Xiao Liang; Zhu, Zhen An; Chen, Hong Fang; Chang, Yong Yun; Sun, Zhen Yu; Zhang, Jing Wei; Yu, De Gang; Mao, Yuan Qing] Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Dept Orthoped Surg, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Feng, Kai] Shanghai Jiao Tong Univ Sixth Peoples Hosp 6, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Wang, Hao Wei] Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Coll Stomatol, Dept 2nd Dent Ctr,Sch Med, Shanghai, Peoples R China.
   [Wang, Hao Wei] Natl Clin Res Ctr Oral Dis, Shanghai, Peoples R China.
   [Wang, Hao Wei] Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Wang, Hao Wei] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zhang, JW; Yu, DG; Mao, YQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Dept Orthoped Surg, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM zjw_ys@163.com; ydg163@126.com; yuanqingmao@163.com
RI Feng, Kai/JQI 9878 2023; ydg, nam/GNP 5078 2022; Wang,
   Huiwen/JED 3206 2023
FU Natural Science Foundation of China [81572116, 81772361, 81572158]
FX Natural Science Foundation of China, Grant/Award Number: 81572116,
   81772361 and 81572158
CR Alhamdi JR, 2019, BIOMATERIALS, V196, P90, DOI 10.1016/j.biomaterials.2018.07.012
   Baumann B, 2004, ACTA ORTHOP SCAND, V75, P295, DOI 10.1080/00016470410001222
   Bi Y., 2010, J BONE MINER RES, V16, P2082
   Bi Y, 2010, J ORTHOP RES, V20, P696
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Cui JF, 2014, J SURG RES, V192, P447, DOI 10.1016/j.jss.2014.05.038
   Dai ML, 2018, BIOMATERIALS, V180, P91, DOI 10.1016/j.biomaterials.2018.07.011
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264 6021:3510095
   Feng XK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/160123
   Fuchs AK, 2016, BIOMATERIALS, V85, P78, DOI 10.1016/j.biomaterials.2016.01.064
   Gibon E, 2017, J BIOMED MATER RES B, V105, P2162, DOI 10.1002/jbm.b.33734
   Guo C, 2017, CELLULAR PHYSL BIOCH, V43, P1
   Hachim D, 2017, BIOMATERIALS, V112, P95, DOI 10.1016/j.biomaterials.2016.10.019
   Huang CC, 2014, BIOMED MATER, V9, DOI 10.1088/1748 6041/9/2/025010
   Jiang KY, 2017, BIOMATERIALS, V114, P71, DOI 10.1016/j.biomaterials.2016.11.004
   Kang H, 2018, BIOMATERIALS, V178, P681, DOI 10.1016/j.biomaterials.2018.03.007
   Kapasa ER, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8040042
   Konrad M, 2011, INT J SPORT NUTR EXE, V21, P338, DOI 10.1123/ijsnem.21.4.338
   Kumar M, 2018, BIOMATERIALS, V187, P1, DOI 10.1016/j.biomaterials.2018.09.037
   Lin T, 2014, INFLAMM CELL SIGNAL, V1, P319
   Lin TH, 2014, ACTA BIOMATER, V10, P3747, DOI 10.1016/j.actbio.2014.04.034
   Liu FX, 2013, ACTA PHARMACOL SIN, V34, P1457, DOI 10.1038/aps.2013.99
   Liu FX, 2009, BIOMATERIALS, V30, P1756, DOI 10.1016/j.biomaterials.2008.12.018
   Liu G, 2015, CELL TISSUE RES, V363, P1
   Liu Q, 2016, SCI REP UK, V6, DOI 10.1038/srep36662
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Longhofer LK, 2017, J ORTHOP TRANSL, V8, P5, DOI 10.1016/j.jot.2016.06.026
   Lu XY, 2018, J CELL MOL MED, V22, P5029, DOI 10.1111/jcmm.13785
   Oliveira T, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/704781
   Park K, 2014, INT J MOL MED, V33, P178, DOI 10.3892/ijmm.2013.1557
   Pinto ML, 2017, BIOMATERIALS, V124, P211, DOI 10.1016/j.biomaterials.2017.02.004
   Rao AJ, 2012, ACTA BIOMATER, V8, P2815, DOI 10.1016/j.actbio.2012.03.042
   Shorez JP, 2008, P I MECH ENG H, V222, P865, DOI 10.1243/09544119JEIM358
   Spiller KL, 2015, BIOMATERIALS, V37, P194, DOI 10.1016/j.biomaterials.2014.10.017
   Talior Volodarsky I, 2017, BIOMATERIALS, V144, P199, DOI 10.1016/j.biomaterials.2017.08.019
   Von KM, 2010, J ORTHOP RES, V22, P237
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Xie Z, 2018, DRUG DELIV, V25, P187, DOI 10.1080/10717544.2017.1422295
   Xu F, 2016, MOL MED REP, V14, P2289, DOI 10.3892/mmr.2016.5515
   Yamaguchi M, 2011, INT J MOL MED, V28, P521, DOI 10.3892/ijmm.2011.749
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zou Y, 2016, J VET MED SCI, V78, P1487, DOI 10.1292/jvms.16 0090
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 45
TC 34
Z9 38
U1 1
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAR
PY 2020
VL 24
IS 5
BP 3203
EP 3216
DI 10.1111/jcmm.14995
EA FEB 2020
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KU6OW
UT WOS:000513067100001
PM 32053272
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wieder, R
AF Wieder, Robert
TI Awakening of Dormant Breast Cancer Cells in the Bone Marrow
SO CANCERS
LA English
DT Article
DE dormancy; micrometastases; hematopoietic niche; bone marrow
   microenvironment; osteoblast niche; reawakening
ID FIBROBLAST GROWTH FACTOR; MESENCHYMAL STEM CELLS; DISSEMINATED
   TUMOR CELLS; MAMMARY CARCINOMA CELLS; HEMATOPOIETIC STEM; IN VITRO;
   ENDOTHELIAL CELLS; METASTATIC OUTGROWTH; TRANSCRIPTION FACTOR;
   THERAPEUTIC TARGET
AB Simple Summary: Breast cancer cells travel via the bloodstream to the bone before the cancer is detectable in the breast. These disseminated cells are resistant to adjuvant chemotherapy and hormone therapy administered for the very purpose of eliminating them. They recur steadily for more than 20 years, resulting in incurable diseases. The bone marrow location, or niche, which normally provides a nest for blood forming cells to enable them to generate blood for the entire lifetime of an individual, also protects these disseminated tumor cells and places them into a state of quiescence called dormancy. Dormant cancer cells can wake up from stimulation by life events, including a gradual increase in bone marrow fat cells and loss of estrogen with aging, inflammation, new blood vessel formation, trauma, surgery, abnormal blood clotting conditions, anxiety and depression. Many investigations have tested ways of killing disseminated cells or keeping them dormant, and some have entered clinical trials.
   Up to 40% of patients with breast cancer (BC) have metastatic cells in the bone marrow (BM) at the initial diagnosis of localized disease. Despite definitive systemic adjuvant therapy, these cells survive in the BM microenvironment, enter a dormant state and recur stochastically for more than 20 years. Once they begin to proliferate, recurrent macrometastases are not curable, and patients generally succumb to their disease. Many potential mechanisms for initiating recurrence have been proposed, but no definitive predictive data have been generated. This manuscript reviews the proposed mechanisms that maintain BC cell dormancy in the BM microenvironment and discusses the data supporting specific mechanisms for recurrence. It addresses the well described mechanisms of secretory senescence, inflammation, aging, adipogenic BM conversion, autophagy, systemic effects of trauma and surgery, sympathetic signaling, transient angiogenic bursts, hypercoagulable states, osteoclast activation, and epigenetic modifications of dormant cells. This review addresses proposed approaches for either eliminating micrometastases or maintaining a dormant state.
C1 [Wieder, Robert] Rutgers New Jersey Med Sch, 185 South Orange Ave, MSB F671, Newark, NJ 07103 USA.
   [Wieder, Robert] Canc Inst New Jersey, 185 South Orange Ave, MSB F671, Newark, NJ 07103 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers Cancer Institute of New Jersey
RP Wieder, R (通讯作者)，Rutgers New Jersey Med Sch, 185 South Orange Ave, MSB F671, Newark, NJ 07103 USA.; Wieder, R (通讯作者)，Canc Inst New Jersey, 185 South Orange Ave, MSB F671, Newark, NJ 07103 USA.
EM wiederro@njms.rutgers.edu
OI Wieder, Robert/0000 0002 1005 493X
FU DOD [W81XWH 09 1 0119]; NIH [1 R21 CA142537 01A1]
FX DOD: W81XWH 09 1 0119; NIH: 1 R21 CA142537 01A1.
CR Abdallah BM, 2019, BIOL PROCED ONLINE, V21, DOI 10.1186/s12575 019 0091 3
   Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008 5472.CAN 08 3820
   Aftimos P, 2021, CANCER DISCOV, V11, P2796, DOI 10.1158/2159 8290.CD 20 1647
   Agarwal P, 2019, CELL STEM CELL, V24, P769, DOI 10.1016/j.stem.2019.02.018
   Ahamed J, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI161167
   Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227
   Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616 3631.2001
   Allawi Z, 2012, ANN ONCOL, V23, P866, DOI 10.1093/annonc/mdr316
   Alvarado Moreno JA, 2021, THROMB RES, V206, P55, DOI 10.1016/j.thromres.2021.08.007
   American Cancer Society, 2021, FACTAND FIG
   Bui AT, 2015, CELL CYCLE, V14, P1218, DOI 10.1080/15384101.2015.1014145
   Arandkar S, 2018, P NATL ACAD SCI USA, V115, P6410, DOI 10.1073/pnas.1719076115
   Arnold KM, 2017, ONCOL LETT, V14, P5285, DOI 10.3892/ol.2017.6874
   Asumda FZ, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471 2121 12 44
   Bae SH, 2015, GROWTH FACTORS, V33, P71, DOI 10.3109/08977194.2015.1013628
   Bakhshandeh S, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2111046118
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078 0432.CCR 06 0169
   Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013
   Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444
   Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008 5472.CAN 07 6849
   Barkan D, 2011, CLIN CANCER RES, V17, P7219, DOI 10.1158/1078 0432.CCR 11 0642
   Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008 5472.CAN 09 2356
   Barney LE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz4157
   Barone I, 2020, SEMIN CANCER BIOL, V60, P274, DOI 10.1016/j.semcancer.2019.09.001
   Barrios J, 2009, CANCER MICROENVIRON, V2, P33, DOI 10.1007/s12307 009 0019 6
   Bartosh TJ, 2016, P NATL ACAD SCI USA, V113, pE6447, DOI 10.1073/pnas.1612290113
   Baumann Z, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202114283
   Beerman I, 2017, EXP HEMATOL, V50, P22, DOI 10.1016/j.exphem.2017.01.008
   Ben Eliyahu S, 2020, TRENDS CANCER, V6, P951, DOI 10.1016/j.trecan.2020.06.004
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bensreti H, 2023, CURR OSTEOPOROS REP, V21, P32, DOI 10.1007/s11914 022 00772 5
   Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680
   Bhattacharya A, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 1942 6
   Bible LE, 2015, J TRAUMA ACUTE CARE, V79, P91, DOI 10.1097/TA.0000000000000686
   Bilkovski R, 2010, J BIOL CHEM, V285, P6170, DOI 10.1074/jbc.M109.054338
   Bliss SA, 2016, CANCER RES, V76, P5832, DOI 10.1158/0008 5472.CAN 16 1092
   Borgen E, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058 018 1049 0
   Bowers M, 2015, BLOOD, V125, P2678, DOI 10.1182/blood 2014 06 582924
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Braun S, 2000, J CLIN ONCOL, V18, P80, DOI 10.1200/JCO.2000.18.1.80
   Brenner S, 2004, STEM CELLS, V22, P1128, DOI 10.1634/stemcells.2003 0196
   Brown TA, 2020, BREAST CANCER RES TR, V181, P391, DOI 10.1007/s10549 020 05638 x
   BRUNNER G, 1993, BLOOD, V81, P631
   Buono M, 2010, J EXP MED, V207, P1647, DOI 10.1084/jem.20091022
   Bushnell GG, 2021, NPJ BREAST CANCER, V7, DOI 10.1038/s41523 021 00269 x
   Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768
   Calle AS, 2020, MOL ONCOL, V14, P2271, DOI 10.1002/1878 0261.12704
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Candini O, 2015, STEM CELLS, V33, P939, DOI 10.1002/stem.1897
   Capulli M, 2019, BRIT J CANCER, V121, P157, DOI 10.1038/s41416 019 0501 y
   Carlson P, 2019, NAT CELL BIOL, V21, P238, DOI 10.1038/s41556 018 0267 0
   CARNEY DH, 1984, J CELL BIOCHEM, V26, P181, DOI 10.1002/jcb.240260306
   Carrelha J, 2018, NATURE, V554, P106, DOI 10.1038/nature25455
   Cedervall J, 2015, CANCER RES, V75, P2653, DOI 10.1158/0008 5472.CAN 14 3299
   Chang PY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001097
   Cheleuitte D, 1998, J CLIN ENDOCR METAB, V83, P2043, DOI 10.1210/jc.83.6.2043
   CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131
   Cheng S, 2019, PHARMACOLOGY, V104, P276, DOI 10.1159/000502107
   Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591
   Chitteti BR, 2013, BONE, V54, P58, DOI 10.1016/j.bone.2013.01.038
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Cianfrocca ME, 2006, BRIT J CANCER, V94, P1621, DOI 10.1038/sj.bjc.6603171
   clinicaltrials, S0307 PHAS 3 TRIAL B
   Colleoni M, 2016, J CLIN ONCOL, V34, P927, DOI 10.1200/JCO.2015.62.3504
   Coller HA, 2006, PLOS BIOL, V4, P329, DOI 10.1371/journal.pbio.0040083
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Cook KL, 2014, CLIN CANCER RES, V20, P3222, DOI 10.1158/1078 0432.CCR 13 3227
   COOMBES RC, 1980, J ROY SOC MED, V73, P617, DOI 10.1177/014107688007300904
   Correia AL, 2021, NATURE, V594, P566, DOI 10.1038/s41586 021 03614 z
   Damen MPF, 2021, FEBS J, V288, P6286, DOI 10.1111/febs.15626
   Dar A, 2011, LEUKEMIA, V25, P1286, DOI 10.1038/leu.2011.62
   Dar H, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.14904
   De Cock JM, 2016, CANCER RES, V76, P6778, DOI 10.1158/0008 5472.CAN 16 0608
   de Pedro M, 2015, BREAST CANCER RES TR, V149, P525, DOI 10.1007/s10549 015 3267 9
   DEARNALEY DP, 1981, BRIT J CANCER, V44, P85, DOI 10.1038/bjc.1981.152
   DEBISSCHOP E, 1993, BONE, V14, P133, DOI 10.1016/8756 3282(93)90239 7
   Decker AM, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100781
   Decker AM, 2017, MOL CANCER RES, V15, P1644, DOI 10.1158/1541 7786.MCR 17 0132
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078 0432.CCR 06 3045
   Di Martino JS, 2021, CANCERS, V13, DOI 10.3390/cancers13194916
   Dias MH, 2021, MOL ONCOL, V15, P1975, DOI 10.1002/1878 0261.12979
   Dillekås H, 2014, BREAST CANCER RES TR, V146, P627, DOI 10.1007/s10549 014 3057 9
   Dong Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.733627
   Drescher F, 2020, CANCERS, V12, DOI 10.3390/cancers12040868
   Dygai AM, 2011, B EXP BIOL MED+, V151, P171, DOI 10.1007/s10517 011 1282 3
   El Touny LH, 2014, J CLIN INVEST, V124, P156, DOI 10.1172/JCI70259
   El Shennawy L, 2018, CANCER RES, V78, P974, DOI 10.1158/0008 5472.CAN 17 1686
   Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556 018 0138 8
   Esposito M, 2019, NAT CELL BIOL, V21, P627, DOI 10.1038/s41556 019 0309 2
   Fan LX, 2014, IN VITRO CELL DEV AN, V50, P304, DOI 10.1007/s11626 013 9701 6
   Fane ME, 2022, NATURE, V606, P396, DOI 10.1038/s41586 022 04774 2
   Fang C, 2022, BONE, V158, DOI 10.1016/j.bone.2020.115693
   Fazeli PK, 2013, J CLIN ENDOCR METAB, V98, P935, DOI 10.1210/jc.2012 3634
   Fenig E, 2001, BREAST CANCER RES TR, V70, P27, DOI 10.1023/A:1012522321762
   Fenig E, 1997, CLIN CANCER RES, V3, P135
   Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465
   Foertsch S, 2017, DIS MODEL MECH, V10, P1399, DOI 10.1242/dmm.030916
   Fogarty H, 2021, J THROMB HAEMOST, V19, P2546, DOI 10.1111/jth.15490
   Forget P, 2010, ANESTH ANALG, V110, P1630, DOI 10.1213/ANE.0b013e3181d2ad07
   Francescangeli F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.592891
   Fu JX, 2018, J BIOL CHEM, V293, P7268, DOI 10.1074/jbc.RA117.001684
   Fukuoka M, 2022, CANCER SCI, V113, P2336, DOI 10.1111/cas.15373
   GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497
   GABRILOVE JL, 1993, BLOOD, V81, P909
   GABRILOVE JL, 1994, BLOOD, V83, P907
   Gao H, 2014, P NATL ACAD SCI USA, V111, P16532, DOI 10.1073/pnas.1403234111
   Gao XL, 2017, ONCOTARGETS THER, V10, P5219, DOI 10.2147/OTT.S140854
   Gawrzak S, 2018, NAT CELL BIOL, V20, P211, DOI 10.1038/s41556 017 0021 z
   Gelman IH, 2023, CANCER METAST REV, V42, P255, DOI 10.1007/s10555 022 10076 w
   Georgiou GK, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477 7819 11 213
   Geurts YM, 2017, BREAST CANCER RES TR, V165, P709, DOI 10.1007/s10549 017 4340 3
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092 8674(90)90098 Y
   Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029
   Goeijenbier M, 2012, J MED VIROL, V84, P1680, DOI 10.1002/jmv.23354
   Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465
   Gomez Rosas Patricia, 2021, TH Open, V5, pe56, DOI 10.1055/s 0040 1722609
   Greco Steven J, 2013, Methods Mol Biol, V1024, P87, DOI 10.1007/978 1 62703 453 1_7
   Green D, 2010, CELL CYCLE, V9, P656, DOI 10.4161/cc.9.4.10729
   Griffith JF, 2012, J MAGN RESON IMAGING, V36, P225, DOI 10.1002/jmri.23619
   Grover A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11075
   Guan XN, 2017, MOL CANCER RES, V15, P237, DOI 10.1158/1541 7786.MCR 16 0319
   Guereño M, 2020, EUR J CELL BIOL, V99, DOI 10.1016/j.ejcb.2020.151096
   Guo Z, 2022, PUBLIC HEALTH, V210, P26, DOI 10.1016/j.puhe.2022.06.014
   Haider R, 2020, CANCER AM CANCER SOC, V126, P3991, DOI 10.1002/cncr.32950
   Haldar R, 2023, BRAIN BEHAV IMMUN, V109, P175, DOI 10.1016/j.bbi.2023.01.005
   Haldar R, 2018, FUTURE ONCOL, V14, P1017, DOI 10.2217/fon 2017 0635
   Hamilton MM, 2021, J MED CHEM, V64, P11302, DOI 10.1021/acs.jmedchem.1c00679
   Han HH, 2016, ENDOCR RELAT CANCER, V23, P609, DOI 10.1530/ERC 16 0086
   Hanin L, 2018, B MATH BIOL, V80, P519, DOI 10.1007/s11538 017 0388 9
   Hanin L, 2016, J THEOR BIOL, V394, P172, DOI 10.1016/j.jtbi.2016.01.014
   Hanns P, 2019, CELL STRESS, V3, P221, DOI 10.15698/cst2019.07.192
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Hartkopf AD, 2021, EUR J CANCER, V154, P128, DOI 10.1016/j.ejca.2021.06.028
   Hassan N, 2021, CELL SIGNAL, V77, DOI 10.1016/j.cellsig.2020.109822
   Haÿ E, 2014, J CELL PHYSIOL, V229, P1765, DOI 10.1002/jcp.24629
   He QL, 2017, STEM CELLS, V35, P473, DOI 10.1002/stem.2481
   Hiller J., 2017, PERIOPERATIVE INFLAM, P83
   Ho YH, 2020, HAEMATOLOGICA, V105, P38, DOI 10.3324/haematol.2018.211334
   Hooker RA, 2015, J MUSCULOSKEL NEURON, V15, P83
   Horak CE, 2008, APMIS, V116, P586, DOI 10.1111/j.1600 0463.2008.01213.x
   Huang CL, 2017, ONCOTARGET, V8, P115254, DOI 10.18632/oncotarget.23250
   Huang YQ, 2015, J BIOL CHEM, V290, P17753, DOI 10.1074/jbc.M115.661066
   Huang ZJ, 2015, ONCOTARGET, V6, P39550, DOI 10.18632/oncotarget.6098
   Hughes R, 2021, CANCERS, V13, DOI 10.3390/cancers13061366
   Hyakutake MT, 2019, J EMERG MED, V57, pE49, DOI 10.1016/j.jemermed.2019.02.010
   Indraccolo S, 2006, CELL CYCLE, V5, P1751, DOI 10.4161/cc.5.16.2985
   Itkin T, 2013, CURR OPIN HEMATOL, V20, P237, DOI 10.1097/MOH.0b013e3283606162
   Ito T, 2008, CYTOTECHNOLOGY, V56, P1, DOI 10.1007/s10616 007 9092 1
   Jaguin M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116560
   Janghorban M, 2022, CANCER RES, V82, P885, DOI 10.1158/0008 5472.CAN 21 1230
   Jatoi I, 2011, J CLIN ONCOL, V29, P2301, DOI 10.1200/JCO.2010.32.3550
   Jeng KS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051375
   Jin JF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074497
   Johnson JD, 2019, J ENDOCR SOC, V3, P1302, DOI 10.1210/js.2019 00053
   Johnson RW, 2017, CURR OSTEOPOROS REP, V15, P231, DOI 10.1007/s11914 017 0378 8
   Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408
   Jung YH, 2007, BLOOD, V110, P82, DOI 10.1182/blood 2006 05 021352
   Jung YH, 2015, MOL CANCER RES, V13, P197, DOI 10.1158/1541 7786.MCR 14 0118
   Jung YH, 2011, EXP HEMATOL, V39, P151, DOI 10.1016/j.exphem.2010.11.007
   Kaack MB, 1998, CYTOKINE, V10, P236, DOI 10.1006/cyto.1997.0281
   Kampeerawipakorn O, 2017, ENVIRON RES, V152, P207, DOI 10.1016/j.envres.2016.10.004
   Kanawa M, 2013, CYTOTHERAPY, V15, P1062, DOI 10.1016/j.jcyt.2013.03.015
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590
   Karpatkin S, 2004, J THROMB HAEMOST, V2, P2103, DOI 10.1111/j.1538 7836.2004.01003.x
   Kaur A, 2016, NATURE, V532, P250, DOI 10.1038/nature17392
   Kawamori Y, 2010, BLOOD, V116, P5528, DOI 10.1182/blood 2010 04 279216
   Kent DG, 2009, BLOOD, V113, P6342, DOI 10.1182/blood 2008 12 192054
   Khalil BD, 2021, J EXP MED, V219, DOI 10.1084/jem.20210836
   Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535 7163.MCT 06 0100
   Khurana S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13500
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kim JY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.596364
   Kim M, 2012, MECH AGEING DEV, V133, P215, DOI 10.1016/j.mad.2012.03.014
   Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569
   Kim S, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 01839 4
   Kim S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051671
   Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140 6736(02)09838 0
   Klein CA, 2020, NAT REV CANCER, V20, P681, DOI 10.1038/s41568 020 00300 6
   Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627
   KLEPFISH A, 1993, INT J CANCER, V53, P978
   Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Kolb AD, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058 019 1117 0
   Kondo M, 2015, J DIABETES INVEST, V6, P140, DOI 10.1111/jdi.12272
   Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008 5472.CAN 03 3853
   Krall JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3464
   Krevvata M, 2014, BLOOD, V124, P2834, DOI 10.1182/blood 2013 07 517219
   Krisnawan VE, 2020, CANCERS, V12, DOI 10.3390/cancers12102916
   Krzeszinski JY, 2015, TRENDS PHARMACOL SCI, V36, P360, DOI [10.1016/J.tips.2015.04.006, 10.1016/j.tips.2015.04.006]
   Kugel H, 2001, J MAGN RESON IMAGING, V13, P263, DOI 10.1002/1522 2586(200102)13:2<263::AID JMRI1038>3.0.CO;2 M
   Kurebayashi J, 2017, CANCER SCI, V108, P918, DOI 10.1111/cas.13205
   La Camera G, 2021, CANCER LETT, V521, P155, DOI 10.1016/j.canlet.2021.08.021
   Lai PL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.249
   Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260
   Le Blanc S, 2015, EXP CELL RES, V338, P136, DOI 10.1016/j.yexcr.2015.09.009
   Lerman I, 2018, STEROIDS, V133, P96, DOI 10.1016/j.steroids.2017.11.006
   Lewis C, 2005, AM J PATHOL, V167, P627, DOI 10.1016/S0002 9440(10)62038 X
   Li HJ, 2017, J CLIN INVEST, V127, P1241, DOI 10.1172/JCI89511
   Li R, 2020, CANCERS, V12, DOI 10.3390/cancers12123752
   Li XQ, 2016, CANCER LETT, V380, P78, DOI 10.1016/j.canlet.2016.06.007
   Li ZX, 2006, TRENDS BIOCHEM SCI, V31, P589, DOI 10.1016/j.tibs.2006.08.001
   Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008 5472.CAN 10 2372
   Liu C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.561595
   Liu Y, 2014, MOL MED REP, V9, P333, DOI 10.3892/mmr.2013.1803
   Liu YF, 2017, MOL CELL BIOCHEM, V425, P47, DOI 10.1007/s11010 016 2861 4
   Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Luo XM, 2016, CELL REP, V14, P82, DOI 10.1016/j.celrep.2015.12.016
   Luppi F, 2007, LUNG CANCER, V56, P25, DOI 10.1016/j.lungcan.2006.11.014
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   Magbanua MJM, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523 018 0083 5
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025
   Mandoj C, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1511 x
   Manjili SH, 2022, SEMIN CANCER BIOL, V78, P17, DOI 10.1016/j.semcancer.2021.03.023
   Mansi JL, 1999, LANCET, V354, P197, DOI 10.1016/S0140 6736(98)10175 7
   MANSI JL, 1991, EUR J CANCER, V27, P1552, DOI 10.1016/0277 5379(91)90413 8
   MANSI JL, 1987, BMJ BRIT MED J, V295, P1093, DOI 10.1136/bmj.295.6606.1093
   Marchetti M, 2020, J THROMB HAEMOST, V18, P2220, DOI 10.1111/jth.14891
   Marlow R, 2013, CANCER RES, V73, P6886, DOI 10.1158/0008 5472.CAN 13 0991
   Maryanovich M, 2018, NAT MED, V24, P782, DOI 10.1038/s41591 018 0030 x
   Massafra R, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.576007
   Matzner P, 2020, NAT REV CLIN ONCOL, V17, P313, DOI 10.1038/s41571 019 0319 9
   Matzner P, 2019, BRAIN BEHAV IMMUN, V80, P170, DOI 10.1016/j.bbi.2019.03.005
   Melzer C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115930
   Melzer C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218347
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Miarka L, 2019, CANCERS, V11, DOI 10.3390/cancers11060745
   Miller Ocuin JL, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1605822
   Mittendorf EA, 2016, ONCOTARGET, V7, P66192, DOI 10.18632/oncotarget.11751
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Montagner M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010250
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Mukai H, 2022, BIOCHEM BIOPH RES CO, V628, P116, DOI 10.1016/j.bbrc.2022.08.062
   Munir H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 20982 2
   Najmi S, 2005, CLIN CANCER RES, V11, P2038, DOI 10.1158/1078 0432.CCR 04 1083
   Naume B, 2014, J CLIN ONCOL, V32, P3848, DOI 10.1200/JCO.2014.56.9327
   Naumov GN, 2003, BREAST CANCER RES TR, V82, P199, DOI 10.1023/B:BREA.0000004377.12288.3c
   Nehlin JO, 2019, BONE, V123, P265, DOI 10.1016/j.bone.2019.03.041
   Nicolai L., 2023, J THROMB HAEMOST
   NIERODZIK ML, 1991, J CLIN INVEST, V87, P229, DOI 10.1172/JCI114976
   NIERODZIK MLR, 1992, CANCER RES, V52, P3267
   Nierodzik MLR, 1996, BRIT J HAEMATOL, V92, P452, DOI 10.1046/j.1365 2141.1996.d01 1494.x
   Nilsson SK, 1998, J HISTOCHEM CYTOCHEM, V46, P371, DOI 10.1177/002215549804600311
   Nobre AR, 2022, NAT CANCER, V3, P1165, DOI 10.1038/s43018 022 00424 8
   Nobre AR, 2021, NAT CANCER, V2, P327, DOI 10.1038/s43018 021 00179 8
   Norton L, 2007, NAT CLIN PRACT ONCOL, V4, P671, DOI 10.1038/ncponc1001
   Obradovic MMS, 2019, NATURE, V567, P540, DOI 10.1038/s41586 019 1019 4
   Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092 8674(94)90200 3
   Ou GM, 2010, J GERONTOL A BIOL, V65, P1051, DOI 10.1093/gerona/glq114
   Ozga AJ, 2021, IMMUNITY, V54, P859, DOI 10.1016/j.immuni.2021.01.012
   Pajic M, 2017, CLIN CANCER RES, V23, P7020, DOI 10.1158/1078 0432.CCR 17 1279
   Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830
   Panaroni C, 2015, J BONE MINER RES, V30, P2273, DOI 10.1002/jbmr.2581
   Panigrahy D, 2012, J CLIN INVEST, V122, P178, DOI 10.1172/JCI58128
   Pantano F, 2021, ONCOGENE, V40, P1284, DOI 10.1038/s41388 020 01603 6
   Parker KA, 2022, SEMIN CANCER BIOL, V78, P23, DOI 10.1016/j.semcancer.2021.03.020
   Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791
   Payne KK, 2016, J LEUKOCYTE BIOL, V100, P625, DOI 10.1189/jlb.5A1215 580R
   Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008 5472.CAN 11 3386
   Pommier A, 2018, SCIENCE, V360, P1202, DOI 10.1126/science.aao4908
   Pretorius E, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933 021 01359 7
   Qin SY, 2022, BBA REV CANCER, V1877, DOI 10.1016/j.bbcan.2022.188749
   Quan MY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00287
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Radman M, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.180250
   Ragunathan K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228635
   REDDING WH, 1983, LANCET, V2, P1271
   Rega G, 2007, ARTERIOSCL THROM VAS, V27, P1587, DOI 10.1161/ATVBAHA.107.143081
   Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661
   Retsky Michael, 2005, Int J Surg, V3, P235, DOI 10.1016/j.ijsu.2005.10.017
   Retsky Michael, 2005, Int J Surg, V3, P179, DOI 10.1016/j.ijsu.2005.08.002
   Retsky M, 2013, CURR MED CHEM, V20, P4163
   Retsky Michael W, 2007, Int J Surg, V5, P300, DOI 10.1016/j.ijsu.2006.12.005
   Ricon I, 2019, CANCER AM CANCER SOC, V125, P45, DOI 10.1002/cncr.31594
   Risson E, 2020, NAT CANCER, V1, P672, DOI 10.1038/s43018 020 0088 5
   Robinson NJ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.177
   Roche J, 2016, EUR J MED CHEM, V121, P451, DOI 10.1016/j.ejmech.2016.05.047
   Saba Fakhredin, 2013, Lab Hematol, V19, P8, DOI 10.1532/LH96.12013
   Sanmartin MC, 2021, CRIT REV ONCOL HEMAT, V164, DOI 10.1016/j.critrevonc.2021.103416
   Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442
   Sarsour EH, 2020, J BIOL CHEM, V295, P6946, DOI 10.1074/jbc.RA120.012798
   Satcher RL, 2022, NAT REV CANCER, V22, P85, DOI 10.1038/s41568 021 00406 5
   Sauer S, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.659963
   Scheller EL, 2016, TRENDS ENDOCRIN MET, V27, P392, DOI 10.1016/j.tem.2016.03.016
   Scheller EL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8808
   Schellinger D, 2000, RADIOLOGY, V215, P910, DOI 10.1148/radiology.215.3.r00jn42910
   Shaashua L, 2020, BMC BIOL, V18, DOI 10.1186/s12915 020 00893 2
   Shaashua L, 2017, CLIN CANCER RES, V23, P4651, DOI 10.1158/1078 0432.CCR 17 0152
   Shah SA, 2017, IMMUNOTHERAPY UK, V9, P943, DOI 10.2217/imt 2017 0044
   Sheinboim D, 2022, CANCER RES, V82, P4164, DOI 10.1158/0008 5472.CAN 22 0237
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Shupp AB, 2021, MOL CANCER RES, V19, P1763, DOI 10.1158/1541 7786.MCR 20 0981
   Singh A, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125679
   Sistigu A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02166
   Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Sosa MS, 2017, CANCER DRUG DISCOV D, P1, DOI 10.1007/978 3 319 59242 8_1
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034
   Sriuranpong V, 2003, CANCER RES, V63, P2948
   Stein WD, 2006, CELL CYCLE, V5, P2348, DOI 10.4161/cc.5.20.3349
   Steiner H, 2004, EUR J CANCER, V40, P1066, DOI 10.1016/j.ejca.2003.11.033
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Suh YA, 2002, CANCER RES, V62, P3945
   Sui BD, 2016, SCI REP UK, V6, DOI 10.1038/srep30186
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Taichman RS, 2002, CANCER RES, V62, P1832
   Takasugi M, 2022, MOL ONCOL, V16, P3333, DOI 10.1002/1878 0261.13268
   Takatsuka H, 2003, BONE MARROW TRANSPL, V31, P475, DOI 10.1038/sj.bmt.1703879
   Takeshita S, 2014, J BIOL CHEM, V289, P16699, DOI 10.1074/jbc.M114.547919
   Tamura D, 2008, INT J ONCOL, V33, P17
   Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586 019 1104 8
   Tivari S, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0259 5
   Trotter TN, 2016, AM J PATHOL, V186, P3054, DOI 10.1016/j.ajpath.2016.07.012
   Tsai CY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063119
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Vatner RE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00325
   Vera Ramirez L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04070 6
   Walker ND, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1304 z
   Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wang HS, 1997, CANCER RES, V57, P1750
   Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555 006 9019 x
   Wang R, 2019, EBIOMEDICINE, V45, P108, DOI 10.1016/j.ebiom.2019.06.037
   Wang X, 2020, MOL PSYCHIATR, V25, P3186, DOI 10.1038/s41380 020 00865 6
   Watt AC, 2021, NAT CANCER, V2, P34, DOI 10.1038/s43018 020 00135 y
   Watt MJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5758
   Weidenfeld K, 2016, ONCOTARGET, V7, P71362, DOI 10.18632/oncotarget.12109
   White AC, 2014, NAT CELL BIOL, V16, P99, DOI 10.1038/ncb2889
   Wieder R, 2005, J SURG ONCOL, V89, P207, DOI 10.1002/jso.20199
   Wieder R, 2023, CANCERS, V15, DOI 10.3390/cancers15072014
   Wieder R, 2022, CANCERS, V14, DOI 10.3390/cancers14143344
   Wieder R, 2020, J CANCER, V11, P2808, DOI 10.7150/jca.39091
   Wieder R, 2016, J CANCER, V7, P1587, DOI 10.7150/jca.16012
   WILSON EL, 1991, BLOOD, V77, P954
   Wong CP, 2009, CANCER LETT, V276, P38, DOI 10.1016/j.canlet.2008.10.025
   Xia WZ, 2017, MOL MED REP, V16, P7039, DOI 10.3892/mmr.2017.7430
   Xiao LP, 2010, BONE, V47, P360, DOI 10.1016/j.bone.2010.05.021
   Xu Z, 2018, J LEUKOCYTE BIOL, V104, P597, DOI 10.1002/JLB.3AB0118 005R
   Yan GN, 2014, J PATHOL, V234, P11, DOI 10.1002/path.4349
   Yanagawa Y, 2011, BRAIN BEHAV IMMUN, V25, P1427, DOI 10.1016/j.bbi.2011.04.012
   Yang C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.725204
   Yang FF, 2014, J MED CHEM, V57, P9357, DOI 10.1021/jm5012148
   Yang HB, 2022, J CONTROL RELEASE, V341, P443, DOI 10.1016/j.jconrel.2021.11.005
   Yeh SCA, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 27973 x
   Yeoh JSG, 2006, STEM CELLS, V24, P1564, DOI 10.1634/stemcells.2005 0439
   Yoon KA, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964 017 0181 2
   Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347
   Yumoto K, 2016, SCI REP UK, V6, DOI 10.1038/srep36520
   Zeng J, 2020, J CELL MOL MED, V24, P7590, DOI 10.1111/jcmm.15394
   Zhang HJ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.989167
   Zhang JY, 2020, CANCERS, V12, DOI 10.3390/cancers12082123
   Zhang MM, 2018, CANCER DISCOV, V8, P1006, DOI 10.1158/2159 8290.CD 17 1371
   Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
   Zhang X, 2021, ELIFE, V10, DOI 10.7554/eLife.66275
   Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008 5472.CAN 06 4499
   Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002
   Zheng YH, 2013, J BIOL CHEM, V288, P31488, DOI 10.1074/jbc.M113.499020
   Zhou YL, 2014, GENES CELLS, V19, P676, DOI 10.1111/gtc.12168
   Zhou ZL, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04603 4
   Zong JC, 2016, ONCOL REP, V35, P739, DOI 10.3892/or.2015.4430
NR 378
TC 7
Z9 7
U1 0
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD JUN 1
PY 2023
VL 15
IS 11
AR 3021
DI 10.3390/cancers15113021
PG 47
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA I8EN1
UT WOS:001005062900001
PM 37296983
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kondo, T
   Otsuka, Y
   Aoki, H
   Goto, Y
   Kawaguchi, Y
   Waguri Nagaya, Y
   Miyazawa, K
   Goto, S
   Aoyama, M
AF Kondo, Takao
   Otsuka, Yuto
   Aoki, Hiromasa
   Goto, Yoh
   Kawaguchi, Yohei
   Waguri Nagaya, Yuko
   Miyazawa, Ken
   Goto, Shigemi
   Aoyama, Mineyoshi
TI The Inducible Nitric Oxide Synthase Pathway Promotes Osteoclastogenesis
   under Hypoxic Culture Conditions
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID BONE MARROW; FACTOR I; DIFFERENTIATION; NECROSIS; RESORPTION; FUSION
AB Bone homeostasis depends on the balance between bone resorption by osteoclasts (OCs) and bone formation by osteoblasts. Bone resorption can become excessive under various pathologic conditions, including rheumatoid arthritis. Previous studies have shown that OC formation is promoted under hypoxia. However, the precise mechanisms behind OC formation under hypoxia have not been elucidated. The present study investigated the role of inducible nitric oxide synthase (iNOS) in OC differentiation under hypoxia. Primary bone marrow cells obtained from mice were stimulated with receptor activator of NF KB ligand and macrophage colony stimulating factor to induce OC differentiation. The number of OCs increased in culture under hypoxia (oxygen concentration, 5%) compared with that under normoxia (oxygen concentration, 20%). iNOS gene and protein expression increased in culture under hypoxia. Addition of an iNOS inhibitor under hypoxic conditions suppressed osteoclastogenesis. Addition of a nitric oxide donor to the normoxic culture promoted osteoclastogenesis. Furthermore, insulin like growth factor 2 expression was significantly altered in both iNOS inhibition experiments and nitric oxide donor experiments. These data might provide clues to therapies for excessive osteoclastogenesis under several hypoxic pathologic conditions, including rheumatoid arthritis. (Am J Pathol 2021, 191: 2072 2079; https://doi.org/10.1016/j.ajpath.2021.08.014)
C1 [Kondo, Takao; Otsuka, Yuto; Aoki, Hiromasa; Aoyama, Mineyoshi] Nagoya City Univ, Dept Pathobiol, Grad Sch Pharmaceut Sci, Nagoya, Aichi, Japan.
   [Kawaguchi, Yohei] Nagoya City Univ, Dept Glial Cell Biol, Grad Sch Pharmaceut Sci, Nagoya, Aichi, Japan.
   [Kawaguchi, Yohei; Waguri Nagaya, Yuko] Nagoya City Univ, Dept Orthopaed Surg, Grad Sch Pharmaceut Sci, Nagoya, Aichi, Japan.
   [Goto, Yoh; Miyazawa, Ken; Goto, Shigemi] Aichi Gakuin Univ, Sch Dent, Dept Orthodont, Nagoya, Aichi, Japan.
C3 Nagoya City University; Nagoya City University; Nagoya City University;
   Aichi Gakuin University
RP Aoyama, M (通讯作者)，Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Pathobiol, Mizuho Ku, 3 1 Tanabedori, Nagoya, Aichi 4678603, Japan.
EM aomine@phar.nagoya cu.ac.jp
OI Aoki, Hiromasa/0000 0001 9175 8260; Aoyama,
   Mineyoshi/0000 0002 9976 6465; Otsuka, Yuto/0000 0003 0742 0000;
   Waguri Nagaya, Yuko/0000 0002 5690 7731
FU Japan Society for the Promotion of Science; KAKEN [20K22715, 18K17271,
   19K18473, 20K09465, 20K08211]; Grants in Aid for Scientific Research
   [21K16403, 20K08211, 20K09465, 18K17271, 20K22715, 19K18473] Funding
   Source: KAKEN
FX Supported in part by Japan Society for the Promotion of Science
   grants in aid for scientific research; and KAKEN grants 20K22715 (H.A.)
   , 18K17271 (Y.G.) , 19K18473 (Y.K.) , 20K09465 (Y.W N.) , and 20K08211
   (M.A.) .
CR Arias Salvatierra D, 2011, CELL SIGNAL, V23, P425, DOI 10.1016/j.cellsig.2010.10.017
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Arnett TR, 2003, CALCIF TISSUE INT, V196, P2
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   BARON R, 1986, AM J PATHOL, V122, P363
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chambers TJ, 2000, J PATHOL, V192, P4
   Dunst J, 2001, STRAHLENTHER ONKOL, V177, P153, DOI 10.1007/s00066 001 0804 8
   Fukuoka H, 2005, BIOCHEM BIOPH RES CO, V328, P885, DOI 10.1016/j.bbrc.2005.01.042
   Gaber T, 2005, ANN RHEUM DIS, V64, P971, DOI 10.1136/ard.2004.031641
   Goto Y, 2016, STEM CELLS, V34, P2733, DOI 10.1002/stem.2440
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Herrera BS, 2011, J PERIODONTOL, V82, P1608, DOI 10.1902/jop.2011.100768
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889
   Ma ZZ, 2019, INFLAMM RES, V68, P157, DOI 10.1007/s00011 018 1209 9
   Maridas DE, 2018, JOVE J VIS EXP, DOI 10.3791/56750
   Muzylak M, 2006, CALCIFIED TISSUE INT, V79, P301, DOI 10.1007/s00223 006 0082 7
   Nakao K, 2009, BIOCHEM BIOPH RES CO, V378, P462, DOI 10.1016/j.bbrc.2008.11.083
   Nomura T, 2014, EXP CELL RES, V321, P167, DOI 10.1016/j.yexcr.2013.11.020
   Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Utting JC, 2010, CELL BIOCHEM FUNCT, V28, P374, DOI 10.1002/cbf.1660
   Watanabe Y, 2007, J ORTHOP TRAUMA, V21, P456, DOI 10.1097/BOT.0b013e318126bb56
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 33
TC 14
Z9 15
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD DEC
PY 2021
VL 191
IS 12
BP 2072
EP 2079
DI 10.1016/j.ajpath.2021.08.014
EA NOV 2021
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA XB7JL
UT WOS:000721501600004
PM 34560064
OA Bronze
DA 2025 08 17
ER

PT S
AU Pazianas, M
   Rhim, AD
   Weinberg, AM
   Su, CY
   Lichtenstein, GR
AF Pazianas, Michael
   Rhim, Andrew D.
   Weinberg, Andrew M.
   Su, Chinyu
   Lichtenstein, Gary R.
BE Zaidi, M
TI The effect of anti TNF α therapy on spinal bone mineral density in
   patients with Crohn's disease
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE Crohn's disease; infliximab; BMD; bisphosphonates; corticosteroids
ID NECROSIS FACTOR ALPHA; GLUCOCORTICOID INDUCED OSTEOPOROSIS; SHORT TERM;
   INFLIXIMAB; ALENDRONATE; BUDESONIDE; PREVENTION; MECHANISMS; TURNOVER;
   EFFICACY
AB Proinflammatory cytokines, including tumor necrosis factor alpha (TNF alpha) might be, at least partially, responsible for the development of osteopenia or osteoporosis in Crohn's disease. We investigated whether anti TNF therapy for Crohn's disease could have any skeletal impact. Therefore, we studied the effects of infliximab, a monoclonal antibody against TNF alpha with and without bisphosphonates, on spinal bone mineral density (BMD). The effect of corticosteroids was also analyzed. A retrospective cohort analysis was performed on 61 patients with Crohn's disease and low BMD by serial DXA scans. Twenty three patients were on infliximab and 36 patients were on bisphosphonates. Mean duration between DXA scans was 2.2 +/  0.99 years. After controlling for corticosteroid use, patients with concurrent infliximab and bisphosphonate treatment exhibited a greater increase in BMD compared to those on bisphosphonates alone (+6.7%/year vs. +4.46%/year, P = 0.045); corticosteroids inhibited this effect (P = 0.025). However, infliximab alone had no effects on BMD. Patients receiving bisphosphonates showed a significant increase in lumbar spine BMD compared to those not on bisphosphonates (+3.97% change in T score/year vs.  3.68%/year, P < 0.0001). Concurrent corticosteroid use significantly inhibited this effect (+2.15%/year vs. +4.97%/year, P = 0.0014). Concurrent infliximab use may confer an additional benefit to that already documented for bisphosphonate use alone; bisphosphonates are beneficial in the treatment of low BMD in patients with Crohn's disease, though corticosteroids may partially inhibit this effect.
C1 Univ Penn, Sch Med, Dept Med, Hosp Univ Penn, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Div Gastroenterol, Hosp Univ Penn, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania
RP Pazianas, M (通讯作者)，Univ Penn, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM pazianas@mail.med.upenn.edu
RI Pazianas, Michael/ABE 4572 2020
FU NIDDK NIH HHS [DK 07748] Funding Source: Medline
CR Allali F, 2003, ANN RHEUM DIS, V62, P347, DOI 10.1136/ard.62.4.347
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   Bernstein CN, 2003, GASTROENTEROLOGY, V124, P795, DOI 10.1053/gast.2003.50106
   Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496
   CASCIO VL, 1984, CALCIFIED TISSUE INT, V36, P435, DOI 10.1007/BF02405356
   Cino M, 2002, AM J GASTROENTEROL, V97, P915
   Cohen RD, 2000, AM J GASTROENTEROL, V95, P3469
   D'Haens G, 1998, ALIMENT PHARM THERAP, V12, P419
   De Jong DJ, 2003, DIGEST DIS SCI, V48, P1355, DOI 10.1023/A:1024171529000
   Franchimont N, 2004, ALIMENT PHARM THER, V20, P607, DOI 10.1111/j.1365 2036.2004.02152.x
   Haderslev KV, 2000, GASTROENTEROLOGY, V119, P639, DOI 10.1053/gast.2000.16518
   Hyams JS, 1997, J PEDIATR GASTR NUTR, V24, P289, DOI 10.1097/00005176 199703000 00011
   Klaus J, 2002, GUT, V51, P654, DOI 10.1136/gut.51.5.654
   Lichtenstein GR, 2003, AM J GASTROENTEROL, V98, pS24, DOI 10.1016/j.amjgastroenterol.2003.11.003
   Lin CL, 1996, GASTROENTEROLOGY, V111, P1263, DOI 10.1053/gast.1996.v111.pm8898640
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   PECK WA, 1993, AM J MED, V94, P646
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Reid DM, 2000, J BONE MINER RES, V15, P1006, DOI 10.1359/jbmr.2000.15.6.1006
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Ricart E, 2001, AM J GASTROENTEROL, V96, P722, DOI 10.1111/j.1572 0241.2001.03612.x
   Rutgeerts P, 1999, GASTROENTEROLOGY, V117, P761, DOI 10.1016/S0016 5085(99)70332 X
   Ryan BM, 2004, ALIMENT PHARM THER, V20, P851, DOI 10.1111/j.1365 2036.2004.02097.x
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Sandborn WJ, 2003, BEST PRACT RES CL GA, V17, P105, DOI 10.1053/bega.2002.0345
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schoon E, 2002, AM J GASTROENTEROL, V97, pS272, DOI 10.1016/S0002 9270(02)05310 8
   Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502
   van Deventer SJH, 1999, ALIMENT PHARM THER, V13, P3, DOI 10.1046/j.1365 2036.1999.00024.x
   Von Tirpitz C, 2003, ALIMENT PHARM THER, V17, P807, DOI 10.1046/j.1365 2036.2003.01448.x
   2000, NAT I HLTH CONS DEV, V17, P1
NR 33
TC 49
Z9 50
U1 0
U2 2
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 543
EP 556
DI 10.1196/annals.1346.055
PG 14
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200051
PM 16831950
DA 2025 08 17
ER

PT J
AU Zeng, CY
   Wang, S
   Chen, FL
   Wang, ZM
   Li, JT
   Xie, ZY
   Ma, MJ
   Wang, P
   Shen, HY
   Wu, YF
AF Zeng, Chenying
   Wang, Shan
   Chen, Fenglei
   Wang, Ziming
   Li, Jinteng
   Xie, Zhongyu
   Ma, Mengjun
   Wang, Peng
   Shen, Huiyong
   Wu, Yanfeng
TI Alpinetin alleviates osteoporosis by promoting osteogenic
   differentiation in BMSCs by triggering autophagy via PKA/mTOR/ULK1
   signaling
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE alpinetin; autophagy; bone marrow mesenchymal stem cells; osteogenic
   differentiation; osteoporosis; protein kinase A
ID MESENCHYMAL STEM CELLS; INFLAMMATORY RESPONSE; SMALL MOLECULES; BONE;
   TARGETS; FATE
AB Osteoporosis, a systemic bone disease that is characterized by a reduction in bone mass and destruction of bone microstructure, is becoming a serious problem worldwide. Bone marrow mesenchymal stem cells (BMSCs) can differentiate into bone forming osteoblasts, and play an important role in maintaining homeostasis of bone metabolism, thus being a potential therapeutic target for osteoporosis. Although the phytochemical alpinetin (APT) has been reported to possess a variety of pharmacological activities, it is still unclear whether APT can influence the osteogenic differentiation of on BMSCs and if it can improve osteoporosis. In this study, we found that APT treatment was able to enhance osteogenic differentiation levels of human BMSCs in vitro and mouse ones in vivo as revealed by multiple osteogenic markers including increased alkaline phosphatase activity and osteocalcin expression. Mechanistically, the protein kinase A (PKA)/mTOR/ULK1 signaling was involved in the action of APT to enhance the osteogenic differentiation of BMSCs. In addition, oral administration of APT significantly mitigated the bone loss in a dexamethasone induced mouse model of osteoporosis through strengthening PKA signaling and autophagy. Altogether, these data demonstrate that APT promotes osteogenic differentiation in BMSCs by augmenting the PKA/mTOR/ULK1 autophagy signaling, highlighting its potential therapeutic application for treating osteoporotic diseases.
C1 [Zeng, Chenying; Wang, Shan; Wu, Yanfeng] Sun Yat Sen Univ, Ctr Biotherapy, Affiliated Hosp 8, Shenzhen 518033, Peoples R China.
   [Chen, Fenglei; Wang, Ziming; Li, Jinteng; Xie, Zhongyu; Ma, Mengjun; Wang, Peng; Shen, Huiyong] Sun Yat Sen Univ, Dept Orthoped, Affiliated Hosp 8, Shenzhen 518033, Peoples R China.
   [Shen, Huiyong] Sun Yat Sen Univ, Dept Orthoped, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Wu, YF (通讯作者)，Sun Yat Sen Univ, Ctr Biotherapy, Affiliated Hosp 8, Shenzhen 518033, Peoples R China.; Shen, HY (通讯作者)，Sun Yat Sen Univ, Dept Orthoped, Affiliated Hosp 8, Shenzhen 518033, Peoples R China.
EM shenhuiy@mail.sysu.edu.cn; wuyf@mail.sysu.edu.cn
RI Chen, Fenglei/GVT 9361 2022; Xie, Zhongyu/V 6518 2019
FU National Natural Science Foundation of China [81971518]; KeyArea
   Research and Development Program of Guangdong Province [2019B020236001];
   Shenzhen Key Laboratory of Ankylosing Spondylitis
   [ZDSYS20190902092851024]
FX National Natural Science Foundation of China, Grant/Award Number:
   81971518; the KeyArea Research and Development Program of Guangdong
   Province, Grant/Award Number: 2019B020236001; the Shenzhen Key
   Laboratory of Ankylosing Spondylitis, Grant/Award Number:
   ZDSYS20190902092851024
CR Alonso Bouzon Cristina, 2011, Rev Esp Geriatr Gerontol, V46, P223, DOI 10.1016/j.regg.2011.02.010
   Anthony BA, 2014, TRENDS IMMUNOL, V35, P32, DOI 10.1016/j.it.2013.10.002
   Berry SD, 2019, JAMA INTERN MED, V179, P1103, DOI 10.1001/jamainternmed.2019.0688
   Boya P, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146506
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Cheng M, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.636231
   Ching HS, 2017, CURR STEM CELL RES T, V12, P71, DOI 10.2174/1574888X11666160815095733
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Diem SJ, 2017, J GEN INTERN MED, V32, P1235, DOI 10.1007/s11606 017 4153 4
   Ding QF, 2018, INT J MOL MED, V42, P171, DOI 10.3892/ijmm.2018.3614
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Esbrit P, 2016, CALCIFIED TISSUE INT, V98, P359, DOI 10.1007/s00223 015 0050 1
   Galluzzi L, 2019, CELL, V177, P1682, DOI 10.1016/j.cell.2019.05.026
   Gao Y, 2020, INFLAMMATION, V43, P1742, DOI 10.1007/s10753 020 01248 3
   Han LZ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1498 0
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   He QT, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02623 z
   He XX, 2016, SCI REP UK, V6, DOI 10.1038/srep28370
   Heinrich M, 2018, J ETHNOPHARMACOL, V211, P329, DOI 10.1016/j.jep.2017.08.015
   Hou J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.338
   Hozayen WG, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1140 y
   Huo MX, 2012, INT IMMUNOPHARMACOL, V12, P241, DOI 10.1016/j.intimp.2011.11.017
   Izzo AA, 2020, BRIT J PHARMACOL, V177, P2169, DOI 10.1111/bph.15054
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim JH, 2018, J CELL BIOCHEM, V119, P5571, DOI 10.1002/jcb.26728
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Lane NE, 2019, CURR OSTEOPOROS REP, V17, P1, DOI 10.1007/s11914 019 00498 x
   Lee YY, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1649 3
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Li JT, 2019, CELL DEATH DIFFER, V26, P2652, DOI 10.1038/s41418 019 0328 3
   Li M, 2016, J PINEAL RES, V61, P353, DOI 10.1111/jpi.12353
   Li M, 2020, ELIFE, V9, DOI 10.7554/eLife.59079
   Li M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0627 5
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Liang YJ, 2018, INT IMMUNOPHARMACOL, V62, P309, DOI 10.1016/j.intimp.2018.07.010
   Liu TG, 2019, MICROB PATHOGENESIS, V126, P239, DOI 10.1016/j.micpath.2018.11.007
   Liu X, 2017, BIOCHEM BIOPH RES CO, V485, P421, DOI 10.1016/j.bbrc.2017.02.062
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Lv Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0814 4
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Mäkitie RE, 2016, J BONE MINER RES, V31, P1734, DOI 10.1002/jbmr.2841
   Ng PY, 2019, BIOCHEM SOC T, V47, P639, DOI 10.1042/BST20180445
   Ohata Yasuhisa, 2014, Clin Calcium, V24, P501, DOI CliCa1404501508
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Pierce JL, 2019, BONE, V118, P2, DOI 10.1016/j.bone.2018.05.019
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Qiu JY, 2019, MOLECULES, V24, DOI 10.3390/molecules24193458
   Qiu N, 2012, J CELL BIOCHEM, V113, P967, DOI 10.1002/jcb.23426
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2015, J INTERN MED, V278, P354, DOI 10.1111/joim.12394
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Rodríguez Merchán EC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020767
   Sipos W, 2009, WIEN MED WOCHENSCHR, V159, P230, DOI 10.1007/s10354 009 0647 y
   Song CJ, 2014, CYTOTHERAPY, V16, P1361, DOI 10.1016/j.jcyt.2014.04.006
   Song L, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 020 03249 4
   Szulc P, 2018, BEST PRACT RES CL EN, V32, P725, DOI 10.1016/j.beem.2018.05.003
   Tanaka Shinya, 2017, Clin Calcium, V27, P137, DOI CliCa1701137141
   Tang SA, 2019, STEM CELLS, V37, P270, DOI 10.1002/stem.2937
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Tripathi AK, 2022, APOPTOSIS, V27, P90, DOI 10.1007/s10495 021 01702 z
   Vaisman DN, 2005, BIOL TRACE ELEM RES, V104, P131, DOI 10.1385/BTER:104:2:131
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217
   Vidoni C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0414 7
   Wan YX, 2017, BIOCHEM BIOPH RES CO, V488, P46, DOI 10.1016/j.bbrc.2017.05.004
   Wang JP, 2016, TUMOR BIOL, V37, P9243, DOI 10.1007/s13277 016 4827 2
   Wang TT, 2019, CURR DRUG TARGETS, V20, P354, DOI 10.2174/1389450119666180626120852
   Wang YJ, 2015, BIOTECHNOL ADV, V33, P1626, DOI 10.1016/j.biotechadv.2015.08.005
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wu J, 2018, INT J ONCOL, V52, P1427, DOI 10.3892/ijo.2018.4320
   Wu X, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 01674 1
   Xiao WZ, 2016, CELL MOL BIOL, V62, P95, DOI 10.14715/cmb/2016.62.3.16
   Xie ZY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0766 0
   Xie ZY, 2016, ARTHRITIS RHEUMATOL, V68, P430, DOI 10.1002/art.39433
   Xu S, 2018, LEUKEMIA, V32, P1500, DOI 10.1038/s41375 018 0061 9
   Xu YE, 2019, LIFE SCI, V224, P58, DOI 10.1016/j.lfs.2019.03.051
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
   Zhang JL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.849513
   Zhang T, 2020, J CELL MOL MED, V24, P8430, DOI 10.1111/jcmm.15371
   Zhang Y, 2012, J CELL SCI, V125, P5609, DOI 10.1242/jcs.096032
   Zhao G, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.814370
   Zheng CX, 2020, TRENDS MOL MED, V26, P89, DOI 10.1016/j.molmed.2019.04.008
   Zweifler LE, 2021, J BONE MINER RES, V36, P1979, DOI 10.1002/jbmr.4389
NR 93
TC 18
Z9 19
U1 1
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JAN
PY 2023
VL 37
IS 1
BP 252
EP 270
DI 10.1002/ptr.7610
EA SEP 2022
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 8A8PU
UT WOS:000853802900001
PM 36104214
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Göbel, A
   Kuhlmann, JD
   Link, T
   Wimberger, P
   Browne, AJ
   Rauner, M
   Hofbauer, LC
   Rachner, TD
AF Goebel, Andy
   Kuhlmann, Jan D.
   Link, Theresa
   Wimberger, Pauline
   Browne, Andrew J.
   Rauner, Martina
   Hofbauer, Lorenz C.
   Rachner, Tilman D.
TI Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum
   levels of the Wnt inhibitor dickkopf 1 while not affecting sclerostin in
   breast cancer patients
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Dickkopf 1; Sclerostin; Tamoxifen; Aromatase inhibitors
ID ESTROGEN RECEPTOR MODULATORS; BONE MINERAL DENSITY; OSTEOBLAST
   DIFFERENTIATION; MEVALONATE PATHWAY; BISPHOSPHONATES; OSTEOPOROSIS;
   EXPRESSION; MANAGEMENT; TURNOVER; HORMONE
AB Endocrine therapies, including tamoxifen or aromatase inhibitors, are indispensable for the treatment of patients with estrogen receptor (ER)  and/or progesterone positive breast cancer. Whereas tamoxifen displays partial ER agonistic effects in bone, aromatase inhibitors increase bone resorption and fracture risk. The Wnt inhibitors dickkopf 1 (DKK 1) and sclerostin negatively impact bone formation and are considered targets for the treatment of bone disorders. However, the effect of endocrine therapies on serum DKK 1 and sclerostin levels in patients with primary breast cancer remains elusive.
   Serum DKK 1 and sclerostin levels were measured at primary diagnosis as well as 3 5 days and 12 months after surgery in a cohort of 45 pre  and postmenopausal women with primary estrogen receptor positive breast cancer treated with adjuvant tamoxifen or aromatase inhibitors.
   Mean baseline levels +/  SD for DKK 1 and sclerostin were 29.7 +/  A 14.6 and 27.1 +/  A 16.2 pmol/l, respectively. A significant negative correlation of DKK 1 levels and age was observed (r =  0.32; p < 0.05), but not for sclerostin. Of note, DKK 1 levels were significantly lower in peri  and postmenopausal women compared to premenopausal patients ( 47%; p < 0.05). In tamoxifen treated patients, DKK 1 levels were reduced by 35% (p < 0.01) one year after surgery but remained unaltered in patients treated with aromatase inhibitors. No significant changes were observed for sclerostin.
   DKK 1 serum levels were reduced in breast cancer patients receiving an adjuvant therapy with tamoxifen, possibly contributing to its bone protective properties.
C1 [Goebel, Andy; Browne, Andrew J.; Rauner, Martina; Hofbauer, Lorenz C.; Rachner, Tilman D.] Tech Univ Dresden, Div Endocrinol Diabet & Bone Dis, Dept Med 3, TU Dresden Med Ctr, Fetscherstr 74, D 01307 Dresden, Germany.
   [Goebel, Andy; Kuhlmann, Jan D.; Link, Theresa; Wimberger, Pauline; Browne, Andrew J.; Rauner, Martina; Hofbauer, Lorenz C.; Rachner, Tilman D.] Partner Site Dresden, German Canc Consortium DKTK, Heidelberg, Germany.
   [Goebel, Andy; Kuhlmann, Jan D.; Link, Theresa; Wimberger, Pauline; Browne, Andrew J.; Rauner, Martina; Hofbauer, Lorenz C.; Rachner, Tilman D.] German Canc Res Ctr, Heidelberg, Germany.
   [Kuhlmann, Jan D.; Link, Theresa; Wimberger, Pauline] Tech Univ Dresden, Dept Gynecol & Obstet, Fac Med, Dresden, Germany.
   [Kuhlmann, Jan D.; Link, Theresa; Wimberger, Pauline] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Kuhlmann, Jan D.; Link, Theresa; Wimberger, Pauline] Partner Site Dresden, Natl Ctr Tumor Dis NCT, Dresden, Germany.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.
C3 Technische Universitat Dresden; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Technische Universitat Dresden; Technische Universitat
   Dresden; Carl Gustav Carus University Hospital; Helmholtz Association;
   German Cancer Research Center (DKFZ); Ruprecht Karls University
   Heidelberg; National Center for Tumor Diseases; Technische Universitat
   Dresden
RP Göbel, A (通讯作者)，Tech Univ Dresden, Div Endocrinol Diabet & Bone Dis, Dept Med 3, TU Dresden Med Ctr, Fetscherstr 74, D 01307 Dresden, Germany.; Göbel, A (通讯作者)，Partner Site Dresden, German Canc Consortium DKTK, Heidelberg, Germany.; Göbel, A (通讯作者)，German Canc Res Ctr, Heidelberg, Germany.
EM Andy.Goebel@ukdd.de
RI Rauner, Martina/A 1665 2015; Hofbauer, Lorenz C./G 2490 2010; Hofbauer,
   Lorenz/G 2490 2010
OI Hofbauer, Lorenz C./0000 0002 8691 8423; Rauner,
   Martina/0000 0002 4067 6799; 
FU Deutsche Forschungsgemeinschaft as part of the DFG Research group
   SKELMET [RA 2151/2 1, RA 2151/2 2, RA 2151/3 1, RA 1923/5 1, HO
   1875/15 1, HO 1875/16 1]
FX The authors would like to thank Ms. Franziska Paul and Ms. Josefa Hotzel
   for their excellent technical assistance and Ms. Theresa Reiche for her
   secretarial assistance. The work was funded by the Deutsche
   Forschungsgemeinschaft to TDR (RA 2151/2 1, 2 2, and 3 1), MR (RA
   1923/5 1), and to LCH (HO 1875/15 1 and 16 1) as part of the DFG
   Research group SKELMET.
CR Altundag K, 2006, ONCOLOGIST, V11, P553, DOI 10.1634/theoncologist.11 6 553
   Appelman Dijkstra NM, 2016, CALCIFIED TISSUE INT, V98, P370, DOI 10.1007/s00223 016 0126 6
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bauer M, 2012, BREAST CANCER TARGET, V4, P91, DOI 10.2147/BCTT.S29432
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Brufsky AM, 2008, ONCOLOGIST, V13, P187, DOI 10.1634/theoncologist.2007 0152
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140 6736(07)60200 1
   Criscitiello C, 2011, ONCOTARGETS THER, V4, P1, DOI 10.2147/OTT.S10155
   Dovjak P, 2014, GERONTOLOGY, V60, P493, DOI 10.1159/000358303
   Early Breast Cancer Trialists' Collaborative Group EBCTCG, 2015, LANCET, V386, P1341
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Fabian CJ, 2007, INT J CLIN PRACT, V61, P2051, DOI 10.1111/j.1742 1241.2007.01587.x
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Files JA, 2002, MAYO CLIN P, V85, P560
   Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579
   Gaillard S, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2818
   Göbel A, 2015, BREAST CANCER RES TR, V154, P623, DOI 10.1007/s10549 015 3624 8
   Hadji P, 2009, BREAST, V18, P159, DOI 10.1016/j.breast.2009.03.003
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kyvernitakis I, 2014, J CANCER RES CLIN, V140, P1671, DOI 10.1007/s00432 014 1726 z
   Lehenkari P, 2003, J BONE MINER RES, V18, P473, DOI 10.1359/jbmr.2003.18.3.473
   Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690
   Mendoza Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048
   Michael H, 2007, BRIT J PHARMACOL, V151, P384, DOI 10.1038/sj.bjp.0707232
   Migliaccio S, 2007, CLIN INTERV AGING, V2, P55, DOI 10.2147/ciia.2007.2.1.55
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Perry MJ, 2005, ENDOCRINOLOGY, V146, P1060, DOI 10.1210/en.2004 1114
   Rachner TD, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3616
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   WARD RL, 1993, BONE MINER, V22, P87, DOI 10.1016/S0169 6009(08)80220 6
NR 32
TC 7
Z9 7
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167 6806
EI 1573 7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2017
VL 164
IS 3
BP 737
EP 743
DI 10.1007/s10549 017 4296 3
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EZ5SE
UT WOS:000404777500023
PM 28526959
DA 2025 08 17
ER

PT J
AU Song, F
   Xu, D
   Che, JY
   Huang, M
   Li, HY
AF Song, Fei
   Xu, Dan
   Che, Jiayin
   Huang, Ming
   Li, Hongyang
TI Chitosan hydrogel incorporated with bone marrow mesenchymal stem
   cell derived exosomal TIMP2 to inhibit angiogenesis in
   cholangiocarcinoma
SO TISSUE & CELL
LA English
DT Article
DE Angiogenesis; Chitosan hydrogel; Cholangiocarcinoma; Exosome; Tissue
   inhibitor of metalloproteinase 2
ID MIGRATION; PEPTIDE; VEGF; MICE
AB Objective: Cholangiocarcinoma (CCA) presents a therapeutic challenge due to its aggressiveness and poor survival rates. This study introduces an approach using tissue inhibitor of metalloproteinase 2 (TIMP2) enriched bone marrow mesenchymal stem cell derived exosomes (BMSC Exo) encapsulated in chitosan hydrogels (CS), intending to provide novel insight into the CCA treatment. Methods: BMSC Exo was characterized by using TEM, nanoparticle tracking analysis, and western blotting. Role of TIMP2 in CCA was explored using bioinformatics analysis. Therapeutic efficacy and mechanisms of BMSCExo/CS in CCA were assessed through cell viability tests and colony formation assays. Angiogenic and Wnt/ beta catenin signaling pathways related key factors were detected through RT qPCR or western blotting. Results: BMSC Exo displayed typical cup shaped morphology and was positive for exosomal markers CD9 and TSG101, but negative for endoplasmic reticulum marker Calnexin, with a diameter of 124.6 nm. BMSC Exo combined with CS showed synergistic anti proliferative effects in CCA cells. High expression TIMP2 samples indicated a better prognosis of CCA patients, and BMSC Exo/CS increased the TIMP2 expression in CCA cells. Mechanistically, BMSC Exo/CS TIMP2 overexpression inhibited key factors related to angiogenesis (VEGFA and VEGFR2) and Wnt/beta catenin pathway (beta catenin and c Myc), thereby reducing CCA cell viability. Notably, these inhibitory effects were reversed by a Wnt signaling agonist (BML 284). Conclusion: The study validates the therapeutic potential of BMSC Exo/CS TIMP2 in CCA treatment. This innovative approach targets angiogenesis and Wnt/beta catenin signaling, providing a new avenue for more effective and comprehensive CCA therapies.
C1 [Song, Fei; Che, Jiayin; Huang, Ming; Li, Hongyang] Kunming Med Univ, Affiliated Hosp 3, Dept Minimally Invas Intervent, 519,Kunzhou Rd, Kunming, Yunnan, Peoples R China.
   [Xu, Dan] Pingbian Cty Peoples Hosp, Dept Med Lab, Pingbian, Yunnan, Peoples R China.
C3 Kunming Medical University
RP Li, HY (通讯作者)，Kunming Med Univ, Affiliated Hosp 3, Dept Minimally Invas Intervent, 519,Kunzhou Rd, Kunming, Yunnan, Peoples R China.
EM 198181981@qq.com; 632533054@qq.com; 416214487@qq.com;
   huangming4328@sina.com; lihongyang0212@126.com
FU Natural Science Foundation of China [82360189]; Scientific Research Fund
   of Yunnan Edu cation Department [2023Y0651]; Yunnan Funda mental
   Research Projects [202201AT070954]
FX <BOLD>Funding</BOLD> This work was supported by Natural Science
   Foundation of China [Grant number 82360189] , Scientific Research Fund
   of Yunnan Edu cation Department [Grant number 2023Y0651] and Yunnan
   Funda mental Research Projects [Grant number 202201AT070954] .
CR Ahmad A, 2022, J CELL BIOCHEM, V123, P1938, DOI 10.1002/jcb.30344
   Akad F, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11041031
   Banales JM, 2020, NAT REV GASTRO HEPAT, V17, P557, DOI 10.1038/s41575 020 0310 z
   Borakati A, 2023, WORLD J GASTROENTERO, V29, P1969, DOI 10.3748/wjg.v29.i13.1969
   Cai CP, 2022, WORLD J SURG ONCOL, V20, DOI 10.1186/s12957 022 02511 7
   Cao HS, 2022, INT J BIOL SCI, V18, P5369, DOI 10.7150/ijbs.73949
   Chen MZ, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12729
   Dai J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00261 0
   Fernandez CA, 2010, J BIOL CHEM, V285, P41886, DOI 10.1074/jbc.M110.166439
   Haga H, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.24900
   He S, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110851
   Huang MP, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876 018 0870 3
   Jackson HW, 2017, NAT REV CANCER, V17, P38, DOI 10.1038/nrc.2016.115
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kanugula AK, 2021, ANGIOGENESIS, V24, P647, DOI 10.1007/s10456 021 09775 9
   Kim HJ, 2014, CANCER LETT, V343, P210, DOI 10.1016/j.canlet.2013.10.037
   Li JC, 2024, RADIOL ONCOL, V58, P67, DOI 10.2478/raon 2024 0007
   Liu CT, 2017, J ETHNOPHARMACOL, V196, P213, DOI 10.1016/j.jep.2016.12.019
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Liu WS, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10287
   Mabeta P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232415585
   Mariotti V, 2021, JHEP REP, V3, DOI 10.1016/j.jhepr.2021.100251
   Mei EC, 2021, BIOMACROMOLECULES, V22, P5339, DOI 10.1021/acs.biomac.1c01279
   Melincovici CS, 2018, ROM J MORPHOL EMBRYO, V59, P455
   Mi M, 2012, BIOCHEM BIOPH RES CO, V423, P366, DOI 10.1016/j.bbrc.2012.05.132
   O'Rourke CJ, 2021, HEPATOLOGY, V73, P62, DOI 10.1002/hep.31278
   Peeney D, 2022, CARCINOGENESIS, V43, P405, DOI 10.1093/carcin/bgac037
   Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456 017 9552 y
   Samiraninezhad N, 2023, INT J BIOL MACROMOL, V252, DOI 10.1016/j.ijbiomac.2023.126573
   Shen XZ, 2021, INT J CANCER, V148, P1323, DOI 10.1002/ijc.33323
   Shen ZS, 2020, BIOACT MATER, V5, P1113, DOI 10.1016/j.bioactmat.2020.07.002
   Stetler Stevenson WG, 2023, AM J PATHOL, V193, DOI 10.1016/j.ajpath.2023.08.001
   Valacca C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136797
   Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456 017 9562 9
   Vita F, 2023, CELLS BASEL, V12, DOI 10.3390/cells12060846
   Wu D, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.829136
   Xia YX, 2015, CELL CYCLE, V14, P1666, DOI 10.1080/15384101.2015.1030557
   Xin W, 2021, MOL NEUROBIOL, V58, P6490, DOI 10.1007/s12035 021 02565 w
   Yang RJ, 2022, INT J BIOL SCI, V18, P43, DOI 10.7150/ijbs.62602
   Yu FY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00701 5
   Yuan RY, 2021, MOL THER NUCL ACIDS, V23, P797, DOI 10.1016/j.omtn.2021.01.001
   Zhang KY, 2018, ACS APPL MATER INTER, V10, P30081, DOI 10.1021/acsami.8b08449
   Zhang YM, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01016 x
   Zhu HL, 2024, INT J BIOL MACROMOL, V282, DOI 10.1016/j.ijbiomac.2024.137047
NR 44
TC 1
Z9 1
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040 8166
J9 TISSUE CELL
JI Tissue Cell
PD APR
PY 2025
VL 93
AR 102694
DI 10.1016/j.tice.2024.102694
EA DEC 2024
PG 9
WC Anatomy & Morphology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology
GA R8M8V
UT WOS:001393930500001
PM 39718067
DA 2025 08 17
ER

PT J
AU Saraswati, S
   Deskins, DL
   Holt, GE
   Young, PP
AF Saraswati, Sarika
   Deskins, Desirae L.
   Holt, Ginger E.
   Young, Pampee P.
TI Pyrvinium, a potent small molecule Wnt inhibitor, increases engraftment
   and inhibits lineage commitment of mesenchymal stem cells (MSCs)
SO WOUND REPAIR AND REGENERATION
LA English
DT Article
ID BETA CATENIN; SELF RENEWAL; BONE MARROW; GRANULATION TISSUE;
   DIFFERENTIATION; ACTIVATION; SFRP2; MODEL; OSTEOGENESIS; SUPPRESSION
AB We and others have found that Wnt signaling inhibition is important in mesenchymal stem cell (MSC) self renewal. Pyrvinium was identified as a potent Wnt inhibitor in a chemical screen for small molecules. In the present study, we hypothesized that pyrvinium will enhance MSC self renewal to improve the clinical efficacy of MSC therapy. Pyrvinium increased MSC proliferation in vitro while inhibiting their osteogenic and chondrogenic lineage commitment by reducing cytoplasmic beta catenin. Although MSCs are a promising target for cell therapy, strategies to enhance their survival and maintain their stemness in the wounded area are essential. Using an in vivo model of granulation tissue formation, we demonstrated that pyrvinium enhanced long term MSC engraftment. Pyrvinium treated MSC generated granulation tissue also demonstrated less ectopic differentiation into bone or cartilage. This study highlights the potential of using a therapeutic Wnt inhibitor to enhance MSC driven regenerative therapy.
C1 [Saraswati, Sarika; Deskins, Desirae L.; Young, Pampee P.] Vanderbilt Univ, Sch Med, Dept Pathol, Vanderbilt Orthopaed Inst,Med Ctr, Nashville, TN 37232 USA.
   [Young, Pampee P.] Vanderbilt Univ, Dept Internal Med, Vanderbilt Orthopaed Inst, Nashville, TN 37232 USA.
   [Holt, Ginger E.] Vanderbilt Univ, Med Ctr, Dept Orthopaed & Rehabil, Vanderbilt Orthopaed Inst, Nashville, TN 37232 USA.
   [Deskins, Desirae L.; Young, Pampee P.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Tennessee Valley Healthcare System
RP Young, PP (通讯作者)，Vanderbilt Univ, Sch Med, Dept Pathol, Vanderbilt Orthopaed Inst,Med Ctr, 1161 21st Ave,S C2217A MCN, Nashville, TN 37232 USA.
EM pampee.young@vanderbilt.edu
FU NIH [R01 HL088424, HL08842402S1, RO1 GMO81635]; Veterans Affairs merit
   award
FX This work was supported by NIH grants R01 HL088424, HL08842402S1,
   RO1 GMO81635, and Veterans Affairs merit award (PPY).
CR Alfaro MP, 2010, J BIOL CHEM, V285, P35645, DOI 10.1074/jbc.M110.135335
   Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105
   Alfaro MP, 2011, CELL TRANSPLANT 1111
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Barry Frank P., 2003, Birth Defects Research, V69, P250, DOI 10.1002/bdrc.10021
   Baurand A, 2007, CIRC RES, V100, P1353, DOI 10.1161/01.RES.0000266605.63681.5a
   Cadigan KM, 2008, CURR BIOL, V18, pR943, DOI 10.1016/j.cub.2008.08.017
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Cleland JGF, 2008, EUR J HEART FAIL, V10, P102, DOI 10.1016/j.ejheart.2007.12.004
   Cooney R, 1997, J TRAUMA, V42, P415, DOI 10.1097/00005373 199703000 00008
   Das R, 2010, TISSUE ENG PART B RE, V16, P159, DOI [10.1089/ten.teb.2009.0296, 10.1089/ten.TEB.2009.0296]
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   GLASER JH, 1973, J LAB CLIN MED, V82, P969
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   Hofling AA, 2003, BLOOD, V101, P2054, DOI 10.1182/blood 2002 08 2597
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Jorgensen C, 2004, CURR OPIN BIOTECH, V15, P406, DOI 10.1016/j.copbio.2004.08.003
   Khan M, 2011, STEM CELLS DEV, V20, P67, DOI 10.1089/scd.2009.0397
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Kondo T, 2011, STEM CELLS, V29, P836, DOI 10.1002/stem.624
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578
   Malekar P, 2010, HYPERTENSION, V55, P939, DOI 10.1161/HYPERTENSIONAHA.109.141127
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Oerlemans MIFJ, 2010, BASIC RES CARDIOL, V105, P631, DOI 10.1007/s00395 010 0100 9
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev bioeng 070909 105309
   Patel J, 2010, TRANSL RES, V155, P191, DOI 10.1016/j.trsl.2009.08.010
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Qyang Y, 2007, CELL STEM CELL, V1, P165, DOI 10.1016/j.stem.2007.05.018
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Romanov YA, 2005, B EXP BIOL MED+, V140, P138, DOI 10.1007/s10517 005 0430 z
   Saraswati S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015521
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Shan JF, 2005, BIOCHEMISTRY US, V44, P15495, DOI 10.1021/bi0512602
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Wisel S, 2009, J PHARMACOL EXP THER, V329, P543, DOI 10.1124/jpet.109.150839
   Young PP, 2003, MOL THER, V7, P52, DOI 10.1016/S1525 0016(02)00016 5
NR 43
TC 25
Z9 33
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1067 1927
EI 1524 475X
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD MAR APR
PY 2012
VL 20
IS 2
BP 185
EP 193
DI 10.1111/j.1524 475X.2012.00767.x
PG 9
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA 901DY
UT WOS:000300943100150
PM 22332749
OA Green Accepted
DA 2025 08 17
ER

PT S
AU Sofi, HS
   Ashraf, R
   Beigh, MA
   Sheikh, FA
AF Sofi, Hasham S.
   Ashraf, Roqia
   Beigh, Mushtaq A.
   Sheikh, Faheem A.
BE Chun, HJ
   Park, CH
   Kwon, IK
   Khang, G
TI Scaffolds Fabricated from Natural Polymers/Composites by Electrospinning
   for Bone Tissue Regeneration
SO CUTTING EDGE ENABLING TECHNOLOGIES FOR REGENERATIVE MEDICINE
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Bone; Scaffolds; Electrospinning; Regeneration; Nanofibers;
   Hydroxyapatite
ID IN VITRO BIOCOMPATIBILITY; MESENCHYMAL STEM CELLS;
   MECHANICAL PROPERTIES; COMPOSITE SCAFFOLDS; BIOCOMPOSITE SCAFFOLDS;
   COLLAGEN SCAFFOLDS; DRUG DELIVERY; OSTEOGENIC DIFFERENTIATION; SURFACE
   FUNCTIONALIZATION; NANOSTRUCTURED SCAFFOLDS
AB Naturally bone is a hierarchical and highly integrative dynamic tissue that is continuously remodeled by osteoblasts and osteoclasts. Deformities in bone due to trauma and/or disease are highly prevalent and mostly need surgical intervention. However, the methods of surgical treatments are associated with donor site morbidity, infection and/or complete rejection. Bone tissue engineering provides a platform for growth of new bone tissue by fabricating scaffolds along with cells, growth factors and other dynamic forces. The polymeric materials especially natural polymers in their nanofibrous forms have been developed and introduced for bone tissue regeneration. At the nanoscale, natural polymers possess tunable properties and can be surface functionalized or blended with other polymers to provide juncture for cell seeding, proliferation, differentiation and further resulting in regenerated tissue formation. These scaffolds fabricated from natural polymers and additives by electrospinning are bio inspired to mimic the natural extracellular matrix resembling the native collagen of bone. This chapter focuses on the fabrication techniques as state of art nanofi brous scaffolds from natural polymers/additives during the recent years by the process of electrospinning for use in bone tissue regeneration. Further on, this chapter highlights the development in the scaffold fabrication from natural polymers like silk fibroin, chitosan, collagen, gelatin, cellulose, starch and, zein. The importance of add on materials like stem cells, hydroxyapatite, apatite wollanstonite, growth factors, osteogenic cells, bone morphogenic proteins and osteogenic drugs have been discussed and illustrated by various examples for enhancing the formation of new bone tissue. Furthermore, this chapter explains how these natural polymers influence the several signaling pathways to regulate bone regeneration.
C1 [Sofi, Hasham S.; Ashraf, Roqia; Beigh, Mushtaq A.; Sheikh, Faheem A.] Univ Kashmir, Dept Nanotechnol, Srinagar, Jammu & Kashmir, India.
C3 University of Kashmir
RP Sheikh, FA (通讯作者)，Univ Kashmir, Dept Nanotechnol, Srinagar, Jammu & Kashmir, India.
EM faheemnt@uok.edu.in
RI Sheikh, Faheem/N 9542 2019; Sheikh, Faheem A/Q 9166 2018; Shafi,
   Hasham/KLY 9243 2024
OI Sheikh, Faheem A/0000 0003 0942 4398; Shafi, Hasham/0000 0002 0747 6090
CR Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282
   Aliramaji S, 2017, MAT SCI ENG C MATER, V70, P736, DOI 10.1016/j.msec.2016.09.039
   Ao CH, 2017, INT J BIOL MACROMOL, V97, P568, DOI 10.1016/j.ijbiomac.2016.12.091
   Arnett T, 2003, P NUTR SOC, V62, P511, DOI 10.1079/PNS2003268
   Arslan YE, 2017, COLLOID SURFACE B, V154, P160, DOI 10.1016/j.colsurfb.2017.03.034
   Babitha S, 2018, J TISSUE ENG REGEN M, V12, P991, DOI 10.1002/term.2563
   Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850
   Barrère F, 2006, INT J NANOMED, V1, P317
   Bhattacharjee P, 2016, CELL TISSUE RES, V363, P525, DOI 10.1007/s00441 015 2232 6
   Bhattacharjee P, 2015, EUR POLYM J, V71, P490, DOI 10.1016/j.eurpolymj.2015.08.025
   Black Cameron R M, 2015, Curr Mol Biol Rep, V1, P132
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Bretcanu O, 2009, J TISSUE ENG REGEN M, V3, P139, DOI 10.1002/term.150
   Bueno EM, 2009, NAT REV RHEUMATOL, V5, P685, DOI 10.1038/nrrheum.2009.228
   Burg KJL, 2000, BIOMATERIALS, V21, P2347, DOI 10.1016/S0142 9612(00)00102 2
   Cao H, 2010, BONE, V46, P386, DOI 10.1016/j.bone.2009.09.031
   Cao L, 2017, MAT SCI ENG C MATER, V79, P697, DOI 10.1016/j.msec.2017.05.056
   Chahal S, 2015, RSC ADV, V5, P29497, DOI 10.1039/c4ra17087c
   Chen GP, 2002, MACROMOL BIOSCI, V2, P67, DOI 10.1002/1616 5195(20020201)2:2<67::AID MABI67>3.0.CO;2 F
   Chen QZ, 2007, ACTA BIOMATER, V3, P551, DOI 10.1016/j.actbio.2007.01.008
   Cipriano BH, 2008, POLYMER, V49, P4846, DOI 10.1016/j.polymer.2008.08.057
   Covey Dana C, 2008, Instr Course Lect, V57, P65
   COWIN SC, 1976, J ELASTICITY, V6, P313, DOI 10.1007/BF00041724
   CURREY JD, 1984, PHILOS T ROY SOC B, V304, P509, DOI 10.1098/rstb.1984.0042
   d'Aquino R, 2008, STEM CELL REV, V4, P21, DOI 10.1007/s12015 008 9013 5
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Dhand C, 2016, BIOMATERIALS, V104, P323, DOI 10.1016/j.biomaterials.2016.07.007
   Ding HF, 2017, MAT SCI ENG C MATER, V71, P222, DOI 10.1016/j.msec.2016.10.002
   DOSHI J, 1995, J ELECTROSTAT, V35, P151, DOI 10.1016/0304 3886(95)00041 8
   Du GY, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671 017 2316 1
   Dvorak Ewell MM, 2011, J BONE MINER RES, V26, P2935, DOI 10.1002/jbmr.520
   Elango J, 2016, INT J BIOL MACROMOL, V91, P51, DOI 10.1016/j.ijbiomac.2016.05.067
   Farokhi M, 2014, MAT SCI ENG C MATER, V35, P401, DOI 10.1016/j.msec.2013.11.023
   Favi PM, 2016, CELLULOSE, V23, P1263, DOI 10.1007/s10570 016 0867 4
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fratzl P, 2004, J MATER CHEM, V14, P2115, DOI 10.1039/b402005g
   Frohbergh ME, 2012, BIOMATERIALS, V33, P9167, DOI 10.1016/j.biomaterials.2012.09.009
   Goh YF, 2013, J MATER SCI, V48, P3027, DOI 10.1007/s10853 013 7145 8
   Gupta D, 2009, BIOMATERIALS, V30, P2085, DOI 10.1016/j.biomaterials.2008.12.079
   Hayes WC, 1997, BASIC ORTHOPEDIC BIO
   Healy K. E., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P328
   Heuking S, 2009, J DRUG TARGET, V17, P662, DOI 10.1080/10611860903106034
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   HODGSKINSON R, 1992, J MATER SCI MATER M, V3, P377, DOI 10.1007/BF00705371
   Holzwarth JM, 2011, BIOMATERIALS, V32, P9622, DOI 10.1016/j.biomaterials.2011.09.009
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Horner EA, 2010, TISSUE ENG PART B RE, V16, P263, DOI [10.1089/ten.teb.2009.0224, 10.1089/ten.TEB.2009.0224]
   Huo MJ, 2014, FLUORIDE, V47, P320
   Hutmacher DW, 2007, J TISSUE ENG REGEN M, V1, P245, DOI 10.1002/term.24
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Ignatova M, 2013, MACROMOL BIOSCI, V13, P860, DOI 10.1002/mabi.201300058
   Jang JH, 2009, ADV DRUG DELIVER REV, V61, P1065, DOI 10.1016/j.addr.2009.07.008
   Jayakumar R, 2010, PROG MATER SCI, V55, P675, DOI 10.1016/j.pmatsci.2010.03.001
   Jin HJ, 2002, BIOMACROMOLECULES, V3, P1233, DOI 10.1021/bm025581u
   Jo JH, 2009, J BIOMED MATER RES B, V91B, P213, DOI 10.1002/jbm.b.31392
   Ju YJ, 2008, CELL TISSUE RES, V332, P469, DOI 10.1007/s00441 008 0610 z
   Kanczler JM, 2010, BIOMATERIALS, V31, P1242, DOI 10.1016/j.biomaterials.2009.10.059
   Karande TS, 2004, ANN BIOMED ENG, V32, P1728, DOI 10.1007/s10439 004 7825 2
   Katsanevakis E, 2012, ADV POLYM SCI, V246, P63, DOI 10.1007/12_2011_131
   Kaufman JD, 2007, J BIOMED MATER RES A, V81A, P611, DOI 10.1002/jbm.a.30976
   Kavya KC, 2012, J BIOMED NANOTECHNOL, V8, P149, DOI 10.1166/jbn.2012.1363
   Kim DK, 2017, ACS APPL MATER INTER, V9, P1384, DOI 10.1021/acsami.6b14351
   Kim IY, 2008, BIOTECHNOL ADV, V26, P1, DOI 10.1016/j.biotechadv.2007.07.009
   Ko E, 2018, ACS APPL MATER INTER, V10, P7614, DOI 10.1021/acsami.7b03328
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Kwak S, 2016, NANOSCALE RES LETT, V11, P1, DOI 10.1186/s11671 016 1532 4
   Kwon Gi Wan, 2017, Biomater Res, V21, P11, DOI 10.1186/s40824 017 0097 3
   Lai GJ, 2014, CARBOHYD POLYM, V111, P288, DOI 10.1016/j.carbpol.2014.04.094
   Landers R, 2002, BIOMATERIALS, V23, P4437, DOI 10.1016/S0142 9612(02)00139 4
   Levengood SKL, 2014, J MATER CHEM B, V2, P3161, DOI 10.1039/c4tb00027g
   Li CM, 2006, BIOMATERIALS, V27, P3115, DOI 10.1016/j.biomaterials.2006.01.022
   Li D, 2003, NANO LETT, V3, P1167, DOI 10.1021/nl0344256
   Li XM, 2014, J BIOMED MATER RES A, V102, P1580, DOI 10.1002/jbm.a.34801
   Li XM, 2013, J BIOMED MATER RES A, V101, P2424, DOI 10.1002/jbm.a.34539
   Lin HR, 2002, J BIOMED MATER RES, V63, P271, DOI 10.1002/jbm.10183
   Liu HY, 2014, NANOSCALE, V6, P5315, DOI 10.1039/c4nr00355a
   Liu HY, 2012, J PHYS CHEM C, V116, P3334, DOI 10.1021/jp2102226
   Liu L, 2006, MAT SCI ENG A STRUCT, V435, P309, DOI 10.1016/j.msea.2006.07.064
   Liu YD, 2014, ACTA BIOMATER, V10, P5074, DOI 10.1016/j.actbio.2014.08.036
   Lotfi G, 2016, ANN BIOMED ENG, V44, P2132, DOI 10.1007/s10439 015 1516 z
   Marelli B, 2012, BIOMATERIALS, V33, P102, DOI 10.1016/j.biomaterials.2011.09.039
   Martins A, 2007, NANOMEDICINE UK, V2, P929, DOI 10.2217/17435889.2.6.929
   Mehraban M, 2013, J APPL POLYM SCI, V128, P926, DOI [10.1002/APP.38091, 10.1002/app.38091]
   Meng L, 2009, J DENT RES, V88, P22, DOI 10.1177/0022034508327868
   MINOURA N, 1995, BIOCHEM BIOPH RES CO, V208, P511, DOI 10.1006/bbrc.1995.1368
   Mistry Surajit, 2012, J Indian Soc Periodontol, V16, P241, DOI 10.4103/0972 124X.99269
   Nagarajan S, 2017, ACS APPL MATER INTER, V9, P33695, DOI 10.1021/acsami.7b13199
   Naskar D, 2017, BIOMATERIALS, V136, P67, DOI 10.1016/j.biomaterials.2017.05.014
   Nourmohammadi J, 2016, CARBOHYD POLYM, V138, P172, DOI 10.1016/j.carbpol.2015.11.055
   Numata K, 2010, ADV DRUG DELIVER REV, V62, P1497, DOI 10.1016/j.addr.2010.03.009
   Pangon A, 2016, CARBOHYD POLYM, V144, P419, DOI 10.1016/j.carbpol.2016.02.053
   Park SH, 2010, BIOMATERIALS, V31, P6162, DOI 10.1016/j.biomaterials.2010.04.028
   Patra C, 2012, BIOMATERIALS, V33, P2673, DOI 10.1016/j.biomaterials.2011.12.036
   Pittenger MF, 2000, CURR TOP MICROBIOL, V251, P3
   Porter BD, 2000, J BIOMECH ENG T ASME, V122, P286, DOI 10.1115/1.429659
   Porter JR, 2009, BIOTECHNOL PROGR, V25, P1539, DOI 10.1002/btpr.246
   Prabhakaran MP, 2009, ACTA BIOMATER, V5, P2884, DOI 10.1016/j.actbio.2009.05.007
   Regan J, 2013, CURR OSTEOPOROS REP, V11, P126, DOI 10.1007/s11914 013 0145 4
   Ren J, 2008, J MATER SCI MATER M, V19, P1075, DOI 10.1007/s10856 007 3181 8
   Ren K, 2017, MAT SCI ENG C MATER, V78, P324, DOI 10.1016/j.msec.2017.04.084
   Ren X, 2015, BIOMATERIALS, V50, P107, DOI 10.1016/j.biomaterials.2015.01.059
   Ren ZW, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa747f
   Reneker DH, 2008, POLYMER, V49, P2387, DOI 10.1016/j.polymer.2008.02.002
   Reznikov N, 2014, ACTA BIOMATER, V10, P3815, DOI 10.1016/j.actbio.2014.05.024
   Rho JY, 1998, MED ENG PHYS, V20, P92, DOI 10.1016/S1350 4533(98)00007 1
   Rivers TJ, 2002, ADV FUNCT MATER, V12, P33, DOI 10.1002/1616 3028(20020101)12:1<33::AID ADFM33>3.0.CO;2 E
   Rodríguez K, 2014, CARBOHYD POLYM, V100, P143, DOI 10.1016/j.carbpol.2012.12.037
   Romero R, 2017, J BIOMED MATER RES A, V105, P900, DOI 10.1002/jbm.a.35965
   Ruan SQ, 2017, INT ORTHOP, V41, P1899, DOI 10.1007/s00264 017 3522 2
   Rubin MA, 2003, BONE, V33, P270, DOI 10.1016/S8756 3282(03)00194 7
   Sachlos E, 2006, TISSUE ENG, V12, P2479, DOI 10.1089/ten.2006.12.2479
   Salifu AA, 2017, J BIOMED MATER RES A, V105, P779, DOI 10.1002/jbm.a.35954
   Saravanan S, 2016, INT J BIOL MACROMOL, V93, P1354, DOI 10.1016/j.ijbiomac.2016.01.112
   Sell SA, 2010, POLYMERS BASEL, V2, P522, DOI 10.3390/polym2040522
   Seol YJ, 2004, BIOTECHNOL LETT, V26, P1037, DOI 10.1023/B:BILE.0000032962.79531.fd
   Shafi H, 2017, INT J PHARMACEUT, V524, P205, DOI 10.1016/j.ijpharm.2017.03.088
   Shao WL, 2016, MAT SCI ENG C MATER, V67, P599, DOI 10.1016/j.msec.2016.05.081
   Shao WL, 2016, MAT SCI ENG C MATER, V58, P342, DOI 10.1016/j.msec.2015.08.046
   Sharifi E, 2016, MAT SCI ENG C MATER, V59, P533, DOI 10.1016/j.msec.2015.09.037
   Sheikh FA, 2012, EXPRESS POLYM LETT, V6, P41, DOI 10.3144/expresspolymlett.2012.5
   Sheikh FA, 2016, J TISSUE ENG REGEN M, V10, P209, DOI 10.1002/term.1989
   Sheikh FA, 2009, MACROMOL RES, V17, P688, DOI 10.1007/BF03218929
   Sheikh Z, 2015, MATERIALS, V8, P5744, DOI 10.3390/ma8095273
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Singh BN, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa644f
   Singh BN, 2016, CARBOHYD POLYM, V151, P335, DOI 10.1016/j.carbpol.2016.05.088
   Smith JK, 2013, CLIN ORTHOP RELAT R, V471, P3158, DOI 10.1007/s11999 013 2988 5
   Sofia S, 2001, J BIOMED MATER RES, V54, P139, DOI 10.1002/1097 4636(200101)54:1<139::AID JBM17>3.0.CO;2 7
   Sohn HY, 2004, PHYTOMEDICINE, V11, P666, DOI 10.1016/j.phymed.2003.09.005
   Song JH, 2007, J BIOMED MATER RES B, V83B, P248, DOI 10.1002/jbm.b.30790
   Sowjanya JA, 2013, COLLOID SURFACE B, V109, P294, DOI 10.1016/j.colsurfb.2013.04.006
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Tellado SF, 2017, TISSUE ENG PT A, V23, P859, DOI [10.1089/ten.tea.2016.0460, 10.1089/ten.TEA.2016.0460]
   Teti A, 2009, BONE, V44, P11, DOI 10.1016/j.bone.2008.09.017
   Türkkan S, 2017, MAT SCI ENG C MATER, V80, P484, DOI 10.1016/j.msec.2017.06.016
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   Vozzi G, 2014, J BIOMED MATER RES A, V102, P1415, DOI 10.1002/jbm.a.34823
   Wan WB, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S77118
   Wang J, 2012, CELL PROLIFERAT, V45, P121, DOI 10.1111/j.1365 2184.2012.00806.x
   Wang L, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/2/025003
   Wani S., 2017, Mater. Sci. Res. India, V14, P89, DOI [10.13005/msri/140202, DOI 10.13005/MSRI/140202]
   Weiner S, 1999, J STRUCT BIOL, V126, P241, DOI 10.1006/jsbi.1999.4107
   Wu CX, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aa853c
   Wu D, 2017, BIOMACROMOLECULES, V18, P1582, DOI 10.1021/acs.biomac.7b00195
   Xia WS, 2011, FOOD HYDROCOLLOID, V25, P170, DOI 10.1016/j.foodhyd.2010.03.003
   Xu T, 2017, ACS APPL MATER INTER, V9, P21094, DOI 10.1021/acsami.7b01176
   Yin LH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07759 8
   Yin LH, 2017, J MATER SCI MATER M, V28, DOI 10.1007/s10856 017 5898 3
   Yu HY, 2008, J BIOMED MATER RES B, V86B, P541, DOI 10.1002/jbm.b.31054
   Zhang XH, 2008, BIOMATERIALS, V29, P2217, DOI 10.1016/j.biomaterials.2008.01.022
   Zhao X, 2016, J BIOMED NANOTECHNOL, V12, P1285, DOI 10.1166/jbn.2016.2250
   Zhou D, 2017, INT J NANOMED, V12, P2673, DOI 10.2147/IJN.S131251
   Zhou YY, 2015, INT J NANOMED, V10, P3203, DOI 10.2147/IJN.S79241
   Zou FJ, 2017, J BIOMAT SCI POLYM E, V28, P2255, DOI 10.1080/09205063.2017.1392672
NR 155
TC 41
Z9 41
U1 2
U2 53
PU SPRINGER VERLAG SINGAPORE PTE LTD
PI SINGAPORE
PA 152 BEACH ROAD, #21 01/04 GATEWAY EAST, SINGAPORE, 189721, SINGAPORE
SN 0065 2598
EI 2214 8019
BN 978 981 13 0950 2
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2018
VL 1078
BP 49
EP 78
DI 10.1007/978 981 13 0950 2_4
D2 10.1007/978 981 13 0950 2
PG 30
WC Cell & Tissue Engineering; Engineering, Biomedical; Medicine, Research &
   Experimental; Materials Science, Biomaterials
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Research & Experimental Medicine; Materials
   Science
GA BL9PN
UT WOS:000458000700005
PM 30357618
DA 2025 08 17
ER

PT J
AU Zhang, XW
   Wang, HM
   Li, Q
   Li, T
AF Zhang, Xiaowei
   Wang, Haiming
   Li, Qian
   Li, Tao
TI CLDN2 inhibits the metastasis of osteosarcoma cells via down regulating
   the afadin/ERK signaling pathway
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Afadin; Osteosarcoma; Claudin 2; Extracellular signal regulated kinase;
   Metastasis; Tight junction
ID JUNCTIONAL ADHESION MOLECULE; DOMAIN PROTEIN 1 MUPP1; OVARIAN CANCER
   CELLS; TIGHT JUNCTIONS; PDZ DOMAIN; BARRIER FUNCTION; CLAUDINS; BINDING;
   EXPRESSION; THERAPY
AB Background: In an earlier study, we investigated the expression of tight junction protein claudins (CLDNs) in human osteosarcoma (OS) cells, and the CLDN2 was found to be down regulated in primary tumor cells compared with normal osteoblast cells. Here, we sought to explore the effects of CLDN2 on the malignant phenotype of OS and the underlying molecular mechanisms.
   Methods: The expression patterns of CLDN2 and afadin in OS tissues and histologically non neoplastic bone tissues were explored via immunohistochemistry and western blotting. CLDN2 expression levels in an OS cell line stably expressing CLDN2 and an osteoblast cell line with a CLDN2 knockout were confirmed by western blotting and immunofluorescence staining. The malignant phenotype of OS cells and osteoblast cells in vitro was assessed using a cell counting kit 8 assay, transwell assay and wound healing experiment. Western blotting was utilized to detect the activation state of Ras/Raf/MEK/ERK pathway. Moreover, an RNA interference method were used to silence afadin in CLDN2 expressing OS cells.
   Results: Our research group found that CLDN2 and afadin was underexpressed in OS tissues, and the overexpression of CLDN2 significantly inhibited the migration abilities of OS cells. Genetic silencing of afadin in CLDN2 overexpressing OS cells promoted U2OS cell motility and activation of the Ras/Raf/MEK/ERK pathway.
   Conclusions: In this study, we confirmed that CLDN2 expression significantly inhibited the malignant phenotype of OS cells in vitro. Inhibition of the ERK pathway by afadin may be one of the mechanisms by which CLDN2 blocks the metastasis phenotype of OS cells.
C1 [Zhang, Xiaowei; Li, Tao] Shandong Univ, Cent Hosp Zibo, Ctr Translat Med, Gong Qingtuan Rd 54Hao, Zibo, Shandong, Peoples R China.
   [Wang, Haiming] Binzhou Med Coll, Peoples Hosp Linzi Dist, Dept Gen Surg, Zibo, Shandong, Peoples R China.
   [Zhang, Xiaowei; Li, Qian; Li, Tao] Shandong Univ, Cent Hosp Zibo, Dept Orthoped Surg, Zibo, Shandong, Peoples R China.
C3 Shandong University; Binzhou Medical University; Shandong University
RP Li, T (通讯作者)，Shandong Univ, Cent Hosp Zibo, Ctr Translat Med, Gong Qingtuan Rd 54Hao, Zibo, Shandong, Peoples R China.
EM taolichina@126.com
FU National Natural Science Foundation of Shandong Province [ZR2014HM042]
FX This study was supported by National Natural Science Foundation of
   Shandong Province (Code: ZR2014HM042).
CR Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Balda MS, 2008, J CELL SCI, V121, P3677, DOI 10.1242/jcs.023887
   Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064
   Carmena A, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000066
   Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803 456OC
   Cunniffe C, 2014, ANTICANCER RES, V34, P2851
   D'Souza T, 2005, J BIOL CHEM, V280, P26233, DOI 10.1074/jbc.M502003200
   D'Souza T, 2007, EXP CELL RES, V313, P3364, DOI 10.1016/j.yexcr.2007.06.026
   Zavala Zendejas VE, 2011, CANCER INVEST, V29, P1, DOI 10.3109/07357907.2010.512594
   Escudero Esparza A, 2011, FRONT BIOSCI LANDMRK, V16, P1069, DOI 10.2741/3736
   Fujiwara Y, 2015, PROTEIN SCI, V24, P376, DOI 10.1002/pro.2628
   González Mariscal L, 2008, BBA BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018
   Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200
   Hewitt KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 186
   Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351
   Jeansonne B, 2003, CELL MOL BIOL, V49, P13
   Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056
   Koval M, 2013, ANNU REV PHYSIOL, V75, P551, DOI 10.1146/annurev physiol 030212 183809
   Li XC, 2013, ONCOL LETT, V6, P101, DOI 10.3892/ol.2013.1330
   Li X, 2011, INT ORTHOP, V35, P1847, DOI 10.1007/s00264 011 1209 7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu Z, 2012, FUNCTIONS CLAUDIN 7
   Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517
   Merino Gracia J, 2016, J BIOL CHEM, V291, P11581, DOI 10.1074/jbc.M116.724427
   Micke P, 2014, INT J CANCER, V135, P2206, DOI 10.1002/ijc.28857
   Monteiro AC, 2013, MOL BIOL CELL, V24, P2849, DOI 10.1091/mbc.E13 06 0298
   Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008 5472.CAN 05 2782
   Oliveira SS, 2007, CELL MOL LIFE SCI, V64, P17, DOI 10.1007/s00018 006 6314 1
   Osanai M, 2017, PFLUG ARCH EUR J PHY, V469, P55, DOI 10.1007/s00424 016 1877 7
   Ouban A, 2010, HISTOL HISTOPATHOL, V25, P83, DOI 10.14670/HH 25.83
   Salunke AA, 2016, EJSO EUR J SURG ONC, V42, P889, DOI 10.1016/j.ejso.2016.02.255
   Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08 10 1014
   Suh Y, 2017, ONCOGENE, V36, P1167, DOI 10.1038/onc.2016.294
   Tabariés S, 2017, ONCOGENE, V36, P1176, DOI 10.1038/onc.2016.289
   Takasawa K, 2017, CANCER LETT, V403, P66, DOI 10.1016/j.canlet.2017.05.033
   Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955 0674(99)00016 2
   Usami Y, 2006, HUM PATHOL, V37, P569, DOI 10.1016/j.humpath.2005.12.018
   Yang Y, 2008, ONCOL REP, V20, P1077, DOI 10.3892/or_00000112
   Zhang XH, 2015, MED ONCOL, V32, DOI 10.1007/s12032 015 0686 8
NR 39
TC 29
Z9 31
U1 1
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475 2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD OCT 17
PY 2018
VL 18
AR 160
DI 10.1186/s12935 018 0662 4
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GX5LY
UT WOS:000447790600002
PM 30349422
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Salvolini, E
   Orciani, M
   Vignini, A
   Di Primio, R
   Mazzanti, L
AF Salvolini, Eleonora
   Orciani, Monia
   Vignini, Arianna
   Di Primio, Roberto
   Mazzanti, Laura
TI The effects of disodium pamidronate on human polymorphonuclear
   leukocytes and platelets: An in vitro study
SO CELLULAR & MOLECULAR BIOLOGY LETTERS
LA English
DT Article
DE Pamidronate; Polymorphonuclear leukocytes; Platelets; Nitric oxide;
   Intracellular calcium; Myeloperoxidase activity
ID NITRIC OXIDE PATHWAY; BONE RESORPTION; HUMAN NEUTROPHILS;
   BISPHOSPHONATES; MECHANISMS; CELLS; PREDNISOLONE; ALENDRONATE;
   EXPRESSION; GENERATION
AB Recent reports have indicated that, as well as having antiresorptive effects, bisphosphonates could have an application as anti inflammatory drugs. Our aim was to investigate whether this anti inflammatory action could be mediated by the nitric oxide (NO) released by the leukocytes migrating to the site of inflammation. In particular, we investigated in vitro the intracellular calcium concentration ([Ca2+](i)), the level of NO released by PMN and platelets, and the PMN myeloperoxidase activity after incubation with disodium pamidronate, since there was a postulated modulatory effect of this aminosubstituted bisphosphonate on leukocytes both in vitro and in vivo. Our data shows that the pamidronate treatment provoked a significant increase in the [Ca2+](i) parallel to the enhancement in NO release, suggesting a possible activation of constitutive nitric oxide synthase, while the myeloperoxidase activity was significantly reduced. In conclusion, we hypothesized that treatment with pamidronate could stimulate NO production by cells present near the bone compartment, thus constituting a protective mechanism against bone resorption occurring during inflammation. In addition, PMN  and platelet derived NO could act as a negative feed back signal to restrict the inflammatory processes.
C1 [Salvolini, Eleonora; Orciani, Monia; Di Primio, Roberto] Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies Histol, I 60020 Ancona, Italy.
   [Vignini, Arianna; Mazzanti, Laura] Polytech Univ Marche, Inst Biochem, I 60020 Ancona, Italy.
C3 Marche Polytechnic University; Marche Polytechnic University
RP Salvolini, E (通讯作者)，Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies Histol, Via Tronto 10 A, I 60020 Ancona, Italy.
EM e.salvolini@univpm.it
OI orciani, monia/0000 0003 4503 3693; VIGNINI,
   ARIANNA/0000 0002 2496 7932; di primio, roberto/0000 0003 3044 1731
FU RSA grants from the Polytechnic University of Marche, Ancona, Italy
FX This study was supported by RSA grants from the Polytechnic University
   of Marche, Ancona, Italy.
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brown KK, 1998, AM J RESP CELL MOL, V18, P100, DOI 10.1165/ajrcmb.18.1.2314
   Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   Casini A, 1997, HEPATOLOGY, V25, P361
   Chen LY, 1996, J PHARMACOL EXP THER, V276, P253
   COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305
   Corrado A, 2007, JOINT BONE SPINE, V74, P32, DOI 10.1016/j.jbspin.2006.06.005
   De la Cruz JP, 2000, EUR J PHARMACOL, V397, P35, DOI 10.1016/S0014 2999(00)00245 4
   FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495 199141020 00009
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003 2697(82)90118 X
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Guignard S, 2002, JOINT BONE SPINE, V69, P392, DOI 10.1016/S1297 319X(02)00419 0
   Liao CH, 2004, EUR J PHARMACOL, V484, P29, DOI 10.1016/j.ejphar.2003.10.054
   Mazzanti L, 1997, DIABETES, V46, P2069, DOI 10.2337/diabetes.46.12.2069
   Menezes AMA, 2005, J PERIODONTOL, V76, P1901, DOI 10.1902/jop.2005.76.11.1901
   MOILANEN E, 1993, BRIT J PHARMACOL, V109, P852, DOI 10.1111/j.1476 5381.1993.tb13653.x
   NICOLINI FA, 1990, BIOCHEM PHARMACOL, V40, P2265, DOI 10.1016/0006 2952(90)90721 V
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Paul Clark M, 2000, BRIT J PHARMACOL, V131, P1345, DOI 10.1038/sj.bjp.0703704
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Persson J, 2003, J VASC RES, V40, P538, DOI 10.1159/000075677
   Pietschmann P, 1998, CALCIFIED TISSUE INT, V63, P325, DOI 10.1007/s002239900535
   RAO GHR, 1988, ANAL BIOCHEM, V169, P400, DOI 10.1016/0003 2697(88)90303 X
   REID IR, 1986, CALCIFIED TISSUE INT, V38, P38, DOI 10.1007/BF02556593
   RIES WL, 1992, J BONE MINER RES, V7, P931
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Sethi S, 2000, THROMB RES, V100, P223, DOI 10.1016/S0049 3848(00)00320 0
   SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003 2697(83)90019 2
   Van Offel JF, 2001, CLIN EXP RHEUMATOL, V19, P13
   Wallace JL, 2005, MEM I OSWALDO CRUZ, V100, P5, DOI 10.1590/S0074 02762005000900002
   WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006 291X(89)92506 0
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
NR 34
TC 4
Z9 4
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1425 8153
EI 1689 1392
J9 CELL MOL BIOL LETT
JI Cell. Mol. Biol. Lett.
PD SEP
PY 2009
VL 14
IS 3
BP 457
EP 465
DI 10.2478/s11658 009 0012 6
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 464DF
UT WOS:000267484600007
PM 19238333
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Cook, LM
   Araujo, A
   Pow Sang, JM
   Budzevich, MM
   Basanta, D
   Lynch, CC
AF Cook, Leah M.
   Araujo, Arturo
   Pow Sang, Julio M.
   Budzevich, Mikalai M.
   Basanta, David
   Lynch, Conor C.
TI Predictive computational modeling to define effective treatment
   strategies for bone metastatic prostate cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH FACTOR BETA; TGF BETA; MATHEMATICAL MODEL; TUMOR GROWTH;
   PROGRESSION; DRIVEN; CELLS; HETEROGENEITY; GLIOBLASTOMA; INHIBITION
AB The ability to rapidly assess the efficacy of therapeutic strategies for incurable bone metastatic prostate cancer is an urgent need. Pre clinical in vivo models are limited in their ability to define the temporal effects of therapies on simultaneous multicellular interactions in the cancer bone microenvironment. Integrating biological and computational modeling approaches can overcome this limitation. Here, we generated a biologically driven discrete hybrid cellular automaton (HCA) model of bone metastatic prostate cancer to identify the optimal therapeutic window for putative targeted therapies. As proof of principle, we focused on TGF beta because of its known pleiotropic cellular effects. HCA simulations predict an optimal effect for TGF beta inhibition in a pre metastatic setting with quantitative outputs indicating a significant impact on prostate cancer cell viability, osteoclast formation and osteoblast differentiation. In silico predictions were validated in vivo with models of bone metastatic prostate cancer (PAIII and C4 2B). Analysis of human bone metastatic prostate cancer specimens reveals heterogeneous cancer cell use of TGF beta. Patient specific information was seeded into the HCA model to predict the effect of TGF beta inhibitor treatment on disease evolution. Collectively, we demonstrate how an integrated computational/biological approach can rapidly optimize the efficacy of potential targeted therapies on bone metastatic prostate cancer.
C1 [Cook, Leah M.; Lynch, Conor C.] H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA.
   [Araujo, Arturo; Basanta, David] H Lee Moffitt Canc Ctr & Res Inst, Integrated Math Oncol Dept, Tampa, FL 33612 USA.
   [Pow Sang, Julio M.] H Lee Moffitt Canc Ctr & Res Inst, Genitourinary Oncol Dept, Tampa, FL USA.
   [Budzevich, Mikalai M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL USA.
C3 H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer
   Center & Research Institute; H Lee Moffitt Cancer Center & Research
   Institute; H Lee Moffitt Cancer Center & Research Institute
RP Lynch, CC (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA.; Basanta, D (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Integrated Math Oncol Dept, Tampa, FL 33612 USA.
EM david@cancerevo.org; conor.lynch@moffitt.org
RI ; Cook, Leah/AAV 9640 2021
OI Basanta, David/0000 0002 8527 0776; Cook, Leah/0000 0002 9996 7419; 
FU NIH [R01CA143094]; Bankhead Coley award [5BC 01, UO1CA151924]; American
   Cancer Society [PF 13 175 01 CSM]; Department of Defense Prostate Cancer
   Research Program [W81XWH 15 1 0184];  [P30 CA076292]
FX The authors thank Patrick Finn at Genzyme and Scott Lonning (presently
   Cell Signaling) for the 1D11 inhibitor. Funding provided in part through
   NIH R01CA143094 and Bankhead Coley awards (5BC 01) (CCL), UO1CA151924
   (to A.R. Anderson). L.M.C. and A.A. are supported by fellowships from
   the American Cancer Society (PF 13 175 01 CSM) and Department of Defense
   Prostate Cancer Research Program (W81XWH 15 1 0184) respectively. This
   work was also supported in part Core Facilities at the Moffitt Cancer
   Center (P30 CA076292).
CR Altrock PM, 2015, NAT REV CANCER, V15, P730, DOI 10.1038/nrc4029
   Anderson ARA, 2008, NAT REV CANCER, V8, P227, DOI 10.1038/nrc2329
   Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042
   Anderson ARA, 2009, CANCER RES, V69, P8797, DOI 10.1158/0008 5472.CAN 09 0437
   Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Basanta D, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2013.0020
   Basanta D, 2012, MOL PHARMACEUT, V9, P914, DOI 10.1021/mp200458e
   Basanta D, 2009, CANCER RES, V69, P7111, DOI 10.1158/0008 5472.CAN 08 3957
   Benzekry S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003800
   Berges RR, 1995, CLIN CANCER RES, V1, P473
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Biswas S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027090
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255
   Buenzli PR, 2012, J THEOR BIOL, V307, P42, DOI 10.1016/j.jtbi.2012.04.019
   Cook LM, 2014, CANCER METAST REV, V33, P511, DOI 10.1007/s10555 014 9494 4
   Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003
   Ditlev JA, 2013, BIOPHYS J, V104, P520, DOI 10.1016/j.bpj.2012.12.044
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Eikenberry SE, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 24
   Enriquez Navas PM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7842
   Eudy RJ, 2015, CPT PHARMACOMET SYST, V4, P527, DOI 10.1002/psp4.12013
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Fournier PGJ, 2010, BONE, V47, pS268, DOI 10.1016/j.bone.2010.01.332
   Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009
   Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114
   Fuller K, 2000, J CELL SCI, V113, P2445
   Gallaher J., 2014, CLIN EXP ME IN PRESS
   Ganapathy V, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 122
   Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008 5472.CAN 08 3658
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hodde JP, 2004, J SURG RES, V120, P189, DOI 10.1016/j.jss.2003.10.022
   Horn M, 2013, BLOOD, V121, P378, DOI 10.1182/blood 2012 07 441956
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Ince TA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8419
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Ji B, 2014, INT J NUMER METH BIO, V30, P1085, DOI 10.1002/cnm.2645
   Joseph J, 2012, MOL CANCER RES, V10, P282, DOI 10.1158/1541 7786.MCR 11 0404
   Juárez P, 2012, CANCER RES, V72, P6247, DOI 10.1158/0008 5472.CAN 12 1444
   Kaminska B, 2005, ACTA BIOCHIM POL, V52, P329
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Khin ZP, 2014, CANCER RES, V74, P56, DOI 10.1158/0008 5472.CAN 13 2397
   Komarova SV, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00051
   Korpal M, 2010, EUR J CANCER, V46, P1232, DOI 10.1016/j.ejca.2010.02.040
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Leder K, 2014, CELL, V156, P603, DOI 10.1016/j.cell.2013.12.029
   Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065
   Morris JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090353
   Ottewell PD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.10
   PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825
   Rejniak KA, 2011, WIRES SYST BIOL MED, V3, P115, DOI 10.1002/wsbm.102
   Robertson Tessi M, 2015, CANCER RES, V75, P1567, DOI 10.1158/0008 5472.CAN 14 1428
   Rockne R, 2009, J MATH BIOL, V58, P561, DOI 10.1007/s00285 008 0219 6
   Ryser MD, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002703
   Ryser MD, 2009, J BONE MINER RES, V24, P860, DOI 10.1359/JBMR.081229
   SHINAR DM, 1990, ENDOCRINOLOGY, V126, P3153, DOI 10.1210/endo 126 6 3153
   Swanson KR, 2008, BRIT J CANCER, V98, P113, DOI 10.1038/sj.bjc.6604125
   Swanson KR, 2011, CANCER RES, V71, P7366, DOI 10.1158/0008 5472.CAN 11 1399
   Thiolloy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029862
   Thiolloy S, 2009, CANCER RES, V69, P6747, DOI 10.1158/0008 5472.CAN 08 3949
   Zhao BY, 2014, CANCER DISCOV, V4, P166, DOI 10.1158/2159 8290.CD 13 0465
NR 62
TC 37
Z9 40
U1 0
U2 26
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 14
PY 2016
VL 6
AR 29384
DI 10.1038/srep29384
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DQ9YW
UT WOS:000379566200001
PM 27411810
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Altman, AR
   Tseng, WJ
   de Bakker, CMJ
   Huh, BK
   Chandra, A
   Qin, L
   Liu, XS
AF Altman, Allison R.
   Tseng, Wei Ju
   de Bakker, Chantal M. J.
   Huh, Beom Kang
   Chandra, Abhishek
   Qin, Ling
   Liu, X. Sherry
TI A closer look at the immediate trabecula response to combined
   parathyroid hormone and alendronate treatment
SO BONE
LA English
DT Article
DE In vivo mu CT; 3D image registration; Parathyroid hormone;
   Anti resorptive treatment; Trabecular bone microstructure; Animal
   models/rodent
ID POSTMENOPAUSAL WOMEN; ANABOLIC RESPONSE; BONE ARCHITECTURE;
   TERIPARATIDE; PTH; MECHANISMS; OSTEOPOROSIS; IBANDRONATE; COMBINATION;
   TOMOGRAPHY
AB Daily injections of parathyroid hormone (PTH) are the only FDA approved anabolic treatment for osteoporosis: however PTH is only clinically approved for treatment periods of up to 24 months. To enhance its anabolic effect, combining PTH with anti resorptive therapy was proposed and expected to maximize the effectiveness of PTH. The current study aimed to elucidate structural mechanisms through which combination therapy can further improve bone strength over a limited treatment window of 12 days, to more closely examine the early phase of the anabolic window. We examined 30 female rats treated with either vehicle (Veh), alendronate (ALN), PTH, or both PTH and ALN (PTH+ALN). Standard and individual trabecula segmentation (ITS) based microstructural analyses were performed using in vivo micro computed tomography. We found an increase in BV/TV in all treatments with the highest in the PTH+ALN group. Tb.Th* increased in both PTH and PTH+ALN groups well beyond that of the Veh or ALN group. SMI decreased in all treatments with PTH+ALN having the greatest tendency toward plate like structures. ITS confirmed the trend toward more plate like structures with increased plate Tb.N* and increased plate to rod ratio that was most pronounced in the PTH+ALN group. Using image based finite element analysis, we demonstrated that stiffness increased in all treatment groups, again with the largest increase in the PTH+ALN group, indicating the resulting structural implications of increased plate like structure. Static and dynamic bone histomorphometry and a serum resorption marker confirmed that PTH+ALN significantly increased bone formation activities and suppressed bone resorption activities. Overall the results indicate that PTH+ALN treatment has an additive effect due to a preferential increase in plate like structures. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Altman, Allison R.; Tseng, Wei Ju; de Bakker, Chantal M. J.; Huh, Beom Kang; Chandra, Abhishek; Qin, Ling; Liu, X. Sherry] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Liu, XS (通讯作者)，Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, 426C Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM alaltman@mail.med.upenn.edu; weits@mail.med.upenn.edu;
   chantald@seas.upenn.edu; bhuh@seas.upenn.edu; abhic@mail.med.upenn.edu;
   qinling@mail.med.upenn.edu; xiaoweil@mail.med.upenn.edu
RI Liu, Xiaowei Sherry/H 1664 2017; qin, ling/KIB 1029 2024; Liu,
   Xiaowei/H 1664 2017; Chandra, Abhishek/AAG 8781 2020; Tseng,
   Wei Ju/AAC 2819 2022
OI Liu, Xiaowei Sherry/0000 0001 7247 2232; de Bakker,
   Chantal/0000 0001 8421 3385; Chandra, Abhishek/0000 0001 9423 9669; 
FU McCabe Pilot Award; Penn Center for Musculoskeletal Disorders [NIH/NIAMS
   P30 AR050950]; ASBMR Junior Faculty Osteoporosis Basic Research Award;
   NIH/NIDDK [R01 DK09580301]; NIH/NIAMS [T32 AR007132]
FX This study was partially supported by McCabe Pilot Award (to XSL), Penn
   Center for Musculoskeletal Disorders (NIH/NIAMS P30 AR050950), ASBMR
   Junior Faculty Osteoporosis Basic Research Award (to LQ), NIH/NIDDK
   R01 DK09580301 (to LQ), and NIH/NIAMS T32 AR007132 (to CMJdB).
CR Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Boyd SK, 2006, BONE, V39, P854, DOI 10.1016/j.bone.2006.04.017
   Campbell GM, 2011, BONE, V49, P225, DOI 10.1016/j.bone.2011.04.008
   Chandra A, 2013, BONE, V55, P449, DOI 10.1016/j.bone.2013.02.023
   COLLIGNON A, 1995, COMP IMAG VIS, V3, P263
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2013, J BONE MINER RES, V28, P1328, DOI 10.1002/jbmr.1853
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221 8747(84)90026 2
   Guo X.E., 1997, FORMA, V12, P185
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   HOLLISTER SJ, 1994, J BIOMECH, V27, P433, DOI 10.1016/0021 9290(94)90019 1
   Ibanez L., 2005, ITK SOFTWARE GUIDE
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Kinney JH, 1998, J BONE MINER RES, V13, P839, DOI 10.1359/jbmr.1998.13.5.839
   Kostenuik PJ, 2001, ENDOCRINOLOGY, V142, P4295, DOI 10.1210/en.142.10.4295
   Lan SH, 2013, BONE, V56, P83, DOI 10.1016/j.bone.2013.05.014
   Lane NE, 1996, J BONE MINER RES, V11, P614
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Liu XS, 2008, J BONE MINER RES, V23, P223, DOI 10.1359/JBMR.071009
   Liu XS, 2010, J BONE MINER RES, V25, P746, DOI 10.1359/jbmr.090822
   Liu XWS, 2006, J BONE MINER RES, V21, P1608, DOI 10.1359/JBMR.060716
   Muschitz C, 2013, J BONE MINER RES, V28, P196, DOI 10.1002/jbmr.1716
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Samadfam R, 2007, ENDOCRINOLOGY, V148, P2778, DOI 10.1210/en.2006 1475
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   Schafer AL, 2013, OSTEOPOROSIS INT, V24, P2591, DOI 10.1007/s00198 013 2349 y
   Shi XT, 2010, J BIOMECH, V43, P2460, DOI 10.1016/j.jbiomech.2010.05.032
   Shi XT, 2010, BONE, V46, P1260, DOI 10.1016/j.bone.2010.02.005
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Viola P, 1997, INT J COMPUT VISION, V24, P137, DOI 10.1023/A:1007958904918
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Yang X, 2013, BONE, V52, P308, DOI 10.1016/j.bone.2012.09.039
NR 43
TC 26
Z9 32
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2014
VL 61
BP 149
EP 157
DI 10.1016/j.bone.2014.01.008
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AC8WL
UT WOS:000332815700020
PM 24468717
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Shimono, K
   Morrison, TN
   Tung, WE
   Chandraratna, RA
   Williams, JA
   Iwamoto, M
   Pacifici, M
AF Shimono, Kengo
   Morrison, Tiffany N.
   Tung, Wei en
   Chandraratna, Roshantha A.
   Williams, Julie A.
   Iwamoto, Masahiro
   Pacifici, Maurizio
TI Inhibition of Ectopic Bone Formation by a Selective Retinoic Acid
   Receptor α Agonist: A New Therapy for Heterotopic Ossification?
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE heterotopic ossification; chondrogenesis; retinoic acid receptors;
   retinoid agonists
ID RISK FACTORS; IN VIVO; DIFFERENTIATION; HIP; INDOMETHACIN; ANGIOGENESIS;
   PROGRESSIVA; RADIATION; CELLS
AB Heterotopic ossification (HO) consists of formation of ectopic cartilage followed by endochondral bone and is triggered by major surgeries, large wounds, and other conditions. Current therapies, including low dose irradiation, are not always effective and do not target the skeletogenic process directly. Because chondrogenesis requires a decrease of nuclear retinoic acid receptor alpha (RAR alpha) action, we reasoned that pharmacologic activation of this receptor pathway should inhibit HO. Thus, we selected the synthetic retinoid NRX195183, a potent and highly selective RAR alpha agonist, and found that it did inhibit chondrogenesis in mouse limb micromass cultures. We established a mouse HO model consisting of subcutaneous implantation of Matrigel mixed with rhBMP 2. Control mice receiving daily oral doses of vehicle (peanut oil) or retinol (a natural nonactive retinoid precursor) developed large HO like masses by days 9 12 that displayed abundant cartilage, endochondral bone, vessels, and marrow. In contrast, formation of HO like masses was markedly reduced in companion mice receiving daily oral doses of alpha agonist. These ectopic masses contained sharply reduced amounts of cartilage and bone, blood vessels, and TRAP positive osteoclasts, and expressed markedly lower levels of master chondrogenic genes including Sox9, cartilage genes such as collagen XI and X, and osteogenic genes including Runx2. The data provide proof of principle evidence that a pharmacological strategy involving a selective RAR alpha agonist can indeed counteract an ectopic skeletal formation process effectively and efficiently, and could thus represent a novel preventive treatment for HO. (C) 2009 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 28:271 277, 2010
C1 [Shimono, Kengo; Morrison, Tiffany N.; Tung, Wei en; Williams, Julie A.; Iwamoto, Masahiro; Pacifici, Maurizio] Thomas Jefferson Univ, Coll Med, Dept Orthopaed Surg, Philadelphia, PA 19107 USA.
   [Chandraratna, Roshantha A.] NURx Pharmaceut Inc, Irvine, CA 92618 USA.
C3 Thomas Jefferson University
RP Pacifici, M (通讯作者)，Thomas Jefferson Univ, Coll Med, Dept Orthopaed Surg, 1015 Walnut St,501 Curtis Bldg, Philadelphia, PA 19107 USA.
EM maurizio.pacifici@jefferson.edu
FU Vitae Pharmaceuticals [NRX195183]; NuRx Pharmaceuticals [NRX195183];
   Department of the Army, United States Army Medical Research Acquisition
   Activity [W81XWH 07 1 0212]
FX We thank Vitae Pharmaceuticals and NuRx Pharmaceuticals for providing
   NRX195183. This work was solely supported by contract no.
   W81XWH 07 1 0212 from the Department of the Army, United States Army
   Medical Research Acquisition Activity.
CR AHRENGART L, 1991, CLIN ORTHOP RELAT R, P49
   Beard RL, 2002, BIOORG MED CHEM LETT, V12, P3145, DOI 10.1016/S0960 894X(02)00647 9
   Blaner William S., 1994, P229
   Blebea J, 2002, J VASC SURG, V35, P532, DOI 10.1067/mva.2002.120042
   BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623 197355080 00006
   CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301 620X.57B1.36
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chao ST, 2007, ORTHOPEDICS, V30, P457, DOI 10.3928/01477447 20070601 18
   CRAVEN PL, 1971, CLIN ORTHOP RELAT R, P231
   DICESARE PE, 1991, J ORTHOP RES, V9, P855, DOI 10.1002/jor.1100090611
   Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792
   Gaetano C, 2001, CIRC RES, V88, pE38
   GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13
   Glass CK, 2000, GENE DEV, V14, P121
   Herbert KE, 2007, TRANSPLANTATION, V83, P375, DOI 10.1097/01.tp.0000251376.75347.b4
   Hoffman LM, 2006, J CELL BIOL, V174, P101, DOI 10.1083/jcb.200604150
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Karunakar MA, 2006, J BONE JOINT SURG BR, V88B, P1613, DOI 10.1302/0301 620X.88B12.18151
   KWASIGROCH TE, 1980, ANAT EMBRYOL, V161, P105, DOI 10.1007/BF00304671
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256 005 0958 z
   Meiners T, 1997, SPINAL CORD, V35, P443, DOI 10.1038/sj.sc.3100415
   Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955 0674(98)80015 X
   Nilsson Olle S., 1999, Current Opinion in Rheumatology, V11, P127, DOI 10.1097/00002281 199903000 00008
   O'Connor JP, 1998, CLIN ORTHOP RELAT R, P71
   PACIFICI M, 1980, EXP CELL RES, V129, P469, DOI 10.1016/0014 4827(80)90517 0
   SCOTT WJ, 1994, DEV BIOL, V164, P277, DOI 10.1006/dbio.1994.1198
   Sell S, 1998, J ARTHROPLASTY, V13, P854, DOI 10.1016/S0883 5403(98)90189 9
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Subbarao J V, 1999, J Spinal Cord Med, V22, P273
   SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674
   van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309
   Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628
   Walkley CR, 2004, BLOOD, V103, P1286, DOI 10.1182/blood 2003 07 2391
   Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029
   Zasloff MA, 1998, CLIN ORTHOP RELAT R, P121
NR 35
TC 52
Z9 68
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD FEB
PY 2010
VL 28
IS 2
BP 271
EP 277
DI 10.1002/jor.20985
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 544RD
UT WOS:000273675700020
PM 19725108
DA 2025 08 17
ER

PT J
AU Rao, S
   Sigl, V
   Wimmer, RA
   Novatchkova, M
   Jais, A
   Wagner, G
   Handschuh, S
   Uribesalgo, I
   Hagelkruys, A
   Kozieradzki, I
   Tortola, L
   Nitsch, R
   Cronin, SJ
   Orthofer, M
   Branstetter, D
   Canon, J
   Rossi, J
   D'Arcangelo, M
   Botling, J
   Micke, P
   La Fleur, L
   Edlund, K
   Bergqvist, M
   Ekman, S
   Lendl, T
   Popper, H
   Takayanagi, H
   Kenner, L
   Hirsch, FR
   Dougall, W
   Penninger, J
AF Rao, Shuan
   Sigl, Verena
   Wimmer, Reiner Alois
   Novatchkova, Maria
   Jais, Alexander
   Wagner, Gabriel
   Handschuh, Stephan
   Uribesalgo, Iris
   Hagelkruys, Astrid
   Kozieradzki, Ivona
   Tortola, Luigi
   Nitsch, Roberto
   Cronin, Shane J.
   Orthofer, Michael
   Branstetter, Daniel
   Canon, Jude
   Rossi, John
   D'Arcangelo, Manolo
   Botling, Johan
   Micke, Patrick
   La Fleur, Linnea
   Edlund, Karolina
   Bergqvist, Michael
   Ekman, Simon
   Lendl, Thomas
   Popper, Helmut
   Takayanagi, Hiroshi
   Kenner, Lukas
   Hirsch, Fred R.
   Dougall, William
   Penninger, Josef
TI RANK rewires energy homeostasis in lung cancer cells and drives primary
   lung cancer
SO GENES & DEVELOPMENT
LA English
DT Article
DE RANK; energy homeostasis; lung cancer; lung cancer stem like cells
ID OSTEOCLAST DIFFERENTIATION; PROGESTERONE RECEPTORS; TUMOR; DENOSUMAB;
   PROGRESSION; ESTROGEN; OSTEOPROTEGERIN; EXPRESSION; LIGAND; WOMEN
AB Lung cancer is the leading cause of cancer deaths. Besides smoking, epidemiological studies have linked female sex hormones to lung cancer in women; however, the underlying mechanisms remain unclear. Here we report that the receptor activator of nuclear factor kB (RANK), the key regulator of osteoclastogenesis, is frequently expressed in primary lung tumors, an active RANK pathway correlates with decreased survival, and pharmacologic RANK inhibition reduces tumor growth in patient derived lung cancer xenografts. Clonal genetic inactivation of KRas(G12D) in mouse lung epithelial cells markedly impairs the progression of KRas(G12D) driven lung cancer, resulting in a significant survival advantage. Mechanistically, RANK rewires energy homeostasis in human and murine lung cancer cells and promotes expansion of lung cancer stem like cells, which is blocked by inhibiting mitochondrial respiration. Our data also indicate survival differences in KRas(G12D) driven lung cancer between male and female mice, and we show that female sex hormones can promote lung cancer progression via the RANK pathway. These data uncover a direct role for RANK in lung cancer and may explain why female sex hormones accelerate lung cancer development. Inhibition of RANK using the approved drug denosumab may be a therapeutic drug candidate for primary lung cancer.
C1 [Rao, Shuan; Sigl, Verena; Wimmer, Reiner Alois; Novatchkova, Maria; Uribesalgo, Iris; Hagelkruys, Astrid; Kozieradzki, Ivona; Tortola, Luigi; Nitsch, Roberto; Cronin, Shane J.; Orthofer, Michael; Penninger, Josef] Austrian Acad Sci IMBA, Inst Mol Biotechnol, A 1030 Vienna, Austria.
   [Jais, Alexander; Wagner, Gabriel] Med Univ Vienna, Dept Lab Med, A 1090 Vienna, Austria.
   [Jais, Alexander] Max Planck Inst Metab Res, Dept Neuronal Control Metab, D 50931 Cologne, Germany.
   [Handschuh, Stephan] Univ Vet Med, VetCore Facil Res, A 1220 Vienna, Austria.
   [Branstetter, Daniel] Amgen Inc, Dept Pathol, Seattle, WA 98119 USA.
   [Canon, Jude; Dougall, William] Amgen Inc, Dept Oncol Res, Seattle, WA 98119 USA.
   [Rossi, John] Amgen Inc, Dept Mol Sci, Seattle, WA 98119 USA.
   [D'Arcangelo, Manolo; Hirsch, Fred R.] Univ Colorado, Ctr Canc, Aurora, CO 80045 USA.
   [Botling, Johan; Micke, Patrick; La Fleur, Linnea] Uppsala Univ, Dept Immunol Genet & Pathol, S 75185 Uppsala, Sweden.
   [Edlund, Karolina] Leibniz Res Ctr Working Environm & Human Factors, D 44139 Dortmund, Germany.
   [Bergqvist, Michael] Gavle Cent Hosp, Dept Oncol, S 80187 Gavle, Sweden.
   [Ekman, Simon] Karolinska Inst, Dept Oncol Pathol, S 17177 Stockholm, Sweden.
   [Lendl, Thomas] Gregor Mendel Inst Mol Plant Biol GMI, A 1030 Vienna, Austria.
   [Popper, Helmut] Med Univ Graz, Inst Pathol, Res Unit Mol Lung & Pleura Pathol, A 8036 Graz, Austria.
   [Takayanagi, Hiroshi] Univ Tokyo, Dept Immunol, Tokyo 1088639, Japan.
   [Kenner, Lukas] Med Univ Vienna, Dept Clin Pathol, A 1090 Vienna, Austria.
   [Kenner, Lukas] Ludwig Boltzmann Inst Canc Res, A 1090 Vienna, Austria.
   [Kenner, Lukas] Univ Vet Med Vienna, Unit Pathol Lab Anim, A 1220 Vienna, Austria.
   [Dougall, William] QIMR, Berghofer Med Res Inst, Dept Immunol Canc & Infect, Brisbane, Qld 4006, Australia.
C3 Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of
   Molecular Biotechnology (IMBA); Medical University of Vienna; University
   of Veterinary Medicine Vienna; Amgen; Amgen; Amgen; University of
   Colorado System; University of Colorado Anschutz Medical Campus; Uppsala
   University; Dortmund University of Technology; Leibniz Association;
   Leibniz Institut for Arbeitsforschung an der TU Dortmund (IFADO);
   Karolinska Institutet; Austrian Academy of Sciences; Vienna Biocenter
   (VBC); Gregor Mendel Institute of Molecular Plant Biology (GMI); Medical
   University of Graz; University of Tokyo; Medical University of Vienna;
   Ludwig Boltzmann Institute; Ludwig Boltzmann Institute for Cancer
   Research; University of Veterinary Medicine Vienna; QIMR Berghofer
   Medical Research Institute
RP Penninger, J (通讯作者)，Austrian Acad Sci IMBA, Inst Mol Biotechnol, A 1030 Vienna, Austria.
EM josef.penninger@imba.oeaw.ac.at
RI ; Ekman, Simon/AAB 9387 2021; Nitsch, Roberto/AAT 3666 2020; Botling,
   Johan/ABA 2586 2020; Jais, Alexander/AAQ 9102 2021; Wagner,
   Gabriel/MVX 2133 2025; Rao, Shuan/V 3653 2019; Penninger,
   Josef/I 6860 2013
OI Handschuh, Stephan/0000 0002 2140 7892; Rao, Shuan/0000 0002 5268 7006;
   Dougall, William/0000 0001 9487 251X; Uribesalgo,
   Iris/0000 0001 9492 1000; Tortola, Luigi/0000 0002 8480 2080; Jais,
   Alexander/0000 0002 9897 4983; nitsch, roberto/0000 0001 8766 6267;
   D'Arcangelo, Manolo/0000 0003 0409 7762; Kenner,
   Lukas/0000 0003 2184 1338; Botling, Johan/0000 0003 2226 3517;
   Penninger, Josef/0000 0002 8194 3777
FU National Cancer Institute/Colorado Lung Cancer Specialized Program for
   Research Excellence (SPORE) Program; Austrian Science Fund (FWF)
   [P26011]; Marie Sklodowska Curie Initial Training Networks (MCEU ITN)
   ALKATRAS Network [675712]; Institute of Molecular Biotechnology of the
   Austrian Academy of Sciences; Austrian Ministry of Sciences; Austrian
   Academy of Sciences; European Research Council Advanced Grant; Era of
   Hope Innovator award; Marie Curie Actions (MSCA) [675712] Funding
   Source: Marie Curie Actions (MSCA); Grants in Aid for Scientific
   Research [15H05703] Funding Source: KAKEN; Austrian Science Fund (FWF)
   [P26011] Funding Source: Austrian Science Fund (FWF)
FX We thank Tuomas Tammala and Tyler Jacks (Massachusetts Institute of
   Technology, Boston) for sharing their protocol on lung cancer tumor
   spheres. We thank Jeffrey Whitsett for kindly sharing SP C rtTA Cre
   mice. We also thank A. Kavirayani, A. Piszczek, and M. Zeba for expert
   histology service and pathology; Life Science Editors for editorial
   support; and all members of our laboratories for helpful discussions. We
   thank Rebecca Robertson for help with the PDX studies, and Per Liv for
   statistical analysis of the Uppsala cohort. F.R.H. is supported through
   the National Cancer Institute/Colorado Lung Cancer Specialized Program
   for Research Excellence (SPORE) Program. L.K. is supported by the
   Austrian Science Fund (FWF; P26011) and the
   Marie Sklodowska Curie Initial Training Networks (MCEU ITN) ALKATRAS
   Network (675712). J.M.P. is supported by grants from the Institute of
   Molecular Biotechnology of the Austrian Academy of Sciences, the
   Austrian Ministry of Sciences, the Austrian Academy of Sciences, a
   European Research Council Advanced Grant, and an Era of Hope Innovator
   award.
CR [Anonymous], NAT GENET
   Baik CS, 2010, CANCER EPIDEM BIOMAR, V19, P2525, DOI 10.1158/1055 9965.EPI 10 0450
   BEATTIE CW, 1985, CANCER RES, V45, P4206
   Belani CP, 2007, LUNG CANCER, V55, P15, DOI 10.1016/j.lungcan.2006.09.008
   Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107
   Botling J, 2013, CLIN CANCER RES, V19, P194, DOI 10.1158/1078 0432.CCR 12 1139
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Brown Glaberman U, 2013, CLIN PHARMACOL ADV A, V5, P117, DOI 10.2147/CPAA.S30330
   CAGLE PT, 1990, CANCER RES, V50, P6632
   Chen LM, 2011, J CELL BIOCHEM, V112, P933, DOI 10.1002/jcb.23009
   Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140 6736(09)61526 9
   Di Nunno L, 2000, ARCH PATHOL LAB MED, V124, P1467
   Dorn GW, 2015, GENE DEV, V29, P1981, DOI 10.1101/gad.269894.115
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gesta S, 2011, P NATL ACAD SCI USA, V108, P2771, DOI 10.1073/pnas.1019704108
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Hammoud Z, 2008, ENDOCR RELAT CANCER, V15, P475, DOI 10.1677/ERC 08 0002
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Hyde Z, 2012, CANCER EPIDEM BIOMAR, V21, P1319, DOI 10.1158/1055 9965.EPI 12 0129
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129
   Joshi PA, 2015, STEM CELL REP, V5, P31, DOI 10.1016/j.stemcr.2015.05.012
   Knoop KA, 2009, J IMMUNOL, V183, P5738, DOI 10.4049/jimmunol.0901563
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118
   Perl AK, 2009, AM J RESP CELL MOL, V40, P1, DOI 10.1165/rcmb.2008 0011ED
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092 8674(00)81410 5
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Remon J, 2014, CLIN TRANSL ONCOL, V16, P517, DOI 10.1007/s12094 013 1137 7
   Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Schramek D., 2011, IMBS BONEKEY, V8, P237, DOI DOI 10.1138/20110512
   Schramek D, 2011, NAT GENET, V43, P212, DOI 10.1038/ng.767
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Siegel RL, 2015, CA CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
NR 47
TC 33
Z9 34
U1 0
U2 24
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890 9369
EI 1549 5477
J9 GENE DEV
JI Genes Dev.
PD OCT 15
PY 2017
VL 31
IS 20
BP 2099
EP 2112
DI 10.1101/gad.304162.117
PG 14
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA FN3TQ
UT WOS:000415923700007
PM 29118048
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Anand, P
   Mehler, PS
AF Anand, Pratibha
   Mehler, Philip S.
TI Osteoporosis recovery in severe anorexia nervosa: a case report
SO JOURNAL OF EATING DISORDERS
LA English
DT Article
DE Anorexia nervosa; Osteoporosis; Teriparatide; Denosumab; Hormonal
   replacement therapy; Supplementation
ID TERIPARATIDE; WOMEN; DENOSUMAB; ADULT; EXTENSION; FRACTURE
AB BackgroundOsteoporosis represents a common and severe complication in patients with anorexia nervosa (AN) that normally persists despite weight restoration and the resumption of regular menses. The condition may result in significant pain, injury, and disability.Case presentationWe report the only published case of a complete return to normal bone density following many years of severe osteoporosis in a severely malnourished patient with AN. We describe a patient with severe and enduring AN whose osteoporosis, with resultant fractures, was completely reversed. Available patient records, imaging, and laboratory data were evaluated.ConclusionsThis case represents a common yet often improperly treated complication of AN. It demonstrates the potential important clinical role that targeted medicines coupled with a multifaceted supplementation and lifestyle interventions, may have for some very malnourished patients with AN. Medications, in the treatment of osteoporosis in patients with severe AN, may decrease fracture risk, enhance overall bone density, and contribute to an improved quality of life.
C1 [Anand, Pratibha; Mehler, Philip S.] Univ Colorado, Sch Med, Aurora, CO 80045 USA.
   [Mehler, Philip S.] Eating Recovery Ctr Denver, Denver, CO USA.
   [Mehler, Philip S.] Denver Hlth, ACUTE, Denver, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Denver Health Medical Center
RP Anand, P (通讯作者)，Univ Colorado, Sch Med, Aurora, CO 80045 USA.
EM pratibha.anand@ucdenver.edu
CR BILLER BMK, 1989, J CLIN ENDOCR METAB, V68, P548, DOI 10.1210/jcem 68 3 548
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Cosman F, 2015, OSTEOPOROSIS INT, V26, P2045, DOI 10.1007/s00198 015 3037 x
   Fazeli PK, 2014, J CLIN ENDOCR METAB, V99, P1322, DOI 10.1210/jc.2013 4105
   Glaser DL, 1997, SPINE, V22, p12S, DOI 10.1097/00007632 199712151 00003
   Jamieson A, 2016, AM J MED, V129, pE47, DOI 10.1016/j.amjmed.2015.07.040
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lucas AR, 1999, MAYO CLIN PROC, V74, P972
   Mehler PS, 2018, INT J EAT DISORDER, V51, P305, DOI 10.1002/eat.22830
   Misra M, 2006, REV ENDOCR METAB DIS, V7, P91, DOI 10.1007/s11154 006 9005 1
   Mumford J, 2019, J ADOLESCENT HEALTH, V64, P305, DOI 10.1016/j.jadohealth.2018.07.025
   RICHARDSON JD, 1975, ANN SURG, V181, P251, DOI 10.1097/00000658 197503000 00001
   RIGOTTI NA, 1991, JAMA J AM MED ASSOC, V265, P1133, DOI 10.1001/jama.265.9.1133
   Teng K, 2011, CLEV CLIN J MED, V78, P50, DOI 10.3949/ccjm.78a.10023
NR 16
TC 6
Z9 7
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2050 2974
J9 J EAT DISORD
JI J. Eat. Disord.
PD NOV 8
PY 2019
VL 7
IS 1
AR 38
DI 10.1186/s40337 019 0269 8
PG 3
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Nutrition & Dietetics; Psychiatry
GA JL6US
UT WOS:000495665800002
PM 31719982
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Moon, K
   Lee, S
   Cha, J
AF Moon, Keumok
   Lee, Seola
   Cha, Jaeho
TI Bacillus subtilisFermentation ofMalva verticillataLeaves
   Enhances Antioxidant Activity and Osteoblast Differentiation
SO FOODS
LA English
DT Article
DE Malva verticillata; Bacillus subtilis; fermentation; osteoblast
   differentiation
ID NATURAL PRODUCTS; BIOTRANSFORMATION; POLYPHENOLS; PATHWAY; KINASE; TEA;
   L.
AB Malva verticillata, also known as Chinese mallow, is an herbaceous plant with colorful flowers and has been used as a medicine for thousands of years. This study investigated this herb for potential antioxidant activity or an association with osteoblast differentiation.M. verticillateleaves were fermented withB. subtilisMV1 at 30 degrees C for 7 days to enhance their biological activities. The resultant aqueous extract (MVW) and the fermented leaves (MVB) were measured for antioxidant and osteoblast differentiation. The results showed that the total phenolic, flavonoid, and antioxidant activity, as well as the osteoblast differentiation of the MVB increased (2 to 6 times) compared with those of the MVW. MVB induced phosphorylation of p38, extracellular signal regulated kinase in C3H10T1/2 cells, and the phosphorylation was attenuated via transforming growth factor beta (TGF beta) inhibitors. Moreover, runt related transcription factor 2 and osterix in the nucleus increased in a time dependent manner. The messenger RNA expression of alkaline phosphatase and bone sialoprotein increased about 9.4  and 65 fold, respectively, compared to the non treated cells. MVB stimulated C3H10T1/2 cells in the osteoblasts via TGF beta signaling. Thus, fermentedM. verticillataextract exhibited enhanced antioxidant activity and osteoblast differentiation.
C1 [Moon, Keumok; Lee, Seola; Cha, Jaeho] Pusan Natl Univ, Dept Microbiol, Busan 46241, South Korea.
   [Cha, Jaeho] Pusan Natl Univ, Microbiol Resource Res Inst, Busan 46241, South Korea.
C3 Pusan National University; Pusan National University
RP Cha, J (通讯作者)，Pusan Natl Univ, Dept Microbiol, Busan 46241, South Korea.; Cha, J (通讯作者)，Pusan Natl Univ, Microbiol Resource Res Inst, Busan 46241, South Korea.
EM moonko81@nate.com; lsa2715@pusan.ac.kr; jhcha@pusan.ac.kr
RI Lee, Seola/AAC 8684 2021; Cha, Jaeho/AAP 6886 2020
OI Cha, Jaeho/0000 0001 6884 4582
CR [Anonymous], 2012, PHYTOCHEMICALS GLOBA
   [Anonymous], 2012, THESIS
   Azab A., 2017, European Chemical Bulletin, V6, P295, DOI 10.17628/ecb.2017.6.295 320
   Bao LM, 2018, J PHARMACEUT BIOMED, V150, P420, DOI 10.1016/j.jpba.2017.12.044
   Bianchini LF, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01433
   Byun MR, 2014, J BIOL CHEM, V289, P9926, DOI 10.1074/jbc.M113.522870
   Chen P, 2016, SCI REP UK, V6, DOI 10.1038/srep20400
   Dajanta K., 2013, International Food Research Journal, V20, P3125
   Dang Lelamurni A. R., 2017, Journal of the Saudi Society of Agricultural Sciences, V16, P127, DOI 10.1016/j.jssas.2015.04.001
   Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776 004 0815 2
   de Carvalho CCCR, 2006, BIOTECHNOL ADV, V24, P134, DOI 10.1016/j.biotechadv.2005.08.004
   Farhan H., 2012, Asian J Pharm Clin Res, V5, P234
   Gao S, 2013, PROG CHEM, V25, P1553
   Gu Y, 2018, METAB ENG, V50, P109, DOI 10.1016/j.ymben.2018.05.006
   Hegazy MEF, 2015, J ADV RES, V6, P17, DOI 10.1016/j.jare.2014.11.009
   Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Kang HR, 2018, J AGR FOOD CHEM, V66, P2677, DOI 10.1021/acs.jafc.7b05030
   Lee EY, 2016, INT J COSMETIC SCI, V38, P148, DOI 10.1111/ics.12268
   Li YX, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122880
   Madeira JV, 2015, CRIT REV BIOTECHNOL, V35, P75, DOI 10.3109/07388551.2013.803020
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Moon K, 2020, FOODS, V9, DOI 10.3390/foods9010034
   Oliveira L. P. de, 2019, Journal of Agricultural Science (Toronto), V11, P171, DOI 10.5539/jas.v11n15p171
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Sakisaka Y, 2016, BIOCHEM BIOPH RES CO, V478, P527, DOI 10.1016/j.bbrc.2016.07.076
   Seong JS, 2017, J MICROBIOL BIOTECHN, V27, P1961, DOI 10.4014/jmb.1706.06028
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Shim KS, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1295 6
   Song Shuang Hong, 2016, Bone Rep, V5, P262, DOI 10.1016/j.bonr.2016.09.001
   Tarapore RS, 2016, J BONE MINER RES, V31, P52, DOI 10.1002/jbmr.2592
   Velicanski AS, 2014, FOOD TECHNOL BIOTECH, V52, P420, DOI 10.17113/ftb.52.04.14.3611
   Wang QP, 2014, BIOTECHNOL LETT, V36, P2515, DOI 10.1007/s10529 014 1632 0
   Yedavally Yellayi S, 2019, PRIMARY CARE, V46, P175, DOI 10.1016/j.pop.2018.10.014
NR 34
TC 10
Z9 11
U1 2
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2304 8158
J9 FOODS
JI Foods
PD MAY
PY 2020
VL 9
IS 5
AR 671
DI 10.3390/foods9050671
PG 15
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA MB0EB
UT WOS:000542281300132
PM 32456062
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wen, Q
   Zhou, L
   Zhou, CY
   Zhou, MQ
   Luo, W
   Ma, L
AF Wen, Qian
   Zhou, Liang
   Zhou, Chaoying
   Zhou, Mingqian
   Luo, Wei
   Ma, Li
TI Change in hepatocyte growth factor concentration promote mesenchymal
   stem cell mediated osteogenic regeneration
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE hepatocyte growth factor; mesenchymal stem cells; proliferation;
   osteogenic differentiation; avascular necrosis of femoral head
ID MET TYROSINE KINASE; OSTEOBLAST DIFFERENTIATION; AVASCULAR NECROSIS;
   FEMORAL HEAD; GENE THERAPY; MAP KINASE; IN VITRO; EXPRESSION; HGF;
   ACTIVATION
AB Mesenchymal stem cells (MSCs) play a crucial role in tissue repair by secretion of tissue nutrient factors such as hepatocyte growth factor (HGF). However, studies examining the effects of HGF on the proliferation and differentiation of MSCs used different concentrations of HGF and reported conflicting conclusions. This study aimed to determine the mechanisms by which different concentrations of HGF regulate MSC proliferation and osteogenic differentiation, and validate the mechanism in an animal model of early stage avascular necrosis of femoral head (ANFH). Our results demonstrate that a low concentration of HGF (20 ng/ml) preferentially promotes MSC osteogenic differentiation through increased c Met expression and phosphorylation, Akt pathway activation, and increased expression of p27, Runx2 and Osterix. In contrast, a high concentration of HGF (100 ng/ml) strongly induced proliferation by inducing strong activation of the ERK1/2 signalling pathway. As validated by animal experiments, high localized expression of HGF achieved by transplantation of HGF transgenic MSCs into ANFH rabbits increased the number of MSCs. Subsequently, 2 weeks after transplantation, HGF levels decreased and MSCs differentiated into osteoblasts and resulted in efficient tissue repair. Our results demonstrate that sequential concentration changes in HGF control the proliferation and osteogenic differentiation of MSCs in vivo. This phenomenon can be exploited therapeutically to induce bone regeneration and, in turn, improve the efficacy of pharmacological intervention for ANFH treatment.
C1 [Wen, Qian; Zhou, Chaoying; Zhou, Mingqian; Luo, Wei; Ma, Li] So Med Univ, Inst Mol Immunol, Sch Biotechnol, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhou, Liang] Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China.
C3 Southern Medical University   China; Chinese University of Hong Kong
RP Ma, L (通讯作者)，So Med Univ, Inst Mol Immunol, Sch Biotechnol, Guangzhou 510515, Guangdong, Peoples R China.
EM maryhmz@126.com
RI Zhou, Liang/P 4174 2015
OI Zhou, Liang/0000 0001 5973 7873; Ma, Li/0000 0001 5847 2375; Zhou,
   Chao ying/0000 0002 4188 9630
FU State 863 Projects [2007AA02Z458]; Program for New Century Excellent
   Talents in University [NCET 07 0410]; Science and Technology Project of
   Guangzhou [2009Z1 E441]
FX This work was financially supported by State 863 Projects
   (2007AA02Z458), Program for New Century Excellent Talents in University
   (NCET 07 0410) & Science and Technology Project of Guangzhou
   (2009Z1 E441).
CR Ali Benali MA, 2005, BBA GENE STRUCT EXPR, V1730, P56, DOI 10.1016/j.bbaexp.2005.05.011
   ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297
   Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261
   Cai L, 2007, STEM CELLS, V25, P3234, DOI 10.1634/stemcells.2007 0388
   Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116
   COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092 8674(94)90133 3
   CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546
   D'Ippolito G, 2002, BONE, V31, P269, DOI 10.1016/S8756 3282(02)00820 7
   Daltro Gildásio Cerqueira, 2008, Acta ortop. bras., V16, P23
   Duan HF, 2003, MOL THER, V8, P467, DOI 10.1016/S1525 0016(03)00186 2
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Forte G, 2006, STEM CELLS, V24, P23, DOI 10.1634/stemcells.2004 0176
   Fujimoto J, 2000, J GASTROEN HEPATOL, V15, pD33, DOI 10.1046/j.1440 1746.2000.02146.x
   Gangji V, 2004, J BONE JOINT SURG AM, V86A, P1153, DOI 10.2106/00004623 200406000 00006
   Gentile A, 2008, CANCER METAST REV, V27, P85, DOI 10.1007/s10555 007 9107 6
   Hayashi S, 1999, CIRCULATION, V100, P301
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0
   Leshem Y, 2000, J CELL PHYSIOL, V184, P101, DOI 10.1002/(SICI)1097 4652(200007)184:1<101::AID JCP11>3.0.CO;2 D
   Momcilovic O, 2009, STEM CELLS, V27, P1822, DOI 10.1002/stem.123
   Morishita R, 2011, ARTERIOSCL THROM VAS, V31, P713, DOI 10.1161/ATVBAHA.110.219550
   NABEL EG, 1995, CIRCULATION, V91, P541, DOI 10.1161/01.CIR.91.2.541
   NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0
   NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006 291X(84)91253 1
   NAKANISHI S, 1992, J BIOL CHEM, V267, P2157
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22 3 405
   NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006 291X(05)81018 6
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Paku S, 2001, AM J PATHOL, V158, P1313, DOI 10.1016/S0002 9440(10)64082 5
   Rastogi S, 2011, AM J PHYSIOL HEART C, V300, pH1501, DOI 10.1152/ajpheart.00636.2010
   ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896 6273(94)90438 3
   Rosová I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007 1104
   Rosová I, 2010, TISSUE ENG PT A, V16, P2627, DOI [10.1089/ten.tea.2009.0363, 10.1089/ten.TEA.2009.0363]
   Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Sato T, 1999, JPN CIRC J, V63, P906, DOI 10.1253/jcj.63.906
   Schächinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186
   Sheehan SM, 2000, MUSCLE NERVE, V23, P239, DOI 10.1002/(SICI)1097 4598(200002)23:2<239::AID MUS15>3.0.CO;2 U
   SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223
   Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140 6736(03)12110 1
   Standal T, 2007, BLOOD, V109, P3024, DOI 10.1182/blood 2006 07 034884
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wen Q, 2008, GENE THER, V15, P1523, DOI 10.1038/gt.2008.110
   Wen Q, 2008, BIOMED ENVIRON SCI, V21, P398, DOI 10.1016/S0895 3988(08)60060 4
   Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002 9440(10)64058 8
   YANAGITA K, 1993, J BIOL CHEM, V268, P21212
   Yasuda S, 2000, J AM COLL CARDIOL, V36, P115, DOI 10.1016/S0735 1097(00)00675 6
NR 50
TC 41
Z9 46
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2012
VL 16
IS 6
BP 1260
EP 1273
DI 10.1111/j.1582 4934.2011.01407.x
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 947XT
UT WOS:000304468600011
PM 21831134
OA Green Published
DA 2025 08 17
ER

PT J
AU Liu, FF
   Chen, F
   Yang, L
   Qiu, FC
   Zhong, GE
   Gao, S
   Xi, WZ
   Lai, ML
   He, QT
   Chen, Y
   Chen, WM
   Zhang, JP
   Yang, L
AF Liu, Fenfang
   Chen, Fen
   Yang, Le
   Qiu, Fucheng
   Zhong, Guangen
   Gao, Shan
   Xi, Weizhe
   Lai, Meilian
   He, Qiting
   Chen, Ying
   Chen, Weiming
   Zhang, Jiping
   Yang, Lu
TI Melittin acupoint injection in attenuating bone erosion in collagen 
   induced arthritis mice via inhibition of the RANKL/NF κB signaling
   pathway
SO QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
LA English
DT Article
DE Melittin acupoint injection; collagen induced arthritis; bone erosion;
   RANKL; NF KB signaling pathway
ID NF KAPPA B; OSTEOCLASTOGENESIS; RANK; OSTEOIMMUNOLOGY; ACTIVATION;
   IMMUNE
AB Background: Rheumatoid arthritis (RA) is an autoimmune disease leading to chronic joint inflammation. Bone erosion is the most serious pathological condition of RA and the main cause of joint deformities and disability. Melittin acupoint injection (MAI) is an effective traditional Chinese medicine (TCM) method for RA treatment. This study aimed to investigate the effect of MAI on RA bone erosion and to elucidate the underlying mechanism. Methods: A collagen induced arthritis (CIA) mouse model was established as the experimental subject. MAI was administrated once every other day for 28 days to mice with CIA. The effects of MAI on joint diseases were assessed by body weight, arthritis index (AI) score, swollen joint count (SJC) score, and hind paw thickness. Ankle radiological changes were captured by micro computed tomography (micro CT) and histological changes were observed by pathological staining. Organ histological changes, spleen index, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine (Crea) levels of serum were tested to evaluate the toxicity of MAI. Cytokine expression levels were confirmed by enzyme linked immunosorbent assay (ELISA) to evaluate the immunity of CIA mice. Results: MAI administration markedly improved the clinical signs of CIA in mice, including hind paw thickness, AI, and the number of swollen paw joints (most of them P<0.05 or even <0.01). According to histopathological analysis, MAI ameliorated inflammatory cell infiltration, synovial hyperplasia, pannus formation, and bone erosion (all P<0.01). Micro CT and tartrate resistant acid phosphatase (TRAP) staining (P<0.01) also revealed that MAI could relieve bone erosion via reducing the formation of osteoclasts. Not only could MAI relieve the immunological boost [P<0.05 for the high dose MAI (HM) group], but also it had no liver or kidney side effects (P>0.05). In addition, it decreased the serum levels of interleukin (IL) 6 and tumor necrosis factor & alpha; (TNF & alpha;) and increased the serum levels of IL 4 and IL 10 (the majority of P<0.05 or even <0.01). Transcriptome sequencing results indicated that MAI affected the expression of osteoclast differentiation pathway genes, which was connected with the RANKL/NF KB pathway. Conclusions: Based on our findings, MAI could suppress joint inflammation and inhibit RANKL/NFKB mediated osteoclast differentiation to rescue bone erosion in CIA mice, suggesting that MAI can be a potentially therapeutic substance for RA.
C1 [Liu, Fenfang; Chen, Fen; Yang, Le; Gao, Shan; Xi, Weizhe; Lai, Meilian; He, Qiting; Zhang, Jiping; Yang, Lu] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Peoples R China.
   [Qiu, Fucheng] Foshan Hosp TCM, Intens Care Unit, Foshan, Peoples R China.
   [Zhong, Guangen; Chen, Ying; Chen, Weiming; Yang, Lu] Southern Med Univ, Integrated Hosp Tradit Chinese Med, Dept Acupuncture & Rehabil, Guangzhou, Peoples R China.
   [Zhang, Jiping] Southern Med Univ, Sch Tradit Chinese Med, 1023 Shatai South Rd, Guangzhou 510515, Peoples R China.
   [Yang, Lu] Southern Med Univ, Sch Tradit Chinese Med, 1023 Shatai South Rd, Guangzhou 510515, Peoples R China.
   [Yang, Lu] Southern Med Univ, Integrated Hosp Tradit Chinese Med, Dept Acupuncture & Rehabil, Yard 13,Shiliugang Rd, Guangzhou 510330, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China; Southern Medical University
     China; Southern Medical University   China
RP Zhang, JP (通讯作者)，Southern Med Univ, Sch Tradit Chinese Med, 1023 Shatai South Rd, Guangzhou 510515, Peoples R China.; Yang, L (通讯作者)，Southern Med Univ, Sch Tradit Chinese Med, 1023 Shatai South Rd, Guangzhou 510515, Peoples R China.; Yang, L (通讯作者)，Southern Med Univ, Integrated Hosp Tradit Chinese Med, Dept Acupuncture & Rehabil, Yard 13,Shiliugang Rd, Guangzhou 510330, Peoples R China.
EM zhangjp611@163.com; yl800526@163.com
RI Chen, Wei Ming/ABD 2594 2021; He, Qi Ting/I 6799 2013
FU Traditional Chinese Medicine Bureau of Guangdong Province [20202120];
   National Natural Science Foundation of China [81873382]
FX Funding: This research was supported by the Traditional Chinese Medicine
   Bureau of Guangdong Province (No. 20202120) and National Natural Science
   Foundation of China (No. 81873382) .
CR Aghighi Z., 2022, Neuropeptides, V96
   Bae S, 2022, TOXINS BASEL
   Bakkar N, 2010, PHYSIOL REV, V90, P495, DOI 10.1152/physrev.00040.2009
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Cai XY, 2021, PHYTOTHER RES, V35, P1033, DOI 10.1002/ptr.6870
   Chen HW, 2020, J CELL MOL MED, V24, P9067, DOI 10.1111/jcmm.15543
   Chen J, 2016, NEUROSCI BULL, V32, P265, DOI 10.1007/s12264 016 0024 y
   Cheng X, 2022, MOL BIOL REP, V49, P2003, DOI 10.1007/s11033 021 07017 1
   Dar HY, 2018, FRONT BIOSCI LANDMRK, V23, P464, DOI 10.2741/4600
   Du GS, 2021, J CONTROL RELEASE, V336, P537, DOI 10.1016/j.jconrel.2021.07.005
   Fan KJ, 2022, ANN PALLIAT MED, V11, P466, DOI 10.21037/apm 21 1765
   Gao XR, 2022, CELL SIGNAL, V95, DOI 10.1016/j.cellsig.2022.110353
   Hayer S, 2021, ANN RHEUM DIS, V80, P714, DOI 10.1136/annrheumdis 2020 219247
   Hazlewood GS, 2022, J RHEUMATOL, V49, P998, DOI 10.3899/jrheum.210688
   Honma M, 2021, PHARMACOL THERAPEUT, V218, DOI 10.1016/j.pharmthera.2020.107682
   Jimi Eijiro, 2016, Clin Calcium, V26, P298, DOI CliCa1602298304
   Jing WS, 2022, J BIOCHEM MOL TOXIC, V36, DOI 10.1002/jbt.23042
   Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kim SK, 2011, JOINT BONE SPINE, V78, P471, DOI 10.1016/j.jbspin.2011.01.004
   Kondo Y, 2017, RHEUMATOLOGY, V56, P1089, DOI 10.1093/rheumatology/kex046
   Kougkas N, 2022, RHEUMATOL INT, V42, P1849, DOI 10.1007/s00296 022 05166 5
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee HS, 2021, APPL BIOCHEM BIOTECH, V193, P4068, DOI 10.1007/s12010 021 03653 2
   Li YQ, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114602
   Lin TY, 2020, TOXINS BASEL
   Ling YY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.693777
   Liu M, 2018, J CELL PHYSIOL, V233, P6291, DOI 10.1002/jcp.26517
   Liu MH, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000028374
   Lorenzo N, 2017, CLIN EXP MED, V17, P209, DOI 10.1007/s10238 016 0412 7
   Meng XJ, 2019, METABOLITES, V9, DOI 10.3390/metabo9120299
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Otón T, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.101477
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Qian J, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00411 2
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Sha T, 2016, QJM INT J MED, V109, P639, DOI 10.1093/qjmed/hcw055
   Shi L, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.967164
   Shin JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069380
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091 6749(76)90076 2
   Sparks JA, 2019, ANN INTERN MED, V170, pITC1, DOI 10.7326/AITC201901010
   Sun KQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.629968
   Tanaka K, 2019, BONE, V128, DOI 10.1016/j.bone.2019.115034
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Wang Q, 2017, BIOMATERIALS, V122, P10, DOI 10.1016/j.biomaterials.2017.01.008
   Wang WG, 2018, J CELL BIOCHEM, V119, P2084, DOI 10.1002/jcb.26370
   Wang ZJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.655614
   Wehbe R, 2019, MOLECULES, V24, DOI 10.3390/molecules24162997
   Xie Y, 2022, CLIN EXP IMMUNOL, V207, P297, DOI 10.1093/cei/uxac010
   Yang FM, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/9430501
   Yu NN, 2023, ACUPUNCT MED, V41, P96, DOI 10.1177/09645284221085278
   Zhai YK, 2022, MED SCI MONITOR, V28, DOI 10.12659/MSM.935979
   Zhi X, 2020, J CELL MOL MED, V24, P5122, DOI 10.1111/jcmm.15153
NR 57
TC 6
Z9 7
U1 2
U2 15
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2223 4292
EI 2223 4306
J9 QUANT IMAG MED SURG
JI Quant. Imaging Med. Surg.
PD SEP
PY 2023
VL 13
IS 9
BP 5996
EP 6013
DI 10.21037/qims 23 254
EA JUL 2023
PG 18
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA Z0BY2
UT WOS:001034679500001
PM 37711782
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yanik, SC
   Baker, AH
   Mann, KK
   Schlezinger, JJ
AF Yanik, Susan C.
   Baker, Amelia H.
   Mann, Koren K.
   Schlezinger, Jennifer J.
TI Organotins Are Potent Activators of PPARγ and Adipocyte Differentiation
   in Bone Marrow Multipotent Mesenchymal Stromal Cells
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE bone marrow; adipogenesis; organotin; PPAR gamma; RXR
ID RETINOID X RECEPTOR; OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; RXR
   AGONISTS; ROSIGLITAZONE; ADIPOGENESIS; THIAZOLIDINEDIONES; HETERODIMERS;
   MICE; OSTEOPOROSIS
AB Adipocyte differentiation in bone marrow is potentially deleterious to both bone integrity and lymphopoiesis. Here, we examine the hypothesis that organotins, common environmental contaminants that are dual ligands for peroxisome proliferator activated receptor (PPAR) gamma and its heterodimerization partner retinoid X receptor (RXR), are potent activators of bone marrow adipogenesis. A C57Bl/6 derived bone marrow multipotent mesenchymal stromal cell (MSC) line, BMS2, was treated with rosiglitazone, a PPAR gamma agonist, bexarotene, an RXR agonist, or a series of organotins. Rosiglitazone and bexarotene potently activated adipocyte differentiation; however, bexarotene had a maximal efficacy of only 20% of that induced by rosiglitazone. Organotins (tributyltin [TBT], triphenyltin, and dibutyltin) also stimulated adipocyte differentiation (EC(50) of 10 20nM) but with submaximal, structure dependent efficacy. In coexposures, both bexarotene and TBT enhanced rosiglitazone induced adipogenesis. To investigate the contribution of PPAR gamma to TBT induced adipogenesis, we examined expression of PPAR gamma 2, as well as its transcriptional target FABP4. TBT induced PPAR gamma 2 and FABP4 protein expression with an efficacy intermediate between rosiglitazone and bexarotene, similar to lipid accumulation. A PPAR gamma antagonist and PPAR gamma specific small hairpin RNA suppressed TBT induced differentiation, although to a lesser extent than rosiglitazone induced differentiation, suggesting that TBT may engage alternate pathways. TBT and bexarotene, but not rosiglitazone, also induced the expression of TGM2 (an RXR target) and ABCA1 (a liver X receptor target). The results show that an environmental contaminant, acting with the same potency as a therapeutic drug, induces PPAR gamma dependent adipocyte differentiation in bone marrow MSCs. Activation of multiple nuclear receptor pathways by organotins may have significant implications for bone physiology.
C1 [Yanik, Susan C.; Schlezinger, Jennifer J.] Boston Univ, Sch Med, Dept Environm Hlth, Boston, MA 02118 USA.
   [Baker, Amelia H.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
   [Mann, Koren K.] McGill Univ, Dept Oncol, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
   [Mann, Koren K.] McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
C3 Boston University; Boston University; McGill University; McGill
   University; Lady Davis Institute
RP Schlezinger, JJ (通讯作者)，Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St,R 405, Boston, MA 02118 USA.
EM jschlezi@bu.edu
RI ; Baker, Andy/AAO 5250 2021
OI Schlezinger, Jennifer/0000 0001 6834 4369; 
FU Boston University School of Public Health; National Institutes of Health
   [P42 ES007381]
FX Boston University School of Public Health; the Superfund Research
   Program at the National Institutes of Health (P42 ES007381).
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Antizar Ladislao B, 2008, ENVIRON INT, V34, P292, DOI 10.1016/j.envint.2007.09.005
   Carfi M, 2008, TOXICOLOGY, V249, P11, DOI 10.1016/j.tox.2008.03.025
   Cha BS, 2001, DIABETOLOGIA, V44, P444, DOI 10.1007/s001250051642
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254
   Cornelissen G, 2008, MAR POLLUT BULL, V56, P565, DOI 10.1016/j.marpolbul.2007.12.009
   Cui H., 2010, BIOCHEM PHARMACOL, V81, P819
   Ducharme NA, 2008, ENDOCRINOLOGY, V149, P942, DOI 10.1210/en.2007 1713
   Feige JN, 2007, J BIOL CHEM, V282, P19152, DOI 10.1074/jbc.M702724200
   Fromme H, 2005, CHEMOSPHERE, V58, P1377, DOI 10.1016/j.chemosphere.2004.09.092
   Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097 2765(00)80448 7
   Gimble JM, 1996, MOL PHARMACOL, V50, P1087
   Grün F, 2006, MOL ENDOCRINOL, V20, P2141, DOI 10.1210/me.2005 0367
   Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754
   Hiromori Y, 2009, CHEM BIOL INTERACT, V180, P238, DOI 10.1016/j.cbi.2009.03.006
   Idres N, 2005, BIOCHEM PHARMACOL, V69, P1595, DOI 10.1016/j.bcp.2005.02.024
   Kaddatz K, 2010, J BIOL CHEM, V285, P29469, DOI 10.1074/jbc.M110.142018
   Kanayama T, 2005, MOL PHARMACOL, V67, P766, DOI 10.1124/mol.104.008409
   Kannan K, 2010, ARCH ENVIRON CON TOX, V58, P901, DOI 10.1007/s00244 010 9513 6
   Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333
   Kirchner S, 2010, MOL ENDOCRINOL, V24, P526, DOI 10.1210/me.2009 0261
   Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   le Maire A, 2009, EMBO REP, V10, P367, DOI 10.1038/embor.2009.8
   Lecka Czernik B, 2007, ENDOCRINOLOGY, V148, P903, DOI 10.1210/en.2006 1121
   Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lefebvre P, 2010, TRENDS ENDOCRIN MET, V21, P676, DOI 10.1016/j.tem.2010.06.009
   Lefterova MI, 2009, TRENDS ENDOCRIN MET, V20, P107, DOI 10.1016/j.tem.2008.11.005
   Loke YK, 2009, CAN MED ASSOC J, V180, P32, DOI 10.1503/cmaj.080486
   McDonough AK, 2008, NAT CLIN PRACT ENDOC, V4, P507, DOI 10.1038/ncpendmet0920
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Nakanishi T, 2005, MOL ENDOCRINOL, V19, P2502, DOI 10.1210/me.2004 0397
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   PIETRANGELI CE, 1988, EUR J IMMUNOL, V18, P863, DOI 10.1002/eji.1830180606
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Sato M, 2001, BIOCHEM BIOPH RES CO, V280, P646, DOI 10.1006/bbrc.2000.4172
   Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483
   Syversen U, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472 6823 9 10
   Szeles L, 2010, MOL ENDOCRINOL, V24, P2218, DOI 10.1210/me.2010 0215
   Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
   Xu M, 2004, TOXICOL APPL PHARM, V201, P295, DOI 10.1016/j.taap.2004.05.011
NR 49
TC 60
Z9 65
U1 2
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096 6080
J9 TOXICOL SCI
JI Toxicol. Sci.
PD AUG
PY 2011
VL 122
IS 2
BP 476
EP 488
DI 10.1093/toxsci/kfr140
PG 13
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA 807QJ
UT WOS:000293914500023
PM 21622945
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Wang, LS
   Qing, L
   Liu, H
   Liu, N
   Qiao, JT
   Cui, C
   He, TY
   Zhao, RX
   Liu, FQ
   Yan, F
   Wang, C
   Liang, K
   Guo, XH
   Shen, YH
   Hou, XG
   Chen, L
AF Wang, Lingshu
   Qing, Li
   Liu, He
   Liu, Na
   Qiao, Jingting
   Cui, Chen
   He, Tianyi
   Zhao, Ruxing
   Liu, Fuqiang
   Yan, Fei
   Wang, Chuan
   Liang, Kai
   Guo, Xinghong
   Shen, Ying H.
   Hou, Xinguo
   Chen, Li
TI Mesenchymal stromal cells ameliorate oxidative stress induced islet
   endothelium apoptosis and functional impairment via Wnt4 β catenin
   signaling
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Islet endothelium; Mesenchymal stromal cell; Wnt
ID STEM CELLS; BETA CELLS; HYPERGLYCEMIA; INFLAMMATION; DYSFUNCTION;
   PREVALENCE; EXPRESSION; MICE
AB Background: Islet dysfunction and destruction are the common cause for both type 1 and type 2 diabetes mellitus (T2DM). The islets of Langerhans are highly vascularized miniorgans, and preserving the structural integrity and full function of the microvascular endothelium is vital for protecting the islets from the infiltration of immune cells and secondary inflammatory attack. Mesenchymal stromal cell (MSC) based therapies have been proven to promote angiogenesis of the islets; however, the underlying mechanism for the protective role of MSCs in the islet endothelium is still vague.
   Methods: In this study, we used MS 1, a murine islet microvascular endothelium cell line, and an MSC MS1 transwell culturing system to investigate the protective mechanism of rat bone marrow derived MSCs under oxidative stress in vitro. Cell apoptosis was detected by TUNEL staining, annexin V/PI flow cytometry analysis, and cleaved caspase 3 western blotting analysis. Endothelial cell activation was determined by expression of intercellular cell adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), as well as eNOS phosphorylation/activation. The changes of VCAM 1, eNOS, and the beta catenin expression were also tested in the isolated islets of T2DM rats infused with MSCs.
   Results: We observed that treating MS 1 cells with H2O2 triggered significant apoptosis, induction of VCAM expression, and reduction of eNOS phosphorylation. Importantly, coculturing MS 1 cells with MSCs prevented oxidative stress induced apoptosis, eNOS inhibition, and VCAM elevation in MS 1 cells. Similar changes in VCAM 1 and eNOS phosphorylation could also be observed in the islets isolated from T2DM rats infused with MSCs. Moreover, MSCs cocultured with MS 1 in vitro or their administration in vivo could both result in an increase of beta catenin, which suggested activation of the beta catenin dependent Wnt signaling pathway. In MS 1 cells, activation of the beta catenin dependent Wnt signaling pathway partially mediated the protective effects of MSCs against H2O2 induced apoptosis and eNOS inhibition. Furthermore, MSCs produced a significant amount of Wnt4 and Wnt5a. Although both Wnt4 and Wnt5a participated in the interaction between MSCs and MS 1 cells, Wnt4 exhibited a protective role while Wnt5a seemed to show a destructive role in MS 1 cells.
   Conclusions: Our observations provide evidence that the orchestration of the MSC secreted Wnts could promote the survival and improve the endothelial function of the injured islet endothelium via activating the beta catenin dependent Wnt signaling in target endothelial cells. This finding might inspire further in vivo studies.
C1 [Wang, Lingshu; Qing, Li; Liu, He; Qiao, Jingting; Cui, Chen; He, Tianyi; Zhao, Ruxing; Liu, Fuqiang; Yan, Fei; Wang, Chuan; Liang, Kai; Guo, Xinghong; Hou, Xinguo; Chen, Li] Shandong Univ, Dept Endocrinol, Inst Endocrinol & Metab, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.
   [Liu, Na] Shandong Univ, Coll Publ Hlth, Jinan 250012, Shandong, Peoples R China.
   [Shen, Ying H.] Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Shen, Ying H.] Texas Heart Inst, Houston, TX 77025 USA.
C3 Shandong University; Shandong University; Baylor College of Medicine;
   Texas Heart Institute
RP Hou, XG; Chen, L (通讯作者)，Shandong Univ, Dept Endocrinol, Inst Endocrinol & Metab, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.
EM houxinguo@medmail.com.cn; chenli3@medmail.com.cn
RI guo, xinghong/HPF 1832 2023; He, TY/KIB 8606 2024; shen,
   ying/HHS 5635 2022; hou, xinguo/KHT 6105 2024
OI Guo, Xinghong/0000 0002 3843 9970; hou, xinguo/0000 0003 2045 1290
FU National Natural Science Foundation of China [81370943, 81670706,
   81400769, 81500591, 81500592]; Shandong Provincial Department of Science
   and Technology Innovation and Achievement Transformation Special Grant
   [2014ZZCX02201]; International Science and Technology Cooperation
   Project Of Shandong Province [2010GHZ20201]; Qilu Research Foundation
   [2015QLMS12]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81370943, No. 81670706, No. 81400769, No. 81500591, No.
   81500592), Shandong Provincial Department of Science and
   Technology Innovation and Achievement Transformation Special Grant (No.
   2014ZZCX02201), the International Science and Technology Cooperation
   Project Of Shandong Province (No. 2010GHZ20201), and Qilu Research
   Foundation (No. 2015QLMS12).
CR Aly H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066131
   Bell GI, 2012, STEM CELLS DEV, V21, P97, DOI 10.1089/scd.2010.0583
   Borg DJ, 2014, DIABETOLOGIA, V57
   Bretón Romero R, 2016, ARTERIOSCL THROM VAS, V36, P561, DOI 10.1161/ATVBAHA.115.306578
   Bronckaers A, 2014, PHARMACOL THERAPEUT, V143, P181, DOI 10.1016/j.pharmthera.2014.02.013
   Cai JQ, 2016, DIABETES CARE, V39, P149, DOI 10.2337/dc15 0171
   Cao XK, 2016, BIOMED PHARMACOTHER, V78, P156, DOI 10.1016/j.biopha.2016.01.007
   Chakrabarti D, 1996, DIABETES, V45, P1336, DOI 10.2337/diabetes.45.10.1336
   Dabernat S, 2009, DIABETOLOGIA, V52, P1608, DOI 10.1007/s00125 009 1411 y
   Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750
   Fuster JJ, 2015, DIABETES, V64, P1235, DOI 10.2337/db14 1164
   Heller C, 2011, AM J PHYSIOL ENDOC M, V301, pE864, DOI 10.1152/ajpendo.00144.2011
   Jansson L, 2016, UPSALA J MED SCI, V121, P81, DOI 10.3109/03009734.2016.1164769
   Ji ATQ, 2015, DIABETES, V64, P926, DOI 10.2337/db14 1042
   Johansson U, 2008, DIABETES, V57, P2393, DOI 10.2337/db07 0981
   Jurewicz M, 2010, DIABETES, V59, P3139, DOI 10.2337/db10 0542
   Kim J, 2010, J IMMUNOL, V185, P1274, DOI 10.4049/jimmunol.1000181
   Kozinski K, 2016, SCI REP UK, V6, DOI 10.1038/srep31553
   Krützfeldt J, 2010, DIABETOLOGIA, V53, P123, DOI 10.1007/s00125 009 1578 2
   Leroux L, 2010, MOL THER, V18, P1545, DOI 10.1038/mt.2010.108
   Liu XB, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt446
   Madec AM, 2009, DIABETOLOGIA, V52, P1391, DOI 10.1007/s00125 009 1374 z
   Medarova Z, 2007, DIABETES, V56, P2677, DOI 10.2337/db07 0822
   Menke A, 2015, JAMA J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029
   Mounayar M, 2015, STEM CELLS, V33, P1892, DOI 10.1002/stem.1986
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Olsson R, 2006, INT J BIOCHEM CELL B, V38, P710, DOI 10.1016/j.biocel.2006.02.004
   Rackham CL, 2011, DIABETOLOGIA, V54, P1127, DOI 10.1007/s00125 011 2053 4
   Rackham CL, 2016, DIABETES, V65, P129, DOI 10.2337/db15 0990
   Ring A, 2014, STEM CELL REV REP, V10, P512, DOI 10.1007/s12015 014 9515 2
   Ring L, 2014, CELL SIGNAL, V26, P260, DOI 10.1016/j.cellsig.2013.11.021
   Si YL, 2012, DIABETES, V61, P1616, DOI 10.2337/db11 1141
   Song M, 2015, STEM CELLS DEV, V24, P1648, DOI 10.1089/scd.2014.0459
   Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241
   Takamoto I, 2014, DIABETOLOGIA, V57, P542, DOI 10.1007/s00125 013 3131 6
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Xie ZY, 2016, STEM CELLS, V34, P627, DOI 10.1002/stem.2238
   Xu Y, 2013, JAMA J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118
   Yao DD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.107
   Zhang B, 2015, STEM CELLS, V33, P2158, DOI 10.1002/stem.1771
NR 40
TC 50
Z9 55
U1 2
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD AUG 14
PY 2017
VL 8
AR 188
DI 10.1186/s13287 017 0640 0
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FD7QN
UT WOS:000407720700006
PM 28807051
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hirakawa, H
   Gatanaga, H
   Ochi, H
   Fukuda, T
   Sunamura, S
   Oka, S
   Takeda, S
   Sato, S
AF Hirakawa, Hiroyuki
   Gatanaga, Hiroyuki
   Ochi, Hiroki
   Fukuda, Toru
   Sunamura, Satoko
   Oka, Shinichi
   Takeda, Shu
   Sato, Shingo
TI Antiretroviral Therapy Containing HIV Protease Inhibitors Enhances
   Fracture Risk by Impairing Osteoblast Differentiation and Bone Quality
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; protease inhibitor (PI); integrase strand transfer inhibitor
   (INSTI); bone quality; osteoblast differentiation
ID MINERAL DENSITY
AB Long term antiretroviral therapy is associated with increased fracture risk, but the mechanism remains elusive. We measured serum undercarboxylated osteocalcin and pentosidine (markers of poor bone quality) in human immunodeficiency virus infected patients treated with protease inhibitors (PIs) or an integrase strand transfer inhibitor containing regimen. The results demonstrated significantly higher undercarboxylated osteocalcin and pentosidine in PI treated patients. Switching to integrase strand transfer inhibitor significant decreased these markers. We also showed impaired bone mechanical properties with higher undercarboxylated osteocalcin level in PI treated mice and inhibited osteoblast differentiation in PI treated osteogenic cells. The results confirmed the adverse effects of PIs on bone quality and osteoblast differentiation.
C1 [Hirakawa, Hiroyuki; Ochi, Hiroki; Fukuda, Toru; Sunamura, Satoko; Takeda, Shu; Sato, Shingo] Tokyo Med & Dent Univ, Grad Sch, Dept Physiol & Cell Biol, Tokyo, Japan.
   [Sato, Shingo] Tokyo Med & Dent Univ, Grad Sch, Dept Orthopaed Surg, Tokyo, Japan.
   Fac Med, Tokyo, Japan.
   [Gatanaga, Hiroyuki; Oka, Shinichi] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Japan Institute for Health Security (JIHS); National Center for Global
   Health & Medicine   Japan
RP Sato, S (通讯作者)，1 5 45 Yushima,Bunkyo Ku, Tokyo 1138510, Japan.
EM satoshin.phy2@tmd.ac.jp
RI ; Fukuda, Toru/JZE 9097 2024
OI Sato, Shingo/0000 0002 6227 5910; 
FU National Center for Global Health and Medicine [28 SI 1102]; Japan
   Agency for Medical Research and Development [AIDS H26, AIDS H28];
   Grants in Aid for Scientific Research [17J07892, 16H01633] Funding
   Source: KAKEN
FX This work was supported by the National Center for Global Health and
   Medicine (grant 28 SI 1102) and the Japan Agency for Medical Research
   and Development (grants AIDS H26 and AIDS H28).
CR Bolland MJ, 2011, J CLIN ENDOCR METAB, V96, P2721, DOI 10.1210/jc.2011 0591
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Duvivier C, 2009, AIDS, V23, P817, DOI 10.1097/QAD.0b013e328328f789
   Hansen AB, 2011, HIV MED, V12, P157, DOI 10.1111/j.1468 1293.2010.00864.x
   Hansen ABE, 2012, AIDS, V26, P285, DOI 10.1097/QAD.0b013e32834ed8a7
   Liu G, 1998, CALCIFIED TISSUE INT, V62, P286, DOI 10.1007/s002239900432
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Modarresi R, 2009, AM J PATHOL, V174, P123, DOI 10.2353/ajpath.2009.080484
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Shiraki M, 2008, J BONE MINER METAB, V26, P93, DOI 10.1007/s00774 007 0784 6
   Shiraki M, 2010, J BONE MINER METAB, V28, P578, DOI 10.1007/s00774 010 0167 2
   Tominaga H, 2008, MOL BIOL CELL, V19, P5373, DOI 10.1091/mbc.E08 03 0329
   Yin MT, 2012, AIDS, V26, P2175, DOI 10.1097/QAD.0b013e328359a8ca
   Young B, 2011, CLIN INFECT DIS, V52, P1061, DOI 10.1093/cid/ciq242
NR 15
TC 16
Z9 18
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022 1899
EI 1537 6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 15
PY 2017
VL 215
IS 12
BP 1893
EP 1897
DI 10.1093/infdis/jix246
PG 5
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA EZ0GV
UT WOS:000404380700018
PM 28525596
OA Bronze
DA 2025 08 17
ER

PT J
AU Yamamoto, S
   Jorgensen, HS
   Zhao, JH
   Karaboyas, A
   Komaba, H
   Vervloet, M
   Mazzaferro, S
   Cavalier, E
   Bieber, B
   Robinson, B
   Evenepoel, P
   Fukagawa, M
AF Yamamoto, Suguru
   Jorgensen, Hanne Skou
   Zhao, Junhui
   Karaboyas, Angelo
   Komaba, Hirotaka
   Vervloet, Marc
   Mazzaferro, Sandro
   Cavalier, Etienne
   Bieber, Brian
   Robinson, Bruce
   Evenepoel, Pieter
   Fukagawa, Masafumi
TI Alkaline Phosphatase and Parathyroid Hormone Levels: International
   Variation and Associations With Clinical Outcomes in the DOPPS
SO KIDNEY INTERNATIONAL REPORTS
LA English
DT Article
DE alkaline phosphatase; fractures; hemodialysis; mortality; parathyroid
   hormone
ID CORONARY ARTERY CALCIFICATION; DIALYSIS OUTCOMES; HEMODIALYSIS PATIENTS;
   PRACTICE PATTERNS; KIDNEY DISEASE; BONE TURNOVER; RENAL OSTEODYSTROPHY;
   SKELETAL RESISTANCE; MORTALITY; RISK
AB Introduction: Secondary hyperparathyroidism (SHPT) increases the risk of fractures and cardiovascular (CV) disease in patients on hemodialysis (HD). The relationship between parathyroid hormone (PTH) and outcomes has been inconsistent, possibly due to variable bone responsiveness to PTH. The KDIGO guideline suggests monitoring total alkaline phosphatase (ALP), but the role of ALP versus PTH in the management of mineral and bone disorder (MBD) is not clear. Methods: The analysis included 28,888 patients on HD in 9 countries in Dialysis Outcomes and Practice Patterns Study (DOPPS) phase 3 to 7 (2005   2021). The primary exposures of interest were normalized ALP and PTH, which are raw values divided by facility upper normal limit, measured at study enrollment. Cox models were used to estimate hazard ratios of all  cause or CV mortality and any or hip fracture adjusted for potential confounders. Linear mixed models, adjusted for potential confounders, were employed to investigate the relationship between normalized ALP levels and patient characteristics. Results: Normalized PTH showed a J shaped association with all  cause or CV mortality, and a weak linear association with fracture. In contrast, normalized ALP showed a strong association with all outcomes. Factors associated with higher ALP levels after controlling for PTH included Black race, longer dialysis vintage, diabetes mellitus, hypocalcemia, hypophosphatemia, elevated C  reactive protein (CRP), and the use of cinacalcet. Conclusion: Total ALP is a more robust exposure of adverse outcomes than PTH in patients on HD. PTH responsiveness is affected by race, primary renal disease, comorbidities, and mineral metabolism and therapy. Our results indicate that it may be useful to evaluate target organ response, rather than PTH alone when considering the consequences of (SHPT).
C1 [Yamamoto, Suguru] Niigata Univ, Grad Sch Med & Dent Sci, Div Clin Nephrol & Rheumatol, 1 757 Asahimachi Dori, Niigata 9518510, Japan.
   [Jorgensen, Hanne Skou; Evenepoel, Pieter] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Nephrol & Renal Transplantat Res Grp, Leuven, Belgium.
   [Jorgensen, Hanne Skou] Aarhus Univ, Inst Clin Med, Aarhus, Denmark.
   [Zhao, Junhui; Karaboyas, Angelo; Bieber, Brian] Aalborg Univ Hosp, Dept Nephrol, Aalborg, Denmark.
   [Zhao, Junhui; Karaboyas, Angelo; Bieber, Brian] Arbor Res Collaborat Hlth, Ann Arbor, MI USA.
   [Komaba, Hirotaka; Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Isehara, Japan.
   [Vervloet, Marc] Amsterdam Univ Med Ctr, Dept Nephrol, Amsterdam, Netherlands.
   [Mazzaferro, Sandro] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy.
   [Cavalier, Etienne] Univ Liege, CHU Liege, Dept Clin Chem, Sart Tilman, Liege, Belgium.
   [Robinson, Bruce] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI USA.
   [Evenepoel, Pieter] Univ Hosp Leuven, Dept Nephrol & Renal Transplantat, Louvain, Belgium.
C3 Niigata University; KU Leuven; Aarhus University; Aalborg University;
   Aalborg University Hospital; Arbor Research Collaborative for Health;
   Tokai University; Sapienza University Rome; University of Liege;
   University of Michigan System; University of Michigan; KU Leuven;
   University Hospital Leuven
RP Yamamoto, S (通讯作者)，Niigata Univ, Grad Sch Med & Dent Sci, Div Clin Nephrol & Rheumatol, 1 757 Asahimachi Dori, Niigata 9518510, Japan.
EM yamamots@med.niigata u.ac.jp
RI Cavalier, Etienne/E 8661 2011; P, Evenepoel/D 9597 2018; Vervoort,
   G.M.M./L 4718 2015; Komaba, Hirotaka/C 9199 2011; Yamamoto,
   Suguru/F 8066 2014; Mazzaferro, Sandro/E 9321 2012; Jørgensen,
   Hanne/AAO 4285 2021
OI Jorgensen, Hanne Mari Skou/0000 0002 0881 2615; Yamamoto,
   Suguru/0000 0002 8279 2966
FU Kyowa Kirin; Kyowa Kirin Co. Global; Grants in Aid for Scientific
   Research [20K08628] Funding Source: KAKEN
FX This manuscript was directly supported by Kyowa Kirin. Global support
   for ongoing DOPPS Programs is provided without restriction on
   publications by a variety of funders (details in https://
   www.dopps.org/AboutUs/Support.aspx) . This manuscript was directly
   supported by Kyowa Kirin Co. Global support for the ongoing DOPPS
   Programs is provided without restriction on publications by a variety of
   funders. For details see https:// www.dopps.org/AboutUs/Support.aspx.
   All grants were made to Arbor Research Collaborative for Health and not
   to co authors directly. None of the funders had any role in study
   design; collec tion, analysis, and interpretation of data; writing the
   report; or the decision to submit this report for publication.
CR Abramowitz M, 2010, CLIN J AM SOC NEPHRO, V5, P1064, DOI 10.2215/CJN.08621209
   Beddhu S, 2010, CLIN NEPHROL, V74, P91
   Blayney MJ, 2008, KIDNEY INT, V74, P655, DOI 10.1038/ki.2008.248
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Chen ZM, 2021, PERITON DIALYSIS INT, V41, P236, DOI 10.1177/0896860820918131
   Coen G, 2009, AM J NEPHROL, V29, P145, DOI 10.1159/000151769
   Díaz Tocados JM, 2019, KIDNEY INT, V95, P1064, DOI 10.1016/j.kint.2018.12.015
   Evenepoel P, 2022, J CLIN ENDOCR METAB, V107, pE4350, DOI 10.1210/clinem/dgac522
   Evenepoel P, 2019, ADV CHRONIC KIDNEY D, V26, P472, DOI 10.1053/j.ackd.2019.09.006
   Evenepoel P, 2019, KIDNEY INT, V95, P412, DOI 10.1016/j.kint.2018.09.018
   Evenepoel P, 2016, KIDNEY INT, V90, P1184, DOI 10.1016/j.kint.2016.06.041
   Fan Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13387 z
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   Haarhaus M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14102124
   Ishirnura E, 2014, KIDNEY BLOOD PRESS R, V39, P299, DOI 10.1159/000355807
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Jansz TT, 2020, OSTEOPOROSIS INT, V31, P515, DOI 10.1007/s00198 019 05187 0
   Jorgensen HS, 2022, AM J KIDNEY DIS, V79, P667, DOI 10.1053/j.ajkd.2021.07.027
   Jorgensen HS, 2020, KIDNEY INT, V98, P514, DOI 10.1016/j.kint.2020.04.013
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Lamina C, 2020, NEPHROL DIAL TRANSPL, V35, P478, DOI 10.1093/ndt/gfz060
   Lee DK, 2020, KOREAN J ANESTHESIOL, V73, P503, DOI 10.4097/kja.20137
   Li C, 2019, KIDNEY DIS BASEL, V5, P118, DOI 10.1159/000494924
   Little RJA., 1987, Statistical Analysis with Missing Data
   LLACH F, 1975, J CLIN ENDOCR METAB, V41, P339, DOI 10.1210/jcem 41 2 339
   Fernandez Martín JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099
   MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187
   Malluche HH, 2015, J AM SOC NEPHROL, V26, P2534, DOI 10.1681/ASN.2014070686
   Maruyama Y, 2014, NEPHROL DIAL TRANSPL, V29, P1532, DOI 10.1093/ndt/gfu055
   MASSRY SG, 1973, ANN INTERN MED, V78, P357, DOI 10.7326/0003 4819 78 3 357
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Pisoni RL, 2004, AM J KIDNEY DIS, V44, pS7, DOI 10.1053/j.ajkd.2004.08.005
   Regidor DL, 2008, J AM SOC NEPHROL, V19, P2193, DOI 10.1681/ASN.2008010014
   Salam S, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115699
   Sanchez Navarro M R, 2002, An Med Interna, V19, P449
   Shantouf R, 2009, CLIN J AM SOC NEPHRO, V4, P1106, DOI 10.2215/CJN.06091108
   Sprague SM, 2016, AM J KIDNEY DIS, V67, P559, DOI 10.1053/j.ajkd.2015.06.023
   Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744 9987.12030
   Taylor JMG, 2002, AM J EPIDEMIOL, V156, P774, DOI 10.1093/aje/kwf110
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213
   Wesseling Perry K, 2010, J CLIN ENDOCR METAB, V95, P2772, DOI 10.1210/jc.2009 1909
   Yamamoto S, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882 018 1056 5
   Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523 1755.2000.07413.x
NR 46
TC 13
Z9 13
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2468 0249
J9 KIDNEY INT REP
JI Kidney Int. Rep.
PD APR
PY 2024
VL 9
IS 4
BP 863
EP 876
DI 10.1016/j.ekir.2024.01.002
EA APR 2024
PG 14
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA RA8E9
UT WOS:001225035700001
PM 38765600
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Peng, QW
   Wang, J
   Han, M
   Zhao, MH
   Li, KS
   Lu, TM
   Guo, QY
   Jiang, Q
AF Peng, Qiuwei
   Wang, Jian
   Han, Man
   Zhao, Minghong
   Li, Kesong
   Lu, Tianming
   Guo, Qiuyan
   Jiang, Quan
TI Tanshinone IIA inhibits osteoclastogenesis in rheumatoid arthritis via
   LDHC regulated ROS generation
SO CHINESE MEDICINE
LA English
DT Article
DE Tanshinone IIA; Rheumatoid arthritis; Osteoclast; Lactate dehydrogenase;
   Reactive oxygen species
ID SYNOVIAL FIBROBLASTS; BONE EROSION; DIAGNOSIS; MICE
AB Rheumatoid arthritis (RA) is characterized by bone destruction in the afflicted joints, and during the process of bone destruction, osteoclasts play a crucial role. Tanshinone IIA (Tan IIA) has shown anti inflammatory effects in RA. However, the exact molecular mechanisms by which it delays bone destruction remain largely unexplained. Here, we found that Tan IIA decreased the severity of and ameliorated bone loss in an AIA rat model. In vitro, Tan IIA inhibited RANKL induced osteoclast differentiation. By activity based protein analysis (ABPP) combined with LC MS/MS, we discovered that Tan IIA covalently binds to the lactate dehydrogenase subunit LDHC and inhibits its enzymatic activity. Moreover, we found that Tan IIA inhibits the generation of osteoclast specific markers by reducing the accumulation of reactive oxygen species (ROS), thus reducing osteoclast differentiation. Finally, our results reveal that Tan IIA suppresses osteoclast differentiation via LDHC mediated ROS generation in osteoclasts. Tan IIA can thus be regarded as an effective drug for the treatment of bone damage in RA.
C1 [Peng, Qiuwei; Wang, Jian; Han, Man; Li, Kesong; Jiang, Quan] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Rheumatol, Beijing 100053, Peoples R China.
   [Zhao, Minghong] Gannan Med Univ, Sch Clin Med 1, Ganzhou 341000, Peoples R China.
   [Lu, Tianming] Guangxi Med Univ, Sch Publ Hlth, Nanning 530021, Guangxi, Peoples R China.
   [Guo, Qiuyan] China Acad Chinese Med Sci, Artemisnin Res Ctr, Beijing 100700, Peoples R China.
   [Guo, Qiuyan] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS;
   Gannan Medical University; Guangxi Medical University; China Academy of
   Chinese Medical Sciences; China Academy of Chinese Medical Sciences;
   Institute of Chinese Materia Medica, CACMS
RP Jiang, Q (通讯作者)，China Acad Chinese Med Sci, Guanganmen Hosp, Dept Rheumatol, Beijing 100053, Peoples R China.; Guo, QY (通讯作者)，China Acad Chinese Med Sci, Artemisnin Res Ctr, Beijing 100700, Peoples R China.; Guo, QY (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
EM qyguo@icmm.ac.cn; jiang.quan@hotmai.com
RI ; Wang, Jian/AAE 4412 2020; Guo, Qiuyan/JBS 3104 2023
OI Guo, qiuyan/0009 0007 8005 3995; Lu, Tianming/0000 0003 3103 6973
FU National Natural Science Foundation of China [82230121, ZZ13 YQ 033 C1];
   Scientific and Technological Innovation Project of Chinese Academy of
   Traditional Chinese Medicine [82104480]; CACMS Innovation Fund
   [CI2021A01511]; Fundamental Research Funds for the Central public
   welfare research institutes [CI2021A01503]; Young Elite Scientists
   Sponsorship Program by CACM [2021QNRC2B29]; Fundamental Research Funds
   for the Central public welfare research institutes [ZZ14 YQ 060,
   ZZ16 ND 10 9]
FX This research received financial support from the National Natural
   Science Foundation of China (82230121), Scientific and Technological
   Innovation Project of Chinese Academy of Traditional Chinese Medicine
   (CI2021A01511), CACMS Innovation Fund (CI2021A01503), the Fundamental
   Research Funds for the Central public welfare research institutes
   (ZZ13 YQ 033 C1) the National Natural Science Foundation of China
   (82104480), the Young Elite Scientists Sponsorship Program by CACM
   (2021QNRC2B29), the Fundamental Research Funds for the Central public
   welfare research institutes (ZZ14 YQ 060), the Fundamental Research
   Funds for the Central public welfare research institutes (ZZ16 ND 10 9)
CR Ahn H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153886
   Arra M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17242 0
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507
   Cardoso RS, 2020, BENEF MICROBES, V11, P33, DOI 10.3920/BM2019.0038
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   EVERSE J, 1973, ADV ENZYMOL RAMB, V37, P61
   Feldmann M, 2001, TRANSPLANT P, V33, P2085, DOI 10.1016/S0041 1345(01)01958 3
   Feng YB, 2018, CANCER MED US, V7, P6124, DOI 10.1002/cam4.1820
   Gamal RM, 2018, CLIN RHEUMATOL, V37, P3239, DOI 10.1007/s10067 018 4318 5
   Goldberg E, 2010, J ANDROL, V31, P86, DOI 10.2164/jandrol.109.008367
   Guo QQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00230
   Han YM, 2005, BIOL PHARM BULL, V28, P1795, DOI 10.1248/bpb.28.1795
   Hanlon MM, 2023, RHEUMATOLOGY, V62, P2611, DOI 10.1093/rheumatology/keac640
   Hazra B, 2004, J CHROMATOGR B, V812, P259, DOI 10.1016/j.jchromb.2004.08.007
   Jie LG, 2014, BIOL PHARM BULL, V37, P1366, DOI 10.1248/bpb.b14 00301
   Kwak HB, 2006, EXP MOL MED, V38, P256, DOI 10.1038/emm.2006.31
   Kwak HB, 2008, EUR J PHARMACOL, V601, P30, DOI 10.1016/j.ejphar.2008.10.034
   Li BE, 2020, FASEB J, V34, P11058, DOI 10.1096/fj.202000771R
   Li GQ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180626
   Li WJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.912933
   Li YQ, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114602
   Lin YJ, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.1038421
   Majithia V, 2007, AM J MED, V120, P936, DOI 10.1016/j.amjmed.2007.04.005
   McGarry T, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1237
   Petrasca A, 2020, RHEUMATOLOGY, V59, P2816, DOI 10.1093/rheumatology/kez682
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Rucci N, 2016, MATRIX BIOL, V52 54, P176, DOI 10.1016/j.matbio.2016.02.009
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Seeuws S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3119
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Takahashi K, 2002, BIOCHEM PHARMACOL, V64, P745, DOI 10.1016/S0006 2952(02)01250 9
   Tanaka Yoshiya, 2018, Clin Calcium, V28, P630, DOI CliCa1805630636
   Tang J, 2019, EXP THER MED, V17, P3299, DOI 10.3892/etm.2019.7371
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wu H, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00595 3
   Zhang S, 2017, CLIN EXP IMMUNOL, V190, P29, DOI 10.1111/cei.12993
   Zhou Yanmeng, 2010, Zhongguo Zhong Yao Za Zhi, V35, P2923
   Zhou YS, 2018, INT J RHEUM DIS, V21, P1709, DOI 10.1111/1756 185X.13345
NR 41
TC 12
Z9 13
U1 3
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD MAY 15
PY 2023
VL 18
IS 1
AR 54
DI 10.1186/s13020 023 00765 1
PG 14
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA G4ON2
UT WOS:000988968400001
PM 37189204
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Park, S
   Kim, JH
   Son, Y
   Goh, SH
   Oh, S
AF Park, Seoyoung
   Kim, Joo Hyun
   Son, Younglim
   Goh, Sung Ho
   Oh, Sangtaek
TI Longan (Dimocarpus longan Lour.) Fruit Extract Stimulates
   Osteoblast Differentiation via Erk1/2 Dependent RUNX2 Activation
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Longan fruit extract; osteoblast differentiation; Erk1/2 pathway; herbal
   medicine
AB Longan (Dimocarpus longan Lour.) has been used as a traditional oriental medicine and possesses a number of physiological activities. In this study, we used cell based herbal extract screening to identify longan fruit extract (LFE) as an activator of osteoblast differentiation. LFE up regulated alkaline phosphatase (ALP) activity, induced mineralization, and activated Runx2 gene expression in MC3T3 E1 cells. Furthermore, treatment of MC3T3 E1 cells with LFE promoted the phosphorylation of extracellular signal regulated kinase1/2 (Erk1/2); however, abrogation of Erk1/2 activation with PD98059 resulted in down regulation of the phospho SMAD1/5/8 and Runx2 levels, which in turn reduced the ALP activity. Our findings suggest that LFE exerts its osteogenic activity through activation of the ERK signaling pathway and may have potential as an herbal therapeutic or a preventive agent for the treatment of osteoporosis.
C1 [Park, Seoyoung; Kim, Joo Hyun; Son, Younglim; Oh, Sangtaek] Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 02707, South Korea.
   [Goh, Sung Ho] Natl Canc Ctr, Canc Genom Branch, Goyang 10408, South Korea.
C3 Kookmin University; National Cancer Center   Korea (NCC)
RP Oh, S (通讯作者)，Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 02707, South Korea.
EM ohsa@kookmin.ac.kr
OI Goh, Sung Ho/0000 0001 8617 7680
FU High Value added Food Technology Development Program   Ministry of
   Agriculture, Food and Rural Affairs [114030 3]
FX This work was supported by the High Value added Food Technology
   Development Program (114030 3) funded by the Ministry of Agriculture,
   Food and Rural Affairs
CR Apriyanto DR, 2015, JPN J INFECT DIS
   Bokui N, 2008, FEBS LETT, V582, P365, DOI 10.1016/j.febslet.2007.12.006
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Fitzpatrick LA, 2002, MAYO CLIN PROC, V77, P453, DOI 10.4065/77.5.453
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Lin Chih Cheng, 2012, World J Exp Med, V2, P78, DOI 10.5493/wjem.v2.i4.78
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729
   Rangkadilok N, 2012, FITOTERAPIA, V83, P545, DOI 10.1016/j.fitote.2011.12.023
   Redi IR, 2002, EXPERT OPIN DRUG SAF, V1, P93
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tseng HC, 2014, INT J FOOD SCI NUTR, V65, P589, DOI 10.3109/09637486.2014.886181
   Yang CX, 2008, SEP PURIF TECHNOL, V63, P226, DOI 10.1016/j.seppur.2008.05.004
   Zhang W, 2014, J BONE MINER RES, V29, P1232, DOI 10.1002/jbmr.2116
   ZHOU H, 1994, J BONE MINER RES, V9, P1489
NR 17
TC 14
Z9 16
U1 2
U2 24
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635 4 YEOGSAM DONG, KANGNAM GU, SEOUL
   135 703, SOUTH KOREA
SN 1017 7825
EI 1738 8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD JUN
PY 2016
VL 26
IS 6
BP 1063
EP 1066
DI 10.4014/jmb.1601.01092
PG 4
WC Biotechnology & Applied Microbiology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Microbiology
GA DP8RS
UT WOS:000378766000009
PM 26975768
DA 2025 08 17
ER

PT J
AU Pountos, I
   Panteli, M
   Walters, G
   Giannoudis, PV
AF Pountos, Ippokratis
   Panteli, Michalis
   Walters, Gavin
   Giannoudis, Peter V.
TI NSAIDs inhibit bone healing through the downregulation of TGF β3
   expression during endochondral ossification
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Mesenchymal stem cells; Bone healing; NSAIDs; Chondrocytes; Endochondral
   ossification
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE COX 2 INHIBITION;
   IN VITRO; TNF ALPHA; CHONDROCYTES; CARTILAGE; PROLIFERATION;
   CHONDROGENESIS; PROSTAGLANDINS; OSTEOGENESIS
AB Introduction & aims: Non Steroidal Anti Inflammatory drugs (NSAIDs) are potent inhibitors of posttraumatic pain. Several studies have highlighted that NSAIDs could exert a negative effect on bone healing process possibly by down regulating chondrogenesis and endochondral ossification. The aim of the study is to explore the potential mechanism though which NSAIDs can affect chondrogenesis.
   M&M: Trabecular bone from the fracture site was isolated from 10 patients suffering from long bone fractures. Mesenchymal Stem Cells (MSCs) were isolated following collagenase digestion and functional assays to assess the effect of diclofenac sodium on chondrogenesis were performed. Gene expression analysis of 84 key molecules was performed.
   Results: Diclofenac sodium inhibits chondrogenic differentiation and induces a strong inhibition of prostaglandin E 2 (PGE 2) production during chondrogenic differentiation. Replenishment of PGE 2 did not reverse this negative effect. Chondrogenic inhibition is similar in cells treated only for the first week of chondrogenic differentiation or continuously for 3 weeks. Gene analysis shows a strong downregulation of TGF beta 3 and FGF 1 while TNF was upregulated.
   Conclusion: NSAIDs seem to affect the transition phase of mesenchymal stem cells towards functional chondrocytes. This effect is unrelated to the endogenous production of PGE 2. The downregulation of the expression of key molecules like TGF beta 3 seem to be the underlying mechanism. (C) 2021 Elsevier Ltd. All rights reserved.
C1 [Pountos, Ippokratis; Panteli, Michalis; Walters, Gavin; Giannoudis, Peter V.] Univ Leeds, Sch Med, Acad Dept Trauma & Orthopaed, Leeds, W Yorkshire, England.
C3 University of Leeds
RP Pountos, I (通讯作者)，Univ Leeds, Sch Med, Acad Dept Trauma & Orthopaed, Leeds, W Yorkshire, England.
EM pountos@doctors.org.uk
RI Pountos, Ippokratis/AAB 5697 2019; Giannoudis, Peter/AAA 3617 2020
OI Panteli, Michalis/0000 0002 0905 1432
CR ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131 199505000 00006
   Attur M, 2008, J IMMUNOL, V181, P5082, DOI 10.4049/jimmunol.181.7.5082
   Barlic A, 2015, BIOLOGICALS, V43, P171, DOI 10.1016/j.biologicals.2015.03.001
   Bassleer C, 1997, PHARMACOLOGY, V54, P49, DOI 10.1159/000139469
   CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Chijimatsu R, 2019, J TISSUE ENG REGEN M, V13, P446, DOI 10.1002/term.2795
   Crisostomo PR, 2006, SHOCK, V26, P575, DOI 10.1097/01.shk.0000235087.45798.93
   Davies M E, 1992, Mediators Inflamm, V1, P71, DOI 10.1155/S0962935192000140
   Dolkart O, 2014, AM J SPORT MED, V42, P2869, DOI 10.1177/0363546514545856
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Frost A, 1997, ACTA ORTHOP SCAND, V68, P91, DOI 10.3109/17453679709003987
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Huang XB, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27602 y
   HUO MH, 1991, J ORTHOPAED RES, V9, P383, DOI 10.1002/jor.1100090310
   Jakob M, 2004, RHEUMATOLOGY, V43, P852, DOI 10.1093/rheumatology/keh197
   Juurikka K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184506
   Kim TH, 2018, TISSUE ENG REGEN MED, V15, P263, DOI 10.1007/s13770 018 0119 9
   Kurmis AP, 2012, J BONE JOINT SURG AM, V94A, P815, DOI 10.2106/JBJS.J.01743
   Langhans SA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00006
   Leblanc KT, 2015, J CELL PHYSIOL, V230, P440, DOI 10.1002/jcp.24727
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Mastbergen SC, 2005, OSTEOARTHR CARTILAGE, V13, P519, DOI 10.1016/j.joca.2005.02.004
   Mastbergen SC, 2002, RHEUMATOLOGY, V41, P801, DOI 10.1093/rheumatology/41.7.801
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Pountos I, 2005, INJURY, V36, P8, DOI 10.1016/j.injury.2005.07.028
   Pountos I, 2006, J BONE JOINT SURG BR, V88B, P421, DOI 10.1302/0301 620x.88B4.17060
   Pountos I., 2011, INT J INTERF, V3, P19, DOI DOI 10.2147/IJICMR.S10200
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Pountos I, 2011, EXPERT OPIN DRUG SAF, V10, P935, DOI 10.1517/14740338.2011.589833
   Pountos I, 2011, J CELL MOL MED, V15, P525, DOI 10.1111/j.1582 4934.2010.01006.x
   Sefat F, 2016, CYTOKINE, V83, P118, DOI 10.1016/j.cyto.2016.04.008
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Szentléleky E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010168
   YAMAGUCHI DT, 1989, AM J PHYSIOL, V257, pF755, DOI 10.1152/ajprenal.1989.257.5.F755
   Zigon Branc S, 2018, BIOTECHNOL PROGR, V34, P1045, DOI 10.1002/btpr.2629
NR 38
TC 7
Z9 7
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD JUN
PY 2021
VL 52
IS 6
BP 1294
EP 1299
DI 10.1016/j.injury.2021.01.007
EA MAY 2021
PG 6
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA SJ0XL
UT WOS:000655253400009
PM 33472741
DA 2025 08 17
ER

PT J
AU Deng, ZD
   Sun, SL
   Zhou, N
   Peng, YM
   Cheng, L
   Yu, XC
   Yuan, YX
   Guo, MJ
   Xu, M
   Cheng, YX
   Zhou, F
   Li, NG
   Yang, Y
   Gu, CY
AF Deng, Zhendong
   Sun, Shanliang
   Zhou, Nian
   Peng, Yumeng
   Cheng, Long
   Yu, Xichao
   Yuan, Yuxia
   Guo, Mengjie
   Xu, Min
   Cheng, Yuexin
   Zhou, Fan
   Li, Nianguang
   Yang, Ye
   Gu, Chunyan
TI PNPO Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and
   Osteoclastogenesis by Activating the Wnt/β Catenin Pathway
SO ADVANCED SCIENCE
LA English
DT Article
DE dishevelled 3; eltrombopag; multiple myeloma; pyridoxine 5 ' phosphate
   oxidase; wnt/beta catenin pathway
ID PYRIDOXINE 5' PHOSPHATE OXIDASE; SIGNALING PATHWAY; MOLECULAR
   CLASSIFICATION; CELASTROL; CELLS; EXPRESSION; BINDING; MICROENVIRONMENT;
   INHIBITORS; GAPDH
AB Multiple myeloma (MM) is a cancer of plasma cells caused by abnormal gene expression and interactions within the bone marrow (BM) niche. The BM environment significantly influences the progression of MM. Celastrol, a natural compound derived from traditional Chinese medicine, exhibits significant anticancer effects. This study aimed to identify specific targets of celastrol and develop more effective and less toxic treatment options for MM. Celastrol is used as a probe to determine its specific target, pyridoxine 5 ' phosphate oxidase (PNPO). Increased levels of PNPO are associated with poor outcomes in MM patients, and PNPO promotes MM cell proliferation and induces osteoclast differentiation through exosomes. Mechanistically, PNPO oxidizes disheveled 3M282 (DVL3), leading to abnormal activation of the Wnt/beta catenin pathway. Based on the critical sites of PNPOR95/K117, Eltrombopag is identified as a potential therapeutic candidate for MM. In addition, the experiments showed its efficacy in mouse models. Eltrombopag inhibited the growth of MM cells and reduced bone lesions by disrupting the interaction between PNPO and DVL3, as supported by preliminary clinical trials. The study highlights the importance of PNPO as a high risk gene in the development of MM and suggests that Eltrombopag may be a promising treatment option.
C1 [Deng, Zhendong; Gu, Chunyan] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing 210022, Peoples R China.
   [Deng, Zhendong; Peng, Yumeng; Cheng, Long; Yu, Xichao; Yuan, Yuxia; Guo, Mengjie; Yang, Ye; Gu, Chunyan] Nanjing Univ Chinese Med, Sch Med, Nanjing 210023, Peoples R China.
   [Sun, Shanliang; Li, Nianguang] Nanjing Univ Chinese Med, Natl & Local Collaborat Engn Ctr Chinese Med Resou, Nanjing 210023, Peoples R China.
   [Zhou, Nian; Zhou, Fan] Jingan Dist Zhabei Cent Hosp, Dept Hematol & Oncol, Shanghai 200070, Peoples R China.
   [Zhou, Nian; Xu, Min; Cheng, Yuexin; Zhou, Fan] Yangtze River Delta Cty Hematol Union, Shanghai 200070, Peoples R China.
   [Xu, Min] Zhangjiagang First Peoples Hosp, Dept Hematol, Zhangjiagang 215600, Peoples R China.
   [Cheng, Yuexin] Xuzhou Med Univ, Yancheng Peoples Hosp 1, Dept Hematol, Yancheng Clin Coll, Yancheng 224006, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Xuzhou Medical
   University
RP Gu, CY (通讯作者)，Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing 210022, Peoples R China.; Yang, Y; Gu, CY (通讯作者)，Nanjing Univ Chinese Med, Sch Med, Nanjing 210023, Peoples R China.; Li, NG (通讯作者)，Nanjing Univ Chinese Med, Natl & Local Collaborat Engn Ctr Chinese Med Resou, Nanjing 210023, Peoples R China.; Zhou, F (通讯作者)，Jingan Dist Zhabei Cent Hosp, Dept Hematol & Oncol, Shanghai 200070, Peoples R China.; Zhou, F (通讯作者)，Yangtze River Delta Cty Hematol Union, Shanghai 200070, Peoples R China.
EM zfzbzxyy@126.com; linianguang@njucm.edu.cn; 290422@njucm.edu.cn;
   guchunyan@njucm.edu.cn
RI Sun, ShanLiang/MVY 0327 2025; Zhou, Fan/AAG 9824 2019; Cheng,
   Long/ADJ 1122 2022
FU National Natural Science Foundation of China; Experiment Center for
   Science and Technology of Nanjing University of Chinese Medicine;
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (Integration of Chinese and Western Medicine);  [82173849]
FX The authors would like to thank the participants who generously
   contributed to this study. In particular, the authors would like to
   thank the Experiment Center for Science and Technology of Nanjing
   University of Chinese Medicine to provide the necessary equipment. This
   work was supported by the National Natural Science Foundation of China
   82173849; the Priority Academic Program Development of Jiangsu Higher
   Education Institutions (Integration of Chinese and Western Medicine).
CR An G, 2016, BLOOD, V128, P1590, DOI 10.1182/blood 2016 03 707547
   Ansari Pour N, 2023, BLOOD, V141, P620, DOI 10.1182/blood.2022017010
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkh131, 10.1093/nar/gkw1099]
   Ash J, 2017, J CHEM INF MODEL, V57, P1286, DOI 10.1021/acs.jcim.7b00048
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Bai JP, 2003, EUR J PHARMACOL, V464, P9, DOI 10.1016/S0014 2999(03)01351 7
   Bellon M, 2013, BLOOD, V121, P5045, DOI 10.1182/blood 2012 07 439109
   Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood 2005 01 0034
   Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood 2009 12 261032
   Casado P, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r37
   Chong PSY, 2019, CANCER RES, V79, P4679, DOI 10.1158/0008 5472.CAN 19 0343
   Ciapaite J, 2020, BBA MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165607
   Dando I, 2017, FREE RADICAL BIO MED, V113, P176, DOI 10.1016/j.freeradbiomed.2017.09.022
   Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405
   Driscoll JJ, 2010, BLOOD, V115, P2827, DOI 10.1182/blood 2009 03 211045
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Gammons MV, 2016, MOL CELL, V64, P92, DOI 10.1016/j.molcel.2016.08.026
   Garcés JJ, 2020, LEUKEMIA, V34, P589, DOI 10.1038/s41375 019 0588 4
   Guan YH, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI149856
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747 0285.2007.00483.x
   Hao M., 2023, ADV SCI WEINH, V10
   Henry E, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005199
   Hosen N, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 020 00113 y
   Hou JH, 2020, ONCOTARGETS THER, V13, P959, DOI 10.2147/OTT.S235944
   Hu DY, 2021, PHARMACOL THERAPEUT, V223, DOI 10.1016/j.pharmthera.2021.107817
   Jin CH, 2019, MOLECULES, V24, DOI 10.3390/molecules24112162
   Kannaiyan R, 2011, BRIT J PHARMACOL, V164, P1506, DOI 10.1111/j.1476 5381.2011.01449.x
   Khayat M, 2008, MOL GENET METAB, V94, P431, DOI 10.1016/j.ymgme.2008.04.008
   Kirova DG, 2022, DEV CELL, V57, P1712, DOI 10.1016/j.devcel.2022.06.008
   Kuang CM, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 37699 z
   Kusy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035733
   Liang J, 2017, CELL RES, V27, P329, DOI 10.1038/cr.2016.159
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Liu QH, 2022, CELL BIOL TOXICOL, V38, P979, DOI 10.1007/s10565 021 09628 7
   Liu Y, 2024, J AM CHEM SOC, V146, P3675, DOI 10.1021/jacs.3c08622
   LOKHORST HM, 1994, BLOOD, V84, P2269
   Madrzak J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7718
   Nieborowska Skorska M, 2012, BLOOD, V119, P4253, DOI 10.1182/blood 2011 10 385658
   Pal D, 2023, CANCERS, V15, DOI 10.3390/cancers15102808
   Palandri F, 2021, BLOOD, V138, P571, DOI 10.1182/blood.2021010735
   Qu H, 2023, CLIN PHARMACOL THER, V114, P201, DOI 10.1002/cpt.2918
   Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001
   Ren WM, 2019, AGING US, V11, P2151, DOI 10.18632/aging.101908
   Ren ZM, 2018, BLOOD, V131, P982, DOI 10.1182/blood 2017 07 797050
   Ria R, 2014, CLIN CANCER RES, V20, P847, DOI 10.1158/1078 0432.CCR 13 1950
   Savvidou I, 2022, CANCERS, V14, DOI 10.3390/cancers14030840
   Savvidou I, 2017, MOL CANCER THER, V16, P1765, DOI 10.1158/1535 7163.MCT 16 0624
   Schneider M, 2018, BMC PLANT BIOL, V18, DOI 10.1186/s12870 018 1390 6
   Shivakumar D, 2012, J CHEM THEORY COMPUT, V8, P2553, DOI 10.1021/ct300203w
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sies H, 2022, NAT REV MOL CELL BIO, V23, P499, DOI 10.1038/s41580 022 00456 z
   Su N, 2016, ONCOL LETT, V12, P4623, DOI 10.3892/ol.2016.5289
   Tessoulin B, 2014, BLOOD, V124, P1626, DOI 10.1182/blood 2014 01 548800
   Touani FK, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/6663467
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Vlachodimitropoulou E, 2017, BLOOD, V130, P1923, DOI 10.1182/blood 2016 10 740241
   Wang SF, 2011, DRUG CHEM TOXICOL, V34, P61, DOI 10.3109/01480545.2010.494664
   Wang Y., 2023, HAEMATOLOGICA, V20, P256
   Wang ZF, 2023, BRIT J HAEMATOL, V202, P422, DOI 10.1111/bjh.18842
   Winkler T, 2019, BLOOD, V133, P2575, DOI 10.1182/blood.2019000478
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CC, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13326
   Wu MQ, 2018, AM J TRANSL RES, V10, P2078
   Yin Z, 2023, FREE RADICAL BIO MED, V203, P86, DOI 10.1016/j.freeradbiomed.2023.04.003
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood 2005 11 013458
   Zhang L., 2021, FRONT CELL DEV BIOL, V9
   Zhang LY, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419 017 0050 3
   Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00990 3
   Zhang YN, 2009, NAT CHEM BIOL, V5, P217, DOI 10.1038/nchembio.152
   Zhang YJ, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.684
   Zhong YL, 2019, EUR J PHARMACOL, V853, P184, DOI 10.1016/j.ejphar.2019.03.036
   Zhuang JL, 2019, BLOOD, V133, P1572, DOI 10.1182/blood 2018 06 859686
NR 74
TC 3
Z9 3
U1 8
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD FEB
PY 2025
VL 12
IS 5
DI 10.1002/advs.202407681
EA DEC 2024
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA U5S4T
UT WOS:001373867400001
PM 39656865
OA gold
DA 2025 08 17
ER

PT J
AU Yu, W
   Bien Aime, S
   Mattos, M
   Alsadun, S
   Wada, K
   Rogado, S
   Fiorellini, J
   Graves, D
   Uhrich, K
AF Yu, Weiling
   Bien Aime, Stephan
   Mattos, Marcelo
   Alsadun, Sarah
   Wada, Keisuke
   Rogado, Sarah
   Fiorellini, Joseph
   Graves, Dana
   Uhrich, Kathryn
TI Sustained, localized salicylic acid delivery enhances diabetic bone
   regeneration via prolonged mitigation of inflammation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE diabetic bone healing; control inflammation; salicylic acid; controlled
   and sustained drug delivery; histology
ID PERIODONTAL DISEASE; SPINAL FUSION; POLY(ANHYDRIDE ESTER); FRACTURE;
   MODULATION; EXPRESSION; MECHANISM; APOPTOSIS; RELEASE; CELLS
AB Diabetes is a metabolic disorder caused by insulin resistance and/or deficiency and impairs bone quality and bone healing due to altered gene expression, reduced vascularization, and prolonged inflammation. No effective treatments for diabetic bone healing are currently available, and most existing treatments do not directly address the diabetic complications that impair bone healing. We recently demonstrated that sustained and localized delivery of salicylic acid (SA) via an SA based polymer provides a low cost approach to enhance diabetic bone regeneration. Herein, we report mechanistic studies that delve into the biological action and local pharmacokinetics of SA releasing polymers shown to enhance diabetic bone regeneration. The results suggest that low SA concentrations were locally maintained at the bone defect site for more than 1 month. As a result of the sustained SA release, a significantly reduced inflammation was observed in diabetic animals, which in turn, yielded reduced osteoclast density and activity, as well as increased osteoblastogenesis. Based upon these results, localized and sustained SA delivery from the SA based polymer effectively improved bone regeneration in diabetic animals by affecting both osteoclasts and osteoblasts, thereby providing a positive basis for clinical treatments. (c) 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 2595 2603, 2016.
C1 [Yu, Weiling; Uhrich, Kathryn] Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.
   [Bien Aime, Stephan; Uhrich, Kathryn] Rutgers State Univ, Dept Chem & Chem Biol, 610 Taylor Rd, Piscataway, NJ 08854 USA.
   [Mattos, Marcelo; Alsadun, Sarah; Wada, Keisuke; Fiorellini, Joseph; Graves, Dana] Univ Penn, Sch Dent Med, Dept Periodont, 240 South 40th St, Philadelphia, PA 19104 USA.
   [Rogado, Sarah] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 610 Taylor Rd, Piscataway, NJ USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University System; Rutgers University New Brunswick; University of
   Pennsylvania; Rutgers University System; Rutgers University New
   Brunswick
RP Uhrich, K (通讯作者)，Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.; Uhrich, K (通讯作者)，Rutgers State Univ, Dept Chem & Chem Biol, 610 Taylor Rd, Piscataway, NJ 08854 USA.
EM keuhrich@rutgers.edu
RI Wada, Keisuke/AAW 7752 2021; Uhrich, Kathryn/I 2099 2013
OI Uhrich, Kathryn/0000 0001 7273 7528
FU NIH [R01AR060055, R01DE 017732, R01 DE13207, R44AA020163]
FX Contract grant sponsor: NIH; contract grant numbers: R01AR060055,
   R01DE 017732, R01 DE13207, R44AA020163
CR Alblowi J, 2009, AM J PATHOL, V175, P1574, DOI 10.2353/ajpath.2009.090148
   Bezerra BD, 2012, J CLIN PERIODONTOL, V39, P333, DOI 10.1111/j.1600 051X.2011.01847.x
   Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478 7954 8 29
   Chaudhary SB, 2008, J AM ACAD ORTHOP SUR, V16, P159, DOI 10.5435/00124635 200803000 00007
   Control CoD, 2014, NAT DIAB STAT REP
   Elavarasu S, 2012, J PHARM BIOALLIED SC, V4, pS256, DOI 10.4103/0975 7406.100244
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Govender PV, 2002, NEUROSURG FOCUS, V13, P1
   Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437
   Ji JG, 2011, CARBOHYD POLYM, V85, P803, DOI 10.1016/j.carbpol.2011.03.051
   Kang J, 2012, INFECT IMMUN, V80, P2247, DOI 10.1128/IAI.06371 11
   Kini U., 2012, RADIONUCLIDE HYBRID, P29, DOI [DOI 10.1007/978 3 642 02400 9_2, 10.1007/978 3 642 02400 9_2]
   Ko KI, 2015, DIABETOLOGIA, V58, P633, DOI 10.1007/s00125 014 3470 y
   Liu R, 2006, J DENT RES, V85, P510, DOI 10.1177/154405910608500606
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McCarty MF, 2006, INTEGR CANCER THER, V5, P252, DOI 10.1177/1534735406291499
   Mountziaris PM, 2008, TISSUE ENG PART B RE, V14, P179, DOI 10.1089/ten.teb.2008.0038
   Mountziaris PM, 2011, TISSUE ENG PART B RE, V17, P393, DOI [10.1089/ten.teb.2011.0182, 10.1089/ten.TEB.2011.0182]
   Ouimet MA, 2015, MACROMOL BIOSCI, V15, P342, DOI 10.1002/mabi.201400238
   Ouimet MA, 2012, J BIOACT COMPAT POL, V27, P540, DOI 10.1177/0883911512464605
   Pacios S, 2013, AM J PATHOL, V183, P1928, DOI 10.1016/j.ajpath.2013.08.017
   Pacios S, 2012, FASEB J, V26, P1423, DOI 10.1096/fj.11 196279
   PALEEV NR, 1989, KARDIOLOGIYA, V29, P72
   Panda H, 2010, HDB DRUGS NATURAL SO
   PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116
   Ramanujam CL, 2012, CLIN PODIATR MED SUR, V29, P589, DOI 10.1016/j.cpm.2012.07.005
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P71, DOI 10.1111/j.1600 0501.2009.01805.x
   Roszer T, 2011, INFLAMM RES, V60, P3, DOI 10.1007/s00011 010 0246 9
   SIMMONS DJ, 1985, CLIN ORTHOP RELAT R, P100
   Wada K, 2013, J CONTROL RELEASE, V171, P33, DOI 10.1016/j.jconrel.2013.06.024
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Wu YY, 2015, INT J ORAL SCI, V7, P63, DOI 10.1038/ijos.2015.2
   Zhang HX, 2015, J BIOMED MATER RES A, V103, P3250, DOI 10.1002/jbm.a.35463
   Zhang XM, 2004, J IMMUNOL, V173, P3514, DOI 10.4049/jimmunol.173.5.3514
NR 36
TC 10
Z9 11
U1 0
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD OCT
PY 2016
VL 104
IS 10
BP 2595
EP 2603
DI 10.1002/jbm.a.35781
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DW7VR
UT WOS:000383861400021
PM 27194511
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Garcia Gomez, A
   Li, TL
   de la Calle Fabregat, C
   Rodríguez Ubreva, J
   Ciudad, L
   Català Moll, F
   Godoy Tena, G
   Martín Sánchez, M
   San Segundo, L
   Muntión, S
   Morales, X
   Ortiz de Solórzano, C
   Oyarzabal, J
   José Enériz, ES
   Esteller, M
   Agirre, X
   Prosper, F
   Garayoa, M
   Ballestar, E
AF Garcia Gomez, Antonio
   Li, Tianlu
   de la Calle Fabregat, Carlos
   Rodriguez Ubreva, Javier
   Ciudad, Laura
   Catala Moll, Francesc
   Godoy Tena, Gerard
   Martin Sanchez, Montserrat
   San Segundo, Laura
   Muntion, Sandra
   Morales, Xabier
   Ortiz de Solorzano, Carlos
   Oyarzabal, Julen
   San Jose Eneriz, Edurne
   Esteller, Manel
   Agirre, Xabier
   Prosper, Felipe
   Garayoa, Mercedes
   Ballestar, Esteban
TI Targeting aberrant DNA methylation in mesenchymal stromal cells as a
   treatment for myeloma bone disease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MULTIPLE MYELOMA; STEM CELLS; MARROW; DIFFERENTIATION; GAMMOPATHY;
   EXPRESSION; FRACTURES; PROFILE; DNMT1; IMAGE
AB Multiple myeloma (MM) progression and myeloma associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM 272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM 272 treatment prevents tumor associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM 272 is able to reverse MBD. Mesenchymal stromal cells (MSCs) have been shown to support multiple myeloma (MM) development. Here, MSCs isolated from the bone marrow of MM patients are shown to have altered DNA methylation patterns and a methyltransferase inhibitor reverts MM associated bone loss and reduces tumour burden in MM murine models.
C1 [Garcia Gomez, Antonio; Li, Tianlu; de la Calle Fabregat, Carlos; Rodriguez Ubreva, Javier; Ciudad, Laura; Catala Moll, Francesc; Godoy Tena, Gerard; Ballestar, Esteban] Josep Carreras Leukaemia Res Inst IJC, Epigenet & Immune Dis Grp, Barcelona 08916, Spain.
   [Garcia Gomez, Antonio; Li, Tianlu; de la Calle Fabregat, Carlos; Rodriguez Ubreva, Javier; Ciudad, Laura; Catala Moll, Francesc; Ballestar, Esteban] Bellvitge Biomed Res Inst IDIBELL, Chromatin & Dis Grp, Canc Epigenet & Biol Programme PEBC, Barcelona 08908, Spain.
   [Martin Sanchez, Montserrat; San Segundo, Laura; Muntion, Sandra; Garayoa, Mercedes] Univ Salamanca, IBMCC, CSIC, Ctr Invest Canc, Salamanca 37007, Spain.
   [Martin Sanchez, Montserrat; San Segundo, Laura; Muntion, Sandra; Garayoa, Mercedes] Hosp Univ Salamanca, IBSAL, Salamanca 37007, Spain.
   [Morales, Xabier; Ortiz de Solorzano, Carlos] Univ Navarra, Ctr Appl Med Res CIMA, Imaging Platform, IDISNA, Pamplona 31008, Spain.
   [Oyarzabal, Julen] Univ Navarra, Mol Therapeut Program, Ctr Appl Med Res CIMA, Small Mol Discovery Platform, Pamplona 31008, Spain.
   [San Jose Eneriz, Edurne; Agirre, Xabier; Prosper, Felipe] Univ Navarra, Div Hematooncol, Ctr Appl Med Res CIMA, IDISNA, Pamplona 31008, Spain.
   [Esteller, Manel] Josep Carreras Leukaemia Res Inst IJC, Barcelona, Catalonia, Spain.
   [Esteller, Manel] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.
   [Esteller, Manel] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Catalonia, Spain.
   [Esteller, Manel] Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain.
C3 Institut de Recerca Contra la Leucemia Josep Carreras (IJC); Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); University of
   Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC);
   CSIC USAL   Instituto de Biologia Molecular y Celular del Cancer de
   Salamanca (IBMCC); University of Navarra; University of Navarra;
   University of Navarra; Institut de Recerca Contra la Leucemia Josep
   Carreras (IJC); CIBER   Centro de Investigacion Biomedica en Red;
   CIBERONC; ICREA; University of Barcelona
RP Garcia Gomez, A; Ballestar, E (通讯作者)，Josep Carreras Leukaemia Res Inst IJC, Epigenet & Immune Dis Grp, Barcelona 08916, Spain.; Garcia Gomez, A; Ballestar, E (通讯作者)，Bellvitge Biomed Res Inst IDIBELL, Chromatin & Dis Grp, Canc Epigenet & Biol Programme PEBC, Barcelona 08908, Spain.
EM nonogarcia85@gmail.com; eballestar@carrerasresearch.org
RI San Segundo, Laura/E 6441 2018; Ortiz de Solorzano, Carlos/G 3278 2010;
   Prosper, Felipe/H 6859 2017; Esteller, Manel/L 5956 2014; Garayoa,
   Mercedes/O 6039 2017; Ballestar, Esteban/ABG 8561 2020; Ortiz de
   Solorzano, Carlos/G 3278 2010; Rodriguez Ubreva, javier/HTP 5081 2023;
   de+la+Calle Fabregat, Carlos/AAQ 4258 2020; Agirre,
   Xabier/ABE 4110 2020; Català Moll, Francesc/KOC 4223 2024; Morales,
   Xabier/NES 6247 2025
OI Muntion Olave, Sandra/0000 0001 7164 0767; RODRIGUEZ UBREVA,
   JAVIER/0000 0003 4707 4536; Prosper, Felipe/0000 0001 6115 8790;
   Ballestar, Esteban/0000 0002 1400 2440; Ortiz de Solorzano,
   Carlos/0000 0001 8720 0205; de la Calle Fabregat,
   Carlos/0000 0002 3026 3069; Godoy Tena, Gerard/0000 0003 3832 5794;
   Catala Moll, Francesc/0000 0002 2354 8648; Morales Urteaga,
   Xabier/0000 0003 0303 9958; 
FU Spanish Ministry of Science and Innovation [SAF2014 55942 R,
   SAF2017 88086 R]; FEDER funds/European Regional Development Fund
   (ERDF) a way to build Europe; Multiple Myeloma Research Foundation
   (MMRF); Spanish Ministry of Science, Innovation and Universities
   (MCIU/AEI/FEDER, UE) [RTI2018 094494 B C22]; Spanish FIS ISCIII
   [PI15/02156, PI19/01384]; FEDER; Asociacion Espanola Contra el Cancer
   (AECC); Instituto de Salud Carlos III (ISCIII) [PI17/00701, PI19/01352];
   TRASCAN (EPICA and Immunocell); Fundacio La Marato de TV3; Accelerator
   award CRUK/AIRC/AECC joint funder partnership, CIBERONC [CB16/12/00489];
   FEDER funds; Fundacion Ramon Areces (PREMAMM)
FX We thank CERCA Program/Generalitat de Catalunya and the Josep Carreras
   Foundation for institutional support. E.B. was funded by the Spanish
   Ministry of Science and Innovation (grant numbers SAF2014 55942 R and
   SAF2017 88086 R), co funded by FEDER funds/European Regional Development
   Fund (ERDF) a way to build Europe, and a Senior Research Award from the
   Multiple Myeloma Research Foundation (MMRF). C.O. d. S. was funded by
   the Spanish Ministry of Science, Innovation and Universities, under
   grant RTI2018 094494 B C22 (MCIU/AEI/FEDER, UE). M.G. received financial
   support from the Spanish FIS ISCIII (PI15/02156 and PI19/01384) and
   FEDER. A.G.G is funded by a postdoctoral contract of the Asociacion
   Espanola Contra el Cancer (AECC). F.P. was funded by grants from
   Instituto de Salud Carlos III (ISCIII), PI17/00701 and PI19/01352,
   TRASCAN (EPICA and Immunocell), Fundacio La Marato de TV3, the
   Accelerator award CRUK/AIRC/AECC joint funder partnership, CIBERONC
   (CB16/12/00489) and co financed with FEDER funds and Fundacion Ramon
   Areces (PREMAMM).
CR Adamik J, 2017, MOL CANCER RES, V15, P405, DOI 10.1158/1541 7786.MCR 16 0242 T
   Agirre X, 2015, GENOME RES, V25, P478, DOI 10.1101/gr.180240.114
   Amodio N, 2017, EXPERT OPIN THER TAR, V21, P91, DOI 10.1080/14728222.2016.1266339
   [Anonymous], 2017, HUGENE10STTRANSCRIPT
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Bárcena Varela M, 2019, HEPATOLOGY, V69, P587, DOI 10.1002/hep.30168
   Cakouros D, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072 018 0247 4
   Capp JP, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00355
   Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   da Silva RA, 2019, BONE, V125, P74, DOI 10.1016/j.bone.2019.04.026
   Das DS, 2016, LEUKEMIA, V30, P2187, DOI 10.1038/leu.2016.96
   Das R, 2016, NAT MED, V22, P1351, DOI 10.1038/nm.4202
   Dhodapkar MV, 2016, BLOOD, V128, P2599, DOI 10.1182/blood 2016 09 692954
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Garayoa M, 2009, LEUKEMIA, V23, P1515, DOI 10.1038/leu.2009.65
   Garcia Gomez A, 2018, CLIN IMMUNOL, V196, P64, DOI 10.1016/j.clim.2018.02.013
   Garcia Gomez A, 2014, ONCOTARGET, V5, P8284, DOI 10.18632/oncotarget.2058
   Garcia Gomez Antonio, 2014, World J Stem Cells, V6, P322, DOI 10.4252/wjsc.v6.i3.322
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Ghobrial IM, 2018, NAT REV CLIN ONCOL, V15, P219, DOI 10.1038/nrclinonc.2017.197
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2010, LEUKEMIA, V24, P1368, DOI 10.1038/leu.2010.96
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Håkelien AM, 2014, STEM CELLS, V32, P2780, DOI 10.1002/stem.1759
   Hansen K. D, 2016, UMINAHUMANMETHYLATIO
   Harada T, 2017, LEUKEMIA, V31, P2670, DOI 10.1038/leu.2017.144
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Heuck CJ, 2013, J IMMUNOL, V190, P2966, DOI 10.4049/jimmunol.1202493
   Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125
   Iyyanar PPR, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00929
   Jeong BC, 2018, BIOCHEM BIOPH RES CO, V499, P696, DOI 10.1016/j.bbrc.2018.03.214
   Kaneshiro S, 2015, J BONE MINER METAB, V33, P486, DOI 10.1007/s00774 014 0612 8
   Kanzler B, 1998, DEVELOPMENT, V125, P2587
   Koch CM, 2013, GENOME RES, V23, P248, DOI 10.1101/gr.141945.112
   Kristinsson SY, 2010, BLOOD, V116, P2651, DOI 10.1182/blood 2010 04 282848
   Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46
   Lanctôt C, 1999, DEVELOPMENT, V126, P1805
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Ledergor G, 2018, NAT MED, V24, P1867, DOI 10.1038/s41591 018 0269 2
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Panaroni C, 2017, CURR OSTEOPOROS REP, V15, P483, DOI 10.1007/s11914 017 0397 5
   Pizard A, 2005, MOL CELL BIOL, V25, P5073, DOI 10.1128/MCB.25.12.5073 5083.2005
   Rabal O, 2018, J MED CHEM, V61, P6518, DOI 10.1021/acs.jmedchem.7b01926
   Rabal O, 2018, J MED CHEM, V61, P6546, DOI 10.1021/acs.jmedchem.7b01925
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Rajkumar SV, 2016, AM J HEMATOL, V91, P720, DOI 10.1002/ajh.24402
   Reagan MR, 2012, CLIN CANCER RES, V18, P342, DOI 10.1158/1078 0432.CCR 11 2212
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   José Enériz ES, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15424
   San Miguel JF, 2015, NAT REV CLIN ONCOL, V12, P71, DOI 10.1038/nrclinonc.2014.216
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Segovia C, 2019, NAT MED, V25, P1073, DOI 10.1038/s41591 019 0499 y
   Seifert A, 2015, WORLD J STEM CELLS, V7, P583, DOI 10.4252/wjsc.v7.i3.583
   Sundararajan S, 2016, CURR HEMATOL MALIG R, V11, P102, DOI 10.1007/s11899 016 0305 6
   Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood 2018 11 852459
   Teschendorff AE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10478
   Teschendorff AE, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003709
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   Todoerti K, 2010, EXP HEMATOL, V38, P141, DOI 10.1016/j.exphem.2009.11.009
   van Nieuwenhuijzen N, 2018, CANCER RES, V78, P2449, DOI 10.1158/0008 5472.CAN 17 3115
   Verlinden L, 2013, BONE, V55, P465, DOI 10.1016/j.bone.2013.03.023
   Wei XF, 2019, J CELL BIOCHEM, V120, P6515, DOI 10.1002/jcb.27942
   Xu S, 2012, LEUKEMIA, V26, P2546, DOI 10.1038/leu.2012.126
   Xu S, 2018, LEUKEMIA, V32, P1500, DOI 10.1038/s41375 018 0061 9
   Yan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090846
   Zhou WW, 2014, ONCOL LETT, V8, P2130, DOI 10.3892/ol.2014.2481
NR 78
TC 33
Z9 36
U1 1
U2 23
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 18
PY 2021
VL 12
IS 1
AR 421
DI 10.1038/s41467 020 20715 x
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA PX7CV
UT WOS:000611511500002
PM 33462210
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, Z
   Xu, Q
   Song, C
   Mi, BG
   Zhang, HH
   Kang, HL
   Liu, HY
   Sun, YL
   Wang, J
   Lei, ZW
   Guan, HF
   Li, F
AF Zhang, Zheng
   Xu, Qian
   Song, Chao
   Mi, Baoguo
   Zhang, Honghua
   Kang, Honglei
   Liu, Huiyong
   Sun, Yunlong
   Wang, Jia
   Lei, Zhuowei
   Guan, Hanfeng
   Li, Feng
TI Serum  and Glucocorticoid inducible Kinase 1 is Essential for
   Osteoclastogenesis and Promotes Breast Cancer Bone Metastasis
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID CA2+ INFLUX; SGK1; ACTIVATION; EXPRESSION; GENES; DIFFERENTIATION;
   INHIBITION; CELLS; RANK; RESISTANCE
AB Bone metastasis is a severe complication associated with various carcinomas. It causes debilitating pain and pathologic fractures and dramatically impairs patients' quality of life. Drugs aimed at osteoclast formation significantly reduce the incidence of skeletal complications and are currently the standard treatment for patients with bone metastases. Here, we reported that serum  and glucocorticoid inducible kinase 1 (SGK1) plays a pivotal role in the formation and function of osteoclasts by regulating the Ca2+ release activated Ca2+ channel Orai1. We showed that SGK1 inhibition represses osteoclastogenesis in vitro and prevents bone loss in vivo. Furthermore, we validated the effect of SGK1 on bone metastasis by using an intracardiac injection model in mice. Inhibition of SGK1 resulted in a significant reduction in bone metastasis. Subsequently, the Oncomine and the OncoLnc database were employed to verify the differential expression and the association with clinical outcome of SGK1 gene in patients with breast cancer. Our data mechanistically demonstrated the regulation of the SGK1 in the process of osteoclastogenesis and revealed SGK1 as a valuable target for curing bone metastasis diseases.
C1 [Zhang, Zheng; Song, Chao; Zhang, Honghua; Kang, Honglei; Liu, Huiyong; Sun, Yunlong; Wang, Jia; Lei, Zhuowei; Guan, Hanfeng; Li, Feng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Hubei, Peoples R China.
   [Xu, Qian] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Hubei, Peoples R China.
   [Mi, Baoguo] Xi An Jiao Tong Univ, Honghui Hosp, Coll Med, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Xi'an Jiaotong University
RP Guan, HF (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Hubei, Peoples R China.; Li, F (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430000, Hubei, Peoples R China.
EM hguan@hust.edu.cn; lifengmd@hust.edu.cn
OI Li, Feng/0000 0002 7961 3728; Zhang, Honghua/0000 0001 6517 7649; Zhang,
   Zheng/0000 0002 3242 5738
FU National Natural Science Foundation of China [81572857, 81401762,
   81472133]
FX This work was supported by National Natural Science Foundation of China
   (no. 81572857, to H. Guan; no. 81401762, to J. Wang; and 81472133 to F.
   Li)
CR Andersen MN, 2013, J BIOL CHEM, V288, P36841, DOI 10.1074/jbc.M113.525931
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   BelAiba RS, 2006, CIRC RES, V98, P828, DOI 10.1161/01.RES.0000210539.54861.27
   Borst O, 2012, BLOOD, V119, P251, DOI 10.1182/blood 2011 06 359976
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Campbell JP, 2012, JOVE J VIS EXP, DOI 10.3791/4260
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004
   Di Cristofano A, 2017, CURR TOP DEV BIOL, V123, P49, DOI 10.1016/bs.ctdb.2016.11.006
   Di Pietro N, 2010, MOL ENDOCRINOL, V24, P370, DOI 10.1210/me.2009 0265
   Dong YH, 2017, CELL SIGNAL, V34, P55, DOI 10.1016/j.cellsig.2017.03.004
   Du YN, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01581
   Dynes JL, 2016, P NATL ACAD SCI USA, V113, P440, DOI 10.1073/pnas.1523410113
   Eylenstein A, 2011, FASEB J, V25, P2012, DOI 10.1096/fj.10 178210
   Fagerli UM, 2011, ONCOGENE, V30, P3198, DOI 10.1038/onc.2011.79
   Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gdowski AS, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0578 1
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Guan HF, 2015, CELL SIGNAL, V27, P969, DOI 10.1016/j.cellsig.2015.02.006
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549 009 0674 9
   Hall BA, 2012, BREAST CANCER RES TR, V135, P469, DOI 10.1007/s10549 012 2161 y
   Hammond M, 2009, BIOORG MED CHEM LETT, V19, P4441, DOI 10.1016/j.bmcl.2009.05.051
   Hewavitharana T, 2007, CELL CALCIUM, V42, P173, DOI 10.1016/j.ceca.2007.03.009
   Hwang SY, 2012, CELL CALCIUM, V52, P488, DOI 10.1016/j.ceca.2012.10.001
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Ishikawa J, 2003, J IMMUNOL, V170, P4441, DOI 10.4049/jimmunol.170.9.4441
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12 218230
   Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016
   Lou YY, 2017, FASEB J, V31, P447, DOI 10.1096/fj.201600760R
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Maus M, 2017, CELL METAB, V25, P698, DOI 10.1016/j.cmet.2016.12.021
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mochizuki T, 2018, J BONE MINER METAB, V36, P431, DOI 10.1007/s00774 017 0848 1
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Orlacchio A, 2017, CANCER RES, V77, P6914, DOI 10.1158/0008 5472.CAN 17 2105
   Parekh AB, 2011, TRENDS BIOCHEM SCI, V36, P78, DOI 10.1016/j.tibs.2010.07.013
   Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sigl V, 2014, CYTOKINE GROWTH F R, V25, P205, DOI 10.1016/j.cytogfr.2014.01.002
   Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342
   Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200
   Vallon V, 2006, J MOL MED, V84, P396, DOI 10.1007/s00109 005 0027 z
   Voelkl J, 2018, J CLIN INVEST, V128, P3024, DOI 10.1172/JCI96477
   Voelkl J, 2018, J AM SOC NEPHROL, V29, P1636, DOI [10.1681/ASN.2017050492, 10.1681/asn.2017050492]
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103
   Zhang Y, 2015, SCI REP UK, V5, DOI 10.1038/srep13575
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03 11 0786
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
   Zhou YD, 2011, J CELL PHYSIOL, V226, P1082, DOI 10.1002/jcp.22423
NR 56
TC 24
Z9 26
U1 2
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD FEB
PY 2020
VL 19
IS 2
BP 650
EP 660
DI 10.1158/1535 7163.MCT 18 0783
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KK8TK
UT WOS:000513008800028
PM 31694887
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Lobato, JV
   Mauricio, AC
   Rodrigues, JM
   Cavaleiro, MV
   Cortez, PP
   Xavier, L
   Botelho, C
   Hussain, NS
   Santos, JD
AF Lobato, J. V.
   Mauricio, A. C.
   Rodrigues, J. M.
   Cavaleiro, M. V.
   Cortez, P. P.
   Xavier, L.
   Botelho, C.
   Hussain, N. Sooraj
   Santos, J. D.
TI Jaw avascular osteonecrosis after treatment of multiple myeloma with
   zoledronate
SO JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY
LA English
DT Article
DE bisphosphonates; multipte myeloma; avascular osteonecrosis; jaw
ID BONE METASTASES; BISPHOSPHONATES; PAMIDRONATE; DISEASE; HYPERCALCEMIA;
   OSTEOCLASTS; RESORPTION; MECHANISMS; NECROSIS; CANCER
AB Purpose: Multiple myeloma, the second most common haematopoietic cancer, which represents the collection of plasma cell neoplasms that invariably becomes fatal when self renewing myeloma cells begin unrestrained proliferation. The major clinical manifestation of multiple myeloma is related to the toss of bone through osteolysis. This can lead to pathologic fractures, spinal cord compression, hypercalcaemia, and pain. It is also a major cause of morbidity and mortality in these patients, who frequently require radiation therapy, surgery and analgesic medications. Bisphosphonates are specific inhibitors of osteoclastic activity, and are currently used to prevent bone complications and to treat malignant hypercalcaemia in patients with multiple myeloma, or bone metastases from breast and prostate cancers. Hence, osteonecrosis of the mandible has been reported in three patients from Centro Hospitalar de Vila Nova de Gaia (CHVNG) with multiple myeloma treated for over 18 48 months with intravenous zoledronate, commonly prescribed for multiple myeloma therapy. Although, this report alerts clinicians about the potential complication of bone necrosis in patients receiving bisphosphonate therapy, many questions remain concerning the underlying pathogenesis of this process.
   Patients and methods: The medical and dental records of three patients with multiple myeloma, who were treated in CHVNG in the past 4 years, were reviewed. These three patients presented exposed bone and osteonecrosis of the mandible, and shared one common clinical feature: all of them were treated with bisphosphonate zoledronate, administered intravenously for long periods. Sequential orthopantomograms (OPGs) and histological evaluation have been analysed from the biopsies of the non healing dental extraction sites of these patients.
   Results: After a routine dental extraction, these patients developed avascular osteonecrosis of the mandible and secondary bone infection with Actinomyces israelii (actinomycotic osteomyelitis), with no evidence of metastatic disease evaluated by biopsy. In these three described clinical cases, surgical debridment without flap elevation, intensive antibiotherapy and the suspension of the zoledronate treatment allowed a partial recovery of the patients.
   The purpose of this clinical report is to point out that patients suffering from multiple myeloma can develop bone osteonecrosis induced by treatment with bisphosphonates. Research to determine the mechanism of this dental phenomenon is needed to fully validate and substantiate the possible link between bisphosphonate treatment of multiple myeloma or other cancer diseases and avascular osteonecrosis of the jaws. Until then, clinicians involved in the care of patients at risk should consider this possible complication. (c) 2006 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
C1 [Lobato, J. V.; Mauricio, A. C.; Rodrigues, J. M.; Cavaleiro, M. V.; Cortez, P. P.] Univ Porto, Inst Ciencias & Tecnol Agrarias & Agro Alimentare, CECA, P 4485661 Vairao, Portugal.
   [Lobato, J. V.] CHVNG, Serv Estomatol, P 4434502 Vila Nova De Gaia, Portugal.
   [Mauricio, A. C.; Cortez, P. P.] Univ Porto, ICBAS, Dept Clin Vet, P 4099330 Oporto, Portugal.
   [Rodrigues, J. M.] Hosp Sao Joao, Serv Cirurg Plast & Resconstrutiva, P 4200319 Oporto, Portugal.
   [Xavier, L.] CHVNG, Serv Hematol, P 4434502 Vila Nova De Gaia, Portugal.
   [Botelho, C.; Hussain, N. Sooraj; Santos, J. D.] Univ Porto, Fac Engn, P 4200465 Oporto, Portugal.
   [Botelho, C.; Hussain, N. Sooraj; Santos, J. D.] INEB Inst Engn Biomed, Lab Biomat, P 4150180 Oporto, Portugal.
C3 Universidade do Porto; Universidade do Porto; Sao Joao Hospital;
   Universidade do Porto; Universidade do Porto
RP Mauricio, AC (通讯作者)，Univ Porto, Inst Ciencias & Tecnol Agrarias & Agro Alimentare, CECA, Campus Agrario Vairao,Rua Padre Armando Quintas, P 4485661 Vairao, Portugal.
EM ana.cotette@mail.icav.up.pt
RI Botelho, Claudia/K 7523 2012; Nandyala, SOORAJ/I 3307 2013; Maurício,
   Ana/AAD 3601 2021; Santos, Jose Domingos/Q 9462 2018; SANTOS,
   JOAO/KHE 1146 2024; Mauricio, Ana Colette/E 8917 2013; Nandyala,
   Sooraj/I 3307 2013; Cortez, Paulo/AFG 8528 2022
OI Botelho, Claudia/0000 0001 8221 419X; Pegado Cortez,
   Paulo/0000 0001 7132 6786; Santos, Jose Domingos/0000 0002 6871 9850;
   Mauricio, Ana Colette/0000 0002 0018 9363; Nandyala,
   Sooraj/0000 0002 2736 5224; Rodrigues, Jorge Manuel/0000 0003 1889 4914
CR [Anonymous], J CLIN ONCOL
   BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397
   Berenson JR, 2005, BEST PRACT RES CL HA, V18, P653, DOI 10.1016/j.beha.2005.03.001
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Berestetski A, 2001, BEITRAGE ZF, V7, P3
   Brincker H, 1998, BRIT J HAEMATOL, V101, P280, DOI 10.1046/j.1365 2141.1998.00695.x
   Carter G, 2005, MED J AUSTRALIA, V182, P413, DOI 10.5694/j.1326 5377.2005.tb06761.x
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coukell AJ, 1998, DRUG AGING, V12, P149, DOI 10.2165/00002512 199812020 00007
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   KYLE RA, 1975, MAYO CLIN PROC, V50, P29
   KYLE RA, 1975, NEW ENGL J MED, V293, P1334, DOI 10.1056/NEJM197512252932602
   Lacerna L, 2003, SEMIN ONCOL, V30, P150, DOI 10.1053/j.seminoncol.2003.08.017
   Lipton A, 2001, SEMIN ONCOL, V28, P54, DOI 10.1016/S0093 7754(01)90233 7
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Melo Maico D, 2005, J Can Dent Assoc, V71, P111
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   MUNDY GR, 1986, SEMIN ONCOL, V13, P291
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Pereira J, 1998, J PALLIATIVE CARE, V14, P25, DOI 10.1177/082585979801400205
   Purcell PM, 2005, MED J AUSTRALIA, V182, P417, DOI 10.5694/j.1326 5377.2005.tb06762.x
   PUROHIT OP, 1995, BRIT J CANCER, V72, P1289, DOI 10.1038/bjc.1995.502
   Robinson NA, 2004, ANN ACAD MED SINGAP, V33, P48
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
   Van Poznak Catherine H, 2002, Cancer Control, V9, P480
   Vannucchi Alessandro M, 2005, Br J Haematol, V128, P738, DOI 10.1111/j.1365 2141.2005.05382.x
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
NR 39
TC 9
Z9 11
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1748 6815
EI 1878 0539
J9 J PLAST RECONSTR AES
JI J. Plast. Reconstr. Aesthet. Surg.
PY 2008
VL 61
IS 1
BP 99
EP 106
DI 10.1016/j.bjps.2006.06.016
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 255TI
UT WOS:000252679900016
PM 18068658
DA 2025 08 17
ER

PT J
AU Wang, T
   Guo, S
   Zhang, H
AF Wang, Ting
   Guo, Shu
   Zhang, Hua
TI Synergistic Effects of Controlled Released BMP 2 and VEGF from
   nHAC/PLGAs Scaffold on Osteogenesis
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN; GROWTH FACTOR DELIVERY; OSTEOBLAST
   DIFFERENTIATION; COMPOSITE SCAFFOLD; IN VITRO; COLLAGEN; HYDROXYAPATITE;
   EXPRESSION; THERAPY; PLGA
AB Tissue engineering bones take great advantages in massive bone defect repairing; under the induction of growth factors, seed cells differentiate into osteoblasts, and the scaffold materials gradually degrade and are replaced with neogenetic bones, which simulates the actual pathophysiological process of bone regeneration. However, mechanism research is required and further developed to instruct elements selection and optimization. In the present study, we prepared vascular endothelial growth factor/bone morphogenetic protein 2  nanohydroxyapatite/collagen (VEGF/ BMP 2  nHAC/PLGAs) scaffolds and inoculated mouse MC3T3 E1 preosteoblasts to detect osteogenic indexes and activation of related signaling pathways. The hypothesis is to create a three dimensional environment that simulates bone defect repairing, and p38 mitogen activated kinase (p38) inhibitor was applied and osterix shRNA was transferred into mouse MC3T3 E1 preosteoblasts to further investigate the molecular mechanism of crosstalk between BMP 2 and VEGF. Our results demonstrated the following: (1) BMP 2 and VEGF were sustainably released from PLGAs microspheres. (2) nHAC/PLGAs scaffold occupied a three dimensional porous structure and has excellent physical properties. (3) MC3T3 E1 cells proliferated and differentiated well in the scaffold. (4) Osteogenic differentiation related factors expression of VEGF/BMP 2 loaded scaffold was obviously higher than that of other groups; p38 inhibitor SB203580 decreased the nucleus/cytoplasm ratio of osterix expression. To conclude, the active artificial bone we prepared could provide a favorable growth space for MC3T3 E1 cells, and osteogenesis and maturation reinforced by simultaneous VEGF and BMP 2 treatment may be mainly through the activation of the p38 MAPK pathway to promote nuclear translocation of osterix protein.
C1 [Wang, Ting; Guo, Shu; Zhang, Hua] China Med Univ, Hosp 1, Dept Plast Surg, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University
RP Guo, S (通讯作者)，China Med Univ, Hosp 1, Dept Plast Surg, Shenyang 110001, Liaoning, Peoples R China.
EM sguo@cmu.edu.cn
RI Wang, Ting/ABG 3298 2022; Guo, Shu/O 3404 2019
OI Guo, Shu/0000 0001 9094 1602
FU Key Laboratory for Immunology and Dermatology of Health's Ministry, The
   First Hospital of China Medical University; National Natural Science
   Foundation of China [51272286]; Liaoning Medical Peak Construction
   Project [2010014]; Natural Science Foundation of Liaoning province
   [20102296]
FX The present article enjoys supports from Key Laboratory for Immunology
   and Dermatology of Health's Ministry, The First Hospital of China
   Medical University. This work was financially supported by National
   Natural Science Foundation of China (grant no. 51272286), Liaoning
   Medical Peak Construction Project (2010014), and Natural Science
   Foundation of Liaoning province (20102296).
CR Alluri R, 2018, J BIOMED MATER RES A, V106, P1104, DOI 10.1002/jbm.a.36310
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Benglis D, 2008, NEUROSURGERY, V62, P423, DOI 10.1227/01.neu.0000326030.24220.d8
   Brigham MD, 2009, TISSUE ENG PT A, V15, P1645, DOI 10.1089/ten.tea.2008.0441
   Burkus JK, 2002, J SPINAL DISORD TECH, V15, P337, DOI 10.1097/00024720 200210000 00001
   Çakir Özkan N, 2017, J ORAL MAXIL SURG, V75, DOI 10.1016/j.joms.2016.08.020
   Choi JW, 2017, MATERIALS, V10, DOI 10.3390/ma10101110
   Cui QJ, 2013, CURR PHARM DESIGN, V19, P3374, DOI 10.2174/1381612811319190004
   Cunniffe GM, 2016, ACS APPL MATER INTER, V8, P23477, DOI 10.1021/acsami.6b06596
   Díaz E, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7070173
   Ferreira AM, 2012, ACTA BIOMATER, V8, P3191, DOI 10.1016/j.actbio.2012.06.014
   Hoshi Kazuto, 2000, Acta Anatomica Nipponica, V75, P457
   Hu JZ, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 114
   Hu K, 2017, DEV DYNAM, V246, P227, DOI 10.1002/dvdy.24463
   Jaganathan KS, 2005, INT J PHARMACEUT, V294, P23, DOI 10.1016/j.ijpharm.2004.12.026
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kang EJ, 2013, INT J ORAL MAX IMPL, V28, P749, DOI 10.11607/jomi.2825
   Kapoor DN, 2015, THER DELIV, V6, P41, DOI [10.4155/TDE.14.91, 10.4155/tde.14.91]
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Li B, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/2869572
   Li CJ, 2015, J CELL PHYSIOL, V230, P2671, DOI 10.1002/jcp.24983
   Luginbuehl V, 2004, EUR J PHARM BIOPHARM, V58, P197, DOI 10.1016/j.ejpb.2004.03.004
   Mai ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061600
   Mathieu M, 2013, BONE, V53, P391, DOI 10.1016/j.bone.2013.01.005
   Merceron C, 2011, CELL TRANSPLANT, V20, P1575, DOI 10.3727/096368910X557191
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Mukherjee A, 2010, MOL CELL BIOL, V30, P1018, DOI 10.1128/MCB.01401 09
   Nie DM, 2015, J HUAZHONG U SCI MED, V35, P694, DOI 10.1007/s11596 015 1492 4
   Padmanabhan SK, 2015, J NANOSCI NANOTECHNO, V15, P504, DOI 10.1166/jnn.2015.9489
   Rau JV, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3741428
   Rosset P, 2014, ORTHOP TRAUMATOL SUR, V100, pS107, DOI 10.1016/j.otsr.2013.11.010
   Ruan SQ, 2017, INT ORTHOP, V41, P1899, DOI 10.1007/s00264 017 3522 2
   Sarker B, 2015, ADV HEALTHC MATER, V4, P176, DOI 10.1002/adhm.201400302
   Sharmin F, 2017, J ORTHOP RES, V35, P1086, DOI 10.1002/jor.23287
   Subbiah R, 2015, ADV HEALTHC MATER, V4, P1982, DOI 10.1002/adhm.201500341
   Wang JH, 2016, MAT SCI ENG C MATER, V61, P705, DOI 10.1016/j.msec.2015.12.097
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang DW, 2018, BIOACT MATER, V3, P129, DOI 10.1016/j.bioactmat.2017.08.004
   Zhou J, 2017, COLLOID SURFACE B, V152, P124, DOI 10.1016/j.colsurfb.2016.12.041
NR 41
TC 31
Z9 34
U1 0
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2018
VL 2018
AR 3516463
DI 10.1155/2018/3516463
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA GW2TJ
UT WOS:000446738800001
PM 30345299
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Kapadia, RA
   Guntur, AR
   Reinhold, MI
   Naski, MC
AF Kapadia, RA
   Guntur, AR
   Reinhold, MI
   Naski, MC
TI Glycogen synthase kinase 3 controls endochondral bone development:
   Contribution of fibroblast growth factor 18
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE glycogen synthase kinase; FGF18; bone; cartilage; chondrocyte;
   beta catenin
ID FIBROBLAST GROWTH FACTOR; GLYCOGEN SYNTHASE KINASE 3; SYNOVIAL JOINT
   FORMATION; FACTOR RECEPTOR 3 GENE; INDIAN HEDGEHOG; CHONDROCYTE
   DIFFERENTIATION; TERMINAL DIFFERENTIATION; CUBITUS INTERRUPTUS; NEGATIVE
   REGULATOR; SIGNALING PATHWAY
AB Glycogen synthase kinase 3 (GSK3) inhibits signaling pathways that are essential for bone development. To study the requirement for GSK activity during endochondral bone development, we inhibited GSK3 in cultured metatarsal bones with pharmacological antagonists. Interestingly, we find that inhibition of GSK3 strongly repressed chondrocyte and perichondrial osteoblast differentiation. Moreover, chondrocyte proliferation was inhibited, whereas perichondrial cell proliferation was stimulated. These results mirror the effects of fibroblast growth factor signaling (FGF), suggesting the FGF expression is induced. Indeed, we showed that (1) FGF18 expression is stimulated following inhibition of GSK3 and (2) GSK3 regulates FGF18 expression through the control of beta catenin levels. Stimulation of cultured metatarsal with FGF18 had similar effects on the differentiation and proliferation of chondrocytes and perichondrial cells as GSK3 repression. This suggests that the regulation of FGF18 expression is a major function of GSK3 during endochondral bone development. Consistent with this, we showed that the effect of GSK3 inhibition on chondrocyte proliferation is repressed in tissues lacking a receptor for FGF18, FGF receptor 3. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Naski, MC (通讯作者)，Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM naski@uthscsa.edu
CR Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Ballock RT, 2003, J BONE JOINT SURG AM, V85A, P715, DOI 10.2106/00004623 200304000 00021
   Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903
   Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930
   BOHME K, 1995, EXP CELL RES, V216, P191, DOI 10.1006/excr.1995.1024
   Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496 390
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092 8674(00)81069 7
   DIEUDONNE SC, 1994, J BONE MINER RES, V9, P771
   Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597
   Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097 2765(01)00253 2
   Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301
   Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704
   Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092 8674(01)00222 7
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432 1033.1981.tb05628.x
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733
   KATO Y, 1990, J BIOL CHEM, V265, P5903
   Kawakami Y, 2001, CELL, V104, P891, DOI 10.1016/S0092 8674(01)00285 9
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35
   Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602
   Mancilla EE, 1998, ENDOCRINOLOGY, V139, P2900, DOI 10.1210/en.139.6.2900
   McEwen DG, 1999, J BIOL CHEM, V274, P30934, DOI 10.1074/jbc.274.43.30934
   Naski MC, 1998, DEVELOPMENT, V125, P4977
   Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200
   OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216
   OBERLENDER SA, 1994, DEVELOPMENT, V120, P177
   Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702
   Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097 2765(00)00053 8
   Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092 8674(02)00664 5
   Reinhold MI, 2004, MOL ENDOCRINOL, V18, P241, DOI 10.1210/me.2003 0312
   Reinhold MI, 2004, J BIOL CHEM, V279, P38209, DOI 10.1074/jbc.M404855200
   Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169
   Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a
   Serra R, 1999, J CELL BIOL, V145, P783, DOI 10.1083/jcb.145.4.783
   Shima K, 2003, IEEE T ENERGY CONVER, V18, P63, DOI 10.1109/TEC.2002.808337
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960 9822(02)70790 2
   Tomita M, 2002, J BIOL CHEM, V277, P42214, DOI 10.1074/jbc.C200504200
   van der Eerden BCJ, 2003, ENDOCR REV, V24, P782, DOI 10.1210/er.2002 0033
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   WOODGETT JR, 2001, SCI STKE, pRE12
   Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324
NR 55
TC 29
Z9 36
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0012 1606
EI 1095 564X
J9 DEV BIOL
JI Dev. Biol.
PD SEP 15
PY 2005
VL 285
IS 2
BP 496
EP 507
DI 10.1016/j.ydbio.2005.07.029
PG 12
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA 974ES
UT WOS:000232574700016
PM 16109394
DA 2025 08 17
ER

PT J
AU Hofmann, A
   Ritz, U
   Hessmann, MH
   Schmid, C
   Tresch, A
   Rompe, JD
   Meurer, A
   Rommens, PM
AF Hofmann, A.
   Ritz, U.
   Hessmann, M. H.
   Schmid, C.
   Tresch, A.
   Rompe, J. D.
   Meurer, A.
   Rommens, P. M.
TI Cell viability, osteoblast differentiation, and gene expression are
   altered in human osteoblasts from hypertrophic fracture non unions
SO BONE
LA English
DT Article
DE fracture healing; fracture non union; microarray; osteoblast; gene
   expression
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; IGF BINDING
   PROTEIN 5; MATURE OSTEOBLASTS; BETA CATENIN; SAMPLE SIZE; GROWTH; WNT;
   RAT; MARROW
AB Recent studies have provided evidence that the number and proliferation capacity of bone marrow derived mesenchymal stem cells, as well as the number of osteoprogenitor cells are reduced in patients with fracture non unions. For fracture non unions that do not heal after appropriate surgical intervention, the question arises as to what extent systemic cellular dysfunctions should be considered as being pathogenetic factors. For this purpose, we have examined the hypothesis that the cell function of osteoblasts isolated from patients with fracture non unions may differ from those of normal control individuals in an identical and controlled in vitro situation. We analyzed the osteoblast cell viability, formation of alkaline phosphatase positive (CFU ALP) and mineralization positive (CFU M) colony forming units, as well as global differences of gene expression in osteoblasts from patients with fracture non unions and from control individuals. We found that cell viability and CFU M formation were significantly reduced in non union osteoblasts. This was accompanied by significant differences in osteoblast gene expression as revealed by Affymetrix microarray analysis and RT PCR. We identified a set of significantly down regulated factors in non union osteoblasts that are involved in regulation of osteoblast proliferation and differentiation processes (canonical Wnt , IGF , TGF beta , and FGF signaling pathways). The results of the present study strongly support the hypothesis that cell viability, differentiation, and gene expression of osteoblasts may be altered in patients who develop recurrent and recalcitrant fracture non unions. Proteins involved in Wnt , IGF, TGF beta , and FGF signaling pathways may be of particular interest and may unveil new potential therapies. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Hofmann, A.; Ritz, U.; Hessmann, M. H.; Schmid, C.; Rommens, P. M.] Johannes Gutenberg Univ Mainz, Sch Med, Dept Trauma Surg, D 55101 Mainz, Germany.
   [Tresch, A.] Johannes Gutenberg Univ Mainz, Sch Med, IMBEI, Mainz, Germany.
   [Rompe, J. D.] OrthoTrauma Evaluat Ctr, Mainz, Germany.
   [Meurer, A.] Johannes Gutenberg Univ Mainz, Sch Med, Dept Orthopaed Surg, Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; Johannes Gutenberg University of Mainz
RP Hofmann, A (通讯作者)，Johannes Gutenberg Univ Mainz, Sch Med, Dept Trauma Surg, Langenbeckstr 1, D 55101 Mainz, Germany.
EM Hofmann.trauma surgery@gmx.net
RI Ritz, Ulrike/N 6871 2016; Hofmann, Alexander/C 3943 2013
OI Meurer, Andrea M./0000 0002 1878 9551
CR Amaar YG, 2006, AM J PHYSIOL CELL PH, V290, pC900, DOI 10.1152/ajpcell.00563.2004
   ANDRESS DL, 1995, J BIOL CHEM, V270, P28289
   ANDRESS DL, 1992, J BIOL CHEM, V267, P22467
   BENTZ H, 1991, MATRIX, V11, P269, DOI 10.1016/S0934 8832(11)80234 9
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Caetano AR, 2004, GENETICS, V168, P1529, DOI 10.1534/genetics.104.029595
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034
   Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dobbin K, 2005, BIOSTATISTICS, V6, P27, DOI 10.1093/biostatistics/kxh015
   ENNEKING WF, 1980, J BONE JOINT SURG AM, V62, P1039, DOI 10.2106/00004623 198062070 00001
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Fuchs S, 2007, TISSUE ENG, V13, P2577, DOI 10.1089/ten.2007.0022
   Gagliardi AD, 2005, AM J PHYSIOL ENDOC M, V288, pE92, DOI 10.1152/ajpendo.00268.2004
   Gangji V, 1998, ENDOCRINOLOGY, V139, P2287, DOI 10.1210/en.139.5.2287
   Ge GX, 2004, J BIOL CHEM, V279, P41626, DOI 10.1074/jbc.M406630200
   GERIS L, 2007, J THEOR BIOL
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356
   Han ES, 2004, J GERONTOL A BIOL, V59, P306
   Hernigou P, 1997, REV CHIR ORTHOP, V83, P33
   Hofmann A, 2005, J ORTHOP RES, V23, P846, DOI 10.1016/j.orthres.2004.11.012
   Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761
   Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766
   JOHNSON EE, 1987, J BONE JOINT SURG AM, V69A, P375
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151
   Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102
   Kendziorski CM, 2003, BIOSTATISTICS, V4, P465, DOI 10.1093/biostatistics/4.3.465
   Kerr M Kathleen, 2003, Methods Mol Biol, V224, P137
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Kutz WE, 2005, MOL CELL BIOL, V25, P414, DOI 10.1128/MCB.25.1.414 421.2005
   Kveiborg M, 2002, APMIS, V110, P410, DOI 10.1034/j.1600 0463.2002.100507.x
   Lawton DM, 1999, J CLIN PATHOL MOL PA, V52, P92, DOI 10.1136/mp.52.2.92
   Lawton DM, 1997, J CLIN PATHOL MOL PA, V50, P194, DOI 10.1136/mp.50.4.194
   Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182
   Meyer RA, 2007, BONE, V40, P1554, DOI 10.1016/j.bone.2007.01.013
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Murphy D, 2002, ADV PHYSIOL EDUC, V26, P256, DOI 10.1152/advan.00043.2002
   Panagiotis M, 2005, INJURY, V36, pS30, DOI 10.1016/j.injury.2005.10.008
   Peng XJ, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 26
   Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717
   Perinpanayagam H, 2001, J ORTHOPAED RES, V19, P993, DOI 10.1016/S0736 0266(01)00045 6
   Ramstad VE, 2003, CALCIFIED TISSUE INT, V72, P57, DOI 10.1007/s00223 002 2047 9
   Seebach C, 2007, CALCIFIED TISSUE INT, V80, P294, DOI 10.1007/s00223 007 9020 6
   Silha JV, 2003, J BONE MINER RES, V18, P1834, DOI 10.1359/jbmr.2003.18.10.1834
   Soucacos PN, 2006, INJURY, V37, pS41, DOI 10.1016/j.injury.2006.02.040
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471 213X 2 8
   Yoshiko Y, 1997, MOL BIOL CELL, V8, P2516
   Yoshiko Y, 1999, ENDOCRINOLOGY, V140, P1869, DOI 10.1210/en.140.4.1869
   Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003 0130
   Yoshioka S, 2006, BIOCHEM BIOPH RES CO, V341, P88, DOI 10.1016/j.bbrc.2005.12.157
   Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491
NR 59
TC 58
Z9 65
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2008
VL 42
IS 5
BP 894
EP 906
DI 10.1016/j.bone.2008.01.013
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 292IQ
UT WOS:000255260100008
PM 18314404
DA 2025 08 17
ER

PT J
AU Zhang, YX
   Ma, C
   Liu, XQ
   Wu, ZK
   Yan, P
   Ma, N
   Fan, QM
   Zhao, QH
AF Zhang, Yongxing
   Ma, Chao
   Liu, Xuqiang
   Wu, Zhenkai
   Yan, Peng
   Ma, Nan
   Fan, Qiming
   Zhao, Qinghua
TI Epigenetic landscape in PPARγ2 in the enhancement of adipogenesis of
   mouse osteoporotic bone marrow stromal cell
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Osteoporosis; PPAR gamma; Adipogenesis; Epigenetics; Bone marrow stromal
   cells; beta Catenin
ID PROTEIN RESTRICTED DIET; MESENCHYMAL STEM CELLS; FAT CONTENT; ADIPOCYTE
   DIFFERENTIATION; CHROMATIN MODIFICATIONS; DNA METHYLATION; PREGNANT
   RATS; EXPRESSION; OSTEOGENESIS; PROMOTER
AB Osteoporosis is one of the most prevalent skeletal system diseases; yet, its pathophysiological mechanisms remain elusive. Adipocytes accumulate remarkably in the bone marrow of osteoporotic patients. The potential processes and molecular mechanisms underlying adipogenesis in osteoporotic BMSCs have attracted significant attention as adipocytes and osteoblasts share common precursor cells. Some environmental factors influence bone mass through epigenetic mechanisms; however, the role of epigenetic modifications in osteoporosis is just beginning to be investigated, and there is still little data regarding their involvement In the current study, we investigated how epigenetic modifications, including DNA methylation and histone modifications, lead to adipogenesis in the bone marrow during osteoporosis. A glucocorticoid induced osteoporosis (GIO) mouse model was established, and BMSCs were isolated from the bone marrow. Compared with normal BMSCs, osteoporotic BMSCs had significantly increased adipogenesis potential and decreased osteogenesis potential. In osteoporotic BMSCs, PPAR gamma 2 regulatory region DNA hypo methylation, histone 3 and 4 hyper acetylation and H3K9 hypodi methylation were observed. These epigenetic modifications were involved not only in PPAR gamma 2 expression but also in osteoporotic BMSC adipogenic differentiation potential. We also found that Wnt/beta catenin signal played an important role in the establishment and maintenance of epigenetic modifications at PPAR gamma 2 promoter in osteoporotic BMSCs. Finally, we inhibited adipogenesis and rescued osteogenesis of osteoporotic BMSCs by modulating those epigenetic modifications. Our study provides a deeper insight into the pathophysiology of osteoporosis and identifies PPAR gamma 2 as a new target for osteoporosis therapy based on epigenetic mechanisms. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Yongxing; Yan, Peng; Zhao, Qinghua] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Orthopaed, Shanghai 200080, Peoples R China.
   [Ma, Chao] XuZhou Cent Hosp, Dept Spine Surg, Xuzhou 221009, Jiangsu, Peoples R China.
   [Liu, Xuqiang] Nanchang Univ, Affiliated Hosp 1, Dept Orthopaed, Nanchang 330019, Jiangxi, Peoples R China.
   [Wu, Zhenkai] Shanghai Jiao Tong Univ, Sch Med, Shanghai XinHua Hosp, Dept Pediat Orthopaed, Shanghai 200092, Peoples R China.
   [Ma, Nan] Univ Rostock, Dept Cardiac Surg, D 18055 Rostock, Germany.
   [Fan, Qiming] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthoped Surg,Shanghai Key Lab Orthoped Impl, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Nanchang University; Shanghai Jiao Tong
   University; University of Rostock; Shanghai Jiao Tong University
RP Fan, QM (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthoped Surg,Shanghai Key Lab Orthoped Impl, Shanghai 200011, Peoples R China.
EM chillow@163.com; sawboneszhao@163.com
RI Zhang, Yongxing/GZL 1366 2022; Ma, Nan/L 1282 2013
OI Ma, Nan/0000 0003 4006 1003
FU National Natural Science Foundation of China [81000778, 81370050];
   Municipal Natural Science Foundation of Shanghai [14ZR1433100]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81000778 and 81370050) and the Municipal Natural
   Science Foundation of Shanghai (No. 14ZR1433100).
CR Blake GM, 2009, BONE, V44, P495, DOI 10.1016/j.bone.2008.11.003
   CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538
   Esteller Manel, 2011, Genes Cancer, V2, P604, DOI 10.1177/1947601911423096
   Fan QM, 2012, J PATHOL, V228, P45, DOI 10.1002/path.4033
   Fan QM, 2009, J CELL MOL MED, V13, P2489, DOI 10.1111/j.1582 4934.2008.00606.x
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Griffith JF, 2005, RADIOLOGY, V236, P945, DOI 10.1148/radiol.2363041425
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Heijmans BT, 2009, EPIGENETICS US, V4, P526, DOI 10.4161/epi.4.8.10265
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krings A, 2012, BONE, V50, P546, DOI 10.1016/j.bone.2011.06.016
   La Thangue NB, 2004, J CHEMOTHERAPY, V16, P64, DOI 10.1179/joc.2004.16.Supplement 1.64
   Lecka Czernik B, 2012, BONE, V50, P534, DOI 10.1016/j.bone.2011.06.032
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382
   Lillycrop KA, 2008, BRIT J NUTR, V100, P278, DOI 10.1017/S0007114507894438
   Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X
   MELTON LJ, 1995, J BONE MINER RES, V10, P175
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Musri MM, 2010, J BIOL CHEM, V285, P30034, DOI 10.1074/jbc.M110.151209
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Rodríguez JP, 2008, CURR STEM CELL RES T, V3, P208, DOI 10.2174/157488808785740325
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Santos FPS, 2010, EXPERT REV ANTICANC, V10, P9, DOI [10.1586/era.09.164, 10.1586/ERA.09.164]
   Santos Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Shoback D, 2007, J CLIN ENDOCR METAB, V92, P747, DOI 10.1210/jc.2007 0042
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Steger DJ, 2010, GENE DEV, V24, P1035, DOI 10.1101/gad.1907110
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092 8674(94)90006 X
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   van Beekum O, 2008, ENDOCRINOLOGY, V149, P1840, DOI 10.1210/en.2007 0977
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168
   Yeung DKW, 2005, J MAGN RESON IMAGING, V22, P279, DOI 10.1002/jmri.20367
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
   Zhang QY, 2012, CELL CYCLE, V11, P4310, DOI 10.4161/cc.22224
   Zhang Y.X., 2015, J BIOCH
   Zhao QH, 2013, FEBS J, V280, P5801, DOI 10.1111/febs.12500
NR 46
TC 23
Z9 28
U1 1
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925 4439
EI 1879 260X
J9 BBA MOL BASIS DIS
JI Biochim. Biophys. Acta Mol. Basis Dis.
PD NOV
PY 2015
VL 1852
IS 11
BP 2504
EP 2516
DI 10.1016/j.bbadis.2015.08.020
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CS5QJ
UT WOS:000362132700017
PM 26319419
OA Bronze
DA 2025 08 17
ER

PT J
AU Kaur, H
   Siraki, AG
   Sharma, M
   Uludag, H
   Dederich, DN
   Flood, P
   El Bialy, T
AF Kaur, Harmanpreet
   Siraki, Arno G.
   Sharma, Monika
   Uludag, Hasan
   Dederich, Douglas N.
   Flood, Patrick
   El Bialy, Tarek
TI REACTIVE OXYGEN SPECIES MEDIATE THERAPEUTIC ULTRASOUND INDUCED,
   MITOGEN ACTIVATED PROTEIN KINASE ACTIVATION IN C28/I2 CHONDROCYTES
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Reactive oxygen species; Superoxide; Chondrocytes; Low intensity pulsed
   ultrasound
ID INTENSITY PULSED ULTRASOUND; MECHANOTRANSDUCTION PATHWAY; MANDIBULAR
   CONDYLE; HUMAN OSTEOBLASTS; NADPH OXIDASE; NITRIC OXIDE; CELL GROWTH;
   IN VITRO; DIPHENYLENEIODONIUM; DIFFERENTIATION
AB Low intensity pulsed ultrasound (LIPUS) has been used for the treatment of non healing fractures because of its therapeutic properties of stimulating enhancing endochondral bone formation. However, its mechanism of action remains unclear. In this study, we hypothesized that LIPUS activates mitogen activated protein kinases through generation of reactive oxygen species. C28/I2 cells were stimulated with LIPUS for 10 and 20 min, while the control group was treated using a sham LIPUS transducer. Through quantitative reverse transcription polymerase chain reaction and immunoblot analyses, we determined that LIPUS application increased reactive oxygen species generation and cell viability in C28/I2 cells. There were increases in the phosphorylation level of ERK1/2 and in expression of SOX9, COL2 A1 and ACAN genes. These effects were reversed when cells were treated with diphenylene iodonium, which is known to inhibit NADPH oxidase. It was concluded that exposure of chondrocytes to LIPUS led to reactive oxygen species generation, which activated MAPK signaling and further increased chondrocyte specific gene markers involved in chondrocyte differentiation and extracellular matrix formation. (C) 2018 World Federation for Ultrasound in Medicine & Biology. All rights reserved.
C1 [Kaur, Harmanpreet; Dederich, Douglas N.; Flood, Patrick; El Bialy, Tarek] Univ Alberta, Dept Dent, Edmonton, AB, Canada.
   [Siraki, Arno G.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada.
   [Sharma, Monika] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.
   [Uludag, Hasan] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB, Canada.
C3 University of Alberta; University of Alberta; University of Alberta;
   University of Alberta
RP Kaur, H (通讯作者)，Univ Alberta, Ctr Pharm & Hlth Res, 7 020 Katz Grp, Edmonton, AB T6G 2E1, Canada.
EM kaur3@ualberta.ca
RI KAUR, HARMANPREET/HJJ 0554 2023
OI Siraki, Arno/0000 0001 8317 947X; Sharma, Monika/0000 0002 7258 1399
FU McIntyre Fund, Division of Orthodontics, Department of Dentistry,
   Faculty of Medicine and Dentistry, University of Alberta; Dr. Hasan
   Uludag, Department of Biomedical Engineering, Department of Chemical and
   Material Engineering, University of Alberta
FX This study was supported in part by the McIntyre Fund, Division of
   Orthodontics, Department of Dentistry, Faculty of Medicine and
   Dentistry, University of Alberta, and Dr. Hasan Uludag, Department of
   Biomedical Engineering, Department of Chemical and Material Engineering,
   University of Alberta.
CR Bartosz G, 2009, BIOCHEM PHARMACOL, V77, P1303, DOI 10.1016/j.bcp.2008.11.009
   Boutros T, 2008, PHARMACOL REV, V60, P261, DOI 10.1124/pr.107.00106
   Busse JW, 2009, BMJ BRIT MED J, V338, DOI 10.1136/bmj.b351
   Cheng K, 2014, ULTRASOUND MED BIOL, V40, P1609, DOI 10.1016/j.ultrasmedbio.2014.03.002
   Cheung WH, 2011, ULTRASOUND MED BIOL, V37, P231, DOI 10.1016/j.ultrasmedbio.2010.11.016
   Choi BH, 2007, P I MECH ENG H, V221, P527, DOI 10.1243/09544119JEIM201
   El Bialy T, 2010, TISSUE ENG PART C ME, V16, P1315, DOI 10.1089/ten.TEC.2009.0564
   Fanghänel J, 2007, ANN ANAT, V189, P314, DOI 10.1016/j.aanat.2007.02.024
   Fujisawa T, 2007, MOL BIOTECHNOL, V37, P13, DOI 10.1007/s12033 007 0053 x
   Hasanova GI, 2011, J TISSUE ENG REGEN M, V5, P815, DOI 10.1002/term.384
   Hsu SH, 2004, BIOMOL ENG, V21, P99, DOI 10.1016/j.bioeng.2004.06.001
   Ikeda K, 2006, LIFE SCI, V79, P1936, DOI 10.1016/j.lfs.2006.06.029
   Jortikka MO, 1997, ANN RHEUM DIS, V56, P255, DOI 10.1136/ard.56.4.255
   Kaur H, 2017, ULTRASOUND MED BIOL, V43, P2699, DOI 10.1016/j.ultrasmedbio.2017.07.002
   Kaur H, 2017, J ULTRAS MED, V36, P109, DOI 10.7863/ultra.15.06063
   Kuroda S, 2009, OSTEOARTHR CARTILAGE, V17, P1408, DOI 10.1016/j.joca.2009.04.025
   Kusuyama J, 2014, J BIOL CHEM, V289, P10330, DOI 10.1074/jbc.M113.546382
   Leskinen JJ, 2012, ULTRASOUND MED BIOL, V38, P777, DOI 10.1016/j.ultrasmedbio.2012.01.019
   Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891 5849(02)01325 4
   MAJANDER A, 1994, J BIOL CHEM, V269, P21037
   Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023
   Morita K, 2007, J EXP MED, V204, P1613, DOI 10.1084/jem.20062525
   MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301 5629(88)90111 1
   Oralová V, 2015, BONE, V76, P97, DOI 10.1016/j.bone.2015.02.031
   Peshavariya HM, 2007, FREE RADICAL RES, V41, P699, DOI 10.1080/10715760701297354
   Plotnikov A, 2011, BBA MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Sanders SA, 1997, EUR J BIOCHEM, V245, P541, DOI 10.1111/j.1432 1033.1997.00541.x
   Sato H, 2005, AM J ORTHOD DENTOFAC, V128, P766, DOI 10.1016/j.ajodo.2005.05.046
   Sato M, 2014, ANN BIOMED ENG, V42, P2156, DOI 10.1007/s10439 014 1081 x
   Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804
   Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978 0 12 405881 1.00002 1
   STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974
   Takeuchi R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2451
   Tanaka E, 2015, ANN BIOMED ENG, V43, P871, DOI 10.1007/s10439 015 1274 y
   Tazzeo T, 2009, BRIT J PHARMACOL, V158, P790, DOI 10.1111/j.1476 5381.2009.00394.x
   Uddin SMZ, 2013, ULTRASOUND MED BIOL, V39, P804, DOI 10.1016/j.ultrasmedbio.2012.11.016
   Whitney NP, 2012, ULTRASOUND MED BIOL, V38, P1734, DOI 10.1016/j.ultrasmedbio.2012.06.002
   Xue H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0074366, 10.1371/journal.pone.0068926]
NR 39
TC 4
Z9 4
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD OCT
PY 2018
VL 44
IS 10
BP 2105
EP 2114
DI 10.1016/j.ultrasmedbio.2018.05.025
PG 10
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA GS8GW
UT WOS:000443947900004
PM 30037475
DA 2025 08 17
ER

PT J
AU Huston, A
   Leleu, X
   Jia, XY
   Moreau, AS
   Ngo, HT
   Runnels, J
   Anderson, J
   Alsayed, Y
   Roccaro, A
   Vallet, S
   Hatjiharissi, E
   Tai, YT
   Sportelli, P
   Munshi, N
   Richardson, P
   Hideshima, T
   Roodman, DG
   Anderson, KC
   Ghobrial, IM
AF Huston, Alissa
   Leleu, Xavier
   Jia, Xiaoying
   Moreau, Anne Sophie
   Ngo, Hai T.
   Runnels, Judith
   Anderson, Judy
   Alsayed, Yazan
   Roccaro, Aldo
   Vallet, Sonia
   Hatjiharissi, Evdoxia
   Tai, Yu Tsu
   Sportelli, Peter
   Munshi, Nikhil
   Richardson, Paul
   Hideshima, Teru
   Roodman, David G.
   Anderson, Kenneth C.
   Ghobrial, Irene M.
TI Targeting Akt and heat shock protein 90 produces synergistic multiple
   myeloma cell cytotoxicity in the bone marrow microenvironment
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GROWTH FACTOR I; MAMMALIAN TARGET; PHOSPHATIDYLINOSITOL 3 KINASE/AKT;
   MTOR INHIBITORS; SURVIVAL; PATHWAY; KINASE; ROLES; PROLIFERATION;
   EXPRESSION
AB Purpose: We hypothesized that targeting both Akt and heat shock protein (HSP) 90 would induce cytotoxic activity against multiple myeloma (MM) cells and target the bone marrow (BM) microenvironment to inhibit angiogenesis, osteoclast formation, as well as migration and adhesion of MM cells.
   Experimental Design: MM cell lines were incubated with perifosine (5 and 10 mu mol/L) and 17 (dimethylaminoethylamino) 17 demethoxygeldanamycin (17 DMAG; 50 and 100 nmol/L) alone and in combination.
   Results: The combination of Akt inhibitor perifosine and HSP90 inhibitor 17 DMAG was synergistic in inducing MM cell cytotoxicity, evidenced by inhibition of DNA synthesis and induction of apoptosis. In addition, perifosine and 17 DMAG almost completely inhibited osteoclast formation: perifosine interfered with both early and late stages of osteoclast progenitor development, whereas 17 DMAG targeted only early stages: We next showed that combined therapy overcomes tumor growth and resistance induced by BM stromal cells and endothelial cells as well as the proliferative effect of exogenous interleukin 6, insulin like growth factor I, and vascular endothelial growth factor. Moreover, the combination also induced apoptosis and growth inhibition in endothelial cells and inhibited angiogenesis. Finally, we showed that the two agents prevented migration of MM cells toward stromal derived factor 1 and vascular endothelial growth factor, which are present in the BM milieu, and also prevented adhesion of MM cells to fibronectin.
   Conclusions: This study provides the preclinical framework for treatment protocols targeting both the Akt and HSP pathways in MM.
C1 [Leleu, Xavier; Jia, Xiaoying; Moreau, Anne Sophie; Ngo, Hai T.; Runnels, Judith; Roccaro, Aldo; Vallet, Sonia; Hatjiharissi, Evdoxia; Tai, Yu Tsu; Munshi, Nikhil; Richardson, Paul; Hideshima, Teru; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Huston, Alissa; Anderson, Judy; Alsayed, Yazan] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA.
   [Leleu, Xavier; Jia, Xiaoying; Moreau, Anne Sophie; Ngo, Hai T.; Runnels, Judith; Roccaro, Aldo; Vallet, Sonia; Hatjiharissi, Evdoxia; Tai, Yu Tsu; Munshi, Nikhil; Richardson, Paul; Hideshima, Teru; Anderson, Kenneth C.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA USA.
   [Leleu, Xavier; Moreau, Anne Sophie] CHRU, Serv Malad Sang, Lille, France.
   [Leleu, Xavier; Moreau, Anne Sophie] CHRU, Immunol Lab, Lille, France.
   [Roodman, David G.] Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA.
   [Sportelli, Peter] Keryx Biopharmaceut, New York, NY USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; University of Rochester; Harvard University; Harvard
   Medical School; Universite de Lille; CHU Lille; Universite de Lille; CHU
   Lille; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Magee Womens Research Institute
RP Ghobrial, IM (通讯作者)，Dana Farber Canc Inst, 44 Binney St,Mayer 548A, Boston, MA 02115 USA.
EM irene_ghobrial@dfci.harvard.edu
RI Vallet, Sonia/AHE 3935 2022; Roccaro, Aldo/J 9252 2014; Anderson,
   Kenneth/ACP 5073 2022; LELEU, Xavier/ABP 5732 2022; Munshi,
   Nikhil/ABE 2338 2021; Hatjiharissi, Evdoxia/AAG 7425 2020
OI Vallet, Sonia/0000 0003 0146 8089; Roccaro, Aldo/0000 0002 1872 5128; 
CR Alexandrakis MG, 2004, CLIN CHEM LAB MED, V42, P1122, DOI 10.1515/CCLM.2004.230
   Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood 2006 07 035857
   Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163 7258(98)00013 8
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092 8674(00)80674 1
   Duus J, 2006, LEUKEMIA LYMPHOMA, V47, P1369, DOI 10.1080/10428190500472123
   Francis LK, 2006, CLIN CANCER RES, V12, P6826, DOI 10.1158/1078 0432.CCR 06 1331
   Frost P, 2007, ONCOGENE, V26, P2255, DOI 10.1038/sj.onc.1210019
   Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200
   Giuliani N, 2006, CURR PHARM BIOTECHNO, V7, P423, DOI 10.2174/138920106779116955
   Gupta Deepak, 2002, Rev Clin Exp Hematol, V6, P301, DOI 10.1046/j.1468 0734.2002.00082.x
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood 2005 08 3434
   Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232
   Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194
   Kaur G, 2004, CLIN CANCER RES, V10, P4813, DOI 10.1158/1078 0432.CCR 03 0795
   Kyle RA, 2004, CANCER AM CANCER SOC, V101, P2667, DOI 10.1002/cncr.20652
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Malozemoff A.P., 1990, HIGH TEMPERATURE SUP, P3
   McCollum AK, 2006, CANCER RES, V66, P10967, DOI 10.1158/0008 5472.CAN 06 1629
   Menu E, 2004, BRIT J CANCER, V90, P1076, DOI 10.1038/sj.bjc.6601613
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood 2005 03 1158
   Möller C, 2003, LEUKEMIA, V17, P203, DOI 10.1038/sj.leu.2402717
   Moreau AS, 2007, BLOOD, V109, P4964, DOI 10.1182/blood 2006 10 054577
   Oba Y, 2005, EXP HEMATOL, V33, P272, DOI 10.1016/j.exphem.2004.11.015
   Pagnucco G, 2004, ANN NY ACAD SCI, V1028, P390, DOI 10.1196/annals.1322.047
   Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923
   Phekoo KJ, 2004, BRIT J HAEMATOL, V127, P299, DOI 10.1111/j.1365 2141.2004.05207.x
   Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood 2004 07 2909
   Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428
   Richardson P, 2006, BLOOD, V108, p124A
   Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008 5472.CAN 05 1195
   Ruiter GA, 2003, ANTI CANCER DRUG, V14, P167, DOI 10.1097/00001813 200302000 00011
   Sahara N, 2006, EXP HEMATOL, V34, P736, DOI 10.1016/j.exphem.2006.02.012
   Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535 7163.MCT 05 0068
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103
   Tai YT, 2003, CANCER RES, V63, P5850
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Tu YP, 2000, CANCER RES, V60, P6763
   Vanriet Ivan, 2005, Haematologica, V90, P436
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Zhang J, 2003, ONCOGENE, V22, P6289, DOI 10.1038/sj.onc.1206718
NR 45
TC 59
Z9 67
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2008
VL 14
IS 3
BP 865
EP 874
DI 10.1158/1078 0432.CCR 07 1299
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 258QK
UT WOS:000252882400034
PM 18245550
OA Bronze
DA 2025 08 17
ER

PT J
AU Kettenberger, U
   Ston, J
   Thein, E
   Procter, P
   Pioletti, DP
AF Kettenberger, Ulrike
   Ston, Julien
   Thein, Eric
   Procter, Philip
   Pioletti, Dominique P.
TI Does locally delivered Zoledronate influence pen implant bone formation?
     Spatio temporal monitoring of bone remodeling in vivo
SO BIOMATERIALS
LA English
DT Article
DE Drug delivery; Hydrogel; Bisphosphonate; Implant; Dynamic
   histomorphometry; MicroCT
ID BISPHOSPHONATE TREATMENT; OSTEOBLAST APOPTOSIS; TITANIUM IMPLANTS;
   CANCELLOUS BONE; PROXIMAL TIBIA; SCREW FIXATION; CORTICAL BONE; ACID;
   IMPROVES; MECHANISMS
AB Bisphosphonates are known for their strong inhibitory effect on bone resorption. Their influence on bone formation however is less clear. In this study we investigated the spatio temporal effect of locally delivered Zoledronate on pen implant bone formation and resorption in an ovariectomized rat femoral model. A cross linked hyaluronic acid hydrogel was loaded with the drug and applied bilaterally in predrilled holes before inserting polymer screws. Static and dynamic bone parameters were analyzed based on in vivo microCT scans performed first weekly and then biweekly. The results showed that the locally released Zoledronate boosted bone formation rate up to 100% during the first 17 days after implantation and reduced the bone resorption rate up to 1000% later on. This shift in bone remodeling resulted in an increase in bone volume fraction (BV/TV) by 300% close to the screw and 100% further away. The double effect on bone formation and resorption indicates a great potential of Zoledronateloaded hydrogel for enhancement of pen implant bone volume which is directly linked to improved implant fixation. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Kettenberger, Ulrike; Ston, Julien; Pioletti, Dominique P.] Ecole Polytech Fed Lausanne, Inst Bioengn, Lab Biomech Orthoped, CH 1015 Lausanne, Switzerland.
   [Thein, Eric] Univ Lausanne Hosp CHUV, Orthopaed & Traumatol Dept, Lausanne, Switzerland.
   [Procter, Philip] Uppsala Univ, Dept Engn Sci, Uppsala, Sweden.
C3 Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne; University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV); Uppsala University
RP Pioletti, DP (通讯作者)，Ecole Polytech Fed Lausanne, STI, IBI, LBO, Stn 19, CH 1015 Lausanne, Switzerland.
EM dominique.pioletti@epfl.ch
RI ; Procter, Philip/N 4714 2019; Pioletti, Dominique/C 5697 2008
OI Procter, Philip/0000 0002 3219 1177; Pioletti,
   Dominique/0000 0001 5535 5296; Ston, Julien/0000 0002 4853 2685
FU KTI grant [11098.1]
FX Special thanks to Sandra Jaccoud at the LBO for her assistance during
   surgeries and for the preparation of the histology slides. Thanks to
   Caroline Sieger Fernandes for the English proof reading of the
   manuscript. We benefited from the help of Prof. Brigitte von Rechenberg,
   Dr. Karina Klein and Dr. Salim Darwiche at the University of Zurich for
   the interpretation of the histology slides. This study was partially
   supported by a KTI grant (Project no. 11098.1).
CR Alghamdi HS, 2013, BIOMATERIALS, V34, P3747, DOI 10.1016/j.biomaterials.2013.02.033
   Allen MR, 2006, CALCIFIED TISSUE INT, V79, P255, DOI 10.1007/s00223 006 0031 5
   Amanat N, 2008, MED ENG PHYS, V30, P843, DOI 10.1016/j.medengphy.2007.09.008
   Andersson T, 2010, J MATER SCI MATER M, V21, P3029, DOI 10.1007/s10856 010 4154 x
   Arnoldi J, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 97
   Åstrand J, 2004, J ORTHOP RES, V22, P244, DOI 10.1016/j.orthres.2003.08.008
   Astrand J, 2006, BMC MUSCULOSKEL DIS, P7
   Back DA, 2012, BMC MUSCULOSKEL DIS, P13
   Belfrage O, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 240
   Bergman K, 2009, J BIOMED MATER RES A, V91A, P1111, DOI 10.1002/jbm.a.32289
   Bobyn JD, 2014, CLIN ORTHOP RELAT R, V472, P687, DOI 10.1007/s11999 013 3120 6
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Brouwers JEM, 2008, CALCIFIED TISSUE INT, V82, P202, DOI 10.1007/s00223 007 9084 3
   Brouwers JEM, 2007, J ORTHOP RES, V25, P1325, DOI 10.1002/jor.20439
   Cheng Q, 2013, PROCEEDINGS OF THE 2013 INTERNATIONAL CONFERENCE ON MATERIAL SCIENCE AND ENVIRONMENTAL ENGINEERING (MSEE 2013), P1
   Cottrell JA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/597641
   Ferretti A, 2002, ANAT EMBRYOL, V206, P21, DOI 10.1007/s00429 002 0265 6
   Franchi Marco, 2004, ScientificWorldJournal, V4, P1083
   Fuchs RK, 2008, J BONE MINER RES, V23, P1689, DOI [10.1359/jbmr.080501, 10.1359/JBMR.080501]
   Futami T, 2000, J PERIODONTOL, V71, P287, DOI 10.1902/jop.2000.71.2.287
   Gasser JA, 2008, J BONE MINER RES, V23, P544, DOI 10.1359/JBMR.071207
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Greiner S, 2007, J BIOMED MATER RES A, V80A, P769, DOI 10.1002/jbm.a.30950
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Hilding M, 2007, ACTA ORTHOP, V78, P795, DOI 10.1080/17453670710014572
   Hogan HA, 2000, J BONE MINER RES, V15, P284, DOI 10.1359/jbmr.2000.15.2.284
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Jakobsen T, 2010, CLIN ORTHOP RELAT R, V468, P867, DOI 10.1007/s11999 009 1099 9
   Kisiel M., 2013, Plos One, V8
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Marco F, 2005, MICRON, V36, P630, DOI 10.1016/j.micron.2005.07.008
   Martínez Alvarez C, 2013, J SURG RES, V183, P654, DOI 10.1016/j.jss.2013.03.009
   Martínez Sanz E, 2012, J TISSUE ENG REGEN M, V6, ps15, DOI 10.1002/term.1593
   McKenzie K, 2011, CLIN ORTHOP RELAT R, V469, P514, DOI 10.1007/s11999 010 1527 x
   Meyer U, 2004, BIOMATERIALS, V25, P1959, DOI 10.1016/j.biomaterials.2003.08.070
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pazianas M, 2010, THER CLIN RISK MANAG, V6, P325
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Probst A, 1997, J INVEST SURG, V10, P77, DOI 10.3109/08941939709032137
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roshan Ghias A, 2011, CLIN BIOMECH, V26, P1039, DOI 10.1016/j.clinbiomech.2011.06.004
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schulte FA, 2011, BONE, V48, P433, DOI 10.1016/j.bone.2010.10.007
   Seeman E, 2009, CRIT REV EUKAR GENE, V19, P219, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.40
   Srisubut S, 2007, ORAL SURG ORAL MED O, V104, pE11, DOI 10.1016/j.tripleo.2007.04.022
   Stadelmann VA, 2008, EUR CELLS MATER, V16, P10, DOI 10.22203/eCM.v016a02
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   TOBIAS JH, 1993, BONE, V14, P619, DOI 10.1016/8756 3282(93)90083 M
   Waarsing JH, 2004, BONE, V34, P163, DOI 10.1016/j.bone.2003.08.012
   WALKER KVR, 1972, CELL TISSUE KINET, V5, P409, DOI 10.1111/j.1365 2184.1972.tb00379.x
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Wirth AJ, 2012, J ORTHOP RES, V30, P178, DOI 10.1002/jor.21532
   Wirth AJ, 2011, BONE, V49, P473, DOI 10.1016/j.bone.2011.05.001
   Yakacki CM, 2010, J BIOMECH, V43, P1953, DOI 10.1016/j.jbiomech.2010.03.013
NR 62
TC 22
Z9 24
U1 1
U2 54
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2014
VL 35
IS 37
BP 9995
EP 10006
DI 10.1016/j.biomaterials.2014.09.005
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AR5QX
UT WOS:000343639700025
PM 25241159
OA Green Published
DA 2025 08 17
ER

PT J
AU Dalbeth, N
   Smith, T
   Nicolson, B
   Clark, B
   Callon, K
   Naot, D
   Haskard, DO
   McQueen, FM
   Reid, IR
   Cornish, J
AF Dalbeth, Nicola
   Smith, Timothy
   Nicolson, Bridget
   Clark, Barnaby
   Callon, Karen
   Naot, Dorit
   Haskard, Dorian O.
   McQueen, Fiona M.
   Reid, Ian R.
   Cornish, Jillian
TI Enhanced osteoclastogenesis in patients with tophaceous gout   Urate
   crystals promote osteoclast development through interactions with
   stromal cells
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID NECROSIS FACTOR ALPHA; RHEUMATOID ARTHRITIS; BONE RESORPTION;
   OSTEOPROTEGERIN LIGAND; DIFFERENTIATION FACTOR; MONOHYDRATE CRYSTALS;
   JOINT DESTRUCTION; HUMAN BLOOD; MACROPHAGES; INFLAMMATION
AB Objective. To analyze cellular mechanisms of bone erosion in gout.
   Methods. Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) from patients with gout were analyzed for the presence of osteoclast precursors. Fixed tophus and bone samples were analyzed by immunohistochemistry. Mechanisms of osteoclastogenesis were studied by culturing murine preosteoclast RAW 264.7 cells, bone marrow stromal ST2 cells, and human synovial fibroblasts with monosodium. urate monohydrate (MSU) crystals.
   Results. PBMCs from patients with severe erosive gout had the preferential ability to form osteoclast like cells in culture with RANKL and monocyte colony stimulating factor (M CSF). The number of PBMC derived tartrate resistant acid phosphatase (TRAP)positive multinucleated cells strongly correlated with the number of tophi (r = 0.6296, P = 0.630). Patients with severe erosive and tophaceous gout also had higher circulating concentrations of RANKL and M CSF. Furthermore, greater numbers of TRAP positive multinucleated cells were cultured from SFMCs derived from gouty knee effusions than from paired PBMCs (P = 0.004). Immunohistochemical Analysis demonstrated numerous multinucleated cells expressing osteoclast markers within tophi and at the interface between soft tissue and bone. MSU crystals did not directly promote osteoclast formation from RAW 264.7 cells in vitro. However, MSU crystals inhibited osteoprotegerin gene and protein expression in ST2 cells and human synovial fibroblasts, without significantly altering RANKL gene expression. Conditioned medium from ST2 cells cultured with MSU crystals promoted osteoclast formation from RAW 264.7 cells in the presence of RANKL.
   Conclusion. Chronic tophaceous and erosive gout is characterized by enhanced osteoclast development. These data provide a rationale for the study of osteoclast targeted therapies for the prevention of bone damage in chronic gout.
C1 [Dalbeth, Nicola; Smith, Timothy; Nicolson, Bridget; Clark, Barnaby; Callon, Karen; Naot, Dorit; McQueen, Fiona M.; Reid, Ian R.; Cornish, Jillian] Univ Auckland, Dept Med, Bone Res Grp, Fac Med & Hlth Sci, Auckland, New Zealand.
   [Haskard, Dorian O.] Univ London Imperial Coll Sci Technol & Med, London, England.
C3 University of Auckland; Imperial College London
RP Dalbeth, N (通讯作者)，Univ Auckland, Dept Med, Bone Res Grp, Fac Med & Hlth Sci, 85 Pk Rd, Auckland, New Zealand.
EM n.dalbeth@auckland.ac.nz
OI Naot, Dorit/0000 0001 9498 2639; Reid, Ian/0000 0001 6021 5458
CR Adamopoulos IE, 2006, J PATHOL, V208, P35, DOI 10.1002/path.1891
   ALWAN WH, 1989, ANN RHEUM DIS, V48, P476, DOI 10.1136/ard.48.6.476
   BLOCH C, 1980, AM J ROENTGENOL, V134, P781, DOI 10.2214/ajr.134.4.781
   Bouchard L, 2002, J IMMUNOL, V168, P5310, DOI 10.4049/jimmunol.168.10.5310
   BRAILSFORD JF, 1959, BRIT J RADIOL, V32, P472, DOI 10.1259/0007 1285 32 379 472
   Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075
   Dalbeth N, 2007, RHEUMATOLOGY, V46, P1804, DOI 10.1093/rheumatology/kem246
   Dalbeth N, 2007, ARTHRIT RHEUM ARTHR, V57, P1067, DOI 10.1002/art.22891
   DENKO CW, 1976, J RHEUMATOL, V3, P54
   DIGIOVINE FS, 1991, J CLIN INVEST, V87, P1375, DOI 10.1172/JCI115142
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   GREGORETTI MG, 1995, LEUKEMIA, V9, P1392
   HASSELBACHER P, 1981, T ASSOC AM PHYSICIAN, V94, P243
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Hsieh MS, 2003, J CELL BIOCHEM, V89, P791, DOI 10.1002/jcb.10530
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Landis RC, 2002, ARTHRITIS RHEUM, V46, P3026, DOI 10.1002/art.10614
   Liu R, 2004, ARTHRITIS RHEUM, V50, P247, DOI 10.1002/art.11486
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   Neale SD, 2000, BONE, V27, P409, DOI 10.1016/S8756 3282(00)00345 8
   O'Gradaigh D, 2003, RHEUMATOLOGY, V42, P1429, DOI 10.1093/rheumatology/keg375
   PALMER DG, 1989, AM J CLIN PATHOL, V91, P190, DOI 10.1093/ajcp/91.2.190
   Pouliot M, 1998, BLOOD, V91, P1769, DOI 10.1182/blood.V91.5.1769.1769_1769_1776
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04 1823fje
   Sabokbar A, 1997, ANN RHEUM DIS, V56, P414, DOI 10.1136/ard.56.7.414
   Schweyer S, 2000, VIRCHOWS ARCH, V437, P534, DOI 10.1007/s004280000282
   Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365 2141.2000.02379.x
   Shen ZX, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1938
   Takano H, 2004, RHEUMATOLOGY, V43, P435, DOI 10.1093/rheumatology/keh077
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   WALLACE SL, 1977, ARTHRITIS RHEUM US, V20, P895, DOI 10.1002/art.1780200320
   WATT I, 1975, CLIN RADIOL, V26, P27, DOI 10.1016/S0009 9260(75)80004 3
   Yagnik DR, 2000, ARTHRITIS RHEUM, V43, P1779, DOI 10.1002/1529 0131(200008)43:8<1779::AID ANR14>3.0.CO;2 2
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 38
TC 120
Z9 128
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD JUN
PY 2008
VL 58
IS 6
BP 1854
EP 1865
DI 10.1002/art.23488
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 313EW
UT WOS:000256724900035
PM 18512794
DA 2025 08 17
ER

PT J
AU Feng, YL
   Tang, XL
AF Feng, Yan Ling
   Tang, Xu Lei
TI Effect of glucocorticoid induced oxidative stress on the expression of
   Cbfa1
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Glucocorticoids; Osteoblasts; Oxidative stress; Cbfa1; Osteoporosis
ID OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; GENE EXPRESSION;
   BONE FORMATION; CELL CULTURES; DEXAMETHASONE; RUNX2; RAT;
   MINERALIZATION; PATHWAYS
AB Glucocorticoids therapy is strongly limited since extended glucocorticoids can cause serious side effects, including increased susceptibility to develop the bone disease osteoporosis. Despite its side effects recognized importance to clinicians, seldom is known about how glucocorticoids directly impact bone forming osteoblasts. Previous studies showed that dexamethasone (DEX) induces excessive production of reactive oxygen species (ROS), and causes oxidative stress in rat hippocampal slice cultures. To assess the implications and investigate the mechanisms of glucocorticoid elicited osteoporosis, we hypothesize that DEX exposure induces oxidative stress which leads to decreased Cbfa1 mRNA expression, and predict that the antioxidant N acetylcysteine (NAC) mitigates the damaging effects of DEX. Oxidative stress is implicated in osteoporosis. Furthermore, the osteoblast transcriptional factor Cbfa1 is reported to play a protective role against osteoporosis in postmenopausal women. Cells treated with (0.1, 1, 10 mu M) DEX exhibited signs of oxidative damages including depletion in total antioxidant capacity (T AOC), increased ROS formation, and enhanced lipid peroxidation. Cbfa1 mRNA expression, by RT PCR, was significantly reduced after exposure to (0.1, 1, 10 mu M) DEX. Pretreatment with the antioxidant NAC (2 mM) prevented DEX induced decrease in Cbfa1 mRNA. This study provides insight into the underlying mechanisms of high dose DEX induced osteotoxicity. DEX (0.1, 1, 10 mu M) decreases the expression of Cbfa1 mRNA and inhibits differentiation and function of osteoblasts by inducing oxidative stress. The antioxidant NAC can mitigate the oxidative stress damaging effects of DEX. In addition, this study distinguishes itself by identifying Cbfa1 as a target for high dose DEX induced osteotoxicity. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Feng, Yan Ling; Tang, Xu Lei] Lanzhou Univ, Hosp 1, Lanzhou 730000, Peoples R China.
C3 Lanzhou University
RP Tang, XL (通讯作者)，Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 Donggang West Rd, Lanzhou 730000, Peoples R China.
EM xulei_tang@126.com
RI Feng, Y. L./E 2411 2017
CR Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Atmani H, 2003, J CELL BIOCHEM, V89, P364, DOI 10.1002/jcb.10507
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Bera S, 2010, NEOPLASIA, V12, P980, DOI 10.1593/neo.101146
   Bertaux K, 2006, BONE, V38, P943, DOI 10.1016/j.bone.2005.11.025
   Bjelakovic G, 2007, J Basic Clin Physiol Pharmacol, V18, P115
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007
   Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe
   Iuchi T, 2003, CIRC RES, V92, P81, DOI 10.1161/01.RES.0000050588.35034.3C
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kim HJ, 2010, BMB REP, V43, P524, DOI 10.5483/BMBRep.2010.43.8.524
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   Lee YJ, 2006, NEUROSCI LETT, V392, P27, DOI 10.1016/j.neulet.2005.08.065
   Mackinnon ES, 2011, OSTEOPOROSIS INT, V22, P1091, DOI 10.1007/s00198 010 1308 0
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Maio R, 2012, CARDIOVASC THER, V30, P85, DOI 10.1111/j.1755 5922.2010.00183.x
   Mikami Y, 2007, BIOCHEM BIOPH RES CO, V362, P368, DOI 10.1016/j.bbrc.2007.07.192
   Mondo CK, 2006, CLIN EXP HYPERTENS, V28, P73, DOI 10.1080/10641960500468219
   Qiao SJ, 2009, ENDOCRINOLOGY, V150, P4163, DOI 10.1210/en.2009 0195
   Sato H, 2010, J CLIN BIOCHEM NUTR, V47, P224, DOI 10.3164/jcbn.10 58
   Shao J, 2009, PHARMAZIE, V64, P674, DOI 10.1691/ph.2009.9561
   Shuto M, 2009, J PHARMACOL SCI, V110, P424, DOI 10.1254/jphs.09107FP
   Vaughan T, 2004, BONE, V34, P1029, DOI 10.1016/j.bone.2004.02.004
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   You JM, 2009, CAN J PHYSIOL PHARM, V87, P440, DOI [10.1139/y09 027, 10.1139/Y09 027]
NR 36
TC 62
Z9 64
U1 0
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD JAN 25
PY 2014
VL 207
BP 26
EP 31
DI 10.1016/j.cbi.2013.11.004
PG 6
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 297MX
UT WOS:000330260700006
PM 24239970
DA 2025 08 17
ER

PT J
AU Tian, H
   Jiang, T
   Yang, K
   Ning, RN
   Wang, TQ
   Zhou, Q
   Qian, ND
   Huang, P
   Guo, L
   Jiang, M
   Xi, XB
   Xu, X
   Deng, LF
AF Tian, Hao
   Jiang, Tao
   Yang, Kai
   Ning, Ruonan
   Wang, Tianqi
   Zhou, Qi
   Qian, Niandong
   Huang, Ping
   Guo, Lei
   Jiang, Min
   Xi, Xiaobing
   Xu, Xing
   Deng, Lianfu
TI α Asarone Attenuates Osteoclastogenesis and Prevents Against
   Oestrogen Deficiency Induced Osteoporosis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE <p>alpha asarone (ASA)</p>; osteoclasts; osteoporosis (OP); bone
   resorption; bone loss
ID NF KAPPA B; CATHEPSIN K; BONE; DIFFERENTIATION; MICE; OSTEONECROSIS;
   EXPRESSION; OSTEOPETROSIS; SUPPRESSION; JAW
AB Osteoporosis (OP) is defined as low bone mineral density which features over activated osteoclasts (OCs) and bone resorption. Targeting excessive OCs activity is thought to be an effective therapeutic approach for OP treatment. alpha asarone (ASA), a compound from the traditional Chinese medicinal herb Acorus tatarinowii, has been widely used as a therapeutic agent against several diseases such as epilepsy, cough, bronchitis and asthma for many years. Recently, it was reported that ASA derived lignins which were purified from Acorus tatarinowii root tissues effectively suppressed both RANKL induced osteoclastogenesis and bone resorption. Besides, a classic Chinese formulation Bajitianwan (BJTW) which consisted of root and rhizome of Acorus tatarinowii Schott also showed positive effects on age related bone loss. In the present study, we aimed to study the effects of ASA on osteoclastogenesis in vitro and in vivo. As illustrated by TRAP staining, ASA was capable of inhibiting RANKL induced osteoclastogenesis in a dose dependent manner, not only at an early stage, but also in the late stage. Besides, it also effectively suppressed bone resorption of mature OCs in a pit resorption assay. The formation of F actin ring during osteoclastogenesis, which was important in OCs bone resorption, was impaired as well. Subsequent mechanism experiments exposed that ASA inhibited osteoclastogenesis related genes in a time dependent manner through AKT, p38 and NF kappa B, followed by NFATc1/c fos signaling pathway. Notably, our in vivo study uncovered that ASA was capable of improving the bone microstructure in oestrogen deficiency induced OP models. Thus, our current work highlighted the important role of an old drug ASA in bone metabolism especially in OCs differentiation. ASA may find its potential as a lead compound to treat excessive OCs activity induced bone loss diseases and more structure optimization is further needed.
C1 [Tian, Hao; Jiang, Tao; Yang, Kai; Ning, Ruonan; Wang, Tianqi; Zhou, Qi; Qian, Niandong; Huang, Ping; Guo, Lei; Jiang, Min; Xi, Xiaobing; Xu, Xing; Deng, Lianfu] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Sch Med,Shanghai Key Lab Prevent &, Shanghai, Peoples R China.
   [Jiang, Tao] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Endocrine & Metab Dis, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Jiang, M; Xi, XB; Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Sch Med,Shanghai Key Lab Prevent &, Shanghai, Peoples R China.
EM jiangm263@163.com; skxixiaobing@163.com; xuxing0510315@126.com
RI ; Huang, Ping/AAE 7205 2019; Yang, Kai/JQW 2039 2023; guo,
   leixin/HPF 6884 2023; Ning, Ruonan/IZP 7626 2023; Zhou,
   Qi/JGM 4026 2023; Wang, Tianqi/KIC 1831 2024
OI Yang, Kai/0000 0002 5544 7817; 
FU Shanghai Municipal Health Bureau young scientific research project
   [201940149]; Shanghai Talent Development Funding Scheme [2020093];
   Shanghai Sailing Program [21YF1441900]; Shanghai Flagship Hospital of
   Integrated Traditional Chinese and Western Medicine construction Program
   [ZY (2021 2023) 0205 01]
FX This work was supported by Shanghai Municipal Health Bureau young
   scientific research project (No. 201940149), Shanghai Talent Development
   Funding Scheme (No. 2020093), Shanghai Sailing Program (No.
   21YF1441900), Shanghai Flagship Hospital of Integrated Traditional
   Chinese and Western Medicine construction Program (ZY
   (2021 2023) 0205 01).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   BOYDE A, 1991, CALCIFIED TISSUE INT, V49, P65, DOI 10.1007/BF02565123
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chellian R, 2017, PHYTOMEDICINE, V32, P41, DOI 10.1016/j.phymed.2017.04.003
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Egloff Juras C, 2018, J ORAL PATHOL MED, V47, P66, DOI 10.1111/jop.12646
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Ghayor C, 2015, INFLAMM RES, V64, P527, DOI 10.1007/s00011 015 0833 x
   Hewitt C, 2007, J ORAL PATHOL MED, V36, P319, DOI 10.1111/j.1600 0714.2007.00540.x
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kawahara M, 2021, INT J IMPLANT DENT, V7, DOI 10.1186/s40729 021 00323 0
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Liu ZC, 2019, FASEB J, V33, P9828, DOI 10.1096/fj.201802242RR
   Neuberger A, 2019, DRUG DISCOV TODAY, V24, P1, DOI 10.1016/j.drudis.2018.06.012
   Nishio E, 2019, BIOCHEM BIOPHYS REP, V20, DOI 10.1016/j.bbrep.2019.100671
   Park SH, 2017, ONCOTARGET, V8, P7370, DOI 10.18632/oncotarget.14566
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Shin JW, 2014, BIOMOL THER, V22, P17, DOI 10.4062/biomolther.2013.102
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stephens M, 2021, SCI DATA, V8, DOI 10.1038/s41597 021 01012 8
   Strittmatter SM, 2014, NAT MED, V20, P590, DOI 10.1038/nm.3595
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Uebel T, 2021, J APPL TOXICOL, V41, P1166, DOI 10.1002/jat.4112
   VANDEWIJNGAERT FP, 1986, J HISTOCHEM CYTOCHEM, V34, P1317, DOI 10.1177/34.10.3745910
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Xu WM, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.112992
   Xu XH, 2016, INT IMMUNOPHARMACOL, V34, P212, DOI 10.1016/j.intimp.2016.03.001
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zeng LL, 2021, NEUROSCIENCE, V458, P141, DOI 10.1016/j.neuroscience.2020.12.026
   Zhang YX, 2019, CELL BIOL INT, V43, P1471, DOI 10.1002/cbin.11197
   Zhang YX, 2018, INT IMMUNOPHARMACOL, V65, P199, DOI 10.1016/j.intimp.2018.09.030
   Zhu H, 2021, J CHROMATOGR A, V1643, DOI 10.1016/j.chroma.2021.462080
NR 45
TC 14
Z9 14
U1 1
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 18
PY 2022
VL 13
AR 780590
DI 10.3389/fphar.2022.780590
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 1C0KK
UT WOS:000792817500001
PM 35370648
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Manzano Moreno, FJ
   de Luna Bertos, E
   Toledano Osorio, M
   Urbano Arroyo, P
   Ruiz, C
   Toledano, M
   Osorio, R
AF Manzano Moreno, Francisco Javier
   de Luna Bertos, Elvira
   Toledano Osorio, Manuel
   Urbano Arroyo, Paula
   Ruiz, Concepcion
   Toledano, Manuel
   Osorio, Raquel
TI Biomimetic Collagen Membranes as Drug Carriers of Geranylgeraniol to
   Counteract the Effect of Zoledronate
SO BIOMIMETICS
LA English
DT Article
DE zoledronate; collagen membranes; osteoblast; geranylgeraniol
ID BISPHOSPHONATE RELATED OSTEONECROSIS; IN VITRO; OSTEOGENIC
   DIFFERENTIATION; OSTEOCLAST FORMATION; PORCINE PERICARDIUM; MEVALONATE
   PATHWAY; ANTIGENIC PROFILE; BONE REGENERATION; GENE EXPRESSION;
   GROWTH FACTOR
AB To counteract the effect of zoledronate and decrease the risk of osteonecrosis of the jaw (BRONJ) development in patients undergoing guided bone regeneration surgery, the use of geranylgeraniol (GGOH) has been proposed. Collagen membranes may act as biomimetical drug carriers. The objective of this study was to determine the capacity of collagen based membranes doped with GGOH to revert the negative impact of zoledronate on the growth and differentiation of human osteoblasts. MG 63 cells were cultured on collagen membranes. Two groups were established: (1) undoped membranes and (2) membranes doped with geranylgeraniol. Osteoblasts were cultured with or without zoledronate (50 mu M). Cell proliferation was evaluated at 48 h using the MTT colorimetric method. Differentiation was tested by staining mineralization nodules with alizarin red and by gene expression analysis of bone morphogenetic proteins 2 and 7, alkaline phosphatase (ALP), bone morphogenetic proteins 2 and 7 (BMP 2 and BMP 7), type I collagen (Col I), osterix (OSX), osteocalcin (OSC), osteoprotegerin (OPG), receptor for RANK (RANKL), runt related transcription factor 2 (Runx 2), TGF beta 1 and TGF beta receptors (TGF beta R1, TGF beta R2, and TGF beta R3), and vascular endothelial growth factor (VEGF) with real time PCR. One way ANOVA or Kruskal Wallis and post hoc Bonferroni tests were applied (p < 0.05). Scanning electron microscopy (SEM) observations were also performed. Treatment of osteoblasts with 50 mu M zoledronate produced a significant decrease in cell proliferation, mineralization capacity, and gene expression of several differentiation markers if compared to the control (p < 0.001). When osteoblasts were treated with zoledronate and cultured on GGOH doped membranes, these variables were, in general, similar to the control group (p > 0.05). GGOH applied on collagen membranes is able to reverse the negative impact of zoledronate on the proliferation, differentiation, and gene expression of different osteoblasts' markers.
C1 [Manzano Moreno, Francisco Javier] Univ Granada, Sch Dent, Dept Stomatol, Biomed Grp BIO277, Granada 18071, Spain.
   [Manzano Moreno, Francisco Javier; de Luna Bertos, Elvira; Ruiz, Concepcion; Toledano, Manuel; Osorio, Raquel] Inst Invest Biosanit, ibsGranada, Granada 18012, Spain.
   [de Luna Bertos, Elvira; Ruiz, Concepcion] Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Granada 18016, Spain.
   [Toledano Osorio, Manuel; Urbano Arroyo, Paula; Toledano, Manuel; Osorio, Raquel] Univ Granada, Fac Dent, Colegio Maximo Cartuja S N, Granada 18071, Spain.
   [Ruiz, Concepcion] Univ Granada, Inst Neurosci, Ctr Invest Biomed CIBM, Parque Tecnol Salud PTS, Granada 18071, Spain.
   [Toledano Osorio, Manuel] Univ Complutense Madrid, Fac Dent, Postgrad Program Specializat Periodontol, Madrid 28040, Spain.
C3 University of Granada; University of Granada; University of Granada;
   University of Granada; Complutense University of Madrid
RP de Luna Bertos, E (通讯作者)，Inst Invest Biosanit, ibsGranada, Granada 18012, Spain.; de Luna Bertos, E (通讯作者)，Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Granada 18016, Spain.
EM fjmanza@ugr.es; elviradlb@ugr.es; mantoled@ucm.es;
   paulaurbanoarroyo7@gmail.com; crr@ugr.es; toledano@ugr.es;
   rosorio@ugr.es
RI Osorio, Raquel/E 7913 2017; De Luna Bertos, Elvira/F 8544 2016;
   Toledano, Manuel/E 7923 2017; Manzano Moreno, Francisco/B 1771 2015;
   Concepcion, Ruiz/L 2808 2014; Ruiz, Concepcion/L 2808 2014;
   Manzano Moreno, Francisco Javier/B 1771 2015
OI De Luna Bertos, Elvira/0000 0002 4381 5942; Concepcion,
   Ruiz/0000 0003 4332 6812; Manzano Moreno, Francisco
   Javier/0000 0002 3176 7613
FU MCIN/AEI 10.13039/501100011033
FX No Statement Available
CR Abbasnezhad N, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13081230
   Abou Neel EA, 2013, ADV DRUG DELIVER REV, V65, P429, DOI 10.1016/j.addr.2012.08.010
   Bornert F, 2021, CLIN EXP DENT RES, V7, P711, DOI 10.1002/cre2.414
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Chin KY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.878556
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Deng Yuejia, 2022, Dent Clin North Am, V66, P659, DOI 10.1016/j.cden.2022.05.011
   Evans K D, 2009, Open Orthop J, V3, P83, DOI 10.2174/1874325000903010083
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gu K, 2004, CELLS TISSUES ORGANS, V176, P28, DOI 10.1159/000075025
   Hiruma Y, 2004, BIOCHEM BIOPH RES CO, V314, P24, DOI 10.1016/j.bbrc.2003.12.051
   Ho HJ, 2018, BIOSCI BIOTECH BIOCH, V82, P956, DOI 10.1080/09168451.2017.1415129
   Horner A, 2001, BONE, V28, P65, DOI 10.1016/S8756 3282(00)00422 1
   Manzano Moreno FJ, 2018, INT J MED SCI, V15, P359, DOI 10.7150/ijms.22627
   Manzano Moreno FJ, 2016, J ORAL MAXIL SURG, V74, P1765, DOI 10.1016/j.joms.2016.03.028
   Manzano Moreno FJ, 2015, CLIN ORAL INVEST, V19, P895, DOI 10.1007/s00784 014 1309 z
   Manzano Moreno FJ, 2013, CLIN ORAL INVEST, V17, P1349, DOI 10.1007/s00784 012 0811 4
   Jawad M, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2022.13193
   Jia JJ, 2013, BONE, V52, P424, DOI 10.1016/j.bone.2012.10.017
   Lala R, 2000, ACTA PAEDIATR, V89, P188, DOI 10.1080/080352500750028816
   Lane JM, 2001, CLIN ORTHOP RELAT R, P6
   Latifi L, 2017, MICROPOR MESOPOR MAT, V250, P148, DOI 10.1016/j.micromeso.2017.05.026
   Li HJ, 2022, MOLECULES, V27, DOI 10.3390/molecules27175548
   Li XL, 2006, ANN NY ACAD SCI, V1068, P26, DOI 10.1196/annals.1346.006
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P396, DOI 10.1016/j.jcms.2014.12.008
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   MELCHER AH, 1976, J PERIODONTOL, V47, P256, DOI 10.1902/jop.1976.47.5.256
   Ng HW, 2020, GELS BASEL, V6, DOI 10.3390/gels6040046
   Otto M, 2022, ORAL MAXILLOFAC SURG, V26, P321, DOI 10.1007/s10006 021 00982 8
   Patntirapong S, 2021, ACTA HISTOCHEM, V123, DOI 10.1016/j.acthis.2020.151659
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   pubchem.ncbi.nlm.nih, PubChem Geranylgeraniol
   Radu ER, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14235249
   Ragni E, 2013, J CELL MOL MED, V17, P168, DOI 10.1111/j.1582 4934.2012.01660.x
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P567, DOI 10.1111/j.1600 0501.2010.01922.x
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rothamel D, 2012, INT J ORAL MAX IMPL, V27, P146
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Saadeh PB, 1999, AM J PHYSIOL CELL PH, V277, pC628, DOI 10.1152/ajpcell.1999.277.4.C628
   Braga Vilela AS, 2008, J MEMBRANE BIOL, V221, P15, DOI 10.1007/s00232 007 9081 5
   Sandrini E, 2005, J BIOMED MATER RES B, V73B, P392, DOI 10.1002/jbm.b.30241
   Sanz M, 2019, J CLIN PERIODONTOL, V46, P82, DOI 10.1111/jcpe.13123
   Schmidt C, 2002, J BIOMED MATER RES, V63, P252, DOI 10.1002/jbm.10185
   Shen BJ, 2010, J CELL BIOCHEM, V109, P406, DOI 10.1002/jcb.22412
   Silverman SL, 2007, SEMIN ARTHRITIS RHEU, V37, P1, DOI 10.1016/j.semarthrit.2006.12.003
   Sims NA, 2014, ARCH BIOCHEM BIOPHYS, V561, P22, DOI 10.1016/j.abb.2014.05.015
   Street John, 2009, J Orthop Surg Res, V4, P19, DOI 10.1186/1749 799X 4 19
   Thavornyutikarn B, 2023, ACS APPL BIO MATER, V6, P1658, DOI 10.1021/acsabm.3c00110
   Toledano Osorio M, 2023, J PERIODONTAL RES, V58, P296, DOI 10.1111/jre.13091
   Toledano Osorio M, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14040840
   Toledano Osorio M, 2021, J DENT, V109, DOI 10.1016/j.jdent.2021.103676
   Toledano Osorio M, 2021, J DENT, V105, DOI 10.1016/j.jdent.2021.103580
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Xie Y, 2022, J MEMBRANE SCI LETT, V2, DOI 10.1016/j.memlet.2022.100020
   Zafar S, 2016, CLIN ORAL INVEST, V20, P2023, DOI 10.1007/s00784 015 1706 y
   Zagho MM, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10070739
NR 62
TC 0
Z9 0
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2313 7673
J9 BIOMIMETICS BASEL
JI Biomimetics
PD JAN
PY 2024
VL 9
IS 1
AR 4
DI 10.3390/biomimetics9010004
PG 18
WC Engineering, Multidisciplinary; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GH8V3
UT WOS:001151878700001
PM 38248578
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pawade, TA
   Doris, MK
   Bing, R
   White, AC
   Forsyth, L
   Evans, E
   Graham, C
   Williams, MC
   van Beek, EJR
   Fletcher, A
   Adamson, PD
   Andrews, JPM
   Cartlidge, TRG
   Jenkins, WSA
   Syed, M
   Fujisawa, T
   Lucatelli, C
   Fraser, W
   Ralston, SH
   Boon, N
   Prendergast, B
   Newby, DE
   Dweck, MR
AF Pawade, Tania A.
   Doris, Mhairi K.
   Bing, Rong
   White, Audrey C.
   Forsyth, Laura
   Evans, Emily
   Graham, Catriona
   Williams, Michelle C.
   van Beek, Edwin J. R.
   Fletcher, Alison
   Adamson, Philip D.
   Andrews, Jack P. M.
   Cartlidge, Timothy R. G.
   Jenkins, William S. A.
   Syed, Maaz
   Fujisawa, Takeshi
   Lucatelli, Christophe
   Fraser, William
   Ralston, Stuart H.
   Boon, Nicholas
   Prendergast, Bernard
   Newby, David E.
   Dweck, Marc R.
TI Effect of Denosumab or Alendronic Acid on the Progression of Aortic
   Stenosis A Double Blind Randomized Controlled Trial
SO CIRCULATION
LA English
DT Article
DE alendronate; aortic stenosis; computed tomography; X ray; calcium
   signaling; denosumab
ID VASCULAR CALCIFICATION; VALVE STENOSIS; DISEASE PROGRESSION; TOMOGRAPHY;
   PREVALENCE; PREDICTORS; SOCIETY; WOMEN; HEART
AB BACKGROUND: Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms. We aimed to establish whether inhibition of these pathways with denosumab or alendronic acid could reduce disease progression in aortic stenosis.
   METHODS: In a single center, parallel group, double blind randomized controlled trial, patients >50 years of age with calcific aortic stenosis (peak aortic jet velocity >2.5 m/s) were randomized 2:1:2:1 to denosumab (60 mg every 6 months), placebo injection, alendronic acid (70 mg once weekly), or placebo capsule. Participants underwent serial assessments with Doppler echocardiography, computed tomography aortic valve calcium scoring, and F 18 sodium fluoride positron emission tomography and computed tomography. The primary end point was the calculated 24 month change in aortic valve calcium score.
   RESULTS: A total of 150 patients (mean age, 72 +/  8 years; 21% women) with calcific aortic stenosis (peak aortic jet velocity, 3.36 m/s [2.93 3.82 m/s]; aortic valve calcium score, 1152 AU [655 2065 AU]) were randomized and received the allocated trial intervention: denosumab (n=49), alendronic acid (n=51), and placebo (injection n=25, capsule n=25; pooled for analysis). Serum C terminal telopeptide, a measure of bone turnover, halved from baseline to 6 months with denosumab (0.23 [0.18 0.33 mu g/L] to 0.11 mu g/L [0.08 0.17 mu g/L]) and alendronic acid (0.20 [0.14 0.28 mu g/L] to 0.09 mu g/L [0.08 0.13 mu g/L]) but was unchanged with placebo (0.23 [0.17 0.30 mu g/L] to 0.26 mu g/L [0.16 0.31 mu g/L]). There were no differences in 24 month change in aortic valve calcium score between denosumab and placebo (343 [198 804 AU] versus 354 AU [76 675 AU]; P=0.41) or alendronic acid and placebo (326 [138 813 AU] versus 354 AU [76 675 AU]; P=0.49). Similarly, there were no differences in change in peak aortic jet velocity or F 18 sodium fluoride aortic valve uptake.
   CONCLUSIONS: Neither denosumab nor alendronic acid affected progression of aortic valve calcification in patients with calcific aortic stenosis. Alternative pathways and mechanisms need to be explored to identify disease modifying therapies for the growing population of patients with this potentially fatal condition.
C1 [Pawade, Tania A.; Doris, Mhairi K.; Bing, Rong; White, Audrey C.; Williams, Michelle C.; Adamson, Philip D.; Andrews, Jack P. M.; Cartlidge, Timothy R. G.; Jenkins, William S. A.; Syed, Maaz; Fujisawa, Takeshi; Boon, Nicholas; Newby, David E.; Dweck, Marc R.] Univ Edinburgh, British Heart Fdn, Ctr Cardiovasc Sci, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.
   [Forsyth, Laura] Univ Edinburgh, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland.
   [Evans, Emily; Graham, Catriona] Univ Edinburgh, Edinburgh Clin Res Facil, Edinburgh, Midlothian, Scotland.
   [van Beek, Edwin J. R.; Fletcher, Alison; Lucatelli, Christophe] Univ Edinburgh, Edinburgh Imaging, Edinburgh, Midlothian, Scotland.
   [Ralston, Stuart H.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland.
   [Adamson, Philip D.] Univ Otago, Christchurch Heart Inst, Dunedin, New Zealand.
   [Fraser, William] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England.
   [Prendergast, Bernard] Kings Coll London, London, England.
C3 University of Edinburgh; University of Edinburgh; University of
   Edinburgh; University of Edinburgh; University of Edinburgh; University
   of Otago; University of East Anglia; University of London; King's
   College London
RP Dweck, MR (通讯作者)，Univ Edinburgh, British Heart Fdn, Ctr Cardiovasc Sci, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.
EM marc.dweck@ed.ac.uk
RI ; Williams, Michelle/K 7555 2012; Adamson, Philip/AAC 3699 2019;
   Fujisawa, Takeshi/F 9451 2010; Newby, David/AAB 1364 2019; Dweck,
   Marc/AAY 1509 2021
OI dweck, marc/0000 0001 9847 5917; Newby, David/0000 0001 7971 4628;
   Graham, Catriona/0000 0003 1889 712X; Syed,
   Maaz Bin Junaid/0000 0003 0530 8306; Fujisawa,
   Takeshi/0000 0002 6627 3218; van Beek, Edwin/0000 0002 2777 5071;
   Williams, Michelle/0000 0003 3556 2428
FU British Heart Foundation [FS/14/78/31020, CH/09/002, RG/16/10/32375,
   RE/18/5/34216, FS/ICRF/20/26002]; Heart Foundation of New Zealand Senior
   Fellowship [1844]; Scottish Imaging Network; Wellcome Trust
   [WT103782AIA]; Sir Jules Thorn Award for Biomedical Research 2015
   [15/JTA]; British Heart Foundation [RG/16/10/32375, FS/14/78/31020,
   CH/09/002/26360, FS/ICRF/20/26002, FS/13/77/30488, FS/16/19/31982]
   Funding Source: researchfish
FX This trial was funded by the British Heart Foundation (FS/14/78/31020).
   D.E.N. (CH/09/002, RG/16/10/32375, RE/18/5/34216), M.R.D.
   (FS/14/78/31020), and M.C.W. (FS/ICRF/20/26002) are supported by the
   British Heart Foundation. P.D.A. is supported by a Heart Foundation of
   New Zealand Senior Fellowship (1844). E.J.R.v.B. is supported by the
   Scottish Imaging Network (www.sinapse.ac.uk).D.E.N.is also the recipient
   of a Wellcome Trust Senior Investigator Award (WT103782AIA). M.R.D. is
   the recipient of the Sir Jules Thorn Award for Biomedical Research 2015
   (15/JTA).
CR AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735 1097(90)90282 T
   Aksoy O, 2012, J AM COLL CARDIOL, V59, P1452, DOI 10.1016/j.jacc.2012.01.024
   Baumgartner H, 2018, EUR HEART J, V39, P1980, DOI [10.1093/eurheartj/ehx636, 10.1093/eurheartj/ehx391]
   Baumgartner H, 2009, J AM SOC ECHOCARDIOG, V22, P1, DOI 10.1016/j.echo.2008.11.029
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chan KL, 2010, CIRCULATION, V121, P306, DOI 10.1161/CIRCULATIONAHA.109.900027
   Chen CL, 2020, OSTEOPOROSIS INT, V31, P1507, DOI 10.1007/s00198 020 05391 3
   Cowell SJ, 2005, NEW ENGL J MED, V352, P2389, DOI 10.1056/NEJMoa043876
   Dayanand P, 2018, CURR CARDIOL REV, V14, P192, DOI 10.2174/1573403X14666180619103258
   Doris MK, 2020, HEART, V106, P1906, DOI 10.1136/heartjnl 2020 317125
   Durko AP, 2018, EUR HEART J, V39, P2635, DOI 10.1093/eurheartj/ehy107
   Dweck MR, 2014, CIRC CARDIOVASC IMAG, V7, P371, DOI 10.1161/CIRCIMAGING.113.001508
   Dweck MR, 2012, CIRCULATION, V125, P76, DOI 10.1161/CIRCULATIONAHA.111.051052
   Elmariah S, 2010, J AM COLL CARDIOL, V56, P1752, DOI 10.1016/j.jacc.2010.05.050
   Farhat GN, 2006, J BONE MINER RES, V21, P1839, DOI 10.1359/JBMR.060903
   Goody PR, 2020, ARTERIOSCL THROM VAS, V40, P885, DOI 10.1161/ATVBAHA.119.313067
   Hak AE, 2000, ARTERIOSCL THROM VAS, V20, P1926, DOI 10.1161/01.ATV.20.8.1926
   Harkness A, 2020, ECHO RES PRACT, V7, pG1, DOI 10.1530/ERP 19 0050
   Hekimian G, 2013, EUR HEART J, V34, P1915, DOI 10.1093/eurheartj/ehs450
   Jenkins WSA, 2015, J AM COLL CARDIOL, V66, P1200, DOI 10.1016/j.jacc.2015.06.1325
   Massera D, 2020, J NUCL CARDIOL, V27, P962, DOI 10.1007/s12350 018 01542 6
   Morony S, 2008, CIRCULATION, V117, P411, DOI 10.1161/CIRCULATIONAHA.107.707380
   Osnabrugge RLJ, 2013, J AM COLL CARDIOL, V62, P1002, DOI 10.1016/j.jacc.2013.05.015
   Otto CM, 2021, CIRCULATION, V143, pe72, DOI [10.1161/CIR.0000000000000923, 10.1161/CIR.0000000000000932, 10.1016/j.jacc.2020.11.018, 10.1016/j.jacc.2020.11.035]
   OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844
   Otto CM, 1997, CIRCULATION, V95, P2262, DOI 10.1161/01.CIR.95.9.2262
   Pawade T, 2019, JACC CARDIOVASC IMAG, V12, P1835, DOI 10.1016/j.jcmg.2019.01.045
   Pawade T, 2018, CIRC CARDIOVASC IMAG, V11, DOI 10.1161/CIRCIMAGING.117.007146
   Pawade TA, 2016, CIRC CARDIOVASC IMAG, V9, DOI 10.1161/CIRCIMAGING.116.005131
   Pawade TA, 2015, J AM COLL CARDIOL, V66, P561, DOI 10.1016/j.jacc.2015.05.066
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Rajamannan NM, 2011, CIRCULATION, V124, P1783, DOI 10.1161/CIRCULATIONAHA.110.006767
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903
   Rossebo AB, 2008, NEW ENGL J MED, V359, P1343, DOI 10.1056/NEJMoa0804602
   SANSONI P, 1995, J BONE MINER RES, V10, P1719
   Skolnick AH, 2009, AM J CARDIOL, V104, P122, DOI 10.1016/j.amjcard.2009.02.051
   Yutzey KE, 2014, ARTERIOSCL THROM VAS, V34, P2387, DOI 10.1161/ATVBAHA.114.302523
NR 38
TC 104
Z9 111
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 7322
EI 1524 4539
J9 CIRCULATION
JI Circulation
PD JUN 22
PY 2021
VL 143
IS 25
BP 2418
EP 2427
DI 10.1161/CIRCULATIONAHA.121.053708
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA SW1MI
UT WOS:000664281700010
PM 33913339
OA Green Accepted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Shi, XC
   Xia, B
   Zhang, JF
   Zhang, RX
   Zhang, DY
   Liu, H
   Xie, BC
   Wang, YL
   Wu, JW
AF Shi, Xiao Chen
   Xia, Bo
   Zhang, Jian Feng
   Zhang, Rui Xin
   Zhang, Dan Yang
   Liu, Huan
   Xie, Bao Cai
   Wang, Yong Liang
   Wu, Jiang Wei
TI Optineurin promotes myogenesis during muscle regeneration in mice by
   autophagic degradation of GSK3β
SO PLOS BIOLOGY
LA English
DT Article
ID ANKYRIN REPEAT PROTEIN; BETA CATENIN; EPIGENETIC REGULATION; OPTN
   OPTINEURIN; WNT; RECEPTOR; CELLS; DIFFERENTIATION; SEQUESTRATION;
   SPECIFICATION
AB Skeletal muscle regeneration is essential for maintaining muscle function in injury and muscular disease. Myogenesis plays key roles in forming new myofibers during the process. Here, through bioinformatic screen for the potential regulators of myogenesis from 5 independent microarray datasets, we identify an overlapping differentially expressed gene (DEG) optineurin (OPTN). Optn knockdown (KD) delays muscle regeneration in mice and impairs C2C12 myoblast differentiation without affecting their proliferation. Conversely, Optn overexpression (OE) promotes myoblast differentiation. Mechanistically, OPTN increases nuclear levels of beta catenin and enhances the T cell factor/lymphoid enhancer factor (TCF/LEF) transcription activity, suggesting activation of Wnt signaling pathway. The activation is accompanied by decreased protein levels of glycogen synthase kinase 3 beta (GSK3 beta), a negative regulator of the pathway. We further show that OPTN physically interacts with and targets GSK3 beta for autophagic degradation. Pharmacological inhibition of GSK3 beta rescues the impaired myogenesis induced by Optn KD during muscle regeneration and myoblast differentiation, corroborating that GSK3 beta is the downstream effector of OPTN mediated myogenesis. Together, our study delineates the novel role of OPTN as a potential regulator of myogenesis and may open innovative therapeutic perspectives for muscle regeneration.
C1 [Shi, Xiao Chen; Xia, Bo; Zhang, Jian Feng; Zhang, Rui Xin; Zhang, Dan Yang; Liu, Huan; Xie, Bao Cai; Wang, Yong Liang; Wu, Jiang Wei] Northwest A&F Univ, Coll Anim Sci & Technol, Key Lab Anim Genet Breeding & Reprod Shaanxi Prov, Yangling, Shaanxi, Peoples R China.
C3 Northwest A&F University   China
RP Wang, YL; Wu, JW (通讯作者)，Northwest A&F Univ, Coll Anim Sci & Technol, Key Lab Anim Genet Breeding & Reprod Shaanxi Prov, Yangling, Shaanxi, Peoples R China.
EM yongliang.wang@nwafu.edu.cn; wujiangwei@nwafu.edu.cn
RI Liu, Huan/HIK 2282 2022; Xia, Bo/AAE 5330 2021; Zhang,
   Jianfeng/HOA 6524 2023; Zhang, Danyang/CAI 2223 2022; Zhang,
   Ruixin/LBI 2317 2024
OI Wang, Yongliang/0000 0002 1494 0496; xie, baocai/0000 0003 0611 0131;
   Huan, Liu/0009 0005 6103 2115; 
FU Key R&D Program of Shaanxi Province [2020NY 012]
FX The authors would like to thank Dr. Jun Cui (School of Life Sciences,
   Sun Yat sen university, Guangzhou, PRC) for the generous provision of
   valuable Atg5 /  HEK293T cell lines; Dr. Qing yong Meng (College of
   Biological Sciences, China Agricultural University, Beijing, PRC) for
   generous provision of the TOP flash/FOP flash and Renilla luciferase
   expression plasmids; and Life Science Research Core Services of
   Northwest A&F University for image analysis.
CR Belli R, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00897
   Bentzinger CF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008342
   Berg TO, 1998, J BIOL CHEM, V273, P21883, DOI 10.1074/jbc.273.34.21883
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Borello U, 2006, DEVELOPMENT, V133, P3723, DOI 10.1242/dev.02517
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Chal J, 2017, DEVELOPMENT, V144, P2104, DOI 10.1242/dev.151035
   Chang NC, 2016, TRENDS MOL MED, V22, P479, DOI 10.1016/j.molmed.2016.04.002
   Chargé SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Cheng X, 2019, MOL CELL, V73, P788, DOI 10.1016/j.molcel.2018.12.017
   Comai G, 2014, CURR TOP DEV BIOL, V110, P1, DOI 10.1016/B978 0 12 405943 6.00001 4
   Das S, 2017, CELL REP, V21, P3003, DOI 10.1016/j.celrep.2017.11.038
   Demonbreun AR, 2017, CURR OPIN PHARMACOL, V34, P7, DOI 10.1016/j.coph.2017.03.008
   Deng ZQ, 2017, TRENDS CELL BIOL, V27, P491, DOI 10.1016/j.tcb.2017.01.001
   Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200
   Fiacco E, 2016, CELL DEATH DIFFER, V23, P1839, DOI 10.1038/cdd.2016.70
   Fortini P, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.50
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021
   Girardi F, 2018, PROG MOL BIOL TRANSL, V153, P157, DOI 10.1016/bs.pmbts.2017.11.026
   Giudice J, 2017, CURR OPIN PHARMACOL, V34, P49, DOI 10.1016/j.coph.2017.05.005
   Hagen T, 2006, J BIOL CHEM, V281, P35021, DOI 10.1074/jbc.M607003200
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Howe LR, 2003, CANCER RES, V63, P1906
   Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973
   Kim CH, 2008, MOL CELL BIOL, V28, P2941, DOI 10.1128/MCB.01682 07
   Klionsky DJ., 2021, P ADV NEUR INF PROC, V17, P1, DOI [DOI 10.1080/15548627.2020.1797280, 10.1080/15548627.2020.1797280]
   Laure L, 2009, FEBS J, V276, P669, DOI 10.1111/j.1742 4658.2008.06814.x
   Li FX, 2018, AUTOPHAGY, V14, P66, DOI 10.1080/15548627.2017.1391970
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050
   Liu ZZ, 2021, AUTOPHAGY, V17, P2766, DOI 10.1080/15548627.2020.1839286
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lorzadeh S, 2021, BBA MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2020.118926
   Lybrand DB, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.164145
   Ma ZZ, 2019, J MOL HISTOL, V50, P75, DOI 10.1007/s10735 018 9808 x
   Maruyama H, 2010, NATURE, V465, P223, DOI 10.1038/nature08971
   Masters JR, 2002, NAT REV CANCER, V2, P315, DOI 10.1038/nrc775
   Meadows E, 2008, DEV BIOL, V322, P406, DOI 10.1016/j.ydbio.2008.07.024
   Nagaraj N, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.81
   Ogawa R, 2015, DEVELOPMENT, V142, P51, DOI 10.1242/dev.112557
   Padman BS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08335 6
   Pansters NAM, 2015, BBA MOL BASIS DIS, V1852, P490, DOI 10.1016/j.bbadis.2014.12.006
   Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092 8674(03)00437 9
   Qiu YP, 2022, AUTOPHAGY, V18, P73, DOI 10.1080/15548627.2021.1908722
   Rancourt A, 2018, FASEB J, V32, P6445, DOI 10.1096/fj.201701151RRR
   Ranganathan R, 2020, FRONT NEUROSCI SWITZ, V14, DOI 10.3389/fnins.2020.00684
   Rezaie T, 2005, GENOMICS, V85, P131, DOI 10.1016/j.ygeno.2004.10.011
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200
   Romero M, 2018, NAT CELL BIOL, V20, P443, DOI 10.1038/s41556 018 0072 9
   Shi XC, 2018, BRIT J NUTR, V120, P977, DOI [10.1017/S000711451800226X, 10.1017/s000711451800226x]
   Shi Y, 2005, AM J PATHOL, V166, P303, DOI 10.1016/S0002 9440(10)62254 7
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Sin J, 2016, AUTOPHAGY, V12, P369, DOI 10.1080/15548627.2015.1115172
   Sincennes MC, 2016, STEM CELL TRANSL MED, V5, P282, DOI 10.5966/sctm.2015 0266
   Slowicka K, 2016, TRENDS IMMUNOL, V37, P621, DOI 10.1016/j.it.2016.07.002
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399
   Suzuki A, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.168351
   Suzuki A, 2015, MOL CELL BIOL, V35, P1763, DOI 10.1128/MCB.01180 14
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176
   van der Velden JLJ, 2006, AM J PHYSIOL CELL PH, V290, pC453, DOI 10.1152/ajpcell.00068.2005
   Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405
   Wong YC, 2015, AUTOPHAGY, V11, P422, DOI 10.1080/15548627.2015.1009792
   Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Yu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063490
   Zhang K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07638 4
   Zhang Z, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1763 2
NR 74
TC 9
Z9 10
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1544 9173
EI 1545 7885
J9 PLOS BIOL
JI PLoS. Biol.
PD APR
PY 2022
VL 20
IS 4
AR e3001619
DI 10.1371/journal.pbio.3001619
PG 25
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA 1C7AY
UT WOS:000793268400003
PM 35476671
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, CG
   Wang, L
   Yang, T
   Su, SL
   Hu, YH
   Zhong, D
AF Wang, Cheng Gong
   Wang, Long
   Yang, Ting
   Su, Shi Long
   Hu, Yi He
   Zhong, Da
TI Pseudogene PTENP1 sponges miR 214 to regulate the expression of PTEN to
   modulate osteoclast differentiation and attenuate osteoporosis
SO CYTOTHERAPY
LA English
DT Article
DE MiR 214; Osteoporosis; Osteoclast differentiation; Pseudogene PTENP1;
   PTEN
ID POSTMENOPAUSAL OSTEOPOROSIS; CANCER; RNA
AB Background aims: Osteoporosis (OP) is a common bone metabolic disease with a high incidence. Our study aimed to explore the pseudogene PTENP1/miR 214/PTEN axis to modulate the osteoclast differentiation in osteoporosis.
   Methods: Patients with osteoporosis were recruited in our study, and RANKL induced osteoclast differentiation and ovariectomy induced osteoporosis mouse model were established in vitro and in vivo, respectively.
   Results: Pseudogene PTENP1 and PTEN were significantly down regulated and miR 214 was up regulated in osteoporosis patients. In addition, overexpression of PTENP1 or silence of miR 214 inhibited the expression levels of osteoclast specific markers and osteoclast differentiation induced by RANKL. Overexpression of PTENP1 or silence of miR 214 also inhibited the levels of phosphorylation of PI3K and AKT, p65 nuclear translocation, I kappa B alpha degradation and the expression level of NFATc1. AlsoSilence of PTENP1 or overexpression of miR 214 induced the osteoclast differentiation under normal physiological condition. Pseudogene PTENP1 sponged miR 214 to regulate the expression of PTEN.
   Conclusions: In an ovariectomy induced osteoporosis mouse model, obvious pathological changes in bone tissues were found, and bone marrow mononuclear cells in this group were more likely to differentiate into osteoclasts. Therefore, pseudogene PTENP1 sponged miR 214 to regulate the expression of PTEN to inhibit osteoclast differentiation and attenuate osteoporosis by suppressing the PI3K/AKT/NF kappa B signaling pathway. (C) 2020 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.
C1 [Wang, Cheng Gong; Wang, Long; Yang, Ting; Su, Shi Long; Hu, Yi He; Zhong, Da] Cent South Univ, Dept Orthopaed, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
C3 Central South University
RP Zhong, D (通讯作者)，Cent South Univ, Dept Orthopaed, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM dr_zhongda@126.com
RI wang, long/IZE 1764 2023; Su, Shilong/HSH 7452 2023
OI Su, ShiLong/0000 0001 9489 820X
FU Young Science Foundation of the National Natural Science Foundation of
   China [81902308]; General Project of National Natural Science Foundation
   of China [81974360]; Natural Science Foundation of Hunan Province
   [2020JJ5924]
FX This work was supported by the Young Science Foundation of the National
   Natural Science Foundation of China (grant 81902308), a General Project
   of National Natural Science Foundation of China (grant 81974360) and
   Natural Science Foundation of Hunan Province (grant 2020JJ5924).
CR Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   Del Fattore A, 2008, ARCH BIOCHEM BIOPHYS, V473, P147, DOI 10.1016/j.abb.2008.01.011
   Devor EJ, 2006, J HERED, V97, P186, DOI 10.1093/jhered/esj022
   Graham TR, 2009, PROSTATE, V69, P168, DOI 10.1002/pros.20870
   Hao M, 2016, ONCOTARGET, V7, P19589, DOI 10.18632/oncotarget.7319
   Hu XL, 2018, CANCERS, V10, DOI 10.3390/cancers10080256
   Kim YJ, 2005, J BIOL CHEM, V280, P21515, DOI 10.1074/jbc.M502230200
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li F, 2013, PHYTOMEDICINE, V20, P549, DOI 10.1016/j.phymed.2013.01.001
   Marx J, 2004, SCIENCE, V305, P1420, DOI 10.1126/science.305.5689.1420
   Muhammad A, 2018, BIOMED PHARMACOTHER, V107, P571, DOI 10.1016/j.biopha.2018.08.018
   Nakasa T, 2011, ARTHRITIS RHEUM US, V63, P1582, DOI 10.1002/art.30321
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood 2010 10 311415
   Wang XX, 2016, SCI REP UK, V6, DOI 10.1038/srep31506
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Xu DF, 2020, INT J ONCOL, V56, P494, DOI 10.3892/ijo.2019.4937
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008 5472.CAN 07 2488
   Yang L, 2016, CELL PHYSIOL BIOCHEM, V38
   Yi J, 2019, MOL MED REP, V19, P414, DOI 10.3892/mmr.2018.9662
   Yu G, 2014, MOL CANCER THER, V13, P3086, DOI 10.1158/1535 7163.MCT 14 0245
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zhang BF, 2020, J CELL MOL MED, V24, P1099, DOI 10.1111/jcmm.14846
   Zhang RP, 2017, ONCOTARGET, V8, P26079, DOI 10.18632/oncotarget.15317
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
NR 30
TC 17
Z9 18
U1 1
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PD AUG
PY 2020
VL 22
IS 8
BP 412
EP 423
DI 10.1016/j.jcyt.2020.04.090
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA MN3IC
UT WOS:000550737200003
PM 32561161
DA 2025 08 17
ER

PT J
AU Wang, K
   Han, LH
   Wang, N
   Wang, YM
   Wang, JF
AF Wang, Kai
   Han, Lihua
   Wang, Na
   Wang, Yiming
   Wang, Jingfeng
TI Sialoglycoprotein from Gadous morhua eggs improve high bone
   turnover activity via down regulating BMP 2/Smads and Wnt/β catenin
   signal pathways
SO FOOD SCIENCE AND BIOTECHNOLOGY
LA English
DT Article
DE Gadous morhua eggs; Sialoglycoprotein; Bone turnover; BMP 2/Smads;
   Wnt/beta catenin
ID OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN; GENE EXPRESSION;
   OSTEOPOROSIS; ESTROGEN; LRP5; MASS
AB The effect of sialoglycoprotein isolated from Gadous morhua eggs (Gm SGP) on ovariectomized (OVX) induced osteoporosis, which is characterized by high bone turnover activity was investigated. Results revealed that Gm SGP significantly increased bone mineral density, enhanced bone biomechanical properties and repaired the microstructure of the trabecular bone. Also, the treatment with Gm SGP remarkably decreased biochemical marker contents or activities, such as serum BALP, PICP, BMP 2, TrACP, Cath K, urine Ca and P, leading to the reduction in bone turnover. The elevation in the rate of bone formative process contributed in the increase of bone turnover. Both BMP 2/Smads and Wnt/beta catenin signaling pathways played an important role in osteogenesis. Gm SGP suppressed the key factors expression in these two pathways such as BMP 2, Smad1, Smad4, Lrp 5b, Runx2, Osx, ALP, Col1, OCN and beta catenin. These findings might provide some theoretical basis for the application of Gm SGP as a potential anti osteoporotic drug or as functional food.
C1 [Wang, Kai; Han, Lihua; Wang, Na; Wang, Yiming; Wang, Jingfeng] Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Shandong, Peoples R China.
C3 Ocean University of China
RP Wang, JF (通讯作者)，Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Shandong, Peoples R China.
EM jfwang@ouc.edu.cn
RI Wang, Kai/HTS 5222 2023; Wang, Yiming/M 1759 2017
OI Wang, Kai/0000 0001 5447 8710; 
FU National Natural Science Foundation of China [31371876]; National
   Primary Research & Developement Plan [2017YFF0207805]
FX This study was supported by National Natural Science Foundation of China
   (No. 31371876) and National Primary Research & Developement Plan. (No.
   2017YFF0207805).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Brewer L, 2011, EUR J CLIN PHARMACOL, V67, P321, DOI 10.1007/s00228 011 0999 2
   CAO PC, 2014, ALTERN MED
   Chung SL, 2014, J ORTHOP RES, V32, P1572, DOI 10.1002/jor.22715
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Genant HK, 2017, J BONE MINER RES, V32, P181, DOI 10.1002/jbmr.2932
   Gerstenfeld LC, 1996, LAB INVEST, V74, P895
   Herrero S, 2016, EUR J PHARMACOL, V779, P8, DOI 10.1016/j.ejphar.2016.02.053
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Hu SW, 2014, J FUNCT FOODS, V10, P128, DOI 10.1016/j.jff.2014.05.012
   INOUE S, 1997, N COMP BIOC B, V29, P143
   Jian J, 2015, ACTA PHARM SIN B, V5, P454, DOI 10.1016/j.apsb.2015.06.005
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keen Richard W, 2003, Curr Osteoporos Rep, V1, P66, DOI 10.1007/s11914 003 0011 x
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Leboime A, 2010, JOINT BONE SPINE, V77, pS107, DOI 10.1016/S1297 319X(10)70004 X
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Ma J, 2013, J AGR FOOD CHEM, V61, P339, DOI 10.1021/jf300651d
   Ma YL, 2009, CHIN J OSTEOPOROS BO, V43, pS99
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Wang F, 2016, J AGR FOOD CHEM, V64, P2875, DOI 10.1021/acs.jafc.5b06132
   Wang Q, 2008, J FOOD LIPIDS, V15, P222, DOI 10.1111/j.1745 4522.2008.00114.x
   Wirries A, 2013, INT IMMUNOPHARMACOL, V15, P381, DOI 10.1016/j.intimp.2012.12.033
   Wu YC, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00080
   Xia GH, 2016, FOOD FUNCT, V7, P704, DOI 10.1039/c5fo00955c
   Xia GH, 2015, J AGR FOOD CHEM, V63, P9550, DOI 10.1021/acs.jafc.5b04263
   Yang X, 2016, FOOD CHEM TOXICOL, V97, P120, DOI 10.1016/j.fct.2016.09.004
   Zhan QP, 2017, FOOD FUNCT, V8, P1094, DOI [10.1039/C6FO01346E, 10.1039/c6fo01346e]
NR 34
TC 5
Z9 6
U1 0
U2 13
PU KOREAN SOCIETY FOOD SCIENCE & TECHNOLOGY KOSFOST
PI SEOUL
PA #605, KOREA SCI TECHNOL CENT, 635 4 YEOKSAM DONG, KANGNAM GU, SEOUL,
   135 703, SOUTH KOREA
SN 1226 7708
EI 2092 6456
J9 FOOD SCI BIOTECHNOL
JI Food Sci. Biotechnol.
PD OCT
PY 2018
VL 27
IS 5
BP 1455
EP 1465
DI 10.1007/s10068 018 0379 0
PG 11
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA GV7ON
UT WOS:000446317700025
PM 30319856
OA Green Published
DA 2025 08 17
ER

PT J
AU Dai, YF
   Li, Z
   Fu, M
   Li, YQ
   Xue, CH
   Wang, JF
AF Dai, Yufeng
   Li, Zhuo
   Fu, Meng
   Li, Yanqi
   Xue, Changhu
   Wang, Jingfeng
TI Peptides from Euphausia superba Promote Longitudinal Bone Growth
   by Accelerating Growth Plate Chondrocyte Proliferation and Hypertrophy
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Peptides from antarctic krill; endochondral ossification; longitudinal
   bone growth; bone morphogenetic protein 2; runt related transcription
   factor 2; osterix
ID OSTEOBLAST DIFFERENTIATION; MORPHOGENETIC PROTEIN 2; AMINO ACID;
   EXPRESSION; HORMONE; WNT; MECHANISMS; MODEL; RUNX2; IGF 1
AB Background: With the improvements in living standards, height is getting more attention. Malnutrition is one of the main causes of children's short stature; therefore, nutritional intervention in adolescence is the key to prevent short stature. The peptides from Antarctic Krill (AKPs), the ideal protein model, act in bone formation and anti osteoporosis. However, the studies on promoting longitudinal bone growth by AKPs have not been reported.
   Methods: Three week old male ICR mice, to construct the adolescent mice model, randomly divided into three groups: normal group, casein group (casein, 300 mg/kgmiddotBW), and AKPs group (AKPs, 300 mg/kgmiddotBW). After 21 days of drug administration, the effects of AKPs on serum biochemical indexes and femur histomorphology of mice, and the mechanism of AKPs promoting longitudinal bone growth was discussed.
   Results: AKPs significantly increased longitudinal bone growth and improved bone strength. In addition, AKPs remarkably promoted proliferation and hypertrophy of chondrocytes in the growth plate. The further mechanism revealed that AKPs increased serum Growth Hormone (GH) and Insulin Like Growth Factors 1(IGF 1) contents, which activated the downstream GH/IGF 1 axis signaling pathways. Moreover, AKPs induced the secretion and expression of bone morphogenetic protein 2 (BMP2) and triggered the activation of BMP2 dependent Smads signaling. AKPs also activated Wnt/beta catenin signaling, and synergistically activated the expression of Runt related transcription factor 2 (Runx 2) and Osterix (OSX).
   Conclusion: AKPs promoted longitudinal bone growth by activating GH/IGF 1 axis, BMP 2/Smads and Wnt/beta catenin pathways, suggesting AKPs to be a potential nutrient fortifier for longitudinal bone growth.
C1 [Dai, Yufeng; Li, Zhuo; Fu, Meng; Li, Yanqi; Xue, Changhu; Wang, Jingfeng] Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Peoples R China.
C3 Ocean University of China
RP Xue, CH; Wang, JF (通讯作者)，Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Peoples R China.
EM xuech@ouc.edu.cn; jfwang@ouc.edu.cn
RI li, yanqi/HZM 5831 2023; Dai, Yufeng/KBX 4156 2024
OI Dai, Yufeng/0000 0002 6598 8203; 
FU National Key R&D Program of China [2018YFC0311203]
FX This study was supported by National Key R&D Program of China
   (2018YFC0311203) .
CR Amano K, 2014, J BIOL CHEM, V289, P24898, DOI 10.1074/jbc.M114.570507
   Ammann P, 2002, J BONE MINER RES, V17, P1264, DOI 10.1359/jbmr.2002.17.7.1264
   Aziz MSR, 2014, J BIOMECH ENG T ASME, V136, DOI 10.1115/1.4027057
   BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092 8674(93)90680 O
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bass S, 1999, J CLIN INVEST, V104, P795, DOI 10.1172/JCI7060
   Burdan F, 2009, FOLIA HISTOCHEM CYTO, V47, P5, DOI 10.2478/v10042 009 0007 1
   Butler AA, 2001, ANNU REV PHYSIOL, V63, P141, DOI 10.1146/annurev.physiol.63.1.141
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Choi YH, 2018, J CELL BIOCHEM, V119, P748, DOI 10.1002/jcb.26238
   de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945 053X(00)00094 9
   FAO/WHO, 1997, JOINT FAO WHO FOOD S, P1
   Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027
   Fujita S, 2012, J ORTHOP RES, V30, P401, DOI 10.1002/jor.21535
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Gu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.444
   Guo HF, 2010, J MED CHEM, V53, P1819, DOI 10.1021/jm901685n
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Hussein A, 2017, THER ADV ENDOCRINOL, V8, P75, DOI 10.1177/2042018817707464
   Ikeda T, 2005, J BONE MINER METAB, V23, P337, DOI 10.1007/s00774 005 0610 y
   ISGAARD J, 1986, AM J PHYSIOL, V250, pE367, DOI 10.1152/ajpendo.1986.250.4.E367
   Kamboj Manmohan, 2005, Indian Journal of Pediatrics, V72, P149, DOI 10.1007/BF02760701
   Kim HK, 2014, MOLECULES, V19, P12909, DOI 10.3390/molecules190912909
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim MY, 2010, J MED FOOD, V13, P1376, DOI 10.1089/jmf.2010.1007
   Lee JH, 2018, BIOCHEM BIOPH RES CO, V505, P1103, DOI 10.1016/j.bbrc.2018.10.046
   Lee SH, 2012, J TRADIT CHIN MED, V32, P453, DOI 10.1016/S0254 6272(13)60054 0
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Maes C, 2013, CALCIFIED TISSUE INT, V92, P307, DOI 10.1007/s00223 012 9689 z
   Maghnie M, 2018, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00374
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Moon PD, 2015, BIOFACTORS, V41, P190, DOI 10.1002/biof.1213
   Musumeci G, 2013, INT J MOL SCI, V14, P15767, DOI 10.3390/ijms140815767
   Netchine I, 2011, BEST PRACT RES CL EN, V25, P181, DOI 10.1016/j.beem.2010.08.005
   Perrini S, 2010, J ENDOCRINOL, V205, P201, DOI 10.1677/JOE 09 0431
   Pichler K, 2014, INT ORTHOP, V38, P881, DOI 10.1007/s00264 013 2163 3
   Rad EB, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18044 z
   Sarig S, 2004, BONE, V35, P108, DOI 10.1016/j.bone.2004.02.020
   Sayama C, 2015, J NEUROSURG PEDIATR, V16, P14, DOI 10.3171/2015.2.PEDS14533
   Srinivasaiah S, 2019, TISSUE ENG PART C ME, V25, P197, DOI [10.1089/ten.tec.2018.0368, 10.1089/ten.TEC.2018.0368]
   Tanaka Mikako, 2003, Clin Calcium, V13, P604
   Tritos NA, 2016, PROG MOL BIOL TRANSL, V138, P193, DOI 10.1016/bs.pmbts.2015.10.008
   Wang F, 2017, J FOOD BIOCHEM, V41, DOI 10.1111/jfbc.12381
   Wang K, 2019, J AGR FOOD CHEM, V67, P3125, DOI 10.1021/acs.jafc.8b05841
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wu SF, 2015, ENDOCRINOLOGY, V156, P2541, DOI 10.1210/en.2014 1983
   Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463
   Yan B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11151
   Yu YY, 2010, BONE, V47, P65, DOI 10.1016/j.bone.2010.03.012
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zhan QP, 2019, FOOD BIOSCI, V28, P170, DOI 10.1016/j.fbio.2019.02.002
   Zuo CL, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0013 z
NR 54
TC 7
Z9 7
U1 7
U2 39
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 2010
EI 1873 4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PY 2021
VL 22
IS 14
BP 1866
EP 1877
DI 10.2174/1381612826666200612170316
PG 12
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA UT3SB
UT WOS:000698038400004
PM 32532190
DA 2025 08 17
ER

PT J
AU Shu, J
   Wang, Y
   Zhang, GP
   Shu, XD
   Xu, TT
   Zhang, JW
   Wu, F
   He, J
AF Shu, Jun
   Wang, Yao
   Zhang, Guangpeng
   Shu, Xuedong
   Xu, Tingting
   Zhang, Junwei
   Wu, Fang
   He, Jing
TI Fructose mineralized black phosphorus for syncretic bone regeneration
   and tumor suppression
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
AB Black phosphorus (BPs) nanosheets with their inherent and selective chemotherapeutic effects have recently been identified as promising cancer therapeutic agents, but challenges in surface functionalization hinder satisfactory enhancement of their selectivity between tumors and normal cells. To address this issue, we developed a novel biomineralization inspired strategy to synthesize CaBPs Na2FDP@CaCl2 nanosheets, aiming to achieve enhanced and selective anticancer bioactivity along with accelerated osteoblast activity. Benefiting from the in situ mineralization and fructose modification, CaBPs Na2FDP@CaCl2 exhibited improved pH responsive degradation behavior and targeted therapy for osteosarcoma. The in vitro results indicated that CaBPs Na2FDP@CaCl2 exhibited efficient uptake and quick degradation by GLUT5 positive 143B osteosarcoma cells, enhancing BPs driven chemotherapeutic effects through ATP level disturbance mediated apoptosis of tumor cells. Moreover, CaBPs Na2FDP@CaCl2 underwent gradual degradation into PO43 , Ca2+ and fructose in MC3T3 E1 cells, eliminating systemic toxicity. Intracellular Ca2+ bound to calmodulin (CaM), activating Ca2+/CaM dependent signaling cascades, thereby enhancing osteoblast differentiation and mineralization in pro osteoblastic cells. In vivo experiments affirmed the anti tumor capability, inhibition of tumor recurrence and bone repair promotion of CaBPs Na2FDP@CaCl2. This study not only broadens the application of BPs in bone tumor therapy but also provides a versatile surface functionalization strategy for nanotherapeutic agents.
   CaBPs Na2FDP@CaCl2 exhibited dual functions of antitumor and osteogenesis. It achieved targeted therapy for tumors due to pH response degradation and GLUT5 targeting, and promoted osteoblast differentiation in the form of Ca2+ CaM during degradation.
C1 [Shu, Jun; Wang, Yao; Zhang, Guangpeng; Shu, Xuedong; Xu, Tingting; Zhang, Junwei; Wu, Fang; He, Jing] Sichuan Univ, Coll Biomed Engn, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
C3 Sichuan University
RP He, J (通讯作者)，Sichuan Univ, Coll Biomed Engn, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
EM jinghe30@scu.edu.cn
RI He, Jing/JTT 9706 2023; Wu, Fang/D 7264 2011
OI Wu, Fang/0000 0001 5268 9098
FU Natural Science Foundation of Sichuan Province [2023YFB3813002]; Key
   Research and Development Project of the 14th Five Year Plan [31971257,
   32271397]; National Natural Science Foundation of China [2022NSFSC0360];
   Natural Science Foundation of Sichuan Province [[2023] 020]; Guizhou
   Province Innovation Talent Team Construction for the Efficient and
   Comprehensive Utilization of Unique Food and Medicinal Materials
FX This work was supported by the Key Research and Development Project of
   the 14th Five Year Plan (no. 2023YFB3813002), the National Natural
   Science Foundation of China (no. 31971257 and 32271397), the Natural
   Science Foundation of Sichuan Province (no. 2022NSFSC0360), and the
   Guizhou Province Innovation Talent Team Construction for the Efficient
   and Comprehensive Utilization of Unique Food and Medicinal Materials
   (Platform Talent CXTD [2023] 020).
CR Chen MY, 2022, ADV SCI, V9, DOI 10.1002/advs.202103895
   Chen ZW, 2013, BIOMATERIALS, V34, P1364, DOI 10.1016/j.biomaterials.2012.10.060
   Cui ZK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11511 3
   Geng SY, 2020, THERANOSTICS, V10, P4720, DOI 10.7150/thno.43092
   Gong F, 2022, CHEM US, V8, P268, DOI 10.1016/j.chempr.2021.11.020
   Han B, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002232
   Hu HZ, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00933 1
   Hu X, 2022, COORDIN CHEM REV, V473, DOI 10.1016/j.ccr.2022.214821
   Jiao L, 2020, ACS CENTRAL SCI, V6, P747, DOI 10.1021/acscentsci.0c00071
   Jing XR, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202201349
   Kong N, 2020, NANO LETT, V20, P3943, DOI 10.1021/acs.nanolett.0c01098
   Li R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw3896
   Liu LL, 2022, SENSOR ACTUAT B CHEM, V369, DOI 10.1016/j.snb.2022.132303
   Ma G., 2020, NAT COMMUN, V11, P1
   McMillan A, 2018, BIOMATERIALS, V161, P240, DOI 10.1016/j.biomaterials.2018.01.006
   Murugan R, 2005, J CRYST GROWTH, V274, P209, DOI 10.1016/j.jcrysgro.2004.09.069
   Ouyang J, 2021, ACCOUNTS MATER RES, V2, P489, DOI 10.1021/accountsmr.1c00039
   Pan T, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202003069
   Qi C, 2013, CHEM ASIAN J, V8, P88, DOI 10.1002/asia.201200901
   Schmitz SI, 2020, BIOACT MATER, V5, P55, DOI 10.1016/j.bioactmat.2019.12.005
   Shao JD, 2020, ADV SCI, V7, DOI 10.1002/advs.202000439
   Shao XM, 2021, NAT NANOTECHNOL, V16, P1150, DOI 10.1038/s41565 021 00952 x
   Song LP, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202102298
   Suwannakul N, 2022, GENES DIS, V9, P1727, DOI 10.1016/j.gendis.2021.09.002
   Tan P, 2022, ADV SCI, V9, DOI 10.1002/advs.202105955
   Wang DD, 2020, ADV SCI, V7, DOI 10.1002/advs.201901293
   Wang SH, 2019, NANO LETT, V19, P5587, DOI 10.1021/acs.nanolett.9b02127
   Wang T, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27816 1
   Wolkers WF, 2004, CARBOHYD RES, V339, P1077, DOI 10.1016/j.carres.2004.01.016
   Wong KKL, 2020, P NATL ACAD SCI USA, V117, P2004, DOI 10.1073/pnas.1912894117
   Wu W, 2020, THERANOSTICS, V10, P2859, DOI 10.7150/thno.41279
   Xiao YP, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202209291
   Xiong Y, 2024, CHEM ENG J, V481, DOI 10.1016/j.cej.2024.148614
   Xu Y, 2022, BIOACT MATER, V16, P271, DOI 10.1016/j.bioactmat.2022.02.024
   Yang BW, 2018, ADV MATER, V30, DOI 10.1002/adma.201705611
   Yokota K, 2021, ARTHRITIS RHEUMATOL, V73, P1145, DOI 10.1002/art.41666
   ZamoraLeon SP, 1996, P NATL ACAD SCI USA, V93, P1847, DOI 10.1073/pnas.93.5.1847
   Zeng XW, 2018, ADV SCI, V5, DOI 10.1002/advs.201800510
   Zhang CL, 2022, NANOSCALE, V14, P898, DOI 10.1039/d1nr06220d
   Zhang K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6946
   Zhang XG, 2021, BIOACT MATER, V6, P472, DOI 10.1016/j.bioactmat.2020.08.024
   Zhang Y, 2019, BIOMATERIALS, V189, P48, DOI 10.1016/j.biomaterials.2018.10.022
   Zhao Y, 2022, ADV SCI, V9, DOI 10.1002/advs.202204535
   Zhao Z, 2019, THERANOSTICS, V9, P4508, DOI 10.7150/thno.34314
   Zheng DW, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00387 1
   Zhou WH, 2019, ANGEW CHEM INT EDIT, V58, P769, DOI 10.1002/anie.201810878
   Zhu YQ, 2019, ANGEW CHEM INT EDIT, V58, P4581, DOI 10.1002/anie.201814320
NR 47
TC 1
Z9 1
U1 1
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD MAY 22
PY 2024
VL 12
IS 20
BP 4882
EP 4898
DI 10.1039/d4tb00564c
EA APR 2024
PG 17
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA RP2C5
UT WOS:001209292700001
PM 38682491
DA 2025 08 17
ER

PT J
AU Feng, RT
   Anderson, G
   Xiao, GZ
   Elliott, G
   Leoni, L
   Mapara, MY
   Roodman, GD
   Lentzsch, S
AF Feng, Rentian
   Anderson, Gulsum
   Xiao, Guozhi
   Elliott, Gary
   Leoni, Lorenzo
   Mapara, Markus Y.
   Roodman, G. David
   Lentzsch, Suzanne
TI SDX 308, a nonsteroidal anti inflammatory agent, inhibits NF κB
   activity, resulting in strong inhibition of osteoclast
   formation/activity and multiple myeloma cell growth
SO BLOOD
LA English
DT Article
ID TUMOR NECROSIS FACTOR; HUMAN BONE MARROW; TRANSCRIPTION FACTOR;
   SIGNALING CASCADES; REGULATORY SUBUNIT; KINASE COMPLEX; IN VITRO;
   ACTIVATION; ETODOLAC; GENERATION
AB Multiple myeloma is characterized by increased osteoclast activity that results in bone destruction and lytic lesions. With the prolonged overall patient survival achieved by new treatment modalities, additional drugs are required to inhibit bone destruction. We focused on a novel and more potent structural analog of the nonsteroidal anti inflammatory drug etodolac, known as SDX 308, and its effects on osteoclastogenesis and multiple myeloma cells. SDX 101 is another structural analog of etodolac that is already used in clinical trials for the treatment of B cell chronic lymphocytic leukemia (B CLL). Compared with SDX 101, a 10 fold lower concentration of SDX 308 induced potent (60% 80%) inhibition of osteoclast formation, and a 10  to 100 fold lower concentration inhibited multiple myeloma cell proliferation. Bone resorption was completely inhibited by SDX 308, as determined in dentin based bone resorption assays. SDX 308 decreased constitutive and RANKL stimulated NF kappa B activation and osteoclast formation in an osteoclast cellular model, RAW 264.7. SDX 308 effectively suppressed TNF alpha induced IKK gamma and I kappa B alpha phosphorylation and degradation and subsequent NF kappa B activation in human multiple myeloma cells. These results indicate that SDX 308 effectively inhibits multiple myeloma cell proliferation and osteoclast activity, potentially by controlling NF kappa B activation signaling. We propose that SDX 308 is a promising therapeutic candidate to inhibit multiple myeloma growth and osteoclast activity and that it should receive attention for further study.
C1 Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA 15260 USA.
   Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA.
   Galen Strategies Consulting Serv, San Diego, CA USA.
   Mondobiotech, Gentiino, Switzerland.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Lentzsch, S (通讯作者)，Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA 15260 USA.
EM lentzschs@upmc.edu
RI mapara, markus/A 2134 2013
FU NCATS NIH HHS [UL1 TR000005] Funding Source: Medline
CR Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029
   ANDERSON G, 2005, BLOOD
   ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood 2003 06 2151
   CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0
   DEMERSON CA, 1983, J MED CHEM, V26, P1778, DOI 10.1021/jm00366a025
   DEMULDER A, 1993, ENDOCRINOLOGY, V133, P1978, DOI 10.1210/en.133.5.1978
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   HUMBER LG, 1986, J MED CHEM, V29, P871, DOI 10.1021/jm00155a047
   KANEKAL S, 2004, EUR J CANCER, V2, P383
   Koh KR, 2005, BLOOD, V105, P3833, DOI 10.1182/blood 2004 03 0828
   Lentzsch S, 2004, LEUKEMIA, V18, P1883, DOI 10.1038/sj.leu.2403486
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   LEONI LM, 2004, BLOOD, P104
   MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo 120 6 2326
   Nakamura S, 2006, LEUKEMIA RES, V30, P123, DOI 10.1016/j.leukres.2005.06.009
   Ono K, 2002, J BONE MINER RES, V17, P774, DOI 10.1359/jbmr.2002.17.5.774
   REID CDL, 1992, J IMMUNOL, V149, P2681
   Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261
   SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0
   Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
   Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988
   Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103
   Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yasui H, 2005, BLOOD, V106, P706, DOI 10.1182/blood 2005 02 0838
NR 31
TC 44
Z9 52
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD MAR 1
PY 2007
VL 109
IS 5
BP 2130
EP 2138
DI 10.1182/blood 2006 07 027458
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 142HW
UT WOS:000244641100054
PM 17095620
OA hybrid
DA 2025 08 17
ER

PT J
AU Morris, EV
   Edwards, CM
AF Morris, Emma, V
   Edwards, Claire M.
TI Myeloma and marrow adiposity: Unanswered questions and future directions
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE multiple myeloma; bone marrow adipocytes; obesity; adipokines;
   adiponectin
ID MULTIPLE MYELOMA; BONE MARROW; CIRCULATING ADIPONECTIN; OBESITY; TISSUE;
   HETEROGENEITY; ADIPOCYTES; MECHANISM; CANCER; CELLS
AB Multiple myeloma (MM) is a haematological malignancy characterised by the proliferation and accumulation of terminally differentiated abnormal plasma cells in the bone marrow. Patients suffer from bone pain, factures, anaemia, osteolytic lesions and renal failure. Despite recent advancement in therapy MM remains an incurable disease due to the emergences of drug resistance and frequent relapse. For many decades, research has been heavily focused on understanding the relationship between bone cells such as osteoblast, osteocytes and osteoclasts and the infiltrating tumour cells. However, it is now clear that the tumour supportive bone microenvironment including cellular and non cellular components play an important role in driving MM progression and bone disease. One of the most abundant cell types in the bone microenvironment is the bone marrow adipocyte (BMAd). Once thought of as inert space filling cells, they have now been recognised as having specialised functions, signalling in an autocrine, paracrine and endocrine manner to support normal systemic homeostasis. BMAds are both an energy store and a source of secreted adipokines and bioactive substances, MM cells are able to hijack this metabolic machinery to fuel migration, growth and survival. With global obesity on the rise, it has never been more important to further understand the contribution these cells have in both normal and disease settings. The aim of this review is to summarise the large body of emerging evidence supporting the interplay between BMAds and MM cells and to delineate how they fit into the vicious cycle of disease. (c) 2021 Elsevier Ltd. All rights reserved.
C1 [Morris, Emma, V; Edwards, Claire M.] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.
   [Edwards, Claire M.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.
   Univ Oxford, Botnar Res Ctr, Old Rd, Oxford OX3 7LD, England.
C3 University of Oxford; University of Oxford; University of Oxford
RP Morris, EV (通讯作者)，Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.
EM emma.morris@nds.ox.ac.uk
RI Edwards, Claire/D 7114 2011
OI Edwards, Claire/0000 0002 1257 5659
FU Blood Cancer UK
FX This work was funded by Blood Cancer UK.
CR ALEXANIAN R, 1968, BLOOD, V31, P1
   Bazarbachi AH, 2019, LEUKEMIA, V33, P2343, DOI 10.1038/s41375 019 0561 2
   Brighton TA, 2019, CLIN CANCER RES, V25, P3772, DOI 10.1158/1078 0432.CCR 18 3470
   Cawthorn WP, 2014, CELL METAB, V20, P368, DOI 10.1016/j.cmet.2014.06.003
   Chang SH, 2017, JNCI J NATL CANCER I, V109, DOI 10.1093/jnci/djw264
   Chen BY, 2006, BIOCHEM BIOPH RES CO, V341, P549, DOI 10.1016/j.bbrc.2006.01.004
   Craft CS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54036 x
   De Veirman K, 2016, CANCER LETT, V377, P17, DOI 10.1016/j.canlet.2016.04.024
   Deng T., OBESITY INFLAMMATION
   Diedrich JD, 2018, CURR OSTEOPOROS REP, V16, P443, DOI 10.1007/s11914 018 0453 9
   Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928
   Faict S, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 018 0139 7
   Fairfield H, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.584683
   Fairfield H, 2021, CANCER RES, V81, P634, DOI 10.1158/0008 5472.CAN 20 1088
   Fairfield H, 2019, BONE, V118, P77, DOI 10.1016/j.bone.2018.01.023
   Fakhari S, 2019, IRAN J IMMUNOL, V16, P142, DOI [10.22034/IJI.2019.80257, 10.22034/iji.2019.80257]
   Falank C, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00067
   Farrell M, 2019, CL LYMPH MYELOM LEUK, V19, pE89, DOI 10.1016/j.clml.2019.09.145
   Favreau M, 2017, LEUKEMIA, V31, P2678, DOI 10.1038/leu.2017.146
   Fowler JA, 2011, BLOOD, V118, P5872, DOI 10.1182/blood 2011 01 330407
   Gross JP, 2017, ONCOTARGET, V8, P68460, DOI 10.18632/oncotarget.19536
   Gu JY, 2021, CYTOKINE, V138, DOI 10.1016/j.cyto.2020.155358
   Gurevitch O, 2007, MED HYPOTHESES, V69, P531, DOI 10.1016/j.mehy.2007.01.052
   Hardouin P, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00085
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Hasegawa T, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 71
   Herroon MK, 2019, MOL CANCER RES, V17, P2508, DOI 10.1158/1541 7786.MCR 19 0540
   Hofmann JN, 2017, OBESITY, V25, P1317, DOI 10.1002/oby.21894
   Jurczyszyn A, 2015, LEUKEMIA RES, V39, P400, DOI 10.1016/j.leukres.2014.12.010
   Lauby Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602
   Lazar I, 2016, CANCER RES, V76, P4051, DOI 10.1158/0008 5472.CAN 16 0651
   Lee MJ, 2013, MOL ASPECTS MED, V34, P1, DOI 10.1016/j.mam.2012.10.001
   Leone E, 2013, CLIN CANCER RES, V19, P2096, DOI 10.1158/1078 0432.CCR 12 3325
   Li F, 2015, ONCOTARGET, V6, P38270, DOI 10.18632/oncotarget.5681
   Liu Z., MATURE ADIPOCYTES BO
   Liu ZY, 2020, INT J MOL MED, V45, P1112, DOI 10.3892/ijmm.2020.4475
   Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015
   Lwin ST, 2015, LEUKEMIA, V29, P507, DOI 10.1038/leu.2014.295
   Maden M, 2016, CANCER BIOMARK, V17, P391, DOI 10.3233/CBM 160654
   Manier S, 2017, BLOOD, V129, P2429, DOI 10.1182/blood 2016 09 742296
   Morris EV, 2020, J BONE MINER RES, V35, P942, DOI 10.1002/jbmr.3951
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492
   Nigro E., NEW INSIGHT ADIPONEC
   Olechnowicz SWZ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50591 5
   Ouchi N, 2007, CLIN CHIM ACTA, V380, P24, DOI 10.1016/j.cca.2007.01.026
   Pamuk G.E., LEPTIN RESISTIN LEVE
   Pang J., RESISTIN INDUCES MUL
   Parida S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102519
   Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001
   Reseland J.E., ABNORMAL ADIPOKINE L
   Rios Colon L, 2020, CELLS BASEL, V9, DOI 10.3390/cells9091988
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Rossi M, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305 5839.2015.12.13
   Sadie Van Gijsen H, 2013, CELL MOL LIFE SCI, V70, P2331, DOI 10.1007/s00018 012 1211 2
   Sebo ZL, 2019, ENDOCR REV, V40, P1187, DOI 10.1210/er.2018 00138
   Singhal V, 2019, BONE, V118, P69, DOI 10.1016/j.bone.2018.01.009
   Smets T, 2018, METHODS MOL BIOL, V1792, P47, DOI 10.1007/978 1 4939 7865 6_4
   Tan WCC, 2020, CANCER COMMUN, V40, P135, DOI 10.1002/cac2.12023
   Teras LR, 2014, BRIT J HAEMATOL, V166, P667, DOI 10.1111/bjh.12935
   Trotter T.N., ADIPOCYTE LINEAGE CE
   Veld J, 2016, SKELETAL RADIOL, V45, P1277, DOI 10.1007/s00256 016 2425 4
   Wang SH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1220 2
   Westhrin M, 2018, BIOMARK RES, V6, DOI 10.1186/s40364 018 0134 y
   Yang DJ, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0221 6
   Yu W., ADIPOCYTES SECRETED
   Zijlstra A, 2018, NAT CELL BIOL, V20, P228, DOI 10.1038/s41556 018 0049 8
NR 68
TC 6
Z9 7
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD JUL
PY 2021
VL 35
IS 4
SI SI
AR 101541
DI 10.1016/j.beem.2021.101541
EA SEP 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA WJ8ED
UT WOS:000709270900003
PM 34006450
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Cui, J
   Li, XQ
   Wang, SC
   Su, YM
   Chen, X
   Cao, LH
   Zhi, X
   Qiu, ZL
   Wang, Y
   Jiang, H
   Huang, BT
   Ji, F
   Su, JC
AF Cui, Jin
   Li, Xiaoqun
   Wang, Sicheng
   Su, Yiming
   Chen, Xiao
   Cao, Liehu
   Zhi, Xin
   Qiu, Zili
   Wang, Yao
   Jiang, Hao
   Huang, Biaotong
   Ji, Fang
   Su, Jiacan
TI Triptolide prevents bone loss via suppressing osteoclastogenesis through
   inhibiting PI3K AKT NFATc1 pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone loss; ovariectomy; PI3K AKT NFATc1; triptolide; tumour
ID NF KAPPA B; PARTICLE INDUCED OSTEOLYSIS; RECEPTOR ACTIVATOR;
   PROINFLAMMATORY CYTOKINES; RANKL; ESTROGEN; OSTEOPOROSIS; HEALTH;
   LIGAND; P53
AB Bone loss (osteopenia) is a common complication in human solid tumour. In addition, after surgical treatment of gynaecological tumour, osteoporosis often occurs due to the withdrawal of oestrogen. The major characteristic of osteoporosis is the low bone mass with micro architectural deteriorated bone tissue. And the main cause is the overactivation of osteoclastogenesis, which is one of the most important therapeutic targets. Inflammation could induce the interaction of RANKL/RANK, which is the promoter of osteoclastogenesis. Triptolide is derived from the traditional Chinese herb lei gong teng, presented multiple biological effects, including anti cancer, anti inflammation and immunosuppression. We hypothesized that triptolide could inhibits osteoclastogenesis by suppressing inflammation activation. In this study, we confirmed that triptolide could suppress RANKL induced osteoclastogenesis in bone marrow mononuclear cells (BMMCs) and RAW264.7 cells and inhibited the osteoclast bone resorption functions. PI3K AKT NFATc1 pathway is one of the most important downstream pathways of RANKL induced osteogenesis. The experiments in vitro indicated that triptolide suppresses the activation of PI3K AKT NFATc1 pathway and the target point located at the upstream of AKT because both NFATc1 overexpression and AKT phosphorylation could ameliorate the triptolide suppression effects. The expression of MDM2 was elevated, which demonstrated the MDM p53 induced cell death might contribute to the osteoclastogenesis suppression. Ovariectomy induced bone loss and inflammation activation were also found to be ameliorated in the experiments in vivo. In summary, the new effect of anti cancer drug triptolide was demonstrated to be anti osteoclastogenesis, and we demonstrated triptolide might be a promising therapy for bone loss caused by tumour.
C1 [Cui, Jin; Chen, Xiao; Cao, Liehu; Wang, Yao; Jiang, Hao; Ji, Fang; Su, Jiacan] Second Mil Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Cui, Jin; Chen, Xiao; Su, Jiacan] China South Korea Bioengn Ctr, Shanghai, Peoples R China.
   [Li, Xiaoqun; Zhi, Xin] Second Mil Med Univ, Shanghai Changhai Hosp, Grad Management Unit, Shanghai, Peoples R China.
   [Wang, Sicheng] Zhongye Hosp, Shanghai, Peoples R China.
   [Su, Yiming; Huang, Biaotong] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
   [Qiu, Zili] Jinling High Sch, Nanjing, Peoples R China.
C3 Naval Medical University; Naval Medical University; Shanghai University
RP Ji, F; Su, JC (通讯作者)，China South Korea Bioengn Ctr, Dept Orthoped, Shanghai, Peoples R China.
EM jiacansu@126.com
RI ; ji, fang/JXN 5517 2024; Cui, Jin/HDL 7327 2022; Su,
   Jiacan/N 7068 2019; Wang, Sicheng/LXV 9883 2024; Chen, Xiao/N 1298 2017
OI Qiu, Zili/0009 0009 5582 0210; Su, Jiacan/0000 0001 7080 263X; 
FU National Natural Science Foundation of China [81701364, 81901426];
   National Natural Science Foundation Key Research Program in Aging
   [91749204]; National key research and development plan [2018YFC2001500];
   Shanghai Sailing Program [19YF1447400]; Science and Technology Support
   Project in Biomedical Field of Shanghai; Science and Technology
   Innovation Plan [18431902300]; Technology Commission Key Program
   [15411950600]; National Science Foundation General Program [81771491];
   Changhai Hospital Initial Foundation [2018QNA012]
FX National Natural Science Foundation of China, Grant/Award Number:
   81701364 and 81901426; National Natural Science Foundation Key Research
   Program in Aging, Grant/Award Number: 91749204; National key research
   and development plan, Grant/Award Number: 2018YFC2001500; Sponsored by
   Shanghai Sailing Program, Grant/Award Number: 19YF1447400; Science and
   Technology Support Project in Biomedical Field of Shanghai; Science and
   Technology Innovation Plan, Grant/Award Number: 18431902300; Technology
   Commission Key Program, Grant/Award Number: 15411950600; National
   Science Foundation General Program, Grant/Award Number: 81771491;
   Changhai Hospital Initial Foundation, Grant/Award Number: 2018QNA012
CR Aquilano K, 2013, ANTIOXID REDOX SIGN, V18, P386, DOI 10.1089/ars.2012.4615
   Baldelli S, 2016, AGING US, V8, P3450, DOI 10.18632/aging.101139
   Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Castle PE, 2018, ANN INTERN MED, V168, P20, DOI 10.7326/M17 1609
   Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen ZW, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1058 3
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Feng Q, 2017, ONCOTARGET, V8, P27820, DOI 10.18632/oncotarget.15482
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Hickey M, 2010, HUM REPROD UPDATE, V16, P131, DOI 10.1093/humupd/dmp037
   Huang JB, 2015, MOL CELL ENDOCRINOL, V399, P346, DOI 10.1016/j.mce.2014.10.016
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Jia M, 2015, BEST PRACT RES CL EN, V29, P557, DOI 10.1016/j.beem.2015.04.008
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kong LB, 2017, CELL PHYSIOL BIOCHEM, V43, P1425, DOI 10.1159/000481874
   Laroche A, 2017, ONCOTARGET, V8, P53968, DOI 10.18632/oncotarget.16345
   Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li FQ, 2018, CELL PHYSIOL BIOCHEM, V45, P917, DOI 10.1159/000487286
   Li X, 2014, ARTHROSCOPY, V30, P1483, DOI 10.1016/j.arthro.2014.03.020
   Liu CF, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/626038
   Pino AM, 2010, J BONE MINER RES, V25, P492, DOI 10.1359/jbmr.090802
   Matulonis UA, 2019, ANN ONCOL, V30, P1080, DOI 10.1093/annonc/mdz135
   Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198
   Mei X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1736 x
   Miao Q, 2012, INT J MOL SCI, V13, P56, DOI 10.3390/ijms13010056
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Moriwaki S, 2013, PLOS ONE, V9
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097 4652(199708)172:2<230::AID JCP10>3.3.CO;2 Z
   Novella S, 2012, ARTERIOSCL THROM VAS, V32, P2035, DOI 10.1161/ATVBAHA.112.250308
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Park B, 2014, BIOCHIMIE, V105, P129, DOI 10.1016/j.biochi.2014.07.003
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688
   Quach JM, 2015, J BONE MINER RES, V30, P886, DOI 10.1002/jbmr.2415
   Shinozaki S, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005375
   Shukla P, 2017, J BIOL CHEM, V292, P4686, DOI 10.1074/jbc.M116.764779
   Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Wu Q, 2015, MED SCI MONITOR, V21
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu HH, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8048170
   Yang SM, 2003, MOL CANCER THER, V2, P65
   Yang WZ, 2016, CELL PHYSIOL BIOCHEM, V38, P2366, DOI 10.1159/000445589
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhang PP, 2016, CANCER LETT, V376, P95, DOI 10.1016/j.canlet.2016.01.011
   Zheng Y, 2011, ARTERIOSCL THROM VAS, V31, P2781, DOI 10.1161/ATVBAHA.111.224907
   Zhi X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00022
   Zhou ZL, 2012, NAT PROD REP, V29, P457, DOI 10.1039/c2np00088a
NR 56
TC 40
Z9 47
U1 1
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2020
VL 24
IS 11
BP 6149
EP 6161
DI 10.1111/jcmm.15229
EA APR 2020
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA LX7LP
UT WOS:000529061900001
PM 32347017
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jie, ZW
   Xie, Z
   Xu, WB
   Zhao, XD
   Jin, G
   Sun, XW
   Huang, B
   Tang, P
   Wang, GL
   Shen, SY
   Qin, A
   Fan, SW
AF Jie, Zhiwei
   Xie, Ziang
   Xu, Wenbin
   Zhao, Xiangde
   Jin, Gu
   Sun, Xuewu
   Huang, Bao
   Tang, Pan
   Wang, Gangliang
   Shen, Shuying
   Qin, An
   Fan, Shunwu
TI SREBP 2 aggravates breast cancer associated osteolysis by promoting
   osteoclastogenesis and breast cancer metastasis
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE SREBP 2; Osteoclast; Breast cancer; Osteolysis; Therapy
ID TERMINAL DIFFERENTIATION; BONE; MICROENVIRONMENT; TRANSCRIPTION;
   ACTIVATION; CHOLESTEROL; EXPRESSION; FATOSTATIN; DISEASE; CELLS
AB Bone is one of the most common sites of breast cancer metastasis and a major cause of high mortality in these patients. Thus, further understanding the molecular mechanisms regulating breast cancer induced osteolysis is critical for the development of more effective treatments. In this study, we demonstrated that important roles sterol regulatory element binding protein 2 (SREBP 2) play in osteoclast formation a function, and in breast cancer metastasis. SREBP 2 expression was found to be induced during the early stages of osteoclast formation under the control of the RANKL/cAMP response element binding protein (CREB) signaling cascade. SREBP 2 is subsequently translocated into the nucleus where it participates with other transcriptional factors to induce the expression of NFATcl required for mature osteoclast formation. Additionally, SREBP 2 was also found to be highly expressed in breast cancer tissues and correlated with a poor prognosis. SREBP 2 was similarly under the transcriptional control of CREB and its induction regulates the expression of matrix metalloproteinases (MMPs), key degradative enzymes involved in bone metastases by breast cancer cells. Accordingly, targeting of SREBP 2 with Fatostatin which specifically inhibits SCAP (SREBP cleavage activating protein) and prevents SREBP activation, attenuated breast cancer induced osteolysis in vivo. Collectively, our results suggest that SREBP 2 plays a critical role in regulating osteoclastogenesis and contributes to breast cancer induced osteolysis. Thus, SREBP 2 inhibition is a potential therapeutic approach for breast cancer patients with osteolytic bone lesions.
C1 [Jie, Zhiwei; Xie, Ziang; Xu, Wenbin; Zhao, Xiangde; Sun, Xuewu; Huang, Bao; Wang, Gangliang; Shen, Shuying; Fan, Shunwu] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou 310016, Zhejiang, Peoples R China.
   [Xie, Ziang; Xu, Wenbin; Zhao, Xiangde; Sun, Xuewu; Huang, Bao; Wang, Gangliang; Shen, Shuying] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310016, Zhejiang, Peoples R China.
   [Jin, Gu] Zhejiang Canc Hosp, Dept Bone & Soft Tissue Surg, Hangzhou 310022, Zhejiang, Peoples R China.
   [Tang, Pan] Zhejiang Univ, Huzhou Hosp, Dept Orthoped, Huzhou 313003, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed,Shanghai Peoples Hosp 9, Shanghai 200011, Peoples R China.
C3 Zhejiang University; Zhejiang Cancer Hospital; Zhejiang University;
   Shanghai Jiao Tong University
RP Fan, SW (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou 310016, Zhejiang, Peoples R China.; Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed,Shanghai Peoples Hosp 9, Shanghai 200011, Peoples R China.
EM dr_qinan@163.com; 0099203@zju.edu.cn
RI ; Qin, An/J 2518 2019; Tang, Pan/AIC 2118 2022
OI Jie, Zhiwei/0000 0002 9469 4490; 
FU National Natural Science Foundation of China [81772373, 81572167,
   81772387, 81472064]; National Key R&D Program of China [2018YFC1105200];
   Key Research and Development Plan in Zhejiang province [2018C03060];
   Health Department of Zhejiang Province [2017KY024]
FX This work was supported by the National Natural Science Foundation of
   China (81772373; 81572167; 81772387; 81472064), National Key R&D Program
   of China (No. 2018YFC1105200), the Key Research and Development Plan in
   Zhejiang province (No. 2018C03060), and the Health Department of
   Zhejiang Province (grant number 2017KY024).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758
   Bai XY, 2018, CANCER LETT, V412, P224, DOI 10.1016/j.canlet.2017.10.027
   Bellanger A, 2017, J PATHOL, V242, P73, DOI 10.1002/path.4882
   Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585 013 9624 3
   Borgquist S, 2017, J CLIN ONCOL, V35, P1179, DOI 10.1200/JCO.2016.70.3116
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chen M, 2018, NAT GENET, V50, P206, DOI 10.1038/s41588 017 0027 2
   Chen W, 2018, J PATHOL, V244, P271, DOI 10.1002/path.5001
   Drake MT, 2010, MOL INTERV, V10, P141, DOI 10.1124/mi.10.3.5
   Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017
   Gholkar AA, 2016, J BIOL CHEM, V291, P17001, DOI 10.1074/jbc.C116.737346
   Hada N, 2012, BONE, V50, P226, DOI 10.1016/j.bone.2011.10.028
   Inoue K, 2015, BBA MOL BASIS DIS, V1852, P2432, DOI 10.1016/j.bbadis.2015.08.018
   Inoue K, 2014, J BONE MINER RES, V29, P1823, DOI 10.1002/jbmr.2229
   Jie ZW, 2019, J CELL PHYSIOL, V234, P4167, DOI 10.1002/jcp.27171
   Kommalapati A, 2017, CRIT REV ONCOL HEMAT, V120, P217, DOI 10.1016/j.critrevonc.2017.09.003
   Kondo A, 2017, CELL REP, V18, P2228, DOI 10.1016/j.celrep.2017.02.006
   Koob S, 2017, Z ORTHOP UNFALLCHIR, V155, P716, DOI 10.1055/s 0043 116799
   Li XY, 2014, MOL CANCER THER, V13, P855, DOI 10.1158/1535 7163.MCT 13 0797
   Li YJ, 2017, HEPATOLOGY, V66, P481, DOI 10.1002/hep.29206
   Lipton Allan, 2011, Curr Opin Support Palliat Care, V5, P258, DOI 10.1097/SPC.0b013e328349731c
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   Mittal S, 2018, EXPERT REV MOL DIAGN, V18, P227, DOI 10.1080/14737159.2018.1439382
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Musso G, 2013, PROG LIPID RES, V52, P175, DOI 10.1016/j.plipres.2012.11.002
   Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884
   Park JH, 2017, MOL CELLS, V40, P706
   Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shimano H, 2017, NAT REV ENDOCRINOL, V13, P710, DOI 10.1038/nrendo.2017.91
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0417 0
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yoneda T, 2015, BBA BIOMEMBRANES, V1848, P2677, DOI 10.1016/j.bbamem.2015.02.004
NR 46
TC 37
Z9 40
U1 2
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925 4439
EI 1879 260X
J9 BBA MOL BASIS DIS
JI Biochim. Biophys. Acta Mol. Basis Dis.
PD JAN
PY 2019
VL 1865
IS 1
BP 115
EP 125
DI 10.1016/j.bbadis.2018.10.026
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA HC0MM
UT WOS:000451492500012
PM 30394316
DA 2025 08 17
ER

PT J
AU Liu, Y
   Liu, WJ
   Yu, ZQ
   Zhang, Y
   Li, YH
   Xie, DT
   Xie, G
   Fan, L
   He, SP
AF Liu, Ying
   Liu, Wenjie
   Yu, Ziqiang
   Zhang, Yan
   Li, Yinghua
   Xie, Dantao
   Xie, Gang
   Fan, Li
   He, Shipeng
TI A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized
   osteoporosis by blocking RANKL mediated MAPK and NF κB pathways
SO CELL DEATH & DISEASE
LA English
DT Article
ID DIFFERENTIATION FACTOR; BET; MECHANISMS; PROTEINS; UPDATE; DRUGS; JQ1
AB Bromodomain containing protein 4 (BRD4) has emerged as a promising treatment target for bone related disorders. (+) JQ1, a thienotriazolodiazepine compound, has been shown to inhibit pro osteoclastic activity in a BRD4 dependent approach and impede bone loss caused by ovariectomy (OVX) in vivo. However, clinical trials of (+) JQ1 are limited because of its poor druggability. In this study, we synthesized a new (+) JQ1 derivative differing in structure and chirality. One such derivative, (+) ND, exhibited higher solubility and excellent inhibitory activity against BRD4 compared with its analogue (+) JQ1. Interestingly, ( ) JQ1 and ( ) ND exhibited low anti proliferative activity and had no significant inhibitory effect on RANKL induced osteoclastogenesis as compared with (+) JQ1 and (+) ND, suggesting the importance of chirality in the biological activity of compounds. Among these compounds, (+) ND displayed the most prominent inhibitory effect on RANKL induced osteoclastogenesis. Moreover, (+) ND could inhibit osteoclast specific gene expression, F actin ring generation, and bone resorption in vitro and prevent bone loss in OVX mice. Collectively, these findings indicated that (+) ND represses RANKL stimulated osteoclastogenesis and averts OVX triggered osteoporosis by suppressing MAPK and NF kappa B signalling cascades, suggesting that it may be a prospective candidate for osteoporosis treatment.
C1 [Liu, Ying; Yu, Ziqiang; Zhang, Yan; Li, Yinghua; He, Shipeng] Shanghai Univ, Inst Translat Med, 99 Shangda Rd, Shanghai 200444, Peoples R China.
   [Liu, Wenjie; Xie, Dantao; Xie, Gang] Shantou Univ, Affiliated Hosp 2, Med Coll, Dept Orthoped, 22 Xinling Rd, Shantou 515041, Peoples R China.
   [Fan, Li] Naval Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
C3 Shanghai University; Shantou University; Naval Medical University
RP He, SP (通讯作者)，Shanghai Univ, Inst Translat Med, 99 Shangda Rd, Shanghai 200444, Peoples R China.; Fan, L (通讯作者)，Naval Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
EM smmuxlb@163.com; heshipeng@shu.edu.cn
OI Li, Yinghua/0000 0002 2391 6738
FU National Natural Science Foundation of China [82003567, 91849129];
   Shanghai Sailing Program [20YF1414100]
FX This work was funded by grants from National Natural Science Foundation
   of China (NO. 82003567 and 91849129), Sponsored by Shanghai Sailing
   Program (NO. 20YF1414100).
CR Alqahtani A, 2019, FUTUR SCI OA, V5, DOI 10.4155/fsoa 2018 0115
   Alvarado Garcia Alberto, 2015, Rev Med Inst Mex Seguro Soc, V53, P214
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Baud'huin M, 2017, BONE, V94, P10, DOI 10.1016/j.bone.2016.09.020
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Caffarelli C, 2017, CLIN INTERV AGING, V12, P1819, DOI 10.2147/CIA.S138002
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Devaiah BN, 2016, NAT STRUCT MOL BIOL, V23, P540, DOI 10.1038/nsmb.3228
   Diniz TC, 2018, EXPERT OPIN THER PAT, V28, P81, DOI 10.1080/13543776.2017.1384816
   Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0915 9
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Garcia PL, 2018, MOL CANCER THER, V17, P107, DOI 10.1158/1535 7163.MCT 16 0922
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Han JK, 2018, J CELL BIOCHEM, V119, P7310, DOI 10.1002/jcb.27028
   He SP, 2018, J MED CHEM, V61, P7245, DOI [10.1021/acs.jmedchem.8b0064, 10.1021/acs.jmedchem.8b00664]
   Huang T, 2018, GENET RES, V100, DOI 10.1017/S0016672318000034
   Huang WH, 2016, MINI REV MED CHEM, V16, P1403, DOI 10.2174/1389557516666160611014130
   Jiang YF, 2017, BBA MOL BASIS DIS, V1863, P3001, DOI 10.1016/j.bbadis.2017.08.009
   Kim K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020601
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Li N, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0789 1
   Liu D, 2019, TRENDS FOOD SCI TECH, V91, P586, DOI 10.1016/j.tifs.2019.07.038
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Meng S, 2014, J DENT RES, V93, P657, DOI 10.1177/0022034514534261
   Miao WH, 2019, CONNECT TISSUE RES, V60, P487, DOI 10.1080/03008207.2019.1593392
   Moyer MW, 2011, NAT MED, V17, P1325, DOI 10.1038/nm1111 1325
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159 8290.CD 12 0418
   Qiu HF, 2016, ONCOTARGET, V7, P66809, DOI 10.18632/oncotarget.11631
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Shi XY, 2018, PHARMAZIE, V73, P491, DOI 10.1691/ph.2018.8480
   Shibahara T, 2019, TOHOKU J EXP MED, V247, P75, DOI 10.1620/tjem.247.75
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Vrtacnik P, 2014, CLIN CHEM LAB MED, V52, P589, DOI 10.1515/cclm 2013 0770
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 37
TC 27
Z9 30
U1 2
U2 31
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN 26
PY 2021
VL 12
IS 7
AR 654
DI 10.1038/s41419 021 03939 7
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA TC6HU
UT WOS:000668743100003
PM 34175898
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zheng, XD
   Yu, Y
   Shao, BY
   Gan, N
   Chen, L
   Yang, DQ
AF Zheng, Xuedan
   Yu, Yang
   Shao, Binyi
   Gan, Ning
   Chen, Liang
   Yang, Deqin
TI Osthole improves therapy for osteoporosis through increasing autophagy
   of mesenchymal stem cells
SO EXPERIMENTAL ANIMALS
LA English
DT Article
DE autophagy; mesenchymal stem cells; osteoblast differentiation;
   osteoporosis; osthole
ID BONE MARROW; POSTMENOPAUSAL WOMEN; INDUCED APOPTOSIS; OSTEOGENIC
   DIFFERENTIATION; CNIDIUM MONNIERI; OSTEOBLASTS; PREVENTION; MICE;
   INHIBITION; FRACTURES
AB Osteoporosis is a common skeletal disorder resulting in elevated fracture risk. Improvement of osteogenic differentiation is thought to be the top priority in osteoporosis treatment projects. Significant characteristics of bone marrow mesenchymal stem cells (BMMSCs), especially attractive ability to differentiate into osteoblasts, have made them alternatives for osteoporosis treatment. However, therapeutic effect with BMMSCs remains to be improved. Here, osthole, a bioactive simple coumarin derivative extracted from many medicinal plants, was introduced to pre stimulate BMMSCs and then applied in osteoporosis therapy. The results showed that osthole treated BMMSCs (OBMMSCs) brought a better outcome than BMMSCs alone in estrogen deficiency induced osteoporosis model. And elevated autophagy level was suggested to be the underlying mechanism of the ability of osthole to promote osteoblast differentiation, which is indicated by the upregulation of protein and mRNA expression level of autophagy associated genes, Beclin1 and LC3. We concluded from these experiments that OBMMSCs are more effective than BMMSCs in osteoporosis treatment maybe through upregulation level of autophagy level induced by osthole.
C1 [Zheng, Xuedan; Yu, Yang; Shao, Binyi; Gan, Ning; Chen, Liang; Yang, Deqin] Chongqing Med Univ, Dept Endodont, Stomatol Hosp, 426 Songshi Bei Rd, Chongqing 401147, Peoples R China.
   [Zheng, Xuedan; Yu, Yang; Shao, Binyi; Gan, Ning; Chen, Liang; Yang, Deqin] Chongqing Key Lab Oral Dis & Biomed Sci, 426 Songshi Bei Rd, Chongqing 401147, Peoples R China.
   [Zheng, Xuedan; Yu, Yang; Shao, Binyi; Gan, Ning; Chen, Liang; Yang, Deqin] Chongqing Municipal Key Lab Oral Biomed Engn High, 426 Songshi Bei Rd, Chongqing 401147, Peoples R China.
C3 Chongqing Medical University
RP Yang, DQ (通讯作者)，Chongqing Med Univ, Dept Endodont, Stomatol Hosp, 426 Songshi Bei Rd, Chongqing 401147, Peoples R China.; Yang, DQ (通讯作者)，Chongqing Key Lab Oral Dis & Biomed Sci, 426 Songshi Bei Rd, Chongqing 401147, Peoples R China.; Yang, DQ (通讯作者)，Chongqing Municipal Key Lab Oral Biomed Engn High, 426 Songshi Bei Rd, Chongqing 401147, Peoples R China.
EM yangdeqin@hospital.cqmu.edu.cn
RI Yang, Deqin/LCD 5734 2024
OI Yang, Deqin/0000 0002 2579 8384
FU National Natural Science Foundation of China [31571508, 31371473,
   81800979, 81700958]
FX This work was supported by the National Natural Science Foundation of
   China (31571508, 31371473 to D.Y, 81800979 to Y.Y and 81700958 to L.C).
CR Ahmed SF, 2009, ENDOCR DEV, V16, P170, DOI 10.1159/000223695
   Baltzer AWA, 2001, GENE THER, V8, P1770, DOI 10.1038/sj.gt.3301594
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Cai J, 1991, Zhongguo Zhong Yao Za Zhi, V16, P451
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Florencio Silva R, 2017, REV ASSOC MED BRAS, V63, P173, DOI 10.1590/1806 9282.63.02.173
   Gao LN, 2013, BIOMATERIALS, V34, P9937, DOI 10.1016/j.biomaterials.2013.09.017
   Han YD, 2018, INT J MOL MED, V41, P800, DOI 10.3892/ijmm.2017.3270
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev genet 102808 114910
   Hu HY, 2016, CELL PHYSIOL BIOCHEM, V38, P2375, DOI 10.1159/000445590
   Ichioka N, 2002, STEM CELLS, V20, P542, DOI 10.1634/stemcells.20 6 542
   Kumar S, 2004, HUM GENE THER, V15, P1197, DOI 10.1089/hum.2004.15.1197
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lewiecki EM, 2010, MATURITAS, V66, P182, DOI 10.1016/j.maturitas.2010.02.008
   Li DY, 2017, EUR REV MED PHARMACO, V21, P5548, DOI 10.26355/eurrev_201712_13991
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Lin PC, 2011, CELL TRANSPLANT, V20, P71, DOI 10.3727/096368910X532747
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Matsuda H, 2002, BIOL PHARM BULL, V25, P809, DOI 10.1248/bpb.25.809
   Ming LG, 2011, PHARMACOLOGY, V88, P33, DOI 10.1159/000328776
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   Okamoto T, 2001, INT J MOL MED, V7, P307
   Okamoto Y, 2011, IMPLANT DENT, V20, P236, DOI 10.1097/ID.0b013e3182199543
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Piemontese M, 2016, SCI REP UK, V6, DOI 10.1038/srep24262
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Rubin MR, 2005, DRUGS, V65, P2481, DOI 10.2165/00003495 200565170 00005
   Shen GY, 2018, CELL MOL LIFE SCI, V75, P2683, DOI 10.1007/s00018 018 2776 1
   Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44
   Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269
   Spanou A, 2015, ORAL DIS, V21, P927, DOI 10.1111/odi.12333
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tang YH, 2018, MOL MED REP, V17, P158, DOI 10.3892/mmr.2017.7840
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wang Z, 2006, TISSUE ENG, V12, P1753, DOI 10.1089/ten.2006.12.1753
   Wong HL, 2012, CHIN J INTEGR MED, V18, P903, DOI 10.1007/s11655 012 1293 3
   Xia WB, 2012, J BONE MINER RES, V27, P125, DOI 10.1002/jbmr.519
   You L, 2009, NAT PROD COMMUN, V4, P297
   Yu Y, 2017, EXP ANIM TOKYO, V66, P167, DOI 10.1538/expanim.16 0094
   Zhang HW, 2010, EXPERT REV PROTEOMIC, V7, P103, DOI 10.1586/EPR.09.90
   Zhang LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037865
   Zhang QY, 2007, PLANTA MED, V73, P13, DOI 10.1055/s 2006 951724
   Zheng LW, 2017, J INVEST MED, V65, P1014, DOI 10.1136/jim 2017 000426
   Zheng Y, 2014, MOL MED REP, V10, P3003, DOI 10.3892/mmr.2014.2624
   Zimecki M, 2009, Z NATURFORSCH C, V64, P361
NR 52
TC 17
Z9 26
U1 1
U2 27
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1 2 3 SUGAMO, TOSHIMA KU, TOKYO, 170 0002, JAPAN
SN 1341 1357
EI 1881 7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PY 2019
VL 68
IS 4
BP 453
EP 463
DI 10.1538/expanim.18 0178
PG 11
WC Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences; Zoology
GA JK6SD
UT WOS:000494971400008
PM 31155553
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shen, Y
   Wang, HM
   Xie, HW
   Zhang, JT
   Ma, QL
   Wang, SY
   Yuan, PT
   Xue, H
   Hong, HX
   Fan, SW
   Xu, WB
   Xie, Z
AF Shen, Yang
   Wang, Haoming
   Xie, Hongwei
   Zhang, Jiateng
   Ma, Qingliang
   Wang, Shiyu
   Yuan, Putao
   Xue, Hong
   Hong, Huaxing
   Fan, Shunwu
   Xu, Wenbin
   Xie, Ziang
TI L arginine promotes angio osteogenesis to enhance oxidative
   stress inhibited bone formation by ameliorating mitophagy
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE angiogenesis; L arginine; mitophagy; Osteogenesis
ID OSTEOPOROSIS; AUTOPHAGY; ANGIOGENESIS; MECHANISMS; VESSELS; AGE
AB Background: Osteoporosis is one of the most common bone diseases in middle aged and elderly populations worldwide. The development of new drugs to treat the disease is a key focus of research. Current treatments for osteoporosis are mainly directed at promoting osteoblasts and inhibiting osteoclasts. However, there is currently no ideal approach for osteoporosis treatment. L arginine is a semi essential amino acid involved in a number of cellular processes, including nitric production, protein biosynthesis, and immune responses. We previously reported that L arginine derived compounds can play a regulatory role in bone homeostasis. Purpose: To investigate the specific effect of L arginine on bone homeostasis. Methods: Mildly aged and ovariectomized mouse models were used to study the effects of L arginine on osteogenesis and angiogenesis, assessed by micro computed tomography and immunostaining of bone tissue. The effect of L arginine on osteogenesis, angiogenesis, and adipogenesis was further studied in vitro using osteoblasts obtained from cranial cap bone, endothelial cells, and an adipogenic cell line. Specific methods to assess these processes included lipid staining, cell migration, tube forming, and wound healing assays. Protein and mRNA expression was determined for select biomarkers. Results: We found that L arginine attenuated bone loss and promoted osteogenesis and angiogenesis. L arginine increased the activity of vascular endothelial cells, whereas it inhibited adipogenesis in vitro. In addition, we found that L arginine altered the expression of PINK1/Parkin and Bnip3 in the mitochondria of osteoblast lineage and endothelial cells, thereby promoting mitophagy and protecting cells from ROS. Similarly, L arginine treatment effectively ameliorated osteoporosis in an ovariectomized mouse model. Conclusion: L arginine promotes angio osteogenesis, and inhibits adipogenesis, effects mediated by the PINK1/ Parkin  and Bnip3 mediated mitophagy. The Translational Potential of this Article: L arginine supplementation may be an effective adjunct therapy in the treatment of osteoporosis.
C1 [Shen, Yang; Wang, Haoming; Xie, Hongwei; Zhang, Jiateng; Ma, Qingliang; Wang, Shiyu; Yuan, Putao; Xue, Hong; Fan, Shunwu; Xu, Wenbin; Xie, Ziang] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.
   [Shen, Yang; Wang, Haoming; Xie, Hongwei; Zhang, Jiateng; Ma, Qingliang; Wang, Shiyu; Yuan, Putao; Xue, Hong; Fan, Shunwu; Xu, Wenbin; Xie, Ziang] Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou, Peoples R China.
   [Hong, Huaxing] Wenzhou Med Univ, Dept Orthopaed, Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China.
C3 Zhejiang University; Wenzhou Medical University
RP Fan, SW; Xu, WB; Xie, Z (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.
EM 0099203@zju.edu.cn; xuwenbin@zju.edu.cn; ziang_xie@zju.edu.cn
RI WANG, Haoming/A 5033 2009; Yu, Shicheng/D 5033 2018
FU National Natural Science Foundation of China [82102591, 82372440,
   81972089, 82002334, 82101647]; Key Project of National Natural Science
   Foundation of China [82330077]; Natural Science Foundation of Zhe jiang
   Province [LQ22H060001, Y23H060039, Z20H060003, Q20H060042]; Zhejiang
   Medical and Health Science and Technology Program [2016KYB326]; Union
   Fund Project of National Natural Science Foundation of China [U21A20351]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 82102591, 82372440, 81972089, 82002334, 82101647) ;
   The Key Project of National Natural Science Foundation of China (grant
   number 82330077) ; Natural Science Foundation of Zhe jiang Province
   (grant number LQ22H060001, Y23H060039, Z20H060003, Q20H060042) ;
   Zhejiang Medical and Health Science and Technology Program (grant number
   2016KYB326) ; Union Fund Project of National Natural Science Foundation
   of China (grant number U21A20351) .
CR Alvares TS, 2012, APPL PHYSIOL NUTR ME, V37, P115, DOI [10.1139/h11 144, 10.1139/H11 144]
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Bravo San Pedro JM, 2017, CIRC RES, V120, P1812, DOI 10.1161/CIRCRESAHA.117.311082
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Colleluori DM, 2001, BIOCHEMISTRY US, V40, P9356, DOI 10.1021/bi010783g
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Deng R, 2021, AUTOPHAGY, V17, P3011, DOI 10.1080/15548627.2020.1850609
   Dong BZ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34869 3
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Gogoi M, 2016, CURR OPIN MICROBIOL, V29, P43, DOI 10.1016/j.mib.2015.10.005
   Greenwood C, 2018, AGING DIS, V9, P976, DOI 10.14336/AD.2018.0124
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Guo YY, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101915
   Jin QH, 2018, REDOX BIOL, V14, P576, DOI 10.1016/j.redox.2017.11.004
   Kerr JS, 2017, TRENDS NEUROSCI, V40, P151, DOI 10.1016/j.tins.2017.01.002
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li LP, 2021, ANTIOXID REDOX SIGN, V35, P1, DOI 10.1089/ars.2020.8200
   Li MY, 2023, REDOX BIOL, V61, DOI 10.1016/j.redox.2023.102649
   Li Q, 2018, CELL BIOL TOXICOL, V34, P263, DOI 10.1007/s10565 017 9417 6
   Liu F, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101963
   Ma LS, 2018, AGING DIS, V9, P938, DOI 10.14336/AD.2017.1207
   Ma QL, 2022, J BONE MINER RES, V37, P152, DOI 10.1002/jbmr.4435
   Madhu V, 2020, J BONE MINER RES, V35, P1504, DOI 10.1002/jbmr.4019
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mizushima N, 2020, NEW ENGL J MED, V383, P1564, DOI 10.1056/NEJMra2022774
   Mocchegiani E, 2006, AGEING RES REV, V5, P281, DOI 10.1016/j.arr.2006.06.001
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Pickles S, 2018, CURR BIOL, V28, pR170, DOI 10.1016/j.cub.2018.01.004
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sun K, 2021, AUTOPHAGY, V17, P2082, DOI 10.1080/15548627.2020.1822097
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Wang S, 2020, INT J BIOL SCI, V16, P2675, DOI 10.7150/ijbs.46627
   Wei Z, 2023, NATURE, V618, pE21, DOI 10.1038/s41586 023 06244 9
   Wei Z, 2022, NATURE, V609, P348, DOI 10.1038/s41586 022 05111 3
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xie Z, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27629 2
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhang Y, 2021, ADV SCI, V8, DOI 10.1002/advs.202100808
NR 49
TC 16
Z9 16
U1 11
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD MAY
PY 2024
VL 46
BP 53
EP 64
DI 10.1016/j.jot.2024.03.003
EA MAY 2024
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA ZL5Q9
UT WOS:001275472000001
PM 38808262
OA gold
DA 2025 08 17
ER

PT J
AU Rapposelli, S
   Gambari, L
   Digiacomo, M
   Citi, V
   Lisignoli, G
   Manferdini, C
   Calderone, V
   Calderone, V
AF Rapposelli, Simona
   Gambari, Laura
   Digiacomo, Maria
   Citi, Valentina
   Lisignoli, Gina
   Manferdini, Cristina
   Calderone, Vincenzo
   Grassi, Francesco
TI A Novel H2S releasing Amino Bisphosphonate which combines bone
   anti catabolic and anabolic functions
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HYDROGEN SULFIDE; IN VITRO; ALENDRONATE; INHIBITION; APOPTOSIS; CELLS;
   AMINOBISPHOSPHONATES; DIFFERENTIATION; ISOTHIOCYANATES; OSTEONECROSIS
AB Bisphosphonates (BPs) are the first line treatment of bone loss resulting from various pathological conditions. Due to their high affinity to bone they have been used to develop conjugates with proanabolic or anti catabolic drugs. We recently demontrated that hydrogen sulfide (H2S), promotes osteogenesis and inhibits osteoclast differentiation. Here we developed an innovative molecule, named DM 22, obtained from the combination of alendronate (AL) and the H2S releasing moiety arylisothiocyanate. DM 22 and AL were assayed in vitro in the concentration range 1 33 mu M for effects on viability and function of human osteoclasts (h OCs) and mesenchymal stromal cells (h MSCs) undergoing osteogenic differentiation. Amperometric measures revealed that DM 22 releases H2S at a slow rate with a thiol dependent mechanism. DM 22 significantly inhibited h OCs differentiation and function, maintaining a residual h OCs viability even at the high dose of 33 mu M. Contrary to AL, in h MSCs DM 22 did not induce cytotoxicity as revealed by LDH assay, significantly stimulated mineralization as measured by Alizarin Red staining and increased mRNA expression of Collagen I as compared to control cultures. In conclusion, DM 22 is a new BP which inhibits h OCs function and stimulate osteogenic differentiation of h MSCs, without cytotoxicity. DM 22 is an ideal candidate for a novel family of osteoanabolic drugs.
C1 [Rapposelli, Simona; Digiacomo, Maria; Citi, Valentina; Calderone, Vincenzo] Univ Pisa, Dipartimento Farm, Via Bonanno 6, I 56126 Pisa, Italy.
   [Gambari, Laura; Grassi, Francesco] Ist Ortoped Rizzoli, Lab RAMSES, Via Barbiano 1 10, I 40136 Bologna, Italy.
   [Lisignoli, Gina; Manferdini, Cristina] Ist Ortoped Rizzoli, SC Lab Immunoreumatol & Rigeneraz Tissutale, Via Barbiano 1 10, I 40136 Bologna, Italy.
C3 University of Pisa; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto
   Ortopedico Rizzoli
RP Calderone, V (通讯作者)，Ist Ortoped Rizzoli, Lab RAMSES, Via Barbiano 1 10, I 40136 Bologna, Italy.
EM francesco.grassi@ior.it
RI CALDERONE, VINCENZO/L 9288 2015; Rapposelli, Simona/D 1595 2010; Grassi,
   Francesco/AAE 2443 2021; Lisignoli, Gina/K 4384 2016; Calderone,
   Vincenzo/L 9288 2015; manferdini, cristina/K 2680 2018; Gambari,
   Laura/K 4431 2018; Citi, Valentina/AAE 3857 2019; DIGIACOMO,
   MARIA/AAK 3365 2021
OI CALDERONE, VINCENZO/0000 0002 1441 5421; Rapposelli,
   Simona/0000 0003 0146 6358; Lisignoli, Gina/0000 0003 2837 9967; Citi,
   Valentina/0000 0001 9261 8497; Grassi, Francesco/0000 0002 5127 9561;
   Gambari, Laura/0000 0001 8126 5040; 
FU Grant Ricerca Finalizzata from the italian Ministry of Health
   [PE 2011 02348395]; Istituto Ortopedico Rizzoli
FX This work was financially supported by the following Grants: Grant
   Ricerca Finalizzata # PE 2011 02348395, from the italian Ministry of
   Health and Grant 5x1000 from Istituto Ortopedico Rizzoli.
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Benavides GA, 2007, P NATL ACAD SCI USA, V104, P17977, DOI 10.1073/pnas.0705710104
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Calderone V, 2016, EXPERT OPIN DRUG DIS, V11, P163, DOI 10.1517/17460441.2016.1122590
   Citi V, 2014, PLANTA MED, V80, P610, DOI 10.1055/s 0034 1368591
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Egorov M, 2011, EUR J ORG CHEM, V2011, P7148, DOI 10.1002/ejoc.201101094
   Fournier PGJ, 2008, CANCER RES, V68, P8945, DOI 10.1158/0008 5472.CAN 08 2195
   Gambari L, 2017, J CELL PHYSIOL, V232, P3574, DOI 10.1002/jcp.25825
   Gambari L, 2014, PHARMACOL RES, V87, P99, DOI 10.1016/j.phrs.2014.06.014
   Grassi F, 2016, J BONE MINER RES, V31, P949, DOI 10.1002/jbmr.2757
   Grassi F, 2011, J CELL PHYSIOL, V226, P982, DOI 10.1002/jcp.22411
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kharazmi M, 2014, RHEUMATOLOGY, V53, P1911, DOI 10.1093/rheumatology/keu286
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Liu Y, 2014, CELL STEM CELL, V15, P66, DOI 10.1016/j.stem.2014.03.005
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   MA S, 2017, SCI REP UK, V7
   Martelli A, 2014, VASC PHARMACOL, V60, P32, DOI 10.1016/j.vph.2013.11.003
   Martelli A, 2013, ACS MED CHEM LETT, V4, P904, DOI 10.1021/ml400239a
   Martelli A, 2012, MED RES REV, V32, P1093, DOI 10.1002/med.20234
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Patntirapong S, 2014, J CLIN PHARM THER, V39, P349, DOI 10.1111/jcpt.12149
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Schem C., 2016, J BONE MINER RES
   Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433
NR 40
TC 36
Z9 39
U1 0
U2 17
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 20
PY 2017
VL 7
AR 11940
DI 10.1038/s41598 017 11608 z
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FH5DL
UT WOS:000411183800028
PM 28931828
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gnant, M
   Dubsky, P
   Fitzal, F
   Blaha, P
   Schoppmann, S
   Steger, G
   Marth, C
   Samonigg, H
   Hüttner, K
   Fohler, H
   Ruecklinger, E
   Jakesz, R
   Greil, R
AF Gnant, Michael
   Dubsky, Peter
   Fitzal, Florian
   Blaha, Peter
   Schoppmann, Sebastian
   Steger, Guenther
   Marth, Christian
   Samonigg, Hellmut
   Huettner, Katharina
   Fohler, Hannes
   Ruecklinger, Ernst
   Jakesz, Raimund
   Greil, Richard
CA Austrian Breast Colorectal Canc St
TI Maintaining Bone Density in Patients Undergoing Treatment for Breast
   Cancer: Is There an Adjuvant Benefit?
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Bone loss; Bisphosphonates; Clodronate; Disease recurrence; Endocrine
   therapy; Risedronate; Zoledronic acid
ID PLUS ZOLEDRONIC ACID; 10 YEAR FOLLOW UP; MINERAL DENSITY; PREMENOPAUSAL
   WOMEN; POSTMENOPAUSAL WOMEN; ENDOCRINE THERAPY; AROMATASE INHIBITOR;
   CLODRONATE TREATMENT; IMPROVED SURVIVAL; OVARIAN FAILURE
AB Women undergoing treatment for breast cancer often experience a marked decrease in bone mineral density. This decrease is observed with chemotherapy as well as endocrine therapy and is more pronounced and rapid than normal postmenopausal bone loss. Pharmacologic intervention is, therefore, necessary in many cases to preserve bone health and prevent fractures. Many small studies have demonstrated that cancer therapy induced bone loss (CTIBL) is effectively prevented by bone targeted therapies, such as bisphosphonates and other inhibitors of bone resorption. Recently, several trials have confirmed the efficacy of bisphosphonates in the prevention of CTIBL in both premenopausal and postmenopausal women with early stage breast cancer. In addition, concomitant treatment with zoledronic acid 4 mg every 6 months and standard adjuvant endocrine therapy has been reported to significantly improve disease free survival and decrease disease recurrence in bone as well as other sites compared with standard therapy alone. Zoledronic acid treatment has also decreased residual tumor volume in the neoadjuvant setting. Furthermore, long term follow up of a single study in patients with bone marrow micrometastases from breast cancer revealed overall survival benefits for patients receiving clodronate 1600 mg/day compared with placebo; however, combined results from several trials of clodronate are inconclusive. Overall, a large body of evidence Is accumulating to support the potential adjuvant benefits of bisphosphonates in the treatment of early stage breast cancer. Results from ongoing studies are expected to further elucidate the benefits of bisphosphonates in maintaining bone health and improving clinical outcomes in patients with breast cancer.
C1 [Gnant, Michael; Dubsky, Peter; Fitzal, Florian; Blaha, Peter; Schoppmann, Sebastian; Jakesz, Raimund] Med Univ Vienna, Dept Surg, A 1090 Vienna, Austria.
   [Steger, Guenther] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria.
   [Marth, Christian] Med Univ Innsbruck, Innsbruck, Austria.
   [Samonigg, Hellmut] Med Univ Graz, Graz, Austria.
   [Huettner, Katharina; Fohler, Hannes; Ruecklinger, Ernst] Austrian Breast & Colorectal Canc Study Grp, Vienna, Austria.
   [Greil, Richard] Paracelsus Med Univ Salzburg, Salzburg, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Innsbruck; Medical University of Graz; Paracelsus Private
   Medical University
RP Gnant, M (通讯作者)，Med Univ Vienna, Dept Surg, Wahringer Gurtel 18 20, A 1090 Vienna, Austria.
EM michael.gnant@meduniwien.ac.at
RI Schoppmann, Sebastian F./K 1530 2017; Schoppmann, Sebastian/M 5831 2019;
   Greil, Richard/C 7673 2017; Gnant, Michael/AAN 7054 2020
OI Schoppmann, Sebastian F./0000 0002 1725 7086; Gnant,
   Michael/0000 0003 1002 2118
FU Novartis Pharmaceuticals
FX Financial support for medical editorial assistance was provided by
   Novartis Pharmaceuticals. The authors thank Shalini Murthy, PhD, ProEd
   Communications Inc.(R), for her medical editorial assistance with this
   article.
CR Aapro MS, 2004, BREAST, V13, pS29, DOI 10.1016/j.breast.2004.09.005
   Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140 6736(05)66544 0
   [Anonymous], 2007, Global Cancer Facts Figures 2007
   Avilés A, 2007, MED ONCOL, V24, P227, DOI 10.1007/BF02698044
   Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718
   BJARNASON K, 1995, OSTEOPOROSIS INT, V5, P35, DOI 10.1007/BF01623656
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brodie A, 1999, J STEROID BIOCHEM, V69, P205, DOI 10.1016/S0960 0760(99)00051 5
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   Brufsky A, 2008, ONCOLOGIST, V13, P503, DOI 10.1634/theoncologist.2007 0206
   BRUNING PF, 1990, BRIT J CANCER, V61, P308, DOI 10.1038/bjc.1990.58
   *CLINICALTRIALS GO, STUD DET TREATM EFF
   Confavreux CB, 2007, BONE, V41, P346, DOI 10.1016/j.bone.2007.06.004
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508
   El Hajj Fuleihan G, 2005, J CLIN ENDOCR METAB, V90, P3209, DOI 10.1210/jc.2004 1444
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Finkelstein JS, 2008, J CLIN ENDOCR METAB, V93, P861, DOI 10.1210/jc.2007 1876
   Frassoldati A, 2008, 33 C EUR SOC MED ONC
   Gnant M, 2008, ANN ONCOL, V19, P44
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gnant MFX, 2007, J CLIN ONCOL, V25, P820, DOI 10.1200/JCO.2005.02.7102
   Greenspan SL, 2008, J CLIN ONCOL, V26, P2644, DOI 10.1200/JCO.2007.15.2967
   Ha TC, 2007, BRIT J CANCER, V96, P1796, DOI 10.1038/sj.bjc.6603661
   Hershman DL, 2008, J CLIN ONCOL, V26, P4739, DOI 10.1200/JCO.2008.16.4707
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   HINES SL, 2008, J CLIN ONCOL S, V26, pS12
   Lester J., 2008, J CLIN ONCOL, V26, p19s
   Lin A, 2007, BREAST CANCER RES TR, V106, pS40
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lipton Allan, 2008, Curr Opin Support Palliat Care, V2, P197, DOI 10.1097/SPC.0b013e32830baac2
   Lower EE, 1999, J WOMEN HEALTH GEN B, V8, P949, DOI 10.1089/jwh.1.1999.8.949
   Mazzuoli G, 2000, BONE, V26, P381, DOI 10.1016/S8756 3282(00)00242 8
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mystakidou K, 2005, MED ONCOL, V22, P195, DOI 10.1385/MO:22:2:195
   NORDIN BEC, 1990, J CLIN ENDOCR METAB, V70, P83, DOI 10.1210/jcem 70 1 83
   Pai A, 2008, J CLIN ONCOL, V26, P4209, DOI 10.1200/JCO.2008.16.0523
   Pfeilschifter J, 2000, J CLIN ONCOL, V18, P1570, DOI 10.1200/JCO.2000.18.7.1570
   POUILLES JM, 1995, J BONE MINER RES, V10, P1531
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1413
   Rack BK, 2007, BREAST CANCER RES TR, V106, pS40
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341
   Saarto T, 2001, BRIT J CANCER, V84, P1047, DOI 10.1054/bjoc.2001.1729
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   Saarto T, 2008, J CLIN ONCOL, V26, P4289, DOI 10.1200/JCO.2007.15.4997
   Schenk N, 2007, EJC SUPPL, V5, P186, DOI 10.1016/S1359 6349(07)70770 X
   Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306
   SHAPIRO CL, 2008, 44 ANN M AM SOC CLIN
   Singh S, 2007, BREAST CANCER RES TR, V106, pS9
   Van PC, 2007, BREAST CANCER RES TR, V106, pS37
   Vehmanen L, 2001, EUR J CANCER, V37, P2373, DOI 10.1016/S0959 8049(01)00317 3
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Warming L, 2002, OSTEOPOROSIS INT, V13, P105, DOI 10.1007/s001980200001
   Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   ZAGHLOUL MS, 2008, J CLIN ONCOL S, V26, pS257
   Zhang HC, 2002, CALCIFIED TISSUE INT, V70, P153, DOI 10.1007/s00223 001 1037 7
NR 66
TC 9
Z9 10
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1526 8209
EI 1938 0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD JUN
PY 2009
VL 9
SU 1
BP S18
EP S27
DI 10.3816/CBC.2009.s.002
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 462ZO
UT WOS:000267397900002
PM 19561003
DA 2025 08 17
ER

PT J
AU Xu, LC
   Song, X
   Carroll, G
   You, LD
AF Xu, Liangcheng
   Song, Xin
   Carroll, Gwennyth
   You, Lidan
TI Novel in vitro microfluidic platfor for osteocyte
   mechanotransduction studies
SO INTEGRATIVE BIOLOGY
LA English
DT Article
DE microfluidic; osteocyte; osteoclast; bone remodeling; fluid shear
   stress; mechanical loading
AB Osteocytes are the major mechanosensing cells in bone remodeling. Current in vitro bone mechanotransduction research use macroscale devices such as flow chambers; however, in vitro microfluidic devices provide an optimal tool to better understand this biological process with its flexible design, physiologically relevant dimensions and high throughput capabilities. This project aims to design and fabricate a multi shear stress, co culture platform to study the interaction between osteocytes and other bone cells under varying flow conditions. Standard microfluidic design utilizing changing geometric parameters is used to induce different flow rates that are directly proportional to the levels of shear stress, with devices fabricated from standard polydimethylsiloxane (PDMS) based softlithography processes. Each osteocyte channel (OCY) is connected to an adjacent osteoclast channel (OC) by 20 mu m perfusion channels for cellular signaling molecule transport. Significant differences in RANKL levels are observed between channels with different shear stress levels, and we observed that pre osteoclast differentiation was directly affected by adjacent flow stimulated osteocytes. Significant decrease in the number of differentiating osteoclasts is observed in the OC channel adjacent to the 2 Pa shear stress OCY channel, while differentiation adjacent to the 0.5 Pa shear stress OCY channel is unaffected compared with no flow controls. Addition of zoledronic acid showed a significant decrease in osteoclast differentiation, compounding to effect instigated by increasing fluid shear stress. Using this platform, we are able to mimic the interaction between osteocytes and osteoclasts in vitro under physiologically relevant bone interstitial fluid flow shear stress. Our novel microfluidic co culture platform provides an optimal tool for bone cell mechanistic studies and provides a platform for the discovery of potential drug targets for clinical treatments of bone related diseases.
C1 [Xu, Liangcheng; Song, Xin; Carroll, Gwennyth; You, Lidan] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.
   [You, Lidan] Univ Toronto, Dept Mech & Ind Engn, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto
RP You, LD (通讯作者)，Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.; You, LD (通讯作者)，Univ Toronto, Dept Mech & Ind Engn, Toronto, ON, Canada.
EM youlidan@mie.utoronto.ca
RI ; You, Lidan/HOC 7310 2023
OI Song, Xin/0000 0003 0313 1631; 
CR Atkinson EG, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10186
   Benam KH, 2016, NAT METHODS, V13, P151, DOI [10.1038/NMETH.3697, 10.1038/nmeth.3697]
   Cheng BX, 2001, ENDOCRINOLOGY, V142, P3464, DOI 10.1210/en.142.8.3464
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   El Khassawna T, 2017, AM J PATHOL, V187, P1686, DOI 10.1016/j.ajpath.2017.04.005
   Friend J, 2010, BIOMICROFLUIDICS, V4, DOI 10.1063/1.3259624
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hinton PV, 2018, CURR OSTEOPOROS REP, V16, P746, DOI 10.1007/s11914 018 0485 1
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Khan OF, 2012, TISSUE ENG PT A, V18, P744, DOI [10.1089/ten.tea.2011.0058, 10.1089/ten.TEA.2011.0058]
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Li J, 2012, J BIOMECH, V45, P247, DOI 10.1016/j.jbiomech.2011.10.037
   Li M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37091 8
   Li X, 2015, MICROSYST NANOENG, V1, DOI 10.1038/micronano.2015.14
   Liao CS, 2017, BONE, V101, P10, DOI 10.1016/j.bone.2017.04.003
   Ma YHV, 2018, J CELL BIOCHEM, V119, P5665, DOI 10.1002/jcb.26745
   Ma YHV, 2019, J CELL BIOCHEM, V120, P7590, DOI 10.1002/jcb.28034
   Middleton K, 2017, J BIOMECH, V59, P35, DOI 10.1016/j.jbiomech.2017.05.012
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Pathak JL, 2015, CALCIFIED TISSUE INT, V97, P169, DOI 10.1007/s00223 015 9999 z
   Simfia I, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112005
   Sottnik JL, 2014, J CELL BIOCHEM, V115, P1420, DOI 10.1002/jcb.24793
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Ste Marie L G, 1995, J SOGC, V17, P1205, DOI [DOI 10.1016/S1701 2163(16)30562 X, 10.1016/s1701 2163(16)30562 x.]
   Sun S, 2010, LAB CHIP, V10, P2093, DOI 10.1039/c003994b
   SUTERA SP, 1993, ANNU REV FLUID MECH, V25, P1, DOI 10.1146/annurev.fl.25.010193.000245
   Trkov S, 2010, J TISSUE ENG REGEN M, V4, P205, DOI 10.1002/term.231
   Verbruggen SW, 2016, J MECH BEHAV BIOMED, V62, P158, DOI 10.1016/j.jmbbm.2016.05.004
   Wang XT, 2019, MED SCI MONITOR, V25, P5961, DOI 10.12659/MSM.915986
   Weinstein RS, 2011, ENDOCRINOLOGY, V152, P3323, DOI 10.1210/en.2011 0170
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xu LCH, 2019, J ORTHOP RES, V37, P1681, DOI 10.1002/jor.24302
   Yang W., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P386
   You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 39
TC 9
Z9 11
U1 0
U2 27
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1757 9694
EI 1757 9708
J9 INTEGR BIOL UK
JI Integr. Biol.
PD DEC
PY 2020
VL 12
IS 12
BP 303
EP 310
DI 10.1093/intbio/zyaa025
EA JAN 2021
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA RF0UE
UT WOS:000634562700002
PM 33420790
DA 2025 08 17
ER

PT J
AU Tanaka, M
   Yoshida, K
   Fukuma, S
   Ito, K
   Matsushita, K
   Fukagawa, M
   Fukuhara, S
   Akizawa, T
AF Tanaka, Motoko
   Yoshida, Kazuki
   Fukuma, Shingo
   Ito, Kazuko
   Matsushita, Kazutaka
   Fukagawa, Masafumi
   Fukuhara, Shunichi
   Akizawa, Tadao
TI Effects of Secondary Hyperparathyroidism Treatment on Improvement in
   Anemia: Results from the MBD 5D Study
SO PLOS ONE
LA English
DT Article
ID MARGINAL STRUCTURAL MODELS; CHRONIC RENAL FAILURE; PARATHYROID HORMONE;
   HEMODIALYSIS PATIENTS; CURATIVE PARATHYROIDECTOMY; INTRAVENOUS
   CALCITRIOL; MARROW FIBROSIS; ERYTHROPOIESIS; DISEASE; CINACALCET
AB Objectives
   Anemia is an important prognostic factor in hemodialysis patients. It has been reported that parathyroidectomy ameliorates anemia and reduces the requirement of postoperative erythropoiesis stimulating agents. The objective of this study was to assess the effect of cinacalcet, which is considered as a pharmacological parathyroidectomy, on anemia in hemodialysis patients.
   Methods
   We used data from a prospective cohort of Japanese hemodialysis patients with secondary hyperparathyroidism; the criteria were: intact parathyroid hormone concentrations >= 180 pg/mL or use of an intravenous or oral vitamin D receptor activator. All patients were cinacalcet naive at study enrollment. The main outcome measure was achievement of the target hemoglobin level (>= 10.0 g/dL), which was measured repeatedly every 6 months. Cinacalcet exposure was defined as cumulative time since initiation. Both conventional longitudinal models and marginal structural models were adjusted for confounding factors.
   Results
   Among 3,201 cinacalcet naive individuals at baseline, cinacalcet was initiated in 1,337 individuals during the follow up. Cinacalcet users were slightly younger; included more patients with chronic glomerulonephritis and fewer with diabetes; were more likely to have a history of parathyroidectomy; and were more often on activated vitamin D agents, phosphate binders, and iron supplements. After adjusting for both time invariant and time varying potential confounders, including demographics, comorbidities, comedications, and laboratory values, each additional 6 month duration on cinacalcet was associated with a 1.1 fold increase in the odds of achieving the target hemoglobin level.
   Conclusions
   Cinacalcet may improve anemia in chronic hemodialysis patients with secondary hyperparathyroidism, possibly through pathways both within and outside the parathyroid hormone pathways. Further investigations are warranted to delineate the roles of cinacalcet not only in the management of chronic kidney disease mineral and bone disorder but also in anemia control.
C1 [Tanaka, Motoko; Ito, Kazuko; Matsushita, Kazutaka] Akebono Clin, Dept Nephrol, Kumamoto, Japan.
   [Yoshida, Kazuki] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Yoshida, Kazuki] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Yoshida, Kazuki; Fukuma, Shingo] IHope Int, Inst Hlth Outcomes & Proc Evaluat Res, Kyoto, Japan.
   [Fukuma, Shingo; Fukuhara, Shunichi] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Healthcare Epidemiol, Kyoto, Japan.
   [Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa, Japan.
   [Fukuhara, Shunichi] Fukushima Med Univ Hosp, Dept Innovat Res & Educ Clinicians & Trainees DiR, Fukushima, Japan.
   [Akizawa, Tadao] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Kyoto University;
   Tokai University; Fukushima Medical University; Showa University
RP Tanaka, M (通讯作者)，Akebono Clin, Dept Nephrol, Kumamoto, Japan.
EM tanaka@matusita kai.or.jp
RI ; Fukuma, Shingo/S 6584 2019
OI Fukagawa, Masafumi/0000 0002 7832 2339; Fukagawa,
   Misato/0000 0003 1117 9213; Yoshida, Kazuki/0000 0002 2030 3549; Fukuma,
   Shingo/0000 0002 8379 8761
FU Kyowa Hakko Kirin
FX The MBD 5D study was supported by unrestricted research grants from
   Kyowa Hakko Kirin. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aucella F, 2003, NEPHRON CLIN PRACT, V95, pC121, DOI 10.1159/000074837
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Battistella M, 2011, CLIN NEPHROL, V76, P99, DOI 10.5414/CN106640
   Bhadada SK, 2009, CLIN ENDOCRINOL, V70, P527, DOI 10.1111/j.1365 2265.2008.03346.x
   Bhadada SK, 2012, J CLIN ENDOCR METAB, V97, P1420, DOI 10.1210/jc.2011 2845
   BOGIN E, 1982, J CLIN INVEST, V69, P1017, DOI 10.1172/JCI110505
   Brancaccio D, 2004, J AM SOC NEPHROL, V15, pS21, DOI 10.1097/01.ASN.0000093369.09194.12
   Coe LM, 2014, J BIOL CHEM, V289, P9795, DOI 10.1074/jbc.M113.527150
   Cole SR, 2005, AM J EPIDEMIOL, V162, P471, DOI 10.1093/aje/kwi216
   Conzo G, 2013, ANN ITAL CHIR, V84, P25
   Drüeke TB, 2006, NEPHROL DIAL TRANSPL, V21, P2072, DOI 10.1093/ndt/gfl206
   Fukagawa M, 2008, THER APHER DIAL, V12, P514, DOI 10.1111/j.1744 9987.2008.00648.x
   Fukuhara S, 2011, THER APHER DIAL, V15, P169, DOI 10.1111/j.1744 9987.2010.00906.x
   Hernan M.J. Robins., 2016, CAUSAL INFERENCE
   Hernán MA, 2002, STAT MED, V21, P1689, DOI 10.1002/sim.1144
   Horl Walter H, 2004, Nephrol Dial Transplant, V19 Suppl 5, pV2, DOI 10.1093/ndt/gfh1049
   Keithi Reddy SR, 2008, KIDNEY INT, V74, P782, DOI 10.1038/ki.2008.245
   Khan S, 2000, Semin Dial, V13, P112, DOI 10.1046/j.1525 139x.2000.00036.x
   Khan S, 1999, J AM SOC NEPHROL, V10, P610
   Ly J, 2004, AM J KIDNEY DIS, V44, P715, DOI 10.1053/j.ajkd.2004.06.018
   Massry S G, 1983, Kidney Int Suppl, V16, pS204
   MEYTES D, 1981, J CLIN INVEST, V67, P1263, DOI 10.1172/JCI110154
   Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876
   Mpio I, 2011, NEPHROL THER, V7, P229, DOI 10.1016/j.nephro.2011.01.008
   Neves PL, 2006, INT UROL NEPHROL, V38, P175, DOI 10.1007/s11255 004 1563 0
   NISSENSON AR, 1991, ANN INTERN MED, V114, P402, DOI 10.7326/0003 4819 114 5 402
   PAYNE RB, 1973, BMJ BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643
   RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304
   Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231
   Reichel H, 2003, NEPHROL DIAL TRANSPL, V18, P759, DOI 10.1093/ndt/gfg144
   Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648 200009000 00011
   Türk S, 2002, NEPHRON, V90, P188, DOI 10.1159/000049041
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Xia H, 1999, J AM SOC NEPHROL, V10, P1309
NR 34
TC 23
Z9 25
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2016
VL 11
IS 10
AR e0164865
DI 10.1371/journal.pone.0164865
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DZ9NZ
UT WOS:000386204500072
PM 27764168
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Qian, KJ
   Xu, HZ
   Dai, T
   Shi, KQ
AF Qian, Kejun
   Xu, Huazhong
   Dai, Teng
   Shi, Keqing
TI Effects of Tanshinone IIA on osteogenic differentiation of mouse bone
   marrow mesenchymal stem cells
SO NAUNYN SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Article
DE Tanshinone IIA; Bone disease; Mesenchymal stem cells; Osteogenesis;
   Osteoclastogenesis
ID ESTROGEN RECEPTOR ACTIVATION; RATS
AB Tanshinone IIA (TSA) is a lipophilic diterpene purified from the Chinese herb Danshen, which exhibits potent antioxidant and anti inflammatory properties. Effect of TSA remains largely uninvestigated on the osteogenic differentiation of bone marrow mesenchymal stem cells (BM MSCs), which are widely used in cell based therapy of bone diseases. In the present study, both ALP activity at day 7 and calcium content at day 24 were upregulated during the osteogenesis of mouse BM MSCs treated with TSA (1 and 5 mu M), demonstrating that it promoted the osteogenesis at both early and late stages. We found that TSA promoted osteogenesis and inhibited osteoclastogenesis, evident by RT PCR analysis of osteogenic marker gene expressions. However, osteogenesis was inhibited by TSA at 20 mu M. We further revealed that TSA (1 and 5 mu M) upregulated BMP and Wnt signaling. Co treatment with Wnt inhibitor DKK 1 or BMP inhibitor noggin significantly decreased the TSA promoted osteogenesis, indicating that upregulation of BMP and Wnt signaling plays a significant role and contributes to the TSA promoted osteogenesis. Of clinical interest, our study suggests TSA as a promising therapeutic strategy during implantation of BM MSCs for a more effective treatment of bone diseases.
C1 [Qian, Kejun; Xu, Huazhong; Dai, Teng; Shi, Keqing] Nanjing Med Univ, Affiliated Wuxi Hosp 2, Dept Orthopaed Surg, Wuxi 214001, Peoples R China.
C3 Nanjing Medical University
RP Shi, KQ (通讯作者)，Nanjing Med Univ, Affiliated Wuxi Hosp 2, Dept Orthopaed Surg, 68 Zhongshan Rd, Wuxi 214001, Peoples R China.
EM kqshi23@163.com
RI Shi, Keqing/GZK 5146 2022
CR [Anonymous], 2014, EVID BASED COMPL ALT, DOI DOI 10.1155/2014/267976
   Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brighton CT, 1997, J ORTHOP TRAUMA, V11, P244, DOI 10.1097/00005131 199705000 00002
   Dai ZK, 2012, J NAT MED TOKYO, V66, P192, DOI 10.1007/s11418 011 0576 0
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Dong XR, 2009, CANCER BIOTHER RADIO, V24, P681, DOI 10.1089/cbr.2009.0640
   Fan GW, 2009, J STEROID BIOCHEM, V113, P275, DOI 10.1016/j.jsbmb.2009.01.011
   Fu JJ, 2007, EUR J PHARMACOL, V568, P213, DOI 10.1016/j.ejphar.2007.04.031
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Kim HJ, 2010, AMINO ACIDS, V39, P1217, DOI 10.1007/s00726 010 0557 8
   Kobayashi Yasuhiro, 2012, Clin Calcium, V22, P1701, DOI CliCa121117011706
   Kwak HB, 2006, EXP MOL MED, V38, P256, DOI 10.1038/emm.2006.31
   Kwak HB, 2008, EUR J PHARMACOL, V601, P30, DOI 10.1016/j.ejphar.2008.10.034
   Lam BYH, 2003, PHYTOMEDICINE, V10, P286, DOI 10.1078/094471103322004776
   Lin CY, 2013, J CELL BIOCHEM, V114, P2061, DOI 10.1002/jcb.24553
   Liu X, 2015, CELL PHYSIOL BIOCHEM, V35, P1744, DOI 10.1159/000373986
   Liu YW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103229
   Marcellini S, 2012, BIOESSAYS, V34, P953, DOI 10.1002/bies.201200061
   Oni O O, 1992, J Bone Joint Surg Am, V74, P633
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Ren ZH, 2010, PHYTOMEDICINE, V17, P212, DOI 10.1016/j.phymed.2009.08.010
   Shang QH, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/756519
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wilson CG, 2013, J DENT RES, V92, P409, DOI 10.1177/0022034513483771
   Xu SW, 2013, EXPERT OPIN THER PAT, V23, P149, DOI 10.1517/13543776.2013.743995
   Yang LQ, 2014, ONCOL REP, V32, P1303, DOI 10.3892/or.2014.3293
   Yin X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038381, 10.1371/journal.pone.0051853]
   Yu QX, 2014, INT IMMUNOPHARMACOL, V22, P277, DOI 10.1016/j.intimp.2014.07.002
   Zhang L, 2012, NEURAL REGEN RES, V7, P2882, DOI 10.3969/j.issn.1673 5374.2012.36.005
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
NR 32
TC 19
Z9 22
U1 1
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0028 1298
EI 1432 1912
J9 N S ARCH PHARMACOL
JI Naunyn Schmiedebergs Arch. Pharmacol.
PD NOV
PY 2015
VL 388
IS 11
BP 1201
EP 1209
DI 10.1007/s00210 015 1154 x
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CU4SW
UT WOS:000363521300009
PM 26231349
DA 2025 08 17
ER

PT J
AU Xu, HH
   Tao, L
   Cao, JF
   Zhang, P
   Zeng, H
   Zhao, HY
AF Xu, Huihui
   Tao, Li
   Cao, Jinfeng
   Zhang, Peng
   Zeng, Hui
   Zhao, Hongyan
TI Yi Shen Juan Bi Pill alleviates bone destruction in inflammatory
   arthritis under postmenopausal conditions by regulating ephrinB2
   signaling
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE collagen induced arthritis; ovariectomy; bone destruction; Yi Shen Juan
   Bi Pill; ephrinB2
ID RHEUMATOID ARTHRITIS; MENOPAUSE; OSTEOPOROSIS; PATHWAY; WOMEN; AGE
AB Yi Shen Juan Bi Pill (YSJB) is a traditional Chinese medicine (TCM) formulation that has a therapeutic effect upon rheumatoid arthritis (RA), but how YSJB affects bone destruction in arthritis under postmenopausal conditions is not known. We evaluated the therapeutic role of YSJB in bone destruction in postmenopausal arthritis, We used collagen induced arthritis (CIA) rats who had been ovariectomized (OVX) as models and explored the possible mechanism from the synovium and bone marrow (BM). Arthritis was generated after ovariectomy or sham surgery for 12 weeks. After 14 days of primary immunization, rats were administered YSJB or estradiol valerate (EV) for 28 days. YSJB could prevent bone destruction in the inflamed joints of rats in the OVX + CIA group. CIA promoted osteoclast differentiation significantly in the synovial membrane according to tartrate resistant acid phosphatase (TRACP) staining, and OVX tended to aggravate the inflammatory reaction of CIA rats according to hematoxylin and eosin staining. Immunohistochemistry revealed that the synovium did not have significant changes in erythropoietin producing hepatocellular interactor (ephrin)B2 or erythropoietin producing hepatocellular (eph) B4 expression after YSJB treatment, but YSJB treatment reduced nuclear factor of activated T cells (NFATc)1 expression. The BM of rats in the OVX + CIA exhibited remarkable increases in the number of osteoclasts and NFATc1 expression, as well as significantly reduced expression of ephrinB2 and ephB4 compared with the CIA group and sham group. YSJB treatment reduced NFATc1 expression significantly but also increased ephrinB2 expression in the BM markedly. These data suggest that YSJB exhibit a bone protective effect, it may be a promising therapeutic strategy for alleviating bone destruction in arthritis under postmenopausal conditions, and one of the mechanisms is associated with the modulation of ephrinB2 signaling.
C1 [Xu, Huihui; Zeng, Hui] Peking Univ, Dept Bone & Joint Surg, Shenzhen Hosp, Shenzhen, Peoples R China.
   [Xu, Huihui; Zeng, Hui] Peking Univ, Natl & Local Joint Engn Res Ctr Orthopaed Biomat, Shenzhen Hosp, Shenzhen, Peoples R China.
   [Xu, Huihui; Zhang, Peng] Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Translat Med Res & Dev, Shenzhen, Peoples R China.
   [Xu, Huihui; Tao, Li; Cao, Jinfeng; Zhao, Hongyan] China Acad Chinese Med Sci, Expt Res Ctr, Beijing Key Lab Res Chinese Med Prevent & Treatmen, Beijing, Peoples R China.
C3 Peking University; Peking University; Chinese Academy of Sciences;
   Shenzhen Institute of Advanced Technology, CAS; Experimental Research
   Center, CACMS; China Academy of Chinese Medical Sciences
RP Zeng, H (通讯作者)，Peking Univ, Dept Bone & Joint Surg, Shenzhen Hosp, Shenzhen, Peoples R China.; Zeng, H (通讯作者)，Peking Univ, Natl & Local Joint Engn Res Ctr Orthopaed Biomat, Shenzhen Hosp, Shenzhen, Peoples R China.; Zhang, P (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Translat Med Res & Dev, Shenzhen, Peoples R China.; Zhao, HY (通讯作者)，China Acad Chinese Med Sci, Expt Res Ctr, Beijing Key Lab Res Chinese Med Prevent & Treatmen, Beijing, Peoples R China.
EM peng.zhang@siat.ac.cn; zenghui_36@163.com; zhaohongyan1997@163.com
FU National Natural Science Foundation of China;  [82074299]
FX Funding This study was supported by the National Natural Science
   Foundation of China (82074299).
CR Banas T, 2016, MENOPAUSE, V23, P1130, DOI 10.1097/GME.0000000000000674
   Chakraborty D, 2022, J MOL ENDOCRINOL, V69, pR25, DOI 10.1530/JME 22 0010
   Engdahl C, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1586 z
   Ge YW, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1404915
   Hang XY, 2021, J INFLAMM RES, V14, P843, DOI 10.2147/JIR.S295222
   Heidari B, 2014, CASP J INTERN MED, V5, P213
   Huang M, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2982480
   Ibáñez L, 2011, INFLAMMATION, V34, P585, DOI 10.1007/s10753 010 9266 4
   Kim JS, 2020, CELLS BASEL, V9, DOI 10.3390/cells9122720
   Krepelka P, 2021, CES GYNEKOL, V86, P217, DOI 10.48095/cccg2021217
   Kurowska W, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081778
   Kvien TK, 2006, ANN NY ACAD SCI, V1069, P212, DOI 10.1196/annals.1351.019
   Li SN, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.113061
   Li TC, 2021, AM J ORTHOD DENTOFAC, V159, pE217, DOI 10.1016/j.ajodo.2020.07.035
   Li X, 2020, EXP THER MED, V20, P1764, DOI 10.3892/etm.2020.8848
   Liu H, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2314 6
   Luukkonen J, 2022, MEDIAT INFLAMM, V2022, DOI 10.1155/2022/2606916
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   Matsuo K, 2010, ADV EXP MED BIOL, V658, P95, DOI 10.1007/978 1 4419 1050 9_10
   Mollard E, 2018, RHEUMATOLOGY, V57, P798, DOI 10.1093/rheumatology/kex526
   Nishioku T, 2020, BIOCHEM BIOPH RES CO, V530, P455, DOI 10.1016/j.bbrc.2020.05.088
   Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013
   Perera PK, 2011, J ETHNOPHARMACOL, V134, P171, DOI 10.1016/j.jep.2010.11.065
   Perera PK, 2010, INDIAN J PHARMACOL, V42, P65, DOI 10.4103/0253 7613.64489
   Prieto Potin I, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0664 5
   Romanovsky AA, 2006, ANN NY ACAD SCI, V1069, P183, DOI 10.1196/annals.1351.016
   Sammaritano LR, 2012, AUTOIMMUN REV, V11, pA430, DOI 10.1016/j.autrev.2011.11.006
   Sapir Koren R, 2017, BONE, V103, P102, DOI 10.1016/j.bone.2017.06.020
   Shah L, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.10944
   Shen LL, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6430407
   Stojanovic A, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9458587
   Stubelius A, 2011, CLIN IMMUNOL, V140, P37, DOI 10.1016/j.clim.2011.03.006
   Tazaki Y, 2018, COMP BIOCHEM PHYS A, V225, P46, DOI 10.1016/j.cbpa.2018.06.011
   Valverde Franco G, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0965 6
   van der Woude D, 2018, BEST PRACT RES CL RH, V32, P174, DOI 10.1016/j.berh.2018.10.005
   Vatrasresth J, 2021, BMC WOMENS HEALTH, V21, DOI 10.1186/s12905 021 01508 w
   Wallenius M, 2009, SCAND J RHEUMATOL, V38, P178, DOI 10.1080/03009740802400594
   Wu M, 2016, INT J MOL MED, V37, P565, DOI 10.3892/ijmm.2016.2457
   Xia Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.746786
   Xiao Cheng, 2009, Chin Med, V4, P13, DOI 10.1186/1749 8546 4 13
   Zhang Y, 2022, CELL SIGNAL, V96, DOI 10.1016/j.cellsig.2022.110376
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao HY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00262
   Zhao HY, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/102641
NR 44
TC 1
Z9 1
U1 3
U2 29
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 30
PY 2022
VL 13
AR 1010640
DI 10.3389/fphar.2022.1010640
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5I9MN
UT WOS:000868673900001
PM 36249763
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU von Borstel, D
   Taguibao, RA
   Strle, NA
   Burns, JE
AF von Borstel, Donald
   Taguibao, Roberto A.
   Strle, Nicholas A.
   Burns, Joseph E.
TI Giant cell tumor of the bone: aggressive case initially treated with
   denosumab and intralesional surgery
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Giant cell tumor; Denosumab; Imaging; MRI
ID PHASE II TRIAL; OPEN LABEL
AB Giant cell tumor of the bone (GCTB) is a locally aggressive benign tumor, which has historically been treated with wide surgical excision. We report a case of a 29 year old male with histology proven GCTB of the distal ulna. The initial imaging study was a contrast enhanced magnetic resonance imaging (MRI) examination of the left wrist, which was from an outside facility performed before presenting to our institution. On the initial MRI, the lesion had homogenous T2 hyperintense and T1 hypointense signal with expansive remodeling of the osseous contour. A radiographic study performed upon presentation to our institution 1 month later showed progression of the lesion with atypical imaging characteristics. After confirming the diagnosis, denosumab therapy was implemented allowing for reconstitution of bone and intralesional treatment. The patient was treated with five doses of denosumab over the duration of 7 weeks. Therapeutic changes of the GCTB were evaluated by radiography and a post treatment MRI. This MRI was interpreted as suspicious for worsening disease due to the imaging appearance of intralesional signal heterogeneity, increased perilesional fluid like signal, and circumferential cortical irregularity. However, on subsequent intralesional curettage and bone autografting 6 weeks later, no giant cells were seen on the specimen. Thus, the appearance on the MRI, rather than representing a manifestation of lesion aggressiveness or a non responding tumor, conversely represented the imaging appearance of a positive response to denosumab therapy. On follow up evaluation, 5 months after intralesional treatment, the patient had recurrent disease and is now scheduled for wide excision with joint prosthesis.
C1 [von Borstel, Donald; Strle, Nicholas A.] Oklahoma State Univ, Med Ctr, Dept Radiol, 744 W 9th St, Tulsa, OK 74127 USA.
   [Taguibao, Roberto A.] Univ Calif Irvine, Dept Pathol, UCI Med Ctr, 101 City Dr South,Route 140, Orange, CA 92868 USA.
   [Burns, Joseph E.] Univ Calif Irvine, Dept Radiol Sci, UCI Med Ctr, 101 City Dr South,Route 140, Orange, CA 92868 USA.
C3 Oklahoma State University System; Oklahoma State University Center for
   Health Sciences; University of California System; University of
   California Irvine; University of California System; University of
   California Irvine
RP von Borstel, D (通讯作者)，Oklahoma State Univ, Med Ctr, Dept Radiol, 744 W 9th St, Tulsa, OK 74127 USA.
EM donaldvonborstel@yahoo.com
CR Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chakarun CJ, 2013, RADIOGRAPHICS, V33, P197, DOI 10.1148/rg.331125089
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Fletcher C. D. M. B. J., 2013, WHO CLASSIFICATION T, V5
   GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104
   Hu MI, 2013, JNCI J NATL CANCER I, V105, P1417, DOI 10.1093/jnci/djt225
   Jagiello Wieczorek E, 2015, EXPERT OPIN ORPHAN D, V3, P1219, DOI 10.1517/21678707.2015.1086336
   Kalil R. K., 2015, TUMORS TUMOR LIKE LE, P351
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P1181, DOI 10.1007/s11999 010 1560 9
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Murphey MD, 2001, RADIOGRAPHICS, V21, P1283, DOI 10.1148/radiographics.21.5.g01se251283
   Purohit Shaligram, 2007, Indian J Orthop, V41, P91, DOI 10.4103/0019 5413.32037
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   Wang H C, 2005, J SURG ONCOL, V18, P4415
   Werner M, 2006, INT ORTHOP, V30, P484, DOI 10.1007/s00264 006 0215 7
NR 19
TC 16
Z9 17
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364 2348
EI 1432 2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD APR
PY 2017
VL 46
IS 4
BP 571
EP 578
DI 10.1007/s00256 017 2588 7
PG 8
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA EM1KN
UT WOS:000395076600017
PM 28188337
DA 2025 08 17
ER

PT J
AU Shang, W
   Xiong, SJ
AF Shang, Wei
   Xiong, Shijiang
TI Phenytoin Is Promoting the Differentiation of Dental Pulp Stem Cells
   into the Direction of Odontogenesis/Osteogenesis by Activating BMP4/Smad
   Pathway
SO DISEASE MARKERS
LA English
DT Article
ID ODONTOGENIC DIFFERENTIATION; SIGNALING PATHWAY; DEXAMETHASONE; DPSCS
AB Background. The purpose of this study was the evaluation of the potential and mechanism of phenytoin to promote differentiation of human dental pulp stem cells (hDPSC) into odontoblasts/osteoblasts. Methods. Fourth generation human hDPSC originating from healthy pulp of third molars was cultured in control as well as phenytoin containing media (PHT) for 14 days. qPCR was applied to detect the expression of DSPP, DMP1, and ALP genes. Western blot analysis was used to confirm the findings. One way analysis of variance (ANOVA) was used for statistical analysis (p < 0.05). Information about phenytoin was assessed from PubChem database, while targets of phenytoin were assessed from six databases. Drug targets were extracted based on the differentially expressed genes (||logFC|| >= 1, p < 0.05) in the experimental group (50 mg/L PHT, 14 days). GO BP and KEGG pathway enrichment analysis on the obtained drug targets was performed and the target protein functional network diagram was constructed. Results. A concentration below 200 mg/L PHT had no obvious toxicity to hDPSC. The expression of DSPP, DMP1, and ALP genes in the 50 mg/L PHT concentration group increased significantly. The WB experiment showed that the protein content of BMP4, Smad1/5/9, and p Smad1/5 was significantly increased in 50 mg/L PHT in comparison with the NC group (the group without treatment of PHT) at 14 days. Conclusion. Phenytoin has the ability of promoting the differentiation of hDPSC into odontoblasts and osteoblasts. BMP4/Smad pathway, inducing odontogenic/osteogenic differentiation of hDPSC, appears a main process in this context.
C1 [Xiong, Shijiang] Shandong Univ, Dept VIP Ctr, Sch & Hosp Stomatol, Jinan 250012, Shandong, Peoples R China.
   Shandong Prov Key Lab Oral Tissue Regenerat, Jinan 250012, Shandong, Peoples R China.
   Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University
RP Xiong, SJ (通讯作者)，Shandong Univ, Dept VIP Ctr, Sch & Hosp Stomatol, Jinan 250012, Shandong, Peoples R China.
EM xiongsj@sdu.edu.cn
CR Alliot Licht B, 2005, CELL TISSUE RES, V321, P391, DOI 10.1007/s00441 005 1115 7
   Anitua E, 2018, CYTOTHERAPY, V20, P479, DOI 10.1016/j.jcyt.2017.12.011
   Arya R, 2012, ACTA NEUROL SCAND, V125, P149, DOI 10.1111/j.1600 0404.2011.01535.x
   Asgary S, 2014, J ENDODONT, V40, P387, DOI 10.1016/j.joen.2013.09.017
   Asgharian Rezaee M, 2020, REP BIOCHEM MOL BIOL, V9, P331, DOI 10.29252/rbmb.9.3.331
   Bakhtiar H, 2018, PROG BIOMATER, V7, P249, DOI 10.1007/s40204 018 0100 7
   Ballini A, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3292810
   Bostanci N, 2018, MOL CELL PROTEOMICS, V17, P1392, DOI 10.1074/mcp.RA118.000718
   El Sayed KMF, 2019, TISSUE ENG PART B RE, V25, P445, DOI [10.1089/ten.teb.2019.0106, 10.1089/ten.TEB.2019.0106]
   Feng YJ, 2015, INT J CLIN EXP PATHO, V8, P8268
   Gopinath VK, 2020, ACTA ODONTOL SCAND, V78, P281, DOI 10.1080/00016357.2019.1702716
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Guo T, 2018, J DENT RES, V97, P1331, DOI 10.1177/0022034518788037
   Hesselink JMK, 2017, J NEUROL, V264, P1617, DOI 10.1007/s00415 017 8391 5
   Hu XL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1278 x
   Jia SH, 2013, DEVELOPMENT, V140, P423, DOI 10.1242/dev.081927
   Kim Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225778
   Koide M, 2009, J BONE MINER RES, V24, P1469, DOI [10.1359/jbmr.090302, 10.1359/JBMR.090302]
   Lambrichts I, 2017, J ENDODONT, V43, pS12, DOI 10.1016/j.joen.2017.06.001
   Liu MY, 2018, MOL MED REP, V18, P893, DOI 10.3892/mmr.2018.9033
   Liu ZJ, 2020, J CELL PHYSIOL, V235, P3350, DOI 10.1002/jcp.29223
   Morsczeck C, 2019, ARCH ORAL BIOL, V99, P150, DOI 10.1016/j.archoralbio.2019.01.012
   Okada Akinobu, 2005, Journal of Toxicological Sciences, V30, P145, DOI 10.2131/jts.30.145
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Shah D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020434
   Ching HS, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12092125
   Sonoda S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21183 6
   Sui BD, 2020, J ENDODONT, V46, pS46, DOI 10.1016/j.joen.2020.06.027
   Taraslia V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010158
   Téclès O, 2005, ARCH ORAL BIOL, V50, P103, DOI 10.1016/j.archoralbio.2004.11.009
   Wang H, 2019, J CELL PHYSIOL, V234, P12897, DOI 10.1002/jcp.27954
   Wang Y, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110266
   Xiao XJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3871496
   Xin BC, 2020, PATHOL ONCOL RES, V26, P1677, DOI 10.1007/s12253 019 00746 6
   Youssef AR, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 019 0827 0
NR 35
TC 4
Z9 4
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278 0240
EI 1875 8630
J9 DIS MARKERS
JI Dis. Markers
PD APR 21
PY 2022
VL 2022
AR 7286645
DI 10.1155/2022/7286645
PG 16
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA 1C9AP
UT WOS:000793403900001
PM 35493301
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xie, BC
   Zeng, ZW
   Liao, SY
   Zhou, CH
   Wu, LH
   Xu, DH
AF Xie, Baocheng
   Zeng, Zhanwei
   Liao, Shiyi
   Zhou, Chenhui
   Wu, Longhuo
   Xu, Daohua
TI Kaempferol Ameliorates the Inhibitory Activity of Dexamethasone in the
   Osteogenesis of MC3T3 E1 Cells by JNK and p38 MAPK Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE kaempferol; osteogenic differentiation; dexamethasone; osteoporosis; JNK
   and p38 MAPK signaling pathways
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; MESENCHYMAL STEM CELLS; SIGNALING
   PATHWAY; DIFFERENTIATION; PROLIFERATION; P38; TRANSCRIPTION; MECHANISMS;
   GROWTH
AB Kaempferol has been reported to exhibit beneficial effect on the osteogenic differentiation in mesenchymal stem cells (MSC) and osteoblasts. In our previous study, dexamethasone (DEX) demonstrated inhibitory effect on MC3T3 E1 cells differentiation. In this study, we mainly explored the protective effect of kaempferol on the inhibitory activity of DEX in the osteogenesis of MC3T3 E1 cells. We found that kaempferol ameliorated the proliferation inhibition, cell cycle arrest, and cell apoptosis and increased the activity of alkaline phosphatase (ALP) and the mineralization in DEX treated MC3T3 E1 cells. Kaempferol also significantly enhanced the expression of osterix (Osx) and runt related transcription factor 2 (Runx2) in MC3T3 E1 cells treated with DEX. In addition, kaempferol attenuated DEX induced reduction of cyclin D1 and Bcl 2 expression and elevation of p53 and Bax expression. Kaempferol also activated JNK and p38 MAPK pathways in DEX treated MC3T3 E1 cells. Furthermore, kaempferol improved bone mineralization in DEX induced bone damage in a zebrafish larvae model. These data suggested that kaempferol ameliorated the inhibitory activity of DEX in the osteogenesis of MC3T3 E1 cells by activating JNK and p38 MAPK signaling pathways. Kaempferol exhibited great potentials in developing new drugs for treating glucocorticoid induced osteoporosis.
C1 [Xie, Baocheng; Zeng, Zhanwei; Liao, Shiyi; Xu, Daohua] Guangdong Med Univ, Marine Biomed Res Inst, Publ Serv Platform South China Sea R&D Marine Bio, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Peoples R China.
   [Xie, Baocheng] Southern Med Univ, Affiliated Dongguan Hosp, Dept Pharm, Dongguan, Peoples R China.
   [Zeng, Zhanwei; Liao, Shiyi; Xu, Daohua] Guangdong Med Univ, Key Lab Tradit Chinese Med & New Pharm Dev, Dongguan, Peoples R China.
   [Zhou, Chenhui] Guangdong Med Univ, Sch Nursing, Dongguan, Peoples R China.
   [Wu, Longhuo] Gannan Med Univ, Coll Pharm, Ganzhou, Peoples R China.
C3 Guangdong Medical University; Southern Medical University   China;
   Guangdong Medical University; Guangdong Medical University; Gannan
   Medical University
RP Xu, DH (通讯作者)，Guangdong Med Univ, Marine Biomed Res Inst, Publ Serv Platform South China Sea R&D Marine Bio, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Peoples R China.; Xu, DH (通讯作者)，Guangdong Med Univ, Key Lab Tradit Chinese Med & New Pharm Dev, Dongguan, Peoples R China.; Wu, LH (通讯作者)，Gannan Med Univ, Coll Pharm, Ganzhou, Peoples R China.
EM longhwu@hotmail.com; daohuax108@163.com
RI Liao, Shiyi/HTQ 5043 2023; Xie, Baocheng/GQQ 8354 2022
OI Xie, baocheng/0000 0002 7109 402X; 
FU Discipline construction project of Guangdong Medical University
   [4SG21002G]; National Natural Science Foundation of China [82000842,
   82060407]; Guangdong Basic and Applied Basic Research Foundation
   [2021A1515010151]; Dongguan Science and technology of social development
   Program [202050715001197]
FX The work was supported by Discipline construction project of Guangdong
   Medical University (4SG21002G), National Natural Science Foundation of
   China (82000842, 82060407); Guangdong Basic and Applied Basic Research
   Foundation (2021A1515010151); Dongguan Science and technology of social
   development Program (202050715001197).
CR Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Byun MR, 2012, BONE, V50, P364, DOI 10.1016/j.bone.2011.10.035
   Carnovali M, 2016, PHARMACOL RES, V104, P1, DOI 10.1016/j.phrs.2015.12.009
   Chen AY, 2013, FOOD CHEM, V138, P2099, DOI 10.1016/j.foodchem.2012.11.139
   Chen ZG, 2016, INT J MOL MED, V37, P329, DOI 10.3892/ijmm.2015.2432
   Fan SL, 2018, LIFE SCI, V207, P205, DOI 10.1016/j.lfs.2018.06.006
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Güler Yüksel M, 2018, CALCIFIED TISSUE INT, V102, P592, DOI 10.1007/s00223 017 0335 7
   Gupta N, 2021, J DRUG DELIV SCI TEC, V64, DOI 10.1016/j.jddst.2021.102666
   Hardwick LJA, 2015, CELL TISSUE RES, V359, P187, DOI 10.1007/s00441 014 1895 8
   HARRISON G, 1995, J BONE MINER RES, V10, P568, DOI 10.1002/jbmr.5650100409
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Kim GT, 2014, INT J MOL MED, V33, P863, DOI 10.3892/ijmm.2014.1658
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Ma JJ, 2015, BIOCHEM J, V469, P399, DOI 10.1042/BJ20150151
   Molitorisova M, 2021, EUR J PHARMACOL, V891, DOI 10.1016/j.ejphar.2020.173698
   Sato T, 2008, BIOCHEM BIOPH RES CO, V377, P126, DOI 10.1016/j.bbrc.2008.09.114
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Song HB, 2015, ONCOL REP, V33, P868, DOI 10.3892/or.2014.3662
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE 11 0646
   Urrego D, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0094
   Vandewalle J, 2018, TRENDS ENDOCRIN MET, V29, P42, DOI 10.1016/j.tem.2017.10.010
   Wang CG, 2018, J NAT MED TOKYO, V72, P929, DOI 10.1007/s11418 018 1228 4
   Wang FJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08158 z
   Wang Y, 2014, CELL PROLIFERAT, V47, P241, DOI 10.1111/cpr.12099
   Wang YS, 2017, PHARM BIOL, V55, P2196, DOI 10.1080/13880209.2017.1397177
   Wu JH, 2021, PHYTOTHER RES, V35, P2034, DOI 10.1002/ptr.6946
   Wysokinski D, 2015, DNA CELL BIOL, V34, P305, DOI 10.1089/dna.2014.2688
   Yang L, 2010, J CELL BIOCHEM, V110, P1342, DOI 10.1002/jcb.22649
   Yang X, 2017, CURR MOL MED, V17, P488, DOI 10.2174/1566524018666171219101142
   Yoon HY, 2012, J BONE MINER METAB, V30, P509, DOI 10.1007/s00774 012 0350 8
   Yu W, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122150
   Zha X, 2016, J NAT MED TOKYO, V70, P634, DOI 10.1007/s11418 016 0993 1
   Zhang X, 2015, MOL CELL BIOCHEM, V407, P41, DOI 10.1007/s11010 015 2452 9
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589
NR 40
TC 42
Z9 47
U1 0
U2 48
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 5
PY 2021
VL 12
AR 739326
DI 10.3389/fphar.2021.739326
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WI5ZX
UT WOS:000708439300001
PM 34675808
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Qi, J
   Chi, LQ
   Faber, J
   Koller, B
   Banes, AJ
AF Qi, Jie
   Chi, Liqun
   Faber, James
   Koller, Beverly
   Banes, Albert J.
TI ATP reduces gel compaction in osteoblast populated collagen gels
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE adenosine triphosphate; three dimensional culture; purinoceptor;
   osteoblast; extracellular matrix
ID EXTRACELLULAR NUCLEOTIDES; FIBROBLAST CONTRACTION; ADENINE NUCLEOTIDES;
   GENE EXPRESSION; P2 RECEPTORS; BONE; CELLS; INTEGRIN; ADENOSINE;
   APOPTOSIS
AB Bone remodeling is a localized process, but regulated by systemic signals such as hormones, cytokines, and mechanical loading. The mechanism by which bone cells convert these systemic signals into local signals is not completely understood. It is broadly accepted that the "prestress" in cytoskeleton of cells affects the magnitude of cellular responses to mechanical stimuli. Prestress derives from stiff cytoskeletal proteins and their connections within the cell and from cell contractility upon attaching to matrix. In an in vitro model of three dimensional gel compaction, the relative cellular prestress levels in the same matrix environment were determined by matrix compaction rate: a greater compaction rate resulted in a higher level of prestress. In the present study, the effects of ATP on the prestress of osteoblasts were studied using mouse MC3T3 E1 cells grown in three dimensional bioartificial tissues (BATs). ATP (>= 100 mu M) reduced the compaction rate of BATs in a dose dependent manner. ADP, 2' (or 3') O (4 benzoylbenzoyl) ATP, and UTP, but not alpha,beta methylene ATP, also reduced the compaction rate but to a lesser extent. Pyridoxal phosphate 6 azophenyl 2', 4' disulfonic acid tetrasodium did not block the effect of ATP on BAT compaction rate. These results indicate that both P2X and P2Y receptors are involved in ATP induced reduction of BAT compaction rate. Steady fluid flow and RT PCR results showed that ATP reduced cell attachment on type I collagen by downregulating the expression of integrin alpha(1). These results suggest a potential role for P2 receptors in matrix remodeling and repair and as a potential drug target in treatment of bone diseases.
C1 Flexcell Int Corp, Hillsborough, NC 27278 USA.
   Joint Dept Biomed Engn, Raleigh, NC USA.
   N Carolina State Univ, Dept Cell & Mol Physiol, Raleigh, NC 27695 USA.
   N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA.
   N Carolina State Univ, Curriculum Appl & Mat Sci, Raleigh, NC 27695 USA.
C3 North Carolina State University; North Carolina State University; North
   Carolina State University
RP Banes, AJ (通讯作者)，Flexcell Int Corp, 437 Dimmocks Mill Rd,Ste 28, Hillsborough, NC 27278 USA.
EM ajbvault@med.unc.edu
FU NHLBI NIH HHS [HL65284] Funding Source: Medline; NIAMS NIH HHS [AR38121]
   Funding Source: Medline
CR Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95 043
   Beigi R, 1999, AM J PHYSIOL CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267
   Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756 3282(01)00430 6
   Brunschweiger A, 2006, CURR MED CHEM, V13, P289, DOI 10.2174/092986706775476052
   CAMPBELL CG, 1993, J BIOL CHEM, V268, P15399
   Chen CS, 1999, OSTEOARTHR CARTILAGE, V7, P81, DOI 10.1053/joca.1998.0164
   Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898 6568(00)00083 8
   Dignass AU, 1998, EUR J CLIN INVEST, V28, P554
   Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098 2299(200003)49:3<187::AID DDR9>3.0.CO;2 F
   Doctor RB, 2005, AM J PHYSIOL GASTR L, V288, pG779, DOI 10.1152/ajpgi.00325.2004
   Dubyak GR, 2003, MOL PHARMACOL, V63, P773, DOI 10.1124/mol.63.4.773
   Elfervig MK, 2001, OSTEOARTHR CARTILAGE, V9, P518, DOI 10.1053/joca.2000.0435
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   FROST HM, 1992, J BONE MINER RES, V7, P253
   Garvin J, 2003, TISSUE ENG, V9, P967, DOI 10.1089/107632703322495619
   Giesen EBW, 2003, CLIN BIOMECH, V18, P358, DOI 10.1016/S0268 0033(03)00018 4
   Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918
   Grinnell F, 1999, CURR TOPICS PATHOL, V93, P61
   Hansen RK, 2000, ENDOCR RELAT CANCER, V7, P95, DOI 10.1677/erc.0.0070095
   Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945 053X(00)00076 7
   Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756 3282(00)00351 3
   IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709
   Kennedy C, 2000, MOL PHARMACOL, V57, P926
   Kennedy C, 2000, J AUTONOM NERV SYST, V81, P158, DOI 10.1016/S0165 1838(00)00133 8
   KIRKPATRICK KA, 1992, GEN PHARMACOL VASC S, V23, P1045, DOI 10.1016/0306 3623(92)90284 Q
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   LUTHJE J, 1989, KLIN WOCHENSCHR, V67, P317, DOI 10.1007/BF01741386
   Maaser K, 2002, BRIT J CANCER, V86, P636, DOI 10.1038/sj.bjc.6600100
   Mattana A, 2001, INFECT IMMUN, V69, P4134, DOI 10.1128/IAI.69.6.4134 4140.2001
   North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563
   OHASHI H, 1995, EXP CELL RES, V218, P418, DOI 10.1006/excr.1995.1174
   Olson MF, 2004, TRENDS CELL BIOL, V14, P111, DOI 10.1016/j.tcb.2004.01.005
   Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735
   PODRASKY E, 1997, AM J PHYSIOL HEART C, V273, pH2380
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Racine Samson L, 1997, J BIOL CHEM, V272, P30911, DOI 10.1074/jbc.272.49.30911
   Rehman Q, 2001, ARTHRITIS RES, V3, P221, DOI 10.1186/ar305
   Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732
   STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012 1606(82)90388 8
   Su YJ, 1999, CHINESE MED J PEKING, V112, P720
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Tsuzaki M, 2003, J CELL BIOCHEM, V89, P556, DOI 10.1002/jcb.10534
   Vigne P, 1996, BRIT J PHARMACOL, V119, P360, DOI 10.1111/j.1476 5381.1996.tb15994.x
   Wen LT, 2003, BRIT J PHARMACOL, V140, P1009, DOI 10.1038/sj.bjp.0705523
   WOLFE L A, 1989, International Journal of Oral and Maxillofacial Implants, V4, P311
   WONG GL, 1984, J BIOL CHEM, V259, P4019
   Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709
   Zent R, 1998, EXP CELL RES, V240, P134, DOI 10.1006/excr.1998.4008
   ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279
   Zhu C, 2000, ANNU REV BIOMED ENG, V2, P189, DOI 10.1146/annurev.bioeng.2.1.189
NR 50
TC 22
Z9 28
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
EI 1522 1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD MAR
PY 2007
VL 102
IS 3
BP 1152
EP 1160
DI 10.1152/japplphysiol.00535.2006
PG 9
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 143LF
UT WOS:000244722400045
PM 17122380
DA 2025 08 17
ER

PT J
AU Chlebowski, RT
   Col, N
AF Chlebowski, Rowan T.
   Col, Nananda
TI Bisphosphonates and Breast Cancer Prevention
SO ANTI CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Adjuvant treatment; Anti cancer; Bisphosphonates; Early breast cancer;
   Prevention; Zoledronic acid
ID INDUCED BONE LOSS; RECEIVING ADJUVANT LETROZOLE; RANDOMIZED
   CONTROLLED TRIAL; PLUS ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; FOLLOW UP;
   PREMENOPAUSAL WOMEN; CLODRONATE TREATMENT; ANTITUMOR ACTIVITY; AMERICAN
   SOCIETY
AB Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal related events in metastatic disease and to mitigate bone loss associated with cancer therapy in early stage disease. In addition, adjuvant breast cancer trials evaluating the oral bisphosphonate clodronate suggested a reduction in cancer recurrence, but the findings were mixed, with 2 positive and 1 negative report. In the Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 study, adding the intravenous bisphosphonate zoledronic acid to endocrine therapy in premenopausal breast cancer patients significantly prolonged disease free survival versus endocrine therapy alone (hazard ratio = 0.68; p = 0.008) at 62 months, and reduced local, regional, and distant recurrences. Clinical trial findings from other adjuvant trials (Z FAST, ZO FAST), neoadjuvant studies, and studies involving disseminated tumor cells (DTCs) are generally supportive of the ABCSG 12 conclusion, and recent data from AZURE suggest the importance of menopausal status. Preclinical studies provide data on the mechanisms of action that could mediate bisphosphonate direct and indirect anti cancer effects. Recently, several observational studies (2 cohort studies and 2 case control analyses) have associated oral bisphosphonate use with a lower breast cancer incidence. Such reports require cautious interpretation because confounding by indication is an issue: bisphosphonates are prescribed for women with low bone mineral density, and women with low bone density are at decreased breast cancer risk.
C1 [Chlebowski, Rowan T.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA.
   [Col, Nananda] Dartmouth Med Sch, Hanover, NH USA.
   [Col, Nananda] Shared Decis Making Resources, Hanover, NH USA.
C3 Lundquist Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; Dartmouth College
RP Chlebowski, RT (通讯作者)，Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St, Torrance, CA 90502 USA.
EM rchlebowski@gmail.com
RI ; Col, Nananda/AAE 3445 2019
OI Col, Nananda/0000 0001 7106 662X; 
FU AstraZeneca; Novartis; Pfizer; Amgen; Novartis Pharmaceuticals
   Corporation; National Heart, Lung, and Blood Institute, National
   Institutes of Health, U.S. Department of Health and Human Services
   [N01WH22110, 24152, 32100 2, 32105 6, 32108 9, 32111 13, 32115,
   32118 32119, 32122, 42107 26, 42129 32, 44221]
FX Dr. Chlebowski reports that he has received consulting fees from
   AstraZeneca, Novartis, and Pfizer; lecture fees from AstraZeneca and
   Novartis; and grant funding from Amgen. Dr. Cole has no industry
   relations.Dr. Chlebowski takes responsibility for the content of the
   manuscript. He provided the initial draft of the manuscript and provided
   critical revisions of the manuscript for important intellectual content.
   Financial support for formatting assistance was provided by Novartis
   Pharmaceuticals Corporation. We thank ProEd Communications, Inc.(R) for
   formatting assistance with this manuscript.The WHI program described in
   this report is funded by the National Heart, Lung, and Blood Institute,
   National Institutes of Health, U.S. Department of Health and Human
   Services through contracts N01WH22110, 24152, 32100 2, 32105 6, 32108 9,
   32111 13, 32115, 32118 32119, 32122, 42107 26, 42129 32, and 44221.
CR Aapro M, 2006, BREAST, V15, pS30, DOI 10.1016/j.breast.2006.01.005
   Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   [Anonymous], 32 ANN SAN ANT BREAS
   [Anonymous], Clinician's Guide to Prevention and Treatment of Osteoporosis
   [Anonymous], 33 ANN SAN ANT BREAS
   Bedard PL, 2009, J CLIN ONCOL, V27, P4043, DOI 10.1200/JCO.2008.21.4908
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Brufsky A, 2008, ONCOLOGIST, V13, P503, DOI 10.1634/theoncologist.2007 0206
   Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   Cauley JA, 1996, JAMA J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404
   Chen Z, 2008, CANCER AM CANCER SOC, V113, P907, DOI 10.1002/cncr.23674
   Chlebowski R, 2009, BREAST, V18, pS1, DOI 10.1016/S0960 9776(09)70002 5
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Coleman R, 2011, CANCER AM CANCER SOC, V117, P11, DOI 10.1002/cncr.25529
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197 2456(86)90046 2
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   El Hajj Fuleihan G, 2005, J CLIN ENDOCR METAB, V90, P3209, DOI 10.1210/jc.2004 1444
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   ELOMAA I, 1987, BONE, V8, pS53
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green J, 2010, CANCER INVEST, V28, P944, DOI 10.3109/07357907.2010.512598
   Greenberg S, 2010, J CLIN ONCOL S, V28, p114s
   Hadji P, 2008, ANN ONCOL, V19, P1407, DOI 10.1093/annonc/mdn164
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hines SL, 2010, BREAST, V19, P92, DOI 10.1016/j.breast.2009.12.001
   Lester JE, 2008, CLIN CANCER RES, V14, P6336, DOI 10.1158/1078 0432.CCR 07 5101
   Mamounas Eleftherios P, 2003, Clin Med Res, V1, P309
   Markopoulos C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2565
   Mauri D, 2010, J NATL COMPR CANC NE, V8, P279, DOI 10.6004/jnccn.2010.0020
   Meunier PJ, 1999, OSTEOPOROSIS INT, V10, P330, DOI 10.1007/s001980050236
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Rack B, 2008, DEUT MED WOCHENSCHR, V133, P285, DOI 10.1055/s 2008 1046707
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Robbins J, 2007, JAMA J AM MED ASSOC, V298, P2389, DOI 10.1001/jama.298.20.2389
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Schenk N., 2007, ECCO 14 EUR CANC C S
   TEVAARWERK A, 2007, J CLIN ONCOL 1 S, V25, pS711
   US National Institutes of Health, 2011, STUD DEN ADJ TREATM
   Van Poznak C, 2010, J CLIN ONCOL, V28, P967, DOI 10.1200/JCO.2009.24.5902
   Vassiliou V, 2010, STRAHLENTHER ONKOL, V186, P367, DOI 10.1007/s00066 010 2066 9
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V88, P255, DOI 10.1007/s00223 011 9463 7
   Visvanathan K, 2009, J CLIN ONCOL, V27, P3235, DOI 10.1200/JCO.2008.20.5179
   WARD RL, 1993, BONE MINER, V22, P87, DOI 10.1016/S0169 6009(08)80220 6
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Winter MC, 2008, 31 ANN SAN ANT BREAS
NR 57
TC 9
Z9 11
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871 5206
J9 ANTI CANCER AGENT ME
JI Anti Cancer Agents Med. Chem.
PD FEB
PY 2012
VL 12
IS 2
BP 144
EP 150
PG 7
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 936TK
UT WOS:000303612700008
PM 21864227
DA 2025 08 17
ER

PT J
AU Guo, X
   Xue, MT
   Chen, F
   Guo, QF
   Zhou, X
   Lin, H
   Chen, Y
AF Guo, Xiang
   Xue, Mintao
   Chen, Fei
   Guo, Qunfeng
   Zhou, Xin
   Lin, Han
   Chen, Yu
TI Local delivery and controlled release of miR 34a loaded in
   hydroxyapatite/ mesoporous organosilica nanoparticles composite coated
   implant wire to accelerate bone fracture healing
SO BIOMATERIALS
LA English
DT Article
DE Mesoporous organosilica nanoparticle; Medical implant; microRNA 34a;
   Differentially expressed gene; Bone fracture
ID ZOLEDRONIC ACID; GENE DELIVERY; DIFFERENTIATION; REGENERATION; SIRNA;
   MICRORNA 34A; OSTEOBLASTS; PROMOTION; BETA
AB Immediate mechanical stability is a prerequisite for fracture healing. In addition to bringing immediate me chanical stability in fracture site, implants with bioactive coating can release active substance to accelerate bone fracture healing. However, limited drug loading capacity of established coatings weakens their biological functions, which urges the engineering of more effective coating biomaterials for accelerating fracture healing. Herein, mesoporous organosilica nanoparticles (MONs), as miR 34a delivers, are loaded onto hydroxyapatite (HA) coated Kirschner wire to engineer a HA/MONs@miR 34a composite coating. The composite coating can effectively deliver miR 34a into osteoclasts, generate gene dose dependent inhibiting effect on differentiation and resorptive activity of osteoclasts by regulating multiple downstream gene expression at the early stage of fracture healing, which additionally exhibits decent bone regeneration potentials as evidenced in rat tibial fracture model. In particular, differentially expressed genes regulated by miR 34a are identified using RNA seq followed by bioinformatics analysis. Functional enrichment analysis reveals that genes with altered expression mainly distribute in mainly distribute in DNA replication and cell cycle, which are associated with the devel opment of osteoclasts. This work not only demonstrates the high clinical translation potential of HA/ MONs@miR 34a to accelerate fracture healing, but also reveals the underlying molecular mechanism of regu lating physiological functions of osteoclasts based on analysis of singlecell RNA sequencing.
C1 [Guo, Xiang; Xue, Mintao; Chen, Fei; Guo, Qunfeng; Zhou, Xin] Navy Med Univ, Affiliated Hosp 2, Dept Orthoped, Shanghai 200003, Peoples R China.
   [Lin, Han; Chen, Yu] Chinese Acad Sci, Shanghai Inst Ceram, State Lab High Performance Ceram & Superfine Micr, Shanghai 200050, Peoples R China.
   [Chen, Yu] Shanghai Univ, Sch Life Sci, Shanghai 200444, Peoples R China.
C3 Naval Medical University; Chinese Academy of Sciences; Shanghai
   Institute of Ceramics, CAS; Shanghai University
RP Lin, H; Chen, Y (通讯作者)，Chinese Acad Sci, Shanghai Inst Ceram, State Lab High Performance Ceram & Superfine Micr, Shanghai 200050, Peoples R China.
EM linhan@mail.sic.ac.cn; chenyuedu@shu.edu.cn
RI Guo, Xiang/LXU 6530 2024; Lin, Han/N 9999 2019; Chen, Yu/N 8463 2015
OI Lin, Han/0000 0003 1663 5468; Zhou, Xin/0000 0002 0930 8023; Chen,
   Yu/0000 0002 8206 3325
FU National Natural Science Foundation of China [81672131, 81871754,
   52002391]
FX Acknowledgements We acknowledge the financial supports from the National
   Natural Science Foundation of China (Grants No. 81672131, 81871754 and
   52002391) .
CR Alenezi A, 2018, INT J ORAL MAX IMPL, V33, pE1, DOI 10.11607/jomi.6333
   Banerjee J, 2015, ADV EXP MED BIOL, V888, P291, DOI 10.1007/978 3 319 22671 2_15
   Beavers KR, 2015, ADV DRUG DELIVER REV, V88, P123, DOI 10.1016/j.addr.2014.12.006
   Clements BA, 2007, BIOMATERIALS, V28, P4693, DOI 10.1016/j.biomaterials.2007.07.023
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Deng XW, 2014, BIOMATERIALS, V35, P4333, DOI 10.1016/j.biomaterials.2014.02.006
   Dundar S, 2017, J CRANIOFAC SURG, V28, P935, DOI 10.1097/SCS.0000000000003568
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Fu YM, 2014, J ORTHOP RES, V32, P744, DOI 10.1002/jor.22594
   Gao K, 2009, MOL PHARMACEUT, V6, P651, DOI 10.1021/mp800134q
   Greiner S, 2009, J BIOMED MATER RES A, V91A, P288, DOI 10.1002/jbm.a.32245
   Greiner SH, 2008, ACTA ORTHOP, V79, P717, DOI 10.1080/17453670810016768
   Hardy JG, 2009, ORG BIOMOL CHEM, V7, P789, DOI 10.1039/b818469k
   Karasik David, 2012, Bonekey Rep, V1, P114, DOI 10.1038/bonekey.2012.114
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kim HJ, 2012, J CELL BIOL, V199, P1145, DOI 10.1083/jcb.201204067
   Krishnamurthy S, 2015, NANOMEDICINE UK, V10, P143, DOI 10.2217/nnm.14.154
   Kwon BJ, 2018, EUR CELLS MATER, V35, P1, DOI 10.22203/eCM.v035a01
   Lei Z, 2017, ACS APPL MATER INTER, V9, P9437, DOI 10.1021/acsami.7b00209
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Li X, 2011, BIOMATERIALS, V32, P9546, DOI 10.1016/j.biomaterials.2011.08.068
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Liu WJ, 2020, J CELL MOL MED, V24, P9786, DOI 10.1111/jcmm.15560
   Lopes HB, 2016, J BIOMAT SCI POLYM E, V27, P1369, DOI 10.1080/09205063.2016.1203217
   Lozano C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00375
   Lu CH, 2013, BIOTECHNOL ADV, V31, P1695, DOI 10.1016/j.biotechadv.2013.08.015
   Nakagawa T, 2020, BIOCHEM GENET, V58, P473, DOI 10.1007/s10528 020 09961 2
   Nugent M, 2015, ADV EXP MED BIOL, V889, P201, DOI 10.1007/978 3 319 23730 5_11
   Peng WX, 2017, EXP BIOL MED, V242, P1234, DOI 10.1177/1535370217703975
   Pereira M, 2020, ELIFE, V9, DOI 10.7554/eLife.55549
   Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490
   Shi SJ, 2014, J CONTROL RELEASE, V194, P228, DOI 10.1016/j.jconrel.2014.09.005
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Vergarajauregui S, 2020, ELIFE, V9, DOI 10.7554/eLife.61669
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Wildemann B, 2004, J CONTROL RELEASE, V95, P249, DOI 10.1016/j.jconrel.2003.11.014
   Wu MY, 2015, ADV MATER, V27, P215, DOI 10.1002/adma.201404256
   Yang BW, 2018, ADV MATER, V30, DOI 10.1002/adma.201705611
   You ZW, 2012, ACTA BIOMATER, V8, P502, DOI 10.1016/j.actbio.2011.11.004
   Zambetti GP, 2006, J CELL BIOL, V172, P795, DOI 10.1083/jcb.200601114
   Zhao SC, 2015, ACTA BIOMATER, V12, P270, DOI 10.1016/j.actbio.2014.10.015
   Zhu M, 2014, ACS APPL MATER INTER, V6, P5456, DOI 10.1021/am405013t
   Zwolak P, 2018, ARCH ORTHOP TRAUM SU, V138, P13, DOI 10.1007/s00402 017 2818 4
NR 43
TC 27
Z9 27
U1 6
U2 78
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2022
VL 280
AR 121300
DI 10.1016/j.biomaterials.2021.121300
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 0P0MJ
UT WOS:000783917300005
PM 34920369
DA 2025 08 17
ER

PT J
AU Seeman, E
   Delmas, PD
   Hanley, DA
   Sellmeyer, D
   Cheung, AM
   Shane, E
   Kearns, A
   Thomas, T
   Boyd, SK
   Boutroy, S
   Bogado, C
   Majumdar, S
   Fan, M
   Libanati, C
   Zanchetta, J
AF Seeman, Ego
   Delmas, Pierre D.
   Hanley, David A.
   Sellmeyer, Deborah
   Cheung, Angela M.
   Shane, Elizabeth
   Kearns, Ann
   Thomas, Thierry
   Boyd, Steven K.
   Boutroy, Stephanie
   Bogado, Cesar
   Majumdar, Sharmila
   Fan, Michelle
   Libanati, Cesar
   Zanchetta, Jose
TI Microarchitectural Deterioration of Cortical and Trabecular Bone:
   Differing Effects of Denosumab and Alendronate
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE DENOSUMAB; ALENDRONATE; HR PQCT; VOLUMETRIC BONE MINERAL DENSITY;
   CORTICAL THICKNESS
ID FRACTURE RISK REDUCTION; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS;
   MINERAL DENSITY; TURNOVER; STRENGTH; MASS; BMD; MECHANISMS; PHASE 2
AB The intensity of bone remodeling is a critical determinant of the decay of cortical and trabecular microstructure after menopause. Denosumab suppresses remodeling more than alendronate, leading to greater gains in areal bone mineral density (aBMD). These greater gains may reflect differing effects of each drug on bone microarchitecture and strength. In a phase 2 double blind pilot study, 247 postmenopausal women were randomized to denosumab (60 mg subcutaneous 6 monthly), alendronate (70 mg oral weekly), or placebo for 12 months. All received daily calcium and vitamin D. Morphologic changes were assessed using high resolution peripheral quantitative computed tomography (HR pQCT) at the distal radius and distal tibia and QCT at the distal radius. Denosumab decreased serum C telopeptide more rapidly and markedly than alendronate. In the placebo arm, total, cortical, and trabecular BMD and cortical thickness decreased ( 2.1% to  0.8%) at the distal radius after 12 months. Alendronate prevented the decline ( 0.6% to 2.4%, p = .051 to <.001 versus placebo), whereas denosumab prevented the decline or improved these variables (0.3% to 3.4%, p < .001 versus placebo). Changes in total and cortical BMD were greater with denosumab than with alendronate (p <= .024). Similar changes in these parameters were observed at the tibia. The polar moment of inertia also increased more in the denosumab than alendronate or placebo groups (p < .001). Adverse events did not differ by group. These data suggest that structural decay owing to bone remodeling and progression of bone fragility may be prevented more effectively with denosumab. (c) 2010 American Society for Bone and Mineral Research.
C1 [Seeman, Ego] Univ Melbourne, Austin Hlth, Melbourne, Vic, Australia.
   [Delmas, Pierre D.; Boutroy, Stephanie] INSERM, U831, F 69008 Lyon, France.
   [Delmas, Pierre D.; Boutroy, Stephanie] Univ Lyon, Lyon, France.
   [Hanley, David A.; Boyd, Steven K.] Univ Calgary, Calgary, AB, Canada.
   [Sellmeyer, Deborah] Johns Hopkins Univ, Baltimore, MD USA.
   [Cheung, Angela M.] Univ Hlth Network, Toronto, ON, Canada.
   [Cheung, Angela M.] Univ Toronto, Toronto, ON, Canada.
   [Shane, Elizabeth] Columbia Presbyterian Med Ctr, New York, NY 10032 USA.
   [Kearns, Ann] Mayo Clin, Rochester, MN USA.
   [Thomas, Thierry] INSERM, U890, St Etienne, France.
   [Thomas, Thierry] Univ Hosp, St Etienne, France.
   [Bogado, Cesar; Zanchetta, Jose] Inst Invest Metabol, Buenos Aires, DF, Argentina.
   [Majumdar, Sharmila] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Fan, Michelle; Libanati, Cesar] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 Florey Institute of Neuroscience & Mental Health; Howard Florey
   Institute Affiliates; Austin Research Institute; University of
   Melbourne; Institut National de la Sante et de la Recherche Medicale
   (Inserm); University of Calgary; Johns Hopkins University; University of
   Toronto; University Health Network Toronto; University of Toronto;
   Columbia University; NewYork Presbyterian Hospital; Mayo Clinic;
   Institut National de la Sante et de la Recherche Medicale (Inserm); CHU
   de St Etienne; University of California System; University of California
   San Francisco; Amgen
RP Seeman, E (通讯作者)，Austin Hlth, Dept Endocrinol, Heidelberg, Vic 3084, Australia.
EM egos@unimelb.edu.au
RI Thomas, Thierry/JZE 4328 2024; Libanati, Cesar/LGZ 1518 2024; Seeman,
   Ego/AAC 3656 2019; Boyd, Steven/E 9595 2010
OI Seeman, Ego/0000 0002 9692 048X; Boyd, Steven/0000 0002 2930 5997;
   Cheung, Angela M./0000 0001 8332 0744
FU Amgen, Inc.
FX We dedicate this paper to the memory of Professor Pierre Delmas, who was
   instrumental in the development of this protocol. We are indebted to Amy
   Foreman Wykert, PhD, of Amgen, Inc., and Jonathan Latham, PharmD, of
   PharmaScribe, LLC, for assistance with manuscript formatting and version
   control, preparation of figures, reference management, and collating the
   authors' comments during manuscript preparation. We thank Dr Michael
   Ominsky for his review of the manuscript and valuable comments. Amgen,
   Inc., supported the study and the development of this manuscript.
   Clinicaltrials.gov registration: NCT00293813 (registered February 17,
   2006).
CR Ammann P, 2003, OSTEOPOROSIS INT, V14, pS13, DOI 10.1007/s00198 002 1345 4
   Augat P, 2006, AGE AGEING, V35, P27, DOI 10.1093/ageing/afl081
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Boutroy S, 2005, J CLIN ENDOCR METAB, V90, P6508, DOI 10.1210/jc.2005 1258
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Bruyere O, 2007, J CLIN ENDOCR METAB, V92, P3076, DOI 10.1210/jc.2006 2758
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Kanis JA, 2003, BONE, V32, P468, DOI 10.1016/S8756 3282(03)00061 9
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Laib A, 1998, Technol Health Care, V6, P329
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   MacNeil JA, 2007, MED ENG PHYS, V29, P1096, DOI 10.1016/j.medengphy.2006.11.002
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Ominsky MS, 2008, CALCIFIED TISSUE INT, V82, pS240
   Ominsky MS, 2006, J BONE MINER RES, V21, pS72
   Ominsky MS, 2008, J BONE MINER RES, V23, pS40
   Ominsky MS, 2008, J BONE MINER RES, V23, pS22
   REID C, 2009, J BONE MINER RES  S1, V24, pS353
   REID I, 2009, J BONE MINER RES  S1, V24, pS9
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sornay Rendu E, 2007, J BONE MINER RES, V22, P425, DOI 10.1359/JBMR.061206
   VANDEROOST J, 2009, J BONE MINER RES  S1, V24, pS157
   Watts NB, 2005, J BONE MINER RES, V20, P2097, DOI 10.1359/JBMR.050814
   Zebaze RMD, 2005, LANCET, V366, P1523, DOI 10.1016/S0140 6736(05)67618 0
NR 29
TC 224
Z9 244
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2010
VL 25
IS 8
BP 1886
EP 1894
DI 10.1002/jbmr.81
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 643UO
UT WOS:000281325000020
PM 20222106
OA Green Accepted, Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Tran, PT
   Dang, NH
   Kim, O
   Cuong, PV
   Dat, NT
   Hwangbo, C
   Minh, CV
   Lee, JH
AF Phuong Thao Tran
   Nguyen Hai Dang
   Kim, Okhwa
   Pham Van Cuong
   Nguyen Tien Dat
   Hwangbo, Cheol
   Chau Van Minh
   Jeong Hyung Lee
TI Ethanol extract of Polyscias fruticosa leaves suppresses
   RANKL mediated osteoclastogenesis in vitro and LPS induced bone
   loss in vivo
SO PHYTOMEDICINE
LA English
DT Article
DE Polyscias fruticose leaves; Osteoclastogenesis; RANKL; c Fos; NFATc1
ID NF KAPPA B; RECEPTOR ACTIVATOR; OLEANOLIC ACID; DIFFERENTIATION; NFATC1;
   PROLIFERATION; INFLAMMATION; MECHANISMS; EXPRESSION; PATHWAY
AB Background: Many bone related diseases such as osteoporosis and rheumatoid arthritis are commonly associated with the excessive activity of osteoclasts. Polyscias fruticosa has been used as traditional medicine for the treatment of ischemia and inflammation and also eaten as a salad. However, its effect on the bone related diseases has not been investigated yet.
   Purpose: This study aimed to investigate the effect of ethanol extract of P. fruticosa on RANKL induced osteoclastogenesis in vitro and LPS induced bone loss in mouse, and evaluate anti osteoclastogenic activities of its major constituents.
   Methods: BMMs or RAW264.7 cells were treated with ethanol extract from P. fruticose leaves (EEPL), followed by an evaluation of cell viability, RANKL induced osteoclast differentiation, actin ring formation, and resorption pits activity. Effects of EEPL on RANKL induced phosphorylation of MAPKs were evaluated by Western blotting. The expression levels of NFATc1 and c Fos were evaluated by Western blotting or immunofluorescence assay. The expression levels of osteoclast specific marker genes were evaluated by Western blotting and reverse transcription qPCR analysis. A LPS induced murine bone loss model was used to evaluate the protective effect of EEPL on inflammation induced bone loss. HPLC analysis was performed to identify the major constituents of EEPL.
   Results: EEPL significantly inhibited RANKL induced osteoclast differentiation by decreasing the number of osteoclasts, osteoclast actin ring formation, and bone resorption. EEPL suppressed RANKL induced phosphorylation of p38 and JNK MAPKs, as well as the expression of c Fos and NFATc1. EEPL decreased the expression levels of osteoclast marker genes, including MMP 9, TRAP and CtsK. Mice treated with EEPL significantly protected the mice from LPS induced osteoclast formation and bone destruction as indicated by micro CT and histological analysis of femurs. We also identified 3 O [beta D glucopyranosyl (1  > 4) beta D glucuronopyranosyl] oleanolic acid 28 O beta D glucopyranosyl ester (1) and quercitrin (3) as the active constituents in EEPL for inhibiting RANKL induced osteoclast differentiation.
   Conclusion: The results showed that EEPL exerted anti osteoclastogenic activity in vitro and in vivo by inhibiting RANKL induced osteoclast differentiation and function, and suggested that EEPL could have beneficial applications for preventing or inhibiting osteoclast mediated bone diseases.
C1 [Phuong Thao Tran; Kim, Okhwa; Jeong Hyung Lee] Kangwon Natl Univ, Dept Biochem, Coll Nat Sci, Chunchon 24341, Gangwon Do, South Korea.
   [Nguyen Hai Dang; Pham Van Cuong; Chau Van Minh] Vietnam Acad Sci & Technol, Adv Ctr Bioorgan Chem, Inst Marine Biochem, 18 Hoang Quoc Viet, Hanoi, Vietnam.
   [Nguyen Tien Dat] Vietnam Acad Sci & Technol, Ctr Res & Technol Transfer, 18 Hoang Quoc Viet, Hanoi, Vietnam.
   [Hwangbo, Cheol] Gyeongsang Natl Univ, Coll Nat Sci, Plus BK21, Div Life Sci,Div Appl Life Sci,PMBBRC, Jinju 52828, South Korea.
C3 Kangwon National University; Vietnam Academy of Science & Technology
   (VAST); Vietnam Academy of Science & Technology (VAST); Gyeongsang
   National University
RP Lee, JH (通讯作者)，Kangwon Natl Univ, Dept Biochem, Coll Nat Sci, Chunchon 24341, Gangwon Do, South Korea.
EM jhlee36@kangwon.ac.kr
OI Dat, Nguyen Tien/0000 0003 3645 5157; Nguyen, Hai
   Dang/0000 0002 4470 8321; Hwangbo, Cheol/0000 0001 6505 3080
FU National Research Foundation (NRF) of Korea [2018R1D1A1B07047187];
   Institute of Marine Biochemistry (IMBC) [HSB18 CS08]
FX This research was supported by the grants from the National Research
   Foundation (NRF) of Korea (2018R1D1A1B07047187) and from the Institute
   of Marine Biochemistry (IMBC) coded HSB18 CS08.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   BENSITA MB, 1998, ANCIENT SCI LIFE, V17, P313
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choo YY, 2017, INT IMMUNOPHARMACOL, V52, P230, DOI 10.1016/j.intimp.2017.09.018
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Do T., 2000, VIETNAMESE MED PLANT, P828
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Huan VD, 1998, PHYTOCHEMISTRY, V47, P451, DOI 10.1016/S0031 9422(97)00618 3
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Koffuor GA, 2016, PHARM BIOL, V54, P1354, DOI 10.3109/13880209.2015.1077465
   Li JX, 2005, PLANTA MED, V71, P673, DOI 10.1055/s 2005 871275
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Logar DB, 2007, J BONE MINER METAB, V25, P219, DOI 10.1007/s00774 007 0753 0
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Luyen N, 2012, JMM, V17, P348
   Ma B, 2018, TOXICOL APPL PHARM, V353, P87, DOI 10.1016/j.taap.2018.05.025
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Tran PT, 2018, INT J MOL MED, V42, P569, DOI 10.3892/ijmm.2018.3627
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Sethi G, 2007, CHEM BIOL, V14, P738, DOI 10.1016/j.chembiol.2007.07.002
   Sultana N, 2008, J ENZYM INHIB MED CH, V23, P739, DOI [10.1080/14756360701633187, 10.1080/14756360701633187 ]
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2007, J BIOL CHEM, V282, P18980, DOI 10.1074/jbc.M610938200
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Hanh TTH, 2016, J CHEM NY, V2016, DOI 10.1155/2016/2082946
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yu WF, 2012, J BIOL CHEM, V287, P13694, DOI 10.1074/jbc.M112.355610
   Zhao DF, 2018, J PHARMACOL SCI, V137, P76, DOI 10.1016/j.jphs.2018.03.007
NR 41
TC 11
Z9 11
U1 0
U2 14
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUN
PY 2019
VL 59
AR 152908
DI 10.1016/j.phymed.2019.152908
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA IF4JW
UT WOS:000473048600032
PM 30981187
DA 2025 08 17
ER

PT J
AU Huang, RY
   Chang, HY
   Chih, SM
   Van Dyke, T
   Cheng, CD
   Sung, CE
   Weng, PW
   Shieh, YS
   Cheng, WC
AF Huang, Ren Yeong
   Chang, Hua Yang
   Chih, Shu Mi
   Van Dyke, Thomas
   Cheng, Chia Dan
   Sung, Cheng En
   Weng, Pei Wei
   Shieh, Yi Shing
   Cheng, Wan Chien
TI Silibinin alleviates inflammation induced bone loss by modulating
   biological interaction between human gingival fibroblasts and monocytes
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE fibroblasts; inflammation; osteoclasts; periodontitis; RANK ligand;
   Silybin
ID PORPHYROMONAS GINGIVALIS; EXPERIMENTAL PERIODONTITIS; HOST MODULATION;
   DIFFERENTIATION; RANKL; CELLS; OSTEOCLASTOGENESIS; OSTEOPROTEGERIN;
   DESTRUCTION; POLYPHENOLS
AB BackgroundSilibinin has shown various pharmacological effects that could be attributed to its antioxidant, anti inflammatory, and immunoregulatory properties. However, the therapeutic potential of silibinin for periodontitis has not been investigated. MethodsThe therapeutic effects of silibinin in ligation induced experimental periodontitis were investigated using biochemical, histological, and immunohistochemical methods. The effects of silibinin on the osteoclastogenesis of RAW264.7 cells were investigated using TRAP staining, quantitative polymerase chain reaction (qPCR), pit formation, and immunoblotting. Moreover, its effects on inflammatory cytokine production, RANKL expression, and oxidative stress in lipopolysaccharide (LPS) stimulated human gingival fibroblasts (HGFs) were evaluated using qPCR and flow cytometry. A coculture system was established to elucidate the effects of silibinin on the crosstalk between LPS stimulated HGFs and undifferentiated monocytes. ResultsSilibinin significantly reduced the alveolar bone loss, decreased the gingival inflammation and RANKL expression, and decreased the RANKL/osteoprotegerin ratio in gingival tissues in experimental periodontitis. The in vitro results showed that silibinin inhibited RANKL induced osteoclast differentiation and function of RAW264.7 cells and suppressed RANKL induced nuclear factor of activated T cells 1 (NFATc1) induction and translocation through the nuclear factor & kappa;B and mitogen activated protein kinase signaling pathways. Silibinin decreased the inflammatory cytokine level and oxidative stress production in LPS stimulated HGFs; significantly suppressed membrane bound RANKL expression on LPS stimulated HGFs; and significantly disrupted TRAP(+) cell differentiation in the coculture system. ConclusionsSilibinin effectively inhibits inflammation induced bone loss in experimental periodontitis based on the regulation of stimulated HGFs by inhibiting the expression of inflammatory and osteoclastogenic mediators. Collectively, targeting the inflamed HGF resolution that mediates osteogenesis may use silibinin as a potential drug repurposing candidate for modulating alveolar bone destruction in periodontitis. Silibinin effectively inhibits inflammation induced bone loss in experimental periodontitis based on the regulation of stimulated HGFs by inhibiting the expression of inflammatory and osteoclastogenic mediators.
C1 [Huang, Ren Yeong; Chang, Hua Yang; Chih, Shu Mi; Cheng, Chia Dan; Sung, Cheng En; Cheng, Wan Chien] Triserv Gen Hosp, Sch Dent, Dept Periodontol, Taipei, Taiwan.
   [Huang, Ren Yeong; Chang, Hua Yang; Chih, Shu Mi; Cheng, Chia Dan; Sung, Cheng En; Shieh, Yi Shing; Cheng, Wan Chien] Natl Def Med Ctr, Taipei, Taiwan.
   [Chang, Hua Yang; Chih, Shu Mi; Cheng, Chia Dan] Natl Def Med Ctr, Grad Inst Dent Sci, Taipei, Taiwan.
   [Van Dyke, Thomas] Harvard Sch Dent Med, Oral Med Infect & Immun, Boston, MA USA.
   [Van Dyke, Thomas] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA.
   [Weng, Pei Wei] Taipei Med Univ, Shuang Ho Hosp, Dept Orthoped, New Taipei, Taiwan.
   [Weng, Pei Wei] Taipei Med Univ, Dept Orthoped, Coll Med, Taipei, Taiwan.
   [Shieh, Yi Shing] Triserv Gen Hosp, Sch Dent, Dept Operat Dent & Endodont, Taipei, Taiwan.
C3 Tri Service General Hospital; National Defense Medical University;
   National Defense Medical University; Harvard University; Harvard School
   of Dental Medicine; Harvard University; Harvard University Medical
   Affiliates; Forsyth Institute; Taipei Medical University; Shuang Ho
   Hospital; Taipei Medical University; Tri Service General Hospital
RP Cheng, WC (通讯作者)，Triserv Gen Hosp, Sch Dent, Dept Periodontol, Taipei, Taiwan.; Cheng, WC (通讯作者)，Natl Def Med Ctr, Taipei, Taiwan.
EM wan chien.cheng@mail.ndmctsgh.edu.tw
RI Huang, Ren Yeong/N 2202 2019
OI Huang, Ren Yeong/0000 0003 2306 8828
FU Tri Service General Hospital, National Defense Medical Center
   [TSGH C101 039, TSGH C108 032, TSGH E 110208, TSGH D 111146]; Ministry
   of National Defense [MAB 108 080, MND MAB 110 127]
FX ACKNOWLEDGMENTS This study was partially supported by the grants from
   Tri Service General Hospital, National Defense Medical Center
   (TSGH C101 039, TSGH C108 032, TSGH E 110208, and TSGH D 111146), and
   the grants of Ministry of National Defense (MAB 108 080 and
   MND MAB 110 127) in Taiwan. The authors acknowledge Dr. Jen Kun Chen,
   Ms. Shihg Ju Lai, Ms. Sih Yu Chen, and Mr. Wei Neng Liao (National
   Health Research Institutes) for micro CT imaging and analysis, and Dr.
   Yi Jen Peng and Mr. Guo lun Lan (Department of Pathology, Tri Service
   General Hospital) for histological preparation, and Dr. Fang Yi Tseng,
   Ms. Tian Syuan Lin, Ms. Sing Zong Ho, and Mr. Po Yan Hsiao (National
   Defense Medical Center) for their help in in vivo and in vitro analyses.
CR AlQranei MS, 2020, J ORAL BIOSCI, V62, P123, DOI 10.1016/j.job.2020.02.002
   Balta MG, 2021, J DENT RES, V100, P798, DOI 10.1177/0022034521995157
   Bartold PM, 2017, PERIODONTOL 2000, V75, P317, DOI 10.1111/prd.12169
   Belibasakis GN, 2007, MICROB PATHOGENESIS, V43, P46, DOI 10.1016/j.micpath.2007.03.001
   Brunetti G, 2005, J PERIODONTOL, V76, P1675, DOI 10.1902/jop.2005.76.10.1675
   Bullon P, 2009, J DENT RES, V88, P503, DOI 10.1177/0022034509337479
   Cheng WC, 2010, J PERIODONTAL RES, V45, P788, DOI 10.1111/j.1600 0765.2010.01301.x
   Cheng WC, 2016, EUR J IMMUNOL, V46, P2211, DOI 10.1002/eji.201545871
   Costa Rodrigues J, 2011, CELL PROLIFERAT, V44, P264, DOI 10.1111/j.1365 2184.2011.00751.x
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI [10.1111/bph.15193, 10.1136/bmjos 2020 100115]
   Fitzsimmons TR, 2018, CLIN ORAL INVEST, V22, P919, DOI 10.1007/s00784 017 2171 6
   Govindaraj P, 2011, MITOCHONDRION, V11, P504, DOI 10.1016/j.mito.2011.01.009
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kidd PM, 2009, ALTERN MED REV, V14, P226
   Kim JH, 2009, MOL CELLS, V28, P201, DOI 10.1007/s10059 009 0123 y
   Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351
   Kook SH, 2009, J CELL BIOCHEM, V106, P1010, DOI 10.1002/jcb.22086
   Li X, 2016, EXP CELL RES, V347, P212, DOI 10.1016/j.yexcr.2016.08.007
   Lu Sheng Hua, 2013, STUDY EVIDENCE BASED, V2013, DOI DOI 10.1155/2013/634095
   Mau LP, 2016, J FUNCT FOODS, V22, P243, DOI 10.1016/j.jff.2016.01.025
   Nagasawa T, 2002, CLIN EXP IMMUNOL, V130, P338, DOI 10.1046/j.1365 2249.2002.01990.x
   Naruishi K, 2018, J CELL PHYSIOL, V233, P6393, DOI 10.1002/jcp.26521
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Ramasamy K, 2008, CANCER LETT, V269, P352, DOI 10.1016/j.canlet.2008.03.053
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Shanmugam K, 2008, MOL NUTR FOOD RES, V52, P427, DOI 10.1002/mnfr.200700180
   Singh RP, 2009, CLIN DERMATOL, V27, P479, DOI 10.1016/j.clindermatol.2009.05.012
   Tajmohammadi A, 2018, PHYTOTHER RES, V32, P1933, DOI 10.1002/ptr.6153
   Taubman MA, 2005, J PERIODONTOL, V76, P2033, DOI 10.1902/jop.2005.76.11 S.2033
   Tipton DA, 2011, J PERIODONTAL RES, V46, P39, DOI 10.1111/j.1600 0765.2010.01306.x
   Tunyogi Csapo M, 2008, ARTHRITIS RHEUM US, V58, P2397, DOI 10.1002/art.23653
   Van Dyke TE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00511
   Wang X, 2020, J AGR FOOD CHEM, V68, P11644, DOI 10.1021/acs.jafc.0c04791
   Wei D, 2010, AUST DENT J, V55, P70, DOI 10.1111/j.1834 7819.2009.01123.x
   Ying XZ, 2013, EUR J PHARMACOL, V721, P225, DOI 10.1016/j.ejphar.2013.09.031
NR 36
TC 6
Z9 7
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD JUL
PY 2023
VL 94
IS 7
BP 905
EP 918
DI 10.1002/JPER.22 0535
EA MAR 2023
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA M7ES5
UT WOS:000945387900001
PM 36716169
DA 2025 08 17
ER

PT J
AU Ofotokun, I
   Weitzmann, MN
AF Ofotokun, Ighovwerha
   Weitzmann, M. Neale
TI HIV 1 infection and antiretroviral therapies: risk factors for
   osteoporosis and bone fracture
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Article
DE AIDS; HIV; OPG; osteoclast; osteoporosis; RANKL
ID ACTIVATED T CELLS; MINERAL DENSITY; VITAMIN D; OSTEOCLAST FORMATION;
   B CELLS; OSTEOPROTEGERIN; RANKL; MEN; ALENDRONATE; PREVALENCE
AB Purpose of review
   Patients with HIV 1 infection/AIDS are living longer due to the success of highly active antiretroviral therapy (HAART). However, serious metabolic complications including bone loss and fractures are becoming common. Understanding the root causes of bone loss and its potential implications for aging AIDS patients will be critical to the design of effective interventions to stem a tidal wave of fractures in a population chronically exposed to HAART.
   Recent findings
   Paradoxically, bone loss may occur not only due to HIV/AIDS but also as a consequence of HAART. The cause and mechanisms driving these distinct forms of bone loss, however, are complex and controversial. This review examines our current understanding of the underlying causes of HIV 1 and HAART associated bone loss, and recent findings pertaining to the relevance of the immuno skeletal interface in this process.
   Summary
   It is projected that by 2015 more than half of the HIV/AIDS population in the USA will be over the age of 50 and the synergy between HIV and/or HAART related bone loss with age associated bone loss could lead to a significant health threat. Aggressive antiresorptive therapy may be warranted in high risk patients.
C1 [Weitzmann, M. Neale] Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, Atlanta, GA USA.
   [Ofotokun, Ighovwerha] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
   [Weitzmann, M. Neale] Atlanta VA Med Ctr, Decatur, GA USA.
C3 Emory University; Emory University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Atlanta VA Health Care System;
   Atlanta VA Medical Center
RP Weitzmann, MN (通讯作者)，101 Woodruff Circle,1305 WMRB, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
RI Ofotokun, Ighovwerha/L 6545 2015
FU NIAMS [AR059364, AR053607, AR056090]; Biomedical Laboratory Research &
   Development Service of the VA Office of Research and Development
   [5I01BX000105]; NIAID [K23 A1073119]
FX The authors gratefully acknowledge financial support from NIAMS
   (AR059364) to M.N.W. and I.O., and AR053607 to M.N.W. M.N.W. is also
   supported in part by NIAMS grant AR056090 and by a grant from the
   Biomedical Laboratory Research & Development Service of the VA Office of
   Research and Development (5I01BX000105). I.O. is also supported in part
   by K23 A1073119 from NIAID.
CR Arnsten JH, 2007, AIDS, V21, P617, DOI 10.1097/QAD.0b013e3280148c05
   Bolland MJ, 2007, J CLIN ENDOCR METAB, V92, P1283, DOI 10.1210/jc.2006 2216
   Brainsky A, 1997, J AM GERIATR SOC, V45, P281, DOI 10.1111/j.1532 5415.1997.tb00941.x
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Brown TT, 2009, JAIDS J ACQ IMM DEF, V51, P554, DOI 10.1097/QAI.0b013e3181adce44
   Chakravarti A, 2008, LAB INVEST, V88, P171, DOI 10.1038/labinvest.3700701
   Clay PG, 2008, ANN PHARMACOTHER, V42, P670, DOI 10.1345/aph.1K465
   Deeks Steven G, 2009, Top HIV Med, V17, P118
   Duvivier C, 2009, AIDS, V23, P817, DOI 10.1097/QAD.0b013e328328f789
   Epstein S, 2006, CLIN THER, V28, P151, DOI 10.1016/j.clinthera.2006.02.007
   Gallant JE, 2004, JAMA J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Gibellini D, 2010, NEW MICROBIOL, V33, P109
   Grigsby IF, 2010, BIOCHEM BIOPH RES CO, V391, P1324, DOI 10.1016/j.bbrc.2009.12.039
   Grund B, 2009, AIDS, V23, P1519, DOI 10.1097/QAD.0b013e32832c1792
   Guaraldi G, 2004, HIV CLIN TRIALS, V5, P269, DOI 10.1310/MD8V 5DLG EN3T BRHX
   Huang J, 2009, AIDS, V23, P51, DOI 10.1097/QAD.0b013e32831c8adc
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewis JR, 2006, INJURY, V37, P698, DOI 10.1016/j.injury.2006.04.121
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Libois A, 2010, MATURITAS, V65, P51, DOI 10.1016/j.maturitas.2009.10.009
   Mack KA, 2003, JAIDS J ACQ IMM DEF, V33, pS68, DOI 10.1097/00126334 200306012 00003
   Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030 200305020 00005
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McComsey GA, 2007, AIDS, V21, P2473, DOI 10.1097/QAD.0b013e3282ef961d
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524
   Mondy K, 2005, JAIDS J ACQ IMM DEF, V38, P426, DOI 10.1097/01.qai.0000145352.04440.1e
   Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569
   Mueller NJ, 2010, AIDS, V24, P1127, DOI 10.1097/QAD.0b013e328337b161
   Negredo E, 2005, AIDS, V19, P343
   Nguyen ND, 2007, J CLIN ENDOCR METAB, V92, P955, DOI 10.1210/jc.2006 1476
   Paccou J, 2009, JOINT BONE SPINE, V76, P637, DOI 10.1016/j.jbspin.2009.10.003
   Phillips P, 1997, JAMA J AM MED ASSOC, V277, P1747, DOI 10.1001/jama.277.22.1747
   Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298
   Rifas L, 2009, ARTHRITIS RHEUM US, V60, P3324, DOI 10.1002/art.24877
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Taubman MA, 2005, J PERIODONTOL, V76, P2033, DOI 10.1902/jop.2005.76.11 S.2033
   Taylor A, 2010, BONE, V46, pS56, DOI 10.1016/j.bone.2010.01.131
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Tebas P, 2007, 14 C RETR OPP INF, P837
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   van Vonderen MGA, 2009, AIDS, V23, P1367, DOI 10.1097/QAD.0b013e32832c4947
   Vikulina T, 2010, P NATL ACAD SCI USA, V107, P13848, DOI 10.1073/pnas.1003020107
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Waysdorf Susan L, 2002, Elder Law J, V10, P47
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yadav A, 2009, VIROLOGY, V385, P126, DOI 10.1016/j.virol.2008.11.039
   Yin M, 2005, OSTEOPOROSIS INT, V16, P1345, DOI 10.1007/s00198 005 1845 0
   Yin MT, 2010, J CLIN ENDOCR METAB, V95, P620, DOI 10.1210/jc.2009 0708
   Yin MT, 2010, JAIDS J ACQ IMM DEF, V53, P202, DOI 10.1097/QAI.0b013e3181bf6471
   Yun TJ, 1998, J IMMUNOL, V161, P6113
NR 58
TC 51
Z9 57
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1752 296X
EI 1752 2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD DEC
PY 2010
VL 17
IS 6
BP 523
EP 529
DI 10.1097/MED.0b013e32833f48d6
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 691FU
UT WOS:000285066500005
PM 20844427
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Neto, E
   Monteiro, AC
   Pereira, CL
   Simoes, M
   Conde, JP
   Chu, V
   Sarmento, B
   Lamghari, M
AF Neto, Estrela
   Monteiro, Ana Carolina
   Pereira, Catarina Leite
   Simoes, Miguel
   Conde, Joao Pedro
   Chu, Virginia
   Sarmento, Bruno
   Lamghari, Meriem
TI Micropathological Chip Modeling the Neurovascular Unit Response to
   Inflammatory Bone Condition
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE inflammation; nanoparticles; neurovascularization; organ on a chip;
   osteoarthritis
ID BLOOD BRAIN BARRIER; COLONY STIMULATING FACTOR; PLGA BASED
   NANOPARTICLES; MESENCHYMAL STEM CELLS; DORSAL ROOT GANGLION; IN VITRO
   MODEL; ENDOTHELIAL CELLS; OSTEOBLAST DIFFERENTIATION; MICROVASCULAR
   NETWORKS; NERVOUS SYSTEM
AB Organ on a chip in vitro platforms accurately mimic complex microenvironments offering the ability to recapitulate and dissect mechanisms of physiological and pathological settings, revealing their major importance to develop new therapeutic targets. Bone diseases, such as osteoarthritis, are extremely complex, comprising of the action of inflammatory mediators leading to unbalanced bone homeostasis and de regulation of sensory innervation and angiogenesis. Although there are models to mimic bone vascularization or innervation, in vitro platforms merging the complexity of bone, vasculature, innervation, and inflammation are missing. Therefore, in this study a microfluidic based neuro vascularized bone chip (NVB chip) is proposed to 1) model the mechanistic interactions between innervation and angiogenesis in the inflammatory bone niche, and 2) explore, as a screening tool, novel strategies targeting inflammatory diseases, using a nano based drug delivery system. It is possible to set the design of the platform and achieve the optimized conditions to address the neurovascular network under inflammation. Moreover, this system is validated by delivering anti inflammatory drug loaded nanoparticles to counteract the neuronal growth associated with pain perception. This reliable in vitro tool will allow understanding the bone neurovascular system, enlightening novel mechanisms behind the inflammatory bone diseases, bone destruction, and pain opening new avenues for new therapies discovery.
C1 [Neto, Estrela; Monteiro, Ana Carolina; Pereira, Catarina Leite; Simoes, Miguel; Sarmento, Bruno; Lamghari, Meriem] Univ Porto, I3S Inst Invest & Inovacao Saude, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.
   [Neto, Estrela; Monteiro, Ana Carolina; Pereira, Catarina Leite; Simoes, Miguel; Sarmento, Bruno; Lamghari, Meriem] Univ Porto, INEB Inst Nacl Engn Biomed, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.
   [Conde, Joao Pedro; Chu, Virginia] Inst Engn Sistemas & Computadores INESC, Microsyst & Nanotechnol, Rua Alves Redol 9, P 1000029 Lisbon, Portugal.
   [Sarmento, Bruno] CESPU, Inst Invest & Formacao Avancada Ciencias & Tecnol, Rua Cent Gandra 137, P 4585116 Gandra, Portugal.
C3 Universidade do Porto; i3S   Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade de
   Lisboa
RP Neto, E; Lamghari, M (通讯作者)，Univ Porto, I3S Inst Invest & Inovacao Saude, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.; Neto, E; Lamghari, M (通讯作者)，Univ Porto, INEB Inst Nacl Engn Biomed, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.
EM estrela.neto@ineb.up.pt; lamghari@ineb.up.pt
RI Conde, Joao/F 8533 2012; Lamghari, Meriem/K 2159 2013; Conde, Joao
   Pedro/F 8533 2012; Neto, Estrela/M 2561 2013; Chu, Virginia/I 6048 2014;
   Sarmento, Bruno/J 6265 2013; Monteiro, Ana Carolina/AAX 6136 2021;
   Pereira, Catarina/IYT 1280 2023
OI Lamghari, Meriem/0000 0002 2500 4548; Monteiro, Ana
   Carolina/0000 0001 5507 403X; Conde, Joao Pedro/0000 0002 5677 3024;
   Neto, Estrela/0000 0003 2334 2292; Chu, Virginia/0000 0002 5306 4409;
   Sarmento, Bruno/0000 0001 5763 7553; Moubarrad,
   Meriem/0009 0006 8440 912X; Leite Pereira, Catarina/0000 0001 8703 1245
FU European Union [953121]; i3S Scientific Platforms: BioSciences Screening
   and Bioimaging [PPBI POCI 01 0145 FEDER 022122]; H2020   Industrial
   Leadership [953121] Funding Source: H2020   Industrial Leadership
FX This work has received funding from the European Union's Horizon 2020
   research and innovation programme under grant agreement No 953121
   (FLAMIN GO  From pathobiology to synovia on chip: driving rheumatoid
   arthritis to the precision medicine goal). The authors acknowledge the
   support of the i3S Scientific Platforms: BioSciences Screening and
   Bioimaging, members of the national infrastructure PPBI  Portuguese
   Platform of Bioimaging (PPBI POCI 01 0145 FEDER 022122). The authors
   would like to acknowledge Ana Silva for expert assistance with graphical
   design.
CR Adriani G, 2017, LAB CHIP, V17, P448, DOI 10.1039/c6lc00638h
   Adzemovic MZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039794
   Ahn J, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00168
   Alcendor DJ, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt379
   Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456 009 9146 4
   Bersini S, 2016, BIOMATERIALS, V76, P157, DOI 10.1016/j.biomaterials.2015.10.057
   Bersini S, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5520 5
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Binshtok AM, 2008, J NEUROSCI, V28, P14062, DOI 10.1523/JNEUROSCI.3795 08.2008
   Bischel LL, 2012, JALA J LAB AUTOM, V17, P96, DOI 10.1177/2211068211426694
   Bonelli P, 2012, INT J NANOMED, V7, P5683, DOI 10.2147/IJN.S34723
   Bongio M, 2016, NANOMEDICINE UK, V11, P1073, DOI 10.2217/nnm 2015 0021
   Booth R, 2014, ANN BIOMED ENG, V42, P2379, DOI 10.1007/s10439 014 1086 5
   Brazill JM, 2019, J BONE MINER RES, V34, P1393, DOI 10.1002/jbmr.3822
   Brown JA, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974 016 0760 y
   Burt Pichat B, 2005, ENDOCRINOLOGY, V146, P503, DOI 10.1210/en.2004 0884
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Campisi M, 2018, BIOMATERIALS, V180, P117, DOI 10.1016/j.biomaterials.2018.07.014
   Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158
   Catala M, 2013, HAND CLINIC, V115, P29, DOI 10.1016/B978 0 444 52902 2.00003 5
   Chang SF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129685
   Chartier SR, 2014, PAIN, V155, P2323, DOI 10.1016/j.pain.2014.08.026
   Cheng H, 2017, DRUG DISCOV TODAY, V22, P1336, DOI 10.1016/j.drudis.2017.04.021
   Chenu C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P132
   Chenu C, 2005, JOINT BONE SPINE, V72, P481, DOI 10.1016/j.jbspin.2005.10.007
   Chung B, 2019, MICRO NANO SYST LETT, V7, DOI 10.1186/s40486 019 0092 7
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Critser PJ, 2010, MICROVASC RES, V80, P23, DOI 10.1016/j.mvr.2010.03.001
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Doggui S, 2012, J ALZHEIMERS DIS, V30, P377, DOI 10.3233/JAD 2012 112141
   Driban JB, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/691412
   Eitner A, 2013, OSTEOARTHR CARTILAGE, V21, P1383, DOI 10.1016/j.joca.2013.06.018
   Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018 005 5175 3
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   Falanga AP, 2017, BIOTECHNOL BIOENG, V114, P1087, DOI 10.1002/bit.26221
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Frost CO, 2016, CURR OPIN PHARMACOL, V28, P31, DOI 10.1016/j.coph.2016.02.007
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Gkiatas I, 2017, FRONT PHYS, V5, DOI 10.3389/fphy.2017.00044
   Glassman PM, 2020, ADV DRUG DELIVER REV, V157, P96, DOI 10.1016/j.addr.2020.06.013
   Grässel S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0485 1
   Grasman JM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04460 8
   Griep LM, 2013, BIOMED MICRODEVICES, V15, P145, DOI 10.1007/s10544 012 9699 7
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Haep L, 2015, INFLAMM BOWEL DIS, V21, P2360, DOI 10.1097/MIB.0000000000000490
   Hasegawa T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 82167 7
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   HENKE C, 1993, AM J PATHOL, V143, P1189
   Hesh CA, 2020, MICROMACHINES BASEL, V11, DOI 10.3390/mi11010018
   Ho YT, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00750 3
   Ibáñez L, 2016, J BONE MINER RES, V31, P1899, DOI 10.1002/jbmr.2868
   Inamdar NK, 2011, CURR OPIN BIOTECH, V22, P681, DOI 10.1016/j.copbio.2011.05.512
   Jain NX, 2014, J MUSCULOSKEL NEURON, V14, P78
   Jeon JS, 2015, P NATL ACAD SCI USA, V112, P214, DOI 10.1073/pnas.1417115112
   Jeon JS, 2014, INTEGR BIOL UK, V6, P555, DOI 10.1039/c3ib40267c
   Jiang LL, 2019, MICROMACHINES BASEL, V10, DOI 10.3390/mi10060375
   Jimenez Andrade JM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3826
   Jusoh N, 2015, LAB CHIP, V15, P3984, DOI 10.1039/c5lc00698h
   Kindstedt E, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05654 w
   Kopitar Jerala N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00873
   Langer V, 2019, J CLIN INVEST, V129, P4691, DOI 10.1172/JCI124884
   Lawlor KE, 2004, P NATL ACAD SCI USA, V101, P11398, DOI 10.1073/pnas.0404328101
   Leitao L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0096 1
   Lisowska B, 2018, DRUG DES DEV THER, V12, P1809, DOI 10.2147/DDDT.S164565
   Liu XN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22131 1
   Lozoya Agullo I, 2018, EUR J PHARM SCI, V115, P119, DOI 10.1016/j.ejps.2017.12.009
   Ma QM, 2020, NANOSCALE, V12, P15512, DOI 10.1039/d0nr02397c
   Ma Xiaojing, 2015, F1000Res, V4, DOI 10.12688/f1000research.7010.1
   Madaboosi N, 2015, ANALYST, V140, P4423, DOI 10.1039/c5an00364d
   Madej MP, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00335
   Madel MB, 2020, ELIFE, V9, DOI 10.7554/eLife.54493
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Mannino RG, 2018, BIOMICROFLUIDICS, V12, DOI 10.1063/1.5024901
   Mansoorifar A, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202006796
   Mantyh PW, 2014, EUR J NEUROSCI, V39, P508, DOI 10.1111/ejn.12462
   Maoz BM, 2018, NAT BIOTECHNOL, V36, P865, DOI 10.1038/nbt.4226
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Martins A, 2010, IUBMB LIFE, V62, P611, DOI 10.1002/iub.361
   Martins C, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701035
   Marturano Kruik A, 2018, P NATL ACAD SCI USA, V115, P1256, DOI 10.1073/pnas.1714282115
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Mei XT, 2019, INTEGR BIOL UK, V11, P119, DOI 10.1093/intbio/zyz008
   Mitchell S.A.T., 2018, CURR OSTEOPOROS REP, V23, P7014
   Nakai K, 2005, CANCER SCI, V96, P766, DOI 10.1111/j.1349 7006.2005.00102.x
   Nakao K, 2009, BIOCHEM BIOPH RES CO, V378, P462, DOI 10.1016/j.bbrc.2008.11.083
   Neto E, 2016, J NEUROSCI, V36, P11573, DOI 10.1523/JNEUROSCI.1748 16.2016
   Neto E, 2014, INTEGR BIOL UK, V6, P586, DOI 10.1039/c4ib00035h
   Ngo T.X., 2014, Int. J. Tissue Regen, V5, P37
   Ni SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13476 9
   Nunes AF, 2010, FEBS J, V277, P263, DOI 10.1111/j.1742 4658.2009.07482.x
   Osaki T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23512 1
   Papademetriou I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205158
   Papadimitropoulos A, 2011, EUR CELLS MATER, V21, P445, DOI 10.22203/eCM.v021a33
   Park D, 2020, TRENDS BIOTECHNOL, V38, P99, DOI 10.1016/j.tibtech.2019.06.006
   Park JW, 2013, LAB CHIP, V13, P509, DOI 10.1039/c2lc41081h
   Patel MS, 2007, CALCIFIED TISSUE INT, V80, P337, DOI 10.1007/s00223 007 9015 3
   Phaam TL, 2020, NANOMEDICINE UK, V15, P1897, DOI 10.2217/nnm 2020 0114
   Pinho Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Pitake S, 2019, FRONT NEUROSCI SWITZ, V13, DOI 10.3389/fnins.2019.01009
   Privratsky J.R., 2010, LIFE SCI, V17, P3
   Privratsky JR, 2014, CELL TISSUE RES, V355, P607, DOI 10.1007/s00441 013 1779 3
   Raasch M, 2016, BIOMICROFLUIDICS, V10, DOI 10.1063/1.4955184
   Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040
   Rainsford K. D., 2009, Inflammopharmacology, V17, P275, DOI 10.1007/s10787 009 0016 x
   Ramasamy SK, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5046953
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Ramasamy SK, 2016, ANNU REV CELL DEV BI, V32, P649, DOI 10.1146/annurev cellbio 111315 124936
   Rao RR, 2012, ANGIOGENESIS, V15, P253, DOI 10.1007/s10456 012 9257 1
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020
   Rezvantalab S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01260
   Ribeiro da Silva M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 33360 8
   Romeo SG, 2019, NAT CELL BIOL, V21, P430, DOI 10.1038/s41556 019 0304 7
   Schaible HG, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0470 8
   Shafieyan Y, 2012, J BIOMED MATER RES A, V100A, P1573, DOI 10.1002/jbm.a.34097
   Shiratori T, 2018, J IMMUNOL, V200, P218, DOI 10.4049/jimmunol.1602035
   Silva DI, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419 017 0034 3
   Sisask G, 2013, AUTON NEUROSCI BASIC, V177, P237, DOI 10.1016/j.autneu.2013.05.005
   Soares RRG, 2014, LAB CHIP, V14, P4284, DOI 10.1039/c4lc00695j
   Sousa DM, 2016, SCI REP UK, V6, DOI 10.1038/srep33470
   Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029
   Szekanecz Z, 2007, NAT CLIN PRACT RHEUM, V3, P635, DOI 10.1038/ncprheum0647
   Taberner L, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107903
   Takeshita M, 2012, RHEUMATOLOGY, V51, P1790, DOI 10.1093/rheumatology/kes173
   Terrell Hall TB, 2017, FLUIDS BARRIERS CNS, V14, DOI 10.1186/s12987 017 0050 9
   Tomeh MA, 2020, MOL PHARMACEUT, V17, P4421, DOI 10.1021/acs.molpharmaceut.0c00913
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Uwamori H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17411 0
   van der Helm MW, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1142493
   Vasconcelos DM, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0950 5
   Vu MN, 2019, ACS APPL NANO MATER, V2, P1844, DOI 10.1021/acsanm.8b02056
   Wang JD, 2016, MOL PHARMACEUT, V13, P895, DOI 10.1021/acs.molpharmaceut.5b00805
   Wang T, 2018, NEUROSCI LETT, V668, P154, DOI 10.1016/j.neulet.2018.01.031
   Wei HM, 2005, FEBS LETT, V579, P1272, DOI 10.1016/j.febslet.2005.01.020
   Whelan IT, 2021, BIOFABRICATION, V13, DOI 10.1088/1758 5090/ac04f7
   Wolff A, 2015, J PHARM SCI US, V104, P2727, DOI 10.1002/jps.24329
   Xie YL, 2020, NAT REV RHEUMATOL, V16, P547, DOI 10.1038/s41584 020 0469 2
   Yoneda T, 2015, BBA BIOMEMBRANES, V1848, P2677, DOI 10.1016/j.bbamem.2015.02.004
   Yurtdas Kirimlioglu G, 2020, DRUG DEV IND PHARM, V46, P1133, DOI 10.1080/03639045.2020.1776319
   Zhang Y, 2020, STROKE, V51, P3701, DOI 10.1161/STROKEAHA.120.031728
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Ziebart Thomas, 2011, Clin Oral Investig, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 144
TC 25
Z9 25
U1 7
U2 75
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JUN
PY 2022
VL 11
IS 11
AR 2102305
DI 10.1002/adhm.202102305
EA FEB 2022
PG 16
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA 1X4HL
UT WOS:000760896400001
PM 35158409
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Fliefel, RM
   Entekhabi, SA
   Ehrenfeld, M
   Otto, S
AF Fliefel, Riham M.
   Entekhabi, Saleh A.
   Ehrenfeld, Michael
   Otto, Sven
TI Geranylgeraniol (GGOH) as a Mevalonate Pathway Activator in the Rescue
   of Bone Cells Treated with Zoledronic Acid: An In Vitro Study
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; PROTEIN PRENYLATION; INDUCE
   APOPTOSIS; OSTEOBLAST; JAW; PROLIFERATION; INHIBITION; MECHANISMS;
   MODEL; RAT
AB Bisphosphonates (BPs) are the keystone to treat bone disorders. Despite the great benefits of BPs, medication related osteonecrosis of the jaw (MRONJ) arouse as a potential side effect. Nitrogen containing BPs (N BPs) as zoledronate (ZA) act by the inhibition of specific enzymes of the mevalonate pathway resulting in altering protein prenylation which is required for the posttranslational maturation of the small GTP binding proteins. Geranylgeraniol (GGOH) is an intermediate product in the mevalonate pathway having positive effects on different cell types treated with BPs by salvaging protein prenylation improving cell viability and proliferation in tissue regeneration, thus overcoming N BP induced apoptosis. Here, the effect of different concentrations of zoledronate (ZA) on the bone cells has been investigated by cell viability assay, live/dead staining, and western blot to understand if GGOH was able to rescue bone cells and levels of statistical significance were indicated at P<0.05, P<0.01, P<0.001, and P<0.0001. Although the high concentration of ZA had significantly decreased the cell viability in the bone cells, GGOH reversed the action of ZA on the cells while at very high concentration; it caused severe reduction in the cell viability. Rap1A, a member of the GTPases family, was expressed in the negative controls but was absent in cells treated with high concentrations of ZA. The addition of GGOH had increased the expression of Rap1A up to a certain limit. The experiments proved that ZA acts directly on the mevalonate pathway and protein prenylation and that GGOH could be applied as a future local therapy to MRONJ.
C1 [Fliefel, Riham M.; Entekhabi, Saleh A.; Otto, Sven] Ludwig Maximilians Univ Munchen, Expt Surg & Regenerat Med ExperiMed, D 80336 Munich, Germany.
   [Fliefel, Riham M.; Ehrenfeld, Michael; Otto, Sven] Ludwig Maximilians Univ Munchen, Dept Oral & Maxillofacial Surg, D 80337 Munich, Germany.
   [Fliefel, Riham M.] Alexandria Univ, Dept Oral & Maxillofacial Surg, Alexandria 21500, Egypt.
C3 University of Munich; University of Munich; Egyptian Knowledge Bank
   (EKB); Alexandria University
RP Fliefel, RM (通讯作者)，Ludwig Maximilians Univ Munchen, Expt Surg & Regenerat Med ExperiMed, D 80336 Munich, Germany.; Fliefel, RM (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Oral & Maxillofacial Surg, D 80337 Munich, Germany.; Fliefel, RM (通讯作者)，Alexandria Univ, Dept Oral & Maxillofacial Surg, Alexandria 21500, Egypt.
EM riham.fliefel@med.uni muenchen.de; saleh_entekhabi@yahoo.de;
   michael.ehrenfeld@med.uni muenchen.de; otto_sven@web.de
RI Fliefel, Riham/O 1145 2018
OI Fliefel, Riham/0000 0002 3458 2227
FU AO Foundation [AOCMF 64 21O]
FX This work was supported by the AO Foundation (grant number
   AOCMF 64 21O).
CR Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Carmona G, 2009, BLOOD, V113, P488, DOI 10.1182/blood 2008 02 138438
   Cozin M, 2011, J ORAL MAXIL SURG, V69, P2564, DOI 10.1016/j.joms.2011.03.005
   Curra C, 2016, ACTA CIR BRAS, V31, P308, DOI 10.1590/S0102 865020160050000003
   Draenert GF, 2012, J CRANIO MAXILL SURG, V40, pE369, DOI 10.1016/j.jcms.2012.01.028
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Gong L, 2011, PHARMACOGENET GENOM, V21, P50, DOI 10.1097/FPC.0b013e328335729c
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P1079, DOI 10.1007/s00784 014 1320 4
   Hamanaka T, 2015, VIROLOGY, V486, P63, DOI 10.1016/j.virol.2015.09.002
   Ho HJ, 2018, BIOSCI BIOTECH BIOCH, V82, P956, DOI 10.1080/09168451.2017.1415129
   Huang X, 2016, MOL MED REP, V13, P613, DOI 10.3892/mmr.2015.4627
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Johnson TE, 2004, TOXICOL APPL PHARM, V200, P237, DOI 10.1016/j.taap.2004.04.010
   Komatsu K, 2013, J ENDOCRINOL, V219, P145, DOI 10.1530/JOE 13 0040
   Koneski F, 2018, J CRANIO MAXILL SURG, V46, P230, DOI 10.1016/j.jcms.2017.11.007
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Li PF, 2018, EXP THER MED, V15, P5330, DOI 10.3892/etm.2018.6120
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Masuda Y, 2006, BIOCHEM BIOPH RES CO, V346, P454, DOI 10.1016/j.bbrc.2006.05.161
   Nualkaew N, 2005, TETRAHEDRON LETT, V46, P8727, DOI 10.1016/j.tetlet.2005.10.048
   Otto S, 2017, J CRANIO MAXILL SURG, V45, P1503, DOI 10.1016/j.jcms.2017.07.002
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Otto S, 2010, J ORAL MAXIL SURG, V68, P1158, DOI 10.1016/j.joms.2009.07.079
   Pabst AM, 2017, CLIN ORAL INVEST, V21, P771, DOI 10.1007/s00784 016 1842 z
   Pabst AM, 2015, J CRANIO MAXILL SURG, V43, P688, DOI 10.1016/j.jcms.2015.03.014
   Peter B, 2005, J BONE JOINT SURG BR, V87B, P1157, DOI 10.1302/0301 620X.87B8
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Räikkönen J, 2010, BIOCHEM PHARMACOL, V79, P777, DOI 10.1016/j.bcp.2009.10.003
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wasserzug O, 2017, AM J RHINOL ALLERGY, V31, P36, DOI 10.2500/ajra.2017.31.4395
   Wimalawansa SJ, 2008, EXPERT OPIN DRUG SAF, V7, P491, DOI 10.1517/14740338.7.4.491 
   Wu YG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143777
   Yang ZB, 2002, PLANT CELL, V14, pS375, DOI 10.1105/tpc.001065
   Yoshikawa N, 2009, J SURG RES, V153, P246, DOI 10.1016/j.jss.2008.04.021
   Zafar S, 2016, CLIN ORAL INVEST, V20, P2023, DOI 10.1007/s00784 015 1706 y
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 40
TC 21
Z9 22
U1 1
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2019
VL 2019
AR 4351327
DI 10.1155/2019/4351327
PG 9
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HJ0ID
UT WOS:000456841600001
PM 30728841
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Liao, JY
   Wei, Q
   Zou, YL
   Fan, JM
   Song, DZ
   Cui, J
   Zhang, WW
   Zhu, YX
   Ma, C
   Hu, X
   Qu, XY
   Chen, LQ
   Yu, XY
   Zhang, ZC
   Wang, C
   Zhao, C
   Zeng, ZY
   Zhang, RY
   Yan, SJ
   Wu, TT
   Wu, XY
   Shu, Y
   Lei, JY
   Li, YS
   Luu, HH
   Lee, MJ
   Reid, RR
   Ameer, GA
   Wolf, JM
   He, TC
   Huang, W
AF Liao, Junyi
   Wei, Qiang
   Zou, Yulong
   Fan, Jiaming
   Song, Dongzhe
   Cui, Jing
   Zhang, Wenwen
   Zhu, Yunxiao
   Ma, Chao
   Hu, Xue
   Qu, Xiangyang
   Chen, Liqun
   Yu, Xinyi
   Zhang, Zhicai
   Wang, Claire
   Zhao, Chen
   Zeng, Zongyue
   Zhang, Ruyi
   Yan, Shujuan
   Wu, Tingting
   Wu, Xingye
   Shu, Yi
   Lei, Jiayan
   Li, Yasha
   Luu, Hue H.
   Lee, Michael J.
   Reid, Rusell R.
   Ameer, Guillermo A.
   Wolf, Jennifer Moriatis
   He, Tong Chuan
   Huang, Wei
TI Notch Signaling Augments BMP9 Induced Bone Formation by Promoting the
   Osteogenesis Angiogenesis Coupling Process in Mesenchymal Stem Cells
   (MSCs)
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE BMP9 signaling; Notch signaling; Osteogenesis; angiogenesis coupling;
   Mesenchymal stem cells; Bone repair; Regenerative medicine
ID HUMAN OSTEOSARCOMA GROWTH; MORPHOGENETIC PROTEINS; OSTEO/ODONTOBLASTIC
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; ADIPOSE TISSUE;
   TUMOR GROWTH; BMP9; PROLIFERATION; PATHWAY; WNT
AB Background/Aims: Mesenchymal stem cells (MSCs) are multipotent progenitors that activation of BMP9 and Notch signaling yields effective osteogenesis angiogenesis coupling in MSCs. Methods: Recently characterized immortalized mouse adipose derived progenitors (iMADs) were used as MSC source. Transgenes BMP9, NICD and dnNotch1 were expressed Osteogenic activity was assessed by in vitro assays and in vivo ectopic bone formation model.Results: BMP9 upregulated expression of Notch receptors and ligands in iMADs. Constitutively active form of Notch1 NICD1 enhanced BMP9 induced osteogenic differentiation both in vitro and in vivo, which was effectively inhibited by dominant negative form of Notch1 dnNotch1. BMP9 and NICD1 transduced MSCs implanted with a biocompatible scaffold yielded highly mature bone with extensive vascularization. NICD1 enhanced BMP9 induced expression of key angiogenic regulators in iMADs and Vegfa in ectopic bone, which was blunted by dnNotch1. Conclusion: Notch signaling may play an important role in BMP9 induced osteogenesis and angiogenesis. It's conceivable that simultaneous activation of the BMP9 and Notch pathways engineering. (C) 2017 The Author( s) Published by S. Karger AG, Basel.
C1 [Liao, Junyi; Hu, Xue; Chen, Liqun; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Wei] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400016, Peoples R China.
   [Liao, Junyi; Hu, Xue; Chen, Liqun; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Wei] Chongqing Med Univ, Affiliated Hosp 1, Dept Blood Transfus, Chongqing, Peoples R China.
   [Liao, Junyi; Hu, Xue; Chen, Liqun; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Wei] Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing, Peoples R China.
   [Liao, Junyi; Hu, Xue; Chen, Liqun; Yu, Xinyi; Zhao, Chen; Wu, Xingye; Lei, Jiayan; Huang, Wei] Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Chongqing, Peoples R China.
   [Liao, Junyi; Wei, Qiang; Zou, Yulong; Fan, Jiaming; Song, Dongzhe; Cui, Jing; Zhang, Wenwen; Ma, Chao; Hu, Xue; Qu, Xiangyang; Chen, Liqun; Yu, Xinyi; Zhang, Zhicai; Wang, Claire; Zhao, Chen; Zeng, Zongyue; Zhang, Ruyi; Yan, Shujuan; Wu, Tingting; Wu, Xingye; Shu, Yi; Lei, Jiayan; Li, Yasha; Luu, Hue H.; Lee, Michael J.; Reid, Rusell R.; Wolf, Jennifer Moriatis; He, Tong Chuan] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Wei, Qiang; Zou, Yulong; Fan, Jiaming; Cui, Jing; Qu, Xiangyang; Zeng, Zongyue; Zhang, Ruyi; Yan, Shujuan; Shu, Yi; Li, Yasha; He, Tong Chuan] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
   [Wei, Qiang; Zou, Yulong; Fan, Jiaming; Cui, Jing; Qu, Xiangyang; Zeng, Zongyue; Zhang, Ruyi; Yan, Shujuan; Shu, Yi; Li, Yasha; He, Tong Chuan] Chongqing Med Univ, Affiliated Hosp, Chongqing, Peoples R China.
   [Song, Dongzhe] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Zhang, Wenwen] Binzhou Med Univ, Affiliated Yantai Hosp, Dept Lab Med & Clin Diagnost, Yantai, Peoples R China.
   [Zhu, Yunxiao; Zhang, Zhicai; Ameer, Guillermo A.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Ma, Chao; Wu, Tingting] Wuhan Univ, Affiliated Zhongnan Hosp, Dept Neurosurg, Wuhan, Peoples R China.
   [Ma, Chao; Wu, Tingting] Wuhan Univ, Affiliated Zhongnan Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Peoples R China.
   Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed Surg, Wuhan, Peoples R China.
   [Reid, Rusell R.] Univ Chicago, Med Ctr, Dept Surg, Sect Plast Surg, Chicago, IL 60637 USA.
   [Ameer, Guillermo A.] Feinberg Sch Med, Dept Surg, Chicago, IL USA.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University; University of Chicago;
   University of Chicago Medical Center; Chongqing Medical University;
   Chongqing Medical University; Sichuan University; Binzhou Medical
   University; Northwestern University; Wuhan University; Wuhan University;
   Huazhong University of Science & Technology; University of Chicago;
   University of Chicago Medical Center; Northwestern University; Feinberg
   School of Medicine
RP Huang, W (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400016, Peoples R China.; He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, 5841 South Maryland Ave,MC 3079, Chicago, IL 60637 USA.
EM tche@uchicago.edu; huangwei68@263.net
RI Ameer, Guillermo/B 6765 2009; wu, tingting/H 8032 2012; YU,
   XINYI/NKP 6249 2025; Junyi, Liao/AAP 9076 2020
OI Wei, Qiang/0000 0003 3750 3042; Zeng, Zongyue/0000 0002 4333 5412
FU National Institutes of Health [AT004418, DE020140]; US Department of
   Defense [0R130096]; Scoliosis Research Society; 973 Program of the
   Ministry of Science and Technology (MOST) of China [2011CB707906];
   National Natural Science Foundation of China [81371972, 81572142];
   Science and Technology Research Project of Chongqing Municipal Education
   Commission of China [KJ1500217]; China Scholarship Council; the
   Outstanding Predoctorate Research Fellowship from Chongqing Medical
   University [CY1315098]; University of Chicago Cancer Center Support
   Grant [P30CA014599]; National Center for Advancing Translational
   Sciences of the National Institutes of Health [UL1 TR000430]; Graduate
   Research and Innovation Project from Chongqing Education Commission
FX The reported work was supported in part by research grants from the
   National Institutes of Health (AT004418, DE020140 to TCH and RRR), the
   US Department of Defense (0R130096 to JIAVV), the Scoliosis Research
   Society (TCH and MIL), the 973 Program of the Ministry of Science and
   Technology (MOST) of China (# 2011CB707906 to TCH), the National Natural
   Science Foundation of China (#81371972 and #81572142 to WH), and the
   Science and Technology Research Project of Chongqing Municipal Education
   Commission of China (KJ1500217 to JC). junyi Liao was a recipient of the
   Predoctoral Fellowship from the China Scholarship Council, the Graduate
   Research and Innovation Project from Chongqing Education Commission and
   the Outstanding Predoctorate Research Fellowship from Chongqing Medical
   University (#CY1315098). This project was also supported in part by The
   University of Chicago Cancer Center Support Grant (P30CA014599) and the
   National Center for Advancing Translational Sciences of the National
   Institutes of Health through Grant Number UL1 TR000430. Funding sources
   were not involved in the study design; in the collection, analysis and
   interpretation of data; in the writing of the report; and in the
   decision to submit the paper for publication.
CR Alexander D, 2015, CELL PHYSIOL BIOCHEM, V35, P2244, DOI 10.1159/000374029
   Almubarak S, 2016, BONE, V83, P197, DOI 10.1016/j.bone.2015.11.011
   Bara JJ, 2016, J ORTHOP RES, V34, P17, DOI 10.1002/jor.23055
   Barabaschi GDG, 2015, ADV EXP MED BIOL, V881, P79, DOI 10.1007/978 3 319 22345 2_5
   Bolós V, 2007, ENDOCR REV, V28, P339, DOI 10.1210/er.2006 0046
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Canalis E, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.117pe17
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Chen X, 2013, CELL PHYSIOL BIOCHEM, V32, P1083, DOI 10.1159/000354508
   Chen X, 2015, GENES DIS, V2, P96, DOI 10.1016/j.gendis.2014.12.001
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004
   Deng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113064
   Deng YL, 2016, CELL PHYSIOL BIOCHEM, V39, P871, DOI 10.1159/000447797
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Dishowitz MI, 2014, J BIOMED MATER RES A, V102, P1558, DOI 10.1002/jbm.a.34825
   Engin F, 2010, BONE, V46, P274, DOI 10.1016/j.bone.2009.05.027
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   Greenhill Claire, 2014, Nat Rev Endocrinol, V10, P250, DOI 10.1038/nrendo.2014.28
   Guruharsha KG, 2012, NAT REV GENET, V13, P654, DOI 10.1038/nrg3272
   Halvorsen YC, 2000, INT J OBESITY, V24, pS41, DOI 10.1038/sj.ijo.0801503
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Hill CR, 2014, BONE, V62, P10, DOI 10.1016/j.bone.2014.01.019
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kapur SK, 2015, CLIN PLAST SURG, V42, P155, DOI 10.1016/j.cps.2014.12.010
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lampot JD, 2015, CELL TRANSPLANT, V24, P1053, DOI 10.3727/096368914X681054
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Li RF, 2016, INT J MED SCI, V13, P8, DOI 10.7150/ijms.13333
   Li YS, 2015, CELL PHYSIOL BIOCHEM, V37, P2375, DOI 10.1159/000438591
   Liao Z, 2015, CURR CANCER DRUG TAR, V15, P726, DOI 10.2174/1568009615666150629132157
   Liu X, 2013, J CELL MOL MED, V17, P1160, DOI 10.1111/jcmm.12097
   Louvi A, 2012, SEMIN CELL DEV BIOL, V23, P473, DOI 10.1016/j.semcdb.2012.02.005
   Lu S, 2016, AM J TRANSL RES, V8, P3710
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther G, 2011, CURR GENE THER, V11, P229
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Maes Christa, 2014, Bonekey Rep, V3, P578, DOI 10.1038/bonekey.2014.73
   Morabito C, 2015, CELL PHYSIOL BIOCHEM, V36, P259, DOI 10.1159/000374069
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Raisin S, 2016, BIOMATERIALS, V104, P223, DOI 10.1016/j.biomaterials.2016.07.017
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Rastegar Farbod, 2010, World J Stem Cells, V2, P67, DOI 10.4252/wjsc.v2.i4.67
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shenaq DS, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/519028
   Shui W, 2014, J BIOMED MATER RES A, V102, P3429, DOI 10.1002/jbm.a.35006
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tatara AM, 2016, J BONE JOINT SURG AM, V98, P1132, DOI 10.2106/JBJS.16.00299
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Teven CM, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/201371
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Wang JH, 2014, STEM CELLS DEV, V23, P1405, DOI 10.1089/scd.2013.0580
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang Y, 2013, J ORTHOP RES, V31, P1796, DOI 10.1002/jor.22427
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Yan ZJ, 2015, CELLS TISSUES ORGANS, V201, P38, DOI 10.1159/000439268
   Yang J, 2014, BIOMACROMOLECULES, V15, P3942, DOI 10.1021/bm5010004
   Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144
   Yavropoulou MP, 2014, HORM INT J ENDOCRINO, V13, P24, DOI 10.1007/BF03401318
   Ye JX, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/2/025021
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhou NA, 2015, CELL PHYSIOL BIOCHEM, V36, P44, DOI 10.1159/000374052
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 90
TC 81
Z9 92
U1 1
U2 40
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 41
IS 5
BP 1905
EP 1923
DI 10.1159/000471945
PG 19
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA EY7LW
UT WOS:000404173800015
PM 28384643
OA gold
DA 2025 08 17
ER

PT J
AU Fu, YC
   Fu, TF
   Wang, HJ
   Lin, CW
   Lee, GH
   Wu, SC
   Wang, CK
AF Fu, Yin Chih
   Fu, Tzu Fun
   Wang, Hung Jen
   Lin, Che Wei
   Lee, Gang Hui
   Wu, Shun Cheng
   Wang, Chih Kuang
TI Aspartic acid based modified PLGA PEG nanoparticles for bone targeting:
   In vitro and in vivo evaluation
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bone targeting; Aspartic acid; Nanoparticle; PLGA PEG; Drugs delivery
ID PARATHYROID HORMONE; DELIVERY SYSTEM; DRUG DELIVERY; MACROMOLECULAR
   THERAPEUTICS; POSTMENOPAUSAL WOMEN; STRONTIUM RANELATE; MINERAL DENSITY;
   OSTEOPOROSIS; CANCER; POLY(D,L LACTIDE CO GLYCOLIDE)
AB Nanoparticles (NP) that target bone tissue were developed using PLGA PEG (poly(lactic co glycolic acid) polyethylene glycol) diblock copolymers and bone targeting moieties based on aspartic acid, (Asp)(n(1,3)). These NP are expected to enable the transport of hydrophobic drugs. The molecular structures were examined by H 1 NMR or identified using mass spectrometry and Fourier transform infrared (FT IR) spectra. The NP were prepared using the water miscible solvent displacement method, and their size characteristics were evaluated using transmission electron microscopy (TEM) and dynamic light scattering. The bone targeting potential of the NP was evaluated in vitro using hydroxyapatite affinity assays and in vivo using fluorescent imaging in zebrafish and rats. It was confirmed that the average particle size of the NP was <200 nm and that the dendritic Asp(3) moiety of the PLGA PEG Asp(3) NP exhibited the best apatite mineral binding ability. Preliminary findings in vivo bone affinity assays in zebrafish and rats indicated that the PLGA PEG ASP(3) NP may display increased bone targeting efficiency compared with other PLGA PEG based NP that lack a dendritic Asp(3) moiety. These NP may act as a delivery system for hydrophobic drugs, warranting further evaluation of the treatment of bone disease. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Fu, Yin Chih; Lin, Che Wei; Wu, Shun Cheng; Wang, Chih Kuang] Kaohsiung Med Univ, Coll Life Sci, Dept Med & Appl Chem, Kaohsiung 807, Taiwan.
   [Fu, Yin Chih] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Fu, Yin Chih] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Dept Orthopaed, Kaohsiung 807, Taiwan.
   [Fu, Tzu Fun; Lee, Gang Hui] Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan 70101, Taiwan.
   [Wang, Hung Jen; Lin, Che Wei; Wang, Chih Kuang] Kaohsiung Med Univ, Coll Life Sci, Dept Med & Appl Chem, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University Hospital; National
   Cheng Kung University; Kaohsiung Medical University
RP Wang, CK (通讯作者)，Kaohsiung Med Univ, Coll Life Sci, Dept Med & Appl Chem, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM ckwang@kmu.edu.tw
RI ; Lin, Che Wei/U 3528 2017; Fu, Yin Chih/D 5035 2009; Wang,
   Chih Kuang/D 4440 2009; Fu, Tzu Fun/G 7820 2011; Wu,
   Shun Cheng/E 2989 2010
OI Wu, Shun Cheng/0000 0003 4219 3413; Wang,
   Chih Kuang/0000 0002 4398 6979; Lee, Gang Hui/0000 0002 1428 1611; 
FU Ministry of Science and Technology in Taiwan [NSC 101 2628 E 037 002];
   Ministry of Economic Affairs in Taiwan [101 EC 17 A 19 S1 176]
FX The authors gratefully acknowledge the support for this research by the
   Ministry of Science and Technology in Taiwan (NSC 101 2628 E 037 002),
   and Ministry of Economic Affairs in Taiwan (101 EC 17 A 19 S1 176).
CR Alexander A., 2012, AM J DRUG DISCOVERY, V2, P143
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   COUVREUR P, 1993, ADV DRUG DELIVER REV, V10, P141, DOI 10.1016/0169 409X(93)90046 7
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Heneweer C, 2012, THER DELIV, V3, P645, DOI 10.4155/TDE.12.38
   Higano CS, 2004, UROL CLIN N AM, V31, P331, DOI 10.1016/j.ucl.2004.01.001
   Ho ML, 2008, J CONTROL RELEASE, V128, P142, DOI 10.1016/j.jconrel.2008.02.012
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Huang SR, 2008, THESIS KAOHSIUNG MED
   Jiang B, 2012, DRUG DELIV, V19, P317, DOI 10.3109/10717544.2012.714809
   Li JP, 2008, ANTI CANCER AGENT ME, V8, P64, DOI 10.2174/187152008783330824
   Lips P, 2010, OSTEOPOROSIS INT, V21, P61, DOI 10.1007/s00198 009 0946 6
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Lu B, 2003, DRUG DELIV, V10, P87, DOI 10.1080/713840364
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Miller RG, 2006, AM J HEMATOL, V81, P236, DOI 10.1002/ajh.20541
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013
   Murphy MB, 2007, BIOMACROMOLECULES, V8, P2237, DOI 10.1021/bm070121s
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pamujula S, 2008, J PHARM PHARMACOL, V60, P283, DOI 10.1211/jpp.60.3.0002
   Park S, 2010, MICROSC RES TECHNIQ, V73, P857, DOI 10.1002/jemt.20845
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Roux C, 2006, J BONE MINER RES, V21, P536, DOI 10.1359/JBMR.060101
   Sai HS, 2012, MED CHEM, V2, P68
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Sheweita SA, 2007, CURR DRUG METAB, V8, P519
   Stolnik S, 2001, J DRUG TARGET, V9, P361, DOI 10.3109/10611860108998772
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wischke C, 2010, PHARM RES DORDR, V27, P2063, DOI 10.1007/s11095 010 0202 y
   Wisse E, 1996, TOXICOL PATHOL, V24, P100, DOI 10.1177/019262339602400114
   YASHROY RC, 1990, J BIOSCIENCE, V15, P93, DOI 10.1007/BF02703373
NR 39
TC 52
Z9 54
U1 1
U2 114
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD NOV
PY 2014
VL 10
IS 11
BP 4583
EP 4596
DI 10.1016/j.actbio.2014.07.015
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AR8XJ
UT WOS:000343854400004
PM 25050775
DA 2025 08 17
ER

PT J
AU Lin, Y
   Chen, M
   Guo, WB
   Qiu, SL
   Chen, LH
   Liu, WE
AF Lin, Yu
   Chen, Min
   Guo, Wenbin
   Qiu, Shengliang
   Chen, Lihui
   Liu, Wenge
TI Zoledronic acid relieves steroid induced avascular necrosis of femoral
   head via inhibiting FOXD3 mediated ANXA2 transcriptional
   activation
SO BONE
LA English
DT Article
DE Zoledronic acid; SANFH; Osteoclast autophagy; FOXD3; PI3K/AKT/mTOR
   pathway
ID OSTEONECROSIS; AUTOPHAGY; PATHWAY; DIFFERENTIATION; CANCER; RANKL
AB Background: Zoledronic acid (ZOL) is a type of bisphosphonate with good therapeutic effects on orthopaedic diseases. However, the pharmacological functions of ZOL on steroid induced avascular necrosis of femoral head (SANFH) and the underlying mechanism remain unclear, which deserve further research. Methods: SANFH models both in vivo and in vitro were established by dexamethasone (Dex) stimulation. Osteoclastogenesis was examined by TRAP staining. Immunofluorescence was employed to examine autophagy marker (LC3) level. Cell apoptosis was analyzed by TUNEL staining. The interaction between Foxhead box D3 protein (FOXD3) and Annexin A2 (ANXA2) promoter was analyzed using ChIP and dual luciferase reporter gene assays. Results: Dex aggravated osteoclastogenesis and induced osteoclast differentiation and autophagy in vitro, which was abrogated by ZOL treatment. PI3K inhibitor LY294002 abolished the inhibitory effect of ZOL on Dex induced osteoclast differentiation and autophagy. FOXD3 overexpression neutralized the downregulation effects of ZOL on Dex induced osteoclasts by transcriptionally activating ANXA2. ANXA2 knockdown reversed the effect of FOXD3 overexpression on ZOL mediated biological effects in Dex treated osteoclasts. In addition, ZOL improved SANFH symptoms in rats. Conclusion: ZOL alleviated SANFH through regulating FOXD3 mediated ANXA2 transcriptional activity and then promoting PI3K/AKT/mTOR pathway, revealing that FOXD3 might be a target for ZOL in SANFH treatment.
C1 [Lin, Yu; Chen, Min; Liu, Wenge] Fujian Med Univ, Union Hosp, Dept Orthoped, 29,Xinquan Rd, Fuzhou 350000, Fujian, Peoples R China.
   [Lin, Yu] Fujian Pingtan Comprehens Expt Area Hosp, Dept Orthoped, Fuzhou 350400, Fujian, Peoples R China.
   [Guo, Wenbin] Pingtan Comprehens Expt Area Hosp, Dept Pathol, Fuzhou 350400, Fujian, Peoples R China.
   [Qiu, Shengliang] Fujian Med Univ, Union Hosp, Dept Pathol, Fuzhou 350000, Fujian, Peoples R China.
   [Chen, Lihui] Fujian Pingtan Comprehens Expt Area Hosp, Lab Med, 2 Linhu 7th Rd Beicuo Town Pingtan Comprehens Expt, Fuzhou 350400, Fujian, Peoples R China.
C3 Fujian Medical University; Fujian Medical University
RP Liu, WE (通讯作者)，Fujian Med Univ, Union Hosp, Dept Orthoped, 29,Xinquan Rd, Fuzhou 350000, Fujian, Peoples R China.; Chen, LH (通讯作者)，Fujian Pingtan Comprehens Expt Area Hosp, Lab Med, 2 Linhu 7th Rd Beicuo Town Pingtan Comprehens Expt, Fuzhou 350400, Fujian, Peoples R China.
EM leifchenfly@163.com; wengeunion@fjmu.edu.cn
RI guo, wenbin/GQB 2018 2022; Guo, Wenbin/GQB 2018 2022; Chen,
   Lihui/ABP 5066 2022
OI Guo, Wenbin/0000 0002 4484 2715; 
FU Startup Fund for scientific research, Fujian Medical University
   [2020QH1096]
FX This work was supported by Startup Fund for scientific research, Fujian
   Medical University (2020QH1096) .
CR Benedek TG, 2011, CLIN EXP RHEUMATOL, V29, pS5
   Black R, 2019, EUR CELLS MATER, V38, P246, DOI 10.22203/eCM.v038a17
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Deng FY, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.011700
   Fan Meng, 2012, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V34, P330, DOI 10.3881/j.issn.1000 503X.2012.04.004
   Fang L, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/6360133
   Fu LJ, 2020, CALCIFIED TISSUE INT, V107, P60, DOI 10.1007/s00223 020 00687 2
   Fumoto T, 2014, J BONE MINER RES, V29, P830, DOI 10.1002/jbmr.2096
   Geng XL, 2015, EXP THER MED, V10, P1066, DOI 10.3892/etm.2015.2615
   Heras Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hernigou P, 2016, CLIN ORTHOP SURG, V8, P1, DOI 10.4055/cios.2016.8.1.1
   Huang J, 2017, GENESIS, V55, DOI 10.1002/dvg.23040
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Johannesen J, 2009, BONE, V45, P898, DOI 10.1016/j.bone.2009.04.255
   Kadaru Tarun, 2021, J Bone Metab, V28, P51, DOI 10.11005/jbm.2021.28.1.51
   Ke DS, 2024, BIOMED J, V47, DOI 10.1016/j.bj.2023.100605
   Li G, 2020, CELL CYCLE, V19, P551, DOI 10.1080/15384101.2020.1717043
   Li YG, 2021, OPEN LIFE SCI, V16, P1130, DOI 10.1515/biol 2021 0102
   Liu B, 2023, ORTHOP SURG, V15, P256, DOI 10.1111/os.13584
   Liu GH, 2018, ONCOGENE, V37, P1519, DOI 10.1038/s41388 017 0062 6
   Luo P, 2018, INT ORTHOP, V42, P1747, DOI 10.1007/s00264 018 3994 8
   Oh JY, 2019, CANCERS, V11, DOI 10.3390/cancers11111812
   Özenci AM, 2013, ACTA ORTHOP TRAUMATO, V47, P430, DOI 10.3944/AOTT.2013.3136
   Pandey S, 2012, INDIAN J EXP BIOL, V50, P455
   Qi BC, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11030873
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sarkar S, 2017, MOL CANCER RES, V15, P1678, DOI 10.1158/1541 7786.MCR 17 0287
   Sarkarat F, 2014, TRAUMA MON, V19, P13, DOI 10.5812/traumamon.17196
   Shi CG, 2014, BONE, V68, P67, DOI 10.1016/j.bone.2014.08.004
   Sun D, 2021, ANAL CELL PATHOL, V2021, DOI 10.1155/2021/1328682
   Thompson AR, 2020, AM J PHYS MED REHAB, V99, pE54, DOI 10.1097/PHM.0000000000001202
   van den Blink QU, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010604.pub2
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096361
   Wang G, 2022, CELL CYCLE, V21, P49, DOI 10.1080/15384101.2021.1988377
   Wang LN, 2019, JOVE J VIS EXP, DOI 10.3791/58895
   Wu Z, 2021, MOL CARCINOGEN, V60, P859, DOI 10.1002/mc.23350
   Xu W, 2019, STEM CELLS, V37, P582, DOI 10.1002/stem.2984
   Xu ZR, 2020, APPL MICROBIOL BIOT, V104, P575, DOI 10.1007/s00253 019 10257 8
   Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130
   Xue XH, 2018, MOL MED REP, V17, P3751, DOI 10.3892/mmr.2017.8349
   Yang C, 2022, AUTOPHAGY, V18, P2817, DOI 10.1080/15548627.2022.2048432
   Yin HB, 2017, ONCOTARGET, V8, P33644, DOI 10.18632/oncotarget.16853
   Zhang DL, 2018, SCIENCE, V359, P1520, DOI 10.1126/science.aal2022
   Zhang XH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15037674
   Zhao B, 2021, CELL MOL BIOL, V67, P123, DOI 10.14715/cmb/2021.67.5.17
   Zhao J, 2021, J ORTHOP TRANSL, V27, P132, DOI 10.1016/j.jot.2020.08.005
   Zhou X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194781
   Zhu JH, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7203584
   Zhu LL, 2014, EMBO REP, V15, P1286, DOI 10.15252/embr.201438643
NR 49
TC 2
Z9 2
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2024
VL 188
AR 117222
DI 10.1016/j.bone.2024.117222
EA AUG 2024
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA D3J8H
UT WOS:001295189300001
PM 39102974
DA 2025 08 17
ER

PT J
AU Deng, B
   Jia, LQ
   Tan, HY
   Yao, X
   Gao, FY
   Pan, L
   Cui, J
   Xiang, Q
AF Deng, Bo
   Jia, Li qun
   Tan, Huang ying
   Yao, Xuan
   Gao, Fu yun
   Pan, Lin
   Cui, Jian
   Xiang, Qing
TI Effects of Sangu Decoction on Osteoclast Activity in a Rat Model of
   Breast Cancer Bone Metastasis
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID DRYNARIAE RHIZOMA EXTRACTS; MECHANISMS; SCOPOLETIN; RANKL; INHIBITION;
   EXPRESSION; DIAGNOSIS; MARKERS; GROWTH
AB Bone metastasis (BM) is amajor clinical problem for which current treatments lack full efficacy. The Traditional Chinese Medicine (TCM) Sangu Decoction (SGD) has been widely used to treat BM in China. However, no in vivo experiments to date have investigated the effects of TCM on osteoclast activity in BM. In this study, the protective effect and probable mechanism of SGD were evaluated. The model was established using the breast cancer MRMT 1 cells injected into the tibia of rat. SGD was administrated, compared with Zoledronic acid as a positive control. The development of the bone tumor and osteoclast activity was monitored by radiological analysis. TRAP stain was used to identify osteoclasts quantity and activity. TRAP 5b in serum or bone tumor and TRAP mRNA were also quantified. Radiological examination showed that SGD inhibited tumor proliferation and preserved the cortical and trabecular bone structure. In addition, a dramatic reduction of TRAP positive osteoclasts was observed and TRAP 5b levels in serum and bone tumor decreased significantly. It also reduced the mRNA expression of TRAP. The results indicated that SGD exerted potent antiosteoclast property that could be directly related to its TRAP inhibited activity. In addition it prevented bone tumor proliferation in BM model.
C1 [Deng, Bo; Jia, Li qun; Tan, Huang ying; Yao, Xuan; Gao, Fu yun; Pan, Lin; Cui, Jian; Xiang, Qing] China Japan Friendship Hosp, Dept Oncol Integrat Chinese & Western Med, Beijing 100029, Peoples R China.
   [Deng, Bo] Beijing Univ Chinese Med, Sch Clin Chinese Med, Beijing 100029, Peoples R China.
   [Yao, Xuan] Capital Med Univ, Beijing Tongren Hosp, TCM Dept, Beijing 100730, Peoples R China.
C3 China Japan Friendship Hospital; Beijing University of Chinese Medicine;
   Capital Medical University
RP Jia, LQ (通讯作者)，China Japan Friendship Hosp, Dept Oncol Integrat Chinese & Western Med, Beijing 100029, Peoples R China.
EM liqun jia@hotmail.com
RI jia, liqun/HNR 4156 2023
FU National Fund of Natural Sciences [30772858]; Eleventh Five year
   National Plan for Supporting Sciences and Technology [2008BAI53B023];
   Postdoctoral Fund of Sciences of China [2012M510358]
FX This work was supported by the National Fund of Natural Sciences (no.
   30772858), the Eleventh Five year National Plan for Supporting Sciences
   and Technology (no. 2008BAI53B023), and the Postdoctoral Fund of
   Sciences (no. 2012M510358) of China.
CR Anuja GI, 2010, J ETHNOPHARMACOL, V132, P456, DOI 10.1016/j.jep.2010.08.038
   Cazzaniga ME, 2006, ONCOLOGY BASEL, V71, P374, DOI 10.1159/000107772
   Coleman R, 2008, CANCER TREAT REV, V34, P629, DOI 10.1016/j.ctrv.2008.05.001
   Deng B., 2010, CHINESE J INTEGRATIV, V18, P94
   Fili S, 2009, CANCER LETT, V283, P10, DOI 10.1016/j.canlet.2009.01.011
   Hiraga T, 2006, CANCER RES, V66, P2067, DOI 10.1158/0008 5472.CAN 05 2012
   Huang Q, 2012, CANCER EPIDEMIOL, V36, P94, DOI 10.1016/j.canep.2011.02.001
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003
   Lim SH, 2011, PHYTOMEDICINE, V18, P425, DOI 10.1016/j.phymed.2011.02.002
   Liu WK, 2012, BIOORG MED CHEM LETT, V22, P5008, DOI 10.1016/j.bmcl.2012.06.014
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manuele MG, 2006, LIFE SCI, V79, P2043, DOI 10.1016/j.lfs.2006.06.045
   Martin TJ, 2000, ENDOCR RELAT CANCER, V7, P271, DOI 10.1677/erc.0.0070271
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304 3959(01)00437 7
   Middlemiss T, 2011, CLIN ONCOL UK, V23, P387, DOI 10.1016/j.clon.2011.03.003
   Moon PD, 2007, EUR J PHARMACOL, V555, P218, DOI 10.1016/j.ejphar.2006.10.021
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Narducci P, 2011, ACTA HISTOCHEM, V113, P73, DOI 10.1016/j.acthis.2009.10.003
   Oliveira AMAG, 2006, EUR J MED CHEM, V41, P367, DOI 10.1016/j.ejmech.2005.10.016
   Ooi LL, 2010, BONE, V47, P795, DOI 10.1016/j.bone.2010.07.012
   Pan R, 2011, VASC PHARMACOL, V54, P18, DOI 10.1016/j.vph.2010.11.001
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Rose AAN, 2006, B CANCER, V93, P931
   Roudier MP, 2006, CLIN EXP METASTAS, V23, P167, DOI 10.1007/s10585 006 9026 x
   TAKEKOSHI T, 1984, ONCOLOGY BASEL, V41, P245, DOI 10.1159/000225832
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Walker K, 2002, PAIN, V100, P219, DOI 10.1016/S0304 3959(02)00040 4
   Wong RWK, 2006, J ORAL MAXIL SURG, V64, P828, DOI 10.1016/j.joms.2006.01.017
   Zhang Y., 2007, WORLD CLIN DRUGS, V28, P333
NR 32
TC 4
Z9 6
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2012
VL 2012
AR 381904
DI 10.1155/2012/381904
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 038ES
UT WOS:000311158600001
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Komagamine, M
   Komatsu, N
   Ling, R
   Okamoto, K
   Tianshu, S
   Matsuda, K
   Takeuchi, T
   Kaneko, Y
   Takayanagi, H
AF Komagamine, Masatsugu
   Komatsu, Noriko
   Ling, Rui
   Okamoto, Kazuo
   Tianshu, Shi
   Matsuda, Kotaro
   Takeuchi, Tsutomu
   Kaneko, Yuko
   Takayanagi, Hiroshi
TI Effect of JAK inhibitors on the three forms of bone damage in autoimmune
   arthritis: joint erosion, periarticular osteopenia, and systemic bone
   loss
SO INFLAMMATION AND REGENERATION
LA English
DT Article
DE JAK inhibitor; Autoimmune arthritis; Bone damage; Osteoclast; Osteoblast
ID RHEUMATOID ARTHRITIS; RANKL; OSTEOCLASTOGENESIS; OSTEOPOROSIS;
   DESTRUCTION; TH17
AB BackgroundThe types of bone damage in rheumatoid arthritis (RA) include joint erosion, periarticular osteoporosis, and systemic osteoporosis. Janus kinase (JAK) inhibitors ameliorate inflammation and joint erosion in RA, but their effect on the three types of bone loss have not been reportedly explored in depth. We aimed to clarify how JAK inhibitors influence the various types of bone loss in arthritis by modulating osteoclastic bone resorption and/or osteoblastic bone formation.MethodsCollagen induced arthritis (CIA) mice were treated with a JAK inhibitor after the onset of arthritis. Micro computed tomography (& mu;CT) and histological analyses (bone morphometric analyses) on the erosive calcaneocuboid joint, periarticular bone (distal femur or proximal tibia), and vertebrae were performed. The effect of four different JAK inhibitors on osteoclastogenesis under various conditions was examined in vitro.ResultsThe JAK inhibitor ameliorated joint erosion, periarticular osteopenia and systemic bone loss. It reduced the osteoclast number in all the three types of bone damage. The JAK inhibitor enhanced osteoblastic bone formation in the calcaneus distal to inflammatory synovium in the calcaneocuboid joints, periarticular region of the tibia and vertebrae, but not the inflamed calcaneocuboid joint. All the JAK inhibitors suppressed osteoclastogenesis in vitro to a similar extent in the presence of osteoblastic cells. Most of the JAK inhibitors abrogated the suppressive effect of Th1 cells on osteoclastogenesis by inhibiting IFN & gamma; signaling in osteoclast precursor cells, while a JAK inhibitor did not affect this effect due to less ability to inhibit IFN & gamma; signaling.ConclusionsThe JAK inhibitor suppressed joint erosion mainly by inhibiting osteoclastogenesis, while it ameliorated periarticular osteopenia and systemic bone loss by both inhibiting osteoclastogenesis and promoting osteoblastogenesis. These results indicate that the effect of JAK inhibitors on osteoclastogenesis and osteoblastogenesis depends on the bone damage type and the affected bone area. In vitro studies suggest that while JAK inhibitors inhibit osteoclastic bone resorption, their effects on osteoclastogenesis in inflammatory environments vary depending on the cytokine milieu, JAK selectivity and cytokine signaling specificity. The findings reported here should contribute to the strategic use of antirheumatic drugs against structural damages in RA.
C1 [Komagamine, Masatsugu; Komatsu, Noriko; Ling, Rui; Tianshu, Shi; Matsuda, Kotaro; Takayanagi, Hiroshi] Univ Tokyo, Grad Sch Med, Dept Immunol, Tokyo, Japan.
   [Komagamine, Masatsugu; Takeuchi, Tsutomu; Kaneko, Yuko] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, Tokyo, Japan.
   [Okamoto, Kazuo] Univ Tokyo, Grad Sch Med, Dept Osteoimmunol, Tokyo, Japan.
   [Okamoto, Kazuo] Univ Tokyo, Fac Med, Tokyo, Japan.
   [Takeuchi, Tsutomu] Saitama Med Univ, Saitama, Japan.
C3 University of Tokyo; Keio University; University of Tokyo; University of
   Tokyo; Saitama Medical University
RP Komatsu, N; Takayanagi, H (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Immunol, Tokyo, Japan.
EM koma im@m.u tokyo.ac.jp; takayana@m.u tokyo.ac.jp
OI Komagamine, Masatsugu/0009 0008 7898 9134
FU We thank NC. Huynh, K. Kusubata, S. Yin, A. Suematsu and K. Kubo for
   thoughtful discussion and technical assistance. H.T was supported by
   Japan Agency for Medical Research and Development (AMED): JP22ek0410073,
   JP23ek0410108, AMED CREST: JP22gm1210008, AME [JP22ek0410073,
   JP23ek0410108]; Japan Agency for Medical Research and Development (AMED)
   [JP22gm1210008]; AMED CREST [JP223fa627001]; AMED Japan Initiative for
   World leading Vaccine Research and Development Centers [21H05046]; Japan
   Society for the Promotion of Science (JSPS) [JP22ek0410100]; AMED
   [22H03195]; JSPS [JPMJFR205Z]; JST FOREST program; Grants in Aid for
   Scientific Research [21K18254, 23K24106, 23K24454, 21H05046] Funding
   Source: KAKEN
FX We thank NC. Huynh, K. Kusubata, S. Yin, A. Suematsu and K. Kubo for
   thoughtful discussion and technical assistance. H.T was supported by
   Japan Agency for Medical Research and Development (AMED): JP22ek0410073,
   JP23ek0410108, AMED CREST: JP22gm1210008, AMED Japan Initiative for
   World leading Vaccine Research and Development Centers (JP223fa627001)
   and Japan Society for the Promotion of Science (JSPS): Grants in Aid for
   Scientific Research S (21H05046). N.K was supported by AMED
   JP22ek0410100, JSPS Grants in Aid for Scientific Research B (22H02844)
   and JST FOREST program (JPMJFR2261). K.O was supported by JSPS
   Grants in Aid for Scientific Research B (22H03195) and JST FOREST
   program (JPMJFR205Z).
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Burmester GR, 2018, LANCET, V391, P2503, DOI 10.1016/S0140 6736(18)31115 2
   Combe B, 2021, ANN RHEUM DIS, V80, P848, DOI 10.1136/annrheumdis 2020 219214
   Cox L, 2011, CHEM BIOL, V18, P277, DOI 10.1016/j.chembiol.2011.03.002
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Engdahl C, 2017, J BONE MINER RES, V32, P1681, DOI 10.1002/jbmr.3158
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gadina M, 2019, RHEUMATOLOGY, V58, P4, DOI 10.1093/rheumatology/key432
   Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Iwata T, 2016, OSTEOPOROSIS INT, V27, P691, DOI 10.1007/s00198 015 3256 1
   Kim SY, 2012, J BONE MINER RES, V27, P789, DOI 10.1002/jbmr.1489
   Kleyer A, 2014, ANN RHEUM DIS, V73, P854, DOI 10.1136/annrheumdis 2012 202958
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Komatsu N, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150274
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kubo S, 2014, ANN RHEUM DIS, V73, P2192, DOI 10.1136/annrheumdis 2013 203756
   Maeshima K, 2012, ARTHRITIS RHEUM US, V64, P1790, DOI 10.1002/art.34329
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   McLornan DP, 2021, LANCET, V398, P803, DOI 10.1016/S0140 6736(21)00438 4
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Parmentier JM, 2018, BMC RHEUMATOL, V2, DOI 10.1186/s41927 018 0031 x
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226
   Sugahara S, 2022, J PHARMACOL SCI, V148, P134, DOI 10.1016/j.jphs.2021.10.006
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Tanaka Y, 2022, NAT REV RHEUMATOL, V18, P133, DOI 10.1038/s41584 021 00726 8
   Tanaka Y, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061241
   Traves PG, 2021, ANN RHEUM DIS, V80, P865, DOI 10.1136/annrheumdis 2020 219012
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wu HX, 2016, JOINT BONE SPINE, V83, P525, DOI 10.1016/j.jbspin.2015.09.002
   Yari S, 2023, INFLAMM REGEN, V43, DOI 10.1186/s41232 023 00268 4
NR 40
TC 8
Z9 9
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1880 8190
J9 INFLAMM REGEN
JI Inflamm. Regen.
PD SEP 19
PY 2023
VL 43
IS 1
AR 44
DI 10.1186/s41232 023 00293 3
PG 14
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine
GA S4EG4
UT WOS:001070710000001
PM 37726797
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, TT
   Bai, RS
   Wang, ZM
   Qin, YT
   Wang, JW
   Wei, YH
   Zhao, RF
   Nie, GJ
   Han, B
AF Yu, Tingting
   Bai, Rushui
   Wang, Zeming
   Qin, Yuting
   Wang, Jingwei
   Wei, Yaohua
   Zhao, Ruifang
   Nie, Guangjun
   Han, Bing
TI Colon targeted engineered postbiotics nanoparticles alleviate
   osteoporosis through the gut bone axis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BUTYRATE; ACIDS
AB The potential for mitigating intestinal inflammation through the gut bone axis in the treatment of osteoporosis is significant. While various gut derived postbiotics or bacterial metabolites have been created as dietary supplements to prevent or reverse bone loss, their efficacy and safety still need improvement. Herein, a colon targeted drug delivery system is developed using surface engineering of polyvinyl butyrate nanoparticles by shellac resin to achieve sustained release of postbiotics butyric acid at the colorectal site. These engineered postbiotics nanoparticles can effectively suppress macrophage inflammatory activation, modulate the redox balance, and regulate the composition of the gut microbiota, thereby restoring epithelial barriers, inhibiting bacterial invasion, and down regulating pro inflammatory responses. As a result, the remission of systemic inflammation is accompanied by a rebalancing of osteoblast and osteoclast activity, alleviating inflammatory bowel disease related and post menopausal bone loss. Specifically, the treatment of engineered postbiotics nanoparticles can also improve the quality and quantity of bone with restoration of deteriorative mechanical properties, which indicating a therapeutic potential on fracture prevention. This study provides valuable insights into the gut bone axis and establishes a promising and safe therapeutic strategy for osteoporosis.
C1 [Yu, Tingting; Bai, Rushui; Wang, Jingwei; Han, Bing] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Beijing, Peoples R China.
   [Yu, Tingting; Bai, Rushui; Wang, Jingwei; Han, Bing] Natl Ctr Stomatol, Beijing, Peoples R China.
   [Yu, Tingting; Bai, Rushui; Wang, Jingwei; Han, Bing] Natl Engn Res Ctr Oral Biomat & Digital Med Device, Beijing, Peoples R China.
   [Bai, Rushui; Wang, Zeming; Qin, Yuting; Wang, Jingwei; Wei, Yaohua; Zhao, Ruifang; Nie, Guangjun] Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing, Peoples R China.
   [Wang, Zeming; Zhao, Ruifang; Nie, Guangjun] Univ Chinese Acad Sci, Ctr Mat Sci & Optoelect Engn, Beijing, Peoples R China.
C3 Peking University; Chinese Academy of Sciences; Key Laboratory for
   Biological Effects of Nanomaterials & Nanosafety, CAS; National Center
   for Nanoscience & Technology, CAS; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS
RP Han, B (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Beijing, Peoples R China.; Han, B (通讯作者)，Natl Ctr Stomatol, Beijing, Peoples R China.; Han, B (通讯作者)，Natl Engn Res Ctr Oral Biomat & Digital Med Device, Beijing, Peoples R China.; Zhao, RF; Nie, GJ (通讯作者)，Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing, Peoples R China.; Zhao, RF; Nie, GJ (通讯作者)，Univ Chinese Acad Sci, Ctr Mat Sci & Optoelect Engn, Beijing, Peoples R China.
EM zhaorf@nanoctr.cn; niegj@nanoctr.cn; kqbinghan@bjmu.edu.cn
RI ; Yu, Tingting/HKN 1852 2023; Nie, Guangjun/A 9954 2011; Han,
   Bing/ISU 7800 2023; Wang, Jingwei/GZB 0655 2022
OI Zhao, Ruifang/0000 0002 2735 2159; Bai, Rushui/0000 0002 1718 7233;
   Wang, Jingwei/0000 0001 6508 934X; nie, guangjun/0000 0001 5040 9793;
   Han, Bing/0000 0003 4584 1092; 
FU the Fundamental Research Center Project of the National Natural Science
   Foundation of China (T2288102), the Strategic Priority Research Program
   of Chinese Academy of Sciences (XDB36000000) [2022YFA1206100,
   2021YFC2400403, 2023YFC2509903]; National Key R&D Program of China
   [T2288102]; Fundamental Research Center Project of the National Natural
   Science Foundation of China [52473120, 52373123, U21A2055]; National
   Natural Science Foundation of China [XDB36000000]; Strategic Priority
   Research Program of Chinese Academy of Sciences [Z211100002921066];
   Beijing Municipal Science Technology Commission [2021QNRC001]; Young
   Elite Scientist Sponsorship Program by CAST [202304584382]; Beijing Nova
   Program
FX This work was financially supported by grants from the National Key R&D
   Program of China (2022YFA1206100 to T.Y., 2021YFC2400403 to B.H.,
   2023YFC2509903 to Y.W.), the Fundamental Research Center Project of the
   National Natural Science Foundation of China (T2288102 to G.N.), the
   National Natural Science Foundation of China (52473120 to B.H., 52373123
   to T.Y., U21A2055 to B.H.), the Strategic Priority Research Program of
   Chinese Academy of Sciences (XDB36000000 to G.N.), the Beijing Municipal
   Science Technology Commission (Z211100002921066 to B.H.), the Young
   Elite Scientist Sponsorship Program by CAST (2021QNRC001 to T.Y.) and
   the Beijing Nova Program (202304584382 to R.Z.). We thank Luzheng Xu and
   Qilong Wang from the Peking University Medical and Health Analysis
   Center for their assistance with Micro CT image scanning and processing.
CR Alex P, 2009, INFLAMM BOWEL DIS, V15, P341, DOI 10.1002/ibd.20753
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Bott KN, 2023, J BONE MINER RES, V38, P198, DOI 10.1002/jbmr.4740
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573 018 0008 x
   Ding K, 2020, AGING DIS, V11, P438, DOI 10.14336/AD.2019.0523
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721
   Ghosh SS, 2020, J ENDOCR SOC, V4, DOI 10.1210/jendso/bvz039
   Gonzalez Rodriguez E, 2020, J CLIN ONCOL, V38, P1641, DOI 10.1200/JCO.19.02678
   Guo JW, 2023, CELL REP MED, V4, DOI 10.1016/j.xcrm.2022.100881
   Guo MY, 2023, GUT MICROBES, V15, DOI 10.1080/19490976.2023.2190304
   Hinrichsen F, 2021, CELL METAB, V33, P2355, DOI 10.1016/j.cmet.2021.11.004
   Hua S, 2015, NANOMED NANOTECHNOL, V11, P1117, DOI 10.1016/j.nano.2015.02.018
   Kang SS, 2016, ARCH PHARM RES, V39, P1519, DOI 10.1007/s12272 016 0804 y
   Ke K, 2019, J BONE MINER RES, V34, P1880, DOI 10.1002/jbmr.3759
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kitamoto S, 2020, CELL, V182, P447, DOI 10.1016/j.cell.2020.05.048
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041
   Kong N, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00196 y
   Le HH, 2022, CELL HOST MICROBE, V30, P798, DOI 10.1016/j.chom.2022.05.002
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Li GF, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1968257
   Li K, 2016, RSC ADV, V6, P33547, DOI 10.1039/c6ra03720h
   Li XG, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.875473
   Liu JH, 2021, ADV SCI, V8, DOI 10.1002/advs.202004831
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Merlotti D, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052713
   Mu YM, 2021, ACS APPL BIO MATER, V4, P2335, DOI 10.1021/acsabm.0c01105
   Odenwald MA, 2017, NAT REV GASTRO HEPAT, V14, P9, DOI 10.1038/nrgastro.2016.169
   Ott C, 2013, NAT REV GASTRO HEPAT, V10, P585, DOI 10.1038/nrgastro.2013.117
   Pedersen AB, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2416
   Peng LY, 2007, PEDIATR RES, V61, P37, DOI 10.1203/01.pdr.0000250014.92242.f3
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Potrykus M, 2021, NUTRIENTS, V13, DOI 10.3390/nu13113839
   Qaseem A, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 1034
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Raqib R, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471 2334 12 111
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Salminen S, 2021, NAT REV GASTRO HEPAT, V18, P649, DOI 10.1038/s41575 021 00440 6
   Schirmer M, 2019, NAT REV MICROBIOL, V17, P497, DOI 10.1038/s41579 019 0213 6
   Shin W, 2018, P NATL ACAD SCI USA, V115, pE10539, DOI 10.1073/pnas.1810819115
   Soós B, 2022, NAT REV RHEUMATOL, V18, P249, DOI 10.1038/s41584 022 00764 w
   Tilg H, 2008, GUT, V57, P684, DOI 10.1136/gut.2006.117382
   Tyagi AM, 2018, IMMUNITY, V49, P1116, DOI 10.1016/j.immuni.2018.10.013
   Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612
   Wang RY, 2023, NAT BIOMED ENG, V7, P38, DOI 10.1038/s41551 022 00972 5
   Xu JQ, 2023, ADV MATER, V35, DOI 10.1002/adma.202207890
   Yang JM, 2022, MICROBIOME, V10, DOI 10.1186/s40168 022 01347 3
   Yang WJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18262 6
   Yu TT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2025 z
   Yuan Y, 2021, ACS NANO, V15, P18794, DOI 10.1021/acsnano.1c07121
   Zaiss MM, 2021, NAT REV RHEUMATOL, V17, P224, DOI 10.1038/s41584 021 00585 3
   Zaiss MM, 2019, J CLIN INVEST, V129, P3018, DOI 10.1172/JCI128521
   Zigmond E, 2012, IMMUNITY, V37, P1076, DOI 10.1016/j.immuni.2012.08.026
   Zuo L, 2020, CELL MOL GASTROENTER, V10, P327, DOI 10.1016/j.jcmgh.2020.04.001
NR 59
TC 1
Z9 1
U1 52
U2 64
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 30
PY 2024
VL 15
IS 1
AR 10893
DI 10.1038/s41467 024 55263 1
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA Q7I6T
UT WOS:001386373100036
PM 39738035
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Roccaro, AM
   Leleu, X
   Sacco, A
   Moreau, AS
   Hatjiharissi, E
   Jia, X
   Xu, L
   Ciccarelli, B
   Patterson, CJ
   Ngo, HT
   Russo, D
   Vacca, A
   Dammacco, F
   Anderson, KC
   Ghobrial, IM
   Treon, SP
AF Roccaro, Aldo M.
   Leleu, Xavier
   Sacco, Antonio
   Moreau, Anne Sophie
   Hatjiharissi, Evcloxia
   Jia, Xiaoying
   Xu, Lian
   Ciccarelli, Bryan
   Patterson, Christopher J.
   Ngo, Hai T.
   Russo, Domenico
   Vacca, Angelo
   Dammacco, Franco
   Anderson, Kenneth C.
   Ghobrial, Irene M.
   Treon, Steven P.
TI Resveratrol exerts antiproliferative activity and induces apoptosis in
   Waldenstrom's macroglobulinemia
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CELL CYCLE ARREST; CHRONIC LYMPHOCYTIC LEUKEMIA; MULTIPLE MYELOMA;
   GROWTH INHIBITION; SIGNALING PATHWAY; DOWN REGULATION; IN VITRO; CANCER;
   EXPRESSION; AKT
AB Purpose: Resveratrol (3,4, 5 tri hydroxy trans stilbene) is an antioxidant constituent of a wide variety of plant species including grapes. It has gained considerable attention because of its anticancer properties, as shown in solid and hematologic malignancies. Whether resveratrol could inhibit proliferation or induce cytotoxicity in Waldenstrom's macroglobulinemia (WM) was investigated.
   Experimental Design: We studied resveratrol induced inhibition of proliferation and induction of cytotoxicity in WM cell lines,WM primary tumor cells, IgM secreting cells, and peripheral blood mononuclear cells. The mechanisms of action and different signaling pathways involved were studied using Western blot and gene expression profile analysis. Resveratrol activity was also evaluated in the bone marrow microenvironment. We finally investigated whether or not resveratrol could have any synergistic effect if used in combination with other drugs widely used in the treatment of WM.
   Results: A schematic image illustrating the location and expression of the aurora kinases A, B, and C during mitosis. Resveratrol inhibited proliferation and induced cytotoxicity against WM cells, IgM secreting cells, as well as primary WM cells, without affecting peripheral blood mononuclear cells; down regulated Akt, extracellular signal regulated kinase mitogen activated protein kinases, and Wnt signaling pathways, as well as Akt activity; induced cell cycle arrest and apoptosis; and triggered c Jun NH2 terminal kinase activation, followed by the activation of intrinsic and extrinsic caspase pathways. Lastly, adherence to bone marrow stromal cells did not confer protection to WM cells against resveratrol induced cytotoxicity. Furthermore, resveratrol showed synergistic cytotoxicity when combined with dexamethasone, fludarabine, and bortezomib.
   Conclusion: Our data show that resveratrol has significant antitumor activity in WM, providing the framework for clinical trials in this disease.
C1 [Roccaro, Aldo M.; Leleu, Xavier; Sacco, Antonio; Moreau, Anne Sophie; Hatjiharissi, Evcloxia; Jia, Xiaoying; Xu, Lian; Ciccarelli, Bryan; Patterson, Christopher J.; Ngo, Hai T.; Anderson, Kenneth C.; Ghobrial, Irene M.; Treon, Steven P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
   [Russo, Domenico] Univ Brescia, Sch Med, Unit Blood Dis & Cell Therapies, Brescia, Italy.
   [Vacca, Angelo; Dammacco, Franco] Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, Bari, Italy.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard Medical School; University of Brescia;
   Universita degli Studi di Bari Aldo Moro
RP Roccaro, AM (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, 44 Binney St,Mayer Bldg,M548, Boston, MA 02115 USA.
EM aldo_roccaro@dfci.harvard.edu
RI Roccaro, Aldo/J 9252 2014; Hatjiharissi, Evdoxia/AAG 7425 2020;
   Anderson, Kenneth/ACP 5073 2022; Vacca, Angelo/AAC 9558 2022; LELEU,
   Xavier/ABP 5732 2022; Russo, Domenico/C 3947 2011; Sacco,
   Antonio/K 4681 2016; Dammacco, Franco/ABG 5728 2020
OI Roccaro, Aldo/0000 0002 1872 5128; Sacco, Antonio/0000 0003 2945 9416; 
CR Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Alkhalaf M, 2006, FREE RADICAL BIO MED, V41, P318, DOI 10.1016/j.freeradbiomed.2006.04.019
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   Bernhard D, 2003, CANCER LETT, V195, P193, DOI 10.1016/S0304 3835(03)00157 5
   Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood 2006 02 003988
   Cal C., 2003, Current Medicinal Chemistry   Anti Cancer Agents, V3, P77, DOI 10.2174/1568011033353443
   Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood 2004 04 1670
   Chen CI, 2007, J CLIN ONCOL, V25, P1570, DOI 10.1200/JCO.2006.07.8659
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014 5793(02)03093 4
   Dimopoulos MA, 2005, HAEMATOLOGICA, V90, P1655
   Elmali N, 2007, INFLAMMATION, V30, P1, DOI 10.1007/s10753 006 9012 0
   Faber AC, 2006, BIOCHEM PHARMACOL, V72, P1246, DOI 10.1016/j.bcp.2006.08.009
   Ghobrial IM, 2003, LANCET ONCOL, V4, P679, DOI 10.1016/S1470 2045(03)01246 4
   Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111
   Gutiérrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520
   Hatjiharissi E, 2007, CANCER RES, V67, P3777, DOI 10.1158/0008 5472.CAN 06 3089
   Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood 2002 08 2543
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood 2005 08 3434
   Horvath Z, 2006, NUCLEOS NUCLEOT NUCL, V25, P1019, DOI 10.1080/15257770600890574
   Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471
   Joe AK, 2002, CLIN CANCER RES, V8, P893
   Johnson SA, 2005, CLIN LYMPHOMA, V5, P294, DOI 10.3816/CLM.2005.n.020
   Juan ME, 2002, J NUTR, V132, P257, DOI 10.1093/jn/132.2.257
   Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323
   Kimura Y, 2001, J NUTR, V131, P1844, DOI 10.1093/jn/131.6.1844
   Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280
   Leleu X, 2007, BLOOD, V110, P4417, DOI 10.1182/blood 2007 05 092098
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Longo PG, 2007, LEUKEMIA, V21, P110, DOI 10.1038/sj.leu.2404417
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025
   Mokni M, 2007, ARCH BIOCHEM BIOPHYS, V457, P1, DOI 10.1016/j.abb.2006.10.015
   Moreau AS, 2007, BLOOD, V109, P4964, DOI 10.1182/blood 2006 10 054577
   Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03 0168rev
   Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365 2141.2005.05630.x
   Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb 2001 2 2 reviews3004
   Santos DD, 2007, EXP HEMATOL, V35, P1366, DOI 10.1016/j.exphem.2007.05.022
   Sexton É, 2006, MOL CANCER, V5, DOI 10.1186/1476 4598 5 45
   Tang HY, 2006, MOL CANCER THER, V5, P2034, DOI 10.1158/1535 7163.MCT 06 0216
   Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619
   Treon SP, 2006, BLOOD, V107, P3442, DOI 10.1182/blood 2005 02 0833
   Treon SP, 2007, CLIN CANCER RES, V13, P3320, DOI 10.1158/1078 0432.CCR 06 2511
   Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223
   Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood 2006 04 016907
   Wolter F, 2001, J NUTR, V131, P2197, DOI 10.1093/jn/131.8.2197
   Zhang T, 2001, CANCER RES, V61, P8664
NR 47
TC 68
Z9 73
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2008
VL 14
IS 6
BP 1849
EP 1858
DI 10.1158/1078 0432.CCR 07 1750
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 275LL
UT WOS:000254072900033
PM 18347188
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, YK
   Zhou, ZY
   Liu, F
AF Liu, Ya Ke
   Zhou, Zhen Yu
   Liu, Fan
TI Transcriptome changes during TNF α promoted osteogenic differentiation
   of dental pulp stem cells (DPSCs)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE DPSCs; Osteogenic differentiation; TNF Alpha; RNA Seq; TGF beta; PIK3
ID OSTEOBLAST DIFFERENTIATION; TAZ EXPRESSION; BONE FORMATION; PATHWAY;
   MARROW; TISSUE
AB Dental pulp stem cells (DPSCs), due to the ease of isolation and their capacities of multi lineage differentiation, are considered as attractive resources for regenerative medicine. In a previous study, we showed that TNF alpha. promoted the osteogenic differentiation of DPSCs via the NF kappa B signaling pathway. However, the mechanisms of such differentiation were largely unknown. Here, we examined the gene expression profiles between undifferentiated, partially differentiated and fully differentiated DPSCs induced by TNF alpha by performing the next generation sequencing technique (RNA Seq). Our results revealed a continuous transition of the transcriptome changes during TNF alpha promoted osteogenic differentiation of DPSC. Bioinformatics analysis revealed a relatively general to specific transformation of the involved signaling pathways from the early to late stages of differentiation. Gene regulatory network analysis highlighted novel, key genes that are essential for osteogenic differentiation at different time points. These results were further validated by quantitative RT PCR, confirming the high reliability of the RNA Seq. Our data therefore will not only provide novel insights into the molecular mechanisms that drive the osteogenic differentiation of DPSCs, but also promote the studies of bone tissue engineering that utilizes DPSCs as a crucial resource. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Liu, Ya Ke; Zhou, Zhen Yu; Liu, Fan] Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong 226001, Jiangsu, Peoples R China.
C3 Nantong University
RP Liu, F (通讯作者)，Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong 226001, Jiangsu, Peoples R China.
EM liufan195705@126.com
CR Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Byun MR, 2014, BONE, V58, P72, DOI 10.1016/j.bone.2013.09.024
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   d'Aquino R, 2009, J EXP ZOOL PART B, V312B, P408, DOI 10.1002/jez.b.21263
   Feng XM, 2013, CELL BIOL INT, V37, P1267, DOI 10.1002/cbin.10141
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Huang H, 2011, CELL PROLIFERAT, V44, P420, DOI 10.1111/j.1365 2184.2011.00769.x
   Huang J, 2014, BIOMATERIALS, V35, P9649, DOI 10.1016/j.biomaterials.2014.08.016
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Laino G, 2005, J BONE MINER RES, V20, P1394, DOI 10.1359/JBMR.050325
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   Ponnaiyan Deepa, 2014, Eur J Dent, V8, P307, DOI 10.4103/1305 7456.137631
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Suzuki E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112566
   Tatullo M, 2015, J TISSUE ENG REGEN M, V9, P1205, DOI 10.1002/term.1899
   Zhang RP, 2011, J BIOL CHEM, V286, P41083, DOI 10.1074/jbc.M111.258715
   Zheng Y, 2009, J DENT RES, V88, P249, DOI 10.1177/0022034509333804
   Zhou SH, 2011, J CELL BIOCHEM, V112, P1651, DOI 10.1002/jcb.23079
NR 22
TC 14
Z9 16
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 5
PY 2016
VL 476
IS 4
BP 426
EP 430
DI 10.1016/j.bbrc.2016.05.137
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DR4QE
UT WOS:000379886500038
PM 27237976
DA 2025 08 17
ER

PT J
AU Qian, WQ
   Su, Y
   Zhang, YJ
   Yao, NW
   Gu, N
   Zhang, X
   Yin, H
AF Qian, Weiqing
   Su, Yan
   Zhang, Yajie
   Yao, Nianwei
   Gu, Nin
   Zhang, Xu
   Yin, Hong
TI Secretome analysis of rat osteoblasts during icariin treatment induced
   osteogenesis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE icariin; osteoblasts; secretome; two dimensional electrophoresis;
   western blot
ID EPITHELIUM DERIVED FACTOR; BONE MINERAL DENSITY; C MYC ONCOGENE;
   RISK FACTORS; OVARIECTOMIZED RATS; EPIMEDIUM KOREANUM;
   CELL PROLIFERATION; BREVICORNUM MAXIM; GENE EXPRESSION; DOWN REGULATION
AB Osteoporosis is a serious public health problem and icariin (ICA) is the active component of the Epimedium sagittatum, a traditional Chinese medicinal herb. The present study aimed to investigate the effects and underlying mechanisms of ICA as a potential therapy for osteoporosis. Calvaria osteoblasts were isolated from newborn rats and treated with ICA. Cell viability, apoptosis, alkaline phosphatase activity and calcium deposition were analyzed. Bioinformatics analyses were performed to identify differentially expressed proteins (DEPs) in response to ICA treatment. Western blot analysis was performed to validate the expression of DEPs. ICA administration promoted osteoblast viability, alkaline phosphatase activity, calcium deposition and inhibited osteoblast apoptosis. Secretome analysis of ICA treated cells was performed using two dimensional gel electrophoresis and matrix assisted laser desorption/ionization time of flight mass spectrometry. A total of 56 DEPs were identified, including serpin family F member 1 (PEDF), protein disulfide isomerase family A, member 3 (PDIA3), nuclear protein, co activator of histone transcription (NPAT), c Myc and heat shock protein 70 (HSP70). These proteins were associated with signaling pathways, including Fas and p53. Bioinformatics and western blot analyses confirmed that the expression levels of the six DEPs were upregulated following ICA treatment. These genes may be directly or indirectly involved in ICA mediated osteogenic differentiation and osteogenesis. It was demonstrated that ICA treatment promoted osteogenesis by modulating the expression of PEDF, PDIA3, NPAT and HSP70 through signaling pathways, including Fas and p53.
C1 [Qian, Weiqing; Yao, Nianwei; Yin, Hong] Nanjing Univ Chinese Med, Affiliated Hosp 3, Dept Orthoped, 1 Jinling Rd, Nanjing 210001, Jiangsu, Peoples R China.
   [Su, Yan] Nanjing Med Univ, Reprod Ctr, Obstet & Gynecol Hosp, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhang, Yajie] Nanjing Univ Chinese Med, Affiliated Hosp 3, Lab Ctr, Nanjing 210023, Jiangsu, Peoples R China.
   [Gu, Nin] Nanjing Univ Chinese Med, Affiliated Hosp 3, Cardiovasc Dept, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhang, Xu] Nanjing Univ Chinese Med, Sch Med & Life Sci, 138 Xianlin Ave, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing Medical University;
   Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine
RP Yin, H (通讯作者)，Nanjing Univ Chinese Med, Affiliated Hosp 3, Dept Orthoped, 1 Jinling Rd, Nanjing 210001, Jiangsu, Peoples R China.; Zhang, X (通讯作者)，Nanjing Univ Chinese Med, Sch Med & Life Sci, 138 Xianlin Ave, Nanjing 210023, Jiangsu, Peoples R China.
EM zhangxu0114@126.com; hongyin0114@126.com
RI Zhang, Yajie/J 6726 2017; zhang, ya jie/J 6726 2017
OI Zhang, Xu/0000 0002 1959 1758; zhang, ya jie/0000 0003 2510 6015
FU Science Foundation of Traditional Chinese Medicine Administration,
   Jiangsu Province [LB09083]
FX The present study was funded by the Science Foundation of Traditional
   Chinese Medicine Administration, Jiangsu Province (grant no. LB09083).
CR Ahn HJ, 2006, TRANSPL P, V38, P2074, DOI 10.1016/j.transproceed.2006.06.106
   Bakker A, 2013, METHODS MOL MED, V80, P19
   Banerjee D, 2014, CELL STRESS CHAPERON, V19, P401, DOI 10.1007/s12192 013 0469 0
   Bogan R, 2013, J BONE MINER RES, V28, P1531, DOI 10.1002/jbmr.1892
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brusotti G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05666 6
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Chang H, 2003, BIOMED ENVIRON SCI, V16, P83
   Chen BJ, 2014, INT J BIOL SCI, V10, P1084, DOI 10.7150/ijbs.10190
   Chen EM, 2015, FEBS LETT, V589, P4088, DOI 10.1016/j.febslet.2015.11.021
   Chen GM, 2016, EXP THER MED, V12, P279, DOI 10.3892/etm.2016.3333
   Chen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071955
   Chen JX, 2010, J BIOL CHEM, V285, P37041, DOI 10.1074/jbc.M110.157115
   Chen KM, 2005, PHARMAZIE, V60, P939
   Cheung AM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Coutu DL, 2008, J BIOL CHEM, V283, P17991, DOI 10.1074/jbc.M708029200
   Díez Pérez A, 2014, J BONE MINER RES, V29, P260, DOI 10.1002/jbmr.2023
   Doroudi M, 2014, ESSENTIAL ROLES PDIA
   Duan P, 2017, ENVIRON TOXICOL, V32, P739, DOI 10.1002/tox.22274
   Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601
   Gattu AK, 2013, FASEB J, V27, P4384, DOI 10.1096/fj.13 232900
   Han YT, 2017, CELL BIOL INT, V41, P1296, DOI 10.1002/cbin.10838
   Ho TC, 2007, CARDIOVASC RES, V76, P213, DOI 10.1016/j.cardiores.2007.06.032
   Honda H, 2013, J ARTIF ORGANS, V16, P305, DOI 10.1007/s10047 013 0711 7
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jarvis CL, 2016, CANCER RES, V76, DOI 10.1158/1538 7445.AM2016 288
   KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187
   KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0
   Kurt Sirin O, 2014, GENE, V540, P226, DOI 10.1016/j.gene.2014.02.028
   Lee MK, 1995, PLANTA MED, V61, P523, DOI 10.1055/s 2006 959362
   Li X F, 2013, EVID BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/652317
   Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026
   Liu HR, 2017, EXP THER MED, V13, P1360, DOI 10.3892/etm.2017.4128
   Ma X, 2007, J CHROMATOGR B, V859, P170, DOI 10.1016/j.jchromb.2007.09.027
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092
   Mi HY, 2009, METHODS MOL BIOL, V563, P123, DOI 10.1007/978 1 60761 175 2_7
   Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078 0432.CCR 12 0977
   Miyamoto Takeshi, 2015, Keio Journal of Medicine, V64, P44, DOI 10.2302/kjm.2015 0003 RE
   Nelius T, 2013, CANCER RES, V73, DOI 10.1158/1538 7445.AM2013 5097
   Odén A, 2015, OSTEOPOROSIS INT, V26, P2243, DOI 10.1007/s00198 015 3154 6
   Powell TJ, 2007, J IMMUNOL, V178, P1030, DOI 10.4049/jimmunol.178.2.1030
   Qian WQ, 2011, CHINA MED HERALD, V8, P23
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Sun HL, 2013, STEM CELLS, V31, P2183, DOI 10.1002/stem.1455
   Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Vadde R, 2016, J FUNCT FOODS, V25, P267, DOI 10.1016/j.jff.2016.06.007
   Xing XM, 2006, PROTEOMICS, V6, P2916, DOI 10.1002/pmic.200401355
   Xue LM, 2016, J ETHNOPHARMACOL, V192, P370, DOI 10.1016/j.jep.2016.07.037
   Xue LM, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/241416
   Yang LJ, 2013, J ETHNOPHARMACOL, V145, P715, DOI 10.1016/j.jep.2012.11.031
   Zambelli Pierre Yves, 2014, Rev Med Suisse, V10, P116
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05 4313fje
   Zhang W, 2012, CELL BIOCHEM FUNCT, V30, P297, DOI 10.1002/cbf.2801
   Zhao JY, 2004, CELL CYCLE, V3, P695
   Zhao YQ, 2011, MOL VIS, V17, P768
   Zheng LL, 2015, J BIOL CHEM, V290, P29290, DOI 10.1074/jbc.M115.659201
   Zirath H, 2013, P NATL ACAD SCI USA, V110, P10258, DOI 10.1073/pnas.1222404110
NR 60
TC 11
Z9 18
U1 0
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2018
VL 17
IS 5
BP 6515
EP 6525
DI 10.3892/mmr.2018.8715
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GD5OR
UT WOS:000430556800036
PM 29532868
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Sohn, H
   Ko, Y
   Park, M
   Kim, D
   Moon, YL
   Jeong, YJ
   Lee, H
   Moon, Y
   Jeong, BC
   Kim, O
   Lim, W
AF Sohn, HongMoon
   Ko, Youngjong
   Park, Mineon
   Kim, Donghwi
   Moon, Young Lae
   Jeong, Yeon Joo
   Lee, Hyeonjun
   Moon, Yeonhee
   Jeong, Byung Chul
   Kim, Okjoon
   Lim, Wonbong
TI Effects of Light Emitting Diode Irradiation on RANKL Induced
   Osteoclastogenesis
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE low level light therapy; osteoclastogenesis; osteoporosis; reactive
   oxygen species
ID LEVEL LASER THERAPY; REACTIVE OXYGEN; BONE RESORPTION; SIGNALING
   PATHWAY; DIFFERENTIATION; CELLS; PROLIFERATION; ACTIVATION; PROTEIN;
   RATS
AB Background and Objective: Bone homeostasis is maintained by a balance between osteoblastic bone formation and osteoclastic bone resorption, where intracellular reactive oxygen species (ROS) are crucial mediators of osteoclastogenesis. Recently, low level light therapy (LLLT), a form of laser medicine used in various clinical fields, was shown to alleviate oxidative stress by scavenging intracellular ROS. The present study aimed to investigate the impact of 635 nm irradiation from a light emitting diode (LED) on osteoclastogenesis from receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) stimulated mouse bone marrow derived macrophages (BMMs).
   Study Design/Materials and Methods: The effects of LED irradiation on osteoclastogenesis were assessed in tartrate resistant acid phosphatase (TRAP), 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT), cell viability, and resorption pit formation, respectively. Quantitative real time polymerase chain reaction (qPCR) and Western blot analyses were also performed to assess mRNA expression of osteoclastogenesis related genes and phosphorylation of extracellular signal regulated kinase 1/2 (ERK 1/2), p38, and c Jun N terminal kinase (JNK). NF kappa B activity was assayed by luciferase reporter assay and Intracellular ROS generation was investigated by the 2',7' dichlorodihydrofluorescein diacetate (H2DCF DA) detection method.
   Results: LED irradiation significantly inhibited RANKL mediated osteoclast differentiation from BMMs and mRNA expression of TRAP, osteoclast associated immunoglobulin like receptor (OSCAR), and dendrocyte expressed seven transmembrane protein (DC STAMP). Exposure to LED light likewise significantly decreased RANKL facilitated NF kappa B activity, p38 and ERK phosphorylation and intracellular ROS generation, and increased gene expression of nuclear factor E2 related factor 2 (Nrf2).
   Conclusions: Taken together, the results presented herein show that LED irradiation downregulates osteoclastogenesis by reducing ROS production. Therefore, LED irradiation/LLLT might be useful as an alternative, conservative approach to osteoporosis management. (C) 2015 Wiley Periodicals, Inc.
C1 [Sohn, HongMoon; Ko, Youngjong; Park, Mineon; Kim, Donghwi; Moon, Young Lae; Jeong, Yeon Joo; Lee, Hyeonjun; Lim, Wonbong] Chosun Univ Hosp, Dept Orthopaed Surg, Kwangju 501759, South Korea.
   [Moon, Yeonhee] Chodang Univ, Dept Dent Hyg, Jeollanam Do, South Korea.
   [Jeong, Byung Chul] Chonnam Natl Univ, Sch Dent, Med Res Ctr Biomineralizat Disorders, Kwangju, South Korea.
   [Kim, Okjoon] Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Kwangju, South Korea.
   [Lim, Wonbong] Chosun Univ, Sch Med, Dept Premed Program, Kwangju 501759, South Korea.
C3 Chosun University; Chonnam National University; Chonnam National
   University; Chosun University
RP Lim, W (通讯作者)，Chosun Univ, Sch Med, Dept Premed Program, Kwangju 501759, South Korea.
EM wonbong@chosun.ac.kr
OI Kim, OkJoon/0000 0002 6347 1411; Lee, Hyeonjoon/0000 0002 6423 4514
FU Chosun University
FX Contract grant sponsor: Chosun University.
CR Aihara N, 2006, LASER MED SCI, V21, P24, DOI 10.1007/s10103 005 0368 4
   Akyol UK, 2010, PHOTOMED LASER SURG, V28, P411, DOI 10.1089/pho.2008.2478
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Garavello Freltas I, 2003, J PHOTOCH PHOTOBIO B, V70, P81, DOI 10.1016/S1011 1344(03)00058 7
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   HONMURA A, 1992, LASER SURG MED, V12, P441, DOI 10.1002/lsm.1900120414
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kanzaki H, 2014, FREE RADICAL BIO MED, V77, P239, DOI 10.1016/j.freeradbiomed.2014.09.006
   Kim HH, 2014, J BONE METABOLISM, V21, P269
   Kolamunne RT, 2013, REDOX BIOL, V1, P418, DOI 10.1016/j.redox.2013.08.002
   Lee CH, 2014, J PHARMACOL SCI, V124, P344, DOI 10.1254/jphs.13174FP
   Lee SH, 2013, J NAT PROD, V76, P615, DOI 10.1021/np300824h
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Lim HJ, 2014, LASER MED SCI, V29, P659, DOI 10.1007/s10103 013 1363 9
   Lim WB, 2011, LASER SURG MED, V43, P344, DOI 10.1002/lsm.21038
   Lim W, 2007, LASER SURG MED, V39, P614, DOI 10.1002/lsm.20533
   Lim W, 2013, PHOTOCHEM PHOTOBIOL, V89, P199, DOI 10.1111/j.1751 1097.2012.01225.x
   Lim W, 2012, PHOTOMED LASER SURG, V30, P451, DOI 10.1089/pho.2011.3199
   Lubart R, 2006, PHOTOMED LASER SURG, V24, P179, DOI 10.1089/pho.2006.24.179
   Lucas C, 2003, LASER MED SCI, V18, P72, DOI 10.1007/s10103 003 0259 5
   Volpato LER, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3602850
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Srinivasan S, 2010, ANN NY ACAD SCI, V1192, P245, DOI 10.1111/j.1749 6632.2009.05377.x
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vinck EM, 2003, LASER MED SCI, V18, P95, DOI 10.1007/s10103 003 0262 x
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 38
TC 27
Z9 28
U1 0
U2 6
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0196 8092
EI 1096 9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD NOV
PY 2015
VL 47
IS 9
BP 745
EP 755
DI 10.1002/lsm.22413
PG 11
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology; Surgery
GA CX0JD
UT WOS:000365381800008
PM 26391894
DA 2025 08 17
ER

PT J
AU Cheng, L
   Zhou, SG
   Zhao, Y
   Sun, YQ
   Xu, Z
   Yuan, B
   Chen, XS
AF Cheng, Li
   Zhou, Shenguan
   Zhao, Yin
   Sun, Yanqing
   Xu, Zheng
   Yuan, Bo
   Chen, Xiongsheng
TI Tanshinone IIA attenuates osteoclastogenesis in ovariectomized mice by
   inactivating NF κB and Akt signaling pathways
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Tanshinone IIA; postmenopausal osteoporosis; osteoclastogenesis; RANK
   ligand
ID BONE LOSS; DIFFERENTIATION; INHIBITION; ACTIVATION; EXPRESSION;
   MANAGEMENT; HEALTH; LIGAND; CELLS; MAPK
AB Osteoporosis is a common disease associated with age and menopausal status. Postmenopausal osteoporosis is the most common type of primary osteoporosis and is accompanied by increased risk of osteoporotic fracture. Natural and herbal compounds have long been used to prevent and treat many human diseases. Here, we demonstrated that tanshinone IIA prevented ovariectomy induced bone loss in an in vivo mouse model that closely mimics osteoporosis. In addition, we found that tanshinone IIA inhibited the receptor activator of nuclear factor NF kappa B ligand (RANKL) induced osteoclast differentiation and osteoclastogenesis in vitro. Tanshinone IIA treatment also abrogated RANKL induced activation of the NF kappa B pathway, PI3 kinase/Akt signaling, and the mitogen activated protein kinase (MAPK) pathways, including nuclear translocation of NF kappa B p65 and phosphorylation of I kappa B, extracellular signal regulated kinase (ERK), p38, and Akt. Inactivation of these pathways resulted in deceased expression of osteoclastogenesis related markers. These results suggest that tanshinone IIA, a natural drug, has the potential to treat and prevent bone loss diseases, including postmenopausal osteoporosis.
C1 [Cheng, Li; Zhou, Shenguan; Zhao, Yin; Sun, Yanqing; Xu, Zheng; Yuan, Bo; Chen, Xiongsheng] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthopaed, Spine Ctr, Fengyang Rd 415, Shanghai 200003, Peoples R China.
   [Cheng, Li] Wenzhou Med Univ, Cixi Peoples Hosp, Dept Orthopaed, Cixi 35300, Zhejiang, Peoples R China.
C3 Naval Medical University; Wenzhou Medical University
RP Chen, XS (通讯作者)，Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthopaed, Spine Ctr, Fengyang Rd 415, Shanghai 200003, Peoples R China.
EM cxspine@smmu.edu.cn
RI cheng, li/LIC 1945 2024
FU Shanghai Municipal Science and Technology Commission [16XD1403400]
FX This work was supported by the Major Project of Basic Research of
   Shanghai Municipal Science and Technology Commission (16XD1403400). The
   project leader is Professor Chen Xiongsheng, the communication author of
   the article. Professor Chen is a famous orthopedics expert in our
   country. He works in Shanghai Changzheng Hospital. The amount of funding
   is three hundred thousand yuan. The experiments were performed at Second
   Military Medical University and Wenzhou Medical University.
CR Brenneman SK, 2006, J BONE MINER RES, V21, P809, DOI 10.1359/JBMR.060301
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   GEUSENS P, 2015, RMD OPEN, V1, DOI DOI 10.1136/RMDOPEN 2015 000051265573744632141
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Kim K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020601
   Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109 004 0555 y
   Kwak HB, 2006, EXP MOL MED, V38, P256, DOI 10.1038/emm.2006.31
   Kwak HB, 2008, EUR J PHARMACOL, V601, P30, DOI 10.1016/j.ejphar.2008.10.034
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lecart MP, 2011, EXPERT OPIN PHARMACO, V12, P2533, DOI 10.1517/14656566.2011.618123
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lewiecki EM, 2009, J WOMENS HEALTH, V18, P1615, DOI 10.1089/jwh.2008.1086
   Li DZ, 2014, J BONE MINER METAB, V32, P494, DOI 10.1007/s00774 013 0530 1
   Li SM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16980 4
   Li YH, 2015, BBA GEN SUBJECTS, V1850, P813, DOI 10.1016/j.bbagen.2015.01.007
   Lombardi MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185426
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Park EK, 2004, BIOCHEM BIOPH RES CO, V325, P1472, DOI 10.1016/j.bbrc.2004.10.197
   Porter JL, 2017, STATPEARLS
   Reginster J Y, 2014, Rev Med Liege, V69, P441
   Su CC, 2018, INT J MOL MED, V41, P2389, DOI 10.3892/ijmm.2018.3407
   Tsubaki M, 2007, MOL CELL BIOCHEM, V304, P53, DOI 10.1007/s11010 007 9485 7
   Xu QQ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9852536
   Yang JX, 2016, CELL PHYSIOL BIOCHEM, V40, P195, DOI 10.1159/000452537
   Zhang HY, 2013, CNS NEUROSCI THER, V19, P20, DOI 10.1111/cns.12013
   Zhi X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00022
   Zhou P, 2006, J IMMUNOL, V177, P8777, DOI 10.4049/jimmunol.177.12.8777
   Zhou Yanmeng, 2010, Zhongguo Zhong Yao Za Zhi, V35, P2923
   Zhu J, 2017, EUR J PHARMACOL, V815, P427, DOI 10.1016/j.ejphar.2017.09.047
NR 33
TC 32
Z9 38
U1 1
U2 12
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2018
VL 10
IS 5
BP 1457
EP 1468
PG 12
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GH4GC
UT WOS:000433360300017
PM 29887959
DA 2025 08 17
ER

PT J
AU Platt, C
   Inward, C
   McGraw, M
   Dudley, J
   Tizard, J
   Burren, C
   Saleem, MA
AF Platt, Caroline
   Inward, Carol
   McGraw, Mary
   Dudley, Jan
   Tizard, Jane
   Burren, Christine
   Saleem, Moin A.
TI Middle term use of Cinacalcet in paediatric dialysis patients
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE Calcimimetic; End stage renal failure; Metabolic bone disease;
   Paediatric; Calcium; Phosphate; Parathyroid hormone
ID INTERMITTENT CALCITRIOL THERAPY; SECONDARY HYPERPARATHYROIDISM; RENAL
   OSTEODYSTROPHY; HEMODIALYSIS PATIENTS; VITAMIN D; RECEPTOR; DISEASE;
   GROWTH; CHILDREN; CALCIUM
AB The effects of the calcimimetic drug Cinacalcet were assessed in six children with uncontrolled hyperparathyroidism secondary to stage 5 chronic kidney disease (CKD). Data were collected retrospectively regarding bone biochemistry and medications. Patients were between the ages of 11 months and 14 years on commencing Cinacalcet at initial doses of 0.4 1.4 mg/kg. Treatment, which was well tolerated in the majority and still on going in five patients, was for periods ranging between 3 months and 3 years. All six cases saw at least an 86% reduction in serum parathyroid hormone (PTH). Hypophosphataemia and/or hypocalcaemia were observed in three cases. Overall, achievement of UK Renal Association targets for corrected calcium (Ca), phosphate (P) and the calcium x phosphate product (Ca x P) were unaffected. We conclude that Cinacalcet is an effective treatment for correcting and sustaining correction of uncontrollable PTH levels seen in a difficult group of patients. Importantly, it has allowed the avoidance of parathyroidectomy for a significant time period in all cases. There remain questions about the effect of Cinacalcet on linear growth amongst paediatric dialysis patients, and future studies should aim to address this.
C1 [Platt, Caroline] Royal Hosp Sick Children, Childrens Renal Unit, Bristol BS2 8BJ, Avon, England.
   [Inward, Carol; McGraw, Mary; Dudley, Jan; Tizard, Jane; Burren, Christine; Saleem, Moin A.] Bristol Royal Hosp Children, Bristol, Avon, England.
C3 Bristol Royal Hospital For Children; Bristol Royal Hospital For Children
RP Platt, C (通讯作者)，Royal Hosp Sick Children, Childrens Renal Unit, Upper Maudlin St, Bristol BS2 8BJ, Avon, England.
EM cazardron@doctors.org.uk
RI Burren, Christine/AAE 5845 2019
OI Burren, Christine/0000 0002 3778 2945; Saleem, Moin/0000 0002 9808 4518
CR [Anonymous], CIN TREATM SEC HYP P
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   BROWN EM, 1994, NEPHROL DIAL TRANSPL, V9, P1703
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   D'Haese PC, 2003, KIDNEY INT, V63, pS73, DOI 10.1046/j.1523 1755.63.s85.18.x
   Francisco A, 2008, EXPERT OPIN PHARMACO, V9, P795
   Goldsmith D, 2004, KIDNEY INT, V66, P1315, DOI 10.1111/j.1523 1755.2004.00895.x
   Goodman WG, 2003, PEDIATR NEPHROL, V18, P1206, DOI 10.1007/s00467 003 1290 2
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   Klaus G, 2006, PEDIATR NEPHROL, V21, P151, DOI 10.1007/s00467 005 2082 7
   Kuizon BD, 1998, KIDNEY INT, V53, P205, DOI 10.1046/j.1523 1755.1998.00724.x
   Langman CB, 2005, AM J KIDNEY DIS, V46, pS6, DOI 10.1053/j.ajkd.2005.07.024
   LEFEBVRE A, 1989, KIDNEY INT, V36, P1112, DOI 10.1038/ki.1989.309
   Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Muscheites J, 2008, PEDIATR NEPHROL, V23, P1823, DOI 10.1007/s00467 008 0810 5
   Nakagawa K, 2008, NEPHROL DIAL TRANSPL, V23, P2761, DOI 10.1093/ndt/gfn143
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   Sajid Crockett S, 2008, METABOLISM, V57, P517, DOI 10.1016/j.metabol.2007.11.014
   Salusky IB, 1998, KIDNEY INT, V54, P907, DOI 10.1046/j.1523 1755.1998.00045.x
   Salusky IB, 2001, J AM SOC NEPHROL, V12, P1978, DOI 10.1681/ASN.V1291978
   Silverstein DM, 2008, PEDIATR NEPHROL, V23, P1817, DOI 10.1007/s00467 007 0742 5
   Sterrett JR, 2007, CLIN NEPHROL, V68, P10
   Tasic V, 2005, TURKISH J PEDIATR, V47, P13
   Waller S, 2003, PEDIATR NEPHROL, V18, P1236, DOI 10.1007/s00467 003 1284 0
   Wu SF, 2004, FASEB J, V18, P143, DOI 10.1096/fj.03 0294fje
   2007, PERITONEAL HEAMODIAL
NR 30
TC 27
Z9 30
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0931 041X
EI 1432 198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD JAN
PY 2010
VL 25
IS 1
BP 143
EP 148
DI 10.1007/s00467 009 1294 7
PG 6
WC Pediatrics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Urology & Nephrology
GA 521XX
UT WOS:000271961000017
PM 19838738
DA 2025 08 17
ER

PT J
AU Jinteng, L
   Peitao, X
   Wenhui, Y
   Guiwen, Y
   Feng, Y
   Xiaojun, X
   Zepeng, S
   Jiajie, L
   Yunshu, C
   Zhaoqiang, Z
   Yipeng, Z
   Zhikun, L
   Pei, F
   Qian, C
   Dateng, L
   Zhongyu, X
   Yanfeng, W
   Huiyong, S
AF Jinteng, Li
   Peitao, Xu
   Wenhui, Yu
   Guiwen, Ye
   Feng, Ye
   Xiaojun, Xu
   Zepeng, Su
   Jiajie, Lin
   Yunshu, Che
   Zhaoqiang, Zhang
   Yipeng, Zeng
   Zhikun, Li
   Pei, Feng
   Qian, Cao
   Dateng, Li
   Zhongyu, Xie
   Yanfeng, Wu
   Huiyong, Shen
TI BMAL1 TTK H2Bub1 loop deficiency contributes to impaired BM MSC mediated
   bone formation in senile osteoporosis
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID STEM CELLS; MONOUBIQUITINATION; BMAL1; ALIGNMENT; PLATFORM; THERAPY
AB During the aging process, the reduced osteogenic differentiation of bone marrow mesenchymal stem cells (BM MSCs) results in decreased bone formation, which contributes to senile osteopo rosis. Previous studies have confirmed that interrupted circa dian rhythm plays an indispensable role in age related disease. However, the mechanism underlying the impaired osteogenic differentiation of BM MSCs during aging and its relationship with interrupted circadian rhythm remains unclear. In this study, we confirmed that the circadian rhythm was interrupted in aging mouse skeletal systems. The level of the core rhythm component BMAL1 but not that of CLOCK in the osteoblast lineage was decreased in senile osteoporotic specimens from both human and mouse. BMAL1 targeted TTK as a circadian  controlled gene to phosphorylate MDM2 and regulate H2Bub1 level, while H2Bub1 in turn regulated the expression of BMAL1. The osteogenic capacity of BM MSCs was maintained by a positive loop formed by BMAL1 TTK MDM2 H2Bub1. Furthermore, we demonstrated that using bone targeting re combinant adeno associated virus 9 (rAAV9) to enhance Bmal1 or Ttk might have a therapeutic effect on senile osteopo rosis and delays bone repair in aging mice. In summary, our study indicated that targeting the BMAL1 TTK MDM2 H2Bub1 axis via bone targeting rAAV9 might be a promising strategy for the treatment of senile osteoporosis.
C1 [Jinteng, Li; Peitao, Xu; Wenhui, Yu; Guiwen, Ye; Feng, Ye; Xiaojun, Xu; Zepeng, Su; Jiajie, Lin; Yunshu, Che; Zhaoqiang, Zhang; Yipeng, Zeng; Zhikun, Li; Zhongyu, Xie; Huiyong, Shen] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, Shenzhen 518003, Peoples R China.
   [Pei, Feng; Qian, Cao; Yanfeng, Wu] Sun Yat Sen Univ, Affiliated Hosp 8, Ctr Biotherapy, Shenzhen 518003, Peoples R China.
   [Dateng, Li] Southern Methodist Univ, Dept Stat Sci, Dallas, TX USA.
C3 Sun Yat Sen University; Sun Yat Sen University; Southern Methodist
   University
RP Zhongyu, X; Huiyong, S (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, Shenzhen 518003, Peoples R China.; Yanfeng, W (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 8, Ctr Biotherapy, Shenzhen 518003, Peoples R China.
EM xiezhy23@mail.sysu.edu.cn; wuyf@mail.sysu.edu.cn;
   shenhuiy@mail.sysu.edu.cn
RI Yu, Wenhui/MIP 9844 2025
FU Shenzhen Key Medical Discipline Construction Fund [82172385]; National
   Natu  ral Science Foundation of China [82172349, 82002267,
   RCBS20200714114909007]; Shenzhen Science and Technology Program
   [JCYJ20210324115007019];  [ZDSYS20190902092851024]
FX ACKNOWLEDGMENTS This study was supported by the Shenzhen Key Medical
   Discipline Construction Fund (ZDSYS20190902092851024) , the National
   Natu  ral Science Foundation of China (82172385, 82172349, and 82002267)
   , and the Shenzhen Science and Technology Program (RCBS20200714114909007
   and JCYJ20210324115007019) .
CR Allada R, 2021, NEW ENGL J MED, V384, P550, DOI 10.1056/NEJMra1802337
   Berson A, 2018, TRENDS NEUROSCI, V41, P587, DOI 10.1016/j.tins.2018.05.005
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Dudek M, 2016, J CLIN INVEST, V126, P365, DOI 10.1172/JCI82755
   Fang Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03815 4
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Hung FY, 2018, NUCLEIC ACIDS RES, V46, P10669, DOI 10.1093/nar/gky749
   Jacobi D, 2015, CELL METAB, V22, P709, DOI 10.1016/j.cmet.2015.08.006
   Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee JH, 2022, J INTEGR MED JIM, V20, P83, DOI 10.1016/j.joim.2021.11.003
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576 019 0205 4
   Li GC, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28990 6
   Li JT, 2019, CELL DEATH DIFFER, V26, P2652, DOI 10.1038/s41418 019 0328 3
   Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025
   Longo VD, 2016, CELL METAB, V23, P1048, DOI 10.1016/j.cmet.2016.06.001
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Najafova Z, 2021, CELL DEATH DIFFER, V28, P700, DOI 10.1038/s41418 020 00614 w
   Olivos DJ, 2018, J CELL BIOCHEM, V119, P8830, DOI 10.1002/jcb.27133
   Patke A, 2020, NAT REV MOL CELL BIO, V21, P67, DOI 10.1038/s41580 019 0179 2
   Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029
   Ramírez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Samoilova EM, 2021, J PERS MED, V11, DOI 10.3390/jpm11111050
   Samsa WE, 2016, BONE, V84, P194, DOI 10.1016/j.bone.2016.01.006
   Sancar A, 2021, SCIENCE, V371, P42, DOI 10.1126/science.abb0738
   Sato S, 2017, CELL, V170, P664, DOI 10.1016/j.cell.2017.07.042
   Song QX, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1777 1
   Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150
   Tamayo AG, 2015, NAT STRUCT MOL BIOL, V22, P759, DOI 10.1038/nsmb.3076
   Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020
   Ulgherait M, 2021, NATURE, V598, P353, DOI 10.1038/s41586 021 03934 0
   Von Bank H, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101259
   Wagner HJ, 2021, ADV SCI, V8, DOI 10.1002/advs.202004018
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573 019 0012 9
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yu ZC, 2016, NUCLEIC ACIDS RES, V44, P1133, DOI 10.1093/nar/gkv1173
   Yuan GS, 2017, J BONE MINER RES, V32, P861, DOI 10.1002/jbmr.3046
   Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024
   Zhang WQ, 2018, CIRC RES, V123, P773, DOI 10.1161/CIRCRESAHA.118.312497
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
   Zhao ZY, 2020, ADV SCI, V7, DOI 10.1002/advs.202002680
   Zheng QY, 2021, MOL THER METH CLIN D, V22, P293, DOI 10.1016/j.omtm.2021.06.009
NR 52
TC 6
Z9 8
U1 14
U2 37
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD MAR 14
PY 2023
VL 31
BP 568
EP 585
DI 10.1016/j.omtn.2023.02.014
EA FEB 2023
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA Q6FW5
UT WOS:001058470600001
PM 36910712
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, H
   Jin, WW
   Fu, CH
   Dai, PF
   Yu, YT
   Huo, Q
   Yu, LJ
AF Liu, Hao
   Jin, Wenwen
   Fu, Chunhua
   Dai, Penfei
   Yu, Yuantao
   Huo, Qin
   Yu, Longjiang
TI Discovering anti osteoporosis constituents of maca (Lepidium
   meyenii) by combined virtual screening and activity verification
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE Lepidium meyenii; Osteoporosis; Macamide; Virtual screening; Activity
   verification
ID OSTEOBLASTIC MC3T3 E1 CELLS; ESTROGEN RECEPTOR ALPHA; MOUSE
   CEREBRAL CORTEX; ENDOCANNABINOID SYSTEM; POSTMENOPAUSAL WOMEN; FLEXIBLE
   DOCKING; HORMONE LEVELS; FEMALE RATS; BONE; EXPRESSION
AB Maca (Lepidium meyenii Walp.) is a traditional medicine and nutritional supplement from South America with many pharmacological effects, such as enhancing female and male fertility, improving sexual dysfunction, preventing osteoporosis and relieving menopausal syndrome. Until now, the active principles behind most of these effects have not been clarified, severely hindering the exploitation and application of maca products. In this study, the effective anti osteoporotic components of maca are uncovered. Through virtual screening against estrogen receptor and verification of pharmacological activity on osteoblasts, we found that N benzylpalmitamide is an active constituent of maca in preventing osteoporosis. As well, N benzyl palmitamide promotes osteoblast proliferation, differentiation and mineralization, plus it benefits bone formation through enhanced expression of osteogenesis related genes, such as bone morphogenetic protein 2, core binding factor alpha 1, type 1 collagen and alkaline phosphatase. The effects of N benzyl palmitamide on enhanced bone formation are very likely through the estrogen receptor pathway, as N benzyl palmitamide also increases the expression of ER alpha and ER beta genes. Clarifying single component biological activity will greatly enable exploitation and application of maca as a medication and health supplement to prevent osteoporosis. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Liu, Hao; Jin, Wenwen; Fu, Chunhua; Dai, Penfei; Yu, Yuantao; Huo, Qin; Yu, Longjiang] Huazhong Univ Sci & Technol, Inst Resource Biol & Biotechnol, Dept Biotechnol, Coll Life Sci & Technol, Wuhan 430074, Peoples R China.
   [Jin, Wenwen; Fu, Chunhua; Yu, Longjiang] Minist Educ, Key Lab Mol Biophys, Wuhan 430074, Peoples R China.
   [Jin, Wenwen; Dai, Penfei; Yu, Yuantao; Yu, Longjiang] Wuhan Inst Biotechnol, Wuhan Huashite Ind Biotechnol Dev Co Ltd, Wuhan 430075, Peoples R China.
C3 Huazhong University of Science & Technology
RP Jin, WW (通讯作者)，Huazhong Univ Sci & Technol, Inst Resource Biol & Biotechnol, Dept Biotechnol, Coll Life Sci & Technol, 1037 Luoyu Rd, Wuhan 430074, Peoples R China.
EM jww@hust.edu.cn; yulongjiang@hust.edu.cn
FU National Natural Science Foundation of China [J1103514]; Nature Science
   Foundation of Hubei Province [2012FFB02607]; Independent Innovation
   Research Foundation of Huazhong University of Science and Technology
   [2015TS091]
FX This work was supported by National Natural Science Foundation of China
   (Grant NoJ1103514), Nature Science Foundation of Hubei Province (No.
   2012FFB02607), Independent Innovation Research Foundation of Huazhong
   University of Science and Technology (No. 2015TS091). The authors are
   grateful to Ms. Gu of Analytical and Testing Centre of Huazhong
   University of Science and Technology for her valuable analysis.
CR Bab I, 2008, BRIT J PHARMACOL, V153, P182, DOI 10.1038/sj.bjp.0707593
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Brooks NA, 2008, MENOPAUSE, V15, P1157, DOI 10.1097/gme.0b013e3181732953
   Choi EM, 2012, INFLAMMATION, V35, P1204, DOI 10.1007/s10753 012 9430 0
   Clément C, 2010, AGRON J, V102, P431, DOI 10.2134/agronj2009.0315
   Cui BL, 2003, J NAT PROD, V66, P1101, DOI 10.1021/np030031i
   DiGirolamo DJ, 2007, J BIOL CHEM, V282, P31666, DOI 10.1074/jbc.M705219200
   Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450
   Farina EK, 2011, AM J CLIN NUTR, V93, P1142, DOI 10.3945/ajcn.110.005926
   Gonzales C, 2010, FORSCH KOMPLEMENTMED, V17, P137, DOI 10.1159/000315214
   Gonzales G.F., 2012, EVID BASED COMPL ALT, V18, P72
   Gonzales GF, 2003, J ENDOCRINOL, V176, P163, DOI 10.1677/joe.0.1760163
   Hajdu Z, 2014, J NAT PROD, V77, P1663, DOI 10.1021/np500292g
   Harvey N, 2014, J BONE MINER RES, V29, P1917, DOI 10.1002/jbmr.2286
   Herman AP, 2013, CURR OPIN PHARMACOL, V13, P435, DOI 10.1016/j.coph.2013.02.002
   Idris Aymen I, 2012, Front Endocrinol (Lausanne), V3, P136, DOI 10.3389/fendo.2012.00136
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Kono R, 2011, BIOSCI BIOTECH BIOCH, V75, P1907, DOI 10.1271/bbb.110264
   Krane SM, 2005, J EXP MED, V201, P841, DOI 10.1084/jem.20050354
   Lee MS, 2011, MATURITAS, V70, P227, DOI 10.1016/j.maturitas.2011.07.017
   Li GY, 2001, ECON BOT, V55, P255, DOI 10.1007/BF02864563
   Lóránd T, 2010, CURR MED CHEM, V17, P3542, DOI 10.2174/092986710792927813
   McCollom MM, 2005, PHYTOCHEM ANALYSIS, V16, P463, DOI 10.1002/pca.871
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muhammad I, 2002, PHYTOCHEMISTRY, V59, P105, DOI 10.1016/S0031 9422(01)00395 8
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411
   Poluzzi E, 2014, CURR MED CHEM, V21, P417
   Pomatto V, 2011, GEN COMP ENDOCR, V174, P30, DOI 10.1016/j.ygcen.2011.08.001
   Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477
   Reid IR, 2013, EUR J INTERN MED, V24, P691, DOI 10.1016/j.ejim.2013.03.012
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rollinger JM, 2005, PLANTA MED, V71, P399, DOI 10.1055/s 2005 864132
   Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sharma PK, 2006, NEUROBIOL AGING, V27, P880, DOI 10.1016/j.neurobiolaging.2005.04.003
   Shen CL, 2008, OSTEOPOROSIS INT, V19, P979, DOI 10.1007/s00198 007 0527 5
   Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Thakur MK, 2007, NEUROCHEM INT, V50, P314, DOI 10.1016/j.neuint.2006.08.019
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Uchiyama F, 2014, J ETHNOPHARMACOL, V151, P897, DOI 10.1016/j.jep.2013.11.058
   Vajdos FF, 2007, PROTEIN SCI, V16, P897, DOI 10.1110/ps.062729207
   Valentová K, 2006, CELL BIOL TOXICOL, V22, P91, DOI 10.1007/s10565 006 0033 0
   Viereck V, 2002, J CELL BIOCHEM, V86, P348, DOI 10.1002/jcb.10220
   Wärnmark A, 2002, J BIOL CHEM, V277, P21862, DOI 10.1074/jbc.M200764200
   Wu H, 2013, BIOORGAN MED CHEM, V21, P5188, DOI 10.1016/j.bmc.2013.06.034
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhang YZ, 2014, INDIAN J PHARMACOL, V46, P416, DOI 10.4103/0253 7613.135955
   Zhang YZ, 2006, J ETHNOPHARMACOL, V105, P274, DOI 10.1016/j.jep.2005.12.013
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
NR 55
TC 32
Z9 37
U1 0
U2 68
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0963 9969
EI 1873 7145
J9 FOOD RES INT
JI Food Res. Int.
PD NOV
PY 2015
VL 77
SI SI
BP 215
EP 220
DI 10.1016/j.foodres.2015.06.028
PN 2
PG 6
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA CZ9HY
UT WOS:000367409900017
DA 2025 08 17
ER

PT J
AU D'Arcy, P
   Maruwge, W
   Wolahan, B
   Ma, LM
   Brodin, B
AF D'Arcy, Padraig
   Maruwge, Wessen
   Wolahan, Barry
   Ma, Limin
   Brodin, Bertha
TI Oncogenic Functions of the Cancer Testis Antigen SSX on the
   Proliferation, Survival, and Signaling Pathways of Cancer Cells
SO PLOS ONE
LA English
DT Article
ID SYT; EXPRESSION; GENES; PROTEINS; FUSION; IDENTIFICATION; CATENIN
AB SSX is a transcription factor with elusive oncogenic functions expressed in a variety of human tumors of epithelial and mesenchymal origin. It has raised substantial interest as a target for cancer therapy since it elicits humoral responses and displays restricted expression to cancer, spermatogonia and mesenchymal stem cells. Here, we investigated the oncogenic properties of SSX by employing a RNA interference to knock down the endogenous expression of SSX in melanoma and osteosarcoma cell lines. Depletion of SSX expression resulted in reduced proliferation with cells accumulating in the G1 phase of the cell cycle. We found that the growth promoting and survival properties of SSX are mediated in part though modulation of MAPK/Erk and Wnt signaling pathways, since SSX silencing inhibited Erk mediated signaling and transcription of cMYC and Akt 1. We also found that SSX forms a transient complex with beta catenin at the G1 S phase boundary resulting in the altered expression of beta catenin target genes such as E cadherin, snail 2 and vimentin, involved in epithelial mesenchymal transitions. Importantly the silencing of SSX expression in in vivo significantly impaired the growth of melanoma tumor xenografts. Tumor biopsies from SSX silenced tumors displayed reduced cyclin A staining, indicative of low proliferation and predominantly cycloplasmic beta catenin compared to SSX expressing tumors. The present study demonstrates a previously unknown function of SSX, that as an oncogene and as a tumor target for the development of novel anti cancer drugs.
C1 [D'Arcy, Padraig; Maruwge, Wessen; Wolahan, Barry; Ma, Limin; Brodin, Bertha] Canc Ctr Karolinska, Dept Oncol Pathol, Stockholm, Sweden.
C3 Karolinska Institutet
RP Brodin, B (通讯作者)，Canc Ctr Karolinska, Dept Oncol Pathol, Stockholm, Sweden.
EM Bertha.Brodin@.ki.se
RI ; D'Arcy, Pádraig/F 7633 2018; D'Arcy, Padraig/F 7633 2018; Brodin,
   Bertha/JCN 8339 2023
OI Brodin, Bertha/0000 0003 0551 7976; D'Arcy, Padraig/0000 0001 6671 7600;
   
FU Swedish Children Cancer Foundation; Lillian Sagens och Curt Ericssons
   Forskningsstiftelse; Stockholm Cancer Foundation
FX This work was supported by grants from the Swedish Children Cancer
   Foundation, the Lillian Sagens och Curt Ericssons Forskningsstiftelse,
   and the Stockholm Cancer Foundation to Bertha Brodin. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ayyoub M, 2002, J IMMUNOL, V168, P1717, DOI 10.4049/jimmunol.168.4.1717
   Caballero OL, 2013, ONCOTARGET, V4, P531, DOI 10.18632/oncotarget.921
   Chen L, 2012, INT J ONCOL, V40, P1986, DOI 10.3892/ijo.2012.1369
   CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894 502
   CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460 2075.1995.tb07228.x
   Cronwright G, 2005, CANCER RES, V65, P2207, DOI 10.1158/0008 5472.CAN 04 1882
   Cuffel C, 2011, INT J CANCER, V128, P2625, DOI 10.1002/ijc.25607
   de Bruijn DRH, 2008, ONCOGENE, V27, P653, DOI 10.1038/sj.onc.1210688
   dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813
   dos Santos NR, 2000, CANCER RES, V60, P1654
   dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549
   Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007
   FOGH J, 1977, JNCI J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221
   Gure AO TO, 1987, INT J CANCER, V72, P965
   Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200
   Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122
   Lim J, 2011, J PATHOL, V224, P473, DOI 10.1002/path.2919
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Neumann F, 2011, CANCER IMMUNOL IMMUN, V60, P1333, DOI 10.1007/s00262 011 1030 6
   Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413
   SalazarOnfray F, 1997, CANCER RES, V57, P4348
   Scanlan Matthew J, 2004, Cancer Immun, V4, P1
   Smith HA, 2011, CANCER RES, V71, P6785, DOI 10.1158/0008 5472.CAN 11 2127
   Smith HA, 2011, J IMMUNOTHER, V34, P569, DOI 10.1097/CJI.0b013e31822b5b1d
   Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613
   Taylor BJ, 2005, J IMMUNOTHER, V28, P564, DOI 10.1097/01.cji.0000175685.36239.e5
   Türeci Ö, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097 0215(19980703)77:1<19::AID IJC4>3.0.CO;2 2
NR 27
TC 40
Z9 40
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2014
VL 9
IS 4
AR e95136
DI 10.1371/journal.pone.0095136
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AL1WP
UT WOS:000338917300008
PM 24787708
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Gioia, R
   Tonelli, F
   Ceppi, I
   Biggiogera, M
   Leikin, S
   Fisher, S
   Tenedini, E
   Yorgan, TA
   Schinke, T
   Tian, K
   Schwartz, JM
   Forte, F
   Wagener, R
   Villani, S
   Rossi, A
   Forlino, A
AF Gioia, Roberta
   Tonelli, Francesca
   Ceppi, Ilaria
   Biggiogera, Marco
   Leikin, Sergey
   Fisher, Shannon
   Tenedini, Elena
   Yorgan, Timur A.
   Schinke, Thorsten
   Tian, Kun
   Schwartz, Jean Marc
   Forte, Fabiana
   Wagener, Raimund
   Villani, Simona
   Rossi, Antonio
   Forlino, Antonella
TI The chaperone activity of 4PBA ameliorates the skeletal phenotype of
   Chihuahua, a zebrafish model for dominant osteogenesis imperfecta
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID IV MOUSE MODEL; ENDOPLASMIC RETICULUM; MURINE MODEL; MISFOLDED
   PROCOLLAGEN; COLLAGEN; BONE; STRESS; PROTEIN; GENOME; LETHAL
AB Classical osteogenesis imperfecta (OI) is a bone disease caused by type I collagen mutations and characterized by bone fragility, frequent fractures in absence of trauma and growth deficiency. No definitive cure is available for OI and to develop novel drug therapies, taking advantage of a repositioning strategy, the small teleost zebrafish (Danio rerio) is a particularly appealing model. Its small size, high proliferative rate, embryo transparency and small amount of drug required make zebrafish the model of choice for drug screening studies, when a valid disease model is available. We performed a deep characterization of the zebrafish mutant Chihuahua, that carries a G574D (p.G736D) substitution in the alpha 1 chain of type I collagen. We successfully validated it as a model for classical OI. Growth of mutants was delayed compared with WT. X ray, mCT, alizarin red/alcian blue and calcein staining revealed severe skeletal deformity, presence of fractures and delayed mineralization. Type I collagen extracted from different tissues showed abnormal electrophoretic migration and low melting temperature. The presence of endoplasmic reticulum (ER) enlargement due to mutant collagen retention in osteoblasts and fibroblasts of mutant fish was shown by electron and confocal microscopy. Two chemical chaperones, 4PBA and TUDCA, were used to ameliorate the cellular stress and indeed 4PBA ameliorated bone mineralization in larvae and skeletal deformities in adult, mainly acting on reducing ER cisternae size and favoring collagen secretion. In conclusion, our data demonstrated that ER stress is a novel target to ameliorate OI phenotype; chemical chaperones such as 4PBA may be, alone or in combination, a new class of molecules to be further investigated for OI treatment.
C1 [Gioia, Roberta; Tonelli, Francesca; Ceppi, Ilaria; Rossi, Antonio; Forlino, Antonella] Univ Pavia, Dept Mol Med, Biochem Unit, Via Taramelli 3 B, I 27100 Pavia, Italy.
   [Biggiogera, Marco] Univ Pavia, Dept Biol & Biotechnol, Pavia, Italy.
   [Leikin, Sergey] Eunice Kennedy Shriver NICHD, Sect Phys Biochem, NIH, Bethesda, MD USA.
   [Fisher, Shannon] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.
   [Tenedini, Elena] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Ctr Genome Res, Modena, Italy.
   [Yorgan, Timur A.; Schinke, Thorsten] Univ Hamburg, Inst Osteol & Biomech, Ctr Med Expt, Hamburg, Germany.
   [Tian, Kun; Schwartz, Jean Marc] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Forte, Fabiana; Wagener, Raimund] Univ Cologne, Fac Med, Ctr Biochem, Ctr Mol Med, Cologne, Germany.
   [Villani, Simona] Univ Pavia, Dept Publ Hlth & Expt & Forens Med, Unit Biostat & Clin Epidemiol, Pavia, Italy.
C3 University of Pavia; University of Pavia; National Institutes of Health
   (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Boston University; Universita di
   Modena e Reggio Emilia; University of Hamburg; University of Manchester;
   University of Cologne; University of Pavia
RP Forlino, A (通讯作者)，Univ Pavia, Dept Mol Med, Biochem Unit, Via Taramelli 3 B, I 27100 Pavia, Italy.
EM aforlino@unipv.it
RI ; Leikin, Sergey/A 5518 2008; Tonelli, Francesca/AAJ 5858 2021; Rossi,
   Antonio/E 9935 2012; Biggiogera, Marco/AAH 3543 2019; Villani,
   Simona/HSH 3595 2023; Schwartz, Jean Marc/AAS 8274 2020; tenedini,
   elena/ABB 3411 2020
OI Ceppi, Ilaria/0000 0001 6496 8983; Leikin, Sergey/0000 0001 7095 0739;
   /0000 0003 2517 6515; TENEDINI, Elena/0000 0003 0285 765X; Schwartz,
   Jean Marc/0000 0002 6472 0184; Tonelli, Francesca/0000 0002 2111 917X; 
FU Fondazione Cariplo [20130612]; Telethon [GGP13098]; European Community,
   FP7, 'Sybil' project [602300]; Fondazione Telethon
FX The work was supported by Fondazione Cariplo (grant No. 20130612),
   Telethon (grant No. GGP13098) and the European Community, FP7, 'Sybil'
   project (grant No. 602300). Funding to pay the Open Access publication
   charges for this article was provided by Fondazione Telethon.
CR Besio R, 2015, Adv. Regen. Biol, V2, P27964, DOI DOI 10.3402/ARB.V2.27964
   Bianchi L, 2015, HUM MOL GENET, V24, P6118, DOI 10.1093/hmg/ddv328
   Bianchi L, 2012, J PROTEOMICS, V75, P4717, DOI 10.1016/j.jprot.2012.01.038
   Blum M, 2015, DEV CELL, V35, P145, DOI 10.1016/j.devcel.2015.09.017
   Boot Handford RP, 2010, CELL TISSUE RES, V339, P197, DOI 10.1007/s00441 009 0877 8
   Braasch I, 2016, NAT GENET, V48, P427, DOI 10.1038/ng.3526
   Briggs MD, 2015, EXPERT OPIN ORPHAN D, V3, P1137, DOI 10.1517/21678707.2015.1083853
   Chen F, 2014, J BONE MINER RES, V29, P1412, DOI 10.1002/jbmr.2177
   Cho SY, 2015, HUM MUTAT, V36, P191, DOI 10.1002/humu.22731
   Cortez L, 2014, PRION, V8, P197, DOI 10.4161/pri.28938
   Coulon SM, 2012, EAT BEHAV, V13, P42, DOI 10.1016/j.eatbeh.2011.09.003
   Daley E, 2010, J BONE MINER RES, V25, P247, DOI 10.1359/jbmr.090720
   de Almeida SF, 2007, J BIOL CHEM, V282, P27905, DOI 10.1074/jbc.M702672200
   Duran I, 2015, GENE EXPR PATTERNS, V19, P60, DOI 10.1016/j.gep.2015.07.004
   Durán I, 2011, DEV BIOL, V354, P160, DOI 10.1016/j.ydbio.2011.03.014
   Fass DM, 2011, ACS MED CHEM LETT, V2, P39, DOI 10.1021/ml1001954
   Fisher S, 2003, DEV BIOL, V264, P64, DOI 10.1016/S0012 1606(03)00399 3
   Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952
   Fleming A, 2004, DEVELOPMENT, V131, P873, DOI 10.1242/dev.00952
   Flicek P, 2014, NUCLEIC ACIDS RES, V42, pD749, DOI 10.1093/nar/gkt1196
   Forlino A, 1999, J BIOL CHEM, V274, P37923, DOI 10.1074/jbc.274.53.37923
   Forlino A, 2007, MATRIX BIOL, V26, P604, DOI 10.1016/j.matbio.2007.06.005
   Forlino A, 2007, PROTEOMICS, V7, P1877, DOI 10.1002/pmic.200600919
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Garbes L, 2015, AM J HUM GENET, V96, P432, DOI 10.1016/j.ajhg.2015.01.002
   Gioia R, 2012, STEM CELLS, V30, P1465, DOI 10.1002/stem.1107
   Gistelinck C, 2016, SCI REP UK, V6, DOI 10.1038/srep21540
   Gistelinck C, 2016, J BONE MINER RES, V31, P1930, DOI 10.1002/jbmr.2977
   Gonzales APW, 2014, METHOD ENZYMOL, V546, P377, DOI 10.1016/B978 0 12 801185 0.00018 0
   Gorman KF, 2007, COMP BIOCHEM PHYS C, V145, P28, DOI 10.1016/j.cbpc.2006.10.004
   Gray RS, 2014, DEV BIOL, V386, P72, DOI 10.1016/j.ydbio.2013.11.028
   Huang CC, 2009, DEV BIOL, V332, P360, DOI 10.1016/j.ydbio.2009.06.003
   Iannitti T, 2011, DRUGS R&D, V11, P227, DOI 10.2165/11591280 000000000 00000
   Ishida Y, 2009, AUTOPHAGY, V5, P1217, DOI 10.4161/auto.5.8.10168
   Ishida Y, 2009, MOL BIOL CELL, V20, P2744, DOI 10.1091/mbc.E08 11 1092
   Ishikawa Y, 2016, P NATL ACAD SCI USA, V113, pE6036, DOI 10.1073/pnas.1609571113
   Ishikawa Y, 2013, BBA MOL CELL RES, V1833, P2479, DOI 10.1016/j.bbamcr.2013.04.008
   Ito S, 2017, SEMIN CELL DEV BIOL, V62, P142, DOI 10.1016/j.semcdb.2016.11.005
   Kamoun Goldrat AS, 2007, J BONE MINER METAB, V25, P211, DOI 10.1007/s00774 007 0750 3
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Li N, 2009, DEV DYNAM, V238, P459, DOI 10.1002/dvdy.21838
   Lin YY, 2011, HUM MOL GENET, V20, P1763, DOI 10.1093/hmg/ddr059
   Lindahl K, 2013, INT J MED SCI, V10, P1333, DOI 10.7150/ijms.5774
   Lisse TS, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040007
   Luo T, 2015, CHEM BIOL INTERACT, V242, P99, DOI 10.1016/j.cbi.2015.09.025
   MacRae CA, 2015, NAT REV DRUG DISCOV, V14, P721, DOI 10.1038/nrd4627
   Makareeva E, 2008, J BIOL CHEM, V283, P4787, DOI 10.1074/jbc.M705773200
   Makareeva E, 2011, TRENDS CELL BIOL, V21, P168, DOI 10.1016/j.tcb.2010.11.007
   Marlowe A, 2002, J MED GENET, V39, P382, DOI 10.1136/jmg.39.6.382
   Matoori S, 2015, ADV DRUG DELIVER REV, V90, P55, DOI 10.1016/j.addr.2015.04.009
   Mertz EL, 2016, MATRIX BIOL, V52 54, P29, DOI 10.1016/j.matbio.2016.03.005
   Mirigian LS, 2016, J BONE MINER RES, V31, P1608, DOI 10.1002/jbmr.2824
   Moro E, 2013, MOL GENET GENOMICS, V288, P231, DOI 10.1007/s00438 013 0750 z
   Morvan Dubois G, 2003, J MOL EVOL, V57, P501, DOI 10.1007/s00239 003 2502 x
   Nosengo N, 2016, NATURE, V534, P314, DOI 10.1038/534314a
   Parichy DM, 2009, DEV DYNAM, V238, P2975, DOI 10.1002/dvdy.22113
   Potnuru P, 2020, CUREUS J MED SCIENCE, V12, DOI [10.1038/nature12111, 10.7759/cureus.11549]
   Rousseau J, 2014, EUR J HUM GENET, V22, P667, DOI 10.1038/ejhg.2013.198
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Shapiro Jr, 2014, OSTEOGENESIS IMPERFECTA: A TRANSLATIONAL APPROACH TO BRITTLE BONE DISEASE, P1
   Shen Bin, 2007, Chin J Traumatol, V10, P360
   Trendowski M, 2014, IN VIVO, V28, P1021
   Vang Sheila, 2014, Glob Adv Health Med, V3, P58, DOI 10.7453/gahmj.2014.017
   Wagner Martin, 2016, F1000Res, V5, DOI 10.12688/f1000research.8012.1
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Weigele J, 2016, J ANAT, V229, P92, DOI 10.1111/joa.12480
   WOOD A, 1984, J CELL SCI, V66, P205
   WOOD A, 1982, ANAT RECORD, V204, P349, DOI 10.1002/ar.1092040408
NR 70
TC 66
Z9 69
U1 2
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
EI 1460 2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2017
VL 26
IS 15
BP 2897
EP 2911
DI 10.1093/hmg/ddx171
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FA8PA
UT WOS:000405706800008
PM 28475764
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Adler, RA
AF Adler, Robert A.
TI Update on osteoporosis in men
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE osteoporosis; men; fracture; bisphosphonates; denosumab; teriparatide
ID BONE MINERAL DENSITY; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HIP FRACTURE;
   OLDER MEN; VERTEBRAL FRACTURES; ANDROGEN DEPRIVATION; ANTIRESORPTIVE
   THERAPY; SECONDARY OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; TESTOSTERONE
   LEVELS
AB Osteoporosis in men remains under diagnosed and under appreciated. After a low trauma fracture, a man is less likely to have evaluation and treatment. The lifetime risk for osteoporotic fracture in older men may range from 13 to 25%, and as men live longer, there will be more fractures. Newer strategies for determining which men should have bone density testing are emerging. Information from observational studies are providing insights that allow targeted testing and treatment of those men at the highest risk for fracture. Treatment with most of the same medications used in women is efficacious and generally safe. Nonetheless, the fear of side effects of treatments for an asymptomatic disorder (before a fracture) and other barriers have made management challenging in men at risk for fracture. This review provides updates on epidemiology, pathophysiology, evaluation and treatment of male osteoporosis. Published by Elsevier Ltd.
C1 [Adler, Robert A.] McGuire Vet Affairs Med Ctr, Endocrinol & Metab Sect, Endocrinol & Metab, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.
   [Adler, Robert A.] McGuire Vet Affairs Med Ctr, Endocrinol & Metab Sect, Internal Med, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.
   [Adler, Robert A.] Virginia Commonwealth Univ, Sch Med, Div Endocrine, Endocrinol & Metab, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Adler, Robert A.] Virginia Commonwealth Univ, Sch Med, Div Endocrine, Internal Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Adler, Robert A.] McGuire Vet Affairs Med Ctr, Endocrinol & Metab Sect, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.
C3 Hunter Holmes McGuire Veterinary Affairs Medical Center; Hunter Holmes
   McGuire Veterinary Affairs Medical Center; Virginia Commonwealth
   University; Virginia Commonwealth University; Hunter Holmes McGuire
   Veterinary Affairs Medical Center
RP Adler, RA (通讯作者)，McGuire Vet Affairs Med Ctr, Endocrinol & Metab Sect, Endocrinol & Metab, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.; Adler, RA (通讯作者)，McGuire Vet Affairs Med Ctr, Endocrinol & Metab Sect, Internal Med, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.; Adler, RA (通讯作者)，Virginia Commonwealth Univ, Sch Med, Div Endocrine, Endocrinol & Metab, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Adler, RA (通讯作者)，Virginia Commonwealth Univ, Sch Med, Div Endocrine, Internal Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Adler, RA (通讯作者)，McGuire Vet Affairs Med Ctr, Endocrinol & Metab Sect, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.
EM Robert.adler@va.gov
CR Abrahamsen B, 2016, BMJ BRIT MED J, V353, DOI 10.1136/bmj.i3365
   Adler RA, 2011, J ENDOCRINOL INVEST, V34, P481, DOI [10.1007/BF03346716, 10.3275/7753]
   Adler RA, 2018, EUR J ENDOCRINOL, V178, pR81, DOI 10.1530/EJE 17 1002
   Adler RA, 2016, ENDOCRINE, V51, P222, DOI 10.1007/s12020 015 0748 x
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Adler RA, 2011, THER ADV MUSCULOSKEL, V3, P191, DOI 10.1177/1759720X11411600
   Adler RA, 2012, CLIN BIOCHEM, V45, P894, DOI 10.1016/j.clinbiochem.2012.01.024
   Ahmed LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107695
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   [Anonymous], 2017, BMJ BRIT MED J, DOI DOI 10.1136/BMJ.J1415
   Antonio L, 2016, J CLIN ENDOCR METAB, V101, P2647, DOI 10.1210/jc.2015 4106
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bliuc D, 2016, CURR OPIN RHEUMATOL, V28, P413, DOI 10.1097/BOR.0000000000000300
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boonen S, 2012, NEW ENGL J MED, V367, P1714, DOI 10.1056/NEJMoa1204061
   Bruder JM, 2006, UROLOGY, V67, P152, DOI 10.1016/j.urology.2005.07.017
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Calonge N, 2011, ANN INTERN MED, V154, P356, DOI 10.7326/0003 4819 154 5 201103010 00307
   Cauley JA, 2016, J BONE MINER RES, V31, P1810, DOI 10.1002/jbmr.2836
   Cawthon PM, 2016, THER ADV MUSCULOSKEL, V8, P15, DOI 10.1177/1759720X15621227
   Chaganti RK, 2010, OSTEOPOROSIS INT, V21, P1307, DOI 10.1007/s00198 009 1105 9
   Clynes MA, 2015, CALCIFIED TISSUE INT, V97, P445, DOI 10.1007/s00223 015 0044 z
   Colon Emeric C, 2017, J BONE MINER RES  S1, V32
   Crandall CJ, 2014, ANN INTERN MED, V161, P711, DOI 10.7326/M14 0317
   Diem SJ, 2017, J GEN INTERN MED, V32, P1235, DOI 10.1007/s11606 017 4153 4
   Ensrud KE, 2014, BMJ BRIT MED J, V349, DOI 10.1136/bmj.g4120
   Ettinger B, 2013, OSTEOPOROSIS INT, V24, P1185, DOI 10.1007/s00198 012 2215 3
   Fink HA, 2016, OSTEOPOROSIS INT, V27, P331, DOI 10.1007/s00198 015 3356 y
   Fitzpatrick LA, 2002, MAYO CLIN PROC, V77, P453, DOI 10.4065/77.5.453
   Fuleihan GE, 2015, J BONE MINER RES, V30, P1119, DOI 10.1002/jbmr.2536
   Greenspan SL, 2008, J CLIN ENDOCR METAB, V93, P2, DOI 10.1210/jc.2007 1402
   Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724
   Harvey NC, 2018, J BONE MINER RES, V33, P510, DOI 10.1002/jbmr.3331
   Hellstein JW, 2011, J AM DENT ASSOC, V142, P1243, DOI 10.14219/jada.archive.2011.0108
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011 0385, 10.1210/jc.2011 1193]
   Hopkins RB, 2012, OSTEOPOROSIS INT, V23, P921, DOI 10.1007/s00198 011 1652 8
   Imel EA, 2016, BONE, V83, P267, DOI 10.1016/j.bone.2015.11.021
   Javaid MK, 2002, BEST PRACT RES CL EN, V16, P349, DOI 10.1053/beem.2002.0199
   Jean S, 2013, J BONE MINER RES, V28, P1283, DOI 10.1002/jbmr.1863
   Jennings LA, 2010, J AM GERIATR SOC, V58, P650, DOI 10.1111/j.1532 5415.2010.02769.x
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Katzman WB, 2016, OSTEOPOROSIS INT, V27, P899, DOI 10.1007/s00198 015 3478 2
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Kaze AD, 2018, OSTEOPOROSIS INT, V29, P31, DOI 10.1007/s00198 017 4294 7
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Khosla S, 2001, J CLIN ENDOCR METAB, V86, P3555, DOI 10.1210/jc.86.8.3555
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Langdahl BL, 2015, J CLIN ENDOCR METAB, V100, P1335, DOI 10.1210/jc.2014 4079
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lewiecki EM, 2018, OSTEOPOROSIS INT, V29, P717, DOI 10.1007/s00198 017 4345 0
   Mackey DC, 2007, JAMA J AM MED ASSOC, V298, P2381, DOI 10.1001/jama.298.20.2381
   Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   Orwoll ES, 2010, J BONE MINER RES, V25, P2239, DOI 10.1002/jbmr.119
   Orwoll ES, 2010, BONE, V46, P970, DOI 10.1016/j.bone.2009.12.034
   Pasco JA, 2014, OSTEOPOROSIS INT, V25, P857, DOI 10.1007/s00198 013 2561 9
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Ringe JD, 2006, RHEUMATOL INT, V26, P427, DOI 10.1007/s00296 005 0004 4
   Rosen CJ, 1998, J CLIN ENDOCR METAB, V83, P2286, DOI 10.1210/jc.83.7.2286
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Ryan CS, 2011, OSTEOPOROSIS INT, V22, P1845, DOI 10.1007/s00198 010 1421 0
   Ryan LE, 2012, CURR OSTEOPOROS REP, V10, P286, DOI 10.1007/s11914 012 0120 5
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Safford MM, 2014, JCR J CLIN RHEUMATOL, V20, P357, DOI 10.1097/RHU.0000000000000170
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Snyder PJ, 2017, JAMA INTERN MED, V177, P471, DOI 10.1001/jamainternmed.2016.9539
   Solomon DH, 2014, J BONE MINER RES, V29, P1929, DOI 10.1002/jbmr.2202
   Tory HO, 2015, SEMIN ARTHRITIS RHEU, V44, P483, DOI 10.1016/j.semarthrit.2014.09.011
   Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198 007 0550 6
   Travison TG, 2017, J CLIN ENDOCR METAB, V102, P1161, DOI 10.1210/jc.2016 2935
   Unnanuntana A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180325
   Van Pottelbergh I, 2004, J CLIN ENDOCR METAB, V89, P4949, DOI 10.1210/jc.2003 032081
   van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383
   Vokes TJ, 2010, OSTEOPOROSIS INT, V21, P2083, DOI 10.1007/s00198 010 1185 6
   Watts NB, 2012, J CLIN ENDOCR METAB, V97, P1802, DOI 10.1210/jc.2011 3045
   Wright NC, 2017, OSTEOPOROSIS INT, V28, P1225, DOI 10.1007/s00198 016 3865 3
   Yang SM, 2016, J BONE MINER RES, V31, P1753, DOI 10.1002/jbmr.2849
   Zhao JG, 2017, JAMA J AM MED ASSOC, V318, P2466, DOI 10.1001/jama.2017.19344
NR 92
TC 48
Z9 51
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD OCT
PY 2018
VL 32
IS 5
BP 759
EP 772
DI 10.1016/j.beem.2018.05.007
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HC0NP
UT WOS:000451495400011
PM 30449553
DA 2025 08 17
ER

PT J
AU Jiang, HJ
   Zhong, JL
   Li, WJ
   Dong, JH
   Xian, CJ
   Shen, YK
   Yao, LF
   Wu, Q
   Wang, LP
AF Jiang, Huaji
   Zhong, Jialiang
   Li, Wenjun
   Dong, Jianghui
   Xian, Cory J.
   Shen, Yung Kang
   Yao, Lufeng
   Wu, Qiang
   Wang, Liping
TI Gentiopicroside promotes the osteogenesis of bone mesenchymal stem cells
   by modulation of β catenin BMP2 signalling pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE BMP pathway; Gentiopicroside; osteogenic factors; osteogenic parameters;
   osteoporosis; Wnt/beta catenin pathway
ID STIMULATES OSTEOBLAST DIFFERENTIATION; IN VITRO; OSTEOPOROSIS;
   MINERALIZATION; EXPRESSION; THERAPY; INJURY
AB Osteoporosis is characterized by increased bone fragility, and the drugs used at present to treat osteoporosis can cause adverse reactions. Gentiopicroside (GEN), a class of natural compounds with numerous biological activities such as anti resorptive properties and protective effects against bone loss. Therefore, the aim of this work was to explore the effect of GEN on bone mesenchymal stem cells (BMSCs) osteogenesis for a potential osteoporosis therapy. In vitro, BMSCs were exposed to GEN at different doses for 2 weeks, whereas in vivo, ovariectomized osteoporosis was established in mice and the therapeutic effect of GEN was evaluated for 3 months. Our results in vitro showed that GEN promoted the activity of alkaline phosphatase, increased the calcified nodules in BMSCs and up regulated the osteogenic factors (Runx2, OSX, OCN, OPN and BMP2). In vivo, GEN promoted the expression of Runx2, OCN and BMP2, increased the level of osteogenic parameters, and accelerated the osteogenesis of BMSCs by activating the BMP pathway and Wnt/beta catenin pathway, effect that was inhibited using the BMP inhibitor Noggin and Wnt/beta catenin inhibitor DKK1. Silencing the beta catenin gene and BMP2 gene blocked the osteogenic differentiation induced by GEN in BMSCs. This block was also observed when only beta catenin was silenced, although the knockout of BMP2 did not affect beta catenin expression induced by GEN. Therefore, GEN promotes BMSC osteogenesis by regulating beta catenin BMP signalling, providing a novel strategy in the treatment of osteoporosis.
C1 [Jiang, Huaji; Li, Wenjun; Wu, Qiang] Shantou Univ, Med Coll, Yuebei Peoples Hosp, Dept Orthopaed, Huimin South Rd 13, Shaoguan, Guangdong, Peoples R China.
   [Jiang, Huaji] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China.
   [Zhong, Jialiang] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Clin Lab, Shenzhen, Peoples R China.
   [Dong, Jianghui; Xian, Cory J.; Wang, Liping] Univ South Australia, UniSA Clin & Hlth Sci, Adelaide, SA 5001, Australia.
   [Shen, Yung Kang] Taipei Med Univ, Coll Oral Med, Sch Dent Technol, Taipei, Taiwan.
   [Yao, Lufeng] Ningbo 6 Hosp, Dept Foot & Ankle Surg, Ningbo, Peoples R China.
C3 Shantou University; Southern Medical University   China; Sun Yat Sen
   University; University of South Australia; Taipei Medical University
RP Wu, Q (通讯作者)，Shantou Univ, Med Coll, Yuebei Peoples Hosp, Dept Orthopaed, Huimin South Rd 13, Shaoguan, Guangdong, Peoples R China.; Wang, LP (通讯作者)，Univ South Australia, UniSA Clin & Hlth Sci, Adelaide, SA 5001, Australia.
EM yuebeiwuqiang@aliyun.com; liping.wang@mymail.unisa.edu.au
RI Dong, Jianghui/J 1442 2014; Xian, Cory/D 2646 2009
OI Dong, Jianghui/0000 0003 3961 1688; /0000 0001 9355 1167; Shen,
   Yung Kang/0000 0003 4209 3551
FU Australia National Health and Medical Research Council (NHMRC)
   [1158402]; National Natural Science Foundation of China (NSFC)
   [81671928]; Ningbo Science &Technology Program [202003N4243]; Zhejiang
   Medical Science &Technology Program [2021KY329]
FX This work was funded by Australia National Health and Medical Research
   Council (NHMRC) (1158402), National Natural Science Foundation of China
   (NSFC) (81671928), Ningbo Science &Technology Program (202003N4243), and
   Zhejiang Medical Science &Technology Program ( 2021KY329).
CR Adler BJ, 2014, NAT REV ENDOCRINOL, V10, P737, DOI 10.1038/nrendo.2014.169
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Casanovas G, 2009, J MOL MED, V87, P471, DOI 10.1007/s00109 009 0447 2
   Chen FQ, 2018, BIOMED PHARMACOTHER, V100, P142, DOI 10.1016/j.biopha.2018.02.014
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Dören M, 2000, HUM REPROD UPDATE, V6, P419, DOI 10.1093/humupd/6.5.419
   Elchaninov D. V., 2009, Klinicheskaya Laboratornaya Diagnostika, P21
   Grassi F, 2016, J BONE MINER RES, V31, P949, DOI 10.1002/jbmr.2757
   Han Y, 2017, PHARMACOL RES, V119, P463, DOI 10.1016/j.phrs.2017.03.002
   He Y, 2020, J BIOMED MATER RES A, V108, P50, DOI 10.1002/jbm.a.36791
   Hernlund E., 2013, ARCH OSTEOPOROS, V8, P1, DOI DOI 10.1007/S11657 013 0136 1
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Huang WQ, 2017, CALCIFIED TISSUE INT, V100, P392, DOI 10.1007/s00223 017 0242 y
   Jian J, 2015, ACTA PHARM SIN B, V5, P454, DOI 10.1016/j.apsb.2015.06.005
   Jiang HJ, 2017, CELL TISSUE RES, V367, P257, DOI 10.1007/s00441 016 2528 1
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li HF, 2015, DRUG DES DEV THER, V9, P5169, DOI 10.2147/DDDT.S81578
   Li XF, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/652317
   Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896 6273(00)00148 3
   Liu N, 2016, CAN J PHYSIOL PHARM, V94, P769, DOI 10.1139/cjpp 2015 0462
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Ma ZP, 2015, CELL TISSUE RES, V361, P467, DOI 10.1007/s00441 015 2115 x
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   Miyamoto K, 2011, J EXP MED, V208, P2175, DOI 10.1084/jem.20101890
   Oichi T, 2019, CELL MOL LIFE SCI, V76, P4795, DOI 10.1007/s00018 019 03188 0
   Pang JL, 2006, INT ENDOD J, V39, P527, DOI 10.1111/j.1365 2591.2006.01104.x
   PECK WA, 1993, AM J MED, V94, P646
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Qi Q., 2019, CELL MOL LIFE SCI, P1
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rauner M, 2016, NEW ENGL J MED, V375, P1902, DOI 10.1056/NEJMc1609768
   Raut N, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104350
   Rosset P, 2014, ORTHOP TRAUMATOL SUR, V100, pS107, DOI 10.1016/j.otsr.2013.11.010
   Rulifson IC, 2007, P NATL ACAD SCI USA, V104, P6247, DOI 10.1073/pnas.0701509104
   Silvério KG, 2012, J PERIODONTAL RES, V47, P309, DOI 10.1111/j.1600 0765.2011.01433.x
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Wang YD, 2018, J MOL CELL CARDIOL, V123, P150, DOI 10.1016/j.yjmcc.2018.09.001
   Weckesser S, 2007, PHYTOMEDICINE, V14, P508, DOI 10.1016/j.phymed.2006.12.013
   Xiao JJ, 2015, MOL CELL BIOCHEM, V409, P113, DOI 10.1007/s11010 015 2517 9
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Yang Y, 2018, PHYTOTHER RES, V32, P259, DOI 10.1002/ptr.5965
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
   Zhu B, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1876 7
NR 51
TC 16
Z9 17
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD DEC
PY 2021
VL 25
IS 23
BP 10825
EP 10836
DI 10.1111/jcmm.16410
EA NOV 2021
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA XI3FJ
UT WOS:000718649200001
PM 34783166
OA Green Published
DA 2025 08 17
ER

PT J
AU Pascaud, P
   Bareille, R
   Bourget, C
   Amédée, J
   Rey, C
   Sarda, S
AF Pascaud, P.
   Bareille, R.
   Bourget, C.
   Amedee, J.
   Rey, C.
   Sarda, S.
TI Interaction between a bisphosphonate, tiludronate and nanocrystalline
   apatite: in vitro viability and proliferation of HOP and HBMSC
   cells
SO BIOMEDICAL MATERIALS
LA English
DT Article
ID HUMAN BONE; TRICALCIUM PHOSPHATE; RAMAN SPECTRA; ADSORPTION;
   ALENDRONATE; OSTEOBLAST; MATURATION; GROWTH; BIOMATERIALS; MECHANISMS
AB Nanocrystalline apatites (NCA) are the inorganic components of mineralized tissues and they have been recently proposed as biomaterials for drug delivery systems. Bisphosphonates (BPs) are currently the reference drugs used to treat diseases involving bone disorders such as osteoporosis. Nevertheless, the interaction phenomena between BP molecules and apatite nanocrystals of bone are not well understood. Therefore, the adsorption characteristics have been examined and cellular activity of tiludronate molecules on NCA as models of bone mineral has been investigated. Adsorption experiments of tiludronate onto NCA were carried out and revealed a Langmuir type adsorption isotherm. The uptake of tiludronate molecules is associated with a release of phosphate ions, indicating that the main reaction is an ion exchange process involving surface anions. The results evidence the strong affinity of BP molecules for the apatitic surface. The interactions of NCA tiludronate associations with human osteoprogenitor cells and human bone marrow stromal cells do not reveal any cytotoxicity and evidence the activity of adsorbed tiludronate molecules. Moreover, an evolution of the physico chemical characteristics of the apatitic substrate during biological study was observed, highlighting the existence of dynamic interactions. This work contributes to clarifying the reaction mechanisms between BPs and biomimetic apatites.
C1 [Pascaud, P.; Rey, C.; Sarda, S.] Univ Toulouse, CIRIMAT Carnot Inst, CNRS INPT UPS, ENSIACET, F 31030 Toulouse 04, France.
   [Bareille, R.; Bourget, C.; Amedee, J.] INSERM, U1026, F 33076 Bordeaux, France.
   [Bareille, R.; Bourget, C.; Amedee, J.] Univ Bordeaux Segalen, F 33076 Bordeaux, France.
C3 Universite Federale Toulouse Midi Pyrenees (ComUE); Universite de
   Toulouse; Institut National Polytechnique de Toulouse; Universite
   Toulouse III   Paul Sabatier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Bordeaux
RP Pascaud, P (通讯作者)，Univ Toulouse, CIRIMAT Carnot Inst, CNRS INPT UPS, ENSIACET, 4 Allee Emile Monso,BP 44362, F 31030 Toulouse 04, France.
EM stephanie.sarda@iut tlse3.fr
RI AMEDEE, Joelle/F 3369 2013
OI Sarda, Stephanie/0000 0002 9525 4403
FU AAP CNRS
FX The authors thank Sanofi Aventis for generously providing tiludronate
   (di sodium((4 chlorophenyl)thio)methylene bisphosphonate) hemihydrate
   sample. This work was supported by AAP CNRS 2009 project 'Longevite et
   Vieillissement'.
CR Al Kattan A, 2010, ADV ENG MATER, V12, pB224, DOI 10.1002/adem.200980084
   Autefage H, 2009, J BIOMED MATER RES B, V91B, P706, DOI 10.1002/jbm.b.31447
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Boanini E, 2007, ADV MATER, V19, P2499, DOI 10.1002/adma.200602497
   Bohic S, 2000, BONE, V26, P341, DOI 10.1016/S8756 3282(99)00276 8
   Bonnery M, 1994, EP Patent, Patent No. 0582515
   Brandi ML, 2006, J BONE MINER RES, V21, P183, DOI 10.1359/JBMR.050917
   Charlot G., 1974, CHIMIE ANAL QUANTITA
   Coleman R, 2011, EXPERT OPIN DRUG SAF, V10, P133, DOI 10.1517/14740338.2011.540387
   DENISSEN H, 1994, BONE MINER, V25, P123, DOI 10.1016/S0169 6009(08)80254 1
   Eichert D, 2004, KEY ENG MATER, V254 2, P927, DOI 10.4028/www.scientific.net/KEM.254 256.927
   Eichert D, 2009, BIOMATERIALS RES ADV
   Elliott SN, 1997, LIFE SCI, V62, P77, DOI 10.1016/S0024 3205(97)01040 0
   Eriksen EF, 2007, J BONE MINER RES, V22, P1, DOI 10.1359/JBMR.060910
   Errassifi F, 2010, CERAM TRANS, V218, P159
   Errassifi F, 2011, THESIS U CADI AYYAD
   Errassifi F, 2009, P COV 3 MARR MOR 18, P153
   Fleisch H., 2000, BISPHOSPHONATES BONE
   Fromigué O, 2002, J ENDOCRINOL INVEST, V25, P539, DOI 10.1007/BF03345497
   Grossmann G, 2000, MAGN RESON CHEM, V38, P11, DOI 10.1002/(SICI)1097 458X(200001)38:1<11::AID MRC597>3.0.CO;2 V
   Hoffman A, 2001, INT J PHARM, V220, P1, DOI 10.1016/S0378 5173(01)00654 8
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Juillard A, 2010, BONE, V47, P895, DOI 10.1016/j.bone.2010.07.018
   Kos M., 2009, Biosci. Hypotheses, V2, P34, DOI [DOI 10.1016/J.BIHY.2008.08.004, 10.1016/j.bihy.2008.08.004]
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   McLeod K, 2006, J BIOMED MATER RES A, V79A, P271, DOI 10.1002/jbm.a.30792
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   MONTEL G, 1981, J CRYST GROWTH, V53, P74, DOI 10.1016/0022 0248(81)90057 9
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Penel G, 1998, CALCIFIED TISSUE INT, V63, P475, DOI 10.1007/s002239900561
   Quizat S, 1999, MATER RES BULL, V34, P2279
   Rey C, 2007, MATERIALWISS WERKST, V38, P996, DOI 10.1002/mawe.200700229
   Rey C, 2007, MAT SCI ENG C BIO S, V27, P198, DOI 10.1016/j.msec.2006.05.015
   REY C, 1989, CALCIFIED TISSUE INT, V45, P157, DOI 10.1007/BF02556059
   Rey C, 1995, CELL MATER, V5, P345
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Roussiere H, 2008, CHEM MATER, V20, P182, DOI 10.1021/cm702584d
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Scherrer P., 1918, Nachr. Ges. Wiss. Gottingen, P98
   VILAMITJANAAMEDEE J, 1993, IN VITRO CELL DEV AN, V29, P699
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wood RW, 1932, PHYS REV, V42, P0386, DOI 10.1103/PhysRev.42.386
   Wood RW, 1930, PHYS REV, V36, P1431, DOI 10.1103/PhysRev.36.1431
NR 50
TC 15
Z9 15
U1 0
U2 23
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD OCT
PY 2012
VL 7
IS 5
AR 054108
DI 10.1088/1748 6041/7/5/054108
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 016VN
UT WOS:000309547900009
PM 22972389
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Cai, XP
   Zhang, XX
   Dong, Y
   Pan, X
   Lai, MW
   Zhang, YM
   Chen, YJ
   Li, XH
   Li, X
   Liu, JX
   Zhang, YG
   Ma, F
AF Zhou, Ya
   Cai, Xinping
   Zhang, Xiuxiu
   Dong, Yong
   Pan, Xu
   Lai, Mowen
   Zhang, Yimeng
   Chen, Yijin
   Li, Xiaohong
   Li, Xia
   Liu, Jiaxin
   Zhang, Yonggang
   Ma, Feng
TI Mesenchymal stem/stromal cells from human pluripotent stem cell derived
   brain organoid enhance the ex vivo expansion and maintenance of
   hematopoietic stem/progenitor cells
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE MSCs; Human brain organoids; HSCs; Wnt signaling pathway; HSC
   transplantation
ID UMBILICAL CORD BLOOD; BONE MARROW; STROMAL CELLS; PROFILES; NICHES
AB BackgroundMesenchymal stem/stromal cells (MSCs) are of great therapeutic value due to their role in maintaining the function of hematopoietic stem/progenitor cells (HSPCs). MSCs derived from human pluripotent stem cells represent an ideal alternative because of their unlimited supply. However, the role of MSCs with neural crest origin derived from HPSCs on the maintenance of HSPCs has not been reported.MethodsFlow cytometric analysis, RNA sequencing and differentiation ability were applied to detect the characteristics of stromal cells from 3D human brain organoids. Human umbilical cord blood CD34+ (UCB CD34+) cells were cultured in different coculture conditions composed of stromal cells and umbilical cord MSCs (UC MSCs) with or without a cytokine cocktail. The hematopoietic stroma capacity of stromal cells was tested in vitro with the LTC IC assay and in vivo by cotransplantation of cord blood nucleated cells and stroma cells into immunodeficient mice. RNA and proteomic sequencing were used to detect the role of MSCs on HSPCs.ResultsThe stromal cells, derived from both H1 hESCs and human induced pluripotent stem cells forebrain organoids, were capable of differentiating into the classical mesenchymal derived cells (osteoblasts, chondrocytes, and adipocytes). These cells expressed MSC markers, thus named pluripotent stem cell derived MSCs (pMSCs). The pMSCs showed neural crest origin with CD271 expression in the early stage. When human UCB CD34+ HSPCs were cocultured on UC MSCs or pMSCs, the latter resulted in robust expansion of UCB CD34+ HSPCs in long term culture and efficient maintenance of their transplantability. Comparison by RNA sequencing indicated that coculture of human UCB CD34+ HSPCs with pMSCs provided an improved microenvironment for HSC maintenance. The pMSCs highly expressed the Wnt signaling inhibitors SFRP1 and SFRP2, indicating that they may help to modulate the cell cycle to promote the maintenance of UCB CD34+ HSPCs by antagonizing Wnt activation.ConclusionsA novel method for harvesting MSCs with neural crest origin from 3D human brain organoids under serum free culture conditions was reported. We demonstrate that the pMSCs support human UCB HSPC expansion in vitro in a long term culture and the maintenance of their transplantable ability. RNA and proteomic sequencing indicated that pMSCs provided an improved microenvironment for HSC maintenance via mechanisms involving cell cell contact and secreted factors and suppression of Wnt signaling. This represents a novel method for large scale production of MSCs of neural crest origin and provides a potential approach for development of human hematopoietic stromal cell therapy for treatment of dyshematopoiesis.
C1 [Zhou, Ya; Cai, Xinping; Zhang, Xiuxiu; Dong, Yong; Pan, Xu; Lai, Mowen; Zhang, Yimeng; Chen, Yijin; Li, Xiaohong; Li, Xia; Liu, Jiaxin; Zhang, Yonggang; Ma, Feng] Chinese Acad Med Sci & Peking Union Med Coll, Ctr Stem Cell Res & Applicat, Inst Blood Transfus, Huacai Rd 26, Chengdu 610052, Peoples R China.
   [Cai, Xinping] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosys, Inst Hematol & Blood Dis Hosp, Tianjin 300020, Peoples R China.
   [Dong, Yong] Chengdu Med Coll, Sch Basic Med Sci, Dept Immunol, Chengdu, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Blood Transfusion   CAMS; Peking Union Medical College;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Hematology & Blood Diseases Hospital   CAMS; Peking Union
   Medical College; Chengdu Medical College
RP Zhang, YG; Ma, F (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Ctr Stem Cell Res & Applicat, Inst Blood Transfus, Huacai Rd 26, Chengdu 610052, Peoples R China.
EM yonggangzhang@ibt.pumc.edu.cn; mafeng@ibt.pumc.edu.cn
RI pan, xu/KJL 1993 2024; chen, yijin/MGA 2909 2025
FU National Natural Science Foundation of China; State Key Laboratory of
   Experimental Hematology, CAMS PUMC
FX We thank Professor Tao Cheng at the State Key Laboratory of Experimental
   Hematology, CAMS & PUMC for generously providing the H1 hESC line.
CR Chen L, 2014, SCIENCE, V345, P1580, DOI 10.1126/science.1251033
   Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445
   Chin CJ, 2018, STEM CELL REP, V10, P436, DOI 10.1016/j.stemcr.2017.12.005
   Costa MHG, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700088
   Crippa S, 2018, HEMASPHERE, V2, DOI 10.1097/HS9.0000000000000151
   Domingues MJ, 2017, J CELL BIOCHEM, V118, P1984, DOI 10.1002/jcb.25905
   Dong Y, 2020, J LEUKOCYTE BIOL, V108, P1711, DOI 10.1002/JLB.1A0520 179R
   Dzierzak E, 2018, CELL STEM CELL, V22, P639, DOI 10.1016/j.stem.2018.04.015
   Fajardo Orduña GR, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6061729
   Famili F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.380
   Ferrell PI, 2014, STEM CELLS DEV, V23, P1355, DOI 10.1089/scd.2013.0497
   Greiner J F W, 2011, Eur Cell Mater, V22, P403
   Han YL, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105788
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   He QL, 2017, STEM CELLS, V35, P473, DOI 10.1002/stem.2481
   Heo JS, 2016, INT J MOL MED, V37, P115, DOI 10.3892/ijmm.2015.2413
   Huynh HD, 2008, STEM CELLS, V26, P1628, DOI 10.1634/stemcells.2008 0064
   Isern J, 2014, ELIFE, V3, DOI 10.7554/eLife.03696
   Kadekar D, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0194 y
   Kamiya D, 2022, NPJ REGEN MED, V7, DOI 10.1038/s41536 022 00241 8
   Khan JA, 2016, SCIENCE, V351, P176, DOI 10.1126/science.aad0084
   Lee Thedieck C, 2022, ADV DRUG DELIVER REV, V181, DOI 10.1016/j.addr.2021.114069
   Li ZA, 2012, CELL STEM CELL, V11, P663, DOI 10.1016/j.stem.2012.07.004
   Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312
   Lin NYC, 2019, P NATL ACAD SCI USA, V116, P5399, DOI 10.1073/pnas.1815208116
   Liu TM, 2021, WORLD J STEM CELLS, V13, P1826, DOI 10.4252/wjsc.v13.i12.1826
   Lo Nigro A, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.746298
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Luis TC, 2009, BLOOD, V113, P546, DOI 10.1182/blood 2008 06 163774
   Ma F, 2008, P NATL ACAD SCI USA, V105, P13087, DOI 10.1073/pnas.0802220105
   Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264
   Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337
   Morikawa S, 2009, BIOCHEM BIOPH RES CO, V379, P1114, DOI 10.1016/j.bbrc.2009.01.031
   Moslem M, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/843058
   Nakajima H, 2009, BIOCHEM BIOPH RES CO, V390, P65, DOI 10.1016/j.bbrc.2009.09.067
   Nakamura Ishizu A, 2013, BBA GEN SUBJECTS, V1830, P2404, DOI 10.1016/j.bbagen.2012.08.023
   Nakatsuka R, 2015, CELL TRANSPLANT, V24, P97, DOI 10.3727/096368913X674675
   Namkoong B, 2016, ACTA BIOMATER, V31, P301, DOI 10.1016/j.actbio.2015.12.004
   Oostendorp RAJ, 2005, STEM CELLS, V23, P842, DOI 10.1634/stemcells.2004 0120
   Oostendorp RAJ, 2002, BLOOD, V99, P1183, DOI 10.1182/blood.V99.4.1183
   Pinho S, 2019, NAT REV MOL CELL BIO, V20, P303, DOI 10.1038/s41580 019 0103 9
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Pisciotta A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00547
   Qian XY, 2016, CELL, V165, P1238, DOI 10.1016/j.cell.2016.04.032
   Renström J, 2009, CELL STEM CELL, V5, P157, DOI 10.1016/j.stem.2009.05.020
   Sá da Bandeira D, 2017, PHARMACOL THERAPEUT, V171, P104, DOI 10.1016/j.pharmthera.2016.11.006
   Sheng GJ, 2015, BMC DEV BIOL, V15, DOI 10.1186/s12861 015 0094 5
   Sorrentino A, 2008, EXP HEMATOL, V36, P1035, DOI 10.1016/j.exphem.2008.03.004
   Stanko P, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8973613
   Tormin A, 2011, BLOOD, V117, P5067, DOI 10.1182/blood 2010 08 304287
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Wagner WG, 2007, STEM CELLS, V25, P2638, DOI 10.1634/stemcells.2007 0280
   Wang HY, 2019, THERANOSTICS, V9, P1683, DOI 10.7150/thno.30487
   Wang XF, 2016, STEM CELLS, V34, P380, DOI 10.1002/stem.2242
   Wang XF, 2014, STEM CELL REP, V3, DOI 10.1016/j.stemcr.2014.04.020
   Wei QZ, 2018, IMMUNITY, V48, P632, DOI 10.1016/j.immuni.2018.03.024
   Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779
   Zhang CC, 2008, BLOOD, V111, P3415, DOI 10.1182/blood 2007 11 122119
   Zou Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149023
NR 59
TC 4
Z9 4
U1 2
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAR 5
PY 2024
VL 15
IS 1
AR 68
DI 10.1186/s13287 023 03624 w
PG 18
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KH8O1
UT WOS:001179162400001
PM 38443990
OA gold
DA 2025 08 17
ER

PT J
AU Sheng, MHC
   Lau, KHW
   Lakhan, R
   Ahmed, AI
   Rundle, CH
   Biswanath, P
   Baylink, DJ
AF Sheng, Matilda H.  C.
   Lau, Kin Hing William
   Lakhan, Ram
   Ahmed, Abu Shufian Ishtiaq
   Rundle, Charles H.
   Biswanath, Patra
   Baylink, David J.
TI Unique Regenerative Mechanism to Replace Bone Lost During Dietary Bone
   Depletion in Weanling Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID PARATHYROID HORMONE PTH; CALCIUM DEFICIENT RATS; MESENCHYMAL STEM CELLS;
   VITAMIN D RECEPTOR; PRIMARY HYPERPARATHYROIDISM; MINERAL DENSITY;
   GENE THERAPY; RESORPTION; DIFFERENTIATION; REPLETION
AB The present study was undertaken to determine the mechanism whereby calcitropic hormones and mesenchymal stem cell progeny changes are involved in bone repletion, a regenerative bone process that restores the bone lost to calcium deficiency. To initiate depletion, weanling mice with a mixed C57BL/6 (75%) and CD1 (25%) genetic background were fed a calcium deficient diet (0.01%) for 14 days. For repletion, the mice were fed a control diet containing 1.2% calcium for 14 days. Depletion decreased plasma calcium and increased plasma parathyroid hormone, 1,25(OH) 2D (calcitriol), and C terminal telopeptide of type I collagen. These plasma parameters quickly returned toward normal on repletion. The trabecular bone volume and connectivity decreased drastically during depletion but were completely restored by the end of repletion. This bone repletion process largely resulted from the development of new bone formation. When bromodeoxyuridine (BrdU) was administered in the middle of depletion for 3 days and examined by fluorescence activated cell sorting at 7 days into repletion, substantial increases in BrdU incorporation were seen in several CD105 subsets of cells of osteoblastic lineage. When BrdU was administered on days 1 to 3 of repletion and examined 11 days later, no increases in BrdU were seen in these subsets. Additionally, osteocytes that stained positively for BrdU were increased during depletion. In conclusion, the results of the present study have established a unique regenerative mechanism to initiate bone repair during the bone insult. Calcium homeostatic mechanisms and the bone repletion mechanism are opposing functions but are simultaneously orchestrated such that both endpoints are optimized. These results have potential clinical relevance for disease entities such as type 2 osteoporosis.
C1 [Sheng, Matilda H.  C.; Lau, Kin Hing William; Lakhan, Ram; Ahmed, Abu Shufian Ishtiaq; Biswanath, Patra; Baylink, David J.] Loma Linda Univ, Sch Med, Dept Med, Regenerat Med Div, 11234 Anderson St, Loma Linda, CA 92354 USA.
   [Lau, Kin Hing William; Rundle, Charles H.] Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA.
C3 Loma Linda University
RP Sheng, MHC (通讯作者)，Loma Linda Univ, Sch Med, Dept Med, Regenerat Med Div, 11234 Anderson St, Loma Linda, CA 92354 USA.
EM MSheng@LLU.edu
RI Ahmed, Abu/CAJ 2986 2022
OI Ahmed, Abu/0000 0002 7931 8972; Lau, Kin Hing/0000 0003 1109 5052
FU Telemedicine and Advanced Technology Research Center at the US Army
   Medical Research and Material Command [W81XWH 08 1 0697]
FX This work was supported by the Telemedicine and Advanced Technology
   Research Center at the US Army Medical Research and Material Command
   (Grant W81XWH 08 1 0697). The views, opinions, and/or findings contained
   in this report are those of the authors and should not be construed as
   an official Department of the Army position, policy, or decision, unless
   so designated by other documentation.
CR Åkesson K, 1998, J CLIN ENDOCR METAB, V83, P1921, DOI 10.1210/jc.83.6.1921
   Aubin JE, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P85, DOI 10.1016/B978 0 12 373884 4.00026 4
   BAYLINK D, 1973, AM J PHYSIOL, V224, P1345, DOI 10.1152/ajplegacy.1973.224.6.1345
   Ben Awadh AN, 2014, ENDOCRINOLOGY, V155, P2797, DOI 10.1210/en.2014 1046
   Boonen S, 1999, J BONE MINER RES, V14, P2150, DOI 10.1359/jbmr.1999.14.12.2150
   Chapuy MC, 2002, OSTEOPOROSIS INT, V13, P257, DOI 10.1007/s001980200023
   Chen WQ, 2015, P NATL ACAD SCI USA, V112, pE3893, DOI 10.1073/pnas.1501759112
   Crane Ashley M, 2013, Methods Mol Biol, V1014, P65, DOI 10.1007/978 1 62703 432 6_4
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   D'Amelio P, 2015, OSTEOPOROSIS INT, V26, P2785, DOI 10.1007/s00198 015 3189 8
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Di Bernardo G, 2010, J CELL PHYSIOL, V222, P474, DOI 10.1002/jcp.21976
   Divieti P, 2001, ENDOCRINOLOGY, V142, P916, DOI 10.1210/en.142.2.916
   DRIVDAHL RH, 1984, AM J PHYSIOL, V246, pR190, DOI 10.1152/ajpregu.1984.246.2.R190
   Eisman John A, 2014, Bonekey Rep, V3, P499, DOI 10.1038/bonekey.2013.233
   Friedl G, 2007, J ORTHOP RES, V25, P1454, DOI 10.1002/jor.20433
   Fudge NJ, 2010, ENDOCRINOLOGY, V151, P886, DOI 10.1210/en.2009 1010
   Garcia LA, 2011, ENDOCRINOLOGY, V152, P2976, DOI 10.1210/en.2011 0159
   GORE SD, 1993, EXP HEMATOL, V21, P1702
   Henriksen K, 2012, BONE, V51, P353, DOI 10.1016/j.bone.2012.06.007
   Huhtakangas JA, 2004, MOL ENDOCRINOL, V18, P2660, DOI 10.1210/me.2004 0116
   Ishibashi O, 2006, LIFE SCI, V79, P1657, DOI 10.1016/j.lfs.2006.05.024
   Larriba MJ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00060
   Keung AJ, 2016, SCIENCE, V351, P661, DOI 10.1126/science.aaf1647
   Kodama Y, 2000, BONE, V27, P445, DOI 10.1016/S8756 3282(00)00340 9
   KOVACS CS, 1995, J CLIN ENDOCR METAB, V80, P3036, DOI 10.1210/jc.80.10.3036
   Lamy Olivier, 2014, Bonekey Rep, V3, P579, DOI 10.1038/bonekey.2014.74
   Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003
   Lau KHW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115897
   Leoutsakos B, 2006, PARATHYROIDS, P337
   Li AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113785
   Lieben L, 2013, J STEROID BIOCHEM, V136, P102, DOI 10.1016/j.jsbmb.2012.09.019
   Lieben L, 2013, BONE, V54, P237, DOI 10.1016/j.bone.2012.10.007
   Lieben L, 2012, J CLIN INVEST, V122, P1803, DOI 10.1172/JCI45890
   LIU CC, 1974, ENDOCRINOLOGY, V95, P1011, DOI 10.1210/endo 95 4 1011
   LIU CC, 1982, METAB BONE DIS RELAT, V4, P201, DOI 10.1016/0221 8747(82)90019 4
   LIU CC, 1978, METAB BONE DIS RELAT, V1, P269, DOI 10.1016/0221 8747(78)90012 7
   Meng H, 2014, DIABETES METAB RES, V30, P457, DOI 10.1002/dmrr.2566
   Meyer MB, 2014, J BIOL CHEM, V289, P19539, DOI 10.1074/jbc.M114.578104
   MOHAN S, 1991, CLIN ORTHOP RELAT R, P30
   Mundy GR, 1999, CLIN CHEM, V45, P1347
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Orr HA, 2005, NAT REV GENET, V6, P119, DOI 10.1038/nrg1523
   OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo 128 3 1496
   Paggiosi MA, 2015, OSTEOPOROSIS INT, V26, P1773, DOI 10.1007/s00198 015 3078 1
   PIETSCHMANN P, 1991, KLIN WOCHENSCHR, V69, P351, DOI 10.1007/BF02115782
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583
   REISS E, 1970, J CLIN INVEST, V49, P2146, DOI 10.1172/JCI106432
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   Sheng MHC, 2002, BONE, V30, P486, DOI 10.1016/S8756 3282(01)00693 7
   Shimada A, 2008, J IMMUNOL METHODS, V339, P11, DOI 10.1016/j.jim.2008.07.013
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729
   Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood 2010 01 264507
   STAUFFER M, 1973, AM J PHYSIOL, V225, P269, DOI 10.1152/ajplegacy.1973.225.2.269
   Tai V, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h4183
   THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653
   Veevers Lowe J, 2011, J CELL SCI, V124, P1288, DOI 10.1242/jcs.076935
   Wang XK, 2016, INT J AGRON, V2016, DOI [10.1007/s10753 015 0217 y, 10.1155/2016/3961903]
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood 2004 02 0526
   Xiong JH, 2014, BONE, V66, P146, DOI 10.1016/j.bone.2014.06.006
   Yamamoto M, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/576358
   Yamamoto M, 2014, ARCH ORAL BIOL, V59, P310, DOI 10.1016/j.archoralbio.2013.12.006
   Yanai I, 2016, THE SOC OF GENES
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Zager RA, 2008, KIDNEY INT, V74, P674, DOI 10.1038/ki.2008.251
NR 70
TC 3
Z9 3
U1 0
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD APR
PY 2017
VL 158
IS 4
BP 714
EP 729
DI 10.1210/en.2016 1379
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ER3SK
UT WOS:000398718200006
PM 28324039
OA Bronze
DA 2025 08 17
ER

PT J
AU Cui, YL
   Zhao, XY
   Mei, LJ
   Pei, JJ
   Wang, S
   Shao, Y
   Tao, YDO
   Zhang, XL
   Jiang, L
AF Cui, Yulei
   Zhao, Xiaoying
   Mei, Lijuan
   Pei, Jinjin
   Wang, Shuo
   Shao, Yun
   Tao, Yanduo
   Zhang, Xiaoling
   Jiang, Lei
TI Osteon Myospalacem Baileyi attenuates osteoclast differentiation through
   RANKL induced NFAT pathways
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Osteon Myospalacem Baileyi; RANKL; Osteoclast differentiation; ERK;
   NFATc1
ID BONE LOSS
AB Ethnopharmacological relevance: Osteon Myospalacem Baileyi, known as Sai long gu (Tibetan language, means "blind rat bone"), is the whole skeleton of Tibet plateau rodentia animal Myospalacem Baileyi. Osteon Myospalacem Baileyi had been widely used in the Tibet region as an anti osteoporosis drug and since 1991 Osteon Myospalacem Baileyi has been listed in the Pharmacopoeia of People's Republic of China as the first class animal new medical material. However, the mechanism of its anti osteoporosis activities is still unclear. It is very desirable to solve this problem for further study.
   Materials and methods: in this study, preparative chromatography was employed to produce the active fraction ET4 from Osteon Myospalacem Baileyi crude. Flow cytometry and MTT assay were used to evaluate the toxicities of ET4. BMM cells were separated from mouse bone marrow to test the inhibition effects of ET4 on osteoclastogenesis. Western blot was used to find out the pathways, through which ET4 could act on osteoclastogenesis. Q PCR was used to test the osteoclastogenesis marker genes. At last, immunofluorescence confocal microscopy was used to test the osteoclastogenesis master protein NFATc1 nuclei translocation.
   Results: In this study we report that ET4, at the dose of 60 mu g/mL, significantly inhibited the formation of osteoclasts. Notably, ET4 did not affect the BMM viability at that dose. In addition, Osteon Myospalacem Baileyi could inhibit the expression of osteoclast marker genes, including cathepsin K (CTSK), nuclear factor of activated T cells cytoplasmic 1 (NFATc1), tartrate resistant acid phosphatase (TRAP, Acp5) dendrite cell specific trans membrane protein (DC STAMP), calcitonin receptor (CTR), osteoclast associated and immunoglobulin like receptor (OSCAR). Mechanistically, ET4 dose  and time dependently blocked the RANKL induced activation of ERK and c Fos as well as the induction of NFATcl which is essential for OC formation.
   Conclusions: These data suggest that ET4 might be a useful alternative therapy in preventing or treating osteolytic diseases.
C1 [Cui, Yulei; Mei, Lijuan; Pei, Jinjin; Wang, Shuo; Shao, Yun; Tao, Yanduo; Jiang, Lei] Chinese Acad Sci, Northwest Plateau Inst Biol, Key Lab Tibetan Med Res, Xining 810001, Qinghai, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] SJTUSM, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai 200025, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Chinese Acad Sci, SIBS, Shanghai 200025, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] SJTUSM, Xin Hua Hosp, Dept Orthoped Surg, Shanghai 200092, Peoples R China.
   [Pei, Jinjin] Shaanxi Univ Technol, Shaanxi Key Lab Bioresources & Biol, Henzhong 723001, Peoples R China.
   [Cui, Yulei; Wang, Shuo] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
C3 Chinese Academy of Sciences; Northwest Institute of Plateau Biology,
   CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences;
   Shanghai Jiao Tong University; Shaanxi University of Technology; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS
RP Zhang, XL (通讯作者)，SJTUSM, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai 200025, Peoples R China.; Zhang, XL (通讯作者)，Chinese Acad Sci, SIBS, Shanghai 200025, Peoples R China.; Zhang, XL (通讯作者)，SJTUSM, Xin Hua Hosp, Dept Orthoped Surg, Shanghai 200092, Peoples R China.; Jiang, L (通讯作者)，23 Xinning Rd, Xining, Qinghai, Peoples R China.
EM Chrisjiang27@163.com
RI ; Zhang, Xiaoling/J 1666 2016; shao, yun/KLC 3238 2024; cui,
   yulei/ACM 6486 2022
OI Zhang, Xiaoling/0000 0002 0134 1347; Cui, Yulei/0000 0002 9777 2431
FU Natural Science Foundation of Qinghai [2016 ZJ 942Q]; West Light
   Foundation of the Chinese Academy of Sciences [Y629071211]; National
   Natural Science Foundation of China [81572123, 31701243]; Science and
   Technology Commission of Shanghai Municipality [14431900900,
   15411951100, 16430723500]; Shanghai Municipal Education
   Commission Gaofeng Clinical Medicine Grant Support [20161314]
FX This work was supported by grants from Natural Science Foundation of
   Qinghai (No. 2016 ZJ 942Q), West Light Foundation of the Chinese Academy
   of Sciences (No. Y629071211), National Natural Science Foundation of
   China (No. 81572123, No. 31701243), Science and Technology Commission of
   Shanghai Municipality (No. 14431900900, 15411951100, 16430723500),
   Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant
   Support (No. 20161314).
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Breuksch I, 2016, J BONE ONCOL, V5, P143, DOI 10.1016/j.jbo.2016.06.004
   Goessl C, 2012, ANN NY ACAD SCI, V1263, P29, DOI 10.1111/j.1749 6632.2012.06674.x
   Hiraga T, 2016, EXPERT OPIN INV DRUG, V25, P319, DOI 10.1517/13543784.2016.1142972
   Jiang L, 2014, J SEP SCI, V37, P3060, DOI 10.1002/jssc.201400564
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Jonasson G, 2016, CLIN COSMET INV DENT, V8, P95, DOI 10.2147/CCIDE.S92774
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   McDonald M. M., 2016, CALCIF TISSUE INT
   Nakamura I, 2012, MOD RHEUMATOL, V22, P167, DOI 10.1007/s10165 011 0530 8
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nevius E, 2016, CLIN REV ALLERG IMMU, V51, P59, DOI 10.1007/s12016 015 8520 9
   Ping H., 2002, SHANDONG J TRADIT CH, V21, P231
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
NR 14
TC 5
Z9 6
U1 0
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 1
PY 2018
VL 213
BP 65
EP 71
DI 10.1016/j.jep.2017.10.007
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA FS6TP
UT WOS:000419930700009
PM 29107144
DA 2025 08 17
ER

PT J
AU Clarke, BL
   Khan, AA
   Rubin, MR
   Schwarz, P
   Vokes, T
   Shoback, DM
   Gagnon, C
   Palermo, A
   Abbott, LG
   Hofbauer, LC
   Kohlmeier, L
   Cetani, F
   Pihl, S
   An, XB
   Smith, AR
   Lai, BY
   Ukena, J
   Sibley, CT
   Shu, AD
   Rejnmark, L
AF Clarke, Bart L.
   Khan, Aliya A.
   Rubin, Mishaela R.
   Schwarz, Peter
   Vokes, Tamara
   Shoback, Dolores M.
   Gagnon, Claudia
   Palermo, Andrea
   Abbott, Lisa G.
   Hofbauer, Lorenz C.
   Kohlmeier, Lynn
   Cetani, Filomena
   Pihl, Susanne
   An, Xuebei
   Smith, Alden R.
   Lai, Bryant
   Ukena, Jenny
   Sibley, Christopher T.
   Shu, Aimee D.
   Rejnmark, Lars
TI Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism:
   52 Week Results From the Phase 3 PaTHway Trial
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE hypoparathyroidism; parathyroid hormone; hormone replacement therapy;
   hypocalcemia; palopegteriparatide; quality of life
AB Context: Conventional therapy for hypoparathyroidism aims to alleviate symptoms of hypocalcemia but does not address insufficient parathyroid hormone (PTH) levels. Objective: Assess the long term efficacy and safety of TransCon PTH (palopegteriparatide) for hypoparathyroidism. Design: Phase 3 trial with a 26 week, double blind, placebo controlled period followed by a 156 week, open label extension (OLE). Setting: Twenty one sites across North America and Europe. Participants: A total of 82 adults with hypoparathyroidism were randomized and received study drug and 78 completed week 52. Intervention(s): All OLE participants received TransCon PTH administered once daily. Main Outcome Measure(s): Multicomponent efficacy endpoint: proportion of participants at week 52 who achieved normal serum calcium (8.310.6 mg/dL) and independence from conventional therapy (<= 600 mg/day of elemental calcium and no active vitamin D). Other efficacy endpoints included patient reported outcomes and bone mineral density. Safety was assessed by 24 hour urine calcium and treatment emergent adverse events. Results: At week 52, 81% (63/78) met the multicomponent efficacy endpoint, 95% (74/78) achieved independence from conventional therapy, and none required active vitamin D. Patient reported outcomes showed sustained improvements in quality of life, physical functioning, and wellbeing. Mean bone mineral density Z scores decreased toward age  and sex matched norms from baseline to week 52. Mean (SD) 24 hour urine calcium excretion decreased from 376 (168) mg/day at baseline to 195 (114) mg/day at week 52. Most treatment emergent adverse events were mild or moderate and none led to trial discontinuation during the OLE. Conclusion: At week 52 of the PaTHway trial, TransCon PTH showed sustained efficacy, safety, and tolerability in adults with hypoparathyroidism.
C1 [Clarke, Bart L.] Mayo Clin, Endocrinol, E18 A, Rochester, MN 55905 USA.
   [Khan, Aliya A.] McMaster Univ, Endocrinol Metab & Geriatr, Hamilton, ON L8S 4L8, Canada.
   [Rubin, Mishaela R.] Columbia Univ, Endocrinol, New York, NY 10032 USA.
   [Schwarz, Peter] Rigshosp, Internal Med & Endocrinol, DK 2100 Copenhagen, Denmark.
   [Vokes, Tamara] Univ Chicago, Endocrinol Diabet & Metab, Chicago, IL 60637 USA.
   [Shoback, Dolores M.] Univ Calif San Francisco, VA Med Ctr, Endocrinol, San Francisco, CA 94143 USA.
   [Gagnon, Claudia] Univ Laval, CHU Quebec, Res Ctr, Endocrinol & Nephrol, Quebec City, PQ G1V 4G2, Canada.
   [Gagnon, Claudia] Univ Laval, Dept Med, Quebec City, PQ G1V 0A6, Canada.
   [Palermo, Andrea] Fdn Policlin Campus Biomed, Unit Metab Bone & Thyroid Disorders, I 00128 Rome, Italy.
   [Palermo, Andrea] Campus Biomed Univ, Unit Endocrinol & Diabet, I 00128 Rome, Italy.
   [Abbott, Lisa G.] Northern Nevada Endocrinol, Endocrinol, Reno, NV 89511 USA.
   [Abbott, Lisa G.] Univ Nevada, Endocrinol, Reno, NV 89557 USA.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Med Ctr, Endocrinol Diabet & Metab Bone Dis, D 01307 Dresden, Germany.
   [Kohlmeier, Lynn] Arthrit Northwest Res Ctr, Endocrinol & Spokane Osteoporosis, Spokane, WA 99223 USA.
   [Cetani, Filomena] Univ Hosp Pisa, Endocrine Unit, I 56126 Pisa, Italy.
   [Pihl, Susanne] Ascendis Pharm A S, Clin Pharmacol & Bioanal, DK 2900 Hellerup, Denmark.
   [An, Xuebei] Ascendis Pharm Inc, Biostat, Palo Alto, CA 94304 USA.
   [Smith, Alden R.] Ascendis Pharm Inc, Global Hlth Econ Outcomes Res, Palo Alto, CA 94304 USA.
   [Lai, Bryant; Ukena, Jenny; Sibley, Christopher T.; Shu, Aimee D.] Ascendis Pharm Inc, Endocrine Med Sci, 1000 Page Mill Rd, Palo Alto, CA 94304 USA.
   [Rejnmark, Lars] Aarhus Univ Hosp, Clin Med & Endocrinol, DK 8200 Aarhus N, Denmark.
C3 Mayo Clinic; McMaster University; Columbia University; University of
   Copenhagen; Copenhagen University Hospital; Rigshospitalet; University
   of Chicago; University of California System; University of California
   San Francisco; Laval University; Laval University Hospital; Laval
   University; Fondazione Policlinico Universitario Campus Bio Medico;
   University Campus Bio Medico   Rome Italy; Nevada System of Higher
   Education (NSHE); University of Nevada Reno; Technische Universitat
   Dresden; University of Pisa; Azienda Ospedaliero Universitaria Pisana;
   Aarhus University
RP Shu, AD (通讯作者)，Ascendis Pharm Inc, Endocrine Med Sci, 1000 Page Mill Rd, Palo Alto, CA 94304 USA.
EM ads@ascendispharma.com
RI Palermo, Andrea/D 7406 2015; palermo, andrea/D 7406 2015; Hofbauer,
   Lorenz/G 2490 2010; Hofbauer, Lorenz C./G 2490 2010; Sibley,
   Christopher/C 9900 2013; Schwarz, Peter/AAF 1558 2020
OI Palermo, Andrea/0000 0002 1143 4926; Hofbauer, Lorenz
   C./0000 0002 8691 8423; 
FU Ascendis Pharma Bone Diseases A/S, Hellerup, Denmark; Ascendis Pharma
   Inc.
FX The authors thank the trial participants and their families,
   investigators, and the trial staff. Medical writing support was provided
   by Kristin Hirahatake, PhD, of Ascendis Pharma Inc.
CR Ahmed I., 2022, J ENDOCR SOC, V6, pA193, DOI DOI 10.1210/JENDSO/BVAC150.398
   Brandi ML, 2016, J CLIN ENDOCR METAB, V101, P2273, DOI 10.1210/jc.2015 3907
   Brod M, 2021, J PATIENT REP OUTCOM, V5, DOI 10.1186/s41687 021 00320 2
   Brod M, 2020, PATIENT, V13, P151, DOI 10.1007/s40271 019 00388 5
   Büttner M, 2017, ENDOCRINE, V58, P14, DOI 10.1007/s12020 017 1377 3
   Holten Andersen L, 2019, J BONE MINER RES, V34, P2075, DOI 10.1002/jbmr.3824
   Karpf DB, 2020, J BONE MINER RES, V35, P1430, DOI 10.1002/jbmr.4016
   Khan AA, 2023, J BONE MINER RES, V38, P14, DOI 10.1002/jbmr.4726
   Khan AA, 2022, J BONE MINER RES, V37, P2568, DOI 10.1002/jbmr.4691
   Khan AA, 2022, J CLIN ENDOCR METAB, V107, pE372, DOI 10.1210/clinem/dgab577
   Kontogeorgos G, 2022, ENDOCR CONNECT, V11, DOI 10.1530/EC 21 0379
   Mannstadt Michael, 2017, Nat Rev Dis Primers, V3, P17080, DOI 10.1038/nrdp.2017.80
   Maruish ME, 2011, USERS MANUAL SF 36V2
   Palermo A., 2022, ECE 2022 MAY 21 24 2
   Rubin M., 2022, ASBMR 2022 ANN M SEP
   Rubin Mishaela R, 2020, F1000Res, V9, DOI 10.12688/f1000research.22717.1
   Shoback DM, 2016, J CLIN ENDOCR METAB, V101, P2300, DOI 10.1210/jc.2015 3909
   Siggelkow H, 2020, CLIN ENDOCRINOL, V92, P159, DOI 10.1111/cen.14128
   Silva BC, 2021, REV ENDOCR METAB DIS, V22, P789, DOI 10.1007/s11154 020 09614 0
NR 19
TC 8
Z9 8
U1 3
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2025
VL 110
IS 4
BP 951
EP 960
DI 10.1210/clinem/dgae693
EA OCT 2024
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 3BA1D
UT WOS:001346006300001
PM 39376010
OA hybrid
DA 2025 08 17
ER

PT J
AU Sun, YX
   Zhang, JF
   Xu, J
   Xu, LL
   Wu, TY
   Wang, B
   Pan, XH
   Li, G
AF Sun, Yu Xin
   Zhang, Jin Fang
   Xu, Jia
   Xu, Liang Liang
   Wu, Tian Yi
   Wang, Bin
   Pan, Xiao Hua
   Li, Gang
TI MicroRNA 144 3p inhibits bone formation in distraction osteogenesis
   through targeting Connexin 43
SO ONCOTARGET
LA English
DT Article
DE distraction osteogenesis; mesenchymal stem cells; microRNAs; miR 144
ID INDUCED SIGNAL TRANSDUCTION; DOWN REGULATION; OSTEOBLAST;
   DIFFERENTIATION; MIR 144
AB Distraction osteogenesis (DO), one of effective therapies for bone regeneration, has been received more attention in recent years. However, the underlying mechanism remains elusive. Recently, microRNAs (miRNAs) have been reported to play important roles in regulating osteogenesis and bone formation. We therefore provided the hypothesis that miRNAs could involve in the DO mediated bone regeneration. After successfully established the DO model of rats, a miRNA microarray was performed to find the differently expressed miRNAs in DO and control groups in this study. As one of the most downregulated miRNAs, miR 144 3p was found to be decreased during osteogenic differentiation in mesenchymal stem cells of rats (rBMSCs) and DO model. And miR 144 3p overexpression suppressed the osteogenesis while its inhibitor promoted osteogenesis. Furthermore, Connexin 43, an essential regulator for osteogenesis, was validated to be a novel target for miR 144 3p. Finally, miR 144 3p inhibitor modified MSCs promoted mineralization of distracted bone in rat DO model. In conclusion, miR144  3p was found to regulate osteogenesis and inhibition of miR 144 3p resulted in acceleration of mineralization of DO, which not only give clues to understanding the mechanism of DO but also provide a potential therapeutic target in clinical practice.
C1 [Sun, Yu Xin; Pan, Xiao Hua; Li, Gang] Bao An Dist Peoples Hosp, Dept Orthopaed & Traumatol, Shenzhen, Peoples R China.
   [Sun, Yu Xin; Zhang, Jin Fang; Xu, Liang Liang; Wu, Tian Yi; Wang, Bin; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Dept Orthopaed & Traumatol,Li Ka Shing Inst Hlth, Shatin, Hong Kong, Peoples R China.
   [Sun, Yu Xin; Zhang, Jin Fang; Xu, Liang Liang; Wu, Tian Yi; Wang, Bin; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Lui Che Woo Inst Innovat Med, Shatin, Hong Kong, Peoples R China.
   [Sun, Yu Xin; Zhang, Jin Fang; Li, Gang] Chinese Univ Hong Kong, Shenzhen Res Inst, CUHK ACC Space Med Ctr Hlth Maintenance Musculosk, Shenzhen, Peoples R China.
   [Xu, Jia] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Shanghai, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Key Lab Regenerat Med,Minist Educ, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital; The Chinese
   University of Hong Kong, Shenzhen; CUHK Shenzhen Research Institute;
   Shanghai Jiao Tong University; Chinese University of Hong Kong
RP Pan, XH; Li, G (通讯作者)，Bao An Dist Peoples Hosp, Dept Orthopaed & Traumatol, Shenzhen, Peoples R China.; Li, G (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Dept Orthopaed & Traumatol,Li Ka Shing Inst Hlth, Shatin, Hong Kong, Peoples R China.; Li, G (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Lui Che Woo Inst Innovat Med, Shatin, Hong Kong, Peoples R China.; Li, G (通讯作者)，Chinese Univ Hong Kong, Shenzhen Res Inst, CUHK ACC Space Med Ctr Hlth Maintenance Musculosk, Shenzhen, Peoples R China.; Li, G (通讯作者)，Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Key Lab Regenerat Med,Minist Educ, Hong Kong, Hong Kong, Peoples R China.
EM 568282414@qq.com; gangli@cuhk.edu.hk
RI Li, Gang/J 7830 2018; Kang, Qinglin/IUM 3978 2023; WANG,
   BIN/O 2346 2019; SUN, Yuxin/B 5440 2016; Liangliang, XU/K 9185 2019
OI Li, Gang/0000 0002 3981 2239; WANG, BIN/0000 0002 1348 1494; Xu,
   Liangliang/0000 0002 5249 7480; 
FU National Natural Science Foundation of China [81371946, 81374568]; Hong
   Kong Government Research Grant Council, General Research Fund [470813,
   14119115, 9054014]; China Shenzhen City Science and Technology Bureau
   [GJHZ20140419120051680, JCYJ20150630165236960]; SMART; Lui Che Woo
   Institute of Innovative Medicine; Chinese University of Hong Kong
FX The work was partially supported by grants from National Natural Science
   Foundation of China (81371946 and 81374568); Hong Kong Government
   Research Grant Council, General Research Fund (470813, 14119115 and
   9054014) and grants from China Shenzhen City Science and Technology
   Bureau (GJHZ20140419120051680 and JCYJ20150630165236960). This study was
   also supported in part by SMART program, Lui Che Woo Institute of
   Innovative Medicine, The Chinese University of Hong Kong and the
   research was made possible by resources donated by Lui Che Woo
   Foundation Limited.
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Aronson J, 1997, J ORTHOPAED RES, V15, P221, DOI 10.1002/jor.1100150210
   Chaible LM, 2011, TOXICOL PATHOL, V39, P1046, DOI 10.1177/0192623311422075
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Dhaliwal K, 2016, J PLAST RECONSTR AES, V69, pE19, DOI 10.1016/j.bjps.2015.11.003
   Fu WM, 2015, J HEPATOL, V63, P886, DOI 10.1016/j.jhep.2015.05.016
   Genovesi LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023935
   Guo YW, 2013, FEBS J, V280, P4531, DOI 10.1111/febs.12417
   [康夏 Kang Xia], 2013, [第三军医大学学报, Journal of Third Military Medical University], V35, P922
   Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931
   Li SN, 2015, J ORTHOP RES, V33, P1008, DOI 10.1002/jor.22830
   Li XT, 2013, J ORTHOP RES, V31, P1959, DOI 10.1002/jor.22448
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Lim K.T., 2014, Biomed Res Int, V2014, P316803, DOI DOI 10.1155/2014/316803
   Liu YH, 2011, MOL IMMUNOL, V48, P1084, DOI 10.1016/j.molimm.2011.02.001
   Loiselle AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081399
   Loiselle AE, 2013, J ORTHOP RES, V31, P147, DOI 10.1002/jor.22178
   Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060
   Morcos MW, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/842975
   Nugent M, 2016, OSTEOARTHR CARTILAGE, V24, P573, DOI 10.1016/j.joca.2015.10.018
   PALEY D, 1990, CLIN ORTHOP RELAT R, P81
   Papaioannou G, 2013, P NATL ACAD SCI USA, V110, pE3291, DOI 10.1073/pnas.1302797110
   Penzkofer D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101153
   Redova M, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 55
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   SUN Y, 2017, SCI REP UK, V7
   Sun YX, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/412327
   Tirumuru N, 2011, HEPATOLOGY, V54, p1328A
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516
   Zhao MD, 2014, INT J MOL MED, V34, P1565, DOI 10.3892/ijmm.2014.1963
NR 32
TC 20
Z9 21
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 27
PY 2017
VL 8
IS 52
BP 89913
EP 89922
DI 10.18632/oncotarget.20984
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FL3BP
UT WOS:000414097100042
PM 29163798
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Sawai, Y
   Murata, H
   Koto, K
   Matsui, T
   Horie, N
   Ashihara, E
   Maekawa, T
   Fushiki, S
   Kubo, T
AF Sawai, Yasushi
   Murata, Hiroaki
   Koto, Kazutaka
   Matsui, Takaaki
   Horie, Naoyuki
   Ashihara, Eishi
   Maekawa, Taira
   Fushiki, Shinji
   Kubo, Toshikazu
TI Effects of low intensity pulsed ultrasound on osteosarcoma and cancer
   cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE low intensity pulsed ultrasound; metastatic bone tumor; treatment;
   cancer; osteosarcoma; osteoblast
ID AKT PATHWAY; EXPRESSION; GROWTH; APOPTOSIS; ERK; OSTEOBLASTS;
   ENHANCEMENT; ACTIVATION; MECHANISMS; RANKL
AB Metastatic bone tumors cause pain and pathological fractures due to bone destruction. If we could enhance new osteogenic activities and prevent progression of osteolytic change by malignant cells, patients could achieve satisfactory activity of daily living. Low intensity pulsed ultrasound (LIPUS), which leads to bone formation by osteoblasts, has been used for the treatment of fractures. LIPUS has been reported to enhance the effect of an anticancer drug on lymphoma and liver cancer cells. However, there have been no reports of proliferation, vascularization and migration effects on cancer cells. In this study, we investigated the effects of LIPUS treatment on cancer and osteosarcoma cells and specifically whether it promotes bone formation without accelerating proliferation of tumor cells. We used MC3T3 El cells, a mouse osteoblast cell line, LM8, a mouse osteosarcoma cell line, SaOS2, a human osteosarcoma cell line, 786 O, a human renal cancer cell line, PC 3, a human prostate cancer cell line, and A549, a human lung cancer cell line. The expression of extracellular signal regulated kinase (ERK1/2), Akt, beta catenin, vascular endothelial growth factor (VEGF), and cell migration were analyzed. LIPUS stimulation did not affect proliferation of all the cells examined. The phosphorylation of ERK1/2 and Akt was induced by LIPUS stimulation in MC3T3 El, LM8, SaOS2 and A549 cells, but not in PC 3 and 786 O cells. LIPUS stimulation did not significantly increase beta catenin. VEGF protein levels and cell migration were significantly increased only in MC3T3 E1 cells. It may be concluded that LIPUS stimulation on metastatic bone tumors induces differentiation of osteoblasts without proliferation of tumor cells. Our study suggests that LIPUS may be a new method of treatment without surgery for metastatic bone tumors.
C1 [Sawai, Yasushi; Murata, Hiroaki; Koto, Kazutaka; Matsui, Takaaki; Horie, Naoyuki; Kubo, Toshikazu] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, Kyoto 6028566, Japan.
   [Sawai, Yasushi; Koto, Kazutaka; Fushiki, Shinji] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pathol & Appl Neurobiol, Kamigyo Ku, Kyoto 6028566, Japan.
   [Ashihara, Eishi; Maekawa, Taira] Kyoto Univ Hosp, Dept Transfus Med & Cell Therapy, Sakyo Ku, Shogoin, Kyoto 6068507, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine; Kyoto University
RP Murata, H (通讯作者)，Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, 465 Kawaramachi Hirokoji, Kyoto 6028566, Japan.
EM murah@koto.kpu m.ac.jp
FU Grants in Aid for Scientific Research [24659461, 24390244, 23591404]
   Funding Source: KAKEN
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Borsje MA, 2010, ANGLE ORTHOD, V80, P498, DOI 10.2319/060809 318.1
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742 4658.2009.07366.x
   Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   Dimitriou R., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P253
   DUARTE LR, 1983, ARCH ORTHOP TRAUM SU, V101, P153, DOI 10.1007/BF00436764
   Dyson M, 1983, Ultrasound Med Biol, VSuppl 2, P61
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Ito M, 2000, ULTRASOUND MED BIOL, V26, P161, DOI 10.1016/S0301 5629(99)00110 6
   Iwabuchi S, 2005, BIOMATERIALS, V26, P7104, DOI 10.1016/j.biomaterials.2005.05.004
   Jin CY, 2007, CARCINOGENESIS, V28, P1058, DOI 10.1093/carcin/bgl251
   Kondo T, 2009, J MED ULTRASON, V36, P61, DOI 10.1007/s10396 009 0212 8
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Lu H, 2008, ULTRASOUND MED BIOL, V34, P1248, DOI 10.1016/j.ultrasmedbio.2008.01.009
   Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Rutten S, 2007, J TRAUMA, V62, P902, DOI 10.1097/01.ta.0000238663.33796.fb
   Suzuki A, 2009, ACTA BIOCH BIOPH SIN, V41, P108, DOI 10.1093/abbs/gmn012
   Takeuchi R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2451
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tano K, 2010, FEBS LETT, V584, P4575, DOI 10.1016/j.febslet.2010.10.008
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
NR 26
TC 19
Z9 29
U1 1
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD AUG
PY 2012
VL 28
IS 2
BP 481
EP 486
DI 10.3892/or.2012.1816
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 970VM
UT WOS:000306160400011
PM 22614439
OA Bronze
DA 2025 08 17
ER

PT J
AU Raphael Mizrahi, B
   Attar Namdar, M
   Chourasia, M
   Cascio, MG
   Shurki, A
   Tam, J
   Neuman, M
   Rimmerman, N
   Vogel, Z
   Shteyer, A
   Pertwee, RG
   Zimmer, A
   Kogan, NM
   Bab, I
   Gabet, Y
   Zaidi, M
AF Raphael Mizrahi, Bitya
   Attar Namdar, Malka
   Chourasia, Mukesh
   Cascio, Maria G.
   Shurki, Avital
   Tam, Joseph
   Neuman, Moshe
   Rimmerman, Neta
   Vogel, Zvi
   Shteyer, Arie
   Pertwee, Roger G.
   Zimmer, Andreas
   Kogan, Natalya M.
   Bab, Itai
   Gabet, Yankel
   Zaidi, Mone
TI Osteogenic growth peptide is a potent anti inflammatory and bone
   preserving hormone via cannabinoid receptor type 2
SO ELIFE
LA English
DT Article
DE osteogenic growth peptide; endocannabinoid; CB2; cannabinoid receptor;
   bone; immunoregulation; H4(99 103); Human; Mouse
ID MOLECULAR DYNAMICS; MUSCARINIC TONE; AGONIST; CB2; INHIBITION;
   ENDOCANNABINOIDS; QUANTIFICATION; IDENTIFICATION; PENTAPEPTIDE;
   EXPRESSION
AB The endocannabinoid system consists mainly of 2 arachidonoylglycerol and anandamide, as well as cannabinoid receptor type 1 and type 2 (CB2). Based on previous studies, we hypothesized that a circulating peptide previously identified as osteogenic growth peptide (OGP) maintains a bone protective CB2 tone. We tested OGP activity in mouse models and cells, and in human osteoblasts. We show that the OGP effects on osteoblast proliferation, osteoclastogenesis, and macrophage inflammation in vitro, as well as rescue of ovariectomy induced bone loss and prevention of ear edema in vivo are all abrogated by genetic or pharmacological ablation of CB2. We also demonstrate that OGP binds at CB2 and may act as both an agonist and positive allosteric modulator in the presence of other lipophilic agonists. In premenopausal women, OGP circulating levels significantly decline with age. In adult mice, exogenous administration of OGP completely prevented age related bone loss. Our findings suggest that OGP attenuates age related bone loss by maintaining a skeletal CB2 tone. Importantly, they also indicate the occurrence of an endogenous peptide that signals via CB2 receptor in health and disease.
C1 [Raphael Mizrahi, Bitya; Gabet, Yankel] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, Tel Aviv, Israel.
   [Attar Namdar, Malka; Neuman, Moshe; Kogan, Natalya M.; Bab, Itai] Hebrew Univ Jerusalem, Inst Dent Sci, Fac Dent Med, Bone Lab, Jerusalem, Israel.
   [Chourasia, Mukesh; Shurki, Avital; Tam, Joseph] Hebrew Univ Jerusalem, Inst Drug Res, Fac Med, Jerusalem, Israel.
   [Cascio, Maria G.; Pertwee, Roger G.] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland.
   [Rimmerman, Neta; Vogel, Zvi] Weizmann Inst Sci, Dept Neurobiol, Rehovot, Israel.
   [Shteyer, Arie] Hadassah Hebrew Univ Hosp, Dept Oral & Maxillofacial Surg, Jerusalem, Israel.
   [Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, Bonn, Germany.
C3 Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of
   Jerusalem; Hebrew University of Jerusalem; University of Aberdeen;
   Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah
   University Hospital; Hadassah University Medical Center; University of
   Bonn
RP Raphael Mizrahi, B; Gabet, Y (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, Tel Aviv, Israel.
EM bityar@tau.ac.il; yankel@tauex.tau.ac.il
RI ; Raphael Mizrahi, Bitya/GLR 8221 2022; Chourasia, Mukesh/S 3976 2016;
   Kogan, Natalya M./KHT 6734 2024; Pertwee, Roger/E 1312 2011; Gabet,
   Yankel/I 6244 2019
OI Raphael Mizrahi, Bitya/0000 0001 8629 1088; Chourasia,
   Mukesh/0000 0002 4565 5348; Gabet, Yankel/0000 0002 7494 0631; Kogan,
   Natalya M./0000 0002 6792 3841; Tam, Joseph/0000 0002 0948 0093
FU Israel Science Foundation [1822/12, 1367/12, 1086/17]; American Society
   for Bone and Mineral Research
FX Israel Science Foundation 1822/12 Yankel Gabet Israel Science Foundation
   1367/12 Yankel Gabet Israel Science Foundation 1086/17 Yankel Gabet
   American Society for Bone and Mineral Research Gap award Yankel Gabet
   The funders had no role in study design, data collection and
   interpretation, or the decision to submit the work for publication.
CR Alreja M, 2000, J NEUROSCI, V20, P8103
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bab I, 2002, BIOPOLYMERS, V66, P33, DOI 10.1002/bip.10202
   Bab I, 1999, J PEPT RES, V54, P408, DOI 10.1034/j.1399 3011.1999.00135.x
   BAB I, 1992, EMBO J, V11, P1867, DOI 10.1002/j.1460 2075.1992.tb05238.x
   Bab I., 2007, MICROTOMOGRAPHIC ATL, DOI [10.1007/978 0 387 39258 5, DOI 10.1007/978 0 387 39258 5]
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Bajayo A, 2005, P NATL ACAD SCI USA, V102, P12956, DOI 10.1073/pnas.0502562102
   Bar Shavit Z, 2008, AUTOIMMUNITY, V41, P195, DOI 10.1080/08916930701694469
   Bauer M, 2012, J BIOL CHEM, V287, P36944, DOI 10.1074/jbc.M112.382481
   BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014 5793(95)01207 U
   Benito C, 2005, J NEUROSCI, V25, P2530, DOI 10.1523/JNEUROSCI.3923 04.2005
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Blankman JL, 2013, PHARMACOL REV, V65, P849, DOI 10.1124/pr.112.006387
   Blaschke M, 2018, ADV CLIN EXP MED, V27, P45, DOI 10.17219/acem/67561
   Bonnick Sydney L, 2006, Clin Cornerstone, V8, P28, DOI 10.1016/S1098 3597(06)80063 3
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014 2999(00)00211 9
   Cascio MG, 2010, BRIT J PHARMACOL, V159, P129, DOI 10.1111/j.1476 5381.2009.00515.x
   Chen YC, 2000, J PEPT RES, V56, P147, DOI 10.1034/j.1399 3011.2000.00763.x
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Eswar Narayanan, 2006, Curr Protoc Bioinformatics, VChapter 5, pUnit, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s47, 10.1002/cpps.20, 10.1002/cpbi.3, 10.1002/0471250953.bi0506s15]
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gartland A, 2012, METHODS MOL BIOL, V806, P337, DOI 10.1007/978 1 61779 367 7_22
   Gavish H, 1997, BIOCHEMISTRY US, V36, P14883, DOI 10.1021/bi971670t
   Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045
   GREENBERG Z, 1993, BIOCHIM BIOPHYS ACTA, V1178, P273, DOI 10.1016/0167 4889(93)90204 3
   GREENBERG Z, 1995, J CLIN ENDOCR METAB, V80, P2330, DOI 10.1210/jc.80.8.2330
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hashimotodani Y, 2013, J PHYSIOL LONDON, V591, P4765, DOI 10.1113/jphysiol.2013.254474
   Horváth B, 2012, BRIT J PHARMACOL, V165, P2462, DOI 10.1111/j.1476 5381.2011.01381.x
   Hua T, 2017, NATURE, V547, P468, DOI 10.1038/nature23272
   Hurst DP, 2013, CHEM PHYS LIPIDS, V169, P46, DOI 10.1016/j.chemphyslip.2013.01.009
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Jo S, 2017, J COMPUT CHEM, V38, P1114, DOI 10.1002/jcc.24660
   Jonsson KO, 2006, LIFE SCI, V78, P598, DOI 10.1016/j.lfs.2005.05.059
   Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370
   Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Kou JP, 2005, BIOL PHARM BULL, V28, P1234, DOI 10.1248/bpb.28.1234
   Kralick AE, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00099
   Li XT, 2019, CELL, V176, P459, DOI 10.1016/j.cell.2018.12.011
   Mackie K, 2005, HANDB EXP PHARMACOL, V168, P299
   Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254
   Malfitano AM, 2014, SEMIN IMMUNOL, V26, P369, DOI 10.1016/j.smim.2014.04.002
   MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006 2952(95)00109 D
   Miwa JM, 2012, PHYSIOLOGY, V27, P187, DOI 10.1152/physiol.00002.2012
   Munk C, 2019, NAT METHODS, V16, P151, DOI 10.1038/s41592 018 0302 x
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Ngoh EN, 2016, GASTROENTEROLOGY, V150, P465, DOI 10.1053/j.gastro.2015.09.049
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228
   Ossola CA, 2016, J PERIODONTOL, V87, P725, DOI 10.1902/jop.2016.150612
   Pandey P, 2020, J BIOMOL STRUCT DYN, V38, P32, DOI 10.1080/07391102.2019.1567384
   Pándy Szekeres G, 2018, NUCLEIC ACIDS RES, V46, pD440, DOI 10.1093/nar/gkx1109
   Patil C, 2004, IMMUNOL INVEST, V33, P213, DOI 10.1081/IMM 120034231
   Petrucci V, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09808 8
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Prime TA, 2009, P NATL ACAD SCI USA, V106, P10764, DOI 10.1073/pnas.0903250106
   Racz I, 2008, J NEUROSCI, V28, P12136, DOI 10.1523/JNEUROSCI.3402 08.2008
   San Miguel SM, 2005, J BIOL CHEM, V280, P37495, DOI 10.1074/jbc.M503861200
   Schattauer SS, 2019, J BIOL CHEM, V294, P16884, DOI 10.1074/jbc.RA119.009592
   SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352
   Smith E, 2005, NUCLEIC ACIDS RES, V33, P1298, DOI 10.1093/nar/gki248
   Smoum R, 2015, P NATL ACAD SCI USA, V112, P8774, DOI 10.1073/pnas.1503395112
   Smoum R, 2010, P NATL ACAD SCI USA, V107, P17710, DOI 10.1073/pnas.0912479107
   Spreafico A, 2006, J CELL BIOCHEM, V98, P1007, DOI 10.1002/jcb.20836
   Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389
   Sun LL, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974 017 0913 7
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471 4159.1993.tb03576.x
   Wang WX, 2003, ANAL CHEM, V75, P4818, DOI 10.1021/ac026468x
   Wu CWK, 2005, J NEUROSCI, V25, P4232, DOI 10.1523/JNEUROSCI.4957 04.2005
   Yirmiya R, 2006, P NATL ACAD SCI USA, V103, P16876, DOI 10.1073/pnas.0604234103
NR 77
TC 9
Z9 10
U1 0
U2 15
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD MAY 23
PY 2022
VL 11
AR e65834
DI 10.7554/eLife.65834
PG 25
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 1W0SQ
UT WOS:000806492100001
PM 35604006
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hou, J
   Hu, ZT
   Xu, WY
   Di, YJ
   Song, CL
   Wu, F
   Liu, JT
   Guo, YH
AF Hou, Jie
   Hu, Zhitian
   Xu, Wenyu
   Di, Yujing
   Song, Chunli
   Wu, Fan
   Liu, Jintao
   Guo, Yinhan
TI The similarity of pharmacokinetics, pharmacodynamics, safety, and
   immunogenicity between recombinant fully human anti RANKL monoclonal
   antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese
   subjects: A single center, randomized, double blind, single dose,
   parallel controlled clinical study
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Anti RANKL; Denosumab; Biosimilar; MW032; Pharmacokinetics; Safety
ID BONE
AB Objective: To compare the pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity between MW032 (denosumab biosimilar) and Xgeva (R) (denosumab) in healthy Chinese subjects.
   Study design: In this single center, randomized, double blind, single dose, parallel controlled design study, 120 healthy male subjects were randomized 1:1 to receive a single dose subcutaneous injection of 120 mg MW032 or Xgeva (R), with an observation period of 161 days. The primary endpoint was the bioequivalence of PK parameters (Cmax, AUC0 t), and secondary endpoints including PD parameters, safety, and immunogenicity.
   Results: One hundred and twelve subjects completed the study, including 56 subjects in each group. The geometric mean ratio and 90% CI for AUC0_t and Cmax were 1.117 (1.034, 1.205) and 1.060 (0.984, 1.142), respectively, which were both within the equivalence interval (0.8, 1.25). The inter subject variation ranged from 21.37% to 27.37%. The PD parameters between MW032 and Xgeva (R) were similar. There was no statistically significant difference in the positive incidence of anti drug antibody test between the two groups. Both MW032 and Xgeva (R) appeared to be well tolerated and no Grade 3 or above serious adverse reactions occurred. The adverse reactions observed in the study were reported for denosumab generally. Moreover, there were no high incidence or previously unreported adverse reactions.
   Conclusion: This study evidenced that the PK profiles of MW032, a denosumab biosimilar, and Xgeva (R) were bioequivalent. We also found that the PDs, safety, and immunogenicity were similar between the two drugs. Therefore, our results supported the next confirmatory studies for the development of MW032.
C1 [Hou, Jie; Di, Yujing; Song, Chunli] Peking Univ PKU Care, Luzhong Hosp, Phase I Ctr, Zibo, Shandong, Peoples R China.
   [Hu, Zhitian; Xu, Wenyu; Wu, Fan; Liu, Jintao; Guo, Yinhan] Mabwell Shanghai Biosci Co Ltd, Shanghai, Peoples R China.
RP Guo, YH (通讯作者)，Mabwell Shanghai Biosci Co Ltd, Shanghai, Peoples R China.
RI Liu, Jintao/JEF 1290 2023
FU Mabwell (Shanghai) Bioscience Co., Ltd. Shanghai, China
FX Funding This work was supported by the Mabwell (Shanghai) Bioscience
   Co., Ltd. Shanghai, China.
CR Amgen, 2021, AMG PROLIA DEN PRESC
   [Anonymous], RECOMBINANT FU UNPUB
   [Anonymous], 2010, XGEV DEN INJ
   [Anonymous], 2020, CHINESE J OSTEOPOROS, V13, DOI [10.3969/j.issn.1674 2591, DOI 10.3969/J.ISSN.1674 2591]
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Center for drug evaluation NMPA, 2005, TECHNICAL GUIDELINES
   Center for drug evaluation NMPA, 2015, TECHNICAL GUIDELINES
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Chinese Society of Osteoporosis and Bone Mineral Research, 2015, Zhonghua Guzhi Shusong He Gukuangyan Jibing Zazhi, V8, P283, DOI 103969/j.issn.16742591
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   National Medical Products Administration National Health Commission of the people's Republic of China, GOOD CLIN PRACT 2020
   Poon M, 2012, J BONE ONCOL, V1, P74, DOI 10.1016/j.jbo.2012.10.001
   State Administration for Market Regulation, PROV DRUG REG
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Zhang H, 2021, EXPERT OPIN INV DRUG, V30, P185, DOI 10.1080/13543784.2021.1863371
   Zhang H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01329
NR 16
TC 6
Z9 6
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2022
VL 107
AR 108666
DI 10.1016/j.intimp.2022.108666
EA MAR 2022
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 1C6AS
UT WOS:000793200100006
PM 35286913
DA 2025 08 17
ER

PT J
AU Sage, AP
   Lu, JX
   Atti, E
   Tetradis, S
   Ascenzi, MG
   Adams, DJ
   Demer, LL
   Tintut, Y
AF Sage, Andrew P.
   Lu, Jinxiu
   Atti, Elisa
   Tetradis, Sotirios
   Ascenzi, Maria Grazia
   Adams, Douglas J.
   Demer, Linda L.
   Tintut, Yin
TI Hyperlipidemia Induces Resistance to PTH Bone Anabolism in Mice via
   Oxidized Lipids
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OXIDIZED LIPIDS; HYPERLIPIDEMIA; PARATHYROID HORMONE; OSTEOANABOLISM;
   OSTEOPOROSIS
ID LOW DENSITY LIPOPROTEIN; HIGH FAT DIET; HUMAN SECONDARY OSTEONS; E NULL
   MICE; PARATHYROID HORMONE; OSTEOBLASTIC CELLS; MINERAL DENSITY;
   DEFICIENT MICE; VASCULAR CELL; DIFFERENTIATION
AB In hyperlipidemia, oxidized lipids accumulate in vascular tissues and trigger atherosclerosis. Such lipids also deposit in bone tissues, where they may promote osteoporosis. We found previously that oxidized lipids attenuate osteogenesis and that parathyroid hormone (PTH) bone anabolism is blunted in hyperlipidemic mice, suggesting that osteoporotic patients with hyperlipidemia may develop resistance to PTH therapy. To determine if oxidized lipids account for this PTH resistance, we blocked lipid oxidation products in hyperlipidemic mice with an ApoA I mimetic peptide, D 4F, and the bone anabolic response to PTH treatment was assessed. Skeletally immature Ldlr( / ) mice were placed on a high fat diet and treated with D 4F peptide and/or with intermittent PTH(1 34) injections. As expected, D 4F attenuated serum lipid oxidation products and tissue lipid deposition induced by the diet. Importantly, D 4F treatment attenuated the adverse effects of dietary hyperlipidemia on PTH anabolism by restoring micro computed tomographic parameters of bone quality cortical mineral content, area, and thickness. D 4F significantly reduced serum markers of bone resorption but not bone formation. PTH and D 4F, together but not separately, also promoted bone anabolism in an alternative model of hyperlipidemia, Apoe( / ) mice. In normolipemic mice, D 4F cotreatment did not further enhance the anabolic effects of PTH, indicating that the mechanism is through its effects on lipids. These findings suggest that oxidized lipids mediate hyperlipidemia induced PTH resistance in bone through modulation of bone resorption. (C) 2011 American Society for Bone and Mineral Research.
C1 [Tintut, Yin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Div Cardiol,Dept Med, Los Angeles, CA 90095 USA.
   [Lu, Jinxiu; Demer, Linda L.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA.
   [Atti, Elisa; Tetradis, Sotirios] Univ Calif Los Angeles, Dept Dent, Los Angeles, CA 90095 USA.
   [Ascenzi, Maria Grazia] Univ Calif Los Angeles, Dept Orthoped Surg, Los Angeles, CA 90095 USA.
   [Adams, Douglas J.] Univ Connecticut, Ctr Hlth, Dept Orthoped Surg, New England Musculoskeletal Inst, Farmington, CT USA.
   [Demer, Linda L.] Univ Calif Los Angeles, Dept Biomed Engn, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; University of Connecticut; University of
   California System; University of California Los Angeles
RP Tintut, Y (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Div Cardiol,Dept Med, A2 237,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM ytintut@mednet.ucla.edu
RI Adams, David/GMW 8541 2022; Demer, Linda/I 5770 2013; Sage,
   Andrew/JKH 5873 2023
OI Demer, Linda/0000 0002 9618 6895; Sage, Andrew/0000 0001 7255 3497
FU National Institutes of Health [DK076009, DK081346, DK081346 S1,
   HL081202]; Laubisch Endowment at UCLA
FX This research was supported by grants from the National Institutes of
   Health (DK076009, DK081346, DK081346 S1, and HL081202) and the Laubisch
   Endowment at UCLA. We thank M Huang, L Hon, G Hough, F Ye, and JW Combs
   for their expert technical assistance, Dr R Pereira (UCLA Bone
   Histomorphometric Laboratory) for histomorphometric analysis, and Dr M
   Navab for guidance.
CR Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Ascenzi MG, 2008, J BIOMECH, V41, P3426, DOI 10.1016/j.jbiomech.2008.09.010
   Ascenzi MG, 2006, J STRUCT BIOL, V153, P14, DOI 10.1016/j.jsb.2005.08.007
   Bilezikian J, 2005, ASBMR 27 ANN M
   Brodeur MR, 2008, FREE RADICAL BIO MED, V44, P506, DOI 10.1016/j.freeradbiomed.2007.08.030
   Buga GM, 2006, J LIPID RES, V47, P2148, DOI 10.1194/jlr.M600214 JLR200
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Elis S, 2010, J BONE MINER RES, V25, P2051, DOI 10.1002/jbmr.100
   Furnkranz A, 2005, ARTERIOSCL THROM VAS, V25, P633, DOI 10.1161/01.ATV.0000153106.03644.a0
   Hirasawa H, 2007, J BONE MINER RES, V22, P1020, DOI 10.1359/JBMR.070330
   Huang MS, 2008, J BONE MINER RES, V23, P1672, DOI 10.1359/JBMR.080513
   Huang MS, 2008, BIOCHEM BIOPH RES CO, V374, P553, DOI 10.1016/j.bbrc.2008.07.062
   Huang MS, 2007, J BIOL CHEM, V282, P21237, DOI 10.1074/jbc.M701341200
   Ionova Martin SS, 2010, BONE, V46, P217, DOI 10.1016/j.bone.2009.10.015
   Knudsen VK, 2008, EUR J CLIN NUTR, V62, P463, DOI 10.1038/sj.ejcn.1602745
   Laurila A, 2001, ARTERIOSCL THROM VAS, V21, P991, DOI 10.1161/01.ATV.21.6.991
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Liang C, 2009, BIRTH DEFECTS RES B, V86, P362, DOI 10.1002/bdrb.20204
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Morony S, 2008, CIRCULATION, V117, P411, DOI 10.1161/CIRCULATIONAHA.107.707380
   Navab M, 2000, J LIPID RES, V41, P1481
   Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1426, DOI 10.1161/01.ATV.0000167412.98221.1a
   Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87
   Navab M, 2001, J LIPID RES, V42, P1308
   Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831
   Parhami F, 1999, J BONE MINER RES, V14, P2067, DOI 10.1359/jbmr.1999.14.12.2067
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Parhami F, 2001, J BONE MINER RES, V16, P182, DOI 10.1359/jbmr.2001.16.1.182
   Patel A, 2010, EPILEPSIA, V51, P1277, DOI 10.1111/j.1528 1167.2009.02488.x
   Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200
   Shah PK, 2001, CIRCULATION, V103, P3047, DOI 10.1161/hc2501.092494
   Tankó LB, 2003, CALCIFIED TISSUE INT, V73, P15, DOI 10.1007/s00223 002 2070 x
   Tintut Y, 2004, ARTERIOSCL THROM VAS, V24, pE6, DOI 10.1161/01.ATV.0000112023.62695.7f
   Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200
   Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427
   Tsukii K, 1998, BIOCHEM BIOPH RES CO, V246, P337, DOI 10.1006/bbrc.1998.8610
   Turek JJ, 2003, J NUTR BIOCHEM, V14, P24, DOI 10.1016/S0955 2863(02)00221 8
   Van Lenten BJ, 2008, J LIPID RES, V49, P2302, DOI 10.1194/jlr.M800075 JLR200
   Wu SF, 2004, J BIOL CHEM, V279, P4642, DOI 10.1074/jbc.M305518200
   Xiao Y, 2011, NUTRITION, V27, P214, DOI 10.1016/j.nut.2009.11.012
   Xu MS, 2010, BONE, V47, P341, DOI 10.1016/j.bone.2010.05.006
NR 42
TC 68
Z9 78
U1 0
U2 8
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2011
VL 26
IS 6
BP 1197
EP 1206
DI 10.1002/jbmr.312
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 770SP
UT WOS:000291109100006
PM 21611962
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhang, J
   Zheng, LJ
   Wang, ZY
   Pei, HL
   Hu, WT
   Nie, J
   Shang, P
   Li, BY
   Hei, TK
   Zhou, GM
AF Zhang, Jian
   Zheng, Lijun
   Wang, Ziyang
   Pei, Hailong
   Hu, Wentao
   Nie, Jing
   Shang, Peng
   Li, Bingyan
   Hei, Tom K.
   Zhou, Guangming
TI Lowering iron level protects against bone loss in focally irradiated and
   contralateral femurs through distinct mechanisms
SO BONE
LA English
DT Article
DE Ionizing radiation; Bone loss; Iron homeostasis; Osteoclasts; Hepcidin
ID RADIATION THERAPY; OSTEOCLAST DIFFERENTIATION; BODY IRRADIATION;
   TRABECULAR BONE; SERUM IRON; HEPCIDIN; MICE; DEFEROXAMINE; PREVENTS;
   STRENGTH
AB Radiation therapy leads to increased risk of late onset fragility and bone fracture due to the loss of bone mass. On the other hand, iron overloading causes osteoporosis by enhancing bone resorption. It has been shown that total body irradiation increases iron level, but whether the systemic bone loss is related to the changes in iron level and hepcidin regulation following bone irradiation remains unknown. To investigate the potential link between them, we first created an animal model of radiation induced systemic bone loss by targeting the mid shaft femur with a single 2 Gy dose of X rays. We found that mid shaft femur focal irradiation led to structural deterioration in the distal region of the trabecular bone with increased osteoclasts surface and expressions of bone resorption markers in both irradiated and contralateral femurs relative to non irradiated controls. Following irradiation, reduced hepcidin activity of the liver contributed to elevated iron levels in the serum and liver. By injecting hepcidin or deferoxamine (an iron chelator) to reduce iron level, deterioration of trabecular bone micro architecture in irradiated mice was abrogated. The ability of iron chelation to inhibit radiation induced osteoclast differentiation was observed in vitro as well. We further showed that ionizing radiation (IR) directly stimulated osteoclast differentiation and bone resorption in bone marrow cells isolated not from contralateral femurs but from directly irradiated femurs. These results suggest that increased iron levels after focal radiation is at least one of the main reasons for systemic bone loss. Furthermore, bone loss in directly irradiated bones is not only due to the elevated iron level, but also from increased osteoclast differentiation. In contrast, the bone loss in the contralateral femurs is mainly due to the elevated iron level induced by IR alone. These novel findings provide proof of principle evidence for the use of iron chelation or hepcidin as therapeutic treatments for IR induced osteoporosis.
C1 [Zhang, Jian; Zheng, Lijun; Wang, Ziyang; Pei, Hailong; Hu, Wentao; Nie, Jing; Li, Bingyan; Hei, Tom K.; Zhou, Guangming] Soochow Univ, State Key Lab Radiat Med & Protect, Sch Radiat Med & Protect, Med Coll, Suzhou, Peoples R China.
   [Zhang, Jian; Zheng, Lijun; Wang, Ziyang; Pei, Hailong; Hu, Wentao; Nie, Jing; Hei, Tom K.; Zhou, Guangming] Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou, Peoples R China.
   [Shang, Peng] Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Inst Special Environm Biophys, Sch Life Sci, Xian, Shaanxi, Peoples R China.
   [Shang, Peng] Northwestern Polytech Univ, Res & Dev Inst Shenzhen, Shenzhen, Peoples R China.
   [Li, Bingyan] Soochow Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Med Coll, Suzhou, Peoples R China.
   [Hei, Tom K.] Columbia Univ, Ctr Radiol Res, Coll Phys & Surg, New York, NY USA.
C3 Soochow University   China; Northwestern Polytechnical University;
   Northwestern Polytechnical University; Soochow University   China;
   Columbia University
RP Hei, TK (通讯作者)，630 West 168th St,VC11 205, New York, NY 10032 USA.; Zhou, GM (通讯作者)，199 Renai Rd, Suzhou 215123, Peoples R China.
EM tkh1@cumc.columbia.edu; gmzhou@suda.edu.cn
RI ; li, bingyan/NDS 7931 2025; Hu, Wentao/HGD 0217 2022
OI Zhang, Jian/0000 0002 6117 3285; 
FU National Natural Science Foundation of China [31600674]; China
   Postdoctoral Science Foundation [2017M610352]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions
FX This work was supported by the National Natural Science Foundation of
   China (31600674), Project funded by China Postdoctoral Science
   Foundation (2017M610352), and the Project Funded by the Priority
   Academic Program Development of Jiangsu Higher Education Institutions.
CR Alwood JS, 2015, J INTERF CYTOK RES, V35, P480, DOI 10.1089/jir.2014.0152
   Bandstra ER, 2008, RADIAT RES, V169, P607, DOI 10.1667/RR1310.1
   Baschant U, 2016, HAEMATOLOGICA, V101, P1499, DOI 10.3324/haematol.2016.144808
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Chandra A, 2013, BONE, V55, P449, DOI 10.1016/j.bone.2013.02.023
   Chen B, 2014, CALCIFIED TISSUE INT, V94, P353, DOI 10.1007/s00223 013 9817 4
   Chung JH, 2014, J PERIODONTAL RES, V49, P563, DOI 10.1111/jre.12136
   Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019
   Donneys A, 2013, PLAST RECONSTR SURG, V131, p711E, DOI 10.1097/PRS.0b013e3182865c57
   Donneys A, 2013, BONE, V52, P318, DOI 10.1016/j.bone.2012.10.014
   Felice PA, 2013, PLAST RECONSTR SURG, V132, p542E, DOI 10.1097/PRS.0b013e31829fe548
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Ganz T, 2011, ANNU REV MED, V62, P347, DOI 10.1146/annurev med 050109 142444
   Hoes MF, 2018, EUR J HEART FAIL, V20, P910, DOI 10.1002/ejhf.1154
   Igdem S, 2010, INT J RADIAT ONCOL, V77, P818, DOI 10.1016/j.ijrobp.2009.05.059
   Ikushima H, 2006, GYNECOL ONCOL, V103, P1100, DOI 10.1016/j.ygyno.2006.06.038
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jia D, 2011, RADIAT RES, V176, P624, DOI 10.1667/RR2505.1
   Kawamura K, 2018, J RADIAT RES, V59, DOI 10.1093/jrr/rrx091
   Keenawinna L, 2013, RADIAT RES, V180, P89, DOI 10.1667/RR3200.1
   Kim BJ, 2012, J BONE MINER RES, V27, P2279, DOI 10.1002/jbmr.1692
   Kondo H, 2009, RADIAT RES, V171, P283, DOI 10.1667/RR1463.1
   Kwon JW, 2008, AM J ROENTGENOL, V191, P987, DOI 10.2214/AJR.07.3634
   Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102
   Li GF, 2012, OSTEOPOROSIS INT, V23, P2403, DOI 10.1007/s00198 012 1982 1
   Meynard D, 2014, BLOOD, V123, P168, DOI 10.1182/blood 2013 06 427757
   Mitchell MJ, 1998, RADIOGRAPHICS, V18, P1125, DOI 10.1148/radiographics.18.5.9747611
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Oest ME, 2018, J BONE MINER RES, V33, P99, DOI 10.1002/jbmr.3289
   Sándor N, 2015, MUTAT RES GEN TOX EN, V793, P142, DOI 10.1016/j.mrgentox.2015.06.009
   Tanno T, 2007, NAT MED, V13, P1096, DOI 10.1038/nm1629
   Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458
   Xie LH, 2016, RADIAT ENVIRON BIOPH, V55, P81, DOI 10.1007/s00411 015 0623 4
   Xu XY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0527 0
   Xu Z, 2017, BONE, V94, P152, DOI 10.1016/j.bone.2016.09.023
   Zhang J, 2018, CONNECT TISSUE RES, V59, P509, DOI 10.1080/03008207.2018.1439482
   Zhang J, 2017, J RADIAT RES, V58, P791, DOI 10.1093/jrr/rrx026
   Zhang P, 2018, J MOL ENDOCRINOL, V60, P299, DOI 10.1530/JME 17 0301
   Zhang XH, 2013, RADIAT RES, V179, P684, DOI 10.1667/RR3142.1
   Zhao GY, 2015, INFLAMMATION, V38, P718, DOI 10.1007/s10753 014 9982 2
NR 46
TC 37
Z9 41
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2019
VL 120
BP 50
EP 60
DI 10.1016/j.bone.2018.10.005
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HL1PP
UT WOS:000458471700007
PM 30304704
DA 2025 08 17
ER

PT J
AU Yu, WH
   Li, FG
   Chen, XY
   Li, JT
   Wu, YH
   Huang, LH
   Wang, Z
   Li, PL
   Wang, T
   Lahn, BT
   Xiang, AP
AF Yu, Wei Hua
   Li, Fu Gui
   Chen, Xiao Yong
   Li, Jian Tao
   Wu, Yan Heng
   Huang, Li Hua
   Wang, Zhen
   Li, Panlong
   Wang, Tao
   Lahn, Bruce T.
   Xiang, Andy Peng
TI PPARγ suppression inhibits adipogenesis but does not promote
   osteogenesis of human mesenchymal stem cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE PPAR gamma; RNAi; Human mesenchymal stem cells; Adipogenesis;
   Osteogenesis
ID ACTIVATED RECEPTOR GAMMA; ADIPOCYTE DIFFERENTIATION; BONE MARROW;
   OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; STROMAL CELLS;
   ROSIGLITAZONE; POLYMORPHISMS; LINEAGE; GENE
AB Mesenchymal stem cells (MSCs) are the common progenitors of osteoblasts and adipocytes. A reciprocal relationship exists between osteogenesis and adipogenesis in the bone marrow, and the identification of signaling pathways that stimulate MSC osteogenesis at the expense of adipogenesis is of great importance from the viewpoint of developing new therapeutic treatments for bone loss. The adipogenic transcription factor peroxisome proliferator activated receptors gamma(PPAR gamma) has been reported to play a vital role in modulating mesenchymal lineage allocation within the bone marrow compartment, stimulating adipocyte development at the expense of osteoblast differentiation. Hence, PPAR gamma may be a valuable target for drugs intended to enhance bone mass. However, little direct evidence is available for the role played by PPAR gamma in human mesenchymal lineage allocation. In this study, using human MSCs as an in vitro model, we showed that the two isoforms of PPAR gamma, PPAR gamma 1 and PPAR gamma 2, were differentially induced during hMSC adipogenesis, whereas only PPAR gamma 1 was detected during osteogenesis. BADGE and GW9662, two potential antagonists of PPAR gamma, as well as lentivirus mediated knockdown of PPAR gamma, inhibited hMSC adipogenesis but did not significantly affect osteogenesis. PPAR gamma knockdown did not significantly influence the expression level of the osteogenic transcription factor Runx2. Together, these results suggest that PPAR gamma is not the master factor regulating mesenchymal lineage determination in human bone marrow. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Yu, Wei Hua; Li, Fu Gui; Chen, Xiao Yong; Li, Jian Tao; Li, Panlong; Wang, Tao; Lahn, Bruce T.; Xiang, Andy Peng] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou 510080, Guangdong, Peoples R China.
   [Wu, Yan Heng] Jinan Univ, Dept Med Imaging, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.
   [Huang, Li Hua] Guangdong Pharmaceut Univ, Key Lab Modulating Liver Treat Hyperlipemia SATCM, Level Lab Lipid Metab SATCM 3, Guangzhou 510006, Guangdong, Peoples R China.
   [Wang, Zhen] Guangzhou Blood Ctr, Inst Blood Transfus, Guangzhou 510095, Guangdong, Peoples R China.
   [Lahn, Bruce T.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
   [Lahn, Bruce T.] Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA.
   [Xiang, Andy Peng] Sun Yat Sen Univ, Dept Biochem, Zhongshan Med Sch, Guangzhou 510080, Guangdong, Peoples R China.
   [Xiang, Andy Peng] Sun Yat Sen Univ, Cell Gene Therapy Translat Med Res Ctr, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Jinan University; Guangdong Pharmaceutical
   University; Guangzhou Blood Center; Chinese Academy of Medical Sciences
     Peking Union Medical College; Institute of Blood Transfusion   CAMS;
   University of Chicago; Howard Hughes Medical Institute; University of
   Chicago; Sun Yat Sen University; Sun Yat Sen University
RP Xiang, AP (通讯作者)，Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Key Lab Stem Cells & Tissue Engn, Minist Educ, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
EM xiangp@mail.sysu.edu.cn
RI ; Chen, Xiaoyong/GZH 3499 2022; Wang, Tao/K 3518 2016
OI Xiang, Peng/0000 0003 3409 5012; Chen, Xiaoyong/0000 0002 5973 4143; 
FU National Natural Science Foundation of China [81000362, 30928015];
   National Basic Research Program of China [2009CB522100, 2010CB945400,
   2011CBA01100]; Key Scientific and Technological Projects of Guangdong
   Province [2007A032100003]; Natural Science Foundation of Guangdong
   Province [4203004]; Key Scientific and Technological Program of
   Guangzhou City [2008A1 E4011 5, 2010U1 E00551]; Program for New Century
   Excellent Talents in University; Fundamental Research Funds for the
   Central Universities [09ykpy79, 10ykzd02]
FX This research was supported by the National Natural Science Foundation
   of China (81000362 and 30928015), National Basic Research Program of
   China (2009CB522100, 2010CB945400 and 2011CBA01100) the Key Scientific
   and Technological Projects of Guangdong Province (2007A032100003), the
   Natural Science Foundation of Guangdong Province (4203004), the Key
   Scientific and Technological Program of Guangzhou City (Nos.
   2008A1 E4011 5 and 2010U1 E00551), the Program for New Century Excellent
   Talents in University and the Fundamental Research Funds for the Central
   Universities (09ykpy79 and 10ykzd02). The funding agencies had no role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Benvenuti S, 2007, J ENDOCRINOL INVEST, V30, pRC26, DOI 10.1007/BF03350807
   Bruedigam C, 2008, FEBS LETT, V582, P1618, DOI 10.1016/j.febslet.2008.04.012
   Bruedigam C, 2010, STEM CELLS, V28, P916, DOI 10.1002/stem.405
   Cheng S, 2006, ANN RHEUM DIS, V65, P1394, DOI 10.1136/ard.2006.051904
   Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004 1013.2003
   David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006 1704
   Elabd C, 2008, STEM CELLS, V26, P2399, DOI 10.1634/stemcells.2008 0127
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Kim TH, 2007, MOL CELLS, V24, P388
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Madec AM, 2009, DIABETOLOGIA, V52, P1391, DOI 10.1007/s00125 009 1374 z
   Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367
   Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qian SW, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 47
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Rotolin S, 2006, J CELL PHYSIOL, V209, P967, DOI 10.1002/jcp.20804
   Schiller PC, 2001, J BIOL CHEM, V276, P14133, DOI 10.1074/jbc.M011055200
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   Wahli W, 2008, CELL METAB, V7, P188, DOI 10.1016/j.cmet.2008.02.005
   Wan DC, 2006, P NATL ACAD SCI USA, V103, P12335, DOI 10.1073/pnas.0604849103
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wolf NS, 2003, EXP CELL RES, V290, P346, DOI 10.1016/S0014 4827(03)00321 5
   Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873
   Yamashita A, 2006, FEBS LETT, V580, P4121, DOI 10.1016/j.febslet.2006.06.057
   Zieleniak A, 2008, ARCH IMMUNOL THER EX, V56, P331, DOI 10.1007/s00005 008 0037 y
NR 30
TC 68
Z9 72
U1 0
U2 24
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD FEB
PY 2012
VL 44
IS 2
BP 377
EP 384
DI 10.1016/j.biocel.2011.11.013
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 889JC
UT WOS:000300069000016
PM 22120652
DA 2025 08 17
ER

PT J
AU Probert, C
   Dottorini, T
   Speakman, A
   Hunt, S
   Nafee, T
   Fazeli, A
   Wood, S
   Brown, JE
   James, V
AF Probert, C.
   Dottorini, T.
   Speakman, A.
   Hunt, S.
   Nafee, T.
   Fazeli, A.
   Wood, S.
   Brown, J. E.
   James, V.
TI Communication of prostate cancer cells with bone cells via extracellular
   vesicle RNA; a potential mechanism of metastasis
SO ONCOGENE
LA English
DT Article
ID STIMULATE ANGIOGENESIS; MEMBRANE VESICLES; NICHE FORMATION; STEM CELLS;
   EXOSOMES; EXPRESSION; GROWTH; MICROVESICLES; MICRORNAS; PROTEINS
AB The role of extracellular vesicles (EVs) as vehicles for cell to cell communication between a tumour and its environment is a relatively new concept. The hypothesis that EVs may be critical in co opting tissues by tumours to generate distant metastatic niches is particularly pertinent to prostate cancer (PCa), where metastatic tropism to bone predominates over other tissue types. The potential role of EVs as a means of communication between PCa cells and cells of the bone stroma such as osteoblasts, is yet to be fully explored. In this study, we demonstrate that PCa cell EVs both enhance osteoblast viability and produce a significantly more supportive growth environment for PCa cells when grown in co culture with EV treated osteoblasts (p < 0.005). Characterisation of the RNA cargo of EVs produced by the bone metastatic PCa cell line PC3, highlights the EV RNA cargo is significantly enriched in genes relating to cell surface signalling, cell cell interaction, and protein translation (p < 0.01). Using novel techniques to track RNA, we demonstrate the delivery of a set of PCa RNAs to osteoblast via PCa EVs and show the effect on osteoblast endogenous transcript abundance. Taken together, by using proof of concept studies we demonstrate for the first time the contribution of the RNA element of the PCa EV cargo, providing evidence to support PCa EV communication via RNA molecules as a potential novel route to mediate bone metastasis. We propose targeting PCa EVs could offer a potentially important preventative therapy for men at risk of metastatic PCa.
C1 [Probert, C.; Dottorini, T.; Speakman, A.; James, V.] Univ Nottingham, Sch Vet Med & Sci, Nottingham LE12 5RD, England.
   [Dottorini, T.] Univ Nottingham, Adv Data Anal Ctr, Nottingham LE12 5RD, England.
   [Hunt, S.] Univ Sheffield, Sch Clin Dent, Sheffield S10 2TA, S Yorkshire, England.
   [Nafee, T.; Fazeli, A.] Univ Sheffield, Acad Unit Reprod & Dev Med, Jessop Wing, Jessop Wing, Sheffield S10 2SF, S Yorkshire, England.
   [Fazeli, A.] Univ Tartu, Inst Biomed & Translat Med, Dept Pathophysiol, Tartu, Estonia.
   [Wood, S.; Brown, J. E.] Univ Sheffield, Western Pk Hosp, Dept Oncol & Metab, Whitham Rd, Sheffield S10 2SJ, S Yorkshire, England.
C3 University of Nottingham; University of Nottingham; University of
   Sheffield; University of Sheffield; University of Tartu; University of
   Sheffield; Weston Park Hospital
RP James, V (通讯作者)，Univ Nottingham, Sch Vet Med & Sci, Nottingham LE12 5RD, England.
EM victoria.james@nottingham.ac.uk
RI ; Fazeli, Alireza/G 3679 2010
OI James, Victoria/0000 0002 9926 2953; Hunt, Stuart/0000 0001 5572 1030;
   Probert, Catherine/0009 0008 6205 8247; Fazeli,
   Alireza/0000 0003 0870 9914; Dottorini, Tania/0000 0001 7733 906X
FU Prostate Cancer Research UK [PA14 007]
FX We thank Dr Nigel Mongan, Professor Susan Anderson (University of
   Nottingham) and Dr Penny Ottewell (University of Sheffield) for
   supplying reagents. C.P was supported by funding from Prostate Cancer
   Research UK (PA14 007) awarded to VJ and JEB.
CR Anderson SI, 1998, J MATER SCI MATER M, V9, P731, DOI 10.1023/A:1008955002955
   Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595
   Center MM, 2012, EUR UROL, V61, P1079, DOI 10.1016/j.eururo.2012.02.054
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev cellbio 101512 122326
   Costa Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169
   Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677
   Cunningham D., 2015, J. Biol. Methods, V2, DOI 10.14440/jbm.2015.63
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Di Silvo I., 1995, THESIS
   Ekström K, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18389
   Foj L, 2017, PROSTATE, V77, P573, DOI 10.1002/pros.23295
   Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008 5472.CAN 11 0241
   He M, 2015, CARCINOGENESIS, V36, P1008, DOI 10.1093/carcin/bgv081
   Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799
   Hessvik NP, 2012, BBA GENE REGUL MECH, V1819, P1154, DOI 10.1016/j.bbagrm.2012.08.016
   Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008 5472.CAN 10 4455
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Huang W, 2015, GENET TEST MOL BIOMA, V19, P469, DOI 10.1089/gtmb.2015.0088
   Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 319
   Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822
   Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450
   Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003
   Lässer C, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 9
   Li M, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0502
   Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200
   Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   Morhayim Jess, 2016, Curr Mol Biol Rep, V2, P48
   Nolte 't Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658
   Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010
   Rodríguez M, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0726 4
   Sánchez CA, 2016, ONCOTARGET, V7, P3993, DOI 10.18632/oncotarget.6540
   Sharp TV, 2004, P NATL ACAD SCI USA, V101, P16531, DOI 10.1073/pnas.0407123101
   Suetsugu A, 2013, ADV DRUG DELIVER REV, V65, P383, DOI 10.1016/j.addr.2012.08.007
   Théry C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Van Deun J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24858
   Wang X, 2015, ONCOL REP, V33, P2445, DOI 10.3892/or.2015.3843
   Yao GQ, 2002, CALCIFIED TISSUE INT, V70, P339, DOI 10.1007/s00223 001 1079 x
   Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150
   Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042
NR 45
TC 69
Z9 72
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD MAR 7
PY 2019
VL 38
IS 10
BP 1751
EP 1763
DI 10.1038/s41388 018 0540 5
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA HN8DD
UT WOS:000460423800013
PM 30353168
OA Green Accepted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Langdahl, BL
   Teglbjærg, CS
   Ho, PR
   Chapurlat, R
   Czerwinski, E
   Kendler, DL
   Reginster, JY
   Kivitz, A
   Lewiecki, EM
   Miller, PD
   Bolognese, MA
   McClung, MR
   Bone, HG
   Ljunggren, Ö
   Abrahamsen, B
   Gruntmanis, U
   Yang, YC
   Wagman, RB
   Mirza, F
   Siddhanti, S
   Orwoll, E
AF Langdahl, Bente L.
   Teglbjaerg, Christence Stubbe
   Ho, Pei Ran
   Chapurlat, Roland
   Czerwinski, Edward
   Kendler, David L.
   Reginster, Jean Yves
   Kivitz, Alan
   Lewiecki, E. Michael
   Miller, Paul D.
   Bolognese, Michael A.
   McClung, Michael R.
   Bone, Henry G.
   Ljunggren, Osten
   Abrahamsen, Bo
   Gruntmanis, Ugis
   Yang, Yu Ching
   Wagman, Rachel B.
   Mirza, Faisal
   Siddhanti, Suresh
   Orwoll, Eric
TI A 24 Month Study Evaluating the Efficacy and Safety of Denosumab for the
   Treatment of Men With Low Bone Mineral Density: Results From the ADAMO
   Trial
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; FRACTURE
AB Context: One in 4 men in the United States aged >50 years will have an osteoporosis related fracture. Fewer data are available on osteoporosis treatment in men than in women.
   Objective: The purpose of this study was to evaluate denosumab therapy in men with low bone mineral density (BMD).
   Design: This was a phase 3 study with 2 treatment periods: a previously reported 12 month double blind, placebo controlled phase and a 12 month open label phase.
   Setting: This was a multicenter study conducted in North America and Europe.
   Participants: A total of 228 men entered the open label phase and 219 completed the study. Intervention: Men from the original denosumab (long term) and placebo (crossover) groups received 60 mg of denosumab sc every 6 months. Main Outcome Measures: BMD, serum collagen type I C telopeptide, and safety were measured.
   Results: During the open label phase, continued BMD increases occurred with long term denosumab treatment (2.2% lumbar spine, 0.9% total hip, 1.3% femoral neck, 1.3% trochanter, and 0.2% 1/3 radius), resulting in cumulative 24 month gains from baseline of 8.0%, 3.4%, 3.4%, 4.6%, and 0.7%, respectively (all P < .01). The crossover group showed BMD gains after 12 months of denosumab treatment similar to those of the long term denosumab group during the first treatment year. Significant reductions in serum collagen type I C teleopeptide were observed after denosumab administration. Adverse event rates were similar between groups, and no new safety signals were identified.
   Conclusions: In men with low BMD, denosumab treatment for a second year continued to increase BMD, maintained reductions in bone resorption, and was well tolerated. BMD increased in men initiating denosumab during the second year. These effects were similar to those previously seen in postmenopausal women with osteoporosis and in men with prostate cancer receiving androgen deprivation therapy.
C1 [Langdahl, Bente L.] Aarhus Univ Hosp, DK 8000 Aarhus, Denmark.
   [Teglbjaerg, Christence Stubbe] Ctr Clin & Basic Res, DK 2750 Ballerup, Denmark.
   [Ho, Pei Ran; Yang, Yu Ching; Wagman, Rachel B.; Mirza, Faisal; Siddhanti, Suresh] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Chapurlat, Roland] Univ Lyon, Hop Edouard Herriot, INSERM UMR 1033, F 69437 Lyon, France.
   [Czerwinski, Edward] Krakow Med Ctr, PL 31501 Krakow, Poland.
   [Kendler, David L.] Univ British Columbia, Vancouver, BC V6T 1Z4, Canada.
   [Reginster, Jean Yves] Univ Liege, B 4000 Liege, Belgium.
   [Kivitz, Alan] Altoona Ctr Clin Res, Duncansville, PA 16635 USA.
   [Lewiecki, E. Michael] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM 87106 USA.
   [Miller, Paul D.] Colorado Ctr Bone Res, Lakewood, CO 80227 USA.
   [Bolognese, Michael A.] Bethesda Hlth Res Ctr, Bethesda, MD 20817 USA.
   [McClung, Michael R.] Oregon Osteoporosis Ctr, Portland, OR 97213 USA.
   [Bone, Henry G.] Michigan Bone & Mineral Clin, Detroit, MI 48236 USA.
   [Ljunggren, Osten] Uppsala Univ, S 75105 Uppsala, Sweden.
   [Abrahamsen, Bo] Univ Southern Denmark, DK 5000 Odense, Denmark.
   [Abrahamsen, Bo] Glostrup Cty Hosp, DK 5000 Odense, Denmark.
   [Abrahamsen, Bo] Univ Southern Denmark, DK 5000 Copenhagen, Denmark.
   [Abrahamsen, Bo] Glostrup Cty Hosp, DK 5000 Copenhagen, Denmark.
   [Gruntmanis, Ugis] Dallas Vet Affairs Med Ctr, Dallas, TX 75390 USA.
   [Gruntmanis, Ugis] Univ Texas Southwestern, Dallas, TX 75390 USA.
   [Orwoll, Eric] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
C3 Aarhus University; Center Clinical & Basic Research; Amgen; CHU Lyon;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; University of British Columbia;
   University of Liege; Altoona Center for Clinical Research; New Mexico
   Clinical Research & Osteoporosis Center; Colorado Center For Bone
   Research; Oregon Osteoporosis Center; Uppsala University; University of
   Southern Denmark; University of Southern Denmark; University of
   Copenhagen; University of Texas System; University of Texas Southwestern
   Medical Center; Oregon Health & Science University
RP Langdahl, BL (通讯作者)，Aarhus Univ Hosp, Dept Endocrinol & Internal Med THG, DK 8000 Aarhus C, Denmark.
EM bente.langdahl@aarhus.rm.dk
RI ; Gruntmanis, Ugis/AAN 5582 2020; Lewiecki, E./B 3706 2018; Wang,
   Yuhui/JTT 7711 2023; Reginster, Jean Yves/AGC 6097 2022; McClung,
   Michael/ABA 4100 2021; CHAPURLAT, ROLAND/AAU 1165 2021; Abrahamsen,
   Bo/B 8920 2008
OI Mirza, Faisal/0000 0003 2937 3700; Abrahamsen, Bo/0000 0002 2730 6080; 
FU Amgen Inc.
FX This study was funded by Amgen Inc.
CR [Anonymous], JUST FOR MEN
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Gallagher AM, 2008, J BONE MINER RES, V23, P1569, DOI 10.1359/JBMR.080510
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003 4819 152 6 201003160 00008
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Li Y, 2013, CHINESE MED J PEKING, V126, P457, DOI 10.3760/cma.j.issn.0366 6999.20121626
   Novartis Pharmaceuticals, 2014, RECL ZOL AC INJ PRES
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
NR 10
TC 80
Z9 87
U1 0
U2 6
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2015
VL 100
IS 4
BP 1335
EP 1342
DI 10.1210/jc.2014 4079
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG5UN
UT WOS:000353361500039
PM 25607608
OA Bronze
DA 2025 08 17
ER

PT J
AU Smink, JJ
   Tunn, PU
   Leutz, A
AF Smink, Jeske J.
   Tunn, Per Ulf
   Leutz, Achim
TI Rapamycin inhibits osteoclast formation in giant cell tumor of bone
   through the C/EBPβ   MafB axis
SO JOURNAL OF MOLECULAR MEDICINE JMM
LA English
DT Article
DE Giant cell tumor; Osteoclast; C/EBP beta; mTOR; MafB
ID BINDING PROTEIN BETA; FACTOR KAPPA B; RECEPTOR ACTIVATOR; TRANSLATIONAL
   CONTROL; EXPRESSION; DIFFERENTIATION; LIGAND; OSTEOPROTEGERIN; UPSTREAM;
   MODEL
AB Giant cell tumor (GCT) of bone is a benign type of tumor, but the presence of hyperactive multinucleated giant osteoclasts cause local osteolytic lesions, increasing morbidity in patients. To specifically target hyperactive multinucleated giant osteoclasts in GCTs, one would envisage the usage of osteoclast inhibitors or genetic modulation of osteoclastogenesis. Recently, we have found that the translationally regulated balance between the transcription factor C/EBP beta long (LAP) and short (LIP) protein isoforms regulates osteoclast differentiation. Here, we report that GCTs express high levels of the LIP C/EBP beta isoform, which in mice cause giant osteoclast formation. In mice, inhibition of mTOR activity by rapamycin decreased osteoclast differentiation by shifting the alternative translation initiation of C/EBP beta isoforms towards LAP. Similarly, rapamycin treatment of GCT cell cultures derived from seven different patients strongly reduced formation of giant osteoclasts and bone resorption. This was accompanied by an increase in MafB, previously shown to be the mediator of the effect of rapamycin on osteoclast differentiation in mice. These data suggest that C/EBP beta is a determinant of giant osteoclast formation in GCT and that pharmacological adjustment of the C/EBP beta isoform ratio could serve as a potential novel therapeutic approach.
C1 [Smink, Jeske J.; Leutz, Achim] Max Delbrueck Ctr Mol Med, D 13125 Berlin, Germany.
   [Smink, Jeske J.; Leutz, Achim] Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany.
   [Tunn, Per Ulf] HELIOS Klinikum Berlin Buch, Sarcom Ctr Berlin Brandenburg, Dept Tumor Orthopaed, Berlin, Germany.
   [Leutz, Achim] Humboldt Univ, Inst Biol, D 10099 Berlin, Germany.
C3 Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Helios Kliniken; Humboldt University of
   Berlin
RP Leutz, A (通讯作者)，Max Delbrueck Ctr Mol Med, Robert Roessle Str 10, D 13125 Berlin, Germany.
EM aleutz@mdc berlin.de
RI Leutz, Achim/K 9643 2013
OI Leutz, Achim/0000 0001 8259 927X
CR Atkins GJ, 2000, J BONE MINER RES, V15, P640, DOI 10.1359/jbmr.2000.15.4.640
   Atkins GJ, 2001, BONE, V28, P370, DOI 10.1016/S8756 3282(01)00404 5
   Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Berenson James R, 2008, Curr Opin Support Palliat Care, V2, P204, DOI 10.1097/SPC.0b013e3283090475
   Boyce BF, 2006, ANN NY ACAD SCI, V1068, P447, DOI 10.1196/annals.1346.042
   Calkhoven CF, 2000, GENE DEV, V14, P1920
   Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130
   Chang SS, 2004, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000141372.54456.80
   Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Jundt F, 2005, BLOOD, V106, P1801, DOI 10.1182/blood 2004 11 4513
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   Ng PKS, 2010, J CELL BIOCHEM, V110, P438, DOI 10.1002/jcb.22556
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Smink JJ, 2010, J MOL MED, V88, P227, DOI 10.1007/s00109 009 0567 8
   Smink JJ, 2009, EMBO J, V28, P1769, DOI 10.1038/emboj.2009.127
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Thomas DM, 2009, CURR OPIN ONCOL, V21, P338, DOI 10.1097/CCO.0b013e32832c951d
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008 5472.CAN 04 3135
   Werner M, 2006, INT ORTHOP, V30, P484, DOI 10.1007/s00264 006 0215 7
   Wethmar K, 2010, BIOESSAYS, V32, P885, DOI 10.1002/bies.201000037
   Wethmar K, 2010, GENE DEV, V24, P15, DOI 10.1101/gad.557910
NR 25
TC 29
Z9 33
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946 2716
J9 J MOL MED
JI J. Mol. Med.
PD JAN
PY 2012
VL 90
IS 1
BP 25
EP 30
DI 10.1007/s00109 011 0823 6
PG 6
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 916WX
UT WOS:000302135000004
PM 22071989
DA 2025 08 17
ER

PT J
AU Al Mamun, MA
   Asim, MMH
   Sahin, MAZ
   Al Bari, MAA
AF Al Mamun, Md Abdullah
   Asim, Md Muzammal Haque
   Sahin, Md Ali Zaber
   Al Bari, Md Abdul Alim
TI Flavonoids compounds from Tridax procumbens inhibit osteoclast
   differentiation by down regulating c Fos activation
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone resorption; cathepsin K; osteoclast differentiation; Tridax
   procumbens flavonoid
ID MEDICINAL PLANTS; BONE; OSTEOPROTEGERIN; CELLS; MECHANISM
AB The total flavonoids from Tridax procumbens (TPFs) have been reported significantly to suppress on RANKL induced osteoclast differentiation and bone resorption in mouse primary cultured osteoclasts. However, the effects of ethyl ether fraction of Tridax procumbens flavonoids (TPF) on osteoclastogenesis remain unknown. In this study, we investigated the effects of TPF on lipopolysaccharides (LPS) induced osteoclast differentiation, actin ring formation, and explored its molecular mechanism in vitro. Matured osteoclast was counted as the number of tartrate resistant acid phosphatase (TRAP) positive multinucleated cells, and activity of osteoclast was assessed by performing the pit formation assays. Real time polymerase chain reaction (RT PCR) was performed for evaluation of the expression of osteoclast differentiation related genes. TPF reduced the TRAP positive multinucleated osteoclasts, inhibited TRAP and acid phosphatase (ACP) activities and decreased the expression of osteoclast differentiating genes, including cathepsin K, metalloproteinase 2 (MMP 2), MMP 9, MMP 13 and osteoclast associated receptor (OSCAR). Furthermore, osteoclast dependent actin rings formation and resorption pits were dramatically inhibited by the treatment with TPF. TPF markedly decreased the expression levels of transcription factors such as c Fos, nuclear factor of activated T cells cytoplasmic 1 (NFATc1) and activator protein 1 (AP 1). Taken together, our findings indicated that TPF suppressed both osteoclast differentiation and activities. Therefore, TPF might be a promising and emerging drug candidate for the treatment of bone diseases such as osteoporosis.
C1 [Al Mamun, Md Abdullah; Asim, Md Muzammal Haque; Sahin, Md Ali Zaber] Shahjalal Univ Sci & Technol, Dept Genet Engn & Biotechnol, Sylhet 3114, Bangladesh.
   [Al Bari, Md Abdul Alim] Univ Rajshahi, Dept Pharm, Rajshahi, Bangladesh.
C3 Shahjalal University of Science & Technology (SUST); University of
   Rajshahi
RP Al Mamun, MA (通讯作者)，Shahjalal Univ Sci & Technol, Dept Genet Engn & Biotechnol, Sylhet 3114, Bangladesh.
EM mssohel@yahoo.com
RI Al Bari, Abdul Alim/AAT 4301 2020; Al Bari, Md. Abdul Alim/C 2946 2018
OI Al Bari, Md. Abdul Alim/0000 0002 1777 3662
FU Shahjalal University of Science and Technology [LS012015, LS022016]
FX Shahjalal University of Science and Technology, Grant/Award Number:
   LS012015 and LS022016
CR Al Mamun MA, 2019, J DENT ORAL HLTH, V6, P1
   Al Mamun MA, 2017, BIOL RES, V50, DOI 10.1186/s40659 017 0134 7
   Al Mamun MA, 2015, BIOL RES, V48, DOI 10.1186/s40659 015 0043 6
   Al Mamun MA, 2015, BIOL RES, V48, DOI [10.1186/s40659 015 0056 1, 10.1186/S40659 015 0056 1]
   Blumer MJF, 2012, MECH DEVELOP, V129, P162, DOI 10.1016/j.mod.2012.04.003
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bull H, 2002, J CLIN PATHOL MOL PA, V55, P65
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Essawi T, 2000, J ETHNOPHARMACOL, V70, P343, DOI 10.1016/S0378 8741(99)00187 7
   Kobayashi Y, 2004, J BONE MINER METAB, V22, P318, DOI 10.1007/s00774 003 0489 4
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   Mun SH, 2009, J PHARMACOL SCI, V111, P13, DOI 10.1254/jphs.09134FP
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   RECIO MC, 1989, PHYTOTHER RES, V3, P117, DOI 10.1002/ptr.2650030402
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Sharma B., 2009, INT J APPL RES NAT P, V1, P5
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 26
TC 18
Z9 18
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD FEB
PY 2020
VL 24
IS 4
BP 2542
EP 2551
DI 10.1111/jcmm.14948
EA JAN 2020
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KM4OO
UT WOS:000506301700001
PM 31919976
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU King, BJ
   Lehman, JS
   Valinotti, JCS
AF King, Brian J.
   Lehman, Julia S.
   Valinotti, Julio C. Sartori
TI Denosumab induced cutaneous hypersensitivity reaction with distinct
   clinical and histopathologic findings
SO JOURNAL OF CUTANEOUS PATHOLOGY
LA English
DT Article
DE cutaneous hypersensitivity; dermatopathology; drug eruption
ID POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; REDUCTION
AB Cutaneous reactions from targeted biologics are increasingly common. We describe a case of a cutaneous lichenoid drug eruption from the RANK inhibitor denosumab and a previously unreported lymphohistiocytic reaction pattern. The clinical and histopathological details of this case will aid in recognition, diagnosis, and treatment of drug rashes from denosumab.
C1 [King, Brian J.; Lehman, Julia S.; Valinotti, Julio C. Sartori] Mayo Clin, Dept Dermatol & Lab Med, Rochester, MN USA.
   [Lehman, Julia S.] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic
RP Valinotti, JCS (通讯作者)，Mayo Clin, Dept Dermatol, 200 First St Southwest, Rochester, MN 55905 USA.
EM sartorivalinotti.julio@mayo.edu
OI King, Brian/0000 0001 7904 6009
CR Amgen Inc, 2010, PROL DEN PACK INS
   Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Bridgeman MB, 2011, CLIN THER, V33, P1547, DOI 10.1016/j.clinthera.2011.10.008
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   Lewiecki EM, 2014, J CLIN DENSITOM, V17, P490, DOI 10.1016/j.jocd.2013.09.018
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Silva Fernandez L, 2013, REUMATOL CLIN, V9, P42, DOI [10.1016/j.reuma.2012.06.007, 10.1016/j.reumae.2012.06.020]
   Toulis KA, 2010, OSTEOPOROSIS INT, V21, P1963, DOI 10.1007/s00198 009 1145 1
NR 11
TC 9
Z9 9
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6987
EI 1600 0560
J9 J CUTAN PATHOL
JI J. Cutan. Pathol.
PD FEB
PY 2018
VL 45
IS 2
BP 156
EP 158
DI 10.1111/cup.13070
PG 3
WC Dermatology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology; Pathology
GA FS6YL
UT WOS:000419944200011
PM 29076163
DA 2025 08 17
ER

PT J
AU Panwar, P
   Soe, K
   Guido, RVC
   Bueno, RVC
   Delaisse, JM
   Brömme, D
AF Panwar, Preety
   Soe, Kent
   Guido, Rafael V. C.
   Bueno, Renata V. C.
   Delaisse, Jean Marie
   Broemme, Dieter
TI A novel approach to inhibit bone resorption: exosite inhibitors against
   cathepsin K
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID POSTMENOPAUSAL OSTEOPOROSIS; ODANACATIB; TARGET; DEGRADATION;
   OSTEOCLAST; PHARMACOLOGY; COLLAGENASE; DEFICIENCY; EXPRESSION; DOCKING
AB Background and PurposeCathepsin K (CatK) is a major drug target for the treatment of osteoporosis. Potent active site directed inhibitors have been developed and showed variable success in clinical trials. These inhibitors block the entire activity of CatK and thus may interfere with other pathways. The present study investigates the antiresorptive effect of an exosite inhibitor that selectively inhibits only the therapeutically relevant collagenase activity of CatK.
   Experimental ApproachHuman osteoclasts and fibroblasts were used to analyse the effect of the exosite inhibitor, ortho dihydrotanshinone (DHT1), and the active site inhibitor, odanacatib (ODN), on bone resorption and TGF ss 1 degradation. Cell cultures, Western blot, light and scanning electron microscopy as well as energy dispersive X ray spectroscopy, molecular modelling and enzymatic assays were used to evaluate the inhibitors.
   Key ResultsDHT1 selectively inhibited the collagenase activity of CatK, without affecting the viability of osteoclasts. Both inhibitors abolished the formation of resorption trenches, with DHT1 having a slightly higher IC50 value than ODN. Maximal reductions of other resorption parameters by DHT1 and ODN were comparable, respectively 41% and 33% for total resorption surface, 46% and 48% for resorption depths, and 83% and 61% for C terminal telopetide fragment (CTX) release. DHT1 did not affect the turnover of fibrosis associated TGF ss 1 in fibroblasts, whereas 500 nM ODN was inhibitory.
   Conclusions and ImplicationsOur study shows that an exosite inhibitor of CatK can specifically block bone resorption without interfering with other pathways.
C1 [Panwar, Preety; Broemme, Dieter] Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada.
   [Panwar, Preety; Broemme, Dieter] Ctr Blood Res, Vancouver, BC, Canada.
   [Panwar, Preety; Soe, Kent; Delaisse, Jean Marie] Univ Southern Denmark, Inst Reg Hlth Res, Lillebaelt Hosp, Clin Cell Biol,Vejle Hospital, Vejle, Denmark.
   [Guido, Rafael V. C.; Bueno, Renata V. C.] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Inovacao Biodiversidade & Farmacos, Lab Quim Med & Computac, Sao Carlos, SP, Brazil.
   [Broemme, Dieter] Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.
C3 University of British Columbia; University of Southern Denmark;
   Lillebaelt Hospital; Universidade de Sao Paulo; University of British
   Columbia
RP Brömme, D (通讯作者)，Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, 2350 Hlth Sci Mallm, Vancouver, BC V6T 1Z3, Canada.
EM dbromme@dentistry.ubc.ca
RI Guido, Rafael/A 7450 2009; Soe, Kent/N 3618 2017; Bueno,
   Renata/B 6865 2013
OI Guido, Rafael/0000 0002 7187 0818; Delaisse,
   Jean Marie/0000 0001 7370 1500; Soe, Kent/0000 0001 7402 314X; 
FU Canadian Institutes of Health Research grants [MOP89974, MOP201209];
   Canada Research Chair award; Vejle Hospital/Lillebaelt Hospital, Denmark
FX This work was supported by the Canadian Institutes of Health Research
   grants MOP89974 and MOP201209 (D. B.). D. B. was supported by a Canada
   Research Chair award and funding by Vejle Hospital/Lillebaelt Hospital,
   Denmark. We are grateful to the CFI supported UBC Centre for
   High Throughput Phenogenomics facility for the use of the SEM.
CR Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451
   Bai XL, 2014, CELL SIGNAL, V26, P2030, DOI 10.1016/j.cellsig.2014.06.001
   Bertazzo S, 2013, NAT MATER, V12, P576, DOI [10.1038/NMAT3627, 10.1038/nmat3627]
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Bühling F, 2004, AM J PATHOL, V164, P2203, DOI 10.1016/S0002 9440(10)63777 7
   Chapurlat RD, 2014, EXPERT OPIN PHARMACO, V15, P559, DOI 10.1517/14656566.2014.881470
   Chen YG, 2009, CELL RES, V19, P58, DOI 10.1038/cr.2008.315
   Cherney MM, 2011, J BIOL CHEM, V286, P8988, DOI 10.1074/jbc.M110.126706
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Dauth S, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471 2202 12 74
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Desmarais S, 2008, MOL PHARMACOL, V73, P147, DOI 10.1124/mol.107.039511
   Dossetter AG, 2012, J MED CHEM, V55, P6363, DOI 10.1021/jm3007257
   Du X, 2013, J BIOL CHEM, V288, P34871, DOI 10.1074/jbc.M113.510008
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Guo Y, 2014, J ETHNOPHARMACOL
   Helali AM, 2013, CURR DRUG TARGETS, V14, P1591, DOI 10.2174/13894501113149990202
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03 1273rev
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Li ZQ, 2008, J MOL BIOL, V383, P78, DOI 10.1016/j.jmb.2008.07.038
   Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200
   Linnevers CJ, 1997, PROTEIN SCI, V6, P919
   Panwar P, 2013, J BIOL CHEM, V288, P5940, DOI 10.1074/jbc.M112.419689
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Quintanilla Dieck MJ, 2009, EXP DERMATOL, V18, P596, DOI 10.1111/j.1600 0625.2009.00855.x
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Sharma V, 2015, BIOCHEM J, V465, P163, DOI 10.1042/BJ20140809
   Sims NA, 2014, CURR OSTEOPOROS REP, V12, P98, DOI 10.1007/s11914 014 0196 1
   Soe K, 2013, BONE, V56, P191, DOI 10.1016/j.bone.2013.06.007
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Sun L, 2012, J CHROMATOGR B, V885, P15, DOI 10.1016/j.jchromb.2011.12.004
   Zhang DW, 2011, RESP RES, V12, DOI 10.1186/1465 9921 12 72
   Zhuo Y, 2014, BONE, V67, P269, DOI 10.1016/j.bone.2014.07.013
NR 43
TC 59
Z9 64
U1 2
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JAN
PY 2016
VL 173
IS 2
BP 396
EP 410
DI 10.1111/bph.13383
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DA4RN
UT WOS:000367788100012
PM 26562357
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Hyväri, L
   Ojansivu, M
   Juntunen, M
   Kartasalo, K
   Miettinen, S
   Vanhatupa, S
AF Hyvari, Laura
   Ojansivu, Miina
   Juntunen, Miia
   Kartasalo, Kimmo
   Miettinen, Susanna
   Vanhatupa, Sari
TI Focal Adhesion Kinase and ROCK Signaling Are Switch Like Regulators of
   Human Adipose Stem Cell Differentiation towards Osteogenic and
   Adipogenic Lineages
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID MATRIX INTERACTIONS; BONE MARROW; IN VITRO; CYTOSKELETAL; FAK;
   MODULATION; ACTIVATION; PATHWAY; TENSION; IMAGE
AB Adipose tissue is an attractive stem cell source for soft and bone tissue engineering applications and stem cell therapies. The adipose derived stromal/stem cells (ASCs) have a multilineage differentiation capacity that is regulated through extracellular signals. The cellular events related to cell adhesion and cytoskeleton have been suggested as central regulators of differentiation fate decision. However, the detailed knowledge of these molecular mechanisms in human ASCs remains limited. This study examined the significance of focal adhesion kinase (FAK), Rho Rho associated protein kinase (Rho ROCK), and their downstream target extracellular signal regulated kinase 1/2 (ERK1/2) on hASCs differentiation towards osteoblasts and adipocytes. Analyses of osteogenic markers RUNX2A, alkaline phosphatase, and matrix mineralization revealed an essential role of active FAK, ROCK, and ERK1/2 signaling for the osteogenesis of hASCs. Inhibition of these kinases with specific small molecule inhibitors diminished osteogenesis, while inhibition of FAK and ROCK activity led to elevation of adipogenic marker genes AP2 and LEP and lipid accumulation implicating adipogenesis. This denotes to a switch like function of FAK and ROCK signaling in the osteogenic and adipogenic fates of hASCs. On the contrary, inhibition of ERK1/2 kinase activity deceased adipogenic differentiation, indicating that activation of ERK signaling is required for both adipogenic and osteogenic potential. Our findings highlight the reciprocal role of cell adhesion mechanisms and actin dynamics in regulation of hASC lineage commitment. This study enhances the knowledge of molecular mechanisms dictating hASC differentiation and thus opens possibilities for more efficient control of hASC differentiation.
C1 [Hyvari, Laura; Ojansivu, Miina; Juntunen, Miia; Miettinen, Susanna; Vanhatupa, Sari] Univ Tampere, BioMediTech Inst, Adult Stem Cell Res Grp, Tampere, Finland.
   [Hyvari, Laura; Ojansivu, Miina; Juntunen, Miia; Kartasalo, Kimmo; Miettinen, Susanna; Vanhatupa, Sari] Univ Tampere, Fac Med & Life Sci, Tampere, Finland.
   [Hyvari, Laura; Ojansivu, Miina; Juntunen, Miia; Miettinen, Susanna; Vanhatupa, Sari] Tampere Univ Hosp, Sci Ctr, Tampere, Finland.
   [Kartasalo, Kimmo] Univ Tampere, BioMediTech Inst, Computat Biol Grp, Tampere, Finland.
   [Kartasalo, Kimmo] Tampere Univ Technol, BioMediTech Inst, Tampere, Finland.
   [Kartasalo, Kimmo] Tampere Univ Technol, Fac Biomed Sci & Engn, Tampere, Finland.
C3 Tampere University; Tampere University; Tampere University; Tampere
   University Hospital; Tampere University; Tampere University; Tampere
   University
RP Miettinen, S (通讯作者)，Univ Tampere, BioMediTech Inst, Adult Stem Cell Res Grp, Tampere, Finland.; Miettinen, S (通讯作者)，Univ Tampere, Fac Med & Life Sci, Tampere, Finland.; Miettinen, S (通讯作者)，Tampere Univ Hosp, Sci Ctr, Tampere, Finland.
EM susanna.miettinen@uta.fi
RI ; Miettinen, Susanna/HKN 3477 2023
OI Miettinen, Susanna/0000 0002 0647 9556; Hyvari,
   Laura/0000 0002 9893 0323; Juntunen, Miia/0000 0001 5282 4376; Ojansivu,
   Miina/0000 0002 5493 3530; Kartasalo, Kimmo/0000 0002 9470 4783
FU Competitive State Research Financing of the Expert Responsibility area
   of Tampere University Hospital; Tekes (The Finnish Funding Agency for
   Innovation); Academy of Finland; Jane and Aatos Erkko Foundation;
   Doctoral Programme in Biomedicine and Biotechnology, University of
   Tampere; Doctoral Programme of Computing and Electrical Engineering,
   Tampere University of Technology
FX The authors thank Ms. Anna Maija Honkala, Ms. Sari Kalliokoski, and
   Tampere Imaging Facility, BioMediTech and Faculty of Medicine and Life
   Sciences, University of Tampere for technical assistance. This study was
   financially supported by the Competitive State Research Financing of the
   Expert Responsibility area of Tampere University Hospital, Tekes (The
   Finnish Funding Agency for Innovation), Academy of Finland, and Jane and
   Aatos Erkko Foundation. Research funding of Doctoral Programme in
   Biomedicine and Biotechnology, University of Tampere, and Doctoral
   Programme of Computing and Electrical Engineering, Tampere University of
   Technology, are gratefully acknowledged.
CR Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Galateanu B, 2012, INT J MOL SCI, V13, P15881, DOI 10.3390/ijms131215881
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Gu HJ, 2011, BIOMATERIALS, V32, P7023, DOI 10.1016/j.biomaterials.2011.06.003
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Martínez Lorenzo MJ, 2009, J ORTHOP RES, V27, P1499, DOI 10.1002/jor.20898
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kortum RL, 2005, MOL CELL BIOL, V25, P7592, DOI 10.1128/MCB.25.17.7592 7604.2005
   Kyllönen L, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt165
   Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709
   Li JJ, 2007, BIOCHEM BIOPH RES CO, V357, P648, DOI 10.1016/j.bbrc.2007.03.184
   Lindroos B, 2009, CYTOTHERAPY, V11, P958, DOI 10.3109/14653240903233081
   Liu QH, 2009, TISSUE ENG PT A, V15, P3487, DOI [10.1089/ten.tea.2009.0175, 10.1089/ten.TEA.2009.0175]
   Luk CT, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14360
   Luo WJ, 2008, EXP CELL RES, V314, P3382, DOI 10.1016/j.yexcr.2008.07.003
   Lv HW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0083 4
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055
   Müller P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071283
   Ojansivu M, 2015, ACTA BIOMATER, V21, P190, DOI 10.1016/j.actbio.2015.04.017
   Panayiotou R, 2016, ELIFE, V5, DOI 10.7554/eLife.15460
   Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009
   Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Santos A, 2010, CYTOTHERAPY, V12, P924, DOI 10.3109/14653241003774011
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schofield AV, 2012, J BIOL CHEM, V287, P43620, DOI 10.1074/jbc.M112.394965
   Scuteri Arianna, 2014, International Journal of Stem Cells, V7, P127, DOI 10.15283/ijsc.2014.7.2.127
   Shih YRV, 2011, J BONE MINER RES, V26, P730, DOI 10.1002/jbmr.278
   Simons PJ, 2005, CYTOKINE, V32, P94, DOI 10.1016/j.cyto.2005.08.003
   Stucki U, 2001, CLIN ORAL IMPLAN RES, V12, P121, DOI 10.1034/j.1600 0501.2001.012002121.x
   Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002
   Tirkkonen L, 2013, EUR CELLS MATER, V25, P144, DOI 10.22203/eCM.v025a10
   Tomakidi P, 2014, CELL TISSUE RES, V357, P515, DOI 10.1007/s00441 014 1945 2
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   Vanhatupa S, 2015, STEM CELL TRANSL MED, V4, P1391, DOI 10.5966/sctm.2015 0042
   Varinli H, 2015, J LIPID RES, V56, P2206, DOI 10.1194/jlr.D059758
   Viale Bouroncle S, 2014, CELL TISSUE RES, V357, P345, DOI 10.1007/s00441 014 1869 x
   Vishnubalaji R, 2012, CELL TISSUE RES, V347, P419, DOI 10.1007/s00441 011 1306 3
   Walters NJ, 2015, ACTA BIOMATER, V11, P3, DOI 10.1016/j.actbio.2014.09.038
   Xu BY, 2014, J BIOSCI BIOENG, V117, P624, DOI 10.1016/j.jbiosc.2013.10.018
   Yim EKF, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt132
NR 47
TC 39
Z9 43
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2018
VL 2018
AR 2190657
DI 10.1155/2018/2190657
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GU8BP
UT WOS:000445558400001
PM 30275837
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Choi, JH
   Sung, SE
   Kang, KK
   Lee, S
   Sung, M
   Park, WT
   Kim, YI
   Seo, MS
   Lee, GW
AF Choi, Joo Hee
   Sung, Soo Eun
   Kang, Kyung Ku
   Lee, Sijoon
   Sung, Minkyoung
   Park, Wook Tae
   Kim, Young In
   Seo, Min Soo
   Lee, Gun Woo
TI Extracellular Vesicles from Human Adipose Tissue Derived Mesenchymal
   Stem Cells Suppress RANKL Induced Osteoclast Differentiation via
   miR122 5p
SO BIOCHEMICAL GENETICS
LA English
DT Article
DE Osteoclast; Mesenchymal stem cells; Extracellular vesicles; miR122 5p
ID PREVENTS BONE LOSS; FACTOR KAPPA B; NUCLEAR FACTOR; SIGNAL TRANSDUCTION;
   RECEPTOR ACTIVATOR; C FOS; NFATC1; OSTEOPOROSIS; P38; PRECURSORS
AB Researchers are increasingly interested in cell therapy using mesenchymal stem cells (MSCs) as an alternative remedy for osteoporosis, with fewer side effects. Thus, we isolated and characterized extracellular vesicles (EVs) from human adipose tissue derived MSCs (hMSCs) and investigated their inhibitory effects on RANKL induced osteoclast differentiation. Purified EVs were collected from the supernatant of hMSCs by tangential flow filtration. Characterization of EVs included typical evaluation of the size and concentration of EVs by nanoparticle tracking analysis and morphology analysis using transmission electron microscopy. hMSC EVs inhibited RANKL induced differentiation of bone marrow derived macrophages (BMDMs) into osteoclasts in a dose dependent manner. F actin ring formation and bone resorption were also reduced by EV treatment of osteoclasts. In addition, EVs decreased RANKL induced phosphorylation of p38 and JNK and expression of osteoclastogenesis related genes in BMDMs treated with RANKL. To elucidate which part of the hMSC EVs plays a role in the inhibition of osteoclast differentiation, we analyzed miRNA profiles in hMSC EVs. The results showed that has miR122 5p was present at significantly high read counts. Overexpression of miR122 5p in BMDMs significantly inhibited RANKL induced osteoclast differentiation and induced defects in F actin ring formation and bone resorption. Our results also revealed that RANKL induced phosphorylation of p38 and JNK and osteoclast specific gene expression was decreased by miR122 5p transfection, which was consistent with the results of hMSC EVs. These findings suggest that hMSC EVs containing miR122 5p inhibit RANKL induced osteoclast differentiation via the downregulation of molecular mechanisms and could be a preventive candidate for destructive bone diseases.
C1 [Choi, Joo Hee; Sung, Soo Eun; Kang, Kyung Ku; Lee, Sijoon; Sung, Minkyoung] Daegu Gyeongbuk Med Innovat Fdn, Lab Anim Ctr, Daegu 41061, South Korea.
   [Park, Wook Tae; Lee, Gun Woo] Yeungnam Univ, Coll Med, Med Ctr, Dept Orthoped Surg, 170 Hyonchung Ro, Daegu 42415, South Korea.
   [Kim, Young In] Cellexobio Co Ltd, Daegu 42415, South Korea.
   [Seo, Min Soo] Kyungpook Natl Univ, Coll Vet Med, Dept Vet Tissue Engn, Lab Vet Tissue Engn, 80 Daehak Ro, Daegu 41566, South Korea.
C3 Yeungnam University; Kyungpook National University (KNU)
RP Lee, GW (通讯作者)，Yeungnam Univ, Coll Med, Med Ctr, Dept Orthoped Surg, 170 Hyonchung Ro, Daegu 42415, South Korea.; Seo, MS (通讯作者)，Kyungpook Natl Univ, Coll Vet Med, Dept Vet Tissue Engn, Lab Vet Tissue Engn, 80 Daehak Ro, Daegu 41566, South Korea.
EM msseo@knu.ac.kr; gwlee1871@gmail.com
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2022R1C1C1005410, 2020R1F1A1072045, RS 2023 00219725]
FX This research was supported by the National Research Foundation of Korea
   (NRF) grants funded by the Korea government (MSIT) (No.
   2022R1C1C1005410, 2020R1F1A1072045, and RS 2023 00219725).
CR Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Cho SW, 2012, TISSUE ENG PT A, V18, P1067, DOI [10.1089/ten.tea.2011.0355, 10.1089/ten.TEA.2011.0355]
   Choi JH, 2020, INT J MED SCI, V17, P632, DOI 10.7150/ijms.39622
   Choi JH, 2017, PHYTOMEDICINE, V34, P6, DOI 10.1016/j.phymed.2017.07.006
   Chu BX, 2020, J CELL MOL MED, V24, P14366, DOI 10.1111/jcmm.16055
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X
   Eguia A, 2020, MED ORAL PATOL ORAL, V25, pE71, DOI 10.4317/medoral.23191
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev biochem 060308 103103
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Fu YX, 2015, MOL MED REP, V12, P6939, DOI 10.3892/mmr.2015.4284
   Geusens P, 2012, THER ADV MUSCULOSKEL, V4, P225, DOI 10.1177/1759720X12438080
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Grigoriadis AE, 2010, BLOOD, V115, P2769, DOI 10.1182/blood 2009 07 234690
   Guo J, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.12979
   Guo LJ, 2014, EXP CELL RES, V321, P142, DOI 10.1016/j.yexcr.2013.12.001
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Janockova J, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929 021 00736 4
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lässer C, 2018, MOL ASPECTS MED, V60, P1, DOI 10.1016/j.mam.2018.02.002
   Lee JH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134774
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li XH, 2019, INT J CLIN EXP PATHO, V12, P4077
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Liang YX, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065703
   Liao W, 2019, CLIN SCI, V133, P1955, DOI 10.1042/CS20181064
   Mandourah AY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26525 y
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Meng YC, 2020, MOL THER NUCL ACIDS, V20, P345, DOI 10.1016/j.omtn.2019.11.038
   Miyamoto Takeshi, 2015, Keio Journal of Medicine, V64, P44, DOI 10.2302/kjm.2015 0003 RE
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   O'Brien K, 2020, NAT REV MOL CELL BIO, V21, P585, DOI 10.1038/s41580 020 0251 y
   Panach L, 2015, CALCIFIED TISSUE INT, V97, P495, DOI 10.1007/s00223 015 0036 z
   Pei ZJ, 2017, PHARMAZIE, V72, P344, DOI 10.1691/ph.2017.6404
   Pers YM, 2015, OSTEOARTHR CARTILAGE, V23, P2027, DOI 10.1016/j.joca.2015.07.004
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200
   Sung M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189960
   Sung SE, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10030678
   Sung SE, 2022, ASIAN SPINE J, V16, P153, DOI 10.31616/asj.2021.0129
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum Steven L, 2016, Rheumatology (Oxford), V55, pii61
   Tofiño Vian M, 2018, CELL PHYSIOL BIOCHEM, V47, P11, DOI 10.1159/000489739
   Tomomura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130174
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weivoda MM, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115757
   Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001
   Zhang L, 2021, J BIOSCI BIOENG, V131, P671, DOI 10.1016/j.jbiosc.2021.02.007
   Zhang SQ, 2017, MOL MED REP, V16, P3994, DOI 10.3892/mmr.2017.7039
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 63
TC 6
Z9 6
U1 4
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0006 2928
EI 1573 4927
J9 BIOCHEM GENET
JI Biochem. Genet.
PD AUG
PY 2024
VL 62
IS 4
BP 2830
EP 2852
DI 10.1007/s10528 023 10569 5
PG 23
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA L4X1O
UT WOS:001350752900029
PM 38017286
DA 2025 08 17
ER

PT J
AU Zhang, YP
   Xing, YX
   Jia, LL
   Ji, YW
   Zhao, B
   Wen, Y
   Xu, X
AF Zhang, Yunpeng
   Xing, Yixiao
   Jia, Linglu
   Ji, Yawen
   Zhao, Bin
   Wen, Yong
   Xu, Xin
TI An In Vitro Comparative Study of Multisource Derived Mesenchymal Stem
   Cells for Bone Tissue Engineering
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE mesenchymal stem cells; proliferation; apoptosis; osteogenic
   differentiation; signaling pathway
ID OSTEOGENIC DIFFERENTIATION; ADIPOSE TISSUE; SIGNALING PATHWAY; STROMAL
   CELLS; DENTAL PULP; MARROW; PROLIFERATION; MULTIPOTENT; EXPRESSION;
   APOPTOSIS
AB Mesenchymal stem cells (MSCs) have been considered promising tools for tissue engineering and regenerative medicine. However, the optimal cell source for bone regeneration remains controversial. To better identify seed cells for bone tissue engineering, we compared MSCs from seven different tissues, including four from dental origins, dental pulp stem cells (DPSCs), periodontal ligament stem cells (PDLSCs), gingival MSCs (GMSCs), and dental follicle stem cells (DFSCs); two from somatic origins, bone marrow derived MSCs (BM MSCs) and adipose derived stem cells (ADSCs); and one from birth associated perinatal tissue umbilical cord (UCMSCs). We cultured the cells under a standardized culture condition and studied their biological characteristics. According to our results, these cells exhibited similar immunophenotype and had potential for multilineage differentiation. MSCs from dental and perinatal tissues proliferated more rapidly than those from somatic origins. Simultaneously, DPSCs and PDLSCs owned stronger antiapoptotic ability under the microenvironment of oxidative stress combined with serum deprivation. In respect to osteogenic differentiation, the two somatic MSCs, BM MSCs and ADSCs, demonstrated the strongest ability for osteogenesis compared to PDLSCs and DFSCs, which were just a little bit weaker than the formers. However, GMSCs and UCMSCs were the most pertinacious ones to differentiate to osteoblasts. We also revealed that the canonical intracellular protein kinase based cascade signaling pathways, including PI3K/AKT, MAPK/ERK, and p38 MAPK, possessed different levels of activation in different MSCs after osteoblast induction. Our conclusions suggest that PDLSCs might be a good potential alternative to BM MSCs for bone tissue engineering.
C1 [Zhang, Yunpeng; Xing, Yixiao; Jia, Linglu; Ji, Yawen; Zhao, Bin; Wen, Yong; Xu, Xin] Shandong Univ, Sch Stomatol, 44 1 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Yunpeng; Xing, Yixiao; Jia, Linglu; Ji, Yawen; Zhao, Bin; Wen, Yong; Xu, Xin] Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.
C3 Shandong University
RP Wen, Y; Xu, X (通讯作者)，Shandong Univ, Sch Stomatol, 44 1 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM wenyong@sdu.edu.cn; xinxu@sdu.edu.cn
RI LINGLU, JIA/HGA 3173 2022; zhang, shizhou/GZA 8192 2022
OI Zhang, Yunpeng/0000 0003 3547 9720; Jia, Linglu/0000 0002 7074 8861
FU Shandong Provincial key research and development program [2016GSF201115,
   2016GSF201220, 2017GSF18117]; Shandong Provincial Natural
   ScienceFoundation [ZR2018MH018, ZR2017MH031]; Young Scholars Program of
   Shandong University [2015WLJH53]; Construction Engineering Special Fund
   of Taishan Scholars [ts201511106]
FX We thank Dr. Weiting Gu from Qilu hospital for the collection of
   umbilical cords. This work was supported by grants from Shandong
   Provincial key research and development program (2016GSF201115,
   2016GSF201220, and 2017GSF18117), Shandong Provincial Natural
   ScienceFoundation (ZR2018MH018 and ZR2017MH031), Young Scholars Program
   of Shandong University (2015WLJH53), and the Construction Engineering
   Special Fund of Taishan Scholars (ts201511106).
CR Aenlle KK, 2014, MOL ENDOCRINOL, V28, P722, DOI 10.1210/me.2013 1286
   Alt EU, 2012, STEM CELL RES, V8, P215, DOI 10.1016/j.scr.2011.11.002
   Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142 9612(02)00156 4
   Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092 8674(03)00687 1
   Bojic S, 2014, HISTOL HISTOPATHOL, V29, P699, DOI 10.14670/HH 29.699
   Byun MR, 2014, BONE, V58, P72, DOI 10.1016/j.bone.2013.09.024
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   D'Alimonte I, 2017, STEM CELLS DEV, V26, P843, DOI 10.1089/scd.2016.0190
   Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001
   Estrela Carlos, 2011, Braz. Dent. J., V22, P91
   Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181
   Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Hernández Monjaraz B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040944
   Hoogduijn MJ, 2014, CURR OPIN ORGAN TRAN, V19, P41, DOI 10.1097/MOT.0000000000000036
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   Isobe Y, 2016, INT J ORAL MAX SURG, V45, P124, DOI 10.1016/j.ijom.2015.06.022
   Jia LL, 2017, INT J MED SCI, V14, P1118, DOI 10.7150/ijms.19814
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim JM, 2014, EUR J PHARMACOL, V726, P1, DOI 10.1016/j.ejphar.2014.01.013
   Li CS, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3764372
   Li CY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0066 5
   Li XY, 2014, INT J MOL MED, V34, P695, DOI 10.3892/ijmm.2014.1821
   Liu JL, 2016, INT J MOL MED, V37, P173, DOI 10.3892/ijmm.2015.2412
   Mareschi K, 2001, HAEMATOLOGICA, V86, P1099
   Moradi SL, 2018, J CELL PHYSIOL, V233, P6509, DOI 10.1002/jcp.26606
   Mosna F, 2010, STEM CELLS DEV, V19, P1449, DOI 10.1089/scd.2010.0140
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092 8674(93)90509 O
   Park BW, 2012, DIFFERENTIATION, V83, P249, DOI 10.1016/j.diff.2012.02.008
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ren HJ, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3516574
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi RZ, 2008, BIOCHEM BIOPH RES CO, V376, P247, DOI 10.1016/j.bbrc.2008.09.004
   Sonowal H, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 71
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Tamaki Y, 2013, ODONTOLOGY, V101, P121, DOI 10.1007/s10266 012 0075 0
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   Tomar GB, 2010, BIOCHEM BIOPH RES CO, V393, P377, DOI 10.1016/j.bbrc.2010.01.126
   Viale Bouroncle S, 2015, MOL CELL BIOCHEM, V406, P199, DOI 10.1007/s11010 015 2437 8
   Wang JA, 2008, ACTA PHARMACOL SIN, V29, P74, DOI 10.1111/j.1745 7254.2008.00716.x
   Wang XY, 2015, APOPTOSIS, V20, P273, DOI 10.1007/s10495 014 1074 0
   Wu YG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143777
   Yu BH, 2014, J BIOMATER APPL, V29, P243, DOI 10.1177/0885328214521846
   Zhang X, 2015, MOL CELL BIOCHEM, V407, P41, DOI 10.1007/s11010 015 2452 9
   Zhang ZJ, 2012, J CELL BIOCHEM, V113, P888, DOI 10.1002/jcb.23418
   Zhou H, 2015, SCI REP UK, V5, DOI 10.1038/srep12898
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 50
TC 87
Z9 90
U1 1
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD DEC 1
PY 2018
VL 27
IS 23
BP 1634
EP 1645
DI 10.1089/scd.2018.0119
EA OCT 2018
PG 12
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA HC5BM
UT WOS:000448019300001
PM 30234437
DA 2025 08 17
ER

PT J
AU Baldazzi, V
   Tassi, R
   Lapini, A
   Lunghi, A
   Garofoli, E
   Caruso, S
   Carini, M
   Mazzanti, R
AF Baldazzi, Valentina
   Tassi, Renato
   Lapini, Alberto
   Lunghi, Alice
   Garofoli, Eleonora
   Caruso, Salvatore
   Carini, Marco
   Mazzanti, Roberto
TI Sunitinib induced hyperparathyroidism
SO CANCER
LA English
DT Article
DE metastatic renal cell carcinoma; sunitinib; hyperparathyroidism;
   hypophosphatemia; bone
ID RENAL CELL CARCINOMA; GROWTH FACTOR; IMATINIB MESYLATE; BONE FORMATION;
   ALTERED BONE; OSTEONECROSIS
AB BACKGROUND: Sunitinib malate is an orally bioavailable tyrosine kinase inhibitor that is active against many tyrosine kinase receptors involving crucial pathways in both healthy tissues and malignant tissues. Because its use in clinical practice is quite recent, many of its possible side effects remain unknown. In this report, the authors describe the incidence of new onset hyperparathyroidism in a cohort of patients with metastatic renal cell carcinoma who received treatment with sunitinib. METHODS: Twenty six patients who received first line sunitinib for metastatic renal cell carcinoma were enrolled in this study for a mineral and parathyroid function assessment. Plasma levels of intact parathyroid hormone; serum levels of calcium, phosphorus, 25 hydroxyvitamin D3, and 1,25 dihydrovitamin D3; and urinary 24 hour calcium and phosphorus excretion all were measured in each patient. Biochemical evaluations were performed before the beginning of treatment and at the end of each sunitinib treatment period. RESULTS: Eighteen of 26 patients (69.2%) developed hyperparathyroidism with normal serum calcium levels, and 6 of them developed hypophosphatemia. Patients presented with a mean elevation of parathyroid hormone after 2.2 cycles of sunitinib. The levels of 25 OH vitamin D3 were stable over the course of treatment, whereas 1,25 OH vitamin D3 levels were increased in 5 hyperparathyroid patients. Those who presenting with elevated parathyroid hormone levels had low or undetectable urinary calcium levels. Parathyroid hormone elevation usually persisted but did not progress during long term therapy with sunitinib. Permanent treatment interruption resulted in a resolution of hyperparathyroidism. CONCLUSIONS: Hyperparathyroidism developed in an high percentage of patients on sunitinib. Therefore, the authors concluded that sunitinib may affect parathyroid function and bone mineral homeostasis, possibly resulting in abnormal bone remodeling. Cancer 2012;118: 316572. (C) 2011 American Cancer Society.
C1 [Mazzanti, Roberto] Univ Florence, Ist Toscano Tumori, Med Oncol Unit 2, Careggi Univ Hosp,Dept Internal Med,AOU Careggi, I 50134 Florence, Italy.
   [Lapini, Alberto; Carini, Marco] Univ Florence, Careggi Univ Hosp, Urol Unit 1, I 50134 Florence, Italy.
C3 ISPRO Istituto per lo studio, la prevenzione e la rete oncologica;
   University of Florence; Azienda Ospedaliero Universitaria Careggi;
   University of Florence; Azienda Ospedaliero Universitaria Careggi
RP Mazzanti, R (通讯作者)，Univ Florence, Ist Toscano Tumori, Med Oncol Unit 2, Careggi Univ Hosp,Dept Internal Med,AOU Careggi, Largo Brambilla 3, I 50134 Florence, Italy.
EM r.mazzanti@unifi.it
RI Carini, Marco/N 2502 2014
CR AACE/AAES Task Force on Primary Hyperparathyroidism, 2005, Endocr Pract, V11, P49
   Baldazzi V, 2010, UROL ONCOL
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   CANALIS E, 1992, GROWTH REGULAT, V2, P151
   COCHRAN DL, 1993, BONE, V14, P53, DOI 10.1016/8756 3282(93)90256 A
   Dixon T, 2006, CURR MED RES OPIN, V22, P405, DOI 10.1185/030079906X89810
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Gore ME, 2009, LANCET ONCOL, V10, P757, DOI 10.1016/S1470 2045(09)70162 7
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Joensuu H, 2006, NEW ENGL J MED, V355, P628
   Jönsson S, 2008, HAEMATOL HEMATOL J, V93, P1101, DOI 10.3324/haematol.12373
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293
   Norden Zfoni A, 2007, CLIN CANCER RES, V13, P2643, DOI 10.1158/1078 0432.CCR 06 0919
   O'Sullivan S, 2009, J CLIN ENDOCR METAB, V94, P1131, DOI 10.1210/jc.2008 2324
   Osorio S, 2007, AM J HEMATOL, V82, P394, DOI 10.1002/ajh.20778
   Owen S, 2006, NEW ENGL J MED, V355, P627
   Pfizer Inc, 2006, SUT SUN MAL
   Rock EP, 2007, ONCOLOGIST, V12, P107, DOI 10.1634/theoncologist.12 1 107
   Schmidinger M, 2011, CANCER AM CANCER SOC, V117, P534, DOI 10.1002/cncr.25422
   van Cruijsen H, 2008, CLIN CANCER RES, V14, P5884, DOI 10.1158/1078 0432.CCR 08 0656
   Vandyke K, 2010, BLOOD, V115, P766, DOI 10.1182/blood 2009 08 237404
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yu XH, 1997, AM J PHYSIOL CELL PH, V272, pC1709, DOI 10.1152/ajpcell.1997.272.5.C1709
NR 28
TC 18
Z9 20
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0008 543X
EI 1097 0142
J9 CANCER AM CANCER SOC
JI Cancer
PD JUN 15
PY 2012
VL 118
IS 12
BP 3165
EP 3172
DI 10.1002/cncr.26435
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 952AB
UT WOS:000304761000021
PM 21956360
OA Bronze
DA 2025 08 17
ER

PT J
AU Elabd, C
   Ichim, TE
   Miller, K
   Anneling, A
   Grinstein, V
   Vargas, V
   Silva, FJ
AF Elabd, C.
   Ichim, T. E.
   Miller, K.
   Anneling, A.
   Grinstein, V.
   Vargas, V.
   Silva, F. J.
TI Comparing atmospheric and hypoxic cultured mesenchymal stem cell
   transcriptome: implication for stem cell therapies targeting
   intervertebral discs
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Hypoxia; Mesenchymal stem cells; RNA sequencing; Transcriptome; Cell
   therapy; Orthopedic application; Intervertebral disc
ID PROTEIN TYROSINE KINASE; BONE MARROW; NUCLEUS PULPOSUS; STROMAL CELLS;
   IN VITRO; CARTILAGE CELLS; OXYGEN TENSION; ANTIGEN 4; DIFFERENTIATION;
   PROLIFERATION
AB Background: Mesenchymal stem cells (MSCs) represent an attractive avenue for cellular therapies targeting degenerative diseases. MSC in vitro expansion is required in order to obtain therapeutic numbers during the manufacturing process. It is known that culture conditions impact cellular properties and behavior after in vivo transplantation. In this study, we aimed at evaluating the benefit of hypoxic culturing of human bone marrow derived mesenchymal stem cells on cell fitness and whole genome expression and discussed its implication on cellular therapies targeting orthopedic diseases such as chronic lower back pain.
   Methods: Human bone marrow mesenchymal stem cells (hBMMSCs) were isolated from fresh human anticoagulated whole bone marrow and were cultured side by side in atmospheric (20% O 2) and hypoxic (5% O 2) oxygen partial pressure for up to 3 passages. Stem cell fitness was assessed by clonogenic assay, cell surface marker expression and differentiation potential. Whole genome expression was performed by mRNA sequencing. Data from clonogenic assays, cell surface marker by flow cytometry and gene expression by quantitative PCR were analyzed by two tailed paired Student's t test. Data from mRNA sequencing were aligned to hg19 using Tophat 2.0.13 and analyzed using Cufflinks 2.1.1.
   Results: Hypoxic culturing of hBMMSCs had positive effects on cell fitness, as evidenced by an increased clonogenicity and improved differentiation potential towards adipocyte and chondrocyte lineages. No difference in osteoblast differentiation or in cell surface markers were observed. Only a small subset of genes (34) were identified by mRNA sequencing to be significantly dysregulated by hypoxia. When clustered by biological function, these genes were associated with chondrogenesis and cartilage metabolism, inflammation and immunomodulation, cellular survival, migration and proliferation, vasculogenesis and angiogenesis.
   Conclusions: Hypoxic culturing positively impacted hBMMSCs fitness and transcriptome, potentially improving inherent properties of these cells that are critical for the development of successful cellular therapies. Hypoxic culturing should be considered for the in vitro expansion of hBMMSCs during manufacturing of cellular therapies targeting orthopedic disorders such as lower back pain.
C1 [Ichim, T. E.] Immune Advisors LLC, La Jolla, CA 92037 USA.
   [Elabd, C.; Miller, K.; Anneling, A.; Grinstein, V.; Vargas, V.; Silva, F. J.] BioRestorat Therapies Inc, 40 Marcus Dr,Suite 1, Melville, NY 11747 USA.
RP Silva, FJ (通讯作者)，BioRestorat Therapies Inc, 40 Marcus Dr,Suite 1, Melville, NY 11747 USA.
EM fj74582@gmail.com
CR Abdelsaid MA, 2013, ANTIOXID REDOX SIGN, V19, P2199, DOI 10.1089/ars.2012.4761
   Adesida AB, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt100
   Aust L, 2004, CYTOTHERAPY, V6, P7, DOI 10.1080/14653240310004539
   Basciano L, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471 2121 12 12
   Boyette LB, 2014, STEM CELL TRANSL MED, V3, P241, DOI 10.5966/sctm.2013 0079
   Bucher C, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/326828
   Calzolari A, 2010, TRANSL ONCOL, V3, P123, DOI 10.1593/tlo.09274
   Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582 4934.2011.01258.x
   Choi H, 2016, AUTOPHAGY, V12, P1631, DOI 10.1080/15548627.2016.1192753
   Choi JR, 2014, BIOCHEM BIOPH RES CO, V448, P218, DOI 10.1016/j.bbrc.2014.04.096
   Deleuze V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040484
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dos Santos F, 2010, J CELL PHYSIOL, V223, P27, DOI 10.1002/jcp.21987
   Ejtehadifar M, 2015, ADV PHARM BULL, V5, P141, DOI 10.15171/apb.2015.021
   El Haddad M, 2012, J CELL SCI, V125, P6147, DOI 10.1242/jcs.115220
   Fehrer C, 2007, AGING CELL, V6, P745, DOI 10.1111/j.1474 9726.2007.00336.x
   Fotia C, 2015, CYTOTECHNOLOGY, V67, P1073, DOI 10.1007/s10616 014 9731 2
   Frank JW, 1996, SPINE, V21, P2908, DOI 10.1097/00007632 199612150 00024
   Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011
   Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441 003 0745 x
   Goldberg A, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018 017 0534 y
   GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755
   Heyman SN, 2016, ACTA PHYSIOL, V216, P395, DOI 10.1111/apha.12613
   Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008 6363(96)00063 6
   Holzwarth C, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 11
   Hu XY, 2008, J THORAC CARDIOV SUR, V135, P799, DOI 10.1016/j.jtcvs.2007.07.071
   Hu XY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 303
   Hudson KD, 2017, TISSUE ENG PT A, V23, P293, DOI [10.1089/ten.TEA.2016.0270, 10.1089/ten.tea.2016.0270]
   Kanda S, 2011, FRONT BIOSCI LANDMRK, V16, P1024, DOI 10.2741/3732
   Kawabata H, 2000, J BIOL CHEM, V275, P16618, DOI 10.1074/jbc.M908846199
   Kelly Goss MR, 2014, MICROCIRCULATION, V21, P345, DOI 10.1111/micc.12107
   Knaup KX, 2014, MOL CARCINOGEN, V53, P970, DOI 10.1002/mc.22065
   Koo Y, 2016, ANGIOGENESIS, V19, P173, DOI 10.1007/s10456 016 9498 5
   Kraut N, 1998, EMBO J, V17, P6276, DOI 10.1093/emboj/17.21.6276
   Kuta A, 2016, DEVELOPMENT, V143, P2367, DOI 10.1242/dev.131037
   Lafont JE, 2010, INT J EXP PATHOL, V91, P99, DOI 10.1111/j.1365 2613.2010.00707.x
   Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549
   Lee CR, 2007, EUR SPINE J, V16, P2174, DOI 10.1007/s00586 007 0475 y
   Lee JS, 2015, BONE, V78, P34, DOI 10.1016/j.bone.2015.04.044
   Li JH, 2008, J ENDOCRINOL INVEST, V31, P103, DOI 10.1007/BF03345575
   Li Yan, 2015, Asian Pac J Cancer Prev, V16, P2953
   Lin ZY, 2012, BIOMED PHARMACOTHER, V66, P454, DOI 10.1016/j.biopha.2012.04.001
   Lukov GL, 2011, LEUKEMIA RES, V35, P405, DOI 10.1016/j.leukres.2010.07.023
   Lv FJ, 2014, RHEUMATOLOGY, V53, P600, DOI 10.1093/rheumatology/ket303
   MacQueen L, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0179
   Macrin D, 2017, STEM CELL REV REP, V13, P741, DOI 10.1007/s12015 017 9759 8
   Malone JH, 2011, BMC BIOL, V9, DOI 10.1186/1741 7007 9 34
   Ohnishi S, 2007, STEM CELLS, V25, P1166, DOI 10.1634/stemcells.2006 0347
   Påhlman S, 2018, CELL TISSUE RES, V372, P269, DOI 10.1007/s00441 017 2701 1
   Pezzi A, 2017, J CELL BIOCHEM, V118, P3072, DOI 10.1002/jcb.25953
   Phinney DG, 1999, J CELL BIOCHEM, V72, P570
   Rahmani Neishaboor E, 2010, WOUND REPAIR REGEN, V18, P401, DOI 10.1111/j.1524 475X.2010.00598.x
   Richardson SM, 2016, METHODS, V99, P69, DOI 10.1016/j.ymeth.2015.09.015
   Rutges J, 2010, OSTEOARTHR CARTILAGE, V18, P416, DOI 10.1016/j.joca.2009.09.009
   Sangrar W, 2004, EXP HEMATOL, V32, P935, DOI 10.1016/j.exphem.2004.07.004
   Shoji K, 2013, AM J PATHOL, V182, P2191, DOI 10.1016/j.ajpath.2013.02.024
   Sperber SM, 2008, DEV BIOL, V321, P101, DOI 10.1016/j.ydbio.2008.06.004
   Sternberg H, 2013, REGEN MED, V8, P125, DOI [10.2217/RME.12.117, 10.2217/rme.12.117]
   Sternberg H, 2012, REGEN MED, V7, P481, DOI [10.2217/RME.12.29, 10.2217/rme.12.29]
   Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020
   Tsai CC, 2012, AM J BLOOD RES, V2, P148
   Urban JPG, 2004, SPINE, V29, P2700, DOI 10.1097/01.brs.0000146499.97948.52
   van den Akker GGH, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4597
   Wagegg M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046483
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Wilson CW, 2014, CELL ADHES MIGR, V8, P76, DOI 10.4161/cam.28115
   Wu En Hui, 2007, Shengli Xuebao, V59, P227
   Xu K, 2011, DEV CELL, V20, P526, DOI 10.1016/j.devcel.2011.02.010
   Xu K, 2009, DEV BIOL, V329, P269, DOI 10.1016/j.ydbio.2009.02.033
   Ye Q, 2013, J BIOL CHEM, V288, P9881, DOI 10.1074/jbc.M113.450593
NR 71
TC 50
Z9 52
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD AUG 10
PY 2018
VL 16
AR 222
DI 10.1186/s12967 018 1601 9
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GP9YI
UT WOS:000441271900002
PM 30097061
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Park, J
   Leung, CY
   Matralis, AN
   Lacbay, CM
   Tsakos, M
   De Troconiz, GF
   Berghuis, AM
   Tsantrizos, YS
AF Park, Jaeok
   Leung, Chun Yuen
   Matralis, Alexios N.
   Lacbay, Cyrus M.
   Tsakos, Michail
   De Troconiz, Guillermo Fernandez
   Berghuis, Albert M.
   Tsantrizos, Youla S.
TI Pharmacophore Mapping of Thienopyrimidine Based Monophosphonate (ThP MP)
   Inhibitors of the Human Farnesyl Pyrophosphate Synthase
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; MICROWAVE ASSISTED SYNTHESIS;
   ZOLEDRONIC ACID; IN VIVO; PROTEIN PRENYLATION; MEVALONATE PATHWAY;
   BREAST CANCER; ACTIVE SITE; DISCOVERY; MECHANISM
AB The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C 15 isoprenoid farnesyl pyrophosphate (FPP). FPP plays a crucial role in the post translational prenylation of small GTPases that perform a plethora of cellular functions. Although hFPPS is a well established therapeutic target for lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and distribution into nonskeletal tissues. Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non bisphosphonate drugs for potentially treating nonskeletal diseases. Hit  to lead optimization of a new series of thienopyrimidine based monosphosphonates (ThP MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS. Their interactions with the allosteric pocket of the enzyme were characterized by crystallography, and the results provide further insight into the pharmacophore requirements for allosteric inhibition.
C1 [Leung, Chun Yuen; Matralis, Alexios N.; Lacbay, Cyrus M.; Tsakos, Michail; De Troconiz, Guillermo Fernandez; Tsantrizos, Youla S.] McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada.
   [Park, Jaeok; Berghuis, Albert M.; Tsantrizos, Youla S.] McGill Univ, Dept Biochem, 3649 Promenade Sir William Osler, Montreal, PQ H3G 0B1, Canada.
   [Berghuis, Albert M.; Tsantrizos, Youla S.] McGill Univ, Grp Rech Axe Struct Prot, 3649 Promenade Sir William Osler, Montreal, PQ H3G 0B1, Canada.
C3 McGill University; McGill University; McGill University
RP Tsantrizos, YS (通讯作者)，McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada.; Tsantrizos, YS (通讯作者)，McGill Univ, Dept Biochem, 3649 Promenade Sir William Osler, Montreal, PQ H3G 0B1, Canada.; Tsantrizos, YS (通讯作者)，McGill Univ, Grp Rech Axe Struct Prot, 3649 Promenade Sir William Osler, Montreal, PQ H3G 0B1, Canada.
EM Youla.tsantrizos@mcgill.ca
RI ; Park, Jaeok/U 6904 2019; Berghuis, Albert/A 6495 2008
OI Park, Jaeok/0000 0002 8180 3950; Berghuis, Albert/0000 0002 2663 025X;
   Tsakos, Michail/0000 0002 7309 2167
FU Canadian Institute of Health Research (CIHR)
FX Financial support for this work was provided by the Canadian Institute
   of Health Research (CIHR) research grants to A.M.B. and Y.S.T.
CR Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Bhagat S, 2008, J ORG CHEM, V73, P6029, DOI 10.1021/jo8009006
   Bjornstad V, 2009, SYNTHETIC COMMUN, V39, P1793, DOI 10.1080/00397910802590936
   Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   De Schutter JW, 2014, J MED CHEM, V57, P5764, DOI 10.1021/jm500629e
   Dias LC, 2003, SYNTHESIS STUTTGART, P603
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eckert GP, 2009, NEUROBIOL DIS, V35, P251, DOI 10.1016/j.nbd.2009.05.005
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fujimoto T, 2014, ORG PROCESS RES DEV, V18, P1041, DOI 10.1021/op500121w
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gritzalis D, 2015, BIOORG MED CHEM LETT, V25, P1117, DOI 10.1016/j.bmcl.2014.12.089
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Han FB, 2015, ACS MED CHEM LETT, V6, P434, DOI 10.1021/ml5005014
   Hesse S, 2007, TETRAHEDRON LETT, V48, P5261, DOI 10.1016/j.tetlet.2007.05.136
   Hooff GP, 2010, BBA MOL CELL BIOL L, V1801, P896, DOI 10.1016/j.bbalip.2010.03.014
   Hottman DA, 2014, MOL NEUROBIOL, V50, P177, DOI 10.1007/s12035 013 8627 z
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Jang WB, 1997, SYNTHETIC COMMUN, V27, P4101, DOI 10.1080/00397919708005457
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Keglevich G, 2012, MOLECULES, V17, P12821, DOI 10.3390/molecules171112821
   Kowalik J., 1981, SYNTHESIS STUTTGART, V1981, P57
   Leung CY, 2013, J MED CHEM, V56, P7939, DOI 10.1021/jm400946f
   Leung CY, 2013, BIOORGAN MED CHEM, V21, P2229, DOI 10.1016/j.bmc.2013.02.006
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Ling Q, 2016, PROG NEURO PSYCHOPH, V66, P80, DOI 10.1016/j.pnpbp.2015.11.013
   Liu JG, 2014, BBA GEN SUBJECTS, V1840, P1051, DOI 10.1016/j.bbagen.2013.11.006
   Liu YL, 2015, ACS MED CHEM LETT, V6, P349, DOI 10.1021/ml500528x
   Maier L., 2006, PHOSPHORUS SULFUR, V53, P43
   Marzinzik AL, 2015, CHEMMEDCHEM, V10, P1884, DOI 10.1002/cmdc.201500338
   McDonald SL, 2014, SYNLETT, V25, P2233, DOI 10.1055/s 0034 1378324
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600 065X.2006.00479.x
   Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Nguyen UTT, 2009, NAT CHEM BIOL, V5, P227, DOI 10.1038/nchembio.149
   Park J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14132
   Park J, 2014, FRONT CHEM, V2, DOI [10.3389/fchem.2014.00050, 10.3389/fchem.2014.00077]
   Reid PC, 2007, J CELL MOL MED, V11, P383, DOI 10.1111/j.1582 4934.2007.00054.x
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Sather AC, 2015, J AM CHEM SOC, V137, P13433, DOI 10.1021/jacs.5b09308
   Sheldrick GM, 2010, ACTA CRYSTALLOGR D, V66, P479, DOI 10.1107/S0907444909038360
   Shestopalov AM, 2009, TETRAHEDRON LETT, V50, P5257, DOI 10.1016/j.tetlet.2009.07.015
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Song Y., 2013, Pyrazine Kinase Inhibitors, Patent No. [US 2013/0131040 Al, 20130131040, US2013/0131040 Al]
   Thorn A, 2011, J APPL CRYSTALLOGR, V44, P1285, DOI [10.1107/S0021889811041768, 10.1107/S00218898110417681285]
   Wan ZK, 2007, J ORG CHEM, V72, P10194, DOI 10.1021/jo7020373
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701
   Woodring JL, 2015, MEDCHEMCOMM, V6, P339, DOI 10.1039/c4md00441h
NR 53
TC 24
Z9 29
U1 0
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 9
PY 2017
VL 60
IS 5
BP 2119
EP 2134
DI 10.1021/acs.jmedchem.6b01888
PG 16
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA EN9BQ
UT WOS:000396296100034
PM 28208018
DA 2025 08 17
ER

PT J
AU Zhang, R
   Pan, YL
   Hu, SJ
   Kong, XH
   Juan, W
   Mei, QB
AF Zhang, Rong
   Pan, Ya Lei
   Hu, Shi Jie
   Kong, Xiang He
   Juan, Wang
   Mei, Qi Bing
TI Effects of total lignans from Eucommia ulmoides barks prevent
   bone loss in vivo and in vitro
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Osteoblast; Osteoporosis; Ovariectomy; Eucommia ulmoides Oliv. total
   saponins
ID POSTMENOPAUSAL WOMEN; HORMONE THERAPY; RAT MODEL; DIFFERENTIATION;
   OSTEONECROSIS; OSTEOPOROSIS; MASS; JAW; PROLIFERATION; ARCHITECTURE
AB Ethnopharmacological relevance: The present study systematically investigate the in vivo and in vitro effect of total lignans (TL) extracted from Eucommia ulmoides Oliv. barks on bone formation using ovariectomy rat model and primary cultures of rat osteoblasts.
   Materials and methods: Eighty 3 month old female Sprague Dawley rats were used and randomly assigned into sham operated group (SHAM) and five ovariectomy (OVX) subgroups, i.e. OVX with vehicle (OVX); OVX with 17 alpha ethinylestradiol (E 2, 25 mu g/kg/day); OVX with TL of graded doses (20, 40, or 80 mg/kg/day). The treatment began 4 weeks after the surgery and lasted for 16 weeks, in vitro experiments were performed to determine the potential mechanisms of the anti osteoporotic effect of TL.
   Results: Treatment with TL significantly prevent OVX induced decrease in biomechanical quality of femur such as maximum stress and Young's modulus. The mechanical changes were associated with the prevention of a further BMD decrease or even with some improvements in microarchitecture. TL inhibited BMD decrease in the femur caused by OVX, which was accompanied by a significant decrease in skeletal remodeling, as was evidenced by the decreased levels of the bone turnover markers. mu CT analysis of the femoral metaphysis showed how to prevent the deterioration of trabecular microarchitecture. TL induced primary osteoblastic cell proliferation and differentiation, inhibition of osteoclastogenesis through an increase in osteoprotegrin (OPG) and a decrease in NE kappa B ligand (RANKL) expression in vitro.
   Conclusions: We concluded that TL treatment can effectively suppress the loss of bone mass induced by OVX and in vitro evidence suggests this could be through actions on both osteoblasts and osteoclasts. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhang, Rong] Fourth Mil Med Univ, Xijing Hosp, Inst Neurosurg, Xian 710032, Peoples R China.
   [Hu, Shi Jie; Mei, Qi Bing] Fourth Mil Med Univ, Dept Pharmacol, Sch Pharm, Xian 710032, Peoples R China.
   [Pan, Ya Lei; Kong, Xiang He; Juan, Wang; Mei, Qi Bing] Northwestern Polytech Univ, Sch Life Sci, Xian 710072, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Northwestern
   Polytechnical University
RP Mei, QB (通讯作者)，Fourth Mil Med Univ, Dept Pharmacol, Sch Pharm, 17 West Changle Rd, Xian 710032, Peoples R China.
EM qbmei@fmmu.edu.cn
FU National Natural Science Foundation of China [81201517, 81073037]
FX We thank Prof. Y.W. Guo (Shaanxi Food and Drug Administration) for his
   assistance for Eucommia ulmoides Oliv. identification; and Dr. Rui Zhang
   (Department of Molecular Biology, Fourth Military Medical University)
   for his assistance for PCR analysis. This work was supported by National
   Natural Science Foundation of China (81201517 and 81073037).
CR [Anonymous], 2010, PHARMACOPOEIA PEOPLE
   [Anonymous], 1996, GUIDE CARE USE LAB A
   Bonjour JP, 2012, J NUTR, V142, P698, DOI 10.3945/jn.111.153692
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   delaPiedra C, 1997, CLIN CHIM ACTA, V265, P225, DOI 10.1016/S0009 8981(97)00131 9
   Devareddy L, 2006, BONE, V38, P686, DOI 10.1016/j.bone.2005.10.024
   Deyama T, 2001, ACTA PHARMACOL SIN, V22, P1057
   Donahue HJ, 2000, AM J PHYSIOL CELL PH, V278, pC315, DOI 10.1152/ajpcell.2000.278.2.C315
   Ederveen AGH, 2001, J BONE MINER RES, V16, P1674, DOI 10.1359/jbmr.2001.16.9.1674
   Foidart JM, 2007, CLIMACTERIC, V10, P54, DOI 10.1080/13697130701598324
   Gaumet N, 1997, ARCH PHYSIOL BIOCHEM, V105, P435, DOI 10.1076/apab.105.5.435.3292
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Jiang MM, 2009, PLANTA MED, V75, P340, DOI 10.1055/s 0028 1112212
   Kawasaki T., 2000, J HEALTH SCI, V22, P29
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Laib A, 2001, OSTEOPOROSIS INT, V12, P936, DOI 10.1007/s001980170022
   Laib A, 2000, MED BIOL ENG COMPUT, V38, P326, DOI 10.1007/BF02347054
   Lee MK, 2007, BIOL PHARM BULL, V30, P814, DOI 10.1248/bpb.30.814
   Leskelä HV, 2006, BONE, V39, P1026, DOI 10.1016/j.bone.2006.05.003
   Miura H, 1995, ENDOCR J, V42, P797, DOI 10.1507/endocrj.42.797
   Morch LS, 2009, JAMA J AM MED ASSOC, V302, P298, DOI 10.1001/jama.2009.1052
   Müller R, 2004, J BONE MINER RES, V19, P1787, DOI 10.1359/JBMR.040809
   O'Ryan FS, 2012, J ORAL MAXIL SURG, V70, P1844, DOI 10.1016/j.joms.2011.08.033
   PASTOUREAU P, 1995, OSTEOPOROSIS INT, V5, P143, DOI 10.1007/BF02106092
   Rachner TD, 2013, MAYO CLIN PROC, V88, P418, DOI 10.1016/j.mayocp.2013.01.002
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Stevenson JC, 2005, MATURITAS, V51, P113, DOI 10.1016/j.maturitas.2005.01.012
   Turner CH, 1999, J BIOMECH, V32, P437, DOI 10.1016/S0021 9290(98)00177 8
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   TURNER CH, 1995, J DENT RES, V74, P1475, DOI 10.1177/00220345950740080701
   Ulrich D, 1999, BONE, V25, P55, DOI 10.1016/S8756 3282(99)00098 8
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Yang XJ, 2007, J ASIAN NAT PROD RES, V9, P583, DOI 10.1080/10286020500530433
   Yin J, 2008, PLANTA MED, V74, P1451, DOI 10.1055/s 2008 1081340
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
NR 38
TC 51
Z9 66
U1 1
U2 42
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD AUG 8
PY 2014
VL 155
IS 1
BP 104
EP 112
DI 10.1016/j.jep.2014.04.031
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA AN8KV
UT WOS:000340854000009
PM 24786573
DA 2025 08 17
ER

PT J
AU Gül, D
   Schweitzer, A
   Khamis, A
   Knauer, SK
   Ding, GB
   Freudelsperger, L
   Karampinis, I
   Strieth, S
   Hagemann, J
   Stauber, RH
AF Guel, Desiree
   Schweitzer, Andrea
   Khamis, Aya
   Knauer, Shirley K.
   Ding, Guo Bin
   Freudelsperger, Laura
   Karampinis, Ioannis
   Strieth, Sebastian
   Hagemann, Jan
   Stauber, Roland H.
TI Impact of Secretion Active Osteoblast Specific Factor 2 in Promoting
   Progression and Metastasis of Head and Neck Cancer
SO CANCERS
LA English
DT Article
DE metastases; HPV; biomarker; therapy resistance; methylation; oral
   cancer; protein secretion
ID SQUAMOUS CELL CARCINOMA; PERIOSTIN PROMOTES; ADHESION MOLECULE;
   GENE EXPRESSION; TUMOR MICROENVIRONMENT; CISPLATIN RESISTANCE; PLATINUM
   RESISTANCE; PROGNOSTIC MARKER; TREATMENT OPTIONS; STROMAL CELLS
AB Simple Summary Head and neck cancers (HNC) exhibit poor survival due to metastases. Our study identified osteoblast specific factor 2 (OSF 2) as overexpressed in primary tumors, lymph node metastases, and the tumor microenvironment. High OSF 2 levels correlate with metastatic disease and reduced survival of HPV negative HNC patients. OSF 2's active secretion signal seems to promote metastases by supporting the tumor microenvironment via the ss1 integrin induced PI3K and Akt/PKB signaling pathway. We suggest OSF 2 as a potential biomarker and drug target to control (HPV negative) HNC metastasis and disease management. Treatment success of head and neck cancer (HNC) is still hampered by tumor relapse due to metastases. Our study aimed to identify biomarkers by exploiting transcriptomics profiles of patient matched metastases, primary tumors, and normal tissue mucosa as well as the TCGA HNC cohort data sets. Analyses identified osteoblast specific factor 2 (OSF 2) as significantly overexpressed in lymph node metastases and primary tumors compared to normal tissue. High OSF 2 levels correlate with metastatic disease and reduced overall survival of predominantly HPV negative HNC patients. No significant correlation was observed with tumor localization or therapy response. These findings were supported by the fact that OSF 2 expression was not elevated in cisplatin resistant HNC cell lines. OSF 2 was strongly expressed in tumor associated fibroblasts, suggesting a tumor microenvironment promoting function. Molecular cloning and expression studies of OSF 2 variants from patients identified an evolutionary conserved bona fide protein secretion signal ((1)MIPFLPMFSLLLLLIVNPINA(21)). OSF 2 enhanced cell migration and cellular survival under stress conditions, which could be mimicked by the extracellular administration of recombinant protein. Here, OSF 2 executes its functions via ss1 integrin, resulting in the phosphorylation of PI3K and activation of the Akt/PKB signaling pathway. Collectively, we suggest OSF 2 as a potential prognostic biomarker and drug target, promoting metastases by supporting the tumor microenvironment and lymph node metastases survival rather than by enhancing primary tumor proliferation or therapy resistance.
C1 [Guel, Desiree; Schweitzer, Andrea; Khamis, Aya; Freudelsperger, Laura; Hagemann, Jan; Stauber, Roland H.] Univ Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Mol & Cellular Oncol, D 55131 Mainz, Germany.
   [Khamis, Aya] Alexandria Univ, Fac Dent, Oral Pathol Dept, Alexandria, Egypt.
   [Knauer, Shirley K.] Univ Duisburg Essen, Ctr Med Biotechnol ZMB, Inst Mol Biol, Univ Str, D 45117 Essen, Germany.
   [Ding, Guo Bin; Stauber, Roland H.] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Minist Educ, Taiyuan 030006, Peoples R China.
   [Karampinis, Ioannis] Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Acad Thorac Ctr, D 55131 Mainz, Germany.
   [Strieth, Sebastian] Univ Med Ctr Bonn, Dept Otorhinolaryngol, D 53127 Bonn, Germany.
C3 Johannes Gutenberg University of Mainz; Egyptian Knowledge Bank (EKB);
   Alexandria University; University of Duisburg Essen; Shanxi University;
   Johannes Gutenberg University of Mainz; University of Bonn
RP Gül, D; Stauber, RH (通讯作者)，Univ Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Mol & Cellular Oncol, D 55131 Mainz, Germany.; Stauber, RH (通讯作者)，Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Minist Educ, Taiyuan 030006, Peoples R China.
EM guel@uni mainz.de; andrea.schweitzer@gmx.de; ayakhamis@uni mainz.de;
   shirley.knauer@uni due.de; dinggb2012@sxu.edu.cn;
   laura.freudelsperger@unimedizin mainz.de;
   ioannis.karampinis@unimedizin mainz.de; sebastian.strieth@ukbonn.de;
   jan.hagemann@unimedizin mainz.de; rstauber@uni mainz.de
RI ; Khamis, Aya/U 8732 2018; Ding, Guo Bin/D 7410 2013; Knauer,
   Shirley/E 7931 2012; Gül, Desiree/HZL 0661 2023
OI Ding, Guo Bin/0000 0002 3012 179X; Khamis, Aya/0000 0001 5324 9932;
   Guel, Desiree/0000 0002 2446 5756; Hagemann, Jan/0000 0002 9846 7850;
   Karampinis, Ioannis/0000 0003 2742 9045; Knauer,
   Shirley/0000 0003 4321 0924; Strieth, Sebastian/0000 0003 0177 1926
FU Else Kroner Fresenius Foundation [2015_A233]; Stiftung Tumorforschung
   Kopf Hals (TF OSF); DAAD/TransMed [ST35]; Deutsche
   Forschungsgemeinschaft [STR 1014, HA8065]; Science Support Program of
   the University Hospital Mainz
FX This study was supported by Else Kroner Fresenius Foundation
   (2015_A233), Stiftung Tumorforschung Kopf Hals (TF OSF), DAAD/TransMed
   (ST35), Deutsche Forschungsgemeinschaft (STR 1014; HA8065), and the
   Science Support Program of the University Hospital Mainz.
CR Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685
   Allen CT, 2013, HEAD NECK J SCI SPEC, V35, P1669, DOI 10.1002/hed.23202
   Alsahafi E, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1769 9
   Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535 6108(04)00081 9
   Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009
   Beltz A, 2019, EJSO EUR J SURG ONC, V45, P1046, DOI 10.1016/j.ejso.2019.02.032
   Bier C, 2011, J BIOL CHEM, V286, P3007, DOI 10.1074/jbc.M110.161646
   Bockhorst C, 2021, EPIGENOMICS UK, V13, P113, DOI 10.2217/epi 2020 0208
   Bottos A, 2014, NATURE, V514, P309, DOI 10.1038/514309a
   Campbell JD, 2018, CELL REP, V23, P194, DOI 10.1016/j.celrep.2018.03.063
   Castilho RM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071506
   Chen SMY, 2020, MOL CARCINOGEN, V59, P766, DOI 10.1002/mc.23162
   Cho JH, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2018.11.004
   Choi KU, 2011, INT J CANCER, V128, P332, DOI 10.1002/ijc.25341
   Chu L, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820977535
   Cohen RB, 2014, CANCER TREAT REV, V40, P567, DOI 10.1016/j.ctrv.2013.10.002
   Denaro N, 2014, ONCOLOGY BASEL, V86, P212, DOI 10.1159/000357712
   Deuss E, 2020, CANCERS, V12, DOI 10.3390/cancers12113358
   Dingerdissen HM, 2018, NUCLEIC ACIDS RES, V46, pD1128, DOI 10.1093/nar/gkx907
   Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140 6736(07)60781 8
   El Naggar AK, 2002, ONCOGENE, V21, P8206, DOI 10.1038/sj.onc.1206021
   ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825
   Engels K, 2007, J PATHOL, V211, P532, DOI 10.1002/path.2134
   Engels K, 2009, J CLIN PATHOL, V62, P448, DOI 10.1136/jcp.2008.063859
   Engels K, 2008, CANCER RES, V68, P5159, DOI 10.1158/0008 5472.CAN 08 0406
   Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Ferlito A, 2001, ORL J OTO RHIN LARYN, V63, P202, DOI 10.1159/000055740
   Fetz V, 2009, INT J CANCER, V124, P2033, DOI 10.1002/ijc.24182
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008 5472.CAN 03 2144
   Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587 020 0546 8
   Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754
   González González L, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00225
   Gribko A, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11112040
   Gribko A, 2019, INT J NANOMED, V14, P4187, DOI 10.2147/IJN.S198319
   Gül D, 2022, BIOL CHEM, V403, P869, DOI 10.1515/hsz 2021 0287
   Habtemichael N, 2010, GENE, V469, P9, DOI 10.1016/j.gene.2010.08.007
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Hu WX, 2016, CELL PHYSIOL BIOCHEM, V38, P1199, DOI 10.1159/000443068
   Hu YJ, 2017, J CANCER RES CLIN, V143, P745, DOI 10.1007/s00432 016 2279 0
   Ismail RS, 2000, CANCER RES, V60, P6744
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jou A, 2017, ONCOL RES TREAT, V40, P328, DOI 10.1159/000477127
   Kanno A, 2008, INT J CANCER, V122, P2707, DOI 10.1002/ijc.23332
   Khurshid Zohaib, 2020, Eur J Dent, V14, P462, DOI 10.1055/s 0040 1714037
   Kii I, 2019, ADV EXP MED BIOL, V1132, P23, DOI 10.1007/978 981 13 6657 4_3
   Kikuchi Y, 2014, AM J PATHOL, V184, P859, DOI 10.1016/j.ajpath.2013.11.012
   Kim CJ, 2005, INT J CANCER, V117, P51, DOI 10.1002/ijc.21120
   Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200
   Knauer SK, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.25
   Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864 015 1847 z
   Kudo Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044488
   Künzel J, 2019, BIOL CHEM, V400, P1465, DOI 10.1515/hsz 2019 0141
   Kyutoku M, 2011, INT J MOL MED, V28, P181, DOI 10.3892/ijmm.2011.712
   Kzhyshkowska J, 2004, J LEUKOCYTE BIOL, V76, P1151, DOI 10.1189/jlb.0504300
   Le QT, 2003, CLIN CANCER RES, V9, P59
   Lee YJ, 2013, MOL THER, V21, P1004, DOI 10.1038/mt.2013.30
   Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115
   Liu YF, 2019, ADV EXP MED BIOL, V1132, P125, DOI 10.1007/978 981 13 6657 4_13
   Luo SD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/508587
   Ma HD, 2020, CELL REP, V30, P793, DOI 10.1016/j.celrep.2019.12.075
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001
   Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   Méndez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875
   New J, 2017, CANCER RES, V77, P6679, DOI 10.1158/0008 5472.CAN 17 1077
   Oo KK, 2021, BMC CANCER, V21, DOI 10.1186/s12885 020 07761 w
   Oosting SF, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00815
   Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79
   Paolillo M, 2017, CANCERS, V9, DOI 10.3390/cancers9080095
   Park JJ, 2020, ANTICANCER RES, V40, P2627, DOI 10.21873/anticanres.14233
   Price KAR, 2012, CURR TREAT OPTION ON, V13, P35, DOI 10.1007/s11864 011 0176 y
   Ritchie KE, 2013, CANCER LETT, V338, P41, DOI 10.1016/j.canlet.2012.07.025
   Röcken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424
   Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018 009 0013 7
   Sasaki H, 2003, BREAST CANCER RES TR, V77, P245, DOI 10.1023/A:1021899904332
   Sasaki H, 2001, CANCER AM CANCER SOC, V92, P843, DOI 10.1002/1097 0142(20010815)92:4<843::AID CNCR1391>3.0.CO;2 P
   Sasaki H, 2001, JPN J CANCER RES, V92, P869, DOI 10.1111/j.1349 7006.2001.tb01174.x
   Shao R, 2004, BIOCHEM BIOPH RES CO, V321, P788, DOI 10.1016/j.bbrc.2004.07.033
   Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992 4003.2004
   Siemer S, 2021, ACS NANO, V15, P18541, DOI 10.1021/acsnano.1c08632
   Siemer S, 2021, CANCERS, V13, DOI 10.3390/cancers13194831
   Stauber RH, 2006, TRAFFIC, V7, P1461, DOI 10.1111/j.1600 0854.2006.00486.x
   Stauber RH, 2012, CANCER RES, V72, P2912, DOI 10.1158/0008 5472.CAN 12 0150
   Stauber RH, 2012, ONCOTARGET, V3, P31
   Sterzynska K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163927
   Sung PL, 2016, ONCOTARGET, V7, P4036, DOI 10.18632/oncotarget.6700
   Tai IT, 2005, CARCINOGENESIS, V26, P908, DOI 10.1093/carcin/bgi034
   TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271
   Trothe J, 2018, EXP DERMATOL, V27, P1352, DOI 10.1111/exd.13789
   Vardaki I, 2016, ONCOTARGET, V7, P74966, DOI 10.18632/oncotarget.11663
   Watermann C, 2021, CLIN CANCER RES, V27, P632, DOI 10.1158/1078 0432.CCR 20 0197
   Welkoborsky HJ, 2003, ONCOLOGY BASEL, V65, P60, DOI 10.1159/000071206
   Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043
   Xouri G, 2010, SEMIN CELL DEV BIOL, V21, P40, DOI 10.1016/j.semcdb.2009.11.017
   Xu CJ, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935 021 02441 6
   Ye D, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22622
   Yoshioka N, 2002, EXP CELL RES, V279, P91, DOI 10.1006/excr.2002.5590
   Yu BB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1116 6
   Zacksenhaus E, 2021, CANCERS, V13, DOI 10.3390/cancers13040717
   Zacksenhaus E, 2017, TRENDS CANCER, V3, P768, DOI 10.1016/j.trecan.2017.09.002
   Zhu DX, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.694800
NR 104
TC 4
Z9 4
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD MAY
PY 2022
VL 14
IS 9
AR 2337
DI 10.3390/cancers14092337
PG 26
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 1E4PW
UT WOS:000794473600001
PM 35565465
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Manglaviti, S
   Bini, M
   Apollonio, G
   Zecca, E
   Galli, G
   Sangaletti, S
   Labianca, A
   Sottotetti, E
   Brambilla, M
   Occhipinti, M
   Proto, C
   Prelaj, A
   Signorelli, D
   De Toma, A
   Viscardi, G
   Beninato, T
   Mazzeo, L
   Bottiglieri, A
   Leporati, R
   Fotia, G
   Ganzinelli, M
   Portararo, P
   Garassino, MC
   de Braud, FGM
   Lo Russo, G
   Torri, V
   Ferrara, R
AF Manglaviti, Sara
   Bini, Marta
   Apollonio, Giulia
   Zecca, Ernesto
   Galli, Giulia
   Sangaletti, Sabina
   Labianca, Alice
   Sottotetti, Elisa
   Brambilla, Marta
   Occhipinti, Mario
   Proto, Claudia
   Prelaj, Arsela
   Signorelli, Diego
   De Toma, Alessandro
   Viscardi, Giuseppe
   Beninato, Teresa
   Mazzeo, Laura
   Bottiglieri, Achille
   Leporati, Rita
   Fotia, Giuseppe
   Ganzinelli, Monica
   Portararo, Paola
   Garassino, Marina Chiara
   de Braud, Filippo G. M.
   Lo Russo, Giuseppe
   Torri, Valter
   Ferrara, Roberto
TI High bone tumor burden to identify advanced non small cell lung cancer
   patients with survival benefit upon bone targeted agents and immune
   checkpoint inhibitors
SO LUNG CANCER
LA English
DT Article
DE Non  small cell lung cancer; Immunotherapy; Bone targeted agents;
   Denosumab; High bone tumor burden
ID ZOLEDRONIC ACID; PHASE III; SKELETAL METASTASES; SOLID TUMORS;
   DOUBLE BLIND; DENOSUMAB; THERAPY; TRIAL; ORGANIZATION; PLACEBO
AB Background: Bone targeted agents (BTA), such as denosumab (DN) and zoledronic acid (ZA), have historically reduced the risk of skeletal related events in cancer patients with bone metastases (BM), with no improvement in survival outcomes. In the immunotherapy era, BM have been associated with poor prognosis upon immune  checkpoint inhibitors (ICI). Currently, the impact of bone tumor burden on survival upon BTAs in advanced non small cell lung cancer (aNSCLC) patients treated with ICI remains unknown. Methods: Data from ICI treated aNSCLC patients with BM (4/2013 5/2022) in one institution were retrospec tively collected. BTA ICI concurrent treatment was defined as BTA administration at any time before or within 90 days from ICI start. High bone tumor burden (HBTB) was defined as >= 3 sites of BM. Median OS (mOS) was estimated with Kaplan Meier. Aikaike's information criterion (AIC) was used to select the best model for data analysis adjusted for clinical variables. Results: Of 134 patients included, 51 (38 %) received BTA. At a mFU of 39.6 months (m), BTA ICIs concurrent treatment did not significantly impact on mOS [8.3 m (95% CI 3.9 12.8) versus (vs) 6.8 m (95% CI 4.0 9.6) p = 0.36]; these results were confirmed after adjustment for clinical variables selected by AIC. A multivariate model showed a significant interaction between BTA use and HBTB or radiation therapy to BM. In subgroup analyses, only HBTB confirmed to be associated with significantly longer mOS [8.3 m (95% CI 2.4 14.2) vs 3.5 m (95% CI 2.9 4.1), p = 0.003] and mPFS [3.0 m (95% CI 1.6 4.4) vs 1.8 m (95% CI 1.6 2.0) p = 0.001] upon BTA ICI concurrent treatment, with the most pronounced OS benefit observed for DN ICI concurrent regimen [15.2 m (95% CI 0.1 30.7) vs 3.5 m (95% CI 2.9 4.1) p = 0.002]. Conclusions: In the immunotherapy era, HBTB can identify patients experiencing survival benefit with BTA, especially with DN ICI combination. HBTB should be included as a stratification factor in the upcoming trials assessing BTA and ICI combinations in patients with aNSCLC and BM.
C1 [Manglaviti, Sara; Bini, Marta; Apollonio, Giulia; Galli, Giulia; Labianca, Alice; Sottotetti, Elisa; Brambilla, Marta; Occhipinti, Mario; Proto, Claudia; Prelaj, Arsela; Signorelli, Diego; De Toma, Alessandro; Viscardi, Giuseppe; Beninato, Teresa; Mazzeo, Laura; Bottiglieri, Achille; Leporati, Rita; Fotia, Giuseppe; Ganzinelli, Monica; Garassino, Marina Chiara; de Braud, Filippo G. M.; Lo Russo, Giuseppe; Ferrara, Roberto] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy.
   [Zecca, Ernesto] Fdn IRCCS Ist Nazl Tumori, Palliat Care Pain Therapy & Rehabil Unit, Milan, Italy.
   [Sangaletti, Sabina; Portararo, Paola; Ferrara, Roberto] Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, Milan, Italy.
   [Signorelli, Diego] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy.
   [Viscardi, Giuseppe] Univ Campania Luigi Vanvitelli, Precis Med Dept, Naples, Italy.
   [Garassino, Marina Chiara; Ferrara, Roberto] Univ Chicago, Div Biol Sci, Chicago, IL USA.
   [de Braud, Filippo G. M.] Univ Milan, Oncol & Hematooncol Dept, Milan, Italy.
   [Torri, Valter] Ist Ricovero & Cura Carattere Sci IRCCS, Ist Ric Farmacol Mario Negri, Methodol Clin Res Lab, Milan, Italy.
   [Ferrara, Roberto] Univ Vita Salute San Raffaele, Milan, Italy.
   [Ferrara, Roberto] IRCCS Osped San Raffaele, Med Oncol, Milan, Italy.
C3 Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS
   Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale
   Tumori Milan; Ospedale Niguarda Ca' Granda; Universita della Campania
   Vanvitelli; University of Chicago; University of Milan; Istituto di
   Ricerche Farmacologiche Mario Negri IRCCS; Fondazione IRCCS Istituto
   Nazionale Tumori Milan; Vita Salute San Raffaele University; Vita Salute
   San Raffaele University; IRCCS Ospedale San Raffaele
RP Ferrara, R (通讯作者)，Univ Vita Salute San Raffaele, Milan, Italy.
EM ferrara.roberto@hsr.it
RI Ferrara, Roberto/AAP 8881 2020; Manglaviti, Sara/LJL 3989 2024;
   Garassino, Marina/D 7128 2017; Prelaj, Arsela/ABB 1872 2020; Lo Russo,
   Giuseppe/AAC 8951 2022; Signorelli, Diego/KCY 0819 2024; Ganzinelli,
   Monica/K 4548 2016; Zecca, Ernesto/K 2159 2018; Galli,
   Giulia/R 9535 2019; Occhipinti, Mario/LSI 6712 2024; Sangaletti,
   Sabina/AAB 5873 2019; Viscardi, Giuseppe/LSJ 6060 2024; Brambilla,
   Marta/KTI 2001 2024; Proto, Claudia/L 2657 2017; Leporati,
   Rita/LIG 4566 2024; Sottotetti, Elisa/Q 4516 2019
OI Brambilla, Marta/0000 0003 1148 7056; Leporati,
   Rita/0000 0001 6671 9809; Fotia, Giuseppe/0000 0002 2071 8971;
   Manglaviti, Sara/0000 0003 2693 0743; Zecca,
   Ernesto/0000 0003 1689 0370; Galli, Giulia/0000 0001 7287 4848; Mazzeo,
   Laura/0000 0001 9226 8861; 
CR Ahmed AA, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0267642
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Asano Y, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.871675
   Bongiovanni A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.697298
   Cao YN, 2021, J THORAC DIS, V13, P4668, DOI 10.21037/jtd 21 150
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Dall'Olio FG, 2022, NAT REV CLIN ONCOL, V19, P75, DOI 10.1038/s41571 021 00564 3
   De Castro J, 2015, CLIN LUNG CANCER, V16, P431, DOI 10.1016/j.cllc.2015.06.004
   De Felice M, 2023, CURR PROB CANCER, V47, DOI 10.1016/j.currproblcancer.2022.100947
   Decroisette C, 2022, ANN ONCOL, V33, pS1028, DOI 10.1016/j.annonc.2022.07.1161
   Faget J, 2018, J THORAC ONCOL, V13, P387, DOI 10.1016/j.jtho.2017.11.121
   Fiorica F, 2021, CANCERS, V13, DOI 10.3390/cancers13102352
   Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
   Hendriks LEL, 2016, J THORAC ONCOL, V11, P155, DOI 10.1016/j.jtho.2015.10.001
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Katakami N, 2014, J THORAC ONCOL, V9, P231, DOI 10.1097/JTO.0000000000000051
   Landi L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0793 8
   LeVasseur N, 2016, CANCER TREAT REV, V50, P183, DOI 10.1016/j.ctrv.2016.09.013
   Li HS, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.908436
   Liede A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1480301
   Mannavola F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01652
   Peters S, 2019, CLIN TRANSL ONCOL, V21, P977, DOI 10.1007/s12094 018 02023 5
   Peters S, 2020, J THORAC ONCOL, V15, P1647, DOI 10.1016/j.jtho.2020.06.011
   Qiang HP, 2022, TRANSL LUNG CANCER R, V11, P87, DOI 10.21037/tlcr 21 1033
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tanaka H, 2020, J RADIAT RES, V61, P494, DOI 10.1093/jrr/rraa020
   Theelen WSME, 2020, LANCET RESP MED, V9, P467, DOI 10.1016/S2213 2600(20)30391 X
   Theelen WSME, 2019, JAMA ONCOL, V5, P1276, DOI 10.1001/jamaoncol.2019.1478
   Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630
   Udagawa HK, 2017, J CANCER RES CLIN, V143, P1075, DOI 10.1007/s00432 017 2350 5
NR 33
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169 5002
EI 1872 8332
J9 LUNG CANCER
JI Lung Cancer
PD DEC
PY 2023
VL 186
AR 107417
DI 10.1016/j.lungcan.2023.107417
EA OCT 2023
PG 7
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Respiratory System
GA Y5IZ4
UT WOS:001105605200001
PM 37918061
DA 2025 08 17
ER

PT J
AU Zhu, SP
   Rea, SL
   Cheng, T
   Feng, HT
   Walsh, JP
   Ratajczak, T
   Tickner, J
   Pavlos, N
   Xu, HZ
   Xu, JK
AF Zhu, Sipin
   Rea, Sarah L.
   Cheng, Taksum
   Feng, Hao Tian
   Walsh, John P.
   Ratajczak, Thomas
   Tickner, Jennifer
   Pavlos, Nathan
   Xu, Hua Zi
   Xu, Jiake
TI Bafilomycin A1 Attenuates Osteoclast Acidification and Formation,
   Accompanied by Increased Levels of SQSTM1/p62 Protein
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BAFILOMYCIN A1; V ATPases; p62; ACIDIFICATION; OSTEOCLASTOGENESIS
ID VACUOLAR H+ ATPASE; BONE RESORBING OSTEOCLASTS; CARBONIC ANHYDRASE II;
   RESORPTION IN VITRO; KAPPA B LIGAND; PAGETS DISEASE; V ATPASE;
   ANTIRESORPTIVE AGENTS; SEQUESTOSOME 1/P62; RECEPTOR ACTIVATOR
AB Vacuolar proton pump H+ adenosine triphosphatases (V ATPases) play an important role in osteoclast function. Further understanding of the cellular and molecular mechanisms of V ATPase inhibition is vital for the development of anti resorptive drugs specifically targeting osteoclast V ATPases. In this study, we observed that bafilomycin A1, a naturally occurring inhibitor of V ATPases, increased the protein level of SQSTM1/p62, a known negative regulator of osteoclast formation. Consistently, we found that bafilomycin A1 diminishes the intracellular accumulation of the acidotropic probe lysotracker in osteoclast like cells; indicative of reduced acidification. Further, bafilomycin A1 inhibits osteoclast formation with attenuation of cell fusion and multi nucleation of osteoclast like cells during osteoclast differentiation. Taken together, these data indicate that bafilomycin A1 attenuates osteoclast differentiation in part via increased levels of SQSTM1/p62 protein, providing further mechanistic insight into the effect of V ATPase inhibition in osteoclasts. J. Cell. Biochem. 117: 1464 1470, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Zhu, Sipin; Xu, Hua Zi] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325035, Zhejiang, Peoples R China.
   [Zhu, Sipin; Feng, Hao Tian; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA 6009, Australia.
   [Rea, Sarah L.; Ratajczak, Thomas] Univ Western Australia, Mol Endocrinol Lab, Harry Perkins Inst Med Res, Crawley, WA 6009, Australia.
   [Rea, Sarah L.; Ratajczak, Thomas] Univ Western Australia, UWA Ctr Med Res, Crawley, WA 6009, Australia.
   [Rea, Sarah L.; Walsh, John P.] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia.
   [Cheng, Taksum; Pavlos, Nathan] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Crawley, WA 6009, Australia.
   [Walsh, John P.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA 6009, Australia.
C3 Wenzhou Medical University; University of Western Australia; University
   of Western Australia; Harry Perkins Institute of Medical Research;
   University of Western Australia; Sir Charles Gairdner Hospital;
   University of Western Australia; University of Western Australia;
   University of Western Australia
RP Xu, HZ (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325035, Zhejiang, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA 6009, Australia.
EM spinexu@163.com; jiake.xu@uwa.edu.au
RI Rea, Sarah/GYJ 4753 2022; Tickner, Jennifer/H 5965 2014; Walsh,
   John/AAY 2254 2020
OI Rea, Sarah Lyn/0000 0002 2181 9491; Xu, Jiake/0000 0003 2021 8309;
   Walsh, John/0000 0002 1766 2612; /0000 0002 2151 3433; Tickner,
   Jennifer/0000 0002 5020 0671; Pavlos, Nathan/0000 0001 7003 188X; 
FU Arthritis Foundation of Australia; National Health and Medical Research
   Council of Australia [APP1027932]; National Natural Science Foundation
   of China [81228013]; Opening Project of Zhejiang Provincial Top Key
   Discipline of Clinical Medicine [LKFJ017]
FX Grant sponsor: Arthritis Foundation of Australia; Grant sponsor:
   National Health and Medical Research Council of Australia; Grant number:
   APP1027932; Grant sponsor: National Natural Science Foundation of China;
   Grant number: 81228013; Grant sponsor: Opening Project of Zhejiang
   Provincial Top Key Discipline of Clinical Medicine; Grant number:
   LKFJ017.
CR AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247
   Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004
   CHATTERJEE D, 1992, J EXP BIOL, V172, P193
   Cheng T, 2009, MOL ENDOCRINOL, V23, P35, DOI 10.1210/me.2007 0465
   Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324
   Farina C, 2001, FARMACO, V56, P113, DOI 10.1016/S0014 827X(01)01013 8
   Farina C, 1999, DRUG DISCOV TODAY, V4, P163, DOI 10.1016/S1359 6446(99)01321 5
   Feng HT, 2008, J BIOL CHEM, V283, P13194, DOI 10.1074/jbc.M709712200
   Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Kartner N, 2014, EXPERT OPIN DRUG DIS, V9, P505, DOI 10.1517/17460441.2014.902155
   Kelling DJ, 1997, ANN NY ACAD SCI, V834, P600, DOI 10.1111/j.1749 6632.1997.tb52329.x
   LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235
   LAITALA T, 1993, J BONE MINER RES, V8, P119
   Laitala Leinonen T, 1999, J CELL SCI, V112, P3657
   LaitalaLeinonen T, 1996, MOL BIOL CELL, V7, P129, DOI 10.1091/mbc.7.1.129
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200
   Müller O, 2003, J CELL SCI, V116, P1107, DOI 10.1242/jcs.00328
   Müller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Pavlos NJ, 2011, MOL CELL BIOL, V31, P1551, DOI 10.1128/MCB.00834 10
   Qin A, 2012, INT J BIOCHEM CELL B, V44, P1422, DOI 10.1016/j.biocel.2012.05.014
   Rea SL, 2006, J BONE MINER RES, V21, P1136, DOI 10.1359/JBMR.060405
   Rea SL, 2013, ENDOCR REV, V34, P501, DOI 10.1210/er.2012 1034
   Rea SL, 2009, J BONE MINER RES, V24, P1216, DOI [10.1359/jbmr.090214, 10.1359/JBMR.090214]
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   Wooten MW, 2008, J BIOL CHEM, V283, P6783, DOI 10.1074/jbc.M709496200
   Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH 22.443
   Xu J, 2003, J CELL BIOCHEM, V88, P1256, DOI 10.1002/jcb.10477
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yip KHM, 2006, AM J PATHOL, V169, P503, DOI 10.2353/ajpath.2006.050960
NR 34
TC 11
Z9 12
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN
PY 2016
VL 117
IS 6
BP 1464
EP 1470
DI 10.1002/jcb.25442
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DI8HB
UT WOS:000373741000019
PM 27043248
DA 2025 08 17
ER

PT J
AU Cook, GJR
   Azad, GK
   Taylor, BP
   Lee, E
   Morrison, MS
   Hughes, S
   Morris, S
   Rudman, S
   Chowdhury, S
   Goh, V
AF Cook, Gary J. R.
   Azad, Gurdip K.
   Taylor, Benjamin P.
   Lee, Eugene
   Morrison, Matthew S.
   Hughes, Simon
   Morris, Stephen
   Rudman, Sarah
   Chowdhury, Simon
   Goh, Vicky
TI Imaging αvβ3 integrin expression in skeletal
   metastases with <SUP>99m</SUP>Tc maraciclatide single photon emission
   computed tomography: detection and therapy response assessment
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE Prostate cancer; Bone metastases; Tc 99m Maraciclatide; Osteoclast
ID RESISTANT PROSTATE CANCER; BONE METASTASES; OSTEOCLASTS; OSTEOLYSIS;
   PEPTIDE
AB Purpose Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of Tc 99m maraciclatide, a radiopharmaceutical targeting alpha(v)beta(3) integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy.
   Methods The study group comprised 17 men with bone predominant metastatic PCa who underwent whole body planar and single photon emission computed tomography/computed tomography (SPECT/CT) imaging with Tc 99m maraciclatide before (n = 17) and 12 weeks after (n = 11) starting treatment with abiraterone. Tumour to normal bone (T:N) ratios, tumour to muscle (T:M) ratios and CT Hounsfield units (HU) were measured in up to five target metastases in each subject. An oncologist blinded to study scans assessed clinical responses up to 24 weeks using conventional criteria.
   Results Before treatment, metastases showed specific Tc 99m maraciclatide accumulation (mean planar T:N and T:M ratios 1.43 and 3.06; SPECT T:N and T:M ratios 3.1 and 5.19, respectively). Baseline sclerotic lesions (389 740 HU) showed lower T:M ratios (4.22 vs. 7.04, p = 0.02) than less sclerotic/lytic lesions (46 381 HU). Patients with progressive disease (PD; n = 5) showed increased planar T:N and T:M ratios (0.29 and 12.1%, respectively) and SPECT T:N and T:M ratios (11.9 and 20.2%, respectively). Patients without progression showed decreased planar T:N and T:M ratios (0.27 and  8.0%, p = 1.0 and 0.044, respectively) and SPECT T:N and T:M ratios ( 21.9, and  27.2%, p = 0.3 and 0.036, respectively). The percentage change in CT HU was inversely correlated with the percentage change in SPECT T:M ratios (r =  0.59, p = 0.006).
   Conclusions Tc 99m maraciclatide accumulates in PCa bone metastases in keeping with increased alpha(v)beta(3) integrin expression. Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar and SPECT T:M ratios after 12 weeks of treatment differed between patients with and without PD and Tc 99m maraciclatide imaging may be a potential method for assessing early response.
C1 [Cook, Gary J. R.; Azad, Gurdip K.; Goh, Vicky] Kings Coll London, Sch Biomed Engn & Imaging Sci, Canc Imaging Dept, London, England.
   [Cook, Gary J. R.; Lee, Eugene] Guys & St Thomas Hosp NHS Trust, Nucl Med Dept, London, England.
   [Taylor, Benjamin P.; Hughes, Simon; Morris, Stephen; Rudman, Sarah] Guys & St Thomas Hosp NHS Trust, Urooncol Dept, London, England.
   [Morrison, Matthew S.] GE Healthcare, Grove Ctr, Med Diagnost, Amersham, England.
C3 University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; General
   Electric; GE Healthcare
RP Cook, GJR (通讯作者)，Kings Coll London, Sch Biomed Engn & Imaging Sci, Canc Imaging Dept, London, England.; Cook, GJR (通讯作者)，Guys & St Thomas Hosp NHS Trust, Nucl Med Dept, London, England.
EM gary.cook@kcl.ac.uk
RI Goh, Vicky/AAG 2708 2020; Taylor, Benjamin P./HNQ 1332 2023
OI Goh, Vicky/0000 0002 2321 8091; Cook, Gary/0000 0002 8732 8134; 
FU King's College London/University College London Comprehensive Cancer
   Imaging Centres   Cancer Research UK; Engineering and Physical Sciences
   Research Council; Medical Research Council; Department of Health
   [C1519/A16463]; Prostate Cancer UK [PA12 04]; National Institute of
   Health Research Clinical Research Network (NIHR CRN); Cancer Research UK
   [16463] Funding Source: researchfish
FX This study was financially supported by the King's College
   London/University College London Comprehensive Cancer Imaging Centres
   funded by Cancer Research UK and the Engineering and Physical Sciences
   Research Council in association with the Medical Research Council and
   the Department of Health (C1519/A16463) and Prostate Cancer UK (PA12 04)
   and was supported by the National Institute of Health Research Clinical
   Research Network (NIHR CRN).
CR Bach Gansmo T, 2006, J NUCL MED, V47, P1434
   Beer AJ, 2016, ONCOTARGET, V7, P28151, DOI 10.18632/oncotarget.8611
   Clamp A, 2004, LANCET ONCOL, V5, P607, DOI 10.1016/S1470 2045(04)01596 7
   Coleman RE, 2012, NAT REV CLIN ONCOL, V9, P76, DOI 10.1038/nrclinonc.2011.198
   Galson Deborah L, 2012, Bonekey Rep, V1, P135, DOI 10.1038/bonekey.2012.135
   Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270
   Hoefeler H, 2014, J BONE ONCOL, V3, P40, DOI 10.1016/j.jbo.2014.04.001
   Hua J, 2005, CIRCULATION, V111, P3255, DOI 10.1161/CIRCULATIONAHA.104.485029
   Imbriaco M, 1998, CLIN CANCER RES, V4, P1765
   Miao WB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111221
   Muhlhausen Ute, 2011, Contrast Media Mol Imaging, V6, P413, DOI 10.1002/cmmi.435
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Putz E, 1999, CANCER RES, V59, P241
   Rehman Y, 2012, DRUG DES DEV THER, V6, P13, DOI 10.2147/DDDT.S15850
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
   Sprague JE, 2007, J NUCL MED, V48, P311
   Teitelbaum SL, 2006, ANN NY ACAD SCI, V1068, P95, DOI 10.1196/annals.1346.017
   Wadas TJ, 2009, J NUCL MED, V50, P1873, DOI 10.2967/jnumed.109.067140
NR 19
TC 12
Z9 12
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619 7070
EI 1619 7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD JUN
PY 2018
VL 45
IS 6
BP 898
EP 903
DI 10.1007/s00259 017 3926 7
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA GD9KU
UT WOS:000430832400002
PM 29396636
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Migliario, M
   Pittarella, P
   Fanuli, M
   Rizzi, M
   Renò, F
AF Migliario, Mario
   Pittarella, Pamela
   Fanuli, Matteo
   Rizzi, Manuela
   Reno, Filippo
TI Laser induced osteoblast proliferation is mediated by ROS production
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Low energy laser; Osteoblast proliferation; Reactive oxygen species;
   Antioxidant
ID CELL PROLIFERATION; PI3K/AKT PATHWAY; IRRADIATION; THERAPY;
   DIFFERENTIATION; INVOLVEMENT; ACTIVATION
AB Low level laser therapy (LLLT) is widely used in regenerative medicine and in dental therapy by virtue of its beneficial effects in a plethora of pathological conditions. In this study, the effect of a 980 nm diode laser on pre osteoblasts proliferation has been evaluated, along with reactive oxygen species (ROS) production. We hypothesized that ROS were a key factor in LLLT induced pre osteoblasts proliferation, as it is known that ROS can induce the activation of many biological pathways, leading to cell proliferation, differentiation or apoptosis. Murine pre osteoblasts MC3T3 cells were irradiated with different energy outputs (1 50 J) in the absence or presence of the antioxidant N Acetyl L cysteine (NAC). Laser treatment, in the absence of NAC, was able to induce a fluence dependent statistically significant increase in ROS generation, while the presence of NAC strongly inhibited it. Cell proliferation, measured after laser stimulation, was significantly increased both at low and higher energy, with a peak at 10 J in the absence of the antioxidant. On the contrary, in the presence of NAC, laser irradiation was not able to induce any cell proliferation, suggesting a crucial role of ROS in this laser induced cell effect. These results suggest that LLLT may be a useful tool for bone regeneration therapy and an effective range of fluences to be used is indicated.
C1 [Migliario, Mario; Fanuli, Matteo] Univ Piemonte Orientale, Dept Hlth Sci, Dent Clin, I 28100 Novara, Italy.
   [Pittarella, Pamela; Rizzi, Manuela; Reno, Filippo] Univ Piemonte Orientale, Dept Hlth Sci, Innovat Res Lab Wound Healing, I 28100 Novara, Italy.
C3 University of Eastern Piedmont Amedeo Avogadro; University of Eastern
   Piedmont Amedeo Avogadro
RP Renò, F (通讯作者)，Univ Piemonte Orientale, Dept Hlth Sci, Innovat Res Lab Wound Healing, Via Solaroli 17, I 28100 Novara, Italy.
EM filippo.reno@med.unipmn.it
RI ; Migliario, Mario/AAB 3945 2019; Rizzi, Manuela/AAE 9202 2021; Renò,
   Filippo/AAA 5591 2019
OI RIZZI, Manuela/0000 0002 6174 7111; Migliario, Mario/0000 0003 1627 4164
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Angiero F, 2012, LASER MED SCI, V27, P383, DOI 10.1007/s10103 011 0900 7
   Arakaki N, 2013, BIOMED RES TOKYO, V34, P161, DOI 10.2220/biomedres.34.161
   Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453
   Fujimoto T, 2012, LASER SURG MED, V44, P685, DOI 10.1002/lsm.22065
   Fujimura T, 2013, LASERS MED SCI
   Gao XJ, 2006, J CELL PHYSIOL, V206, P441, DOI 10.1002/jcp.20484
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 4
   Grossman N, 1998, LASER SURG MED, V22, P212, DOI 10.1002/(SICI)1096 9101(1998)22:4<212::AID LSM5>3.0.CO;2 S
   Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826
   Huertas RM, 2013, BIOL RES NURS
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Khadra M, 2004, ORAL SURG ORAL MED O, V97, P693, DOI 10.1016/j.tripleo.2003.11.008
   Kushibiki T, 2013, PHOTOMED LASER SURG, V31, P95, DOI 10.1089/pho.2012.3361
   Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3
   Migliario M, 2013, LASER MED SCI, V28, P565, DOI 10.1007/s10103 012 1112 5
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pyo SJ, 2013, LASER MED SCI, V28, P543, DOI 10.1007/s10103 012 1109 0
   Sicilia A, 2009, J CLIN PERIODONTOL, V36, P650, DOI 10.1111/j.1600 051X.2009.01433.x
   Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639
   Stock K, 2012, LASER SURG MED, V44, P815, DOI 10.1002/lsm.22091
   Wu SN, 2009, J CELL PHYSIOL, V218, P603, DOI 10.1002/jcp.21636
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529
   Zhang LL, 2009, J CELL PHYSIOL, V219, P553, DOI 10.1002/jcp.21697
   Zhang Y, 2013, J CELL BIOCHEM, V114, P2595, DOI 10.1002/jcb.24607
NR 27
TC 89
Z9 95
U1 1
U2 22
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JUL
PY 2014
VL 29
IS 4
BP 1463
EP 1467
DI 10.1007/s10103 014 1556 x
PG 5
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA AK7ZB
UT WOS:000338645800020
PM 24595962
DA 2025 08 17
ER

PT J
AU Comeau Gauthier, M
   Tarchala, M
   Luna, JLRG
   Harvey, E
   Merle, G
AF Comeau Gauthier, Marianne
   Tarchala, Magdalena
   Luna, Jose Luis Ramirez Garcia
   Harvey, Edward
   Merle, Geraldine
TI Unleashing β catenin with a new anti Alzheimer drug for bone tissue
   regeneration
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Glycogen synthase kinase 3 beta; Osteoblast; Bone regeneration; Femur;
   Fracture
ID GSK 3 INHIBITOR TIDEGLUSIB; FRACTURE REPAIR; OSTEOTOMY MODEL; WNT;
   LITHIUM; OSTEOBLAST; MICE; QUANTIFICATION; ACTIVATION; PARAMETERS
AB The Wnt/beta catenin signaling pathway is critical for bone differentiation and regeneration. Tideglusib, a selective FDA approved glycogen synthase kinase 3 beta(GSK 3 beta) inhibitor, has been shown to promote dentine formation, but its effect on bone has not been examined. Our objective was to study the effect of localized Tideglusib administration on bone repair. Bone healing between Tideglusib treated and control mice was analysed at 7, 14 and 28 days postoperative (PO) with microCT, dynamic histomorphometry and immunohistology. There was a local downregulation of GSK 3 beta in Tideglusib animals, resulting in a significant increase in the amount of new bone formation with both enhanced cortical bone bridging and medullary bone deposition. The bone formation in the Tideglusib group was characterized by early osteoblast differentiation with down regulation of GSK 3 beta at day 7 and 14, and higher accumulation of active beta catenin at day 14. Here, for the first time, we show a positive effect of Tideglusib on bone formation through the inactivation of GSK 3 beta. Furthermore, the findings suggest that Tideglusib does not interfere with precursor cell recruitment and commitment, contrary to other GSK 3 beta antagonists such as lithium chloride. Taken together, the results indicate that Tideglusib could be used directly at a fracture site during the initial intraoperative internal fixation without the need for further surgery, injection or drug delivery system. This FDA approved drug may be useful in the future for the prevention of nonunion in patients presenting with a high risk for fracture healing. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Comeau Gauthier, Marianne; Tarchala, Magdalena; Luna, Jose Luis Ramirez Garcia; Harvey, Edward] McGill Univ, Dept Surg, Div Orthoped Surg, Montreal, PQ, Canada.
   [Comeau Gauthier, Marianne; Luna, Jose Luis Ramirez Garcia] McGill Univ, Fac Med, Expt Surg, Rue Montaigne, Montreal, PQ, Canada.
   [Tarchala, Magdalena; Luna, Jose Luis Ramirez Garcia] Montreal Gen Hosp, 1650 Cedar Ave,Room A10 110, Montreal, PQ H3G 1A4, Canada.
   [Harvey, Edward] Montreal Gen Hosp, Bone Engn Labs, 1650 Cedar Ave,Room C10 124, Montreal, PQ H3G 1A4, Canada.
   [Merle, Geraldine] Chem Engn Dept, Polytech JA Bombardier Bldg Polytech Montreal, Montreal, PQ H3C 3A7, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University
RP Merle, G (通讯作者)，Chem Engn Dept, Polytech JA Bombardier Bldg Polytech Montreal, Montreal, PQ H3C 3A7, Canada.
EM marianne.comeau gauthier@mail.mcgill.ca;
   magdalena.tarchala@mail.mcgill.ca;
   jose.ramirezgarcialuna@mail.mcgill.ca; edward.harvey@mcgill.ca;
   geraldine.merle@polymtl.ca
RI ; Ramirez GarciaLuna, Jose/I 6798 2019; Tarchala, MD, MSc, FRCSC,
   Magdalena/HGE 2176 2022
OI Ramirez GarciaLuna, Jose Luis/0000 0002 3953 9762; 
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   [Anonymous], 2014, IMMUNOHISTOCHEMISTRY
   Arioka M, 2014, BIOCHEM PHARMACOL, V90, P397, DOI 10.1016/j.bcp.2014.06.011
   Bao QW, 2017, EXP CELL RES, V350, P123, DOI 10.1016/j.yexcr.2016.11.013
   Behrends DA, 2017, CLIN ORTHOP RELAT R, V475, P906, DOI 10.1007/s11999 016 5159 7
   Beier EE, 2014, J ORTHOP RES, V32, P1397, DOI 10.1002/jor.22677
   Bernick J, 2014, J BONE JOINT SURG AM, V96A, P1990, DOI 10.2106/JBJS.N.00057
   Castano D, 2019, TISSUE ENG PT A, V25, P554, DOI [10.1089/ten.tea.2018.0191, 10.1089/ten.TEA.2018.0191]
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2017, INT J CLIN EXP MED, V10, P14904
   Chiba S, 2001, J VET MED SCI, V63, P603, DOI 10.1292/jvms.63.603
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   del Ser T, 2013, J ALZHEIMERS DIS, V33, P205, DOI 10.3233/JAD 2012 120805
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Drager J, 2017, TISSUE ENG PT A, V23, P1372, DOI [10.1089/ten.tea.2016.0526, 10.1089/ten.TEA.2016.0526]
   Feng G, 2015, INT IMMUNOPHARMACOL, V24, P7, DOI 10.1016/j.intimp.2014.11.010
   Follak N, 2004, BONE, V35, P144, DOI 10.1016/j.bone.2004.03.011
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Heilmann A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084232
   Intini G, 2015, BONE, V75, P151, DOI 10.1016/j.bone.2015.01.008
   Iyama S, 1997, J PERIODONTOL, V68, P1169, DOI 10.1902/jop.1997.68.12.1169
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Kim NG, 2009, P NATL ACAD SCI USA, V106, P5165, DOI 10.1073/pnas.0810185106
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lau KHW, 2016, BONE, V92, P18, DOI 10.1016/j.bone.2016.08.005
   Lauing KL, 2014, ALCOHOL ALCOHOLISM, V49, P399, DOI 10.1093/alcalc/agu006
   Alpan AL, 2020, J CRANIOFAC SURG, V31, P1477, DOI 10.1097/SCS.0000000000006326
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li X, 2018, LIFE SCI, V208, P33, DOI 10.1016/j.lfs.2018.06.036
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu DC, 2019, CLIN EXP PHARMACOL P, V46, P652, DOI 10.1111/1440 1681.13088
   Livingstone C, 2006, J PSYCHOPHARMACOL, V20, P347, DOI 10.1177/0269881105057515
   Loiselle AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081399
   Lovestone S, 2015, J ALZHEIMERS DIS, V45, P75, DOI 10.3233/JAD 141959
   Low SA, 2017, NANOMEDICINE UK, V12, P185, DOI 10.2217/nnm 2016 0340
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Malashichev YB, 2006, Behavioral and morphological asymmetries in vertebrates
   Domínguez JM, 2012, J BIOL CHEM, V287, P893, DOI 10.1074/jbc.M111.306472
   Masuda Y, 2020, IN VIVO, V34, P1071, DOI 10.21873/invivo.11877
   McGee Lawrence ME, 2013, BIOCHEM BIOPH RES CO, V441, P886, DOI 10.1016/j.bbrc.2013.10.155
   Mishra P, 2019, ANN CARD ANAESTH, V22, P67, DOI 10.4103/aca.ACA_157_18
   Monfoulet L, 2010, BONE, V46, P447, DOI 10.1016/j.bone.2009.09.007
   Monfoulet L, 2010, CALCIFIED TISSUE INT, V86, P72, DOI 10.1007/s00223 009 9314 y
   Morse A, 2015, BONE, V71, P155, DOI 10.1016/j.bone.2014.10.018
   Nam D, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen 2019 031545
   Neves VCM, 2018, J DENT RES, V97, P416, DOI 10.1177/0022034517743431
   Neves VCM, 2017, SCI REP UK, V7, DOI 10.1038/srep39654
   Nishikawa K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103103
   Norris BL, 2018, J ORTHOP TRAUMA, V32, pS12, DOI 10.1097/BOT.0000000000001124
   Onwubiko A., 2018, NAT MED, V9, P1, DOI [DOI 10.1038/s41591 020 0897 1, 10.1016/j.jcmgh.2020.11.009]
   Palomo V, 2017, EXPERT OPIN THER PAT, V27, P657, DOI 10.1080/13543776.2017.1259412
   Ramirez Garcia Luna JL, 2019, J CELL PHYSIOL, V234, P3078, DOI 10.1002/jcp.27128
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Rietveld T, 2017, J COMMUN DISORD, V69, P44, DOI 10.1016/j.jcomdis.2017.07.002
   Ruifrok AC, 2003, APPL IMMUNOHISTO M M, V11, P85, DOI 10.1097/00022744 200303000 00014
   Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291
   Runyan CM, 2017, J CRANIOFAC SURG, V28, P1380, DOI 10.1097/SCS.0000000000003625
   Salazar VS, 2019, ELIFE, V8, DOI 10.7554/eLife.42386
   Schinke T, 2010, J BONE MINER RES, V25, P1193, DOI 10.1002/jbmr.122
   Secreto Frank J, 2009, Curr Osteoporos Rep, V7, P64
   Shu J, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938 016 0161 6
   Silkstone D, 2008, NAT CLIN PRACT RHEUM, V4, P413, DOI 10.1038/ncprheum0838
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Suen PK, 2014, J ORTHOP RES, V32, P997, DOI 10.1002/jor.22636
   Taciak B, 2018, J PHYSIOL PHARMACOL, V69, DOI 10.26402/jpp.2018.2.07
   Takahashi Yanaga F, 2013, BIOCHEM PHARMACOL, V86, P191, DOI 10.1016/j.bcp.2013.04.022
   Tolosa E, 2014, MOVEMENT DISORD, V29, P470, DOI 10.1002/mds.25824
   Townsend MH, 2017, ONCOTARGETS THER, V10, P1921, DOI 10.2147/OTT.S128416
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   Vachhani K, 2018, J BIOMECH, V66, P153, DOI 10.1016/j.jbiomech.2017.09.043
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   Xu HY, 2014, BMB REP, V47, P666, DOI 10.5483/BMBRep.2014.47.12.193
   Yin P, 2018, CANCER SCI, V109, P3368, DOI 10.1111/cas.13771
   Young EY, 2013, CLIN ORTHOP RELAT R, V471, P1593, DOI 10.1007/s11999 012 2704 x
   Zaugg LK, 2020, J DENT RES, V99, P544, DOI 10.1177/0022034520908593
   Zhang L, 2018, TISSUE ENG A
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516
   Zuo YY, 2018, NEPHROLOGY, V23, P38, DOI 10.1111/nep.13472
NR 81
TC 12
Z9 13
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD NOV
PY 2020
VL 51
IS 11
BP 2449
EP 2459
DI 10.1016/j.injury.2020.07.035
PG 11
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA OI4FM
UT WOS:000583236600013
PM 32829895
DA 2025 08 17
ER

PT J
AU Hansen, MS
   Madsen, K
   Price, M
   Soe, K
   Omata, Y
   Zaiss, MM
   Gorvin, CM
   Frost, M
   Rauch, A
AF Hansen, Morten S.
   Madsen, Kaja
   Price, Maria
   Soe, Kent
   Omata, Yasunori
   Zaiss, Mario M.
   Gorvin, Caroline M.
   Frost, Morten
   Rauch, Alexander
TI Transcriptional reprogramming during human osteoclast differentiation
   identifies regulators of osteoclast activity
SO BONE RESEARCH
LA English
DT Article
ID SOMATOSTATIN RECEPTOR SUBTYPE 2; BONE RESORPTION; GROWTH HORMONE; CELLS;
   POTENT; MICE; OSTEOBLASTOGENESIS; PHARMACOLOGY; ANTAGONISTS; DEFICIENCY
AB Enhanced osteoclastogenesis and osteoclast activity contribute to the development of osteoporosis, which is characterized by increased bone resorption and inadequate bone formation. As novel antiosteoporotic therapeutics are needed, understanding the genetic regulation of human osteoclastogenesis could help identify potential treatment targets. This study aimed to provide an overview of transcriptional reprogramming during human osteoclast differentiation. Osteoclasts were differentiated from CD14+ monocytes from eight female donors. RNA sequencing during differentiation revealed 8 980 differentially expressed genes grouped into eight temporal patterns conserved across donors. These patterns revealed distinct molecular functions associated with postmenopausal osteoporosis susceptibility genes based on RNA from iliac crest biopsies and bone mineral density SNPs. Network analyses revealed mutual dependencies between temporal expression patterns and provided insight into subtype specific transcriptional networks. The donor specific expression patterns revealed genes at the monocyte stage, such as filamin B (FLNB) and oxidized low density lipoprotein receptor 1 (OLR1, encoding LOX 1), that are predictive of the resorptive activity of mature osteoclasts. The expression of differentially expressed G protein coupled receptors was strong during osteoclast differentiation, and these receptors are associated with bone mineral density SNPs, suggesting that they play a pivotal role in osteoclast differentiation and activity. The regulatory effects of three differentially expressed G protein coupled receptors were exemplified by in vitro pharmacological modulation of complement 5 A receptor 1 (C5AR1), somatostatin receptor 2 (SSTR2), and free fatty acid receptor 4 (FFAR4/GPR120). Activating C5AR1 enhanced osteoclast formation, while activating SSTR2 decreased the resorptive activity of mature osteoclasts, and activating FFAR4 decreased both the number and resorptive activity of mature osteoclasts. In conclusion, we report the occurrence of transcriptional reprogramming during human osteoclast differentiation and identified SSTR2 and FFAR4 as antiresorptive G protein coupled receptors and FLNB and LOX 1 as potential molecular markers of osteoclast activity. These data can help future investigations identify molecular regulators of osteoclast differentiation and activity and provide the basis for novel antiosteoporotic targets.
C1 [Hansen, Morten S.; Madsen, Kaja; Frost, Morten; Rauch, Alexander] Odense Univ Hosp, Dept Endocrinol, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.
   [Hansen, Morten S.; Madsen, Kaja; Frost, Morten; Rauch, Alexander] Univ Southern Denmark, Fac Hlth Sci, Dept Clin Res, DK 5000 Odense C, Denmark.
   [Hansen, Morten S.; Soe, Kent] Univ Southern Denmark, Dept Clin Res, Pathol Res Unit, Clin Cell Biol, DK 5230 Odense C, Denmark.
   [Price, Maria; Gorvin, Caroline M.] Univ Birmingham, Inst Metab & Syst Res IMSR, Birmingham B15 2TT, England.
   [Price, Maria; Gorvin, Caroline M.] Univ Birmingham, Ctr Diabet Endocrinol & Metab CEDAM, Birmingham B15 2TT, England.
   [Price, Maria; Gorvin, Caroline M.] Univ Birmingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham B15 2TT, England.
   [Price, Maria; Gorvin, Caroline M.] Univ Nottingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham B15 2TT, England.
   [Soe, Kent] Univ Southern Denmark, Dept Mol Med, DK 5000 Odense C, Denmark.
   [Omata, Yasunori] Univ Tokyo, Fac Med, Dept Orthoped Surg, Tokyo 1138655, Japan.
   [Omata, Yasunori; Zaiss, Mario M.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, D 91054 Erlangen, Germany.
   [Omata, Yasunori; Zaiss, Mario M.] Univ Klinikum Erlangen, D 91054 Erlangen, Germany.
   [Zaiss, Mario M.] Friedrich Alexander Univ Erlangen Nurnberg, Deutsch Zentrum Immuntherapie DZI, D 91054 Erlangen, Germany.
   [Frost, Morten; Rauch, Alexander] Odense Univ Hosp, Steno Diabet Ctr Odense, DK 5000 Odense C, Denmark.
C3 University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; University of Southern Denmark; University of
   Birmingham; University of Birmingham; University of Birmingham;
   University of Nottingham; University of Southern Denmark; University of
   Tokyo; University of Erlangen Nuremberg; University of Erlangen
   Nuremberg; University of Erlangen Nuremberg; University of Southern
   Denmark; Odense University Hospital
RP Frost, M; Rauch, A (通讯作者)，Odense Univ Hosp, Dept Endocrinol, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.; Frost, M; Rauch, A (通讯作者)，Univ Southern Denmark, Fac Hlth Sci, Dept Clin Res, DK 5000 Odense C, Denmark.; Frost, M; Rauch, A (通讯作者)，Odense Univ Hosp, Steno Diabet Ctr Odense, DK 5000 Odense C, Denmark.
EM mmfnielsen@health.sdu.dk; arauch@health.sdu.dk
RI Soe, Kent/N 3618 2017; Zaiss, Mario/ABE 7125 2021; Frost,
   Morten/G 9410 2011; Gorvin, Caroline/T 2406 2019; Hansen,
   Morten/AAX 6228 2020; Rauch, Alexander/AAY 5235 2021
OI Soe, Kent/0000 0001 7402 314X; Hansen, Morten
   Svarer/0000 0001 8269 8542; Rauch, Alexander/0000 0002 9429 7356;
   Gorvin, Caroline/0000 0002 1361 9174; Madsen, Kaja/0000 0002 2647 6715;
   Price, Maria/0000 0002 8274 4905; Omata, Yasunori/0000 0002 8912 7483;
   /0000 0002 5608 1589; 
FU Lundbeckfonden (Lundbeck Foundation) [NNF18OC0052699, NNF18OC0055047];
   Jacob Bastholm Olesen at the Department of Clinical Cell Biology, Odense
   University Hospital, Denmark   Novo Nordisk Foundation [18/17553];
   Region of Southern Denmark [A3147]; Odense University Hospital;
   University of Southern Denmark [R335 2019 2195]; Lundbeck Foundation;
   Academy of Medical Sciences Springboard Award; British Heart Foundation;
   Diabetes UK; Global Challenges Research Fund; Government Department of
   Business, Energy and Industrial Strategy; Wellcome Trust
   [224155/Z/21/Z]; Royal Society; Wellcome Trust [224155/Z/21/Z] Funding
   Source: Wellcome Trust; Steno Diabetes Center Odense (SDCO) [SDCO
   Research 001] Funding Source: researchfish
FX We would like to thank Jacob Bastholm Olesen at the Department of
   Clinical Cell Biology, Odense University Hospital, Denmark, for
   providing ideas for the study setup and Ronnie Nielsen at the Department
   of Biochemistry and Molecular Biology, University of Southern Denmark,
   for analyzing the samples. This work was funded by grants from the Novo
   Nordisk Foundation (NNF18OC0052699) (M.S.H.) and NNF18OC0055047 (M.F.),
   the Region of Southern Denmark (ref: 18/17553 (M.S.H.)), Odense
   University Hospital (ref: A3147) (M.F.), a faculty fellowship from the
   University of Southern Denmark (K.M.), the Lundbeck Foundation (ref:
   R335 2019 2195) (K.M. and A.R.), an Academy of Medical Sciences
   Springboard Award supported by the British Heart Foundation, Diabetes
   UK, the Global Challenges Research Fund, the Government Department of
   Business, Energy and Industrial Strategy and the Wellcome Trust (ref:
   SBF004 | 1034, C.M.G), and a Sir Henry Dale Fellowship jointly funded by
   the Wellcome Trust and the Royal Society (Grant Number 224155/Z/21/Z to
   C.M.G.).
CR Ahn SH, 2016, ENDOCRINOLOGY, V157, P2621, DOI 10.1210/en.2015 1855
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Arnett TR, 2008, J NUTR, V138, p415S, DOI 10.1093/jn/138.2.415S
   Balwierz PJ, 2014, GENOME RES, V24, P869, DOI 10.1101/gr.169508.113
   Blixt N, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115466
   Bo Q, 2022, CELL DISCOV, V8, DOI 10.1038/s41421 022 00405 2
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carullo G, 2021, J MED CHEM, V64, P4312, DOI 10.1021/acs.jmedchem.0c01002
   CHAMBERS TJ, 1983, J CLIN ENDOCR METAB, V57, P819, DOI 10.1210/jcem 57 4 819
   Cipriani C, 2018, J ENDOCRINOL INVEST, V41, P1359, DOI 10.1007/s40618 018 0898 9
   Clowes JA, 2003, J CLIN ENDOCR METAB, V88, P4867, DOI 10.1210/jc.2002 021447
   Coates BA, 2019, BONE, V127, P577, DOI 10.1016/j.bone.2019.07.022
   Cody James J, 2011, Int J Biochem Mol Biol, V2, P183
   D'Amelio P, 2004, FASEB J, V18, P410, DOI 10.1096/fj.04 2214fje
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   D'Angelo R, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109764
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Diepenhorst N, 2018, PHARMACOL THERAPEUT, V184, P1, DOI 10.1016/j.pharmthera.2017.10.015
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Farrington Rock C, 2008, HUM MOL GENET, V17, P631, DOI 10.1093/hmg/ddm188
   Fink HA, 2019, ANN INTERN MED, V171, P37, DOI 10.7326/M19 0533
   Gallois A, 2010, J BONE MINER RES, V25, P661, DOI 10.1359/jbmr.090829
   Gendaszewska Darmach E, 2019, TRENDS MOL MED, V25, P915, DOI 10.1016/j.molmed.2019.07.003
   Gillespie M, 2022, NUCLEIC ACIDS RES, V50, pD687, DOI 10.1093/nar/gkab1028
   Gordon JAR, 2010, MOL CELL BIOL, V30, P3531, DOI 10.1128/MCB.00889 09
   Gorman DM, 2021, J MED CHEM, V64, P16598, DOI 10.1021/acs.jmedchem.1c01174
   Hansen MS, 2023, EUR J ENDOCRINOL, V188, DOI 10.1093/ejendo/lvac004
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544 06
   Hauser AS, 2022, ELIFE, V11, DOI 10.7554/eLife.74107
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hobolt Pedersen AS, 2014, CALCIFIED TISSUE INT, V95, P73, DOI 10.1007/s00223 014 9864 5
   Hofland LJ, 1996, BAILLIERE CLIN ENDOC, V10, P163, DOI 10.1016/S0950 351X(96)80362 4
   Hudson BD, 2013, MOL PHARMACOL, V84, P710, DOI 10.1124/mol.113.087783
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jemtland R, 2011, J BONE MINER RES, V26, P1793, DOI 10.1002/jbmr.396
   Kasonga AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125145
   Kavaliauskaite G, 2023, NAR GENOM BIOINFORM, V5, DOI 10.1093/nargab/lqad101
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim HJ, 2016, J CELL PHYSIOL, V231, P844, DOI 10.1002/jcp.25133
   Kishikawa A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00157
   Kooistra AJ, 2021, NUCLEIC ACIDS RES, V49, pD335, DOI 10.1093/nar/gkaa1080
   Korotkevich G., 2021, bioRxiv, DOI [DOI 10.1101/060012, DOI 10.1101/060012V3]
   Kovtun A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14444 3
   Krakow D, 2004, NAT GENET, V36, P405, DOI 10.1038/ng1319
   Lee B, 2016, IMMUNOL LETT, V171, P50, DOI 10.1016/j.imlet.2016.02.002
   Lehenkari P, 1998, EXP CELL RES, V242, P128, DOI 10.1006/excr.1998.4071
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Levaot N, 2015, BONE, V79, P21, DOI 10.1016/j.bone.2015.05.021
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Liu YZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116792
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Luo J, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0059 6
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   March DR, 2004, MOL PHARMACOL, V65, P868, DOI 10.1124/mol.65.4.868
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Merrild DMH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.32
   Milligan G, 2017, CHEM REV, V117, P67, DOI 10.1021/acs.chemrev.6b00056
   Modinger Y, 2018, SEMIN IMMUNOL, V37, P53, DOI 10.1016/j.smim.2018.01.001
   Moller AMJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176368
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Moura SR, 2023, bioRxiv, DOI [10.1101/2023.10.24.563436, 10.1101/2023.10.24.563436, DOI 10.1101/2023.10.24.563436]
   Muñoz Fuentes V, 2018, CONSERV GENET, V19, P995, DOI 10.1007/s10592 018 1072 9
   Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244
   Nakayachi M, 2015, BONE, V75, P170, DOI 10.1016/j.bone.2015.02.025
   Omata Y, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10631
   Pandey S, 2019, J BIOL CHEM, V294, P9416, DOI 10.1074/jbc.RA119.007485
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Pobanz JM, 2000, J PERIODONTAL RES, V35, P137, DOI 10.1034/j.1600 0765.2000.035003137.x
   Rashid S, 2023, GENES BASEL, V14, DOI 10.3390/genes14040916
   Ren SG, 2003, J CLIN ENDOCR METAB, V88, P4239, DOI 10.1210/jc.2003 030303
   Riihonen R, 2007, BONE, V40, P1021, DOI 10.1016/j.bone.2006.11.028
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862
   Rumpler M, 2013, CALCIFIED TISSUE INT, V93, P526, DOI 10.1007/s00223 013 9786 7
   Schoenmaker T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076822
   Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225
   Shimpukade B, 2012, J MED CHEM, V55, P4511, DOI 10.1021/jm300215x
   Signorelli M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859 016 1203 6
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Sorensen KV, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103407
   Sorensen MG, 2007, J BONE MINER METAB, V25, P36, DOI 10.1007/s00774 006 0725 9
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Toyama C, 2022, TRANSPL IMMUNOL, V72, DOI 10.1016/j.trim.2022.101559
   Tulipano G, 2002, ENDOCRINOLOGY, V143, P1218, DOI 10.1210/en.143.4.1218
   Wang YJ, 2021, J CELL MOL MED, V25, P1712, DOI 10.1111/jcmm.16273
   Wilson SG, 2009, J BONE MINER RES, V24, P1989, DOI [10.1359/JBMR.090530, 10.1359/jbmr.090530]
   Woodruff TM, 2005, J PHARMACOL EXP THER, V314, P811, DOI 10.1124/jpet.105.086835
   Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 2 r14
   Zhou X, 2007, P NATL ACAD SCI USA, V104, P3919, DOI 10.1073/pnas.0608360104
   Zhou Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19196 2
NR 100
TC 20
Z9 20
U1 5
U2 16
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD JAN 24
PY 2024
VL 12
IS 1
AR 5
DI 10.1038/s41413 023 00312 6
PG 19
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FS1B1
UT WOS:001147741200001
PM 38263167
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kiyosaki, T
   Mitsui, N
   Suzuki, N
   Shimizu, N
AF Kiyosaki, Takeshi
   Mitsui, Narihiro
   Suzuki, Naoto
   Shimizu, Noriyoshi
TI Low Level Laser Therapy Stimulates Mineralization Via Increased Runx2
   Expression and ERK Phosphorylation in Osteoblasts
SO PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
ID GROWTH FACTOR I; BONE NODULE FORMATION; RAT CALVARIAL CELLS; IGF I;
   IRRADIATION; PATHWAY; MAPK; DIFFERENTIATION; PROLIFERATION; RECEPTOR
AB Objective: This study examined the effects of low level laser therapy (LLLT) on osteoblasts via insulin like growth factor I (IGF I) signal transduction. Background: Because orthodontic treatment is usually accompanied by bone formation, if bone formation can be promoted, the treatment and retention periods will be shorter. Recently, we reported the stimulatory effects of LLLT on bone formation. It was dependent on increased IGF I, which plays an essential role in the anabolic regulation of bone metabolism. However, the signal transduction of IGF I stimulated by LLLT was not elucidated. Materials and Methods: Mouse osteoblastic MC3T3 E1 cells were cultured with or without LLLT (0.96 3.82 J/cm(2)), and the expression of IGF I and Runt related transcription factor 2 (Runx2) and the phosphorylation of extracellular signal regulated kinase (ERK) were determined by using real time PCR and Western blot analysis. Results: LLLT at 1.91 J/cm(2) significantly increased the expression of IGF I and Runx2 and of ERK phosphorylation. Cyclolignan picropodophyllin (PPP; an IGF I receptor inhibitor) partly inhibited the LLLT induced expression of these factors. Moreover, when conditioned medium from the LLLT (1.91 J/cm(2)) cells was added to the MC3T3 E1 culture, the calcium content in the mineralized nodules increased significantly. PPP or noggin [a bone morphogenetic protein (BMP) antagonist] partly inhibited the LLLT induced change in calcium content, and the addition of both PPP and noggin inhibited most of the LLLT induced change in calcium content. Conclusion: These results suggest that LLLT stimulates in vitro mineralization through increased IGF I and BMP production, through Runx2 expression and ERK phosphorylation in osteoblasts.
C1 [Kiyosaki, Takeshi; Mitsui, Narihiro; Shimizu, Noriyoshi] Nihon Univ, Sch Dent, Dept Orthodont, Chiyoda Ku, Tokyo 1018310, Japan.
   [Suzuki, Naoto] Nihon Univ, Sch Dent, Dept Biochem, Chiyoda Ku, Tokyo 101, Japan.
   [Suzuki, Naoto] Nihon Univ, Sch Dent, Dent Res Ctr, Div Funct Morphol,Chiyoda Ku, Tokyo 101, Japan.
   [Shimizu, Noriyoshi] Nihon Univ, Sch Dent, Dent Res Ctr, Div Clin Res,Chiyoda Ku, Tokyo 101, Japan.
C3 Nihon University; Nihon University; Nihon University; Nihon University
RP Shimizu, N (通讯作者)，Nihon Univ, Sch Dent, Dept Orthodont, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
EM shimizu n@dent.nihon u.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [19592369]; Dental Center at Nihon University School of Dentistry;
   Promotion and Mutual Aid Corporation for Private Schools of Japan;
   Grants in Aid for Scientific Research [19592369] Funding Source: KAKEN
FX This study was supported by a grant from the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan to promote
   multidisciplinary research projects (19592369), by a grant from the
   Dental Center at Nihon University School of Dentistry, and by a special
   research grant from the Promotion and Mutual Aid Corporation for Private
   Schools of Japan.
CR ABERGEL RP, 1984, J AM ACAD DERMATOL, V11, P1142, DOI 10.1016/S0190 9622(84)80194 2
   AMARNANI S, 1993, J BONE MINER RES, V8, P157
   CANALIS E, 1993, BONE, V14, P273, DOI 10.1016/8756 3282(93)90151 Y
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Cruz DR, 2004, LASER SURG MED, V35, P117, DOI 10.1002/lsm.20076
   DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv 10 1 68
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   FUJIMOTO K, LASERS SURG IN PRESS
   Hübler R, 2010, LASER MED SCI, V25, P213, DOI 10.1007/s10103 009 0691 2
   Kim SK, 2007, BIOFACTORS, V29, P187, DOI 10.1002/biof.5520290403
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Nakasaki M, 2008, BONE, V43, P869, DOI 10.1016/j.bone.2008.07.241
   Olney RC, 2003, MED PEDIATR ONCOL, V41, P228, DOI 10.1002/mpo.10342
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pei Y, 2003, ACTA PHARMACOL SIN, V24, P975
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   Renno ACM, 2007, PHOTOMED LASER SURG, V25, P275, DOI 10.1089/pho.2007.2055
   Saito S, 1997, AM J ORTHOD DENTOFAC, V111, P525, DOI 10.1016/S0889 5406(97)70152 5
   Saracino S, 2009, LASER SURG MED, V41, P298, DOI 10.1002/lsm.20762
   Shakouri SK, 2010, LASER MED SCI, V25, P73, DOI 10.1007/s10103 009 0670 7
   Shimizu N, 2007, LASER SURG MED, V39, P551, DOI 10.1002/lsm.20521
   Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479
   ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460 2075.1986.tb04528.x
   Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
NR 25
TC 32
Z9 38
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549 5418
EI 1557 8550
J9 PHOTOMED LASER SURG
JI Photomed. Laser Surg.
PD AUG
PY 2010
VL 28
SU 1
BP S167
EP S172
DI 10.1089/pho.2009.2693
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 635PE
UT WOS:000280667300019
PM 20649430
DA 2025 08 17
ER

PT J
AU Siddhivarn, C
   Banes, A
   Champagne, C
   Riché, EL
   Weerapradist, W
   Offenbacher, SP
AF Siddhivarn, C
   Banes, A
   Champagne, C
   Riché, EL
   Weerapradist, W
   Offenbacher, SP
TI Prostaglandin D2 pathway and peroxisome
   proliferator activated receptor γ 1 expression are induced by mechanical
   loading in an osteoblastic cell line
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE cyclooxygenase; mechanical loading; peroxisome proliferator activated
   receptor; prostaglandin D 2 synthase
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARACHIDONIC ACID; CANCELLOUS BONE;
   PPAR GAMMA; DIFFERENTIATION; IDENTIFICATION; CALCIFICATION;
   BIOSYNTHESIS; MACROPHAGES; THROMBOXANE
AB Objective: The hypothesis underlying the current study was that the arachidonic acid cascade, specifically activation of the prostaglandin (PG) D 2 pathway in osteoblasts, is an anabolic signal induced by mechanical loading.
   Background: Previous studies have shown that mechanical loading of osteoblasts triggers cyclooxygenase (COX) 2, PGE(2) and prostacyclin (PGI(2)) synthesis. Since modest mechanical loading of osteoblasts promotes bone formation, we sought to determine whether mechanical stress activates the osteoblastic PGD(2) pathway resulting in the synthesis of osteogenic cyclopentenones, including Delta(12)PGJ(2).
   Methods: Osteoblast monolayers were stretched using a Bioflex apparatus at a frequency of 1 Hz with 1% elongation. Cells and cell media were collected at various time points: 5, 10, 15, 30 min; and 1, 4, 16, 24 h. RNA was extracted for quantitative reverse transcriptase polymerase chain reaction (RT PCR). In certain experiments, cells were pre labeled with C 14 arachidonic acid prior to stretching. Radiolabeled metabolites in cell media were identified by reverse phase high performance liquid chromatography (RP HPLC). Osteoblasts were evaluated for an induction in bone nodule formation by stretching.
   Results: Mechanical strain significantly increased mRNA expression of COX 1, COX 2, PGD(2) synthase and peroxisome proliferator activated receptor (PPAR) gamma 1, but not of PPAR gamma 2 as compared to control unstretched cells (p < 0.05). Mechanical loading stimulated the release of PGE(2), PGD(2) and the PGD(2) metabolite Delta(12)PGJ(2). Mechanical strain resulted in the induction of bone nodules.
   Conclusions: This report indicates that mechanical loading of osteoblasts results in activation of PGD(2) and the concomitant expression of transcription factor PPAR gamma 1 mRNA. The coordinated synthesis of Delta(12)PGJ(2), a natural ligand for PPAR gamma 1, with the increased expression of PPAR gamma 1, suggests that biomechanical transduction pathways that initially involve the activation of cyclooxygenases may also involve the activation of the Delta(12)PGJ(2) PPAR pathway.
C1 Univ N Carolina, Ctr Oral & Syst Dis, Sch Dent, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Periodontol, Sch Dent, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Orthopaed, Sch Med, Chapel Hill, NC 27599 USA.
   Mahidol Univ, Dept Oral Pathol, Fac Dent, Bangkok 10700, Thailand.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Mahidol University
RP Univ N Carolina, Ctr Oral & Syst Dis, Sch Dent, Room 222 DRC,CB 7455, Chapel Hill, NC 27599 USA.
EM Steve_Offenbacher@Dentistry.UNC.edu
FU NCRR NIH HHS [RR00046] Funding Source: Medline; NIDCR NIH HHS [P60 DE
   13079] Funding Source: Medline
CR CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Cowin SC, 1998, AM J MED SCI, V316, P184, DOI 10.1097/00000441 199809000 00006
   Crofford LJ, 1997, J RHEUMATOL, V24, P15
   Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635 200405000 00001
   Diascro DD, 1998, J BONE MINER RES, V13, P96, DOI 10.1359/jbmr.1998.13.1.96
   Dieter P, 2000, BIOCHEM BIOPH RES CO, V276, P488, DOI 10.1006/bbrc.2000.3496
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092 8674(95)90193 0
   FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189
   FUKUSHIMA M, 1982, BIOCHEM BIOPH RES CO, V109, P626, DOI 10.1016/0006 291X(82)91986 6
   Giesen EBW, 2003, CLIN BIOMECH, V18, P358, DOI 10.1016/S0268 0033(03)00018 4
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Greene M. E., 1995, Gene Expression, V4, P281
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Joldersma M, 2000, J BIOMECH, V33, P53, DOI 10.1016/S0021 9290(99)00172 4
   Kamata A, 1998, BIOCHEM BIOPH RES CO, V246, P404, DOI 10.1006/bbrc.1998.8632
   KAWATA R, 1995, J IMMUNOL, V155, P818
   KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822
   KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092 8674(95)90194 9
   KOJIMA A, 1980, PROSTAG OTH LIPID M, V20, P171, DOI 10.1016/0090 6980(80)90016 7
   KOSHIHARA Y, 1991, ADV PROSTAG THROMB L, V21, P847
   KOSHIHARA Y, 1989, BIOCHEM BIOPH RES CO, V159, P1206, DOI 10.1016/0006 291X(89)92238 9
   Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894
   Maxey KM, 2000, PROSTAG OTH LIPID M, V62, P15, DOI 10.1016/S0090 6980(00)00072 1
   Mikuni Takagaki Y, 1999, J BONE MINER METAB, V17, P57, DOI 10.1007/s007740050065
   Montague CT, 2002, DIABETES OBES METAB, V4, P356, DOI 10.1046/j.1463 1326.2002.00200.x
   POWELL WS, 1980, PROSTAG OTH LIPID M, V20, P947, DOI 10.1016/0090 6980(80)90144 6
   Ramfjord S P., 1959, J Periodontol, V30, P95
   RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345
   SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634
   SHER T, 1993, BIOCHEMISTRY US, V32, P5598, DOI 10.1021/bi00072a015
   SHORT E, 1990, ANAT RECORD, V227, P391, DOI 10.1002/ar.1092270402
   SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163 7258(91)90054 P
   TAKAGI T, 1993, CALCIFIED TISSUE INT, V52, P442, DOI 10.1007/BF00571334
   TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090 6980(91)90001 V
   Terespolsky MS, 2002, AM J ORTHOD DENTOFAC, V121, P620, DOI 10.1067/mod.2002.123342
   TERRAGNO A, 1981, PROSTAG OTH LIPID M, V21, P101, DOI 10.1016/0090 6980(81)90200 8
   Turner CH, 1998, BONE, V23, P399, DOI 10.1016/S8756 3282(98)00118 5
   Xu JQ, 1997, J CELL BIOCHEM, V64, P618, DOI 10.1002/(SICI)1097 4644(19970315)64:4<618::AID JCB10>3.0.CO;2 8
NR 40
TC 19
Z9 22
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD APR
PY 2006
VL 41
IS 2
BP 92
EP 100
DI 10.1111/j.1600 0765.2005.00834.x
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 023EH
UT WOS:000236108000002
PM 16499711
DA 2025 08 17
ER

PT J
AU Ehnert, S
   Zhao, J
   Pscherer, S
   Freude, T
   Dooley, S
   Kolk, A
   Stöckle, U
   Nussler, AK
   Hube, R
AF Ehnert, Sabrina
   Zhao, Jian
   Pscherer, Stefan
   Freude, Thomas
   Dooley, Steven
   Kolk, Andreas
   Stoeckle, Ulrich
   Nussler, Andreas Klaus
   Hube, Robert
TI Transforming growth factor β1 inhibits bone morphogenic
   protein (BMP) 2 and BMP 7 signaling via upregulation of Ski related
   novel protein N (SnoN): possible mechanism for the failure of BMP
   therapy?
SO BMC MEDICINE
LA English
DT Article
DE alkaline phosphatase; mineralized matrix; osteoblasts; rhBMPs; TGF beta
ID TGF BETA; DENSITY; OSTEOPOROSIS; FUSION; CELLS
AB Background: Bone morphogenic proteins (BMPs) play a key role in bone formation. Consequently, it was expected that topical application of recombinant human (rh) BMP 2 and rhBMP 7 would improve the healing of complex fractures. However, up to 36% of fracture patients do not respond to this therapy. There are hints that a systemic increase in transforming growth factor beta(1) (TGF beta(1)) interferes with beneficial BMP effects. Therefore, in the present work we investigated the influence of rhTGF beta(1) on rhBMP signaling in primary human osteoblasts, with the aim of more specifically delineating the underlying regulatory mechanisms.
   Methods: BMP signaling was detected by adenoviral Smad binding element reporter assays. Gene expression was determined by reverse transcription polymerase chain reaction (RT PCR) and confirmed at the protein level by western blot. Histone deacetylase (HDAC) activity was determined using a test kit. Data sets were compared by one way analysis of variance.
   Results: Our findings showed that Smad1/5/8 mediated rhBMP 2 and rhBMP 7 signaling is completely blocked by rhTGFb1. We then investigated expression levels of genes involved in BMP signaling and regulation (for example, Smad1/5/8, TGF beta receptors type I and II, noggin, sclerostin, BMP and activin receptor membrane bound inhibitor (BAMBI), v ski sarcoma viral oncogene homolog (Ski), Ski related novel protein N (SnoN) and Smad ubiquitination regulatory factors (Smurfs)) and confirmed the expression of regulated genes at the protein level. Smad7 and SnoN were significantly induced by rhTGF beta(1) treatment while expression of Smad1, Smad6, TGF beta RII and activin receptor like kinase 1 (Alk1) was reduced. Elevated SnoN expression was accompanied by increased HDAC activity. Addition of an HDAC inhibitor, namely valproic acid, fully abolished the inhibitory effect of rhTGF beta(1) on rhBMP 2 and rhBMP 7 signaling.
   Conclusions: rhTGF beta 1 effectively blocks rhBMP signaling in osteoblasts. As possible mechanism, we postulate an induction of SnoN that increases HDAC activity and thereby reduces the expression of factors required for efficient BMP signaling. Thus, inhibition of HDAC activity may support bone healing during rhBMP therapy in patients with elevated TGF beta serum levels.
C1 [Ehnert, Sabrina; Freude, Thomas; Stoeckle, Ulrich; Nussler, Andreas Klaus] Univ Tubingen, BG Trauma Ctr, D 72076 Tubingen, Germany.
   [Zhao, Jian; Nussler, Andreas Klaus] Tech Univ Munich, MRI, Dept Traumatol, D 81675 Munich, Germany.
   [Pscherer, Stefan] Kliniken Sudostbayern AG, Klinikum Traunstein, Dept Nephrol, D 83278 Traunstein, Germany.
   [Dooley, Steven] Heidelberg Univ, Univ Hosp Mannheim, Dept Med 2, D 68175 Mannheim, Germany.
   [Kolk, Andreas] Tech Univ Munich, MRI, Dept Oro & Maxillofacial Surg, D 81675 Munich, Germany.
   [Hube, Robert] OCM Clin Munich, Dept Orthopaed Surg, D 81368 Munich, Germany.
C3 Eberhard Karls University of Tubingen; Technical University of Munich;
   Ruprecht Karls University Heidelberg; Technical University of Munich
RP Ehnert, S (通讯作者)，Univ Tubingen, BG Trauma Ctr, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
EM sehnert@bgu tuebingen.de
RI Nussler, Andreas/H 3557 2019; Ehnert, Sabrina/AAE 8163 2019; Dooley,
   Steven/T 6491 2018
OI Ehnert, Sabrina/0000 0003 4347 1702; 
FU BBraun foundation
FX The work was partially supported by the BBraun foundation.
CR Aksoy A, 2011, J PEDIATR ENDOCR MET, V24, P703, DOI 10.1515/JPEM.2011.019
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baskin DS, 2003, SPINE, V28, P1219, DOI 10.1097/00007632 200306150 00003
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   BORDER WA, 1994, NEW ENGL J MED, V331, P1286
   Burkus JK, 2009, J BONE JOINT SURG AM, V91A, P1181, DOI 10.2106/JBJS.G.01485
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Geibel PT, 2009, J SPINAL DISORD TECH, V22, P315, DOI 10.1097/BSD.0b013e31817d8161
   Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756 3282(98)00078 7
   JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195
   Köppel H, 2011, NEPHROL DIAL TRANSPL, V26, P3852, DOI 10.1093/ndt/gfr324
   Leach J, 2009, J CLIN NEUROSCI, V16, P1417, DOI 10.1016/j.jocn.2009.02.012
   Leask A, 2007, CARDIOVASC RES, V74, P207, DOI 10.1016/j.cardiores.2006.07.012
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Machado MC, 2010, J EXP THER ONCOL, V9, P85
   Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo 124 6 2991
   Ouyang DY, 2011, J PROTEOMICS, V74, P2180, DOI 10.1016/j.jprot.2011.06.016
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   ROSEN D, 1994, BONE, V15, P355, DOI 10.1016/8756 3282(94)90300 X
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Shimer AL, 2009, INJURY, V40, P32
   Triantafyllou N, 2010, J NEUROL SCI, V290, P131, DOI 10.1016/j.jns.2009.12.015
   Vaccaro AR, 2008, SPINE, V33, P2850, DOI 10.1097/BRS.0b013e31818a314d
   Wang SN, 2004, J BIOL CHEM, V279, P23200, DOI 10.1074/jbc.M311998200
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Wu LD, 2007, INT ORTHOP, V31, P605, DOI 10.1007/s00264 006 0235 3
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
NR 33
TC 63
Z9 66
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741 7015
J9 BMC MED
JI BMC Med.
PD SEP 7
PY 2012
VL 10
AR 101
DI 10.1186/1741 7015 10 101
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 055BJ
UT WOS:000312389700001
PM 22958403
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wu, YW
   Tu, QS
   Valverde, P
   Zhang, J
   Murray, D
   Dong, LQ
   Cheng, J
   Jiang, H
   Rios, M
   Morgan, E
   Tang, ZH
   Chen, JK
AF Wu, Yuwei
   Tu, Qisheng
   Valverde, Paloma
   Zhang, Jin
   Murray, Dana
   Dong, Lily Q.
   Cheng, Jessica
   Jiang, Hua
   Rios, Maribel
   Morgan, Elise
   Tang, Zhihui
   Chen, Jake
TI Central adiponectin administration reveals new regulatory mechanisms of
   bone metabolism in mice
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE adiponectin; hypothalamus; adaptor protein containing pleckstrin
   homology domain, phosphotyrosine domain, and leucine zipper motif 1;
   bone marrow stromal cells; tryptophan hydroxylase 2
ID SYMPATHETIC NERVOUS SYSTEM; DOPAMINE BETA HYDROXYLASE; PPAR GAMMA;
   INSULIN RESISTANCE; SUPPRESSING OSTEOCLAST; HISTONE DEMETHYLASES; LEPTIN
   REGULATION; EXPRESSION; DIFFERENTIATION; HYPOTHALAMUS
AB Adiponectin (APN), the most abundant adipocyte secreted adipokine, regulates energy homeostasis and exerts well characterized insulinsensitizing properties. The peripheral or central effects of APN regulating bone metabolism are beginning to be explored but are still not clearly understood. In the present study, we found that APN knockout (APN KO) mice fed a normal diet exhibited decreased trabecular structure and mineralization and increased bone marrow adiposity compared with wild type (WT) mice. APN intracerebroventricular infusions decreased uncoupling protein 1 (UCP1) expression in brown adipose tissue, epinephrine and norepinephrine serum levels, and osteoclast numbers, whereas osteoblast osteogenic marker expression and trabecular bone mass increased in APN KO and WT mice. In addition, centrally administered APN increased hypothalamic tryptophan hydroxylase 2 (TPH2), cocaine  and amphetamine regulated transcript (CART), and 5 hydroxytryptamine (serotonin) receptor 2C (Htr2C) expressions but decreased hypothalamic cannabinoid receptor 1 expression. Treatment of immortalized mouse neurons with APN demonstrated that APN mediated effects on TPH2, CART, and Htr2C expression levels were abolished by downregulating adaptor protein containing pleckstrin homology domain, phosphotyrosine domain, and leucine zipper motif (APPL) 1 expression. Pharmacological increase in sympathetic activity stimulated adipogenic differentiation of bone marrow stromal cells (BMSC) and reversed APN induced expression of the lysine specific demethylases involved in regulating their commitment to the osteoblastic lineage. In conclusion, we found that APN regulates bone metabolism via central and peripheral mechanisms to decrease sympathetic tone, inhibit osteoclastic differentiation, and promote osteoblastic commitment of BMSC.
C1 [Wu, Yuwei; Tu, Qisheng; Zhang, Jin; Murray, Dana; Cheng, Jessica; Jiang, Hua; Chen, Jake] Tufts Univ, Sch Dent Med, Div Oral Biol, Boston, MA 02111 USA.
   [Wu, Yuwei; Tang, Zhihui] Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100871, Peoples R China.
   [Wu, Yuwei; Tang, Zhihui] Peking Univ, Sch & Hosp Stomatol, Dent Ctr 2, Beijing 100871, Peoples R China.
   [Valverde, Paloma] Wentworth Inst Technol, Dept Sci, Boston, MA USA.
   [Dong, Lily Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Rios, Maribel] Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA.
   [Morgan, Elise] Boston Univ, Dept Mech Engn, Boston, MA 02215 USA.
   [Morgan, Elise] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
   [Morgan, Elise] Boston Univ, Dept Orthoped Surg, Boston, MA 02215 USA.
   [Chen, Jake] Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA.
   [Chen, Jake] Sackler Grad Sch Biomed Sci, Boston, MA USA.
C3 Tufts University; Peking University; Peking University; University of
   Texas System; University of Texas Health Science Center at San Antonio;
   Tufts University; Boston University; Boston University; Boston
   University; Tufts University
RP Chen, JK (通讯作者)，Tufts Univ, Sch Dent Med, Div Oral Biol, 1 Kneeland St,DHS 643, Boston, MA 02111 USA.
EM jk.chen@tufts.edu
RI Chen, Jake/A 2857 2009; wu, yuwei/JNR 3924 2023; Morgan,
   Elise/L 1706 2013
OI Rios, Maribel/0000 0003 1760 8090; Tu, Qisheng/0000 0003 0639 8761
FU National Institute of Dental Research [R01 DE 16710, R01 DE 21464];
   International Association for Dental Research and Academy of
   Osseointegration (Innovation in Implant Sciences); Tufts Center for
   Neuroscience Research [P30 NS047243]
FX This work was supported by National Institute of Dental Research Grants
   R01 DE 16710 and R01 DE 21464 (to J. Chen), the International
   Association for Dental Research and Academy of Osseointegration
   (Innovation in Implant Sciences Award to J. Chen), and the Tufts Center
   for Neuroscience Research (P30 NS047243).
CR Agger K, 2008, CURR OPIN GENET DEV, V18, P159, DOI 10.1016/j.gde.2007.12.003
   Bjursell M, 2007, DIABETES, V56, P583, DOI 10.2337/db06 1432
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Coope A, 2008, FEBS LETT, V582, P1471, DOI 10.1016/j.febslet.2008.03.037
   Driessler F, 2010, J MOL ENDOCRINOL, V45, P175, DOI 10.1677/JME 10 0015
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Festuccia WT, 2010, AM J PHYSIOL REG I, V299, pR159, DOI 10.1152/ajpregu.00821.2009
   Guillod Maximin E, 2009, J ENDOCRINOL, V200, P93, DOI 10.1677/JOE 08 0348
   Kajimura D, 2013, CELL METAB, V17, P901, DOI 10.1016/j.cmet.2013.04.009
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200
   Kubota N, 2007, CELL METAB, V6, P55, DOI 10.1016/j.cmet.2007.06.003
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee HW, 2009, STEM CELLS, V27, P2254, DOI 10.1002/stem.144
   Luo E, 2012, ACTA BIOMATER, V8, P734, DOI 10.1016/j.actbio.2011.10.029
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   Mao XM, 2006, NAT CELL BIOL, V8, P516, DOI 10.1038/ncb1404
   McCauley LK, 2010, J CLIN INVEST, V120, P3440, DOI 10.1172/JCI44786
   MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225
   Murphy Kevin, 2005, Briefings in Functional Genomics & Proteomics, V4, P95, DOI 10.1093/bfgp/4.2.95
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Padmalayam I, 2013, CURR PHARM DESIGN, V19, P5755, DOI 10.2174/13816128113199990360
   Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200
   Qi Y, 2004, NAT MED, V10, P524, DOI 10.1038/nm1029
   RUSH RA, 1980, CRC CR REV CL LAB SC, V12, P241, DOI 10.3109/10408368009108731
   Scarpace PJ, 1998, AM J PHYSIOL ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shklyaev S, 2003, P NATL ACAD SCI USA, V100, P14217, DOI 10.1073/pnas.2333912100
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   THOENEN H, 1971, P NATL ACAD SCI USA, V68, P1598, DOI 10.1073/pnas.68.7.1598
   Thundyil J, 2012, BRIT J PHARMACOL, V165, P313, DOI 10.1111/j.1476 5381.2011.01560.x
   Tian L, 2012, ATHEROSCLEROSIS, V221, P66, DOI 10.1016/j.atherosclerosis.2011.12.014
   Tsao TS, 2002, EUR J PHARMACOL, V440, P213, DOI 10.1016/S0014 2999(02)01430 9
   Tu QS, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.152405
   Vachharajani V, 2012, OBESITY, V20, P498, DOI 10.1038/oby.2011.316
   Villarreal Molina T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049285
   Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200
   Walther DJ, 2003, BIOCHEM PHARMACOL, V66, P1673, DOI 10.1016/S0006 2952(03)00556 2
   Wang F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068497
   Williams GA, 2009, ENDOCRINOLOGY, V150, P3603, DOI 10.1210/en.2008 1639
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yamaguchi N, 2007, FEMS IMMUNOL MED MIC, V49, P28, DOI 10.1111/j.1574 695X.2006.00164.x
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
NR 51
TC 53
Z9 64
U1 0
U2 16
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD JUN 15
PY 2014
VL 306
IS 12
BP E1418
EP E1430
DI 10.1152/ajpendo.00048.2014
PG 13
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA AK4UD
UT WOS:000338418700008
PM 24780611
OA Green Published
DA 2025 08 17
ER

PT J
AU Hadjicharalambous, C
   Alexaki, VI
   Alpantaki, K
   Chatzinikolaidou, M
AF Hadjicharalambous, Chrystalleni
   Alexaki, Vasileia Ismini
   Alpantaki, Kalliopi
   Chatzinikolaidou, Maria
TI Effects of NSAIDs on the osteogenic differentiation of human adipose
   tissue derived stromal cells
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE adipose tissue derived stromal cells; NSAIDs; osteogenic differentiation
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BONE FORMATION; COX 2; INHIBITORS;
   PARECOXIB; GLUCOCORTICOIDS; PROLIFERATION; MECHANISMS; LORNOXICAM;
   MELOXICAM
AB Objectives Non steroidal anti inflammatory drugs (NSAIDs), used in the treatment of musculoskeletal pathologies, have been associated with impaired bone healing, possibly through inhibition of osteogenic differentiation. The adipose tissue (AT) is regarded as an attractive source of stromal cells for autologous cell transplantation in the bone. The effects of NSAIDs on human AT derived stromal cells (hADSCs) are unknown.
   Methods We examined the effect of several NSAIDs including meloxicam, parecoxib, lornoxicam, diclofenac and paracetamol on the proliferation of hADSCs by means of the PrestoBlue (R) viability assay, and the osteogenic differentiation capacity of hADSCs by means of the alkaline phosphatase (ALP) activity, calcium deposition by alizarin red staining and osteogenic gene expression by semi quantitative PCR.
   Key findings Most of the drugs enhanced hADSC cell growth, while either positively affecting or not influencing alkaline phosphatase (ALP) activity, calcium deposition and osteogenic gene expression. Moreover, selective COX 2 inhibitor NSAIDs, such as meloxicam or parecoxib, were advantageous over the non selective COX 1 and COX 2 inhibitor NSAIDs lornoxicam and diclofenac.
   Conclusions Altogether through this study, we show that NSAIDs, possibly depending on their selectivity for COX inhibition, leave the osteogenic differentiation capacity of hADSCs unaltered or might even enhance it.
C1 [Hadjicharalambous, Chrystalleni; Chatzinikolaidou, Maria] Univ Crete, Dept Mat Sci & Technol, Iraklion, Greece.
   [Hadjicharalambous, Chrystalleni; Chatzinikolaidou, Maria] Fdn Res & Technol Hellas FORTH, IESL, Iraklion, Greece.
   [Alexaki, Vasileia Ismini] Tech Univ Dresden, Fac Med, Dept Clin Pathobiochem, Dresden, Germany.
   [Alpantaki, Kalliopi] Univ Hosp Heraklion, Dept Orthoped & Trauma, Iraklion, Greece.
C3 University of Crete; Technische Universitat Dresden; University Hospital
   of Heraklion
RP Chatzinikolaidou, M (通讯作者)，Dept Mat Sci & Technol, POB 2208, Iraklion 71003, Greece.; Chatzinikolaidou, M (通讯作者)，IESL FORTH, POB 2208, Iraklion 71003, Greece.; Alexaki, VI (通讯作者)，Dept Clin Pathobiochem, Fetscherstr 74, D 01307 Dresden, Germany.
EM Ismini.Alexaki@uniklinikum dresden.de; mchatzin@materials.uoc.gr
RI Chatzinikolaidou, Maria/H 1061 2014; Alexaki, Vasileia/K 5527 2019
OI Chatzinikolaidou, Maria/0000 0002 2749 2506; Alexaki, Vasileia
   Ismini/0000 0003 3935 8985; Hadjicharalambous,
   Chrystalleni/0000 0001 6830 974X
FU Greek Ministry of Education, Lifelong Learning and Religious Affairs
   grant [II 3438]
FX This work was supported by the Excellence Grant 'Aristeia II 3438' of
   the Greek Ministry of Education, Lifelong Learning and Religious Affairs
   grant.
CR Alexaki VI, 2012, CELL TRANSPLANT, V21, P2441, DOI 10.3727/096368912X637064
   Alexaki VI, 2009, J IMMUNOL, V183, P5948, DOI 10.4049/jimmunol.0901186
   Barba M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/416391
   Beck Alexander, 2005, Oper Orthop Traumatol, V17, P569, DOI 10.1007/s00064 005 1152 0
   Berg J, 1999, INFLAMM RES, V48, P369, DOI 10.1007/s000110050474
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Borglum JD, 1997, MOL CELL ENDOCRINOL, V131, P67, DOI 10.1016/S0303 7207(97)00094 4
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Davies NM, 1999, CLIN PHARMACOKINET, V36, P115, DOI 10.2165/00003088 199936020 00003
   Fang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088874
   Furst DE, 1997, SEMIN ARTHRITIS RHEU, V26, P21, DOI 10.1016/S0049 0172(97)80049 2
   Gajraj NM, 2007, CURR TOP MED CHEM, V7, P235, DOI 10.2174/156802607779941323
   Gimble JM, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt19
   Graham GG, 2013, INFLAMMOPHARMACOLOGY, V21, P201, DOI 10.1007/s10787 013 0172 x
   Hadjicharalambous C, 2015, J BIOMED MATER RES A, V103, P3834, DOI 10.1002/jbm.a.35527
   Hadjicharalambous C, 2015, J BIOMED MATER RES A, V103, P3612, DOI 10.1002/jbm.a.35475
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hinz B, 2008, FASEB J, V22, P383, DOI 10.1096/fj.07 8506com
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Levi B, 2011, STEM CELLS, V29, P576, DOI 10.1002/stem.612
   LIAN JB, 1988, CLIN ORTHOP RELAT R, P267
   Linero I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107001
   Melief SM, 2013, STEM CELL TRANSL MED, V2, P455, DOI 10.5966/sctm.2012 0184
   MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693
   Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Pountos I, 2011, J CELL MOL MED, V15, P525, DOI 10.1111/j.1582 4934.2010.01006.x
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Rose P, 2004, CLIN DRUG INVEST, V24, P227, DOI 10.2165/00044011 200424040 00004
   SIFFERT RS, 1951, J EXP MED, V93, P415, DOI 10.1084/jem.93.5.415
   Steinert AF, 2012, STEM CELL TRANSL MED, V1, P237, DOI 10.5966/sctm.2011 0036
   Tacconelli S, 2004, CURR PHARM DESIGN, V10, P589, DOI 10.2174/1381612043453108
   Talley JJ, 2000, J MED CHEM, V43, P1661, DOI 10.1021/jm000069h
NR 38
TC 10
Z9 14
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3573
EI 2042 7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD NOV
PY 2016
VL 68
IS 11
BP 1403
EP 1408
DI 10.1111/jphp.12595
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EC7JO
UT WOS:000388313800007
PM 27523985
DA 2025 08 17
ER

PT J
AU Molagoda, IMN
   Athapaththu, AMGK
   Park, EK
   Choi, YH
   Jeon, YJ
   Kim, GY
AF Molagoda, Ilandarage Menu Neelaka
   Athapaththu, Athapaththu Mudiyanselage Gihan Kavinda
   Park, Eui Kyun
   Choi, Yung Hyun
   Jeon, You Jin
   Kim, Gi Young
TI Fermented Oyster (Crassostrea gigas) Extract Cures and Prevents
   Prednisolone Induced Bone Resorption by Activating Osteoblast
   Differentiation
SO FOODS
LA English
DT Article
DE fermented oyster; prednisolone; osteoblast; osteoclast
ID BISPHOSPHONATE THERAPY; INDUCED OSTEOPOROSIS; ESTRADIOL 17 BETA;
   BIOACCUMULATION; METABOLISM; MECHANISMS; BENEFITS; RISKS
AB Osteoporosis is a bone resorptive disease characterized by the loss of bone density, causing an increase in bone fragility. In our previous study, we demonstrated that gamma aminobutyric acid enriched fermented oyster (Crassostrea gigas) extract (FO) stimulated osteogenesis in MC3T3 E1 preosteoblast cells and vertebral formation in zebrafish. However, the efficacy of FO in prednisolone (PDS) induced bone resorption remains unclear. In this study, we evaluated the osteogenic potential of FO in MC3T3 E1 preosteoblast cells and zebrafish larvae under both PDS pretreated and PDS post treated conditions. We found that FO recovered osteogenic activity by upregulating osteoblast markers, such as alkaline phosphatase (ALP), runt related transcription factor 2, and osterix, in both PDS pretreated and post treated MC3T3 E1 osteoblast cells and zebrafish larvae. In both conditions, PDS induced decrease in calcification and ALP activity was recovered in the presence of FO. Furthermore, vertebral resorption in zebrafish larvae induced by pretreatment and post treatment with PDS was restored by treatment with FO, along with the recovery of osteogenic markers and downregulation of osteoclastogenic markers. Finally, whether FO disturbs the endocrine system was confirmed according to the Organization for Economic Cooperation and Development guideline 455. We found that FO did not stimulate estrogen response element luciferase activity or proliferation in MCF7 cells. Additionally, in ovariectomized mice, no change in uterine weight was observed during FO feeding. These results indicate that FO effectively prevents and treats PDS induced osteoporosis without endocrine disturbances.
C1 [Molagoda, Ilandarage Menu Neelaka; Athapaththu, Athapaththu Mudiyanselage Gihan Kavinda; Jeon, You Jin; Kim, Gi Young] Jeju Natl Univ, Dept Marine Life Sci, Jeju 63243, South Korea.
   [Molagoda, Ilandarage Menu Neelaka; Athapaththu, Athapaththu Mudiyanselage Gihan Kavinda; Kim, Gi Young] Jeju Natl Univ, Res Inst Basic Sci, Jeju 63243, South Korea.
   [Molagoda, Ilandarage Menu Neelaka] Rajarata Univ Sri Lanka, Fac Technol, Dept Bioproc Technol, Mihintale 50300, Sri Lanka.
   [Athapaththu, Athapaththu Mudiyanselage Gihan Kavinda; Park, Eui Kyun] Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol & Regenerat Med, Daegu 41940, South Korea.
   [Choi, Yung Hyun] Dong Eui Univ, Dept Biochem, Coll Korean Med, Busan 47227, South Korea.
C3 Jeju National University; Jeju National University; Rajarata University
   of Sri Lanka; Kyungpook National University (KNU); Dong Eui University
RP Kim, GY (通讯作者)，Jeju Natl Univ, Dept Marine Life Sci, Jeju 63243, South Korea.; Kim, GY (通讯作者)，Jeju Natl Univ, Res Inst Basic Sci, Jeju 63243, South Korea.
EM neelakagm2012@gmail.com; gihankavinda@yahoo.com; epark@knu.ac.kr;
   choiyh@deu.ac.kr; youjinj@jejunu.ac.kr; immunkim@jejunu.ac.kr
RI ; Kim, Kyoung Sook/A 7768 2017; Jeon, You Jin/AAR 5061 2020; Molagoda,
   Neelaka/ABE 4537 2021
OI Choi, Yung Hyun/0000 0002 1454 3124; Kim, Gi Young/0000 0002 6878 0790;
   Jeon, You Jin/0000 0003 3299 7266; Molagoda,
   Neelaka/0000 0002 6922 8121; 
CR Athapaththu AMGK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011254
   Bateman ME, 2017, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00171
   Becker Daniel E, 2013, Anesth Prog, V60, P25, DOI 10.2344/0003 3006 60.1.25
   Bergström I, 2018, BONE, V112, P10, DOI 10.1016/j.bone.2018.04.002
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Chen JR, 2017, MOLECULES, V22, DOI 10.3390/molecules22122068
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   Dai JH, 2020, FOOD SCI NUTR, DOI 10.1002/fsn3.1653
   Daston GP, 2003, TOXICOL SCI, V74, P245, DOI 10.1093/toxsci/kfg105
   Di Cosmo A, 2002, MOL REPROD DEV, V61, P367, DOI 10.1002/mrd.10014
   Fan JJ, 2019, ENVIRON POLLUT, V247, P999, DOI 10.1016/j.envpol.2019.01.113
   Flower R.J., 2009, XPHARM COMPREHENSIVE, P1, DOI [10.1016/B978 008055232 3.62455 9, DOI 10.1016/B978 008055232 3.62455 9]
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   He HL, 2018, BIOMED PHARMACOTHER, V101, P981, DOI 10.1016/j.biopha.2018.02.082
   Ihn HJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061392
   Ilias I., 2018, ENDOCRINOLOGY BOOK
   Jeong JW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061439
   Kassi E, 2017, ONCOTARGET, V8, P7220, DOI 10.18632/oncotarget.13997
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kitamura K, 2013, COMP BIOCHEM PHYS A, V166, P74, DOI 10.1016/j.cbpa.2013.04.023
   Le Curieux Belfond O, 2005, J EXP MAR BIOL ECOL, V325, P125, DOI 10.1016/j.jembe.2005.04.027
   Liberman AC, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00235
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Mitra R, 2011, PM&R, V3, P466, DOI 10.1016/j.pmrj.2011.02.017
   Molagoda IMN, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114676
   Molagoda IMN, 2020, MAR DRUGS, V18, DOI 10.3390/md18090472
   Molagoda IMN, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110711
   Payer J, 2010, DRUG HEALTHC PATIENT, V2, P49
   Raeder J, 2009, ACUTE PAIN MANAGEMENT, P377, DOI 10.1017/CBO9780511576706.025
   Rizzoli R, 2018, CALCIFIED TISSUE INT, V102, P489, DOI 10.1007/s00223 017 0317 9
   Sathasivam S, 2008, NAT CLIN PRACT NEURO, V4, P317, DOI 10.1038/ncpneuro0810
   Sousa AR, 2017, CLIN EXP ALLERGY, V47, P890, DOI 10.1111/cea.12954
   Sun B, 2016, HISTOL HISTOPATHOL, V31, P647, DOI 10.14670/HH 11 702
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 2004, ENDOCRINOLOGY, V145, P1980, DOI 10.1210/en.2003 1133
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
NR 37
TC 4
Z9 7
U1 0
U2 14
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2304 8158
J9 FOODS
JI Foods
PD MAR
PY 2022
VL 11
IS 5
AR 678
DI 10.3390/foods11050678
PG 15
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA ZR8VX
UT WOS:000768056500001
PM 35267311
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, Z
   Xu, J
   Li, S
   Cui, HQ
   Zhang, GM
   Ni, XM
   Wang, J
AF Xu, Zhe
   Xu, Jing
   Li, Shuo
   Cui, Hanqiang
   Zhang, Guiming
   Ni, Xiangmin
   Wang, Jian
TI S Equol enhances osteoblastic bone formation and prevents bone loss
   through OPG/RANKL via the PI3K/Akt pathway in
   streptozotocin induced diabetic rats
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE diabetic osteoporosis (DOP); S Equol; estrogen receptor beta (ER beta);
   AKT; osteoprotegerin (OPG); receptor activator of nuclear factor kappa B
   ligand (RANKL)
ID ESTROGEN RECEPTOR ALPHA; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; SOY
   ISOFLAVONES; RISK; CELLS; OSTEOPROTEGERIN; METABOLITE; MECHANISM; TYPE 1
AB BackgroundThis study aimed to explore whether S Equol delays diabetes induced osteoporosis and the molecular mechanisms underlying its therapeutic effects.Materials and methodsThirty five male Sprague Dawley rats were randomized into five groups. The diabetic osteoporosis (DOP) group and three S Equol treatment groups were intraperitoneally injected with streptozotocin (STZ) to develop a DOP model. After the 12 week intervention, bone transformation indicators were detected using an enzyme linked immunosorbent assay kit; bone mineral density (BMD) and bone microstructure were obtained using dual energy X ray absorptiometry and microCT; morphological changes in the bone tissue were investigated using HE staining; bone morphogenetic proteins were detected using immunohistochemical staining. ROS17/2.8 cells were cultured in vitro, and Cell Counting Kit 8 was used to test the protective effects of S Equol in osteoblastic cells in a high fat and high glucose environment. Furthermore, the expression of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), estrogen receptor beta(ER beta), phosphorylated Akt (pAKT)/protein kinase B (AKT), and osteocalcin (OC) in bone tissue and ROS17/2.8 cells was assessed using reverse transcription polymerase chain reaction (RT PCR) and western blotting. To determine whether ER beta and phosphatidylinositol 3'  kinase (PI3K)/AKT signaling pathways are involved in the process, LY294002 (PI3K signaling pathway inhibitor) and small interfering RNA targeting ER beta mRNA (si ER beta) were used to verify the function of the ER beta mediated PI3K/AKT pathway in this process.ResultsAfter the 12 week intervention, S Equol enhanced BMD, improved bone microarchitecture in DOP rats (P < 0.05), and improved markers of bone metabolism (P < 0.05). In vitro, 10( 6) mmol/L S Equol was selected to significantly protect osteoblasts from high  and high glucose environments (P < 0.05). Gene expression of OPG, ER beta, pAKT/AKT, and OC was upregulated compared to the DOP group, and RANKL was downregulated compared to the DOP group (P < 0.05) both in bone tissue and osteoblastic cells. The promotion of OPG and pAKT/AKT is mediated by LY294002 and siER beta.ConclusionS Equol binds to ER beta to regulate OPG/RANKL via the PI3K/AKT pathway and improve DOP. Our results demonstrate the potential role of S Equol in the treatment of DOP by targeting ER beta. Thus, S Equol may have the potential to be an adjuvant drug for treating DOP.
C1 [Xu, Zhe; Li, Shuo; Cui, Hanqiang; Zhang, Guiming; Ni, Xiangmin; Wang, Jian] Army Med Univ, Mil Med Univ 3, Xinqiao Hosp, Dept Nutr, Chongqing, Peoples R China.
   [Xu, Jing] Army Med Univ, Mil Med Univ 3, Xinqiao Hosp, Dept Endocrinol, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University
RP Ni, XM; Wang, J (通讯作者)，Army Med Univ, Mil Med Univ 3, Xinqiao Hosp, Dept Nutr, Chongqing, Peoples R China.
EM ni_xiangmin@163.com; wangjian1996@aliyun.com
RI Zhang, Guiming/H 9616 2012
FU National Natural Science Foundation of China; National Science Fund for
   Young Scholars of China;  [81973040];  [81602855]
FX Funding This work was partly supported by the National Natural Science
   Foundation of China (81973040) and National Science Fund for Young
   Scholars of China (81602855).
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Anagnostis P, 2018, ENDOCRINE, V60, P373, DOI 10.1007/s12020 018 1548 x
   Arjmandi BH, 2002, J NUTR BIOCHEM, V13, P130, DOI 10.1016/S0955 2863(02)00172 9
   Bjerre M, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193 1801 2 658
   Blázquez Medela AM, 2011, CURR MOL MED, V11, P401
   Center JR, 2007, JAMA J AM MED ASSOC, V297, P387, DOI 10.1001/jama.297.4.387
   Chen C, 2019, BIOL TRACE ELEM RES, V188, P441, DOI 10.1007/s12011 018 1433 8
   Chen K, 2020, NUTR METAB, V17, DOI 10.1186/s12986 020 0426 8
   Chen LR, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112649
   Gong W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163964
   Gunes M, 2021, J DIABETES COMPLICAT, V35, DOI 10.1016/j.jdiacomp.2021.108073
   Hamrick MW, 2008, OSTEOPOROSIS INT, V19, P905, DOI 10.1007/s00198 007 0487 9
   Han YY, 2018, DRUG DES DEV THER, V12, P137, DOI 10.2147/DDDT.S148457
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Horiuchi H, 2017, J NUTR, V147, P1631, DOI 10.3945/jn.117.250860
   Huang LW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137054
   International Diabetes Federation, 2019, IDF DIABETES ATLAS
   Karim K, 2021, PHYTOMEDICINE, V91, DOI 10.1016/j.phymed.2021.153677
   Kelly PM, 2017, MOLECULES, V22, DOI 10.3390/molecules22091440
   Komori T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122045
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Lin IC, 2016, J NUTR BIOCHEM, V32, P101, DOI 10.1016/j.jnutbio.2016.02.012
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Matsumoto T, 2021, J BONE MINER METAB, V39, P91, DOI 10.1007/s00774 020 01153 7
   Mayo B, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092231
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mitri J, 2014, ENDOCRIN METAB CLIN, V43, P205, DOI 10.1016/j.ecl.2013.09.010
   Morito K, 2002, BIOL PHARM BULL, V25, P48, DOI 10.1248/bpb.25.48
   Muthyala RS, 2004, BIOORGAN MED CHEM, V12, P1559, DOI 10.1016/j.bmc.2003.11.035
   Nie QX, 2022, FOOD CHEM, V371, DOI 10.1016/j.foodchem.2021.131106
   Nishimura Y, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00281
   Patil I., 2021, J Open Source Softw, V6, P3167, DOI [DOI 10.21105/JOSS.03167, https://doi.org/10.21105/joss.03167]
   Qi SS, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.759843
   Sacerdote A, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892 019 1201 y
   Schwartz AV, 2011, JAMA J AM MED ASSOC, V305, P2184, DOI 10.1001/jama.2011.715
   Schwen RJ, 2012, FOOD CHEM TOXICOL, V50, P2074, DOI 10.1016/j.fct.2012.03.048
   Setchell KDR, 2002, J NUTR, V132, P3577, DOI 10.1093/jn/132.12.3577
   Shen WJ, 2022, BBA MOL BASIS DIS, V1868, DOI 10.1016/j.bbadis.2022.166449
   Sun J, 2016, INT IMMUNOPHARMACOL, V40, P32, DOI 10.1016/j.intimp.2016.08.014
   Thent ZC, 2018, LIFE SCI, V210, P214, DOI 10.1016/j.lfs.2018.08.057
   Tousen Y, 2016, BRIT J NUTR, V116, P247, DOI 10.1017/S0007114516001537
   Valentini A, 2020, NUTR METAB CARDIOVAS, V30, P49, DOI 10.1016/j.numecd.2019.08.018
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vilaca T, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115457
   Wang T, 2020, MOLECULES, V25, DOI 10.3390/molecules25051165
   Xie CL, 2021, J SCI FOOD AGR, V101, P1499, DOI 10.1002/jsfa.10763
   Yamamoto M, 2016, CURR OSTEOPOROS REP, V14, P320, DOI 10.1007/s11914 016 0332 1
   Yamamoto M, 2012, J CLIN ENDOCR METAB, V97, P1277, DOI 10.1210/jc.2011 2537
   Yamamoto M, 2009, J BONE MINER RES, V24, P702, DOI 10.1359/JBMR.081207
   Yang XH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44766 3
   Yoshikata R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257332
   Zhao FJ, 2021, AGING US, V13, P6945, DOI 10.18632/aging.202552
NR 54
TC 9
Z9 12
U1 1
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 861X
J9 FRONT NUTR
JI Front. Nutr.
PD OCT 21
PY 2022
VL 9
AR 986192
DI 10.3389/fnut.2022.986192
PG 17
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 5Y9IY
UT WOS:000879595200001
PM 36337646
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, TT
   Jia, QY
   Chen, T
   Yin, H
   Tian, XT
   Lin, X
   Liu, Y
   Zhao, YJ
   Wang, YJ
   Shi, Q
   Huang, CG
   Xu, H
   Liang, QQ
AF Wang, Tengteng
   Jia, Qingyun
   Chen, Tao
   Yin, Hao
   Tian, Xiaoting
   Lin, Xi
   Liu, Yang
   Zhao, Yongjian
   Wang, Yongjun
   Shi, Qi
   Huang, Chenggang
   Xu, Hao
   Liang, Qianqian
TI Alleviation of Synovial Inflammation of Juanbi Tang on Collagen Induced
   Arthritis and TNF Tg Mice Model
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Juanbi Tang; rheumatoid arthritis; collagen induced arthritis;
   synoviocyte; tumor necrosis factor
ID NF KAPPA B; TUMOR NECROSIS FACTOR; RHEUMATOID ARTHRITIS; MOUSE MODEL;
   ACID; TARGET; CELLS
AB Rheumatoid arthritis (RA) is a chronic autoimmune disease that is primarily characterized by synovial inflammation. In this study, we found that a traditional Chinese decoction, Juanbi Tang (JBT), JBT attenuated the symptoms of collagen induced arthritis (CIA) mice and in tumor necrosis factor transgenic (TNF Tg) mice by attenuating the arthritis index and hind paw thickness. According to histopathological staining of ankle sections, JBT significantly decreased the area of inflammation and reduced bone destruction of ankle joints in both these two types of mice. Moreover, decreased tartaric acid phosphatase positive osteoclasts were observed in the JBT group compared with those found in the control group. We also revealed that JBT suppressed monocytes and T cells as well as the production of CCL2, CCR6, and CXCR3 ligands. We next used high performance liquid chromatography to investigate the components and pharmacological properties of this classical herbal medicine in traditional Chinese medicine. Based on network pharmacology, we performed computational prediction simulation of the potential targets of JBT, which indicated the NF kappa B pathway as its target, which was confirmed in vitro. JBT suppressed the production of pro inflammatory cytokines including interleukin 6 (IL 6) and IL 8, and inhibited the expression of matrix metalloproteinase 1 in fibroblast like synoviocytes derived from RA patients (MH7A cells). Furthermore, JBT also suppressed the phosphorylation of p38, JNK, and p65 in TNF alpha treated MH7A cells. In summary, this study proved that JBT could inhibit synovial inflammation and bone destruction, possibly by blocking the phosphorylation of NF kappa B pathway mediated production of proinflammatory effectors.
C1 [Wang, Tengteng; Chen, Tao; Liu, Yang; Zhao, Yongjian; Wang, Yongjun; Shi, Qi; Xu, Hao; Liang, Qianqian] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China.
   [Wang, Tengteng; Chen, Tao; Liu, Yang; Zhao, Yongjian; Wang, Yongjun; Shi, Qi; Xu, Hao; Liang, Qianqian] Shanghai Univ Tradit Chinese Med, Inst Spine, Shanghai, Peoples R China.
   [Jia, Qingyun] Linyi Peoples Hosp, Trauma Surg Dept, Ward 2, Linyi, Shandong, Peoples R China.
   [Chen, Tao; Liu, Yang; Zhao, Yongjian; Wang, Yongjun; Shi, Qi; Xu, Hao; Liang, Qianqian] Shanghai Univ Tradit Chinese Med, Key Lab Theory & Therapy Muscles & Bones, Minist Educ, Shanghai, Peoples R China.
   [Yin, Hao; Tian, Xiaoting; Huang, Chenggang] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China.
   [Lin, Xi] Univ Rochester, Dept Pathol & Lab Med, Rochester, NY USA.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Chinese Academy of Sciences; Shanghai Institute of
   Materia Medica, CAS; University of Rochester
RP Xu, H; Liang, QQ (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China.; Xu, H; Liang, QQ (通讯作者)，Shanghai Univ Tradit Chinese Med, Inst Spine, Shanghai, Peoples R China.; Xu, H; Liang, QQ (通讯作者)，Shanghai Univ Tradit Chinese Med, Key Lab Theory & Therapy Muscles & Bones, Minist Educ, Shanghai, Peoples R China.
EM hoxu@163.com; liangqianqiantcm@126.com
RI xu, hao/NMK 5605 2025
OI Chen, Tao/0000 0001 6325 5260
FU National Natural Science Foundation [81822050, 81920108032, 81673990,
   81873321]; Leading Medical Talents in Shanghai [2019LJ02]; Dawn Plan of
   Shanghai Municipal Education Commission [19SG39]; Program for Innovative
   Research Team of the Ministry of Science and Technology of China
   [2015RA4002]; Research Project of Shanghai Science and Technology
   Commission [17401971100]; Shanghai TCM Medical Center of Chronic Disease
   [2017ZZ01010]; "Innovation Team" development projects [IRT1270]; Three
   Years Action to Accelerate the Development of Traditional Chinese
   Medicine Plan [ZY(2018 2020) CCCX3003]
FX This work was sponsored by research grants from the National Natural
   Science Foundation (81822050, 81920108032, and 81673990 to QL, 81873321
   to HX), Leading Medical Talents in Shanghai (2019LJ02 to QL), Dawn Plan
   of Shanghai Municipal Education Commission (19SG39 to QL), Shanghai TCM
   Medical Center of Chronic Disease (2017ZZ01010 to YW), The Program for
   Innovative Research Team of the Ministry of Science and Technology of
   China (2015RA4002 to YW), Research Project of Shanghai Science and
   Technology Commission (17401971100 to QL), "Innovation Team" development
   projects (IRT1270 to YW), and Three Years Action to Accelerate the
   Development of Traditional Chinese Medicine Plan [ZY(2018 2020) CCCX3003
   to YW].
CR Alam J, 2017, BIOMED PHARMACOTHER, V92, P615, DOI 10.1016/j.biopha.2017.05.055
   Baek SY, 2014, ACTA PHARMACOL SIN, V35, P1177, DOI 10.1038/aps.2014.58
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Cao Z, 2017, MOL MED REP, V16, P2740, DOI 10.3892/mmr.2017.6886
   Chen P., 2018, J HEFEI U TECHNOL NA, V41, P415
   Chen Y, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/7067691
   Cheng X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195326
   Filer A, 2017, ANN RHEUM DIS, V76, P2105, DOI 10.1136/annrheumdis 2017 211286
   GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017, Lancet, V390, P1211, DOI 10.1016/S0140 6736(17)32154 2
   Guo RL, 2009, ARTHRITIS RHEUM US, V60, P2666, DOI 10.1002/art.24764
   Ji BC, 2017, INT J MOL MED, V40, P1709, DOI 10.3892/ijmm.2017.3177
   Jia Q, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00094
   Jiang XQ, 2015, J ETHNOPHARMACOL, V174, P270, DOI 10.1016/j.jep.2015.08.026
   Kang LJ, 2018, BRIT J PHARMACOL, V175, P4295, DOI 10.1111/bph.14486
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Korb Pap A, 2016, RHEUMATOLOGY, V55, P64, DOI 10.1093/rheumatology/kew347
   Kumar RA, 2018, INT IMMUNOPHARMACOL, V65, P348, DOI 10.1016/j.intimp.2018.10.016
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Li Q., 2011, NEW CHIN MED, V43, P52
   Li Z., 2011, TCM RES, V24, P51
   Liu CC, 2017, MOL MED REP, V16, P1369, DOI 10.3892/mmr.2017.6698
   Lou LX, 2016, EXP THER MED, V11, P2054, DOI 10.3892/etm.2016.3136
   Luchetti MM, 2017, CURR PHARM BIOTECHNO, V18, P989, DOI 10.2174/1389201019666171226151852
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Miyazawa K, 1998, J BIOCHEM TOKYO, V124, P1153, DOI 10.1093/oxfordjournals.jbchem.a022233
   Ni J., 2014, ZHEJIANG J TRADIT CH, V49, P818
   Niu X., 2018, PHARM CLIN MED, V34, P6
   Niu X x., 2018, J Anhui Univ Chin Med, V37, P71
   Ornbjerg LM, 2017, CLIN RHEUMATOL, V36, P781, DOI 10.1007/s10067 016 3489 1
   Roman Blas JA, 2006, OSTEOARTHR CARTILAGE, V14, P839, DOI 10.1016/j.joca.2006.04.008
   Sun Y, 2018, EXP THER MED, V16, P4037, DOI 10.3892/etm.2018.6696
   Vashistha B, 2017, NUTR NEUROSCI, V20, P60, DOI 10.1179/1476830514Y.0000000165
   Wang WF, 2017, INT IMMUNOPHARMACOL, V48, P61, DOI 10.1016/j.intimp.2017.04.025
   Wangyang YF, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180982
   Wen XD, 2018, INT J BIOL SCI, V14, P1732, DOI 10.7150/ijbs.24232
   Xu RG, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658 018 0086 0
   Xu X., 2018, J CELL MOL IMMUNOL, V34, P110
   Xu X., 2017, J Mol Immunol, V33, P736
   Yu Q., 2015, CHIN NATL FOLK MED, V24, P1
   Zhang LM, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1722 9
   Zhang L, 2018, MOL THER METH CLIN D, V9, P153, DOI 10.1016/j.omtm.2018.02.006
   Zhang R, 2019, INFLAMMATION, V42, P496, DOI 10.1007/s10753 018 0906 4
   Zhao L, 2015, J ETHNOPHARMACOL, V172, P100, DOI 10.1016/j.jep.2015.06.031
NR 43
TC 18
Z9 26
U1 0
U2 32
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 14
PY 2020
VL 11
AR 45
DI 10.3389/fphar.2020.00045
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KR3FD
UT WOS:000517502900001
PM 32116720
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jeon, S
   Yu, DW
   Kim, S
   Kim, SW
   Jeon, I
AF Jeon, Seongmin
   Yu, Dongwoo
   Kim, Sungho
   Kim, Sang Woo
   Jeon, Ikchan
TI Comparison of radiological and functional outcomes of conservative
   treatment with teriparatide and denosumab in thoracolumbar osteoporotic
   vertebral fracture
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Denosumab; Fracture healing; Osteoporosis; Spine; Teriparatide
ID POSTMENOPAUSAL WOMEN; BONE; JAPANESE; MODEL; PAIN
AB Teriparatide and denosumab, anti osteoporosis medications with different mechanisms, have been widely used in the patients with osteoporotic vertebral fracture (OVF) considered as advanced osteoporosis. Teriparatide has been shown to enhance bone formation and fracture healing in OVF, but there are still no sufficient evidences discussing about the role of denosumab in newly developed OVF. In this study, we found the similar radiological deformation and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar (TL) OVF, and teriparatide showed a more frequent incidence of fracture union with paravertebral bone bridge formation compared to denosumab.Introduction Teriparatide and denosumab have been widely used to treat advanced osteoporosis and prevent subsequent fractures in patients with OVCF. Unlike teriparatide, which is considered to be effective in fracture healing, there is still no clear role and evidence for the effect of denosumab in acute OVCF. This study compared the radiological and functional outcomes of conservative treatment with teriparatide and denosumab in TL OVF.Methods This retrospective study enrolled 78 women with mean age of 74.69 +/  7.66 (60 92) years diagnosed as a TL OVF with no neurological deficits. All patients were treated conservatively with teriparatide (34 of group T, once daily 20 mu g) or denosumab (44 of group D, once 6 months 60 mg) for 6 months. We evaluated the radiological deformation (kyphotic angle, segmental vertebral kyphotic angle, and compression ratio) and the incidence of fracture union with paravertebral bone bridge formation (FUPB) and functional outcomes using the visual analog scale (VAS) and Oswestry Disability Index (ODI) at 0, 3, and 6 months.Results In the radiological deformation and functional outcomes, there were no significant differences at 0, 3, and 6 months between the two groups (P > 0.05). However, the incidence of FUPB at 6 months was higher in group T (20/34, 58.8%) compared to group D (11/44, 25.0%) (P = 0.004), and teriparatide was the most statistically significant factor for achieving FUPB (OR 4.486, P = 0.012) in multivariable logistic analysis.Conclusions Teriparatide and denosumab, despite of their different pharmacological mechanisms, showed similar radiological deformation and functional outcomes in the conservative treatment of TL OVF. However, teriparatide showed a significantly higher incidence of fracture union with paravertebral bone bridge formation.
C1 [Jeon, Seongmin; Yu, Dongwoo; Kim, Sang Woo; Jeon, Ikchan] Yeungnam Univ, Yeungnam Univ Hosp, Coll Med, Dept Neurosurg, 170 Hyeonchung St, Daegu 42415, South Korea.
   [Kim, Sungho] Bogang Hosp, Dept Neurosurg, Daegu, South Korea.
C3 Yeungnam University; Yeungnam University Hospital
RP Jeon, I (通讯作者)，Yeungnam Univ, Yeungnam Univ Hosp, Coll Med, Dept Neurosurg, 170 Hyeonchung St, Daegu 42415, South Korea.
EM yee4374@naver.com; icarus0810@hanmail.net; shkimynmed@hanmail.net;
   sw902@ynu.ac.kr; jicns@ynu.ac.kr
RI Jeon, Ikchan/AAZ 6368 2020; Kim, Sang Woo/NWH 1519 2025
OI Jeon, Seongmin/0000 0002 2445 3552; Kim, Sungho/0000 0002 9969 1707;
   Jeon, Ikchan/0000 0002 1293 2724; Yu, Dongwoo/0000 0003 2100 5452; 
FU Chunma Medical Research Foundation, Korea
FX This work was supported by a grant from the Chunma Medical Research
   Foundation, Korea, 2022.
CR Adami S, 2012, J BONE JOINT SURG AM, V94A, P2113, DOI 10.2106/JBJS.K.00774
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Camacho PM, 2016, ENDOCR PRACT, V22, P1111, DOI 10.4158/EP161435.ESGL
   Chiowchanwisawakit P, 2011, ARTHRITIS RHEUM US, V63, P2215, DOI 10.1002/art.30393
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dohke T, 2018, J BONE MINER METAB, V36, P499, DOI 10.1007/s00774 017 0865 0
   Fairbank J C, 1980, Physiotherapy, V66, P271
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632 200011150 00017
   Friedl G, 2007, J ORTHOP RES, V25, P1454, DOI 10.1002/jor.20433
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Goldhahn J, 2012, CALCIFIED TISSUE INT, V90, P343, DOI 10.1007/s00223 012 9587 4
   Hamano H, 2016, CALCIFIED TISSUE INT, V98, P140, DOI 10.1007/s00223 015 0068 4
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Iwata A, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1509 1
   Kim JW, 2018, J KOREAN NEUROSURG S, V61, P494, DOI 10.3340/jkns.2017.0216
   Kitaguchi K, 2019, ASIAN SPINE J, V13, P763, DOI 10.31616/asj.2018.0311
   Liu Y, 2018, OSTEOPOROSIS INT, V29, P1009, DOI 10.1007/s00198 018 4507 8
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Min HK, 2019, OSTEOPOROSIS INT, V30, P2249, DOI 10.1007/s00198 019 05125 0
   Moen MD, 2011, DRUG AGING, V28, P63, DOI 10.2165/11203300 000000000 00000
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Park HJ, 2016, ACTA RADIOL, V57, P74, DOI 10.1177/0284185115580487
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632 200012150 00006
   Ross PD, 1995, INT J EPIDEMIOL, V24, P1171, DOI 10.1093/ije/24.6.1171
   Schett G, 2007, ANN RHEUM DIS, V66, P709, DOI 10.1136/ard.2007.071159
   Sugimoto T, 2020, J BONE MINER METAB, V38, P848, DOI 10.1007/s00774 020 01119 9
   Tsuchie H, 2016, J BONE MINER METAB, V34, P86, DOI 10.1007/s00774 014 0646 y
   Tsujio T, 2011, SPINE, V36, P1229, DOI 10.1097/BRS.0b013e3181f29e8d
   Umekawa M, 2019, NEUROSPINE, V16, P780, DOI 10.14245/ns.1938184.092
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Yamamoto T, 2013, J BONE MINER METAB, V31, P199, DOI 10.1007/s00774 012 0403 z
   Yu D, 2020, J KOREAN NEUROSURG S, V63, P794, DOI 10.3340/jkns.2020.0110
   Zhao Z, 2019, CLIN RHEUMATOL, V38, P465, DOI 10.1007/s10067 018 4284 y
NR 36
TC 2
Z9 3
U1 2
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2024
VL 35
IS 5
BP 795
EP 804
DI 10.1007/s00198 024 07025 4
EA JAN 2024
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OF1V9
UT WOS:001147503100001
PM 38261013
DA 2025 08 17
ER

PT J
AU Havens, PL
   Kiser, JJ
   Stephensen, CB
   Hazra, R
   Flynn, PM
   Wilson, CM
   Rutledge, B
   Bethel, J
   Pan, CG
   Woodhouse, LR
   Van Loan, MD
   Liu, N
   Lujan Zilbermann, J
   Baker, A
   Kapogiannis, BG
   Gordon, CM
   Mulligan, K
AF Havens, Peter L.
   Kiser, Jennifer J.
   Stephensen, Charles B.
   Hazra, Rohan
   Flynn, Patricia M.
   Wilson, Craig M.
   Rutledge, Brandy
   Bethel, James
   Pan, Cynthia G.
   Woodhouse, Leslie R.
   Van Loan, Marta D.
   Liu, Nancy
   Lujan Zilbermann, Jorge
   Baker, Alyne
   Kapogiannis, Bill G.
   Gordon, Catherine M.
   Mulligan, Kathleen
CA Adolescent Med Trials Network HIV
TI Association of Higher Plasma Vitamin D Binding Protein and Lower Free
   Calcitriol Levels with Tenofovir Disoproxil Fumarate Use and Plasma and
   Intracellular Tenofovir Pharmacokinetics: Cause of a Functional Vitamin
   D Deficiency?
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV INFECTED PATIENTS; OPTIMIZED BACKGROUND REGIMEN;
   PARATHYROID HORMONE; ANTIRETROVIRAL THERAPY; TUBULAR DYSFUNCTION;
   ALKALINE PHOSPHATASE; SALVAGE THERAPY; RENAL FAILURE; CALCIUM; ADULTS
AB Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study of HIV infected youth on stable treatment with regimens containing TDF (n = 118) or lacking TDF (n = 85), we measured cross sectional associations of TDF use with markers of renal function, vitamin D calcium parathyroid hormone balance, phosphate metabolism (tubular reabsorption of phosphate and fibroblast growth factor 23 [FGF23]), and bone turnover. Pharmacokinetic pharmacodynamic associations with plasma tenofovir and intracellular tenofovir diphosphate concentrations were explored among those receiving TDF. The mean age was 20.9 (standard deviation [SD], 2.0) years; 63% were male; and 52% were African American. Compared to the no TDF group, the TDF group showed lower mean estimated glomerular filtration rates and tubular reabsorption of phosphate, as well as higher parathyroid hormone and 1,25 dihydroxy vitamin D[1,25 OH(2) D] levels. The highest quintile of plasma tenofovir concentrations was associated with higher vitamin D binding protein, lower free 1,25 OH(2) D, higher 25 OH vitamin D, and higher serum calcium. The highest quintile of intracellular tenofovir diphosphate concentration was associated with lower FGF23. Higher plasma tenofovir concentrations were associated with higher vitamin D binding protein and lower free 1,25 OH(2) D, suggesting a functional vitamin D deficiency explaining TDF associated increased parathyroid hormone. The finding of lower FGF23 accompanying higher intracellular tenofovir diphosphate suggests that different mechanisms mediate TDF associated changes in phosphate handling. Separate pharmacokinetic properties may be associated with distinct TDF toxicities: tenofovir with parathyroid hormone and altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23 regulation.
C1 [Havens, Peter L.; Pan, Cynthia G.] Med Coll Wisconsin, Childrens Hosp Wisconsin, Childrens Res Inst, Milwaukee, WI 53226 USA.
   [Kiser, Jennifer J.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO USA.
   [Stephensen, Charles B.; Woodhouse, Leslie R.; Van Loan, Marta D.] USDA ARS, Western Human Nutr Res Ctr, Davis, CA USA.
   [Hazra, Rohan; Kapogiannis, Bill G.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
   [Flynn, Patricia M.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
   [Wilson, Craig M.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Rutledge, Brandy; Bethel, James; Liu, Nancy] WESTAT Corp, Rockville, MD 20850 USA.
   [Lujan Zilbermann, Jorge] Univ S Florida, Coll Med, Tampa, FL USA.
   [Baker, Alyne] Tulane Univ, New Orleans, LA 70118 USA.
   [Gordon, Catherine M.] Hasbro Childrens Hosp, Providence, RI USA.
   [Gordon, Catherine M.] Brown Univ, Providence, RI 02912 USA.
   [Mulligan, Kathleen] Univ Calif San Francisco, San Francisco, CA 94143 USA.
C3 Medical College of Wisconsin; Children's Hospital of Wisconsin;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; United States Department of Agriculture (USDA); National
   Institutes of Health (NIH)   USA; NIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); St Jude
   Children's Research Hospital; University of Alabama System; University
   of Alabama Birmingham; Westat; State University System of Florida;
   University of South Florida; Tulane University; Hasbro Children's
   Hospital; Brown University; University of California System; University
   of California San Francisco
RP Havens, PL (通讯作者)，Med Coll Wisconsin, Childrens Hosp Wisconsin, Childrens Res Inst, Milwaukee, WI 53226 USA.
EM phavens@mcw.edu; kathleen.mulligan@ucsf.edu
RI Flynn, Patricia/N 8146 2018; Stephensen, Charles/AAF 1742 2021; Havens,
   Patrick/MAI 4858 2025; Gordon, Catherine/GOH 1814 2022
OI Wilson, Craig/0000 0001 6869 1053
FU General Clinical Research Center Program of the National Center for
   Research Resources; National Institutes of Health; Department of Health
   and Human Services; Children's National Medical Center [M01RR020359];
   University of Pennsylvania/Children's Hospital of Philadelphia
   [NCRRUL1 RR 024134]; University of California at San Francisco
   [UL1 RR024131]; Seattle Children's Hospital [UL1 RR025014]; Texas
   Children's Hospital and Baylor College of Medicine [M01 RR00188]; Boston
   University Medical Center [UL1 RR02517]; SUNY Stony Brook [M01 RR10710];
   Louisiana Board of Regents RC/EEP [RC/EEP 06]; Adolescent Trials Network
   for HIV/AIDS Interventions (ATN) from the National Institutes of Health
   through the Eunice Kennedy Shriver National Institute of Child Health
   and Human Development [U01HD 040533, U01 HD 040474]; National Institutes
   on Drug Abuse; Mental Health; National Institute of Allergy and
   Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (NICHD); National Institute of
   Mental Health (NIMH) [U01 A1068632]
FX Eight of these sites utilized their General Clinical Research Center
   (GCRC)/Pediatric Clinical Research Center (PCRC) for the study; the
   centers were supported by grants from the General Clinical Research
   Center Program of the National Center for Research Resources, National
   Institutes of Health, and Department of Health and Human Services under
   the following grant numbers: Children's National Medical Center,
   M01RR020359; University of Pennsylvania/Children's Hospital of
   Philadelphia, NCRRUL1 RR 024134; University of California at San
   Francisco, UL1 RR024131; Seattle Children's Hospital, UL1 RR025014;
   Texas Children's Hospital and Baylor College of Medicine, M01 RR00188;
   Boston University Medical Center, UL1 RR02517; and SUNY Stony Brook,
   M01 RR10710. The Tulane University Health Sciences Center utilized its
   Clinical and Translational Research Center (CTRC) for the study; the
   center was supported in whole or in part by funds provided through the
   Louisiana Board of Regents RC/EEP (RC/EEP 06).This work was supported by
   the Adolescent Trials Network for HIV/AIDS Interventions (ATN) from the
   National Institutes of Health (U01HD 040533 and U01 HD 040474] through
   the Eunice Kennedy Shriver National Institute of Child Health and Human
   Development [B. Kapogiannis]), with supplemental funding from the
   National Institutes on Drug Abuse (N. Borek) and Mental Health (P.
   Brouwers and S. Allison). The protocol was coendorsed by the
   International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
   Support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD), and
   the National Institute of Mental Health (NIMH) (U01 A1068632). The study
   was scientifically reviewed by the ATN's Therapeutic Leadership Group.
   Network, scientific, and logistical support was provided by the ATN
   Coordinating Center (C. Wilson and C. Partlow) at The University of
   Alabama at Birmingham. Network operations and analytic support was
   provided by the ATN Data and Operations Center at Westat, Inc. (J.
   Korelitz and B. Driver).
CR [Anonymous], 2011, I MED US COMM REV DI
   Bech A, 2012, HIV MED, V13, P558, DOI 10.1111/j.1468 1293.2012.01015.x
   Bech A, 2012, HIV CLIN TRIALS, V13, P350, DOI 10.1310/hct1306 350
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   BIKLE DD, 1985, J CLIN ENDOCR METAB, V61, P969, DOI 10.1210/jcem 61 5 969
   Buchacz K, 2006, HIV MED, V7, P451, DOI 10.1111/j.1468 1293.2006.00407.x
   Childs KE, 2010, AIDS RES HUM RETROV, V26, P855, DOI 10.1089/aid.2009.0308
   Coca S, 2002, AM J MED SCI, V324, P342, DOI 10.1097/00000441 200212000 00011
   Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681
   CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716
   Delahunty T, 2006, J CHROMATOGR B, V830, P6, DOI 10.1016/j.jchromb.2005.10.015
   Essig M, 2007, JAIDS J ACQ IMM DEF, V46, P256, DOI 10.1097/QAI.0b013e3181142f31
   Fernandez Fernandez B, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/354908
   Fux CA, 2007, AIDS, V21, P1483, DOI 10.1097/QAD.0b013e328216f15b
   Fux CA, 2008, ANTIVIR THER, V13, P1077
   Gafni RI, 2006, PEDIATRICS, V118, pE711, DOI 10.1542/peds.2005 2525
   Gallant JE, 2004, JAMA J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gupta SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045716
   Havens PL, 2012, J CLIN ENDOCR METAB, V97, P4004, DOI 10.1210/jc.2012 2600
   Havens PL, 2012, CLIN INFECT DIS, V54, P1013, DOI 10.1093/cid/cir968
   Hazra R, 2005, PEDIATRICS, V116, pE846, DOI 10.1542/peds.2005 0975
   Judd A, 2010, AIDS, V24, P525, DOI 10.1097/QAD.0b013e3283333680
   Kinai E, 2005, AIDS, V19, P2031, DOI 10.1097/01.aids.0000194130.05264.83
   Kinai E, 2009, AIDS RES HUM RETROV, V25, P387, DOI 10.1089/aid.2008.0202
   King T, 2006, J CHROMATOGR B, V843, P147, DOI 10.1016/j.jchromb.2006.05.043
   Kiser JJ, 2008, ANTIMICROB AGENTS CH, V52, P631, DOI 10.1128/AAC.00761 07
   Labarga P, 2009, AIDS, V23, P689, DOI 10.1097/QAD.0b013e3283262a64
   Laing CJ, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P117
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898 1906.2005
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   Maggi P, 2012, AIDS PATIENT CARE ST, V26, P5, DOI 10.1089/apc.2011.0185
   Marks KH, 1996, PEDIATR NEPHROL, V10, P364
   Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011
   Martin A, 2009, CLIN INFECT DIS, V49, P1591, DOI 10.1086/644769
   Masiá M, 2012, AIDS RES HUM RETROV, V28, P242, DOI [10.1089/aid.2011.0052, 10.1089/AID.2011.0052]
   Nelson MR, 2007, AIDS, V21, P1273, DOI 10.1097/QAD.0b013e3280b07b33
   Pattanaungkul S, 2000, J CLIN ENDOCR METAB, V85, P4023, DOI 10.1210/jc.85.11.4023
   Peacock M, 2002, J BONE MINER RES, V17, pN87
   Poizot Martin I, 2012, J ACQ IMMUN DEF SYND, DOI 10.1097/QAI.0b013e31827ce4ee
   Rodríguez Nóvoa S, 2009, CLIN INFECT DIS, V48, pE108, DOI 10.1086/598507
   Rosenvinge MM, 2010, JAIDS J ACQ IMM DEF, V54, P496, DOI 10.1097/QAI.0b013e3181caebaa
   Saidenberg Kermanac'h N, 2011, JOINT BONE SPINE, V78, P306, DOI 10.1016/j.jbspin.2010.11.007
   Speeckaert M, 2006, CLIN CHIM ACTA, V372, P33, DOI 10.1016/j.cca.2006.03.011
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   STJOHN A, 1992, NEPHRON, V61, P422
   Uzum AK, 2010, EUR J ENDOCRINOL, V163, P825, DOI 10.1530/EJE 10 0591
   Vervloet MG, 2011, CLIN J AM SOC NEPHRO, V6, P383, DOI 10.2215/CJN.04730510
   Woodward CLN, 2009, HIV MED, V10, P482, DOI 10.1111/j.1468 1293.2009.00716.x
   Zolopa A, 2013, 20 C RETR OPP INF
NR 50
TC 52
Z9 53
U1 0
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0066 4804
EI 1098 6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2013
VL 57
IS 11
BP 5619
EP 5628
DI 10.1128/AAC.01096 13
PG 10
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA 235ZY
UT WOS:000325764000054
PM 24002093
OA Green Published
DA 2025 08 17
ER

PT J
AU Nanjundaiah, SM
   Venkatesha, SH
   Yu, H
   Tong, L
   Stains, JP
   Moudgil, KD
AF Nanjundaiah, Siddaraju M.
   Venkatesha, Shivaprasad H.
   Yu, Hua
   Tong, Li
   Stains, Joseph P.
   Moudgil, Kamal D.
TI Celastrus and Its Bioactive Celastrol Protect against Bone Damage in
   Autoimmune Arthritis by Modulating Osteoimmune Cross talk
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; SYNOVIAL T CELLS; RHEUMATOID ARTHRITIS;
   OSTEOCLAST FORMATION; IN VITRO; TEA POLYPHENOLS; SUPPRESSES;
   DESTRUCTION; RESORPTION; INFLIXIMAB
AB Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by bone erosion and cartilage destruction in the joints. Many of the conventional antiarthritic drugs are effective in suppressing inflammation, but they do not offer protection against bone damage. Furthermore, the prolonged use of these drugs is associated with severe adverse reactions. Thus, new therapeutic agents that can control both inflammation and bone damage but with minimal side effects are sought. Celastrus is a Chinese herb that has been used for centuries in folk medicine for the treatment of various inflammatory diseases. However, its utility for protection against inflammation induced bone damage in arthritis and the mechanisms involved therein have not been examined. We tested celastrus and its bioactive component celastrol for this attribute in the adjuvant induced arthritis model of RA. The treatment of arthritic rats with celastrus/celastrol suppressed inflammatory arthritis and reduced bone and cartilage damage in the joints as demonstrated by histology and bone histomorphometry. The protective effects against bone damage are mediated primarily via the inhibition of defined mediators of osteoclastic bone remodeling (e. g. receptor activator of nuclear factor kappa B ligand (RANKL)), the deviation of RANKL/osteoprotegerin ratio in favor of antiosteoclastic activity, and the reduction in osteoclast numbers. Furthermore, both theupstreaminducers(proinflammatory cytokines) and the down stream effectors (MMP 9) of the osteoclastogenic mediators were altered. Thus, celastrus and celastrol controlled inflammation induced bone damage by modulating the osteoimmune cross talk. These natural products deserve further consideration and evaluation as adjuncts to conventional therapy for RA.
C1 [Nanjundaiah, Siddaraju M.; Venkatesha, Shivaprasad H.; Yu, Hua; Moudgil, Kamal D.] Univ Maryland, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA.
   [Moudgil, Kamal D.] Univ Maryland, Dept Med, Sch Med, Div Rheumatol, Baltimore, MD 21201 USA.
   [Stains, Joseph P.] Univ Maryland, Dept Orthopaed, Sch Med, Baltimore, MD 21201 USA.
   [Tong, Li] So Med Univ, Sch Tradit Chinese Med, Guangzhou 510510, Guangdong, Peoples R China.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   Southern Medical University   China
RP Moudgil, KD (通讯作者)，Univ Maryland, Dept Microbiol & Immunol, Sch Med, 685 W Baltimore St,HSF 1,Suite 380, Baltimore, MD 21201 USA.
EM kmoud001@umaryland.edu
RI yu, hua/F 8948 2012; Venkatesha, Shivaprasad/S 3141 2016
FU National Institutes of Health [R01AT004321]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01AT004321.
CR Ahmed S, 2008, P NATL ACAD SCI USA, V105, P14692, DOI 10.1073/pnas.0802675105
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Astry B, 2011, J INTERF CYTOK RES, V31, P927, DOI 10.1089/jir.2011.0094
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chung DJ, 2006, J CELL SCI, V119, P4187, DOI 10.1242/jcs.03162
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dai SM, 2004, ANN RHEUM DIS, V63, P1379, DOI 10.1136/ard.2003.018481
   Fonseca JE, 2009, CLIN RHEUMATOL, V28, P1213, DOI 10.1007/s10067 009 1207 y
   FRANCK H, 1994, J RHEUMATOL, V21, P1256
   Franco GCN, 2011, EXP CELL RES, V317, P1454, DOI 10.1016/j.yexcr.2011.03.014
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Gorman CL, 2008, BEST PRACT RES CL RH, V22, P221, DOI 10.1016/j.berh.2008.01.003
   Grassi F, 2004, J CELL PHYSIOL, V199, P244, DOI 10.1002/jcp.10445
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hahn B, 2004, JCR J CLIN RHEUMATOL, V10, pS3, DOI 10.1097/01.rhu.0000130683.61892.b2
   HILL PA, 1995, ENDOCRINOLOGY, V136, P124, DOI 10.1210/en.136.1.124
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535 7163.MCT 09 0133
   Jones D, 2011, J CLIN INVEST, V121, P2534, DOI 10.1172/JCI46262
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   Kannaiyan R, 2011, APOPTOSIS, V16, P1028, DOI 10.1007/s10495 011 0629 6
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim DH, 2009, EUR J CLIN INVEST, V39, P819, DOI 10.1111/j.1365 2362.2009.02186.x
   Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351
   Kim WK, 2011, J CELL BIOCHEM, V112, P3159, DOI 10.1002/jcb.23242
   Kim Y, 2011, CELL PHYSIOL BIOCHEM, V28, P175, DOI 10.1159/000331729
   Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018
   Komeh Nkrumah SA, 2012, PHYTOTHER RES, V26, P54, DOI 10.1002/ptr.3509
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kremers HM, 2004, J RHEUMATOL, V31, P2366
   Li YW, 2006, CANCER RES, V66, P4816, DOI 10.1158/0008 5472.CAN 05 3752
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Lipsky PE., 2008, HARRISONS PRINCIPLE, V17th, P2083
   Liu Z, 2011, MOLECULES, V16, P5283, DOI 10.3390/molecules16065283
   Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739
   Maruotti N, 2011, CLIN EXP MED, V11, P137, DOI 10.1007/s10238 010 0117 2
   Mou HB, 2011, TOXICOL IN VITRO, V25, P1027, DOI 10.1016/j.tiv.2011.03.023
   Ohshima S, 2002, ARTHRITIS RHEUM, V46, P1094, DOI 10.1002/art.10143
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rajaiah R, 2011, J BIOL CHEM, V286, P2817, DOI 10.1074/jbc.M110.187013
   Schett G, 2006, WIEN MED WOCHENSCHR, V156, P34, DOI 10.1007/s10354 005 0244 7
   Sellers RS, 1997, J BONE JOINT SURG AM, V79A, P1452, DOI 10.2106/00004623 199710000 00002
   Shahrara S, 2005, ARTHRITIS RHEUM, V52, P1907, DOI 10.1002/art.21033
   Shen CL, 2010, OSTEOPOROSIS INT, V21, P1841, DOI 10.1007/s00198 009 1122 8
   Shen CL, 2011, J NUTR BIOCHEM, V22, P673, DOI 10.1016/j.jnutbio.2010.05.007
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202
   Strand V, 2004, RHEUMATOLOGY, V43, P10, DOI 10.1093/rheumatology/keh202
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tong L, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2268
   Tozawa K, 2011, INT J ONCOL, V39, P1117, DOI 10.3892/ijo.2011.1161
   Venkatesha SH, 2011, J BIOL CHEM, V286, P15138, DOI 10.1074/jbc.M111.226365
   Wu SH, 2004, J CHROMATOGR A, V1028, P171, DOI 10.1016/j.chroma.2003.11.072
   Xu S., 2011, RHEUMATOL I IN PRESS
   Yadav VR, 2010, TOXINS, V2, P2428, DOI 10.3390/toxins2102428
   Yang YH, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/642027
   Yu H, 2011, ARTHRITIS RHEUM US, V63, P981, DOI 10.1002/art.30219
   Zhang F, 2010, CONNECT TISSUE RES, V51, P359, DOI 10.3109/03008200903456942
   Zhao BH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3379
NR 63
TC 82
Z9 88
U1 0
U2 27
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 22
PY 2012
VL 287
IS 26
BP 22216
EP 22226
DI 10.1074/jbc.M112.356816
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 974GH
UT WOS:000306418600060
PM 22549786
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Rivadeneira, J
   Barrio, DA
   Arrambide, G
   Gambino, D
   Bruzzone, L
   Etcheverry, SB
AF Rivadeneira, Josefina
   Barrio, Daniel A.
   Arrambide, Gabriel
   Gambino, Dinorah
   Bruzzone, Liliana
   Etcheverry, Susana B.
TI Biological effects of a complex of vanadium(V) with salicylaldehyde
   semicarbazone in osteoblasts in culture: Mechanism of action
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article; Proceedings Paper
CT 6th International Vanadium Symposium
CY JUL 17 19, 2008
CL Calouste Gulbenkian Fdn, Lisbon, PORTUGAL
HO Calouste Gulbenkian Fdn
DE Vanadium; Semicarbazones; Osteoblasts; Cytotoxicity; Oxidative stress;
   Actin fibers
ID INDUCED CELL DEATH; HYDROGEN PEROXIDE; OXIDATIVE STRESS; MORPHOLOGICAL
   TRANSFORMATION; VANADYL(IV) COMPLEXES; ANTILEUKEMIC AGENT;
   ANTITUMOR ACTIVITY; N ACETYLCYSTEINE; GROWTH FACTOR; VANADATE
AB Vanadium compounds display important pharmacological actions in vivo and in vitro systems. Semicarbazones are versatile ligands with therapeutic effects. Herein, we report the effects of (VO2) O V(salicylalde hydesemicarbazone) (V(V) Salsem) on two osteoblast cell lines in culture (MC3T3 E1 and UMR106). V(V) Salsem inhibited cell proliferation in a dose response manner. At 100 mu M, the complex caused an inhibition of ca. 48% and 38% for the normal and the tumoral osteoblasts, respectively (p < 0.001). This inhibition Could be partially reversed to 35% and 28% by NAC (N acetylcysteine) and a mixture of vitamins E and C. Changes in cell proliferation correlated with morphological alterations and the disruption of actin cytoskeleton fibers. The complex also enhanced the level of ROS (reactive oxygen species) up to ca. 100% over basal in both cell lines. Activation of ERK signalling cascade was also observed. These events led to apoptosis (up to 44% in MC3T3 E1 and 33% in UMR106 cells). Scavengers of ROS and inhibitors of ERK cascade allowed to elucidate the mechanisms involved in the cytotoxicity. In conclusion, V(V) Salsem displayed cytotoxic effects oil osteoblasts ill culture through the production of free radicals and the activation of ERK cascade. These mechanisms triggered the apoptotic events that conveyed to cell death. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Rivadeneira, Josefina; Barrio, Daniel A.; Etcheverry, Susana B.] UNLP, Fac Ciencias Exactas, Catedra Biquim Patol, RA 1900 La Plata, Argentina.
   [Rivadeneira, Josefina; Etcheverry, Susana B.] UNLP, Fac Ciencias Exactas, CEQUINOR, CONICET, La Plata, Buenos Aires, Argentina.
   [Arrambide, Gabriel; Gambino, Dinorah] Univ Republica, Fac Quim, Montevideo, Uruguay.
   [Bruzzone, Liliana] UNLP, Fac Ciencias Exactas, Dept Quim, RA 1900 La Plata, Argentina.
C3 National University of La Plata; National University of La Plata;
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   Universidad de la Republica, Uruguay; National University of La Plata
RP Etcheverry, SB (通讯作者)，UNLP, Fac Ciencias Exactas, Catedra Biquim Patol, RA 1900 La Plata, Argentina.
EM etcheverry@biol.unlp.edu.ar
RI Barrio, Daniel/AAG 6938 2019; Gambino, Dinorah/AFL 6104 2022
OI Bruzzone, Liliana/0000 0001 7960 0145; Gambino,
   Dinorah/0000 0001 8678 7374
CR ANKE M, 1989, 6TH INTERNATIONAL TRACE ELEMENT SYMP 1989, VOLS 1 5, P17
   [Anonymous], J CELL BIOCH F
   ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891 5849(89)90066 X
   Baigi MG, 2008, TOXICOL IN VITRO, V22, P1547, DOI 10.1016/j.tiv.2008.06.008
   Barrio DA, 2003, J BIOL INORG CHEM, V8, P459, DOI 10.1007/s00775 002 0438 z
   Barrio DA, 2006, CAN J PHYSIOL PHARM, V84, P765, DOI 10.1139/Y06 021
   Beraldo H, 2004, MINI REV MED CHEM, V4, P31, DOI 10.2174/1389557043487484
   Blázquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00 0122com
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Caicedo M., 2008, J BIOMED MAT RES A, V86
   Capella LS, 2002, ARCH BIOCHEM BIOPHYS, V406, P65, DOI 10.1016/S0003 9861(02)00408 3
   Capella MAM, 2007, CELL BIOL TOXICOL, V23, P413, DOI 10.1007/s10565 007 9003 4
   Chae HJ, 2000, IMMUNOPHARM IMMUNOT, V22, P317, DOI 10.3109/08923970009016423
   Chien PS, 2006, BIOCHEM BIOPH RES CO, V339, P562, DOI 10.1016/j.bbrc.2005.11.045
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300 483X(00)00181 5
   Cortizo AM, 1997, BIOMETALS, V10, P127, DOI 10.1023/A:1018335324447
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   CORTIZO AM, 2000, METAL IONS BIOL MED, V6, P714
   Cortizo AM, 2006, INT J BIOCHEM CELL B, V38, P1171, DOI 10.1016/j.biocel.2005.12.007
   DJORDJEVIC C, 1995, MET IONS BIOL SYST, V31, P595
   Domingo JL, 1996, REPROD TOXICOL, V10, P175, DOI 10.1016/0890 6238(96)00019 6
   DONOFRIO F, 1994, FEBS LETT, V340, P269, DOI 10.1016/0014 5793(94)80152 5
   EMMENDORFFER A, 1990, J IMMUNOL METHODS, V131, P269, DOI 10.1016/0022 1759(90)90198 5
   ERCHEVERRY SB, 1997, ARCH BIOCHEM BIOPHYS, V338, P7
   Etcheverry SB, 1997, ARCH BIOCHEM BIOPHYS, V338, P7, DOI 10.1006/abbi.1996.9778
   ETCHEVERRY SB, 2008, BIOL INORG CHEM, V13, P345
   Etcheverry SB, 2007, BIOORGAN MED CHEM, V15, P6418, DOI 10.1016/j.bmc.2007.06.056
   Etcheverry SB, 2007, ACS SYM SER, V974, P204
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   Ferrer EG, 2006, J BIOL INORG CHEM, V11, P791, DOI 10.1007/s00775 006 0122 9
   FLANAGAN RJ, 1991, AM J MED, V91, pS131, DOI 10.1016/0002 9343(91)90296 A
   Giovannini C, 2008, J NUTR BIOCHEM, V19, P118, DOI 10.1016/j.jnutbio.2007.01.010
   Gresser M.J., 1990, Vanadium in Biological Systems, P63
   Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200
   Huang CS, 2001, J BIOL CHEM, V276, P22397, DOI 10.1074/jbc.M010828200
   ISSELS RD, 1988, BIOCHEM PHARMACOL, V37, P881, DOI 10.1016/0006 2952(88)90176 1
   Ivancsits S, 2002, MUTAT RES GEN TOX EN, V519, P25, DOI 10.1016/S1383 5718(02)00138 9
   KOTHE G, 1991, J IMMUNOL METHODS, V138, P133
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lu Y, 2007, FREE RADICAL BIO MED, V43, P1061, DOI 10.1016/j.freeradbiomed.2007.06.021
   Luber B, 2000, CELL ADHES COMMUN, V7, P391, DOI 10.3109/15419060009109021
   Mohamadin AM, 2007, BASIC CLIN PHARMACOL, V100, P84, DOI 10.1111/j.1742 7843.2006.00003.x
   Molinuevo MS, 2004, CANCER CHEMOTH PHARM, V53, P163, DOI 10.1007/s00280 003 0708 7
   Narla RK, 2001, CLIN CANCER RES, V7, P1094
   Narla RK, 2001, LEUKEMIA LYMPHOMA, V41, P625, DOI 10.3109/10428190109060353
   Naziroglu M, 2008, J NEUROL SCI, V270, P152, DOI 10.1016/j.jns.2008.03.003
   NIELSEN FH, 1995, MET IONS BIOL SYST, V31, P543
   Noblía P, 2005, J INORG BIOCHEM, V99, P443, DOI 10.1016/j.jinorgbio.2004.10.019
   Noblía P, 2004, EUR J INORG CHEM, P322, DOI 10.1022/ejic.200300421
   OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201
   Osinska Królicka I, 2004, J INORG BIOCHEM, V98, P2087, DOI 10.1016/j.jinorgbio.2004.09.013
   Pandey SK, 1999, BIOCHEMISTRY US, V38, P14667, DOI 10.1021/bi9911886
   Parcell Stephen, 2002, Altern Med Rev, V7, P22
   Park JH, 2008, ONCOL REP, V20, P379, DOI 10.3892/or_00000018
   Perrone GG, 2008, BBA MOL CELL RES, V1783, P1354, DOI 10.1016/j.bbamcr.2008.01.023
   Qin Y, 2008, CELL BIOL INT, V32, P224, DOI 10.1016/j.cellbi.2007.08.028
   Reed DJ., 1984, PHARMACOL REV, V36, P25
   Rivadeneira J, 2007, BIOL TRACE ELEM RES, V118, P159, DOI 10.1007/s12011 007 0025 9
   SABBIONI E, 1993, CARCINOGENESIS, V14, P2565, DOI 10.1093/carcin/14.12.2565
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Sálice VC, 1999, MOL CELL BIOCHEM, V198, P119, DOI 10.1023/A:1006997830346
   SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1
   SILVESTRI F, 1995, ANN ITAL MED INT, V10
   STOSSEL TP, 1989, J BIOL CHEM, V264, P18261
   Szucs S, 1998, CYTOMETRY, V33, P19, DOI 10.1002/(SICI)1097 0320(19980901)33:1<19::AID CYTO3>3.0.CO;2 6
   Thompson KH, 1999, CHEM REV, V99, P2561, DOI 10.1021/cr980427c
   Torres M, 2002, ANN NY ACAD SCI, V973, P345, DOI 10.1111/j.1749 6632.2002.tb04663.x
   Upreti RK, 1995, MOL CELL BIOCHEM, V153, P167, DOI 10.1007/BF01075934
   vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097 0320(19960601)24:2<131::AID CYTO5>3.0.CO;2 M
   Wang YZ, 2000, AM J RESP CELL MOL, V22, P590, DOI 10.1165/ajrcmb.22.5.3882
   Yang XG, 2004, PHARM RES DORDR, V21, P1026, DOI 10.1023/B:PHAM.0000029293.89113.d5
   YE J, 1997, MOL CELL BIOCHEM, V202, P9
   Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585
   YIN XF, 1992, MOL CELL BIOCHEM, V115, P85
   Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464
NR 75
TC 57
Z9 58
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162 0134
EI 1873 3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD APR
PY 2009
VL 103
IS 4
SI SI
BP 633
EP 642
DI 10.1016/j.jinorgbio.2008.11.009
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Chemistry
GA 429EU
UT WOS:000264904400021
PM 19117608
OA Green Published
DA 2025 08 17
ER

PT J
AU Eckert, D
   Rapp, F
   Tsedeke, AT
   Kraft, D
   Wente, I
   Molendowska, J
   Basheer, S
   Langhans, M
   Meckel, T
   Friedrich, T
   Donaubauer, AJ
   Becker, I
   Frey, B
   Fournier, C
AF Eckert, Denise
   Rapp, Felicitas
   Tsedeke, Ayele Taddese
   Kraft, Daniela
   Wente, Isabell
   Molendowska, Jessica
   Basheer, Sidra
   Langhans, Markus
   Meckel, Tobias
   Friedrich, Thomas
   Donaubauer, Anna Jasmina
   Becker, Ina
   Frey, Benjamin
   Fournier, Claudia
TI Modulation of Differentiation and Bone Resorbing Activity of Human
   (Pre ) Osteoclasts After X Ray Exposure
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE osteoclastogenesis; inflammation; musculo  skeletal disorders; low dose
   radiotherapy; x ray; NFATc 1; chronic degenerative and inflammatory
   diseases
ID IMMUNE SYSTEM; RHEUMATOID ARTHRITIS; IONIZING RADIATION; PROGENITOR
   CELLS; CANCER TREATMENT; IRRADIATION; THERAPY; MECHANISMS; DISEASES
AB Low dose radiotherapy (LD RT) is a local treatment option for patients with chronic degenerative and inflammatory diseases, in particular musculoskeletal diseases. Despite reported analgesic and anti inflammatory effects, cellular and molecular mechanisms related to osteoimmunological effects are still elusive. Here we test the hypothesis that X irradiation inhibits the differentiation of precursor osteoclasts into mature osteoclasts (mOC) and their bone resorbing activity. Circulating monocytes from healthy donors were isolated and irradiated after attachment with single or fractionated X ray doses, comparable to an LD RT treatment scheme. Then monocytes underwent ex vivo differentiation into OC during cultivation up to 21 days, under conditions mimicking the physiological microenvironment of OC on bone. After irradiation, apoptotic frequencies were low, but the total number of OC precursors and mOC decreased up to the end of the cultivation period. On top, we observed an impairment of terminal differentiation, i.e. a smaller fraction of mOC, reduced resorbing activity on bone, and release of collagen fragments. We further analyzed the effect of X irradiation on multinucleation, resulting from the fusion of precursor OC, which occurs late during OC differentiation. At 21 days after exposure, the observation of smaller cellular areas and a reduced number of nuclei per mOC suggest an impaired fusion of OC precursors to form mOC. Before, at 14 days, the nuclear translocation of Nuclear Factor Of Activated T Cells 1 (NFATc1), a master regulator of osteoclast differentiation and fusion, was decreased. In first results, obtained in the frame of a longitudinal LD RT study, we previously reported a pain relieving effect in patients. However, in a subgroup of patients suffering from Calcaneodynia or Achillodynia, we did not observe a consistent decrease of established blood markers for resorption and formation of bone, or modified T cell subtypes involved in regulating these processes. To assess the relevance of changes in bone metabolism for other diseases treated with LD RT will be subject of further studies. Taken together, we observed that in vitro X irradiation of monocytes results in an inhibition of the differentiation into bone resorbing OC and a concomitant reduction of resorbing activity. The detected reduced NFATc1 signaling could be one underlying mechanism.
C1 [Eckert, Denise; Rapp, Felicitas; Tsedeke, Ayele Taddese; Kraft, Daniela; Wente, Isabell; Molendowska, Jessica; Basheer, Sidra; Friedrich, Thomas; Fournier, Claudia] Gesell Schwerionenforsch GSI Helmholtzzent Schweri, Dept Biophys, Darmstadt, Germany.
   [Langhans, Markus; Meckel, Tobias] Tech Univ Darmstadt, Dept Macromol & Paper Chem & Membrane Dynam, Darmstadt, Germany.
   [Donaubauer, Anna Jasmina; Becker, Ina; Frey, Benjamin] Univ Klinikum Erlangen, Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Radiat Oncol, Translat Radiobiol, Erlangen, Germany.
   [Donaubauer, Anna Jasmina; Becker, Ina; Frey, Benjamin] Univ Klinikum Erlangen, Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Radiat Oncol, Erlangen, Germany.
   [Rapp, Felicitas] Heidelberg Univ, Med Fac Mannheim, Dept Hematol & Oncol, Mannheim, Germany.
C3 Technical University of Darmstadt; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg
RP Fournier, C (通讯作者)，Gesell Schwerionenforsch GSI Helmholtzzent Schweri, Dept Biophys, Darmstadt, Germany.
EM c.fournier@gsi.de
RI Frey, Benjamin/D 9565 2017; Friedrich, Thomas/K 6748 2013; Meckel,
   Tobias/F 4372 2010; Donaubauer, Anna Jasmina/AAM 5529 2021
OI Tsedeke, Ayele Taddese/0000 0001 7493 2511
FU Bundesministerium fuer Bildung und Forschung (BMBF) [02NUK050A,
   02NUK050E]; Department of Radiation Oncology at Universitaetsklinikum
   Erlangen
FX This work was in part funded by the Bundesministerium fuer Bildung und
   Forschung (BMBF; GREWIS alpha, 02NUK050A and 02NUK050E). The IMMO LDRT01
   trial is funded by Department of Radiation Oncology at
   Universitaetsklinikum Erlangen.
CR Becker D, 2009, INT J RADIAT BIOL, V85, P1051, DOI 10.3109/09553000903232850
   Bindu S, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114147
   Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104016
   Cucu A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00882
   Cummings Brian S, 2012, Curr Protoc Pharmacol, VChapter 12, DOI 10.1002/0471141755.ph1208s56
   D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003
   de Vries TJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00505
   Deloch L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103197
   Deloch L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01834
   Donaubauer AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740742
   Donaubauer AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165854
   Ehnert S, 2021, WORLD J STEM CELLS, V13, P1667, DOI 10.4252/wjsc.v13.i11.1667
   Falcke SE, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113574
   Fardellone P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/484280
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Frey B, 2015, CANCER LETT, V368, P230, DOI 10.1016/j.canlet.2015.04.010
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Gevorgyan A, 2007, J CRANIOFAC SURG, V18, P1001, DOI 10.1097/scs.0b013e31812f7584
   Ginaldi L, 2016, CURR MED CHEM, V23, P3754, DOI 10.2174/0929867323666160907162546
   Handforth C, 2018, CALCIFIED TISSUE INT, V102, P251, DOI 10.1007/s00223 017 0369 x
   Hildebrandt G, 2003, INT J RADIAT BIOL, V79, P993, DOI 10.1080/09553000310001636639
   Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338
   Jiang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.684007
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kirkpatrick J, 2017, J ANAT, V230, P743, DOI 10.1111/joa.12607
   Kleinhans C, 2015, J BIOTECHNOL, V205, P101, DOI 10.1016/j.jbiotec.2014.11.039
   Large M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748 717X 9 80
   Lees RL, 2001, BONE, V28, P187, DOI 10.1016/S8756 3282(00)00433 6
   Lima F, 2017, RADIAT RES, V188, P433, DOI 10.1667/RR14414.1
   Lucatto SC, 2011, ACTA CIR BRAS, V26, P475, DOI 10.1590/S0102 86502011000600012
   Ma QY, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00121 1
   Marchev AS, 2017, ANN NY ACAD SCI, V1401, P114, DOI 10.1111/nyas.13407
   Mei LW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.734774
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Nakamura H, 2014, BIOCHEM BIOPH RES CO, V455, P305, DOI 10.1016/j.bbrc.2014.11.009
   Nakatsukasa H, 2008, J RADIAT RES, V49, P381, DOI 10.1269/jrr.08002
   Oest ME, 2015, J ORTHOP RES, V33, P334, DOI 10.1002/jor.22761
   Okamoto K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3323
   Ott OJ, 2019, STRAHLENTHER ONKOL, V195, P285, DOI 10.1007/s00066 018 1412 1
   Rajpura A, 2011, HIP INT, V21, P385, DOI 10.5301/HIP.2011.8538
   RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092 8674(78)90101 0
   Rödel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358
   Rühle PF, 2017, AUTOIMMUNITY, V50, P133, DOI 10.1080/08916934.2017.1284819
   Sawajiri M, 2003, RADIAT ENVIRON BIOPH, V42, P219, DOI 10.1007/s00411 003 0204 9
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Seegenschmiedt MH, 2004, STRAHLENTHER ONKOL, V180, P718, DOI 10.1007/s00066 004 9197 9
   Simoniello P, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00294
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140 6736(14)61704 9
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vesprey Alexander, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1836
   Vlot MC, 2018, BONE, V114, P215, DOI 10.1016/j.bone.2018.06.011
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Wu XJ, 2005, J BIOL CHEM, V280, P29964, DOI 10.1074/jbc.M500710200
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zhai JL, 2019, INT J MOL MED, V44, P2265, DOI 10.3892/ijmm.2019.4369
   Zhang J, 2017, J RADIAT RES, V58, P791, DOI 10.1093/jrr/rrx026
   Zhou XZ, 2009, ARCH ORTHOP TRAUM SU, V129, P125, DOI 10.1007/s00402 008 0634 6
NR 67
TC 4
Z9 5
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 4
PY 2022
VL 13
AR 817281
DI 10.3389/fimmu.2022.817281
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 1J3PR
UT WOS:000797832300001
PM 35603191
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Schott, H
   Goltz, D
   Schott, TC
   Jauch, C
   Schwendener, RA
AF Schott, Herbert
   Goltz, Daniel
   Schott, Timm C.
   Jauch, Claudia
   Schwendener, Reto A.
TI N<SUP>4</SUP> [Alkyl (hydroxyphosphono)phosphonate] cytidine New
   drugs covalently linking antimetabolites (5 FdU, araU or AZT) with
   bone targeting bisphosphonates (alendronate or pamidronate)
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Antimetabolite BPs; Bone targeting; 2 ' Deoxy 5 fluorouridine (5 FdU);
   Azidothymidine (AZT); Arabinofuranosylcytosine (araC); Alendronate
ID ZOLEDRONIC ACID; LINKED PHOSPHONATES; IN VITRO; TRANSPLANTABLE
   OSTEOSARCOMA; ANTITUMOR ACTIVITY; DELIVERY SYSTEMS; PROSTATE CANCER;
   BREAST CANCER; AGENTS; HYDROXYAPATITE
AB Amino bisphosphonates (alendronate, pamidronate) were covalently linked in a three step synthesis, with protected and triazolylated derivatives of therapeutically used nucleoside analogs (5 FdU, araC, AZT) by substitution of their triazolyl residue. From the deprotected and chromatographically purified reaction mixtures N 4 [alkyl (hydroxyphosphono) phosphonate] cytidine combining two differently cytotoxic functions were obtained. This new family of bisphosphonates (BPs) contains as novelty an alkyl side chain with a cytotoxic nucleoside. The BPs moiety allows for a high binding to hydroxyapatite which is a prerequisite for bone targeting of the drugs. In vitro binding of 5 FdU alendronate (5 FdU ale) to hydroxyapatite showed a sixfold increased binding of these BPs as compared to 5 FdU.
   Exploratory cytotoxic properties of 5 FdU ale were tested on a panel of human tumor cell lines resulting in growth inhibition ranging between 5% and 38%. The determination of IC50 concentrations of the conjugate in Lewis lung carcinoma and murine macrophages showed an incubation time dependent growth inhibition with higher sensitivity towards the tumor cells. We assume that the antimetabolite BPs can be cleaved into different active metabolites that may exert cytotoxic and other therapeutic effects. However, the underlying mechanisms of these promising new antimetabolite BPs conjugates remain to be evaluated in future experiments. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Schott, Herbert; Goltz, Daniel] Univ Tubingen, Inst Organ Chem, D 72076 Tubingen, Germany.
   [Schott, Timm C.] Univ Tubingen Hosp, Dept Orthodont, D 72076 Tubingen, Germany.
   [Jauch, Claudia; Schwendener, Reto A.] Univ Zurich, Inst Mol Canc Res, CH 8057 Zurich, Switzerland.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; University of Zurich
RP Schott, H (通讯作者)，Univ Tubingen, Inst Organ Chem, Morgenstelle 18, D 72076 Tubingen, Germany.
EM herbert.schott@uni tuebingen.de
RI Schwendener, Reto/F 6373 2011; Schott, Timm/K 7339 2017
CR ADZAMLI IK, 1991, INVEST RADIOL, V26, P143, DOI 10.1097/00004424 199102000 00009
   ADZAMLI IK, 1993, MAGN RESON MED, V29, P505, DOI 10.1002/mrm.1910290412
   Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Budman DR, 2006, ONCOLOGY BASEL, V70, P147, DOI 10.1159/000093006
   CHEN H, 2005, W CHINA J PHARM SCI, V2, P10
   Chhikara BS, 2010, EXPERT OPIN DRUG DEL, V7, P1399, DOI 10.1517/17425247.2010.527330
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Coleman Robert, 2009, Curr Opin Support Palliat Care, V3, P213, DOI 10.1097/SPC.0b013e32832f4149
   DIVAKAR KJ, 1982, J CHEM SOC PERK T 1, P1171, DOI 10.1039/p19820001171
   Fabulet O, 1995, PHOSPHORUS SULFUR, V101, P225, DOI 10.1080/10426509508042521
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   Gao Y, 2003, SYNTHETIC COMMUN, V33, P2635, DOI 10.1081/SCC 120021984
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Kalek M, 2005, TETRAHEDRON LETT, V46, P2417, DOI 10.1016/j.tetlet.2005.02.069
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   KLENNER T, 1990, J CANCER RES CLIN, V116, P341, DOI 10.1007/BF01612916
   KLENNER T, 1990, CLIN EXP METASTAS, V8, P345, DOI 10.1007/BF01810680
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Migianu E, 2005, NUCLEOS NUCLEOT NUCL, V24, P121, DOI 10.1081/NCN 200051890
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432 1327.2000.01606.x
   Ora M, 2008, J ORG CHEM, V73, P4123, DOI 10.1021/jo800317e
   Pan HZ, 2008, MOL PHARMACEUT, V5, P548, DOI 10.1021/mp800003u
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   Reinholz MM, 2010, BONE, V47, P12, DOI 10.1016/j.bone.2010.03.006
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   SCHOTT H, 1994, LIEBIGS ANN CHEM, P465
   SCHOTT H, 1989, PREPARATIVE SCALE CH, V46, P269
   SCHOTT S, 2001, PHARM ZTG, V146, P24
   Song YC, 2008, BIOORGAN MED CHEM, V16, P8959, DOI 10.1016/j.bmc.2008.08.047
   STURTZ G, 1993, EUR J MED CHEM, V28, P899, DOI 10.1016/0223 5234(93)90043 E
   STURTZ G, 1992, EUR J MED CHEM, V27, P825, DOI 10.1016/0223 5234(92)90117 J
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   Vepsäläinen JJ, 2002, CURR MED CHEM, V9, P1201, DOI 10.2174/0929867023369998
   Vitha T, 2008, LANGMUIR, V24, P1952, DOI 10.1021/la702753j
   Vogt U, 2004, ONCOL REP, V12, P1109
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   WINGEN F, 1986, J CANCER RES CLIN, V111, P209, DOI 10.1007/BF00389236
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Winter MC, 2009, CURR OPIN ONCOL, V21, P499, DOI 10.1097/CCO.0b013e328331c794
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 52
TC 20
Z9 22
U1 0
U2 18
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUN 1
PY 2011
VL 19
IS 11
BP 3520
EP 3526
DI 10.1016/j.bmc.2011.04.015
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 768RQ
UT WOS:000290955400027
PM 21536448
DA 2025 08 17
ER

PT J
AU Liang, X
   Xue, JL
   Ge, XX
   Li, J
   Li, HP
   Xue, LQ
   Di, LJ
   Tang, WB
   Song, GH
   Li, Q
   Jiang, HF
   Zhao, W
   Lin, FJ
   Shao, B
   Yang, XG
   Wu, ZF
   Zhang, TY
   Wang, CC
   Guo, Y
AF Liang, Xu
   Xue, Junli
   Ge, Xiaoxiao
   Li, Jin
   Li, Huiping
   Xue, Liqiong
   Di, Lijun
   Tang, Wenbo
   Song, Guohong
   Li, Qun
   Jiang, Hanfang
   Zhao, Wei
   Lin, Fengjuan
   Shao, Bin
   Yang, Xiugao
   Wu, Zhufeng
   Zhang, Tianyi
   Wang, Chenchen
   Guo, Ye
TI Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in
   patients with bone metastases from solid tumors
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE bone metastasis; JMT103; RANKL; phase 1 study; pharmacokinetics;
   N telopeptide
ID GIANT CELL TUMOR; BREAST CANCER; CLINICAL FEATURES; SKELETAL
   COMPLICATIONS; LIGAND INHIBITOR; PROSTATE CANCER; DOUBLE BLIND;
   PHASE II; DENOSUMAB; PHARMACOKINETICS
AB Bone metastases are common complications of solid tumors. The outcome is poor despite major progress in cancer therapies. We describe a multicenter, open label, phase 1, dose escalation and expansion trial of JMT103, a novel fully humanized receptor activator of nuclear factor kappa B ligand (RANKL) targeting monoclonal antibody, in adults with bone metastases from solid tumors. The study assessed the safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103. Patients received JMT103 at doses of 0.5, 1.0, 2.0, and 3.0 mg/kg every 4 weeks for 3 cycles. Among 59 patients enrolled, 20 and 39 patients participated in the dose escalation and dose expansion phases, respectively. One dose limiting toxicity was observed at 2.0 mg/kg. The maximum tolerated dose was not determined. Treatment related adverse events were reported in 29 (49.2%) patients, most commonly hypophosphatemia (30.5%), hypocalcemia (23.7%), and hypermagnesemia (10.2%). No treatment related serious adverse events were reported. Two patients died due to disease progression, which were attributed to gastric cancer and lung neoplasm malignant respectively. Dose proportionality occurred between exposure levels and administered dose was within a dose range of 0.5 to 3.0 mg/kg. The suppression of urinary N telopeptide corrected for creatinine was rapid, significant, and sustained across all doses of JMT103, with the median change from baseline ranging from  61.4% to  92.2% at day 141. JMT103 was well tolerated in patients with bone metastases from solid tumors, with a manageable safety profile. Bone antiresorptive activity shows the potential of JMT103 for treatment of bone metastases from solid tumors.Registration No.: NCT03550508; URL: https://www.clinicaltrials.gov/
C1 [Liang, Xu; Li, Huiping; Di, Lijun; Song, Guohong; Jiang, Hanfang; Shao, Bin] Peking Univ Canc Hosp & Inst, Dept Breast Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.
   [Xue, Junli; Ge, Xiaoxiao; Li, Jin; Xue, Liqiong; Tang, Wenbo; Li, Qun; Zhao, Wei; Lin, Fengjuan; Guo, Ye] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China.
   [Yang, Xiugao; Wu, Zhufeng; Zhang, Tianyi; Wang, Chenchen] CSPC ZhongQi Pharmaceut Technol Shijiazhuang Co Lt, Clin Sci Div, Shijiazhuang, Peoples R China.
C3 Tongji University
RP Li, HP (通讯作者)，Peking Univ Canc Hosp & Inst, Dept Breast Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.; Guo, Y (通讯作者)，Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China.
EM huipingli2012@hotmail.com; pattrickguo@gmail.com
RI ZHANG, TIANYI/HLW 7929 2023; Jiang, Hanfang/KVB 0431 2024; liang,
   xu/KOD 4016 2024; Lin, Feng/MGT 7827 2025; Li, Jinluan/HTO 3028 2023;
   huiping, li/GZM 9712 2022; Di, Li jun/B 3352 2011; zhao,
   wei/IQS 1144 2023
OI Yang, Xiugao/0000 0002 7101 7606; Jiang, Hanfang/0000 0002 3502 7073
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Bongiovanni A, 2022, SUPPORT CARE CANCER, V30, P5737, DOI 10.1007/s00520 022 06990 y
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brown JE, 2003, BRIT J CANCER, V89, P2031, DOI 10.1038/sj.bjc.6601437
   Cazzato RL, 2021, DIAGN INTERV IMAG, V102, P355, DOI 10.1016/j.diii.2020.12.008
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Costa L, 2002, J CLIN ONCOL, V20, P850, DOI 10.1200/JCO.20.3.850
   De Vita A, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020372
   Fang J, 2015, CLIN TRANSL ONCOL, V17, P173, DOI 10.1007/s12094 014 1247 x
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gaspar N, 2021, LANCET ONCOL, V22, P1312, DOI 10.1016/S1470 2045(21)00387 9
   Gdowski AS, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0578 1
   Harding JJ, 2018, J NATL COMPR CANC NE, V16, P50, DOI 10.6004/jnccn.2017.7024
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Jawad MU, 2022, J SURG ONCOL, V125, P766, DOI 10.1002/jso.26765
   Jeong H, 2021, INT J CANCER, V149, P917, DOI 10.1002/ijc.33613
   Kumagai Y, 2011, BONE, V49, P1101, DOI 10.1016/j.bone.2011.08.007
   Kumta SM, 2003, LIFE SCI, V73, P1427, DOI 10.1016/S0024 3205(03)00434 X
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Liu J., 2015, China patent, Patent No. [CN201410168618.9, 2014101686189]
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Mercatali L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111827
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Niu XH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.11526
   Piccioli A, 2015, J ORTHOP TRAUMATOL, V16, P81, DOI 10.1007/s10195 015 0344 0
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Segaliny AI, 2019, EBIOMEDICINE, V45, P39, DOI 10.1016/j.ebiom.2019.06.047
   Sohn W, 2014, BRIT J CLIN PHARMACO, V78, P477, DOI 10.1111/bcp.12355
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tsukamoto S, 2021, CURR ONCOL, V28, P3347, DOI 10.3390/curroncol28050290
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xu GJ, 2022, ETHNIC HEALTH, V27, P329, DOI 10.1080/13557858.2020.1734775
   Yee AJ, 2012, CLIN INTERV AGING, V7, P331, DOI 10.2147/CIA.S14566
   Yonemori K, 2008, CANCER SCI, V99, P1237, DOI 10.1111/j.1349 7006.2008.00803.x
   Yu Y, 2019, NEURAL COMPUT, V31, P1235, DOI 10.1162/neco_a_01199
NR 43
TC 6
Z9 7
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 5
PY 2022
VL 12
AR 971594
DI 10.3389/fonc.2022.971594
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 3X5KU
UT WOS:000843080400001
PM 35992822
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Man, XF
   Tan, SW
   Tang, HN
   Guo, Y
   Tang, CY
   Tang, J
   Zhou, CL
   Zhou, HD
AF Man, Xiao Fei
   Tan, Shu Wen
   Tang, Hao Neng
   Guo, Yue
   Tang, Chen Yi
   Tang, Jun
   Zhou, Ci La
   Zhou, Hou De
TI MiR 503 inhibits adipogenesis by targeting bone morphogenetic protein
   receptor 1a
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Adipogenesis; BMPR1a; miR 503; PI3K/Akt
ID PLURIPOTENT STEM CELLS; OSTEOBLAST DIFFERENTIATION; ADIPOCYTE
   DIFFERENTIATION; COMMITMENT; EXPRESSION; C3H10T1/2; INSULIN; ADIPOSE;
   KINASE; ROLES
AB Adipogenesis plays a key role in the regulation of whole body energy homeostasis and is critically related to obesity. To overcome obesity and its associated disorders, it is necessary to elucidate the molecular mechanisms involved in adipogenesis. An adipogenesis related miRNA array analysis demonstrated that miR 503 was differentially expressed before and after adipocyte differentiation; however, the exact role of miR 503 in adipocyte differentiation is unclear. Thus, the objective of this study was to further examine miR 503 in adipocyte differentiation. We found significantly decreased expression of miR 503 during adipocyte differentiation process. Using bioinformatic analysis, miR 503 was identified as a potential regulator of Bone Morphogenetic Protein Receptor 1a (BMPR1a). We then validated BMPR1a as the target of miR 503 using a dual luciferase assay, and found decreased miR 503 and increased BMPR1a expression during adipogenesis. Overexpression of miR 503 in preadipocytes repressed expression of BMPR1a and adipogenic related factors such as CCAAT/enhancer binding protein a (C/EBP alpha), proliferatoractivated receptor gamma (PPAR gamma), and adipocyte protein 2 (AP2). In addition, miR 503 overexpression impaired the phosphoinositol 3 kinase (PI3K)/Akt pathway. Inhibition of miR 503 had the opposite effect. Additionally, BMPR1a interference by siRNA attenuated adipocyte differentiation and the accumulation of lipid droplets via downregulating the PI3K/Akt signaling pathway. Our study provides the first evidence of the role miR 503 plays in adipocyte differentiation by regulating BMPR1a via the PI3K/Akt pathway, which may become a novel target for obesity therapy.
C1 [Man, Xiao Fei; Tan, Shu Wen; Tang, Hao Neng; Guo, Yue; Tang, Chen Yi; Tang, Jun; Zhou, Ci La; Zhou, Hou De] Cent South Univ, Xiangya Hosp 2, Inst Endocrinol & Metab, Changsha, Hunan, Peoples R China.
C3 Central South University
RP Zhou, HD (通讯作者)，Cent South Univ, Xiangya Hosp 2, Inst Endocrinol & Metab, Changsha, Hunan, Peoples R China.
EM houdezhou@csu.edu.cn
RI ; Zhou, Hou De/IQU 6646 2023
OI Tang, Jun/0000 0002 6908 1027; Zhou, Hou De/0000 0001 9131 4141; 
FU National Natural Science Foundation of China [81370975, 81070278]
FX The authors gratefully thank the Metabolic Syndrome Research Center at
   the Second Xiangya Hospital of Central South University for technical
   assistance. This work was supported by grants from the National Natural
   Science Foundation of China (81370975, 81070278).
CR Andreeva A, 2014, DEV CELL, V29, P20, DOI 10.1016/j.devcel.2014.02.008
   Ariffin JK, 2016, J LEUKOCYTE BIOL
   Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005
   Böttcher Y, 2009, DIABETES, V58, P2119, DOI 10.2337/db08 1458
   Bowers RR, 2006, P NATL ACAD SCI USA, V103, P13022, DOI 10.1073/pnas.0605789103
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319 329.2001
   Gerin I, 2010, AM J PHYSIOL ENDOC M, V299, pE198, DOI 10.1152/ajpendo.00179.2010
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Ghosh Choudhury N, 2003, FEBS LETT, V544, P181, DOI 10.1016/S0014 5793(03)00507 6
   Huang HY, 2009, P NATL ACAD SCI USA, V106, P12670, DOI 10.1073/pnas.0906266106
   Ito H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146564
   Jin WZ, 2006, DEV CELL, V10, P461, DOI 10.1016/j.devcel.2006.02.016
   Kang M, 2013, MOL BIOL REP, V40, P5027, DOI 10.1007/s11033 013 2603 6
   Karbiener M, 2009, BIOCHEM BIOPH RES CO, V390, P247, DOI 10.1016/j.bbrc.2009.09.098
   Kishigami S, 2005, CYTOKINE GROWTH F R, V16, P265, DOI 10.1016/j.cytogfr.2005.04.002
   Kobielak K, 2007, P NATL ACAD SCI USA, V104, P10063, DOI 10.1073/pnas.0703004104
   Kwon DN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/236385
   Lee EK, 2011, MOL CELL BIOL, V31, P626, DOI 10.1128/MCB.00894 10
   Li H, 2008, SPINE, V33, P2394, DOI 10.1097/BRS.0b013e3181838fe5
   Mallanna SK, 2010, DEV BIOL, V344, P16, DOI 10.1016/j.ydbio.2010.05.014
   Menor M, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0500 5
   Nishimura R, 2003, FRONT BIOSCI, V8, pS275, DOI 10.2741/1049
   Nishio M, 2012, CELL METAB, V16, P394, DOI 10.1016/j.cmet.2012.08.001
   Ortega FJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009022
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Schleinitz D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016155
   Schulz TJ, 2009, CYTOKINE GROWTH F R, V20, P523, DOI 10.1016/j.cytogfr.2009.10.019
   Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060
   Sui XZ, 2009, CIRC RES, V104, P887, DOI 10.1161/CIRCRESAHA.108.192328
   Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101
   Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221
   WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582
   Yang Z, 2011, STEM CELLS DEV, V20, P259, DOI 10.1089/scd.2010.0072
   Zhang HB, 2010, MOL CELL BIOL, V30, P4224, DOI 10.1128/MCB.00363 10
NR 37
TC 18
Z9 20
U1 0
U2 4
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 6
BP 2727
EP 2737
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DQ0RL
UT WOS:000378907500023
PM 27398155
DA 2025 08 17
ER

PT J
AU Lee, JS
   Kim, MH
   Lee, H
   Yang, WM
AF Lee, Jae Sung
   Kim, Mi Hye
   Lee, Haesu
   Yang, Woong Mo
TI Anemarrhena asphodeloides Bunge ameliorates osteoporosis by
   suppressing osteoclastogenesis
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Anemarrhena asphodeloides Bunge; osteoporosis; bone mineral density;
   bone mineral content; osteoclast
ID NF KAPPA B; NECROSIS FACTOR ALPHA; POSTMENOPAUSAL WOMEN;
   BONE RESORPTION; DIFFERENTIATION; FRACTURES; ESTROGEN; BMD; LIGAND; RISK
AB Anemarrhena asphodeloides Bunge has been traditionally used in Korean medicine for its antipyretic, diuretic, sedative, and antitussive effects. In the present study, the effects of an ethanol extract of A. asphodeloides Bunge (AAB) on osteoporosis and its underlying mechanisms on bone remod eling were investigated. Osteoporosis was induced in ICR strain mice by ovariectomy. The mice were divided into four groups: Sham, ovariectomized, 17 beta estradiol and 100 mg/kg AAB. The treatment was continued for 4 weeks. Bone mineral density (BMD) and bone mineral content (BMC) were measured using dual energy X ray absorptiometry. In addition, Raw 264.7 cells were treated in the presence of 0.1, 1 and 10 mu g/ml AAB with 100 ng/ml receptor activator of nuclear factor B ligand (RANKL) to induce osteoclast formation and stained with tartrate resistant acid phosphatase. In addition, levels of osteoclast related factors were analyzed to investigate the signaling cascades in osteoclasts. The results demonstrated that AAB treatment reversed the decreases of both BMD and BMC in osteoporotic femurs. Additionally, the formation of osteoclasts was significantly suppressed by the AAB treatment in RANKL stimulated Raw 264.7 cells. Compared with cells treated with RANKL alone, the AAB treated osteoclasts had significantly decreased tumor necrosis factor alpha and interleukin 6. The protein levels of c fos were also decreased in the AAB treated osteoclasts. Furthermore, the RANKL induced nuclear translocation of nuclear factor kappa B was attenuated in osteoclasts by the AAB treatment compared with cells treated with RANKL alone. Finally, AAB treatment downregulated the phosphorylation of mitogen activated protein kinases. The present results demonstrated that AAB exhibited ameliorative effects on osteoporosis by inhibiting osteoclastogenesis, and suggested that AAB may be a potential candidate for the treatment of osteoporosis.
C1 [Lee, Jae Sung; Kim, Mi Hye; Lee, Haesu; Yang, Woong Mo] Kyung Hee Univ, Coll Korean Med, Dept Convergence Korean Med Sci, 26 Kyungheedaeo Ro, Seoul 02447, South Korea.
C3 Kyung Hee University
RP Yang, WM (通讯作者)，Kyung Hee Univ, Coll Korean Med, Dept Convergence Korean Med Sci, 26 Kyungheedaeo Ro, Seoul 02447, South Korea.
EM wmyang@khu.ac.kr
RI ; Yang, Woong/AAH 9185 2020
OI Yang, Woong Mo/0000 0001 5308 2386; 
FU National Research Foundation of Korea   Korea government
   [NRF 2017R1A6A3A11032500]
FX The present study was supported by the National Research Foundation of
   Korea funded by the Korea government (grant no.
   NRF 2017R1A6A3A11032500).
CR Body JJ, 2012, OSTEOPOROSIS INT, V23, pS1, DOI 10.1007/s00198 011 1891 8
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cao JJ, 2005, J BONE MINER RES, V20, P1659, DOI 10.1359/JBMR.050503
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   CHRISTIANSEN C, 1991, AM J MED, V90, P107
   El Maataoui A, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905 015 0199 9
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Gui YY, 2015, BIOSCI TRENDS, V9, P169, DOI 10.5582/bst.2015.01011
   Hamrick I, 2015, WIEN MED WOCHENSCHR, V165, P54, DOI 10.1007/s10354 014 0335 4
   Hansen PJ, 2013, CLIN ORAL INVEST, V17, P1829, DOI 10.1007/s00784 012 0873 3
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   He CC, 2010, J ETHNOPHARMACOL, V127, P229, DOI 10.1016/j.jep.2009.11.016
   Jackson RD, 2006, J BONE MINER RES, V21, P817, DOI 10.1359/JBMR.060312
   Jeon EJ, 2016, MOL NUTR FOOD RES, V60, P2587, DOI 10.1002/mnfr.201600257
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kelley GA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 177
   Kim MH, 2014, FOOD FUNCT, V5, P1594, DOI 10.1039/c4fo00133h
   Lee H, 2018, MOL MED REP, V17, P3758, DOI 10.3892/mmr.2017.8309
   Lee HF, 2018, ASIAN GEOGR, V35, P123, DOI 10.1080/10225706.2018.1504807
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Moyer VA, 2013, ANN INTERN MED, V158, P478, DOI 10.7326/0003 4819 158 6 201303190 00588
   Nian H, 2006, ACTA PHARMACOL SIN, V27, P728, DOI 10.1111/j.1745 7254.2006.00328.x
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Rahman MM, 2015, BONE, V81, P392, DOI 10.1016/j.bone.2015.08.008
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yokota K, 2014, ARTHRITIS RHEUMATOL, V66, P121, DOI 10.1002/art.38218
   Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202
NR 40
TC 4
Z9 5
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD DEC
PY 2018
VL 42
IS 6
BP 3613
EP 3621
DI 10.3892/ijmm.2018.3908
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GY9GV
UT WOS:000448950200062
PM 30272269
OA Bronze
DA 2025 08 17
ER

PT J
AU Lecourt, S
   Mouly, E
   Freida, D
   Cras, A
   Ceccaldi, R
   Heraoui, D
   Chomienne, C
   Marolleau, JP
   Arnulf, B
   Porcher, R
   Caillaud, C
   Vanneaux, V
   Belmatoug, N
   Larghero, J
AF Lecourt, Severine
   Mouly, Enguerran
   Freida, Delphine
   Cras, Audrey
   Ceccaldi, Raphael
   Heraoui, Djazia
   Chomienne, Christine
   Marolleau, Jean Pierre
   Arnulf, Bertrand
   Porcher, Raphael
   Caillaud, Catherine
   Vanneaux, Valerie
   Belmatoug, Nadia
   Larghero, Jerome
TI A Prospective Study of Bone Marrow Hematopoietic and Mesenchymal Stem
   Cells in Type 1 Gaucher Disease Patients
SO PLOS ONE
LA English
DT Article
ID ENZYME REPLACEMENT THERAPY; MULTIPLE MYELOMA; GLUCOCEREBROSIDASE
   ACTIVITY; MODEL; STORAGE; DIFFERENTIATION; MACROPHAGE; CYTOKINES;
   REGISTRY; ASSAY
AB Gaucher disease (GD) is an autosomal recessive disorder characterized by lysosomal glucocerebrosidase (GBA) deficiency leading to hematological and skeletal manifestations. Mechanisms underlying these symptoms have not yet been elucidated. In vivo, bone marrow (BM) mesenchymal stem cells (MSCs) have important role in the regulation of bone mass and in the support of hematopoiesis, thus representing potential candidate that could contribute to the disease. GBA deficiency may also directly impair hematopoietic stem/progenitors cells (HSPCs) intrinsic function and induce hematological defect. In order to evaluate the role of BM stem cells in GD pathophysiology, we prospectively analyzed BM MSCs and HSPCs properties in a series of 10 patients with type 1 GD. GBA activity was decreased in all tested cell subtypes. GD MSCs had an impaired growth potential, morphological and cell cycle abnormalities, decreased capacities to differentiate into osteoblasts. Moreover, GD MSCs secreted soluble factors that stimulated osteoclasts resorbing activities. In vitro and in vivo primitive and mature hematopoiesis were similar between patients and controls. However, GD MSCs had a lower hematopoietic supportive capacity than those from healthy donors. These data suggest that BM microenvironment is altered in GD and that MSCs are key components of the manifestations observed in GD.
C1 [Lecourt, Severine; Freida, Delphine; Cras, Audrey; Vanneaux, Valerie; Larghero, Jerome] Hop St Louis, AP HP, Unite Therapie Cellulaire, Paris, France.
   [Lecourt, Severine; Freida, Delphine; Cras, Audrey; Vanneaux, Valerie; Larghero, Jerome] Ctr Invest Clin Biotherapies CIC BT501, Paris, France.
   [Lecourt, Severine; Cras, Audrey; Chomienne, Christine; Larghero, Jerome] Hop St Louis, INSERM UMRS940, Inst Univ Hematol, Paris, France.
   [Mouly, Enguerran; Arnulf, Bertrand] Univ Paris Diderot, EA3963, Sorbonne Paris Cite, Inst Univ Hematol, Paris, France.
   [Ceccaldi, Raphael] Hop St Louis, INSERM U944, Inst Univ Hematol, Paris, France.
   [Heraoui, Djazia; Belmatoug, Nadia] Hop Beaujon, AP HP, Serv Med Interne, Ctr Reference Malad Lysosomales, Clichy, France.
   [Marolleau, Jean Pierre] Hop Amiens, Dept Hematol Clin, Amiens, France.
   [Arnulf, Bertrand] Hop St Louis, AP HP, Dept Immunohematol, Paris, France.
   [Porcher, Raphael] Hop St Louis, AP HP, Dept Biostat & Informat Med, Paris, France.
   [Caillaud, Catherine] Hop Cochin, Lab Genet Metab, F 75674 Paris, France.
   [Lecourt, Severine; Freida, Delphine; Cras, Audrey; Vanneaux, Valerie; Larghero, Jerome] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Saint Louis   APHP; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Saint Louis   APHP; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Universite Paris Cite; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Saint Louis   APHP; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Beaujon   APHP;
   Universite de Picardie Jules Verne (UPJV); CHU Amiens; Universite Paris
   Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Saint Louis   APHP; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Saint Louis   APHP;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Cochin   APHP; Universite Paris Cite
RP Larghero, J (通讯作者)，Hop St Louis, AP HP, Unite Therapie Cellulaire, Paris, France.
EM jerome.larghero@sls.aphp.fr
RI ; Vanneaux, Valérie/D 7853 2017; Cras, Audrey/Q 8784 2017; Vanneaux,
   Valerie/D 7853 2017
OI Ceccaldi, Raphael/0000 0003 3049 4278; FREIDA,
   Delphine/0009 0001 4818 713X; Porcher, Raphael/0000 0002 5277 4679;
   CHOMIENNE, Christine/0000 0001 5513 5752; Cras,
   Audrey/0000 0002 6894 9584; Vanneaux, Valerie/0000 0003 0813 2318
FU Genzyme SAS; Genzyme; Shire; Actelion; Pfizer
FX The authors state that SL was sponsored as a doctoral student and has
   been reimbursed for congress travel from Genzyme SAS. NB has consulting
   fees, fees for speaking. NB received grants (Genzyme, Shire, Actelion,
   Pfizer) donated to APRIMI (Association pour la Promotion de la Recherche
   en Infectiologie et Medecine Interne) and to the Department of Clinical
   Research of the Assistance Publique Hopitaux de Paris. This does not
   alter the authors' adherence to all the PLOS ONE policies on sharing
   data and materials.
CR Allen MJ, 1997, QJM MON J ASSOC PHYS, V90, P19
   Arnulf B, 2007, LEUKEMIA, V21, P158, DOI 10.1038/sj.leu.2404466
   Barak V, 1999, EUR CYTOKINE NETW, V10, P205
   Berger J, 2010, BRIT J HAEMATOL, V150, P93, DOI 10.1111/j.1365 2141.2010.08214.x
   Campeau PM, 2009, BLOOD, V114, P3181, DOI 10.1182/blood 2009 02 205708
   Charrow J, 2000, ARCH INTERN MED, V160, P2835, DOI 10.1001/archinte.160.18.2835
   Ciana G, 2003, CALCIFIED TISSUE INT, V72, P185, DOI 10.1007/s00223 001 2072 0
   CONZELMANN E, 1984, DEV NEUROSCI BASEL, V6, P58, DOI 10.1159/000112332
   de Fost M, 2008, ANN HEMATOL, V87, P439, DOI 10.1007/s00277 008 0441 8
   Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980
   Enquist IB, 2006, P NATL ACAD SCI USA, V103, P13819, DOI 10.1073/pnas.0606016103
   Enquist IB, 2009, STEM CELLS, V27, P744, DOI 10.1634/stemcells.2008 0844
   Grabowski GA, 2008, LANCET, V372, P1263, DOI 10.1016/S0140 6736(08)61522 6
   Hein LK, 2008, J LIPID RES, V49, P1725, DOI 10.1194/jlr.M800092 JLR200
   Hollak CEM, 1997, BLOOD CELL MOL DIS, V23, P201, DOI 10.1006/bcmd.1997.0137
   Kobayashi Y, 2005, J BIOL CHEM, V280, P24035, DOI 10.1074/jbc.M500926200
   Lecourt S., 2011, Stem cells and development, P1
   Lecourt S, 2010, STEM CELLS DEV
   LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337
   Lorincz M, 1997, BLOOD, V89, P3412, DOI 10.1182/blood.V89.9.3412
   Majumdar MK, 2003, J BIOMED SCI, V10, P228, DOI 10.1159/000068710
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Mucci JM, 2012, GENE, V509, P51, DOI 10.1016/j.gene.2012.07.071
   Neto H, 2011, BIOCHEM J, V437, P13, DOI 10.1042/BJ20110153
   Pastores GM, 2004, SEMIN HEMATOL, V41, P4, DOI 10.1053/j.seminhematol.2004.07.009
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Rudensky B, 2003, BLOOD CELL MOL DIS, V30, P97, DOI 10.1016/S1079 9796(03)00010 X
   Rudzki Z, 2003, EUR J HAEMATOL, V70, P273, DOI 10.1034/j.1600 0609.2003.00047.x
   Schueler UH, 2004, J INHERIT METAB DIS, V27, P649, DOI 10.1023/B:BOLI.0000042959.44318.7c
   Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   van Breemen MJ, 2007, BBA MOL BASIS DIS, V1772, P788, DOI 10.1016/j.bbadis.2007.04.002
   Weinreb NJ, 2002, AM J MED, V113, P112, DOI 10.1016/S0002 9343(02)01150 6
NR 35
TC 26
Z9 28
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 25
PY 2013
VL 8
IS 7
AR e69293
DI 10.1371/journal.pone.0069293
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 191SQ
UT WOS:000322433300030
PM 23935976
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Avnet, S
   Salerno, M
   Quacquaruccio, G
   Granchi, D
   Giunti, A
   Baldini, N
AF Avnet, Sofia
   Salerno, Manuela
   Quacquaruccio, Gianni
   Granchi, Donatella
   Giunti, Armando
   Baldini, Nicola
TI IGF2 derived from SH SY5Y neuroblastoma cells induces the
   osteoclastogenesis of human monocytic precursors
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Neuroblastoma; IGF2; Osteoclastogenesis; IGF1R; Osteolytic tumors
ID GROWTH FACTOR II; KAPPA B LIGAND; IN VITRO; RECEPTOR ACTIVATOR; BONE
   METASTASES; DIFFERENTIATION; PROLIFERATION; MECHANISMS; LINE;
   OSTEOPROTEGERIN
AB The insulin like growth factors 2 (IGF2) is a peptide hormone that binds to the insulin like growth factor 1 receptor (IGF1R) and is abundantly stored in bone. IGF1R is deeply involved in the pathogenesis of many cancers that growth within bone and is also involved in osteoclast biology. Among different cell lines representative of osteolytic tumors, we found a very high expression of IGF2 in SH SY5Y cells derived from neuroblastoma (NB). We previously showed that NB cells induce an osteolytic process through the Osteoprotegerin/RANKL/RANK and the canonical Wnt pathway system. Here, we hypothesized that NB promotes osteoclastogenesis also via IGF2. First, we demonstrated the presence of IGF1R on the osteoclast basolateral membrane, and we observed a cyclic IGF1R activation along with the differentiation process, also when induced by SH SY5Y. Moreover, we found that IGF2 mRNA expression in SH SY5Y cells was further increased when co cultured with mesenchymal stromal cells, suggesting that IGF2 is important for NB interaction with the bone microenvironment. Finally, the treatment of SH SY5Y cells with an anti IGF2 siRNA or the addition of anti IGF1R molecules impaired NB induced osteoclastogenesis, even though the chemoattraction of monocytes by NB cells was unaffected. Our findings suggest that in IGF2 producing osteolytic tumors IGF1R is a good candidate for targeted therapies in combination with conventional drugs. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Avnet, Sofia; Salerno, Manuela; Quacquaruccio, Gianni; Granchi, Donatella; Giunti, Armando; Baldini, Nicola] Ist Ortoped Rizzoli, Lab Orthopaed Pathophysiol & Regenerat Med, I 40136 Bologna, Italy.
   [Giunti, Armando; Baldini, Nicola] Univ Bologna, Dept Orthopaed Surg, I 40136 Bologna, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; University of Bologna
RP Avnet, S (通讯作者)，Ist Ortoped Rizzoli, Lab Orthopaed Pathophysiol & Regenerat Med, Via Barbiano 1 10, I 40136 Bologna, Italy.
EM sofia.avnet@ior.it
RI Avnet, Sofia/B 3220 2018; Baldini, Nicola/J 4806 2016; Granchi,
   Donatella/J 3647 2016
OI Avnet, Sofia/0000 0002 7843 0591; Baldini, Nicola/0000 0003 2228 3833;
   Granchi, Donatella/0000 0001 7225 0023
FU Italian Association for Cancer Research; Italian Ministry of Health
FX This research was supported by grants from the Italian Association for
   Cancer Research and from the Italian Ministry of Health. There is no
   conflict of interest between authors and the research described in the
   paper. We thank M. Rubini (Dipartimento Medicina Sperimentale e
   Diagnostica, University of Ferrara. Italy) for providing pep922 and
   pY1316 MAb, and M.L. Brandi (Dipartimento di Medicina Interna,
   University of Firenze, Italy) for providing the FLG 29.1 cell line. S.A.
   was involved in study design, in performing the experiments, in the
   collection, analysis and interpretation of data, in the writing of the
   report, and in the decision to submit the paper for publication. M.S.
   and G.Q. were involved in performing the experiments. D.G. and A.G.
   provided writing assistance. N.B. was involved in study design, and in
   writing of the paper.
CR Alatalo SL, 2000, CLIN CHEM, V46, P1751
   Avnet S, 2004, ANTICANCER RES, V24, P1705
   Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008 5472.CAN 08 2645
   BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006 291X(05)80249 9
   BLOTTIERE HM, 1995, BIOMATERIALS, V16, P497, DOI 10.1016/0142 9612(95)98824 X
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   Chihara K, 1997, HORM RES, V48, P45, DOI 10.1159/000191328
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426 199905000 00005
   Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945 053X(00)00051 2
   ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042
   Fiedler J, 2006, BIOCHEM BIOPH RES CO, V345, P1177, DOI 10.1016/j.bbrc.2006.05.034
   FIORELLI G, 1994, J CELL PHYSIOL, V160, P482, DOI 10.1002/jcp.1041600311
   GATTEI V, 1992, J CELL BIOL, V116, P437, DOI 10.1083/jcb.116.2.437
   Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200
   Granchi D, 2006, INT J CANCER, V119, P146, DOI 10.1002/ijc.21783
   Granchi D, 2004, INT J CANCER, V111, P829, DOI 10.1002/ijc.20308
   Granchi D, 2008, INT J CANCER, V123, P1526, DOI 10.1002/ijc.23654
   Granchi D, 2011, BONE, V48, P152, DOI 10.1016/j.bone.2010.06.028
   Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172
   Guicheux J, 1998, BONE, V22, P25, DOI 10.1016/S8756 3282(97)00224 X
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hirbe AC, 2010, CURR PHARM DESIGN, V16, P1284, DOI 10.2174/138161210791034012
   Hou P, 1997, J BONE MINER RES, V12, P534, DOI 10.1359/jbmr.1997.12.4.534
   Husheem M, 2005, CALCIFIED TISSUE INT, V76, P222, DOI 10.1007/s00223 004 0123 z
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kim B, 2004, ONCOGENE, V23, P130, DOI 10.1038/sj.onc.1206924
   Kimura T, 2010, CLIN CANCER RES, V16, P121, DOI 10.1158/1078 0432.CCR 09 0982
   Kominsky SL, 2008, CANCER RES, V68, P1261, DOI 10.1158/0008 5472.CAN 07 6122
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   Menu E, 2004, BRIT J CANCER, V90, P1076, DOI 10.1038/sj.bjc.6601613
   MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075
   Musarò A, 1999, NATURE, V400, P581, DOI 10.1038/23060
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562
   Rucci N, 2005, J CELL SCI, V118, P3263, DOI 10.1242/jcs.02436
   Sohara Y, 2005, CANCER RES, V65, P1129, DOI 10.1158/0008 5472.CAN 04 2853
   Sohara Y, 2003, CANCER RES, V63, P3026
   SULLIVAN KA, 1995, AM J PATHOL, V147, P1790
   Sullivan KA, 1997, BRAIN RES, V744, P199, DOI 10.1016/S0006 8993(96)01078 5
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanno B, 2006, CLIN CANCER RES, V12, P6772, DOI 10.1158/1078 0432.CCR 06 1479
   van Golen CM, 2006, CANCER RES, V66, P6570, DOI 10.1158/0008 5472.CAN 05 1448
   Vandooren B, 2009, ARTHRITIS RHEUM US, V60, P1020, DOI 10.1002/art.24413
   Wang YM, 2006, J BONE MINER RES, V21, P1350, DOI 10.1359/JBMR.060610
   Wilson TJ, 2009, CANCER RES, V69, P3188, DOI 10.1158/0008 5472.CAN 08 1956
   Wittrock J, 2002, ANTICANCER RES, V22, P4205
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Zini N, 2008, J CELL BIOCHEM, V105, P34, DOI 10.1002/jcb.21796
NR 52
TC 11
Z9 12
U1 0
U2 3
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD SEP 10
PY 2011
VL 317
IS 15
BP 2147
EP 2158
DI 10.1016/j.yexcr.2011.05.030
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 804VP
UT WOS:000293682400007
PM 21672538
DA 2025 08 17
ER

PT J
AU Petty, SJ
   Milligan, CJ
   Todaro, M
   Richards, KL
   Kularathna, PK
   Pagel, CN
   French, CR
   Hill Yardin, EL
   O'Brien, TJ
   Wark, JD
   Mackie, EJ
   Petrou, S
AF Petty, Sandra J.
   Milligan, Carol J.
   Todaro, Marian
   Richards, Kay L.
   Kularathna, Pamuditha K.
   Pagel, Charles N.
   French, Chris R.
   Hill Yardin, Elisa L.
   O'Brien, Terence J.
   Wark, John D.
   Mackie, Eleanor J.
   Petrou, Steven
TI The antiepileptic medications carbamazepine and phenytoin inhibit native
   sodium currents in murine osteoblasts
SO EPILEPSIA
LA English
DT Article
DE Epilepsy; Bone health; Osteoblast; Voltage gated sodium channel;
   Electrophysiology
ID BONE MINERAL DENSITY; FRACTURE RISK; ANTICONVULSANT THERAPY; ION
   CHANNELS; CELLS; EPILEPSY; EXPRESSION; NEURONS; DISEASE; HEALTH
AB Objective: Fracture risk is a serious comorbidity in epilepsy and may relate to the use of antiepileptic drugs (AEDs). Many AEDs inhibit ion channel function, and the expression of these channels in osteoblasts raises the question of whether altered bone signaling increases bone fragility. We aimed to confirm the expression of voltage gated sodium (Na V) channels in mouse osteoblasts, and to investigate the action of carbamazepine and phenytoin on Na V channels.
   Methods: Immunocytochemistry was performed on primary calvarial osteoblasts extracted from neonatal C57BL/6J mice and additional RNA sequencing (RNASeq) was included to confirm expression of Na V. Whole cell patch clamp recordings were made to identify the native currents expressed and to assess the actions of carbamazepine (50 mu M) or phenytoin (50 mu M).
   Results: Na V expression was demonstrated with immunocytochemistry, RNA sequencing, and functionally, with demonstration of robust tetrodotoxin sensitive and voltage activated inward currents. Application of carbamazepine or phenytoin resulted in significant inhibition of current amplitude for carbamazepine (31.6 +/  5.9%, n = 9; p < 0.001), and for phenytoin (35.5 +/  6.9%, n = 7; p < 0.001).
   Significance: Mouse osteoblasts express Na V, and native Na V currents are blocked by carbamazepine and phenytoin, supporting our hypothesis that AEDs can directly influence osteoblast function and potentially affect bone strength.
C1 [Petty, Sandra J.; Todaro, Marian; French, Chris R.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med, Parkville, Vic, Australia.
   [Petty, Sandra J.; Milligan, Carol J.; Richards, Kay L.; Petrou, Steven] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia.
   [Petty, Sandra J.; French, Chris R.; O'Brien, Terence J.] Royal Melbourne Hosp, Dept Neurol, Parkville, Vic, Australia.
   [Petty, Sandra J.] Ormond Coll, Acad Ctr, Parkville, Vic, Australia.
   [Petty, Sandra J.; French, Chris R.; O'Brien, Terence J.; Wark, John D.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia.
   [Kularathna, Pamuditha K.; Pagel, Charles N.; Mackie, Eleanor J.] Univ Melbourne, Fac Vet & Agr Sci, Parkville, Vic, Australia.
   [Hill Yardin, Elisa L.] Univ Melbourne, Dept Physiol, Parkville, Vic, Australia.
   [Wark, John D.] Royal Melbourne Hosp, Bone & Mineral Med, Parkville, Vic, Australia.
C3 University of Melbourne; Melbourne Health; Royal Melbourne Hospital;
   Florey Institute of Neuroscience & Mental Health; Melbourne Health;
   Royal Melbourne Hospital; Melbourne Health; Royal Melbourne Hospital;
   University of Melbourne; University of Melbourne; University of
   Melbourne; Melbourne Health; Royal Melbourne Hospital
RP Petty, SJ (通讯作者)，Univ Melbourne, Dept Med, 1st Floor,Kenneth Myer Bldg, Parkville, Vic 3052, Australia.
EM pettys@unimelb.edu.au
RI ; Petrou, Steven/M 8332 2013; French, Chris/AHA 1801 2022; Pagel,
   Charles/A 8890 2014; O'Brien, Terence/L 8102 2013; Mackie,
   Eleanor/B 2045 2008
OI Petrou, Steven/0000 0002 4960 6375; Pagel, Charles/0000 0002 7844 2242;
   Milligan, Carol/0000 0003 0353 7228; French,
   Christopher/0000 0002 1445 8704; O'Brien, Terence/0000 0002 7198 8621;
   Hill Yardin, Elisa/0000 0002 4146 7198; Mackie,
   Eleanor/0000 0002 8057 5407; Petty, Sandra/0000 0002 4227 6190
FU Molly McDonnell Foundation Scholarship; DW Keir Fellowship in Medical
   Research at The Royal Melbourne Hospital; University of Melbourne Early
   Career Researcher (ECR) grant; Brain Foundation; Royal Melbourne
   Hospital Home Lottery; RACP Servier Barry Young Fellowship in
   Neuroscience; Royal Melbourne Hospital; MBC Postdoctoral Medical
   Research Fellowship at The Melbourne Brain Centre RMH; NHMRC Centre for
   Research Excellence Grant [1001216]; Ormond College Parkville
FX The authors would like to sincerely acknowledge the following
   organizations for funding received during the development of this study
   including: the Molly McDonnell Foundation Scholarship (2009), DW Keir
   Fellowship in Medical Research at The Royal Melbourne Hospital (January
   2010 June 2012), University of Melbourne Early Career Researcher (ECR)
   grant (2010), Brain Foundation Research Grant in Aid (2011), The Royal
   Melbourne Hospital Home Lottery Grants in Aid (2012), RACP Servier Barry
   Young Fellowship in Neuroscience (2012), The Royal Melbourne Hospital
   Victor Hurley Grants in Aid (2013), MBC Postdoctoral Medical Research
   Fellowship at The Melbourne Brain Centre RMH (June 2012 2014), and
   (NHMRC Centre for Research Excellence Grant 1001216). Dr. Sandra Petty
   held the Thwaites Gutch Fellowship at Ormond College Parkville
   2011 2015.
CR Andress DL, 2002, ARCH NEUROL CHICAGO, V59, P781, DOI 10.1001/archneur.59.5.781
   [Anonymous], 2013, Australian code for the care and use of animals for scientific purposes, V8th, DOI DOI 10.1017/S0962728600005674
   Black JA, 1996, DEV NEUROSCI BASEL, V18, P139, DOI 10.1159/000111403
   Black JA, 2013, NEURON, V80, P280, DOI 10.1016/j.neuron.2013.09.012
   CHAKKALAKAL DA, 1989, J MATER RES, V4, P1034, DOI 10.1557/JMR.1989.1034
   CHESNOYMARCHAIS D, 1994, J MEMBRANE BIOL, V140, P173
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Ensrud KE, 2008, NEUROLOGY, V71, P723, DOI 10.1212/01.wnl.0000324919.86696.a9
   Feldkamp J, 2000, EXP CLIN ENDOCR DIAB, V108, P37
   Fitzpatrick LA, 2004, EPILEPSY BEHAV, V5, pS3, DOI 10.1016/j.yebeh.2003.11.026
   HODGKIN AL, 1952, J PHYSIOL LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764
   Ke CB, 2012, NEUROSCIENCE, V227, P80, DOI 10.1016/j.neuroscience.2012.09.046
   Lee RH, 2010, AM J GERIATR PHARMAC, V8, P34, DOI 10.1016/j.amjopharm.2010.02.003
   Moro Alvarez MJ, 2009, EUR NEUROL, V62, P219, DOI 10.1159/000229309
   Namadurai S, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.140192
   Pack AM, 2011, CURR TREAT OPTION NE, V13, P346, DOI 10.1007/s11940 011 0133 x
   Pagel CN, 2009, BONE, V44, P813, DOI 10.1016/j.bone.2008.12.031
   Pangalos M, 2011, J BIOENERG BIOMEMBR, V43, P311, DOI 10.1007/s10863 011 9354 7
   Patino GA, 2010, NEUROSCI LETT, V486, P53, DOI 10.1016/j.neulet.2010.06.050
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Petty SJ, 2007, OSTEOPOROSIS INT, V18, P129, DOI 10.1007/s00198 006 0185 z
   Petty SJ, 2005, NEUROLOGY, V65, P1358, DOI 10.1212/01.wnl.0000180910.72487.18
   Ramsköld D, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000598
   Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756 3282(96)00260 8
   Sander JW, 2003, CURR OPIN NEUROL, V16, P165, DOI 10.1097/00019052 200304000 00008
   Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445
   Savio Galimberti E, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00124
   SCHIRRMACHER K, 1993, CALCIFIED TISSUE INT, V53, P53, DOI 10.1007/BF01352015
   Sun JQ, 2014, J BIOMECH, V47, P3903, DOI 10.1016/j.jbiomech.2014.10.003
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trapnell C, 2009, NAT BIOTECHNOL, V27, P455, DOI 10.1038/nbt0509 455
   Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064
   Vestergaard P, 2005, ACTA NEUROL SCAND, V112, P277, DOI 10.1111/j.1600 0404.2005.00474.x
   Vestergaard P, 2004, EPILEPSIA, V45, P1330, DOI 10.1111/j.0013 9580.2004.18804.x
   Waxman SG, 2012, J PHYSIOL LONDON, V590, P2601, DOI 10.1113/jphysiol.2012.228460
   Zanello LP, 2006, STEROIDS, V71, P291, DOI 10.1016/j.steroids.2005.09.012
   Zanello LP, 2003, BONE, V33, P71, DOI 10.1016/S8756 3282(03)00162 5
NR 37
TC 19
Z9 20
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0013 9580
EI 1528 1167
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2016
VL 57
IS 9
BP 1398
EP 1405
DI 10.1111/epi.13474
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA EB8QJ
UT WOS:000387655600013
PM 27440235
OA Green Published
DA 2025 08 17
ER

PT J
AU Wisanwattana, W
   Wongkrajang, K
   Cao, DY
   Shi, XK
   Zhang, ZH
   Zhou, ZY
   Li, F
   Mei, QG
   Wang, C
   Suksamrarn, A
   Zhang, GL
   Wang, F
AF Wisanwattana, Wisanee
   Wongkrajang, Kanjana
   Cao, Dong yi
   Shi, Xiao ke
   Zhang, Zhong hui
   Zhou, Zong yuan
   Li, Fu
   Mei, Qing gang
   Wang, Chun
   Suksamrarn, Apichart
   Zhang, Guo lin
   Wang, Fei
TI Inhibition of Phosphodiesterase 5 Promotes the Aromatase Mediated
   Estrogen Biosynthesis in Osteoblastic Cells by Activation of
   cGMP/PKG/SHP2 Pathway
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE icariin analogs; aromatase; osteoblast; PDE5; estrogen biosynthesis
AB Mechanical stimulation induces bone growth and remodeling by the secondary messenger, cyclic guanosine 3', 5' monophosphate (cGMP), in osteoblasts. However, the role of cGMP in the regulation of estrogen biosynthesis, whose deficiency is a major cause of osteoporosis, remains unclear. Here, we found that the prenylated flavonoids, 3 O methoxymethyl 7 O benzylicaritin (13), 7 O benzylicaritin (14), and 4' O methyl 8 isopentylkaempferol (15), which were synthesized using icariin analogs, promoted estrogen biosynthesis in osteoblastic UMR106 cells, with calculated EC50 values of 1.53, 3.45, and 10.57 mu M, respectively. 14 and 15 increased the expression level of the bone specific promoter I.4 driven aromatase, the only enzyme that catalyzes estrogen formation by using androgens as substrates, in osteoblastic cells. 14 inhibited phosphodiesterase 5 (PDE5), stimulated intracellular cGMP level and promoted osteoblast cell differentiation. Inhibition of cGMP dependent protein kinase G (PKG) abolished the stimulatory effect of 14 on estrogen biosynthesis and osteoblast cell differentiation. Further, PKG activation by 14 stimulated the activity of SHP2 (Src homology 2 domain containing tyrosine phosphatase 2), thereby activating Src and ERK (extracellular signal regulated kinase) signaling and increasing ERK dependent aromatase expression in osteoblasts. Our findings reveal a previously unknown role of cGMP in the regulation of estrogen biosynthesis in the bone. These results support the further development of 14 as a PKG activating drug to mimic the anabolic effects of mechanical stimulation of bone in the treatment of osteoporosis.
C1 [Wisanwattana, Wisanee; Cao, Dong yi; Shi, Xiao ke; Zhou, Zong yuan; Li, Fu; Mei, Qing gang; Wang, Chun; Zhang, Guo lin; Wang, Fei] Chinese Acad Sci, Chengdu Inst Biol, Ctr Nat Prod Res, Chengdu, Peoples R China.
   [Wisanwattana, Wisanee; Cao, Dong yi; Shi, Xiao ke; Zhou, Zong yuan] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Wongkrajang, Kanjana] Pibulsongkram Rajabhat Univ, Fac Sci & Technol, Dept Chem, Phitsanulok, Thailand.
   [Zhang, Zhong hui] Sichuan Univ, Coll Chem Engn, Chengdu, Peoples R China.
   [Suksamrarn, Apichart] Ramkhamhang Univ, Fac Sci, Dept Chem, Bangkok, Thailand.
   [Suksamrarn, Apichart] Ramkhamhang Univ, Fac Sci, Ctr Excellent Innovat Chem, Bangkok, Thailand.
C3 Chinese Academy of Sciences; Chengdu Institute of Biology, CAS; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS;
   Pibulsongkram Rajabhat University; Sichuan University; Ramkhamhaeng
   University; Ramkhamhaeng University
RP Zhang, GL; Wang, F (通讯作者)，Chinese Acad Sci, Chengdu Inst Biol, Ctr Nat Prod Res, Chengdu, Peoples R China.
EM zhanggl@cib.ac.cn; wangfei@cib.ac.cn
RI Suksamrarn, Apichart/R 8782 2019; Wang, Chunzai/C 9712 2009; Wang,
   Fei/ABE 3386 2021
FU National Natural Science Foundation of China [21861142007, 21977092,
   21550110193]; Science & Technology Department of Sichuan Province
   [2019YSF0106]; CAS TWAS President's PhD Fellowship Program; Chinese
   Academy of Sciences President's International Fellowship Initiative
   [2016CTF092]; Biological Resources Programme, Chinese Academy of
   Sciences [KFJ BRP 008]; National New Drug Innovation Major Project of
   China [2018ZX09711001 001 006]; Thailand Research Fund [DBG6180030]
FX This work was supported by the National Natural Science Foundation of
   China (No. 21861142007, 21977092, 21550110193), Science & Technology
   Department of Sichuan Province (No. 2019YSF0106), CAS TWAS President's
   PhD Fellowship Program, Chinese Academy of Sciences President's
   International Fellowship Initiative (No. 2016CTF092), Biological
   Resources Programme, Chinese Academy of Sciences (KFJ BRP 008), and the
   National New Drug Innovation Major Project of China
   (2018ZX09711001 001 006). Support from The Thailand Research Fund (No.
   DBG6180030) is gratefully acknowledged.
CR Alp HH, 2017, EXP BIOL MED, V242, P1051, DOI 10.1177/1535370217703352
   Aversa A, 2011, J SEX MED, V8, P696, DOI 10.1111/j.1743 6109.2010.02152.x
   Catalano S, 2009, MOL ENDOCRINOL, V23, P1634, DOI 10.1210/me.2009 0039
   Cui J, 2013, TRENDS MOL MED, V19, P197, DOI 10.1016/j.molmed.2012.12.007
   Dell'Agli M, 2008, J NAT PROD, V71, P1513, DOI 10.1021/np800049y
   Enjuanes A, 2005, EUR J ENDOCRINOL, V153, P981, DOI 10.1530/eje.1.02032
   Eyre LJ, 1998, J BONE MINER RES, V13, P996, DOI 10.1359/jbmr.1998.13.6.996
   Galliher Beckley AJ, 2009, IUBMB LIFE, V61, P979, DOI 10.1002/iub.245
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gong Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.510
   Guo AJ, 2012, CHIN MED UK, V7, DOI 10.1186/1749 8546 7 10
   Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092 8674(03)00196 X
   He Z, 2012, MOL CELL BIOL, V32, P1867, DOI 10.1128/MCB.06712 11
   Horstman AM, 2012, J GERONTOL A BIOL, V67, P1140, DOI 10.1093/gerona/gls068
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huyut Z, 2018, MED SCI MONIT BASIC, V24, P47, DOI 10.12659/MSMBR.908504
   Igbe I, 2017, ONCOTARGET, V8, P113734, DOI 10.18632/oncotarget.22556
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kim SM, 2020, P NATL ACAD SCI USA, V117, P14386, DOI 10.1073/pnas.2000950117
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Li F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08203 7
   Lu DF, 2012, EUR J PHARMACOL, V691, P275, DOI 10.1016/j.ejphar.2012.07.005
   Ma HP, 2011, J ETHNOPHARMACOL, V134, P519, DOI 10.1016/j.jep.2011.01.001
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349 7006.2009.01257.x
   Mei QG, 2015, BEILSTEIN J ORG CHEM, V11, DOI 10.3762/bjoc.11.135
   Mei QG, 2015, BEILSTEIN J ORG CHEM, V11, DOI 10.3762/bjoc.11.33
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Ming LG, 2013, ENDOCRINOLOGY, V154, P1202, DOI 10.1210/en.2012 2086
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   O'Shaughnessy MC, 2000, BIOCHEM BIOPH RES CO, V277, P604, DOI 10.1006/bbrc.2000.3714
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Pal S, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115305
   Pu WC, 2016, BIOORG MED CHEM LETT, V26, P5497, DOI 10.1016/j.bmcl.2016.10.013
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Rabal O, 2016, J MED CHEM, V59, P8967, DOI 10.1021/acs.jmedchem.6b00908
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Ribot C, 2006, JOINT BONE SPINE, V73, P37, DOI 10.1016/j.jbspin.2005.02.005
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Shozu M, 1998, MOL CELL ENDOCRINOL, V139, P117, DOI 10.1016/S0303 7207(98)00069 0
   Simpson ER, 2004, SEMIN REPROD MED, V22, P11
   Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703
   Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914
   Yang LJ, 2013, J ETHNOPHARMACOL, V145, P715, DOI 10.1016/j.jep.2012.11.031
   Yang LJ, 2011, J ETHNOPHARMACOL, V135, P553, DOI 10.1016/j.jep.2011.03.056
   Yang XM, 2015, TRENDS FOOD SCI TECH, V44, P93, DOI 10.1016/j.tifs.2015.03.007
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhang Y, 2008, ARCH PHARM RES, V31, P1534, DOI 10.1007/s12272 001 2147 5
NR 52
TC 8
Z9 8
U1 0
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAR 12
PY 2021
VL 12
AR 636784
DI 10.3389/fendo.2021.636784
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA RC8FG
UT WOS:000633029200001
PM 33776932
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, J
   Ahn, SH
   Chen, Z
   Kang, S
   Choi, DK
   Moon, C
   Min, SH
   Park, BJ
   Lee, TH
AF Lee, Jinkyung
   Ahn, Sun Hee
   Chen, Zhihao
   Kang, Sohi
   Choi, Dong Kyu
   Moon, Changjong
   Min, Sang Hyun
   Park, Byung Ju
   Lee, Tae Hoon
TI N [2 (4 Acetyl 1 Piperazinyl)Phenyl] 2 (3 Methylphenoxy)Acetamide
   (NAPMA) Inhibits Osteoclast Differentiation and Protects against
   Ovariectomy Induced Osteoporosis
SO MOLECULES
LA English
DT Article
DE NAPMA; osteoclast; ovariectomy; osteoporosis; bone loss; bone resorption
ID NF KAPPA B; BONE RESORPTION; RECEPTOR ACTIVATOR; RANKL; EXPRESSION;
   NFATC1; OSTEOIMMUNOLOGY; PRECURSORS; IMMUNE; MAPK
AB Osteoclasts are large, multinucleated cells responsible for bone resorption and are induced in response to the regulatory activity of receptor activator of nuclear factor kappa B ligand (RANKL). Excessive osteoclast activity causes pathological bone loss and destruction. Many studies have investigated molecules that specifically inhibit osteoclast activity by blocking RANKL signaling or bone resorption. In recent years, we screened compounds from commercial libraries to identify molecules capable of inhibiting RANKL induced osteoclast differentiation. Consequently, we reported some compounds that are effective at attenuating osteoclast activity. In this study, we found that N [2 (4 acetyl 1 piperazinyl)phenyl] 2 (3 methylphenoxy)acetamide (NAPMA) significantly inhibited the formation of multinucleated tartrate resistant acid phosphatase (TRAP) positive cells from bone marrow derived macrophages in a dose dependent manner, without cytotoxic effects. NAPMA downregulated the expression of osteoclast specific markers, such as c Fos, NFATc1, DC STAMP, cathepsin K, and MMP 9, at the transcript and protein levels. Accordingly, bone resorption and actin ring formation were decreased in response to NAPMA treatment. Furthermore, we demonstrated the protective effect of NAPMA against ovariectomy induced bone loss using micro CT and histological analysis. Collectively, the results showed that NAPMA inhibited osteoclast differentiation and attenuated bone resorption. It is thus a potential drug candidate for the treatment of osteoporosis and other bone diseases associated with excessive bone resorption.
C1 [Lee, Jinkyung; Park, Byung Ju; Lee, Tae Hoon] Chonnam Natl Univ, Sch Dent, Dent Sci Res Inst, Dept Oral Biochem, Gwangju 61186, South Korea.
   [Ahn, Sun Hee] Korea Photon Technol Inst KOPTI, Dept Biohlth Res Ctr, Gwangju 61007, South Korea.
   [Chen, Zhihao; Lee, Tae Hoon] Chonnam Natl Univ, Grad Sch, Dept Mol Med BK21plus, Gwangju 61186, South Korea.
   [Kang, Sohi; Moon, Changjong] Chonnam Natl Univ, Coll Vet Med, Dept Vet Anat, Gwangju 61186, South Korea.
   [Kang, Sohi; Moon, Changjong] Chonnam Natl Univ, BK21 FOUR Program, Gwangju 61186, South Korea.
   [Choi, Dong Kyu; Min, Sang Hyun] DGMIF, New Drug Dev Ctr, 80 Chumbok Ro, Daegu 41061, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University; Chonnam National University
RP Park, BJ; Lee, TH (通讯作者)，Chonnam Natl Univ, Sch Dent, Dent Sci Res Inst, Dept Oral Biochem, Gwangju 61186, South Korea.; Lee, TH (通讯作者)，Chonnam Natl Univ, Grad Sch, Dept Mol Med BK21plus, Gwangju 61186, South Korea.
EM wlsrud1945@naver.com; sun3193@kopti.re.kr; chinaczhihao@gmail.com;
   shrloveu@gmail.com; dongkyu@dgmif.re.kr; moonc@chonnam.ac.kr;
   shmin03@dgmif.re.kr; bjpark@jnu.ac.kr; thlee83@jnu.ac.kr
RI Lee, Tae Hoon/AAR 3708 2021; Choi, dongKyu/LKL 2959 2024; Moon,
   Changjong/AAI 2005 2020
OI KANG, Sohi/0000 0003 4689 5797; ZHIHAO, CHEN/0000 0002 8433 5400; Lee,
   Jinkyung/0000 0003 1613 6490; Moon, Changjong/0000 0003 2451 0374; Lee,
   Tae Hoon/0000 0003 0105 1750; 
FU Bio& Medical Technology Development Program [2016M3A9B6903087]; Basic
   Science Research Program of the National Research Foundation (NRF)  
   Ministry of Science, ICT & Future Planning [2019R1A2C1084080]
FX This work was supported by the Bio& Medical Technology Development
   Program (2016M3A9B6903087), and Sun hee Ahn was supported by the Basic
   Science Research Program (2019R1A2C1084080) of the National Research
   Foundation (NRF), funded by the Ministry of Science, ICT & Future
   Planning.
CR Ahn SH, 2018, MOLECULES, V23, DOI 10.3390/molecules23123139
   Ahn SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071835
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen WX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1914 5
   Chen Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205196
   Cho E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113436
   Choi BY, 2016, MOL MED REP, V13, P4014, DOI 10.3892/mmr.2016.5015
   Cooper C, 2005, RHEUMATOLOGY, V44, P36, DOI 10.1093/rheumatology/kei060
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Dobbs M B, 1999, Iowa Orthop J, V19, P43
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gallagher JC, 2013, CLIN OBSTET GYNECOL, V56, P749, DOI 10.1097/GRF.0b013e3182a982c2
   Han SY, 2018, INT J MOL MED, V42, P331, DOI 10.3892/ijmm.2018.3603
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khosla S, 2009, NEW ENGL J MED, V361, P818, DOI 10.1056/NEJMe0905480
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim MH, 2009, J CELL PHYSIOL, V221, P618, DOI 10.1002/jcp.21892
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Koehne T, 2018, CLIN ORAL INVEST, V22, P2345, DOI 10.1007/s00784 018 2335 z
   KOHN SR, 1982, J REPROD FERTIL, V66, P185
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Miyazaki T, 2011, ANAL BIOCHEM, V410, P7, DOI 10.1016/j.ab.2010.11.014
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Park JH, 2017, MOL CELLS, V40, P706
   Qin SN, 2015, INT J MOL SCI, V16, P26599, DOI 10.3390/ijms161125972
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Trzeciakiewicz A, 2010, J NUTR BIOCHEM, V21, P424, DOI 10.1016/j.jnutbio.2009.01.017
   Ulrich D, 1999, BONE, V25, P55, DOI 10.1016/S8756 3282(99)00098 8
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01188
   Xing LP, 2012, WORLD J ORTHOP, V3, P212, DOI 10.5312/wjo.v3.i12.212
   Yamashita M, 2010, REGUL PEPTIDES, V162, P99, DOI 10.1016/j.regpep.2010.03.003
   Yang J, 2015, INT J ORAL SCI, V7, P95, DOI 10.1038/ijos.2015.7
   Yun IG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092494
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zhong ZY, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01530
NR 55
TC 3
Z9 3
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2020
VL 25
IS 20
AR 4855
DI 10.3390/molecules25204855
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ON9UJ
UT WOS:000587035800001
PM 33096734
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zaidi, M
   Iqbal, J
   Blair, HC
   Zallone, A
   Davies, T
   Sun, L
AF Zaidi, Mone
   Iqbal, Jameel
   Blair, Harry C.
   Zallone, Alberta
   Davies, Terry
   Sun, Li
TI Paradigm Shift in the Pathophysiology of Postmenopausal and Thyrotoxic
   Osteoporosis
SO MOUNT SINAI JOURNAL OF MEDICINE
LA English
DT Article
DE bone loss; follicle stimulating hormone; osteoclast; osteopenia;
   postmenopausal osteoporosis; thyroid stimulating hormone; thyrotoxic
   osteoporosis
ID BONE MINERAL DENSITY; THYROID STIMULATING HORMONE; ENDOGENOUS
   SUBCLINICAL HYPERTHYROIDISM; SERUM TSH; TURNOVER MARKERS; RECOMBINANT
   TSH; ESTROGEN; WOMEN; CELLS; DIFFERENTIATION
AB Bone loss is an inevitable result of getting older in both sexes. This loss is accelerated in women in the early years following menopause and in both sexes with drugs and diseases, prominently hyperthyroidism. Postmenopausal osteoporosis and hyperthyroid osteoporosis, both of which are widely recognized clinical entities, have been thought to arise from low estrogen levels and high thyroid hormone levels, respectively. However, when estrogen declines, follicle stimulating hormone, an anterior pituitary hormone, rises. Likewise, when thyroid hormone levels rise in hyperthyroidism, thyroid stimulating hormone levels fall. We have used a complement of mouse genetic, pharmacological, and cell biological approaches to unravel a direct action of follicle stimulating hormone and thyroid stimulating hormone on bone remodeling and bone mass. Apart from establishing a novel pituitary bone axis of physiological significance, our studies challenge the existing I hormone, 1 disease paradigm in endocrinology and Suggest that a plurality of hormonal disturbances involving pituitary hormones cause Postmenopausal and hyperthyroid osteoporoses. New therapeutic targets thus emerge from these studies. Mt Sinai J Med 76:4 74 483, 2009. (C) 2009 Mount Sinai School of Medicine
C1 [Zaidi, Mone; Iqbal, Jameel; Davies, Terry; Sun, Li] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA.
   [Blair, Harry C.] Univ Pittsburgh, Dept Pathol & Cell Biol, Pittsburgh, PA USA.
   [Zallone, Alberta] Univ Bari, Dept Histol, Bari, Italy.
C3 Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; Universita
   degli Studi di Bari Aldo Moro
RP Zaidi, M (通讯作者)，Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA.
EM mone.zaidi@mssm.edu
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Akhter MP, 2007, BONE, V41, P111, DOI 10.1016/j.bone.2007.03.019
   Albagha OME, 2005, J BONE MINER RES, V20, pS341
   Albright F, 1941, J AMER MED ASSOC, V116, P2465, DOI 10.1001/jama.1941.02820220007002
   ALLAIN TJ, 1992, J ENDOCRINOL, V133, P327, DOI 10.1677/joe.0.1330327
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   BARAN DT, 1994, THYROID, V4, P143, DOI 10.1089/thy.1994.4.143
   Bassett JHD, 2007, MOL ENDOCRINOL, V21, P1893, DOI 10.1210/me.2007 0157
   Bassett JHD, 2007, MOL ENDOCRINOL, V21, P1095, DOI 10.1210/me.2007 0033
   Bassett JHD, 2009, J MOL ENDOCRINOL, V42, P269, DOI 10.1677/JME 08 0142
   Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003 4819 134 7 200104030 00009
   BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169
   Dawson Hughes B, 2001, NEW ENGL J MED, V345, P989, DOI 10.1056/NEJM200109273451310
   DEMENIS E, 1992, HORM RES, V37, P217, DOI 10.1159/000182315
   Devleta B, 2004, J BONE MINER METAB, V22, P360, DOI 10.1007/s00774 004 0495 1
   FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365 2265.1993.tb02403.x
   Gao JJ, 2007, ENDOCRINOLOGY, V148, P2613, DOI 10.1210/en.2006 1404
   Giusti Massimo, 2007, Hormones (Athens), V6, P304
   Göthe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329
   Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003 4819 130 9 199905040 00016
   Grimnes G, 2008, THYROID, V18, P1147, DOI 10.1089/thy.2008.0158
   Gürlek A, 1999, THYROID, V9, P539, DOI 10.1089/thy.1999.9.539
   Hase H, 2006, P NATL ACAD SCI USA, V103, P12849, DOI 10.1073/pnas.0600427103
   Heemstra KA, 2008, EUR J ENDOCRINOL, V159, P69, DOI 10.1530/EJE 08 0038
   Iqbal J, 2006, P NATL ACAD SCI USA, V103, P14925, DOI 10.1073/pnas.0606805103
   Ishikawa Y, 1998, J BONE MINER RES, V13, P1398, DOI 10.1359/jbmr.1998.13.9.1398
   Jagger CJ, 1996, J CLIN INVEST, V98, P2351, DOI 10.1172/JCI119047
   Kim CH, 1999, J ENDOCRINOL, V160, P97, DOI 10.1677/joe.0.1600097
   Kindblom JM, 2005, BONE, V36, P607, DOI 10.1016/j.bone.2005.01.017
   Kisakol G, 2003, ENDOCR J, V50, P657, DOI 10.1507/endocrj.50.657
   La Vignera S, 2008, Minerva Ginecol, V60, P475
   Martini G, 2008, THYROID, V18, P455, DOI 10.1089/thy.2007.0166
   Mazziotti G, 2005, J BONE MINER RES, V20, P480, DOI 10.1359/JBMR.041126
   Mikosch P, 2008, THYROID, V18, P27, DOI 10.1089/thy.2007.0186
   Miyaura C, 2001, BIOCHEM BIOPH RES CO, V280, P1062, DOI 10.1006/bbrc.2001.4246
   Morris MS, 2007, BONE, V40, P1128, DOI 10.1016/j.bone.2006.12.001
   Murphy E, 2004, CLIN ENDOCRINOL, V61, P285, DOI 10.1111/j.1365 2265.2004.02053.x
   Nagata M, 2007, ENDOCR J, V54, P625, DOI 10.1507/endocrj.K06 201
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Novack DV, 2003, CELL, V115, P129, DOI 10.1016/S0092 8674(03)00812 2
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Randolph JF, 2004, J CLIN ENDOCR METAB, V89, P1555, DOI 10.1210/jc.2003 031183
   Rannevik G, 2008, MATURITAS, V61, P67, DOI 10.1016/j.maturitas.2008.09.010
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   ROSS DS, 1994, THYROID, V4, P319, DOI 10.1089/thy.1994.4.319
   Sampath TK, 2007, J BONE MINER RES, V22, P849, DOI 10.1359/JBMR.070302
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756 3282(01)00643 3
   Sowers MR, 2006, J CLIN ENDOCR METAB, V91, P1261, DOI 10.1210/jc.2005 1836
   Sowers MR, 2003, OSTEOPOROSIS INT, V14, P191, DOI 10.1007/s00198 002 1329 4
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561
   Stepnick LS., 2004, Bone Health and Osteoporosis: A Report of the Surgeon General, P68
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105
   van der Deure WM, 2008, CLIN ENDOCRINOL, V68, P175, DOI 10.1111/j.1365 2265.2007.03016.x
   von Recklinghausen F D., 1891, Die Fibrose oder deformierende Ostitis, die Osteomalazie und die osteoplastische Carzinose in ihren gegenseitigen Beziehungen, Festchrift Rudolf Virchow (Ed)
   WENZEL KW, 1994, THYROID, V4, P508, DOI 10.1089/thy.1994.4.508
   Wu YL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000586
   Xu ZR, 2009, CLIN CHIM ACTA, V400, P8, DOI 10.1016/j.cca.2008.09.027
   Zaidi M, 2006, THYROID, V16, P1075, DOI 10.1089/thy.2006.16.1075
   Zofkova Ivana, 2008, Endocr Regul, V42, P121
NR 64
TC 2
Z9 2
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0027 2507
EI 1931 7581
J9 MT SINAI J MED
JI Mt. Sinai J. Med.
PD SEP OCT
PY 2009
VL 76
IS 5
BP 474
EP 483
DI 10.1002/msj.20136
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 504JK
UT WOS:000270612200010
PM 19787657
DA 2025 08 17
ER

PT J
AU Wang, WZ
   Tseng, WJ
   Zhao, HB
   Azar, T
   Pei, SP
   Jiang, X
   Dyment, N
   Liu, S
AF Wang, Wenzheng
   Tseng, Wei Ju
   Zhao, Hongbo
   Azar, Tala
   Pei, Shaopeng
   Jiang, Xi
   Dyment, Nathaniel
   Liu, Sherry
TI Activation, development, and attenuation of modeling  and
   remodeling based bone formation in adult rats
SO BIOMATERIALS
LA English
DT Article
DE Bone histomorphometry; Anabolic treatments; Animal model; Osteoporosis;
   Modeling and remodeling based bone formation
ID PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; CANCELLOUS
   BONE; LINING CELLS; TERIPARATIDE; RESORPTION; THERAPY; MICROSTRUCTURE;
   OSTEOPOROSIS
AB Activation of modeling based bone formation (MBF  bone formation without prior activation of bone resorp tion), has been identified as an important mechanism by which anabolic agents, such as intermittent parathyroid hormone (PTH), rapidly elicit new bone formation. Using a novel cryohistology imaging platform, coupled with sequential multicolor fluorochrome injections, we demonstrated that MBF and remodeling based bone formation (RBF) in the adult rat tibia model have similar contributions to trabecular bone homeostasis. PTH treatment resulted in a 2.4 4.9 fold greater bone formation rate over bone surface (BFR/BS) by RBF and a 4.3 8.5 fold greater BFR/BS by MBF in male, intact female, and ovariectomized female rats. Moreover, regardless of bone formation type, once a formation site is activated by PTH, mineral deposition continues throughout the entire treatment duration. Furthermore, by tracking the sequence of multicolor fluorochrome labels, we discovered that MBF, a highly efficient but often overlooked regenerative mechanism, is activated more rapidly but attenuated faster than RBF in response to PTH. This suggests that MBF and RBF contribute differently to PTH's anabolic effect in rats: MBF has a greater contribution to the acute elevation in bone mass at the early stage of treatment while RBF contributes to the sustained treatment effect.
C1 [Wang, Wenzheng; Tseng, Wei Ju; Zhao, Hongbo; Azar, Tala; Pei, Shaopeng; Jiang, Xi; Dyment, Nathaniel; Liu, Sherry] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.
   [Wang, Wenzheng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed Surg, Wuhan, Hubei, Peoples R China.
C3 University of Pennsylvania; Huazhong University of Science & Technology
RP Liu, S (通讯作者)，Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, 332A Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.
EM xiaoweil@pennmedicine.upenn.edu
RI Dyment, Nathaniel/AAD 6747 2021; Tseng, Wei Ju/AAC 2819 2022; Pei,
   Shaopeng/AAZ 4395 2021; Liu, Xiaowei/H 1664 2017; Z, HB/KHX 5716 2024;
   Liu, Xiaowei Sherry/H 1664 2017
OI Wang, Wenzheng/0000 0002 0372 4173; Tseng, Wei Ju/0000 0001 8783 5104;
   Liu, Xiaowei Sherry/0000 0001 7247 2232
FU Penn Center for Musculoskeletal Diseases (PCMD); National Institute of
   Arthritis and Musculoskeletal and Skin Diseases of the National
   Institutes of Health (NIH/NIAMS) [P30 AR069619, T32 AR007132,
   K01 AR066743, R01 AR077598]; National Science Foundation (NSF)
   [1661858]; Directorate For Engineering; Div Of Civil, Mechanical, &
   Manufact Inn [1661858] Funding Source: National Science Foundation
FX Research reported in this publication was supported by the Penn Center
   for Musculoskeletal Diseases (PCMD), the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases of the National Institutes of
   Health (NIH/NIAMS) under Award Number P30 AR069619, T32 AR007132,
   K01 AR066743 (to XSL), and R01 AR077598 (to XSL), and National Science
   Foundation (NSF) under Award Number 1661858 (to XSL).
CR Altman AR, 2015, BONE, V81, P370, DOI 10.1016/j.bone.2015.07.037
   Birkhold AI, 2015, BONE, V75, P210, DOI 10.1016/j.bone.2015.02.027
   Birkhold AI, 2014, BIOMATERIALS, V35, P9290, DOI 10.1016/j.biomaterials.2014.07.051
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce RW, 2017, BONE, V101, P77, DOI 10.1016/j.bone.2017.04.005
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2019, BONE, V120, P246, DOI 10.1016/j.bone.2018.10.020
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cui L, 2001, J BONE MINER METAB, V19, P29, DOI 10.1007/s007740170057
   de Bakker CMJ, 2015, BONE, V73, P198, DOI 10.1016/j.bone.2014.12.061
   Dempster DW, 2018, J BONE MINER RES, V33, P627, DOI 10.1002/jbmr.3350
   Dempster DW, 2018, J BONE MINER RES, V33, P298, DOI 10.1002/jbmr.3309
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dyment NA, 2016, JOVE J VIS EXP, DOI 10.3791/54468
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   F A D Administration, 2005, Estimating the maximum safe starting dose in initialclinical trialsfor therapeutics in adult healthy volunteers
   FROST HM, 1990, ANAT RECORD, V226, P403, DOI 10.1002/ar.1092260402
   Ganghoffer JF, 2012, INT J ENG SCI, V50, P166, DOI 10.1016/j.ijengsci.2011.08.004
   Giorgio I, 2021, MATH MECH SOLIDS, V26, P1074, DOI 10.1177/1081286520978516
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Hodsman AB, 2003, J CLIN ENDOCR METAB, V88, P5212, DOI 10.1210/jc.2003 030768
   HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756 3282(93)90190 L
   Jee W. S. S., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P232
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Johnson H.J., 2013, The itk software guide third edition updated for itk version 4.5
   Kawamoto T, 2000, HISTOCHEM CELL BIOL, V113, P331
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kobayashi S, 2003, BONE, V32, P163, DOI 10.1016/S8756 3282(02)00947 X
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kousteni Stavroula, 2008, Curr Osteoporos Rep, V6, P72, DOI 10.1007/s11914 008 0013 9
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Lambers FM, 2011, BONE, V49, P1340, DOI 10.1016/j.bone.2011.08.035
   Lan SH, 2013, BONE, V56, P83, DOI 10.1016/j.bone.2013.05.014
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lekszycki T, 2012, ZAMM Z ANGEW MATH ME, V92, P426, DOI 10.1002/zamm.201100082
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Pennypacker BL, 2014, J BONE MINER RES, V29, P1847, DOI 10.1002/jbmr.2211
   Schulte FA, 2011, BONE, V48, P433, DOI 10.1016/j.bone.2010.10.007
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033 2909.86.2.420
   Takahashi H., 1964, Henry Ford Hosp Med Bull, V12, P359
   Tseng W.J., 2020, ANN M ORTH RES SOC 2
   Zhao H., 2020, BONE, V48, P157
NR 47
TC 6
Z9 6
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2021
VL 276
AR 121015
DI 10.1016/j.biomaterials.2021.121015
EA JUL 2021
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA UI0EW
UT WOS:000690293000002
PM 34273687
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Costa, V
   Raimondi, L
   Conigliaro, A
   Salamanna, F
   Carina, V
   De Luca, A
   Bellavia, D
   Alessandro, R
   Fini, M
   Giavaresi, G
AF Costa, Viviana
   Raimondi, Lavinia
   Conigliaro, Alice
   Salamanna, Francesca
   Carina, Valeria
   De Luca, Angela
   Bellavia, Daniele
   Alessandro, Riccardo
   Fini, Milena
   Giavaresi, Gianluca
TI Hypoxia inducible factor 1. may regulate the commitment of mesenchymal
   stromal cells toward angio osteogenesis by mirna 675 5P
SO CYTOTHERAPY
LA English
DT Article
DE hypoxia; mesenchymal stromal cells; miR 675 5p; osteoblast commitment;
   regenerative medicine
ID STEM CELLS; OSTEOBLAST DIFFERENTIATION; BONE FORMATION; IN VIVO;
   ANGIOGENESIS; MARROW; VEGF; H19; REGENERATION; PROGRESSION
AB Background aims. During bone formation, angiogenesis and osteogenesis are regulated by hypoxia, which is able to induce blood vessel formation, as well as recruit and differentiate human mesenchymal stromal cells (hMSCs). The molecular mechanisms involved in HIF 1 alpha response and hMSC differentiation during bone formation are still unclear. This study aimed to investigate the synergistic role of hypoxia and hypoxia mimetic microRNA miR 675 5p in angiogenesis response and osteo chondroblast commitment of hMSCs. Methods. By using a suitable in vitro cell model of hMSCs (maintained in hypoxia or normoxia), the role of HIF 1 alpha and miR 675 5p in angiogenesis and osteogenesis coupling was investigated, using fluorescence activated cell sorting (FACS), gene expression and protein analysis. Results. Hypoxia induced miR 675 5p expression and a hypoxia angiogenic response, as demonstrated by increase in vascular endothelial growth factor messenger RNA and protein release. MiR 675 5p overexpression in normoxia promoted the down regulation of MSC markers and the up regulation of osteoblast and chondroblast markers, as demonstrated by FACS and protein analysis. Moreover, miR 675 5p depletion in a low oxygen condition partially abolished the hypoxic response, including angiogenesis, and in particular restored the MSC phenotype, demonstrated by cytofluorimetric analysis. In addition, current preliminary data suggest that the expression of miR 675 5p during hypoxia plays an additive role in sustaining Wnt/beta catenin pathways and the related commitment of hMSCs during bone ossification. Discussion. MiR 675 5p may trigger complex molecular mechanisms that promote hMSC osteoblastic differentiation through a dual strategy: increasing HIF 1 alpha response and activating Wnt/beta catenin signaling.
C1 [Costa, Viviana; Raimondi, Lavinia; Carina, Valeria; De Luca, Angela; Bellavia, Daniele; Giavaresi, Gianluca] Rizzoli Orthoped Inst, Bologna, Italy.
   [Costa, Viviana; Raimondi, Lavinia; Carina, Valeria; De Luca, Angela; Bellavia, Daniele; Giavaresi, Gianluca] Rizzoli Orthoped Inst, Innovat Technol Platforms Tissue Engn Theranost &, Via Div 83, I 90133 Palermo, Italy.
   [Conigliaro, Alice] Sapienza Univ Rome, Dept Cellular Biotechnol & Hematol, Rome, Italy.
   [Salamanna, Francesca; Fini, Milena; Giavaresi, Gianluca] Rizzoli Orthoped Inst, Lab Preclin & Surg Studies, Bologna, Italy.
   [Alessandro, Riccardo] Univ Palermo, Sect Biol & Genet, Dept Biopathol & Med Biotechnol, Palermo, Italy.
   [Alessandro, Riccardo] CNR, Inst Biomed & Mol Immunol, Palermo, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli;
   Sapienza University Rome; IRCCS Istituto Ortopedico Rizzoli; University
   of Palermo; Consiglio Nazionale delle Ricerche (CNR); Istituto di
   Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM CNR)
RP Costa, V (通讯作者)，Rizzoli Orthoped Inst, Innovat Technol Platforms Tissue Engn Theranost &, Via Div 83, I 90133 Palermo, Italy.
EM viviana.costa@ior.it
RI Giavaresi, Gianluca/J 5583 2016; Conigliaro, Alice/L 5590 2019;
   Raimondi, Lavinia/K 4085 2016; Fini, Milena/J 4808 2016; Conigliaro,
   Alice/J 8717 2016; COSTA, VIVIANA/K 4084 2016; carina,
   valeria/K 2001 2016; deluca, angela/ABD 3384 2020; costa,
   viviana/K 4084 2016; De Luca, Angela/ABD 3384 2020; Salamanna,
   Francesca/J 6032 2016; Bellavia, Daniele/H 9774 2019
OI Raimondi, Lavinia/0000 0001 9394 2002; Fini, Milena/0000 0002 3732 3570;
   Conigliaro, Alice/0000 0002 3037 835X; Giavaresi,
   Gianluca/0000 0001 7843 5969; carina, valeria/0000 0002 7323 8023;
   costa, viviana/0000 0002 2425 6460; De Luca, Angela/0000 0001 5493 9441;
   Salamanna, Francesca/0000 0001 7402 4054; Bellavia,
   Daniele/0000 0003 3308 9112
FU National Operational Programme for Research and Competitiveness
   [PON03_00011, PON01_00829]; Italian Ministry of Health
FX The authors thank the National Operational Programme for Research and
   Competitiveness 2007 2013 for providing equipment (project PON03_00011,
   "Potenziamento strutturale di una rete di eccellenza per la ricerca
   preclinica e clinica sulla terapia personalizzata in oncologia e in
   medicina rigenerativa"). The study was developed through funding from
   the Italian Ministry of Health by the "Ricerca Corrente" and the
   National Operational Programme for Research and Competitiveness
   2007 2013 (project PON01_00829, "Piattaforme Tecnologiche per
   l'Ingegneria Tissutale").
CR Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Bentovim L, 2012, DEVELOPMENT, V139, P4473, DOI 10.1242/dev.083881
   Bluteau G, 2007, BONE, V40, P568, DOI 10.1016/j.bone.2006.09.024
   Carulli Christian, 2013, Front Endocrinol (Lausanne), V4, P106, DOI 10.3389/fendo.2013.00106
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Costa V, 2017, ONCOTARGET, V8, P24292, DOI 10.18632/oncotarget.14464
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Dey BK, 2014, GENE DEV, V28, P491, DOI 10.1101/gad.234419.113
   Drager J, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.4
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Götz W, 2012, ANN ANAT, V194, P171, DOI 10.1016/j.aanat.2011.10.002
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Guo L, 2011, EXP HEMATOL, V39, P608, DOI 10.1016/j.exphem.2011.01.011
   He PH, 2016, AM J TRANSL RES, V8, P1780
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546
   Kusumbe AP, 2014, NAT MED, V20, P1238, DOI 10.1038/nm.3747
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Leys C, 2013, J EXP SOC PSYCHOL, V49, P764, DOI 10.1016/j.jesp.2013.03.013
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo Dico A, 2016, THERANOSTICS, V6, P1105, DOI 10.7150/thno.14700
   Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535 6108(02)00240 4
   Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007
   Rabbany SY, 2003, TRENDS MOL MED, V9, P109, DOI 10.1016/S1471 4914(03)00021 2
   Rankin Erinn B, 2011, Curr Osteoporos Rep, V9, P46, DOI 10.1007/s11914 011 0047 2
   Riddle RC, 2009, J MOL MED, V87, P583, DOI 10.1007/s00109 009 0477 9
   Roberts CL, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/1513281
   Seki K, 2003, J BIOL CHEM, V278, P41862, DOI 10.1074/jbc.M308336200
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005
   Simpson AHRW, 2006, J BONE JOINT SURG BR, V88B, P701, DOI 10.1302/0301 620X.88B6
   Sun TH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020236
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE 11 0646
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Wang Y, 2007, ANN NY ACAD SCI, V1117, P1, DOI 10.1196/annals.1402.049
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659
   Zhang FY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0187 x
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zou D, 2011, CELL PROLIFERAT, V44, P234, DOI 10.1111/j.1365 2184.2011.00747.x
NR 46
TC 46
Z9 54
U1 0
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PD DEC
PY 2017
VL 19
IS 12
BP 1412
EP 1425
DI 10.1016/j.jcyt.2017.09.007
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA FO7UE
UT WOS:000417081700005
PM 29111380
DA 2025 08 17
ER

PT J
AU Hu, YW
   Nyman, J
   Muhonen, P
   Väänänen, HK
   Laitala Leinonen, T
AF Hu, YW
   Nyman, J
   Muhonen, P
   Väänänen, HK
   Laitala Leinonen, T
TI Inhibition of the osteoclast V ATPase by small interfering RNAs
SO FEBS LETTERS
LA English
DT Article
DE osteoclast; V ATPase; a3 isoform; knockdown; siRNA
ID VACUOLAR H+ ATPASE; INFANTILE MALIGNANT OSTEOPETROSIS;
   CARBONIC ANHYDRASE II; RESORPTION IN VITRO; BONE RESORPTION; PROTON
   PUMP; MOLECULAR CLONING; A3 ISOFORM; PLASMA MEMBRANE; RUFFLED BORDER
AB The multisubunit enzyme V ATPase harbours isoforms of individual subunits. a3 is one of four 116 kDa subunit a isoforms, and it is crucial for bone resorption. We used small interfering RNA (siRNA) molecules to knock down a3 in rat osteoclast cultures. Labeled siRNA molecules entered osteoclasts via endocytosis and knocked down the a3 mRNA. Bone resorption was decreased in siRNA treated samples due to decreased acidification and osteoclast inactivation. Expression of at did not respond to decreased a3 levels, suggesting that a1 does not compensate for a3 in osteoclast cultures. Subunit a3 is thus an interesting target for novel nucleic acid therapy. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Turku, Dept Anat, Inst Biomed, FIN 20520 Turku, Finland.
C3 University of Turku
RP Laitala Leinonen, T (通讯作者)，Univ Turku, Dept Anat, Inst Biomed, Kiinamyllynkatu 10, FIN 20520 Turku, Finland.
EM tilale@utu.fi
RI Nyman, Johan/JFA 6141 2023
CR BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Hurst IR, 2004, J BONE MINER RES, V19, P499, DOI 10.1359/JBMR.0301238
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Kawasaki Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235
   Laitala Leinonen T, 1999, J CELL SCI, V112, P3657
   LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Lehenkari P, 1998, EXP CELL RES, V242, P128, DOI 10.1006/excr.1998.4071
   Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   MANOLSON MF, 1992, J EXP BIOL, V172, P105
   Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200
   MANOLSON MF, 1994, J BIOL CHEM, V269, P14064
   Michigami T, 2002, BONE, V30, P436, DOI 10.1016/S8756 3282(01)00684 6
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824
   Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200
   PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003 2697(91)90542 2
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   Scimeca JC, 2003, HUM MUTAT, V21, P151, DOI 10.1002/humu.10165
   SELANDER K, 1994, CALCIFIED TISSUE INT, V55, P368, DOI 10.1007/BF00299317
   Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006 291X(90)91709 2
   SUNDQUIST KT, 1994, J BONE MINER RES, V9, P1575
   TKUKITA T, 2004, J EXP MED, V200, P941
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200
   Väänänen HK, 2000, J CELL SCI, V113, P377
   VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305
   Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145
NR 36
TC 20
Z9 22
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0014 5793
EI 1873 3468
J9 FEBS LETT
JI FEBS Lett.
PD SEP 12
PY 2005
VL 579
IS 22
BP 4937
EP 4942
DI 10.1016/j.febslet.2005.07.078
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 963WU
UT WOS:000231837800004
PM 16115623
OA Bronze
DA 2025 08 17
ER

PT J
AU Tsutsumi, S
   Yasumoto, Y
   Ito, M
AF Tsutsumi, Satoshi
   Yasumoto, Yukimasa
   Ito, Masanori
TI Idiopathic calvarial thinning
SO NEUROLOGIA MEDICO CHIRURGICA
LA English
DT Article
DE calvarial thinning; symmetrical manifestation; diabetes mellitus
ID DIABETES MELLITUS; MASSIVE OSTEOLYSIS; DISEASE; OSTEOPOROSIS
AB An 82 year old diabetic female had been aware of gradually enlarging, painless scalp depressions in the bilateral parietal regions for more than 6 years. She had no history of head injury, or inflammatory or malignant disease. Her family history was unremarkable for hereditary bone disease. She had diabetes mellitus which had been well controlled with orally administered drugs. Blood examination showed normal renal and liver functions with normal serum calcium, magnesium, and phosphorus concentrations, in addition to normal parathyroid hormone and calcitonin levels. Neuroimaging including skull radiography, head computed tomography, and magnetic resonance imaging demonstrated symmetric thinning in the bilateral parietal bones attributed to loss of diploe and thinning of the outer table. The inner table was intact without associated soft tissue mass or vascular lesions. Technetium 99m methylene diphosphate systemic bone scintigraphy showed mild hypoaccumulation in the affected calvarium on the left. No other pathological findings were found by systemic examination. She underwent open biopsy for histological verification which revealed homogeneous membranous bone tissue with regressed diploe, absence of osteoblasts, absence of osteoclastic appearance, and absence of findings of underlying malignancy. There was no markedly fibrovascular connective tissue typical of Gorham Stout disease. Calvarial thinning in the present case may have been caused by an undetermined complex mechanism.
C1 [Tsutsumi, Satoshi; Yasumoto, Yukimasa; Ito, Masanori] Juntendo Univ Urayasu Hosp, Dept Neurol Surg, Chiba, Japan.
C3 Juntendo University
RP Tsutsumi, S (通讯作者)，Juntendo Univ, Dept Neurosurg, Urayasu Hosp, 2 1 1 Tomioka, Chiba 2790021, Japan.
EM shotaro@juntendo urayasu.jp
CR Devlin RD, 1996, J CLIN ENDOCR METAB, V81, P1893, DOI 10.1210/jc.81.5.1893
   Duarte VMG, 2005, J BONE MINER METAB, V23, P58, DOI 10.1007/s00774 004 0542 y
   Inaba M, 2004, J BONE MINER METAB, V22, P287, DOI 10.1007/s00774 004 0501 7
   Inzerillo AM, 2004, REV ENDOCR METAB DIS, V5, P261, DOI 10.1023/B:REMD.0000032415.83124.20
   Lee S, 2003, ARCH OTOLARYNGOL, V129, P1340, DOI 10.1001/archotol.129.12.1340
   Lo CP, 2004, AM J NEURORADIOL, V25, P415
   Möller G, 1999, J BONE JOINT SURG BR, V81B, P501, DOI 10.1302/0301 620X.81B3.9468
NR 7
TC 13
Z9 15
U1 0
U2 2
PU JAPAN NEUROSURGICAL SOC
PI TOKYO
PA 5 25 16 HONGO, BUNKYO KU, TOKYO, 113 0033, JAPAN
SN 0470 8105
EI 1349 8029
J9 NEUROL MED CHIR
JI Neurol. Med. Chir.
PD JUN
PY 2008
VL 48
IS 6
BP 275
EP 278
DI 10.2176/nmc.48.275
PG 4
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Surgery
GA 314QZ
UT WOS:000256825200012
PM 18574336
OA gold
DA 2025 08 17
ER

PT J
AU De Schutter, JW
   Shaw, J
   Lin, YS
   Tsantrizos, YS
AF De Schutter, Joris W.
   Shaw, Joseph
   Lin, Yih Shyan
   Tsantrizos, Youla S.
TI Design of potent bisphosphonate inhibitors of the human farnesyl
   pyrophosphate synthase via targeted interactions with the active site
   'capping' phenyls
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Nitrogen containing bisphosphonates; Farnesyl pyrophosphate synthase
ID NITROGEN CONTAINING BISPHOSPHONATES; T CELLS; MULTIPLE MYELOMA; CANCER;
   RECOGNITION; APOPTOSIS; THERAPY; DRUGS
AB Nitrogen containing bisphosphonates (N BPs) are potent active site inhibitors of the human farnesyl pyrophosphate synthase (hFPPS) and valuable human therapeutics for the treatment of bone related malignancies. N BPs are also useful in combination chemotherapy for patients with breast, prostate and multiple myeloma cancers. A structure based approach was employed in order to design inhibitors that exhibit higher lipophilicity and better occupancy for the GPP sub pocket of hFPPS than the current therapeutic drugs. These novel analogs were designed to bind deeper into the GPP sub pocket by displacing the side chains of the 'capping' residue Phe 113 and engaging in favorable p interactions with the side chain of Phe112. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [De Schutter, Joris W.; Lin, Yih Shyan; Tsantrizos, Youla S.] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada.
   [Shaw, Joseph; Tsantrizos, Youla S.] McGill Univ, Dept Biochem, Montreal, PQ H3G 0B1, Canada.
C3 McGill University; McGill University
RP Tsantrizos, YS (通讯作者)，McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 0B8, Canada.
EM youla.tsantrizos@mcgill.ca
RI ; Shaw, Joseph/ACC 3521 2022
OI Shaw, Joseph/0000 0002 2405 7912; 
CR [Anonymous], J CARCINOGENESIS
   Battiste M.A., 1987, CHEM CYCLOPROPYL GRO, V1, P255
   Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   De Schutter JW, 2010, BIOORG MED CHEM LETT, V20, P5781, DOI 10.1016/j.bmcl.2010.07.133
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Gagnon A, 2010, ORG PREP PROCED INT, V42, P1, DOI 10.1080/00304940903507788
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Li JQ, 2009, J IMMUNOL, V182, P8118, DOI 10.4049/jimmunol.0900101
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Lorenz JC, 2004, J ORG CHEM, V69, P327, DOI 10.1021/jo030312v
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Molander GA, 2001, ORG LETT, V3, P393, DOI 10.1021/ol006896u
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Morgan G. J., 1989, LANCET, V2010, P376
   Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600 065X.2006.00479.x
   Naoe M, 2010, ONCOL RES, V18, P493, DOI 10.3727/096504010X12671222663638
   Ran J, 2006, J PHYS CHEM A, V110, P9702, DOI 10.1021/jp0555403
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Tsuzuki S, 2006, J PHYS CHEM A, V110, P10163, DOI 10.1021/jp064206j
   Yin JJ, 2007, J ORG CHEM, V72, P4554, DOI 10.1021/jo070189y
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 26
TC 16
Z9 18
U1 0
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD SEP 15
PY 2012
VL 20
IS 18
BP 5583
EP 5591
DI 10.1016/j.bmc.2012.07.019
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 006GY
UT WOS:000308808700029
PM 22884353
DA 2025 08 17
ER

PT J
AU Singh, S
   Roy, R
   Meena, VK
   Vashisth, P
   Kalyanasundaram, D
AF Singh, Sonu
   Roy, Rahul
   Meena, Vijay Kumar
   Vashisth, Priya
   Kalyanasundaram, Dinesh
TI Nanotextured and drug loaded Neovius Ti6Al4V ELI scaffolds with
   osteogenesis and anti cancer potential
SO MATERIALS & DESIGN
LA English
DT Article
DE Dual drug delivery; Open cell lattices; Multiscale surface topography;
   Neovius architecture; Additive manufacturing; Ti6Al4V ELI; Laser bed
   powder fusion
ID CELL APOPTOSIS; DELIVERY; TI 6AL 4V; MECHANISM; BAICALEIN
AB Introduction: The use of Ti6Al4V for orthopedic implants though widely accepted, is 10X stiffer than bone, that leads to stress shielding and aseptic loosening. Further, oral delivery demands significantly large dosage of drugs. To address these twin challenges, we have fabricated open cell porous scaffolds capable of sustained dual drug delivery. Drug delivery from open cell porous Ti6Al4V implants is a promising approach for in situ delivery in orthopedic and dental implant applications.Methodology: In this study, selective laser melting technology was used to fabricate open cell porous Ti6Al4V ELI scaffolds of 50 % volume fractions with Neovius architecture (NOCL). Electrochemical anodization was used to create micro and nano scale surface features for efficient drug loading. The two payloads: an osteogenic agent (Baicalein) and an anti cancerous drug (Paclitaxel) were then loaded to different levels for differential release. An osteogenic agent was loaded in the nano reservoirs while paclitaxel was mixed with poloxamer and coated over the scaffold.Results: The mechanical stiffness of the designed NOCL lattices is approximately 1.29 +/  0.05 GPa, which is comparable to the human bone. This helps to reduce stress shielding effect. The scaffolds loaded with baicalein and paclitaxel yielded a sustained drug release profiles, releasing 57 % and 79 % of the pharmaceuticals over a 7  day period, respectively. Additionally, the baicalein loaded nano reservoirs promote osteoblast differentiation in mesenchymal stem cells. As a result, bio inspired 3D printed open cell porous titanium scaffolds loaded with dual drugs offer a workable solution to the problems associated with orthopedic implants.
C1 [Singh, Sonu; Roy, Rahul; Vashisth, Priya; Kalyanasundaram, Dinesh] Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, India.
   [Meena, Vijay Kumar] CSIR, Cent Sci Instruments Org, Chandigarh 160030, India.
   [Vashisth, Priya; Kalyanasundaram, Dinesh] All India Inst Med Sci, Dept Biomed Engn, New Delhi 110029, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Delhi; Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Scientific Instruments Organisation
   (CSIO); All India Institute of Medical Sciences (AIIMS) New Delhi
RP Kalyanasundaram, D (通讯作者)，Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, India.
EM dineshk.iitdelhi@gmail.com
RI ; Kalyanasundaram, Dinesh/AAY 7593 2021; Singh, Sonu/KRQ 6054 2024
OI Singh, Sonu/0000 0002 6036 7790; Roy, Rahul/0000 0003 2262 3375; 
FU Prime Ministers Research Fellowship (PMRF) , Ministry of Education,
   Government of India; Indian Council of Medical research (ICMR) , India
FX The authors would like to acknowledge the funding from the Prime
   Ministers Research Fellowship (PMRF) , Ministry of Education, Government
   of India to Sonu Singh. The author would also like to acknowledge the
   generous funding from Indian Council of Medical research (ICMR) , India
   for mPRAGATI towards MedTech Products. The authors thank the Central
   Research Facility (CRF) and Sophisticated Analytical & Technical Help
   Institutes (SATHI) at Indian Institute of Technology Delhi for using the
   resources.
CR Arjunan A, 2020, J MECH BEHAV BIOMED, V102, DOI 10.1016/j.jmbbm.2019.103517
   Asnaashari S, 2023, CANCER CELL INT, V23, DOI 10.1186/s12935 023 03052 z
   Awad A, 2021, ADV DRUG DELIVER REV, V174, P406, DOI 10.1016/j.addr.2021.04.025
   Burton HE, 2019, MAT SCI ENG C MATER, V94, P901, DOI 10.1016/j.msec.2018.10.052
   Cerqueira A, 2022, BIOMATER ADV, V137, DOI 10.1016/j.bioadv.2022.212826
   Chacón JM, 2022, BIO DES MANUF, V5, P808, DOI 10.1007/s42242 022 00200 8
   Cho H, 2015, AAPS PHARMSCITECH, V16, P10, DOI 10.1208/s12249 014 0251 3
   Cui NA, 2022, GELS BASEL, V8, DOI 10.3390/gels8060360
   Cui YT, 2021, MATER DESIGN, V206, DOI 10.1016/j.matdes.2021.109753
   El Malla S., 2016, European Journal of Pharmaceutical and Medical Research, V3, P348
   Fallah A, 2022, J MECH BEHAV BIOMED, V134, DOI 10.1016/j.jmbbm.2022.105418
   Fathi M, 2022, J DRUG DELIV SCI TEC, V71, DOI 10.1016/j.jddst.2022.103320
   Gao Y, 2016, MED CHEM RES, V25, P1515, DOI 10.1007/s00044 016 1607 x
   Goto M, 2021, J BIOMATER APPL, V35, P1153, DOI 10.1177/0885328220968218
   Heydariyan Z, 2023, J DRUG DELIV SCI TEC, V84, DOI 10.1016/j.jddst.2023.104401
   Dang HP, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/ab14ff
   Hou YH, 2022, BIO DES MANUF, V5, P556, DOI 10.1007/s42242 022 00182 7
   Kang Y, 2023, BIO DES MANUF, V6, P26, DOI 10.1007/s42242 022 00214 2
   Kaschel FR, 2020, ACTA MATER, V188, P720, DOI 10.1016/j.actamat.2020.02.056
   Kaur M, 2019, MAT SCI ENG C MATER, V102, P844, DOI 10.1016/j.msec.2019.04.064
   Li JS, 2022, COLLOID SURFACE B, V218, DOI 10.1016/j.colsurfb.2022.112700
   Li J, 2022, BIOFABRICATION, V14, DOI 10.1088/1758 5090/ac6051
   Liu C, 2023, J MATER SCI TECHNOL, V135, P111, DOI 10.1016/j.jmst.2022.07.011
   Liu H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101681
   Liu SY, 2010, CHEMOTHERAPY, V56, P101, DOI 10.1159/000305257
   Losic D, 2015, EXPERT OPIN DRUG DEL, V12, P103, DOI 10.1517/17425247.2014.945418
   Ma X, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12010047
   Ma Z, 2019, INT J NANOMED, V14, P2029, DOI 10.2147/IJN.S197889
   Mondal S, 2019, J DRUG DELIV SCI TEC, V53, DOI 10.1016/j.jddst.2019.101131
   Münz F, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18862 1
   Nogueira RP, 2021, INT J NANOMED, V16, P667, DOI 10.2147/IJN.S285805
   Pan Q, 2016, DNA CELL BIOL, V35, P646, DOI 10.1089/dna.2016.3312
   Pang SM, 2023, BIOFABRICATION, V15, DOI 10.1088/1758 5090/acb387
   Park SY, 2021, MATER DESIGN, V206, DOI 10.1016/j.matdes.2021.109778
   Ren B, 2021, MAT SCI ENG C MATER, V118, DOI 10.1016/j.msec.2020.111505
   Rodríguez Contreras A, 2020, SURF COAT TECH, V403, DOI 10.1016/j.surfcoat.2020.126381
   Sakhi M, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.855294
   Sandomierski M, 2023, J DRUG DELIV SCI TEC, V80, DOI 10.1016/j.jddst.2023.104176
   Sandomierski M, 2023, J BIOMED MATER RES B, V111, P1005, DOI 10.1002/jbm.b.35209
   Sandomierski M, 2022, J BIOMED MATER RES B, V110, P431, DOI 10.1002/jbm.b.34919
   Singh S, 2022, BIOMED MATER, V17, DOI 10.1088/1748 605X/ac6922
   Spece H, 2021, J BIOMED MATER RES B, V109, P1436, DOI 10.1002/jbm.b.34803
   Tamaddon M, 2022, BIO DES MANUF, V5, P481, DOI 10.1007/s42242 021 00177 w
   Tan BZ, 2023, J MATER SCI TECHNOL, V136, P54, DOI 10.1016/j.jmst.2022.07.016
   Tang HJ, 2021, MAT SCI ENG C MATER, V120, DOI 10.1016/j.msec.2020.111760
   Wang C, 2021, MAT SCI ENG C MATER, V131, DOI 10.1016/j.msec.2021.112499
   Wang JW, 2021, ADV DRUG DELIVER REV, V174, P294, DOI 10.1016/j.addr.2021.04.019
   Wang NY, 2022, BIOMATER ADV, V137, DOI 10.1016/j.bioadv.2022.212829
   Wu JN, 2019, INT J NANOMED, V14, P733, DOI 10.2147/IJN.S187664
   Xu ZM, 2022, J DRUG DELIV SCI TEC, V68, DOI 10.1016/j.jddst.2021.103053
   Yan CZ, 2015, J MECH BEHAV BIOMED, V51, P61, DOI 10.1016/j.jmbbm.2015.06.024
   Zhang AB, 2021, BIO DES MANUF, V4, P87, DOI 10.1007/s42242 020 00102 7
   Zhang YN, 2022, BIOMATER ADV, V133, DOI 10.1016/j.msec.2022.112651
   Zhang YF, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11102489
   Zhu Y, 2021, J BIOMATER APPL, V35, P1119, DOI 10.1177/0885328221997998
   Zou SJ, 2022, MATER DESIGN, V219, DOI 10.1016/j.matdes.2022.110803
NR 56
TC 5
Z9 5
U1 7
U2 37
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD JAN
PY 2024
VL 237
AR 112570
DI 10.1016/j.matdes.2023.112570
EA DEC 2023
PG 12
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA EY5G1
UT WOS:001142503000001
OA gold
DA 2025 08 17
ER

PT J
AU Sanders, JM
   Song, YC
   Chan, JMW
   Zhang, JH
   Jennings, S
   Kosztowski, T
   Odeh, S
   Flessner, R
   Schwerdtfeger, C
   Kotsikorou, E
   Meints, GA
   Gómez, AO
   González Pacanowska, D
   Raker, AM
   Wang, H
   van Beek, ER
   Papapoulos, SE
   Morita, CT
   Oldfield, E
AF Sanders, JM
   Song, YC
   Chan, JMW
   Zhang, JH
   Jennings, S
   Kosztowski, T
   Odeh, S
   Flessner, R
   Schwerdtfeger, C
   Kotsikorou, E
   Meints, GA
   Gómez, AO
   González Pacanowska, D
   Raker, AM
   Wang, H
   van Beek, ER
   Papapoulos, SE
   Morita, CT
   Oldfield, E
TI Pyridinium 1 yl bisphosphonates are potent inhibitors of farnesyl
   diphosphate synthase and bone resorption
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DELTA T CELLS; PYROPHOSPHATE SYNTHASE; IN VITRO; LEISHMANIA DONOVANI;
   TRYPANOSOMA BRUCEI; MEVALONATE PATHWAY; ALENDRONATE; ACID; RISEDRONATE;
   ACTIVATION
AB We report the design, synthesis and testing of a series of novel bisphosphonates, pyridinium 1 yl hydroxy bisphosphonates, based on the results of comparative molecular similarity indices analysis and pharmacophore modeling studies of farnesyl diphosphate synthase (FPPS) inhibition, human V gamma 2V delta 2 T cell activation and bone resorption inhibition. The most potent molecules have high activity against an expressed FPPS from Leishmania major, in Dictyostelium discoideum growth inhibition, in gamma delta T cell activation and in an in vitro bone resorption assay. As such, they represent useful new leads for the discovery of new bone resorption, antiinfective and anticancer drugs.
C1 Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   CSIC, Lopez Neyra Inst Parasitol & Biomed, Granada, Spain.
   Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
   Univ Iowa, Interdisciplinary Grp Immunol, Iowa City, IA 52242 USA.
   Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, Leiden, Netherlands.
   Univ Illinois, Dept Biophys, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Instituto
   de Parasitologia y Biomedicina Lopez Neyra (IPBLN); University of Iowa;
   University of Iowa; Leiden University   Excl LUMC; Leiden University;
   Leiden University Medical Center (LUMC); University of Illinois System;
   University of Illinois Urbana Champaign
RP Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.
EM eo@chad.ses.uiuc.edu
RI Chan, Julian/AAT 6244 2021; Chan, Julian/D 3448 2013; Morita,
   Craig/C 1365 2011
OI Gonzalez Pacanowska, Dolores/0000 0002 4303 5209; Kotsikorou,
   Evangelia/0000 0002 8398 2139; Chan, Julian/0000 0002 2734 6496; Morita,
   Craig/0000 0001 8496 8294; 
CR ALFEREV IS, 1995, RUSS CHEM B+, V44, P1528, DOI 10.1007/BF00714446
   ALFEREV IS, 1995, Patent No. 1089953
   ALFEREV IS, 1997, Patent No. 9708178
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   BESLER BH, 1990, J COMPUT CHEM, V11, P431, DOI 10.1002/jcc.540110404
   BREUER E, 1996, Patent No. 9631227
   Cohen H., 1996, Pharmaceutical Research (New York), V13, pS139
   Cohen H, 1999, PHARMACEUT RES, V16, P1399, DOI 10.1023/A:1018951025493
   Cohen H, 1998, PHARMACEUT RES, V15, P606, DOI 10.1023/A:1011990129437
   COMARTIE TH, 1998, Patent No. 5756423
   Cramer R D 3rd, 1989, Prog Clin Biol Res, V291, P161
   Cromartie TH, 1999, PESTIC BIOCHEM PHYS, V63, P114, DOI 10.1006/pest.1999.2397
   DANENBERG H, 2000, Patent No. 0003677
   Dawson NA, 2003, EXPERT OPIN PHARMACO, V4, P705, DOI 10.1517/14656566.4.5.705
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Frisch M., 2004, GAUSSIAN 03, P4
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   GOLOMB G, 2004, Patent No. 6719998
   Grossmann G, 2000, MAGN RESON CHEM, V38, P11, DOI 10.1002/(SICI)1097 458X(200001)38:1<11::AID MRC597>3.0.CO;2 V
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Kato Y, 2001, J IMMUNOL, V167, P5092, DOI 10.4049/jimmunol.167.9.5092
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010
   Klein BY, 1998, J CELL BIOCHEM, V68, P186, DOI 10.1002/(SICI)1097 4644(19980201)68:2<186::AID JCB5>3.0.CO;2 R
   Kotsikorou E, 2003, J MED CHEM, V46, P2932, DOI 10.1021/jm030054u
   Krapcho AP, 1998, J FLUORINE CHEM, V90, P139, DOI 10.1016/S0022 1139(98)00190 0
   Kunzmann V, 2000, BLOOD, V96, P384
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   MIYAURA N, 1981, SYNTHETIC COMMUN, V11, P513, DOI 10.1080/00397918108063618
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Moreno B, 2001, BIOCHEM BIOPH RES CO, V284, P632, DOI 10.1006/bbrc.2001.5009
   Patlas N, 1999, TERATOLOGY, V60, P68, DOI 10.1002/(SICI)1096 9926(199908)60:2<68::AID TERA10>3.0.CO;2 H
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   ROGERS MJ, 1994, J BONE MINER RES, V9, P1029
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Sambrook PN, 2004, J INTERN MED, V255, P503, DOI 10.1111/j.1365 2796.2004.01317.x
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   SINGH UC, 1984, J COMPUT CHEM, V5, P129, DOI 10.1002/jcc.540050204
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Vasireddy S, 2003, CLIN RHEUMATOL, V22, P376, DOI 10.1007/s10067 003 0762 x
   *WACC INC, CAT VERS 4 8
   Wang LS, 2001, J CLIN INVEST, V108, P1349, DOI 10.1172/JCI200113584
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929 931.2002
   Zhang LD, 2000, SYNTHESIS STUTTGART, P1733
   2003, Patent No. 03097655
NR 57
TC 78
Z9 87
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 21
PY 2005
VL 48
IS 8
BP 2957
EP 2963
DI 10.1021/jm040209d
PG 7
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 917DH
UT WOS:000228435700025
PM 15828834
DA 2025 08 17
ER

PT J
AU Cao, HJ
   Zheng, LZ
   Wang, N
   Wang, LY
   Li, Y
   Li, D
   Lai, YX
   Wang, XL
   Qjn, L
AF Cao, Hui Juan
   Zheng, Li Zhen
   Wang, Nan
   Wang, Lin Ying
   Li, Ye
   Li, Dan
   Lai, Yu Xiao
   Wang, Xin Luan
   Qjn, Ling
TI Src blockage by siRNA inhibits VEGF induced vascular hyperpemeability
   and osteoclast activity   an in vitro mechanism study for
   preventing destructive repair of osteonecrosis
SO BONE
LA English
DT Article
DE Destructive repair; Osteonecrosis; VEGF; c Src; Vascular permeability;
   Osteoclasts activity
ID ENDOTHELIAL GROWTH FACTOR; HUMAN FEMORAL HEAD; C SRC; BONE RESORPTION;
   KINASE ACTIVITY; CLINICAL IMPLICATIONS; DIFFERENTIATION;
   PHOSPHORYLATION; ANGIOGENESIS; PERMEABILITY
AB Introduction: Destructive repair is the pathological feature of ONFH characterized with the elevated vascular permeability and persistent bone resorption, which is associated with higher VEGF expression, activated c Src, and vascular leakage. Activated c Src also participates in mediating endothelial permeability and osteoclasts activity. However, the molecular mechanism of the VEGF and c Src contributing to the destructive repair process remains unknown. The purpose of this study is to delineate the role of VEGF and c Src in triggering destructive repair of osteonecrosis in vitro, as well as to elucidate if VEGF mediating vascular permeability and osteoclastic bone resorption are Src dependent.
   Methods: We employed pharmacological VEGF to induce higher endothelial permeability and osteoclasts activity for simulating related pathological features of destructive repair in vitro. Src specific pp60(c src)siRNA was used for determining the contribution of VEGF and Src to destructive repair. The primary endothelial cells and osteoclasts were treated with 50 ng/ml VEGF and/or transfected with the pp60(c src)siRNA, while equivalent PBS and non targeting siRNA were treated in the control groups.
   Results: VEGF enhanced Src bioactivity through promoting dephosphorylation of Src at Y527 and phosphorylation of Src at Y416. Meanwhile, Src specific pp60(c src)siRNA significantly reduced Src expression in both cells. VEGF destroyed the junctional integrity of endothelial cells resulting in higher endothelial permeability. However, Src blockade significantly relieved VEGF induced actin stress and inhibited caveolae and VVOs formation, meanwhile further stabilized the complex beta catenin/VE cadherin/Flk 1 through decreasing phosphorylation of VE cadherin, ultimately decreasing VEGF mediating higher vascular permeability. In addition, VEGF promoted osteoclasts formation and function without affecting the adhesion activity and cytoskeleton. We further found that Src blockade significantly impaired cytoskeleton resulting in a lower adhesion activity through down regulation of phosphorylation of Src, Pyla and Cbl, and ultimately inhibited osteoclasts formation and function.
   Conclusions: These findings provide a new insight into VEGF and c Src mode of reaction in triggering destructive repair of osteonecrosis and further indicate that VEGF mediating vascular permeability and osteodasts activity are Src dependent. Blockade of Src may have great potential as an effective therapy targeting destructive repair in osteonecrosis. (c) 2014 Elsevier Inc. All rights reserved.
C1 [Cao, Hui Juan; Wang, Nan; Wang, Lin Ying; Li, Ye; Li, Dan; Lai, Yu Xiao; Wang, Xin Luan; Qjn, Ling] Chinese Acad Sci, Translat Med R&D Ctr, Inst Biomed & Hlth Engn, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
   [Zheng, Li Zhen; Wang, Xin Luan; Qjn, Ling] Chinese Univ Hong Kong, Musculoskeletal Res Lab, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Cao, Hui Juan; Wang, Nan; Wang, Lin Ying; Li, Ye; Li, Dan; Lai, Yu Xiao; Wang, Xin Luan; Qjn, Ling] Shenzhen Bioact Mat Engn Lab Med, Shenzhen, Peoples R China.
   [Wang, Lin Ying] Univ Sci & Technol China, Nano Sci & Technol Inst, Suzhou, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese University of Hong Kong; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS
RP Wang, XL (通讯作者)，Shenzhen Univ Town, 1068 Xueyuan Ave, Shenzhen, Peoples R China.
EM hj.cao@siat.ac.cn; zhenglz@ort.cuhk.edu.hk; wangnan@siat.ac.cn;
   wangliny@siat.ac.cn; ye.li1@siat.ac.cn; danli@siat.ac.cn;
   yx.lai@siat.ac.cn; xl.wang@siat.ac.cn; lingqin@cuhk.edu.hk
RI Li, Ye/GLN 3702 2022; Cao, Huijuan/NOF 8016 2025; Wang,
   Linying/MXL 3427 2025; Wang, Nan/GRY 3150 2022; Zheng,
   Lizhen/C 6550 2014; Lai, Yuxiao/AFN 1336 2022
OI LI, Ye/0000 0002 2481 6894; Wang, Nan/0009 0006 1132 8054; 
FU National Science Foundation of China [81171771]; General Research Fund
   of HongKong [473011]; NSFC DG RTD [51361130034]; European Union
   [NMP3 SL 2013 604517]
FX This work was financially supported by National Science Foundation of
   China (No. 81171771), General Research Fund of HongKong (No. 473011) and
   NSFC DG RTD Joint Scheme (No. 51361130034) and the European Union's 7th
   Framework Program under grant agreement (No. NMP3 SL 2013 604517). We
   thank Dr. Ge Zhang and Dr. Tao Tang for the guidance in the study plan.
CR Alessio N, 2013, CELL MOL LIFE SCI, V70, P1637, DOI 10.1007/s00018 012 1224 x
   Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105
   BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757
   Chou MT, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471 2091 3 32
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Gary RK, 2005, ANAL BIOCHEM, V343, P329, DOI 10.1016/j.ab.2005.06.003
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P273
   GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P284
   GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P283
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Liu ZJ, 2003, FASEB J, V17, P1931, DOI 10.1096/fj.02 1171fje
   Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Monaghan Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894
   Mont MA, 1998, CLIN ORTHOP RELAT R, pS314
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P16, DOI 10.2106/JBJS.F.00457
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Nakajima A, 2009, J BONE MINER RES, V24, P1162, DOI [10.1359/jbmr.090205, 10.1359/JBMR.090205]
   Phemister DB, 2008, CLIN ORTHOP RELAT R, V466, P1020, DOI 10.1007/s11999 008 0206 7
   Plenk H, 2001, CLIN ORTHOP RELAT R, P42
   Plenk H Jr, 2000, ORTHOPADE, V29, P389
   Purev E, 2009, MOL BIOL CELL, V20, P4021, DOI 10.1091/mbc.E09 03 0248
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343
   TAKAOKA K, 1981, ARCH ORTHOP TRAUM SU, V99, P109, DOI 10.1007/BF00389746
   van Dongen S, 2008, NAT METHODS, V5, P1023, DOI 10.1038/nmeth.1267
   Vasile E, 1999, J HISTOCHEM CYTOCHEM, V47, P159, DOI 10.1177/002215549904700205
   Wallez Y, 2007, ONCOGENE, V26, P1067, DOI 10.1038/sj.onc.1209855
   Wang YW, 2010, PHARM RES DORDR, V27, P1273, DOI 10.1007/s11095 010 0099 5
   Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130
   Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702
   Xu LL, 2014, J ORTHOP TRANSL, V2, P1, DOI 10.1016/j.jot.2013.11.002
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Zhang G, 2010, BONE, V47, pS401, DOI 10.1016/j.bone.2010.09.185
   Zhang G, 2009, ARTHRITIS RHEUM US, V60, P2966, DOI 10.1002/art.24847
   Zhang W, 2014, J ORTHOP TRANSL, V2, P56, DOI 10.1016/j.jot.2014.02.002
NR 41
TC 25
Z9 33
U1 2
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2015
VL 74
BP 58
EP 68
DI 10.1016/j.bone.2014.12.060
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CD6HE
UT WOS:000351189400007
PM 25554601
DA 2025 08 17
ER

PT J
AU Yang, L
   Huang, JH
   Yang, SY
   Cui, W
   Wang, JP
   Zhang, YP
   Li, JF
   Guo, XD
AF Yang, Liang
   Huang, Jinghuan
   Yang, Shuyi
   Cui, Wei
   Wang, Jianping
   Zhang, Yinping
   Li, Jingfeng
   Guo, Xiaodong
TI Bone Regeneration Induced by Local Delivery of a Modified PTH Derived
   Peptide from Nanohydroxyapatite/Chitosan Coated True Bone Ceramics
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE parathyroid hormone; bone targeting; drug local delivery; true bone
   ceramics; bone regeneration
ID GROWTH FACTOR DELIVERY; PARATHYROID HORMONE; BMP 2 RELATED PEPTIDE;
   OSTEOBLASTIC CELLS; IN VIVO; BIOACTIVITY; PROFILES; TURNOVER; TIME; RAT
AB A novel PTH derived peptide, PTHdP, including a repetitive aspartic acid sequence at the C terminal and phosphorylated serine at the N terminal has been previously designed. To evaluate its potential as a bone growth factor for bone tissue engineering, true bone ceramics incorporated with nanohydroxyapatite coating and chitosan (CH/TBC) was developed as a desired three dimensional porous delivery carrier in this study. In vitro results showed that PTHdP could be loaded with high efficiency and subsequently released in a controlled and sustained manner from CH/TBC. Bioactivity of released PTHdP was retained and able to exert a significant effect on promoting or inhibiting osteogenesis actions when exposed intermittently or continuously, respectively, for MC3T3 E1 cell culture. As evaluated in a critical size rabbit radial defect model by radiographic and histological examination, the combination of CH/TBC scaffolds with PTHdP exhibited a remarkably stronger capacity to stimulate new bone formation than control and pure CH/TBC groups. These results indicated the novel PTHdP peptide achieved high affinity to bone mineral without interference in bioactivity, and local delivery of PTHdP from apatite materials could be a promising alternative for future bone tissue engineering.
C1 [Yang, Liang; Wang, Jianping; Zhang, Yinping; Li, Jingfeng] Wuhan Univ, Zhongnan Hosp, Dept Orthoped, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Yang, Liang; Yang, Shuyi; Cui, Wei; Guo, Xiaodong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthoped, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
   [Huang, Jinghuan] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthoped, 600 Yishan Rd, Shanghai 200233, Peoples R China.
C3 Wuhan University; Huazhong University of Science & Technology; Shanghai
   Jiao Tong University
RP Li, JF (通讯作者)，Wuhan Univ, Zhongnan Hosp, Dept Orthoped, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.; Guo, XD (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthoped, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
EM jingfengli@whu.edu.cn; xiaodongguo@hust.edu.cn
RI Guo, Xiaodong/GQP 5299 2022; Yang, Liang/HMP 5879 2023
OI Cui, Wei/0000 0002 8097 415X; 
FU National Natural Sciences Foundation of China [81301538, 81672158,
   81371939]; National Key Research and Development Program of China
   [2016YFC1100102]; Youth Science and Technology Morning Program of Wuhan
   [2014072704011256]; High level Personnel Program of Wuhan University
   [600400002]; Zhongnan Hospital of Wuhan University Science, Technology
   and Innovation Seed Fund [cxpy2016035]
FX This research was supported by the National Natural Sciences Foundation
   of China (Nos. 81301538, 81672158, 81371939), the National Key Research
   and Development Program of China (2016YFC1100102), the Youth Science and
   Technology Morning Program of Wuhan (2014072704011256), High level
   Personnel Program of Wuhan University (600400002), and Zhongnan Hospital
   of Wuhan University Science, Technology and Innovation Seed Fund
   (cxpy2016035).
CR Arrighi I, 2009, BIOMATERIALS, V30, P1763, DOI 10.1016/j.biomaterials.2008.12.023
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Babensee JE, 2000, PHARM RES DORDR, V17, P497, DOI 10.1023/A:1007502828372
   Bodde EWH, 2008, J BIOMED MATER RES A, V85A, P206, DOI 10.1002/jbm.a.31549
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Chintamaneni S, 2010, OSTEOPOROSIS INT, V21, P1059, DOI 10.1007/s00198 009 1061 4
   Choi S, 2010, ACTA BIOMATER, V6, P3426, DOI 10.1016/j.actbio.2010.03.020
   Coetzee M, 2007, J NUTR BIOCHEM, V18, P54, DOI 10.1016/j.jnutbio.2006.03.002
   dos Santos PL, 2013, J ORAL MAXIL SURG, V71, P505, DOI 10.1016/j.joms.2012.10.017
   El Ghannam A, 2005, EXPERT REV MED DEVIC, V2, P87, DOI 10.1586/17434440.2.1.87
   Fischer J, 2011, J CRANIO MAXILL SURG, V39, P54, DOI 10.1016/j.jcms.2010.03.016
   Hedberg EL, 2005, TISSUE ENG, V11, P1356, DOI 10.1089/ten.2005.11.1356
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Jansen JA, 2005, J CONTROL RELEASE, V101, P127, DOI 10.1016/j.jconrel.2004.07.005
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   JONGEN JWJM, 1993, J CELL PHYSIOL, V155, P36, DOI 10.1002/jcp.1041550106
   Jung RE, 2007, CLIN ORAL IMPLAN RES, V18, P319, DOI 10.1111/j.1600 0501.2007.01342.x
   Kamo K, 2010, J BONE MINER METAB, V28, P634, DOI 10.1007/s00774 010 0178 z
   Lane JM, 1999, CLIN ORTHOP RELAT R, pS107
   Lee JY, 2002, J CONTROL RELEASE, V78, P187, DOI 10.1016/S0168 3659(01)00498 9
   Leone Bay A, 2001, PHARMACEUT RES, V18, P964, DOI 10.1023/A:1010936227570
   Li JF, 2013, BIOMED MATER, V8, DOI 10.1088/1748 6041/8/3/035005
   Li JF, 2011, J ORTHOP RES, V29, P1745, DOI 10.1002/jor.21439
   Lin ZY, 2010, J CONTROL RELEASE, V144, P190, DOI 10.1016/j.jconrel.2010.02.016
   Liu SX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120402
   Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142 9612(99)00011 3
   Mendonça G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Minamide A, 2001, EUR SPINE J, V10, pS185, DOI 10.1007/s005860100274
   Minamide A, 1999, SPINE, V24, P1863, DOI 10.1097/00007632 199909150 00002
   Missana LR, 2014, J BIOMED MATER RES A, V102, P4358, DOI 10.1002/jbm.a.35114
   Murphy CM, 2015, J BONE MINER RES, V30, P1022, DOI 10.1002/jbmr.2424
   Niu XF, 2009, J CONTROL RELEASE, V134, P111, DOI 10.1016/j.jconrel.2008.11.020
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   PARFITT AM, 1976, METABOLISM, V25, P1033, DOI 10.1016/0026 0495(76)90133 5
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   Quattrocchi E, 2004, CLIN THER, V26, P841, DOI 10.1016/S0149 2918(04)90128 2
   Raiche AT, 2004, J BIOMED MATER RES A, V69A, P342, DOI 10.1002/jbm.a.30006
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Reynolds DG, 2009, J BONE MINER RES, V24, P899, DOI 10.1359/JBMR.081232
   Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504
   Sharon JL, 2008, BIOMATERIALS, V29, P3137, DOI 10.1016/j.biomaterials.2008.04.019
   Sous M, 1998, BIOMATERIALS, V19, P2147, DOI 10.1016/S0142 9612(98)00118 5
   STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275
   Sun TF, 2018, J TISSUE ENG REGEN M, V12, P864, DOI 10.1002/term.2371
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Tao ZS, 2016, J BIOMATER APPL, V30, P952, DOI 10.1177/0885328215610898
   Vasita R, 2006, EXPERT REV MED DEVIC, V3, P29, DOI 10.1586/17434440.3.1.29
   Walpole AR, 2003, MATERIALWISS WERKST, V34, P1064, DOI 10.1002/mawe.200300707
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang JP, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006637
   Webster TJ, 2000, BIOMATERIALS, V21, P1803, DOI 10.1016/S0142 9612(00)00075 2
   Wei GB, 2004, BIOMATERIALS, V25, P345, DOI 10.1016/S0142 9612(03)00528 3
   Yadav MC, 2011, BONE, V49, P250, DOI 10.1016/j.bone.2011.03.770
   Yewle JN, 2013, BIOMATERIALS, V34, P3141, DOI 10.1016/j.biomaterials.2013.01.059
   Yu XH, 2011, J BIOMED MATER RES B, V97B, P345, DOI 10.1002/jbm.b.31820
   Zhao MD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146301
NR 59
TC 23
Z9 27
U1 1
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD SEP
PY 2018
VL 4
IS 9
BP 3246
EP 3258
DI 10.1021/acsbiomaterials.7b00780
PG 25
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GT5DU
UT WOS:000444526900013
PM 33435063
DA 2025 08 17
ER

PT J
AU Toor, RH
   Tasadduq, R
   Lian, JB
   Stein, JL
   Stein, GS
   Shakoori, AR
AF Toor, Rabail Hassan
   Tasadduq, Raazia
   Lian, Jane B.
   Stein, Janet L.
   Stein, Gary S.
   Shakoori, Abdul Rauf
TI Cissus quadrangularis (Hexane Fraction) Inhibits RANK L Induced
   Osteoclast Differentiation of Murine Macrophage RAW264.7 Cell Line
SO PAKISTAN JOURNAL OF ZOOLOGY
LA English
DT Article
DE Osteoclast differentiation; Bone remodeling; Cissus quadrangularis;
   Tartrate resistant acid phosphatase (TRAP) activity; Bone resorption;
   Anti osteoporotic therapeutic activity
ID BONE LOSS; GENE EXPRESSION; RESVERATROL; CONSTITUENTS; OVARIECTOMY;
   GROWTH; MATRIX METALLOPROTEINASE 9; IDENTIFICATION; LOCALIZATION;
   EXTRACT
AB Amid the numerous health concerns faced by the world, osteoporosis a silent epidemic is a major health concern, since it affects millions of people all around the world. Recognizing the limited treatment options for osteoporotic patients, along with their long term use safety concerns, our research group focused on investigating efficacious, inexpensive and safe alternative therapies for osteoporosis. Investigating the osteogenic potential of CQ, our research group previously reported osteogenic stimulatory effects of CQ (hexane fraction). The present study explores anti resorptive effects of CQ H on bones. We utilized RAW264.7 murine macrophage cell line as osteoclast precursors, and resveratrol (RSV) as a standard for its anti osteoclast activity. Upon RANK L induction of RAW264.7 cells to differentiate into osteoclasts, we found 10ng/ml CQ H as most efficacious concentration for inhibiting osteoclastogenesis with 57.8% inhibition of TRAP activity. Whereas, in comparison 20ng/ml RSV showed 49.9% inhibition of TRAP activity. Expression of osteoclast marker genes such as NFATc1, ACP 5, CTSK, MMP 9 and CTR corroborated our results. Distinct downregulation of marker genes was observed in CQ H and RSV treated differentiated cells compared to the positive control. Moreover, the downregulation was enhanced in CQ H treated osteoclasts compared to RSV treatment. This study presents in vitro findings on the osteoclast inhibition activity of CQ and provide evidence of anti osteoporotic therapeutic property of CQ. Further studies on isolation and functional characterization of active compounds of signaling pathways that mediate osteoclastogenesis will contribute further insights on the anti osteoporotic therapeutic activity of CQ.
C1 [Toor, Rabail Hassan; Shakoori, Abdul Rauf] Univ Punjab, Sch Biol Sci, Quaid i Azam Campus, Lahore, Pakistan.
   [Tasadduq, Raazia] Kinnaird Coll Women Univ, Dept Biochem, Jail Rd, Lahore, Pakistan.
   [Toor, Rabail Hassan; Lian, Jane B.; Stein, Janet L.; Stein, Gary S.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT USA.
C3 University of Punjab; University of Vermont
RP Shakoori, AR (通讯作者)，Univ Punjab, Sch Biol Sci, Quaid i Azam Campus, Lahore, Pakistan.
EM arshakoori.sbs@pu.edu.pk
RI Toor, Rabail/AAP 2803 2021; SHAKOORI, FARAH/MCI 6446 2025
FU Research grant of Pakistan Academy of Sciences [5 9/PAS/22]; NIH [R01
   AR039588]
FX This work is financially supported by the research grant of Pakistan
   Academy of Sciences Ref. #5 9/PAS/22 dated 27.7.2016 and NIH grant R01
   AR039588 (Stein/Lian) . Gary Stein is the AJ Perelman Professor,
   University of Vermont.
CR Adesanya SA, 1999, J NAT PROD, V62, P1694, DOI 10.1021/np9902744
   Bafna PS, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114355
   BAILEY PJ, 1980, ANTIMICROB AGENTS CH, V17, P549, DOI 10.1128/AAC.17.4.549
   Baker SJ, 2006, BIOORG MED CHEM LETT, V16, P5963, DOI 10.1016/j.bmcl.2006.08.130
   Benkovic SJ, 2005, J MED CHEM, V48, P7468, DOI 10.1021/jm050676a
   BHUTANI KK, 1984, PHYTOCHEMISTRY, V23, P407, DOI 10.1016/S0031 9422(00)80341 6
   Blumer MJF, 2012, MECH DEVELOP, V129, P162, DOI 10.1016/j.mod.2012.04.003
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Busek P, 2004, INT J BIOCHEM CELL B, V36, P408, DOI 10.1016/S1357 2725(03)00262 0
   Butler M, 2003, Animal Cell Culture and Technology, DOI [10.4324/9780203427835, DOI 10.4324/9780203427835]
   Chen C, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23471
   Christensen Jon, 2015, BMC Res Notes, V8, P322, DOI 10.1186/s13104 015 1284 8
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Eijken H.J. M., 2007, Human osteoblast differentiation and bone formation: Growth factors, hormones and regulatory networks
   Eswaran R., 2012, ASIAN J PHARM CLIN R, V2, P139
   Gabbay KH, 2010, J BIOL CHEM, V285, P19510, DOI 10.1074/jbc.M110.110247
   Garima Mishra Garima Mishra, 2010, International Journal of PharmTech Research, V2, P1298
   Guerra JM, 2019, J BONE MINER METAB, V37, P780, DOI 10.1007/s00774 018 0983 3
   Gupta M, 2018, INDIAN J TRADIT KNOW, V17, P460
   GUPTA MM, 1991, PHYTOCHEMISTRY, V30, P875, DOI 10.1016/0031 9422(91)85270 A
   GUPTA MM, 1990, PHYTOCHEMISTRY, V29, P336, DOI 10.1016/0031 9422(90)89067 J
   Habold C, 2011, J BONE MINER METAB, V29, P15, DOI 10.1007/s00774 010 0187 y
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Hsiao CY, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00613
   Jain Anurag, 2008, J Int Acad Periodontol, V10, P59
   Jiang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.684007
   Kong YY, 2000, EXP GERONTOL, V35, P947, DOI 10.1016/S0531 5565(00)00178 9
   Kumar, 2012, ARCH APPL SCI RES, V4, P1782
   Kumar M, 2010, PHYTOMEDICINE, V17, P993, DOI 10.1016/j.phymed.2010.03.014
   Kumar P, 2019, NAT PROD RES, V33, P233, DOI 10.1080/14786419.2018.1443099
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Luchian I, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031806
   Mehta M, 2001, PHYTOCHEM ANALYSIS, V12, P91, DOI 10.1002/pca.569
   Mizutani K, 2000, J NUTR SCI VITAMINOL, V46, P78, DOI 10.3177/jnsv.46.78
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Nagani K., 2013, J PHARMACOGN PHYTOCH, V2, P149
   OKADA Y, 1995, LAB INVEST, V72, P311
   Parthipan B., 2015, Journal of Pharmacognosy and Phytochemistry, V4, P216
   Patel N, 2015, J ORTHOP RES, V33, P1474, DOI 10.1002/jor.22795
   Pathomwichaiwat T, 2015, J ETHNOPHARMACOL, V160, P52, DOI 10.1016/j.jep.2014.11.026
   Patil VS, 2019, INDIAN J PHARM EDUC, V53, pS332, DOI 10.5530/ijper.53.3s.103
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365 2613.2000.00176.x
   Potu BK, 2009, UPSALA J MED SCI, V114, P140, DOI 10.1080/03009730902891784
   Potu Bhagath Kumar, 2010, Chang Gung Med J, V33, P252
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rao GV., 2011, LINNRES J CHEM SCI, V1, P25
   Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71
   Reid IR, 2008, SEMIN CELL DEV BIOL, V19, P473, DOI 10.1016/j.semcdb.2008.08.002
   Reithmeier A, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3616 7
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Sen M. K., 2012, International Journal of Green Pharmacy, V6, P169, DOI 10.4103/0973 8258.104924
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Shalehin N, 2020, J DENT SCI, V15, P437, DOI 10.1016/j.jds.2019.09.009
   Shirwaikar A, 2003, J ETHNOPHARMACOL, V89, P245, DOI 10.1016/j.jep.2003.08.004
   Singh G, 2007, NAT PROD RES, V21, P522, DOI 10.1080/14786410601130471
   Singh Nimisha, 2013, Natl J Maxillofac Surg, V4, P52, DOI 10.4103/0975 5950.117884
   Singh Vibha, 2011, Natl J Maxillofac Surg, V2, P132, DOI 10.4103/0975 5950.94466
   Song L, 2017, ADV CLIN CHEM, V82, P1, DOI 10.1016/bs.acc.2017.06.005
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Thakur A, 2009, PHARMACOGN RES, V1, P213
   Toor RH, 2019, J CELL PHYSIOL, V234, P23082, DOI 10.1002/jcp.28869
   Toor RH, 2020, CRIT REV EUKAR GENE, V30, P519, DOI 10.1615/CritRevEukaryotGeneExpr.2020036843
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Vijayakumar B., 2005, Thesis
   Xie JB, 2020, INT J ENDOCRINOL, V2020, DOI 10.1155/2020/3236828
   Yang LJ, 2011, J ETHNOPHARMACOL, V135, P553, DOI 10.1016/j.jep.2011.03.056
NR 75
TC 0
Z9 0
U1 0
U2 3
PU ZOOLOGICAL SOC PAKISTAN
PI LAHORE
PA UNIV PUNJAB, NEW CAMPUS, C/O DEPT ZOOLOGY, LAHORE, PAKISTAN
SN 0030 9923
J9 PAK J ZOOL
JI Pak. J. Zool.
PD DEC
PY 2023
VL 55
IS 6
BP 2707
EP 2722
DI 10.17582/journal.pjz/20220312001022
PG 16
WC Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Zoology
GA FF5R4
UT WOS:001144365800010
OA gold
DA 2025 08 17
ER

PT J
AU Wu, ZX
   Wu, HL
   Li, C
   Fu, FS
   Ding, JX
   Shao, SY
   Li, K
   Yu, X
   Su, YG
   Liang, JM
   Lin, XX
   Yuan, GX
   Zhou, J
   Song, FM
   Zhao, JM
   Xu, JK
   Liu, Q
   Xu, F
AF Wu, Zuoxing
   Wu, Hailun
   Li, Chen
   Fu, Fangsheng
   Ding, Jiaxin
   Shao, Siyuan
   Li, Kai
   Yu, Xiao
   Su, Yuangang
   Liang, Jiamin
   Lin, Xixi
   Yuan, Guixin
   Zhou, Juan
   Song, Fangming
   Zhao, Jinmin
   Xu, Jiake
   Liu, Qian
   Xu, Feng
TI Daphnetin attenuates LPS induced osteolysis and RANKL mediated
   osteoclastogenesis through suppression of ERK and NFATc1 pathways
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE daphnetin; MAPK; osteoclast; osteolysis
ID BONE RESORPTION; COUMARIN; DIFFERENTIATION; ACTIVATION; INDUCTION;
   CANCER; GENE
AB Aseptic prosthetic loosening and periprosthetic infection resulting in inflammatory osteolysis is a leading complication of total joint arthroplasty (TJA). Excessive bone destruction around the bone and prosthesis interface plays a key role in the loosening prostheses leading to revision surgery. The bacterial endotoxins or implant derived wear particles induced inflammatory response is the major cause of the elevated osteoclast formation and activity. Thus, agents or compounds that can attenuate the inflammatory response and/or inhibit the elevated osteoclastogenesis and excessive bone resorption would provide a promising therapeutic avenue to prevent aseptic prosthetic loosening in TJA. Daphnetin (DAP), a natural coumarin derivative, is clinically used in Traditional Chinese Medicine for the treatment of rheumatoid arthritis due to its anti inflammatory properties. In this study, we report for the first time that DAP could protect against lipopolysaccharide induced inflammatory bone destruction in a murine calvarial osteolysis model in vivo. This protective effect of DAP can in part be attributed to its direct inhibitory effect on RANKL induced osteoclast differentiation, fusion, and bone resorption in vitro. Biochemical analysis found that DAP inhibited the activation of the ERK and NFATc1 signaling cascades. Collectively, our findings suggest that DAP as a natural compound has potential for the treatment of inflammatory osteolysis.
C1 [Wu, Zuoxing; Li, Chen; Fu, Fangsheng; Ding, Jiaxin; Shao, Siyuan; Li, Kai; Yu, Xiao; Su, Yuangang; Liang, Jiamin; Lin, Xixi; Song, Fangming; Zhao, Jinmin; Xu, Jiake; Xu, Feng] Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
   [Wu, Hailun; Zhou, Juan] Guangxi Med Univ, Dept Gynecol Oncol, Affiliated Tumor Hosp, Nanning, Guangxi, Peoples R China.
   [Yuan, Guixin] Shantou Univ, Med Coll, Affiliated Hosp 2, Dept Orthoped, Shantou, Guangdong, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Res Ctr Regenerat Med, Nanning 530000, Guangxi, Peoples R China.
   [Xu, Feng] Jiaotong Univ, Sch Med, Peoples Hosp Shanghai 9, Dept Subject Planning Shanghai, Shanghai, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Shantou
   University; University of Western Australia; Guangxi Medical University;
   Shanghai Jiao Tong University
RP Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Res Ctr Regenerat Med, Nanning 530000, Guangxi, Peoples R China.; Xu, F (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Subject Planning, Shanghai 200000, Peoples R China.
EM luoboqian@hotmail.com; xufenghhou@163.com
RI ; wu, zuoxing/JCN 5560 2023; xi, lin/JOK 1026 2023; zhao,
   jin/LBH 0351 2024; Wu, Hailun/LMO 7656 2024; Su, Yuangang/KKU 6952 2024
OI Xu, Jiake/0000 0003 2021 8309; Zhao, Jinmin/0000 0001 8423 0425; Zhao,
   Jinmin/0000 0002 1047 8820; 
FU Guangxi Collaborative Innovation Center for Biomedicine talent
   cultivation [GCICB TC 2017001]; National Natural Science Foundation of
   China [81772373, 81572167, 81501910]; Natural Science Foundation of
   Guangxi Province [2015GXNSFCA414001, 2015GXNSFDA139019]; Project of
   BAGUI Scholar [82102304002024c]
FX Guangxi Collaborative Innovation Center for Biomedicine talent
   cultivation, Grant/Award Number: GCICB TC 2017001; National Natural
   Science Foundation of China, Grant/Award Numbers: 81772373, 81572167,
   81501910; Natural Science Foundation of Guangxi Province, Grant/Award
   Numbers: 2015GXNSFCA414001, 2015GXNSFDA139019; Project of BAGUI Scholar,
   Grant/Award Number: 82102304002024c
CR Abe T, 2014, J IMMUNOL, V193, P1383, DOI 10.4049/jimmunol.1400970
   Agelaki S, 2002, INFECT IMMUN, V70, P6068, DOI 10.1128/IAI.70.11.6068 6074.2002
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Bhattacharyya SS, 2009, EUR J PHARMACOL, V614, P128, DOI 10.1016/j.ejphar.2009.04.015
   Bi Y., 2010, J BONE MINER RES, V16, P2082
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen XY, 2018, MOL MED REP, V17, P884, DOI 10.3892/mmr.2017.8008
   David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099
   Deepak R, 2016, 2016 SECOND IEEE INTERNATIONAL CONFERENCE ON RESEARCH IN COMPUTATIONAL INTELLIGENCE AND COMMUNICATION NETWORKS (ICRCICN), P1, DOI 10.1109/ICRCICN.2016.7813541
   Fylaktakidou KC, 2004, CURR PHARM DESIGN, V10, P3813, DOI 10.2174/1381612043382710
   Gao Q, 2008, J ETHNOPHARMACOL, V120, P259, DOI 10.1016/j.jep.2008.08.031
   Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898 6568(00)00149 2
   Gwam CU, 2017, J ARTHROPLASTY, V32, P2088, DOI 10.1016/j.arth.2017.02.046
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Hitoshi H., 2010, J CELL BIOCHEM, V101, P122
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Ishida M, 2015, AM J TRANSPLANT, V15
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Kong LB, 2017, INT IMMUNOPHARMACOL, V51, P31, DOI 10.1016/j.intimp.2017.07.003
   Lamoral Theys D, 2010, CURR MED CHEM, V17, P812, DOI 10.2174/092986710790712183
   Liang SC, 2010, DRUG METAB DISPOS, V38, P973, DOI 10.1124/dmd.109.030734
   Liu J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2816056
   Liu RH, 2004, J NUTR, V134, p3479S, DOI 10.1093/jn/134.12.3479S
   Maatouk M, 2017, CELL STRESS CHAPERON, V22, P775, DOI 10.1007/s12192 017 0808 7
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Matsuo Koichi, 2004, Keio Journal of Medicine, V53, P78, DOI 10.2302/kjm.53.78
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Monti M, 2007, BBA GEN SUBJECTS, V1770, P1437, DOI 10.1016/j.bbagen.2007.06.013
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Park SH, 2016, PHYTOTHER RES, V30, P604, DOI 10.1002/ptr.5565
   Qin R. X., 2009, STRAIT PHARM J
   Saeed J, 2016, IMMUNOL LETT, V175, P8, DOI 10.1016/j.imlet.2016.04.004
   Skoglund B, 2002, J BONE JOINT SURG BR, V84B, P767, DOI 10.1302/0301 620X.84B5.11775
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Venugopala KN, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/963248
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Williams B, 2017, INFLAMMOPHARMACOLOGY, V25, P55, DOI 10.1007/s10787 016 0306 z
   Xu F., 2010, IUBMB LIFE, V57, P389
   Xu J., 2000, BONE, V27, P32, DOI [10.1016/s8756 3282(00)80105 2, DOI 10.1016/S8756 3282(00)80105 2]
   YANG YZ, 1992, AM J TROP MED HYG, V46, P15, DOI 10.4269/ajtmh.1992.46.15
   Yao RF, 2011, EUR J PHARMACOL, V670, P286, DOI 10.1016/j.ejphar.2011.08.019
   Yu D., 2003, CHEMINFORM, V34, P322
   Yu WW, 2014, J AGR FOOD CHEM, V62, P12315, DOI 10.1021/jf503667v
   Yu WW, 2014, INT IMMUNOPHARMACOL, V21, P1, DOI 10.1016/j.intimp.2014.04.005
   Zhuo S., 2016, J YUNNAN U TRADITION
NR 48
TC 30
Z9 30
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2019
VL 234
IS 10
BP 17812
EP 17823
DI 10.1002/jcp.28408
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA IH7ML
UT WOS:000474688200091
PM 30815894
DA 2025 08 17
ER

PT J
AU Koblenzer, M
   Weiler, M
   Fragoulis, A
   Rütten, S
   Pufe, T
   Jahr, H
AF Koblenzer, Maximilian
   Weiler, Marek
   Fragoulis, Athanassios
   Ruetten, Stephan
   Pufe, Thomas
   Jahr, Holger
TI Physiological Mineralization during In Vitro Osteogenesis in a
   Biomimetic Spheroid Culture Model
SO CELLS
LA English
DT Article
DE spheroid culture; osteoblast progenitors; osteogenic differentiation;
   physiological biomineralization; volumetric micro CT quantification;
   Fourier transform infrared spectroscopy (FT IR)
ID 3 DIMENSIONAL CELL CULTURE; GENE EXPRESSION; DRUG DISCOVERY; BONE MASS;
   OSTEOBLAST DIFFERENTIATION; ALKALINE PHOSPHATASE; MC3T3 E1 CELLS;
   STEM CELLS; OSTEOPONTIN; OSTEOCALCIN
AB Bone health targeting drug development strategies still largely rely on inferior 2D in vitro screenings. We aimed at developing a scaffold free progenitor cell based 3D biomineralization model for more physiological high throughput screenings. MC3T3 E1 pre osteoblasts were cultured in alpha MEM with 10% FCS, at 37 degrees C and 5% CO2 for up to 28 days, in non adherent V shaped plates to form uniformly sized 3D spheroids. Osteogenic differentiation was induced by 10 mM beta glycerophosphate and 50 mu g/mL ascorbic acid. Mineralization stages were assessed through studying expression of marker genes, alkaline phosphatase activity, and calcium deposition by histochemistry. Mineralization quality was evaluated by Fourier transformed infrared (FTIR) and scanning electron microscopic (SEM) analyses and quantified by micro CT analyses. Expression profiles of selected early  and late stage osteoblast differentiation markers indicated a well developed 3D biomineralization process with strongly upregulated Col1a1, Bglap and Alpl mRNA levels and type I collagen  and osteocalcin positive immunohistochemistry (IHC). A dynamic biomineralization process with increasing mineral densities was observed during the second half of the culture period. SEM Energy Dispersive X ray analyses (EDX) and FTIR ultimately confirmed a native bone like hydroxyapatite mineral deposition ex vivo. We thus established a robust and versatile biomimetic, and high throughput compatible, cost efficient spheroid culture model with a native bone like mineralization for improved pharmacological ex vivo screenings.
C1 [Koblenzer, Maximilian; Fragoulis, Athanassios; Pufe, Thomas; Jahr, Holger] Uniklin RWTH Aachen, Dept Anat & Cell Biol, D 52074 Aachen, Germany.
   [Weiler, Marek] Rhein Westfal TH Aachen, Inst Expt Mol Imaging, D 52074 Aachen, Germany.
   [Ruetten, Stephan] Uniklin RWTH Aachen, Electron Microscope Facil, D 52074 Aachen, Germany.
   [Jahr, Holger] Maastricht Univ, Dept Orthopaed Surg, Lab Expt Orthoped, Med Ctr, NL 6229 ER Maastricht, Netherlands.
C3 RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen
   University; RWTH Aachen University; RWTH Aachen University Hospital;
   Maastricht University
RP Koblenzer, M; Jahr, H (通讯作者)，Uniklin RWTH Aachen, Dept Anat & Cell Biol, D 52074 Aachen, Germany.; Jahr, H (通讯作者)，Maastricht Univ, Dept Orthopaed Surg, Lab Expt Orthoped, Med Ctr, NL 6229 ER Maastricht, Netherlands.
EM maximilian.koblenzer@rwth aachen.de; h.jahr@maastrichtuniversity.nl
RI Jahr, Holger/IZE 7142 2023; Jahr, Holger/M 3099 2015; Fragoulis,
   Athanassios/O 1191 2019
OI Jahr, Holger/0000 0001 7308 5584; Pufe, Thomas/0000 0002 7886 9211;
   Fragoulis, Athanassios/0000 0002 6973 3080
FU Interdisciplinary Centre for Clinical Research within the faculty of
   Medicine at the RWTH Aachen University [IZKF OC 1]; Federal Ministry of
   Education and Research (BMBF); Ministry of Culture and Science of the
   State of North Rhine Westphalia (MKW) [OPSF597]; Medical Faculty of the
   RWTH Aachen University [IA 692092, IA 691513]
FX This research was supported by a grant from the Interdisciplinary Centre
   for Clinical Research within the faculty of Medicine at the RWTH Aachen
   University (IZKF OC 1), the Federal Ministry of Education and Research
   (BMBF) and the Ministry of Culture and Science of the State of North
   Rhine Westphalia (MKW) under the Excellence Strategy of the Federal
   Government and the Lander (OPSF597), and the Medical Faculty of the RWTH
   Aachen University (START program; IA 692092 and IA 691513).
CR Abzhanov A, 2007, DEVELOPMENT, V134, P3133, DOI 10.1242/dev.002709
   Addison WN, 2015, BONE, V71, P244, DOI 10.1016/j.bone.2014.11.003
   Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200
   Alcorta Sevillano N, 2020, CELLS BASEL, V9, DOI 10.3390/cells9122630
   Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014
   Amarilio R, 2007, DEVELOPMENT, V134, P3917, DOI 10.1242/dev.008441
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756 3282(88)90005 1
   Bicer M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02094 8
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223 001 1121 z
   Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003
   Brown KM, 2013, THER ADV PSYCHOPHARM, V3, P163, DOI 10.1177/2045125312471963
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cowan CM, 2007, TISSUE ENG, V13, P501, DOI 10.1089/ten.2006.0141
   Curcio E, 2007, BIOMATERIALS, V28, P5487, DOI 10.1016/j.biomaterials.2007.08.033
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Deegan AJ, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475 925X 13 136
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dunwoodie SL, 2009, DEV CELL, V17, P755, DOI 10.1016/j.devcel.2009.11.008
   Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   El Serafi AT, 2011, EUR CELLS MATER, V21, P558, DOI 10.22203/eCM.v021a42
   Fang Y, 2017, SLAS DISCOV, V22, P456, DOI 10.1177/1087057117696795
   Fragoulis A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157853
   Fragoulis A, 2019, TOXICOL SCI, V169, P485, DOI 10.1093/toxsci/kfz055
   Franz Odendaal TA, 2011, FRONT BIOSCI LANDMRK, V16, P2734, DOI 10.2741/3882
   Gaitán Salvatella I, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.672518
   Gibon E, 2012, TISSUE ENG PT A, V18, P968, DOI [10.1089/ten.tea.2011.0545, 10.1089/ten.TEA.2011.0545]
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gremse F, 2016, THERANOSTICS, V6, P328, DOI 10.7150/thno.13624
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Hall BK, 1995, INT J DEV BIOL, V39, P881
   HAUSCHKA PV, 1982, BIOCHEMISTRY US, V21, P2538, DOI 10.1021/bi00539a038
   Hellingman CA, 2011, CELL TRANSPLANT, V20, P925, DOI 10.3727/096368910X539119
   Holm E, 2014, BIOCHEM J, V464, P355, DOI 10.1042/BJ20140702
   Hongisto V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077232
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Hunter GK, 2013, CALCIFIED TISSUE INT, V93, P348, DOI 10.1007/s00223 013 9698 6
   Hwang PW, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44575 8
   Imamura A, 2020, BIOCHEM BIOPH RES CO, V523, P458, DOI 10.1016/j.bbrc.2019.12.066
   Jabalee J, 2013, J ANAT, V223, P311, DOI 10.1111/joa.12095
   Jähn K, 2010, EUR CELLS MATER, V20, P149
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   Jansen JHW, 2010, J ORTHOP RES, V28, P390, DOI 10.1002/jor.20991
   Jin YF, 2017, J BONE MINER METAB, V35, P497, DOI 10.1007/s00774 016 0783 6
   Kale S, 2000, NAT BIOTECHNOL, V18, P954, DOI 10.1038/79439
   Kanis JA, 2017, OSTEOPOROSIS INT, V28, P2023, DOI 10.1007/s00198 017 4009 0
   Karasik D, 2016, NAT REV RHEUMATOL, V12, P323, DOI 10.1038/nrrheum.2016.48
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim J, 2021, J BIOSCI BIOENG, V132, P651, DOI 10.1016/j.jbiosc.2021.09.004
   Kim J, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00288
   Köhler Forsberg O, 2022, JAMA PSYCHIAT, V79, P454, DOI 10.1001/jamapsychiatry.2022.0337
   Kollmer Melanie, 2013, J Dev Biol Tissue Eng, V5, P18
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kubo Y, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020263
   Langhans SA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00006
   Li L, 2017, SCI REP UK, V7, DOI 10.1038/srep45204
   Lin Ruei Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Luttrell LM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0204197
   Miron RJ, 2012, J DENT RES, V91, P736, DOI 10.1177/0022034511435260
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Paccou J, 2018, JOINT BONE SPINE, V85, P693, DOI 10.1016/j.jbspin.2018.01.007
   Palumbo C, 2003, J ANAT, V203, P589, DOI 10.1046/j.1469 7580.2003.00247.x
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Peng WC, 2018, CELL, V175, P1607, DOI 10.1016/j.cell.2018.11.012
   Poundarik AA, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19253 w
   Provot S, 2007, J CELL BIOL, V177, P451, DOI 10.1083/jcb.200612023
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Restle L, 2015, ADV MATER SCI ENG, V2015, DOI 10.1155/2015/268930
   ROACH HI, 1994, CELL BIOL INT, V18, P617, DOI 10.1006/cbir.1994.1088
   Roberts SJ, 2015, BONE, V70, P10, DOI 10.1016/j.bone.2014.08.007
   Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saleh F, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7132529
   Sloan SA, 2018, NAT PROTOC, V13, P2062, DOI 10.1038/s41596 018 0032 7
   Souza W, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45797 6
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   van der Linden Jacqueline C, 2006, Drug Discov Today Technol, V3, P213, DOI 10.1016/j.ddtec.2006.06.006
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   VanDussen KL, 2015, GUT, V64, P911, DOI 10.1136/gutjnl 2013 306651
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Warden SJ, 2010, BONE, V46, P985, DOI 10.1016/j.bone.2009.12.031
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   WEINREB M, 1990, J BONE MINER RES, V5, P831
   zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432 0436.2003.700602.x
NR 98
TC 27
Z9 27
U1 3
U2 20
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD SEP
PY 2022
VL 11
IS 17
AR 2702
DI 10.3390/cells11172702
PG 23
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 4L3LI
UT WOS:000852532200001
PM 36078105
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Emch, MJ
   Wicik, Z
   Aspros, KGM
   Vukajlovic, T
   Pitel, KS
   Narum, AK
   Weivoda, MM
   Tang, XJ
   Kalari, KR
   Turner, RT
   Iwaniec, UT
   Monroe, DG
   Subramaniam, M
   Hawse, JR
AF Emch, Michael J.
   Wicik, Zofia
   Aspros, Kirsten G. M.
   Vukajlovic, Tanja
   Pitel, Kevin S.
   Narum, Anders K.
   Weivoda, Megan M.
   Tang, Xiaojia
   Kalari, Krishna R.
   Turner, Russell T.
   Iwaniec, Urszula T.
   Monroe, David G.
   Subramaniam, Malayannan
   Hawse, John R.
TI Estrogen regulated miRs in bone enhance osteoblast differentiation and
   matrix mineralization
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID POSTMENOPAUSAL OSTEOPOROSIS; TRABECULAR BONE; EXPRESSION; BETA;
   RECEPTORS; NETWORK; RNA
AB Estrogen signaling is critical for the development and mainte nance of healthy bone, and age related decline in estrogen levels contributes to the development of post menopausal osteopo rosis. Most bones consist of a dense cortical shell and an internal mesh like network of trabecular bone that respond differently to internal and external cues such as hormonal signaling. To date, no study has assessed the transcriptomic dif ferences that occur specifically in cortical and trabecular bone compartments in response to hormonal changes. To investigate this, we employed a mouse model of post menopausal osteopo rosis (ovariectomy, OVX) and estrogen replacement therapy (ERT). mRNA and miR sequencing revealed distinct transcrip tomic profiles between cortical and trabecular bone in the setting of OVX and ERT. Seven miRs were identified as likely contributors to the observed estrogen mediated mRNA expres sion changes. Of these, four miRs were prioritized for further study and decreased predicted target gene expression in bone cells, enhanced the expression of osteoblast differentiation markers, and altered the mineralization capacity of primary os teoblasts. As such, candidate miRs and miR mimics may have therapeutic relevance for bone loss resulting from estrogen depletion without the unwanted side effects of hormone replacement therapy and therefore represent novel therapeutic approaches to combat diseases of bone loss.
C1 [Emch, Michael J.; Aspros, Kirsten G. M.; Vukajlovic, Tanja; Pitel, Kevin S.; Weivoda, Megan M.; Subramaniam, Malayannan; Hawse, John R.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
   [Wicik, Zofia] Inst Psychiat & Neurol, Dept Neurochem, Sobieskiego 9 St, PL 02957 Warsaw, Poland.
   [Wicik, Zofia] Med Univ Warsaw, Ctr Preclin Res & Technol CePT, Dept Expt & Clin Pharmacol, Banacha 1B St, PL 02097 Warsaw, Poland.
   [Narum, Anders K.; Weivoda, Megan M.] Mayo Clin, Hematol Oncol, Rochester, MN 55905 USA.
   [Tang, Xiaojia; Kalari, Krishna R.] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN 55905 USA.
   [Turner, Russell T.; Iwaniec, Urszula T.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Skeletal Biol Lab, Corvallis, OR 97331 USA.
   [Turner, Russell T.; Iwaniec, Urszula T.] Oregon State Univ, Ctr Hlth Aging Res, Corvallis, OR 97331 USA.
   [Monroe, David G.] Mayo Clin, Coll Med, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA.
   [Monroe, David G.] Mayo Clin, Div Endocrinol, Coll Med, Rochester, MN 55905 USA.
   [Hawse, John R.] Mayo Clin, Dept Canc Biol, Rochester, MN USA.
C3 Mayo Clinic; Institute of Psychiatry & Neurology; Medical University of
   Warsaw; Mayo Clinic; Mayo Clinic; Oregon State University; Oregon State
   University; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Hawse, JR (通讯作者)，Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
EM hawse.john@mayo.edu
RI ; Wicik, Zofia/G 1325 2018
OI Narum, Anders/0009 0008 1832 7956; Wicik, Zofia/0000 0002 2857 1986;
   Emch, Michael/0000 0001 8670 8138
FU National Institutes of Health [R01AG063707]; Eisenberg foundation; Mayo
   Foundation; Mayo Clinic Graduate School of Biomedical Sciences; 
   [R01DE14036]
FX & nbsp;We would like to thank the Mayo Clinic Genome Analysis Core and
   the Bioinformatics Core for their time and effort in running the mRNA
   and miR sequencing and performing primary and secondary analysis of the
   data. This work was supported by the National Institutes of Health
   (R01DE14036 to J.R.H. and M.S., R01AG063707 to D.G.M.) ; the Eisenberg
   foundation to J.R.H.; the Mayo Foundation to J.R.H.; and the Mayo Clinic
   Graduate School of Biomedical Sciences to M.J.E.
CR Agas D, 2019, J CELL PHYSIOL, V234, P192, DOI 10.1002/jcp.26837
   An JH, 2014, J BONE MINER RES, V29, P644, DOI 10.1002/jbmr.2060
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Arora S, 2013, MOL GENET GENOMICS, V288, P77, DOI 10.1007/s00438 013 0734 z
   Barbano R, 2017, SCI REP UK, V7, DOI 10.1038/srep45283
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chakraborty C, 2021, J ADV RES, V28, P127, DOI 10.1016/j.jare.2020.08.012
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   Elango J, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155559
   Eyster KM, 2016, METHODS MOL BIOL, V1366, P1, DOI 10.1007/978 1 4939 3127 9_1
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Fuentes N, 2019, ADV PROTEIN CHEM STR, V116, P135, DOI 10.1016/bs.apcsb.2019.01.001
   Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037
   Goodyear SR, 2009, BONE, V44, P899, DOI 10.1016/j.bone.2009.01.008
   Guberman JM, 2011, DATABASE OXFORD, DOI 10.1093/database/bar041
   Kalari KR, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 224
   Kaur J, 2022, GENE, V835, DOI 10.1016/j.gene.2022.146642
   Kelly NH, 2014, BONE, V68, P1, DOI 10.1016/j.bone.2014.07.022
   Khosla S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031211
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kinsella RJ, 2011, DATABASE OXFORD, DOI 10.1093/database/bar030
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Lee B, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90517
   Liu H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1285 y
   Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008 5472.CAN 09 2206
   Mann SN, 2020, EXP GERONTOL, V142, DOI 10.1016/j.exger.2020.111113
   Mao D, 2021, J ORAL PATHOL MED, V50, P236, DOI 10.1111/jop.13131
   Miranda TB, 2013, CANCER RES, V73, P5130, DOI 10.1158/0008 5472.CAN 13 0742
   Nassa G, 2014, MOL CELL PROTEOMICS, V13, P1076, DOI 10.1074/mcp.M113.030403
   Ott SM, 2018, AM J NEPHROL, V47, P373, DOI 10.1159/000489672
   Panni S, 2020, BBA GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194417
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Reese JM, 2017, ONCOTARGET, V8, P96506, DOI 10.18632/oncotarget.21787
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Roforth MM, 2012, J BONE MINER RES, V27, P891, DOI 10.1002/jbmr.1502
   Ru YB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku631
   Serguienko A, 2018, BIOL PROCED ONLINE, V20, DOI 10.1186/s12575 018 0079 4
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Subramaniam M, 2005, MOL CELL BIOL, V25, P1191, DOI 10.1128/MCB.25.3.1191 1199.2005
   Subramaniam M, 2010, BIOCHEM BIOPH RES CO, V392, P72, DOI 10.1016/j.bbrc.2009.12.171
   Subramaniam M, 2018, J CELL PHYSIOL, V233, P3540, DOI 10.1002/jcp.26211
   Subramaniam M, 2016, BIOCHEM BIOPH RES CO, V470, P528, DOI 10.1016/j.bbrc.2016.01.112
   Sukocheva OA, 2022, SEMIN CANCER BIOL, V82, P35, DOI 10.1016/j.semcancer.2020.12.004
   Sun DW, 2023, CONNECT TISSUE RES, V64, P126, DOI 10.1080/03008207.2022.2108415
   Sun ZF, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 423
   Wang L, 2021, THERANOSTICS, V11, P1732, DOI 10.7150/thno.45302
   Wang LB, 2021, MOL CELL BIOCHEM, V476, P575, DOI 10.1007/s11010 020 03927 z
   Wicik Z., 2021, WIZBIONET
   Wicik Z, 2021, GENOMICS, V113, P503, DOI 10.1016/j.ygeno.2020.09.041
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xu X, 2020, AM J TRANSL RES, V12, P4251
   Zheng CY, 2020, MECH DEVELOP, V162, DOI 10.1016/j.mod.2020.103612
   Zogg H, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052736
NR 55
TC 4
Z9 5
U1 1
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD SEP 12
PY 2023
VL 33
BP 28
EP 41
DI 10.1016/j.omtn.2023.05.026
EA JUN 2023
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA P9RX9
UT WOS:001053990500001
PM 37359348
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Low, SA
   Nielsen, JJ
   Coakley, CM
   Thomas, M
   Mbachu, EU
   Chen, CL
   Jones Hall, Y
   Tremblay, MI
   Hicks, JR
   Low, PS
AF Low, Stewart A.
   Nielsen, Jeffery J.
   Coakley, Cheyanne M.
   Thomas, Mini
   Mbachu, Ephraim U.
   Chen, Christopher L.
   Jones Hall, Yava
   Tremblay, Madeleine I.
   Hicks, Jonathan R.
   Low, Philip S.
TI An engineered dual function peptide to repair fractured bones
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Fracture healing; Anabolic peptide; Targeted delivery; PTHR1 receptor
ID MICE; ABALOPARATIDE; PAIN
AB Targeted drug delivery, often referred to as "smart " drug delivery, is a process whereby a therapeutic drug is delivered to specific parts of the body in a manner that increases its concentration at the desired sites relative to others. This approach is poised to revolutionize medicine as exemplified by the recent FDA approval of Cytalux (FDA approves pioneering drug for ovarian cancer surgery  Purdue University News) which is a folate receptor targeted intraoperative near infrared (NIR) imaging agent that was developed in our laboratories. Fracture  associated morbidities and mortality affect a significant portion of world population. United states, Canada and Europe alone spent $48 billion in treating osteoporosis related fractures although this number doesn't count the economic burden due to loss in productivity. It is estimated that by 2050 ca 21 million hip fractures would occur globally which will be leading cause of premature death and disability. Despite the need for improvement in the treatment for fracture repair, methods for treating fractures have changed little in recent decades. Systemic delivery of fracture homing bone anabolics holds great promise as a therapeutic strategy in this regard. Here we report the design of a fracture targeted peptide comprised of a payload that binds and activates the parathyroid hormone receptor (PTHR1) and is linked to a targeting ligand comprised of 20 D glutamic acids (D Glu(20)) that directs accumulation of the payload specifically at fracture sites. This targeted delivery results in reduction of fracture healing times to < 1/2 while creating repaired bones that are > 2 fold stronger than saline treated controls in mice. Moreover, this hydroxyapatite targeted peptide can be administered without detectable toxicity to healthy tissues or modification of healthy bones in dogs. Additionally, since similar results are ob tained upon treatment of osteoporotic and diabetic fractures in mice, and pain resolution is simultaneously accelerated by this approach, we conclude that this fracture targeted anabolic peptide displays significant po tential to revolutionize the treatment of bone fractures.
C1 [Low, Stewart A.; Tremblay, Madeleine I.; Low, Philip S.] Purdue Univ, Dept Chem, 720 Clin Dr, W Lafayette, IN 47907 USA.
   [Nielsen, Jeffery J.; Low, Philip S.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN USA.
   [Coakley, Cheyanne M.] Purdue Univ, Dept Biochem, W Lafayette, IN USA.
   [Thomas, Mini] Novosteo Inc, 1281 Win Hentschel Blvd, W Lafayette, IN 47906 USA.
   [Mbachu, Ephraim U.; Hicks, Jonathan R.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN USA.
   [Chen, Christopher L.] Purdue Univ, Coll Hlth & Human Sci, W Lafayette, IN USA.
   [Jones Hall, Yava] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University; Purdue University System; Purdue University; Purdue
   University System; Purdue University; Purdue University System; Purdue
   University; Purdue University System; Purdue University
RP Low, SA; Low, PS (通讯作者)，Purdue Univ, Dept Chem, 720 Clin Dr, W Lafayette, IN 47907 USA.
EM stewart.low@gmail.com; plow@purdue.edu
RI Low, Stewart/JTU 2123 2023; Jones Hall, Yava/ABF 3101 2021
OI Low, Stewart/0000 0002 7387 3545; Hicks, Jonathan/0000 0002 6312 484X;
   Thomas, Mini/0009 0006 2328 4191
FU Purdue University, Indiana CTSI; National Institute of Dental &
   Craniofacial Research of the National Institutes of Health [R44DE028713]
FX This research was supported in part by gifted funds from Purdue
   University, Indiana CTSI, and National Institute of Dental &
   Craniofacial Research of the National Institutes of Health under Award
   Number R44DE028713. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Agarwal A, 2017, NONUNIONS DIAGNOSIS
   Alblowi J, 2009, AM J PATHOL, V175, P1574, DOI 10.2353/ajpath.2009.090148
   [Anonymous], 2005, Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Pharmacology and Toxicology Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
   Bentler SE, 2009, AM J EPIDEMIOL, V170, P1290, DOI 10.1093/aje/kwp266
   Börjesson AE, 2012, AM J PHYSIOL ENDOC M, V302, pE1381, DOI 10.1152/ajpendo.00646.2011
   Brenner AI, 2012, SEMIN NUCL MED, V42, P11, DOI 10.1053/j.semnuclmed.2011.07.005
   Bunck MC, 2011, DIABETES OBES METAB, V13, P374, DOI 10.1111/j.1463 1326.2010.01355.x
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cheung WH, 2016, INJURY, V47, pS21, DOI 10.1016/S0020 1383(16)47004 X
   Chew CK, 2017, MATURITAS, V97, P53, DOI 10.1016/j.maturitas.2016.12.003
   Choi S, 2007, GENES BRAIN BEHAV, V6, P425, DOI 10.1111/j.1601 183X.2006.00268.x
   Cobos EJ, 2012, PAIN, V153, P876, DOI 10.1016/j.pain.2012.01.016
   Dong J, 2001, Peptides: the wave of the future, P668, DOI [10.1007/978 94 010 0464 0_311, DOI 10.1007/978 94 010 0464 0_311]
   Epstein Nancy E, 2013, Surg Neurol Int, V4, pS343, DOI 10.4103/2152 7806.114813
   Ferreira Rivea Ines, 2002, J Dent Educ, V66, P1381
   Fracture Trends, FRACTURE TRENDS BMUS
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Henderson S, 2019, J BONE JOINT SURG AM, V101, P1399, DOI 10.2106/JBJS.18.01297
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Karataglis D, 2011, INJURY, V42, P330, DOI 10.1016/j.injury.2010.10.016
   Leamon CP, 2002, BIOCONJUGATE CHEM, V13, P1200, DOI 10.1021/bc0200430
   Low SA, 2015, BIOMACROMOLECULES, V16, P3145, DOI 10.1021/acs.biomac.5b00777
   Lynch JR, 2008, J AM ACAD ORTHOP SUR, V16, P88, DOI 10.5435/00124635 200802000 00006
   Moberg L, 2016, LUNDS U FRACTURES PO
   Moran DS, 2008, SPORTS MED, V38, P345, DOI 10.2165/00007256 200838040 00005
   Nielsen JJ, 2021, J CONTROL RELEASE, V329, P570, DOI 10.1016/j.jconrel.2020.09.047
   Nielsen JJ, 2020, CURR OSTEOPOROS REP, V18, P449, DOI 10.1007/s11914 020 00604 4
   Noldus LPJJ, 2001, BEHAV RES METH INS C, V33, P398, DOI 10.3758/BF03195394
   Nozaki C, 2012, J PHARMACOL EXP THER, V342, P799, DOI 10.1124/jpet.111.188987
   Nyman JS, 2011, BONE, V48, P733, DOI 10.1016/j.bone.2010.12.016
   Shi ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168691
   Tella SH, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1300
   Wehren Lois E, 2003, Curr Osteoporos Rep, V1, P78, DOI 10.1007/s11914 003 0013 8
   Zhang XL, 2008, BIOL TRACE ELEM RES, V121, P233, DOI 10.1007/s12011 007 8043 1
NR 34
TC 7
Z9 7
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT
PY 2022
VL 350
BP 688
EP 697
DI 10.1016/j.jconrel.2022.06.068
EA SEP 2022
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 4M5DZ
UT WOS:000853344900001
PM 36030992
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Lee, Y
   Chang, EJ
   Kim, HM
   Hong, SP
   Lee, ZH
   Ryu, J
   Kim, HH
AF Kim, Hyung Joon
   Lee, Youngkyun
   Chang, Eun Ju
   Kim, Hyun Man
   Hong, Sam Pyo
   Lee, Zang Hee
   Ryu, Jiyoon
   Kim, Hong Hee
TI Suppression of osteoclastogenesis by
   N,N dimethyl D erythro sphingosine:: A sphingosine kinase
   inhibition independent action
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID NF KAPPA B; MAP KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RECEPTOR
   ACTIVATOR; NUCLEAR FACTOR; SIGNAL TRANSDUCTION; HUMAN MACROPHAGES;
   INTRACELLULAR PH; C FOS; PROTEIN
AB N,N Dimethyl D erythro sphingosine (DMS) competitively inhibits sphingosine kinase (SPHK) and has been widely used to assess the role of SPHK during cellular events, including motility, proliferation, and differentiation. In the present study, the effect of DMS on the differentiation of bone marrow macrophages (BMMs) to osteoclasts was investigated. When the osteoclast precursor cells were treated with DMS, the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis was completely blocked. We were surprised to find, however, that knock down of SPHK by small interfering RNA (siRNA) in BMMs did not reduce osteoclastogenesis. Furthermore, both overexpression of SPHK and exogenous addition of sphingosine 1 phosphate, the product of SPHK activity, failed to overcome the antiosteoclastogenic effect of DMS. These results suggest that DMS inhibited osteoclastogenesis independently of SPHK. Subsequent characterization of the DMS mediated suppression of osteoclastogenesis revealed that DMS did not affect RANKL induced activation of JNK, p38, NF kappa B, and Ca2+ oscillation. On the other hand, DMS strongly inhibited two separate signaling pathways, the RANKL induced activation of ERK and Akt, which eventually converged on the transcription factors c Fos and NFATc1. There was significant increase in the osteoclast formation in the presence of DMS when BMMs were overexpressed with c Fos, suggesting that c Fos was a critical downstream target of DMS for the inhibition of osteoclastogenesis. Taken together, our data demonstrate that DMS has an antiosteoclastogenic function independently of its SPHK inhibitory activity. Considering previously reported anticancer properties of DMS, our study may also propose that DMS is an ideal drug candidate for bone metastases, for which osteoclastic bone resorption is crucial.
C1 Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, BK21, Seoul, South Korea.
   Seoul Natl Univ, Sch Dent, Dept Oral Pathol, DRI, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU)
RP Kim, HH (通讯作者)，Seoul Natl Univ, Dept Cell & Dev Biol, 28 Yeongon Dong,Chongno Gu, Seoul 110749, South Korea.
EM hhbkim@snu.ac.kr
RI Lee, Youngkyun/D 2667 2011; Kim, Hyung Joon/ABD 3143 2020; Ryu,
   Jiyoon/M 8573 2019
OI Kim, Hyung Joon/0000 0002 2962 9553; 
CR Alfonso A, 2003, BIOCHEM PHARMACOL, V65, P465, DOI 10.1016/S0006 2952(02)01519 8
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Edsall LC, 1998, BIOCHEMISTRY US, V37, P12892, DOI 10.1021/bi980744d
   ENDO K, 1991, CANCER RES, V51, P1613
   Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873
   Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200
   Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200
   HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176
   Huang CS, 1996, MOL CELL BIOL, V16, P6427
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   IGARASHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1411, DOI 10.1016/0006 291X(89)91827 5
   Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722
   Lee C, 2005, J LEUKOCYTE BIOL, V78, P1016, DOI 10.1189/jlb.0105056
   Lee EH, 2006, J PHARMACOL SCI, V100, P289, DOI 10.1254/jphs.FPJ05009X
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Matsuo Koichi, 2004, Keio Journal of Medicine, V53, P78, DOI 10.2302/kjm.53.78
   Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596
   Monick MM, 2004, AM J RESP CELL MOL, V30, P844, DOI 10.1165/rcmb.2003 0424OC
   Moonga BS, 1998, EXP PHYSIOL, V83, P717, DOI 10.1113/expphysiol.1998.sp004153
   Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460 2075.1991.tb08021.x
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758 7768.2002
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tauzin L, 2007, J LIPID RES, V48, P66, DOI 10.1194/jlr.M600399 JLR200
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955 0674(96)80067 6
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   Wilden PA, 1998, AM J PHYSIOL HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359 7369.2004
   Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499
   Yadav M, 2006, J IMMUNOL, V176, P5494, DOI 10.4049/jimmunol.176.9.5494
   Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893 04.2004
NR 43
TC 37
Z9 41
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0026 895X
EI 1521 0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD AUG
PY 2007
VL 72
IS 2
BP 418
EP 428
DI 10.1124/mol.107.034173
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 193OH
UT WOS:000248282900022
PM 17504945
DA 2025 08 17
ER

PT J
AU Zeng, FE
   Wade, A
   Harbert, K
   Patel, S
   Holley, JS
   Dehghanpuor, CK
   Hopwood, T
   Marino, S
   Sophocleous, A
   Idris, AI
AF Zeng, Feier
   Wade, Abbie
   Harbert, Kade
   Patel, Shrina
   Holley, Joshua S.
   Dehghanpuor, Cornelia K.
   Hopwood, Thomas
   Marino, Silvia
   Sophocleous, Antonia
   Idris, Aymen I.
TI Classical cannabinoid receptors as target in cancer induced bone pain: a
   systematic review, meta analysis and bioinformatics validation
SO SCIENTIFIC REPORTS
LA English
DT Article
DE CB1; CB2; Pain; Cancer; Animal models; Bone; Preclinical
ID ENDOCANNABINOID SYSTEM; BREAST CANCER; DOUBLE BLIND; OSTEOCLAST
   ACTIVITY; ADJUNCTIVE THERAPY; MEDICAL CANNABIS; OROMUCOSAL SPRAY;
   MECHANISMS; MANAGEMENT; TRPV1
AB To test the hypothesis that genetic and pharmacological modulation of the classical cannabinoid type 1 (CB1) and 2 (CB2) receptors attenuate cancer induced bone pain, we searched Medline, Web of Science and Scopus for relevant skeletal and non skeletal cancer studies from inception to July 28, 2022. We identified 29 animal and 35 human studies. In mice, a meta analysis of pooled studies showed that treatment of osteolysis bearing males with the endocannabinoids AEA and 2 AG (mean difference [MD]   24.83, 95% confidence interval [(CI) C 95%]   34.89,   14.76, p < 0.00001) or the synthetic cannabinoid (CB) agonists ACPA, WIN55,212 2, CP55,940 (CB1/2 non selective) and AM1241 (CB2 selective) (MD   28.73, (CI) C 95%   45.43,   12.02, p = 0.0008) are associated with significant reduction in paw withdrawal frequency. Consistently, the synthetic agonists AM1241 and JWH015 (CB2 selective) increased paw withdrawal threshold (MD 0.89, (CI) C 95% 0.79, 0.99, p < 0.00001), and ACEA (CB1 selective), AM1241 and JWH015 (CB2 selective) reduced spontaneous flinches (MD   4.85, (CI) C 95%   6.74,   2.96, p < 0. 00001) in osteolysis bearing male mice. In rats, significant increase in paw withdrawal threshold is associated with the administration of ACEA and WIN55,212 2 (CB1/2 non selective), JWH015 and AM1241 (CB2 selective) in osteolysis bearing females (MD 8.18, (CI) C 95% 6.14, 10.21, p < 0.00001), and treatment with AM1241 (CB2 selective) increased paw withdrawal thermal latency in males (mean difference [MD]: 3.94, (CI) C 95% 2.13, 5.75, p < 0.0001), confirming the analgesic capabilities of CB1/2 ligands in rodents. In human, treatment of cancer patients with medical cannabis (standardized MD   0.19, (CI) C 95%   0.35,   0.02, p = 0.03) and the plant derived delta 9 THC (20 mg) (MD 3.29, CI 2.24, 4.33, p < 0.00001) or its synthetic derivative NIB (4 mg) (MD 2.55, (CI) C 95% 1.58, 3.51, p < 0.00001) are associated with reduction in pain intensity. Bioinformatics validation of KEGG, GO and MPO pathway, function and process enrichment analysis of mouse, rat and human data revealed that CB1 and CB2 receptors are enriched in a cocktail of nociceptive and sensory perception, inflammatory, immune modulatory, and cancer pathways. Thus, we cautiously conclude that pharmacological modulators of CB1/2 receptors show promise in the treatment of cancer induced bone pain, however further assessment of their effects on bone pain in genetically engineered animal models and cancer patients is warranted.
C1 [Zeng, Feier; Wade, Abbie; Harbert, Kade; Patel, Shrina; Holley, Joshua S.; Dehghanpuor, Cornelia K.; Hopwood, Thomas; Idris, Aymen I.] Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, England.
   [Marino, Silvia] Univ Arkansas Med Sci UAMS, Dept Physiol & Cell Biol, BioMed 2 238 2, Little Rock, AR USA.
   [Sophocleous, Antonia] European Univ Cyprus, Sch Sci, Dept Life Sci, 6 Diogenes St, CY 1516 Nicosia, Cyprus.
C3 University of Sheffield; University of Arkansas System; University of
   Arkansas Medical Sciences; European University Cyprus
RP Idris, AI (通讯作者)，Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, England.; Sophocleous, A (通讯作者)，European Univ Cyprus, Sch Sci, Dept Life Sci, 6 Diogenes St, CY 1516 Nicosia, Cyprus.
EM a.sophocleous@euc.ac.cy; aymen.idris@sheffield.ac.uk
OI Zeng, Feier/0000 0001 9235 0750
CR Aielli F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020280
   Anderson SP, 2019, J ONCOL PRACT, V15, P202, DOI 10.1200/JOP.18.00562
   Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476 5381.2010.00729.x
   Aviram J, 2020, PHARMACEUTICALS BASE, V13, DOI 10.3390/ph13120435
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bar Sela G, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419881498
   Bar Sela G, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/510392
   Brazill JM, 2019, J BONE MINER RES, V34, P1393, DOI 10.1002/jbmr.3822
   Burton AW, 2007, PAIN MED, V8, P189, DOI 10.1111/j.1526 4637.2006.00220.x
   Calcaterra SL, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 06887 1
   Caraceni A, 2001, ACTA ANAESTH SCAND, V45, P1067, DOI 10.1034/j.1399 6576.2001.450903.x
   Caraceni A, 2019, CANCERS, V11, DOI 10.3390/cancers11040510
   Castillo Arellano J, 2023, MOLECULES, V28, DOI 10.3390/molecules28073271
   Chapman S, 2021, SUPPORT CARE CANCER, V29, P6589, DOI 10.1007/s00520 021 06202 z
   Chien CS, 2013, EUR J PHARMACOL, V718, P350, DOI 10.1016/j.ejphar.2013.08.011
   Chow J, 2007, BBA MOL CELL RES, V1773, P565, DOI 10.1016/j.bbamcr.2007.01.001
   Clohisy DR, 2003, CLIN ORTHOP RELAT R, pS279, DOI 10.1097/01.blo.0000093059.96273.56
   Côté M, 2016, ANN OTO RHINOL LARYN, V125, P317, DOI 10.1177/0003489415612801
   Croker JA, 2022, INNOV AGING, V6, DOI 10.1093/geroni/igab048
   Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142
   Cunha P, 2011, J PHARM BIOALLIED SC, V3, P350, DOI 10.4103/0975 7406.84435
   DAVIES BH, 1974, BRIT J CLIN PHARMACO, V1, P301, DOI 10.1111/j.1365 2125.1974.tb00257.x
   Davila D, 2015, SEMIN NUCL MED, V45, P3, DOI 10.1053/j.semnuclmed.2014.07.004
   de Almeida AS, 2019, CELL MOL NEUROBIOL, V39, P605, DOI 10.1007/s10571 019 00666 8
   Dehghan F, 2014, SCAND J MED SCI SPOR, V24, pE220, DOI 10.1111/sms.12149
   del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369
   Demuth DG, 2006, LIFE SCI, V78, P549, DOI 10.1016/j.lfs.2005.05.055
   Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719
   Deuis JR, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00284
   Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
   Di Marzo V, 2008, NAT REV DRUG DISCOV, V7, P438, DOI 10.1038/nrd2553
   Do EK, 2021, CANCER AM CANCER SOC, V127, P4040, DOI 10.1002/cncr.33794
   Donahue HJ, 2000, BONE, V26, P417, DOI 10.1016/S8756 3282(00)00245 3
   Dumbili EW, 2020, J DRUG ISSUES, V50, P286, DOI 10.1177/0022042620912805
   Dy SM, 2008, J CLIN ONCOL, V26, P3879, DOI 10.1200/JCO.2007.15.9517
   Elefteriou F, 2018, PHYSIOL REV, V98, P1083, DOI 10.1152/physrev.00014.2017
   Ellingson HM, 2020, CURR OPIN SUPPORT PA, V14, P107, DOI 10.1097/SPC.0000000000000496
   Elliott DA, 2016, SUPPORT CARE CANCER, V24, P3517, DOI 10.1007/s00520 016 3180 8
   Fallon MT, 2017, BRIT J PAIN, V11, P119, DOI 10.1177/2049463717710042
   Figura N, 2018, HEMATOL ONCOL CLIN N, V32, P447, DOI 10.1016/j.hoc.2018.01.006
   Gardner K, 2019, CRIT REV ONCOL HEMAT, V133, P33, DOI 10.1016/j.critrevonc.2018.10.008
   Ghosh AK, 2010, CANCER LETT, V287, P142, DOI 10.1016/j.canlet.2009.06.007
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Good PD, 2020, J PALLIAT MED, V23, P650, DOI 10.1089/jpm.2019.0540
   Grimison P, 2020, ANN ONCOL, V31, P1553, DOI 10.1016/j.annonc.2020.07.020
   Guerrero AV, 2008, NEUROSCI LETT, V433, P77, DOI 10.1016/j.neulet.2007.12.053
   Guzmán M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165 6147(00)01586 8
   Hald A, 2008, PHARMACOL BIOCHEM BE, V91, P38, DOI 10.1016/j.pbb.2008.04.021
   Hammond CJ, 2020, INT REV PSYCHIATR, V32, P221, DOI 10.1080/09540261.2020.1713056
   Hooijmans CR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0187271
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471 2288 14 43
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2010, CALCIFIED TISSUE INT, V87, P285, DOI 10.1007/s00223 010 9378 8
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Ji DX, 2017, N S ARCH PHARMACOL, V390, P1211, DOI 10.1007/s00210 017 1419 7
   Jiang W, 2017, PHYTOTHER RES, V31, P1298, DOI 10.1002/ptr.5849
   Johnstad PG, 2020, J CANNABIS RES, V2, DOI 10.1186/s42238 020 00032 2
   Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187
   Karanian DA, 2005, EUR J PHARMACOL, V508, P47, DOI 10.1016/j.ejphar.2004.12.009
   Katchan V, 2016, AUTOIMMUN REV, V15, P513, DOI 10.1016/j.autrev.2016.02.008
   Khasabova IA, 2011, PHARMACOL RES, V64, P60, DOI 10.1016/j.phrs.2011.03.007
   Klein A, 2018, INT J DRUG POLICY, V53, P65, DOI 10.1016/j.drugpo.2017.12.004
   Lau JK, 2014, APOPTOSIS, V19, P1190, DOI 10.1007/s10495 014 1007 y
   Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105
   Li BT, 2014, J CLIN MED, V3, P1, DOI 10.3390/jcm3010001
   Lichtman AH, 2018, J PAIN SYMPTOM MANAG, V55, P179, DOI 10.1016/j.jpainsymman.2017.09.001
   Lozano Ondoua AN, 2013, NEUROSCI LETT, V557, P52, DOI 10.1016/j.neulet.2013.08.003
   Lu CE, 2017, CELL MOL NEUROBIOL, V37, P101, DOI 10.1007/s10571 016 0349 0
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   Mantyh P, 2013, PAIN, V154, pS54, DOI 10.1016/j.pain.2013.07.044
   Mantyh PW, 2019, BRIT J CLIN PHARMACO, V85, P1103, DOI 10.1111/bcp.13801
   Manzanares J, 2006, CURR NEUROPHARMACOL, V4, P239, DOI 10.2174/157015906778019527
   Marino S, 2020, CALCIFIED TISSUE INT, V107, P72, DOI 10.1007/s00223 020 00689 0
   Marino S, 2019, EBIOMEDICINE, V44, P452, DOI 10.1016/j.ebiom.2019.05.048
   Marino S, 2017, PHARMACOL RES, V119, P391, DOI 10.1016/j.phrs.2017.02.023
   Martin TA, 2014, SEMIN CELL DEV BIOL, V36, P224, DOI 10.1016/j.semcdb.2014.09.008
   Marx J, 2006, SCIENCE, V311, P322, DOI 10.1126/science.311.5759.322
   Matias I, 2002, EUR J BIOCHEM, V269, P3771, DOI 10.1046/j.1432 1033.2002.03078.x
   Mechoulam R, 2005, BRIT J PHARMACOL, V146, P913, DOI 10.1038/sj.bjp.0706415
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Milgrom DP, 2017, CURR OSTEOPOROS REP, V15, P76, DOI 10.1007/s11914 017 0354 3
   Mlost J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228870
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   Mulvihill MM, 2013, LIFE SCI, V92, P492, DOI 10.1016/j.lfs.2012.10.025
   Naziroglu M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179950
   Nersesyan Hrachya, 2007, Ther Clin Risk Manag, V3, P381
   Oostinga D, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115272
   Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2
   Pagotto U, 2006, ENDOCR REV, V27, P73, DOI 10.1210/er.2005 0009
   Palace ZJ, 2019, J AM MED DIR ASSOC, V20, P94, DOI 10.1016/j.jamda.2018.11.013
   Pertwee RG, 2006, BRIT J PHARMACOL, V147, pS163, DOI 10.1038/sj.bjp.0706406
   Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341
   Rahn EJ, 2009, NEUROTHERAPEUTICS, V6, P713, DOI 10.1016/j.nurt.2009.08.002
   Rome S, 2017, CLIN J ONCOL NURS, V21, P47, DOI 10.1188/17.CJON.S5.47 59
   Rossi F, 2014, BRIT J PHARMACOL, V171, P2621, DOI 10.1111/bph.12542
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Rossi F, 2015, PHARMACOL RES, V99, P194, DOI 10.1016/j.phrs.2015.06.010
   Ryan R, 2016, How to GRADE the Quality of the Evidence
   Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460
   Saghafi N, 2011, NEUROSCI LETT, V488, P247, DOI 10.1016/j.neulet.2010.11.039
   Schleider LBL, 2018, EUR J INTERN MED, V49, P37, DOI 10.1016/j.ejim.2018.01.023
   Scourfield A., 2019, Toxicology Communications, V3, P7, DOI [DOI 10.1080/24734306.2018.1563739, 10.1080/24734306.2018]
   Sexton Michelle, 2021, Journal of the National Cancer Institute Monographs, V2021, P86, DOI 10.1093/jncimonographs/lgab011
   Sharir H, 2012, J NEUROIMMUNE PHARM, V7, P856, DOI 10.1007/s11481 012 9351 6
   Shefchek KA, 2020, NUCLEIC ACIDS RES, V48, pD704, DOI 10.1093/nar/gkz997
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Sophocleous A, 2017, AGING CELL, V16, P1051, DOI 10.1111/acel.12638
   Sophocleous A, 2015, J BIOL CHEM, V290, P22049, DOI 10.1074/jbc.M115.649608
   STAQUET M, 1978, CLIN PHARMACOL THER, V23, P397
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   Sun J, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109504
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Thompson AL, 2020, J PHARMACOL EXP THER, V373, P230, DOI 10.1124/jpet.119.262337
   Metin CU, 2022, BMC CANCER, V22, DOI 10.1186/s12885 022 09736 5
   Uhelski ML, 2013, NEUROSCIENCE, V247, P84, DOI 10.1016/j.neuroscience.2013.05.003
   Wang Dan, 2012, Zhonghua Yi Xue Za Zhi, V92, P440, DOI 10.3760/cma.j.issn.00376 2491 2012.07.003
   Weber LV, 2016, BREAST CANCER TARGET, V8, P243, DOI 10.2147/BCTT.S121610
   Wells G A., 2014, Appl Eng Agric, V18, P727
   Wu TTL, 2014, CELL CALCIUM, V56, P59, DOI 10.1016/j.ceca.2014.04.006
   Yoneda T, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.58
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236047
   Zheng XQ, 2022, J ADV RES, V35, P117, DOI 10.1016/j.jare.2021.06.006
NR 125
TC 3
Z9 3
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 9
PY 2024
VL 14
IS 1
AR 5782
DI 10.1038/s41598 024 56220 0
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA LG0H3
UT WOS:001185505600001
PM 38461339
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Gao, BY
   Honda, Y
   Yamada, Y
   Tanaka, T
   Takeda, Y
   Nambu, T
   Baba, S
AF Gao, Beiyuan
   Honda, Yoshitomo
   Yamada, Yoichi
   Tanaka, Tomonari
   Takeda, Yoshihiro
   Nambu, Takayuki
   Baba, Shunsuke
TI Utility of Thermal Cross Linking in Stabilizing Hydrogels with
   Beta Tricalcium Phosphate and/or Epigallocatechin Gallate for Use in
   Bone Regeneration Therapy
SO POLYMERS
LA English
DT Article
DE cross link; hydrogel; bone graft materials; beta TCP; bone regeneration
   therapy
ID MESENCHYMAL STEM CELLS; GREEN TEA CATECHIN; OSTEOGENIC DIFFERENTIATION;
   IN VITRO; GELATIN; EGCG; NANOFIBERS; SCAFFOLDS; MECHANISM; RELEASE
AB beta tricalcium phosphate (beta TCP) granules are commonly used materials in dentistry or orthopedic surgery. However, further improvements are required to raise the operability and bone forming ability of beta TCP granules in a clinical setting. Recently, we developed epigallocatechin gallate (EGCG) modified gelatin sponges as a novel biomaterial for bone regeneration. However, there is no study on using the above material for preparing hydrogel incorporating beta TCP granules. Here, we demonstrate that vacuum heating treatment induced thermal cross linking in gelatin sponges modified with EGCG and incorporating beta TCP granules (vhEc GS beta) so that the hydrogels prepared from vhEc GS beta showed high stability, beta TCP granule retention, operability, and cytocompatibility. Additionally, microcomputed tomography morphometry revealed that the hydrogels from vhEc GS beta had significantly higher bone forming ability than beta TCP alone. Tartrate resistant acid phosphatase staining demonstrated that the number of osteoclasts increased at three weeks in defects treated with the hydrogels from vhEc GS beta compared with that around beta TCP alone. The overall results indicate that thermal cross linking treatment for the preparation of sponges (precursor of hydrogels) can be a promising process to enhance the bone forming ability. This insight should provide a basis for the development of novel materials with good operativity and bone forming ability for bone regenerative medicine.
C1 [Gao, Beiyuan; Yamada, Yoichi; Takeda, Yoshihiro; Baba, Shunsuke] Osaka Dent Univ, Dept Implantol, Osaka 5731121, Japan.
   [Honda, Yoshitomo] Osaka Dent Univ, Dept Oral Anat, Osaka 5731121, Japan.
   [Tanaka, Tomonari] Kyoto Inst Technol, Dept Biobased Mat Sci, Kyoto 6068585, Japan.
   [Nambu, Takayuki] Osaka Dent Univ, Dept Bacteriol, Osaka 5731121, Japan.
C3 Kyoto Institute of Technology
RP Honda, Y (通讯作者)，Osaka Dent Univ, Dept Oral Anat, Osaka 5731121, Japan.; Tanaka, T (通讯作者)，Kyoto Inst Technol, Dept Biobased Mat Sci, Kyoto 6068585, Japan.
EM gao19940307@gmail.com; honda y@cc.osaka dent.ac.jp;
   yamada.yo0925@gmail.com; t tanaka@kit.ac.jp;
   takeda y@cc.osaka dent.ac.jp; nambu t@cc.osaka dent.ac.jp;
   aba s@cc.osaka dent.ac.jp
RI ; Tanaka, Tomonari/GPP 2232 2022; Honda, Yoshitomo/AAC 3994 2020
OI Tanaka, Tomonari/0000 0002 7050 9043; Honda,
   Yoshitomo/0000 0002 4392 2318; Gao, Beiyuan/0000 0002 5421 2936
FU Grant in Aid for Scientific Research [19K19063]; Grants in Aid for
   Scientific Research [19K19063] Funding Source: KAKEN
FX This research was funded by Grant in Aid for Scientific Research, grant
   number 19K19063.
CR Abbasi N, 2020, J SCI ADV MATER DEV, V5, P1, DOI 10.1016/j.jsamd.2020.01.007
   Basu P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123980
   Brum ID, 2021, INT J NANOMED, V16, P3473, DOI 10.2147/IJN.S301470
   Calixto S, 2018, MOLECULES, V23, DOI 10.3390/molecules23082064
   Campiglio CE, 2019, MATERIALS, V12, DOI 10.3390/ma12152476
   Catoira MC, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6318 7
   Chang CY, 2017, INT J NANOMED, V12, P279, DOI 10.2147/IJN.S114754
   Chen CH, 2005, OSTEOPOROSIS INT, V16, P2039, DOI 10.1007/s00198 005 1995 0
   Chen KY, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/283941
   Chen ST, 2019, MOLECULES, V24, DOI 10.3390/molecules24010156
   Brum ID, 2020, MATERIALS, V13, DOI 10.3390/ma13204598
   Dorozhkin SV, 2013, MAT SCI ENG C MATER, V33, P3085, DOI 10.1016/j.msec.2013.04.002
   Ehrmann A, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13121973
   Gaspar Pintiliescu A, 2019, MAR DRUGS, V17, DOI 10.3390/md17100589
   GREGORY TM, 1974, J RES NBS A PHYS CH, VA 78, P667, DOI 10.6028/jres.078A.042
   Hameed AM, 2018, TROP LIFE SCI RES, V29, P213, DOI 10.21315/tlsr2018.29.2.15
   Hannink G, 2011, INJURY, V42, pS22, DOI 10.1016/j.injury.2011.06.008
   Hara E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103232
   Hayashi K, 2019, MATER TODAY BIO, V4, DOI 10.1016/j.mtbio.2019.100031
   Ho CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176327
   Honda Y, 2020, J HARD TISSUE BIOL, V29, P77, DOI 10.2485/jhtb.29.77
   Honda Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23040876
   Honda Y, 2015, INT J MOL SCI, V16, P14143, DOI 10.3390/ijms160614143
   Huang AQ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236042
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ishak WHW, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8100749
   Kaida K, 2015, INT J MOL SCI, V16, P27988, DOI 10.3390/ijms161226081
   Kakuta A, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 019 0161 2
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Kujawa J, 2021, SCI TOTAL ENVIRON, V801, DOI 10.1016/j.scitotenv.2021.149647
   Lai JY, 2010, J MATER SCI MATER M, V21, P1899, DOI 10.1007/s10856 010 4035 3
   Ledari SA, 2020, FOOD SCI NUTR, V8, P6487, DOI 10.1002/fsn3.1939
   Li J, 2021, ACTA BIOMATER, V126, P496, DOI 10.1016/j.actbio.2021.03.021
   Liu J, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 019 0768 7
   Liu LL, 2019, INT J NANOMED, V14, P3491, DOI 10.2147/IJN.S193192
   Mah YJ, 2014, ARCH ORAL BIOL, V59, P539, DOI 10.1016/j.archoralbio.2014.02.011
   Mereles D, 2011, INT J MOL SCI, V12, P5592, DOI 10.3390/ijms12095592
   Nakayama M, 2015, BIOSCI BIOTECH BIOCH, V79, P845, DOI 10.1080/09168451.2014.993356
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Omata K, 2014, J TISSUE ENG REGEN M, V8, P604, DOI 10.1002/term.1553
   Perikamana SKM, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201800392
   Prasertsung I, 2010, SURF COAT TECH, V205, pS133, DOI 10.1016/j.surfcoat.2010.06.063
   Rebers L, 2019, GELS BASEL, V5, DOI 10.3390/gels5010004
   Saito K, 2016, RSC ADV, V6, P64165, DOI 10.1039/c6ra07602e
   Saleem M, 2020, SCI TECHNOL ADV MAT, V21, P242, DOI 10.1080/14686996.2020.1748520
   Sasayama S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123803
   Sazuka M, 1997, BIOSCI BIOTECH BIOCH, V61, P1504, DOI 10.1271/bbb.61.1504
   Shin JH, 2016, INT J MOL MED, V38, P1075, DOI 10.3892/ijmm.2016.2694
   Shin YS, 2014, ORAL DIS, V20, P281, DOI 10.1111/odi.12109
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Torres Giner S, 2009, ACS APPL MATER INTER, V1, P218, DOI 10.1021/am800063x
   Yu D, 2020, J ZHEJIANG UNIV SC B, V21, P871, DOI 10.1631/jzus.B2000355
   Yusof MR, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11091468
   Zhang YJ, 2018, ACTA PHARM SIN B, V8, P34, DOI 10.1016/j.apsb.2017.11.005
NR 54
TC 3
Z9 3
U1 3
U2 21
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4360
J9 POLYMERS BASEL
JI Polymers
PD JAN
PY 2022
VL 14
IS 1
AR 40
DI 10.3390/polym14010040
PG 14
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA ZF8MR
UT WOS:000759824400001
PM 35012062
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shapiro, JR
   Kantipuly, A
   Rowe, D
AF Shapiro, J. R.
   Kantipuly, A.
   Rowe, D.
TI OSTEOGENESIS IMPERFECTA: CURRENT AND FUTURE TREATMENTS
SO DRUGS OF THE FUTURE
LA English
DT Article
ID GROWTH HORMONE TREATMENT; COLLAGEN MESSENGER RNA; MESENCHYMAL
   STEM CELLS; I COLLAGEN; MURINE MODEL; MOLECULAR CHAPERONE; ORAL
   ALENDRONATE; MOUSE MODEL; BONE; CHILDREN
AB Osteo genesis imperfecta (OI) is a heritable disease of bone due to mutations involving type I collagen synthesis. Current concerns in both children and adults involve the effectiveness of intravenous and orally administered bisphosphonates, which are generally considered the standard of care. However, questions remain in terms of fracture prevention rates in children and adults, as well as questions related to dosing schedules and the duration of bisphosphonate treatment. This paper reviews collagen synthesis in OI as related to potential treatment strategies. Potential pharmacological treatments for OI involve: RANK If good inhibitors, cathepsin K and sclerostin inhibitors. Teriparatide is currently in clinical trials. Molecular strategies include the use of hammerhead ribozymes and siRNA methodology to silence the mutant COL7 allele. Fetal intrauterine mesenchymal cell transplantation has shown promising results despite limited trials. In the situation of quantitative collagen defects, genetic treatment would involve the addition of a COL1 functional allele into the mesenchymal stem cells of a patient. In dominant/negative COL1 mutations the strategy would be to silence the mutant allele (gene targeting). Stem cell therapy involving induced pleuripotent stem cells as a means of repopulating the marrow with functional osteoblasts producing normal type I collagen may offer great therapeutic potential.
C1 [Shapiro, J. R.; Kantipuly, A.] Kennedy Krieger Inst, Baltimore, MD 21205 USA.
   [Rowe, D.] Univ Connecticut, Ctr Hlth, Storrs, CT 06269 USA.
C3 Kennedy Krieger Institute; University of Connecticut
RP Shapiro, JR (通讯作者)，Kennedy Krieger Inst, 801 N Broadway, Baltimore, MD 21205 USA.
EM shapiroj@kennedykrieger.org
FU Charitable and Research Foundation, Punta Gorda, Florida, U.S.A.
FX The authors received financial support from the Charitable and Research
   Foundation, Punta Gorda, Florida, U.S.A.
CR Adami S, 2003, J BONE MINER RES, V18, P126, DOI 10.1359/jbmr.2003.18.1.126
   [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD005088.PUB2]
   Antoniazzi F, 1996, J PEDIATR US, V129, P432, DOI 10.1016/S0022 3476(96)70077 X
   Ashihara E, 2010, CURR DRUG TARGETS, V11, P345, DOI 10.2174/138945010790711897
   Åström E, 2002, ARCH DIS CHILD, V86, P356, DOI 10.1136/adc.86.5.356
   AUGUST GP, 1977, J PEDIATR US, V91, P1001, DOI 10.1016/S0022 3476(77)80916 5
   Baldridge D, 2008, HUM MUTAT, V29, P1435, DOI 10.1002/humu.20799
   Bargman R, 2010, CONNECT TISSUE RES, V51, P123, DOI 10.3109/03008200903108472
   Bishop N, 2010, J BONE MINER RES, V25, P32, DOI 10.1359/jbmr.090712
   BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145
   Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065 3233(05)70009 7
   Byers P H, 1995, Connect Tissue Res, V31, P257, DOI 10.3109/03008209509010818
   Cabral WA, 2007, NAT GENET, V39, P359, DOI 10.1038/ng1968
   Castillo H, 2009, DEV MED CHILD NEUROL, V51, P17, DOI 10.1111/j.1469 8749.2008.03222.x
   Chamberlain JR, 2008, MOL THER, V16, P187, DOI 10.1038/sj.mt.6300339
   Chevrel G, 2006, J BONE MINER RES, V21, P300, DOI 10.1359/JBMR.051015
   CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701
   Christiansen HE, 2010, AM J HUM GENET, V86, P389, DOI 10.1016/j.ajhg.2010.01.034
   Davies M, 2009, SHAKESPEARE, V5, P1, DOI 10.1080/17450910902764256
   Dawson PA, 2000, NUCLEIC ACIDS RES, V28, P4013, DOI 10.1093/nar/28.20.4013
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   DEVOGELAER JP, 1987, SKELETAL RADIOL, V16, P360, DOI 10.1007/BF00350961
   DiMeglio LA, 2006, J BONE MINER RES, V21, P132, DOI 10.1359/JBMR.051006
   Du ZW, 2009, STEM CELLS, V27, P1032, DOI 10.1002/stem.38
   FEDARKO NS, 1995, J BONE MINER RES, V10, P1122
   Forlino A, 1999, J BIOL CHEM, V274, P37923, DOI 10.1074/jbc.274.53.37923
   GERTNER J, 1980, CALCIFIED TISSUE INT, V31, P62
   GLORIEUX FH, 2001, LANCET S45, V358
   Glorieux FH, 2007, PEDIATRICS, V119, pS163, DOI 10.1542/peds.2006 2023I
   Goodchild John, 2002, Expert Opin Ther Targets, V6, P235, DOI 10.1517/14728222.6.2.235
   Guillot PV, 2008, BLOOD, V111, P1717, DOI 10.1182/blood 2007 08 105809
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   HANDSCHEL J, 2010, TISSUE ENG A
   Hockemeyer D, 2009, NAT BIOTECHNOL, V27, P851, DOI 10.1038/nbt.1562
   Horwitz EM, 2001, BLOOD, V97, P1227, DOI 10.1182/blood.V97.5.1227
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Isabel E, 2010, BIOORG MED CHEM LETT, V20, P887, DOI 10.1016/j.bmcl.2009.12.083
   Ishikawa Y, 2008, J BIOL CHEM, V283, P31584, DOI 10.1074/jbc.M802535200
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kadler KE, 2007, J CELL SCI, V120, P1955, DOI 10.1242/jcs.03453
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kuznetsova NV, 2004, MATRIX BIOL, V23, P101, DOI 10.1016/j.matbio.2004.03.002
   LANE JM, 1973, J TRAUMA, V13, P863, DOI 10.1097/00005373 197313100 00004
   Le Blanc K, 2005, TRANSPLANTATION, V79, P1607, DOI 10.1097/01.TP.0000159029.48678.93
   Lindahl Katarina, 2008, Int J Med Sci, V5, P361
   Lowenstein EJ, 2009, CHILD NERV SYST, V25, P515, DOI 10.1007/s00381 009 0817 7
   MALEBRANCHE N, 1674, TRAITE RECHERCH VERI
   Marini JC, 2003, J BONE MINER RES, V18, P237, DOI 10.1359/jbmr.2003.18.2.237
   Marini JC, 2009, NAT REV ENDOCRINOL, V5, P241, DOI 10.1038/nrendo.2009.58
   McCarthy Kateri, 2008, Expert Rev Endocrinol Metab, V3, P771, DOI 10.1586/17446651.3.6.771
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Millington Ward S, 2005, TRENDS MOL MED, V11, P299, DOI 10.1016/j.molmed.2005.04.006
   Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039
   Nagata K, 2003, SEMIN CELL DEV BIOL, V14, P275, DOI 10.1016/j.semcdb.2003.09.020
   Niyibizi C, 2001, J CELL BIOCHEM, V83, P84, DOI 10.1002/jcb.1209
   Panaroni C, 2009, BLOOD, V114, P459, DOI 10.1182/blood 2008 12 195859
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Pochampally RR, 2005, GENE THER, V12, P1119, DOI 10.1038/sj.gt.3302514
   Räikkönen J, 2010, BIOCHEM PHARMACOL, V79, P777, DOI 10.1016/j.bcp.2009.10.003
   Rauch F, 2009, J BONE MINER RES, V24, P1282, DOI [10.1359/jbmr.090213, 10.1359/JBMR.090213]
   ROSENBERG N, 2010, EXP CLIN ENDOCRINOL
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   SILLENCE DO, 1978, LANCET, V1, P1041
   Smicun Y, 2003, GENE THER, V10, P2005, DOI 10.1038/sj.gt.3302108
   SMITH ER, 1983, BRITTLE BONE SYNDROM, P5
   Sokolic R, 2008, CURR OPIN HEMATOL, V15, P375, DOI 10.1097/MOH.0b013e328302c807
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Steiner RD, 1993, GENE REV
   Toudjarska I, 2001, ANTISENSE NUCLEIC A, V11, P341, DOI 10.1089/108729001753231722
   van Dijk FS, 2009, AM J HUM GENET, V85, P521, DOI 10.1016/j.ajhg.2009.09.001
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
   Zou JZ, 2009, CELL STEM CELL, V5, P97, DOI 10.1016/j.stem.2009.05.023
NR 74
TC 1
Z9 1
U1 0
U2 15
PU PROUS SCIENCE, SAU THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377 8282
EI 2013 0368
J9 DRUG FUTURE
JI Drug Future
PD JUL
PY 2010
VL 35
IS 7
BP 575
EP 584
DI 10.1358/dof.2010.035.07.1485772
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 658XW
UT WOS:000282529500007
DA 2025 08 17
ER

PT J
AU Chakhtoura, M
   Azar, ST
AF Chakhtoura, Marlene
   Azar, Sami T.
TI Incretin Based Therapies: Bone Protective Effects
SO ENDOCRINE METABOLIC & IMMUNE DISORDERS DRUG TARGETS
LA English
DT Article
DE Dipeptidyl peptidase 4 inhibitors; glucagon like peptide 1 agonists;
   incretin therapy; osteoporosis; type 2 diabetes mellitus
ID GLUCAGON LIKE PEPTIDE 1; DEPENDENT INSULINOTROPIC PEPTIDE; GLYCATION
   END PRODUCTS; MESENCHYMAL STEM CELLS; DIABETES MELLITUS;
   CLINICAL PRACTICE; SCLEROSTIN LEVELS; CALCITONIN GENE; BODY WEIGHT;
   FRACTURES
AB Type 2 Diabetes Mellitus (T2D) and osteoporosis have been found recently to be tightly correlated. In fact, T2D can result in bone loss through different mechanisms resulting in alteration of bone matrix and inhibition of bone formation. Fracture risk also increases significantly. New antidiabetic agents, dipeptidyl peptidase 4 inhibitors and glucagon like peptide  1 agonists have shown promise in many fields beyond glycemic control. Benefits on the skeletal system are multiple through direct stimulation of osteoblasts, inhibition of advanced glycation end products and inhibition of bone resorption. However, clinical evidence in humans is still not enough to allow definitive conclusions.
C1 [Chakhtoura, Marlene; Azar, Sami T.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Endocrinol, New York, NY 10017 USA.
C3 American University of Beirut
RP Azar, ST (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, 3 Dag Hammarskjold Plaza,8th Floor, New York, NY 10017 USA.
EM sazar@aub.edu.lb
OI Chakhtoura, Marlene/0000 0003 0012 986X
CR Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc14 S081, 10.2337/dc11 S011, 10.2337/dc13 S067, 10.2337/dc13 S011, 10.2337/dc11 S062, 10.2337/dc10 S062, 10.2337/dc10 S011, 10.2337/dc12 s064, 10.2337/dc12 s011]
   [Anonymous], 2003, The Diabetes Atlas, VSecond
   Ban K, 2009, J AM SOC HYPERTENS, V3, P245, DOI 10.1016/j.jash.2009.04.001
   Bjarnason NH, 2002, BONE, V30, P307, DOI 10.1016/S8756 3282(01)00662 7
   Bollag RJ, 2000, ENDOCRINOLOGY, V141, P1228, DOI 10.1210/en.141.3.1228
   Bollag RJ, 2001, MOL CELL ENDOCRINOL, V177, P35, DOI 10.1016/S0303 7207(01)00405 1
   Bunck MC, 2011, DIABETES OBES METAB, V13, P374, DOI 10.1111/j.1463 1326.2010.01355.x
   Bunck MC, 2012, J DIABETES, V4, P181, DOI 10.1111/j.1753 0407.2011.00168.x
   Ceccarelli Elena, 2013, Front Endocrinol (Lausanne), V4, P73, DOI 10.3389/fendo.2013.00073
   Clowes JA, 2005, J BONE MINER RES, V20, P1497, DOI 10.1359/JBMR.050524
   Conti F., 2013, AGING CLIN EXP RES
   Cornish J, 1999, J BONE MINER RES, V14, P1302, DOI 10.1359/jbmr.1999.14.8.1302
   Cornish J, 1998, AM J PHYSIOL ENDOC M, V274, pE827, DOI 10.1152/ajpendo.1998.274.5.E827
   Dempster David W, 2011, Am J Manag Care, V17 Suppl 6, pS164
   Gallagher E.J., 2013, DIABETES METAB RES R
   Gaudio A, 2012, J CLIN ENDOCR METAB, V97, P3744, DOI 10.1210/jc.2012 1901
   Gennari L, 2012, J CLIN ENDOCR METAB, V97, P1737, DOI 10.1210/jc.2011 2958
   Ginter Emil, 2012, Adv Exp Med Biol, V771, P42
   Gupta Vishal, 2012, Indian J Endocrinol Metab, V16 Suppl 1, pS47, DOI 10.4103/2230 8210.94259
   Handelsman Y, 2011, ENDOCR PRACT, V17, P1, DOI 10.4158/EP.17.S2.1
   Hein GE, 2006, CLIN CHIM ACTA, V371, P32, DOI 10.1016/j.cca.2006.03.017
   Heinemann DF, 2000, GERIATRICS, V55, P31
   Henriksen DB, 2004, BONE, V34, P140, DOI 10.1016/j.bone.2003.09.009
   Henriksen DB, 2003, J BONE MINER RES, V18, P2180, DOI 10.1359/jbmr.2003.18.12.2180
   Henriksen DB, 2007, BONE, V40, P723, DOI 10.1016/j.bone.2006.09.025
   Hirsch PF, 2003, ENDOCRINE, V21, P201, DOI 10.1385/ENDO:21:3:201
   Holst J.J., 2013, TRENDS ENDOCRINOL ME
   Holst JJ, 2007, PHYSIOL REV, V87, P1409, DOI 10.1152/physrev.00034.2006
   Holst JJ, 2004, AM J PHYSIOL ENDOC M, V287, pE199, DOI 10.1152/ajpendo.00545.2003
   Hosaka H, 2008, PEPTIDES, V29, P1390, DOI 10.1016/j.peptides.2008.03.015
   Ishibashi Y, 2010, BIOCHEM BIOPH RES CO, V391, P1405, DOI 10.1016/j.bbrc.2009.12.075
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jeppesen PB, 2009, GASTROENT RES PRACT, V2009, DOI 10.1155/2009/616054
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   Kyle KA, 2011, ENDOCRINOLOGY, V152, P457, DOI 10.1210/en.2010 1098
   Lamari Y, 1996, FEBS LETT, V393, P248, DOI 10.1016/0014 5793(96)00895 2
   Leslie WD, 2012, J BONE MINER RES, V27, P2231, DOI 10.1002/jbmr.1759
   Matsui T, 2011, PHARMACOL RES, V63, P383, DOI 10.1016/j.phrs.2011.02.003
   McCarthy AD, 2004, INT J BIOCHEM CELL B, V36, P840, DOI 10.1016/j.biocel.2003.09.006
   McIntosh CHS, 2010, VITAM HORM, V84, P21, DOI [10.1016/B978 0 12 381517 0.00002 3, 10.1016/S0083 6729(10)84016 6]
   MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855
   Monami M, 2011, DIABETES CARE, V34, P2474, DOI 10.2337/dc11 1099
   Moseley KF, 2012, CURR OPIN ENDOCRINOL, V19, P128, DOI 10.1097/MED.0b013e328350a6e1
   Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08 9025
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Nuche Berenguer B, 2011, J ENDOCRINOL, V209, P203, DOI 10.1530/JOE 11 0015
   Nuche Berenguer B, 2010, J CELL PHYSIOL, V225, P585, DOI 10.1002/jcp.22243
   Nuche Berenguer B, 2009, CALCIFIED TISSUE INT, V84, P453, DOI 10.1007/s00223 009 9220 3
   OPARA EC, 1993, PANCREAS, V8, P39, DOI 10.1097/00006676 199301000 00009
   Pacheco Pantoja Elda L., 2011, BMC Physiology, V11, P12, DOI 10.1186/1472 6793 11 12
   Petit MA, 2010, J BONE MINER RES, V25, P285, DOI 10.1359/jbmr.090725
   Raun K, 2007, DIABETES, V56, P8, DOI 10.2337/db06 0565
   Roglic G, 2005, DIABETES CARE, V28, P2130, DOI 10.2337/diacare.28.9.2130
   Sanguineti R, 2008, ANN NY ACAD SCI, V1126, P166, DOI 10.1196/annals.1433.044
   Santana RB, 2003, DIABETES, V52, P1502, DOI 10.2337/diabetes.52.6.1502
   Sanz C, 2010, AM J PHYSIOL ENDOC M, V298, pE634, DOI 10.1152/ajpendo.00460.2009
   Shi YC, 2012, BONE, V50, P430, DOI 10.1016/j.bone.2011.10.001
   Thornberry NA, 2009, BEST PRACT RES CL EN, V23, P479, DOI 10.1016/j.beem.2009.03.004
   Walsh JS, 2009, CLIN REV BONE MINER, V7, P230, DOI 10.1007/s12018 009 9052 8
   Walsh JS, 2010, ARCH BIOCHEM BIOPHYS, V503, P11, DOI 10.1016/j.abb.2010.06.020
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wong I.P., PLOS ONE, V7
   Yamada C, 2008, ENDOCRINOLOGY, V149, P574, DOI 10.1210/en.2007 1292
   Yamamoto M, 2009, J BONE MINER RES, V24, P702, DOI 10.1359/JBMR.081207
   Zengin A, 2010, TRENDS ENDOCRIN MET, V21, P411, DOI 10.1016/j.tem.2010.02.004
NR 66
TC 4
Z9 7
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871 5303
EI 2212 3873
J9 ENDOCR METAB IMMUNE
JI Endocr. Metab. Immune Disord. Drug Targets
PD DEC
PY 2013
VL 13
IS 4
BP 289
EP 294
PG 6
WC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
GA AB8WB
UT WOS:000332069600002
PM 24138054
DA 2025 08 17
ER

PT J
AU Poole, KES
   Treece, GM
   Gee, AH
   Brown, JP
   McClung, MR
   Wang, A
   Libanati, C
AF Poole, Kenneth E. S.
   Treece, Graham M.
   Gee, Andrew H.
   Brown, Jacques P.
   McClung, Michael R.
   Wang, Andrea
   Libanati, Cesar
TI Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur:
   A 3D Bone Mapping Study in Women With Osteoporosis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE FEMORAL NECK FRACTURES; HIP FRACTURE; FEMALE; OSTEOPOROSIS;
   POSTMENOPAUSAL OSTEOPOROSIS; DENOSUMAB; COMPUTED TOMOGRAPHY;
   COMPUTATIONAL ANATOMY
ID HIP FRACTURE; POSTMENOPAUSAL WOMEN; PROXIMAL FEMUR; FEMORAL NECK;
   TRABECULAR BONE; PREDICTION; STRENGTH; DENSITY; AGE; IMPROVEMENTS
AB Women with osteoporosis treated for 36 months with twice yearly injections of denosumab sustained fewer hip fractures compared with placebo. Treatment might improve femoral bone at locations where fractures typically occur. To test this hypothesis, we used 3D cortical bone mapping of postmenopausal women with osteoporosis to investigate the timing and precise location of denosumab versus placebo effects in the hips. We analyzed clinical computed tomography scans from 80 female participants in FREEDOM, a randomized trial, wherein half of the study participants received subcutaneous denosumab 60mg twice yearly and the others received placebo. Cortical 3D bone thickness maps of both hips were created from scans at baseline, 12, 24, and 36 months. Cortical mass surface density maps were also created for each visit. After registration of each bone to an average femur shape model followed by statistical parametric mapping, we visualized and quantified statistically significant treatment effects. The technique allowed us to pinpoint systematic differences between denosumab and control and to display the results on a 3D average femur model. Denosumab treatment led to an increase in femoral cortical mass surface density and thickness, already evident by the third injection (12 months). Overall, treatment with denosumab increased femoral cortical mass surface density by 5.4% over 3 years. One third of the increase came from increasing cortical density, and two thirds from increasing cortical thickness, relative to placebo. After 36 months, cortical mass surface density and thickness had increased by up to 12% at key locations such as the lateral femoral trochanter versus placebo. Most of the femoral cortex displayed a statistically significant relative difference by 36 months. Osteoporotic cortical bone responds rapidly to denosumab therapy, particularly in the hip trochanteric region. This mechanism may be involved in the robust decrease in hip fractures observed in denosumab treated women at increased risk of fracture. (c) 2014 American Society for Bone and Mineral Research.
C1 [Poole, Kenneth E. S.] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England.
   [Treece, Graham M.; Gee, Andrew H.] Univ Cambridge, Dept Engn, Cambridge CB2 0QQ, England.
   [Brown, Jacques P.] Univ Laval, CHU Quebec Res Ctr, Quebec City, PQ, Canada.
   [McClung, Michael R.; Wang, Andrea] Oregon Osteoporosis Ctr, Portland, OR USA.
   [Libanati, Cesar] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 University of Cambridge; University of Cambridge; Laval University;
   Oregon Osteoporosis Center; Amgen
RP Poole, KES (通讯作者)，Univ Cambridge, Addenbrookes Hosp, Dept Med, Box 157, Cambridge CB2 0QQ, England.
EM kp254@nhs.net
RI ; McClung, Michael/ABA 4100 2021; Poole, Kenneth/IAQ 7105 2023;
   Libanati, Cesar/LGZ 1518 2024
OI McClung, Michael/0000 0002 7827 0778; Brown,
   Jacques/0000 0003 1910 788X; 
FU Amgen Inc., Thousand Oaks, CA, USA; Arthritis Research UK; Evelyn Trust;
   Cambridge NIHR Biomedical Research Centre; Versus Arthritis [20109]
   Funding Source: researchfish
FX This study was funded by Amgen Inc., Thousand Oaks, CA, USA. Cambridge
   Bone Group is supported by Arthritis Research UK, The Evelyn Trust, and
   Cambridge NIHR Biomedical Research Centre.
CR Bessho M, 2009, BONE, V45, P226, DOI 10.1016/j.bone.2009.04.241
   Black DM, 2008, J BONE MINER RES, V23, P1326, DOI [10.1359/jbmr.080316, 10.1359/JBMR.080316]
   Borggrefe J, 2010, J BONE MINER RES, V25, P472, DOI 10.1359/jbmr.090820
   Carballido Gamio J, 2013, J BONE MINER RES, V28, P537, DOI 10.1002/jbmr.1802
   Cristofolini L, 2009, P I MECH ENG H, V223, P273, DOI 10.1243/09544119JEIM497
   Cristofolinial L, 2007, J BIOMECH, V40, P2837, DOI 10.1016/j.jbiomech.2007.03.015
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   de Bakker PM, 2009, J BIOMECH, V42, P1917, DOI 10.1016/j.jbiomech.2009.05.001
   FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402
   Genant HK, 2013, BONE, V56, P482, DOI 10.1016/j.bone.2013.07.011
   Genant HK, 2013, J BONE MINER RES  S1, V28, pS180
   GLUER CC, 1994, J BONE MINER RES, V9, P671
   Holzer G, 2009, J BONE MINER RES, V24, P468, DOI 10.1359/JBMR.081108
   Johannesdottir F, 2011, BONE, V48, P1268, DOI 10.1016/j.bone.2011.03.776
   Keaveny TM, 2014, J BONE MINER RES, V29, P158, DOI 10.1002/jbmr.2024
   Kostenuik PJ, 2011, BONE, V49, P151, DOI 10.1016/j.bone.2011.03.769
   Mayhew PM, 2005, LANCET, V366, P129, DOI 10.1016/S0140 6736(05)66870 5
   McClung MR, 2013, J CLIN DENSITOM, V16, P250, DOI 10.1016/j.jocd.2012.02.014
   Nawathe S, 2014, J BONE MINER RES, V29, P507, DOI 10.1002/jbmr.2033
   Parker MJ, 1997, ACTA ORTHOP SCAND, V68, P325, DOI 10.3109/17453679708996170
   Poole KES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038466
   Poole KES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016190
   Poole KES, 2010, J BONE MINER RES, V25, P482, DOI 10.1359/jbmr.090734
   Rueckert D, 2003, IEEE T MED IMAGING, V22, P1014, DOI 10.1109/TMI.2003.815865
   Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Thomas CDL, 2009, J BONE MINER RES, V24, P1808, DOI [10.1359/JBMR.090504, 10.1359/jbmr.090504]
   Treece GM, 2012, MED IMAGE ANAL, V16, P952, DOI 10.1016/j.media.2012.02.008
   Treece GM, 2010, MED IMAGE ANAL, V14, P276, DOI 10.1016/j.media.2010.01.003
   Viceconti M, 2012, J BIOMECH, V45, P421, DOI 10.1016/j.jbiomech.2011.11.048
   Wainwright SA, 2005, J CLIN ENDOCR METAB, V90, P2787, DOI 10.1210/jc.2004 1568
   Worsley K.J., 2009, NEUROIMAGE, V47, pS102, DOI [DOI 10.1016/S1053 8119(09)70882 1, 10.1016/S1053 8119(09)70882 1]
   Zimmermann EA, 2011, P NATL ACAD SCI USA, V108, P14416, DOI 10.1073/pnas.1107966108
NR 33
TC 68
Z9 71
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2015
VL 30
IS 1
BP 46
EP 54
DI 10.1002/jbmr.2325
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AX4PR
UT WOS:000346914600006
PM 25088963
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Yadav, VK
   Balaji, S
   Suresh, PS
   Liu, XS
   Lu, X
   Li, ZS
   Guo, XE
   Mann, JJ
   Balapure, AK
   Gershon, MD
   Medhamurthy, R
   Vidal, M
   Karsenty, G
   Ducy, P
AF Yadav, Vijay K.
   Balaji, Santhanam
   Suresh, Padmanaban S.
   Liu, X. Sherry
   Lu, Xin
   Li, Zhishan
   Guo, X. Edward
   Mann, J. John
   Balapure, Anil K.
   Gershon, Michael D.
   Medhamurthy, Rudraiah
   Vidal, Marc
   Karsenty, Gerard
   Ducy, Patricia
TI Pharmacological inhibition of gut derived serotonin synthesis is a
   potential bone anabolic treatment for osteoporosis
SO NATURE MEDICINE
LA English
DT Article
ID TRYPTOPHAN HYDROXYLASE INHIBITORS; PARATHYROID HORMONE; DISORDERS;
   SYSTEM; MICE; MASS
AB Osteoporosis is a disease of low bone mass most often caused by an increase in bone resorption that is not sufficiently compensated for by a corresponding increase in bone formation(1). As gut derived serotonin (GDS) inhibits bone formation(2), we asked whether hampering its biosynthesis could treat osteoporosis through an anabolic mechanism (that is, by increasing bone formation). We synthesized and used LP533401, a small molecule inhibitor of tryptophan hydroxylase 1 (Tph 1), the initial enzyme in GDS biosynthesis. Oral administration of this small molecule once daily for up to six weeks acts prophylactically or therapeutically, in a dose dependent manner, to treat osteoporosis in ovariectomized rodents because of an isolated increase in bone formation. These results provide a proof of principle that inhibiting GDS biosynthesis could become a new anabolic treatment for osteoporosis.
C1 [Yadav, Vijay K.; Karsenty, Gerard] Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10027 USA.
   [Balaji, Santhanam; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
   [Balaji, Santhanam; Vidal, Marc] Ctr Canc Syst Biol, Boston, MA USA.
   [Balaji, Santhanam; Vidal, Marc] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Suresh, Padmanaban S.; Medhamurthy, Rudraiah] Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India.
   [Liu, X. Sherry; Lu, Xin; Guo, X. Edward] Columbia Univ, Dept Biomed Engn, New York, NY USA.
   [Li, Zhishan; Gershon, Michael D.; Ducy, Patricia] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
   [Mann, J. John] Columbia Univ, Dept Psychiat, New York, NY USA.
   [Balapure, Anil K.] Cent Drug Res Inst, Tissue & Cell Culture Unit, Lucknow 226001, Uttar Pradesh, India.
C3 Columbia University; Harvard University; Harvard Medical School; Harvard
   University; Harvard University Medical Affiliates; Dana Farber Cancer
   Institute; Indian Institute of Science (IISC)   Bangalore; Columbia
   University; Columbia University; Columbia University; Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Karsenty, G (通讯作者)，Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10027 USA.
EM gk2172@columbia.edu; pd2193@columbia.edu
RI yadav, VIJAY/Q 2540 2016; Liu, Xiaowei/H 1664 2017; P.S,
   Suresh/AAX 9666 2020; Liu, Xiaowei Sherry/H 1664 2017; Mann, J
   John/IAN 5825 2023
OI Yadav, Vijay Kumar/0000 0003 2345 2846; Liu, Xiaowei
   Sherry/0000 0001 7247 2232; BALAPURE, ANIL/0000 0003 1213 4586
FU US National Institutes of Health; International Bone and Mineral Society
FX We thank M. T. Rached, Y. Y. Huang, N. Suda and G. Ren for help in
   experiments and D. Landry (Organic Chemistry, Columbia University) for
   providing LP533401 for the initial stages of these experiments. Special
   thanks go to S. Kousteni and J. Martin for helpful suggestions. This
   work was supported by grants from the US National Institutes of Health
   (V.K.Y., G. K. and P. D.) and a Gideon and Sevgi Rodan fellowship from
   International Bone and Mineral Society (V.K.Y.).
CR Andersson N, 2004, ACTA ORTHOP SCAND, V75, P201, DOI 10.1080/00016470412331294465
   Bilezikian JP, 2009, J BONE MINER RES, V24, P373, DOI [10.1359/JBMR.090105, 10.1359/jbmr.090105]
   Chen JJ, 2001, J NEUROSCI, V21, P6348, DOI 10.1523/JNEUROSCI.21 16 06348.2001
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   FELDKAMP LA, 1989, J BONE MINER RES, V4, P3, DOI 10.1002/jbmr.5650040103
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   FROST M, J BONE MINE IN PRESS
   Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002
   GUNDERSEN HJG, 1993, BONE, V14, P217, DOI 10.1016/8756 3282(93)90144 Y
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Liu QY, 2008, J PHARMACOL EXP THER, V325, P47, DOI 10.1124/jpet.107.132670
   MANN JJ, 1992, ARCH GEN PSYCHIAT, V49, P442
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shi ZC, 2008, J MED CHEM, V51, P3684, DOI 10.1021/jm800338j
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Vegni FE, 2004, NEW ENGL J MED, V350, P189
   Wang L, 2002, BIOCHEMISTRY US, V41, P12569, DOI 10.1021/bi026561f
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
NR 25
TC 277
Z9 325
U1 2
U2 63
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2010
VL 16
IS 3
BP 308
EP U103
DI 10.1038/nm.2098
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 565KA
UT WOS:000275289500036
PM 20139991
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nemeth, EF
AF Nemeth, Edward F.
TI ZT 031, a cyclized analog of parathyroid hormone(1 31) for the potential
   treatment of osteoporosis
SO IDRUGS
LA English
DT Article
ID FEMORAL TRABECULAR BONE; C ACTIVATION DOMAIN; POSTMENOPAUSAL WOMEN;
   BIOMECHANICAL PROPERTIES; OVARIECTOMIZED RATS; MINERAL DENSITY; CORTICAL
   BONE; SHORT TERM; BIOCHEMICAL MARKERS; HUMAN PTH(1 34)
AB ZT 031 is a cyclic 31 amino acid analog of parathyroid hormone (PTH) that is in development by Zelos Therapeutics Inc for the treatment of osteoporosis and other bone related disorders. ZT 031 activates the PTH type 1 receptor   the molecular target of the currently marketed osteogenic peptides PTH and PTH(1 34). Daily subcutaneous injections of ZT 031 prevented bone loss and replaced bone that had already been lost in an ovariectomized rat model of osteoporosis. Daily subcutaneous injections of ZT 031 in gonad intact monkeys increased bone mineral density (BMD) at cortical and cancellous bone sites and increased serum levels of bone formation markers. The daily subcutaneous administration of ZT 031 to postmenopausal women with osteoporosis elicited a dose dependent increase in BMD of the lumbar spine, proximal femur and total hip area. Plasma levels of bone formation markers were significantly increased above baseline after 1 month of dosing, and prior to increases in bone resorption markers. ZT 031 was demonstrated to be safe and well tolerated; episodes of hypercalcemia were infrequent and observed with a frequency greater than with placebo only at the highest doses tested for the drug. Although available data are limited, the results obtained following treatment with ZT 031 have generally been at least as favorable as those obtained with other osteogenic PTH peptides. A novel dosing paradigm has been planned for the drug.
C1 MetisMedica, Toronto, ON M5R 1G6, Canada.
RP Nemeth, EF (通讯作者)，MetisMedica, 32 Elgin Ave, Toronto, ON M5R 1G6, Canada.
EM nemeth.ed@gmail.com
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   ALLEN MJ, 2004, ORTHOPEDICS RES SOC
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   Andress DL, 2008, KIDNEY INT, V73, P1345, DOI 10.1038/ki.2008.60
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Barbier JR, 1997, J MED CHEM, V40, P1373, DOI 10.1021/jm960743o
   BARCLAY L, 2006, INT OSTEOPOROSIS FOU
   Bauer DC, 2006, J CLIN ENDOCR METAB, V91, P1370, DOI 10.1210/jc.2005 1712
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Brommage R, 1999, J CLIN ENDOCR METAB, V84, P3757, DOI 10.1210/jc.84.10.3757
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Epstein S, 2006, CLIN THER, V28, P151, DOI 10.1016/j.clinthera.2006.02.007
   FELSENFELD AJ, 2001, SPECTRUM RENAL OSTEO, P185
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fox J, 2007, BONE, V41, P321, DOI 10.1016/j.bone.2007.04.197
   Fox J, 2007, CALCIFIED TISSUE INT, V81, P53, DOI 10.1007/s00223 007 9036 y
   Fox J, 2002, CURR OPIN PHARMACOL, V2, P338, DOI 10.1016/S1471 4892(02)00154 6
   Fox J, 2006, CALCIFIED TISSUE INT, V79, P262, DOI 10.1007/s00223 006 0108 1
   Fox J, 2007, J BONE MINER RES, V22, P260, DOI 10.1359/JBMR.061101
   Friedman PA, 1999, ENDOCRINOLOGY, V140, P301, DOI 10.1210/en.140.1.301
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Girotra M, 2006, REV ENDOCR METAB DIS, V7, P113, DOI 10.1007/s11154 006 9007 z
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Henry JG, 1997, J CLIN ENDOCR METAB, V82, P900, DOI 10.1210/jc.82.3.900
   HODSMAN A, 2007, J BONE MINER RES S1, V22
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P1603, DOI 10.1210/jc.2002 020773
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   JOLETTE J, 2005, J BONE MINER RES, V20
   JOLETTE J, 2003, AM SOC BONE MINER, V25, P19
   Jolette J, 2006, TOXICOL PATHOL, V34, P929, DOI 10.1080/01926230601072301
   JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53
   JOUISHOMME H, 1994, J BONE MINER RES, V9, P943
   Kenakin T, 2005, NAT REV DRUG DISCOV, V4, P919, DOI 10.1038/nrd1875
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Lindsay R, 1997, OSTEOPOROSIS INT, V7, P1
   LINDSAY R, 1993, J CLIN ENDOCR METAB, V77, P1535, DOI 10.1210/jc.77.6.1535
   Martin TJ, 2008, OSTEOPOROSIS INT, V19, P1125, DOI 10.1007/s00198 008 0575 5
   MEHTA NM, 2002, AM SOC BONE MINER RE
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   Miller Paul D, 2004, Endocr Pract, V10, P139
   Morley P, 2001, CALCIFIED TISSUE INT, V68, P95, DOI 10.1007/BF02678147
   Morley P, 1999, EUR J ENDOCRINOL, V141, P70, DOI 10.1530/eje.0.1410070
   MORLEY P, 2006, INT OSTEOPOROSIS FOU
   MORLEY P, 2007, J BONE MINER RES S1, V22
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   *NAT KIDN FDN, AM J KIDN DIS S3, V42, P1
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   *NEKT THER, 2008, FORM 10 K FISC YEAR
   Nemeth EF, 2006, KIDNEY INT, V70, pS22, DOI 10.1038/sj.ki.5001598
   Nozaka K, 2008, BONE, V42, P90, DOI 10.1016/j.bone.2007.08.041
   ODEA L, 2007, ANN MEET ENDOCRINE S, V89
   Plotkin H, 1998, J CLIN ENDOCR METAB, V83, P2786, DOI 10.1210/jc.83.8.2786
   Potts JT, 1997, J ENDOCRINOL, V154, pS15
   Reeve J, 1991, Osteoporos Int, V1, P162, DOI 10.1007/BF01625448
   RIXON RH, 1994, J BONE MINER RES, V9, P1179
   ROSENBLATT M, 1982, COMPR ENDOCRINOL, P103
   Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330
   Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112
   Schwietert HR, 1997, CLIN PHARMACOL THER, V61, P360, DOI 10.1016/S0009 9236(97)90169 7
   Takasu H, 1998, ENDOCRINOLOGY, V139, P4293, DOI 10.1210/en.139.10.4293
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tashjian AH, 2008, J BONE MINER RES, V23, P803, DOI 10.1359/JBMR.080208
   Thompson C, 2005, MUTAGENESIS, V20, P345, DOI 10.1093/mutage/gei045
   *US FDA, 1994, FDA GUID
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Vahle JL, 2007, TOXICOL PATHOL, V35, P1045, DOI 10.1080/01926230701748354
   Whitfield J, 2003, CANCER LETT, V200, P107, DOI 10.1016/S0304 3835(03)00162 9
   Whitfield JF, 1998, CALCIFIED TISSUE INT, V63, P423, DOI 10.1007/s002239900551
   Whitfield JF, 1997, CALCIFIED TISSUE INT, V60, P26, DOI 10.1007/s002239900181
   Whitfield JF, 2000, CALCIFIED TISSUE INT, V66, P307, DOI 10.1007/s002230010061
   Whitfield JF, 1996, CALCIFIED TISSUE INT, V58, P81, DOI 10.1007/BF02529728
   WHITFIELD JF, 1995, TRENDS PHARMACOL SCI, V16, P382, DOI 10.1016/S0165 6147(00)89079 3
   Whitfield JF, 1997, J BONE MINER RES, V12, P1246, DOI 10.1359/jbmr.1997.12.8.1246
   Whitfield JF, 2001, J BONE MINER RES, V16, P441, DOI 10.1359/jbmr.2001.16.3.441
   Whitfield JF, 1999, CELL SIGNAL, V11, P159, DOI 10.1016/S0898 6568(98)00055 2
   WILLICK GE, 2004, CURR MED CHEM, V11, P2599
   Yang DH, 2006, BONE, V38, P485, DOI 10.1016/j.bone.2005.10.009
   *ZEL THER, 2008, EM IND REN BON DIS
   *ZEL THER, 2008, FRACT REP
   *ZEL THER, 2008, PIP OST
   *ZEL THER, 2008, COMP COMM
NR 93
TC 3
Z9 3
U1 0
U2 3
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1369 7056
EI 2040 3410
J9 IDRUGS
JI IDrugs
PD NOV
PY 2008
VL 11
IS 11
BP 827
EP 840
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 368SX
UT WOS:000260643900014
PM 18988128
DA 2025 08 17
ER

PT J
AU Black, DM
   Condra, K
   Adams, AL
   Eastell, R
AF Black, Dennis M.
   Condra, Katherine
   Adams, Annette L.
   Eastell, Richard
TI Bisphosphonates and the risk of atypical femur fractures
SO BONE
LA English
DT Article
DE Fracture; Atypical femur fracture; Osteoporosis; Bisphosphonates
ID CORTICAL STRESS LESIONS; FEMORAL FRACTURES; POSTMENOPAUSAL WOMEN;
   ALENDRONATE THERAPY; OSTEOPOROSIS; BONE; DIAPHYSEAL; DENOSUMAB;
   DISCONTINUATION; PREVENTION
AB Bisphosphonates are effective in reducing hip and other fractures. However, concerns about atypical femur fractures (AFFs) have contributed to substantially decreased bisphosphonate use, and hip fracture rates may be increasing. Despite this impact, important uncertainties remain regarding AFF risks including the association between bisphosphonate use and other risk factors such as BMD, age, weight, and race.
   To address this evidence gap, a cohort study of 196,129 women >= 50 years of age in the Southern California Kaiser Permanente HMO women (with >= 1 bisphosphonate prescription) were studied; the primary outcome was radiographically adjudicated AFF between 2007 and 2017. Risk factors including bisphosphonate use and race were obtained from electronic health records. Multivariable Cox models were used for analysis. Benefit risk was modeled for 1 10 years of bisphosphonates to compare fractures prevented vs. AFFs associated. Among 196,129 women, 277 (0.1%) sustained AFFs. After multivariable adjustment, AFF risk increased with longer bisphosphonate duration: hazard ratio (HR) increased from HR = 8.9 (95%CI: 2.8,28) for 3 5 years to HR = 43.5 (13.7138.1) for >8 years. Hip BMD, surprisingly, was not associated with AFF risk. Other risk factors included Asian ancestry (HR = 4.8 (3.6, 6.6)), short stature, overweight, and glucocorticoid use. Bisphosphonate discontinuation was associated with rapid decrease in AFF risk. Decreases in osteoporotic and hip fractures risk during 1 10 years of bisphosphonates far outweighed the increase AFF risk in Caucasians, but less so in Asians. In Caucasians, after 3 years 149 hip fractures were prevented with 2 AFFs associated compared to 91 and 8 in Asians.
   The evidence for several potential mechanisms is summarized with femoral geometry being the most likely to explain AFF risk differences between Asians and Caucasians. The results from this new study add to the evidence base for AFF risk factors and will help inform clinical decision making for individual patients about initiation and duration of bisphosphonate therapy and drug holidays.
C1 [Black, Dennis M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St,2nd Floor,Box 0560, San Francisco, CA 94143 USA.
   [Condra, Katherine] San Francisco VA Hlth Care Syst, Dept Endocrinol & Metab, San Francisco, CA USA.
   [Eastell, Richard] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Black, Dennis M.; Adams, Annette L.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA.
C3 University of California System; University of California San Francisco;
   University of Sheffield; Kaiser Permanente
RP Black, DM (通讯作者)，Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St,2nd Floor,Box 0560, San Francisco, CA 94143 USA.
EM Dennis.Black@ucsf.edu
RI Eastell, Richard/G 5851 2011
CR Adams AL, 2018, J BONE MINER RES, V33, P1252, DOI 10.1002/jbmr.3420
   Armamento Villareal R, 2006, NEW ENGL J MED, V355, P2048, DOI 10.1056/NEJMc062268
   Austin DC, 2017, ACTA ORTHOP, V88, P351, DOI 10.1080/17453674.2016.1277412
   Bauer D., 2020, J BONE MINER RES VIR
   Bauer DC, 2014, JAMA INTERN MED, V174, P1126, DOI 10.1001/jamainternmed.2014.1232
   Black D., 2012, J BONE MINER RES, V27
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Black DM, 2019, ENDOCR REV, V40, P333, DOI 10.1210/er.2018 00001
   Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Brixen K, 2013, J CLIN ENDOCR METAB, V98, P571, DOI 10.1210/jc.2012 2972
   Curtis E.M., OSTEOPOROSIS TREATME, V2021, P97
   Curtis JR, 2020, MED CARE, V58, P419, DOI 10.1097/MLR.0000000000001294
   Dennison EM, 2019, OSTEOPOROSIS INT, V30, P1733, DOI 10.1007/s00198 019 05002 w
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Ettinger B, 2013, BONE, V55, P495, DOI 10.1016/j.bone.2013.02.004
   Feldstein AC, 2012, J BONE MINER RES, V27, P977, DOI 10.1002/jbmr.1550
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Haider IT, 2019, CURR OSTEOPOROS REP, V17, P281, DOI 10.1007/s11914 019 00525 x
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim TY, 2019, J BONE MINER RES, V34, P810, DOI 10.1002/jbmr.3654
   Koh JSB, 2011, SINGAP MED J, V52, P77
   Koh JSB, 2010, J ORTHOP TRAUMA, V24, P75, DOI 10.1097/BOT.0b013e3181b6499b
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Maratt J, 2014, J ORTHOP TRAUMA, V28, P6, DOI 10.1097/BOT.0b013e31829ff3c9
   McClung MR, 2019, LANCET DIABETES ENDO, V7, P899, DOI 10.1016/S2213 8587(19)30346 8
   N.O.F. American Society for Bone and Mineral Research National Bone Health Alliance Mayo Clinic and International Osteoporosis Foundation, 2016, CALL ACT ADDR CRIS T
   Naylor KE, 2016, OSTEOPOROSIS INT, V27, P21, DOI 10.1007/s00198 015 3145 7
   Nguyen HH, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115319
   Oh Y, 2014, J ORTHOP SCI, V19, P579, DOI 10.1007/s00776 014 0572 9
   Papapoulos S, 2021, J BONE MINER RES, V36, P1225, DOI 10.1002/jbmr.4284
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sasaki S, 2012, J BONE MINER METAB, V30, P561, DOI 10.1007/s00774 012 0358 0
   Schilcher J, 2015, J BONE MINER RES, V30, P2127, DOI 10.1002/jbmr.2547
   Schilcher J, 2014, ACTA ORTHOP, V85, P6, DOI 10.3109/17453674.2014.885355
   Schilcher J, 2015, ACTA ORTHOP, V86, P100, DOI 10.3109/17453674.2015.1004149
   Selga J, 2016, OSTEOPOROSIS INT, V27, P827, DOI 10.1007/s00198 015 3355 z
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Sullivan KJ, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018 015 0332 3
   Taormina DP, 2014, BONE, V63, P1, DOI 10.1016/j.bone.2014.02.006
   Taylor AJ, 2011, OSTEOPOROSIS INT, V22, P1263, DOI 10.1007/s00198 010 1300 8
   U.S. Food and Drug Administration, 2010, FDA DRUG SAFETY COMM
   van der Velde RY, 2017, BONE, V94, P50, DOI 10.1016/j.bone.2016.10.013
   Yoo Hyunseung, 2017, Hip Pelvis, V29, P127, DOI 10.5371/hp.2017.29.2.127
   Zhou W, 2021, CURR OSTEOPOROS REP, V19, P123, DOI 10.1007/s11914 021 00658 y
NR 50
TC 27
Z9 28
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2022
VL 156
AR 116297
DI 10.1016/j.bone.2021.116297
EA JAN 2022
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZZ8ZH
UT WOS:000773552400002
PM 34920168
DA 2025 08 17
ER

PT J
AU Chernets, N
   Zhang, J
   Steinbeck, MJ
   Kurpad, DS
   Koyama, E
   Friedman, G
   Freeman, TA
AF Chernets, Natalie
   Zhang, Jun
   Steinbeck, Marla J.
   Kurpad, Deepa S.
   Koyama, Eiki
   Friedman, Gary
   Freeman, Theresa A.
TI Nonthermal Atmospheric Pressure Plasma Enhances Mouse Limb Bud Survival,
   Growth, and Elongation
SO Tissue Engineering Part A
LA English
DT Article
ID ARTICULAR CARTILAGE FORMATION; STEM CELLS; NITRIC OXIDE; MITOCHONDRIAL
   BIOGENESIS; ANTIOXIDANT ENZYMES; BASEMENT MEMBRANE; OXIDATIVE STRESS;
   ORGAN CULTURE; BETA CATENIN; WOUND REPAIR
AB The enhanced differentiation of mesenchymal cells into chondrocytes or osteoblasts is of paramount importance in tissue engineering and regenerative therapies. A newly emerging body of evidence demonstrates that appendage regeneration is dependent on reactive oxygen species (ROS) production and signaling. Thus, we hypothesized that mesenchymal cell stimulation by nonthermal (NT) plasma, which produces and induces ROS, would (1) promote skeletal cell differentiation and (2) limb autopod development. Stimulation with a single treatment of NT plasma enhanced survival, growth, and elongation of mouse limb autopods in an in vitro organ culture system. Noticeable changes included enhanced development of digit length and definition of digit separation. These changes were coordinated with enhanced Wnt signaling in the distal apical epidermal ridge (AER) and presumptive joint regions. Autopod development continued to advance for approximately 144 h in culture, seemingly overcoming the negative culture environment usually observed in this in vitro system. Real time quantitative polymerase chain reaction analysis confirmed the up regulation of chondrogenic transcripts. Mechanistically, NT plasma increased the number of ROS positive cells in the dorsal epithelium, mesenchyme, and the distal tip of each phalange behind the AER, determined using dihydrorhodamine. The importance of ROS production/signaling during development was further demonstrated by the stunting of digital outgrowth when anti oxidants were applied. Results of this study show NT plasma initiated and amplified ROS intracellular signaling to enhance development of the autopod. Parallels between development and regeneration suggest that the potential use of NT plasma could extend to both tissue engineering and clinical applications to enhance fracture healing, trauma repair, and bone fusion.
C1 [Chernets, Natalie; Friedman, Gary] Drexel Univ, Dept Elect & Comp Engn, Philadelphia, PA 19104 USA.
   [Zhang, Jun; Kurpad, Deepa S.; Freeman, Theresa A.] Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA.
   [Zhang, Jun] Jilin Univ, Dept Orthoped, Hosp 2, Changchun 130023, Jilin, Peoples R China.
   [Steinbeck, Marla J.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.
   [Steinbeck, Marla J.] Drexel Univ, Dept Orthoped Surg, Coll Med, Philadelphia, PA 19104 USA.
   [Koyama, Eiki] Childrens Hosp Philadelphia, Div Orthoped Surg, Philadelphia, PA 19104 USA.
C3 Drexel University; Thomas Jefferson University; Jilin University; Drexel
   University; Drexel University; University of Pennsylvania; Pennsylvania
   Medicine; Childrens Hospital of Philadelphia
RP Freeman, TA (通讯作者)，Thomas Jefferson Univ, Dept Orthopaed Surg, 501 Curtis Bldg,1015 Walnut St, Philadelphia, PA 19107 USA.
EM theresa.freeman@jefferson.edu
RI Zhang, Donglei/AAB 7572 2022
OI Freeman, Theresa/0000 0002 5959 5884
FU NIH [1 R01 EB 013011 01, 5 R03 DE020840 03]
FX Special thanks are due to Drs. Irving Shapiro, Maurizio Pacifici, Motomi
   Enomoto Iwamoto, and Masahiro Iwamoto for their valuable discussions
   during the study. Special thanks are also due to Carol Diallo for
   laboratory support and Alex Fridman from the Drexel Plasma Institute for
   helpful insights on plasma conditions. This work was supported by NIH
   Grants 1 R01 EB 013011 01 (Freeman) and 5 R03 DE020840 03 (Freeman).
CR Benazet JD, 2013, GENESIS, V51, P660, DOI 10.1002/dvg.22412
   BROWNING TH, 1969, J CLIN INVEST, V48, P1423, DOI 10.1172/JCI106108
   Castagna R, 2009, TOXICOL IN VITRO, V23, P365, DOI 10.1016/j.tiv.2008.12.016
   Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen CT, 2010, BBA GEN SUBJECTS, V1800, P257, DOI 10.1016/j.bbagen.2009.09.001
   Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   Eliasson B., 1994, Pure Appl. Chem, V66, P1275, DOI DOI 10.1351/PAC199466061275)
   Enomoto Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802
   Fischer LJ, 2009, J SURG RES, V152, P157, DOI 10.1016/j.jss.2008.06.029
   Frank S, 1999, FASEB J, V13, P2002, DOI 10.1096/fasebj.13.14.2002
   Freeman TA, 2009, J ORTHOP RES, V27, P673, DOI 10.1002/jor.20771
   Fridman AA., 2013, Plasma Medicine
   Fridman G, 2006, PLASMA CHEM PLASMA P, V26, P425, DOI 10.1007/s11090 006 9024 4
   Funato Y, 2006, NAT CELL BIOL, V8, P501, DOI 10.1038/ncb1405
   Goodman R, 2009, INT J RADIAT BIOL, V85, P851, DOI [10.3109/09553000903072488, 10.1080/09553000903072488]
   Griffin Michelle, 2011, Eplasty, V11, pe34
   Grow M, 2006, DEV DYNAM, V235, P2667, DOI 10.1002/dvdy.20897
   Hoffman DS, 1996, INT J DEV BIOL, V40, P953
   Iwamoto M, 2007, DEV BIOL, V305, P40, DOI 10.1016/j.ydbio.2007.01.037
   Ji AR, 2010, EXP MOL MED, V42, P175, DOI 10.3858/emm.2010.42.3.018
   Jung CW, 2001, NEUROSCI LETT, V304, P157, DOI 10.1016/S0304 3940(01)01784 0
   Koyama E, 2008, DEV BIOL, V316, P62, DOI 10.1016/j.ydbio.2008.01.012
   Lee Y, 2005, DEVELOPMENT, V132, P5173, DOI 10.1242/dev.02101
   Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209
   Love NR, 2013, NAT CELL BIOL, V15, P222, DOI 10.1038/ncb2659
   MESCHER AL, 1976, J EXP ZOOL, V195, P117, DOI 10.1002/jez.1401950111
   Neufeld DA, 1996, ANAT RECORD, V245, P122
   Neufeld DA, 1996, ANAT RECORD, V246, P155
   Oktyabrsky ON, 2007, BIOCHEMISTRY MOSCOW+, V72, P132, DOI 10.1134/S0006297907020022
   Pall ML, 2013, J CELL MOL MED, V17, P958, DOI 10.1111/jcmm.12088
   Parasassi T, 2010, THESCIENTIFICWORLDJO, V10, P1192, DOI 10.1100/tsw.2010.104
   Parivar K, 2006, INT J RADIAT BIOL, V82, P455, DOI 10.1080/09553000600863056
   PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0
   Pieper GM, 1997, J PHARMACOL EXP THER, V283, P138
   Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897
   Salas Vidal E, 1998, EXP CELL RES, V238, P136, DOI 10.1006/excr.1997.3828
   Scarlett SS, 2009, BBA BIOMEMBRANES, V1788, P1168, DOI 10.1016/j.bbamem.2009.02.006
   Schnabel D, 2006, DEV BIOL, V291, P291, DOI 10.1016/j.ydbio.2005.12.023
   Siemens C.W., 1862, J FRANKLIN I, V74, P166, DOI [10.1016/0016 0032(62)90468 4, DOI 10.1016/0016 0032(62)90468 4]
   Stallmeyer B, 1999, J INVEST DERMATOL, V113, P1090, DOI 10.1046/j.1523 1747.1999.00784.x
   Steinbeck MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082143
   Suy S, 1998, J BIOL CHEM, V273, P17871, DOI 10.1074/jbc.273.28.17871
   Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87
   Vasiliauskas D, 2003, DEV BIOL, V262, P94, DOI 10.1016/S0012 1606(03)00360 9
   Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364
NR 47
TC 22
Z9 22
U1 0
U2 19
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JAN 1
PY 2015
VL 21
IS 1 2
BP 300
EP 309
DI 10.1089/ten.tea.2014.0039
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA CA1YQ
UT WOS:000348706100011
PM 25102046
OA Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Daponte, V
   Tonelli, F
   Masiero, C
   Syx, D
   Exbrayat Héritier, C
   Biggiogera, M
   Willaert, A
   Rossi, A
   Coucke, PJ
   Ruggiero, F
   Forlino, A
AF Daponte, Valentina
   Tonelli, Francesca
   Masiero, Cecilia
   Syx, Delfien
   Exbrayat Heritier, Chloe
   Biggiogera, Marco
   Willaert, Andy
   Rossi, Antonio
   Coucke, Paul J.
   Ruggiero, Florence
   Forlino, Antonella
TI Cell differentiation and matrix organization are differentially affected
   during bone formation in osteogenesis imperfecta zebrafish models with
   different genetic defects impacting collagen type I structure
SO MATRIX BIOLOGY
LA English
DT Article
DE Cell differentiation; Collagen; Fin regeneration; Osteogenesis
   imperfecta; Zebrafish
ID FIN REGENERATION; PROLYL 3 HYDROXYLATION; RETINOIC ACID; MURINE MODEL;
   MOUSE MODEL; OSTEOBLAST; OSTEOCLASTOGENESIS; MECHANISMS; INHIBITION;
   EXPRESSION
AB Osteogenesis imperfecta (OI) is a family of rare heritable skeletal disorders associated with dominant muta tions in the collagen type I encoding genes and recessive defects in proteins involved in collagen type I syn thesis and processing and in osteoblast differentiation and activity. Historically, it was believed that the OI bone phenotype was only caused by abnormal collagen type I fibrils in the extracellular matrix, but more recently it became clear that the altered bone cell homeostasis, due to mutant collagen retention, plays a rele vant role in modulating disease severity in most of the OI forms and it is correlated to impaired bone cell differ entiation. Despite in vitro evidence, in vivo data are missing. To better understand the physiopathology of OI, we used two zebrafish models: Chihuahua (Chi/+), carrying a dominant p.G736D substitution in the a1 chain of collagen type I, and the recessive p3h1 / , lacking prolyl 3 hydroxylase (P3h1) enzyme. Both models share the delay of collagen type I folding, resulting in its overmodification and partial intracellular retention. The regeneration of the bony caudal fin of Chi/+ and p3h1 /  was employed to investigate the impact of abnormal collagen synthesis on bone cell differentiation. Reduced regenerative ability was evident in both models, but it was associated to impaired osteoblast differentiation and osteoblastogenesis/adipogenesis switch only in Chi/+. On the contrary, reduced osteoclast number and activity were found in both models dur ing regeneration. The dominant OI model showed a more detrimental effect in the extracellular matrix organi zation. Interestingly, the chemical chaperone 4 phenylbutyrate (4 PBA), known to reduce cellular stress and increase collagen secretion, improved bone formation only in p3h1 /  by favoring caudal fin growth without affecting bone cell markers expression. Taken together, our in vivo data proved the negative impact of struc turally abnormal collagen type I on bone formation but revealed a gene mutation specific effect on bone cell differentiation and matrix organization in OI. These, together with the distinct ability to respond to the chaper one treatment, underline the need for precision medicine approaches to properly treat the disease.& COPY; 2023 Elsevier B.V. All rights reserved.
C1 [Daponte, Valentina; Tonelli, Francesca; Masiero, Cecilia; Rossi, Antonio; Forlino, Antonella] Univ Pavia, Dept Mol Med, Biochem Unit, Pavia, Italy.
   [Syx, Delfien; Willaert, Andy; Coucke, Paul J.] Univ Ghent, Ctr Med Genet, Dept Biomol Med, Ghent, Belgium.
   [Syx, Delfien; Willaert, Andy; Coucke, Paul J.] Ghent Univ Hosp, Ghent, Belgium.
   [Exbrayat Heritier, Chloe; Ruggiero, Florence] UCBL Lyon 1, CNRS UMR5242, Ecole Normale Super Lyon, Inst Genomique Fonct Lyon, F 69007 Lyon, France.
   [Biggiogera, Marco] Univ Pavia, Dept Biol & Biotechnol, Pavia, Italy.
   [Forlino, Antonella] Univ Pavia, Dept Mol Med, Biochem Unit, Via Taramelli 3B, I 27100 Pavia, Italy.
C3 University of Pavia; Ghent University; Ghent University; Ghent
   University Hospital; Centre National de la Recherche Scientifique
   (CNRS); CNRS   National Institute for Biology (INSB); CHU Lyon; Ecole
   Normale Superieure de Lyon (ENS de LYON); Universite Claude Bernard Lyon
   1; University of Pavia; University of Pavia
RP Forlino, A (通讯作者)，Univ Pavia, Dept Mol Med, Biochem Unit, Via Taramelli 3B, I 27100 Pavia, Italy.
EM aforlino@unipv.it
RI Biggiogera, Marco/AAH 3543 2019; Daponte, Valentina/KYO 7338 2024;
   Tonelli, Francesca/AAJ 5858 2021; Willaert, Andy/AAZ 9111 2020; Coucke,
   Paul/AAO 2954 2020
OI Daponte, Valentina/0000 0002 8059 6283; Tonelli,
   Francesca/0000 0002 2111 917X; RUGGIERO, Florence/0000 0003 2915 5359
FU Italian Ministry of Education, University and Research (MIUR);
   Associazione Italiana Osteogenesi Imperfetta (ASITOI); Research
   Foundation Flanders;  [12Q5920N]
FX & nbsp;This research was funded by a Grant of the Italian Ministry of
   Education, University and Research (MIUR) to the Department of Molecular
   Medicine of the University of Pavia under the initiative "Dipartimenti
   di Eccellenza (2018 2022 and 2023 2027) " and by the support of
   Associazione Italiana Osteogenesi Imperfetta (ASITOI) to AF. DS is a
   senior postdoctoral researcher (12Q5920N) supported by the Research
   Foundation Flanders. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ansorge HL, 2009, J BIOL CHEM, V284, P8427, DOI 10.1074/jbc.M805582200
   Bader HL, 2013, J BIOL CHEM, V288, P6777, DOI 10.1074/jbc.M112.430637
   Bader HL, 2009, MATRIX BIOL, V28, P32, DOI 10.1016/j.matbio.2008.09.580
   Bensimon Brito A, 2012, EVOL DEV, V14, P116, DOI 10.1111/j.1525 142X.2011.00526.x
   Besio R, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.038521
   Besio R, 2018, BBA MOL BASIS DIS, V1864, P1642, DOI 10.1016/j.bbadis.2018.02.002
   Blum N, 2015, DEVELOPMENT, V142, P2894, DOI 10.1242/dev.120204
   Cardeira J, 2016, SCI REP UK, V6, DOI 10.1038/srep39191
   Cardeira da Silva J, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2209231119
   CASTAGNOLA P, 1992, EUR J CELL BIOL, V59, P340
   Desvignes T, 2018, DEV DYNAM, V247, P832, DOI 10.1002/dvdy.24630
   Durán I, 2011, DEV BIOL, V354, P160, DOI 10.1016/j.ydbio.2011.03.014
   Fisher S, 2003, DEV BIOL, V264, P64, DOI 10.1016/S0012 1606(03)00399 3
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Fratzl Zelman N, 2016, J CLIN ENDOCR METAB, V101, P3516, DOI 10.1210/jc.2016 1334
   Fratzl Zelman N, 2016, BONE, V85, P15, DOI 10.1016/j.bone.2016.01.018
   Gagliardi A, 2017, J PROTEOMICS, V167, P46, DOI 10.1016/j.jprot.2017.08.007
   Garibaldi N, 2021, MATRIX BIOL, V98, P1, DOI 10.1016/j.matbio.2021.03.001
   Gemberling M, 2013, TRENDS GENET, V29, P611, DOI 10.1016/j.tig.2013.07.003
   Gerri C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15492
   Gioia R, 2017, HUM MOL GENET, V26, P2897, DOI 10.1093/hmg/ddx171
   Gioia R, 2012, STEM CELLS, V30, P1465, DOI 10.1002/stem.1107
   Gistelinck C, 2018, P NATL ACAD SCI USA, V115, pE8037, DOI 10.1073/pnas.1722200115
   Henke K, 2017, GENETICS, V207, P609, DOI 10.1534/genetics.117.300187
   Huang CC, 2009, DEV BIOL, V332, P360, DOI 10.1016/j.ydbio.2009.06.003
   Hudson DM, 2013, CONNECT TISSUE RES, V54, P245, DOI 10.3109/03008207.2013.800867
   Hulley PA, 2017, J PATHOL, V242, P322, DOI 10.1002/path.4906
   Imrie D, 2010, DEV DYNAM, V239, P3013, DOI 10.1002/dvdy.22443
   Ishikawa Y, 2013, BBA MOL CELL RES, V1833, P2479, DOI 10.1016/j.bbamcr.2013.04.008
   Izu Y, 2021, MATRIX BIOL, V95, P52, DOI 10.1016/j.matbio.2020.10.004
   Jain M, 2019, GENET MED, V21, P275, DOI 10.1038/s41436 018 0045 1
   Jovanovic M, 2022, ENDOCR REV, V43, P61, DOI 10.1210/endrev/bnab017
   Kague E, 2016, DEV BIOL, V413, P160, DOI 10.1016/j.ydbio.2016.03.011
   Kaneto CM, 2017, EUR J MED GENET, V60, P326, DOI 10.1016/j.ejmg.2017.04.003
   Kato T, 2000, OPHTHALMIC RES, V32, P215, DOI 10.1159/000055616
   Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014
   Leger AJ, 2010, J BONE MINER METAB, V28, P510, DOI 10.1007/s00774 010 0171 6
   Li HT, 2010, AM J PATHOL, V176, P2405, DOI 10.2353/ajpath.2010.090704
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Marzin P, 2020, THER ADV ENDOCRINOL, V11, DOI 10.1177/2042018820904016
   McGowan LM, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10461
   Mirigian LS, 2016, J BONE MINER RES, V31, P1608, DOI 10.1002/jbmr.2824
   Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039
   Mullan LA, 2017, J CLIN INVEST, V127, P3861, DOI 10.1172/JCI93094
   Nauroy P, 2019, MATRIX BIOL, V75 76, P82, DOI 10.1016/j.matbio.2018.07.005
   Paganini C, 2021, BIOCHEM PHARMACOL, V185, DOI 10.1016/j.bcp.2021.114452
   Panaroni C, 2009, BLOOD, V114, P459, DOI 10.1182/blood 2008 12 195859
   Pfefferli C, 2015, REGENERATION, V2, P72, DOI 10.1002/reg2.33
   Poss KD, 2003, DEV DYNAM, V226, P202, DOI 10.1002/dvdy.10220
   Potnuru P, 2020, CUREUS J MED SCIENCE, V12, DOI [10.1038/nature12111, 10.7759/cureus.11549]
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Reich A., 2012, PROGRAM AM SOC BONE
   SANTAMARIA JA, 1991, J ANAT, V176, P9
   Sehring IM, 2020, WIRES DEV BIOL, V9, DOI 10.1002/wdev.367
   Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955 0674(00)00194 0
   Shi XN, 2020, EPIGENETICS US, V15, P632, DOI 10.1080/15592294.2019.1700032
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Smith A, 2006, DEV BIOL, V299, P438, DOI 10.1016/j.ydbio.2006.08.016
   Sousa S, 2011, DEVELOPMENT, V138, P3897, DOI 10.1242/dev.064717
   Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034
   Tomecka MJ, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037630
   Tonelli F, 2020, MATRIX BIOL, V90, P40, DOI 10.1016/j.matbio.2020.03.004
   Tonelli F, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1002914
   Tonelli F, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00489
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   Valenti MT, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081911
   van der Meulen T, 2005, BBA GENE STRUCT EXPR, V1729, P105, DOI 10.1016/j.bbaexp.2005.03.008
   Vanhauwaert S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109091
   Vanoevelen J, 2011, FASEB J, V25, P3197, DOI 10.1096/fj.11 183145
   Vranka JA, 2010, J BIOL CHEM, V285, P17253, DOI 10.1074/jbc.M110.102228
   Witten PE, 2010, J APPL ICHTHYOL, V26, P257, DOI 10.1111/j.1439 0426.2010.01416.x
   Witten PE, 2009, BIOL REV, V84, P315, DOI 10.1111/j.1469 185X.2009.00077.x
NR 72
TC 9
Z9 9
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0945 053X
EI 1569 1802
J9 MATRIX BIOL
JI Matrix Biol.
PD AUG
PY 2023
VL 121
BP 105
EP 126
DI 10.1016/j.matbio.2023.06.003
EA JUN 2023
PG 22
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA N7SR1
UT WOS:001038970800001
PM 37336269
OA hybrid
DA 2025 08 17
ER

PT J
AU Cheng, LL
   Ge, MM
   Lan, Z
   Ma, ZL
   Chi, WN
   Kuang, WH
   Sun, K
   Zhao, XB
   Liu, Y
   Feng, YQ
   Huang, YD
   Luo, MG
   Li, LP
   Zhang, B
   Hu, XY
   Xu, LN
   Liu, XH
   Huo, Y
   Deng, HT
   Yang, JL
   Xi, QR
   Zhang, YH
   Siegenthaler, JA
   Chen, LG
AF Cheng, Lili
   Ge, Mengmeng
   Lan, Zhou
   Ma, Zhilong
   Chi, Wenna
   Kuang, Wenhua
   Sun, Kun
   Zhao, Xinbin
   Liu, Ye
   Feng, Yaqian
   Huang, Yuedong
   Luo, Maoguo
   Li, Liping
   Zhang, Bin
   Hu, Xiaoyu
   Xu, Lina
   Liu, Xiaohui
   Huo, Yi
   Deng, Haiteng
   Yang, Jinliang
   Xi, Qiaoran
   Zhang, Yonghui
   Siegenthaler, Julie A.
   Chen, Ligong
TI Zoledronate dysregulates fatty acid metabolism in renal tubular
   epithelial cells to induce nephrotoxicity
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Zoledronate; TGF beta 1 signaling; Fatty acid transporter; Lipid
   accumulation; Renal fibrosis
ID CHRONIC KIDNEY DISEASE; MYOFIBROBLAST ACTIVATION; LIPID ACCUMULATION;
   BISPHOSPHONATES; INHIBITION; TOXICITY; FIBROSIS; ALPHA; LIVER;
   MECHANISMS
AB Zoledronate is a bisphosphonate that is widely used in the treatment of metabolic bone diseases. However, zoledronate induces significant nephrotoxicity associated with acute tubular necrosis and renal fibrosis when administered intravenously. There is speculation that zoledronate induced nephrotoxicity may result from its pharmacological activity as an inhibitor of the mevalonate pathway but the molecular mechanisms are not fully understood. In this report, human proximal tubular HK 2 cells and mouse models were combined to dissect the molecular pathways underlying nephropathy caused by zoledronate treatments. Metabolomic and proteomic assays revealed that multiple cellular processes were significantly disrupted, including the TGF beta pathway, fatty acid metabolism and small GTPase signaling in zoledronate treated HK 2 cells (50 mu M) as compared with those in controls. Zoledronate treatments in cells (50 mu M) and mice (3 mg/kg) increased TGF beta/Smad3 pathway activation to induce fibrosis and kidney injury, and specifically elevated lipid accumulation and expression of fibrotic proteins. Conversely, fatty acid transport protein Slc27a2 deficiency or co administration of PPARA agonist fenofibrate (20 mg/kg) prevented zoledronate induced lipid accumulation and kidney fibrosis in mice, indicating that over expression of fatty acid transporter SLC27A2 and defective fatty acid beta oxidation following zoledronate treatments were significant factors contributing to its nephrotoxicity. These pharmacological and genetic studies provide an important mechanistic insight into zoledronate associated kidney toxicity that will aid in development of therapeutic prevention and treatment options for this nephropathy.
C1 [Cheng, Lili; Ge, Mengmeng; Lan, Zhou; Ma, Zhilong; Chi, Wenna; Kuang, Wenhua; Sun, Kun; Zhao, Xinbin; Liu, Ye; Feng, Yaqian; Huang, Yuedong; Li, Liping; Zhang, Yonghui; Chen, Ligong] Tsinghua Univ, Sch Pharmaceut Sci, Beijing 100084, Peoples R China.
   [Ge, Mengmeng; Luo, Maoguo; Xi, Qiaoran] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China.
   [Chi, Wenna; Yang, Jinliang; Zhang, Yonghui; Chen, Ligong] Sichuan Univ, West China Med, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy & Canc Ctr,West China Ho, Chengdu, Sichuan, Peoples R China.
   [Zhang, Bin; Hu, Xiaoyu] Tsinghua Univ, Inst Immunol, Sch Med, Beijing, Peoples R China.
   [Xu, Lina; Liu, Xiaohui] Tsinghua Univ, Sch Life Sci, Technol Ctr Prot Sci, Beijing, Peoples R China.
   [Huo, Yi; Deng, Haiteng] Tsinghua Univ, Sch Life Sci, MOE, Key Lab Bioinformat, Beijing, Peoples R China.
   [Siegenthaler, Julie A.] Univ Colorado, Dept Pediat, Denver Anschutz Med Campus, Aurora, CO USA.
C3 Tsinghua University; Tsinghua University; Sichuan University; Tsinghua
   University; Tsinghua University; Tsinghua University; University of
   Colorado System; University of Colorado Anschutz Medical Campus
RP Chen, LG (通讯作者)，Tsinghua Univ, Sch Pharmaceut Sci, Beijing 100084, Peoples R China.; Chen, LG (通讯作者)，Sichuan Univ, West China Med, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy & Canc Ctr,West China Ho, Chengdu, Sichuan, Peoples R China.
EM ligongchen@biomed.tsinghua.edu.cn
RI ; Chen, Ligong/AAE 8536 2020; Liu, Xiaohui/CAG 5979 2022; Hu,
   Xiaoyu/D 5403 2017; Sun, Kun/Q 6479 2018; Li, LiPing/HKE 9058 2023;
   Huang, Jingyi/KCY 2239 2024
OI Cheng, Lili/0000 0001 8009 1069; Deng, Haiteng/0000 0001 9496 1280; Hu,
   Xiaoyu/0000 0002 4289 6998; , Julie/0000 0003 3700 6441; Liu,
   Ye/0000 0002 1901 669X
FU National Natural Science Foundation of China [81470839]; Tsinghua
   University Initiative Scientific Research Program [20161080086];
   National 1000 Talent Program [20141770980]; Nation Science and
   Technology Major Projects for Major New Drugs Innovation and Develop
   [2017ZX09101 005 004 002]; Tsinghua Peking Joint Center for Life
   Sciences
FX This work is supported by National Natural Science Foundation of China
   (No. 81470839), Tsinghua University Initiative Scientific Research
   Program (No. 20161080086), National 1000 Talent Program (No.
   20141770980), Nation Science and Technology Major Projects for Major New
   Drugs Innovation and Develop (No. 2017ZX09101 005 004 002) and a
   starting fund from Tsinghua Peking Joint Center for Life Sciences.
CR Anderson CM, 2013, MOL ASPECTS MED, V34, P516, DOI 10.1016/j.mam.2012.07.010
   Bergner R, 2015, PHARMACOL RES, V99, P16, DOI 10.1016/j.phrs.2015.04.016
   Böttinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chen LG, 2014, P NATL ACAD SCI USA, V111, P9983, DOI 10.1073/pnas.1314939111
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   FRITZ IB, 1963, J LIPID RES, V4, P279
   Fu XL, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/6720420
   González Guerrero C, 2017, ARCH TOXICOL, V91, P1925, DOI 10.1007/s00204 016 1830 8
   Harada Y, 2016, ARCH TOXICOL, V90, P3061, DOI 10.1007/s00204 016 1669 z
   Herman Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501
   Ibrahim WH, 2003, AM J VET RES, V64, P1265, DOI 10.2460/ajvr.2003.64.1265
   Jennings P, 2015, ARCH TOXICOL, V89, P101, DOI 10.1007/s00204 014 1237 3
   Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762
   Karkampouna S, 2016, ARCH TOXICOL, V90, P347, DOI 10.1007/s00204 014 1436 y
   Kim JH, 2004, KIDNEY INT, V66, P1826, DOI 10.1111/j.1523 1755.2004.00956.x
   Li S, 2008, CELL METAB, V8, P105, DOI 10.1016/j.cmet.2008.06.013
   Lin YH, 2014, OCUL IMMUNOL INFLAMM, V10, P1
   Liu H, 2016, ARCH TOXICOL, V90, P1383, DOI 10.1007/s00204 015 1559 9
   Lühe A, 2008, TOXICOL IN VITRO, V22, P899, DOI 10.1016/j.tiv.2008.01.006
   Maluf DG, 2014, AM J TRANSPLANT, V14, P1152, DOI 10.1111/ajt.12696
   Manickam N, 2014, AM J PHYSIOL RENAL, V307, pF159, DOI 10.1152/ajprenal.00546.2013
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   McKay RR, 2014, EUR UROL, V66, P502, DOI 10.1016/j.eururo.2014.02.040
   Mizejewski G., 2015, J HEMATOL THROMBO DI, V3, P191, DOI [10.4172/2329 8790.1000191, DOI 10.4172/2329 8790.1000191]
   Munier A, 2005, ANN PHARMACOTHER, V39, P1194, DOI 10.1345/aph.1E589
   Muratsu D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067906
   Ott SM, 2012, KIDNEY INT, V82, P833, DOI 10.1038/ki.2012.253
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Pillon NJ, 2015, AM J PHYSIOL ENDOC M, V309, pE35, DOI 10.1152/ajpendo.00611.2014
   Polinati PP, 2009, FAT ACID OXID DISORD, DOI [10.1002/9780470015902.a0003067.pub2, DOI 10.1002/9780470015902.A0003067.PUB2]
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Sanchez Niño MD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.1
   Sanjabi S, 2009, CURR OPIN PHARMACOL, V9, P447, DOI 10.1016/j.coph.2009.04.008
   Susztak K, 2005, PLOS MED, V2, P152, DOI 10.1371/journal.pmed.0020045
   Toussaint ND, 2009, CLIN J AM SOC NEPHRO, V4, P221, DOI 10.2215/CJN.02550508
   Tsou PS, 2014, AM J PHYSIOL CELL PH, V307, pC2, DOI 10.1152/ajpcell.00060.2014
   van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353
   Verhulst A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121861
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Yoon SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7546
   Zhan M, 2014, AM J PHYSIOL RENAL, V307, pF385, DOI 10.1152/ajprenal.00338.2014
   Zhao X., 2017, Tumor Biol, V2017
NR 44
TC 30
Z9 32
U1 0
U2 28
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0340 5761
EI 1432 0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD JAN
PY 2018
VL 92
IS 1
BP 469
EP 485
DI 10.1007/s00204 017 2048 0
PG 17
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA FT1RK
UT WOS:000422913700030
PM 28871336
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Cang, DW
   Zou, GY
   Yang, C
   Shen, XF
   Li, F
   Wu, Y
   Ji, B
AF Cang, Dingwei
   Zou, Guoyou
   Yang, Chi
   Shen, Xiaofei
   Li, Feng
   Wu, Ya
   Ji, Biao
TI Dencichine prevents ovariectomy induced bone loss and inhibits
   osteoclastogenesis by inhibiting RANKL associated NF κB and MAPK
   signaling pathways
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Dencichine; Osteoclastogenesis; NF kappa B; MAPK; Signaling pathway
ID RECEPTOR ACTIVATOR; IN VITRO; DIFFERENTIATION; CELLS; INJURY; MMP 9;
   VIVO
AB Aims: To investigate the effect of dencichine on osteoclastogenesis in vivo and in vitro.
   Methods: RANKL induced osteoclastogenesis were treated with different concentrations of dencichine. Pit forming assays were applied to evaluate the degree of bone resorption. Osteoclastogenic markers were detected by real time quantitative PCR (RT qPCR) and Western blot. Micro CT was conducted to investigate the effects of dencichine on osteoclastogenesis in ovariectomized (OVX) mice.
   Results: Dencichine suppressed osteoclastogenesis through the inhibition of phosphorylation of p65, p50 (NF kappa B pathway), p38, ERK and JNK (MAPKs pathway) in vitro. Furthermore, dencichine inhibited the function of osteoclasts in a dose dependent manner. In addition, the expression levels of the nuclear factor of activated T cells 1 (NFATc1) and osteoclastogenesis markers were decreased by dencichine, including MMP 9, Cathepsin K (CTSK), Tartrate Resistant Acid Phosphatase (TRAP), C FOS, dendritic cell specific transmembrane protein (DC STAMP). In vivo data proved that dencichine alleviated ovariectomy induced bone loss and osteoclastogenesis in mice.
   Conclusion: Our results demonstrate that dencichine alleviates OVX induced bone loss in mice and inhibits RANKL mediated osteoclastogenesis via inhibition of NF kappa B and MAPK pathways in vitro, suggesting that dencichine might serve as a promising candidate for treatment of bone loss diseases, including PMOP and rheumatoid arthritis. (C) 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Cang, Dingwei; Zou, Guoyou; Shen, Xiaofei; Li, Feng; Wu, Ya; Ji, Biao] Yancheng City 1 Peoples Hosp, Dept Orthopaed, 166 Yulong West Rd, Yancheng 224006, Jiangsu, Peoples R China.
   [Yang, Chi] Rochen Pharma Co Ltd, Dept R&D, Shanghai 201514, Peoples R China.
RP Wu, Y; Ji, B (通讯作者)，Yancheng City 1 Peoples Hosp, Dept Orthopaed, 166 Yulong West Rd, Yancheng 224006, Jiangsu, Peoples R China.
EM 1343401049@stu.suda.edu.cn; jbbch@163.com
RI shen, xiaofei/LRT 1082 2024
FU Yancheng City No.1 People's Hospital
FX This work was supported by Yancheng City No.1 People's Hospital.
CR Ahn SJ, 2015, AM J CHINESE MED, V43, P715, DOI 10.1142/S0192415X15500445
   Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   [Anonymous], 2018, INT J MOL SCI
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chandra A, 2018, FASEB J, V32, P52, DOI 10.1096/fj.201700375R
   Chen K, 2019, J CELL PHYSIOL, V234, P6477, DOI 10.1002/jcp.27385
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Collins FL, 2017, BONE, V97, P94, DOI 10.1016/j.bone.2017.01.002
   Ding SL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00297
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Hu ZQ, 2019, J PHOTOCH PHOTOBIO B, V191, P6, DOI 10.1016/j.jphotobiol.2018.11.009
   Huang C, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118146
   Huang LF, 2014, THROMB RES, V133, P848, DOI 10.1016/j.thromres.2014.02.009
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Jin HM, 2019, J CELL MOL MED, V23, P522, DOI 10.1111/jcmm.13955
   Kim K, 2016, GENE DEV, V30, P208, DOI 10.1101/gad.268714.115
   Lee EJ, 2017, SCI REP UK, V7, DOI 10.1038/srep40240
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li HJ, 2017, J CLIN INVEST, V127, P1241, DOI 10.1172/JCI89511
   Li J, 2017, EUR J PHARMACOL, V812, P196, DOI 10.1016/j.ejphar.2017.06.024
   Li J, 2015, SCI REP UK, V5, DOI 10.1038/srep17605
   Liu C, 2018, EUR J MED CHEM, V145, P661, DOI 10.1016/j.ejmech.2018.01.022
   Liu Q, 2016, SCI REP UK, V6, DOI 10.1038/srep36662
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Ortuño MJ, 2016, NAT MED, V22, P1170, DOI 10.1038/nm.4166
   Qian LQ, 2015, CANCER LETT, V368, P126, DOI 10.1016/j.canlet.2015.07.035
   Seo BK, 2016, J ETHNOPHARMACOL, V193, P227, DOI 10.1016/j.jep.2016.07.022
   Sigl V, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160230
   Swart E, 2016, CLIN ORTHOP RELAT R, V474, P222, DOI 10.1007/s11999 015 4494 4
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Wang F, 2015, INT IMMUNOPHARMACOL, V28, P764, DOI 10.1016/j.intimp.2015.08.003
   Wang LL, 2018, ACTA BIOMATER, V73, P488, DOI 10.1016/j.actbio.2018.04.013
   Wang RK, 2019, INJURY, V50, P432, DOI 10.1016/j.injury.2018.09.013
   Wei QS, 2019, J ORTHOP TRANSL, V18, P65, DOI 10.1016/j.jot.2018.11.002
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xiao Y, 2018, THER DELIV, V9, P245, DOI 10.4155/tde 2017 0106
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhi X, 2020, J CELL MOL MED, V24, P785, DOI 10.1111/jcmm.14790
   Zhi X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00022
NR 44
TC 6
Z9 8
U1 0
U2 5
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD AUG
PY 2021
VL 146
IS 4
BP 206
EP 215
DI 10.1016/j.jphs.2021.04.004
EA MAY 2021
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SP8SP
UT WOS:000659933800004
PM 34116734
OA gold
DA 2025 08 17
ER

PT J
AU Kanterewicz, E
   Peris, P
   Puigoriol, E
   Yáñez, A
   Rosique, P
   del Rio, L
AF Kanterewicz, Eduardo
   Peris, Pilar
   Puigoriol, Emma
   Yanez, Aina
   Rosique, Pau
   del Rio, Luis
CA FRODOS Res Grp
TI Distribution of serum βCTX in a population based study of
   postmenopausal women taking into account different anti osteoporotic
   therapies (the FRODOS Cohort)
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Bisphosphonates; Bone turnover markers; Bone mineral density; beta CTX;
   Postmenopausal osteoporosis
ID BONE TURNOVER MARKERS; BIOCHEMICAL MARKERS; MINERAL DENSITY;
   ELDERLY WOMEN; BISPHOSPHONATE TREATMENT; FRACTURE; SUPPRESSION;
   PREDICTION; RALOXIFENE; HEALTHY
AB This cross sectional study evaluated the distribution of serum cross linked C telopeptides of collagen type I (beta CTXs) in postmenopausal women, the characteristics of bone remodeling, and the factors influencing this bone marker, especially the use of anti osteoporotic drugs. Women (n = 4,175) aged 59 70 years randomly selected from the community were invited to participate, measuring beta CTXs and lumbar and femoral bone mineral density at recruitment. Risk factors for osteoporosis and the use of anti osteoporotic treatment were collected with a structured questionnaire. We evaluated the percentage of women with increased (beta CTXs > 0.620 ng/mL) and decreased bone turnover (beta CTXs < 0.100 ng/mL) and those reaching the so called treatment target (values of beta CTXs within the lower half of the reference range for healthy young premenopausal women). Two thousand nine hundred sixty eight women (70 %) participated (2,405 non treated and 563 treated). Increased and decreased bone turnover was observed in 16.4 and 1.8 %, respectively, of non treated women with significant differences compared with treated women (9.7 and 14.2 %, respectively, p < 0.001); 28 % of non treated osteoporotic individuals had increased bone turnover versus 14 % of osteopenic participants and 8.8 % of women with normal bone density (p < 0.001). Women receiving bisphosphonates presented the highest percentages of decreased bone turnover (27 %) and beta CTXs (43 %) within the treatment target. Increased bone turnover is observed in 16.4 % of non treated postmenopausal women and is more frequent in individuals with osteoporosis, whereas decreased bone turnover is unusual. Most participants taking bisphosphonates had values within the treatment target, but nearly one quarter had decreased bone turnover.
C1 [Kanterewicz, Eduardo] Hosp Gen Vic, Rheumatol Unit, Vic 08500, Barcelona, Spain.
   [Peris, Pilar] CIBERehd, Rheumatol Serv, Hosp Clin & Prov, Barcelona, Spain.
   [Puigoriol, Emma] Hosp Gen Vic, Epidemiol Unit, Vic 08500, Barcelona, Spain.
   [Yanez, Aina] Fundacio Caubet Cimera, Epidemiol Unit, Balearic Islands, Spain.
   [Rosique, Pau] Hosp Gen Vic, Biochem Lab, Vic 08500, Barcelona, Spain.
   [del Rio, Luis] CETIR Ctr Med, Densitometry Unit, Barcelona, Spain.
C3 CIBER   Centro de Investigacion Biomedica en Red; CIBEREHD
RP Kanterewicz, E (通讯作者)，Hosp Gen Vic, Rheumatol Unit, C Francesc Pla 1, Vic 08500, Barcelona, Spain.
EM ekanterewicz@chv.cat
RI Del Rio, Luis/H 3037 2016; Yañez, Aina/AAF 7087 2021; Puigoriol,
   Emma/K 3648 2017; Kanterewicz, Eduardo/G 5196 2015
OI Puigoriol, Emma/0000 0002 5510 2480; Yanez, Aina M/0000 0001 8527 3937
FU Spanish "Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos
   III" [PI05/1430]
FX This study was supported by a grant (PI05/1430) from the Spanish
   "Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos III".
   Roche Diagnostics kindly provided reagents to determine beta CTXs.
CR Berecki Gisolf J, 2008, MENOPAUSE, V15, P984, DOI 10.1097/gme.0b013e31816be98a
   Bergmann P, 2009, INT J CLIN PRACT, V63, P19, DOI 10.1111/j.1742 1241.2008.01911.x
   Cadarette SM, 2008, ANN INTERN MED, V148, P637, DOI 10.7326/0003 4819 148 9 200805060 00003
   Civitelli R, 2009, OSTEOPOROSIS INT, V20, P843, DOI 10.1007/s00198 009 0838 9
   Compston Juliet, 2007, Curr Osteoporos Rep, V5, P179
   Delmas PD, 2008, OSTEOPOROSIS INT, V19, P1153, DOI 10.1007/s00198 007 0545 3
   Delmas PD, 2009, J BONE MINER RES, V24, P1544, DOI [10.1359/JBMR.090310, 10.1359/jbmr.090310]
   Eekman DA, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 167
   Eisman J, 2004, J BONE MINER RES, V19, P1969, DOI 10.1359/JBMR.040905
   Epstein S, 2005, MAYO CLIN PROC, V80, P379, DOI 10.4065/80.3.379
   Ettinger B, 2006, MENOPAUSE, V13, P404, DOI 10.1097/01.gme.0000188735.61994.5b
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Gerdhem P, 2004, J BONE MINER RES, V19, P386, DOI 10.1359/JBMR.0301244
   Glover SJ, 2008, BONE, V42, P623, DOI 10.1016/j.bone.2007.12.218
   Glover SJ, 2009, J BONE MINER RES, V24, P389, DOI 10.1359/JBMR.080703
   Ivaska KK, 2010, J BONE MINER RES, V25, P393, DOI 10.1359/jbmr.091006
   Johnston CC, 2000, ARCH INTERN MED, V160, P3444, DOI 10.1001/archinte.160.22.3444
   Kanterewicz E, 2011, BONE, V48, P667, DOI 10.1016/j.bone.2010.10.002
   Kanterewicz E, 2009, MED CLIN BARCELONA, V133, P609, DOI 10.1016/j.medcli.2009.03.038
   Karsdal MA, 2006, DRUGS, V66, P1909, DOI 10.2165/00003495 200666150 00002
   Kruger MC, 2010, BONE, V46, P759, DOI 10.1016/j.bone.2009.10.036
   Landfeldt E, 2012, OSTEOPOROSIS INT, V23, P433, DOI 10.1007/s00198 011 1549 6
   Langsetmo LA, 2009, OSTEOPOROSIS INT, V20, P283, DOI 10.1007/s00198 008 0656 5
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   Lewiecki E Michael, 2010, Curr Osteoporos Rep, V8, P15, DOI 10.1007/s11914 010 0004 5
   Looker AC, 2000, OSTEOPOROSIS INT, V11, P467, DOI 10.1007/s001980070088
   Luz Rentero Maria, 2008, Open Rheumatol J, V2, P58, DOI 10.2174/1874312900802010058
   Martínez J, 2009, CLIN CHIM ACTA, V409, P70, DOI 10.1016/j.cca.2009.08.020
   Melton LJ, 1997, J BONE MINER RES, V12, P1083, DOI 10.1359/jbmr.1997.12.7.1083
   Miller Paul D, 2007, Curr Osteoporos Rep, V5, P38, DOI 10.1007/BF02938621
   Minisola S, 2008, J Endocrinol Invest, V31, P28
   Peris P, 2011, BONE, V49, P706, DOI 10.1016/j.bone.2011.06.027
   Reyes García R, 2013, ACTA DIABETOL, V50, P47, DOI 10.1007/s00592 011 0347 0
   Rogers A, 2009, BONE, V45, P1044, DOI 10.1016/j.bone.2009.07.089
   Rohr Christine I., 2004, Journal of the American Osteopathic Association, V104, P281
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Thomas SDC, 2010, CALCIFIED TISSUE INT, V86, P367, DOI 10.1007/s00223 010 9354 3
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   Woitge HW, 1999, J BONE MINER RES, V14, P792, DOI 10.1359/jbmr.1999.14.5.792
NR 40
TC 8
Z9 10
U1 0
U2 13
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2013
VL 31
IS 2
BP 231
EP 239
DI 10.1007/s00774 012 0410 0
PG 9
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 104TJ
UT WOS:000316017700014
PM 23223942
DA 2025 08 17
ER

PT J
AU Gobin, B
   Moriceau, G
   Ory, B
   Charrier, C
   Brion, R
   Blanchard, F
   Redini, F
   Heymann, D
AF Gobin, Berengere
   Moriceau, Gatien
   Ory, Benjamin
   Charrier, Celine
   Brion, Regis
   Blanchard, Frederic
   Redini, Francoise
   Heymann, Dominique
TI Imatinib Mesylate Exerts Anti Proliferative Effects on Osteosarcoma
   Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; TYROSINE KINASE; FACTOR RECEPTOR; SOFT TISSUE;
   IN VITRO; PHASE II; BONE; TARGET; PROLIFERATION; THERAPY
AB Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine kinase inhibitor, was originally developed for the treatment of chronic myeloid leukemia. Several studies revealed that imatinib mesylate inhibits osteoclast differentiation through the M CSFR pathway and activates osteoblast differentiation through PDGFR pathway, two key cells involved in the vicious cycle controlling the tumour development. The present study investigated the in vitro effects of imatinib mesylate on the proliferation, apoptosis, cell cycle, and migration ability of five osteosarcoma cell lines (human: MG 63, HOS; rat: OSRGA; mice: MOS J, POS 1). Imatinib mesylate was also assessed as a curative and preventive treatment in two syngenic osteosarcoma models: MOS J (mixed osteoblastic/osteolytic osteosarcoma) and POS 1 (undifferentiated osteosarcoma). Imatinib mesylate exhibited a dose dependent anti proliferative effect in all cell lines studied. The drug induced a G0/G1 cell cycle arrest in most cell lines, except for POS 1 and HOS cells that were blocked in the S phase. In addition, imatinib mesylate induced cell death and strongly inhibited osteosarcoma cell migration. In the MOS J osteosarcoma model, oral administration of imatinib mesylate significantly inhibited the tumour development in both preventive and curative approaches. A phospho receptor tyrosine kinase array kit revealed that PDGFR alpha, among 7 other receptors (PDFGFR beta, Axl, RYK, EGFR, EphA2 and 10, IGF1R), appears as one of the main molecular targets for imatinib mesylate. In the light of the present study and the literature, it would be particularly interesting to revisit therapeutic evaluation of imatinib mesylate in osteosarcoma according to the tyrosine kinase receptor status of patients.
C1 [Gobin, Berengere; Moriceau, Gatien; Ory, Benjamin; Charrier, Celine; Brion, Regis; Blanchard, Frederic; Redini, Francoise; Heymann, Dominique] INSERM, UMR 957, Nantes, France.
   [Gobin, Berengere; Moriceau, Gatien; Ory, Benjamin; Charrier, Celine; Brion, Regis; Blanchard, Frederic; Redini, Francoise; Heymann, Dominique] Nantes Atlantique Univ, Univ Nantes, Nantes, France.
   [Ory, Benjamin; Charrier, Celine; Brion, Regis; Blanchard, Frederic; Redini, Francoise; Heymann, Dominique] Equipe LIGUE Natl Canc 2012, Nantes, France.
   [Brion, Regis; Redini, Francoise; Heymann, Dominique] CHU Nantes, F 44035 Nantes 01, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; Nantes Universite; CHU de Nantes
RP Heymann, D (通讯作者)，INSERM, UMR 957, Nantes, France.
EM dominique.heymann@univ nantes.fr
RI Heymann, Dominique/AAC 6014 2019; ory, benjamin/K 8231 2015; REDINI,
   Francoise/K 7981 2015; Charrier, Céline/K 9198 2015; Blanchard,
   Frederic/K 8018 2015
OI ory, benjamin/0000 0002 2622 7356; Heymann,
   Dominique/0000 0001 7777 0669; Blanchard, Frederic/0000 0003 1055 2573
FU Pharma Novartis (Rueil Malmaison, France); Region des Pays de la Loire;
   INSERM
FX This work was supported by a grant from Pharma Novartis
   (Rueil Malmaison, France) and Berengere Gobin received a PhD fellowship
   from the Region des Pays de la Loire and INSERM. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Ando Kosei, 2013, Cancers (Basel), V5, P591, DOI 10.3390/cancers5020591
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Bond M, 2008, PEDIATR BLOOD CANCER, V50, P254, DOI 10.1002/pbc.21132
   Chawla SP, 2012, J CLIN ONCOL, V30, P78, DOI 10.1200/JCO.2011.35.6329
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Dib IE, 2006, EUR J PHARMACOL, V551, P27, DOI 10.1016/j.ejphar.2006.09.007
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fritsche Guenther R, 2010, HISTOPATHOLOGY, V57, P836, DOI 10.1111/j.1365 2559.2010.03713.x
   Han J, 2013, BIOCHEM BIOPH RES CO, V435, P493, DOI 10.1016/j.bbrc.2013.05.019
   Heymann D., 2011, IBMS BoneKEy, V8, P402
   Hingorani P, 2009, CLIN CANCER RES, V15, P3416, DOI 10.1158/1078 0432.CCR 08 1657
   Joliat MJ, 2002, IN VIVO, V16, P223
   Kamijo A, 2002, CANCER LETT, V188, P213, DOI 10.1016/S0304 3835(02)00433 0
   Kitagawa D, 2013, GENES CELLS, V18, P110, DOI 10.1111/gtc.12022
   KLEIN B, 1977, INT J CANCER, V20, P112, DOI 10.1002/ijc.2910200118
   Kubo T, 2008, CANCER AM CANCER SOC, V112, P2119, DOI 10.1002/cncr.23437
   Kuijjer ML, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 245
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lavenus S, 2011, EUR CELLS MATER, V22, P84, DOI 10.22203/eCM.v022a07
   Lee JA, 2012, CANCER RES TREAT, V44, P202, DOI 10.4143/crt.2012.44.3.202
   Macheda ML, 2008, CURR CANCER DRUG TAR, V8, P454, DOI 10.2174/156800908785699324
   Manara MC, 2010, CLIN CANCER RES, V16, P530, DOI 10.1158/1078 0432.CCR 09 0816
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   McGary EC, 2002, CLIN CANCER RES, V8, P3584
   McQueen P, 2011, EXPERT REV ANTICANC, V11, P1223, DOI [10.1586/era.11.94, 10.1586/ERA.11.94]
   Miiji LNO, 2011, INT J CLIN EXP PATHO, V4, P775
   Mohseny AB, 2011, STEM CELLS, V29, P397, DOI 10.1002/stem.596
   Moriceau G, 2012, CANCER AM CANCER SOC, V118, P750, DOI 10.1002/cncr.26336
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Parkkila S, 2009, BIOORG MED CHEM LETT, V19, P4102, DOI 10.1016/j.bmcl.2009.06.002
   PosthumaDeBoer J, 2013, BRIT J CANCER, V109, P2142, DOI 10.1038/bjc.2013.578
   Rettew AN, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.34
   Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood 2007 07 102061
   ROSEN G, 1976, CANCER AM CANCER SOC, V37, P1, DOI 10.1002/1097 0142(197601)37:1<1::AID CNCR2820370102>3.0.CO;2 3
   Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339
   Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027
   Truitt L, 2011, BIOCHEM CELL BIOL, V89, P115, DOI [10.1139/o10 145, 10.1139/O10 145]
   Vandyke K, 2010, BLOOD, V115, P766, DOI 10.1182/blood 2009 08 237404
   Verweij J, 2003, EUR J CANCER, V39, P2006, DOI 10.1016/S0959 8049(02)00836 5
   Winger JA, 2009, BMC STRUCT BIOL, V9, DOI 10.1186/1472 6807 9 7
   Zhang Y, 2013, INT J IMMUNOPATH PH, V26, P179, DOI 10.1177/039463201302600117
NR 45
TC 40
Z9 42
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2014
VL 9
IS 3
AR e90795
DI 10.1371/journal.pone.0090795
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AC4GP
UT WOS:000332479400132
PM 24599309
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Kim, KJ
   Leutou, AS
   Yeon, JT
   Choi, SW
   Kim, SH
   Yee, ST
   Choi, KH
   Nam, SJ
   Son, YJ
AF Kim, Kwang Jin
   Leutou, Alain Simplice
   Yeon, Jeong Tae
   Choi, Sik Won
   Kim, Seong Hwan
   Yee, Sung Tae
   Choi, Kyung Hee
   Nam, Sang Jip
   Son, Young Jin
TI The Inhibitory Effect of Alisol A 24 Acetate from Alisma
   canaliculatum on Osteoclastogenesis
SO INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID GENE EXPRESSION; DC STAMP; BONE; DIFFERENTIATION; FUSION; NFATC1;
   MECHANISMS; IMMUNE
AB Osteoporosis is a disease that decreases bone mass. The number of patients with osteoporosis has been increasing, including an increase in patients with bone fractures, which lead to higher medical costs. Osteoporosis treatment is all important in preventing bone loss. One strategy for osteoporosis treatment is to inhibit osteoclastogenesis. Osteoclasts are bone resorbing multinucleated cells, and overactive osteoclasts and/or their increased number are observed in bone disorders including osteoporosis and rheumatoid arthritis. Bioactivity guided fractionations led to the isolation of alisol A 24 acetate from the dried tuber of Alisma canaliculatum. Alisol A 24 acetate inhibited RANKL mediated osteoclast differentiation by downregulating NFATc1, which plays an essential role in osteoclast differentiation. Furthermore, it inhibited the expression of DC STAMP and cathepsin K, which are related to cell cell fusion of osteoclasts and bone resorption, respectively. Therefore, alisol A 24 acetate could be developed as a new structural scaffold for inhibitors of osteoclast differentiation in order to develop new drugs against osteoporosis.
C1 [Kim, Kwang Jin; Yee, Sung Tae; Choi, Kyung Hee; Son, Young Jin] Sunchon Natl Univ, Dept Pharm, Sunchon, Jeonnam, South Korea.
   [Leutou, Alain Simplice; Nam, Sang Jip] Ewha Womans Univ, Dept Chem & Nano Sci, Global Top Program 5, Seoul 120750, South Korea.
   [Yeon, Jeong Tae] Sunchon Natl Univ, Res Inst Basic Sci, Sunchon 540742, South Korea.
   [Choi, Sik Won; Kim, Seong Hwan] Korea Res Inst Chem Technol, Lab Translat Therapeut, Pharmacol Res Ctr, Div Drug Discovery Res, Taejon 305600, South Korea.
C3 Sunchon National University; Ewha Womans University; Sunchon National
   University; Korea Research Institute of Chemical Technology (KRICT)
RP Nam, SJ (通讯作者)，Ewha Womans Univ, Dept Chem & Nano Sci, Global Top Program 5, Seoul 120750, South Korea.
EM sjnam@ewha.ac.kr; sony@sunchon.ac.kr
RI ; Jin Ho, Seo/B 3621 2014; Kim, Seong/AAA 6086 2021
OI Leutou, Alain Simplice/0000 0002 2594 9007; Choi,
   Sik Won/0000 0003 1726 2536
FU Ministry of Trade, Industry Energy (MOTIE); Korea Institute for
   Advancement of Technology (KIAT) through the Inter ER Cooperation
   Projects [R0002020]; Suncheon Research Center for Natural Medicines
FX This work was financially supported by the Ministry of Trade, Industry &
   Energy (MOTIE) and Korea Institute for Advancement of Technology (KIAT)
   through the Inter ER Cooperation Projects (R0002020) and the Suncheon
   Research Center for Natural Medicines.
CR Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Ershler W. B., 2000, FRONT BIOMED, V1, P41
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hossain ME, 2012, POULTRY SCI, V91, P3121, DOI 10.3382/ps.2012 02333
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Peng GP, 2003, PHYTOCHEMISTRY, V63, P877, DOI 10.1016/S0031 9422(03)00222 X
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Terasawa K, 1993, Nihon Sanka Fujinka Gakkai Zasshi, V45, P1155
   Upadhyay R. K., 2011, Journal of Pharmacy Research, V4, P1179
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   XIU RJ, 1988, JAMA J AM MED ASSOC, V260, P1755, DOI 10.1001/jama.260.12.1755
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yagi M, 2006, J BONE MINER METAB, V24, P355, DOI 10.1007/s00774 006 0697 9
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yeon JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088974
   [朱国元 Zhu Guoyuan], 2002, [天然产物研究与开发, Natural Product R & Da], V14, P85
NR 30
TC 7
Z9 7
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 8337
EI 1687 8345
J9 INT J ENDOCRINOL
JI Int. J. Endocrinol.
PY 2015
VL 2015
AR 132436
DI 10.1155/2015/132436
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CO5SB
UT WOS:000359217700001
PM 26273291
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Dempster, DW
   Zhou, H
   Rao, SD
   Recknor, C
   Miller, PD
   Leder, BZ
   Annett, M
   Ominsky, MS
   Mitlak, BH
AF Dempster, David W.
   Zhou, Hua
   Rao, Sudhaker D.
   Recknor, Chris
   Miller, Paul D.
   Leder, Benjamin Z.
   Annett, Miriam
   Ominsky, Michael S.
   Mitlak, Bruce H.
TI Early Effects of Abaloparatide on Bone Formation and Resorption Indices
   in Postmenopausal Women With Osteoporosis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANABOLICS; BONE HISTOMORPHOMETRY; BONE MODELING AND REMODELING; CLINICAL
   TRIAL; OSTEOPOROSIS
ID PARATHYROID HORMONE; BASE LINE; TERIPARATIDE; THERAPY; HISTOMORPHOMETRY;
   FRACTURES; DENOSUMAB; TURNOVER; RECEPTOR; UPDATE
AB Anabolic osteoporosis drugs improve bone mineral density by increasing bone formation. The objective of this study was to evaluate the early effects of abaloparatide on indices of bone formation and to assess the effect of abaloparatide on modeling based formation (MBF), remodeling based formation (RBF), and overflow MBF (oMBF) in transiliac bone biopsies. In this open label, single arm study, 23 postmenopausal women with osteoporosis were treated with 80 mu g abaloparatide daily. Subjects received double fluorochrome labels before treatment and before biopsy collection at 3 months. Change in dynamic histomorphometry indices in four bone envelopes were assessed. Median mineralizing surface per unit of bone surface (MS/BS) increased to 24.7%, 48.7%, 21.4%, and 16.3% of total surface after 3 months of abaloparatide treatment, representing 5.5 , 5.2 , 2.8 , and 12.9 fold changes, on cancellous, endocortical, intracortical, and periosteal surfaces (p < .001 versus baseline for all). Mineral apposition rate (MAR) was significantly increased only on intracortical surfaces. Bone formation rate (BFR/BS) was significantly increased on all four bone envelopes. Significant increases versus baseline were observed in MBF on cancellous, endocortical, and periosteal surfaces, for oMBF on cancellous and endocortical surfaces, and for RBF on cancellous, endocortical, and intracortical surfaces. Overall, modeling based formation (MBF + oMBF) accounted for 37% and 23% of the increase in bone forming surface on the endocortical and cancellous surfaces, respectively. Changes from baseline in serum biomarkers of bone turnover at either month 1 or month 3 were generally good surrogates for changes in histomorphometric endpoints. In conclusion, treatment with abaloparatide for 3 months stimulated bone formation on cancellous, endocortical, intracortical, and periosteal envelopes in transiliac bone biopsies obtained from postmenopausal women with osteoporosis. These increases reflected stimulation of both remodeling  and modeling based bone formation, further elucidating the mechanisms by which abaloparatide improves bone mass and lowers fracture risk. (c) 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Dempster, David W.; Zhou, Hua] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY USA.
   [Rao, Sudhaker D.] Henry Ford Hlth Syst, Bone & Mineral Res Lab, Detroit, MI USA.
   [Recknor, Chris] United Osteoporosis Ctrs, Gainesville, GA USA.
   [Miller, Paul D.] Colorado Ctr Bone Hlth, Lakewood, CO USA.
   [Leder, Benjamin Z.] Harvard Med Sch, Mass Gen Hosp, Boston, MA 02115 USA.
   [Annett, Miriam; Ominsky, Michael S.; Mitlak, Bruce H.] Radius Hlth Inc, 22 Boston Wharf Rd,7th Floor, Boston, MA 02210 USA.
C3 Henry Ford Health System; Henry Ford Hospital; Harvard University;
   Harvard Medical School; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Radius Health, Inc.
RP Mitlak, BH (通讯作者)，Radius Hlth Inc, 22 Boston Wharf Rd,7th Floor, Boston, MA 02210 USA.
EM bmitlak@radiuspharm.com
RI Rao, Sudhaker/ABG 8204 2021
OI Dempster, David/0000 0002 2262 4039; Mitlak, Bruce/0000 0001 7050 0703;
   Leder, Benjamin/0000 0002 2051 0505; Rao, Sudhaker/0000 0002 2200 1800
FU Radius Health, Inc.
FX Funding for this study (NCT03710889, available from
   www.clinicaltrials.gov) was provided by Radius Health, Inc. All listed
   authors meet the criteria for authorship set forth by the International
   Committee for Medical Journal Editors. Editorial support (Sarah
   Hummasti, PhD) and graphic services were provided by AOIC, LLC, and were
   funded by Radius Health, Inc.
CR Arlt H, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100291
   Besschetnova T, 2019, BONE, V124, P148, DOI 10.1016/j.bone.2019.04.025
   Boyce RW, 1996, J BONE MINER RES, V11, P600
   Camacho PM, 2020, ENDOCR PRACT, V26, P564, DOI 10.4158/GL 2020 0524
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Cosman F, 2017, J BONE MINER RES, V32, P17, DOI 10.1002/jbmr.2991
   Cosman F, 2016, J CLIN ENDOCR METAB, V101, P1498, DOI 10.1210/jc.2015 3698
   Deal CL, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100230
   Dempster D, 2017, J BONE MINER RES, V32, pS268
   Dempster DW, 2018, J BONE MINER RES, V33, P298, DOI 10.1002/jbmr.3309
   Dempster DW, 2016, J CLIN ENDOCR METAB, V101, P1353, DOI 10.1210/jc.2015 4181
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dempster DW, 2012, J CLIN ENDOCR METAB, V97, P2799, DOI 10.1210/jc.2012 1262
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Doyle N, 2018, OSTEOPOROSIS INT, V29, P685, DOI 10.1007/s00198 017 4323 6
   Eastell R, 2019, OSTEOPOROSIS INT, V30, P667, DOI 10.1007/s00198 018 04819 1
   Eriksen EF, 2019, J BONE MINER RES, V34, P17
   Hauge EM, 2001, BONE, V28, P556, DOI 10.1016/S8756 3282(01)00424 0
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Moreira CA, 2017, BONE, V97, P314, DOI 10.1016/j.bone.2016.11.004
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Rizzoli R, 2001, J MOL ENDOCRINOL, V26, P79, DOI 10.1677/jme.0.0260079
   Rubin MR, 2011, J BONE MINER RES, V26, P2727, DOI 10.1002/jbmr.452
   Varela A, 2017, J BONE MINER RES, V32, P24, DOI 10.1002/jbmr.3003
   Winzenrieth R, 2021, OSTEOPOROSIS INT, V32, P575, DOI 10.1007/s00198 020 05806 1
NR 31
TC 28
Z9 33
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2021
VL 36
IS 4
BP 644
EP 653
DI 10.1002/jbmr.4243
EA JAN 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA RL9YV
UT WOS:000612489500001
PM 33434314
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Liu, D
   Cao, F
   Li, H
   Tao, L
   Zhu, Y
AF Liu, D.
   Cao, F.
   Li, H.
   Tao, L.
   Zhu, Y.
TI Employing single cell RNA sequencing coupled with an array of
   bioinformatics approaches to ascertain the shared genetic
   characteristics between osteoporosis and obesity
SO BONE & JOINT RESEARCH
LA English
DT Article
ID TOTAL HIP ARTHROPLASTY; BONE; PACKAGE
AB Aims This study examined the relationship between obesity (OB) and osteoporosis (OP), aiming to identify shared genetic markers and molecular mechanisms to facilitate the development of therapies that target both conditions simultaneously. Methods Using weighted gene co expression network analysis (WGCNA), we analyzed datasets from the Gene Expression Omnibus (GEO) database to identify co expressed gene modules in OB and OP. These modules underwent Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and protein protein interaction analysis to discover Hub genes. Machine learning refined the gene selection, with further validation using additional datasets. Single cell analysis emphasized specific cell subpopulations, and enzyme linked immunosorbent assay (ELISA), protein blotting, and cellular staining were used to investigate key genes. Results WGCNA revealed critical gene modules for OB and OP, identifying the Toll like receptor (TLR) TLR ) signalling pathway as a common factor. TLR2 was the most significant gene, with a pronounced expression in macrophages. Elevated TLR2 expression correlated with increased adipose accumulation, inflammation, and osteoclast differentiation, linking it to OP development. Conclusion Our study underscores the pivotal role of TLR2 in connecting OP and OB. It highlights the influence of TLR2 in macrophages, driving both diseases through a pro inflammatory mechanism. These insights propose TLR2 as a potential dual therapeutic target for treating OP and OB.
C1 [Liu, D.; Cao, F.; Li, H.; Tao, L.; Zhu, Y.] China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Peoples R China.
C3 China Medical University
RP Zhu, Y (通讯作者)，China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Peoples R China.
EM zhuyuedr@163.com
FU National Natural Science Foundation of China [32200943, 82072387];
   Shenyang Young and Middle aged Innovative Talent Project [RC210171]
FX Funding statement The authors disclose receipt of the following
   financial or material support for the research, authorship, and/or
   publication of this article: funding from the National Natural Science
   Foundation of China (32200943, 82072387) and the Shenyang Young and
   Middle aged Innovative Talent Project (RC210171) .
CR Abe S, 2022, BONE JOINT OPEN, V3, P261, DOI 10.1302/2633 1462.33.BJO 2022 0004.R1
   AlQranei MS, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865 021 00409 9
   Alquicira Hernandez J, 2021, BIOINFORMATICS, V37, P2485, DOI 10.1093/bioinformatics/btab003
   [Anonymous], 2023, STRING FUNCTIONAL PR
   Arabpour M, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107823
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Braun T, 2012, CURR OSTEOPOROS REP, V10, P101, DOI 10.1007/s11914 012 0104 5
   Bukowski BR, 2023, BONE JOINT J, V105B, P254, DOI [10.1302/0301 620X.105B3.BJJ 2022 0870.R1, 10.1302/0301 620X.105B3.BJJ 2022 0870]
   Cândido FG, 2014, INT J MOL SCI, V15, P6569, DOI 10.3390/ijms15046569
   Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978 1 4939 7493 1_12
   Chen L, 2023, ACS NANO, V17, P3153, DOI 10.1021/acsnano.2c12440
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Cohen A, 2013, J CLIN ENDOCR METAB, V98, P2562, DOI 10.1210/jc.2013 1047
   Colleselli K, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241512464
   Dai X, 2023, BONE JOINT RES, V12, P580, DOI 10.1302/2046 3758.129.BJR 2023 0102.R1
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Fintini D, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00200
   Gao DY, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01102
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Goulding A, 2005, J BONE MINER RES, V20, P2090, DOI 10.1359/JBMR.050820
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Guerrero Romero F, 2023, MOL BIOL REP, V50, P4723, DOI 10.1007/s11033 023 08338 z
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Howe AM, 2022, MOL NEUROBIOL, V59, P2348, DOI 10.1007/s12035 022 02756 z
   Jialal I, 2014, J CLIN ENDOCR METAB, V99, P39, DOI 10.1210/jc.2013 3092
   Kan B, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04643 5
   Kanehisa M, 2023, NUCLEIC ACIDS RES, V51, pD587, DOI 10.1093/nar/gkac963
   Kassem A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156708
   Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647
   Kawai T, 2021, AM J PHYSIOL CELL PH, V320, pC375, DOI 10.1152/ajpcell.00379.2020
   Kong XR, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 31413 1
   Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592 019 0619 0
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Lim KH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011247
   Lim WK, 2007, BIOINFORMATICS, V23, pI282, DOI 10.1093/bioinformatics/btm201
   Liu GW, 2023, CRIT REV FOOD SCI, V63, P10032, DOI 10.1080/10408398.2022.2074961
   Lu LY, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.788576
   Lu Q, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.684976
   Madel MB, 2023, ELIFE, V12, DOI 10.7554/eLife.82037
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Mogensen UB, 2012, J STAT SOFTW, V50, P1
   Mu L, 2021, CIRC CARDIOVASC QUAL, V14, DOI 10.1161/CIRCOUTCOMES.120.007292
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev physiol 022516 034339
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Pliner HA, 2019, NAT METHODS, V16, P983, DOI 10.1038/s41592 019 0535 3
   Qiu XJ, 2017, NAT METHODS, V14, P309, DOI [10.1038/NMETH.4150, 10.1038/nmeth.4150]
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Sang L, 2018, WORLD J GASTROENTERO, V24, P2605, DOI 10.3748/wjg.v24.i24.2605
   Simon SM, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 30313 8
   Watanabe N, 2022, BONE JOINT RES, V11, P873, DOI 10.1302/2046 3758.1112.BJR 2022 0252.R1
   Williamson TK, 2022, BONE JOINT J, V104B, P1249, DOI 10.1302/0301 620X.104B11.BJJ 2022 0574.R1
   Xiang CG, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106566
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Xie H, 2023, BONE JOINT RES, V12, P423, DOI 10.1302/2046 3758.127.BJR 2022 0420.R1
   Xu ZY, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1140804
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang SL, 2023, IMMUN INFLAMM DIS, V11, DOI 10.1002/iid3.992
   Zhang YQ, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/nargab/lqaa078
   Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007
NR 60
TC 0
Z9 0
U1 4
U2 10
PU BRITISH EDITORIAL SOC BONE & JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD OCT
PY 2024
VL 13
IS 10
BP 573
EP 587
DI 10.1302/2046 3758.1310.BJR 2023 0366.R1
PG 15
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA J2V8Y
UT WOS:001335704800001
PM 39412449
OA gold
DA 2025 08 17
ER

PT J
AU Brunova, J
   Kratochvilova, S
   Stepankova, J
AF Brunova, Jana
   Kratochvilova, Simona
   Stepankova, Jitka
TI Osteoporosis Therapy With Denosumab in Organ Transplant Recipients
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE osteoporosis; denosumab; solid organ transplantation; monoclonal
   antibody; dual energy X ray absorptiometry
ID MINERAL DENSITY LOSS; RENAL TRANSPLANTATION; BONE DISEASE;
   POSTMENOPAUSAL WOMEN; KIDNEY; PREVENTION; MANAGEMENT
AB Objective: Osteoporosis and fragility fractures represent serious complications for the solid organ transplant population. The recommended osteoporosis therapy for organ recipients involves supplementation with calcium and vitamin D and bisphosphonate administration. However, these options can prove limited for patients with impaired renal function. An alternative therapy option is offered by denosumab, a monoclonal antibody that targets receptor activator of nuclear factor kappa B ligand.
   Patients and methods: We evaluated 63 patients with osteoporosis (23 males and 40 females, age 56.4 +/  13.1 years) following solid organ transplantation (15 diabetic patients after simultaneous transplantation of the kidney and pancreas, 34 patients after kidney transplantation, and 14 patients with liver grafts). Osteoporosis was diagnosed according to standard DEXA examination using the Lunar Prodigy apparatus. Transplanted patients with impaired renal function were treated for osteoporosis of the lumbar spine (L spine) and/or proximal femur with calcium and vitamin D supplementation and 60 mg of denosumab every 6 months between the years 2012 and 2017. The mean duration of the therapy was 1.65 +/  0.7 years.
   Results: After denosumab therapy, L spine T scores improved across the whole group, ranging from  2.7 +/  0.09 to  1.8 +/  1.0 (p < 0.001). T score values for the proximal femur increased from  2.5 +/  0.8 to  2.0 +/  0.7 after the therapy (p < 0.01). We observed only a mild, statistically insignificant improvement in distal forearm T scores. The mean increase in L spine bone mineral density (BMD) was 11.5 +/  6.2% in subjects with osteoporosis at this site and 10.4 +/  6.1% in the case of all patients. BMD of the proximal femur increased by 10.4 +/  8.3% in patients with osteoporosis and by 7.5 +/  7.3% in all patients. Denosumab therapy decreased the prevalence of osteoporosis in the L spine from 75 to 27% (p < 0.001) and proximal femur osteoporosis from 54 to 36% (p < 0.05). Denosumab therapy reduced elevated levels of osteocalcin and beta crosslaps (beta CTX) in comparison with baseline levels (p < 0.001) across the whole group of graft recipients.
   Conclusion: Denosumab therapy was well tolerated and improved bone density in our group of solid organ transplant recipients. The indications are that denosumab could be a viable therapeutic option for transplanted patients with osteoporosis, especially in those with renal function impairment or bisphosphonate intolerance.
C1 [Brunova, Jana; Kratochvilova, Simona; Stepankova, Jitka] Inst Clin & Expt Med IKEM, Prague, Czech Republic.
C3 Institute for Clinical & Experimental Medicine (IKEM)
RP Brunova, J (通讯作者)，Inst Clin & Expt Med IKEM, Prague, Czech Republic.
EM jabv@medicon.cz
FU Ministry of Health, Czech Republic conceptual development of research
   organization ("Institute for Clinical and Experimental Medicine IKEM")
   [IN 00023001]
FX Supported by Ministry of Health, Czech Republic conceptual development
   of research organization ("Institute for Clinical and Experimental
   Medicine IKEM, IN 00023001").
CR Alis G, 2017, TRANSPL P, V49, P509, DOI 10.1016/j.transproceed.2017.01.040
   Alshayeb HM, 2013, AM J KIDNEY DIS, V61, P310, DOI 10.1053/j.ajkd.2012.07.022
   Bonani M, 2016, AM J TRANSPLANT, V16, P1882, DOI 10.1111/ajt.13692
   Bonani M, 2012, TRANSPLANTATION, V94, P887, DOI 10.1097/00007890 201211271 01745
   Bonani M, 2017, TRANSPLANTATION, V101, P2139, DOI 10.1097/TP.0000000000001547
   Bonani M, 2016, KIDNEY BLOOD PRESS R, V41, P614, DOI 10.1159/000447930
   Brunova J, 2016, OSTEOL B, V21, P111
   Carlini RG, 2000, AM J KIDNEY DIS, V36, P160, DOI 10.1053/ajkd.2000.8289
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Damasiewicz MJ, 2017, NEPHROLOGY, V22, P65, DOI 10.1111/nep.13028
   Dave V, 2015, AM J NEPHROL, V41, P129, DOI 10.1159/000380960
   Dounousi E, 2015, INT UROL NEPHROL, V47, P503, DOI 10.1007/s11255 014 0862 3
   Early C, 2016, OSTEOPOROSIS INT, V27, P1425, DOI 10.1007/s00198 015 3367 8
   Ebeling PR, 2009, J CLIN ENDOCR METAB, V94, P1483, DOI 10.1210/jc.2009 0205
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Faienza MF, 2018, EXPERT OPIN BIOL TH, V18, P149, DOI 10.1080/14712598.2018.1401607
   Gregorini M, 2017, TRANSPL P, V49, P650, DOI 10.1016/j.transproceed.2017.02.023
   Jamal SA, 2012, CURR RHEUMATOL REP, V14, P217, DOI 10.1007/s11926 012 0243 9
   Kantalar Zadeh K, 2012, CURR OPIN NEPHROL HY, V21, P389, DOI [10.1097/MNH.0b013e3283546ee0, DOI 10.1097/MNH.0B013E3283546EE0]
   Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006
   Khan A, 2016, OSTEOPOROSIS INT, V27, P853, DOI 10.1007/s00198 015 3335 3
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003 4819 150 9 200905050 00006
   Löfdahl E, 2017, TRANSPLANT REV ORLAN, V31, P232, DOI 10.1016/j.trre.2017.08.002
   Lou I, 2015, ANN SURG, V262, P653, DOI 10.1097/SLA.0000000000001431
   Monegal A, 2013, CALCIFIED TISSUE INT, V93, P571, DOI 10.1007/s00223 013 9797 4
   Kulak CAM, 2012, CURR OSTEOPOROS REP, V10, P48, DOI 10.1007/s11914 011 0083 y
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Perrin P, 2013, AM J TRANSPLANT, V13, P2653, DOI 10.1111/ajt.12425
   Rocha A, 2016, J BONE MINER METAB, V34, P209, DOI 10.1007/s00774 015 0657 3
   Wada Y, 2016, TOHOKU J EXP MED, V238, P205, DOI 10.1620/tjem.238.205
NR 30
TC 37
Z9 40
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD APR 17
PY 2018
VL 9
AR 162
DI 10.3389/fendo.2018.00162
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GD0PQ
UT WOS:000430203100001
PM 29720961
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Guo, HH
   Zhang, J
   Hao, SW
   Jin, QH
AF Guo, Haohui
   Zhang, Jian
   Hao, Shaowen
   Jin, Qunhua
TI Adenovirus mediated small interfering RNA targeting tumor necrosis
   factor α inhibits titanium particle induced osteoclastogenesis and bone
   resorption
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE tumor necrosis factor alpha; osteoclast; RAW264.7 macrophages; NFATc1;
   small interfering RNA; titanium particles osteolysis; osteoclast
ID FACTOR KAPPA B; COLONY STIMULATING FACTOR; TNF ALPHA; PERIPROSTHETIC
   OSTEOLYSIS; RECEPTOR ACTIVATOR; GENE THERAPY; OSTEOBLAST
   DIFFERENTIATION; NUCLEAR FACTOR; RANK LIGAND; OSTEOPROTEGERIN LIGAND
AB Wear particles are phagocytosed by macrophages, resulting in cellular activation and the release of pro inflammatory factors, which cause periprosthetic osteolysis and subsequent aseptic loosening, the most common causes of total joint arthroplasty (TJA) failure. During this pathological process, tumor necrosis factor (TNF) alpha plays an important role in wear particle induced osteolysis. Therefore, in this study, we used adenovirus mediated small interfering RNA (siRNA) targeting TNF alpha to suppress the TNF alpha release from activated macrophages in response to titanium particles. Our results showed that recombinant adenovirus (Ad TNF alpha siRNA) suppressed the TNF alpha release from activated macrophages in response to titanium particles, and reduced titanium particle induced osteoclastogenesis and bone resorption in the presence of receptor activator of nuclear factor kappa B ligand (RANKL). In addition, the conditioned medium of macrophages challenged with titanium particles (Ti CM) stimulated osteoprogenitor RANKL expression. The conditioned medium of macrophages challenged with titanium particles and Ad TNF alpha siRNA (Ti Ad CM) reduced the mRNA expression in MC3T3 E1 cells compared to Ti CM. Based on these data, TNF alpha strongly synergizes with RANKL to promote osteoclast differentiation. Furthermore, TNF alpha promoted osteoclast differentiation by stimulating osteoprogenitor RANKL expression. Ad TNF alpha siRNA effectively suppressed osteoclast differentiation and bone resorption following exposure to titanium particles in the presence of RANKL. In addition, recombinant adenovirus (Ad TNF alpha siRNA) does not have a toxic effect on the murine macrophage cell line, RAW264.7. Consequently, it can be concluded that recombinant adenovirus mediated siRNA targeting TNF alpha (Ad TNF alpha siRNA) may provide a novel therapeutic approach for the treatment of periprosthetic osteolysis.
C1 [Guo, Haohui; Hao, Shaowen; Jin, Qunhua] Ningxia Med Univ, Affiliated Hosp, Dept Orthoped Surg, Yinchuan, Peoples R China.
   [Zhang, Jian] Xi An Jiao Tong Univ, Sch Med, Dept Pathol, Xian 710049, Peoples R China.
C3 Ningxia Medical University; Xi'an Jiaotong University
RP Jin, QH (通讯作者)，Ningxia Med Univ, Affiliated Hosp, Yinchuan, Peoples R China.
EM jinqunhua@sina.com
OI Jin, Qunhua/0000 0001 7616 3357
FU National Natural Science Foundation of China (NSFC) [81060146]
FX This study was supported by the National Natural Science Foundation of
   China (NSFC, grant no. 81060146).
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Abu Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417
   Abu Amer Yousef, 2005, Current Drug Targets   Immune Endocrine and Metabolic Disorders, V5, P347, DOI 10.2174/1568008054863808
   AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   ALI M, 1994, GENE THER, V1, P367
   AlSaffar N, 1996, AM J CLIN PATHOL, V105, P628
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Archibeck M J, 2001, Instr Course Lect, V50, P185
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   BANDARA G, 1992, DNA CELL BIOL, V11, P227, DOI 10.1089/dna.1992.11.227
   BANDARA G, 1993, P NATL ACAD SCI USA, V90, P10764, DOI 10.1073/pnas.90.22.10764
   Bao JJ, 1996, HUM GENE THER, V7, P355, DOI 10.1089/hum.1996.7.3 355
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Evans CH, 2009, MOL THER, V17, P231, DOI 10.1038/mt.2008.265
   Friedman R J, 1994, Instr Course Lect, V43, P233
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Gallo J, 2008, PHYSIOL RES, V57, P339, DOI 10.33549/physiolres.931140
   Gallo Jiri, 2002, Biomedical Papers (Olomouc), V146, P21
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   GOLDRING SR, 1993, J BONE JOINT SURG AM, V75A, P799, DOI 10.2106/00004623 199306000 00001
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Hallab NJ, 2009, BULL HOSP JT DIS, V67, P182
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Hikiji H, 2000, AM J PHYSIOL ENDOC M, V278, pE1031, DOI 10.1152/ajpendo.2000.278.6.E1031
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Jacobs JJ, 2001, CLIN ORTHOP RELAT R, P71
   Kadoya Y, 1998, ACTA ORTHOP SCAND, V69, P1
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kaufman AM, 2008, J BIOMED MATER RES A, V84A, P464, DOI 10.1002/jbm.a.31467
   KIM KJ, 1993, CLIN ORTHOP RELAT R, P142
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190
   Kurokouchi K, 1998, J BONE MINER RES, V13, P1290, DOI 10.1359/jbmr.1998.13.8.1290
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Lee SS, 2003, CELL SIGNAL, V15, P339, DOI 10.1016/S0898 6568(02)00118 3
   Liu FX, 2009, BIOMATERIALS, V30, P1756, DOI 10.1016/j.biomaterials.2008.12.018
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Rakshit DS, 2006, J BONE JOINT SURG AM, V88A, P788, DOI 10.2106/JBJS.E.00711
   Sabokbar A, 1995, J ARTHROPLASTY, V10, P810, DOI 10.1016/S0883 5403(05)80080 4
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   SHANBHAG AS, 1995, J ARTHROPLASTY, V10, P498, DOI 10.1016/S0883 5403(05)80152 4
   SMITH AE, 1995, ANNU REV MICROBIOL, V49, P807
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Taki N, 2007, BONE, V40, P1276, DOI 10.1016/j.bone.2006.12.053
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wang W, 1997, J BONE JOINT SURG BR, V79B, P849, DOI 10.1302/0301 620X.79B5.7780
   Xu JW, 1996, CLIN EXP RHEUMATOL, V14, P643
   Yamanaka Y, 2008, J ORTHOP RES, V26, P1577, DOI 10.1002/jor.20714
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 79
TC 10
Z9 10
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD AUG
PY 2013
VL 32
IS 2
BP 296
EP 306
DI 10.3892/ijmm.2013.1416
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 190VR
UT WOS:000322370800005
PM 23760678
OA Bronze
DA 2025 08 17
ER

PT J
AU Luo, Q
   Kang, Q
   Song, WX
   Luu, HH
   Luo, XJ
   An, NL
   Luo, JY
   Deng, ZL
   Jiang, W
   Yin, H
   Chen, J
   Sharff, KA
   Tang, N
   Bennett, E
   Haydon, RC
   He, TC
AF Luo, Qing
   Kang, Quan
   Song, Wen Xin
   Luu, Hue H.
   Luo, Xiaoji
   An, Naili
   Luo, Jinyong
   Deng, Zhong Liang
   Jiang, Wei
   Yin, Hong
   Chen, Jin
   Sharff, Katie A.
   Tang, Ni
   Bennett, Erwin
   Haydon, Rex C.
   He, Tong Chuan
TI Selection and validation of optimal siRNA target sites for RNAi mediated
   gene silencing
SO GENE
LA English
DT Article
DE beta catenin signaling; expression knockdown; RNA interference; short
   interfering RNA; Wnt signaling
ID SMALL INTERFERING RNA; OSTEOBLAST DIFFERENTIATION; STABLE SUPPRESSION;
   MAMMALIAN CELLS; BETA CATENIN; EXPRESSION; SYSTEM; IDENTIFICATION;
   INHIBITOR; LIBRARIES
AB RNA interference (RNAi) mediated gene silencing has become a valuable tool for functional studies, reverse genomics, and drug discoveries. One major challenge of using RNAi is to identify the most effective short interfering RNAs (siRNAs) sites of a given gene. Although several published bioinformatic prediction models have proven useful, the process to select and validate optimal siRNA sites for a given gene remains empirical and laborious. Here, we developed a fluorescence based selection system using a retroviral vector backbone, namely pSOS, which was based on the premise that candidate siRNAs would knockdown the chimeric transcript between GFP and target gene. The expression of siRNA was driven by the opposing convergent H1 and U6 promoters. This configuration simplifies the cloning of duplex siRNA oligonucleotide cassettes. We demonstrated that GFP signal reduction was closely correlated with siRNA knockdown efficiency of human beta catenin, as well as with the inhibition of beta catenin/TcA signaling activity. The pSOS should not only facilitate the selection and validation of candidate siRNA sites, but also provide efficient delivery tools of siRNAs via viral vectors in mammalian cells. Thus, the pSOS system represents an efficient and user friendly strategy to select and validate siRNA target sites. (c) 2007 Elsevier B.V. All rights reserved.
C1 Chongqing Univ Med Sci, Childrens Hosp, Chongqing 400016, Peoples R China.
   Chongqing Univ Med Sci, Minist Educ, Key Lab Diagnost Med, Chongqing 400016, Peoples R China.
   Univ Chicago, Med Ctr, Dept Surg, Oncol Mol Lab, Chicago, IL 60637 USA.
   Scripps Res Inst, La Jolla, CA 92037 USA.
C3 Chongqing Medical University; Chongqing Medical University; University
   of Chicago; University of Chicago Medical Center; Scripps Research
   Institute
RP He, TC (通讯作者)，Chongqing Univ Med Sci, Childrens Hosp, Chongqing 400016, Peoples R China.
EM tche@surgery.bsd.uchicago.edu
CR Aravin A, 2005, FEBS LETT, V579, P5830, DOI 10.1016/j.febslet.2005.08.009
   Arziman Z, 2005, NUCLEIC ACIDS RES, V33, pW582, DOI 10.1093/nar/gki468
   Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040
   Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535 6108(02)00122 8
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Chen MH, 2005, P NATL ACAD SCI USA, V102, P2356, DOI 10.1073/pnas.0401549101
   Dillon CP, 2005, ANNU REV PHYSIOL, V67, P147, DOI 10.1146/annurev.physiol.67.040403.130716
   Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129
   Echeverri CJ, 2006, NAT REV GENET, V7, P373, DOI 10.1038/nrg1836
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017
   Kaykas A, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471 2121 5 16
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502 500
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Mäkinen PI, 2006, J GENE MED, V8, P433, DOI 10.1002/jgm.860
   Medema RH, 2004, BIOCHEM J, V380, P593, DOI 10.1042/BJ20040260
   Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872
   Montgomery Mary K, 2004, Methods Mol Biol, V265, P3
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535 6108(02)00092 2
   Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399
   Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502 505
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Sandy P, 2005, BIOTECHNIQUES, V39, P215, DOI 10.2144/05392RV01
   Scherer LJ, 2003, NAT BIOTECHNOL, V21, P1457, DOI 10.1038/nbt915
   Seyhan AA, 2005, RNA, V11, P837, DOI 10.1261/rna.7285805
   Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599
   Sui G, 2005, METH MOL B, V309, P205
   Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528
   Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619
   Tran N, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472 6750 3 21
   van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865
   Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901 746
   Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100
   Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304 3835(03)00013 2
   Zhou L, 2002, BIOTECHNIQUES, V33, P1126, DOI 10.2144/02335dd07
NR 43
TC 73
Z9 109
U1 0
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD JUN 15
PY 2007
VL 395
IS 1 2
BP 160
EP 169
DI 10.1016/j.gene.2007.02.030
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 174HU
UT WOS:000246933800018
PM 17449199
DA 2025 08 17
ER

PT J
AU Takasu, H
AF Takasu, Hisashi
TI Anti osteoclastogenic action of active vitamin D
SO NUTRITION REVIEWS
LA English
DT Article; Proceedings Paper
CT 22nd Marabou Symposium on the Changing Faces of Vitamin D
CY JUN 01 03, 2007
CL Stockholm, SWEDEN
DE active vitamin D; c Fos; osteoclastogenesis
ID BONE RESORPTION; 1,25 DIHYDROXYVITAMIN D 3; DOUBLE BLIND; RAT MODEL;
   OSTEOPOROSIS; ALFACALCIDOL; SUPPLEMENTATION; FRACTURES; ESTROGEN; ANALOG
AB Active vitamin D and its analogs, which have been recognized to potentiate both bone resorption and formation, increase bone volume by inhibiting accelerated bone resorption at pharmacological doses. This mechanism is, at least in part, independent of intestinal and renal calcium regulating activities. The study described here found that active vitamin D directly acts upon osteoclast precursor cells and suppresses their differentiation in vitro. Screening vitamin D analogs for this activity led to a new candidate of bone effective drug, suggesting the importance of this activity even in vivo. These findings provide new insight into understanding the effect of vitamin D on bone and the possibility of using active vitamin D as a therapeutic agent. (C) 2008 International Life Sciences Institute.
C1 Fuji Gotemba Res Lab, Chugai Pharmaceut Co Ltd, Shizuoka 4128513, Japan.
C3 Chugai Pharmaceutical Co., Ltd.; Roche Holding; Roche Holding Japan
RP Takasu, H (通讯作者)，Fuji Gotemba Res Lab, Chugai Pharmaceut Co Ltd, 1 135 Komakado, Shizuoka 4128513, Japan.
EM takasuhss@chugai pharm.co.jp
CR Endo KI, 2000, J BONE MINER RES, V15, P175, DOI 10.1359/jbmr.2000.15.1.175
   Häuselmann HJ, 2003, OSTEOPOROSIS INT, V14, P2, DOI 10.1007/s00198 002 1301 3
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Matsumoto T, 2005, J CLIN ENDOCR METAB, V90, P5031, DOI 10.1210/jc.2004 2552
   Papadimitropoulos E, 2002, ENDOCR REV, V23, P560, DOI 10.1210/er.2001 8002
   RAISZ LG, 1972, SCIENCE, V175, P768, DOI 10.1126/science.175.4023.768
   Shiraishi A, 2000, J BONE MINER RES, V15, P770, DOI 10.1359/jbmr.2000.15.4.770
   Shiraishi A, 1999, CALCIFIED TISSUE INT, V65, P311, DOI 10.1007/s002239900704
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201
   Trivedi DP, 2003, BMJ BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469
   Uchiyama Y, 2002, BONE, V30, P582, DOI 10.1016/S8756 3282(02)00682 8
   Ueno Y, 2003, J CELL BIOCHEM, V90, P267, DOI 10.1002/jcb.10623
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897 391
NR 15
TC 5
Z9 6
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0029 6643
J9 NUTR REV
JI Nutr. Rev.
PD OCT
PY 2008
VL 66
IS 10
SU 2
BP S113
EP S115
DI 10.1111/j.1753 4887.2008.00098.x
PG 3
WC Nutrition & Dietetics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 353GJ
UT WOS:000259553800004
PM 18844837
OA Bronze
DA 2025 08 17
ER

PT J
AU Wichelmann, TA
   Ahdi, HS
   Pandravada, S
   Ehrenpreis, ED
AF Wichelmann, Thomas Adam
   Ahdi, Hardeep S.
   Pandravada, Sasirekha
   Ehrenpreis, Eli D.
TI A Summary of the Rare Reports of Osteonecrosis of the Jaw Associated
   With Tumor Necrosis a Inhibitors in the United States Food and Drug
   Administration's Adverse Event Reporting System Database
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID MEDICATION RELATED OSTEONECROSIS; RHEUMATOID ARTHRITIS; RISK FACTORS
AB Purpose: Recent case reports highlight an association between osteonecrosis of the jaw (ONJ) and antitumor necrosis factor (anti TNF) medications. Our study reviewed and described reports of anti TNF associated ONJ reported to the United States of America's Food and Drug Administration Adverse Event Reporting System to explore this potential adverse drug reaction further.
   Methods: Using the Food and Drug Administration Adverse Event Reporting System database, we identified reported cases of ONJ between 2010 and 2021. Cases were included in our study if they reported any prior or concomitant anti TNF medication use. Additionally, only adults (age 18+) and reports from healthcare professionals were included. Cases lacking subject age or gender were excluded. After duplicates were removed, a dataset was created and demographics were described including age, gender, and indication for use. Naranjo scoring was conducted to assess adverse drug reaction probability. Subject demographics were then separately described for cases without reported denosumab or bisphosphonate therapy history and compared to those with reported history or concomitant denosumab or bisphosphonate therapy.
   Results: Over twenty thousand cases of ONJ were reported. Forty four potential cases (0.22%) of anti TNF medication associated ONJ were identified and reviewed. Of these, female gender comprised 77.3% (35 cases) and there was an average age of 61.3 years +/  13.7 years. Twenty cases (45.5%) had no prior/concomitant bisphosphonate or denosumab therapy. Of these, 55% (11 cases) were female and the average age was 54.5 +/  17.3 years. Rheumatoid arthritis was the most frequent indication for use (5 cases, 25%) followed by inflammatory bowel disease (IBD) and psoriatic arthritis (4 cases each, 20%) in this cohort.
   Conclusions: Twenty potential cases of anti TNF associated ONJ without prior or concomitant medications known to be associated with ONJ were identified and described. Interestingly, male gender was more frequent and subjects were younger in these cases compared to those with prior/concomitant bisphosphonates or denosumab therapy. Naranjo scoring indicated a probable interaction for three cases. Further studies are needed to clarify the association of ONJ and anti TNF therapy, including investigating potential mechanisms and reporting future cases with sufficient detail to assess possible confounding factors.
   (c) 2023 Published by Elsevier Inc. on behalf of the American Association of Oral and Maxillofacial Surgeons
C1 [Wichelmann, Thomas Adam; Ahdi, Hardeep S.; Pandravada, Sasirekha] Advocate Lutheran Gen Hosp, Dept Internal Med, Park Ridge, IL USA.
   [Ehrenpreis, Eli D.] Advocate Lutheran Gen Hosp, Dept Internal Med, Res & Scholarly Act, Park Ridge, IL 60068 USA.
   E2Bio Life Sci, Evanston, IL USA.
RP Ehrenpreis, ED (通讯作者)，Advocate Lutheran Gen Hosp, Dept Internal Med, Res & Scholarly Act, Park Ridge, IL 60068 USA.
EM e2bioconsults@gmail.com
RI Ehrenpreis, Eli/F 4586 2017
OI , Thomas/0000 0003 3732 9478
CR Aghaloo T, 2015, ORAL MAXIL SURG CLIN, V27, P489, DOI 10.1016/j.coms.2015.06.001
   Alatawi YM, 2017, EXPERT OPIN DRUG SAF, V16, P761, DOI 10.1080/14740338.2017.1323867
   [Anonymous], Questions and Answers on FDA's adverse event reporting system (FAERS)
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Brijs K, 2020, INT J ORAL MAX SURG, V49, P317, DOI 10.1016/j.ijom.2019.08.007
   Dennison EM, 1998, BMJ BRIT MED J, V316, P789, DOI 10.1136/bmj.316.7134.789
   Favia G, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.905355
   Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242
   Ganesan K., 2021, StatPearls
   Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128
   Hanauer SB, 2002, GUT, V51, P182, DOI 10.1136/gut.51.2.182
   Kaibuchi N, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101072
   Kang MH, 2018, J KOR ASSOC ORAL MAX, V44, P225, DOI 10.5125/jkaoms.2018.44.5.225
   Kruchko DH, 2020, GastroHep, V2, P117
   Li J, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.746396
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Murayama H, 2018, PHARMACOL RES PERSPE, V6, DOI 10.1002/prp2.373
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Patek TM, 2020, DRUG SAFETY, V43, P17, DOI 10.1007/s40264 019 00873 8
   Preidl RHM, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471 230X 14 6
   Rogers JR, 2019, DRUG SAFETY, V42, P85, DOI 10.1007/s40264 018 0703 x
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Sacco R, 2020, BRIT J ORAL MAX SURG, V58, P25, DOI 10.1016/j.bjoms.2019.09.023
   Solomon DH, 2013, OSTEOPOROSIS INT, V24, P237, DOI 10.1007/s00198 012 2042 6
   Tracey D, 2008, PHARMACOL THERAPEUT, V117, P244, DOI 10.1016/j.pharmthera.2007.10.001
   Tsao C, 2013, J ORAL MAXIL SURG, V71, P1360, DOI 10.1016/j.joms.2013.02.016
   Zhang XY, 2016, J BONE MINER RES, V31, P336, DOI 10.1002/jbmr.2693
NR 28
TC 3
Z9 3
U1 1
U2 1
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD OCT
PY 2023
VL 81
IS 10
BP 1311
EP 1318
DI 10.1016/j.joms.2023.06.015
EA OCT 2023
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA W2HU6
UT WOS:001089901000001
PM 37480941
DA 2025 08 17
ER

PT J
AU Kozutsumi, R
   Kuroshima, S
   Al Omari, FA
   Hayano, H
   Nakajima, K
   Kakehashi, H
   Sawase, T
AF Kozutsumi, Ryohei
   Kuroshima, Shinichiro
   Al Omari, Farah A.
   Hayano, Hiroki
   Nakajima, Kazunori
   Kakehashi, Hiroe
   Sawase, Takashi
TI Depletion of macrophages deteriorates bisphosphonate related
   osteonecrosis of the jaw like lesions in mice
SO BONE
LA English
DT Article
DE Bisphosphonates; BRONJ; Macrophages; Osteoclasts; Wound healing; Mice
ID LIPOSOME ENCAPSULATED CLODRONATE; MEDICATION RELATED OSTEONECROSIS;
   BONE RESORPTION; TISSUE MACROPHAGES; OSTEAL MACROPHAGES; IN VIVO; CELLS;
   REPOPULATION; MECHANISM; DYNAMICS
AB Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a potentially intractable disease with no definitive pathophysiology and no treatment and prevention strategies. This study aimed to investigate whether time selective depletion of macrophages worsens BRONJ like lesions in mice. A murine model of high prevalence BRONJ like lesions in combination with zoledronate/chemotherapeutic drug administration and tooth extraction was created according to the methods of our previous studies. Daily intra oral submucosal administration of clodronate loaded liposomes, which temporarily depletes systemic macrophages, was performed immediately after tooth extraction. Spleens, femora, tibiae, and maxillae were dissected 2 weeks after extraction to evaluate BRONJ like lesions and systemic conditions by micro computed tomography analysis, histomorphometric and immunofluorescent analyses, and serum chemistry with ELISA. Depletion of macrophages significantly decreased the numbers of local and systemic macrophages and osteoclasts on the bone surface, which markedly worsened osseous healing, with increased necrotic bone and empty lacunae in the existing alveolar bone and newly formed bone in the extraction sockets, and soft tissue healing, with decreased collagen production and increased infiltration of polymorphonuclear cells. Interestingly, the depletion of macrophages significantly shifted macrophage polarization to M1 macrophages through an increase in F4/80+CD38+ M1 macrophages and a decrease in F4/ 80+CD163+ M2 macrophages, with decreases in the total number of F4/80+ macrophages. These data demonstrated that severe inhibition of osteoclasts in bone tissue and polarization shifting of macrophages in soft tissue are essential factors associated with BRONJ.
C1 [Kozutsumi, Ryohei; Kuroshima, Shinichiro; Al Omari, Farah A.; Hayano, Hiroki; Nakajima, Kazunori; Sawase, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Appl Prosthodont, Nagasaki 8528588, Japan.
   [Kakehashi, Hiroe] Kyushu Univ, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral & Maxillofacial Oncol, Fukuoka 8128582, Japan.
   [Kuroshima, Shinichiro] Nagasaki Univ, Grad Sch Biomed Sci, Dept Appl Prosthodont, 1 7 1 Sakamoto, Nagasaki, Nagasaki 8528588, Japan.
C3 Nagasaki University; Kyushu University; Nagasaki University
RP Kuroshima, S (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Appl Prosthodont, 1 7 1 Sakamoto, Nagasaki, Nagasaki 8528588, Japan.
EM kuroshima@nagasaki u.ac.jp
OI Kuroshima, Shinichiro/0000 0001 9891 9987
FU JSPS KAKENHI [JSPS23K18364, 22H03283, 21K09980, 21K10074, 20K18607]
FX <B>Acknowledgements</B> This work was supported by grant support from
   JSPS KAKENHI (Grant Nos JSPS23K18364, 22H03283, 21K09980, 21K10074, and
   20K18607) .
CR Aguirre JI, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116168
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Batoon L, 2019, BIOMATERIALS, V196, P51, DOI 10.1016/j.biomaterials.2017.10.033
   Bensi C, 2021, OR SURG OR MED OR PA, V132, P182, DOI 10.1016/j.oooo.2021.03.006
   BIEWENGA J, 1995, CELL TISSUE RES, V280, P189, DOI 10.1007/BF00304524
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   DELEMARRE FGA, 1990, J LEUKOCYTE BIOL, V47, P251, DOI 10.1002/jlb.47.3.251
   Diskin C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00270
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gkouveris I, 2022, CANCERS, V14, DOI 10.3390/cancers14020330
   Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004
   Hayano H, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115308
   Huja SS, 2006, ANAT REC PART A, V288A, P1243, DOI 10.1002/ar.a.20396
   Hutchinson M, 2010, J ORAL MAXIL SURG, V68, P2232, DOI 10.1016/j.joms.2010.05.003
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Kaneko H, 2023, J CLIN MED, V12, DOI 10.3390/jcm12051914
   KANIS JA, 1994, INT J ONCOL, V5, P713
   Kawahara M, 2021, INT J IMPLANT DENT, V7, DOI 10.1186/s40729 021 00323 0
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Kozutsumi R, 2022, CALCIFIED TISSUE INT, V110, P104, DOI 10.1007/s00223 021 00890 9
   Krzyszczyk P, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00419
   Kuroshima S, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1308 8
   Kuroshima S, 2018, BONE, V112, P177, DOI 10.1016/j.bone.2018.05.001
   Kuroshima S, 2018, J BONE MINER RES, V33, P154, DOI 10.1002/jbmr.3292
   Landén NX, 2016, CELL MOL LIFE SCI, V73, P3861, DOI 10.1007/s00018 016 2268 0
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   LEPORE L, 1991, CLIN EXP RHEUMATOL, V9, P33
   Locati M, 2020, ANNU REV PATHOL MECH, V15, P123, DOI 10.1146/annurev pathmechdis 012418 012718
   Loeffler J, 2018, TRENDS ENDOCRIN MET, V29, P99, DOI 10.1016/j.tem.2017.11.008
   Lu HX, 2020, EUR J IMMUNOL, V50, P795, DOI 10.1002/eji.201948414
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Michalski MN, 2019, J DENT RES, V98, P459, DOI 10.1177/0022034518821685
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Mohamad SF, 2017, BLOOD ADV, V1, P2520, DOI 10.1182/bloodadvances.2017011304
   NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670
   Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305
   Paschalidi P, 2021, CLIN ORAL INVEST, V25, P2845, DOI 10.1007/s00784 020 03602 z
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Ravosa MJ, 2011, ARCH ORAL BIOL, V56, P491, DOI 10.1016/j.archoralbio.2010.11.003
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Ruytinx P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01930
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287
   Tamaki S, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115560
   van Eenige R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237096
   Wasnik S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98773
   Williams DW, 2014, AM J PATHOL, V184, P3084, DOI 10.1016/j.ajpath.2014.07.010
   Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zhao SJ, 2020, J BONE MINER RES, V35, P2015, DOI 10.1002/jbmr.4099
NR 57
TC 8
Z9 8
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2023
VL 177
AR 116899
DI 10.1016/j.bone.2023.116899
EA SEP 2023
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA U1CY0
UT WOS:001082264700001
PM 37708951
OA Bronze
DA 2025 08 17
ER

PT J
AU Yamada, S
   Chea, C
   Furusho, H
   Oda, K
   Shiba, F
   Tanimoto, K
   Tate, SI
   Miyauchi, M
   Takata, T
AF Yamada, Sakura
   Chea, Chanbora
   Furusho, Hisako
   Oda, Kanae
   Shiba, Fumie
   Tanimoto, Kotaro
   Tate, Shin ichi
   Miyauchi, Mutsumi
   Takata, Takashi
TI Effects of novel lactoferrin peptides on LPS induced alveolar bone
   destruction in a rat model
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE lactoferrin; osteoclastogenesis; peptide drug; periodontitis; TNF
   receptor associated factor 6
ID BOVINE LACTOFERRIN; RHEUMATOID ARTHRITIS; TOPICAL APPLICATION;
   OSTEOCLASTOGENESIS; INHIBITION
AB To develop novel bovine lactoferrin (bLF) peptides targeting bLF tumour necrosis factor (TNF) receptor associated factor 6 (TRAF6) binding sites, we identified two peptides that could target bLF TRAF6 binding sites using structural analysis. Moreover, another peptide that could bind to the TRAF6 dimerization area was selected from the bLF sequence. The effects of each peptide on cytokine expression in lipopolysaccharide (LPS) stimulated osteoblasts (ST2) and on osteoclastogenesis were examined using an LPS treated co culture of primary bone marrow cells (BMCs) with ST2 cells and a single culture of osteoclast precursor cells (RAW D) treated with soluble receptor activator of NF kappa B ligand. Finally, the effectiveness of these peptides against LPS induced alveolar bone destruction was assessed. Two of the three peptides significantly suppressed LPS induced TNF alpha and interleukin 1 beta expression in ST2 cells. Additionally, these peptides inhibited and reversed LPS induced receptor activator of NF kappa B ligand (RANKL) upregulation and osteoprotegerin (OPG) downregulation, respectively. Furthermore, both peptides significantly reduced LPS induced osteoclastogenesis in the BMC ST2 co culture and RANKL induced osteoclastogenesis in RAW D cells. In vivo, topical application of these peptides significantly reduced the osteoclast number by downregulating RANKL and upregulating OPG in the periodontal ligament. It is indicated that the novel bLF peptides can be used to treat periodontitis associated bone destruction.
C1 [Yamada, Sakura; Chea, Chanbora; Furusho, Hisako; Oda, Kanae; Miyauchi, Mutsumi; Takata, Takashi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, 1 2 3 Kasumi,Minami Ku, Hiroshima 7348553, Japan.
   [Yamada, Sakura; Oda, Kanae; Tanimoto, Kotaro] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Orthodont & Craniofacial Dev Biol, Hiroshima, Japan.
   [Chea, Chanbora] Univ Puthisastra, Fac Dent, Phnom Penh, Cambodia.
   [Shiba, Fumie; Miyauchi, Mutsumi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Collaborat Res Lab Oral Inflammat Regulat, Hiroshima, Japan.
   [Tate, Shin ichi] Hiroshima Univ, Grad Sch Integrated Sci Life, Lab Mol Biophys, Hiroshima, Japan.
   [Tate, Shin ichi] Hiroshima Univ, SKCM2, Hiroshima, Japan.
   [Takata, Takashi] Shunan Univ, Yamaguchi, Japan.
C3 Hiroshima University; Hiroshima University; Hiroshima University;
   Hiroshima University; Hiroshima University
RP Miyauchi, M; Takata, T (通讯作者)，Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, 1 2 3 Kasumi,Minami Ku, Hiroshima 7348553, Japan.
EM mmiya@hiroshima u.ac.jp; ttakata@shunan u.ac.jp
RI Tate, Shin ichi/E 3057 2015; Furusho, Hisako/H 2351 2019; Chea,
   Chanbora/HZM 1449 2023; Miyauchi, Mutsumi/G 5268 2019; Shiba,
   Fumie/KWV 0964 2024
OI Shiba, Fumie/0000 0002 8011 5750; 
FU JSPS KAKENHI [16H05503, 20K18758, 24K20060]
FX This work was supported by JSPS KAKENHI [Grant Numbers 16H05503,
   20K18758, 24K20060] to TT and SY.
CR AlQranei MS, 2020, J ORAL BIOSCI, V62, P123, DOI 10.1016/j.job.2020.02.002
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Carr LE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.604080
   Dosseva Panova VT., 2014, Folia medica, V56, P152, DOI DOI 10.2478/FOLMED 2014 0022
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   How KY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00053
   Inubushi T, 2012, J BIOL CHEM, V287, P23527, DOI 10.1074/jbc.M111.324673
   Koike T, 2014, J RHEUMATOL, V41, P15, DOI 10.3899/jrheum.130466
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Legrand D, 2016, J PEDIATR US, V173, pS10, DOI 10.1016/j.jpeds.2016.02.071
   LONNERDAL B, 1995, ANNU REV NUTR, V15, P93, DOI 10.1146/annurev.nu.15.070195.000521
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Miyauchi M, 2004, HISTOCHEM CELL BIOL, V121, P291, DOI 10.1007/s00418 004 0636 6
   Miyauchi M, 2001, HISTOCHEM CELL BIOL, V116, P57
   Moots RJ, 2015, CLIN EXP RHEUMATOL, V33, P737
   NAGASAWA T, 1974, J DAIRY SCI, V57, P1159, DOI 10.3168/jds.S0022 0302(74)85030 7
   Oates TW, 2002, J CLIN PERIODONTOL, V29, P137, DOI 10.1034/j.1600 051x.2002.290208.x
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Preshaw PM, 2018, PERIODONTOL 2000, V76, P131, DOI 10.1111/prd.12148
   Romao VC, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1445 3
   Rosa L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091985
   Sako Y, 2008, ACS CHEM BIOL, V3, P241, DOI 10.1021/cb800010p
   Shi JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01849
   van Dam PA, 2019, CRIT REV ONCOL HEMAT, V133, P85, DOI 10.1016/j.critrevonc.2018.10.011
   Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193
   Yamano E, 2010, LAB INVEST, V90, P1236, DOI 10.1038/labinvest.2010.80
   Yamauchi K, 2000, FOOD CHEM TOXICOL, V38, P503, DOI 10.1016/S0278 6915(00)00036 3
   Yamauchi Koji, 2000, Journal of Toxicological Sciences, V25, P63
   Yanagisawa S, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0263254
   Yao Z., 2013, The Open Arthritis Journal, V2, P7, DOI [10.2174/1876539400902010007, DOI 10.2174/1876539400902010007]
   Yin Q, 2009, NAT STRUCT MOL BIOL, V16, P658, DOI 10.1038/nsmb.1605
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 33
TC 2
Z9 2
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1747 0277
EI 1747 0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD JUL
PY 2024
VL 104
IS 1
AR e14574
DI 10.1111/cbdd.14574
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA XJ3X5
UT WOS:001261288500001
PM 38958121
OA hybrid
DA 2025 08 17
ER

PT J
AU Siddiqi, MH
   Siddiqi, MZ
   Kang, S
   Noh, HY
   Ahn, S
   Simu, SY
   Aziz, MA
   Sathishkumar, N
   Pérez, ZEJ
   Yang, DC
AF Siddiqi, Muhammad Hanif
   Siddiqi, Muhammad Zubair
   Kang, Sera
   Noh, Hae Yong
   Ahn, Sungeun
   Simu, Shakina Yesmin
   Aziz, Mohamed Antar
   Sathishkumar, Natarajan
   Perez, Zuly Elizabeth Jimenez
   Yang, Deok Chun
TI Inhibition of Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7
   Cells via RANKL, JNK and p38 MAPK Pathways Through a Modulation of
   Cathepsin K: An In Silico and In Vitro Study
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE ginsenosides; osteoclast; RANKL; bone resorption; p38 MAPK/ERK; NF kB;
   RAW264.7 cells
ID NF KAPPA B; RECEPTOR ACTIVATOR; DOWN REGULATION; EXPRESSION; ESTROGEN;
   NFATC1; DOCKING; IMMUNE; GROWTH
AB Various studies have demonstrated that overexpression of cathepsin K (Cat K) causes excessive bone loss, which ultimately leads to a variety of bone diseases including osteoporosis. Therefore, inhibition of Cat K signifies a potential therapeutic target in osteoporosis treatment. Ginsenoside Rg3 is one of the most promising compound of Panax ginseng Meyer (P. ginseng) with numerous biological activities. Thus, in recent study the inhibitory effect of Rg3 isolated from P. ginseng was investigated in order to impede the osteoclast activity by an in silico approach followed by in vitro study validation using RAW264.7 cells through the investigation of different biological activity prediction such as absorption distribution metabolism and excretion (ADMET) properties against Cat K protein. The docking results of our study showed that Rg3 is a non toxic compound and may act as a drug like molecule. Additionally, the molecular interaction of Rg3 with the active residues of Cat K markedly describes its inhibitory effects on osteoclastogenesis. Findings of the present study exhibited that Rg3 significantly reduced receptor activator of nuclear factor kappa B ligand (RANKL) induced tartrate resistant acid phosphatase (TRAP) activity, pit formation (actin rings), and TRAP positive multinucleated cells development in RAW264.7 cells. Furthermore, Rg3 dose dependently reduced the mRNA expression levels of osteoclast specific markers such as RANK, TRAP, and Cat K induced by RANKL through the down regulation of p38, extracellular signal regulated kinase, and c Jun N terminal kinase (JNK) pathways. In conclusion, in silico docking study and in vitro validation together suggested that Rg3 inhibits osteoclastogenesis and reduces bone resorption through the inhibition of Cat K. Therefore, Rg3 might be a useful therapeutic agent for the treatment of osteoporosis and proper bone formation. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Siddiqi, Muhammad Hanif; Siddiqi, Muhammad Zubair; Kang, Sera; Noh, Hae Yong; Ahn, Sungeun; Simu, Shakina Yesmin; Aziz, Mohamed Antar; Sathishkumar, Natarajan; Perez, Zuly Elizabeth Jimenez; Yang, Deok Chun] Kyung Hee Univ, Coll Life Sci, Grad Sch Biotechnol, Yongin 449701, Gyeonggido, South Korea.
C3 Kyung Hee University
RP Yang, DC (通讯作者)，Kyung Hee Univ, Coll Life Sci, Grad Sch Biotechnol, Ginseng Genet Resource Bank, Yongin 449701, Gyeonggido, South Korea.
EM dcyang@khu.ac.kr
RI Natarajan, Sathishkumar/LCE 2379 2024
OI Natarajan, Sathishkumar/0000 0002 9001 8495; JIMENEZ PEREZ, ZULY
   ELIZABETH/0000 0002 2945 7536
FU iPET [312064 03 1 HD040, 313038 03 1 SB010]; Korea Institute of Planning
   and Evaluation for Technology in Food, Agriculture, Forestry and
   Fisheries, Republic of Korea
FX This research was supported by iPET (312064 03 1 HD040 and
   313038 03 1 SB010), Korea Institute of Planning and Evaluation for
   Technology in Food, Agriculture, Forestry and Fisheries, Republic of
   Korea. The ginseng sample used in this study was provided by Ginseng
   Bank Kyung Hee University.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bai CX, 2003, EUR J PHARMACOL, V476, P35, DOI 10.1016/S0014 2999(03)02174 5
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Body JJ, 2002, BONE, V30, p75S
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   BROMME D, 1995, BIOL CHEM H S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   He L, 2012, BONE, V50, P1207, DOI 10.1016/j.bone.2012.03.022
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Igarashi Y, 2002, J CHROMATOGR B, V781, P345, DOI 10.1016/S1570 0232(02)00431 2
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kanno S, 2004, TOXICOLOGY, V203, P211, DOI 10.1016/j.tox.2004.06.015
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Long CL, 2012, J BONE MINER RES, V27, P2476, DOI 10.1002/jbmr.1707
   Luo XJ, 2008, INT J ONCOL, V32, P975, DOI 10.1007/978 3 540 77385 6
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096 987X(19981115)19:14<1639::AID JCC10>3.0.CO;2 B
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758 2946 3 33
   O'Regan RM, 2001, ONCOLOGY NY, V15, P1177
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Poroikov VV, 2003, J CHEM INF COMP SCI, V43, P228, DOI 10.1021/ci020048r
   Ravikumar M, 2008, CHEM BIOL DRUG DES, V72, P79, DOI 10.1111/j.1747 0285.2008.00667.x
   Rhim H, 2002, EUR J PHARMACOL, V436, P151, DOI 10.1016/S0014 2999(01)01613 2
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Siddiqi MH, 2014, J PHARM PHARMACOL, V66, P1763, DOI 10.1111/jphp.12306
   Siddiqi MH, 2014, PHYTOTHER RES, V28, P1447, DOI 10.1002/ptr.5146
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo 122 4 1373
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Weitzmann MN, 2006, ANN NY ACAD SCI, V1068, P256, DOI 10.1196/annals.1346.030
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Xu TM, 2007, CHINESE MED J PEKING, V120, P584, DOI 10.1097/00029330 200704010 00011
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yue PYK, 2006, BIOCHEM PHARMACOL, V72, P437, DOI 10.1016/j.bcp.2006.04.034
NR 44
TC 33
Z9 34
U1 0
U2 47
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD SEP
PY 2015
VL 29
IS 9
BP 1286
EP 1294
DI 10.1002/ptr.5374
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CQ8FY
UT WOS:000360843100002
PM 26059856
DA 2025 08 17
ER

PT J
AU Davies, OG
   Grover, LM
   Lewis, MP
   Liu, Y
AF Davies, Owen G.
   Grover, Liam M.
   Lewis, Mark P.
   Liu, Yang
TI PDGF is a potent initiator of bone formation in a tissue engineered
   model of pathological ossification
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE bone; PDGF; skeletal muscle; inflammation; osteoprogenitor; heterotopic
   ossification
ID GROWTH FACTOR BETA; MUSCLE SATELLITE CELLS; HETEROTOPIC OSSIFICATION;
   OSTEOGENIC DIFFERENTIATION; STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   MESENCHYMAL PROGENITORS; C2C12 MYOBLASTS; SKELETAL MUSCLE; EXPRESSION
AB Heterotopic ossification (HO) is a debilitating condition defined by the rapid formation of bone in soft tissues. What makes HO fascinating is first the rate at which bone is deposited, and second the fact that this bone is structurally and compositionally similar to that of a healthy adult. If the mechanisms governing HO are understood, they have the potential to be exploited for the development of potent osteoinductive therapies. With this aim, a tissue engineered skeletal muscle was used model to better understand the role of inflammation on this debilitating phenomenon. It was shown that myoblasts could be divided into two distinct populations: myogenic cells and undifferentiated reserve' cells. Gene expression analysis of myogenic and osteoregulatory markers confirmed that reserve' cells were primed for osteogenic differentiation but had a reduced capacity for myogenesis. Osteogenic differentiation was significantly enhanced in the presence of platelet derived growth factor (PDGF) BB and bone morphogenetic protein 2 (BMP2), and correlated with conversion to a Sca 1(+)/CD73(+) phenotype. Alizarin red staining showed that PDGF BB promoted significantly more mineral deposition than BMP2. Finally, it was shown that PDGF induced mineralization was blocked in the presence of the pro inflammatory cytokines tumour necrosis factor  and interleukin 1. In conclusion, the present study identified that PDGF BB is a potent osteoinductive factor in a model of tissue engineered skeletal muscle, and that the osteogenic capacity of this protein was modulated in the presence of pro inflammatory cytokines. These findings reveal a possible mechanism by which HO develops following trauma. Importantly, these findings have implications for the induction and control of bone formation for regenerative medicine. Copyright (c) 2016 John Wiley & Sons, Ltd.
C1 [Davies, Owen G.; Liu, Yang] Loughborough Univ Technol, Wolfson Sch Mech & Mfg Engn, Ctr Biol Engn, Ashby Rd, Loughborough LE11 3TU, Leics, England.
   [Grover, Liam M.] Univ Birmingham, Sch Chem Engn, Birmingham, W Midlands, England.
   [Davies, Owen G.; Lewis, Mark P.] Loughborough Univ Technol, Sch Sport Exercise & Hlth Sci, NCSEM, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Loughborough, Leics, England.
C3 Loughborough University; University of Birmingham; Loughborough
   University
RP Davies, OG (通讯作者)，Loughborough Univ Technol, Wolfson Sch Mech & Mfg Engn, Ctr Biol Engn, Ashby Rd, Loughborough LE11 3TU, Leics, England.
EM o.g.davies@lboro.ac.uk
RI Liu, Yang/A 4046 2011; Grover, Liam/F 2713 2011
OI Liu, Yang/0000 0002 7959 9698; Davies, Owen/0000 0003 0808 8695; Grover,
   Liam/0000 0002 9774 7412
FU Defence Science and Technology Laboratory (Dstl); EPSRC (Engineering and
   Physical Sciences Research Council, UK) Centre for Innovative
   Manufacturing in Regenerative Medicine; National Centre for Sport and
   Exercise Medicine (NCSEM) England; SkelGen; EPSRC [EP/I017801/1] Funding
   Source: UKRI; Engineering and Physical Sciences Research Council
   [EP/I017801/1, 1378639] Funding Source: researchfish; National Centre
   for the Replacement, Refinement and Reduction of Animals in Research
   (NC3Rs) [G0900762/1] Funding Source: researchfish
FX The authors acknowledge Alex Chan at the Loughborough University Centre
   for Biological Engineering for his expertise and assistance with flow
   cytometry. This work was directly funded by the Defence Science and
   Technology Laboratory (Dstl) and supported by the EPSRC (Engineering and
   Physical Sciences Research Council, UK) Centre for Innovative
   Manufacturing in Regenerative Medicine, The National Centre for Sport
   and Exercise Medicine (NCSEM) England and FP7 PEOPLE 2012 IRSES
   (SkelGen).
CR Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432 0436.2001.680412.x
   Barksby HE, 2006, ARTHRITIS RHEUM US, V54, P540, DOI 10.1002/art.21574
   Beckmann JT, 2014, AM J SPORT MED, V42, P1359, DOI 10.1177/0363546514526361
   Blumenfeld I, 2000, CELLS TISSUES ORGANS, V167, P121, DOI 10.1159/000016775
   Boucher P, 2004, TRENDS CARDIOVAS MED, V14, P55, DOI 10.1016/j.tcm.2003.12.001
   Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097
   Chakkalakal JV, 2014, DEVELOPMENT, V141, P1649, DOI 10.1242/dev.100842
   Charatcharoenwitthaya N, 2007, J BONE MINER RES, V22, P724, DOI 10.1359/JBMR.070207
   Chen XP, 2005, MOL BIOL CELL, V16, P3140, DOI 10.1091/mbc.E05 03 0218
   Chromy BA, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 281
   Coipeau P, 2009, CYTOTHERAPY, V11, P584, DOI 10.1080/14653240903079385
   COLACHIS SC, 1993, PARAPLEGIA, V31, P51, DOI 10.1038/sc.1993.8
   Davies OG, 2015, CALCIFIED TISSUE INT, V97, P432, DOI 10.1007/s00223 015 0034 1
   Deato MDE, 2007, GENE DEV, V21, P2137, DOI 10.1101/gad.1583407
   Evans KN, 2012, J ORTHOP TRAUMA, V26, pE204, DOI 10.1097/BOT.0b013e31825d60a5
   Forsberg JA, 2014, CLIN ORTHOP RELAT R, V472, P2845, DOI 10.1007/s11999 014 3694 7
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Hoff P, 2013, BONE, V55, P93, DOI 10.1016/j.bone.2013.03.020
   Holmes C, 2007, J BONE MINER RES, V22, P1373, DOI 10.1359/JBMR.070604
   Kaihara S, 2004, GENE THER, V11, P439, DOI 10.1038/sj.gt.3302176
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553
   Kocic J, 2012, BBA MOL CELL RES, V1823, P838, DOI 10.1016/j.bbamcr.2012.01.001
   Komaki M, 2004, J CELL SCI, V117, P1457, DOI 10.1242/jcs.00965
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003
   Liu RJ, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 51
   Liu T, 2006, MOL CELL PROTEOMICS, V5, P1899, DOI 10.1074/mcp.M600068 MCP200
   McGann CJ, 2001, P NATL ACAD SCI USA, V98, P13699, DOI 10.1073/pnas.221297398
   Mu XD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016699
   Mu XD, 2011, J CELL MOL MED, V15, P679, DOI 10.1111/j.1582 4934.2010.01042.x
   Nasi S, 2016, ANN RHEUM DIS, V75, P1372, DOI 10.1136/annrheumdis 2015 207487
   Ono Y, 2011, CELL DEATH DIFFER, V18, P222, DOI 10.1038/cdd.2010.95
   PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306 4522(93)90583 2
   Péault B, 2007, MOL THER, V15, P867, DOI 10.1038/mt.sj.6300145
   Peterson JR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008810
   PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825
   Pignolo RJ, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 80
   Salasznyk RM, 2004, CELL COMMUN ADHES, V11, P137, DOI 10.1080/15419060500242836
   Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109
   Shi ST, 2013, CELL MOL LIFE SCI, V70, P407, DOI 10.1007/s00018 012 1054 x
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Stuelsatz P, 2010, J BIOL CHEM, V285, P12670, DOI 10.1074/jbc.M109.063966
   Suutre S, 2009, GROWTH FACTORS, V27, P114, DOI 10.1080/08977190802703976
   Takedachi M, 2012, J CELL PHYSIOL, V227, P2622, DOI 10.1002/jcp.23001
   Tsioumpekou M, 2016, CELL SIGNAL, V28, P1422, DOI 10.1016/j.cellsig.2016.06.013
   Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014
   Werner Clement M L, 2013, HSS J, V9, P166, DOI 10.1007/s11420 013 9335 y
   YOSHIKAWA H, 1988, BONE, V9, P391, DOI 10.1016/8756 3282(88)90121 4
   Zhao XK, 2016, SCI REP UK, V6, DOI 10.1038/srep19276
NR 50
TC 17
Z9 17
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JAN
PY 2018
VL 12
IS 1
BP E355
EP E367
DI 10.1002/term.2320
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA FT8VL
UT WOS:000423431200033
PM 27696748
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, H
   Ma, Y
   Li, J
   Zhou, C
   Xu, AT
   Xu, YB
   He, FM
AF Wang, Hui
   Ma, Yang
   Li, Jia
   Zhou, Chuan
   Xu, Antian
   Xu, Yangbo
   He, Fuming
TI Modulating autophagy by strontium doped micro/nano rough titanium
   surface for promotion of osteogenesis and inhibition of
   osteoclastogenesis
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Strontium; Implant; Autophagy; Osseointegration; Osteoclastogenesis
ID OSTEOBLAST DIFFERENTIATION; RANELATE; STIMULATION; DEGRADATION;
   INVOLVEMENT; RECEPTOR
AB Although it has been demonstrated that implant surfaces treated with strontium (Sr) promote osseointegration, the underlying intracellular mechanism remains unknown. Autophagy is a vital intracellular degradation mechanism that plays an essential role in maintaining bone homeostasis. Therefore, while designing implant biomaterials, it is critical to consider the autophagy mechanism. In this study, we fabricated Sr doped micro/nano rough titanium implant surface by hydrothermal treatment (SLA+Sr). The in vitro results revealed that the SLA+Sr surface promoted osteogenic differentiation of bone marrow derived mesenchymal stem cells (BMSCs) via autophagy activation. The SLA+Sr surface, on the other hand, inhibited osteoclast differentiation by downregulating autophagy. Additionally, in vivo, the SLA+Sr implant improved osseointegration, inhibited osteoclastogenesis, and upregulated autophagy levels in surrounding bone tissue cells. Our findings established a novel centralized mechanism by which SLA+Sr regulated osteogenesis and osteoclastogenesis during the osseointegration process through autophagy regulation. Moreover, endowing implants with the ability to modulate autophagy may be a promising strategy for enhancing implant osseointegration in the future translational medicine field.
C1 [Wang, Hui; Ma, Yang; Li, Jia; Zhou, Chuan; Xu, Antian; Xu, Yangbo; He, Fuming] Zhejiang Univ, Stomatol Hosp,Canc Ctr, Sch Stomatol,Key Lab Oral Biomed Res Zhejiang Pro, Sch Med,Clin Res Ctr Oral Dis Zhejiang Prov,Dept, Hangzhou 310006, Peoples R China.
C3 Zhejiang University
RP He, FM (通讯作者)，Zhejiang Univ, Stomatol Hosp,Canc Ctr, Sch Stomatol,Key Lab Oral Biomed Res Zhejiang Pro, Sch Med,Clin Res Ctr Oral Dis Zhejiang Prov,Dept, Hangzhou 310006, Peoples R China.
EM hfm@zju.edu.cn
RI wang, hui/GRS 4730 2022
FU National Natural Science Foundation of China [31670970]; Key Research
   and Development Program of Science and Technology Department of Zhejiang
   Province [2019C03081]; Educational Reform Project of School Medicine of
   Zhejiang University [jgyb20202049]
FX This study was funded by the National Natural Science Foundation of
   China (No. 31670970), the Key Research and Development Program of
   Science and Technology Department of Zhejiang Province (No. 2019C03081),
   and the Educational Reform Project of School Medicine of Zhejiang
   University (NO. jgyb20202049).
CR Arai A, 2019, J BONE MINER RES, V34, P1753, DOI 10.1002/jbmr.3756
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Cao YN, 2013, PANCREAS, V42, P301, DOI 10.1097/MPA.0b013e31825b9f2c
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Chen WS, 2021, BIOMATER SCI UK, V9, P4922, DOI 10.1039/d1bm00691f
   Chen Y, 2016, INT J ORAL MAX IMPL, V31, pE102, DOI 10.11607/jomi.4415
   Chen ZT, 2019, ACTA BIOMATER, V96, P568, DOI 10.1016/j.actbio.2019.06.058
   Cheng Y, 2019, INT J MOL MED, V44, P652, DOI 10.3892/ijmm.2019.4216
   Cui X, 2020, BIOACT MATER, V5, P334, DOI 10.1016/j.bioactmat.2020.02.016
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Glenske K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030826
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Huang TB, 2019, BIOMATER SCI UK, V7, P1101, DOI 10.1039/c8bm01411f
   Ion R, 2018, COATINGS, V8, DOI 10.3390/coatings8090294
   Jaber FA, 2019, J CELL PHYSIOL, V234, P12105, DOI 10.1002/jcp.27071
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Li LJ, 2019, ACTA BIOMATER, V96, P674, DOI 10.1016/j.actbio.2019.07.007
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Montaseri A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101398
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Nuschke A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt530
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Saidak Z, 2012, AGING CELL, V11, P467, DOI 10.1111/j.1474 9726.2012.00804.x
   SEGLEN PO, 1982, P NATL ACAD SCI BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Song W, 2016, ACS APPL MATER INTER, V8, P33475, DOI 10.1021/acsami.6b11699
   Wang H, 2019, ACS APPL MATER INTER, V11, P7615, DOI 10.1021/acsami.8b21558
   Wang SN, 2019, COLLOID SURFACE B, V176, P38, DOI 10.1016/j.colsurfb.2018.12.056
   Wang Z, 2021, COLLOID SURFACE B, V204, DOI 10.1016/j.colsurfb.2021.111802
   Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152
   Xiao L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00490
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V359, P399, DOI 10.1007/s11010 011 1034 8
   Zach F, 2018, J BIOL CHEM, V293, P9530, DOI 10.1074/jbc.RA118.002449
   Zhang WJ, 2016, NANOSCALE, V8, P5291, DOI 10.1039/c5nr08580b
   Zhang XR, 2021, J MATER CHEM B, V9, P3489, DOI 10.1039/d0tb02991b
NR 40
TC 12
Z9 14
U1 3
U2 67
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD FEB
PY 2022
VL 210
AR 112246
DI 10.1016/j.colsurfb.2021.112246
EA DEC 2021
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA XV3TV
UT WOS:000734869300001
PM 34883339
DA 2025 08 17
ER

PT J
AU Genant, HK
   Engelke, K
   Hanley, DA
   Brown, JP
   Omizo, M
   Bone, HG
   Kivitz, AJ
   Fuerst, T
   Wang, H
   Austin, M
   Libanati, C
AF Genant, H. K.
   Engelke, K.
   Hanley, D. A.
   Brown, J. P.
   Omizo, M.
   Bone, H. G.
   Kivitz, A. J.
   Fuerst, T.
   Wang, H.
   Austin, M.
   Libanati, C.
TI Denosumab improves density and strength parameters as measured by QCT of
   the radius in postmenopausal women with low bone mineral density
SO BONE
LA English
DT Article
DE QCT; BMD; Denosumab; Distal radius; Postmenopausal women
ID QUANTITATIVE COMPUTED TOMOGRAPHY; VERTEBRAL FRACTURE RISK;
   FINITE ELEMENT ANALYSIS; DISTAL RADIUS; CORTICAL BONE; HIP FRACTURE;
   NONINVASIVE ASSESSMENT; GEOMETRIC PROPERTIES; OSTEOPOROSIS; PREDICTION
AB Background: Bone strength is determined by both cortical and trabecular bone compartments and can be evaluated radiologically through measurement of bone density and geometry. Quantitative computed tomography (QCT) separately assesses cortical and trabecular bone reliably at various sites, including the distal radius where there is a gradation of cortical and trabecular bone. We evaluated the effect of denosumab, a fully human monoclonal antibody that inhibits RANK ligand, on distal radius QCT in women with low bone mass to assess the impact of this novel therapy separately on trabecular and cortical bone.
   Methods: Postmenopausal women (n=332) with spine areal bone mineral density (BMD) T scores between  1.0 and  2.5 received denosumab 60 mg or placebo every 6 months during the 24 month study. QCT measurements along the distal radius were made using a whole body computed tomography scanner and were used to determine the percentage change from baseline in volumetric BMD; volumetric bone mineral content (BMC); cortical thickness; volume; circumference; and density weighted polar moment of inertia (PMI), a derived index of bone strength.
   Results: Denosumab treatment significantly increased total BMD and BMC along the radius (proximal, distal, and ultradistal sections). At 24 months, the ultradistal region had the greatest percentage increase in total BMD (4.7% [95% CI, 3.6 5.7]; P<0.001) and total BMC (5.7% [95% CI, 4.8 6.6]: P<0.001) over placebo. When cortical and trabecular bone at the proximal and distal regions were separately assessed, cortical bone had significant (P<0.001) increases in BMD, BMC, and thickness, and trabecular bone had a significant increase in BMD relative to placebo (P<0.05). Bone strength, estimated by density weighted PMI, significantly increased compared with placebo after 6 months of treatment, with the largest percentage increase occurring at 24 months in the ultradistal region (6.6% [95% CI, 5.6 7.6]; P<0.0001).
   Conclusions: QCT measurements demonstrated that denosumab significantly increased BMD, BMC, and PMI along the radius over 24 months. Additionally, denosumab prevented the decrease in QCT measured cortical thickness observed in the placebo group. These data extend the evidence from previous dual energy X ray absorptiometry studies for a positive effect of denosumab on both the cortical and trabecular bone compartments and propose a possible mechanism for the reduction in fracture risk achieved with denosumab therapy. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Genant, H. K.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
   [Genant, H. K.; Fuerst, T.] Synarc Inc, San Francisco, CA USA.
   [Engelke, K.] Synarc Inc, Hamburg, Germany.
   [Engelke, K.] Univ Erlangen Nurnberg, Inst Med Phys, Erlangen, Germany.
   [Hanley, D. A.] Univ Calgary, Calgary, AB, Canada.
   [Brown, J. P.] Univ Laval, CHUQ, Quebec City, PQ, Canada.
   [Omizo, M.] Oregon Osteoporosis Ctr, Portland, OR USA.
   [Bone, H. G.] Michigan Bone & Mineral Clin, Detroit, MI USA.
   [Kivitz, A. J.] Altoona Ctr Clin Res, Duncansville, PA USA.
   [Wang, H.; Austin, M.; Libanati, C.] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 University of California System; University of California San Francisco;
   Synarc; Synarc; University of Erlangen Nuremberg; University of Calgary;
   Laval University; Laval University Hospital; Oregon Osteoporosis Center;
   Altoona Center for Clinical Research; Amgen
RP Genant, HK (通讯作者)，Univ Calif San Francisco, Dept Radiol, 505 Parnassus Ave, San Francisco, CA 94143 USA.
EM harry.genant@ucsf.edu
RI ; Libanati, Cesar/LGZ 1518 2024
OI Brown, Jacques/0000 0003 1910 788X; 
FU Amgen Inc., Thousand Oaks, CA, USA
FX This study was funded by Amgen Inc., Thousand Oaks, CA, USA.
CR Augat P, 1998, OSTEOPOROSIS INT, V8, P299, DOI 10.1007/s001980050068
   Augat P, 1996, J BONE MINER RES, V11, P1356
   Augat P, 1998, J ORTHOPAED RES, V16, P629, DOI 10.1002/jor.1100160517
   BAGI C, 1995, BONE, V16, P559, DOI 10.1016/8756 3282(95)00078 R
   Bagi CM, 2006, BONE, V38, P136, DOI 10.1016/j.bone.2005.07.028
   Barrett Connor E, 2005, J BONE MINER RES, V20, P185, DOI 10.1359/JBMR.041007
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Black DM, 2008, J BONE MINER RES, V23, P1326, DOI [10.1359/jbmr.080316, 10.1359/JBMR.080316]
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bonel HM, 2004, J CLIN DENSITOM, V7, P169, DOI 10.1385/JCD:7:2:169
   Bousson V, 2006, OSTEOPOROSIS INT, V17, P855, DOI 10.1007/s00198 006 0074 5
   Boutroy S, 2008, J BONE MINER RES, V23, P392, DOI 10.1359/JBMR.071108
   Bouxsein ML, 2008, NAT CLIN PRACT RHEUM, V4, P310, DOI 10.1038/ncprheum0798
   Bouxsein ML, 1999, OSTEOPOROSIS INT, V10, P505, DOI 10.1007/s001980050261
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Cummings S, 2009, OSTEOPOROSIS INT, V20, P16
   CUMMINGS S, 2009, J BONE MINER RES, V24, pS87
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Damilakis J, 2007, EUR RADIOL, V17, P1591, DOI 10.1007/s00330 006 0511 z
   Eckstein F, 2004, ANN BIOMED ENG, V32, P487, DOI 10.1023/B:ABME.0000017543.20342.07
   Engelke K, 2008, J CLIN DENSITOM, V11, P123, DOI 10.1016/j.jocd.2007.12.010
   Engelke K, 2009, BONE, V45, P110, DOI 10.1016/j.bone.2009.03.669
   Eswaran SK, 2006, J BONE MINER RES, V21, P307, DOI 10.1359/JBMR.051027
   FAULKNER KG, 1991, RADIOLOGY, V179, P669, DOI 10.1148/radiology.179.3.2027972
   Firooabadi R, 2008, J ORTHOP TRAUMA, V22, pS83, DOI 10.1097/BOT.0b013e31815ea2a4
   GENANT HK, 1985, J COMPUT ASSIST TOMO, V9, P602, DOI 10.1097/00004728 198505000 00042
   Genant HK, 1996, J BONE MINER RES, V11, P707
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Holzer G, 2009, J BONE MINER RES, V24, P468, DOI 10.1359/JBMR.081108
   JEE WSS, 1991, ANAT RECORD, V230, P332, DOI 10.1002/ar.1092300306
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Keaveny TM, 2008, J BONE MINER RES, V23, P1974, DOI [10.1359/jbmr.080805, 10.1359/JBMR.080805]
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   MacNeil JA, 2007, BONE, V41, P129, DOI 10.1016/j.bone.2007.02.029
   McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003 4819 128 4 199802150 00001
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Melton LJ, 2007, J BONE MINER RES, V22, P1442, DOI 10.1359/JBMR.070514
   Mikkola T, 2007, OSTEOPOROSIS INT, V18, P1083, DOI 10.1007/s00198 007 0352 x
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Muller ME, 2003, OSTEOPOROSIS INT, V14, P345, DOI 10.1007/s00198 003 1380 9
   Riggs BL, 2004, J BONE MINER RES, V19, P1945, DOI 10.1359/JBMR.040916
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Schneider P, 2001, OSTEOPOROSIS INT, V12, P639, DOI 10.1007/s001980170063
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Siris ES, 2004, J BONE MINER RES, V19, P1215, DOI 10.1359/JBMR.040508
   Tommasini SM, 2005, J BONE MINER RES, V20, P1372, DOI 10.1359/JBMR.050326
   Ural A, 2009, J BIOMECH, V42, P22, DOI 10.1016/j.jbiomech.2008.10.011
   Wainwright SA, 2005, J CLIN ENDOCR METAB, V90, P2787, DOI 10.1210/jc.2004 1568
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
   Watts NB, 2005, J BONE MINER RES, V20, P2097, DOI 10.1359/JBMR.050814
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 54
TC 59
Z9 63
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2010
VL 47
IS 1
BP 131
EP 139
DI 10.1016/j.bone.2010.04.594
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 615QN
UT WOS:000279150400016
PM 20399288
DA 2025 08 17
ER

PT J
AU Iwaniec, UT
   Yuan, D
   Power, RA
   Wronski, TJ
AF Iwaniec, Urszula T.
   Yuan, Dawn
   Power, Rachel A.
   Wronski, Thomas J.
TI Strain dependent variations in the response of cancellous bone to
   ovariectomy in mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE mouse; ovariectomy; estrogen depletion; transgenic; knockout; bone
   histomorphometry
ID INBRED STRAINS; ANIMAL MODELS; ESTROGEN; OSTEOPOROSIS; MENOPAUSE;
   RECEPTOR; THERAPY
AB Introduction: The ovariectomized (OVX) rat is the most widely used preclinical rodent model for postmenopausal osteoporosis. However, the underlying mechanisms of bone disorders, including osteoporosis, have been explored predominantly in the mouse. The purpose of this study was to evaluate mice (129P3 and C5713L/6 inbred strains and their F 2 hybrid offspring, B6129PF2), commonly used for gene knockout and overexpression studies, for their potential as preclinical models of postmenopausal bone loss.
   Materials and Methods: The mice were OVX or sham operated at 4 months of age and killed at 1 or 3 months after surgery. Lumbar vertebrae and distal femora were subjected to histomorphometric assessment.
   Results: Mice in the two strains and the F 2 hybrids (will be referred to as strain for the remainder of the abstract) lost vertebral cancellous bone after OVX; bone volume (BV/TV) was 20% and 27% lower at 1 and 3 months after surgery, respectively. The decreased cancellous BV/TV was associated with an increase in osteoclast surface at I month after OVX in the 129P3 strain only. Osteoblast surface was increased by 20% with OVX at both 1 and 3 months after surgery, irrespective of mouse strain. However, bone formation rate was not altered by OVX in any of the mouse strains. In contrast to the lumbar vertebrae, cancellous bone loss in response to OVX differed in the distal femur among the three mouse strains. OVX had no significant effect on distal femur BV/TV in the B6129PF2 mouse strain. In the C57BL/6 strain, cancellous BV/TV was reduced by OVX at I month after surgery but not at 3 months after surgery, whereas distal femur BV/TV in 129P3 mice was reduced at 3 months after surgery. Osteoclast surface was not affected by OVX at either time point in the C5713L/6 strain, but was increased by 116% at I month after surgery in the 129P3 strain. Osteoblast surface was increased with OVX at 1 month after surgery, irrespective of strain, whereas bone formation rate was not altered by OVX at either time point in any of the strains.
   Conclusions: The magnitude of cancellous bone loss and cellular indices of increased bone turnover in response to OVX varied with mouse strain and skeletal site, but in general, were less pronounced and less consistent than in the Sprague Dawley rat. Although mouse models will continue to provide insights into genetic influences on bone mass and turnover, caution should be exercised when using 129P3 and C5713L/6 mice, and their F 2 hybrids, as models for postmenopausal bone loss and preclinical testing of potential therapies for osteoporosis.
C1 Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA.
   Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA.
C3 Oregon State University; State University System of Florida; University
   of Florida
RP Iwaniec, UT (通讯作者)，Oregon State Univ, Dept Nutr & Exercise Sci, 211A Milam Hall, Corvallis, OR 97331 USA.
EM Urszula.Iwaniec@oregonstate.edu
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Baron R., 1983, Bone histomorphometry: Techniques and interpretation, P13
   Beamer WG, 2001, J BONE MINER RES, V16, P1195, DOI 10.1359/jbmr.2001.16.7.1195
   Bellino FL, 2000, MENOPAUSE, V7, P14, DOI 10.1097/00042192 200007010 00004
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Cuzzocrea S, 2003, ENDOCRINOLOGY, V144, P1098, DOI 10.1210/en.2002 220597
   Frost H.M., 1983, Bone Histomorphometry: Techniques and Interpretation, P109
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037
   Kimmel Donald B., 1996, P671
   Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006
   Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819
   Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316
   Mödder UIL, 2004, EUR J ENDOCRINOL, V151, P503, DOI 10.1530/eje.0.1510503
   Mödder UIL, 2004, ENDOCRINOLOGY, V145, P913, DOI 10.1210/en.2003 1089
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   RAISZ LG, 1988, NEW ENGL J MED, V318, P818
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   Samuels A, 1999, J BONE MINER RES, V14, P178, DOI 10.1359/jbmr.1999.14.2.178
   Sims NA, 2003, J CLIN INVEST, V111, P1319, DOI 10.1172/JCI200317246
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Turner R T, 2001, Rev Endocr Metab Disord, V2, P117, DOI 10.1023/A:1010067326811
   Turner RT, 1999, J BONE MINER RES, V14, P187, DOI 10.1359/jbmr.1999.14.2.187
   Usui M, 2004, P NATL ACAD SCI USA, V101, P6653, DOI 10.1073/pnas.0303093101
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Wronski TJ, 1998, PHARM TOXIC, P59
   Wronski TJ., 1992, CELLS MAT, V1, P69
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   ZENG GQ, 1998, BONE S, V23, pS448
   Zhou H, 2003, BONE, V32, P513, DOI 10.1016/S8756 3282(03)00057 7
NR 32
TC 60
Z9 70
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2006
VL 21
IS 7
BP 1068
EP 1074
DI 10.1359/JBMR.060402
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 057MW
UT WOS:000238600900015
PM 16813527
DA 2025 08 17
ER

PT J
AU Hagg, A
   Colgan, TD
   Thomson, RE
   Qian, HW
   Lynch, GS
   Gregorevic, P
AF Hagg, Adam
   Colgan, Timothy D.
   Thomson, Rachel E.
   Qian, Hongwei
   Lynch, Gordon S.
   Gregorevic, Paul
TI Using AAV vectors expressing the β2 adrenoceptor or associated Gα
   proteins to modulate skeletal muscle mass and muscle fibre size
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PARATHYROID HORMONE; FORMOTEROL; GROWTH; HYPERTROPHY; CLENBUTEROL;
   RECEPTOR; TRIAL; RATS; DIFFERENTIATION; STIMULATION
AB Anabolic beta(2) adrenoceptor (beta(2) AR) agonists have been proposed as therapeutics for treating muscle wasting but concerns regarding possible off target effects have hampered their use. We investigated whether beta(2) AR mediated signalling could be modulated in skeletal muscle via gene delivery to the target tissue, thereby avoiding the risks of beta(2) AR agonists. In mice, intramuscular administration of a recombinant adeno associated virus based vector (rAAV vector) expressing the beta(2) AR increased muscle mass by >20% within 4 weeks. This hypertrophic response was comparable to that of 4 weeks' treatment with the beta(2) AR agonist formoterol, and was not ablated by mTOR inhibition. Increasing expression of inhibitory (G alpha i2) and stimulatory (G alpha sL) G protein subunits produced minor atrophic and hypertrophic changes in muscle mass, respectively. Furthermore, G alpha i2 over expression prevented AAV:beta(2) AR mediated hypertrophy. Introduction of the non muscle G alpha s isoform, G alpha sXL elicited hypertrophy comparable to that achieved by AAV: beta(2) AR. Moreover, G alpha sXL gene delivery was found to be capable of inducing hypertrophy in the muscles of mice lacking functional beta(1)  and beta(2) ARs. These findings demonstrate that gene therapy based interventions targeting the beta(2) AR pathway can promote skeletal muscle hypertrophy independent of ligand administration, and highlight novel methods for potentially modulating muscle mass in settings of disease.
C1 [Hagg, Adam; Colgan, Timothy D.; Thomson, Rachel E.; Qian, Hongwei; Gregorevic, Paul] Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia.
   [Hagg, Adam; Colgan, Timothy D.; Lynch, Gordon S.; Gregorevic, Paul] Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia.
   [Gregorevic, Paul] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
   [Gregorevic, Paul] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
C3 Baker Heart and Diabetes Institute; University of Melbourne; Monash
   University; University of Washington; University of Washington Seattle
RP Gregorevic, P (通讯作者)，Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia.; Gregorevic, P (通讯作者)，Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia.; Gregorevic, P (通讯作者)，Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.; Gregorevic, P (通讯作者)，Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
EM paul.gregorevic@bakeridi.edu.au
RI ; Gregorevic, Paul/AAH 6040 2021; Lynch, Gordon/G 9553 2015
OI Hagg, Adam/0000 0001 7951 743X; Thomson, Rachel/0000 0003 3802 8597;
   Gregorevic, Paul/0000 0002 7418 8945; 
FU National Health and Medical Research Council (NHMRC) [509313, 1026231];
   NHMRC [1046782]; Pfizer Australia; Victorian Government
FX The authors thank Dr Catherine E. Winbanks and Dr Lucy Cassar
   (previously Baker IDI Heart and Diabetes Institute), Mr Timur Naim
   (Department of Physiology, University of Melbourne) and Mr Stephen Cody
   and Dr Iska Carmichael (Micro Imaging facility, AMREP campus) for
   technical guidance. This work was supported by Project Grant funding
   (509313; 1026231 awarded to G.S.L. and P.G.) from the National Health
   and Medical Research Council (NHMRC). P.G. is supported by a NHMRC
   Career Development Fellowship (1046782) and previously, a Senior
   Research Fellowship sponsored by Pfizer Australia. The Baker IDI Heart &
   Diabetes Institute is supported in part by the Operational
   Infrastructure Support Program of the Victorian Government. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Blankinship MJ, 2004, MOL THER, V10, P671, DOI 10.1016/j.ymthe.2004.07.016
   Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372
   Buchlis G, 2012, BLOOD, V119, P3038, DOI 10.1182/blood 2011 09 382317
   Burniston JG, 2002, J APPL PHYSIOL, V93, P1824, DOI 10.1152/japplphysiol.00139.2002
   Chen M, 2009, AM J PHYSIOL CELL PH, V296, pC930, DOI 10.1152/ajpcell.00443.2008
   Church JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101379
   COSTELLI P, 1995, J CLIN INVEST, V95, P2367, DOI 10.1172/JCI117929
   Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362
   Dror RO, 2011, P NATL ACAD SCI USA, V108, P18684, DOI 10.1073/pnas.1110499108
   Duncan ND, 2000, CLIN SCI, V98, P339, DOI 10.1042/CS19990069
   Gonçalves DAP, 2009, ENDOCRINOLOGY, V150, P5395, DOI 10.1210/en.2009 0428
   Goodman CA, 2011, FASEB J, V25, P1028, DOI 10.1096/fj.10 168799
   Gregorevic P, 2005, AM J PHYSIOL HEART C, V289, pH344, DOI 10.1152/ajpheart.01254.2004
   Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085
   Greig CA, 2014, SUPPORT CARE CANCER, V22, P1269, DOI 10.1007/s00520 013 2081 3
   Harcourt LJ, 2007, NEUROMUSCULAR DISORD, V17, P47, DOI 10.1016/j.nmd.2006.08.012
   He Q, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa9953
   Hinkle RT, 2002, MUSCLE NERVE, V25, P729, DOI 10.1002/mus.10092
   Jiang Guang Liang, 2011, ISRN Pharm, V2011, P981254, DOI 10.5402/2011/981254
   Joassard OR, 2013, INT J BIOCHEM CELL B, V45, P2444, DOI 10.1016/j.biocel.2013.07.019
   Johnston AJ, 2015, CELL, V162, P1365, DOI 10.1016/j.cell.2015.08.031
   Kimura S, 2014, SCI REP UK, V4, DOI 10.1038/srep05066
   Kissel JT, 1998, NEUROLOGY, V50, P1402, DOI 10.1212/WNL.50.5.1402
   Kline WO, 2007, J APPL PHYSIOL, V102, P740, DOI 10.1152/japplphysiol.00873.2006
   Koopman R, 2010, J PHYSIOL LONDON, V588, P4811, DOI 10.1113/jphysiol.2010.196725
   Linglart AS, 2006, ENDOCRINOLOGY, V147, P2253, DOI 10.1210/en.2005 1487
   MALTIN CA, 1986, BIOSCIENCE REP, V6, P811, DOI 10.1007/BF01117104
   Mariot V, 2011, BONE, V48, P312, DOI 10.1016/j.bone.2010.09.032
   Mendell JR, 2015, MOL THER, V23, P192, DOI 10.1038/mt.2014.200
   Minetti GC, 2014, MOL CELL BIOL, V34, P619, DOI 10.1128/MCB.00957 13
   Minetti GC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002038
   Pearen MA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 448
   Premont RT, 2007, ANNU REV PHYSIOL, V69, P511, DOI 10.1146/annurev.physiol.69.022405.154731
   Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701
   Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101 1009
   RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695 143
   Ryall JG, 2007, J GERONTOL A BIOL, V62, P813, DOI 10.1093/gerona/62.8.813
   Ryall JG, 2010, CLIN EXP PHARMACOL P, V37, P397, DOI 10.1111/j.1440 1681.2009.05312.x
   Ryall JG, 2004, J PHYSIOL LONDON, V555, P175, DOI 10.1113/jphysiol.2003.056770
   Salva MZ, 2007, MOL THER, V15, P320, DOI 10.1038/sj.mt.6300027
   Skura CL, 2008, NEUROLOGY, V70, P137, DOI 10.1212/01.WNL.0000287070.00149.a9
   Toledo M, 2014, J CACHEXIA SARCOPENI, V5, P315, DOI 10.1007/s13539 014 0153 y
   von Maltzahn J, 2012, NAT CELL BIOL, V14, P186, DOI 10.1038/ncb2404
   Weinstein LS, 2007, PHARMACOL THERAPEUT, V115, P271, DOI 10.1016/j.pharmthera.2007.03.013
   Winbanks CE, 2011, J BIOL CHEM, V286, P13805, DOI 10.1074/jbc.M110.192625
NR 45
TC 20
Z9 40
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 14
PY 2016
VL 6
AR 23042
DI 10.1038/srep23042
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DG2AN
UT WOS:000371868700001
PM 26972746
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, SY
   Lee, KS
   Yi, SH
   Kook, SH
   Lee, JC
AF Lee, Seung Youp
   Lee, Keun Soo
   Yi, Sea Hyun
   Kook, Sung Ho
   Lee, Jeong Chae
TI Acteoside Suppresses RANKL Mediated Osteoclastogenesis by Inhibiting
   c Fos Induction and NF κB Pathway and Attenuating ROS Production
SO PLOS ONE
LA English
DT Article
ID REHMANNIA GLUTINOSA; BONE RESORPTION; MOLECULAR BASIS; MICE LACKING;
   DIFFERENTIATION; CELL; MACROPHAGES; ACTIVATION; RECEPTOR; OSTEOPOROSIS
AB Numerous studies have reported that inflammatory cytokines are important mediators for osteoclastogenesis, thereby causing excessive bone resorption and osteoporosis. Acteoside, the main active compound of Rehmannia glutinosa, which is used widely in traditional Oriental medicine, has anti inflammatory and antioxidant potentials. In this study, we found that acteoside markedly inhibited osteoclast differentiation and formation from bone marrow macrophages (BMMs) and RAW264.7 macrophages stimulated by the receptor activator of nuclear factor kappaB (NF kappa B) ligand (RANKL). Acteoside pretreatment also prevented bone resorption by mature osteoclasts in a dose dependent manner. Acteoside (10 mu M) attenuated RANKL stimulated activation of p38 kinase, extracellular signal regulated kinases, and c Jun N terminal kinase, and also suppressed NF kB activation by inhibiting phosphorylation of the p65 subunit and the inhibitor k beta alpha. In addition, RANKL mediated increases in the expression of c Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) and in the production of tumor necrosis factor a, interleukin (IL) 1 beta, and IL 6 were apparently inhibited by acteoside pretreatment. Further, oral acteoside reduced ovariectomy induced bone loss and inflammatory cytokine production to control levels. Our data suggest that acteoside inhibits osteoclast differentiation and maturation from osteoclastic precursors by suppressing RANKL induced activation of mitogen activated protein kinases and transcription factors such as NF kappa B, c Fos, and NFATc1. Collectively, these results suggest that acteoside may act as an anti resorptive agent to reduce bone loss by blocking osteoclast activation.
C1 [Lee, Seung Youp] Chonbuk Natl Univ, Res Inst Clin Med, Chonbuk Natl Univ Hosp, Biomed Res Inst, Jeonju, Chonbuk, South Korea.
   [Lee, Seung Youp; Yi, Sea Hyun; Kook, Sung Ho; Lee, Jeong Chae] Chonbuk Natl Univ, Dept Orthodont, Inst Oral Biosci, Jeonju, Chonbuk, South Korea.
   [Lee, Seung Youp; Yi, Sea Hyun; Kook, Sung Ho; Lee, Jeong Chae] Chonbuk Natl Univ, Sch Dent, Jeonju, Chonbuk, South Korea.
   [Lee, Keun Soo; Lee, Jeong Chae] Chonbuk Natl Univ, Dept Bioact Mat Sci, Res Ctr Bioact Mat, Jeonju, Chonbuk, South Korea.
C3 Jeonbuk National University; Jeonbuk National University Hospital;
   Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University
RP Lee, JC (通讯作者)，Chonbuk Natl Univ, Dept Orthodont, Inst Oral Biosci, Jeonju, Chonbuk, South Korea.
EM leejc88@jbnu.ac.kr
FU funds of Biomedical Research Institute, Chonbuk National University
   Hospital; Chonbuk National University, Jeonju, South Korea
FX This paper was supported by funds of Biomedical Research Institute,
   Chonbuk National University Hospital. This work was in part supported by
   research funds endowed to Dr. Sung Ho Kook from Chonbuk National
   University, Jeonju, South Korea, in 2013. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abramson SB, 2002, RHEUMATOLOGY, V41, P972, DOI 10.1093/rheumatology/41.9.972
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Cho ES, 2012, MOL CELLS, V33, P173, DOI 10.1007/s10059 012 2240 z
   Cho ES, 2010, J CELL BIOCHEM, V111, P1260, DOI 10.1002/jcb.22849
   Chun JC, 2002, PESTIC BIOCHEM PHYS, V72, P153, DOI 10.1016/S0048 3575(02)00008 1
   Cosentino Gomes D, 2012, INT J MOL SCI, V13, P10697, DOI 10.3390/ijms130910697
   Del Fattore A, 2010, ARCH BIOCHEM BIOPHYS, V503, P28, DOI 10.1016/j.abb.2010.07.020
   Fang M, 2011, J PHARM PHARMACOL, V63, P120, DOI 10.1111/j.2042 7158.2010.01162.x
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hwang JM, 2010, INT IMMUNOPHARMACOL, V10, P526, DOI 10.1016/j.intimp.2010.01.016
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jules J, 2012, J BIOL CHEM, V287, P15728, DOI 10.1074/jbc.M111.296228
   Kim H, 1998, INT J IMMUNOPHARMACO, V20, P231, DOI 10.1016/S0192 0561(98)00037 X
   Kim HN, 2012, EUR J PHARMACOL, V691, P69, DOI 10.1016/j.ejphar.2012.07.034
   Kim JH, 2009, MOL CELLS, V28, P201, DOI 10.1007/s10059 009 0123 y
   Kim SS, 2005, REDOX REP, V10, P311, DOI 10.1179/135100005X83734
   Kim T, 2013, J ETHNOPHARMACOL, V146, P83, DOI 10.1016/j.jep.2012.11.037
   Kook SH, 2013, J PERIODONT IN PRESS
   Lee JC, 2012, FREE RADICAL BIO MED, V53, P742, DOI 10.1016/j.freeradbiomed.2012.06.002
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022
   Lu J, 2013, TOXICOL IN VITRO, V27, P1007, DOI 10.1016/j.tiv.2013.01.011
   Motojima H, 2013, J NATURAL M IN PRESS
   Nakanishi A, 2013, MOL MED REP, V7, P1896, DOI 10.3892/mmr.2013.1446
   Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev biophys 083012 130338
   Qi W, 2012, OSTEOPOROSIS INT, V23, P2347, DOI 10.1007/s00198 011 1842 4
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rho J, 2004, MOL CELLS, V17, P1
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schapoval EES, 1998, J ETHNOPHARMACOL, V60, P53, DOI 10.1016/S0378 8741(97)00136 0
   Son YO, 2011, J PHARM PHARMACOL, V63, P1309, DOI 10.1111/j.2042 7158.2011.01335.x
   Son YO, 2009, APOPTOSIS, V14, P796, DOI 10.1007/s10495 009 0353 7
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tam DNN, 2012, TOXICOL APPL PHARM, V259, P329, DOI 10.1016/j.taap.2012.01.010
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   TOMODA M, 1994, CHEM PHARM BULL, V42, P1666, DOI 10.1248/cpb.42.1666
   Tsai HY, 2008, EUR J PHARMACOL, V588, P124, DOI 10.1016/j.ejphar.2008.04.024
   Xiong QB, 1998, PLANTA MED, V64, P120, DOI 10.1055/s 2006 957387
   Yu JY, 2012, TOXICOL IN VITRO, V26, P561, DOI 10.1016/j.tiv.2012.01.022
NR 47
TC 67
Z9 76
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 4
PY 2013
VL 8
IS 12
AR e80873
DI 10.1371/journal.pone.0080873
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 265KD
UT WOS:000327949300052
PM 24324641
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Sun, B
   Wu, HQ
   Lu, JJ
   Zhang, RC
   Shen, XL
   Gu, YF
   Shi, CG
   Zhang, Y
   Yuan, W
AF Sun, Bin
   Wu, Huiqiao
   Lu, Jiajia
   Zhang, Rongcheng
   Shen, Xiaolong
   Gu, Yifei
   Shi, Changgui
   Zhang, Ying
   Yuan, Wen
TI Irisin reduces bone fracture by facilitating osteogenesis and
   antagonizing TGF 8/Smad signaling in a growing mouse model of
   osteogenesis imperfecta
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Irisin; TGF 8; Bone fracture; Osteogenesis imperfecta; Osteogenesis
ID TGF BETA; REPRESSION; MECHANISMS; CARTILAGE; STRENGTH; CHILDREN
AB Objective: Osteogenesis imperfecta (OI) is a congenital disorder characterized by muscle defect and skeletal fragility, and no cure is yet available. Crosstalk between bone and muscle has become a new coming focus of therapeutic strategy in OI. Irisin, a secreted myokine, was found to be involved in regulating bone metabolism, and may be beneficial for the treatment of OI. However, its effects in OI have yet to be determined. This study sought to determine whether Irisin therapy is capable of reducing fracture risk in OI and to investigate the po tential mechanisms of action.Methods: Fibronectin type III domain containing 5 (FNDC5)/Irisin expression was assessed by enzyme linked immunosorbent assay (ELISA) and immunohistochemical staining. In vivo, X ray was used for fracture count ing and micro CT, dynamic histomorphometry analysis, immunohistochemistry, histomorphometry, and biome chanical test were used to evaluate the effects of Irisin on fracture frequency and bone quality in OI mouse model, oim/oim mouse. In vitro, osteogenesis related gene expressions were determined by quantitative real time PCR (qRT PCR), western blot, and osteoblastogenesis assay were assessed by alkaline phosphatase (ALP) staining and alizarin red S (ARS) staining. Mechanistically, cell immunofluorescence staining, co immunoprecipitation (co IP) molecular docking, western blot, luciferase reporter assay, and chromatin immunoprecipitation (ChIP) assay were used for elucidating the mechanisms of how Irisin antagonized transforming growth factor 8 (TGF 8)/Smad signaling in oim/oim osteoblasts and further attenuated the inhibitory effect of TGF 81 on osteogenic differentiation.Results: Musculoskeletal system related FNDC5/Irisin was decreased in the serum, muscle, and bone in oim/oim mice. Irisin administration reduced bone fracture and attenuated bone abnormalities by improving bone mass and strength and facilitating the expression of osteogenic differentiation markers. In vivo study and in vitro experi ments showed that Irisin antagonized TGF 8/Smad signaling by interfering with TGF 81 TGF 8 receptor II (T8RII) binding. In oim/oim osteoblasts, Irisin alleviated TGF 81 induced suppression of osteogenic differentiation through both integrin dependent and integrin independent mechanisms. Independent of integrin receptors, Irisin affected osteogenesis by activating ERK/p38 signaling and counteracting TGF 8/Smad2/3 signaling. In particular, Irisin alleviated TGF 81 induced inhibition of Runx2 function at the osteocalcin promoter through decreasing Smad2/3 signaling and inducing HADC4/5 degeneration.Conclusions: Collectively, Irisin could effectively reduce bone fracture in oim/oim mice through promoting osteogenesis and counteracting TGF beta/Smad signaling. Translational potential statement: Findings from this study provided evidence for using Irisin as a potential ther apeutic reagent to prevent the progression of OI.
C1 [Sun, Bin; Wu, Huiqiao; Lu, Jiajia; Zhang, Rongcheng; Shen, Xiaolong; Gu, Yifei; Shi, Changgui; Zhang, Ying; Yuan, Wen] Naval Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
   [Shi, Changgui; Zhang, Ying; Yuan, Wen] Naval Med Univ, Changzheng Hosp, Dept Orthopaed, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
C3 Naval Medical University; Naval Medical University
RP Shi, CG; Zhang, Y; Yuan, W (通讯作者)，Naval Med Univ, Changzheng Hosp, Dept Orthopaed, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM sunbinspine@smmu.edu.cn; wuhq1028@smmu.edu.cn; edward03218@163.com;
   zhangrcspine@163.com; spineshen@163.com; guyifei0001@126.com;
   charlieshi@smmu.edu.cn; zy_spine@smmu.edu.cn; yuanwencspine@163.com
RI ; Lu, Edward/HTN 3532 2023; Gu, Yifei/HTS 7141 2023; Sun,
   Bin/ACU 8491 2022
OI Lu, Jiajia/0000 0003 0957 592X; 
FU National Natural Science Foundation of China [82072394, 81802120,
   81902235]; Shanghai Sailing Program [19YF1447600]
FX This work was supported by the National Natural Science Foundation of
   China [82072394, 81802120, 81902235] and Shanghai Sailing Program
   [19YF1447600].
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Berman AG, 2020, BONE, V132, DOI 10.1016/j.bone.2019.115061
   Bonewald L, 2019, BONE, V120, P212, DOI 10.1016/j.bone.2018.11.002
   Brizola E, 2014, PEDIATR PHYS THER, V26, P245, DOI 10.1097/PEP.0000000000000042
   Clark EM, 2008, J BONE MINER RES, V23, P173, DOI 10.1359/JBMR.071010
   Colaianni G, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/902186
   Colaianni G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02557 8
   Colaianni G, 2015, P NATL ACAD SCI USA, V112, P12157, DOI 10.1073/pnas.1516622112
   Crane JL, 2016, METHODS MOL BIOL, V1344, P287, DOI 10.1007/978 1 4939 2966 5_18
   Delos D, 2008, J ORTHOP RES, V26, P153, DOI 10.1002/jor.20469
   El Gazzar A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020625
   Gentry BA, 2010, MATRIX BIOL, V29, P638, DOI 10.1016/j.matbio.2010.06.006
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Gremminger VL, 2019, J BONE MINER RES, V34, P1646, DOI 10.1002/jbmr.3732
   Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Iemura S, 2020, J BONE MINER METAB, V38, P161, DOI 10.1007/s00774 019 01043 7
   Jovanovic M, 2022, ENDOCR REV, V43, P61, DOI 10.1210/endrev/bnab017
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kim H, 2019, CELL, V178, P507, DOI 10.1016/j.cell.2019.06.028
   Li HT, 2010, AM J PATHOL, V176, P2405, DOI 10.2353/ajpath.2010.090704
   Liu LF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.668759
   Ma YX, 2018, FASEB J, V32, P5813, DOI 10.1096/fj.201700983RR
   Maak S, 2021, ENDOCR REV, V42, P436, DOI 10.1210/endrev/bnab003
   Momenzadeh S, 2021, BIOCHIMIE, V189, P144, DOI 10.1016/j.biochi.2021.06.016
   Nikander R, 2011, J BONE MINER RES, V26, P1638, DOI 10.1002/jbmr.363
   Peng H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01646 6
   Qi YP, 2021, ENVIRON TOXICOL PHAR, V84, DOI 10.1016/j.etap.2021.103613
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Shi CG, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/4243105
   Shi CG, 2016, J BONE MINER RES, V31, P1003, DOI 10.1002/jbmr.2770
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Song IW, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI152571
   Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 5 215
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tournis S, 2018, METABOLISM, V80, P27, DOI 10.1016/j.metabol.2017.06.001
   Wang JG, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00769
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Ye C, 2022, J ORTHOP TRANSL, V32, P1, DOI 10.1016/j.jot.2021.06.004
   Zhang J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.56
   Zhao YT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166182
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
   Zhu XF, 2021, J CELL PHYSIOL, V236, P664, DOI 10.1002/jcp.29894
NR 43
TC 17
Z9 19
U1 2
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JAN
PY 2023
VL 38
BP 175
EP 189
DI 10.1016/j.jot.2022.10.012
EA NOV 2022
PG 15
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 6R3PB
UT WOS:000892218300005
PM 36439629
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yin, H
   Wang, SF
   Zhang, YF
   Wu, M
   Wang, JW
   Ma, Y
AF Yin Heng
   Wang Shanfu
   Zhang Yafeng
   Wu Mao
   Wang JianWei
   Ma Yong
TI Zuogui Pill improves the dexamethasone induced osteoporosis progression
   in zebrafish larvae
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoporosis; TGF beta; Smad 3; Zuogui Pill
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; OSTEOBLAST; DISEASE
AB The current study was to evaluate the protective effects of Chinese medicine prescription Zuogui Pill (ZGP) on osteoporosis (OP) in zebrafish larvae induced by dexamethasone. Alizarin Red staining, calcium and phosphorus determination were performed to evaluate the effect of ZGP on bone mineralization. Hydroxyproline (HP), Alkaline phosphatase (ALP), and tartrate resistant acid phosphatase (TRAP) were also measured by commercial kits. We found that ZGP had positive effects in increasing bone mineral content (BMC), strengthening bone biomechanical, promoting bone formation, inhibiting bone resorption, and mediating protein levels of TGF beta 1/Smads signaling pathway. The findings demonstrated that ZGP treatments inhibited the phosphorylation of TGF beta and p Smad 3 as well as the expressions of collagen I and collagen II by western blot. Taken together, we demonstrated that ZGP may prevent osteoporosis via reversing the imbalance of bone fomation/bone resorption and activating the TGF beta Smad signal.
C1 [Yin Heng; Wang Shanfu; Zhang Yafeng; Wu Mao; Wang JianWei] Nanjing Univ Chinese Med, Wuxi Hosp, Wuxi, Peoples R China.
   [Ma Yong] Nanjing Univ Chinese Med, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine
RP Wang, JW; Ma, Y (通讯作者)，Nanjing Univ Chinese Med, Nanjing, Jiangsu, Peoples R China.
EM wangjianweitcm@163.com; mayongdoctor@126.com
RI Yin, Heng/G 5412 2010
FU key item of Wuxi medical management center [YGZXZ1517]; Wuxi Wei
   Planning Commission Project [QNRC042, Q201609]; National Natural Science
   Foundation of China [81473692]
FX This work was supported by key item of Wuxi medical management center
   (YGZXZ1517), Wuxi Wei Planning Commission Project (QNRC042, Q201609) and
   National Natural Science Foundation of China (81473692).
CR [Anonymous], EVIDENCE BASED COMPL
   Atfi A., 2008, REGULATORS SMAD2 3 T
   Choi EM, 2011, INT IMMUNOPHARMACOL, V11, P1541, DOI 10.1016/j.intimp.2011.05.011
   Cipriani C., 2017, BR J CLIN PHARM
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Desai S., 2017, J ETHNOPHARMACOL
   Goldsmith P, 2004, CURR OPIN PHARMACOL, V4, P504, DOI 10.1016/j.coph.2004.04.005
   Liu MJ, 2011, J TRADIT CHIN MED, V31, P98, DOI 10.1016/S0254 6272(11)60020 4
   Mansour A., 2017, TISSUE ENG A
   Park WY, 2017, TRANSPL P, V49, P1033, DOI 10.1016/j.transproceed.2017.03.038
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Persson P, 1999, J FISH BIOL, V54, P669, DOI 10.1111/j.1095 8649.1999.tb00645.x
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Suzuki N, 2009, LIFE SCI, V84, P482, DOI 10.1016/j.lfs.2009.01.008
   Wang Jing, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P781, DOI 10.3736/jcim20100809
   Wang YW, 2014, J ANAL METHODS CHEM, V2014, DOI 10.1155/2014/737961
   Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797
   Yan Y., 2017, J ETHNOPHARMACOL
NR 18
TC 44
Z9 49
U1 1
U2 37
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2018
VL 97
BP 995
EP 999
DI 10.1016/j.biopha.2017.11.029
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FR4NC
UT WOS:000419041300119
PM 29136778
DA 2025 08 17
ER

PT J
AU Takahata, M
   Maher, JR
   Juneja, SC
   Inzana, J
   Xing, LP
   Schwarz, EM
   Berger, AJ
   Awad, HA
AF Takahata, Masahiko
   Maher, Jason R.
   Juneja, Subhash C.
   Inzana, Jason
   Xing, Lianping
   Schwarz, Edward M.
   Berger, Andrew J.
   Awad, Hani A.
TI Mechanisms of bone fragility in a mouse model of glucocorticoid treated
   rheumatoid arthritis Implications for insufficiency fracture risk
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID TUMOR NECROSIS FACTOR; COLLAGEN CROSS LINKS; MICRO COMPUTED TOMOGRAPHY;
   INFLAMMATORY ARTHRITIS; INDUCED OSTEOPOROSIS; HUMAN OSTEOBLASTS;
   TRABECULAR BONE; CORTICAL BONE; UP REGULATION; FACTOR ALPHA
AB Objective Glucocorticoid (GC) therapy is associated with increased risk of fracture in patients with rheumatoid arthritis (RA). To elucidate the cause of this increased risk, we examined the effects of chronic erosive inflammatory arthritis and GC treatment on bone quality, structure, and biomechanical properties in a murine model.
   Methods Mice with established arthritis and expressing human tumor necrosis factor alpha (TNF alpha) transgene (Tg) and their wild type (WT) littermates were continually treated with GC (prednisolone 5 mg/kg/day via subcutaneous controlled release pellet) or placebo for 14, 28, or 42 days. Microstructure, biomechanical properties, chemical composition, and morphology of the tibiae and lumbar vertebral bodies were assessed by micro computed tomography, biomechanical testing, Raman spectroscopy, and histology, respectively. Serum markers of bone turnover were also determined.
   Results TNF Tg and GC treatment additively decreased mechanical strength and stiffness in both the tibiae and the vertebral bodies. GC treatment in the TNF Tg mice increased the ductility of tibiae under torsional loading. These changes were associated with significant alterations in the biochemical and structural composition of the mineral and organic components of the bone matrix, a decrease in osteoblast activity and bone formation, and an increase in osteoclast activity.
   Conclusion Our findings indicate that the concomitant decrease in bone strength and increase in bone ductility associated with chronic inflammation and GC therapy, coupled with the significant changes in the bone quality and structure, may increase the susceptibility of the bone to failure under low energy loading. This may explain the mechanism of symptomatic insufficiency fractures in patients with RA receiving GC therapy who do not have radiographic manifestations of fracture.
C1 [Awad, Hani A.] Univ Rochester, Dept Biomed Engn, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14620 USA.
C3 University of Rochester
RP Awad, HA (通讯作者)，Univ Rochester, Dept Biomed Engn, Ctr Musculoskeletal Res, Med Ctr, Box 665,601 Elmwood Ave, Rochester, NY 14620 USA.
EM hani_awad@urmc.rochester.edu
RI Takahata, Masahiko/E 1929 2012; Mostafa, Taymour/H 6834 2019; Awad,
   Hani/G 6976 2014; Berger, Andrew/C 5774 2014
OI Awad, Hani/0000 0003 2197 2610; Juneja, Subhash/0000 0002 8536 5724;
   Inzana, Jason/0000 0002 5221 273X; 
FU University of Rochester Provost's Multidisciplinary Award; NIH
   [R21 AR 061285, R01 AR 048697, R01 AR 053586, R01 AR 54041,
   P30 AR 061307]; MedImmune; Regeneron; Codevax; LAGeT; DePuy; Johnson
   Johnson; Affinergy
FX Supported in part by a University of Rochester Provost's
   Multidisciplinary Award and by NIH grants R21 AR 061285, R01 AR 048697,
   R01 AR 053586, R01 AR 54041, and P30 AR 061307.Dr. Schwarz has received
   consulting fees, speaking fees, and/or honoraria from MedImmune,
   Regeneron, Codevax, and LAGeT (less than $10,000 each) and from DePuy
   and Johnson & Johnson (more than $10,000), and he has served as an
   expert witness on behalf of Smith & Nephew. Dr. Awad has received
   consulting fees from Affinergy and an honorarium from the
   Musculoskeletal Transplant Foundation (less than $10,000 each).
CR Akkus O, 2004, BONE, V34, P443, DOI 10.1016/j.bone.2003.11.003
   Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   Battaglia TC, 2003, J BIOMECH ENG T ASME, V125, P615, DOI 10.1115/1.1611513
   Bi XH, 2011, J BIOMECH, V44, P297, DOI 10.1016/j.jbiomech.2010.10.009
   Bonewald L. F., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P101
   Boskey AL, 1999, J BONE MINER RES, V14, P330, DOI 10.1359/jbmr.1999.14.3.330
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brodt MD, 1999, J BONE MINER RES, V14, P2159, DOI 10.1359/jbmr.1999.14.12.2159
   Burr DB, 2002, BONE, V31, P8, DOI 10.1016/S8756 3282(02)00815 3
   BURSTEIN AH, 1975, J BONE JOINT SURG AM, V57, P956, DOI 10.2106/00004623 197557070 00013
   CURREY JD, 1988, J BIOMECH, V21, P131, DOI 10.1016/0021 9290(88)90006 1
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223 002 1049 y
   Goldring SR, 2006, DYNAMICS BONE CARTIL, P843
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Keaveny T.M., 2001, BONE MECH HDB
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Li P, 2003, SPRINGER SEMIN IMMUN, V25, P19, DOI 10.1007/s00281 003 0125 3
   Maher JR, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3613933
   Maher JR, 2010, APPL SPECTROSC, V64, P61, DOI 10.1366/000370210790571936
   Nampei A, 2008, MOD RHEUMATOL, V18, P170, DOI 10.1007/s10165 008 0032 5
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Paschalis EP, 2003, J BONE MINER RES, V18, P1942, DOI 10.1359/jbmr.2003.18.11.1942
   Paschalis EP, 2001, J BONE MINER RES, V16, P1821, DOI 10.1359/jbmr.2001.16.10.1821
   Paschalis EP, 2004, J BONE MINER RES, V19, P2000, DOI 10.1359/JBMR.040820
   Pennisi P, 2006, CLIN ORTHOP RELAT R, P39, DOI 10.1097/01.blo.0000200238.29931.1f
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Proulx ST, 2007, ANN NY ACAD SCI, V1117, P106, DOI 10.1196/annals.1402.016
   REILLY DT, 1974, J BONE JOINT SURG AM, VA 56, P1001, DOI 10.2106/00004623 197456050 00012
   Reynolds DG, 2007, J BIOMECH, V40, P3178, DOI 10.1016/j.jbiomech.2007.04.004
   Silva MJ, 2006, J BONE MINER RES, V21, P78, DOI 10.1359/JBMR.050909
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467 9868.00346
   Turner C H, 1989, J Biomech Eng, V111, P256
   Valcourt U, 2007, J BIOL CHEM, V282, P5691, DOI 10.1074/jbc.M610536200
   van Staa TP, 2006, ARTHRITIS RHEUM US, V54, P3104, DOI 10.1002/art.22117
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Viguet Carrin S, 2006, BONE, V39, P1073, DOI 10.1016/j.bone.2006.05.013
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474 9726.2009.00545.x
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Zhao L, 2011, STEM CELLS, V29, P1601, DOI 10.1002/stem.703
NR 51
TC 36
Z9 40
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD NOV
PY 2012
VL 64
IS 11
BP 3649
EP 3659
DI 10.1002/art.34639
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 030CC
UT WOS:000310544500018
PM 22832945
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jeffcoach, DR
   Sams, VG
   Lawson, CM
   Enderson, BL
   Smith, ST
   Kline, H
   Barlow, PB
   Wylie, DR
   Krumenacker, LA
   McMillen, JC
   Pyda, J
   Daley, BJ
AF Jeffcoach, David R.
   Sams, Valerie G.
   Lawson, Christy M.
   Enderson, Blaine L.
   Smith, Scott T.
   Kline, Heather
   Barlow, Patrick B.
   Wylie, Douglas R.
   Krumenacker, Laura A.
   McMillen, James C.
   Pyda, Jordan
   Daley, Brian J.
CA Univ Tennessee Med Ctr
TI Nonsteroidal anti  inflammatory drugs' impact on nonunion and infection
   rates in long  bone fractures
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE NSAIDs; long bone; fractures; healing; nonunion
ID ANTIINFLAMMATORY DRUGS; RISK
AB BACKGROUND There is a dearth of clinical data regarding the effect of nonsteroidal anti inflammatory drugs (NSAIDs) on long bone fracture (LBF) healing in the acute trauma setting. The orthopedic community believes that the use of NSAIDs in the postoperative period will result in poor healing and increased infectious complications. We hypothesized that, first, NSAID use would not increase nonunion/malunion and infection rates after LBF. Second, we hypothesized that tobacco use would cause higher rates of these complications.
   METHODS A retrospective study of all patients with femur, tibia, and/or humerus fractures between October 2009 and September 2011 at a Level 1 academic trauma center was performed . In addition to nonunion/malunion and infection rates, patient records were reviewed for demographic data, mechanism of fracture, type of fracture, tobacco use, Injury Severity Score (ISS), comorbidities, and medications given.
   RESULTS During the 24 month period, 1,901 patients experienced LBF; 231 (12.1%) received NSAIDs; and 351 (18.4%) were smokers. The overall complication rate including nonunion/malunion and infection was 3.2% (60 patients). Logistic regression analysis with adjusted odds ratios were calculated on the risk of complications given NSAID use and/or smoking, and we found that a patient is significantly more likely to have a complication if he or she received an NSAID (odds ratio, 2.17; 95% confidence interval, 1.15 4.10; p < 0.016) in the inpatient postoperative setting. Likewise, smokers are significantly more likely to have complications (odds ratio, 3.19; 95% confidence interval, 1.84 5.53; p < 0.001).
   CONCLUSION LBF patients who received NSAIDs in the postoperative period were twice as likely and smokers more than three times likely to suffer complications such as nonunion/malunion or infection. We recommend avoiding NSAID in traumatic LBF.
   LEVEL OF EVIDENCE Epidemiologic & therapeutic study; level II.
C1 [Jeffcoach, David R.; Sams, Valerie G.; Lawson, Christy M.; Enderson, Blaine L.; Pyda, Jordan; Daley, Brian J.] Univ Tennessee, Med Ctr, Dept Surg, Knoxville, TN 37920 USA.
   [Wylie, Douglas R.; Krumenacker, Laura A.; McMillen, James C.] Univ Tennessee, Med Ctr, Dept Pharm, Knoxville, TN 37920 USA.
   [Smith, Scott T.; Kline, Heather] Univ Tennessee, Med Ctr, Knoxville, TN 37920 USA.
   [Barlow, Patrick B.] Univ Tennessee, Dept Stat, Grad Sch Med, Knoxville, TN 37996 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; University of Tennessee System; University of Tennessee
   Health Science Center; University of Tennessee System; University of
   Tennessee Health Science Center
RP Jeffcoach, DR (通讯作者)，Univ Tennessee, Med Ctr, Dept Surg, 1924 Alcoa Highway Box U 11, Knoxville, TN 37920 USA.
EM djeffcoach@utmck.edu
RI Smith, Scott/M 8785 2016
OI Barlow, Patrick/0000 0001 5063 4317
CR ADOLPHSON P, 1993, ARCH ORTHOP TRAUM SU, V112, P127, DOI 10.1007/BF00449987
   Andersen T, 2001, SPINE, V26, P2623, DOI 10.1097/00007632 200112010 00018
   [Anonymous], 2002, VA DOD CLIN PRACT GU
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Clarke S, 2005, EMERG MED J, V22, P652, DOI 10.1136/emj.2005.028647
   Dodwell ER, 2010, CALCIFIED TISSUE INT, V87, P193, DOI 10.1007/s00223 010 9379 7
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Fransen M, 2004, COCHRANE DATABASE SY, V3
   Goudas L, 2001, EVIDENCE REPORTS TEC
   Harvey E J, 2002, Am J Orthop (Belle Mead NJ), V31, P518
   Karladani AH, 2001, ARCH ORTHOP TRAUM SU, V121, P325, DOI 10.1007/s004020000252
   Reuben SS, 2001, ANESTH ANALG, V93, P803, DOI 10.1097/00000539 200109000 00057
   Rushfeldt CF, 2011, INT J COLORECTAL DIS, V26, P1501, DOI 10.1007/s00384 011 1285 6
   Spiro AS, 2010, J ORTHOP RES, V28, P785, DOI 10.1002/jor.21044
   Van Staa TP, 2000, BONE, V27, P563, DOI 10.1016/S8756 3282(00)00361 6
NR 16
TC 71
Z9 79
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163 0755
EI 2163 0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD MAR
PY 2014
VL 76
IS 3
BP 779
EP 783
DI 10.1097/TA.0b013e3182aafe0d
PG 5
WC Critical Care Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Surgery
GA AB8YW
UT WOS:000332077100044
PM 24553548
DA 2025 08 17
ER

PT J
AU Pal, S
   Porwal, K
   Khanna, K
   Gautam, MK
   Malik, MY
   Rashid, M
   Macleod, RJ
   Wahajuddin, M
   Parameswaran, V
   Bellare, JR
   Chattopadhyay, N
AF Pal, Subhashis
   Porwal, Konica
   Khanna, Kunal
   Gautam, Manoj Kumar
   Malik, Mohd Yaseen
   Rashid, Mamunur
   Macleod, R. John
   Wahajuddin, Muhammad
   Parameswaran, Venkitanarayanan
   Bellare, Jayesh R.
   Chattopadhyay, Naibedya
TI Oral dosing of pentoxifylline, a pan phosphodiesterase inhibitor
   restores bone mass and quality in osteopenic rabbits by an osteogenic
   mechanism: A comparative study with human parathyroid hormone
SO BONE
LA English
DT Article
DE Pharmacokinetics; Bone turnover; Bone quality; Bone formation; Bone
   resorption; Osteopenia
ID SENSING RECEPTOR ANTAGONIST; POSTMENOPAUSAL WOMEN; TRABECULAR BONE;
   CORTICAL BONE; OSTEOPOROSIS; DENSITY; DRUG; DISCONTINUATION; MANAGEMENT;
   INCREASES
AB The non selective phosphodiesterase inhibitor pentoxifylline (TX) is used for the treatment of intermittent claudication due to artery occlusion. Previous studies in rodents have reported salutary effects of the intraperitoneal administration of PTX in segmental bone defect and fracture healing, as well as stimulation of bone formation. We determined the effect of orally dosed PTX in skeletally mature ovariectomized (OVX) rabbits with osteopenia. The half maximal effective concentration (EC50) of PTX in rabbit bone marrow stromal cells was 3.07 +/  1.37 nM. The plasma PTX level was 2.05 +/  0.522 nM after a single oral dose of 12.5mg/kg, which was one sixth of the adult human dose of PTX. Four months of daily oral dosing of PTX at 12.5 mg/kg to osteopenic rabbits completely restored bone mineral density, bone mineral content (BMC), microarchitecture and bone strength to the level of the sham operated (ovary intact) group. The bone strength to BMC relationship between PTX and sham was similar. The bone restorative effect of PTX was observed in both axial and appendicular bones. In osteopenic rabbits, PTX increased serum amino terminal propeptide, mineralized nodule formation by stromal cells and osteogenic gene expression in bone. PTX reversed decreased calcium weight percentage and poor crystal packing found in osteopenic rabbits. Furthermore, similar to parathyroid hormone (PTH), PTX had no effect on bone resorption. Taken together, our data show that PTX completely restored bone mass, bone strength and bone mineral properties by an anabolic mechanism. PTX has the potential to become an oral osteogenic drug for the treatment of post menopausal osteoporosis.
C1 [Pal, Subhashis; Porwal, Konica; Chattopadhyay, Naibedya] CSIR, CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Khanna, Kunal; Bellare, Jayesh R.] Indian Inst Technol, Dept Chem Engn, Mumbai 400076, Maharashtra, India.
   [Gautam, Manoj Kumar; Parameswaran, Venkitanarayanan] Indian Inst Technol Kanpur, Dept Mech Engn, Kanpur 208016, Uttar Pradesh, India.
   [Malik, Mohd Yaseen; Rashid, Mamunur; Wahajuddin, Muhammad] CDRI CSIR, Div Pharmaceut, Lucknow 226031, Uttar Pradesh, India.
   [Macleod, R. John] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Indian Institute of Technology
   System (IIT System); Indian Institute of Technology (IIT)   Bombay;
   Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Kanpur; Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI); Queens
   University   Canada
RP Chattopadhyay, N (通讯作者)，CSIR Cent Drug Res Inst, Endocrinol Div, Lucknow 226021, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI ; Bellare, Jayesh/AAO 8713 2020;   , Wahajuddin/B 4413 2010; Pal,
   Subhashis/IXD 3635 2023; Chattopadhyay, Naibedya/AAF 2058 2019; Rashid,
   Mamunur/AAQ 1623 2021; Malik, Muhammad/X 5316 2018
OI Porwal, Konica/0000 0002 6447 4681; Pal, Subhashis/0000 0002 3916 5545;
   Rashid, Mamunur/0000 0003 3122 2784; , Wahajuddin/0000 0003 3362 7558;
   Malik, Mohd Yaseen/0000 0002 5514 0364; Chattopadhyay,
   Naibedya/0000 0003 2473 0246; 
FU Council of Scientific and Industrial Research, India
FX Council of Scientific and Industrial Research, India.
CR Aleksyniene R, 2009, ACTA ORTHOP, V80, P716, DOI 10.3109/17453670903350032
   Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev med 070313 022841
   Best BM, 2003, CURR THER RES CLIN E, V64, P96, DOI 10.1016/S0011 393X(03)00018 3
   Castañeda S, 2006, SKELETAL RADIOL, V35, P34, DOI 10.1007/s00256 005 0022 z
   Champion S, 2014, CARDIOVASC THER, V32, P159, DOI 10.1111/1755 5922.12076
   Cho ES, 2005, YONSEI MED J, V46, P149, DOI 10.3349/ymj.2005.46.1.149
   Corsello SM, 2017, NAT MED, V23, P405, DOI 10.1038/nm.4306
   Cosman F, 2016, OSTEOPOROSIS INT, V27, P377, DOI 10.1007/s00198 015 3392 7
   DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122
   Feil R, 2006, EMBO REP, V7, P149, DOI 10.1038/sj.embor.7400627
   Finkelstein JS, 2008, J CLIN ENDOCR METAB, V93, P861, DOI 10.1210/jc.2007 1876
   Fonseca H, 2014, SPORTS MED, V44, P37, DOI 10.1007/s40279 013 0100 7
   FRAMPTON JE, 1995, DRUG AGING, V7, P480, DOI 10.2165/00002512 199507060 00007
   GILSANZ V, 1988, AM J PHYSIOL, V255, pE416, DOI 10.1152/ajpendo.1988.255.4.E416
   GRARDEL B, 1994, OSTEOPOROSIS INT, V4, P204, DOI 10.1007/BF01623240
   Hara K, 2002, BONE, V31, P575, DOI 10.1016/S8756 3282(02)00874 8
   Hock J. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P33
   Khan K, 2012, MOL NUTR FOOD RES, V56, P1860, DOI 10.1002/mnfr.201200200
   Khan MP, 2016, J BONE MINER RES, V31, P615, DOI 10.1002/jbmr.2719
   Kinoshita T, 2000, BONE, V27, P811, DOI 10.1016/S8756 3282(00)00395 1
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008 2630
   LESKO LJ, 1986, J ALLERGY CLIN IMMUN, V78, P723, DOI 10.1016/0091 6749(86)90052 7
   Li BF, 2010, ACTA ORTHOP, V81, P396, DOI 10.3109/17453674.2010.483986
   Liu XL, 2012, MED ENG PHYS, V34, P2, DOI 10.1016/j.medengphy.2011.06.010
   Luz Rentero Maria, 2008, Open Rheumatol J, V2, P58, DOI 10.2174/1874312900802010058
   McCarty MF, 2016, OPEN HEART, V3, DOI 10.1136/openhrt 2015 000365
   Modi A, 2017, OSTEOPOROSIS INT, V28, P1355, DOI 10.1007/s00198 016 3886 y
   Moola Kumar S, 2015, J Pharm Anal, V5, P371, DOI 10.1016/j.jpha.2014.09.001
   Morley Paul, 2005, Expert Opin Drug Deliv, V2, P993, DOI 10.1517/17425247.2.6.993
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   PANG PKT, 1980, PHARMACOLOGY, V21, P213, DOI 10.1159/000137435
   Paschalis EP, 2011, CLIN ORTHOP RELAT R, V469, P2170, DOI 10.1007/s11999 010 1751 4
   Paschalis EP, 2003, J BONE MINER RES, V18, P769, DOI 10.1359/jbmr.2003.18.4.769
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Polyzos SA, 2015, EXPERT OPIN INV DRUG, V24, P145, DOI 10.1517/13543784.2015.973021
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Roschger P, 1998, BONE, V23, P319, DOI 10.1016/S8756 3282(98)00112 4
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Tripathi JK, 2015, BIOMATERIALS, V56, P92, DOI 10.1016/j.biomaterials.2015.03.046
   Vashghani Farahani Mohammad Mahdi, 2017, Lab Anim Res, V33, P15, DOI 10.5625/lar.2017.33.1.15
   WANG HH, 1984, EUR J PHARMACOL, V97, P209
   1993, BONE MINER, V23, P301
   2015, ACTA ORTHOP TRAUMATO, V49, P676, DOI DOI 10.3944/AOTT.2015.15.0158
   2016, EXPERT REV ANTICANC, V16, P423, DOI DOI 10.1586/14737140.2016.1159515
   2007, J BONE MINER RES, V22, P849, DOI DOI 10.1359/JBMR.070302
   2002, J BIOL CHEM, V277, P2219
NR 47
TC 15
Z9 15
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2019
VL 123
BP 28
EP 38
DI 10.1016/j.bone.2019.03.010
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HY1PW
UT WOS:000467890000005
PM 30858147
DA 2025 08 17
ER

PT J
AU Han, TZ
   Mignatti, P
   Abramson, SB
   Attur, M
AF Han, Tianzhen
   Mignatti, Paolo
   Abramson, Steven B.
   Attur, Mukundan
TI Periostin interaction with discoidin domain receptor 1 (DDR1) promotes
   cartilage degeneration
SO PLOS ONE
LA English
DT Article
ID GENE EXPRESSION; ARTICULAR CARTILAGE; BETA CATENIN; OSTEOARTHRITIS;
   REVEALS; PATHWAY; IDENTIFICATION; DEGRADATION; INHIBITION; DISCOVERY
AB Osteoarthritis (OA) is characterized by progressive loss of articular cartilage accompanied by the new bone formation and, often, a synovial proliferation that culminates in pain, loss of joint function, and disability. However, the cellular and molecular mechanisms of OA progression and the relative contributions of cartilage, bone, and synovium remain unclear. We recently found that the extracellular matrix (ECM) protein periostin (Postn, or osteoblast specific factor, OSF 2) is expressed at high levels in human OA cartilage. Multiple groups have also reported elevated expression of Postn in several rodent models of OA. We have previously reported that in vitro Postn promotes collagen and proteoglycan degradation in human chondrocytes through AKT/beta catenin signaling and downstream activation of MMP 13 and ADAMTS4 expression. Here we show that Postn induces collagen and proteoglycan degradation in cartilage by signaling through discoidin domain receptor 1 (DDR1), a receptor tyrosine kinase. The genetic deficiency or pharmacological inhibition of DDR1 in mouse chondrocytes blocks Postn induced MMP 13 expression. These data show that Postn is signaling though DDR1 is mechanistically involved in OA pathophysiology. Specific inhibitors of DDR1 may provide therapeutic opportunities to treat OA.
C1 [Han, Tianzhen; Mignatti, Paolo; Abramson, Steven B.; Attur, Mukundan] NYU Langone Orthoped Hosp, NYU Grossman Sch Med, Div Rheumatol, Dept Med, New York, NY 10003 USA.
RP Attur, M (通讯作者)，NYU Langone Orthoped Hosp, NYU Grossman Sch Med, Div Rheumatol, Dept Med, New York, NY 10003 USA.
EM mukundan.attur@nyulangone.org
RI ; Attur, Mukundan/O 1578 2019
OI ATTUR, MUKUNDAN/0000 0001 7080 8118; Mignatti,
   Paolo/0000 0002 8157 457X; Abramson, Steven/0000 0002 0668 6344
FU National Institute of Health [AR054817, AR068341, AR070934]
FX Funding for this project provided by the National Institute of Health
   grant AR054817, AR068341, and AR070934. The funders had no role in study
   design, data collection, and analysis, decision to publish, or
   preparation of the manuscript
CR Alfieri C, 2015, NEPHROL DIAL TRANSPL, V30, P1965, DOI 10.1093/ndt/gfv074
   [Anonymous], PLOS ONE
   Attur M, 2015, FASEB J, V29, P4107, DOI 10.1096/fj.15 272427
   Balakrishnan L, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559 0275 11 6
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Brophy RH, 2019, OSTEOARTHR CARTILAGE, V27, P1778, DOI 10.1016/j.joca.2019.08.002
   Brophy RH, 2016, AM J SPORT MED, V44, P2064, DOI 10.1177/0363546516643810
   Cai L, 2019, FASEB J, V33, P8386, DOI 10.1096/fj.201802281R
   Chijimatsu R, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0682 3
   Chinzei N, 2018, OSTEOARTHR CARTILAGE, V26, P588, DOI 10.1016/j.joca.2018.01.017
   Chinzei N, 2019, ARTHRITIS RHEUMATOL, V71, P370, DOI 10.1002/art.40730
   Chou CH, 2015, OSTEOARTHR CARTILAGE, V23, P571, DOI 10.1016/j.joca.2014.12.020
   Chou CH, 2013, OSTEOARTHR CARTILAGE, V21, P450, DOI 10.1016/j.joca.2012.11.016
   Chou CH, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4380
   Coelho NM, 2018, CELL ADHES MIGR, V12, P348, DOI 10.1080/19336918.2018.1448353
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Das S, 2006, CANCER RES, V66, P8123, DOI 10.1158/0008 5472.CAN 06 1215
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fu HL, 2013, J BIOL CHEM, V288, P7430, DOI 10.1074/jbc.R112.444158
   Gao MS, 2013, J MED CHEM, V56, P3281, DOI 10.1021/jm301824k
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Hakuno D, 2010, J CLIN INVEST, V120, P2292, DOI 10.1172/JCI40973
   Honsawek S, 2015, JOINT BONE SPINE, V82, P352, DOI 10.1016/j.jbspin.2015.01.023
   Jia Y, 2019, LIFE SCI, V226, P91, DOI 10.1016/j.lfs.2019.04.021
   Jonason JH, 2015, METHODS MOL BIOL, V1226, P11, DOI 10.1007/978 1 4939 1619 1_2
   Karimaian A, 2017, DNA REPAIR, V51, P14, DOI 10.1016/j.dnarep.2017.01.003
   Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002
   Katsara O, 2017, ARTHRITIS RHEUMATOL, V69, P586, DOI 10.1002/art.39947
   Kerroch M, 2016, SCI REP UK, V6, DOI 10.1038/srep21262
   Kim BJ, 2015, BONE, V81, P435, DOI 10.1016/j.bone.2015.08.014
   Kim HG, 2013, ACS CHEM BIOL, V8, P2145, DOI 10.1021/cb400430t
   Kormann R, 2019, J AM SOC NEPHROL
   Kumar P, 2018, J BIOL CHEM, V293, P12781, DOI 10.1074/jbc.RA117.001601
   Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200
   Leitinger B, 2014, INT REV CEL MOL BIO, V310, P39, DOI 10.1016/B978 0 12 800180 6.00002 5
   Li GH, 2010, ATHEROSCLEROSIS, V208, P358, DOI 10.1016/j.atherosclerosis.2009.07.046
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P705, DOI 10.1002/art.33388
   Lourido L, 2014, J PROTEOME RES, V13, P6096, DOI 10.1021/pr501024p
   MATSUZAWA M, 2015, J PERIODONTAL RES, V50, P855, DOI DOI 10.1111/JRE.12277
   Nakazeki F, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27009 9
   Neuhaus B, 2011, CELL MOL LIFE SCI, V68, P3757, DOI 10.1007/s00018 011 0676 8
   Oka T, 2007, CIRC RES, V101, P313, DOI 10.1161/CIRCRESAHA.107.149047
   Orecchia P, 2011, EUR J CANCER, V47, P2221, DOI 10.1016/j.ejca.2011.04.026
   Rammal H, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00055
   Schminke B, 2014, CELL MOL LIFE SCI, V71, P1081, DOI 10.1007/s00018 013 1436 8
   Soomro I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211670
   Watanabe T, 2012, ARCH ORAL BIOL, V57, P52, DOI 10.1016/j.archoralbio.2011.07.010
   Xu HF, 2011, MATRIX BIOL, V30, P16, DOI 10.1016/j.matbio.2010.10.004
NR 49
TC 29
Z9 32
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2020
VL 15
IS 4
AR e0231501
DI 10.1371/journal.pone.0231501
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA LS8RF
UT WOS:000536647300015
PM 32330138
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, ZH
   Zhao, F
   Liang, C
   Hu, LF
   Li, DJ
   Zhang, Y
   Yin, C
   Chen, L
   Wang, LY
   Lin, X
   Su, PH
   Ma, JH
   Yang, CF
   Tian, Y
   Zhang, WJ
   Li, Y
   Peng, SL
   Chen, WY
   Zhang, G
   Qian, AR
AF Chen, Zhihao
   Zhao, Fan
   Liang, Chao
   Hu, Lifang
   Li, Dijie
   Zhang, Yan
   Yin, Chong
   Chen, Lei
   Wang, Luyao
   Lin, Xiao
   Su, Peihong
   Ma, Jianhua
   Yang, Chaofei
   Tian, Ye
   Zhang, Wenjuan
   Li, Yu
   Peng, Songlin
   Chen, Weiyi
   Zhang, Ge
   Qian, Airong
TI Silencing of miR 138 5p sensitizes bone anabolic action to mechanical
   stimuli
SO THERANOSTICS
LA English
DT Article
DE mechanoresponsive; miR 138 5p; sensitize; bone formation; osteoporosis
ID MESENCHYMAL STEM CELLS; REGULATES OSTEOGENIC DIFFERENTIATION; PROMOTES
   OSTEOBLAST DIFFERENTIATION; MICRORNA; OSTEOSARCOMA; LIGAMENT; CLUSTER;
   STRESS; RNA
AB Emerging evidence is revealing that microRNAs (miRNAs) play essential roles in mechanosensing for regulating osteogenesis. However, no mechanoresponsive miRNAs have been identified in human bone specimens.
   Methods: Bedridden and aged patients, hindlimb unloaded and aged mice, and Random Positioning Machine and primary aged osteoblasts were adopted to simulate mechanical unloading conditions at the human, animal and cellular levels, respectively. Treadmill exercise and Flexcell cyclic mechanical stretching were used to simulate mechanical loading in vivo and in vitro, respectively.
   Results: Here, we found increased miR 138 5p levels with a lower degree of bone formation in bone specimens from bedridden and aged patients. Lossand gain of function studies showed that miR 138 5p directly targeted microtubule actin crosslinking factor 1 (MACF1) to inhibit osteoblast differentiation under different mechanical conditions. Regarding translational medicine, bone targeted inhibition of miR 138 5p attenuated the decrease in the mechanical bone anabolic response in hindlimb unloaded mice. Moreover, bone targeted inhibition of miR 138 5p sensitized the bone anabolic response to mechanical loading in both miR 138 5p transgenic mice and aged mice to promote bone formation.
   Conclusion: These data suggest that miR 138 5p as a mechanoresponsive miRNA accounts for the mechanosensitivity of the bone anabolic response and that inhibition of miR 138 5p in osteoblasts may be a novel bone anabolic sensitization strategy for ameliorating disuse or senile osteoporosis.
C1 [Chen, Zhihao; Zhao, Fan; Hu, Lifang; Li, Dijie; Zhang, Yan; Yin, Chong; Chen, Lei; Lin, Xiao; Su, Peihong; Ma, Jianhua; Yang, Chaofei; Tian, Ye; Zhang, Wenjuan; Li, Yu; Qian, Airong] Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn,Sch Life Sci, Key Lab Space Biosci & Biotechnol,NPU UAB Joint L, Lab Bone Metab,Xian Key Lab Special Med & Hlth En, Xian 710072, Shaanxi, Peoples R China.
   [Chen, Zhihao; Zhao, Fan; Liang, Chao; Hu, Lifang; Li, Dijie; Zhang, Yan; Yin, Chong; Chen, Lei; Wang, Luyao; Lin, Xiao; Su, Peihong; Ma, Jianhua; Yang, Chaofei; Tian, Ye; Zhang, Wenjuan; Li, Yu; Zhang, Ge; Qian, Airong] Northwestern Polytech Univ Hong Kong Baptist Univ, Xian 710072, Shaanxi, Peoples R China.
   [Liang, Chao; Wang, Luyao; Peng, Songlin; Zhang, Ge] Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Sch Chinese Med, Hong Kong 999077, Peoples R China.
   [Peng, Songlin] Jinan Univ, Sch Med, Southern Univ Sci & Technol, Dept Spine Surg,Shenzhen Peoples Hosp, Shenzhen 518020, Peoples R China.
   [Chen, Weiyi] Taiyuan Univ Technol, Coll Biomed Engn, Shanxi Key Lab Mat Strength & Struct Impact, Taiyuan 030024, Peoples R China.
   [Liang, Chao] Southern Univ Sci & Technol, Dept Biol, Shenzhen 518055, Peoples R China.
C3 Northwestern Polytechnical University; Hong Kong Baptist University;
   Jinan University; Southern University of Science & Technology; Taiyuan
   University of Technology; Southern University of Science & Technology
RP Qian, AR (通讯作者)，Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn,Sch Life Sci, Key Lab Space Biosci & Biotechnol,NPU UAB Joint L, Lab Bone Metab,Xian Key Lab Special Med & Hlth En, Xian 710072, Shaanxi, Peoples R China.; Zhang, G; Qian, AR (通讯作者)，Northwestern Polytech Univ Hong Kong Baptist Univ, Xian 710072, Shaanxi, Peoples R China.; Peng, SL; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Sch Chinese Med, Hong Kong 999077, Peoples R China.; Peng, SL (通讯作者)，Jinan Univ, Sch Med, Southern Univ Sci & Technol, Dept Spine Surg,Shenzhen Peoples Hosp, Shenzhen 518020, Peoples R China.; Chen, WY (通讯作者)，Taiyuan Univ Technol, Coll Biomed Engn, Shanxi Key Lab Mat Strength & Struct Impact, Taiyuan 030024, Peoples R China.
EM psling824@163.com; chenweiyi@tyut.edu.cn; zhangge@hkbu.edu.hk;
   qianair@nwpu.edu.cn
RI chen, zhihao/GXM 3816 2022; Zhang, Ge/N 4150 2013; Lin,
   Xiao/LYP 2289 2024; Li, Dijie/KVB 3667 2024; Chen, Lei/AAT 6684 2021;
   Li, Yuzhu/HHN 5062 2022; Li, YiXue/JRW 6306 2023; peng,
   sl/ISA 1370 2023; Liang, Chao/AAS 6999 2021; Hu, Lifang/W 8020 2019;
   Chen, Zhihao/ACK 3514 2022; chen, weiyu/M 5972 2018; Zhang,
   Yan/MTF 5312 2025
OI Liang, Chao/0000 0002 5617 3483; Zhang, Yan/0000 0001 6213 4416; Chen,
   Zhihao/0000 0003 0128 1409; Peng, Songlin/0000 0002 4042 7071; Qian,
   Airong/0000 0002 0740 9218; 
FU Natural Science Foundation of China [31570940, 81772017, 31400725,
   81700784, 81872129, 81700780, 82072106, 32071517, 32000924, 81922081,
   81801871]; Innovation Foundation for Doctor Dissertation of Northwestern
   Polytechnical University [CX201821]; China Postdoctoral Science
   Foundation [2018T111099, 2017M610653, 2017M613196]; Fundamental Research
   Funds for the Central Universities [3102018zy053, 3102019ghxm012];
   Shenzhen Science and Technology Project [JCYJ20160229174320053]; Young
   Talent Fund of University Association for Science and Technology in
   Shaanxi, China [20170401]; Natural Science Basic Research Plan in
   Shaanxi Province of China [2018JM3040]; Shaanxi Provincial Key RD
   Program [2018KWZ 10]; Shaanxi Postdoctoral Science Foundation
   [2017BSHEDZZ13]
FX The authors would like to thank Dr. Hong Zhou (The University of Sydney,
   Australia) for generously providing MC3T3 E1 cell line. This work was
   supported by the Natural Science Foundation of China (31570940,
   81772017, 31400725, 81700784, 81872129, 81700780, 82072106, 32071517,
   32000924, 81922081 and 81801871), the Innovation Foundation for Doctor
   Dissertation of Northwestern Polytechnical University (CX201821), the
   China Postdoctoral Science Foundation (2018T111099, 2017M610653,
   2017M613196), the Fundamental Research Funds for the Central
   Universities (3102018zy053, 3102019ghxm012), the Shenzhen Science and
   Technology Project (JCYJ20160229174320053), Young Talent Fund of
   University Association for Science and Technology in Shaanxi, China
   (20170401), the Project Supported by Natural Science Basic Research Plan
   in Shaanxi Province of China (2018JM3040), Shaanxi Provincial Key R&D
   Program (2018KWZ 10), Shaanxi Postdoctoral Science Foundation
   (2017BSHEDZZ13).
CR Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006
   Bellavia D, 2019, BONE, V122, P52, DOI 10.1016/j.bone.2019.02.013
   Cao YJ, 2015, INT J MOL MED, V36, P760, DOI 10.3892/ijmm.2015.2275
   Carina V, 2020, CALCIFIED TISSUE INT, V107, P301, DOI 10.1007/s00223 020 00724 0
   Chen N, 2016, J DENT RES, V95, P1425, DOI 10.1177/0022034516657043
   Chen Z, 2017, INT J MOL SCI, V18
   Chen ZY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082864
   Costa V, 2019, INT J MOL SCI, V20
   Costa V, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121495
   Eimori K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156991
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Fassett JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073887
   Feng L, 2020, MOL THER NUCL ACIDS, V21, P1017, DOI 10.1016/j.omtn.2020.07.018
   Feng L, 2018, MOL THER NUCL ACIDS, V11, P345, DOI 10.1016/j.omtn.2018.03.004
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580 018 0045 7
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Hu LF, 2018, J CELL PHYSIOL, V233, P1574, DOI 10.1002/jcp.26059
   Hu ZB, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1581 6
   Hu ZB, 2015, SCI REP UK, V5, DOI 10.1038/srep18655
   Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116
   Ibrahim M, 2016, FOLIA BIOL PRAGUE, V62, P175
   Javaheri B, 2019, CURR OSTEOPOROS REP, V17, P560, DOI 10.1007/s11914 019 00553 7
   Jiang BE, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046 016 0348 5
   Li B, 2017, INT J MOL MED, V40, P1105, DOI 10.3892/ijmm.2017.3086
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li D, 2019, J CELL PHYSIOL, V234, P21316, DOI 10.1002/jcp.28736
   Li J, 2015, BONE, V78, P130, DOI 10.1016/j.bone.2015.05.003
   Ling SK, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00069
   Liu N, 2020, THERANOSTICS, V10, P7492, DOI 10.7150/thno.44309
   Mohan S, 2015, PHYSIOL GENOMICS, V47, P33, DOI 10.1152/physiolgenomics.00107.2014
   Pagnotti GM, 2019, NAT REV ENDOCRINOL, V15, P339, DOI 10.1038/s41574 019 0170 1
   Qian AR, 2009, BIOELECTROMAGNETICS, V30, P545, DOI 10.1002/bem.20511
   Qiu WX, 2020, J CELL MOL MED, V24, P317, DOI 10.1111/jcmm.14729
   Qu B, 2014, BIOCHEM BIOPH RES CO, V448, P241, DOI 10.1016/j.bbrc.2014.04.091
   Rittweger J, 2010, BONE, V46, P137, DOI 10.1016/j.bone.2009.08.051
   Sun TH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020236
   Tsukamoto S, 2018, LEUKEMIA, V32, P1739, DOI 10.1038/s41375 018 0161 6
   Wang H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0210 5
   Wang H, 2016, SCI REP UK, V6, DOI 10.1038/srep23170
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Wu JJ, 2018, BONE, V108, P62, DOI 10.1016/j.bone.2017.12.013
   Xiang J, 2020, MOL MED REP, V22, P3715, DOI 10.3892/mmr.2020.11489
   Yan J, 2014, BIOMATERIALS, V35, P7734, DOI 10.1016/j.biomaterials.2014.05.089
   Yang SD, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12890
   Yin C, 2018, J CELL PHYSIOL, V233, P5405, DOI 10.1002/jcp.26374
   Yin RF, 2020, HUM CELL, V33, P569, DOI 10.1007/s13577 020 00352 8
   Yu DZ, 2015, INT J CLIN EXP PATHO, V8, P14946
   Yuan Y, 2017, J CELL PHYSIOL, V232, P1239, DOI 10.1002/jcp.25688
   Zhang L, 2017, CONNECT TISSUE RES, V58, P155, DOI 10.1080/03008207.2016.1197212
   Zhang LJ, 2020, BIOCHEM BIOPH RES CO, V522, P164, DOI 10.1016/j.bbrc.2019.11.057
   Zhang Y, 2018, HUM GENE THER, V29, P259, DOI 10.1089/hum.2017.153
   Zhao F, 2020, CELLS BASEL, V9, DOI 10.3390/cells9030616
   Zhou TF, 2020, ELIFE, V9, DOI 10.7554/eLife.52779
   Zhu ZQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150026
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 60
TC 34
Z9 41
U1 3
U2 39
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 26
BP 12263
EP 12278
DI 10.7150/thno.53009
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA OV8UL
UT WOS:000592477800013
PM 33204341
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, DP
   Su, Y
   He, Q
   Zhang, YJ
   Gu, N
   Zhang, X
   Yan, K
   Yao, NW
   Qian, WQ
AF Zhang, Dapeng
   Su, Yan
   He, Qiang
   Zhang, Yajie
   Gu, Ning
   Zhang, Xu
   Yan, Kun
   Yao, Nianwei
   Qian, Weiqing
TI Icariin Exerts Estrogen Like Actions on Proliferation of Osteoblasts in
   Vitro via Membrane Estrogen Receptors Mediated Non nuclear Effects
SO IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Icariin; Osteoblasts; Non nuclear Effects; Cell Proliferation
ID BOVINE SERUM ALBUMIN; UP REGULATION; DIFFERENTIATION; DRUG
AB Background: According to reports, icariin (ICA) is a bone anabolic agent able to prevent osteoporosis in both ovariectomized rats and postmenopausal women. However, its effect on osteoblast proliferation remains to be determined, and the underlying mecha nism remains to be elucidated.Methods: Icariin bovine serum albumin (BSA) conjugates were purified by Sephadex G 25 gel chromatography technology. Primary osteoblasts from neonatal rats were used to evaluate the effects of ICA, ICA BSA, ICA BSA + ICI182780, and ICA BSA + PD98059. 3 (4,5 dimethyl thiazol 2 yl) 2,5 diphenyl tetrazolium bromide (MTT) and propidium iodide (PI) staining assays were used to detect the proliferation of osteoblasts after drug exposure. The intracellular calcium ions were detected using a confocal microscope with Fluo 3/AM as the fluorescent indicator. Western blot was capitalized on to measure the relative content of phospho extracellular signal regulated kinase (p ERK).Results: Primary osteoblasts in culture were detected by histochemical staining of alkaline phosphatase, and calcified nodules were obtained by sequential digestion. Icariin and bovine serum albumin could form conjugate, which could be purified by Sephadex G 25 gel chromatography technology. MTT and flow cytometry results show that ICA BSA conjugate significantly facilitated the pro liferation of osteoblasts (P < 0.05). The intracellular calcium ions also ascended vastly in the cells treated with ICA BSA conjugate (P < 0.01). Icariin bovine serum albumin exposure rapidly activated the extracellular signal regulated kinase (ERK) signaling. Fur thermore, ICA and ICA BSA mediated actions on osteoblasts were signally alleviated after dealing with ERK inhibitor PD98059 or estrogen receptor (ER) antagonist ICI182780, which might have a relation to the repression of ERK phosphorylation.Conclusions: Icariin could serve as estrogen in osteoblast cells by the rapid nongenomic ER signaling pathway independent of ligand and estrogen response element (ERE) and mediated by mitogen activated protein kinase (MAPK).
C1 [Zhang, Dapeng; He, Qiang; Yan, Kun; Yao, Nianwei; Qian, Weiqing] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Dept Orthoped, Nanjing 210022, Jiangsu, Peoples R China.
   [Zhang, Dapeng; He, Qiang; Yan, Kun] Nanjing Univ Chinese Med, Nanjing 210023, Jiangsu, Peoples R China.
   [Su, Yan] Nanjing Med Univ, Obstet & Gynecol Hosp, Reprod Ctr, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhang, Yajie] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Cent Lab, Nanjing 210022, Jiangsu, Peoples R China.
   [Gu, Ning] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Dept Cardiovasc Med, Nanjing 210022, Jiangsu, Peoples R China.
   [Zhang, Xu] Nanjing Univ Chinese Med, Sch Med & Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing Medical University; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing University of
   Chinese Medicine
RP Qian, WQ (通讯作者)，Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Dept Orthoped, Nanjing 210022, Jiangsu, Peoples R China.
EM qwq68@126.com
RI Gu, Ning/AAY 7095 2020; Qiang, He/JVZ 8615 2024; Zhang,
   Yajie/J 6726 2017
OI He, Qiang/0000 0003 1640 1776
FU Na tional Natural Science Foundation of China [30872726]
FX Funding/Support: This work was supported by the Na tional Natural
   Science Foundation of China (No. 30872726) .
CR Bani Yaseen AD, 2011, J LUMIN, V131, P1042, DOI 10.1016/j.jlumin.2011.01.019
   Boehmler DJ, 2020, LANGMUIR, V36, P1053, DOI 10.1021/acs.langmuir.9b03251
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Fuks B B, 1975, Bull Exp Biol Med, V77, P792
   Ho MX, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00474
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Jattinagoudar L, 2016, SPECTROCHIM ACTA A, V156, P164, DOI 10.1016/j.saa.2015.11.026
   Kong XH, 2012, INT J MOL MED, V29, P1090, DOI 10.3892/ijmm.2012.941
   Kotrych D, 2016, EUR J OBSTET GYN R B, V199, P92, DOI 10.1016/j.ejogrb.2016.01.037
   Lazrak A, 2020, AM J PHYSIOL LUNG C, V318, pL459, DOI 10.1152/ajplung.00429.2019
   Leboffe L, 2020, CURR MED CHEM, V27, P4907, DOI 10.2174/0929867326666190320105316
   Liu SQ, 2014, IRAN J PHARM RES, V13, P1019
   Lorenzo J, 2003, J CLIN INVEST, V111, P1641, DOI 10.1172/JCI200318812
   Mallarkey G, 2016, THER ADV MUSCULOSKEL, V8, P3, DOI 10.1177/1759720X15623489
   Marino M, 2012, STEROIDS, V77, P910, DOI 10.1016/j.steroids.2012.02.019
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Mishra BH, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115160
   Molina Bolívar JA, 2014, J LUMIN, V156, P141, DOI 10.1016/j.jlumin.2014.08.011
   Pham CV, 2021, J FISH BIOL, V98, P1039, DOI 10.1111/jfb.14241
   Qian WQ, 2011, CHINA MED HERALD, V8, P23
   Serge NE, 2017, PREP BIOCHEM BIOTECH, V47, P1016, DOI 10.1080/10826068.2017.1373289
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Xu T, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/8981650
   Xu X, 2020, SPECTROCHIM ACTA A, V228, DOI 10.1016/j.saa.2019.117706
   Xu YX, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172794
   Yang SH, 2013, GENE, V513, P1, DOI 10.1016/j.gene.2012.10.033
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
   Zhu YN, 2014, MONATSH CHEM, V145, P167, DOI 10.1007/s00706 013 0991 x
   Zuo S, 2019, DRUG DES DEV THER, V13, P3949, DOI 10.2147/DDDT.S203094
NR 30
TC 1
Z9 1
U1 1
U2 6
PU BRIEFLAND
PI Shertogenbosch
PA 25 Derde Morgen, Shertogenbosch, NETHERLANDS
SN 1735 0328
EI 1726 6890
J9 IRAN J PHARM RES
JI Iran. J. Pharm. Res.
PD DEC
PY 2022
VL 21
IS 1
AR e127000
DI 10.5812/ijpr 127000
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 9N3GL
UT WOS:000942804100007
PM 36942079
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Huang, KC
   Lee, DY
   Chuang, PY
   Yang, TY
   Su, YP
   Chang, SF
AF Huang, Kuo Chin
   Lee, Ding Yu
   Chuang, Po Yao
   Yang, Tien Yu
   Su, Yu Ping
   Chang, Shun Fu
TI Crosslinking chitosan with glucose via the modified Maillard reaction
   promotes the osteoinduction of mouse MC3T3 E1 pre osteoblasts
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE cell biomaterial construct; chitosan; glucose; Maillard reaction;
   osteoinduction
ID DEXTROSE PROLOTHERAPY; BONE; INTEGRIN; DIFFERENTIATION; ADSORPTION
AB Bone defects are a common clinical issue, but therapeutic efficiency can be challenging in cases of more considerable traumas or elderly patients with degenerated physiological metabolism. To address this issue, a more suitable cell biomaterial construct promoting bone regeneration has been extensively investigated, with the chitosan scaffold being considered a potential candidate. In this study, chitosan was cross linked with different doses of glucose (CTS 10 similar to 50%Glc) using a modified Maillard reaction condition to develop a more appropriate cell biomaterial construct. Mouse MC3T3 E1 pre osteoblasts were seeded onto the scaffolds to examine their osteoinductive capability. The results showed that CTS Glc scaffolds with higher glucose contents effectively improved the adhesion and survival of mouse MC3T3 E1 pre osteoblasts and promoted their differentiation and mineralization. It was further demonstrated that the membrane integrin alpha 5 subunit of pre osteoblasts is the primary adhesion molecule that communicates with CTS Glc scaffolds. After that, Akt signaling was activated, and then bone morphogenetic protein 4 was secreted to initiate the osteoinduction of pre osteoblasts. The prepared CTS Glc scaffold, with enhanced osteoinduction capability and detailed mechanism elucidations, offers a promising candidate material for advancing bone tissue engineering and clinical regenerative medicine. As a result, this study presents a potential tool for future clinical treatment of bone defects.
C1 [Huang, Kuo Chin] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan.
   [Huang, Kuo Chin; Chuang, Po Yao; Yang, Tien Yu] Chang Gung Mem Hosp, Dept Orthopaed Surg, Chiayi Branch, Chiayi, Taiwan.
   [Lee, Ding Yu] Natl Taiwan Ocean Univ, Dept Biosci & Biotechnol, Keelung, Taiwan.
   [Su, Yu Ping] Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei, Taiwan.
   [Su, Yu Ping] Natl Yang Ming Chiao Tung Univ, Sch Med, Dept Surg, Taipei, Taiwan.
   [Chang, Shun Fu] Chang Gung Mem Hosp, Dept Med Res & Dev, Chiayi Branch, Chiayi, Taiwan.
   [Chang, Shun Fu] Chiayi Chang Gung Univ Sci & Technol, Ctr Gen Educ, Chiayi, Taiwan.
   [Su, Yu Ping] Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
   [Chang, Shun Fu] Chang Gung Mem Hosp, Dept Med Res & Dev, Chiayi Branch, 6, West Sec, Jiapu Rd, Puzi City 613, Chiayi County, Taiwan.
C3 Chang Gung University; Chang Gung Memorial Hospital; National Taiwan
   Ocean University; National Yang Ming Chiao Tung University; Chang Gung
   Memorial Hospital; Taipei Veterans General Hospital; Chang Gung Memorial
   Hospital
RP Su, YP (通讯作者)，Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.; Chang, SF (通讯作者)，Chang Gung Mem Hosp, Dept Med Res & Dev, Chiayi Branch, 6, West Sec, Jiapu Rd, Puzi City 613, Chiayi County, Taiwan.
EM ypsu@vghtpe.gov.tw; sfchang@cgmh.org.tw
RI Chuang, Po Yao/MVW 9079 2025; Su, Yu Ping/IYS 1117 2023; HUANG,
   Kuo Chin/S 7371 2019
OI Chang, Shun Fu/0000 0002 2276 7785
FU This work was supported by the National Science and Technology Council,
   Taiwan (110 2314 B 182A 014, 110 2314 B 182 006, 106 2314 B 182 012),
   Chiayi Chang Gung Memorial Hospital, Taiwan (CMRPG6L0201, CMRPG6K0051,
   CMRPG6H0611 12), and Taipei Veterans Genera [110 2314 B 182A 014,
   110 2314 B 182 006, 106 2314 B 182 012]; National Science and Technology
   Council, Taiwan [CMRPG6L0201, CMRPG6K0051, CMRPG6H0611 12]; Chiayi Chang
   Gung Memorial Hospital, Taiwan [V112C 083, V111C 132]; Taipei Veterans
   General Hospital, Taiwan
FX This work was supported by the National Science and Technology Council,
   Taiwan (110 2314 B 182A 014, 110 2314 B 182 006, 106 2314 B 182 012),
   Chiayi Chang Gung Memorial Hospital, Taiwan (CMRPG6L0201, CMRPG6K0051,
   CMRPG6H0611 12), and Taipei Veterans General Hospital, Taiwan (V112C 083
   and V111C 132). Moreover, we would like to acknowledge the service
   support (BD FACSCanto II flow cytometer) provided by the Precious
   Instrumentation Core Laboratory, Chiayi Chang Gung Memorial Hospital.
CR Affes S, 2022, FOOD CHEM, V366, DOI 10.1016/j.foodchem.2021.130530
   Ahsan SM, 2018, INT J BIOL MACROMOL, V110, P97, DOI 10.1016/j.ijbiomac.2017.08.140
   Bae Geonhyeong, 2021, Anesth Pain Med (Seoul), V16, P81, DOI 10.17085/apm.20078
   Bai Y., 2021, MOL MED REP, V23, P23
   Rodríguez Merchán EC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063352
   Cecchi S, 2016, J ORTHOP TRANSL, V4, P28, DOI 10.1016/j.jot.2015.08.001
   Chang SF, 2017, J CELL PHYSIOL, V232, P2741, DOI 10.1002/jcp.25869
   Chen CL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.755615
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Choi B, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00173 5
   De Franceschi N, 2015, J CELL SCI, V128, P839, DOI 10.1242/jcs.161653
   Fan LH, 2015, INT J BIOL MACROMOL, V79, P830, DOI 10.1016/j.ijbiomac.2015.04.013
   Fromigué O, 2012, J CELL BIOCHEM, V113, P3029, DOI 10.1002/jcb.24181
   Gao SW, 2019, J ZHEJIANG UNIV SC B, V20, P467, DOI 10.1631/jzus.B1900197
   Gullón B, 2016, CARBOHYD POLYM, V137, P382, DOI 10.1016/j.carbpol.2015.10.075
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hauser RA, 2016, CLIN MED INSIGHTS AR, V9, P139, DOI 10.4137/CMAMD.S39160
   Hotait ZS, 2022, AM J PHYSIOL CELL PH, V323, pC791, DOI 10.1152/ajpcell.00225.2022
   Kim J., 2021, MAT BASEL, V14, P14
   Kowalczyk P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052324
   Kyzas GZ, 2015, MAR DRUGS, V13, P312, DOI 10.3390/md13010312
   Lai WF, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000028216
   Mao LW, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01417 x
   Marie PJ, 2013, NAT REV ENDOCRINOL, V9, P288, DOI 10.1038/nrendo.2013.4
   Mobasheri A, 2008, ADV ANAT EMBRYOL CEL, V200, P1
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Muzzarelli RAA, 2015, MAR DRUGS, V13, P7314, DOI 10.3390/md13127068
   Oryan A, 2014, BIOFACTORS, V40, P459, DOI 10.1002/biof.1177
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Rahimi M, 2022, INT J BIOL MACROMOL, V215, P346, DOI 10.1016/j.ijbiomac.2022.06.079
   Ressler A, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14163430
   Rezasoltani Z, 2017, J PAIN RES, V10, P1179, DOI 10.2147/JPR.S127633
   Rodríguez Vázquez M, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/821279
   Sacco P., 2020, MOLECULES, V25, P25
   Sahariah P, 2017, BIOMACROMOLECULES, V18, P3846, DOI 10.1021/acs.biomac.7b01058
   Shao PL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030506
   Smith CO, 2021, STEM CELLS DEV, V30, P149, DOI 10.1089/scd.2020.0141
   Tian YH, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.899760
   Tran TN., 2019, POLYMERS BASEL, V11, P11
   Tsai SW, 2018, INT J MED SCI, V15, P1251, DOI 10.7150/ijms.24170
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Zhu LW, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.810880
NR 42
TC 0
Z9 0
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD MAR
PY 2024
VL 112
IS 3
BP 436
EP 448
DI 10.1002/jbm.a.37640
EA NOV 2023
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FM0A3
UT WOS:001099543700001
PM 37933797
DA 2025 08 17
ER

PT J
AU Huang, ZY
   Luo, R
   Yang, L
   Chen, HQ
   Zhang, XY
   Han, JW
   Wang, HX
   Zhou, ZY
   Wang, Z
   Shao, L
AF Huang, Zhaoyang
   Luo, Rong
   Yang, Liu
   Chen, Haiqi
   Zhang, Xinyao
   Han, Jiawen
   Wang, Hongxia
   Zhou, Zhongyang
   Wang, Zhao
   Shao, Lan
TI CPT1A Mediated Fatty Acid Oxidation Promotes Precursor Osteoclast Fusion
   in Rheumatoid Arthritis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE CPT1A; fatty acid oxidation; osteoclast fusion; fusogenic molecule;
   clathrin; rheumatoid arthritis
ID FACTOR C/EBP BETA; CELL FUSION; CLASSIFICATION; ETOMOXIR; EXPRESSION;
   PODOSOMES; CRITERIA; DISEASE
AB The overproduction of osteoclasts, leading to bone destruction in patients with rheumatoid arthritis (RA), is well established. However, little is known about the metabolic dysfunction of osteoclast precursors (OCPs) in RA. Herein, we show that increasing fatty acid oxidation (FAO) induces OCP fusion. Carnitine palmitoyltransferase IA (CPT1A), which is important for carnitine transportation and is involved in FAO in the mitochondria, is upregulated in RA patients. This metabolic change further increases the expression of clathrin heavy chain (CLTC) and clathrin light chain A (CLTA) by enhancing the binding of the transcription factor CCAAT/enhancer binding protein beta (C/EBP beta) to the promoters of CLTA and CLTC. This drives clathrin dependent endocytosis pathway, which attenuates fusion receptors in the cellular membrane and contributes to increased podosome structure formation. This study reveals a new mechanism through which FAO metabolism participates in joint destruction in RA and provides a novel therapeutic direction for the development of drugs against bone destruction in patients with RA.
C1 [Huang, Zhaoyang; Luo, Rong; Chen, Haiqi; Han, Jiawen; Zhou, Zhongyang; Shao, Lan] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou, Peoples R China.
   [Yang, Liu] Guangzhou Med Univ, Affiliated Hosp 3, Dept Rheumatol, Guangzhou, Peoples R China.
   [Zhang, Xinyao] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China.
   [Wang, Hongxia] Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou, Peoples R China.
   [Wang, Zhao] Guangzhou Med Univ, Affiliated Hosp 3, Dept Orthopaed, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen
   University; Southern Medical University   China; Guangzhou Medical
   University
RP Shao, L (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou, Peoples R China.
EM shaolan@mail.sysu.edu.cn
RI Chen, Haiqi/J 7468 2019; Luo, Le/I 6459 2013
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   ASINS G, 1994, BIOCHEM PHARMACOL, V47, P1373, DOI 10.1016/0006 2952(94)90336 0
   Banerjee D, 2020, J MOL CELL CARDIOL, V139, P148, DOI 10.1016/j.yjmcc.2020.01.004
   Chiu YH, 2012, J BONE MINER RES, V27, P79, DOI 10.1002/jbmr.531
   Durand M, 2011, BONE, V48, P588, DOI 10.1016/j.bone.2010.10.167
   Gambari L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176001
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   HEGARDT FG, 1995, GEN PHARMACOL, V26, P897, DOI 10.1016/0306 3623(94)00281 Q
   Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005
   Herms A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8176
   Hobolt Pedersen AS, 2014, CALCIFIED TISSUE INT, V95, P73, DOI 10.1007/s00223 014 9864 5
   Ishii M, 2006, J BONE MINER RES, V21, P965, DOI 10.1359/JBMR.060308
   Ishii T, 2018, FASEB J, V32, P4016, DOI 10.1096/fj.201701424R
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kim H, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010089
   Knobloch M, 2017, CELL REP, V20, P2144, DOI 10.1016/j.celrep.2017.08.029
   Koduru SV, 2018, J BIOL CHEM, V293, P15055, DOI 10.1074/jbc.RA117.000633
   Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Lim J, 2016, DEVELOPMENT, V143, P339, DOI 10.1242/dev.126227
   Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962 8924(03)00128 4
   Ma JD, 2019, ARTHRITIS RHEUMATOL, V71, P1252, DOI 10.1002/art.40868
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Mensah KA, 2010, J CELL PHYSIOL, V223, P76, DOI 10.1002/jcp.22012
   Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141
   Muruganandan S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072277
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Oikawa T, 2012, J CELL BIOL, V197, P553, DOI 10.1083/jcb.201111116
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029
   Raulien N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00609
   Rodgers LC, 2020, RHEUMATOLOGY, V59, P869, DOI 10.1093/rheumatology/kez378
   Schlaepfer IR, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqz046
   Sens KL, 2010, J CELL BIOL, V191, P1013, DOI 10.1083/jcb.201006006
   Shao L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9917
   Shao L, 2009, J EXP MED, V206, P1435, DOI 10.1084/jem.20082251
   Shen Y, 2017, NAT IMMUNOL, V18, P1025, DOI 10.1038/ni.3808
   Shin NY, 2014, J CELL BIOL, V207, P73, DOI 10.1083/jcb.201401137
   Smink JJ, 2010, J MOL MED, V88, P227, DOI 10.1007/s00109 009 0567 8
   Smink JJ, 2009, EMBO J, V28, P1769, DOI 10.1038/emboj.2009.127
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Su Q, 2019, J AUTOIMMUN, V100, P27, DOI 10.1016/j.jaut.2019.02.007
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   van der Heijde D, 2013, ANN RHEUM DIS, V72, P479, DOI 10.1136/annrheumdis 2012 202779
   Wang ZR, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc 2020 001758
   Witwicka H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128275
   Xu FY, 2003, J LIPID RES, V44, P415, DOI 10.1194/jlr.M200335 JLR200
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Zeisbrich M, 2018, ANN RHEUM DIS, V77, P1053, DOI 10.1136/annrheumdis 2017 212647
NR 51
TC 12
Z9 12
U1 3
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD FEB 22
PY 2022
VL 13
AR 838664
DI 10.3389/fimmu.2022.838664
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA ZU3YL
UT WOS:000769778800001
PM 35273614
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bigham, A
   Fasolino, I
   Borsacchi, S
   Valente, C
   Calucci, L
   Turacchio, G
   Pannico, M
   Serrano Ruiz, M
   Ambrosio, L
   Raucci, MG
AF Bigham, Ashkan
   Fasolino, Ines
   Borsacchi, Silvia
   Valente, Carmen
   Calucci, Lucia
   Turacchio, Gabriele
   Pannico, Marianna
   Serrano Ruiz, Manuel
   Ambrosio, Luigi
   Raucci, Maria Grazia
TI A theragenerative bio nanocomposite consisting of black phosphorus
   quantum dots for bone cancer therapy and regeneration
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Bioactive glass; Black phosphorus; Microwave treatment; Bone cancer
   therapy; Tissue regeneration
ID MESOPOROUS BIOACTIVE GLASSES; SOL GEL SYNTHESIS; NANOPARTICLES
AB Recently, the term theragenerative has been proposed for biomaterials capable of inducing therapeutic approaches followed by repairing/regenerating the tissue/organ. This study is focused on the design of a new theragenerative nanocomposite composed of an amphiphilic non ionic surfactant (Pluronic F127), bioactive glass (BG), and black phosphorus (BP). The nanocomposite was prepared through a two step synthetic strategy, including a microwave treatment that turned BP nanosheets (BPNS) into quantum dots (BPQDs) with 5 +/  2 nm dimensions in situ. The effects of surfactant and microwave treatment were assessed in vitro: the surfactant distributes the ions homogenously throughout the composite and the microwave treatment chemically stabilizes the composite. The presence of BP enhanced bioactivity and promoted calcium phosphate formation in simulated body fluid. The inherent anticancer activity of BP containing nanocomposites was tested against osteosarcoma cells in vitro, finding that 150 mu g mL 1 was the lowest concentration which prevented the proliferation of SAOS 2 cells, while the counterpart without BP did not affect the cell growth rate. Moreover, the apoptosis pathways were evaluated and a mechanism of action was proposed. NIR irradiation was applied to induce further proliferation suppression on SAOS 2 cells through hyperthermia. The inhibitory effects of bare BP nanomaterials and nanocomposites on the migration and invasion of bone cancer, breast cancer, and prostate cancer cells were assessed in vitro to determine the anticancer potential of nanomaterials against primary and secondary bone cancers. The regenerative behavior of the nanocomposites was tested with healthy osteoblasts and human mesenchymal stem cells; the BPQDs incorporated nanocomposite significantly promoted the proliferation of osteoblast cells and induced the osteogenic differentiation of stem cells. This study introduces a new multifunctional theragenerative platform with promising potential for simultaneous bone cancer therapy and regeneration.
C1 [Bigham, Ashkan; Fasolino, Ines; Ambrosio, Luigi; Raucci, Maria Grazia] Natl Res Council Italy IPCB CNR, Natl Res Council Italy IPCB CNR, Viale John Fitzgerald Kennedy 54, Mostra Oltremare, I 80125 Naples, Italy.
   [Bigham, Ashkan] Univ Naples Federico II, Dept Chem Mat & Prod Engn, Piazzale V Tecchio 80, I 80125 Naples, Italy.
   [Borsacchi, Silvia; Calucci, Lucia] Italian Natl Res Council CNR, Inst Chem OrganoMetall Cpds ICCOM, via G Moruzzi 1, I 56124 Pisa, Italy.
   [Borsacchi, Silvia; Calucci, Lucia] Ctr Instrument Sharing Univ Pisa CISUP, Ctr Instrument Sharing, I 56126 Pisa, Italy.
   [Valente, Carmen; Turacchio, Gabriele] Natl Res Council CNR, Inst Expt Endocrinol & Oncol G Salvatore IEOS, Via Pietro Castellino 111, I 80131 Naples, Italy.
   [Pannico, Marianna] Inst Polymers, Inst Polymers Composites & Biomat, Pozzuoli, Italy.
   [Serrano Ruiz, Manuel] Natl Res Council CNR, Natl Res Council, Sesto Fiorentino, Italy.
   [Turacchio, Gabriele] Natl Res Council CNR, Inst Translat Pharmacol IFT, Via Carducci 32, Laquila 67100, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto per i Polimeri,
   Compositi e Biomateriali (IPCB CNR); University of Naples Federico II;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze
   (IN CNR); Isituto di Chimica dei Composti Organometallici (ICCOM CNR);
   Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e
   Oncologia "Gaetano Salvatore" (IEOS CNR); Consiglio Nazionale delle
   Ricerche (CNR); Istituto per i Polimeri, Compositi e Biomateriali
   (IPCB CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di
   Farmacologia Traslazionale (IFT CNR)
RP Raucci, MG (通讯作者)，Natl Res Council Italy IPCB CNR, Natl Res Council Italy IPCB CNR, Viale John Fitzgerald Kennedy 54, Mostra Oltremare, I 80125 Naples, Italy.
EM mariagrazia.raucci@cnr.it
RI ; Bigham, Ashkan/ABA 7104 2021; Pannico, Marianna/AAC 5599 2019; Raucci,
   Maria/AAV 8444 2020; Borsacchi, Silvia/N 8210 2015; Calucci,
   Lucia/O 8826 2014
OI fasolino, ines/0000 0002 9568 3945; Serrano Ruiz,
   Manuel/0000 0002 6372 3586; Bigham, Ashkan/0000 0001 7442 3549; Raucci,
   Maria Grazia/0000 0002 0516 4181; 
FU CISUP (Centre for Instrument Sharing University of Pisa)
FX The authors acknowledge support from Progetto MIUR PRIN2017 ACTION,
   Grant No. 2017SZ5WZB and POR Campania FESR 2014 2020 (Campania imaging
   Infrastructure for Research in Oncology  C.I.R.O) . The authors also
   thank Maria Rosaria Bonetti for lab technical support, Cristina Del
   Barone for facilitating microscopy analysis, Dr. Antonio Pennetta for
   ICP analysis and Dr. Roberta Marzella for support to project management.
   CISUP (Centre for Instrument Sharing University of Pisa) and the
   EUroBioImaging (EUBI) Facility at CNR (Naples) are acknowledged for the
   use of the Bruker Avance NEO 500 Solid State NMR spectrometer and of
   AxioVision microscope (Carl Zeiss Micro Imaging GmbH) , respectively.r  
   C.I.R.O) . The authors also thank Maria Rosaria Bonetti for lab
   tech nical support, Cristina Del Barone for facilitating microscopy
   analysis, Dr. Antonio Pennetta for ICP analysis and Dr. Roberta Marzella
   for support to project management. CISUP (Centre for Instrument
   Sharing University of Pisa) and the EUroBioImaging (EUBI) Facility at
   CNR (Naples) are acknowledged for the use of the Bruker Avance NEO 500
   Solid State NMR spectrometer and of AxioVision microscope (Carl Zeiss
   Micro Imaging GmbH) , respectively.
CR Agafonov M, 2019, J MOL LIQ, V274, P770, DOI 10.1016/j.molliq.2018.11.060
   Ansari M, 2018, J AM CERAM SOC, V101, P3649, DOI 10.1111/jace.15510
   Ashrafizadeh M, 2023, MED RES REV, V43, P2115, DOI 10.1002/med.21971
   Ashrafizadeh M, 2022, J CONTROL RELEASE, V351, P50, DOI 10.1016/j.jconrel.2022.08.001
   Aslankoohi N, 2020, ACS APPL BIO MATER, V3, P3621, DOI 10.1021/acsabm.0c00257
   Barrioni BR, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6288 9
   Bigham A., 2023, ACS PUBLICATIONS, P251, DOI DOI 10.1021/BK 2023 1436.CH011
   Bigham A, 2023, ADV MATER, V35, DOI 10.1002/adma.202302858
   Bigham A, 2022, CHEM ENG J, V432, DOI 10.1016/j.cej.2021.134146
   Bigham A, 2021, MAT SCI ENG C MATER, V127, DOI 10.1016/j.msec.2021.112242
   Bigham A, 2021, J EUR CERAM SOC, V41, P941, DOI 10.1016/j.jeurceramsoc.2020.07.073
   Bigham A, 2020, MAT SCI ENG C MATER, V109, DOI 10.1016/j.msec.2019.110579
   Bigham A, 2016, CERAM INT, V42, P17185, DOI 10.1016/j.ceramint.2016.08.009
   Bossard C, 2019, ACS BIOMATER SCI ENG, V5, P5906, DOI 10.1021/acsbiomaterials.9b01245
   Brent JR, 2014, CHEM COMMUN, V50, P13338, DOI 10.1039/c4cc05752j
   Brusatin G, 2018, NAT MATER, V17, P1063, DOI 10.1038/s41563 018 0180 8
   Cao N., 2012, ISRN Chem. Eng, V2012, P1, DOI DOI 10.5402/2012/516461
   Chen BD, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002621
   Cheng L, 2020, SMALL, V16, DOI 10.1002/smll.202005433
   Comsa S, 2015, ANTICANCER RES, V35, P3147
   Dey AD, 2022, SEMIN CANCER BIOL, V86, P396, DOI 10.1016/j.semcancer.2022.06.003
   Du KX, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10010139
   Fasolino I, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85310 6
   Foroughi F, 2016, MAT SCI ENG C MATER, V68, P774, DOI 10.1016/j.msec.2016.07.028
   Hassanzadeh Tabrizi SA, 2016, MAT SCI ENG C MATER, V58, P737, DOI 10.1016/j.msec.2015.09.020
   Hu K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16513 0
   Izquierdo Barba I, 2010, MICROPOR MESOPOR MAT, V132, P442, DOI 10.1016/j.micromeso.2010.03.025
   Ji LJ, 2014, MICROPOR MESOPOR MAT, V184, P122, DOI 10.1016/j.micromeso.2013.10.007
   Khamsehashari N, 2018, MATER CHEM PHYS, V205, P283, DOI 10.1016/j.matchemphys.2017.11.034
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kong N, 2020, NANO LETT, V20, P3943, DOI 10.1021/acs.nanolett.0c01098
   Kuzmenka D, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121192
   Li LL, 2021, MAT SCI ENG C MATER, V121, DOI 10.1016/j.msec.2020.111812
   Li LQ, 2017, NAT MATER, V16, P1164, DOI 10.1038/nmat5049
   Li SH, 2023, INT J BIOL MACROMOL, V239, DOI 10.1016/j.ijbiomac.2023.124209
   Liu XF, 2020, ACS BIOMATER SCI ENG, V6, P4653, DOI 10.1021/acsbiomaterials.0c00612
   Liu XF, 2019, ACS APPL MATER INTER, V11, P23558, DOI 10.1021/acsami.9b04121
   Liu Y, 2021, NEW CARBON MATER, V36, P779, DOI 10.1016/S1872 5805(21)60073 2
   López Noriega A, 2006, CHEM MATER, V18, P3137, DOI 10.1021/cm060488o
   Maleki A, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202203430
   Martini F, 2019, J PHYS CHEM LETT, V10, P5122, DOI 10.1021/acs.jpclett.9b01788
   Miao YL, 2023, BIOACT MATER, V21, P97, DOI 10.1016/j.bioactmat.2022.08.005
   Migneco C, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10122571
   Moser SC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00794
   Mussi V, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12121994
   Ouyang J, 2018, J MATER CHEM B, V6, P6302, DOI 10.1039/c8tb01669k
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Pijuan J, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00107
   Poologasundarampillai G, 2011, SOFT MATTER, V7, P10241, DOI 10.1039/c1sm06171b
   Qin L, 2019, J COLLOID INTERF SCI, V556, P232, DOI 10.1016/j.jcis.2019.08.058
   Qu GB, 2020, CHEM REV, V120, P2288, DOI 10.1021/acs.chemrev.9b00445
   Rafienia M, 2018, MATER LETT, V225, P89, DOI 10.1016/j.matlet.2018.04.094
   Raucci MG, 2019, ACS APPL MATER INTER, V11, P9333, DOI 10.1021/acsami.8b21592
   Rezaei Y, 2014, SYNTH REACT INORG M, V44, P692, DOI 10.1080/15533174.2013.783869
   Rocton N, 2020, APPL SURF SCI, V505, DOI 10.1016/j.apsusc.2019.144076
   Schumacher M, 2021, BIOACT MATER, V6, P1921, DOI 10.1016/j.bioactmat.2020.12.007
   Shao JD, 2018, ADV SCI, V5, DOI 10.1002/advs.201700848
   Sharifi E, 2022, ADV SCI, V9, DOI 10.1002/advs.202102678
   Suchy T, 2021, MATERIALS, V14, DOI 10.3390/ma14164388
   Sun CX, 2016, BIOMATERIALS, V91, P81, DOI 10.1016/j.biomaterials.2016.03.022
   Tao W, 2017, ADV MATER, V29, DOI 10.1002/adma.201603276
   Tu ZX, 2018, ADV MATER, V30, DOI 10.1002/adma.201706709
   Wang YQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10761 5
   Wang ZM, 2019, SMALL, V15, DOI 10.1002/smll.201901560
   Wu L, 2018, SMALL, V14, DOI 10.1002/smll.201801405
   Xing CY, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701510
   Xu XY, 2022, MATER TODAY ADV, V13, DOI 10.1016/j.mtadv.2022.100209
   Yang BW, 2018, ADV MATER, V30, DOI 10.1002/adma.201705611
   Youness RA, 2018, SILICON NETH, V10, P1151, DOI 10.1007/s12633 017 9587 0
   Yu BB, 2012, LANGMUIR, V28, P17465, DOI 10.1021/la303768b
   Yun HS, 2007, MATER LETT, V61, P4569, DOI 10.1016/j.matlet.2007.02.075
   Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661
   Zeng GD, 2020, ACTA BIOMATER, V118, P1, DOI 10.1016/j.actbio.2020.10.004
   Zhang PS, 2022, NANO TODAY, V42, DOI 10.1016/j.nantod.2021.101335
   Zhang Y, 2021, ADV MATER, V33, DOI 10.1002/adma.202100113
   Zhao Y, 2023, CARBOHYD POLYM, V300, DOI 10.1016/j.carbpol.2022.120264
   Zhou LM, 2022, BIOENG TRANSL MED, V7, DOI 10.1002/btm2.10274
   Zhou WH, 2019, ANGEW CHEM INT EDIT, V58, P769, DOI 10.1002/anie.201810878
   Zhu XJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06437 1
   Zhu YJ, 2014, CHEM REV, V114, P6462, DOI 10.1021/cr400366s
NR 80
TC 23
Z9 23
U1 5
U2 50
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD MAY
PY 2024
VL 35
BP 99
EP 121
DI 10.1016/j.bioactmat.2024.01.018
PG 23
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA JJ9R3
UT WOS:001172922400001
PM 38283385
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chang, JY
   Jiang, ZL
   Jin, W
   Wang, YH
   Li, J
   Chen, JY
   Li, H
   Feng, L
AF Chang, Jinyuan
   Jiang, Zhenglong
   Jin, Wei
   Wang, Yaohan
   Li, Jie
   Chen, Jiayang
   Li, Hao
   Feng, Li
TI The Molecular Mechanism of Traditional Chinese Medicine Prescription:
   Gu tong Formula in Relieving Osteolytic Bone Destruction
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID INDUCED OSTEOCLAST FORMATION; MESENCHYMAL TRANSITION; RECEPTOR
   ACTIVATOR; CANCER CELLS; DIFFERENTIATION; PHARMACOLOGY; EXPRESSION;
   ALKALINE; COLLAGEN
AB Bone metastasis is a common complication in patients with advanced tumors, causing pain and bone destruction and affecting their quality of life. Typically, complementary and alternative medicine (CAM), with unique theoretical guidance, has played key roles in the treatment of tumor related diseases. Gu tong formula (GTF), as a representative prescription of traditional Chinese medicine, has been demonstrated to be an effective clinical medication for the relief of cancer pain. However, the molecular mechanism of GTF in the treatment of osteolytic metastasis is still unclear. Herein, we employ network pharmacology and molecular dynamics methods to uncover the potential treatment mechanism, indicating that GTF can reduce the levels of serum IL6 and TGFBI and thus limit the scope of bone cortical damage. Among the active compounds, sesamin and deltoin can bind stably with IL6 and TGFBI, respectively, and have the potential to become anti inflammatory and anticancer drugs. Although the reasons for the therapeutic effect of GTF are complex and comprehensive, this work provides biological plausibility in the treatment of osteolytic metastases, which has a guiding significance for the treatment of cancer pain with CAM.
C1 [Chang, Jinyuan; Jiang, Zhenglong; Jin, Wei; Li, Jie; Chen, Jiayang; Feng, Li] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing 100021, Peoples R China.
   [Wang, Yaohan] Beijing Hosp Integrated Tradit Chinese & Western, Dept Oncol, Beijing 100039, Peoples R China.
   [Li, Hao] Beijing Univ Chinese Med, Beijing 100029, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Cancer Institute & Hospital   CAMS; Peking Union Medical College;
   Beijing University of Chinese Medicine
RP Feng, L (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing 100021, Peoples R China.
EM fengli663@126.com
RI CHEN, JIA YANG/M 8413 2014; Chang, Jinyuan/C 4833 2014
FU Cancer Discipline Construction Project of Integrated Traditional Chinese
   and Western Medicine of Peking Union Medical College [20192010302];
   National Natural Science Foundation of China [81873283]; basic
   scientific research business fee of Central Public Welfare Scientific
   Research Institutes and Clinical and Translational Medicine Research
   [2019XK320072]
FX This research was supported by the Cancer Discipline Construction
   Project of Integrated Traditional Chinese and Western Medicine of Peking
   Union Medical College (20192010302), the National Natural Science
   Foundation of China (81873283), and the basic scientific research
   business fee of Central Public Welfare Scientific Research Institutes
   and Clinical and Translational Medicine Research (2019XK320072).
CR Beigoli S, 2019, J BIOMOL STRUCT DYN, V37, P2265, DOI 10.1080/07391102.2018.1491421
   Bingwen L., 2017, TRADITIONAL CHINESE
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Bosc N, 2019, J CHEMINFORMATICS, V11, DOI 10.1186/s13321 018 0325 4
   Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Chamani J, 2006, J COLLOID INTERF SCI, V297, P561, DOI 10.1016/j.jcis.2005.11.035
   Chamani J, 2006, J COLLOID INTERF SCI, V293, P52, DOI 10.1016/j.jcis.2005.06.015
   Chang JY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7617261
   Choi JA, 2001, INT J ONCOL, V19, P837
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Dareini M, 2020, SPECTROCHIM ACTA A, V228, DOI 10.1016/j.saa.2019.117528
   Dobson CM, 2004, NATURE, V432, P824, DOI 10.1038/nature03192
   Engin HB, 2014, CURR PHARM DESIGN, V20, P1201, DOI 10.2174/13816128113199990066
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Gong JY, 2013, BIOINFORMATICS, V29, P1827, DOI 10.1093/bioinformatics/btt270
   Guo QJ, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/854307
   Haider M, 2016, CLIN EXP METASTAS, V33, P239, DOI 10.1007/s10585 015 9773 7
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758 2946 4 17
   Hinck AP, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022103
   Imran M, 2019, MOLECULES, V24, DOI 10.3390/molecules24122277
   Jo E, 2015, NEOPLASIA, V17, P525, DOI 10.1016/j.neo.2015.06.004
   Khashkhashi Moghadam S, 2022, J MOL LIQ, V356, DOI 10.1016/j.molliq.2022.119042
   Kwofie SK, 2019, TOXINS, V11, DOI 10.3390/toxins11030181
   Li H, 1998, BIOL PHARM BULL, V21, P1322, DOI 10.1248/bpb.21.1322
   Li JJ, 2017, ACTA PHARMACOL SIN, V38, P1369, DOI 10.1038/aps.2017.13
   Liang W., 1992, ACTA PHARM SIN B, V9, P684
   Liu CX, 2015, CHIN HERB MED, V7, P3, DOI 10.1016/S1674 6384(15)60014 4
   Lu Q, 2015, PHARMACOL RES, V99, P237, DOI 10.1016/j.phrs.2015.06.006
   Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655
   Marjani N, 2022, LUMINESCENCE, V37, P310, DOI 10.1002/bio.4173
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Ohshiba T, 2003, BRIT J CANCER, V88, P1318, DOI 10.1038/sj.bjc.6600858
   Omokehinde T, 2020, CANCERS, V12, DOI 10.3390/cancers12020326
   POND SM, 1984, CLIN PHARMACOKINET, V9, P1, DOI 10.2165/00003088 198409010 00001
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sadeghzadeh F, 2020, PROTEIN PEPTIDE LETT, V27, P1007, DOI 10.2174/1871530320666200425203636
   SINGH P, 1995, J PHARM SCI, V84, P1342, DOI 10.1002/jps.2600841115
   Takashima M, 2019, FOOD CHEM TOXICOL, V132, DOI 10.1016/j.fct.2019.110669
   Wakabayashi H, 2018, BREAST CANCER TOKYO, V25, P566, DOI 10.1007/s12282 018 0853 9
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0254 6
   Wang XM, 2009, PAIN, V142, P275, DOI 10.1016/j.pain.2009.02.001
   Wang XY, 2020, GENES BASEL, V11, DOI 10.3390/genes11040435
   Wang YH, 2021, CHIN J INTEGR MED, V27, P713, DOI 10.1007/s11655 020 3423 x
   Wang ZX, 2021, BRIT J PHARMACOL, V178, P1133, DOI 10.1111/bph.15350
   Wu LC, 2017, J CELL BIOCHEM, V118, P1308, DOI 10.1002/jcb.25672
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yin YK, 2017, J TRADIT CHIN MED, V37, P30
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zare Feizabadi N, 2021, DNA CELL BIOL, V40, P1039, DOI 10.1089/dna.2021.0052
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zheng JH, 2018, CANCERS, V10, DOI 10.3390/cancers10110461
NR 57
TC 4
Z9 4
U1 2
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JUL 13
PY 2022
VL 2022
AR 4931368
DI 10.1155/2022/4931368
PG 18
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 4P2VA
UT WOS:000855254200004
PM 35872837
OA Green Published, hybrid
DA 2025 08 17
ER

PT S
AU Piva, R
   Penolazzi, L
   Borgatti, M
   Lampronti, I
   Lambertini, E
   Torreggiani, E
   Gambari, R
AF Piva, Roberta
   Penolazzi, Letizia
   Borgatti, Monica
   Lampronti, Ilaria
   Lambertini, Elisabetta
   Torreggiani, Elena
   Gambari, Roberto
BE Diederich, M
TI Apoptosis of Human Primary Osteoclasts Treated with Molecules Targeting
   Nuclear Factor κB
SO NATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Apoptosis 2008 World   From Mechanisms to Applications
CY JAN 23 26, 2008
CL Luxembourg, LUXEMBOURG
DE osteoclast; rheumatoid arthritis; osteoporosis; apoptosis; medicinal
   plants; Emblica officinalis
ID PROLIFERATION STIMULATING ACTIVITY; EMBLICA OFFICINALIS; TRANSCRIPTION
   FACTORS; INDUCTION; DIFFERENTIATION; PRODUCTS; EXTRACTS; FRUIT
AB Osteoclasts (OCs) are involved in several pathologies associated with bone loss, including rheumatoid arthritis, osteoporosis, bone metastasis of myeloma, osteosarcoma, and breast cancer. In this review we determined the effects of natural compounds, including extracts from medicinal plants, on differentiation and survival of human primary OCs obtained from peripheral blood. We found that OCs from umbilical cord blood and peripheral blood behave differently in response to molecules inducing apoptosis in this experimental system. Apoptosis induced by decoy oligonucleotides was reproducibly obtained in OCs from peripheral blood but not in OCs derived from cord blood. With respect to effects of medicinal plants, we found that crude extracts of Emblica officinalis are able to induce specifically programmed cell death of mature OCs without altering the process of osteoclastogenesis. E. officinalis specifically increased the expression levels of Fas, a critical member of the apoptotic pathway. Gel shift experiments BioPharmaNet demonstrate that E. officinalis extracts specifically compete with the binding of a transcription factor involved in osteoclastogenesis NF kappa B to its specific target DNA sequences. This might explain the observed effects of E. officinalis on the expression levels of IL 6, an NF kappa B specific target gene. We suggest the application of natural products as an alternative tool for therapy applied to bone diseases.
C1 [Piva, Roberta; Penolazzi, Letizia; Borgatti, Monica; Lampronti, Ilaria; Lambertini, Elisabetta; Torreggiani, Elena; Gambari, Roberto] Univ Ferrara, Dept Biochem & Mol Biol, I 44100 Ferrara, Italy.
   [Gambari, Roberto] Univ Ferrara, Ctr Biotechnol, I 44100 Ferrara, Italy.
C3 University of Ferrara; University of Ferrara
RP Gambari, R (通讯作者)，Univ Ferrara, Dept Biochem & Mol Biol, Via Fossato Mortara 74, I 44100 Ferrara, Italy.
EM gam@unife.it
RI Lampronti, Ilaria/F 5522 2016; Torreggiani, Elena/J 6404 2016; Gambari,
   Roberto/F 9555 2015; Borgatti, Monica/G 2611 2015
OI Lampronti, Ilaria/0000 0002 1972 7766; Piva,
   Roberta/0000 0003 2663 6210; Torreggiani, Elena/0000 0001 7874 2002;
   Gambari, Roberto/0000 0001 9205 6033; Penolazzi,
   Letizia/0000 0002 1293 5087; Borgatti, Monica/0000 0001 8470 2496
FU Consorzio Interuniversitario di Biotecnologie, Italy; Associazione
   Italiana Ricerca sul Cancro; Associazione Veneta per la Lotta alla
   Talassemia, Italy; SPINNER e PRIITT; Fondazione Cassa di Risparmio di
   Padova e Rovigo; the STAMINA Project of Ferrara University; the UE
   ITHANET Project; Italian Cystic Fibrosis Research Foundation [15/2004]
FX R.G. is funded by the Consorzio Interuniversitario di Biotecnologie,
   Italy, Associazione Italiana Ricerca sul Cancro, Associazione Veneta per
   la Lotta alla Talassemia, Italy, SPINNER e PRIITT (EU, Obiettivo 2),
   Fondazione Cassa di Risparmio di Padova e Rovigo, the STAMINA Project of
   Ferrara University, and the UE ITHANET Project. This work was supported
   by grants from the Italian Cystic Fibrosis Research Foundation (grant
   #15/2004).
CR Ahmad I, 1998, J ETHNOPHARMACOL, V62, P183, DOI 10.1016/S0378 8741(98)00055 5
   Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635
   Anila L, 2002, J ETHNOPHARMACOL, V79, P81, DOI 10.1016/S0378 8741(01)00361 0
   ASMAWI MZ, 1993, J PHARM PHARMACOL, V45, P581, DOI 10.1111/j.2042 7158.1993.tb05605.x
   Bhattacharya A, 2000, PHYTOMEDICINE, V7, P173, DOI 10.1016/S0944 7113(00)80091 4
   Blair HC, 2006, REV ENDOCR METAB DIS, V7, P23, DOI 10.1007/s11154 006 9010 4
   Funk JL, 2006, J NAT PROD, V69, P351, DOI 10.1021/np050327j
   Giuliani N, 2006, CURR PHARM BIOTECHNO, V7, P423, DOI 10.2174/138920106779116955
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hidaka S, 1999, PHYTOTHER RES, V13, P14, DOI 10.1002/(SICI)1099 1573(199902)13:1<14::AID PTR375>3.0.CO;2 V
   Jose JK, 2001, J ETHNOPHARMACOL, V75, P65, DOI 10.1016/S0378 8741(00)00378 0
   LAMPRONTI I, EVID BASED COMPLEMEN, V5, P303
   Matsuzaki K, 1999, ENDOCRINOLOGY, V140, P925, DOI 10.1210/en.140.2.925
   Meng F, 2004, PHARMAZIE, V59, P643
   New SA, 2003, P NUTR SOC, V62, P889, DOI 10.1079/PNS2003310
   Penolazzi L, 2003, BIOCHEM PHARMACOL, V66, P1189, DOI 10.1016/S0006 2952(03)00470 2
   Penolazzi L, 2006, INT J MOL MED, V18, P807
   Piva R, 2005, APOPTOSIS, V10, P1079, DOI 10.1007/s10495 005 0618 8
   Piva R, 2006, ANN NY ACAD SCI, V1091, P509, DOI 10.1196/annals.1378.092
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Ramprasath VR, 2006, CHEM BIOL INTERACT, V160, P183, DOI 10.1016/j.cbi.2005.11.009
   Sánchez Conde M, 2005, HIV CLIN TRIALS, V6, P197, DOI 10.1310/ED57 EU48 RK6A E5U0
   Scartezzini P, 2006, J ETHNOPHARMACOL, V104, P113, DOI 10.1016/j.jep.2005.08.065
   Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200
   Sohail MT, 2005, PHYTOTHER RES, V19, P365, DOI 10.1002/ptr.1680
   Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217
   Sultana Sarwat, 2005, Indian Journal of Experimental Biology, V43, P430
   Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae
   Tamm I, 1998, CANCER RES, V58, P5315
   THAKUR CP, 1984, INDIAN J MED RES, V79, P142
   Wang DW, 2001, PLANTA MED, V67, P748, DOI 10.1055/s 2001 18343
   Yin J, 2004, BIOL PHARM BULL, V27, P583, DOI 10.1248/bpb.27.583
NR 32
TC 25
Z9 26
U1 0
U2 4
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
SN 0077 8923
BN 978 1 57331 737 5
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2009
VL 1171
BP 448
EP 456
DI 10.1111/j.1749 6632.2009.04906.x
PG 9
WC Multidisciplinary Sciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA BKZ03
UT WOS:000269657300058
PM 19723088
DA 2025 08 17
ER

PT J
AU Saracino, S
   Mozzati, M
   Martinasso, G
   Pol, R
   Canuto, RA
   Muzio, G
AF Saracino, Silvia
   Mozzati, Marco
   Martinasso, Germana
   Pol, Renato
   Canuto, Rosa A.
   Muzio, Giuliana
TI Superpulsed Laser Irradiation Increases Osteoblast Activity Via
   Modulation of Bone Morphogenetic Factors
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE BMPs; calcium deposits; MG 63 cells; superpulsed laser; TGF beta 2
ID CARRAGEENAN INDUCED INFLAMMATION; MESSENGER RNA EXPRESSION; PPAR GAMMA
   INSUFFICIENCY; RAT CALVARIAL CELLS; GROWTH FACTOR BETA; SUBPLANTAR
   MUSCLE; NODULE FORMATION; IN VITRO; DOWN REGULATION; THERAPY
AB Background and Objective: Laser therapy is a new approach applicable in different medical fields when bone loss occurs, including orthopedics and dentistry. It has also been used to induce soft tissue healing, for pain relief, bone, and nerve regeneration. With regard to bone synthesis, laser exposure has been shown to increase osteoblast activity and decrease osteoclast number, by inducing alkaline phosphatase (ALP), osteopontin, and bone sialoprotein expression. Studies have investigated the effects of continuous or pulsed laser irradiation, but no data are yet available on the properties of superpulsed laser irradiation. This study thus aimed to investigate the effect of superpulsed laser irradiation on osteogenic activity of human osteoblast like cells, paying particular attention to investigating the molecular mechanisms underlying the effects of this type of laser radiation.
   Study Design/Materials and Methods: Human osteoblast like MG 63 cells were exposed to 3, 7, or 10 superpulsed laser irradiation (pulse width 200 nanoseconds, minimum peak power 45 W, frequency 30 kHz, total energy 60 J, exposure time 5 minutes). The following parameters were evaluated: cell growth and viability (light microscopy, lactate dehydrogenase release), calcium deposits (Alizarin Red S staining), expression of bone morphogenetic factors (real time PCR).
   Results: Superpulsed laser irradiation decreases cell growth, induces expression of TGF beta 2, BMP 4, and BMP 7, type I collagen, ALP, and osteocalcin, and increases the size and the number of calcium deposits. The stimulatory effect is maximum on day 10, that is, after seven applications.
   Conclusions: Reported results show that superpulsed laser irradiation, like the continuous and pulsed counterparts, possesses osteogenic properties, inducing the expression of molecules known to be important mediators of bone formation and, as a consequence, increasing calcium deposits in human MG 63 cells. Moreover, the data suggest a new potential role for PPAR gamma as a regulator of osteoblast proliferation. Lasers Surg. Med. 41:298 304, 2009. (C) 2009 Wiley Liss, Inc.
C1 [Saracino, Silvia; Martinasso, Germana; Canuto, Rosa A.; Muzio, Giuliana] Univ Turin, Dept Expt Med & Oncol, I 10125 Turin, Italy.
   [Mozzati, Marco; Pol, Renato] Univ Turin, Sect Prosthet Dent, Dept Biomed Sci & Human Oncol, Sch Dent, I 10126 Turin, Italy.
C3 University of Turin; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino
RP Muzio, G (通讯作者)，Univ Turin, Dept Expt Med & Oncol, Corso Raffaello 30, I 10125 Turin, Italy.
EM giuliana.muzio@unito.it
OI Muzio, Giuliana/0000 0003 2730 1957
FU Regione Piemonte, Italy; University of Turin, Italy; Heraeus Kulzer
   GmbH; Division Dentistry, Hanau, Germany
FX This research was supported by grants from Regione Piemonte, Italy,
   University of Turin, Italy, and Heraeus Kulzer GmbH, Division Dentistry,
   Hanau, Germany. We thank Mrs Frances Cooper for revising the English.
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Albertini R, 2007, INFLAMM RES, V56, P228, DOI 10.1007/s00011 007 6211 6
   Albertini R, 2008, PHOTOMED LASER SURG, V26, P19, DOI 10.1089/pho.2007.2119
   Arany PR, 2007, WOUND REPAIR REGEN, V15, P866, DOI 10.1111/j.1524 475X.2007.00306.x
   Bortone F, 2008, INT IMMUNOPHARMACOL, V8, P206, DOI 10.1016/j.intimp.2007.09.004
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   de Oliveira RF, 2008, PHOTOMED LASER SURG, V26, P6, DOI 10.1089/pho.2007.2112
   Dianzani MU, 1999, ACTA BIOCHIM POL, V46, P61, DOI 10.18388/abp.1999_4184
   Gordon KJ, 2008, BBA MOL BASIS DIS, V1782, P197, DOI 10.1016/j.bbadis.2008.01.006
   HARRIS SE, 1994, J BONE MINER RES, V9, P855
   Hasegawa T, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 71
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   KARU T, 1994, J PHOTOCH PHOTOBIO B, V24, P155, DOI 10.1016/1011 1344(94)07016 4
   Karu T., 1992, Laser Application in Medicine and Surgery, P253
   Kawaguchi H, 2005, J BONE MINER METAB, V23, P275, DOI 10.1007/s00774 005 0599 2
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076 6879(55)01072 0
   Lin TH, 2007, BONE, V41, P562, DOI 10.1016/j.bone.2007.06.017
   Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3
   Martinasso G, 2007, PPAR RES, V2007, DOI 10.1155/2007/93416
   Matsui Satoshi, 2008, J Oral Sci, V50, P75, DOI 10.2334/josnusd.50.75
   MORIMOTO Y, 1994, LASER SURG MED, V15, P191, DOI 10.1002/lsm.1900150207
   Muzio G, 2006, APOPTOSIS, V11, P265, DOI 10.1007/s10495 006 3559 y
   Muzio G, 2003, TOXICOLOGY, V187, P149, DOI 10.1016/S0300 483X(03)00055 6
   Muzio G, 2006, FREE RADICAL BIO MED, V40, P1929, DOI 10.1016/j.freeradbiomed.2006.01.020
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   OBRADOVI RR, 2008, LASERS MED SCI  0620
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Reis SRA, 2008, PHOTOMED LASER SURG, V26, P307, DOI 10.1089/pho.2007.2151
   Rinaldi M, 2001, FREE RADICAL RES, V34, P629, DOI 10.1080/10715760100300521
   Saltmarche AE, 2008, INT WOUND J, V5, P351, DOI 10.1111/j.1742 481X.2008.00491.x
   Soares LP, 2008, PHOTOMED LASER SURG, V26, P10, DOI 10.1089/pho.2007.2115
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Termaat MF, 2005, J BONE JOINT SURG AM, V87A, P1367, DOI 10.2106/JBJS.D.02585
   Tschoep K, 2001, J MOL MED JMM, V79, P306, DOI 10.1007/s001090100204
   Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479
   Wahli W, 2008, CELL METAB, V7, P188, DOI 10.1016/j.cmet.2008.02.005
   Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Zambuzzi WF, 2009, MOL CELL BIOCHEM, V322, P143, DOI 10.1007/s11010 008 9951 x
NR 43
TC 59
Z9 62
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0196 8092
EI 1096 9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD APR
PY 2009
VL 41
IS 4
BP 298
EP 304
DI 10.1002/lsm.20762
PG 7
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology; Surgery
GA 436HS
UT WOS:000265404000008
PM 19347943
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Yao, C
   Zhu, MS
   Han, XG
   Xu, Q
   Dai, M
   Nie, T
   Liu, XQ
AF Yao, Cong
   Zhu, Meisong
   Han, Xiuguo
   Xu, Qiang
   Dai, Min
   Nie, Tao
   Liu, Xuqiang
TI A Bone Targeting Enoxacin Delivery System to Eradicate Staphylococcus
   Aureus Related Implantation Infections and Bone Loss
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE implant infection; enoxacin; aspartic acid octapeptide; mesoporous
   silica nanoparticles; bone targeting
ID MESOPOROUS SILICA NANOPARTICLES; DRUG DELIVERY; DIFFERENTIATION;
   OSTEOCLASTOGENESIS; RESORPTION; CEMENT; AGENTS
AB Post operative infections in orthopaedic implants are severe complications that require urgent solutions. Although conventional antibiotics limit bacterial biofilm formation, they ignore the bone loss caused by osteoclast formation during post operative orthopaedic implant related infections. Fortunately, enoxacin exerts both antibacterial and osteoclast inhibitory effects, playing a role in limiting infection and preventing bone loss. However, enoxacin lacks specificity in bone tissue and low bioavailability related adverse effects, which hinders translational practice. Here, we developed a nanosystem (Eno@MSN D) based on enoxacin (Eno) loaded mesoporous silica nanoparticles (MSN), decorated with the eight repeating sequences of aspartate (D Asp8), and coated with polyethylene glycol The release results suggested that Eno@MSN D exhibits a high sensitivity to acidic environment. Moreover, this Eno@MSN D delivery nanosystem exhibited both antibacterial and anti osteoclast properties in vitro. The cytotoxicity assay revealed no cytotoxicity at the low concentration (20 mu g/ml) and Eno@MSN D inhibited RANKL induced osteoclast differentiation. Importantly, Eno@MSN D allowed the targeted release of enoxacin in infected bone tissue. Bone morphometric analysis and histopathology assays demonstrated that Eno@MSN D has antibacterial and antiosteoclastic effects in vivo, thereby preventing implant related infections and bone loss. Overall, our study highlights the significance of novel biomaterials that offer new alternatives to treat and prevent orthopaedic Staphylococcus aureus related implantation infections and bone loss.
C1 [Yao, Cong; Zhu, Meisong; Xu, Qiang; Dai, Min; Nie, Tao; Liu, Xuqiang] Nanchang Univ, Dept Orthoped, Artificial Joints Engn & Technol Res Ctr Jiangxi, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Han, Xiuguo] Shanghai Jiao Tong Univ, Dept Orthopaed, Xinhua Hosp, Sch Med, Shanghai, Peoples R China.
C3 Nanchang University; Shanghai Jiao Tong University
RP Nie, T; Liu, XQ (通讯作者)，Nanchang Univ, Dept Orthoped, Artificial Joints Engn & Technol Res Ctr Jiangxi, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
EM ncnietao@163.com; shliuxuqiang@163.com
RI DAI, M/GPS 8291 2022
FU National Natural Science Foundation [81601912, 81860404]; Shanghai
   Sailing Program of Shanghai Science and Technology Innovation Action
   Plan [20YF1429800]
FX Funding This work was supported by the National Natural Science
   Foundation (Grant Nos. 81601912 and 81860404) and Shanghai Sailing
   Program of Shanghai Science and Technology Innovation Action Plan (Grant
   No. 20YF1429800).
CR Bagherifard S, 2017, MAT SCI ENG C MATER, V71, P1241, DOI 10.1016/j.msec.2016.11.011
   BEDARD J, 1989, ANTIMICROB AGENTS CH, V33, P1379, DOI 10.1128/AAC.33.8.1379
   Benoit DSW, 2016, NANOMEDICINE UK, V11, P873, DOI 10.2217/nnm 2016 0014
   Buommino E, 2014, MINI REV MED CHEM, V14, P1169
   Campoccia D, 2010, BIOMATERIALS, V31, P6363, DOI 10.1016/j.biomaterials.2010.05.005
   Chaudhary Z, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00225
   Chen SH, 2018, BONE, V106, P52, DOI 10.1016/j.bone.2017.09.011
   Dapunt U, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/728619
   Fu YC, 2014, ACTA BIOMATER, V10, P4583, DOI 10.1016/j.actbio.2014.07.015
   Gupta A, 2019, CHEM SOC REV, V48, P415, DOI 10.1039/c7cs00748e
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Johnson EN, 2007, CLIN INFECT DIS, V45, P409, DOI 10.1086/520029
   Lazzarini L, 2004, J BONE JOINT SURG AM, V86A, P2305, DOI 10.2106/00004623 200410000 00028
   Lee JE, 2010, J AM CHEM SOC, V132, P552, DOI 10.1021/ja905793q
   Li Y, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00313 19
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Liu KS, 2018, J VASC SURG, V68, P597, DOI 10.1016/j.jvs.2017.07.142
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Lu J, 2010, SMALL, V6, P1794, DOI 10.1002/smll.201000538
   Lynch AS, 2010, EXPERT OPIN THER PAT, V20, P1373, DOI 10.1517/13543776.2010.505923
   Martínez Carmona M, 2018, ACTA BIOMATER, V65, P393, DOI 10.1016/j.actbio.2017.11.007
   Masarudin MJ, 2015, NANOTECHNOL SCI APPL, V8, P67, DOI 10.2147/NSA.S91785
   Nie BE, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.01766 16, 10.1128/AAC.01766 16]
   Nielsen JJ, 2020, CURR OSTEOPOROS REP, V18, P449, DOI 10.1007/s11914 020 00604 4
   Noukrati H, 2016, MAT SCI ENG C MATER, V59, P177, DOI 10.1016/j.msec.2015.09.070
   Oliveira TC, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111765
   Ostrov DA, 2009, J MED CHEM, V52, P5144, DOI 10.1021/jm900277z
   Radovic Moreno AF, 2012, ACS NANO, V6, P4279, DOI 10.1021/nn3008383
   Ravichandran R, 2013, J BIOMAT SCI POLYM E, V24, P1988, DOI 10.1080/09205063.2013.816930
   Russo T, 2017, BIOACT MATER, V2, P156, DOI 10.1016/j.bioactmat.2017.05.002
   Schierholz JM, 2001, J HOSP INFECT, V49, P87, DOI 10.1053/jhin.2001.1052
   Sun JY, 2009, ACTA BIOMATER, V5, P1284, DOI 10.1016/j.actbio.2008.10.011
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Toro EJ, 2012, J BIOL CHEM, V287, P17894, DOI 10.1074/jbc.M111.280511
   Wang LL, 2017, INT J NANOMED, V12, P1227, DOI 10.2147/IJN.S121956
   Wang XY, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/6/065707
   Yang SB, 2018, ACS APPL MATER INTER, V10, P14299, DOI 10.1021/acsami.7b15678
   Zhang DL, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6261 7
   Zhang Y, 2017, INT J NANOMED, V12, DOI 10.2147/IJN.S127715
   Zhou W, 2020, ACTA BIOMATER, V101, P128, DOI 10.1016/j.actbio.2019.10.023
   Zhou XJ, 2015, ACS APPL MATER INTER, V7, P15777, DOI 10.1021/acsami.5b02636
   Zhu YJ, 2015, CHEM ASIAN J, V10, P284, DOI 10.1002/asia.201402715
NR 42
TC 6
Z9 6
U1 4
U2 41
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD NOV 16
PY 2021
VL 9
AR 749910
DI 10.3389/fbioe.2021.749910
PG 17
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA XH7RJ
UT WOS:000725626800001
PM 34869262
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Gonçalves Zillo, TO
   Pugliese, LS
   Sales, VMT
   Mori, MAD
   Squaiella Baptistao, CC
   Longo Maugéri, IM
   Lopes, JD
   de Oliveira, SM
   Monteiro, AC
   Pesquero, JB
AF Goncalves Zillo, Thais Oliveira
   Pugliese, Livia Souza
   Toledo Sales, Vicencia Micheline
   da Silva Mori, Marcelo Alves
   Squaiella Baptistao, Carla Cristina
   Longo Maugeri, Ieda Maria
   Lopes, Jose Daniel
   de Oliveira, Suzana Macedo
   Monteiro, Ana Carolina
   Pesquero, Joao Bosco
TI Increased bone loss and amount of osteoclasts in kinin B1 receptor
   knockout mice
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE Bdkrb1; bone loss; kinin; osteoclast; periodontitis
ID TUMOR NECROSIS FACTOR; NF KAPPA B; NITRIC OXIDE; MOLECULAR MECHANISMS;
   PERIODONTAL DISEASE; TRYPANOSOMA CRUZI; T LYMPHOCYTE; FACTOR ALPHA;
   BRADYKININ; ACTIVATION
AB Aim The pathophysiology of periodontal diseases involves aspects of immunity and bone remodelling. Considering the role of the kinin B1 receptor (Bdkrb1) in inflammation and healing, the purpose of this study was to evaluate the contribution of Bdkrb1 to the pathogenesis of periodontitis. Material and Methods We used a model of ligature induced experimental periodontitis (LIEP) in mice lacking Bdkrb1 (Bdkrb1 / ) to test the role of this receptor in bone loss and cytokine secretion by lymph nodes cells. Angiotensin converting enzyme inhibitor (ACEi) was used as a pharmacological strategy to support the genetic model. Also, autonomous effect of Bdkrb1 deletion was evaluated in osteoclasts precursors from bone marrow. Results Bdkrb1 /  mice exhibit increased bone loss and IL 17 secretion in response to LIEP when compared to wild type. LIEP does not modify TNF , IFN  and IL 10 levels in Bdkrb1 /  mice after 21days. Bone marrow cells from Bdkrb1 /  displayed increased differentiation into functional osteoclasts with consistent artificial calcium phosphate degradation. Furthermore, treatment of mice with ACEi prevented bone destruction. Conclusion Bdkrb1 participates in the pathogenesis of LIEP bone loss possibly through mechanisms that involve modulation of the TH17 response, thereby demonstrating its role in the development of periodontitis.
C1 [Goncalves Zillo, Thais Oliveira; Toledo Sales, Vicencia Micheline; da Silva Mori, Marcelo Alves; de Oliveira, Suzana Macedo; Pesquero, Joao Bosco] Univ Fed Sao Paulo, Dept Biofis, BR 04039032 Sao Paulo, Brazil.
   [Pugliese, Livia Souza; Longo Maugeri, Ieda Maria; Lopes, Jose Daniel] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Disciplina Imunol, BR 04039032 Sao Paulo, Brazil.
   [Squaiella Baptistao, Carla Cristina] Inst Butantan, Lab Imunoquim, Sao Paulo, Brazil.
   [Monteiro, Ana Carolina] MEDEX, Inst Nacl Canc CPQ, Rio De Janeiro, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP); Instituto Butantan
RP Pesquero, JB (通讯作者)，Univ Fed Sao Paulo, Rua Pedro de Toledo,669,9 Andar, BR 04039032 Sao Paulo, Brazil.
EM jbpesquero@unifesp.br
RI Squaiella Baptistão, Carla/K 2557 2013; Longo Maugeri, Ieda
   Maria/B 9764 2012; Pesquero, Joao Bosco/C 1470 2012; Monteiro, Ana
   Carolina/AAX 6136 2021; Mori, Marcelo/R 2881 2018; Pesquero,
   Joao/C 1470 2012; Pugliese, Livia/E 7865 2013; Longo Maugeri,
   Ieda/B 9764 2012
OI Longo Maugeri, Ieda Maria/0000 0003 4184 8414; Pesquero, Joao
   Bosco/0000 0002 4507 632X; Squaiella Baptistao, Carla
   Cristina/0000 0002 4187 798X; Monteiro, Ana
   Carolina/0000 0001 7899 6264; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [Proc.
   2008/06676 8]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [08/06676 8] Funding Source: FAPESP
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP   Proc. 2008/06676 8). The authors declare
   that they have no conflict of interests.
CR Araújo RC, 2001, BIOL CHEM, V382, P91, DOI 10.1515/BC.2001.014
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brechter AB, 2008, BONE, V43, P72, DOI 10.1016/j.bone.2008.02.003
   Brechter AB, 2007, ARTHRITIS RHEUM US, V56, P910, DOI 10.1002/art.22445
   Brunius G, 2005, REGUL PEPTIDES, V126, P183, DOI 10.1016/j.regpep.2004.09.005
   Daoussis D, 2010, SEMIN ARTHRITIS RHEU, V39, P369, DOI 10.1016/j.semarthrit.2008.10.008
   FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo 127 5 2592
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   GUSTAFSON GT, 1984, BIOCHEM J, V219, P329, DOI 10.1042/bj2190329
   Hodge JM, 2007, J CELL BIOCHEM, V102, P759, DOI 10.1002/jcb.21331
   JOHNSON IH, 1975, J PERIODONTAL RES, V10, P332, DOI 10.1111/j.1600 0765.1975.tb00042.x
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kinane DF, 2011, J CLIN PERIODONTOL, V38, P44, DOI 10.1111/j.1600 051X.2010.01682.x
   Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Leeb Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   LERNER UH, 1994, ORAL SURG ORAL MED O, V78, P481, DOI 10.1016/0030 4220(94)90043 4
   LJUNGGREN O, 1990, BRIT J PHARMACOL, V101, P382, DOI 10.1111/j.1476 5381.1990.tb12718.x
   Loiola RA, 2011, PEPTIDES, V32, P1700, DOI 10.1016/j.peptides.2011.06.010
   Molinaro G, 2002, J PHARMACOL EXP THER, V303, P232, DOI 10.1124/jpet.102.038067
   Monteiro AC, 2006, J IMMUNOL, V177, P6325, DOI 10.4049/jimmunol.177.9.6325
   Monteiro AC, 2007, PLOS PATHOG, V3, P1730, DOI 10.1371/journal.ppat.0030185
   Niedbala W, 2011, P NATL ACAD SCI USA, V108, P9220, DOI 10.1073/pnas.1100667108
   Pesquero JB, 1996, BIOCHEM BIOPH RES CO, V220, P219, DOI 10.1006/bbrc.1996.0384
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   Prat A, 1999, NEUROLOGY, V53, P2087, DOI 10.1212/WNL.53.9.2087
   Pugliese LS, 2012, IMMUNOBIOLOGY, V217, P336, DOI 10.1016/j.imbio.2011.07.014
   REGOLI D, 1980, PHARMACOL REV, V32, P1
   Santos EL, 2009, BIOCHEM PHARMACOL, V78, P951, DOI 10.1016/j.bcp.2009.06.018
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schenkein HA, 2006, PERIODONTOL 2000, V40, P77, DOI 10.1111/j.1600 0757.2005.00144.x
   Schulze Topphoff U, 2009, NAT MED, V15, P788, DOI 10.1038/nm.1980
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Teng YTA, 2006, J DENT RES, V85, P209, DOI 10.1177/154405910608500302
   VantHof RJ, 1997, J BONE MINER RES, V12, P1797, DOI 10.1359/jbmr.1997.12.11.1797
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 36
TC 22
Z9 25
U1 0
U2 18
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD JUL
PY 2013
VL 40
IS 7
BP 653
EP 660
DI 10.1111/jcpe.12097
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 157MN
UT WOS:000319900500001
PM 23534940
DA 2025 08 17
ER

PT J
AU Crasto, GJ
   Kartner, N
   Yao, YQ
   Li, KY
   Bullock, L
   Datti, A
   Manolson, MF
AF Crasto, Gazelle J.
   Kartner, Norbert
   Yao, Yeqi
   Li, Keying
   Bullock, Liv
   Datti, Alessandro
   Manolson, Morris F.
TI Luteolin inhibition of V ATPase a3 d2 interaction decreases osteoclast
   resorptive activity
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE VACUOLAR H plus  ATPase; PROTON TRANSPORT; BIOFLAVONOIDS; OSTEOPOROSIS;
   DRUG DISCOVERY
ID VACUOLAR H+ ATPASE; PROTON PUMP; ESSENTIAL COMPONENT; A3 ISOFORM;
   D SUBUNIT; IN VITRO; BONE; EXPRESSION; DISEASE; TRANSPORT
AB V ATPase mediated acid secretion is required for osteoclast bone resorption. Osteoclasts are enriched in V ATPase a3 and d2 subunit isoforms, and disruption of either of their genes impairs bone resorption. Using purified fusion proteins of a3 N terminal domain (NTa3) and full length d subunits we determined in a solid phase binding assay that half maximal binding of d1 or d2 to immobilized NTa3 occurs at 3.1 +/  0.4 or 3.6 +/  0.6nM, respectively, suggesting equally high affinity interactions. A high throughput modification of this assay was then used to screen chemical libraries for a3d2 interaction inhibitors, and luteolin, a naturally occurring flavonoid, was identified, with half maximal inhibition at 2.4 +/  0.9 mu M. Luteolin did not significantly affect NIH/3T3 or RAW 264.7 cell viability, nor did it affect cytokine induced osteoclastogenesis of RAW 264.7 cells or bone marrow mononuclear cells at concentrations 40 mu M. Luteolin inhibited osteoclast bone resorption with an EC50 of approximately 2.5 mu M, without affecting osteoclast actin ring formation. Luteolin treated osteoclasts produced deeper resorption pits, but with decreased surface area, resulting in overall decreased pit volume. Luteolin did not affect transcription, or protein levels, of V ATPase subunits a3, d2, and E, or V1V0 assembly. Previous work has shown that luteolin can be effective in reducing bone resorption, and our studies suggest that this effect of luteolin may be through disruption of osteoclast V ATPase a3d2 interaction. We conclude that the V ATPase a3d2 interaction is a viable target for novel anti resorptive therapeutics that potentially preserve osteoclastosteoblast signaling important for bone remodeling. J. Cell. Biochem. 114: 929941, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Crasto, Gazelle J.; Kartner, Norbert; Yao, Yeqi; Li, Keying; Bullock, Liv; Manolson, Morris F.] Univ Toronto, Fac Dent, Dent Res Inst, Toronto, ON M5G 1G6, Canada.
   [Datti, Alessandro] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
   [Datti, Alessandro] Univ Perugia, Dept Expt Med & Biochem Sci, I 06100 Perugia, Italy.
   [Manolson, Morris F.] Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada.
C3 University of Toronto; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; University of Perugia;
   University of Toronto
RP Manolson, MF (通讯作者)，Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G6, Canada.
EM m.manolson@dentistry.utoronto.ca
RI ; Datti, Alessandro/ABA 1108 2021
OI Manolson, Morris/0000 0001 8755 5460; Datti,
   Alessandro/0000 0001 6824 7382; 
FU Canadian Institutes of Health Research [FRN79322]; Canadian Arthritis
   Network [2008 02 DAP 02]; Canadian Arthritis Society
FX Grant sponsor: Canadian Institutes of Health Research; Grant number:
   FRN79322; Grant sponsor: Canadian Arthritis Network; Grant number:
   2008 02 DAP 02.We thank the following for their contributions to this
   work: Drs. Beth S. Lee and Brooke McMichael (Deptartment of Physiology
   and Cell Biology, Ohio State University College of Medicine, Columbus,
   OH) for providing cDNA clones for mouse a3 subunits, anti a3, and anti E
   antibodies, and helpful discussions on Methods; Dr. Mario Filion
   (Alethia Biotherapeutics, Montreal, Canada) for his kind gift of anti d2
   antibodies; Frederick Vizeacoumar and Thomas Sun (Samuel Lunenfeld
   Research Institute SMART robotics facility, Mt. Sinai Hospital, Toronto,
   Canada) for help with high throughput screening; Feryal Sarraf and Nancy
   Valiquette (Faculty of Dentistry, University of Toronto, Toronto,
   Canada) for help with ivory sectioning and staining; Kirsten Krastel,
   Gursonika Binepal, Martha Cordova (Faculty of Dentistry, University of
   Toronto) for help with qRT PCR and related discussions; Michael Woodside
   and Paul Partouis for advice and training in confocal microscopy; and
   the Toronto Zoo for the donation of elephant ivory. G.J.C. was supported
   by a scholarship from the Canadian Arthritis Society.
CR Attoub S, 2011, EUR J PHARMACOL, V651, P18, DOI 10.1016/j.ejphar.2010.10.063
   Brideau C, 2003, J BIOMOL SCREEN, V8, P634, DOI 10.1177/1087057103258285
   Chinnam N, 2010, INT J BIOL MACROMOL, V46, P478, DOI 10.1016/j.ijbiomac.2010.03.009
   Choi EM, 2007, CELL BIOL INT, V31, P870, DOI 10.1016/j.cellbi.2007.01.038
   DAVID P, 1994, J BIOL CHEM, V269, P30158
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Finnigan GC, 2011, MOL BIOL CELL, V22, P3176, DOI 10.1091/mbc.E11 03 0244
   Furuike S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1215
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200
   Hinton A, 2009, PFLUG ARCH EUR J PHY, V457, P589, DOI 10.1007/s00424 007 0382 4
   Hong S, 2008, MICROBIOL MOL BIOL R, V72, P590, DOI 10.1128/MMBR.00016 08
   Kanadaswami C, 2005, IN VIVO, V19, P895
   Kartner N, 2010, J BIOL CHEM, V285, P37476, DOI 10.1074/jbc.M110.123281
   Kawasaki Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Kim T, 2010, BIOCHEM BIOPH RES CO, V403, P73, DOI 10.1016/j.bbrc.2010.10.117
   Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lemieux JM, 2011, IN VITRO CELL DEV AN, V47, P260, DOI 10.1007/s11626 011 9385 8
   Liu AL, 2008, PLANTA MED, V74, P847, DOI 10.1055/s 2008 1074558
   Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200
   MANOLSON MF, 1994, J BIOL CHEM, V269, P14064
   Marjuki H, 2011, CELL MICROBIOL, V13, P587, DOI 10.1111/j.1462 5822.2010.01556.x
   McMichael BK, 2006, BONE, V39, P694, DOI 10.1016/j.bone.2006.04.031
   Merkulova M, 2010, BBA BIOENERGETICS, V1797, P1398, DOI 10.1016/j.bbabio.2010.02.009
   Miura GI, 2003, TRANSGENIC RES, V12, P131, DOI 10.1023/A:1022118627058
   Neri D, 2011, NAT REV DRUG DISCOV, V10, P767, DOI 10.1038/nrd3554
   Newton R, 2000, BRIT J PHARMACOL, V130, P1353, DOI 10.1038/sj.bjp.0703431
   Niikura K, 2007, CANCER CHEMOTH PHARM, V60, P555, DOI 10.1007/s00280 006 0401 8
   Nishi T, 2003, J BIOL CHEM, V278, P46396, DOI 10.1074/jbc.M303924200
   Ochotny N, 2011, J BONE MINER RES, V26, P1484, DOI 10.1002/jbmr.355
   Pangrazio A, 2012, OSTEOPOROSIS INT, V271, P3
   Scimeca JC, 2003, HUM MUTAT, V21, P151, DOI 10.1002/humu.10165
   Seelinger G, 2008, PLANTA MED, V74, P1667, DOI 10.1055/s 0028 1088314
   Shimabukuro K, 2003, P NATL ACAD SCI USA, V100, P14731, DOI 10.1073/pnas.2434983100
   Shin DK, 2012, ACTA BIOMATER, V8, P3524, DOI 10.1016/j.actbio.2012.05.002
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Takahashi N, 2003, METH MOLEC MED, V80, P129
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Toei M, 2010, BIOCHEMISTRY US, V49, P4715, DOI 10.1021/bi100397s
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Zhang J, 2008, ARCH PHARM RES, V31, P850, DOI 10.1007/s12272 001 1237 y
   Zhang ZY, 2008, J BIOL CHEM, V283, P35983, DOI 10.1074/jbc.M805345200
   Zhao YX, 2011, MOL BIOL REP, V38, P1115, DOI 10.1007/s11033 010 0208 x
NR 49
TC 21
Z9 27
U1 0
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR
PY 2013
VL 114
IS 4
BP 929
EP 941
DI 10.1002/jcb.24434
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 093UU
UT WOS:000315219000020
PM 23129004
DA 2025 08 17
ER

PT S
AU Ruocco, MG
   Karin, M
AF Ruocco, Maria Grazia
   Karin, Michael
BE Choi, YW
TI Control of osteoclast activity and bone loss by IKK subunits: New
   targets for therapy
SO OSTEOIMMUNOLOGY
SE Advances in Experimental Medicine and Biology
LA English
DT Article
ID NF KAPPA B; TUMOR NECROSIS FACTOR; ALPHA MONOCLONAL ANTIBODY;
   RHEUMATOID ARTHRITIS; C SRC; CONCOMITANT METHOTREXATE; MICE LACKING;
   T CELLS; OSTEOPROTEGERIN; ACTIVATION
AB Transcription factor NF kappa B has been well recognized as a pivotal player in osteclastogenesis and inflammation induced bone loss. Here, we discuss our recent results obtained using a genetic approach in mice that indicate the importance of IKK beta, and not IKK alpha, as a transducer of signals from receptor activator of NF kappa B (RANK) to NF kappa B. Ablation of IKK beta results in lack of osteoclastogenesis and unresponsiveness of IKK beta deficient mice to inflammation induced bone loss. In the need of a more effective therapy for the treatment of inflammatory diseases causing bone resorption, specific inhibition of IKK beta represents a logical alternative strategy to the current therapies.
C1 Univ Calif San Diego, Sch Med, Lba Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego
RP Karin, M (通讯作者)，Univ Calif San Diego, Sch Med, Lba Gene Regulat & Signal Transduct, 9500 Gilmann Dr, La Jolla, CA 92093 USA.
EM karinoffice@ucsd.edu
CR Abu Amer Y, 2000, J BIOL CHEM, V275, P27307
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Bolon B, 2002, CELL MOL LIFE SCI, V59, P1569, DOI 10.1007/s00018 002 8530 7
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Breedveld FC, 2004, ANN RHEUM DIS, V63, P149, DOI 10.1136/ard.2003.013961
   Campagnuolo G, 2002, ARTHRITIS RHEUM US, V46, P1926, DOI 10.1002/art.10369
   Campbell IK, 2001, J CLIN INVEST, V107, P1519, DOI 10.1172/JCI12724
   Campbell IK, 2000, J CLIN INVEST, V105, P1799, DOI 10.1172/JCI8298
   Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908
   Danning CL, 2000, ARTHRITIS RHEUM US, V43, P1244, DOI 10.1002/1529 0131(200006)43:6<1244::AID ANR7>3.0.CO;2 2
   den Broeder A, 2002, J RHEUMATOL, V29, P2288
   den Broeder AA, 2002, ANN RHEUM DIS, V61, P311, DOI 10.1136/ard.61.4.311
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140 6736(94)90628 9
   Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218
   Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092 8674(00)80984 8
   Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605
   Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302 221
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kremer JM, 2003, ARTHRITIS RHEUM, V48, P1493, DOI 10.1002/art.11142
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   LEISEN JCC, 1988, J RHEUMATOL, V15, P17
   Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321
   Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092 8674(00)81375 6
   MACNAUL KL, 1990, J IMMUNOL, V145, P4154
   Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074 7613(03)00301 7
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140 6736(99)05246 0
   Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529 0131(199809)41:9<1552::AID ART5>3.0.CO;2 W
   Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860
   Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859
   Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003 4819 130 6 199903160 00004
   Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301
   Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219
   Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281 200305000 00016
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Reddi AH, 1997, CELL, V89, P159, DOI 10.1016/S0092 8674(00)80193 2
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rothwarf DavidM., 1999, Science Signaling, V5, P1
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365 2141.1997.562704.x
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   Seetharaman R, 1999, J IMMUNOL, V163, P1577
   Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677
   Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074 7613(01)00104 2
   Shealy DJ, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar430
   Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Suzuki Y, 1998, J RHEUMATOL, V25, P1154
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401
   Weinblatt ME, 2003, ARTHRITIS RHEUM US, V48, P35, DOI 10.1002/art.10697
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092 8674(00)80406 7
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 82
TC 16
Z9 16
U1 0
U2 1
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
EI 2214 8019
BN 978 0 387 72008 1
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2007
VL 602
BP 125
EP 134
PG 10
WC Immunology; Medicine, Research & Experimental; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine; Orthopedics
GA BGR94
UT WOS:000250200200017
PM 17966397
DA 2025 08 17
ER

PT J
AU Molla, S
   Katti, DR
   Katti, KS
AF Molla, Shahjahan
   Katti, Dinesh R.
   Katti, Kalpana S.
TI In vitro design of mesenchymal to epithelial transition of prostate
   cancer metastasis using 3D nanoclay bone mimetic scaffolds
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE bone; cancer; MET; metastasis; nanoclays; prostrate
ID GROWTH FACTOR RECEPTOR 2; STEM CELLS; E CADHERIN; OSTEOGENIC
   DIFFERENTIATION; HYDROXYAPATITE; MODELS; BIOMATERIALS; OSTEOBLASTS;
   PROGRESSION; EXPRESSION
AB Nanocomposite scaffolds show extensive applications in regenerative medicine and have shown promise as in vitro analogues of human tissue that can be used for the study of diseases. The complex nature of cancer metastasis is recently investigated using several 3D scaffold models. Herein, we report a polymer nanoclay based in vitro tumour model that recapitulates early stage of prostate cancer (PCa) colonization during skeletal metastasis on bone mimetic scaffolds. A unique cell culture system termed as sequential culture (SC) has been applied to create a bone mimetic niche for colonization of PCa cells. Human mesenchymal stem cells (MSCs) were seeded on the bone mimetic scaffolds, where they differentiated into bone cells and then formed mineralized bone matrix without osteogenic supplements. Further, PCa was seeded on MSCs seeded scaffolds. Sequentially cultured PCa cells with MSCs formed self organized multicellular tumoroids with distinct tight cellular junctions and hypoxic core regions. Extensive quantitative reverse transcription polymerase chain reaction experiments were performed to evaluate the expressions of genes related to osteotropic bone metastasis of PCa. On the nanoclay scaffolds, the MSCs differentiated to mature osteoblasts and epithelial to mesenchymal transition was inhibited whereas mesenchymal to epithelial transition was enhanced, as also the hypoxia increased angiogenesis, and finally, PCa cells initiated osteoblastic lesion. Further, the SC technique has significant effects on expression of key metastasis related genes. Therefore, the SC based tumour model can be applied to recapitulate more consistent osteotropic cancer cell behavior in understanding tumour biology. This model also can be implemented for drug screening to target colonization stage of PCa cells in the bone microenvironment.
C1 [Molla, Shahjahan; Katti, Dinesh R.; Katti, Kalpana S.] North Dakota State Univ, Dept Civil & Environm Engn, Fargo, ND 58105 USA.
C3 North Dakota State University Fargo
RP Katti, KS (通讯作者)，North Dakota State Univ, Dept Civil & Environm Engn, Fargo, ND 58105 USA.
EM kalpana.katti@ndsu.edu
RI Katti, Dinesh/A 5440 2010; Katti, Kattesh/G 4167 2017
OI Katti, Dinesh/0000 0001 9866 2683; Katti, Kalpana/0000 0002 1404 4018;
   Molla, MD Shahjahan/0000 0003 3643 2385
FU NDSU Grand Challenges Center for Engineered Cancer Test Beds; NDSU; ND
   EPSCoR; National Science Foundation
FX NDSU Grand Challenges Center for Engineered Cancer Test Beds; NDSU; ND
   EPSCoR; National Science Foundation
CR Ambre Avinash H., 2010, Journal of Nanotechnology in Engineering and Medicine, V1, DOI 10.1115/1.4002149
   Ambre A, 2011, MAT SCI ENG C MATER, V31, P1017, DOI 10.1016/j.msec.2011.03.001
   Ambre AH, 2015, J BIOMED MATER RES A, V103, P2077, DOI 10.1002/jbm.a.35342
   Ambre AH, 2013, J BIOMED MATER RES A, V101, P2644, DOI 10.1002/jbm.a.34561
   Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 258
   Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008 5472.CAN 06 2044
   Chiao JW, 2000, BRIT J CANCER, V83, P360, DOI 10.1054/bjoc.2000.1261
   Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078 0432.CCR 07 1263
   Han HW, 2016, ACTA BIOMATER, V42, P157, DOI 10.1016/j.actbio.2016.06.014
   Howlader N., 2013, SEER CANC STAT REV
   Hutmacher DW, 2010, NAT MATER, V9, P90, DOI 10.1038/nmat2619
   Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024
   Kabashima Niibe A, 2013, CANCER SCI, V104, P157, DOI 10.1111/cas.12059
   Katti KS, 2016, J BIOMED MATER RES A, V104, P1591, DOI 10.1002/jbm.a.35685
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Kulkarni P, 2016, BIOMACROMOLECULES, V17, P2507, DOI 10.1021/acs.biomac.6b00350
   Li YM, 2011, UROL ONCOL SEMIN ORI, V29, P802, DOI 10.1016/j.urolonc.2009.09.016
   Liu YK, 2009, J BIOMED MATER RES A, V90A, P1083, DOI 10.1002/jbm.a.32192
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09 151639
   Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Rey S, 2010, CARDIOVASC RES, V86, P236, DOI 10.1093/cvr/cvq045
   Roberts E., 2013, PROSTATE CANC, V2013, P8
   Saha B, 2008, PROSTATE, V68, P78, DOI 10.1002/pros.20670
   Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018 011 0735 1
   Sokoloff MH, 1998, CANCER METAST REV, V17, P307, DOI 10.1023/A:1006170612253
   Sun T, 2015, EUR UROL, V68, P589, DOI 10.1016/j.eururo.2014.12.037
   Talukdar S, 2013, ADV FUNCT MATER, V23, P5249, DOI 10.1002/adfm.201300312
   Thibault RA, 2010, TISSUE ENG PT A, V16, P431, DOI [10.1089/ten.tea.2009.0583, 10.1089/ten.TEA.2009.0583]
   Verbridge SS, 2010, TISSUE ENG PT A, V16, P2147, DOI [10.1089/ten.tea.2009.0668, 10.1089/ten.TEA.2009.0668]
   Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585 008 9167 1
NR 37
TC 20
Z9 24
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD MAR
PY 2018
VL 12
IS 3
BP 727
EP 737
DI 10.1002/term.2492
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA FY8TG
UT WOS:000427137100062
PM 28603879
OA Bronze
DA 2025 08 17
ER

PT J
AU Marciano, DP
   Kuruvilla, DS
   Boregowda, SV
   Asteian, A
   Hughes, TS
   Garcia Ordonez, R
   Corzo, CA
   Khan, TM
   Novick, SJ
   Park, H
   Kojetin, DJ
   Phinney, DG
   Bruning, JB
   Kamenecka, TM
   Griffin, PR
AF Marciano, David P.
   Kuruvilla, Dana S.
   Boregowda, Siddaraju V.
   Asteian, Alice
   Hughes, Travis S.
   Garcia Ordonez, Ruben
   Corzo, Cesar A.
   Khan, Tanya M.
   Novick, Scott J.
   Park, HaJeung
   Kojetin, Douglas J.
   Phinney, Donald G.
   Bruning, John B.
   Kamenecka, Theodore M.
   Griffin, Patrick R.
TI Pharmacological repression of PPARγ promotes osteogenesis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID STRUCTURAL BASIS; BINDING SITE; LIGAND; ROSIGLITAZONE; ANTAGONISM;
   MODULATOR; CELLS
AB The nuclear receptor peroxisome proliferator activated receptor gamma (PPAR gamma) is the master regulator of adipogenesis and the pharmacological target of the thiazolidinedione (TZD) class of insulin sensitizers. Activation of PPAR gamma by TZDs promotes adipogenesis at the expense of osteoblast formation, contributing to their associated adverse effects on bone. Recently, we reported the development of PPAR gamma antagonist SR1664, designed to block the obesity induced phosphorylation of serine 273 (S273) in the absence of classical agonism, to derive insulin sensitizing efficacy with improved therapeutic index. Here we identify the structural mechanism by which SR1664 actively antagonizes PPAR gamma, and extend these findings to develop the inverse agonist SR2595. Treatment of isolated bone marrow derived mesenchymal stem cells with SR2595 promotes induction of osteogenic differentiation. Together these results identify the structural determinants of ligand mediated PPAR gamma repression, and suggest a therapeutic approach to promote bone formation.
C1 [Marciano, David P.; Kuruvilla, Dana S.; Boregowda, Siddaraju V.; Asteian, Alice; Hughes, Travis S.; Garcia Ordonez, Ruben; Corzo, Cesar A.; Khan, Tanya M.; Novick, Scott J.; Park, HaJeung; Kojetin, Douglas J.; Phinney, Donald G.; Kamenecka, Theodore M.; Griffin, Patrick R.] Scripps Florida, Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL 33458 USA.
   [Bruning, John B.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.
C3 State University System of Florida; University of Florida; Herbert
   Wertheim UF Scripps Institute for Biomedical Innovation & Technology;
   University of Adelaide
RP Griffin, PR (通讯作者)，Scripps Florida, Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL 33458 USA.
EM pgriffin@scripps.edu
RI Phinney, Donald/D 2155 2014; Bruning, John/AAW 8567 2020; Kojetin,
   Douglas/HJY 2066 2023
OI Marciano, David/0000 0001 8868 2138; Bruning, John/0000 0002 6919 1824;
   Park, HaJeung/0000 0003 4898 7919; Kojetin, Douglas/0000 0001 8058 6168;
   Phinney, Donald/0000 0002 8688 2619; Griffin,
   Patrick/0000 0002 3404 690X; Hughes, Travis/0000 0002 5764 5884
FU NCRR NIH HHS [S10 RR027270] Funding Source: Medline; NIDDK NIH HHS [R01
   DK105825, R01 DK101871, DK103116, R00 DK103116, DK097890, DK080261, F32
   DK097890, R24 DK080261, DK101871, K99 DK103116] Funding Source: Medline;
   NIGMS NIH HHS [R01 GM084041, GM084041] Funding Source: Medline; NIH HHS
   [R24 OD018254, OD018254] Funding Source: Medline; NIMH NIH HHS
   [MH084512, U54 MH084512] Funding Source: Medline
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Aubert RE, 2010, DIABETES OBES METAB, V12, P716, DOI 10.1111/j.1463 1326.2010.01225.x
   Bruning JB, 2007, STRUCTURE, V15, P1258, DOI 10.1016/j.str.2007.07.014
   Burton JD, 2008, PPAR RES, V2008, DOI 10.1155/2008/494161
   Carmona MC, 2007, DIABETES, V56, P2797, DOI 10.2337/db06 1734
   Chalmers Michael J, 2007, J Biomol Tech, V18, P194
   Chalmers MJ, 2006, ANAL CHEM, V78, P1005, DOI 10.1021/ac051294f
   Cheng YH, 2009, CELL SIGNAL, V21, P1874, DOI 10.1016/j.cellsig.2009.08.003
   Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383
   Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Higgins LS, 2010, AM J CLIN NUTR, V91, p267S, DOI 10.3945/ajcn.2009.28449E
   Hughes TS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4571
   Itoh T, 2008, NAT STRUCT MOL BIOL, V15, P924, DOI 10.1038/nsmb.1474
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Liu C, 2014, CELL METAB, V19, P722, DOI 10.1016/j.cmet.2014.01.021
   Miles PDG, 2003, AM J PHYSIOL ENDOC M, V284, pE618, DOI 10.1152/ajpendo.00312.2002
   Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538
   Nakano R, 2006, BIOCHEM PHARMACOL, V72, P42, DOI 10.1016/j.bcp.2006.03.023
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Pascal BD, 2012, J AM SOC MASS SPECTR, V23, P1512, DOI 10.1007/s13361 012 0419 6
   Rangwala Shamina M, 2002, Sci STKE, V2002, ppe9, DOI 10.1126/stke.2002.121.pe9
   Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097 2765(01)00353 7
   Ryan KK, 2011, NAT MED, V17, P623, DOI 10.1038/nm.2349
   Seargent JM, 2004, BRIT J PHARMACOL, V143, P933, DOI 10.1038/sj.bjp.0705973
   Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092 8674(00)81717 1
   Taygerly JP, 2013, BIOORGAN MED CHEM, V21, P979, DOI 10.1016/j.bmc.2012.11.058
   Tsukahara T, 2010, MOL CELL, V39, P421, DOI 10.1016/j.molcel.2010.07.022
   Viccica G, 2010, J Endocrinol Invest, V33, P9
   Walkey CJ, 2008, J BIOL CHEM, V283, P24290, DOI 10.1074/jbc.C800139200
   Yue LD, 2005, BIOCHIMIE, V87, P539, DOI 10.1016/j.biochi.2005.02.002
   Zaytseva YY, 2011, ANTICANCER RES, V31, P813
NR 32
TC 103
Z9 113
U1 0
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2015
VL 6
AR 7443
DI 10.1038/ncomms8443
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CL7UH
UT WOS:000357176700009
PM 26068133
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Gnant, M
   Pfeiler, G
   Steger, GG
   Egle, D
   Greil, R
   Fitzal, F
   Wette, V
   Balic, M
   Haslbauer, F
   Melbinger Zeinitzer, E
   Bjelic Radisic, V
   Jakesz, R
   Marth, C
   Sevelda, P
   Mlineritsch, B
   Exner, R
   Fesl, C
   Frantal, S
   Singer, CF
AF Gnant, Michael
   Pfeiler, Georg
   Steger, Guenther G.
   Egle, Daniel
   Greil, Richard
   Fitzal, Florian
   Wette, Viktor
   Balic, Marija
   Haslbauer, Ferdinand
   Melbinger Zeinitzer, Elisabeth
   Bjelic Radisic, Vesna
   Jakesz, Raimund
   Marth, Christian
   Sevelda, Paul
   Mlineritsch, Brigitte
   Exner, Ruth
   Fesl, Christian
   Frantal, Sophie
   Singer, Christian F.
CA Austrian Breast Colorectal Canc St
TI Adjuvant denosumab in postmenopausal patients with hormone
   receptor positive breast cancer (ABCSG 18): disease free survival
   results from a randomised, double blind, placebo controlled, phase 3
   trial
SO LANCET ONCOLOGY
LA English
DT Article
ID PLUS ZOLEDRONIC ACID; CLINICAL PRACTICE; BONE LOSS; THERAPY; WOMEN;
   BISPHOSPHONATES; INHIBITOR; RANKL; METAANALYSIS; PREVENTION
AB Background In postmenopausal women with hormone receptor positive, early stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures. Results from the ABCSG 18 trial showed that use of denosumab as an adjuvant to aromatase inhibitor therapy significantly reduced clinical fractures. Disease free survival outcomes from ABCSG 18 have not yet been reported.
   Methods Postmenopausal patients with early, hormone receptor positive, non metastatic adenocarcinoma of the breast, who had completed their initial adjuvant treatment pathway (surgery, radiotherapy, or chemotherapy, or a combination) and were receiving adjuvant aromatase inhibitors, were enrolled at 58 trial centres in Austria and Sweden into this prospective, double blind, placebo controlled, phase 3 trial. With permuted block randomisation (block sizes 2 and 4, stratified by previous aromatase inhibitor use, total lumbar spine bone mineral density score at baseline, and type of centre), patients were assigned (1: 1) to receive subcutaneous denosumab (60 mg) or matching placebo every 6 months during aromatase inhibitor therapy. The primary endpoint (previously reported) was the time to first clinical fracture after randomisation. The secondary endpoint reported here is disease free survival (defined as time from randomisation to first evidence of local or distant metastasis, contralateral breast cancer, secondary carcinoma, or death from any cause) in the intention to treat population. This study is registered with EudraCT (number 2005 005275 15) and ClinicalTrials.gov (number NCT00556374), and is ongoing for long term follow up.
   Findings Between Dec 18, 2006, and July 22, 2013, 3425 eligible patients were enrolled and randomly assigned; 1711 to the denosumab group and 1709 to the placebo group (with five others withdrawing consent). After a median followup of 73 months (IQR 58 95), 240 (14.0%) patients in the denosumab and 287 (16.8%) in the placebo group had disease free survival events. Disease free survival was significantly improved in the denosumab group versus the placebo group (hazard ratio 0.82, 95% CI 0.69 0.98, Cox p=0.0260; descriptive analysis, without controlling for multiplicity). In the denosumab group, disease free survival was 89.2% (95% CI 87.6 90.8) at 5 years and 80.6% (78.1 83.1) at 8 years of follow up, compared with 87.3% (85.7 89.0) at 5 years and 77.5% (74.8 80.2) and 8 years in the placebo group. No independently adjudicated cases of osteonecrosis of the jaw or confirmed atypical femoral fractures were recorded. The total number of adverse events was similar in the denosumab group (1367 [including 521 serious] adverse events) and the placebo group (1339 [515 serious]). The most common serious adverse events were osteoarthritis (62 [3.6%] of 1709 in the denosumab group vs 58 [3.4%] of 1690 in the placebo group), meniscus injury (23 [1.3%] vs 24 [1.4%]), and cataract (16 [0.9%] vs 28 [1.7%]). One (< 0.1%) treatment related death (due to pneumonia, septic kidney failure, and cardiac decompensation) occurred in the denosumab group.
   Interpretation Denosumab constitutes an effective and safe adjuvant treatment for patients with postmenopausal hormone receptor positive early breast cancer receiving aromatase inhibitor therapy. Copyright (c) 2019 Elsevier Ltd. All rights reserved.
C1 [Gnant, Michael; Fitzal, Florian; Jakesz, Raimund; Exner, Ruth] Med Univ Vienna, Dept Surg, A 1090 Vienna, Austria.
   [Gnant, Michael; Pfeiler, Georg; Fitzal, Florian; Jakesz, Raimund; Exner, Ruth; Singer, Christian F.] Med Univ Vienna, Comprehens Canc Ctr, A 1090 Vienna, Austria.
   [Pfeiler, Georg; Singer, Christian F.] Med Univ Vienna, Dept Gynaecol & Obstet, Vienna, Austria.
   [Steger, Guenther G.] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria.
   [Egle, Daniel; Marth, Christian] Med Univ Innsbruck, Dept Gynaecol, Innsbruck, Austria.
   [Greil, Richard; Mlineritsch, Brigitte] Paracelsus Med Univ Salzburg, Dept Internal Med 3, Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials,Canc Cluster Salzb, Salzburg, Austria.
   [Greil, Richard] Salzburg Canc Res Inst, Salzburg, Austria.
   [Fitzal, Florian] Hosp Sisters Mercy Linz, Breast Hlth Ctr, Linz, Austria.
   [Wette, Viktor] Breast Ctr, Sankt Veit An Der Glan, Austria.
   [Balic, Marija] Med Univ Graz, Dept Oncol, Graz, Austria.
   [Bjelic Radisic, Vesna] Med Univ Graz, Dept Gynaecol, Graz, Austria.
   [Haslbauer, Ferdinand] Hosp Voecklabruck, Dept Internal Med, Voecklabruck, Austria.
   [Melbinger Zeinitzer, Elisabeth] Hosp Wolfsberg, Dept Surg, Wolfsberg, Austria.
   [Sevelda, Paul] Hosp Hietzing, Dept Gynecol, Vienna, Austria.
   [Fesl, Christian; Frantal, Sophie] Austrian Breast & Colorectal Canc Study Grp, Dept Stat, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna; Medical University of Vienna; Medical University
   of Innsbruck; Paracelsus Private Medical University; Medical University
   of Graz; Medical University of Graz; Hietzing Hospital
RP Gnant, M (通讯作者)，Med Univ Vienna, Dept Surg, A 1090 Vienna, Austria.; Gnant, M (通讯作者)，Med Univ Vienna, Comprehens Canc Ctr, A 1090 Vienna, Austria.
EM michael.gnant@meduniwien.ac.at
RI Gnant, Michael/AAN 7054 2020; Greil, Richard/C 7673 2017; Balic,
   Marija/LPQ 3522 2024
FU Amgen
FX Amgen.
CR Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   Ahern E, 2017, CLIN CANCER RES, V23, P5789, DOI 10.1158/1078 0432.CCR 17 0606
   Body JJ, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 384
   Bouvard B, 2014, ANN ONCOL, V25, P843, DOI 10.1093/annonc/mdu008
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bundred NJ, 2008, CANCER AM CANCER SOC, V112, P1001, DOI 10.1002/cncr.23259
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman R, 2017, LANCET ONCOL, V18, P1543, DOI 10.1016/S1470 2045(17)30603 4
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.501
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curigliano G, 2019, ANN ONCOL, V30, P1181, DOI 10.1093/annonc/mdy537
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140 6736(15)61074 1
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gnant M, 2017, BREAST CARE, V12, P102, DOI 10.1159/000475698
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Gnant M, 2014, CANCER TREAT REV, V40, P476, DOI 10.1016/j.ctrv.2013.07.003
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140 6736(16)31891 8, 10.1016/S0140 6736(16)31891 8]
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Khan A, 2016, OSTEOPOROSIS INT, V27, P853, DOI 10.1007/s00198 015 3335 3
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   ROBINS JM, 1991, COMMUN STAT THEORY, V20, P2609, DOI 10.1080/03610929108830654
   Silverman SL, 2011, OSTEOPOROSIS INT, V22, P21, DOI 10.1007/s00198 010 1274 6
   Van Poznak C, 2017, J ONCOL PRACT, V13, P822, DOI 10.1200/JOP.2017.027672
   Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470 2045(07)70385 6
   Yang SP, 2017, ONCOLOGIST, V22, P438, DOI 10.1634/theoncologist.2016 0192
   Yee AJ, 2012, CLIN INTERV AGING, V7, P331, DOI 10.2147/CIA.S14566
NR 39
TC 173
Z9 187
U1 0
U2 48
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470 2045
EI 1474 5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAR
PY 2019
VL 20
IS 3
BP 339
EP 351
DI 10.1016/S1470 2045(18)30862 3
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HN1NK
UT WOS:000459953700041
PM 30795951
DA 2025 08 17
ER

PT J
AU Hong, JQ
   Shi, ZL
   Li, CS
   Ji, XX
   Li, SH
   Chen, YZ
   Jiang, GY
   Shi, MM
   Wang, W
   Zhang, YX
   Hu, B
   Yan, SG
AF Hong, Jianqiao
   Shi, Zhongli
   Li, Congsun
   Ji, Xiaoxiao
   Li, Sihao
   Chen, Yazhou
   Jiang, Guangyao
   Shi, Mingmin
   Wang, Wei
   Zhang, Yongxing
   Hu, Bin
   Yan, Shigui
TI Virtual screening identified natural Keap1 Nrf2 PPI inhibitor alleviates
   inflammatory osteoporosis through Nrf2 mir214 Traf3 axis
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Inflammatory osteoporosis; Nrf2; Traf3; Molecular docking; miRNA
ID OSTEOCLAST DIFFERENTIATION; OXIDATIVE STRESS; NUCLEAR FACTOR; PROTEIN
   INTERACTION; GENE EXPRESSION; BONE RESORPTION; NRF2; GLYCOSIDES;
   DOCKING; PATHOGENESIS
AB Overactive osteoclastogenesis is involved in the inflammatory bone loss and could be target for therapy. Here, we applied transcription factor enrichment analysis using public inflammatory osteolysis datasets and identified Nrf2 as the potential therapeutic target. Additionally, in silico screening was performed to dig out Nrf2 Keap1 PPI inhibitor and Forsythoside beta was found to be the best performing PHG compound. We firstly tested the effect of Forsythoside beta in inflammatory osteoporosis models and found it was able to attenuate the bone loss by inhibiting osteoclastogenesis and activating Nrf2 signaling in vivo. Forsythoside beta was capable to suppress the differentiation of osteoclast in time and dose dependent manners in vitro. Further, Forsythoside beta could inhibit the production of reactive oxygen species and induce Nrf2 nuclear translocation by interrupting Nrf2 Keap1 PPI. Recently, Nrf2 was identified as the epigenetic regulator modulating levels of miRNA in various diseases. We discovered that Forsythoside beta could suppress the expression of mir 214 3p, one of most variable miRNAs during osteoclastogenesis. To clarify the undermining mechanism, by utilizing chip seq dataset, we found that Nrf2 could bind to promoter of mir 214 3p and further regulate this miRNA. Collectively, Forsythoside beta was able to prevent bone loss through Nrf2 mir 214 3p Traf3 axis, which could be a promising candidate for treating inflammatory bone loss in the future.
C1 [Hong, Jianqiao; Shi, Zhongli; Li, Congsun; Ji, Xiaoxiao; Li, Sihao; Chen, Yazhou; Jiang, Guangyao; Shi, Mingmin; Wang, Wei; Zhang, Yongxing; Hu, Bin; Yan, Shigui] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped Surg, Sch Med, 88 Jie Fang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
   [Hong, Jianqiao; Shi, Zhongli; Li, Congsun; Ji, Xiaoxiao; Li, Sihao; Chen, Yazhou; Jiang, Guangyao; Shi, Mingmin; Wang, Wei; Zhang, Yongxing; Hu, Bin; Yan, Shigui] Zhejiang Univ, Orthoped Res Inst, Hangzhou, Zhejiang, Peoples R China.
   [Hong, Jianqiao; Shi, Zhongli; Li, Congsun; Ji, Xiaoxiao; Li, Sihao; Chen, Yazhou; Jiang, Guangyao; Shi, Mingmin; Wang, Wei; Zhang, Yongxing; Hu, Bin; Yan, Shigui] Key Lab Motor Syst Dis Res & Precis Therapy Zheji, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Zhang, YX; Hu, B; Yan, SG (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped Surg, Sch Med, 88 Jie Fang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM phenixzyx@zju.edu.cn; 11618327@zju.edu.cn; zrjwsj@zju.edu.cn
OI chen, yazhou/0000 0002 0473 8171
FU National Natural Science Foundation of China [81902279, 81772360];
   Zhejiang Province Medical and Health project [2020391395]
FX This research was supported by National Natural Science Foundation of
   China [grant number 81902279, 81772360] and supported by Zhejiang
   Province Medical and Health project [grant number 2020391395] .
CR An E, 2014, MOL CELL PROTEOMICS, V13, P2687, DOI 10.1074/mcp.M113.034371
   Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Clarke DJB, 2018, NUCLEIC ACIDS RES, V46, pW171, DOI 10.1093/nar/gky458
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573 018 0008 x
   Davies TG, 2016, J MED CHEM, V59, P3991, DOI 10.1021/acs.jmedchem.6b00228
   Demmer RT, 2008, J PERIODONTOL, V79, P2112, DOI [10.1902/jop.2008.080139, 10.1902/jop.2008.080139 ]
   Eichenfield DZ, 2016, ELIFE, V5, DOI 10.7554/eLife.13024
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Frezza C, 2018, NAT PROD RES, V32, P1583, DOI 10.1080/14786419.2017.1392948
   Gao M, 2016, FREE RADICAL BIO MED, V92, P39, DOI 10.1016/j.freeradbiomed.2016.01.005
   Geusens P, 2012, THER ADV MUSCULOSKEL, V4, P225, DOI 10.1177/1759720X12438080
   Gorgulla C, 2020, NATURE, V580, P663, DOI 10.1038/s41586 020 2117 z
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   Guo Y, 2015, FREE RADICAL BIO MED, V88, P337, DOI 10.1016/j.freeradbiomed.2015.06.013
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   JIMENEZ C, 1994, NAT PROD REP, V11, P591, DOI 10.1039/np9941100591
   Jnoff E, 2014, CHEMMEDCHEM, V9, P699, DOI 10.1002/cmdc.201300525
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Ke K, 2015, BONE, V81, P237, DOI 10.1016/j.bone.2015.07.006
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kurinna S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6099
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Li DF, 2019, NUCLEIC ACIDS RES, V47, pW158, DOI 10.1093/nar/gkz348
   Li F, 2013, PHYTOMEDICINE, V20, P549, DOI 10.1016/j.phymed.2013.01.001
   Li M., 2018, INT J MOL SCI, V19
   Li MQ, 2019, FOOD CHEM TOXICOL, V133, DOI 10.1016/j.fct.2019.110758
   Liu HR, 2020, THERANOSTICS, V10, P7319, DOI 10.7150/thno.44054
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep40487
   Liu YZ, 2016, GENE, V581, P152, DOI 10.1016/j.gene.2016.01.036
   Liu ZY, 2019, TOXICOL APPL PHARM, V367, P62, DOI 10.1016/j.taap.2019.02.003
   Lo SC, 2006, EMBO J, V25, P3605, DOI 10.1038/sj.emboj.7601243
   Meng XY, 2011, CURR COMPUT AID DRUG, V7, P146
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Polytarchou C, 2015, GASTROENTEROLOGY, V149, P981, DOI 10.1053/j.gastro.2015.05.057
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Schmoll Dieter, 2017, Drug Discov Today Technol, V24, P11, DOI 10.1016/j.ddtec.2017.10.001
   Sgarbossa A, 2012, CHEM BIOL INTERACT, V199, P87, DOI 10.1016/j.cbi.2012.06.006
   Shah NM, 2013, ONCOTARGET, V4, P1130, DOI 10.18632/oncotarget.1181
   Shanmugam G, 2016, REDOX BIOL, V9, P77, DOI 10.1016/j.redox.2016.06.004
   Sima C, 2016, AM J PATHOL, V186, P1417, DOI 10.1016/j.ajpath.2016.01.013
   Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353
   Sun WJ, 2019, MOL THER, V27, P1039, DOI 10.1016/j.ymthe.2019.02.010
   Sun XW, 2019, FASEB J, V33, P12929, DOI 10.1096/fj.201900887RR
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Takahashi N, 2003, METH MOLEC MED, V80, P129
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang Z, 2016, PHYS CHEM CHEM PHYS, V18, P12964, DOI 10.1039/c6cp01555g
   Wruck CJ, 2011, ANN RHEUM DIS, V70, P844, DOI 10.1136/ard.2010.132720
   Wu AZ, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112857
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Wu LP, 2020, MED RES REV, V40, P2605, DOI 10.1002/med.21717
   Xiao Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/241067
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhuo ZJ, 2020, ADV SCI, V7, DOI 10.1002/advs.201903451
NR 67
TC 14
Z9 15
U1 1
U2 43
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD AUG 1
PY 2021
VL 171
BP 365
EP 378
DI 10.1016/j.freeradbiomed.2021.05.020
EA JUN 2021
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA SV2VU
UT WOS:000663683000004
PM 34000381
DA 2025 08 17
ER

PT J
AU Zheleznyak, A
   Mixdorf, M
   Marsala, L
   Prior, J
   Yang, XX
   Cui, G
   Xu, BG
   Fletcher, S
   Fontana, F
   Lanza, G
   Achilefu, S
AF Zheleznyak, Alexander
   Mixdorf, Matthew
   Marsala, Lynne
   Prior, Julie
   Yang, Xiaoxia
   Cui, Grace
   Xu, Baogang
   Fletcher, Steven
   Fontana, Francesca
   Lanza, Gregory
   Achilefu, Samuel
TI Orthogonal targeting of osteoclasts and myeloma cells for radionuclide
   stimulated dynamic therapy induces multidimensional cell death pathways
SO THERANOSTICS
LA English
DT Article
DE multiple myeloma; bone marrow; tumor microenvironment; orthogonal drug
   delivery; nanomicelles; photosensitizer; Cerenkov radiation
ID BONE MARROW MICROENVIRONMENT; HEMATOPOIETIC STEM CELL; MULTIPLE MYELOMA;
   IN VITRO; LIPID PEROXIDATION; ZOLEDRONIC ACID; DRUG DELIVERY;
   DNA DAMAGE; TUMOR; CANCER
AB Rationale: Multiple myeloma (MM) is a multifocal malignancy of bone marrow plasma cells, characterized by vicious cycles of remission and relapse that eventually culminate in death. The disease remains mostly incurable largely due to the complex interactions between the bone microenvironment (BME) and MM cells (MMC). In the "vicious cycle" of bone disease, abnormal activation of osteoclasts (OCs) by MMC causes severe osteolysis, promotes immune evasion, and stimulates the growth of MMC. Disrupting these cancer stroma interactions would enhance treatment response.
   Methods: To disrupt this cycle, we orthogonally targeted nanomicelles (NM) loaded with non therapeutic doses of a photosensitizer, titanocene (TC), to VLA 4 (alpha 4 beta 1, CD49d/CD29) expressing MMC (MM1.S) and alpha v beta 3 (CD51/CD61) expressing OC. Concurrently, a non lethal dose of a radiopharmaceutical, F 18 fluorodeoxyglucose ([F 18]FDG) administered systemically interacted with TC (radionuclide stimulated therapy, RaST) to generate cytotoxic reactive oxygen species (ROS). The in vitro and in vivo effects of RaST were characterized in MM1.S cell line, as well as in xenograft and isograft MM animal models.
   Results: Our data revealed that RaST induced non enzymatic hydroperoxidation of cellular lipids culminating in mitochondrial dysfunction, DNA fragmentation, and caspase dependent apoptosis of MMC using VLA 4 avid TC NMs. RaST upregulated the expression of BAX, Bcl 2, and p53, highlighting the induction of apoptosis via the BAK independent pathway. The enhancement of multicopper oxidase enzyme F5 expression, which inhibits lipid hydroperoxidation and Fenton reaction, was not sufficient to overcome RaST induced increase in the accumulation of irreversible function perturbing alpha,beta aldehydes that exerted significant and long lasting damage to both DNA and proteins. In vivo, either VLA 4 TC NM or alpha v beta 3 TC NMs RaST induced a significant therapeutic effect on immunocompromised but not immunocompetent MM bearing mouse models. Combined treatment with both VLA 4 TC NM and alpha v beta 3 TC NMs synergistically inhibited osteolysis, reduced tumor burden, and prevented rapid relapse in both in vivo models of MM.
   Conclusions: By targeting MM and bone cells simultaneously, combination RaST suppressed MM disease progression through a multi prong action on the vicious cycle of bone cancer. Instead of using the standard multidrug approach, our work reveals a unique photophysical treatment paradigm that uses nontoxic doses of a single light sensitive drug directed orthogonally to cancer and bone cells, followed by radionuclide stimulated generation of ROS to inhibit tumor progression and minimize osteolysis in both immunocompetent murine and immunocompromised human MM models.
C1 [Zheleznyak, Alexander; Mixdorf, Matthew; Marsala, Lynne; Prior, Julie; Xu, Baogang; Achilefu, Samuel] Washington Univ, Dept Radiol, Sch Med, St Louis, MO 63110 USA.
   [Yang, Xiaoxia; Cui, Grace; Fontana, Francesca; Lanza, Gregory; Achilefu, Samuel] Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA.
   [Fletcher, Steven] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Achilefu, Samuel] Washington Univ, Dept Biomed Engn, St Louis, MO 63105 USA.
   [Achilefu, Samuel] Washington Univ, Dept Biochem & Mol Biophys, Sch Med, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); University
   System of Maryland; University of Maryland Baltimore; Washington
   University (WUSTL); Washington University (WUSTL)
RP Achilefu, S (通讯作者)，Washington Univ, Dept Radiol, Sch Med, St Louis, MO 63110 USA.; Achilefu, S (通讯作者)，Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA.; Achilefu, S (通讯作者)，Washington Univ, Dept Biomed Engn, St Louis, MO 63105 USA.; Achilefu, S (通讯作者)，Washington Univ, Dept Biochem & Mol Biophys, Sch Med, St Louis, MO 63110 USA.
RI ; Yang, Xiaoxia/G 2416 2014; Fontana, Francesca/K 4785 2016; Achilefu,
   Samuel/AAC 2401 2019
OI Fontana, Francesca/0000 0002 5889 9413; Achilefu,
   Samuel/0000 0002 3133 6717
FU National Institutes of Health [R01 CA260855, U54 CA199092, R01 EB030987,
   R01 EB021048, P30 CA091842, P30 CA091842 19S3, S10 OD027042, S10
   OD016237, S10 RR031625, S10 OD020129]; Department of Defense Breast
   Cancer Research Program [W81XWH 16 1 0286]; Siteman Investment Program
   (SIP) Research Development Award; NCI Cancer Center Support Grant [P30
   CA091842]; National Institutes of Health's NCATS Clinical and
   Translational Science Award (CTSA) program [UL1 TR002345]
FX This study was supported by grants from the National Institutes of
   Health (R01 CA260855, U54 CA199092, R01 EB030987, R01 EB021048, P30
   CA091842, P30 CA09184219S3, S10 OD027042, S10 OD016237, S10 RR031625,
   and S10 OD020129) , the Department of Defense Breast Cancer Research
   Program (W81XWH1610286) , and the Siteman Investment Program (SIP)
   Research Development Award. We thank the Alvin J. Siteman Cancer Center
   at Washington University School of Medicine and Barnes Jewish Hospital
   in St. Louis, MO, and the Institute of Clinical and Translational
   Sciences (ICTS) at Washington University in St. Louis, for the use
   shared facilities. The Siteman Cancer Center is supported in part by an
   NCI Cancer Center Support Grant P30 CA091842 and the ICTS is funded by
   the National Institutes of Health's NCATS Clinical and Translational
   Science Award (CTSA) program grant UL1 TR002345. Metabolomics study was
   performed at the Metabolomics Facility at Washington University
   Department of Medicine. Proteomics data were acquired at the Donald
   Danforth Plant Science Center Proteomics Facility in St. Louis.
CR Ai LS, 2013, INT J CANCER, V133, P1074, DOI 10.1002/ijc.28116
   Amend SR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127828
   Anthony BA, 2014, TRENDS IMMUNOL, V35, P32, DOI 10.1016/j.it.2013.10.002
   Asic K, 2016, CRIT REV ONCOL HEMAT, V97, P178, DOI 10.1016/j.critrevonc.2015.08.004
   Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100
   Barley K, 2016, CURR HEMATOL MALIG R, V11, P111, DOI 10.1007/s11899 016 0314 5
   Bergin K, 2017, CL LYMPH MYELOM LEUK, V17, P133, DOI 10.1016/j.clml.2016.12.002
   Bernhardt A, 2017, EUR CELLS MATER, V33, P28, DOI 10.22203/eCM.v033a03
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bolzoni M, 2018, EXPERT REV HEMATOL, V11, P325, DOI 10.1080/17474086.2018.1447921
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471 2121 14 32
   Carper MB, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169 015 0074 1
   Cheng YW, 2005, FOOD CHEM TOXICOL, V43, P617, DOI 10.1016/j.fct.2005.01.007
   Chu J, 2020, NEURAL REGEN RES, V15, P528, DOI 10.4103/1673 5374.266060
   Davidenko N, 2003, J BIOMAT SCI POLYM E, V14, P733, DOI 10.1163/156856203322274978
   de la Puente P, 2017, EUR J HAEMATOL, V98, P529, DOI 10.1111/ejh.12870
   Dewson G, 2009, J CELL SCI, V122, P2801, DOI 10.1242/jcs.038166
   Dimopoulos MA, 2017, BRIT J HAEMATOL, V178, P896, DOI 10.1111/bjh.14787
   Domingues RM, 2013, J PROTEOMICS, V92, P110, DOI 10.1016/j.jprot.2013.06.004
   Esser AK, 2020, THERANOSTICS, V10, P7510, DOI 10.7150/thno.44523
   Esser AK, 2016, NANOMED NANOTECHNOL, V12, P201, DOI 10.1016/j.nano.2015.10.003
   Feng HZ, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006203
   Filippi I, 2018, CELL PHYSIOL BIOCHEM, V46, P203, DOI 10.1159/000488423
   Fontana F, 2020, CLIN CANCER RES
   Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401
   Gandoglia I, 2017, IMMUNOL LETT, V181, P109, DOI 10.1016/j.imlet.2016.11.015
   Gegotek A, 2019, CHEM PHYS LIPIDS, V221, P46, DOI 10.1016/j.chemphyslip.2019.03.011
   Ghobrial IM, 2018, NAT REV CLIN ONCOL, V15, P219, DOI 10.1038/nrclinonc.2017.197
   Guise T. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P570
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hathi DK, 2018, J NUCL MED, V59, P1551, DOI 10.2967/jnumed.118.208744
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hosen N, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 020 00113 y
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233
   Klement GL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf3802
   Köhler M, 2018, CANCER AM CANCER SOC, V124, P2075, DOI 10.1002/cncr.31243
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kotagiri N, 2018, NAT COMMUN, P9
   Kotagiri N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02758 9
   Kotagiri N, 2015, NAT NANOTECHNOL, V10, P370, DOI [10.1038/nnano.2015.17, 10.1038/NNAN0.2015.17]
   Kreuz S, 2016, EPIGENOMICS UK, V8, P843, DOI 10.2217/epi 2016 0002
   Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188
   Kuo LJ, 2008, IN VIVO, V22, P305
   Landau DA, 2014, LEUKEMIA, V28, P34, DOI 10.1038/leu.2013.248
   Lane DD, 2020, RSC ADV, V10, P23759, DOI 10.1039/d0ra01878c
   Lanza GM, 2010, ANGIOGENESIS, V13, P189, DOI 10.1007/s10456 010 9166 0
   Larocca A, 2017, ONCOTARGET, V8, P60656, DOI 10.18632/oncotarget.19269
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Li B, 2020, FASEB J
   Li W, 2012, FREE RADICAL BIO MED, V53, P2054, DOI 10.1016/j.freeradbiomed.2012.09.007
   Liu HM, 2009, CHEM BIOL INTERACT, V179, P81, DOI 10.1016/j.cbi.2008.12.003
   Liu SY, 2017, J MATER CHEM B, V5, P8169, DOI 10.1039/c7tb01968h
   Lomas OC, 2020, CURR OPIN ONCOL, V32, P170, DOI 10.1097/CCO.0000000000000615
   Luchetti F, 2015, STEROIDS, V99, P204, DOI 10.1016/j.steroids.2015.02.008
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6
   Mailankody S, 2010, LEUKEMIA LYMPHOMA, V51, P2159, DOI 10.3109/10428194.2010.525725
   Mali VR, 2014, FREE RADICAL RES, V48, P251, DOI 10.3109/10715762.2013.864761
   Marnett LJ, 1999, MUTAT RES FUND MOL M, V424, P83, DOI 10.1016/S0027 5107(99)00010 X
   Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Miguel JS, 2014, HEMATOL AM SOC HEMAT, P1, DOI 10.1182/asheducation 2014.1.1
   Moreau P, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408 019 0200 1
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Mu CF, 2018, BIOMATERIALS, V155, P191, DOI 10.1016/j.biomaterials.2017.11.029
   Muchtar E, 2018, LEUKEMIA LYMPHOMA, V59, P288, DOI 10.1080/10428194.2017.1334124
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nishihori T, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/6934183
   Olszewski U, 2010, ANTI CANCER AGENT ME, V10, P302, DOI 10.2174/187152010791162261
   Pan D, 2016, WIRES NANOMED NANOBI, V8, P85, DOI 10.1002/wnan.1355
   Papayannopoulou T, 2008, BLOOD, V111, P3923, DOI 10.1182/blood 2007 08 078147
   Park D, 2012, FRONT BIOSCI LANDMRK, V17, P30, DOI 10.2741/3913
   Peña Blanco A, 2018, FEBS J, V285, P416, DOI 10.1111/febs.14186
   Peng L, 2006, NAT CHEM BIOL, V2, P381, DOI 10.1038/nchembio798
   RADL J, 1978, CLIN EXP IMMUNOL, V33, P395
   Raffaghello L, 2015, ONCOTARGET, V6, P2589, DOI 10.18632/oncotarget.2661
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Rankin EB, 2015, MOL GENET METAB, V116, P24, DOI 10.1016/j.ymgme.2015.07.004
   Ribatti D, 2015, INT REV CEL MOL BIO, V314, P259, DOI 10.1016/bs.ircmb.2014.10.004
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Röllig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140 6736(14)60493 1
   Ross MH, 2017, CANCER RES, V77, P6299, DOI 10.1158/0008 5472.CAN 17 1225
   Rossi M, 2018, ONCOTARGET, V9
   Roux S, 2019, BONE, V120, P482, DOI 10.1016/j.bone.2018.12.012
   Sadeghi MM, 2004, CIRCULATION, V110, P84, DOI 10.1161/01.CIR.0000133319.84326.70
   Saxena M, 2018, COORDIN CHEM REV, V363, P109, DOI 10.1016/j.ccr.2018.03.006
   SHIOI A, 1994, CALCIFIED TISSUE INT, V55, P387, DOI 10.1007/BF00299320
   Song EA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081257
   Soodgupta D, 2016, J NUCL MED, V57, P640, DOI 10.2967/jnumed.115.164624
   Stefanick JF, 2019, J CONTROL RELEASE, V311, P190, DOI 10.1016/j.jconrel.2019.08.033
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Tai YT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01822
   Tamura H, 2018, INT J HEMATOL, V107, P278, DOI 10.1007/s12185 018 2405 7
   Terpos E, 2010, LEUKEMIA, V24, P1043, DOI 10.1038/leu.2010.62
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   van de Donk NWCJ, 2016, IMMUNOL REV, V270, P95, DOI 10.1111/imr.12389
   Wang LY, 2017, SEMIN CANCER BIOL, V42, P44, DOI 10.1016/j.semcancer.2016.11.002
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Willis N, 2009, CELL DIV, V4, DOI 10.1186/1747 1028 4 13
   Xiao MQ, 2017, FREE RADICAL BIO MED, V111, P316, DOI 10.1016/j.freeradbiomed.2017.04.363
   Yu VWC, 2016, CURR TOP DEV BIOL, V118, P21, DOI 10.1016/bs.ctdb.2016.01.009
   Zheleznyak A, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1526
   Zheleznyak A, 2012, MOL IMAGING BIOL, V14, P500, DOI 10.1007/s11307 011 0512 4
   Zilka O, 2017, ACS CENTRAL SCI, V3, P232, DOI 10.1021/acscentsci.7b00028
NR 108
TC 6
Z9 6
U1 1
U2 17
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2021
VL 11
IS 16
BP 7735
EP 7754
DI 10.7150/thno.60757
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA TQ8OQ
UT WOS:000678537900007
PM 34335961
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chaiban, J
   Muwakkit, S
   Arabi, A
   Jomaa, L
   Daouk, LO
   El Rassi, R
   Abboud, M
   El Hajj Fuleihan, G
AF Chaiban, Joumana
   Muwakkit, Samar
   Arabi, Asma
   Jomaa, Lamis
   Daouk, Lina Onsi
   El Rassi, Rola
   Abboud, Miguel
   El Hajj Fuleihan, Ghada
TI Modeling Pathways for Low Bone Mass in Children With Malignancies
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Bone disease; malignancies; model; pathophysiology; pediatric
ID ACUTE LYMPHOBLASTIC LEUKEMIA; MINERAL DENSITY; CHILDHOOD CANCER;
   BODY COMPOSITION; PUBERTAL DEVELOPMENT; IMPAIRED DEVELOPMENT;
   HEALTHY CHILDREN; GONADAL FUNCTION; CHEMOTHERAPY; SURVIVORS
AB Children with malignancies have low bone mass. Pathways for metabolic bone disease were investigated in children with cancer by concomitantly assessing lifestyle, clinical, and biochemical predictors of bone mass. Forty one children who were receiving cancer therapy for 61 weeks and 39 controls were studied. Data oil lifestyle factors, biochemical and hormonal parameters, dual energy X ray absorptiometry bone mass measurements, body composition, and bone age were obtained. Compared with controls, patients had higher weight percentile and fat mass, a 6 month delay in bone age, and lower estradiol levels. They also had higher parathyroid hormone levels and lower bone remodeling markers and bone mass. Age, height, lean mass, fat mass, and bone maturation correlated positively with several bone mass variables, so did serum estradiol, testosterone, and markers of bone remodeling. Conversely, corticosteroids, methotrexate (MTX), and intrathecal therapy negatively correlated with bone mass at the spine and hip (R =  0.33 to 0.40, p < 0.04). In the adjusted analyses, bone maturation, serum osteocalcin level, MTX, and intrathecal therapy were significant predictors Of lumbar spine and total body Z scores, bone maturation accounting for the largest proportion in Z score variance. Chemotherapy induced delay in bone maturation and Suppression of bone modeling are major pathophysiologic pathways predicting bone mass in children with malignancies.
C1 [Chaiban, Joumana; Arabi, Asma; Jomaa, Lamis; Daouk, Lina Onsi; El Rassi, Rola; El Hajj Fuleihan, Ghada] Calcium Metab & Osteoporosis Program, Div Endocrinol, Dept Internal Med, Beirut 44072020, Lebanon.
   [Muwakkit, Samar; Abboud, Miguel] Amer Univ Beirut, Med Ctr, Childrens Canc Ctr Lebanon, Dept Pediat, Beirut, Lebanon.
C3 American University of Beirut
RP El Hajj Fuleihan, G (通讯作者)，Calcium Metab & Osteoporosis Program, Div Endocrinol, Dept Internal Med, POB 11 0236, Beirut 44072020, Lebanon.
EM gf01@aub.edu.lb
OI Jomaa, Lamis/0000 0002 3046 4581; El Hajj Fuleihan,
   Ghada/0000 0002 2076 5858; El Rassi, Rola/0000 0002 7388 8712
CR Arabi A, 2004, AM J CLIN NUTR, V80, P1428, DOI 10.1093/ajcn/80.5.1428
   Arikoski P, 1999, J BONE MINER RES, V14, P2002, DOI 10.1359/jbmr.1999.14.12.2002
   Arikoski P, 1999, MED PEDIATR ONCOL, V33, P455, DOI 10.1002/(SICI)1096 911X(199911)33:5<455::AID MPO4>3.0.CO;2 3
   Arikoski P, 1999, ARCH DIS CHILD, V80, P143, DOI 10.1136/adc.80.2.143
   Arikoski P, 1999, J CLIN ENDOCR METAB, V84, P3174, DOI 10.1210/jc.84.9.3174
   Bak M, 2006, PEDIATR NEPHROL, V21, P350, DOI 10.1007/s00467 005 2118 z
   Boot AM, 1999, EUR J CANCER, V35, P1693, DOI 10.1016/S0959 8049(99)00143 4
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chemaitilly W, 2006, J CLIN ENDOCR METAB, V91, P1723, DOI 10.1210/jc.2006 0020
   Cicognani A, 2003, J PEDIATR ENDOCR MET, V16, P321
   Dawson Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198 005 1867 7
   El Hajj Fuleihan G, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.4.e53
   El Hajj Fuleihan G, 2006, J CLIN ENDOCR METAB, V91, P405, DOI 10.1210/jc.2005 1436
   El Hajj Fuleihan G, 2007, INT C SER, V1297, P91
   FLEMING KH, 1994, J NUTR, V124, pS1426, DOI 10.1093/jn/124.suppl_8.1426S
   FULEIHAN GE, 2008, 35 ANN M AM SOC BON
   Gordon CM, 2008, J CLIN DENSITOM, V11, P43, DOI 10.1016/j.jocd.2007.12.005
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hoorweg Nijman JJG, 1999, CLIN ENDOCRINOL, V50, P237, DOI 10.1046/j.1365 2265.1999.00654.x
   Kadan Lottick N, 2001, J PEDIATR US, V138, P898, DOI 10.1067/mpd.2001.113102
   KATZMAN DK, 1991, J CLIN ENDOCR METAB, V73, P1332, DOI 10.1210/jcem 73 6 1332
   Mackie EJ, 1996, MED PEDIATR ONCOL, V27, P74, DOI 10.1002/(SICI)1096 911X(199608)27:2<74::AID MPO2>3.0.CO;2 Q
   Mandel K, 2004, J CLIN ONCOL, V22, P1215, DOI 10.1200/JCO.2004.04.199
   Mulder JE, 2004, J CLIN DENSITOM, V7, P432, DOI 10.1385/JCD:7:4:432
   Murphy AJ, 2006, AM J CLIN NUTR, V83, P70
   Nysom K, 2001, MED PEDIATR ONCOL, V37, P518, DOI 10.1002/mpo.1245
   Pagano Therrien Jesica, 2005, J Pediatr Oncol Nurs, V22, P328, DOI 10.1177/1043454205281760
   Pui C. H., 2004, Annals of Hematology, V83, pS124
   Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603
   Salamoun MM, 2005, EUR J CLIN NUTR, V59, P177, DOI 10.1038/sj.ejcn.1602056
   TANNER JM, 1978, TXB PAEDIAT, V1, P249
   Tillmann V, 2002, J BONE MINER RES, V17, P1073, DOI 10.1359/jbmr.2002.17.6.1073
   van der Sluis IM, 2002, J PEDIATR US, V141, P204, DOI 10.1067/mpd.2002.125728
   Wasilewski Masker K, 2008, PEDIATRICS, V121, pE705, DOI 10.1542/peds.2007 1396
   Zemel BS, 2007, PEDIATR RES, V61, P607, DOI 10.1203/pdr.0b013e318045bdca
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
NR 36
TC 7
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1094 6950
EI 1559 0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD OCT DEC
PY 2009
VL 12
IS 4
BP 441
EP 449
DI 10.1016/j.jocd.2009.06.005
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 519UG
UT WOS:000271793600005
PM 19766031
DA 2025 08 17
ER

PT J
AU Yamaguchi, Y
   Sakai, E
   Sakamoto, H
   Fumimoto, R
   Fukuma, Y
   Nishishita, K
   Okamoto, K
   Tsukuba, T
AF Yamaguchi, Yu
   Sakai, Eiko
   Sakamoto, Hiroshi
   Fumimoto, Reiko
   Fukuma, Yutaka
   Nishishita, Kazuhisa
   Okamoto, Kuniaki
   Tsukuba, Takayuki
TI Inhibitory effects of tert butylhydroquinone on osteoclast
   differentiation via up regulation of heme oxygenase 1 and
   down regulation of HMGB1 release and NFATc1 expression
SO JOURNAL OF APPLIED TOXICOLOGY
LA English
DT Article
DE heme oxygenase 1; osteoclasts; tert butylhydroquinone; nuclear factor of
   activated T cells cytoplasmic 1; high mobility group box 1
ID NF KAPPA B; RANKL INDUCED OSTEOCLASTOGENESIS; PHASE I; INDUCTION;
   ACTIVATION; RECEPTOR; KINASE; TBHQ; ANTIOXIDANT; SUPPRESSION
AB Osteoclasts (OCLs) are multinucleated bone resorbing cells that are differentiated by receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF). Our recent studies have shown that heme oxygenase 1 (HO 1), a stress induced cytoprotective enzyme, plays an important role in OCL differentiation, although the pharmacological significance of this effect remains unknown. In this study, we investigated the effects of tert butylhydroquinone (tBHQ), a pharmacological HO 1 inducer, on in vitro differentiation of bone marrow derived macrophages (BMMs) or murine monocytic cell line RAW D into OCLs. tBHQ inhibited the formation and the bone resorbing activity of OCLs. Moreover, tBHQ treatment decreased the expression of nuclear factor of activated T cells cytoplasmic 1 (NFATc1), a master regulator of OCL differentiation, and of OCL markers transcriptionally regulated by NFATc1, such as Src and cathepsin K. In addition, tBHQ impaired phosphorylation of extracellular signal regulated kinase, p38 mitogen activated protein kinase (MAPK), Jun N terminal kinase, Akt, and inhibitor of nuclear factor kappa B alpha (I kappa B alpha). Finally, we show that tBHQ inhibited the release of high mobility group box 1 (HMGB1), a recently identified activator of OCL differentiation. Thus, tBHQ inhibits OCL differentiation through the HO 1/HMGB1 pathways. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Yamaguchi, Yu; Sakai, Eiko; Sakamoto, Hiroshi; Fumimoto, Reiko; Fukuma, Yutaka; Nishishita, Kazuhisa; Okamoto, Kuniaki; Tsukuba, Takayuki] Nagasaki Univ, Grad Sch Biomed Sci, Div Oral Pathopharmacol, Nagasaki 8528588, Japan.
C3 Nagasaki University
RP Sakai, E (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Div Oral Pathopharmacol, Sakamoto 1 7 1, Nagasaki 8528588, Japan.
EM eiko s@nagasaki u.ac.jp; tsuta@nagasaki u.ac.jp
RI ; Tsukuba, Takayuki/I 9542 2018
OI sakai, eiko/0000 0002 6776 6540; 
FU Ministry of Education, Science and Culture of Japan; Grants in Aid for
   Scientific Research [25462920, 25293383, 24659840, 22592069, 24592836]
   Funding Source: KAKEN
FX This study was supported in part by Grants in Aid for Scientific
   Research from the Ministry of Education, Science and Culture of Japan
   (E.S., T.T.).
CR Alamed J, 2009, J AGR FOOD CHEM, V57, P2969, DOI 10.1021/jf803436c
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cheung KL, 2011, CHEM RES TOXICOL, V24, P670, DOI 10.1021/tx1004369
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Gharavi N, 2007, CURR DRUG METAB, V8, P1, DOI 10.2174/138920007779315035
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Jin W, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/502564
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Keum YS, 2006, PHARM RES, V23, P2586, DOI 10.1007/s11095 006 9094 2
   Khodagholi F, 2011, MOL CELL BIOCHEM, V354, P97, DOI 10.1007/s11010 011 0809 2
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Koh K, 2009, BIOCHEM BIOPH RES CO, V380, P449, DOI 10.1016/j.bbrc.2009.01.082
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li HY, 2007, CHEM RES TOXICOL, V20, P1242, DOI 10.1021/tx700076q
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193
   Xu CJ, 2005, ARCH PHARM RES, V28, P249, DOI 10.1007/BF02977789
   Yamoah K, 2008, MOL ENDOCRINOL, V22, P1141, DOI 10.1210/me.2007 0460
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
NR 31
TC 19
Z9 23
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0260 437X
EI 1099 1263
J9 J APPL TOXICOL
JI J. Appl. Toxicol.
PD JAN
PY 2014
VL 34
IS 1
BP 49
EP 56
DI 10.1002/jat.2827
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA AD9JR
UT WOS:000333581700006
PM 23112101
DA 2025 08 17
ER

PT J
AU Mu, H
   Pang, Y
   Liu, LL
   Li, FS
   Wang, JQ
AF Mu, Hong
   Pang, Ying
   Liu, Lili
   Li, Fengshan
   Wang, Jianqi
TI Citral promotes the cell proliferation, differentiation, and calcium
   mineralization in human osteoblast like MG 63 cells
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Bone biomarkers; citral; MG 63 cells; osteogenic drug; osteoporosis
ID ALKALINE PHOSPHATASE; COLLAGEN; EXPRESSION
AB Background: Osteoporosis tends to be the major consequence of fractures in women above the age of 50 years and men are prone above the age of 65 years. The structure of bone is severely deteriorated by the reduction in bone density which eventually causes both nonfatal and fatal fractures in geriatric population. Recent researches were targeted to discover a drug which increases bone resorption and inhibits bone osteoporosis, thereby preventing fracture risk in older population. Methods: Citral is an aliphatic unsaturated aldehyde present in lemongrass and it renders the lemon fragrance to the lemongrass plant. Citral possesses various pharmacological properties such anti adipogenic, anti inflammatory, antimicrobial, and anti carcinogenic and it also acts as a diuretic agent and stimulates the central nervous system. Therefore, we endeavor to investigate the osteogenic property of citral in vitro condition. Human osteoblast like MG 63 cells were chosen for the current investigation and treated with various doses of citral for different time durations. Results: Citral cytotoxicity effects on MG 63 cell lines and their proliferation were assessed using MTT assay and optical microscopical analysis. Further to analyze the osteoblastic activity of citral on MG 63 osteoblast like cells, we estimated the levels and mRNA expression of bone biomarkers alkaline phosphatase, osteocalcin, and collagen in control and citral treated cells. To confirm the osteoblastic activity of citral, the MG 63 osteoblast like cells were subjected to staining with Alizarin red S. The results of MTT assay and microscopic analysis of citral treated cells proved that citral induces osteoblast like MG 63 cell line proliferation. Osteogenic bone biomarkers such as alkaline phosphatase, osteocalcin, and collagen were significantly increased in citral treated which corroborate the osteogenic activity of citral. Conclusion: Further, the Alizarin red S staining confirmed the induction of mineral deposition in MG 63 cells by citral. Overall, our results authentically proved that citral induces proliferation, maturation, and mineralization in human osteoblast like MG 63 cells.
C1 [Mu, Hong; Pang, Ying; Liu, Lili; Wang, Jianqi] Cangzhou Cent Hosp, Dent Clin, Cangzhou City 061000, Hebei, Peoples R China.
   [Li, Fengshan] Wenan Cty Hosp, Dept Stomatol, Langfang City 065800, Hebei, Peoples R China.
RP Mu, H (通讯作者)，Cangzhou Cent Hosp, Dent Clin, Cangzhou City 061000, Hebei, Peoples R China.
EM 13315777009@sina.cn
RI Wang, Jiandong/KIG 9795 2024
FU Dental Clinic, Cangzhou Central Hospital, Cangzhou City, Hebei Province,
   China
FX We would like to thank Dental Clinic, Cangzhou Central Hospital,
   Cangzhou City, Hebei Province, 061000, China, for their support and
   facilities.
CR Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Brommage R, 2020, HANDB EXP PHARMACOL, V262, P451, DOI 10.1007/164_2019_329
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Canton Gianluca, 2019, Acta Biomed, V90, P25, DOI 10.23750/abm.v90i12 S.8958
   Chhavi S., 2011, Int Res J Pharm, V2, P3
   De Luna Bertos E, 2013, SCI WORLD J, DOI 10.1155/2013/809891
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ekpenyong CE, 2015, CHIN J NAT MEDICINES, V13, P321, DOI 10.1016/S1875 5364(15)30023 6
   Gerald J, 2011, VITAMIN D, VThird
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Guldberg RE, 1997, J BONE MINER RES, V12, P1295, DOI 10.1359/jbmr.1997.12.8.1295
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Jafary F, 2017, INT J TRANSPLANT MED, V8, P195
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Legroux I, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen 2019 001009
   Martins HB, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/2505610
   Modak T, 2011, INDIAN J PHARMACOL, V43, P300, DOI 10.4103/0253 7613.81515
   Moser SC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00794
   Nishijima CM, 2014, EUR J PHARMACOL, V736, P16, DOI 10.1016/j.ejphar.2014.04.029
   PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014 4827(91)90497 I
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Rabbani Syed Imam, 2006, Pak J Pharm Sci, V19, P108
   Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889 8529(02)00055 5
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Tominaga H, 1999, ANAL COMMUN, V36, P47, DOI 10.1039/a809656b
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   VINITKETKUMNUEN U, 1994, MUTAT RES GENET TOX, V341, P71
   Wang BL, 2006, J ENDOCRINOL INVEST, V29, P101, DOI 10.1007/BF03344081
   Wei JW, 2015, REV ENDOCR METAB DIS, V16, P93, DOI 10.1007/s11154 014 9307 7
   WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439
   Zhou YS, 2006, CHINESE MED J PEKING, V119, P1278, DOI 10.1097/00029330 200608010 00008
   zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432 0436.2003.700602.x
NR 38
TC 2
Z9 2
U1 0
U2 11
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0973 1296
EI 0976 4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD APR JUN
PY 2021
VL 17
IS 74
BP 250
EP 255
DI 10.4103/pm.pm_242_20
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TM4HS
UT WOS:000675512600006
DA 2025 08 17
ER

PT S
AU Wimalawansa, SJ
AF Wimalawansa, Sunil J.
BE Zaidi, M
TI Vitamin D: an essential component for skeletal health
SO SKELETAL BIOLOGY AND MEDICINE II: BONE AND CARTILAGE HOMEOSTASIS AND
   BONE DISEASE
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 4th New York Skeletal Biology and Medicine Conference
CY APR 27 30, 2011
CL Mt Sinai Sch Med, New York, NY
HO Mt Sinai Sch Med
DE bone mineral density (BMD); fractures; osteoporosis; rickets;
   supplements; syndrome; osteomalacia; nonskeletal effects; bone turnover
ID BONE MINERAL DENSITY; PARATHYROID HORMONE CONCENTRATIONS; INTESTINAL
   CALCIUM ABSORPTION; SERUM 25 HYDROXYVITAMIN D; INSTITUTE OF MEDICINE; D
   DEFICIENCY; D SUPPLEMENTATION; SECONDARY HYPERPARATHYROIDISM;
   LIQUID CHROMATOGRAPHY; AUTOIMMUNE DISEASES
AB Vitamin D deficiency is increasing worldwide. Ultraviolet rays are supposed to provide humans over 80% of our vitamin D requirement; the rest is received through diet and supplements. In addition to enhancing calcium absorption from the intestine and mineralization of the osteoid tissue, vitamin D has many other physiological effects, including neuromodulation, improving muscle strength and coordination, insulin release, immunity and prevention of infections, and curtailing cancer. Whether the increased incidence of vitamin D deficiency is related to increased incidences of nonskeletal disorders remains to be determined. Serum levels of 25 hydroxyvitamin [25(OH)D] above 30 ng/mL indicate vitamin D sufficiency. An additional 1,000 IU of vitamin D/day is sufficient for most lighter skinned individuals, whereas an extra 2,000 IU/day is needed by the elderly and dark skinned individuals to maintain normal 25(OH)D levels. Additional research is needed to clarify the relationship between vitamin D and the nonskeletal systems, nonclassic functions, and targets of vitamin D.
C1 [Wimalawansa, Sunil J.] Dept Med, Div Endocrinol Metabol & Nutr, New Brunswick, NJ USA.
   [Wimalawansa, Sunil J.] UMDNJ, Robert Wood Johnson Med Sch, Grad Sch Biomed Sci, New Brunswick, NJ USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences
RP Wimalawansa, SJ (通讯作者)，Univ Med & Dent New Jersey, Div Endocrinol, MEB 372, Reg Osteoporosis Ctr, New Brunswick, NJ 08903 USA.
EM wimalasu@umdnj.edu
OI Wimalawansa, Prof. Sunil/0000 0003 1096 8595
CR Adamec J, 2011, J SEP SCI, V34, P11, DOI 10.1002/jssc.201000410
   Adams JS, 1999, J CLIN ENDOCR METAB, V84, P2729, DOI 10.1210/jc.84.8.2729
   [Anonymous], 2005, EUR J CLIN INVEST
   [Anonymous], 2011, AM J HLTH SYST PHARM
   Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004 0360
   Arvold DS, 2009, ENDOCR PRACT, V15, P203, DOI 10.4158/EP.15.3.203
   Avenell A, 2009, COCHRANE DB SYST REV, V2
   Benn BS, 2008, ENDOCRINOLOGY, V149, P3196, DOI 10.1210/en.2007 1655
   Binkley N, 2008, J CLIN ENDOCR METAB, V93, P1804, DOI 10.1210/jc.2007 2340
   Binkley N, 2004, J CLIN ENDOCR METAB, V89, P3152, DOI 10.1210/jc.2003 031979
   Binkley N, 2011, J CLIN ENDOCR METAB, V96, P981, DOI 10.1210/jc.2010 0015
   Binkley N, 2011, J CLIN DENSITOM, V14, P95, DOI 10.1016/j.jocd.2011.03.006
   Binkley Neil, 2008, Curr Osteoporos Rep, V6, P95, DOI 10.1007/s11914 008 0017 5
   Bischoff HA, 2003, J BONE MINER RES, V18, P343, DOI 10.1359/jbmr.2003.18.2.343
   Bischoff Ferrari HA, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Bischoff Ferrari HA, 2004, JAMA J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Bischoff Ferrari HA, 2009, ARCH INTERN MED, V169, P551, DOI 10.1001/archinternmed.2008.600
   Bosomworth NJ, 2011, CAN FAM PHYSICIAN, V57, P16
   Boucher BJ, 2011, PUBLIC HEALTH NUTR, V14, P740, DOI 10.1017/S136898001100022X
   Bouvard B, 2011, JOINT BONE SPINE, V78, P10, DOI 10.1016/j.jbspin.2010.10.011
   Bravo S, 2006, J CELL BIOCHEM, V99, P995, DOI 10.1002/jcb.21031
   Broe KE, 2007, J AM GERIATR SOC, V55, P234, DOI 10.1111/j.1532 5415.2007.01048.x
   Carter GD, 2011, CURR DRUG TARGETS, V12, P19
   Cashman KD, 2011, NAT REV ENDOCRINOL, V7, P566, DOI 10.1038/nrendo.2011.135
   Cauley JA, 2008, ANN INTERN MED, V149, P242, DOI 10.7326/0003 4819 149 4 200808190 00005
   Chapuy MC, 2002, OSTEOPOROSIS INT, V13, P257, DOI 10.1007/s001980200023
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   Cheng SL, 2003, AM J CLIN NUTR, V78, P485, DOI 10.1093/ajcn/78.3.485
   Chun RF, 2008, J ENDOCRINOL, V198, P261, DOI 10.1677/JOE 08 0170
   Chung Mei, 2009, Evid Rep Technol Assess (Full Rep), P1
   Dawson Hughes B, 2010, OSTEOPOROSIS INT, V21, P1151, DOI 10.1007/s00198 010 1285 3
   Dawson Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198 005 1867 7
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DEABREU DAF, 2009, PSYCHONEUROENDOCRINO, V34, P265
   DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898 6568(94)00042 5
   Deplas A, 2004, J Nutr Health Aging, V8, P400
   Diamond T, 1998, MED J AUSTRALIA, V169, P138, DOI 10.5694/j.1326 5377.1998.tb116014.x
   Drechsler C, 2010, EUR HEART J, V31, P2253, DOI 10.1093/eurheartj/ehq246
   Eastell R, 2009, J CLIN ENDOCR METAB, V94, P340, DOI 10.1210/jc.2008 1758
   El Khoury JM, 2011, CLIN BIOCHEM, V44, P66, DOI 10.1016/j.clinbiochem.2010.05.007
   Elwood JM, 2004, CANC PREV CANC CAUSE, V3, P3
   Engel P, 2011, CANCER EPIDEM BIOMAR, V20, P187, DOI 10.1158/1055 9965.EPI 10 1039
   Fleet JC, 2010, CRIT REV CL LAB SCI, V47, P181, DOI 10.3109/10408363.2010.536429
   Flicker L, 2003, J AM GERIATR SOC, V51, P1533, DOI 10.1046/j.1532 5415.2003.51510.x
   Gerdhem P, 2005, OSTEOPOROSIS INT, V16, P1425, DOI 10.1007/s00198 005 1860 1
   Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI [10.1002/14651858.CD007146.pub2, 10.1002/14651858.CD007146.pub3]
   Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604
   Goldstein Deborah, 2009, J Pediatr Nurs, V24, P345, DOI 10.1016/j.pedn.2009.05.005
   Grant WB, 2011, BIOL RES NURS, V13, P117, DOI 10.1177/1099800410396947
   Greenspan SL, 2005, J GERONTOL A BIOL, V60, P754, DOI 10.1093/gerona/60.6.754
   Hathcock JN, 2007, AM J CLIN NUTR, V85, P6, DOI 10.1093/ajcn/85.1.6
   Heaney RP, 2011, J BONE MINER RES, V26, P455, DOI 10.1002/jbmr.328
   Heaney RP, 2011, J CLIN ENDOCR METAB, V96, pE447, DOI 10.1210/jc.2010 2230
   Heaney RP, 2006, J NUTR, V136, P1123, DOI 10.1093/jn/136.4.1123
   Heaney RP, 2003, J AM COLL NUTR, V22, P142, DOI 10.1080/07315724.2003.10719287
   Heaney RP, 2005, J STEROID BIOCHEM, V97, P13, DOI 10.1016/j.jsbmb.2005.06.020
   Heaney RP, 2003, ENDOCRIN METAB CLIN, V32, P181, DOI 10.1016/S0889 8529(02)00063 4
   Heaney RP, 2003, AM J CLIN NUTR, V77, P204, DOI 10.1093/ajcn/77.1.204
   Hewison M, 2007, J STEROID BIOCHEM, V103, P316, DOI 10.1016/j.jsbmb.2006.12.078
   Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   Holick MF, 2005, J CLIN ENDOCR METAB, V90, P3215, DOI 10.1210/jc.2004 2364
   HOLICK MF, 2004, J BONE MINER RES, V19, pSU585
   Holick MF, 2008, J CLIN ENDOCR METAB, V93, P677, DOI 10.1210/jc.2007 2308
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011 0385, 10.1210/jc.2011 1193]
   Holick Michael F, 2011, J Clin Endocrinol Metab, V96, P1, DOI 10.1210/jc.2011 0385
   Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317
   Huang M, 2011, J AOAC INT, V94, P211
   Jafri L, 2011, CLIN BIOCHEM, V44, P864, DOI 10.1016/j.clinbiochem.2011.04.020
   Jenab M, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5500
   Jesudason D, 2002, BONE, V31, P626, DOI 10.1016/S8756 3282(02)00866 9
   Karlsson S, 2010, J STEROID BIOCHEM, V121, P413, DOI 10.1016/j.jsbmb.2010.03.083
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112
   Koike M, 1999, ANTICANCER RES, V19, P1689
   Korpershoek Harmke W, 2010, Ned Tijdschr Geneeskd, V154, pA827
   Kuchuk NO, 2009, J CLIN ENDOCR METAB, V94, P1244, DOI 10.1210/jc.2008 1832
   Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009 0051
   Lappe JM, 2007, AM J CLIN NUTR, V85, P1586, DOI 10.1093/ajcn/85.6.1586
   Lensmeyer GL, 2006, CLIN CHEM, V52, P1120, DOI 10.1373/clinchem.2005.064956
   Li B, 2009, CLIN CHIM ACTA, V404, P144, DOI 10.1016/j.cca.2009.03.043
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003 4819 124 4 199602150 00003
   Lips P, 2010, CLIN ENDOCRINOL, V73, P277, DOI 10.1111/j.1365 2265.2009.03701.x
   Looker AC, 2008, AM J CLIN NUTR, V88, P1519, DOI 10.3945/ajcn.2008.26182
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   MARTI F, 2006, SCHWEIZ RUNDSCH MED, V95, P1953, DOI DOI 10.1024/1661 8157.95.50.1953
   Messinger Rapport B, 2009, NURS CLIN N AM, V44, P187, DOI 10.1016/j.cnur.2009.03.001
   Meyer MB, 2010, J STEROID BIOCHEM, V121, P136, DOI 10.1016/j.jsbmb.2010.02.011
   Morales Tirado V, 2011, CLIN IMMUNOL, V138, P212, DOI 10.1016/j.clim.2010.11.003
   Nogues X, 2010, MATURITAS, V66, P291, DOI 10.1016/j.maturitas.2010.03.012
   Norman AW, 2002, MOL CELL ENDOCRINOL, V197, P1, DOI 10.1016/S0303 7207(02)00273 3
   Okazaki Ryo, 2007, Nihon Naika Gakkai Zasshi, V96, P742
   Orwoll E, 2009, J CLIN ENDOCR METAB, V94, P1214, DOI 10.1210/jc.2008 1784
   Outila TA, 2001, AM J CLIN NUTR, V74, P206
   Parfitt AM., 1990, Metabolic bone disease and clinically related disorders, V2nd, P329
   Pietras SM, 2009, ARCH INTERN MED, V169, P1806, DOI 10.1001/archinternmed.2009.361
   Pilz S, 2011, CURR DRUG TARGETS, V12, P88, DOI 10.2174/138945011793591563
   PITCHER T, 1995, EXP PHYSIOL, V80, P597, DOI 10.1113/expphysiol.1995.sp003870
   Porthouse J, 2005, BMJ BRIT MED J, V330, P1003, DOI 10.1136/bmj.330.7498.1003
   Priemel M, 2010, J BONE MINER RES, V25, P305, DOI 10.1359/jbmr.090728
   Prietl B, 2010, ISR MED ASSOC J, V12, P136
   Rao DS, 2002, J BONE MINER RES, V17, pN75
   Richard C, 2010, J BONE MINER RES, V25, P1627, DOI 10.1002/jbmr.58
   Richardson JP, 2005, AM FAM PHYSICIAN, V71, P241
   Romagnoli E, 2008, J CLIN ENDOCR METAB, V93, P3015, DOI 10.1210/jc.2008 0350
   Rosen CJ, 2011, NEW ENGL J MED, V364, P248, DOI 10.1056/NEJMcp1009570
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Roy DK, 2007, BONE, V40, P200, DOI 10.1016/j.bone.2006.07.004
   Sambrook PN, 2002, MED J AUSTRALIA, V176, P560, DOI 10.5694/j.1326 5377.2002.tb04557.x
   Semba RD, 2010, EUR J CLIN NUTR, V64, P203, DOI 10.1038/ejcn.2009.140
   Serhan E, 2005, RHEUMATOL INT, V25, P276, DOI 10.1007/s00296 003 0430 0
   Seton M, 2005, J CLIN DENSITOM, V8, P454, DOI 10.1385/JCD:8:4:454
   Song YR, 2003, J NUTR, V133, P374, DOI 10.1093/jn/133.2.374
   Strathmann FG, 2011, CLIN CHEM, V57, P1279, DOI 10.1373/clinchem.2010.161174
   Trivedi DP, 2003, BMJ BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469
   van der Meer IM, 2011, OSTEOPOROSIS INT, V22, P1009, DOI 10.1007/s00198 010 1279 1
   Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501
   Wang L, 2010, ANN INTERN MED, V152, P315, DOI [10.7326/0003 4819 152 5 201003020 00010, 10.7326/0003 4819 152 8 201004200 00008]
   Weatherall M, 2000, NEW ZEAL MED J, V113, P137
   Wimalawansa SJ, 2011, VITAMIN D EVERYTHING
   WIMALAWANSA SJ, 2012, CURRENT OSTEOP 0117
   Zhang HL, 2010, NEUROSCI BULL, V26, P445, DOI 10.1007/s12264 010 0731 8
NR 124
TC 15
Z9 16
U1 0
U2 9
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077 8923
BN 978 1 57331 856 3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1240
BP E1
EP E12
DI 10.1111/j.1749 6632.2011.06374.x
PG 12
WC Endocrinology & Metabolism; Multidisciplinary Sciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics
GA BYL14
UT WOS:000299227500014
PM 22360357
DA 2025 08 17
ER

PT J
AU D'Eufemia, P
   Finocchiaro, R
   Celli, M
   Zambrano, A
   Tetti, M
   Villani, C
   Persiani, P
   Mari, E
   Zicari, A
AF D'Eufemia, Patrizia
   Finocchiaro, Roberto
   Celli, Mauro
   Zambrano, Anna
   Tetti, Martina
   Villani, Ciro
   Persiani, Pietro
   Mari, Emanuela
   Zicari, Alessandra
TI High levels of serum prostaglandin E2 in children with
   osteogenesis imperfecta are reduced by neridronate treatment
SO PEDIATRIC RESEARCH
LA English
DT Article
ID PGE(2) PRODUCTION; BISPHOSPHONATES; CLODRONATE
AB Prostaglandin E 2 (PGE(2)) is an activator of bone remodeling, and increase levels of PGE(2) are found in several disorders characterized by chronic inflammation. Bisphosphonates are used in the treatment of osteogenesis imperfecta (01), an inherited disorder characterized by bone fragility and low bone mass. We evaluated the serum PGE(2) (ng/mL) level in 16 children affected by 01 (11 with mild and 5 with severe forms) at basal time and during treatment with neridronate. The levels of PGE(2) in mild and severe forms were increased at basal time compared with controls (13.14 +/  4.2 versus 0.72 +/  0.05, p < 0.01; 15.1 +/  1.5 versus 0.72 +/  0.05, p < 0.01, respectively) and showed a significant decrease after the second (T1) cycle of treatment (mild: 4.97 +/  5.0 versus 13.14 +/  4.2, p < 0.01; severe: 5.32 +/  4.5 versus 15.1 +/  1.5, p < 0.01) with a further significant decrease after the fourth (T2) cycle. The high basal PGE(2) levels in OI, a noninflammatory disorder, could be explained by stress induced release mediated by inducible cyclooxygenase 2 catalyzed pathway. The reduction obtained by treatment with bisphosphonates could be attributed to a direct pharmacological effect since these drugs has been reported to modulate the release of proinflammatory mediators.
C1 [D'Eufemia, Patrizia; Finocchiaro, Roberto; Celli, Mauro; Zambrano, Anna; Tetti, Martina] Univ Roma La Sapienza, Dept Pediat, I 00161 Rome, Italy.
   [Villani, Ciro; Persiani, Pietro] Univ Roma La Sapienza, Dept Orthoped Surg, I 00161 Rome, Italy.
   [Mari, Emanuela; Zicari, Alessandra] Univ Roma La Sapienza, Dept Expt Med, I 00161 Rome, Italy.
C3 Sapienza University Rome; Sapienza University Rome; Sapienza University
   Rome
RP D'Eufemia, P (通讯作者)，Univ Roma La Sapienza, Dept Pediat, Viale Regina Elena 326, I 00161 Rome, Italy.
EM patdeufemia@inwind.it
RI Persiani, Pietro/S 4255 2016; persiani, pietro/S 4255 2016
OI Persiani, Pietro/0000 0001 5795 3337; villani, ciro/0000 0002 0086 4234;
   CELLI, Mauro/0000 0002 0751 2688; 
CR Adami S, 2003, J BONE MINER RES, V18, P126, DOI 10.1359/jbmr.2003.18.1.126
   Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   Buduneli E, 2004, J PERIODONTOL, V75, P1516, DOI 10.1902/jop.2004.75.11.1516
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Dehghani F, 2004, EXP NEUROL, V189, P241, DOI 10.1016/j.expneurol.2004.06.010
   Glorieux FH, 2007, PEDIATRICS, V119, pS163, DOI 10.1542/peds.2006 2023I
   Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747
   Igarashi K, 1997, PROSTAG LEUKOTR ESS, V56, P121, DOI 10.1016/S0952 3278(97)90508 1
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Liu L, 2006, J DENT RES, V85, P757, DOI 10.1177/154405910608500813
   Liu L, 2004, EUR J ORTHODONT, V26, P469, DOI 10.1093/ejo/26.5.469
   Liu XH, 2005, ENDOCRINOLOGY, V146, P1991, DOI 10.1210/en.2004 1167
   McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   STEINMANN BU, 1982, COLLAGEN REL RES, V2, P185
   Tuominen OM, 2006, METHOD FIND EXP CLIN, V28, P361, DOI 10.1358/mf.2006.28.6.1003551
   Wiercinska Drapalo A, 2005, PROSTAG OTH LIPID M, V78, P160, DOI 10.1016/j.prostaglandins.2005.06.006
   Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158
NR 20
TC 15
Z9 16
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 0031 3998
EI 1530 0447
J9 PEDIATR RES
JI Pediatr. Res.
PD FEB
PY 2008
VL 63
IS 2
BP 203
EP 206
DI 10.1203/PDR.0b013e31815efd63
PG 4
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA 255GL
UT WOS:000252645700018
PM 18091347
OA Bronze
DA 2025 08 17
ER

PT J
AU Tao, ZS
   Zhou, WS
   Tu, KK
   Huang, ZL
   Zhou, Q
   Sun, T
   Lv, YX
   Cui, W
   Yang, L
AF Tao, Zhou Shan
   Zhou, Wan Shu
   Tu, Kai Kai
   Huang, Zheng Liang
   Zhou, Qiang
   Sun, Tao
   Lv, Yang Xun
   Cui, Wei
   Yang, Lei
TI Effect exerted by Teriparatide upon Repair Function of β tricalcium
   phosphate to ovariectomised rat's femoral metaphysis defect caused by
   osteoporosis
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Bone defect; beta TCP; Micro CT; Metaphysis; Osteoporosis; PTH
ID PARATHYROID HORMONE 1 34; BONE GRAFT SUBSTITUTES; DISTRACTION
   OSTEOGENESIS; CLINICAL APPLICATIONS; EXTRACELLULAR SIGNAL; MECHANICAL
   STRENGTH; CANCELLOUS BONE; MINERAL DENSITY; MODEL; PTH
AB In this study, we tested the effect of Teriparatide (PTH) in combination with beta tricalcium phosphate (beta TCP) as a bone void filler in an ovariectomised rat distal femoral metaphysis model. beta TCP is a completely resorbable synthetic calcium phosphate and the Teriparatide is a drug that can promote bone formation in the condition of osteoporosis. A critical size defect of 3 mm in diameter, a through hole bone defect, was drilled into each distal femur of the ovariectomised rats. The hole was filled with beta TCP and the rat was injected PTH Teriparatide (30 mu g/kg) in peritoneum 5 times per week. After 4and 8 weeks the animals were killed and the degree of bone healing analysed. In total, 60 animals were investigated. When the beta TCP and PTH were used, histological, biochemistry and histomor phometric evaluations revealed significantly better bone healing in terms of quantity and quality of the newly formed bone. The Ovariectomised rats which suffer from femur metaphysis defect are cured by embedding beta tricalcuim phosphate and intermittently cured by parathyroid hormone (PTH). (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Tao, Zhou Shan; Tu, Kai Kai; Huang, Zheng Liang; Zhou, Qiang; Sun, Tao; Yang, Lei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou 325027, Zhejiang, Peoples R China.
   [Zhou, Wan Shu] Guizhou Med Univ, Affiliated Hosp, Endocrine & Metab Dis Unit, Guiyang 550001, Guizhou, Peoples R China.
   [Lv, Yang Xun] Wenzhou Cent Hosp, Dept Orthopaed Surg, Wenzhou 325000, Zhejiang, Peoples R China.
   [Cui, Wei] Sichuan Prov Orthoped Hosp, Chengdu 610000, Sichuan, Peoples R China.
C3 Wenzhou Medical University; Guizhou Medical University
RP Yang, L (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, 109 Xueyuan Xi Rd, Wenzhou 325027, Zhejiang, Peoples R China.
EM tzs19900327@163.com
RI Huang, Zhengliang/AAG 9868 2019; zhou, qiang/JCE 0302 2023
FU Key disciplines in colleges and universities in Zhejiang province [2011
   GK006]
FX This work is supported by grant from Key disciplines in colleges and
   universities in Zhejiang province in 2011 (surgery) open fund (grant no:
   2011 GK006).
CR Abzhanov A, 2007, DEVELOPMENT, V134, P3133, DOI 10.1242/dev.002709
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Chalidis B, 2007, EXPERT OPIN INV DRUG, V16, P441, DOI 10.1517/13543784.16.4.441
   Childress P, 2010, BONE, V46, P259, DOI 10.1016/j.bone.2009.09.014
   Comelekoglu U, 2007, CLIN RHEUMATOL, V26, P380, DOI 10.1007/s10067 006 0367 2
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   Dhillon RS, 2013, J BONE MINER RES, V28, P586, DOI 10.1002/jbmr.1765
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014
   Esbrit P, 2000, J AM SOC NEPHROL, V11, P1085, DOI 10.1681/ASN.V1161085
   Hao YJ, 2007, BONE, V41, P631, DOI 10.1016/j.bone.2007.06.006
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Hock J. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P33
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Horch HH, 2006, INT J ORAL MAX SURG, V35, P708, DOI 10.1016/j.ijom.2006.03.017
   Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Khan SN, 2000, ORTHOP CLIN N AM, V31, P389, DOI 10.1016/S0030 5898(05)70158 9
   Komatsu DE, 2008, J BONE MINER RES, V23, pS424
   Laurencin C, 2006, EXPERT REV MED DEVIC, V3, P49, DOI 10.1586/17434440.3.1.49
   Le Guehennec L, 2004, Eur Cell Mater, V8, P1
   Le Guehennec L, 2004, EUR CELLS MATER, V8, P10
   Lee JH, 2014, J MATER SCI MATER M, V25, P2141, DOI 10.1007/s10856 014 5250 0
   Lu ZF, 2010, BIOCHEM BIOPH RES CO, V394, P323, DOI 10.1016/j.bbrc.2010.02.178
   McCann RM, 2008, J ORTHOP RES, V26, P384, DOI 10.1002/jor.20505
   Mochizuki K, 2000, J BONE MINER METAB, V18, P194, DOI 10.1007/s007740070020
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   PENG Z, 1994, BONE, V15, P523, DOI 10.1016/8756 3282(94)90276 3
   REEVE J, 1980, BMJ BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   Reynolds DG, 2011, BONE, V48, P562, DOI 10.1016/j.bone.2010.10.003
   Rudert M, 2002, CELLS TISSUES ORGANS, V171, P229, DOI 10.1159/000063125
   Sasso RC, 1998, J BONE JOINT SURG AM, V80A, P631, DOI 10.2106/00004623 199805000 00003
   SCHMITZ JP, 1990, ACTA ANAT, V138, P185
   Seebach C, 2004, J ORTHOP RES, V22, P472, DOI 10.1016/j.orthers.2003.08.018
   Sheyn D, 2013, MOL PHARMACEUT, V10, P4462, DOI 10.1021/mp400292p
   Shim JH, 2014, BIOMED MATER, V9, DOI 10.1088/1748 6041/9/6/065006
   Skripitz R, 2001, J BONE JOINT SURG BR, V83B, P437, DOI 10.1302/0301 620X.83B3.10256
   Turner RT, 2006, J APPL PHYSIOL, V101, P881, DOI 10.1152/japplphysiol.01622.2005
   van der Linden JC, 2001, J BONE MINER RES, V16, P457, DOI 10.1359/jbmr.2001.16.3.457
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Yamauchi M, 2005, AM J PHYSIOL ENDOC M, V288, pE608, DOI 10.1152/ajpendo.00229.2004
   Yassuda DH, 2013, J BIOMED MATER RES A, V101, P1986, DOI 10.1002/jbm.a.34502
   Yun JI, 2010, J CLIN PERIODONTOL, V37, P419, DOI 10.1111/j.1600 051X.2010.01547.x
NR 47
TC 28
Z9 32
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD NOV
PY 2015
VL 46
IS 11
BP 2134
EP 2141
DI 10.1016/j.injury.2015.07.042
PG 8
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA CU9XY
UT WOS:000363901600008
PM 26306803
DA 2025 08 17
ER

PT J
AU Pan, YH
   Li, JW
   Wu, JQ
   Yang, CY
   Wu, SY
   Yang, KH
   Yang, X
   Chen, Q
   Fu, GB
   Liu, C
AF Pan, Yonghao
   Li, Jiawei
   Wu, Jianqun
   Yang, Chengyu
   Wu, Siying
   Yang, Kunhua
   Yang, Xue
   Chen, Qian
   Fu, Guibing
   Liu, Chao
TI Hyperbaric oxygen therapy enhances osteointegration of reimplanted
   cranial flap by regulating osteogenesis angiogenesis coupling
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE angiogenesis osteogenesis coupling; angiopoietin 2; craniectomy;
   hyperbaric oxygen; single cell RNA sequencing
ID ENDOTHELIAL GROWTH FACTOR; DECOMPRESSIVE CRANIECTOMY; PROMOTES
   ANGIOGENESIS; BONE FLAPS; ANGIOPOIETIN 2; CRANIOPLASTY; HYPOXIA;
   STORAGE; CELLS
AB Craniectomy is a lifesaving procedure to alleviate dangerously high intracranial pressure by removing a bone flap from the calvarium. However, the osteointegration of reimplanted bone flap with the existing bone tissue is still a clinical challenge. Hyperbaric oxygen (HBO) therapy has shown efficacy in promoting bone repair and could be a promising treatment for accelerating postoperative recovery. However, the specific cell types that are responsive to HBO treatment are not well understood. In this study, we created a murine model of craniectomy, with reimplantation of the cranial flap after 1 week. The effects of HBO treatment on bone formation and blood vessel formation around reimplanted bone were examined by micro computed tomography, histological staining, and immunofluorescence staining. Single cell RNA sequencing (scRNAseq) was utilized to identify key cell subtypes and signaling pathways after HBO treatment. We found that HBO treatment increased bone volume around reimplanted cranial flaps. HBO also increased the volume of Osterix expressing cells and type H vessels. scRNAseq data showed more mature osteoblasts and endothelial cells, with higher expressions of adhesion and migration related genes after HBO treatment. Cell cell interaction analysis revealed a higher expression level of genes between mature osteoblasts and endothelial cells from the angiopoietin 2 integrin alpha 5 beta 1 pathway. Taken together, HBO therapy promotes the healing process of craniectomy by regulating the crosstalk between vascular endothelial cells and osteogenic cells. These findings provide evidence in a preclinical model that HBO therapy enhances osteointegration by regulating angiogenesis osteogenesis coupling, providing a scientific basis for utilizing HBO therapy for accelerating postoperative recovery after craniectomy.
C1 [Pan, Yonghao; Li, Jiawei; Yang, Chengyu; Wu, Siying; Yang, Kunhua; Liu, Chao] Southern Univ Sci & Technol, Coll Engn, Dept Biomed Engn, Shenzhen, Peoples R China.
   [Pan, Yonghao; Li, Jiawei; Yang, Chengyu; Wu, Siying; Liu, Chao] Southern Univ Sci & Technol, Guangdong Prov Key Lab Adv Biomat, Shenzhen, Peoples R China.
   [Wu, Jianqun] Southern Univ Sci & Technol, Sch Med, Shenzhen, Peoples R China.
   [Yang, Xue; Chen, Qian; Fu, Guibing] Shenzhen Childrens Hosp, Shenzhen, Peoples R China.
   [Liu, Chao] Coll Engn Bldg,1088 Xueyuan Ave,South Room 732, Shenzhen 518055, Peoples R China.
   [Chen, Qian; Fu, Guibing] 7019 Yitian Rd, Shenzhen 518026, Peoples R China.
C3 Southern University of Science & Technology; Southern University of
   Science & Technology; Southern University of Science & Technology;
   Shenzhen Children's Hospital
RP Liu, C (通讯作者)，Coll Engn Bldg,1088 Xueyuan Ave,South Room 732, Shenzhen 518055, Peoples R China.; Chen, Q; Fu, GB (通讯作者)，7019 Yitian Rd, Shenzhen 518026, Peoples R China.
EM chenqian68@126.com; fgbmd@163.com; liuc33@sustech.edu.cn
RI ; Liu, Chao/E 2667 2019
OI Pan, Yonghao/0000 0003 2024 8874; Liu, Chao/0000 0001 6637 1689
FU Natural Science Foundation of Shenzhen Municipality; BGI Genomics Co.,
   Ltd.; SUSTech Core Research Core Research Facilities [2021A1515011447];
   Guangdong Natural Science Foundation [KQTD20200820113012029,
   JCYJ20190809114209434]; Shenzhen Science and Technology Innovation
   Commission [2022B1212010003]; Guangdong Provincial Key Laboratory of
   Advanced Biomaterials
FX We acknowledge the bioinformatics support of Jianhua Yin from BGI
   Genomics Co., Ltd. We acknowledge the assistance of Ying Wang for the
   Micro CT imaging from the SUSTech Core Research Core Research
   Facilities. We thank the SUSTech Animal Facility for animal husbandry.
   This work was supported by the Guangdong Natural Science Foundation
   (2021A1515011447), Shenzhen Science and Technology Innovation Commission
   (KQTD20200820113012029 and JCYJ20190809114209434), Guangdong Provincial
   Key Laboratory of Advanced Biomaterials (2022B1212010003) for financial
   support.
CR Akwii RG, 2022, ANGIOGENESIS, V25, P373, DOI 10.1007/s10456 022 09831 y
   An H, 2019, J PERIODONTAL IMPLAN, V49, P2, DOI 10.5051/jpis.2019.49.1.2
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Augustin HG, 2017, SCIENCE, V357, DOI 10.1126/science.aal2379
   Chan DYC, 2017, J CLIN NEUROSCI, V42, P81, DOI 10.1016/j.jocn.2017.04.016
   Corliss B, 2016, WORLD NEUROSURG, V96, P510, DOI 10.1016/j.wneu.2016.09.025
   David S, 2011, ARTERIOSCL THROM VAS, V31, P2643, DOI 10.1161/ATVBAHA.111.233189
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29
   Gardin C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041452
   Gomei Y, 2010, EXP HEMATOL, V38, P82, DOI 10.1016/j.exphem.2009.11.007
   Grellier M, 2009, J CELL BIOCHEM, V106, P390, DOI 10.1002/jcb.22018
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Han MJ, 2023, J IND ENG CHEM, V120, P121, DOI 10.1016/j.jiec.2022.12.017
   Hellström M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Horner A, 2001, BONE, V28, P65, DOI 10.1016/S8756 3282(00)00422 1
   Hu Y, 2022, RMD OPEN, V8, DOI 10.1136/rmdopen 2022 002314
   Huang NC, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19137866
   Huang X, 2010, INT J MED SCI, V7, P385
   Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21246 9
   Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106
   Lee HS, 2014, J BIOL CHEM, V289, P31330, DOI 10.1074/jbc.M114.572594
   Lee SJ, 2018, J CLIN INVEST, V128, P5018, DOI 10.1172/JCI99659
   Liao ZT, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003 022 03271 6
   Liu X, 2021, NANO TODAY, V40, DOI 10.1016/j.nantod.2021.101248
   Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701 014 2021 0
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Oley MH, 2021, INT J SURG OPEN, V29, P33, DOI 10.1016/j.ijso.2021.01.003
   Peña Villalobos I, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00995
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Percival CJ, 2013, DEV DYNAM, V242, P909, DOI 10.1002/dvdy.23992
   Pohl D, 2012, CURR TREAT OPTION NE, V14, P264, DOI 10.1007/s11940 012 0170 0
   Prameswari N., 2020, Padjadjaran J Dentist, V32, P14
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603 677
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Salmon Gonzalez Z, 2021, HEALTHCARE BASEL, V9, DOI 10.3390/healthcare9121714
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Shafiei M, 2021, J CLIN NEUROSCI, V91, P136, DOI 10.1016/j.jocn.2021.06.042
   SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631
   Xie JY, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00535 8
   Yin J, 2018, BIOMED PHARMACOTHER, V105, P932, DOI 10.1016/j.biopha.2018.06.078
NR 42
TC 2
Z9 2
U1 4
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD OCT
PY 2024
VL 42
IS 10
BP 2197
EP 2209
DI 10.1002/jor.25875
EA MAY 2024
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA J8A2R
UT WOS:001223279500001
PM 38751166
DA 2025 08 17
ER

PT J
AU Zhu, W
   Castro, NJ
   Cui, HT
   Zhou, X
   Boualam, B
   McGrane, R
   Glazer, RI
   Zhang, LG
AF Zhu, Wei
   Castro, Nathan J.
   Cui, Haitao
   Zhou, Xuan
   Boualam, Benchaa
   McGrane, Robert
   Glazer, Robert I.
   Zhang, Lijie Grace
TI A 3D printed nano bone matrix for characterization of breast cancer cell
   and osteoblast interactions
SO NANOTECHNOLOGY
LA English
DT Article
DE 3D printing; nanomaterials; bone model; breast cancer; osteoblast;
   co culture
ID IN VITRO; MULTICELLULAR SPHEROIDS; METASTASIS; MODEL; EXPRESSION; DRUG;
   INTERLEUKIN 8; PROGRESSION; MECHANISMS; RESORPTION
AB Bone metastasis is one of the most prevalent complications of late stage breast cancer, in which the native bone matrix components, including osteoblasts, are intimately involved in tumor progression. The development of a successful in vitro model would greatly facilitate understanding the underlying mechanism of breast cancer bone invasion as well as provide a tool for effective discovery of novel therapeutic strategies. In the current study, we fabricated a series of in vitro bone matrices composed of a polyethylene glycol hydrogel and nanocrystalline hydroxyapatite of varying concentrations to mimic the native bone microenvironment for the investigation of breast cancer bone metastasis. A stereolithography based three dimensional (3D) printer was used to fabricate the bone matrices with precisely controlled architecture. The interaction between breast cancer cells and osteoblasts was investigated in the optimized bone matrix. Using a Transwell (R) system to separate the two cell lines, breast cancer cells inhibited osteoblast proliferation, while osteoblasts stimulated breast cancer cell growth, whereas, both cell lines increased IL 8 secretion. Breast cancer cells co cultured with osteoblasts within the 3D bone matrix formed multi cellular spheroids in comparison to two dimensional monolayers.
   These findings validate the use of our 3D printed bone matrices as an in vitro metastasis model, and highlights their potential for investigating breast cancer bone metastasis.
C1 [Zhu, Wei; Castro, Nathan J.; Cui, Haitao; Zhou, Xuan; McGrane, Robert; Zhang, Lijie Grace] George Washington Univ, Dept Mech & Aerosp Engn, Washington, DC 20052 USA.
   [Boualam, Benchaa] Univ Maryland, Coll Comp Math & Nat Sci, College Pk, MD 20742 USA.
   [Glazer, Robert I.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.
   [Glazer, Robert I.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
   [Zhang, Lijie Grace] George Washington Univ, Dept Biomed Engn, Washington, DC 20052 USA.
   [Zhang, Lijie Grace] George Washington Univ, Dept Med, Washington, DC 20052 USA.
C3 George Washington University; University System of Maryland; University
   of Maryland College Park; Georgetown University; Georgetown University;
   George Washington University; George Washington University
RP Zhang, LG (通讯作者)，George Washington Univ, Dept Mech & Aerosp Engn, Washington, DC 20052 USA.
EM lgzhang@gwu.edu
RI Zhang, Lijie/E 4443 2011; Castro, Nathan/F 9421 2015; Cui,
   Haitao/F 4359 2016; Zhou, Xuan/M 1051 2018
OI Zhang, Lijie Grace/0000 0003 3009 045X; Castro,
   Nathan/0000 0002 2526 3849; 
FU GW Katzen Cancer Research Center Innovative Cancer Pilot Research Grant;
   NIH [1DP2EB020549 01]
FX The authors would like to thank GW Katzen Cancer Research Center
   Innovative Cancer Pilot Research Grant and NIH Director's New Innovator
   Award 1DP2EB020549 01 for financial support.
CR Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alessandri K, 2013, P NATL ACAD SCI USA, V110, P14843, DOI 10.1073/pnas.1309482110
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bendre MS, 2002, CANCER RES, V62, P5571
   Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009
   Charoen KM, 2014, BIOMATERIALS, V35, P2264, DOI 10.1016/j.biomaterials.2013.11.038
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Fong YC, 2008, J BONE MINER RES, V23, P961, DOI 10.1359/JBMR.080206
   FULLER K, 1995, J IMMUNOL, V154, P6065
   García AJ, 1999, MOL BIOL CELL, V10, P785, DOI 10.1091/mbc.10.3.785
   Ghajar CM, 2010, TISSUE ENG PT A, V16, P2153, DOI [10.1089/ten.tea.2010.0135, 10.1089/ten.TEA.2010.0135]
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Hamilton G, 1998, CANCER LETT, V131, P29, DOI 10.1016/S0304 3835(98)00198 0
   Holmes B, 2015, TISSUE ENG PT A, V21, P403, DOI [10.1089/ten.tea.2014.0138, 10.1089/ten.TEA.2014.0138]
   Hsu YL, 2013, ONCOGENE, V32, P4436, DOI 10.1038/onc.2012.444
   Kinder M, 2008, EXP CELL RES, V314, P173, DOI 10.1016/j.yexcr.2007.09.021
   Krishnan V, 2015, J CELL BIOCHEM, V116, P2715, DOI 10.1002/jcb.25250
   LaBarbera DV, 2012, EXPERT OPIN DRUG DIS, V7, P819, DOI 10.1517/17460441.2012.708334
   Mastro AM, 2004, J CELL BIOCHEM, V91, P265, DOI 10.1002/jcb.10746
   Mizushima H, 2009, J CELL SCI, V122, P4277, DOI 10.1242/jcs.054551
   Morgan MP, 2001, MOL CARCINOGEN, V32, P111, DOI 10.1002/mc.1070
   Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Wang M, 2014, TISSUE ENG PART A, V20, P16
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xu X, 2014, BIOTECHNOL ADV, V32, P1256, DOI 10.1016/j.biotechadv.2014.07.009
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yoshii Y, 2011, BIOMATERIALS, V32, P6052, DOI 10.1016/j.biomaterials.2011.04.076
   Zhang LJ, 2009, NANO TODAY, V4, P66, DOI 10.1016/j.nantod.2008.10.014
   Zhu W, 2016, NANOMED NANOTECHNOL, V12, P69, DOI 10.1016/j.nano.2015.09.010
   Zhu W, 2015, ACTA BIOMATER, V14, P164, DOI 10.1016/j.actbio.2014.12.008
NR 34
TC 60
Z9 65
U1 5
U2 108
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957 4484
EI 1361 6528
J9 NANOTECHNOLOGY
JI Nanotechnology
PD AUG 5
PY 2016
VL 27
IS 31
AR 315103
DI 10.1088/0957 4484/27/31/315103
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science; Physics
GA DP9UL
UT WOS:000378842800008
PM 27346678
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Su, CM
   Hu, SL
   Sun, Y
   Zhao, J
   Dai, CQ
   Wang, LH
   Xu, GH
   Tang, CH
AF Su, Chen Ming
   Hu, Sung Lin
   Sun, Yi
   Zhao, Jin
   Dai, Chengqian
   Wang, Lihong
   Xu, Guohong
   Tang, Chih Hsin
TI Myostatin induces tumor necrosis factor α expression in rheumatoid
   arthritis synovial fibroblasts through the PI3K Akt signaling pathway
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE c Jun; myostatin; rheumatoid arthritis; tumor necrosis factor alpha
ID DIFFERENTIATION; INFLAMMATION; CYTOKINES; AP 1
AB In rheumatoid arthritis (RA), a chronic inflammatory disease, loss of muscle mass is an important contributor to the loss of muscle strength in RA patients. Myostatin, a myokine involved in the process of muscle hypertrophy and myogenesis, enhances osteoclast differentiation and inflammation. Here, we investigated the mechanisms of myostatin in RA synovial inflammation. We found a positive correlation between myostatin and tumor necrosis factor alpha (TNF alpha), a well known proinflammatory cytokine, in RA synovial tissue. Our in vitro results also showed that myostatin dose dependently induced TNF alpha expression through the phosphatidylinositol 3 kinase (PI3K) Akt AP 1 signaling pathway. Myostatin treatment of human MH7A cells stimulated AP 1 induced luciferase activity and activation of the c Jun binding site on the TNF alpha promoter. Our results indicated that myostatin increases TNF alpha expression via the PI3K Akt AP 1 signaling pathway in human RA synovial fibroblasts. Myostatin appears to be a promising target in RA therapy.
C1 [Su, Chen Ming; Sun, Yi; Zhao, Jin] Wenzhou Med Univ, Affiliated Dongyang Hosp, Dept Biomed Sci Lab, 60 Wuning West Rd, Dongyang 322100, Zhejiang, Peoples R China.
   [Hu, Sung Lin] China Med Univ, Program Aging, Taichung, Taiwan.
   [Hu, Sung Lin] China Med Univ Hosp, Dept Family Med, Taichung, Taiwan.
   [Dai, Chengqian; Wang, Lihong; Xu, Guohong] Wenzhou Med Univ, Affiliated Dongyang Hosp, Dept Orthoped, Dongyang, Peoples R China.
   [Tang, Chih Hsin] China Med Univ, Sch Med, Dept Pharmacol, Taichung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Dept Biotechnol, Coll Hlth Sci, Taichung, Taiwan.
C3 Wenzhou Medical University; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Hospital   Taiwan;
   Wenzhou Medical University; China Medical University Taiwan; China
   Medical University Taiwan; Asia University Taiwan
RP Su, CM (通讯作者)，Wenzhou Med Univ, Affiliated Dongyang Hosp, Dept Biomed Sci Lab, 60 Wuning West Rd, Dongyang 322100, Zhejiang, Peoples R China.; Tang, CH (通讯作者)，China Med Univ, Grad Inst Basic Med Sci, 91 Hsueh Shih Rd, Taichung 40406, Taiwan.
EM ericsucm@163.com; chtang@mail.cmu.edu.tw
RI Huang, Chien Chung/ABH 8727 2020; Dai, ChengQian/HTQ 2939 2023; Tang,
   Chih/O 5212 2015
OI Su, Chen Ming/0000 0002 9336 4668; 
FU National Natural Science Foundation [81702117]; Ministry of Science and
   Technology [MOST 107 2320 B 039 064 , MOST 107 2320 B 039 019 MY3]
FX National Natural Science Foundation, Grant/Award Number: 81702117;
   Ministry of Science and Technology, Grant/Award Numbers: MOST
   107 2320 B 039 064 , MOST 107 2320 B 039 019 MY3
CR Bain B, 2003, NAT REV DRUG DISCOV, V2, P693, DOI 10.1038/nrd1182
   Baker JF, 2017, J RHEUMATOL, V44, P1777, DOI 10.3899/jrheum.170513
   Castillero E, 2011, AM J PHYSIOL ENDOC M, V300, pE790, DOI 10.1152/ajpendo.00590.2010
   Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917
   Davis JM, 2012, MAYO CLIN PROC, V87, P659, DOI 10.1016/j.mayocp.2012.03.011
   Edwards CJ, 2005, BRIT MED BULL, V73 74, P71, DOI 10.1093/bmb/ldh051
   Falconer J, 2018, ARTHRITIS RHEUMATOL, V70, P984, DOI 10.1002/art.40504
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Gallot YS, 2014, CANCER RES, V74, P7344, DOI 10.1158/0008 5472.CAN 14 0057
   Granet C, 2004, ARTHRITIS RES THER, V6, pR190, DOI 10.1186/ar1159
   Hirota K, 2018, IMMUNITY, V48, P1220, DOI 10.1016/j.immuni.2018.04.009
   Hu SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01747
   Kim S, 2018, CELL PHYSIOL BIOCHEM, V48, P1829, DOI 10.1159/000492505
   Loumaye A, 2015, J CLIN ENDOCR METAB, V100, P2030, DOI 10.1210/jc.2014 4318
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   Mohan AK, 2003, CURR OPIN RHEUMATOL, V15, P179, DOI 10.1097/00002281 200305000 00002
   Onuora Sarah, 2015, Nat Rev Rheumatol, V11, P504, DOI 10.1038/nrrheum.2015.113
   Pereira BC, 2014, INT J SPORTS MED, V35, P139, DOI 10.1055/s 0033 1349077
   Retamales A, 2015, BIOCHEM BIOPH RES CO, V464, P596, DOI 10.1016/j.bbrc.2015.07.018
   Schonthaler HB, 2011, ANN RHEUM DIS, V70, pI109, DOI 10.1136/ard.2010.140533
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Su CM, 2018, BIOCHEM PHARMACOL, V154, P234, DOI 10.1016/j.bcp.2018.05.001
   Su CM, 2015, J IMMUNOL, V195, P3355, DOI 10.4049/jimmunol.1403191
   TETTA C, 1990, ANN RHEUM DIS, V49, P665, DOI 10.1136/ard.49.9.665
   Thalayasingam N, 2011, BEST PRACT RES CL RH, V25, P549, DOI 10.1016/j.berh.2011.10.004
   Trendelenburg AU, 2009, AM J PHYSIOL CELL PH, V296, pC1258, DOI 10.1152/ajpcell.00105.2009
   Turner JD, 2015, CURR OPIN RHEUMATOL, V27, P175, DOI 10.1097/BOR.0000000000000148
   Uluçkan Ö, 2015, CLIN EXP RHEUMATOL, V33, pS44
   Wagner KR, 2005, P NATL ACAD SCI USA, V102, P2519, DOI 10.1073/pnas.0408729102
   Wu LC, 2017, J CELL BIOCHEM, V118, P1308, DOI 10.1002/jcb.25672
   Wu TJ, 2018, ENVIRON TOXICOL, V33, P1061, DOI 10.1002/tox.22618
   Xie Y, 2018, BIOCHEM BIOPH RES CO, V503, P1409, DOI 10.1016/j.bbrc.2018.07.056
NR 32
TC 30
Z9 33
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2019
VL 234
IS 6
BP 9793
EP 9801
DI 10.1002/jcp.27665
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HM2QU
UT WOS:000459314500186
PM 30378113
DA 2025 08 17
ER

PT J
AU Sun, Q
   Zhen, GH
   Li, TP
   Guo, QY
   Li, YS
   Su, WP
   Xue, P
   Wang, X
   Wan, M
   Guan, Y
   Dong, XZ
   Li, SH
   Cai, M
   Cao, X
AF Sun, Qi
   Zhen, Gehua
   Li, Tuo Peter
   Guo, Qiaoyue
   Li, Yusheng
   Su, Weiping
   Xue, Peng
   Wang, Xiao
   Wan, Mei
   Guan, Yun
   Dong, Xinzhong
   Li, Shaohua
   Cai, Ming
   Cao, Xu
TI Parathyroid hormone attenuates osteoarthritis pain by remodeling
   subchondral bone in mice
SO ELIFE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; RADIOGRAPHIC KNEE OSTEOARTHRITIS;
   ARTICULAR CARTILAGE; GAIT ANALYSIS; MOUSE MODEL; RECEPTOR; CHONDROCYTES;
   RAT; PTH; DIFFERENTIATION
AB Osteoarthritis, a highly prevalent degenerative joint disorder, is characterized by joint pain and disability. Available treatments fail to modify osteoarthritis progression and decrease joint pain effectively. Here, we show that intermittent parathyroid hormone (iPTH) attenuates osteoarthritis pain by inhibiting subchondral sensory innervation, subchondral bone deterioration, and articular cartilage degeneration in a destabilized medial meniscus (DMM) mouse model. We found that subchondral sensory innervation for osteoarthritis pain was significantly decreased in PTH treated DMM mice compared with vehicle treated DMM mice. In parallel, deterioration of subchondral bone microarchitecture in DMM mice was attenuated by iPTH treatment. Increased level of prostaglandin E2 in subchondral bone of DMM mice was reduced by iPTH treatment. Furthermore, uncoupled subchondral bone remodeling caused by increased transforming growth factor beta signaling was regulated by PTH induced endocytosis of the PTH type 1 receptor transforming growth factor beta type 2 receptor complex. Notably, iPTH improved subchondral bone microarchitecture and decreased level of prostaglandin E2 and sensory innervation of subchondral bone in DMM mice by acting specifically through PTH type 1 receptor in Nestin(+) mesenchymal stromal cells. Thus, iPTH could be a potential disease modifying therapy for osteoarthritis.
C1 [Sun, Qi; Zhen, Gehua; Li, Tuo Peter; Guo, Qiaoyue; Li, Yusheng; Su, Weiping; Xue, Peng; Wang, Xiao; Wan, Mei; Cao, Xu] Johns Hopkins Univ, Dept Orthopaed Surg, Inst Cell Engn, Sch Med, Baltimore, MD 21218 USA.
   [Sun, Qi; Li, Shaohua; Cai, Ming] Tongji Univ, Shanghai Tenth Peoples Hosp, Sch Med, Dept Orthopaed, Shanghai, Peoples R China.
   [Guan, Yun] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.
   [Dong, Xinzhong] Johns Hopkins Univ, Dept Neurosci, Howard Hughes Med Inst, Sch Med, Baltimore, MD USA.
   [Dong, Xinzhong] Johns Hopkins Univ, Dept Neurosurg, Howard Hughes Med Inst, Sch Med, Baltimore, MD USA.
   [Dong, Xinzhong] Johns Hopkins Univ, Dept Dermatol, Howard Hughes Med Inst, Sch Med, Baltimore, MD USA.
   [Dong, Xinzhong] Johns Hopkins Univ, Ctr Sensory Biol, Howard Hughes Med Inst, Sch Med, Baltimore, MD USA.
   [Cao, Xu] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Tongji University; Johns Hopkins University;
   Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins
   University; Howard Hughes Medical Institute; Howard Hughes Medical
   Institute; Johns Hopkins University; Howard Hughes Medical Institute;
   Johns Hopkins University; Johns Hopkins University
RP Cao, X (通讯作者)，Johns Hopkins Univ, Dept Orthopaed Surg, Inst Cell Engn, Sch Med, Baltimore, MD 21218 USA.; Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
EM xcao11@jhmi.edu
RI ; Wang, Xiao/AAL 8698 2020
OI Zhen, Gehua/0000 0001 7652 6226; guan, yun/0000 0003 1321 6655; Li, Tuo
   Peter/0000 0002 4302 9538; Wang, Xiao/0000 0001 6395 706X; Wan,
   Mei/0000 0001 9404 540X; Su, Weiping/0000 0002 6261 8661; 
FU National Institutes of Health [P01AG066603, 1R01 AG068997]; National
   Institute of Neurological Disorders and Stroke [RF1AG068997] Funding
   Source: NIH RePORTER
FX National Institutes of Health P01AG066603 Xu Cao National Institutes of
   Health 1R01 AG068997 Xu Cao The funders had no role in study design,
   data collection and interpretation, or the decision to submit the work
   for publication.
CR [Anonymous], 2009, MMWR MORBID MORTAL W
   [Anonymous], 2019, NAT COMMUN
   Ashraf S, 2011, ANN RHEUM DIS, V70, P523, DOI 10.1136/ard.2010.137844
   Bedson J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 116
   Bellido M, 2011, OSTEOARTHR CARTILAGE, V19, P1228, DOI 10.1016/j.joca.2011.07.003
   Belluzzi E, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6390182
   Bhosale AM, 2008, BRIT MED BULL, V87, P77, DOI 10.1093/bmb/ldn025
   Brazill JM, 2019, J BONE MINER RES, V34, P1393, DOI 10.1002/jbmr.3822
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Chang JK, 2009, ARTHRITIS RHEUM US, V60, P3049, DOI 10.1002/art.24843
   Chen CH, 2018, J APPL PHYSIOL, V124, P1177, DOI 10.1152/japplphysiol.00871.2017
   Chen H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08097 7
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Cui C, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12755
   Dai MW, 2016, OSTEOARTHR CARTILAGE, V24, P1103, DOI 10.1016/j.joca.2016.01.007
   Devi S, 2014, LANCET, V383, P2197, DOI 10.1016/S0140 6736(14)61069 2
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140 6736(05)71086 2
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Eswaramoorthy R, 2012, ACTA BIOMATER, V8, P2254, DOI 10.1016/j.actbio.2012.03.015
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Funk JL, 2002, BIOCHEM BIOPH RES CO, V297, P890, DOI 10.1016/S0006 291X(02)02263 5
   Geba GP, 2002, JAMA J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537
   Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613
   Hannan MT, 2000, J RHEUMATOL, V27, P1513
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Hirasawa Y, 2000, INT ORTHOP, V24, P1, DOI 10.1007/s002640050001
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Isaac D, 2005, KNEE, V12, P346, DOI 10.1016/j.knee.2004.11.007
   Isales CM, 2000, AM J PHYSIOL ENDOC M, V279, pE654, DOI 10.1152/ajpendo.2000.279.3.E654
   Ishizuka K, 2005, NEUROSCI LETT, V379, P47, DOI 10.1016/j.neulet.2004.12.046
   Karlsson J, 2002, RHEUMATOLOGY, V41, P1240, DOI 10.1093/rheumatology/41.11.1240
   Kc R, 2016, ANN RHEUM DIS, V75, P2133, DOI 10.1136/annrheumdis 2015 208444
   Kim JS, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3485
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Kwoh CK, 2013, NAT REV RHEUMATOL, V9, P7, DOI 10.1038/nrrheum.2012.217
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   Laslett LL, 2014, ANN RHEUM DIS, V73, P824, DOI 10.1136/annrheumdis 2012 202989
   Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis 2011 200970
   Li ZX, 2017, FRONT CELL NEUROSCI, V11, DOI [10.3389/fncel.2017.00040, 10.3389/fncel.2017.00042]
   Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978 0 8213 6262 4
   Lugo L, 2012, OSTEOARTHR CARTILAGE, V20, P1619, DOI 10.1016/j.joca.2012.08.010
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   Massfelder T, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133639
   Mathiessen A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1229 9
   Miller RE, 2017, ARTHRITIS RHEUMATOL, V69, P1429, DOI 10.1002/art.40118
   Morita Y, 2018, J ORTHOP RES, V36, P1959, DOI 10.1002/jor.23840
   Okabe M, 2004, P NATL ACAD SCI USA, V101, P17716, DOI 10.1073/pnas.0406116101
   Orth P, 2014, OSTEOARTHR CARTILAGE, V22, P813, DOI 10.1016/j.joca.2014.03.010
   Orth P, 2013, OSTEOARTHR CARTILAGE, V21, P614, DOI 10.1016/j.joca.2013.01.008
   Pan J, 2012, BONE, V51, P212, DOI 10.1016/j.bone.2011.11.030
   Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91
   Petersson M, 2006, OSTEOARTHR CARTILAGE, V14, P652, DOI 10.1016/j.joca.2006.01.003
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Rahmati M, 2016, BONE, V85, P81, DOI 10.1016/j.bone.2016.01.019
   Reilly KA, 2005, KNEE, V12, P351, DOI 10.1016/j.knee.2005.01.002
   REIMANN I, 1977, ACTA ORTHOP SCAND, V48, P345, DOI 10.3109/17453677708992006
   Sampson ER, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002214
   Schaible HG, 2012, CURR RHEUMATOL REP, V14, P549, DOI 10.1007/s11926 012 0279 x
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Song GJ, 2009, MOL ENDOCRINOL, V23, P1681, DOI 10.1210/me.2009 0098
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Thomas A, 2009, J GERIATR PHYS THER, V32, P33, DOI 10.1519/00139143 200932010 00007
   Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881
   WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092 8674(92)90395 S
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yan JY, 2014, OSTEOARTHR CARTILAGE, V22, P1869, DOI 10.1016/j.joca.2014.07.013
   Yusuf E, 2011, ANN RHEUM DIS, V70, P60, DOI 10.1136/ard.2010.131904
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 74
TC 46
Z9 56
U1 3
U2 30
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD MAR 1
PY 2021
VL 10
AR e66532
DI 10.7554/eLife.66532
PG 26
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA RI0QI
UT WOS:000636614300001
PM 33646122
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Göbel, A
   Thiele, S
   Browne, AJ
   Rauner, M
   Zinna, VM
   Hofbauer, LC
   Rachner, TD
AF Goebel, Andy
   Thiele, Stefanie
   Browne, Andrew J.
   Rauner, Martina
   Zinna, Valentina M.
   Hofbauer, Lorenz C.
   Rachner, Tilman D.
TI Combined inhibition of the mevalonate pathway with statins and
   zoledronic acid potentiates their anti tumor effects in human breast
   cancer cells
SO CANCER LETTERS
LA English
DT Article
DE Breast cancer; Statins; Zoledronic acid; Mevalonate pathway; Apoptosis;
   Rho GTPases
ID HMG COA REDUCTASE; PROTEIN GERANYLGERANYLATION; RHO GTPASES; BONE;
   BISPHOSPHONATES; RAC; METASTASIS; APOPTOSIS; SURVIVAL; CDC42
AB Amino bisphosphonates are antiresorptive drugs for the treatment of osteolytic bone metastases, which are frequently caused by breast and other solid tumors. Like statins, amino bisphosphonates inhibit the mevalonate pathway. Direct anti tumor effects of amino bisphosphonates and statins have been proposed, although high concentrations are required to achieve these effects. Here, we demonstrate that the treatment of different human breast cancer cell lines (MDA MB 231, MDA Bone, and MDA Met) by combined inhibition of the mevalonate pathway using statins and zoledronic acid at the same time significantly reduces the concentrations required to achieve a meaningful anti tumor effect over a single agent approach (50% reduction of cell vitality and 4 fold increase of apoptosis; p < 0.05). The effects were mediated by suppressed protein geranylation that caused an accumulation of GTP bound RhoA and CDC42. Importantly, the knockdown of both proteins prior to mevalonate pathway inhibition reduced apoptosis by up to 65% (p < 0.01), indicating the accumulation of the GTP bound GTPases as the mediator of apoptosis. Our results point to effective anti tumor effects in breast cancer by the combination of statins and zoledronic acid and warrant further validation in preclinical settings. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Goebel, Andy; Thiele, Stefanie; Browne, Andrew J.; Rauner, Martina; Zinna, Valentina M.; Hofbauer, Lorenz C.; Rachner, Tilman D.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, D 01062 Dresden, Germany.
   [Hofbauer, Lorenz C.] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.
   [Hofbauer, Lorenz C.] German Canc Res Ctr, Heidelberg, Germany.
C3 Technische Universitat Dresden; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Rachner, TD (通讯作者)，Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, D 01062 Dresden, Germany.
EM Tilman.Rachner@uniklinikum dresden.de
RI Rauner, Martina/A 1665 2015; Hofbauer, Lorenz/G 2490 2010; Zinna,
   Valentina/AFM 1167 2022; Hofbauer, Lorenz C./G 2490 2010
OI Hofbauer, Lorenz C./0000 0002 8691 8423; Conrad,
   Stefanie/0000 0001 9345 026X; Zinna, Valentina M./0000 0002 1693 5914;
   Rauner, Martina/0000 0002 4067 6799
FU Deutsche Forschungsgemeinschaft as part of the DFG Research group
   SKELMET [RA 2151/2 1, RA 2151/3 1, RA 1923/5 1, HO 1,875/15 1, HO
   1,875/16 1]
FX The authors would like to thank Ms. Josefa Hotzel and Ms. Barbel Zeiler
   for their excellent technical assistance and Ms. Theresa Reiche for her
   secretarial assistance. The work was funded by the Deutsche
   Forschungsgemeinschaft to TDR (RA 2151/2 1 and 3 1), MR (RA 1923/5 1)
   and to LCH (HO 1,875/15 1 and 16 1) as part of the DFG Research group
   SKELMET.
CR Augspach A, 2013, TOXINS, V5, P2241, DOI 10.3390/toxins5112241
   Benad Mehner P, 2014, J BONE ONCOL, V3, P18, DOI 10.1016/j.jbo.2013.11.001
   Bendre MS, 2002, CANCER RES, V62, P5571
   Berndt N, 2011, NAT PROTOC, V6, P1775, DOI 10.1038/nprot.2011.387
   Bjarnadottir O, 2013, BREAST CANCER RES TR, V138, P499, DOI 10.1007/s10549 013 2473 6
   Borgquist S, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2146
   Brown M, 2012, BRIT J CANCER, V106, P1689, DOI 10.1038/bjc.2012.138
   BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140 6736(92)90744 N
   Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9
   Chan KKW, 2003, CLIN CANCER RES, V9, P10
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687
   Clendening JW, 2012, ONCOGENE, V31, P4967, DOI 10.1038/onc.2012.6
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Cordle A, 2005, J BIOL CHEM, V280, P34202, DOI 10.1074/jbc.M505268200
   Costa L, 2007, BREAST, V16, pS16, DOI 10.1016/j.breast.2007.10.005
   Deevi R, 2011, BRIT J CANCER, V105, P1313, DOI 10.1038/bjc.2011.384
   Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Freed Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017
   Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994
   Gnant Michael, 2011, Ther Adv Med Oncol, V3, P293, DOI 10.1177/1758834011420599
   Göbel A, 2015, BREAST CANCER RES TR, V154, P623, DOI 10.1007/s10549 015 3624 8
   Gronich N, 2013, NAT REV CLIN ONCOL, V10, P625, DOI 10.1038/nrclinonc.2013.169
   Hadji P, 2013, J BONE ONCOL, V2, P2, DOI 10.1016/j.jbo.2013.01.001
   Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152
   Hindler K, 2006, ONCOLOGIST, V11, P306, DOI 10.1634/theoncologist.11 3 306
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Katz E, 2012, ONCOTARGET, V3, P608
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim JB, 2004, BREAST CANCER RES, V6, P22, DOI 10.1186/bcr645
   Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955 0674(03)00098 X
   Mariz K, 2015, CLIN EXP METASTAS, V32, P857, DOI 10.1007/s10585 015 9750 1
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Osmak M, 2012, CANCER LETT, V324, P1, DOI 10.1016/j.canlet.2012.04.011
   Ottewell PD, 2012, BREAST CANCER RES TR, V133, P523, DOI 10.1007/s10549 011 1782 x
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 23
   Polyak K., 2011, REV SERIES INTRO HET, V121, P2011, DOI [10.1172/JC160534.3786, DOI 10.1172/JC160534.3786]
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Schmidmaier R, 2006, ANTI CANCER DRUG, V17, P621, DOI 10.1097/01.cad.0000215058.85813.02
   Thurnher M, 2013, BBA MOL CELL BIOL L, V1831, P1009, DOI 10.1016/j.bbalip.2013.03.003
   Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078 0432.CCR 12 0489
   van de Donk NWCJ, 2005, CLIN CANCER RES, V11, P429
   van de Donk NWCJ, 2003, CLIN CANCER RES, V9, P5735
   van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood 2003 03 0970
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011
   Wilke M., 2014, J Bone Oncol, V3, P10, DOI [10.1016/j.jbo.2014.02.001, DOI 10.1016/J.JBO.2014.02.001]
   Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Zhu Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.103
NR 60
TC 36
Z9 39
U1 1
U2 31
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 28
PY 2016
VL 375
IS 1
BP 162
EP 171
DI 10.1016/j.canlet.2016.03.004
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DK0NF
UT WOS:000374608800019
PM 26968247
DA 2025 08 17
ER

PT J
AU Uyama, M
   Sato, MM
   Kawanami, M
   Tamura, M
AF Uyama, Maki
   Sato, Mari M.
   Kawanami, Masamitsu
   Tamura, Masato
TI Regulation of osteoblastic differentiation by the proteasome inhibitor
   bortezomib
SO GENES TO CELLS
LA English
DT Article
ID BONE FORMATION; IN VIVO; MYELOMA; EXPRESSION; PATHWAY; CATENIN; GENE;
   WNT; IDENTIFICATION; REGENERATION
AB In eukaryotic cells, degradation of most intracellular proteins is carried out by the ubiquitin proteasome pathway. Recent investigations suggest that bone metabolism is also regulated by this pathway. The clinical efficacy of bortezomib, a 26S proteasome inhibitor used as an anticancer drug, has been linked to an increase in bone formation. In this study, we show that proteasome inhibitors induce expression of osteoblastic differentiation related genes such as osteocalcin and alkaline phosphatase in C2C12 cells. In contrast, myogenic differentiation is inhibited. Among the proteasome inhibitors tested, bortezomib induced the greatest increase in osteocalcin expression. Although these effects were similar to that of bone morphogenetic protein (BMP) 2, proteasome inhibitors did not induce transcriptional activity of Smad1/4 dependent reporter or BMP2 signaling target gene expression. Transient transfection of osteocalcin promoter luciferase constructs with bortezomib resulted in an increase in luciferase activity. Mutation of OSE2, but not OSE1, sites of the osteocalcin promoter diminished the bortezomib induced activity. Also, Runx2 binding activity and protein levels were induced by bortezomib treatment. These results suggest that the bortezomib induces osteoblastic differentiation by modifying the activity of Runx2 and that the function of the proteasome in controlling degradation of differentiation related transcription factors plays an important role in osteoblast differentiation.
C1 [Uyama, Maki; Sato, Mari M.; Tamura, Masato] Hokkaido Univ, Grad Sch Dent Med, Sapporo, Hokkaido 0608586, Japan.
   [Uyama, Maki; Kawanami, Masamitsu] Hokkaido Univ, Grad Sch Dent Med, Sapporo, Hokkaido 0608586, Japan.
C3 Hokkaido University; Hokkaido University
RP Tamura, M (通讯作者)，Hokkaido Univ, Grad Sch Dent Med, Sapporo, Hokkaido 0608586, Japan.
EM mtamura@den.hokudai.ac.jp
RI Tamura, Masato/B 7304 2009; tamura, masato/B 7304 2009
OI Tamura, Masato/0000 0003 3700 5203; 
FU Japan Ministry of Education, Culture, Sports, Science and Technology
   [22390346, 23659865]; Grants in Aid for Scientific Research [22390346,
   23659865] Funding Source: KAKEN
FX This study was supported in part by the Japan Ministry of Education,
   Culture, Sports, Science and Technology Grants in aid #22390346 and
   #23659865 (MT).
CR Borissenko L, 2007, CHEM REV, V107, P687, DOI 10.1021/cr0502504
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151
   Dahlmann B, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471 2091 8 S1 S3
   de Bettignies G, 2010, BIOCHIMIE, V92, P1530, DOI 10.1016/j.biochi.2010.06.023
   Dick LR, 2010, DRUG DISCOV TODAY, V15, P243, DOI 10.1016/j.drudis.2010.01.008
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365 2443.2002.00573.x
   Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192 2202.2001
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Obama H, 1997, J BIOL CHEM, V272, P11017
   Oerlemans R, 2008, BLOOD, V112, P2489, DOI 10.1182/blood 2007 08 104950
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Sato MM, 2009, BIOCHEM BIOPH RES CO, V383, P125, DOI 10.1016/j.bbrc.2009.03.142
   Sato MM, 2009, GENES CELLS, V14, P141, DOI 10.1111/j.1365 2443.2008.01258.x
   Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340
   Shah JJ, 2009, LEUKEMIA, V23, P1964, DOI 10.1038/leu.2009.173
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Tamura Masato, 2010, Front Biosci (Elite Ed), V2, P1405
   Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359 6101(99)00024 6
   Xing LP, 2010, J CELL BIOCHEM, V110, P554, DOI 10.1002/jcb.22586
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yu SB, 2008, J BIOL CHEM, V283, P5542, DOI 10.1074/jbc.M705653200
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293
NR 39
TC 22
Z9 25
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1356 9597
EI 1365 2443
J9 GENES CELLS
JI Genes Cells
PD JUL
PY 2012
VL 17
IS 7
BP 548
EP 558
DI 10.1111/j.1365 2443.2012.01611.x
PG 11
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 963FR
UT WOS:000305606000003
PM 22702336
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Peng, ZJ
   Zhang, WY
   Hong, H
   Liu, L
AF Peng, Zhengjun
   Zhang, Wenyu
   Hong, Hong
   Liu, Lu
TI Effect of luteolin on oxidative stress and inflammation in the human
   osteoblast cell line hFOB1.19 in an inflammatory microenvironment
SO BMC PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE Luteolin; Chronic apical periodontitis; Inflammation; Oxidative stress;
   NF kappa B signalling pathway
ID INDUCED CYTOTOXICITY; NF KB; ACTIVATION; APOPTOSIS
AB BackgroundPeriapical lesions are characterized by periapical inflammation and damage to periapical tissues and eventually lead to bone resorption and even tooth loss. H2O2 is widely used in root canal therapy for patients with periapical inflammation. Luteolin possesses high anti inflammatory, antioxidant, and anticancer potential. However, the underlying mechanism of the efficacy of H2O2 and luteolin on oxidative stress and inflammatory tissue has not been previously addressed. We aimed to investigate the anti inflammatory and antioxidative effects of luteolin on H2O2 induced cellular oxidative inflammation.MethodsAfter human osteoblasts (hFOB1.19) were treated with lipopolysaccharide (LPS), luteolin, or H2O2, cell proliferation was analysed by using a cell counting kit 8 (CCK 8), cell apoptosis was measured by using flow cytometry, the production of reactive oxygen species (ROS) was evaluated by using an oxidation sensitive probe DCFH DA ROS assay kit, and the expression of genes and proteins was detected by using reverse transcription quantitative polymerase chain reaction (RT qPCR), Western blotting, and enzyme linked immunosorbent assay (ELISA).ResultsWe demonstrated that inflammation is closely related to oxidative stress and that the oxidative stress level in the inflammatory environment is increased. Luteolin inhibited the H2O2 induced increase in the expression of interleukin 6 (IL 6), interleukin 8 (IL 8) and tumour necrosis factor alpha (TNF alpha) and significantly repressed the H2O2 induced increase in ROS, as well as markedly strengthened superoxide dismutase (SOD) activity in hFOB1.19 cells. Moreover, we detected that luteolin may inhibit H2O2 induced hFOB1.19 cell injury by suppressing the NF kappa B pathway.ConclusionWe elucidated that luteolin protected human osteoblasts (hFOB1.19) from H2O2 induced cell injury and inhibited the production of proinflammatory cytokines by suppressing the NF kappa B signalling pathway. Our findings provide a potential drug for treating H2O2 induced periodontitis and cell injury.
C1 [Peng, Zhengjun; Zhang, Wenyu; Hong, Hong; Liu, Lu] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Operat Dent & Endodont, Guanghua Sch Stomatol,Affiliated Stomatol Hosp, 56 Lingyuan Xi Rd, Guangzhou 510055, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Liu, L (通讯作者)，Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Operat Dent & Endodont, Guanghua Sch Stomatol,Affiliated Stomatol Hosp, 56 Lingyuan Xi Rd, Guangzhou 510055, Guangdong, Peoples R China.
EM liulu32@mail.sysu.edu.cn
RI Zhang, Wenyu/AAG 1128 2020; Peng, Zhengjun/GQZ 0773 2022
FU National Natural Science Foundation of China
FX None.
CR Abbasi N, 2016, IRAN J MED SCI, V41, P118
   Barnes PJ, 2020, REDOX BIOL, V33, DOI 10.1016/j.redox.2020.101544
   Braz Silva PH, 2019, ACTA ODONTOL SCAND, V77, P173, DOI 10.1080/00016357.2018.1521005
   Sczepanik FSC, 2020, PERIODONTOL 2000, V84, P45, DOI 10.1111/prd.12342
   Che DN, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106403
   Choi EM, 2011, TOXICOL IN VITRO, V25, P1671, DOI 10.1016/j.tiv.2011.07.004
   Dal Fabbro R, 2019, INT ENDOD J, V52, P329, DOI 10.1111/iej.13014
   Fasoulakis Z, 2021, CHIRURGIA BUCHAREST, V116, P170, DOI 10.21614/chirurgia.116.2.170
   Franza L, 2021, BIOFACTORS, V47, P181, DOI 10.1002/biof.1710
   Ganai SA, 2021, PHYTOTHER RES, V35, P3509, DOI 10.1002/ptr.7044
   Gendrisch F, 2021, BIOFACTORS, V47, P170, DOI 10.1002/biof.1699
   Guan XY, 2021, INT IMMUNOPHARMACOL, V98, DOI 10.1016/j.intimp.2021.107843
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Imran M, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108612
   Karteva Teodora, 2020, Folia Med (Plovdiv), V62, P238, DOI 10.3897/folmed.62.e39599
   Kocic B, 2013, J BUON, V18, P34
   Kou JJ, 2022, ACTA PHARMACOL SIN, V43, P840, DOI 10.1038/s41401 021 00702 8
   Kumar A, 2021, MOLECULES, V26, DOI 10.3390/molecules26216578
   Kwon T, 2021, INT DENT J, V71, P462, DOI 10.1111/idj.12630
   Lai JL, 2017, INFLAMMATION, V40, P1, DOI 10.1007/s10753 016 0447 7
   Li L, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2018.11.034
   Li L, 2021, ACS CHEM NEUROSCI, V12, P3314, DOI 10.1021/acschemneuro.1c00157
   Li M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01023
   Li XJ, 2022, J HEALTHC ENG, V2022, DOI 10.1155/2022/2173434
   Lin LM, 2009, J ENDODONT, V35, P607, DOI 10.1016/j.joen.2009.02.012
   Lin Y, 2008, CURR CANCER DRUG TAR, V8, P634, DOI 10.2174/156800908786241050
   Liu L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/534952
   Liu ZF, 2022, YONSEI MED J, V63, P220, DOI 10.3349/ymj.2022.63.3.220
   Ma YF, 2018, INT J MOL MED, V42, P1925, DOI 10.3892/ijmm.2018.3796
   Mao W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910665
   Minczykowski A, 2001, Clin Oral Investig, V5, P6, DOI 10.1007/s007840000095
   Mitchell JP, 2018, INT REV CEL MOL BIO, V335, P41, DOI 10.1016/bs.ircmb.2017.07.007
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Moniruzzaman M, 2018, BIOL RES, V51, DOI 10.1186/s40659 018 0168 5
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Ohl K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02499
   Ran C, 2023, FBL, V28
   Song JW, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126858
   Suh KS, 2016, CYTOTECHNOLOGY, V68, P2539, DOI 10.1007/s10616 016 9977 y
   Sui LH, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.595530
   Sul OJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26226949
   Sun WL, 2021, BIOORG CHEM, V112, DOI 10.1016/j.bioorg.2021.104966
   Thoma A, 2018, ADV EXP MED BIOL, V1088, P267, DOI 10.1007/978 981 13 1435 3_12
   Wang LN, 2022, BMC ORAL HEALTH, V22, DOI 10.1186/s12903 022 02364 2
   Wang SX, 2020, INFLAMMATION, V43, P95, DOI 10.1007/s10753 019 01099 7
   Weng YT, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101849
   Wu HH., 2021, Biosci Rep, V41, pBSR20192668
   Yang H, 2012, J ENZYM INHIB MED CH, V27, P261, DOI 10.3109/14756366.2011.587415
   Yang Y, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110044
   Yoo HS, 2022, NUTR CANCER, V74, P677, DOI 10.1080/01635581.2021.1903947
   Zhang B, 2021, J PERIODONTAL RES, V56, P991, DOI 10.1111/jre.12912
   Zhang CY, 2023, PHYTOMEDICINE, V116, DOI 10.1016/j.phymed.2023.154865
   Zhang HZ, 2020, INNATE IMMUN LONDON, V26, P259, DOI 10.1177/1753425919887236
   Zhang P, 2024, ACTA HISTOCHEM, V126, DOI 10.1016/j.acthis.2023.152118
   Zhao M, 2021, THERANOSTICS, V11, P1845, DOI 10.7150/thno.50905
   Zhao XJ, 2018, REDOX BIOL, V18, P124, DOI 10.1016/j.redox.2018.07.002
   Zhao YH, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420 020 00356 1
   Zheng YL, 2023, FREE RADICAL BIO MED, V208, P530, DOI 10.1016/j.freeradbiomed.2023.09.014
   Zhou Y, 2018, CANCER MED US, V7, P4012, DOI 10.1002/cam4.1670
NR 59
TC 6
Z9 6
U1 5
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2050 6511
J9 BMC PHARMACOL TOXICO
JI BMC Pharmacol. Toxicol.
PD JUL 12
PY 2024
VL 25
IS 1
AR 40
DI 10.1186/s40360 024 00764 4
PG 14
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA YR3A7
UT WOS:001270158800002
PM 38997762
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cheng, XT
   Zhu, Z
   Liu, YH
   Xue, YY
   Gao, XM
   Wang, J
   Pei, XB
   Wan, QB
AF Cheng, Xinting
   Zhu, Zhou
   Liu, Yanhua
   Xue, Yiyuan
   Gao, Xiaomeng
   Wang, Jian
   Pei, Xibo
   Wan, Qianbing
TI Zeolitic Imidazolate Framework 8 Encapsulating Risedronate
   Synergistically Enhances Osteogenic and Antiresorptive Properties for
   Bone Regeneration
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE zeolitic imidazolate framework 8; risedronate; drug delivery system;
   nanoparticles; bone regeneration
ID BISPHOSPHONATES; RELEASE; CELLS; HYDROXYAPATITE; NANOPARTICLES;
   MECHANISMS; SCAFFOLDS; DESIGN
AB Bisphosphonates (BPs) are routinely administered for the treatment of turnover bone diseases. To avoid the undesirable adverse effects of long term usage of bisphosphonates and improve their bioavailability in the bone microenvironment, we initially encapsulated risedronate (RIS) molecules inside nanoscale zeolitic imidazolate framework 8 particles (nZIF 8) by a one step synthesis method to generate RIS@ZIF 8 nanoparticles. RIS@ZIF 8 nanoparticles displayed high loading encapsulation efficiency (64.21 +/  2.48%), good biocompatibility, controlled drug release capacity, and dual effects for bone regeneration. This work explored the potential of RIS@ZIF 8 nanoparticles, which could not only enhance ATP production, induce extracellular matrix (ECM) mineralization, and upregulate the expression levels of osteogenic genes but also effectively inhibit the formation of multinucleated giant osteocasts and decrease the Rankl/Opg ratio. Overall, RIS@ZIF 8 nanoparticles could be a very promising approach to synergistically enhance osteogenic and antiresorptive properties for bone regeneration, which could be utilized for the local treatment of bone defects.
C1 [Cheng, Xinting; Zhu, Zhou; Liu, Yanhua; Xue, Yiyuan; Gao, Xiaomeng; Wang, Jian; Pei, Xibo; Wan, Qianbing] Sichuan Univ, West China Hosp Stomatol, Dept Prosthodont, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University
RP Pei, XB; Wan, QB (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Prosthodont, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
EM xbpei@hotmail.com; champion@scu.edu.cn
RI Wang, Jian/JWO 7247 2024; Zhu, Zhou/JUF 7436 2023; Pei,
   Xibo/JGD 3532 2023; Gao, Xiaomeng/D 4472 2017
OI Wang, Jian/0000 0002 5137 0330; Wan, Qianbing/0000 0002 0028 5881; Pei,
   Xibo/0000 0003 0386 8262; 
FU National Natural Science Foundation of China [81970984, 81601613,
   81771122, 81970985]; Key Research and Development Project of Sichuan
   Province [2018SZ0037]
FX This work was financed by the National Natural Science Foundation of
   China (Grants 81970984, 81601613, 81771122, and 81970985) and the Key
   Research and Development Project of Sichuan Province (Grant 2018SZ0037).
CR Abdik H, 2019, MOL BIOL REP, V46, P763, DOI 10.1007/s11033 018 4532 x
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Chen JY, 2017, J BIOMED MATER RES A, V105, P834, DOI 10.1002/jbm.a.35960
   Cheng XT, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671 018 2694 z
   Devi S, 2016, ANAL METHODS UK, V8, P4398, DOI 10.1039/c6ay01036a
   Dolci LS, 2019, INT J PHARMACEUT, V554, P245, DOI 10.1016/j.ijpharm.2018.11.023
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Felice B, 2018, MAT SCI ENG C MATER, V93, P724, DOI 10.1016/j.msec.2018.08.009
   Forte L, 2017, COLLOID SURFACE B, V160, P493, DOI 10.1016/j.colsurfb.2017.09.055
   Forte L, 2017, ACTA BIOMATER, V54, P419, DOI 10.1016/j.actbio.2017.02.040
   Jiang ZQ, 2019, BIOMATERIALS, V197, P41, DOI 10.1016/j.biomaterials.2019.01.001
   Kaur H, 2017, J DRUG DELIV SCI TEC, V41, P106, DOI 10.1016/j.jddst.2017.07.004
   Kubo K, 2009, BIOMATERIALS, V30, P5319, DOI 10.1016/j.biomaterials.2009.06.021
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Liu J, 2016, SCI REP UK, V6, DOI 10.1038/srep23667
   Malavasi M, 2016, ARCH ORAL BIOL, V68, P43, DOI 10.1016/j.archoralbio.2016.03.021
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   Mhaskar R., 2017, COCHRANE DB SYST REV, P115
   Park KS, 2006, P NATL ACAD SCI USA, V103, P10186, DOI 10.1073/pnas.0602439103
   Pérez R, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8080592
   Raichur V, 2017, AAPS PHARMSCITECH, V18, P2227, DOI 10.1208/s12249 016 0691 z
   Rawat P, 2015, PHARM RES DORDR, V32, P3149, DOI 10.1007/s11095 015 1692 4
   Ray S, 2018, BIOMATERIALS, V157, P1, DOI 10.1016/j.biomaterials.2017.11.049
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sahana H, 2013, J BIOMED NANOTECHNOL, V9, P193, DOI 10.1166/jbn.2013.1482
   Shen SY, 2019, J ORAL PATHOL MED, V48, P129, DOI 10.1111/jop.12801
   Shi Q, 2011, ANGEW CHEM INT EDIT, V50, P672, DOI 10.1002/anie.201004937
   Song MR, 2018, J MATER SCI, V53, P2351, DOI 10.1007/s10853 017 1716 z
   Sun CY, 2012, DALTON T, V41, P6906, DOI 10.1039/c2dt30357d
   Tiffany AS, 2019, ACTA BIOMATER, V93, P86, DOI 10.1016/j.actbio.2019.05.031
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vasconcelos IB, 2012, RSC ADV, V2, P9437, DOI 10.1039/c2ra21087h
   Wang SZ, 2018, ADV MATER, V30, DOI 10.1002/adma.201800202
   Wu Q, 2018, NANOSCALE HORIZ, V3, DOI 10.1039/c8nh00113h
   Yaghi OM, 2003, NATURE, V423, P705, DOI 10.1038/nature01650
   Yusa K, 2016, SCI REP UK, V6, DOI 10.1038/srep29462
   Zeng YZ, 2019, ACTA BIOMATER, V93, P152, DOI 10.1016/j.actbio.2019.01.060
   Zhang X, 2019, J BIOMATER APPL, V34, P396, DOI 10.1177/0885328219850976
   Zhang X, 2017, ACS APPL MATER INTER, V9, P25171, DOI 10.1021/acsami.7b07800
   Zheng HQ, 2016, J AM CHEM SOC, V138, P962, DOI 10.1021/jacs.5b11720
   Zhuang J, 2014, ACS NANO, V8, P2812, DOI 10.1021/nn406590q
NR 47
TC 18
Z9 23
U1 4
U2 112
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD APR
PY 2020
VL 6
IS 4
BP 2186
EP 2197
DI 10.1021/acsbiomaterials.0c00195
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LD9AU
UT WOS:000526319100033
PM 33455339
DA 2025 08 17
ER

PT J
AU Liu, R
   Jiao, YR
   Huang, M
   Zou, NY
   He, C
   Huang, M
   Chen, KX
   He, WZ
   Liu, L
   Sun, YC
   Xia, ZY
   Quarles, LD
   Yang, HL
   Wang, WS
   Xiao, ZS
   Luo, XH
   Li, CJ
AF Liu, Ran
   Jiao, Yu Rui
   Huang, Mei
   Zou, Nan Yu
   He, Chen
   Huang, Min
   Chen, Kai Xuan
   He, Wen Zhen
   Liu, Ling
   Sun, Yu Chen
   Xia, Zhu Ying
   Quarles, L. Darryl
   Yang, Hai Lin
   Wang, Wei Shan
   Xiao, Zhou Sheng
   Luo, Xiang Hang
   Li, Chang Jun
TI Mechanosensitive protein polycystin 1 promotes periosteal
   stem/progenitor cells osteochondral differentiation in fracture healing
SO THERANOSTICS
LA English
DT Article
DE Polycystin 1; Periosteal Stem/Progenitor Cells; Fracture healing;
   Mechanical stress
ID BONE FORMATION; SKELETAL; IDENTIFICATION; DISRUPTION; PATHWAYS; PIEZO1
AB Background: Mechanical forces are indispensable for bone healing, disruption of which is recognized as a contributing cause to nonunion or delayed union. However, the underlying mechanism of mechanical regulation of fracture healing is elusive. Methods: We used the lineage tracing mouse model, conditional knockout depletion mouse model, hindlimb unloading model and single  cell RNA sequencing to analyze the crucial roles of mechanosensitive protein polycystin 1 (PC1, Pkd1) promotes periosteal stem/progenitor cells (PSPCs) osteochondral differentiation in fracture healing. Results: Our results showed that cathepsin (Ctsk) positive PSPCs are fracture responsive and mechanosensitive and can differentiate into osteoblasts and chondrocytes during fracture repair. We found that polycystin 1 declines markedly in PSPCs with mechanical unloading while increasing in response to mechanical stimulus. Mice with conditional depletion of Pkd1 in Ctsk+ PSPCs show impaired osteochondrogenesis, reduced cortical bone formation, delayed fracture healing, and diminished responsiveness to mechanical unloading. Mechanistically, PC1 facilitates nuclear translocation of transcriptional coactivator TAZ via PC1 C terminal tail cleavage, enhancing osteochondral differentiation potential of PSPCs. Pharmacological intervention of the PC1 TAZ axis and promotion of TAZ nuclear translocation using Zinc01442821 enhances fracture healing and alleviates delayed union or nonunion induced by mechanical unloading. Conclusion: Our study reveals that Ctsk+ PSPCs within the callus can sense mechanical forces through the PC1 TAZ axis, targeting which represents great therapeutic potential for delayed fracture union or nonunion.
C1 [Liu, Ran; Jiao, Yu Rui; Huang, Mei; Zou, Nan Yu; He, Chen; Huang, Min; Chen, Kai Xuan; He, Wen Zhen; Liu, Ling; Sun, Yu Chen; Xia, Zhu Ying; Luo, Xiang Hang; Li, Chang Jun] Cent South Univ, Endocrinol Res Ctr, Dept Endocrinol, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
   [Quarles, L. Darryl; Xiao, Zhou Sheng] Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38163 USA.
   [Yang, Hai Lin] Fuyang Normal Univ, Dept Orthopaed, Affiliated Hosp 2, Fuyang 236000, Anhui, Peoples R China.
   [Wang, Wei Shan] Shihezi Univ, Dept Orthopaed, Affiliated Hosp 1, Shihezi 832061, Peoples R China.
   [Luo, Xiang Hang; Li, Chang Jun] Cent South Univ, Xiangya Hosp, Key Lab Aging related Bone & Joint Dis Prevent & T, Minist Educ, Changsha 410008, Hunan, Peoples R China.
   [Luo, Xiang Hang; Li, Chang Jun] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China.
   [Li, Chang Jun] Cent South Univ, Xiangya Hosp, Lab Anim Ctr, Changsha 410008, Hunan, Peoples R China.
C3 Central South University; University of Tennessee System; University of
   Tennessee Health Science Center; Fuyang Normal University; Shihezi
   University; Central South University; Central South University; Central
   South University
RP Li, CJ (通讯作者)，Cent South Univ, Endocrinol Res Ctr, Dept Endocrinol, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM lichangjun@csu.edu.cn
RI Liu, Ran/NKQ 4268 2025; Ji, Shouxun/AAO 6959 2020
OI Li, Changjun/0000 0003 2718 0921
FU Key Research and Development Program of Hunan Province [2023JJ30896,
   2023JJ41000]; Science and Technology Innovation Program of Hunan
   Province [2022SK2023];  [2023RC1027]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos.82261160397, 82272560, 81922017 to C. J.L. and
   81930022, 91749105 to X. H.L.), the grants R61 AR073518 and R01 AR071930
   to L. Darryl Quarles from the National Institutes of Health (NIH),the
   Hunan Provincial Science and Technology Department (2023JJ30896 to
   C. J.L. 2023JJ41000 to Z. Y.X), the Key Research and Development Program
   of Hunan Province (2022SK2023 to C. J.L.), the Science and Technology
   Innovation Program of Hunan Province (2023RC1027 to C. J.L.).r
   Department (2023JJ30896 to C. J.L. 2023JJ41000 to Z. Y.X) , the Key
   Research and Development Program of Hunan Province (2022SK2023 to
   C. J.L.) , the Science and Technology Innovation Program of Hunan
   Province (2023RC1027 to C. J.L.) .
CR [Anonymous], 2021, Lancet Healthy Longev, V2
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Augat P, 2021, INJURY, V52, pS78, DOI 10.1016/j.injury.2020.10.009
   Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Chapin HC, 2010, J CELL BIOL, V191, P701, DOI 10.1083/jcb.201006173
   Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Dai K, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00166 w
   de Lageneste OD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03124 z
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Deng RX, 2022, ADV SCI, V9, DOI 10.1002/advs.202103343
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Duda GN, 2023, NAT REV RHEUMATOL, V19, P78, DOI 10.1038/s41584 022 00887 0
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Esposito A, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115521
   Ferretti Concetta, 2014, World J Stem Cells, V6, P266, DOI 10.4252/wjsc.v6.i3.266
   Guo QY, 2023, ADV SCI, V10, DOI 10.1002/advs.202305042
   Harris PC, 2014, J CLIN INVEST, V124, P2315, DOI 10.1172/JCI72272
   He WZ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04902 w
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Jeffery EC, 2022, CELL STEM CELL, V29, P1547, DOI 10.1016/j.stem.2022.10.002
   Julien A, 2022, J BONE MINER RES, V37, P1545, DOI 10.1002/jbmr.4616
   Kegelman CD, 2021, J BONE MINER RES, V36, P143, DOI 10.1002/jbmr.4166
   Kengelbach Weigand A, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00158 8
   Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592 019 0619 0
   Li CJ, 2021, CELL METAB, V33, P1957, DOI 10.1016/j.cmet.2021.08.009
   Liu HJ, 2022, NAT GENET, V54, DOI 10.1038/s41588 022 01227 4
   Liu YL, 2022, INT J BIOL SCI, V18, P3961, DOI 10.7150/ijbs.71390
   Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385
   Mo CY, 2022, EMBO J, V41, DOI 10.15252/embj.2021108415
   Mori Y, 2016, J BONE MINER METAB, V34, P606, DOI 10.1007/s00774 015 0711 1
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Nicogossian A, 2003, LANCET, V362, pS8, DOI 10.1016/S0140 6736(03)15055 6
   Ortinau LC, 2019, CELL STEM CELL, V25, P784, DOI 10.1016/j.stem.2019.11.003
   Padovano V, 2017, MOL BIOL CELL, V28, P261, DOI 10.1091/mbc.E16 08 0597
   Qiu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046038
   Ransom RC, 2018, NATURE, V563, P514, DOI 10.1038/s41586 018 0650 9
   Reich KM, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4250940
   Shen H, 2020, J BONE MINER RES, V35, P1494, DOI 10.1002/jbmr.4018
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Sun J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz1410
   Takiar V, 2011, BBA MOL BASIS DIS, V1812, P1337, DOI 10.1016/j.bbadis.2010.11.014
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Vico L, 2018, NAT REV RHEUMATOL, V14, P229, DOI 10.1038/nrrheum.2018.37
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   Xiao ZS, 2008, J BIOL CHEM, V283, P12624, DOI 10.1074/jbc.M710407200
   Xiao ZS, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00295 4
   Xiao ZS, 2018, J CLIN INVEST, V128, P157, DOI 10.1172/JCI93725
   Xiao ZS, 2010, J BIOL CHEM, V285, P1177, DOI 10.1074/jbc.M109.050906
   Xu JJ, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00176 8
   Yang RC, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00269 6
   Zhang HY, 2022, ANN RHEUM DIS, V81, P676, DOI 10.1136/annrheumdis 2021 221513
   Zhen GH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21948 0
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zou NY, 2024, BONE RES, V12, DOI 10.1038/s41413 023 00309 1
   Zou NY, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.818462
NR 59
TC 11
Z9 11
U1 7
U2 31
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2024
VL 14
IS 6
BP 2544
EP 2559
DI 10.7150/thno.93269
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA OL6Q1
UT WOS:001207471400001
PM 38646641
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, MM
   Ji, YT
   Li, Z
   Chen, RR
   Zhou, SH
   Liu, C
   Du, MQ
AF Sun, Minmin
   Ji, Yaoting
   Li, Zhen
   Chen, Rourong
   Zhou, Shuhui
   Liu, Chang
   Du, Minquan
TI Ginsenoside Rb3 Inhibits Pro Inflammatory Cytokines via MAPK/AKT/NF κB
   Pathways and Attenuates Rat Alveolar Bone Resorption in Response to
   Porphyromonas gingivalis LPS
SO MOLECULES
LA English
DT Article
DE anti inflammatory agents; chronic periodontitis; ginsenoside;
   lipopolysaccharides
ID PERIODONTAL LIGAMENT CELLS; ESCHERICHIA COLI LIPOPOLYSACCHARIDE;
   TUMOR NECROSIS FACTOR; DIFFERENTIAL INDUCTION; HOST DEFENSE; EXPRESSION;
   ACTIVATION; INJURY; AGONIST; INNATE
AB Conventional treatments for chronic periodontitis are less effective in controlling inflammation and often relapse. Therefore, it is necessary to explore an immunomodulatory medication as an adjuvant. Ginsenoside Rb3 (Rb3), one of the most abundant active components of ginseng, has been found to possess anti inflammatory and immunomodulatory properties. Here, we detected the anti inflammatory effect of Rb3 on Porphyromonas gingivalis LPS stimulated human periodontal ligament cells and experimental periodontitis rats for the first time. We found that the expression of pro inflammatory mediators, including IL 1 beta, IL 6 and IL 8, upregulated by lipopolysaccharide (LPS) stimulation was remarkably downregulated by Rb3 treatment in a dose dependent manner at both transcriptional and translational levels. Network pharmacological analysis of Rb3 showed that the mitogen activated protein kinase (MAPK) signaling pathway had the highest richness and that p38, JNK, and ERK molecules were potential targets of Rb3 in humans. Western blot analysis revealed that Rb3 significantly suppressed the phosphorylation of p38 MAPK and p65 NF kappa B, as well as decreased the expression of total AKT. In experimental periodontitis rat models, reductions in alveolar bone resorption and osteoclast generation were observed in the Rb3 treatment group. Thus, we can conclude that Rb3 ameliorated Porphyromonas gingivalis LPS induced inflammation by inhibiting the MAPK/AKT/NF kappa B signaling pathways and attenuated alveolar bone resorption in experimental periodontitis rats.
C1 [Liu, Chang; Du, Minquan] Wuhan Univ, Minist Educ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Peoples R China.
   Wuhan Univ, Minist Educ, Sch & Hosp Stomatol, Key Lab Oral Biomed Engn, Wuhan 430079, Peoples R China.
C3 Wuhan University; Wuhan University
RP Liu, C; Du, MQ (通讯作者)，Wuhan Univ, Minist Educ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Peoples R China.
EM sunminmin@whu.edu.cn; yaotingji@whu.edu.cn; lizhen666@whu.edu.cn;
   chenrourong@whu.edu.cn; zshc07@163.com; liuc0728@whu.edu.cn;
   duminquan@whu.edu.cn
RI Sun, Minmin/LXA 9100 2024; liu, chang/E 8250 2012; Du, Min/V 7359 2018;
   Ji, Yaoting/D 2646 2019
FU National Natural Science Foundation of China [81371145, 81771084]
FX This research was funded by the National Natural Science Foundation of
   China, grant number 81371145, 81771084.
CR Aravinthan A, 2015, J GINSENG RES, V39, P206, DOI 10.1016/j.jgr.2014.12.001
   BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265
   Bi JR, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03619 7
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732
   Burns E, 2006, J IMMUNOL, V177, P8296, DOI 10.4049/jimmunol.177.12.8296
   Coats SR, 2003, INFECT IMMUN, V71, P6799, DOI 10.1128/IAI.71.12.6799 6807.2003
   CRAWFORD JM, 1978, J PERIODONTAL RES, V13, P316, DOI 10.1111/j.1600 0765.1978.tb00186.x
   Cui JH, 2012, J PSYCHOPHARMACOL, V26, P697, DOI 10.1177/0269881111415735
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Darveau RP, 2002, INFECT IMMUN, V70, P1867, DOI 10.1128/IAI.70.4.1867 1873.2002
   Drabarek B, 2012, INT J BIOCHEM CELL B, V44, P1390, DOI 10.1016/j.biocel.2012.05.022
   Eskan MA, 2007, INFECT IMMUN, V75, P892, DOI 10.1128/IAI.01604 06
   Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   Gürkan A, 2009, J PERIODONTOL, V80, P1655, DOI 10.1902/jop.2009.090031
   Herath TDK, 2011, J CLIN PERIODONTOL, V38, P694, DOI 10.1111/j.1600 051X.2011.01741.x
   Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477 1482.2001
   Hosokawa Y, 2010, MOL NUTR FOOD RES, V54, pS151, DOI 10.1002/mnfr.200900549
   Jain S, 2010, PERIODONTOL 2000, V54, P53, DOI 10.1111/j.1600 0757.2009.00333.x
   Kim WH, 2016, MOLECULES, V21, DOI 10.3390/molecules21111508
   Lalla E, 2011, NAT REV ENDOCRINOL, V7, P738, DOI 10.1038/nrendo.2011.106
   Li CH, 2007, J PERIODONTOL, V78, P1120, DOI 10.1902/jop.2007.060320
   Li X, 2011, J DENT RES, V90, P1062, DOI 10.1177/0022034510397194
   Liang L, 2014, J PERIODONTOL, V85, P618, DOI 10.1902/jop.2013.130195
   Liu YCG, 2010, PERIODONTOL 2000, V52, P163, DOI 10.1111/j.1600 0757.2009.00321.x
   Llavaneras A, 2001, J PERIODONTOL, V72, P1069, DOI 10.1902/jop.2001.72.8.1069
   Ma LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103628
   Martin M, 2001, J IMMUNOL, V167, P5278, DOI 10.4049/jimmunol.167.9.5278
   Mester A, 2019, J PERIODONTOL, V90, P911, DOI 10.1002/JPER.18 0585
   Ossola CA, 2016, J PERIODONTOL, V87, P725, DOI 10.1902/jop.2016.150612
   Ossola CA, 2012, INFLAMM RES, V61, P941, DOI 10.1007/s00011 012 0485 z
   Parahitiyawa NB, 2009, CLIN MICROBIOL REV, V22, P386, DOI 10.1128/CMR.00011 09
   Pei ZH, 2014, J PERIODONTOL, V85, P1283, DOI 10.1902/jop.2014.130635
   Qu L., 2016, CHIN J GERONTOL, V23, P5791
   Schabbauer G, 2004, ARTERIOSCL THROM VAS, V24, P1963, DOI 10.1161/01.ATV.0000143096.15099.ce
   Seo T, 2012, J MICROBIOL, V50, P311, DOI 10.1007/s12275 012 2146 x
   Shergis JL, 2013, PHYTOTHER RES, V27, P949, DOI 10.1002/ptr.4832
   Sun J, 2019, BIOMED PHARMACOTHER, V109, P254, DOI 10.1016/j.biopha.2018.09.002
   Teng YTA, 2006, J DENT RES, V85, P198, DOI 10.1177/154405910608500301
   Terrizzi AR, 2013, ARCH ORAL BIOL, V58, P1407, DOI 10.1016/j.archoralbio.2013.06.010
   Uehara A, 2007, J DENT RES, V86, P249, DOI 10.1177/154405910708600310
   Wang MY, 2018, BIOMED PHARMACOTHER, V108, P1751, DOI 10.1016/j.biopha.2018.10.018
   Wang YH, 2014, BRIT J PHARMACOL, V171, P3171, DOI 10.1111/bph.12660
   Wang Z, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4063562
   Wara aswapati N, 2013, J PERIODONTOL, V84, P1010, DOI 10.1902/jop.2012.120362
   Xing JJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12627
   Xue CC, 2011, TRIALS, V12, DOI 10.1186/1745 6215 12 164
   Yamamoto T, 2006, J PERIODONTAL RES, V41, P554, DOI 10.1111/j.1600 0765.2006.00905.x
   Yilmaz Ozlem, 2008, Microbiology (Reading), V154, P2897, DOI 10.1099/mic.0.2008/021220 0
   Zhang P, 2011, J BIOL CHEM, V286, P24159, DOI 10.1074/jbc.M110.198085
NR 50
TC 37
Z9 40
U1 3
U2 42
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2020
VL 25
IS 20
AR 4815
DI 10.3390/molecules25204815
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OM0DC
UT WOS:000585698400001
PM 33092290
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Savvidou, I
   Khong, T
   Cuddihy, A
   McLean, C
   Horrigan, S
   Spencer, A
AF Savvidou, Ioanna
   Khong, Tiffany
   Cuddihy, Andrew
   McLean, Catriona
   Horrigan, Stephen
   Spencer, Andrew
TI β Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in
   Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID WNT SIGNALING PATHWAY; BONE DISEASE; CELLS; LEUKEMIA; PROLIFERATION;
   SUMOYLATION; TBL1 TBLR1; ACTIVATION; COMPLEX; TBL1
AB Currently available treatment options are unlikely to be curative for the majority of multiple myeloma patients, emphasizing a continuing role for the introduction of investigational agents that can overcome drug resistance. The canonical Wnt/beta catenin signaling pathway, essential for self renewal, growth, and survival, has been found to be dysregulated in multiple myeloma, particularly in advanced stages of disease. This provides the rationale for evaluating the novel beta catenin inhibitor BC2059 as monotherapy and in combination with proteasome inhibitors in vitro and in vivo. Here, we show nuclear localization of beta catenin in human myeloma cell lines (HMCL), consistent with activation of the canonical Wnt pathway. BC2059 attenuates beta catenin levels, in both the cytoplasm and the nucleus, reducing the transcriptional activity of the TCF4/LEF complex and the expression of its target gene axin 2. Treatment of HMCL with BC2059 inhibits proliferation and induces apoptosis in a dose dependent manner. This is also observed in HMCL stromal cell cocultures, mitigating the protective effect afforded by the stroma. Similarly, BC2059 induces apoptosis in primary multiple myeloma samples in vitro, causing minimal apoptosis on healthy peripheral blood mononuclear cells. Furthermore, it synergizes with the proteasome inhibitor bortezomib both in HMCL and primary multiple myeloma samples. Finally, in xenograft models of human myelomatosis, BC2059 delays tumor growth and prolongs survival with minor on target side effects. Collectively, these results demonstrate the efficacy of targeting the Wnt/beta catenin pathway with BC2059 both in vitro and in vivo, at clinically achievable doses. These findings support further clinical evaluation of BC2059 for the treatment of multiple myeloma. (C) 2017 AACR.
C1 [Savvidou, Ioanna; Khong, Tiffany; Spencer, Andrew] Monash Univ, Myeloma Res Grp, Australian Ctr Blood Dis, Alfred Hosp, Melbourne, Vic, Australia.
   [Cuddihy, Andrew] Peter MacCallum Canc Ctr, Div Canc Res, Melbourne, Vic, Australia.
   [McLean, Catriona] Alfred Hosp, Dept Anat Pathol, Melbourne, Vic, Australia.
   [Horrigan, Stephen] Univ Texas Hlth Sci Ctr Houston, BetaCat Pharmaceut, Houston, TX 77030 USA.
   [Spencer, Andrew] Alfred Hosp, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Vic, Australia.
C3 Monash University; Florey Institute of Neuroscience & Mental Health;
   Howard Florey Institute Affiliates; Peter Maccallum Cancer Center;
   Florey Institute of Neuroscience & Mental Health; Howard Florey
   Institute Affiliates; University of Texas System; University of Texas
   Health Science Center Houston; Florey Institute of Neuroscience & Mental
   Health; Howard Florey Institute Affiliates
RP Spencer, A (通讯作者)，Monash Univ, Alfred Hosp, Ground Floor,South Block,Commercial Rd, Melbourne, Vic 3004, Australia.
EM aspencer@netspace.net.au
RI Savvidou, Ioanna/AAY 8687 2021
OI savvidou, Ioanna/0000 0002 3911 9741; McLean,
   Catriona/0000 0002 0302 5727; Cuddihy, Andrew/0000 0002 9898 0443
FU Monash University (Melbourne, Victoria, Australia); Australian Centre
   for Blood Diseases, Monash University/Alfred Hospital (Melbourne,
   Victoria, Australia)
FX This work was supported by the Monash University (Melbourne, Victoria,
   Australia) and Australian Centre for Blood Diseases, Monash
   University/Alfred Hospital (Melbourne, Victoria, Australia).
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154
   Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939
   Choi HK, 2011, MOL CELL, V43, P203, DOI 10.1016/j.molcel.2011.05.027
   Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Dimitrova YN, 2010, J BIOL CHEM, V285, P13507, DOI 10.1074/jbc.M109.049411
   Donati G, 2014, P NATL ACAD SCI USA, V111, pE1501, DOI 10.1073/pnas.1312880111
   Driscoll JJ, 2010, BLOOD, V115, P2827, DOI 10.1182/blood 2009 03 211045
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Fiskus W, 2015, LEUKEMIA, V29, P1267, DOI 10.1038/leu.2014.340
   Grigson ER, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117693
   Huang HJ, 2015, AM J CANCER RES, V5, P309
   Kim Y, 2011, IN VIVO, V25, P887
   Kim Y, 2011, ANTICANCER RES, V31, P725
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   Li J, 2008, NAT CELL BIOL, V10, P160, DOI 10.1038/ncb1684
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Luis TC, 2012, LEUKEMIA, V26, P414, DOI 10.1038/leu.2011.387
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mikesch JH, 2007, LEUKEMIA, V21, P1638, DOI 10.1038/sj.leu.2404732
   Mitsiades CS, 2011, J CLIN ONCOL, V29, P1916, DOI 10.1200/JCO.2010.34.0760
   Noll JE, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.38
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Park S, 2014, MAR DRUGS, V12, P3231, DOI 10.3390/md12063231
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Schmidt M, 2009, BRIT J HAEMATOL, V144, P796, DOI 10.1111/j.1365 2141.2008.07503.x
   Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Yao H, 2011, BLOOD CANC J, Ve43, P1
   Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120
   Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239
   Zhou LL, 2008, LEUKEMIA RES, V32, P1674, DOI 10.1016/j.leukres.2008.03.039
NR 35
TC 43
Z9 46
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD SEP 1
PY 2017
VL 16
IS 9
BP 1765
EP 1778
DI 10.1158/1535 7163.MCT 16 0624
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FG1IZ
UT WOS:000409550300004
PM 28500235
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Peng, HR
   Qiu, XY
   Cheng, MY
   Zhao, Y
   Song, LT
   Zhu, BJ
   Li, YY
   Liu, C
   Ren, SS
   Miao, LY
AF Peng, Haoran
   Qiu, Xinyi
   Cheng, Mingyue
   Zhao, Yue
   Song, Lutong
   Zhu, Bijun
   Li, Yuyang
   Liu, Chao
   Ren, Shuangshuang
   Miao, Leiying
TI Resveratrol loaded nanoplatform RSV@DTPF promote alveolar bone
   regeneration in OVX rat through remodeling bone immune microenvironment
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
ID MACROPHAGE POLARIZATION; DIFFERENTIATION; PREVENTION; MECHANISMS;
   GRAFTS; DNA; ROS
AB The reconstruction of alveolar bone defect is essential for periodontal regenerative therapy or subsequent prosthetic/implant therapy, particularly in individuals with systemic diseases, such as osteoporosis. ROS accumulation, coupled with aberrant macrophage polarization, is pivotal in the pathogenesis of osteoporosis and contributes to the disequilibrium between bone and the immune system. Consequently, therapeutic strategies targeting the immune microenvironment present a promising approach to the treatment of in situ alveolar bone regeneration in osteoporotic condition. Herein, we present a novel nano platform denoted as RSV@DTPF, designed to target macrophage and facilitate the controllable release of resveratrol in a ROS responsive behavior. This approach aims to modulate the tampered immune microenvironment. The conjugated folate moiety selectively interacts with the folate receptors expressed on the macrophage surface, thereby augmenting cellular uptake. While the thioketal bond would break down when sensing a high level of intracellular ROS and release the encapsulated RSV. In vitro experiments suggested that designated nanoparticles could scavenge ROS effectively and restore the M1/M2 ratio in a lipopolysaccharide (LPS)  stimulated inflammation environment; The co culture experiment provided evidence substantiating the adeptness of the modified immune milieu in fostering osteoblast dif ferentiation, while concurrently impeding osteoclast maturation. Furthermore, through comprehensive imaging and histopathological evaluations, we elucidate the potential of RSV@DTPF in promoting osteogenesis within a periodontal defect model utilizing ovariectomized (OVX) rats. This in vivo study substantiates the advantageous impact of the nanoplatform on alveolar bone regeneration and its associated immunomodulatory effects. In summary, the RSV@DTPF nanoplatform exhibited the capacity to orchestrate immune microenvironmental shifts and enhance alveolar bone generation ability in osteoporosis and also could be expected to be applied in other biomedical fields associated with redox metabolism imbalance.
C1 [Peng, Haoran; Qiu, Xinyi; Cheng, Mingyue; Zhao, Yue; Song, Lutong; Zhu, Bijun; Li, Yuyang; Ren, Shuangshuang; Miao, Leiying] Nanjing Univ, Nanjing Stomatol Hosp, Dept Cariol & Endodont, Med Sch,Affiliated Hosp, Nanjing, Peoples R China.
   [Liu, Chao] Nanjing Univ, Med Sch, Dept Orthodont, Nanjing Stomatol Hosp,Affiliated Hosp, Nanjing, Peoples R China.
   [Peng, Haoran; Qiu, Xinyi; Cheng, Mingyue; Zhao, Yue; Song, Lutong; Zhu, Bijun; Li, Yuyang] Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Cent Lab Stomatol,Affiliated Hosp, Nanjing, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University
RP Ren, SS; Miao, LY (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Dept Cariol & Endodont, Med Sch,Affiliated Hosp, Nanjing, Peoples R China.; Liu, C (通讯作者)，Nanjing Univ, Med Sch, Dept Orthodont, Nanjing Stomatol Hosp,Affiliated Hosp, Nanjing, Peoples R China.
EM dxliuchao@163.com; zjndrenss@163.com; lymiao@nju.edu.cn
RI Peng, haoran/JQV 9583 2023; Liu, Chao/KTH 9395 2024; Zhu,
   Bijun/KFT 0402 2024
FU Natural Science Foundation of Jiangsu Province [BK20221177, BK20200665];
   National Natural Science Foundation of China [82001049]; Medical Science
   and Technology Development Foundation, Nanjing Department of Health
   [ZKX22055]
FX This study was supported by the Natural Science Foundation of Jiangsu
   Province under Grant [BK20221177; BK20200665] ; the National Natural
   Science Foundation of China [No. 82001049] ; and the Key Project
   supported by the Medical Science and Technology Development Foundation,
   Nanjing Department of Health under Grant [number ZKX22055] .
CR Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Brennan MA, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909125
   Burkhardt S, 2001, INT J BIOCHEM CELL B, V33, P775, DOI 10.1016/S1357 2725(01)00052 8
   CARIDE VJ, 1984, J CARDIOVASC PHARM, V6, P996
   Cheuk IW, 2022, CLIN TRANSL ONCOL, V24, P854, DOI 10.1007/s12094 021 02731 5
   D'Autréaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Damani JJ, 2023, J INFLAMM RES, V16, P639, DOI 10.2147/JIR.S397837
   De Santa F, 2019, ANTIOXID REDOX SIGN, V30, P1553, DOI 10.1089/ars.2017.7420
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   El Mohtadi F, 2020, BIOMACROMOLECULES, V21, P305, DOI 10.1021/acs.biomac.9b01348
   Fillingham Y, 2016, BONE JOINT J, V98B, P6, DOI [10.1302/0301 620X.98B1.36350, 10.1302/0301 620X.98B.36350]
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Gao ZH, 2022, EXP GERONTOL, V165, DOI 10.1016/j.exger.2022.111836
   Gong L, 2016, ANN CLIN LAB SCI, V46, P65
   Han J, 2018, ACS NANO, V12, P1959, DOI 10.1021/acsnano.7b09107
   He LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031717
   Jain S, 2015, BIOMATERIALS, V61, P162, DOI 10.1016/j.biomaterials.2015.05.028
   Lassus J, 1998, CLIN ORTHOP RELAT R, P7
   Li HZ, 2016, ANN NY ACAD SCI, V1370, P109, DOI 10.1111/nyas.13102
   Li TC, 2023, BIOMED MATER, V18, DOI 10.1088/1748 605X/acd672
   Marchal J, 2013, ANN NY ACAD SCI, V1290, P67, DOI 10.1111/nyas.12214
   Marchev AS, 2017, ANN NY ACAD SCI, V1401, P114, DOI 10.1111/nyas.13407
   McAllister BS, 2007, J PERIODONTOL, V78, P377, DOI 10.1902/jop.2007.060048
   Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Mobasheri A, 2013, ANN NY ACAD SCI, V1290, P59, DOI 10.1111/nyas.12145
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Narmani A, 2019, DRUG DEVELOP RES, V80, P404, DOI 10.1002/ddr.21545
   Ni C, 2019, BIOMATERIALS, V206, P115, DOI 10.1016/j.biomaterials.2019.03.039
   Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084
   Patel D, 2023, DRUG DELIV TRANSL RE, V13, P419, DOI 10.1007/s13346 022 01222 6
   Ponzetti M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00236
   Qiu XY, 2021, ACTA BIOMATER, V135, P593, DOI 10.1016/j.actbio.2021.08.009
   Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Saxena Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687037
   Sergides C, 2016, EXP THER MED, V11, P164, DOI 10.3892/etm.2015.2895
   Sghaireen MG, 2023, CURR PEDIATR REV, V19, P15, DOI 10.2174/1573396318666220411105715
   Steinz MM, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.819163
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tonelli P, 2011, CLIN CASES MINER BON, V8, P24
   VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022 1759(89)90178 6
   Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749 6632.2010.05842.x
   Wang YF, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100904
   Wang YH, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e50
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wong RHX, 2020, J BONE MINER RES, V35, P2121, DOI 10.1002/jbmr.4115
   Xu HH, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108650
   Yang J, 2019, J AGR FOOD CHEM, V67, P1726, DOI 10.1021/acs.jafc.8b03662
   Yu H, 2021, ASIAN J PHARM SCI, V16, P432, DOI 10.1016/j.ajps.2020.11.001
   Zhang J, 2022, ADV MATER, V34, DOI 10.1002/adma.202202044
   Zhu XD, 2020, J MATERN FETAL NEO M, V33, P4150, DOI 10.1080/14767058.2019.1597846
NR 55
TC 17
Z9 17
U1 17
U2 86
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD NOV 15
PY 2023
VL 476
AR 146615
DI 10.1016/j.cej.2023.146615
EA OCT 2023
PG 12
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA X1YI2
UT WOS:001096473400001
OA hybrid
DA 2025 08 17
ER

PT J
AU Jeka, S
   Dokoupilová, E
   Kivitz, A
   Zuchowski, P
   Vogg, B
   Krivtsova, N
   Sekhar, S
   Banerjee, S
   Schwebig, A
   Poetzl, J
   Body, JJ
   Eastell, R
AF Jeka, Slawomir
   Dokoupilova, Eva
   Kivitz, Alan
   Zuchowski, Pawel
   Vogg, Barbara
   Krivtsova, Natalia
   Sekhar, Susmit
   Banerjee, Samik
   Schwebig, Arnd
   Poetzl, Johann
   Body, Jean Jacques
   Eastell, Richard
TI Equivalence trial of proposed denosumab biosimilar GP2411 and reference
   denosumab in postmenopausal osteoporosis: the ROSALIA study
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE diseases and disorders of/related to bone: osteoporosis; clinical
   trials; bone modeling and remodeling: biochemical markers of bone
   turnover
ID BONE MINERAL DENSITY; WOMEN
AB Denosumab is a monoclonal antibody used to reduce risk of fractures in osteoporosis. ROSALIA was a multicenter, double blind, randomized, integrated phase I/phase III study comparing the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and safety of proposed biosimilar denosumab GP2411 with reference denosumab (REF DMAb) (Prolia (R); Amgen). Postmenopausal women with osteoporosis were randomized 1:1 to 2 60 mg doses of GP2411 or REF DMAb, one at study start and one at week 26. At week 52, the REF DMAb group was re randomized 1:1 to a third dose of REF DMAb or switch to GP2411. The primary efficacy endpoint was percentage change from baseline (%CfB) in LS BMD at week 52. Secondary efficacy endpoints were %CfB in LS BMD, FN BMD, and TH BMD at weeks 26 and 78 (and week 52 for FN BMD and TH BMD). Primary PK and PD endpoints were the area under the serum concentration time curve extrapolated to infinity and maximum drug serum concentration at week 26, and the area under the effect time curve of the %CfB in serum CTX at week 26. Secondary PK and PD endpoints included drug serum concentrations and %CfB in serum CTX and P1NP during the study period. Similar efficacy was demonstrated at week 52, with 95% CIs of the difference in %CfB in LS BMD between treatment groups fully contained within prespecified equivalence margins. Similarity in PK and PD was demonstrated at week 26. Immunogenicity was similar between groups and was not impacted by treatment switch. The rate of new vertebral fractures was comparable. Treatment emergent adverse events were comparable between groups (63.6% [GP2411/GP2411]; 76.0% [REF DMAb/REF DMAb]; 76.6% [REF DMAb/GP2411]). In conclusion, ROSALIA showed similar efficacy, PK and PD, and comparable safety and immunogenicity of GP2411 to REF DMAb in postmenopausal osteoporosis.
C1 [Jeka, Slawomir; Zuchowski, Pawel] Univ Hosp 2 Bydgoszcz, Clin & Dept Rheumatol & Syst Dis Connect Tissue, CM UMK, 85 168Bydgoszcz, KP, PL 85168 Bydgoszcz, KP, Poland.
   [Dokoupilova, Eva] Med Plus Sro, Uherske Hradiste 68601, ZL, Czech Republic.
   [Dokoupilova, Eva] Masaryk Univ, Fac Pharm, Dept Pharmaceut Technol, Brno 61200, JM, Czech Republic.
   [Kivitz, Alan] Altoona Ctr Clin Res, Duncansville, PA 16635 USA.
   [Vogg, Barbara; Krivtsova, Natalia; Sekhar, Susmit; Banerjee, Samik; Schwebig, Arnd; Poetzl, Johann] Hexal AG, Clin Dev Biopharmaceut, D 83607 Holzkirchen, BY, Germany.
   [Body, Jean Jacques] Univ Libre Bruxelles ULB, Univ Hosp Brugmann, Dept Med, B 1020 Brussels, BE, Belgium.
   [Eastell, Richard] Univ Sheffield, Div Clin Med, Sheffield S10 2TN, SYK, England.
C3 Nicolaus Copernicus University; Masaryk University Brno; Altoona Center
   for Clinical Research; Hexal AG; Universite Libre de Bruxelles;
   University of Sheffield
RP Vogg, B (通讯作者)，Hexal AG, Clin Dev Biopharmaceut, D 83607 Holzkirchen, BY, Germany.
EM s.jeka@wp.pl; eva.dokoupil@gmail.com; ajkivitz@yahoo.com;
   p.zuchowski81@gmail.com; barbara.vogg@sandoz.com;
   natalia.krivtsova@sandoz.com; susmit.sekhar@sandoz.com;
   samik.banerjee@sandoz.com; arnd.schwebig@sandoz.com;
   johann.poetzl@sandoz.com; jean jacques.body@chu brugmann.be;
   r.eastell@sheffield.ac.uk
RI Żuchowski, Paweł/GQA 9319 2022; Body, Jean Jacques/G 9785 2015; Eastell,
   Richard/G 5851 2011
OI Krivtsova, Natalia/0009 0009 7326 692X
FU Hexal AG; Hexal AG (a Sandoz company)
FX Editorial support was provided by Syneos Health and funded by Hexal AG
   (a Sandoz company). Final approval of the manuscript rested solely with
   the scientific authors.
CR [Anonymous], 2022, Xgeva (Denosumab) [Package Insert], V2022
   [Anonymous], 2020, Xgeva (Denosumab). European Medicines Agency SmPC, V2020
   [Anonymous], 2022, Prolia (Denosumab). European Medicines Agency SmPC, V2022
   [Anonymous], 2015, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry
   [Anonymous], 2023, Prolia (Denosumab) [Package Insert], V2023
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Canadian Agency for Drugs and Technologies in Health, 2015, Common Drug Review Pharmacoeconomic Report for Prolia [Internet]
   Civoli F, 2020, AAPS J, V22, DOI 10.1208/s12248 019 0386 y
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   European Medicines Agency, 2019, Biosimilars in the EU: information guide for healthcare professionals
   FDA, 2019, IMMUNOGENICITY TESTI
   Karnon J, 2016, COST EFFECT RESOUR A, V14, DOI 10.1186/s12962 016 0060 5
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Kvien TK, 2022, SEMIN ARTHRITIS RHEU, V52, DOI 10.1016/j.semarthrit.2021.11.009
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Moore TJ, 2021, JAMA INTERN MED, V181, P52, DOI 10.1001/jamainternmed.2020.3997
   Niazi SK., 2022, Biologics, V2, P171, DOI [10.3390/biologics2030014, DOI 10.3390/BIOLOGICS2030014]
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Weise M, 2012, BLOOD, V120, P5111, DOI 10.1182/blood 2012 04 425744
   Zheng J, 2015, J PHARMACOKINET PHAR, V42, P333, DOI 10.1007/s10928 015 9422 4
NR 22
TC 10
Z9 10
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR 19
PY 2024
VL 39
IS 3
BP 202
EP 210
DI 10.1093/jbmr/zjae016
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OF1B0
UT WOS:001205748100001
PM 38477751
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Ren, YF
   Zhang, TH
   Zhong, S
   Zhao, YT
   Lv, YN
AF Ren, Yuan Fei
   Zhang, Tie Hui
   Zhong, Sheng
   Zhao, Yan Tao
   Lv, Ya Nan
TI miR 144 suppresses proliferation and induces apoptosis of osteosarcoma
   cells via direct regulation of mTOR expression
SO ONCOLOGY LETTERS
LA English
DT Article
DE osteosarcoma; microRNA 144; mammalian target of rapamycin signaling
   pathway; gene therapy
ID DOWN REGULATION; MICRORNA SIGNATURES; CANCER; METASTASIS; GROWTH; GENES;
   CONSERVATION; TARGET; MIRNA
AB Studied as a type of tumor suppressor, microRNA (miR) performs an important role in growth and apoptosis of various human carcinomas. However, the effects of miR 144 on osteosarcoma growth and apoptosis, as well as possible underlying mechanisms, remain unclear. The present study investigated the expression of miR 144 in osteosarcoma MG 63 and U 2 OS cell lines compared with osteoblast cells. In order to elucidate the effects of miR 144 on osteosarcoma, miR 144 was upregulated in MG 63 and U 2 OS cells by transfecting chemically synthesized miR 144 mimics. Bioinformatics analysis of potential miR 144 target genes was performed using TargetScanHuman 7.0 and confirmed by luciferase assay. This analysis identified mammalian target of rapamycin (mTOR) as a target of miR 144. The present results indicated that the overexpression of miR 144 may significantly inhibit proliferation and promote apoptosis of MG 63 and U 2 cells compared with scramble control. Furthermore, the effects of miR 144 on osteosarcoma were associated with the mTOR signaling pathway via directly targeting the 3' untranslated region of mTOR mRNA, resulting in a decrease in the level of mTOR protein. In summary, miR 144 was demonstrated to act as a tumor suppressor, which inhibits proliferation and promotes apoptosis of osteosarcoma cell lines. In addition, this effect was mediated by direct targeting on mTOR following inhibition of the mTOR signaling pathway. The present study suggested that miR 144 may be a candidate for the gene therapy of osteosarcoma.
C1 [Ren, Yuan Fei; Zhang, Tie Hui; Zhong, Sheng; Zhao, Yan Tao] Dalian Municipal Cent Hosp, Dept Hand & Foot Surg, Dalian 116033, Liaoning, Peoples R China.
   [Lv, Ya Nan] Dalian Municipal Cent Hosp, Dept Radiol, 826 Xinan Rd, Dalian 116033, Liaoning, Peoples R China.
RP Lv, YN (通讯作者)，Dalian Municipal Cent Hosp, Dept Radiol, 826 Xinan Rd, Dalian 116033, Liaoning, Peoples R China.
EM lvyanan1203@163.com
CR Acunzo Mario, 2015, Adv Biol Regul, V57, P1, DOI 10.1016/j.jbior.2014.09.013
   Altuvia Y, 2005, NUCLEIC ACIDS RES, V33, P2697, DOI 10.1093/nar/gki567
   Bologna Molina R, 2013, MED ORAL PATOL ORAL, V18, pE174, DOI 10.4317/medoral.18573
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cao TJ, 2014, TUMOR BIOL, V35, P10759, DOI 10.1007/s13277 014 2017 7
   Castilla Carmen, 2012, Skinmed, V10, P90
   Chen K, 2006, COLD SPRING HARB SYM, V71, P149, DOI 10.1101/sqb.2006.71.039
   Di Leva G, 2014, ANNU REV PATHOL MECH, V9, P287, DOI 10.1146/annurev pathol 012513 104715
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Geissler EK, 2008, AM J TRANSPLANT, V8, P2212, DOI 10.1111/j.1600 6143.2008.02391.x
   Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669
   Guo YW, 2013, FEBS J, V280, P4531, DOI 10.1111/febs.12417
   Huang Fang, 2011, Zhonghua Xin Xue Guan Bing Za Zhi, V39, P353, DOI 10.3760/cma.j.issn.0253 3758.2011.04.015
   Iwaya T, 2012, CARCINOGENESIS, V33, P2391, DOI 10.1093/carcin/bgs288
   Juríková M, 2016, ACTA HISTOCHEM, V118, P544, DOI 10.1016/j.acthis.2016.05.002
   Kalimutho M, 2011, J GASTROENTEROL, V46, P1391, DOI 10.1007/s00535 011 0456 0
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Latronico MVG, 2008, PHYSIOL GENOMICS, V34, P239, DOI 10.1152/physiolgenomics.90254.2008
   Li Yu, 2012, Genomics Proteomics & Bioinformatics, V10, P246, DOI 10.1016/j.gpb.2012.07.005
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923
   Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300 483X(02)00460 2
   Rossing M, 2012, J MOL ENDOCRINOL, V48, P11, DOI 10.1530/JME 11 0039
   Ruggieri P, 2011, EXPERT REV PHARM OUT, V11, P59, DOI 10.1586/ERP.10.91
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171
   Serpico D, 2014, CANCER TREAT REV, V40, P595, DOI 10.1016/j.ctrv.2013.11.002
   Tian YH, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870 014 0226 2
   Tong FY, 2014, DIGEST DIS SCI, V59, P24, DOI 10.1007/s10620 013 2887 3
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang Ping, 2010, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V24, P535
   Wang W, 2015, ONCOTARGET, V6, P10297, DOI 10.18632/oncotarget.3305
   Wang WZ, 2011, INT J CANCER, V129, P1624, DOI 10.1002/ijc.25818
   Xue J, 2014, TUMOR BIOL, V35, P12103, DOI 10.1007/s13277 014 2513 9
   Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122
   Ying SY, 2008, MOL BIOTECHNOL, V38, P257, DOI 10.1007/s12033 007 9013 8
   Yu ML, 2015, CARDIOVASC PATHOL, V24, P375, DOI 10.1016/j.carpath.2015.06.003
   Zha WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074175
   Zhang EY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103440
   Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008 5472.CAN 08 4385
   Zhang XW, 2010, J MOL CELL CARDIOL, V49, P841, DOI 10.1016/j.yjmcc.2010.08.007
   Zhao MD, 2014, INT J MOL MED, V34, P1565, DOI 10.3892/ijmm.2014.1963
NR 43
TC 19
Z9 21
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JAN
PY 2018
VL 15
IS 1
BP 1163
EP 1169
DI 10.3892/ol.2017.7364
PN B
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FX5UC
UT WOS:000426144900064
PM 29387244
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, J
   Li, YZ
   Liu, Y
   Zhang, Q
   Zhang, Q
   Chen, JB
   Yan, X
   Yuan, X
AF Yang, Jing
   Li, Yazhen
   Liu, Ying
   Zhang, Qiang
   Zhang, Qi
   Chen, Junbo
   Yan, Xiao
   Yuan, Xiao
TI Role of the SDF 1/CXCR4 signaling pathway in cartilage and subchondral
   bone in temporomandibular joint osteoarthritis induced by overloaded
   functional orthopedics in rats
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Temporomandibular joint osteoarthritis; Overloaded functional
   orthopedics; Subchondral bone; SDF 1/CXCR4
ID ARTICULAR CARTILAGE; OSTEOGENIC DIFFERENTIATION; APPLIANCE THERAPY;
   ANGIOGENESIS; OSSIFICATION; DEGRADATION; ATTENUATION; CHEMOKINES;
   PHENOTYPE; CONDYLE
AB Objectives: To (i) use a mandibular advancement appliance in rats to investigate the role of the stromal cell derived factor/CXC receptor 4 (SDF 1/CXCR4) signaling pathway in temporomandibular joint osteoarthritis (TMJ OA) induced by overloaded functional orthopedics (OFO) and (ii) provide a cellular and molecular basis for efficacious treatment of skeletal class II malocclusion and avoidance of TMJ OA.
   Method: Male Sprague Dawley rats (6 weeks) were divided randomly into control + normal saline (NS), EXP + ADM3100 (SDF 1 antagonist), EXP + NS, and control + ADM3100 groups. Changes in articular cartilage and subchondral bone after TMJ OA in these four groups were observed by hematoxylin and eosin (H&E), immunofluorescence double staining (IDS), Safranin O staining, immunohistochemical (IHC) staining, real time polymerase chain reaction, and micro computed tomography at 2, 4, and 8 weeks.
   Results: OFO led to increased expression of SDF 1, CXCR4, and matrix metalloproteinase (MMP) 13 and decreased expression of collagen II. The thickness of the hypertrophic cartilage layer was reduced at 4 weeks in the EXP + NS group, and damage to subchondral bone was observed at 2 weeks. Using ADM3100 to inhibit SDF 1 signaling could attenuate expression of MMP13, cartilage damage, and osteoblast differentiation. IDS showed that the areas of expression of SDF 1 and OSX in subchondral bone overlapped.
   Conclusions: Overloaded functional orthopedics (OFO) induced TMJ OA. The destruction of subchondral bone in TMJ OA caused by OFO occurred before damage to cartilage. SDF 1/CXCR4 may induce the osteogenic differentiation and cause cartilage degradation in TMJ OA caused by OFO.
C1 [Yang, Jing; Zhang, Qiang; Yan, Xiao; Yuan, Xiao] Qingdao Univ, Affiliated Hosp, Dept Orthodont, Jiangsu Rd 16, Qingdao 266000, Shandong, Peoples R China.
   [Yang, Jing] Qingdao Stomatol Hosp, Qingdao, Shandong, Peoples R China.
   [Li, Yazhen] Sichuan Univ, West China Sch Stomatol, Chengdu, Sichuan, Peoples R China.
   [Liu, Ying] Shandong Univ, Affiliated Hosp 4, Jinan, Shandong, Peoples R China.
   [Zhang, Qi; Chen, Junbo] Qingdao Univ, Sch Stomatol, Qingdao, Shandong, Peoples R China.
C3 Qingdao University; Sichuan University; Shandong University; Qingdao
   University
RP Yan, X; Yuan, X (通讯作者)，Qingdao Univ, Affiliated Hosp, Dept Orthodont, Jiangsu Rd 16, Qingdao 266000, Shandong, Peoples R China.
EM yuanxiao0409@163.com; yuanxiaoqd@163.com
RI Liu, Ying/KCZ 2417 2024; Wang, Lingwei/KIK 3478 2024; Zhang,
   Qiang/GYU 6211 2022
OI Yuan, Xiao/0000 0003 3590 1805; Chen, junbo/0000 0002 1623 6339
FU National Natural Science Foundation of China [31870929]
FX The study was supported by the National Natural Science Foundation of
   China (31870929).
CR Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340
   Castañeda S, 2012, BIOCHEM PHARMACOL, V83, P315, DOI 10.1016/j.bcp.2011.09.018
   Chen S, 2019, ARCH ORAL BIOL, V97, P67, DOI 10.1016/j.archoralbio.2018.10.005
   Chen Y, 2017, OSTEOARTHR CARTILAGE, V25, P986, DOI 10.1016/j.joca.2017.01.008
   Chu JG, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1399 2
   Cozza P, 2006, AM J ORTHOD DENTOFAC, V129, DOI 10.1016/j.ajodo.2005.11.010
   Ding M, 2002, J BONE JOINT SURG BR, V84B, P900, DOI 10.1302/0301 620X.84B6.11994
   Findlay DM, 2014, CURR OSTEOPOROS REP, V12, P127, DOI 10.1007/s11914 014 0192 5
   Funck Brentano T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033543
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Hosogane N, 2010, INT J BIOCHEM CELL B, V42, P1132, DOI 10.1016/j.biocel.2010.03.020
   Imhof H., 2000, Invest Radiol, V35
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Lacourt M, 2012, OSTEOARTHR CARTILAGE, V20, P572, DOI 10.1016/j.joca.2012.02.004
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li X, 2018, ULTRASOUND MED BIOL
   Liu C, 2013, INT J MED SCI, V10, P1181, DOI 10.7150/ijms.6657
   Liu H, 2017, WOUND REPAIR REGEN, V25, P652, DOI 10.1111/wrr.12552
   Liu YD, 2014, OSTEOARTHR CARTILAGE, V22, P302, DOI 10.1016/j.joca.2013.11.014
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Mazzetti E, 2004, ARTHRITIS RHEUM US, V50, P112, DOI 10.1002/art.11474
   MCNAMARA JA, 1981, ANGLE ORTHOD, V51, P177
   Petrovic A., 1975, DETERMINANTS MANDIBU
   Rabie ABM, 2003, AM J ORTHOD DENTOFAC, V123, P40, DOI 10.1067/mod.2003.45
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Sobue T, 2011, J DENT RES, V90, P512, DOI 10.1177/0022034510390810
   Tanaka E, 2008, J DENT RES, V87, P296, DOI 10.1177/154405910808700406
   Tang GH, 2005, J DENT RES, V84, P166, DOI 10.1177/154405910508400211
   Utreja A, 2016, OSTEOARTHR CARTILAGE, V24, P335, DOI 10.1016/j.joca.2015.08.010
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Wang T, 2013, OSTEOARTHR CARTILAGE, V21, P574, DOI 10.1016/j.joca.2013.01.002
   Wang XH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0047703, 10.1371/journal.pone.0032405]
   Wang Y, 2005, CHANGES EXPRESSION M
   Wang YL, 2014, ORAL DIS, V20, P301, DOI 10.1111/odi.12112
   Wei FY, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3930
   WOODSIDE DG, 1987, AM J ORTHOD DENTOFAC, V92, P181, DOI 10.1016/0889 5406(87)90411 2
   Yang F, 2018, CELL PHYSIOL BIOCHEM, V46, P2561, DOI 10.1159/000489684
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Zhang X, 2013, J ORAL REHABIL, V40, P500, DOI 10.1111/joor.12072
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
NR 40
TC 14
Z9 16
U1 2
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD AUG 14
PY 2020
VL 15
IS 1
AR 330
DI 10.1186/s13018 020 01860 x
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA NE7VZ
UT WOS:000562813200007
PM 32795379
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Frattini, A
   Vezzoni, P
   Villa, A
   Sobacchi, C
AF Frattini, Annalisa
   Vezzoni, Paolo
   Villa, Anna
   Sobacchi, Cristina
TI The dissection of human autosomal recessive osteopetrosis identifies an
   osteoclast poor form due to RANKL deficiency
SO CELL CYCLE
LA English
DT Article
DE osteopetrosis; osteoclast; RANKL; immunological; defects; therapy
ID FACTOR FAMILY MEMBER; COLONY STIMULATING FACTOR; VACUOLAR PROTON PUMP;
   BONE RESORPTION; MALIGNANT OSTEOPETROSIS; TARGETED DISRUPTION; KEY
   REGULATOR; A3 SUBUNIT; C FOS; MUTATIONS
AB Genetic dissection of human recessive osteopetroses (ARO) has identified specific subsets due to a defect in molecules linked to the effector function of mature osteoclasts. While an impairment in osteoclast differentiation in mouse leads to osteopetrosis, the four genes identified so far in classical human ARO (TCIRG1, CLCN7, OSTM1 and PLEKHM1) are all involved in the resorption and/or intracellular traffic of the minerals solubilised from bone matrix. The recent finding that the RANKL gene is mutated in a subset of ARO patients whose biopsies did not show any osteoclast shows that a differentiation defect can be responsible for human ARO and paves the way to a potential rational therapy of this rare disease by soluble RANKL administration.
C1 [Frattini, Annalisa; Vezzoni, Paolo; Villa, Anna; Sobacchi, Cristina] Inst Biomed Technologies, Dept Human Genome, Milan, Italy.
   [Frattini, Annalisa; Vezzoni, Paolo; Villa, Anna; Sobacchi, Cristina] Ist Clin Humanitas, Rozzano, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie
   Biomediche (ITB CNR); IRCCS Humanitas Research Hospital
RP Frattini, A (通讯作者)，Inst Biomed Technologies, Via Fratelli Cervi 93, I 20090 Milan, Italy.
EM annalisa.frattini@itb.cnr.it
RI SOBACCHI, CRISTINA/J 9345 2018; Sobacchi, Cristina/J 9345 2018;
   Frattini, Annalisa/B 7684 2015; Vezzoni, Paolo/R 3416 2019
OI Vezzoni, Paolo/0000 0002 6382 3923; Villa, Anna/0000 0003 4428 9013;
   Sobacchi, Cristina/0000 0002 2684 7184; Frattini,
   Annalisa/0000 0002 1166 3091; 
FU Telethon [GGP07059] Funding Source: Medline; Fondazione Telethon Funding
   Source: Custom
CR BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Blair HC, 2004, J BONE MINER RES, V19, P1329, DOI 10.1359/JBMR.040403
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Flanagan AM, 2000, J BONE MINER RES, V15, P352, DOI 10.1359/jbmr.2000.15.2.352
   Flanagan AM, 2002, BONE, V30, P85, DOI 10.1016/S8756 3282(01)00656 1
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Frattini A, 2005, P NATL ACAD SCI USA, V102, P14629, DOI 10.1073/pnas.0507637102
   Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740
   GERRITSEN EJA, 1994, PEDIATRICS, V93, P247
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   HOLTROP ME, 1981, METAB BONE DIS RELAT, V3, P123, DOI 10.1016/0221 8747(81)90030 8
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jiao XD, 2004, AM J HUM GENET, V75, P878, DOI 10.1086/425080
   JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092 8674(92)90592 Z
   Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923
   Kim D, 2000, J EXP MED, V192, P1467, DOI 10.1084/jem.192.10.1467
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kwee ML, 2005, J BONE MINER RES, V20, P1254, DOI 10.1359/JBMR.050303
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Meadows NA, 2007, J BIOL CHEM, V282, P1891, DOI 10.1074/jbc.M608572200
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049
   Nicholls BM, 2005, J BONE MINER RES, V20, P2264, DOI 10.1359/JBMR.050807
   Odgren PR, 2003, CONNECT TISSUE RES, V44, P264, DOI 10.1080/03008200390181753
   Pangrazio A, 2006, J BONE MINER RES, V21, P1098, DOI 10.1359/JBMR.060403
   Rudolph D, 2000, GENE DEV, V14, P854
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   Scimeca JC, 2003, HUM MUTAT, V21, P151, DOI 10.1002/humu.10165
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SLY WS, 1983, P NATL ACAD SCI BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Susani L, 2004, HUM MUTAT, V24, P225, DOI 10.1002/humu.20076
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Van Wesenbeeck L, 2005, CRIT REV EUKAR GENE, V15, P133, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.40
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Van Wesenbeeck L, 2007, J CLIN INVEST, V117, P919, DOI 10.1172/JCI30328
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 68
TC 10
Z9 10
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4101
EI 1551 4005
J9 CELL CYCLE
JI Cell Cycle
PD DEC 15
PY 2007
VL 6
IS 24
BP 3027
EP 3033
DI 10.4161/cc.6.24.5105
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 258OK
UT WOS:000252877000006
PM 18202550
OA Bronze
DA 2025 08 17
ER

PT J
AU Yu, J
   Chang, SS
   Suratwala, S
   Chung, WS
   Abdelmessieh, P
   Lee, HJ
   Yang, J
   Lee, FYI
AF Yu, J
   Chang, SS
   Suratwala, S
   Chung, WS
   Abdelmessieh, P
   Lee, HJ
   Yang, J
   Lee, FYI
TI Zoledronate induces apoptosis in cells from fibro cellular membrane of
   unicameral bone cyst (UBC)
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE benign bone tumor; unicameral bone cyst; bisphosphonate; apoptosis
ID LYMPHOCYTE DEVELOPMENT; OSTEOCLAST FORMATION; BISPHOSPHONATES; ACID;
   PATHOGENESIS; INHIBITION; MECHANISMS; ACTIVATOR; MARROW; LIGAND
AB Unicameral bone cyst (UBC) is a benign cystic lesion in children which is prone to fracture. Various treatments are available, but recurrence after different types of percutaneous injection therapy can cause bone destruction and pathologic fracture. The potential therapeutic effects of anti resorptive agents, such as bisphosphonates, have not been investigated for UBC. The objective of this study was to characterize the cells from the fibro cellular membrane of unicameral bone cyst (UBC cells) and to determine whether zoledronate, a nitrogen containing bisphosphonate, could induce apoptosis in UBC cells. Flow cytometry and immunoblotting were performed in order to determine whether zoledronate induced apoptosis. Cells derived from normal human trabecular bones were used as controls against UBC cells to compare the effect of zoledronate in inducing apoptosis. Immunohisto/cytochemistry (IHC/ICC) and mini array analyses were performed on tissues and cultured cells. Isolated peripheral blood mononuclear cells were incubated with conditioned media from the UBC cells to determine whether they are capable of inducing osteoclastogenesis. UBC membrane is composed of cells staining positively with CD68, SDF 1, STRO 1 and RANKL, but in vitro cells showed no staining with antibodies to CD68 and STRO 1, suggesting that there was a clonal selection of stromal cells during cell culture. UBC cells also express RUNX2 (runt related transcription factor 2, core binding factor 1), a key transcription factor for osteoblastic differentiation. In addition, media collected from UBC cells induced a generation of multi nucleated osteoclast like cells of peripheral blood mononuclear cells. Zoledronate induced apoptosis of UBC cells in a dose dependent manner. Apoptosis was evidenced by induction of the active cleaved form of caspase 3. The baseline apoptotic fractions were similar in UBC cells and trabecular bone cells. However, in the overall apoptotic fractions in this study, trabecular bone cells showed 17.2% of apoptosis, significantly lower than 24.2% of UBC cells (p value = 0.007). With the various zoledronate concentrations, mean apoptotic fractions of trabecular bone cells was 19.2%, significantly lower than 27.8% of UBC cells (p value = 0.040). With GGOH co treatment in various zoledronate concentrations, 15.1% apoptosis was shown in trabecular bone cells, which was not significantly lower than 20.6% of UBC cells (P value = 0.076). This data suggests that zoledronate causes apoptosis in both UBC and trabecular bone cells by inhibition of the mevalonate pathway. In addition to the known anti osteoclastogenic effect of bisphosphonates, the GGOH inhibitory effects of zoledronate were more prominent in UBC cells than trabecular bone cells, indicating their potential therapeutic role in UBC. (c) 2005 Orthopaedic Research Society. Published by Elsevier Ltd. All rights reserved.
C1 Columbia Univ, Ctr Med, Dept Orthopaed Surg, Ctr Orthopaed Res, New York, NY 10032 USA.
   Columbia Univ, Med Ctr, Dept Anesthesiol, Ctr Orthopaed Res, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Lee, FYI (通讯作者)，Columbia Univ, Ctr Med, Dept Orthopaed Surg, Ctr Orthopaed Res, 630 W 168th St,BB1411, New York, NY 10032 USA.
EM fl127@columbia.edu
OI Suratwala, Sanjeev/0000 0002 8701 0740
CR Bilston LE, 2002, CLIN BIOMECH, V17, P716, DOI 10.1016/S0268 0033(02)00108 0
   Capanna R, 1996, ORTHOP CLIN N AM, V27, P605
   CHAVES D, 1980, INT ORTHOP, V3, P253
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   CHIGIRA M, 1986, ARCH ORTHOP TRAUM SU, V105, P150, DOI 10.1007/BF00433932
   COHEN J, 1960, J BONE JOINT SURG AM, V42, P609, DOI 10.2106/00004623 196042040 00005
   David P, 1996, J BONE MINER RES, V11, P1498, DOI 10.1002/jbmr.5650111017
   de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955 0674(00)00276 3
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Gebhart M, 1996, Acta Orthop Belg, V62, P137
   GERASIMOV AM, 1991, CLIN ORTHOP RELAT R, P53
   GILMAN J, EPICALC 2000 SOFTWAR
   Green JR, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37421
   HashemiNejad A, 1997, J BONE JOINT SURG BR, V79B, P727, DOI 10.1302/0301 620X.79B5.7825
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Killian JT, 1998, J PEDIATR ORTHOPED, V18, P621, DOI 10.1097/00004694 199809000 00013
   Kirkwood B.R., 2003, Essential medical statistics, V2nd ed.
   KOMIYA S, 1993, CLIN ORTHOP RELAT R, P204
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440 1711.1999.00815.x
   Li EC, 2003, CLIN THER, V25, P2669, DOI 10.1016/S0149 2918(03)80327 2
   Lokiec F, 1996, J BONE JOINT SURG BR, V78B, P934, DOI 10.1302/0301 620X78B6.6840
   Lokiec F, 1998, J PEDIATR ORTHOP B, V7, P262, DOI 10.1097/01202412 199810000 00004
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   PARFITT AM, 1991, AM J MED, V91, pS42, DOI 10.1016/0002 9343(91)90246 T
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   RESZKA AA, 2003, CURR RHEUMATOL REP, V51, P65
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roposch A, 2000, J BONE JOINT SURG AM, V82A, P1447, DOI 10.2106/00004623 200010000 00011
   SCAGLIETTI O, 1979, J BONE JOINT SURG BR, V61, P200, DOI 10.1302/0301 620X.61B2.438272
   Schreuder HWB, 1997, J PEDIATR ORTHOPED, V17, P814, DOI 10.1097/00004694 199711000 00022
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531 5565(03)00069 X
   Wilkins R M, 2000, J Am Acad Orthop Surg, V8, P217
   Wyllie A H, 1980, Int Rev Cytol, V68, P251
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
NR 41
TC 23
Z9 24
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD SEP
PY 2005
VL 23
IS 5
BP 1004
EP 1012
DI 10.1016/j.orthres.2005.02.012
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 968PD
UT WOS:000232173600004
PM 15921873
DA 2025 08 17
ER

PT J
AU Xiao, M
   Wang, YK
   Tao, C
   Wang, ZY
   Yang, J
   Chen, ZG
   Zou, ZP
   Li, MM
   Liu, AL
   Jia, CH
   Huang, B
   Yan, B
   Lai, PL
   Ding, CH
   Cai, DZ
   Xiao, GZ
   Jiang, Y
   Bai, XC
AF Xiao, Min
   Wang, Yongkui
   Tao, Chen
   Wang, Zhenyu
   Yang, Jun
   Chen, Zhenguo
   Zou, Zhipeng
   Li, Mangmang
   Liu, Anling
   Jia, Chunhong
   Huang, Bin
   Yan, Bo
   Lai, Pinglin
   Ding, Changhai
   Cai, Daozhang
   Xiao, Guozhi
   Jiang, Yu
   Bai, Xiaochun
TI Osteoblasts support megakaryopoiesis through production of interleukin 9
SO BLOOD
LA English
DT Article
ID STEM CELL NICHE; NF KAPPA B; HEMATOPOIETIC STEM; MEGAKARYOCYTE
   DEVELOPMENT; BONE FORMATION; THROMBOPOIETIN; THROMBOCYTOPENIA;
   EXPRESSION; MTOR; MICE
AB Severe thrombocytopenia is a significant challenge in patients undergoing myelosuppressive chemotherapy for malignancies. Understanding the biology of plateletproducing megakaryocytes development in the bone marrow microenvironment may facilitate the development of novel therapies to stimulate platelet production and prevent thrombocytopenia. We report here that osteoblasts supported megakaryopoiesis by secreting interleukin 9 (IL 9), which stimulated IL 9 receptor (IL 9R)/Stat3 signaling in promotingmegakaryopoiesis. IL 9production in osteoblasts was negatively regulated by the mechanistic target of rapamycin complex 1 (mTORC1) signaling in a NF kappa B dependent manner. Constitutive activation of mTORC1 inhibited IL 9 production in osteoblasts and suppressed megakaryocytic cells expansion, whereas mTORC1 inactivation increased IL 9 production and enhanced megakaryocyte and platelet numbers in mice. In mouse models, we showed that IL 9 administration stimulated megakaryopoiesis, whereas neutralizing endogenous IL 9 or IL 9R depletion in hibited the process. Importantly, we found that low doses of IL 9 efficiently prevented chemotherapy induced thrombocytopenia (CIT) and accelerated platelet recovery after CIT. These data indicate that IL 9 is an essential regulator of megakaryopoiesis and a promising therapeutic agent for treatment of thrombocytopenia such as CIT.
C1 [Xiao, Min; Wang, Yongkui; Tao, Chen; Yang, Jun; Chen, Zhenguo; Zou, Zhipeng; Li, Mangmang; Liu, Anling; Jia, Chunhong; Ding, Changhai; Bai, Xiaochun] Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, State Key Lab Organ Failure Res, Guangzhou, Guangdong, Peoples R China.
   [Xiao, Min; Wang, Yongkui; Wang, Zhenyu; Huang, Bin; Yan, Bo; Lai, Pinglin; Cai, Daozhang; Bai, Xiaochun] Southern Med Univ, Affiliated Hosp 3, Acad Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Xiao, Guozhi] Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China.
   [Xiao, Guozhi] Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen, Peoples R China.
   [Xiao, Guozhi] Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA.
   [Jiang, Yu] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern University of Science & Technology; Southern University
   of Science & Technology; Rush University; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Bai, XC (通讯作者)，Southern Med Univ, Affiliated Hosp 3, Sch Basic Med Sci, Dept Cell Biol, Shatai Nan Rd 1023 1063, Guangzhou 510515, Guangdong, Peoples R China.
EM baixc15@smu.edu.cn
RI Wang, Zhen Yu/G 6872 2015; xiao, min/HMV 8262 2023; LI,
   MANGMANG/J 1683 2015; Ding, Changhai/J 7730 2014; chen,
   tao/KMX 5820 2024
OI Bai, Xiaochun/0000 0001 9631 4781; chen, tao/0000 0003 1543 607X; Ding,
   Changhai/0000 0002 9479 730X; 
FU National Natural Sciences Foundation of China [31500947, 81625015,
   U1301222, 81530070, 31529002]; State Key Development Program for Basic
   Research of China [2013CB945203, 2015CB553602]; Natural Science
   Foundation of Guangdong Province, China [2016A030313631]
FX This work was supported by grants from National Natural Sciences
   Foundation of China (31500947, 81625015, U1301222, 81530070, and
   31529002), the State Key Development Program for Basic Research of China
   (2013CB945203 and 2015CB553602), and the Natural Science Foundation of
   Guangdong Province, China (2016A030313631).
CR Angiolillo DJ, 2013, J AM COLL CARDIOL, V62, pS21, DOI 10.1016/j.jacc.2013.08.704
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cheng YH, 2013, J BONE MINER RES, V28, P1434, DOI 10.1002/jbmr.1876
   Dan HC, 2008, J IMMUNOL, V180, P7582, DOI 10.4049/jimmunol.180.11.7582
   Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308
   Emerson SG, 2007, CELL STEM CELL, V1, P599, DOI 10.1016/j.stem.2007.11.010
   Fujiki H, 2002, EXP HEMATOL, V30, P1373, DOI 10.1016/S0301 472X(02)00966 9
   Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049
   Habart D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055094
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Imbach P, 2011, NEW ENGL J MED, V365, P734, DOI 10.1056/NEJMct1014202
   Kacena MA, 2004, J BONE MINER RES, V19, P652, DOI 10.1359/JBMR.0301254
   Kaplan MH, 2015, NAT REV IMMUNOL, V15, P295, DOI 10.1038/nri3824
   KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0
   Kaye J A, 1996, Curr Opin Hematol, V3, P209
   Kunicki TJ, 2012, ARTERIOSCL THROM VAS, V32, P147, DOI 10.1161/ATVBAHA.111.239392
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lemieux JM, 2010, J CELL BIOCHEM, V109, P927, DOI 10.1002/jcb.22468
   Lieberman L, 2014, BLOOD, V123, P1146, DOI 10.1182/blood 2013 02 435693
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Machlus KR, 2013, J CELL BIOL, V201, P785, DOI 10.1083/jcb.201304054
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nieswandt B, 2015, J CELL BIOL, V209, P327, DOI 10.1083/jcb.201504026
   Noelle RJ, 2010, NAT REV IMMUNOL, V10, P683, DOI 10.1038/nri2848
   Pang LY, 2005, J CLIN INVEST, V115, P3332, DOI 10.1172/JCI26720
   Panuganti S, 2013, TISSUE ENG PT A, V19, P998, DOI [10.1089/ten.tea.2011.0111, 10.1089/ten.TEA.2011.0111]
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Schepers K, 2012, BLOOD, V120, P3425, DOI 10.1182/blood 2011 11 395418
   Shen Y, 2012, CURR OPIN HEMATOL, V19, P250, DOI 10.1097/MOH.0b013e328353c714
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757
   Stassen M, 2001, J IMMUNOL, V166, P4391, DOI 10.4049/jimmunol.166.7.4391
   Sun SJ, 2013, PHYSIOL GENOMICS, V45, P217, DOI 10.1152/physiolgenomics.00056.2012
   Tarnarnyan G, 2016, CRIT REV ONCOL HEMAT, V99, P299, DOI 10.1016/j.critrevonc.2016.01.005
   Vadhan Raj S, 2002, LANCET, V359, P2145, DOI 10.1016/S0140 6736(02)09090 6
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
   YANG YC, 1989, BLOOD, V74, P1880
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 42
TC 33
Z9 38
U1 2
U2 32
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JUN 15
PY 2017
VL 129
IS 24
BP 3196
EP 3209
DI 10.1182/blood 2016 11 749838
PG 14
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA EX5VZ
UT WOS:000403312100011
PM 28450306
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhong, YM
   Xu, YM
   Xue, S
   Zhu, LB
   Lu, HM
   Wang, C
   Chen, HJ
   Sang, WL
   Ma, JZ
AF Zhong, Yiming
   Xu, Yiming
   Xue, Song
   Zhu, Libo
   Lu, Haiming
   Wang, Cong
   Chen, Hongjie
   Sang, Weilin
   Ma, Jinzhong
TI Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis
   and TGF β activity in subchondral bone
SO INFLAMMOPHARMACOLOGY
LA English
DT Article
DE Apoptosis; Nangibotide; Osteoarthritis; Osteoblast; Subchondral bone
ID MESENCHYMAL STEM CELLS; OSTEOCYTE CONTROL; CARTILAGE; WNT;
   RECOMMENDATIONS; RESORPTION; UNIT
AB Osteoarthritis (OA) is a chronic joint disorder that causes cartilage degradation and subchondral bone abnormalities. Nangibotide, also known as LR12, is a dodecapeptide with considerable anti inflammatory properties, but its significance in OA is uncertain. The aim of the study was to determine whether nangibotide could attenuate the progression of OA, and elucidate the underlying mechanism. In vitro experiments showed that nangibotide strongly inhibited TNF alpha induced osteogenic reduction, significantly enhanced osteoblast proliferation and prevented apoptosis in MC3T3 E1 cells. Male C57BL/6 J mice aged 2 months were randomly allocated to three groups: sham, ACLT, and ACLT with nangibotide therapy. Nangibotide suppressed ACLT induced cartilage degradation and MMP 13 expression. MicroCT analysis revealed that nangibotide attenuated in vivo subchondral bone loss induced by ACLT. Histomorphometry results showed that nangibotide attenuated ACLT induced osteoblast inhibition; TUNEL assays and immunohistochemical staining of cleaved caspase3 further confirmed the in vivo anti apoptotic effect of nangibotide on osteoblasts. Furthermore, we found that nangibotide exerted protective effects by suppressing TGF beta signaling mediated by Smad2/3 to restore coupled bone remodeling in the subchondral bone. In conclusion, the findings suggest that nangibotide might exert a protective effect on the bone cartilage unit and maybe an alternative treatment option for OA.
C1 [Zhong, Yiming; Xu, Yiming; Zhu, Libo; Lu, Haiming; Wang, Cong; Chen, Hongjie; Sang, Weilin; Ma, Jinzhong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Xue, Song] Anhui Med Univ, Arthrit Res Inst, Dept Rheumatol & Immunol, Affiliated Hosp 1, Hefei 230022, Peoples R China.
C3 Shanghai Jiao Tong University; Anhui Medical University
RP Sang, WL; Ma, JZ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM sang_weilin@163.com; majinzhong1963@sina.com
RI sang, wei/MZQ 2526 2025; Lu, H./L 1685 2013; Ma, Jinzhong/AAD 9289 2022
OI Xue, Song/0000 0002 2932 5488; 
FU National Natural Science Foundation of China [82172411, 81871795];
   Shanghai Municipal Health and Family Planning Commission [SHDC12017121];
   Songjiang District Science and Technology Project [18sjkjgg18]
FX This work was supported by the National Natural Science Foundation of
   China [grant numbers: 82172411, 81871795], Shanghai Municipal Health and
   Family Planning Commission [grant number: SHDC12017121] and Songjiang
   District Science and Technology Project [grant number: 18sjkjgg18].
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Boer CG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12873 4
   Boufenzer A, 2015, CIRC RES, V116, P1772, DOI 10.1161/CIRCRESAHA.116.305628
   Butterfield NC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20761 5
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Cuvier V, 2018, BRIT J CLIN PHARMACO, V84, P2270, DOI 10.1111/bcp.13668
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Derive M, 2014, ANESTHESIOLOGY, V120, P935, DOI 10.1097/ALN.0000000000000078
   Derive M, 2013, SHOCK, V39, P176, DOI 10.1097/SHK.0b013e31827bcdfb
   Dubar M, 2018, J CLIN PERIODONTOL, V45, P799, DOI 10.1111/jcpe.12925
   Francois B, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen 2020 042921
   Francois B, 2020, INTENS CARE MED, V46, P1425, DOI 10.1007/s00134 020 06109 z
   Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Goldring SR, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000049
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Goldring SR, 2009, MED CLIN N AM, V93, P25, DOI 10.1016/j.mcna.2008.09.006
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Houard X, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0375 6
   Jiang YF, 2017, BBA MOL BASIS DIS, V1863, P3001, DOI 10.1016/j.bbadis.2017.08.009
   Jiao K, 2014, J DENT RES, V93, P140, DOI 10.1177/0022034513513034
   Jolly L, 2018, CARDIOVASC RES, V114, P907, DOI 10.1093/cvr/cvy018
   Kökten T, 2018, J CROHNS COLITIS, V12, P230, DOI 10.1093/ecco jcc/jjx129
   Kwon DG, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031618
   Liu T, 2016, SCI REP UK, V6, DOI 10.1038/srep39473
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   O'Brien CA, 2013, BONE, V54, P258, DOI 10.1016/j.bone.2012.08.121
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Prasadam I, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4333
   Rahmati M, 2016, BONE, V85, P81, DOI 10.1016/j.bone.2016.01.019
   Roos EM, 2016, NAT REV RHEUMATOL, V12, P92, DOI 10.1038/nrrheum.2015.135
   Sapir Koren R, 2014, OSTEOPOROSIS INT, V25, P2685, DOI 10.1007/s00198 014 2808 0
   Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2
   Shi RL, 2018, INT J MOL MED, V41, P2159, DOI 10.3892/ijmm.2018.3443
   Tammaro A, 2016, SCI REP UK, V6, DOI 10.1038/srep38275
   Thankam FG, 2022, MOL CELL BIOCHEM, V477, P701, DOI 10.1007/s11010 021 04321 z
   Thomas A, 2009, J GERIATR PHYS THER, V32, P33, DOI 10.1519/00139143 200932010 00007
   Visweswaran M, 2015, INT J BIOCHEM CELL B, V68, P139, DOI 10.1016/j.biocel.2015.09.008
   Wang YJ, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/2327721
   Yang HJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071503
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 45
TC 7
Z9 7
U1 2
U2 13
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0925 4692
EI 1568 5608
J9 INFLAMMOPHARMACOLOGY
JI Inflammopharmacology
PD JUN
PY 2022
VL 30
IS 3
BP 1107
EP 1117
DI 10.1007/s10787 022 00984 2
EA APR 2022
PG 11
WC Immunology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA 1U7PZ
UT WOS:000779778500001
PM 35391646
DA 2025 08 17
ER

PT J
AU Xiao, BX
   Ackun Farmmer, MA
   Adjei Sowah, E
   Liu, YX
   Chandrasiri, I
   Benoit, DSW
AF Xiao, Baixue
   Ackun Farmmer, Marian A.
   Adjei Sowah, Emmanuela
   Liu, Yuxuan
   Chandrasiri, Indika
   Benoit, Danielle S. W.
TI Advancing Bone Targeted Drug Delivery: Leveraging Biological Factors and
   Nanoparticle Designs to Improve Therapeutic Efficacy
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE nanoparticles; targeted drug delivery; bonetargeting; ligand density;
   biodistribution
ID LIGAND DENSITY; POLYMERIC MICELLES; OSTEOCLAST; PEPTIDE; CALCIUM;
   BIODISTRIBUTION; BINDING; SURFACE; SITES
AB Designing targeted drug delivery systems to effectively treat bone diseases ranging from osteoporosis to nonunion bone defects remains a significant challenge. Previously, nanoparticles (NPs) self assembled from diblock copolymers of poly(styrene alt maleic anhydride) b poly(styrene) (PSMA b PS) delivering a Wnt agonist were shown to effectively target bone and improve healing via the introduction of a peptide with high affinity to tartrate resistant acid phosphatase (TRAP), an enzyme deposited by the osteoclasts during bone remodeling. Despite these promising results, the underlying biological factors governing targeting and subsequent drug delivery system (DDS) design parameters have not been examined to enable the rational design to improve bone selectivity. Therefore, this work investigated the effect of target ligand density, the treatment window after injury, specificity of TRAP binding peptide (TBP), the extent of TRAP deposition, and underlying genetic factors (e.g., mouse strain differences) on TBP NP targeting. Data based on in vitro binding studies and in vivo biodistribution analyses using a murine femoral fracture model suggest that TBP NP TRAP interactions and TBP NP bone accumulation were ligand density dependent; in vitro, TRAP affinity was correlated with ligand density up to the maximum of 200,000 TBP ligands/NP, while NPs with 80,000 TBP ligands showed 2 fold increase in fracture accumulation at day 21 post injury compared with that of untargeted or scrambled controls. While fracture accumulation exhibited similar trends when injected at day 3 compared to that at day 21 postfracture, there were no significant differences observed between TBP functionalized and control NPs, possibly due to saturation of TRAP by NPs at day 3. Leveraging a calcium depletion diet, TRAP deposition and TBP NP bone accumulation were positively correlated, confirming that TRAP TBP binding leads to TBP NP bone accumulation in vivo. Furthermore, TBP NP exhibited similar bone accumulation in both C57BL/6 and BALB/c mouse strains versus control NPs, suggesting the broad applicability of TBP NP regardless of the underlying genetic differences. These studies provide insight into TBP NP design, mechanism, and therapeutic windows, which inform NP design and treatment strategies for fractures and other bone associated diseases that leverage TRAP, such as marrow related hematologic diseases.
C1 [Xiao, Baixue; Ackun Farmmer, Marian A.; Adjei Sowah, Emmanuela; Chandrasiri, Indika; Benoit, Danielle S. W.] Univ Rochester, Dept Biomed Engn, Rochester, NY 14623 USA.
   [Xiao, Baixue; Ackun Farmmer, Marian A.; Adjei Sowah, Emmanuela; Chandrasiri, Indika; Benoit, Danielle S. W.] Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14623 USA.
   [Ackun Farmmer, Marian A.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA.
   [Liu, Yuxuan; Benoit, Danielle S. W.] Univ Rochester, Mat Sci Program, Rochester, NY 14623 USA.
   [Chandrasiri, Indika] ThermoFisher Sci, Middleton, WI 53562 USA.
   [Benoit, Danielle S. W.] Univ Rochester, Dept Chem Engn, Rochester, NY 14623 USA.
   [Benoit, Danielle S. W.] Univ Oregon, Dept Bioengn, Phil & Penny Knight Campus Accelerating Sci Impact, Eugene, OR 97403 USA.
C3 University of Rochester; University of Rochester; University System of
   Maryland; University of Maryland College Park; University of Rochester;
   University of Rochester; University of Oregon
RP Benoit, DSW (通讯作者)，Univ Rochester, Dept Biomed Engn, Rochester, NY 14623 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14623 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Mat Sci Program, Rochester, NY 14623 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Dept Chem Engn, Rochester, NY 14623 USA.; Benoit, DSW (通讯作者)，Univ Oregon, Dept Bioengn, Phil & Penny Knight Campus Accelerating Sci Impact, Eugene, OR 97403 USA.
EM dbenoit@uoregon.edu
RI ; Benoit, Danielle/HKV 4384 2023; Chandrasiri, Indika/AAJ 5182 2021
OI Adjei Sowah, Emmanuela/0000 0002 0219 043X; Benoit,
   Danielle/0000 0001 7137 8164; Xiao, Baixue/0000 0001 8337 8401
FU National Science Foundation (NSF)( [CBET1450987, DMR2103553]; National
   Institutes of Health(NIH) [R01AR064200, R01AR056696, P30 AR06955, R21
   AR081063, R21AG072692, S10OD030302, S10RR026542 01]; Orthopedic Research
   and Education Foundation [20 072]; Orthopedic Trauma Association [6272];
   University of Rochester Medical Center Department of Orthopedics
   Goldstein Award
FX This work was supported by grants from the National Science Foundation
   (NSF)(CBET1450987 and DMR2103553); National Institutes of Health(NIH)
   [R01AR064200, R01AR056696, P30 AR06955, R21 AR081063 (to D.S.W.B.),
   R21AG072692, and S10OD030302, also S10RR026542 01 to AWAD for IVIS];
   Orthopedic Research and Education Foundation grant 20 072 (to D.S.W.B.),
   Orthopedic Trauma Association grant 6272 (to D.S.W.B.); and the
   University of Rochester Medical Center Department of Orthopedics
   Goldstein Award (to D.S.W.B.).
CR Ackun Farmmer MA, 2022, ADV THER GERMANY, V5, DOI 10.1002/adtp.202100100
   Ackun Farmmer MA, 2022, J BIOMED MATER RES A, V110, P229, DOI 10.1002/jbm.a.37279
   Ackun Farmmer MA, 2021, FASEB J, V35, DOI 10.1096/fj.202000938RR
   Ahmad Z, 2014, RSC ADV, V4, P17028, DOI 10.1039/c3ra47370h
   Akhter A, 2014, INT J PHARMACEUT, V475, P227, DOI 10.1016/j.ijpharm.2014.08.048
   Alkilany AM, 2019, ADV DRUG DELIVER REV, V143, P22, DOI 10.1016/j.addr.2019.05.010
   ARO HT, 1990, J ORTHOP RES, V8, P238, DOI 10.1002/jor.1100080213
   Ashby J, 2015, ANAL CHEM, V87, P2213, DOI 10.1021/ac5036814
   Baranello MP, 2014, BIOMACROMOLECULES, V15, P2629, DOI 10.1021/bm500468d
   Benoit D.S. W., 2020, BIOMATER SCI UK, VFourth, P1237, DOI DOI 10.1016/B978 0 12 816137 1.00078 7
   Bertrand N, 2014, ADV DRUG DELIVER REV, V66, P2, DOI 10.1016/j.addr.2013.11.009
   Chandrasiri I., Frontiers in Biomaterials Science, V1, P1, DOI DOI 10.3389/FBIOM.2022.1003172
   Elias DR, 2013, NANOMED NANOTECHNOL, V9, P194, DOI 10.1016/j.nano.2012.05.015
   Feldman EJ, 2011, J CLIN ONCOL, V29, P979, DOI 10.1200/JCO.2010.30.5961
   Fischer V, 2018, EUR CELLS MATER, V35, P365, DOI 10.22203/eCM.v035a25
   Fukushima A, 2006, EXP EYE RES, V82, P210, DOI 10.1016/j.exer.2005.06.010
   GOTHLIN G, 1976, CLIN ORTHOP RELAT R, P201
   Gustafson HH, 2015, NANO TODAY, V10, P487, DOI 10.1016/j.nantod.2015.06.006
   Hartmann W, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 79477 7
   HEATH TD, 1980, SCIENCE, V210, P539, DOI 10.1126/science.7423203
   Hlavacek WS, 1999, BIOPHYS J, V76, P3031, DOI 10.1016/S0006 3495(99)77456 4
   Kodama Y, 2000, BONE, V27, P445, DOI 10.1016/S8756 3282(00)00340 9
   Krohn Grimberghe M, 2020, NAT BIOMED ENG, V4, P1076, DOI 10.1038/s41551 020 00623 7
   Larson N, 2012, CHEM MATER, V24, P840, DOI 10.1021/cm2031569
   LEE KS, 1978, INT J BIOCHEM, V9, P457, DOI 10.1016/0020 711X(78)90075 7
   Li SD, 2010, J CONTROL RELEASE, V145, P178, DOI 10.1016/j.jconrel.2010.03.016
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lim WS, 2010, LEUKEMIA RES, V34, P1214, DOI 10.1016/j.leukres.2010.01.015
   Mai JH, 2014, J CONTROL RELEASE, V187, P22, DOI 10.1016/j.jconrel.2014.04.057
   Maity SK, 2016, ORG LETT, V18, P3026, DOI 10.1021/acs.orglett.6b01442
   Masters EA, 2021, J ORTHOP RES, V39, P389, DOI 10.1002/jor.24962
   Miller K, 2011, MOL PHARMACEUT, V8, P1052, DOI 10.1021/mp200083n
   Mitchell MJ, 2021, NAT REV DRUG DISCOV, V20, P101, DOI 10.1038/s41573 020 0090 8
   Moghaddam A, 2011, INJURY, V42, P758, DOI 10.1016/j.injury.2010.11.017
   Mu CF, 2017, MOL PHARMACEUT, V14, P274, DOI 10.1021/acs.molpharmaceut.6b00872
   Newman MR, 2018, BIOMACROMOLECULES, V19, P71, DOI 10.1021/acs.biomac.7b01193
   Pan HZ, 2008, MOL PHARMACEUT, V5, P548, DOI 10.1021/mp800003u
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Shares BH, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115391
   Sheu TJ, 2002, J BONE MINER RES, V17, P915, DOI 10.1359/jbmr.2002.17.5.915
   Song XN, 2018, BIOMATERIALS, V180, P78, DOI 10.1016/j.biomaterials.2018.07.006
   Subhan MA, 2021, J PERS MED, V11, DOI 10.3390/jpm11060571
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Takahashi T, 2008, PHARM RES DORDR, V25, P2881, DOI 10.1007/s11095 008 9605 4
   Tardi P, 2009, LEUKEMIA RES, V33, P129, DOI 10.1016/j.leukres.2008.06.028
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Wang J, 2020, ACS NANO, V14, P372, DOI 10.1021/acsnano.9b05689
   Wang YC, 2018, EUR J PHARM BIOPHARM, V127, P223, DOI 10.1016/j.ejpb.2018.02.023
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   WRIGHT KR, 1994, CALCIFIED TISSUE INT, V54, P62, DOI 10.1007/BF00316292
   Xiao BX, 2023, ACS APPL MATER INTER, V15, P13993, DOI 10.1021/acsami.2c22471
   Yamauchi Y, 2013, J CELL SCI, V126, P1289, DOI 10.1242/jcs.119685
   Zach F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142211
NR 54
TC 4
Z9 4
U1 4
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD MAR 27
PY 2024
VL 10
IS 4
BP 2224
EP 2234
DI 10.1021/acsbiomaterials.3c01022
EA MAR 2024
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA NJ7W6
UT WOS:001192825800001
PM 38537162
DA 2025 08 17
ER

PT J
AU Dou, C
   Ding, N
   Xing, J
   Zhao, C
   Kang, F
   Hou, T
   Quan, H
   Chen, Y
   Dai, Q
   Luo, F
   Xu, J
   Dong, S
AF Dou, C.
   Ding, N.
   Xing, J.
   Zhao, C.
   Kang, F.
   Hou, T.
   Quan, H.
   Chen, Y.
   Dai, Q.
   Luo, F.
   Xu, J.
   Dong, S.
TI Dihydroartemisinin attenuates lipopolysaccharide induced
   osteoclastogenesis and bone loss via the mitochondria dependent
   apoptosis pathway
SO CELL DEATH & DISEASE
LA English
DT Article
ID CANCER CELLS; IN VITRO; RECEPTOR ACTIVATOR; FREE RADICALS; CYTOCHROME C;
   DIFFERENTIATION; ARTEMISININ; RESORPTION; OSTEOPROTEGERIN; PHARMACOLOGY
AB Dihydroartemisinin (DHA) is a widely used antimalarial drug isolated from the plant Artemisia annua. Recent studies suggested that DHA has antitumor effects utilizing its reactive oxygen species (ROS) yielding mechanism. Here, we reported that DHA is inhibitory on lipopolysaccharide (LPS) induced osteoclast (OC) differentiation, fusion and bone resorption activity in vitro. Intracellular ROS detection revealed that DHA could remarkably increase ROS accumulation during LPS induced osteoclastogenesis. Moreover, cell apoptosis was also increased by DHA treatment. We found that DHA activated caspase 3 increased Bax/Bcl 2 ratio during LPS induced osteoclastogenesis. Meanwhile, the translocation of apoptotic inducing factor (AIF) and the release of cytochrome c from the mitochondria into the cytosol were observed, indicating that ROS mediated mitochondrial dysfunction is crucial in DHA induced apoptosis during LPS induced osteoclastogenesis. In vivo study showed that DHA treatment decreased OC number, prevents bone loss, rescues bone microarchitecture and restores bone strength in LPS induced bone loss mouse model. Together, our findings indicate that DHA is protective against LPS induced bone loss through apoptosis induction of osteoclasts via ROS accumulation and the mitochondria dependent apoptosis pathway. Therefore, DHA may be considered as a new therapeutic candidate for treating inflammatory bone loss.
C1 [Dou, C.; Ding, N.; Xing, J.; Hou, T.; Dai, Q.; Luo, F.; Xu, J.] Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Chongqing 400038, Peoples R China.
   [Dou, C.; Zhao, C.; Kang, F.; Quan, H.; Chen, Y.; Dong, S.] Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.
   [Dong, S.] China Orthoped Regenerat Med Grp, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University
RP Xu, J (通讯作者)，Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Chongqing 400038, Peoples R China.; Dong, S (通讯作者)，Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.
EM xujianzhong1962@163.com; dongshiwu@tmmu.edu.cn
RI Dou, Ce/B 8841 2012; Chen, Yueqi/AAU 1724 2020; Xing,
   Junchao/GWN 0403 2022
OI Dou, Ce/0000 0002 6983 6354; Chen, Yueqi/0000 0001 6975 2874; 
FU Nature Science Foundation of China [81572164]; National Key Technology
   Research and Development Program of China [2012BAI42G01]; National
   High tech R&D Program of China (863 Program) [2015AA020315]; Key project
   of Logistics Research Plan of PLA [BWS13C014]
FX This work was funded by grants from the Nature Science Foundation of
   China (81572164), the National Key Technology Research and Development
   Program of China (2012BAI42G01), the National High tech R&D Program of
   China (863 Program, 2015AA020315) and Key project of Logistics Research
   Plan of PLA (BWS13C014).
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cabello CM, 2012, INVEST NEW DRUG, V30, P1289, DOI 10.1007/s10637 011 9676 7
   Chen H, 2009, ANTI CANCER DRUG, V20, P131, DOI 10.1097/CAD.0b013e3283212ade
   Chen T, 2009, J CELL MOL MED, V13, P1358, DOI 10.1111/j.1582 4934.2008.00360.x
   Dou C, 2016, J CELL PHYSIOL, V231, P558, DOI 10.1002/jcp.24916
   Dou C, 2014, BBA GENE REGUL MECH, V1839, P1084, DOI 10.1016/j.bbagrm.2014.08.002
   Efferth T, 2006, CURR DRUG TARGETS, V7, P407, DOI 10.2174/138945006776359412
   Efferth T, 2004, FREE RADICAL BIO MED, V37, P998, DOI 10.1016/j.freeradbiomed.2004.06.023
   Feng MX, 2016, SCI REP UK, V6, DOI 10.1038/srep19074
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   He Q, 2010, CANCER BIOL THER, V9, P819, DOI 10.4161/cbt.9.10.11552
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Krishna S, 2008, TRENDS PHARMACOL SCI, V29, P520, DOI 10.1016/j.tips.2008.07.004
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li Y, 2012, ACTA PHARMACOL SIN, V33, P1141, DOI 10.1038/aps.2012.104
   Lu JJ, 2011, INVEST NEW DRUG, V29, P1276, DOI 10.1007/s10637 010 9481 8
   Mao HT, 2013, INT J MOL MED, V31, P213, DOI 10.3892/ijmm.2012.1176
   Moon HJ, 2012, BIOCHEM BIOPH RES CO, V418, P247, DOI 10.1016/j.bbrc.2012.01.005
   Nagasawa T, 2007, PERIODONTOL 2000, V43, P65, DOI 10.1111/j.1600 0757.2006.00185.x
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   O'Neill PM, 2010, MOLECULES, V15, P1705, DOI 10.3390/molecules15031705
   Odkhuu E, 2015, INNATE IMMUN LONDON, V21, P194, DOI 10.1177/1753425914524242
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Roué G, 2003, BIOCHIMIE, V85, P741, DOI 10.1016/S0300 9084(03)00129 9
   Schröder K, 2015, CELL MOL LIFE SCI, V72, P25, DOI 10.1007/s00018 014 1712 2
   Sharma R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093696
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Sun J, 2008, AM J PHYSIOL CELL PH, V294, pC1586, DOI 10.1152/ajpcell.00129.2008
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang XD, 2001, GENE DEV, V15, P2922
   Zhou L, 2015, J BONE MINER RES, DOI [10.1002/jbmr.2771, DOI 10.1002/JBMR.2771)]
NR 44
TC 46
Z9 50
U1 1
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR
PY 2016
VL 7
AR e2162
DI 10.1038/cddis.2016.69
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DI4SG
UT WOS:000373489000045
PM 27031959
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, J
   Someren, E
   Mentink, A
   Licht, R
   Dechering, K
   van Blitterswijk, C
   de Boer, J
AF Liu, Jun
   Someren, Eugene
   Mentink, Anouk
   Licht, Ruud
   Dechering, Koen
   van Blitterswijk, Clemens
   de Boer, Jan
TI The effect of PKC activation and inhibition on osteogenic
   differentiation of human mesenchymal stem cells
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE human mesenchymal stem cells; protein kinase C; bone tissue engineering
ID PROTEIN KINASE C; ENDOTHELIAL GROWTH FACTOR; MARROW STROMAL CELLS;
   PARATHYROID HORMONE; OSTEOBLASTIC CELLS; SIGNALING PATHWAYS; DEPENDENT
   PATHWAY; BONE FORMATION; PHORBOL ESTER; IN VITRO
AB Human mesenchymal stem cells (hMSCs) are being considered for several areas of clinical therapy, due to their multipotent nature. For instance, osteogenic hMSCs are applied in bone tissue engineering, but current differentiation protocols need further optimization before they can be clinically applied. Protein kinase C (PKC) family members have been implicated in bone metabolism, which prompted us to use a pharmaceutical approach to manipulate PKC signalling in hMSCs. Inhibition of PKC resulted in a dose dependent inhibition of dexamethasone induced osteogenic differentiation. Surprisingly, PKC activation using phorbol 12 myristate 13 acetate (PMA) also resulted in inhibition of osteogenesis, although we observed that inhibition was more pronounced at low than at high concentrations of PMA. Furthermore, we observed that inhibition of PKC delta blocked alkaline phosphatase (ALP, an early marker of osteogenic differentiation) expression, whereas inhibition of the conventional PKC subfamily and PKC mu. using Go6976 resulted in an induction of ALP activity, collagen (I) expression and mineralization. In conclusion, inhibition of the conventional PKCs/PKC mu. and activation of PKC delta could further benefit osteogenic differentiation of hMSCs in vitro and in vivo, which is currently under investigation. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Liu, Jun; Mentink, Anouk; Licht, Ruud; van Blitterswijk, Clemens; de Boer, Jan] Univ Twente, MIRA Inst Biomed Technol, Dept Tissue Regenerat, NL 7500 AE Enschede, Netherlands.
   [Someren, Eugene] Radboud Univ Nijmegen, Dept Appl Biol, Nijmegen, Netherlands.
   [Someren, Eugene] Radboud Univ Nijmegen, Ctr Mol & Biomol Informat, Nijmegen, Netherlands.
   [Dechering, Koen] Schering Plough Res Inst, Dept Target Discovery, Oss, Netherlands.
C3 University of Twente; Radboud University Nijmegen; Radboud University
   Nijmegen; Merck & Company; Merck & Company Netherlands
RP de Boer, J (通讯作者)，Univ Twente, MIRA Inst Biomed Technol, Dept Tissue Regenerat, POB 217, NL 7500 AE Enschede, Netherlands.
EM j.deboer@tnw.utwente.nl
OI van Blitterswijk, Clemens/0000 0003 2371 4615; de Boer,
   Jan/0000 0001 9188 9324
FU Senter/Novem
FX We wish to thank Dr L. Creemers and Dr W. Dhert from the Department of
   Orthopaedics, UMC Utrecht, and Dr A. Renard from the Medical Spectrum
   Twente Hospital, for their generous supply of bone marrow aspirates. We
   would also thank R. I. Ravestein van Os and R. H. L. van de Wetering,
   from the Department of Target Discovery, Schering Plough Research
   Institute, for performing the microarray tests. The research was
   sponsored by a grant from Senter/Novem.
CR Baylink TM, 1996, J BONE MINER RES, V11, P1413
   Both SK, 2007, TISSUE ENG, V13, P3, DOI 10.1089/ten.2005.0513
   Cardell M, 1998, NEUROSCIENCE, V82, P709
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chan GK, 2003, ENDOCRINOLOGY, V144, P5511, DOI 10.1210/en.2003 0273
   Cheung WMW, 2006, FEBS LETT, V580, P121, DOI 10.1016/j.febslet.2005.11.062
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Boer J, 2006, TISSUE ENG, V12, P2927
   de Bruijn J D, 1999, Adv Dent Res, V13, P74
   Delannoy P, 2001, EXP CELL RES, V269, P154, DOI 10.1006/excr.2001.5301
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Esbrit P, 2000, J AM SOC NEPHROL, V11, P1085, DOI 10.1681/ASN.V1161085
   Geng WD, 2001, J CELL PHYSIOL, V189, P216, DOI 10.1002/jcp.10019
   Ghayor C, 2005, BONE, V36, P93, DOI 10.1016/j.bone.2004.10.007
   Gliki G, 2002, CELL BIOL INT, V26, P751, DOI 10.1016/S1065 6995(02)90926 1
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898 6568(97)00121 6
   Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960 9822(95)00277 6
   Kim BG, 2006, PROTEOMICS, V6, P1166, DOI 10.1002/pmic.200500289
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Lampasso JD, 2002, J BONE MINER RES, V17, P1968, DOI 10.1359/jbmr.2002.17.11.1968
   Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200
   MISCHAK H, 1993, J BIOL CHEM, V268, P6090
   Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955 0674(97)80058 0
   Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626
   NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Radeff JM, 2001, EXP CELL RES, V268, P179, DOI 10.1006/excr.2001.5283
   Richardson JA, 2007, J CELL BIOCHEM, V100, P1131, DOI 10.1002/jcb.21112
   Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460 2075.1996.tb00540.x
   Rougier F, 1998, CYTOKINE, V10, P93, DOI 10.1006/cyto.1997.0262
   Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756 3282(95)00427 0
   Sanders JL, 1996, J BONE MINER RES, V11, P1862
   Siddappa Ramakrishnaiah, 2007, Curr Stem Cell Res Ther, V2, P209, DOI 10.2174/157488807781696267
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402
   SIDDHANTI SR, 1995, ENDOCRINOLOGY, V136, P4834, DOI 10.1210/en.136.11.4834
   SOMJEN D, 1987, BIOCHIM BIOPHYS ACTA, V931, P215, DOI 10.1016/0167 4889(87)90209 6
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Tang CH, 2004, MOL PHARMACOL, V66, P440
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Valín A, 1999, CALCIFIED TISSUE INT, V65, P148, DOI 10.1007/s002239900674
   Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357 2725(01)00163 7
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Weng L, 2006, BIOINFORMATICS, V22, P1111, DOI 10.1093/bioinformatics/btl045
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang XH, 2002, BIOCHEM BIOPH RES CO, V290, P42, DOI 10.1006/bbrc.2001.6176
NR 53
TC 17
Z9 19
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JUL
PY 2010
VL 4
IS 5
BP 329
EP 339
DI 10.1002/term.242
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA 620XR
UT WOS:000279536800001
PM 20033927
DA 2025 08 17
ER

PT J
AU Sosa Henríquez, M
   Torregrosa, O
   Déniz, A
   Saavedra, P
   Ortego, N
   Turrión, A
   Castrillón, JLP
   Díaz Curiel, M
   Gómez Alonso, C
   Martínez, G
   Blázquez, JA
   Olmos Martínez, JM
   Etxebarria, I
   Caeiro, JR
   Mora Peña, D
AF Sosa Henriquez, Manuel
   Torregrosa, Oscar
   Deniz, Alejandro
   Saavedra, Pedro
   Ortego, Norberto
   Turrion, Ana
   Perez Castrillon, Jose Luis
   Diaz Curiel, Manuel
   Gomez Alonso, Carlos
   Martinez, Guillermo
   Antonio Blazquez, Jose
   Manuel Olmos Martinez, Jose
   Etxebarria, Inigo
   Ramon Caeiro, Jose
   Mora Pena, Damian
TI Multiple vertebral fractures after suspension of denosumab. A series of
   56 cases
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
ID TREAT TO TARGET; POSTMENOPAUSAL WOMEN; DISCONTINUATION; OSTEOPOROSIS;
   OSTEONECROSIS
AB Background Denosumab is a monoclonal antibody approved for the treatment of postmenopausal osteoporosis. The withdrawal of denosumab produces an abrupt loss of bone mineral density and may cause multiple vertebral fractures (MVF). Objective The objective of this study is to study the clinical, biochemical, and densitometric characteristics in a large series of postmenopausal women who suffered MVF after denosumab withdrawal. Likewise, we try to identify those factors related to the presence of a greater number of vertebral fractures (VF). Patients and Methods Fifty six patients (54 women) who suffered MVF after receiving denosumab at least for three consecutive years and abruptly suspended it. A clinical examination was carried out. Biochemical bone remodelling markers (BBRM) and bone densitometry at the lumbar spine and proximal femur were measured. VF were diagnosed by magnetic resonance imaging MRI, X ray, or both at dorsal and lumbar spine. Results Fifty six patients presented a total of 192 VF. 41 patients (73.2%) had not previously suffered VF. After discontinuation of the drug, a statistically significant increase in the BBRM was observed. In the multivariate analysis, only the time that denosumab was previously received was associated with the presence of a greater number of VF (P = .04). Conclusions We present the series with the largest number of patients collected to date. 56 patients accumulated 192 new VF. After the suspension of denosumab and the production of MVF, there was an increase in the serum values of the BBRM. The time of denosumab use was the only parameter associated with a greater number of fractures.
C1 [Sosa Henriquez, Manuel] Univ Las Palmas Gran Canaria, Hosp Univ Insular, Invest Grp Osteoporosis & Bone Mineral Metab, Las Palmas Gran Canaria, Canary Islands, Spain.
   [Torregrosa, Oscar] Hosp Gen Univ Elche, Internal Med Serv, Alicante, Spain.
   [Deniz, Alejandro] Hosp Univ Insular, Endocrinol Sect, Las Palmas Gran Canaria, Spain.
   [Saavedra, Pedro] Univ Las Palmas Gran Canaria, Math Dept, Las Palmas Gran Canaria, Spain.
   [Ortego, Norberto] Hosp Univ San Cecilio, Internal Med, Granada, Spain.
   [Turrion, Ana] Hosp Univ Salamanca, Rheumatol Serv, Salamanca, Spain.
   [Perez Castrillon, Jose Luis] Hosp Univ Rio Hortega, Internal Med, Valladolid, Spain.
   [Diaz Curiel, Manuel] Hosp Univ Fdn Jimenez Diaz, Internal Med Serv, Madrid, Spain.
   [Gomez Alonso, Carlos] Hosp Univ Cent Asturias, Internal Med Serv, Oviedo, Spain.
   [Martinez, Guillermo] Hosp Univ 12 Octubre, Endocrinol Serv, Madrid, Spain.
   [Antonio Blazquez, Jose] Hosp Gen Univ Albacete, Internal Med Serv, Albacete, Spain.
   [Manuel Olmos Martinez, Jose] Hosp Univ Marques Valdecilla, Internal Med Serv, Santander, Spain.
   [Etxebarria, Inigo] Hosp Alto Deba, Orthopaed Surg, Guipuzcoa, Spain.
   [Ramon Caeiro, Jose] Univ Hosp Santiago de Compostela, Orthopaed Surg Dept, La Coruna, Spain.
   [Mora Pena, Damian] Hosp Virgen Luz, Internal Med Serv, Cuenca, Spain.
C3 Universidad de Las Palmas de Gran Canaria; Universidad de Las Palmas de
   Gran Canaria; Hospital Universitario San Cecilio; Hospital del Rio
   Hortega; Central University Hospital Asturias; Hospital Universitario 12
   de Octubre; Hospital Universitario Marques de Valdecilla (HUMV);
   Complexo Hospitalario Universitario de Santiago de Compostela; Hospital
   Universitario de Cuenca
RP Sosa Henríquez, M (通讯作者)，Univ Las Palmas Gran Canaria, Hosp Univ Insular, Invest Grp Osteoporosis & Bone Mineral Metab, Las Palmas Gran Canaria, Canary Islands, Spain.
EM manuel.sosa@ulpgc.es
RI ; Sosa Henríquez, Manuel/MZQ 4015 2025; Caeiro, José/ABF 6604 2020;
   Perez Castrillon, Jose Luis/AGI 1029 2022
OI Olmos, Jose M./0000 0002 7765 0891; torregrosa,
   oscar/0000 0001 6618 7988
CR Anastasilakis AD, 2016, OSTEOPOROSIS INT, V27, P1929, DOI 10.1007/s00198 015 3459 5
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053
   Aubry Rozier B, 2016, OSTEOPOROSIS INT, V27, P1923, DOI 10.1007/s00198 015 3380 y
   Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Pérez AD, 2010, REV OSTEOPOR METAB M, V2, P5
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Fernández EF, 2020, REUMATOL CLIN, V16, P480, DOI 10.1016/j.reuma.2018.11.002
   Ferrari S, 2015, OSTEOPOROSIS INT, V26, P2763, DOI 10.1007/s00198 015 3179 x
   Florez H, 2019, SEMIN ARTHRITIS RHEU, V49, P197, DOI 10.1016/j.semarthrit.2019.02.007
   Garber AJ, 2014, DIABETES OBES METAB, V16, P193, DOI 10.1111/dom.12129
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Gonzalez Rodriguez E, 2020, BREAST CANCER RES TR, V179, P153, DOI 10.1007/s10549 019 05458 8
   Iranikhah M, 2018, CONSULT PHARM, V33, P142, DOI 10.4140/TCP.n.2018.142
   Kanis JA, 2010, OSTEOPOROSIS INT, V21, P407, DOI 10.1007/s00198 010 1253 y
   Kanis JA, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0278 z
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Lamy O, 2017, J CLIN ENDOCR METAB, V102, P354, DOI 10.1210/jc.2016 3170
   Lewiecki EM, 2013, J CLIN ENDOCR METAB, V98, P946, DOI 10.1210/jc.2012 3680
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   Niimi R, 2018, OSTEOPOROSIS INT, V29, P769, DOI 10.1007/s00198 017 4334 3
   Niimi R, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 019 0676 0
   Nogués X, 2018, OSTEOPOROSIS INT, V29, P489, DOI 10.1007/s00198 017 4310 y
   Popp AW, 2018, CALCIFIED TISSUE INT, V103, P50, DOI 10.1007/s00223 018 0394 4
   Ramírez L, 2015, ORAL HLTH PREV DENT, V13, P385, DOI 10.3290/j.ohpd.a34055
   Rao SD, 2017, J CLIN ENDOCR METAB, V102, P2111, DOI 10.1210/jc.2016 4037
   Sosa Henríquez M., 2014, Rev Osteoporos Metab Miner, V6, P63
   Henríquez MS, 2019, J ROY SOC MED, V112, P472, DOI 10.1177/0141076819861027
   Sosa Henriquez M., 2009, REV OSTEOPOROS METAB, V1, P53
   Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198 007 0550 6
   Tripto Shkolnik L, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115150
   Tripto Shkolnik L, 2018, CALCIFIED TISSUE INT, V103, P44, DOI 10.1007/s00223 018 0389 1
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tsourdi E, 2011, EUR J ENDOCRINOL, V165, P833, DOI 10.1530/EJE 11 0454
   Zanchetta MB., 2013, J BONE MINER RES, V28, P805
NR 36
TC 8
Z9 10
U1 0
U2 9
PU WILEY HINDAWI
PI LONDON
PA ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 1368 5031
EI 1742 1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD 2021 JUN 30
PY 2021
AR e14550
DI 10.1111/ijcp.14550
EA JUN 2021
PG 7
WC Medicine, General & Internal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Pharmacology & Pharmacy
GA TB6SJ
UT WOS:000668075300001
PM 34145944
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Mdingi, VS
   Gens, L
   Mys, K
   Varga, P
   Zeiter, S
   Marais, LC
   Richards, RG
   Moriarty, FT
   Chittò, M
AF Mdingi, Vuyisa Siphelele
   Gens, Lena
   Mys, Karen
   Varga, Peter
   Zeiter, Stephan
   Marais, Leonard Charles
   Richards, Robert Geoffrey
   Moriarty, Fintan Thomas
   Chitto, Marco
TI Short Term Celecoxib Promotes Bone Formation without Compromising
   Cefazolin Efficacy in an Early Orthopaedic Device Related Infection:
   Evidence from a Rat Model
SO ANTIBIOTICS BASEL
LA English
DT Article
DE non steroidal anti inflammatory drugs (NSAIDs); cyclooxygenase enzymes
   (COX 1 or COX 2); bone healing; orthopaedic device related infection
   (ODRI)
ID MINERAL DENSITY; ANALGESIA; ASPIRIN; IMPACT; DRUGS; NSAID
AB Non steroidal anti inflammatory drugs (NSAIDs) are crucial components of multimodal analgesia for musculoskeletal injuries, targeting cyclooxygenase (COX) enzymes (COX 1 and/or COX 2 isoenzymes). Concerns exist regarding their potential interference with bone healing and orthopaedic device related infections (ODRI), where data are limited. This study aimed to investigate whether the COX selectivity of NSAIDs interfered with antibiotic efficacy and bone changes in the setting of an ODRI. In vitro testing demonstrated that combining celecoxib (a COX 2 inhibitor) with cefazolin significantly enhanced antibacterial efficacy compared to cefazolin alone (p < 0.0001). In vivo experiments were performed using Staphylococcus epidermidis in the rat proximal tibia of an ODRI model. Long and short durations of celecoxib treatment in combination with antibiotics were compared to a control group receiving an antibiotic only. The long celecoxib treatment group showed impaired infection clearance, while the short celecoxib treatment showed increased bone formation (day 6, p < 0.0001), lower bone resorption (day 6, p < 0.0001), and lower osteolysis (day 6, BV/TV: p < 0.0001; BIC: p = 0.0005) compared to the control group, without impairing antibiotic efficacy (p > 0.9999). Given the use of NSAIDs as part of multimodal analgesia, and considering these findings, short term use of COX 2 selective NSAIDs like celecoxib not only aids pain management but also promotes favorable bone changes during ODRI.
C1 [Mdingi, Vuyisa Siphelele; Gens, Lena; Mys, Karen; Varga, Peter; Zeiter, Stephan; Richards, Robert Geoffrey; Moriarty, Fintan Thomas; Chitto, Marco] AO Res Inst Davos, CH 7270 Davos, Switzerland.
   [Mdingi, Vuyisa Siphelele; Marais, Leonard Charles] Univ KwaZulu Natal, Sch Clin Med, Dept Orthopaed Surg, ZA 4041 Durban, South Africa.
C3 AO Foundation; University of Kwazulu Natal
RP Chittò, M (通讯作者)，AO Res Inst Davos, CH 7270 Davos, Switzerland.
EM mdingiv@ukzn.ac.za
RI ; Marais, Leonard Charles/AIC 4689 2022; Mys, Karen/AAP 1774 2020;
   Richards, Robert/I 8235 2015; Varga, Peter/H 6181 2012; Zeiter,
   Stephan/AAI 1880 2021
OI Zeiter, Stephan/0000 0002 8155 4202; Mdingi, Vuyisa/0000 0001 8867 0700;
   Mys, Karen/0000 0001 7045 8998; Richards, Robert/0000 0002 7778 2480;
   Chitto, Marco/0000 0002 9813 9515; Gens, Lena/0000 0001 8844 9096;
   Varga, Peter/0000 0003 2738 6436; 
FU AO Trauma; AO Trauma as part of the Clinical Priority Program (CPP) on
   Bone Infection
FX This research and the APC were funded by AO Trauma as part of the
   Clinical Priority Program (CPP) on Bone Infection.
CR Al Farii Humaid, 2021, OTA Int, V4, pe092, DOI 10.1097/OI9.0000000000000092
   Aliuskevicius M, 2020, J ORTHOP RES, V38, P545, DOI 10.1002/jor.24498
   Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5
   Ayalasomayajula SP, 2004, PHARM RES DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Bernthal NM, 2022, AM J THER, V29, pE219, DOI 10.1097/MJT.0000000000001309
   Bosch DJ, 2022, ANESTHESIOLOGY, V136, P843, DOI 10.1097/ALN.0000000000004141
   Brune K, 2015, J PAIN RES, V8, P105, DOI 10.2147/JPR.S75160
   Burch MA, 2021, EUR CELLS MATER, V41, P739, DOI 10.22203/eCM.v041a47
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Çitil MU, 2015, MIKROBIYOL BUL, V49, P166
   Conaghan PG, 2012, RHEUMATOL INT, V32, P1491, DOI 10.1007/s00296 011 2263 6
   de Vor L, 2020, FEBS LETT, V594, P2556, DOI 10.1002/1873 3468.13767
   Epsley S, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.511799
   Freitag L, 2019, J ORTHOP RES, V37, P541, DOI 10.1002/jor.24210
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   Giannoudis PV, 2008, INJURY, V39, pS5, DOI 10.1016/S0020 1383(08)70010 X
   Goodman SB, 2005, J BIOMED MATER RES A, V72A, P279, DOI 10.1002/jbm.a.30231
   Halawi MJ, 2015, ORTHOPEDICS, V38, pE616, DOI 10.3928/01477447 20150701 61
   Jeffcoach DR, 2014, J TRAUMA ACUTE CARE, V76, P779, DOI 10.1097/TA.0b013e3182aafe0d
   Kasukawa Y, 2007, TOHOKU J EXP MED, V211, P275, DOI 10.1620/tjem.211.275
   KEHLET H, 1993, ANESTH ANALG, V77, P1048
   Kurmis AP, 2012, J BONE JOINT SURG AM, V94A, P815, DOI 10.2106/JBJS.J.01743
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Liu HZ, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 19315 0
   Mao JT, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10102626
   Marquez Lara A, 2016, JBJS REV, V4, DOI 10.2106/JBJS.RVW.O.00055
   Maruyama M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00386
   Matsushima S, 2011, CELLS TISSUES ORGANS, V194, P320, DOI 10.1159/000324642
   Murphy PB, 2023, TRAUMA SURG ACUTE CA, V8, DOI 10.1136/tsaco 2022 001056
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Powers ME, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003871
   Selig DJ, 2022, J CLIN PHARM THER, V47, P1122, DOI 10.1111/jcpt.13669
   Stadelmann VA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 77770 z
   Thangamani S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00750
   Thompson JM, 2019, J ORTHOP RES, V37, P2269, DOI 10.1002/jor.24428
   Welting T J M, 2011, Eur Cell Mater, V22, P420
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
   Zhang L, 2023, BMC ENDOCR DISORD, V23, DOI 10.1186/s12902 023 01309 2
NR 40
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 2079 6382
J9 ANTIBIOTICS BASEL
JI Antibiotics Basel
PD AUG
PY 2024
VL 13
IS 8
AR 715
DI 10.3390/antibiotics13080715
PG 14
WC Infectious Diseases; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases; Pharmacology & Pharmacy
GA F0P8R
UT WOS:001306935600001
PM 39200015
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Das Ghosh, L
   Ravi, V
   Sanpui, P
   Sundaresan, NR
   Chatterjee, K
AF Das Ghosh, Lopamudra
   Ravi, Venkatraman
   Sanpui, Pallab
   Sundaresan, Nagalingam R.
   Chatterjee, Kaushik
TI Keratin mediated attachment of stem cells to augment cardiomyogenic
   lineage commitment
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Keratin; Stem cells; Cardiomyocyte; Regenerative medicine;
   Cardiovascular diseases; Surface engineering
ID HUMAN HAIR KERATINS; BONE MARROW; EXTRACELLULAR MATRIX;
   CARDIAC HYPERTROPHY; HEART FAILURE; DIFFERENTIATION; EXPRESSION;
   BIOMATERIALS; HYDROGELS; PROTEINS
AB The objective of this work was to develop a simple surface modification technique using keratin derived from human hair for efficient cardiomyogenic lineage commitment of human mesenchymal stem cells (hMSCs). Keratin was extracted from discarded human hair containing both the acidic and basic components along with the heterodimers. The extracted keratin was adsorbed to conventional tissue culture polystyrene surfaces at different concentration. Keratin solution of 500 mu g/ml yielded a well coated layer of 12 +/  1 nm thickness with minimal agglomeration. The keratin coated surfaces promoted cell attachment and proliferation. Large increases in the mRNA expression of known cardiomyocyte genes such as cardiac actinin, cardiac troponin and beta myosin heavy chain were observed. Immunostaining revealed increased expression of sarcomeric alpha actinin and tropomyosin whereas Western blots confirmed higher expression of tropomyosin and myocyte enhancer factor 2C in cells on the keratin coated surface than on the non coated surface. Keratin promoted DNA demethylation of the Atp2a2 and Nkx2.5 genes thereby elucidating the importance of epigenetic changes as a possible molecular mechanism underlying the increased differentiation. A global gene expression analysis revealed a significant alteration in the expression of genes involved in pathways associated in cardiomyogenic commitment including cytokine and chemokine signaling, cell cell and cell matrix interactions, Wnt signaling, MAPK signaling, TGF beta signaling and FGF signaling pathways among others. Thus, adsorption of keratin offers a facile and affordable yet potent route for inducing cardiomyogenic lineage commitment of stem cells with important implications in developing xeno free strategies in cardiovascular regenerative medicine. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Das Ghosh, Lopamudra; Sanpui, Pallab; Chatterjee, Kaushik] Dept Mat Engn, Bangalore 560012, Karnataka, India.
   [Das Ghosh, Lopamudra; Sanpui, Pallab; Chatterjee, Kaushik] Indian Inst Sci, Bangalore 560012, Karnataka, India.
   [Ravi, Venkatraman; Sundaresan, Nagalingam R.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.
C3 Indian Institute of Science (IISC)   Bangalore; Indian Institute of
   Science (IISC)   Bangalore
RP Chatterjee, K (通讯作者)，Dept Mat Engn, Bangalore 560012, Karnataka, India.; Chatterjee, K (通讯作者)，Indian Inst Sci, Bangalore 560012, Karnataka, India.
EM kchatterjee@materials.iisc.ernet.in
RI ; Ravi, Venkatraman/C 7967 2014; Sanpui, Pallab/C 7689 2014; Chatterjee,
   Kaushik/AGN 9820 2022
OI Ravi, Venkatraman/0000 0002 1409 682X; Das Ghosh,
   Lopamudra/0000 0003 3867 6711; Sanpui, Pallab/0000 0002 2785 0115;
   Chatterjee, Kaushik/0000 0002 7204 2926; 
FU Department of Biotechnology, India (DBT) India
   [BT/PR8274/MED/31/221/2013]; Department of Science and Technology (DST),
   India; DBT [BT/07/IYBA/2013 10]; DBT IISc
FX This work was funded by the Department of Biotechnology, India (DBT)
   India (BT/PR8274/MED/31/221/2013). K.C. was supported by the Ramanujan
   fellowship from the Department of Science and Technology (DST), India.
   N.R.S. acknowledges support from Ramalingswamy fellowship and the
   Innovative Young Biotechnology Award (BT/07/IYBA/2013 10) from DBT and
   the DBT IISc Partnership Program. Authors gratefully acknowledge
   technical assistance from Dr. Jafar Hasan for SEM, Mr. Sumit Bhal for
   contact angle measurements, Mr. Karthick Jagenanthen for ellipsometry
   and Mrs. Pannaga for confocal imaging. Access to equipments at the
   Center for Nanoscience and Engineering and the Central Confocal Imaging
   Facility of IISc are acknowledged.
CR Ali SA, 1998, DEV BRAIN RES, V110, P31, DOI 10.1016/S0165 3806(98)00091 1
   Antonitsis Polychronis, 2007, Interact Cardiovasc Thorac Surg, V6, P593, DOI 10.1510/icvts.2007.157875
   Asumda FZ, 2012, DIFFERENTIATION, V83, P106, DOI 10.1016/j.diff.2011.10.002
   Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02 0072com
   Bosnakovski D, 2006, BIOTECHNOL BIOENG, V93, P1152, DOI 10.1002/bit.20828
   Byers HM, 2012, PEDIATR RES, V71, P162, DOI 10.1038/pr.2011.24
   Carreño JE, 2006, REV ESP CARDIOL, V59, P473, DOI 10.1016/S1885 5857(06)60796 2
   Celebi N. P. B., 2011, ADV MAT RES, V409, P111
   Chen QZ, 2008, MAT SCI ENG R, V59, P1, DOI 10.1016/j.mser.2007.08.001
   Cheng X., 2010, HDB EPIGENETICS, P9
   CLEMENTS JM, 1994, J CELL SCI, V107, P2127
   Curtis MW, 2009, J CARDIOVASC NURS, V24, P87, DOI 10.1097/01.JCN.0000343562.06614.49
   Das SK, 2012, GREEN CHEM, V14, P1322, DOI 10.1039/c2gc16676c
   de Guzman RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137233
   Dirkx E, 2013, BBA MOL BASIS DIS, V1832, P2414, DOI 10.1016/j.bbadis.2013.07.023
   Dolatshahi Pirouz A, 2011, COLLOID SURFACE B, V84, P18, DOI 10.1016/j.colsurfb.2010.12.004
   Editors, 2012, CIRC RES, V111, pE205, DOI 10.1161/CIRCRESAHA.112.280941
   Flaim CJ, 2008, STEM CELLS DEV, V17, P29, DOI 10.1089/scd.2007.0085
   Fujii T., 2013, J. Biol. Macromol, V13, P92, DOI DOI 10.14533/JBM.13.92
   Ghosh TK, 2009, MOL CELL BIOL, V29, P2205, DOI 10.1128/MCB.01923 08
   Ham TR, 2016, BIOMACROMOLECULES, V17, P225, DOI 10.1021/acs.biomac.5b01328
   Hartrianti P, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/752424
   Hashimoto K, 2007, EPIGENETICS US, V2, P86, DOI 10.4161/epi.2.2.4203
   Higuchi S, 2013, J BIOSCI BIOENG, V115, P320, DOI 10.1016/j.jbiosc.2012.10.004
   Hoch AI, 2014, STEM CELL TRANSL MED, V3, P643, DOI 10.5966/sctm.2013 0196
   Holt Casper D, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0559 0
   Hu X, 2011, BIOMATERIALS, V32, P8979, DOI 10.1016/j.biomaterials.2011.08.037
   Kassiri Z, 2005, THROMB HAEMOSTASIS, V93, P212, DOI 10.1160/TH04 08 0522
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kumar S, 2015, ACS APPL MATER INTER, V7, P3237, DOI 10.1021/am5079732
   Kundu AK, 2006, BIOCHEM BIOPH RES CO, V347, P347, DOI 10.1016/j.bbrc.2006.06.110
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874
   Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200
   Machackova J, 2006, CAN J CARDIOL, V22, P953, DOI 10.1016/S0828 282X(06)70315 4
   MAKAREM R, 1991, Biochemical Society Transactions, V19, p380S
   MARANTO AR, 1994, J BIOL CHEM, V269, P1222
   Martins AM, 2014, BIOMACROMOLECULES, V15, P635, DOI 10.1021/bm401679q
   Mehta A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103485
   Mendis S, 2011, INT J EPIDEMIOL, V40, P139, DOI 10.1093/ije/dyq165
   METZGER JM, 1995, CIRC RES, V76, P710, DOI 10.1161/01.RES.76.5.710
   Meyers VE, 2004, J CELL BIOCHEM, V93, P697, DOI 10.1002/jcb.20229
   Mora MF, 2009, BIOLOGICAL INTERACTIONS ON MATERIALS SURFACES: UNDERSTANDING AND CONTROLLING PROTEIN, CELL, AND TISSUE RESPONSES, P19, DOI 10.1007/978 0 387 98161 1_2
   Musso G, 2014, DEVELOPMENT, V141, P224, DOI 10.1242/dev.099796
   Nakamura A, 2002, BIOL PHARM BULL, V25, P569, DOI 10.1248/bpb.25.569
   Nguyen PD, 2012, AM J PHYSIOL CELL PH, V303, pC1220, DOI 10.1152/ajpcell.00449.2011
   Oda M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003574
   Ozhan G., 2015, CELL REGENERATION, V4
   Qian LC, 2004, BIOMATERIALS, V25, P1331, DOI 10.1016/j.biomaterials.2003.08.013
   Reichl S, 2009, BIOMATERIALS, V30, P6854, DOI 10.1016/j.biomaterials.2009.08.051
   Rose BA, 2010, PHYSIOL REV, V90, P1507, DOI 10.1152/physrev.00054.2009
   Rouse JG, 2010, MATERIALS, V3, P999, DOI 10.3390/ma3020999
   Santiago JA, 2009, TISSUE ENG PT A, V15, P3911, DOI 10.1089/ten.tea.2008.0603
   Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307
   Scopelliti PE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011862
   Sequeira V, 2014, BBA BIOMEMBRANES, V1838, P700, DOI 10.1016/j.bbamem.2013.07.011
   Shim WSN, 2004, BIOCHEM BIOPH RES CO, V324, P481, DOI 10.1016/j.bbrc.2004.09.087
   Shimomura Y, 2005, J INVEST DERM SYMP P, V10, P230, DOI 10.1111/j.1087 0024.2005.10112.x
   Sierpinski P, 2008, BIOMATERIALS, V29, P118, DOI 10.1016/j.biomaterials.2007.08.023
   Sivaraman B, 2009, LANGMUIR, V25, P3050, DOI 10.1021/la8036814
   Stein GS, 2009, BIOCHEM CELL BIOL, V87, P1, DOI 10.1139/O08 094
   Szeverenyi I, 2008, HUM MUTAT, V29, P351, DOI 10.1002/humu.20652
   Taraballi F, 2012, ADV HEALTHC MATER, V1, P513, DOI 10.1002/adhm.201200043
   Tian Y, 2010, PEDIATR CARDIOL, V31, P342, DOI 10.1007/s00246 009 9606 z
   Tijore A, 2015, ADV HEALTHC MATER, V4, P1399, DOI 10.1002/adhm.201500196
   Vallaster M, 2012, ACTA BIOCH BIOPH SIN, V44, P92, DOI 10.1093/abbs/gmr090
   Verma V, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/2/025007
   Wang S, 2012, CELL TISSUE RES, V347, P795, DOI 10.1007/s00441 011 1295 2
   Wei JH, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/4/045002
   Weissberg PL, 2005, HEART, V91, P696, DOI 10.1136/hrt.2004.038224
   Wen ZZ, 2011, J CELL MOL MED, V15, P1032, DOI 10.1111/j.1582 4934.2010.01255.x
   Wu Y., 2015, J BIOMED MAT RES B
   Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614
   Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037
NR 74
TC 10
Z9 11
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD MAR 1
PY 2017
VL 151
BP 178
EP 188
DI 10.1016/j.colsurfb.2016.12.023
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA EL2UJ
UT WOS:000394475400021
PM 28012406
DA 2025 08 17
ER

PT J
AU Shima, K
   Nemoto, W
   Tsuchiya, M
   Tan No, K
   Takano Yamamoto, T
   Sugawara, S
   Endo, Y
AF Shima, Kazuhiro
   Nemoto, Wataru
   Tsuchiya, Masahiro
   Tan No, Koichi
   Takano Yamamoto, Teruko
   Sugawara, Shunji
   Endo, Yasuo
TI The Bisphosphonates Clodronate and Etidronate Exert Analgesic Effects by
   Acting on Glutamate  and/or ATP Related Pain Transmission Pathways
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE analgesic effect; clodronate; etidronate; phosphate transporter; ATP;
   glutamate
ID NITROGEN CONTAINING BISPHOSPHONATES; PHOSPHATE TRANSPORTERS;
   MOLECULAR MECHANISMS; IN VIVO; INHIBITION; INVOLVEMENT; MICE;
   ALENDRONATE; ANTAGONISTS; RECEPTORS
AB Bisphosphonates (BPs) are typical anti bone resorptive drugs, with nitrogen containing BPs (N BPs) being stronger than non nitrogen containing BPs (non N BPs). However, N BPs have inflammatory/necrotic effects, while the non N BPs clodronate and etidronate lack such side effects. Pharmacological studies have suggested that clodronate and etidronate can (i) prevent the side effects of N BPs in mice via inhibition of the phosphate transporter families SLC20 and/or SLC34, through which N BPs enter soft tissue cells, and (ii) also inhibit the phosphate transporter family SLC17. Vesicular transporters for the pain transmitters glutamate and ATP belong to the SLC17 family. Here, we examined the hypothesis that clodronate and etidronate may enter neurons through SLC20/34, then inhibit SLC17 mediated transport of glutamate and/or ATP, resulting in their decrease, and thereby produce analgesic effects. We analyzed in mice the effects of various agents [namely, intrathecally injected clodronate, etidronate, phosphonoformic acid (PFA; an inhibitor of SLC20/34), and agonists of glutamate and ATP receptors] on the nociceptive responses to intraplantar injection of capsaicin. Clodronate and etidronate produced analgesic effects, and these effects were abolished by PFA. The analgesic effects were reduced by N methyl D aspartate (agonist of the NMDA receptor, a glutamate receptor) and alpha,beta methylene ATP (agonist of the P2X receptor, an ATP receptor). SLC20A1, SLC20A2, and SLC34A1 were detected within the mouse lumbar spinal cord. Although we need direct evidence, these results support the above hypothesis. Clodronate and etidronate may be representatives of a new type of analgesic drug. Such drugs, with both anti bone resorptive and unique analgesic effects without the adverse effects associated with N BPs, might be useful for osteoporosis.
C1 [Shima, Kazuhiro; Sugawara, Shunji; Endo, Yasuo] Tohoku Univ, Grad Sch Dent, Div Oral Mol Regulat, Sendai, Miyagi 9808575, Japan.
   [Shima, Kazuhiro; Takano Yamamoto, Teruko] Tohoku Univ, Grad Sch Dent, Div Orthodont & Dentofacial Orthoped, Sendai, Miyagi 9808575, Japan.
   [Nemoto, Wataru; Tan No, Koichi] Tohoku Pharmaceut Univ, Dept Pharmacol, Sendai, Miyagi 9818558, Japan.
   [Tsuchiya, Masahiro] Tohoku Fukushi Univ, Sendai, Miyagi 9818522, Japan.
C3 Tohoku University; Tohoku University; Tohoku Medical & Pharmaceutical
   University
RP Endo, Y (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Oral Mol Regulat, Sendai, Miyagi 9808575, Japan.
EM endo@dent.tohoku.ac.jp
RI Nemoto, Wataru/AAK 6004 2021; Tsuchiya, Masahiro/C 5553 2018; TSUCHIYA,
   MASAHIRO/C 5553 2018
OI Nemoto, Wataru/0000 0003 1253 5523; Tsuchiya,
   Masahiro/0000 0002 7000 4547; Tan No, Koichi/0000 0001 6724 848X; 
FU Grants in Aid for Scientific Research [16K11672] Funding Source: KAKEN
CR Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006
   Crépin S, 2010, EUR J CLIN PHARMACOL, V66, P547, DOI 10.1007/s00228 010 0822 5
   Dobrek L, 2011, POSTEP HIG MED DOSW, V65, P338
   DRIESSEN B, 1994, BRAIN RES, V666, P182, DOI 10.1016/0006 8993(94)90770 6
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Endo Y, 1999, BRIT J PHARMACOL, V126, P903, DOI 10.1038/sj.bjp.0702367
   Forster IC, 2013, MOL ASPECTS MED, V34, P386, DOI 10.1016/j.mam.2012.07.007
   Fujita T, 2009, J BONE MINER METAB, V27, P234, DOI 10.1007/s00774 009 0035 0
   Funayama H, 2005, CALCIFIED TISSUE INT, V76, P448, DOI 10.1007/s00223 004 0180 3
   He Lei, 2009, Human Genomics, V3, P195
   HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014 2999(80)90515 4
   Kim S, 2013, EUR J PHARMACOL, V699, P14, DOI 10.1016/j.ejphar.2012.11.031
   KOSTER R, 1959, FED PROC, V18, P412
   Larsson M, 2011, NEUROSCIENTIST, V17, P256, DOI 10.1177/1073858409349913
   Nemoto W, 2015, NEUROPHARMACOLOGY, V99, P221, DOI 10.1016/j.neuropharm.2015.07.022
   Nishimura M, 2008, DRUG METAB PHARMACOK, V23, P22, DOI 10.2133/dmpk.23.22
   Oizumi T, 2010, J ORAL MAXIL SURG, V68, P1043, DOI 10.1016/j.joms.2009.08.027
   Oizumi T, 2009, BASIC CLIN PHARMACOL, V104, P384, DOI 10.1111/j.1742 7843.2008.00374.x
   Okada S, 2013, TOHOKU J EXP MED, V231, P145, DOI 10.1620/tjem.231.145
   Omote H, 2013, PHYSIOLOGY, V28, P39, DOI 10.1152/physiol.00033.2012
   Omote H, 2011, BIOCHEMISTRY US, V50, P5558, DOI 10.1021/bi200567k
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Reimer RJ, 2004, PFLUG ARCH EUR J PHY, V447, P629, DOI 10.1007/s00424 003 1087 y
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   SAKURADA T, 1994, BRAIN RES, V649, P319, DOI 10.1016/0006 8993(94)91080 4
   SAKURADA T, 1992, NEUROPHARMACOLOGY, V31, P1279, DOI 10.1016/0028 3908(92)90057 V
   Sakurada T, 1998, PHARMACOL BIOCHEM BE, V59, P339, DOI 10.1016/S0091 3057(97)00423 1
   Sato S, 2009, HISTOCHEM CELL BIOL, V131, P583, DOI 10.1007/s00418 009 0556 6
   Tsuda M, 1999, BRIT J PHARMACOL, V127, P449, DOI 10.1038/sj.bjp.0702582
   Tsuda M, 2010, BRAIN RES REV, V63, P222, DOI 10.1016/j.brainresrev.2009.11.003
   Virkki LV, 2007, AM J PHYSIOL RENAL, V293, pF643, DOI 10.1152/ajprenal.00228.2007
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhuo M, 2011, MOL BRAIN, V4, DOI 10.1186/1756 6606 4 31
NR 33
TC 27
Z9 30
U1 0
U2 3
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD MAY
PY 2016
VL 39
IS 5
BP 770
EP 777
DI 10.1248/bpb.b15 00882
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DK8IH
UT WOS:000375169900016
PM 27150146
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, DW
   Zhang, JC
   Fong, CC
   Yao, XS
   Yang, MS
AF Zhang, Dawei
   Zhang, Jinchao
   Fong, Chichun
   Yao, Xinsheng
   Yang, Mengsu
TI Herba epimedii flavonoids suppress osteoclastic differentiation and bone
   resorption by inducing G2/M arrest and apoptosis
SO BIOCHIMIE
LA English
DT Article
DE Icariin; Baohuoside 1; Osteoclast; Bone resorption; G2/M arrest;
   Apoptosis
ID HORMONE REPLACEMENT THERAPY; CELL CYCLE ARREST; RABBIT OSTEOCLASTS;
   IN VIVO; PROLIFERATION; DERIVATIVES; EXPRESSION; GLYCOSIDES
AB Accumulating evidences suggest that Herba epimedii has the potential benefits against osteoporosis. However, previous studies were focused on the crude extract, total flavonoids (IF) and icariin (ICA), and the detailed molecular mechanisms of action and structure activity relationship (SAR) remain unclear. Herein we aimed to systematically investigate the effects of Herba epimedii flavonoids (HEF) on the activity of osteoclasts, and explore the potential SAR. Both ICA and baohuoside 1 (BS) significantly inhibited the proliferation of RAW 264.7 cells (IC50 25 mu M and 67 mu M, respectively). Treatment of ICA resulted in G2/M arrest and apoptosis in RAW 264.7 cells as early as 12 h. Besides, HEF remarkably suppressed vitamin D induced differentiation of osteoclasts in rabbit bone marrow cells and the bone resorption of rabbit mature osteoclasts in vitro. It is notable that the inhibitory effect of 100 mu M ICA and BS on osteoclast formation is almost 90% and the inhibition rate on bone resorption is 50% and 80%, respectively. Besides, RANKL induced osteoclast formation from RAW 264.7 cells and the expression of TRAP, CA II, CTSK and MMP 9 was significantly reduced by the treatment of 25 mu M HEF and 17 beta estradiol (ES), and the inhibitory strength increases in the order TF < ES < ICA < BS, which was blocked by ICI182780 suggesting that the regulation of osteoclast activity might be ER dependent. Furthermore, the free hydroxyl group at C 7 of BS played an important role in the SAR for anti osteoclast action. To conclude, HEF could regulate the formation and activity of osteoclasts by inhibiting the proliferation and differentiation, inducing apoptosis and cell cycle arrest and suppressing bone resorption of osteoclasts. Changes in osteoclast activity are probably mediated predominantly by interaction with nuclear estrogen receptors and via mitochondrial pathway. HEF, especially BS, has great potential for the prevention and treatment of osteoporosis. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Zhang, Dawei; Yao, Xinsheng] Shenyang Pharmaceut Univ, Dept Nat Prod Chem, Shenyang 110016, Liaoning, Peoples R China.
   [Zhang, Dawei] Guangdong Med Coll, Dept Pharmacol, Zhanjiang 524023, Guangdong, Peoples R China.
   [Zhang, Dawei; Fong, Chichun; Yang, Mengsu] City Univ Hong Kong, Dept Biol & Chem, Kowloon, Hong Kong, Peoples R China.
   [Zhang, Jinchao] Hebei Univ, Coll Chem & Environm Sci, Dept Chem, Baoding 071002, Hebei, Peoples R China.
C3 Shenyang Pharmaceutical University; Guangdong Medical University; City
   University of Hong Kong; Hebei University
RP Yao, XS (通讯作者)，Shenyang Pharmaceut Univ, Dept Nat Prod Chem, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China.
EM dwzhanghk@gmail.com; tyaoxs@jnu.edu.cn; bhmyang@cityu.edu.hk
RI Yang, Mengsu/I 5750 2015; Zhang, Dawei/AAE 8366 2020
OI Yang, Mengsu/0000 0003 2083 2296; 
FU National Natural Science Foundation of China (NSFC); Research Grants
   Council (RGC) of the Hong Kong [30418007]
FX This research was supported by The National Natural Science Foundation
   of China (NSFC) and the Research Grants Council (RGC) of the Hong Kong
   Joint Research Scheme. No. 30418007: Modern approach to study the
   osteoprotective effects and active principles of Herba Epimedii and
   Rhizoma Drynariae.
CR Akiyama T, 2005, BIOL PROCED ONLINE, V7, P48, DOI 10.1251/bpo105
   An SJ, 2000, CHIN J OSTEOPOROSIS, V6, P55
   ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo 119 1 119
   Cai YZ, 2006, LIFE SCI, V78, P2872, DOI 10.1016/j.lfs.2005.11.004
   Cárdenas M, 2006, BIOORGAN MED CHEM, V14, P2966, DOI 10.1016/j.bmc.2005.12.021
   Chen WF, 2011, BRIT J NUTR, V105, P180, DOI 10.1017/S0007114510003247
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   David JP, 1998, J BONE MINER RES, V13, P1730, DOI 10.1359/jbmr.1998.13.11.1730
   Davison S, 2003, CLIN ENDOCRINOL, V58, P249, DOI 10.1046/j.1365 2265.2003.01774.x
   Dhanwal DK, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/757102
   Dong XW, 2011, MOLECULES, V16, P8257, DOI 10.3390/molecules16108257
   Ghiotto RCT, 2004, INT J QUANTUM CHEM, V97, P949, DOI 10.1002/qua.10798
   Grünz G, 2012, MECH AGEING DEV, V133, P1, DOI 10.1016/j.mad.2011.11.005
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hu GR, 2002, ANN ALLERG ASTHMA IM, V88, P478, DOI 10.1016/S1081 1206(10)62386 1
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Huang J, 2007, CHINESE SCI BULL, V52, P890, DOI 10.1007/s11434 007 0121 4
   HUGHES DE, 1994, J BONE MINER RES, V9, P39
   Johnell O., 1997, AM J MED, V103, p12S
   Karieb S, 2011, J CELL BIOCHEM, V112, P476, DOI 10.1002/jcb.22935
   Kitaoka M, 1998, PLANTA MED, V64, P511, DOI 10.1055/s 2006 957504
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Leung P C, 2001, Hong Kong Med J, V7, P332
   Li SG, 2010, CANCER LETT, V298, P222, DOI 10.1016/j.canlet.2010.07.009
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Ma KC, 1996, AM J CHINESE MED, V24, P77, DOI 10.1142/S0192415X96000104
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Mukne Alka P, 2011, Pharmacogn Rev, V5, P13, DOI 10.4103/0973 7847.79095
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Odontuya G, 2005, PHYTOTHER RES, V19, P782, DOI 10.1002/ptr.1723
   Plochmann K, 2007, ARCH BIOCHEM BIOPHYS, V460, P1, DOI 10.1016/j.abb.2007.02.003
   Qiu Feng Qiu Feng, 1999, Acta Pharmaceutica Sinica, V34, P222
   Shiao YH, 1998, CARCINOGENESIS, V19, P1203, DOI 10.1093/carcin/19.7.1203
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Wang G, 2006, CANCER LETT, V241, P102, DOI 10.1016/j.canlet.2005.10.050
   Wang Q, 2011, INT J ONCOL, V39, P973, DOI 10.3892/ijo.2011.1086
   Wu H, 2003, PROG DRUG RES, V60, P1
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   Xu M, 2009, OSTEOPOROSIS INT, V20, P519, DOI 10.1007/s00198 008 0724 x
   Yang SH, 2008, J ETHNOPHARMACOL, V115, P104, DOI 10.1016/j.jep.2007.09.011
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhang DW, 2010, METHODS MOL BIOL, V625, P41, DOI 10.1007/978 1 60761 579 8_5
   Zhang JF, 2009, PHYTOMEDICINE, V16, P521, DOI 10.1016/j.phymed.2009.01.003
   Zhang Y, 2008, ARCH PHARM RES, V31, P1534, DOI 10.1007/s12272 001 2147 5
NR 44
TC 66
Z9 74
U1 1
U2 43
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD DEC
PY 2012
VL 94
IS 12
BP 2514
EP 2522
DI 10.1016/j.biochi.2012.06.033
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 056UV
UT WOS:000312517800008
PM 22796380
DA 2025 08 17
ER

PT J
AU Xia, HT
   Cao, DG
   Yang, F
   Yang, WL
   Li, W
   Liu, P
   Wang, SH
   Yang, FY
AF Xia, Hanting
   Cao, Duanguang
   Yang, Fo
   Yang, Wenlong
   Li, Wei
   Liu, Pu
   Wang, Shuhao
   Yang, Fengyun
TI Jiawei Yanghe decoction ameliorates cartilage degradation in vitro and
   vivo via Wnt/β catenin signaling pathway
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Traditional Chinese medicine; Wnt/beta catenin signaling pathway;
   Osteoarthritis; Jiawei yanghe decoction
ID ENDOTHELIAL GROWTH FACTOR; MATRIX METALLOPROTEINASES; ARTICULAR
   CHONDROCYTES; KNEE OSTEOARTHRITIS; WNT; INHIBITION; APOPTOSIS; PROMOTES;
   PROLIFERATION; ACTIVATION
AB Jiawei Yanghe decoction (JWYHD) is a Traditional Chinese Medicine (TCM) formula for the treatment of osteoarthritis (OA), however the underlying mechanisms of action of JWYHD in OA are not fully explored. This study investigates how JWYHD protects cartilage from degradation via Wnt/beta catenin signaling pathway. The chondroprotective and anti inflammatory effect of JWYHD on chondrocytes in vitro and on MIA induced OA rat model in vivo were investigated. In vitro, JWYHD increased the chondrocyte viability against interleukin (IL) 1 beta induced chondrocytes apoptosis and preserved glycosaminoglycans in the extracellular matrix. JWYHD promoted chondrocyte viability against apoptosis, decreased MMP 3, MMP 13, Caspase 3, Caspase 9 via Wnt/beta catenin signaling pathway in both IL 1 beta induced and Lid induced chondrocytes. The qRT PCR and western blot results showed that mRNA and protein expressions of Wnt signaling pathway related genes beta catenin and CyclinD1, apoptosis related genes Casapase 3 and Caspase 9, collagen degradation related genes Metalloproteinase (MMP) 3 and MMP 13 were up regulated, and Col2a1 was down regulated on IL 1 beta induced chondrocytes. Treatment with JWYHD reversed these effects in a dose dependent manner. Licl was used as Wnt/beta catenin signaling pathway activator in chondrocytes to determine the molecular mechanisms. Activation of Wnt signaling pathway by Licl up regulated beta catenin, CyclinD1, Axin2, Caspase 3, Caspase 9, MMP 3, MMP 13 and IL 113. These effects were blocked by JWYHD treatment. Furthermore, 75 Sprawl Dawley rats were used to verify the results obtained in vitro. A total of 75 rats were randomly divided into the control group (no MIA induced OA, received intragastric administration of an equivalent amount of saline), the OA group (MIA induced OA, received intragastric administration of an equivalent amount of saline), and the JWYHD treatment group (MIA induced OA, received intragastric administration of an equivalent amount of various concentrations of JWYHD at 1.4/2.7/5.5 g/kg). After 8 weeks of administration, all rats were sacrificed. JWYHD decreased the MIA induced up regulation of beta catenin, CyclinD1, Caspase 3, Caspase 9, MMP 3 and MMP 13 protein expressions in cartilage. It was also demonstrated that JWYHD decreased serum and synovium pro inflammatory cy  tokines, IL 6 and TNF alpha in MIA induced OA rats and ameliorated the cartilage degradation. Histopathological staining, macroscopic observation and micro CT scan with 3 dimension remodeling showed a cartilage protective effect of JWYHD. In conclusion, JWYHD possess multiple capabilities including preventing chondrocyte apoptosis, preserving integrity of extracellular matrix and anti inflammatory effect in the treatment of OA both in vitro and in vivo.
C1 [Xia, Hanting; Yang, Wenlong] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China.
   [Cao, Duanguang; Yang, Fo; Li, Wei; Liu, Pu; Wang, Shuhao; Yang, Fengyun] Jiangxi Univ Tradit Chinese Med, Nanchang, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University
   of Traditional Chinese Medicine
RP Yang, FY (通讯作者)，Jiangxi Univ Tradit Chinese Med, Nanchang, Jiangxi, Peoples R China.
EM yfy@jxutcm.edu.cn
RI Xia, Hanting/LNP 3775 2024
OI Xia, Hanting/0000 0003 1842 7814
FU Health commission of Jiangxi Province (TCM famous master Xu HZ studio);
   Traditional Chinese Medicine foundation of Health commission of Jiangxi
   Province [2018A371]; Postgraduate Innovation Foundation of Jiangxi
   Province [YC2017 S363]; Special funds for the Construction of
   first class disciplines in Jiangxi Province [JXSYLXK ZHYI012]
FX This study was supported by the Health commission of Jiangxi Province
   (TCM famous master Xu HZ studio), the Traditional Chinese Medicine
   foundation of Health commission of Jiangxi Province (2018A371) and the
   Postgraduate Innovation Foundation of Jiangxi Province (YC2017 S363).
   Special funds for the Construction of first class disciplines in Jiangxi
   Province (JXSYLXK ZHYI012).
CR Aicher WK, 2014, ANN RHEUM DIS, V73, P645, DOI 10.1136/annrheumdis 2013 204308
   Amalinei C, 2010, ROM J MORPHOL EMBRYO, V51, P215
   [Anonymous], [No title captured]
   Bao GF, 2016, INFLAMMATION, V39, P601, DOI 10.1007/s10753 015 0285 z
   Bassiouni HM, 2011, MOD RHEUMATOL, V21, P500, DOI 10.1007/s10165 011 0441 8
   Bigg Heather F., 2001, Current Opinion in Pharmacology, V1, P314, DOI 10.1016/S1471 4892(01)00055 8
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Blom AB, 2010, CURR DRUG TARGETS, V11, P620
   Chen WP, 2014, INT IMMUNOPHARMACOL, V19, P174, DOI 10.1016/j.intimp.2013.12.007
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Enomoto Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802
   Goldring MB, 2000, ARTHRITIS RHEUM US, V43, P1916, DOI 10.1002/1529 0131(200009)43:9<1916::AID ANR2>3.0.CO;2 I
   Goldring SR, 2004, CLIN ORTHOP RELAT R, pS27, DOI 10.1097/01.blo.0000144854.66565.8f
   Guilak F, 2018, MATRIX BIOL, V71 72, P40, DOI 10.1016/j.matbio.2018.05.008
   Haeusler G, 2005, CALCIFIED TISSUE INT, V76, P326, DOI 10.1007/s00223 004 0161 6
   Hawker GA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091286
   Jain A, 2001, ARTHRITIS RHEUM, V44, P1754, DOI 10.1002/1529 0131(200108)44:8<1754::AID ART310>3.0.CO;2 8
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Khanna D, 2007, CURR OPIN PHARMACOL, V7, P344, DOI 10.1016/j.coph.2007.03.002
   Kobayashi K, 2003, J VET MED SCI, V65, P1195, DOI 10.1292/jvms.65.1195
   Li J, 2014, INT IMMUNOPHARMACOL, V23, P85, DOI 10.1016/j.intimp.2014.08.012
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Liu FY, 2015, INT J MOL MED, V36, P1311, DOI 10.3892/ijmm.2015.2331
   Liu FY, 2014, INT J MOL MED, V34, P1573, DOI 10.3892/ijmm.2014.1962
   Liu Q, 2015, OSTEOARTHR CARTILAGE, V23, P1154, DOI 10.1016/j.joca.2015.03.021
   Liu Q, 2017, SCI REP, V7, P1, DOI [DOI 10.1016/j.ydbio.2018.04.009, DOI 10.3389/FCIMB.2017.00181]
   Loeser RF, 2009, OSTEOARTHR CARTILAGE, V17, P971, DOI 10.1016/j.joca.2009.03.002
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Meszaros E, 2012, THER ADV CHRONIC DIS, V3, P219, DOI 10.1177/2040622312454157
   Miclea RL, 2011, OSTEOARTHR CARTILAGE, V19, P1363, DOI 10.1016/j.joca.2011.07.014
   Mistry D, 2004, OSTEOARTHR CARTILAGE, V12, P131, DOI 10.1016/j.joca.2003.10.006
   Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475
   Miyamoto K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184388
   Nalesso G, 2011, J CELL BIOL, V193, P551, DOI 10.1083/jcb.201011051
   Nishida T, 2017, METHODS MOL BIOL, V1489, P273, DOI 10.1007/978 1 4939 6430 7_25
   Oh DW, 2017, DRUG DELIV, V24, P1056, DOI 10.1080/10717544.2017.1346001
   Park JW, 2016, COLLOID SURFACE B, V147, P265, DOI 10.1016/j.colsurfb.2016.07.050
   Reddi AH, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1858
   Sassi N, 2014, J RECEPT SIG TRANSD, V34, P73, DOI 10.3109/10799893.2013.863919
   Sheng ZG, 2008, TOXICOL APPL PHARM, V226, P119, DOI 10.1016/j.taap.2007.08.025
   Shiomi T, 2010, PATHOL INT, V60, P477, DOI 10.1111/j.1440 1827.2010.02547.x
   Shortkroff S, 2007, OSTEOARTHR CARTILAGE, V15, P147, DOI 10.1016/j.joca.2006.07.004
   Sovolyova N, 2014, BIOL CHEM, V395, P1, DOI 10.1515/hsz 2013 0174
   Takegami Y, 2016, BIOCHEM BIOPH RES CO, V473, P255, DOI 10.1016/j.bbrc.2016.03.089
   Tang X, 2016, ARTHRITIS RHEUMATOL, V68, P648, DOI 10.1002/art.39465
   Udo M, 2016, OSTEOARTHR CARTILAGE, V24, P1284, DOI 10.1016/j.joca.2016.02.005
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Wu GW, 2013, INT J MOL MED, V32, P1001, DOI 10.3892/ijmm.2013.1481
   Wu J, 2017, MOL MED REP, V15, P2423, DOI 10.3892/mmr.2017.6278
   Yuasa T, 2008, LAB INVEST, V88, P264, DOI 10.1038/labinvest.3700747
   Zhang YQ, 2017, INT J RHEUM DIS, V20, P941, DOI 10.1111/1756 185X.13050
   Zhou Y, 2016, EUR J PHARMACOL, V789, P109, DOI 10.1016/j.ejphar.2016.07.027
   Zhu M, 2008, ARTHRITIS RHEUM US, V58, P2053, DOI 10.1002/art.23614
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 54
TC 35
Z9 40
U1 2
U2 18
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2020
VL 122
AR 109708
DI 10.1016/j.biopha.2019.109708
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KA7VF
UT WOS:000506005800027
PM 31918279
OA gold
DA 2025 08 17
ER

PT J
AU Ledda, M
   D'Emilia, E
   Giuliani, L
   Marchese, R
   Foletti, A
   Grimaldi, S
   Lisi, A
AF Ledda, Mario
   D'Emilia, Enrico
   Giuliani, Livio
   Marchese, Rodolfo
   Foletti, Alberto
   Grimaldi, Settimio
   Lisi, Antonella
TI Nonpulsed Sinusoidal Electromagnetic Fields as a Noninvasive Strategy in
   Bone Repair: The Effect on Human Mesenchymal Stem Cell Osteogenic
   Differentiation
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; MAGNETIC FIELDS; GENE EXPRESSION;
   MOLECULAR MECHANISMS; OVARIECTOMIZED RATS; RANKL EXPRESSION;
   STIMULATION; FRACTURES; OSTEOPROTEGERIN; MEDICINE
AB In vivo control of osteoblast differentiation is an important process needed to maintain the continuous supply of mature osteoblast cells for growth, repair, and remodeling of bones. The regulation of this process has also an important and significant impact on the clinical strategies and future applications of cell therapy. In this article, we studied the effect of nonpulsed sinusoidal electromagnetic field radiation tuned at calcium ion cyclotron frequency of 50 Hz exposure treatment for bone differentiation of human mesenchymal stem cells (hMSCs) alone or in synergy with dexamethasone, their canonical chemical differentiation agent. Five days of continuous exposure to calcium ion cyclotron resonance affect hMSC proliferation, morphology, and cytoskeletal actin reorganization. By quantitative real time polymerase chain reaction, we also observed an increase of osteoblast differentiation marker expression such as Runx2, alkaline phosphatase (ALP), osteocalcin (OC), and osteopontin (OPN) together with the osteoprotegerin mRNA modulation. Moreover, in these cells, the increase of the protein expression of OPN and ALP was also demonstrated. These results demonstrate bone commitment of hMSCs through a noninvasive and biocompatible differentiating physical agent treatment and highlight possible applications in new regenerative medicine protocols.
C1 [Ledda, Mario; Foletti, Alberto; Grimaldi, Settimio; Lisi, Antonella] CNR, Inst Translat Pharmacol, I 00133 Rome, Italy.
   [D'Emilia, Enrico; Giuliani, Livio] Dipartimento Insediamenti Prod & Interaz Con Ambi, Rome, Italy.
   [Giuliani, Livio] INAIL Florence, Rome, Italy.
   [Marchese, Rodolfo] FBF S Peter Hosp, Res Ctr, Rome, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Farmacologia
   Traslazionale (IFT CNR)
RP Lisi, A (通讯作者)，CNR, Inst Translat Pharmacol IFT CNR, Via Fosso del Cavaliere 100, I 00133 Rome, Italy.
EM antonella.lisi@ift.cnr.it
RI ; Foletti, Alberto/ABH 3384 2021; Lisi, Antonella/C 7024 2015; Ledda,
   Mario/B 5656 2015
OI Lisi, Antonella/0000 0002 5465 9500; Ledda, Mario/0000 0002 0349 8938
FU INAIL [B n.22/DIPIA]
FX This work was supported by the contract grant sponsor INAIL (contract B
   n.22/DIPIA). The authors thank Antonella Greco for
   copyediting/proofreading the English in this article.
CR Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Barnaba SA, 2012, RHEUMATOL INT, V32, P1025, DOI 10.1007/s00296 010 1724 7
   BASSETT CAL, 1982, JAMA J AM MED ASSOC, V247, P623, DOI 10.1001/jama.247.5.623
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   BELLOMO G, 1990, J CELL PHYSIOL, V143, P118, DOI 10.1002/jcp.1041430116
   BURSTONE MS, 1960, ANN NY ACAD SCI, V85, P431, DOI 10.1111/j.1749 6632.1960.tb49972.x
   Canalis E, 2001, J CLIN ENDOCR METAB, V86, P5681, DOI 10.1210/jc.86.12.5681
   Chang K, 2005, J ORTHOP RES, V23, P1308, DOI 10.1016/j.orthres.2005.03.012
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   Chao Edmund Y S, 2003, Eur Cell Mater, V6, P72
   Chao EYS, 2004, CLIN ORTHOP RELAT R, P12, DOI 10.1097/01.blo.0000132263.14046.0c
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cuccurazzu B, 2010, EXP NEUROL, V226, P173, DOI 10.1016/j.expneurol.2010.08.022
   De Carlo F, 2012, TISSUE ENG PT A, V18, P2248, DOI [10.1089/ten.tea.2012.0113, 10.1089/ten.TEA.2012.0113]
   Del Giudice E, 2002, BIOELECTROMAGNETICS, V23, P522, DOI 10.1002/bem.10046
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Fini M, 2006, J BONE JOINT SURG BR, V88B, P123, DOI 10.1302/0301 620X.88B1.16496
   Foletti A, 2013, ELECTROMAGN BIOL MED, V32, P484, DOI 10.3109/15368378.2012.743908
   Formigli L, 2007, J CELL PHYSIOL, V211, P296, DOI 10.1002/jcp.20936
   Funk RHW, 2006, CELLS TISSUES ORGANS, V182, P59, DOI 10.1159/000093061
   Funk RHW, 2009, PROG HISTOCHEM CYTO, V43, P177, DOI 10.1016/j.proghi.2008.07.001
   Gaetani R, 2009, CARDIOVASC RES, V82, P411, DOI 10.1093/cvr/cvp067
   Gan JC, 2006, EUR SPINE J, V15, P1301, DOI 10.1007/s00586 006 0087 y
   Giusti A, 2013, GERIATR GERONTOL INT, V13, P393, DOI 10.1111/j.1447 0594.2012.00915.x
   GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245
   Griffin XL, 2008, INJURY, V39, P419, DOI 10.1016/j.injury.2007.12.014
   Harden R N, 2007, Pain Pract, V7, P248, DOI 10.1111/j.1533 2500.2007.00145.x
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Huang LQ, 2008, CHINESE MED J PEKING, V121, P2095, DOI 10.1097/00029330 200810020 00028
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   Kim HJ, 2010, BMB REP, V43, P524, DOI 10.5483/BMBRep.2010.43.8.524
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Koukouritaki SB, 1996, J CELL BIOCHEM, V62, P251, DOI 10.1002/(SICI)1097 4644(199608)62:2<251::AID JCB13>3.0.CO;2 O
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lane NE, 2010, ANN NY ACAD SCI, V1192, P81, DOI 10.1111/j.1749 6632.2009.05228.x
   Ledda M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061535
   LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202
   Li XL, 2006, ANN NY ACAD SCI, V1068, P26, DOI 10.1196/annals.1346.006
   LIBOFF A R, 1985, Journal of Biological Physics, V13, P99, DOI 10.1007/BF01878387
   Lin HY, 2010, J ORTHOP RES, V28, P265, DOI 10.1002/jor.20964
   Lisi A, 2006, BIOELECTROMAGNETICS, V27, P641, DOI 10.1002/bem.20255
   Liu HF, 2013, BIOELECTROMAGNETICS, V34, P323, DOI 10.1002/bem.21770
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu L, 2012, CELL BIOL TOXICOL, V28, P279, DOI 10.1007/s10565 012 9222 1
   Luo Erping, 2005, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V22, P1168
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Ma Q., 2013, PLOS ONE, V9
   Manni V, 2004, BIOELECTROMAGNETICS, V25, P118, DOI 10.1002/bem.10158
   Manni V, 2002, BIOELECTROMAGNETICS, V23, P298, DOI 10.1002/bem.10023
   Marks RA, 2000, ADV THER, V17, P57, DOI 10.1007/BF02854838
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Otter MW, 1998, CLIN ORTHOP RELAT R, pS90
   Piacentini R, 2008, J CELL PHYSIOL, V215, P129, DOI 10.1002/jcp.21293
   Pilla Arthur A, 2002, J Orthop Sci, V7, P420, DOI 10.1007/s007760200073
   Shen WW, 2010, BIOELECTROMAGNETICS, V31, P113, DOI 10.1002/bem.20535
   Shi HF, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 35
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Sun JS, 2004, BIOMATERIALS, V25, P607, DOI 10.1016/S0142 9612(03)00567 2
   Tsai MT, 2007, BIOELECTROMAGNETICS, V28, P519, DOI 10.1002/bem.20336
   Ventura C, 2004, FASEB J, V18, P155, DOI 10.1096/fj.04 2695fje
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
   Zhadin MN, 1998, BIOELECTROMAGNETICS, V19, P279, DOI 10.1002/(SICI)1521 186X(1998)19:5<279::AID BEM2>3.0.CO;2 Z
   Zhou J, 2013, RHEUMATOL INT, V33, P1135, DOI 10.1007/s00296 012 2499 9
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
NR 69
TC 14
Z9 15
U1 1
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD FEB 1
PY 2015
VL 21
IS 2
BP 207
EP 217
DI 10.1089/ten.tec.2014.0216
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA CA6HR
UT WOS:000349012400010
PM 25087470
DA 2025 08 17
ER

PT J
AU Lee, NH
   Kang, MS
   Kim, TH
   Yoon, DS
   Mandakhbayar, N
   Jo, SB
   Kim, HS
   Knowles, JC
   Lee, JH
   Kim, HW
AF Lee, Na Hyun
   Kang, Min Sil
   Kim, Tae Hyun
   Yoon, Dong Suk
   Mandakhbayar, Nandin
   Bin Jo, Seung
   Kim, Hye Sung
   Knowles, Jonathan C.
   Lee, Jung Hwan
   Kim, Hae Won
TI Dual actions of osteoclastic inhibition and osteogenic stimulation
   through strontium releasing bioactive nanoscale cement imply
   biomaterial enabled osteoporosis therapy
SO BIOMATERIALS
LA English
DT Article
DE Strontium doped nanoglass particles; Osteoporosis treatment;
   Osteoclastic inhibition; Osteogenic stimulation; Osteoblast osteoclast
   interaction
ID BONE FORMATION; TRABECULAR BONE; CROSS TALK; IN VITRO; RANELATE;
   DIFFERENTIATION; ANGIOGENESIS; REGENERATION; OSTEOBLASTS; SCAFFOLDS
AB Repair of defective hard tissues in osteoporotic patients faces significantly challenges with limited therapeutic options. Although biomedical cements are considered promising materials for healthy bone repair, their uses for healing osteoporotic fracture are clinically limited. Herein, strontium releasing nanoscale cement was introduced to provide dual therapeutic actions (pro osteogenesis and anti osteoclastogenesis), eventually for the regeneration of osteoporotic bone defect. The Sr nanocement hardened from the Sr doped nanoscale glass particles was shown to release multiple ions including silicate, calcium and strontium at doses therapeutically relevant over time. When the Sr nanocement was treated to pre osteoblastic cells, the osteogenic mRNA level (Runx2, Opn, Bsp, Ocn), alkaline phosphatase activity, calcium deposition, and target luciferase reporter were stimulated with respect to the case with Sr free nanocement. When treated to pre osteoclastic cells, the Srnanocement substantially reduced the osteoclastogenesis, such as osteoclastic mRNA level (Casr, Nfatc1, c fos, Acp, Ctsk, Mmp 9), tartrate resistant acid trap activity, and bone resorption capacity. In particular, the osteoclastic inhibition resulted in part from the interactive effect of osteoblasts which were activated by the Srnanocement, i.e., blockage of RANKL (receptor activator of nuclear factor kappa B ligand) binding by enhanced osteoprotegerin and the deactivated Nfatc1. The Sr nanocement, administered to an ovariectomized tibia defect (osteoporotic model) in rats, exhibited profound bone regenerative potential in cortical and surrounding trabecular area, including increased bone volume and density, enhanced production of osteopromotive proteins, and more populated osteoblasts, together with reduced signs of osteoclastic bone resorption. These results demonstrate that Sr nanocement, with its dual effects of osteoclastic inhibition and osteogenic stimulation, can be considered an effective nanotherapeutic implantable biomaterial platform for the treatment of osteoporotic bone defects.
C1 [Lee, Na Hyun; Kang, Min Sil; Kim, Tae Hyun; Yoon, Dong Suk; Mandakhbayar, Nandin; Bin Jo, Seung; Kim, Hye Sung; Lee, Jung Hwan; Kim, Hae Won] Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 31116, South Korea.
   [Lee, Na Hyun; Kang, Min Sil; Kim, Tae Hyun; Yoon, Dong Suk; Mandakhbayar, Nandin; Knowles, Jonathan C.; Lee, Jung Hwan; Kim, Hae Won] Dankook Univ, Dept Nanobiomed Sci, Cheonan 31116, South Korea.
   [Lee, Na Hyun; Kang, Min Sil; Kim, Tae Hyun; Yoon, Dong Suk; Mandakhbayar, Nandin; Knowles, Jonathan C.; Lee, Jung Hwan; Kim, Hae Won] Dankook Univ, BK21 NBM Global Res Ctr Regenerat Med, Cheonan 31116, South Korea.
   [Knowles, Jonathan C.] UCL Eastman Dent Inst, Div Biomat & Tissue Engn, 256 Grays Inn Rd, London WC1X 8LD, England.
   [Knowles, Jonathan C.] Discoveries Ctr Regenerat & Precis Med, UCL Campus, London, England.
   [Kim, Hye Sung; Lee, Jung Hwan; Kim, Hae Won] Dankook Univ, Coll Dent, Dept Biomat Sci, Cheonan 31116, South Korea.
   [Kim, Hye Sung; Lee, Jung Hwan; Kim, Hae Won] Dankook Univ, Sch Dent, Dept Regenerat Dent Med, Cheonan 31116, South Korea.
   [Kim, Hye Sung; Knowles, Jonathan C.; Lee, Jung Hwan; Kim, Hae Won] Dankook Univ, Cell & Matter Inst, Cheonan 31116, South Korea.
   [Kim, Hye Sung; Lee, Jung Hwan; Kim, Hae Won] Mech Dent Med Res Ctr, Cheonan 31116, South Korea.
   [Lee, Jung Hwan; Kim, Hae Won] Dankook Univ, UCL Eastman Korea Dent Med Innovat Ctr, Cheonan 31116, South Korea.
C3 Dankook University; Dankook University; Dankook University; University
   of London; University College London; University of London; University
   College London; Dankook University; Dankook University; Dankook
   University; Dankook University
RP Lee, JH; Kim, HW (通讯作者)，Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 31116, South Korea.
EM ducious@gmail.com; kimhw@dku.edu
RI ; Yoon, Dong/K 1077 2019; Kim, Tae/C 8884 2009; Knowles, Jonathan
   Campbell/B 9019 2008; Mandakhbayar, Nandin/D 9427 2014; Lee,
   Jung Hwan/AFK 0831 2022; Kim, So Jung/KIB 4297 2024; Knowles,
   Jonathan/B 9019 2008
OI Lee, Jung Hwan/0000 0001 8678 5459; Lee, Na Hyun/0000 0002 0931 4378;
   Kim, Hye Sung/0000 0002 2182 301X; Knowles, Jonathan
   Campbell/0000 0003 3917 3446; Yoon, Dong Suk/0000 0001 5945 5569; Kim,
   Hae Won/0000 0001 6400 6100; Mandakhbayar, Nandin
   Erdene/0000 0003 0273 377X; 
FU Dankook University (Priority Institute Support Program in 2021, Global
   Research Program); National Research Foundation in Republic of Korea
   [2019R1C1C1002490, 2018R1A2 B3003446, 2018K1A4A3A01064257,
   2019R1A6A1A11034536, 2015K 1A1A2032163, 2021R1A5A2022318]
FX This work was supported by the grants from Dankook University (Priority
   Institute Support Program in 2021, Global Research Program) and National
   Research Foundation (2019R1C1C1002490, 2018R1A2 B3003446,
   2018K1A4A3A01064257, 2019R1A6A1A11034536, 2015K 1A1A2032163,
   2021R1A5A2022318) in Republic of Korea.
CR [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Baek S, 2015, NANOSCALE, V7, P14191, DOI 10.1039/c5nr02730f
   Banerjee I, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004114
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Boldbaatar K, 2019, ACTA BIOMATER, V83, P322, DOI 10.1016/j.actbio.2018.11.025
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brückner R, 2016, J MATER CHEM B, V4, P3121, DOI 10.1039/c5tb02426a
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   Chen ZT, 2016, MATER TODAY, V19, P304, DOI 10.1016/j.mattod.2015.11.004
   Cheng TL, 2015, J TISSUE ENG, V6, DOI 10.1177/2041731415609448
   Cui X, 2020, BIOACT MATER, V5, P334, DOI 10.1016/j.bioactmat.2020.02.016
   Dashnyam K, 2017, BIOMATERIALS, V116, P145, DOI 10.1016/j.biomaterials.2016.11.053
   Forte L, 2019, ACS BIOMATER SCI ENG, V5, P3429, DOI 10.1021/acsbiomaterials.9b00795
   Fragogeorgi EA, 2019, J TISSUE ENG, V10, DOI 10.1177/2041731419854586
   Frasnelli M, 2017, MAT SCI ENG C MATER, V71, P653, DOI 10.1016/j.msec.2016.10.047
   Fu YX, 2015, MOL MED REP, V12, P6939, DOI 10.3892/mmr.2015.4284
   Ge CC, 2020, RSC ADV, V10, P9016, DOI 10.1039/c9ra08909h
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Huang YZ, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4242178
   Hyun J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060961
   Ikeda F.N.R., 2006, J CLIN INVEST, V114, P475
   Islam MT, 2017, J TISSUE ENG, V8, DOI [10.1177/2041731417719170, 10.3329/jesnr.v8i1.24620]
   Jia XS, 2017, ACTA BIOMATER, V53, P495, DOI 10.1016/j.actbio.2017.02.025
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kang MS, 2018, BIOMATERIALS, V162, P183, DOI 10.1016/j.biomaterials.2018.02.005
   Kargozar S, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00161
   Kates SL, 2016, INJURY, V47, pS65, DOI 10.1016/S0020 1383(16)30015 8
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Lavet C, 2017, OSTEOPOROSIS INT, V28, P3475, DOI 10.1007/s00198 017 4156 3
   Lee JH, 2021, PROG MATER SCI, V117, DOI 10.1016/j.pmatsci.2020.100732
   Lee JH, 2017, ACTA BIOMATER, V60, P93, DOI 10.1016/j.actbio.2017.07.021
   Lee MN, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0170 6
   Li DZ, 2019, ACS BIOMATER SCI ENG, V5, P1440, DOI 10.1021/acsbiomaterials.8b01298
   Li M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37091 8
   Lode A, 2018, ACTA BIOMATER, V65, P475, DOI 10.1016/j.actbio.2017.10.036
   Mao LX, 2017, ACTA BIOMATER, V61, P217, DOI 10.1016/j.actbio.2017.08.015
   Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Marie PJ, 2005, OSTEOPOROSIS INT, V16, pS7, DOI 10.1007/s00198 004 1753 8
   Mneimne M, 2011, ACTA BIOMATER, V7, P1827, DOI 10.1016/j.actbio.2010.11.037
   Naruphontjirakul P, 2019, ACTA BIOMATER, V90, P373, DOI 10.1016/j.actbio.2019.03.038
   Nazrun AS, 2014, THER CLIN RISK MANAG, V10, P937, DOI 10.2147/TCRM.S72456
   Nishiguchi A, 2019, BIOMACROMOLECULES, V20, P1385, DOI 10.1021/acs.biomac.8b01767
   Niu Y., BIOACT MATER, V6, P244
   Niu YM, 2021, BIOACT MATER, V6, P244, DOI 10.1016/j.bioactmat.2020.08.012
   O'Donnell S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005326.pub2
   Ochiai N, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0334 5
   Oryan A, 2019, J BIOMED MATER RES B, V107, P50, DOI 10.1002/jbm.b.34094
   Park KH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 74
   Peacock M, 2010, CLIN J AM SOC NEPHRO, V5, pS23, DOI 10.2215/CJN.05910809
   Pemmer B, 2011, J SYNCHROTRON RADIAT, V18, P835, DOI 10.1107/S090904951103038X
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Peticone C, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420954712
   Pilmane M, 2017, MAT SCI ENG C MATER, V78, P1222, DOI 10.1016/j.msec.2017.05.042
   Rama R, 2016, J ELECTROANAL CHEM, V771, P87, DOI 10.1016/j.jelechem.2016.04.001
   Ray S, 2018, BIOMATERIALS, V157, P1, DOI 10.1016/j.biomaterials.2017.11.049
   Reginster JY, 2014, EXPERT OPIN DRUG SAF, V13, P1209, DOI 10.1517/14740338.2014.939169
   Rizzoli R, 2010, RHEUMATOL INT, V30, P1341, DOI 10.1007/s00296 010 1542 y
   Rochette L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030705
   Rohnke M, 2017, J CONTROL RELEASE, V262, P159, DOI 10.1016/j.jconrel.2017.07.036
   Sabareeswaran A, 2013, BIOMATERIALS, V34, P9278, DOI 10.1016/j.biomaterials.2013.08.070
   Sadegh A.B, 2018, BIOMEDICAL J SCI TEC, V5, DOI [10.26717/bjstr.2018.05.001228, DOI 10.26717/BJSTR.2018.05.001228]
   Schröder HC, 2012, J CELL BIOCHEM, V113, P3197, DOI 10.1002/jcb.24196
   Schuhladen K, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119288
   Seo JJ, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120593
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556 018 0142 z
   Weng L, 2017, ACS APPL MATER INTER, V9, P24484, DOI 10.1021/acsami.7b06521
   Weycker Derek, 2016, Bone Rep, V5, P186, DOI 10.1016/j.bonr.2016.07.005
   Wu CT, 2014, ACS APPL MATER INTER, V6, P4264, DOI 10.1021/am4060035
   Xie YJ, 2020, REGEN BIOMATER, V7, P233, DOI 10.1093/rb/rbaa006
   Xing M, 2018, ACTA BIOMATER, V72, P381, DOI 10.1016/j.actbio.2018.03.051
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yang AJ, 2018, CELL PHYSIOL BIOCHEM, V48, P361, DOI 10.1159/000491742
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yoon H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6176
   Zeng JK, 2020, BIOACT MATER, V5, P435, DOI 10.1016/j.bioactmat.2020.03.008
   Zhang W, 2016, ACS APPL MATER INTER, V8, P30747, DOI 10.1021/acsami.6b10378
   Zhang YF, 2013, J MATER CHEM B, V1, P5711, DOI 10.1039/c3tb21047b
   Zhao FJ, 2018, BIOMATERIALS, V178, P36, DOI 10.1016/j.biomaterials.2018.06.004
   Zhu SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep36251
NR 86
TC 99
Z9 101
U1 6
U2 157
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2021
VL 276
AR 121025
DI 10.1016/j.biomaterials.2021.121025
EA JUL 2021
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA UI0EP
UT WOS:000690292300002
PM 34298444
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Ma, XN
   Ma, CX
   Shi, WG
   Zhou, J
   Ma, HP
   Gao, YH
   Xian, CJ
   Chen, KM
AF Ma, X.  N.
   Ma, C.  X.
   Shi, W.  G.
   Zhou, J.
   Ma, H.  P.
   Gao, Y.  H.
   Xian, C. J.
   Chen, K.  M.
TI Primary cilium is required for the stimulating effect of icaritin on
   osteogenic differentiation and mineralization of osteoblasts in vitro
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Primary cilia; Icaritin; Osteoblasts; Small interfering RNA;
   Differentiation; Mineralization
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; MARROW STROMAL
   CELLS; GENE EXPRESSION; FLAVONOIDS; PROLIFERATION; ADIPOGENESIS;
   OSTEOPOROSIS; GLYCOSIDES; MECHANISM
AB Objective Icaritin, one effective metabolite of Herba Epimedii derived flavonoid icariin, has a strong osteogenic activity. However, its action mechanism remains unclear. Since primary cilia have been shown to play a pivotal role in regulating the osteogenesis, we hypothesized primary cilia are indispensable in mediating icaritin osteogenic effect.
   Materials and methods Primary rat calvarial osteoblasts were transfected with siRNA1 targeting intraflagellar transport protein 88 (IFT88), a protein required for ciliogenesis, to prevent formation of primary cilium and were treated with 10( 6) M icaritin.
   Results Alkaline phosphatase (ALP) activity was significantly increased after 3 days in cells transfected with scrambled siRNA control and treated by icaritin (SC+ I group) compared to cells transfected with scrambled siRNA control only (SC group). ALP activity after IFT88 siRNA1 transfection and icaritin treatment (siRNA1+I group) was significantly lower than that of SC+I group. Formation of ALP positively stained colonies after 6 days, osteocalcin secretion after 9 days and formation of calcified nodules after 12 days displayed a similar tendency among the three groups. mRNA expression of osteogenesis related genes ALP, BMP 2, COL1 alpha, RUNX 2 and OSX after 24 h was significantly increased in SC+I group, but was not different with SC group in siRNA1+I group. Protein levels of BMP 2, COL1a, RUNX 2 and OSX after 48 h showed the similar tendency with gene expression.
   Conclusion Primary cilia are important in mediating icaritin stimulated osteogenic differentiation and may be a novel target for pharmacological therapies for bone loss.
C1 [Ma, X.  N.; Shi, W.  G.; Zhou, J.; Gao, Y.  H.; Chen, K.  M.] Lanzhou Gen Hosp, Lanzhou Command CPLA, Inst Orthopaed, Lanzhou 730050, Peoples R China.
   [Ma, X.  N.] Lanzhou Univ, Hosp 1, Dept Endocrinol, Lanzhou 730000, Peoples R China.
   [Ma, C.  X.] Gansu Univ Chinese Med, Dept Lab, Affiliated Hosp, Lanzhou 730000, Peoples R China.
   [Ma, H.  P.] CPLA, Lanzhou Gen Hosp, Dept Pharm, Lanzhou 730050, Peoples R China.
   [Xian, C. J.] Univ South Australia, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
C3 Lanzhou University; Gansu University of Chinese Medicine; University of
   South Australia
RP Chen, KM (通讯作者)，Lanzhou Gen Hosp, Lanzhou Command CPLA, Inst Orthopaed, Lanzhou 730050, Peoples R China.
EM chenkm@lut.cn
RI ; Gao, Yuhai/AHB 5767 2022; Xian, Cory/D 2646 2009; ma,
   chengxu/CAG 5498 2022
OI ma, chengxu/0000 0001 6115 9806; Xian, Cory/0000 0002 8467 2845; 
FU National Natural Science Foundation of China [81270963, 81471090]; Gansu
   Provincial Natural Science Foundation [1506RJZA307]; Senior Research
   Fellowship of NHMRC Australia [1042105]
FX This work was supported by the National Natural Science Foundation of
   China (81270963, 81471090) and the Gansu Provincial Natural Science
   Foundation (1506RJZA307). CJX is supported by a Senior Research
   Fellowship of NHMRC Australia (1042105).
CR Alonso N, 2014, J ENDOCRINOL INVEST, V37, P925, DOI 10.1007/s40618 014 0149 7
   Berbari NF, 2008, P NATL ACAD SCI USA, V105, P4242, DOI 10.1073/pnas.0711027105
   Cairoli E, 2015, J ENDOCRINOL INVEST, V38, P303, DOI 10.1007/s40618 014 0236 9
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen KM, 2005, PHARMAZIE, V60, P939
   Chen SH, 2012, ACTA BIOMATER, V8, P3128, DOI 10.1016/j.actbio.2012.04.030
   Christensen ST, 2008, CURR TOP DEV BIOL, V85, P261, DOI 10.1016/S0070 2153(08)00810 7
   Davenport JR, 2005, AM J PHYSIOL RENAL, V289, pF1159, DOI 10.1152/ajprenal.00118.2005
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Falk N, 2015, CELLS BASEL, V4, P500, DOI 10.3390/cells4030500
   Forschbach V, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.273
   Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774
   Hoey David A, 2012, Front Endocrinol (Lausanne), V3, P75, DOI 10.3389/fendo.2012.00075
   Hoey DA, 2011, BIOCHEM BIOPH RES CO, V412, P182, DOI 10.1016/j.bbrc.2011.07.072
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Irigoín F, 2011, CURR GENOMICS, V12, P285, DOI 10.2174/138920211795860134
   Jin Y, 2013, ANAL CHIM ACTA, V768, P111, DOI 10.1016/j.aca.2013.01.012
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li GW, 2014, MENOPAUSE, V21, P1007, DOI [10.1097/gme.0000000000000201, 10.1097/GME.0000000000000201]
   Li XF, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/652317
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Ma XN, 2013, PLANTA MED, V79, P1501, DOI 10.1055/s 0033 1350802
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Rania G., 2013, J CELL SCI, V126, P2583
   Sheng H, 2013, INT J MED SCI, V10, P782, DOI 10.7150/ijms.6084
   Shi Wen Gui, 2014, Zhongguo Zhong Yao Za Zhi, V39, P2704
   Temiyasathit S, 2010, ANN NY ACAD SCI, V1192, P422, DOI 10.1111/j.1749 6632.2009.05243.x
   Welch A, 2012, J BONE MINER RES, V27, P1872, DOI 10.1002/jbmr.1649
   Wuttke W, 2007, AGEING RES REV, V6, P150, DOI 10.1016/j.arr.2007.05.001
   Xiao HH, 2014, J STEROID BIOCHEM, V143, P141, DOI 10.1016/j.jsbmb.2014.02.019
   Ye HY, 2005, PHYTOMEDICINE, V12, P735, DOI 10.1016/j.phymed.2004.10.002
   Yuan X, 2015, ANN NY ACAD SCI, V1335, P78, DOI 10.1111/nyas.12463
   Zhai YK, 2014, BONE, V66, P189, DOI 10.1016/j.bone.2014.06.016
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhang G, 2006, BONE, V38, P818, DOI 10.1016/j.bone.2005.11.019
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang X, 2014, PHYTOTHER RES, V28, P498, DOI 10.1002/ptr.5027
NR 46
TC 8
Z9 10
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD APR
PY 2017
VL 40
IS 4
BP 357
EP 366
DI 10.1007/s40618 016 0568 8
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EP1NG
UT WOS:000397151000002
PM 27770387
DA 2025 08 17
ER

PT J
AU Yu, KJ
   Li, JK
   Lee, YC
   Yu, GY
   Lin, SC
   Pan, TH
   Satcher, RL
   Titus, MA
   Yu Lee, LY
   Weng, WH
   Gallick, GE
   Lin, SH
AF Yu, Kai Jie
   Li, Jeffrey K.
   Lee, Yu Chen
   Yu, Guoyu
   Lin, Song Chang
   Pan, Tianhong
   Satcher, Robert L.
   Titus, Mark A.
   Yu Lee, Li Yuan
   Weng, Wen Hui
   Gallick, Gary E.
   Lin, Sue Hwa
TI Cabozantinib induced osteoblast secretome promotes survival and
   migration of metastatic prostate cancer cells in bone
SO ONCOTARGET
LA English
DT Article
DE cabozantinib; osteoblast; secretome; anchorage independent growth;
   migration
ID FACTOR BINDING PROTEIN 2; GROWTH FACTOR; TYROSINE PHOSPHATASE;
   DIFFERENTIATION; EXPRESSION; INHIBITOR; IDENTIFICATION; PROLIFERATION;
   RESISTANCE; ANTIGEN
AB Therapies that target cancer cells may have unexpected effects on the tumor microenvironment that affects therapy outcomes or render therapy resistance. Prostate cancer (PCa) bone metastasis is uniquely associated with osteoblastic bone lesions and treatment with cabozantinib, a VEGFR 2 and MET inhibitor, leads to a reduction in number and/or intensity of lesions on bone scans. However, resistance to cabozantinib therapy inevitably occurs. We examined the effect of cabozantinib on osteoblast differentiation and secretion in the context of therapy resistance. We showed that primary mouse osteoblasts express VEGFR2 and MET and cabozantinib treatment decreased osteoblast proliferation but enhanced their differentiation. A genome wide analysis of transcriptional responses of osteoblasts to cabozantinib identified a set of genes accounting for inhibition of proliferation and stimulation of differentiation, and a spectrum of secreted proteins induced by cabozantinib, including pappalysin, IGFBP2, WNT 16, and DKK1. We determined that these proteins were upregulated in the conditioned medium of cabozantinib treated osteoblasts (CBZ CM) compared to control CM. Treatment of C4 2B4 or PC3 mm2 PCa cells with CBZ CM increased the anchorage independent growth and migration of these PCa cells compared to cells treated with control CM. These results suggest that the effect of cabozantinib on the tumor microenvironment may increase tumor cell survival and cause therapy resistance.
C1 [Yu, Kai Jie; Li, Jeffrey K.; Lee, Yu Chen; Yu, Guoyu; Lin, Song Chang; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
   [Titus, Mark A.; Gallick, Gary E.; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Gallick, Gary E.; Lin, Sue Hwa] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX 77030 USA.
   [Yu Lee, Li Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Yu, Kai Jie] Chang Gung Univ Coll Med, Chang Gung Mem Hosp Linkou, Dept Surg, Div Urol, Taoyuan, Taiwan.
   [Yu, Kai Jie; Weng, Wen Hui] Natl Taipei Univ Technol, Dept Chem Engn & Biotechnol, Taipei, Taiwan.
   [Yu, Kai Jie; Weng, Wen Hui] Natl Taipei Univ Technol, Grad Inst Biochem & Biomed Engn, Taipei, Taiwan.
   [Pan, Tianhong; Satcher, Robert L.] Univ Texas MD Anderson Canc Ctr, Dept Orthoped Oncol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   University of Texas Health Science Center Houston; Baylor College of
   Medicine; Chang Gung Memorial Hospital; Chang Gung University; National
   Taipei University of Technology; National Taipei University of
   Technology; University of Texas System; UTMD Anderson Cancer Center
RP Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.; Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Lin, SH (通讯作者)，Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX 77030 USA.
EM slin@mdanderson.org
RI Weng, Wen/AAV 7260 2021; Yu, Kai Jie/GZA 9147 2022; Satcher,
   Robert/K 7308 2018
FU NIH [CA174798, 5P50 CA140388, CA16672]; Prostate Cancer Foundation,
   Cancer Prevention and Research Institute of Texas [CPRIT RP110327, CPRIT
   RP150179, CPRIT RP150282]; University Cancer Foundation via the Sister
   Institute Network Fund at the MD Anderson Cancer Center
FX This work was supported by grants from the NIH including CA174798, 5P50
   CA140388 and CA16672, the Prostate Cancer Foundation, Cancer Prevention
   and Research Institute of Texas (CPRIT RP110327, CPRIT RP150179, CPRIT
   RP150282), funds from the University Cancer Foundation via the Sister
   Institute Network Fund at the MD Anderson Cancer Center.
CR Abdallah BM, 2011, J BONE MINER RES, V26, P1457, DOI 10.1002/jbmr.346
   Chengalvala MV, 2001, BIOCHEMISTRY US, V40, P814, DOI 10.1021/bi0019996
   COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031
   Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078 0432.CCR 13 0839
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   DELWORTH MG, 1995, INT J ONCOL, V6, P293
   Engelmann JC, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004293
   Fioramonti M, 2017, ONCOTARGET, V8, P20113, DOI 10.18632/oncotarget.15390
   Gérard N, 2004, J ENDOCRINOL, V182, P457, DOI 10.1677/joe.0.1820457
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Haider MT, 2015, BONE, V81, P581, DOI 10.1016/j.bone.2015.08.003
   Nguyen HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063219
   Inman BA, 2005, EUR UROL, V47, P695, DOI 10.1016/j.eururo.2004.12.015
   James AW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8362
   KANETY H, 1993, J CLIN ENDOCR METAB, V77, P229, DOI 10.1210/jc.77.1.229
   Kiyama S, 2003, CANCER RES, V63, P3575
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008 5472.CAN 15 1215
   Leibowitz Amit R, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 015 0747 y
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   MAURO LJ, 1994, J BIOL CHEM, V269, P30659
   Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092 8674(00)81472 5
   Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0
   Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015
   O'Sullivan S, 2011, CALCIFIED TISSUE INT, V88, P16, DOI 10.1007/s00223 010 9429 1
   Patnaik A, 2017, CANC DIS
   Singh H, 2017, CLIN CANCER RES, V23, P330, DOI 10.1158/1078 0432.CCR 16 1073
   Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597
   Smith MR, 2014, J CLIN ONCOL, V32, P3391, DOI 10.1200/JCO.2013.54.5954
   Stern PH, 2014, J CELL BIOCHEM, V115, P2033, DOI 10.1002/jcb.24879
   Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890
   Varkaris A, 2016, CLIN CANCER RES, V22, P107, DOI 10.1158/1078 0432.CCR 15 0235
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535 7163.MCT 11 0264
NR 34
TC 11
Z9 13
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 26
PY 2017
VL 8
IS 43
BP 74987
EP 75006
DI 10.18632/oncotarget.20489
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FI2HT
UT WOS:000411760400132
PM 29088840
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, RY
   Qiao, H
   Qian, YR
   Zhen, GH
   Zhao, ZH
   Li, Y
AF Wang, Ruyi
   Qiao, Hui
   Qian, Yuran
   Zhen, Gehua
   Zhao, Zhihe
   Li, Yu
TI Abaloparatide and teriparatide enhance mandibular growth in adolescent
   rats with site specific and mechano related effects
SO EUROPEAN JOURNAL OF ORTHODONTICS
LA English
DT Article
ID CONDYLAR CARTILAGE; PARATHYROID HORMONE; INDIAN HEDGEHOG; PTHRP; BONE;
   CHONDROCYTES; EXPRESSION; APPLIANCE; DIFFERENTIATION; PROLIFERATION
AB Objective Teriparatide (TPTD) and abaloparatide (ABL) are two osteoanabolic drugs targeting parathyroid hormone (PTH)1R signalling. This study aimed to investigate the effects of TPTD and ABL on the adolescent mandibular growth. Method In total, 70 4 week old male Sprague Dawley rats were randomly divided into 14 groups, treated with intermittent TPDT or ABL at various doses, accompanied by mandibular advancement (MA) or not. 3D printing was used to fabricate an innovative splint for MA. After a 4 week treatment, morphological measurement, histological and immunohistochemical analysis were performed. Mandibular condylar chondrocytes (MCCs) were treated with TPTD or ABL, followed by CCK 8 assay, alcian blue staining, real time PCR and immunofluorescent staining. Result In vivo, TPTD or ABL alone increased the condylar length and cartilage thickness, with up regulated SOX9 and COL II, whilst down regulated COL X; however, when combined with MA, the promotive effects were attenuated. TPTD or ABL alone increased the mandibular body height and mandibular angle width, whilst increased the mandibular body length and alveolar bone width when combined with MA. In vitro, TPTD or ABL enhanced the MCC proliferation, glycosaminoglycan synthesis, COL II and SOX9 expression, whilst down regulated COL X, Ihh and PTH1R expression. Conclusion Both ABL and TPTD enhance mandibular growth in adolescent rats with site specific and mechano related effects, including propelling chondrogenesis at the condylar cartilage and promoting bone apposition at other mechano responsive sites. They behave as promising drugs for mandibular growth modification, and in general ABL seems more potent than TPTD in this context.
C1 [Wang, Ruyi; Qiao, Hui; Qian, Yuran; Zhao, Zhihe; Li, Yu] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont,State Key Lab Oral Dis & Natl Cli, Chengdu, Peoples R China.
   [Zhen, Gehua] Johns Hopkins Univ Sch Med, Dept Orthoped Surg, Baltimore, MD USA.
C3 Sichuan University; Johns Hopkins University
RP Li, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont,State Key Lab Oral Dis & Natl Cli, Chengdu, Peoples R China.
EM yuli@scu.edu.cn
RI wang, ruyi/HZJ 1320 2023; Li, Yu/G 6649 2011
OI Li, Yu/0000 0001 8578 7268
FU National Natural Science Foundation of China [31971247]
FX This work was supported by the National Natural Science Foundation of
   China (No. 31971247).
CR Bach FC, 2014, J CELL PHYSIOL, V229, P1999, DOI 10.1002/jcp.24658
   Balkhande PB, 2018, AM J ORTHOD DENTOFAC, V153, P255, DOI 10.1016/j.ajodo.2017.06.023
   Bechtold TE, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246300
   BHASKAR SN, 1953, AM J ANAT, V92, P1, DOI 10.1002/aja.1000920102
   Bhattacharyya S, 2019, BIOCHEM PHARMACOL, V166, P185, DOI 10.1016/j.bcp.2019.05.024
   Delatte M, 2004, EUR J ORAL SCI, V112, P156, DOI 10.1111/j.0909 8836.2004.00108.x
   Deng ZN, 2014, ARCH ORAL BIOL, V59, P1032, DOI 10.1016/j.archoralbio.2014.04.012
   DEVINCENZO JP, 1991, AM J ORTHOD DENTOFAC, V99, P241, DOI 10.1016/0889 5406(91)70006 I
   El Bialy T, 2015, ANGLE ORTHOD, V85, P233, DOI 10.2319/030914 170.1
   Foncatti CF, 2017, AM J ORTHOD DENTOFAC, V152, P663, DOI 10.1016/j.ajodo.2017.03.029
   Huang LJ, 2015, ARCH ORAL BIOL, V60, P622, DOI 10.1016/j.archoralbio.2015.01.003
   Jiang J, 2008, OSTEOARTHR CARTILAGE, V16, P70, DOI 10.1016/j.joca.2007.05.014
   Jiao K, 2010, ARCH ORAL BIOL, V55, P155, DOI 10.1016/j.archoralbio.2009.11.012
   Joshi AS, 2022, ORTHOD CRANIOFAC RES, V25, P183, DOI 10.1111/ocr.12524
   Joshi Nishitha, 2014, J Clin Med Res, V6, P399, DOI 10.14740/jocmr1905w
   Karp SJ, 2000, DEVELOPMENT, V127, P543
   Kaul R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160121
   Le Henaff C, 2020, J BONE MINER RES, V35, P714, DOI 10.1002/jbmr.3930
   Li TF, 2004, EXP CELL RES, V299, P128, DOI 10.1016/j.yexcr.2004.05.025
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Liu Q, 2012, BIOCHEM BIOPH RES CO, V424, P182, DOI 10.1016/j.bbrc.2012.06.106
   Sato FRL, 2014, ORAL MAXILLOFAC SURG, V18, P173, DOI 10.1007/s10006 013 0396 3
   Maycas M, 2017, J BONE MINER RES, V32, P486, DOI 10.1002/jbmr.3007
   MIZOGUCHI I, 1990, HISTOCHEMISTRY, V93, P593, DOI 10.1007/BF00272201
   Mizuhashi K, 2018, NATURE, V563, P254, DOI 10.1038/s41586 018 0662 5
   Ng AFS, 2006, FRONT BIOSCI LANDMRK, V11, P949, DOI 10.2741/1851
   Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487
   Nishida T, 2002, J CELL PHYSIOL, V192, P55, DOI 10.1002/jcp.10113
   O' Brien MH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03428 y
   Ochiai T, 2010, J DENT RES, V89, P349, DOI 10.1177/0022034510363078
   Proff P, 2007, ANN ANAT, V189, P269, DOI 10.1016/j.aanat.2006.09.006
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rabie ABM, 2003, AM J ORTHOD DENTOFAC, V123, P40, DOI 10.1067/mod.2003.45
   Rabie ABM, 2003, J DENT RES, V82, P627, DOI 10.1177/154405910308200811
   Robinson ST, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116171
   Rutgers M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213483
   Saito Y, 2021, J DENT SCI, V16, P287, DOI 10.1016/j.jds.2020.04.002
   San Cheong V, 2021, ACTA BIOMATER, V136, P291, DOI 10.1016/j.actbio.2021.09.035
   Schwartz João Paulo, 2016, Dental Press J. Orthod., V21, P95, DOI 10.1590/2177 6709.21.2.095 101.oar
   Shen G, 2006, EUR J ORTHODONT, V28, P210, DOI 10.1093/ejo/cji123
   Shibata S, 2000, ANAT EMBRYOL, V202, P85, DOI 10.1007/s004290000100
   Shibukawa Y, 2007, DEV DYNAM, V236, P426, DOI 10.1002/dvdy.21036
   Sleeman A, 2019, AM J HEALTH SYST PH, V76, P130, DOI 10.1093/ajhp/zxy022
   Sun L, 2017, J MOL HISTOL, V48, P437, DOI 10.1007/s10735 017 9741 4
   Tang GH, 2004, J DENT RES, V83, P434, DOI 10.1177/154405910408300516
   Tu YL, 2019, J CELL MOL MED, V23, P2933, DOI 10.1111/jcmm.14201
   Tulloch JFC, 2004, AM J ORTHOD DENTOFAC, V125, P657, DOI 10.1016/j.ajodo.2004.02.008
   Wang S, 2018, ANGLE ORTHOD, V88, P624, DOI 10.2319/120417 829.1
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Weisser A, 2002, EXP CELL RES, V279, P1, DOI 10.1006/excr.2002.5580
   Xiong H, 2005, FRONT BIOSCI LANDMRK, V10, P65, DOI 10.2741/1507
   Xiong H, 2004, ANGLE ORTHOD, V74, P86
   Zhang CX, 2020, AM J ORTHOD DENTOFAC, V157, P329, DOI 10.1016/j.ajodo.2019.04.029
   Zhang X, 2020, J WORLD FED ORTHOD, V9, P9, DOI 10.1016/j.ejwf.2020.01.004
   Zhou X, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12470
NR 55
TC 1
Z9 1
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0141 5387
EI 1460 2210
J9 EUR J ORTHODONT
JI Eur. J. Orthodont.
PD MAR 31
PY 2023
VL 45
IS 2
BP 224
EP 234
DI 10.1093/ejo/cjac069
EA DEC 2022
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA D4LA0
UT WOS:000905012900001
PM 36576115
DA 2025 08 17
ER

PT J
AU Sverzut, CE
   Sverzut, AT
   de Matos, FP
   Kato, RB
   Trivellato, AE
   de Oliveira, PT
AF Sverzut, Cassio Edvard
   Sverzut, Alexander Tadeu
   de Matos, Fernando Pando
   Kato, Rogerio Bentes
   Trivellato, Alexandre Elias
   de Oliveira, Paulo Tambasco
TI Mandibular Bisphosphonate Related Osteonecrosis After Dental Implant
   Rehabilitation: A Case Report
SO IMPLANT DENTISTRY
LA English
DT Article
DE titanium implants; osteonecrosis; bisphosphonates; mandible
ID ORAL BISPHOSPHONATES; JAWS; ALENDRONATE; OSTEOPOROSIS
AB It has been a matter of debate as to whether dental implant therapies are suitable for patients subjected to long term use of bisphosphonates (BPs). This report presents a case of a 76 year old woman who developed BPs related osteonecrosis of the jaw (BRONJ) in the left hemimandible after dental implant exposure. The implants and the necrotic crestal bone were removed, and postoperatively, a delay in tissue healing with bone exposure was noticed. The histologic analysis of the block biopsies revealed a lamellar bone tissue exhibiting necrotic areas and bacterial colonies associated with the bone outer surface. The bone implant interface showed viable lamellar bone with enlarged vascular spaces in the areas between the implant threads. The possible mechanisms for the loss of implants in BRONJ patients are discussed, and the potential protocols for dental implant rehabilitation for patients under BP therapies are presented. (Implant Dent 2012;21:449 453)
C1 [Sverzut, Cassio Edvard; Sverzut, Alexander Tadeu; de Matos, Fernando Pando; Kato, Rogerio Bentes; Trivellato, Alexandre Elias] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Oral & Maxillofacial Surg & Periodontol, BR 14040904 Sao Paulo, Brazil.
   [de Oliveira, Paulo Tambasco] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Morphol Stomatol & Physiol, BR 14040904 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Sverzut, CE (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Oral & Maxillofacial Surg & Periodontol, Ave Cafe, BR 14040904 Sao Paulo, Brazil.
EM cesve@forp.usp.br
RI Trivellato, Alexandre/I 2827 2014; Sverzut, Cassio/A 4611 2017; de
   Matos, Fernando/G 9098 2012; Tambasco de Oliveira, Paulo/F 9749 2010;
   Sverzut, Alexander/N 3287 2014; Sverzut, Alexander Tadeu/N 3287 2014
OI Trivellato, Alexandre/0000 0002 7856 2228; Tambasco de Oliveira,
   Paulo/0000 0002 6662 0486; Sverzut, Alexander Tadeu/0000 0001 6199 6276;
   PANDO DE MATOS, FERNANDO/0000 0002 9256 1627
FU State of Sao Paulo Research Foundation (FAPESP, Brazil); National
   Council of Scientific and Technological Development (CNPq, Brazil)
FX The authors acknowledge the support from the State of Sao Paulo Research
   Foundation (FAPESP, Brazil) and the National Council of Scientific and
   Technological Development (CNPq, Brazil).
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Altundal H, 2004, INT J ORAL MAX SURG, V33, P286, DOI 10.1006/ijom.2002.0472
   Assael LA, 2006, J ORAL MAXIL SURG, V64, P877, DOI 10.1016/j.joms.2006.04.003
   Bedogni A, 2010, J ORAL MAXIL SURG, V68, P1662, DOI 10.1016/j.joms.2010.02.037
   Bell BM, 2008, J ORAL MAXIL SURG, V66, P1022, DOI 10.1016/j.joms.2007.12.040
   Bennett CL, 2005, JAMA J AM MED ASSOC, V293, P2131, DOI 10.1001/jama.293.17.2131
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Chacon GE, 2006, J ORAL MAXIL SURG, V64, P1005, DOI 10.1016/j.joms.2006.01.007
   Fugazzotto PA, 2007, J PERIODONTOL, V78, P1664, DOI 10.1902/jop.2007.060514
   Giro G, 2008, ORAL SURG ORAL MED O, V105, P162, DOI 10.1016/j.tripleo.2007.06.010
   Gliklich R, 2009, J ORAL MAXIL SURG, V67, P71, DOI 10.1016/j.joms.2009.01.005
   Grant BT, 2008, J ORAL MAXIL SURG, V66, P223, DOI 10.1016/j.joms.2007.09.019
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Kos M, 2010, J CRANIO MAXILL SURG, V38, P255, DOI 10.1016/j.jcms.2009.06.005
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lee CYS, 2011, IMPLANT DENT, V20, P331, DOI 10.1097/ID.0b013e3182310f03
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2009, IMPLANT DENT, V18, P371, DOI 10.1097/ID.0b013e3181b4aee8
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Nase JB, 2006, J AM DENT ASSOC, V137, P1115, DOI 10.14219/jada.archive.2006.0350
   Ruggiero Salvatore L, 2008, Dent Clin North Am, V52, P111, DOI 10.1016/j.cden.2007.09.002
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Scully Crispian, 2006, Implant Dent, V15, P212, DOI 10.1097/01.id.0000236120.22719.02
   Shirota T, 2009, CLIN ORAL IMPLAN RES, V20, P1402, DOI 10.1111/j.1600 0501.2009.01801.x
   Torres J, 2008, ORAL SURG ORAL MED O, V106, P668, DOI 10.1016/j.tripleo.2008.03.008
   Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007
   Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239
   Yarom N, 2007, OSTEOPOROSIS INT, V18, P1363, DOI 10.1007/s00198 007 0384 2
   Yuan K, 2012, IMPLANT DENT, V21, P3, DOI 10.1097/ID.0b013e3182425c62
NR 31
TC 10
Z9 10
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1056 6163
J9 IMPLANT DENT
JI Implant Dent.
PD DEC
PY 2012
VL 21
IS 6
BP 449
EP 453
DI 10.1097/ID.0b013e3182703c4f
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 038AC
UT WOS:000311146600003
PM 23075811
OA Bronze
DA 2025 08 17
ER

PT J
AU Son, GY
   Yang, YM
   Park, WS
   Chang, I
   Shin, DM
AF Son, G. Y.
   Yang, Y. M.
   Park, W. S.
   Chang, I.
   Shin, D. M.
TI Hypotonic Stress Induces RANKL via Transient Receptor Potential
   Melastatin 3 (TRPM3) and Vaniloid 4 (TRPV4) in Human PDL Cells
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE bone remodeling; regeneration; mechanotransduction; cell signaling;
   osmotic stress; ion channels; periodontal ligament
ID PERIODONTAL LIGAMENT CELLS; FLUID SHEAR STRESS; OSTEOCLAST
   DIFFERENTIATION; ENDOTHELIAL CELLS; CHANNEL; EXPRESSION; FIBROBLASTS;
   FORCE; INHIBITION; ACTIVATION
AB Bone remodeling occurs in response to various types of mechanical stress. The periodontal ligament (PDL) plays an important role in mechanical stress mediated alveolar bone remodeling. However, the underlying mechanism at the cellular level has not been extensively studied. In this study, we investigated the effect of shear stress on the expression of bone remodeling factors, including receptor activator of nuclear factor kappa B (NF B) ligand (RANKL) and osteoprotegerin (OPG), as well as its upstream signaling pathway in primary human PDL cells. We applied hypotonic stress to reproduce shear stress to PDL cells. Hypotonic stress induced the messenger RNA (mRNA) and protein expression of RANKL but not OPG. It also increased intracellular Ca2+ concentration ([Ca2+](i)). Extracellular Ca2+ depletion and nonspecific plasma membrane Ca2+ channel blockers completely inhibited the increase in both [Ca2+](i) and RANKL mRNA expression. We identified the expression and activation of transient receptor potential melastatin 3 (TRPM3) and vaniloid 4 (TRPV4) channels in PDL cells. Pregnenolone sulfate (PS) and 4 phorbol 12, 13 didecanoate (4 PDD), which are agonists of TRPM3 and TRPV4, augmented Ca2+ influx and RANKL mRNA expression. Both pharmacological (2 aminoethoxydiphenyl borate [2 APB], ruthenium red [RR], ononetin [Ono], and HC 067047 [HC]) and genetic (small interfering RNA [siRNA]) inhibitors of TRPM3 and TRPV4 reduced the hypotonic stress mediated increase in [Ca2+](i) and RANKL mRNA expression. Our study shows that hypotonic stress induced RANKL mRNA expression via TRPM3  and TRPV4 mediated extracellular Ca2+ influx and RANKL expression. This signaling pathway in PDL cells may play a critical role in mechanical stress mediated alveolar bone remodeling.
C1 [Son, G. Y.; Yang, Y. M.; Chang, I.; Shin, D. M.] Yonsei Univ, Dept Oral Biol, Coll Dent, Seoul 120752, South Korea.
   [Son, G. Y.; Shin, D. M.] Yonsei Univ, PLUS Project BK21, Coll Dent, Seoul 120752, South Korea.
   [Park, W. S.] Yonsei Univ, Dept Adv Gen Dent, Coll Dent, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System
RP Shin, DM (通讯作者)，Yonsei Univ, Dept Oral Biol, Coll Dent, 50 Yonsei Ro, Seoul 120752, South Korea.
EM dmshin@yuhs.ac
OI Shin, Dong Min/0000 0001 6042 0435; Park, Wonse/0000 0002 2081 1156
FU National Research Foundation of Korea by the Korea Government (MSIP)
   [NRF 2012R1A2A1A01003487]
FX This work was supported by a grant from the National Research Foundation
   of Korea (NRF 2012R1A2A1A01003487) by the Korea Government (MSIP). The
   authors declare no potential conflicts of interest with respect to the
   authorship and/or publication of this article.
CR Akopian AN, 2007, J PHYSIOL LONDON, V583, P175, DOI 10.1113/jphysiol.2007.133231
   Basdra EK, 1997, EUR J ORTHODONT, V19, P615, DOI 10.1093/ejo/19.6.615
   Bergomi M, 2010, J BIOMECH, V43, P1146, DOI 10.1016/j.jbiomech.2009.12.020
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107
   Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200
   Güler AD, 2002, J NEUROSCI, V22, P6408
   Jin M, 2011, TRP CHANNELS, P353
   Kanzaki H, 2006, J DENT RES, V85, P457, DOI 10.1177/154405910608500512
   Kanzaki H, 2001, J DENT RES, V80, P887, DOI 10.1177/00220345010800030801
   KOMATSU K, 1993, ARCH ORAL BIOL, V38, P369, DOI 10.1016/0003 9969(93)90207 3
   Koyama T, 2001, J PHYSIOL LONDON, V532, P759, DOI 10.1111/j.1469 7793.2001.0759e.x
   Luckprom P, 2010, J PERIODONTAL RES, V45, P404, DOI 10.1111/j.1600 0765.2009.01256.x
   Maeda A, 2007, J DENT RES, V86, P629, DOI 10.1177/154405910708600709
   Malek AM, 1996, J CELL SCI, V109, P713
   Nakao K, 2007, J DENT RES, V86, P623, DOI 10.1177/154405910708600708
   Niisato N, 1996, J PERIODONTAL RES, V31, P113, DOI 10.1111/j.1600 0765.1996.tb00472.x
   OGATA Y, 1995, CELL BIOL INT, V19, P637, DOI 10.1006/cbir.1995.1113
   Ohara A, 2006, J DENT RES, V85, P664, DOI 10.1177/154405910608500716
   Pavasant P, 2011, PERIODONTOL 2000, V56, P154, DOI 10.1111/j.1600 0757.2010.00374.x
   Pi SH, 2007, J PERIODONTAL RES, V42, P104, DOI 10.1111/j.1600 0765.2006.00921.x
   Saeki Y, 2007, DRUG METAB REV, V39, P457, DOI 10.1080/03602530701498786
   SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384
   Son AR, 2009, J DENT RES, V88, P1014, DOI 10.1177/0022034509343413
   Sooampon S, 2013, J PERIODONTAL RES, V48, P22, DOI 10.1111/j.1600 0765.2012.01493.x
   Straub I, 2013, BRIT J PHARMACOL, V168, P1835, DOI 10.1111/bph.12076
   Tsuji K, 2004, J BONE MINER METAB, V22, P94, DOI 10.1007/s00774 003 0456 0
   Tsutsumi T, 2013, EUR J ORAL SCI, V121, P538, DOI 10.1111/eos.12083
   Wu L, 2007, AM J PHYSIOL RENAL, V293, pF1699, DOI 10.1152/ajprenal.00462.2006
   Xiao R, 2010, CURR BIOL, V20, pR936, DOI 10.1016/j.cub.2010.09.053
NR 30
TC 22
Z9 25
U1 0
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD MAR
PY 2015
VL 94
IS 3
BP 473
EP 481
DI 10.1177/0022034514567196
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CC2CB
UT WOS:000350151400011
PM 25595364
OA Green Published
DA 2025 08 17
ER

PT J
AU Pauli, C
   Fuchs, B
   Pfirrmann, C
   Bridge, JA
   Hofer, S
   Bode, B
AF Pauli, Chantal
   Fuchs, Bruno
   Pfirrmann, Christian
   Bridge, Julia A.
   Hofer, Silvia
   Bode, Beata
TI Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the
   radius to denosumab therapy
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE Aneurysmal bone cyst; FISH; USP6; Denosumab
ID USP6; ONCOGENES; MECHANISM; CHILDREN; CELL
AB Aneurysmal bone cyst (ABC), once considered a reactive lesion, has been proven to be a neoplasia characterized by rearrangements of the USP6 gene. Aggressive local growth and recurrences are common and therapeutic options may be limited due to the vicinity of crucial structures. We describe a case of a locally aggressive, multinucleated giant cell containing lesion of the forearm of a 21 year old woman, treated with denosumab for recurrent, surgically uncontrollable disease. Under the influence of this RANKL inhibitor, the tumor showed a marked reduction of the content of the osteoclastic giant cells and an extensive metaplastic osteoid production leading to the bony containment, mostly located intracortically in the proximal radius. The diagnosis of a periosteal ABC was confirmed by FISH demonstrating USP6 gene rearrangement on the initial biopsy. Function conserving surgery could be performed, enabling reconstruction of the affected bone. Inhibition of RANKL with denosumab may offer therapeutic option for patients not only with giant cell tumors but also with ABCs.
C1 [Pauli, Chantal; Bode, Beata] Univ Zurich Hosp, Inst Surg Pathol, CH 8091 Zurich, Switzerland.
   [Fuchs, Bruno; Pfirrmann, Christian] Univ Hosp Balgrist, Zurich, Switzerland.
   [Bridge, Julia A.] Univ Nebraska Med Ctr, Dept Pathol Microbiol, Omaha, NE USA.
   [Hofer, Silvia] Univ Zurich Hosp, CH 8091 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Zurich; University Zurich Hospital
RP Bode, B (通讯作者)，Univ Zurich Hosp, Inst Surg Pathol, CH 8091 Zurich, Switzerland.
EM beata.bode@usz.ch
RI Pfirrmann, Christian/E 6032 2012; pauli, chantal/HTT 4689 2023
OI Pfirrmann, Christian/0000 0003 0091 9650; Pauli,
   Chantal/0000 0001 9621 8511
CR Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090
   CAMPANACCI M, 1976, Italian Journal of Orthopaedics and Traumatology, V2, P341
   Cottalorda J, 2004, J PEDIATR ORTHOP B, V13, P389, DOI 10.1097/01202412 200411000 00008
   DABSKA M, 1969, CANCER, V23, P371, DOI 10.1002/1097 0142(196902)23:2<371::AID CNCR2820230213>3.0.CO;2 2
   ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9
   Garg S, 2005, J PEDIATR ORTHOPED, V25, P387, DOI 10.1097/01.bpo.0000152910.16045.ee
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Lange T, 2013, EUR SPINE J, V22, P1417, DOI 10.1007/s00586 013 2715 7
   Lau AW, 2010, J BIOL CHEM, V285, P37111, DOI 10.1074/jbc.M110.175133
   LICHTENSTEIN L, 1953, CANCER AM CANCER SOC, V6, P1228
   Lipton Allan, 2011, Curr Opin Support Palliat Care, V5, P258, DOI 10.1097/SPC.0b013e328349731c
   Maiya S, 2002, EUR RADIOL, V12, P99, DOI 10.1007/s003300101009
   Mankin HJ, 2005, J CLIN ONCOL, V23, P6756, DOI 10.1200/JCO.2005.15.255
   Moen MD, 2011, DRUG AGING, V28, P63, DOI 10.2165/11203300 000000000 00000
   Nielsen GP, 2002, AM J SURG PATHOL, V26, P64, DOI 10.1097/00000478 200201000 00007
   Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008 5472.CAN 03 2827
   Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002 9440(10)63432 3
   OLIVEIRA AM, 2006, J CLIN ONCOL, V24, pE2
   Oliveira Andre M, 2006, J Clin Oncol, V24, pe2, DOI 10.1200/JCO.2005.04.4818
   Peeters SP, 2009, J SURG ONCOL, V100, P719, DOI 10.1002/jso.21410
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Thomas DM, 2012, CURR OPIN ONCOL, V24, P397, DOI 10.1097/CCO.0b013e328354c129
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
   Ye Y, 2010, ONCOGENE, V29, P3619, DOI 10.1038/onc.2010.116
NR 24
TC 34
Z9 39
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477 7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD JAN 20
PY 2014
VL 12
AR 17
DI 10.1186/1477 7819 12 17
PG 6
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Surgery
GA AG3UT
UT WOS:000335346000001
PM 24438319
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Geng, DC
   Xu, YZ
   Yang, HL
   Zhu, GM
   Wang, XB
   Zhu, XS
AF Geng De chun
   Xu Yao zeng
   Yang Hui lin
   Zhu Guang ming
   Wang Xian bin
   Zhu Xue song
TI Cannabinoid receptor 2 selective antagonist negatively regulates
   receptor activator of nuclear factor kappa B ligand mediated
   osteoclastogenesis
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE RAW264.7; osteoclastogenesis; receptor activator of nuclear factor kappa
   B ligand; AM630; cannabinoid receptor 2
ID BONE MASS; DIFFERENTIATION; THERAPY; RANK; MICE; CB2
AB Background The cannabinoid receptor 2 (CB2) is important for bone remodeling. In this study, we investigated the effects of CB2 selective antagonist (AM630) on receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) induced osteoclast differentiation and the underlying signaling pathway using a monocyte macrophage cell line RAW264.7.
   Methods RAW264.7 was cultured with RANKL for 6 days and then treated with AM630 for 24 hours. Mature osteoclasts were measured by tartrate resistant acid phosphatase (TRAP) staining using a commercial kit. Total ribonucleic acid (RNA) was isolated and real time reverse transcriptase polymerase chain reaction (RT PCR) was done to examine the expression of RANK, cathepsin K (CPK) and nuclear factor kappa B (NF kappa B). The extracellular signal regulated kinase (ERK), phosphorylation of ERK (P ERK) and NF kappa B production were tested by Western blotting. The effect of AM630 on RAW264.7 viability was determined using the 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazoliumbromide (MTT) assay.
   Results AM630 did not affect the viability of RAW264.7. However, this CB2 selective antagonist markedly inhibited osteoclast formation and the inhibition rate was dose dependent. The dose of >= 100 nmol/L could reduce TRAP positive cells to the levels that were significantly lower than the control. AM630 suppressed the expression of genes associated with osteoclast differentiation and activation, such as RANK and CPK. An analysis of a signaling pathway showed that AM630 inhibited the RANKL induced activation of ERK, but not NF kappa B.
   Conclusion AM630 could inhibit the osteoclastogenesis from RAW264.7 induced with RANKL. Chin Med J 2011;124(4):586 590
C1 [Geng De chun; Xu Yao zeng; Yang Hui lin; Zhu Guang ming; Wang Xian bin; Zhu Xue song] Soochow Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
C3 Soochow University   China
RP Xu, YZ (通讯作者)，Soochow Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
EM xuyaozeng@163.com
RI Wang, Xianbin/ABH 2720 2020; ZHU, XUESONG/AAI 1933 2020; Geng,
   Dechun/LMO 1733 2024
OI Zhu, Xuesong/0000 0003 3579 2741
FU Jiangsu Province Key Medical Center [ZX200608]; National Nature Science
   Foundation of China [30672140, 81071451]; Colleges and Universities
   Natural Science Foundation in Jiangsu Province [10KJB320019]; Medical
   Science and Technology Department Foundation, Jiangsu Province,
   Department of Health [H201012]; Social Development Projects in Suzhou
   [SS08020]
FX This work was supported by the grants from Jiangsu Province Key Medical
   Center (No. ZX200608), the National Nature Science Foundation of China
   (No. 30672140, No. 81071451), the Colleges and Universities Natural
   Science Foundation in Jiangsu Province (No. 10KJB320019), the Key
   Project Surpported by the Medical Science and Technology Department
   Foundation, Jiangsu Province, Department of Health (No. H201012) and the
   Social Development Projects in Suzhou (No. SS08020).
CR Bab I, 2008, BRIT J PHARMACOL, V153, P182, DOI 10.1038/sj.bjp.0707593
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hou LC, 2009, CHINESE MED J PEKING, V122, P950, DOI 10.3760/cma.j.issn.0366 6999.2009.08.014
   Howlett AC, 2002, PROSTAG OTH LIPID M, V68 9, P619, DOI 10.1016/S0090 6980(02)00060 6
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Patel MS, 2007, CALCIFIED TISSUE INT, V80, P337, DOI 10.1007/s00223 007 9015 3
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Ruan XY, 2008, CHINESE MED J PEKING, V121, P1155, DOI 10.1097/00029330 200807010 00001
   Simsek B, 2004, CHINESE MED J PEKING, V117, P291
   Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   Yamane H, 2009, BONE, V44, P1055, DOI 10.1016/j.bone.2008.05.010
NR 24
TC 14
Z9 18
U1 2
U2 10
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B 9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR E, MUMBAI, 400075,
   INDIA
SN 0366 6999
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD FEB 20
PY 2011
VL 124
IS 4
BP 586
EP 590
DI 10.3760/cma.j.issn.0366 6999.2011.04.019
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 729ZF
UT WOS:000287992500019
PM 21362286
DA 2025 08 17
ER

PT J
AU Tsunekage, Y
   Takeiri, M
   Yoshioka, Y
   Matsumura, S
   Kimura, Y
   Kataoka, K
AF Tsunekage, Yukino
   Takeiri, Masatoshi
   Yoshioka, Yuri
   Matsumura, Shinichi
   Kimura, Yoshihide
   Kataoka, Kohsuke
TI Nasturtium officinale Extract Suppresses Osteoclastogenesis in
   RAW 264 Cells by Inhibiting IκB Kinase β
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE osteoclast; bioactivity; RANKL; IKK beta; Nasturtium officinale;
   NF kappa B; MAPK
ID DIFFERENTIATION; ACTIVATION; INDUCTION; RECEPTOR
AB Osteoclasts are large, multinucleated, bone absorbing cells and play a crucial role in osteolytic bone diseases such as osteopetrosis and rheumatoid arthritis. Therefore, controlling osteoclast differentiation and activation has been considered a promising strategy to prevent and treat osteolytic diseases. In this study, we demonstrate, using the mouse monocyte derived macrophage like cell line RAW 264, that extract from Nasturtium officinale or watercress, an herb of European origin, suppresses receptor activator of nuclear factor kappa B ligand induced osteoclast differentiation in vitro. N. officinale extract decreased the emergence of tartrate resistant acid phosphatase positive differentiated multinuclear cells and inhibited their bone absorbing activity. The extract decreased expression of genes associated with osteoclast differentiation and function. Induction of nuclear factor of activated T cells c1 (NFATc1), the master transcriptional regulator of osteoclastogenesis, was blunted by N. officinale extract. Activation of nuclear factor kappa B and mitogen activated protein kinases pathways, both of which are necessary for NFATc1 induction and osteoclast differentiation, was also suppressed by the extract. Among upstream kinases, activity of I kappa B kinase beta (IKK beta), but not that of TGF beta activated kinase 1, was inhibited by N. officinale extract in vitro. Pharmacological inhibition of IKK beta by a specific inhibitor PS1145 in RAW 264 cells mostly recaptured the inhibitory action of N. officinale extract. These findings provide a novel pharmacological action of N. officinale and its potential usefulness for the prevention of osteoporosis.
C1 [Tsunekage, Yukino; Kataoka, Kohsuke] Yokohama City Univ, Grad Sch Med Life Sci, Lab Mol Med Biosci, Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.
   [Tsunekage, Yukino; Takeiri, Masatoshi; Kimura, Yoshihide] IVY Cosmet Corp, R&D Lab, Saitama 3670115, Japan.
   [Yoshioka, Yuri; Matsumura, Shinichi] Inabata Koryo Co Ltd, Osaka, Japan.
C3 Yokohama City University
RP Kataoka, K (通讯作者)，Yokohama City Univ, Grad Sch Med Life Sci, Lab Mol Med Biosci, Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.; Kimura, Y (通讯作者)，IVY Cosmet Corp, R&D Lab, Saitama 3670115, Japan.
EM kimura yoshihide@ivy.co.jp; kkataoka@yokohama cu.ac.jp
RI MATSUMURA, SHINICHI/JED 9413 2023
OI matsumura, shinichi/0000 0001 5369 4147
FU IVY Cosmetics Corporation; Grants in Aid for Scientific Research
   [21K08561] Funding Source: KAKEN
FX The author(s) declared the following potential conflicts of interest
   with respect to the research, authorship, and/or publication of this
   article: K.K. receives research funding from IVY Cosmetics Corporation.
   Other authors declare no conflict of interest.
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Davis SR, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.4
   Dobbs M B, 1999, Iowa Orthop J, V19, P43
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Klimek Szczykutowicz M, 2018, FITOTERAPIA, V129, P283, DOI 10.1016/j.fitote.2018.05.031
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Murakami A, 2007, BIOFACTORS, V30, P1, DOI 10.1002/biof.5520300101
   Rose P, 2005, TOXICOL APPL PHARM, V209, P105, DOI 10.1016/j.taap.2005.04.010
   Sadeghi H, 2014, PHARM BIOL, V52, P169, DOI 10.3109/13880209.2013.821138
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   von Metzler I, 2007, LEUKEMIA, V21, P2025, DOI 10.1038/sj.leu.2404806
   Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040 6048.2004
NR 22
TC 1
Z9 1
U1 2
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934 578X
EI 1555 9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD JUN
PY 2021
VL 16
IS 6
DI 10.1177/1934578X211020643
PG 9
WC Chemistry, Medicinal; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology
GA SS1JL
UT WOS:000661497500001
OA gold
DA 2025 08 17
ER

PT J
AU Jiang, WJ
   Tian, Y
   Jiang, S
   Liu, SY
   Zhao, XT
   Tian, DL
AF Jiang, Wenjun
   Tian, Ye
   Jiang, Shu
   Liu, Siyang
   Zhao, Xitong
   Tian, Dali
TI MicroRNA 376c suppresses non small cell lung cancer cell growth and
   invasion by targeting LRH 1 mediated Wnt signaling pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Liver receptor homolog 1; Non small cell lung cancer; miR 376c; Wnt
ID LIVER RECEPTOR HOMOLOG 1; ORPHAN NUCLEAR RECEPTOR; COLON CANCER; CDKN1A
   GENE; LRH 1; PROLIFERATION; EXPRESSION; OSTEOSARCOMA; BIOGENESIS;
   METABOLISM
AB MicroRNAs (miRNAs) that negatively regulate gene expression have emerged as novel therapeutic tools for cancer treatment. In this study, we investigated the potential role of Liver receptor homolog 1 (LRH 1), a novel oncogene, in non small cell lung cancer (NSCLC), and examined the regulation of LRH 1 by miRNAs. We found that LRH 1 was highly overexpressed in NSCLC cell lines. Knockdown of LRH 1 by small interfering RNA significantly inhibited NSCLC cell growth and invasion. miR 376c directly targeted the 3' untranslated region (UTR) of LRH 1 and negatively regulated LRH 1 expression, as detected by dual luciferase reporter assay, real time quantitative polymerase chain reaction and Western blot analysis. Further data showed that miR 376c expression was inversely correlated with LRH 1 expression in clinical cancer samples. Overexpression of miR 376c could inhibit NSCLC cell growth and invasion as well as Wnt signaling. In contrast, depletion of miR 376c exhibited the opposite effects. Moreover, these effects of miR 376c overexpression were partially abrogated by overexpression of LRH 1. Taken together, these results indicate that LRH 1 is involved in regulating the growth and invasion of NSCLC cells and that miR 376c inhibits NSCLC cell growth and invasion by targeting LRH 1, providing a novel insight into the potential for development of anti cancer drugs for NSCLC. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Jiang, Wenjun; Tian, Ye; Jiang, Shu; Liu, Siyang; Zhao, Xitong; Tian, Dali] China Med Univ, Affiliated Hosp 4, Dept Thorac Surg, 4 East Chongshan Rd, Shenyang 110032, Peoples R China.
C3 China Medical University
RP Jiang, WJ (通讯作者)，China Med Univ, Affiliated Hosp 4, Dept Thorac Surg, 4 East Chongshan Rd, Shenyang 110032, Peoples R China.
EM wenjunjiang123@163.com
RI Liu, Si Yang/HNI 0818 2023
CR Aigner A, 2011, J MOL MED, V89, P445, DOI 10.1007/s00109 010 0716 0
   Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950
   Barger JF, 2015, RESP MED, V109, P803, DOI 10.1016/j.rmed.2015.02.006
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bayrer JR, 2015, P NATL ACAD SCI USA, V112, P2467, DOI 10.1073/pnas.1500978112
   Benod C, 2013, J BIOL CHEM, V288, P19830, DOI 10.1074/jbc.M112.411686
   Benod C, 2011, P NATL ACAD SCI USA, V108, P16927, DOI 10.1073/pnas.1112047108
   Bianco S, 2015, ONCOGENE, V34, P4509, DOI 10.1038/onc.2014.382
   Chand AL, 2010, ENDOCR RELAT CANCER, V17, P965, DOI 10.1677/ERC 10 0179
   Chand AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031593
   Corzo CA, 2015, MOL PHARMACOL, V87, P296, DOI 10.1124/mol.114.095554
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   Ebrahimi A, 2015, PULM PHARMACOL THER, V34, P55, DOI 10.1016/j.pupt.2015.08.007
   Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008
   Feng B, 2015, CLIN SCI, V128, P619, DOI 10.1042/CS20140530
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Iwaki J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069496
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jin Y, 2013, DNA CELL BIOL, V32, P302, DOI 10.1089/dna.2013.1977
   Kramer HB, 2016, NUCLEIC ACIDS RES, V44, P582, DOI 10.1093/nar/gkv948
   Li ZY, 2015, BIOCHEM BIOPH RES CO, V461, P450, DOI 10.1016/j.bbrc.2015.04.013
   Liang Y, 2015, BIOMED PHARMACOTHER, V75, P137, DOI 10.1016/j.biopha.2015.07.020
   Lin QS, 2014, CANCER LETT, V350, P15, DOI 10.1016/j.canlet.2014.04.017
   Lin QS, 2014, CANCER LETT, V345, P85, DOI 10.1016/j.canlet.2013.11.014
   Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097 2765(00)00050 2
   Miki Y, 2006, CANCER LETT, V244, P24, DOI 10.1016/j.canlet.2005.11.038
   Nadolny C, 2015, CANCER BIOL THER, V16, P997, DOI 10.1080/15384047.2015.1045693
   Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660
   Rottiers V, 2011, COLD SH Q B, V76, P225, DOI 10.1101/sqb.2011.76.011049
   Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102
   Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967
   Stewart DJ, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/djt356
   Thiruchelvam PTR, 2011, BREAST CANCER RES TR, V127, P385, DOI 10.1007/s10549 010 0994 9
   Wang SL, 2008, MOL CELL BIOCHEM, V308, P93, DOI 10.1007/s11010 007 9616 1
   Wang SL, 2005, BIOCHEM BIOPH RES CO, V333, P917, DOI 10.1016/j.bbrc.2005.05.186
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309 228
   Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223
   Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476 4598 11 44
   Zhang QQ, 2016, ONCOL REP, V35, P1831, DOI 10.3892/or.2015.4491
NR 39
TC 30
Z9 33
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 13
PY 2016
VL 473
IS 4
BP 980
EP 986
DI 10.1016/j.bbrc.2016.04.002
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DL7MB
UT WOS:000375823700032
PM 27049310
DA 2025 08 17
ER

PT J
AU Eisenstein, A
   Hilliard, BK
   Pope, SD
   Zhang, CL
   Taskar, P
   Waizman, DA
   Israni Winger, K
   Tian, H
   Luan, HH
   Wang, A
AF Eisenstein, Anna
   Hilliard, Brandon K.
   Pope, Scott D.
   Zhang, Cuiling
   Taskar, Pranali
   Waizman, Daniel A.
   Israni Winger, Kavita
   Tian, Hui
   Luan, Harding H.
   Wang, Andrew
TI Activation of the transcription factor NRF2 mediates the
   anti inflammatory properties of a subset of over the counter and
   prescription NSAIDs
SO IMMUNITY
LA English
DT Article
ID NF KAPPA B; OXIDATIVE STRESS; NUCLEAR FACTOR; DRUGS; EXPRESSION;
   INDUCTION; CELLS; MICE; CYCLOOXYGENASE; OSTEOARTHRITIS
AB Nonsteroidal anti inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) enzymes and are ubiquitously used for their anti inflammatory properties. However, COX inhibition alone fails to explain numerous clinical outcomes of NSAID usage. Screening commonly used NSAIDs in primary human and murine myeloid cells demonstrated that NSAIDs could be differentiated by their ability to induce growth/differentiation factor 15 (GDF15), independent of COX specificity. Using genetic and pharmacologic approaches, NSAID mediated GDF15 induction was dependent on the activation of nuclear factor erythroid 2 related factor 2 (NRF2) in myeloid cells. Sensing by Cysteine 151 of the NRF2 chaperone, Kelch like ECH associated protein 1 (KEAP1) was required for NSAID activation of NRF2 and subsequent anti inflammatory effects both in vitro and in vivo. Myeloid specific deletion of NRF2 abolished NSAID mediated tissue protection in murine models of gout and endotoxemia. This highlights a noncanonical NRF2 dependent mechanism of action for the anti inflammatory activity of a subset of commonly used NSAIDs.
C1 [Eisenstein, Anna] Yale Sch Med, Dept Dermatol, New Haven, CT 06520 USA.
   [Hilliard, Brandon K.; Zhang, Cuiling; Wang, Andrew] Yale Sch Med, Dept Internal Med & Immunobiol, New Haven, CT 06520 USA.
   [Pope, Scott D.; Waizman, Daniel A.; Israni Winger, Kavita] Yale Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.
   [Pope, Scott D.] Howard Hughes Med Inst, New Haven, CT 06510 USA.
   [Taskar, Pranali; Tian, Hui; Luan, Harding H.] NGM Biopharmaceut, San Francisco, CA 94080 USA.
   [Hilliard, Brandon K.] Univ Colorado, Med Scientist Training Program, Anschutz Med Campus, Aurora, CO 80045 USA.
C3 Yale University; Yale University; Yale University; Howard Hughes Medical
   Institute; University of Colorado System; University of Colorado
   Anschutz Medical Campus
RP Wang, A (通讯作者)，Yale Sch Med, Dept Internal Med & Immunobiol, New Haven, CT 06520 USA.; Luan, HH (通讯作者)，NGM Biopharmaceut, San Francisco, CA 94080 USA.
EM hluan@ngmbio.com; andrew.wang@yale.edu
RI ; Taskar, Pranali/KLZ 5537 2024
OI Hilliard, Brandon/0000 0001 5030 4828; Waizman,
   Daniel/0000 0002 3690 7793; Taskar, Pranali/0000 0001 9677 6273; Wang,
   Andrew/0000 0002 6951 8081
FU NIH [K08 AI128745, R01 AI162645]; Charles H. Hood Foundation; Food
   Allergy Science Initiative; Pew Charitable Trusts; NIH/NIAMS [T32
   AR007016 43]; Dermatologist Investigator Research Fellowship from the
   Dermatology Foundation; Yale Center for Clinical Investigation/Yale
   Physician Scientist Development Award; Robert E. Leet and Clara Guthrie
   Patterson Trust; National Institute of Allergy and Infectious Diseases
   [K08AI128745] Funding Source: NIH RePORTER
FX We thank the Wang lab for valuable discussions. We thank Dr. Anton Komar
   (Cleveland State University) for providing bone marrow from
   Eif2a deficient mice. We thank Dr. Masayuki Yamamoto (RIKEN Institute)
   for the KEAP1 C151S transgenic animals. We thank Dr. Andy MacMahon for
   the GDF15 deficient animals (University of Southern California). We
   thank Drs. Ruslan Medzhitov, Michael Brown, DeepDixit, Ruth Franklin,
   and KristaWang for critical review of themanuscript. TheWang lab is
   supported in part by grants fromthe NIH (K08 AI128745 and R01 AI162645),
   the Charles H. Hood Foundation, the Food Allergy Science Initiative, and
   by the Pew Charitable Trusts. A.E. received support from the following
   sources: T32 AR007016 43 fromNIH/NIAMS, Dermatologist Investigator
   Research Fellowship from the Dermatology Foundation, Yale Center for
   Clinical Investigation/Yale Physician Scientist Development Award, and
   the Robert E. Leet and Clara Guthrie Patterson Trust.
CR Abram CL, 2014, J IMMUNOL METHODS, V408, P89, DOI 10.1016/j.jim.2014.05.009
   Al Harbi NO, 2019, EUR J PHARMACOL, V855, P276, DOI 10.1016/j.ejphar.2019.05.026
   ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432 1033.1994.tb20033.x
   ARIASNEGRETE S, 1995, BIOCHEM BIOPH RES CO, V208, P582, DOI 10.1006/bbrc.1995.1378
   Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901
   Bannuru RR, 2015, ANN INTERN MED, V162, P46, DOI 10.7326/M14 1231
   Behnammanesh G, 2020, REDOX BIOL, V32, DOI 10.1016/j.redox.2020.101527
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Blanca Lopez N, 2019, J ASTHMA ALLERGY, V12, P217, DOI 10.2147/JAA.S164806
   Borner T, 2020, CELL METAB, V31, P351, DOI 10.1016/j.cmet.2019.12.004
   Brater DC, 2001, AM J NEPHROL, V21, P1, DOI 10.1159/000046212
   Castiglione GM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16129 4
   Chen QM, 2018, PHYSIOL GENOMICS, V50, P77, DOI 10.1152/physiolgenomics.00041.2017
   Ching TT, 2011, AGING CELL, V10, P506, DOI 10.1111/j.1474 9726.2011.00688.x
   Chubak J, 2016, ANN INTERN MED, V164, P814, DOI 10.7326/M15 2117
   Cilenti F, 2021, IMMUNITY, V54, P1665, DOI 10.1016/j.immuni.2021.05.016
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   Coll AP, 2020, NATURE, V578, P444, DOI 10.1038/s41586 019 1911 y
   CRESTANI F, 1991, BRAIN RES, V542, P330, DOI 10.1016/0006 8993(91)91587 Q
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573 018 0008 x
   da Costa BR, 2017, LANCET, V390, pE21, DOI 10.1016/S0140 6736(17)31744 0
   Day EA, 2019, NAT METAB, V1, P1202, DOI 10.1038/s42255 019 0146 4
   de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022
   de Zeeuw D, 2013, NEW ENGL J MED, V369, P2492, DOI 10.1056/NEJMoa1306033
   Desborough MJR, 2017, BRIT J HAEMATOL, V177, P674, DOI 10.1111/bjh.14520
   Dinkova Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Doña I, 2012, J INVEST ALLERG CLIN, V22, P363
   Foresti R, 2013, PHARMACOL RES, V76, P132, DOI 10.1016/j.phrs.2013.07.010
   Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001
   FU JY, 1990, J BIOL CHEM, V265, P16737
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Gao JX, 2018, J AM CHEM SOC, V140, P4259, DOI 10.1021/jacs.7b11639
   Gil CI, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56922 w
   Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078 0432.CCR 13 1573
   Gurpinar E, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00181
   Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006 2952(96)00181 5
   Hasan R, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71449 1
   He C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004860
   Herndon CM, 2008, PHARMACOTHERAPY, V28, P788, DOI 10.1592/phco.28.6.788
   Hsu JY, 2017, NATURE, V550, P255, DOI 10.1038/nature24042
   INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965
   Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Kavian N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01896
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Kim KH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25098 0
   Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092 8674(95)90126 4
   Lewis KN, 2015, P NATL ACAD SCI USA, V112, P3722, DOI 10.1073/pnas.1417566112
   Li MT, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen 2019 036748
   Liang X, 2015, ELIFE, V4, DOI 10.7554/eLife.08973
   Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386
   Liu J, 2020, J AM SOC NEPHROL, V31, P701, DOI 10.1681/ASN.2019090876
   Lo PC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005109
   Lombard DB, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7628
   Luan HH, 2019, CELL, V178, P1231, DOI 10.1016/j.cell.2019.07.033
   MacLagan T., 1876, LANCET, VI, P585
   Mallinson PI, 2014, SKELETAL RADIOL, V43, P277, DOI 10.1007/s00256 013 1771 8
   McGettigan P, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001098
   Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986
   Mulderrig L, 2021, NATURE, V600, P158, DOI 10.1038/s41586 021 04133 7
   Mullican SE, 2017, NAT MED, V23, P1150, DOI 10.1038/nm.4392
   Nagashima R, 2019, J IMMUNOL, V202, P1331, DOI 10.4049/jimmunol.1801180
   Naidu SD, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26269 9
   Ogawa T, 2020, J IMMUNOL, V205, P907, DOI 10.4049/jimmunol.2000274
   Ong CKS, 2007, CLIN MED RES, V5, P17, DOI 10.3121/cmr.2007.698
   Patel S, 2019, CELL METAB, V29, P707, DOI 10.1016/j.cmet.2018.12.016
   Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538
   Ratnam NM, 2017, J CLIN INVEST, V127, P3796, DOI 10.1172/JCI91561
   Robledinos Antón N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9372182
   Rollason V, 2014, CURR DRUG METAB, V15, P326, DOI 10.2174/1389200215666140202214454
   Saito R, 2016, MOL CELL BIOL, V36, P271, DOI 10.1128/MCB.00868 15
   Santos I, 2020, P NATL ACAD SCI USA, V117, P12281, DOI 10.1073/pnas.1918508117
   Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132
   Schjerning AM, 2020, NAT REV CARDIOL, V17, P574, DOI 10.1038/s41569 020 0366 z
   Schmidt A., 1934, IND CHEMIE IHRER BED
   Schumacher HR, 2004, JCR J CLIN RHEUMATOL, V10, pS18, DOI 10.1097/01.rhu.0000131745.37852.bb
   SHEN TY, 1963, J AM CHEM SOC, V85, P488, DOI 10.1021/ja00887a038
   Shi JY, 2018, METHODS MOL BIOL, V1784, P263, DOI 10.1007/978 1 4939 7837 3_24
   Smith CE, 2017, CELL CHEM BIOL, V24, P281, DOI 10.1016/j.chembiol.2017.02.003
   Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278
   STONE E., 1763, PHILOS T, V53, P195, DOI DOI 10.1098/RSTL.1763.0033
   Suzuki T, 2017, CELL REP, V18, P2045, DOI 10.1016/j.celrep.2017.01.076
   Takaya K, 2012, FREE RADICAL BIO MED, V53, P817, DOI 10.1016/j.freeradbiomed.2012.06.023
   Toth RK, 2017, ANTIOXIDANTS BASEL, V6, DOI 10.3390/antiox6020027
   Trelle S, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7086
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Weng JH, 2021, NAT METAB, V3, P513, DOI 10.1038/s42255 021 00366 y
   WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544
   WINTER CA, 1963, J PHARMACOL EXP THER, V141, P369
   Wu WQ, 2019, MOL MED REP, V20, P1761, DOI 10.3892/mmr.2019.10405
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015
   ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399
   Zhou SF, 2005, DRUG METAB REV, V37, P41, DOI 10.1081/DMR 200028812
NR 98
TC 33
Z9 37
U1 0
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074 7613
EI 1097 4180
J9 IMMUNITY
JI Immunity
PD JUN 14
PY 2022
VL 55
IS 6
BP 1082
EP +
DI 10.1016/j.immuni.2022.04.015
EA JUN 2022
PG 20
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 3F2TY
UT WOS:000830524400003
PM 35588739
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Cheema, AK
   Byrum, SD
   Sharma, NK
   Altadill, T
   Kumar, VP
   Biswas, S
   Balgley, BM
   Hauer Jensen, M
   Tackett, AJ
   Ghosh, SP
AF Cheema, Amrita K.
   Byrum, Stephanie D.
   Sharma, Neel Kamal
   Altadill, Tatiana
   Kumar, Vidya P.
   Biswas, Shukla
   Balgley, Brian M.
   Hauer Jensen, Martin
   Tackett, Alan J.
   Ghosh, Sanchita P.
TI Proteomic Changes in Mouse Spleen after Radiation Induced Injury and its
   Modulation by Gamma Tocotrienol
SO RADIATION RESEARCH
LA English
DT Article
ID TOTAL BODY IRRADIATION; STEM CELL COMPARTMENT; IONIZING RADIATION;
   HEMATOPOIETIC STEM; OXIDATIVE STRESS; BETA CATENIN; BONE MARROW;
   ERYTHROPOIETIN; RECOVERY; THERAPY
AB Gamma tocotrienol (GT3), a naturally occurring vitamin E isomer, a promising radioprotector, has been shown to protect mice against radiation induced hematopoietic and gastrointestinal injuries. We analyzed changes in protein expression profiles of spleen tissue after GT3 treatment in mice exposed to gamma radiation to gain insights into the molecular mechanism of radioprotective efficacy. Male CD2F1 mice, 12 to 14 weeks old, were treated with either vehicle or GT3 at 24 h prior to 7 Gy total body irradiation. Nonirradiated vehicle, nonirradiated GT3 and age matched naive animals were used as controls. Blood and tissues were harvested on days 0, 1, 2, 4, 7, 10 and 14 postirradiation. High resolution mass spectrometry based radioproteomics was used to identify differentially expressed proteins in spleen tissue with or without drug treatment. Subsequent bioinformatic analyses helped delineate molecular markers of biological pathways and networks regulating the cellular radiation responses in spleen. Our results show a robust alteration in spleen proteomic profiles including upregulation of the Wnt signaling pathway and actin cytoskeleton linked proteins in mediating the radiation injury response in spleen. Furthermore, we show that 24 h pretreatment with GT3 attenuates radiation induced hematopoietic injury in the spleen by modulating various cell signaling proteins. Taken together, our results show that the radioprotective effects of GT3 are mediated, via alleviation of radiation induced alterations in biochemical pathways, with wide implications on overall hematopoietic injury. (C) 2018 by Radiation Research Society
C1 [Cheema, Amrita K.; Altadill, Tatiana] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.
   [Cheema, Amrita K.; Altadill, Tatiana] Georgetown Univ, Med Ctr, Dept Biochem, Washington, DC 20007 USA.
   [Cheema, Amrita K.; Altadill, Tatiana] Georgetown Univ, Med Ctr, Dept Mol & Cellular Biol, Washington, DC 20007 USA.
   [Byrum, Stephanie D.; Hauer Jensen, Martin; Tackett, Alan J.] Univ Arkansas Med Sci, Coll Pharm, Div Radiat Hlth, Little Rock, AR 72205 USA.
   [Byrum, Stephanie D.; Hauer Jensen, Martin; Tackett, Alan J.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
   [Sharma, Neel Kamal; Kumar, Vidya P.; Biswas, Shukla; Ghosh, Sanchita P.] Uniformed Serv Univ Hlth Sci, Armed Forces Radiobiol Res Inst, 8901 Wisconsin Ave,Bldg 42, Bethesda, MD 20889 USA.
   [Altadill, Tatiana] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Inst Invest Biomed Bellvitge IDIBELL, Gynecol Dept, Barcelona, Spain.
   [Balgley, Brian M.] Bioproximity LLC, Chantilly, VA USA.
   [Sharma, Neel Kamal; Kumar, Vidya P.] Radiat Res Soc, Bozeman, MT USA.
C3 Georgetown University; Georgetown University; Georgetown University;
   University of Arkansas System; University of Arkansas Medical Sciences;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Central Arkansas Veterans Healthcare System; United States Department of
   Defense; Uniformed Services University of the Health Sciences   USA;
   Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital
   Universitari Vall d'Hebron; Autonomous University of Barcelona
RP Ghosh, SP (通讯作者)，Uniformed Serv Univ Hlth Sci, Armed Forces Radiobiol Res Inst, 8901 Wisconsin Ave,Bldg 42, Bethesda, MD 20889 USA.
EM sanchita.ghosh@usuhs.edu
RI ; Kumar, Vidya/ABH 9877 2020
OI Ghosh, Sanchita/0000 0002 0261 460X; Cheema, Amrita/0000 0003 4877 7583;
   Balgley, Brian/0000 0002 3509 4567; Altadill Vallespi,
   Tatiana/0009 0008 0340 3186
FU U.S. Department of Defense Threat Reduction Agency [H.10016_09_AR_R];
   National Institutes of Health [R01GM106024, R21ES025268, UL1TR000039,
   P20GM103625, S10OD018445, P20GM103429]; National Space Biomedical
   Research [RE03701]; NIAID/NIH [1U01AI133561 01]; National Institute of
   General Medical Sciences of the National Institutes of Health [P20
   GM109005]
FX We acknowledge Gregory Holmes Hampton for editing the manuscript. This
   study was supported by the U.S. Department of Defense Threat Reduction
   Agency (H.10016_09_AR_R, administered by the Henry M. Jackson Foundation
   for the Advancement of Military Medicine, Inc. and the AFRRI Intramural
   funding). Additional funding was provided by: the National Institutes of
   Health (grant nos. R01GM106024, R21ES025268, UL1TR000039, P20GM103625,
   S10OD018445 and P20GM103429 to AJT); the National Space Biomedical
   Research (grant no. RE03701) and the NIAID/NIH (grant no.
   1U01AI133561 01), to AKC; and by an Institutional Development Award from
   the National Institute of General Medical Sciences of the National
   Institutes of Health (grant no. P20 GM109005 to MHJ). Finally, we thank
   the anonymous reviewers who helped us polish the manuscript. The
   opinions contained herein are the private views of the authors, and are
   not necessarily those of the Armed Forces Radiobiology Research
   Institute, the Uniformed Services of the University of the Health
   Sciences, or the Department of Defense. The authors have no conflict of
   interest, financial, or otherwise, to declare.
CR [Anonymous], RAD TOXICOLOGY BONE
   Azimzadeh O, 2014, RADIAT ENVIRON BIOPH, V53, P31, DOI 10.1007/s00411 013 0495 4
   Azimzadeh O, 2013, J PROTEOME RES, V12, P2700, DOI 10.1021/pr400071g
   Azimzadeh O, 2012, J PROTEOMICS, V75, P2384, DOI 10.1016/j.jprot.2012.02.019
   Azimzadeh O, 2011, PROTEOMICS, V11, P3299, DOI 10.1002/pmic.201100178
   Barjaktarovic Z, 2013, RADIOTHER ONCOL, V106, P404, DOI 10.1016/j.radonc.2013.01.017
   Barjaktarovic Z, 2013, RADIAT ENVIRON BIOPH, V52, P87, DOI 10.1007/s00411 012 0439 4
   Barjaktarovic Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027811
   Baskar R, 2012, INT J MED SCI, V9, P193, DOI 10.7150/ijms.3635
   Bentzen SM, 2006, NAT REV CANCER, V6, P702, DOI 10.1038/nrc1950
   Berbée M, 2009, RADIAT RES, V171, P596, DOI 10.1667/RR1632.1
   Bjornson RD, 2008, J PROTEOME RES, V7, P293, DOI 10.1021/pr0701198
   Bykov VN, 2018, INT J RADIAT BIOL, V94, P114, DOI 10.1080/09553002.2018.1416204
   Chen CW, 2005, PROTEOMICS, V5, P4254, DOI 10.1002/pmic.200401295
   Chong ZZ, 2011, CURR NEUROVASC RES, V8, P103
   Congdon KL, 2008, STEM CELLS, V26, P1202, DOI 10.1634/stemcells.2007 0768
   Craig R, 2006, J PROTEOME RES, V5, P1843, DOI 10.1021/pr0602085
   Craig R, 2004, J PROTEOME RES, V3, P1234, DOI 10.1021/pr049882h
   Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092
   DEGOWIN RL, 1968, J LAB CLIN MED, V72, P893
   Dierks S, 2015, ONCOTARGET, V6, P13591, DOI 10.18632/oncotarget.3792
   Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908
   Fliedner T. M., 1984, RESPONSE DIFFERENT S, P209
   Geer LY, 2004, J PROTEOME RES, V3, P958, DOI 10.1021/pr0499491
   Ghosh SP, 2016, RADIAT RES, V185, P485, DOI 10.1667/RR14248.1
   Ghosh SP, 2009, INT J RADIAT BIOL, V85, P598, DOI 10.1080/09553000902985128
   Ghosh SP, 2009, RADIAT RES, V171, P173, DOI 10.1667/RR1367.1
   Hauer Jensen M, 2008, INTESTINAL TOXICITY
   Hengel SM, 2014, PROTEOMES, V2, P382, DOI 10.3390/proteomes2030382
   Jenkins LMM, 2008, MOL CELL PROTEOMICS, V7, P716, DOI 10.1074/mcp.M700482 MCP200
   Korcyl M, 2009, INT J RADIAT BIOL, V85, P1101, DOI 10.3109/09553000903242123
   Kulkarni S, 2010, RADIAT RES, V173, P738, DOI 10.1667/RR1824.1
   Kulkarni SS, 2012, INT IMMUNOPHARMACOL, V14, P495, DOI 10.1016/j.intimp.2012.09.001
   Lento W, 2014, GENE DEV, V28, P995, DOI 10.1101/gad.231944.113
   Lim YB, 2011, PROTEOMICS, V11, P1254, DOI 10.1002/pmic.201000332
   Liu Q, 2010, J CELL SCI, V123, P1116, DOI 10.1242/jcs.058958
   MacLean B, 2006, BIOINFORMATICS, V22, P2830, DOI 10.1093/bioinformatics/btl379
   MAUCH P, 1995, INT J RADIAT ONCOL, V31, P1319, DOI 10.1016/0360 3016(94)00430 S
   NAIDU NV, 1967, NATURE, V214, P1223, DOI 10.1038/2141223a0
   Ossetrova NI, 2014, HEALTH PHYS, V106, P772, DOI 10.1097/HP.0000000000000094
   Pernot E, 2012, MUTAT RES REV MUTAT, V751, P258, DOI 10.1016/j.mrrev.2012.05.003
   Pluder F, 2011, RADIAT ENVIRON BIOPH, V50, P155, DOI 10.1007/s00411 010 0342 9
   Reya T, 2003, RECENT PROG HORM RES, V58, P283, DOI 10.1210/rp.58.1.283
   Satyamitra MM, 2011, RADIAT RES, V175, P736, DOI 10.1667/RR2460.1
   SCHOOLEY JC, 1967, RADIAT RES, V32, P875, DOI 10.2307/3572292
   Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955 0674(00)00194 0
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Singh VK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050663
   Singh VK, 2016, RADIAT RES, V185, P285, DOI 10.1667/RR14127.1
   Singh VK, 2012, RADIAT RES, V177, P628, DOI 10.1667/RR2657.1
   Singh VK, 2009, INT IMMUNOPHARMACOL, V9, P1423, DOI 10.1016/j.intimp.2009.08.020
   Slotta DJ, 2010, PROTEOMICS, V10, P3035, DOI 10.1002/pmic.200900370
   Sriharshan A, 2012, J PROTEOMICS, V75, P2319, DOI 10.1016/j.jprot.2012.02.009
   Srivastava Anjali, 2015, J Proteomics Bioinform, V8, P23
   Staal FJT, 2008, EUR J IMMUNOL, V38, P1788, DOI 10.1002/eji.200738118
   Staessen JA, 2005, PHARMACOGENOMICS, V6, P665, DOI 10.2217/14622416.6.7.665
   Subramanian V, 2018, J PROTEOME RES, V17, P1677, DOI 10.1021/acs.jproteome.8b00001
   Swift SN, 2014, INT J TOXICOL, V33, P450, DOI 10.1177/1091581814554929
   Wang Y, 2006, CELL CYCLE, V5, P35, DOI 10.4161/cc.5.1.2280
   WEISMAN M, 1967, J LAB CLIN MED, V69, P438
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Yuan Y, 2013, RADIAT RES, V179, P62, DOI 10.1667/RR3119.1
NR 62
TC 22
Z9 23
U1 1
U2 14
PU RADIATION RESEARCH SOC
PI LAWRENCE
PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA
SN 0033 7587
EI 1938 5404
J9 RADIAT RES
JI Radiat. Res.
PD NOV
PY 2018
VL 190
IS 5
BP 449
EP 463
DI 10.1667/RR15008.1
PG 15
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics; Radiology,
   Nuclear Medicine & Medical Imaging
GA HC8WE
UT WOS:000452084900001
PM 30070965
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lin, Z
   Xiong, Y
   Sun, Y
   Zeng, RY
   Xue, H
   Hu, YQ
   Chen, L
   Liu, GD
   Panayi, AC
   Zhou, W
   Cao, FQ
   Gao, F
   Mi, BB
   Liu, GH
AF Lin, Ze
   Xiong, Yuan
   Sun, Yun
   Zeng, Ruiyin
   Xue, Hang
   Hu, Yiqiang
   Chen, Lang
   Liu, Guodong
   Panayi, Adriana C.
   Zhou, Wu
   Cao, Faqi
   Gao, Fei
   Mi, Bobin
   Liu, Guohui
TI Circulating MiRNA 21 enriched extracellular vesicles promote bone
   remodeling in traumatic brain injury patients
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID DIFFERENTIATION; COMMUNICATION; FRACTURES
AB Bone fracture: faster healing after traumatic brain injuryExtracellular vesicles enriched with a particular microRNA released following traumatic brain injury (TBI) help fractures heal faster and could inform treatments for skeletal disorders. Patients with TBI and associated fractures experience shorter fracture recovery times than patients with fractures only, but precisely why is unclear. Ze Lin at Huazhong University of Science and Technology, Wuhan, China, and co workers examined molecules released during recovery in samples taken from patients with TBI and fractures, those with fractures only, and mouse models with femur fractures. They found that exosomes (extracellular vesicles that transport metabolites including microRNA) released following TBI are enriched with miRNA 21 5 p, which enhances differentiation of bone forming cells and bone repair. No miRNA 21 5 p enrichment occurred in patients with fractures only. Knocking out exosomal miRNA 21 5 p impaired bone repair in mice, while injecting exosomes from TBI patients boosted bone formation.
   Fracture combined with traumatic brain injury (TBI) is one of the most common and serious types of compound trauma in the clinic and is characterized by dysfunction of cellular communication in injured organs. Our prior studies found that TBI was capable of enhancing fracture healing in a paracrine manner. Exosomes (Exos), as small extracellular vesicles, are important paracrine vehicles for noncell therapy. However, whether circulating Exos derived from TBI patients (TBI Exos) regulate the prohealing effects of fractures remains unclear. Thus, the present study aimed to explore the biological effects of TBI Exos on fracture healing and reveal the potential molecular mechanism. TBI Exos were isolated by ultracentrifugation, and the enriched miR 21 5 p was identified by qRT PCR analysis. The beneficial effects of TBI Exos on osteoblastic differentiation and bone remodeling were determined by a series of in vitro assays. Bioinformatics analyses were conducted to identify the potential downstream mechanisms of the regulatory effect of TBI Exos on osteoblasts. Furthermore, the role of the potential signaling pathway of TBI Exos in mediating the osteoblastic activity of osteoblasts was assessed. Subsequently, a murine fracture model was established, and the effect of TBI Exos on bone modeling was demonstrated in vivo. TBI Exos can be internalized by osteoblasts, and in vitro, suppression of SMAD7 promoted osteogenic differentiation, whereas knockdown of miR 21 5 p in TBI Exos strongly inhibited this bone beneficial effect. Similarly, our results confirmed that preinjection of TBI Exos led to enhanced bone formation, whereas knockdown of exosomal miR 21 5 p substantially impaired this bone beneficial effect in vivo.
C1 [Lin, Ze; Xiong, Yuan; Zeng, Ruiyin; Xue, Hang; Hu, Yiqiang; Chen, Lang; Zhou, Wu; Cao, Faqi; Gao, Fei; Mi, Bobin; Liu, Guohui] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed, Wuhan 430022, Peoples R China.
   [Sun, Yun] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurosurg, Wuhan 430022, Peoples R China.
   [Liu, Guodong] Army Med Univ, Daping Hosp, Med Ctr Trauma & War Injuries, Chongqing 400042, Peoples R China.
   [Panayi, Adriana C.] Brigham & Womens Hosp, Harvard Med Sch, Dept Plast Surg, Boston, MA 02152 USA.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Army Medical University; Harvard University;
   Harvard University Medical Affiliates; Brigham & Women's Hospital;
   Harvard Medical School
RP Gao, F; Mi, BB; Liu, GH (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed, Wuhan 430022, Peoples R China.
EM docgaofei@foxmail.com; mibobin@hust.edu.cn; liuguohui@hust.edu.cn
RI Liu, Guodong/C 5806 2011; Xiong, Yuan/AAQ 3642 2021; chou,
   wu/AAI 1145 2019; Mi, Bobin/LTD 1938 2024; ruiyin, zeng/KUD 0623 2024;
   Panayi, Adriana/HHT 0513 2022
OI Zeng, Ruiyin/0000 0003 4766 7286; Panayi, Adriana/0000 0003 4053 9855;
   Mi, Bobin/0000 0002 6994 4363; Xiong, Yuan/0000 0003 1090 9288; 
FU National Science Foundation of China [82002313, 31900963,
   YCJJ202201015]; Fundamental Research Funds for the Central Universities
   [82072444]; Hubei Province Key Laboratory of Oral and Maxillofacial
   Development and Regeneration [2020kqhm008]; Health Commission of Hubei
   Province [WJ2019Z009]
FX This work was supported by the National Science Foundation of China
   (No.82002313), the Fundamental Research Funds for the Central
   Universities (No.YCJJ202201015), the National Science Foundation of
   China (No. 82072444, 31900963), the Hubei Province Key Laboratory of
   Oral and Maxillofacial Development and Regeneration (No. 2020kqhm008),
   and the Health Commission of Hubei Province(No. WJ2019Z009)
CR Bemben DA, 2021, OSTEOPOROSIS INT, V32, P1369, DOI 10.1007/s00198 020 05805 2
   Ben Ami IS, 2018, J BONE JOINT SURG AM, V100, P930, DOI 10.2106/JBJS.17.01267
   Chen L, 2020, FASEB J, V34, P5208, DOI 10.1096/fj.201901864RR
   Chen WZ, 2018, ACTA BIOMATER, V74, P489, DOI 10.1016/j.actbio.2018.04.043
   Guo QY, 2020, EUR J PHARMACOL, V884, DOI 10.1016/j.ejphar.2020.173394
   Hawkes CP, 2019, BONE, V119, P57, DOI 10.1016/j.bone.2018.03.012
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Hou T, 2020, J MUSCULOSKEL NEURON, V20, P526
   Hu LC, 2021, MOL THER NUCL ACIDS, V23, P1345, DOI 10.1016/j.omtn.2021.02.008
   Li D, 2019, MED SCI MONITOR, V25, P1871, DOI 10.12659/MSM.915727
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li R, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2146 x
   Lieben L, 2009, HORM RES, V71, P134, DOI 10.1159/000178056
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Meyer MB, 2016, J BIOL CHEM, V291, P17829, DOI 10.1074/jbc.M116.736538
   Mi BB, 2020, J CELL MOL MED, V24, P6385, DOI 10.1111/jcmm.15284
   Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029
   Smieszek A, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020479
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375
   Toh WS, 2018, CYTOTHERAPY, V20, P1419, DOI 10.1016/j.jcyt.2018.09.008
   Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011
   Xia W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26302 y
   Xiong Y, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00622 5
   Xiong Y, 2020, SMALL, V16, DOI 10.1002/smll.201904044
   Xiong Y, 2020, J CELL MOL MED, V24, P1076, DOI 10.1111/jcmm.14832
   Xiong Y, 2019, MOL THER NUCL ACIDS, V17, P223, DOI 10.1016/j.omtn.2019.06.001
   Xiong YY, 2020, TRANSL RES, V215, P1, DOI 10.1016/j.trsl.2019.07.013
   Yadav N, 2015, BURNS TRAUMA, V3, DOI 10.1186/s41038 015 0011 y
   Yin ZY, 2020, BRAIN BEHAV IMMUN, V83, P270, DOI 10.1016/j.bbi.2019.11.004
   Yue BL, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12857
   Zhang D, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00964 8
   Zhao F, 2020, CELLS BASEL, V9, DOI 10.3390/cells9030616
   Zohdy M, 2020, CLIN COSMET INV DERM, V13, P431, DOI 10.2147/CCID.S256269
NR 34
TC 23
Z9 24
U1 6
U2 39
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD MAR
PY 2023
VL 55
IS 3
BP 587
EP 596
DI 10.1038/s12276 023 00956 8
EA MAR 2023
PG 10
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA C2UN2
UT WOS:000943077400002
PM 36869070
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Meng, FF
   Xu, Y
   Dan, QQ
   Wei, L
   Deng, YJ
   Liu, J
   He, M
   Liu, W
   Xia, QJ
   Zhou, FH
   Wang, TH
   Wang, XY
AF Meng, Fu fen
   Xu, Yang
   Dan, Qi qin
   Wei, La
   Deng, Ying jie
   Liu, Jia
   He, Mu
   Liu, Wei
   Xia, Qing jie
   Zhou, Fiona H.
   Wang, Ting hua
   Wang, Xi yan
TI Intrathecal injection of lentivirus mediated glial cell line derived
   neurotrophic factor RNA interference relieves bone cancer induced pain
   in rats
SO CANCER SCIENCE
LA English
DT Article
DE Bone cancer pain; GDNF; lentivirus; RNA interference; spinal cord
ID IN VITRO; ACTIVATION; NEURONS; HYPERALGESIA; CONTRIBUTES; MODEL; ERK;
   BISPHOSPHONATES; ASTROCYTES; MICROGLIA
AB Bone cancer pain is a common symptom in cancer patients with bone metastases and the underlying mechanisms are largely unknown. The aim of this study is to explore the endogenous analgesic mechanisms to develop new therapeutic strategies for bone cancer induced pain (BCIP) as a result of metastases. MRMT 1 tumor cells were injected into bilateral tibia of rats and X rays showed that the area suffered from bone destruction, accompanied by an increase in osteoclast numbers. In addition, rats with bone cancer showed apparent mechanical and thermal hyperalgesia at day 28 after intratibial MRMT 1 inoculation. However, intrathecal injection of morphine or lentivirus mediated glial cell line derived neurotrophic factor RNAi (Lvs siGDNF) significantly attenuated mechanical and thermal hyperalgesia, as shown by increases in paw withdrawal thresholds and tail flick latencies, respectively. Furthermore, Lvs siGDNF interference not only substantially downregulated GDNF protein levels, but also reduced substance P immunoreactivity and downregulated the ratio of pERK/ERK, where its activation is crucial for pain signaling, in the spinal dorsal horn of this model of bone cancer induced pain. In this study, Lvs siGDNF gene therapy appeared to be a beneficial method for the treatment of bone cancer pain. As the effect of Lvs siGDNF to relieve pain was similar to morphine, but it is not a narcotic, the use of GDNF RNA interference may be considered as a new therapeutic strategy for the treatment of bone cancer pain in the future.
C1 [Meng, Fu fen; Wei, La] Xinjiang Tumor Hosp, Dept Anesthesia, Urumqi, Peoples R China.
   [Xu, Yang; Dan, Qi qin; Liu, Wei; Wang, Ting hua] Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Dept Anesthesia, Chengdu 610064, Peoples R China.
   [Dan, Qi qin; Liu, Jia; Wang, Ting hua] Kunming Med Univ, Inst Neurosci, Kunming, Peoples R China.
   [Deng, Ying jie] Xinjiang Tradit Chinese Med Hosp, Dept Orthoped 2, Urumqi, Peoples R China.
   [He, Mu; Xia, Qing jie] Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Chengdu 610064, Peoples R China.
   [Zhou, Fiona H.] Univ S Australia, Sansom Inst Hlth, Adelaide, SA 5001, Australia.
   [Wang, Xi yan] Xinjiang Tumor Hosp, Dept Hepatopancreatobiliary Surg, Urumqi, Peoples R China.
C3 Sichuan University; Kunming Medical University; Sichuan University;
   University of South Australia
RP Wang, TH (通讯作者)，17 Sect 3, Chengdu 610041, Sichuan, Peoples R China.
EM tinghua_neuron@263.net; xjwangxiyan@foxmail.com
FU Natural Science Foundation of the Xinjiang Uygur Autonomous Region for
   young researchers [2010211B13]
FX This project was supported by the Natural Science Foundation of the
   Xinjiang Uygur Autonomous Region for young researchers (project no.
   2010211B13; project name, The effect of analgesia in bone cancer pain
   induced by HSV I mediated the expression of HPPE).
CR Alvarez P, 2012, J NEUROPHYSIOL, V108, P2545, DOI 10.1152/jn.00576.2012
   Beard BC, 2007, MOL THER, V15, P1356, DOI 10.1038/sj.mt.6300159
   Cavazzana Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328
   Colburn RW, 1999, EXP NEUROL, V157, P289, DOI 10.1006/exnr.1999.7065
   de Wit R, 2001, PAIN, V91, P339, DOI 10.1016/S0304 3959(00)00455 3
   Doré Savard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013774
   Doyle CA, 1999, NEUROSCIENCE, V89, P17, DOI 10.1016/S0306 4522(98)00276 0
   Fang M, 2003, NEUROSCIENCE, V117, P503, DOI 10.1016/S0306 4522(02)00958 2
   Fang M, 2012, ANTIMICROB AGENTS CH, V56, P5253, DOI 10.1128/AAC.00304 12
   Fu XM, 2007, GLIA, V55, P935, DOI 10.1002/glia.20515
   Fufen M, 2014, ZHONGHUA SHI YAN WAI, V31, P956
   Fulfaro F, 1998, PAIN, V78, P157, DOI 10.1016/S0304 3959(98)00135 3
   Gao Yong Jing, 2009, Open Pain J, V2, P11
   Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Horvath RJ, 2010, NEUROSCIENCE, V169, P843, DOI 10.1016/j.neuroscience.2010.05.030
   Hu S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 278
   HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0
   Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011
   Le Bars D, 2001, PHARMACOL REV, V53, P597
   Li X, 2013, J PHYSIOL SCI, V63, P203, DOI 10.1007/s12576 012 0244 5
   Lipton A, 1997, CANCER, V80, P1668, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1668::AID CNCR17>3.0.CO;2 Y
   Luger NM, 2001, CANCER RES, V61, P4038
   Malin SA, 2006, J NEUROSCI, V26, P8588, DOI 10.1523/JNEUROSCI.1726 06.2006
   Mantyh PW, 2006, NAT REV NEUROSCI, V7, P797, DOI 10.1038/nrn1914
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304 3959(01)00437 7
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234
   Modlich U, 2009, MOL THER, V17, P1919, DOI 10.1038/mt.2009.179
   Montini E, 2009, J CLIN INVEST, V119, P964, DOI 10.1172/JCI37630
   Obata K, 2004, LIFE SCI, V74, P2643, DOI 10.1016/j.lfs.2004.01.007
   Papanikolaou E, 2013, VIRUS RES, V175, P1, DOI 10.1016/j.virusres.2013.03.015
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140 6736(99)01310 0
   Rittelmeyer I, 2013, HEPATOLOGY, V58, P397, DOI 10.1002/hep.26204
   Salamanna F, 2013, ACTA HISTOCHEM, V115, P76, DOI 10.1016/j.acthis.2012.05.005
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Vidal Torres A, 2013, EUR J PHARMACOL, V711, P63, DOI 10.1016/j.ejphar.2013.04.018
   Wang JY, 2012, J ETHNOPHARMACOL, V143, P905, DOI 10.1016/j.jep.2012.08.026
   Wang XW, 2012, NEUROSCIENCE, V217, P172, DOI 10.1016/j.neuroscience.2012.04.065
   Woolf CJ, 1998, PAIN, V77, P227, DOI 10.1016/S0304 3959(98)00099 2
   Yang L, 2013, BRAIN RES, V1515, P39, DOI 10.1016/j.brainres.2013.03.030
   Zhang Y, 2011, ZHONG YAO TONG BAO, V27, P234
   Zhang YL, 2007, NEUROSCI LETT, V419, P153, DOI 10.1016/j.neulet.2007.04.040
   Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022
   Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893 04.2004
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 46
TC 13
Z9 16
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1347 9032
EI 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2015
VL 106
IS 4
BP 430
EP 437
DI 10.1111/cas.12609
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CG5MQ
UT WOS:000353336400014
PM 25611164
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhang, HC
   Ta, N
AF Zhang, Huicun
   Ta, Na
TI Effect of isopsoralen on Smad7 in osteoblastic MC3T3 E1 cells
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE isopsoralen; postmenopausal osteoporosis; MC3T3 E1; type I collagen;
   mothers against decapentaplegic homolog 7
ID GROWTH FACTOR BETA; TGF BETA; BONE FORMATION; POSTMENOPAUSAL
   OSTEOPOROSIS; PSORALEA CORYLIFOLIA; REPLACEMENT THERAPY; ESTROGEN
   THERAPY; BREAST CANCER; RECEPTOR; PHYTOESTROGENS
AB The primary pathological change in postmenopausal osteoporosis (PM OP) is bone collagen loss caused by estrogen depletion. Osteoblasts synthesize type I collagen, which composes the organic matrix of bone. Although isopsoralen stimulates osteoblastic cell proliferation and differentiation, transforming growth factor (TGF) beta 1 is an important cell signaling factor for stimulating collagen synthesis. To explore the association between isopsoralen and the synthesis of collagen in vitro, the molecular and biological association between isopsoralen and TGF beta signaling was examined. (CAGA) 12 luciferase reporter gene was used to measure TGF beta 1 signaling activity. Type I collagen was detected by semiquantitative reverse transcription polymerase chain reaction, and mothers against decapentaplegic homolog 7 (Smad7) protein expression levels were analyzed by western blotting. The expression of collagen in MC3T3 E1 cells stimulated with isopsoralen was significantly upregulated compared with the control groups (P<0.05). Conversely, isopsoralen significantly decreased Smad7 protein expression compared with the control groups (P<0.05). Moreover, it was observed that isopsoralen activates the TGF beta 1 signaling pathway and ultimately promotes collagen synthesis through inhibition of Smad7 protein expression. Therefore, isopsoralen is a potential target for the treatment of PM OP.
C1 [Zhang, Huicun] Capital Univ Med Sci, Beijing Hosp Tradit Chinese Med, Dept Combinat Tradit Chinese & Western Med, 23 Art Gallery Backstreet, Beijing 100010, Peoples R China.
   [Zhang, Huicun] Beijing Inst Tradit Chinese Med, Dept Pathol & Physiol, Beijing 100010, Peoples R China.
   [Ta, Na] China Natl Hlth Dev Res Ctr, Dept Publ Hlth & Risk, Beijing 100019, Peoples R China.
C3 Capital Medical University
RP Zhang, HC (通讯作者)，Capital Univ Med Sci, Beijing Hosp Tradit Chinese Med, Dept Combinat Tradit Chinese & Western Med, 23 Art Gallery Backstreet, Beijing 100010, Peoples R China.
EM zhanghuicun728@126.com
FU Beijing Municipal Administration of Hospitals [PZ, 2016013]; Capital
   Medical University [16JL24]; Beijing Science and Technology Development
   of TCM [QN2016 24]; Beijing Hospital of Traditional Chinese Medicine
   [YJ 201722]
FX The present study was supported by the Fund of Beijing Municipal
   Administration of Hospitals Incubating Program (grant no. PZ, 2016013),
   the Cooperation Fund of Basic and Clinical Research of Capital Medical
   University (grant no. 16JL24), the Fund for Beijing Science and
   Technology Development of TCM (grant no. QN2016 24) and the Fund of
   Beijing Hospital of Traditional Chinese Medicine (grant no. YJ 201722).
CR Arjmandi BH, 2001, J AM COLL NUTR, V20, p398S, DOI 10.1080/07315724.2001.10719175
   Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197 1209
   Bales CW, 2001, J AM COLL NUTR, V20, p417S, DOI 10.1080/07315724.2001.10719178
   BENZ DJ, 1991, J BONE MINER RES, V6, P531
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Bord S, 2001, BONE, V29, P216, DOI 10.1016/S8756 3282(01)00501 4
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen XG, 2005, J CHROMATOGR A, V1089, P87, DOI 10.1016/j.chroma.2005.06.067
   Deady Joan, 2004, J Manag Care Pharm, V10, P33
   Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091
   Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092 8674(00)81696 7
   Dören M, 2000, HUM REPROD UPDATE, V6, P419, DOI 10.1093/humupd/6.5.419
   Estai MA, 2011, CLINICS, V66, P2113, DOI 10.1590/S1807 59322011001200018
   Fitzpatrick Lorraine A., 2006, Arq Bras Endocrinol Metab, V50, P705, DOI 10.1590/S0004 27302006000400016
   Gallagher JC, 1999, MATURITAS, V33, pS57
   Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
   Gonnelli S, 1997, J BONE MINER RES, V12, P624, DOI 10.1359/jbmr.1997.12.4.624
   He ZP, 2005, REPRODUCTION, V130, P333, DOI 10.1530/rep.1.00694
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Jaha Haytham, 2016, Biochem Biophys Rep, V6, P190
   Janiszewska M, 2014, MENOPAUSE REV, V13, P42, DOI 10.5114/pm.2014.41085
   Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287
   Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097 2765(00)00134 9
   Knight DC, 1996, OBSTET GYNECOL, V87, P897
   KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526
   Lanyon L, 2004, J ENDOCRINOL, V182, P183, DOI 10.1677/joe.0.1820183
   Laszlo Adam, 2004, Orvosi Hetilap, V145, P3
   Limer JL, 2004, BREAST CANCER RES, V6, P119, DOI 10.1186/bcr781
   LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092 8674(93)90368 Z
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   MAJESKA RJ, 1994, J BONE JOINT SURG AM, V76A, P713, DOI 10.2106/00004623 199405000 00013
   Marie P, 1997, REV RHUM, V64, P44
   Ming Lei Guo, 2011, Zhong Yao Cai, V34, P404
   Mukasa C, 2003, ENDOCRINOLOGY, V144, P1603, DOI 10.1210/en.2002 220978
   Nikander E, 2004, J CLIN ENDOCR METAB, V89, P1207, DOI 10.1210/jc.2003 031166
   NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo 124 6 2991
   Pardini D, 2007, ARQ BRAS ENDOCRINOL, V51, P938, DOI 10.1590/S0004 27302007000600007
   Peleg S, 2002, ENDOCRINOLOGY, V143, P1625, DOI 10.1210/en.143.5.1625
   Pentti K, 2006, EUR J ENDOCRINOL, V154, P101, DOI 10.1530/eje.1.02059
   Prelevic G M, 2005, Minerva Endocrinol, V30, P27
   Regier DS., 2000, GeneReviewsR
   Rydziel S, 1997, J CELL PHYSIOL, V170, P145, DOI 10.1002/(SICI)1097 4652(199702)170:2<145::AID JCP6>3.0.CO;2 O
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364
   Taxvig C, 2010, NUTR CANCER, V62, P122, DOI 10.1080/01635580903191577
   Virk Baker MK, 2010, PLANTA MED, V76, P1132, DOI 10.1055/s 0030 1250074
   Wang DX, 1999, ELECTROPHORESIS, V20, P1895, DOI 10.1002/(SICI)1522 2683(19990701)20:9<1895::AID ELPS1895>3.3.CO;2 C
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Wu J, 2001, J BONE MINER RES, V16, P1829, DOI 10.1359/jbmr.2001.16.10.1829
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xin D, 2010, PHYTOMEDICINE, V17, P126, DOI 10.1016/j.phymed.2009.05.015
   Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569
   Yamaguchi M, 2000, MOL CELL BIOCHEM, V214, P97, DOI 10.1023/A:1007199120295
   Zhao LH, 2005, CHEM PHARM BULL, V53, P1054, DOI 10.1248/cpb.53.1054
NR 54
TC 6
Z9 9
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD AUG
PY 2017
VL 14
IS 2
BP 1561
EP 1567
DI 10.3892/etm.2017.4688
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FB7BY
UT WOS:000406297300096
PM 28810621
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU van Dinther, M
   Visser, N
   de Gorter, DJJ
   Doorn, J
   Goumans, MJ
   de Boer, J
   ten Dijke, P
AF van Dinther, Maarten
   Visser, Nils
   de Gorter, David J. J.
   Doorn, Joyce
   Goumans, Marie Jose
   de Boer, Jan
   ten Dijke, Peter
TI ALK2 R206H Mutation Linked to Fibrodysplasia Ossificans Progressiva
   Confers Constitutive Activity to the BMP Type I Receptor and Sensitizes
   Mesenchymal Cells to BMP Induced Osteoblast Differentiation and Bone
   Formation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE MORPHOGENETIC PROTEIN; ECTOPIC BONE FORMATION; FIBRODYSPLASIA
   OSSIFICANS PROGRESSIVA; OSTEOBLAST DIFFERENTIATION; SMAD
ID TGF BETA RECEPTOR; MORPHOGENETIC PROTEIN; STEM CELLS; IDENTIFICATION;
   EXPRESSION; PATHWAY; SIGNALS; FKBP12; DOMAIN; VITRO
AB Fibrodysplasia ossificans progressiva (FOP) is a rare disabling disease characterized by heterotopic ossification for which there is currently no treatment available. FOP has been linked recently to a heterozygous R206H mutation in the bone morphogenetic protein (BMP) type I receptor activin receptor like kinase 2 (ALK2). Expression of the mutant ALK2 R206H receptor (FOP ALK2) results in increased phosphorylation of the downstream Smad1 effector proteins and elevated basal BMP dependent transcriptional reporter activity, indicating that FOP ALK2 is constitutively active. FOP ALK2 induced transcriptional activity could be blocked by overexpressing either of the inhibitory Smads, Smad6 or  7, or by treatment with the pharmacological BMP type I receptor inhibitor dorsomorphin. However, in contrast to wild type ALK2, FOP ALK2 is not inhibited by the negative regulator FKBP12. Mesenchymal cells expressing the FOP ALK2 receptor are more sensitive to undergoing BMP induced osteoblast differentiation and mineralization. In vivo bone formation was assessed by loading human mesenchymal stem cells (hMSCs) expressing the ALK2 R206H receptor onto calcium phosphate scaffolds and implantation in nude mice. Compared with control cells FOP ALK2 expressing cells induced increased bone formation. Taken together, the R206H mutation in ALK2 confers constitutive activity to the mutant receptor, sensitizes mesenchymal cells to BMP induced osteoblast differentiation, and stimulates new bone formation. We have generated an animal model that can be used as a stepping stone for preclinical studies aimed at inhibiting the heterotopic: ossification characteristic of FOP. (C) 2010 American Society for Bone and Mineral Research.
C1 [van Dinther, Maarten; Visser, Nils; de Gorter, David J. J.; Goumans, Marie Jose; ten Dijke, Peter] Leiden Univ, Dept Mol Cell Biol, Med Ctr, NL 2300 RC Leiden, Netherlands.
   [van Dinther, Maarten; Visser, Nils; de Gorter, David J. J.; Goumans, Marie Jose; ten Dijke, Peter] Leiden Univ, Ctr Biomed Genet, Med Ctr, NL 2300 RC Leiden, Netherlands.
   [Doorn, Joyce; de Boer, Jan] Univ Twente, Inst Biomed Technol, Dept Tissue Regenerat, NL 7500 AE Enschede, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); Leiden University; Leiden University Medical
   Center (LUMC); Leiden University   Excl LUMC; University of Twente
RP ten Dijke, P (通讯作者)，Leiden Univ, Dept Mol Cell Biol, Med Ctr, Bldg 2,Room R 02 022,Postzone S 1 P,POB 9600, NL 2300 RC Leiden, Netherlands.
EM p.ten_dijke@lumc.nl
RI ; Dijke, Peter/AAG 4660 2021; ten Dijke, Peter/AAG 4660 2021; Goumans,
   Marie/U 1455 2019
OI Goumans, Marie Jose/0000 0001 9344 6746; van Dinther,
   Maarten/0000 0002 9451 8884; ten Dijke, Peter/0000 0002 7234 342X; de
   Boer, Jan/0000 0001 9188 9324
FU Centre for Biomedical Genetics; Dutch Organization for Scientific
   Research [NWO 918.66.606]; IOP Genomics Grant [IGE07001]
FX This work was supported by the Centre for Biomedical Genetics (PtD), the
   Dutch Organization for Scientific Research (NWO 918.66.606), and IOP
   Genomics Grant IGE07001.
CR Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030
   Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866
   David L, 2008, CIRC RES, V102, P914, DOI 10.1161/CIRCRESAHA.107.165530
   Fukuda T, 2008, BIOCHEM BIOPH RES CO, V377, P905, DOI 10.1016/j.bbrc.2008.10.093
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Groppe JC, 2007, CLIN ORTHOP RELAT R, P87, DOI 10.1097/BLO.0b013e318126c049
   Herrera B, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471 2121 10 20
   Huang HY, 2009, P NATL ACAD SCI USA, V106, P12670, DOI 10.1073/pnas.0906266106
   Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092 8674(00)80555 3
   Itoh S, 2007, CURR OPIN CELL BIOL, V19, P176, DOI 10.1016/j.ceb.2007.02.015
   Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002 9440(10)63372 X
   Kaplan FS, 2008, J BONE MINER METAB, V26, P521, DOI 10.1007/s00774 008 0879 8
   Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Korchynskyi O, 2003, J BONE MINER RES, V18, P1177, DOI 10.1359/jbmr.2003.18.7.1177
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687
   OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460 2075.1990.tb07376.x
   Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014 5793(98)00954 5
   Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776 003 0702 2
   SAMPATH TK, 1981, P NATL ACAD SCI BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599
   Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402
   Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060
   Sterrenburg E, 2006, NEUROBIOL DIS, V23, P228, DOI 10.1016/j.nbd.2006.03.004
   TENDIJKE P, 1994, J BIOL CHEM, V269, P16985
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   VERSCHUEREN K, 1995, MECH DEVELOP, V52, P109, DOI 10.1016/0925 4773(95)00395 H
   VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793
   Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092 8674(00)80116 6
   WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460 2075.1995.tb07214.x
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
NR 39
TC 133
Z9 147
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2010
VL 25
IS 6
BP 1208
EP 1215
DI 10.1002/jbmr.091110
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 619PE
UT WOS:000279441300003
PM 19929436
DA 2025 08 17
ER

PT J
AU Jeong, C
   Cho, YJ
   Lee, Y
   Wang, W
   Park, KH
   Roh, E
   Lee, CH
   Son, YJ
   Park, JHY
   Kang, H
   Lee, KW
AF Jeong, Chanhyeok
   Cho, Yeon Jin
   Lee, Yongjin
   Wang, Weihong
   Park, Kyu Hyung
   Roh, Eun
   Lee, Chang Hyung
   Son, Young Jin
   Park, Jung Han Yoon
   Kang, Heonjoong
   Lee, Ki Won
TI Discovery and optimized extraction of the anti osteoclastic agent
   epicatechin 7 O β D apiofuranoside from Ulmus macrocarpa Hance
   bark
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SIGNALING PATHWAYS; BONE; DIFFERENTIATION; RANKL
AB Ulmus macrocarpa Hance bark (UmHb) has been used as a traditional herbal medicine in East Asia for bone concern diseases for a long time. To find a suitable solvent, we, in this study, compared the efficacy of UmHb water extract and ethanol extract which can inhibit osteoclast differentiation. Compared with two ethanol extracts (70% and 100% respectively), hydrothermal extracts of UmHb more effectively inhibited receptor activators of nuclear factor kappa B ligand induced osteoclast differentiation in murine bone marrow derived macrophages. We identified for the first time that (2R,3R) epicatechin 7 O beta D apiofuranoside (E7A) is a specific active compound in UmHb hydrothermal extracts through using LC/MS, HPLC, and NMR techniques. In addition, we confirmed through TRAP assay, pit assay, and PCR assay that E7A is a key compound in inhibiting osteoclast differentiation. The optimized condition to obtain E7A rich UmHb extract was 100 mL/g, 90 degrees C, pH 5, and 97 min. At this condition, the content of E7A was 26.05 +/  0.96 mg/g extract. Based on TRAP assay, pit assay, PCR, and western blot, the optimized extract of E7A rich UmHb demonstrated a greater inhibition of osteoclast differentiation compared to unoptimized. These results suggest that E7A would be a good candidate for the prevention and treatment of osteoporosis related diseases.
C1 [Jeong, Chanhyeok; Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.
   [Jeong, Chanhyeok; Lee, Ki Won] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea.
   [Cho, Yeon Jin; Lee, Chang Hyung; Park, Jung Han Yoon; Kang, Heonjoong; Lee, Ki Won] Seoul Natl Univ, BioMAX Inst, Seoul 08826, South Korea.
   [Lee, Yongjin; Son, Young Jin] Sunchon Natl Univ, Dept Pharm, 315 Maegok Dong, Sunchon 57922, Jeollanam Do, South Korea.
   [Wang, Weihong; Park, Kyu Hyung; Roh, Eun; Kang, Heonjoong] Seoul Natl Univ, Sch Earth & Environm Sci, Lab Marine Drugs, NS 80, Seoul 08826, South Korea.
   [Wang, Weihong; Kang, Heonjoong] Seoul Natl Univ, Res Inst Oceanog, NS 80, Seoul 08826, South Korea.
   [Kang, Heonjoong] Seoul Natl Univ, Interdisciplinary Grad Program Genet Engn, NS 80, Seoul 08826, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon 16229, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Inst Green Bio Sci, Pyeongchang 25354, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Inst Technol, Pyeongchang 25354, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Ctr Food & Bio Convergence, Seoul 08826, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Sunchon National University; Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU)
RP Lee, KW (通讯作者)，Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, BioMAX Inst, Seoul 08826, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, Adv Inst Convergence Technol, Suwon 16229, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, Inst Green Bio Sci, Pyeongchang 25354, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, Inst Technol, Pyeongchang 25354, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, Ctr Food & Bio Convergence, Seoul 08826, South Korea.
EM kiwon@snu.ac.kr
RI ; Jin Ho, Seo/B 3621 2014; Lee, Chang Hyung/MTD 8229 2025
OI Lee, Chang Hyung/0000 0002 1907 4400; 
FU Korea Institute of Planning and Evaluation for Technology in Food,
   Agriculture and Forestry (IPET) through the High Value added Food
   Technology Development Program   Ministry of Agriculture, Food and Rural
   Affairs (MAFRA) [321029 5]; Basic Science Research Program   Ministry of
   Science and ICT [2019R1A2C2005492]; Brain Korea 21 Plus Program of the
   Department of Agricultural Biotechnology, Seoul National University,
   Republic of Korea; Korea Institute of Marine Science & Technology
   Promotion (KIMST)   Ministry of Oceans and Fisheries [20220488]
FX This work was supported by the Korea Institute of Planning and
   Evaluation for Technology in Food, Agriculture and Forestry (IPET)
   through the High Value added Food Technology Development Program, funded
   by the Ministry of Agriculture, Food and Rural Affairs
   (MAFRA)(321029 5), the Basic Science Research Program funded by the
   Ministry of Science and ICT (2019R1A2C2005492), Brain Korea 21 Plus
   Program of the Department of Agricultural Biotechnology, Seoul National
   University, Republic of Korea and the Korea Institute of Marine Science
   & Technology Promotion (KIMST), which is funded by the Ministry of
   Oceans and Fisheries (20220488).
CR Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Bi WT, 2013, J CHROMATOGR A, V1285, P22, DOI 10.1016/j.chroma.2013.02.041
   Chan CL, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0505 1
   Chaves JO, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.507887
   Chethan S, 2007, FOOD CHEM, V105, P862, DOI 10.1016/j.foodchem.2007.02.012
   Choi HG, 2013, PHYTOTHER RES, V27, P1376, DOI 10.1002/ptr.4882
   Choi SI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061200
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Fumoto T, 2014, J BONE MINER RES, V29, P830, DOI 10.1002/jbmr.2096
   Gradin P, 2012, CELLS TISSUES ORGANS, V196, P68, DOI 10.1159/000330806
   Han HJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217112
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim KJ, 2019, MOLECULES, V24, DOI 10.3390/molecules24203735
   Ko CH, 2009, J AGR FOOD CHEM, V57, P7293, DOI 10.1021/jf901545u
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Li ZP, 2006, BIOCHEM BIOPH RES CO, V343, P345, DOI 10.1016/j.bbrc.2006.02.147
   Lu S, 2015, J EXP BOT, V66, P5625, DOI 10.1093/jxb/erv270
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Oh KS, 2008, BIOL PHARM BULL, V31, P2090, DOI 10.1248/bpb.31.2090
   Park JH, 2017, MOL CELLS, V40, P706
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Siddiqui JA, 2011, MENOPAUSE, V18, P198, DOI 10.1097/gme.0b013e3181e84e67
   Suh SJ, 2007, J ETHNOPHARMACOL, V109, P480, DOI 10.1016/j.jep.2006.08.030
   Swarnkar G, 2011, EUR J PHARMACOL, V658, P65, DOI 10.1016/j.ejphar.2011.02.032
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Thoo YY, 2010, FOOD CHEM, V120, P290, DOI 10.1016/j.foodchem.2009.09.064
   Wang WH, 2022, ACS OMEGA, V7, DOI 10.1021/acsomega.1c05305
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   YE G, 1990, Journal of Traditional Chinese Medicine, V10, P97
   Yeon JT, 2015, J NAT PROD, V78, P776, DOI 10.1021/np501017z
   Youn HJ, 2001, VET PARASITOL, V96, P257, DOI 10.1016/S0304 4017(01)00385 5
NR 38
TC 2
Z9 2
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 18
PY 2023
VL 13
IS 1
AR 11102
DI 10.1038/s41598 023 38208 4
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA S0AM4
UT WOS:001067885000008
PM 37423923
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, R
   Thayer, P
   Goldstein, A
   Wagner, WD
AF Wang, Rui
   Thayer, Patrick
   Goldstein, Aaron
   Wagner, William D.
TI Interaction of material stiffness and negative pressure to enhance
   differentiation of bone marrow derived stem cells and osteoblast
   proliferation
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE bone repair material (BRM); chondroitin sulfate (CS); extracellular
   matrix (ECM); mesenchymal stem cells (MSCs); negative pressure wound
   therapy; poly (octanediol citrate) (POC); type I collagen (COL);
   vacuum assisted wound closure
ID CHONDROITIN SULFATE; OSTEOGENESIS; EXPRESSION; MECHANISMS; ELASTOMERS;
   SCAFFOLDS; GENES; TIME
AB Negative pressure wound therapy (NPWT) results in improved wound repair and the combined use of NPWT with elastomeric materials may further stimulate and accelerate tissue repair. No firmly established treatment modalities using both NPWT and biomaterials exist for orthopedic application. The goal of this study was to investigate the response of osteoblasts and bone marrow derived mesenchymal stem cells to negative pressure and to determine whether a newly developed elastic osteomimetic bone repair material (BRM), a blend of type I collagen, chondroitin 6 sulfate, and poly (octanediol citrate) could enhance the osteoblastic phenotype. The results indicate that proliferation and alkaline phosphatase activity of hFOB1.19 osteoblasts were significantly increased with exposure to 12 hr of negative pressure ( 125 mmHg). Follow on studies with rat and human mesenchymal stem cells confirmed that negative pressure enhanced osteoblastic maturation. In addition, a significant interaction of negative pressure and electrospun BRM resulted in increased mRNA expression of alkaline phosphatase, osteopontin, collagen1 alpha 2, and HIF1 alpha, whereas little or no effect on these genes was observed on electrospun collagen or tissue culture plastic. Together, these results suggest that the use of this novel biomaterial, BRM, with NPWT may ultimately translate into a safe and cost effective clinical application to accelerate bone repair.
C1 [Wang, Rui; Wagner, William D.] Wake Forest Univ, Bowman Gray Sch Med, Plast & Reconstruct Surg, Winston Salem, NC USA.
   [Wang, Rui; Thayer, Patrick; Goldstein, Aaron] Wake Forest Univ, Sch Biomed Engn & Sci, Virginia Tech, Biomed Engn & Sci, Winston Salem, NC USA.
   [Goldstein, Aaron] Virginia Tech, Dept Chem Engn, Blacksburg, VA USA.
C3 Wake Forest University; Wake Forest Baptist Medical Center; Virginia
   Polytechnic Institute & State University; Wake Forest University;
   Virginia Polytechnic Institute & State University
RP Wagner, WD (通讯作者)，Dept Plast & Reconstruct Surg, 112 Nutr Bldg,Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM wwagner@wakehealth.edu
RI Goldstein, Aaron/AAA 2005 2021
OI Wagner, William/0000 0002 0405 9953
FU Center for Nanotechnology and Molecular Materials of Wake Forest
   University; Plastic and Reconstructive Surgery Department of Wake Forest
   University School of Medicine
FX Center for Nanotechnology and Molecular Materials of Wake Forest
   University; Plastic and Reconstructive Surgery Department of Wake Forest
   University School of Medicine
CR Birdwhistell KE, 2018, J KNEE SURG, V31, P410, DOI 10.1055/s 0037 1603801
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   San Carlos AC, 2018, REV ESTUD HEMISFERIC, V9, P1
   Chung EJ, 2011, J BIOMED MATER RES A, V96A, P29, DOI 10.1002/jbm.a.32953
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Filipowska J, 2016, BIOTECHNOL BIOENG, V113, P1814, DOI 10.1002/bit.25937
   Huang CY, 2014, CURR PROB SURG, V51, P301, DOI 10.1067/j.cpsurg.2014.04.001
   Kang Y, 2006, J BIOMED MATER RES A, V77A, P331, DOI 10.1002/jbm.a.30607
   Kibbe MR, 2010, J BIOMED MATER RES A, V93A, P314, DOI 10.1002/jbm.a.32537
   Kreke MR, 2008, TISSUE ENG PT A, V14, P529, DOI 10.1089/tea.2007.0068
   Lee J, 2017, OCEAN SYST ENG, V7, P1, DOI 10.12989/ose.2017.7.1.001
   Li D, 2012, J BIOMED MATER RES B, V100B, P1103, DOI 10.1002/jbm.b.32677
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Morykwas MJ, 2006, PLAST RECONSTR SURG, V117, p121S, DOI 10.1097/01.prs.0000225450.12593.12
   Mumcuoglu D, 2018, EUR CELLS MATER, V35, P242, DOI 10.22203/eCM.v035a17
   Qi MC, 2009, INT J ORAL SCI, V1, P143, DOI 10.4248/IJOS.09021
   Qiu HJ, 2006, BIOMATERIALS, V27, P5845, DOI 10.1016/j.biomaterials.2006.07.042
   Rey S, 2010, CARDIOVASC RES, V86, P236, DOI 10.1093/cvr/cvq045
   Rhee SH, 2002, J MATER SCI MATER M, V13, P597, DOI 10.1023/A:1015135112302
   Samavedi S, 2012, BIOMATERIALS, V33, P7727, DOI 10.1016/j.biomaterials.2012.07.008
   Schneiders W, 2009, J ORTHOP RES, V27, P15, DOI 10.1002/jor.20719
   Sharp LA, 2009, ANN BIOMED ENG, V37, P445, DOI 10.1007/s10439 008 9632 7
   Sun DW, 2014, SCI REP UK, V4, DOI 10.1038/srep06912
   Tran RT, 2014, J BIOMED MATER RES A, V102, P2521, DOI 10.1002/jbm.a.34928
   Wang JG, 2005, LIFE SCI, V76, P2817, DOI 10.1016/j.lfs.2004.10.050
   Yang J, 2004, ADV MATER, V16, P511, DOI 10.1002/adma.200306264
   Yang J, 2006, BIOMATERIALS, V27, P1889, DOI 10.1016/j.biomaterials.2005.05.106
   Yang Z, 2014, MOL MED REP, V9, P1331, DOI 10.3892/mmr.2014.1968
   Yu WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089966
   Zhu JH, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0097616, 10.1371/journal.pone.0115507]
NR 30
TC 6
Z9 6
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD FEB
PY 2020
VL 14
IS 2
BP 295
EP 305
DI 10.1002/term.2993
EA JAN 2020
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA KN2NG
UT WOS:000506371400001
PM 31845531
DA 2025 08 17
ER

PT J
AU Ali, D
   Okla, M
   Abuelreich, S
   Vishnubalaji, R
   Ditzel, N
   Hamam, R
   Kowal, JM
   Sayed, A
   Aldahmash, A
   Alajez, NM
   Kassem, M
AF Ali, Dalia
   Okla, Meshail
   Abuelreich, Sarah
   Vishnubalaji, Radhakrishnan
   Ditzel, Nicholas
   Hamam, Rimi
   Kowal, Justyna M.
   Sayed, Ahmed
   Aldahmash, Abdullah
   Alajez, Nehad M.
   Kassem, Moustapha
TI Apigenin and Rutaecarpine reduce the burden of cellular senescence in
   bone marrow stromal stem cells
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE bone marrow stromal stem cells; osteoblasts; senescence; aging;
   antioxidants; osteoporosis
ID OSTEOGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; TGF BETA; GENE
AB Introduction Osteoporosis is a systemic age related disease characterized by reduced bone mass and microstructure deterioration, leading to increased risk of bone fragility fractures. Osteoporosis is a worldwide major health care problem and there is a need for preventive approaches.Methods and results Apigenin and Rutaecarpine are plant derived antioxidants identified through functional screen of a natural product library (143 compounds) as enhancers of osteoblastic differentiation of human bone marrow stromal stem cells (hBMSCs). Global gene expression profiling and Western blot analysis revealed activation of several intra cellular signaling pathways including focal adhesion kinase (FAK) and TGF beta. Pharmacological inhibition of FAK using PF 573228 (5 mu M) and TGF beta using SB505124 (1 mu M), diminished Apigenin  and Rutaecarpine induced osteoblast differentiation. In vitro treatment with Apigenin and Rutaecarpine, of primary hBMSCs obtained from elderly female patients enhanced osteoblast differentiation compared with primary hBMSCs obtained from young female donors. Ex vivo treatment with Apigenin and Rutaecarpine of organotypic embryonic chick femur culture significantly increased bone volume and cortical thickness compared to control as estimated by mu CT scanning.Discussion Our data revealed that Apigenin and Rutaecarpine enhance osteoblastic differentiation, bone formation, and reduce the age related effects of hBMSCs. Therefore, Apigenin and Rutaecarpine cellular treatment represent a potential strategy for maintaining hBMSCs health during aging and osteoporosis.
   In brief, the natural compounds Apigenin and Rutaecarpine enhanced osteoblastic differentiation of hBMSCs and reduced the burden of cellular senescence and inflammation. Our results suggest a possible role for Apigenin and Rutaecarpine as small molecule antioxidant agents that can be used to prevent impaired osteoblastic functions and bone loss associated with aging and osteoporosis.
C1 [Ali, Dalia; Ditzel, Nicholas; Kowal, Justyna M.; Sayed, Ahmed; Kassem, Moustapha] Univ Southern Denmark, Odense Univ Hosp, Dept Endocrinol & Metab, Mol Endocrinol & Stem Cell Res Unit KMEB, Odense, Denmark.
   [Okla, Meshail] King Saud Univ, Coll Appl Med Sci, Dept Community Hlth Sci, Riyadh, Saudi Arabia.
   [Okla, Meshail; Abuelreich, Sarah; Vishnubalaji, Radhakrishnan; Hamam, Rimi; Alajez, Nehad M.] King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh, Saudi Arabia.
   [Aldahmash, Abdullah] Vis Coll, Coll Med, Dept Med Basic Sci, Riyadh, Saudi Arabia.
   [Kassem, Moustapha] Univ Copenhagen, ICMM, Fac Hlth Sci, Copenhagen, Denmark.
C3 University of Southern Denmark; Odense University Hospital; King Saud
   University; King Saud University; University of Copenhagen
RP Ali, D (通讯作者)，Univ Southern Denmark, Odense Univ Hosp, Dept Endocrinol & Metab, Mol Endocrinol & Stem Cell Res Unit KMEB, Odense, Denmark.; Okla, M (通讯作者)，King Saud Univ, Coll Appl Med Sci, Dept Community Hlth Sci, Riyadh, Saudi Arabia.; Okla, M (通讯作者)，King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh, Saudi Arabia.
EM dayesh@health.sdu.dk; meokla@ksu.edu.sa
RI Sayed, Ahmed/KYO 9866 2024; Aldahmash, Abdullah/D 4693 2015; Ali,
   Dalia/KEH 0488 2024; Okla, Meshail/E 9317 2017
OI Ali, Dalia/0000 0002 2852 5971; Okla, Meshail/0000 0003 4855 243X
FU Deanship of Scientific Research at King Saud University Research Group
   [RG 1438 033]; Department of Endocrinology and Metabolism, Molecular
   Endocrinology & Stem Cell Research Unit; Odense University Hospital,
   University of Southern Denmark
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This work was supported
   by the Deanship of Scientific Research at King Saud University Research
   Group No. RG 1438 033. We thank Department of Endocrinology and
   Metabolism, Molecular Endocrinology & Stem Cell Research Unit (KMEB),
   Odense University Hospital, University of Southern Denmark, Odense,
   Denmark for providing experimental and financial support to publish this
   investigation.
CR Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Aldahmash A, 2017, SAUDI J BIOL SCI, V24, P857, DOI 10.1016/j.sjbs.2016.04.006
   Ali D, 2022, AGING CELL, V21, DOI 10.1111/acel.13726
   Ali D, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115252
   Attari F, 2015, DARU, V23, DOI 10.1186/s40199 015 0115 8
   Bhattacharya Semantee, 2011, Pathophysiology, V18, P221, DOI 10.1016/j.pathophys.2011.02.001
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen MW, 2009, J ETHNOPHARMACOL, V125, P75, DOI 10.1016/j.jep.2009.06.013
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Crane JL, 2016, METHODS MOL BIOL, V1344, P287, DOI 10.1007/978 1 4939 2966 5_18
   Di Giacomo C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122320
   Dünker N, 2002, ANAT EMBRYOL, V206, P73, DOI 10.1007/s00429 002 0273 6
   Farr JN, 2019, BONE, V121, P121, DOI 10.1016/j.bone.2019.01.015
   Fukuma Y, 2018, CLIN EXP PHARMACOL P, V45, P863, DOI 10.1111/1440 1681.12941
   Goto T, 2015, CYTOTECHNOLOGY, V67, P357, DOI 10.1007/s10616 014 9694 3
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Hiramatsu K, 2011, J BONE MINER METAB, V29, P493, DOI 10.1007/s00774 010 0248 2
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Ishida K, 2013, BONE, V55, P23, DOI 10.1016/j.bone.2013.03.007
   Jia SJ, 2010, MOLECULES, V15, P1873, DOI 10.3390/molecules15031873
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khosla S, 2020, NAT REV ENDOCRINOL, V16, P263, DOI 10.1038/s41574 020 0335 y
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   Kim M, 2019, ANAT SCI INT, V94, P285, DOI 10.1007/s12565 019 00486 2
   Kowal JM, 2020, STEM CELL TRANSL MED, V9, P189, DOI 10.1002/sctm.19 0171
   Kowal JM, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02338 1
   Lee SH, 2008, MOLECULES, V13, P272, DOI 10.3390/molecules13020272
   Lee SJ, 2012, BIOMOL THER, V20, P487, DOI 10.4062/biomolther.2012.20.5.487
   Leucht P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000390
   Li F, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2302896
   Li Yi ning, 2021, Yaoxue Xuebao, V56, P511, DOI 10.16438/j.0513 4870.2020 1616
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marie PJ, 2011, J CLIN ENDOCR METAB, V96, P600, DOI 10.1210/jc.2010 2113
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Nakamura A, 2009, TISSUE ENG PART C ME, V15, P169, DOI 10.1089/ten.tec.2007.0334
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Shapiro JR, 2017, J BONE MINER RES, V32, P1977, DOI 10.1002/jbmr.3226
   Shirjang S, 2017, CELL IMMUNOL, V315, P1, DOI 10.1016/j.cellimm.2016.12.005
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Sing CW, 2018, J BONE MINER RES, V33, P1422, DOI 10.1002/jbmr.3448
   Szulc Pawel, 2012, Bonekey Rep, V1, P144, DOI 10.1038/bonekey.2012.144
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Udalamaththa VL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0366 4
   Wang L, 2005, PLANTA MED, V71, P416, DOI 10.1055/s 2005 864135
   Wu JQ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0865 3
   Wu YQ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.955983
   Zhang WL, 2014, OBES REV, V15, P957, DOI 10.1111/obr.12228
   Zhang X, 2015, MOL CELL BIOCHEM, V407, P41, DOI 10.1007/s11010 015 2452 9
   Zhao HY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6345857
NR 54
TC 10
Z9 11
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD APR 4
PY 2024
VL 15
AR 1360054
DI 10.3389/fendo.2024.1360054
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OB4D2
UT WOS:001204777900001
PM 38638133
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhu, Y
   Wang, YM
   Jia, YC
   Xu, J
   Chai, YM
AF Zhu, Yu
   Wang, Yanmao
   Jia, Yachao
   Xu, Jia
   Chai, Yimin
TI Catalpol promotes the osteogenic differentiation of bone marrow
   mesenchymal stem cells via the Wnt/ catenin pathway
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Catalpol; Bone marrow mesenchymal stem cells; Wnt;  catenin signalling;
   Bone regeneration
ID STROMAL CELLS; STRATEGIES; REPAIR
AB BackgroundRehmanniae Radix is a traditional herbal medicine in East Asia that has been widely used to treat patients with osteoporosis. However, the effect of catalpol, the primary active principle component of Rehmanniae Radix, on the function of bone marrow mesenchymal stem cells (BMSCs) and the underlying molecular mechanisms associated with its activity remain poorly understood.MethodsThe effect of catalpol on the proliferation of BMSCs was evaluated using a Cell Counting Kit 8 assay. Alkaline phosphatase (ALP) staining, ALP activity and Alizarin Red staining were performed to elucidate the effect of catalpol on the osteogenesis of BMSCs. qRT PCR, Western blotting and immunofluorescence were performed to evaluate the expression of osteo specific markers and the Wnt/ catenin signalling related genes and proteins. Moreover, a rat critical sized calvarial defect model and a rat ovariectomy model were used to assess the effect of catalpol on bone regeneration in vivo.ResultsCatalpol significantly enhanced osteoblast specific gene expression, alkaline phosphatase activity and calcium deposition in BMSCs in vitro. This phenomenon was accompanied by an upregulation of Wnt/ catenin signalling. In addition, the enhanced osteogenesis due to catalpol treatment was partially reversed by a Wnt/ catenin antagonist. Furthermore, catalpol increased the bone healing capacity of BMSCs in a rat critical sized calvarial defect model and attenuated bone loss in a rat ovariectomy model.ConclusionsThese data suggest that catalpol enhances the osteogenic differentiation of BMSCs, partly via activation of the Wnt/ catenin pathway. Catalpol may provide a new strategy for bone tissue engineering and can be a potential agent for the treatment of postmenopausal osteoporosis.
C1 [Zhu, Yu; Wang, Yanmao; Jia, Yachao; Xu, Jia; Chai, Yimin] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Yishan Rd 600, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Xu, J; Chai, YM (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Yishan Rd 600, Shanghai 200233, Peoples R China.
EM xujia0117@126.com; ymchai@sjtu.edu.cn
RI jia, yachao/NYT 3524 2025
FU National Natural Science Foundation of China [81772338, 81572122];
   Interdisciplinary Program of Shanghai Jiao Tong University [YG2017ZD05];
   Shanghai Leading Talent Plan [043]
FX The work was sponsored by grants from the National Natural Science
   Foundation of China (81772338 and 81572122); the Interdisciplinary
   Program of Shanghai Jiao Tong University (YG2017ZD05); and the Shanghai
   Leading Talent Plan (043).
CR Ahmadzadeh A, 2016, CELL TISSUE RES, V363, P321, DOI 10.1007/s00441 015 2300 y
   Alessio N, 2015, ONCOTARGET, V6, P8155, DOI 10.18632/oncotarget.2692
   Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Bouaziz W, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0540 6
   Canalis E, 2018, EUR J ENDOCRINOL, V178, pR33, DOI 10.1530/EJE 17 0920
   Chen YY, 2017, INT IMMUNOPHARMACOL, V43, P140, DOI 10.1016/j.intimp.2016.12.011
   Ding H, 2014, STEM CELLS DEV, V23, P990, DOI 10.1089/scd.2013.0486
   Gan YK, 2008, BIOMATERIALS, V29, P3973, DOI 10.1016/j.biomaterials.2008.06.026
   Gao C, 2012, J ORTHOP RES, V30, P1183, DOI 10.1002/jor.22028
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   Hahn JY, 2008, J AM COLL CARDIOL, V51, P933, DOI 10.1016/j.jacc.2007.11.040
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Huang PS, 2016, HEART FAIL REV, V21, P737, DOI 10.1007/s10741 016 9576 1
   Huang WQ, 2017, CALCIFIED TISSUE INT, V100, P392, DOI 10.1007/s00223 017 0242 y
   Jiang B, 2004, TOXICON, V43, P53, DOI 10.1016/j.toxicon.2003.10.017
   Jiang B, 2015, CURR MED CHEM, V22, P1278, DOI 10.2174/0929867322666150114151720
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024381
   Li DQ, 2004, NEUROSCI RES, V50, P169, DOI 10.1016/j.neures.2004.06.009
   Li M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103841
   Lin C, 2017, BIOMED PHARMACOTHER, V89, P973, DOI 10.1016/j.biopha.2017.02.069
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu HR, 2018, HISTOCHEM CELL BIOL, V149, P393, DOI 10.1007/s00418 018 1643 3
   Liu XL, 2017, INT J BIOL SCI, V13, P232, DOI 10.7150/ijbs.16951
   Ma JL, 2014, STEM CELL TRANSL MED, V3, P98, DOI 10.5966/sctm.2013 0126
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rastogi S, 2013, Musculoskelet Surg, V97, P223, DOI 10.1007/s12306 013 0273 0
   Skovlund E, 2001, J CLIN EPIDEMIOL, V54, P86, DOI 10.1016/S0895 4356(00)00264 X
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Udalamaththa VL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0366 4
   Xu J, 2017, J ORTHOP RES, V35, P1215, DOI 10.1002/jor.23372
   Xu J, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0392 2
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zhang JY, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0391 3
   Zhang Y, 2014, CELL TISSUE RES, V358, P633, DOI 10.1007/s00441 014 2010 x
   Zheng XW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5058609
   Zhu YX, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0694 z
NR 47
TC 65
Z9 79
U1 2
U2 30
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JAN 22
PY 2019
VL 10
AR 37
DI 10.1186/s13287 019 1143 y
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HI5EN
UT WOS:000456475400006
PM 30670092
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, F
   Qin, GQ
   Liu, JZ
   Wang, XN
   Ye, BG
AF Wang, Fei
   Qin, Guoqing
   Liu, Junzhi
   Wang, Xiunan
   Ye, Baoguo
TI Integrated Genome Wide Methylation and Expression Analyses Reveal Key
   Regulators in Osteosarcoma
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID TUMOR SUPPRESSOR GENES; DNA METHYLATION; ABERRANT METHYLATION;
   PROLIFERATION; CHEMOTHERAPY
AB Osteosarcoma (OS) is one of the most common types of primary bone tumors in early adolescence with unsatisfied prognosis. Aberrant DNA methylation had been demonstrated to be related to tumorigenesis and progression of multiple cancers and could serve as the potential biomarkers for the prognosis of human cancers. In conclusion, this study identified 18 downregulated hypomethylation genes and 52 upregulated hypomethylation genes in OS by integrating the analysis the GSE97529 and GSE42572 datasets. Bioinformatics analysis revealed that OS specific methylated genes were involved in regulating multiple biological processes, including chemical synaptic transmission, transcription, response to drug, and regulating immune response. KEGG pathway analysis showed that OS specific methylated genes were associated with the regulation of Hippo, cAMP calcium, MAPK, and Wnt signaling pathways. By analyzing R2 datasets, this study showed that the dysregulation of these OS specific methylated genes was associated with the metastasis free survival time in patients with OS, including CBLN4, ANKMY1, BZW1, KRTCAP3, GZMB, KRTDAP, LY9, PFKFB2, PTPN22, and CLDN7. This study provided a better understanding of the molecular mechanisms underlying the progression and OS and novel biomarkers for the prognosis of OS.
C1 [Wang, Fei] Jilin Univ, China Japan Union Hosp, Dept Orthoped, Changchun, Jilin, Peoples R China.
   [Qin, Guoqing] Jilin Chunguang Rehabil Hosp, Jilin Disabled Persons Rehabil Ctr, Dept Orthoped, Changchun, Jilin, Peoples R China.
   [Liu, Junzhi] Jilin Univ, China Japan Union Hosp, Qual Control Dept, Changchun, Jilin, Peoples R China.
   [Wang, Xiunan] PLA Joint Logist Support Force, Hosp 904, Dept Orthoped, 4799 Xian Rd, Changchun, Jilin, Peoples R China.
   [Ye, Baoguo] Jilin Univ, China Japan Union Hosp, Dept Anesthesiol, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Ye, BG (通讯作者)，Jilin Univ, China Japan Union Hosp, Dept Anesthesiol, Changchun, Jilin, Peoples R China.
EM figo@jlu.edu.cn; 289412728@qq.com; 15827344@qq.com; 234579678@qq.com;
   yebaoguo_cb@126.com
FU Special fund for the key laboratory of Science and Technology Department
   of Jilin Province [20190201282JC]
FX This work was supported by the Special fund for the key laboratory of
   Science and Technology Department of Jilin Province (20190201282JC).
CR Angulo A, 2019, J LEUKOCYTE BIOL, V105, P947, DOI 10.1002/JLB.2MR1018 413R
   BACCI G, 1990, CANCER AM CANCER SOC, V65, P2539, DOI 10.1002/1097 0142(19900601)65:11<2539::AID CNCR2820651125>3.0.CO;2 M
   Barros MC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061334
   Buddingh EP, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569 015 0031 1
   Chen YA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00060
   Cheng Q, 2020, CELL CYCLE, V19, P290, DOI 10.1080/15384101.2019.1707454
   Cui JC, 2011, B CANCER, V98, pE62, DOI 10.1684/bdc.2011.1400
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Ekmekci CG, 2004, AM J HEMATOL, V77, P233, DOI 10.1002/ajh.20186
   Ferrari A, 2016, PROG TUMOR RES, V43, P128, DOI 10.1159/000447083
   He ZZ, 2018, BIOCHEM BIOPH RES CO, V500, P569, DOI 10.1016/j.bbrc.2018.04.091
   Iyer SV, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13561
   Kim M, 2017, AUTOPHAGY, V13, P149, DOI 10.1080/15548627.2016.1239676
   Li L, 2017, ONCOL LETT, V14, P271, DOI 10.3892/ol.2017.6135
   Li Q, 2017, INT J BIOL SCI, V13, P1038, DOI 10.7150/ijbs.19476
   Li SQ, 2009, CANCER LETT, V284, P86, DOI 10.1016/j.canlet.2009.04.019
   Liu HP, 2019, BIOCHEM BIOPH RES CO, V515, P37, DOI 10.1016/j.bbrc.2019.05.001
   Liu W, 2015, FEBS LETT, V589, P3148, DOI 10.1016/j.febslet.2015.08.034
   Lu JC, 2015, ONCOTARGET, V6, P16802, DOI 10.18632/oncotarget.4696
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   McQueen P, 2011, EXPERT REV ANTICANC, V11, P1223, DOI [10.1586/era.11.94, 10.1586/ERA.11.94]
   Morice S., 2020, CANCERS, V12
   Neri F, 2017, NATURE, V543, P72, DOI 10.1038/nature21373
   Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110
   Ozcan SC, 2020, MOL CELL BIOCHEM, V470, P115, DOI 10.1007/s11010 020 03751 5
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Rao Bindal Krithi, 2011, Sarcoma, V2011, P679457, DOI 10.1155/2011/679457
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Simpson E, 2018, JAAPA J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d
   Sonaglio V, 2013, ONCOTARGETS THER, V6, P713, DOI 10.2147/OTT.S44918
   Spainhour JCG, 2019, CANCER INFORM, V18, DOI 10.1177/1176935119828776
   Sreedhar A, 2017, ONCOTARGET, V8, P95504, DOI 10.18632/oncotarget.20762
   Teoh SL, 2017, CURR DRUG TARGETS, V18, P1880, DOI 10.2174/1389450117666160907153338
   Wang H, 2014, CANCER METAST REV, V33, P173, DOI 10.1007/s10555 013 9463 3
   Wang W, 2019, ONCOL LETT, V17, P256, DOI 10.3892/ol.2018.9596
   Windsor RE, 2012, CANCER AM CANCER SOC, V118, P1856, DOI 10.1002/cncr.26472
   Wu SP, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00031
NR 37
TC 9
Z9 12
U1 3
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748 670X
EI 1748 6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD AUG 13
PY 2020
VL 2020
AR 7067649
DI 10.1155/2020/7067649
PG 11
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Mathematical & Computational Biology
GA NH0DQ
UT WOS:000564350700001
PM 32855654
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Fujimura, T
   Furudate, S
   Kambayashi, Y
   Aiba, S
AF Fujimura, Taku
   Furudate, Sadanori
   Kambayashi, Yumi
   Aiba, Setsuya
TI Potential Use of Bisphosphonates in Invasive Extramammary Paget's
   Disease: An Immunohistochemical Investigation
SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY
LA English
DT Article
ID REGULATORY T CELLS; BREAST CANCER CELLS; ZOLEDRONIC ACID; EXPRESSION;
   MACROPHAGES; CARCINOMA; SKIN
AB Invasive extramammary Paget's disease (EMPD) is relatively rare and is reported to be highly metastatic to lymph nodes or even other organs, including bone. Histologically, EMPD shows significant numbers of lymphocytes around the tumor mass, suggesting the possible development of novel immunomodulatory therapy for EMPD by targeting these infiltrating lymphocytes. Previously, bisphosphonates (BPs) were administered for the treatment of malignancy, especially osteolytic bone disease. Recent reports also suggested that BPs might have a direct antitumor effect through several pathways beyond their beneficial effect on bone metastasis. Among them, the abrogation of immunosuppressive cells, myeloid derived suppressor cells (MDSC), by BPs might be one of the optimal methods to induce an antitumor immune response both locally and at sites remote from the tumor. In this study, we employed immunohistochemical staining for immunosuppressive macrophages and cytotoxic T cells in the lesional skin of patients with noninvasive EMPD and those with invasive EMPD.
C1 [Fujimura, Taku; Furudate, Sadanori; Kambayashi, Yumi; Aiba, Setsuya] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi 9808574, Japan.
C3 Tohoku University
RP Fujimura, T (通讯作者)，Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi 9808574, Japan.
EM tfujimura1@mac.com
OI Fujimura, Taku/0000 0001 6809 5833
FU Grants in Aid for Scientific Research [23791249] Funding Source: KAKEN
CR Fehm T, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 308
   Fujimura T, 2012, ACTA DERM VENEREOL, V92, P625, DOI 10.2340/00015555 1453
   Fujimura T, 2012, J INVEST DERMATOL, V132, P1239, DOI 10.1038/jid.2011.416
   Fujimura T, 2010, J DERMATOL SCI, V59, P1, DOI 10.1016/j.jdermsci.2010.05.001
   Gadiot J, 2011, CANCER AM CANCER SOC, V117, P2192, DOI 10.1002/cncr.25747
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092 8674(02)00754 7
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Ishibashi M, 2012, CASE REP DERMATOL, V4, P5, DOI 10.1159/000335999
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kambayashi Y., ACTA DERMAT IN PRESS
   Lloyd J, 2000, J CLIN PATHOL, V53, P742, DOI 10.1136/jcp.53.10.742
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Monhian N, 2005, ARCH FACIAL PLAST S, V7, P238, DOI 10.1001/archfaci.7.4.238
   Pettersen JS, 2011, J INVEST DERMATOL, V131, P1322, DOI [10.1038/jid.2011.9, 10.103/jid.2011.9]
   Rasheed H, 2010, AM J DERMATOPATH, V32, P162, DOI 10.1097/DAD.0b013e3181b72678
   Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920
   Shiomi T., 2012, J EUROPEAN ACAD DERM
   Tiemessen MM, 2007, P NATL ACAD SCI USA, V104, P19446, DOI 10.1073/pnas.0706832104
   Vihinen PP, 2010, MELANOMA RES, V20, P318, DOI 10.1097/CMR.0b013e3283390365
   Zhang G, 2006, ONCOGENE, V25, P7260, DOI 10.1038/sj.onc.1209726
NR 20
TC 7
Z9 7
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1740 2522
EI 1740 2530
J9 CLIN DEV IMMUNOL
JI Clin. Dev. Immunol.
PY 2013
AR 164982
DI 10.1155/2013/164982
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 124YN
UT WOS:000317505200001
PM 23606867
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Estévez, M
   Cicuéndez, M
   Colilla, M
   Vallet Regi, M
   González, B
   Izquierdo Barba, I
AF Estevez, Manuel
   Cicuendez, Monica
   Colilla, Montserrat
   Vallet Regi, Maria
   Gonzalez, Blanca
   Izquierdo Barba, Isabel
TI Magnetic colloidal nanoformulations to remotely trigger
   mechanotransduction for osteogenic differentiation
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Superparamagnetic iron oxide nanoparticles; Thermal decomposition; RGD
   peptide; Osteogenic differentiation; Human bone marrow mesenchymal stem
   cells; Endocytic pathways; Mechanotransduction
ID IRON OXIDE NANOPARTICLES; STEM CELLS; CHONDROGENIC DIFFERENTIATION;
   UNIFORM MAGNETITE; FUNCTIONALIZATION; STIMULATION; PROLIFERATION;
   REGENERATION; OSTEOBLASTS; ACTIVATION
AB Nowadays, diseases associated with an ageing population, such as osteoporosis, require the development of new biomedical approaches to bone regeneration. In this regard, mechanotransduction has emerged as a discipline within the field of bone tissue engineering. Herein, we have tested the efficacy of superparamagnetic iron oxide nanoparticles (SPIONs), obtained by the thermal decomposition method, with an average size of 13 nm, when exposed to the application of an external magnetic field for mechanotransduction in human bone marrowderived mesenchymal stem cells (hBM MSCs). The SPIONs were functionalized with an Arg Gly Asp (RGD) peptide as ligand to target integrin receptors on cell membrane and used in colloidal state. Then, a comprehensive and comparative bioanalytical characterization of non  targeted versus targeted SPIONs was performed in terms of biocompatibility, cell uptake pathways and mechanotransduction effect, demonstrating the osteogenic differentiation of hBM MSCs. A key conclusion derived from this research is that when the magnetic stimulus is applied in the first 30 min of the in vitro assay, i.e. , when the nanoparticles come into contact with the cell membrane surface to initiate endocytic pathways, a successful mechanotransduction effect is observed. Thus, under the application of a magnetic field, there was a significant increase in runt  related transcription factor 2 ( Runx2 ) and alkaline phosphatase ( ALP ) gene expression as well as ALP activity, when cells were exposed to RGD functionalized SPIONs, demonstrating osteogenic differentiation. These findings open new expectations for the use of remotely activated mechanotransduction using targeted magnetic colloidal nanoformulations for osteogenic differentiation by drug  free cell therapy using minimally invasive techniques in cases of bone loss.
C1 [Estevez, Manuel; Colilla, Montserrat; Vallet Regi, Maria; Gonzalez, Blanca; Izquierdo Barba, Isabel] Univ Complutense Madrid, Fac Farm, Dept Quim Ciencias Farmaceut, Inst Invest Sanitaria,Hosp 12 Octubre I 12, Plaza Ramon & Cajal S N, Madrid 28040, Spain.
   [Cicuendez, Monica] Univ Complutense Madrid, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Fac Farm, Dept Quim Ciencias Farmaceut, Madrid 28040, Spain.
   [Colilla, Montserrat; Vallet Regi, Maria; Gonzalez, Blanca; Izquierdo Barba, Isabel] Ctr Invest Biomed Red Bioingn Biomat & Nanomed CIB, Zaragoza, Spain.
C3 Complutense University of Madrid; Hospital Universitario 12 de Octubre;
   Complutense University of Madrid
RP González, B; Izquierdo Barba, I (通讯作者)，Univ Complutense Madrid, Fac Farm, Dept Quim Ciencias Farmaceut, Inst Invest Sanitaria,Hosp 12 Octubre I 12, Plaza Ramon & Cajal S N, Madrid 28040, Spain.
EM ibarba@ucm.es
RI IZQUIERDO BARBA, ISABEL/M 9921 2014; González, Blanca/K 4773 2015;
   Gonzalez, Blanca/K 4773 2015; Colilla, Montserrat/N 4628 2014;
   Vallet Regí, Maria/M 3378 2014
OI Gonzalez, Blanca/0000 0002 0493 6071; Colilla,
   Montserrat/0000 0003 1961 4160; 
FU European Union's Horizon 2020 Research and Innovation Program [814410];
   ERC 2015 AdG (VERDI) [694160]; Ministerio de Ciencia e Innovacion
   (MICINN) [PID2020 117091RB I00]
FX This project has received funding from the European Union's Horizon 2020
   Research and Innovation Program under grant agreement No 814410 (GIOTTO)
   and ERC 2015 AdG (VERDI) Proposal No. 694160. This study was also
   supported by the Ministerio de Ciencia e Innovacion (MICINN)
   PID2020 117091RB I00 grant. We thank the Materials for Medicine and
   Biotechnology Group (Maria del Puerto Morales, Alvaro Gallo Cordova) for
   advice and assistance in the characterization in the analysis services
   of the ICMM CSIC for the characterization of the magnetic properties. We
   are grateful to Prof. Maria del Puerto Morales (ICMM/CSIC) for her
   support and valuable scientific discussions on superparamagnetic iron
   oxide nanoparticles, as well as for her collaborative vision of science
   progress. We also thank the ICTS Centro Nacional de Microscopia
   Electronica (UCM) and Unidad de Citometria de Flujo y Microscopia de
   Fluorescencia from CAI de Tecnicas Biologicas (UCM) .
CR Fattah ARA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00240
   Alipour M, 2020, J BIOMED MATER RES A, V108, P839, DOI 10.1002/jbm.a.36862
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Ba XL, 2011, BIOMATERIALS, V32, P7831, DOI 10.1016/j.biomaterials.2011.06.053
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441 009 0834 6
   Barth A, 2007, BBA BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   Bertrand AA, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000709
   Bierbaum S, 1998, EUR J CELL BIOL, V77, P60, DOI 10.1016/S0171 9335(98)80102 7
   Bobo D, 2016, PHARM RES DORDR, V33, P2373, DOI 10.1007/s11095 016 1958 5
   Connell JJ, 2015, REGEN MED, V10, P757, DOI 10.2217/rme.15.36
   Cullity B.D., 1978, ELEMENTS XRAY DIFFRA
   Del Sol Fernández S, 2022, NANOSCALE, V14, P2091, DOI 10.1039/d1nr06303k
   Dhavalikar P, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000795
   Di XP, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01501 9
   Dias AMGC, 2011, BIOTECHNOL ADV, V29, P142, DOI 10.1016/j.biotechadv.2010.10.003
   DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112
   Estévez M, 2023, J COLLOID INTERF SCI, V650, P560, DOI 10.1016/j.jcis.2023.07.009
   Estevez M, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12020181
   Frey NA, 2009, CHEM SOC REV, V38, P2532, DOI 10.1039/b815548h
   Gaharwar AK, 2020, NAT REV MATER, V5, P686, DOI 10.1038/s41578 020 0209 x
   Gao LZ, 2007, NAT NANOTECHNOL, V2, P577, DOI 10.1038/nnano.2007.260
   Gonçalves AI, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aac78b
   Guo H, 2023, ACS APPL MATER INTER, V15, P47880, DOI 10.1021/acsami.3c07999
   Gutiérrez L, 2019, NANOTECHNOLOGY, V30, DOI 10.1088/1361 6528/aafbff
   Hacliipanayis CG, 2008, SMALL, V4, P1925, DOI 10.1002/smll.200800261
   Hajiali H, 2024, PHARMACEUTICS, V16, DOI 10.3390/pharmaceutics16010021
   Hendesi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115325
   Henstock J, 2015, REGEN MED, V10, P377, DOI [10.2217/RME.15.23, 10.2217/rme.15.23]
   Henstock JR, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418808695
   Henstock JR, 2014, STEM CELL TRANSL MED, V3, P1363, DOI 10.5966/sctm.2014 0017
   Herranz F, 2008, CONTRAST MEDIA MOL I, V3, P215, DOI 10.1002/cmmi.254
   Huang DM, 2009, BIOMATERIALS, V30, P3645, DOI 10.1016/j.biomaterials.2009.03.032
   Huang Y, 2022, THERANOSTICS, V12, P796, DOI 10.7150/thno.67375
   Hufschmid R, 2015, NANOSCALE, V7, P11142, DOI 10.1039/c5nr01651g
   Hughes S, 2007, J BIOMECH, V40, pS96, DOI 10.1016/j.jbiomech.2007.03.002
   Jia YC, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102040
   Kamal NAMA, 2021, DALTON T, V50, P2375, DOI 10.1039/d1dt00116g
   Kanczler JM, 2010, TISSUE ENG PT A, V16, P3241, DOI [10.1089/ten.tea.2009.0638, 10.1089/ten.TEA.2009.0638]
   Kangari P, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02001 1
   Kim EC, 2015, BIOELECTROMAGNETICS, V36, P267, DOI 10.1002/bem.21903
   Kim JA, 2012, NAT NANOTECHNOL, V7, P62, DOI [10.1038/NNANO.2011.191, 10.1038/nnano.2011.191]
   Kong J, 2007, ACTA BIOCH BIOPH SIN, V39, P549, DOI 10.1111/j.1745 7270.2007.00320.x
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Kuo YC, 2015, STEM CELLS, V33, P429, DOI 10.1002/stem.1860
   Lassenberger A, 2017, CHEM MATER, V29, P4511, DOI 10.1021/acs.chemmater.7b01207
   Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e
   Li Z, 2023, MATERIALS, V16, DOI 10.3390/ma16041429
   Lima J, 2015, J MAGN MAGN MATER, V393, P526, DOI 10.1016/j.jmmm.2015.05.087
   Linares J, 2014, ACS APPL MATER INTER, V6, P13697, DOI 10.1021/am5031598
   Liu ZS, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241814326
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Markides H, 2012, J NANOMATER, V2012, DOI 10.1155/2012/614094
   Markides H, 2018, NPJ REGEN MED, V3, DOI 10.1038/s41536 018 0048 1
   Meng HX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.697525
   Mettlen M, 2010, J CELL BIOL, V188, P919, DOI 10.1083/jcb.200908078
   Migliorini F, 2021, EUR J MED RES, V26, DOI 10.1186/s40001 021 00593 9
   Schneider MGM, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14010204
   Morgan EF, 2008, J BONE JOINT SURG AM, V90A, P25, DOI 10.2106/JBJS.G.01164
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   osti, About us
   Pang XC, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 022 01259 6
   Park J, 2004, NAT MATER, V3, P891, DOI 10.1038/nmat1251
   Patil US, 2015, INT J MOL SCI, V16, P24417, DOI 10.3390/ijms161024417
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Pommerenke H, 1996, EUR J CELL BIOL, V70, P157
   Pucci C, 2022, BIOMATER SCI UK, V10, P2103, DOI 10.1039/d1bm01963e
   Puech PH, 2021, OPEN BIOL, V11, DOI 10.1098/rsob.210256
   Redza Dutordoir M, 2016, BBA MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Rees P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10112 4
   Rennick JJ, 2021, NAT NANOTECHNOL, V16, P266, DOI 10.1038/s41565 021 00858 8
   Roca AG, 2007, J PHYS CHEM C, V111, P18577, DOI 10.1021/jp075133m
   Rotherham M, 2018, NANOMED NANOTECHNOL, V14, P173, DOI 10.1016/j.nano.2017.09.008
   Rotherham M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121761
   Ruijtenberg S, 2016, CELL CYCLE, V15, P196, DOI 10.1080/15384101.2015.1120925
   Sahoo Y, 2005, J PHYS CHEM B, V109, P3879, DOI 10.1021/jp045402y
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Salas G, 2012, J MATER CHEM, V22, P21065, DOI 10.1039/c2jm34402e
   Singh N, 2010, NANO REV EXP, V1, DOI 10.3402/nano.v1i0.5358
   Singh RK, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202304821
   Son B, 2015, ADV HEALTHC MATER, V4, P1339, DOI 10.1002/adhm.201400835
   Suciu M, 2020, BEILSTEIN J NANOTECH, V11, P1092, DOI 10.3762/bjnano.11.94
   Vallet Regí M, 2011, ADV MATER, V23, P5177, DOI 10.1002/adma.201101586
   Wang H, 2018, J PROTEOMICS, V179, P122, DOI 10.1016/j.jprot.2018.03.008
   Wang QW, 2017, NANO RES, V10, P626, DOI 10.1007/s12274 016 1322 4
   Wei H, 2021, INT J NANOMED, V16, P6097, DOI 10.2147/IJN.S321984
   Xia HM, 2018, NAT REV MATER, V3, P174, DOI 10.1038/s41578 018 0027 6
   Xia Y, 2018, BIOMATERIALS, V183, P151, DOI 10.1016/j.biomaterials.2018.08.040
   Xie WY, 2023, ADV SCI, V10, DOI 10.1002/advs.202204594
   Yoo S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232315402
   Yu CH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9672
   Yu CH, 2011, P NATL ACAD SCI USA, V108, P20585, DOI 10.1073/pnas.1109485108
   Yu SM, 2016, ACTA BIOMATER, V43, P348, DOI 10.1016/j.actbio.2016.07.024
   Zhang KJ, 2022, ACS APPL NANO MATER, V5, P6597, DOI 10.1021/acsanm.2c00660
   Zhang M, 2024, BIOACT MATER, V31, P368, DOI 10.1016/j.bioactmat.2023.08.016
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
   Zhuang JJ, 2018, ACTA BIOMATER, V71, P49, DOI 10.1016/j.actbio.2018.03.009
NR 96
TC 9
Z9 9
U1 3
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0021 9797
EI 1095 7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD JUN 15
PY 2024
VL 664
BP 454
EP 468
DI 10.1016/j.jcis.2024.03.043
EA MAR 2024
PG 15
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA QU8X8
UT WOS:001223485400001
PM 38484514
OA hybrid
DA 2025 08 17
ER

PT J
AU Kim, TY
   Park, JK
   Aryal, YP
   Lee, ES
   Neupane, S
   Sung, S
   Pokharel, E
   Yeon, CY
   Kim, JY
   Jung, JK
   Yamamoto, H
   An, CH
   Lee, Y
   Sohn, WJ
   Jang, I
   An, SY
   Kim, JY
AF Kim, Tae Young
   Park, Jae Kyung
   Prasad Aryal, Yam
   Lee, Eui Seon
   Neupane, Sanjiv
   Sung, Shijin
   Pokharel, Elina
   Yeon, Chang Yeol
   Kim, Ji Youn
   Jung, Jae Kwang
   Yamamoto, Hitoshi
   An, Chang Hyeon
   Lee, Youngkyun
   Sohn, Wern Joo
   Jang, Il Ho
   An, Seo Young
   Kim, Jae Young
TI Facilitation of Bone Healing Processes Based on the Developmental
   Function of Meox2 in Tooth Loss Lesion
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE periodontitis; signaling pathway; alveolar bone; bone formation; gene
   therapy
ID LIGATURE INDUCED PERIODONTITIS; OSTEOGENIC DIFFERENTIATION; MESENCHYMAL
   INTERACTIONS; LIGAMENT; REVEALS; CELLS; MORPHOGENESIS; MECHANISMS;
   PALATE; GENES
AB In the present study, we examined the bone healing capacity of Meox2, a homeobox gene that plays essential roles in the differentiation of a range of developing tissues, and identified its putative function in palatogenesis. We applied the knocking down of Meox2 in human periodontal ligament fibroblasts to examine the osteogenic potential of Meox2. Additionally, we applied in vivo periodontitis induced experiment to reveal the possible application of Meox2 knockdown for 1 and 2 weeks in bone healing processes. We examined the detailed histomorphological changes using Masson's trichrome staining and micro computed tomography evaluation. Moreover, we observed the localization patterns of various signaling molecules, including alpha SMA, CK14, IL 1 beta, and MPO to examine the altered bone healing processes. Furthermore, we investigated the process of bone formation using immunohistochemistry of Osteocalcin and Runx2. On the basis of the results, we suggest that the knocking down of Meox2 via the activation of osteoblast and modulation of inflammation would be a plausible answer for bone regeneration as a gene therapy. Additionally, we propose that the purpose dependent selection and application of developmental regulation genes are important for the functional regeneration of specific tissues and organs, where the pathological condition of tooth loss lesion would be.
C1 [Kim, Tae Young; Prasad Aryal, Yam; Lee, Eui Seon; Sung, Shijin; Pokharel, Elina; Yeon, Chang Yeol; Lee, Youngkyun; Kim, Jae Young] Kyungpook Natl Univ, Sch Dent, Dept Biochem, IHBR, Daegu 41940, South Korea.
   [Park, Jae Kyung; Jang, Il Ho] Pusan Natl Univ, Sch Dent, Inst Translat Dent Sci, Dept Oral Biochem & Mol Biol, Yangsan 50612, South Korea.
   [Neupane, Sanjiv] SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
   [Kim, Ji Youn] Gachon Univ, Dept Dent Hyg, Coll Hlth Sci, Incheon 21936, South Korea.
   [Jung, Jae Kwang] Kyungpook Natl Univ, Sch Dent, Dept Oral Med, IHBR, Daegu 41940, South Korea.
   [Yamamoto, Hitoshi] Tokyo Dent Coll, Dept Histol & Dev Biol, Tokyo 1010061, Japan.
   [An, Chang Hyeon; An, Seo Young] Kyungpook Natl Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, IHBR, Daegu 41940, South Korea.
   [Sohn, Wern Joo] Daegu Haany Univ, Premajor Cosmet & Pharmaceut, Gyongsan 38610, South Korea.
C3 Kyungpook National University (KNU); Pusan National University; State
   University of New York (SUNY) System; Stony Brook University; Gachon
   University; Kyungpook National University (KNU); Tokyo Dental College;
   Kyungpook National University (KNU); Daegu Haany University
RP Kim, JY (通讯作者)，Kyungpook Natl Univ, Sch Dent, Dept Biochem, IHBR, Daegu 41940, South Korea.; An, SY (通讯作者)，Kyungpook Natl Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, IHBR, Daegu 41940, South Korea.
EM tae09290@gmail.com; dbgk15@naver.com; yamaryal@yahoo.com;
   euiseon3488@gmail.com; sanjiv.knu@gmail.com; shijin1432@gmail.com;
   elinapokharel1996@gmail.com; yhs2669@naver.com; hoho6434@gachon.ac.kr;
   widenmy@knu.ac.kr; hyamamoto@tdc.ac.jp; chan@knu.ac.kr; ylee@knu.ac.kr;
   wjsohn@dhu.ac.kr; ilho.jang@pusan.ac.kr; syan@knu.ac.kr;
   jykim91@knu.ac.kr
RI ; Kim, Mi Kyung/E 8682 2012; Kim, Ji Youn/A 5779 2017
OI Kim, Jae Young/0000 0002 6752 5683; Jang, Il Ho/0000 0002 0820 3035;
   Neupane, Sanjiv/0000 0003 2051 9865; Lee, Youngkyun/0000 0001 9049 6908
FU National Research Foundation of Korea [NRF 2019R1A2C1011226,
   2018R1A2A3075600, 2017R1A5A2015391, 2015R1A2A2A01008180]; Ministry of
   Education, Science and Technology, Republic of Korea
FX This study was supported by the National Research Foundation of Korea
   (grant NRF 2019R1A2C1011226, 2018R1A2A3075600, 2017R1A5A2015391 and
   2015R1A2A2A01008180) funded by the Ministry of Education, Science and
   Technology, Republic of Korea.
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Adhikari N, 2019, J PERIODONTAL RES, V54, P533, DOI 10.1111/jre.12657
   Adhikari N, 2017, HISTOCHEM CELL BIOL, V147, P5, DOI 10.1007/s00418 016 1487 7
   An SY, 2017, HISTOCHEM CELL BIOL, V148, P435, DOI 10.1007/s00418 017 1584 2
   [Anonymous], 2019, CELLS BASEL, DOI DOI 10.3390/CELLS8060537
   Balic A, 2015, CURR TOP DEV BIOL, V115, P157, DOI 10.1016/bs.ctdb.2015.07.006
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Bosshardt DD, 2015, CLIN ORAL IMPLAN RES, V26, P229, DOI 10.1111/clr.12543
   Chen LJ, 2017, ARCH ORAL BIOL, V78, P100, DOI 10.1016/j.archoralbio.2017.01.019
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cho MI, 2000, PERIODONTOL 2000, V24, P9, DOI 10.1034/j.1600 0757.2000.2240102.x
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   de Jong T, 2017, J PERIODONTAL RES, V52, P965, DOI 10.1111/jre.12477
   Deas DE, 2016, PERIODONTOL 2000, V71, P128, DOI 10.1111/prd.12114
   Dentino A, 2013, PERIODONTOL 2000, V61, P16, DOI 10.1111/j.1600 0757.2011.00397.x
   Di Benedetto A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/503754
   Douville JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029099
   Draenert FG, 2014, J BIOMED MATER RES A, V102, P1605, DOI 10.1002/jbm.a.34812
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Franceschi RT, 2004, CELLS TISSUES ORGANS, V176, P95, DOI 10.1159/000075031
   Gasner N.S. e., 2020, Periodontal disease
   Goodman SB, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00230
   Graves DT, 2008, J CLIN PERIODONTOL, V35, P89, DOI 10.1111/j.1600 051X.2007.01172.x
   Graziani F, 2017, PERIODONTOL 2000, V75, P152, DOI 10.1111/prd.12201
   Hägi TT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131056
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hoare A, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/1029857
   How KY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00053
   Huang DL, 2020, STEM CELL REV REP, V16, P41, DOI 10.1007/s12015 019 09940 0
   Iguchi S, 2017, J ORAL SCI, V59, P629, DOI 10.2334/josnusd.16 0033
   Iyyanar Paul P R, 2019, Cell Physiol Biochem, V53, P832, DOI 10.33594/000000176
   Jernvall J, 2012, DEVELOPMENT, V139, P3487, DOI 10.1242/dev.085084
   Jewkes BC, 2018, CHEM SENSES, V43, P53, DOI 10.1093/chemse/bjx066
   Jin JZ, 2006, DEV DYNAM, V235, P539, DOI 10.1002/dvdy.20641
   Jussila M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008425
   Kim JY, 2007, CELL TISSUE RES, V330, P123, DOI 10.1007/s00441 007 0434 2
   Könönen E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081135
   Li JH, 2019, PEERJ, V7, DOI 10.7717/peerj.6589
   Li JY, 2017, DEVELOPMENT, V144, P374, DOI 10.1242/dev.137216
   Li Q, 2007, INT J DEV BIOL, V51, P167, DOI 10.1387/ijdb.062212ql
   Li YZ, 2020, MOL THER METH CLIN D, V18, P291, DOI 10.1016/j.omtm.2020.06.001
   Lin Y, 2018, CURR STEM CELL RES T, V13, P4, DOI 10.2174/1574888X11666161129142525
   Mankoo BS, 2003, DEVELOPMENT, V130, P4655, DOI 10.1242/dev.00687
   Maruyama M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00386
   Mikkola ML, 2006, J MAMMARY GLAND BIOL, V11, P187, DOI 10.1007/s10911 006 9029 x
   Min KK, 2020, J PERIODONTAL RES, V55, P247, DOI 10.1111/jre.12710
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Nakamura T, 2017, J BONE MINER RES, V32, P601, DOI 10.1002/jbmr.3024
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Naruishi K, 2018, J CELL PHYSIOL, V233, P6393, DOI 10.1002/jcp.26521
   Neupane S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155251
   Neupane S, 2018, HISTOCHEM CELL BIOL, V149, P143, DOI 10.1007/s00418 017 1620 2
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Puthiyaveetil JSV, 2016, J CLIN DIAGN RES, V10, pZE5, DOI 10.7860/JCDR/2016/21719.8502
   Salvi GE, 2014, J CLIN PERIODONTOL, V41, P701, DOI 10.1111/jcpe.12266
   Santosh ABR, 2014, ONCOL REV, V8, P1, DOI 10.4081/oncol.2014.239
   Simon D, 2017, BONE, V105, P35, DOI 10.1016/j.bone.2017.08.013
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Smiley CJ, 2015, J AM DENT ASSOC, V146, P525, DOI 10.1016/j.adaj.2015.01.026
   Tang H, 2015, J PERIODONTAL RES, V50, P434, DOI 10.1111/jre.12224
   Tummers M, 2009, J EXP ZOOL PART B, V312B, P309, DOI 10.1002/jez.b.21280
   Valcourt U, 2007, MOL ONCOL, V1, P55, DOI 10.1016/j.molonc.2007.02.002
   Wu Y, 2013, J PERIODONTAL RES, V48, P52, DOI 10.1111/j.1600 0765.2012.01503.x
   Wu YH, 2018, J PERIODONTAL RES, V53, P1009, DOI 10.1111/jre.12600
   Yang XH, 2020, J MOL HISTOL, V51, P55, DOI 10.1007/s10735 020 09856 x
   Yu TS, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.184754
   Zhang ZY, 2002, DEVELOPMENT, V129, P4135
   Zhou T, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9159605
NR 68
TC 10
Z9 10
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 22
AR 8701
DI 10.3390/ijms21228701
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OY2YC
UT WOS:000594115900001
PM 33218046
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU de Faria, LP
   Sueyoshi, G
   de Oliveira, TC
   Holliday, LS
   Arana Chavez, VE
AF de Faria, Lorraine Perciliano
   Sueyoshi, Giuliana
   de Oliveira, Tais Carvalho
   Holliday, L. Shannon
   Arana Chavez, Victor E.
TI Effects of Alendronate and Dexamethasone on Osteoclast Gene Expression
   and Bone Resorption in Mouse Marrow Cultures
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE alendronate; bisphosphonate; cell culture; dexamethasone; gene
   expression; osteoclast
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; MOLECULAR MECHANISMS; IN VITRO;
   OSTEOBLASTS; APOPTOSIS; TISSUE
AB Osteoclasts are cells whose main function is the resorption of bone matrix. However, several factors, including medications, can interfere with the resorption process. Alendronate (ALN), a nitrogen containing type of bisphosphonate, and dexamethasone (DEX), a glucocorticoid, are drugs that may affect the resorption activity. The aim of this study is to investigate the effects of ALN, and/or DEX on osteoclast gene expression and resorption activity in primary mouse marrow cultures stimulated with 1,25 dihydroxyvitamin D3, a model for the bone microenvironment. Cultures were treated only with ALN (10( 5) M), DEX (10( 6) M), and with a combination of both agents. Viability assays performed at days 5, 7, and 9 showed the highest number of viable cells at day 7. All the following assays were then performed at day 7 of cell culture: tartrate resistant acid phosphatase (TRAP) histochemistry, receptor activator of nuclear factor kappa B ligand (RANKL) immunofluorescence, osteoprotegerin (OPG), and RANKL gene expression by qPCR and resorption analysis by scanning electron microscopy. Treatment with ALN, DEX, and the combination of both did not promote significant changes in the number of TRAP+ cells, although larger giant cells were detected in groups treated with DEX. DEX treatment increased the gene expression of RANKL and reduced OPG. The treatment with ALN reduced the depth of the resorption pits, but their inhibitory effect was less effective when administered with DEX:
C1 [de Faria, Lorraine Perciliano; Sueyoshi, Giuliana; de Oliveira, Tais Carvalho; Arana Chavez, Victor E.] Univ Sao Paulo, Sch Dent, Dept Biomat & Oral Biol, BR 05508000 Sao Paulo, SP, Brazil.
   [Holliday, L. Shannon] Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL USA.
C3 Universidade de Sao Paulo; State University System of Florida;
   University of Florida
RP Arana Chavez, VE (通讯作者)，Univ Sao Paulo, Sch Dent, Dept Biomat & Oral Biol, BR 05508000 Sao Paulo, SP, Brazil.
EM vearana@usp.br
RI de Faria, Lorraine/AAR 3971 2020; Arana Chavez, V/G 4948 2012; Holliday,
   Lexie/GYQ 4972 2022
OI Holliday, Lexie/0000 0002 0844 1965; Perciliano de Faria,
   Lorraine/0000 0001 8995 086X
FU CAPES [001]; CNPq
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was partially supported by the Brazilian agencies CAPES (financial code
   001) and CNPq.
CR Al Deeb SK, 2004, TALANTA, V64, P695, DOI 10.1016/j.talanta.2004.03.044
   Arana Chavez VE, 2009, INT J BIOCHEM CELL B, V41, P446, DOI 10.1016/j.biocel.2008.09.007
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Cummings SR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115411
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hildebrandt S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26300 z
   HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983
   Inoue M, 2021, BONE, V148, DOI 10.1016/j.bone.2021.115942
   Jiang Y, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109979
   Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Martins CA, 2015, J ENDODONT, V41, P45, DOI 10.1016/j.joen.2014.07.010
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756 3282(01)00422 7
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   SEEDOR JG, 1991, J BONE MINER RES, V6, P339
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Sousa LHT, 2017, ARCH ORAL BIOL, V77, P55, DOI 10.1016/j.archoralbio.2017.01.014
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Violich DR, 2010, INT ENDOD J, V43, P2, DOI 10.1111/j.1365 2591.2009.01627.x
   Wang LF, 2019, J CELL PHYSIOL, V234, P3207, DOI 10.1002/jcp.27335
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
NR 27
TC 4
Z9 4
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022 1554
EI 1551 5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD FEB
PY 2022
VL 70
IS 2
BP 169
EP 179
AR 00221554211063519
DI 10.1369/00221554211063519
EA DEC 2021
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA YJ5DQ
UT WOS:000736238000001
PM 34915746
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Nelson, AL
   Mancino, C
   Gao, XQ
   Choe, JA
   Chubb, L
   Williams, K
   Czachor, M
   Marcucio, R
   Taraballi, F
   Cooke, JP
   Huard, J
   Bahney, C
   Ehrhart, N
AF Nelson, Anna Laura
   Mancino, Chiara
   Gao, Xueqin
   Choe, Joshua A.
   Chubb, Laura
   Williams, Katherine
   Czachor, Molly
   Marcucio, Ralph
   Taraballi, Francesca
   Cooke, John P.
   Huard, Johnny
   Bahney, Chelsea
   Ehrhart, Nicole
TI β catenin mRNA encapsulated in SM 102 lipid nanoparticles enhances bone
   formation in a murine tibia fracture repair model
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Gene therapy; Fracture healing; Lipid nanoparticles; mRNA; Canonical Wnt
ID ENCODING BMP 2; PATHWAY; OSTEOGENESIS; INDUCTION; CARTILAGE; NONUNION;
   DELIVERY; VACCINES; ACID; MICE
AB Fractures continue to be a global economic burden as there are currently no osteoanabolic drugs approved to accelerate fracture healing. In this study, we aimed to develop an osteoanabolic therapy which activates the Wnt/ beta  catenin pathway, a molecular driver of endochondral ossification. We hypothesize that using an mRNAbased therapeutic encoding beta  catenin could promote cartilage to bone transformation formation by activating the canonical Wnt signaling pathway in chondrocytes. To optimize a delivery platform built on recent advancements in liposomal technologies, two FDA  approved ionizable phospholipids, DLin MC3 DMA (MC3) and SM 102, were used to fabricate unique ionizable lipid nanoparticle (LNP) formulations and then tested for transfection efficacy both in vitro and in a murine tibia fracture model. Using firefly luciferase mRNA as a reporter gene to track and quantify transfection, SM 102 LNPs showed enhanced transfection efficacy in vitro and prolonged transfection, minimal fracture interference and no localized inflammatory response in vivo over MC3 LNPs. The generated beta  catenin GOF mRNA encapsulated in SM 102 LNPs (SM 102  beta  catenin GOF mRNA) showed bioactivity in vitro through upregulation of downstream canonical Wnt genes, axin2 and runx2 . When testing SM 102  beta  catenin GOF mRNA therapeutic in a murine tibia fracture model, histomorphometric analysis showed increased bone and decreased cartilage composition with the 45 mu g concentration at 2 weeks post  fracture. mu CT testing confirmed that SM 102  beta  catenin GOF mRNA promoted bone formation in vivo , revealing significantly more bone volume over total volume in the 45 mu g group. Thus, we generated a novel mRNA based therapeutic encoding a beta  catenin mRNA and optimized an SM 102 based LNP to maximize transfection efficacy with a localized delivery.
C1 [Nelson, Anna Laura; Gao, Xueqin; Czachor, Molly; Huard, Johnny; Bahney, Chelsea] Steadman Philippon Res Inst SPRI, Ctr Regenerat & Personalized Med, Vail, CO USA.
   [Mancino, Chiara; Taraballi, Francesca] Houston Methodist Res Inst, Ctr Musculoskeletal Regenerat, Houston, TX USA.
   [Choe, Joshua A.] Univ Wisconsin Madison, Dept Orthoped & Rehabil, Dept Biomed Engn, Med Scientist Training Program, Madison, WI USA.
   [Nelson, Anna Laura; Ehrhart, Nicole] Colorado State Univ, Sch Biomed Engn, Ft Collins, CO USA.
   [Chubb, Laura; Huard, Johnny; Bahney, Chelsea; Ehrhart, Nicole] Colorado State Univ, Dept Clin Sci, Ft Collins, CO 80523 USA.
   [Williams, Katherine; Ehrhart, Nicole] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO USA.
   [Cooke, John P.] Houston Methodist Res Inst, Ctr RNA Therapeut, Dept Cardiovasc Sci, Houston, TX USA.
   [Marcucio, Ralph; Huard, Johnny; Bahney, Chelsea] Univ Calif San Francisco UCSF, Orthopaed Trauma Inst, San Francisco, CA USA.
C3 Steadman Philippon Research Institute; Houston Methodist; University of
   Wisconsin System; University of Wisconsin Madison; Colorado State
   University System; Colorado State University Fort Collins; Colorado
   State University System; Colorado State University Fort Collins;
   Colorado State University System; Colorado State University Fort
   Collins; Houston Methodist; University of California System; University
   of California San Francisco
RP Bahney, C; Ehrhart, N (通讯作者)，Colorado State Univ, Dept Clin Sci, Ft Collins, CO 80523 USA.
EM cbahney@sprivail.org; nicole.ehrhart@colostate.edu
RI Choe, Joshua/AGZ 1615 2022; Gao, Xueqin/AAA 2571 2019; Taraballi,
   Francesca/I 2184 2019
OI Czachor, Molly/0009 0003 3303 9649
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) of the National Institutes of Health (NIH) [R01 AR077761];
   Musculoskeletal Regeneration Partnership Fund; Orthoregeneration Network
   for Kick Starter Grant [20 166]; National Institute on Aging of the
   National Institutes of Health [F30AG077748]; University of Wisconsin  
   Madison Medical Scientist Training Program [T32GM140935]
FX Research reported in this publication was supported by National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of
   the National Institutes of Health (NIH) under award number R01 AR077761.
   We also gratefully acknowledge philanthropic support from the
   Musculoskeletal Regeneration Partnership Fund by Mary Sue and Michael
   Shannon and by Project Number 20 166 from the Orthoregeneration Network
   for Kick Starter Grant. This work was supported by the National
   Institute on Aging of the National Institutes of Health under Award
   Number F30AG077748 and the University of Wisconsin   Madison Medical
   Scientist Training Program: T32GM140935. All content is solely the
   responsibility of the authors and does not represent the official views
   of National Institutes of Health, Orthoregeneration Network or Shannon
   Foundation. We thank Suzanne Page for her critical role in grant
   management and SPRI operations. All graphics were created with
   BioRender.com .
CR Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153
   Akinc A, 2019, NAT NANOTECHNOL, V14, P1084, DOI 10.1038/s41565 019 0591 y
   Al Kaabi N, 2021, JAMA J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565
   Albertsen CH, 2022, ADV DRUG DELIVER REV, V188, DOI 10.1016/j.addr.2022.114416
   Alluri R, 2019, J BIOMED MATER RES A, V107, P2174, DOI 10.1002/jbm.a.36727
   Alvarez Benedicto E, 2022, BIOMATER SCI UK, V10, P549, DOI 10.1039/d1bm01454d
   Aspenberg Per, 2013, Bonekey Rep, V2, P244, DOI 10.1038/bonekey.2012.244
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Bahney CS, 2014, J BONE MINER RES, V29, P1269, DOI 10.1002/jbmr.2148
   Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bhandari M, 2020, J BONE JOINT SURG AM, V102, P1416, DOI 10.2106/JBJS.19.01008
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brinker MR, 2013, J BONE JOINT SURG AM, V95A, P2170, DOI 10.2106/JBJS.L.00803
   Burdusel AC, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10123158
   Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826
   Carrasco MJ, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 02441 2
   Cauley J, 2021, LANCET HEALTH LONGEV, V2, pE535, DOI 10.1016/S2666 7568(21)00183 5
   Chandra SHV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034479
   Chen T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18375 x
   Cheng XW, 2016, ADV DRUG DELIVER REV, V99, P129, DOI 10.1016/j.addr.2016.01.022
   Clogston JD, 2011, METHODS MOL BIOL, V697, P63, DOI 10.1007/978 1 60327 198 1_6
   Court Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130
   da Silva CC, 2022, HUM MOL GENET, V31, P1622, DOI 10.1093/hmg/ddab349
   Damase TR, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.628137
   Danaei M, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020057
   De Beuckelaer A, 2016, MOL THER, V24, P2012, DOI 10.1038/mt.2016.161
   de la Vega R, 2021, TRANSL RES, V236, P1, DOI 10.1016/j.trsl.2021.04.009
   De La Vega RE, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abl6242
   Dhamdhere GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083650
   Di JX, 2022, PHARM RES DORDR, V39, P105, DOI 10.1007/s11095 022 03166 5
   Dumic Cule I, 2018, INT ORTHOP, V42, P2619, DOI 10.1007/s00264 018 4153 y
   Ekegren CL, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122845
   Elangovan S, 2015, J CONTROL RELEASE, V218, P22, DOI 10.1016/j.jconrel.2015.09.050
   Fong K, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 103
   Fontana G, 2019, MOL THER NUCL ACIDS, V18, P455, DOI 10.1016/j.omtn.2019.09.004
   Gao X., 2023, Int. J. Mol. Sci., V24
   Gao XQ, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121708
   Gao XQ, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1066 z
   Garrison K R., 2008, Cochrane Database ofSystematic Reviews
   Garrison KR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006950.pub2
   Gedaly R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099272
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Gong YP, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00918
   HALL BK, 1986, J EMBRYOL EXP MORPH, V93, P133
   Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931
   Hassett KJ, 2019, MOL THER NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013
   Haxaire C, 2016, AM J PATHOL, V186, P1598, DOI 10.1016/j.ajpath.2016.01.016
   Hu DP, 2017, DEVELOPMENT, V144, P221, DOI 10.1242/dev.130807
   Hwang Y, 2014, SCI REP UK, V4, DOI 10.1038/srep05916
   Kang HP, 2021, J BIOMED MATER RES A, V109, P2346, DOI 10.1002/jbm.a.37217
   Karladani AH, 2001, ARCH ORTHOP TRAUM SU, V121, P325, DOI 10.1007/s004020000252
   Khorsand B, 2017, AAPS J, V19, P438, DOI 10.1208/s12248 016 0034 8
   Kim JC, 2018, AM J CANCER RES, V8, P1823
   Kodama J, 2022, BONE REP, V17, DOI 10.1016/j.bonr.2022.101616
   Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012
   Krauson AJ, 2023, NPJ VACCINES, V8, DOI 10.1038/s41541 023 00742 7
   Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002
   Kulkarni JA, 2018, NUCLEIC ACID THER, V28, P146, DOI 10.1089/nat.2018.0721
   Linares Fernández S, 2020, TRENDS MOL MED, V26, P311, DOI 10.1016/j.molmed.2019.10.002
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Lotter C, 2022, EUR J PHARM BIOPHARM, V172, P134, DOI 10.1016/j.ejpb.2022.02.007
   Malhan D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00666
   Mancino C, 2024, ACS APPL MATER INTER, V16, P15832, DOI 10.1021/acsami.3c18830
   Marcucio RS, 2023, J DENT RES, V102, P13, DOI 10.1177/00220345221125401
   Martin H., 2022, BMJ Specialist Journals
   Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877
   Mihara E, 2016, ELIFE, V5, DOI 10.7554/eLife.11621
   Mundi R, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.7649
   Nelson AL, 2024, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1295313
   Nelson AL, 2022, J TISSUE ENG REGEN M, V16, P961, DOI 10.1002/term.3349
   Nitika, 2022, LIFE BASEL, V12, DOI 10.3390/life12081254
   Panteli M, 2022, J CELL MOL MED, V26, P601, DOI 10.1111/jcmm.17096
   Pogue A.I., 2017, J Alzheimers Dis Parkinsonism, V7, DOI 10.4172/2161 0460.1000403
   Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202
   Popelut A, 2010, BIOMATERIALS, V31, P9173, DOI 10.1016/j.biomaterials.2010.08.045
   Prados B, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04003 0
   Qin SG, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01007 w
   Rajendran AK, 2022, RSC ADV, V12, P8889, DOI 10.1039/d2ra00713d
   Rivera K.O., 2021, bioRxiv
   Sun LJ, 2010, CELL, V140, P436, DOI 10.1016/j.cell.2010.01.041
   Sun XY, 2020, FASEB J, V34, P789, DOI 10.1096/fj.201901229RR
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Uchida S, 2020, MICROMACHINES BASEL, V11, DOI 10.3390/mi11040426
   Utzinger M, 2017, J CONTROL RELEASE, V249, P143, DOI 10.1016/j.jconrel.2017.01.045
   Wei BG, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab044
   Weiss RJ, 2008, ACTA ORTHOP, V79, P526, DOI 10.1080/17453670710015535
   Wong S.A., 2020, bioRxiv
   Wong SSW, 2020, bioRxiv
   Wu Y., 2021, Chinese Journal of Tissue Engineering Research, V25, P2274
   Xu X, 2023, ACS NANOSCI AU, V3, P192, DOI 10.1021/acsnanoscienceau.2c00062
   Zhang MR, 2023, INFLAMM REGEN, V43, DOI 10.1186/s41232 023 00285 3
   Zhang W, 2019, TISSUE ENG PT A, V25, P131, DOI [10.1089/ten.TEA.2018.0112, 10.1089/ten.tea.2018.0112]
   Zhou LM, 2020, DRUG DES DEV THER, V14, P3519, DOI 10.2147/DDDT.S263787
NR 94
TC 9
Z9 9
U1 9
U2 38
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD SEP
PY 2024
VL 39
BP 273
EP 286
DI 10.1016/j.bioactmat.2024.05.020
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA UP9V7
UT WOS:001249389800001
PM 38832305
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sutjandra, L
   Rodriguez, RD
   Doshi, S
   Ma, M
   Peterson, MC
   Jang, GR
   Chow, AT
   Pérez Ruixo, JJ
AF Sutjandra, Liviawati
   Rodriguez, Rachelle D.
   Doshi, Sameer
   Ma, Mark
   Peterson, Mark C.
   Jang, Graham R.
   Chow, Andrew T.
   Jose Perez Ruixo, Juan
TI Population Pharmacokinetic Meta Analysis of Denosumab in Healthy
   Subjects and Postmenopausal Women with Osteopenia or Osteoporosis
SO CLINICAL PHARMACOKINETICS
LA English
DT Article
ID OSTEOCLASTOGENESIS INHIBITORY FACTOR; HUMAN MONOCLONAL ANTIBODY; DRUG
   DISPOSITION MODEL; BONE MINERAL DENSITY; QUANTIFICATION LIMIT; RECEPTOR
   ACTIVATOR; HANDLING DATA; SERUM LEVELS; OSTEOPROTEGERIN; LIGAND
AB Background and Objective: Inhibition of the receptor activator of nuclear factor K B ligand (RANKL) is a therapeutic target for treatment of bone disorders associated with increased bone resorption, such as osteoporosis. The objective of this analysis was to characterize the population pharmacokineics of denosumab (AMG 162; Prate (R)), a fully human IgG2 monoclonal antibody that binds to RANK L, in healthy subjects and postmenopausal women with osteopenia or osteoporosis.
   Methods: A total of 22 944 serum free denosumab concentrations from 495 healthy subjects and 1069 postmenopausal women with osteopenia or osteoporosis were pooled. Denosumab was administered as either a single intravenous dose (n = 36), a single subcutaneous dose (n = 469) or multiple subcutaneous doses (n = 1059), ranging from 0.01 to 3 mg/kg (or 6 210 mg as fixed mass dosages), every 3 or 6 months for up to 48 months. An open, two compartment pharmacokinetic model with a quasi steady state approximation of the target mediated drug disposition model was used to describe denosumab pharmacokinetics, using NONMEM Version 7.1.0 software. Subcutaneous absorption was characterized by the first order absorption rate constant (k(a)), with constant absolute bioavailability over the range of doses that were evaluated. Clearance and volume of distribution parameters were scaled by body weight, using a power model. Model evaluation was performed through visual predictive checks.
   Results: The subcutaneous bioavailability of denosumab was 64%, and the ka was 0.00883 h( 1). The central volume of distribution and linear clearance were 2.49 L/66 kg and 3.06 mL/h/66 kg, respectively. The baseline RANKL level, quasi steady state constant and RANKL degradation rate were 614 ng/mL, 138 ng/mL and 0.00148 h( 1), respectively. Between subject variability in Model parameters was moderate. A fixed dose of 60 mg provided RANKL inhibition similar to that achieved by equivalent body weight based dosing. The effects of age and race on the area under the serum concentration time curve of denosumab were less than 15% over the range of covariate values that were evaluated.
   Conclusions: The non linearity in denosumab pharmacokinetics is probably due to RANKL binding, and denosumab dose adjustment based on the patient demographics is not warranted.
C1 [Sutjandra, Liviawati; Rodriguez, Rachelle D.; Doshi, Sameer; Ma, Mark; Peterson, Mark C.; Jang, Graham R.; Chow, Andrew T.; Jose Perez Ruixo, Juan] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 Amgen
RP Pérez Ruixo, JJ (通讯作者)，Picayo 3, Valencia 46530, Spain.
EM juanjose@amgen.com
RI ; Perez Ruixo, Juan/AAF 3160 2020
OI PEREZ RUIXO, JUAN JOSE/0000 0001 9890 745X; 
FU Amgen Inc.
FX This study was sponsored by Amgen Inc., which was involved in the study
   design; the data collection, analysis and interpretation; the writing of
   the manuscript; and the decision to submit the manuscript for
   publication. Liviawati Sutjandra, Sameer Doshi, Mark Ma, Graham Jang,
   Andrew Chow and Juan Jose Perez Ruixo were employees of Amgen Inc. and
   owned stock in Amgen Inc. at the time when the analysis was conducted.
   Rachelle Rodriguez and Mark Peterson are former employees of Amgen Inc.
   The authors have no other conflicts of interest to declare.
CR Agoram BM, 2007, DRUG DISCOV TODAY, V12, P1018, DOI 10.1016/j.drudis.2007.10.002
   Ahn JE, 2008, J PHARMACOKINET PHAR, V35, P401, DOI 10.1007/s10928 008 9094 4
   Akatsu T, 1998, BIOCHEM BIOPH RES CO, V250, P229, DOI 10.1006/bbrc.1998.9294
   Amgen Inc, 2010, PROL DEN INV BROCH
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Beal SL, 2001, J PHARMACOKINET PHAR, V28, P481, DOI 10.1023/A:1012299115260
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bergstrand M, 2009, AAPS J, V11, P371, DOI 10.1208/s12248 009 9112 5
   Block G, 2010, J AM KIDNEY DIS, V55, pB46
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Byon W, 2008, J PHARMACOKINET PHAR, V35, P101, DOI 10.1007/s10928 007 9078 9
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dirks NL, 2010, CLIN PHARMACOKINET, V49, P633, DOI 10.2165/11535960 000000000 00000
   Elliott R, 2007, OSTEOPOROSIS INT, V18, pS54
   European Medicines Agency, EMA216722010
   Findlay D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2348
   Frame B, 2001, CLIN PHARMACOKINET, V40, P307, DOI 10.2165/00003088 200140040 00006
   Gibiansky L, 2009, EXPERT OPIN DRUG MET, V5, P803, DOI 10.1517/17425250902992901
   Gibiansky L, 2008, J PHARMACOKINET PHAR, V35, P573, DOI 10.1007/s10928 008 9102 8
   Girard P, 2002, 11 M POP APPR GROUP
   Hayashi N, 2007, BRIT J CLIN PHARMACO, V63, P548, DOI 10.1111/j.1365 2125.2006.02803.x
   Hofbauer LC, 2004, CLIN ENDOCRINOL, V60, P214, DOI 10.1046/j.1365 2265.2003.01969.x
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807
   Krippendorff BF, 2009, J PHARMACOKINET PHAR, V36, P239, DOI 10.1007/s10928 009 9120 1
   Kuester K., 2006, PHARMACOKINETICS PHA, P45, DOI DOI 10.1002/9783527609628.CH3
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu JM, 2005, CALCIFIED TISSUE INT, V76, P1, DOI 10.1007/s00223 004 0007 2
   Lobo ED, 2004, J PHARM SCI US, V93, P2645, DOI 10.1002/jps.20178
   Mager DE, 2005, PHARM RES DORDR, V22, P1589, DOI 10.1007/s11095 005 6650 0
   Mager DE, 2001, J PHARMACOKINET PHAR, V28, P507, DOI 10.1023/A:1014414520282
   MAHMOOD I, 2006, CLIN PHARM THERAPEUT
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Olsson Gisleskog P, 2007, CLIN PHARMACOKINET, V46, P159, DOI 10.2165/00003088 200746020 00004
   Perez Ruixo JJ, 2006, BRIT J CLIN PHARMACO, V62, P81, DOI 10.1111/j.1365 2125.2006.02615.x
   Roskos LK, 2004, DRUG DEVELOP RES, V61, P108, DOI 10.1002/ddr.10346
   Savic RM, 2009, AAPS J, V11, P558, DOI 10.1208/s12248 009 9133 0
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
   Yan XY, 2010, J PHARMACOKINET PHAR, V37, P25, DOI 10.1007/s10928 009 9142 8
   Yano Y, 2001, J PHARMACOKINET PHAR, V28, P171, DOI 10.1023/A:1011555016423
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 50
TC 87
Z9 93
U1 0
U2 15
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0312 5963
EI 1179 1926
J9 CLIN PHARMACOKINET
JI Clin. Pharmacokinet.
PY 2011
VL 50
IS 12
BP 793
EP 807
DI 10.2165/11594240 000000000 00000
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 862GI
UT WOS:000298077400004
PM 22087866
DA 2025 08 17
ER

PT J
AU Liu, HJ
   Li, P
   Zhang, SY
   Xiang, JN
   Yang, RC
   Liu, JJ
   Shafiquzzaman, M
   Biswas, S
   Wei, ZY
   Zhang, ZL
   Zhou, X
   Yin, F
   Xie, YL
   Goff, SP
   Chen, L
   Li, BJ
AF Liu, Huijuan
   Li, Ping
   Zhang, Shaoyang
   Xiang, Jinnan
   Yang, Ruichen
   Liu, Jiajia
   Shafiquzzaman, Md
   Biswas, Soma
   Wei, Zhanying
   Zhang, Zhenlin
   Zhou, Xin
   Yin, Feng
   Xie, Yangli
   Goff, Stephen P.
   Chen, Lin
   Li, Baojie
TI Prrx1 marks stem cells for bone, white adipose tissue and dermis
   in adult mice
SO NATURE GENETICS
LA English
DT Article
ID MESENCHYMAL STROMAL CELLS; ADIPOCYTE PRECURSORS; PROGENITOR CELLS; CRE
   RECOMBINASE; EXPRESSION; CHALLENGES; SECRETION; RESIDE
AB Specialized connective tissues, including bone and adipose tissues, control various physiological activities, including mineral and energy homeostasis. However, the identity of stem cells maintaining these tissues throughout adulthood remains elusive. By conducting genetic lineage tracing and cell depletion experiments in newly generated knock in Cre/CreER(T2) lines, we show here that rare Prrx1 expressing cells act as stem cells for bone, white adipose tissue and dermis in adult mice, which are indispensable for the homeostasis and repair of these tissues. Single cell profiling reveals the cycling and multipotent nature of Prrx1 expressing cells and the stemness of these cells is further validated by transplantation assays. Moreover, we identify the cell surface markers for Prrx1 expressing stem cells and show that the activities of these stem cells are regulated by Wnt signaling. These findings expand our knowledge of connective tissue homeostasis/regeneration and may help improve stem cell based therapies.Prrx1 expressing can act as stem cells for bone, white adipose tissue and dermis in adult mice. These cells have a key role in tissue homeostasis and repair and are regulated by Wnt signaling.
C1 [Liu, Huijuan; Li, Ping; Zhang, Shaoyang; Xiang, Jinnan; Yang, Ruichen; Liu, Jiajia; Shafiquzzaman, Md; Biswas, Soma; Li, Baojie] Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai, Peoples R China.
   [Liu, Huijuan; Wei, Zhanying; Zhang, Zhenlin] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Shanghai Clin Res Ctr Bone Dis, Dept Osteoporosis & Bone Dis, Shanghai, Peoples R China.
   [Zhou, Xin; Li, Baojie] Chengdu Univ Tradit Chinese Med, Inst Tradit Chinese Med & Stem Cell Res, Chengdu, Peoples R China.
   [Yin, Feng; Li, Baojie] Tongji Univ, Shanghai East Hosp, Translat Med Ctr Stem Cell Therapy, Shanghai, Peoples R China.
   [Yin, Feng] Tongji Univ Sch Med, East Hosp, Dept Joint & Sports Med, Shanghai, Peoples R China.
   [Xie, Yangli; Chen, Lin] Army Med Univ, Daping Hosp, Ctr Bone Metab & Repair,Res Inst Surg, Dept Wound Repair & Rehabil Med,Trauma Ctr,State, Chongqing, Peoples R China.
   [Goff, Stephen P.] Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.
   [Goff, Stephen P.] Columbia Univ, Dept Microbiol & Immunol, New York, NY USA.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chengdu
   University of Traditional Chinese Medicine; Tongji University; Tongji
   University; Army Medical University; Howard Hughes Medical Institute;
   Columbia University; Columbia University
RP Li, BJ (通讯作者)，Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai, Peoples R China.; Li, BJ (通讯作者)，Chengdu Univ Tradit Chinese Med, Inst Tradit Chinese Med & Stem Cell Res, Chengdu, Peoples R China.; Li, BJ (通讯作者)，Tongji Univ, Shanghai East Hosp, Translat Med Ctr Stem Cell Therapy, Shanghai, Peoples R China.; Chen, L (通讯作者)，Army Med Univ, Daping Hosp, Ctr Bone Metab & Repair,Res Inst Surg, Dept Wound Repair & Rehabil Med,Trauma Ctr,State, Chongqing, Peoples R China.
EM linchen70@163.com; libj@sjtu.edu.cn
RI ; zhang, shaoyang/GPX 2651 2022; liu, jiajia/ISS 0316 2023;
   SHAFIQUZZAMAN/M 7621 2019; Zhou, Xin/KVB 2846 2024; Goff,
   Stephen/JSK 9923 2023; Wang, Zhengtao/AAH 7360 2019
OI Biswas, Soma/0000 0002 1427 2678; Zhang, Shaoyang/0000 0002 1596 0181;
   Shafiquzzaman, Md/0000 0002 4668 0983; 
FU National Key Research and Development Program of China [2018YFA0800803];
   National Natural Science Foundation of China [91749201, 81830075];
   Schaefer Research Scholarship; Major Program of Development Fund for
   Shanghai Zhangjiang National Innovation Demonstration Zone
   [ZJ2018 ZD 004]
FX We thank J. Lu (East China Normal University) and A. Waisman (University
   of Cologne) for providing genetically engineered mice. The work was
   supported by the National Key Research and Development Program of China
   (2018YFA0800803 to B.L.), the National Natural Science Foundation of
   China (91749201 to B.L. and 81830075 to L.C.), the Schaefer Research
   Scholarship (to B.L.) and Major Program of Development Fund for Shanghai
   Zhangjiang National Innovation Demonstration Zone (Stem Cell Strategic
   Biobank and Stem Cell Clinical Technology Transformation Platform;
   ZJ2018 ZD 004 to B.L.). We thank H. Jiang from the Core Facility and
   Technical Service Center for SLSB, School of Life Science and
   Biotechnology, Shanghai Jiao Tong University for technical support with
   FACS analysis.
CR Ambrosi TH, 2021, NATURE, V597, P256, DOI 10.1038/s41586 021 03795 7
   Bänziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Berry R, 2014, CELL METAB, V19, P8, DOI 10.1016/j.cmet.2013.10.003
   Berry R, 2013, NAT CELL BIOL, V15, P302, DOI 10.1038/ncb2696
   Biernaskie J, 2009, CELL STEM CELL, V5, P610, DOI 10.1016/j.stem.2009.10.019
   Brash JT, 2020, CIRC RES, V127, P849, DOI 10.1161/CIRCRESAHA.120.317025
   Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762
   Burl RB, 2018, CELL METAB, V28, P300, DOI 10.1016/j.cmet.2018.05.025
   Caplan AI, 2017, J ORTHOP RES, V35, P1151, DOI 10.1002/jor.23560
   Cattaneo P, 2020, CELL REP, V30, P571, DOI 10.1016/j.celrep.2019.12.046
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chen KG, 2017, STEM CELL REP, V9, P1343, DOI 10.1016/j.stemcr.2017.09.014
   Corvera S, 2021, ANNU REV PHYSIOL, V83, P257, DOI 10.1146/annurev physiol 031620 095446
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Donati G, 2014, P NATL ACAD SCI USA, V111, pE1501, DOI 10.1073/pnas.1312880111
   Driskell RR, 2013, NATURE, V504, P277, DOI 10.1038/nature12783
   El Agha E, 2017, CELL STEM CELL, V21, P166, DOI 10.1016/j.stem.2017.07.011
   Ferrero R, 2020, TRENDS CELL BIOL, V30, P937, DOI 10.1016/j.tcb.2020.09.007
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Haas S, 2018, CELL STEM CELL, V22, P627, DOI 10.1016/j.stem.2018.04.003
   Han XM, 2021, CELL STEM CELL, V28, P1160, DOI 10.1016/j.stem.2021.01.007
   Hepler C, 2018, ELIFE, V7, DOI 10.7554/eLife.39636
   Hepler C, 2017, GENE DEV, V31, P127, DOI 10.1101/gad.293704.116
   Kawanami A, 2009, BIOCHEM BIOPH RES CO, V386, P477, DOI 10.1016/j.bbrc.2009.06.059
   Krueger KC, 2014, STEM CELL REP, V3, P1147, DOI 10.1016/j.stemcr.2014.10.009
   Leavitt T, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108356
   LEUSSINK B, 1995, MECH DEVELOP, V52, P51, DOI 10.1016/0925 4773(95)00389 I
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237
   Matsushita Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14029 w
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Merrick D, 2019, SCIENCE, V364, P353, DOI 10.1126/science.aav2501
   Mizuhashi K, 2018, NATURE, V563, P254, DOI 10.1038/s41586 018 0662 5
   Newton PT, 2019, NATURE, V567, P234, DOI 10.1038/s41586 019 0989 6
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Riazifar M, 2017, ANNU REV PHARMACOL, V57, P125, DOI 10.1146/annurev pharmtox 061616 030146
   Rinkevich Y, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2151
   Rondini EA, 2020, BIOCHEM J, V477, P583, DOI 10.1042/BCJ20190467
   Sanchez Gurmaches J, 2015, STEM CELL REP, V4, P541, DOI 10.1016/j.stemcr.2015.02.008
   Schwalie PC, 2018, NATURE, V559, P103, DOI 10.1038/s41586 018 0226 8
   Scott CC, 2018, ELIFE, V7, DOI 10.7554/eLife.36330
   Seike M, 2018, GENE DEV, V32, P359, DOI 10.1101/gad.311068.117
   Shin W, 2020, DEV CELL, V53, P185, DOI 10.1016/j.devcel.2020.03.019
   Shook B, 2016, ANNU REV CELL DEV BI, V32, P609, DOI 10.1146/annurev cellbio 111315 125426
   Sipp D, 2018, NATURE, V561, P455, DOI 10.1038/d41586 018 06756 9
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   Vanakker O, 2015, ANNU REV GENOM HUM G, V16, P229, DOI 10.1146/annurev genom 090314 050039
   Wagner DE, 2020, NAT REV GENET, V21, P410, DOI 10.1038/s41576 020 0223 2
   Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Wu HG, 2017, STEM CELL REP, V8, P1600, DOI 10.1016/j.stemcr.2017.04.005
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zwick RK, 2018, CELL METAB, V27, P68, DOI 10.1016/j.cmet.2017.12.002
NR 55
TC 41
Z9 46
U1 11
U2 51
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1061 4036
EI 1546 1718
J9 NAT GENET
JI Nat. Genet.
PD DEC
PY 2022
VL 54
IS 12
DI 10.1038/s41588 022 01227 4
EA DEC 2022
PG 38
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA E7VN7
UT WOS:000928010000003
PM 36456880
DA 2025 08 17
ER

PT J
AU Zhou, HR
   Shen, JZ
   Fu, HY
   Zhang, F
AF Zhou, Hua rong
   Shen, Jian zhen
   Fu, Hai ying
   Zhang, Feng
TI Genistein induced Anticancer Effects on Acute Leukemia Cells Involve the
   Regulation of Wnt Signaling Pathway Through H4K20me1 Rather Than DNA
   Demethylation
SO CURRENT MEDICAL SCIENCE
LA English
DT Article
DE genistein; acute leukemia; Wnt pathway; G2; M cell cycle arrest
ID HISTONE MODIFICATION; CYCLE ARREST; APOPTOSIS; GENE; PROMOTER
AB Objective To investigate the effects and mechanisms of genistein on the gene expression in the Wnt pathway in acute leukemia (AL) cells. Methods The expression of Wnt pathway genes and cell cycle related genes were analyzed in two AL cell lines. Pyrophosphate sequencing was performed to determine the methylation degree. Then, the enrichment of H4K20me1 and H3K9ac was determined using ChIP qPCR. Flow cytometry was used to analyze the cell cycle. Results The IC50 of genistein in the two AL cell lines was lower than that for the bone marrow mesenchymal stem cell line. Genistein upregulated H4K20me1, KMT5A and Wnt suppressor genes, including (Wnt5a), and downregulated the downstream target genes of Wnt, such as c myc and beta catenin. The methylation degree and H3K9ac enrichment in the (Wnt5a) promoter region remained unchanged. However, the enrichment of H4K20me1 in the (Wnt5a) promoter and coding regions increased. In addition, genistein upregulated Phospho cdc2, Myt1, Cyclin A, Cyclin E2, p21 and Phospho histone H3, but downregulated Phospho wee1. Cell cycle arrest was induced in the G2/M phase. Conclusion Genistein inhibits the activation of the Wnt pathway by promoting the expression of (Wnt5a) through the activation of KMT5A and enrichment of H4K20me1 in the (Wnt5a) gene promoter and coding regions, rather than demethylation. Genistein also blocks the cell cycle in the G2/M phase. Therefore, genistein is a potential anti leukemia drug.
C1 [Zhou, Hua rong; Shen, Jian zhen; Fu, Hai ying; Zhang, Feng] Fujian Med Univ, Fujian Inst Hematol, Fujian Med Ctr Hematol, Fujian Prov Key Lab Hematol,Union Hosp, Fuzhou 350001, Peoples R China.
C3 Fujian Medical University
RP Shen, JZ (通讯作者)，Fujian Med Univ, Fujian Inst Hematol, Fujian Med Ctr Hematol, Fujian Prov Key Lab Hematol,Union Hosp, Fuzhou 350001, Peoples R China.
EM zhouhuarong2021@163.com; shenjianzhen2021@163.com
RI Zhang, Feng/AAD 8839 2022
FU National Natural Science Foundation of China [81800167]; Natural Science
   Foundation of Fujian Province [2017J05132]; Fujian Provincial Health
   Technology Project [2018 ZQN 40]; Start up Fund Project of Fujian
   Medical University [2016QH020]; Construction Project of Fujian Medical
   Center of Hematology [Min201704]; National and Fujian Provincial Key
   Clinical Specialty Discipline Construction Program, China; Clinical
   Research Center for Hematological Malignancies of Fujian Province
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81800167), the Natural Science Foundation of
   Fujian Province (No. 2017J05132), the Fujian Provincial Health
   Technology Project (No. 2018 ZQN 40), the Start up Fund Project of
   Fujian Medical University (No. 2016QH020), the Construction Project of
   Fujian Medical Center of Hematology (No. Min201704), the National and
   Fujian Provincial Key Clinical Specialty Discipline Construction
   Program, China, and Clinical Research Center for Hematological
   Malignancies of Fujian Province.
CR Bi YL, 2018, PHYTOMEDICINE, V39, P10, DOI 10.1016/j.phymed.2017.12.001
   Chae HS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102420
   Ferrado JB, 2021, COLLOID SURFACE B, V204, DOI 10.1016/j.colsurfb.2021.111777
   Florean C, 2011, EPIGENOMICS UK, V3, P581, DOI [10.2217/epi.11.73, 10.2217/EPI.11.73]
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Hsiao YC, 2019, ENVIRON TOXICOL, V34, P443, DOI 10.1002/tox.22698
   Hsu SC, 2007, ANTICANCER RES, V27, P2415
   Huang JW, 2021, EMBO REP, V22, DOI 10.15252/embr.202050994
   Li YY, 2011, J BIOL CHEM, V286, P13925, DOI 10.1074/jbc.M111.223198
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   McDevitt MA, 2012, SEMIN ONCOL, V39, P109, DOI 10.1053/j.seminoncol.2011.11.003
   Ouyang GL, 2009, CELL BIOL INT, V33, P1237, DOI 10.1016/j.cellbi.2009.08.011
   Phillip CJ, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 145
   Teodoro JG, 2004, GENE DEV, V18, P1952, DOI 10.1101/gad.1198404
   Wakabayashi K, 2009, MOL CELL BIOL, V29, P3544, DOI 10.1128/MCB.01856 08
   Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040955
   Wang ZG, 2010, ANTICANCER RES, V30, P4537
   Yamasaki M, 2010, BIOSCI BIOTECH BIOCH, V74, P2113, DOI 10.1271/bbb.100359
   Zhou HR, 2017, ONCOL REP, V37, P2663, DOI 10.3892/or.2017.5509
   Zhu J, 2018, MOL MED REP, V17, P7265, DOI 10.3892/mmr.2018.8760
NR 20
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2096 5230
EI 2523 899X
J9 CURR MED SCI
JI Curr. Med. Sci.
PD OCT
PY 2021
VL 41
IS 5
BP 869
EP 879
DI 10.1007/s11596 021 2445 8
EA OCT 2021
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA WL5HH
UT WOS:000709250600001
PM 34669117
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhou, YN
   Wu, YQ
   Ma, WD
   Jiang, XQ
   Takemra, A
   Uemura, M
   Xia, LG
   Lin, KL
   Xu, YJ
AF Zhou, Yuning
   Wu, Yuqiong
   Ma, Wudi
   Jiang, Xinquan
   Takemra, Akimichi
   Uemura, Mamoru
   Xia, Lunguo
   Lin, Kaili
   Xu, Yuanjin
TI The effect of quercetin delivery system on osteogenesis and angiogenesis
   under osteoporotic conditions
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS;
   ACTIVATED PROTEIN KINASE; OVARIECTOMIZED RATS; SIGNALING PATHWAYS; HUMAN
   OSTEOBLASTS; BONE TISSUE; DIFFERENTIATION; EXPRESSION
AB Bone regeneration under osteoporotic conditions with impaired angiogenesis, osteogenesis and remodeling represents a great challenge. In the present study, the effects of quercetin on proliferation, osteogenic differentiation and angiogenic factor secretion as well as on the osteoclastogenic factor secretion of ovariectomized (OVX) rat bone marrow derived mesenchymal stem cells (rBMSCs) were first evaluated in vitro. The role of mitogen activated protein kinase (MAPK) signaling pathways and the protein kinase B (AKT) signaling pathway in these processes was also investigated. Finally, hydroxyapatite (HA) bioceramic microspheres with a micro nano hybrid surface (nHA bioceramic microspheres) were fabricated and used as drug delivery carriers of quercetin, and the ability to induce osteogenesis and angiogenesis in vivo was confirmed in an OVX rat critical sized femur defect model. In vitro studies showed that quercetin significantly promoted cell proliferation, ALP activity and the expression of osteogenic and angiogenic factors of OVX rBMSCs as well as inhibited the expression of receptor activator of nuclear factor kB ligand (RANKL) in a dose dependent manner, with a concentration of 1 mu M yielding the greatest effect. Moreover, the activation of the extracellular signal regulated protein kinase (ERK),p38 and AKT signaling pathways was observed in quercetin treated OVX rBMSCs, and the crosstalk among these signaling pathways was evident. Furthermore, the nHA bioceramic microspheres could efficiently release quercetin in a sustained manner, and quercetin loaded in the nHA bioceramic microspheres could promote new bone formation and blood vessel formation in vivo. The present study revealed that quercetin could promote osteogenesis and angiogenesis while inhibiting osteoclastogenesis both in vitro and in vivo under osteoporotic conditions. Moreover, HA bioceramic microspheres with a micro nano hybrid surface could act as injectable drug delivery carriers of quercetin and could be applied for osteoporotic bone regeneration.
C1 [Zhou, Yuning; Ma, Wudi; Xu, Yuanjin] Shanghai Jiao Tong Univ, Dept Oral Surg, Peoples Hosp 9, Sch Med,Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Wu, Yuqiong; Jiang, Xinquan] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Prosthodont, Shanghai, Peoples R China.
   [Wu, Yuqiong; Jiang, Xinquan] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Oral Bioengn Lab,Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Takemra, Akimichi; Uemura, Mamoru] Osaka Dent Univ, Dept Anat, Osaka, Japan.
   [Xia, Lunguo] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Ctr Craniofacial Orthodont,Dept Oral & Craniomaxi, Shanghai, Peoples R China.
   [Lin, Kaili] Tongji Univ, Sch & Hosp Stomatol, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, 399 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Tongji University
RP Xu, YJ (通讯作者)，Shanghai Jiao Tong Univ, Dept Oral Surg, Peoples Hosp 9, Sch Med,Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Xia, LG (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Ctr Craniofacial Orthodont,Dept Oral & Craniomaxi, Shanghai, Peoples R China.; Lin, KL (通讯作者)，Tongji Univ, Sch & Hosp Stomatol, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, 399 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
FU Fund of the National Natural Science Foundation of China [81470713,
   81672134, 81400554]; Science and Technology Commission of Shanghai
   Municipality [14140904100, 15441905300]; Medicine and Engineering Cross
   Project of Shanghai Jiao Tong University [YG2012SM29]; Fund of Shanghai
   Municipal Commission of Health and Family Planning [201540369];
   Excellent Youth Program of Ninth People's Hospital Affiliated to
   Shanghai Jiao Tong University, School of Medicine [jyyq08201621];
   Shanghai Summit & Plateau Disciplines
FX The authors gratefully acknowledge the Fund of the National Natural
   Science Foundation of China (81470713, 81672134 and 81400554), Science
   and Technology Commission of Shanghai Municipality (14140904100 and
   15441905300), Medicine and Engineering Cross Project of Shanghai Jiao
   Tong University (YG2012SM29), the Fund of Shanghai Municipal Commission
   of Health and Family Planning (201540369), and Excellent Youth Program
   of Ninth People's Hospital Affiliated to Shanghai Jiao Tong University,
   School of Medicine (jyyq08201621) and supported by Shanghai Summit &
   Plateau Disciplines.
CR Bavaria MN, 2014, APOPTOSIS, V19, P467, DOI 10.1007/s10495 013 0944 1
   Berendsen AD, 2015, J INTERN MED, V277, P674, DOI 10.1111/joim.12364
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   de Boer VCJ, 2005, J NUTR, V135, P1718, DOI 10.1093/jn/135.7.1718
   Ding WG, 2011, CONNECT TISSUE RES, V52, P25, DOI 10.3109/03008201003783011
   Durao SFO, 2012, INT J ORAL MAX IMPL, V27, P1400
   Feric NT, 2014, BIOMATER SCI UK, V2, P1384, DOI 10.1039/c4bm00073k
   Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552 199601000 00008
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Jeon O, 2011, J BIOMED MATER RES A, V98A, P72, DOI 10.1002/jbm.a.33098
   Jeong W, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.115873
   JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955 0674(94)90141 4
   Kang SW, 2008, J BIOMED MATER RES A, V85A, P747, DOI 10.1002/jbm.a.31572
   Kim Hyun Young, 2013, Prev Nutr Food Sci, V18, P18
   Kim H, 2012, BIOMATERIALS, V33, P7489, DOI 10.1016/j.biomaterials.2012.06.098
   Kim YJ, 2006, BIOCHEM PHARMACOL, V72, P1268, DOI 10.1016/j.bcp.2006.08.021
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li B, 2009, BIOMATERIALS, V30, P6768, DOI 10.1016/j.biomaterials.2009.08.038
   Li CW, 2015, GENET MOL RES, V14, P9215, DOI 10.4238/2015.August.10.1
   Li WL, 2015, INT J CLIN EXP PATHO, V8, P117
   Lin KL, 2013, ACS APPL MATER INTER, V5, P8008, DOI 10.1021/am402089w
   Liu XD, 2014, CELL BIOCHEM BIOPHYS, V69, P141, DOI 10.1007/s12013 013 9780 8
   Liu XH, 2011, NAT MATER, V10, P398, DOI [10.1038/NMAT2999, 10.1038/nmat2999]
   Lu HD, 2015, MOL MED REP, V11, P143, DOI 10.3892/mmr.2014.2769
   Ma HP, 2014, CELL PROLIFERAT, V47, P527, DOI 10.1111/cpr.12147
   Mercau ME, 2014, MOL CELL ENDOCRINOL, V384, P43, DOI 10.1016/j.mce.2014.01.007
   Meyer D, 2001, AM J GASTROENTEROL, V96, P112
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Pufe T, 2007, CALCIFIED TISSUE INT, V80, P184, DOI 10.1007/s00223 006 0275 0
   Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009
   Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200
   Ripamonti U, 2008, J CELL MOL MED, V12, P1029, DOI 10.1111/j.1582 4934.2008.00126.x
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Shen QP, 2013, J PHARM PHARMACOL, V65, P1005, DOI 10.1111/jphp.12054
   Umoh Nsini A, 2014, Ann Clin Exp Hypertens, V2, P1007
   van Houdt CIA, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/3/035003
   Wennström S, 1999, MOL CELL BIOL, V19, P4279
   Winet H, 1996, BONE, V19, pS39, DOI 10.1016/S8756 3282(96)00133 0
   Wu YQ, 2015, J MATER CHEM B, V3, P4871, DOI 10.1039/c5tb00621j
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xia LG, 2014, BIOMATERIALS, V35, P8514, DOI 10.1016/j.biomaterials.2014.06.028
   Xia LU, 2011, CELLS TISSUES ORGANS, V194, P481, DOI 10.1159/000323918
   Xiao Y, 2007, BONE, V40, P700, DOI 10.1016/j.bone.2006.10.021
   Zhou C, 2014, CELL PROLIFERAT, V47, P124, DOI 10.1111/cpr.12097
   Zhou YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129605
NR 48
TC 61
Z9 61
U1 0
U2 95
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD JAN 21
PY 2017
VL 5
IS 3
BP 612
EP 625
DI 10.1039/c6tb02312f
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA EL2DZ
UT WOS:000394431600025
PM 32263677
DA 2025 08 17
ER

PT J
AU Fronczek Sokól, J
   Pytlik, M
AF Fronczek Sokol, Justyna
   Pytlik, Maria
TI Effect of glimepiride on the skeletal system of ovariectomized and
   non ovariectomized rats
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE Glimepiride; Rats; Osteopenia; Bone remodeling; Bone mechanical
   properties
ID H+/K+ ATPASE INHIBITORS; MECHANICAL PROPERTIES; DIABETES MELLITUS; BONE;
   DIFFERENTIATION; PATHWAY; CELLS; OSTEOBLASTS; ALENDRONATE; CHANNELS
AB Background: Diabetes mellitus type 2 and osteoporosis are major health problem, especially in postmenopausal women. Glimepiride is a third generation sulfonylurea derivative and is used as a firstline drug in the treatment of type 2 diabetes mellitus. The effect of this drug on bone tissue is unknown. The aim of the present study was to investigate the influence of glimepiride on the skeletal system in ovariectomized and non ovariectomized rats.
   Methods: The experiment was conducted on 3 month old female Wistar rats, divided into 4 groups (n = 10 per group): I (NOVX) non ovariectomized control rats, II (NOVX + G) non ovariectomized rats receiving glimepiride (0.8 mg/kg po), III (OVX) ovariectomized control rats, IV (OVX + G) ovariectomized rats receiving glimepiride (0.8 mg/kg pa). Bilateral ovariectomy was performed 7 days before the start of the experiment, under ketamine xylazine anesthesia. Glimepiride was administered once daily for 28 days. The effect of glimepiride on the skeletal system was assessed based on macrometric parameters, histomorphometric parameters and mechanical properties of the tibial metaphysis, femoral diaphysis and femoral neck. Bone mass, mineral mass, calcium and phosphorus content, as well as serum estrogen, osteocalcin and RatLaps levels were also studied.
   Results: Estrogen deficiency in ovariectomized rats caused increased bone remodeling, with an intensification of bone resorption and formation, and mineralization impairment. Glimepiride in ovariectomized rats inhibited the development of changes in the skeletal system caused by estrogen deficiency, intensifying bone formation. In the presence of estrogens (in non ovariectomized rats), glimepiride also intensified bone formation, but to a lesser extent.
   Conclusions: Glimepiride, in the therapy of type 2 diabetes mellitus in postmenopausal women, may have a beneficial effect on bone remodeling and may reduce the risk of development of osteoporosis. (c) 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban &Partner Sp. z o.o. All rights reserved.
C1 [Fronczek Sokol, Justyna; Pytlik, Maria] Med Univ Silesia, Dept Pharmacol, Sosnowiec, Poland.
C3 Medical University of Silesia
RP Fronczek Sokól, J (通讯作者)，Med Univ Silesia, Dept Pharmacol, Sosnowiec, Poland.
EM jfspharma@gmail.com; mariapytlik@gmail.com
OI Pytlik, Maria/0000 0003 1907 626X
FU Medical University of Silesia in Katowice [KNW 1 044/D/1/0]
FX The study was supported by Medical University of Silesia in Katowice  
   grant KNW 1 044/D/1/0.
CR Abdulameer SA, 2012, PATIENT PREFER ADHER, V6, P435, DOI 10.2147/PPA.S32745
   Cegiela U, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/921684
   Davis SN, 2004, J DIABETES COMPLICAT, V18, P367, DOI 10.1016/j.jdiacomp.2004.07.001
   Diehlmann A, 2011, TISSUE CELL, V43, P331, DOI 10.1016/j.tice.2011.06.004
   Grassi F, 2006, ENDOCRINOLOGY, V147, P4392, DOI 10.1210/en.2006 0334
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Huang CY, 2010, FASEB J, V24, P3625, DOI 10.1096/fj.10 157370
   Jojima T, 2009, DIABETES OBES METAB, V11, P143, DOI 10.1111/j.1463 1326.2008.00923.x
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Katra B., 2007, NOWA KLIN, V14, P18
   Ma P, 2011, ARCH ORAL BIOL, V56, P307, DOI 10.1016/j.archoralbio.2010.10.009
   Ma P, 2010, METABOLISM, V59, P359, DOI 10.1016/j.metabol.2009.08.003
   Miazgowski Tomasz, 2008, Endokrynol Pol, V59, P224
   Moreau R, 1997, J BONE MINER RES, V12, P1984, DOI 10.1359/jbmr.1997.12.12.1984
   MOSEKILDE L, 1995, BONE, V17, P343
   Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841
   Pytlik M, 2004, CALCIFIED TISSUE INT, V75, P225, DOI 10.1007/s00223 004 0097 x
   Pytlik M, 2012, PHARMACOL REP, V64, P625, DOI 10.1016/S1734 1140(12)70858 7
   Pytlik M, 2012, ACTA POL PHARM, V69, P113
   Seino S, 2012, DIABETES OBES METAB, V14, P9, DOI 10.1111/j.1463 1326.2011.01507.x
   Stürmer EK, 2006, J BONE MINER RES, V21, P89, DOI 10.1359/JBMR.050913
   Taton J, 2001, DIABETOLOGIA, P314
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   WHO, 1999, REP WHO CONS DEF DIA
   Wronski TJ., 1992, CELLS MAT, V1, P69
   Yaturu S, 2009, J DIABETES, V1, P246, DOI 10.1111/j.1753 0407.2009.00049.x
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zinman B, 2010, J CLIN ENDOCR METAB, V95, P134, DOI 10.1210/jc.2009 0572
NR 30
TC 23
Z9 26
U1 0
U2 15
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31 343 KRAKOW, POLAND
SN 1734 1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD JUN
PY 2014
VL 66
IS 3
BP 412
EP 417
DI 10.1016/j.pharep.2013.12.013
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AI5ZG
UT WOS:000336948900011
PM 24905517
DA 2025 08 17
ER

PT J
AU Ke, DS
   Zhu, YR
   Zheng, W
   Fu, XM
   Chen, JY
   Han, JY
AF Ke, Dianshan
   Zhu, Yunrong
   Zheng, Wang
   Fu, Xiaomin
   Chen, Jinyan
   Han, Junyong
TI Autophagy mediated by JNK1 resists apoptosis through TRAF3 degradation
   in osteoclastogenesis
SO BIOCHIMIE
LA English
DT Article
DE TRAF3; JNK1; Autophagy; Apoptosis; RANKL Induced osteoclastogenesis
ID NF KAPPA B; RECEPTOR ACTIVATOR; CELL DEATH; BONE LOSS; RANKL; DOMAIN;
   PHOSPHORYLATION; DIFFERENTIATION; INVOLVEMENT; INHIBITION
AB RANKL induces osteoclastogenesis via JNK1 signal that exerts an anti apoptotic effect during osteoclastogenesis. However, the classic downstream c Jun/AP 1 pathway is not included in anti apoptosis of JNK1. Thus, the detail mechanism underlying JNK1 resisted apoptosis remains unknown during RANKL induced osteoclastogenesis. RANKL induced autophagy results in the degradation of the osteoclastogenesis inhibitor TRAF3, and TRAF3 is thought as a regulator of apoptosis. Given the key effect of JNK1 in mediating autophagy, our study aims to investigate the significance of TRAF3 in bridging JNK1 mediated autophagy and apoptotic resistance during osteoclastogenesis. In this study, by using Bone Marrow derived macrophages (BMMs) as osteoclast precursors (OCPs), we found that RANKL induced TRAF3 degradation was significantly suppressed by JNK inhibitor (SP600125), which was restored by overexpression of Beclinl (key autophagic protein). Nevertheless, TRAF3 silencing partially reversed the reduced osteoclastogenesis under SP600125 intervention. Besides, OCP apoptosis was positively regulated by TRAF3 overexpression, regardless of the application of autophagy inhibitor or SP600125. Remarkably, the enhanced apoptosis caused by the pharmacological inhibition of Beclinl was reversed by TRAF3 silencing. Together, these results suggest that JNK1 mediated autophagy could promote RANKL induced osteoclastogenesis via enhancing TRAF3 degradation. Importantly, JNK1 could prevent OCP apoptosis through autophagy TRAF3 signaling, which provides more potential targets for clinical treatment of pathological bone loss. (C) 2019 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Ke, Dianshan] Peoples Hosp JiangMen, Dept Orthoped, 172 Gaodi Li, Jiangmen 529000, Guangdong, Peoples R China.
   [Zhu, Yunrong] Southeast Univ, Med Coll, Affiliated Jiangyin Hosp, Dept Orthoped, Jiangyin, Jiangsu, Peoples R China.
   [Zheng, Wang] Childrens Natl Med Ctr, Ctr Canc & Immunol Res, Washington, DC 20010 USA.
   [Fu, Xiaomin] Johns Hopkins Univ, Div Metab & Endocrinol, Baltimore, MD USA.
   [Chen, Jinyan; Han, Junyong] Fujian Acad Med Sci, Inst Immunol, Fuzhou, Fujian, Peoples R China.
C3 Southeast University   China; Children's National Health System; Johns
   Hopkins University
RP Ke, DS (通讯作者)，Peoples Hosp JiangMen, Dept Orthoped, 172 Gaodi Li, Jiangmen 529000, Guangdong, Peoples R China.; Zheng, W (通讯作者)，Childrens Natl Med Ctr, Ctr Canc & Immunol Res, Washington, DC 20010 USA.
EM kds8810@163.com; wzheng@cnmc.org
RI Han, Junyong/JKJ 0839 2023; Chen, Jinyan/JJF 7875 2023
OI Zhu, Yunrong/0000 0001 6271 4226; Ke, Dianshan/0000 0003 0260 7191
FU National Natural Science Foundation of China [81600529]; Jiangmen
   Medical and Health Science and Technology Project [2019B001]; Young
   medical talents of Jiangsu Province [QNRC2016132]; Major Program of Wuxi
   Municipal Commission of Health and Family Planning [201708]
FX This work was supported by grants of The National Natural Science
   Foundation of China (81600529), Jiangmen Medical and Health Science and
   Technology Project (2019B001), The Young medical talents of Jiangsu
   Province (QNRC2016132), and Major Program of Wuxi Municipal Commission
   of Health and Family Planning (201708). We want to thank the members of
   Cai lab (National Institute on Aging, NIH) for providing various
   supports.
CR BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chaisson ML, 2002, J CLIN INVEST, V110, P193, DOI 10.1172/JCI200215295
   Chen YQ, 2017, J CELL COMMUN SIGNAL, V11, P219, DOI 10.1007/s12079 016 0364 4
   Chikazu D, 2001, J BONE MINER RES, V16, P2074, DOI 10.1359/jbmr.2001.16.11.2074
   Chung YH, 2014, J CELL PHYSIOL, V229, P1963, DOI 10.1002/jcp.24646
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Devergne O, 1996, MOL CELL BIOL, V16, P7098
   Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Gu H, 2015, TOXICOL SCI, V144, P186, DOI 10.1093/toxsci/kfu271
   Ha J, 2010, J IMMUNOL, V184, P4717, DOI 10.4049/jimmunol.0902444
   Häcker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998
   Hariharan N, 2011, ANTIOXID REDOX SIGN, V14, P2179, DOI 10.1089/ars.2010.3488
   He CY, 2013, DIABETES, V62, P1270, DOI 10.2337/db12 0533
   He WY, 2012, AUTOPHAGY, V8, P1811, DOI 10.4161/auto.22145
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Karakashev S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03031 3
   Ke DS, 2019, FASEB J, V33, P11082, DOI 10.1096/fj.201802597RR
   Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu YW, 2016, SCI REP UK, V6, DOI 10.1038/srep33614
   Lu XM, 2009, BIOCHEM BIOPH RES CO, V390, P494, DOI 10.1016/j.bbrc.2009.09.123
   Ochotny N, 2013, J CELL BIOCHEM, V114, P2823, DOI 10.1002/jcb.24630
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Pattingre S, 2009, AUTOPHAGY, V5, P558, DOI 10.4161/auto.5.4.8390
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   Sambandam Y, 2016, J CELL BIOCHEM, V117, P118, DOI 10.1002/jcb.25255
   Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Sul OJ, 2018, BONE, V116, P279, DOI 10.1016/j.bone.2018.08.014
   T Georgopoulos N, 2006, CELL DEATH DIFFER, V13, P1789, DOI 10.1038/sj.cdd.4401859
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Thurau M, 2006, CELL DEATH DIFFER, V13, P1577, DOI 10.1038/sj.cdd.4401847
   Tiollais P., 2009, HEPATOLOGY, V49, P60
   VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
NR 53
TC 17
Z9 18
U1 0
U2 13
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD DEC
PY 2019
VL 167
BP 217
EP 227
DI 10.1016/j.biochi.2019.10.008
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA JN6FO
UT WOS:000496992000022
PM 31654668
DA 2025 08 17
ER

PT J
AU Morse, LR
   Sudhakar, S
   Danilack, V
   Tun, C
   Lazzari, A
   Gagnon, DR
   Garshick, E
   Battaglino, RA
AF Morse, Leslie R.
   Sudhakar, Supreetha
   Danilack, Valery
   Tun, Carlos
   Lazzari, Antonio
   Gagnon, David R.
   Garshick, Eric
   Battaglino, Ricardo A.
TI Association between sclerostin and bone density in chronic spinal cord
   injury
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE FRACTURE; OSTEOPOROSIS; SCLEROSTIN; SPINAL CORD INJURY;
   REHABILITATION MEDICINE
ID REDUCES OSTEOCYTE EXPRESSION; X RAY ABSORPTIOMETRY; MECHANICAL
   STIMULATION; POTENTIAL TREATMENT; MINERAL DENSITY; OSTEOPOROSIS;
   RESORPTION; DELETION; MICE
AB Spinal cord injury (SCI) results in profound bone loss due to muscle paralysis and the inability to ambulate. Sclerostin, a Wnt signaling pathway antagonist produced by osteocytes, is a potent inhibitor of bone formation. Short term studies in rodent models have shown increased sclerostin in response to mechanical unloading that is reversed with reloading. These studies suggest that complete spinal cord injury, a condition resulting in mechanical unloading of the paralyzed lower extremities, will be associated with high sclerostin levels. We assessed the relationship between circulating sclerostin and bone density in 39 subjects with chronic SCI and 10 without SCI. We found that greater total limb bone mineral content was significantly associated with greater circulating levels of sclerostin. Sclerostin levels were reduced, not elevated, in subjects with SCI who use a wheelchair compared with those with SCI who walk regularly. Similarly, sclerostin levels were lower in subjects with SCI who use a wheelchair compared with persons without SCI who walk regularly. These findings suggest that circulating sclerostin is a biomarker of osteoporosis severity, not a mediator of ongoing bone loss, in long term, chronic paraplegia. This is in contrast to the acute sclerostin mediated bone loss shown in animal models of mechanical unloading in which high sclerostin levels suppress bone formation. Because these data indicate important differences in the relationship between mechanical unloading, sclerostin, and bone in chronic SCI compared with short term rodent models, it is likely that sclerostin is not a good therapeutic target to treat chronic SCI induced osteoporosis. (C) 2012 American Society for Bone and Mineral Research
C1 [Morse, Leslie R.; Battaglino, Ricardo A.] Forsyth Inst, Dept Cytokine Biol, Cambridge, MA 02142 USA.
   [Morse, Leslie R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
   [Morse, Leslie R.; Sudhakar, Supreetha] Spaulding Rehabil Hosp, Boston, MA USA.
   [Morse, Leslie R.] VA Boston Healthcare Syst, Spinal Cord Injury Serv, Boston, MA USA.
   [Danilack, Valery] Harvard Univ, Sch Med, Programs Res, VA Boston, Boston, MA USA.
   [Tun, Carlos] VA Boston Healthcare Syst, Rehabil Med Serv, Boston, MA USA.
   [Lazzari, Antonio] VA Boston Healthcare Syst, Primary Care Sect, Boston, MA USA.
   [Lazzari, Antonio] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Gagnon, David R.] Boston Univ, VA Cooperat Studies Program, VA Boston Healthcare Syst, Sch Publ Hlth,Dept Biostat, Boston, MA USA.
   [Garshick, Eric] VA Boston Healthcare Syst, Med Serv, Pulm & Crit Care Med Sect, Boston, MA USA.
   [Garshick, Eric] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA.
   [Battaglino, Ricardo A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Forsyth
   Institute; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Harvard University Medical
   Affiliates; Spaulding Rehabilitation Hospital; Harvard University;
   Harvard University Medical Affiliates; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Boston Healthcare
   System; Harvard University; Harvard Medical School; Harvard University;
   Harvard University Medical Affiliates; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Boston Healthcare
   System; Harvard University; Harvard University Medical Affiliates; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Boston Healthcare System; Boston University; Harvard University; Harvard
   University Medical Affiliates; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Boston Healthcare System;
   Boston University; Harvard University; Harvard University Medical
   Affiliates; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Boston Healthcare System; Harvard University;
   Harvard University Medical Affiliates; Brigham & Women's Hospital;
   Harvard Medical School; Harvard University; Harvard School of Dental
   Medicine
RP Battaglino, RA (通讯作者)，Forsyth Inst, Dept Cytokine Biol, 245 1st St, Cambridge, MA 02142 USA.
EM rbattaglino@forsyth.org
RI Morse, Leslie/AAU 5608 2020; battaglino, ricardo/D 2892 2015; Garshick,
   Eric/Y 6509 2019
OI Lazzari, Antonio/0000 0003 0256 4742; Gagnon, David/0000 0002 6367 3179;
   
FU National Institute of Child Health and Human Development [R21HD057030,
   R21HD057030 02S1]; National Institute of Arthritis and Musculoskeletal
   and Skin Diseases [1R01AR059270 01]; Office of Research and Development,
   Rehabilitation Research and Development [B6618R]; Massachusetts Veterans
   Epidemiology Research and Information Center, Department of Veterans
   Affairs
FX This study received support from: the National Institute of Child Health
   and Human Development (R21HD057030 and R21HD057030 02S1), the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   (1R01AR059270 01), the Office of Research and Development,
   Rehabilitation Research and Development (Merit Review Grant B6618R), and
   the Massachusetts Veterans Epidemiology Research and Information Center,
   Cooperative Studies Program, Department of Veterans Affairs. We thank
   Sam Davis, clinical research coordinator and technician, Boston VA
   Healthcare System, for assisting with bone density scans; Renee Mikorski
   and Heather Colburn, research assistants, Boston VA Healthcare System,
   for collection of anthropometric data; and C. W. Wolff, research
   coordinator, Spaulding Rehabilitation Hospital, for editorial
   assistance.
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bauman W A, 2000, Phys Med Rehabil Clin N Am, V11, P109
   Dauty M, 2000, BONE, V27, P305, DOI 10.1016/S8756 3282(00)00326 4
   Demirel G, 1998, SPINAL CORD, V36, P822, DOI 10.1038/sj.sc.3100704
   Frey Rindova P, 2000, SPINAL CORD, V38, P26, DOI 10.1038/sj.sc.3100905
   GARLAND DE, 1992, J ORTHOPAED RES, V10, P371, DOI 10.1002/jor.1100100309
   Garshick E, 2005, SPINAL CORD, V43, P408, DOI 10.1038/sj.sc.3101729
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Grandas NF, 2005, ARCH PHYS MED REHAB, V86, P1631, DOI 10.1016/j.apmr.2005.02.006
   Kirshblum SC, 2002, AM J PHYS MED REHAB, V81, P502, DOI 10.1097/00002060 200207000 00006
   Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200
   Lewiecki EM, 2011, EXPERT OPIN BIOL TH, V11, P117, DOI 10.1517/14712598.2011.540565
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Morse L, 2008, OSTEOPOROSIS INT, V19, P645, DOI 10.1007/s00198 007 0494 x
   Morse LR, 2009, OSTEOPOROSIS INT, V20, P385, DOI 10.1007/s00198 008 0671 6
   Morse LR, 2009, PM&R, V1, P240, DOI 10.1016/j.pmrj.2008.10.008
   Morse LR, 2009, ARCH PHYS MED REHAB, V90, P827, DOI 10.1016/j.apmr.2008.12.004
   Morse LR, 2009, AM J PHYS MED REHAB, V88, P57, DOI 10.1097/PHM.0b013e31818a5f87
   Papapoulos SE, 2011, ANN RHEUM DIS, V70, pI119, DOI 10.1136/ard.2010.141150
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Robling A. G., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P354
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
NR 30
TC 57
Z9 61
U1 0
U2 6
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2012
VL 27
IS 2
BP 352
EP 359
DI 10.1002/jbmr.546
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 879ZP
UT WOS:000299373600014
PM 22006831
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhao, Y
   Zhao, Z
   Cui, YM
   Chen, CQ
   Xie, CW
   Yang, Y
AF Zhao, Yi
   Zhao, Ze
   Cui, Yamin
   Chen, Changqing
   Xie, Changwei
   Yang, Yang
TI SYNTHESIS AND EVALUATION OF NOVEL BONE TARGETING IBUPROFEN PRODRUG BASED
   ON DENDRITIC ASPARTIC ACID
SO ACTA POLONIAE PHARMACEUTICA
LA English
DT Article
DE bone targeting; ibuprofen; osteoarthritis; prodrug; dendritic aspartic
   acid
ID DRUG DELIVERY SYSTEMS; OSTEOARTHRITIS; EFFICACY; NSAIDS
AB Bone diseases, such as osteoarthritis, osteomyelitis, are notoriously difficult diseases to treat due to the comparatively low blood flows in bone tissue. Ibuprofen is a well known potent non steroid anti inflammatory drug (NSAID), which plays an important role in the treatment of osteoarthritis. However, its poor bone targeting ability hinders its further application. Herein, several novel dendritic aspartic acid modified ibuprofen prodrugs were designed and further synthesized. The stability of these prodrugs was investigated in buffer solutions and plasma, respectively. In addition, the solubility, hydroxyapatite (HAP) binding, cytotoxicity, acute toxicity, and bone targeting ability in vivo were all evaluated. All the novel prodrugs showed the superior physicochemical property in vitro. The bone targeting study in vivo provided the evidence that these prodrugs could increase ibuprofen levels in bone tissue, among which the Ibu Asp(8) showed the best affinity due to the increased aspartic acid residues conjugated to the drug. The dendritic Asp carriers were efficient as bone targeting moieties, and the conjugation with ibuprofen ensured the increased accumulation of drugs in the bone region. In general, our findings provided a novel and effective drug for the treatment of bone diseases.
C1 [Zhao, Yi; Yang, Yang] Zhengzhou Univ, Translat Med Ctr, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.
   [Zhao, Ze; Chen, Changqing; Xie, Changwei] Henan Polytech Univ, Dept Orthoped, Affiliated Hosp 1, Peoples Hosp Jiaozuo City 2, Jiaozuo 454001, Henan, Peoples R China.
   [Cui, Yamin] Zhengzhou Immuno Biotech Co Ltd, Zhengzhou 450016, Peoples R China.
C3 Zhengzhou University; Henan Polytechnic University
RP Zhao, Y; Yang, Y (通讯作者)，Zhengzhou Univ, Translat Med Ctr, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.
EM zhaoyi0910@163.com; yangyangbio@163.com
RI Yang, Yang/AED 2297 2022; zhao, zhao/JAC 1686 2023; xie,
   Changwei/AAL 6165 2021
OI Yang, Yang/0000 0001 7432 4735; 
FU National Natural Science Foundation of China [81903448, 31900502];
   Fundamental Research Funds for the Universities of Henan Province
   [NSFRF210319]
FX This w ork w as s upported b y t he N ational Natural Science Foundation
   of China (Nos. 81903448 & 31900502), the Fundamental Research Funds for
   the Universities of Henan Province (No. NSFRF210319).
CR Baranowski DC, 2018, J PAIN RES, V11, P2809, DOI 10.2147/JPR.S177967
   Barr AJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0735 x
   Cheng X, 2021, DRUG DELIV, V28, P37, DOI 10.1080/10717544.2020.1856225
   Detaille SI, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.535353
   Gordo AC, 2017, J INT MED RES, V45, P59, DOI 10.1177/0300060516673707
   Honvo G, 2019, DRUG AGING, V36, P45, DOI 10.1007/s40266 019 00661 0
   Jia HY, 2013, J PHARM SCI US, V102, P2341, DOI 10.1002/jps.23580
   Kou LF, 2019, DRUG DELIV, V26, P870, DOI 10.1080/10717544.2019.1660434
   Li C, 2019, ACTA PHARM SIN B, V9, P1145, DOI 10.1016/j.apsb.2019.08.003
   Nadar RA, 2021, MATER TODAY BIO, V9, DOI 10.1016/j.mtbio.2020.100088
   O'Connor JP, 2009, ACTA ORTHOP, V80, P597, DOI 10.3109/17453670903316769
   Paglia DN, 2021, J ORTHOP RES, V39, P2252, DOI 10.1002/jor.24937
   Sarig S, 2004, BONE, V35, P108, DOI 10.1016/j.bone.2004.02.020
   Yang Y, 2020, CHEM PHYS LIPIDS, V228, DOI 10.1016/j.chemphyslip.2020.104882
   Yu Y.K, 2021, LIFE RES, V4, P20
   Zhao Y, 2015, LETT DRUG DES DISCOV, V12, P585, DOI 10.2174/1570180812999150217171229
   Zhao Z, 2020, CHEM PHYS LIPIDS, V226, DOI 10.1016/j.chemphyslip.2019.104832
   Zhao Z, 2019, CHEM PHYS LIPIDS, V223, DOI 10.1016/j.chemphyslip.2019.104785
   Zhu X, 2020, FRONT CELL DEV BIOL, V8
NR 19
TC 2
Z9 2
U1 0
U2 15
PU POLSKIE TOWARZYSTWO FARMACEUTYCZNE
PI WARSAW
PA DLUGA 16, 00 238 WARSAW, POLAND
SN 0001 6837
EI 2353 5288
J9 ACTA POL PHARM
JI ACTA POL. PHARM.
PD MAY JUN
PY 2021
VL 78
IS 3
BP 329
EP 337
DI 10.32383/appdr/137902
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UJ5FM
UT WOS:000691310800004
OA gold
DA 2025 08 17
ER

PT J
AU Lee, DW
   Yun, YP
   Park, K
   Kim, SE
AF Lee, Deok Won
   Yun, Young Pil
   Park, Kyeongsoon
   Kim, Sung Eun
TI Gentamicin and bone morphogenic protein 2 (BMP 2) delivering
   heparinized titanium implant with enhanced antibacterial activity and
   osteointegration
SO BONE
LA English
DT Article
DE Titanium; Gentamicin; Bone morphogenic protein 2; Antibacterial
   activity; Osteointegration
ID BACTERIAL ADHESION; SURFACE FUNCTIONALIZATION; OSTEOBLAST FUNCTIONS; RGD
   PEPTIDE; IN VITRO; INFECTIONS; CHEMISTRY; COATINGS; CHITOSAN; DEFECTS
AB Insufficient bonding of implants to bone tissues and bacterial infections lead to the failure of titanium (Ti) based orthopedic and dental implants. The aim of this study is to develop novel Ti implants that enhance osteoblast functions, while simultaneously decreasing bacterial infections. First, the surface of pristine Ti was functionalized with heparin dopamine by mimicking a mussel adhesion mechanism. Gentamicin sulfate (GS) and/or bone morphogenic protein 2 (BMP 2) was then sequentially immobilized to the heparinized Ti (Hep Ti) surface. The compositions of pristine Ti and Hep Ti with or without gentamicin and/or BMP 2 were characterized by X ray photoelectron spectroscopy (XPS) and the growth of Staphylococcus aureus on the substrates was assayed. Osteoblast functions of all Ti substrates were investigated by cell proliferation assays, alkaline phosphatase (ALP) activity, and calcium deposition. The results showed that the growth of bacteria on GS/Hep Ti and GS/BMP 2/Hep Ti was significantly lower compared to that on the pristine Ti and BMP 2/Hep Ti. In addition, BMP 2/Hep Ti and GS/BMP 2/Hep Ti significantly enhanced ALP activity and calcium mineral deposition of osteoblast cells. Taken together, GS/BMP 2/Hep Ti could achieve the dual functions of excellent antibacterial activity and osteoblast function promotion. Therefore, dual drug (antibiotics and osteoinductive protein) eluting Ti substrates such as GS/BMP 2/Hep Ti are a promising material for the enhanced osteointegration and implant longevity in orthopedics and dentistry. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Park, Kyeongsoon] Korea Basic Sci Inst, Chuncheon Ctr, Div Biol Imaging, Chunchon 200701, Gangwon Do, South Korea.
   [Yun, Young Pil; Kim, Sung Eun] Korea Univ, Coll Med, Guro Hosp, Rare Dis Inst, Seoul 152703, South Korea.
   [Yun, Young Pil; Kim, Sung Eun] Korea Univ, Coll Med, Guro Hosp, Dept Orthoped Surg, Seoul 152703, South Korea.
   [Lee, Deok Won] Kyung Hee Univ, Dent Hosp Gangdong, Sch Dent, Dept Oral & Maxillofacial Surg, Seoul 134727, South Korea.
C3 Korea Basic Science Institute (KBSI); Korea University; Korea University
   Medicine (KU Medicine); Korea University; Korea University Medicine (KU
   Medicine); Kyung Hee University
RP Park, K (通讯作者)，Korea Basic Sci Inst, Chuncheon Ctr, Div Biol Imaging, 192 1 Hyoja 2 Dong, Chunchon 200701, Gangwon Do, South Korea.
EM kspark1223@hanmail.net; sekim10@korea.ac.kr
RI Kim, Miyoung/C 8316 2012; Park, Kyeongsoon/AGQ 9584 2022
OI Park, Kyeongsoon/0000 0002 8558 3983; kim, sung eun/0000 0001 9445 2451;
   
FU Ministry of Health & Welfare, Republic of Korea [A110416]
FX This study was supported by a grant of the Korea Healthcare Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea (A110416).
CR Balasundaram G, 2007, J BIOMED MATER RES A, V80A, P602, DOI 10.1002/jbm.a.30954
   Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599
   Campoccia D, 2006, BIOMATERIALS, V27, P2331, DOI 10.1016/j.biomaterials.2005.11.044
   Chua PH, 2008, BIOMATERIALS, V29, P1412, DOI 10.1016/j.biomaterials.2007.12.019
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Fan XW, 2005, J AM CHEM SOC, V127, P15843, DOI 10.1021/ja0532638
   Gay CV, 2000, POULTRY SCI, V79, P1005, DOI 10.1093/ps/79.7.1005
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Ishibe T, 2009, ORAL SURG ORAL MED O, V108, P867, DOI 10.1016/j.tripleo.2009.06.039
   Kim J, 2007, BIOMATERIALS, V28, P1830, DOI 10.1016/j.biomaterials.2006.11.050
   Kim SE, 2011, BIOMATERIALS, V32, P366, DOI 10.1016/j.biomaterials.2010.09.008
   King GN, 1997, J DENT RES, V76, P1460, DOI 10.1177/00220345970760080801
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Lee H, 2006, P NATL ACAD SCI USA, V103, P12999, DOI 10.1073/pnas.0605552103
   Lee TC, 2006, NEUROSURGERY, V58, P373, DOI 10.1227/01.NEU.0000199725.03186.F6
   MacKintosh EE, 2006, J BIOMED MATER RES A, V78A, P836, DOI 10.1002/jbm.a.30905
   Miron RJ, 2010, BIOMATERIALS, V31, P449, DOI 10.1016/j.biomaterials.2009.09.075
   MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163 7258(91)90014 D
   Oya K, 2009, BIOMATERIALS, V30, P1281, DOI 10.1016/j.biomaterials.2008.11.030
   Park JS, 2008, SMALL, V4, P1950, DOI 10.1002/smll.200701315
   Piskounova S, 2009, J BIOMED MATER RES B, V91B, P780, DOI 10.1002/jbm.b.31456
   Pohler OEM, 2000, INJURY, V31, pS7
   Puleo DA, 1999, BIOMATERIALS, V20, P2311, DOI 10.1016/S0142 9612(99)00160 X
   Rupp F, 2006, J BIOMED MATER RES A, V76A, P323, DOI 10.1002/jbm.a.30518
   Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258
   Schierholz JM, 2001, J HOSP INFECT, V49, P87, DOI 10.1053/jhin.2001.1052
   Shi ZL, 2008, J BIOMED MATER RES A, V86A, P865, DOI 10.1002/jbm.a.31648
   Shi ZL, 2009, BIOMACROMOLECULES, V10, P1603, DOI 10.1021/bm900203w
   Shi ZL, 2009, TISSUE ENG PT A, V15, P417, DOI 10.1089/ten.tea.2007.0415
   TURKSEN K, 1992, J HISTOCHEM CYTOCHEM, V40, P1339, DOI 10.1177/40.9.1506671
   van den Beucken JJJP, 2006, J CONTROL RELEASE, V113, P63, DOI 10.1016/j.jconrel.2006.03.016
   von Eiff C, 2005, DRUGS, V65, P179, DOI 10.2165/00003495 200565020 00003
   Zellin G, 1997, J BIOMED MATER RES, V35, P181
NR 33
TC 150
Z9 167
U1 2
U2 140
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2012
VL 50
IS 4
BP 974
EP 982
DI 10.1016/j.bone.2012.01.007
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 914QU
UT WOS:000301967400021
PM 22289658
DA 2025 08 17
ER

PT J
AU Cheng, X
   Cheng, G
   Xing, X
   Yin, CC
   Cheng, Y
   Zhou, X
   Jiang, S
   Tao, FH
   Deng, HB
   Li, ZB
AF Cheng, Xin
   Cheng, Gu
   Xing, Xin
   Yin, Chengcheng
   Cheng, Yuet
   Zhou, Xue
   Jiang, Shan
   Tao, Fenghua
   Deng, Hongbing
   Li, Zubing
TI Controlled release of adenosine from core shell nanofibers to promote
   bone regeneration through STAT3 signaling pathway
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Adenosine; Coaxial electrospinning; Nanofiber; Bone formation; STAT3
   signaling pathway
ID ACUTE MYOCARDIAL INFARCTION; MYENTERIC MOTONEURONS; DIFFERENTIATION;
   CELLS; A(2A); MULTICENTER; OSTEOBLASTS; FABRICATION; ACTIVATION;
   EXPRESSION
AB Adenosine (Ade) has been identified to stimulate bone formation. However, the use of Ade is severely limited by the accompanying side effects and its very short half life in vivo. This study aimed to fabricate an efficient drugdelivery system to reduce the undesirable side effects and enable the clinical application of Ade for treating large bone defects. The fabricated poly(e caprolactone) (PCL)/Ade polyvinyl alcohol (PVA)((0.3/0.4)) nanofibrous mats with 0.3:0.4 (w/w) ratio of Ade and PVA showed a sustained and controlled release of Ade and facilitated the osteogenic differentiation of bone mesenchymal progenitor cells (BMSCs). A larger amount of newly formed bone was observed in vivo in the cranial defects of the PCL/Ade PVA((0.3/0.4)) group compared with those of the non loaded PCL/PVA nanofibrous mats at 4 and 8 weeks after surgery. Moreover, it is the first time to confirm that Ade mediates the osteogenesis of rat BMSCs through the STAT3 signaling pathway and restrains the osteoclastogenesis of rat bone marrow macrophages (BMMs). These results suggested that this coaxial drug delivery system loaded with Ade provided a promising and clinically relevant platform to controlled release Ade and address large bone defects.
C1 [Cheng, Xin; Cheng, Gu; Xing, Xin; Yin, Chengcheng; Cheng, Yuet; Li, Zubing] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Key Lab Oral Biomed,Minist Educ, Wuhan 430079, Peoples R China.
   [Cheng, Gu; Deng, Hongbing] Wuhan Univ, Hubei Int Sci & Technol Cooperat Base Sustainable, Hubei Key Lab Biomass Resource Chem & Environm Bi, Sch Resource & Environm Sci, Wuhan 430079, Peoples R China.
   [Zhou, Xue] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Wuhan 430030, Peoples R China.
   [Jiang, Shan] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50014 USA.
   [Tao, Fenghua] Wuhan Univ, Renmin Hosp, Dept Orthoped, Wuhan 430060, Peoples R China.
C3 Wuhan University; Wuhan University; Huazhong University of Science &
   Technology; Iowa State University; Wuhan University
RP Li, ZB (通讯作者)，Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Key Lab Oral Biomed,Minist Educ, Wuhan 430079, Peoples R China.; Deng, HB (通讯作者)，Wuhan Univ, Hubei Int Sci & Technol Cooperat Base Sustainable, Hubei Key Lab Biomass Resource Chem & Environm Bi, Sch Resource & Environm Sci, Wuhan 430079, Peoples R China.
EM hbdeng@whu.edu.cn; lizubing@whu.edu.cn
RI ; Xing, Xin/HJP 0675 2023; Jiang, Shan/A 5059 2016; Deng,
   Hongbing/J 5318 2014; Cheng, Yuet/KUD 4809 2024; Yin,
   Chengcheng/ABH 1222 2021
OI Cheng, Yuet/0000 0003 1529 4032; Cheng, Gu/0000 0003 3203 3096; Xing,
   Xin/0000 0001 6417 0664; Deng, Hongbing/0000 0002 9784 6138; 
FU National Natural Science Foundation of China [51873157, 81771051,
   81800943]; Natural Science Foundation of Hubei Province of China
   [2018CFB497]
FX This work was mainly supported by National Natural Science Foundation of
   China (51873157, 81771051 and 81800943), and partially supported by the
   Natural Science Foundation of Hubei Province of China (No.2018CFB497).
CR Abazari MF, 2018, GENE, V671, P50, DOI 10.1016/j.gene.2018.05.115
   Aghaloo TL, 2010, J DENT RES, V89, P1293, DOI 10.1177/0022034510378427
   Boison D, 2002, P NATL ACAD SCI USA, V99, P6985, DOI 10.1073/pnas.092642899
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V561, P13, DOI 10.1016/j.abb.2014.08.009
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5
   Cheng G, 2019, ACS NANO, V13, P6372, DOI 10.1021/acsnano.8b06032
   Cheng G, 2018, INT J PHARMACEUT, V547, P656, DOI 10.1016/j.ijpharm.2018.06.020
   Cheng G, 2018, NANO RES, V11, P3658, DOI 10.1007/s12274 017 1934 3
   Cheng X, 2017, CELL BIOL INT, V41, P659, DOI 10.1002/cbin.10771
   Correia de Sá P, 2006, AUTON NEUROSCI BASIC, V126, P211, DOI 10.1016/j.autneu.2006.02.004
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Duarte Araújo M, 2004, BRIT J PHARMACOL, V141, P925, DOI 10.1038/sj.bjp.0705697
   Dunwiddie T V, 1999, Adv Neurol, V79, P1001
   Feng XR, 2019, J CONTROL RELEASE, V302, P19, DOI 10.1016/j.jconrel.2019.03.020
   Forman MB, 2006, CARDIOVASC DRUG REV, V24, P116, DOI 10.1111/j.1527 3466.2006.00116.x
   Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285
   Gharibi B, 2011, J BONE MINER RES, V26, P2112, DOI 10.1002/jbmr.424
   Gu B, 2018, J CONTROL RELEASE, V289, P35, DOI 10.1016/j.jconrel.2018.09.021
   Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687
   Kang HM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600691
   Katebi M, 2009, J LEUKOCYTE BIOL, V85, P438, DOI 10.1189/jlb.0908520
   Kolachala VL, 2008, AM J PHYSIOL GASTR L, V294, pG401, DOI 10.1152/ajpgi.00454.2007
   Kumar V, 2013, PURINERG SIGNAL, V9, P145, DOI 10.1007/s11302 012 9349 9
   Li D, 2005, SMALL, V1, P83, DOI 10.1002/smll.200400056
   Lu J, 2019, ACS APPL MATER INTER, V11, P10337, DOI 10.1021/acsami.9b01253
   Mahaffey KW, 1999, J AM COLL CARDIOL, V34, P1711, DOI 10.1016/S0735 1097(99)00418 0
   Mathews II, 1998, BIOCHEMISTRY US, V37, P15607, DOI 10.1021/bi9815445
   Mediero A, 2015, ARTHRITIS RHEUMATOL, V67, P849, DOI 10.1002/art.38971
   Mizuno M, 2001, J BIOCHEM TOKYO, V129, P133, DOI 10.1093/oxfordjournals.jbchem.a002824
   Pritchard EM, 2010, J CONTROL RELEASE, V144, P159, DOI 10.1016/j.jconrel.2010.01.035
   Ross AM, 2005, J AM COLL CARDIOL, V45, P1775, DOI 10.1016/j.jacc.2005.02.061
   Saeed SM, 2017, PROG BIOMATER, V6, P39, DOI 10.1007/s40204 017 0062 1
   Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017
   Saraf A, 2010, J CONTROL RELEASE, V143, P95, DOI 10.1016/j.jconrel.2009.12.009
   Sauer AV, 2009, BLOOD, V114, P3216, DOI 10.1182/blood 2009 03 209221
   Strazzulla LC, 2016, PURINERG SIGNAL, V12, P583, DOI 10.1007/s11302 016 9527 2
   Su Y, 2012, ACTA BIOMATER, V8, P763, DOI 10.1016/j.actbio.2011.11.002
   Suzuki S, 2013, J BIOMED MATER RES A, V101, P1345, DOI 10.1002/jbm.a.34427
   Takahama H, 2009, J AM COLL CARDIOL, V53, P709, DOI 10.1016/j.jacc.2008.11.014
   Tan YF, 2018, J CONTROL RELEASE, V284, P39, DOI 10.1016/j.jconrel.2018.06.014
   Torres Giner S, 2012, ADV ENG MATER, V14, pB112, DOI 10.1002/adem.201180006
   Wang CY, 2012, J BIOMAT SCI POLYM E, V23, P167, DOI 10.1163/092050610X545805
   Wei DX, 2018, SMALL, V14, DOI 10.1002/smll.201800063
   Wu TX, 2016, NANO RES, V9, P745, DOI 10.1007/s12274 015 0953 1
   Yegutkin GG, 2008, BBA MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
   Yoon J, 2018, ADV MATER, V30, DOI 10.1002/adma.201704765
   Yu X, 2018, BIOL CHEM, V399, P1313, DOI 10.1515/hsz 2018 0253
   Zamani M, 2013, INT J NANOMED, V8, P2997, DOI 10.2147/IJN.S43575
   Zarekhalili Z, 2017, INT J BIOL MACROMOL, V94, P679, DOI 10.1016/j.ijbiomac.2016.10.042
   Zhang Y, 2019, NANOSCALE, V11, P6315, DOI 10.1039/c8nr09818b
NR 51
TC 41
Z9 42
U1 3
U2 121
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 10
PY 2020
VL 319
BP 234
EP 245
DI 10.1016/j.jconrel.2019.12.048
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA KO4RH
UT WOS:000515538300017
PM 31899269
DA 2025 08 17
ER

PT J
AU Wang, J
   Lee, J
   Burns, D
   Doherty, D
   Brunner, L
   Peterson, M
   DeSilva, B
AF Wang, Jin
   Lee, Jean
   Burns, Daniel
   Doherty, David
   Brunner, Laura
   Peterson, Mark
   DeSilva, Binodh
TI "Fit for Purpose" Method Validation and Application of a Biomarker
   (C terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical
   Studies
SO AAPS JOURNAL
LA English
DT Article
DE bone resorption marker; commercial immunoassay kit; method validation;
   pharmacodynamic (PD) biomarker; serum C terminal telopeptides of type 1
   (CTx)
ID SERUM CROSSLAPS; BONE TURNOVER; MARKERS; SUPPORT
AB Biomarkers are used to study drug effects, exposure response relationships, and facilitate early decision making during development. Denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor kappa B ligand, profoundly inhibits bone resorption. C terminal telopeptides of type I collagen (CTx), a bone resorption biomarker, provides early indications of denosumab effectiveness and informs protracted clinical outcomes (e.g., bone mineral density). Because of the dynamic relationship between denosumab and CTx, a precise and robust assay was desired. Thus, we adopted a fit for purpose approach to modify and validate a commercial CTx diagnostic kit to meet the intended applications of a quantitative pharmacodynamic biomarker for denosumab development. Seven standards were prepared to replace five calibrators provided in the kit. Three quality controls (QC) and two sample controls were used to characterize and monitor assay performance. Robotic workstations were used for standard and QC preparation and assay execution. Method validation experiments were conducted with rigor and procedures similar to those used for drug bioanalysis. The method demonstrated a linear range of 0.0490 2.34 ng/mL with four parameter logistic regression. Inter assay total error of validation samples in serum was <= 26.7%. Extensive tests were conducted on selectivity in sera from target populations, specificity, stability, parallelism, and dilutional linearity. Applications to samples from numerous clinical studies confirmed that the CTx method was reliable, robust, and fit for use as an early indicator of denosumab effectiveness. Refinement supported the confidence for use in pharmacokinetic/pharmacodynamic modeling, dose selections, correlation to clinical effects, and formulation bioequivalence work.
C1 [Wang, Jin; Lee, Jean; Burns, Daniel; Doherty, David; Brunner, Laura; Peterson, Mark; DeSilva, Binodh] Amgen Inc, Dept PKDM, Thousand Oaks, CA 91320 USA.
C3 Amgen
RP Wang, J (通讯作者)，Amgen Inc, Dept PKDM, 1 Amgen Ctr Driver,Mail Stop 30E 3 C, Thousand Oaks, CA 91320 USA.
EM jinw@amgen.com
RI Doherty, David/U 1730 2019
OI DeSilva, Binodh/0000 0001 5404 2570
CR [Anonymous], 2001, Fed. Regist, V66, P28526
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Christgau S, 2000, BONE, V26, P505, DOI 10.1016/S8756 3282(00)00248 9
   Colburn WA, 2003, CLIN PHARMACOKINET, V42, P997, DOI 10.2165/00003088 200342120 00001
   Cremers S, 2006, DRUGS, V66, P2031, DOI 10.2165/00003495 200666160 00001
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS6
   DeSilva B, 2003, PHARM RES DORDR, V20, P1885, DOI 10.1023/B:PHAM.0000003390.51761.3d
   Findlay JWA, 2000, J PHARMACEUT BIOMED, V21, P1249, DOI 10.1016/S0731 7085(99)00244 7
   Fink E, 2000, OSTEOPOROSIS INT, V11, P295, DOI 10.1007/PL00004183
   LEE J, 2009, BIOMARKERS IN PRESS
   Lee J, 2007, AAPS J, V9, pE164, DOI 10.1208/aapsj0902018
   Lee JW, 2009, J CHROMATOGR B, V877, P1259, DOI 10.1016/j.jchromb.2008.11.022
   Lee JW, 2006, PHARM RES, V23, P312, DOI 10.1007/s11095 005 9045 3
   LEE JW, 2009, LIGAND BIND IN PRESS
   *NCCLS, 2004, C48A NCCLS
   NCCLS, 2004, EP17A NCCLS
   Rosenquist C, 1998, CLIN CHEM, V44, P2281
   Shah VP, 2007, AAPS J, V9, pE43, DOI 10.1208/aapsj0901005
   *US DEP HHS, 2001, GUID INC STAT APPR E
   Viswanathan CT, 2007, AAPS J, V9, pE30, DOI 10.1208/aapsj0901004
NR 20
TC 31
Z9 32
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1550 7416
J9 AAPS J
JI AAPS J.
PD JUN
PY 2009
VL 11
IS 2
BP 385
EP 394
DI 10.1208/s12248 009 9115 2
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 496AS
UT WOS:000269940800019
PM 19462251
OA Green Published
DA 2025 08 17
ER

PT J
AU Meads, MB
   Hazlehurst, LA
   Dalton, WS
AF Meads, Mark B.
   Hazlehurst, Lori A.
   Dalton, William S.
TI The bone marrow microenvironment as a tumor sanctuary and contributor to
   drug resistance
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CXCR4 CHEMOKINE RECEPTOR; PROSTATE CANCER METASTASIS; ENDOTHELIAL
   GROWTH FACTOR; CELL CYCLE ARREST; MULTIPLE MYELOMA; SMALL MOLECULE;
   STEM CELLS; MELPHALAN RESISTANCE; INTEGRIN EXPRESSION; CONFERS
   RESISTANCE
AB The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of hematopoietic cells. These cells are supported by fibroblast like bone marrow stromal cells, osteoblasts, and osteoclasts which secrete soluble factors and extracellular matrix proteins that mediate these functions. This rich environment serves as a safe haven not only for normal and malignant hematopoietic cells, but also for epithelial tumor cells that metastasize to bone, offering protection from chemotherapeutic agents by common mechanisms. Soluble factors produced in the bone marrow, such as stromal cell   derived factor 1 and interleukin 6, mediate homing, survival, and proliferation of tumor cells, and integrin mediated adhesion sequesters tumor cells to this protective niche. Environment mediated drug resistance includes a combination of soluble factors and adhesion, and can be subdivided into soluble factor   mediated drug resistance and cell adhesion   mediated drug resistance. Because it is induced immediately by the microenvironment and is independent of epigenetic or genetic changes caused by the selective pressure of drug exposure, environment mediated drug resistance is a form of de novo drug resistance. In this form of drug resistance, tumor cells are transiently and reversibly protected from apoptosis induced by both chemotherapy and physiologic mediators of cell death. This protection allows tumor cells to survive the insult of chemotherapy, leading to minimal residual disease, and thereby increases the probability for the development of acquired drug resistance.
C1 [Meads, Mark B.; Hazlehurst, Lori A.; Dalton, William S.] H Lee Moffitt Canc Ctr & Res Inst, Dept Expt Therapeut, Tampa, FL 33612 USA.
C3 H Lee Moffitt Cancer Center & Research Institute
RP Dalton, WS (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Expt Therapeut, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM William.Dalton@moffitt.org
OI Hazlehurst, Lori/0000 0001 7040 4084
CR Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood 2006 07 035857
   Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554
   Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633
   Arnulf B, 2007, LEUKEMIA, V21, P158, DOI 10.1038/sj.leu.2404466
   BELLAMY WT, 1991, CANCER RES, V51, P995
   Bisping G, 2006, BLOOD, V107, P2079, DOI 10.1182/blood 2004 11 4250
   Bisping G, 2003, BLOOD, V101, P2775, DOI 10.1182/blood 2002 09 2907
   Borsellino N, 1999, CANCER, V85, P134, DOI 10.1002/(SICI)1097 0142(19990101)85:1<134::AID CNCR19>3.3.CO;2 3
   Burger JA, 2000, BLOOD, V96, P2655
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood 2005 08 3182
   Burger JA, 2007, BRIT J HAEMATOL, V137, P288, DOI 10.1111/j.1365 2141.2007.06590.x
   Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood 2004 12 4918
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Catlett Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074 7613(00)80011 4
   Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood 2004 11 4286
   Cheung WC, 2002, LEUKEMIA, V16, P1182, DOI 10.1038/sj.leu.2402481
   COLDMAN AJ, 1986, B MATH BIOL, V48, P279, DOI 10.1016/S0092 8240(86)90028 5
   Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224
   Cortijo J, 2006, BRIT J PHARMACOL, V147, P661, DOI 10.1038/sj.bjp.0706658
   Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Domingo Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078 0432.CCR 05 2767
   Duan ZF, 2006, CLIN CANCER RES, V12, P5055, DOI 10.1158/1078 0432.CCR 06 0861
   Edlund M, 2001, CELL GROWTH DIFFER, V12, P99
   Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483
   Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173
   Gläsner J, 2005, J IMMUNOL, V175, P4724, DOI 10.4049/jimmunol.175.7.4724
   Golay J, 2007, LEUKEMIA, V21, P1892, DOI 10.1038/sj.leu.2404860
   Gruber G, 2005, BRIT J CANCER, V92, P41, DOI 10.1038/sj.bjc.6602278
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   HARDIN J, 1994, BLOOD, V84, P3063
   Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621
   Hazlehurst LA, 2007, BRIT J HAEMATOL, V136, P269, DOI 10.1111/j.1365 2141.2006.06435.x
   Hazlehurst LA, 2006, CANCER RES, V66, P2338, DOI 10.1158/0008 5472.CAN 05 3256
   Hazlehurst LA, 2003, CANCER RES, V63, P7900
   Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897
   Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782
   Hobisch A, 1998, CANCER RES, V58, P4640
   Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849
   Hoyt DG, 1996, CANCER RES, V56, P4146
   Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098
   JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090 4295(83)90147 4
   Juarez J, 2007, LEUKEMIA, V21, P1249, DOI 10.1038/sj.leu.2404684
   Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood 2003 07 2254
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863
   LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076
   Lu Y, 2004, CLIN EXP METASTAS, V21, P399, DOI 10.1007/s10585 005 0056 6
   Lwin T, 2007, BLOOD, V110, P1631, DOI 10.1182/blood 2006 11 060350
   Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909
   Matsuura N, 1996, AM J PATHOL, V148, P55
   McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood 2003 07 2340
   Oshita F, 2004, AM J CLIN ONCOL CANC, V27, P215, DOI 10.1097/01.COC.0000054894.64867.80
   Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008 5472.CAN 05 3071
   Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357
   Sanz Rodríguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346
   SCHADENDORF D, 1993, J PATHOL, V170, P429, DOI 10.1002/path.1711700405
   Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511
   Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544
   Spiegel A, 2004, BLOOD, V103, P2900, DOI 10.1182/blood 2003 06 1891
   Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477 7827 2 2
   Stupp R, 2007, J CLIN ONCOL, V25, P1637, DOI 10.1200/JCO.2006.09.8376
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Taichman RS, 2002, CANCER RES, V62, P1832
   Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008 5472.CAN 03 3693
   Theien BE, 2003, BLOOD, V102, P4464, DOI 10.1182/blood 2003 03 0974
   Uchida D, 2007, MOL CANCER RES, V5, P685, DOI 10.1158/1541 7786.MCR 06 0368
   Voorhees PM, 2007, CLIN CANCER RES, V13, P6469, DOI 10.1158/1078 0432.CCR 07 1293
   Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595
   White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025
   Wimberger P, 2007, GYNECOL ONCOL, V107, P331, DOI 10.1016/j.ygyno.2007.07.073
   Yanamandra N, 2006, CLIN CANCER RES, V12, P591, DOI 10.1158/1078 0432.CCR 05 1792
   Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008 5472.CAN 06 2768
   Yoon Y, 2007, CANCER RES, V67, P7518, DOI 10.1158/0008 5472.CAN 06 2263
   Zeng Z, 2006, MOL CANCER THER, V5, P3113, DOI 10.1158/1535 7163.MCT 06 0228
   Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008 5472.CAN 06 4499
   Zheng DQ, 1999, CANCER RES, V59, P1655
NR 81
TC 448
Z9 505
U1 0
U2 59
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2008
VL 14
IS 9
BP 2519
EP 2526
DI 10.1158/1078 0432.CCR 07 2223
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 297KT
UT WOS:000255616300001
PM 18451212
DA 2025 08 17
ER

PT J
AU Saito, M
   Moore Lotridge, SN
   Uppuganti, S
   Egawa, S
   Yoshii, T
   Robinette, JP
   Posey, SL
   Gibson, BHY
   Cole, HA
   Hawley, GD
   Guelcher, SA
   Tanner, SB
   McCarthy, JR
   Nyman, JS
   Schoenecker, JG
AF Saito, M.
   Moore Lotridge, S. N.
   Uppuganti, S.
   Egawa, S.
   Yoshii, T.
   Robinette, J. P.
   Posey, S. L.
   Gibson, B. H. Y.
   Cole, H. A.
   Hawley, G. D.
   Guelcher, S. A.
   Tanner, S. B.
   McCarthy, J. R.
   Nyman, J. S.
   Schoenecker, J. G.
TI Determining the pharmacologic window of bisphosphonates that mitigates
   severe injury induced osteoporosis and muscle calcification, while
   preserving fracture repair
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bisphosphonate; Fracture; Osteoporosis; Polytrauma; Severe injury;
   Skeletal muscle calcification
ID HETEROTOPIC OSSIFICATION; ZOLEDRONIC ACID; DYSTROPHIC CALCIFICATION;
   BONE; PYROPHOSPHATE; PREVALENCE; PREVENTION; RESORPTION; MORTALITY;
   DISODIUM
AB Following severe injury, biomineralization is disrupted and limited therapeutic options exist to correct these pathologic changes. This study utilized a clinically relevant murine model of polytrauma including a severe injury with concomitant musculoskeletal injuries to identify when bisphosphonate administration can prevent the paradoxical decrease of biomineralization in bone and increased biomineralization in soft tissues, yet not interfere with musculoskeletal repair. Introduction Systemic and intrinsic mechanisms in bone and soft tissues help promote biomineralization to the skeleton, while preventing it in soft tissues. However, severe injury can disrupt this homeostatic biomineralization tropism, leading to adverse patient outcomes due to a paradoxical decrease of biomineralization in bone and increased biomineralization in soft tissues. There remains a need for therapeutics that restore the natural tropism of biomineralization in severely injured patients. Bisphosphonates can elicit potent effects on biomineralization, though with variable impact on musculoskeletal repair. Thus, a critical clinical question remains as to the optimal time to initiate bisphosphonate therapy in patients following a polytrauma, in which bone and muscle are injured in combination with a severe injury, such as a burn. Methods To test the hypothesis that the dichotomous effects of bisphosphonates are dependent upon the time of administration relative to the ongoing biomineralization in reparative bone and soft tissues, this study utilized murine models of isolated injury or polytrauma with a severe injury, in conjunction with sensitive, longitudinal measure of musculoskeletal repair. Results This study demonstrated that if administered at the time of injury, bisphosphonates prevented severe injury induced bone loss and soft tissue calcification, but did not interfere with bone repair or remodeling. However, if administered between 7 and 21 days post injury, bisphosphonates temporally and spatially localized to sites of active biomineralization, leading to impaired fracture callus remodeling and permanence of soft tissue calcification. Conclusion There is a specific pharmacologic window following polytrauma that bisphosphonates can prevent the consequences of dysregulated biomineralization, yet not impair musculoskeletal regeneration.
C1 [Saito, M.; Moore Lotridge, S. N.; Uppuganti, S.; Egawa, S.; Gibson, B. H. Y.; Hawley, G. D.; Nyman, J. S.; Schoenecker, J. G.] Vanderbilt Univ, Med Ctr, Dept Orthopaed & Rehabil, Nashville, TN 37232 USA.
   [Saito, M.; Egawa, S.; Yoshii, T.] Tokyo Med & Dent Univ, Dept Orthopaed Surg, Tokyo, Japan.
   [Moore Lotridge, S. N.; Guelcher, S. A.; Nyman, J. S.; Schoenecker, J. G.] Vanderbilt Univ, Med Ctr, Ctr Bone Biol, Nashville, TN 37232 USA.
   [Robinette, J. P.; Posey, S. L.] Vanderbilt Univ, Med Ctr, Sch Med, Nashville, TN USA.
   [Gibson, B. H. Y.; Schoenecker, J. G.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, 2215 B Garland Ave,1155 Med Res Bldg 4, Nashville, TN 37232 USA.
   [Cole, H. A.] Vanderbilt Univ, Dept Nucl Med, Med Ctr, Nashville, TN USA.
   [Guelcher, S. A.; Nyman, J. S.] Vanderbilt Univ, Dept Biomed Engn, Med Ctr, Nashville, TN 37232 USA.
   [Guelcher, S. A.] Vanderbilt Univ, Dept Chem & Biomol Engn, Med Ctr, Nashville, TN USA.
   [Tanner, S. B.; Schoenecker, J. G.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.
   [Tanner, S. B.] Vanderbilt Univ, Med Ctr, Dept Allergy Pulm & Crit Care, Nashville, TN USA.
   [McCarthy, J. R.] Masonic Med Res Inst, Dept Biomed Res & Translat Med, 2150 Bleecker St, Utica, NY 13501 USA.
   [Nyman, J. S.] Tennessee Valley Hlth Care Syst, Dept Vet Affairs, 1215 21st Ave S,Suite 4200, Nashville, TN 37232 USA.
   [Schoenecker, J. G.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
   [Schoenecker, J. G.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
C3 Vanderbilt University; Institute of Science Tokyo; Tokyo Medical &
   Dental University (TMDU); Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Masonic Medical Research Laboratory; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Tennessee Valley Healthcare
   System; Vanderbilt University; Vanderbilt University
RP Nyman, JS; Schoenecker, JG (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Orthopaed & Rehabil, Nashville, TN 37232 USA.; Nyman, JS; Schoenecker, JG (通讯作者)，Vanderbilt Univ, Med Ctr, Ctr Bone Biol, Nashville, TN 37232 USA.; Schoenecker, JG (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pharmacol, 2215 B Garland Ave,1155 Med Res Bldg 4, Nashville, TN 37232 USA.; Nyman, JS (通讯作者)，Vanderbilt Univ, Dept Biomed Engn, Med Ctr, Nashville, TN 37232 USA.; Schoenecker, JG (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.; Nyman, JS (通讯作者)，Tennessee Valley Hlth Care Syst, Dept Vet Affairs, 1215 21st Ave S,Suite 4200, Nashville, TN 37232 USA.; Schoenecker, JG (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Schoenecker, JG (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
EM Jeffry.s.nyman@vanderbilt.edu; Jon.schoenecker@vumc.org
RI ; Tanner, S Bobo/ABX 4750 2022; Yoshii, Toshitaka/HTL 9865 2023; Saito,
   Masanori/GRR 1714 2022; Nyman, Jeffry/L 5736 2013; Tanner,
   S./KLD 4521 2024
OI Egawa, Satoru/0000 0001 9367 3906; Tanner, S Bobo/0000 0001 5070 5154;
   Moore Lotridge, Stephanie/0000 0002 3045 4199; Posey,
   Samuel/0000 0002 7794 0944; Saito, Masanori/0000 0002 4139 4013;
   Uppuganti, Sasidhar/0000 0002 0656 2122; Schoenecker,
   Jonathan/0000 0002 3097 5496; Gibson, Breanne/0000 0002 2196 8219;
   Robinette, Patton/0000 0002 3765 6754; Nyman,
   Jeffry/0000 0001 7403 7605; 
FU National Institutes of Health [1R01GM126062 01A1, T32GM007628,
   T32AR059039, 1F31HL149340]; Vanderbilt University Medical Center
   Department of Orthopaedics and Rehabilitation; Jeffrey W. Mast Chair in
   Orthopaedics Trauma and Hip Surgery; Department of Veterans Affairs
   [BX005062]; Caitlin Lovejoy Fund; NCI/NIH Cancer Center Support Grant
   [2P30 CA06848514]; Vanderbilt Mouse Metabolic Phenotyping Center Grant
   [5U24DK059637 13]; Center for Small Animal Imaging at the Vanderbilt
   University Institute of Imaging Sciences from the NIH [S10RR027631];
   Replacement and Upgrade of an Optical Imaging System for Small Animals
   in the Vanderbilt Center for Small Animal Imaging [1S10OD021804 01A1];
   National Heart Lung and Blood Institute [F31HL149340] Funding Source:
   NIH RePORTER; National Institute of General Medical Sciences
   [T32GM007628] Funding Source: NIH RePORTER; Grants in Aid for Scientific
   Research [20KK0205] Funding Source: KAKEN
FX Funding for this work was provided by the National Institutes of Health
   ([1R01GM126062 01A1, NIGMS, JGS], [T32GM007628, NIGMS, SNML],
   [T32AR059039, NIAMS, BGHY], [1F31HL149340, NHLBI, BGHY]), the Vanderbilt
   University Medical Center Department of Orthopaedics and Rehabilitation
   (JGS), the Jeffrey W. Mast Chair in Orthopaedics Trauma and Hip Surgery
   (JGS), the Department of Veterans Affairs (JSN, BX005062), and the
   Caitlin Lovejoy Fund (JGS). Use of the Translational Pathology Shared
   Resource was supported by NCI/NIH Cancer Center Support Grant (2P30
   CA06848514) and the Vanderbilt Mouse Metabolic Phenotyping Center Grant
   (5U24DK059637 13). mu CT imaging and analysis were supported in part by
   the Center for Small Animal Imaging at the Vanderbilt University
   Institute of Imaging Sciences (S10RR027631) from the NIH. Grant
   1S10OD021804 01A1 supported the Replacement and Upgrade of an Optical
   Imaging System for Small Animals, housed in the Vanderbilt Center for
   Small Animal Imaging, and used in this proposal. Funding sources for
   this project had no involvement in study design, collection, and
   analysis of data, writing of the report, or decision in submitting this
   article for publication.
CR Aherrahrou Z, 2008, J BIOL CHEM, V283, P7608, DOI 10.1074/jbc.M708290200
   Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Bajwa NM, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00115
   Baker CE, 2018, CLIN REV BONE MINER, V16, P142, DOI 10.1007/s12018 018 9256 x
   Bukata SV, 2011, INJURY, V42, P605, DOI 10.1016/j.injury.2011.03.061
   CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   El Masry MA, 2005, J BONE JOINT SURG BR, V87B, P1272, DOI 10.1302/0301 620X.87B9.16631
   Eriksen EF, 2009, J BONE MINER RES, V24, P1308, DOI [10.1359/JBMR.090209, 10.1359/jbmr.090209]
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Gibson BHY, 2020, RES PRACT THROMB HAE, V4, P469, DOI 10.1002/rth2.12355
   JAY MS, 1981, CLIN PEDIATR, V20, P734, DOI 10.1177/000992288102001108
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Klein GL, 2005, OSTEOPOROSIS INT, V16, P631, DOI 10.1007/s00198 004 1731 1
   Klein GL, 2014, BISPHOSPHONATES PEDI, P101, DOI [10.1007/978 1 4899 7436 5, DOI 10.1007/978 1 4899 7436 5]
   Klein GL, 2021, OSTEOLOGY, V1, P73, DOI [10.3390/osteology1020007, DOI 10.3390/OSTEOLOGY1020007]
   Klein GL, 2020, BONE, V132, DOI 10.1016/j.bone.2019.115194
   Korff S, 2006, VIRCHOWS ARCH, V448, P630, DOI 10.1007/s00428 005 0071 7
   Korff S, 2006, PHYSIOL GENOMICS, V25, P387, DOI 10.1152/physiolgenomics.00010.2006
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Li Qiaoli, 2018, Oncotarget, V9, P30721, DOI 10.18632/oncotarget.10738
   Li YT, 2015, OSTEOPOROSIS INT, V26, P431, DOI 10.1007/s00198 014 2903 2
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Matos MA, 2010, J ORTHOP TRAUMATOL, V11, P7, DOI 10.1007/s10195 010 0083 1
   Mignemi NA, 2017, J BONE MINER RES, V32, P294, DOI 10.1002/jbmr.2973
   Moore SN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159624
   Moore SN, 2015, CELL CYCLE, V14, P1354, DOI 10.1080/15384101.2015.1024585
   Moore Lotridge SN, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2020.100743
   Moore Lotridge SN, 2019, CALCIFIED TISSUE INT, V104, P411, DOI 10.1007/s00223 018 0502 5
   RIFKIN BR, 1979, CELL TISSUE RES, V202, P125
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   RUSSELL RGG, 1970, P ROY SOC MED, V63, P876, DOI 10.1177/003591577006300906
   Scarvell JM, 2013, PHYSICIAN SPORTSMED, V41, P38, DOI 10.3810/psm.2013.05.2011
   Shafer DM, 2008, BURNS, V34, P355, DOI 10.1016/j.burns.2007.04.006
   Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019
   Smith E, 2016, IRISH J MED SCI, V185, P473, DOI 10.1007/s11845 016 1399 5
   SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539
   Tanner S Bobo, 2011, Curr Osteoporos Rep, V9, P156, DOI 10.1007/s11914 011 0061 4
   Ubellacker JM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0815 8
   Yuasa M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198088
   Yuasa M, 2015, J CLIN INVEST, V125, P3117, DOI 10.1172/JCI80313
   Yuasa M, 2014, BONE, V67, P208, DOI 10.1016/j.bone.2014.07.002
NR 44
TC 7
Z9 7
U1 0
U2 3
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD APR
PY 2022
VL 33
IS 4
BP 807
EP 820
DI 10.1007/s00198 021 06208 7
EA OCT 2021
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZV2GU
UT WOS:000713078200001
PM 34719727
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Heo, G
   Jeong, S
   Park, S
   Kim, SJ
   Lee, Y
   Woo, SJ
   Kim, K
   Park, BH
   Rhee, SH
   Im, E
AF Heo, Gwangbeom
   Jeong, Sihyun
   Park, Soyeong
   Kim, Su Jin
   Lee, Yunna
   Woo, Seong Ji
   Kim, Kyunghwan
   Park, Byung Hyun
   Rhee, Sang Hoon
   Im, Eunok
TI Myeloid specific deletion of autotaxin inhibits rheumatoid arthritis and
   osteoclastogenesis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE rheumatoid arthritis; autotaxin; lipid rafts; osteoclastogenesis;
   collagen induced arthritis
ID TOLL LIKE RECEPTORS; LIPID RAFTS; SYNOVIAL TISSUE; TOLL LIKE RECEPTOR 4;
   EXPRESSION; LIPOPOLYSACCHARIDE; DIFFERENTIATION; CHOLESTEROL;
   MACROPHAGES; RELEVANCE
AB Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint swelling, pain, and bone remodeling. We previously reported that autotaxin (ATX) deficiency disrupts lipid rafts in macrophages. Lipid raft disruption results in the dysregulation of RANK signaling, which is crucial for osteoclastogenesis and the pathogenesis of RA. Therefore, we evaluated the effect of ATX deficiency on joint inflammation and osteoclast differentiation. A collagen induced arthritis mouse model was used with myeloid lineage restricted Atx knockout (Atx(Delta ME/Delta ME)) mice and DBA/1 mice treated with the ATX inhibitor PF 8380. Joint inflammation and bone erosion were visualized using hematoxylin and eosin staining and micro computed tomography. Osteoclast differentiation was assessed by tartrate resistant acid phosphatase staining. ATX deficiency suppressed joint inflammation, bone resorption, osteoclast differentiation, and pro inflammatory protein expression in both Atx(Delta ME/Delta ME) mice and PF 8380 treated mice compared to controls. Mean disease score of Atx(+/+) mice at the end of experiment was 3.813, but that of Atx(Delta ME/Delta ME) was 0.185 (p < 0.05). The differentiation of bone marrow derived macrophages into osteoclasts was reduced in Atx(Delta ME/Delta ME) cells compared to Atx(+/+) cells. ATX deficiency suppressed RANKL induced phosphorylation of ERK and Akt and the interaction between RANK and TRAF6. ATX deficiency disrupted lipid rafts and dysregulated RANK distribution in RAW264.7 cells. Actin ring formation was also inhibited in Atx(Delta ME/Delta ME) osteoclasts. ATX deficiency suppressed RA and osteoclast differentiation by disrupting lipid rafts and altering the RANK signaling pathway. This suggests that ATX inhibition may be an effective strategy for developing new disease modifying antirheumatic drugs.
C1 [Heo, Gwangbeom; Jeong, Sihyun; Park, Soyeong; Kim, Su Jin; Lee, Yunna; Im, Eunok] Pusan Natl Univ, Coll Pharm, Dept Pharm, Pusan, South Korea.
   [Heo, Gwangbeom; Park, Soyeong; Lee, Yunna; Im, Eunok] Pusan Natl Univ, Res Inst Drug Dev, Pusan, South Korea.
   [Woo, Seong Ji; Park, Byung Hyun] Chonbuk Natl Univ, Dept Biochem & Mol Biol, Med Sch, Jeonju, South Korea.
   [Kim, Kyunghwan] Chungbuk Natl Univ, Dept Biol Sci & Biotechnol, Cheongju, South Korea.
   [Rhee, Sang Hoon] Oakland Univ, Dept Biol Sci, Rochester, MI USA.
C3 Pusan National University; Pusan National University; Jeonbuk National
   University; Chungbuk National University; Oakland University
RP Im, E (通讯作者)，Pusan Natl Univ, Coll Pharm, Dept Pharm, Pusan, South Korea.; Im, E (通讯作者)，Pusan Natl Univ, Res Inst Drug Dev, Pusan, South Korea.
EM eoim@pusan.ac.kr
FU National Research Foundation of Korea (NRF)   Korean government (MSIT)
   [NRF 2022R1A2C1012377]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This work was supported
   by a National Research Foundation of Korea (NRF) grant funded by the
   Korean government (MSIT) (No. NRF 2022R1A2C1012377 to EI).
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Abdollahi Roodsaz S, 2007, ARTHRITIS RHEUM, V56, P2957, DOI 10.1002/art.22848
   Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Allen A, 2018, BMJ BRIT MED J, V362, DOI 10.1136/bmj.k3015
   Almutairi K, 2021, RHEUMATOL INT, V41, P863, DOI 10.1007/s00296 020 04731 0
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bernhardt A, 2017, EUR CELLS MATER, V33, P28, DOI 10.22203/eCM.v033a03
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Crane JM, 2004, BIOPHYS J, V86, P2965, DOI 10.1016/S0006 3495(04)74347 7
   Douaisi M, 2017, J IMMUNOL, V198, P2310, DOI 10.4049/jimmunol.1500350
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Flammier S, 2019, ARTHRITIS RHEUMATOL, V71, P1801, DOI 10.1002/art.41005
   Gierse J, 2010, J PHARMACOL EXP THER, V334, P310, DOI 10.1124/jpet.110.165845
   Guo LZ, 2024, STEM CELL REV REP, V20, P1971, DOI 10.1007/s12015 024 10759 7
   Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200
   Ha H, 2003, EXP MOL MED, V35, P279, DOI 10.1038/emm.2003.38
   Han GH, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010017
   Huang QQ, 2007, ARTHRITIS RHEUM US, V56, P2192, DOI 10.1002/art.22707
   Hunter TM, 2017, RHEUMATOL INT, V37, P1551, DOI 10.1007/s00296 017 3726 1
   Hussein R, 2022, BIOCHEM BIOPHYS REP, V32, DOI 10.1016/j.bbrep.2022.101373
   Inglis JJ, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2319
   Iwahashi M, 2004, ARTHRITIS RHEUM US, V50, P1457, DOI 10.1002/art.20219
   Keune WJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11248
   Kim SJ, 2020, EMBO REP, V21, DOI 10.15252/embr.201949332
   Köhler BM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070938
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Miyabe Y, 2013, ARTHRITIS RHEUM US, V65, P2037, DOI 10.1002/art.37991
   Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092 8674(03)00882 1
   Nikitopoulou I, 2012, J EXP MED, V209, P923, DOI 10.1084/jem.20112012
   Noailles A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0355 x
   Nothdurfter C, 2007, NAT REV NEUROSCI, V8
   Oike T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11233 w
   Panagopoulos PK, 2018, J MUSCULOSKEL NEURON, V18, P304
   Perrakis A, 2014, J LIPID RES, V55, P1010, DOI 10.1194/jlr.R046391
   Radstake TRDJ, 2004, ARTHRITIS RHEUM US, V50, P3856, DOI 10.1002/art.20678
   Ray R, 2017, BLOOD, V129, P1177, DOI 10.1182/blood 2016 10 743757
   Roelofs MF, 2005, ARTHRITIS RHEUM, V52, P2313, DOI 10.1002/art.21278
   Salgado Polo F, 2019, CANCERS, V11, DOI 10.3390/cancers11101577
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shi JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01849
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Umezu Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Woo SJ, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.124
   Yoon D, 2024, BMC MED, V22, DOI 10.1186/s12916 024 03342 x
   Zidovetzki R, 2007, BBA BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026
NR 54
TC 1
Z9 1
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 18
PY 2024
VL 15
AR 1481699
DI 10.3389/fimmu.2024.1481699
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA R1N6D
UT WOS:001389207700001
PM 39744622
OA gold
DA 2025 08 17
ER

PT J
AU Munisso, MC
   Kang, JH
   Tsurufuji, M
   Yamaoka, T
AF Munisso, Maria Chiara
   Kang, Jeong Hun
   Tsurufuji, Makoto
   Yamaoka, Tetsuji
TI Cilomilast enhances osteoblast differentiation of mesenchymal stem cells
   and bone formation induced by bone morphogenetic protein 2
SO BIOCHIMIE
LA English
DT Article
DE Bone morphogenetic protein 2; Phosphodiesterase 4 inhibitor; Cilomilast;
   Rolipram; Osteoblastic differentiation
ID PHOSPHODIESTERASE INHIBITOR; DIMETHYL SULFOXIDE; EXPRESSION; INDUCTION;
   ROLIPRAM; CBFA1
AB A rapid and efficient method to stimulate bone regeneration would be useful in orthopaedic stem cell therapies. Rolipram is an inhibitor of phosphodiesterase 4 (PDE4), which mediates cyclic adenosine monophosphate (cAMP) degradation. Systemic injection of rolipram enhances osteogenesis induced by bone morphogenetic protein 2 (BMP 2) in mice. However, there is little data on the precise mechanism, by which the PDE4 inhibitor regulates osteoblast gene expression. In this study, we investigated the combined ability of BMP 2 and cilomilast, a second generation PDE4 inhibitor, to enhance the osteoblastic differentiation of mesenchymal stem cells (MSCs). The alkaline phosphatase (ALP) activity of MSCs treated with PDE4 inhibitor (cilomilast or rolipram), BMP 2, and/or H89 was compared with the ALP activity of MSCs differentiated only by osteogenic medium (OM). Moreover, expression of Runx2, osterix, and osteocalcin was quantified using real time polymerase chain reaction (RT PCR). It was found that cilomilast enhances the osteoblastic differentiation of MSCs equally well as rolipram in primary cultured MSCs. Moreover, according to the H89 inhibition experiments, Smad pathway was found to be an important signal transduction pathway in mediating the osteogenic effect of BMP 2, and this effect is intensified by an increase in cAMP levels induced by PDE4 inhibitor. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Munisso, Maria Chiara; Kang, Jeong Hun; Yamaoka, Tetsuji] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, Suita, Osaka 5658565, Japan.
   [Tsurufuji, Makoto] Mitsubishi Chem Corp, R&D Strategy Dept, Corp Strategy Div, Minato Ku, Tokyo 1080014, Japan.
   [Yamaoka, Tetsuji] JST CREST, Chiyoda Ku, Tokyo 1020075, Japan.
C3 National Cerebral & Cardiovascular Center   Japan; Mitsubishi
   International Corporation (MIC); Mitsubishi Chemical Holdings
   Corporation; Mitsubishi Chemical
RP Yamaoka, T (通讯作者)，Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, Suita, Osaka 5658565, Japan.
EM yamtet@ri.ncvc.go.jp
RI Munisso, Maria Chiara/GXV 5409 2022
OI Munisso, Maria Chiara/0000 0003 1616 4934; Kang,
   Jeong Hun/0000 0001 9229 3063
CR Cheung WMW, 2006, FEBS LETT, V580, P121, DOI 10.1016/j.febslet.2005.11.062
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Horiuchi H, 2002, BONE, V30, P589, DOI 10.1016/S8756 3282(02)00681 6
   Horiuchi H, 2001, BONE, V28, P290, DOI 10.1016/S8756 3282(00)00450 6
   Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200
   Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891 2905.2001
   Kaback LA, 2008, J CELL PHYSIOL, V214, P173, DOI 10.1002/jcp.21176
   Kinoshita T, 2000, BONE, V27, P811, DOI 10.1016/S8756 3282(00)00395 1
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Miyamoto K, 1997, BIOCHEM PHARMACOL, V54, P613, DOI 10.1016/S0006 2952(97)00211 6
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Qin L, 2005, J CELL BIOCHEM, V96, P632, DOI 10.1002/jcb.20550
   Rawadi G, 2001, ENDOCRINOLOGY, V142, P4673, DOI 10.1210/en.142.11.4673
   Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006 2952(03)00002 9
   Stephen A.S., 2011, J BIOL CHEM
   Sugama R, 2006, BONE, V38, P206, DOI 10.1016/j.bone.2005.08.006
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Waki Y, 1999, JPN J PHARMACOL, V79, P477, DOI 10.1254/jjp.79.477
NR 22
TC 10
Z9 13
U1 0
U2 12
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD NOV
PY 2012
VL 94
IS 11
BP 2360
EP 2365
DI 10.1016/j.biochi.2012.05.031
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 035FQ
UT WOS:000310929200016
PM 22706281
DA 2025 08 17
ER

PT J
AU Dunford, JE
   Kwaasi, AA
   Rogers, MJ
   Barnett, BL
   Ebetino, FH
   Russell, RGG
   Oppermann, U
   Kavanagh, KL
AF Dunford, James E.
   Kwaasi, Aaron A.
   Rogers, Michael J.
   Barnett, Bobby L.
   Ebetino, Frank H.
   Russell, R. Graham G.
   Oppermann, Udo
   Kavanagh, Kathryn L.
TI Structure activity relationships among the nitrogen containing
   bisphosphonates in clinical use and other analogues: Time dependent
   inhibition of human farnesyl pyrophosphate synthase
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HETEROCYCLE CONTAINING BISPHOSPHONATES; DIPHOSPHATE SYNTHASE;
   BONE RESORPTION; IN VIVO; SUBSTRATE BINDING; MECHANISM;
   PRENYLTRANSFERASE; OSTEOPOROSIS; ALENDRONATE; RESIDUES
AB The nitrogen containing bisphosphonates (N BPs) are the main drugs currently used to treat diseases characterized by excessive bone resorption. The major molecular target of N BPs is farnesylpyrophosphate synthase. N BPs inhibit the enzyme by a mechanism that involves time dependent isomerization of the enzyme. We investigated features of N BPs that confer maximal slow and tight binding by quantifying the initial and final K(i)s and calculating the isomerization constant K isom, for many N BPs. Disruption of the phosphonate carbon phosphonate backbone resulted in loss of potency and reduced K isom. The lack of a,hydroxyl group on the gerninal carbon also reduced K isom. The position of the nitrogen in the side chain was crucial to both Ki and K isom. A correlation of K isom and also final K i with previously published in vivo potency reveals that the isomerization constant (R =  0.77, p < 0.0001) and the final inhibition of FPPS by N BPs (R = 0.74, p < 0.0001) are closely linked to antiresorptive efficacy.
C1 [Dunford, James E.; Kwaasi, Aaron A.; Russell, R. Graham G.] Univ Oxford, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Inst Musculoskeletal Sci,Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
   [Dunford, James E.; Kwaasi, Aaron A.; Oppermann, Udo; Kavanagh, Kathryn L.] Univ Oxford, Botnar Res Ctr, Struct Genom Consortium, Oxford OX3 7LD, England.
   [Rogers, Michael J.] Univ Aberdeen, Inst Med Sci, Bone & Musculoskeletal Res Programme, Aberdeen AB25 2ZD, Scotland.
   [Barnett, Bobby L.] Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA.
   [Ebetino, Frank H.] Procter & Gamble Pharmaceuticals, Mason, OH 45040 USA.
   [Kavanagh, Kathryn L.] Univ Texas Austin, Dept Chem & Biochem, Austin, TX 78712 USA.
C3 University of Oxford; Nuffield Orthopaedic Centre; University of Oxford;
   University of Aberdeen; University System of Ohio; University of
   Cincinnati; Procter & Gamble; University of Texas System; University of
   Texas Austin
RP Dunford, JE (通讯作者)，Univ Oxford, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Inst Musculoskeletal Sci,Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
EM james.dunford@ndos.ox.ac.uk
RI ; Russell, Robert Graham G/JEF 5877 2023; Russell, R/JEF 5877 2023
OI Dunford, James/0000 0002 9932 4042; Russell, Robert Graham
   G/0000 0002 4136 1828; Rogers, Michael/0000 0002 1818 9249
FU Wellcome Trust Funding Source: Medline
CR Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   COPELAND RA, 2000, ENZYMES PRACTICAL GU
   Cosman F, 2007, CLIN THER, V29, P1116, DOI 10.1016/j.clinthera.2007.06.009
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebetino Frank H., 1995, P139
   EVDOKIMOV A, 2006, BONE S1, V3, P49
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   GEDDES AD, 1994, BISPHOSPHONATES STUC, V8
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Hosking D, 2007, J BONE MINER RES, V22, P142, DOI 10.1359/JBMR.061001
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Koyama T, 1996, BIOCHEMISTRY US, V35, P9533, DOI 10.1021/bi960137v
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201
   MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005 2744(69)90420 3
   POULTER CD, 1976, BIOCHEMISTRY US, V15, P1079, DOI 10.1021/bi00650a019
   REED BC, 1976, BIOCHEMISTRY US, V15, P3739, DOI 10.1021/bi00662a015
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   WILIAMS JW, 1979, METHOD ENZYMOL, V63, P437
   Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929 931.2002
   Yin FL, 2006, J AM CHEM SOC, V128, P3524, DOI 10.1021/ja0601639
NR 32
TC 135
Z9 157
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 10
PY 2008
VL 51
IS 7
BP 2187
EP 2195
DI 10.1021/jm7015733
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 284LY
UT WOS:000254709100024
PM 18327899
OA Bronze
DA 2025 08 17
ER

PT J
AU Baksh, D
   Yao, R
   Tuan, RS
AF Baksh, Dolores
   Yao, Raphael
   Tuan, Rocky S.
TI Comparison of proliferative and multilineage differentiation potential
   of human mesenchymal stem cells derived from umbilical cord and bone
   marrow
SO STEM CELLS
LA English
DT Article
DE perivascular cells; bone marrow stromal cells; multi differentiation
ID ENDOTHELIAL CELLS; PROGENITOR CELLS; IN VITRO; OSTEOGENIC
   DIFFERENTIATION; GENE TRANSFER; MATRIX CELLS; THERAPY; TRANSPLANTATION;
   TRANSFECTION; SCAFFOLDS
AB Human umbilical cord perivascular cells (HUCPVCs) have been shown to have a high proliferative potential and the capacity to differentiate into an osteogenic phenotype. HUCPVCs have thus been considered a possible extra embryonic mesenchymal stem cell (MSC) source for cell based therapies. To assess this potential, we compared HUCPVCs to the "gold standard" bone marrow mesenchymal stromal cells (BMSCs) with respect to their proliferation, differentiation, and transfection capacities. HUCPVCs showed a higher proliferative potential than BMSCs and were capable of osteogenic, chondrogenic, and adipogenic differentiation. Interestingly, osteogenic differentiation of HUCPVCs proceeded more rapidly than BMSCs. Additionally, HUCPVCs expressed higher levels of CD146, a putative MSC marker, relative to BMSCs. HUCPVCs showed comparable transfection efficiency as BMSCs using a nucleofection method but were more amenable to transfection with liposomal methods (FuGENE). Gene array analysis showed that HUCPVCs also expressed Wnt signaling pathway genes that have been implicated in the regulation of MSCs. The similar characteristics between HUCPVCs and MSCs support the applicability of HUCPVCs for cell based therapies.
C1 NIAMSD, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Arthritis & Musculoskeletal & Skin Diseases (NIAMS)
RP Tuan, RS (通讯作者)，NIAMSD, Cartilage Biol & Orthopaed Branch, NIH, 50 S Dr,Room 1503,BMSC 8022, Bethesda, MD 20892 USA.
EM tuanr@mail.nih.gov
FU Intramural NIH HHS Funding Source: Medline
CR Aluigi M, 2006, STEM CELLS, V24, P454, DOI 10.1634/stemcells.2005 0198
   Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623 200310000 00010
   Baksh D, 2003, EXP HEMATOL, V31, P723, DOI 10.1016/S0301 472X(03)00106 1
   Blann AD, 2005, THROMB HAEMOSTASIS, V93, P228, DOI 10.1160/TH04 09 0578
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Dannowski H, 2005, EXP EYE RES, V80, P93, DOI 10.1016/j.exer.2004.08.024
   DAVIES JE, 2006, 12 ANN M INT SOC CEL
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Duda DG, 2006, J CLIN ONCOL, V24, P1449, DOI 10.1200/JCO.2005.04.2861
   Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005 0053
   Haleem Smith H, 2005, MOL BIOTECHNOL, V30, P9, DOI 10.1385/MB:30:1:009
   Hamada H, 2005, CANCER SCI, V96, P149, DOI 10.1111/j.1349 7006.2005.00032.x
   Mauck RL, 2007, BIOMECH MODEL MECHAN, V6, P113, DOI 10.1007/s10237 006 0042 1
   McMahon JM, 2006, STEM CELLS DEV, V15, P87, DOI 10.1089/scd.2006.15.87
   Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21 1 50
   Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004 0166
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   SIMMONS PJ, 1991, BLOOD, V78, P55
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Wang YZ, 2005, BIOMATERIALS, V26, P7082, DOI 10.1016/j.biomaterials.2005.05.022
   Weinand C, 2006, BONE, V38, P555, DOI 10.1016/j.bone.2005.10.016
   Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005 0330
   Weiss ML, 2003, EXP NEUROL, V182, P288, DOI 10.1016/S0014 4886(03)00128 6
   Wu HK, 2005, J SURG RES, V126, P193, DOI 10.1016/j.jss.2005.01.016
   Yue B, 2005, CALCIFIED TISSUE INT, V77, P395, DOI 10.1007/s00223 005 0180 y
NR 26
TC 851
Z9 1047
U1 1
U2 104
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701 2884 USA
SN 1066 5099
J9 STEM CELLS
JI Stem Cells
PD JUN
PY 2007
VL 25
IS 6
BP 1384
EP 1392
DI 10.1634/stemcells.2006 0709
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 173XT
UT WOS:000246906500006
PM 17332507
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Yin, C
   Hu, LF
   Chen, ZH
   Zhao, F
   Li, DJ
   Ma, JH
   Ma, XL
   Su, PH
   Qiu, WX
   Yang, CF
   Wang, P
   Li, SY
   Zhang, G
   Wang, LP
   Qian, AR
   Xian, CJ
AF Zhang, Yan
   Yin, Chong
   Hu, Lifang
   Chen, Zhihao
   Zhao, Fan
   Li, Dijie
   Ma, Jianhua
   Ma, Xiaoli
   Su, Peihong
   Qiu, Wuxia
   Yang, Chaofei
   Wang, Pai
   Li, Siyu
   Zhang, Ge
   Wang, Liping
   Qian, Airong
   Xian, Cory J.
TI MACF1 Overexpression by Transfecting the 21 kbp Large Plasmid
   PEGFP C1A ACF7 Promotes Osteoblast Differentiation and Bone Formation
SO HUMAN GENE THERAPY
LA English
DT Article
DE MACF1; large plasmid; osteoblast; bone formation
ID LIPID NANOPARTICLES; ESCHERICHIA COLI; DELIVERY; ACF7; MIGRATION;
   PLAKINS; FAMILY; SIRNA; GENES; MIRNA
AB Microtubule actin crosslinking factor 1 (MACF1) is a large spectraplakin protein known to have crucial roles in regulating cytoskeletal dynamics, cell migration, growth, and differentiation. However, its role and action mechanism in bone remain unclear. The present study investigated optimal conditions for effective transfection of the large plasmid PEGFP C1A ACF7 (approximate to 21 kbp) containing full length human MACF1 cDNA, as well as the potential role of MACF1 in bone formation. To enhance MACF1 expression, the plasmid was transfected into osteogenic cells by electroporation in vitro and into mouse calvaria with nanoparticles. Then, transfection efficiency, osteogenic marker expression, calvarial thickness, and bone formation were analyzed. Notably, MACF1 overexpression triggered a drastic increase in osteogenic gene expression, alkaline phosphatase activity, and matrix mineralization in vitro. Mouse calvarial thickness, mineral apposition rate, and osteogenic marker protein expression were significantly enhanced by local transfection. In addition, MACF1 overexpression promoted  catenin expression and signaling. In conclusion, MACF1 overexpression by transfecting the large plasmid containing full length MACF1 cDNA promotes osteoblast differentiation and bone formation via  catenin signaling. Current data will provide useful experimental parameters for the transfection of large plasmids and a novel strategy based on promoting bone formation for prevention and therapy of bone disorders.
C1 [Zhang, Yan; Yin, Chong; Hu, Lifang; Chen, Zhihao; Zhao, Fan; Li, Dijie; Ma, Jianhua; Ma, Xiaoli; Su, Peihong; Qiu, Wuxia; Yang, Chaofei; Wang, Pai; Li, Siyu; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Bone Metab Lab, Xian, Shaanxi, Peoples R China.
   [Zhang, Yan; Yin, Chong; Hu, Lifang; Chen, Zhihao; Zhao, Fan; Li, Dijie; Ma, Jianhua; Ma, Xiaoli; Su, Peihong; Qiu, Wuxia; Yang, Chaofei; Wang, Pai; Li, Siyu; Zhang, Ge; Qian, Airong] Northwestern Polytech Univ, Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China.
   [Zhang, Yan; Yin, Chong; Hu, Lifang; Chen, Zhihao; Zhao, Fan; Li, Dijie; Ma, Jianhua; Ma, Xiaoli; Su, Peihong; Qiu, Wuxia; Yang, Chaofei; Wang, Pai; Li, Siyu; Zhang, Ge; Qian, Airong] Northwestern Polytech Univ, NPU HKBU Joint Res Ctr Translat Med Musculoskelet, Xian, Shaanxi, Peoples R China.
   [Wang, Liping; Xian, Cory J.] Univ South Australia, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Adelaide, SA, Australia.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; University of South
   Australia
RP Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.; Wang, LP (通讯作者)，Univ South Australia, Sch Pharm & Med Sci, GPO Box 2471, Adelaide, SA 5001, Australia.
EM liping.wang@mymail.unisa.edu.au; qianair@nwpu.edu.cn
RI Xie, Lijing/AAN 3383 2021; Zhang, Ge/N 4150 2013; Zhang,
   Yan/MTF 5312 2025; Wang, Liping/JRY 1318 2023; chen,
   zhihao/GXM 3816 2022; Li, Dijie/KVB 3667 2024; Hu, Lifang/W 8020 2019;
   Xian, Cory/D 2646 2009; Chen, Zhihao/ACK 3514 2022
OI /0000 0001 9355 1167; Zhang, Yan/0000 0001 6213 4416; Chen,
   Zhihao/0000 0003 0128 1409
CR Andersen MO, 2010, MOL THER, V18, P2018, DOI 10.1038/mt.2010.166
   Bao QW, 2017, EXP CELL RES, V350, P123, DOI 10.1016/j.yexcr.2016.11.013
   Bouameur JE, 2014, J INVEST DERMATOL, V134, P885, DOI 10.1038/jid.2013.498
   Campeau P, 2001, GENE THER, V8, P1387, DOI 10.1038/sj.gt.3301532
   Chen HJ, 2006, GENE DEV, V20, P1933, DOI 10.1101/gad.1411206
   Cocco E, 2017, MOL CANCER THER, V16, P323, DOI 10.1158/1535 7163.MCT 16 0501
   Dahlman JE, 2014, NAT NANOTECHNOL, V9, P648, DOI [10.1038/NNANO.2014.84, 10.1038/nnano.2014.84]
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Fassett JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073887
   Goryunov D, 2016, METHOD ENZYMOL, V569, P331, DOI 10.1016/bs.mie.2015.05.022
   Hadjicharalambous C, 2015, J BIOMED MATER RES A, V103, P3834, DOI 10.1002/jbm.a.35527
   Hsu SH, 2013, NANOMED NANOTECHNOL, V9, P1169, DOI 10.1016/j.nano.2013.05.007
   Hu LF, 2018, J CELL PHYSIOL, V233, P1574, DOI 10.1002/jcp.26059
   Hu LF, 2017, SEMIN CELL DEV BIOL, V69, P3, DOI 10.1016/j.semcdb.2017.05.017
   Hu LF, 2016, BMB REP, V49, P37, DOI 10.5483/BMBRep.2016.49.1.185
   Hu LF, 2015, BMB REP, V48, P583, DOI 10.5483/BMBRep.2015.48.10.098
   Jin S, 2009, METHODS MOL BIOL, V544, P547, DOI 10.1007/978 1 59745 483 4_34
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092 8674(03)00813 4
   Kretzmann JA, 2017, CHEM SCI, V8, P2923, DOI 10.1039/c7sc00097a
   Lesueur LL, 2016, MOL THER NUCL ACIDS, V5, DOI 10.1038/mtna.2016.4
   Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962 8924(01)02180 8
   Li D, 2016, SPACE MED MED ENG BE, V29, P8
   Liang Y, 2013, INT J MOL MED, V31, P861, DOI 10.3892/ijmm.2013.1284
   Lindberg MF, 2015, BIOMATERIALS, V59, P1, DOI 10.1016/j.biomaterials.2015.04.024
   Lojk J, 2015, BIOELECTROMAGNETICS, V36, P551, DOI 10.1002/bem.21936
   Margaron Y, 2013, J BIOL CHEM, V288, P1184, DOI 10.1074/jbc.M112.431825
   Muroski ME, 2015, ACS NANO, V9, P124, DOI 10.1021/nn5060305
   Muthiah M, 2013, EXPERT OPIN DRUG DEL, V10, P1259, DOI 10.1517/17425247.2013.798640
   Noordstra I, 2016, J CELL SCI, V129, P4278, DOI 10.1242/jcs.194878
   Norman A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104405
   Nováková J, 2014, FOLIA MICROBIOL, V59, P53, DOI 10.1007/s12223 013 0267 1
   Peister A, 2004, GENE THER, V11, P224, DOI 10.1038/sj.gt.3302163
   Qian AR, 2009, BIOELECTROMAGNETICS, V30, P545, DOI 10.1002/bem.20511
   Qiao CY, 2015, AM J TRANSL RES, V7, P2561
   Robert MA, 2018, HUM GENE THER, V29, P452, DOI 10.1089/hum.2017.101
   Sanchez Soriano N, 2009, J CELL SCI, V122, P2534, DOI 10.1242/jcs.046268
   Shao ZY, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S77837
   SHENG Y, 1995, NUCLEIC ACIDS RES, V23, P1990, DOI 10.1093/nar/23.11.1990
   Sonnenberg A, 2007, EXP CELL RES, V313, P2189, DOI 10.1016/j.yexcr.2007.03.039
   Umebayashi M, 2015, BIORESEARCH OPEN ACC, V4, P164, DOI 10.1089/biores.2014.0057
   Wan QL, 2016, BONE, V86, P10, DOI 10.1016/j.bone.2016.02.010
   Wang QM, 2015, INT J NANOMED, V10, P597, DOI 10.2147/IJN.S74156
   Wiese M, 2010, J IMMUNOL METHODS, V353, P102, DOI 10.1016/j.jim.2009.12.002
   Wu XY, 2008, CELL, V135, P137, DOI 10.1016/j.cell.2008.07.045
   Wu XY, 2011, CELL, V144, P341, DOI 10.1016/j.cell.2010.12.033
   Yan J, 2014, BIOMATERIALS, V35, P7734, DOI 10.1016/j.biomaterials.2014.05.089
   Yang JL, 2012, BIOTECHNOL LETT, V34, P2017, DOI 10.1007/s10529 012 0994 4
   Yin C, 2017, J CELL PHYSL, P8
   Yue JP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11692
   Zhang JY, 2016, BIOCHEM BIOPH RES CO, V469, P196, DOI 10.1016/j.bbrc.2015.11.101
   Zhao Y, 2014, ADV GENET, V88, P13, DOI 10.1016/B978 0 12 800148 6.00002 X
NR 52
TC 21
Z9 24
U1 0
U2 23
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043 0342
EI 1557 7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD FEB
PY 2018
VL 29
IS 2
SI SI
BP 259
EP 270
DI 10.1089/hum.2017.153
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA FW2KN
UT WOS:000425131900018
PM 29334773
DA 2025 08 17
ER

PT J
AU Li, ZS
   Yu, F
   Yu, XF
   Wang, SH
AF Li, Zhongsen
   Yu, Fan
   Yu, Xuefei
   Wang, Shaohua
TI Potential Molecular Mechanism and Biomarker Investigation for Spinal
   Cord Injury Based on Bioinformatics Analysis
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Spinal cord injury; DEGs; Time series gene; Functional and pathway
   analysis; PPI network; TF target gene network
ID CORTICOTROPIN RELEASING HORMONE; TYROSINE HYDROXYLASE; OSTEOBLAST
   DIFFERENTIATION; MESSENGER RNA; EXPRESSION; NEUROTENSIN; RECOVERY;
   ESTRADIOL; DATABASE; MODEL
AB This study aimed to explore the detailed molecular mechanism and biomarkers in spinal cord injury (SCI). Gene expression profiles of GSE125630 were downloaded from the Gene Expression Omnibus (GEO) database, and comprised 14 spinal cord tissues, including contusion SCI group (n = 6, unexercised), complete transection group (n = 4, unexercised), and uninjured control group (n = 4, unexercised). Differentially expressed gene (DEG) and time series gene investigations, functional enrichment analysis, protein protein interaction (PPI) network construction, characteristic gene related disease analysis, and TF target gene interaction studies were performed. A total of 122 DEGs and 409 DEGs were respectively identified in contusion SCI versus control group and complete transection versus control group, respectively. The PPI network investigated 16 characteristic genes including corticotropin releasing hormone (CRH), tyrosine hydroxylase (TH), and neurotensin (NTS). These genes were mainly enriched in functions involving response to ethanol, corticosterone, and estradiol. Eventually, a TF target gene interaction network was constructed with nine TFs [including activating transcription factor 3 (ATF3)] and 10 characteristic genes. The results indicate that regulation of osteoblast differentiation and positive regulation of the BMP signaling pathway may be suppressed in the process of SCI. TH may play a pivotal role in the progression of SCI. In addition, DEGs such as CRH and NTS may be novel targets for SCI therapy.
C1 [Li, Zhongsen; Wang, Shaohua] Anhui Med Univ, Dept Neurosurg, Fuyang Hosp, 99 Huangshan Rd,Fuhe Modern Ind Pk, Fuyang 236000, Anhui, Peoples R China.
   [Yu, Fan] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Rehabil, Shanghai 200080, Peoples R China.
   [Yu, Xuefei] Fuyang Peoples Hosp, Dept Stomatol, Fuyang 236000, Anhui, Peoples R China.
C3 Anhui Medical University; Shanghai Jiao Tong University
RP Wang, SH (通讯作者)，Anhui Med Univ, Dept Neurosurg, Fuyang Hosp, 99 Huangshan Rd,Fuhe Modern Ind Pk, Fuyang 236000, Anhui, Peoples R China.
EM wangsh72622@163.com
RI shaohua, wang/AAB 7904 2022
CR Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Allison DJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974 016 0625 4
   Alysandratos KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048934
   Anderson AJ, 2017, STEM CELL REP, V8, P249, DOI 10.1016/j.stemcr.2016.12.018
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460 9568.1997.tb01497.x
   Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.2307/1165312
   Cepeda MS, 2004, REGUL PEPTIDES, V118, P39, DOI 10.1016/j.regpep.2003.10.027
   Chariker JH, 2019, SCI DATA, V6, DOI 10.1038/s41597 019 0088 4
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cui ZS, 2015, GENET MOL RES, V14, P9109, DOI 10.4238/2015.August.7.20
   DIFIGLIA M, 1982, ANN NY ACAD SCI, V400, P405, DOI 10.1111/j.1749 6632.1982.tb31595.x
   Ernst J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 191
   Finnerup NB, 2004, EUR J NEUROL, V11, P73, DOI 10.1046/j.1351 5101.2003.00725.x
   Garbossa D, 2012, NEUROSURG REV, V35, P293, DOI 10.1007/s10143 012 0385 2
   Hayakawa K, 2012, SPINAL CORD, V50, P493, DOI 10.1038/sc.2011.184
   He JC, 2017, CELL PHYSIOL BIOCHEM, V44, P1224, DOI 10.1159/000485452
   Herman PE, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18757 1
   Hou YN, 2015, INT J CLIN EXP MED, V8, P14926
   Hu JZ, 2017, CURR NEUROVASC RES, V14, P110, DOI 10.2174/1567202614666170313114115
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang SB, 2017, BIOCHEM BIOPH RES CO, V489, P275, DOI 10.1016/j.bbrc.2017.05.158
   Jain NB, 2015, JAMA J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250
   Jiang SD, 2006, CLIN ENDOCRINOL, V65, P555, DOI 10.1111/j.1365 2265.2006.02683.x
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kasai M, 2011, EVID BASED COMPL ALT, V2011, DOI 10.1155/2011/749627
   Ketchesin KD, 2017, STRESS, V20, P449, DOI 10.1080/10253890.2017.1322575
   Kim EH, 2011, ANAT CELL BIOL, V44, P60, DOI 10.5115/acb.2011.44.1.60
   Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978 1 60761 987 1_18
   Lee Hye Min, 2015, J Menopausal Med, V21, P93, DOI 10.6118/jmm.2015.21.2.93
   Lei XJ, 2013, PROTEOMICS, V13, P278, DOI 10.1002/pmic.201200309
   Li B, 2017, SCI REP UK, V7, DOI 10.1038/srep46616
   Lin CW, 2016, NEUROSCI BULL, V32, P137, DOI 10.1007/s12264 016 0017 x
   Liu HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165063
   Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018
   Oliva JM, 2008, EUR NEUROPSYCHOPHARM, V18, P373, DOI 10.1016/j.euroneuro.2007.09.001
   Pantovi R, 2004, CLIN CHEM LAB MED, V42, pA82
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   RYLETT P, 1976, J PHARM PHARMACOL, V28, P559, DOI 10.1111/j.2042 7158.1976.tb02795.x
   Sengelaub DR, 2018, J NEUROTRAUM, V35, P825, DOI 10.1089/neu.2017.5329
   Shimoyama M, 2015, NUCLEIC ACIDS RES, V43, pD743, DOI 10.1093/nar/gku1026
   Simone J, 2015, PSYCHONEUROENDOCRINO, V62, P265, DOI 10.1016/j.psyneuen.2015.08.015
   STANZIONE P, 1983, BRAIN RES, V268, P111, DOI 10.1016/0006 8993(83)90395 5
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tran S, 2017, BEHAV BRAIN RES, V317, P237, DOI 10.1016/j.bbr.2016.09.048
   Tumurbaatar T, 2018, BIOL REPROD, V99, P1216, DOI 10.1093/biolre/ioy145
   Urso ML, 2007, J PHYSIOL LONDON, V579, P877, DOI 10.1113/jphysiol.2006.118042
   Wang LF, 2017, BIOCHEM BIOPH RES CO, V488, P522, DOI 10.1016/j.bbrc.2017.05.079
   Wang W, 2004, NEUROSCI LETT, V371, P133, DOI 10.1016/j.neulet.2004.08.055
   Welling LC, 2010, WORLD NEUROSURG, V74, P388, DOI 10.1016/j.wneu.2010.10.010
   Wu YP, 2017, TOXICOL LETT, V270, P17, DOI 10.1016/j.toxlet.2017.02.002
   YAKSH TL, 1982, ANN NY ACAD SCI, V400, P228, DOI 10.1111/j.1749 6632.1982.tb31572.x
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   [周军 Zhou Jun], 2011, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V21, P239
NR 55
TC 4
Z9 4
U1 0
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0895 8696
EI 1559 1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD SEP
PY 2020
VL 70
IS 9
BP 1345
EP 1353
DI 10.1007/s12031 020 01549 0
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA MV0CS
UT WOS:000532611600002
PM 32406040
DA 2025 08 17
ER

PT J
AU Lin, XZ
   Li, L
   Wu, SL
   Tian, J
   Zheng, WZ
AF Lin, Xiaozong
   Li, Li
   Wu, Shuliang
   Tian, Jun
   Zheng, Weizhuo
TI Activation of GPR30 promotes osteogenic differentiation of MC3T3 E1
   cells: An implication in osteoporosis
SO IUBMB LIFE
LA English
DT Article
DE adenosine monophosphate activated protein kinase (AMPK); anti acetyl CoA
   carboxylase (ACC); bone metabolism; estrogen receptor; G protein coupled
   receptor 30 (GPR30); G1; osteoblast differentiation; osteoporosis; Runx2
ID OSTEOBLAST DIFFERENTIATION; RECEPTOR; DEXAMETHASONE
AB Osteoporosis is an age related disease characterized by reduced bone volume and disturbed bone metabolism. Novel therapies to rescue or prevent reduced bone mass by guiding the differentiation of pluripotent bone marrow stromal cells away from adipocyte differentiation and toward osteoblastic differentiation may serve as a valuable treatment option against osteoporosis. Estrogen has long been recognized as a key effector of bone formation and mineralization, but the exact mechanisms involved remain poorly understood. In the present study, we investigated the role of the estrogen specific G protein coupled receptor 30 (GPR30/GPER) using its specific agonist G1 in MC3T3 E1 preosteoblast cells. Our findings demonstrate that expression of GPR30 is upregulated during osteoblast differentiation and that agonism of GPR30 significantly increases some key markers of mineralization including alkaline phosphatase, osteocalcin, osterix, and type I collagen. We also demonstrate that GPR30 agonism upregulates expression of Runx2, which is recognized as an essential transcription factor involved in bone formation. Additionally, through a series of adenosine monophosphate activated protein kinase (AMPK) inhibition experiments using compound C, we show that the positive effects of GPR30 on mineralization and differentiation of preosteoblasts are mediated through the AMPK/anti acetyl CoA carboxylase (ACC) pathway. Taken together, the findings of the present study demonstrate the potential of GPR30 as a novel target for the treatment and prevention of osteoporosis.
C1 [Lin, Xiaozong; Tian, Jun; Zheng, Weizhuo] Harbin Med Univ, Affiliated Hosp 2, Dept Orthoped, 246 Xuefu Rd, Harbin 150086, Heilongjiang, Peoples R China.
   [Li, Li] Harbin Med Univ, Affiliated Hosp 1, Dept Nucl Med, Harbin, Heilongjiang, Peoples R China.
   [Wu, Shuliang] Harbin Med Univ, Dept Anat, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Zheng, WZ (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Orthoped, 246 Xuefu Rd, Harbin 150086, Heilongjiang, Peoples R China.
EM zhengwz005@163.com
CR Arnatt C, 2019, FASEB J S, V33, P821
   Atkins G.J., 2011, Vitamin D, VThird, P411, DOI DOI 10.1016/B978 0 12 381978 9.10023 X
   Cao HJ, 2019, PHYTOMEDICINE, DOI [10.1016/j.phymed.2019, DOI 10.1016/J.PHYMED.2019]
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Feldman RD, 2017, ANNU REV PHARMACOL, V57, P567, DOI 10.1146/annurev pharmtox 010716 104651
   Ghareghani M, 2018, FUND CLIN PHARMACOL, V32, P181, DOI 10.1111/fcp.12337
   Guo SG, 2016, BIOCHEM BIOPH RES CO, V471, P545, DOI 10.1016/j.bbrc.2016.02.036
   Hewitt SC, 2005, SCIENCE, V307, P1572, DOI 10.1126/science.1110345
   Kang WB, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150146
   Kanis J.A., 2019, Pocket Reference to Osteoporosis, P11, DOI [DOI 10.1007/978 3 319 26757 9_2, 10.1007/978 3 319 26757 92, DOI 10.1007/978 3 319 26757 92]
   Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008 0680
   Khan K, 2015, J NUTR BIOCHEM, V26, P1491, DOI 10.1016/j.jnutbio.2015.07.021
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Li LS, 2018, BIOSCI TRENDS, V12, P266, DOI 10.5582/bst.2018.01013
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Masuhara Masaaki, 2016, Biochem Biophys Rep, V8, P389, DOI 10.1016/j.bbrep.2016.10.013
   Ming Y, 2014, BIOCHEM BIOPH RES CO, V454, P42, DOI 10.1016/j.bbrc.2014.10.033
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Sondergard C, 2019, FASEB J S, V33, P503
   Sun YP, 2019, ARTIF CELL NANOMED B, V47, P1281, DOI 10.1080/21691401.2019.1596924
   Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200
   Trivedi D, 2019, J PUBLIC HLTH EPIDEM, V6, P161
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang YG, 2016, CELL SIGNAL, V28, P1270, DOI 10.1016/j.cellsig.2016.06.004
   Yin QD, 2018, J CELL MOL MED, V22, P6112, DOI 10.1111/jcmm.13888
   Zhang SY, 2018, EUR REV MED PHARMACO, V22, P4792, DOI 10.26355/eurrev_201808_15613
   Zhang ZL, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974 018 1246 x
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 34
TC 16
Z9 18
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1521 6543
EI 1521 6551
J9 IUBMB LIFE
JI IUBMB Life
PD NOV
PY 2019
VL 71
IS 11
BP 1751
EP 1759
DI 10.1002/iub.2118
EA JUL 2019
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA JE0LM
UT WOS:000475112000001
PM 31298483
OA Bronze
DA 2025 08 17
ER

PT J
AU Hansen, KE
   Swenson, ED
   Baltz, B
   Schuna, AA
   Jones, AN
   Elliott, ME
AF Hansen, K. E.
   Swenson, E. D.
   Baltz, B.
   Schuna, A. A.
   Jones, A. N.
   Elliott, M. E.
TI Adherence to alendronate in male veterans
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE adherence; alendronate; medication possession ratio; men; osteoporosis;
   treatment
ID BONE MINERAL DENSITY; LONG TERM EXTENSION; BISPHOSPHONATE THERAPY;
   POSTMENOPAUSAL OSTEOPOROSIS; PARATHYROID HORMONE; VERTEBRAL FRACTURE;
   RANDOMIZED TRIAL; DRUG THERAPY; PERSISTENCE; WOMEN
AB In one Veterans Affairs' medical center, alendronate non adherence was more likely in male veterans who smoke or report side effects, and less likely in men undergoing bone densitometry during therapy. Providers urgently need programs to increase adherence to osteoporosis medications. Initial programs should target patients with risk factors for non adherence.
   Introduction Adherence to osteoporosis therapy in men is unknown. We hypothesized that ca. 50% of men at one center would be adherent to alendronate and one or more patient specific factors would associate with adherence.
   Methods We conducted a retrospective chart review study of male veterans to determine the rates and predictors of alendronate adherence over two years. We excluded women, men who received primary care elsewhere and those who took alendronate for indications other than low bone mass. We defined adherence as a medication possession ratio >= 80% in the first 24 months of therapy.
   Results Adherence in the first 12 and 24 months of therapy was 59% and 54%, respectively. In multivariate analyses, non adherence was more likely in men using tobacco (OR 2.08, 95% CI 1.13, 3.84, p=0.02) and reporting side effects (OR 2.06, 95% CI 1.14, 3.73, p=0.02) and less likely in men undergoing bone density during therapy (OR 0.49, 95% CI 0.26, 0.90, p=0.02).
   Conclusions Alendronate non adherence is more likely in male veterans who smoke or report side effects, and less likely in men having bone densitometry during therapy. Providers urgently need programs to increase adherence to osteoporosis medications. Initial programs should target patients with risk factors for non adherence.
C1 [Hansen, K. E.; Swenson, E. D.; Jones, A. N.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53792 USA.
   [Baltz, B.; Elliott, M. E.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA.
   [Hansen, K. E.; Jones, A. N.] Univ Wisconsin, Osteoporosis Clin Ctr & Res Program, Madison, WI USA.
   [Schuna, A. A.; Elliott, M. E.] William S Middleton Vet Affairs Med Ctr, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Hansen, KE (通讯作者)，Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Mailbox 3244,Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.
EM keh@medicine.wisc.edu
CR Adachi JD, 2001, ARTHRITIS RHEUM US, V44, P202, DOI 10.1002/1529 0131(200101)44:1<202::AID ANR27>3.0.CO;2 W
   Badamgarav E, 2006, MAYO CLIN PROC, V81, P1009, DOI 10.4065/81.8.1009
   Barr RG, 2002, ARCH INTERN MED, V162, P1761, DOI 10.1001/archinte.162.15.1761
   Benner JS, 2002, JAMA J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455
   Binkley Neil, 2002, WMJ, V101, P28
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   Carr AJ, 2006, OSTEOPOROSIS INT, V17, P1638, DOI 10.1007/s00198 006 0166 2
   Clowes JA, 2004, J CLIN ENDOCR METAB, V89, P1117, DOI 10.1210/jc.2003 030501
   Compston J, 2001, CALCIFIED TISSUE INT, V69, P193, DOI 10.1007/s00223 001 1048 4
   Compston JE, 2006, LANCET, V368, P973, DOI 10.1016/S0140 6736(06)69394 X
   Cooper A, 2006, INT J CLIN PRACT, V60, P896, DOI 10.1111/j.1742 1241.2006.01059.x
   Curtis JR, 2006, OSTEOPOROSIS INT, V17, P1268, DOI 10.1007/s00198 006 0136 8
   Downey TW, 2006, SOUTH MED J, V99, P570, DOI 10.1097/01.smj.0000221637.90495.66
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fisher L.D., 1993, BIOSTATISTICS METHOD
   Gold DT, 2006, ANN PHARMACOTHER, V40, P1143, DOI 10.1345/aph.1G534
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   KELEPOURIS N, 1995, ANN INTERN MED, V123, P452, DOI 10.7326/0003 4819 123 6 199509150 00010
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lavigne M, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471 2458 6 66
   Law MR, 1997, BMJ BRIT MED J, V315, P841, DOI 10.1136/bmj.315.7112.841
   Lo JC, 2006, OSTEOPOROSIS INT, V17, P922, DOI 10.1007/s00198 006 0085 2
   McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005
   Miller PD, 2000, CLIN THER, V22, P1433, DOI 10.1016/S0149 2918(00)83042 8
   Morris AB, 2006, PHARMACOTHERAPY, V26, P483, DOI 10.1592/phco.26.4.483
   *NAT OST FDN, 2003, PHYS GUID PREV TREAT
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Papaioannou A, 2003, OSTEOPOROSIS INT, V14, P808, DOI 10.1007/s00198 003 1431 2
   RAYNOR DK, 1993, BRIT MED J, V306, P1158, DOI 10.1136/bmj.306.6886.1158
   Recker RR, 2005, MAYO CLIN PROC, V80, P856, DOI 10.4065/80.7.856
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rossini M, 2006, OSTEOPOROSIS INT, V17, P914, DOI 10.1007/s00198 006 0073 6
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Solomon DH, 2003, CURR OPIN RHEUMATOL, V15, P122, DOI 10.1097/00002281 200303000 00006
   Vik SA, 2006, DRUG AGING, V23, P345, DOI 10.2165/00002512 200623040 00007
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Weycker D, 2006, OSTEOPOROSIS INT, V17, P1645, DOI 10.1007/s00198 006 0179 x
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Wu JYF, 2006, BMJ BRIT MED J, V333, P522, DOI 10.1136/bmj.38905.447118.2F
   Yood RA, 2003, OSTEOPOROSIS INT, V14, P965, DOI 10.1007/s00198 003 1502 4
NR 45
TC 29
Z9 29
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2008
VL 19
IS 3
BP 349
EP 356
DI 10.1007/s00198 007 0471 4
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 258SI
UT WOS:000252889400011
PM 17898921
DA 2025 08 17
ER

PT J
AU Cao, X
   Wang, XX
   Zhang, WX
   Xia, G
   Zhang, LN
   Wen, Z
   He, JS
   Wang, ZL
   Huang, JJ
   Wu, S
AF Cao, Xu
   Wang, Xinxing
   Zhang, Wenxiu
   Xia, Guang
   Zhang, Lina
   Wen, Zi
   He, Jinshen
   Wang, Zili
   Huang, Junjie
   Wu, Song
TI WNT10A induces apoptosis of senescent synovial resident stem cells
   through Wnt/calcium pathway mediated HDAC5 phosphorylation in OA joints
SO BONE
LA English
DT Article
DE Osteoarthritis; Synovial mesenchymal stem cells (SMSCs); Cell
   senescence; Wnt signaling pathway; HDAC5; Cell apoptosis
ID HISTONE DEACETYLASES; OSTEOARTHRITIS; HOMEOSTASIS; INHIBITORS;
   EXPRESSION; SM04690
AB Recently, the accumulation of senescent cells (SnCs) within joints was found to promote osteoarthritis (OA) progression. Our previous study found that Wnt proteins, especially Wnt10a, have marked effects on cellular senescence and joint health. However, the effect of WNT10A on SnCs in OA joints remains unknown.
   In this study, we confirmed that the synovium was the first and most marked site of SnC accumulation in the OA joint, and synovial resident mesenchymal stem cells (SMSCs) seemed to be the main source of these SnCs. In synovium samples from OA patients, WNT10A level inversely correlated with the extent of SnCs accumulation. Therefore, we further explored the possible regulatory role and mechanism of WNT10A in intraarticular senescent SMSCs. In brief, we confirmed that WNT10A could specifically clear these senescent OA SMSCs in vitro experiments and naturally occurring OA models via proapoptotic effects. Mechanistically, WNT10A activated noncanonical Wnt/calcium signaling in senescent OA SMSCs, which in turn induced histone deacetylase 5 (HDAC5) phosphorylation and nuclear export via its downstream Ca2+/calmodulin dependent protein kinase II (CaMKII) to regulate cell fate. The regulation of this pathway significantly improved the regenerative microenvironment of OA, exhibiting its potential as a novel clinical disease modifying OA drugs (DMOADs) target.
C1 [Cao, Xu; Wang, Xinxing; Zhang, Wenxiu; Xia, Guang; Zhang, Lina; Wen, Zi; He, Jinshen; Wang, Zili; Huang, Junjie; Wu, Song] Cent South Univ, Dept Orthopaed, Xiangya Hosp 3, Changsha 410013, Peoples R China.
C3 Central South University
RP Huang, JJ; Wu, S (通讯作者)，Cent South Univ, Dept Orthopaed, Xiangya Hosp 3, Changsha 410013, Peoples R China.
EM hjjhuang@hotmail.com; xy3ws1969@hotmail.com
RI wang, zili/AAP 4723 2021; wen, zi/ISU 0647 2023; He,
   Jinshen/CAG 2514 2022
OI He, Jinshen/0000 0003 0277 3819; 
FU National Natural Science Foundation of China [82072501]; Science and
   Technology Innovation Leading Plan of High Tech Industry in Hunan
   Province [2020SK2011]; Youth Fund Project of Natural Science Foundation
   of Hunan Province [2020JJ5848]; Medical Research Development Fund
   Project [WS865C]
FX This work was supported by the National Natural Science Foundation of
   China (82072501) , Science and Technology Innovation Leading Plan of
   High Tech Industry in Hunan Province (2020SK2011) , Youth Fund Project
   of Natural Science Foundation of Hunan Province (2020JJ5848) , and
   Medical Research Development Fund Project (WS865C) .
CR Chae WJ, 2018, TRENDS IMMUNOL, V39, P830, DOI 10.1016/j.it.2018.08.006
   de Keizer PLJ, 2017, TRENDS MOL MED, V23, P6, DOI 10.1016/j.molmed.2016.11.006
   Deshmukh V, 2018, OSTEOARTHR CARTILAGE, V26, P18, DOI 10.1016/j.joca.2017.08.015
   Dong TY, 2017, ONCOL REP, V38, P1287, DOI 10.3892/or.2017.5777
   Fan JM, 2017, ONCOTARGET, V8, P27105, DOI 10.18632/oncotarget.15637
   Feige P, 2018, CELL STEM CELL, V23, P653, DOI 10.1016/j.stem.2018.10.006
   Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631
   García Velázquez L, 2017, AGEING RES REV, V37, P135, DOI 10.1016/j.arr.2017.06.001
   Gerwin N, 2010, OSTEOARTHR CARTILAGE, V18, pS24, DOI 10.1016/j.joca.2010.05.030
   Huang JJ, 2020, STEM CELLS DEV, V29, P401, DOI 10.1089/scd.2019.0260
   Imai K, 2006, BIOCHEM BIOPH RES CO, V345, P1615, DOI 10.1016/j.bbrc.2006.05.075
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Jones MJ, 2015, AGING CELL, V14, P924, DOI 10.1111/acel.12349
   Khan NM, 2018, PHARMACOL RES, V128, P73, DOI 10.1016/j.phrs.2017.08.007
   Krishnan V, 2011, P NATL ACAD SCI USA, V108, P12325, DOI 10.1073/pnas.1102789108
   Kurth TB, 2011, ARTHRITIS RHEUM US, V63, P1289, DOI 10.1002/art.30234
   Li JL, 2019, ONCOL LETT, V17, P3657, DOI 10.3892/ol.2019.10035
   Loeser RF, 2016, NAT REV RHEUMATOL, V12, P412, DOI 10.1038/nrrheum.2016.65
   Lories RJ, 2013, NAT REV RHEUMATOL, V9, P328, DOI 10.1038/nrrheum.2013.25
   Lu JW, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 438
   Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613
   Muñoz Espín D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Nalesso G, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 82067 w
   Pasyukova EG, 2017, MECH AGEING DEV, V166, P6, DOI 10.1016/j.mad.2017.08.008
   Sen N, 2013, MOL CELL, V52, P406, DOI 10.1016/j.molcel.2013.09.003
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Teiken K, 2018, CLIN SARCOMA RES, V8, DOI 10.1186/s13569 018 0096 8
   Tong WX, 2019, ANN RHEUM DIS, V78, P551, DOI 10.1136/annrheumdis 2018 214200
   Ueland T, 2020, J HYPERTENS, V38, P1347, DOI 10.1097/HJH.0000000000002362
   Wang XB, 2009, GROWTH FACTORS, V27, P40, DOI 10.1080/08977190802625179
   Woo DH, 2016, CELL STEM CELL, V19, P397, DOI 10.1016/j.stem.2016.05.024
   Yazici Y, 2017, OSTEOARTHR CARTILAGE, V25, P1598, DOI 10.1016/j.joca.2017.07.006
NR 32
TC 14
Z9 18
U1 3
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2021
VL 150
AR 116006
DI 10.1016/j.bone.2021.116006
EA MAY 2021
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TF0MS
UT WOS:000670402300010
PM 34000432
DA 2025 08 17
ER

PT J
AU Singh, VK
   Thakur, DC
   Rajak, N
   Mishra, A
   Kumar, A
   Giri, R
   Garg, N
AF Singh, Vipendra Kumar
   Thakur, D. C.
   Rajak, Naina
   Mishra, Anand
   Kumar, Ankur
   Giri, Rajanish
   Garg, Neha
TI The multi protein targeting potential of bioactive syringin in
   inflammatory diseases: using molecular modelling and in silico analysis
   of regulatory elements
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE MD simulation; inflammatory proteins; syringin; multi protein targets;
   GeneMANIA
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACCURATE DOCKING; GLIDE;
   PREDICTION; NSAIDS
AB Inflammation plays a crucial role in the onset or progression of a variety of acute and chronic diseases. Non steroidal anti inflammatory drugs (NSAIDs) are the only available FDA approved therapy. The therapeutic outcome of NSAIDs is still finite due to off target effects and extreme side effects on other vital organs. Bioactive syringin has been manifested to hold anti osteoporosis, cardiac hypertrophy, alter autophagy, anti cancer, neuro preventive effects, etc. However, its multi protein targeting potential in inflammation mostly remains unexplored. In the present work, we have checked the multi protein targeting potential of bioactive glycoside syringin in inflammatory diseases. Based on the binding score of protein ligand complexes, glycoside syringin scored greater than  7 kcal/mol against 12 inflammatory proteins. Our molecular dynamic simulation study (200 ns) confirmed that bioactive syringin remained inside the binding cavity of inflammatory proteins (JAK1, TYK2, and COX1) in a stable conformation. Further, our co expression analysis suggests that these genes play an essential role in multiple pathways and are regulated by multiple miRNAs. Our study demonstrates that bioactive glycoside syringin might be a multi protein targeting potential against inflammatory diseases and could be further investigated utilizing different preclinical approaches.Communicated by Ramaswamy H. Sarma
C1 [Singh, Vipendra Kumar; Thakur, D. C.; Kumar, Ankur; Giri, Rajanish] Indian Inst Technol Mandi, Sch Biosci & Bioengn, Mandi, India.
   [Rajak, Naina; Garg, Neha] Banaras Hindu Univ, Inst Med Sci, Fac Ayurveda, Dept Med Chem, Varanasi, India.
   [Mishra, Anand] CSIR Inst Himalayan Bioresource Technol, Mol Plant Pathol Lab, Palampur, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Mandi; Banaras Hindu University (BHU); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Institute of
   Himalayan Bioresource Technology (IHBT)
RP Garg, N (通讯作者)，Banaras Hindu Univ, Inst Med Sci, Fac Ayurveda, Dept Med Chem, Varanasi, India.
EM nehagarg@bhu.ac.in
RI ; Garg, Neha/AAG 5180 2020; Giri, Rajanish/Q 6530 2018
OI Singh (M.Sc Gold Medalist), PhD, Dr. Vipendra Kumar/0000 0003 4744 2474;
   Garg, Neha/0000 0003 2227 8292; Rajak, Naina/0009 0009 0653 3071; Giri,
   Rajanish/0000 0002 2046 836X
FU Dr. Vipendra Kumar Singh acknowledges the Indian Council of Medical
   Research   Associateship Fellowship, New Delhi, India, and Dr. D. C.
   Thakur acknowledges the ICMR for the Postdoctoral Fellowship. Ms. Naina
   Rajak acknowledges the Council of Scientific an; Indian Council of
   Medical Research   Associateship Fellowship, New Delhi, India; ICMR;
   Council of Scientific and Industrial Research   Senior Research
   Fellowship (CSIR   SRF), New Delhi, India; Institute of Eminence Scheme,
   BHU; Ministry of Electronics and Information Technology (MeitY);
   Department of Science and Technology (DST), Government of India
FX Dr. Vipendra Kumar Singh acknowledges the Indian Council of Medical
   Research   Associateship Fellowship, New Delhi, India, and Dr. D. C.
   Thakur acknowledges the ICMR for the Postdoctoral Fellowship. Ms. Naina
   Rajak acknowledges the Council of Scientific and Industrial Research  
   Senior Research Fellowship (CSIR   SRF), New Delhi, India. Dr. Neha Garg
   would like to acknowledge the seed grant under the Institute of Eminence
   Scheme, BHU, for financial support. The authors highly acknowledge the
   National Supercomputing Mission (NSM) for providing computing resources
   of 'PARAM Himalaya' at IIT Mandi, which is implemented by C DAC and
   supported by the Ministry of Electronics and Information Technology
   (MeitY) and Department of Science and Technology (DST), Government of
   India.
CR Bindu S, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114147
   Cho JY, 2001, J PHARM PHARMACOL, V53, P1287, DOI 10.1211/0022357011776577
   Choi J, 2004, PLANTA MED, V70, P1027, DOI 10.1055/s 2004 832642
   Dai R, 2021, ENVIRON TOXICOL, V36, P433, DOI 10.1002/tox.23049
   Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fürst R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/146832
   Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39
   Greenidge PA, 2013, J CHEM INF MODEL, V53, P201, DOI [10.1021/cI300025v, 10.1021/ci300425v]
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822 010 9349 1
   Gupta N, 2023, RECENT PAT ANTI CANC, V18, P3, DOI 10.2174/1574892817666220512220036
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F
   Huggins DJ, 2019, WIRES COMPUT MOL SCI, V9, DOI 10.1002/wcms.1393
   Kern F, 2020, NUCLEIC ACIDS RES, V48, P12523, DOI 10.1093/nar/gkaa1125
   Kwon KS, 2020, CHIN J INTEGR MED, V26, P670, DOI 10.1007/s11655 020 3188 2
   Lazim R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176339
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI [10.18632/oncotarget.20812, 10.18632/oncotarget.23208]
   Mori DN, 2014, IMMUNOL REV, V258, P132, DOI 10.1111/imr.12146
   Nunes CD, 2020, MOLECULES, V25, DOI 10.3390/molecules25163726
   Pirlamarla P, 2016, TRENDS CARDIOVAS MED, V26, P675, DOI 10.1016/j.tcm.2016.04.011
   Rajak N., 2023, BIOACTIVE PHYTOCHEMI, P89, DOI [https://doi.org/10.2174/9789815123289123010010, DOI 10.2174/9789815123289123010010]
   Salvo F, 2014, EXPERT OPIN DRUG SAF, V13, P573, DOI 10.1517/14740338.2014.907792
   Samtiya M, 2021, FOODS, V10, DOI 10.3390/foods10040839
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822 013 9644 8
   Serrano Antonio, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030076
   Shen ZJ, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110681
   Shivakumar D, 2010, J CHEM THEORY COMPUT, V6, P1509, DOI 10.1021/ct900587b
   Singh VK, 2024, J BIOMOL STRUCT DYN, V42, P12851, DOI 10.1080/07391102.2023.2273440
   Singh VK, 2019, PHYTOTHER RES, V33, P3064, DOI 10.1002/ptr.6508
   Singh VK, 2017, APOPTOSIS, V22, P1273, DOI 10.1007/s10495 017 1404 0
   Sorrenti V, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032019
   Tabarzad M, 2020, MOL BIOL REP, V47, P6193, DOI 10.1007/s11033 020 05562 9
   Tan JY, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107268
   US MR., 2015, Asian Journal of Pharmaceutical and Clinical Research, V8, P20, DOI DOI 10.1016/J.JEP.2017.11.030
   Zhang A, 2017, J SURG RES, V209, P252, DOI 10.1016/j.jss.2016.10.027
   Zhang HH, 2020, ARCH BIOCHEM BIOPHYS, V680, DOI 10.1016/j.abb.2019.108242
NR 38
TC 8
Z9 9
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739 1102
EI 1538 0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD DEC 16
PY 2024
VL 42
IS 23
BP 12851
EP 12862
DI 10.1080/07391102.2023.2273440
EA OCT 2023
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA P9P3Z
UT WOS:001087408900001
PM 37882327
DA 2025 08 17
ER

PT J
AU Gröger, D
   Kerschnitzki, M
   Weinhart, M
   Reimann, S
   Schneider, T
   Kohl, B
   Wagermaier, W
   Schulze Tanzil, G
   Fratzl, P
   Haag, R
AF Groeger, Dominic
   Kerschnitzki, Michael
   Weinhart, Marie
   Reimann, Sabine
   Schneider, Tobias
   Kohl, Benjamin
   Wagermaier, Wolfgang
   Schulze Tanzil, Gundula
   Fratzl, Peter
   Haag, Rainer
TI Selectivity in Bone Targeting with Multivalent Dendritic Polyanion Dye
   Conjugates
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bisphosphonates; bone targeting; conjugates; hydroxyapatite;
   inflammation
ID POLYGLYCEROL SULFATES; HYPERBRANCHED POLYMERS; IN VITRO;
   BISPHOSPHONATES; HYDROXYAPATITE; PROTEINS; BINDING; THERAPEUTICS;
   OSTEOPOROSIS; DERIVATIVES
AB Targeting bone with anionic macromolecules is a potent approach for the development of novel diagnostics and therapeutics for bone related diseases. A highly efficient modular synthesis of dendritic polyglycerol (dPG) polyanion dye conjugates, namely, sulfates, sulfonates, carboxylates, phosphates, phosphonates, and bisphosphonates via click chemistry is presented. By investigating the microarchitecture of stained bone sections with confocal laser scanning microscopy, the bisphosphonate, phosphonate, and phosphate functionalized polymers are identified as strongly penetrating compounds, whereas sulfates, sulfonates, and carboxylates reveal a weaker binding to hydroxyapatite (HA) but a more pronounced affinity toward collagen. In a quantitative HA binding assay, the affinity of the dPG sulfonate, sulfate, and carboxylate toward collagen and the exceptional high HA affinity of the phosphorous containing polyelectrolytes are validated. This shows the potential of dendritic polyphosphates and phosphonates as alternatives to the commonly employed bisphosphonate modification. In cytotoxicity studies with murine fibroblasts, the conjugates have no significant effect on the cell viability at 10( 5)m. All polyanions are taken up into the cells within 24 h. The presented synthetic approach allows versatile extensions for preparing conjugates for selective bone imaging applications, tissue engineering, and drug delivery.
C1 [Groeger, Dominic; Weinhart, Marie; Reimann, Sabine; Haag, Rainer] Free Univ Berlin, Inst Chem & Biochem, Takustr 3, D 14195 Berlin, Germany.
   [Kerschnitzki, Michael; Wagermaier, Wolfgang; Fratzl, Peter] Max Planck Inst Colloids & Interfaces, Dept Biomat, D 14424 Potsdam, Germany.
   [Schneider, Tobias; Kohl, Benjamin; Schulze Tanzil, Gundula] Charite, CBF, Klin Orthopad Unfall & Wiederherstellungschirurg, D 14195 Berlin, Germany.
C3 Free University of Berlin; Max Planck Society; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin
RP Haag, R (通讯作者)，Free Univ Berlin, Inst Chem & Biochem, Takustr 3, D 14195 Berlin, Germany.
EM haag@chemie.fu berlin.de
RI Kohl, Benjamin/AAM 4032 2020; Fratzl, Peter/H 9095 2012; Fratzl,
   Peter/JBJ 6517 2023; Weinhart, Marie/D 1696 2018
OI Fratzl, Peter/0000 0003 4437 7830; Weinhart, Marie/0000 0002 5116 5054;
   Kohl, Benjamin/0000 0002 2298 6830
FU Deutsche Forschungsgemeinschaft (DFG) [SFB 765]; Bundesministerium fur
   Bildung und Forschung (BMBF) [01 EC 1006C, 9133]
FX The authors acknowledge the focus area nanoscale
   (http://www.nanoscale.fu berlin.de) of the Freie Universitat Berlin and
   the Helmholtz Virtual Institute (HVI) for making this highly
   interdisciplinary research possible. For financial support we are
   grateful to the collaborative research centre SFB 765 of the Deutsche
   Forschungsgemeinschaft (DFG). M.K. is supported by the Bundesministerium
   fur Bildung und Forschung (BMBF, grant number: 01 EC 1006C, Project
   9133). Prof. Georg N. Duda and Dr. Hanna Schnell from Julius Wolff
   Institute at Charite are acknowledged for providing the bone samples.
   Dr. Pamela Winchester is thanked for proofreading the manuscript.
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   Bansal G, 2005, J BIOMED MATER RES A, V74A, P618, DOI 10.1002/jbm.a.30334
   Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521 1878(199810)20:10<837::AID BIES9>3.0.CO;2 D
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bosch X, 2011, ACS NANO, V5, P6779, DOI 10.1021/nn203190x
   Bulman Page P. C., 2001, TETRAHEDRON, V57, P1837
   Calderón M, 2010, ADV MATER, V22, P190, DOI 10.1002/adma.200902144
   Caliceti P, 2003, ADV DRUG DELIVER REV, V55, P1261, DOI 10.1016/S0169 409X(03)00108 X
   Cooper C, 2012, CURR MED RES OPIN, V28, P475, DOI 10.1185/03007995.2012.663750
   Currey JD, 2012, J MATER SCI, V47, P41, DOI 10.1007/s10853 011 5914 9
   Dernedde J, 2011, J CARBOHYD CHEM, V30, P347, DOI 10.1080/07328303.2011.608227
   Dernedde J, 2010, P NATL ACAD SCI USA, V107, P19679, DOI 10.1073/pnas.1003103107
   Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fleisch H., 2002, PRINCIPLES BONE BIOL, V2nd, P1361
   Fratzl P, 2004, J MATER CHEM, V14, P2115, DOI 10.1039/b402005g
   Fratzl P, 2007, PROG MATER SCI, V52, P1263, DOI 10.1016/j.pmatsci.2007.06.001
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Groger D., 2013, BIOCONJUGATE CHEM, DOI 10. 1021/bc400047f
   Haag R, 2006, ANGEW CHEM INT EDIT, V45, P1198, DOI 10.1002/anie.200502113
   Hayder M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002212
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Ito M, 1998, CALCIFIED TISSUE INT, V63, P143, DOI 10.1007/s002239900505
   Jin HB, 2012, CHEM SOC REV, V41, P5986, DOI 10.1039/c2cs35130g
   Kerschnitzki M, 2011, J STRUCT BIOL, V173, P303, DOI 10.1016/j.jsb.2010.11.014
   Khandare J, 2010, BIOMATERIALS, V31, P4268, DOI 10.1016/j.biomaterials.2010.02.001
   Kowada T, 2011, J AM CHEM SOC, V133, P17772, DOI 10.1021/ja2064582
   Lalatonne Y, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/747852
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Licha K, 2011, BIOCONJUGATE CHEM, V22, P2453, DOI 10.1021/bc2002727
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Papp I, 2008, CHEM COMMUN, P5851, DOI 10.1039/b813414f
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Reichert S, 2011, SMALL, V7, P820, DOI 10.1002/smll.201002220
   Rho JY, 1998, MED ENG PHYS, V20, P92, DOI 10.1016/S1350 4533(98)00007 1
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Schett G, 2010, ANN RHEUM DIS, V69, P1415, DOI 10.1136/ard.2010.135061
   Siegers C, 2004, CHEM EUR J, V10, P2831, DOI 10.1002/chem.200306073
   Siris ES, 2006, J BONE MINER RES, V21, pP94, DOI 10.1359/JBMR.06S218
   Sisson AL, 2010, SOFT MATTER, V6, P4968, DOI 10.1039/c0sm00149j
   Sousa Herves A, 2013, DENDRIMERS IN BIOMEDICAL APPLICATIONS, P56, DOI 10.1039/9781849737296 00056
   Steinhilber D, 2011, BIOMATERIALS, V32, P1311, DOI 10.1016/j.biomaterials.2010.10.010
   Steinhilber D, 2010, ADV FUNCT MATER, V20, P4133, DOI 10.1002/adfm.201000410
   Tanaka Y, 2013, ARCH ORAL BIOL, V58, P628, DOI 10.1016/j.archoralbio.2012.11.010
   Türk H, 2004, BIOCONJUGATE CHEM, V15, P162, DOI 10.1021/bc034044j
   Ural AU, 2003, INT J HEMATOL, V78, P443, DOI 10.1007/BF02983818
   Vitha T, 2008, LANGMUIR, V24, P1952, DOI 10.1021/la702753j
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271
   Weiner S, 1999, J STRUCT BIOL, V126, P241, DOI 10.1006/jsbi.1999.4107
   Weinhart M, 2011, MACROMOL BIOSCI, V11, P1088, DOI 10.1002/mabi.201100051
   Weinhart M, 2011, BIOMACROMOLECULES, V12, P2502, DOI 10.1021/bm200250f
   Weinhart M, 2011, CHEM COMMUN, V47, P1553, DOI 10.1039/c0cc04002a
   Weinhart M, 2010, CHEM ASIAN J, V5, P1992, DOI 10.1002/asia.201000127
   Zhang SF, 2007, MACROMOL BIOSCI, V7, P656, DOI 10.1002/mabi.200600286
   Zhou HX, 2011, REACT FUNCT POLYM, V71, P356, DOI 10.1016/j.reactfunctpolym.2010.11.018
   Zhou YF, 2010, ADV MATER, V22, P4567, DOI 10.1002/adma.201000369
NR 66
TC 21
Z9 22
U1 1
U2 70
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD MAR
PY 2014
VL 3
IS 3
BP 375
EP 385
DI 10.1002/adhm.201300205
PG 11
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA AC2MW
UT WOS:000332336400009
PM 23996966
DA 2025 08 17
ER

PT J
AU Futamura, N
   Urakawa, H
   Arai, E
   Kozawa, E
   Ishiguro, N
   Nishida, Y
AF Futamura, Naohisa
   Urakawa, Hiroshi
   Arai, Eisuke
   Kozawa, Eiji
   Ishiguro, Naoki
   Nishida, Yoshihiro
TI Hyaluronan synthesis inhibitor supplements the inhibitory effects of
   zoledronic acid on bone metastasis of lung cancer
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Hyaluronan; Lung cancer; Bone metastasis; Zoledronic acid;
   4 Methylumbelliferone
ID ERM PROTEINS; SYNTHASE SUPPRESSOR; CELL ADHESION; IN VITRO;
   4 METHYLUMBELLIFERONE; BREAST; BISPHOSPHONATES; CARCINOMA; CD44;
   ANTITUMOR
AB Hyaluronan is known to have pivotal roles in the growth, migration and invasion of malignant tumors. Bone metastases are critical lesions greatly impairing the quality of patients with malignancies. We investigated whether hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid, which is a conventional therapeutic agent for bone metastasis. We examined the effects of methylumbelliferone, an inhibitor of hyaluronan synthesis and/or ZA on the tumorigenicity of one murine lung carcinoma and two human (A549, SK MES 1) lung cancer cell lines in vitro. The interaction between methylumbelliferone and zoledronic acid was analyzed using Calcucyn software. With a murine bone metastasis model of lung cancer in vivo, we investigated the inhibitory effects and interaction of the two drugs on the progression of metastatic bone lesions. Methylumbelliferone or zoledronic acid treatment individually suppressed proliferation, migration and invasion of 3 cell lines, and combination treatment showed synergistic effects. Although methylumbelliferone as a single agent did not enhance apoptotic activity, it showed additive effects on apoptotic activity to those of zoledronic acid. Co localization of CD44 and ezrin, which might be a pathway of hyaluronan signaling, was abrogated by methylumbelliferone treatment. Combination therapy showed additive inhibitory effects on metastatic bone lesions in vivo, which paralleled the inhibition of hyaluronan accumulation by methylumbelliferone, and inhibition of osteoclastogenesis. Although the detailed mechanisms underlying the synergistic or additive inhibitory effects of these two drugs should be further analyzed, inhibition of hyaluronan synthesis by methylumbelliferone is a promising novel therapeutic candidate for bone metastasis of lung cancer in addition to zoledronic acid.
C1 [Futamura, Naohisa; Urakawa, Hiroshi; Arai, Eisuke; Kozawa, Eiji; Ishiguro, Naoki; Nishida, Yoshihiro] Nagoya Univ, Grad Sch Med, Dept Orthopaed Surg, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Nishida, Y (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Orthopaed Surg, Showa Ku, 65 Tsuruma, Nagoya, Aichi 4668550, Japan.
EM ynishida@med.nagoya u.ac.jp
RI Ishiguro, Naoki/I 1563 2012; Urakawa, Hiroshi/C 3599 2016; Kozawa,
   Eiji/B 9464 2016; Nishida, Yoshihiro/I 7354 2014
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [20591751]; Suzuken Memorial Foundation; Grants in Aid for Scientific
   Research [23592181] Funding Source: KAKEN
FX We thank Eri Ishihara for secretarial assistance. This work was
   supported in part by the Ministry of Education, Culture, Sports, Science
   and Technology of Japan [Grant in Aid 20591751 for Scientific Research
   (C)], and by the Suzuken Memorial Foundation.
CR Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477 3163.75723
   Arai E, 2011, BRIT J CANCER, V105, P1839, DOI 10.1038/bjc.2011.459
   BERTRAND P, 1992, INT J CANCER, V52, P1, DOI 10.1002/ijc.2910520102
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Dass CR, 2007, MOL CANCER THER, V6, P3263, DOI 10.1158/1535 7163.MCT 07 0546
   Dedes PG, 2012, BBA GEN SUBJECTS, V1820, P1926, DOI 10.1016/j.bbagen.2012.07.013
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Duterme C, 2009, J BIOL CHEM, V284, P33495, DOI 10.1074/jbc.M109.044362
   Edward M, 2010, BRIT J DERMATOL, V162, P1224, DOI 10.1111/j.1365 2133.2010.09699.x
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365 2796.1997.00170.x
   Hajime M, 2007, INT J CANCER, V120, P2704, DOI 10.1002/ijc.22349
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hosono K, 2007, AM J PATHOL, V171, P274, DOI 10.2353/ajpath.2007.060828
   Hung TT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019389
   Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200
   Jensen PV, 2004, HISTOCHEM CELL BIOL, V121, P361, DOI 10.1007/s00418 004 0648 2
   Kakizaki I, 2004, J BIOL CHEM, V279, P33281, DOI 10.1074/jbc.M405918200
   KNUDSON W, 1989, CIBA F SYMP, V143, P150
   Kudo D, 2004, BIOCHEM BIOPH RES CO, V321, P783, DOI 10.1016/j.bbrc.2004.07.041
   Kultti A, 2009, EXP CELL RES, V315, P1914, DOI 10.1016/j.yexcr.2009.03.002
   Lokeshwar VB, 2010, CANCER RES, V70, P2613, DOI 10.1158/0008 5472.CAN 09 3185
   Mori T, 2008, J BIOL CHEM, V283, P29602, DOI 10.1074/jbc.M803606200
   Neville Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041
   Nicolatou Galitis O, 2011, ORAL SURG ORAL MED O, V112, P195, DOI 10.1016/j.tripleo.2011.02.037
   Nishida Y, 2005, EXP CELL RES, V307, P194, DOI 10.1016/j.yexcr.2005.03.026
   Pirinen RT, 1998, INT J CANCER, V79, P251, DOI 10.1002/(SICI)1097 0215(19980619)79:3<251::AID IJC7>3.0.CO;2 O
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Santini D, 2010, CURR CANCER DRUG TAR, V10, P46, DOI 10.2174/156800910790980223
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Tofuku K, 2006, INT J ONCOL, V29, P175
   Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391
   Tsuda M, 2004, J BIOL CHEM, V279, P46843, DOI 10.1074/jbc.M401476200
   Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200
   Urakawa H, 2012, J ORTHOP RES, V30, P662, DOI 10.1002/jor.21557
   Urakawa H, 2012, INT J CANCER, V130, P454, DOI 10.1002/ijc.26014
   Woodward RM, 2007, CANCER AM CANCER SOC, V110, P2511, DOI 10.1002/cncr.23058
   Yoshihara S, 2005, FEBS LETT, V579, P2722, DOI 10.1016/j.febslet.2005.03.079
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
   Zhu L, 2010, INT ARCH ALLERGY IMM, V153, P223, DOI 10.1159/000314362
NR 45
TC 13
Z9 13
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD JUN
PY 2013
VL 30
IS 5
BP 595
EP 606
DI 10.1007/s10585 012 9563 4
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 149UC
UT WOS:000319345900005
PM 23288481
DA 2025 08 17
ER

PT J
AU Xu, DH
   Xu, LL
   Zhou, CH
   Lee, WYW
   Wu, T
   Cui, L
   Li, G
AF Xu, Daohua
   Xu, Liangliang
   Zhou, Chenhui
   Lee, Wayne Y. W.
   Wu, Tie
   Cui, Liao
   Li, Gang
TI Salvianolic acid B promotes osteogenesis of human mesenchymal stem cells
   through activating ERK signaling pathway
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Mesenchymal stem cell; Osteogenesis; Salvianolic acid B; Osteoporosis
ID TRANSCRIPTION FACTOR OSTERIX; OSTEOBLAST DIFFERENTIATION;
   ALKALINE PHOSPHATASE; BONE FORMATION; MINERALIZATION; EXPRESSION;
   OSTEOPOROSIS; MAPK; PROLIFERATION; PATHOGENESIS
AB Salvianolic acid B, a major bioactive component of Chinese medicine herb, Salvia miltiorrhiza, is widely used for treatment of cardiovascular diseases. Our recent studies have shown that Salvianolic acid B can prevent development of osteoporosis. However, the underlying mechanisms are still not clarified clearly. In the present study, we aim to investigate the effects of Salvianolic acid B on viability and osteogenic differentiation of human mesenchymal stem cells (hMSCs). The results showed Salvianolic acid B (Sal B) had no obvious toxic effects on hMSCs, whereas Sal B supplementation (5 mu M) increased the alkaline phosphatase activity, osteopontin, Runx2 and osterix expression in hMSCs. Under osteogenic induction condition, Sal B (5 mu M) significantly promoted mineralization; and when the extracellular signal regulated kinases signaling (ERK) pathway was blocked, the anabolic effects of Sal B were diminished, indicating that Sal B promoted osteogenesis of hMSCs through activating ERK signaling pathway. The current study confirms that Sal B promotes osteogenesis of hMSCs with no cytotoxicity, and it may be used as a potential therapeutic agent for the management of osteoporosis. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Xu, Daohua; Zhou, Chenhui; Wu, Tie; Cui, Liao] Guangdong Med Coll, Dept Pharmacol, Dongguan, Peoples R China.
   [Xu, Daohua; Xu, Liangliang; Lee, Wayne Y. W.; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China.
   [Xu, Liangliang; Lee, Wayne Y. W.; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Sch Biomed Sci, MOE Key Lab Regenerat Med, Shatin, Hong Kong, Peoples R China.
   [Lee, Wayne Y. W.; Li, Gang] Chinese Univ Hong Kong, Shenzhen Res Inst, CUHK ACC Space Med Ctr Hlth Maintenance Musculosk, Shenzhen, Peoples R China.
   [Xu, Liangliang; Lee, Wayne Y. W.; Li, Gang] Chinese Univ Hong Kong, Fac Med, Lui Che Woo Inst Innovat Med, Hong Kong, Hong Kong, Peoples R China.
C3 Guangdong Medical University; Chinese University of Hong Kong; Prince of
   Wales Hospital; Chinese University of Hong Kong; Prince of Wales
   Hospital; Chinese University of Hong Kong; CUHK Shenzhen Research
   Institute; The Chinese University of Hong Kong, Shenzhen; Chinese
   University of Hong Kong
RP Cui, L (通讯作者)，Guangdong Med Coll, Dept Pharmacol, Dongguan, Peoples R China.
EM cuiliao@163.com; gangli@cuhk.edu.hk
RI ; Li, Gang/J 7830 2018; Lee, Wayne/H 8298 2013; Liangliang,
   XU/K 9185 2019; Lee, Wayne YW/H 8298 2013
OI Xu, Liangliang/0000 0002 5249 7480; Li, Gang/0000 0002 3981 2239; Lee,
   Wayne YW/0000 0002 0486 360X
FU National Natural Science Foundation of China [30772768]; Natural Science
   Foundation of Guangdong Province [10152402301000000]; Science and
   Technology Planning Project of Dongguan [2011108102019]; Science &
   Technology Innovation Fund of Guangdong Medical College [STIF201104];
   National Basic Science and Development Program, PR China (973 Program)
   [2012CB518105]; Hong Kong Government Research Grant Council, General
   Research Fund [CUHK470813]; SMART program, Lui Che Woo Institute of
   Innovative Medicine, Faculty of Medicine, The Chinese University of Hong
   Kong; Lui Che Woo Foundation Limited, Hong Kong
FX We thank financial support from National Natural Science Foundation of
   China (30772768), Natural Science Foundation of Guangdong Province
   (10152402301000000), Science and Technology Planning Project of Dongguan
   (2011108102019) and Science & Technology Innovation Fund of Guangdong
   Medical College (STIF201104). These works were also supported in part by
   the National Basic Science and Development Program, PR China (973
   Program, 2012CB518105); and Hong Kong Government Research Grant Council,
   General Research Fund (Grant No.: CUHK470813) to Gang Li. This study was
   also supported in part by SMART program, Lui Che Woo Institute of
   Innovative Medicine, Faculty of Medicine, The Chinese University of Hong
   Kong. This research project was supported in part by donation from Lui
   Che Woo Foundation Limited, Hong Kong.
CR Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Chen TH, 2007, BIOCHEM BIOPH RES CO, V355, P913, DOI 10.1016/j.bbrc.2007.02.057
   Cui LN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044737
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   HARRISON G, 1995, J BONE MINER RES, V10, P568, DOI 10.1002/jbmr.5650100409
   He HB, 2008, J ETHNOPHARMACOL, V118, P35, DOI 10.1016/j.jep.2008.03.006
   Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Joe Y, 2012, J PHARMACOL EXP THER, V341, P850, DOI 10.1124/jpet.111.190736
   Kanis JA, 2009, NAT REV RHEUMATOL, V5, P425, DOI 10.1038/nrrheum.2009.139
   Kim DH, 2011, NEUROPHARMACOLOGY, V61, P1432, DOI 10.1016/j.neuropharm.2011.08.038
   Kim YJ, 2006, GENE, V366, P145, DOI 10.1016/j.gene.2005.08.021
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kumar S, 2010, MOL THER, V18, P1026, DOI 10.1038/mt.2009.315
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lee CH, 2011, EUR J PHARMACOL, V668, P383, DOI 10.1016/j.ejphar.2011.06.059
   Lee YW, 2013, EUR J PHARMACOL, V704, P70, DOI 10.1016/j.ejphar.2013.02.015
   Lu BY, 2010, CELL BIOL INT, V34, P1063, DOI 10.1042/CBI20090126
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Orimo H, 2008, MOL CELL BIOCHEM, V315, P51, DOI 10.1007/s11010 008 9788 3
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Park D, 2010, STEM CELLS, V28, P2162, DOI 10.1002/stem.541
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Sandhu SK, 2011, J CLIN PATHOL, V64, P1042, DOI 10.1136/jcp.2010.077842
   Shekkeris AS, 2012, CURR STEM CELL RES T, V7, P127
   Tse WT, 2000, BLOOD, V96, p241A
   Tu QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI 10.1016/j.bbrc.2006.01.092
   Undale A, 2011, J ORTHOP RES, V29, P1804, DOI 10.1002/jor.21480
   Wang R, 2012, J ETHNOPHARMACOL, V144, P592, DOI 10.1016/j.jep.2012.09.048
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xu LL, 2012, INT J BIOCHEM CELL B, V44, P612, DOI 10.1016/j.biocel.2011.12.018
   YAO KL, 1994, J BONE MINER RES, V9, P231
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
NR 44
TC 85
Z9 94
U1 0
U2 39
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUN
PY 2014
VL 51
BP 1
EP 9
DI 10.1016/j.biocel.2014.03.005
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AJ6BL
UT WOS:000337774600001
PM 24657587
DA 2025 08 17
ER

PT J
AU Sabbieti, MG
   Agas, D
   Maggi, F
   Vittori, S
   Marchetti, L
AF Sabbieti, Maria Giovanna
   Agas, Dimitrios
   Maggi, Filippo
   Vittori, Sauro
   Marchetti, Luigi
TI Molecular Mediators Involved in Ferulago campestris
   Essential Oil Effects on Osteoblast Metabolism
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE ESSENTIAL OIL; FERULAGO CAMPESTRIS; OSTEOBLASTS; OSTEOPOROSIS
ID FIBROBLAST GROWTH FACTOR 2; PROMOTER ACTIVITY; BONE MASS;
   DIFFERENTIATION; EXPRESSION; KINASE; GENE; INHIBITION; CYCLIN; CBFA1
AB This study was performed to investigate the effects of the essential oil obtained from fruits of Ferulago campestris (FC) on primary calvarial mouse osteoblasts (COBs). The composition of the oil was dominated by monoterpene hydrocarbons (78.8 80.3%), with myrcene (33.4 39.7%), a pinene (22.7 23.0%), and gamma terpinene (8.1 10.9%) as the major components. Owing to their lipophilic properties, these compounds easily cross cell membranes and affect bone cell function by stimulating or inhibiting specific molecular pathways. We demonstrated, for the first time, that FC oil increased osteoblast proliferation by MAP kinase activation; in addition, oils enhanced the protein kinase AKT, which is known to be critical for control of cell survival, also in presence of the MEK 1 inhibitor PD98059, and this effect was accompanied with a down regulation of pro apototic molecules such as Bax and caspases. Interestingly, FC oil significantly increased Runx2 (Runx2/Pebp2 alpha A/AML3) and phospho Smad1/5/8 protein level, the master regulators of osteoblast differentiation, and their nuclear localization. PD98059 pre treatment further improved Runx2/phospho Smads up regulation. Thus, FC oils influence osteoblast metabolism probably using alternative signaling pathways depending also on the maturation stage of the cells. Taken together our data delineate a positive function of FC oil on osteoblast metabolism, suggesting its possible use as a dietetic integrator in the prevention or in the therapy of pathologies due to impaired bone remodeling. J. Cell. Biochem. 112: 3742 3754, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Sabbieti, Maria Giovanna; Agas, Dimitrios; Marchetti, Luigi] Univ Camerino, Sch Biosci & Biotechnol, I 62032 Camerino, MC, Italy.
   [Maggi, Filippo; Vittori, Sauro] Univ Camerino, Sch Pharm, I 62032 Camerino, MC, Italy.
C3 University of Camerino; University of Camerino
RP Marchetti, L (通讯作者)，Univ Camerino, Sch Biosci & Biotechnol, Via Gentile III da Varano, I 62032 Camerino, MC, Italy.
EM luigi.marchetti@unicam.it
RI Agas, Dimitrios/AAO 9214 2021; Maggi, Filippo/AAI 1551 2020
OI Maggi, Filippo/0000 0003 1375 4744; Sabbieti, Maria
   Giovanna/0000 0002 0838 5748; Agas, Dimitrios/0000 0002 7809 3601
CR Agas D, 2008, J CELL PHYSIOL, V214, P145, DOI 10.1002/jcp.21170
   Aggarwal BB, 2004, ANN NY ACAD SCI, V1030, P434, DOI 10.1196/annals.1329.054
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   [Anonymous], 2007, IDENTIFICATION ESSEN
   Appleton B, 2006, PHARM J, V277, P78
   Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Baser KHC, 2002, PURE APPL CHEM, V74, P527, DOI 10.1351/pac200274040527
   BERESFORD JN, 1993, AM J MED GENET, V45, P163, DOI 10.1002/ajmg.1320450205
   Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280
   Bratton MR, 2010, INT J ONCOL, V37, P541, DOI 10.3892/ijo_00000703
   CANNON JFM, 1993, FLORA EUROPAEA, V1, P359
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0
   Chow JYC, 2007, CARCINOGENESIS, V28, P2321, DOI 10.1093/carcin/bgm159
   CLEGG RJ, 1982, J BIOL CHEM, V257, P2294
   CROWELL PL, 1991, J BIOL CHEM, V266, P17679
   Demirci F, 2000, Z NATURFORSCH C, V55, P886
   Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092 8674(00)81696 7
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eriksson K, 1996, J CHROMATOGR B, V677, P85, DOI 10.1016/0378 4347(95)00435 1
   Fotedar R, 1996, ONCOGENE, V12, P2155
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Goumans MJ, 2000, INT J DEV BIOL, V44, P253
   Hanada M, 2004, BBA PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009
   Holmgren P. K., 1998, INDEX HERBARIORUM GL
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097 2765(03)00180 1
   Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776
   Inoue A, 1996, BIOCHEM BIOPH RES CO, V221, P703, DOI 10.1006/bbrc.1996.0660
   JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685
   Jeong JG, 2008, PHYTOTHER RES, V22, P18, DOI 10.1002/ptr.2247
   Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097 4644(19980601)69:3<353::AID JCB12>3.3.CO;2 W
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khalighi Sigaroodi Farahnaz, 2005, Daru, V13, P100
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Leung A.Y., 1996, ENCY COMMON NATURAL, V2nd
   Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200
   LIU JJ, 1995, MOL CELL BIOL, V15, P3654
   Maggi F, 2010, FLAVOUR FRAG J, V25, P63, DOI 10.1002/ffj.1962
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   Mühlbauer RC, 2003, BONE, V32, P372, DOI 10.1016/S8756 3282(03)00027 9
   Naganawa T, 2008, J CELL BIOCHEM, V103, P1975, DOI 10.1002/jcb.21589
   Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827
   National Institute of Standards and Technology (NIST) Mass Spectrometry Data Center, 2008, 08 NIST
   Niu TH, 2005, GENE, V361, P38, DOI 10.1016/j.gene.2005.07.016
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006 2952(97)00151 2
   Rössig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644 5657.2001
   S Pignatti, 1982, FLORA ITALIA, V2, P230
   Sabbieti MG, 2010, J CELL PHYSIOL, V224, P465, DOI 10.1002/jcp.22143
   Sabbieti MG, 2009, J CELL PHYSIOL, V219, P143, DOI 10.1002/jcp.21661
   Sabbieti MG, 1999, ENDOCRINOLOGY, V140, P434, DOI 10.1210/en.140.1.434
   Salingcarnboriboon RA, 2010, J CELL PHYSIOL, V224, P743, DOI 10.1002/jcp.22176
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Ussar S, 2004, J BIOL CHEM, V279, P43861, DOI 10.1074/jbc.M406240200
   Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499
   Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 68
TC 16
Z9 16
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC
PY 2011
VL 112
IS 12
BP 3742
EP 3754
DI 10.1002/jcb.23306
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 851YV
UT WOS:000297309600029
PM 21815199
DA 2025 08 17
ER

PT J
AU Ringe, JD
   Schacht, E
AF Ringe, J. D.
   Schacht, E.
TI Potential of alfacalcidol for reducing increased risk of falls and
   fractures
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Osteoporosis
ID CORTICOSTEROID INDUCED OSTEOPOROSIS; PLAIN VITAMIN D;
   GLUCOCORTICOID INDUCED OSTEOPOROSIS; HORMONE REPLACEMENT THERAPY; LOW
   CREATININE CLEARANCE; BONE MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS;
   SKELETAL MUSCLE; FUNCTIONAL MOBILITY; PARATHYROID HORMONE
AB There are no general accepted strategies for combined drug treatments in osteoporosis, while in other important chronic diseases combinations of different medications are used as a rule to improve therapeutic results and reduce the risk of adverse events. It is suggested that the success of combined treatments is related to the different modes of action of the respective single therapies. On the other hand it was shown that a strong antiresorptive bisphosphonate is able to blunt at least in part the effects of anabolic parathyroid hormone peptides Calcitriol, the active vitamin D hormone and its prodrug alfacalcidol lead to pleiotropic effects on bone remodelling (antiresorptive, anabolic and enhancing mineralization) and in addition to effects on other important target tissues (e.g. gut, parathyroid glands, muscle). With active D analogs significant improvements in the therapeutic outcome of osteoporosis can be achieved by the resulting improvements of bone quality, calcium absorption and risk reduction of falling. The same beneficial effects cannot be achieved with plain vitamin D due to feedback controlled, limited renal activation or insufficient conversion in the elderly with impairment of renal function. Accordingly alfacalcidol, approved as a treatment for different forms of osteoporosis, is besides adoption as a mono therapy an interesting candidate for combined therapies. There are interesting preclinical trials and clinical pilote studies in the literature proving that a parallel therapy with selectively anti osteoclastic bisphophonates and pleiotropically acting D analogs is able to optimize therapeutic results in osteoporosis. In the AAC Trial (Alfacalcidol Alendronate Combined) we studied 90 patients with established osteoporosis (57 women, 33 men) over two years after alternate allocation to three treatment arms (alfacalcidol plus calcium, alendronate plus plain vitamin D and Ca, and alendronate plus alfacalcidol and Ca). During the 2 year study we observed the significantly highest lumbar spine and hip BMD increases in the combined treatment group (p < 0.001). The number of patients with new vertebral and non vertebral fractures after 2 years was 9 with alfacalcidol alone, 10 with alfacalcidol and plain vitamin D and 2 in the group receiving alendronate plus alfacalidol (p < 0.02). Furthermore there was a lower rate of falls and an earlier reduction in back pain in the patients treated with the active combination. This trial confirms the demonstrated highly significant advantages of this combined treatment regimen used in the pilote studies. Especially in patients with severe osteoporosis this interesting combination of two substances with complete different mechanisms of action should be taken into consideration.
C1 [Ringe, J. D.; Schacht, E.] Univ Cologne, Klinikum Leverkusen, WOC, D 51375 Leverkusen, Germany.
   [Ringe, J. D.; Schacht, E.] Univ Cologne, Klinikum Leverkusen, Med Clin 4, D 51375 Leverkusen, Germany.
C3 University of Cologne; University of Cologne
RP Ringe, JD (通讯作者)，Univ Cologne, Klinikum Leverkusen, WOC, D 51375 Leverkusen, Germany.
EM ringe@klinikum lev.de
CR Adachi JD, 1996, J RHEUMATOL, V23, P995
   Alexandersen P, 1999, J CLIN ENDOCR METAB, V84, P3013, DOI 10.1210/jc.84.9.3013
   [Anonymous], 1992, J Bone Miner Metab
   Bischoff HA, 1999, ARCH PHYS MED REHAB, V80, P54, DOI 10.1016/S0003 9993(99)90307 6
   Bischoff HA, 2001, HISTOCHEM J, V33, P19, DOI 10.1023/A:1017535728844
   Bischoff Ferrari HA, 2004, JAMA J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff Ferrari HA, 2004, J BONE MINER RES, V19, P265, DOI 10.1359/jbmr.2004.19.2.265
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   BOLAND R, 1986, ENDOCR REV, V7, P434, DOI 10.1210/edrv 7 4 434
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   de Nijs RNJ, 2004, OSTEOPOROSIS INT, V15, P589, DOI 10.1007/s00198 004 1614 5
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   DELUCA HF, 1978, ARCH INTERN MED, V138, P836, DOI 10.1001/archinte.138.Suppl_5.836
   Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01 0433rev
   Dukas L, 2005, OSTEOPOROSIS INT, V16, P198, DOI 10.1007/s00198 004 1671 9
   Dukas L, 2003, OSTEOPOROSIS INT, V14, pS34
   Dukas L, 2004, J AM GERIATR SOC, V52, P230, DOI 10.1111/j.1532 5415.2004.52060.x
   Dukas LC, 2005, OSTEOPOROSIS INT, V16, P332, DOI 10.1007/s00198 004 1690 6
   Frediani B, 1998, CLIN DRUG INVEST, V15, P235, DOI 10.2165/00044011 199815030 00008
   Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P3618, DOI 10.1210/jc.86.8.3618
   GAMBACCIANI M, 1995, EUR MENOPAUSE J, V2, P16
   HENDERSONBRIFFA K, 2003, TRANSPLANTATION, V75, P2133
   Huldschinsky K, 1919, DEUT MED WOCHENSCHR, V45, P712, DOI 10.1055/s 0028 1137830
   Inanir A, 2004, J INT MED RES, V32, P570, DOI 10.1177/147323000403200602
   Ito M, 2002, JPN J PHARMACOL, V89, P255, DOI 10.1254/jjp.89.255
   Kanis JA, 1999, KIDNEY INT, V56, pS77, DOI 10.1046/j.1523 1755.1999.07317.x
   Kaptoge S, 2005, BONE, V36, P387, DOI 10.1016/j.bone.2004.11.012
   KIPSHOVEN C, 2008, OSTEOLOGIE, V1, pA55
   Lakatos P, 2000, Z RHEUMATOL, V59, P48
   Lems WF, 1997, ANN RHEUM DIS, V56, P357, DOI 10.1136/ard.56.6.357
   Lips P, 2004, J STEROID BIOCHEM, V89 90, P611, DOI 10.1016/j.jsbmb.2004.03.040
   Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471 4914(02)02294 3
   Mellanby E, 1919, LANCET, V1, P407
   Misra B, 2008, J BONE MINER RES, V23, pS10
   Morabito N, 2003, OSTEOPOROSIS INT, V14, P500, DOI 10.1007/s00198 003 1397 0
   ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521
   Papadimitropoulos E, 2002, ENDOCR REV, V23, P560, DOI 10.1210/er.2001 8002
   Reginster JY, 2003, OSTEOPOROSIS INT, V14, P741, DOI 10.1007/s00198 003 1432 1
   Reginster JY, 1999, OSTEOPOROSIS INT, V9, P75, DOI 10.1007/s001980050118
   Richy F, 2004, OSTEOPOROSIS INT, V15, P301, DOI 10.1007/s00198 003 1570 5
   Richy F, 2008, CALCIFIED TISSUE INT, V82, P102, DOI 10.1007/s00223 008 9102 0
   Ringe J, 2005, RHEUMATOL INT, V25, P296, DOI 10.1007/s00296 004 0570 x
   Ringe JD, 2007, RHEUMATOL INT, V28, P103, DOI 10.1007/s00296 007 0422 6
   Ringe JD, 2007, RHEUMATOL INT, V27, P425, DOI 10.1007/s00296 006 0288 z
   Ringe JD, 2008, J BONE MINER RES, V23, pS349
   Ringe JD, 2005, J RHEUMATOL, V32, P33
   Ringe JD, 2004, RHEUMATOL INT, V24, P63, DOI 10.1007/s00296 003 0361 9
   Ringe JD, 2001, CALCIFIED TISSUE INT, V69, P252, DOI 10.1007/s00223 001 1050 x
   Ringe JD, 2002, RHEUMATOL INT, V22, P27, DOI 10.1007/s00296 002 0193 z
   RINGE JD, 2003, CALCIUM PLUS VITAMIN
   Ringe JD, 2005, ARZNEIMITTELTHERAPIE, V23, P45
   RINGE JD, 2006, ALFACALCIDOL PREVENT
   RINGE JD, 1999, VITAMIND CALCIUM OST
   Runge M., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P127
   Sasaki H, 2008, J BONE MINER RES, V23, pS427
   Schacht E, 1999, CALCIFIED TISSUE INT, V65, P317, DOI 10.1007/s002239900705
   Schaffert S, 2008, IEEE SOFTWARE, V25, P8, DOI 10.1109/MS.2008.95
   Schapira AHV, 2008, EUR J NEUROL, V15, P132
   Scharla SH, 2005, J RHEUMATOL, V32, P26
   Shane E, 2004, NEW ENGL J MED, V350, P767, DOI 10.1056/NEJMoa035617
   SORENSEN OH, 1979, CLIN SCI, V56, P157, DOI 10.1042/cs0560157
   Tanizawa T, 1999, OSTEOPOROSIS INT, V9, P163, DOI 10.1007/s001980050131
   TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Verhaar HJJ, 2000, AGING CLIN EXP RES, V12, P455, DOI 10.1007/BF03339877
   Wu Wong J Ruth, 2004, Curr Opin Investig Drugs, V5, P320
   Youm T, 1999, Am J Orthop (Belle Mead NJ), V28, P190
NR 67
TC 12
Z9 14
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0172 8172
EI 1437 160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD AUG
PY 2009
VL 29
IS 10
BP 1177
EP 1185
DI 10.1007/s00296 008 0835 x
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 477EQ
UT WOS:000268501800008
PM 19159932
DA 2025 08 17
ER

PT J
AU Lei, FZ
   Li, MJ
   Lin, TT
   Zhou, H
   Wang, F
   Su, XX
AF Lei, Fengzhen
   Li, Mujia
   Lin, Tingting
   Zhou, Hong
   Wang, Fei
   Su, Xiaoxia
TI Treatment of inflammatory bone loss in periodontitis by stem
   cell derived exosomes
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Periodontitis; Inflammatory bone loss; PDLSCs; Exosomes; Wnt signaling
ID SUPPRESSES OSTEOGENIC DIFFERENTIATION; EXTRACELLULAR VESICLES; PROMOTES
   PROLIFERATION; LIGAMENT; REPAIR; ANGIOGENESIS; MARROW; NECROSIS;
   DEFECTS; PDLSCS
AB Periodontitis is the primary cause of tooth loss, but there is no effective treatment to repair inflammatory bone loss in periodontitis. Exosomes emerge as essential paracrine factors of mesenchymal stem cells (MSCs) that mediated tissue regeneration. Here, we investigated the potential of exosomes secreted by periodontal ligament stem cells (PDLSCs) as therapeutics for the bone defect in periodontitis. Exosomes secreted from PDLSCs derived from healthy periodontal ligaments (h PDLSCs) and their function were evaluated on PDLSCs isolated from the inflammatory periodontal ligament of periodontitis patients (i PDLSCs). Treatment of exosomes of h PDLSCs led to an increase in the formation of mineralized nodules and the expressions of osteogenic genes and proteins in i PDL SCs. Mechanistically, h PDL SCs exosomes suppressed the over activation of canonical Wnt signaling to recover the osteogenic differentiation capac ity of i PDLSCs. To evaluate the therapeutic of exosomes on inflammatory bone loss, h PDLSCs exosomes loaded with Matrigel or beta TCP were employed to repair bone defects in rat models of periodontitis. Com pared to the vehicle treated control group, h PDLSCs exosomes treated rats resulted in more bone forma tion in the defect of alveolar bone. In conclusion, these results demonstrated that exosomes derived from healthy PDLSCs could rescue the osteogenesis capacity of endogenous stem cells under an inflammatory environment and promote regeneration of alveolar bone. Our findings suggest that MSCs derived exosome is an effective and practical cell free MSC therapeutic for the treatment of periodontitis.
   Statement of significance
   There is no effective treatment to repair inflammatory bone loss in periodontitis. As essential paracrine factors of PDLSCs, exosomes might mediate tissue regeneration during stem cell therapy. Here, we re ported that exosomes secreted from healthy PDLSCs promoted the osteogenic differentiation of PDLSCs derived from periodontitis tissue. Healthy PDLSCs exosomes treatment resulted in accelerated bone for mation in the defect of alveolar bone in rat models of periodontitis. Mechanistically, h PDLSCs exosomes suppressed the over activation of canonical Wnt signaling to recover the osteogenic differentiation ca pacity of inflammatory PDLSCs. These findings suggest that MSCs derived exosome is an effective and practical cell free MSC therapeutic for the treatment of periodontitis. (C) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Lei, Fengzhen; Li, Mujia; Su, Xiaoxia] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Pediat Dent,State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Lei, Fengzhen; Lin, Tingting; Zhou, Hong; Wang, Fei] Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710004, Shaanxi, Peoples R China.
   [Li, Mujia; Su, Xiaoxia] Sichuan Univ, West China Sch Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Lei, Fengzhen; Lin, Tingting; Zhou, Hong; Wang, Fei] Xi An Jiao Tong Univ, Stomatol Hosp, Coll Med, Dept Orthodont, Xian 710004, Peoples R China.
C3 Sichuan University; Xi'an Jiaotong University; Sichuan University; Xi'an
   Jiaotong University
RP Su, XX (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Pediat Dent,State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
EM orthodontist_su@163.com
RI Wang, Fei/AAU 2516 2021
FU National Natural Science Foundation of China [81600912, 82071092]; Key
   Project of Sichuan province [2019YFS0311, 2020YFS0177]; Fundamental
   Research Funds for the Central Universities [YJ201878]
FX This work was supported by grants from the National Natural Science
   Foundation of China [81600912, 82071092]; Key Project of Sichuan
   province [2019YFS0311, 2020YFS0177]; and the Fundamental Research Funds
   for the Central Universities [YJ201878].
CR Akiyama Kentaro, 2012, Methods Mol Biol, V887, P111, DOI 10.1007/978 1 61779 860 3_11
   Aliotta JM, 2016, CARDIOVASC RES, V110, P319, DOI 10.1093/cvr/cvw054
   [Anonymous], 2005, J PERIODONTOL, V76, P1406, DOI 10.1902/jop.2005.76.8.1406
   Bartold PM, 2016, J PERIODONTAL RES, V51, P1, DOI 10.1111/jre.12275
   Bjorge IM, 2017, BIOMATER SCI UK, V6, P60, DOI 10.1039/c7bm00479f
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Chen FM, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0288 1
   Chew JRJ, 2019, ACTA BIOMATER, V89, P252, DOI 10.1016/j.actbio.2019.03.021
   Cho HH, 2006, TISSUE ENG, V12, P111, DOI 10.1089/ten.2006.12.111
   Choi M, 2014, MOL CELLS, V37, P133, DOI 10.14348/molcells.2014.2317
   Coimbra LS, 2011, J PERIODONTOL, V82, P767, DOI 10.1902/jop.2010.100555
   Daoussis D, 2010, SEMIN ARTHRITIS RHEU, V39, P369, DOI 10.1016/j.semarthrit.2008.10.008
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Fei DD, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.687258
   Gangadaran P, 2017, J CONTROL RELEASE, V264, P112, DOI 10.1016/j.jconrel.2017.08.022
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Li B, 2016, SCI REP UK, V6, DOI 10.1038/srep26542
   Li HL, 2017, CELL BIOL INT, V41, P1379, DOI 10.1002/cbin.10869
   Li WY, 2018, ACS APPL MATER INTER, V10, P5240, DOI 10.1021/acsami.7b17620
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Liu L, 2021, TISSUE ENG PT A, V27, P962, DOI [10.1089/ten.tea.2020.0141, 10.1089/ten.TEA.2020.0141]
   Liu N, 2011, J BONE MINER RES, V26, P2082, DOI 10.1002/jbmr.440
   Liu Q, 2015, SCI REP UK, V5, DOI 10.1038/srep13142
   Liu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.65
   Liu WJ, 2014, BBA GEN SUBJECTS, V1840, P1125, DOI 10.1016/j.bbagen.2013.11.003
   Luo X, 2009, BMB REP, V42, P338, DOI 10.5483/BMBRep.2009.42.6.338
   Lv PY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01815 3
   Mohammed E, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040167
   Park JC, 2011, J CLIN PERIODONTOL, V38, P721, DOI 10.1111/j.1600 051X.2011.01716.x
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575
   Pietrokovski Jaime, 2007, J Prosthodont, V16, P141, DOI 10.1111/j.1532 849X.2007.00165.x
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Rager TM, 2016, J PEDIATR SURG, V51, P942, DOI 10.1016/j.jpedsurg.2016.02.061
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi WW, 2020, ACS BIOMATER SCI ENG, V6, P5797, DOI 10.1021/acsbiomaterials.0c00882
   Tang HN, 2016, J CLIN PERIODONTOL, V43, P72, DOI 10.1111/jcpe.12501
   Tomasi C, 2008, J ORAL REHABIL, V35, P23, DOI 10.1111/j.1365 2842.2007.01831.x
   Tomokiyo A, 2019, STEM CELLS DEV, V28, P974, DOI 10.1089/scd.2019.0031
   Torreggiani E, 2014, EUR CELLS MATER, V28, P137, DOI 10.22203/eCM.v028a11
   Wu JY, 2019, ACS BIOMATER SCI ENG, V5, P3561, DOI 10.1021/acsbiomaterials.9b00607
   Xie LK, 2021, ARCH ORAL BIOL, V121, DOI 10.1016/j.archoralbio.2020.104984
   Ying CT, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.565561
   Yu MM, 2021, ACTA BIOMATER, V134, P190, DOI 10.1016/j.actbio.2021.07.026
   Yu Y, 2012, HISTOCHEM CELL BIOL, V137, P513, DOI 10.1007/s00418 011 0908 x
   Zha Y, 2021, THERANOSTICS, V11, P397, DOI 10.7150/thno.50741
   Zhai MM, 2020, ADV SCI, V7, DOI 10.1002/advs.202001334
   Zhang JY, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0391 3
   Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0959 5
   Zhang Z, 2020, INT J MED SCI, V17, P558, DOI 10.7150/ijms.40918
NR 53
TC 137
Z9 147
U1 53
U2 240
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 15
PY 2022
VL 141
BP 333
EP 343
DI 10.1016/j.actbio.2021.12.035
EA MAR 2022
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 2Q0HP
UT WOS:000820110800007
PM 34979326
DA 2025 08 17
ER

PT J
AU Harmatys, KM
   Cole, EL
   Smith, BD
AF Harmatys, Kara M.
   Cole, Erin L.
   Smith, Bradley D.
TI In Vivo Imaging of Bone Using a Deep Red Fluorescent Molecular Probe
   Bearing Multiple Iminodiacetate Groups
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE bone targeting; in vivo imaging; multivalency; iminodiacetate;
   fluorescence molecular imaging; squaraine rotaxane
ID NONINVASIVE OPTICAL DETECTION; 7 DIFFERENT FLUOROCHROMES; DRUG DELIVERY
   SYSTEMS; BISPHOSPHONATE; AGENTS; TISSUE; TETRACYCLINE; DEPOSITION;
   SURFACES; PEPTIDE
AB Deep red fluorescent molecular probes are described that have a dendritic molecular architecture with a squaraine rotaxane core scaffold and multiple peripheral iminodiacetate groups as the bone targeting units. Iminodiacetates have an inherently lower bone affinity than bisphosphonates, and a major goal of the study was to determine how many appended iminodiacetate groups are required for effective deep red fluorescence imaging of bone in living rodents. A series of in vitro and in vivo imaging studies showed that a tetra(iminodiacetate) probe stains bones much more strongly than an analogous bis(iminodiacetate) probe. In addition, a control tetra(iminodipropionate) probe exhibited no bone targeting ability. The tetra(iminodiacetate) probe targeted the same regions of high bone turnover as the near infrared bisphosphonate probe OsteoSense750. Longitudinal studies showed that the fluorescence image signal from living mice treated with the tetra(iminodiacetate) probe was much more stable over 19 days than the signal from OsteoSense750. The narrow emission band of the tetra(iminodiacetate) probe makes it very attractive for inclusion in multiplex imaging protocols that employ a mixture of multiple fluorescent probes in preclinical studies of bone growth or in fluorescence guided surgery. The results also suggest that molecules or nanoparticles bearing multivalent iminodiacetate groups have promise as bone targeting agents with tunable properties for various pharmaceutical applications.
C1 [Harmatys, Kara M.; Cole, Erin L.; Smith, Bradley D.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.
C3 University of Notre Dame
RP Smith, BD (通讯作者)，Univ Notre Dame, Dept Chem & Biochem, 236 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.
EM smith.115@nd.edu
RI ; Cole, Erin/AAF 5367 2020
OI Cole, Erin/0009 0000 6486 4340; 
FU NIH [GM059078]; Notre Dame Integrated Imaging Facility (NDIIF)
FX We are grateful for funding support from the NIH (GM059078) and the
   Notre Dame Integrated Imaging Facility (NDIIF). We thank Sarah Chapman
   in the NDIIF for technical assistance.
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Bhushan KR, 2008, J AM CHEM SOC, V130, P17648, DOI 10.1021/ja807099s
   Brounts SH, 2013, MOL PHARMACEUT, V10, P2086, DOI 10.1021/mp300662r
   CHABEREK S, 1952, J AM CHEM SOC, V74, P5052, DOI 10.1021/ja01140a018
   Choi HS, 2011, ANGEW CHEM INT EDIT, V50, P6258, DOI 10.1002/anie.201102459
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Cole EL, 2012, ORG BIOMOL CHEM, V10, P5769, DOI 10.1039/c2ob06783h
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Gassensmith JJ, 2007, J AM CHEM SOC, V129, P15054, DOI 10.1021/ja075567v
   Gassensmith JJ, 2009, CHEM COMMUN, P6329, DOI 10.1039/b911064j
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Hruby M, 2006, J APPL POLYM SCI, V101, P3192, DOI 10.1002/app.23446
   Johnson JR, 2007, ANGEW CHEM INT EDIT, V46, P5528, DOI 10.1002/anie.200701491
   Kassab K, 2002, J PHOTOCH PHOTOBIO B, V68, P15, DOI 10.1016/S1011 1344(02)00325 1
   Keereweer S, 2011, MOL IMAGING BIOL, V13, P199, DOI 10.1007/s11307 010 0373 2
   Kovar JL, 2011, ANAL BIOCHEM, V416, P167, DOI 10.1016/j.ab.2011.05.011
   Kozloff KM, 2007, J BONE MINER RES, V22, P1208, DOI 10.1359/JBMR.070504
   Kozloff KM, 2010, J BONE MINER RES, V25, P1748, DOI 10.1002/jbmr.66
   Kozloff KM, 2009, BONE, V44, P190, DOI 10.1016/j.bone.2008.10.036
   Kubícek V, 2010, FUTURE MED CHEM, V2, P521, DOI 10.4155/FMC.09.162
   Lee JS, 2010, ACTA BIOMATER, V6, P21, DOI 10.1016/j.actbio.2009.08.003
   Liu DM, 2012, CHEM COMMUN, V48, P2668, DOI 10.1039/c2cc17635a
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   McMahon B, 2009, J AM CHEM SOC, V131, P17542, DOI 10.1021/ja908006r
   Parkesh R, 2006, ORG BIOMOL CHEM, V4, P3611, DOI 10.1039/b606976b
   Pautke C, 2005, BONE, V37, P441, DOI 10.1016/j.bone.2005.05.008
   Pautke C, 2007, J ANAT, V210, P117, DOI 10.1111/j.1469 7580.2006.00660.x
   Pautke C, 2010, J ANAT, V217, P76, DOI 10.1111/j.1469 7580.2010.01237.x
   Pautke C, 2009, J ORAL MAXIL SURG, V67, P471, DOI 10.1016/j.joms.2008.09.037
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Smith BA, 2012, ACS CHEM NEUROSCI, V3, P530, DOI 10.1021/cn3000197
   Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311
   STUART AJ, 1992, AVIAN DIS, V36, P447, DOI 10.2307/1591527
   van Gaalen SM, 2010, TISSUE ENG PART B RE, V16, P209, DOI 10.1089/ten.TEB.2009.0503
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang G, 2011, MOL PHARMACEUT, V8, P1025, DOI 10.1021/mp200028w
   Wen D, 2011, ORAL DIS, V17, P427, DOI 10.1111/j.1601 0825.2010.01772.x
   White AG, 2010, BIOCONJUGATE CHEM, V21, P1297, DOI 10.1021/bc1000998
   Xiao SZ, 2010, ORG LETT, V12, P140, DOI 10.1021/ol902546m
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 44
TC 45
Z9 50
U1 0
U2 48
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
EI 1543 8392
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD NOV
PY 2013
VL 10
IS 11
BP 4263
EP 4271
DI 10.1021/mp400357v
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 248BT
UT WOS:000326669400031
PM 24099089
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nagel, AK
   Ball, LE
AF Nagel, Alexis K.
   Ball, Lauren E.
TI O GlcNAc Modification of the runt Related Transcription
   Factor 2 (Runx2) Links Osteogenesis and Nutrient Metabolism in Bone
   Marrow Mesenchymal Stem Cells
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID ACTIVATED PROTEIN KINASE; HISTONE ACETYLTRANSFERASE ACTIVITY;
   ELECTRON TRANSFER DISSOCIATION; MURINE MC3T3 E1 CELLS; BREAST CANCER
   CELLS; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; SKELETAL
   DEVELOPMENT; OSTEOCALCIN GENE; X CHROMOSOME
AB Runx2 is the master switch controlling osteoblast differentiation and formation of the mineralized skeleton. The post translational modification of Runx2 by phosphorylation, ubiquitinylation, and acetylation modulates its activity, stability, and interactions with transcriptional co regulators and chromatin remodeling proteins downstream of osteogenic signals. Characterization of Runx2 by electron transfer dissociation tandem mass spectrometry revealed sites of O linked N acetylglucosamine (O GlcNAc) modification, a nutrient responsive post translational modification that modulates the action of numerous transcriptional effectors. O GlcNAc modification occurs in close proximity to phosphorylated residues and novel sites of arginine methylation within regions known to regulate Runx2 transactivation. An interaction between Runx2 and the O GlcNAcylated, O GlcNAc transferase enzyme was also detected. Pharmacological inhibition of O GlcNAcase (OGA), the enzyme responsible for the removal of O GlcNAc from Ser/Thr residues, enhanced basal (39.9%) and BMP2/7 induced (43.3%) Runx2 transcriptional activity in MC3T3 E1 pre osteoblasts. In bone marrow derived mesenchymal stem cells differentiated for 6 days in osteogenic media, inhibition of OGA resulted in elevated expression (24.3%) and activity (65.8%) of alkaline phosphatase (ALP) an early marker of bone formation and a transcriptional target of Runx2. Osteogenic differentiation of bone marrow derived mesenchymal stem cells in the presence of BMP2/7 for 8 days culminated in decreased OGA activity (39.0%) and an increase in the abundance of O GlcNAcylated Runx2, as compared with unstimulated cells. Furthermore, BMP2/7 induced ALP activity was enhanced by 35.6% in bone marrow derived mesenchymal stem cells differentiated in the presence of the OGA inhibitor, demonstrating that direct or BMP2/7induced inhibition of OGA is associated with increased ALP activity. Altogether, these findings link O GlcNAc cycling to the Runx2 dependent regulation of the early ALP marker under osteoblast differentiation conditions.
C1 [Nagel, Alexis K.; Ball, Lauren E.] Med Univ S Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA.
   [Nagel, Alexis K.; Ball, Lauren E.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina
RP Ball, LE (通讯作者)，Med Univ S Carolina, Dept Oral Hlth Sci, 173 Ashley Ave BSB 358 MSC 509, Charleston, SC 29425 USA.
EM ballle@musc.edu
RI ; Ball, Lauren/AAD 6972 2019
OI Ball, Lauren/0000 0001 6780 1679; 
FU National Institutes of Health from the NIDCR [R01 DE020925, T32 DE017551
   05]; National Institutes of Health from NCRR [S10 D010731 01]
FX This work was supported by National Institutes of Health Grants R01
   DE020925 and T32 DE017551 05 from the NIDCR, and S10 D010731 01 from the
   NCRR.
CR Alfaro JF, 2012, P NATL ACAD SCI USA, V109, P7280, DOI 10.1073/pnas.1200425109
   Andrés Bergós J, 2012, J BIOL CHEM, V287, P33615, DOI 10.1074/jbc.M112.354241
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Cantin GT, 2008, J PROTEOME RES, V7, P1346, DOI 10.1021/pr0705441
   Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742
   Cheung WD, 2008, J BIOL CHEM, V283, P13009, DOI 10.1074/jbc.M801222200
   Choi D, 2012, HEPATOLOGY, V56, P1546, DOI 10.1002/hep.25809
   Cox J, 2011, J AM SOC MASS SPECTR, V22, P1373, DOI 10.1007/s13361 011 0142 8
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100
   Dehennaut V, 2008, MOL CELL PROTEOMICS, V7, P2229, DOI 10.1074/mcp.M700494 MCP200
   Deplus R, 2013, EMBO J, V32, P645, DOI 10.1038/emboj.2012.357
   Dhonukshe Rutten RAM, 2005, J BONE MINER RES, V20, P921, DOI 10.1359/JBMR.050202
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843
   Gambetta MC, 2009, SCIENCE, V325, P93, DOI 10.1126/science.1169727
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Goldberg H, 2011, AM J PHYSIOL ENDOC M, V301, pE713, DOI 10.1152/ajpendo.00108.2011
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432 1327.1999.00439.x
   Guo AL, 2014, MOL CELL PROTEOMICS, V13, P372, DOI 10.1074/mcp.O113.027870
   Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev biochem 060608 102511
   Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859
   Hsieh TJ, 2012, J CELL PHYSIOL, V227, P108, DOI 10.1002/jcp.22707
   Imbard A, 2013, INT J ENV RES PUB HE, V10, P4352, DOI 10.3390/ijerph10094352
   Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097 0177(199904)214:4<279::AID AJA1>3.0.CO;2 W
   Jang H, 2012, CELL STEM CELL, V11, P62, DOI 10.1016/j.stem.2012.03.001
   Javed A, 2009, CELLS TISSUES ORGANS, V189, P133, DOI 10.1159/000151719
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Kim EJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055296
   Kim HS, 2009, FEBS LETT, V583, P2474, DOI 10.1016/j.febslet.2009.06.052
   Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925 4773(98)00210 X
   Kim SH, 2007, BIOCHEM BIOPH RES CO, V362, P325, DOI 10.1016/j.bbrc.2007.07.149
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lee M, 2010, J BIOL CHEM, V285, P38014, DOI 10.1074/jbc.M110.142141
   Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925 4773(02)00050 3
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lubas WA, 1997, J BIOL CHEM, V272, P9316
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Maury JJP, 2013, STEM CELL RES, V11, P926, DOI 10.1016/j.scr.2013.06.004
   Mi WY, 2011, BBA MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009
   Moffatt P, 2013, AM J HUM GENET, V92, P252, DOI 10.1016/j.ajhg.2012.12.001
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nagel AK, 2013, MOL CELL PROTEOMICS, V12, P945, DOI 10.1074/mcp.M112.026633
   O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680 1690.2004
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Ogawa M, 2012, BBA GEN SUBJECTS, V1820, P24, DOI 10.1016/j.bbagen.2011.10.011
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pande S, 2013, J CELL PHYSIOL, V228, P1784, DOI 10.1002/jcp.24339
   Park OJ, 2010, J BIOL CHEM, V285, P3568, DOI 10.1074/jbc.M109.055053
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rexach JE, 2010, NAT CHEM BIOL, V6, P645, DOI [10.1038/nchembio.412, 10.1038/NCHEMBIO.412]
   Robinson KA, 2007, AM J PHYSIOL ENDOC M, V292, pE884, DOI 10.1152/ajpendo.00569.2006
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Selvamurugan N, 2009, FEBS LETT, V583, P1141, DOI 10.1016/j.febslet.2009.02.040
   Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497
   Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339 3351.2003
   Sinclair DAR, 2009, P NATL ACAD SCI USA, V106, P13427, DOI 10.1073/pnas.0904638106
   Soung DY, 2012, J BONE MINER RES, V27, P1585, DOI 10.1002/jbmr.1601
   Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611
   Trinidad JC, 2012, MOL CELL PROTEOMICS, V11, P215, DOI 10.1074/mcp.O112.018366
   Vaes BLT, 2010, BONE, V46, P514, DOI 10.1016/j.bone.2009.09.033
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Wang YC, 2014, CELL RES, V24, P143, DOI 10.1038/cr.2013.151
   Wang Z, 2008, P NATL ACAD SCI USA, V105, P13793, DOI 10.1073/pnas.0806216105
   Wang Z, 2007, MOL CELL PROTEOMICS, V6, P1365, DOI 10.1074/mcp.M600453 MCP200
   Wang ZH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000526
   Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo reports/kvf193
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982 7992.2002
   Yamagata K, 2008, MOL CELL, V32, P221, DOI 10.1016/j.molcel.2008.09.013
   Yang L, 2013, DEV BIOL, V380, P99, DOI 10.1016/j.ydbio.2013.04.031
   Yoon WJ, 2013, J CELL PHYSIOL, V228, P2377, DOI 10.1002/jcp.24403
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Yuzwa SA, 2008, NAT CHEM BIOL, V4, P483, DOI 10.1038/nchembio.96
   Zhao P, 2011, J PROTEOME RES, V10, P4088, DOI 10.1021/pr2002726
   Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821
   Zou WG, 2011, J CLIN INVEST, V121, P4383, DOI 10.1172/JCI59041
NR 87
TC 57
Z9 59
U1 2
U2 26
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
SN 1535 9476
EI 1535 9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD DEC
PY 2014
VL 13
IS 12
BP 3381
EP 3395
DI 10.1074/mcp.M114.040691
PG 15
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AU5DC
UT WOS:000345626400013
PM 25187572
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Bergemann, N
   Parzer, P
   Mundt, C
   Auler, B
AF Bergemann, N.
   Parzer, P.
   Mundt, C.
   Auler, B.
TI High bone turnover but normal bone mineral density in women suffering
   from schizophrenia
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE bone mineral density; bone turnover; intact parathyroid hormone; 17
   beta oestradiol; osteocalcin; schizophrenia
ID BIOCHEMICAL MARKERS; PROLACTIN; OSTEOPOROSIS; METABOLISM; NEUROLEPTICS;
   HYPERPROLACTINEMIA; MEDICATION; THERAPY; CALCIUM; PSYCHOPATHOLOGY
AB Background. A potential association between schizophrenia and osteoporosis or osteopenia has recently been reported. Various factors affect bone mineral density (BMD) such as polyclipsia, nicotine, alcohol abuse, lack of physical activity, an unbalanced diet, a lack of ultraviolet exposure and/or vitamin D. In addition, decreased BMD in women with schizophrenia has been attributed to drug induced hyperprolactinaemia and/or secondary hypogonadism. This study was undertaken because empirical evidence from larger patient cohorts is limited and the data are still controversial.
   Method. Seventy two premenopausal, regularly menstruating women suffering from schizophrenia and 71 age  and sex matched healthy controls were included in the study. Biochemical markers of bone turnover (serum osteocalcin, urinary pyridinium crosslinks), parathyroid hormone and 25 hydroxyvitamin D were measured. BMD at the femoral neck and lumbar spine was determined by dual energy X ray absorptiometry in a subgroup of 59 patients. In addition, 17 beta oestradiol, prolactin, testosterone, gonadotrophins and dehydroepiandrosterone sulfate were measured.
   Results. Compared with healthy controls, both markers of formation and resorption were increased in women with schizophrenia. However, in the subgroup of 59 patients, BMD was within the normal range. In women suffering from schizophrenia, testosterone levels were higher than in controls, and serum oestradiol levels were lower compared with the normal range.
   Conclusions. Despite significantly increased bone turnover, we conclude that premenopausal and regularly menstruating women suffering from schizophrenia have normal spine and hip BMD. This may be due to the opposite effects of the various parameters influencing bone metabolism, especially of the gonadal hormones, and due to an intact coupling mechanism.
C1 [Bergemann, N.; Mundt, C.] Heidelberg Univ, Dept Gen Psychiat, D 69115 Heidelberg, Germany.
   [Parzer, P.] Heidelberg Univ, Dept Child & Adolescent Psychiat, D 69115 Heidelberg, Germany.
   [Auler, B.] Heidelberg Univ, Dept Gen Internal & Psychosomat Med, D 69115 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg
RP Bergemann, N (通讯作者)，Heidelberg Univ, Dept Gen Psychiat, Voss Str 4, D 69115 Heidelberg, Germany.
EM niels.bergemann@med.uni heidelberg.de
CR Abraham G, 2003, AM J PSYCHIAT, V160, P1618, DOI 10.1176/appi.ajp.160.9.1618
   Abraham G, 1996, BIOL PSYCHIAT, V40, P430, DOI 10.1016/0006 3223(96)82517 0
   Abraham G, 2003, SCHIZOPHR RES, V59, P17, DOI 10.1016/S0920 9964(01)00321 8
   ABRAHAM G, 1995, BIOL PSYCHIAT, V38, P131, DOI 10.1016/0006 3223(95)00062 L
   AlAdwani A, 1997, AM J PSYCHIAT, V154, P1173
   [Anonymous], 1993, The ICD 10 classification of mental and behavioural disorders: diagnostic criteria for research
   *APA, 1994, DIAGN STAT MAN MENT
   BAASTRUP PC, 1980, NEUROPSYCHOBIOLOGY, V6, P56, DOI 10.1159/000117734
   Bácsi K, 2007, CALCIFIED TISSUE INT, V80, P154, DOI 10.1007/s00223 006 0227 8
   Becker D, 2003, J CLIN PSYCHIAT, V64, P761, DOI 10.4088/JCP.v64n0704
   Bergemann N, 2005, SCHIZOPHR RES, V73, P357, DOI 10.1016/j.schres.2004.06.013
   Bergemann N, 2007, PSYCHOL MED, V37, P1427, DOI 10.1017/S0033291707000578
   Bilici M, 2002, INT J NEUROSCI, V112, P817, DOI 10.1080/00207450290025833
   DELVA NJ, 1989, BIOL PSYCHIAT, V26, P781, DOI 10.1016/0006 3223(89)90119 4
   Erler K, 1998, WIEN KLIN WOCHENSCHR, V110, P5
   Farhat G, 2002, NEUROLOGY, V58, P1348, DOI 10.1212/WNL.58.9.1348
   Feldkamp J, 2000, EXP CLIN ENDOCR DIAB, V108, P37
   Fujimaki T, 1994, Nihon Sanka Fujinka Gakkai Zasshi, V46, P423
   GOFF DC, 1992, AM J PSYCHIAT, V149, P1189
   GREEN AI, 1988, ENDOCRIN METAB CLIN, V17, P213, DOI 10.1016/S0889 8529(18)30442 0
   Haddad PM, 2004, DRUGS, V64, P2291, DOI 10.2165/00003495 200464200 00003
   Halbreich U, 1996, SCHIZOPHRENIA BULL, V22, P447, DOI 10.1093/schbul/22.3.447
   HALBREICH U, 1995, PSYCHOSOM MED, V57, P485, DOI 10.1097/00006842 199509000 00011
   HIGUCHI T, 1987, NEUROPSYCHOBIOLOGY, V18, P185, DOI 10.1159/000118415
   HOUSTON BK, 1975, J CLIN PSYCHOL, V31, P26, DOI 10.1002/1097 4679(197501)31:1<26::AID JCLP2270310109>3.0.CO;2 W
   Howes OD, 2005, J CLIN PSYCHOPHARM, V25, P259, DOI 10.1097/01.jcp.0000162798.87249.4d
   Hummer M, 2004, CURR MED RES OPIN, V20, P189, DOI 10.1185/030079903125002865
   KASPERK C, 1990, J CLIN ENDOCR METAB, V71, P1322, DOI 10.1210/jcem 71 5 1322
   Keely E J, 1997, Endocr Pract, V3, P209
   LINDHOLM J, 1991, J CLIN ENDOCR METAB, V73, P118, DOI 10.1210/jcem 73 1 118
   Mak TWL, 1998, J CLIN ENDOCR METAB, V83, P3857, DOI 10.1210/jc.83.11.3857
   Maric N, 2005, SCHIZOPHR RES, V73, P351, DOI 10.1016/j.schres.2004.07.016
   McEvoy JP, 2005, SCHIZOPHR RES, V80, P19, DOI 10.1016/j.schres.2005.07.014
   Meaney AM, 2007, SCHIZOPHR RES, V93, P136, DOI 10.1016/j.schres.2007.01.013
   Meaney AM, 2004, BRIT J PSYCHIAT, V184, P503, DOI 10.1192/bjp.184.6.503
   Meaney AM, 2003, J PSYCHOPHARMACOL, V17, P455, DOI 10.1177/0269881103174011
   Misra M, 2004, J CLIN PSYCHIAT, V65, P1607, DOI 10.4088/JCP.v65n1205
   MONIZ C, 1994, BRIT MED BULL, V50, P67, DOI 10.1093/oxfordjournals.bmb.a072885
   Naidoo U, 2003, PSYCHONEUROENDOCRINO, V28, P97, DOI 10.1016/S0306 4530(02)00129 4
   O'Keane V, 2005, J CLIN PSYCHOPHARM, V25, P26, DOI 10.1097/01.jcp.0000150223.31007.e0
   PETTY RG, 1999, SCHIZOPHR RES S, V35, P67
   PLENGE P, 1982, ACTA PSYCHIAT SCAND, V66, P361, DOI 10.1111/j.1600 0447.1982.tb06718.x
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   PRATT DA, 1992, ANAL BIOCHEM, V207, P168, DOI 10.1016/0003 2697(92)90519 D
   ROGERS GA, 1987, AM J PSYCHIAT, V144, P388
   Seibel MJ, 1997, EXP CLIN ENDOCR DIAB, V105, P125, DOI 10.1055/s 0029 1211740
   Seibel MJ, 2003, J ENDOCRINOL INVEST, V26, P464, DOI 10.1007/BF03345204
   Seibel MJ, 1999, J CLIN DENSITOM, V2, P299, DOI 10.1385/JCD:2:3:299
   SHETH RD, 1995, J PEDIATR US, V127, P256, DOI 10.1016/S0022 3476(95)70304 7
   SLEMENDA CW, 1994, NEW ENGL J MED, V330, P430, DOI 10.1056/NEJM199402103300611
NR 50
TC 26
Z9 28
U1 0
U2 9
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013 2473 USA
SN 0033 2917
EI 1469 8978
J9 PSYCHOL MED
JI Psychol. Med.
PD AUG
PY 2008
VL 38
IS 8
BP 1195
EP 1201
DI 10.1017/S003329170800319X
PG 7
WC Psychology, Clinical; Psychiatry; Psychology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Psychiatry
GA 332CB
UT WOS:000258058300014
PM 18366816
DA 2025 08 17
ER

PT J
AU Dong, M
   Wu, SX
   Xu, HJ
   Yu, XX
   Wang, LN
   Bai, H
   Niu, WD
AF Dong, Ming
   Wu, Saixuan
   Xu, Huijun
   Yu, Xinxin
   Wang, Lina
   Bai, Hua
   Niu, Weidong
TI FBS Derived Exosomes as a Natural Nano Scale Carrier for Icariin Promote
   Osteoblast Proliferation
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE exosomes; ICA; osteoblast; proliferation; FBS
ID STROMAL CELLS; DELIVERY; PATHWAY; DIFFERENTIATION
AB Icariin is a class IV drug of low solubility, permeability, and poor bioavailability. Synthetic nanomaterials have developed rapidly. However, some literatures point out that synthetic nanomaterials such as liposomes, aptamers, metal nanoparticles, and nanogels have high toxicity and are affected by the reticuloendothelial system or mononuclear phagocyte system. It is known that exosomes could be used as an ideal clinical drug delivery vehicle to avoid the above mentioned problems to a certain extent. Studies have shown that drugs can be loaded into exosomes by passive and active loading. We used Fetal bovine serum (FBS) exosomes to carry Icariin for the first time in this experiment, FBS exosomes Icariin (FBS EXO ICA) more effectively promoted the proliferation of osteoblasts and bone regeneration than Icariin alone. FBS EXO ICA could become a new nano scale drug formulation for treating diseases associated with bone loss.
C1 [Dong, Ming; Wu, Saixuan; Yu, Xinxin; Wang, Lina; Bai, Hua; Niu, Weidong] Dalian Med Univ, Sch Stomatol, Dalian, Peoples R China.
   [Xu, Huijun] Bozhou Peoples Hosp, Dept Stomatol, Bozhou, Peoples R China.
C3 Dalian Medical University
RP Bai, H; Niu, WD (通讯作者)，Dalian Med Univ, Sch Stomatol, Dalian, Peoples R China.
EM baihua113@hotmail.com; 13840886663@139.com
FU National Natural Science Foundation of China [81171538, 81300869];
   Natural Science Foundation of Liaoning Province [LZ2019038]
FX This work was supported by the National Natural Science Foundation of
   China (81171538 and 81300869) and Natural Science Foundation of Liaoning
   Province (LZ2019038).
CR Agrawal AK, 2017, NANOMED NANOTECHNOL, V13, P1627, DOI 10.1016/j.nano.2017.03.001
   Aqil F, 2016, EXP MOL PATHOL, V101, P12, DOI 10.1016/j.yexmp.2016.05.013
   Aswad H, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896 016 0262 0
   Beninson LA, 2015, IMMUNOL LETT, V163, P187, DOI 10.1016/j.imlet.2014.10.019
   Cao LH, 2019, MOLECULES, V24, DOI 10.3390/molecules24203700
   Chen SS, 2019, EXP THER MED, V18, P4774, DOI 10.3892/etm.2019.8132
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   Currey JD, 2003, J BIOMECH, V36, P1487, DOI 10.1016/S0021 9290(03)00124 6
   Eitan E, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26373
   Fonseca P, 2016, INT REV CEL MOL BIO, V326, P175, DOI 10.1016/bs.ircmb.2016.04.004
   Ghayad SE, 2016, SCI REP UK, V6, DOI 10.1038/srep37088
   Greening DW, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.134890
   Hu LL, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2743 x
   Huo CH, 2019, CHIN J CHROMATOGR, V37, P863, DOI 10.3724/SP.J.1123.2019.04022
   Jiang Shao Yan, 2018, Sichuan Da Xue Xue Bao Yi Xue Ban, V49, P530
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Lehrich BM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113538
   Li HT, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01617
   Li RW, 2017, MAT SCI ENG C MATER, V80, P156, DOI 10.1016/j.msec.2017.05.136
   Luo ZW, 2019, NANOSCALE, V11, P20884, DOI 10.1039/c9nr02791b
   Mathur P, 2018, ARTIF CELL NANOMED B, V46, pS115, DOI 10.1080/21691401.2017.1414825
   Munagala R, 2016, CANCER LETT, V371, P48, DOI 10.1016/j.canlet.2015.10.020
   Nakamura Y, 2015, FEBS LETT, V589, P1257, DOI 10.1016/j.febslet.2015.03.031
   Narayanan R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3808674
   Niculescu AB, 2020, MOL PSYCHIATR, V25, P1651, DOI 10.1038/s41380 019 0602 2
   Ochieng J, 2009, EXP CELL RES, V315, P1875, DOI 10.1016/j.yexcr.2009.03.010
   Odeh F, 2020, MOLECULES, V25, DOI 10.3390/molecules25010003
   Oftadeh R, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4029176
   Patel MM, 2017, CNS DRUGS, V31, P109, DOI 10.1007/s40263 016 0405 9
   Qayoom I, 2020, BIOMACROMOLECULES, V21, P328, DOI 10.1021/acs.biomac.9b01327
   Shelke GV, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24783
   Suk KH, 2017, CURR MED CHEM, V24, P3310, DOI 10.2174/0929867324666170502122444
   Trelis M, 2016, INT J PARASITOL, V46, P799, DOI 10.1016/j.ijpara.2016.07.003
   Wei HX, 2019, INT J NANOMED, V14, P8603, DOI 10.2147/IJN.S218988
   Wu XL, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.116879
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Xu YX, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172794
   Yu G, 2018, BIOMATERIALS, V162, P71, DOI 10.1016/j.biomaterials.2018.02.003
   Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1562 9
   Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770
   Zhang YB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9424186
   Zhang YT, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12570
   Zhao K, 2016, CURR DRUG DELIV, V13, P494, DOI 10.2174/156720181304160521004609
   Zhao PP, 2018, CHEMOSPHERE, V200, P612, DOI 10.1016/j.chemosphere.2018.02.157
   Zhu HY, 2018, DRUG DES DEV THER, V12, P4023, DOI 10.2147/DDDT.S179989
   Zuo S, 2019, DRUG DES DEV THER, V13, P3949, DOI 10.2147/DDDT.S203094
NR 48
TC 36
Z9 40
U1 1
U2 64
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD FEB 26
PY 2021
VL 9
AR 615920
DI 10.3389/fbioe.2021.615920
PG 10
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA QV1ZN
UT WOS:000627776500001
PM 33718337
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Pountos, I
   Giannoudis, PV
   Jones, E
   English, A
   Churchman, S
   Field, S
   Ponchel, F
   Bird, H
   Emery, P
   McGonagle, D
AF Pountos, Ippokratis
   Giannoudis, Peter V.
   Jones, Elena
   English, Anne
   Churchman, Sarah
   Field, Sarah
   Ponchel, Frederique
   Bird, Howard
   Emery, Paul
   McGonagle, Dennis
TI NSAIDS inhibit in vitro MSC chondrogenesis but not osteogenesis:
   implications for mechanism of bone formation inhibition in man
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone healing; MSCs; NSAIDs; COX 1; COX 2
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RETRACTED ARTICLE. SEE; MESENCHYMAL
   STEM CELLS; TRABECULAR BONE; FRACTURE; MELOXICAM; DIFFERENTIATION;
   CYCLOOXYGENASE; EXPRESSION; APOPTOSIS
AB The non steroidal anti inflammatory drugs (NSAIDs) are widely used for analgesia but may inhibit bone formation. We investigated whether the reported NSAID effect on bone is related to inhibition of bone marrow mesenchymal stem cell (MSC) proliferation and osteogenic and chondrogenic differentiation and evaluated both cyclooxygenase (COX) 1 and COX 2 specific drugs. The effects of seven COX 1 and COX 2 inhibitors on MSC proliferation and osteogenic and chondrogenic differentiation were tested using Vybrant, sodium 3' [1 (phenylaminocarbonyl)  3,4 tetrazolium] bis (4 methoxy 6 nitro) benzene sulfonic acid hydrate (XTT), functional and quantitative assays of MSC differentiation. The MSC expression of COX 1 and COX 2 and prostaglandin E2 (PGE 2) levels were evaluated serially during lineage differentiation by quantitative PCR and ELISA. None of the NSAIDs at broad range of concentration (range 10 3 to 100 mu g/ml) significantly affected MSC proliferation. Surprisingly, MSC osteogenic differentiation inhibition was not evident. However, NSAIDs affected chondrogenic potential with a reduction in sulphated glycosaminoglycans (sGAG) content by 45% and 55% with diclofenac and ketorolac, respectively (P < 0.05 compared to controls). Parecoxib and meloxicam, more COX 2 specific reagents inhibited sGAG to a lesser degree, 22% and 27% respectively (P < 0.05 compared to controls). Cartilage pellet immunohistochemistry confirmed the above results. Pellet chondrogenesis was associated with increased COX 1 expression levels but not COX 2, and COX 1 specific drugs suppressed MSC PGE 2 more than COX 2 specific inhibitors. These findings suggest that NSAIDs may inhibit bone formation via blockage of MSC chondrogenic differentiation which is an important intermediate phase in normal endochondral bone formation.
C1 [Pountos, Ippokratis; Giannoudis, Peter V.; Jones, Elena; English, Anne; Churchman, Sarah; Field, Sarah; Ponchel, Frederique; Bird, Howard; Emery, Paul; McGonagle, Dennis] Univ Leeds, Sect Musculoskeletal Dis, LIMM, Leeds, W Yorkshire, England.
C3 University of Leeds
RP Giannoudis, PV (通讯作者)，Leeds Gen Infirm, Leeds Biomed Res Unit LBMRU, Acad Dept Trauma & Orthopaed, Great George St, Leeds LS1 3EX, W Yorkshire, England.
EM pgiannoudi@aol.com
RI emery, paul/B 3560 2013; Giannoudis, Peter/AAA 3617 2020; Churchman,
   Sarah/L 1828 2013; Jones, Elena/F 3136 2010; Pountos,
   Ippokratis/AAB 5697 2019; Ponchel, frederique/AAL 1224 2021
OI Churchman, Sarah/0000 0003 0172 3975; ponchel,
   frederique/0000 0002 3969 7701; Pountos, Ippokratis/0000 0002 0050 5151;
   Jones, Elena/0000 0001 9365 2283
FU AO foundation [03 G92]; National Institute for Health Research
   [NF SI 0508 10299] Funding Source: researchfish; Versus Arthritis;
   Cancer Research UK [18475] Funding Source: researchfish
FX This study was supported with a grant by the AO foundation, grant
   number: 03 G92.
CR *ABPI, 2009, COMP DAT SHEETS SUMM
   ADOLPHSON P, 1993, ARCH ORTHOP TRAUM SU, V112, P127, DOI 10.1007/BF00449987
   Ali M, 2001, J CLIN INVEST, V107, P519, DOI 10.1172/JCI8027
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Baek SJ, 2005, MOL PHARMACOL, V67, P356, DOI 10.1124/mol.104.005108
   Bain BJ, 2001, J CLIN PATHOL, V54, P657, DOI 10.1136/jcp.54.9.657
   BASSLEER C, 1992, CLIN RHEUMATOL, V11, P60, DOI 10.1007/BF02207086
   Bassleer C, 1997, PHARMACOLOGY, V54, P49, DOI 10.1159/000139469
   Beck Alexander, 2005, Oper Orthop Traumatol, V17, P569, DOI 10.1007/s00064 005 1152 0
   Boursinos LA, 2009, J MUSCULOSKEL NEURON, V9, P44
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Davies NM, 1999, CLIN PHARMACOKINET, V36, P115, DOI 10.2165/00003088 199936020 00003
   DAVIS TRC, 1988, BRIT J CLIN PRACT, V42, P184
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Evans CE, 2004, J BONE JOINT SURG BR, V86B, P444, DOI 10.1302/0301 620X.86B3.14592
   Gajraj NM, 2003, REGION ANESTH PAIN M, V28, P456, DOI 10.1016/j.rapm.2003.09.001
   GARAVITO RM, 1999, BIOCHIM BIOPHYS ACTA, V23, P278
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Glassman SD, 1998, SPINE, V23, P834, DOI 10.1097/00007632 199804010 00020
   HARDMAN J, 2001, PHARMACOL BASIS THER, P643
   Ho CC, 2003, EUR J CLIN INVEST, V33, P875, DOI 10.1046/j.1365 2362.2003.01240.x
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Hynninen VV, 2009, ANTIMICROB AGENTS CH, V53, P587, DOI 10.1128/AAC.00530 08
   Jakob M, 2004, RHEUMATOLOGY, V43, P852, DOI 10.1093/rheumatology/keh197
   Jones EA, 2002, ARTHRITIS RHEUM US, V46, P3349, DOI 10.1002/art.10696
   Karachalios T, 2007, J BONE JOINT SURG BR, V89B, P1253, DOI 10.1302/0301 620X.89B9.19050
   MA Y, 1995, BONE, V17, pS267, DOI 10.1016/8756 3282(95)00302 T
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   MCEVOY GK, 2004, AHFS DRUG INFORM, P534
   Nöth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736 0266(02)00018 9
   Ou YC, 2007, EUR J PHARMACOL, V563, P49, DOI 10.1016/j.ejphar.2007.01.071
   Paralkar VM, 2002, J CELL PHYSIOL, V190, P207, DOI 10.1002/JCP.10048
   Pountos I, 2005, INJURY, V36, P8, DOI 10.1016/j.injury.2005.07.028
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Reuben SS, 2005, CAN J ANAESTH, V52, P506, DOI 10.1007/BF03016531
   Reuben SS, 2005, J BONE JOINT SURG AM, V87A, P536, DOI 10.2106/JBJS.D.02283
   Reuben SS, 2002, J ARTHROPLASTY, V17, P26, DOI 10.1054/arth.2002.27677
   Rice PL, 2001, CANCER RES, V61, P1541
   Rihn JA, 2008, J BONE JOINT SURG AM, V90A, P2014
   Rose P, 2004, CLIN DRUG INVEST, V24, P227, DOI 10.2165/00044011 200424040 00004
   Sakaguchi Y, 2004, BLOOD, V104, P2728, DOI 10.1182/blood 2003 12 4452
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   Sell S, 1999, Z RHEUMATOL, V58, P13, DOI 10.1007/s003930050148
   Tuli R, 2003, MOL BIOTECHNOL, V23, P37, DOI 10.1385/MB:23:1:37
   Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Wolfesberger B, 2006, J VET PHARMACOL THER, V29, P15, DOI 10.1111/j.1365 2885.2006.00704.x
   Wurnig C, 1999, CLIN ORTHOP RELAT R, P150
   Yamakawa K, 2008, ARTHRITIS RHEUM US, V58, P172, DOI 10.1002/art.23158
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 53
TC 50
Z9 57
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAR
PY 2011
VL 15
IS 3
BP 525
EP 534
DI 10.1111/j.1582 4934.2010.01006.x
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 740ME
UT WOS:000288798000007
PM 20070439
OA hybrid, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Maugg, D
   Rothenaigner, I
   Schorpp, K
   Potukuchi, HK
   Korsching, E
   Baumhoer, D
   Hadian, K
   Smida, J
   Nathrath, M
AF Maugg, Doris
   Rothenaigner, Ina
   Schorpp, Kenji
   Potukuchi, Harish Kumar
   Korsching, Eberhard
   Baumhoer, Daniel
   Hadian, Kamyar
   Smida, Jan
   Nathrath, Michaela
TI New Small Molecules Targeting Apoptosis and Cell Viability in
   Osteosarcoma
SO PLOS ONE
LA English
DT Article
ID BONE MARROW; LINES; P53; CYTOTOXICITY; CHEMOTHERAPY; DISCOVERY;
   MEDICINES; NECROSIS; SURVIVAL; SARCOMAS
AB Despite the option of multimodal therapy in the treatment strategies of osteosarcoma (OS), the most common primary malignant bone tumor, the standard therapy has not changed over the last decades and still involves multidrug chemotherapy and radical surgery. Although successfully applied in many patients a large number of patients eventually develop recurrent or metastatic disease in which current therapeutic regimens often lack efficacy. Thus, new therapeutic strategies are urgently needed. In this study, we performed a phenotypic high throughput screening campaign using a 25,000 small molecule diversity library to identify new small molecules selectively targeting osteosarcoma cells. We could identify two new small molecules that specifically reduced cell viability in OS cell lines U2OS and HOS, but affected neither hepatocellular carcinoma cell line (HepG2) nor primary human osteoblasts (hOB). In addition, the two compounds induced caspase 3 and 7 activity in the U2OS cell line. Compared to conventional drugs generally used in OS treatment such as doxorubicin, we indeed observed a greater sensitivity of OS cell viability to the newly identified compounds compared to doxorubicin and staurosporine. The p53 negative OS cell line Saos 2 almost completely lacked sensitivity to compound treatment that could indicate a role of p53 in the drug response. Taken together, our data show potential implications for designing more efficient therapies in OS.
C1 [Maugg, Doris; Baumhoer, Daniel; Smida, Jan; Nathrath, Michaela] Helmholtz Zentrum Munchen, Natl Res Ctr Environm Hlth, Inst Radiat Biol, Clin Cooperat Grp Osteosarcoma, Neuherberg, Germany.
   [Maugg, Doris; Smida, Jan; Nathrath, Michaela] Tech Univ Munich, Dept Pediat, D 80290 Munich, Germany.
   [Maugg, Doris; Smida, Jan; Nathrath, Michaela] Tech Univ Munich, Childrens Canc Res Ctr, D 80290 Munich, Germany.
   [Nathrath, Michaela] Klinikum Kassel, Dept Pediat Oncol, Kassel, Germany.
   [Rothenaigner, Ina; Schorpp, Kenji; Hadian, Kamyar] Helmholtz Zentrum Munchen, Natl Res Ctr Environm Hlth, Assay Dev & Screening Platform, Inst Mol Toxicol & Pharmacol, Neuherberg, Germany.
   [Potukuchi, Harish Kumar] Tech Univ Munich, Lehrstuhl Organ Chem 1, Garching, Germany.
   [Potukuchi, Harish Kumar] Tech Univ Munich, Catalysis Res Ctr, Garching, Germany.
   [Potukuchi, Harish Kumar] Helmholtz Zentrum Munchen, Natl Res Ctr Environm Hlth, Inst Biol Struct, Neuherberg, Germany.
   [Korsching, Eberhard] Univ Munster, Inst Bioinformat, D 48149 Munster, Germany.
   [Baumhoer, Daniel] Univ Basel Hosp, Inst Pathol, Bone Tumor Reference Ctr, CH 4031 Basel, Switzerland.
C3 Helmholtz Association; Helmholtz Center Munich   German Research Center
   for Environmental Health; Technical University of Munich; Technical
   University of Munich; Klinikum Kassel; Helmholtz Association;
   Helmholtz Center Munich   German Research Center for Environmental
   Health; Technical University of Munich; Technical University of Munich;
   Helmholtz Association; Helmholtz Center Munich   German Research Center
   for Environmental Health; University of Munster; University of Basel
RP Maugg, D (通讯作者)，Helmholtz Zentrum Munchen, Natl Res Ctr Environm Hlth, Inst Radiat Biol, Clin Cooperat Grp Osteosarcoma, Neuherberg, Germany.
EM doris.maugg@gmx.net
RI ; Hadian, Kamyar/B 6314 2013; Smida, Jan/P 2486 2014; Potukuchi,
   Harish/N 7684 2013; Maugg, Doris/P 2491 2014
OI Smida, Jan/0000 0001 6055 8207; Hadian, Kamyar/0000 0001 8727 2575; 
FU Translational Sarcoma Research Network (TranSarNet) [FKZ 01GM0870, FKZ
   01GM0869]; European TRANSCAN I consortium PROspective VAlidation of
   Biomarkers in Ewing Sarcoma for personalized translational medicine [FZK
   01KT1310]; Bundesministerium fur Bildung und Forschung; Helmholtz
   Zentrum Munchen
FX This work was funded by the Translational Sarcoma Research Network
   (TranSarNet) FKZ 01GM0870 to JS, MN, DM, and FKZ 01GM0869 to EK, and by
   the European TRANSCAN I consortium PROspective VAlidation of Biomarkers
   in Ewing Sarcoma for personalized translational medicine FZK 01KT1310 to
   EK. All authors were supported by the Bundesministerium fur Bildung und
   Forschung. Financial support to HKP from Helmholtz Zentrum Munchen is
   gratefully acknowledged. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abraham VC, 2008, J BIOMOL SCREEN, V13, P527, DOI 10.1177/1087057108318428
   Baumhoer D, 2012, CANCER GENET NY, V205, P212, DOI 10.1016/j.cancergen.2012.03.001
   Bayani J, 2003, GENE CHROMOSOME CANC, V36, P7, DOI 10.1002/gcc.10132
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bielack SS, 2009, J CLIN ONCOL, V27, P557, DOI 10.1200/JCO.2008.16.2305
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Calvert RJ, 2013, IN VITRO CELL DEV AN, V49, P95, DOI 10.1007/s11626 012 9573 1
   Cao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106249
   Carmody LC, 2012, J BIOMOL SCREEN, V17, P1204, DOI 10.1177/1087057112458317
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chipoy C, 2007, ONCOGENE, V26, P6653, DOI 10.1038/sj.onc.1210492
   Conrad C, 2008, STEM CELLS DEV, V17, P23, DOI 10.1089/scd.2007.0159
   De Boer JP, 2012, ONCOTARGET, V3, P1169
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Ferrari S, 2007, CURR OPIN ONCOL, V19, P341, DOI 10.1097/CCO.0b013e328122d73f
   Fleuren EDG, 2014, BBA REV CANCER, V1845, P266, DOI 10.1016/j.bbcan.2014.02.005
   FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297
   Fulda S, 2013, CANCER LETT, V332, P369, DOI 10.1016/j.canlet.2010.10.003
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Guerzoni C, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 137
   Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236
   Khanna C, 2014, CLIN CANCER RES, V20, P4200, DOI 10.1158/1078 0432.CCR 13 2574
   Koul D, 2012, CLIN CANCER RES, V18, P184, DOI 10.1158/1078 0432.CCR 11 1558
   Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169 409X(00)00129 0
   Ma D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028780
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Manara MC, 2010, CLIN CANCER RES, V16, P530, DOI 10.1158/1078 0432.CCR 09 0816
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Niles AL, 2015, METHODS MOL BIOL, V1219, P21, DOI 10.1007/978 1 4939 1661 0_3
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717
   Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100
   Perry JA, 2014, P NATL ACAD SCI US
   Poos K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003210
   Ribi S, 2015, ONCOTARGET
   Sampson VB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00132
   Schorpp K, 2014, J BIOMOL SCREEN, V19, P715, DOI 10.1177/1087057113516861
   Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426
   Shimizu T, 2014, CANCER RES, V74, P6531, DOI 10.1158/0008 5472.CAN 14 0914
   Silva MT, 2010, FEBS LETT, V584, P4491, DOI 10.1016/j.febslet.2010.10.046
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259
   Swinney DC, 2013, J BIOMOL SCREEN, V18, P1186, DOI 10.1177/1087057113501199
   Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480
   Tacar O, 2014, J PHARM PHARM
   THALMEIER K, 1994, BLOOD, V83, P1799
   Van Maerken T, 2014, CANCER LETT, V344, P157, DOI 10.1016/j.canlet.2013.11.002
   van Maldegem AM, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045 3329 2 5
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008 5472.CAN 04 3135
   Wawer MJ, 2014, P NATL ACAD SCI USA, V111, P10911, DOI 10.1073/pnas.1410933111
   Yen ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006 0295
   Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506
NR 54
TC 15
Z9 16
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2015
VL 10
IS 6
AR e0129058
DI 10.1371/journal.pone.0129058
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CJ7ST
UT WOS:000355700700140
PM 26039064
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kaneko, K
   Kusunoki, N
   Hasunuma, T
   Kawai, S
AF Kaneko, Kaichi
   Kusunoki, Natsuko
   Hasunuma, Tomoko
   Kawai, Shinichi
TI Changes of Serum Soluble Receptor Activator for Nuclear Factor κB Ligand
   after Glucocorticoid Therapy Reflect Regulation of Its Expression by
   Osteoblasts
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID INDUCED OSTEOPOROSIS; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN
   LIGAND; RHEUMATIC DISEASES; BONE METABOLISM; MESSENGER RNA; CELLS;
   INTERLEUKIN 1; STIMULATION; MECHANISMS
AB Context: Osteoporosis is a serious complication of systemic glucocorticoid therapy. The role of serum soluble receptor activator for nuclear factor kappa B ligand (RANKL) in glucocorticoid induced osteoporosis remains unclear.
   Objective: The objective of the study was to clarify the influence of serum soluble RANKL on the osteoprotegerin (OPG)/RANKL/receptor activator for nuclear factor kappa B system in patients with systemic autoimmune diseases receiving glucocorticoid therapy.
   Patients and Methods: Sixty patients (40women) with systemic autoimmune diseases who received initial glucocorticoid therapy with prednisolone (30 60 mg/d) plus bisphosphonate therapy were prospectively enrolled. Serum soluble RANKL and OPG levels were measured at 0, 1, 2, 3, and 4 wk after starting glucocorticoid therapy. The effects of dexamethasone on production of RANKL and OPG mRNA and protein by cultured normal human osteoblasts were evaluated by RT PCR and ELISA, respectively.
   Results: The mean serum soluble RANKL level of the patients was unchanged by glucocorticoid therapy. Because the distribution of serum soluble RANKL was bimodal, the patients were stratified into two groups. Serum soluble RANKL decreased significantly in the higher soluble RANKL group (>= 0.16 pmol/liter), whereas it increased significantly in the lower soluble RANKL group. The mean serum OPG level of the patients decreased significantly. Bone mineral density increased in the higher soluble RANKL group after starting glucocorticoid therapy, whereas it decreased in the lower soluble RANKL group. In cultures of unstimulated human osteoblasts, RANKL mRNA expression was increased and OPG mRNA was decreased by dexamethasone. Up regulation of RANKL and OPG mRNA by IL 6 was suppressed by dexamethasone.
   Conclusion: Serum soluble RANKL might be a useful marker of bone remodeling in patients with systemic autoimmune diseases receiving glucocorticoid therapy. (J Clin Endocrinol Metab 97: E1909 E1917, 2012)
C1 [Kawai, Shinichi] Toho Univ, Fac Med, Sch Med, Div Rheumatol,Ota Ku, Tokyo 1438541, Japan.
   [Hasunuma, Tomoko] Kitasato Univ, Res Ctr Clin Pharmacol, Tokyo 1088642, Japan.
C3 Kitasato University
RP Kawai, S (通讯作者)，Toho Univ, Fac Med, Sch Med, Div Rheumatol,Ota Ku, 6 11 1 Omori Nishi, Tokyo 1438541, Japan.
EM skawai@med.toho u.ac.jp
RI ; Hasunuma, Tomoko/AAL 5130 2020
OI KANEKO, KAICHI/0000 0002 2082 6948; 
FU Heisei 20 and 23 Strategic Research Foundation grants from the Japanese
   Ministry of Education, Culture, Sports, Science, and Technology; Japan
   Society for the Promotion of Science [JSPS 23591449]; Nakatomi
   Foundation; Takeda Science Foundation; Grants in Aid for Scientific
   Research [23591449] Funding Source: KAKEN
FX This work was supported by Heisei 20 and 23 Strategic Research
   Foundation grants from the Japanese Ministry of Education, Culture,
   Sports, Science, and Technology (to Toho University), Grant JSPS
   23591449 from the Japan Society for the Promotion of Science (to S.K.),
   and grants from the Nakatomi Foundation and Takeda Science Foundation
   (to N.K.).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   BERTOUCH JV, 1983, ANN RHEUM DIS, V42, P655, DOI 10.1136/ard.42.6.655
   Buttgereit F, 2004, ARTHRITIS RHEUM US, V50, P3408, DOI 10.1002/art.20583
   Chung H, 2001, J KOREAN MED SCI, V16, P769, DOI 10.3346/jkms.2001.16.6.769
   Cutolo M, 2009, RHEUMATOLOGY, V48, P210, DOI 10.1093/rheumatology/ken394
   den Uyl D, 2011, CLIN EXP RHEUMATOL, V29, pS93
   Fauci A, 2012, HARRISONS PRINCIPLES, P3135
   Findlay DM, 2011, OSTEOPOROSIS INT, V22, P2597, DOI 10.1007/s00198 011 1740 9
   GABAY C, 1994, ARTHRITIS RHEUM, V37, P1744, DOI 10.1002/art.1780371206
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Kim H, 2003, J BONE MINER METAB, V21, P311, DOI 10.1007/s00774 003 0426 6
   Kondo T, 2008, J CELL BIOCHEM, V103, P335, DOI 10.1002/jcb.21414
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Maricic M, 2011, RHEUM DIS CLIN N AM, V37, P415, DOI 10.1016/j.rdc.2011.07.003
   Nawata H, 2005, J BONE MINER METAB, V23, P105, DOI 10.1007/s00774 004 0596 x
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Rogers A, 2005, J CLIN ENDOCR METAB, V90, P6323, DOI 10.1210/jc.2005 0794
   Sasaki N, 2002, BONE, V30, P853, DOI 10.1016/S8756 3282(02)00742 1
   STUART RA, 1995, CLIN EXP RHEUMATOL, V13, P17
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   von Tirpitz C, 2003, EUR J GASTROEN HEPAT, V15, P1165, DOI 10.1097/00042737 200311000 00003
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 27
TC 12
Z9 13
U1 0
U2 7
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0021 972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD OCT 1
PY 2012
VL 97
IS 10
BP E1909
EP E1917
DI 10.1210/jc.2012 1971
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 018MH
UT WOS:000309664400010
PM 22791764
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Wang, Z
   Zhou, F
   Feng, X
   Li, H
   Duan, C
   Wu, Y
   Xiong, Y
AF Wang, Z.
   Zhou, F.
   Feng, X.
   Li, H.
   Duan, C.
   Wu, Y.
   Xiong, Y.
TI FoxO1/NLRP3 Inflammasome Promotes Age Related Alveolar Bone Resorption
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE aging; osteoblasts; forkhead transcription factor; inflammasomes;
   oxidative stress
ID OXIDATIVE STRESS; FOXO1; OSSEOINTEGRATION; CATENIN
AB Periodontitis is the utmost common chronic oral disease that exhibits intense susceptibility to aging. Aging is characterized by persistent sterile low grade inflammation, leading to age related periodontal complications represented by alveolar bone loss. Currently, forkhead transcription factor O1 (FoxO1) is generally believed to have a significant role in body development, senescence, cell viability, and oxidative stress in numerous organs and cells. However, the role of this transcription factor in mediating age related alveolar bone resorption has not been examined. In this study, FoxO1 deficiency was discovered to have a beneficial correlation with halting the progression of alveolar bone resorption in aged mice. To further investigate the function of FoxO1 in age related alveolar bone resorption, osteoblastic specific FoxO1 knockout mice were generated, leading to an amelioration in alveolar bone loss compared to aged matched wild type mice, manifested as enhanced osteogenic potential. Mechanistically, we identified enhancement of the NLRP3 inflammasome signaling in FoxO1 deficient osteoblasts in the high dose of reactive oxygen species. Concordant with our study, MCC950, a specific inhibitor of NLRP3 inflammasome, greatly rescued osteoblast differentiation under oxidative stress. Our data shed light on the manifestations of FoxO1 depletion in osteoblasts and propose a possible mechanism for the therapy of age related alveolar bone loss.
C1 [Wang, Z.; Zhou, F.; Feng, X.; Li, H.; Duan, C.; Wu, Y.; Xiong, Y.] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, 14 Third Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.
   [Wang, Z.; Zhou, F.; Li, H.; Wu, Y.; Xiong, Y.] Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, 14 Third Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Xiong, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, 14 Third Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.; Xiong, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, 14 Third Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.
EM xiongraise@163.com
OI Wang, Zhanqi/0000 0002 5907 9134
FU National Natural Science Foundation of China [8001084, 81970966];
   Natural Science Foundation of Sichuan Province [2023NSFSC1513,
   2023NSFSC0574]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the National Natural Science Foundation of China (Nos.
   8001084 and 81970966) and by the Natural Science Foundation of Sichuan
   Province (Nos. 2023NSFSC1513 and 2023NSFSC0574). All authors gave their
   final approval and agree to be accountable for all aspects of the work.
CR Afonina IS, 2015, IMMUNITY, V42, P991, DOI 10.1016/j.immuni.2015.06.003
   Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Bi JR, 2019, CYTOKINE, V114, P135, DOI 10.1016/j.cyto.2018.11.011
   Bokov A, 2004, MECH AGEING DEV, V125, P811, DOI 10.1016/j.mad.2004.07.009
   Calissi G, 2021, NAT REV DRUG DISCOV, V20, P21, DOI 10.1038/s41573 020 0088 2
   Chung S, 2015, J LEUKOCYTE BIOL, V97, P327, DOI 10.1189/jlb.3A0514 251R
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Coutel X, 2019, BONE, V127, P343, DOI 10.1016/j.bone.2019.06.031
   Dye BA, 2012, PERIODONTOL 2000, V58, P10, DOI 10.1111/j.1600 0757.2011.00413.x
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Graves DT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02530
   Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532 5415.1972.tb00787.x
   Jiang N, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.752546
   Kawahara Y, 2020, J DENT RES, V99, P830, DOI 10.1177/0022034520913250
   Kousteni Stavroula, 2011, Curr Osteoporos Rep, V9, P60, DOI 10.1007/s11914 011 0054 3
   Lai PL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.249
   Lei LH, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107781
   Li CY, 2021, CELL DEATH DIFFER, V28, P1705, DOI 10.1038/s41418 020 00695 7
   Liu CJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29633 6
   Ludovico P, 2014, FEMS YEAST RES, V14, P33, DOI 10.1111/1567 1364.12070
   McKee CM, 2020, J LEUKOCYTE BIOL, V108, P937, DOI 10.1002/JLB.3MR0720 513R
   Moon KM, 2021, REDOX BIOL, V46, DOI 10.1016/j.redox.2021.102101
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Ren L, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5557095
   Wang YN, 2021, J DENT RES, V100, P658, DOI 10.1177/0022034520983245
   Wu Y, 2016, J DENT RES, V95, P460, DOI 10.1177/0022034515625962
   Xiong Yi, 2022, Cell Signal, V99, P110438, DOI 10.1016/j.cellsig.2022.110438
   Xiong Y, 2017, J BIOL CHEM, V292, P20270, DOI 10.1074/jbc.M117.796367
   Xiong Y, 2017, BIOCHEM BIOPH RES CO, V494, P626, DOI 10.1016/j.bbrc.2017.10.024
   Zhang CY, 2015, J CELL BIOL, V209, P289, DOI 10.1083/jcb.201409032
   Zhang J, 2020, J CLIN PERIODONTOL, V47, P451, DOI 10.1111/jcpe.13258
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 38
TC 10
Z9 10
U1 4
U2 24
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JUL
PY 2023
VL 102
IS 8
SI SI
BP 919
EP 928
DI 10.1177/00220345231164104
EA MAY 2023
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA M4ZK2
UT WOS:001002854900001
PM 37203197
DA 2025 08 17
ER

PT J
AU Sarkar, N
   Morton, H
   Bose, S
AF Sarkar, Naboneeta
   Morton, Hailey
   Bose, Susmita
TI Effects of vitamin C on osteoblast proliferation and osteosarcoma
   inhibition using plasma coated hydroxyapatite on titanium implants
SO SURFACE & COATINGS TECHNOLOGY
LA English
DT Article
DE In vitro vitamin C release; Plasma coated HAp; Load bearing Ti implant;
   Osteoblast cell culture; Osteosarcoma cell culture
ID CALCIUM PHOSPHATE CERAMICS; DRUG DELIVERY; IN VITRO; BONE; COATINGS;
   CANCER; ASCORBATE; MECHANISMS; RELEASE
AB Plasma sprayed hydroxyapatite (HAp) coated titanium (Ti) implants are being extensively used in orthopedic surgeries and post tumor resection to repair load bearing segmental bone defects. In this study, vitamin C, an abundantly available natural biomolecule, is loaded onto plasma sprayed HAp coated commercially pure titanium (cpTi) surface to evaluate its chemopreventive and osteogenic properties, suggesting its clinical significance as an alternative or adjunct therapy in the treatment for osteosarcoma bone resection. Controlled release of vitamin C from HAp coated cpTi implant is assessed by in vitro drug release study, where KorsmeyerPeppas model is applied to understand the release kinetics. After 21 days, the implants loaded with 400 and 800 mu g of vitamin C have shown a cumulative release of 62.7 and 74.1% in acidic microenvironment, whereas, 50.9% and 53.1% of total vitamin C release are observed from the implants loaded with 400 and 800 mu g of vitamin C in physiological pH, respectively. To understand the effects of in vitro vitamin C release on osteosarcoma and osteoblast cellular activity, MG 63 (human osteosarcoma) and hFOB (human fetal osteoblast) cells are cultured on the surface of the implant and MTT cell viability assay and FESEM is carried out at 3 and 7 days of culture. Presence of high dosages 25 mM vitamin C shows a statistically significant (p <= 0.05) decrease in osteosarcoma cell viability after 3 days, while both 5 mM and 25 mM vitamin C reduce cellular viability by 2.5 folds (p <= 0.05) compared to the control after 7 days. Interestingly, the presence of vitamin C shows no obvious signs of cytotoxicity towards osteoblast cell line at day 3 and day 7, as confirmed by the MTT assay. Additionally, the FESEM images depict layers of hFOB cellular morphology on the surface of the implants, suggesting excellent cytocompatibility towards the osteoblast cells. These results suggest that vitamin C loaded HAp coated cpTi implant with improved osteogenic and chemopreventive properties can be considered as a promising reconstructive option to repair the post tumor resection defects in osteosarcoma.
C1 [Sarkar, Naboneeta; Morton, Hailey; Bose, Susmita] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
C3 Washington State University
RP Bose, S (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
EM sbose@wsu.edu
OI Sarkar, Naboneeta/0000 0002 1795 7947
FU NIH [1R01 AR 066361]
FX Researchers would like to acknowledge the assistance from Dr. Dongxu Ke
   for sample preparation and financial support from NIH [Grant
   #1R01 AR 066361].
CR Aghajanian P, 2015, J BONE MINER RES, V30, P1945, DOI 10.1002/jbmr.2709
   Bandyopadhyay A, 2010, ACTA BIOMATER, V6, P1640, DOI 10.1016/j.actbio.2009.11.011
   Bigi A, 2005, BIOMATERIALS, V26, P4085, DOI 10.1016/j.biomaterials.2004.10.034
   Bose S, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110096
   Bose S, 2018, MATER TODAY CHEM, V8, P110, DOI 10.1016/j.mtchem.2018.03.005
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Bose S, 2011, JOM US, V63, P93, DOI 10.1007/s11837 011 0065 7
   BRAM S, 1980, NATURE, V284, P629, DOI 10.1038/284629a0
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685
   Caritá AC, 2020, NANOMED NANOTECHNOL, V24, DOI 10.1016/j.nano.2019.102117
   Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102
   Chin KY, 2018, CURR DRUG TARGETS, V19, P439, DOI 10.2174/1389450116666150907100838
   CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303
   Du JA, 2010, CLIN CANCER RES, V16, P509, DOI 10.1158/1078 0432.CCR 09 1713
   Golde David W, 2003, Integr Cancer Ther, V2, P158, DOI 10.1177/1534735403002002009
   Gulati K, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556 276X 6 571
   Hainfeld JF, 2008, J PHARM PHARMACOL, V60, P977, DOI 10.1211/jpp.60.8.0005
   Kannan S, 2011, ACTA BIOMATER, V7, P1835, DOI 10.1016/j.actbio.2010.12.009
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kim D, 2017, YONSEI MED J, V58, P453, DOI 10.3349/ymj.2017.58.2.453
   Lee EJ, 2017, PROG MATER SCI, V89, P392, DOI 10.1016/j.pmatsci.2017.06.003
   Long M, 1998, BIOMATERIALS, V19, P1621, DOI 10.1016/S0142 9612(97)00146 4
   Lv HW, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698 017 0044 8
   Ngo B, 2019, NAT REV CANCER, V19, P271, DOI 10.1038/s41568 019 0135 7
   Parent M, 2017, J CONTROL RELEASE, V252, P1, DOI 10.1016/j.jconrel.2017.02.012
   Park S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00762
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Roy M, 2012, ACS APPL MATER INTER, V4, P1341, DOI 10.1021/am201610q
   Roy M, 2011, J BIOMED MATER RES B, V99B, P258, DOI 10.1002/jbm.b.31893
   Roy M, 2011, SURF COAT TECH, V205, P2785, DOI 10.1016/j.surfcoat.2010.10.042
   Sarkar N, 2020, ACS APPL MATER INTER, V12, P13644, DOI 10.1021/acsami.9b22474
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   SCHWARZ RI, 1987, ANN NY ACAD SCI, V498, P172, DOI 10.1111/j.1749 6632.1987.tb23760.x
   Vahabzadeh S, 2015, ACTA BIOMATER, V17, P47, DOI 10.1016/j.actbio.2015.01.022
   van der Reest J, 2016, CELL RES, V26, P269, DOI 10.1038/cr.2016.7
   Verron E, 2014, DRUG DISCOV TODAY, V19, P1419, DOI 10.1016/j.drudis.2014.04.004
   Vissers MCM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00809
   Yeung WK, 2013, J BIOMED MATER RES B, V101B, P939, DOI 10.1002/jbm.b.32899
   Zhang M, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703932
NR 40
TC 15
Z9 16
U1 1
U2 26
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0257 8972
J9 SURF COAT TECH
JI Surf. Coat. Technol.
PD JUL 25
PY 2020
VL 394
AR 125793
DI 10.1016/j.surfcoat.2020.125793
PG 9
WC Materials Science, Coatings & Films; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Physics
GA MA7NZ
UT WOS:000542100500013
PM 32612317
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Pollari, S
   Käkönen, SM
   Edgren, H
   Wolf, M
   Kohonen, P
   Sara, H
   Guise, T
   Nees, M
   Kallioniemi, O
AF Pollari, Sirkku
   Kakonen, Sanna Maria
   Edgren, Henrik
   Wolf, Maija
   Kohonen, Pekka
   Sara, Henri
   Guise, Theresa
   Nees, Matthias
   Kallioniemi, Olli
TI Enhanced serine production by bone metastatic breast cancer cells
   stimulates osteoclastogenesis
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Bone metastasis; Osteoclast; L serine
ID HORMONE RELATED PROTEIN; AMINO ACID TRANSPORTER; IN VITRO; RECEPTOR
   ACTIVATOR; NUCLEAR FACTOR; EXPRESSION; OSTEOLYSIS; THERAPY; BIOLOGY;
   SYSTEM
AB Since bone metastatic breast cancer is an incurable disease, causing significant morbidity and mortality, an understanding of the underlying molecular mechanisms would be highly valuable. Here, we describe in vitro and in vivo evidences for the importance of serine biosynthesis in the metastasis of breast cancer to bone. We first characterized the bone metastatic propensity of the MDA MB 231(SA) cell line variant as compared to the parental MDA MB 231 cells by radiographic and histological observations in the inoculated mice. Genome wide gene expression profiling of this isogenic cell line pair revealed that all the three genes involved in the l serine biosynthesis pathway, phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), and phosphoserine phosphatase (PSPH) were upregulated in the highly metastatic variant. This pathway is the primary endogenous source for l serine in mammalian tissues. Consistently, we observed that the proliferation of MDA MB 231(SA) cells in serine free conditions was dependent on PSAT1 expression. In addition, we observed that l serine is essential for the formation of bone resorbing human osteoclasts and may thus contribute to the vicious cycle of osteolytic bone metastasis. High expression of PHGDH and PSAT1 in primary breast cancer was significantly associated with decreased relapse free and overall survival of patients and malignant phenotypic features of breast cancer. In conclusion, high expression of serine biosynthesis genes in metastatic breast cancer cells and the stimulating effect of l serine on osteoclastogenesis and cancer cell proliferation indicate a functionally critical role for serine biosynthesis in bone metastatic breast cancer and thereby an opportunity for targeted therapeutic interventions.
C1 [Pollari, Sirkku; Kohonen, Pekka; Sara, Henri; Nees, Matthias] VTT Tech Res Ctr Finland, Turku, Finland.
   [Pollari, Sirkku; Kohonen, Pekka; Sara, Henri; Nees, Matthias] Turku Ctr Biotechnol, Turku, Finland.
   [Kakonen, Sanna Maria] Univ Turku, Inst Biomed, Dept Anat, FIN 20520 Turku, Finland.
   [Edgren, Henrik; Wolf, Maija; Kallioniemi, Olli] Univ Helsinki, FIMM, Helsinki, Finland.
   [Guise, Theresa] Indiana Univ, Div Endocrinol, Indianapolis, IN 46204 USA.
C3 VTT Technical Research Center Finland; University of Turku; University
   of Turku; University of Helsinki; Indiana University System; Indiana
   University Indianapolis
RP Pollari, S (通讯作者)，VTT Tech Res Ctr Finland, Turku, Finland.
EM ext sirkku.pollari@vtt.fi
RI Nees, Matthias/W 6596 2018; Kallioniemi, Olli/H 5111 2011; Kallioniemi,
   Olli/H 4738 2012; Kohonen, Pekka/F 9596 2011
OI Nees, Matthias/0000 0002 9034 301X; Kakonen,
   Sanna Maria/0000 0001 9393 6235; Kallioniemi, Olli/0000 0002 3231 0332;
   Kohonen, Pekka/0000 0002 7845 3611
FU Academy of Finland Center of Excellence; TIME; Drug Discovery Graduate
   School; National Cancer Institute [R01 CA69158]; Finnish Cancer
   Organisations; Sigrid Juselius Foundation; Finnish Cultural Foundation
FX This study was supported by the Academy of Finland Center of Excellence
   grant (Center of Excellence in Translational Genome Scale Biology
   2006 2011), TIME (Disseminated Tumour Cells as Targets for Inhibiting
   Metastasis of Epithelial Tumours) project, Drug Discovery Graduate
   School, NIH grant R01 CA69158 from the National Cancer Institute, and by
   grants from the Finnish Cancer Organisations, the Sigrid Juselius
   Foundation, and the Finnish Cultural Foundation. We thank Barry G.
   Grubbs and Rami Kakonen for excellent technical assistance in the mouse
   studies, Pharmatest Services Ltd (http://www.pharmatest.fi/) for
   technical help and discussions regarding the osteoclast cultures, and
   John Patrick Mpindi for help in bioinformatic analyses.
CR Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   Alatalo SL, 2000, CLIN CHEM, V46, P1751
   ARRIZA JL, 1993, J BIOL CHEM, V268, P15329
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bröer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264 6021:3460705
   Chaudhry FA, 2002, J NEUROSCI, V22, P62, DOI 10.1523/JNEUROSCI.22 01 00062.2002
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Lewis RM, 2007, PLACENTA, V28, P445, DOI 10.1016/j.placenta.2006.06.014
   Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008 5472.CAN 05 0064
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Ogawa T, 2006, J BONE MINER METAB, V24, P373, DOI 10.1007/s00774 006 0705 0
   *R DEV COR TEAM, 2004, R LANG ENV STAT COMP
   SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065 2571(84)90021 9
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   VARGAS SJ, 1992, J BONE MINER RES, V7, P971
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
NR 27
TC 207
Z9 233
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167 6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2011
VL 125
IS 2
BP 421
EP 430
DI 10.1007/s10549 010 0848 5
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 695AW
UT WOS:000285344000010
PM 20352489
DA 2025 08 17
ER

PT J
AU Matsuzaki, E
   Hirose, H
   Fujimasa, S
   Yoshimoto, S
   Yanagi, T
   Matsumoto, K
   Nikaido, M
   Minakami, M
   Matsumoto, N
   Anan, H
AF Matsuzaki, Etsuko
   Hirose, Haruna
   Fujimasa, Seishiro
   Yoshimoto, Shohei
   Yanagi, Tsukasa
   Matsumoto, Kazuma
   Nikaido, Misaki
   Minakami, Masahiko
   Matsumoto, Noriyoshi
   Anan, Hisashi
TI Sphingosine 1 phosphate receptor 2 agonist induces bone formation in rat
   apicoectomy and alveolar bone defect model
SO JOURNAL OF DENTAL SCIENCES
LA English
DT Article
DE Bone formation; Osteoblastic differentiation marker; Rat apicoectomy and
   alveolar bone defect; Sphingosine 1 phosphate; Sphingosine 1 phosphate
   receptor 2 agonist
ID SPHINGOSINE 1 PHOSPHATE; EXPRESSION; S1P(1); DRUG
AB Background/purpose: Sphingosine 1 phosphate (S1P) is a lipid mediator that exerts its physiological functions in vivo through receptors. In the bone, S1P induces osteoblast differentiation. Here, we investigated the effects of S1P receptor agonists on the expression of osteoblast differentiation markers locally in the bone. Then, a rat apicoectomy and alveolar bone defect model was established to extend S1P applications to endodontics, and the effect of local administration of S1P receptor agonist on postoperative bone formation was examined.
   Materials and methods: Sphingosine 1 phosphate receptor (S1PR) 1/S1PR3 agonists, S1PR2 agonists, and their signal related agents were intraperitoneally administered to mice. Using the mRNA collected from the tibial bone, the expression of osteoblast differentiation markers was evaluated by real time reverse transcriptase quantitative polymerase chain reaction. An apicoectomy and alveolar bone defect model was established on the mesial root of the rat mandibular first molar. Bone formation parameters were measured by micro computed tomography analysis 3 weeks after the procedure.
   Results: Intraperitoneal administration of S1PR2 agonist significantly increased the mRNA expression of osteoblast differentiation markers, including alkaline phosphatase (ALP), osteopontin (OPN), bone sialoprotein (BSP), and osteocalcin, in the local tibial bone of mice. The S1PR2/Rho associated coiled coil forming kinase (ROCK) signaling was thought to be involved in the upregulated mRNA expression of ALP, OPN, and BSP. In the rat apical defects, bone formation parameters significantly increased following local administration of S1PR2 agonist.
   Conclusion: In the rat apicoectomy and alveolar bone defect model, therapeutic agents targeting S1PR2 agonist are effective against osteogenesis. (C) 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V.
C1 [Matsuzaki, Etsuko; Hirose, Haruna; Fujimasa, Seishiro; Matsumoto, Kazuma; Nikaido, Misaki; Minakami, Masahiko; Matsumoto, Noriyoshi; Anan, Hisashi] Fukuoka Dent Coll, Sect Operat Dent & Endodontol, Dept Odontol, Fukuoka, Japan.
   [Matsuzaki, Etsuko; Yoshimoto, Shohei] Fukuoka Dent Coll, Oral Med Res Ctr, Fukuoka, Japan.
   [Yoshimoto, Shohei] Fukuoka Dent Coll, Div Biomed Sci, Sect Pathol, Dept Morphol Biol, Fukuoka, Japan.
   [Yanagi, Tsukasa] Fukuoka Dent Coll, Sect Oral Implantol, Dept Oral Rehabil, Fukuoka, Japan.
C3 Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Fukuoka
   Dental College (FDC); Fukuoka Dental College (FDC)
RP Matsuzaki, E (通讯作者)，Fukuoka Dent Coll, Sect Operat Dent & Endodontol, Dept Odontol, 2 15 1 Tamura,Sawara Ku, Fukuoka 8140193, Japan.
EM matsuzaki@college.fdcnet.ac.jp
FU JSPS [JP20K9969, 17K11729, 20K9967, 17K11728]; Grants in Aid for
   Scientific Research [21H03117, 20K09969] Funding Source: KAKEN
FX This study was supported by JSPS Grant in Aid for Scientific Research
   (JP20K9969, 17K11729 to E. Matsuzaki, 20K9967, 17K11728 to H. Anan). We
   would like to thank Editage (www.editage.jp) for their English language
   editing services.
CR Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200
   Bankovich AJ, 2010, J BIOL CHEM, V285, P22328, DOI 10.1074/jbc.M110.123299
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Brizuela L, 2014, MOL ONCOL, V8, P1181, DOI 10.1016/j.molonc.2014.04.001
   Chi HB, 2011, TRENDS PHARMACOL SCI, V32, P16, DOI 10.1016/j.tips.2010.11.002
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Higashi K, 2016, BONE, V93, P1, DOI 10.1016/j.bone.2016.09.003
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   Matsuzaki E, 2013, BONE, V55, P315, DOI 10.1016/j.bone.2013.04.008
   Moriishi T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008586
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200
   Torabinejad M, 2009, J ENDODONT, V35, P930, DOI 10.1016/j.joen.2009.04.023
   Weske S, 2019, BONE, V125, P1, DOI 10.1016/j.bone.2019.04.015
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Xiao L, 2018, J BONE MINER RES, V33, P1090, DOI 10.1002/jbmr.3396
   Xiao L, 2015, J ENDODONT, V41, P479, DOI 10.1016/j.joen.2014.10.010
   Yoneda N, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03628 6
NR 23
TC 12
Z9 12
U1 1
U2 8
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N 412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1991 7902
EI 2213 8862
J9 J DENT SCI
JI J. Dental Sci.
PD APR
PY 2022
VL 17
IS 2
BP 787
EP 794
DI 10.1016/j.jds.2021.10.004
EA MAR 2022
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 6H1ZQ
UT WOS:000885247300017
PM 35756763
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shen, HS
   Kushioka, J
   Toya, M
   Utsunomiya, T
   Hirata, H
   Huang, EE
   Tsubosaka, M
   Gao, Q
   Li, XP
   Teissier, V
   Zhang, N
   Goodman, SB
AF Shen, Huaishuang
   Kushioka, Junichi
   Toya, Masakazu
   Utsunomiya, Takeshi
   Hirata, Hirohito
   Huang, Ejun Elijah
   Tsubosaka, Masanori
   Gao, Qi
   Li, Xueping
   Teissier, Victoria
   Zhang, Ning
   Goodman, Stuart B.
TI Sex differences in the therapeutic effect of unaltered versus NF?B
   sensing IL 4 over expressing mesenchymal stromal cells in a murine model
   of chronic inflammatory bone loss
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE sex differences; chronic inflammatory bone loss; wear particles;
   mesenchymal stromal cell; macrophage
ID B DECOY OLIGODEOXYNUCLEOTIDE; PERIPROSTHETIC OSTEOLYSIS; BIOLOGIC
   TREATMENTS; WEAR PARTICLES; STEM CELLS; HIP; ARTHROPLASTY; OSTEOGENESIS;
   REPLACEMENT; MECHANISMS
AB Wear particles from joint arthroplasties induce chronic inflammation associated with prolonged upregulation of nuclear factor kappa B (NF kappa B) signaling in macrophages and osteoclasts, which leads to osteolysis and implant loosening. Mesenchymal stromal cell (MSC) based therapy showed great potential for immunomodulation and mitigation of osteolysis in vivo, especially in the chronic phase of inflammation. We previously generated genetically modified MSCs that secrete the anti inflammatory cytokine interleukin 4 (IL 4) in response to NF kappa B activation (NF kappa B IL 4 MSCs). However, whether the impact of sexual difference in the internal environment can alter the therapeutic effects of IL 4 over secreting MSCs that simultaneously mitigate prolonged inflammation and enhance bone formation remains unknown. This study investigated the therapeutic effects of unaltered MSCs versus NF kappa B IL 4 MSCs in mitigating chronic inflammation and enhancing bone formation in male and female mice. The murine model was established by continuous infusion of polyethylene particles contaminated with lipopolysaccharide (cPE) into the medullary cavity of the distal femur for 6 weeks to induce chronic inflammation. Unaltered MSCs or NF kappa B IL 4 MSCs were infused into the femoral intramedullary cavity in sex matched groups beginning 3 weeks after primary surgery. Femurs were harvested at 6 weeks, and bone marrow density was measured with micro computational tomography. Numbers of osteoclast like cells, osteoblasts, and macrophages were evaluated with histochemical and immunofluorescence staining. cPE infusion resulted in severe bone loss at the surgery site, increased tartrate resistant acid phosphatase positive osteoclasts and M1 pro inflammatory macrophages, and decreased alkaline phosphatase expression. MSC based therapy effectively decreased local bone loss and polarized M1 macrophages into an M2 anti inflammatory phenotype. In females, unaltered MSCs demonstrated a larger impact in enhancing the osteogenesis, but they demonstrated similar anti inflammatory effects compared to NF kappa B IL 4 MSCs. These results demonstrated that local inflammatory bone loss can be effectively modulated via MSC based treatments in a sexually dimorphic manner, which could be an efficacious therapeutic strategy for treatment of periprosthetic osteolysis in both genders.
C1 [Shen, Huaishuang; Kushioka, Junichi; Toya, Masakazu; Hirata, Hirohito; Huang, Ejun Elijah; Tsubosaka, Masanori; Gao, Qi; Li, Xueping; Teissier, Victoria; Zhang, Ning; Goodman, Stuart B.] Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
   [Utsunomiya, Takeshi] Kyushu Univ, Dept Orthopaed Surg, Fukuoka, Japan.
   [Goodman, Stuart B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
C3 Stanford University; Kyushu University; Stanford University
RP Goodman, SB (通讯作者)，Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.; Goodman, SB (通讯作者)，Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
EM goodbone@stanford.edu
RI Gao, Qi/HIZ 9551 2022; Kushioka, Junichi/ABH 8046 2020; Zhang,
   Ning/AHA 3443 2022; Goodman, Stuart/AAZ 7499 2020; Shen,
   Huaishuang/GLV 4432 2022
OI Toya, Masakazu/0000 0002 1244 8326; Goodman, Stuart/0000 0002 1919 3717;
   Zhang, Ning/0000 0002 9513 9288; , Qi/0000 0003 0175 566X
FU NIH from NIAMS [R01AR073145, R01AR063717]; Ellenburg Chair in Surgery at
   Stanford University
FX This work was supported by the NIH grants R01AR073145 and R01AR063717
   from NIAMS and the Ellenburg Chair in Surgery at Stanford University.
CR Abdelaal MS, 2020, ORTHOP CLIN N AM, V51, P169, DOI 10.1016/j.ocl.2019.11.003
   Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Bankhead P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17204 5
   Becker JB, 2005, ENDOCRINOLOGY, V146, P1650, DOI 10.1210/en.2004 1142
   Biswas Debajit K, 2005, Sci STKE, V2005, ppe27, DOI 10.1126/stke.2882005pe27
   Brooks PJ, 2019, AM J PATHOL, V189, P1145, DOI 10.1016/j.ajpath.2019.02.006
   Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Evans KE, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 4
   Gallo J, 2013, ACTA BIOMATER, V9, P8046, DOI 10.1016/j.actbio.2013.05.005
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Goodman SB, 2005, CLIN ORTHOP RELAT R, P39, DOI 10.1097/01.blo.0000149998.88218.05
   Goodman SB, 2007, BIOMATERIALS, V28, P5044, DOI 10.1016/j.biomaterials.2007.06.035
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Goodman SB, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00230
   Granchi D, 2005, BIOMATERIALS, V26, P2371, DOI 10.1016/j.biomaterials.2004.07.045
   Greenfield EM, 2010, J BIOL CHEM, V285, P32378, DOI 10.1074/jbc.M110.136895
   Haffner Luntzer M, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.712494
   Ishida M, 2018, ENDOCRINOLOGY, V159, P3775, DOI 10.1210/en.2018 00639
   Kashfi K, 2021, CELLS BASEL, V10, DOI 10.3390/cells10113194
   Knewtson KE, 2022, TISSUE ENG PART B RE, V28, P789, DOI [10.1089/ten.TEB.2021.0094, 10.1089/ten.teb.2021.0094]
   Kurtz SM, 2014, J BONE JOINT SURG AM, V96A, P624, DOI 10.2106/JBJS.M.00285
   Laurent M, 2014, ASIAN J ANDROL, V16, P213, DOI 10.4103/1008 682X.122356
   Lin TH, 2016, ACTA BIOMATER, V41, P273, DOI 10.1016/j.actbio.2016.05.038
   Lin TH, 2014, ACTA BIOMATER, V10, P3747, DOI 10.1016/j.actbio.2014.04.034
   Lin T, 2019, TISSUE ENG PT A, V25, P1096, DOI [10.1089/ten.tea.2018.0292, 10.1089/ten.TEA.2018.0292]
   Lin T, 2018, J BIOMED MATER RES A, V106, P2744, DOI 10.1002/jbm.a.36504
   Lin T, 2017, CYTOTHERAPY, V19, P1025, DOI 10.1016/j.jcyt.2017.06.008
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Locati M, 2020, ANNU REV PATHOL MECH, V15, P123, DOI 10.1146/annurev pathmechdis 012418 012718
   Loi F, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0276 5
   Lorenzo J, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092086
   Ma T, 2009, J BIOMED MATER RES B, V88B, P250, DOI 10.1002/jbm.b.31175
   Maruyama M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00386
   Mauvais Jarvis F, 2017, CELL METAB, V25, P1216, DOI 10.1016/j.cmet.2017.04.033
   Mun SH, 2021, J BONE MINER RES, V36, P1104, DOI 10.1002/jbmr.4270
   Nathan K, 2019, BONE JOINT RES, V8, P481, DOI 10.1302/2046 3758.810.BJR 2018 0231.R2
   Nich Christophe, 2011, Arthritis Res Ther, V13, pR100, DOI 10.1186/ar3381
   Pajarinen J, 2017, TISSUE ENG PART C ME, V23, P1003, DOI [10.1089/ten.tec.2017.0166, 10.1089/ten.TEC.2017.0166]
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Price A. J., 2018, Lancet, V392, P1672, DOI [DOI 10.1016/S0140 6736(18)32344 4, 10.1016/S0140 6736(18)32344 4]
   Sandberg K, 2015, FASEB J, V29, P1646, DOI 10.1096/fj.14 269548
   Schwarz EM, 2008, J AM ACAD ORTHOP SUR, V16, pS72, DOI 10.5435/00124635 200800001 00015
   Schwarz EM, 2003, J ORTHOPAED RES, V21, P1049, DOI 10.1016/S0736 0266(03)00093 7
   Schwarz EM, 2000, ARTHRITIS RES, V2, P165, DOI 10.1186/ar81
   Shepherd R, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604000
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Smith RL, 2014, CLIN ORTHOP RELAT R, V472, P3740, DOI 10.1007/s11999 014 3765 9
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Ueno M, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.755964
   Utsunomiya T, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.631063
   Utsunomiya T, 2021, J BIOMED MATER RES A, V109, P1828, DOI 10.1002/jbm.a.37175
   Valerio MS, 2018, J DENT RES, V97, P1416, DOI 10.1177/0022034518798825
   Valerio MS, 2017, J PERIODONTAL RES, V52, P377, DOI 10.1111/jre.12401
   Walsh NC, 2004, CURR OPIN RHEUMATOL, V16, P419, DOI 10.1097/01.bor.0000127824.42507.68
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu ML, 2015, J PHARMACOL TOX MET, V71, P1, DOI 10.1016/j.vascn.2014.11.003
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Zarei A, 2019, JBMR PLUS, V3, P14, DOI 10.1002/jbm4.10066
   Zhang N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.757830
   Zhang N, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02086 8
NR 62
TC 6
Z9 8
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD AUG 15
PY 2022
VL 10
AR 962114
DI 10.3389/fbioe.2022.962114
PG 12
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 4F3AL
UT WOS:000848386500001
PM 36046680
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Collins, FL
   Rios Arce, ND
   Schepper, JD
   Parameswaran, N
   McCabe, LR
AF Collins, Fraser L.
   Rios Arce, Naiomy D.
   Schepper, Jonathan D.
   Parameswaran, Narayanan
   McCabe, Laura R.
TI The Potential of Probiotics as a Therapy for Osteoporosis
SO MICROBIOLOGY SPECTRUM
LA English
DT Article
ID HELVETICUS FERMENTED MILK; COLONY STIMULATING FACTOR; BONE MINERAL
   DENSITY; GUT MICROBIOTA; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST
   DIFFERENTIATION; OXIDATIVE STRESS; GENE EXPRESSION; T CELLS; RESORPTION
AB Osteoporosis, characterized by low bone mass and micro architectural deterioration of bone tissue with increased risk of fracture, can be categorized into two forms: primary and secondary, depending on whether it occurs as part of the natural aging process (estrogen deficiency) or as part of disease pathology. In both forms bone loss is due to an imbalance in the bone remodeling process, with resorption/formation skewed more toward bone loss. Recent studies and emerging evidence consistently demonstrate the potential of the intestinal microbiota to modulate bone health. This review discusses the process of bone remodeling and the pathology of osteoporosis and introduces the intestinal microbiota and its potential to influence bone health. In particular, we highlight recent murine studies that examine how probiotic supplementation can both increase bone density in healthy individuals and protect against primary (estrogen deficiency) as well as secondary osteoporosis. Potential mechanisms are described to account for how probiotic treatments could be exerting their beneficial effect on bone health.
C1 [Collins, Fraser L.; Rios Arce, Naiomy D.; Schepper, Jonathan D.; Parameswaran, Narayanan; McCabe, Laura R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Biomed Imaging Res Ctr, E Lansing, MI 48824 USA.
C3 Michigan State University; Michigan State University; Michigan State
   University
RP Parameswaran, N; McCabe, LR (通讯作者)，Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.; McCabe, LR (通讯作者)，Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA.; McCabe, LR (通讯作者)，Michigan State Univ, Biomed Imaging Res Ctr, E Lansing, MI 48824 USA.
EM narap@msu.edu; mccabel@msu.edu
RI Collins, Fraser/AAT 7889 2020; Parameswaran, Narayanan/V 1969 2019;
   McCabe, Laura/AGS 5131 2022
OI McCabe, Laura/0000 0001 5407 162X; Parameswaran,
   Narayanan/0000 0002 8894 5564; 
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   [R01 DK101050]; National Center for Complementary and Alternative
   Medicine (NCCAM) [R01 AT007695]; National Institutes of Health; National
   Institute of Diabetes and Digestive and Kidney Diseases [P30DK020572]
   Funding Source: NIH RePORTER
FX We acknowledge support from grants R01 DK101050 from the National
   Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and R01
   AT007695 from the National Center for Complementary and Alternative
   Medicine (NCCAM), National Institutes of Health.
CR Amdekar S, 2012, MOL CELL BIOCHEM, V368, P155, DOI 10.1007/s11010 012 1354 3
   Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   [Anonymous], 2002, Guidelines for the evaluation of probiotics in food
   [Anonymous], FACTS AND STAT
   [Anonymous], 2006, 85 FAO WHO
   [Anonymous], 2014, ADV MICROBIOL NY, DOI [DOI 10.4236/AIM.2014.414112, 10.1002/fsn3.1452]
   Arunachalam KD, 1999, NUTR RES, V19, P1559, DOI 10.1016/S0271 5317(99)00112 8
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   BISMAR H, 1995, J CLIN ENDOCR METAB, V80, P3351, DOI 10.1210/jc.80.11.3351
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Broekaert IJ, 2007, PEDIATR RES, V62, P139, DOI 10.1203/PDR.0b013e31809fd85e
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Caballero Franco C, 2007, AM J PHYSIOL GASTR L, V292, pG315, DOI 10.1152/ajpgi.00265.2006
   Campbell JM, 1997, J NUTR, V127, P130, DOI 10.1093/jn/127.1.130
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo 123 3 1442
   Chiang SS, 2011, J AGR FOOD CHEM, V59, P7734, DOI 10.1021/jf2013716
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Coe LM, 2013, J CELL PHYSIOL, V228, P689, DOI 10.1002/jcp.24177
   Coe LM, 2011, J CELL PHYSIOL, V226, P477, DOI 10.1002/jcp.22357
   Collins FL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153180
   Crittenden RG, 2003, INT J FOOD MICROBIOL, V80, P217, DOI 10.1016/S0168 1605(02)00170 8
   Czerucka D, 2007, ALIMENT PHARM THER, V26, P767, DOI 10.1111/j.1365 2036.2007.03442.x
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eastell R., 2005, MEDICINE, V33, P61
   Edwards Claire M, 2008, Int J Med Sci, V5, P263
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   FAO and WHO, 2006, 85 FAO WHO
   Fitzpatrick LA, 2002, MAYO CLIN PROC, V77, P453, DOI 10.4065/77.5.453
   Foo C, 2007, GYNECOL ENDOCRINOL, V23, P535, DOI 10.1080/09513590701556483
   Fukuda S, 2014, SEMIN IMMUNOPATHOL, V36, P103, DOI 10.1007/s00281 013 0399 z
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Garcia Moreno C, 2004, BONE, V35, P170, DOI 10.1016/j.bone.2004.02.021
   Ghanem KZ, 2004, MILCHWISSENSCHAFT, V59, P472
   Ghishan FK, 2011, AM J PHYSIOL GASTR L, V300, pG191, DOI 10.1152/ajpgi.00496.2010
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jin LZ, 1997, WORLD POULTRY SCI J, V53, P351, DOI 10.1079/WPS19970028
   Jones RM, 2018, BONE, V115, P59, DOI 10.1016/j.bone.2017.04.009
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Khan RU, 2013, WORLD POULTRY SCI J, V69, P621, DOI 10.1017/S0043933913000627
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Kim BJ, 2012, BIOCHEM BIOPH RES CO, V424, P170, DOI 10.1016/j.bbrc.2012.06.100
   Kim JG, 2009, INT DAIRY J, V19, P690, DOI 10.1016/j.idairyj.2009.06.009
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kristensen HB, 2013, J BONE MINER RES, V28, P574, DOI 10.1002/jbmr.1760
   Kruger MC, 2009, DAIRY SCI TECHNOL, V89, P219, DOI 10.1051/dst/2009012
   LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Loh G, 2012, GUT MICROBES, V3, P544, DOI 10.4161/gmic.22156
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Matsuguchi T, 2003, CLIN DIAGN LAB IMMUN, V10, P259, DOI 10.1128/CDLI.10.2.259 266.2003
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McCabe L, 2015, CURR OSTEOPOROS REP, V13, P363, DOI 10.1007/s11914 015 0292 x
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   McCabe LR, 2011, CRIT REV EUKAR GENE, V21, P187, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.70
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P575, DOI 10.1002/jcp.21626
   Mutus R, 2006, POULTRY SCI, V85, P1621, DOI 10.1093/ps/85.9.1621
   NAHASHON SN, 1994, POULTRY SCI, V73, P1699, DOI 10.3382/ps.0731699
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Narva M, 2004, ANN NUTR METAB, V48, P228, DOI 10.1159/000080455
   Narva M, 2004, LIFE SCI, V75, P1727, DOI 10.1016/j.lfs.2004.04.011
   Nava G. M., 2005, Animal Health Research Reviews, V6, P105, DOI 10.1079/AHR2005103
   Ohlsson C, 2015, TRENDS ENDOCRIN MET, V26, P69, DOI 10.1016/j.tem.2014.11.004
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   Painter Stephanie E, 2006, Endocr Pract, V12, P436
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Parvaneh K, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/897639
   PECK WA, 1993, AM J MED, V94, P646
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   PLAVNIK I, 1980, POULTRY SCI, V59, P459, DOI 10.3382/ps.0590459
   Reid IR, 2015, J INTERN MED, V277, P690, DOI 10.1111/joim.12339
   Rizzo DC., 2015, Fundamentals of Anatomy and Physiology, V4
   Robey PG., 2006, PRIMER METABOLIC BON, V6th, P12
   Rodrigues FC, 2012, J MED FOOD, V15, P664, DOI 10.1089/jmf.2011.0296
   Rovensky Jozef, 2004, Clin Dev Immunol, V11, P267, DOI 10.1080/17402520400001660
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sjogren K, 2012, BONE, V50, pS91, DOI [10.1016/j.bone.2012.02.272, 10.1002/jbmr.1588]
   Sougioultzis S, 2006, BIOCHEM BIOPH RES CO, V343, P69, DOI 10.1016/j.bbrc.2006.02.080
   SUDA N, 1993, BIOCHIM BIOPHYS ACTA, V1157, P318, DOI 10.1016/0304 4165(93)90116 P
   SULLIVAN TW, 1994, POULTRY SCI, V73, P879, DOI 10.3382/ps.0730879
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2010, ANN NY ACAD SCI, V1192, P117, DOI 10.1111/j.1749 6632.2009.05303.x
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951
   Tomofuji T, 2012, NUTR RES, V32, P301, DOI 10.1016/j.nutres.2012.03.006
   Turner RT, 2013, J BONE MINER RES, V28, P22, DOI 10.1002/jbmr.1734
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zhang J, 2015, ENDOCRINOLOGY, V156, P3169, DOI 10.1210/EN.2015 1308
NR 119
TC 125
Z9 135
U1 2
U2 43
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 2165 0497
J9 MICROBIOL SPECTR
JI Microbiol. Spectr.
PD AUG
PY 2017
VL 5
IS 4
AR BAD 0015 2016
DI 10.1128/microbiolspec.BAD 0015 2016
PG 16
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA FI8CN
UT WOS:000412228600016
PM 28840819
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nie, YP
   Liu, HY
   Lei, L
   Wu, QS
AF Nie, Yu Peng
   Liu, Huanyan
   Lei, Lei
   Wu, Qishan
TI Effect of Berberine on Treatment of Periodontitis: a Meta Analysis
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE berberine; clinical use; inflammation; in vitro and in vivo experiment
   periodontitis
ID IN VITRO; BONE; FIBROBLAST; DIFFERENTIATION; DEGRADATION; EXPRESSION;
   OSTEOBLAST; PATHWAY; VIVO
AB Berberine, an isoquinoline alkaloid derived from medicinal plants, can prevent extracellular MMPs from degrading. Berberine's influence on periodontal MMP expression was studied in vitro and in vivo. Berberine contains anti inflammatory, anti tumor, lower blood cholesterol, lower blood glucose, anti  osteoporosis, anti osteoarthritis, and anti osteoarthritis properties, according to pharmacological investigations. The goal of this review study was to look at berberine's preventive effects on inflammation and alveolar bone loss in ligature induced periodontitis, as well as its mechanism of action and future usage and development. To determine the effect of berberine on periodontitis, PubMed, EMBASE, the Cochrane Library, Google Scholar were searched. All the above databases were searched from the available date of inception until the latest issue of 2022. With the removal of duplicates, the titles and abstract of 9 studies have remained. Finally, 6articles were included in our meta analysis. The heterogeneity result showed that the included studies had clinical and statistical homogeneity. As shown in plot analysis, the berberine containing group had a higher reduction of inflammation than the control group. BBR's anti inflammatory properties in periodontitis. BBR as a pleiotropic agent is efficacious in exerting anti inflammatory effects
C1 [Nie, Yu Peng; Liu, Huanyan; Lei, Lei; Wu, Qishan] Qingdao Univ, Dept Stomatol, Affiliated Taian City Cent Hosp, Tai An 271099, Shandong, Peoples R China.
C3 Qingdao University
RP Wu, QS (通讯作者)，Qingdao Univ, Dept Stomatol, Affiliated Taian City Cent Hosp, Tai An 271099, Shandong, Peoples R China.
EM wuqishan523@outlook.com
CR Aimetti M, 2014, INT J ESTHET DENT, V9, P251
   [Anonymous], 2009, MODERN TRAD CHIN MED
   Baker DD, 2004, CURR OPIN BIOTECH, V15, P576, DOI 10.1016/j.copbio.2004.09.003
   Basha RY, 2015, MAT SCI ENG C MATER, V57, P452, DOI 10.1016/j.msec.2015.07.016
   Bebek G, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 335
   Blasco Baque V, 2017, GUT, V66, P872, DOI 10.1136/gutjnl 2015 309897
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394
   Burcelin R, 2011, ACTA DIABETOL, V48, P257, DOI 10.1007/s00592 011 0333 6
   Cai B, 2018, ACS APPL MATER INTER, V10, P25099, DOI 10.1021/acsami.8b06648
   Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   Chen PF, 2018, MAT SCI ENG C MATER, V91, P190, DOI 10.1016/j.msec.2018.05.034
   Chen W, 2011, AAPS PHARMSCITECH, V12, P705, DOI 10.1208/s12249 011 9632 z
   Chinese Pharmacopoeia Commission, 2020, CHINESE PHARMACOPOEI, V1, P305
   Colby S.L., 2014, The baby boom cohort in the United States: 2012 to 2060
   Cui GL, 2009, J BIOL CHEM, V284, P28420, DOI 10.1074/jbc.M109.012674
   Delloye C, 2007, J BONE JOINT SURG BR, V89B, P574, DOI 10.1302/0301 620X.89B5.19039
   Deng YJ, 2016, CELL REP, V14, P2224, DOI 10.1016/j.celrep.2016.02.021
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Dinesh P, 2018, CYTOKINE, V106, P54, DOI 10.1016/j.cyto.2018.03.005
   Duplomb L, 2007, STEM CELLS, V25, P544, DOI 10.1634/stemcells.2006 0395
   Fatahian A, 2020, REV PHYSIOL BIOCH P, V178, P83, DOI 10.1007/112_2020_42
   Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Gu LP, 2021, ARCH ORAL BIOL, V122, DOI 10.1016/j.archoralbio.2020.104992
   Haftcheshmeh SM, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102593
   Haftcheshmeh SM, 2019, J CELL BIOCHEM, V120, P1827, DOI 10.1002/jcb.27487
   Jia X, 2019, J DENT RES, V98, P107, DOI 10.1177/0022034518797275
   Kim S, 2008, PHYTOMEDICINE, V15, P340, DOI 10.1016/j.phymed.2007.09.011
   KOWASHI Y, 1979, ARCH ORAL BIOL, V24, P645, DOI 10.1016/0003 9969(79)90112 2
   Kuo PJ, 2012, J PERIODONTAL RES, V47, P431, DOI 10.1111/j.1600 0765.2011.01450.x
   Lee CH, 2007, PHARMACOL RES, V56, P193, DOI 10.1016/j.phrs.2007.06.003
   Lind M, 1998, J BONE JOINT SURG BR, V80B, P924, DOI 10.1302/0301 620X.80B5.8710
   Lohinai Z, 1998, BRIT J PHARMACOL, V123, P353, DOI 10.1038/sj.bjp.0701604
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   McCarty MF, 2014, AGE, V36, P641, DOI 10.1007/s11357 013 9595 y
   McMahon RE, 2013, J BIOMED MATER RES B, V101B, P387, DOI 10.1002/jbm.b.32823
   Meyle J, 2017, J CLIN PERIODONTOL, V44, P1215, DOI 10.1111/jcpe.12781
   Haftcheshmeh SM, 2020, BIOFACTORS, V46, P341, DOI 10.1002/biof.1603
   Moore WR, 2001, ANZ J SURG, V71, P354, DOI 10.1046/j.1440 1622.2001.2128.x
   Moussa Nabil Takahiro, 2020, Dent Clin North Am, V64, P473, DOI 10.1016/j.cden.2019.12.011
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Olivares Navarrete R, 2012, J BONE MINER RES, V27, P1773, DOI 10.1002/jbmr.1628
   Owen GR, 2018, J BIOMED MATER RES B, V106, P2493, DOI 10.1002/jbm.b.34049
   PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600 0765.1991.tb01649.x
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Park JW, 2017, MOLECULES, V22, DOI 10.3390/molecules22081259
   Pretzl B, 2019, CLIN ORAL INVEST, V23, P3073, DOI 10.1007/s00784 018 2727 0
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Qiu HW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051514
   Rahigude AB, 2012, MED HYPOTHESES, V79, P440, DOI 10.1016/j.mehy.2012.06.016
   Rahimi K, 2021, CURR MED CHEM, V28, P1549, DOI 10.2174/0929867327666200515101228
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Shao A., 2018, BIO TECHNOL, V46, pS359
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Sujitha S, 2020, EUR J PHARM BIOPHARM, V149, P170, DOI 10.1016/j.ejpb.2020.02.007
   Sujitha S, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105703
   Sun HL, 2018, J INFECT DIS, V217, P667, DOI 10.1093/infdis/jix574
   Sun Q, 2019, J DENT, V82, P91, DOI 10.1016/j.jdent.2019.01.015
   Sundararaj KP, 2009, J BIOL CHEM, V284, P13714, DOI 10.1074/jbc.M806573200
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Tu HP, 2013, PHYTOMEDICINE, V20, P1203, DOI 10.1016/j.phymed.2013.06.001
   Yu Z.H., 2008, HUA 11 KOUQIANGYIXUE, V26, P8286
   Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002 9440(10)64660 3
NR 66
TC 0
Z9 0
U1 0
U2 3
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326 2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PY 2023
VL 42
IS 6
BP 1266
EP 1276
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA K9PO2
UT WOS:001019683900019
DA 2025 08 17
ER

PT J
AU Kook, SH
   Son, YO
   Hwang, JM
   Kim, EM
   Lee, CB
   Jeon, YM
   Kim, JG
   Lee, JC
AF Kook, Sung Ho
   Son, Young Ok
   Hwang, Jung Min
   Kim, Eun Mi
   Lee, Choon Bong
   Jeon, Young Mi
   Kim, Jong Ghee
   Lee, Jeong Chae
TI Mechanical Force Inhibits Osteoclastogenic Potential of Human
   Periodontal Ligament Fibroblasts Through OPG Production and ERK Mediated
   Signaling
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE CENTRIFUGAL FORCE; PERIODONTAL LIGAMENT FIBROBLASTS; GINGIVAL
   FIBROBLASTS; OSTEOPROTEGERIN; OSTEOCLASTOGENESIS; EXTRACELLULAR
   SIGNAL REGULATED KINASE
ID KAPPA B LIGAND; HUMAN GINGIVAL FIBROBLASTS; COLLAGEN TYPE I; RECEPTOR
   ACTIVATOR; UP REGULATION; CENTRIFUGAL FORCE; OSTEOPROTEGERIN; CELLS;
   EXPRESSION; DIFFERENTIATION
AB Periodontal ligament and gingival fibroblasts play important roles in bone remodeling. Periodontal ligament fibroblasts stimulate bone remodeling while gingival fibroblasts protect abnormal bone resorption. However, few studies had examined the differences in stimulation of osteoclast formation between the two fibroblast populations. The precise effect of mechanical forces on osteoclastogenesis of these populations is also unknown. This study revealed that more osteoclast like cells were induced in the co cultures of bone marrow cells with periodontal ligament than gingival fibroblasts, and this was considerably increased when anti osteoprotegerin (OPG) antibody was added to the co cultures. mRNA levels of receptor activator of nuclear factor kappaB ligand (RANKL) were increased in both populations when they were cultured with dexamethasone and vitamin D 3. Centrifugal forces inhibited osteoclastogenesis of both populations, and this was likely related to the force induced OPG up regulation. Inhibition of extracellular signal regulated kinase (ERK) signaling by a pharmacological inhibitor (10 mu M PD98059) or by siERK transfection suppressed the force induced OPG up regulation along with the augmentation of osteoclast like cells that were decreased by the force. These results suggest that periodontal ligament fibroblasts are naturally better at osteoclast induction than gingival fibroblasts, and that centrifugal force inhibited osteoclastogenesis of the periodontal fibroblasts through OPG production and ERK activation. J. Cell. Biochem. 106: 1010 1019, 2009. (c) 2009 Wiley Liss, Inc.
C1 [Kook, Sung Ho] Chonbuk Natl Univ, Div Biol Sci, Jeonju 561756, South Korea.
   [Kook, Sung Ho; Hwang, Jung Min; Kim, Eun Mi; Lee, Choon Bong; Jeon, Young Mi; Kim, Jong Ghee; Lee, Jeong Chae] Chonbuk Natl Univ, Inst Oral Biosci, Jeonju 561756, South Korea.
   [Kook, Sung Ho; Hwang, Jung Min; Kim, Eun Mi; Lee, Choon Bong; Jeon, Young Mi; Kim, Jong Ghee; Lee, Jeong Chae] Chonbuk Natl Univ, 21 Century Educ Ctr Adv Publ Dent Hlth, BK Program 21, Jeonju 561756, South Korea.
   [Son, Young Ok] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.
   [Hwang, Jung Min; Kim, Eun Mi; Lee, Jeong Chae] Chonbuk Natl Univ, Dept Bioact Mat Sci, Jeonju 561756, South Korea.
   [Hwang, Jung Min; Kim, Eun Mi; Lee, Jeong Chae] Chonbuk Natl Univ, Res Ctr Bioact Mat, Jeonju 561756, South Korea.
   [Lee, Choon Bong; Jeon, Young Mi; Kim, Jong Ghee; Lee, Jeong Chae] Chonbuk Natl Univ, Dept Orthodont, Sch Dent, Jeonju 561756, South Korea.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University; University of Kentucky; Jeonbuk National
   University; Jeonbuk National University; Jeonbuk National University
RP Lee, JC (通讯作者)，Chonbuk Natl Univ, Dept Orthodont, Sch Dent, Jeonju 561756, South Korea.
EM lcejc88@chonbuk.ac.kr
RI Son, Youngok/ACC 1831 2022; Kim, Eun Mi/AFL 8735 2022; Son,
   Young Ok/P 3675 2015
OI Son, Youngok/0000 0003 0154 4061; 
FU Chonbuk National University [KRF 2006 005 J03102]
FX This work was supported by Korea Research Foundation Grant endowed to
   RCBM in Chonbuk National University (KRF 2006 005 J03102).
CR BERKOVITZ BKB, 1990, EUR J ORTHODONT, V12, P51, DOI 10.1093/ejo/12.1.51
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   de Vries TJ, 2006, J CELL BIOCHEM, V98, P370, DOI 10.1002/jcb.20795
   Hasegawa T, 2002, J PERIODONTAL RES, V37, P405, DOI 10.1034/j.1600 0765.2002.01603.x
   HASSELL TM, 1983, ARCH ORAL BIOL, V28, P617, DOI 10.1016/0003 9969(83)90010 9
   Hofbauer LC, 2001, CANCER AM CANCER SOC, V92, P460, DOI 10.1002/1097 0142(20010801)92:3<460::AID CNCR1344>3.0.CO;2 D
   Hofbauer LC, 2000, J CLIN ENDOCR METAB, V85, P2355, DOI 10.1210/jc.85.7.2355
   Hormdee D, 2005, CLIN EXP IMMUNOL, V142, P490, DOI 10.1111/j.1365 2249.2005.02937.x
   Howard PS, 1998, J PERIODONTAL RES, V33, P500
   Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087
   Jeon YM, 2009, MOL CELL BIOCHEM, V320, P45, DOI 10.1007/s11010 008 9897 z
   Kanzaki H, 2006, J DENT RES, V85, P457, DOI 10.1177/154405910608500512
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052
   Kondo T, 2008, J CELL BIOCHEM, V103, P335, DOI 10.1002/jcb.21414
   KOOK SH, J PERIODONT IN PRESS
   Kook SH, 2008, MOL CELL BIOCHEM, V309, P133, DOI 10.1007/s11010 007 9651 y
   Lee JC, 2001, J BIOCHEM MOL BIOL, V34, P463
   Lekic P, 1996, ANAT REC, V245, P327
   Nagasawa T, 2002, CLIN EXP IMMUNOL, V130, P338, DOI 10.1046/j.1365 2249.2002.01990.x
   Nishijima Y, 2006, Orthod Craniofac Res, V9, P63, DOI 10.1111/j.1601 6343.2006.00340.x
   Peverali FA, 2001, MOL MED, V7, P68, DOI 10.1007/BF03401840
   Redlich M, 2004, ARCH ORAL BIOL, V49, P119, DOI 10.1016/j.archoralbio.2003.08.002
   Redlich M, 2004, J PERIODONTAL RES, V39, P27, DOI 10.1111/j.1600 0765.2004.00700.x
   Redlich M, 1998, ARCH ORAL BIOL, V43, P313, DOI 10.1016/S0003 9969(97)00108 8
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SODEK J, 1979, J BIOL CHEM, V254, P496
   Wada N, 2001, J PERIODONTAL RES, V36, P56, DOI 10.1034/j.1600 0765.2001.00604.x
   Wada N, 2004, BONE, V35, P629, DOI 10.1016/j.bone.2004.04.023
   Yamaguchi M, 2006, J DENT RES, V85, P751, DOI 10.1177/154405910608500812
NR 30
TC 31
Z9 36
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR 15
PY 2009
VL 106
IS 6
BP 1010
EP 1019
DI 10.1002/jcb.22086
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 443UE
UT WOS:000265935500007
PM 19206164
DA 2025 08 17
ER

PT J
AU Huang, KC
   Huang, TW
   Chuang, PY
   Yang, TY
   Chang, SF
AF Huang, Kuo Chin
   Huang, Tsan Wen
   Chuang, Po Yao
   Yang, Tien Yu
   Chang, Shun Fu
TI Zoledronate induces cell cycle arrest and differentiation by
   upregulating p21 in mouse MC3T3 E1 preosteoblasts
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE zoledronate; cell cycle arrest; osteogenic differentiation; p21;
   osteocalcin
ID TOTAL HIP ARTHROPLASTY; OSTEOBLAST DIFFERENTIATION; BONE; APOPTOSIS;
   GROWTH; ACID; BISPHOSPHONATE; PROLIFERATION; ACTIVATION
AB Background: Increasing research has recently been focused on the supplementary use of drugs such as bisphosphonates that are known to influence bone turnover to prevent and treat periprosthetic bone loss and subsequent implant loosening following total joint replacements. However, there are still concerns about the conflicting effects of bisphosphonate treatment on osteoblastic bone formation in the literature.
   Methods: In this study, we investigate the role of zoledronate (ZOL) in regulating cell cycle distribution and differentiation in mouse MC3T3 E1 preosteoblasts and also explore the mechanism underlying this effect of ZOL. We examined the expression levels of osteocalcin (OCN) by quantitative polymerase chain reaction (qPCR), the total amount of CDK6, p21 and p27 proteins by Western blot analysis, and the cell cycle distribution by flow cytometric analysis in mouse MC3T3 E1 preosteoblasts to evaluate the effect of ZOL. Small interfering RNAs (siRNAs) were used to assess the individual contributions of genes to specific osteoblast phenotypes.
   Results: In addition to increased OCN expression, we found that ZOL treatment induces the G(0)/G(1), arrest and results in the increase of p21 and p27 expressions and decrease of CDK6 expression in mouse MC3T3 E1 preosteoblasts. Both p21 and p27 mediates ZOL induced cell cycle exit; however, p21, but not p27, is responsible for the increase of ZOL induced OCN expression in these cells.
   Conclusions: These results endorse that ZOL might have an anabolic effect on osteoblasts. The CDK inhibitor p21 plays a key role in regulating osteoblast differentiation by controlling proliferation related events in mouse MC3T3 E1 preosteoblasts.
C1 [Huang, Kuo Chin; Huang, Tsan Wen; Chuang, Po Yao; Yang, Tien Yu] Chiayi Chang Gung Mem Hosp, Dept Orthopaed Surg, Puzi 61363, Chiayi, Taiwan.
   [Huang, Kuo Chin] Chang Gung Univ, Coll Med, Taoyuan 33302, Taiwan.
   [Chang, Shun Fu] Chiayi Chang Gung Mem Hosp, Dept Med Res & Dev, Puzi 61363, Chiayi, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial
   Hospital
RP Huang, KC; Chang, SF (通讯作者)，Chiayi Chang Gung Mem Hosp, 6,West Sec,Chiapu Rd, Putz City 61363, Chiayi, Taiwan.
EM kc2672@gmail.com; sfchang@cgmh.org.tw
RI Chuang, Po Yao/MVW 9079 2025; HUANG, Kuo Chin/S 7371 2019
OI Chang, Shun Fu/0000 0002 2276 7785; 
FU Chang Gung Memorial Hospital, Taiwan [CMRPG 6B0531 3, CMRPG 6G0061];
   Taiwan National Science Council [NSC95 2314 B 182A 087]
FX This work was supported by grants from the Chang Gung Memorial Hospital,
   Taiwan (Grant Nos. CMRPG 6B0531 3 and CMRPG 6G0061) and from the Taiwan
   National Science Council (Grant No. NSC95 2314 B 182A 087).
CR Amirhosseini Mehdi, 2017, Bone Rep, V7, P17, DOI 10.1016/j.bonr.2017.07.003
   Back DA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 42
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Cleemann R, 2018, J ORTHOP RES, V36, P1406, DOI 10.1002/jor.23766
   Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962 8924(02)00043 0
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   Drissi H, 1999, CANCER RES, V59, P3705
   Friedl G, 2009, J BONE JOINT SURG AM, V91A, P274, DOI 10.2106/JBJS.G.01193
   Gou WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091317
   Hnit SST, 2015, INT J BIOCHEM CELL B, V68, P9, DOI 10.1016/j.biocel.2015.08.005
   Huang KC, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0818 5
   Huang TW, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1577 2
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Jakobsen T, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1802 z
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Knusten AR, 2014, J ARTHROPLASTY, V29, P1292, DOI 10.1016/j.arth.2014.01.015
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Ollivere B, 2012, J BONE JOINT SURG BR, V94B, P10, DOI 10.1302/0301 620X.94B1.28047
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Prieto Alhambra D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7222
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sciandra M, 2014, J BONE MINER RES, V29, P1295, DOI 10.1002/jbmr.2141
   Scott DF, 2013, J ARTHROPLASTY, V28, P671, DOI 10.1016/j.arth.2012.08.007
   Soria G, 2010, DNA REPAIR, V9, P358, DOI 10.1016/j.dnarep.2009.12.003
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021
   Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097 2765(01)00327 6
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Yamato K, 2000, EXP CELL RES, V257, P198, DOI 10.1006/excr.2000.4876
   Yamato K, 2001, ONCOGENE, V20, P4383, DOI 10.1038/sj.onc.1204572
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
   Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955 0674(97)80077 4
   Zhu M, 2015, J BONE MINER RES, V30, P1969, DOI 10.1002/jbmr.2544
   2014, CLIN ORTHOP RELAT R, V472, P3740, DOI DOI 10.1007/S11999 014 3765 9
NR 37
TC 11
Z9 11
U1 1
U2 4
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2019
VL 16
IS 5
BP 751
EP 756
DI 10.7150/ijms.32612
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA HY2IU
UT WOS:000467944400016
PM 31217743
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Sato, S
   Takahashi, S
   Asamoto, M
   Naiki, T
   Naiki Ito, A
   Asai, K
   Shirai, T
AF Sato, Shinya
   Takahashi, Satoru
   Asamoto, Makoto
   Naiki, Taku
   Naiki Ito, Aya
   Asai, Kiyofumi
   Shirai, Tomoyuki
TI Tranilast Suppresses Prostate Cancer Growth and Osteoclast
   Differentiation In Vivo and In Vitro
SO PROSTATE
LA English
DT Article
DE Tranilast; bone microenvironment; prostate cancer; bone metastasis;
   osteoclast
ID COLLAGEN ACCUMULATION; PROLIFERATION; CELL; INHIBITION; MECHANISMS;
   FIBROBLASTS; PROGRESSION; METASTASIS; ACTIVATION; OSTEOLYSIS
AB BACKGROUND. In bone metastatic sites, prostate cancer cells proliferate on interacting with osteoclasts. Tranilast, which is used for an antiallergic drug, has been shown to inhibit growth of several cancers and stromal cells. The present study was conducted to assess suppressive effects of Tranilast on prostate cancer growth and osteoclast differentiation in vivo and in vitro.
   METHODS. In vivo, rat prostate cancer tissue was transplanted onto cranial bones of F344 rats and Tranilast was given for 9 days at doses of 0, 200, or 400 mg/kg/day. In vitro, human prostate cancer cell lines, LNCaP, PC3, and DU145, the rat prostate cancer cell line, PLS 10, and rat bone marrow cells were similarly treated with the agent.
   RESULTS. In vivo, tumor volumes were significantly decreased in the high dose group. While cell proliferation did not appear to be affected, apoptosis was induced and tumor necrosis was apparent. Cranial bone defects were decreased in the high dose group. In vitro, cell proliferation rates of all four cell lines were reduced by Tranilast and increased apoptosis was observed in LNCaP and PLS 10. In addition, Tranilast significantly reduced osteoclast differentiation of rat bone marrow cells. Western blot analysis of PLS 10 and LNCaP revealed that phospho GSK3 beta was up regulated and phospho Akt was down regulated.
   CONCLUSIONS. Tranilast here suppressed rat prostate cancer growth and osteoclast differentiation. Growth of human prostate cancer cells was also inhibited. Thus, this agent deserves consideration as a candidate for conventional therapy of bone metastatic prostate cancer. Prostate 70: 229 238, (C) 2010. 2009 Wiley Liss, Inc.
C1 [Sato, Shinya; Takahashi, Satoru; Asamoto, Makoto; Naiki, Taku; Naiki Ito, Aya; Shirai, Tomoyuki] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Aichi 4678601, Japan.
   [Naiki, Taku] Nagoya City Univ, Grad Sch Med Sci, Dept Nephrourol, Nagoya, Aichi 4678601, Japan.
   [Asai, Kiyofumi] Nagoya City Univ, Grad Sch Med Sci, Dept Mol Neurol, Nagoya, Aichi 4678601, Japan.
C3 Nagoya City University; Nagoya City University; Nagoya City University
RP Sato, S (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Aichi 4678601, Japan.
EM satopin@med.nagoya cu.ac.jp
RI ; Asai, Kiyofumi/H 2356 2014; Sato, Shinya/ACQ 7312 2022; Naiki,
   Taku/AEC 7521 2022
OI Naiki, Taku/0000 0002 7638 6048; Sato, Shinya/0000 0002 2155 2379; Asai,
   Kiyofumi/0000 0001 7015 2251; 
CR AZUMA H, 1976, BRIT J PHARMACOL, V58, P483, DOI 10.1111/j.1476 5381.1976.tb08614.x
   Beningo KA, 2004, P NATL ACAD SCI USA, V101, P18024, DOI 10.1073/pnas.0405747102
   Blanco Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052
   Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757
   BRESCIA FJ, 1992, J CLIN ONCOL, V10, P149, DOI 10.1200/JCO.1992.10.1.149
   Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Fukuyama J, 1996, JPN J PHARMACOL, V70, P321, DOI 10.1254/jjp.70.321
   Hiroi Makoto, 2002, Journal of Nippon Medical School, V69, P224, DOI 10.1272/jnms.69.224
   Horning JL, 2008, MOL PHARMACEUT, V5, P849, DOI 10.1021/mp800047v
   ISAJI M, 1987, BIOCHEM PHARMACOL, V36, P469, DOI 10.1016/0006 2952(87)90353 4
   Isaji M, 1997, BRIT J PHARMACOL, V122, P1061, DOI 10.1038/sj.bjp.0701493
   ISAJI M, 1994, LIFE SCI, V55, pPL287, DOI 10.1016/0024 3205(94)00668 7
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   KATO K, 1998, J TOXICOL PATHOL, V11, P27
   Ko SC, 2002, ONCOGENE, V21, P7175, DOI 10.1038/sj.onc.1205869
   Kusama H, 1999, ATHEROSCLEROSIS, V143, P307, DOI 10.1016/S0021 9150(98)00308 6
   Lechner S, 2003, LAB INVEST, V83, P1321, DOI 10.1097/01.LAB.0000085189.47968.F8
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Major Pierre P, 2005, Support Cancer Ther, V2, P234, DOI 10.3816/SCT.2005.n.017
   Miyazawa K, 1995, ATHEROSCLEROSIS, V118, P213, DOI 10.1016/0021 9150(95)05607 6
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Murahashi K, 1998, INT J ONCOL, V13, P1235
   Nakanishi H, 1996, JPN J CANCER RES, V87, P1218, DOI 10.1111/j.1349 7006.1996.tb03136.x
   Nie L, 1997, CELL CALCIUM, V22, P75, DOI 10.1016/S0143 4160(97)90107 X
   Noguchi N, 2003, ORAL ONCOL, V39, P240, DOI 10.1016/S1368 8375(02)00092 1
   Platten M, 2001, INT J CANCER, V93, P53, DOI 10.1002/ijc.1289
   Qiu D, 2009, INT J CANCER, V124, P443, DOI 10.1002/ijc.23911
   Ramasamy R, 2007, TRANSPLANTATION, V83, P71, DOI 10.1097/01.tp.0000244572.24780.54
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sato S, 2008, CANCER SCI, V99, P316, DOI 10.1111/j.1349 7006.2007.00690.x
   Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200
   SHIRAI T, 1991, CANCER RES, V51, P1264
   Speight JL, 2007, J CLIN ONCOL, V25, P987, DOI 10.1200/JCO.2006.10.3218
   SUZAWA H, 1992, JPN J PHARMACOL, V60, P91, DOI 10.1254/jjp.60.91
   Taplin ME, 2006, J CLIN ONCOL, V24, P5408, DOI 10.1200/JCO.2006.06.6589
   Tuma RS, 2008, J NATL CANCER I, V100, P1752, DOI 10.1093/jnci/djn456
   Venè R, 2008, CANCER RES, V68, P6987, DOI 10.1158/0008 5472.CAN 07 6362
   Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248
   Yashiro M, 1997, ANTICANCER RES, V17, P895
   Yatsunami J, 2000, INT J ONCOL, V17, P1151
NR 42
TC 16
Z9 19
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD FEB 15
PY 2010
VL 70
IS 3
BP 229
EP 238
DI 10.1002/pros.21056
PG 10
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 561DG
UT WOS:000274955100001
PM 19790239
DA 2025 08 17
ER

PT J
AU Akbar, MA
   Nardo, D
   Chen, MJ
   Elshikha, AS
   Ahamed, R
   Elsayed, EM
   Bigot, C
   Holliday, LS
   Song, SH
AF Akbar, Mohammad Ahsanul
   Nardo, David
   Chen, Mong Jen
   Elshikha, Ahmed S.
   Ahamed, Rubina
   Elsayed, Eslam M.
   Bigot, Claire
   Holliday, L. Shannon
   Song, Sihong
TI α 1 Antitrypsin Inhibits RANKL induced Osteoclast Formation and
   Functions
SO MOLECULAR MEDICINE
LA English
DT Article
ID MOUSE MODEL; MATURE OSTEOCLASTS; BONE LOSS; IN VITRO; DIFFERENTIATION;
   OSTEOPOROSIS; ACTIVATION; THERAPY; LIGAND; EXPRESSION
AB Osteoporosis is a global public health problem affecting more than 200 million people worldwide. We previously showed that treatment with alpha 1 antitrypsin (AAT), a multifunctional protein with antiinflammatory properties, mitigated bone loss in an ovariectomized mouse model. However, the underlying mechanisms of the protective effect of AAT on bone tissue are largely unknown. In this study, we investigated the effect of AAT on osteoclast formation and function in vitro. Our results showed that AAT dose dependently inhibited the formation of receptor activator of nuclear factor.B ligand (RANKL) induced osteoclasts derived from mouse bone marrow macrophage/monocyte (BMM) lineage cells and the RAW 264.7 murine macrophage cell line. To elucidate the possible mechanisms underlying this inhibition, we tested the effect of AAT on the gene expression of cell surface molecules, transcription factors and cytokines associated with osteoclast formation. We showed that AAT inhibited macrophage colony stimulating factor (M CSF) induced cell surface RANK expression in osteoclast precursor cells. In addition, AAT inhibited RANKL induced TNF alpha production, cell surface CD9 expression and dendritic cell specific transmembrane protein (DC STAMP) gene expression. Importantly, AAT treatment significantly inhibited osteoclast associated mineral resorption. Together, these results uncover new mechanisms for the protective effects of AAT and strongly support the notion that AAT has therapeutic potential for the treatment of osteoporosis.
C1 [Akbar, Mohammad Ahsanul; Nardo, David; Chen, Mong Jen; Elshikha, Ahmed S.; Ahamed, Rubina; Elsayed, Eslam M.; Bigot, Claire; Song, Sihong] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA.
   [Holliday, L. Shannon] Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL USA.
   [Holliday, L. Shannon] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL USA.
   [Elsayed, Eslam M.] Zagazig Univ, Dept Microbiol & Immunol, Fac Pharm, Zagazig, Egypt.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; Egyptian Knowledge Bank (EKB);
   Zagazig University
RP Song, SH (通讯作者)，1345 Ctr Dr,P3 20 JHMHC,POB 100494, Gainesville, FL 32610 USA.
EM shsong@ufl.edu
RI Holliday, Lexie/GYQ 4972 2022; Elsayed, Eslam M./JXL 9249 2024
OI Holliday, Lexie/0000 0002 0844 1965; Nardo, David/0000 0003 3009 7686
FU Zagazig University; Egyptian government; University of Florida
FX EME is a Visting scholar from Zagazig University and is supported by a
   scholarship from the Egyptian government. We thank Dr. Jay Cao (US
   Department of Agriculture, Agriculture Research Service's Grand Forks
   Human Nutrition Research Center) for his assistance with part of the
   gene expression studies and suggestions regarding induction of
   osteoclast formation. This work was supported by a grant from the
   University of Florida.
CR Akbar MA, 2016, HUM GENE THER, V27, P679, DOI 10.1089/hum.2016.029
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bergin DA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007116
   Bergin DA, 2010, J CLIN INVEST, V120, P4236, DOI 10.1172/JCI41196
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Collin Osdoby P, 2003, METH MOLEC MED, V80, P153
   Grimstein C, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 21
   Grimstein C, 2010, J GENE MED, V12, P35, DOI 10.1002/jgm.1409
   Hough FS, 2014, SAMJ S AFR MED J, V104, P279, DOI 10.7196/SAMJ.7505
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Janciauskiene SM, 2011, RESP MED, V105, P1129, DOI 10.1016/j.rmed.2011.02.002
   JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092 8674(92)90592 Z
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JW, 2010, BIOCHEM PHARMACOL, V80, P352, DOI 10.1016/j.bcp.2010.04.014
   Lu YQ, 2006, HUM GENE THER, V17, P625, DOI 10.1089/hum.2006.17.625
   Ma H, 2010, DIABETOLOGIA, V53, P2198, DOI 10.1007/s00125 010 1829 2
   Mohanka M, 2012, EXPERT OPIN BIOL TH, V12, P685, DOI 10.1517/14712598.2012.676638
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nanes MS, 2014, SEMIN NUCL MED, V44, P439, DOI 10.1053/j.semnuclmed.2014.06.006
   Petrache I, 2009, BIOL TARGETS THER, V3, P193
   Romas E, 2006, RHEUM DIS CLIN N AM, V32, P759, DOI 10.1016/j.rdc.2006.07.004
   Shapiro L, 2001, FASEB J, V15, P115, DOI 10.1096/fj.00 0311com
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Song S, 2004, GENE THER, V11, P181, DOI 10.1038/sj.gt.3302156
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Takahashi Naoyuki, 2007, V135, P285
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531 5565(03)00069 X
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Xing LP, 2012, WORLD J ORTHOP, V3, P212, DOI 10.5312/wjo.v3.i12.212
   Yao GQ, 2005, CALCIFIED TISSUE INT, V76, P371, DOI 10.1007/s00223 004 0099 8
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang B, 2007, DIABETES, V56, P1316, DOI 10.2337/db06 1273
   Zou W, 2005, J CELL PHYSIOL, V202, P371, DOI 10.1002/jcp.20127
   Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202
NR 41
TC 21
Z9 23
U1 1
U2 4
PU FEINSTEIN INST MED RES
PI MANHASSET
PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA
SN 1076 1551
EI 1528 3658
J9 MOL MED
JI Mol. Med.
PY 2017
VL 23
BP 57
EP 69
DI 10.2119/molmed.2016.00170
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA EU4ER
UT WOS:000400983100003
PM 28332697
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yun, HM
   Cho, MH
   Jeong, H
   Kim, SH
   Jeong, YH
   Park, KR
AF Yun, Hyung Mun
   Cho, Mi Hyeon
   Jeong, Hoibin
   Kim, Soo Hyun
   Jeong, Yun Hee
   Park, Kyung Ran
TI Osteogenic Activities of Trifolirhizin as a Bioactive Compound for the
   Differentiation of Osteogenic Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone; differentiation; osteoblast; RUNX2; Sophora flavescens;
   trifolirhizin
ID MESENCHYMAL STEM CELLS; SOPHORA FLAVESCENS; PROMOTES OSTEOGENESIS;
   ALKALINE PHOSPHATASE; NATURAL PRODUCTS; OSTEOBLAST; FLAVONOIDS;
   MINERALIZATION; MECHANISMS; INDUCTION
AB Plant extracts are widely used as traditional medicines. Sophora flavescens Aiton derived natural compounds exert various beneficial effects, such as anti inflammatory, anticancer, antioxidant, and antiregenerative activities, through their bioactive compounds, including flavonoids and alkaloids. In the present study, we investigated the biological effects of an S. flavescens derived flavonoid, trifolirhizin (trifol), on the stimulation of osteogenic processes during osteoblast differentiation. Trifol (>98% purity) was successfully isolated from the root of S. flavescens and characterized. Trifol did not exhibit cellular toxicity in osteogenic cells, but promoted alkaline phosphatase (ALP) staining and activity, with enhanced expression of the osteoblast differentiation markers, including Alp, ColI, and Bsp. Trifol induced nuclear runt related transcription factor 2 (RUNX2) expression during the differentiation of osteogenic cells, and concomitantly stimulated the major osteogenic signaling proteins, including GSK3 beta, beta catenin, and Smad1/5/8. Among the mitogen activated protein kinases (MAPKs), Trifol activated JNK, but not ERK1/2 and p38. Trifol also increased the osteoblast mediated bone forming phenotypes, including transmigration, F actin polymerization, and mineral apposition, during osteoblast differentiation. Overall, trifol exhibits bioactive activities related to osteogenic processes via differentiation, migration, and mineralization. Collectively, these results suggest that trifol may serve as an effective phytomedicine for bone diseases such as osteoporosis.
C1 [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Cho, Mi Hyeon; Jeong, Hoibin] Korea Basic Sci Inst KBSI, Seoul 02841, South Korea.
   [Kim, Soo Hyun; Jeong, Yun Hee] Natl Dev Inst Korean Med, Gyongsan 38540, South Korea.
   [Park, Kyung Ran] Korea Basic Sci Inst KBSI, Gwangju 61751, South Korea.
C3 Kyung Hee University; Korea Basic Science Institute (KBSI); Korea Basic
   Science Institute (KBSI)
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.; Park, KR (通讯作者)，Korea Basic Sci Inst KBSI, Gwangju 61751, South Korea.
EM yunhm@khu.ac.kr; mhcho1@kbsi.re.kr; hoibinjeong4@kbsi.re.kr;
   beluga81@nikom.or.kr; jyh@nikom.or.kr; krpark83@kbsi.re.kr
RI ; Kim, Soo Hyun/D 1577 2019
OI Yun, Hyung Mun/0000 0001 6504 1610; 
FU Kyung Hee University
FX We thank the Seoul Center of the Korea Basic Science Institute (KBSI)
   for experimental assistance.
CR Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Aratanechemuge Y, 2004, ONCOL REP, V12, P1183
   Aryaei A, 2014, J BIOMED MATER RES A, V102, P3282, DOI 10.1002/jbm.a.34993
   Bernardini S, 2018, NAT PROD RES, V32, P1926, DOI 10.1080/14786419.2017.1356838
   Broz A, 2017, J BIOMED MATER RES A, V105, P1469, DOI 10.1002/jbm.a.35969
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chiou WF, 2011, LIFE SCI, V88, P335, DOI 10.1016/j.lfs.2010.12.009
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Deng T, 2021, BMC ENDOCR DISORD, V21, DOI 10.1186/s12902 021 00715 8
   Di YY, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.100753
   Fabricant DS, 2001, ENVIRON HEALTH PERSP, V109, P69, DOI 10.2307/3434847
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Gu SM, 2016, ONCOTARGET, V7, P15382, DOI 10.18632/oncotarget.8097
   Histing T, 2012, J SURG RES, V175, P271, DOI 10.1016/j.jss.2011.03.052
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Huang R, 2017, NAT PROD RES, V31, P2228, DOI 10.1080/14786419.2017.1297992
   Huang XB, 2021, NAT PROD RES, V35, P4317, DOI 10.1080/14786419.2020.1712382
   Hyun SK, 2008, BIOL PHARM BULL, V31, P154, DOI 10.1248/bpb.31.154
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Jin JH, 2010, J ETHNOPHARMACOL, V127, P589, DOI 10.1016/j.jep.2009.12.020
   Kalbacova M, 2010, CARBON, V48, P4323, DOI 10.1016/j.carbon.2010.07.045
   Khotib J, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14070615
   Kobayashi T, 2021, METHODS MOL BIOL, V2230, P3, DOI 10.1007/978 1 0716 1028 2_1
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Li Min, 2020, Zhongguo Gu Shang, V33, P933, DOI 10.12200/j.issn.1003 0034.2020.10.009
   Liang J, 2022, PEERJ, V10, DOI 10.7717/peerj.13939
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu YH, 2020, J CELL MOL MED, V24, P12308, DOI 10.1111/jcmm.15647
   Lu XG, 2016, ONCOL REP, V36, P2785, DOI 10.3892/or.2016.5125
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057
   Ogata Y, 2008, J PERIODONTAL RES, V43, P127, DOI 10.1111/j.1600 0765.2007.01014.x
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111362
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136899
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052483
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rosenberg N, 2012, RAMBAM MAIMONIDES ME, V3, DOI 10.5041/RMMJ.10080
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Shalehin N, 2020, J DENT SCI, V15, P437, DOI 10.1016/j.jds.2019.09.009
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Sun DD, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00281 w
   Sun P, 2022, PHYTOMEDICINE, V100, DOI 10.1016/j.phymed.2022.154054
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Tong ZC, 2020, NANOSCALE RES LETT, V15, DOI 10.1186/s11671 020 03415 9
   Wei GF, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 86970 0
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xue C, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13740
   Xue XF, 2017, BIOMATERIALS, V134, P22, DOI 10.1016/j.biomaterials.2017.04.039
   Yang XZ, 2015, J ETHNOPHARMACOL, V171, P161, DOI 10.1016/j.jep.2015.05.043
   Yang Y, 2021, J BIOMED MATER RES A, V109, P1429, DOI 10.1002/jbm.a.37134
   Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2022, CELLS BASEL, V11, DOI 10.3390/cells11233887
   Yun HM, 2023, BIOFACTORS, V49, P127, DOI 10.1002/biof.1878
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang Jie, 2000, Zhongguo Kangshengsu Zazhi, V25, P37
   Zhang L, 2007, J PHARMACEUT BIOMED, V44, P1019, DOI 10.1016/j.jpba.2007.04.019
   Zhang Q, 2022, CLIN EXP PHARMACOL P, V49, P787, DOI 10.1111/1440 1681.13654
   Zhou HP, 2009, J AGR FOOD CHEM, V57, P4580, DOI 10.1021/jf900340b
NR 68
TC 2
Z9 3
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2023
VL 24
IS 23
AR 17103
DI 10.3390/ijms242317103
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AN1F8
UT WOS:001119046500001
PM 38069425
OA gold
DA 2025 08 17
ER

PT J
AU Cho, TH
   Kim, IS
   Lee, B
   Park, SN
   Ko, JH
   Hwang, SJ
AF Cho, Tae Hyung
   Kim, In Sook
   Lee, Beomseok
   Park, Si Nae
   Ko, Jae Hyung
   Hwang, Soon Jung
TI Early and Marked Enhancement of New Bone Quality by Alendronate Loaded
   Collagen Sponge Combined with Bone Morphogenetic Protein 2 at High Dose:
   A Long Term Study in Calvarial Defects in a Rat Model
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE alendronate; collagen sponge; early dense ossification; high dose; long
   term study; rhBMP 2
ID MARROW STROMAL CELLS; FORMATION IN VIVO; ZOLEDRONIC ACID; POSTMENOPAUSAL
   OSTEOPOROSIS; OSTEOGENIC DIFFERENTIATION; CONTROLLED RELEASE;
   CALCIUM PHOSPHATE; BISPHOSPHONATES; REGENERATION; DELIVERY
AB Choice of appropriate biomaterial is a key factor for the success of recombinant human bone morphogenetic protein (rhBMP) 2 therapy. Inspired by osteogenic cell differentiating and osteoclast suppressing capabilities of alendronate (ALN), we manufactured a composite type of ALN loaded collagen sponge (ALN CS), which controls the early detrimental effect of high dose rhBMP 2. This study aimed to evaluate ALN CS as a high dose rhBMP 2 carrier by investigating its initial biomolecular effect and efficacy on intramembranous ossification at 1, 4, 8, and 24 weeks using a rat calvarial defect model compared with nonloaded CS. The in vitro rhBMP 2 release in the ALN CS showed a low initial burst and steady release phase during the rest period despite lack of calcium compared with that in CS alone. ALN release showed the same tendency as rhBMP 2 release. In vitro characterization showed that osteoblast differentiation and mineralization of mesenchymal stromal cells were more enhanced with ALN CS. The ALN CS BMP group showed higher expression of bone forming and  resorbing markers in vivo than the CS BMP group after the first 7 days, which might be attributable to the relatively large amount of rhBMP 2 remaining. However, osteoclast activation in the ALN CS BMP group was significantly reduced compared with the CS BMP group. Radiological and histological analyses revealed that ALN CS BMP promoted early and dense ossification at the initial defect, with 100% greater bone mass, 20% greater bone density, and less fatty marrow tissue than CS BMP, which continued during the whole healing period. However, CS or ALN CS alone failed to show complete defect closure even at the 24 week healing interval. Our results demonstrate that ALN CS has remarkable advantages over CS alone in high dose BMP 2 delivery, with potent suppression of resorption, early and dense ossification at the target area with less fatty marrow formation, and continuation of bone quality over the long term, which highlights its great clinical potential as a rhBMP carrier for bone regeneration at intramembranous ossification sites.
C1 [Cho, Tae Hyung; Kim, In Sook; Lee, Beomseok; Hwang, Soon Jung] Seoul Natl Univ, Dent Res Inst, Seoul, South Korea.
   [Cho, Tae Hyung; Hwang, Soon Jung] Seoul Natl Univ, Dent Hosp, Clin Dent Res Inst, Seoul, South Korea.
   [Park, Si Nae; Ko, Jae Hyung] Dalim Tissen Co Ltd, Regenerat Med Res Ctr, Seoul, South Korea.
   [Hwang, Soon Jung] Seoul Natl Univ, Plus Program BK21, Sch Dent, Dept Oral & Maxillofacial Surg, 101 Daehak Ro, Seoul 03080, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Hwang, SJ (通讯作者)，Seoul Natl Univ, Plus Program BK21, Sch Dent, Dept Oral & Maxillofacial Surg, 101 Daehak Ro, Seoul 03080, South Korea.
EM sjhwang@snu.ac.kr
FU Korea Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI15C1898]
FX This research was supported by a grant from the Korea Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea
   (HI15C1898). The authors thank Novosis Dent; BioAlpha, Inc., for
   providing the rhBMP 2.
CR Aghaloo T, 2007, MOL THER, V15, P1872, DOI 10.1038/sj.mt.6300270
   Autefage H, 2009, J BIOMED MATER RES B, V91B, P706, DOI 10.1002/jbm.b.31447
   Bhakta G, 2013, ACTA BIOMATER, V9, P9098, DOI 10.1016/j.actbio.2013.07.008
   Bhakta G, 2012, BIOMATERIALS, V33, P6113, DOI 10.1016/j.biomaterials.2012.05.030
   Boerckel JD, 2011, BIOMATERIALS, V32, P5241, DOI 10.1016/j.biomaterials.2011.03.063
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Bosemark P, 2013, ACTA ORTHOP, V84, P106, DOI 10.3109/17453674.2013.773123
   Bougioukli S, 2016, BONE, V84, P93, DOI 10.1016/j.bone.2015.12.052
   Cafro AM, 2008, CLIN LYMPHOMA MYELOM, V8, P111, DOI 10.3816/CLM.2008.n.013
   Chan BP, 2008, EUR SPINE J, V17, pS467, DOI 10.1007/s00586 008 0745 3
   Chatterjee B, 2003, CELL COMMUN ADHES, V10, P37, DOI 10.1080/15419060302064
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776 004 0815 2
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   GILBERT S, 2000, DEV BIOL
   Gomes PS, 2011, LAB ANIM UK, V45, P14, DOI 10.1258/la.2010.010085
   Hassler N, 2015, OSTEOPOROSIS INT, V26, P339, DOI 10.1007/s00198 014 2929 5
   Honma T, 2008, ORAL DIS, V14, P457, DOI 10.1111/j.1601 0825.2007.01401.x
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hulsart Billström G, 2013, BIOMACROMOLECULES, V14, P3055, DOI 10.1021/bm400639e
   Hur W, 2016, J CONTROL RELEASE, V222, P97, DOI 10.1016/j.jconrel.2015.12.007
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Khan SN, 2004, EXPERT OPIN BIOL TH, V4, P741
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   Kim JS, 2015, CLIN IMPLANT DENT R, V17, P1103, DOI 10.1111/cid.12223
   Kim RY, 2016, TISSUE ENG PT A, V22, P801, DOI [10.1089/ten.TEA.2015.0537, 10.1089/ten.tea.2015.0537]
   Kim RY, 2014, BIOMATERIALS, V35, P1869, DOI 10.1016/j.biomaterials.2013.11.029
   Kim SE, 2012, J MATER SCI MATER M, V23, P2739, DOI 10.1007/s10856 012 4729 9
   Kim SE, 2011, BIOMATERIALS, V32, P366, DOI 10.1016/j.biomaterials.2010.09.008
   Komatsu K, 2013, J ENDOCRINOL, V219, P145, DOI 10.1530/JOE 13 0040
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Liao J, 2013, INT J ORAL MAX IMPL, V28, P1027, DOI 10.11607/jomi.3030
   Lim S. S., 2016, ORAL SURG ORAL MED O, V123, P8
   Little DG, 2005, J BONE MINER RES, V20, P2044, DOI 10.1359/JBMR.050712
   Lo KWH, 2012, ADV DRUG DELIVER REV, V64, P1277, DOI 10.1016/j.addr.2012.03.014
   Lu SX, 2013, J CLIN PERIODONTOL, V40, P688, DOI 10.1111/jcpe.12109
   Luhmann SJ, 2005, SPINE, V30, pS110, DOI 10.1097/01.brs.0000175184.27407.6a
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P396, DOI 10.1016/j.jcms.2014.12.008
   Murphy CM, 2014, ACTA BIOMATER, V10, P2250, DOI 10.1016/j.actbio.2014.01.016
   Murphy CM, 2010, CELL ADHES MIGR, V4, P377, DOI 10.4161/cam.4.3.11747
   Murphy CM, 2010, BIOMATERIALS, V31, P461, DOI 10.1016/j.biomaterials.2009.09.063
   Naidu A, 2008, ORAL SURG ORAL MED O, V106, P5, DOI 10.1016/j.tripleo.2008.03.036
   Orwoll ES, 2010, J BONE MINER RES, V25, P2239, DOI 10.1002/jbmr.119
   Cattalini J, 2012, TISSUE ENG PART B RE, V18, P323, DOI 10.1089/ten.teb.2011.0737
   Paggiosi MA, 2014, OSTEOPOROSIS INT, V25, P2729, DOI 10.1007/s00198 014 2817 z
   Perri B, 2007, SPINE J, V7, P235, DOI 10.1016/j.spinee.2006.04.010
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rouwkema J, 2008, TRENDS BIOTECHNOL, V26, P434, DOI 10.1016/j.tibtech.2008.04.009
   Sciadini MF, 2000, J ORTHOP RES, V18, P289, DOI 10.1002/jor.1100180218
   Scott MA, 2012, STEM CELLS DEV, V21, P655, DOI 10.1089/scd.2011.0517
   Seeherman HJ, 2010, J BONE JOINT SURG AM, V92A, P411, DOI 10.2106/JBJS.H.01732
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Simmonds MC, 2013, ANN INTERN MED, V158, P877, DOI 10.7326/0003 4819 158 12 201306180 00005
   Stepan J J, 2003, Endocr Regul, V37, P225
   Sugiyama O, 2005, MOL THER, V11, P390, DOI 10.1016/j.ymthe.2004.10.019
   Swiontkowski MF, 2006, J BONE JOINT SURG AM, V88A, P1258, DOI 10.2106/JBJS.E.00499
   Tanzer M, 2005, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000194728.62996.2d
   Uludag H, 2001, J BONE JOINT SURG AM, V83A, pS128
   Visser R, 2009, BIOMATERIALS, V30, P2032, DOI 10.1016/j.biomaterials.2008.12.046
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Walker David H, 2002, Neurosurg Focus, V13, pe3
   Wikesjö UME, 1999, J CLIN PERIODONTOL, V26, P392, DOI 10.1034/j.1600 051X.1999.260610.x
   Woodard JR, 2007, BIOMATERIALS, V28, P45, DOI 10.1016/j.biomaterials.2006.08.021
   Yoshinari M, 2001, BIOMATERIALS, V22, P709, DOI 10.1016/S0142 9612(00)00234 9
NR 70
TC 23
Z9 24
U1 0
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD DEC
PY 2017
VL 23
IS 23 24
BP 1343
EP 1360
DI 10.1089/ten.tea.2016.0557
PG 18
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA FP0WM
UT WOS:000417329100006
PM 28457207
DA 2025 08 17
ER

PT J
AU Capulli, M
   Maurizi, A
   Ventura, L
   Rucci, N
   Teti, A
AF Capulli, Mattia
   Maurizi, Antonio
   Ventura, Luca
   Rucci, Nadia
   Teti, Anna
TI Effective Small Interfering RNA Therapy to Treat CLCN7 dependent
   Autosomal Dominant Osteopetrosis Type 2
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
DE bone disease; bone resorption; gene silencing; osteoclast;
   osteopetrosis; siRNA therapy
ID SIRNA THERAPEUTICS; SYSTEMIC DELIVERY; IN VIVO; DISEASE; DESIGN;
   DISCRIMINATION; NANOPARTICLES; GENERATION; PATHWAY; CANCER
AB In about 70% of patients affected by autosomal dominant osteopetrosis type 2 (ADO2), osteoclast activity is reduced by heterozygous mutations of the CLCN7 gene, encoding the ClC 7 chloride/hydrogen antiporter. CLCN7(G215R) , CLCN7(R767W) , and CLCN7(R286W) specific siRNAs silenced transfected mutant mRNA/EGFP in HEK293 cells, in RAW264.7 cells and in human osteoclasts, with no change of CLCN7(WT) mRNA and no effect of scrambled siRNA on the mutant transcripts. Osteoclasts from Clcn7(G213R) ADO2 mice showed reduced bone resorption, a condition rescued by Clcn7(G213R) specific siRNA. Treatment of ADO2 mice with Clcn7(G213R) specific siRNA induced increase of bone resorption variables and decrease of trabecular bone mass, leading to an overall improvement of the osteopetrotic bone phenotype. Treatment did not induce overt adverse effects and was effective also with siRNAs specific for other mutants. These results demonstrate that a siRNA based experimental treatment of ADO2 is feasible, and underscore a translational impact for future strategy to cure this therapeutically neglected form of osteopetrosis.
C1 [Capulli, Mattia; Maurizi, Antonio; Rucci, Nadia; Teti, Anna] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
   [Ventura, Luca] San Salvatore Hosp, Dept Pathol, Laquila, Italy.
C3 University of L'Aquila
RP Teti, A (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM annamaria.teti@univaq.it
RI Capulli, Mattia/K 6604 2016; Maurizi, Antonio/AAI 7728 2020; Ventura,
   Luca/ABD 4170 2020
OI Capulli, Mattia/0000 0003 0449 6720; Rucci, Nadia/0000 0002 1371 8252;
   Teti, Anna Maria/0000 0002 5887 4419; Maurizi,
   Antonio/0000 0002 7027 4694; 
FU Telethon [GGP06019, GGP09018, GGP14014]; European Union
   [FP7 HEALTH 2013 INNOVATION   602300]; Marie Curie fellowships from the
   European Union [FP7 PEOPLE 2011 IRSES   295181]
FX This work has been supported by the Telethon Grants GGP06019, GGP09018
   and GGP14014, and by the European Union funded project SYBIL  
   FP7 HEALTH 2013 INNOVATION   602300 to A.T. M.C. and A.M. were
   recipients of Marie Curie fellowships from the European Union funded
   project INTERBONE   FP7 PEOPLE 2011 IRSES   295181. The invention of
   this article has been protected with the patent applications N.
   RM2014A000272 and PCT/IB2015/053730. Authors state no conflict of
   interest. M.C. and A.M. contributed to study design, performed the
   experiments, and collected the data. L.V. performed the
   histopathological analysis. N.R. contributed to study design and
   supervised the work. A.T. designed the study, supervised the work, and
   wrote the manuscript. All Authors reviewed and approved the manuscript.
   We are indebted to Rita Di Massimo for her contribution in editing the
   manuscript.
CR Alam I, 2015, J BONE MINER RES
   Alam I, 2014, BONE, V59, P66, DOI 10.1016/j.bone.2013.10.021
   Albers Schonberg, 1904, Munch Med Wochenschr, V5, P365
   Anasagasti A, 2012, VISION RES, V75, P117, DOI 10.1016/j.visres.2012.09.012
   Angart P, 2013, PHARMACEUTICALS BASE, V6, P440, DOI 10.3390/ph6040440
   [Anonymous], 1987, ACM siggraph computer graphics, DOI [DOI 10.1145/37401.37422, DOI 10.1145/37402.37422]
   Bénichou OD, 2000, BONE, V26, P87, DOI 10.1016/S8756 3282(99)00244 6
   Bollerslev J, 2013, EUR J ENDOCRINOL, V169, pR39, DOI 10.1530/EJE 13 0136
   Bonnet ME, 2013, J CONTROL RELEASE, V170, P183, DOI 10.1016/j.jconrel.2013.05.015
   Boudreau RL, 2012, METHOD ENZYMOL, V507, P275, DOI 10.1016/B978 0 12 386509 0.00014 4
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014 5793(95)01298 2
   Burnett JC, 2011, BIOTECHNOL J, V6, P1130, DOI 10.1002/biot.201100054
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V561, P13, DOI 10.1016/j.abb.2014.08.009
   Chu K, 2006, J BONE MINER RES, V21, P1089, DOI 10.1359/JBMR.060409
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Del Fattore A, 2008, BONE, V42, P19, DOI 10.1016/j.bone.2007.08.029
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Essex S, 2015, GENE THER, V22, P257, DOI 10.1038/gt.2014.97
   Farooqi AA, 2014, ONCOTARGETS THER, V7, P2035, DOI 10.2147/OTT.S49652
   FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740
   Gindy ME, 2014, MOL PHARMACEUT, V11, P4143, DOI 10.1021/mp500367k
   Gomes da Silva LC, 2014, CELL MOL LIFE SCI, V71, P1417, DOI 10.1007/s00018 013 1502 2
   Graves AR, 2008, NATURE, V453, P788, DOI 10.1038/nature06907
   Günther M, 2011, EUR J PHARM BIOPHARM, V77, P438, DOI 10.1016/j.ejpb.2010.11.007
   Higuchi Y, 2010, BIODRUGS, V24, P195, DOI 10.2165/11534450 000000000 00000
   Hu P, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20140124
   Huang H, 2009, NUCLEIC ACIDS RES, V37, P7560, DOI 10.1093/nar/gkp835
   Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002 9440(10)63267 1
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lu XL, 2013, HEART RHYTHM, V10, P128, DOI 10.1016/j.hrthm.2012.09.124
   Martínez T, 2013, HUM GENET, V132, P481, DOI 10.1007/s00439 013 1288 1
   Moazed D, 2009, NATURE, V457, P413, DOI 10.1038/nature07756
   Ohnishi Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002248
   Paul BM, 2014, WIRES DEV BIOL, V3, P465, DOI 10.1002/wdev.152
   Peacock H, 2011, J ORG CHEM, V76, P7295, DOI 10.1021/jo2012225
   Pedrioli DML, 2012, J INVEST DERMATOL, V132, P1627, DOI 10.1038/jid.2012.28
   PRATT AJ, 1991, IEEE T BIO MED ENG, V38, P306, DOI 10.1109/10.133215
   Rucci N, 2009, J CELL BIOL, V187, P669, DOI 10.1083/jcb.200906014
   Schultheis B, 2014, J CLIN ONCOL, V32, P4141, DOI 10.1200/JCO.2013.55.0376
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Teti Anna, 2011, Curr Osteoporos Rep, V9, P264, DOI 10.1007/s11914 011 0078 8
   Tilesi F, 2009, CURR OPIN MOL THER, V11, P156
   Waguespack SG, 2007, J CLIN ENDOCR METAB, V92, P771, DOI 10.1210/jc.2006 1986
   Wang YW, 2012, ADV DRUG DELIVER REV, V64, P1341, DOI 10.1016/j.addr.2011.09.002
   Weinert S, 2010, SCIENCE, V328, P1401, DOI 10.1126/science.1188072
   Yoon HY, 2014, SCI REP UK, V4, DOI 10.1038/srep06878
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 52
TC 23
Z9 26
U1 0
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD SEP 1
PY 2015
VL 4
BP 1
EP 13
DI 10.1038/mtna.2015.21
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DC0ML
UT WOS:000368911400001
PM 26325626
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gu, WH
   Chen, K
   Zhao, XY
   Geng, H
   Li, J
   Qin, YX
   Bai, X
   Chang, YN
   Xia, SB
   Zhang, JX
   Ma, SH
   Wu, ZH
   Xing, GY
   Xing, GM
AF Gu, Weihong
   Chen, Kui
   Zhao, Xiaoyi
   Geng, Huan
   Li, Juan
   Qin, Yanxia
   Bai, Xue
   Chang, Ya Nan
   Xia, Shibo
   Zhang, Jiaxin
   Ma, Sihan
   Wu, Zhonghua
   Xing, Gengyan
   Xing, Gengmei
TI Highly Dispersed Fullerenols Hamper Osteoclast Ruffled Border Formation
   by Perturbing Ca<SUP>2+</SUP> Bundles
SO SMALL
LA English
DT Article
DE actin; fullerenol; osteoporosis; ruffled borders; synchrotron radiation
   small angle X ray scattering (SAXS)
ID F ACTIN; CELLULAR UPTAKE; IN VITRO; NANOPARTICLES; CALCIUM;
   ORGANIZATION; POLYAMINES; MECHANISM; DIFFERENTIATION; CYTOTOXICITY
AB Osteoporosis, a common and serious bone disorder affecting aged people and postmenopausal women, is characterized by osteoclast overactivity. One therapeutic strategy is suppressing the bone resorption function of hyperactive osteoclasts, but there is no effective drug in clinical practice so far. Herein, it is demonstrated that fullerenols suppress the bone resorption of osteoclasts by inhibiting ruffled borders (RBs) formation. The RBs formation, which is supported by well aligned actin bundles (B actins), is a critical event for osteoclast bone resorption. To facilitate this function, osteoclast RBs dynamics is regulated by variable microenvironments to bundle F actins, protrude cell membrane, and so on. B actin perturbation by fullerenols is determined here, offering an opportunity to regulate osteoclast function by destroying RBs. In vivo, the therapeutic effect of fullerenols on overactive osteoclasts is confirmed in a mouse model of lipopolysaccharide induced bone erosion. Collectively, the findings suggest that fullerenols adhere to F actin surfaces and inhibit RBs formation in osteoclasts, mainly through hampering Ca2+ from bundling F actins, and this is likely due to the stereo hindrance effect caused by adherent fullerenols.
C1 [Gu, Weihong; Chen, Kui; Li, Juan; Qin, Yanxia; Bai, Xue; Chang, Ya Nan; Xia, Shibo; Zhang, Jiaxin; Ma, Sihan; Xing, Gengmei] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
   [Gu, Weihong; Chen, Kui; Zhao, Xiaoyi; Bai, Xue; Xia, Shibo; Zhang, Jiaxin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Zhao, Xiaoyi; Wu, Zhonghua] Chinese Acad Sci, Inst High Energy Phys, Beijing Synchrotron Radiat Facil, Beijing 100049, Peoples R China.
   [Geng, Huan; Xing, Gengyan] Chinese Peoples Armed Police Forces, Gen Hosp, Dept Orthoped, Beijing 100039, Peoples R China.
C3 Chinese Academy of Sciences; Key Laboratory for Biological Effects of
   Nanomaterials & Nanosafety, CAS; Institute of High Energy Physics, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS
RP Xing, GM (通讯作者)，Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.; Xing, GY (通讯作者)，Chinese Peoples Armed Police Forces, Gen Hosp, Dept Orthoped, Beijing 100039, Peoples R China.
EM xgy1350138@163.com; xinggm@ihep.ac.cn
RI ; Wu, Zhonghua/V 8258 2019; Chen, Kui/HNJ 6568 2023; Li,
   Juan/F 1448 2014
OI Wu, Zhonghua/0000 0001 9823 8145; Wu, Zhonghua/0000 0002 8036 022X;
   Chang, Yanan/0000 0003 4745 6876; Li, Juan/0000 0003 4110 3295; Chen,
   Kui/0000 0001 6754 4940
FU National Basic Research Program of China (973 Program) [2015CB930104];
   National Natural Science Foundation of China [81873914, 11405185];
   Xiejialin Foundation of IHEP [Y8546180U2]
FX W.G. and K.C. contributed equally to this work. This work was
   financially supported by the National Basic Research Program of China
   (973 Program) (No. 2015CB930104), the National Natural Science
   Foundation of China (Nos. 81873914 and 11405185), as well as Xiejialin
   Foundation of IHEP (No. Y8546180U2). The authors would like to
   appreciate the scientists Wenqiang Hua, Feng Tian, Jinyou Lin, and other
   staff members at the Shanghai Synchrotron Radiation Facility (SSRF) for
   their help with SAXS work. The authors would like to acknowledge Xueqing
   Xing, Zhihong Li, and Guang Mo from Beijing Synchrotron Radiation
   Facility (BSRF) for performing the SAXS analyses. The authors would like
   to thank Yongsheng Chen, Gang Ji, and Wei Ding for excellent technical
   support with TEM imaging and also gratefully acknowledge the support of
   the TEM facilities at the Center for Biological Imaging, Institute of
   Biophysics, Chinese Academy of Sciences. W.G. performed the AFM, TEM,
   SAXS, and FLIM experiments. K.C. and Y.Q. performed the bone erosion
   assay in vivo. X.Z. and Z.W. contributed to the SAXS analysis. H.G.,
   X.B., and Y.C. performed the 3D cell cultures and imaging. J.L., G.Y.X.,
   and G.M.X. conceived the project. S.X., J.Z., and S.M. prepared the AFM
   and TEM samples. W.G. and Y.Q. performed the RT qPCR assay. W.G. and
   G.M.X. analyzed all the data and wrote the manuscript with help from
   G.Y.X.
CR AIMAR C, 1992, BIOL CELL, V76, P23, DOI 10.1016/0248 4900(92)90191 3
   Akisaka T, 2006, J ELECTRON MICROSC, V55, P53, DOI 10.1093/jmicro/dfl012
   Angelini TE, 2005, EUR PHYS J E, V16, P389, DOI 10.1140/epje/i2004 10097 9
   Angelini TE, 2003, P NATL ACAD SCI USA, V100, P8634, DOI 10.1073/pnas.1533355100
   Berezin MY, 2010, CHEM REV, V110, P2641, DOI 10.1021/cr900343z
   Blanchoin L, 2014, PHYSIOL REV, V94, P235, DOI 10.1152/physrev.00018.2013
   Breitbart H, 1997, Rev Reprod, V2, P165, DOI 10.1530/revreprod/2.3.165
   Broedersz CP, 2014, REV MOD PHYS, V86, P995, DOI 10.1103/RevModPhys.86.995
   Chiang LY, 1996, TETRAHEDRON, V52, P4963, DOI 10.1016/0040 4020(96)00104 4
   CHIANG LY, 1995, J CHEM SOC CHEM COMM, P1283, DOI 10.1039/c39950001283
   Costigliola N, 2010, BIOPHYS J, V99, P1053, DOI 10.1016/j.bpj.2010.06.010
   Dellinger AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126290
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Gao MM, 2015, ANGEW CHEM INT EDIT, V54, P11088, DOI 10.1002/anie.201504247
   GAWLITTA W, 1981, CELL TISSUE RES, V215, P249
   Geng H, 2017, NANOSCALE, V9, P12516, DOI 10.1039/c7nr04365a
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   Grebowski J, 2013, POSTEP HIG MED DOSW, V67, P859
   Gu WH, 2018, NANOSCALE, V10, P1750, DOI 10.1039/c7nr07231g
   Jansen S, 2011, J BIOL CHEM, V286, P30087, DOI 10.1074/jbc.M111.251439
   Jin H, 2000, J NEUROSCI RES, V62, P600, DOI 10.1002/1097 4547(20001115)62:4<600::AID JNR15>3.0.CO;2 F
   Jin JJ, 2016, J BIOMED NANOTECHNOL, V12, P1234, DOI 10.1166/jbn.2016.2251
   Johnson Lyles DN, 2010, TOXICOL APPL PHARM, V248, P249, DOI 10.1016/j.taap.2010.08.008
   Kakugo A, 2003, BIOCONJUGATE CHEM, V14, P1185, DOI 10.1021/bc0340722
   Kessenich C R, 1997, Rehabil Nurs, V22, P192
   Kundrak J, 2008, INT J ADV MANUF TECH, V38, P110, DOI 10.1007/s00170 007 1086 9
   Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164
   Li J, 2012, CARBON, V50, P460, DOI 10.1016/j.carbon.2011.08.073
   Li ZH, 2014, INSTRUM SCI TECHNOL, V42, P128, DOI 10.1080/10739149.2013.845845
   Li ZP, 2006, BIOCHEM BIOPH RES CO, V343, P345, DOI 10.1016/j.bbrc.2006.02.147
   Lin JQ, 2010, ACS NANO, V4, P5421, DOI 10.1021/nn1010792
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   Nakamura S, 2012, J NIPPON MED SCH, V79, P248, DOI 10.1272/jnms.79.248
   Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Purdy KR, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.058105
   Sbrana F, 2008, AM J PHYSIOL CELL PH, V295, pC160, DOI 10.1152/ajpcell.00014.2008
   Schmähling J, 2007, WEAR, V262, P1360, DOI 10.1016/j.wear.2007.01.025
   Schnauss J, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8080274
   Schreiber RC, 2004, NEUROSCIENCE, V128, P741, DOI 10.1016/j.neuroscience.2004.07.014
   Scott DI, 2009, BONE, V44, pS325, DOI 10.1016/j.bone.2009.03.618
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sharma S, 2011, NANO LETT, V11, P825, DOI 10.1021/nl104159v
   Shikinaka K, 2008, BIOMACROMOLECULES, V9, P537, DOI 10.1021/bm701068n
   Sowa GZ, 2006, J PHYS CHEM B, V110, P22279, DOI 10.1021/jp063371w
   SUNKARA PS, 1979, EXP CELL RES, V119, P63, DOI 10.1016/0014 4827(79)90335 5
   Takatsuki H, 2014, BBA GEN SUBJECTS, V1840, P1933, DOI 10.1016/j.bbagen.2014.01.012
   Takito J, 2015, J CELL PHYSIOL, V230, P395, DOI 10.1002/jcp.24723
   Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Väänänen HK, 2000, J CELL SCI, V113, P377
   vansder Eerden B. C. J., 2005, P NATL ACAD SCI USA, V102, P17507
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Volkmann N, 2001, J CELL BIOL, V153, P947, DOI 10.1083/jcb.153.5.947
   [王九令 Wang Jiuling], 2015, [科学通报, Chinese Science Bulletin], V60, P1976
   Wang TT, 2012, ACS NANO, V6, P1251, DOI 10.1021/nn203892h
   Wang W., 2007, NUCL TECH, V30
   Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585 006 9014 1
   Wong Ekkabut J, 2008, NAT NANOTECHNOL, V3, P363, DOI 10.1038/nnano.2008.130
   Xiao Cui B., 2009, BASIC CLIN MED, V29, P423
   Xing GM, 2004, J PHYS CHEM B, V108, P11473, DOI 10.1021/jp0487962
   Yudoh K, 2009, INT J NANOMED, V4, P233
   ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006 291X(89)91143 1
   Zhou J, 2015, CALCIFIED TISSUE INT, V96, P465, DOI 10.1007/s00223 015 9967 7
NR 65
TC 11
Z9 13
U1 1
U2 66
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD NOV 28
PY 2018
VL 14
IS 48
AR 1802549
DI 10.1002/smll.201802549
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA HC1NG
UT WOS:000451566800009
PM 30334332
DA 2025 08 17
ER

PT J
AU Li, MY
   Wang, JJ
   Yu, YJ
   Zhou, YQ
   Shi, YQ
   Zhang, WJ
   Son, G
   Ge, J
   Zhao, J
   Yang, C
   Wang, SY
AF Li, Mengyu
   Wang, Jiajia
   Yu, Yejia
   Zhou, Yuqiong
   Shi, Yueqi
   Zhang, Wenjie
   Son, Geehun
   Ge, Jing
   Zhao, Jun
   Yang, Chi
   Wang, Shaoyi
TI Characterization of Mesenchymal Stem Cells Derived from
   Bisphosphonate Related Osteonecrosis of the Jaw Patients' Gingiva
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Bisphosphonates; Osteonecrosis; Gingival mesenchymal stem cells;
   Transplantation; Wound healing; Microenvironment; Oral mucosa
ID HUMAN ORAL MUCOSA; ZOLEDRONIC ACID; BONE TURNOVER; GROWTH; PATHOGENESIS;
   EXPRESSION; MANAGEMENT; THERAPY; PROFILE; CANCER
AB Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a clinical condition that specifically occurs in the oral cavity, characterized by retarded wound healing in oral mucosa accelerating the exposure of bone. Moreover, the pathological mechanism remains poorly understood. Gingival mesenchymal stem cells (GMSCs) play a critical role in gingival healing and soft tissue regeneration. Although previous studies have showed that bisphosphonates (BPs) are highly toxic to healthy GMSC, there is overall lack of direct evidence demonstrating the characterization of GMSCs derived from BRONJ patients. In present study, we isolated GMSCs for the first time from the central area of BRONJ patients' gingiva (center BRONJ GMSCs) and the peripheral area (peri BRONJ GMSCs), and found that they exhibited decreased proliferation, adhesion, migration capacities and underwent early apoptosis in vitro compared control GMSCs. Notably, the central and peripheral BRONJ GMSCs transplantation in a mice excisional skin model also displayed lower cell survival rate and poor healing effects than that of controls. Mechanistically, TGF beta 1 signaling pathway was suppressed not only in BRONJ patients' gingival lesions but also in BRONJ GMSCs transplantation animal model. The results above suggested that under the microenvironment of BRONJ patients, the dysfunction of GMSCs and the suppressed TGF beta 1 signaling pathway may be the vital factors in impaired gingival healing, thus contributing to persistent exposure of underlying bone and development of BRONJ. This study provides new insights into the prevention for BRONJ by improving the functions of GMSCs and upregulating TGF beta 1 in accelerating gingival wound healing.
C1 [Li, Mengyu; Wang, Jiajia; Yu, Yejia; Zhou, Yuqiong; Shi, Yueqi] Shanghai Jiao Tong Univ, Sch Med, Ninth Peoples Hosp,Shanghai Key Lab Stomatol, Dept Oral Surg,Shanghai Engn Res Ctr Adv Dent Tec, Shanghai, Peoples R China.
   [Li, Mengyu; Wang, Jiajia; Yu, Yejia; Zhou, Yuqiong; Shi, Yueqi; Zhang, Wenjie; Son, Geehun; Ge, Jing; Zhao, Jun; Yang, Chi; Wang, Shaoyi] Shanghai Jiao Tong Univ, Sch Med, Ninth Peoples Hosp, Shanghai Res Inst Stomatol,Natl Clin Res Ctr Oral, Shanghai, Peoples R China.
   [Zhang, Wenjie] Shanghai Jiao Tong Univ, Sch Med, Ninth Peoples Hosp,Shanghai Key Lab Stomatol, Dept Prosthodont,Shanghai Engn Res Ctr Adv Dent T, Shanghai, Peoples R China.
   [Son, Geehun; Ge, Jing; Yang, Chi; Wang, Shaoyi] Shanghai Jiao Tong Univ, Sch Med, Ninth Peoples Hosp, Dept Oral Surg,Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Zhao, Jun] Shanghai Jiao Tong Univ, Sch Med, Ninth Peoples Hosp, Dept Orthodont,Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong
   University
RP Yang, C; Wang, SY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ninth Peoples Hosp, Shanghai Res Inst Stomatol,Natl Clin Res Ctr Oral, Shanghai, Peoples R China.; Yang, C; Wang, SY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ninth Peoples Hosp, Dept Oral Surg,Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
EM 1014836807@qq.com; 1813511208@qq.com; yuyejia0208@163.com;
   zyqjyhospital@outlook.com; 1344097578@qq.com; zhangwenjie586@126.com;
   2855973748@qq.com; 2044328567@qq.com; yuzj 260@hotmail.com;
   yangchi63@hotmail.com; wangshaoyi163@aliyun.com
RI ; Zhang, Wenjie/O 5336 2014
OI Zhang, Wenjie/0000 0002 7753 695X; 
FU National Natural Science Foundation of China [81271114, 32071361,
   81200815, 3200100402]; Shanghai Rising star Program [20QA1405700];
   Science and Technology Commission of Shanghai Municipality [19411962000,
   17441902000, 18441903000]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (grant number. 81271114, 32071361, 81200815 and
   3200100402), Shanghai Rising star Program (grant number. 20QA1405700)
   and Science and Technology Commission of Shanghai Municipality (grant
   number. 19411962000, 17441902000 and 18441903000).
CR Agis H, 2010, J DENT RES, V89, P40, DOI 10.1177/0022034509354298
   Albadawi H, 2013, J SURG RES, V182, P339, DOI 10.1016/j.jss.2012.10.033
   Allen MR, 2008, EXPERT OPIN DRUG MET, V4, P1371, DOI 10.1517/17425255.4.11.1371 
   Alsalleeh F, 2014, J ENDODONT, V40, P1505, DOI 10.1016/j.joen.2014.01.035
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bandyopadhyay B, 2006, J CELL BIOL, V172, P1093, DOI 10.1083/jcb.200507111
   Beanes Steven R., 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403005817
   Belibasakis GN, 2019, ADV EXP MED BIOL, V1197, P1, DOI 10.1007/978 3 030 28524 1_1
   Chen LW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007119
   Cozin M, 2011, J ORAL MAXIL SURG, V69, P2564, DOI 10.1016/j.joms.2011.03.005
   Diniz IMA, 2016, J PROSTHODONT, V25, P105, DOI 10.1111/jopr.12316
   Galiano RD, 2004, WOUND REPAIR REGEN, V12, P485, DOI 10.1111/j.1067 1927.2004.12404.x
   Han NN, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1324 8
   Hawthorne B, 2021, J BIOMED MATER RES B, V109, P1967, DOI 10.1002/jbm.b.34861
   He LH, 2017, J DENT RES, V96, P539, DOI 10.1177/0022034517691507
   Hesse B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088481
   Hokugo A, 2019, BONE, V123, P115, DOI 10.1016/j.bone.2019.03.027
   Ikeda T, 2015, BONE, V73, P217, DOI 10.1016/j.bone.2014.12.021
   Jabbour Z, 2016, INT J ORAL MAX SURG, V45, P1162, DOI 10.1016/j.ijom.2015.12.017
   Manzano Moreno FJ, 2019, INT J MED SCI, V16, P1534, DOI 10.7150/ijms.36994
   Manzano Moreno FJ, 2016, J ORAL MAXIL SURG, V74, P1765, DOI 10.1016/j.joms.2016.03.028
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Kim RH, 2011, J DENT RES, V90, P810, DOI 10.1177/0022034511402995
   Kishimoto H, 2019, JPN DENT SCI REV, V55, P95, DOI 10.1016/j.jdsr.2018.09.002
   Komatsu Y, 2016, INT J MOL MED, V38, P139, DOI 10.3892/ijmm.2016.2582
   Kou XX, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aai8524
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Lee RS, 2017, INT J MOL MED, V40, P623, DOI 10.3892/ijmm.2017.3066
   Li L, 2020, FEBS OPEN BIO, V10, P2750, DOI 10.1002/2211 5463.13013
   Li MY, 2020, STEM CELLS DEV, V29, P156, DOI 10.1089/scd.2019.0151
   Li S, 2020, BIOORG CHEM, V94, DOI 10.1016/j.bioorg.2019.103385
   Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053
   Lodyga M, 2020, SEMIN CELL DEV BIOL, V101, P123, DOI 10.1016/j.semcdb.2019.12.010
   Miscianinov V, 2018, MOL THER, V26, P1996, DOI 10.1016/j.ymthe.2018.05.002
   Mori HM, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1128 7
   Park SA, 2015, WOUND REPAIR REGEN, V23, P251, DOI 10.1111/wrr.12272
   Patntirapong S, 2019, ACTA HISTOCHEM, V121, P400, DOI 10.1016/j.acthis.2019.02.007
   Paulo S, 2019, MATERIALS, V12, DOI 10.3390/ma12111840
   Ristow O, 2018, J CRANIO MAXILL SURG, V46, P815, DOI 10.1016/j.jcms.2018.03.005
   Ristow O, 2014, J ORAL MAXIL SURG, V72, P903, DOI 10.1016/j.joms.2013.11.005
   Ristow O, 2014, J CANCER RES CLIN, V140, P487, DOI 10.1007/s00432 014 1588 4
   Sato K, 2005, J BIOMECH, V38, P1895, DOI 10.1016/j.jbiomech.2004.08.012
   Shi Q, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00904
   Tang YM, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119727
   Taniguchi N, 2020, J PERIODONTOL, V91, P947, DOI 10.1002/JPER.19 0385
   Toshniwal P, 2019, FEBS LETT, V593, P3149, DOI 10.1002/1873 3468.13658
   Treves Manusevitz S, 2013, J CLIN PERIODONTOL, V40, P73, DOI 10.1111/jcpe.12016
   Turri A, 2016, BIOMATERIALS, V84, P167, DOI 10.1016/j.biomaterials.2016.01.034
   Yuan A, 2020, OR SURG OR MED OR PA, V129, P133, DOI 10.1016/j.oooo.2019.08.018
   Zhang ML, 2017, STEM CELL TRANSL MED, V6, P2126, DOI 10.1002/sctm.17 0033
   Zhang QZ, 2012, J DENT RES, V91, P1011, DOI 10.1177/0022034512461016
   Zhou YQ, 2021, INT J MED SCI, V18, P2209, DOI 10.7150/ijms.56408
NR 54
TC 5
Z9 5
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD JAN
PY 2022
VL 18
IS 1
BP 378
EP 394
DI 10.1007/s12015 021 10241 8
EA SEP 2021
PG 17
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA YQ2YD
UT WOS:000698326700001
PM 34553308
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Egashira, K
   Kajiya, H
   Tsutsumi, T
   Taniguchi, Y
   Kakura, K
   Ohno, J
   Kido, H
AF Egashira, Kei
   Kajiya, Hiroshi
   Tsutsumi, Takashi
   Taniguchi, Yusuke
   Kakura, Kae
   Ohno, Jun
   Kido, Hirofumi
TI AMPK activation enhances osteoblast differentiation on a titanium disc
   via autophagy
SO INTERNATIONAL JOURNAL OF IMPLANT DENTISTRY
LA English
DT Article
DE Titanium disc; AMP activated protein kinase; Osteoblast differentiation;
   Autophagy; Osseointegration
ID DENTAL IMPLANTS; MITOCHONDRIAL DYSFUNCTION; ADIPONECTIN RECEPTOR;
   BONE FORMATION; KINASE; CELLS; RISK; MINERALIZATION; INHIBITION;
   EXPRESSION
AB PurposeThe acquisition of osseointegration during implant therapy is slower and poorer in patients with diabetes compared with healthy persons. The serum concentration of adiponectin in patients with type II diabetes is lower than that of healthy persons via the suppression of AMP activated protein kinase (AMPK). Therefore, we hypothesized that the AMPK activation enhances bone formation around implants, resulting in the improved acquisition of osseointegration. The purpose of this study was to evaluate the impact of AMPK activation on osteoblast differentiation and its mechanism of downstream signaling on titanium disc (Ti).MethodsConfluent mouse pre osteoblasts (MC3T3 E1) cells (1 x 105 cells/well) were cultured with BMP 2 for osteoblast differentiation, in the presence or absence AICAR, an AMPK activator. We examined the effects of AMPK activation on osteoblast differentiation and the underlying mechanism on a Ti using a CCK8 assay, a luciferase assay, quantitative RT PCR, and western blotting.ResultsAlthough the proliferation rate of osteoblasts was not different between a Ti and a tissue culture polystyrene dish, the addition of AICAR, AMPK activator slightly enhanced osteoblast proliferation on the Ti. AICAR enhanced the BMP 2 dependent transcriptional activity on the Ti, leading to upregulation in the expression of osteogenesis associated molecules. AICAR simultaneously upregulated the expression of autophagy associated molecules on the Ti, especially LC3 II. AdipoRon, an adiponectin receptor type1/type2 activator activated AMPK, and upregulated osteogenesis associated molecules on Ti.ConclusionsAMPK activation enhances osteoblast differentiation on a Ti via autophagy, suggesting that it promotes the acquisition of osseointegration during implant therapy.
C1 [Egashira, Kei; Taniguchi, Yusuke; Kakura, Kae; Kido, Hirofumi] Fukuoka Dent Coll, Dept Oral Rehabil, Sect Oral Implantol, Fukuoka, Japan.
   [Egashira, Kei; Kajiya, Hiroshi; Tsutsumi, Takashi; Ohno, Jun] Fukuoka Dent Coll, Oral Med Res Ctr, Fukuoka, Japan.
   [Kajiya, Hiroshi] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Fukuoka 8140193, Japan.
   [Tsutsumi, Takashi] Fukuoka Dent Coll, Dept Gen Dent, Sect Gen Dent, Fukuoka, Japan.
C3 Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Fukuoka
   Dental College (FDC); Fukuoka Dental College (FDC)
RP Kajiya, H (通讯作者)，Fukuoka Dent Coll, Oral Med Res Ctr, Fukuoka, Japan.; Kajiya, H (通讯作者)，Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Fukuoka 8140193, Japan.
EM kajiya@fdcnet.ac.jp
RI Ohno, Jun/K 3466 2019
FU JSPS KAKENHI [21K09990, 22K21005]; Grants in Aid for Scientific Research
   [21K09990] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI (grant numbers: 21K09990 and
   22K21005). We kindly thank the pGL4/Id plasmid gift from Dr. Katagiri.
   We would like to thank Enago (Academic Proofing Service; www.enago.jp)
   for the English language review.
CR Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Burkewitz K, 2014, CELL METAB, V20, P10, DOI 10.1016/j.cmet.2014.03.002
   Chung SJ, 2017, AUTOPHAGY, V13, P1386, DOI 10.1080/15548627.2017.1332565
   Daimon M, 2003, DIABETES CARE, V26, P2015, DOI 10.2337/diacare.26.7.2015
   Nobre MD, 2016, J ORAL REHABIL, V43, P863, DOI 10.1111/joor.12435
   Doll C, 2015, EUR J ORAL IMPLANTOL, V8, P405
   Dubey Rajendra Kumar, 2013, Natl J Maxillofac Surg, V4, P142, DOI 10.4103/0975 5950.127642
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Hu XF, 2017, ACTA BIOMATER, V61, P233, DOI 10.1016/j.actbio.2017.06.020
   Huang BR, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.697738
   Huang CY, 2010, J CELL PHYSIOL, V224, P475, DOI 10.1002/jcp.22145
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Jian M, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1492 6
   Kanazawa I, 2018, BIOCHEM BIOPH RES CO, V503, P1955, DOI 10.1016/j.bbrc.2018.07.141
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Khan MP, 2015, DIABETES, V64, P2609, DOI 10.2337/db14 1611
   Kim AY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8585
   Kim JE, 2008, BONE, V43, P394, DOI 10.1016/j.bone.2008.03.021
   Ko FC, 2021, J BONE MINER RES, V36, P1510, DOI 10.1002/jbmr.4312
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li SS, 2009, JAMA J AM MED ASSOC, V302, P179, DOI 10.1001/jama.2009.976
   Li X, 2020, EXP THER MED, V19, P2690, DOI 10.3892/etm.2020.8490
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Lin YY, 2014, BONE, V64, P147, DOI 10.1016/j.bone.2014.03.051
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Mu W, 2018, PHARMACOL RES, V129, P462, DOI 10.1016/j.phrs.2017.11.020
   de Morais JAND, 2009, CLIN ORAL IMPLAN RES, V20, P796, DOI 10.1111/j.1600 0501.2009.01716.x
   Nicolas S, 2020, METABOLISM, V103, DOI 10.1016/j.metabol.2019.154027
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Nuschke A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt530
   Okada Iwabu M, 2018, ENDOCR J, V65, P971, DOI 10.1507/endocrj.EJ18 0310
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Saito N, 2022, J PERIODONTAL RES, V57, P412, DOI 10.1111/jre.12972
   Shetty S, 2009, TRENDS PHARMACOL SCI, V30, P234, DOI 10.1016/j.tips.2009.02.004
   Shyng YC, 2006, INT J PROSTHODONT, V19, P513
   Takatani T, 2011, MOL CELL ENDOCRINOL, V339, P114, DOI 10.1016/j.mce.2011.04.003
   Vansana P, 2022, J DENT SCI, V17, P1225, DOI 10.1016/j.jds.2021.12.003
   Veldhuis Vlug AG, 2017, METABOLISM, V67, P106, DOI 10.1016/j.metabol.2016.11.013
   Wu SB, 2014, BBA GEN SUBJECTS, V1840, P1331, DOI 10.1016/j.bbagen.2013.10.034
   Wu YC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143435
   Yamaguchi Toru, 2012, Bonekey Rep, V1, P36, DOI 10.1038/bonekey.2012.27
   Yamauchi T, 2013, CELL METAB, V17, P185, DOI 10.1016/j.cmet.2013.01.001
   Yasunaga M, 2019, J HARD TISSUE BIOL, V28, P63, DOI 10.2485/jhtb.28.63
   Zhou X, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578 021 00639 9
   Ziqubu K, 2023, LIFE SCI, V313, DOI 10.1016/j.lfs.2022.121273
NR 46
TC 3
Z9 3
U1 1
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
EI 2198 4034
J9 INT J IMPLANT DENT
JI INT. J. IMPLANT. DENT.
PD JAN 29
PY 2024
VL 10
IS 1
AR 2
DI 10.1186/s40729 024 00525 2
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GD5J3
UT WOS:001150737500001
PM 38286943
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yen, ML
   Su, JL
   Chien, CL
   Tseng, KW
   Yang, CY
   Chen, WF
   Chang, CC
   Kuo, ML
AF Yen, ML
   Su, JL
   Chien, CL
   Tseng, KW
   Yang, CY
   Chen, WF
   Chang, CC
   Kuo, ML
TI Diosgenin induces hypoxia inducible factor 1 activation and angiogenesis
   through estrogen receptor related phosphatidylinositol 3 kinase/Akt and
   p38 mitogen activated protein kinase pathways in osteoblasts
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; FACTOR EXPRESSION; CARCINOMA CELLS; CANCER
   CELLS; FACTOR 1 ALPHA; INDUCTION; BONE; GENE; 17 BETA ESTRADIOL;
   TRANSACTIVATION
AB Diosgenin, extracted from the root of wild yam ( Dioscorea villosa), has been reported to demonstrate an opportunity for medical application. Vascular endothelial growth factor A (VEGF A) plays an important role in bone related angiogenesis, a critical process occurring during bone formation and fracture healing. In this study, we examine whether diosgenin is able to induce VEGF A expression and to promote angiogenesis in osteoblasts. For murine MC3T3 E1 preosteoblast like cells, VEGF A mRNA and protein expression seemed to be significantly elevated in response to diosgenin in a concentration dependent fashion. Conditioned media prepared from cells treated with diosgenin induced strong angiogenic activity in either in vitro or ex vivo angiogenesis assay. Furthermore, diosgenin treatment increased the stability and activity of HIF 1 alpha protein. Inhibition of HIF 1 alpha activity by transfection with DN HIF 1 alpha significantly diminished diosgenin mediated VEGF A up regulation. The use of pharmacological inhibitors or genetic inhibition revealed that both the phosphatidylinositol 3 kinase (PI3K)/Akt and p38 signaling pathways were potentially required for diosgenin induced HIF 1 activation and subsequent VEGF A up regulation. It is noteworthy that an estrogen receptor binding assay revealed that diosgenin has the strong ability to replace [H 3]estradiol bound to estrogen receptor (IC50, 10 nM). In addition, the specific estrogen receptor antagonists ICI 182,780 (faslodex) and tamoxifen were noted to be able to strongly inhibit diosgenin induced, src kinase dependent Akt and p38 MAPK activation. Taken together, such results provide evidence that diosgenin up regulates VEGF A and promotes angiogenesis in preosteoblast like cells by a hypoxia inducible factor 1 alpha dependent mechanism involving the activation of src kinase, p38 MAPK, and Akt signaling pathways via estrogen receptor.
C1 Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, Taipei 10764, Taiwan.
   Natl Taiwan Univ, Coll Med, Dept Anat & Cell Biol, Taipei 10764, Taiwan.
   Natl Taiwan Univ Hosp, Dept Primary Care Med, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Traumatol & Surg, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; National Taiwan University Hospital
RP Kuo, ML (通讯作者)，Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, 1 Sect 1,Jenai Rd, Taipei 10764, Taiwan.
EM toxkml@ha.mc.ntu.edu.tw
RI ; Kuo, Min Liang/C 4872 2009
OI KUO, MIN LIANG/0000 0002 7139 0144; CHIEN,
   CHUNG LIANG/0000 0001 9806 486X; YEN, MEN LUH/0000 0003 3800 3664; 
CR ARADHANA A R R, 1992, Indian Journal of Experimental Biology, V30, P367
   Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200
   Barnes GL, 1999, J BONE MINER RES, V14, P1805, DOI 10.1359/jbmr.1999.14.11.1805
   BRIGHTON CT, 1978, CLIN ORTHOP RELAT R, V136, P22
   Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709
   Deckers M, 2001, LAB INVEST, V81, P5, DOI 10.1038/labinvest.3780207
   ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092 8674(95)90487 5
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Gao N, 2004, TOXICOL APPL PHARM, V196, P124, DOI 10.1016/j.taap.2003.12.002
   Gao N, 2002, J BIOL CHEM, V277, P45041, DOI 10.1074/jbc.M202775200
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gierthy JF, 1996, J CELL BIOCHEM, V60, P173, DOI 10.1002/(SICI)1097 4644(19960201)60:2<173::AID JCB2>3.0.CO;2 U
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262
   HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   Higdon K, 2001, Biomed Sci Instrum, V37, P281
   Hiltunen MO, 2003, FASEB J, V17, P1147, DOI 10.1096/fj.02 0514fje
   Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01 0546fje
   Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200
   Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Kim HH, 2002, CYTOKINE, V17, P14, DOI 10.1006/cyto.2001.0985
   Komesaroff P A, 2001, Climacteric, V4, P144
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Maity A, 2000, CANCER RES, V60, P5879
   Mori Abe A, 2003, J ENDOCRINOL, V178, P417, DOI 10.1677/joe.0.1780417
   Mukundan H, 2004, J CARDIOVASC PHARM, V44, P93, DOI 10.1097/00005344 200407000 00013
   Nishida T, 2000, J CELL PHYSIOL, V184, P197, DOI 10.1002/1097 4652(200008)184:2<197::AID JCP7>3.0.CO;2 R
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   REEVE J, 1988, J CLIN ENDOCR METAB, V66, P1124, DOI 10.1210/jcem 66 6 1124
   Sautour M, 2004, PLANTA MED, V70, P90, DOI 10.1055/s 2004 815467
   Scott A, 2001, Biomed Sci Instrum, V37, P13
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006 2952(02)01168 1
   Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877
   Su JL, 2004, CANCER RES, V64, P554, DOI 10.1158/0008 5472.CAN 03 1301
   Taraboletti G, 2004, EUR J CANCER, V40, P881, DOI 10.1016/j.ejca.2004.01.002
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
NR 39
TC 70
Z9 88
U1 1
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0026 895X
EI 1521 0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD OCT
PY 2005
VL 68
IS 4
BP 1061
EP 1073
DI 10.1124/mol.104.010082
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 966EK
UT WOS:000232002500016
PM 15998873
DA 2025 08 17
ER

PT J
AU Yi, XJ
   Liu, X
   Kenney, HM
   Duan, R
   Lin, X
   Schwarz, E
   Yao, ZQ
AF Yi, Xiangjiao
   Liu, Xin
   Kenney, H. Mark
   Duan, Rong
   Lin, Xi
   Schwarz, Edward
   Yao, Zhenqiang
TI TNF Polarized Macrophages Produce Insulin like 6 Peptide to Stimulate
   Bone Formation in Rheumatoid Arthritis in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANTI TNF THERAPY; AUTOIMMUNE ARTHRITIS; BONE TURNOVER; OSTEOBLAST;
   OSTEOCLAST; OSTEOPOROSIS; TNF TRANSGENIC MICE
ID TUMOR NECROSIS FACTOR; MINERAL DENSITY; UP REGULATION; POSTMENOPAUSAL
   OSTEOPOROSIS; INFLAMMATORY ARTHRITIS; TURNOVER MARKERS; TRANSGENIC MICE;
   T CELLS; ALPHA; DIFFERENTIATION
AB The risk of osteoporosis is increased in rheumatoid arthritis (RA). Anti tumor necrosis factor (TNF) therapy has markedly improved the outcomes of RA patients but does not improve osteoporosis in some reports. This could be a combined result of disease severity and other therapeutic agents, such as glucocorticoids that accelerate osteoporosis progression. We evaluated the effects of anti TNF therapy on osteoporosis in an animal model of RA and explored the possible mechanisms involved. Six week old TNF transgenic (TNF Tg) mice with early stage erosive arthritis were treated with TNF antibody (Ab) or control immunoglobulin (IgG) weekly for 4 weeks. We found that TNF Ab completely blocked the development of erosive arthritis in TNF Tg mice, but only slightly increased vertebral bone mass, associated with reduction in parameters of both bone resorption and formation. Similarly, TNF Ab slightly increased trabecular bone mass in tibias of 8 month old TNF Tg mice with advanced erosive arthritis. Interestingly, TNF alpha increased osteoblast differentiation from mouse bone marrow stromal cells (BMSCs) containing large number of macrophages but not from pure mesenchymal progenitor cells (MPCs). TNF alpha polarized macrophages (TPMs) did not express iNos and Arginase 1, typical markers of inflammatory and resident macrophages. Interestingly, TPMs stimulated osteoblast differentiation, unlike resident and inflammatory macrophages polarized by IL 4 and interferon lambda, respectively. RNA seq analysis indicated that TPMs produced several anabolic factors, including Jagged1 and insulin like 6 (INSL6). Importantly, inhibition of either Jagged1 or INSL6 blocked TNF alpha induced osteoblast differentiation. Furthermore, INSL6 Ab significantly decreased the expansion of TNF induced MPCs in BMSCs, and anti TNF Ab reduced INSL6 expression by macrophages in vitro and in TNF Tg mice in vivo. We conclude that TPMs produce INSL6 to stimulate bone formation and anti TNF Ab blocks not only enhanced bone resorption but also the anabolic effect of TPMs on bone, limiting its effect to increase bone mass in this model of RA. (c) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Yi, Xiangjiao; Liu, Xin; Kenney, H. Mark; Duan, Rong; Lin, Xi; Schwarz, Edward; Yao, Zhenqiang] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Ctr Musculoskeletal Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
   [Schwarz, Edward] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Dept Orthoped Surg, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester
RP Yao, ZQ (通讯作者)，Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Ctr Musculoskeletal Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM zhenqiang_yao@urmc.rochester.edu
RI ; YI, XIANGJIAO/HNC 3802 2023
OI Schwarz, Edward/0000 0002 4854 9698; Yi, Xiangjiao/0000 0002 3782 3954;
   Kenney, H. Mark/0000 0002 0598 3232; Yao, Zhenqiang/0000 0002 4664 3648
FU National Institutes of Health (NIH) [R01AG049994, P30 AR069655]
FX Dr Brendan Boyce provided consultant advice and language editing for
   this article. The authors thank Lindsay Schnur for micro CT imaging and
   analysis. The research was supported by National Institutes of Health
   (NIH) R01AG049994 and P30 AR069655. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the funding source.
CR Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Amici SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01593
   Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2790, DOI 10.1002/1529 0131(200112)44:12<2790::AID ART466>3.0.CO;2 X
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P710, DOI 10.1136/annrheumdis 2012 202698
   Beek KJ, 2019, J BONE MINER RES, V34, P1041, DOI 10.1002/jbmr.3684
   Bell RD, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2039 z
   Blom AB, 2004, OSTEOARTHR CARTILAGE, V12, P627, DOI 10.1016/j.joca.2004.03.003
   Bouta EM, 2017, ARTHRITIS RHEUMATOL, V69, P1187, DOI 10.1002/art.40047
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Burnicka Turek O, 2009, ENDOCRINOLOGY, V150, P4348, DOI 10.1210/en.2009 0201
   Canalis E, 2003, CURR OPIN RHEUMATOL, V15, P454, DOI 10.1097/00002281 200307000 00013
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Cuzzocrea S, 2003, ENDOCRINOLOGY, V144, P1098, DOI 10.1210/en.2002 220597
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Glass GE, 2011, P NATL ACAD SCI USA, V108, P1585, DOI 10.1073/pnas.1018501108
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Grochowski CM, 2016, GENE, V576, P381, DOI 10.1016/j.gene.2015.10.065
   Hafez EA, 2011, CLIN MED INSIGHTS AR, V4, P87, DOI 10.4137/CMAMD.S7773
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Hill CR, 2014, BONE, V62, P10, DOI 10.1016/j.bone.2014.01.019
   Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kawai VK, 2012, CURR OPIN RHEUMATOL, V24, P576, DOI 10.1097/BOR.0b013e328356d212
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lawal RA, 2017, J BONE MINER RES, V32, P1320, DOI 10.1002/jbmr.3106
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Lee JS, 2020, RHEUMATOL INT, V40, P481, DOI 10.1007/s00296 019 04418 1
   Lei W, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64018 z
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Lodder MC, 2004, ANN RHEUM DIS, V63, P1576, DOI 10.1136/ard.2003.016253
   Lok S, 2000, BIOL REPROD, V62, P1593, DOI 10.1095/biolreprod62.6.1593
   Looker AC, 2010, J BONE MINER RES, V25, P64, DOI 10.1359/jbmr.090706
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Maruyama S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008441
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   McMahon MS, 2008, BULL HOSP JT DIS, V66, P280
   Mia S, 2014, SCAND J IMMUNOL, V79, P305, DOI 10.1111/sji.12162
   Monaco C, 2015, INT IMMUNOL, V27, P55, DOI 10.1093/intimm/dxu102
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791
   Orsolini G, 2016, CALCIFIED TISSUE INT, V98, P580, DOI 10.1007/s00223 016 0114 x
   Rahman K, 2017, J CLIN INVEST, V127, P2904, DOI 10.1172/JCI75005
   Raterman HG, 2019, DRUG AGING, V36, P1061, DOI 10.1007/s40266 019 00714 4
   RIANCHO JA, 1995, J ENDOCRINOL INVEST, V18, P174, DOI 10.1007/BF03347799
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Rossini M, 2011, J RHEUMATOL, V38, P997, DOI 10.3899/jrheum.100829
   Solomon DH, 2017, ARTHRITIS RHEUMATOL, V69, P1741, DOI 10.1002/art.40156
   Sucur A, 2020, IMMUNOL LETT, V223, P106, DOI 10.1016/j.imlet.2020.04.010
   Suzuki T, 2018, THER CLIN RISK MANAG, V14, P453, DOI 10.2147/TCRM.S156350
   Takahata M, 2012, ARTHRITIS RHEUM US, V64, P3649, DOI 10.1002/art.34639
   Taylor PC, 2009, NAT REV RHEUMATOL, V5, P578, DOI 10.1038/nrrheum.2009.181
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zhao ZJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135728
NR 70
TC 14
Z9 15
U1 2
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2021
VL 36
IS 12
BP 2426
EP 2439
DI 10.1002/jbmr.4447
EA OCT 2021
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA XU2TT
UT WOS:000708155100001
PM 34585777
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Wu, JQ
   Niu, LY
   Yang, KP
   Xu, JD
   Zhang, DJ
   Ling, JT
   Xia, PP
   Wu, YT
   Liu, X
   Liu, JP
   Zhang, J
   Yu, P
AF Wu, Jiaqiang
   Niu, Liyan
   Yang, Kangping
   Xu, Jingdong
   Zhang, Deju
   Ling, Jitao
   Xia, Panpan
   Wu, Yuting
   Liu, Xiao
   Liu, Jianping
   Zhang, Jing
   Yu, Peng
TI The role and mechanism of RNA binding proteins in bone metabolism and
   osteoporosis
SO AGEING RESEARCH REVIEWS
LA English
DT Article
DE Osteoporosis; Bone metabolism; Therapy; RNA binding proteins
ID PRE MESSENGER RNA; ALTERNATIVE POLYADENYLATION; OSTEOGENIC
   DIFFERENTIATION; TRANSLATIONAL REGULATION; CBF BETA; IN VITRO;
   OSTEOCLAST; GENE; PRINCIPLES; RECEPTOR
AB Osteoporosis is a prevalent chronic metabolic bone disease that poses a significant risk of fractures or mortality in elderly individuals. Its pathophysiological basis is often attributed to postmenopausal estrogen deficiency and natural aging, making the progression of primary osteoporosis among elderly people, especially older women, seemingly inevitable. The treatment and prevention of osteoporosis progression have been extensively discussed. Recently, as researchers delve deeper into the molecular biological mechanisms of bone remodeling, they have come to realize the crucial role of posttranscriptional gene control in bone metabolism homeostasis. RNA binding proteins, as essential actors in posttranscriptional activities, may exert influence on osteoporosis progression by regulating the RNA life cycle. This review compiles recent findings on the involvement of RNA binding proteins in abnormal bone metabolism in osteoporosis and describes the impact of some key RNA binding proteins on bone metabolism regulation. Additionally, we explore the potential and rationale for modulating RNA binding proteins as a means of treating osteoporosis, with an overview of drugs that target these proteins.
C1 [Wu, Jiaqiang; Zhang, Jing; Yu, Peng] Jiujiang Clin Precis Med Res Ctr, Jiujiang 332000, Jiangxi, Peoples R China.
   [Wu, Jiaqiang; Yang, Kangping] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Nanchang 330006, Peoples R China.
   [Wu, Jiaqiang] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Med Ctr 1, Beijing, Peoples R China.
   [Niu, Liyan] Nanchang Univ, HuanKui Coll, Nanchang 330006, Peoples R China.
   [Xu, Jingdong] Nanchang Univ, Queen Mary Coll, Nanchang 330006, Peoples R China.
   [Zhang, Deju] Univ Hong Kong, Sch Biol Sci, Food & Nutr Sci, Pokfulam Rd, Hong Kong 999077, Peoples R China.
   [Ling, Jitao; Xia, Panpan; Liu, Jianping; Yu, Peng] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Dept Endocrinol & Metab, 1 Minde Rd, Nanchang 330006, Peoples R China.
   [Ling, Jitao; Xia, Panpan; Liu, Jianping; Yu, Peng] Inst Study Endocrinol & Metab Jiangxi Prov, Nanchang 330006, Peoples R China.
   [Liu, Xiao] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Cardiol, Guangzhou 510275, Peoples R China.
   [Zhang, Jing] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Dept Anesthesiol, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhang, Jing] Nanchang Univ, Dept Anesthesiol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.
   [Yu, Peng] Nanchang Univ, Affiliated Hosp 2, Dept Endocrinol & Metab, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Chinese People's Liberation Army General Hospital;
   Nanchang University; Nanchang University; University of Hong Kong;
   Nanchang University; Sun Yat Sen University; Nanchang University;
   Nanchang University; Nanchang University
RP Zhang, J (通讯作者)，Nanchang Univ, Dept Anesthesiol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.; Yu, P (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Dept Endocrinol & Metab, Nanchang, Jiangxi, Peoples R China.
EM zhangjing666doc@163.com; yu8220182@163.com
RI zhang, deju/GSM 8984 2022; Wu, Jiaqiang/KBA 3593 2024; Yang,
   Kangping/IUN 7629 2023; xiao, liu/X 7526 2019
OI Yang, Kangping/0000 0003 1298 0846; Zhang, Jing/0000 0001 9576 2275; 
FU Natural Science Foundation of China [82160371, 82100869, 82360162];
   Natural Science Foundation in Jiangxi Province [20212BAB216047,
   20224ACB216009, 20212BAB216051]; Jiangxi Province Thousands of Plans
   [jxsq2023201105]; Young Elite Scientists Sponsorship Program by JXAST
   [2023QT05]; Hengrui Diabetes Metabolism Research Fund
   [Z 2017 26 2202 4]; Natural Science Foundation of Guangdong
   [202201011395]; Basic and Applied Basic Research Project of Guangzhou
   [202201011395]
FX This work was supported by the Natural Science Foundation of China (No.
   82160371 to J.Z., No.82100869 and No.82360162 to P.Y.) ; Natural Science
   Foundation in Jiangxi Province grant (No.20212BAB216047 to P.Y.,
   No.20224ACB216009 and No. 20212BAB216051 to J.Z.) ; the Jiangxi Province
   Thousands of Plans (No. jxsq2023201105 to P.Y.) ; Young Elite Scientists
   Sponsorship Program by JXAST (No. 2023QT05 to J.Z.) and the Hengrui
   Diabetes Metabolism Research Fund (No. Z 2017 26 2202 4 to P.Y.) ;
   Natural Science Foundation of Guangdong (202201011395 to X.L.) ; Basic
   and Applied Basic Research Project of Guangzhou (202201011395 to X.L.) .
CR Adeli K, 2011, AM J PHYSIOL ENDOC M, V301, pE1051, DOI 10.1152/ajpendo.00399.2011
   Aibar Almazán A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169465
   Aita R, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102213
   Akaike Y, 2014, MOL CELL BIOL, V34, P2857, DOI 10.1128/MCB.00333 14
   Alarcón CR, 2015, CELL, V162, P1299, DOI 10.1016/j.cell.2015.08.011
   AlzhanovaEricsson AT, 1996, GENE DEV, V10, P2881, DOI 10.1101/gad.10.22.2881
   Anbazhagan R, 2022, CELLS BASEL, V11, DOI 10.3390/cells11040613
   Anderson PH, 2008, J BONE MINER RES, V23, P1789, DOI [10.1359/jbmr.080616, 10.1359/JBMR.080616]
   Arafa EA, 2023, BIOMED PHARMACOTHER, V161, DOI 10.1016/j.biopha.2023.114461
   Auweter SD, 2006, NUCLEIC ACIDS RES, V34, P4943, DOI 10.1093/nar/gkl620
   Baulin E, 2020, NUCLEIC ACIDS RES, V48, P8675, DOI 10.1093/nar/gkaa610
   Bennett CG, 2016, NUCLEIC ACIDS RES, V44, P3788, DOI 10.1093/nar/gkw207
   Bikle D, 2020, NAT REV ENDOCRINOL, V16, P234, DOI 10.1038/s41574 019 0312 5
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Boo SH, 2020, EXP MOL MED, V52, P400, DOI 10.1038/s12276 020 0407 z
   Bouillon R, 2019, ENDOCR REV, V40, P1109, DOI 10.1210/er.2018 00126
   Braga EA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113620
   Brumbaugh J, 2018, CELL, V172, P106, DOI 10.1016/j.cell.2017.11.023
   Bruzzone L, 2020, EMBO REP, V21, DOI 10.15252/embr.201948425
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cáceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55
   Cammas A, 2007, MOL BIOL CELL, V18, P5048, DOI 10.1091/mbc.E07 06 0603
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Chae MJ, 2009, EXP MOL MED, V41, P824, DOI 10.3858/emm.2009.41.11.088
   Charron F, 2017, DEV CELL, V43, P655, DOI 10.1016/j.devcel.2017.12.008
   Chen A, 2010, IET SYST BIOL, V4, P52, DOI 10.1049/iet syb.2008.0151
   Chen DJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12540
   Chen GY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00208 x
   Chen GY, 2021, INT J BIOL SCI, V17, P4409, DOI 10.7150/ijbs.64533
   Chen GH, 2022, FREE RADICAL BIO MED, V180, P95, DOI 10.1016/j.freeradbiomed.2022.01.012
   Chen H, 2006, J BIOL CHEM, V281, P39114, DOI 10.1074/jbc.M608006200
   Chen LS, 2022, ACTA PHARMACOL SIN, V43, P1311, DOI 10.1038/s41401 021 00756 8
   Chen W, 2018, J PATHOL, V244, P271, DOI 10.1002/path.5001
   Chen XW, 2018, PROTEIN CELL, V9, P848, DOI 10.1007/s13238 017 0480 9
   Chen XY, 2022, MOL METAB, V62, DOI 10.1016/j.molmet.2022.101515
   Chiodini I, 2018, EUR J ENDOCRINOL, V178, pD13, DOI 10.1530/EJE 18 0113
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092 8674(95)90325 9
   Das BK, 2022, ELIFE, V11, DOI 10.7554/eLife.73539
   de Moor CH, 2001, INT REV CYTOL, V203, P567
   DeLuca H F, 1986, Adv Exp Med Biol, V196, P361
   Deng Q, 2019, ELIFE, V8, DOI 10.7554/eLife.50208
   Dhatariya K, 2018, THER ADV ENDOCRINOL, V10, DOI 10.1177/2042018818807599
   Ding FZ, 2022, THERANOSTICS, V12, P7550, DOI 10.7150/thno.77630
   Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018 012 1252 6
   Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760
   DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445
   Du TS, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2548 3
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Erson Bensan AE, 2016, J MOL ENDOCRINOL, V57, pF29, DOI 10.1530/JME 16 0070
   Fabbiano F, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12043
   Feng L, 2020, MOL THER NUCL ACIDS, V21, P1017, DOI 10.1016/j.omtn.2020.07.018
   Fitzpatrick LA, 2002, MAYO CLIN PROC, V77, P453, DOI 10.4065/77.5.453
   Flores MVC, 2008, NAT CELL BIOL, V10, P346, DOI 10.1038/ncb1697
   Fujiwara T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.213
   Gabut M, 2011, CELL, V147, P132, DOI 10.1016/j.cell.2011.08.023
   García Mauriño SM, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00071
   Glaser DL, 1997, SPINE, V22, p12S, DOI 10.1097/00007632 199712151 00003
   Gu DR, 2017, BIOCHEM BIOPH RES CO, V482, P1073, DOI 10.1016/j.bbrc.2016.11.160
   Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250
   Guo CL, 2016, CELL BIOL INT, V40, P847, DOI 10.1002/cbin.10539
   Guo JW, 2016, ONCOTARGET, V7, P45249, DOI 10.18632/oncotarget.9932
   Guo XY, 2020, NATURE, V579, P427, DOI 10.1038/s41586 020 2078 2
   Guo YY, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101915
   Hamamura K, 2015, CELL SIGNAL, V27, P353, DOI 10.1016/j.cellsig.2014.11.020
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   He L, 2013, CELL SIGNAL, V25, P552, DOI 10.1016/j.cellsig.2012.11.015
   He MY, 2022, STEM CELL TRANSL MED, V11, P987, DOI 10.1093/stcltm/szac049
   He SY, 2023, NAT REV GENET, V24, P276, DOI 10.1038/s41576 022 00550 0
   He Y, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116182
   Heo JS, 2017, INT J MOL MED, V40, P1486, DOI 10.3892/ijmm.2017.3142
   Heyes E, 2021, LEUKEMIA, V35, P2526, DOI 10.1038/s41375 021 01169 6
   Hollander JM, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003 022 04156 4
   Horita M, 2021, J CELL BIOCHEM, V122, P696, DOI 10.1002/jcb.29896
   Hou YC, 2018, CLIN CHIM ACTA, V484, P179, DOI 10.1016/j.cca.2018.05.035
   Hsieh CJ, 2015, INT J ONCOL, V46, P555, DOI 10.3892/ijo.2014.2769
   Huang ZH, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420 022 01056 8
   Huh JE, 2016, SCI REP UK, V6, DOI 10.1038/srep22511
   Iadevaia V, 2015, BIOMOLECULES, V5, P2207, DOI 10.3390/biom5042207
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Imtiyaz Z, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.670254
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Itoh M, 2002, NUCLEIC ACIDS RES, V30, P5452, DOI 10.1093/nar/gkf673
   Ivanov P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032813
   Izquierdo JM, 2008, J BIOL CHEM, V283, P19077, DOI 10.1074/jbc.M800017200
   Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838
   Jia XS, 2019, J CELL MOL MED, V23, P2667, DOI 10.1111/jcmm.14166
   Jin FJ, 2022, INT J BIOL SCI, V18, P4482, DOI 10.7150/ijbs.72487
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Johnstone O, 2001, ANNU REV GENET, V35, P365, DOI 10.1146/annurev.genet.35.102401.090756
   Kameo Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax0938
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kaur K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175471
   Ke DS, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00449 w
   Keene JD, 2010, ENDOCRINOLOGY, V151, P1391, DOI 10.1210/en.2009 1250
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Kim HJ, 2022, EXP MOL MED, V54, P1146, DOI 10.1038/s12276 022 00820 1
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Kloc M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126553
   Kohara Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082745
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kunder N, 2022, J NEUROSCI, V42, P9129, DOI 10.1523/JNEUROSCI.1630 22.2022
   Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247
   Lan L, 2020, CANCERS, V12, DOI 10.3390/cancers12082221
   Lange MJ, 2017, NUCLEIC ACIDS RES, V45, P6087, DOI 10.1093/nar/gkx155
   Lee MH, 2020, J CELL PHYSIOL, V235, P3874, DOI 10.1002/jcp.29281
   Leidal AM, 2020, NAT CELL BIOL, V22, P187, DOI 10.1038/s41556 019 0450 y
   Lepelletier L, 2017, J NEUROSCI, V37, P1685, DOI 10.1523/JNEUROSCI.3016 16.2016
   Letarouilly JG, 2019, GENOMICS, V111, P793, DOI 10.1016/j.ygeno.2018.05.001
   Li CW, 2022, CELL DEATH DIFFER, V29, P1123, DOI 10.1038/s41418 021 00904 x
   Li D, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24021403
   Li D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051660
   Li JY, 2020, J CLIN INVEST, V130, P1767, DOI 10.1172/JCI133473
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li LF, 2022, BIOCHEM BIOPH RES CO, V610, P70, DOI 10.1016/j.bbrc.2022.04.041
   Li YH, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00289 2
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu HR, 2018, HISTOCHEM CELL BIOL, V149, P343, DOI 10.1007/s00418 017 1629 6
   Liu JM, 2021, AGING US, V13, P23361, DOI 10.18632/aging.203630
   Liu ZL, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03073 w
   Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178
   Luteijn MJ, 2013, NAT REV GENET, V14, P523, DOI 10.1038/nrg3495
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Mallarino LE, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 72905 8
   Martinez FJ, 2016, NEURON, V92, P780, DOI 10.1016/j.neuron.2016.09.050
   McCloskey A, 2012, SCIENCE, V335, P1643, DOI 10.1126/science.1218469
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Meirow Y, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00206 z
   Mitchell SF, 2014, MOL CELL, V54, P547, DOI 10.1016/j.molcel.2014.04.033
   Majd RM, 2020, METAB BRAIN DIS, V35, P1241, DOI 10.1007/s11011 020 00600 8
   Müller McNicoll M, 2013, NAT REV GENET, V14, P275, DOI 10.1038/nrg3434
   Muñoz M, 2020, CLIN OBSTET GYNECOL, V63, P770, DOI 10.1097/GRF.0000000000000572
   Niu NN, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2016.50
   Olina AV, 2018, BIOCHEMISTRY MOSCOW+, V83, P483, DOI 10.1134/S0006297918050024
   Omata Y, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 45909 3
   Ortiz Sánchez P, 2019, CIRC RES, V125, P170, DOI 10.1161/CIRCRESAHA.118.314515
   Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092 8674(00)80241 X
   Ottoz DSM, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200328
   Park Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd6495
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3
   PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0
   Pope SD, 2018, MOL CELL, V71, P389, DOI 10.1016/j.molcel.2018.07.017
   Rahman MA, 2013, SCI REP UK, V3, DOI 10.1038/srep02931
   Rai C, 2021, INT J BIOL MACROMOL, V193, P137, DOI 10.1016/j.ijbiomac.2021.10.076
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rauwel B, 2020, J BONE MINER RES, V35, P753, DOI 10.1002/jbmr.3943
   Ravindranathan S, 2010, J MOL BIOL, V396, P732, DOI 10.1016/j.jmb.2009.12.004
   Richard S, 2005, PLOS GENET, V1, P676, DOI 10.1371/journal.pgen.0010074
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Rougemaille M, 2008, BIOL CELL, V100, P327, DOI 10.1042/BC20070143
   Ruiz FX, 2020, CURR OPIN STRUC BIOL, V61, P113, DOI 10.1016/j.sbi.2019.11.011
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Schichl YM, 2009, J BIOL CHEM, V284, P29571, DOI 10.1074/jbc.M109.031237
   Seufert L, 2022, NAT REV NEPHROL, V18, P153, DOI 10.1038/s41581 021 00497 1
   Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583
   Shen GS, 2018, BBA MOL BASIS DIS, V1864, P3644, DOI 10.1016/j.bbadis.2018.09.015
   Shi XC, 2019, EXP THER MED, V18, P2393, DOI 10.3892/etm.2019.7849
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stagsted LVW, 2021, ELIFE, V10, DOI 10.7554/eLife.63088
   Subramania S, 2019, NUCLEIC ACIDS RES, V47, P4181, DOI 10.1093/nar/gkz099
   Suo JL, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00202 3
   Takahashi N, 2013, J STEROID BIOCHEM, V136, P171, DOI 10.1016/j.jsbmb.2012.11.010
   Tanaka T, 2022, EXP MOL MED, V54, P753, DOI 10.1038/s12276 022 00779 z
   Trajanoska K, 2019, BONE, V126, P2, DOI 10.1016/j.bone.2019.04.005
   Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Valverde R, 2008, FEBS J, V275, P2712, DOI 10.1111/j.1742 4658.2008.06411.x
   Van Nostrand EL, 2020, NATURE, V583, P711, DOI 10.1038/s41586 020 2077 3
   Villarroya Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980
   Vuong JK, 2016, CELL REP, V17, P2766, DOI 10.1016/j.celrep.2016.11.034
   Wang CS, 2023, BONE, V168, DOI 10.1016/j.bone.2022.116652
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang P, 2016, MOL CELL, V63, P306, DOI 10.1016/j.molcel.2016.05.041
   Wang XY, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964 021 00765 4
   Wang XY, 2023, CELL BIOSCI, V13, DOI 10.1186/s13578 023 00968 x
   Wang XP, 2023, HUM CELL, V36, P178, DOI 10.1007/s13577 022 00825 y
   Watts NB, 2021, ENDOCR PRACT, V27, P379, DOI 10.1016/j.eprac.2021.02.001
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wei XA, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202115373
   Wiedner HJ, 2021, NAT STRUCT MOL BIOL, V28, P465, DOI 10.1038/s41594 021 00601 w
   Witten JT, 2011, TRENDS GENET, V27, P89, DOI 10.1016/j.tig.2010.12.001
   Wu MR, 2017, P NATL ACAD SCI USA, V114, P10119, DOI 10.1073/pnas.1619294114
   Wu MR, 2014, INT J BIOL SCI, V10, P861, DOI 10.7150/ijbs.8521
   Wu PH, 2021, NAT REV MOL CELL BIO, V22, P239, DOI 10.1038/s41580 021 00336 y
   Wu W, 2021, HISTOL HISTOPATHOL, V36, P807, DOI 10.14670/HH 18 323
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xiao PP, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.149276
   Xiao R, 2019, CELL, V178, P107, DOI 10.1016/j.cell.2019.06.001
   Xiao Y, 2023, EMBO J, V42, DOI 10.15252/embj.2022111762
   Xu Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161261
   Xu XH, 2022, LAB INVEST, V102, P1000, DOI 10.1038/s41374 022 00792 w
   Yang C, 2022, AUTOPHAGY, V18, P2817, DOI 10.1080/15548627.2022.2048432
   Yang J, 2016, P NATL ACAD SCI USA, V113, pE1953, DOI 10.1073/pnas.1517935113
   Yang SY, 2016, CELL SIGNAL, V28, P880, DOI 10.1016/j.cellsig.2016.04.003
   Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422 018 0040 8
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Yeganeh M, 2013, MOL BIOL REP, V40, P4391, DOI 10.1007/s11033 013 2528 0
   Yi Q, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.954376
   Yokoshi M, 2014, MOL CELL, V55, P186, DOI 10.1016/j.molcel.2014.05.022
   Yoon DS, 2023, J BIOMED SCI, V30, DOI 10.1186/s12929 023 00920 8
   You L, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 11
   Yu X, 2022, J CELL MOL MED, V26, P60, DOI 10.1111/jcmm.16982
   Zhang H, 2021, AGING US, V13, P11296, DOI 10.18632/aging.202817
   Zhang LL, 2016, CELL PHYSIOL BIOCHEM, V40, P681, DOI 10.1159/000452580
   Zhang L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1005665
   Zhang PP, 2022, CELLS BASEL, V11, DOI 10.3390/cells11152357
   Zhang P, 2012, J BONE MINER METAB, V30, P568, DOI 10.1007/s00774 012 0359 z
   Zhang XW, 2007, NATURE, V450, P741, DOI 10.1038/nature05998
   Zhang YZ, 2020, AM J PHYSIOL CELL PH, V319, pC208, DOI 10.1152/ajpcell.00009.2020
   Zhang Z, 2019, CURR STEM CELL RES T, V14, P239, DOI 10.2174/1574888X14666181205122729
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zhao YY, 2018, NUCLEIC ACIDS RES, V46, P4771, DOI 10.1093/nar/gky134
   Zhong ZY, 2023, REDOX BIOL, V63, DOI 10.1016/j.redox.2023.102711
   Zhou Q, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202101467
   Zhou R, 2017, NUCLEIC ACIDS RES, V45, P606, DOI 10.1093/nar/gkw851
   Zhou XC, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14051012
   Zhou YR, 2019, CALCIFIED TISSUE INT, V104, P70, DOI 10.1007/s00223 018 0469 2
   Zhou ZM, 2023, J CELL PHYSIOL, V238, P195, DOI 10.1002/jcp.30919
   Zhu H, 2007, J BIOL CHEM, V282, P2203, DOI 10.1074/jbc.M609349200
   Zizková R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23147875
NR 228
TC 9
Z9 9
U1 6
U2 30
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568 1637
EI 1872 9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD APR
PY 2024
VL 96
AR 102234
DI 10.1016/j.arr.2024.102234
EA MAR 2024
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA OT2A0
UT WOS:001209452200001
PM 38367813
DA 2025 08 17
ER

PT J
AU Tamura, Y
   Kawao, N
   Yano, M
   Okada, K
   Okumoto, K
   Chiba, Y
   Matsuo, O
   Kaji, H
AF Tamura, Yukinori
   Kawao, Naoyuki
   Yano, Masato
   Okada, Kiyotaka
   Okumoto, Katsumi
   Chiba, Yasutaka
   Matsuo, Osamu
   Kaji, Hiroshi
TI Role of Plasminogen Activator Inhibitor 1 in Glucocorticoid Induced
   Diabetes and Osteopenia in Mice
SO DIABETES
LA English
DT Article
ID AMELIORATES INSULIN RESISTANCE; SKELETAL MUSCLE REGENERATION;
   CARDIOVASCULAR RISK; BONE FORMATION; FEMALE MICE; OLD DRUGS; MECHANISMS;
   RECEPTOR; OBESITY; METABOLISM
AB Long term use of glucocorticoids (GCs) causes numerous adverse effects, including glucose/lipid abnormalities, osteoporosis, and muscle wasting. The pathogenic mechanism, however, is not completely understood. In this study, we used plasminogen activator inhibitor 1 (PAI 1) deficient mice to explore the role of PAI 1 in GC induced glucose/lipid abnormalities, osteoporosis, and muscle wasting. Corticosterone markedly increased the levels of circulating PAI 1 and the PAI 1 mRNA level in the white adipose tissue of wild type mice. PAI 1 deficiency significantly reduced insulin resistance and glucose intolerance but not hyperlipidemia induced by GC. An in vitro experiment revealed that active PAI 1 treatment inhibits insulin induced phosphorylation of Akt and glucose uptake in HepG2 hepatocytes. However, this was not observed in 3T3 L1 adipocytes and C2C12 myotubes, indicating that PAI 1 suppressed insulin signaling in hepatocytes. PAI 1 deficiency attenuated the GC induced bone loss presumably via inhibition of apoptosis of osteoblasts. Moreover, the PAI 1 deficiency also protected from GC induced muscle loss. In conclusion, the current study indicated that PAI 1 is involved in GC induced glucose metabolism abnormality, osteopenia, and muscle wasting in mice. PAI 1 may be a novel therapeutic target to mitigate the adverse effects of GC.
C1 [Tamura, Yukinori; Kawao, Naoyuki; Yano, Masato; Okada, Kiyotaka; Kaji, Hiroshi] Kinki Univ, Fac Med, Dept Physiol & Regenerat Med, Osakasayama, Japan.
   [Okumoto, Katsumi] Kinki Univ, Life Sci Res Inst, Osakasayama, Japan.
   [Chiba, Yasutaka] Kinki Univ Hosp, Clin Res Ctr, Osakasayama, Japan.
   [Matsuo, Osamu] Kinki Univ, Fac Med, Osakasayama, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University); Kindai University (Kinki University); Kindai University
   (Kinki University)
RP Kaji, H (通讯作者)，Kinki Univ, Fac Med, Dept Physiol & Regenerat Med, Osakasayama, Japan.
EM hkaji@med.kindai.ac.jp
RI Yano, Masato/L 1299 2013; Kaji, Hiroshi/AAI 5628 2020; MATSUO,
   OSAMU/AAM 9703 2020
OI Matsuo, Osamu/0000 0002 9806 2204; Kawao, Naoyuki/0000 0002 4148 5476
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [26860152, 24590289]; Japan Osteoporosis Foundation; Takeda Science
   Foundation; Kinki University; Grants in Aid for Scientific Research
   [26860152, 24590289] Funding Source: KAKEN
FX This study was supported by grants in aid 26860152 and 24590289 from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan
   (to Y.T. and H.K., respectively) and grants from the Japan Osteoporosis
   Foundation, the Takeda Science Foundation, and Kinki University.
CR Blackburn D, 2002, J GEN INTERN MED, V17, P717, DOI 10.1046/j.1525 1497.2002.10649.x
   Brennan Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377
   Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180
   Conde J, 2011, BIOFACTORS, V37, P413, DOI 10.1002/biof.185
   Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117
   Darmon P, 2006, AM J PHYSIOL ENDOC M, V291, pE995, DOI 10.1152/ajpendo.00654.2005
   Dimova E, 2008, THROMB HAEMOSTASIS, V100, P992, DOI 10.1160/TH08 07 0490
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   Erem C, 2009, J ENDOCRINOL INVEST, V32, P169, DOI 10.1007/BF03345709
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Hasselgren PO, 2010, CURR OPIN CLIN NUTR, V13, P423, DOI 10.1097/MCO.0b013e32833a5107
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Herrmann M, 2009, STEROIDS, V74, P245, DOI 10.1016/j.steroids.2008.11.009
   Hoekstra T, 2004, THROMB HAEMOSTASIS, V91, P861, DOI 10.1160/TH03 08 0546
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Kaji Hiroshi, 2014, [Journal of Bone Metabolism, 대한골대사학회지], V21, P29
   Kaji H, 2013, CURR OPIN CLIN NUTR, V16, P272, DOI 10.1097/MCO.0b013e32835fe6a5
   Karasik D, 2008, ANN HUM GENET, V72, P696, DOI 10.1111/j.1469 1809.2008.00447.x
   Kawao N, 2013, J BONE MINER RES, V28, P1561, DOI 10.1002/jbmr.1921
   Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Koh TJ, 2005, AM J PHYSIOL CELL PH, V289, pC217, DOI 10.1152/ajpcell.00555.2004
   KONKLE BA, 1992, BLOOD, V79, P2636
   Krause MP, 2011, DIABETES, V60, P1964, DOI 10.2337/db11 0007
   Kuo T, 2013, MOL CELL ENDOCRINOL, V380, P79, DOI 10.1016/j.mce.2013.03.003
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   López Alemany R, 2003, EUR J BIOCHEM, V270, P814, DOI 10.1046/j.1432 1033.2003.03453.x
   Ma LJ, 2004, DIABETES, V53, P336, DOI 10.2337/diabetes.53.2.336
   Mathieu P, 2010, CLIN PHARMACOL THER, V87, P407, DOI 10.1038/clpt.2009.311
   Miao HM, 2012, INFLAMM RES, V61, P349, DOI 10.1007/s00011 011 0417 3
   Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521 2532.2001
   Morange PE, 2000, ARTERIOSCL THROM VAS, V20, P1150, DOI 10.1161/01.ATV.20.4.1150
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Naderi J, 2009, AM J PATHOL, V175, P763, DOI 10.2353/ajpath.2009.081009
   Oishi K, 2007, THROMB HAEMOSTASIS, V98, P864, DOI 10.1160/TH07 04 0268
   Pan Y, 2013, MOL CELL ENDOCRINOL, V367, P116, DOI 10.1016/j.mce.2012.12.027
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Schakman O, 2009, HORM RES, V72, P36, DOI 10.1159/000229762
   Seki T, 2001, J CELL PHYSIOL, V189, P72, DOI 10.1002/jcp.1140
   Siegel C, 2010, J NEUROSCI RES, V88, P2765, DOI 10.1002/jnr.22406
   Strehl C, 2013, MOL CELL ENDOCRINOL, V380, P32, DOI 10.1016/j.mce.2013.01.026
   Tamura Y, 2008, ARTERIOSCL THROM VAS, V28, P2195, DOI 10.1161/ATVBAHA.108.168633
   Tamura Y, 2014, ENDOCRINOLOGY, V155, P1708, DOI 10.1210/en.2013 1888
   Tamura Y, 2013, DIABETES, V62, P3170, DOI 10.2337/db12 1552
   Tanaka K, 2012, J BIOL CHEM, V287, P11616, DOI 10.1074/jbc.M111.292193
   van Raalte DH, 2009, EUR J CLIN INVEST, V39, P81, DOI 10.1111/j.1365 2362.2008.02067.x
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Yuen KCJ, 2013, DIABETIC MED, V30, P651, DOI 10.1111/dme.12184
   Zhang ZF, 2010, PHYTOMEDICINE, V17, P14, DOI 10.1016/j.phymed.2009.09.007
NR 50
TC 55
Z9 60
U1 1
U2 17
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311 1717 USA
SN 0012 1797
EI 1939 327X
J9 DIABETES
JI Diabetes
PD JUN
PY 2015
VL 64
IS 6
BP 2194
EP 2206
DI 10.2337/db14 1192
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CJ3GH
UT WOS:000355370900033
PM 25552599
OA Bronze
DA 2025 08 17
ER

PT J
AU Shimoda, K
   Mitsuoka, T
   Ueda, K
   Suemune, H
   Hirai, G
   Aso, M
AF Shimoda, Kazuma
   Mitsuoka, Takahiro
   Ueda, Kenta
   Suemune, Hiroshi
   Hirai, Go
   Aso, Mariko
TI Synthesis of dendritic bisphosphonates as bone targeting ligands
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Bisphosphonate; Bone targeting; Conjugate; Multivalent interaction
ID PROTEINS; AGENTS; ACID); DRUG
AB A dendritic bisphosphonate carrying three bisphosphonate (BP) units in close proximity was designed as a ligand to conjugate large therapeutic molecules for their bone selective delivery. The Bu3P catalyzed conjugate addition of nitromethane to vinylidene bisphosphonate was effective to construct a quaternary carbon center carrying BP units. Owing to multivalent interactions, the dendritic bisphosphonate showed considerable affinity for the bone mineral hydroxyapatite even in the presence of a competitor, demonstrating potential as a bone targeting ligand. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shimoda, Kazuma; Mitsuoka, Takahiro; Ueda, Kenta] Kyushu Univ, Fac Pharmaceut Sci, Higashi Ku, 3 1 1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
   [Suemune, Hiroshi; Hirai, Go; Aso, Mariko] Kyushu Univ, Grad Sch Pharmaceut Sci, Higashi Ku, 3 1 1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University
RP Aso, M (通讯作者)，Kyushu Univ, Grad Sch Pharmaceut Sci, Higashi Ku, 3 1 1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
EM aso@phar.kyushu u.ac.jp
RI Hirai, Go/M 3752 2019
OI Hirai, Go/0000 0003 3420 555X
FU Japan Osteoporosis Foundation (JOF)
FX Funding from Japan Osteoporosis Foundation (JOF) is gratefully
   acknowledged.
CR Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Chaleix V, 2007, TETRAHEDRON LETT, V48, P703, DOI 10.1016/j.tetlet.2006.11.094
   Chen HY, 2012, BIOCONJUGATE CHEM, V23, P1915, DOI 10.1021/bc3003088
   DEGENHARDT CR, 1986, J ORG CHEM, V51, P3488, DOI 10.1021/jo00368a017
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Kiessling LL, 2006, ANGEW CHEM INT EDIT, V45, P2348, DOI 10.1002/anie.200502794
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Nakatake H, 2011, CHEM PHARM BULL, V59, P710, DOI 10.1248/cpb.59.710
   NEWKOME GR, 1991, J ORG CHEM, V56, P7162, DOI 10.1021/jo00025a038
   Panahifar A, 2013, ACS APPL MATER INTER, V5, P5219, DOI 10.1021/am4010495
   Ruffoni A, 2012, TETRAHEDRON, V68, P1951, DOI 10.1016/j.tet.2011.12.052
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P1115, DOI 10.1021/bp000066y
   Winckler W, 1996, PHOSPHORUS SULFUR, V112, P137, DOI 10.1080/10426509608046357
   Xu DZ, 2014, TETRAHEDRON, V70, P176, DOI 10.1016/j.tet.2013.11.103
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 19
TC 2
Z9 2
U1 0
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040 4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD DEC 19
PY 2018
VL 59
IS 51
BP 4528
EP 4531
DI 10.1016/j.tetlet.2018.11.028
PG 4
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA HE6EJ
UT WOS:000453495800020
DA 2025 08 17
ER

PT J
AU Kondegowda, NG
   Filipowska, J
   Do, JS
   Leon Rivera, N
   Li, R
   Hampton, R
   Ogyaadu, S
   Levister, C
   Penninger, JM
   Reijonen, H
   Levy, CJ
   Vasavada, RC
AF Kondegowda, Nagesha Guthalu
   Filipowska, Joanna
   Do, Jeong su
   Leon Rivera, Nancy
   Li, Rosemary
   Hampton, Rollie
   Ogyaadu, Selassie
   Levister, Camilla
   Penninger, Josef M.
   Reijonen, Helena
   Levy, Carol J.
   Vasavada, Rupangi C.
TI RANKL/RANK is required for cytokine induced beta cell death;
   osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes
SO SCIENCE ADVANCES
LA English
DT Article
ID KAPPA B LIGAND; HUMAN PANCREATIC ISLETS; RECEPTOR ACTIVATOR;
   BONE RESORPTION; APOPTOSIS; EXPRESSION; PROLIFERATION; DENOSUMAB;
   CHILDREN; MELLITUS
AB Treatment for type 1 diabetes (T1D) requires stimulation of functional beta cell regeneration and survival under stress. Previously, we showed that inhibition of the RANKL/RANK [receptor activator of nuclear factor kappa beta (NF kappa B) ligand] pathway, by osteoprotegerin and the anti osteoporotic drug denosumab, induces rodent and human beta cell proliferation. We demonstrate that the RANK pathway mediates cytokine induced rodent and human beta cell death through RANK TRAF6 interaction and induction of NF kappa B activation. Osteoprotegerin and denosumab protected beta cells against this cytotoxicity. In human immune cells, osteoprotegerin and denosumab reduce proinflammatory cytokines in activated T cells by inhibiting RANKL induced activation of monocytes. In vivo, osteoprotegerin reversed recent onset T1D in nonobese diabetic/Ltj mice, reduced insulitis, improved glucose homeostasis, and increased plasma insulin, beta cell proliferation, and mass in these mice. Serum from T1D subjects induced human beta cell death and dysfunction, but not alpha cell death. Osteoprotegerin and denosumab reduced T1D serum induced beta cell cytotoxicity and dysfunction. Inhibiting RANKL/RANK could have therapeutic potential.
C1 [Kondegowda, Nagesha Guthalu; Filipowska, Joanna; Leon Rivera, Nancy; Vasavada, Rupangi C.] City Hope Natl Med Ctr, Arthur Riggs Diabet & Metab Res Inst, Dept Translat Res & Cellular Therapeut, Duarte, CA 91010 USA.
   [Kondegowda, Nagesha Guthalu; Filipowska, Joanna; Li, Rosemary; Hampton, Rollie; Ogyaadu, Selassie; Levister, Camilla; Levy, Carol J.; Vasavada, Rupangi C.] Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA.
   [Do, Jeong su; Reijonen, Helena] City Hope Natl Med Ctr, Arthur Riggs Diabet & Metab Res Inst, Dept Immunol & Theranost, Duarte, CA 91010 USA.
   [Ogyaadu, Selassie; Levister, Camilla; Levy, Carol J.] Icahn Sch Med Mt Sinai, Div Endocrinol & Bone Dis, New York, NY 10029 USA.
   [Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A 1030 Vienna, Austria.
   [Penninger, Josef M.] Univ British Columbia, Life Sci Inst, Dept Med Genet, Vancouver, BC, Canada.
   [Vasavada, Rupangi C.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA.
C3 City of Hope; Icahn School of Medicine at Mount Sinai; City of Hope;
   Icahn School of Medicine at Mount Sinai; Austrian Academy of Sciences;
   Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA);
   University of British Columbia; Icahn School of Medicine at Mount Sinai
RP Vasavada, RC (通讯作者)，City Hope Natl Med Ctr, Arthur Riggs Diabet & Metab Res Inst, Dept Translat Res & Cellular Therapeut, Duarte, CA 91010 USA.; Vasavada, RC (通讯作者)，Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA.; Vasavada, RC (通讯作者)，Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA.
EM rvasavada@coh.org
RI su, Jeong/G 9483 2014; Penninger, Josef/I 6860 2013
OI Penninger, Josef/0000 0002 8194 3777; Hampton,
   Rollie/0000 0003 3285 6957; Li, Rosemary/0000 0002 2605 634X;
   Leon Rivera, Nancy/0000 0003 0231 492X; Guthalu Kondegowda,
   Nagesha/0000 0003 1738 6176; Do, Jeong su/0000 0002 2375 2585
FU National Institutes of Health [R01DK102893, R01DK125856]; Juvenile
   Diabetes Research Foundation (JDRF) [17 2012 37]; Wanek Family
   Foundation; JDRF Postdoctoral Award [3 PDF 2020 936 A N]; Canada 150
   grant in functional genomics; T. von Zastrow Foundation; Margie and
   Robert E. Petersen Foundation
FX This work was supported by National Institutes of Health grants
   R01DK102893 and R01DK125856 (R.C.V. and N.G.K.); Juvenile Diabetes
   Research Foundation (JDRF) grant 17 2012 37 (R.C.V.); Wanek Family
   Foundation to Cure Type 1 Diabetes Innovative Grant (R.C.V. and H.R.);
   an anonymous SS donor (R.C.V.); JDRF Postdoctoral Award
   3 PDF 2020 936 A N (J.F.); Canada 150 grant in functional genomics
   (J.M.P.); the T. von Zastrow Foundation (J.M.P.); and the Margie and
   Robert E. Petersen Foundation (H.R.).
CR Alankus B, 2021, J EXP MED, V218, DOI 10.1084/jem.20200517
   Alnek K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142976
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Atkinson MA, 2019, LANCET DIABETES ENDO, V7, P52, DOI 10.1016/S2213 8587(18)30112 8
   Atkinson MA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002757
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Bharti AC, 2004, APOPTOSIS, V9, P677, DOI 10.1023/B:APPT.0000045780.10463.c6
   Bishop RT, 2020, CANCER LETT, V488, P27, DOI 10.1016/j.canlet.2020.05.021
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Bradshaw EM, 2009, J IMMUNOL, V183, P4432, DOI 10.4049/jimmunol.0900576
   Bru Tari E, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45853 1
   Cabrera O, 2006, P NATL ACAD SCI USA, V103, P2334, DOI 10.1073/pnas.0510790103
   Capparelli C, 2003, J BONE MINER RES, V18, P852, DOI 10.1359/jbmr.2003.18.5.852
   Caraher EM, 1997, BIOCHEM SOC T, V25, pS319, DOI 10.1042/bst025319s
   Chaparro RJ, 2010, EXPERT REV CLIN IMMU, V6, P939, DOI [10.1586/eci.10.68, 10.1586/ECI.10.68]
   Chen YG, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00051
   Chrysis D, 2017, PEDIATR DIABETES, V18, P277, DOI 10.1111/pedi.12384
   Cnop M., 2005, DIABETES, V54, pS97, DOI [10.2337/diabetes.54.suppl_2.s97, DOI 10.2337/DIABETES.54.SUPPL_2.S97]
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Dogan Y, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/59206
   Duan CC, 2021, IMMUNOL INVEST, V50, P101, DOI 10.1080/08820139.2019.1710531
   Erbagci AB, 2001, CLIN BIOCHEM, V34, P645, DOI 10.1016/S0009 9120(01)00275 2
   Eschler DC, 2018, BIORESEARCH OPEN ACC, V7, P123, DOI 10.1089/biores.2018.0013
   Fasolino M, 2022, NAT METAB, V4, P284, DOI 10.1038/s42255 022 00531 x
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   Glasnovc A, 2018, NEUROIMMUNOMODULAT, V25, P23, DOI 10.1159/000488988
   Guerrini MM, 2015, IMMUNITY, V43, P1174, DOI 10.1016/j.immuni.2015.10.017
   Hanada R, 2010, BIOL CHEM, V391, P1365, DOI 10.1515/BC.2010.149
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Huang BB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.563509
   JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306
   Kang S, 2010, ENDOCRINOLOGY, V151, P5638, DOI 10.1210/en.2009 0478
   Karalazou P, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052 019 0748 1
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kondegowda NG, 2012, DIABETOLOGIA, V55, P1721, DOI 10.1007/s00125 012 2501 9
   Kondegowda NG, 2015, CELL METAB, V22, P77, DOI 10.1016/j.cmet.2015.05.021
   Kondegowda NG, 2010, DIABETES, V59, P3131, DOI 10.2337/db09 1796
   Kutlu B, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755 8794 2 3
   Li RS, 2020, DIABETES, V69, P1463, DOI 10.2337/db19 0909
   Lleo A, 2021, EXPERT REV CLIN IMMU, V17, P933, DOI 10.1080/1744666X.2021.1971972
   Lo B, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 203
   Lou XY, 2022, DIABET METAB SYND OB, V15, P3831, DOI 10.2147/DMSO.S390483
   Loureiro MB, 2014, DIABETES RES CLIN PR, V103, P452, DOI 10.1016/j.diabres.2013.12.018
   Lu JL, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1122
   Luo G, 2018, MOL MED REP, V17, P6605, DOI 10.3892/mmr.2018.8698
   Marahleh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02925
   McGee Lawrence ME, 2018, J CELL PHYSIOL, V233, P2671, DOI 10.1002/jcp.26148
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Mozar A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158414
   Müller I, 2003, CANCER RES, V63, P1772
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Ominsky MS, 2009, J BONE MINER RES, V24, P1234, DOI [10.1359/JBMR.090215, 10.1359/jbmr.090215]
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Ortis F, 2006, MOL ENDOCRINOL, V20, P1867, DOI 10.1210/me.2005 0268
   Osako MK, 2012, CIRCULATION, V126
   Pan XF, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.690082
   Papadaki M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00097
   Pineros AR, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.111011
   Plesner A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102843
   Powers AC, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI142242
   Pritzker LB, 2004, MOL BIOL CELL, V15, P2834, DOI 10.1091/mbc.E04 01 0059
   Roep BO, 2021, NAT REV ENDOCRINOL, V17, P150, DOI 10.1038/s41574 020 00443 4
   Rutti S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28117 2
   Sacaan AI, 2017, MOL CANCER RES, V15, P1531, DOI 10.1158/1541 7786.MCR 17 0172
   Sayama K, 2005, DIABETOLOGIA, V48, P1560, DOI 10.1007/s00125 005 1829 9
   Schaum N, 2018, NATURE, V562, P367, DOI 10.1038/s41586 018 0590 4
   Schrader J, 2007, DIABETOLOGIA, V50, P1243, DOI 10.1007/s00125 007 0672 6
   Shah VN, 2018, CURR OPIN ENDOCRINOL, V25, P231, DOI 10.1097/MED.0000000000000421
   Shoda LKM, 2005, IMMUNITY, V23, P115, DOI 10.1016/j.immuni.2005.08.002
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Sosenko JM, 2013, DIABETES, V62, P4179, DOI 10.2337/db13 0656
   Stolina M, 2007, J IMMUNOL, V179, P7497, DOI 10.4049/jimmunol.179.11.7497
   Sun L, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/4106518
   Szymanska Malgorzata, 2020, Pediatr Endocrinol Diabetes Metab, V26, P10, DOI 10.5114/pedm.2020.94391
   Tang S, 2019, INT J CLIN EXP PATHO, V12, P2324
   Tsentidis C, 2016, OSTEOPOROSIS INT, V27, P1631, DOI 10.1007/s00198 015 3422 5
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200
   von dem Knesebeck A, 2012, NEOPLASIA, V14, P526, DOI 10.1596/neo.12360
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Warshauer JT, 2020, CELL METAB, V31, P46, DOI 10.1016/j.cmet.2019.11.017
   Williams K, 2011, DIABETOLOGIA, V54, P2867, DOI 10.1007/s00125 011 2260 z
   Wu DJ, 2016, J AUTOIMMUN, V73, P73, DOI 10.1016/j.jaut.2016.06.004
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zou W, 2005, J CELL PHYSIOL, V202, P371, DOI 10.1002/jcp.20127
NR 92
TC 11
Z9 12
U1 0
U2 20
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD NOV 3
PY 2023
VL 9
IS 44
AR eadf5238
DI 10.1126/sciadv.adf5238
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA X2FT9
UT WOS:001096672100005
PM 37910614
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Brennan Speranza, TC
   Henneicke, H
   Gasparini, SJ
   Blankenstein, KI
   Heinevetter, U
   Cogger, VC
   Svistounov, D
   Zhang, YQ
   Cooney, GJ
   Buttgereit, F
   Dunstan, CR
   Gundberg, C
   Zhou, H
   Seibel, MJ
AF Brennan Speranza, Tara C.
   Henneicke, Holger
   Gasparini, Sylvia J.
   Blankenstein, Katharina I.
   Heinevetter, Uta
   Cogger, Victoria C.
   Svistounov, Dmitri
   Zhang, Yaqing
   Cooney, Gregory J.
   Buttgereit, Frank
   Dunstan, Colin R.
   Gundberg, Caren
   Zhou, Hong
   Seibel, Markus J.
TI Osteoblasts mediate the adverse effects of glucocorticoids on fuel
   metabolism
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; DEPENDENT CARBOXYLASE
   ACTIVITY; MATRIX GLA PROTEIN; GLUCOSE METABOLISM; INSULIN RESISTANCE;
   BONE FORMATION; BETA CELL; OSTEOCALCIN; EXPRESSION; DEXAMETHASONE
AB Long term glucocorticoid treatment is associated with numerous adverse outcomes, including weight gain, insulin resistance, and diabetes; however, the pathogenesis of these side effects remains obscure. Glucocorticoids also suppress osteoblast function, including osteocalcin synthesis. Osteocalcin is an osteoblast specific peptide that is reported to be involved in normal murine fuel metabolism. We now demonstrate that osteoblasts play a pivotal role in the pathogenesis of glucocorticoid induced dysmetabolism. Osteoblast targeted disruption of glucocorticoid signaling significantly attenuated the suppression of osteocalcin synthesis and prevented the development of insulin resistance, glucose intolerance, and abnormal weight gain in corticosterone treated mice. Nearly identical effects were observed in glucocorticoid treated animals following heterotopic (hepatic) expression of both carboxylated and uncarboxylated osteocalcin through gene therapy, which additionally led to a reduction in hepatic lipid deposition and improved phosphorylation of the insulin receptor. These data suggest that the effects of exogenous high dose glucocorticoids on insulin target tissues and systemic energy metabolism are mediated, at least in part, through the skeleton.
C1 [Brennan Speranza, Tara C.; Henneicke, Holger; Gasparini, Sylvia J.; Blankenstein, Katharina I.; Heinevetter, Uta; Zhang, Yaqing; Dunstan, Colin R.; Zhou, Hong; Seibel, Markus J.] Univ Sydney, ANZAC Res Inst, Bone Res Program, Sydney, NSW 2006, Australia.
   [Henneicke, Holger; Blankenstein, Katharina I.; Heinevetter, Uta; Buttgereit, Frank] Charite, Dept Rheumatol & Clin Immunol, D 13353 Berlin, Germany.
   [Henneicke, Holger; Blankenstein, Katharina I.; Heinevetter, Uta; Buttgereit, Frank] Deutsch Rheumaforschungszentrum, Berlin, Germany.
   [Heinevetter, Uta; Buttgereit, Frank] Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany.
   [Cogger, Victoria C.; Svistounov, Dmitri] Univ Sydney, Ctr Educ & Res Ageing, Sydney, NSW 2006, Australia.
   [Cogger, Victoria C.; Svistounov, Dmitri] Univ Sydney, Sydney Med Sch, ANZAC Res Inst, Sydney, NSW 2006, Australia.
   [Cogger, Victoria C.; Svistounov, Dmitri] Concord Repatriat Gen Hosp, Sydney, NSW, Australia.
   [Cooney, Gregory J.] Garvan Inst Med Res, Diabet & Obes Program, Sydney, NSW, Australia.
   [Dunstan, Colin R.] Univ Sydney, Fac Engn, Sydney, NSW 2006, Australia.
   [Gundberg, Caren] Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT USA.
   [Seibel, Markus J.] Univ Sydney, Concord Hosp, Dept Endocrinol & Metab, Sydney, NSW 2006, Australia.
C3 University of Sydney; ANZAC Research Institute; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Leibniz Association; Deutsches Rheuma Forschungszentrum (DRFZ);
   University of Sydney; University of Sydney; ANZAC Research Institute;
   Concord Repatriation General Hospital; Garvan Institute of Medical
   Research; University of Sydney; Yale University; Concord Repatriation
   General Hospital; University of Sydney
RP Brennan Speranza, TC (通讯作者)，Concord Repatriat Gen Hosp, ANZAC Res Inst, Bone Res Program, Concord Hosp, Hosp Rd, Sydney, NSW 2139, Australia.
EM tara@anzac.edu.au; markus.seibel@sydney.edu.au
RI ; Henneicke, Holger/H 3383 2016; Dunstan, Colin/G 6214 2013
OI Buttgereit, Frank/0000 0003 2534 550X; Zhou, Hong/0000 0001 5899 9660;
   Dunstan, Colin/0000 0001 7586 4071; Speranza, Tara/0000 0001 5472 4969;
   Seibel, Markus J/0000 0002 2701 378X; Henneicke,
   Holger/0000 0003 1746 9369; Gasparini, Sylvia/0000 0002 3612 6428
FU NHMRC [402462, 632819]; NHMRC Early Career Training Fellowship; Yale
   Diabetes Endocrinology Research Center [DK04735]; Yale Core Center for
   Musculoskeletal Diseases [AR46032]; Bundesministerium fur Bildung und
   Forschung (BMBF); State of Berlin, BCRT; DFG [Bu 1015/9 1,
   SPP1468 Immunobone]
FX We are grateful to Janine Street and Markus Herrmann for their technical
   assistance with animal tissue collection and Elysia Neist for cloning
   procedures. We thank Barbara Kream for providing the Col2.3 11bHSD2 mice
   and William Philbrick for making the osteocalcin (wtOCN) and mutant
   osteocalcin (mu OCN) constructs. We would also like to thank Sonia
   Bustamante and the Bioanalytical Mass Spectrometry Facility at the
   University of New South Wales for mass spectrometry readings of serum
   corticosterone levels. Support was provided by project grants from the
   NHMRC (402462 and 632819), and T.C. Brennan Speranza is the recipient of
   an NHMRC Early Career Training Fellowship. In addition, support was
   provided for C. Gundberg by the following NIH grants: Yale Diabetes
   Endocrinology Research Center DK04735 and Yale Core Center for
   Musculoskeletal Diseases AR46032. This work was further supported in
   part by the Bundesministerium fur Bildung und Forschung (BMBF) and the
   State of Berlin, BCRT Grant I and II to U. Heinevetter and F.
   Buttgereit, and the DFG (Bu 1015/9 1; SPP1468 Immunobone).
CR Anagnostis P, 2009, J CLIN ENDOCR METAB, V94, P2692, DOI 10.1210/jc.2009 0370
   Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736
   Baudrand R, 2011, STEROIDS, V76, P1575, DOI 10.1016/j.steroids.2011.09.010
   Besse C, 2005, OBES RES, V13, P306, DOI 10.1038/oby.2005.41
   Brandon AE, 2011, ARCH BIOCHEM BIOPHYS, V509, P133, DOI 10.1016/j.abb.2011.03.008
   Bujalska IJ, 2006, J MOL ENDOCRINOL, V37, P327, DOI 10.1677/jme.1.02048
   Buttgereit F, 2008, LANCET, V371, P205, DOI 10.1016/S0140 6736(08)60132 4
   Calvo MS, 1996, ENDOCR REV, V17, P333, DOI 10.1210/er.17.4.333
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Chinetti Gbaguidi G, 2012, ARTERIOSCL THROM VAS, V32, P677, DOI 10.1161/ATVBAHA.111.241364
   Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200
   de Oliveira C, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476 511X 10 11
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Ferron M, 2012, BONE, V50, P568, DOI 10.1016/j.bone.2011.04.017
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fukushima A, 2010, DIABETES, V59, P1906, DOI 10.2337/db09 1365
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Gathercole LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026223
   Gilbert KA, 2003, AM J PHYSIOL LUNG C, V285, pL569, DOI 10.1152/ajplung.00426.2002
   Gounarides JS, 2008, ENDOCRINOLOGY, V149, P758, DOI 10.1210/en.2007 1214
   Gundberg CM, 2003, OSTEOPOROSIS INT, V14, pS37, DOI 10.1007/s00198 003 1471 7
   Gundberg CM, 1998, J CLIN ENDOCR METAB, V83, P3258, DOI 10.1210/jc.83.9.3258
   Haas JT, 2012, CELL METAB, V15, P873, DOI 10.1016/j.cmet.2012.05.002
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   Henneicke H, 2011, BONE, V49, P733, DOI 10.1016/j.bone.2011.06.013
   Herrmann M, 2009, STEROIDS, V74, P245, DOI 10.1016/j.steroids.2008.11.009
   Hibbitt OC, 2007, J GENE MED, V9, P488, DOI 10.1002/jgm.1041
   Hozuki T, 2010, INTERNAL MED, V49, P371, DOI 10.2169/internalmedicine.49.2551
   HUBBARD BR, 1989, J BIOL CHEM, V264, P14145
   Hult M, 2009, MOL CELL ENDOCRINOL, V301, P109, DOI 10.1016/j.mce.2008.09.038
   INGRAM RT, 1994, J CLIN INVEST, V93, P989, DOI 10.1172/JCI117106
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kanazawa I, 2011, BONE, V48, P720, DOI 10.1016/j.bone.2010.12.020
   Kassi E, 2011, CANCER LETT, V302, P1, DOI 10.1016/j.canlet.2010.10.020
   LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo 123 5 2390
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Macfarlane DP, 2008, J ENDOCRINOL, V197, P189, DOI 10.1677/JOE 08 0054
   Marinlarena AM, 2011, ENDOCR REV, V32, pP2
   Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Oosterwerff MM, 2013, CLIN ENDOCRINOL, V78, P242, DOI 10.1111/j.1365 2265.2012.04391.x
   PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   REID IR, 1986, J CLIN ENDOCR METAB, V62, P379, DOI 10.1210/jcem 62 2 379
   SAMBROOK P, 1990, J BONE MINER RES, V5, P1211
   Schakman O, 2008, J ENDOCRINOL, V197, P1, DOI 10.1677/JOE 07 0606
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Simanainen U, 2011, PROSTATE, V71, P289, DOI 10.1002/pros.21242
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   STRACK AM, 1995, AM J PHYSIOL REG I, V268, pR142, DOI 10.1152/ajpregu.1995.268.1.R142
   Tiganis T, 2013, FEBS J, V280, P445, DOI 10.1111/j.1742 4658.2012.08563.x
   Tomlinson JJ, 2006, ENDOCRINOLOGY, V147, P5284, DOI 10.1210/en.2006 0267
   WALLIN R, 1991, PEDIATR RES, V30, P281, DOI 10.1203/00006450 199109000 00017
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Yeap BB, 2010, EUR J ENDOCRINOL, V163, P265, DOI 10.1530/EJE 10 0414
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
NR 58
TC 154
Z9 164
U1 0
U2 19
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 2012
VL 122
IS 11
BP 4172
EP 4189
DI 10.1172/JCI63377
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 031WP
UT WOS:000310673600043
PM 23093779
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Diaz Hernandez, ME
   Murakami, K
   Murata, S
   Khan, NM
   Shenoy, SPV
   Henke, K
   Yamada, H
   Drissi, H
AF Diaz Hernandez, Martha E.
   Murakami, Kimihide
   Murata, Shizumasa
   Khan, Nazir M.
   Shenoy, Sreekala P. V.
   Henke, Katrin
   Yamada, Hiroshi
   Drissi, Hicham
TI Inhibition of KDM2/7 Promotes Notochordal Differentiation of hiPSCs
SO CELLS
LA English
DT Article
DE human iPSC; notochordal cells; intervertebral disc degeneration;
   epigenetics; bulk RNA transcriptomics; differentiation; KDM
ID STEM CELLS; DEMETHYLASES; PHYSIOLOGY; NETWORKS; DISEASE; ROLES; GENE
AB Intervertebral disc disease (IDD) is a debilitating spine condition that can be caused by intervertebral disc (IVD) damage which progresses towards IVD degeneration and dysfunction. Recently, human pluripotent stem cells (hPSCs) were recognized as a valuable resource for cell based regenerative medicine in skeletal diseases. Therefore, adult somatic cells reprogrammed into human induced pluripotent stem cells (hiPSCs) represent an attractive cell source for the derivation of notochordal like cells (NCs) as a first step towards the development of a regenerative therapy for IDD. Utilizing a differentiation method involving treatment with a four factor cocktail targeting the BMP, FGF, retinoic acid, and Wnt signaling pathways, we differentiate CRISPR/Cas9 generated mCherry reporter knock in hiPSCs into notochordal like cells. Comprehensive analysis of transcriptomic changes throughout the differentiation process identified regulation of histone methylation as a pivotal driver facilitating the differentiation of hiPSCs into notochordal like cells. We further provide evidence that specific inhibition of histone demethylases KDM2A and KDM7A/B enhanced the lineage commitment of hiPSCs towards notochordal like cells. Our results suggest that inhibition of KDMs could be leveraged to alter the epigenetic landscape of hiPSCs to control notochord specific gene expression. Thus, our study highlights the importance of epigenetic regulators in stem cell based regenerative approaches for the treatment of disc degeneration.
C1 [Diaz Hernandez, Martha E.; Murakami, Kimihide; Murata, Shizumasa; Khan, Nazir M.; Shenoy, Sreekala P. V.; Henke, Katrin; Drissi, Hicham] Emory Univ, Dept Orthopaed, Atlanta, GA 30329 USA.
   [Diaz Hernandez, Martha E.; Drissi, Hicham] Atlanta VA Med Ctr, Decatur, GA 30033 USA.
   [Murakami, Kimihide; Murata, Shizumasa; Yamada, Hiroshi] Wakayama Med Univ, Dept Orthopaed Surg, Wakayama 6418510, Japan.
C3 Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Atlanta VA Medical Center; Atlanta VA Health Care
   System; Wakayama Medical University
RP Drissi, H (通讯作者)，Emory Univ, Dept Orthopaed, Atlanta, GA 30329 USA.; Drissi, H (通讯作者)，Atlanta VA Med Ctr, Decatur, GA 30033 USA.
EM martha.elena.diaz.hernandez@emory.edu; km042087@wakayama med.ac.jp;
   shizuman@wakayama med.ac.jp; mohd.n.khan@emory.edu;
   sshenoy@wakehealth.edu; yamacha@wakayama med.ac.jp;
   hicham.drissi@emory.edu
RI ; Khan, Nazir/D 1514 2019; Diaz Hernandez, Martha Elena/LMQ 0323 2024;
   Henke, Katrin/W 5033 2019
OI Henke, Katrin/0000 0002 1282 3616; Yamada, Hiroshi/0000 0002 7694 883X;
   Diaz Hernandez, Martha Elena/0000 0003 0225 981X; 
FU Department of Orthopaedics, Emory University School of Medicine
FX This research was supported by funding through the Department of
   Orthopaedics, Emory University School of Medicine.
CR Alvarez Errico D, 2015, NAT REV IMMUNOL, V15, P7, DOI 10.1038/nri3777
   Ben Abdelkhalek H, 2004, GENE DEV, V18, P1725, DOI 10.1101/gad.303504
   Boland MJ, 2014, CIRC RES, V115, P311, DOI 10.1161/CIRCRESAHA.115.301517
   Chan SCW, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13598
   Davis K, 2021, J MOL CELL CARDIOL, V158, P89, DOI 10.1016/j.yjmcc.2021.05.018
   Deng P, 2015, INT J ORAL SCI, V7, P197, DOI 10.1038/ijos.2015.41
   Diaz Hernandez ME, 2020, J CELL PHYSIOL, V235, P5241, DOI 10.1002/jcp.29411
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Gökbuget D, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.164772
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hsiao EC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002532
   Huang B, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0018 0
   Keller A, 2018, HUM REPROD UPDATE, V24, P162, DOI 10.1093/humupd/dmx042
   Khan NM, 2017, CHEM BIOL INTERACT, V274, P13, DOI 10.1016/j.cbi.2017.06.025
   Kyu HH, 2018, LANCET, V392, P1859, DOI 10.1016/S0140 6736(18)32335 3
   Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010
   Leung VYL, 2006, EUR SPINE J, V15, pS406, DOI 10.1007/s00586 006 0183 z
   Liu ZQ, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00171 z
   Liu Z, 2015, J MOL CELL BIOL, V7, P505, DOI 10.1093/jmcb/mjv022
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Purcell DJ, 2012, J CELL BIOCHEM, V113, P2406, DOI 10.1002/jcb.24114
   R Core Team R, A Language and Environment for Statistical Computing
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ruiz AR, 2021, CELL TISSUE RES, V386, P309, DOI 10.1007/s00441 021 03498 5
   Sakai D, 2008, EUR SPINE J, V17, pS452, DOI 10.1007/s00586 008 0743 5
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Stein GS, 2010, CRIT REV EUKAR GENE, V20, P149, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.50
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Ukita K, 2009, MECH DEVELOP, V126, P791, DOI 10.1016/j.mod.2009.08.003
   Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238
   Wu LT, 2015, STEM CELL REP, V5, P10, DOI 10.1016/j.stemcr.2015.05.016
   Yang XY, 2019, J CELL MOL MED, V23, P2149, DOI 10.1111/jcmm.14126
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Zhang YL, 2020, CELL REP, V30, P2791, DOI 10.1016/j.celrep.2020.01.100
NR 34
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD SEP
PY 2024
VL 13
IS 17
AR 1482
DI 10.3390/cells13171482
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA F6S1M
UT WOS:001311086800001
PM 39273051
OA gold
DA 2025 08 17
ER

PT J
AU Deng, P
   Zhou, CC
   Alvarez, R
   Hong, C
   Wang, CY
AF Deng, Peng
   Zhou, Chenchen
   Alvarez, Ruth
   Hong, Christine
   Wang, Cun Yu
TI Inhibition of IKK/NF κB Signaling Enhances Differentiation of
   Mesenchymal Stromal Cells from Human Embryonic Stem Cells
SO STEM CELL REPORTS
LA English
DT Article
ID BONE MARROW; PLURIPOTENCY; DERIVATION
AB Embryonic stem cell derived mesenchymal stromal cells (MSCs; also known as mesenchymal stem cells) represent a promising source for bone regenerative medicine. Despite remarkable advances in stem cell biology, the molecular mechanism regulating differentiation of human embryonic stem cells (hESCs) into MSCs remains poorly understood. Here, we report that inhibition of I kappa B kinase (IKK)/nuclear factor kappa B (NF kappa B) signaling enhances differentiation of hESCs into MSCs by expediting the loss of pluripotent markers and increasing the expression of MSC surface markers. In addition, a significantly higher quantity of MSCs was produced from hESCs with IKK/NF kappa B suppression. These isolated MSCs displayed evident multipotency with capacity to terminally differentiate into osteoblasts, chondrocytes, and adipocytes in vitro and to form bone in vivo. Collectively, our data provide important insights into the role of NF kappa B in mesenchymal lineage specification during hESC differentiation, suggesting that IKK inhibitors could be utilized as an adjuvant in generating MSCs for cell mediated therapies.
C1 [Deng, Peng; Zhou, Chenchen; Alvarez, Ruth; Wang, Cun Yu] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, Los Angeles, CA 90095 USA.
   [Hong, Christine] Univ Calif Los Angeles, Sch Dent, Div Growth & Dev, Sect Orthodont, Los Angeles, CA 90095 USA.
   [Wang, Cun Yu] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Wang, CY (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, Los Angeles, CA 90095 USA.; Hong, C (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Growth & Dev, Sect Orthodont, Los Angeles, CA 90095 USA.; Wang, CY (通讯作者)，Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA 90095 USA.
EM chong@dentistry.ucla.edu; cwang@dentistry.ucla.edu
RI Zhou, Chen/GQA 7454 2022; Wang, Chunlei/F 3593 2012
FU UCLA Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell
   Research Innovation Award; NIH/NIDCR [R01DE016513]; National Cancer
   Institute [P30CA016042] Funding Source: NIH RePORTER
FX This work was supported by the UCLA Eli & Edythe Broad Center of
   Regenerative Medicine and Stem Cell Research Innovation Award and
   NIH/NIDCR grant R01DE016513. We thank Dr. Jinghua Tang for technical
   support on cell culture.
CR Alvarez R, 2015, INT J ORAL SCI, V7, P213, DOI 10.1038/ijos.2015.42
   Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112
   Arpornmaeklong P, 2009, STEM CELLS DEV, V18, P955, DOI 10.1089/scd.2008.0310
   Bakkar N, 2012, J CELL BIOL, V196, P497, DOI 10.1083/jcb.201108118
   Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Choo A, 2011, METHODS MOL BIOL, V690, P175, DOI 10.1007/978 1 60761 962 8_12
   Deng P, 2015, INT J ORAL SCI, V7, P197, DOI 10.1038/ijos.2015.41
   Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015 007 0004 8
   Dutta D, 2011, STEM CELLS, V29, P618, DOI 10.1002/stem.605
   Földes G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010501
   Kang HB, 2007, STEM CELLS DEV, V16, P615, DOI 10.1089/scd.2007.0014
   Karp JM, 2006, STEM CELLS, V24, P835, DOI 10.1634/stemcells.2005 0383
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Li O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055319
   Lüningschrör P, 2012, STEM CELLS, V30, P655, DOI 10.1002/stem.1033
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Ramadoss S, 2011, MOL CELL BIOL, V31, P924, DOI 10.1128/MCB.00576 10
   Stappenbeck TS, 2009, SCIENCE, V324, P1666, DOI 10.1126/science.1172687
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Torres J, 2008, NAT CELL BIOL, V10, P194, DOI 10.1038/ncb1680
   Villa Diaz LG, 2012, STEM CELLS, V30, P1174, DOI 10.1002/stem.1084
   Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 19
   Yang CB, 2010, STEM CELLS, V28, P1970, DOI 10.1002/stem.528
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
NR 31
TC 38
Z9 42
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213 6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD APR 12
PY 2016
VL 6
IS 4
BP 456
EP 465
DI 10.1016/j.stemcr.2016.02.006
PG 10
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DI8ZW
UT WOS:000373792100003
PM 26972683
OA Green Published
DA 2025 08 17
ER

PT J
AU Kaczmarczyk Sedlak, I
   Zych, M
   Rotko, K
   Sedlak, L
AF Kaczmarczyk Sedlak, Ilona
   Zych, Maria
   Rotko, Katarzyna
   Sedlak, Lech
TI Effects of thalidomide on the development of bone damage caused by
   prednisolone in rats
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE bone; glucocorticosteroids; osteoporosis; prednisolone; rat; thalidomide
ID GROWTH HORMONE; CORTICAL BONE; MINERAL DENSITY; SKELETAL SYSTEM;
   DOWN REGULATION; MECHANISM; OSTEOBLASTS; BORTEZOMIB; THERAPY; ANALOGS
AB Background: The methods used in treatment of osteoporosis induced by glucocorticosteroids are not effective enough. There is a need for new drugs which could be useful in counteracting the influence of glucocorticosteroids on osseous tissue. The aim of the present study was to investigate the effects of thalidomide on the development of osteoporosis induced by glucocorticoid (prednisolone) in rats.
   Methods: The experiments were carried out on 3 month old male Wistar rats. The animals were divided into 4 groups: I   control rats; II   prednisolone (10 mg/kg po); III   prednisolone (10 mg/kg po) + thalidomide (15 mg/kg po); IV   prednisolone (10 mg/kg po) + thalidomide (60 mg/kg po). The drugs were administered for 3 weeks. The body mass gain, bone mass in the tibia, femur and L 4 vertebra, histomorphometric parameters of the tibia (width of osteoid, diaphysis transverse growth, area of the transverse cross sectional of the bone marrow cavity and the cortical bone) and the femur (width of trabeculae, width of epiphyseal cartilage, diaphysis transverse growth, area of the transverse cross sectional of the bone marrow cavity and the cortical bone) were studied.
   Results: Prednisolone induced osteoporotic skeletal changes in mature male rats (decreases in the bone mass, the width of the periosteal and endosteal osteoid, the transverse cross sectional area of the cortical bone, the width of trabeculae, and the diaphysis transverse growth were observed). Thalidomide administered at a dose of 15 mg/kg po inhibited the development of changes in macrometric and histomorphometric parameters induced by prednisolone in the skeletal system of rats.
   Conclusion: The results may constitute indirect evidence for possible clinical trials conducted in order to define the possibility to apply thalidomide in treatment of bone diseases in humans.
C1 [Kaczmarczyk Sedlak, Ilona; Zych, Maria; Sedlak, Lech] Med Univ Silesia, Dept Pharmacognosy & Phytochem, PL 41200 Sosnowiec, Poland.
   [Rotko, Katarzyna] Med Univ Silesia, Dept Pharmacol, PL 41200 Sosnowiec, Poland.
C3 Medical University of Silesia; Medical University of Silesia
RP Kaczmarczyk Sedlak, I (通讯作者)，Med Univ Silesia, Dept Pharmacognosy & Phytochem, Jagiellonska 4, PL 41200 Sosnowiec, Poland.
EM farmafit@sum.edu.pl
RI ; Sedlak, Lech/V 5275 2019
OI Zych, Maria/0000 0002 7231 0505; Sedlak, Lech/0000 0001 7763 7753;
   Kaczmarczyk Zebrowska, Ilona/0000 0002 3137 1694; 
FU Medical University of Silesia [KNW 1 012/10]
FX This study was supported by grant No. KNW 1 012/10 from Medical
   University of Silesia.
CR Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   Angeli A, 2000, Ann Ital Med Int, V15, P47
   Benvenuti S, 2000, CLIN EXP RHEUMATOL, V18, pS64
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   Ching DWT, 2003, JCR J CLIN RHEUMATOL, V9, P96, DOI 10.1097/01.RHU.0000062620.10630.21
   De Matteo M, 2010, LEUKEMIA RES, V34, P243, DOI 10.1016/j.leukres.2009.07.017
   Delany AM, 2001, MOL ENDOCRINOL, V15, P1781, DOI 10.1210/me.15.10.1781
   Folwarczna J, 2007, PHARMACOL REP, V59, P349
   FROST HM, 1969, CALC TISS RES, V3, P211, DOI 10.1007/BF02058664
   Haslett PAJ, 1998, SEMIN ONCOL, V25, P53
   Kaczmarczyk Sedlak I, 2008, THESIS MED U SILESIA
   Kaczmarczyk Sedlak I, 2006, PHARMACOL REP, V58, P540
   Kaczmarczyk Sedlak I, 2009, PHARMACOL REP, V61, P529, DOI 10.1016/S1734 1140(09)70096 9
   Kaplan G, 2000, AIDS RES HUM RETROV, V16, P1345, DOI 10.1089/08892220050140892
   Lan CCE, 2007, J DERMATOL, V34, P237, DOI 10.1111/j.1346 8138.2007.00260.x
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   LINDGREN JU, 1984, CALCIFIED TISSUE INT, V36, P591, DOI 10.1007/BF02405372
   LOCKER D, 1971, ARCH INT PHARMACOD T, V194, P39
   Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061
   Melchert M, 2007, INT J BIOCHEM CELL B, V39, P1489, DOI 10.1016/j.biocel.2007.01.022
   Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525
   Moghadam Kia S, 2010, INT J DERMATOL, V49, P239, DOI 10.1111/j.1365 4632.2009.04322.x
   Munemasa S, 2008, INT J ONCOL, V33, P129
   Natsui K, 2006, OSTEOPOROSIS INT, V17, P105, DOI 10.1007/s00198 005 1923 3
   Noa Miriam, 2004, Drugs R D, V5, P281, DOI 10.2165/00126839 200405050 00004
   Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Okafor MC, 2003, PHARMACOTHERAPY, V23, P481, DOI 10.1592/phco.23.4.481.32115
   Ortoft G, 1996, BONE, V18, P581, DOI 10.1016/8756 3282(96)00077 4
   Ortoft G, 1998, CALCIFIED TISSUE INT, V63, P14, DOI 10.1007/s002239900483
   Ortoft G, 1995, BONE, V17, P543, DOI 10.1016/8756 3282(95)00386 X
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   Pennisi P, 2005, J BONE MINER METAB, V23, P134, DOI 10.1007/s00774 004 0551 x
   Quach H, 2010, LEUKEMIA, V24, P22, DOI 10.1038/leu.2009.236
   REID IR, 1990, ARCH INTERN MED, V150, P2545, DOI 10.1001/archinte.150.12.2545
   Reid IR, 1998, J CLIN ENDOCR METAB, V83, P1860, DOI 10.1210/jc.83.6.1860
   Rieman DJ, 2001, BONE, V28, P282, DOI 10.1016/S8756 3282(00)00445 2
   Shah SK, 2006, J AM OSTEOPATH ASSOC, V106, P653
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   Steinbuch M, 2004, OSTEOPOROSIS INT, V15, P323, DOI 10.1007/s00198 003 1548 3
   Terpos E, 2007, LEUKEMIA, V21, P1875, DOI 10.1038/sj.leu.2404843
   Tkocz Kwiatkowska J, 1998, POL J PHARMACOL, V50, P253
   Tosi P, 2006, EUR J HAEMATOL, V76, P399, DOI 10.1111/j.0902 4441.2005.t01 1 EJH2520.x
   United States Pharmacopeia Dispensing Information, 2004, DRUG INF HLTH CAR PR, VI, P2648
NR 46
TC 11
Z9 12
U1 0
U2 16
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1734 1140
EI 2299 5684
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD MAR APR
PY 2012
VL 64
IS 2
BP 386
EP 395
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 962LN
UT WOS:000305546700018
PM 22661190
DA 2025 08 17
ER

PT J
AU Hollenberg, AM
   Smith, CO
   Shum, LC
   Awad, H
   Eliseev, RA
AF Hollenberg, Alex M.
   Smith, Charles O.
   Shum, Laura C.
   Awad, Hani
   Eliseev, Roman A.
TI Lactate Dehydrogenase Inhibition With Oxamate Exerts Bone Anabolic
   Effect
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE; OSTEOBLAST; LACTATE DEHYDROGENASE; GLYCOLYSIS; MITOCHONDRIA;
   OXAMATE
ID MESENCHYMAL STEM CELLS; OXIDATIVE STRESS; CANCER CELLS; MITOCHONDRIAL
   DYSFUNCTION; HEXOKINASE II; DIFFERENTIATION; OSTEOBLAST; APOPTOSIS;
   GLYCOLYSIS; METABOLISM
AB Cellular bioenergetics is a promising new therapeutic target in aging, cancer, and diabetes because these pathologies are characterized by a shift from oxidative to glycolytic metabolism. We have previously reported such glycolytic shift in aged bone as a major contributor to bone loss in mice. We and others also showed the importance of oxidative phosphorylation (OxPhos) for osteoblast differentiation. It is therefore reasonable to propose that stimulation of OxPhos will have bone anabolic effect. One strategy widely used in cancer research to stimulate OxPhos is inhibition of glycolysis. In this work, we aimed to evaluate the safety and efficacy of pharmacological inhibition of glycolysis to stimulate OxPhos and promote osteoblast bone forming function and bone anabolism. We tested a range of glycolytic inhibitors including 2 deoxyglucose, dichloroacetate, 3 bromopyruvate, and oxamate. Of all the studied inhibitors, only a lactate dehydrogenase (LDH) inhibitor, oxamate, did not show any toxicity in either undifferentiated osteoprogenitors or osteoinduced cells in vitro. Oxamate stimulated both OxPhos and osteoblast differentiation in osteoprogenitors. In vivo, oxamate improved bone mineral density, cortical bone architecture, and bone biomechanical strength in both young and aged C57BL/6J male mice. Oxamate also increased bone formation by osteoblasts without affecting bone resorption. In sum, our work provided a proof of concept for the use of anti glycolytic strategies in bone and identified a small molecule LDH inhibitor, oxamate, as a safe and efficient bone anabolic agent. (c) 2020 American Society for Bone and Mineral Research (ASBMR).
C1 [Hollenberg, Alex M.; Smith, Charles O.; Shum, Laura C.; Awad, Hani; Eliseev, Roman A.] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY USA.
C3 University of Rochester
RP Eliseev, RA (通讯作者)，Univ Rochester, Med Ctr, 601 Elmwood Ave,Rm 1 8541, Rochester, NY 14642 USA.
EM roman_eliseev@urmc.rochester.edu
RI Mostafa, Taymour/H 6834 2019; Awad, Hani/G 6976 2014
OI Awad, Hani/0000 0003 2197 2610; Shum, Laura/0000 0002 0167 4133
FU NIH [R01 AR072601, R21 AR07928, R01 AR070613, P30 AR069655 5278];
   Orthopaedic Research and Education Foundation; Musculoskeletal
   Transplant Foundation
FX Financial support was provided by NIH (R01 AR072601 and R21 AR07928 to
   RAE; and R01 AR070613 and P30 AR069655 5278 to HA) and by a grant to RAE
   from the Orthopaedic Research and Education Foundation with additional
   funding provided by the Musculoskeletal Transplant Foundation. We thank
   Dr. Paul Brookes for the use of Seahorse apparatus, the histology core
   within the Center for Musculoskeletal Research (Kathy Maltby, Sarah
   Mack, and Jeffery Fox), the mu CT core within the Center for
   Musculoskeletal Research (Michael Thullen), and the biomechanics core
   (Emma Gira).
CR Abdel Wahab AF, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104511
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Becerikli M, 2017, J CELL MOL MED, V21, P2773, DOI 10.1111/jcmm.13192
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   Caslin HL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03026
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Coleman MC, 2008, FREE RADICAL BIO MED, V44, P322, DOI 10.1016/j.freeradbiomed.2007.08.032
   Dunbar EM, 2014, INVEST NEW DRUG, V32, P452, DOI 10.1007/s10637 013 0047 4
   Eliseev RA, 2007, NEUROBIOL AGING, V28, P1532, DOI 10.1016/j.neurobiolaging.2006.06.022
   ERNST M, 1988, P NATL ACAD SCI USA, V85, P2307, DOI 10.1073/pnas.85.7.2307
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Figueiredo PA, 2009, J GERONTOL A BIOL, V64, P21, DOI 10.1093/gerona/gln048
   Forni MF, 2016, STEM CELLS, V34, P743, DOI 10.1002/stem.2248
   Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011
   Granchi C, 2012, CHEMMEDCHEM, V7, P1318, DOI 10.1002/cmdc.201200176
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Harrison CM, 2011, ENVIRON HEALTH PERSP, V119, P676, DOI 10.1289/ehp.1002857
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Hwang ES, 2009, CELL MOL LIFE SCI, V66, P2503, DOI 10.1007/s00018 009 0034 2
   Intlekofer AM, 2019, NAT METAB, V1, P177, DOI 10.1038/s42255 019 0032 0
   Jae HJ, 2009, KOREAN J RADIOL, V10, P596, DOI 10.3348/kjr.2009.10.6.596
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Lane RK, 2015, BBA BIOENERGETICS, V1847, P1387, DOI 10.1016/j.bbabio.2015.05.021
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011
   Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   McManus MJ, 2014, MOL CELL NEUROSCI, V63, P13, DOI 10.1016/j.mcn.2014.09.002
   Miskimins WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085576
   Nunomura A, 2006, J NEUROPATH EXP NEUR, V65, P631, DOI 10.1097/01.jnen.0000228136.58062.bf
   Pattappa G, 2011, J CELL PHYSIOL, V226, P2562, DOI 10.1002/jcp.22605
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Saito Mitsuru, 2013, Front Endocrinol (Lausanne), V4, P72, DOI 10.3389/fendo.2013.00072
   Samuvel DJ, 2009, J IMMUNOL, V182, P2476, DOI 10.4049/jimmunol.0802059
   Santos D, 2015, MOL NEUROBIOL, V52, P573, DOI 10.1007/s12035 014 8893 4
   Seo BJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123893
   Shares BH, 2018, J BIOL CHEM, V293, P16019, DOI 10.1074/jbc.RA118.004102
   Shin MK, 2019, ARCH PHARM RES, V42, P113, DOI 10.1007/s12272 019 01127 y
   Shum LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155709
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Si YG, 2009, METAB ENG, V11, P382, DOI 10.1016/j.ymben.2009.08.001
   Smith CO, 2018, FASEB J, V32, P6135, DOI 10.1096/fj.201800139R
   Stroup J, 2008, AM J HEALTH SYST PH, V65, P532, DOI 10.2146/ajhp070171
   Tao L, 2017, BIOCHEM PHARMACOL, V125, P12, DOI 10.1016/j.bcp.2016.11.001
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914
   Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11
   Xu D, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0514 4
   Yamasaki M, 2016, BIOCHEM BIOPH RES CO, V473, P654, DOI 10.1016/j.bbrc.2016.03.115
   Yang Y, 2014, ONCOTARGET, V5, P11886, DOI 10.18632/oncotarget.2620
   Ye WR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150303
   Zhao Z, 2015, CANCER LETT, V358, P17, DOI 10.1016/j.canlet.2014.11.046
   Zhu J, 2016, AM J TRANSL RES, V8, P4812
NR 61
TC 33
Z9 39
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2020
VL 35
IS 12
BP 2432
EP 2443
DI 10.1002/jbmr.4142
EA SEP 2020
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PE3BA
UT WOS:000570801200001
PM 32729639
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chen, Y
   Yang, YR
   Fan, XL
   Lin, P
   Yang, H
   Chen, XZ
   Xu, XD
AF Chen, Ying
   Yang, Yu Run
   Fan, Xiao Liang
   Lin, Peng
   Yang, Huan
   Chen, Xing Zuo
   Xu, Xiao Dong
TI miR 206 inhibits osteogenic differentiation of bone marrow mesenchymal
   stem cells by targetting glutaminase
SO BIOSCIENCE REPORTS
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; METABOLISM; MICRORNAS; CANCER
AB Osteoblast mediated bone formation is a complex process involving various pathways and regulatory factors, including cytokines, growth factors, and hormones. Investigating the regulatory mechanisms behind osteoblast differentiation is important for bone regeneration therapy. miRNAs are known as important regulators, not only in a variety of cellular processes, but also in the pathogenesis of bone diseases. In the present study, we investigated the potential roles of miR 206 during osteoblast differentiation. We report that miR 206 expression was significantly down regulated in human bone marrow mesenchymal stem cells (BMSCs) at days 7 and 14 during osteogenic induction. Furthermore, miR 206 overexpressing BMSCs showed attenuated alkaline phosphatase (ALP) activity, Alizarin Red staining, and osteocalcin secretion. The mRNA levels of osteogenic markers, Runx2 and Osteopontin (OPN), were significantly down regulated in miR 206 overexpressing BMSCs. We observed that significantly increased glutamine uptake at days 7 and 14 during the osteogenic induction and inhibition of glutamine metabolism by knocking down glutaminase (GLS) suppressed osteogenic differentiation of BMSCs. Here, we discover that miR 206 could directly bind to the 3' UTR region of GLS mRNA, resulting in suppressed GLS expression and glutamine metabolism. Finally, restoration of GLS in miR 206 overexpressing BMSCs led to recovery of glutamine metabolism and osteogenic differentiation. In summary, these results reveal a new insight into the mechanisms of the miR 206 mediated osteogenesis through regulating glutamine metabolism. Our study may contribute to the development of therapeutic agents against bone diseases.
C1 [Chen, Ying; Yang, Yu Run; Lin, Peng; Yang, Huan; Chen, Xing Zuo; Xu, Xiao Dong] China Japan Friendship Hosp, Dept Orthopaed, 2 Yinghuayuan East St, Beijing 100029, Peoples R China.
   [Fan, Xiao Liang] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Orthopaed, Hangzhou 310006, Zhejiang, Peoples R China.
C3 China Japan Friendship Hospital; Nanjing Medical University
RP Yang, YR (通讯作者)，China Japan Friendship Hosp, Dept Orthopaed, 2 Yinghuayuan East St, Beijing 100029, Peoples R China.
EM yangyurunpz@sina.com
CR Ahmed MI, 2011, J CELL SCI, V124, P3399, DOI 10.1242/jcs.086710
   BILTZ RM, 1983, MINER ELECTROL METAB, V9, P125
   Budd Emma, 2017, Curr Mol Biol Rep, V3, P263, DOI 10.1007/s40610 017 0076 4
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Chen ZH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081684
   Cluntun AA, 2017, TRENDS CANCER, V3, P169, DOI 10.1016/j.trecan.2017.01.005
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Guo Q, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.22
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Huang C, 2017, CELL TISSUE RES, V368, P229, DOI 10.1007/s00441 016 2462 2
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li BB, 2018, CURR STEM CELL RES T, V13, P26, DOI 10.2174/1574888X12666170605112727
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Nakasa T, 2015, CURR GENOMICS, V16, P441, DOI 10.2174/1389202916666150817213630
   Park J, 2015, PHYSIOL RES, V64, P711, DOI 10.33549/physiolres.932901
   Paul P, 2018, J CELL PHYSIOL, V233, P2007, DOI 10.1002/jcp.25854
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Teti Anna, 2013, Bonekey Rep, V2, P449, DOI 10.1038/bonekey.2013.183
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Winbanks CE, 2011, J BIOL CHEM, V286, P13805, DOI 10.1074/jbc.M110.192625
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
NR 29
TC 39
Z9 41
U1 1
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144 8463
EI 1573 4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD MAR 29
PY 2019
VL 39
AR BSR20181108
DI 10.1042/BSR20181108
PN 3
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HU7IE
UT WOS:000465453700006
PM 30804229
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dieudonne, FX
   Sévère, N
   Biosse Duplan, M
   Weng, JJ
   Su, Y
   Marie, PJ
AF Dieudonne, Francois Xavier
   Severe, Nicolas
   Biosse Duplan, Martin
   Weng, Jing Jie
   Su, Yeu
   Marie, Pierre J.
TI Promotion of Osteoblast Differentiation in Mesenchymal Cells Through
   Cbl Mediated Control of STAT5 Activity
SO STEM CELLS
LA English
DT Article
DE Mesenchymal cells; c Cbl ubiquitin ligase; Ubiquitination; RUNX2;
   Osteoblast differentiation; STAT5
ID OSTEOGENIC DIFFERENTIATION; TRANSCRIPTIONAL CONTROL; STROMAL CELLS;
   STEM CELLS; C CBL; GROWTH; GENE; RUNX2; ACTIVATION; DEGRADATION
AB The identification of the molecular mechanisms controlling the degradation of regulatory proteins in mesenchymal stromal cells (MSC) may provide clues to promote MSC osteogenic differentiation and bone regeneration. Ubiquitin ligase dependent degradation of proteins is an important process governing cell fate. In this study, we investigated the role of the E3 ubiquitin ligase c Cbl in MSC osteoblast differentiation and identified the mechanisms involved in this effect. Using distinct shRNA targeting c Cbl, we showed that c Cbl silencing promotes osteoblast differentiation in murine and human MSC, as demonstrated by increased alkaline phosphatase activity, expression of phenotypic osteoblast marker genes (RUNX2, ALP, type 1 collagen), and matrix mineralization in vitro. Coimmunoprecipitation analyses showed that c Cbl interacts with the transcription factor STAT5, and that STAT5 forms a complex with RUNX2, a master transcription factor controlling osteoblastogenesis. Silencing c Cbl decreased c Cbl mediated STAT5 ubiquitination, increased STAT5 protein level and phosphorylation, and enhanced STAT5 and RUNX2 transcriptional activity. The expression of insulin like growth factor 1 (IGF 1), a target gene of STAT5, was increased by c Cbl silencing in MSC and in bone marrow stromal cells isolated from c Cbl deficient mice, suggesting that IGF 1 contributes to osteoblast differentiation induced by c Cbl silencing in MSC. Consistent with these findings, pharmacological inhibition of STAT5 activity, or neutralization of IGF 1 activity, abrogated the positive effect of c Cbl knockdown on MSC osteogenic differentiation. Taken together, the data provide a novel functional mechanism by which the ubiquitin ligase c Cbl regulates the osteoblastic differentiation program in mesenchymal cells by controlling Cbl mediated STAT5 degradation and activity. STEM Cells2013;31:1340 1349
C1 [Dieudonne, Francois Xavier; Severe, Nicolas; Marie, Pierre J.] INSERM, Lab Osteoblast Biol & Pathol, U606, Paris, France.
   [Dieudonne, Francois Xavier; Severe, Nicolas; Marie, Pierre J.] Univ Paris Diderot, Sorbonne Paris Cite, UMR 606, Paris, France.
   [Biosse Duplan, Martin] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Weng, Jing Jie; Su, Yeu] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Harvard University; Harvard School of Dental
   Medicine; National Yang Ming Chiao Tung University
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, UMR 606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI Soueidan, Assem/P 1781 2014; Biosse Duplan, Martin/H 7491 2017; Duplan,
   Martin/H 7491 2017
OI Soueidan, Assem/0000 0001 8759 2165; Biosse Duplan,
   Martin/0000 0001 9417 3970; 
FU Agence Nationale de la Recherche [ANR 09 BLAN 0402 01 Promotos];
   Ministere de la Recherche (Paris, France)
FX This work was supported in part by a grant from the Agence Nationale de
   la Recherche (ANR 09 BLAN 0402 01 Promotos) to P.J.M. N.S. was a
   recipient of a Ph.D. Award from the Ministere de la Recherche (Paris,
   France). We thank Dr. Roland Baron (Harvard Dental School of Medicine,
   USA) for sharing bones from c Cbl knockout mice. M. B. D. is currently
   affiliated with Service Odontologie Bretonneau, AP HP, INSERM U781,
   Universite Paris Descartes, Paris, France.
CR Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097 4644(20010401)81:1<23::AID JCB1021>3.0.CO;2 H
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Brennan T, 2011, CALCIFIED TISSUE INT, V89, P396, DOI 10.1007/s00223 011 9531 z
   Carbonare LD, 2012, STEM CELL REV REP, V8, P891, DOI 10.1007/s12015 011 9337 4
   Chiusaroli R, 2003, DEV BIOL, V261, P537, DOI 10.1016/S0012 1606(03)00299 9
   Ciechanover A, 2005, ANGEW CHEM INT EDIT, V44, P5944, DOI 10.1002/anie.200501428
   Clemens TL, 2004, GROWTH HORM IGF RES, V14, P195, DOI 10.1016/j.ghir.2003.12.008
   Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760
   DiGirolamo DJ, 2007, J BIOL CHEM, V282, P31666, DOI 10.1074/jbc.M705219200
   Dufour C, 2008, BONE, V42, P1032, DOI 10.1016/j.bone.2008.02.009
   Eleswarapu S, 2009, MOL ENDOCRINOL, V23, P2026, DOI 10.1210/me.2009 0178
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Gan YJ, 2010, MOL ENDOCRINOL, V24, P644, DOI 10.1210/me.2009 0357
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Glimcher LH, 2007, ANN NY ACAD SCI, V1116, P174, DOI 10.1196/annals.1402.044
   Gronthos Stan, 2008, V449, P45, DOI 10.1007/978 1 60327 169 1_3
   Grove JE, 2004, STEM CELLS, V22, P487, DOI 10.1634/stemcells.22 4 487
   Guenou H, 2006, AM J PATHOL, V169, P1303, DOI 10.2353/ajpath.2006.060102
   Hassan MQ, 2006, J BIOL CHEM, V281, P40515, DOI 10.1074/jbc.M604508200
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908
   Joung YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047477
   Kaabeche K, 2005, J CELL SCI, V118, P1223, DOI 10.1242/jcs.01679
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200
   Kawai M, 2012, J CELL BIOCHEM, V113, P1447, DOI 10.1002/jcb.23442
   Khosla S, 2010, STEM CELLS, V28, P2124, DOI 10.1002/stem.546
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Mikami Y, 2010, J CELL PHYSIOL, V223, P123, DOI 10.1002/jcp.22017
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2 3.30
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   Niu TH, 2005, GENE, V361, P38, DOI 10.1016/j.gene.2005.07.016
   Ogawa S, 2008, J BIOCHEM, V143, P695, DOI 10.1093/jb/mvn022
   Orosco A, 2007, CANCER RES, V67, P3708, DOI 10.1158/0008 5472.CAN 06 4164
   Oyajobi BO, 1999, J BONE MINER RES, V14, P351, DOI 10.1359/jbmr.1999.14.3.351
   Paukku K, 2004, CYTOKINE GROWTH F R, V15, P435, DOI 10.1016/j.cytogfr.2004.09.001
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   Ryan PE, 2006, TRENDS BIOCHEM SCI, V31, P79, DOI 10.1016/j.tibs.2005.12.004
   Salingcarnboriboon RA, 2010, J CELL PHYSIOL, V224, P743, DOI 10.1002/jcp.22176
   Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762
   Sévère N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.217
   Sévère N, 2012, J BONE MINER RES, V27, P2108, DOI 10.1002/jbmr.1667
   Sévère N, 2011, J BIOL CHEM, V286, P24443, DOI 10.1074/jbc.M110.197525
   Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694
   Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193
   Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100
   Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
NR 62
TC 36
Z9 40
U1 1
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2013
VL 31
IS 7
BP 1340
EP 1349
DI 10.1002/stem.1380
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 176XB
UT WOS:000321339000013
PM 23533197
OA Bronze
DA 2025 08 17
ER

PT J
AU Ghuloum, FI
   Stevens, LA
   Johnson, CA
   Riobo Del Galdo, NA
   Amer, MH
AF Ghuloum, Fatmah I.
   Stevens, Lee A.
   Johnson, Colin A.
   Riobo Del Galdo, Natalia A.
   Amer, Mahetab H.
TI Towards modular engineering of cell signalling: Topographically textured
   microparticles induce osteogenesis via activation of canonical hedgehog
   signalling
SO BIOMATERIALS ADVANCES
LA English
DT Article
DE Extracellular matrix; Hedgehog signalling; Mesenchymal cells;
   Microparticles; Microtopography; Osteogenesis; Topography
ID MESENCHYMAL STEM CELLS; IN VITRO; OSTEOBLAST DIFFERENTIATION; MESOPOROUS
   SILICA; GROWTH FACTORS; TGF BETA; EXPRESSION; MECHANISM; FATE;
   PROLIFERATION
AB Polymer microparticles possess great potential as functional building blocks for advanced bottom up engineering of complex tissues. Tailoring the three dimensional architectural features of culture substrates has been shown to induce osteogenesis in mesenchymal stem cells in vitro, but the molecular mechanisms underpinning this remain unclear. This study proposes a mechanism linking the activation of Hedgehog signalling to the osteoinductive effect of surface engineered, topographically textured polymeric microparticles. In this study, mesenchymal progenitor C3H10T1/2 cells were cultured on smooth and dimpled poly(D,L lactide) microparticles to assess differences in viability, cellular morphology, proliferation, and expression of a range of Hedgehog signalling components and osteogenesis related genes. Dimpled microparticles induced osteogenesis and activated the Hedgehog signalling pathway relative to smooth microparticles and 2D cultured controls without the addition of exogenous biochemical factors. We observed upregulation of the osteogenesis markers Runt related transcription factor2 (Runx2) and bone gamma carboxyglutamate protein 2 (Bglap2), as well as the Hedgehog signalling components, glioma associated oncogene homolog 1 (Gli1), Patched1 (Ptch1), and Smoothened (Smo). Treatment with the Smo antagonist KAAD cyclopamine confirmed the involvement of Smo in Gli1 target gene activation, with a significant reduction in the expression of Gli1, Runx2 and Bglap2 (p <= 0.001) following KAAD cyclopamine treatment. Overall, our study demonstrates the role of the topographical microenvironment in the modulation of Hedgehog signalling, highlighting the potential for tailoring substrate topographical design to offer cellinstructive 3D microenvironments. Topographically textured microparticles allow the modulation of Hedgehog signalling in vitro without adding exogenous biochemical agonists, thereby eliminating potential confounding artefacts in high throughput drug screening applications.
C1 [Ghuloum, Fatmah I.; Riobo Del Galdo, Natalia A.; Amer, Mahetab H.] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds, England.
   [Ghuloum, Fatmah I.] Kuwait Univ, Fac Sci, Dept Biol Sci, Kuwait, Kuwait.
   [Stevens, Lee A.] Univ Nottingham, Fac Engn, Low Carbon Energy & Resources Technol Res Grp, Nottingham, England.
   [Johnson, Colin A.; Riobo Del Galdo, Natalia A.] Univ Leeds, Leeds Inst Med Res, Fac Med & Hlth, Leeds, England.
   [Riobo Del Galdo, Natalia A.] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds, England.
C3 University of Leeds; Kuwait University; University of Nottingham;
   University of Leeds; University of Leeds
RP Amer, MH (通讯作者)，Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds, England.
EM m.amer@leeds.ac.uk
RI ; Riobo Del Galdo, Natalia/AAP 2938 2020
OI Amer, Mahetab/0000 0002 1493 3181; Johnson, Colin/0000 0002 2979 8234;
   GHULOUM, FATMAH/0000 0001 6538 5683
FU University Academic Fellowship (University of Leeds, UK); Kuwait
   University, Kuwait; Faculty of Biological Sciences Bioimaging facility  
   Wellcome Trust [WT104918MA, 062164/Z/00/Z]; Wellcome Trust
FX MA acknowledges funding by a University Academic Fellowship (University
   of Leeds, UK) . FG is supported by a scholarship from Kuwait University,
   Kuwait. We thank Dr. Ruth Hughes from the Faculty of Biological Sciences
   Bioimaging facility for support with the Zeiss LSM880 Airyscan confocal
   microscope, funded by a Wellcome Trust (WT104918MA) . We thank John
   Harrington and Stuart Micklethwaite from Leeds Electron Microscopy and
   Spectroscopy Centre (LEMAS) for their support. Finally, we acknowledge
   Tayah Hopes for her invaluable support with RT qPCR, Dr. Iain Manfield
   (Wellcome Trust  funded Bio  molecular Interactions Facility, Astbury
   Centre; 062164/Z/00/Z) , and Helena Brown (Sorby Environmental Fluid
   Dynamics Laboratory) . For the purpose of open access, the authors have
   applied a creative commons attribution (CC BY) public copyright licence
   to any Author Accepted Manuscript version arising from this submission.
CR Abagnale G, 2015, BIOMATERIALS, V61, P316, DOI 10.1016/j.biomaterials.2015.05.030
   Al Wahabi A, 2019, J BIOMED MATER RES B, V107, P2288, DOI 10.1002/jbm.b.34321
   Alvarez Paino M, 2019, ACS APPL MATER INTER, V11, P34560, DOI 10.1021/acsami.9b04769
   Amer MH, 2021, BIOMATERIALS, V266, DOI 10.1016/j.biomaterials.2020.120450
   Bangs F, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028175
   Bernard AB, 2014, BIOTECHNOL BIOENG, V111, P1028, DOI 10.1002/bit.25153
   Bernardo MP, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 05207 w
   Cai JQ, 2012, CELL BIOL INT, V36, P349, DOI 10.1042/CBI20110284
   Cantagrel V, 2008, AM J HUM GENET, V83, P170, DOI 10.1016/j.ajhg.2008.06.023
   Cao JL, 2012, NAT CELL BIOL, V14, P697, DOI 10.1038/ncb2512
   Chakravorty N, 2014, CLIN ORAL IMPLAN RES, V25, P475, DOI 10.1111/clr.12178
   Chao KJ, 2005, CR CHIM, V8, P727, DOI 10.1016/j.crci.2005.01.004
   Chaudhary JK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182128
   Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302
   Chen JC, 2016, FASEB J, V30, P1504, DOI 10.1096/fj.15 276402
   Chignola R, 2000, CELL PROLIFERAT, V33, P219, DOI 10.1046/j.1365 2184.2000.00174.x
   Ching JK, 2010, AM J PHYSIOL CELL PH, V299, pC1171, DOI 10.1152/ajpcell.00514.2009
   Chiu CY, 2006, MICROPOR MESOPOR MAT, V91, P244, DOI 10.1016/j.micromeso.2005.12.003
   Cho AN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24775 5
   Cui JY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084212
   Dalby Matthew J, 2007, Methods Mol Biol, V370, P121
   Deng Y, 2015, INT J NANOMED, V10, P1425, DOI 10.2147/IJN.S75557
   Donos N, 2011, CLIN ORAL IMPLAN RES, V22, P390, DOI 10.1111/j.1600 0501.2010.02105.x
   DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112
   Fallica B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048024
   Gao R, 2020, MOL MED REP, V22, P1119, DOI 10.3892/mmr.2020.11200
   Geoghegan IP, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 88633 6
   Geoghegan IP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41095 3
   Ghuloum FI, 2022, MATER TODAY BIO, V17, DOI 10.1016/j.mtbio.2022.100502
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Guo XS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197442
   Gurski L.A., 2017, Oncol Issues, V25, P20, DOI [10.1080/10463356.2010.11883480, DOI 10.1080/10463356.2010.11883480]
   Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235
   Huang LJ, 2015, ARCH ORAL BIOL, V60, P622, DOI 10.1016/j.archoralbio.2015.01.003
   Ikegame M, 2019, J HISTOCHEM CYTOCHEM, V67, P107, DOI 10.1369/0022155418793588
   Jemtland R, 2003, BONE, V32, P611, DOI 10.1016/S8756 3282(03)00092 9
   Johnson GP, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115846
   Johnson GP, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222737
   Kim EJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055296
   Kim SY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/452175
   Kitaura Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109597
   KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291
   Koh B, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578 020 00438 8
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Kopf J, 2012, BMC BIOL, V10, DOI 10.1186/1741 7007 10 37
   Lee SY, 2023, SLAS DISCOV, V28, P119, DOI 10.1016/j.slasd.2023.03.006
   Lin EH, 2016, ONCOTARGET, V7, P24179, DOI 10.18632/oncotarget.8253
   Lin Y, 2018, ARTIF CELL NANOMED B, V46, pS1141, DOI 10.1080/21691401.2018.1533845
   Lin Y, 2017, INT J NANOMED, V12, P3267, DOI 10.2147/IJN.S135045
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu XZ, 2022, J SCI ADV MATER DEV, V7, DOI 10.1016/j.jsamd.2022.100437
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou HY, 2019, P NATL ACAD SCI USA, V116, P23143, DOI 10.1073/pnas.1910166116
   McNamara L., 2011, COMPR BIOMATER, V2, P169, DOI [10.1016/b978 0 08 055294 1.00068 4, DOI 10.1016/B978 0 08 055294 1.00068 4, 10.1016/B978 0 08 055294 1.00068 4]
   Miron RJ, 2017, CLIN ORAL INVEST, V21, P801, DOI 10.1007/s00784 016 1825 0
   Miyoshi H, 2014, TISSUE ENG PART B RE, V20, P609, DOI [10.1089/ten.teb.2013.0728, 10.1089/ten.TEB.2013.0728]
   Montgomery SR, 2014, J BONE MINER RES, V29, P1872, DOI 10.1002/jbmr.2213
   Morrow D, 2007, AM J PHYSIOL CELL PH, V292, pC488, DOI 10.1152/ajpcell.00337.2005
   Onodera S, 2020, STEM CELL REP, V15, P125, DOI 10.1016/j.stemcr.2020.05.008
   Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691
   Pirkmajer S, 2011, AM J PHYSIOL CELL PH, V301, pC272, DOI 10.1152/ajpcell.00091.2011
   Pitaval A, 2010, J CELL BIOL, V191, P303, DOI 10.1083/jcb.201004003
   Puza F, 2022, ADV ENG MATER, DOI 10.1002/adem.202200777
   Robotti F, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29167 2
   Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106
   Ru LY, 2023, OPEN LIFE SCI, V18, DOI 10.1515/biol 2022 0706
   Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066
   Shah JV, 2010, J CELL BIOL, V191, P233, DOI 10.1083/jcb.201009048
   Shao YY, 2012, BONE, V50, P79, DOI 10.1016/j.bone.2011.08.033
   Shi Y, 2015, P NATL ACAD SCI USA, V112, P4678, DOI 10.1073/pnas.1502301112
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Smith CEL, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.622822
   Souza AG, 2018, CURR PHARM DESIGN, V24, P1689, DOI 10.2174/1381612824666180404152304
   Souza PG, 2023, J FUNCT BIOMATER, V14, DOI 10.3390/jfb14020079
   Stavenschi E, 2017, J BIOMECH, V55, P99, DOI 10.1016/j.jbiomech.2017.02.002
   Suzuki S, 2020, LAB INVEST, V100, P916, DOI 10.1038/s41374 020 0421 8
   Takebe H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020677
   Teperino R, 2014, SEMIN CELL DEV BIOL, V33, P81, DOI 10.1016/j.semcdb.2014.05.007
   Tevlin R, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2809
   Thompson CL, 2014, OSTEOARTHR CARTILAGE, V22, P490, DOI 10.1016/j.joca.2013.12.016
   Tolbert CE, 2013, CELL ADHES MIGR, V7, P219, DOI 10.4161/cam.23184
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Wang JF, 2014, INT J MOL SCI, V15, P10150, DOI 10.3390/ijms150610150
   Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133
   Wheway G, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00008
   Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282
   Wildemann B, 2004, J CONTROL RELEASE, V95, P249, DOI 10.1016/j.jconrel.2003.11.014
   Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010
   Xie YR, 2021, INT J BIOCHEM CELL B, V137, DOI 10.1016/j.biocel.2021.106026
   Yu TT, 2020, MACROMOL MATER ENG, V305, DOI 10.1002/mame.201900759
   Zhang JW, 2017, ACTA BIOMATER, V57, P487, DOI 10.1016/j.actbio.2017.04.004
   Zhao L, 2009, CALCIFIED TISSUE INT, V84, P56, DOI 10.1007/s00223 008 9189 3
   Zhao MY, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420940560
   Zhou H, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13162
NR 94
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2772 9508
J9 BIOMATER ADV
JI Biomater. Adv.
PD NOV
PY 2023
VL 154
AR 213652
DI 10.1016/j.bioadv.2023.213652
EA OCT 2023
PG 15
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA Z6BT2
UT WOS:001112912500001
PM 37837904
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Li, J
   Waugh, LJ
   Hui, SL
   Burr, DB
   Warden, SJ
AF Li, Jiliang
   Waugh, Lauren J.
   Hui, Siu L.
   Burr, David B.
   Warden, Stuart J.
TI Low intensity pulsed ultrasound and nonsteroidal anti inflammatory drugs
   have opposing effects during stress fracture repair
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE stress fracture; therapeutic ultrasound; cyclooxygenase 2 inhibitor;
   fracture healing
ID PROSTAGLANDIN E 2 PRODUCTION; IN VIVO; BONE FORMATION; RAT ULNA;
   NITRIC OXIDE; LONG BONES; OSTEOBLASTS; MICRODAMAGE; CELLS;
   CYCLOOXYGENASE
AB Low intensity pulsed ultrasound (LIPUS) and nonsteroidal anti inflammatory drugs (NSAIDs) were used to treat stress fracture. Bilateral stress fractures were induced in the ulnas of 48 adult rats. Animals were divided into two groups (NSAID and VEH), and treated 5 days per week with celecoxib (5 mg/kg) mixed in a vehicle solution of polyethylene glycol and saline (NSAID) or vehicle alone (VEH). One to three hours following drug administration, all animals were treated with unilateral active LIPUS and contralateral inactive LIPUS. Equal numbers of ulnas from each drug group were histologically evaluated at 2, 4, and 8 weeks following induction of stress fracture. Neither LIPUS nor NSAID influenced bone resorption, but each had significant and opposite effects on intracortical bone formation rate. These effects indicate that LIPUS may be used to facilitate stress fracture repair whereas NSAID may delay tissue level repair of stress fractures. There was no interaction between LIPUS and NSAID, indicating that the beneficial LIPUS effect was not mediated by the cyclooxygenase 2 pathway. LIPUS accelerated stress fracture healing, whereas the NSAID delayed repair. When used in combination, the beneficial LIPUS effect was not impaired by the detrimental NSAID effect. (C) 2007 Orthopaedic Research Society.
C1 Indiana Univ Purdue Univ, Sch Sci, Dept Biol, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Med, Dept Med, Div Biostat, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Indiana University System; Indiana University
   Indianapolis; Indiana University System; Indiana University
   Indianapolis; Indiana University System; Indiana University Indianapolis
RP Li, J (通讯作者)，Indiana Univ Purdue Univ, Sch Sci, Dept Biol, Indianapolis, IN 46202 USA.
EM jilili@iupui.edu
RI Warden, Stuart/C 5287 2012
OI Warden, Stuart/0000 0002 6415 4936
CR Bentolila V, 1998, BONE, V23, P275, DOI 10.1016/S8756 3282(98)00104 5
   Brand J C Jr, 1999, Iowa Orthop J, V19, P26
   BURR DB, 1995, BONE, V17, P431, DOI 10.1016/S8756 3282(95)00241 3
   Burr DB., 2001, MUSCULOSKELETAL FATI
   Cirino G, 1998, BIOCHEM PHARMACOL, V55, P105, DOI 10.1016/S0006 2952(97)00215 3
   Colopy SA, 2004, BONE, V35, P881, DOI 10.1016/j.bone.2004.05.024
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Hsieh YF, 1999, BONE, V25, P379, DOI 10.1016/S8756 3282(99)00181 7
   Hsieh YF, 2002, J ORTHOP RES, V20, P764, DOI 10.1016/S0736 0266(01)00161 9
   Jensen JE, 1998, MED SCI SPORT EXER, V30, P783, DOI 10.1097/00005768 199806000 00001
   Kannus P, 2003, SCAND J MED SCI SPOR, V13, P150, DOI 10.1034/j.1600 0838.2003.02225.x
   Kokubu T, 1999, BIOCHEM BIOPH RES CO, V256, P284, DOI 10.1006/bbrc.1999.0318
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   Li JK, 2003, BIOMATERIALS, V24, P2379, DOI 10.1016/S0142 9612(03)00033 4
   Li JL, 1999, J BONE MINER RES, V14, P969, DOI 10.1359/jbmr.1999.14.6.969
   Li JL, 2005, BONE, V37, P819, DOI 10.1016/j.bone.2005.06.022
   Mayr E, 2000, ARCH ORTHOP TRAUM SU, V120, P1
   Milgrom C, 2004, BONE, V35, P418, DOI 10.1016/j.bone.2004.04.016
   MORI S, 1993, BONE, V14, P103, DOI 10.1016/8756 3282(93)90235 3
   Naruse K, 2000, BIOCHEM BIOPH RES CO, V268, P216, DOI 10.1006/bbrc.2000.2094
   Nolte PA, 2001, J TRAUMA, V51, P693, DOI 10.1097/00005373 200110000 00012
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P514
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P308
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Rue JPH, 2004, ORTHOPEDICS, V27, P1192, DOI 10.3928/0147 7447 20041101 18
   Sena K, 2005, ULTRASOUND MED BIOL, V31, P703, DOI 10.1016/j.ultrasmedbio.2005.01.013
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Stewart GW, 2005, CLIN J SPORT MED, V15, P92, DOI 10.1097/01.jsm.0000152716.06883.e0
   Sun JS, 2001, J BIOMED MATER RES, V57, P449, DOI 10.1002/1097 4636(20011205)57:3<449::AID JBM1188>3.0.CO;2 0
   Tami AE, 2003, J ORTHOP RES, V21, P1018, DOI 10.1016/S0736 0266(03)00099 8
   TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686
   Tsai C L, 1992, Chin J Physiol, V35, P27
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Warden SJ, 2005, SPORTS MED, V35, P271, DOI 10.2165/00007256 200535040 00001
   Warden SJ, 2003, SPORTS MED, V33, P95, DOI 10.2165/00007256 200333020 00002
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 38
TC 27
Z9 31
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD DEC
PY 2007
VL 25
IS 12
BP 1559
EP 1567
DI 10.1002/jor.20461
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 234QR
UT WOS:000251179300003
PM 17593538
DA 2025 08 17
ER

PT J
AU Liao, MY
   Zhu, X
   Lu, YM
   Yi, XP
   Hu, YH
   Zhao, YM
   Ye, ZS
   Guo, X
   Liang, MH
   Jin, X
   Zhang, H
   Wang, XH
   Zhao, ZM
   Chen, YP
   Yan, H
AF Liao, Mengyu
   Zhu, Xu
   Lu, Yumei
   Yi, Xiaoping
   Hu, Youhui
   Zhao, Yumeng
   Ye, Zhisheng
   Guo, Xu
   Liang, Minghui
   Jin, Xin
   Zhang, Hong
   Wang, Xiaohong
   Zhao, Ziming
   Chen, Yupeng
   Yan, Hua
TI Multi omics profiling of retinal pigment epithelium reveals
   enhancer driven activation of RANK NFATc1 signaling in traumatic
   proliferative vitreoretinopathy
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HUMAN MONOCLONAL ANTIBODY; MESENCHYMAL TRANSITION; OSTEOCLAST
   DIFFERENTIATION; EPIGENETIC REGULATION; PREVENTS DEVELOPMENT; GLOBE
   INJURIES; RISK FACTORS; P TEFB; RANKL; PATHOGENESIS
AB During the progression of proliferative vitreoretinopathy (PVR) following ocular trauma, previously quiescent retinal pigment epithelial (RPE) cells transition into a state of rapid proliferation, migration, and secretion. The elusive molecular mechanisms behind these changes have hindered the development of effective pharmacological treatments, presenting a pressing clinical challenge. In this study, by monitoring the dynamic changes in chromatin accessibility and various histone modifications, we chart the comprehensive epigenetic landscape of RPE cells in male mice subjected to traumatic PVR. Coupled with transcriptomic analysis, we reveal a robust correlation between enhancer activation and the upregulation of the PVR associated gene programs. Furthermore, by constructing transcription factor regulatory networks, we identify the aberrant activation of enhancer driven RANK NFATc1 pathway as PVR advanced. Importantly, we demonstrate that intraocular interventions, including nanomedicines inhibiting enhancer activity, gene therapies targeting NFATc1 and antibody therapeutics against RANK pathway, effectively mitigate PVR progression. Together, our findings elucidate the epigenetic basis underlying the activation of PVR associated genes during RPE cell fate transitions and offer promising therapeutic avenues targeting epigenetic modulation and the RANK NFATc1 axis for PVR management.
   Here the authors elucidate the epigenetic basis underlying the activation of PVR associated genes during RPE cell fate transitions and offers potential therapeutic avenues targeting epigenetic modulation and the RANK NFATc1 axis for PVR management.
C1 [Liao, Mengyu; Zhao, Yumeng; Ye, Zhisheng; Guo, Xu; Liang, Minghui; Wang, Xiaohong; Yan, Hua] Tianjin Med Univ, Tianjin Inst Eye Hlth & Eye Dis, China UK Belt & Rd Ophthalmol Joint Lab, Int Joint Lab Ocular Dis,Minist Educ,Tianjin Key L, Tianjin, Peoples R China.
   [Zhu, Xu; Lu, Yumei; Yi, Xiaoping; Chen, Yupeng] Tianjin Med Univ, Dept Biochem & Mol Biol, Key Lab Immune Microenvironm & Dis, Sch Basic Med Sci,Minist Educ,State Key Lab Expt H, Tianjin, Peoples R China.
   [Hu, Youhui; Zhao, Ziming] Xuzhou Med Univ, Dept Pharm, Xuzhou, Peoples R China.
   [Hu, Youhui; Zhao, Ziming] Xuzhou Med Univ, Clin Pharm, Jiangsu Key Lab New Drug Res, Xuzhou, Peoples R China.
   [Liang, Minghui] Nankai Univ, Sch Med, Tianjin, Peoples R China.
   [Jin, Xin; Zhang, Hong] Harbin Med Univ, Affiliated Hosp 1, Hosp Eye, Harbin 150001, Heilongjiang, Peoples R China.
   [Wang, Xiaohong] Tianjin Med Univ, Sch Basic Med Sci, Dept Pharmacol, Tianjin Key Lab Inflammat Biol, Tianjin, Peoples R China.
   [Chen, Yupeng] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Xuzhou Medical
   University; Xuzhou Medical University; Nankai University; Harbin Medical
   University; Tianjin Medical University; Tianjin Medical University
RP Yan, H (通讯作者)，Tianjin Med Univ, Tianjin Inst Eye Hlth & Eye Dis, China UK Belt & Rd Ophthalmol Joint Lab, Int Joint Lab Ocular Dis,Minist Educ,Tianjin Key L, Tianjin, Peoples R China.; Chen, YP (通讯作者)，Tianjin Med Univ, Dept Biochem & Mol Biol, Key Lab Immune Microenvironm & Dis, Sch Basic Med Sci,Minist Educ,State Key Lab Expt H, Tianjin, Peoples R China.; Zhao, ZM (通讯作者)，Xuzhou Med Univ, Dept Pharm, Xuzhou, Peoples R China.; Zhao, ZM (通讯作者)，Xuzhou Med Univ, Clin Pharm, Jiangsu Key Lab New Drug Res, Xuzhou, Peoples R China.; Chen, YP (通讯作者)，Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin, Peoples R China.
EM zmzhao@xzhmu.edu.cn; ychen@tmu.edu.cn; zyyyanhua@tmu.edu.cn
RI Wang, Xiaohong/S 4334 2019; Jin, Xin/ABF 1329 2020; Chen,
   Yupeng/T 5275 2019
OI Lu, Yumei/0009 0008 2519 8371; Zhao, Yumeng/0009 0009 1140 8419; Yi,
   Xiaoping/0009 0009 5133 5146; Liao, Mengyu/0000 0003 1915 2058
FU National Natural Science Foundation of China (National Science
   Foundation of China) [2021YFC2401404]; National Key RD Program
   [32241018, 82070689, 82330031, 82401296, 82271896]; National Natural
   Science Foundation of China [GZC20231924]; Postdoctoral Fellowship
   Program of CPSF
FX This work was supported by grants from the National Key R&D Program
   (2021YFC2401404 to H.Y.), the National Natural Science Foundation of
   China (32241018 and 82070689 to Y.C., 82330031 to H.Y., 82401296 to
   M.L., and 82271896 to X.Z.), and Postdoctoral Fellowship Program of CPSF
   (GZC20231924 to M.L.).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Azegami Nanako, 2022, Mass Spectrom (Tokyo), V11, pA0110, DOI 10.5702/massspectrometry.A0110
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bhagwat AS, 2016, CELL REP, V15, P519, DOI 10.1016/j.celrep.2016.03.054
   Boles NC, 2020, STEM CELL REP, V14, P631, DOI 10.1016/j.stemcr.2020.03.009
   Cardillo JA, 1997, OPHTHALMOLOGY, V104, P1166, DOI 10.1016/S0161 6420(97)30167 5
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976 500X.119726
   Colyer MH, 2008, OPHTHALMOLOGY, V115, P2087, DOI 10.1016/j.ophtha.2008.05.013
   Delgado Tirado S, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 77254 0
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   El Gendy MA, 2020, INT J PHARMACEUT, V582, DOI 10.1016/j.ijpharm.2020.119313
   Fernandez Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143
   Galvao J, 2014, FASEB J, V28, P1317, DOI 10.1096/fj.13 235440
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Han H, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.9.29
   Hatanaka H, 2021, BIOCHEM BIOPH RES CO, V544, P31, DOI 10.1016/j.bbrc.2021.01.060
   He S, 2015, INVEST OPHTH VIS SCI, V56, P5579, DOI 10.1167/iovs.14 16258
   Iribarne M, 2008, AM J PATHOL, V172, P1030, DOI 10.2353/ajpath.2008.070605
   Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027
   Jin Y, 2018, BLOOD, V131, P2138, DOI 10.1182/blood 2017 09 808063
   Jin Y, 2017, RETINA J RET VIT DIS, V37, P1236, DOI 10.1097/IAE.0000000000001350
   Khan MA, 2015, RETINA J RET VIT DIS, V35, P165, DOI 10.1097/IAE.0000000000000447
   Knyazer B, 2008, CLIN EXP OPHTHALMOL, V36, P836, DOI 10.1111/j.1442 9071.2009.01922.x
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Laich Y, 2022, INVEST OPHTH VIS SCI, V63, DOI 10.1167/iovs.63.5.17
   Li XH, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.86
   Lipinski DM, 2013, PROG RETIN EYE RES, V32, P22, DOI 10.1016/j.preteyeres.2012.09.001
   Liu B, 2019, LAB INVEST, V99, P1874, DOI 10.1038/s41374 019 0307 9
   Morescalchi F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/269787
   Nacev BA, 2020, NAT REV CANCER, V20, P608, DOI 10.1038/s41568 020 0288 4
   Nagai N, 2022, ADV DRUG DELIVER REV, V191, DOI 10.1016/j.addr.2022.114582
   Nawaz A, 2022, GELS BASEL, V8, DOI 10.3390/gels8070412
   Oh ES, 2021, NAT REV GENET, V22, P533, DOI 10.1038/s41576 021 00348 6
   Pastor JC, 2002, PROG RETIN EYE RES, V21, P127, DOI 10.1016/S1350 9462(01)00023 4
   Pennock S, 2014, PROG RETIN EYE RES, V40, P16, DOI 10.1016/j.preteyeres.2013.12.006
   Perino M, 2016, DEV CELL, V38, P610, DOI 10.1016/j.devcel.2016.08.004
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Shang P., 2018, J. Vis. Exp., V133, P56997
   Soler MVC, 2002, EXP EYE RES, V75, P491, DOI 10.1006/exer.2002.2031
   Storm T, 2020, J CELL SCI, V133, DOI 10.1242/jcs.238279
   Szczesniak AM, 2017, NEUROPHARMACOLOGY, V113, P627, DOI 10.1016/j.neuropharm.2016.08.030
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Vasdev N, 2022, J BIOMAT SCI POLYM E, V33, P1901, DOI 10.1080/09205063.2022.2088527
   Voss TC, 2014, NAT REV GENET, V15, P69, DOI 10.1038/nrg3623
   Wada I, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11102080
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573 019 0012 9
   Wang XR, 2022, GENES DIS, V9, P1062, DOI 10.1016/j.gendis.2020.12.012
   Wang ZY, 2021, EXP EYE RES, V213, DOI 10.1016/j.exer.2021.108859
   Wilkinson AC, 2017, CELL SYST, V5, P319, DOI 10.1016/j.cels.2017.07.004
   Wu T, 2018, CELL REP, V25, P1756, DOI 10.1016/j.celrep.2018.10.003
   Xiao W, 2014, J CELL MOL MED, V18, P646, DOI 10.1111/jcmm.12212
   Xu RM, 2021, PROTEIN CELL, V12, P7, DOI 10.1007/s13238 020 00757 z
   Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoo K, 2017, MOL VIS, V23, P933
   Zhang BJ, 2016, NATURE, V537, P553, DOI 10.1038/nature19361
   Zhang QQ, 2023, CELL METAB, V35, P943, DOI 10.1016/j.cmet.2023.04.015
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
   Zou H, 2020, PEERJ, V8, DOI 10.7717/peerj.10136
NR 67
TC 2
Z9 3
U1 8
U2 19
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 25
PY 2024
VL 15
IS 1
AR 7324
DI 10.1038/s41467 024 51624 y
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA D7Q3F
UT WOS:001298087400002
PM 39183203
OA gold
DA 2025 08 17
ER

PT J
AU Kim, WY
   Lee, JB
   Kim, HY
   Woo, SU
   Son, GS
   Bae, JW
AF Kim, Woo Young
   Lee, Jae Bok
   Kim, Hoon Yub
   Woo, Sang Uk
   Son, Gil Soo
   Bae, Jeoung Won
TI Achievement of the National Kidney Foundation Kidney Disease Outcomes
   Quality Initiative: recommended serum calcium, phosphate and parathyroid
   hormone values with parathyroidectomy in patients with secondary
   hyperparathyroidism
SO JOURNAL OF THE KOREAN SURGICAL SOCIETY
LA English
DT Article
DE Parathyroidectomy; Parathyroid hormone; Calcium; Phosphates
ID MINERAL METABOLISM; DIALYSIS OUTCOMES; BONE METABOLISM; MEDICAL THERAPY;
   MORTALITY RISK; TARGET VALUES; SHORT TERM; CINACALCET;
   AUTOTRANSPLANTATION; ASSOCIATION
AB Purpose: The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF K/DOQI) 2003 has established guidelines for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease   minerals and bone disorder (CKD MBD). This study evaluated parathyroidectomy in SHPT patients for the achievement of the NKF K/DOQI recommended values of serum calcium, phosphate, and parathyroid hormone (PTH).
   Methods: Between January 2005 and December 2010, parathyroidectomy was performed as recommended by the NKF K/DOQI guidelines in 81 patients with SHPT and CKD MBD. Serum PTH, calcium, and phosphate levels were measured prior to and 6, 12, 36, and 60 months after parathyroidectomy.
   Results: Calcium, phosphate, and PTH levels dropped shortly after parathyroidectomy; however, a slight increase showed in the long term. Calcium levels increased for up to 60 months. Phosphate and PTH levels increased for up to 36 months but tended to decrease slightly at 60 months. The mean values were within the target ranges, except for PTH at 36 months. The target parameters of serum phosphate (42.9 61.1% of patients) and serum calcium (a peak of 61.1% of patients at 36 months, but only 28.6% at 60 months) were achieved the most. Less than 34% of patients achieved the recommended range for PTH.
   Conclusion: Parathyroidectomy was not an optimal procedure for achieving all the biochemical parameters recommended by the NKF K/DOQI. Although it was helpful in attaining the recommended values for serum calcium and phosphate in SHPT patients resistant to medical therapy, the PTH levels did not fall within the recommended range.
C1 [Kim, Woo Young; Lee, Jae Bok; Woo, Sang Uk] Korea Univ Coll Med, Korea Univ Guro Hosp, Dept Surg, Seoul 152703, South Korea.
   [Kim, Hoon Yub; Bae, Jeoung Won] Korea Univ Coll Med, Korea Univ Anam Hosp, Dept Surg, Seoul 152703, South Korea.
   [Son, Gil Soo] Korea Univ Coll Med, Korea Univ Ansan Hosp, Dept Surg, Ansan, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine); Korea University;
   Korea University Medicine (KU Medicine)
RP Lee, JB (通讯作者)，Korea Univ Coll Med, Korea Univ Guro Hosp, Dept Surg, 148 Gurodong Ro, Seoul 152703, South Korea.
EM jbleemd@korea.ac.kr
RI KIM, SUNJONG/JXN 0257 2024; Woo, Sang/C 8417 2009; Kim,
   Su jin/F 2905 2014
CR Al Aly Z, 2004, AM J NEPHROL, V24, P422, DOI 10.1159/000080087
   Barreto FC, 2008, KIDNEY INT, V73, P771, DOI 10.1038/sj.ki.5002769
   Chou FF, 2010, WORLD J SURG, V34, P2350, DOI 10.1007/s00268 010 0711 1
   Coen G, 2001, NEPHRON, V88, P149, DOI 10.1159/000045976
   Dussol B, 2007, RENAL FAILURE, V29, P579, DOI 10.1080/08860220701392447
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   GAGNE ER, 1992, J AM SOC NEPHROL, V3, P1008
   Gal Moscovici A, 2005, CLIN NEPHROL, V63, P284
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Ghani A, 2012, OTOLARYNG HEAD NECK, V146, P220, DOI 10.1177/0194599811428272
   Mazzaferro S, 2008, NEPHROL DIAL TRANSPL, V23, P2319, DOI 10.1093/ndt/gfm931
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Narayan R, 2007, AM J KIDNEY DIS, V49, P801, DOI 10.1053/j.ajkd.2007.03.009
   Noordzij M, 2005, AM J KIDNEY DIS, V46, P925, DOI 10.1053/j.ajkd.2005.08.013
   Rayes N, 2008, ARCH SURG CHICAGO, V143, P756, DOI 10.1001/archsurg.143.8.756
   Rudser KD, 2007, J AM SOC NEPHROL, V18, P2401, DOI 10.1681/ASN.2007010022
   Schneider R, 2010, SURGERY, V148, P1091, DOI 10.1016/j.surg.2010.09.009
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tominaga Y, 2003, NEPHROL DIAL TRANSPL, V18, P65, DOI 10.1093/ndt/gfg1017
   Tominaga Y, 2008, THER APHER DIAL, V12, pS21, DOI 10.1111/j.1744 9987.2008.00627.x
   Ureña P, 2009, NEPHROL DIAL TRANSPL, V24, P2852, DOI 10.1093/ndt/gfp144
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 23
TC 5
Z9 6
U1 0
U2 29
PU KOREAN SURGICAL SOCIETY
PI SEOUL
PA 3304HO, 101 DONG, BROWNSTONE SEOUL, 335, JUNGMIN DONG, JUNG GU, SEOUL,
   100 859, SOUTH KOREA
SN 2233 7903
EI 2093 0488
J9 J KOREAN SURG SOC
JI J. Korean Surg. Soc.
PD JUL
PY 2013
VL 85
IS 1
BP 25
EP 29
DI 10.4174/jkss.2013.85.1.25
PG 5
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 174NO
UT WOS:000321162900005
PM 23833757
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, JS
   Ryder, KD
   Bethel, JA
   Ramirez, R
   Duncan, RL
AF Zhang, Jinsong
   Ryder, Kimberly D.
   Bethel, Jody A.
   Ramirez, Raymund
   Duncan, Randall L.
TI PTH induced actin depolymerization increases mechanosensitive channel
   activity to enhance mechanically stimulated Ca<SUP>2+</SUP> signaling in
   osteoblasts
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Proceedings Paper
CT 50th Annual Meeting of the Orthopaedic Research Society
CY MAR 07 10, 2004
CL San Francisco, CA
SP Orthopaed Res Soc
DE mechanotransduction; PTH; intracellular Ca2+; actin cytoskeleton; fluid
   shear; osteoblasts
ID FLUID SHEAR STRESS; PROTEIN KINASE A; PARATHYROID HORMONE; ION CHANNELS;
   TRANSDUCTION PATHWAYS; PROSTAGLANDIN RELEASE; MC3T3 E1 OSTEOBLASTS;
   CALCIUM CHANNELS; BONE CELLS; MECHANOTRANSDUCTION
AB Disruption of the actin cytoskeleton with cytochalasin D enhanced the mechanically induced increase in intracellular Ca2+ ([Ca2+](i)) in osteoblasts in a manner similar to that of PTH. Stabilization of actin with phalloidin prevented the PTH enhanced [Ca2+](i) response to shear. Patch clamp analyses show that the MSCC is directly influenced by alterations in actin integrity.
   Introduction: PTH significantly enhances the fluid shear induced increase in [Ca2+](i) in osteoblasts, in part, through increased activation of both the mechanosensitive, cation selective channel (MSCC) and L type voltage sensitive Ca2+ channel (L VSCC). Both stimuli have been shown to produce dynamic changes in the organization of the actin cytoskeleton. In this study, we examined the effects of alterations in actin polymerization on [Ca2+](i) and MSCC activity in MC3T3 E1 and UMR 106.01. osteoblasts in response to shear PTH pretreatment.
   Materials and Methods: MC3T3 E1 or UMR 106.01 cells were plated onto type I collagen coated quartz slides, allowed to proliferate to 60% confluency, and mounted on a modified parallel plate chamber and subjected to 12 dynes/cm(2). For patch clamp studies, cells were plated on collagen coated glass coverslips, mounted on the patch chamber, and subjected to pipette suction. Modulators of actin cytoskeleton polymerization were added 30 minutes before the experiments, whereas channel inhibitors were added 10 minutes before mechanical stimulation. All drugs were maintained in the flow medium for the duration of the experiment.
   Results and Conclusions: Depolymerization of actin with 1 5 mu M cytochalasin D (cyto D) augmented the peak [Ca2+]i response and increased the number of cells responding to shear, similar to the increased responses induced by pretreatment with 50 nM PTH. Stabilization of actin with phalloidin prevented the PTH enhanced [Ca2+]i response to shear. Inhibition of the MSCC with Gd3+ significantly blocked both the peak Ca2+ response and the number of cells responding to shear in cells pretreated with either PTH or cyto D. Inhibition of the L VSCC reduced the peak [Ca2+] i response to shear in cells pretreated with PTH, but not with cyto D. Patch clamp analyses found that addition of PTH or cyto D significantly increased the MSCC open probability in response to mechanical stimulation, whereas phalloidin significantly attenuated the PTH enhanced MSCC activation. These data indicate that actin reorganization increases MSCC activity in a manner similar to PTH and may be one mechanism through which PTH may reduce the mechanical threshold of osteoblasts.
C1 Univ Delaware, Dept Sci Biol, Newark, DE 19716 USA.
   Univ Delaware, Dept Engn Mech, Newark, DE 19716 USA.
   Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46204 USA.
C3 University of Delaware; University of Delaware; Indiana University
   System; Indiana University Indianapolis
RP Duncan, RL (通讯作者)，Univ Delaware, Dept Sci Biol, 319 Wolf Hall, Newark, DE 19716 USA.
EM rlduncan@udel.edu
RI ; Duncan, Randall/AAK 3888 2020; Zhang, Jinsong/AAF 9981 2021
OI Duncan, Randall/0000 0001 5733 6603; 
FU NIAMS NIH HHS [AR043222] Funding Source: Medline; NIDDK NIH HHS
   [DK058246] Funding Source: Medline
CR Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   BUCKLEY MJ, 1988, BONE MINER, V4, P225
   CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882
   CARVALHO RS, 1994, J BONE MINER RES, V9, P999
   Chow JWM, 1998, AM J PHYSIOL ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146
   Cukovic D, 2001, FEBS LETT, V498, P87, DOI 10.1016/S0014 5793(01)02505 4
   DAVIDSON RM, 1990, PFLUG ARCH EUR J PHY, V416, P646, DOI 10.1007/BF00370609
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   DUNCAN R, 1989, FEBS LETT, V251, P17, DOI 10.1016/0014 5793(89)81420 6
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   DUNCAN RL, 1992, FEBS LETT, V307, P219, DOI 10.1016/0014 5793(92)80771 8
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   FROST HM, 1987, BONE MINER, V2, P73
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   GUHARAY F, 1984, J PHYSIOL LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317
   GUNNESS M, 1993, BONE, V14, P277, DOI 10.1016/8756 3282(93)90152 Z
   Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01 0855com
   Howe AK, 2004, BBA MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005
   Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021 9290(96)84536 2
   JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142 9612(91)90186 E
   Kamkin A, 2003, PFLUG ARCH EUR J PHY, V446, P220, DOI 10.1007/s00424 003 1018 y
   Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095
   Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010
   LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205
   Li W, 1997, AM J PHYSIOL ENDOC M, V273, pE599, DOI 10.1152/ajpendo.1997.273.3.E599
   LOMRI A, 1990, BONE MINER, V10, P1, DOI 10.1016/0169 6009(90)90045 H
   LOMRI A, 1988, BIOCHIM BIOPHYS ACTA, V970, P333, DOI 10.1016/0167 4889(88)90133 4
   Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439
   Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849
   Martin RB., 1989, STRUCTURE FUNCTION A
   MILLER SS, 1976, SCIENCE, V192, P1340, DOI 10.1126/science.1273593
   MOSEKILDE L, 1994, ENDOCRINOLOGY, V134, P2126, DOI 10.1210/en.134.5.2126
   Nakamura M, 2000, AM J PHYSIOL CELL PH, V279, pC480, DOI 10.1152/ajpcell.2000.279.2.C480
   Norvell SM, 2004, J APPL PHYSIOL, V96, P957, DOI 10.1152/japplphysiol.00869.2003
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Pascarel C, 1999, EXP PHYSIOL, V84, P1043, DOI 10.1111/j.1469 445X.1999.01876.x
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224
   Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756 3282(96)00260 8
   REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113
   REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45
   Ryder KD, 2001, J BONE MINER RES, V16, P240, DOI 10.1359/jbmr.2001.16.2.240
   Sakai K, 1998, CALCIFIED TISSUE INT, V63, P515, DOI 10.1007/s002239900567
   Terzic A, 1996, J PHYSIOL LONDON, V492, P395, DOI 10.1113/jphysiol.1996.sp021316
   Tetradis S, 1997, ENDOCRINOLOGY, V138, P3594, DOI 10.1210/en.138.9.3594
   WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711
NR 50
TC 35
Z9 46
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2006
VL 21
IS 11
BP 1729
EP 1737
DI 10.1359/JBMR.060722
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 099MR
UT WOS:000241599600008
PM 17002579
OA Bronze
DA 2025 08 17
ER

PT J
AU Cao, SY
   Wang, Y
   Zhang, YL
   Ren, JY
   Fan, BJ
   Deng, Y
   Yin, WZ
AF Cao, Shuyan
   Wang, Yi
   Zhang, Yalong
   Ren, Jingyi
   Fan, Bingjie
   Deng, Ying
   Yin, Wenzhe
TI Naringenin can Inhibit the Pyroptosis of Osteoblasts by Activating the
   Nrf2/HO 1 Signaling Pathway and Alleviate the Differentiation Disorder
   of Osteoblasts Caused by Microgravity
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE SMG; naringenin; pyroptosis; oxidativestress; Nrf2
ID GLUCOCORTICOID INDUCED APOPTOSIS; OXIDATIVE STRESS RESPONSE; NLRP3
   INFLAMMASOME; TRABECULAR BONE; OSTEOCLASTOGENESIS; SPACEFLIGHT;
   METABOLISM; PREVENTION; VIVO
AB Naringenin (4,5,7 trihydroxyflavone, NAR) is an effective active ingredient in Rhizoma Drynariae, which has many biological functions, encompassing anti inflammatory and  oxidant functions. Prior research has shown that NOD like receptor pyrin domain containing protein 3 (NLRP3) inflammasomes possessed a significant contribution to osteoporosis. However, the NAR impact on bone loss caused by microgravity remains unclear. Classical microgravity simulation methods were used to induce simulated microgravity (SMG) in mice and cells. Microcomputed tomography, immunohistochemical examination, and hematoxylin and eosin staining were implemented to ascertain alterations in bone microstructure and morphology in mice subsequent to NAR gavage. Cellular investigations were implemented encompassing quantitative real time polymerase chain reaction, Western blotting, and immunofluorescence labeling to investigate the molecular mechanism behind NAR resistance to microgravity induced bone loss. Our research has shown that NAR can significantly enhance the SMG stimulated alterations in bone microstructure and morphology in mice, mainly by increasing the trabecular thickness, bone volume fraction, and trabecular number while increasing the bone trabecula number. Cell experiments also showed that SMG caused the activation of inflammatory corpuscles of NLRP3 and induced pyroptosis simultaneously, which can be confirmed by the upregulation of protein and mRNA expression levels such as those of NLRP3, cleaved caspase 1, gasdermin D, and apoptosis associated speck like protein. The occurrence of pyroptosis further led to the disorder of osteogenic differentiation, which showed that the osteopontin, Runt related transcription factor 2, bone morphogenetic protein 2, and alkaline phosphatase expression levels were decreased. The intervention of NAR can activate the nuclear factor erythroid 2 related factor 2/heme oxygenase 1 (Nrf2/HO 1) pathway, reverse this phenomenon via controlling the reactive oxygen species generation in cells and correcting mitochondrial malfunction, weaken the pyroptosis of osteoblasts (OBs), and promote osteogenic differentiation. In summary, NAR could hinder the pyroptosis of OBs caused by SMG and promote osteogenic differentiation via activating the Nrf2/HO 1 pathway. This provides a unique view for inhibiting bone loss under weightlessness and confirms the NAR capacity in treating microgravity stimulated bone loss, giving new ideas and methods for future space medicine development.
C1 [Cao, Shuyan; Yin, Wenzhe] Harbin Med Univ, Affiliated Hosp 2, Dept Orthopaed, Harbin 150001, Heilongjiang, Peoples R China.
   [Wang, Yi; Deng, Ying] Harbin Med Univ, Affiliated Hosp 2, Dept Emergency, Harbin 150001, Heilongjiang, Peoples R China.
   [Zhang, Yalong] Harbin Med Univ, Affiliated Hosp 2, Dept Rehabil, Harbin 150001, Heilongjiang, Peoples R China.
   [Ren, Jingyi] Harbin Med Univ, Affiliated Hosp 2, Dept Crit Care Med, Harbin 150001, Heilongjiang, Peoples R China.
   [Fan, Bingjie] Guizhou Med Univ, Affiliated Hosp, Dept Hematol, Guiyang 550000, Guizhou, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University; Harbin Medical University; Guizhou Medical University
RP Yin, WZ (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Orthopaed, Harbin 150001, Heilongjiang, Peoples R China.; Deng, Y (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Emergency, Harbin 150001, Heilongjiang, Peoples R China.
EM drhyj0435@163.com; hydywz@163.com
RI fan, bingjie/HWQ 6593 2023
FU National Natural Science Foundation of China [81873093]
FX This investigation received funding from the National Natural Science
   Foundation of China (grant no.81873093).
CR Andreyev AI, 2005, BIOCHEMISTRY MOSCOW+, V70, P200, DOI 10.1007/s10541 005 0102 7
   Arioz BI, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01511
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Beck M, 2014, INT J MOL MED, V34, P606, DOI 10.3892/ijmm.2014.1785
   Bertholet AM, 2016, NEUROBIOL DIS, V90, P3, DOI 10.1016/j.nbd.2015.10.011
   Blanc S, 1998, J CLIN ENDOCR METAB, V83, P4289, DOI 10.1210/jc.83.12.4289
   Bodet C, 2008, J PERIODONTAL RES, V43, P400, DOI 10.1111/j.1600 0765.2007.01055.x
   Bosemark P, 2014, J ORTHOP RES, V32, P721, DOI 10.1002/jor.22599
   Cai SM, 2016, ANTIOXID REDOX SIGN, V24, P795, DOI 10.1089/ars.2015.6498
   Cheng KW, 2009, CHEM RES TOXICOL, V22, P1483, DOI 10.1021/tx9001644
   Cui L, 2012, INT J MOL SCI, V13, P14251, DOI 10.3390/ijms131114251
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Diao Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30992 8
   Fan JB, 2023, FREE RADICAL BIO MED, V208, P807, DOI 10.1016/j.freeradbiomed.2023.09.032
   Fan JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2317 3
   Gerbaix M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03014 2
   Giacomello M, 2020, NAT REV MOL CELL BIO, V21, P204, DOI 10.1038/s41580 020 0210 7
   Grimm D, 2016, BONE, V87, P44, DOI 10.1016/j.bone.2015.12.057
   Gunn J, 1991, Aust Fam Physician, V20, P188
   Guo HH, 2023, INFLAMMOPHARMACOLOGY, V31, P745, DOI 10.1007/s10787 023 01148 6
   He F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134777
   Hsiao FY, 2017, JPN J CLIN ONCOL, V47, P935, DOI 10.1093/jjco/hyx111
   Huang CC, 2020, DRUG DES DEV THER, V14, P4901, DOI 10.2147/DDDT.S269223
   Ichim G, 2015, MOL CELL, V57, P860, DOI 10.1016/j.molcel.2015.01.018
   Indo HP, 2015, J CLIN BIOCHEM NUTR, V56, P1, DOI 10.3164/jcbn.14 42
   Jayaraman J, 2011, FUND CLIN PHARMACOL, V25, P682, DOI 10.1111/j.1472 8206.2010.00899.x
   JEE WSS, 1983, AM J PHYSIOL, V244, pR310, DOI 10.1152/ajpregu.1983.244.3.R310
   Ji MT, 2023, MOLECULES, V28, DOI 10.3390/molecules28010198
   Jiang MX, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420 020 00349 0
   Jin X, 2022, NPJ MICROGRAVITY, V8, DOI 10.1038/s41526 022 00210 x
   Kang R, 2018, CELL HOST MICROBE, V24, P97, DOI 10.1016/j.chom.2018.05.009
   Kim SH, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115650
   Kumar K, 2019, MITOCHONDRION, V48, P1, DOI 10.1016/j.mito.2018.06.003
   La VD, 2009, J PERIODONTAL RES, V44, P193, DOI 10.1111/j.1600 0765.2008.01107.x
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Lin BH, 2023, J AGR FOOD CHEM, V71, P17362, DOI 10.1021/acs.jafc.3c03501
   Lin H, 2015, BIOCHEM BIOPH RES CO, V460, P422, DOI 10.1016/j.bbrc.2015.03.049
   Liu QY, 2018, MOL IMMUNOL, V103, P115, DOI 10.1016/j.molimm.2018.09.010
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Mahalanobish S, 2020, FOOD CHEM TOXICOL, V144, DOI 10.1016/j.fct.2020.111588
   Martinez RM, 2015, J NAT PROD, V78, P1647, DOI 10.1021/acs.jnatprod.5b00198
   Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600 065X.2011.01044.x
   Minutoli L, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2183026
   Mo RB, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12608
   Montgomery G, 2019, J ELECTROMYOGR KINES, V44, P124, DOI 10.1016/j.jelekin.2018.12.004
   Mouasni S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1412 9
   Pan ZF, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154330
   Qiu Z, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/8151836
   Quintana Cabrera R, 2023, MOL CELL, V83, P857, DOI 10.1016/j.molcel.2023.02.012
   Rani N, 2016, CURR PHARM DESIGN, V22, P4341, DOI 10.2174/1381612822666160530150936
   Salehi B, 2019, PHARMACEUTICALS BASE, V12, DOI 10.3390/ph12010011
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Schieffer L, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11010149
   Shen YL, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989 018 0253 5
   Smith BJ, 2002, J NUTR, V132, P190, DOI 10.1093/jn/132.2.190
   Smith JK, 2020, LIFE BASEL, V10, DOI 10.3390/life10090207
   Song DZ, 2018, J CELL PHYSIOL, V233, P9674, DOI 10.1002/jcp.26882
   Su LJ, 2023, AUTOPHAGY, V19, P401, DOI 10.1080/15548627.2022.2084862
   Sun LB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1761 4
   Sun ZY, 2019, J CELL BIOCHEM, V120, P4009, DOI 10.1002/jcb.27685
   Swaffield TP, 2018, AEROSP MED HUM PERF, V89, P1060, DOI 10.3357/AMHP.5007.2018
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Tian Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102132
   Tsuchiya K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010426
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Wen J, 2021, NEUROPHARMACOLOGY, V182, DOI 10.1016/j.neuropharm.2020.108380
   Xin M, 2015, OSTEOPOROSIS INT, V26, P2665, DOI 10.1007/s00198 015 3153 7
   Yang HY, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012947
   Yang JC, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115108
   Yang J, 2017, CELL MOL IMMUNOL, V14, P65, DOI 10.1038/cmi.2016.29
   Zhang B, 2022, COMPUT INTEL NEUROSC, V2022, DOI 10.1155/2022/6031129
   Zhang CG, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.607017
NR 74
TC 1
Z9 1
U1 3
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021 8561
EI 1520 5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV 7
PY 2024
VL 72
IS 46
BP 25586
EP 25600
DI 10.1021/acs.jafc.4c05370
EA NOV 2024
PG 15
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA M7Y2N
UT WOS:001350031700001
PM 39506307
OA hybrid
DA 2025 08 17
ER

PT J
AU Xu, BB
   Dong, FH
   Yang, P
   Wang, ZH
   Yan, M
   Fang, J
   Zhang, Y
AF Xu, Bingbing
   Dong, Fanhe
   Yang, Pei
   Wang, Zihan
   Yan, Ming
   Fang, Jian
   Zhang, Yun
TI Boric Acid Inhibits RANKL Stimulated Osteoclastogenesis In Vitro and
   Attenuates LPS Induced Bone Loss In Vivo
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Boric acid; RANKL; Osteoclastogenesis; PERK eIF2 alpha pathway; LPS;
   Bone loss
ID BORON CONTAINING COMPOUNDS; EXPERIMENTAL PERIODONTITIS; DIFFERENTIATION;
   CELLS; RESORPTION; PATHWAYS; THERAPY; DISEASE
AB Boron and boric acid (BA) can promote osteogenic differentiation and reduce bone resorption, which controls bone growth and maintenance of bone tissue. It has been reported that BA activates PERK eIF2 alpha signaling to induce cytoplasmic stress granules and cell senescence in human prostate DU 145 cells. However, whether BA can affect osteoclasts formation and LPS induced inflammatory bone loss, and the role of the PERK eIF2 alpha pathway in the process, remains unknown. In vitro, RAW264.7 cells were pre treated with boric acid (BA, 1, 10, 100 mu mol/L) for 4 h, and then incubated with receptor activator of nuclear factor kappaB ligand (RANKL, 50 ng/mL) in the presence or absence of BA for 5 days. CCK 8 and tartrate resistant acid phosphatase (TRAP) were used to examine cell viability, osteoclastogenesis, and bone resorption; quantitative real time PCR was performed to examine mRNA levels of c Fos, nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), TRAP, and cathepsin K; western blotting was used to examine protein expressions of glucose regulated protein 78 (GRP78), protein kinase R (PKR) like endoplasmic reticulum kinase (PERK), phosphorylated PERK (p PERK), eukaryotic initiation factor 2 alpha (eIF2 alpha), and phosphorylated eIF2 alpha (p eIF2 alpha). In vivo, lipopolysaccharide (LPS) induced bone loss model in mice was established, and micro computed tomography (micro CT) scanning, bone biochemical analysis, and osteoclastogenic cytokines were detected to evaluate the effect of BA on LPS induced bone loss. In our vitro results showed that BA treatment for 5 days inhibited osteoclasts formation as well as osteoclastic bone resorption in a dose dependent manner. The expression of osteoclasts marker genes c Fos, NFATc1, TRAP, and cathepsin K were attenuated by BA. Immunoblotting analysis demonstrated that BA attenuated RANKL induced PERK eIF2 alpha pathway activation. The in vivo data indicated that BA significantly prevented lipopolysaccharide (LPS) induced bone loss. Our findings strongly suggest that BA may be a promising agent for the treatment of bone destructive diseases caused by excessive osteoclastogenesis.
C1 [Xu, Bingbing; Dong, Fanhe; Yang, Pei; Wang, Zihan; Fang, Jian; Zhang, Yun] Shaoxing Univ, Coll Med, Huancheng West Rd 508, Shaoxing 312000, Peoples R China.
   [Yan, Ming] Hangzhou Dianzi Univ, Sch Automat, Xiasha Higher Educ Zone, 1158 2nd Ave, Hangzhou 310018, Peoples R China.
C3 Shaoxing University; Hangzhou Dianzi University
RP Zhang, Y (通讯作者)，Shaoxing Univ, Coll Med, Huancheng West Rd 508, Shaoxing 312000, Peoples R China.
EM zhangyunbme@126.com
FU Natural Science Foundation of Zhejiang Province [LY21H060001]; Zhejiang
   Public Welfare Technology Application Research Project [LGF18H060006];
   National Undergraduate Innovation and Entrepreneurship Training Program
   [202110349006]
FX This work was supported by Natural Science Foundation of Zhejiang
   Province (LY21H060001), Zhejiang Public Welfare Technology Application
   Research Project (LGF18H060006), and National Undergraduate Innovation
   and Entrepreneurship Training Program (202110349006).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Aydin S, 2019, MOL BIOL REP, V46, P5465, DOI 10.1007/s11033 019 05002 3
   Barranco WT, 2006, BRIT J CANCER, V94, P884, DOI 10.1038/sj.bjc.6603009
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen Yue liang, 2018, Jiepou Xuebao, V49, P98, DOI 10.16098/j.issn.0529 1356.2018.01.016
   Geyikoglu F, 2019, BIOL TRACE ELEM RES, V192, P214, DOI 10.1007/s12011 019 1649 2
   Gorustovich AA, 2019, BIOL TRACE ELEM RES, V188, P221, DOI 10.1007/s12011 018 1499 3
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Hacioglu C, 2020, BIOL TRACE ELEM RES, V193, P400, DOI 10.1007/s12011 019 01739 x
   Hadidi L, 2021, J ORTHOP TRAUMA, V35, pE165, DOI 10.1097/BOT.0000000000001974
   Hadrup N, 2021, REGUL TOXICOL PHARM, V121, DOI 10.1016/j.yrtph.2021.104873
   Hakki SS, 2021, BIOL TRACE ELEM RES, V199, P1534, DOI 10.1007/s12011 020 02257 x
   Hakki SS, 2010, J TRACE ELEM MED BIO, V24, P243, DOI 10.1016/j.jtemb.2010.03.003
   Hasegawa H, 2010, J BIOL CHEM, V285, P25448, DOI 10.1074/jbc.M109.068742
   He L, 2013, CELL SIGNAL, V25, P552, DOI 10.1016/j.cellsig.2012.11.015
   Henderson KA, 2015, BIOMETALS, V28, P133, DOI 10.1007/s10534 014 9809 5
   Heymann D, 2005, DRUG DISCOV TODAY, V10, P242, DOI 10.1016/S1359 6446(04)03265 9
   Khaliq H, 2018, BIOL TRACE ELEM RES, V186, P31, DOI 10.1007/s12011 018 1284 3
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kim JH, 2018, J IMMUNOL, V200, P1661, DOI 10.4049/jimmunol.1701036
   Kobylewski SE, 2017, BIOL TRACE ELEM RES, V176, P278, DOI 10.1007/s12011 016 0824 y
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Liu GY, 2016, CELL TISSUE RES, V363, P427, DOI 10.1007/s00441 015 2205 9
   Liu YJ, 2018, J BIOMATER APPL, V32, P765, DOI 10.1177/0885328217740730
   Lv SM, 2016, INT ORTHOP, V40, P1545, DOI 10.1007/s00264 015 3021 2
   Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Moon HJ, 2012, BIOCHEM BIOPH RES CO, V418, P247, DOI 10.1016/j.bbrc.2012.01.005
   Ralston SH, 2012, CALCIFIED TISSUE INT, V91, P97, DOI 10.1007/s00223 012 9599 0
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rouschop KM, 2013, P NATL ACAD SCI USA, V110, P4622, DOI 10.1073/pnas.1210633110
   Saglam M, 2014, J PERIODONTAL RES, V49, P472, DOI 10.1111/jre.12126
   Shalehin N, 2020, J DENT SCI, V15, P437, DOI 10.1016/j.jds.2019.09.009
   Yamada H, 2015, J PERIODONTAL RES, V50, P500, DOI 10.1111/jre.12232
   Yamada KE, 2019, BIOL TRACE ELEM RES, V188, P2, DOI 10.1007/s12011 018 1498 4
   Zhang LY, 2020, TOXICOL RES UK, V9, P544, DOI 10.1093/toxres/tfaa053
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
NR 39
TC 5
Z9 6
U1 1
U2 31
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD MAR
PY 2023
VL 201
IS 3
BP 1388
EP 1397
DI 10.1007/s12011 022 03231 5
EA APR 2022
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 8P3PP
UT WOS:000782162900003
PM 35397103
DA 2025 08 17
ER

PT J
AU Kang, WS
   Sun, ST
   Nguyen, K
   Kashemirov, B
   McKenna, CE
   Hacking, SA
   Quesnel, AM
   Sewell, WF
   McKenna, MJ
   Jung, DH
AF Kang, Woo Seok
   Sun, Shuting
   Nguyen, Kim
   Kashemirov, Boris
   McKenna, Charles E.
   Hacking, S. Adam
   Quesnel, Alicia M.
   Sewell, William F.
   McKenna, Michael J.
   Jung, David H.
TI Non Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Bisphosphonates; Fluorescence imaging; Inner ear drug delivery;
   Otosclerosis
ID FLUORESCENTLY LABELED BISPHOSPHONATES; SENSORINEURAL HEARING LOSS;
   FAR ADVANCED OTOSCLEROSIS; ROUND WINDOW MEMBRANE; SCALA TYMPANI;
   IN VIVO; CONCENTRATION GRADIENT; BONE TURNOVER; IMPLANTATION;
   PHARMACOKINETICS
AB Hypothesis Local delivery of bisphosphonates results in superior localization of these compounds for the treatment of cochlear otosclerosis, without ototoxicity.
   Background Otosclerosis is a common disorder of abnormal bone remodeling within the human otic capsule. It is a frequent cause of conductive hearing loss from stapes fixation. Large lesions that penetrate the cochlear endosteum and injure the spiral ligament result in sensorineural hearing loss. Nitrogen containing bisphosphonates (e.g., zoledronate) are potent inhibitors of bone remodeling with proven efficacy in the treatment of metabolic bone diseases, including otosclerosis. Local delivery to the cochlea may allow for improved drug targeting, higher local concentrations, and the avoidance of systemic complications. In this study, we use a fluorescently labeled bisphosphonate compound (6 FAM ZOL) to determine drug localization and concentration within the otic capsule. Various methods for delivery are compared. Ototoxicity is evaluated by auditory brainstem responses and distortion product otoacoustic emissions.
   Methods 6 FAM ZOL was administered to guinea pigs via intraperitoneal injection, placement of alginate beads onto the round window membrane, or microfluidic pump infusion via a cochleostomy. Hearing was evaluated. Specimens were embedded into resin blocks, ground to a mid modiolar section, and quantitatively imaged using fluorescence microscopy.
   Results There was a dose dependent increase in fluorescent signal after systemic 6 FAM ZOL treatment. Local delivery via the round window membrane or a cochleostomy increased delivery efficiency. No significant ototoxicity was observed after either systemic or local 6 FAM ZOL delivery.
   Conclusion These findings establish important preclinical parameters for the treatment of cochlear otosclerosis in humans.
C1 [Kang, Woo Seok; Quesnel, Alicia M.; McKenna, Michael J.; Jung, David H.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
   [Kang, Woo Seok; Quesnel, Alicia M.; Sewell, William F.; McKenna, Michael J.; Jung, David H.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
   [Kang, Woo Seok; Quesnel, Alicia M.; McKenna, Michael J.; Jung, David H.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
   [Sun, Shuting; Nguyen, Kim; Kashemirov, Boris; McKenna, Charles E.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA.
   [Hacking, S. Adam] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   Eye & Ear Infirmary; Harvard University; Harvard University Medical
   Affiliates; Massachusetts Eye & Ear Infirmary; Harvard University;
   Harvard Medical School; University of Southern California; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Harvard Medical School
RP Jung, DH (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM david_jung@meei.harvard.edu
RI Sun, Shuting/N 1807 2014; Nguyen, Kim/JWP 3649 2024; Hacking,
   Adam/F 3645 2010
OI Sun, Shuting/0000 0002 3635 9029; 
FU NIDCD [R01 DC009837]; Harvard Catalyst | The Harvard Clinical and
   Translational Science Center (National Center for Research Resources and
   the National Center for Advancing Translational Sciences, National
   Institutes of Health) [8UL1TR000170 05]; Harvard Catalyst | The Harvard
   Clinical and Translational Science Center (Harvard University)
FX The authors thank Doug Hayden, PhD, for assistance with the
   biostatistical analyses, and Kris Kristiansen for excellent technical
   support. This work was primarily supported by NIDCD grant R01 DC009837,
   with additional support from Harvard Catalyst | The Harvard Clinical and
   Translational Science Center (National Center for Research Resources and
   the National Center for Advancing Translational Sciences, National
   Institutes of Health Award 8UL1TR000170 05, and financial contributions
   from Harvard University and its affiliated academic health care
   centers). The content is solely the responsibility of the authors and
   does not necessarily represent the official views of Harvard Catalyst,
   Harvard University, and its affiliated academic health care centers, or
   the National Institutes of Health.
CR Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Bae S, 2014, INT J MOL MED, V34, P559, DOI 10.3892/ijmm.2014.1802
   BALLE V, 1984, ANN OTO RHINOL LARYN, V93, P105, DOI 10.1177/000348948409300201
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chole RA, 2001, OTOL NEUROTOL, V22, P249, DOI 10.1097/00129492 200103000 00023
   Clayton AE, 2004, J LARYNGOL OTOL, V118, P617, DOI 10.1258/0022215041917790
   Doherty JK, 2004, OTOL NEUROTOL, V25, P457, DOI 10.1097/00129492 200407000 00010
   Ealy M, 2011, ADV OTO RHINO LARYNG, V70, P122, DOI 10.1159/000322488
   Frisch T, 2000, ANN OTO RHINOL LARYN, V109, P33, DOI 10.1177/000348940010900106
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   KHETARPAL U, 1990, ANN OTO RHINOL LARYN, V99, P1, DOI 10.1177/00034894900990S301
   Khoo XJ, 2013, BIOMATERIALS, V34, P1281, DOI 10.1016/j.biomaterials.2012.10.025
   Kozloff KM, 2010, J BONE MINER RES, V25, P1748, DOI 10.1002/jbmr.66
   Lajud SA, 2013, J CONTROL RELEASE, V166, P268, DOI 10.1016/j.jconrel.2012.12.031
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Lipton A, 2005, EXPERT OPIN BIOL TH, V5, P817, DOI 10.1517/14712598.5.6.817
   Marshall AH, 2005, LARYNGOSCOPE, V115, P1728, DOI 10.1097/01.mlg.0000171052.34196.ef
   McKenna TJ, 2004, OTOL NEUROTOL, V25, P447, DOI 10.1097/00129492 200407000 00008
   Mynatt R, 2006, JARO J ASSOC RES OTO, V7, P182, DOI 10.1007/s10162 006 0034 y
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Plontke SK, 2008, OTOL NEUROTOL, V29, P401, DOI 10.1097/MAO.0b013e318161aaae
   Plontke SK, 2007, LARYNGOSCOPE, V117, P1191, DOI 10.1097/MLG.0b013e318058a06b
   Quesnel AM, 2012, OTOL NEUROTOL, V33, P1308, DOI 10.1097/MAO.0b013e318268d1b3
   Rama López J, 2006, OTOL NEUROTOL, V27, P153, DOI 10.1097/01.mao.0000197387.29534.26
   Ramsden R, 2007, ADV OTO RHINO LARYNG, V65, P328, DOI 10.1159/000098855
   Rasband W., Image processing and analysis in Java
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Santos F, 2012, OTOL NEUROTOL, V33, P1562, DOI 10.1097/MAO.0b013e31826bf19b
   Semaan MT, 2012, AM J OTOLARYNG, V33, P608, DOI 10.1016/j.amjoto.2012.05.001
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   Sun S, 2013, CHEMISTRY
   Sun ST, 2011, PHOSPHORUS SULFUR, V186, P970, DOI 10.1080/10426507.2010.526674
   Turek J, 2012, CALCIFIED TISSUE INT, V90, P202, DOI 10.1007/s00223 012 9570 0
   U.S. Food and Drug Administration, 2011, FULL PRESCR INF RECL
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
   Wang XB, 2014, OTOL NEUROTOL, V35, P459, DOI 10.1097/MAO.0000000000000261
   Wang XB, 2011, LARYNGOSCOPE, V121, P385, DOI 10.1002/lary.21370
   Wen D, 2011, ORAL DIS, V17, P427, DOI 10.1111/j.1601 0825.2010.01772.x
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
NR 43
TC 23
Z9 26
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1531 7129
EI 1537 4505
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD JUL
PY 2015
VL 36
IS 6
BP 953
EP 960
DI 10.1097/MAO.0000000000000786
PG 8
WC Clinical Neurology; Otorhinolaryngology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Otorhinolaryngology
GA CL3TO
UT WOS:000356873700002
PM 25996080
OA Green Accepted
DA 2025 08 17
ER

PT B
AU Pazianas, M
   Russell, RGG
AF Pazianas, Michael
   Russell, R. Graham G.
BE Zaidi, M
TI Potential therapeutic effects of oral bisphosphonates on the intestine
SO SKELETAL BIOLOGY AND MEDICINE II: BONE AND CARTILAGE HOMEOSTASIS AND
   BONE DISEASE
SE Annals of the New York Academy of Sciences Series
LA English
DT Article; Proceedings Paper
CT 4th New York Skeletal Biology and Medicine Conference
CY APR 27 30, 2011
CL Mt Sinai Sch Med, New York, NY
HO Mt Sinai Sch Med
DE bisphosphonates; colonic mucosa; inflammation; cancer; chemoprophylaxis
ID INFLAMMATORY BOWEL DISEASE; ZOLEDRONIC ACID; RHO GTPASES; CELLS; RAS;
   ALENDRONATE; MONOLAYERS; MONOCYTES; TRANSPORT; COLITIS
AB Bisphosphonates are the principal drugs prescribed for the prevention of osteoporotic fractures. They are bone specific but poorly absorbed. In oral formulations, almost 99% of the administered dose remains within the intestinal tract and reaches the small and large bowel. Although the nitrogen containing bisphosphonates can irritate the distal esophageal/gastric mucosa, they improve drug induced colitis in animal models and exhibit antitumor properties on intestinal cells in vitro. Several recent epidemiological studies provide evidence of a reduced risk of colorectal cancer in osteoporotic patients treated with oral bisphosphonates, notably alendronate. In this review, we will explore the possible mechanisms of action underlying these effects and raise the question of whether these agents might be used in the chemoprophylaxis against colorectal cancer.
C1 [Pazianas, Michael; Russell, R. Graham G.] Univ Oxford, Dept Orthopaed Rheumatol & Musculoskelet Sci, Botnar Res Ctr, Inst Musculoskelet Sci, Oxford OX3 7LD, England.
   [Russell, R. Graham G.] Univ Sheffield, NIHR Bone Biomed Res Unit, Sheffield S10 2TN, S Yorkshire, England.
   [Russell, R. Graham G.] Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England.
C3 University of Oxford; University of Sheffield
RP Pazianas, M (通讯作者)，Univ Oxford, Dept Orthopaed Rheumatol & Musculoskelet Sci, Botnar Res Ctr, Inst Musculoskelet Sci, Oxford OX3 7LD, England.
EM Michael.Pazianas@ndorms.ox.ac.uk
RI Pazianas, Michael/ABE 4572 2020; Russell, R/JEF 5877 2023; Russell,
   Robert Graham G/JEF 5877 2023
OI Russell, Robert Graham G/0000 0002 4136 1828
CR ABRAHAMSEN B, 2010, OSTEOPOROSIS INT S1, V47, pS53
   Ballester I, 2007, BRIT J PHARMACOL, V151, P206, DOI 10.1038/sj.bjp.0707227
   BENZAID I, 2010, IBMS BONEKEY, V7, P208, DOI DOI 10.1138/20100450
   Biswas SK, 2010, J LEUKOCYTE BIOL, V88, P877, DOI 10.1189/jlb.0310153
   Blank MA, 2000, ALIMENT PHARM THER, V14, P1215
   BOULENC X, 1993, BIOCHEM PHARMACOL, V46, P1591, DOI 10.1016/0006 2952(93)90328 T
   Burn J., 2011, Lancet
   Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106
   Clark EA, 2001, NATURE, V411, P974, DOI 10.1038/35082119
   Coffelt SB, 2009, BBA REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004
   DRESSMAN JB, 1990, PHARM RES DORDR, V7, P756, DOI 10.1023/A:1015827908309
   Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097 0215(19990531)81:5<682::AID IJC2>3.0.CO;2 B
   GREEN J, 2010, BMJ BRIT MED J, V341, P4444
   GRIMM MC, 1995, CLIN EXP IMMUNOL, V100, P291, DOI 10.1111/j.1365 2249.1995.tb03667.x
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Jedinak A, 2010, IMMUNOBIOLOGY, V215, P242, DOI 10.1016/j.imbio.2009.03.004
   JEMAL A, 2011, CANC J CLIN, V61, P134
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   *KENN STAT U CHEM, AN GASTR TRACT DRUG
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   LICHTENBERGER LM, 1995, ANNU REV PHYSIOL, V57, P565, DOI 10.1146/annurev.ph.57.030195.003025
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIN JH, 1994, J PHARM SCI US, V83, P1741, DOI 10.1002/jps.2600831218
   Nugent SG, 2001, GUT, V48, P571, DOI 10.1136/gut.48.4.571
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Pazianas M, 2010, THER CLIN RISK MANAG, V6, P325
   Pazianas M, 2010, J BONE MINER RES, V25, P2, DOI 10.1359/jbmr.091201
   Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304 3835(01)00528 6
   Rennert G, 2011, J CLIN ONCOL, V29, P1146, DOI 10.1200/JCO.2010.33.7485
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   RUIFROK PG, 1983, BIOCHEM PHARMACOL, V32, P637, DOI 10.1016/0006 2952(83)90487 2
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sassa S, 2009, ANTICANCER RES, V29, P4615
   Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540
   Schmidt C, 2010, J NATL CANCER I, V102, P453, DOI 10.1093/jnci/djq114
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   SINGH H, 2011, CANCER         0805
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Todaro M, 2009, J IMMUNOL, V182, P7287, DOI 10.4049/jimmunol.0804288
   TWISS IM, 1994, J PHARM SCI, V83, P699, DOI 10.1002/jps.2600830521
   Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
NR 43
TC 10
Z9 10
U1 0
U2 4
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
BN 978 1 57331 856 3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1240
BP E19
EP E25
DI 10.1111/j.1749 6632.2011.06372.x
PG 7
WC Endocrinology & Metabolism; Multidisciplinary Sciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics
GA BYL14
UT WOS:000299227500017
PM 22360293
DA 2025 08 17
ER

PT J
AU Kim, SM
   Taneja, C
   Perez Pena, H
   Ryu, V
   Gumerova, A
   Li, WL
   Ahmad, N
   Zhu, LL
   Liu, P
   Mathew, M
   Korkmaz, F
   Gera, S
   Sant, D
   Hadelia, E
   Ievleva, K
   Kuo, TC
   Miyashita, H
   Liu, L
   Tourkova, I
   Stanley, S
   Lizneva, D
   Iqbal, J
   Sun, L
   Tamler, R
   Blair, HC
   New, MI
   Haider, S
   Yuen, T
   Zaidi, M
AF Kim, Se Min
   Taneja, Charit
   Perez Pena, Helena
   Ryu, Vitaly
   Gumerova, Anisa
   Li, Wenliang
   Ahmad, Naseer
   Zhu, Ling Ling
   Liu, Peng
   Mathew, Mehr
   Korkmaz, Funda
   Gera, Sakshi
   Sant, Damini
   Hadelia, Elina
   Ievleva, Kseniia
   Kuo, Tan Chun
   Miyashita, Hirotaka
   Liu, Li
   Tourkova, Irina
   Stanley, Sarah
   Lizneva, Daria
   Iqbal, Jameel
   Sun, Li
   Tamler, Ronald
   Blair, Harry C.
   New, Maria I.
   Haider, Shozeb
   Yuen, Tony
   Zaidi, Mone
TI Repurposing erectile dysfunction drugs tadalafil and vardenafil to
   increase bone mass
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE osteoporosis; resorption; cyclic GMP; PDE5 inhibitor; computational;
   modeling
ID SOLUBLE GUANYLATE CYCLASE; NITRIC OXIDE PRODUCTION; 3 DIMENSIONAL
   STRUCTURES; OXIDATIVE DAMAGE; NERVOUS SYSTEM; IN VITRO; RESORPTION;
   PROTEIN; PHOSPHODIESTERASE 5; EXPRESSION
AB We report that two widely  used drugs for erectile dysfunction, tadalafil and vardenafil, trigger bone gain in mice through a com  bination of anabolic and antiresorptive actions on the skeleton. Both drugs were found to enhance osteoblastic bone formation in vivo using a unique gene footprint and to inhibit osteoclast for  mation. The target enzyme, phosphodiesterase 5A (PDE5A), was found to be expressed in mouse and human bone as well as in specific brain regions, namely the locus coeruleus, raphe pallidus, and paraventricular nucleus of the hypothalamus. Localization of PDE5A in sympathetic neurons was confirmed by coimmunolabeling with dopamine ? hydroxylase, as well as by retrograde bone  brain tracing using a sympathetic nerve  specific pseudorabies virus, PRV152. Both drugs elicited an antianabolic sympathetic imprint in osteoblasts, but with net bone gain. Unlike in humans, in whom vardenafil is more potent than tadalafil, the relative potencies were reversed with respect to their osteoprotective actions in mice. Struc  tural modeling revealed a higher binding energy of tadalafil to mouse PDE5A compared with vardenafil, due to steric clashes of vardenafil with a single methionine residue at position 806 in mouse PDE5A. Collectively, our findings suggest that a balance between peripheral and central actions of PDE5A inhibitors on bone forma  tion together with their antiresorptive actions specify the osteopro  tective action of PDE5A blockade.
C1 [Kim, Se Min; Taneja, Charit; Ryu, Vitaly; Gumerova, Anisa; Ahmad, Naseer; Zhu, Ling Ling; Liu, Peng; Mathew, Mehr; Korkmaz, Funda; Gera, Sakshi; Sant, Damini; Hadelia, Elina; Ievleva, Kseniia; Kuo, Tan Chun; Miyashita, Hirotaka; Lizneva, Daria; Iqbal, Jameel; Sun, Li; New, Maria I.; Yuen, Tony; Zaidi, Mone] Icahn Sch Med Mt Sinai, Mt Sinai Bone Program, New York, NY 10029 USA.
   [Kim, Se Min; Taneja, Charit; Ryu, Vitaly; Gumerova, Anisa; Ahmad, Naseer; Zhu, Ling Ling; Liu, Peng; Mathew, Mehr; Korkmaz, Funda; Gera, Sakshi; Sant, Damini; Hadelia, Elina; Ievleva, Kseniia; Kuo, Tan Chun; Miyashita, Hirotaka; Stanley, Sarah; Lizneva, Daria; Iqbal, Jameel; Sun, Li; Tamler, Ronald; Yuen, Tony; Zaidi, Mone] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Perez Pena, Helena; Li, Wenliang; Haider, Shozeb] UCL, Dept Pharmaceut & Biol Chem, Sch Pharm, London WC1N 1AX, England.
   [Ievleva, Kseniia] Sci Ctr Family Hlth & Human Reprod Problems, Dept Reprod Hlth, Irkutsk 664003, Russia.
   [Liu, Li; Tourkova, Irina; Blair, Harry C.] Pittsburgh Vet Affairs Healthcare Syst, Dept Pathol, Pittsburgh, PA 15240 USA.
   [Liu, Li; Tourkova, Irina; Blair, Harry C.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA.
   [New, Maria I.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; University of London; University College London; University
   of London School of Pharmacy; Irkutsk Science Centre of the Russian
   Academy of Sciences; Scientific Centre for Family Health & Human
   Reproduction Problems; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Icahn School of Medicine at
   Mount Sinai
RP Kim, SM; New, MI (通讯作者)，Icahn Sch Med Mt Sinai, Mt Sinai Bone Program, New York, NY 10029 USA.; Kim, SM (通讯作者)，Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.; New, MI (通讯作者)，Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.
EM se min.kim@mountsinai.org; maria.new@mssm.edu
RI ; Taneja, Charit/AAD 5330 2022; Lizneva, Daria/R 5572 2016; Kim,
   Se Min/AAA 5672 2021; Haider, Shozeb/B 4577 2011; AHMAD,
   NASEER/MAH 2950 2025; Ievleva, Kseniia/G 1011 2017; Li,
   Wenliang/F 2907 2014
OI Mathew, Mehr/0000 0002 5454 0753; Miyashita,
   Hirotaka/0000 0002 0433 9779; Korkmaz, Funda/0000 0002 9174 8369; Zaidi,
   Mone/0000 0001 5911 9522; Gera, Sakshi/0000 0002 1615 6259; Yuen,
   Tony/0009 0001 6000 8827; , Helena/0000 0001 7938 4307; Kuo,
   Tan Chun/0000 0001 5301 755X; Lizneva, Daria/0000 0002 2901 4268;
   Ievleva, Kseniia/0000 0002 0177 234X; Stanley,
   Sarah/0000 0002 0253 2663; Kim, Se Min/0000 0003 0877 7562
FU NIH [R01 AR67066, R01 DK113627, U19 AG60917, AR055208]; M.I.N.
   Children's Hormone Research Foundation
FX We thank Jay Cao, PhD for his assistance with mu CT interpretation.
   Support was provided by the NIH Grants (R01 AR67066, R01 DK113627, and
   U19 AG60917, to M.Z.; AR055208, to H.C.B.). M.I.N. is supported by the
   M.I.N. Children's Hormone Research Foundation.
CR ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503
   ABRAMS J, 1995, ARCH INTERN MED, V155, P357, DOI 10.1001/archinte.155.4.357
   Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Alp HH, 2017, EXP BIOL MED, V242, P1051, DOI 10.1177/1535370217703352
   Bajayo A, 2012, P NATL ACAD SCI USA, V109, P15455, DOI 10.1073/pnas.1206061109
   Barnes H, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012621.pub2
   Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5
   Bender AT, 2004, NEUROCHEM INT, V45, P853, DOI 10.1016/j.neuint.2004.03.015
   Bischoff E, 2004, INT J IMPOT RES, V16, pS11, DOI 10.1038/sj.ijir.3901208
   Blount MA, 2004, MOL PHARMACOL, V66, P144, DOI 10.1124/mol.66.1.144
   Bu RF, 2003, BONE, V33, P760, DOI 10.1016/j.bone.2003.07.006
   Campion JM, 2003, AM FAM PHYSICIAN, V67, P1521
   Collin Osdoby P, 2000, J BONE MINER RES, V15, P474, DOI 10.1359/jbmr.2000.15.3.474
   COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305
   Corbin JD, 2004, NEUROCHEM INT, V45, P859, DOI 10.1016/j.neuint.2004.03.016
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Epstein S, 2003, J BONE MINER RES, V18, P2083, DOI 10.1359/jbmr.2003.18.12.2083
   Gong Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.510
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Griffiths MJD, 2005, NEW ENGL J MED, V353, P2683, DOI 10.1056/NEJMra051884
   Hamilton Celeste J, 2013, Bonekey Rep, V2, P259, DOI 10.1038/bonekey.2012.259
   Histing T, 2011, J ORTHOP RES, V29, P867, DOI 10.1002/jor.21324
   Homer BL, 2015, TOXICOL PATHOL, V43, P411, DOI 10.1177/0192623314546559
   Huyut Z, 2018, MED SCI MONIT BASIC, V24, P47, DOI 10.12659/MSMBR.908504
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   Liu L, 2019, BRAIN RES BULL, V153, P223, DOI 10.1016/j.brainresbull.2019.09.001
   Liu L, 2012, J BIOL CHEM, V287, P43312, DOI 10.1074/jbc.M112.422766
   MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936
   Nakano Y, 2014, ASIAN J ANDROL, V16, P892, DOI 10.4103/1008 682X.126377
   Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082
   Ramdani G, 2018, J ENDOCRINOL, V238, P203, DOI 10.1530/JOE 18 0286
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   Robinson LJ, 2009, EXP CELL RES, V315, P1287, DOI 10.1016/j.yexcr.2009.01.014
   Schlienger RG, 2004, JAMA J AM MED ASSOC, V292, P1326, DOI 10.1001/jama.292.11.1326
   Selvin E, 2007, AM J MED, V120, P151, DOI 10.1016/j.amjmed.2006.06.010
   Silverton SF, 1999, BIOCHEM BIOPH RES CO, V259, P73, DOI 10.1006/bbrc.1999.0703
   SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404
   Smith BN, 2000, P NATL ACAD SCI USA, V97, P9264, DOI 10.1073/pnas.97.16.9264
   Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647
   Spencer SH, 2016, J MANAG CARE SPEC PH, V22, P818, DOI 10.18553/jmcp.2016.22.7.818
   Sun L, 2008, BIOCHEM BIOPH RES CO, V371, P900, DOI 10.1016/j.bbrc.2008.03.114
   Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Takeda S, 2008, BONE, V42, P837, DOI 10.1016/j.bone.2008.01.005
   Tamma R, 2009, P NATL ACAD SCI USA, V106, P7149, DOI 10.1073/pnas.0901890106
   Tao AX, 2019, J CHEM INF MODEL, V59, P18, DOI 10.1021/acs.jcim.8b00633
   Tóth ZE, 2007, J HISTOCHEM CYTOCHEM, V55, P545, DOI 10.1369/jhc.6A7134.2007
   Wang LQ, 2018, AM J PHYSIOL ENDOC M, V315, pE446, DOI 10.1152/ajpendo.00130.2018
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wimalawansa S, 2000, J BONE MINER RES, V15, P1119, DOI 10.1359/jbmr.2000.15.6.1119
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P3025, DOI 10.1517/14656560802197162 
   Wu CH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004024
   Wu CH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153467
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756 3282(02)00688 9
   Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59
   Zhang XG, 2013, IRAN J PHARM RES, V12, P557
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zhu LL, 2012, P NATL ACAD SCI USA, V109, P14574, DOI 10.1073/pnas.1212806109
NR 64
TC 18
Z9 19
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 23
PY 2020
VL 117
IS 25
BP 14386
EP 14394
DI 10.1073/pnas.2000950117
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA MH5JA
UT WOS:000546764000001
PM 32513693
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Kalvelyte, A
   Krestnikova, N
   Stulpinas, A
   Bukelskiene, V
   Bironaite, D
   Baltriukiene, D
   Imbrasaite, A
AF Kalvelyte, Audrone
   Krestnikova, Natalija
   Stulpinas, Aurimas
   Bukelskiene, Virginija
   Bironaite, Daiva
   Baltriukiene, Daiva
   Imbrasaite, Ausra
TI Long term muscle derived cell culture: multipotency and susceptibility
   to cell death stimuli
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE cell death; differentiation; multipotency; muscle derived stem cell
   lines
ID HUMAN SKELETAL MUSCLE; STEM CELLS; ADIPOSE TISSUE; PHOSPHATIDYLINOSITOL
   3 KINASE; OSTEOBLAST DIFFERENTIATION; MYOBLAST TRANSPLANTATION;
   MOLECULAR MECHANISMS; PROGENITOR CELLS; SURVIVAL; DISTINCT
AB Improvement in the yield of adult organism stem cells, and the ability to manage their differentiation and survival potential are the major goals in their application in regenerative medicine and in the adult stem cell research. We have demonstrated that adult rabbit muscle derived cell lines with an unlimited proliferative potential in vitro can differentiate into myogenic, osteogenic, adipogenic and neurogenic lineages. Studies of cell survival in vitro showed that differentiated cells, except neurogenic ones, are more resistant to apoptosis inducers compared to proliferating cells. Resistance to death signals correlated with the level of protein kinase AKT phosphorylation. Skeletal muscle derived cell lines can be multipurpose tools in therapy. Enhanced resistance of differentiated cells to certain types of damage shows their potential for long term survival and maintenance in an organism.
C1 [Kalvelyte, Audrone; Krestnikova, Natalija; Stulpinas, Aurimas; Bukelskiene, Virginija; Bironaite, Daiva; Baltriukiene, Daiva; Imbrasaite, Ausra] Vilnius State Univ, Inst Biochem, LT 08662 Vilnius, Lithuania.
C3 Vilnius University
RP Kalvelyte, A (通讯作者)，Vilnius State Univ, Inst Biochem, Mokslininku Str 12, LT 08662 Vilnius, Lithuania.
EM audrone.kalvelyte@bchi.vu.lt
RI ; Stulpinas, Aurimas/JWP 5824 2024
OI Bironaite, Daiva/0000 0002 2172 1697; Krestnikova,
   Natalija/0000 0002 8354 8746
FU Lithuanian State Science and Studies Foundation [C 07023]
FX The work presented in this report was supported by the Lithuanian State
   Science and Studies Foundation [Grant No. C 07023].
CR Alessandri G, 2004, LANCET, V364, P1872, DOI 10.1016/S0140 6736(04)17443 6
   AMRI EZ, 1991, J LIPID RES, V32, P1449
   [Anonymous], 2005, SEMIN CARDIOL
   Asakura A, 2002, EXP HEMATOL, V30, P1339, DOI 10.1016/S0301 472X(02)00954 2
   Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432 0436.2001.680412.x
   Baltriukiene D, 2008, BIOLOGIJA, V54, P213
   Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221
   Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113
   Bironaite D, 2009, CELL BIOL INT, V33, P711, DOI 10.1016/j.cellbi.2009.03.007
   Blum JS, 2004, J ORTHOP RES, V22, P411, DOI 10.1016/j.orthres.2003.08.006
   Burdzinska A, 2008, FOLIA HISTOCHEM CYTO, V46, P401, DOI 10.2478/v10042 008 0060 1
   Cecchi C, 2008, NEUROCHEM RES, V33, P2516, DOI 10.1007/s11064 008 9627 7
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Deasy BM, 2005, MOL BIOL CELL, V16, P3323, DOI 10.1091/mbc.E05 02 0169
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Dhawan J, 2005, TRENDS CELL BIOL, V15, P666, DOI 10.1016/j.tcb.2005.10.007
   Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056
   Fernyhough ME, 2008, CELLS TISSUES ORGANS, V188, P359, DOI 10.1159/000134007
   Vázquez Vela MEF, 2008, ARCH MED RES, V39, P715, DOI 10.1016/j.arcmed.2008.09.005
   Fujio Y, 2001, CELL DEATH DIFFER, V8, P1207, DOI 10.1038/sj.cdd.4400919
   Fujio Y, 1999, MOL CELL BIOL, V19, P5073
   Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018
   George S, 2009, PHOTOMED LASER SURG, V27, P669, DOI 10.1089/pho.2008.2354
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Haider HK, 2008, J MOL CELL CARDIOL, V45, P554, DOI 10.1016/j.yjmcc.2008.05.004
   Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006 2952(00)00372 5
   Hashimoto N, 2006, BIOCHEM BIOPH RES CO, V348, P1383, DOI 10.1016/j.bbrc.2006.08.006
   IRINTCHEV A, 1995, J NEUROCYTOL, V24, P319, DOI 10.1007/BF01186543
   Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077
   Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842
   Kook SH, 2006, MOL CELLS, V22, P239
   Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350 6361.2004
   Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131
   Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256 3265.2000
   Le Ricousse Roussanne S, 2007, EXP CELL RES, V313, P1337, DOI 10.1016/j.yexcr.2007.01.022
   Lecourt S, 2010, EXP CELL RES, V316, P2513, DOI 10.1016/j.yexcr.2010.04.020
   Leppä S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369 4378.2001
   Lim JA, 2008, FREE RADICAL RES, V42, P798, DOI 10.1080/10715760802429021
   Luo W, 2008, EXP GERONTOL, V43, P154, DOI 10.1016/j.exger.2007.11.002
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Menasché P, 2006, EUR HEART J SUPPL, V8, pH52, DOI 10.1093/eurheartj/sul063
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Oshima H, 2005, MOL THER, V12, P1130, DOI 10.1016/j.ymthe.2005.07.686
   Park JS, 2007, EXP MOL MED, V39, P483, DOI 10.1038/emm.2007.53
   Péault B, 2007, MOL THER, V15, P867, DOI 10.1038/mt.sj.6300145
   Peng H, 2007, CURR OPIN PHARMACOL, V3, P329
   Pouzet B, 2000, CIRCULATION, V102, P210
   Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257
   RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069
   Rotwein P, 2009, J CELL PHYSIOL, V219, P503, DOI 10.1002/jcp.21692
   Schultz SS, 2006, WOUND REPAIR REGEN, V14, P224, DOI 10.1111/j.1743 6109.2006.00114.x
   Sirmenis R, 2007, LIETUVOS CHIRURG VIL, V5, P260
   Sirmenis R, 2011, MEDICINA LITHUANIA, V47, P607, DOI 10.3390/medicina47110088
   Smith MI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005097
   Stulpinas A, 2008, BIOLOGIJA, V54, P221
   Stulpinas A, 2012, CELL BIOL TOXICOL, V28, P103, DOI 10.1007/s10565 011 9210 x
   Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106
   Tamaki T, 2007, STEM CELLS, V25, P2283, DOI 10.1634/stemcells.2006 0746
   Usas A, 2007, BIOMATERIALS, V28, P5401, DOI 10.1016/j.biomaterials.2007.09.008
   Valverde AM, 2005, ACTA PHYSIOL SCAND, V183, P59, DOI 10.1111/j.1365 201X.2004.01384.x
   Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200
   Vettor R, 2009, AM J PHYSIOL ENDOC M, V297, pE987, DOI 10.1152/ajpendo.00229.2009
   Wada MR, 2002, DEVELOPMENT, V129, P2987
   Wu XY, 2010, CELL TISSUE RES, V340, P549, DOI 10.1007/s00441 010 0978 4
   Xiao RJ, 2011, APOPTOSIS, V16, P221, DOI 10.1007/s10495 010 0566 9
   Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200
   Zhang L, 2007, CELL CYCLE, V6, P1479
   Zhang Zhen xing, 2006, Zhonghua Yi Xue Za Zhi, V86, P2756
NR 68
TC 9
Z9 9
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD APR
PY 2013
VL 37
IS 4
BP 292
EP 304
DI 10.1002/cbin.10036
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 107MP
UT WOS:000316222000004
PM 23359426
DA 2025 08 17
ER

PT J
AU Gokalp, D
   Tuzcu, A
   Bahceci, M
   Arikan, S
   Ozmen, CA
   Cil, T
AF Gokalp, Deniz
   Tuzcu, Alpaslan
   Bahceci, Mithat
   Arikan, Senay
   Ozmen, Cihan Akgul
   Cil, Timucin
TI Sheehan's syndrome and its impact on bone mineral density
SO GYNECOLOGICAL ENDOCRINOLOGY
LA English
DT Article
DE Bone mineral density; osteoporosis; PTH; Sheehan's syndrome
ID GROWTH HORMONE DEFICIENCY; PARATHYROID HORMONE; REPLACEMENT THERAPY;
   CHILDHOOD ONSET; PITUITARY; OSTEOPOROSIS; MASS; HYPOPITUITARISM; ADULTS;
   WOMEN
AB Introduction. Although there have been few studies investigating osteoporosis in isolated hormone deficiencies or other causes of hypopituitarism, the relationship between Sheehan's syndrome (SS) and osteoporosis has not been investigated. In the present study, we aimed to evaluate bone mineral density (BMD) in patients with SS in comparison with healthy women.
   Methods. Sixty one patients with SS and 62 matched healthy controls were included. Biochemical, hormonal assessments and BMD evaluations were carried out in patients and controls, and a subgroup analysis according to menopausal status was done (premenopausal < 50 years; postmenopausal > 50 years).
   Results. The mean levels of serum anterior pituitary hormones were significantly lower in pre  and postmenopausal patients with SS compared with respective control groups (p < 0.0001). For both pre  and postmenopausal subjects, compared with respective controls, serum calcium and ALP levels, femur T score, femur Z score, spine (L1 L5) T score, spine (L1 L5) Z score and BMD values were lower, and phosphorus and parathyroid hormone (PTH) levels were higher in patients with SS.
   Conclusions. Patients with SS had low BMD. The possible mechanism responsible for osteoporosis may be hypogonadism, growth hormone deficiency and disorders of parathyroid hormone and calcium metabolism. But the contribution of each anterior pituitary hormone deficiency on bone loss should be clarified in further prospective studies.
C1 [Gokalp, Deniz; Tuzcu, Alpaslan; Bahceci, Mithat; Arikan, Senay] Dicle Univ, Sch Med, Dept Endocrinol, TR 21280 Diyarbakir, Turkey.
   [Ozmen, Cihan Akgul] Dicle Univ, Sch Med, Dept Radiol, TR 21280 Diyarbakir, Turkey.
   [Cil, Timucin] Dicle Univ, Sch Med, Dept Internal Med, TR 21280 Diyarbakir, Turkey.
C3 Dicle University; Dicle University; Dicle University
RP Gokalp, D (通讯作者)，Dicle Univ, Sch Med, Dept Endocrinol, TR 21280 Diyarbakir, Turkey.
EM dgokalp@dicle.edu.tr
RI cil, timucin/HJZ 1735 2023; Cil, Timucin/HJZ 1735 2023; Ozmen,
   Cihan/F 3779 2017
OI cil, timucin/0000 0002 5033 1479; 
CR Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365 2265.1999.00695.x
   Ahmad AM, 2003, J CLIN ENDOCR METAB, V88, P2860, DOI 10.1210/jc.2002 021787
   Ahmad AM, 2003, BONE, V32, P170, DOI 10.1016/S8756 3282(02)00952 3
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919
   DASH RJ, 1993, AUST NZ J MED, V23, P26, DOI 10.1111/j.1445 5994.1993.tb00533.x
   DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63
   DEBOER H, 1994, J BONE MINER RES, V9, P1319
   Dökmetas HS, 2006, GYNECOL ENDOCRINOL, V22, P279, DOI 10.1080/09513590600630504
   HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669
   KAUFMAN JM, 1992, J CLIN ENDOCR METAB, V74, P118, DOI 10.1210/jc.74.1.118
   Kovacs K, 2003, LANCET, V361, P520, DOI 10.1016/S0140 6736(03)12490 7
   Lamberts SWJ, 1998, LANCET, V352, P127
   LEES B, 1995, OSTEOPOROSIS INT, V5, P344, DOI 10.1007/BF01622256
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Monson JP, 2002, HORM RES, V58, P52, DOI 10.1159/000064765
   OZBEY N, 1994, ISRAEL J MED SCI, V30, P826
   PECK WA, 1993, AM J MED, V94, P646
   SCHEITHAUER BW, 1990, MAYO CLIN PROC, V65, P461, DOI 10.1016/S0025 6196(12)60946 X
   SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002 9343(83)90878 1
   Sheehan HL, 1937, J PATHOL BACTERIOL, V45, P189, DOI 10.1002/path.1700450118
   Wüster C, 2001, J BONE MINER RES, V16, P398, DOI 10.1359/jbmr.2001.16.2.398
NR 22
TC 10
Z9 14
U1 0
U2 0
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0951 3590
EI 1473 0766
J9 GYNECOL ENDOCRINOL
JI Gynecol. Endocrinol.
PD MAY
PY 2009
VL 25
IS 5
BP 344
EP 349
DI 10.1080/09513590802630096
PG 6
WC Endocrinology & Metabolism; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Obstetrics & Gynecology
GA 473DQ
UT WOS:000268186100011
PM 19903041
DA 2025 08 17
ER

PT J
AU Geduk, A
   Atesoglu, EB
   Tarkun, P
   Mehtap, O
   Hacihanefioglu, A
   Demirsoy, ET
   Baydemir, C
AF Geduk, Ayfer
   Atesoglu, Elif B.
   Tarkun, Pinar
   Mehtap, Ozgur
   Hacihanefioglu, Abdullah
   Demirsoy, Esra T.
   Baydemir, Canan
TI The Role of β Catenin in Bcr/Abl Negative Myeloproliferative Neoplasms:
   An Immunohistochemical Study
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article
DE Angiogenesis; Essential thrombocytemia; Primary myelofibrosis;
   Thrombopoiesis; Wnt/beta catenin signaling pathway
ID ACUTE MYELOID LEUKEMIA; PATHWAY; MODULATION; CELLS; PROLIFERATION;
   ANGIOGENESIS; EXPRESSION; DISORDERS; THERAPY; CANCER
AB The dysregulation of the Wnt/beta catenin signaling pathway causes various diseases. In this study we aimed to reveal the role of beta catenin in bcr/abl negative myeloproliferative neoplasms. The expression of beta catenin was examined in bone marrow with immunohistochemical method in 66 patients and in 30 control participants. The results suggest that beta catenin has a role in the angiogenesis of primary myelofibrosis and in the thrombopoiesis of policythemia vera and essential thrombocytemia.
   Introduction: beta Catenin is a multifunctional protein that acts as a central effector molecule in the Wnt signaling pathway. Aberrant activation of the Wnt/beta catenin signaling pathway causes various diseases including cancer. In this study we evaluated beta catenin expression in bcr/abl negative myeloproliferative neoplasms (MPNs). Materials and Methods: The expression of beta catenin was evaluated in bone marrow using immunohistochemical methods in 66 patients with bcr/abl negative myeloproliferative neoplasms (MPNs) and in 30 healthy control subjects. Immunreactive score (IRS; staining intensity x percentage of positive stained cells) was used for the evaluation of the cell staining reaction. Results: IRS of megakaryocytes (IRSmega) was higher in essential thrombocytemia (ET) compared with the control group (P = .022) and primary myelofibrosis (PMF; P = .001). IRS of vascular endothelial cells (IRSvas) was higher in the bcr/abl negative MPN compared with the control group (P = .024). Also, IRSvas was higher in the PMF compared with the control group (P = .001), policythemia vera (PV; P = .005), and ET (P = .006). A positive correlation was detected between IRSmega and platelet counts (P = .019). Conclusion: Results of this study suggest that the Wnt/beta catenin signaling pathway has a role in the angiogenesis of PMF and in the thrombopoiesis of PV and ET. Hence, targeting the Wnt/beta catenin signaling pathway could open new avenues for novel therapeutic approaches in bcr/abl negative MPNs. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Geduk, Ayfer; Atesoglu, Elif B.; Tarkun, Pinar; Mehtap, Ozgur; Hacihanefioglu, Abdullah; Demirsoy, Esra T.] Kocaeli Univ, Fac Med, Dept Hematol, Kocaeli, Turkey.
   [Baydemir, Canan] Kocaeli Univ, Fac Med, Dept Biostat & Med Informat, Kocaeli, Turkey.
C3 Kocaeli University; Kocaeli University
RP Geduk, A (通讯作者)，Eski Istanbul Yolu,11 Km, TR 41380 Umuttepe, Kocaeli, Turkey.
EM ayfergeduk@hotmail.com
RI Gedük, Ayfer/AAS 1881 2020; Hacıhanefioğlu, Abdullah/G 1501 2018;
   TARKUN, PINAR/G 1478 2018; Atesoglu, Elif/G 5166 2018
CR Al Mudallal SS, 2010, IRAQI J MED SCI, V8, P25
   Arora B, 2004, LEUKEMIA LYMPHOMA, V45, P2373, DOI 10.1080/10428190400003267
   Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728
   Chen Q, 2014, CHIN J INTEGR MED, V20, P743, DOI 10.1007/s11655 014 1810 x
   Corrêa S, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 303
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Gandillet A, 2011, LEUKEMIA, V25, P770, DOI 10.1038/leu.2011.17
   Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009
   Jauregui MP, 2008, HUM PATHOL, V39, P1454, DOI 10.1016/j.humpath.2008.02.007
   Kim Y, 2011, IN VIVO, V25, P887
   Levine R.L., 2006, Hematology Am. Soc. Hematol. Educ. Program, V510, P233, DOI DOI 10.1182/ASHEDUCATI0N 2006.1.233
   Liu YC, 2010, J CELL BIOCHEM, V111, P402, DOI 10.1002/jcb.22714
   Moskalev EA, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 213
   Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959 437X(99)80003 3
   Quasnichka H, 2006, CIRC RES, V99, P1329, DOI 10.1161/01.RES.0000253533.65446.33
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Schmidt M, 2011, IN VIVO, V25, P325
   Serinsöz E, 2004, BRIT J HAEMATOL, V126, P313, DOI 10.1111/j.1365 2141.2004.05049.x
   Suzuki Rikio, 2007, Tokai J Exp Clin Med, V32, P131
   Thakur R, 2013, J CELL MOL MED, V17, P449, DOI 10.1111/jcmm.12033
NR 20
TC 11
Z9 11
U1 0
U2 5
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 2152 2650
EI 2152 2669
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD DEC
PY 2015
VL 15
IS 12
BP 785
EP 789
DI 10.1016/j.clml.2015.08.084
PG 5
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA DF3XZ
UT WOS:000371283200011
PM 26422250
DA 2025 08 17
ER

PT J
AU Namba, T
   Ichii, O
   Nakamura, T
   Masum, MA
   Otani, Y
   Otsuka Kanazawa, S
   Elewa, YHA
   Kon, Y
AF Namba, Takashi
   Ichii, Osamu
   Nakamura, Teppei
   Masum, Md Abdul
   Otani, Yuki
   Otsuka Kanazawa, Saori
   Elewa, Yaser Hosny Ali
   Kon, Yasuhiro
TI Feature Article: Altered morpho functional features of bones in
   autoimmune disease prone BXSB/MpJ Yaa mice
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Autoimmune disease; BXSB; MpJ Yaa; bone; calcium; hematology;
   histopathology
ID RHEUMATOID ARTHRITIS; MINERAL DENSITY; OSTEOPOROSIS; OSTEOCLASTOGENESIS;
   INVOLVEMENT; PHOSPHATASE; MANAGEMENT; ACTIVATOR; RECEPTOR; PROTEIN
AB Bones play crucial roles in motility, electrolyte metabolism, and immunity. Clinical cases have suggested bone dysfunction in several systemic autoimmune diseases. This study exhibited altered bone morpho functions in BXSB/MpJ Yaa as a murine autoimmune disease model. During clinical examinations, the serum Ca level was significantly higher in BXSB/MpJ Yaa than the healthy control BXSB/MpJ at the early stage (two to four months), but that in BXSB/MpJ Yaa decreased with advancing age. Further, the increase of urinary Ca with nephritis and white blood cells with mild anemia proceeded in BXSB/MpJ Yaa with advancing age. The thyroid and parathyroid gland morphologies and serum parathormone level did not differ among strains, but the tibia was smaller in BXSB/MpJ Yaa than in BXSB/MpJ especially during the late stage (six months). Histologically, osteoclasts and osteoblasts showed increased and decreased tendencies, respectively, in BXSB/MpJ Yaa during the early stage, and osteoclasts and bone area significantly increased and decreased, respectively, compared with BXSB/MpJ at later stages. The bone morphological indices were affected by the expression of BXSB/MpJ Yaa mutation genes and inflammatory genes in BXSB/MpJ Yaa. In conclusion, systemic autoimmune diseases in BXSB/MpJ Yaa are associated with the morpho functional abnormalities of bones, calcium dynamics, and hematopoiesis, and each factor contributes to forming the phenotypes in this disease. Impact statement Bone disease, such as osteoporosis and rheumatoid arthritis, increases because of the progression of an aging society. Autoimmune disease are important and predisposing factors for the pathogenesis of the bone disease; however, the pathological mechanism is unclear. We have demonstrated that systemic autoimmune disease in BXSB/MpJ Yaa is closely associated with the morpho functional abnormalities of bones including bone marrow and has complicated pathology. The abnormalities are characterized by altered regulations of serum calcium, anemia tendency, and hematopoiesis with increased WBCs and decreased PLs, short length and low mass of long bones, imbalance in the populations of osteoclasts and osteoblasts, and increased expression of candidate genes for causing and/or exacerbating their phenotypes. Therefore, BXSB/MpJ Yaa serves as a model to elucidate bone phenotypes in systemic autoimmune disease that would be affected by the factors in the bone as well as the other immune and/or mineral metabolism organs both in human and experimental medicine.
C1 [Namba, Takashi; Ichii, Osamu; Nakamura, Teppei; Masum, Md Abdul; Otani, Yuki; Otsuka Kanazawa, Saori; Elewa, Yaser Hosny Ali; Kon, Yasuhiro] Hokkaido Univ, Lab Anat, Dept Basic Vet Sci, Fac Vet Med, Sapporo, Hokkaido 0600818, Japan.
   [Nakamura, Teppei] Japan Food Res Labs, Sect Biol Safety Res, Chitose Lab, Chitose 0660052, Japan.
   [Elewa, Yaser Hosny Ali] Zagazig Univ, Fac Vet Med, Dept Histol & Cytol, Zagazig 44519, Egypt.
C3 Hokkaido University; Egyptian Knowledge Bank (EKB); Zagazig University
RP Ichii, O (通讯作者)，Hokkaido Univ, Lab Anat, Dept Basic Vet Sci, Fac Vet Med, Sapporo, Hokkaido 0600818, Japan.
EM ichi o@vetmed.hokudai.ac.jp
RI ; Ichii, Osamu/JFB 2112 2023; Elewa, Yaser/ABD 8332 2020
OI NAKAMURA, Teppei/0000 0003 3204 0245; Ichii, Osamu/0000 0002 6643 1554; 
CR Agmon Levin N, 2013, CLIN REV ALLERG IMMU, V45, P256, DOI 10.1007/s12016 012 8342 y
   Alzabin S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3875
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bimonte S, 2011, DEV BIOL, V349, P179, DOI 10.1016/j.ydbio.2010.09.020
   Borsy A, 2009, MOL GENET GENOMICS, V281, P301, DOI 10.1007/s00438 008 0413 7
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chen S, 2014, INT J MOL MED, V33, P840, DOI 10.3892/ijmm.2014.1644
   Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Haywood MEK, 2004, J IMMUNOL, V161, P2753
   Huang Qi Quan, 2009, Curr Rheumatol Rep, V11, P357
   Iwakura Y, 2002, CYTOKINE GROWTH F R, V13, P341, DOI 10.1016/S1359 6101(02)00021 7
   Jacques J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099626
   Jeremiah MP, 2015, AM FAM PHYSICIAN, V92, P261
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kawano S, 2013, EUR J IMMUNOL, V43, P770, DOI 10.1002/eji.201243057
   Kimura J, 2014, SCI REP UK, V4, DOI 10.1038/srep07290
   Kimura J, 2013, AM J NEPHROL, V38, P27, DOI 10.1159/000353093
   Kosenda K, 2013, CLIN EXP OPHTHALMOL, V41, P788, DOI 10.1111/ceo.12083
   Liu XH, 2005, ENDOCRINOLOGY, V146, P1991, DOI 10.1210/en.2004 1167
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McLendon AN, 2014, WOMENS HEALTH, V10, P59, DOI [10.2217/whe.13.73, 10.2217/WHE.13.73]
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Moll T, 2005, J IMMUNOL, V174, P702, DOI 10.4049/jimmunol.174.2.702
   Chulilla JAM, 2009, WORLD J GASTROENTERO, V15, P4627, DOI 10.3748/wjg.15.4627
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peacock M, 2010, CLIN J AM SOC NEPHRO, V5, pS23, DOI 10.2215/CJN.05910809
   Pisitkun P, 2006, SCIENCE, V312, P1669, DOI 10.1126/science.1124978
   Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365 2613.2000.00176.x
   Prakash SK, 2000, HUM MOL GENET, V9, P477, DOI 10.1093/hmg/9.4.477
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667
   Rossini M, 2016, RHEUMATOL INT, V36, P469, DOI 10.1007/s00296 015 3387 x
   Sacre SM, 2008, J IMMUNOL, V181, P8002, DOI 10.4049/jimmunol.181.11.8002
   Saliba W, 2009, J AM BOARD FAM MED, V22, P574, DOI 10.3122/jabfm.2009.05.090026
   Santiago Raber ML, 2008, J IMMUNOL, V181, P1556, DOI 10.4049/jimmunol.181.2.1556
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sharma S, 2008, CLIN CANCER RES, V14, P3262, DOI 10.1158/1078 0432.CCR 07 4153
   SHIMAMURA R, 1990, BLOOD, V76, P977
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Zhang Y, 2015, HUM MOL GENET, V24, P274, DOI 10.1093/hmg/ddu429
   Zhao HB, 2002, BIOCHEM BIOPH RES CO, V293, P1060, DOI 10.1016/S0006 291X(02)00326 1
NR 49
TC 6
Z9 6
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535 3702
EI 1535 3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD APR
PY 2019
VL 244
IS 5
BP 333
EP 343
DI 10.1177/1535370219832810
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA HV4DQ
UT WOS:000465937400001
PM 30818998
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Xu, SJ
   Shao, M
   Wang, QS
   Huang, YQ
   Huang, JF
   Wang, DT
   Sun, YQ
   Jiang, T
   Li, YX
AF Xu, Shaojun
   Shao, Min
   Wang, Qinsheng
   Huang, Yongqing
   Huang, Jianfeng
   Wang, Datian
   Sun, Youqiang
   Jiang, Tao
   Li, Yongxian
TI Ecdysterone Promotes Osteoblast Differentiation Through ERα Mediated
   AMPKα Signal Inhibition and β Catenin Signal Activation
SO NANOSCIENCE AND NANOTECHNOLOGY LETTERS
LA English
DT Article
DE Ecdysterone; Osteoblasts; Differentiation; ER alpha; AMPK; beta Catenin
ID GASTRIC CANCER RISK; UNIVERSAL TAGGED ARRAYS; PROTEIN KINASE PATHWAY;
   MESENCHYMAL STEM CELLS; SINGLE BASE EXTENSION; MAGNETIC NANOPARTICLES;
   NORTHERN JIANGSU; OSTEOGENIC DIFFERENTIATION; CARBON NANOTUBES; RAPID
   DETECTION
AB Achyranthes bidentata is a traditional Chinese medicine used for osteoporosis treatment for many years; however, the mechanism through which it cures the disease is largely unclear. Ecdysterone is an active component of Achyranthes bidentata. We hypothesized that it played a vital role in alleviating the osteoporosis disease symptoms. Therefore, this study was conducted to investigate the underlying mechanism, which ecdysterone adopts to influence the osteoblast's functioning. The results of CCK8 assay showed that ecdysterone stimulation could increase osteoblasts viability significantly while alkaline phosphatase (ALP) assay and immunocytochemical staining also manifested increased expression of ALP, Collagen I, and osteoprotegerin upon ecdysterone incitement. These results imply that ecdysterone stimulus could promote osteoblasts differentiation. Furthermore, the RT PCR and WB showed ecdysterone exposure could substantially upregulated the expression of ER alpha, instead of ER alpha and ERR alpha. Similarly, the expression of critical molecules of osteogenetic differentiation, such as p AMPK alpha and beta catenin, was also increased after ecdysteronetreatment. In order to further probe the underlying mechanisms, osteoblasts were transfected with siRNA to silence the ER alpha gene, and the expression of p AMPK alpha, beta catenin, and osteogenetic biomarkers was recorded with or without ecdysterone treatment. These results confirmed that ecdysterone promoted osteoblasts differentiation mainly through ER alpha, and ER alpha may mediate the AMPK alpha inhibition and beta catenin activation in this process.
C1 [Xu, Shaojun; Huang, Yongqing; Huang, Jianfeng; Jiang, Tao] Guangzhou Univ Chinese Med, Sch Clin Med 3, Guangzhou 510405, Guangdong, Peoples R China.
   [Xu, Shaojun] Guangzhou Orthoped Hosp, Guangzhou 510045, Guangdong, Peoples R China.
   [Shao, Min; Wang, Qinsheng] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Dept Orthopaed, Guangzhou 510240, Guangdong, Peoples R China.
   [Wang, Datian] Hainan Prov Hosp Tradit Chinese Med, Dept Orthopaed, Haikou 570000, Hainan, Peoples R China.
   [Sun, Youqiang; Li, Yongxian] Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou 510405, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Shao, M (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 3, Dept Orthopaed, Guangzhou 510240, Guangdong, Peoples R China.
RI Huang, Jianfeng/F 8634 2011
FU Third Affiliated Hospital of Guangzhou; University of Chinese Medicine;
   Guangzhou University of Chinese Medicine; National Natural Science
   Foundation of China [81373654]
FX All authors sincerely acknowledge the support given by the Third
   Affiliated Hospital of Guangzhou, University of Chinese Medicine and
   Guangzhou University of Chinese Medicine, and thank the funding support
   from National Natural Science Foundation of China (No. 81373654).
CR Ahadian S, 2016, J NANOSCI NANOTECHNO, V16, P8862, DOI 10.1166/jnn.2016.12729
   Al Azzawi F, 2008, GYNECOL ENDOCRINOL, V24, P601, DOI 10.1080/09513590802296245
   Ali Z, 2017, BIOMATER SCI UK, V5, P57, DOI 10.1039/c6bm00527f
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   [Anonymous], SCI CHINA CHEM
   Auld KL, 2012, J MOL ENDOCRINOL, V48, P177, DOI 10.1530/JME 11 0140
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Chen H, 2016, NANOSCI NANOTECH LET, V8, P1118, DOI 10.1166/nnl.2016.2278
   Chen XH, 2016, J BIOBASED MATER BIO, V10, P308, DOI 10.1166/jbmb.2016.1592
   Cidlinsky N, 2016, CELL ONCOL, V39, P389, DOI 10.1007/s13402 016 0290 8
   Deng Y, 2013, J BIOMED NANOTECHNOL, V9, P1378, DOI 10.1166/jbn.2013.1633
   Deng Y, 2011, ADV SCI LETT, V4, P442, DOI 10.1166/asl.2011.1219
   Deng Y, 2009, J BIOMED NANOTECHNOL, V5, P551, DOI 10.1166/jbn.2009.1068
   Dungani R, 2016, J BIOBASED MATER BIO, V10, P258, DOI 10.1166/jbmb.2016.1585
   Elingarami S, 2015, J NANOSCI NANOTECHNO, V15, P4815, DOI 10.1166/jnn.2015.10028
   Elingarami S, 2014, SCI ADV MATER, V6, P899, DOI 10.1166/sam.2014.1853
   Fernandes G, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.36
   Findlay DM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.28
   Foo C, 2007, GYNECOL ENDOCRINOL, V23, P535, DOI 10.1080/09513590701556483
   Gennari L, 2010, CLIN INTERV AGING, V5, P19
   Góra A, 2016, J NANOSCI NANOTECHNO, V16, P19, DOI 10.1166/jnn.2016.11604
   Guan L, 2016, NANOSCI NANOTECH LET, V8, P1033, DOI 10.1166/nnl.2016.2274
   Guo P, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.28
   Guo SM, 2016, J BIOBASED MATER BIO, V10, P34, DOI 10.1166/jbmb.2016.1566
   Hardie DG, 2006, J PHYSIOL LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Huang RR, 2017, SCI CHINA CHEM, V60, P786, DOI 10.1007/s11426 016 0491 7
   Huang RR, 2015, SCI CHINA CHEM, V58, P1122, DOI 10.1007/s11426 015 5344 7
   Huang YF, 2015, SCI CHINA CHEM, V58, P1759, DOI 10.1007/s11426 015 5437 3
   Jeon J, 2016, J NANOSCI NANOTECHNO, V16, P11849, DOI 10.1166/jnn.2016.13606
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Jiang HR, 2013, J NANOSCI NANOTECHNO, V13, P1617, DOI 10.1166/jnn.2013.7103
   Jin L, 2014, THERANOSTICS, V4, P240, DOI 10.7150/thno.6914
   Jin L, 2015, J NANOSCI NANOTECHNO, V15, P7966, DOI 10.1166/jnn.2015.11223
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 51
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kim DH, 2015, J NANOSCI NANOTECHNO, V15, P5520, DOI 10.1166/jnn.2015.10463
   Knoll GA, 2016, J NANOSCI NANOTECHNO, V16, P2464, DOI 10.1166/jnn.2016.12039
   Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006
   Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007
   Li F, 2015, J BIOMED NANOTECHNOL, V11, P1776, DOI 10.1166/jbn.2015.2151
   Li H., 2010, ANAL BIOCHEM, V405, P141
   Li KK, 2016, J NANOSCI NANOTECHNO, V16, P12407, DOI 10.1166/jnn.2016.13763
   Li P, 2016, J NANOSCI NANOTECHNO, V16, P4718, DOI 10.1166/jnn.2016.12412
   Li S, 2013, J BIOMED NANOTECHNOL, V9, P1254, DOI 10.1166/jbn.2013.1610
   Li S, 2013, J BIOMED NANOTECHNOL, V9, P689, DOI 10.1166/jbn.2013.1568
   Li S, 2012, THERANOSTICS, V2, P967, DOI 10.7150/thno.5032
   Li TT, 2017, SCI CHINA CHEM, V60, P370, DOI 10.1007/s11426 016 0159 2
   Li XX, 2016, NANOSCI NANOTECH LET, V8, P1135, DOI 10.1166/nnl.2016.2268
   Li Y., 2007, CHIN J TISSUE ENG RE, V11, P7065
   Li ZQ, 2016, J BIOBASED MATER BIO, V10, P71, DOI 10.1166/jbmb.2016.1581
   Liao JF, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.18
   Liu C, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.12
   Liu HN, 2010, BIOSENS BIOELECTRON, V26, P1442, DOI 10.1016/j.bios.2010.07.078
   Liu HN, 2009, ANAL BIOCHEM, V386, P126, DOI 10.1016/j.ab.2008.11.035
   Liu KK, 2016, J NANOSCI NANOTECHNO, V16, P6648, DOI 10.1166/jnn.2016.11392
   Liu M, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.14
   Liu M, 2016, CELL PROLIFERAT, V49, P409, DOI 10.1111/cpr.12266
   Liu M, 2015, THERANOSTICS, V5, P71, DOI 10.7150/thno.10117
   Liu Y, 2017, SCI CHINA CHEM, V60, P329, DOI 10.1007/s11426 016 0253 2
   Liu Y, 2016, NANOSCI NANOTECH LET, V8, P785, DOI 10.1166/nnl.2016.2264
   Lv LW, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.37
   Mao LL, 2017, SCI CHINA CHEM, V60, P157, DOI 10.1007/s11426 016 0021 0
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Morita J, 2016, J BIOBASED MATER BIO, V10, P151, DOI 10.1166/jbmb.2016.1583
   Mou XB, 2015, J BIOMED NANOTECHNOL, V11, P2057, DOI 10.1166/jbn.2015.2113
   Oakhill JS, 2009, ACTA PHYSIOL, V196, P3, DOI 10.1111/j.1748 1716.2009.01977.x
   Osman Y, 2016, J BIOBASED MATER BIO, V10, P119, DOI 10.1166/jbmb.2016.1582
   Qin L, 2005, J BONE MINER METAB, V23, P55, DOI 10.1007/BF03026324
   Qin ZD, 2016, NANOSCI NANOTECH LET, V8, P1047, DOI 10.1166/nnl.2016.2242
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Roh SC, 2016, NANOSCI NANOTECH LET, V8, P38, DOI 10.1166/nnl.2016.2090
   Rubin MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.1
   Sari DP, 2016, J NANOSCI NANOTECHNO, V16, P8909, DOI 10.1166/jnn.2016.12742
   Seeman E, 2004, MED J AUSTRALIA, V180, P298, DOI 10.5694/j.1326 5377.2004.tb05931.x
   Shah MAA, 2014, J BIOMED NANOTECHNOL, V10, P2332, DOI 10.1166/jbn.2014.1981
   Shao X., 2007, SMALL, V13
   Shariati SRP, 2016, J NANOSCI NANOTECHNO, V16, P8966, DOI 10.1166/jnn.2016.12737
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI [10.1152/physrev.00011.2008, 10.15252/embj.201488104]
   Tang LR, 2016, J BIOBASED MATER BIO, V10, P27, DOI 10.1166/jbmb.2016.1570
   Tian L, 2009, J BIOMED NANOTECHNOL, V5, P511, DOI 10.1166/jbn.2009.1066
   Tian TR, 2016, J NANOSCI NANOTECHNO, V16, P9381, DOI 10.1166/jnn.2016.126811
   Trzeciak T, 2016, J NANOSCI NANOTECHNO, V16, P9022, DOI 10.1166/jnn.2016.12733
   Trzeciak T, 2016, J NANOSCI NANOTECHNO, V16, P8948, DOI 10.1166/jnn.2016.12732
   Venkatesan J, 2016, J NANOSCI NANOTECHNO, V16, P8881, DOI 10.1166/jnn.2016.12730
   Wang DW, 2015, CELL PHYSIOL BIOCHEM, V36, P1563, DOI 10.1159/000430319
   Wang JH, 2015, SCI CHINA CHEM, V58, P1774, DOI 10.1007/s11426 015 5483 x
   Wang P, 2016, J BIOBASED MATER BIO, V10, P229, DOI 10.1166/jbmb.2016.1600
   Wang Y, 2016, J NANOSCI NANOTECHNO, V16, P12275, DOI 10.1166/jnn.2016.12954
   Wen J, 2016, J NANOSCI NANOTECHNO, V16, P3077, DOI 10.1166/jnn.2016.12463
   Xi ZJ, 2016, NANOSCI NANOTECH LET, V8, P1061, DOI 10.1166/nnl.2016.2246
   Xi ZJ, 2015, ACS APPL MATER INTER, V7, P11215, DOI 10.1021/acsami.5b01180
   Xu Y. L., 2005, J INT OBST GY, V5, P274
   Yan JP, 2016, J BIOBASED MATER BIO, V10, P339, DOI 10.1166/jbmb.2016.1609
   Ye BL, 2017, SCI CHINA PHYS MECH, V60, DOI 10.1007/s11433 016 0425 x
   Yi H, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.50
   Yin LF, 2015, SCI CHINA CHEM, V58, P1912, DOI 10.1007/s11426 015 5471 1
   Yu J, 2016, J NANOSCI NANOTECHNO, V16, P7069, DOI 10.1166/jnn.2016.13033
   Zancanela DC, 2016, J NANOSCI NANOTECHNO, V16, P9487, DOI 10.1166/jnn.2016.12045
   Zeng XL, 2016, NANOSCI NANOTECH LET, V8, P688, DOI 10.1166/nnl.2016.2206
   Zhang G, 2006, BONE, V38, P818, DOI 10.1016/j.bone.2005.11.019
   Zhang J, 2015, BONE RES, V3, DOI 10.1038/boneres.2014.48
   Zhang YY, 2015, SCI ADV MATER, V7, P532, DOI 10.1166/sam.2015.2130
   Zhang YY, 2014, SCI ADV MATER, V6, P1146, DOI 10.1166/sam.2014.1877
   Zhao LJ, 2016, J PROTEOME RES, V15, P2327, DOI 10.1021/acs.jproteome.6b00409
   Zhong J, 2016, BONE RES, V4, DOI 10.1038/boneres.2015.36
   Zhou D, 2015, SCI CHINA CHEM, V58, P979, DOI 10.1007/s11426 014 5265 x
NR 110
TC 2
Z9 4
U1 0
U2 27
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1941 4900
EI 1941 4919
J9 NANOSCI NANOTECH LET
JI Nanosci. Nanotechnol. Lett.
PD SEP
PY 2017
VL 9
IS 9
BP 1419
EP 1426
DI 10.1166/nnl.2017.2438
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science; Physics
GA FP1OM
UT WOS:000417383100021
DA 2025 08 17
ER

PT J
AU Moscatelli, I
   Löfvall, H
   Thudium, CS
   Rothe, M
   Montano, C
   Kertész, Z
   Sirin, M
   Schulz, A
   Schambach, A
   Henriksen, K
   Richter, J
AF Moscatelli, Ilana
   Lofvall, Henrik
   Thudium, Christian Schneider
   Rothe, Michael
   Montano, Carmen
   Kertesz, Zsuzsanna
   Sirin, Mehtap
   Schulz, Ansgar
   Schambach, Axel
   Henriksen, Kim
   Richter, Johan
TI Targeting NSG Mice Engrafting Cells with a Clinically Applicable
   Lentiviral Vector Corrects Osteoclasts in Infantile Malignant
   Osteopetrosis
SO HUMAN GENE THERAPY
LA English
DT Article
DE IMO; gene therapy; MSC; lentiviral vector
ID AUTOSOMAL RECESSIVE OSTEOPETROSIS; CHRONIC GRANULOMATOUS DISEASE;
   GENE THERAPY; TRANSPLANTATION; EXPRESSION; TCIRG1; SUBUNIT
AB Infantile malignant osteopetrosis (IMO) is a rare, lethal, autosomal recessive disorder characterized by nonfunctional osteoclasts. More than 50% of the patients have mutations in the TCIRG1 gene, encoding for a subunit of the osteoclast proton pump. The aim of this study was to develop a clinically applicable lentiviral vector expressing TCIRG1 to correct osteoclast function in IMO. Two mammalian promoters were compared: elongation factor 1 short (EFS) promoter and chimeric myeloid promoter (ChimP). EFS promoter was chosen for continued experiments, as it performed better. IMO osteoclasts corrected in vitro by a TCIRG1 expressing lentiviral vector driven by EFS (EFS T) restored Ca2+ release to 92% and the levels of the bone degradation product CTX I to 95% in the media compared to control osteoclasts. IMO CD34(+) cells from five patients transduced with EFS T were transplanted into NSG mice. Bone marrow was harvested 9 19 weeks after transplantation, and human CD34(+) cells were selected, expanded, and seeded on bone slices. Vector corrected IMO osteoclasts had completely restored Ca2+ release. CTX I levels in the media were 33% compared to normal osteoclasts. Thus, in summary, evidence is provided that transduction of IMO CD34+ cells with the clinically applicable EFS T vector leads to full rescue of osteoclasts in vitro and partial rescue of osteoclasts generated from NSG mice engrafting hematopoietic cells. This supports the continued clinical development of gene therapy for IMO.
C1 [Moscatelli, Ilana; Lofvall, Henrik; Montano, Carmen; Kertesz, Zsuzsanna; Richter, Johan] Lund Univ, Dept Mol Med & Gene Therapy, Lund Strateg Ctr Stem Cell Biol, Lund, Sweden.
   [Lofvall, Henrik; Thudium, Christian Schneider; Henriksen, Kim] Nord Biosci, Herlev, Denmark.
   [Rothe, Michael; Schambach, Axel] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany.
   [Sirin, Mehtap; Schulz, Ansgar] Univ Med Ctr, Dept Pediat & Adolescent Med, Ulm, Germany.
C3 Lund University; Nordic Bioscience; Hannover Medical School; Ulm
   University
RP Richter, J (通讯作者)，Dept Mol Med & Gene Therapy, BMC A12, S 22184 Lund, Sweden.
EM Johan.Richter@med.lu.se
RI ; Schambach, Axel/C 5491 2011
OI Schambach, Axel/0000 0003 2743 0070; Lofvall, Henrik/0000 0002 3296 2023
FU Danish Research Foundation (Den Danske Forskningsfond); Swedish
   Childhood Cancer Foundation; Clinical Research Award from Lund
   University Hospital, The Foundations of Lund University Hospital; EU
   (ERARE initiative, project OSTEOPETR); EU (FP7 Health 2010 CELL PID)
   [261387]; Marie Curie Initial Training Networks (Euroclast,
   FP7 People 2013 ITN) [607446]; Center of Excellence grant in life
   sciences from the Swedish Foundation for Strategic Research
FX We thank Adrian Thrasher and Manuel Grez for the ChimP construct, and
   Christopher Baum and Axel Schambach (Hannover Medical School, Germany)
   for providing us with the lentiviral vectors. K.H. is supported by the
   Danish Research Foundation (Den Danske Forskningsfond). J.R. is
   supported by grants from The Swedish Childhood Cancer Foundation and a
   Clinical Research Award from Lund University Hospital, The Foundations
   of Lund University Hospital. A.S. is partially supported by grants from
   the EU (ERARE initiative, project OSTEOPETR). A.S. and M.R. were
   supported by the EU (FP7 Health 2010 CELL PID: #261387). H.L. is
   supported by Marie Curie Initial Training Networks (Euroclast,
   FP7 People 2013 ITN: #607446). The Lund Stem Cell Center is supported by
   a Center of Excellence grant in life sciences from the Swedish
   Foundation for Strategic Research. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Askmyr M, 2009, CURR GENE THER, V9, P150, DOI 10.2174/156652309788488613
   Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280
   Carbonaro DA, 2014, MOL THER, V22, P607, DOI 10.1038/mt.2013.265
   De Ravin SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8856
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Flores C, 2010, J BONE MINER RES, V25, P2069, DOI 10.1002/jbmr.90
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Grez M, 2011, MOL THER, V19, P28, DOI 10.1038/mt.2010.232
   Hacein Bey Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314
   Johansson MK, 2007, BLOOD, V109, P5178, DOI 10.1182/blood 2006 12 061382
   Modlich U, 2006, BLOOD, V108, P2545, DOI 10.1182/blood 2005 08 024976
   Modlich U, 2009, MOL THER, V17, P1919, DOI 10.1038/mt.2009.179
   Moscatelli I, 2013, BONE, V57, P1, DOI 10.1016/j.bone.2013.07.026
   Orchard P, 2013, BIOL BLOOD MARROW TR, V19, pS58, DOI 10.1016/j.bbmt.2012.10.026
   Rathinam C, 2011, BLOOD, V118, P3119, DOI 10.1182/blood 2010 12 326926
   Rittelmeyer I, 2013, HEPATOLOGY, V58, P397, DOI 10.1002/hep.26204
   Santilli G, 2011, MOL THER, V19, P122, DOI 10.1038/mt.2010.226
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schulz AS, 2002, BLOOD, V99, P3458, DOI 10.1182/blood.V99.9.3458
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088
   Steward CG, 2005, BIOL BLOOD MARROW TR, V11, P115, DOI 10.1016/j.bbmt.2004.11.001
   Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002 9440(10)63798 4
   Thudium CS, 2012, CURR PROTEIN PEPT SC, V13, P141
   Thudium CS, 2016, CALCIFIED TISSUE INT, V99, P638, DOI 10.1007/s00223 016 0187 6
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Zhou S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062333
   Zhou S, 2010, BLOOD, V116, P900, DOI 10.1182/blood 2009 10 250209
   Zychlinski D, 2008, MOL THER, V16, P718, DOI 10.1038/mt.2008.5
NR 31
TC 11
Z9 13
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043 0342
EI 1557 7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD AUG
PY 2018
VL 29
IS 8
BP 938
EP 949
DI 10.1089/hum.2017.053
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA GP9SX
UT WOS:000441257800010
PM 28726516
DA 2025 08 17
ER

PT J
AU Sangai, T
   Fujimoto, H
   Miyamoto, S
   Maeda, H
   Nakamura, M
   Ishii, G
   Nagai, K
   Nagashima, T
   Miyazaki, M
   Ochiai, A
AF Sangai, Takafumi
   Fujimoto, Hiroshi
   Miyamoto, Shin'ichi
   Maeda, Hiroyuki
   Nakamura, Michio
   Ishii, Genichiro
   Nagai, Kanji
   Nagashima, Takeshi
   Miyazaki, Masaru
   Ochiai, Atsushi
TI Roles of osteoclasts and bone derived IGFs in the survival and growth of
   human breast cancer cells in human adult bone implanted into nonobese
   diabetic/severe combined immunodeficient mice
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE antibody therapy; insulin like growth factor; osteoclastogenesis
   inhibitory factor/osteoprotegerin; osteoclast; breast cancer; bone tumor
ID HUMAN PROSTATE CANCER; FACTOR I RECEPTOR; OSTEOPROTEGERIN OPG;
   INHIBITORY FACTOR; BISPHOSPHONATE THERAPY; METASTASIS; LIGAND;
   APOPTOSIS; ANTIBODY; DIFFERENTIATION
AB Human breast cancer frequently metastasizes to bone, and effective therapies for patients with bone metastasis are required. However, the molecular mechanism for the bone metastasis of human breast cancer has not yet been fully elucidated. The present study aimed to evaluate the importance of active osteoclasts and bone derived insulin like growth factors (IGFs) for the survival and growth of breast cancer cells in bone. Human breast cancer cell line MCF 7 cells were injected into human adult bone (HAB) implanted into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. The mice were then treated with recombinant human osteoclastogenesis inhibitory factor/osteoprotegerin (rhOCIF/OPG), a decoy receptor for receptor activator of NF kappaB ligand (RANKL), or an anti human IGF monoclonal antibody. Histomorphometric analyses revealed that both treatments significantly decreased the tumor area of MCF 7 cells in cross sections of the implanted HAB to about 30% of the tumor area in control mice, but had no effect on the growth of subcutaneously injected MCF 7 cells. Consistent with the results for the tumor area in HAB, there were fewer osteoclasts in the implanted HAB in rhOCIF/OPG treated mice than in vehicle treated mice. However, treatment with the anti human IGF monoclonal antibody had no effect on the number of osteoclasts in HAB. The results indicate that the active osteoclasts induced by RANKL and the IGFs released as a result of bone resorption by these osteoclasts play crucial roles in the survival and growth of human breast cancer cells in bone and suggest that neutralization of bone derived IGFs will be effective in preventing the development of bone tumors in breast cancer patients.
C1 [Sangai, Takafumi; Fujimoto, Hiroshi; Miyamoto, Shin'ichi; Maeda, Hiroyuki; Nakamura, Michio; Ishii, Genichiro; Ochiai, Atsushi] Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba 2778577, Japan.
   [Sangai, Takafumi; Fujimoto, Hiroshi; Nagashima, Takeshi; Miyazaki, Masaru] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chiba, Japan.
   [Nagai, Kanji] Natl Canc Ctr Hosp E, Div Thorac Oncol, Chiba, Japan.
C3 National Cancer Center   Japan; Chiba University; National Cancer Center
     Japan
RP Ochiai, A (通讯作者)，Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, 6 5 1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.
EM aochiai@east.ncc.go.jp
RI Ishii, Genichiro/E 2913 2012
CR Bagi CM, 2005, ADV DRUG DELIVER REV, V57, P995, DOI 10.1016/j.addr.2004.12.014
   Bartucci M, 2001, CANCER RES, V61, P6747
   Body JJ, 2006, CLIN CANCER RES, V12, p6258S, DOI 10.1158/1078 0432.CCR 06 0840
   CONOVER CA, 1994, J BIOL CHEM, V269, P7076
   Diel IJ, 2000, BRIT J CANCER, V82, P1381, DOI 10.1054/bjoc.1999.1077
   Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443
   Dunn SE, 1998, CANCER RES, V58, P3353
   Goya M, 2004, CANCER RES, V64, P6252, DOI 10.1158/0008 5472.CAN 04 0919
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Hiraga T, 2001, CANCER RES, V61, P4418
   Holen I, 2002, CANCER RES, V62, P1619
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115
   Lipton A, 2004, ONCOLOGIST, V9, P38, DOI 10.1634/theoncologist.9 90004 38
   Maloney EK, 2003, CANCER RES, V63, P5073
   Marshman E, 2002, BREAST CANCER RES, V4, P231, DOI 10.1186/bcr535
   Morony S, 2001, CANCER RES, V61, P4432
   Neville Webbe HL, 2004, BREAST CANCER RES TR, V86, P269
   NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Sachdev D, 2003, CANCER RES, V63, P627
   Salahifar H, 1997, ENDOCRINOLOGY, V138, P1683, DOI 10.1210/en.138.4.1683
   Sano A, 2007, INT J ONCOL, V30, P1493
   Shipman CM, 2003, CANCER RES, V63, P912
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Solomayer EF, 2000, BREAST CANCER RES TR, V59, P271, DOI 10.1023/A:1006308619659
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yonou H, 2003, CANCER RES, V63, P2096
   Yonou H, 2001, CANCER RES, V61, P2177
   Zhang XH, 2005, BREAST CANCER RES TR, V93, P159, DOI 10.1007/s10549 005 4626 8
NR 36
TC 12
Z9 13
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD JUN
PY 2008
VL 25
IS 4
BP 401
EP 410
DI 10.1007/s10585 008 9144 8
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 306MT
UT WOS:000256253200012
PM 18307047
DA 2025 08 17
ER

PT J
AU Mahmood, A
   Harkness, L
   Schroder, HD
   Abdallah, BM
   Kassem, M
AF Mahmood, Amer
   Harkness, Linda
   Schroder, Henrik Daa
   Abdallah, Basem M.
   Kassem, Moustapha
TI Enhanced Differentiation of Human Embryonic Stem Cells to Mesenchymal
   Progenitors by Inhibition of TGF β/Activin/Nodal Signaling Using
   SB 431542
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HUMAN EMBRYONIC STEM CELLS; TGF beta SIGNALING; SKELETAL MYOBLASTS;
   OSTEOBLAST DIFFERENTIATION; MESENCHYMAL DIFFERENTIATION
ID MUSCLE SATELLITE CELLS; BONE MARROW; SKELETAL MUSCLE; OSTEOGENIC CELLS;
   GENE EXPRESSION; GROWTH FACTOR; LIFE SPAN; TRANSPLANTATION; MOUSE; PAX7
AB Directing differentiation of human embryonic stem cells (hESCs) into specific cell types using an easy and reproducible protocol is a prerequisite for the clinical use of hESCs in regenerative medicine procedures. Here, we report a protocol for directing the differentiation of hESCs into mesenchymal progenitor cells. We demonstrate that inhibition of transforming growth factor beta (TGF beta)/activin/nodal signaling during embryoid body (EB) formation using SB 431542 (SB) in serum free medium markedly upregulated paraxial mesodermal markers (TBX6, TBX5) and several myogenic developmental markers, including early myogenic transcriptional factors (Myf5, Pax7), as well as myocyte committed markers [NCAM, CD34, desmin, MHC: (fast), alpha smooth muscle actin, Nkx2.5, cTNT]. Continuous inhibition of TGF beta signaling in EB outgrowth cultures (SB OG) enriched for myocyte progenitor cells; markers were PAX7(+) (25%), MYOD1(+) (52%), and NCAM(+) (CD56) (73%). DNA microarray analysis revealed differential upregulation of 117 genes (>2 fold compared with control cells) annotated to myogenic development and function. Moreover, these cells showed the ability to contract (80% of the population) and formed myofibers when implanted intramuscularly in vivo. Interestingly, SB OG cells cultured in 10% fetal bovine serum (FBS) developed into a homogeneous population of mesenchymal progenitors that expressed CD markers characteristic of mesenchymal stem cells (MSCs): CD44(+) (100%), CD73(+) (98%), CD146(+) (96%), and CD166(+) (88%) with the ability to differentiate into osteoblasts, adipocytes, and chondrocytes in vitro and in vivo. Furthermore, microarray analysis of these cells revealed downregulation of genes related to myogenesis: MYH3 ( 167.9 fold), ACTA1 ( 161 fold), MYBPH ( 139 fold), ACTC ( 100.3 fold), MYH8 ( 45.5 fold), and MYOT ( 41.8 fold) and marked upregulation of genes related to mesoderm derived cell lineages. In conclusion, our data provides a simple and versatile protocol for directing the differentiation of hESCs into a myogenic lineage and then further into mesenchymal progenitors by blocking the TGF beta signaling pathway. (C) 2010 American Society for Bone and Mineral Research.
C1 [Abdallah, Basem M.] Univ So Denmark, Odense Univ Hosp, Mol Endocrinol Lab KMEB, Ctr Med Biotechnol, Odense, Denmark.
   [Mahmood, Amer; Harkness, Linda; Abdallah, Basem M.; Kassem, Moustapha] Odense Univ Hosp, Dept Endocrinol, DK 5000 Odense, Denmark.
   [Schroder, Henrik Daa] Odense Univ Hosp, Inst Pathol, DK 5000 Odense, Denmark.
   [Mahmood, Amer; Kassem, Moustapha] King Saud Univ, Stem Cell Unit, Dept Anat, Riyadh, Saudi Arabia.
C3 University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; Odense University Hospital; University of Southern
   Denmark; Odense University Hospital; King Saud University
RP Abdallah, BM (通讯作者)，Univ So Denmark, Odense Univ Hosp, Mol Endocrinol Lab KMEB, Ctr Med Biotechnol, Odense, Denmark.
EM babdallah@health.sdu.dk
RI ; Kassem, Moustapha/J 7688 2013; Schroder, Henrik Daa/E 2077 2013;
   Harkness, Linda/A 5654 2017; Mahmood, Amer/A 9514 2011; Schrøder,
   Henrik/E 2077 2013; Abdallah, Basem/G 5667 2017
OI Mahmood, Amer/0000 0002 9199 0120; Kassem,
   Moustapha/0000 0003 1557 0869; Schroder, Henrik Daa/0000 0001 7588 235X;
   Abdallah, Basem/0000 0003 0324 8055; Harkness, Linda/0000 0002 1648 9301
FU Lundbeck Foundation; Velux Foundation; region of Southern Denmark;
   Danish Postgraduate School of Molecular Metabolism, University of
   Southern Denmark
FX We thank Lone Christiansen for excellent technical assistance with the
   immunohistochemistry. This study was supported by a grant from the
   Lundbeck Foundation, a grant from the Velux Foundation, and a grant from
   the region of Southern Denmark. AM has received a PhD fellowship from
   the Danish Postgraduate School of Molecular Metabolism, University of
   Southern Denmark.
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Abdallah BM, 2006, BONE, V39, P181, DOI 10.1016/j.bone.2005.12.082
   Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Abdallah BM, 2007, J BIOL CHEM, V282, P7339, DOI 10.1074/jbc.M607530200
   Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432 0436.2001.680412.x
   Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533
   Ben Hur T, 2004, STEM CELLS, V22, P1246, DOI 10.1634/stemcells.2004 0094
   Bettiol E, 2007, DIFFERENTIATION, V75, P669, DOI 10.1111/j.1432 0436.2007.00174.x
   Bielby RC, 2004, TISSUE ENG, V10, P1518, DOI 10.1089/ten.2004.10.1518
   Blanco Bose WE, 2001, DEV BIOL, V233, P148, DOI 10.1006/dbio.2001.0177
   Bonassar LJ, 1997, EXP CELL RES, V234, P1, DOI 10.1006/excr.1997.3574
   Carlson ME, 2008, NATURE, V454, P528, DOI 10.1038/nature07034
   Caspi O, 2007, J AM COLL CARDIOL, V50, P1884, DOI 10.1016/j.jacc.2007.07.054
   Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326
   Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330
   Crook JM, 2007, CELL STEM CELL, V1, P490, DOI 10.1016/j.stem.2007.10.004
   D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163
   D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Frandsen U, 2007, BIOCHEM BIOPH RES CO, V362, P568, DOI 10.1016/j.bbrc.2007.07.200
   Gensch N, 2008, DEVELOPMENT, V135, P1597, DOI 10.1242/dev.019331
   Graichen R, 2008, DIFFERENTIATION, V76, P357, DOI 10.1111/j.1432 0436.2007.00236.x
   Haldar M, 2008, DEV CELL, V14, P437, DOI 10.1016/j.devcel.2008.01.002
   Hashimoto N, 2008, MECH DEVELOP, V125, P257, DOI 10.1016/j.mod.2007.11.004
   Holterman CE, 2007, J CELL BIOL, V179, P911, DOI 10.1083/jcb.200709083
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Kärner E, 2007, STEM CELLS DEV, V16, P39, DOI 10.1089/scd.2006.0010
   Karp JM, 2006, STEM CELLS, V24, P835, DOI 10.1634/stemcells.2005 0383
   KASSEM M, 1993, J BONE MINER RES, V8, P1453
   Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605
   Khojasteh A, 2008, ORAL SURG ORAL MED O, V106, P356, DOI 10.1016/j.tripleo.2007.10.017
   Kim S, 2008, BIOMATERIALS, V29, P1043, DOI 10.1016/j.biomaterials.2007.11.005
   Kitamura R, 2007, CIRC RES, V101, P78, DOI 10.1161/CIRCRESAHA.106.147264
   Koay EJ, 2007, STEM CELLS, V25, P2183, DOI 10.1634/stemcells.2007 0105
   Kontula K, 2005, CARDIOVASC RES, V67, P379, DOI 10.1016/j.cardiores.2005.04.027
   Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393
   Lee G, 2007, NAT BIOTECHNOL, V25, P1468, DOI 10.1038/nbt1365
   Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085
   Leor J, 2007, HEART, V93, P1278, DOI 10.1136/hrt.2006.093161
   LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676
   Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011
   Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892
   McDevitt TC, 2005, J MOL CELL CARDIOL, V39, P865, DOI 10.1016/j.yjmcc.2005.09.007
   Moore JC, 2005, REPROD TOXICOL, V20, P377, DOI 10.1016/j.reprotox.2005.04.012
   Mummery C, 2002, J ANAT, V200, P233, DOI 10.1046/j.1469 7580.2002.00031.x
   Olivier EN, 2006, STEM CELLS, V24, P1914, DOI 10.1634/stemcells.2005 0648
   Péault B, 2007, MOL THER, V15, P867, DOI 10.1038/mt.sj.6300145
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prokhorova T.A., 2008, STEM CELLS DEV
   Rajasingh J, 2007, CIRC RES, V101, P910, DOI 10.1161/CIRCRESAHA.107.156786
   Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594
   Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044
   Relaix F, 2004, GENE DEV, V18, P1088, DOI 10.1101/gad.301004
   Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200
   Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092 8674(00)00066 0
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Smith JR, 2008, DEV BIOL, V313, P107, DOI 10.1016/j.ydbio.2007.10.003
   Sottile V, 2003, CLONING STEM CELLS, V5, P149, DOI 10.1089/153623003322234759
   Stamataki D, 2001, FEBS LETT, V499, P274, DOI 10.1016/S0014 5793(01)02556 X
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092 8674(00)80189 0
   van Tuyn J, 2005, CARDIOVASC RES, V67, P245, DOI 10.1016/j.cardiores.2005.04.013
   Wada MR, 2002, DEVELOPMENT, V129, P2987
   Wallace GQ, 2008, AM J PATHOL, V173, P792, DOI 10.2353/ajpath.2008.080259
   Watanabe T, 2006, CANCER RES, V66, P3370, DOI 10.1158/0008 5472.CAN 05 3834
   Wier WG, 1999, CIRC RES, V85, P770, DOI 10.1161/01.RES.85.9.770
   WIER WG, 1993, BIOPHYS J, V65, P2270, DOI 10.1016/S0006 3495(93)81287 6
   Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91
   Yeo GW, 2007, PLOS COMPUT BIOL, V3, P1951, DOI 10.1371/journal.pcbi.0030196
   Zammit PS, 2006, J CELL SCI, V119, P1824, DOI 10.1242/jcs.02908
   Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zhou Y, 2008, BIOCHEM BIOPH RES CO, V376, P542, DOI 10.1016/j.bbrc.2008.09.032
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 80
TC 103
Z9 126
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2010
VL 25
IS 6
BP 1216
EP 1233
DI 10.1002/jbmr.34
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 619PE
UT WOS:000279441300004
PM 20200949
OA Bronze
DA 2025 08 17
ER

PT J
AU Jang, B
   Kim, Y
   Song, J
   Kim, YW
   Lee, WY
AF Jang, Boyun
   Kim, Youngsoo
   Song, Jungbin
   Kim, Young Woo
   Lee, Won Yung
TI Identifying Herbal Candidates and Active Ingredients Against
   Postmenopausal Osteoporosis Using Biased Random Walk on a Multiscale
   Network
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE postmenopausal osteoporosis; herbs; active ingredients; multiscale
   network
ID CONJUGATED ESTROGENS; CIMICIFUGA RACEMOSA; SALVIA MILTIORRHIZA;
   DOUBLE BLIND; BONE LOSS
AB Postmenopausal osteoporosis is a major global health concern, particularly affecting aging women, and necessitates innovative treatment options. Herbal medicine, with its multi compound, multi target characteristics, offers a promising approach for complex diseases. In this study, we applied multiscale network and random walk based analyses to identify candidate herbs and their active ingredients for postmenopausal osteoporosis, focusing on their underlying mechanisms. A dataset of medicinal herbs, their active ingredients, and protein targets was compiled, and diffusion profiles were calculated to assess the propagation effects. Through correlation analysis, we prioritized herbs based on their relevance to osteoporosis, identifying the top candidates like Benincasae Semen, Glehniae Radix, Corydalis Tuber, and Houttuyniae Herba. Gene Set Enrichment Analysis (GSEA) revealed that the 49 core protein targets of these herbs were significantly associated with pathways related to inflammation, osteoclast differentiation, and estrogen metabolism. Notably, compounds such as falcarindiol from Glehniae Radix and tetrahydrocoptisine from Corydalis Tuber previously unstudied for osteoporosis were predicted to interact with inflammation related proteins, including IL6, IL1B, and TNF, affecting key biological processes like apoptosis and cell proliferation. This study advances the understanding of herbal therapies for osteoporosis and offers a framework for discovering novel therapeutic agents.
C1 [Jang, Boyun; Kim, Youngsoo] IntegroMediLab Co Ltd, Seoul 04626, South Korea.
   [Song, Jungbin] Kyung Hee Univ, Coll Korean Med, Dept Herbal Pharmacol, Seoul 02447, South Korea.
   [Kim, Young Woo] Dongguk Univ, Sch Korean Med, Gyeonju 38066, South Korea.
   [Lee, Won Yung] Wonkwang Univ, Sch Korean Med, Iksan 54538, South Korea.
   [Lee, Won Yung] Wonkwang Univ, Res Ctr Tradit Korean Med, Iksan 54538, South Korea.
C3 Kyung Hee University; Dongguk University; Wonkwang University; Wonkwang
   University
RP Kim, YW (通讯作者)，Dongguk Univ, Sch Korean Med, Gyeonju 38066, South Korea.; Lee, WY (通讯作者)，Wonkwang Univ, Sch Korean Med, Iksan 54538, South Korea.; Lee, WY (通讯作者)，Wonkwang Univ, Res Ctr Tradit Korean Med, Iksan 54538, South Korea.
EM ywk@dongguk.ac.kr; wonyung21@wku.ac.kr
OI Kim, Young Woo/0000 0002 3323 7106; Jang, Boyun/0000 0002 6054 7679
FU Korean government (MSIT) [2022R1A2C1092168, RS 2023 00243363,
   RS 2023 00218419, RS 2024 00335030]; National Research Foundation of
   Korea (NRF)   Korean government (MSIT) [RS 2020 KH093754]; Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI)   Ministry of Health & Welfare, Republic of Korea
FX This research was supported by grants from the National Research
   Foundation of Korea (NRF) funded by the Korean government (MSIT) (grant
   numbers 2022R1A2C1092168, RS 2023 00243363, RS 2023 00218419, and
   RS 2024 00335030) and the Korea Health Technology R&D Project through
   the Korea Health Industry Development Institute (KHIDI), funded by the
   Ministry of Health & Welfare, Republic of Korea (grant number:
   RS 2020 KH093754).
CR Adejuyigbe B, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241914583
   Alhassen L, 2021, MOLECULES, V26, DOI 10.3390/molecules26247498
   García Pérez MA, 2009, FERTIL STERIL, V91, P1347, DOI 10.1016/j.fertnstert.2008.03.042
   Chae HJ, 2004, IMMUNOPHARM IMMUNOT, V26, P135, DOI 10.1081/IPH 120029951
   Charachit N, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020221
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fang ZQ, 2023, BIOINFORMATICS, V39, DOI 10.1093/bioinformatics/btac757
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Ge Q, 2018, EUR J PHARMACOL, V833, P50, DOI 10.1016/j.ejphar.2018.05.021
   Gene Ontology Consortium, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI DOI 10.1093/NAR/GKU1179
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Han SY, 2024, CURR ISSUES MOL BIOL, V46, P3081, DOI 10.3390/cimb46040193
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Islam MT, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6349041
   Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076
   Katayama Y, 1996, J BONE MINER RES, V11, P931, DOI 10.1002/jbmr.5650110709
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim JH, 2019, INT J MOL MED, V44, P913, DOI 10.3892/ijmm.2019.4269
   Kim JY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1300 0
   Kim YW, 2024, J GINSENG RES, V48, P373, DOI 10.1016/j.jgr.2024.01.005
   Koopmans F, 2019, NEURON, V103, P217, DOI 10.1016/j.neuron.2019.05.002
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Li SY, 2023, J ETHNOPHARMACOL, V317, DOI 10.1016/j.jep.2023.116831
   Li ZQ, 2016, AM J PHYSIOL ENDOC M, V310, pE355, DOI 10.1152/ajpendo.00309.2015
   Lim SK, 1997, J CLIN ENDOCR METAB, V82, P1001, DOI 10.1210/jc.82.4.1001
   Lin Hui, 2024, Shanghai Kou Qiang Yi Xue, V33, P255
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Lotinun S, 2003, BONE, V33, P124, DOI 10.1016/S8756 3282(03)00081 4
   Luo T, 2024, PHYTOMEDICINE, V134, DOI 10.1016/j.phymed.2024.155999
   Ma Y, 2019, J CELL BIOCHEM, V120, P16052, DOI 10.1002/jcb.28886
   Nian H, 2006, ACTA PHARMACOL SIN, V27, P728, DOI 10.1111/j.1745 7254.2006.00328.x
   Noor F, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15050572
   Tran PT, 2018, INT J MOL MED, V42, P569, DOI 10.3892/ijmm.2018.3627
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Qi T, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.752540
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Reginster JY, 2011, DRUGS, V71, P65, DOI 10.2165/11587570 000000000 00000
   Ruiz C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21770 8
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Sancho D, 2012, ANNU REV IMMUNOL, V30, P491, DOI 10.1146/annurev immunol 031210 101352
   Slupski W, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051609
   Sudarshan K, 2024, CHEM ASIAN J, V19, DOI 10.1002/asia.202400380
   Sugiyama MG, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 02432 7
   Sun JJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000461
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Thielen NGM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090969
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wei PP, 2024, PHYTOMEDICINE, V123, DOI 10.1016/j.phymed.2023.155195
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wuttke W, 2003, MATURITAS, V44, pS67, DOI 10.1016/S0378 5122(02)00350 X
   Wuttke W, 2006, MENOPAUSE, V13, P185, DOI 10.1097/01.gme.0000174470.44822.57
   Xiao HH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00932
   Xu TS, 2024, PHYTOMEDICINE, V128, DOI 10.1016/j.phymed.2024.155375
   Zanotti S, 2009, J ENDOCRINOL, V201, P263, DOI 10.1677/JOE 08 0514
   Zhang XJ, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0290289
   Zhang Y, 2011, OSTEOPOROSIS INT, V22, P703, DOI 10.1007/s00198 010 1240 3
   Zhao BK, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.615191
   Zhao XY, 2017, J AGR FOOD CHEM, V65, P9647, DOI 10.1021/acs.jafc.7b03666
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
   Zou J, 2024, ACS CENTRAL SCI, V10, P628, DOI 10.1021/acscentsci.3c01414
NR 60
TC 2
Z9 2
U1 3
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2024
VL 25
IS 22
AR 12322
DI 10.3390/ijms252212322
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA N6F6R
UT WOS:001365279000001
PM 39596387
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, CL
   Zhu, F
   Cheng, YY
   Sun, ZL
   Li, YW
   Song, DW
AF Zhang, Chenglin
   Zhu, Fang
   Cheng, Yiyun
   Sun, Zhenliang
   Li, Yiwen
   Song, Dianwen
TI A targeted and core shell structured gambogic acid nanomedicine for
   ameliorating breast cancer associated osteolysis
SO NANO TODAY
LA English
DT Article
DE Breast cancer; Osteolysis; Bone targeting; Gambogic acid; Core shell
   structured nanomedicine; Mild photothermal therapy; Heat shock protein
   90
ID PHOTOTHERMAL THERAPY; BONE METASTASIS; DELIVERY; INHIBITION
AB The treatment of breast cancer associated bone tumors is of critical importance and highly challenging, primarily owing to the malignant interplay between tumor proliferation and osteolysis within the bone tumor microenvironment. Although many efforts have been devoted, it is still urgent and desirable to find a robust therapeutic agent that can simultaneously and efficiently inhibit the proliferation of bone tumor and osteoclast differentiation. In this work, we have fabricated a bone targeting nanoplatform based on bioinspired polydopamine coated gambogic acid nanoparticles (GA@PDA NPs) integrated with mild temperature photothermal therapy (PTT) and chemotherapy towards the treatment of bone tumors. In particular, GA not only inhibits osteoclast differentiation and proliferation of bone tumor cells, but also downregulates heat shock protein 90 (Hsp90) in the treated tumor cells to sensitize the PTT effect, and the resulting core shell structured nanomedicine could allow the spatiotemporal control of chemotherapy and mild temperature PTT. Those bioinspired nanomedicine could exhibit excellent tumor suppression and osteolysis inhibition against a xenograft tumor bone metastasis model, and this novel nanoformulation provides a creative paradigm for the treatment of breast cancer associated osteolysis.
C1 [Zhang, Chenglin] Navy Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai 200003, Peoples R China.
   [Zhu, Fang; Sun, Zhenliang] Southern Med Univ, Fengxian Hosp, Shanghai 201499, Peoples R China.
   [Zhu, Fang; Cheng, Yiyun] East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell T, Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
   [Zhu, Fang; Li, Yiwen] Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.
   [Song, Dianwen] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai 201620, Peoples R China.
C3 Naval Medical University; Southern Medical University   China; East
   China Normal University; Sichuan University; Shanghai Jiao Tong
   University
RP Sun, ZL (通讯作者)，Southern Med Univ, Fengxian Hosp, Shanghai 201499, Peoples R China.; Li, YW (通讯作者)，Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.; Song, DW (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai 201620, Peoples R China.
EM zhenliang6@126.com; ywli@scu.edu.cn; osongdianwen@126.com
RI Li, Yifei/AAB 4210 2019
FU Shanghai Jiao Tong University Medical Industrial Intersection Key
   Project [ZH2018ZDA18]; National Natural Science Foundation of China
   [81571828, 52225311]; Changzheng hospital pyramid talent project [YQ70D]
FX C.Z. and F.Z. contributed equally to this work. This work was
   financially supported by Shanghai Jiao Tong University
   Medical Industrial Intersection Key Project (ZH2018ZDA18) , the National
   Natural Science Foundation of China (81571828 and 52225311) , and
   Changzheng hospital pyramid talent project (YQ70D) .
CR Bai WJ, 2022, MACROMOLECULES, V55, P6426, DOI 10.1021/acs.macromol.2c01440
   Bai WJ, 2022, MACROMOLECULES, V55, P3493, DOI 10.1021/acs.macromol.2c00506
   Banik K, 2018, CANCER LETT, V416, P75, DOI 10.1016/j.canlet.2017.12.014
   Bouyssou JMC, 2016, CANCER LETT, V380, P315, DOI 10.1016/j.canlet.2015.11.028
   Chiou AE, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf2283
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Dang GP, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202210275
   Deng R, 2021, AUTOPHAGY, V17, P3011, DOI 10.1080/15548627.2020.1850609
   Federico C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19932 1
   Gao P, 2022, CHINESE CHEM LETT, V33, P575, DOI 10.1016/j.cclet.2021.08.023
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   Han LF, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120228
   He C, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202006214
   Hu JF, 2020, BIOMATER SCI UK, V8, P4940, DOI 10.1039/d0bm01070g
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Huang YJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24564 0
   Jiang W, 2022, BIOACT MATER, V12, P169, DOI 10.1016/j.bioactmat.2021.10.017
   Jin ZK, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202103391
   Kang YA, 2018, ACTA BIOMATER, V68, P137, DOI 10.1016/j.actbio.2017.12.028
   Lavrador P, 2018, J CONTROL RELEASE, V273, P51, DOI 10.1016/j.jconrel.2018.01.021
   Li CW, 2022, CELL DEATH DIFFER, V29, P1123, DOI 10.1038/s41418 021 00904 x
   Oláh T, 2022, ADV SCI, V9, DOI 10.1002/advs.202201692
   Pang YC, 2021, BIOACT MATER, V6, P712, DOI 10.1016/j.bioactmat.2020.09.006
   Resnick E, 2019, J AM CHEM SOC, V141, P8951, DOI 10.1021/jacs.9b02822
   Sun KY, 2022, BIOACT MATER, V8, P435, DOI 10.1016/j.bioactmat.2021.06.016
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Tang WL, 2018, BIOMATERIALS, V166, P13, DOI 10.1016/j.biomaterials.2018.03.004
   Wang CP, 2015, SMALL, V11, P2080, DOI 10.1002/smll.201403315
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang XH, 2020, SCI CHINA CHEM, V63, P1295, DOI 10.1007/s11426 020 9797 3
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wang Z, 2020, SMALL, V16, DOI 10.1002/smll.201907042
   Wu KR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25473 y
   Xie C, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121741
   Xu X, 2020, J CONTROL RELEASE, V324, P493, DOI 10.1016/j.jconrel.2020.03.028
   Yang L, 2019, ACS APPL MATER INTER, V11, P30360, DOI 10.1021/acsami.9b10956
   Yang P, 2021, CHEM SOC REV, V50, P8319, DOI 10.1039/d1cs00374g
   Yi XL, 2021, RESEARCH CHINA, V2021, DOI 10.34133/2021/9816594
   Yim KH, 2016, P NATL ACAD SCI USA, V113, pE4801, DOI 10.1073/pnas.1606655113
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Yu WQ, 2021, ADV DRUG DELIVER REV, V178, DOI 10.1016/j.addr.2021.113909
   Zeng YZ, 2019, ACTA BIOMATER, V93, P152, DOI 10.1016/j.actbio.2019.01.060
   Zhang HQ, 2011, ACTA BIOMATER, V7, P2960, DOI 10.1016/j.actbio.2011.03.020
   Zhou ZJ, 2019, BIOMATERIALS, V203, P63, DOI 10.1016/j.biomaterials.2019.02.023
   Zhou ZJ, 2017, BIOMATERIALS, V141, P116, DOI 10.1016/j.biomaterials.2017.06.030
   Zou Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb4696
NR 46
TC 3
Z9 3
U1 9
U2 32
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1748 0132
EI 1878 044X
J9 NANO TODAY
JI Nano Today
PD OCT
PY 2024
VL 58
AR 102423
DI 10.1016/j.nantod.2024.102423
EA AUG 2024
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA C5I4K
UT WOS:001289697800001
DA 2025 08 17
ER

PT J
AU Corbett, K
   Ruether, D
   Seiden Long, I
   Kline, G
AF Corbett, Kathryn
   Ruether, Dean
   Seiden Long, Isolde
   Kline, Gregory
TI Resolution of PTHrP Mediated Hypercalcemia Following Treatment with Dual
   BRAF/MEK Inhibition for BRAFV600E Positive Metastatic Ameloblastoma
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Hypercalcemia; Malignancy; PTHrP; Bone turnover; Osteoporosis; Targeted
   therapy
ID HORMONE RELATED PROTEIN; EXPRESSION
AB Ameloblastoma is a rare odontogenic tumor which may be complicated by hypercalcemia in advanced disease. Tumoral parathyroid hormone related peptide (PTHrP) production and local osteolysis from paracrine factors have been proposed as mechanisms. Mitogen activated protein kinase (MAPK) inhibitors have been successfully used in ameloblastomas with BRAF V600E mutation to reduce symptoms and decrease tumor burden. Serum calcium has been observed to normalize following treatment with MAPK inhibitors; however, the response of PTHrP and markers of bone turnover has not been reported. We describe a case of a 55 year old female with PTHrP mediated hypercalcemia secondary to BRAF V600E positive ameloblastoma with pulmonary metastases. Following treatment with dabrafenib and trametinib, the patient experienced the regression of pulmonary lesions and normalization of serum calcium, PTHrP, and markers of bone turnover. Tissue samples of ameloblastoma carrying BRAF V600E mutation are more likely to express PTHrP than tissue samples carrying wild type BRAF. In our case, resolution of PTHrP mediated hypercalcemia following initiation of BRAF/MEK inhibition provides additional evidence that the MAPK pathway contributes to PTHrP synthesis. It also raises the question of whether MAPK inhibitors would be effective in treating PTHrP mediated hypercalcemia associated with other malignancies harboring BRAF V600E mutation.
C1 [Corbett, Kathryn] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada.
   [Ruether, Dean] Univ Calgary, Dept Med, Div Oncol, Calgary, AB, Canada.
   [Seiden Long, Isolde] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada.
   [Seiden Long, Isolde] Alberta Precis Labs, Calgary, AB, Canada.
   [Kline, Gregory] Univ Calgary, Dept Med, Div Endocrinol & Metab, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.
C3 University of Calgary; University of Calgary; University of Calgary;
   University of Calgary
RP Kline, G (通讯作者)，Univ Calgary, Dept Med, Div Endocrinol & Metab, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.
EM gregory.kline@ahs.ca
OI Kline, Gregory/0000 0002 8129 9360; , Isolde/0000 0002 1796 3159;
   Corbett, Kathryn/0000 0003 0253 6135
CR Abdelsayed RA, 2004, ORAL SURG ORAL MED O, V97, P208, DOI 10.1016/j.tripleo.2003.10.003
   Abramson Z, 2022, ORAL ONCOL, V128, DOI 10.1016/j.oraloncology.2022.105854
   Asonitis Nikolaos, 2017, Endocrinol Diabetes Metab Case Rep, V2017, DOI 10.1530/EDM 17 0118
   Broudic Guibert M, 2019, J MED CASE REP, V13, DOI 10.1186/s13256 019 2140 6
   Cheung CHY, 2018, CL LYMPH MYELOM LEUK, V18, pE315, DOI 10.1016/j.clml.2018.05.008
   Donovan PJ, 2015, J CLIN ENDOCR METAB, V100, P2024, DOI 10.1210/jc.2014 4250
   Donovan PJ, 2013, J CLIN ENDOCR METAB, V98, P4023, DOI 10.1210/jc.2013 2016
   Fregnani ER, 2017, HISTOPATHOLOGY, V70, P473, DOI 10.1111/his.13095
   Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Kaye Frederic J, 2015, J Natl Cancer Inst, V107, P378, DOI 10.1093/jnci/dju378
   Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317
   Lo Tom Edward Ngo, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr 2014 205491
NR 14
TC 2
Z9 2
U1 2
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2024
VL 114
IS 4
BP 444
EP 449
DI 10.1007/s00223 023 01177 x
EA JAN 2024
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LZ0Z5
UT WOS:001153697700001
PM 38252285
DA 2025 08 17
ER

PT J
AU Veronick, JA
   Assanah, F
   Piscopo, N
   Kutes, Y
   Vyas, V
   Nair, LS
   Huey, BD
   Khan, Y
AF Veronick, James A.
   Assanah, Fayekah
   Piscopo, Nicole
   Kutes, Yasemin
   Vyas, Varun
   Nair, Lakshmi S.
   Huey, Bryan D.
   Khan, Yusuf
TI Mechanically Loading Cell/Hydrogel Constructs with Low Intensity Pulsed
   Ultrasound for Bone Repair
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE bone; hydrogels; cell therapy; acoustic radiation force; LIPUS
ID ACOUSTIC RADIATION FORCE; FLUID SHEAR STRESS; ACTIN CYTOSKELETON;
   IN VITRO; CELL; EXPRESSION; OSTEOBLASTS; STRAIN; DIFFERENTIATION;
   ACCELERATION
AB Low intensity pulsed ultrasound (LIPUS) has been shown to be effective for orthopedic fracture repair and nonunion defects, but the specific mechanism behind its efficacy is still unknown. Previously, we have shown a measurable acoustic radiation force at LIPUS intensities traditionally used for clinical treatment and have applied this force to osteoblastic cells encapsulated in type I collagen hydrogels. Our goal in this study is to provide insight and inform the appropriate design of a cell therapy approach to bone repair in which osteoblasts are embedded in collagen hydrogels, implanted into a bony defect, and then transdermally stimulated using LIPUS derived acoustic radiation force to enhance bone formation at the earliest time points after bone defect repair. To this end, in this study, we demonstrate the ability to measure local hydrogel deformations in response to LIPUS induced acoustic radiation force and reveal that hydrogel deformation varies with both LIPUS intensity and hydrogel stiffness. Specifically, hydrogel deformation is positively correlated with LIPUS intensity and this deformation is further increased by reducing the stiffness of the hydrogel. We have also shown that encapsulated osteoblastic cells respond to increases in LIPUS intensity by upregulating both cyclooxygenase 2 and prostaglandin E 2 (PGE(2)), both implicated in new bone formation and well established responses to the application of fluid forces on osteoblast cells. Finally, we demonstrate that combining an increase in LIPUS with a three dimensional culture environment upregulates both markers beyond their expression noted from either experimental condition alone, suggesting that both LIPUS and hydrogel encapsulation, when combined and modulated appropriately, can enhance osteoblastic response considerably. These studies provide important information toward a clinically relevant cell therapy treatment for bone defects that allows the transdermal application of mechanical loading to bone defects without physically destabilizing the defect site.
C1 [Veronick, James A.; Assanah, Fayekah; Nair, Lakshmi S.; Khan, Yusuf] Univ Connecticut, Dept Biomed Engn, Storrs, CT USA.
   [Piscopo, Nicole] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA.
   [Kutes, Yasemin; Vyas, Varun; Nair, Lakshmi S.; Huey, Bryan D.; Khan, Yusuf] Univ Connecticut, Dept Mat Sci & Engn, Storrs, CT USA.
   [Nair, Lakshmi S.; Khan, Yusuf] Univ Connecticut, Ctr Hlth, Dept Orthopaed Surg, 263 Farmington Ave,MC3711, Farmington, CT 06030 USA.
   [Nair, Lakshmi S.; Khan, Yusuf] Univ Connecticut, Ctr Hlth, Inst Regenerat Engn, Farmington, CT USA.
C3 University of Connecticut; University of Wisconsin System; University of
   Wisconsin Madison; University of Connecticut; University of Connecticut;
   University of Connecticut
RP Khan, Y (通讯作者)，Univ Connecticut, Ctr Hlth, Dept Orthopaed Surg, 263 Farmington Ave,MC3711, Farmington, CT 06030 USA.
EM ykhan@uchc.edu
RI Khan, Mohd/J 7466 2015; Huey, Bryan/G 7512 2014; Vyas,
   Varun/AAA 7983 2021
OI ASSANAH, FAYEKAH/0000 0003 0269 2867
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [R21AR064432]
FX Research reported in this publication was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases of the
   National Institutes of Health under Award Number R21AR064432. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Caliari SR, 2016, BIOMATERIALS, V103, P314, DOI 10.1016/j.biomaterials.2016.06.061
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Doinikov AA, 2003, REC RES DEV ACOUST, V1, P39
   Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573
   Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006 3495(04)74140 5
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fernandez Bances I, 2013, CYTOTHERAPY, V15, P571, DOI 10.1016/j.jcyt.2013.01.004
   FROST HM, 1992, BONE MINER, V19, P257, DOI 10.1016/0169 6009(92)90875 E
   Gardinier J, 2014, AM J PHYSIOL CELL PH, V306, pC1058, DOI 10.1152/ajpcell.00254.2013
   Gebauer D, 2005, ULTRASOUND MED BIOL, V31, P1391, DOI 10.1016/j.ultrasmedbio.2005.06.002
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Guignandon A, 2003, CELL COMMUN ADHES, V10, P69, DOI 10.1080/cac.10.2.69.83
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Jagodzinski M, 2007, INJURY, V38, pS3, DOI 10.1016/j.injury.2007.02.005
   Jansen JH, 2006, J ORTHOP RES, V24, P1480, DOI 10.1002/jor.20186
   KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45
   Malone AMD, 2007, AM J PHYSIOL CELL PH, V292, pC1830, DOI 10.1152/ajpcell.00352.2005
   Mehrotra M, 2006, BIOCHEM BIOPH RES CO, V341, P1225, DOI 10.1016/j.bbrc.2006.01.084
   Mikuni Takagaki Y, 1999, J BONE MINER METAB, V17, P57, DOI 10.1007/s007740050065
   Mooney DJ, 2008, CELL STEM CELL, V2, P205, DOI 10.1016/j.stem.2008.02.005
   Motokawa M, 2005, J DENT RES, V84, P422, DOI 10.1177/154405910508400505
   Nightingale K, 2002, ULTRASOUND MED BIOL, V28, P227, DOI 10.1016/S0301 5629(01)00499 9
   Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006
   Parvizi J, 2002, J ORTHOPAED RES, V20, P51, DOI 10.1016/S0736 0266(01)00069 9
   Pasternak MM, 2015, CELL CYCLE, V14, P2891, DOI 10.1080/15384101.2015.1069925
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Polacheck WJ, 2016, NAT METHODS, V13, P415, DOI [10.1038/NMETH.3834, 10.1038/nmeth.3834]
   Rawool NM, 2003, J ULTRAS MED, V22, P145, DOI 10.7863/jum.2003.22.2.145
   Reher P, 1997, ULTRASOUND MED BIOL, V23, P1251, DOI 10.1016/S0301 5629(97)00031 8
   Sant'Anna EF, 2005, J ORTHOP RES, V23, P646, DOI 10.1016/j.orthres.2004.09.007
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Tang L, 2006, BIOCHEM BIOPH RES CO, V344, P122, DOI 10.1016/j.bbrc.2006.03.123
   Uzer G, 2012, CELL MOL BIOENG, V5, P266, DOI 10.1007/s12195 012 0231 1
   Veronick J, 2016, EXP BIOL MED, V241, P1149, DOI 10.1177/1535370216649061
   Viola F, 2005, IEEE T ULTRASON FERR, V52, P80, DOI 10.1109/TUFFC.2005.1397352
   Walker WF, 2000, PHYS MED BIOL, V45, P1437, DOI 10.1088/0031 9155/45/6/303
   Wells RG, 2008, HEPATOLOGY, V47, P1394, DOI 10.1002/hep.22193
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   You LD, 2001, J BIOMECH, V34, P1375, DOI 10.1016/S0021 9290(01)00107 5
NR 41
TC 20
Z9 23
U1 1
U2 26
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD FEB
PY 2018
VL 24
IS 3 4
BP 254
EP 263
DI 10.1089/ten.tea.2016.0547
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA FU2EE
UT WOS:000423661000007
PM 28610471
OA Green Published
DA 2025 08 17
ER

PT J
AU Yang, G
   Kim, YN
   Kim, H
   Lee, BK
AF Yang, Gwanghyun
   Kim, Young Nam
   Kim, Hyunjeong
   Lee, Bu Kyu
TI Effect of Human Umbilical Cord Matrix Derived Mesenchymal Stem Cells on
   Bisphosphonate Related Osteonecrosis of the Jaw
SO TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE Mesenchymal stem cells; Human umbilical cord; Bisphosphonates;
   Osteonecrosis; Bone regeneration; Hyperparathyroidism
ID MEDICATION RELATED OSTEONECROSIS; IN VITRO; OSTEOGENIC DIFFERENTIATION;
   STROMAL CELLS; BONE MARROW; THERAPY; BLOOD; MODEL
AB Background: Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a severe sequela caused by bisphosphonates (BPs), which are widely used to treat osteoporosis or other malignancies. However, the mechanism underlying BRONJ remains unclear. Recently, human umbilical cord derived mesenchymal stem cells (hUC MSCs) have been studied for treatment of diverse diseases and injuries. This study aimed to investigate the therapeutic effects of hUC MSCs in BRONJ. Methods: The therapeutic effects of hUC MSCs were examined in rat bone marrow (rBM) derived cells using cell viability, colony forming, and real time PCR assays and FACS for analyzing essential proinflammatory and bone regeneration markers in vitro. To demonstrate the in vivo therapeutic and adverse effects of transfused hUC MSCs, micro CT, H&E staining, IHC (Angiogenesis marker gene expression) staining, and parathyroid hormone (PTH)/calcium assay were conducted in a BRONJ induced animal model. Results: BP induced cytotoxicity and inflammation in rBM derived cells decreased, after co culture with hUC MSCs. The expression levels of bone regeneration markers (RUNX2, OSX, and BMP 2) significantly increased in BP treated rBM derived cells, after co culture with hUC MSCs. The BP induced abnormal shift in RANKL/OPG expression ratio in rBM derived cells was normalized by hUC MSCs. Consistent with these in vitro results, transfused hUC MSCs markedly decreased BRONJ and significantly healed injured mucosa in the BRONJ induced animal model. The animals exhibited serious destruction of the kidney structure and increases in serum PTH and calcium levels, which were significantly normalized by hUC MSC transfusion. Conclusion: hUC MSCs exerted therapeutic effects on BRONJ in vitro and in vivo through their anti cytotoxicity, anti inflammatory activity and ability to recover bone regeneration.
C1 [Yang, Gwanghyun; Kim, Young Nam; Kim, Hyunjeong; Lee, Bu Kyu] Univ Ulsan, Coll Med, Asan Med Ctr, Biomed Engn Res Ctr,Asan Inst Life Sci, Seoul, South Korea.
   [Lee, Bu Kyu] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oral & Maxillofacial Surg, Seoul, South Korea.
C3 University of Ulsan; Asan Medical Center; University of Ulsan; Asan
   Medical Center
RP Lee, BK (通讯作者)，Univ Ulsan, Coll Med, Asan Med Ctr, Biomed Engn Res Ctr,Asan Inst Life Sci, Seoul, South Korea.; Lee, BK (通讯作者)，Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oral & Maxillofacial Surg, Seoul, South Korea.
EM bukyu.lee@gmail.com
FU Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
   [2016 569, 2018 327]
FX We would like to thank Asan stem cell center for providing hUC MSCs. We
   also thank Professor Woo Chan Son for the assistance with
   histopathologic evaluation, Asan Medical Center, for the use of their
   shared equipment, services, and expertise. This study was supported by a
   Grant (No. 2016 569) from the Asan Institute for Life Sciences, Asan
   Medical Center, Seoul, Korea. This study was supported by a grant
   (2018 327) from the Asan Institute for Life Sciences, Asan Medical
   Center, Seoul, Korea.
CR Agrillo A, 2012, EUR REV MED PHARMACO, V16, P1741
   Allam E, 2011, ORAL DIS, V17, P291, DOI 10.1111/j.1601 0825.2010.01739.x
   Bagan J, 2009, ORAL ONCOL, V45, P551, DOI 10.1016/j.oraloncology.2009.01.002
   Boomsma RA, 2007, INT J CARDIOL, V122, P17, DOI 10.1016/j.ijcard.2006.11.022
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
   GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707
   Hansen T, 2006, VIRCHOWS ARCH, V449, P448, DOI 10.1007/s00428 006 0261 y
   He LH, 2017, J DENT RES, V96, P539, DOI 10.1177/0022034517691507
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Kaibuchi N, 2016, ACTA BIOMATER, V42, P400, DOI 10.1016/j.actbio.2016.06.022
   Kim J, 2020, AM J DENT, V33, P115
   Koch FP, 2012, CLIN ORAL INVEST, V16, P79, DOI 10.1007/s00784 010 0477 8
   Kos M, 2010, INT J ORAL MAX SURG, V39, P1097, DOI 10.1016/j.ijom.2010.04.054
   Kos M, 2015, J CRANIO MAXILL SURG, V43, P863, DOI 10.1016/j.jcms.2015.04.018
   Kossl J, 2021, STEM CELLS DEV, V30, P418, DOI 10.1089/scd.2020.0195
   Leizaola Cardesa IO, 2016, MED ORAL PATOL ORAL, V21, pE236, DOI 10.4317/medoral.20927
   Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012
   Li YS, 2013, STEM CELLS DEV, V22, P2047, DOI 10.1089/scd.2012.0615
   Malgieri A, 2010, INT J CLIN EXP MED, V3, P248
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P396, DOI 10.1016/j.jcms.2014.12.008
   Mathieu P, 2012, J NEUROIMMUNOL, V246, P43, DOI 10.1016/j.jneuroim.2012.03.004
   Matsuura Y, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0367 3
   Melcher M, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0601 7
   Mittal S., 2014, Journal of Dental and Allied Sciences, V3, P34, DOI DOI 10.4103/2277 4696.156527
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Ogata K, 2015, BONE, V74, P95, DOI 10.1016/j.bone.2015.01.011
   Pettersson LF, 2017, TISSUE ENG REGEN MED, V14, P763
   Prasanna SJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0014189, 10.1371/journal.pone.0009016]
   Rachakatla RS, 2008, CANCER INVEST, V26, P662, DOI 10.1080/07357900701871134
   Ribatti D, 2007, CLIN RHEUMATOL, V26, P1094, DOI 10.1007/s10067 006 0455 3
   Rosella D, 2016, J INT SOC PREV COMMU, V6, P97, DOI 10.4103/2231 0762.178742
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Shi LL, 2011, AM J MED SCI, V342, P212, DOI 10.1097/MAJ.0b013e3182112b90
   Shin Sang Hun, 2016, Maxillofac Plast Reconstr Surg, V38, P48, DOI 10.1186/s40902 016 0095 8
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   Sun J, 2015, MOL MED REP, V12, P4230, DOI 10.3892/mmr.2015.3954
   Tanna N, 2017, BRIT DENT J, V222, P121, DOI 10.1038/sj.bdj.2017.79
   Wang Y, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200241
   Weiss ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007 1028
   Zhang QZ, 2015, J BONE MINER RES, V30, P2300, DOI 10.1002/jbmr.2577
   Zhu H, 2017, SCI REP UK, V7, DOI 10.1038/srep39889
NR 44
TC 12
Z9 15
U1 0
U2 10
PU KOREAN TISSUE ENGINEERING REGENERATIVE MEDICINE SOC
PI SEOCHO GU
PA 1414 SEOCHO WORLD OFFICETEL 19, SEOUN RO, SEOCHO GU, SEOUL 06732, SOUTH
   KOREA
SN 1738 2696
EI 2212 5469
J9 TISSUE ENG REGEN MED
JI Tissue Eng. Regen. Med.
PD DEC
PY 2021
VL 18
IS 6
BP 975
EP 988
DI 10.1007/s13770 021 00372 x
EA AUG 2021
PG 14
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA WZ4OM
UT WOS:000681145600001
PM 34347277
OA Green Published
DA 2025 08 17
ER

PT J
AU El Miedany, Y
   Paruk, F
   Kalla, A
   Adebajo, A
   El Gaafary, M
   El Maghraoui, A
   Ngandeu, M
   Dey, D
   Gadallah, N
   Elwy, M
   Moosajee, F
   Abu Zaid, MH
   Galal, S
   Miladi, S
   Hassan, W
   Fadlelmola, A
   Saber, S
AF El Miedany, Y.
   Paruk, Farhanah
   Kalla, Asgar
   Adebajo, A.
   El Gaafary, Maha
   El Maghraoui, Abdellah
   Ngandeu, Madeleine
   Dey, Dzifa
   Gadallah, Naglaa
   Elwy, Mohamed
   Moosajee, Farzana
   Abu Zaid, Mohammed Hassan
   Galal, Salwa
   Miladi, Soussen
   Hassan, Waleed
   Fadlelmola, Abubaker
   Saber, Sally
TI Consensus evidence based clinical practice guidelines for the diagnosis
   and treat to target management of osteoporosis in Africa: an initiative
   by the African Society of Bone Health and Metabolic Bone Diseases
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Osteoporosis; Guidelines; Africa; Bisphosphonates; Denosumab;
   Parathyroid hormone; Romosozumab; FRAX; Falls; African osteoporosis
   guidelines
ID POSTMENOPAUSAL OSTEOPOROSIS; FRACTURE; WOMEN; RISK; PREVALENCE; THERAPY;
   DELPHI
AB .Summary The objective of this consensus statement is to inform the clinical practice communities, research centres and policymakers across Africa of the results of the recommendations for osteoporosis prevention, diagnosis and management. The developed guideline provides state of the art information and presents the conclusions and recommendations of the consensus panel regarding these issues.
   Purpose To reach an African expert consensus on a treat to target strategy, based on current evidence for best practice, for the management of osteoporosis and prevention of fractures.
   Method A 3 round Delphi process was conducted with 17 osteoporosis experts from different African countries. All rounds were conducted online. In round 1, experts reviewed a list of 21 key clinical questions. In rounds 2 and 3, they rated the statements stratified under each domain for its fit (on a scale of 1 9). After each round, statements were retired, modified or added in view of the experts' suggestions and the percent agreement was calculated. Statements receiving rates of 7 9 by more than 75% of experts' votes were considered as achieving consensus.
   Results The developed guidelines adopted a fracture risk centric approach. Results of round 1 revealed that of the 21 proposed domains, 10 were accepted whereas 11 were amended. In round 2, 32 statements were presented: 2 statements were retired for similarity, 9 statements reached consensus, whereas modifications were suggested for 21 statements. After the 3rd round of rating, the experts came to consensus on the 32 statements. Frequency of high rate recommendation ranged from 83.33 to 100%. The response rate of the experts was 100%. An algorithm for the osteoporosis management osteoporosis was suggested.
   Conclusion This study is an important step in setting up a standardised osteoporosis service across the continent. Building a single model that can be applied in standard practice across Africa will enable the clinicians to face the key challenges of managing osteoporosis; furthermore, it highlights the unmet needs for the policymakers responsible for providing bone health care together with and positive outcomes of patients' care.
C1 [El Miedany, Y.] Canterbury Christ Church Univ, Canterbury, Kent, England.
   [El Miedany, Y.] Kings Coll London, London, England.
   [Paruk, Farhanah] Univ KwaZulu Natal, Durban, South Africa.
   [Kalla, Asgar] Univ Cape Town, Cape Town, South Africa.
   [Adebajo, A.] Univ Sheffield, Sheffield, S Yorkshire, England.
   [El Gaafary, Maha] Ain Shams Univ, Community & Publ Hlth, Cairo, Egypt.
   [El Maghraoui, Abdellah] Mohamed V Univ, Rabat, Morocco.
   [Ngandeu, Madeleine] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon.
   [Dey, Dzifa] Univ Ghana, Med Sch, Accra, Ghana.
   [Gadallah, Naglaa; Elwy, Mohamed; Galal, Salwa; Saber, Sally] Ain Shams Univ, Rheumatol & Rehabil, Cairo, Egypt.
   [Moosajee, Farzana] Tygerberg Hosp, Cape Town, South Africa.
   [Moosajee, Farzana] Stellenbosch Univ, Cape Town, South Africa.
   [Abu Zaid, Mohammed Hassan] Tanta Univ, Rheumatol & Rehabiliat, Tanta, Egypt.
   [Miladi, Soussen] Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia.
   [Hassan, Waleed] Benha Univ, Rheumatol & Rehabil, Banha, Egypt.
   [Fadlelmola, Abubaker] Ahmed Gasim Teaching Hosp, Khartoum, Sudan.
C3 Canterbury Christ Church University; University of London; King's
   College London; University of Kwazulu Natal; University of Cape Town;
   University of Sheffield; Egyptian Knowledge Bank (EKB); Ain Shams
   University; Mohammed V University in Rabat; University of Yaounde I;
   University of Ghana; Egyptian Knowledge Bank (EKB); Ain Shams
   University; Tygerberg Hospital; Stellenbosch University; Egyptian
   Knowledge Bank (EKB); Tanta University; Universite de Tunis El Manar;
   Faculte de Medecine de Tunis (FMT); Egyptian Knowledge Bank (EKB); Benha
   University
RP El Miedany, Y (通讯作者)，Canterbury Christ Church Univ, Canterbury, Kent, England.; El Miedany, Y (通讯作者)，Kings Coll London, London, England.
EM yasserelmiedany@gmail.com; paruk@ukzn.ac.za; kallaa@iafrica.com;
   a.o.adebajo@sheffield.ac.uk; maha_elgaafary@med.asu.edu.eg;
   a.elmaghraoui@um5.net.ma; ngandeum@yahoo.fr; dzifakay@gmail.com;
   naglagadallah@gmail.com; elwy.mohamed@yahoo.com; farzana@sun.ac.za;
   drmhassan113@yahoo.com; dr_salwa07@yahoo.com; Saoussenmiladi@gmail.com;
   waleed22101979@yahoo.com; Abubakerfadlelmola@gmail.com;
   Sally_saber@med.asu.edu.eg
RI ; El Miedany, Yasser/M 6778 2013; Gadallah, Naglaa/MTF 1481 2025; galal,
   salwa/HJH 9452 2023; Abd Elaziz, Sally/ISA 3925 2023; Miedany,
   Yasser/GLR 7689 2022; Miladi, Saoussen/HPB 7278 2023; Abu Zaid,
   Mohammed/J 2244 2019
OI saber, sally/0000 0001 8162 4699; Miladi, Saoussen/0000 0002 3596 8025;
   Dey, Ida Dzifa/0000 0002 3339 5112; El Miedany,
   Yasser/0000 0002 4543 692X; Gadallah, Naglaa/0000 0003 3523 6972;
   Abu Zaid, Mohammed Hassan/0000 0001 8436 8598; El Maghraoui,
   Abdellah/0000 0003 0668 5680; 
CR [Anonymous], 2011, OXF LEV EV 2
   Atiase Yacoba, 2020, Ghana Med J, V54, P58, DOI 10.4314/gmj.v54i1.9
   Ben Aissa R, 2006, TUN MED, V84
   Billek Sawhney B., 2019, INT PHYS MED REHAB J, V4, P91
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Cauley JA, 2007, J BONE MINER RES, V22, P1816, DOI 10.1359/JBMR.070713
   Diamond IR, 2014, J CLIN EPIDEMIOL, V67, P401, DOI 10.1016/j.jclinepi.2013.12.002
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   El Maghraoui A, 2015, NUTR METAB, V12, DOI 10.1186/s12986 015 0041 2
   El Miedany Y, 2021, EGYPT RHEUMATOL REH, V48, DOI 10.1186/s43166 020 00056 9
   El Miedany YE., 2014, WORLD J RHEUMATOL, V4, P14, DOI [10.5499/wjr.v4.i2.14, DOI 10.5499/WJR.V4.I2.14]
   European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
   Gheita T.A., 2018, International Journal of Clinical Rheumatology, V13, P134, DOI DOI 10.4172/1758 4272.1000177
   Handa R, 2008, BEST PRACT RES CL RH, V22, P693, DOI 10.1016/j.berh.2008.04.002
   Haouichat C, 2014, ANN RHEUM DIS, V73, P760, DOI 10.1136/annrheumdis 2014 eular.2980
   International Osteoporosis Foundation, 2018, WHAT IS OST 2018
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kamiya Yumiko, 2016, POP DIV UN REG WORKS
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kanis JA, 2011, OSTEOPOROSIS INT, V22, P809, DOI 10.1007/s00198 010 1524 7
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P417, DOI 10.1007/s001980170112
   Kinsella K., 2009, International population report
   Leclercq E, 2013, J PEDIATR US, V162, P629, DOI 10.1016/j.jpeds.2012.09.012
   Leslie WD, 2012, J BONE MINER RES, V27, P1243, DOI 10.1002/jbmr.1582
   Lewiecki EM, 2008, OSTEOPOROSIS INT, V19, P1363, DOI 10.1007/s00198 008 0661 8
   Lewiecki EM, 2017, CURR OSTEOPOROS REP, V15, P103, DOI 10.1007/s11914 017 0350 7
   Lewiecki EM, 2010, AM FAM PHYSICIAN, V82, P749
   Meeta M, 2020, J MID LIFE HEALTH, V11, P96, DOI 10.4103/jmh.JMH_143_20
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   National Institute of Aging, NEW CENS REP AG TREN
   National Osteoporosis Foundation, JOINT GUID COVID 19
   Nogués X, 2018, OSTEOPOROSIS INT, V29, P489, DOI 10.1007/s00198 017 4310 y
   Ouzzif Z, 2012, RHEUMATOL INT, V32, P123, DOI 10.1007/s00296 010 1551 x
   Paruk F, 2021, CLIN RHEUMATOL, V40, P3419, DOI 10.1007/s10067 020 05335 6
   Paruk F, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0409 1
   Peled R., 2007, ARCH OSTEOPOROS, V2, P45, DOI 10.1007/s11657 007 0013 x
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Rayens M.K., 2000, Policy, Politics, and Nursing Practice, V1, P308, DOI DOI 10.1177/152715440000100409
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Rowe G, 1999, INT J FORECASTING, V15, P353, DOI 10.1016/S0169 2070(99)00018 7
   von der Gracht HA, 2012, TECHNOL FORECAST SOC, V79, P1525, DOI 10.1016/j.techfore.2012.04.013
NR 43
TC 10
Z9 10
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD DEC
PY 2021
VL 16
IS 1
AR 176
DI 10.1007/s11657 021 01035 z
PG 20
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA XA1QN
UT WOS:000720430800001
PM 34792646
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Yang, BY
   Fu, CR
   Wu, YL
   Liu, YB
   Zhang, Z
   Chen, X
   Wu, DL
   Gan, ZQ
   Chen, ZY
   Cao, Y
AF Yang, Benyi
   Fu, Chaoran
   Wu, Yilin
   Liu, Yuanbo
   Zhang, Zhen
   Chen, Xin
   Wu, Dongle
   Gan, Ziqi
   Chen, Zhengyuan
   Cao, Yang
TI γ Secretase inhibitors suppress IL 20 mediated osteoclastogenesis via
   Notch signalling and are affected by Notch2 in vitro
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE BMMs; IL 20; Notch signalling pathway; osteoclast; rheumatoid arthritis
ID RHEUMATOID ARTHRITIS; RECEPTOR AXIS; BONE; DIFFERENTIATION; ACTIVATION;
   IMMUNE; CELLS; OSTEOIMMUNOLOGY; EPIDEMIOLOGY; EXPRESSION
AB Rheumatoid arthritis (RA) is a chronic immune disease involving the small joints, which often causes irreversible damage. In recent years, elevated interleukin 20 (IL 20) has been observed in synovial fluid, while IL 20 receptor overexpression has been observed in synovial cells. IL 20 is a pleiotropic cytokine that participates in various immune diseases. Further understanding of the relationship between IL 20 and RA can help to identify a potential clinical treatment for RA. This study demonstrated that IL 20 can regulate osteoclast differentiation and function in a dose dependent manner, while influencing the expression of Notch signalling. Quantitative reverse transcription polymerase chain reaction and western blotting showed that gamma secretase inhibiting drugs can reverse the effects of IL 20. The effects of Notch2 on IL 20 induced osteoclastogenesis were investigated by immunofluorescence and Notch2 gene silencing via transfection of small interfering RNA; the results showed that Notch2 obviously affected the expression levels of the key protein NFATc1 and downstream osteoclastic proteins. In conclusion, we found that IL 20 regulated the osteoclastogenesis in a dose dependent manner via Notch signalling, primarily by means of Notch2 activity. This study may help to find new targets for RA treatment.
C1 [Yang, Benyi; Fu, Chaoran; Wu, Yilin; Liu, Yuanbo; Zhang, Zhen; Chen, Xin; Wu, Dongle; Gan, Ziqi; Chen, Zhengyuan; Cao, Yang] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou, Peoples R China.
   [Yang, Benyi; Fu, Chaoran; Wu, Yilin; Liu, Yuanbo; Zhang, Zhen; Chen, Xin; Wu, Dongle; Gan, Ziqi; Chen, Zhengyuan; Cao, Yang] Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
C3 Sun Yat Sen University
RP Yang, BY (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Orthodont, 56 Lingyuanxi Rd, Guangzhou 510055, Peoples R China.
EM caoyang@mail.sysu.edu.cn
OI Zhang, Zhen/0000 0002 8990 5441; Fu, Chaoran/0000 0001 8658 5959
FU Natural Science Foundation of Guangdong Province [2017A030313529];
   National Natural Science Foundation of China [81970963]
FX This study was supported by grants from the Natural Science Foundation
   of Guangdong Province (No. 2017A030313529) and National Natural Science
   Foundation of China (No. 81970963).
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Ando K, 2003, ONCOGENE, V22, P7796, DOI 10.1038/sj.onc.1206965
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Ashley JW, 2015, J CELL BIOCHEM, V116, P2598, DOI 10.1002/jcb.25205
   Bauer RC, 2010, HUM MUTAT, V31, P594, DOI 10.1002/humu.21231
   Chen J, 2018, J LEUKOCYTE BIOL, V104, P953, DOI 10.1002/JLB.MR1117 471R
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Choi BY, 2018, THERANOSTICS, V8, P4795, DOI 10.7150/thno.26093
   Dinesh P, 2018, CYTOKINE, V106, P54, DOI 10.1016/j.cyto.2018.03.005
   Ferron M, 2014, ARCH BIOCHEM BIOPHYS, V561, P137, DOI 10.1016/j.abb.2014.05.022
   Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056
   Güner G, 2020, SEMIN CELL DEV BIOL, V105, P27, DOI 10.1016/j.semcdb.2020.05.019
   Han MS, 2015, ANN CLIN LAB SCI, V45, P110
   Ho DM, 2020, WIRES DEV BIOL, V9, DOI 10.1002/wdev.358
   Hosaka Y, 2013, P NATL ACAD SCI USA, V110, P1875, DOI 10.1073/pnas.1207458110
   Hsu YH, 2016, SCI REP UK, V6, DOI 10.1038/srep24339
   Jiao Z, 2010, SCAND J RHEUMATOL, V39, P26, DOI 10.3109/03009740903124424
   Jin WJ, 2016, CELL SIGNAL, V28, P357, DOI 10.1016/j.cellsig.2016.01.016
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Kim HR, 2019, J CLIN MED, V8, DOI 10.3390/jcm8071012
   Kragstrup TW, 2017, CLIN EXP IMMUNOL, V189, P342, DOI 10.1111/cei.12973
   Kragstrup TW, 2016, SCAND J RHEUMATOL, V45, P53, DOI 10.1080/03009742.2016.1203022
   Kragstrup TW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02226
   Kragstrup TW, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0964 7
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lin QY, 2019, ACS CHEM NEUROSCI, V10, P2560, DOI 10.1021/acschemneuro.9b00051
   Liu ZY, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa3792
   Majewski J, 2011, HUM MUTAT, V32, P1114, DOI 10.1002/humu.21546
   Meng BW, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12874
   Mijailovic I, 2020, J PERIODONTOL, V91, P554, DOI 10.1002/JPER.18 0755
   Murata Akihiko, 2016, Biology Basel, V5, DOI 10.3390/biology5010005
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Nakazawa M, 2001, ARTHRITIS RHEUM US, V44, P1545, DOI 10.1002/1529 0131(200107)44:7<1545::AID ART278>3.0.CO;2 Q
   Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873
   Okamoto K, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a031245
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Otón T, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.101477
   Park JS, 2015, ANN RHEUM DIS, V74, P267, DOI 10.1136/annrheumdis 2013 203467
   Ponio JBD, 2007, HUM MOL GENET, V16, P2683, DOI 10.1093/hmg/ddm222
   Sekine C, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3758
   Shi YC, 2012, BONE, V50, P430, DOI 10.1016/j.bone.2011.10.001
   Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang J, 2019, NAT NEUROSCI, V22, P91, DOI 10.1038/s41593 018 0285 z
   Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586 020 2222 z
   Wei X, 2020, J BIOMED MATER RES A, V108, P2150, DOI 10.1002/jbm.a.36972
   Wu J, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00019
   Yu J, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115474
   Zhao BH, 2017, CURR OSTEOPOROS REP, V15, P126, DOI 10.1007/s11914 017 0358 z
NR 50
TC 4
Z9 4
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0300 9475
EI 1365 3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD AUG
PY 2022
VL 96
IS 2
AR e13169
DI 10.1111/sji.13169
EA MAY 2022
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 3C5WF
UT WOS:000792525400001
PM 35384009
DA 2025 08 17
ER

PT J
AU Hua, S
   Zhang, XX
AF Hua, Shan
   Zhang, Xuexue
TI Effects of Achyranthes bidentata alcohol on proliferation
   capacity of osteoblasts and miRNA in Runx2
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE Achyranthes bidentata; osteoblasts; proliferation; Runx2; ERK
ID MAP KINASE; DIFFERENTIATION; OSTEOPOROSIS; POLYSACCHARIDES; EXPRESSION
AB Achyranthes bidentata is a herbal plant commonly used in the treatment of osteoporosis and bone nonunion with traditional Chinese medicine. Achyranthes bidentata alcohol is a major component extracted from Achyranthes bidentata, which has been proved to be able to exert a variety of pharmacological effects, such as anti inflammation, antipyresis, anti rheumatism, diuresis and anti osteoporosis. Thirty male Sprague Dawley rats aged 4 weeks were used in the experiment. All primary rat osteoblasts were cultured and amplified for further experiments. The osteoblasts were divided into six groups (5 rats in each group): the culture medium control group, the 25 mu g/ml achyranthol group, the 50 mu g/ml achyranthol group, the 100 mu g/ml achyranthol group, 200 mu g/ml achyranthol group, and the 25 mu M PD98059+200 mu g/ml achyranthol group. In this study, the effect of Achyranthes bidentata alcohol on the proliferation of osteoblasts was detected via methyl thiazolyl tetrazolium (MTT) assay. The effect of Achyranthes bidentata alcohol on the alkaline phosphatase (ALP) activity in osteoblasts was analyzed via ALP assay. The effect of Achyranthes bidentata alcohol on the expression of osteoblast marker gene, Runt related transcription factor 2 (Runx2), was detected via reverse transcription quantitative polymerase chain reaction (RT qPCR) and immunohistochemistry. Moreover, the phosphorylation or activation of extracellular signal regulated kinase (ERK) in osteoblasts induced by Achyranthes bidentata alcohol was analyzed using western blotting. Achyranthes bidentata alcohol increased cell proliferation in a dose dependent manner, increased the micro ribonucleic acid (miRNA) level in Runx2, enhanced the ALP activity in osteoblasts, and stimulated the activation of ERK (P<0.05). The expression of Runx2 with the inhibitor PD98059 was decreased significantly compared with that in the Achyranthes bidentata alcohol group (P<0.01). Immunohistochemical results manifested that the percentage of Runx2 positive cells in treated tissues was obviously higher than that in untreated tissues (P<0.01). Therefore, Achyranthes bidentata alcohol promotes the proliferation capacity of osteoblasts in a dose dependent manner, enhances the expression of miRNA in Runx2, and stimulates the osteogenic differentiation of osteoblasts through activating the ERK signal transduction pathway.
C1 [Hua, Shan] Nanchang Univ, Med Coll, Nanchang 330031, Jiangxi, Peoples R China.
   [Zhang, Xuexue] Nanchang Univ, Affiliated Hosp 1, Dept Pain Management, 17 Yongwai Zhengjie St, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University
RP Zhang, XX (通讯作者)，Nanchang Univ, Affiliated Hosp 1, Dept Pain Management, 17 Yongwai Zhengjie St, Nanchang 330006, Jiangxi, Peoples R China.
EM vvr4704@163.com
RI Hua, Shan/AHC 1593 2022
CR Alanay Y, 2010, AM J HUM GENET, V86, P551, DOI 10.1016/j.ajhg.2010.02.022
   Berger I, 2007, HISTOL HISTOPATHOL, V22, P1231, DOI 10.14670/HH 22.1231
   Chen Xiao ming, 2005, Yaoxue Xuebao, V40, P32
   Deng HB, 2003, BIOMED ENVIRON SCI, V16, P267
   Han SB, 2005, ARCH PHARM RES, V28, P902, DOI 10.1007/BF02973875
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jin LQ, 2007, INT IMMUNOPHARMACOL, V7, P568, DOI 10.1016/j.intimp.2006.12.009
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li JX, 2005, PLANTA MED, V71, P673, DOI 10.1055/s 2005 871275
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lühe A, 2008, TOXICOL IN VITRO, V22, P899, DOI 10.1016/j.tiv.2008.01.006
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Niu YB, 2011, PHYTOTHER RES, V25, P1700, DOI 10.1002/ptr.3414
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460 2075.1995.tb07046.x
   Shen HM, 2008, BRAIN RES BULL, V77, P274, DOI 10.1016/j.brainresbull.2008.08.002
   Shibeshi Workineh, 2006, Afr Health Sci, V6, P108
   Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415
   Wattel A, 2004, J CELL BIOCHEM, V92, P285, DOI 10.1002/jcb.20071
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Zhang ML, 2018, INT J BIOL MACROMOL, V112, P433, DOI 10.1016/j.ijbiomac.2018.01.204
   Zhang R, 2012, J ETHNOPHARMACOL, V139, P12, DOI 10.1016/j.jep.2011.05.034
   Zhou Zhi Dong, 2013, Zhongguo Zhong Yao Za Zhi, V38, P1056
NR 27
TC 9
Z9 11
U1 3
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD SEP
PY 2019
VL 18
IS 3
BP 1545
EP 1550
DI 10.3892/etm.2019.7723
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA IZ8MG
UT WOS:000487358600006
PM 31410108
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Wilson, S
   Hashamiyan, S
   Clarke, L
   Saftig, P
   Mort, J
   Dejica, VM
   Brömme, D
AF Wilson, Susan
   Hashamiyan, Saadat
   Clarke, Lorne
   Saftig, Paul
   Mort, John
   Dejica, Valeria M.
   Bromme, Dieter
TI Glycosaminoglycan Mediated Loss of Cathepsin K Collagenolytic Activity
   in MPS I Contributes to Osteoclast and Growth Plate Abnormalities
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID MUCOPOLYSACCHARIDOSIS TYPE VI; HEPARAN SULFATE PROTEOGLYCAN;
   ALPHA L IDURONIDASE; LYSOSOMAL STORAGE; BONE RESORPTION; FELINE MODEL;
   TARGETED DISRUPTION; VINYL SULFONES; THERAPY; DISEASE
AB Mucopolysaccharidoses are a group of lysosomal storage diseases characterized by the build up of glycosaminoglycans (GAGs) and severe skeletal abnormalities. As GAGs can regulate the collagenolytic activity of the major osteoclastic protease cathepsin K, we investigated the presence and activity of cathepsin K and its co localization with GAGs in mucopolysaccharidosis (MPS) type I bone. The most dramatic difference between MPS I and wild type mice was an increase in the amount of cartilage in the growth plates in MPS I bones. Though the number of cathepsin K expressing osteoclasts; was increased in MPS I mice, these mice revealed a significant reduction in cathepsin K mediated cartilage degradation. As excess heparan and dermatan sulfates inhibit type II collagen degradation by cathepsin K and the spatial overlap between cathepsin K and heparan sulfate strongly increased in MPS I mice, the build up of subepiphyseal cartilage is speculated to be a direct consequence of cathepsin K inhibition by MPS I associated GAGs. Moreover, isolated MPS I and Ctsk( / ) osteoclasts displayed fewer actin rings and formed fewer resorption pits on dentine disks, as compared with wild type cells. These results suggest that the accumulation of GAGs in murine MPS I bone has an inhibitory effect on cathepsin K activity, resulting in impaired osteoclast activity and decreased cartilage resorption, which may contribute to the bone pathology seen in MPS diseases. (Am J Pathol 2009, 175:2053 2062; DOI: 10.2353/ajpath.2009.090211)
C1 [Bromme, Dieter] Univ British Columbia, Inst Life Sci, Fac Dent, Vancouver, BC V6T 1Z3, Canada.
   [Clarke, Lorne] Univ British Columbia, Dept Med Genet, British Columbia Inst Child & Family Hlth, Vancouver, BC V6T 1Z3, Canada.
   [Saftig, Paul] Univ Kiel, Inst Biochem, D 2300 Kiel, Germany.
   Shriners Hosp Children, Montreal, PQ, Canada.
   [Mort, John; Dejica, Valeria M.] McGill Univ, Montreal, PQ, Canada.
C3 University of British Columbia; University of British Columbia; Child &
   Family Research Institute; University of Kiel; McGill University
RP Brömme, D (通讯作者)，Univ British Columbia, Inst Life Sci, Fac Dent, 2222 Hlth Sci Mall,Rm 4559, Vancouver, BC V6T 1Z3, Canada.
EM dbromme@interchange.ubc.ca
RI ; Saftig, Paul/A 7966 2010
OI Clarke, Lorne/0000 0003 0512 7281; 
FU National Institutes of Health [AIR 48669, DK 072070]; Canada Research
   Chair award
FX Supported in part by National Institutes of Health Grants AIR 48669 and
   DK 072070. D.B. was supported by the Canada Research Chair award.
CR ABREU S, 1995, CALCIFIED TISSUE INT, V57, P185, DOI 10.1007/BF00310256
   Ballock RT, 2003, J BONE JOINT SURG AM, V85A, P715, DOI 10.2106/00004623 200304000 00021
   BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010
   BROMME D, 1995, BIOL CHEM H S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379
   Burrow TA, 2007, CURR OPIN PEDIATR, V19, P628, DOI 10.1097/MOP.0b013e3282f161f2
   Byers RJ, 1999, J CLIN PATHOL, V52, P23, DOI 10.1136/jcp.52.1.23
   Byers S, 1997, BONE, V21, P425, DOI 10.1016/S8756 3282(97)00175 0
   Chung S, 2007, MOL GENET METAB, V90, P181, DOI 10.1016/j.ymgme.2006.08.001
   Clarke LA, 1997, HUM MOL GENET, V6, P503, DOI 10.1093/hmg/6.4.503
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   Dejica VM, 2008, AM J PATHOL, V173, P161, DOI 10.2353/ajpath.2008.070494
   Desnick R. J., 2001, PYCNODYSOSTOSIS CATH, P3453
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Evers M, 1996, P NATL ACAD SCI USA, V93, P8214, DOI 10.1073/pnas.93.16.8214
   Everts V, 2003, CALCIFIED TISSUE INT, V73, P380, DOI 10.1007/s00223 002 2092 4
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Graebert KS, 1997, EXP CELL RES, V231, P214, DOI 10.1006/excr.1996.3456
   HASKINS ME, 1992, VET PATHOL, V29, P112, DOI 10.1177/030098589202900203
   HASKINS ME, 1983, AM J PATHOL, V112, P27
   Herati RS, 2008, MOL GENET METAB, V95, P142, DOI 10.1016/j.ymgme.2008.07.003
   Hoebertz A, 2003, BONE RES PROTOCOLS, P53
   Hou WS, 2002, ARTHRITIS RHEUM, V46, P663, DOI 10.1002/art.10114
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Li Xiaoming, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P209
   Li ZQ, 2008, J MOL BIOL, V383, P78, DOI 10.1016/j.jmb.2008.07.038
   Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200
   Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200
   Li ZQ, 2000, BIOCHEMISTRY US, V39, P529, DOI 10.1021/bi992251u
   Linnevers CJ, 1997, PROTEIN SCI, V6, P919
   METCALF JA, 2009, MOL GENET METAB
   Monroy MA, 2002, BONE, V30, P352, DOI 10.1016/S8756 3282(01)00679 2
   NAKAMURA H, 1994, J BONE MINER RES, V9, P1289, DOI 10.1002/jbmr.5650090819
   Nakano K, 2004, ARTHRITIS RHEUM US, V50, P2450, DOI 10.1002/art.20367
   NEUFELD EF, 2001, MUCOPOLYSACCHARIDOSE, P3419
   Nuttall JD, 1999, CALCIFIED TISSUE INT, V65, P47, DOI 10.1007/s002239900656
   PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002
   Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074 7613(00)80249 6
   Russell C, 1998, CLIN GENET, V53, P349
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004
   Simonaro CM, 2008, AM J PATHOL, V172, P112, DOI 10.2353/ajpath.2008.070564
   Simonaro CM, 2005, PEDIATR RES, V57, P701, DOI 10.1203/01.PDR.0000156510.96253.5A
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
NR 47
TC 75
Z9 75
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2009
VL 175
IS 5
BP 2053
EP 2062
DI 10.2353/ajpath.2009.090211
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 515BH
UT WOS:000271440800027
PM 19834056
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, JX
   Yue, WF
   Zhu, MJ
   Sreejayan, N
   Du, M
AF Zhao, Junxing
   Yue, Wanfu
   Zhu, Mei J.
   Sreejayan, Nair
   Du, Min
TI AMP activated protein kinase (AMPK) cross talks with canonical Wnt
   signaling via phosphorylation of β catenin at Ser 552
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE AMP activated protein kinase; beta Catenin; Phosphorylation; C3H10T1/2;
   Adipogenesis
ID SKELETAL MUSCLE; ADIPOCYTE DIFFERENTIATION; MYOGENIC DIFFERENTIATION;
   CELL FACTOR; ADIPOGENESIS; INHIBITION; APOPTOSIS; GROWTH; AICAR;
   MINIREVIEW
AB AMP activated protein kinase (AMPK) is a key regulator of energy metabolism; its activity is regulated by a plethora of physiological conditions, exercises and many anti diabetic drugs. Recent studies show that AMPK involves in cell differentiation but the underlying mechanism remains undefined. Wingless Int 1 (Wnt)/beta catenin signaling pathway regulates the differentiation of mesenchymal stem cells through enhancing beta catenin/T cell transcription factor 1 (TCF) mediated transcription. The objective of this study was to determine whether AMPK cross talks with Wnt/beta catenin signaling through phosphorylation of beta catenin. C3H10T1/2 mesenchymal cells were used. Chemical inhibition of AMPK and the expression of a dominant negative AMPK decreased phosphorylation of beta catenin at Ser 552. The beta catenin/TCF mediated transcription was correlated with AMPK activity. In vitro, pure AMPK phosphorylated beta catenin at Ser 552 and the mutation of Ser 552 to Ala prevented such phosphorylation, which was further confirmed using [gamma P 32]ATP autoradiography. In conclusion, AMPK phosphorylates beta catenin at Ser 552, which stabilizes beta catenin, enhances beta catenin/TCF mediated transcription, expanding AMPK from regulation of energy metabolism to cell differentiation and development via cross talking with the Wnt/beta catenin signaling pathway. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Zhao, Junxing; Yue, Wanfu; Zhu, Mei J.; Du, Min] Univ Wyoming, Dept Anim Sci, Dev Biol Grp, Laramie, WY 82071 USA.
   [Sreejayan, Nair] Univ Wyoming, Coll Hlth Sci, Sch Pharm, Laramie, WY 82071 USA.
C3 University of Wyoming; University of Wyoming
RP Du, M (通讯作者)，Dept 3684,1000 E Univ Ave, Laramie, WY 82071 USA.
EM mindu@uwyo.edu
RI Du, Min/H 4311 2011; Zhu, Mei Jun/A 4248 2013
OI Zhao, Junxing/0009 0001 9414 9847; Du, Min/0000 0002 7232 072X
FU NIH INBRE [P20RR016474, 1R03HD057506]; USDA [2008 35206 18826]
FX The work was supported by NIH INBRE P20RR016474 and 1R03HD057506, and
   USDA 2008 35206 18826.
CR Al Khalili L, 2004, AM J PHYSIOL CELL PH, V286, pC1410, DOI 10.1152/ajpcell.00444.2003
   Armstrong DD, 2005, AM J PHYSIOL CELL PH, V289, pC853, DOI 10.1152/ajpcell.00093.2005
   Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959 437X(00)00215 X
   Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87
   CHRISTODOULIDES C, 2008, TRENDS ENDOCRINOL ME
   Dagon Y, 2006, BIOCHEM BIOPH RES CO, V340, P43, DOI 10.1016/j.bbrc.2005.11.159
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Giri S, 2006, NUTR METAB, V3, DOI 10.1186/1743 7075 3 31
   Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106
   Habinowski SA, 2001, BIOCHEM BIOPH RES CO, V286, P852, DOI 10.1006/bbrc.2001.5484
   Hardie DG, 2007, SCIENCE, V315, P1671, DOI 10.1126/science.1140737
   Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003 0982
   Hardie DG., 2007, NAT REV MOL CELL BIO
   Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063 9072.2005
   Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200
   Koh HJ, 2008, CURR OPIN CLIN NUTR, V11, P227, DOI 10.1097/MCO.0b013e3282fb7b76
   KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092 8674(84)90274 5
   Laroche Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801
   Mermelstein CS, 2007, DIFFERENTIATION, V75, P184, DOI 10.1111/j.1432 0436.2006.00129.x
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097 2765(01)00251 9
   Mukherjee P, 2008, MOL CANCER, V7, DOI 10.1186/1476 4598 7 37
   Okamura M, 2009, P NATL ACAD SCI USA, V106, P5819, DOI 10.1073/pnas.0901676106
   Osler ME, 2008, ENDOCRINOLOGY, V149, P935, DOI 10.1210/en.2007 1441
   Petersen KF, 2005, PLOS MED, V2, P879, DOI 10.1371/journal.pmed.0020233
   Röckl KSC, 2007, DIABETES, V56, P2062, DOI 10.2337/db07 0255
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Shang YC, 2007, CYTOTHERAPY, V9, P667, DOI 10.1080/14653240701508437
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Singh R, 2006, ENDOCRINOLOGY, V147, P141, DOI 10.1210/en.2004 1649
   Singh R, 2009, ENDOCRINOLOGY, V150, P1259, DOI 10.1210/en.2008 0858
   Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005
   Steinberg GR, 2009, FRONT BIOSCI LANDMRK, V14, P1902, DOI 10.2741/3350
   Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   Tong J, 2008, J ANIM SCI, V86, P1296, DOI 10.2527/jas.2007 0794
   Tong JF, 2009, J CELL BIOCHEM, V108, P458, DOI 10.1002/jcb.22272
   Tong JF, 2009, AM J PHYSIOL ENDOC M, V296, pE917, DOI 10.1152/ajpendo.90924.2008
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Wang G, 2006, P NATL ACAD SCI USA, V103, P4640, DOI 10.1073/pnas.0509341103
   Winder WW, 1996, AM J PHYSIOL ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299
   Xue Y, 2008, MOL CELL PROTEOMICS, V7, P1598, DOI 10.1074/mcp.M700574 MCP200
   Yada E, 2006, J VET MED SCI, V68, P479, DOI 10.1292/jvms.68.479
   Yan X, 2010, ENDOCRINOLOGY, V151, P380, DOI 10.1210/en.2009 0849
   Zhu MJ, 2008, J PHYSIOL LONDON, V586, P2651, DOI 10.1113/jphysiol.2007.149633
   Zhu MJ, 2004, BIOL REPROD, V71, P1968, DOI 10.1095/biolreprod.104.034561
NR 47
TC 77
Z9 91
U1 0
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 23
PY 2010
VL 395
IS 1
BP 146
EP 151
DI 10.1016/j.bbrc.2010.03.161
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 591JZ
UT WOS:000277298000028
PM 20361929
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zur, Y
   Katchkovsky, S
   Itzhar, A
   Abramovitch Dahan, CV
   Stepensky, D
   Papo, N
   Levaot, N
AF Zur, Yuval
   Katchkovsky, Svetlana
   Itzhar, Amit
   Abramovitch Dahan, Chen Viki
   Stepensky, David
   Papo, Niv
   Levaot, Noam
TI Preventing osteoporotic bone loss in mice by promoting balanced bone
   remodeling through M CSFRGD, a dual antagonist to c FMS and
   αvβ3 receptors
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Osteoporosis; M CSF; alpha v beta 3 integrin; c FMS; Bone metabolism;
   Osteoclast
ID OSTEOCLAST DIFFERENTIATION; SERUM ALBUMIN; CATHEPSIN K; ALENDRONATE;
   OSTEOPROTEGERIN; MANAGEMENT; INTEGRINS; PROTEINS; THERAPY; FUSION
AB Osteoporosis is a common, age related disease caused by imbalanced bone remodeling. Current treatments either shut down bone resorption or robustly stimulate bone formation. Here, we describe a novel compound that inhibits osteoclast activity without causing apparent disruptions to bone formation by targeting both c FMS (i.e., osteoclast differentiation) and alpha v(33 integrin (i.e., osteoclastic bone resorption) receptors. We show that human serum albumin (HSA) conjugated M CSFRGD protein (M CSFRGD HSA) effectively inhibits the activity of both receptors, with a three fold higher serum half life compared to the unconjugated M CSFRGD. We then treated ovariectomized mice with different doses of M CSFRGD HSA, alendronate, or a monospecific control protein. The bispecific M CSFRGD HSA was superior to a monospecific control in alleviating bone loss and reducing osteoclast distribution and function. M CSFRGD HSA and alendronate effectively prevented ovariectomy induced bone loss, but M CSFRGD HSA had a milder inhibitory effect on osteoclast distribution and activity. Moreover, alendronate halted bone formation, while M CSFRGD HSA treated mice showed an increased level of serum amino terminal propeptide of type I collagen, a bone formation marker. Our data indicate that the mild reduction in osteoclast activity facilitated by the bispecific M CSFRGD HSA allows the maintenance of certain levels of bone formation and may be superior to treatments that induce osteoclast depletion.
C1 [Zur, Yuval; Itzhar, Amit; Papo, Niv] Ben Gurion Univ Negev, Avram & Stella Goldstein Goren, Dept Biotechnol Engn, Beer Sheva 8410501, Israel.
   [Katchkovsky, Svetlana; Abramovitch Dahan, Chen Viki; Levaot, Noam] Bengurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, IL 8410501 Beer Sheva, Israel.
   [Stepensky, David] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem & Pharmacol, IL 8410501 Beer Sheva, Israel.
C3 Ben Gurion University of the Negev; Ben Gurion University of the Negev;
   Ben Gurion University of the Negev
RP Papo, N (通讯作者)，Ben Gurion Univ Negev, Avram & Stella Goldstein Goren, Dept Biotechnol Engn, Beer Sheva 8410501, Israel.; Levaot, N (通讯作者)，Bengurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, IL 8410501 Beer Sheva, Israel.
EM papo@bgu.ac.il; levaot@bgu.ac.il
RI Levaot, Noam/AAA 3052 2022
FU Israel Science Founda tion [357/18, 1615/19]; Rosetrees Foundation
   [OoR2022\100004]
FX This work was supported by grants from the Israel Science Founda tion
   no. 357/18 (NL) and 1615/19 (NP) , the Rosetrees Foundation no.
   OoR2022\100004 (NP) .
CR [Anonymous], 2001, Jama, V285, P785
   Bandeira L, 2022, ARCH ENDOCRIN METAB, V66, P707, DOI 10.20945/2359 3997000000566
   Belvisi L, 2001, ORG LETT, V3, P1001, DOI 10.1021/ol007049u
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carter PJ, 2011, EXP CELL RES, V317, P1261, DOI 10.1016/j.yexcr.2011.02.013
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476 5381.2009.00190.x
   Chapurlat RD, 2015, THER ADV MUSCULOSKEL, V7, P103, DOI 10.1177/1759720X15580903
   Chaudhury C, 2003, J EXP MED, V197, P315, DOI 10.1084/jem.20021829
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   Douglass TG, 2008, INT IMMUNOPHARMACOL, V8, P1354, DOI 10.1016/j.intimp.2008.04.016
   DOWEIKO JP, 1991, JPEN PARENTER ENTER, V15, P207, DOI 10.1177/0148607191015002207
   Elegheert J, 2012, NAT STRUCT MOL BIOL, V19, P938, DOI 10.1038/nsmb.2367
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   FDA, Drug Approval Package: FETROJA (Cefiderocol)
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Guterman Ram G, 2018, J CELL PHYSIOL, V233, P617, DOI 10.1002/jcp.25922
   Horváthy DB, 2017, BIOFACTORS, V43, P315, DOI 10.1002/biof.1337
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879
   Ishida K, 2004, INT J MOL MED, V14, P1077
   Jensen PR, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115850
   Karsenty G, 2022, CELL METAB, V34, P805, DOI 10.1016/j.cmet.2022.04.010
   Katchkovsky S, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04127 2
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Knaufs M. J., J. Biol. Chem. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin 2 chemically modified with water soluble polymers*, V263, P15064
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li Z, 2017, PHARM RES DORDR, V34, P2131, DOI 10.1007/s11095 017 2219 y
   MAACK T, 1979, KIDNEY INT, V16, P251, DOI 10.1038/ki.1979.128
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miller PD, 2008, BEST PRACT RES CL EN, V22, P849, DOI 10.1016/j.beem.2008.07.004
   Minisola S, 2019, THER ADV MUSCULOSKEL, V11, DOI 10.1177/1759720X19877994
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Nilsen J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32817 0
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Omar I, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31428 z
   Richter Wolfgang F, 2014, Drug Metab Dispos, V42, P1881, DOI 10.1124/dmd.114.059238
   Richter WF, 2012, AAPS J, V14, P559, DOI 10.1208/s12248 012 9367 0
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   Samadfam R, 2007, ENDOCRINOLOGY, V148, P2778, DOI 10.1210/en.2006 1475
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sehgal A, 2021, SEMIN IMMUNOL, V54, DOI 10.1016/j.smim.2021.101509
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Song L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8417814
   Stoner KL, 2015, PATIENT, V8, P145, DOI 10.1007/s40271 014 0075 y
   Usach I, 2019, ADV THER, V36, P2986, DOI 10.1007/s12325 019 01101 6
   vanBeek ER, 1997, BONE, V20, P335, DOI 10.1016/S8756 3282(97)00006 9
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Yamane H, 2009, BONE, V44, P1055, DOI 10.1016/j.bone.2008.05.010
   Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007
   Zhao HL, 2008, PROTEIN EXPRES PURIF, V61, P73, DOI 10.1016/j.pep.2008.04.013
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
   Zur Y, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2002979
NR 56
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC
PY 2024
VL 282
AR 136821
DI 10.1016/j.ijbiomac.2024.136821
EA OCT 2024
PN 2
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA L2B1E
UT WOS:001348814000001
PM 39447795
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhang, WJ
   Tian, Y
   He, HY
   Chen, R
   Ma, YF
   Guo, H
   Yuan, Y
   Liu, CS
AF Zhang, Wenjing
   Tian, Yu
   He, Hongyan
   Chen, Rui
   Ma, Yifan
   Guo, Han
   Yuan, Yuan
   Liu, Changsheng
TI Strontium attenuates rhBMP 2 induced osteogenic differentiation via
   formation of Sr rhBMP 2 complex and suppression of Smad dependent
   signaling pathway
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Sr ions; rhBMP 2; Sr rhBMP 2 complex; Bone formation
ID BONE MORPHOGENETIC PROTEIN 2; OSTEOBLAST DIFFERENTIATION;
   NUCLEAR FACTOR; SILK FIBROIN; RECEPTOR; RECOGNITION; RANELATE; BMP 2;
   OSTEOCALCIN; EXPRESSION
AB Strontium (Sr2+) has pronounced effects on stimulating bone formation and inhibiting bone resorption in bone regeneration. In this current study, the effect and the underlying mechanism involved of Sr2+ on the biological activity of bone morphogenetic protein 2 (BMP 2) were studied in detail with pluripotent skeletal muscle myogenic progenitor C2C12 model cell line. The results indicated that Sr2+ could bind recombinant human BMP 2 (rhBMP 2) rapidly, even in the presence of Ca2+ and Mg2+, and inhibited rhBMP 2 induced osteogenic differentiation in vitro and osteogenetic efficiency in vivo. Further studies demonstrated that Sr2+ treatment undermined the binding capacity of rhBMP 2 with its receptor BMPRIA and thus attenuated Smad 1/5/8 phosphorylation without affecting their dephosphorylation in C2C12 cells. Furthermore, circular dichroism spectroscopy, fluorescence spectroscopy and X ray photoelectron spectroscopy all revealed that the inhibitory effect of Sr2+ on the rhBMP 2 osteogenic activity was associated with the formation of Sr rhBMP 2 complex and ensuing enhancement of (3 sheet structure. Our work suggests the activity of rhBMP 2 to induce osteogenic differentiation was decreased by directly interaction with free Sr ions in solution, which should provide guide and assist for development of BMP 2 based materials for bone regeneration.
   Statement of Significance
   Due to easy denaturation and ensuing the reduced activity of rhBMP 2, preserving/enhancing the capacity of rhBMP 2 to induce osteogenic differentiation is of critical importance in developing the protein based therapy. Cations as effective elements influence the conformation and thereby the bioactivity of protein. Strontium (Sr2+), stimulating bone formation and inhibiting bone resorption, has been incorporated into biomaterials/scaffold to improve the bioactivity for bone regeneration applications. However, Sr2+ induced changes in the conformation and bioactivity of BMP 2 have never been investigated. In this study, the formation of Sr rhBMP 2 complex inhibited the osteogenic differentiation in vitro and osteogenetic efficiency in vivo through the inhibition of BMP/Smad signaling pathway, providing guidance for development of Sr containing BMP 2 based bone scaffold/matrice and other Sr dopped protein therapy. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Zhang, Wenjing; Tian, Yu; Chen, Rui; Ma, Yifan; Yuan, Yuan; Liu, Changsheng] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
   [Zhang, Wenjing; Tian, Yu; Liu, Changsheng] E China Univ Sci & Technol, Minist Educ, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China.
   [He, Hongyan; Chen, Rui; Yuan, Yuan; Liu, Changsheng] E China Univ Sci & Technol, Minist Educ, Engn Res Ctr Biomed Mat, Shanghai 200237, Peoples R China.
   [Guo, Han] Chinese Acad Sci, Shanghai Inst Appl Phys, Shanghai 201800, Peoples R China.
C3 East China University of Science & Technology; East China University of
   Science & Technology; East China University of Science & Technology;
   Chinese Academy of Sciences; Shanghai Institute of Applied Physics, CAS
RP Yuan, Y; Liu, CS (通讯作者)，E China Univ Sci & Technol, Minist Educ, Engn Res Ctr Biomed Mat, Shanghai 200237, Peoples R China.; Yuan, Y; Liu, CS (通讯作者)，E China Univ Sci & Technol, Minist Educ, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
EM yyuan@ecust.edu.cn; liucs@ecust.edu.cn
RI ; yuan, Yuan/ISA 0923 2023; Zhang, Wenjing/B 5983 2019; Ma,
   Yifan/AAB 4406 2019
OI Ma, Yifan/0000 0002 9371 4365; Zhang, Wenjing/0000 0002 6076 8017
FU National Basic Research Program of China (973 Program) [2012CB933600];
   111 Project [B14018]; National Natural Science Foundation of China
   [31100679, 31330028, 31470924]
FX The authors declare they have no conflicts of interest. This work was
   supported by grants from the National Basic Research Program of China
   (973 Program, No. 2012CB933600), the 111 Project (B14018), the National
   Natural Science Foundation of China (No. 31100679, 31330028 and
   31470924).
CR Andersen OZ, 2013, BIOMATERIALS, V34, P5883, DOI 10.1016/j.biomaterials.2013.04.031
   Boanini E, 2014, BIOMATERIALS, V35, P5619, DOI 10.1016/j.biomaterials.2014.03.053
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Broege A, 2013, J BIOL CHEM, V288, P37230, DOI 10.1074/jbc.M113.496950
   Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198 002 1343 6
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Cnudde SE, 2007, J AM CHEM SOC, V129, P1586, DOI 10.1021/ja065722q
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Huang BL, 2015, ACTA BIOMATER, V27, P275, DOI 10.1016/j.actbio.2015.09.007
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Jang H, 2014, BONE, V61, P10, DOI 10.1016/j.bone.2013.12.028
   Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756
   Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314
   Kläning E, 2014, BONE, V66, P90, DOI 10.1016/j.bone.2014.05.020
   Kursula P, 2014, ACTA CRYSTALLOGR D, V70, P24, DOI 10.1107/S1399004713024437
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li JJ, 2011, BONE, V48, P321, DOI 10.1016/j.bone.2010.09.033
   Li ZY, 2013, BIOCHEM BIOPH RES CO, V440, P215, DOI 10.1016/j.bbrc.2013.09.036
   Lin KL, 2013, BIOMATERIALS, V34, P10028, DOI 10.1016/j.biomaterials.2013.09.056
   Llinas P, 2006, PROTEIN SCI, V15, P1691, DOI 10.1110/ps.062123806
   Luca L, 2010, J CONTROL RELEASE, V147, P38, DOI 10.1016/j.jconrel.2010.06.011
   Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003
   Mi L, 2012, BIOMATERIALS, V33, P2001, DOI 10.1016/j.biomaterials.2011.11.071
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Peng SL, 2009, CELL PHYSIOL BIOCHEM, V23, P165, DOI 10.1159/000204105
   Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590
   Thangaratnarajah C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6491
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Verberckmoes SC, 2003, KIDNEY INT, V64, P534, DOI 10.1046/j.1523 1755.2003.00123.x
   Xin YC, 2009, ACS NANO, V3, P3228, DOI 10.1021/nn9007675
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yang YH, 2004, BIOMACROMOLECULES, V5, P773, DOI 10.1021/bm0343848
   Zhang W., 2015, SCI REP, V5
   Zhang YH, 2012, SOFT MATTER, V8, P5543, DOI 10.1039/c2sm25099c
   Zhao LZ, 2013, BIOMATERIALS, V34, P19, DOI 10.1016/j.biomaterials.2012.09.041
NR 37
TC 37
Z9 39
U1 1
U2 98
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 15
PY 2016
VL 33
BP 290
EP 300
DI 10.1016/j.actbio.2016.01.042
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DH3LO
UT WOS:000372688700029
PM 26828127
DA 2025 08 17
ER

PT J
AU Xu, ML
   Bi, CWC
   Kong, AYY
   Dong, TTX
   Wong, YH
   Tsim, KWK
AF Xu, Miranda L.
   Bi, Cathy W. C.
   Kong, Ava Y. Y.
   Dong, Tina T. X.
   Wong, Yung H.
   Tsim, Karl W. K.
TI Flavonoids induce the expression of acetylcholinesterase in cultured
   osteoblasts
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article; Proceedings Paper
CT 12th International Meeting on Cholinesterases / 6th International
   Conference on Paraoxonase
CY 2015
CL Elche, SPAIN
DE AChE; PRiMA; Flavonoid; Estrogen; Osteoporosis
ID TRANSCRIPTION CONTROL; REPLACEMENT THERAPY; P2Y(1) RECEPTORS;
   GENE EXPRESSION; DIFFERENTIATION; ESTROGEN; CELLS; BONE;
   CHOLINESTERASES; TRANSDUCTION
AB Flavonoids, a group of natural compounds mainly derived from plants, are known to possess osteogenic effects in bone cells. Here, we aimed to test if flavonoid could induce a cholinergic enzyme, acetylcholinesterase (AChE), as well as bone differentiation. In cultured rat osteoblasts, twenty flavonoids, deriving from Chinese herbs and having known induction of alkaline phosphatase (ALP(1)) expression, were tested for its induction activity on AChE expression. Eleven flavonoids showed the induction, and five of them had robust activation of AChE expression, including baicalin, calycosin, genistin, hyperin and pratensein: the induction of AChE included the levels of mRNA, protein and enzymatic activity. Moreover, the flavonoid induced AChE expression in cultured osteoblast was in proline rich membrane anchor (PRiMA)  linked tetrameric globular form (G(4)) only. In parallel, the expression of PRiMA was also induced by the application of flavonoids. The flavonoid induced AChE in the cultures was not affected by estrogen receptor blocker, ICI 182,780. Taken together, the induction of PRiMA linked AChE in osteoblast should be independent to classical estrogen signaling pathway. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Xu, Miranda L.; Bi, Cathy W. C.; Kong, Ava Y. Y.; Dong, Tina T. X.; Wong, Yung H.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.
   [Xu, Miranda L.; Bi, Cathy W. C.; Kong, Ava Y. Y.; Dong, Tina T. X.; Wong, Yung H.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China.
C3 Hong Kong University of Science & Technology; Hong Kong University of
   Science & Technology
RP Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.; Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China.
EM botsim@ust.hk
OI Tsim, Karl/0000 0003 4808 1674; XU, Miranda Li/0000 0001 7660 0051;
   Wong, Yung Hou/0000 0002 0123 7697
CR BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Choi C. Y., 2008, 13 INT INT S COL MEC
   Choi RCY, 2003, J NEUROSCI, V23, P4445
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Collins Burow BM, 2000, NUTR CANCER, V38, P229, DOI 10.1207/S15327914NC382_13
   FROST HM, 1990, ANAT RECORD, V226, P433, DOI 10.1002/ar.1092260405
   Genever PG, 1999, BONE, V24, P297, DOI 10.1016/S8756 3282(98)00187 2
   Grisaru D, 1999, MOL CELL BIOL, V19, P788
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Guo AJ, 2012, CHIN MED UK, V7, DOI 10.1186/1749 8546 7 10
   Huang ZY, 2010, FEBS LETT, V584, P22, DOI 10.1016/j.febslet.2009.11.026
   Inkson CA, 2004, BONE, V35, P819, DOI 10.1016/j.bone.2004.05.026
   Kanis JA., 2007, WHO technical report, V66
   LAYER PG, 1990, BIOESSAYS, V12, P415, DOI 10.1002/bies.950120904
   Lips KS, 2007, EUR UROL, V51, P1042, DOI 10.1016/j.eururo.2006.10.028
   Massoulié J, 2005, CHEM BIOL INTERACT, V157, P3, DOI 10.1016/j.cbi.2005.10.002
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   Perry C, 2002, ONCOGENE, V21, P8428, DOI 10.1038/sj.onc.1205945
   Sato T, 2010, FEBS LETT, V584, P817, DOI 10.1016/j.febslet.2010.01.001
   Schairer C, 2000, JAMA J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485
   Siow NL, 2010, MOL PHARMACOL, V78, P1059, DOI 10.1124/mol.110.066506
   Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140 6736(98)05066 1
   UMEZU Y, 1993, ARCH HISTOL CYTOL, V56, P217, DOI 10.1679/aohc.56.217
   Vaya J, 2004, CURR MED CHEM, V11, P1333, DOI 10.2174/0929867043365251
   Vogel Höpker A, 2012, PROTEIN PEPTIDE LETT, V19, P155
   Walker LM, 2001, BONE, V28, P603, DOI 10.1016/S8756 3282(01)00427 6
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Xie HDQ, 2010, J BIOL CHEM, V285, P11537, DOI 10.1074/jbc.M109.038711
   Zheng YZ, 2010, PLANTA MED, V76, P439, DOI 10.1055/s 0029 1186222
   Zhu JTT, 2007, J AGR FOOD CHEM, V55, P2438, DOI 10.1021/jf063299z
NR 30
TC 21
Z9 24
U1 2
U2 26
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD NOV 25
PY 2016
VL 259
SI SI
BP 295
EP 300
DI 10.1016/j.cbi.2016.03.025
PN B
PG 6
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA ED4TC
UT WOS:000388843500035
PM 27019979
DA 2025 08 17
ER

PT J
AU Zhu, XF
   Amir, E
   Singh, G
   Clemons, M
   Addison, C
AF Zhu, Xiaofu
   Amir, Eitan
   Singh, Gurmit
   Clemons, Mark
   Addison, Christina
TI Bone targeted therapy for metastatic breast cancer Where do we go from
   here? A commentary from the BONUS 8 meeting
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Breast cancer; Bone metastasis; Targeted therapy; Oncodynamics; Meeting
   summary
ID SUPPRESSOR CELLS; ZOLEDRONIC ACID; DOUBLE BLIND; PHASE III; T CELLS;
   GLUTAMATE; PAIN; BISPHOSPHONATES; COMPLICATIONS; EXPERIENCE
AB The annual Bone and The Oncologist New Updates (BONUS 8) conference focuses on the current understanding and dilemmas in the treatment and prevention of bone metastasis in cancer, as well as novel research on bone homeostasis and cancer induced bone loss. We present commentaries from experts for their own take on where they feel the field of bone targeted therapies for metastatic breast cancer is moving, or needs to move, if we are to make further progress. (C) 2014 Elsevier GmbH. All rights reserved
C1 [Zhu, Xiaofu; Clemons, Mark] Univ Ottawa, Ottawa Hosp, Div Med Oncol, Ottawa, ON, Canada.
   [Zhu, Xiaofu; Clemons, Mark] Univ Ottawa, Fac Med, Ottawa, ON, Canada.
   [Amir, Eitan] Univ Ottawa, Div Med Oncol & Hematol, Ottawa, ON, Canada.
   [Amir, Eitan] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
   [Singh, Gurmit] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   [Clemons, Mark; Addison, Christina] Ottawa Hosp, Inst Res, Canc Therapeut Program, Ottawa, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Ottawa; University of Toronto; University Health
   Network Toronto; Princess Margaret Cancer Centre; McMaster University;
   University of Ottawa; Ottawa Hospital Research Institute
RP Zhu, XF (通讯作者)，Ottawa Hosp, Ctr Canc, Div Med Oncol, 501 Smyth Rd, Ottawa, ON, Canada.
RI Amir, Eitan/L 6052 2019
OI Amir, Eitan/0000 0002 3706 525X
FU Amgen; Novartis; Roche; Janssen
FX Funding for the BONUS 8 meeting comes in the form of unrestricted
   educational grants from Amgen, Novartis, Roche and, Janssen. These
   companies had no input into this Commentary.
CR Berman AT, 2013, CLIN BREAST CANCER, V13, P88, DOI 10.1016/j.clbc.2012.11.001
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Clemons M, 2012, CURR ONCOL, V19, P259, DOI 10.3747/co.19.1011
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cowan Robert W, 2012, Front Endocrinol (Lausanne), V3, P89, DOI 10.3389/fendo.2012.00089
   Coxon JP, 2004, PROSTATE CANCER P D, V7, P99, DOI 10.1038/sj.pcan.4500705
   Danilin S, 2012, ONCOIMMUNOLOGY, V1, P1484, DOI 10.4161/onci.21990
   Fralick M, 2012, J BONE ONCOL, V1, P69, DOI 10.1016/j.jbo.2012.10.003
   Gazerani P, 2006, PAIN, V124, P338, DOI 10.1016/j.pain.2006.06.015
   Gordon JAR, 2009, J CELL BIOCHEM, V107, P1118, DOI 10.1002/jcb.22211
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Hutton B, 2013, J BONE ONCOL, V2, P123, DOI 10.1016/j.jbo.2013.05.001
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kuchuk I, 2012, J BONE ONCOL, V1, P95, DOI 10.1016/j.jbo.2012.09.001
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Kuchuk I, 2012, CURR ONCOL, V19, pE364, DOI 10.3747/co.19.1008
   Kuchuk I, 2012, CURR ONCOL, V19, pE303, DOI 10.3747/co.19.1009
   Kuchuk I, 2013, J BONE ONCOL, V2, P154, DOI 10.1016/j.jbo.2013.07.004
   Kuchuk I, 2013, J BONE ONCOL, V2, P38, DOI 10.1016/j.jbo.2012.12.001
   Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470 2045(11)70002 X
   Monu NR, 2012, IMMUNOL INVEST, V41, P595, DOI 10.3109/08820139.2012.673191
   Morimoto R, 2006, EMBO J, V25, P4175, DOI 10.1038/sj.emboj.7601317
   Murrough JW, 2012, CURR PSYCHIAT REP, V14, P643, DOI 10.1007/s11920 012 0321 8
   Reufsteck C, 2012, CLIN EXP METASTAS, V29, P441, DOI 10.1007/s10585 012 9462 8
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Russell K, 2013, J BONE ONCOL, V2, P167, DOI 10.1016/j.jbo.2013.06.001
   Russell K, 2012, J BONE ONCOL, V1, P12, DOI 10.1016/j.jbo.2012.04.003
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Sanacora G, 2008, NAT REV DRUG DISCOV, V7, P426, DOI 10.1038/nrd2462
   Seidlitz EP, 2010, CAN J PHYSIOL PHARM, V88, P929, DOI [10.1139/Y10 070, 10.1139/y10 070]
   Seidlitz EP, 2009, CLIN EXP METASTAS, V26, P781, DOI 10.1007/s10585 009 9277 4
   Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914 012 0103 6
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Svensson P, 2005, J OROFAC PAIN, V19, P109
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   Valverde P, 2008, J BONE MINER RES, V23, P1775, DOI 10.1359/JBMR.080605
   Waraich P, 2004, CAN J PSYCHIAT, V49, P124, DOI 10.1177/070674370404900208
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Wong MHF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub3
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
NR 44
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD MAR
PY 2014
VL 3
IS 1
BP 1
EP 4
DI 10.1016/j.jho.2014.01.001
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CB5MR
UT WOS:000349672100001
PM 26909291
DA 2025 08 17
ER

PT J
AU Hsieh, CL
   Huang, HS
   Chen, KC
   Saka, T
   Chiang, CY
   Chung, LWK
   Sung, SY
AF Hsieh, Chia Ling
   Huang, Hsu Shan
   Chen, Kuan Chou
   Saka, Teigi
   Chiang, Chih Ying
   Chung, Leland W. K.
   Sung, Shian Ying
TI A Novel Salicylanilide Derivative Induces Autophagy Cell Death in
   Castration Resistant Prostate Cancer via ER Stress Activated PERK
   Signaling Pathway
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID ENDOPLASMIC RETICULUM STRESS; INHIBITORS; THERAPY; CYCLE; NICLOSAMIDE;
   INDUCTION; PHASE; P53
AB Metastatic castration resistant prostate cancer (CRPC) is currently incurable. Cancer growth and progression is intimately affected by its interaction with host microenvironment. Cotargeting of the stroma and prostate cancer is therefore an emerging therapeutic strategy for metastatic CRPC. Cancer induced osteoclastogenesis is known to contribute to CRPC bone metastasis. This study is to extend pharmacologic value of our synthesized LCC03, a derivative of 5 (2',4' difluorophenyl) salicylanilide that has previously testified for its osteoclastogenesis activity, by exploring its additional cytotoxic properties and underlying mechanism in CRPC cells. LCC03 was chemically synthesized and examined for cell growth inhibition in a serial of CRPC cell lines. We demonstrated that LCC03 dose dependently suppressed proliferation and retarded cell cycle progression in CRPC cells. The classical autophagy features, including autophagosome formation and LC3 II conversion, were dramatically shown in LCC03 treated CRPC cells, and it was associated with the suppressed AKT/mTOR signaling pathways, a major negative regulator of autophagy. Moreover, an expanded morphology of the endoplasmic reticulum (ER), increased expression of the ER stress markers GRP78 and PERK, and eIF2 alpha phosphorylation were observed. Blockage of autophagy and PERK pathways using small molecule inhibitors or shRNA knockdown reversed LCC03 induced autophagy and cell death, thus indicating that the PERK eIF2 alpha pathway contributed to the LCC03  induced autophagy. Furthermore, treatment of tumor bearing mice with intraperitoneal administered LCC03 suppressed the growth of CRPC xenografts in mouse bone without systemic toxicity. The dual action of 5 (2',4' difluorophenyl) salicylanilide on targeting both the osteoclasts and the tumor cells strongly indicates that LCC03 is a promising anticancer candidate for preventing and treating metastatic CRPC.
C1 [Hsieh, Chia Ling; Chiang, Chih Ying; Sung, Shian Ying] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, 250 Wu Hsing St, Taipei 11031, Taiwan.
   [Hsieh, Chia Ling; Sung, Shian Ying] Taipei Med Univ, TMU Res Ctr Canc Translat Med, Taipei, Taiwan.
   [Huang, Hsu Shan] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Mol Biol & Drug Discovery, Taipei, Taiwan.
   [Chen, Kuan Chou; Saka, Teigi] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.
   [Chen, Kuan Chou] Taipei Med Univ, Dept Urol, Coll Med, Taipei, Taiwan.
   [Chen, Kuan Chou] Taipei Med Univ, Shuang Ho Hosp, Dept Urol, New Taipei, Taiwan.
   [Chung, Leland W. K.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.
   [Sung, Shian Ying] Taipei Med Univ, Joint Clin Res Ctr, Off Human Res, Taipei, Taiwan.
   [Sung, Shian Ying] Taipei Med Univ, Taipei Med Univ Hosp, Clin Res Ctr, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Taipei Medical
   University; Taipei Medical University; Taipei Medical University; Taipei
   Medical University; Shuang Ho Hospital; Cedars Sinai Medical Center;
   Taipei Medical University; Taipei Medical University; Taipei Medical
   University Hospital
RP Sung, SY (通讯作者)，Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, 250 Wu Hsing St, Taipei 11031, Taiwan.
EM ssung@tmu.edu.tw
OI Huang, Hsu Shan/0000 0001 8162 5608
FU Ministry of Science and Technology in Taiwan [MOST 107 2320 B038 057,
   106 2320 B 038 056, 106 2320 B 038 055, 106 2113 M 038 003]; Taipei
   Medical University [DP2 107 21121 C 01]; "TMU Research Center of Cancer
   Translational Medicine" from The Featured Areas Research Center Program
   by the Ministry of Education (MOE)
FX We would like to acknowledge Ms. Huei Min Chen for her exceptional
   technical support for TEM at Taipei Medical University Core Facility.
   This work was supported in part by Ministry of Science and Technology in
   Taiwan (Grant No. MOST 107 2320 B038 057 and 106 2320 B 038 056 to C. L.
   Hsieh, 106 2320 B 038 055 to S. Y. Sung, and 106 2113 M 038 003 to H. S.
   Huang), Taipei Medical University (Grant No. DP2 107 21121 C 01), and
   the "TMU Research Center of Cancer Translational Medicine" from The
   Featured Areas Research Center Program within the framework of the
   Higher Education Sprout Project by the Ministry of Education (MOE).
CR Back SH, 2012, ANNU REV BIOCHEM, V81, P767, DOI 10.1146/annurev biochem 072909 095555
   Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300
   Brown ME, 2008, BIOORGAN MED CHEM, V16, P8760, DOI 10.1016/j.bmc.2008.07.024
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chen CL, 2016, EUR J MED CHEM, V117, P70, DOI 10.1016/j.ejmech.2016.04.007
   Chen CL, 2014, J MED CHEM, V57, P8072, DOI 10.1021/jm5007897
   Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752
   Chen YR, 2016, ONCOTARGET, V7, P1984, DOI 10.18632/oncotarget.6539
   Chung LWK, 2003, UROLOGY, V62, P44, DOI 10.1016/S0090 4295(03)00796 9
   Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fiorini C, 2015, BBA MOL CELL RES, V1853, P549, DOI 10.1016/j.bbamcr.2014.12.016
   Garcia JA, 2008, MOL CANCER THER, V7, P1347, DOI 10.1158/1535 7163.MCT 07 2408
   Hayes AR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191455
   Hotamisligil GS, 2010, NAT MED, V16, P396, DOI 10.1038/nm0410 396
   Hung SC, 2010, MOL PHARMACEUT, V7, P2312, DOI 10.1021/mp1002834
   Imramovsky A, 2013, EUR J MED CHEM, V68, P253, DOI 10.1016/j.ejmech.2013.08.009
   Imramovsky A, 2009, BIOORGAN MED CHEM, V17, P3572, DOI 10.1016/j.bmc.2009.04.008
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Kauerova T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081219
   Kluth M, 2014, INT J CANCER, V135, P1369, DOI 10.1002/ijc.28784
   Krátky M, 2011, MINI REV MED CHEM, V11, P956, DOI 10.2174/138955711797068382
   Krátky M, 2013, MOLECULES, V18, P3674, DOI 10.3390/molecules18043674
   Krátky M, 2012, MOLECULES, V17, P9426, DOI 10.3390/molecules17089426
   Lee CC, 2015, EUR J MED CHEM, V98, P115, DOI 10.1016/j.ejmech.2015.05.015
   Leo S, 2011, CHEMOTHERAPY, V57, P115, DOI 10.1159/000323581
   Li YH, 2014, CANCER LETT, V349, P8, DOI 10.1016/j.canlet.2014.04.003
   Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778
   Liu FL, 2017, INT J MED SCI, V14, P840, DOI 10.7150/ijms.19268
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   Murrow L, 2013, ANNU REV PATHOL MECH, V8, P105, DOI 10.1146/annurev pathol 020712 163918
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453 06
   Omlin A, 2014, THER ADV UROL, V6, P3, DOI 10.1177/1756287213509677
   Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012
   Rathkopf DE, 2015, CANCER AM CANCER SOC, V121, P3853, DOI 10.1002/cncr.29578
   Sano R, 2013, BBA MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Smith MR, 2008, UROL ONCOL SEMIN ORI, V26, P420, DOI 10.1016/j.urolonc.2007.11.004
   Sung SY, 2014, ONCOTARGET, V5, P9911, DOI 10.18632/oncotarget.2478
   Tasdemir E, 2007, CELL CYCLE, V6, P2263, DOI 10.4161/cc.6.18.4681
   Thomas SE, 2013, J BIOL CHEM, V288, P7606, DOI 10.1074/jbc.M112.424655
   Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143
   Wang BL, 2015, J INORG BIOCHEM, V142, P118, DOI 10.1016/j.jinorgbio.2014.10.003
   Zhu XF, 2006, CANCER SCI, V97, P84, DOI 10.1111/j.1349 7006.2006.00143.x
NR 44
TC 23
Z9 23
U1 0
U2 21
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JAN
PY 2020
VL 19
IS 1
BP 101
EP 111
DI 10.1158/1535 7163.MCT 19 0387
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KA3AE
UT WOS:000505667900009
PM 31530650
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Lin, ZY
   Huang, S
   LingHu, XT
   Wang, YX
   Wang, B
   Zhong, SW
   Xie, SY
   Xu, XH
   Yu, A
   Nagai, A
   Kobayashi, Y
   Wa, QD
   Huang, S
AF Lin, Zhuoyuan
   Huang, Sheng
   LingHu, Xitao
   Wang, Yixiao
   Wang, Bin
   Zhong, Shaowen
   Xie, Shangyan
   Xu, Xiaohong
   Yu, Aorigele
   Nagai, Atsushi
   Kobayashi, Yuta
   Wa, Qingde
   Huang, Shuai
TI Perillaldehyde inhibits bone metastasis and receptor activator of
   nuclear factor κB ligand (RANKL) signaling induced osteoclastogenesis in
   prostate cancer cell lines
SO BIOENGINEERED
LA English
DT Article
ID FRUTESCENS; PATTERNS; AUTOPSY; PATHWAY
AB Perillaldehyde (PAH), one of the active ingredients of the traditional Chinese medicine (TCM) plant Perilla frutescens, is widely used and exerts crucial anti cancer activities. The aim of current study is to illustrate the potential mechanisms of PAH mediated regulation of bone metastasis and osteoclastogenesis in prostate cancer (PCa) cell lines. Effects of PAH on proliferation, invasion and migration of PC 3 cells were assessed with the Cell Counting Kit 8 (CCK 8) assay and Transwell assays, respectively. Effects of PAH on stem cell characteristics of PC 3 cells were evaluated by cell matrix adhesion assay, colony formation assay, spheroid formation assay, as well as western blot . The anti metastasis and anti osteoclastogenesis activity of PAH in RAW264.7 cells was examined by osteoclast differentiation assay and western blot. The protein levels of CD133 and CD44 in PC 3 cells and the activity of nuclear factor kappa B (NF kappa B) signaling pathway in RAW264.7 cells were measured by western blot. PAH suppressed proliferation, invasion and migration of PC 3 cells, prevented stem cell characteristics including cell matrix adhesion, colony formation, spheroid formation as well as CD133 and CD44 expression. PAH inhibited bone metastasis and osteoclastogenesis via repressing the activation of NF kappa B pathway as well as (RANKL)   and cancer cell induced osteoclastogenesis in PCa cells. These findings suggested the potential therapeutic effects of PAH on the metastasis of patients with PCa.
C1 [Lin, Zhuoyuan; Wang, Bin; Zhong, Shaowen; Xie, Shangyan; Xu, Xiaohong; Huang, Shuai] Guangzhou Med Univ, Dept Urol, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Huang, Sheng] Nanchang Univ, Dept Orthoped, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [LingHu, Xitao; Wang, Yixiao; Wa, Qingde] Zunyi Med Univ, Dept Orthoped, Affiliated Hosp 2, Zunyi, Guizhou, Peoples R China.
   [Yu, Aorigele; Nagai, Atsushi; Kobayashi, Yuta] Shimane Univ, Grad Sch Med, Izumo, Shimane, Japan.
C3 Guangzhou Medical University; Nanchang University; Zunyi Medical
   University; Shimane University
RP Wa, QD (通讯作者)，Zunyi Med Coll, Dept Orthopaed Surg, Affiliated Hosp 2, Intersect Xinpu Ave & Xinlong Ave Xinpu New Dist, Zunyi 563000, Guizhou, Peoples R China.
EM wqd887zsy@126.com
RI Lin, Zhuoyuan/IUO 8154 2023; Devendran, Arthisree/KBC 4946 2024
FU National Natural Science Foundation of China [81872172, 81702671,
   81860322]; Guangzhou Health and Family Planning Science and Technology
   Project [20191A011078, 20201A011077]; Guangzhou Science and Technology
   Planning Project [202002030014]; Natural Science Foundation of Guangdong
   Fund [20201A011077]; Program for Science and Technology Project of
   Guizhou Province, Qiankehe Platform Talents [[2021] 5613]
FX This research was supported by grants from the National Natural Science
   Foundation of China [81872172, 81702671, 81860322], Guangzhou Health and
   Family Planning Science and Technology Project [20191A011078,
   20201A011077] and Guangzhou Science and Technology Planning Project [No.
   202002030014], Natural Science Foundation of Guangdong Fund
   [20201A011077], The Program for Science and Technology Project of
   Guizhou Province, Qiankehe Platform Talents (No. [2021] 5613).
CR Ahmed HM, 2019, FOOD CHEM, V275, P730, DOI 10.1016/j.foodchem.2018.09.155
   Asif M, 2011, ORIENTAL PHARM EXP M, V11, P51, DOI 10.1007/s13596 011 0002 x
   Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Burton LJ, 2015, CARCINOGENESIS, V36, P1019, DOI 10.1093/carcin/bgv084
   de Groot AF, 2018, CANCER TREAT REV, V62, P18, DOI 10.1016/j.ctrv.2017.10.010
   Díaz de Cerio E, 2018, ANAL BIOANAL CHEM, V410, P3547, DOI 10.1007/s00216 018 0914 0
   Elegbede JA, 2003, LIFE SCI, V73, P2831, DOI 10.1016/S0024 3205(03)00701 X
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005
   Huang S, 2016, ONCOL REP, V36, P2025, DOI 10.3892/or.2016.4997
   Lee H, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041263
   Liu JM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004475
   Omari Siaw E, 2016, INT J PHARMACEUT, V513, P68, DOI 10.1016/j.ijpharm.2016.08.042
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Peng XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020341
   RANA A, 1993, BRIT J UROL, V72, P933, DOI 10.1111/j.1464 410X.1993.tb16301.x
   Saita E, 2012, J OLEO SCI, V61, P113, DOI 10.5650/jos.61.113
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Song YC, 2018, LIFE SCI, V206, P117, DOI 10.1016/j.lfs.2018.05.038
   Teo MY, 2019, ANNU REV MED, V70, P479, DOI 10.1146/annurev med 051517 011947
   Tian J, 2016, J AGR FOOD CHEM, V64, P7404, DOI 10.1021/acs.jafc.6b03546
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang CZ, 2020, CANCER SCI, V111, P3600, DOI 10.1111/cas.14606
   Xu LX, 2014, BIOCHEM BIOPH RES CO, V454, P65, DOI 10.1016/j.bbrc.2014.10.025
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zuo JW, 2015, ONCOL REP, V33, P1388, DOI 10.3892/or.2015.3708
NR 28
TC 27
Z9 28
U1 5
U2 34
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD FEB 1
PY 2022
VL 13
IS 2
BP 2710
EP 2719
DI 10.1080/21655979.2021.2001237
PG 10
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA YN8NK
UT WOS:000747509200001
PM 34738877
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, XM
   Zhang, YJ
   Chen, F
   Khutsishvili, I
   Fehringer, EV
   Marky, LA
   Bayles, KW
   Wang, D
AF Liu, Xin Ming
   Zhang, Yijia
   Chen, Fu
   Khutsishvili, Irine
   Fehringer, Edward V.
   Marky, Luis A.
   Bayles, Kenneth W.
   Wang, Dong
TI Prevention of Orthopedic Device Associated Osteomyelitis Using
   Oxacillin Containing Biomineral Binding Liposomes
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE bisphosphonates; liposomes; orthopaedic implant; osteomyelitis;
   oxacillin
ID IMPLANT RELATED INFECTIONS; TARGETED DRUG DELIVERY; CLICK CHEMISTRY;
   BONE; ARTHROPLASTY; DISEASES; RELEASE; HIP
AB To develop novel biomineral binding liposomes (BBL) for the prevention of orthopedic implant associated osteomyelitis.
   A biomineral binding lipid, alendronate tri(ethyleneglycol) cholesterol conjugate (ALN TEG Chol), was synthesized through Cu(I) catalyzed Huisgen 1,3 dipolar cycloaddition (a versatile click reaction). Mixing with other excipients, the new lipid was used to develop BBL. Thermodynamic behavior was studied by differential scanning calorimetry (DSC). In vitro biomineral binding potential and kinetics were evaluated on hydroxyapatite (HA, a widely used material for orthopedic implant devices) particles. Oxacillin was encapsulated into BBL and used for in vitro evaluation in preventing Staphylococcus aureus biofilm formation.
   DSC analysis showed that ALN TEG Chol could inhibit the phase transition of liposomes by reducing its cooperativity, yielding liposomes with thermodynamic stability similar to liposomes containing regular cholesterol. BBL showed fast and strong binding ability to HA. Oxacillin loading BBL demonstrated significantly better preventive efficacy against bacteria colonization when challenged with S. aureus isolate, implying its potential in preventing orthopedic implant associated osteomyelitis.
   In this proof of concept study, novel BBL has been successfully developed and validated for reducing the frequency of implantable device related infections.
C1 [Liu, Xin Ming; Zhang, Yijia; Chen, Fu; Khutsishvili, Irine; Marky, Luis A.; Wang, Dong] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Fehringer, Edward V.] Univ Nebraska Med Ctr, Dept Orthopaed Surg & Rehabil, Omaha, NE 68198 USA.
   [Bayles, Kenneth W.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Wang, D (通讯作者)，Univ Nebraska Med Ctr, Dept Pharmaceut Sci, 986025 Nebraska Med Ctr,COP 3026, Omaha, NE 68198 USA.
EM dwang@unmc.edu
FU NIH [R01 AI038901, P01 AI83211, R01 AR053325]; NSF [MCB 1122029]; UNeMed
   Corporation; Direct For Biological Sciences; Div Of Molecular and
   Cellular Bioscience [1122029] Funding Source: National Science
   Foundation
FX This work was supported in part by NIH grants R01 AI038901 (KWB), P01
   AI83211 (KWB), R01 AR053325 (DW), a NSF grant MCB 1122029 (LAM) and an
   Innovation Grant from UNeMed Corporation (DW).
CR Abraham SA, 2005, METHOD ENZYMOL, V391, P71, DOI 10.1016/S0076 6879(05)91004 5
   Anada T, 2009, BIOORG MED CHEM LETT, V19, P4148, DOI 10.1016/j.bmcl.2009.05.117
   Bernthal NM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012580
   Bolean M, 2010, BIOPHYS CHEM, V152, P74, DOI 10.1016/j.bpc.2010.08.002
   Boucher H, 1951, CLIN INFECT DIS, V51, pS183
   Bozic KJ, 2009, J BONE JOINT SURG AM, V91A, P128, DOI 10.2106/JBJS.H.00155
   Diaz Rodriguez P, J MAT SCI MAT MED, V22, P339
   El Husseiny M, 2011, J BONE JOINT SURG BR, V93B, P151, DOI 10.1302/0301 620X.93B2.24933
   Gaitanis A, METHODS MOL BIOL, V624, P385
   GILLASPY AF, 1995, INFECT IMMUN, V63, P3373, DOI 10.1128/IAI.63.9.3373 3380.1995
   Halling KK, 2004, BBA BIOMEMBRANES, V1664, P161, DOI 10.1016/j.bbamem.2004.05.006
   Harris LG, 2006, INJURY, V37, P3, DOI 10.1016/j.injury.2006.04.003
   Hein CD, 2008, PHARM RES DORDR, V25, P2216, DOI 10.1007/s11095 008 9616 1
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b
   Jett BD, 1997, BIOTECHNIQUES, V23, P648, DOI 10.2144/97234bm22
   Khoo X, 2010, BIOMATERIALS, V31, P9285, DOI 10.1016/j.biomaterials.2010.08.031
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521 3773(20010601)40:11<2004::AID ANIE2004>3.3.CO;2 X
   Kumar V., 2007, ROBBINS BASIC PATHOL, V8, P810
   Kurtz SM, 2008, J ARTHROPLASTY, V23, P984, DOI 10.1016/j.arth.2007.10.017
   Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406
   Liu XM, 2008, BIOMATERIALS, V29, P1686, DOI 10.1016/j.biomaterials.2007.12.023
   Liu XM, 2007, J CONTROL RELEASE, V122, P54, DOI 10.1016/j.jconrel.2007.06.021
   Liu XM, 2007, BIOMACROMOLECULES, V8, P2653, DOI 10.1021/bm070430i
   MADER JT, 1993, CLIN ORTHOP RELAT R, P87
   MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911
   Ohvo Rekilä H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163 7827(01)00020 0
   OSTERMANN PAW, 1994, ORTHOPEDICS, V17, P397
   Pan HZ, 2008, MOL PHARMACEUT, V5, P548, DOI 10.1021/mp800003u
   Price JS, 1996, J BIOMED MATER RES, V30, P281, DOI 10.1002/(SICI)1097 4636(199603)30:3<281::AID JBM2>3.0.CO;2 M
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521 3773(20020715)41:14<2596::AID ANIE2596>3.0.CO;2 4
   Schmidmaier G, 2006, INJURY, V37, P105, DOI 10.1016/j.injury.2006.04.016
   Seligson D, 1999, CLIN ORTHOP RELAT R, P30
   Takahashi T, 2008, PHARM RES DORDR, V25, P2881, DOI 10.1007/s11095 008 9605 4
   Tanaka KSE, 2008, BIOORGAN MED CHEM, V16, P9217, DOI 10.1016/j.bmc.2008.09.010
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P935, DOI 10.1016/j.addr.2004.12.012
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang G, MOL PHARM, V8, P1025
   Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031
   Yoshinari M, 2010, BIOFOULING, V26, P103, DOI 10.1080/08927010903216572
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 41
TC 32
Z9 35
U1 0
U2 24
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724 8741
EI 1573 904X
J9 PHARM RES DORDR
JI Pharm. Res.
PD NOV
PY 2012
VL 29
IS 11
BP 3169
EP 3179
DI 10.1007/s11095 012 0812 7
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 025QG
UT WOS:000310206100020
PM 22733150
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, XY
   Harimoto, K
   Fuji, R
   Liu, J
   Li, LY
   Wang, P
   Akaike, T
   Wang, Z
AF Wang, Xiaoyan
   Harimoto, Kenichi
   Fuji, Ryosuke
   Liu, Jing
   Li, Liyuan
   Wang, Pan
   Akaike, Toshihiro
   Wang, Zhao
TI Pinctada fucata mantle gene 4 (PFMG4) from pearl oyster mantle
   enhances osteoblast differentiation
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE MC3T3 E1; Pinctada fucata; Pinctada fucata mantle gene 4 (PFMG4);
   biomineralization
ID BIOMECHANICAL PROPERTIES; NONENZYMATIC GLYCATION; IN VITRO; BONE;
   PROLIFERATION; EXPRESSION; PHENOTYPE
AB The organic matrix of nacre has been reported for its effect on osteogenesis. It was found that PFMG4 (Pinctada fucata mantle gene 4) with an N terminal signal peptide could be secreted into nacre of Pinctada fucata (P. fucata). Here, we report that PFMG4 is highly expressed in mantle tissue and has high homology with C1q protein in different species. In MC3T3 E1 osteoblast cells, we found that highly expressed PFMG4 could suppress cell proliferation and type I collagen expression, but it could increase alkaline phosphatase activity and mineralized deposition. These results show that PFMG4 has potential ability in enhancing osteoblast differentiation, suggesting a new idea in developing medicine for the therapy of osteoporosis.
C1 [Wang, Xiaoyan; Harimoto, Kenichi; Fuji, Ryosuke; Liu, Jing; Li, Liyuan; Wang, Pan; Wang, Zhao] Tsinghua Univ, Sch Med, Minist Educ, Prot Sci Key Lab, Beijing 100084, Peoples R China.
   [Wang, Xiaoyan] Natl Univ Def Technol, Sch Sci, Dept Chem & Biol, Changsha, Hunan, Peoples R China.
   [Harimoto, Kenichi; Fuji, Ryosuke; Akaike, Toshihiro] Tokyo Inst Technol, Dept Biomol Engn, Sch Biosci & Biotechnol, Yokohama, Kanagawa 227, Japan.
C3 Tsinghua University; National University of Defense Technology   China;
   Institute of Science Tokyo; Tokyo Institute of Technology
RP Wang, Z (通讯作者)，Tsinghua Univ, Sch Med, Minist Educ, Prot Sci Key Lab, Beijing 100084, Peoples R China.
EM zwang@tsinghua.edu.cn
RI liyuan, li/JQX 0247 2023; Liu, Jing/G 4712 2017
FU National Basic Research Program (973 Project) of China [2007CB507406];
   Tsinghua Yue Yuen Medical Sciences Fund [THYY20070008]; National
   University of Defense Technology Yu Yan Fund [JC12 02 14]
FX This work was financially supported by the National Basic Research
   Program (973 Project) of China [grant number 2007CB507406], the
   Tsinghua Yue Yuen Medical Sciences Fund [grant number THYY20070008], and
   National University of Defense Technology Yu Yan Fund [grant number
   JC12 02 14].
CR Atlan G, 1999, BIOMATERIALS, V20, P1017, DOI 10.1016/S0142 9612(98)90212 5
   Bank RA, 1998, BIOCHEM J, V330, P345, DOI 10.1042/bj3300345
   Bradke BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103199
   Choi EM, 2012, EXP TOXICOL PATHOL, V64, P211, DOI 10.1016/j.etp.2010.08.008
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025
   GUNDBERG CM, 1986, J BIOL CHEM, V261, P4557
   Innamorati G, 2006, CELL SIGNAL, V18, P761, DOI 10.1016/j.cellsig.2005.11.004
   Kröger N, 2009, SCIENCE, V325, P1351, DOI 10.1126/science.1177055
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   Liu HL, 2007, BIOCHEMISTRY US, V46, P844, DOI 10.1021/bi061881a
   Miyamoto H, 1996, P NATL ACAD SCI USA, V93, P9657, DOI 10.1073/pnas.93.18.9657
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85
   Roumenina LT, 2005, BIOCHEMISTRY US, V44, P14097, DOI 10.1021/bi051186n
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sudo S, 1997, NATURE, V387, P563, DOI 10.1038/42391
   van Leeuwen JPTM, 2001, CRIT REV EUKAR GENE, V11, P199, DOI 10.1615/CritRevEukarGeneExpr.v11.i1 3.100
   Vashishth D, 2001, BONE, V28, P195, DOI 10.1016/S8756 3282(00)00434 8
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang ML, 2002, J ORTHOP RES, V20, P1175, DOI 10.1016/S0736 0266(02)00076 1
   Wang XY, 2011, J BONE MINER RES, V26, P1964, DOI 10.1002/jbmr.394
   Wang XY, 2011, BIOSCI BIOTECH BIOCH, V75, P991, DOI 10.1271/bbb.100821
   Wang XY, 2011, COMP BIOCHEM PHYS B, V158, P173, DOI 10.1016/j.cbpb.2010.11.004
   Wang XY, 2010, BIOL PHARM BULL, V33, P1891, DOI 10.1248/bpb.33.1891
   ZHENG MH, 1992, PATHOL RES PRACT, V188, P1104, DOI 10.1016/S0344 0338(11)81263 X
   Zhou YJ, 2010, COMP BIOCHEM PHYS B, V156, P158, DOI 10.1016/j.cbpb.2010.02.012
NR 27
TC 16
Z9 17
U1 0
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916 8451
EI 1347 6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD APR 3
PY 2015
VL 79
IS 4
BP 558
EP 565
DI 10.1080/09168451.2014.987206
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry; Food Science & Technology
GA CG7JK
UT WOS:000353479000005
PM 25485793
OA Bronze
DA 2025 08 17
ER

PT J
AU Yang, LY
   Liu, SY
   Mu, S
   Man, XJ
   Ba, G
   Guo, R
   Li, Y
   Zhou, L
   Yang, LQ
   Fu, Q
AF Yang, Liyu
   Liu, Shengye
   Mu, Shuai
   Man, Xiangji
   Ba, Gen
   Guo, Ran
   Li, Yan
   Zhou, Long
   Yang, Liqing
   Fu, Qin
TI Leonurine hydrochloride promotes osteogenic differentiation and
   increases osteoblastic bone formation in ovariectomized mice by
   Wnt/β catenin pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoporosis; Osteoblasts; Differentiation; Wnt/beta catenin pathway
ID INDUCED INCOMPLETE ABORTION; POSTMENOPAUSAL WOMEN; SIGNALING PATHWAY;
   CELLS; EXPRESSION; PREVENTION; RESORPTION; FRACTURES; THERAPY; OSTERIX
AB Leonurine hydrochloride (LH) is a synthetic chemical compound derived from leonurine that can be extracted from Leonurus sibiricus and possesses antioxidant, anti apoptosis, and neuroprotective activities. In previous studies, LH has been demonstrated to attenuate osteoclast activity and prevent bone loss. However, it is unknown whether LH accelerates bone formation and promotes osteogenic differentiation. We systematically examined the effects of LH on ovariectomized induced osteoporotic mice and the MC3T3 E1 osteoblastic cell line. The results revealed that LH enhanced differentiation of MC3T3 E1 cells, with a dose dependent increase in alkaline phosphatase (ALP) activity. Moreover, LH upregulated osteogenesis related gene expression, including osterix, alpha 1 type 1 collagen, runt related transcription factor 2 (Runx2) and ALP, as shown by quantitative reverse transcription polymerase chain reaction analysis. At the same time, elevated expression of low density lipoprotein receptor related protein 5 and beta catenin mRNA was detected in the Wnt/beta catenin pathway. A western blot analysis revealed that LH dose dependently increased the expression of Runx2 and beta catenin, and promoted phosphorylation of glycogen synthase kinase 3 beta in vitro. The in vivo results showed that administering LH (15 mg/kg/d) for 8 weeks alleviated destruction of the trabecular microstructure caused by osteoporosis. LH increased the bone mineral density and trabecular number, decreased trabecular separation according to a micro computed tomography scan. In addition, LH enhanced the expression of beta catenin and Runx2 in vivo. In conclusion, LH promoted osteogenic differentiation and bone formation in vivo and in vitro, which alleviated osteoporosis through activation of the Wnt/beta catenin pathway. (C) 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY NC ND license.
C1 [Yang, Liyu; Liu, Shengye; Mu, Shuai; Man, Xiangji; Ba, Gen; Guo, Ran; Li, Yan; Zhou, Long; Yang, Liqing; Fu, Qin] China Med Univ, Dept Orthopaed, Shengjing Hosp, Sanhao St 36, Shenyang 110003, Liaoning, Peoples R China.
C3 China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Dept Orthopaed, Shengjing Hosp, Sanhao St 36, Shenyang 110003, Liaoning, Peoples R China.
EM fuqincmu@126.com
RI Liu, Shengye/HKE 2627 2023; 杨, 立宇/GZM 5725 2022
FU Outstanding Scientific Fund of Shengjing Hospital [MD31]; Science
   Foundation of new teachers of China Medical University [G116]
FX This study was supported by Grants from the Outstanding Scientific Fund
   of Shengjing Hospital (MD31) and Science Foundation of new teachers of
   China Medical University(G116).
CR Bandeira L, 2017, EXPERT OPIN BIOL TH, V17, P255, DOI 10.1080/14712598.2017.1280455
   Chen JJ, 2013, FOOD CHEM TOXICOL, V62, P499, DOI 10.1016/j.fct.2013.09.019
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Einhorn TA, 2014, J ORTHOP TRAUMA, V28, P433, DOI 10.1097/BOT.0000000000000023
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hohenhaus MH, 2007, DRUGS, V67, P2311, DOI 10.2165/00003495 200767160 00002
   Hopkins RB, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 209
   HU S Y, 1976, American Journal of Chinese Medicine, V4, P219, DOI 10.1142/S0192415X76000305
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   KONG Y C, 1976, American Journal of Chinese Medicine, V4, P373, DOI 10.1142/S0192415X76000470
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Levine JP, 2007, GERIATRICS US, V62, P22
   Li HF, 2015, DRUG DES DEV THER, V9, P5169, DOI 10.2147/DDDT.S81578
   Li X, 2013, EUR J OBSTET GYN R B, V169, P299, DOI 10.1016/j.ejogrb.2013.02.022
   Li X, 2011, EUR J OBSTET GYN R B, V159, P375, DOI 10.1016/j.ejogrb.2011.09.006
   LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501
   Liu HC, 2012, BRAIN RES, V1474, P73, DOI 10.1016/j.brainres.2012.07.028
   Liu XH, 2010, EUR J PHARMACOL, V649, P236, DOI 10.1016/j.ejphar.2010.08.056
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loh KP, 2010, STROKE, V41, P2661, DOI 10.1161/STROKEAHA.110.589895
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Migliorati CA, 2009, REV RECENT CLIN TRIA, V4, P99, DOI 10.2174/157488709788185978
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Orija IB, 2003, CLIN ENDOCRINOL, V59, P657, DOI 10.1046/j.1365 2265.2003.01833.x
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Qi J, 2010, BIOL PHARM BULL, V33, P1958, DOI 10.1248/bpb.33.1958
   Qu LP, 2017, EUR REV MED PHARMACO, V21, P1234
   Satpathy Swaha, 2015, J Complement Integr Med, V12, P251, DOI 10.1515/jcim 2015 0034
   Serigano K, 2010, J ORTHOP RES, V28, P1267, DOI 10.1002/jor.21147
   Sun TH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171281
   Takahashi Yanaga F, 2009, J PHARMACOL SCI, V109, P179, DOI 10.1254/jphs.08R28FM
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Xu LJ, 2018, CALCIFIED TISSUE INT, V103, P400, DOI 10.1007/s00223 018 0428 y
   Ying XZ, 2013, EUR J PHARMACOL, V721, P225, DOI 10.1016/j.ejphar.2013.09.031
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zha X, 2016, J NAT MED TOKYO, V70, P634, DOI 10.1007/s11418 016 0993 1
   Zhang LL, 2015, MENOPAUSE, V22, P1021, DOI 10.1097/GME.0000000000000466
   Zhang W, 2012, CURR OSTEOPOROS REP, V10, P93, DOI 10.1007/s11914 011 0086 8
NR 40
TC 16
Z9 19
U1 1
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 12
PY 2018
VL 504
IS 4
BP 941
EP 948
DI 10.1016/j.bbrc.2018.09.008
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GX4EU
UT WOS:000447681200049
PM 30224063
OA hybrid
DA 2025 08 17
ER

PT J
AU Gemoll, T
   Epping, F
   Heinrich, L
   Fritzsche, B
   Roblick, UJ
   Szymczak, S
   Hartwig, S
   Depping, R
   Bruch, HP
   Thorns, C
   Lehr, S
   Paech, A
   Habermann, JK
AF Gemoll, Timo
   Epping, Franziska
   Heinrich, Lisa
   Fritzsche, Britta
   Roblick, Uwe J.
   Szymczak, Silke
   Hartwig, Sonja
   Depping, Reinhard
   Bruch, Hans Peter
   Thorns, Christoph
   Lehr, Stefan
   Paech, Andreas
   Habermann, Jens K.
TI Increased cathepsin D protein expression is a biomarker for
   osteosarcomas, pulmonary metastases and other bone malignancies
SO ONCOTARGET
LA English
DT Article
DE osteosarcoma; bone malignancies; two dimensional gel electrophoresis;
   CTSD; mass spectrometry
ID COMPARATIVE PROTEOMIC ANALYSIS; CELL CYCLE PROGRESSION;
   PROGNOSTIC FACTORS; OSTEOBLASTIC CELL; CANCER; SURVIVAL; TUMOR;
   OVEREXPRESSION; CENTROSOME; MECHANISMS
AB Cancer proteomics provide a powerful approach to identify biomarkers for personalized medicine. Particularly, biomarkers for early detection, prognosis and therapeutic intervention of bone cancers, especially osteosarcomas, are missing. Initially, we compared two dimensional gel electrophoresis (2 DE) based protein expression pattern between cell lines of fetal osteoblasts, osteosarcoma and pulmonary metastasis derived from osteosarcoma. Two independent statistical analyses by means of PDQuest (R) and SameSpot (R) software revealed a common set of 34 differentially expressed protein spots (p < 0.05). 17 Proteins were identified by mass spectrometry and subjected to Ingenuity Pathway Analysis resulting in one high ranked network associated with Gene Expression, Cell Death and Cell To Cell Signaling and Interaction. Ran/TC4 binding protein (RANBP1) and Cathepsin D (CTSD) were further validated by Western Blot in cell lines while the latter one showed higher expression differences also in cytospins and in clinical samples using tissue microarrays comprising osteosarcomas, metastases, other bone malignancies, and control tissues. The results show that protein expression patterns distinguish fetal osteoblasts from osteosarcomas, pulmonary metastases, and other bone diseases with relevant sensitivities between 55.56% and 100% at >= 87.50% specificity. Particularly, CTSD was validated in clinical material and could thus serve as a new biomarker for bone malignancies and potentially guide individualized treatment regimes.
C1 [Gemoll, Timo; Epping, Franziska; Heinrich, Lisa; Fritzsche, Britta; Roblick, Uwe J.; Bruch, Hans Peter; Habermann, Jens K.] Med Univ Lubeck, Sect Translat Surg Oncol & Biobanking, Dept Surg, D 23538 Lubeck, Germany.
   [Gemoll, Timo; Epping, Franziska; Heinrich, Lisa; Fritzsche, Britta; Roblick, Uwe J.; Bruch, Hans Peter; Habermann, Jens K.] Univ Med Ctr Schleswig Holstein, Lubeck, Germany.
   [Szymczak, Silke] Univ Med Ctr Schleswig Holstein, Inst Med Informat & Stat, Kiel, Germany.
   [Hartwig, Sonja; Lehr, Stefan] German Diabet Ctr DZD, Inst Clin Biochem & Pathobiochem, Dusseldorf, Germany.
   [Depping, Reinhard] Med Univ Lubeck, Inst Physiol, D 23538 Lubeck, Germany.
   [Thorns, Christoph] Univ Med Ctr Schleswig Holstein, Inst Pathol, Lubeck, Germany.
   [Paech, Andreas] Univ Med Ctr Schleswig Holstein, Dept Orthopaed & Traumatol, Lubeck, Germany.
C3 University of Lubeck; University of Kiel; Schleswig Holstein University
   Hospital; University of Kiel; Schleswig Holstein University Hospital;
   German Center for Diabetes Research (DZD); Leibniz Association;
   Deutsches Diabetes Zentrum (DDZ); University of Lubeck; University of
   Kiel; Schleswig Holstein University Hospital; University of Kiel;
   Schleswig Holstein University Hospital
RP Habermann, JK (通讯作者)，Med Univ Lubeck, Sect Translat Surg Oncol & Biobanking, Dept Surg, D 23538 Lubeck, Germany.
EM Jens.Habermann@chirurgie.uni luebeck.de
RI Habermann, Jens/E 2968 2010; Bruch, Hans Peter/E 7731 2010; Szymczak,
   Silke/C 6625 2013; Roblick, Uwe/F 5906 2011; Depping,
   Reinhard/B 6880 2018; Gemoll, Timo/P 6547 2019
OI Fritzsche, Britta/0000 0002 2783 1512; Depping,
   Reinhard/0000 0002 4860 6058; Szymczak, Silke/0000 0002 8897 9035;
   Habermann, Jens K./0000 0002 3127 4755; 
FU Werner and Clara Kreitz Foundation; Ad Infinitum Foundation; German
   Cancer Aid Foundation [108446]
FX Grants from the Werner and Clara Kreitz Foundation and the Ad Infinitum
   Foundation are gratefully acknowledged. This study was performed in
   connection with the Surgical Center for Translational Oncology Lubeck
   (SCTO L) and the North German Tumorbank of Colorectal Cancer (ColoNet),
   the latter being generously supported by the German Cancer Aid
   Foundation (DKH e.V. # 108446).
CR Alaiya AA, 2002, INT J CANCER, V98, P895, DOI 10.1002/ijc.10288
   Battistoni A, 1997, J CELL SCI, V110, P2345
   Bhattacharyya S, 2007, EXPERT REV PROTEOMIC, V4, P371, DOI 10.1586/14789450.4.3.371
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757
   Byrum S, 2010, ANN NY ACAD SCI, V1192, P222, DOI 10.1111/j.1749 6632.2009.05220.x
   Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559
   Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624
   Folio C, 2011, CANCER BIOMARK, V10, P35, DOI 10.3233/CBM 2012 0227
   Folio C, 2009, J PROTEOME RES, V8, P3882, DOI 10.1021/pr900113w
   Fuchs B, 2007, GENE, V399, P137, DOI 10.1016/j.gene.2007.05.003
   GARCIA M, 1990, ONCOGENE, V5, P1809
   Gemoll T, 2012, CELL MOL LIFE SCI, V69, P325, DOI 10.1007/s00018 011 0752 0
   Gemoll T, 2011, CELL MOL LIFE SCI, V68, P3261, DOI 10.1007/s00018 011 0628 3
   Guo QC, 2007, ACTA PHARMACOL SIN, V28, P850, DOI 10.1111/j.1745 7254.2007.00603.x
   Hawkins DS, 2003, CANCER AM CANCER SOC, V98, P2447, DOI 10.1002/cncr.11799
   Hellman U, 2000, EXS, V88, P43
   Husmann K, 2008, MOL CARCINOGEN, V47, P66, DOI 10.1002/mc.20362
   Kirana Chandra, 2012, Int J Proteomics, V2012, P245819, DOI 10.1155/2012/245819
   Letson G D, 2001, Cancer Control, V8, P239
   Li Y, 2010, CANCER GENET CYTOGEN, V198, P97, DOI 10.1016/j.cancergencyto.2010.01.003
   Liaudet Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007
   Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313
   Liu XD, 2009, CANCER INVEST, V27, P345, DOI 10.1080/07357900802438577
   Maire G, 2011, CANCER GENET NY, V204, P138, DOI 10.1016/j.cancergen.2010.12.012
   Maynadier M, 2013, INT J ONCOL, V43, P1683, DOI 10.3892/ijo.2013.2095
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Murphey MD, 1997, RADIOGRAPHICS, V17, P1205, DOI 10.1148/radiographics.17.5.9308111
   Pantel K, 2001, SEMIN CANCER BIOL, V11, P327, DOI 10.1006/scbi.2001.0388
   Pruitt FL, 2013, PROSTATE, V73, P476, DOI 10.1002/pros.22589
   Ragland BD, 2002, LAB INVEST, V82, P365, DOI 10.1038/labinvest.3780431
   REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216
   Rensen WM, 2009, ONCOGENE, V28, P1748, DOI 10.1038/onc.2009.24
   Saenger Y, 2014, CLIN CANC RES OFFICI
   Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214
   Spreafico A, 2006, PROTEOMICS, V6, P3520, DOI 10.1002/pmic.200500858
   Stiller CA, 2001, EUR J CANCER, V37, P760, DOI 10.1016/S0959 8049(01)00004 1
   ZEILLINGER R, 1992, EUR J CANCER, V28A, P1413, DOI 10.1016/0959 8049(92)90533 8
NR 38
TC 34
Z9 37
U1 3
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 30
PY 2015
VL 6
IS 18
BP 16517
EP 16526
DI 10.18632/oncotarget.4140
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CO2UL
UT WOS:000359012000077
PM 26203049
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Lee, A
   Yang, H
   Kim, T
   Ha, H
   Hwang, YH
AF Lee, Ami
   Yang, Hyun
   Kim, Taesoo
   Ha, Hyunil
   Hwang, Youn Hwan
TI Identification and pharmacokinetics of bioavailable anti resorptive
   phytochemicals after oral administration of Psoralea
   corylifolia L.
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Psoralea corylifolia L; Osteoporosis; Mass spectrometry;
   Pharmacokinetics; Osteoclast; Cathepsin K
ID LIQUID CHROMATOGRAPHY; COMPONENTS; EXTRACT; CONSTITUENTS; OSTEOPOROSIS;
   FLAVONOIDS; DISCOVERY; MEDICINES; PLASMA; AGENTS
AB Osteoporosis and resulting bone fractures are the major health issues associated with morbidity in the aging population; however, there is no effective treatment that does not cause severe side effects. In East Asia, dried seeds of Psoralea corylifolia L. (PC) have traditionally been used as an herbal medicine to manage urinary tract, cutaneous, and gastrointestinal disorders, as well as bone health. However, the mechanism of action and active biocomponents of PC are unclear. Here, we adopted a pharmacokinetic (PK) study aiming to identify the bioavailable phytochemicals in aqueous and ethanolic extracts of PC (APC) and (EPC), respectively. In addition, we aimed to determine anti resorptive constituents of PC, which accounted for its beneficial effects on bone health. To this end, we used ultra performance liquid chromatography tandem mass spectrometry (UPLC MS/ MS). A rapid, sensitive, and reliable UPLC MS/MS method was developed and determined the 17 PC ingredients. In the PK study, nine components (two chalcones, two coumarins, one coumestan, two flavonoids, and two isoflavonoids) were observed between 36 and 48 h after oral administration of APC or EPC. Among the bioavailable ingredients, four PC constituents (psoralidin, isobavachin, corylifol A, and neobavaisoflavone) inhibited M CSF and RANKL induced osteoclast differentiation in bone marrow derived macrophages. In addition, two chalcones and two isoflavonoids markedly inhibited cathepsin K activity, and their binding modes to cathepsin K were determined by molecular docking. In summary, our data suggest that bioavailable multi components of PC could contribute to the management of bone health.
C1 [Lee, Ami; Yang, Hyun; Kim, Taesoo; Ha, Hyunil; Hwang, Youn Hwan] Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.
   [Lee, Ami; Hwang, Youn Hwan] Univ Sci & Technol UST, Korean Convergence Med Major KIOM, Daejeon 34054, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); University of Science &
   Technology (UST)
RP Ha, H; Hwang, YH (通讯作者)，Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.
EM hyunil74@kiom.re.kr; hyhhwang@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
FU Korea Institute of Oriental Medicine, Ministry of Science and ICT, the
   Repubic of Korea [KSN2013330]
FX This work was supported by the Korea Institute of Oriental Medicine,
   Ministry of Science and ICT, the Repubic of Korea (Grant number
   KSN2013330) .
CR Abubakar AR, 2020, J PHARM BIOALLIED SC, V12, P1, DOI 10.4103/jpbs.JPBS_175_19
   [Anonymous], 1995, J MOD STOMATOL
   Aungst BJ, 2017, J PHARM SCI US, V106, P921, DOI 10.1016/j.xphs.2016.12.002
   Chen HW, 2020, J CELL MOL MED, V24, P9067, DOI 10.1111/jcmm.15543
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen Y, 2010, MOLECULES, V15, P8478, DOI 10.3390/molecules15118478
   Chopra B, 2013, FITOTERAPIA, V90, P44, DOI 10.1016/j.fitote.2013.06.016
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978 1 4939 2269 7_19
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gao QQ, 2016, J CHROMATOGR B, V1011, P128, DOI 10.1016/j.jchromb.2015.12.044
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Hwang YH, 2019, PLANTA MED, V85, P1128, DOI 10.1055/a 0989 2585
   Hwang YH, 2018, MOLECULES, V23, DOI 10.3390/molecules23071598
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Kaza M, 2019, J PHARMACEUT BIOMED, V165, P381, DOI 10.1016/j.jpba.2018.12.030
   Koul B, 2019, J ETHNOPHARMACOL, V232, P201, DOI 10.1016/j.jep.2018.11.036
   Li A, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2493 9
   Li Y, 2020, XENOBIOTICA, V50, P997, DOI 10.1080/00498254.2020.1732496
   Lim SH, 2009, BRIT J NUTR, V101, P1031, DOI 10.1017/S0007114508066750
   Lu J, 2018, J ENZYM INHIB MED CH, V33, P890, DOI 10.1080/14756366.2018.1465417
   Nam SW, 2005, CLIN TOXICOL, V43, P589, DOI 10.1081/CLT 200068863
   Panwar P, 2018, BRIT J PHARMACOL, V175, P902, DOI 10.1111/bph.14133
   Qiu ZC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122116
   Sanchez CP, 2008, MOL MICROBIOL, V67, P1081, DOI 10.1111/j.1365 2958.2008.06108.x
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Shi PY, 2018, DRUG METAB REV, V50, P161, DOI 10.1080/03602532.2017.1417424
   Song L, 2019, BASIC CLIN PHARMACOL, V125, P527, DOI 10.1111/bcpt.13287
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun S, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/1983780
   Tang L, 2012, J AGR FOOD CHEM, V60, P3223, DOI 10.1021/jf201987k
   Tang XY, 2020, J PHARMACEUT BIOMED, V177, DOI 10.1016/j.jpba.2019.112836
   Tsai MH, 2007, AM J CHINESE MED, V35, P669, DOI 10.1142/S0192415X07005168
   U.S.F.a.D. Administration, 2018, BIOAN METH VAL
   Xie YA, 2010, J ETHNOPHARMACOL, V131, P290, DOI 10.1016/j.jep.2010.06.038
   Xing H, 2020, J PHARM PHARMACOL, V72, P1865, DOI 10.1111/jphp.13337
   Xu MJ, 2012, RAPID COMMUN MASS SP, V26, P2343, DOI 10.1002/rcm.6361
   Yan R, 2018, CHIN MED UK, V13, DOI 10.1186/s13020 018 0183 z
   Yang YF, 2018, PHYTOMEDICINE, V38, P166, DOI 10.1016/j.phymed.2017.12.002
   Yao ZH, 2017, J CHROMATOGR B, V1041, P104, DOI 10.1016/j.jchromb.2016.12.026
   Zeng X, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00034
   Zhai YK, 2017, EUR J PHARMACOL, V801, P62, DOI 10.1016/j.ejphar.2017.03.001
   Zhang GB, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/621423
   Zhang JW, 2012, CURR DRUG METAB, V13, P558, DOI 10.2174/1389200211209050558
   Zhang KM, 2017, RSC ADV, V7, P28876, DOI 10.1039/c7ra02369c
   Zhang WJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00743
   Zhang XN, 2016, AM J CHINESE MED, V44, P35, DOI 10.1142/S0192415X16500038
   Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007
   Zhou ZX, 2020, J SEP SCI, V43, P2804, DOI 10.1002/jssc.202000286
NR 51
TC 16
Z9 19
U1 2
U2 16
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2021
VL 144
AR 112300
DI 10.1016/j.biopha.2021.112300
EA OCT 2021
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA WO7JS
UT WOS:000712626700005
PM 34653758
OA gold
DA 2025 08 17
ER

PT J
AU Bhagavatham, SKS
   Pulukool, SK
   Pradhan, SS
   Saiswaroop, R
   Naik, AA
   Darshan, VMD
   Sivaramakrishnan, V
AF Bhagavatham, Sai Krishna Srimadh
   Pulukool, Sujith Kumar
   Pradhan, Sai Sanwid
   Saiswaroop, R.
   Naik, Ashwin Ashok
   Darshan, Datta V. M.
   Sivaramakrishnan, Venketesh
TI Systems biology approach delineates critical pathways associated with
   disease progression in rheumatoid arthritis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE Rheumatoid arthritis; systems analysis; disease biology; biomarkers;
   therapeutics
ID SINGLE NUCLEOTIDE POLYMORPHISMS; TRANSCRIPTION FACTOR EGR 1; ANDROGEN
   RECEPTOR; PPAR BETA/DELTA; INFLAMMATORY ARTHRITIS; SYNOVIAL FIBROBLASTS;
   OXIDATIVE STRESS; CYTOKINE LEVELS; CRITICAL ROLES; I INTERFERON
AB Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease leading to inflammation, cartilage cell death, synoviocyte proliferation, and increased and impaired differentiation of osteoclasts and osteoblasts leading to joint erosions and deformities. Transcriptomics, proteomics, and metabolomics datasets were analyzed to identify the critical pathways that drive the RA pathophysiology. Single nucleotide polymorphisms (SNPs) associated with RA were analyzed for the functional implications, clinical outcomes, and blood parameters later validated by literature. SNPs associated with RA were grouped into pathways that drive the immune response and cytokine production. Further gene set enrichment analysis (GSEA) was performed on gene expression omnibus (GEO) data sets of peripheral blood mononuclear cells (PBMCs), synovial macrophages, and synovial biopsies from RA patients showed enrichment of Th1, Th2, Th17 differentiation, viral and bacterial infections, metabolic signalling and immunological pathways with potential implications for RA. The proteomics data analysis presented pathways with genes involved in immunological signaling and metabolic pathways, including vitamin B12 and folate metabolism. Metabolomics datasets analysis showed significant pathways like amino acyl tRNA biosynthesis, metabolism of amino acids (arginine, alanine aspartate, glutamate, glutamine, phenylalanine, and tryptophan), and nucleotide metabolism. Furthermore, our commonality analysis of multi omics datasets identified common pathways with potential implications for joint remodeling in RA. Disease modifying anti rheumatic drugs (DMARDs) and biologics treatments were found to modulate many of the pathways that were deregulated in RA. Overall, our analysis identified molecular signatures associated with the observed symptoms, joint erosions, potential biomarkers, and therapeutic targets in RA. Communicated by Ramaswamy H. Sarma
C1 [Bhagavatham, Sai Krishna Srimadh; Pulukool, Sujith Kumar; Pradhan, Sai Sanwid; Saiswaroop, R.; Naik, Ashwin Ashok; Darshan, Datta V. M.; Sivaramakrishnan, Venketesh] Sri Sathya Sai Inst Higher Learning, Dept Biosci, Dis Biol Lab, Anantapur 515134, Andhra Pradesh, India.
C3 Sri Sathya Sai Institute of Higher Learning
RP Bhagavatham, SKS; Sivaramakrishnan, V (通讯作者)，Sri Sathya Sai Inst Higher Learning, Dept Biosci, Dis Biol Lab, Anantapur 515134, Andhra Pradesh, India.
EM saikrishna.srimadh@gmail.com; s.venketesh@gmail.com
RI swaroop, Sai/JRY 3552 2023; Srimadh Bhagavatham, Sai
   Krishna/E 6615 2012; Naik, Ashwin/KHZ 1078 2024; Sivaramakrishnan,
   Venketesh/J 2025 2012
OI Naik, Ashwin/0000 0002 3097 7336; , Saiswaroop
   Rajaratnam/0000 0001 7163 5263; V M, Datta Darshan/0000 0003 1324 7101;
   Srimadh Bhagavatham, Sai Krishna/0000 0003 2236 5847; Sivaramakrishnan,
   Venketesh/0000 0003 3094 5905; Pradhan, Sai Saniwd/0000 0002 5461 8047;
   Pulukool, Sujith kumar/0000 0003 4098 6233
FU administration of Sri Sathya Sai Institute of Higher Learning (SSSIHL);
   Department of Biosciences, SSSIHL, Prasanthi Nilayam, Anantapur, India;
   University Grants Commission, Basic Scientific Research, New Delhi,
   India [F.4 1/2006 (BSR)/7 164/2007 (BSR)]; Council of Scientific and
   Industrial Research, New Delhi, India [CSIR UGC NET2121530422];
   Department of Biotechnology (DBT) Project, New Delhi, India
   [BT/PR8226/BRB/10/1224/2013]; Department of Science and Technology
   (DST), New Delhi, India [EMR/2017/005381]; Department of Science and
   Technology (DST)  FIST, New Delhi, India [SR/FST/LSI 616/2014];
   Department of Biotechnology Bioinformatics (DBT BIF) Facility, New
   Delhi, India [BT/BI/25/063/2012]; University Grants Commission (UGC)
    special assistance program (SAP), New Delhi, India
   [F.3 19/2018/DRS III(SAP II)]
FX We thank the administration of Sri Sathya Sai Institute of Higher
   Learning (SSSIHL), for the and the Department of Biosciences, SSSIHL,
   Prasanthi Nilayam, Anantapur, India for infrastructure and financial
   support. We thank University Grants Commission, Basic Scientific
   Research, New Delhi, India (F.4 1/2006 (BSR)/7 164/2007 (BSR)) and
   Council of Scientific and Industrial Research, New Delhi, India
   (CSIR UGC NET2121530422) for the student fellowship. We also thank the
   funding agencies Department of Biotechnology (DBT) Project, New Delhi,
   India (BT/PR8226/BRB/10/1224/2013), Department of Science and Technology
   (DST), New Delhi, India (EMR/2017/005381), Department of Science and
   Technology (DST)  FIST, New Delhi, India (SR/FST/LSI 616/2014),
   Department of Biotechnology Bioinformatics (DBT BIF) Facility, New
   Delhi, India (BT/BI/25/063/2012), University Grants Commission (UGC)
    special assistance program (SAP), New Delhi, India (UGC SAP III:
   F.3 19/2018/DRS III(SAP II)) for financial and infrastructure support.
CR Abboud G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01973
   Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Afrasiabian S, 2013, J RES MED SCI, V18, P252
   Aicher WK, 1999, INT IMMUNOL, V11, P47, DOI 10.1093/intimm/11.1.47
   Al Saadany HM, 2016, EGYPT RHEUMATOL, V38, P1, DOI 10.1016/j.ejr.2015.01.001
   Alexander D, 2002, BIOL CHEM, V383, P1845, DOI 10.1515/BC.2002.208
   Almutairi K, 2021, RHEUMATOL INT, V41, P863, DOI 10.1007/s00296 020 04731 0
   Alunno A, 2017, BMC RHEUMATOL, V1, DOI 10.1186/s41927 017 0001 8
   Alyssa T., 2020, ACR CONVERGENCE, V2020, P72
   Anderson NM, 2018, PROTEIN CELL, V9, P216, DOI 10.1007/s13238 017 0451 1
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Bhagavatham SKS, 2022, MED HYPOTHESES, V159, DOI 10.1016/j.mehy.2021.110751
   Bhagavatham SKS, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 94607 5
   Biniecka M, 2016, ANN RHEUM DIS, V75, P2192, DOI 10.1136/annrheumdis 2015 208476
   Borgo C, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00567 7
   Brink M, 2013, ARTHRITIS RHEUM US, V65, P899, DOI 10.1002/art.37835
   Broeren MGA, 2016, HUM GENE THER, V27, P244, DOI 10.1089/hum.2015.127
   Brunner JS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14285 1
   Bustamante MF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1303 3
   Carlberg K, 2017, ANN RHEUM DIS, V76, pA58, DOI 10.1136/annrheumdis 2016 211052.16
   Casamassimi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081652
   Castro C, 2010, J ALLERGY CLIN IMMUN, V125, pS238, DOI 10.1016/j.jaci.2009.09.041
   Celardo I, 2014, ONCOTARGET, V5, P1279, DOI 10.18632/oncotarget.1778
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 128
   Chimenti MS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.246
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310
   Conde MB, 2002, RESP MED, V96, P607, DOI 10.1053/rmed.2001.1273
   Coras R, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040827
   Cutolo M, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2804
   D'Cruz LG, 2020, J PERS MED, V10, DOI 10.3390/jpm10040149
   De Baets G, 2012, NUCLEIC ACIDS RES, V40, pD935, DOI 10.1093/nar/gkr996
   de Jong TD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00902
   Decara J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00730
   Demoruelle MK, 2012, CURR RHEUMATOL REP, V14, P472, DOI 10.1007/s11926 012 0275 1
   Dong H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00024
   Edilova MI, 2021, BIOMED J, V44, P172, DOI 10.1016/j.bj.2020.06.010
   Fang QH, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3830212
   Fearon U, 2019, CLIN EXP IMMUNOL, V197, P170, DOI 10.1111/cei.13228
   Fillatreau S, 2018, CLIN IMMUNOL, V186, P26, DOI 10.1016/j.clim.2017.07.020
   Gan L, 2018, BIOMARK RES, V6, DOI 10.1186/s40364 018 0122 2
   Ghanem ENB, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005126
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Gu JX, 2013, INT J CLIN EXP PATHO, V6, P2872
   Guma M, 2015, ANN RHEUM DIS, V74, P1399, DOI 10.1136/annrheumdis 2014 205696
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043
   Havis E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051664
   He M, 2019, INT J RHEUM DIS, V22, P38, DOI 10.1111/1756 185X.13062
   Hernandez G, 2020, HAEMATOLOGICA, V105, P585, DOI 10.3324/haematol.2018.197210
   Hofmann MA, 2002, GENES IMMUN, V3, P123, DOI 10.1038/sj.gene.6363861
   Holecek M, 2018, NUTR METAB, V15, DOI 10.1186/s12986 018 0271 1
   Hua Lin, 2012, Genomics Proteomics & Bioinformatics, V10, P23, DOI 10.1016/S1672 0229(11)60030 2
   Huang L W, 2001, Kaohsiung J Med Sci, V17, P358
   Iebba Filippo, 2011, Recenti Prog Med, V102, P175, DOI 10.1701/624.7291
   Jimeno R, 2015, J MOL MED, V93, P457, DOI 10.1007/s00109 014 1232 4
   Jules J, 2018, BONE, V107, P104, DOI 10.1016/j.bone.2017.05.009
   Kang K, 2017, IMMUNITY, V47, P235, DOI 10.1016/j.immuni.2017.07.017
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Karsdal MA, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3280
   Kawaguchi Y, 2007, IMMUNOGENETICS, V59, P441, DOI 10.1007/s00251 007 0213 y
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Ketavarapu S, 2013, J CLIN DIAGN RES, V7, P613, DOI 10.7860/JCDR/2013/4761.2865
   Kim HS, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4048
   Kim S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097501
   Klimenta B., 2020, GENETICS APPL, V4, P30
   Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200
   Li J, 2018, CLIN RHEUMATOL, V37, P1493, DOI 10.1007/s10067 018 4021 6
   Li Mingxin, 2016, Mediators Inflamm, V2016, P9280529
   Littlewood Evans A, 2016, J EXP MED, V213, P1655, DOI 10.1084/jem.20160061
   Liu F, 2007, BONE, V40, P1135, DOI 10.1016/j.bone.2006.12.003
   Lorin J, 2014, MOL NUTR FOOD RES, V58, P101, DOI 10.1002/mnfr.201300033
   Lotfi N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01265
   Luz Crawford P, 2016, ANN RHEUM DIS, V75, P2166, DOI 10.1136/annrheumdis 2015 208696
   Madsen RK, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3243
   Manzoni C, 2018, BRIEF BIOINFORM, V19, P286, DOI 10.1093/bib/bbw114
   Mateen S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178879
   Mateen S, 2016, CLIN CHIM ACTA, V455, P161, DOI 10.1016/j.cca.2016.02.010
   McCormack WJ, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2729
   McHugh J, 2020, NAT REV RHEUMATOL, V16, P128, DOI 10.1038/s41584 020 0387 3
   Mertens M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005121.pub3
   Mohamad NV, 2019, AGING MALE, V22, P129, DOI 10.1080/13685538.2018.1482487
   Moller SH, 2022, CELL MOL IMMUNOL, V19, P370, DOI 10.1038/s41423 021 00753 1
   Moon YM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4089
   Moore BA, 2000, BBA MOL BASIS DIS, V1502, P307, DOI 10.1016/S0925 4439(00)00056 9
   Mousavi MJ, 2021, AUTOIMMUN HIGHLIGHTS, V12, DOI 10.1186/s13317 020 00145 x
   Mun S, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7490723
   Muskardin TLW, 2018, NAT REV RHEUMATOL, V14, P214, DOI 10.1038/nrrheum.2018.31
   Naik AA, 2022, MED HYPOTHESES, V161, DOI 10.1016/j.mehy.2022.110808
   Naik AA, 2021, GENE REP, V25, DOI 10.1016/j.genrep.2021.101383
   Naik AA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 75197 0
   Nakerakanti SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021911
   Narayanan A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10817 w
   Nevius E, 2016, CLIN REV ALLERG IMMU, V51, P59, DOI 10.1007/s12016 015 8520 9
   Niewold TB, 2007, QJM INT J MED, V100, P193, DOI 10.1093/qjmed/hcm015
   Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1546357, 10.1080/14397595.2018.1533514]
   Ohl K, 2018, PEDIATR RHEUMATOL, V16, DOI 10.1186/s12969 018 0253 x
   Okamoto H, 2011, J INFLAMM LOND, V8, DOI 10.1186/1476 9255 8 21
   Oscanoa J, 2020, NUCLEIC ACIDS RES, V48, pW185, DOI 10.1093/nar/gkaa420
   Osiri M, 2016, CLIN RHEUMATOL, V35, P1673, DOI 10.1007/s10067 016 3306 x
   Owen SA, 2013, PHARMACOGENOMICS J, V13, P227, DOI 10.1038/tpj.2012.7
   Ozaki M, 2001, RHEUMATOLOGY, V40, P592, DOI 10.1093/rheumatology/40.5.592
   Panfili E, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091280
   Parisi D, 2020, COMPUT STRUCT BIOTEC, V18, P1043, DOI 10.1016/j.csbj.2020.04.004
   Pawlik A, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1064 1
   Peeters JGC, 2015, CELL REP, V12, P1986, DOI 10.1016/j.celrep.2015.08.046
   Perl A, 2011, TRENDS MOL MED, V17, P395, DOI 10.1016/j.molmed.2011.01.014
   Price DK, 2010, J UROLOGY, V184, P2297, DOI 10.1016/j.juro.2010.08.005
   Pucino V, 2019, CELL METAB, V30, P1055, DOI 10.1016/j.cmet.2019.10.004
   Pulukool SK, 2022, CYTOKINE, V151, DOI 10.1016/j.cyto.2022.155807
   Pulukool SK, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 89137 z
   Ratneswaran A, 2017, J MOL MED, V95, P431, DOI 10.1007/s00109 016 1501 5
   Richard MLL, 2014, J IMMUNOL, V193, P2661, DOI 10.4049/jimmunol.1302779
   Rodríguez Carrio J, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02007
   Rodriguez Garcia S.C., 2021, FRONT MED LAUSANNE, V8, P745
   Rodríguez Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698
   Romano RA, 2012, J DENT RES, V91, P125, DOI 10.1177/0022034511411302
   Roy DG, 2020, CELL METAB, V31, P250, DOI 10.1016/j.cmet.2020.01.006
   Rupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00794
   Russell PK, 2012, J MOL ENDOCRINOL, V49, P1, DOI 10.1530/JME 12 0014
   Saad MN, 2016, J ADV RES, V7, P1, DOI 10.1016/j.jare.2015.01.008
   Saha R, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 98086 6
   Sato S, 2014, ARTHRITIS RHEUMATOL, V66, P3436, DOI 10.1002/art.38818
   Schoels M, 2011, J RHEUMATOL, V38, P20, DOI 10.3899/jrheum.101070
   Scholtysek C, 2013, NAT MED, V19, P608, DOI 10.1038/nm.3146
   Scott David L, 2010, Lancet, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Sellam J, 2014, ARTHRITIS RHEUMATOL, V66, P2015, DOI 10.1002/art.38671
   Shao P, 2017, MOL MED REP, V16, P5257, DOI 10.3892/mmr.2017.7285
   Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Su SK, 2016, J CELL SCI, V129, P2343, DOI 10.1242/jcs.185546
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Swaroop RS, 2023, J BIOMOL STRUCT DYN, V41, P5548, DOI 10.1080/07391102.2022.2090441
   Takahashi S, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1283 3
   Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501
   Taniguchi Y, 2017, ARTHRITIS RHEUMATOL, V69, P598, DOI 10.1002/art.39976
   Tasaki S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05044 4
   Tavasolian F, 2021, COMB CHEM HIGH T SCR, V24, P195, DOI 10.2174/1386207323666200605150024
   Teixeira VH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006803
   Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267
   Trenkmann M, 2011, ANN RHEUM DIS, V70, P1482, DOI 10.1136/ard.2010.143040
   Tsai PH, 2015, STEM CELLS DEV, V24, P2561, DOI 10.1089/scd.2015.0066
   Tsuchiya H, 2021, ANN RHEUM DIS, V80, P440, DOI 10.1136/annrheumdis 2020 218189
   Van Beek JP, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1890
   van Wietmarschen H, 2009, JCR J CLIN RHEUMATOL, V15, P330, DOI 10.1097/RHU.0b013e3181ba3926
   van Wietmarschen HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044331
   Vasanthi P., 2007, APLAR J RHEUMATOL, V10, P270, DOI DOI 10.1111/J.1479 8077.2007.00305.X
   Vasko R., 2016, J ARTHRITIS, V5, P1
   Vijayan V, 2014, BRIT J PHARMACOL, V171, P107, DOI 10.1111/bph.12434
   Wagner N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165723
   Wang B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579687
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wang S, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205 018 1311 2
   Wang YP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062061
   Wasserman AM, 2011, AM FAM PHYSICIAN, V84, P1245
   Whitaker JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124254
   Wilfahrt DN, 2019, J IMMUNOL, V202
   Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141
   Wu WJ, 2016, REDOX BIOL, V10, P157, DOI 10.1016/j.redox.2016.08.011
   Xing R, 2016, INT J MOL MED, V38, P1125, DOI 10.3892/ijmm.2016.2722
   Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006
   Yang MB, 2008, ENDOCRINE, V33, P245, DOI 10.1007/s12020 008 9092 8
   Yano F, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43948 3
   Yap HY, 2018, CELLS BASEL, V7, DOI 10.3390/cells7100161
   Yarilina A, 2008, NAT IMMUNOL, V9, P378, DOI 10.1038/ni1576
   Yoshida N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12993
   Yusti Gabriel, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6040101
   Zhang MZ, 2019, BIOINFORMATICS, V35, P1792, DOI 10.1093/bioinformatics/bty860
   Zhang RJ, 2014, DATABASE OXFORD, DOI 10.1093/database/bau090
   Zhang W, 2016, OSTEOARTHR CARTILAGE, V24, P827, DOI 10.1016/j.joca.2015.12.004
   Zhou J, 2016, J PHARMACEUT BIOMED, V127, P60, DOI 10.1016/j.jpba.2016.02.004
   Zhou YZ, 2019, ARTIF CELL NANOMED B, V47, P1766, DOI 10.1080/21691401.2019.1607362
NR 173
TC 12
Z9 12
U1 0
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739 1102
EI 1538 0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD SEP 22
PY 2023
VL 41
IS 14
BP 6969
EP 6990
DI 10.1080/07391102.2022.2115555
EA AUG 2022
PG 22
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA N0BY9
UT WOS:000848779500001
PM 36047508
DA 2025 08 17
ER

PT J
AU Roser Page, S
   Vikulina, T
   Zayzafoon, M
   Weitzmann, MN
AF Roser Page, Susanne
   Vikulina, Tatyana
   Zayzafoon, Majd
   Weitzmann, M. Neale
TI CTLA 4Ig Induced T Cell Anergy Promotes Wnt 10b Production and Bone
   Formation in a Mouse Model
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID SECRETED OSTEOCLASTOGENIC FACTOR; KAPPA B LIGAND; RHEUMATOID ARTHRITIS;
   ESTROGEN DEFICIENCY; PARATHYROID HORMONE; RECEPTOR ACTIVATOR; ANABOLIC
   ACTIVITY; IN VIVO; MICE; MASS
AB Objective. Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by severe joint erosion and systemic osteoporosis. Chronic T cell activation is a hallmark of RA, and agents that target the CD28 receptor on T cells, which is required for T cell activation, are being increasingly used as therapies for RA and other inflammatory diseases. Lymphocytes play complex roles in the regulation of the skeleton, and although activated T cells and B cells secrete cytokines that promote skeletal decline, under physiologic conditions lymphocytes also have key protective roles in the stabilization of skeletal mass. Consequently, disruption of T cell costimulation may have unforeseen consequences for physiologic bone turnover. This study was undertaken to investigate the impact of pharmacologic CD28 T cell costimulation blockade on physiologic bone turnover and structure.
   Methods. C57BL6 mice were treated with CTLA 4Ig, a pharmacologic CD28 antagonist or with irrelevant control antibody (Ig), and serum biochemical markers of bone turnover were quantified by enzyme linked immunosorbent assay. Bone mineral density and indices of bone structure were further measured by dual x ray absorptiometry and micro computed tomography, respectively, and static and dynamic indices of bone formation were quantified using bone histomorphometry.
   Results. Pharmacologic disruption of CD28 T cell costimulation in mice significantly increased bone mass and enhanced indices of bone structure, a consequence of enhanced bone formation, concurrent with enhanced secretion of the bone anabolic factor Wnt 10b by T cells.
   Conclusion. Inhibition of CD28 costimulation by CTLA 4Ig promotes T cell Wnt 10b production and bone formation and may represent a novel anabolic strategy for increasing bone mass in osteoporotic conditions.
C1 [Roser Page, Susanne; Weitzmann, M. Neale] Atlanta VAMC, Decatur, GA USA.
   [Vikulina, Tatyana; Weitzmann, M. Neale] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   [Zayzafoon, Majd] Univ Alabama Birmingham, Birmingham, AL USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Health Care System; Emory University; University of Alabama
   System; University of Alabama Birmingham
RP Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1305 WMB, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
FU VA Office of Research and Development, Biomedical Laboratory Research
   and Development Service [5I01BX000105]; NIH (National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [NIAMS] [AR 053607,
   AR 056090, AR 059364]; National Institute on Aging [AG 040013]; NIH
   (NIAMS) [P30 AR 46031]
FX Supported by the VA Office of Research and Development, Biomedical
   Laboratory Research and Development Service (grant 5I01BX000105). Dr.
   Weitzmann's work was supported in part by the NIH (National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [NIAMS] grants
   AR 053607, AR 056090, and AR 059364 and National Institute on Aging
   grant AG 040013). Histomorphometry was performed at the University of
   Alabama at Birmingham Center for Metabolic Bone Disease Histomorphometry
   and Molecular Analysis Core Laboratory, which is supported by the NIH
   (NIAMS grant P30 AR 46031).
CR Axmann R, 2008, ANN RHEUM DIS, V67, P1603, DOI 10.1136/ard.2007.080713
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bedi B, 2010, ANN NY ACAD SCI, V1192, P215, DOI 10.1111/j.1749 6632.2009.05216.x
   Bjorgo E, 2010, MOL CELL BIOL, V30, P1660, DOI 10.1128/MCB.00696 09
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Deodhar AA, 1996, BRIT J RHEUMATOL, V35, P309
   DEQUEKER J, 1995, CLIN EXP RHEUMATOL, V13, P21
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Fournier C, 2005, JOINT BONE SPINE, V72, P527, DOI 10.1016/j.jbspin.2004.12.012
   GOUGH AKS, 1994, ANN RHEUM DIS, V53, P14, DOI 10.1136/ard.53.1.14
   Grassi F, 2007, P NATL ACAD SCI USA, V104, P15087, DOI 10.1073/pnas.0703610104
   GYARMATI J, 1983, THYMUS, V5, P383
   Hardiman G, 1997, CYTOGENET CELL GENET, V77, P278, DOI 10.1159/000134597
   He XW, 2001, J RHEUMATOL, V28, P2168
   Ilowite NT, 2008, CURR OPIN RHEUMATOL, V20, P613, DOI 10.1097/BOR.0b013e3283060778
   Jarry CR, 2013, HUM IMMUNOL, V74, P861, DOI 10.1016/j.humimm.2013.04.013
   Kamphorst AO, 2010, J IMMUNOL, V185, P3426, DOI 10.4049/jimmunol.1001205
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Michelangeli F, 1975, Ann Anesthesiol Fr, V16, P429
   Najafian N, 2000, EXPERT OPIN INV DRUG, V9, P2147, DOI 10.1517/13543784.9.9.2147
   Ofotokun I, 2011, DISCOV MED, V11, P385
   Ofotokun I, 2010, CURR OPIN ENDOCRINOL, V17, P523, DOI 10.1097/MED.0b013e32833f48d6
   Ouji Y, 2006, BIOCHEM BIOPH RES CO, V342, P1063, DOI 10.1016/j.bbrc.2006.02.028
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rifas L, 2009, ARTHRITIS RHEUM US, V60, P3324, DOI 10.1002/art.24877
   Sayegh MH, 1999, J CLIN INVEST, V103, P1223, DOI 10.1172/JCI6952
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Vikulina T, 2010, P NATL ACAD SCI USA, V107, P13848, DOI 10.1073/pnas.1003020107
   Vital Edward M, 2006, Ther Clin Risk Manag, V2, P365, DOI 10.2147/tcrm.2006.2.4.365
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Yanaba K, 2007, J IMMUNOL, V179, P1369, DOI 10.4049/jimmunol.179.2.1369
   Yun TJ, 1998, J IMMUNOL, V161, P6113
   Zha YY, 2006, NAT IMMUNOL, V7, P1166, DOI 10.1038/ni1394
NR 40
TC 44
Z9 49
U1 0
U2 5
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD APR
PY 2014
VL 66
IS 4
BP 990
EP 999
DI 10.1002/art.38319
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AJ0QR
UT WOS:000337361000026
PM 24757150
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chen, R
   Wang, J
   Liu, CS
AF Chen, Rui
   Wang, Jing
   Liu, Changsheng
TI Biomaterials Act as Enhancers of Growth Factors in Bone Regeneration
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE biomaterials; bone regeneration; bone morphogenetic proteins; growth
   factors; scaffolds
ID MESENCHYMAL STEM CELLS; MORPHOGENIC PROTEIN 2 BMP 2;
   FACTOR DELIVERY SYSTEMS; SIZE DEFECT MODEL; IN VIVO; OSTEOBLAST
   DIFFERENTIATION; CALCIUM PHOSPHATE; DUAL DELIVERY; OSTEOGENIC
   DIFFERENTIATION; SIGNALING PATHWAYS
AB Inspired by the physiological events of the wound healing cascade, the integration of biomaterials and growth factors is generally accepted as an emerging and powerful strategy for bone regenerative therapy. As a type of biological mediator, growth factors play a key role in functional bone regeneration. In this review, recent progress in the enhancement of bone related growth factors via a biomaterial strategy will be discussed. Two main reinforcing mechanisms, temporal regulation and efficacy manipulation, are described in detail, highlighting the potential capability of biomaterials to harness the interactions between growth factors and specific cells. The effects of biomaterials for promoting bone formation via growth factor mediated osteogenesis are further elucidated. Finally, an outlook of the prospects in terms of superior communication among growth factors, cells, and biomaterials in the microenvironment is presented, which might provide new directions for the design of medical devices for bone regeneration.
C1 [Chen, Rui; Wang, Jing; Liu, Changsheng] East China Univ Sci & Technol, Key Lab Ultrafine Mat, Minist Educ, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
   [Chen, Rui; Wang, Jing; Liu, Changsheng] East China Univ Sci & Technol, Engn Res Ctr Biomed Mat, Minist Educ, Shanghai 200237, Peoples R China.
C3 East China University of Science & Technology; East China University of
   Science & Technology
RP Wang, J; Liu, CS (通讯作者)，East China Univ Sci & Technol, Key Lab Ultrafine Mat, Minist Educ, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.; Wang, J; Liu, CS (通讯作者)，East China Univ Sci & Technol, Engn Res Ctr Biomed Mat, Minist Educ, Shanghai 200237, Peoples R China.
EM biomatwj@163.com; liucs@ecust.edu.cn
RI Chen, Rui/D 4733 2017
FU National Natural Science Foundation of China [31330028, 31470923,
   31271011]; National Basic Research Program of China (973 Program)
   [2012CB933600]; Major Basic Research Foundation of Shanghai Science and
   Technique Committee [14JC1490800]; Shanghai International Incorporation
   Program [155207111000]; New Century Excellent Talents in University
   [NCET 12 0856]; 111 Project [B14018]
FX The authors are indebted to the financial support from the National
   Natural Science Foundation of China (No. 31330028, No. 31470923, and No.
   31271011), National Basic Research Program of China (973 Program, No.
   2012CB933600), Major Basic Research Foundation of Shanghai Science and
   Technique Committee (14JC1490800), and Shanghai International
   Incorporation Program (155207111000). This study is also supported by
   New Century Excellent Talents in University (No. NCET 12 0856) and 111
   Project (B14018).
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103
   Alzhavan O, 2013, CARBON, V59, P200, DOI 10.1016/j.carbon.2013.03.010
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   [Anonymous], 2013, BONEKEY REP
   Axelrad TW, 2008, J BONE JOINT SURG BR, V90B, P1617, DOI 10.1302/0301 620X.90B12.20975
   Balmayor ER, 2015, ADV DRUG DELIVER REV, V94, P13, DOI 10.1016/j.addr.2015.04.022
   Barhanpurkar AP, 2012, BIOCHEM BIOPH RES CO, V418, P669, DOI 10.1016/j.bbrc.2012.01.074
   Basha RY, 2015, MAT SCI ENG C MATER, V57, P452, DOI 10.1016/j.msec.2015.07.016
   Beachler DC, 2016, J BONE JOINT SURG AM, V98, P1064, DOI 10.2106/JBJS.15.01106
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Bessa PC, 2010, J CONTROL RELEASE, V142, P312, DOI 10.1016/j.jconrel.2009.11.003
   Billström GH, 2013, INJURY, V44, pS28, DOI 10.1016/S0020 1383(13)70007 X
   Blokhuis TJ, 2000, J TRAUMA, V48, P179, DOI 10.1097/00005373 200001000 00037
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003
   Brandi ML, 2006, J BONE MINER RES, V21, P183, DOI 10.1359/JBMR.050917
   Brydone AS, 2010, P I MECH ENG H, V224, P1329, DOI 10.1243/09544119JEIM770
   Budiraharjo R, 2013, J BIOMAT SCI POLYM E, V24, P645, DOI 10.1080/09205063.2012.703949
   Cai L, 2014, ACTA BIOMATER, V10, P1751, DOI 10.1016/j.actbio.2013.12.028
   Cao LY, 2014, BIOMATERIALS, V35, P684, DOI 10.1016/j.biomaterials.2013.10.005
   Caplan AI, 2011, J ORTHOP RES, V29, P1795, DOI 10.1002/jor.21462
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Carreira AC, 2014, J DENT RES, V93, P335, DOI 10.1177/0022034513518561
   Carter Percy H., 2006, Endocrine Metabolic & Immune Disorders Drug Targets, V6, P59
   Caverzasio J, 2013, J BONE MINER RES, V28, P260, DOI 10.1002/jbmr.1748
   Charles LF, 2015, EXP GERONTOL, V64, P62, DOI 10.1016/j.exger.2015.02.006
   Chen FM, 2016, PROG POLYM SCI, V53, P86, DOI 10.1016/j.progpolymsci.2015.02.004
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165 6147(00)01676 X
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Delloye C, 2007, J BONE JOINT SURG BR, V89B, P574, DOI 10.1302/0301 620X.89B5.19039
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   DiGiovanni CW, 2013, J BONE JOINT SURG AM, V95A, P1184, DOI 10.2106/JBJS.K.01422
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ding J, 2009, LIFE SCI, V84, P499, DOI 10.1016/j.lfs.2009.01.013
   Dolatshahi Pirouz A, 2010, ACS NANO, V4, P2874, DOI 10.1021/nn9017872
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   Fan VH, 2007, STEM CELLS, V25, P1241, DOI 10.1634/stemcells.2006 0320
   Fantauzzo KA, 2014, GENE DEV, V28, P1005, DOI 10.1101/gad.238709.114
   Farokhi M, 2016, J CONTROL RELEASE, V225, P152, DOI 10.1016/j.jconrel.2016.01.033
   Fernandez Yague MA, 2015, ADV DRUG DELIVER REV, V84, P1, DOI 10.1016/j.addr.2014.09.005
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Franz S, 2011, BIOMATERIALS, V32, P6692, DOI 10.1016/j.biomaterials.2011.05.078
   Gan Q, 2015, J MATER CHEM B, V3, P2056, DOI 10.1039/c4tb01897d
   García AJ, 2005, BIOMATERIALS, V26, P7525, DOI 10.1016/j.biomaterials.2005.05.029
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Geuze RE, 2012, TISSUE ENG PT A, V18, P2052, DOI [10.1089/ten.tea.2011.0560, 10.1089/ten.TEA.2011.0560]
   Girardi FP, 1999, J BONE JOINT SURG BR, V81B, P825, DOI 10.1302/0301 620X.81B5.9244
   Glass GE, 2011, P NATL ACAD SCI USA, V108, P1585, DOI 10.1073/pnas.1018501108
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Gothard D, 2014, EUR CELLS MATER, V28, P166, DOI 10.22203/eCM.v028a13
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Gunton JE, 2015, BONE, V80, P89, DOI 10.1016/j.bone.2015.02.029
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1817, DOI 10.1007/s10529 009 0099 x
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   He QF, 2011, ACTA BIOMATER, V7, P1084, DOI 10.1016/j.actbio.2010.10.022
   Hintze V, 2014, BIOMACROMOLECULES, V15, P3083, DOI 10.1021/bm5006855
   Ho CY, 2015, TISSUE ENG PT A, V21, P594, DOI [10.1089/ten.tea.2013.0762, 10.1089/ten.TEA.2013.0762]
   Hollinger JO, 2008, J BONE JOINT SURG AM, V90A, P48, DOI 10.2106/JBJS.G.01231
   Huang BL, 2016, SCI REP UK, V6, DOI 10.1038/srep24323
   Huang BL, 2015, ACTA BIOMATER, V27, P275, DOI 10.1016/j.actbio.2015.09.007
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Huang RL, 2015, BIOMATERIALS, V67, P308, DOI 10.1016/j.biomaterials.2015.07.047
   Jeon O, 2011, J CONTROL RELEASE, V154, P258, DOI 10.1016/j.jconrel.2011.06.027
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Johnson AJW, 2011, ACTA BIOMATER, V7, P16, DOI 10.1016/j.actbio.2010.07.012
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kim HD, 2002, J BIOMED MATER RES, V59, P573, DOI 10.1002/jbm.10011
   Kim MS, 2006, TISSUE ENG, V12, P2863, DOI 10.1089/ten.2006.12.2863
   Kim SE, 2014, CARBOHYD POLYM, V114, P123, DOI 10.1016/j.carbpol.2014.08.005
   Kim SE, 2011, BIOMATERIALS, V32, P366, DOI 10.1016/j.biomaterials.2010.09.008
   Kim YH, 2015, ADV DRUG DELIVER REV, V94, P28, DOI 10.1016/j.addr.2015.06.003
   Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955 2235(89)90012 4
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013
   Lauzon MA, 2012, J CONTROL RELEASE, V162, P502, DOI 10.1016/j.jconrel.2012.07.041
   Lee KB, 2012, J ORTHOP RES, V30, P1985, DOI 10.1002/jor.22160
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Li L, 2015, BIOMATERIALS, V37, P218, DOI 10.1016/j.biomaterials.2014.10.015
   Li PP, 2014, J BONE MINER METAB, V32, P627, DOI 10.1007/s00774 013 0538 6
   Li XR, 2008, LANGMUIR, V24, P14145, DOI 10.1021/la802984a
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Liu HH, 2013, BIOMATERIALS, V34, P4404, DOI 10.1016/j.biomaterials.2013.02.048
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu JY, 2016, ADV MATER, V28, P4025, DOI 10.1002/adma.201505375
   Lu JY, 2013, ADV FUNCT MATER, V23, P3494, DOI 10.1002/adfm.201203637
   Lu L, 2000, BIOMATERIALS, V21, P1837, DOI 10.1016/S0142 9612(00)00047 8
   Luginbuehl V, 2004, EUR J PHARM BIOPHARM, V58, P197, DOI 10.1016/j.ejpb.2004.03.004
   Ma SY, 2015, ASIAN PAC J TROP MED, V8, P53, DOI 10.1016/S1995 7645(14)60187 5
   Mandracchia V J, 2001, Clin Podiatr Med Surg, V18, P55
   Martino MM, 2015, ADV DRUG DELIVER REV, V94, P41, DOI 10.1016/j.addr.2015.04.007
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   MEGHJI S, 1992, BRIT DENT J, V172, P235, DOI 10.1038/sj.bdj.4807835
   Mehta M, 2012, ADV DRUG DELIVER REV, V64, P1257, DOI 10.1016/j.addr.2012.05.006
   Migliorini E, 2016, CYTOKINE GROWTH F R, V27, P43, DOI 10.1016/j.cytogfr.2015.11.008
   Nguyen MK, 2014, PROG POLYM SCI, V39, P1235, DOI 10.1016/j.progpolymsci.2013.12.001
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Moore WR, 2001, ANZ J SURG, V71, P354, DOI 10.1046/j.1440 1622.2001.2128.x
   Na K, 2007, BIOMATERIALS, V28, P2631, DOI 10.1016/j.biomaterials.2007.02.008
   Nampoothiri KM, 2010, BIORESOURCE TECHNOL, V101, P8493, DOI 10.1016/j.biortech.2010.05.092
   Nath SD, 2015, CARBOHYD POLYM, V115, P160, DOI 10.1016/j.carbpol.2014.08.077
   Newman MR, 2016, CURR OPIN BIOTECH, V40, P125, DOI 10.1016/j.copbio.2016.02.029
   Niu XF, 2009, J CONTROL RELEASE, V134, P111, DOI 10.1016/j.jconrel.2008.11.020
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   North HA, 2015, J NEUROSCI, V35, P3725, DOI 10.1523/JNEUROSCI.4546 14.2015
   Oh JH, 2012, BIOMATERIALS, V33, P4089, DOI 10.1016/j.biomaterials.2012.02.028
   Onishi T, 1998, BONE, V22, P605, DOI 10.1016/S8756 3282(98)00056 8
   Osta B., 2014, FRONT IMMUNOL, P5
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Patois E, 2009, J BIOMED MATER RES A, V91A, P324, DOI 10.1002/jbm.a.32211
   Pavlovic M., 2013, HDB MED HEALTHCARE T, P267, DOI [10.1007/978 1 4614 8495 0_11, DOI 10.1007/978 1 4614 8495 0_11]
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Pohl TLM, 2012, ACTA BIOMATER, V8, P772, DOI 10.1016/j.actbio.2011.10.019
   Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Ramoshebi Lentsha N, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004969
   Maia FR, 2013, ACTA BIOMATER, V9, P8773, DOI 10.1016/j.actbio.2013.08.004
   Ren X, 2015, BIOMATERIALS, V50, P107, DOI 10.1016/j.biomaterials.2015.01.059
   Reyes CD, 2004, J BIOMED MATER RES A, V69A, P591, DOI 10.1002/jbm.a.30034
   Ripamonti U, 2008, J CELL MOL MED, V12, P2609, DOI 10.1111/j.1582 4934.2008.00312.x
   Rogel MR, 2008, J MATER CHEM, V18, P4233, DOI 10.1039/b804692a
   Rose FRAJ, 2004, J PHARM PHARMACOL, V56, P415, DOI 10.1211/0022357023312
   Rouwkema J., 2016, TRENDS BIOTECHNOL, V0
   Samorezov JE, 2015, ADV DRUG DELIVER REV, V84, P45, DOI 10.1016/j.addr.2014.11.018
   SANTAVIRTA S, 1990, J BONE JOINT SURG BR, V72, P597, DOI 10.1302/0301 620X.72B4.2166048
   Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590
   Schmidt Bleek K, 2016, CYTOKINE GROWTH F R, V27, P141, DOI 10.1016/j.cytogfr.2015.11.006
   Schwab EH, 2015, NANO LETT, V15, P1526, DOI 10.1021/acs.nanolett.5b00315
   Seo BB, 2015, J CONTROL RELEASE, V209, P67, DOI 10.1016/j.jconrel.2015.04.023
   Singh S, 2011, BIOMATERIALS, V32, P2059, DOI 10.1016/j.biomaterials.2010.11.038
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Tanaka T, 2012, Open Biomed Eng J, V6, P98, DOI 10.2174/1874120701206010098
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Thompson JB, 2001, NATURE, V414, P773, DOI 10.1038/414773a
   URIST MR, 1971, J DENT RES, V50, P1392, DOI 10.1177/00220345710500060601
   Vaccaro AR, 2008, SPINE J, V8, P457, DOI 10.1016/j.spinee.2007.03.012
   Vasita R, 2006, EXPERT REV MED DEVIC, V3, P29, DOI 10.1586/17434440.3.1.29
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   Wan L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102010
   WEISS RE, 1981, J CLIN INVEST, V68, P815, DOI 10.1172/JCI110319
   Wongpanit P, 2010, J BIOMAT SCI POLYM E, V21, P1403, DOI 10.1163/092050609X12517858243706
   Wu B, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/4/044111
   Xia LG, 2013, J MATER CHEM B, V1, P5403, DOI 10.1039/c3tb20945h
   Xiao CW, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/1/015013
   Xiao YT, 2007, BIOCHEM BIOPH RES CO, V362, P550, DOI 10.1016/j.bbrc.2007.08.045
   Xu JK, 2012, J BIOL CHEM, V287, P26200, DOI 10.1074/jbc.M112.349811
   Yamachika E, 2009, J BIOMED MATER RES A, V88A, P599, DOI 10.1002/jbm.a.31833
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
   Young S, 2009, TISSUE ENG PT A, V15, P2347, DOI 10.1089/ten.tea.2008.0510
   Yu YM, 2015, ACS APPL MATER INTER, V7, P9982, DOI 10.1021/acsami.5b02324
   Yun YR, 2012, REGEN MED, V7, P369, DOI [10.2217/RME.12.1, 10.2217/rme.12.1]
   Zhang J, 2015, BIOMATERIALS, V53, P251, DOI 10.1016/j.biomaterials.2015.02.097
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
   Zhang WJ, 2016, ACTA BIOMATER, V33, P290, DOI 10.1016/j.actbio.2016.01.042
   Zhang WJ, 2015, SCI REP UK, V5, DOI 10.1038/srep12694
   Zhou HJ, 2009, BIOMATERIALS, V30, P1715, DOI 10.1016/j.biomaterials.2008.12.016
   Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044
   Zu Y, 2015, J BIOMECH, V48, P3950, DOI 10.1016/j.jbiomech.2015.09.027
NR 165
TC 100
Z9 110
U1 4
U2 216
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD DEC
PY 2016
VL 26
IS 48
BP 8810
EP 8823
DI 10.1002/adfm.201603197
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA EH5KT
UT WOS:000391812700002
DA 2025 08 17
ER

PT J
AU Li, ZG
   Mathew, P
   Yang, J
   Starbuck, MW
   Zurita, AJ
   Liu, J
   Sikes, C
   Multani, AS
   Efstathiou, E
   Lopez, A
   Wang, J
   Fanning, TV
   Prieto, VG
   Kundra, V
   Vazquez, ES
   Troncoso, P
   Raymond, AK
   Logothetis, CJ
   Lin, SH
   Maity, S
   Navone, NM
AF Li, Zhi Gang
   Mathew, Paul
   Yang, Jun
   Starbuck, Michael W.
   Zurita, Arnado J.
   Liu, Jie
   Sikes, Charles
   Multani, Asha S.
   Efstathiou, Eleni
   Lopez, Adriana
   Wang, Jing
   Fanning, Tina V.
   Prieto, Victor G.
   Kundra, Vikas
   Vazquez, Elba S.
   Troncoso, Patricia
   Raymond, Austin K.
   Logothetis, Christopher J.
   Lin, Sue Hwa
   Maity, Sankar
   Navone, Nora M.
TI Androgen receptor negative human prostate cancer cells induce
   osteogenesis in mice through FGF9 mediated mechanisms
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID GROWTH FACTOR; OSTEOBLAST DIFFERENTIATION; OSTEOLYTIC LESIONS; BONE
   METASTASES; EXPRESSION; MODEL; ESTABLISHMENT; CARCINOMA; GENES; LINES
AB In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic bone metastases. However, responses to these therapies are typically brief, and the mechanism underlying androgen independent progression is not clear. Here, we established what we believe to be the first human androgen receptor negative prostate cancer xenografts whose cells induced an osteoblastic reaction in bone and in the subcutis of immunodeficient mice. Accordingly, these cells grew in castrated as well as intact male mice. We identified FGF9 as being overexpressed in the xenografts relative to other bone derived prostate cancer cells and discovered that FGF9 induced osteoblast proliferation and new bone formation in a bone organ assay. Mice treated with FGF9 neutralizing antibody developed smaller bone rumors and reduced bone formation. Finally, we found positive FGF9 immunostaining in prostate cancer cells in 24 of 56 primary tumors derived from human organ confined prostate cancer and in 25 of 25 bone metastasis cases studied. Collectively, these results suggest that FGF9 contributes to prostate cancer induced new bone formation and may participate in the osteoblastic progression of prostate cancer in bone. Androgen receptor null cells may contribute to the castration resistant osteoblastic progression of prostate cancer cells in bone and provide a preclinical model for studying therapies that target these cells.
C1 [Li, Zhi Gang; Mathew, Paul; Yang, Jun; Starbuck, Michael W.; Zurita, Arnado J.; Liu, Jie; Sikes, Charles; Efstathiou, Eleni; Logothetis, Christopher J.; Navone, Nora M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77030 USA.
   [Multani, Asha S.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA.
   [Lopez, Adriana] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
   [Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
   [Fanning, Tina V.; Prieto, Victor G.; Troncoso, Patricia; Raymond, Austin K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Kundra, Vikas] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA.
   [Vazquez, Elba S.] Univ Buenos Aires, Sch Sci, Dept Biol Chem, Buenos Aires, DF, Argentina.
   [Vazquez, Elba S.] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
   [Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.
   [Maity, Sankar] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center
RP Navone, NM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 15 Holcombe Blvd,T7 3920, Houston, TX 77030 USA.
EM nnavone@mdanderson.org
RI Wang, Jing/A 2551 2012; Yao, Jun/JAC 5608 2023; Vazquez,
   Elba/D 5134 2019
OI Maity, Sankar/0000 0002 2387 6545; Vazquez, Elba/0000 0002 0460 0236;
   Lopez, Adriana/0000 0001 9169 800X
CR Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658
   Baron R., 1983, Bone histomorphometry: Techniques and interpretation, P13
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Burd CJ, 2006, ENDOCR RELAT CANCER, V13, P979, DOI 10.1677/erc.1.01115
   CATALONA WJ, 1994, NEW ENGL J MED, V331, P996
   CHARHON SA, 1983, CANCER AM CANCER SOC, V51, P918, DOI 10.1002/1097 0142(19830301)51:5<918::AID CNCR2820510526>3.0.CO;2 J
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008
   Cho Vega JH, 2005, MODERN PATHOL, V18, P577, DOI 10.1038/modpathol.3800327
   CLARKE NW, 1993, EUR UROL, V24, P286
   Cohen P, 2006, HORM RES, V65, P3, DOI 10.1159/000090640
   COOK GB, 1968, J UROLOGY, V99, P87, DOI 10.1016/S0022 5347(17)62647 8
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   Doherty A, 1999, J PATHOL, V188, P278, DOI 10.1002/(SICI)1096 9896(199907)188:3<278::AID PATH358>3.0.CO;2 G
   Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464 410X.2005.05526.x
   Eswarakumar VP, 2002, DEVELOPMENT, V129, P3783
   Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003
   Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465
   Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Freshney RI., 1994, Culture of animal cells : A manual of basic technique, V3rd
   Garrett IR, 2003, METH MOLEC MED, V80, P183
   Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097 4652(199907)180:1<53::AID JCP6>3.0.CO;2 P
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406
   Izbicka E, 1997, CALCIFIED TISSUE INT, V60, P210, DOI 10.1007/s002239900216
   Jackson RA, 2006, GENE, V379, P79, DOI 10.1016/j.gene.2006.04.028
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kundra V, 2007, PROSTATE, V67, P50, DOI 10.1002/pros.20494
   Kwabi Addo B, 2004, ENDOCR RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535
   Lee YP, 2002, CANCER RES, V62, P5564
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li ZG, 2008, ONCOGENE, V27, P596, DOI 10.1038/sj.onc.1210694
   Lian JB, 2003, J CELL PHYSIOL, V196, P301, DOI 10.1002/jcp.10316
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nadiminty N, 2006, CLIN CANCER RES, V12, P1420, DOI 10.1158/1078 0432.CCR 05 1849
   Navone NM, 1998, CANCER METAST REV, V17, P361, DOI 10.1023/A:1006165017279
   Navone NM, 1997, CLIN CANCER RES, V3, P2493
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   Ornitz DM, 2001, GENOME BIOL, V2
   PATHAK S, 1976, J REPROD MED, V17, P25
   Pienta KJ, 2006, CLIN CANCER RES, V12, P1665, DOI 10.1158/1078 0432.CCR 06 0067
   Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140 6736(04)16044 3
   Rubin J, 2006, PROSTATE, V66, P789, DOI 10.1002/pros.20379
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Thalmann GN, 2000, PROSTATE, V44, P91
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959 437X(02)00012 6
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   WLODARSKI KH, 1985, CLIN ORTHOP RELAT R, P248
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   Yang J, 2001, CANCER RES, V61, P5652
NR 55
TC 151
Z9 165
U1 0
U2 9
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2008
VL 118
IS 8
BP 2697
EP 2710
DI 10.1172/JCI33093
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 333IS
UT WOS:000258146800009
PM 18618013
OA Green Accepted, Bronze, Green Published
DA 2025 08 17
ER

EF